Selegiline B-Chemical 0 0.9999596
- O 0 0.097488336
induced O 0 0.002430279
postural B-Disease 0 0.9902181
hypotension I-Disease 0 0.9999795
in O 0 0.0017395995
Parkinson B-Disease 0 0.9982286
' I-Disease 0 0.00095519575
s I-Disease 0 0.000673599
disease I-Disease 0 0.06085688
: O 0 0.00056600216
a O 0 0.00030497188
longitudinal O 0 0.0003968948
study O 0 0.00021887514
on O 0 0.00013437773
the O 0 0.00019391117
effects O 0 0.00036463977
of O 0 0.00087660336
drug O 0 0.061703883
withdrawal O 0 0.015838224
. O 0 0.0029232563

OBJECTIVES O 0 0.0045570782
: O 0 0.0035919603
The O 0 0.0009266412
United O 0 0.0014435186
Kingdom O 0 0.0023326534
Parkinson B-Disease 0 0.96028244
' I-Disease 0 0.0012451588
s I-Disease 0 0.0008763904
Disease I-Disease 0 0.0014367362
Research O 0 0.0007740024
Group O 0 0.0012236993
( O 0 0.00046107924
UKPDRG O 0 0.0008829011
) O 0 0.00058830366
trial O 0 0.00031974085
found O 0 0.00016202402
an O 0 0.00018226125
increased O 0 0.00023515332
mortality O 0 0.000820482
in O 0 0.00013129445
patients O 0 0.0003186915
with O 0 0.00026409756
Parkinson B-Disease 0 0.9982627
' I-Disease 0 0.0004593175
s I-Disease 0 0.00040124325
disease I-Disease 0 0.35692573
( O 0 0.00097146456
PD B-Disease 0 0.99926955
) O 0 0.00046727923
randomized O 0 0.00028331965
to O 0 7.000343e-05
receive O 0 8.747613e-05
10 O 0 0.0001372257
mg O 0 0.070833586
selegiline B-Chemical 0 0.99999213
per O 0 0.00014310626
day O 0 9.907316e-05
and O 0 0.0003185925
L B-Chemical 1 0.9990097
- I-Chemical 1 0.9451093
dopa I-Chemical 1 0.99997425
compared O 0 0.00019587054
with O 0 0.0002788268
those O 0 0.000459517
taking O 0 0.0013451402
L B-Chemical 1 0.9985417
- I-Chemical 1 0.9525421
dopa I-Chemical 1 0.99993837
alone O 0 0.0033226882
. O 0 0.0035196452

Recently O 0 0.003361741
, O 0 0.0032043548
we O 0 0.0007472189
found O 0 0.0007581302
that O 0 0.0004904231
therapy O 0 0.0009390608
with O 0 0.0012131712
selegiline B-Chemical 0 0.9999962
and O 0 0.0033818071
L B-Chemical 1 0.9997776
- I-Chemical 1 0.99328434
dopa I-Chemical 1 0.99998665
was O 0 0.00021154339
associated O 0 0.00013513264
with O 0 0.00012020754
selective O 0 0.0002474845
systolic B-Disease 0 0.989251
orthostatic I-Disease 0 0.9999765
hypotension I-Disease 0 0.999998
which O 0 0.0003822724
was O 0 0.00021060895
abolished O 0 0.00033651333
by O 0 0.0004303843
withdrawal O 0 0.0056424057
of O 0 0.0022494122
selegiline B-Chemical 0 0.9999815
. O 0 0.0046311733

This O 0 0.0045307176
unwanted O 0 0.003310103
effect O 0 0.001034252
on O 0 0.0007840172
postural O 0 0.022941483
blood O 0 0.0083698565
pressure O 0 0.008654252
was O 0 0.0004467797
not O 0 0.00032745753
the O 0 0.0003172555
result O 0 0.00039301752
of O 0 0.0006733028
underlying O 0 0.001405098
autonomic O 0 0.08540506
failure O 0 0.037936825
. O 0 0.003496922

The O 0 0.0019716017
aims O 0 0.0018465512
of O 0 0.0012797186
this O 0 0.0008842153
study O 0 0.0006416398
were O 0 0.00030204674
to O 0 0.00017708926
confirm O 0 8.763728e-05
our O 0 0.00013426374
previous O 0 0.0001239914
findings O 0 0.00018740945
in O 0 0.00013564333
a O 0 0.000184909
separate O 0 9.364234e-05
cohort O 0 0.0002892113
of O 0 0.00013279112
patients O 0 0.00026711152
and O 0 9.300374e-05
to O 0 5.657265e-05
determine O 0 2.383731e-05
the O 0 4.8043967e-05
time O 0 4.419404e-05
course O 0 7.4640666e-05
of O 0 8.089485e-05
the O 0 7.546976e-05
cardiovascular O 0 0.019642686
consequences O 0 0.000116226816
of O 0 0.00016283622
stopping O 0 0.0025987318
selegiline B-Chemical 0 0.99999857
in O 0 0.00012677631
the O 0 7.0724476e-05
expectation O 0 9.431447e-05
that O 0 6.389565e-05
this O 0 0.000104460276
might O 0 6.203074e-05
shed O 0 0.00016212989
light O 0 0.00017892728
on O 0 6.9615446e-05
the O 0 8.37275e-05
mechanisms O 0 9.959868e-05
by O 0 0.00017221385
which O 0 0.00025564447
the O 0 0.00026993302
drug O 0 0.020851199
causes O 0 0.0017804276
orthostatic B-Disease 0 0.99990964
hypotension I-Disease 0 0.99997497
. O 0 0.004020889

METHODS O 0 0.003830396
: O 0 0.002488888
The O 0 0.0006715834
cardiovascular O 0 0.0038602308
responses O 0 0.00049280626
to O 0 0.0003606
standing O 0 0.0007078015
and O 0 0.00045101758
head O 0 0.0019140653
- O 0 0.0022551506
up O 0 0.00029589786
tilt O 0 0.0013131278
were O 0 0.00017437349
studied O 0 0.00020435407
repeatedly O 0 0.0001586108
in O 0 0.00024310465
PD B-Disease 0 0.99806637
patients O 0 0.00066508836
receiving O 0 0.00066967396
selegiline B-Chemical 0 0.99999297
and O 0 0.00040223435
as O 0 0.00032305496
the O 0 0.0003976494
drug O 0 0.008475521
was O 0 0.0009898711
withdrawn O 0 0.0036463162
. O 0 0.0025904777

RESULTS O 0 0.005530767
: O 0 0.0047781104
Head O 0 0.005113943
- O 0 0.0040104818
up O 0 0.000918541
tilt O 0 0.0026625618
caused O 0 0.0006589511
systolic B-Disease 0 0.97636604
orthostatic I-Disease 0 0.9999534
hypotension I-Disease 0 0.99999666
which O 0 0.00047700625
was O 0 0.00017665111
marked O 0 0.00020337908
in O 0 0.00010853945
six O 0 6.621006e-05
of O 0 0.00014652124
20 O 0 0.00025244316
PD B-Disease 0 0.99769056
patients O 0 0.0005313764
on O 0 0.0002041206
selegiline B-Chemical 0 0.99999666
, O 0 0.0005718569
one O 0 0.00014509117
of O 0 0.00020902873
whom O 0 0.0004825854
lost O 0 0.0003784647
consciousness O 0 0.42310506
with O 0 0.0006267153
unrecordable O 0 0.2706449
blood O 0 0.008512381
pressures O 0 0.005834047
. O 0 0.0026383332

A O 0 0.044565056
lesser O 0 0.012161403
degree O 0 0.0054527414
of O 0 0.005580071
orthostatic B-Disease 0 0.99975926
hypotension I-Disease 0 0.99995327
occurred O 0 0.0027205027
with O 0 0.002449791
standing O 0 0.0056525334
. O 0 0.005441344

Orthostatic B-Disease 0 0.99887234
hypotension I-Disease 0 0.99993455
was O 0 0.0018418799
ameliorated O 0 0.0064191157
4 O 0 0.00033982162
days O 0 0.00016451738
after O 0 0.0001409136
withdrawal O 0 0.0009933326
of O 0 0.00065449264
selegiline B-Chemical 0 0.99999547
and O 0 0.00051778794
totally O 0 0.00059705565
abolished O 0 0.00027605103
7 O 0 0.00014843229
days O 0 0.00010410884
after O 0 0.00013369176
discontinuation O 0 0.0009921929
of O 0 0.00053861237
the O 0 0.0008349853
drug O 0 0.012587065
. O 0 0.0032556267

Stopping O 0 0.821075
selegiline B-Chemical 0 0.99997675
also O 0 0.0013568009
significantly O 0 0.00077736157
reduced B-Disease 0 0.00044336042
the I-Disease 0 0.00022845874
supine I-Disease 0 0.00049512426
systolic I-Disease 0 0.0034073908
and I-Disease 0 0.00021472879
diastolic I-Disease 0 0.07241898
blood I-Disease 0 0.0016276739
pressures I-Disease 0 0.0007478968
consistent O 0 0.00017284756
with O 0 0.0002391698
a O 0 0.00040644538
previously O 0 0.0003862828
undescribed O 0 0.00046188096
supine O 0 0.0018176084
pressor O 0 0.055898026
action O 0 0.0015624297
. O 0 0.0026761857

CONCLUSION O 0 0.018653905
: O 0 0.0042518163
This O 0 0.0014792847
study O 0 0.00072070956
confirms O 0 0.00030185416
our O 0 0.0002988837
previous O 0 0.00026760757
finding O 0 0.00037441688
that O 0 0.0004474926
selegiline B-Chemical 0 0.999995
in O 0 0.00037820154
combination O 0 0.000490577
with O 0 0.0009192755
L B-Chemical 1 0.99974316
- I-Chemical 1 0.9928595
dopa I-Chemical 1 0.99998593
is O 0 0.00032708122
associated O 0 0.00035645033
with O 0 0.00050034944
selective O 0 0.0022543191
orthostatic B-Disease 0 0.9998778
hypotension I-Disease 0 0.9999695
. O 0 0.004140774

The O 0 0.0016184733
possibilities O 0 0.0014240483
that O 0 0.00086542044
these O 0 0.0008525748
cardiovascular O 0 0.06622722
findings O 0 0.0005963609
might O 0 0.0001917521
be O 0 0.00021298499
the O 0 0.00015398188
result O 0 0.00014781283
of O 0 0.00020962908
non O 0 0.00047979708
- O 0 0.0026273895
selective O 0 0.00034301897
inhibition O 0 0.0005515429
of O 0 0.0018652484
monoamine O 0 0.9999887
oxidase O 0 0.99985707
or O 0 0.00050934387
of O 0 0.0011466214
amphetamine B-Chemical 1 0.99999416
and O 0 0.0019597067
metamphetamine B-Chemical 0 0.99989593
are O 0 0.0007852124
discussed O 0 0.0010745033
. O 0 0.0022439149

Further O 0 0.0028636095
studies O 0 0.0024762775
on O 0 0.0011382153
effects O 0 0.0012497391
of O 0 0.0015811222
irrigation O 0 0.0029947504
solutions O 0 0.001972288
on O 0 0.0011453448
rat O 0 0.0030677116
bladders O 0 0.015685998
. O 0 0.005425564

Further O 0 0.002159619
studies O 0 0.0017699474
on O 0 0.00069959246
the O 0 0.0005292355
effects O 0 0.0004823766
of O 0 0.0005251619
certain O 0 0.00047435326
irrigating O 0 0.0050098374
fluids O 0 0.00069225987
on O 0 0.00016475443
the O 0 0.00020750288
rat O 0 0.00048000386
bladder O 0 0.002240139
for O 0 0.00025745967
18 O 0 0.0004147644
hours O 0 0.00039369302
are O 0 0.0006257918
reported O 0 0.0014274821
. O 0 0.0028432002

The O 0 0.0019431574
results O 0 0.0014381078
have O 0 0.0009440774
shown O 0 0.00042610327
that O 0 0.00039547603
the O 0 0.00037117093
degradation O 0 0.0003954677
product O 0 0.00040955105
p B-Chemical 0 0.0012791563
- I-Chemical 0 0.0021774718
choloroaniline I-Chemical 0 0.0007663136
is O 0 0.00022538497
not O 0 0.00022109952
a O 0 0.0003860336
significant O 0 0.00035608845
factor O 0 0.0049159103
in O 0 0.0006655662
chlorhexidine B-Chemical 0 0.9963521
- I-Chemical 0 0.13936235
digluconate I-Chemical 0 0.93133664
associated O 0 0.0016572942
erosive O 0 0.98860455
cystitis B-Disease 0 0.9989141
. O 0 0.0039872346

A O 0 0.015111987
high O 0 0.0022116231
percentage O 0 0.0010427901
of O 0 0.0015037503
kanamycin B-Chemical 0 0.9991873
- O 0 0.14879593
colistin B-Chemical 0 0.99989045
and O 0 0.0012201687
povidone B-Chemical 0 0.99977106
- I-Chemical 0 0.24525444
iodine I-Chemical 0 0.99975425
irrigations O 0 0.003058737
were O 0 0.00013411365
associated O 0 0.0001502364
with O 0 0.00026101482
erosive O 0 0.9727011
cystitis B-Disease 0 0.9990646
and O 0 0.00024954925
suggested O 0 0.00016309634
a O 0 0.00030253697
possible O 0 0.00020543562
complication O 0 0.0024998197
with O 0 0.00056588807
human O 0 0.00085602014
usage O 0 0.0012528485
. O 0 0.0026326778

Picloxydine B-Chemical 0 0.76549053
irrigations O 0 0.012096589
appeared O 0 0.0010976535
to O 0 0.0005923465
have O 0 0.00041594057
a O 0 0.00052478863
lower O 0 0.00042311527
incidence O 0 0.0006410717
of O 0 0.00053959584
erosive O 0 0.9934999
cystitis B-Disease 0 0.9996494
but O 0 0.0002873816
further O 0 0.00012540421
studies O 0 0.00019550443
would O 0 0.00010954357
have O 0 0.00010032521
to O 0 9.21689e-05
be O 0 9.433479e-05
performed O 0 8.540984e-05
before O 0 6.621063e-05
it O 0 0.00017946669
could O 0 0.00010174162
be O 0 0.0001404429
recommended O 0 0.00015306828
for O 0 0.00015028082
use O 0 0.00026521238
in O 0 0.00045813818
urological O 0 0.0020933263
procedures O 0 0.0012570238
. O 0 0.0024372346

Effects O 0 0.004617464
of O 0 0.005260148
tetrandrine B-Chemical 0 0.9999523
and O 0 0.0040687653
fangchinoline B-Chemical 0 0.9987073
on O 0 0.0006291215
experimental O 0 0.0010783189
thrombosis B-Disease 0 0.9997874
in O 0 0.00049715803
mice O 0 0.00022086795
and O 0 0.000723011
human O 0 0.0017824789
platelet B-Disease 0 0.9981998
aggregation I-Disease 0 0.6235621
. O 0 0.005315605

Tetrandrine B-Chemical 0 0.99954957
( O 0 0.032844137
TET B-Chemical 0 0.998307
) O 0 0.0053468356
and O 0 0.0018035271
fangchinoline B-Chemical 0 0.99897885
( O 0 0.009318425
FAN B-Chemical 0 0.9996964
) O 0 0.0017941615
are O 0 0.00027742886
two O 0 0.00021524903
naturally O 0 0.00046811003
occurring O 0 0.0004581965
analogues O 0 0.0016492403
with O 0 0.00096541183
a O 0 0.002298278
bisbenzylisoquinoline B-Chemical 0 0.9922275
structure O 0 0.0035915677
. O 0 0.004646471

The O 0 0.0019735997
present O 0 0.0013991533
study O 0 0.0012910375
was O 0 0.0006550262
undertaken O 0 0.00042169789
to O 0 0.00023690051
investigate O 0 0.000111534435
the O 0 0.00017754034
effects O 0 0.00025175168
of O 0 0.00059969065
TET B-Chemical 0 0.9996685
and O 0 0.00085577584
FAN B-Chemical 0 0.99971586
on O 0 0.00013082067
the O 0 0.0001226161
experimental O 0 0.00028528203
thrombosis B-Disease 0 0.99992573
induced O 0 0.0002328708
by O 0 0.00025843235
collagen O 0 0.88890284
plus O 0 0.0007360416
epinephrine B-Chemical 0 0.99993885
( O 0 0.001068352
EP B-Chemical 0 0.96572536
) O 0 0.00051227503
in O 0 0.00011844525
mice O 0 6.8465626e-05
, O 0 0.00040731055
and O 0 0.0005554058
platelet B-Disease 0 0.9993886
aggregation I-Disease 0 0.4985223
and O 0 0.0012276885
blood B-Disease 2 0.9661509
coagulation I-Disease 2 0.9980355
in O 0 0.0009632541
vitro O 0 0.0014846298
. O 0 0.002624285

In O 0 0.0020023363
the O 0 0.0014867052
in O 0 0.0010545369
vivo O 0 0.00083512213
study O 0 0.00076419115
, O 0 0.00077090337
the O 0 0.0003239543
administration O 0 0.0005873067
( O 0 0.000542317
50 O 0 0.00037883196
mg O 0 0.0022450353
/ O 0 0.00084646
kg O 0 0.0005679317
, O 0 0.00037018044
i O 0 0.0003607124
. O 0 0.00018364548
p O 0 0.0003197872
. O 0 0.0001949365
) O 0 0.00047183057
of O 0 0.00040458332
TET B-Chemical 0 0.99948955
and O 0 0.0007789481
FAN B-Chemical 0 0.99975604
in O 0 0.00015732611
mice O 0 4.9739618e-05
showed O 0 9.965558e-05
the O 0 0.00010484377
inhibition O 0 0.00022379328
of O 0 0.00036295023
thrombosis B-Disease 0 0.9999529
by O 0 0.0002019778
55 O 0 0.00020681591
% O 0 0.00022976287
and O 0 0.00011989694
35 O 0 0.00014217703
% O 0 0.00027062232
, O 0 0.00029768105
respectively O 0 0.00046788476
, O 0 0.00072826544
while O 0 0.0011882127
acetylsalicylic B-Chemical 0 0.9999989
acid I-Chemical 0 0.999564
( O 0 0.024245737
ASA B-Chemical 0 0.99918145
, O 0 0.0005012782
50 O 0 0.0002601634
mg O 0 0.0023653915
/ O 0 0.000631616
kg O 0 0.00041413764
, O 0 0.00027332685
i O 0 0.00028934644
. O 0 0.00015299501
p O 0 0.00028648975
. O 0 0.00018015112
) O 0 0.0004302448
, O 0 0.00035587346
a O 0 0.00029859456
positive O 0 0.00025657527
control O 0 0.00032229972
, O 0 0.0006211515
showed O 0 0.0003816461
only O 0 0.0005629572
30 O 0 0.00061450974
% O 0 0.0014558029
inhibition O 0 0.0020568448
. O 0 0.003301032

In O 0 0.0021116904
the O 0 0.0017667027
vitro O 0 0.0016989488
human O 0 0.0023894862
platelet B-Disease 0 0.99867475
aggregations I-Disease 0 0.0290865
induced O 0 0.0005209094
by O 0 0.0003513763
the O 0 0.00025692632
agonists O 0 0.0018822995
used O 0 0.00023183158
in O 0 0.00025612462
tests O 0 0.0008819535
, O 0 0.0013766702
TET B-Chemical 0 0.9992648
and O 0 0.0011021453
FAN B-Chemical 0 0.99961853
showed O 0 0.00051211804
the O 0 0.0005096081
inhibitions O 0 0.0517298
dose O 0 0.004428067
dependently O 0 0.49804103
. O 0 0.0039694235

In O 0 0.0019685184
addition O 0 0.0012816851
, O 0 0.0025765526
neither O 0 0.0016036304
TET B-Chemical 0 0.9991085
nor O 0 0.001180436
FAN B-Chemical 0 0.9997551
showed O 0 0.0003998522
any O 0 0.0002270633
anticoagulation O 0 0.002534337
activities O 0 0.000114975126
in O 0 0.0001037489
the O 0 8.585406e-05
measurement O 0 8.746795e-05
of O 0 0.00012186509
the O 0 0.00011037516
activated O 0 0.00017094205
partial O 0 0.0004097817
thromboplastin O 0 0.9824958
time O 0 0.00016376283
( O 0 0.00074227335
APTT O 0 0.99679935
) O 0 0.0007195591
, O 0 0.0005469895
prothrombin O 0 0.5589612
time O 0 0.00015450799
( O 0 0.0005200858
PT O 0 0.008717378
) O 0 0.00063467596
and O 0 0.00030385566
thrombin O 0 0.08217964
time O 0 0.00019484416
( O 0 0.00060157245
TT O 0 0.0030972885
) O 0 0.00083529955
using O 0 0.00034727875
human O 0 0.00082863955
- O 0 0.017079825
citrated O 0 0.94439805
plasma O 0 0.057846528
. O 0 0.003489824

These O 0 0.0019788898
results O 0 0.0013717283
suggest O 0 0.0007710055
that O 0 0.00092609756
antithrombosis O 0 0.08081998
of O 0 0.0019631847
TET B-Chemical 0 0.9996024
and O 0 0.0020171315
FAN B-Chemical 0 0.9997031
in O 0 0.00033425467
mice O 0 0.00010839962
may O 0 0.00017438296
be O 0 0.0002035166
mainly O 0 0.00022835488
related O 0 0.00016494241
to O 0 0.00027111996
the O 0 0.00046646103
antiplatelet O 0 0.732344
aggregation O 0 0.0043172534
activities O 0 0.0015858497
. O 0 0.0030370883

Angioedema B-Disease 0 0.99874485
due O 0 0.0034025593
to O 0 0.002896522
ACE B-Chemical 0 0.98863786
inhibitors I-Chemical 0 0.0065870937
: O 0 0.0035865696
common O 0 0.0016730264
and O 0 0.0020286718
inadequately O 0 0.024227459
diagnosed O 0 0.014140429
. O 0 0.0053163236

The O 0 0.0020693135
estimated O 0 0.0019862377
incidence O 0 0.0024432752
of O 0 0.0022293334
angioedema B-Disease 0 0.99988055
during O 0 0.0013542172
angiotensin B-Chemical 0 0.99998605
- I-Chemical 0 0.3293488
converting I-Chemical 0 0.0017956884
enzyme I-Chemical 0 0.0025669457
( I-Chemical 0 0.0015899206
ACE I-Chemical 0 0.984177
) I-Chemical 0 0.001350012
inhibitor I-Chemical 0 0.000785992
treatment O 0 0.00022812115
is O 0 0.00015433734
between O 0 0.00017583021
1 O 0 0.00030459499
and O 0 0.0002952835
7 O 0 0.0003039507
per O 0 0.00043291796
thousand O 0 0.0010905843
patients O 0 0.0023291516
. O 0 0.0027632471

This O 0 0.0040458115
potentially O 0 0.0018064289
serious O 0 0.0027371396
adverse O 0 0.002668883
effect O 0 0.0005127588
is O 0 0.00041587974
often O 0 0.000490844
preceded O 0 0.00040745505
by O 0 0.00035624363
minor O 0 0.0006759166
manifestations O 0 0.010445663
that O 0 0.00032321672
may O 0 0.00038431425
serve O 0 0.00063999236
as O 0 0.0008154569
a O 0 0.001950797
warning O 0 0.0039592152
. O 0 0.0037110045

Cocaine B-Chemical 0 0.9998455
- O 0 0.15777612
induced O 0 0.0035257193
mood B-Disease 0 0.99937266
disorder I-Disease 0 0.999199
: O 0 0.0018081522
prevalence O 0 0.0006287481
rates O 0 0.00052872626
and O 0 0.0008408369
psychiatric B-Disease 2 0.99993086
symptoms O 0 0.43900606
in O 0 0.00034075405
an O 0 0.00045137087
outpatient O 0 0.001937314
cocaine B-Chemical 0 0.9993168
- O 0 0.004988781
dependent O 0 0.00074652216
sample O 0 0.0021762622
. O 0 0.0030631516

This O 0 0.004578065
paper O 0 0.002698027
attempts O 0 0.0012291721
to O 0 0.0005294327
examine O 0 0.00022196067
and O 0 0.00033010173
compare O 0 0.000146118
prevalence O 0 0.0003374147
rates O 0 0.00029319755
and O 0 0.00026567065
symptom O 0 0.0006027268
patterns O 0 0.0001688745
of O 0 0.00032524785
DSM O 0 0.013217073
substance O 0 0.60909134
- O 0 0.003951408
induced O 0 0.0004409409
and O 0 0.00068355177
other O 0 0.0012415578
mood B-Disease 0 0.9990368
disorders I-Disease 0 0.9971035
. O 0 0.0044352175

243 O 0 0.028217418
cocaine B-Chemical 0 0.99922943
- O 0 0.018049272
dependent O 0 0.0008369854
outpatients O 0 0.008329166
with O 0 0.0010063435
cocaine B-Chemical 0 0.9997904
- O 0 0.026607184
induced O 0 0.00071880413
mood B-Disease 0 0.9996977
disorder I-Disease 0 0.99969137
( O 0 0.0020903074
CIMD B-Disease 0 0.98678386
) O 0 0.0010066695
, O 0 0.00041446427
other O 0 0.0002801495
mood B-Disease 0 0.99944276
disorders I-Disease 0 0.9975846
, O 0 0.00045888298
or O 0 0.00015099788
no O 0 0.0002657839
mood B-Disease 0 0.9993285
disorder I-Disease 0 0.9970783
were O 0 0.0001546287
compared O 0 0.00010517983
on O 0 0.00013142395
measures O 0 0.0003084492
of O 0 0.0011018836
psychiatric B-Disease 2 0.9998779
symptoms O 0 0.8604776
. O 0 0.0034702998

The O 0 0.0033428972
prevalence O 0 0.004065637
rate O 0 0.003636631
for O 0 0.0023601323
CIMD B-Disease 0 0.7833768
was O 0 0.0016147348
12 O 0 0.0010719565
% O 0 0.00195059
at O 0 0.0013011562
baseline O 0 0.0022741582
. O 0 0.0047543696

Introduction O 0 0.004108522
of O 0 0.0025836648
the O 0 0.0018256526
DSM O 0 0.015379113
- O 0 0.014293679
IV O 0 0.18326946
diagnosis O 0 0.0018968956
of O 0 0.0011405954
CIMD B-Disease 0 0.9866094
did O 0 0.00067096984
not O 0 0.0003396076
substantially O 0 0.00036996749
affect O 0 0.0002443791
rates O 0 0.00039926596
of O 0 0.00044904096
the O 0 0.00051032845
other O 0 0.0013894757
depressive B-Disease 2 0.999969
disorders I-Disease 0 0.997962
. O 0 0.004394896

Patients O 0 0.0053933677
with O 0 0.0030772504
CIMD B-Disease 0 0.9262718
had O 0 0.0011798418
symptom O 0 0.002329034
severity O 0 0.0009141945
levels O 0 0.00022933588
between O 0 0.00019552586
those O 0 0.00029166663
of O 0 0.00030130098
patients O 0 0.0005606985
with O 0 0.00033851503
and O 0 0.00043476062
without O 0 0.0006755692
a O 0 0.0027269076
mood B-Disease 0 0.9992078
disorder I-Disease 0 0.99856806
. O 0 0.004257062

These O 0 0.0018540367
findings O 0 0.0015990934
suggest O 0 0.00065077987
some O 0 0.0007535463
validity O 0 0.0007530672
for O 0 0.00035876155
the O 0 0.00033523503
new O 0 0.00053383707
DSM O 0 0.0074904193
- O 0 0.006625286
IV O 0 0.13954972
diagnosis O 0 0.0008985299
of O 0 0.00058242737
CIMD B-Disease 0 0.99289083
, O 0 0.000996097
but O 0 0.00032017397
also O 0 0.00018608713
suggest O 0 0.00012483704
that O 0 0.00019164517
it O 0 0.000385997
requires O 0 0.00020995054
further O 0 0.0003944081
specification O 0 0.0013102994
and O 0 0.0010994577
replication O 0 0.002861425
. O 0 0.003335356

Effect O 0 0.0039568204
of O 0 0.0046234513
fucoidan B-Chemical 0 0.9977882
treatment O 0 0.0021699981
on O 0 0.0012735351
collagenase O 0 0.9703873
- O 0 0.014235226
induced O 0 0.0016295041
intracerebral B-Disease 0 0.9937822
hemorrhage I-Disease 2 0.999747
in O 0 0.0016649035
rats O 0 0.0030457072
. O 0 0.0034611812

Inflammatory O 0 0.01885599
cells O 0 0.002947045
are O 0 0.0013493245
postulated O 0 0.0011440794
to O 0 0.0005989296
mediate O 0 0.00036962415
some O 0 0.00058248296
of O 0 0.000717407
the O 0 0.000774861
brain B-Disease 0 0.09772873
damage I-Disease 0 0.798583
following O 0 0.0014903777
ischemic B-Disease 0 0.9998684
stroke I-Disease 0 0.99965835
. O 0 0.005171883

Intracerebral B-Disease 0 0.9858614
hemorrhage I-Disease 2 0.99985266
is O 0 0.0021003364
associated O 0 0.0015337317
with O 0 0.0014149358
more O 0 0.0023785424
inflammation B-Disease 0 0.84356683
than O 0 0.0031806554
ischemic B-Disease 0 0.9998211
stroke I-Disease 0 0.9995944
. O 0 0.007064414

We O 0 0.0026624543
tested O 0 0.0018465398
the O 0 0.0016195002
sulfated O 0 0.20071343
polysaccharide O 0 0.4152994
fucoidan B-Chemical 0 0.9998566
, O 0 0.0031623605
which O 0 0.00057775795
has O 0 0.00019972074
been O 0 0.00021249351
reported O 0 0.00021336692
to O 0 0.00014094115
reduce O 0 0.0001530166
inflammatory O 0 0.13950482
brain B-Disease 0 0.21397182
damage I-Disease 0 0.79423463
, O 0 0.00041504484
in O 0 0.00012635802
a O 0 0.00018047229
rat O 0 0.00016154225
model O 0 9.532915e-05
of O 0 0.0002123651
intracerebral B-Disease 0 0.9856699
hemorrhage I-Disease 2 0.9999316
induced O 0 0.0001368615
by O 0 0.00011626074
injection O 0 0.00011838598
of O 0 0.00020520929
bacterial O 0 0.000868868
collagenase O 0 0.8526915
into O 0 0.00030322073
the O 0 0.00053956266
caudate O 0 0.028202109
nucleus O 0 0.0011931083
. O 0 0.0021760187

Rats O 0 0.0058997436
were O 0 0.0015575502
treated O 0 0.0014286496
with O 0 0.000612822
seven O 0 0.0003317625
day O 0 0.00026885298
intravenous O 0 0.0012154406
infusion O 0 0.0007489117
of O 0 0.00050664996
fucoidan B-Chemical 0 0.9984738
( O 0 0.00094220927
30 O 0 0.00033876326
micrograms O 0 0.0018464449
h O 0 0.0005435534
- O 0 0.0017512392
1 O 0 0.0006572542
) O 0 0.0012851628
or O 0 0.0009784928
vehicle O 0 0.004418204
. O 0 0.0039644255

The O 0 0.004422229
hematoma B-Disease 0 0.96163595
was O 0 0.0021706626
assessed O 0 0.0013405194
in O 0 0.0010581445
vivo O 0 0.0010363819
by O 0 0.0011729376
magnetic O 0 0.0029257215
resonance O 0 0.0050970656
imaging O 0 0.003421751
. O 0 0.0043805484

Motor O 0 0.028206801
behavior O 0 0.0031549614
, O 0 0.0023320718
passive O 0 0.0013214286
avoidance O 0 0.00200903
, O 0 0.0011947914
and O 0 0.0005876153
skilled O 0 0.0010790804
forelimb O 0 0.0044612037
function O 0 0.00038400773
were O 0 0.00034935845
tested O 0 0.00033938183
repeatedly O 0 0.0004065138
for O 0 0.000400723
six O 0 0.00046399006
weeks O 0 0.00075892825
. O 0 0.0025473079

Fucoidan B-Chemical 0 0.9982134
- O 0 0.030601734
treated O 0 0.0024672975
rats O 0 0.0012196708
exhibited O 0 0.0004699048
evidence O 0 0.0003093828
of O 0 0.0004719039
impaired B-Disease 0 0.012984031
blood I-Disease 0 0.13384208
clotting I-Disease 0 0.9415201
and O 0 0.0003659933
hemodilution B-Disease 0 0.9982718
, O 0 0.00043329864
had O 0 0.0001742894
larger O 0 0.0004236906
hematomas B-Disease 0 0.9994173
, O 0 0.00040129776
and O 0 0.00014644986
tended O 0 0.00014984411
to O 0 9.419996e-05
have O 0 0.00010532496
less O 0 0.00023783791
inflammation B-Disease 0 0.29867518
in O 0 0.00014642067
the O 0 0.000117364805
vicinity O 0 0.00013575566
of O 0 0.00022788963
the O 0 0.00029274923
hematoma B-Disease 0 0.9583852
after O 0 0.00024146037
three O 0 0.00028171507
days O 0 0.00059440994
. O 0 0.0019610838

They O 0 0.003775189
showed O 0 0.0014116148
significantly O 0 0.0011260246
more O 0 0.000852907
rapid O 0 0.0005493114
improvement O 0 0.000392256
of O 0 0.0002882998
motor O 0 0.0006591144
function O 0 0.00014125247
in O 0 0.00012516086
the O 0 8.739126e-05
first O 0 6.354782e-05
week O 0 7.036551e-05
following O 0 0.00010090087
hemorrhage B-Disease 2 0.99890053
and O 0 0.00016000665
better O 0 0.0002104169
memory O 0 0.023194276
retention O 0 0.00052603794
in O 0 0.00024827768
the O 0 0.00026325235
passive O 0 0.00061480905
avoidance O 0 0.0017850446
test O 0 0.001991505
. O 0 0.0027795422

Acute O 0 0.09882062
white B-Disease 0 0.011353197
matter I-Disease 0 0.008354966
edema I-Disease 0 0.999813
and O 0 0.0015748686
eventual O 0 0.0028767185
neuronal B-Disease 0 0.0121391155
loss I-Disease 0 0.0013085371
in O 0 0.00030813203
the O 0 0.00026043065
striatum O 0 0.0017636517
adjacent O 0 0.00021198981
to O 0 0.00015246856
the O 0 0.00021891312
hematoma B-Disease 0 0.99306184
did O 0 0.00033865933
not O 0 0.00023223733
differ O 0 0.00025762248
between O 0 0.00025511294
the O 0 0.0003913258
two O 0 0.0005136298
groups O 0 0.0016179527
. O 0 0.0028653953

Investigation O 0 0.005888603
of O 0 0.0021853184
more O 0 0.001735061
specific O 0 0.00066426175
anti O 0 0.0017458525
- O 0 0.0060518803
inflammatory O 0 0.0044807675
agents O 0 0.0008872366
and O 0 0.00043767304
hemodiluting O 0 0.0026953442
agents O 0 0.0008467867
are O 0 0.00033153736
warranted O 0 0.00047973671
in O 0 0.00094707886
intracerebral B-Disease 0 0.9668433
hemorrhage I-Disease 2 0.9995977
. O 0 0.0040727346

Recurarization O 0 0.025232777
in O 0 0.007572717
the O 0 0.006031484
recovery O 0 0.008689695
room O 0 0.010596727
. O 0 0.011992974

A O 0 0.030207476
case O 0 0.0039090803
of O 0 0.0028945121
recurarization O 0 0.052589864
in O 0 0.0012857609
the O 0 0.0009781162
recovery O 0 0.0015382605
room O 0 0.0017262849
is O 0 0.0014027568
reported O 0 0.0025548085
. O 0 0.0043837223

Accumulation O 0 0.0053324755
of O 0 0.0030805783
atracurium B-Chemical 0 0.99912447
in O 0 0.00083844224
the O 0 0.00047357052
intravenous O 0 0.0017876107
line O 0 0.0003346226
led O 0 0.00030997358
to O 0 0.00026781176
recurarization O 0 0.01054278
after O 0 0.00017667554
flushing O 0 0.0072533013
the O 0 0.0002324223
line O 0 0.00033987855
in O 0 0.00038982846
the O 0 0.000503237
recovery O 0 0.0012430797
room O 0 0.0020118665
. O 0 0.002651073

A O 0 0.36272076
respiratory B-Disease 0 0.6647748
arrest I-Disease 0 0.3953781
with O 0 0.0050228178
severe O 0 0.3133226
desaturation B-Disease 0 0.9996331
and O 0 0.0043672957
bradycardia B-Disease 0 0.99597174
occurred O 0 0.0034733221
. O 0 0.0045914673

Circumstances O 0 0.014275766
leading O 0 0.0024280883
to O 0 0.0010512938
this O 0 0.00079651206
event O 0 0.0007953612
and O 0 0.00036458712
the O 0 0.00019772969
mechanisms O 0 0.00016080274
enabling O 0 0.0002788781
a O 0 0.0005515497
neuromuscular B-Disease 0 0.7601456
blockade I-Disease 0 0.013674124
to O 0 0.00015585033
occur O 0 0.00013753708
, O 0 0.00018105864
following O 0 6.0963896e-05
the O 0 8.3242354e-05
administration O 0 0.00019604464
of O 0 0.00015923558
a O 0 0.00026506497
small O 0 0.00036424436
dose O 0 0.0005919292
of O 0 0.0005262588
relaxant O 0 0.27702263
, O 0 0.0011370591
are O 0 0.00066916866
discussed O 0 0.0012035994
. O 0 0.0026501338

The O 0 0.0017074944
haemodynamic O 0 0.0052030357
effects O 0 0.00089204375
of O 0 0.0011200204
propofol B-Chemical 0 0.9996468
in O 0 0.00044854067
combination O 0 0.0004499442
with O 0 0.00061446545
ephedrine B-Chemical 0 0.9999701
in O 0 0.00045503755
elderly O 0 0.15805149
patients O 0 0.0009491054
( O 0 0.0008354134
ASA O 0 0.9413512
groups O 0 0.00052095007
3 O 0 0.00040232184
and O 0 0.0005899671
4 O 0 0.0008401593
) O 0 0.002736165
. O 0 0.0029469682

The O 0 0.0022850772
marked O 0 0.0034077794
vasodilator O 0 0.94396496
and O 0 0.0010280836
negative O 0 0.0007564473
inotropic O 0 0.3013821
effects O 0 0.00041845706
of O 0 0.00061059056
propofol B-Chemical 0 0.9996252
are O 0 0.00023611261
disadvantages O 0 0.0001460311
in O 0 0.0004902602
frail O 0 0.041429482
elderly O 0 0.18633893
patients O 0 0.003992824
. O 0 0.0032287382

We O 0 0.0019740015
investigated O 0 0.0011255613
the O 0 0.00064473273
safety O 0 0.0005172084
and O 0 0.00035552352
efficacy O 0 0.00027511176
of O 0 0.00024345165
adding O 0 0.00019423221
different O 0 0.00013801633
doses O 0 0.00048525937
of O 0 0.00042354688
ephedrine B-Chemical 0 0.9999676
to O 0 0.00035678744
propofol B-Chemical 0 0.9998282
in O 0 0.00020026766
order O 0 0.00013488469
to O 0 0.00023202374
obtund O 0 0.0022511843
the O 0 0.0005796336
hypotensive B-Disease 0 0.986134
response O 0 0.00152523
. O 0 0.0025741349

The O 0 0.0020077273
haemodynamic O 0 0.0065283477
effects O 0 0.0009972835
of O 0 0.00085390283
adding O 0 0.0006232547
15 O 0 0.00046361823
, O 0 0.0005425818
20 O 0 0.00025738162
or O 0 0.00018240034
25 O 0 0.00030361357
mg O 0 0.0023228598
of O 0 0.00031090944
ephedrine B-Chemical 0 0.9999292
to O 0 0.00015658812
200 O 0 0.00031211047
mg O 0 0.0021396647
of O 0 0.00018042409
propofol B-Chemical 0 0.9997236
were O 0 9.3059454e-05
compared O 0 5.600635e-05
to O 0 6.585221e-05
control O 0 0.00010294277
in O 0 0.00012283413
40 O 0 0.0002145301
ASA O 0 0.9229757
3 O 0 0.00012739483
/ O 0 0.00039421994
4 O 0 8.9698406e-05
patients O 0 0.00015078751
over O 0 7.885871e-05
60 O 0 0.00013580448
years O 0 0.00018817185
presenting O 0 0.0003724358
for O 0 0.00025100412
genito O 0 0.0036542453
- O 0 0.0049898494
urinary O 0 0.030495392
surgery O 0 0.0021632893
. O 0 0.002496766

The O 0 0.0016752618
addition O 0 0.0010246846
of O 0 0.0021790306
ephedrine B-Chemical 0 0.9999256
to O 0 0.0012474925
propofol B-Chemical 0 0.9998789
appears O 0 0.00023426577
to O 0 0.00016367073
be O 0 0.00013546858
an O 0 0.00012576372
effective O 0 9.727019e-05
method O 0 0.00012959463
of O 0 0.00017999315
obtunding O 0 0.035228014
the O 0 0.00016734624
hypotensive B-Disease 0 0.9805054
response O 0 0.0001426319
to O 0 0.00015634763
propofol B-Chemical 0 0.99959654
at O 0 0.00012388008
all O 0 0.00014659125
doses O 0 0.0003732549
used O 0 0.00025314698
in O 0 0.00041690242
this O 0 0.00082888914
study O 0 0.0015968008
. O 0 0.0025385404

However O 0 0.0031518675
, O 0 0.0042214813
marked O 0 0.0029854875
tachycardia B-Disease 2 0.99651635
associated O 0 0.00078107015
with O 0 0.00040311264
the O 0 0.00022390342
use O 0 0.00020821395
of O 0 0.0003891562
ephedrine B-Chemical 0 0.9999534
in O 0 0.00018550004
combination O 0 0.00019303804
with O 0 0.00024488967
propofol B-Chemical 0 0.9999124
occurred O 0 0.0001414649
in O 0 8.15135e-05
the O 0 6.650912e-05
majority O 0 7.584985e-05
of O 0 0.00013152527
patients O 0 0.00038233656
, O 0 0.00030390578
occasionally O 0 0.00031637325
reaching O 0 0.0002988529
high O 0 0.00030922063
levels O 0 0.00028866093
in O 0 0.00041875578
individual O 0 0.000612851
patients O 0 0.0022200549
. O 0 0.0023142013

Due O 0 0.0026490907
to O 0 0.0016998498
the O 0 0.001243881
risk O 0 0.0037320873
of O 0 0.0009233204
this O 0 0.0009795505
tachycardia B-Disease 2 0.99913496
inducing O 0 0.0014185888
myocardial B-Disease 0 0.9998022
ischemia I-Disease 0 0.99994457
, O 0 0.00055344735
we O 0 7.8135396e-05
would O 0 9.599178e-05
not O 0 9.232097e-05
recommend O 0 9.778373e-05
the O 0 7.955147e-05
use O 0 9.5641095e-05
in O 0 0.00013838228
elderly O 0 0.040061805
patients O 0 0.00035449665
of O 0 0.00015129968
any O 0 0.00013298549
of O 0 0.00022968557
the O 0 0.00036763214
ephedrine B-Chemical 0 0.99996877
/ O 0 0.07489371
propofol B-Chemical 0 0.9998671
/ O 0 0.0060284026
mixtures O 0 0.0016392595
studied O 0 0.0020885684
. O 0 0.0027340683

Gemcitabine B-Chemical 0 0.998428
plus O 0 0.005174668
vinorelbine B-Chemical 0 0.9992285
in O 0 0.0021332675
nonsmall B-Disease 0 0.9944833
cell I-Disease 0 0.0019705945
lung I-Disease 0 0.1500153
carcinoma I-Disease 0 0.99787927
patients O 0 0.00094320567
age O 0 0.00034657298
70 O 0 0.00021959987
years O 0 0.0002133356
or O 0 0.00017423171
older O 0 0.00071266905
or O 0 0.00027947463
patients O 0 0.00076062756
who O 0 0.0007540006
cannot O 0 0.0024743383
receive O 0 0.0016888985
cisplatin B-Chemical 0 0.9992206
. O 0 0.0043172576

Oncopaz O 0 0.065705776
Cooperative O 0 0.04498631
Group O 0 0.05160412
. O 0 0.03179915

BACKGROUND O 0 0.015318312
: O 0 0.0037732671
Although O 0 0.0007694294
the O 0 0.0007760963
prevalence O 0 0.0011193063
of O 0 0.0012878327
nonsmall B-Disease 0 0.9955746
cell I-Disease 0 0.0020155753
lung I-Disease 0 0.33666676
carcinoma I-Disease 0 0.9995365
( O 0 0.0039693257
NSCLC B-Disease 0 0.99949884
) O 0 0.0005954135
is O 0 0.00010045579
high O 0 0.0001461735
among O 0 0.0001917742
elderly O 0 0.063529074
patients O 0 0.00036585444
, O 0 0.00017542145
few O 0 5.786326e-05
data O 0 9.5212956e-05
are O 0 5.450626e-05
available O 0 4.5330515e-05
regarding O 0 3.8952094e-05
the O 0 5.8682635e-05
efficacy O 0 0.00010299501
and O 0 0.0001605403
toxicity B-Disease 0 0.18392992
of O 0 0.00028032428
chemotherapy O 0 0.0023077903
in O 0 0.00019683618
this O 0 0.00031769773
group O 0 0.00063759333
of O 0 0.000934902
patients O 0 0.0030204165
. O 0 0.0025679253

Recent O 0 0.003098564
reports O 0 0.0017139504
indicate O 0 0.0005834486
that O 0 0.0005081102
single O 0 0.00038509138
agent O 0 0.0007692992
therapy O 0 0.0005169189
with O 0 0.00045982396
vinorelbine B-Chemical 0 0.9994474
( O 0 0.0015207625
VNB B-Chemical 0 0.99103886
) O 0 0.00058464997
or O 0 0.00023671694
gemcitabine B-Chemical 0 0.99931145
( O 0 0.0012132289
GEM B-Chemical 0 0.99817896
) O 0 0.0005114358
may O 0 8.9480636e-05
obtain O 0 6.227802e-05
a O 0 0.00015355712
response O 0 0.000113606315
rate O 0 0.0001797599
of O 0 0.00015040496
20 O 0 0.00016811104
- O 0 0.0006218635
30 O 0 9.709244e-05
% O 0 0.00018432947
in O 0 0.000113859984
elderly O 0 0.016642207
patients O 0 0.00032703634
, O 0 0.00018728957
with O 0 0.00011030656
acceptable O 0 0.00014292571
toxicity B-Disease 0 0.04230271
and O 0 0.00014680876
improvement O 0 0.00019800874
in O 0 0.00017835053
symptoms O 0 0.0011071765
and O 0 0.00028121166
quality O 0 0.00032796178
of O 0 0.00080310844
life O 0 0.0015715582
. O 0 0.0026909946

In O 0 0.0017085415
the O 0 0.0012410725
current O 0 0.0010356205
study O 0 0.0006681481
the O 0 0.00032866947
efficacy O 0 0.00034606847
and O 0 0.00038957325
toxicity B-Disease 0 0.10023448
of O 0 0.0002476011
the O 0 0.00014690454
combination O 0 0.00022238983
of O 0 0.00032288625
GEM B-Chemical 0 0.99891686
and O 0 0.0004304231
VNB B-Chemical 0 0.9957497
in O 0 0.00016470492
elderly O 0 0.040736306
patients O 0 0.0003402843
with O 0 0.00017823561
advanced O 0 0.017685141
NSCLC B-Disease 0 0.99957603
or O 0 0.00012367952
those O 0 0.00012346613
with O 0 0.000112136426
some O 0 0.00011566428
contraindication O 0 0.0001250906
to O 0 0.00016073698
receiving O 0 0.0005200454
cisplatin B-Chemical 0 0.9992933
were O 0 0.0007293288
assessed O 0 0.0010784356
. O 0 0.0021645504

METHODS O 0 0.0045140954
: O 0 0.003472271
Forty O 0 0.002705982
- O 0 0.002903228
nine O 0 0.00065065647
patients O 0 0.0009718368
with O 0 0.00067327806
advanced O 0 0.009945448
NSCLC B-Disease 0 0.99825567
were O 0 0.00030238475
included O 0 0.00021392832
, O 0 0.00035040922
38 O 0 0.00025984336
of O 0 0.00019045381
whom O 0 0.00027492686
were O 0 0.00013627704
age O 0 0.00023996469
> O 0 0.00040445488
/ O 0 0.00077461964
= O 0 0.0004939839
70 O 0 0.00017798512
years O 0 0.00015763093
and O 0 0.00012559391
11 O 0 0.00013004312
were O 0 9.287311e-05
age O 0 0.0001626714
< O 0 0.0001922209
70 O 0 0.00015787958
years O 0 0.00018826229
but O 0 0.00019655489
who O 0 0.00025172957
had O 0 0.00017948193
some O 0 0.00021518112
contraindication O 0 0.00027171025
to O 0 0.00041034198
receiving O 0 0.0013936529
cisplatin B-Chemical 0 0.9992286
. O 0 0.0035676581

All O 0 0.0035928786
patients O 0 0.0043306863
were O 0 0.0020972907
evaluable O 0 0.0026496095
for O 0 0.0012187428
response O 0 0.0018515685
and O 0 0.0033016675
toxicity B-Disease 0 0.45049855
. O 0 0.007821009

Treatment O 0 0.007899986
was O 0 0.0022363279
comprised O 0 0.0020408789
of O 0 0.002074959
VNB B-Chemical 0 0.9834051
, O 0 0.0015427102
25 O 0 0.00096572685
mg O 0 0.00539348
/ O 0 0.0019109552
m O 0 0.0020616278
( O 0 0.00067404495
2 O 0 0.00034501136
) O 0 0.0005556862
, O 0 0.00045969902
plus O 0 0.00040661148
GEM B-Chemical 0 0.9844738
, O 0 0.00064038654
1000 O 0 0.00076056225
mg O 0 0.0038977065
/ O 0 0.0011560903
m O 0 0.001488043
( O 0 0.00047029735
2 O 0 0.00025451696
) O 0 0.0004388558
, O 0 0.00031795012
both O 0 0.00016726299
on O 0 0.00017667656
Days O 0 0.0010697622
1 O 0 0.0003561071
, O 0 0.0004786507
8 O 0 0.00030304387
, O 0 0.00054188975
and O 0 0.00041626248
15 O 0 0.00042399063
every O 0 0.00033072795
28 O 0 0.00073963846
days O 0 0.00084976974
. O 0 0.0026868072

Patients O 0 0.00430653
received O 0 0.0017768982
a O 0 0.0015314987
minimum O 0 0.000702561
of O 0 0.0007044724
three O 0 0.00039280835
courses O 0 0.0011273813
unless O 0 0.0009941639
progressive O 0 0.0075077843
disease O 0 0.14912187
was O 0 0.0015916722
detected O 0 0.0017075608
. O 0 0.003917791

RESULTS O 0 0.0048489263
: O 0 0.0032776196
One O 0 0.0014332796
hundred O 0 0.0013003981
sixty O 0 0.0015560198
- O 0 0.0018108194
five O 0 0.00032954017
courses O 0 0.0006541708
were O 0 0.00039875042
administered O 0 0.00060499937
, O 0 0.0007650392
with O 0 0.0005586378
a O 0 0.0008409507
median O 0 0.0005667339
of O 0 0.0012339366
3 O 0 0.0017936358
. O 0 0.003353743

6 O 0 0.010846774
courses O 0 0.014271956
per O 0 0.010295299
patient O 0 0.012453371
. O 0 0.016644742

The O 0 0.0023918913
overall O 0 0.001938513
response O 0 0.0015541693
rate O 0 0.0017521856
was O 0 0.0010007671
26 O 0 0.0011445464
% O 0 0.0013687413
( O 0 0.0011201147
95 O 0 0.0010835727
% O 0 0.00089915295
confidence O 0 0.0011220045
interval O 0 0.0007099904
, O 0 0.0011075098
15 O 0 0.0008540721
- O 0 0.0027888492
41 O 0 0.0022276898
% O 0 0.0031829572
) O 0 0.0052839047
. O 0 0.005098159

Two O 0 0.002859464
patients O 0 0.0034297195
attained O 0 0.0020437876
a O 0 0.001299688
complete O 0 0.0005828944
response O 0 0.00056274375
( O 0 0.0008323304
4 O 0 0.0003668049
% O 0 0.0006916809
) O 0 0.0007016219
and O 0 0.00035179895
11 O 0 0.0003944713
patients O 0 0.0005898609
( O 0 0.00062392716
22 O 0 0.0005664957
% O 0 0.0007780604
) O 0 0.00096185604
achieved O 0 0.0007208036
a O 0 0.0012077441
partial O 0 0.0016161951
response O 0 0.0019385978
. O 0 0.0036159393

Eastern O 0 0.009253249
Cooperative O 0 0.004621832
Oncology O 0 0.0017690497
Group O 0 0.0023364294
performance O 0 0.00072639156
status O 0 0.00048694416
improved O 0 0.00057155616
in O 0 0.00032299833
35 O 0 0.000333179
% O 0 0.00044208948
of O 0 0.00023052344
those O 0 0.00024775104
patients O 0 0.0003398393
with O 0 0.00015524607
an O 0 0.00013763049
initial O 0 9.232969e-05
value O 0 0.00013745711
> O 0 0.0003111695
0 O 0 0.00018983177
, O 0 0.00020311803
whereas O 0 0.00010774315
relief O 0 0.00014920495
of O 0 0.00010470651
at O 0 7.501901e-05
least O 0 9.435656e-05
1 O 0 0.00012253394
symptom O 0 0.00028770012
without O 0 0.00010419842
worsening O 0 0.0012802775
of O 0 0.00013708093
other O 0 0.00014933817
symptoms O 0 0.002185983
was O 0 0.0001612883
noted O 0 0.00020210052
in O 0 0.00023348154
27 O 0 0.00045097322
patients O 0 0.0007035774
( O 0 0.00084624067
55 O 0 0.00095972413
% O 0 0.0018011353
) O 0 0.0033846337
. O 0 0.0033019702

The O 0 0.0015825477
median O 0 0.0009518901
time O 0 0.0007290832
to O 0 0.00071227254
progression O 0 0.0016034327
was O 0 0.00041144015
16 O 0 0.000337009
weeks O 0 0.0001587989
and O 0 0.0002655104
the O 0 0.00026308576
1 O 0 0.0004287239
- O 0 0.0011671387
year O 0 0.00035304323
survival O 0 0.0007385263
rate O 0 0.0008882161
was O 0 0.00093173364
33 O 0 0.0021208148
% O 0 0.0035109576
. O 0 0.0038759396

Toxicity B-Disease 0 0.26386106
was O 0 0.022982122
mild O 0 0.15685907
. O 0 0.027478565

Six O 0 0.0038710195
patients O 0 0.0040863147
( O 0 0.0025991325
12 O 0 0.0009420126
% O 0 0.001595511
) O 0 0.0014262327
had O 0 0.0005897288
World O 0 0.00073567376
Health O 0 0.00037616008
Organization O 0 0.00024815628
Grade O 0 0.0018097871
3 O 0 0.00030282323
- O 0 0.0010921308
4 O 0 0.00028466553
neutropenia B-Disease 0 0.8180059
, O 0 0.00046455985
2 O 0 0.00024995214
patients O 0 0.00036511788
( O 0 0.00031019057
4 O 0 0.00015239949
% O 0 0.0003431776
) O 0 0.00041850534
had O 0 0.00021196801
Grade O 0 0.002246918
3 O 0 0.0002068561
- O 0 0.0009675685
4 O 0 0.00022887891
thrombocytopenia B-Disease 0 0.9968272
, O 0 0.00039308792
and O 0 0.00021681552
2 O 0 0.00024730855
patients O 0 0.00040718884
( O 0 0.00039760594
4 O 0 0.00023583678
% O 0 0.0005892647
) O 0 0.0008872763
had O 0 0.00065653113
Grade O 0 0.008179387
3 O 0 0.0014180649
neurotoxicity B-Disease 0 0.96897775
. O 0 0.0040820544

Three O 0 0.003674872
patients O 0 0.004407142
with O 0 0.0026848095
severe O 0 0.020683268
neutropenia B-Disease 0 0.9921629
( O 0 0.0021766683
6 O 0 0.0008099612
% O 0 0.0017577407
) O 0 0.0024474463
died O 0 0.00286161
of O 0 0.002897147
sepsis B-Disease 2 0.99481344
. O 0 0.006585029

The O 0 0.0014524638
median O 0 0.00094758923
age O 0 0.0012799723
of O 0 0.0007868865
those O 0 0.00073104823
patients O 0 0.00097424426
developing O 0 0.0008237075
Grade O 0 0.00536954
3 O 0 0.00029219736
- O 0 0.0010893724
4 O 0 0.00020246023
neutropenia B-Disease 0 0.75506663
was O 0 0.0001292397
significantly O 0 0.00014440945
higher O 0 0.00013972106
than O 0 9.900836e-05
that O 0 7.836656e-05
of O 0 0.0001288779
the O 0 0.00010670985
remaining O 0 0.00014248538
patients O 0 0.0003563304
( O 0 0.00026889553
75 O 0 0.0002164716
years O 0 0.00016618703
vs O 0 0.00022210905
. O 0 0.00017668314
72 O 0 0.00024732933
years O 0 0.00031270465
; O 0 0.0006375806
P O 0 0.0056184595
= O 0 0.0013597393
0 O 0 0.00090943364
. O 0 0.0010853519
047 O 0 0.016986378
) O 0 0.0042615174
. O 0 0.003932487

CONCLUSIONS O 0 0.016535977
: O 0 0.003491478
The O 0 0.00072549673
combination O 0 0.0009265662
of O 0 0.0011358622
GEM B-Chemical 0 0.99686074
and O 0 0.0011905949
VNB B-Chemical 0 0.99575543
is O 0 0.00029205953
moderately O 0 0.0010638138
active O 0 0.0002559923
and O 0 0.00019613738
well O 0 0.00017786685
tolerated O 0 0.0003838357
except O 0 0.0001540734
in O 0 0.00020843226
patients O 0 0.0004976485
age O 0 0.0005533205
> O 0 0.0010845895
/ O 0 0.0023396448
= O 0 0.0021795325
75 O 0 0.0017612919
years O 0 0.0019454281
. O 0 0.0029845324

This O 0 0.006213641
age O 0 0.0042928634
group O 0 0.0031514151
had O 0 0.0020395906
an O 0 0.0020430963
increased O 0 0.0025873182
risk O 0 0.010138476
of O 0 0.0050259265
myelosuppression B-Disease 0 0.99856746
. O 0 0.0077161347

Therefore O 0 0.0017728943
the O 0 0.0014874296
prophylactic O 0 0.001624154
use O 0 0.0008757438
of O 0 0.0014994679
granulocyte O 0 0.9994417
- O 0 0.2252562
colony O 0 0.13037163
stimulating O 0 0.0023070048
factor O 0 0.0072652767
should O 0 0.00025184097
be O 0 0.0003486955
considered O 0 0.00040126813
with O 0 0.0005946718
this O 0 0.0009975391
treatment O 0 0.0015532848
. O 0 0.0028959077

New O 0 0.0043058433
chemotherapy O 0 0.0038555206
combinations O 0 0.000634217
with O 0 0.0006057064
higher O 0 0.000495204
activity O 0 0.0002786421
and O 0 0.00035738776
lower O 0 0.0004874869
toxicity B-Disease 0 0.13608953
are O 0 0.00021286402
needed O 0 0.00018696644
for O 0 0.00026780917
elderly O 0 0.028550912
patients O 0 0.0012177802
with O 0 0.001051393
advanced O 0 0.054165326
NSCLC B-Disease 0 0.99857926
. O 0 0.0043270006

A O 0 0.32525143
selective O 0 0.06316158
dopamine B-Chemical 0 0.99990284
D4 O 0 0.9995697
receptor O 0 0.1116117
antagonist O 0 0.8506218
, O 0 0.007725421
NRA0160 B-Chemical 1 0.99816954
: O 0 0.0027971484
a O 0 0.0013674416
preclinical O 0 0.00236975
neuropharmacological O 0 0.14511164
profile O 0 0.002342116
. O 0 0.0038205178

NRA0160 B-Chemical 1 0.992336
, O 0 0.008353613
5 B-Chemical 0 0.002959529
- I-Chemical 0 0.007064845
[ I-Chemical 0 0.0039691976
2 I-Chemical 0 0.0012244777
- I-Chemical 0 0.0027125503
( I-Chemical 0 0.0010002733
4 I-Chemical 0 0.00047484363
- I-Chemical 0 0.0015019594
( I-Chemical 0 0.00061973534
3 I-Chemical 0 0.00032041644
- I-Chemical 0 0.0010577132
fluorobenzylidene I-Chemical 0 0.00063289376
) I-Chemical 0 0.0013060581
piperidin I-Chemical 0 0.105136134
- I-Chemical 0 0.0066848164
1 I-Chemical 0 0.0006638026
- I-Chemical 0 0.00911408
yl I-Chemical 0 0.9751986
) I-Chemical 0 0.00561172
ethyl I-Chemical 0 0.9991503
] I-Chemical 0 0.016068047
- I-Chemical 0 0.0026182136
4 I-Chemical 0 0.00020979466
- I-Chemical 0 0.0009611854
( I-Chemical 0 0.00034427538
4 I-Chemical 0 0.00019888309
- I-Chemical 0 0.0022470893
fluorophenyl I-Chemical 0 0.36895195
) I-Chemical 0 0.0019998595
thiazole I-Chemical 0 0.5475239
- I-Chemical 0 0.009585009
2 I-Chemical 0 0.00032279387
- I-Chemical 0 0.0044194963
carboxamide I-Chemical 0 0.32345778
, O 0 0.00042786732
has O 0 8.8838824e-05
a O 0 0.00016653824
high O 0 0.00015260237
affinity O 0 0.0001827987
for O 0 0.00010577477
human O 0 0.00020796
cloned O 0 0.0005567513
dopamine B-Chemical 0 0.99996984
D4 O 0 0.9993979
. O 0 0.0002300849
2 O 0 0.00020911363
, O 0 0.00059362664
D4 O 0 0.9811694
. O 0 0.00018632505
4 O 0 0.00013237682
and O 0 0.0002518484
D4 O 0 0.97063005
. O 0 0.00018510126
7 O 0 0.00012057902
receptors O 0 0.0002961146
, O 0 0.00030300635
with O 0 0.00022352164
Ki O 0 0.004224968
values O 0 0.00017999863
of O 0 0.00019170111
0 O 0 0.00025474204
. O 0 0.00016491095
5 O 0 0.00015436235
, O 0 0.000287634
0 O 0 0.00025241548
. O 0 0.00018305684
9 O 0 0.00017545425
and O 0 0.0002435654
2 O 0 0.0003352635
. O 0 0.0003488162
7 O 0 0.0004381623
nM O 0 0.0023396693
, O 0 0.0022994145
respectively O 0 0.0035147616
. O 0 0.0040439926

NRA0160 B-Chemical 1 0.99160343
is O 0 0.0020491672
over O 0 0.0010339819
20 O 0 0.0008812252
, O 0 0.0009402502
000fold O 0 0.0008726082
more O 0 0.0006614481
potent O 0 0.00057356467
at O 0 0.00033061855
the O 0 0.00064478867
dopamine B-Chemical 0 0.9999219
D4 O 0 0.9990189
. O 0 0.00033106992
2 O 0 0.00023727212
receptor O 0 0.00037061865
compared O 0 0.00014540058
with O 0 0.00024614978
the O 0 0.00027136874
human O 0 0.00058329845
cloned O 0 0.0018465117
dopamine B-Chemical 0 0.9999306
D2L O 0 0.99969757
receptor O 0 0.027917404
. O 0 0.004370336

NRA0160 B-Chemical 1 0.9952951
has O 0 0.0018238081
negligible O 0 0.001598357
affinity O 0 0.0010476679
for O 0 0.00046020283
the O 0 0.00040329873
human O 0 0.00055286137
cloned O 0 0.0012924334
dopamine B-Chemical 0 0.9999584
D3 O 0 0.9999387
receptor O 0 0.007746874
( O 0 0.0009655517
Ki O 0 0.0071421596
= O 0 0.00075906777
39 O 0 0.00033275908
nM O 0 0.0016603683
) O 0 0.0008304933
, O 0 0.0006029546
rat O 0 0.0009398427
serotonin B-Chemical 0 0.99949217
( O 0 0.00067632034
5 B-Chemical 0 0.00026714944
- I-Chemical 0 0.0035184699
HT I-Chemical 0 0.98911244
) O 0 0.00079022325
2A O 0 0.0002821968
receptors O 0 0.0004601431
( O 0 0.00047268815
Ki O 0 0.0031008006
= O 0 0.00064027606
180 O 0 0.0003017172
nM O 0 0.0012172891
) O 0 0.0006575114
and O 0 0.00032005925
rat O 0 0.00094078435
alpha1 O 0 0.9157683
adrenoceptor O 0 0.9994179
( O 0 0.0021696454
Ki O 0 0.018578159
= O 0 0.002468975
237 O 0 0.0024273377
nM O 0 0.005330961
) O 0 0.0048066285
. O 0 0.004026832

NRA0160 B-Chemical 1 0.9971861
and O 0 0.015771944
clozapine B-Chemical 0 0.9999919
antagonized O 0 0.97659373
locomotor O 0 0.99905926
hyperactivity B-Disease 2 0.99999833
induced O 0 0.001860775
by O 0 0.001553812
methamphetamine B-Chemical 1 0.99993396
( O 0 0.005223014
MAP B-Chemical 0 0.6340037
) O 0 0.0019317736
in O 0 0.00092635525
mice O 0 0.0008211472
. O 0 0.0030560917

NRA0160 B-Chemical 1 0.997182
and O 0 0.0138705075
clozapine B-Chemical 0 0.99999154
antagonized O 0 0.93459576
MAP B-Chemical 0 0.9966593
- O 0 0.027852569
induced O 0 0.0005393611
stereotyped O 0 0.052872036
behavior O 0 0.00041391817
in O 0 0.00016513708
mice O 0 7.271503e-05
, O 0 0.0002680263
although O 0 0.00013635647
their O 0 0.00012305712
effects O 0 0.00015832054
did O 0 0.00021645363
not O 0 0.00016814983
exceed O 0 0.00025689715
50 O 0 0.00025223315
% O 0 0.00036859754
inhibition O 0 0.0002833164
, O 0 0.0004154589
even O 0 0.00026711557
at O 0 0.00019039572
the O 0 0.00025078646
highest O 0 0.00047484136
dose O 0 0.0011247441
given O 0 0.0008643211
. O 0 0.0023411135

NRA0160 B-Chemical 1 0.9974226
and O 0 0.010888525
clozapine B-Chemical 0 0.9999882
significantly O 0 0.0031107909
induced O 0 0.0019209426
catalepsy B-Disease 0 0.99998355
in O 0 0.0005189123
rats O 0 0.00061953213
, O 0 0.0004289737
although O 0 0.00016240482
their O 0 0.00013442655
effects O 0 0.00016751644
did O 0 0.00022554642
not O 0 0.00017682603
exceed O 0 0.000260529
50 O 0 0.00024429848
% O 0 0.00030276377
induction O 0 0.00013505238
even O 0 0.00022334458
at O 0 0.00017225592
the O 0 0.00023497401
highest O 0 0.00045549622
dose O 0 0.0010918123
given O 0 0.0008515283
. O 0 0.0023221804

NRA0160 B-Chemical 1 0.99740195
and O 0 0.01060536
clozapine B-Chemical 0 0.99998677
significantly O 0 0.002193644
reversed O 0 0.0011849733
the O 0 0.00038465217
disruption O 0 0.0003350724
of O 0 0.00048338136
prepulse O 0 0.72593653
inhibition O 0 0.0007158031
( O 0 0.000937537
PPI O 0 0.003100531
) O 0 0.0008105001
in O 0 0.0003464066
rats O 0 0.00073271315
produced O 0 0.0006671593
by O 0 0.0018005437
apomorphine B-Chemical 0 0.99985516
. O 0 0.0045920257

NRA0160 B-Chemical 1 0.99683243
and O 0 0.008642875
clozapine B-Chemical 0 0.99998236
significantly O 0 0.0020246387
shortened O 0 0.0014674076
the O 0 0.0010311232
phencyclidine B-Chemical 0 0.99999714
( O 0 0.008409767
PCP B-Chemical 0 0.9986395
) O 0 0.0017064469
- O 0 0.0014486442
induced O 0 0.00021219834
prolonged O 0 0.00041820598
swimming O 0 0.008191404
latency O 0 0.0006643991
in O 0 0.00024759216
rats O 0 0.00044388333
in O 0 0.0003486526
a O 0 0.00077212387
water O 0 0.0037101917
maze O 0 0.49826357
task O 0 0.006537691
. O 0 0.003606873

These O 0 0.0019106496
findings O 0 0.0017702348
suggest O 0 0.00081656064
that O 0 0.0010931314
NRA0160 B-Chemical 1 0.9961712
may O 0 0.0004902014
have O 0 0.00027711559
unique O 0 0.00026482882
antipsychotic O 0 0.99018186
activities O 0 0.00016813797
without O 0 0.0001677447
the O 0 0.00015907986
liability O 0 0.0077821896
of O 0 0.00026599533
motor O 0 0.00095899607
side O 0 0.0005357578
effects O 0 0.00028777338
typical O 0 0.00046630637
of O 0 0.00065979164
classical O 0 0.0018089294
antipsychotics O 0 0.9975757
. O 0 0.0029667811

Warfarin B-Chemical 0 0.9987997
- O 0 0.030993814
induced O 0 0.0034836063
artery B-Disease 2 0.99570906
calcification I-Disease 2 0.9997471
is O 0 0.00138708
accelerated O 0 0.002416605
by O 0 0.0013012188
growth O 0 0.008280326
and O 0 0.0041860645
vitamin B-Chemical 0 0.99987745
D I-Chemical 0 0.9983454
. O 0 0.010989923

The O 0 0.0017125623
present O 0 0.0011402469
studies O 0 0.0010669286
demonstrate O 0 0.00040928178
that O 0 0.0005831732
growth O 0 0.005176355
and O 0 0.0020063785
vitamin B-Chemical 0 0.9999801
D I-Chemical 0 0.9993799
treatment O 0 0.00045505687
enhance O 0 0.00013200435
the O 0 0.00011979329
extent O 0 0.00013492766
of O 0 0.00027550728
artery B-Disease 2 0.99802136
calcification I-Disease 2 0.99995494
in O 0 0.00013205192
rats O 0 0.00014046046
given O 0 4.3339696e-05
sufficient O 0 4.8410508e-05
doses O 0 0.0002413232
of O 0 0.00024347763
Warfarin B-Chemical 0 0.99971646
to O 0 0.00013583762
inhibit O 0 0.00017320806
gamma O 0 0.6716767
- O 0 0.29640153
carboxylation O 0 0.66084427
of O 0 0.00040600993
matrix O 0 0.075521275
Gla O 0 0.973333
protein O 0 0.0003425559
, O 0 0.0006041001
a O 0 0.0006523883
calcification B-Disease 0 0.9997873
inhibitor O 0 0.0019510987
known O 0 0.00013624676
to O 0 9.7740005e-05
be O 0 9.7116135e-05
expressed O 0 6.987483e-05
by O 0 0.00015406603
smooth O 0 0.0014027315
muscle O 0 0.0017821656
cells O 0 0.0003167345
and O 0 0.00033852307
macrophages O 0 0.00086087186
in O 0 0.0004289573
the O 0 0.000604571
artery O 0 0.15882547
wall O 0 0.013386946
. O 0 0.0031876082

The O 0 0.0017126325
first O 0 0.0009912688
series O 0 0.0010774169
of O 0 0.0006436334
experiments O 0 0.00034025835
examined O 0 0.00027261247
the O 0 0.00021589178
influence O 0 0.00015930817
of O 0 0.0002688094
age O 0 0.0004227377
and O 0 0.00028189726
growth O 0 0.0008648376
status O 0 0.00026514966
on O 0 0.00026745017
artery B-Disease 2 0.99129313
calcification I-Disease 2 0.99992454
in O 0 0.0012515426
Warfarin B-Chemical 0 0.9997265
- O 0 0.006786274
treated O 0 0.0016352253
rats O 0 0.0023812118
. O 0 0.0027854631

Treatment O 0 0.006015719
for O 0 0.0012869702
2 O 0 0.0010108723
weeks O 0 0.00048072066
with O 0 0.000988629
Warfarin B-Chemical 0 0.99856746
caused O 0 0.0005954047
massive O 0 0.0019108697
focal O 0 0.0067966618
calcification B-Disease 0 0.99742657
of I-Disease 0 0.00025290114
the I-Disease 0 0.00015065588
artery I-Disease 0 0.03511026
media O 0 0.0003931803
in O 0 0.00013190406
20 O 0 0.0001499067
- O 0 0.00053565565
day O 0 9.1937676e-05
- O 0 0.00050716085
old O 0 0.0001455715
rats O 0 0.00020086144
and O 0 0.00015088517
less O 0 0.00022451137
extensive O 0 0.00024345465
focal O 0 0.0018067592
calcification B-Disease 0 0.9948665
in O 0 0.00029945528
42 O 0 0.0004184367
- O 0 0.0011369513
day O 0 0.00030589497
- O 0 0.001745325
old O 0 0.0010897139
rats O 0 0.0022272514
. O 0 0.0029495668

In O 0 0.0022815664
contrast O 0 0.0028351746
, O 0 0.002911785
no O 0 0.0016553608
artery B-Disease 2 0.9972184
calcification I-Disease 2 0.9998888
could O 0 0.00047620278
be O 0 0.00030488148
detected O 0 0.00016547422
in O 0 0.00020220153
10 O 0 0.00022851583
- O 0 0.0007303885
month O 0 0.000118067146
- O 0 0.00058435183
old O 0 0.00019694133
adult O 0 0.00021939121
rats O 0 0.0002639151
even O 0 0.00019822088
after O 0 0.00010838329
4 O 0 0.00017138073
weeks O 0 0.00017852968
of O 0 0.0007469843
Warfarin B-Chemical 0 0.99674976
treatment O 0 0.0017941353
. O 0 0.0028575407

To O 0 0.0012179832
directly O 0 0.00082708395
examine O 0 0.0003988795
the O 0 0.0004591411
importance O 0 0.00035306695
of O 0 0.00058739434
growth O 0 0.0028841235
to O 0 0.0006331001
Warfarin B-Chemical 0 0.99985003
- O 0 0.0065798895
induced O 0 0.0003335979
artery B-Disease 2 0.9977946
calcification I-Disease 2 0.9999442
in O 0 0.00015758135
animals O 0 7.8276484e-05
of O 0 0.00010875215
the O 0 8.289326e-05
same O 0 7.678589e-05
age O 0 0.00019738874
, O 0 0.00023006211
20 O 0 0.0001430427
- O 0 0.0005364193
day O 0 9.123689e-05
- O 0 0.0005117335
old O 0 0.00013127881
rats O 0 0.00016377862
were O 0 8.5675194e-05
fed O 0 0.00017998526
for O 0 7.036162e-05
2 O 0 8.526076e-05
weeks O 0 4.0437477e-05
either O 0 6.6795845e-05
an O 0 9.527935e-05
ad O 0 0.00028603507
libitum O 0 0.017565055
diet O 0 0.0009077537
or O 0 0.00012123446
a O 0 0.00018368225
6 O 0 0.000117895936
- O 0 0.00064303284
g O 0 0.0005428153
/ O 0 0.0006570024
d O 0 0.00027059266
restricted O 0 0.00017400245
diet O 0 0.001009483
that O 0 0.00018152069
maintains O 0 0.00029786048
weight O 0 0.0008241468
but O 0 0.0008330541
prevents O 0 0.001267345
growth O 0 0.013944147
. O 0 0.004290465

Concurrent O 0 0.0050752982
treatment O 0 0.0016056861
of O 0 0.0010375774
both O 0 0.0007220556
dietary O 0 0.004156893
groups O 0 0.0008141548
with O 0 0.0008745852
Warfarin B-Chemical 0 0.9995585
produced O 0 0.00031358955
massive O 0 0.0013692576
focal O 0 0.0055231084
calcification B-Disease 0 0.99781704
of I-Disease 0 0.00019487388
the I-Disease 0 0.000118515185
artery I-Disease 0 0.034835983
media O 0 0.00029458222
in O 0 8.710505e-05
the O 0 7.443753e-05
ad O 0 0.0003162065
libitum O 0 0.06819264
- O 0 0.0009419076
fed O 0 0.00025752353
rats O 0 0.00023723886
but O 0 0.00014267924
no O 0 0.000114237795
detectable O 0 0.00016627295
artery B-Disease 2 0.9953296
calcification I-Disease 2 0.9999409
in O 0 0.00020754621
the O 0 0.00014209058
restricted O 0 0.00020011952
- O 0 0.002148796
diet O 0 0.0035566015
, O 0 0.0011646688
growth O 0 0.008050198
- O 0 0.012114683
inhibited O 0 0.0022704082
group O 0 0.003353147
. O 0 0.0037314955

Although O 0 0.0016665346
the O 0 0.0011141363
explanation O 0 0.000493526
for O 0 0.00045825087
the O 0 0.000352292
association O 0 0.00024920117
between O 0 0.00036877536
artery B-Disease 2 0.99527067
calcification I-Disease 2 0.9999398
and O 0 0.00061851053
growth O 0 0.0024276264
status O 0 0.00028228937
cannot O 0 0.00085628405
be O 0 0.00015140994
determined O 0 0.00010448317
from O 0 9.6692005e-05
the O 0 8.464742e-05
present O 0 8.994277e-05
study O 0 0.00014952711
, O 0 0.00019484862
there O 0 8.423619e-05
was O 0 9.609142e-05
a O 0 0.0001179851
relationship O 0 5.19374e-05
between O 0 8.274549e-05
higher O 0 0.000246362
serum O 0 0.16066895
phosphate B-Chemical 0 0.86163837
and O 0 0.00020309226
susceptibility O 0 0.00027356512
to O 0 0.00016255169
artery B-Disease 2 0.99776304
calcification I-Disease 2 0.99996805
, O 0 0.00036104355
with O 0 0.0001102483
30 O 0 8.0446065e-05
% O 0 0.00014496727
higher O 0 9.2938935e-05
levels O 0 9.4775074e-05
of O 0 0.00021469788
serum O 0 0.18956651
phosphate B-Chemical 0 0.8512172
in O 0 0.00017934524
young O 0 0.0006126086
, O 0 0.00022287552
ad O 0 0.00035108064
libitum O 0 0.07161681
- O 0 0.0007225984
fed O 0 0.00017837246
rats O 0 0.0001364604
compared O 0 5.6920824e-05
with O 0 8.413552e-05
either O 0 7.9781734e-05
of O 0 9.6655865e-05
the O 0 7.5558695e-05
groups O 0 0.00012014702
that O 0 6.960788e-05
was O 0 9.639041e-05
resistant O 0 0.00017912513
to O 0 0.00019063315
Warfarin B-Chemical 0 0.9998708
- O 0 0.0035843123
induced O 0 0.00021450779
artery B-Disease 2 0.9986964
calcification I-Disease 2 0.9999757
, O 0 0.0006171713
ie O 0 0.00029328672
, O 0 0.0002228033
the O 0 9.264402e-05
10 O 0 0.00012585621
- O 0 0.0004934954
month O 0 7.121227e-05
- O 0 0.00039535973
old O 0 0.0001294968
rats O 0 0.00018146807
and O 0 0.00013344559
the O 0 0.00012493182
restricted O 0 0.00019556278
- O 0 0.0020040676
diet O 0 0.0035411064
, O 0 0.0011055209
growth O 0 0.007770809
- O 0 0.011847396
inhibited O 0 0.0017866825
young O 0 0.0071380828
rats O 0 0.0034475436
. O 0 0.0032612977

This O 0 0.0042465967
observation O 0 0.0014440184
suggests O 0 0.0006849555
that O 0 0.00061251316
increased O 0 0.0008911518
susceptibility O 0 0.0009850351
to O 0 0.00067741144
Warfarin B-Chemical 0 0.9997986
- O 0 0.0072309976
induced O 0 0.00046200887
artery B-Disease 2 0.9984585
calcification I-Disease 2 0.9999448
could O 0 0.0002254634
be O 0 0.00019672059
related O 0 0.00014288974
to O 0 0.00025018127
higher O 0 0.00065992615
serum O 0 0.1214993
phosphate B-Chemical 0 0.81837046
levels O 0 0.002203007
. O 0 0.003456375

The O 0 0.0019318083
second O 0 0.0013423502
set O 0 0.00087282696
of O 0 0.0007243364
experiments O 0 0.0004101019
examined O 0 0.00035230373
the O 0 0.000311303
possible O 0 0.00027565414
synergy O 0 0.0008403282
between O 0 0.0007149513
vitamin B-Chemical 0 0.9999597
D I-Chemical 0 0.99941075
and O 0 0.004950952
Warfarin B-Chemical 0 0.9997564
in O 0 0.0017571552
artery B-Disease 2 0.9953713
calcification I-Disease 2 0.999721
. O 0 0.004823554

High O 0 0.005129831
doses O 0 0.005562121
of O 0 0.004416181
vitamin B-Chemical 0 0.99993145
D I-Chemical 0 0.9989071
are O 0 0.00086947094
known O 0 0.00048517293
to O 0 0.00034811144
cause O 0 0.00061641523
calcification B-Disease 0 0.9938956
of I-Disease 0 0.00029065146
the I-Disease 0 0.0001915014
artery I-Disease 0 0.054018524
media O 0 0.0005599044
in O 0 0.00020767626
as O 0 0.00021703786
little O 0 0.00028833363
as O 0 0.00034135784
3 O 0 0.00034249222
to O 0 0.0003789528
4 O 0 0.0005563637
days O 0 0.00068322977
. O 0 0.002148119

High O 0 0.004372785
doses O 0 0.0036543407
of O 0 0.0018088844
the O 0 0.0021407765
vitamin B-Chemical 0 0.99997437
K I-Chemical 0 0.9999857
antagonist O 0 0.99919754
Warfarin B-Chemical 0 0.999959
are O 0 0.00028157007
also O 0 0.0001802049
known O 0 0.00016614806
to O 0 0.0001550508
cause O 0 0.00034454034
calcification B-Disease 0 0.9960156
of I-Disease 0 0.00018018924
the I-Disease 0 0.00011966793
artery I-Disease 0 0.12764019
media O 0 0.00058229425
, O 0 0.00029460865
but O 0 0.00012350759
at O 0 6.74185e-05
treatment O 0 8.4315274e-05
times O 0 5.8436864e-05
of O 0 0.000109761684
2 O 0 0.00011537149
weeks O 0 5.998612e-05
or O 0 0.000104717976
longer O 0 0.000118485004
yet O 0 0.00025531175
not O 0 0.0003051272
at O 0 0.00040644268
1 O 0 0.0008429792
week O 0 0.00078940555
. O 0 0.0021976472

In O 0 0.0019158472
the O 0 0.0014650319
current O 0 0.0013555262
study O 0 0.0010413497
, O 0 0.00090840145
we O 0 0.00023866772
investigated O 0 0.00028943943
the O 0 0.00022601185
synergy O 0 0.0003775474
between O 0 0.00014426137
these O 0 0.00015227037
2 O 0 0.00014854924
treatments O 0 0.00013935953
and O 0 0.00011533354
found O 0 0.000104044724
that O 0 8.973948e-05
concurrent O 0 0.00056062103
Warfarin B-Chemical 0 0.9998356
administration O 0 0.00040609142
dramatically O 0 0.00013427192
increased O 0 0.00015391334
the O 0 7.7361954e-05
extent O 0 9.912172e-05
of O 0 0.00022590326
calcification B-Disease 0 0.9984634
in O 0 0.0001311328
the O 0 0.00010013063
media O 0 0.0004809957
of O 0 0.00056294486
vitamin B-Chemical 0 0.9999901
D I-Chemical 0 0.9998123
- O 0 0.10378972
treated O 0 0.00059434364
rats O 0 0.00038515453
at O 0 0.00018261402
3 O 0 0.00024067776
and O 0 0.00035996767
4 O 0 0.00047856563
days O 0 0.000618139
. O 0 0.0020128875

There O 0 0.0036684482
was O 0 0.0019467451
a O 0 0.0015733443
close O 0 0.0007552595
parallel O 0 0.00067106256
between O 0 0.00032572297
the O 0 0.00028575945
effect O 0 0.00031004834
of O 0 0.00087130384
vitamin B-Chemical 0 0.99997544
D I-Chemical 0 0.9992766
dose O 0 0.0013632986
on O 0 0.00019211847
artery B-Disease 2 0.99375147
calcification I-Disease 2 0.99992645
and O 0 0.00017278956
the O 0 8.303036e-05
effect O 0 0.0001102583
of O 0 0.00044770344
vitamin B-Chemical 0 0.9999908
D I-Chemical 0 0.99965274
dose O 0 0.00088072073
on O 0 7.841561e-05
the O 0 9.981156e-05
elevation O 0 0.003889125
of O 0 0.00025315952
serum O 0 0.3434928
calcium B-Chemical 0 0.999185
, O 0 0.0006333309
which O 0 0.00018070197
suggests O 0 9.6237774e-05
that O 0 0.00024111275
vitamin B-Chemical 0 0.99999046
D I-Chemical 0 0.99973243
may O 0 0.00030511786
induce O 0 0.00022832002
artery B-Disease 2 0.99857605
calcification I-Disease 2 0.9999429
through O 0 0.00026632778
its O 0 0.00033448928
effect O 0 0.0003276274
on O 0 0.0005765298
serum O 0 0.34501386
calcium B-Chemical 0 0.9978744
. O 0 0.0046507465

Because O 0 0.0029466487
Warfarin B-Chemical 0 0.99793315
treatment O 0 0.001316983
had O 0 0.000594037
no O 0 0.000339437
effect O 0 0.00027331174
on O 0 0.0002162521
the O 0 0.00026030405
elevation O 0 0.005324116
in O 0 0.00033176536
serum O 0 0.098547526
calcium B-Chemical 0 0.99488384
produced O 0 0.00027104942
by O 0 0.0004974406
vitamin B-Chemical 0 0.99998605
D I-Chemical 0 0.99954504
, O 0 0.0007445247
the O 0 0.0001256768
synergy O 0 0.00029870338
between O 0 0.00019801235
Warfarin B-Chemical 0 0.999894
and O 0 0.0008658952
vitamin B-Chemical 0 0.9999919
D I-Chemical 0 0.99971133
is O 0 0.00021401788
probably O 0 0.00015593642
best O 0 0.00010126484
explained O 0 9.7256365e-05
by O 0 9.09727e-05
the O 0 7.977405e-05
hypothesis O 0 0.00012133089
that O 0 0.00017816781
Warfarin B-Chemical 0 0.9997987
inhibits O 0 0.00013899311
the O 0 0.00013879448
activity O 0 0.00015018399
of O 0 0.00041561638
matrix O 0 0.05565621
Gla O 0 0.96236503
protein O 0 0.0007198955
as O 0 0.00066609704
a O 0 0.0022219403
calcification B-Disease 0 0.999241
inhibitor O 0 0.01868789
. O 0 0.0035526338

High O 0 0.0054559023
levels O 0 0.0023450893
of O 0 0.0027345193
matrix O 0 0.052863885
Gla O 0 0.9360566
protein O 0 0.0009594022
are O 0 0.0003540532
found O 0 0.0002554868
at O 0 0.0001562667
sites O 0 0.00014772378
of O 0 0.00031844128
artery B-Disease 2 0.99062634
calcification I-Disease 2 0.9998945
in O 0 0.00017967728
rats O 0 0.0002562338
treated O 0 0.00034829017
with O 0 0.000423812
vitamin B-Chemical 0 0.99998736
D I-Chemical 0 0.99971837
plus O 0 0.0017018926
Warfarin B-Chemical 0 0.9999298
, O 0 0.00036771517
and O 0 0.00012133009
chemical O 0 0.0001468425
analysis O 0 0.00010637164
showed O 0 9.455021e-05
that O 0 8.4269785e-05
the O 0 0.0001142587
protein O 0 0.00017616837
that O 0 0.00014758592
accumulated O 0 0.00024125924
was O 0 0.0002804344
indeed O 0 0.0003812156
not O 0 0.0007374781
gamma B-Chemical 0 0.9174708
- I-Chemical 0 0.2451839
carboxylated I-Chemical 0 0.94710183
. O 0 0.0046382123

These O 0 0.0019309077
observations O 0 0.0016004347
indicate O 0 0.00068890804
that O 0 0.000712034
although O 0 0.0007775449
the O 0 0.00080407824
gamma B-Chemical 0 0.88492656
- I-Chemical 0 0.13372374
carboxyglutamate I-Chemical 0 0.06578053
residues O 0 0.00062173995
of O 0 0.00059647433
matrix O 0 0.05132526
Gla O 0 0.9542742
protein O 0 0.0003249943
are O 0 0.00013249223
apparently O 0 0.00017857243
required O 0 5.4023345e-05
for O 0 7.3866315e-05
its O 0 0.00012953508
function O 0 0.00010459424
as O 0 0.00015362244
a O 0 0.00050598534
calcification B-Disease 0 0.9996977
inhibitor O 0 0.002890537
, O 0 0.00039876698
they O 0 0.00012577751
are O 0 9.645827e-05
not O 0 0.00010024107
required O 0 8.374082e-05
for O 0 0.00015738989
its O 0 0.00037778448
accumulation O 0 0.00048614276
at O 0 0.00058365887
calcification B-Disease 0 0.9902623
sites O 0 0.0012737075
. O 0 0.0026610468

Test O 0 0.009174949
conditions O 0 0.0018980867
influence O 0 0.0010229455
the O 0 0.0009502559
response O 0 0.00090203393
to O 0 0.0008280148
a O 0 0.0014423692
drug O 0 0.004975521
challenge O 0 0.0009094432
in O 0 0.001370984
rodents O 0 0.0030803066
. O 0 0.0042507057

These O 0 0.0019985302
studies O 0 0.0019628166
were O 0 0.001004713
conducted O 0 0.00075779355
to O 0 0.0003367001
examine O 0 0.00014786144
the O 0 0.00019996216
differential O 0 0.00024227994
response O 0 0.00018099321
to O 0 0.00014817604
a O 0 0.00025026978
drug O 0 0.0011929275
challenge O 0 8.080511e-05
under O 0 7.585751e-05
varied O 0 9.872732e-05
experimental O 0 8.797236e-05
test O 0 0.000105470695
conditions O 0 8.357825e-05
routinely O 0 6.798502e-05
employed O 0 9.297661e-05
to O 0 8.894614e-05
study O 0 0.00017225723
drug O 0 0.0043823677
- O 0 0.0013028916
induced O 0 0.00017771004
behavioral O 0 0.0008835819
and O 0 0.00027574113
neurophysiological O 0 0.0010881065
responses O 0 0.00043930445
in O 0 0.0006831344
rodents O 0 0.0017745205
. O 0 0.002536923

Apomorphine B-Chemical 0 0.99991286
, O 0 0.010468898
a O 0 0.0048478516
nonselective O 0 0.9267422
dopamine B-Chemical 0 0.9999112
agonist I-Chemical 0 0.28553674
, O 0 0.0010174778
was O 0 0.0002423183
selected O 0 0.00014811699
due O 0 0.0001116762
to O 0 0.000119802775
its O 0 0.00019755594
biphasic O 0 0.0004480443
behavioral O 0 0.0005037512
effects O 0 0.00013232307
, O 0 0.0002872082
its O 0 0.00016267232
ability O 0 0.00010723712
to O 0 0.00011274995
induce O 0 0.00013348364
hypothermia B-Disease 0 0.9994137
, O 0 0.000434812
and O 0 0.00013536813
to O 0 9.245541e-05
produce O 0 7.88236e-05
distinct O 0 9.655251e-05
changes O 0 0.00020102678
to O 0 0.00030807304
dopamine B-Chemical 0 0.9997013
turnover O 0 0.00086805667
in O 0 0.0003399477
the O 0 0.00040461452
rodent O 0 0.0010067205
brain O 0 0.0038640832
. O 0 0.002452791

From O 0 0.0025741202
such O 0 0.0012862245
experiments O 0 0.00074640766
there O 0 0.00057602697
is O 0 0.0004074298
evidence O 0 0.00029107303
that O 0 0.00022350543
characterization O 0 0.00020970503
and O 0 0.00025223315
detection O 0 0.00023999464
of O 0 0.0006482694
apomorphine B-Chemical 0 0.9999913
- O 0 0.012936744
induced O 0 0.00016859776
activity O 0 0.000121577235
in O 0 0.00015938035
rodents O 0 0.00027805986
critically O 0 0.00025119827
depends O 0 0.00012815096
upon O 0 0.00016165119
the O 0 0.0002739765
test O 0 0.000605845
conditions O 0 0.000826293
employed O 0 0.0016786691
. O 0 0.0029031164

In O 0 0.0020711739
rats O 0 0.0029632878
, O 0 0.0023438013
detection O 0 0.0010132403
of O 0 0.0018661666
apomorphine B-Chemical 0 0.99997663
- O 0 0.07907625
induced O 0 0.0010470962
hyperactivity B-Disease 2 0.99999285
was O 0 0.0004169056
facilitated O 0 0.00032414956
by O 0 0.00022904458
a O 0 0.00029771513
period O 0 0.00016069178
of O 0 0.00030978007
acclimatization O 0 0.0017284474
to O 0 0.0003206762
the O 0 0.0004030911
test O 0 0.0009479689
conditions O 0 0.0014940659
. O 0 0.002926722

Moreover O 0 0.0032629815
, O 0 0.0034692509
test O 0 0.0016008012
conditions O 0 0.00084786623
can O 0 0.00039782526
impact O 0 0.0002606363
upon O 0 0.00020474277
other O 0 0.00023614663
physiological O 0 0.00030553178
responses O 0 0.00029376216
to O 0 0.00041852388
apomorphine B-Chemical 0 0.99991906
such O 0 0.00040630088
as O 0 0.0004910467
drug O 0 0.026420096
- O 0 0.007036656
induced O 0 0.0017018514
hypothermia B-Disease 0 0.99852717
. O 0 0.0045182053

In O 0 0.0017500619
mice O 0 0.0010826194
, O 0 0.004649431
apomorphine B-Chemical 0 0.99987316
produced O 0 0.00054030836
qualitatively O 0 0.0002897545
different O 0 0.00015998833
responses O 0 0.00017184445
under O 0 0.00012852177
novel O 0 0.00010995392
conditions O 0 0.0001296117
when O 0 9.690597e-05
compared O 0 0.00010613263
to O 0 0.0001264525
those O 0 0.00019274728
behaviors O 0 0.00037945094
elicited O 0 0.0002114581
in O 0 0.00028983378
the O 0 0.000362381
home O 0 0.00085035496
test O 0 0.0013475406
cage O 0 0.0038411627
. O 0 0.0033097065

Drug O 0 0.9232371
- O 0 0.016743997
induced O 0 0.0014250122
gross O 0 0.0017915869
activity O 0 0.00041253652
counts O 0 0.00033951725
were O 0 0.00027068143
increased O 0 0.0003138019
in O 0 0.00018388097
the O 0 0.00014013535
novel O 0 0.00015793937
exploratory O 0 0.00053322915
box O 0 0.00021314468
only O 0 0.00020737194
, O 0 0.00030166283
while O 0 0.00015113903
measures O 0 0.00017318262
of O 0 0.0003182965
stereotypic O 0 0.39268792
behavior O 0 0.0005922396
were O 0 0.00034479698
similar O 0 0.00031588803
in O 0 0.00065461296
both O 0 0.0012070059
. O 0 0.0027216927

By O 0 0.0026813133
contrast O 0 0.00409749
, O 0 0.010654752
apomorphine B-Chemical 0 0.9999528
- O 0 0.038356323
induced O 0 0.0009259859
locomotion O 0 0.0062586823
was O 0 0.0005901058
more O 0 0.000744497
prominent O 0 0.0010087999
in O 0 0.00046553978
the O 0 0.00047633715
novel O 0 0.0007773052
exploratory O 0 0.0028838178
box O 0 0.0023920736
. O 0 0.003886621

Dopamine B-Chemical 0 0.9991775
turnover O 0 0.008566649
ratios O 0 0.0043517575
( O 0 0.09952083
DOPAC B-Chemical 0 0.9999975
: O 0 0.33926177
DA B-Chemical 0 0.99985695
and O 0 0.019870326
HVA B-Chemical 0 0.9999993
: O 0 0.13054782
DA B-Chemical 0 0.9997882
) O 0 0.0011170001
were O 0 0.00016632401
found O 0 0.00013645882
to O 0 0.00010852342
be O 0 0.00010757704
lower O 0 0.00013301555
in O 0 9.612149e-05
those O 0 0.00010597578
animals O 0 6.771276e-05
exposed O 0 0.000116902615
to O 0 8.4623774e-05
the O 0 9.164645e-05
exploratory O 0 0.0003280609
box O 0 0.00013627978
when O 0 9.644687e-05
compared O 0 0.00012552505
to O 0 0.00018064547
their O 0 0.0002857382
home O 0 0.0006743027
cage O 0 0.001667741
counterparts O 0 0.0016411569
. O 0 0.0029282754

However O 0 0.0040277047
, O 0 0.013260036
apomorphine B-Chemical 0 0.9999393
- O 0 0.030962443
induced O 0 0.00077522185
reductions O 0 0.0008888087
in O 0 0.0008482666
striatal O 0 0.80295926
dopamine B-Chemical 0 0.99979955
turnover O 0 0.00087220717
were O 0 0.00020720687
detected O 0 0.00013393779
in O 0 0.00018439804
both O 0 0.00020734899
novel O 0 0.00030014696
and O 0 0.0005036538
home O 0 0.0009841308
cage O 0 0.0022331956
environments O 0 0.0022858176
. O 0 0.003200333

The O 0 0.0016924274
implications O 0 0.0014052225
of O 0 0.0011434228
these O 0 0.0007323564
findings O 0 0.0007174946
are O 0 0.00038025266
discussed O 0 0.00032225458
with O 0 0.00033545995
particular O 0 0.0002187708
emphasis O 0 0.00043943012
upon O 0 0.00019755613
conducting O 0 0.00036115298
psychopharmacological O 0 0.20411421
challenge O 0 0.0004058863
tests O 0 0.0011748519
in O 0 0.0009432993
rodents O 0 0.002260498
. O 0 0.0031132454

Hemolysis B-Disease 0 0.99734
of O 0 0.00423636
human O 0 0.0029709984
erythrocytes O 0 0.26066726
induced O 0 0.0011951022
by O 0 0.0012777093
tamoxifen B-Chemical 1 0.99842024
is O 0 0.00052160595
related O 0 0.00031704965
to O 0 0.0004084529
disruption O 0 0.0005915375
of O 0 0.0011271568
membrane O 0 0.004298776
structure O 0 0.0024638178
. O 0 0.0040367935

Tamoxifen B-Chemical 0 0.99894875
( O 0 0.027047986
TAM B-Chemical 1 0.99972445
) O 0 0.005233688
, O 0 0.0015298343
the O 0 0.00056920724
antiestrogenic O 0 0.15894918
drug O 0 0.0144515885
most O 0 0.0003346242
widely O 0 0.00019901112
prescribed O 0 0.00054104096
in O 0 0.00012844041
the O 0 0.00013294708
chemotherapy O 0 0.0013309233
of O 0 0.00033377288
breast B-Disease 0 0.9944199
cancer I-Disease 0 0.99977237
, O 0 0.0008579067
induces O 0 0.00016449792
changes O 0 0.00024484695
in O 0 0.0002364582
normal O 0 0.00087030104
discoid O 0 0.932445
shape O 0 0.0006075852
of O 0 0.00078370876
erythrocytes O 0 0.77433974
and O 0 0.0053688237
hemolytic B-Disease 0 0.99998426
anemia I-Disease 0 0.99998
. O 0 0.007208337

This O 0 0.0041645668
work O 0 0.0018713324
evaluates O 0 0.00088878843
the O 0 0.00056625984
effects O 0 0.0006090471
of O 0 0.0012094993
TAM B-Chemical 1 0.9998883
on O 0 0.00031718443
isolated O 0 0.00036701633
human O 0 0.0004330969
erythrocytes O 0 0.25239336
, O 0 0.0004917814
attempting O 0 0.00023870596
to O 0 0.0001012467
identify O 0 5.5906457e-05
the O 0 8.364873e-05
underlying O 0 0.00012344916
mechanisms O 0 9.67861e-05
on O 0 0.00020033258
TAM B-Chemical 1 0.9999759
- O 0 0.15469728
induced O 0 0.0011940207
hemolytic B-Disease 0 0.9999982
anemia I-Disease 0 0.9999976
and O 0 0.0003493222
the O 0 0.00015010512
involvement O 0 0.0003531762
of O 0 0.00035358116
biomembranes O 0 0.66518533
in O 0 0.00034893575
its O 0 0.0006237565
cytostatic O 0 0.08112291
action O 0 0.0007774241
mechanisms O 0 0.0010679634
. O 0 0.002741883

TAM B-Chemical 1 0.99942964
induces O 0 0.008525996
hemolysis B-Disease 0 0.9996302
of O 0 0.005233047
erythrocytes O 0 0.48354906
as O 0 0.0015306743
a O 0 0.0016724188
function O 0 0.0011819431
of O 0 0.0021523342
concentration O 0 0.00493997
. O 0 0.005109689

The O 0 0.0023251616
extension O 0 0.002158037
of O 0 0.0028357867
hemolysis B-Disease 0 0.99951005
is O 0 0.00078041584
variable O 0 0.0005092121
with O 0 0.0007163273
erythrocyte O 0 0.6095782
samples O 0 0.0005246683
, O 0 0.00059563405
but O 0 0.0003091113
12 O 0 0.00017661373
. O 0 0.00021907849
5 O 0 0.0002959543
microM O 0 0.28670913
TAM B-Chemical 1 0.9998714
induces O 0 0.00046284686
total O 0 0.00092041667
hemolysis B-Disease 0 0.99979216
of O 0 0.00087079924
all O 0 0.00066237856
tested O 0 0.0008831502
suspensions O 0 0.002643925
. O 0 0.0029899604

Despite O 0 0.0027872173
inducing O 0 0.0031554324
extensive O 0 0.0034656494
erythrocyte O 0 0.84743273
lysis O 0 0.0113265505
, O 0 0.007768773
TAM B-Chemical 1 0.9998604
does O 0 0.0006011033
not O 0 0.00044779386
shift O 0 0.0005729232
the O 0 0.00042112745
osmotic O 0 0.002828121
fragility O 0 0.075823925
curves O 0 0.0009273169
of O 0 0.0016191686
erythrocytes O 0 0.17371106
. O 0 0.004282324

The O 0 0.0039002877
hemolytic B-Disease 0 0.9966175
effect O 0 0.0018232802
of O 0 0.003217807
TAM B-Chemical 1 0.99989426
is O 0 0.00067888363
prevented O 0 0.00076228887
by O 0 0.00035890625
low O 0 0.0005066934
concentrations O 0 0.0008461415
of O 0 0.0008769241
alpha B-Chemical 0 0.998156
- I-Chemical 0 0.93040854
tocopherol I-Chemical 0 0.9999974
( O 0 0.03318081
alpha B-Chemical 0 0.99334854
- I-Chemical 0 0.06121334
T I-Chemical 0 0.14696969
) O 0 0.0014123255
and O 0 0.0006162513
alpha B-Chemical 0 0.99712473
- I-Chemical 0 0.95145524
tocopherol I-Chemical 0 0.9999988
acetate I-Chemical 0 0.9998379
( O 0 0.014406127
alpha B-Chemical 0 0.9948873
- I-Chemical 0 0.11942421
TAc I-Chemical 0 0.20024785
) O 0 0.00082524616
( O 0 0.00036207025
inactivated O 0 0.00015076222
functional O 0 0.00027736375
hydroxyl B-Chemical 0 0.9992557
) O 0 0.0012989857
indicating O 0 0.00016147003
that O 0 0.00028717972
TAM B-Chemical 1 0.99997866
- O 0 0.12705085
induced O 0 0.0006688926
hemolysis B-Disease 0 0.99994636
is O 0 0.00030866015
not O 0 0.00025938323
related O 0 0.00025623987
to O 0 0.00056236034
oxidative O 0 0.56680965
membrane O 0 0.032499634
damage O 0 0.2752148
. O 0 0.0031564587

This O 0 0.0049648546
was O 0 0.001824765
further O 0 0.0010491177
evidenced O 0 0.0012908076
by O 0 0.0006733952
absence O 0 0.00047618625
of O 0 0.0011850449
oxygen B-Chemical 1 0.9998073
consumption O 0 0.086657725
and O 0 0.0007722718
hemoglobin O 0 0.9838859
oxidation O 0 0.59236395
both O 0 0.00021485167
determined O 0 0.00019165759
in O 0 0.000255057
parallel O 0 0.00056421687
with O 0 0.0012234399
TAM B-Chemical 1 0.9999323
- O 0 0.09997592
induced O 0 0.0025479947
hemolysis B-Disease 0 0.9997366
. O 0 0.005488824

Furthermore O 0 0.0038991133
, O 0 0.004897096
it O 0 0.0023379673
was O 0 0.0010748248
observed O 0 0.0007781319
that O 0 0.00089677225
TAM B-Chemical 1 0.9998722
inhibits O 0 0.0007275517
the O 0 0.0011861126
peroxidation O 0 0.9999858
of O 0 0.0010511961
human O 0 0.0007552538
erythrocytes O 0 0.52940494
induced O 0 0.0005248296
by O 0 0.0014254438
AAPH B-Chemical 0 0.99999785
, O 0 0.0017238475
thus O 0 0.00037549122
ruling O 0 0.0011585708
out O 0 0.0006810984
TAM B-Chemical 1 0.99994373
- O 0 0.027591612
induced O 0 0.0007961551
cell O 0 0.0028275936
oxidative O 0 0.8815142
stress O 0 0.45271885
. O 0 0.004431247

Hemolysis B-Disease 0 0.9974124
caused O 0 0.0041301143
by O 0 0.0037043742
TAM B-Chemical 1 0.9997484
was O 0 0.001016927
not O 0 0.0005133105
preceded O 0 0.00046949
by O 0 0.00033838465
the O 0 0.00031155095
leakage O 0 0.006570434
of O 0 0.0005953761
K B-Chemical 0 0.9994881
( O 0 0.0012300067
+ O 0 0.0014383647
) O 0 0.00049743394
from O 0 0.00013125426
the O 0 0.000118308206
cells O 0 0.0002096173
, O 0 0.0003087099
also O 0 0.00013465094
excluding O 0 0.00017632013
a O 0 0.00031486846
colloid O 0 0.10766625
- O 0 0.0023894713
osmotic O 0 0.00079394324
type O 0 0.00028802096
mechanism O 0 0.00012504098
of O 0 0.00050325587
hemolysis B-Disease 0 0.9999547
, O 0 0.00076519453
according O 0 0.00014159473
to O 0 0.00012731615
the O 0 0.00013504672
effects O 0 0.00021861069
on O 0 0.0002984449
osmotic O 0 0.0039042244
fragility O 0 0.21107614
curves O 0 0.0015304412
. O 0 0.0024632902

However O 0 0.0045641786
, O 0 0.012088893
TAM B-Chemical 1 0.99954563
induces O 0 0.0013476408
release O 0 0.0018008143
of O 0 0.0006769957
peripheral O 0 0.0013152994
proteins O 0 0.00037590662
of O 0 0.00052293635
membrane O 0 0.004771145
- O 0 0.0062620784
cytoskeleton O 0 0.0008715397
and O 0 0.00037722717
cytosol O 0 0.0005618939
proteins O 0 0.00030204243
essentially O 0 0.00032046105
bound O 0 0.00037167073
to O 0 0.0006489411
band O 0 0.0018444185
3 O 0 0.0014318274
. O 0 0.0026034873

Either O 0 0.02909347
alpha B-Chemical 0 0.97832173
- I-Chemical 0 0.13203605
T I-Chemical 0 0.19850758
or O 0 0.002551332
alpha B-Chemical 0 0.98224866
- I-Chemical 0 0.11437841
TAc I-Chemical 0 0.110312365
increases O 0 0.00072462583
membrane O 0 0.0019502317
packing O 0 0.0013089853
and O 0 0.00060805905
prevents O 0 0.00088568166
TAM B-Chemical 1 0.9997881
partition O 0 0.0011396647
into O 0 0.0004884755
model O 0 0.0010145284
membranes O 0 0.00558082
. O 0 0.0034132022

These O 0 0.0017173459
effects O 0 0.0013064202
suggest O 0 0.00066874846
that O 0 0.000606603
the O 0 0.0005381256
protection O 0 0.00070303946
from O 0 0.000822634
hemolysis B-Disease 0 0.999907
by O 0 0.0014824789
tocopherols B-Chemical 0 0.99999535
is O 0 0.00031596152
related O 0 0.00012380932
to O 0 0.00014219763
a O 0 0.00033418587
decreased O 0 0.0012742765
TAM B-Chemical 1 0.999964
incorporation O 0 0.00068331446
in O 0 0.00022465999
condensed O 0 0.0012566143
membranes O 0 0.0014586268
and O 0 0.00016808909
the O 0 0.00012777904
structural O 0 0.0002450576
damage O 0 0.011116298
of O 0 0.0003467169
the O 0 0.00039066927
erythrocyte O 0 0.8409707
membrane O 0 0.0036019546
is O 0 0.00048542782
consequently O 0 0.0010275636
avoided O 0 0.0015536161
. O 0 0.0026919674

Therefore O 0 0.0034083966
, O 0 0.013426979
TAM B-Chemical 1 0.9997894
- O 0 0.13829313
induced O 0 0.002080451
hemolysis B-Disease 0 0.9997137
results O 0 0.00051776477
from O 0 0.00032539363
a O 0 0.00039186137
structural O 0 0.00025616345
perturbation O 0 0.00021761247
of O 0 0.00028555634
red O 0 0.00055566814
cell O 0 0.0006092367
membrane O 0 0.0038726784
, O 0 0.0004482224
leading O 0 0.0001725429
to O 0 0.000102919315
changes O 0 0.00011855203
in O 0 8.9604706e-05
the O 0 7.6129545e-05
framework O 0 9.678628e-05
of O 0 0.00015593506
the O 0 0.00020883628
erythrocyte O 0 0.8350715
membrane O 0 0.0024655813
and O 0 0.00021765377
its O 0 0.00029096368
cytoskeleton O 0 0.0005753998
caused O 0 0.00021404219
by O 0 0.000224837
its O 0 0.0003452817
high O 0 0.0004259745
partition O 0 0.0006600972
in O 0 0.00054690585
the O 0 0.00080936676
membrane O 0 0.004771557
. O 0 0.0029160948

These O 0 0.0025588719
defects O 0 0.0039964174
explain O 0 0.0013626055
the O 0 0.0011407987
abnormal O 0 0.008872287
erythrocyte O 0 0.48308003
shape O 0 0.0007090836
and O 0 0.00043924164
decreased O 0 0.00054013083
mechanical O 0 0.00038877554
stability O 0 0.0002762345
promoted O 0 0.0006664199
by O 0 0.0008960078
TAM B-Chemical 1 0.9998841
, O 0 0.0020279402
resulting O 0 0.0009438756
in O 0 0.002523855
hemolytic B-Disease 0 0.99997115
anemia I-Disease 0 0.9999713
. O 0 0.007917038

Additionally O 0 0.0034220207
, O 0 0.004576894
since O 0 0.0014881343
membrane O 0 0.0064409547
leakage O 0 0.034423895
is O 0 0.00049133226
a O 0 0.0005470711
final O 0 0.00040429665
stage O 0 0.0013062322
of O 0 0.000477518
cytotoxicity O 0 0.81158364
, O 0 0.000556473
the O 0 0.00013012993
disruption O 0 0.00011895765
of O 0 0.0001340653
the O 0 9.693009e-05
structural O 0 0.00012619737
characteristics O 0 0.00011981249
of O 0 0.0002347183
biomembranes O 0 0.8282339
by O 0 0.0004962003
TAM B-Chemical 1 0.99995506
may O 0 0.0001598575
contribute O 0 0.00012192878
to O 0 0.00010977247
the O 0 0.00010994197
multiple O 0 0.00013868044
mechanisms O 0 0.00015789765
of O 0 0.0003888842
its O 0 0.0008295189
anticancer O 0 0.022211479
action O 0 0.0017570931
. O 0 0.0028502033

Changes O 0 0.004377986
of O 0 0.004250407
sodium B-Chemical 0 0.99782616
and O 0 0.0040369104
ATP B-Chemical 0 0.996223
affinities O 0 0.001344329
of O 0 0.0006619419
the O 0 0.00043266156
cardiac O 0 0.002171504
( O 0 0.0013800331
Na B-Chemical 0 0.9959913
, O 0 0.0026684322
K B-Chemical 0 0.999564
) O 0 0.005891649
- O 0 0.009089163
ATPase O 0 0.0010525866
during O 0 0.00024763486
and O 0 0.00043066606
after O 0 0.00043826443
nitric B-Chemical 0 0.9971802
oxide I-Chemical 0 0.96915025
deficient O 0 0.0029808884
hypertension B-Disease 2 0.99993706
. O 0 0.0057109087

In O 0 0.0023077442
the O 0 0.0021652933
cardiovascular O 0 0.07369287
system O 0 0.002036269
, O 0 0.004653418
NO B-Chemical 0 0.9947014
is O 0 0.0006089096
involved O 0 0.000398743
in O 0 0.00035537133
the O 0 0.00027674012
regulation O 0 0.00020004036
of O 0 0.0005305715
a O 0 0.000877036
variety O 0 0.0007683932
of O 0 0.0010748274
functions O 0 0.0016903694
. O 0 0.0036493056

Inhibition O 0 0.013349947
of O 0 0.012012454
NO B-Chemical 0 0.99570113
synthesis O 0 0.013201286
induces O 0 0.004315757
sustained O 0 0.017064301
hypertension B-Disease 2 0.999843
. O 0 0.013220949

In O 0 0.0017161447
several O 0 0.0010800626
models O 0 0.0011518877
of O 0 0.0018339125
hypertension B-Disease 2 0.9999567
, O 0 0.0037994303
elevation O 0 0.016444543
of O 0 0.0007010354
intracellular O 0 0.0012150081
sodium B-Chemical 0 0.9981742
level O 0 0.00049914024
was O 0 0.00048299588
documented O 0 0.0007500298
in O 0 0.0007768902
cardiac O 0 0.004663823
tissue O 0 0.0041251946
. O 0 0.00303176

To O 0 0.0012201825
assess O 0 0.00078336743
the O 0 0.0008430648
molecular O 0 0.0011273148
basis O 0 0.0005861514
of O 0 0.00079070235
disturbances O 0 0.48908263
in O 0 0.0005312891
transmembraneous O 0 0.004163487
transport O 0 0.0006753226
of O 0 0.0004712036
Na B-Chemical 0 0.9973085
+ O 0 0.0021952593
, O 0 0.00035411477
we O 0 8.9180365e-05
studied O 0 0.0001898535
the O 0 0.00010939023
response O 0 0.00013354629
of O 0 0.00019688274
cardiac O 0 0.0014048464
( O 0 0.0007837553
Na B-Chemical 0 0.9976768
, O 0 0.0019035293
K B-Chemical 0 0.9997646
) O 0 0.006707061
- O 0 0.01916751
ATPase O 0 0.0012648026
to O 0 0.00030093495
NO B-Chemical 0 0.9990907
- O 0 0.017636381
deficient O 0 0.00030706168
hypertension B-Disease 2 0.9999882
induced O 0 0.0002249159
in O 0 0.00016501572
rats O 0 0.00042612723
by O 0 0.00033873777
NO B-Chemical 0 0.99959844
- O 0 0.10192161
synthase O 0 0.011125816
inhibition O 0 0.00023892432
with O 0 0.00016710612
40 O 0 0.00019275372
mg O 0 0.0018486355
/ O 0 0.0005719678
kg O 0 0.0004351217
/ O 0 0.00076429674
day O 0 0.0002223434
N B-Chemical 0 0.9907665
( I-Chemical 0 0.0016707194
G I-Chemical 0 0.77732635
) I-Chemical 0 0.0055612265
- I-Chemical 0 0.11590706
nitro I-Chemical 0 0.99883145
- I-Chemical 0 0.54468197
L I-Chemical 0 0.9994091
- I-Chemical 0 0.89916074
arginine I-Chemical 0 0.96838814
methyl I-Chemical 0 0.9995926
ester I-Chemical 0 0.99954766
( O 0 0.03178088
L B-Chemical 0 0.9992111
- I-Chemical 0 0.7627746
NAME I-Chemical 0 0.99991286
) O 0 0.0016044573
for O 0 0.00031731813
4 O 0 0.0003629561
four O 0 0.00036251923
weeks O 0 0.0006166862
. O 0 0.002194688

After O 0 0.0019299019
4 O 0 0.0018223118
- O 0 0.0034148325
week O 0 0.00070688466
administration O 0 0.0011650908
of O 0 0.0012768132
L B-Chemical 0 0.99263835
- I-Chemical 0 0.5198347
NAME I-Chemical 0 0.99982136
, O 0 0.0009773681
the O 0 0.00027639075
systolic O 0 0.018987548
blood O 0 0.0026009846
pressure O 0 0.0038206724
( O 0 0.0008210893
SBP O 0 0.015400065
) O 0 0.0012319773
increased O 0 0.0008319601
by O 0 0.00090164866
36 O 0 0.0015653274
% O 0 0.0032451628
. O 0 0.0037367106

Two O 0 0.0020741317
weeks O 0 0.0010578885
after O 0 0.00076839287
terminating O 0 0.0013697728
the O 0 0.00071568275
treatment O 0 0.0007642519
, O 0 0.0011182575
the O 0 0.00065777125
SBP O 0 0.010323757
recovered O 0 0.00076274114
to O 0 0.0008179547
control O 0 0.0013809581
value O 0 0.0025968885
. O 0 0.004219477

When O 0 0.002333157
activating O 0 0.002020725
the O 0 0.0017596546
( O 0 0.0041550184
Na B-Chemical 0 0.99524313
, O 0 0.006430957
K B-Chemical 0 0.99937266
) O 0 0.009995345
- O 0 0.019312259
ATPase O 0 0.0016072937
with O 0 0.0004456394
its O 0 0.00066716055
substrate O 0 0.0014898479
ATP B-Chemical 0 0.99896026
, O 0 0.0008146414
no O 0 0.00022352589
changes O 0 0.00026268527
in O 0 0.00026438682
Km O 0 0.0018315074
and O 0 0.00027820145
Vmax O 0 0.003200032
values O 0 0.00022360838
were O 0 0.00021367798
observed O 0 0.00028776788
in O 0 0.00067148573
NO B-Chemical 0 0.9973035
- O 0 0.008730173
deficient O 0 0.0010889496
rats O 0 0.0027190992
. O 0 0.0031714707

During O 0 0.002286466
activation O 0 0.0020236783
with O 0 0.0024183176
Na B-Chemical 0 0.9928839
+ O 0 0.006103969
, O 0 0.0014141457
the O 0 0.00056310376
Vmax O 0 0.007026026
remained O 0 0.0005368274
unchanged O 0 0.00048178976
, O 0 0.00055220304
however O 0 0.00036409652
the O 0 0.000379944
K B-Chemical 0 0.9995394
( O 0 0.0033419156
Na B-Chemical 0 0.9988537
) O 0 0.001092879
increased O 0 0.0002845337
by O 0 0.00017076022
50 O 0 0.00024319644
% O 0 0.00035888044
, O 0 0.00027290368
indicating O 0 0.000111056754
a O 0 0.00025369253
profound O 0 0.0005535188
decrease O 0 0.0001855807
in O 0 0.00012392424
the O 0 0.00010469322
affinity O 0 0.00019164625
of O 0 0.00019960802
the O 0 0.00025122368
Na B-Chemical 0 0.9983119
+ O 0 0.0053065037
- O 0 0.002271495
binding O 0 0.00018284524
site O 0 0.00024396564
in O 0 0.0007138256
NO B-Chemical 0 0.99805474
- O 0 0.009644494
deficient O 0 0.0010596213
rats O 0 0.0026398166
. O 0 0.0030858715

After O 0 0.0017375811
recovery O 0 0.00251154
from O 0 0.0018121091
hypertension B-Disease 2 0.99986565
, O 0 0.0018702479
the O 0 0.00043533812
activity O 0 0.0003005493
of O 0 0.000502758
( O 0 0.0014499106
Na B-Chemical 0 0.9976705
, O 0 0.0030319935
K B-Chemical 0 0.9996872
) O 0 0.007398243
- O 0 0.017926829
ATPase O 0 0.0011368921
increased O 0 0.00034353408
, O 0 0.00034141284
due O 0 0.000102509024
to O 0 0.00010676197
higher O 0 0.00016001533
affinity O 0 0.0002318161
of O 0 0.00024203266
the O 0 0.00031723463
ATP B-Chemical 0 0.9993894
- O 0 0.009460884
binding O 0 0.00011270727
site O 0 0.00011070782
, O 0 0.00032578662
as O 0 0.00017170885
revealed O 0 0.00016670537
from O 0 0.00021836674
the O 0 0.00029760384
lowered O 0 0.0028809796
Km O 0 0.0058061313
value O 0 0.00090617803
for O 0 0.0012268877
ATP B-Chemical 0 0.9923773
. O 0 0.004857784

The O 0 0.0062752916
K B-Chemical 0 0.99398154
( O 0 0.011712157
Na B-Chemical 0 0.9871531
) O 0 0.0040251957
value O 0 0.001354779
for O 0 0.0011860986
Na B-Chemical 0 0.9672308
+ O 0 0.004269369
returned O 0 0.0011704017
to O 0 0.00096017314
control O 0 0.0015463657
value O 0 0.0028513547
. O 0 0.004651934

Inhibition O 0 0.007779263
of O 0 0.0075197215
NO B-Chemical 0 0.9989611
- O 0 0.46469867
synthase O 0 0.07265035
induced O 0 0.00093392265
a O 0 0.0013817725
reversible O 0 0.022143416
hypertension B-Disease 2 0.9999876
accompanied O 0 0.0015058159
by O 0 0.0005457222
depressed B-Disease 2 0.9993649
Na B-Chemical 0 0.99960285
+ O 0 0.012846697
- O 0 0.0056718416
extrusion O 0 0.0021470962
from O 0 0.0001354753
cardiac O 0 0.00052099524
cells O 0 0.00017587548
as O 0 0.00013829734
a O 0 0.00019273385
consequence O 0 0.00010733993
of O 0 0.00025964674
deteriorated O 0 0.18112239
Na B-Chemical 0 0.9990332
+ O 0 0.0037332007
- O 0 0.0012957149
binding O 0 0.000108054286
properties O 0 0.00012844775
of O 0 0.0002626056
the O 0 0.00032833972
( O 0 0.0014636262
Na B-Chemical 0 0.9976833
, O 0 0.0047598085
K B-Chemical 0 0.999376
) O 0 0.014258397
- O 0 0.020534921
ATPase O 0 0.0066492897
. O 0 0.004180949

After O 0 0.0015771572
recovery O 0 0.0020009705
of O 0 0.0012640824
blood O 0 0.0036942794
pressure O 0 0.0037948196
to O 0 0.00035635353
control O 0 0.00031640643
values O 0 0.0002995669
, O 0 0.00044386872
the O 0 0.00022621534
extrusion O 0 0.0018164839
of O 0 0.00043063133
Na B-Chemical 0 0.9965947
+ O 0 0.0015406853
from O 0 0.00017241052
cardiac O 0 0.00056889653
cells O 0 0.00018154511
was O 0 0.00012642948
normalized O 0 8.201398e-05
, O 0 0.00026118458
as O 0 0.00014114974
revealed O 0 0.00012697327
by O 0 0.00015993373
restoration O 0 0.00024149721
of O 0 0.00025406724
the O 0 0.00028506995
( O 0 0.001212757
Na B-Chemical 0 0.997584
, O 0 0.0036640947
K B-Chemical 0 0.99949706
) O 0 0.010202589
- O 0 0.013672735
ATPase O 0 0.003341595
activity O 0 0.0015448374
. O 0 0.0034636126

Effects O 0 0.0032991609
of O 0 0.0021524306
long O 0 0.001699603
- O 0 0.004357988
term O 0 0.0009372614
pretreatment O 0 0.0038304392
with O 0 0.0012270345
isoproterenol B-Chemical 0 0.99984396
on O 0 0.0009927423
bromocriptine B-Chemical 0 0.9999887
- O 0 0.035460047
induced O 0 0.0007673568
tachycardia B-Disease 2 0.9982503
in O 0 0.00088129373
conscious O 0 0.008550198
rats O 0 0.002432958
. O 0 0.0026853585

It O 0 0.004967343
has O 0 0.0013678944
been O 0 0.001022582
shown O 0 0.0004968134
that O 0 0.0008166548
bromocriptine B-Chemical 0 0.99997914
- O 0 0.040755358
induced O 0 0.0005671151
tachycardia B-Disease 2 0.9992582
, O 0 0.00061271165
which O 0 0.00019156112
persisted O 0 0.00011552341
after O 0 9.043151e-05
adrenalectomy O 0 0.03501895
, O 0 0.00029765719
is O 0 0.00012289223
( O 0 0.0002730651
i O 0 0.00031963692
) O 0 0.00036400414
mediated O 0 8.877428e-05
by O 0 0.00020350012
central O 0 0.0023845388
dopamine B-Chemical 0 0.9999678
D2 O 0 0.9982969
receptor O 0 0.0009892856
activation O 0 0.0001503307
and O 0 0.00015277388
( O 0 0.00026064127
ii O 0 0.00019714536
) O 0 0.0003634107
reduced O 0 0.00014300573
by O 0 0.00011582994
5 O 0 0.00012721348
- O 0 0.0007479973
day O 0 0.00012261739
isoproterenol B-Chemical 0 0.99982125
pretreatment O 0 0.0066158655
, O 0 0.00027323773
supporting O 0 8.4100546e-05
therefore O 0 9.5865085e-05
the O 0 7.44503e-05
hypothesis O 0 9.4811505e-05
that O 0 8.574467e-05
this O 0 0.00013201126
effect O 0 0.00012854236
is O 0 0.00014467505
dependent O 0 0.00013634698
on O 0 0.00019095713
sympathetic O 0 0.0032536678
outflow O 0 0.54941106
to O 0 0.0004737152
the O 0 0.00073323597
heart O 0 0.024695175
. O 0 0.0026625216

This O 0 0.0046793125
study O 0 0.0021555875
was O 0 0.001007049
conducted O 0 0.0007202262
to O 0 0.00030495878
examine O 0 0.00012389282
whether O 0 0.00011079929
prolonged O 0 0.00046745344
pretreatment O 0 0.0030498973
with O 0 0.0007402868
isoproterenol B-Chemical 0 0.99991333
could O 0 0.0003111048
abolish O 0 0.0006127
bromocriptine B-Chemical 0 0.9999927
- O 0 0.04136487
induced O 0 0.00060209667
tachycardia B-Disease 2 0.9985965
in O 0 0.0007236238
conscious O 0 0.008344865
rats O 0 0.0021434277
. O 0 0.0023792188

Isoproterenol B-Chemical 0 0.9998443
pretreatment O 0 0.022285292
for O 0 0.0009898127
15 O 0 0.00064430246
days O 0 0.00033092475
caused O 0 0.00048219773
cardiac B-Disease 0 0.06777391
hypertrophy I-Disease 2 0.99974877
without O 0 0.0005351721
affecting O 0 0.00041611487
baseline O 0 0.00032013006
blood O 0 0.0020812983
pressure O 0 0.0049005435
and O 0 0.0008980707
heart O 0 0.010864015
rate O 0 0.00247573
. O 0 0.003147855

In O 0 0.0018035542
control O 0 0.0016872734
rats O 0 0.0020203749
, O 0 0.0022609604
intravenous O 0 0.057490546
bromocriptine B-Chemical 0 0.99992526
( O 0 0.0010718144
150 O 0 0.00051891257
microg O 0 0.0006592664
/ O 0 0.0013040879
kg O 0 0.0009895632
) O 0 0.0008382082
induced O 0 0.00046410086
significant O 0 0.0009852232
hypotension B-Disease 0 0.99972767
and O 0 0.0025658
tachycardia B-Disease 2 0.99746335
. O 0 0.0040833647

Bromocriptine B-Chemical 0 0.9998647
- O 0 0.12201061
induced O 0 0.0025909173
hypotension B-Disease 0 0.9998221
was O 0 0.0008712124
unaffected O 0 0.0010099992
by O 0 0.00068984745
isoproterenol B-Chemical 0 0.99989474
pretreatment O 0 0.03292958
, O 0 0.00072917907
while O 0 0.00032771364
tachycardia B-Disease 2 0.9987871
was O 0 0.00018648925
reversed O 0 0.00025027862
to O 0 0.00011616343
significant O 0 0.00019813755
bradycardia B-Disease 0 0.996867
, O 0 0.00029911488
an O 0 0.00011493579
effect O 0 8.925617e-05
that O 0 9.426303e-05
was O 0 0.00012884976
partly O 0 0.00017391138
reduced O 0 0.00018404885
by O 0 0.00016252193
i O 0 0.00041821797
. O 0 0.00021411994
v O 0 0.0018093212
. O 0 0.0005086632
domperidone B-Chemical 0 0.9999944
( O 0 0.0007870267
0 O 0 0.0003625693
. O 0 0.00026708882
5 O 0 0.0003463074
mg O 0 0.0023289032
/ O 0 0.0021622714
kg O 0 0.0023912122
) O 0 0.003471832
. O 0 0.003320459

Neither O 0 0.0032297631
cardiac O 0 0.009137982
vagal O 0 0.018733278
nor O 0 0.001157601
sympathetic O 0 0.0057441974
tone O 0 0.012467946
was O 0 0.0010970341
altered O 0 0.0013661732
by O 0 0.0020722456
isoproterenol B-Chemical 0 0.99940145
pretreatment O 0 0.09324487
. O 0 0.0056599244

In O 0 0.0019724614
isolated O 0 0.0020737655
perfused O 0 0.03482562
heart O 0 0.017668812
preparations O 0 0.0007849106
from O 0 0.00061175466
isoproterenol B-Chemical 0 0.9997631
- O 0 0.0113312295
pretreated O 0 0.0014148738
rats O 0 0.0004596907
, O 0 0.00041307224
the O 0 0.0002374387
isoproterenol B-Chemical 0 0.9998734
- O 0 0.0039162985
induced O 0 0.00012379455
maximal O 0 0.00016865597
increase O 0 8.337773e-05
in O 0 7.4450014e-05
left O 0 0.00020161607
ventricular O 0 0.02794537
systolic O 0 0.036783572
pressure O 0 0.0022534248
was O 0 8.124537e-05
significantly O 0 9.9505836e-05
reduced O 0 0.00011312084
, O 0 0.00016208396
compared O 0 6.274029e-05
with O 0 0.00011536049
saline O 0 0.00086411403
- O 0 0.0013188085
pretreated O 0 0.0005684759
rats O 0 0.00023575495
( O 0 0.0002118199
the O 0 9.822221e-05
EC50 O 0 0.019580664
of O 0 0.00015423303
the O 0 0.00019232575
isoproterenol B-Chemical 0 0.9999374
- O 0 0.006061605
induced O 0 0.0001091204
increase O 0 9.6422125e-05
in O 0 9.227653e-05
left O 0 0.00027007255
ventricular O 0 0.045984235
systolic O 0 0.047044232
pressure O 0 0.0023476197
was O 0 0.0001742701
enhanced O 0 0.0002411222
approximately O 0 0.00042992033
22 O 0 0.000747455
- O 0 0.0022882952
fold O 0 0.0013551279
) O 0 0.0039283503
. O 0 0.0033317332

These O 0 0.001964796
results O 0 0.0013825379
show O 0 0.0008190333
that O 0 0.00066235993
15 O 0 0.00075135205
- O 0 0.0026928817
day O 0 0.00049624755
isoproterenol B-Chemical 0 0.99974924
pretreatment O 0 0.012672667
not O 0 0.00026672342
only O 0 0.0002982651
abolished O 0 0.00039339217
but O 0 0.00046831492
reversed O 0 0.0038199117
bromocriptine B-Chemical 0 0.9999974
- O 0 0.07337379
induced O 0 0.00026151253
tachycardia B-Disease 2 0.9993949
to O 0 0.00018678361
bradycardia B-Disease 0 0.99733055
, O 0 0.0002412045
an O 0 9.0800655e-05
effect O 0 6.980224e-05
that O 0 7.188213e-05
is O 0 8.090635e-05
mainly O 0 9.613157e-05
related O 0 5.162803e-05
to O 0 6.607376e-05
further O 0 8.830847e-05
cardiac O 0 0.0023013942
beta O 0 0.8830081
- O 0 0.19797204
adrenoceptor O 0 0.9992673
desensitization O 0 0.0007895541
rather O 0 9.461839e-05
than O 0 9.099049e-05
to O 0 0.00011461827
impairment O 0 0.0513345
of O 0 0.000283509
autonomic O 0 0.0036120864
regulation O 0 0.00014554927
of O 0 0.00047296082
the O 0 0.00074161007
heart O 0 0.032376945
. O 0 0.0026331113

They O 0 0.0041626827
suggest O 0 0.001210171
that O 0 0.0011400273
, O 0 0.0018036145
in O 0 0.00075090514
normal O 0 0.0010226493
conscious O 0 0.0032285617
rats O 0 0.0006329568
, O 0 0.0004604266
the O 0 0.00018981783
central O 0 0.00049006235
tachycardia B-Disease 2 0.99741733
of O 0 0.00066645717
bromocriptine B-Chemical 0 0.99998844
appears O 0 0.00012537553
to O 0 0.00011721673
predominate O 0 0.00029547416
and O 0 0.000120439865
to O 0 9.763754e-05
mask O 0 0.0002092768
the O 0 0.00014359917
bradycardia B-Disease 0 0.98574835
of O 0 0.0002208052
this O 0 0.0002757086
agonist O 0 0.009420391
at O 0 0.00036160555
peripheral O 0 0.055986803
dopamine B-Chemical 0 0.99990284
D2 O 0 0.9969885
receptors O 0 0.0068464126
. O 0 0.0031557113

A O 0 0.026410371
developmental O 0 0.0047941227
analysis O 0 0.0016206346
of O 0 0.0017257221
clonidine B-Chemical 0 0.9998646
' O 0 0.0015108163
s O 0 0.00055708224
effects O 0 0.00026371586
on O 0 0.00020770574
cardiac O 0 0.0008614992
rate O 0 0.00039045213
and O 0 0.0003157047
ultrasound O 0 0.00069794426
production O 0 0.0006807064
in O 0 0.0007063494
infant O 0 0.0026643148
rats O 0 0.002752712
. O 0 0.0031621198

Under O 0 0.0037256996
controlled O 0 0.0020018923
conditions O 0 0.0014205445
, O 0 0.0018373592
infant O 0 0.0016597147
rats O 0 0.0009028199
emit O 0 0.00069075957
ultrasonic O 0 0.0010251486
vocalizations O 0 0.0012987246
during O 0 0.00017707676
extreme O 0 0.00035545946
cold O 0 0.0004501939
exposure O 0 0.00017812703
and O 0 0.00012896124
after O 0 7.483373e-05
administration O 0 0.00022202586
of O 0 0.00020001538
the O 0 0.00024374244
alpha O 0 0.23616888
( O 0 0.00086169125
2 O 0 0.00046115814
) O 0 0.0016772591
adrenoceptor O 0 0.998483
agonist O 0 0.27467102
, O 0 0.008385258
clonidine B-Chemical 0 0.9999093
. O 0 0.004514498

Previous O 0 0.0020707578
investigations O 0 0.0019274042
have O 0 0.00094223034
determined O 0 0.0006256945
that O 0 0.00047454814
, O 0 0.00080788386
in O 0 0.0003331066
response O 0 0.0003044757
to O 0 0.0003594259
clonidine B-Chemical 0 0.9999274
, O 0 0.0004977159
ultrasound O 0 0.0003836228
production O 0 0.00023583138
increases O 0 0.00016298503
through O 0 0.00013473866
the O 0 0.00014621153
2nd O 0 0.00035039717
- O 0 0.0009618715
week O 0 0.00017623421
postpartum O 0 0.00049858674
and O 0 0.00051908515
decreases O 0 0.0010366748
thereafter O 0 0.0016901456
. O 0 0.0029182131

Given O 0 0.0014315034
that O 0 0.0015088625
sympathetic O 0 0.0063222446
neural O 0 0.00196477
dominance O 0 0.0017141755
exhibits O 0 0.0005245276
a O 0 0.00049552036
similar O 0 0.000184055
developmental O 0 0.00049244217
pattern O 0 0.00019105875
, O 0 0.00032771923
and O 0 0.00015459773
given O 0 9.366869e-05
that O 0 0.0001477263
clonidine B-Chemical 0 0.99997354
induces O 0 0.00014941122
sympathetic O 0 0.0039142403
withdrawal O 0 0.001212559
and O 0 0.00015979257
bradycardia B-Disease 0 0.9926771
, O 0 0.0001840055
we O 0 4.137902e-05
hypothesized O 0 7.3903306e-05
that O 0 0.00013179454
clonidine B-Chemical 0 0.9999809
' O 0 0.0005492258
s O 0 0.00020410019
developmental O 0 0.0002255004
effects O 0 9.12837e-05
on O 0 7.996361e-05
cardiac O 0 0.00047347456
rate O 0 0.00018939354
and O 0 0.00016020067
ultrasound O 0 0.00040434467
production O 0 0.0003610771
would O 0 0.00031541492
mirror O 0 0.0011351033
each O 0 0.0005453052
other O 0 0.0011469186
. O 0 0.002596654

Therefore O 0 0.0022620265
, O 0 0.0033914847
in O 0 0.0011529305
the O 0 0.000631934
present O 0 0.00040343887
experiment O 0 0.0003036489
, O 0 0.0005263278
the O 0 0.00019455531
effects O 0 0.0002318672
of O 0 0.0004985052
clonidine B-Chemical 0 0.9999764
administration O 0 0.00089053804
( O 0 0.00031801226
0 O 0 0.00016904542
. O 0 0.00010369252
5 O 0 0.00010441256
mg O 0 0.0007195251
/ O 0 0.00042851755
kg O 0 0.00032561086
) O 0 0.0002475683
on O 0 7.5217715e-05
cardiac O 0 0.00036146218
rate O 0 0.00015182758
and O 0 0.00011119101
ultrasound O 0 0.00024476313
production O 0 0.0001774185
were O 0 0.00010896339
examined O 0 9.778429e-05
in O 0 0.00014292027
2 O 0 0.00021779741
- O 0 0.0008724607
, O 0 0.00032108402
8 O 0 0.00020806353
- O 0 0.00091319217
, O 0 0.00040039042
15 O 0 0.00026328702
- O 0 0.0010556198
, O 0 0.00046716924
and O 0 0.00033771934
20 O 0 0.00042725957
- O 0 0.0013874983
day O 0 0.00041311045
- O 0 0.0021355615
old O 0 0.0013309093
rats O 0 0.0026002578
. O 0 0.0033968315

Age O 0 0.033390816
- O 0 0.009709778
related O 0 0.0009157717
changes O 0 0.0007900015
in O 0 0.00050604827
ultrasound O 0 0.00076379324
production O 0 0.00047820635
corresponded O 0 0.00021751807
with O 0 0.00022587288
changes O 0 0.00020192102
in O 0 0.00016812289
cardiovascular O 0 0.0074301413
variables O 0 0.00018490214
, O 0 0.00019110412
including O 0 8.010786e-05
baseline O 0 0.00012402389
cardiac O 0 0.00055208075
rate O 0 0.00035508804
and O 0 0.00061070675
clonidine B-Chemical 0 0.99996257
- O 0 0.01884012
induced O 0 0.0014164046
bradycardia B-Disease 0 0.9978569
. O 0 0.0034313384

This O 0 0.0037205205
experiment O 0 0.0012121362
is O 0 0.00083031517
discussed O 0 0.0005816364
with O 0 0.00046527956
regard O 0 0.00024848513
to O 0 0.00021877914
the O 0 0.000158778
hypothesis O 0 0.0001569674
that O 0 0.00013140029
ultrasound O 0 0.0003653811
production O 0 0.00024987326
is O 0 0.00012452055
the O 0 0.000118821394
acoustic O 0 0.0005642287
by O 0 0.00016874525
- O 0 0.0009042728
product O 0 0.0001400938
of O 0 0.00013086548
a O 0 0.00018982834
physiological O 0 0.00017647704
maneuver O 0 0.005137983
that O 0 8.820134e-05
compensates O 0 9.436016e-05
for O 0 0.00017309711
clonidine B-Chemical 0 0.999946
' O 0 0.00065270264
s O 0 0.00033086233
detrimental O 0 0.00026988023
effects O 0 0.00029173112
on O 0 0.0003948153
cardiovascular O 0 0.09101308
function O 0 0.0012738797
. O 0 0.0025884614

Recurrent O 0 0.006762313
use O 0 0.001924996
of O 0 0.0018074051
newer O 0 0.0043080267
oral B-Chemical 0 0.016411604
contraceptives I-Chemical 0 0.6719173
and O 0 0.0012314568
the O 0 0.00095037086
risk O 0 0.004983175
of O 0 0.0025758175
venous B-Disease 0 0.9867138
thromboembolism I-Disease 0 0.9999316
. O 0 0.0070115

The O 0 0.00206866
epidemiological O 0 0.0024910443
studies O 0 0.0012597513
that O 0 0.0005941497
assessed O 0 0.0005612243
the O 0 0.00044945124
risk O 0 0.0020211788
of O 0 0.0006846876
venous B-Disease 0 0.9828235
thromboembolism I-Disease 0 0.99999404
( O 0 0.0074318787
VTE B-Disease 2 0.9998184
) O 0 0.00060696446
associated O 0 0.00014236776
with O 0 0.00015040152
newer O 0 0.00085825834
oral B-Chemical 0 0.011635813
contraceptives I-Chemical 0 0.9066797
( O 0 0.0015547534
OC B-Chemical 0 0.99947923
) O 0 0.0010468384
did O 0 0.00017673333
not O 0 0.00010372239
distinguish O 0 5.947831e-05
between O 0 8.162768e-05
patterns O 0 0.000120218865
of O 0 0.0002747382
OC B-Chemical 0 0.99576724
use O 0 0.00018744696
, O 0 0.00030023482
namely O 0 0.0001909708
first O 0 0.0001418339
- O 0 0.000894662
time O 0 0.00019407914
users O 0 0.0006581753
, O 0 0.0011384467
repeaters O 0 0.0112881
and O 0 0.0012648265
switchers O 0 0.007706491
. O 0 0.00334247

Data O 0 0.0044083004
from O 0 0.001802003
a O 0 0.0019097079
Transnational O 0 0.0018488368
case O 0 0.0009694217
- O 0 0.0022226973
control O 0 0.00044823953
study O 0 0.0003797917
were O 0 0.0002083051
used O 0 0.00015653991
to O 0 0.00012787728
assess O 0 7.99005e-05
the O 0 0.00015661994
risk O 0 0.0012961024
of O 0 0.00044425542
VTE B-Disease 2 0.9996971
for O 0 0.0001339825
the O 0 0.00011781108
latter O 0 0.00026883683
patterns O 0 0.000108919965
of O 0 0.00015562787
use O 0 0.0001566752
, O 0 0.0003257478
while O 0 0.00020038533
accounting O 0 0.0003292613
for O 0 0.00021095203
duration O 0 0.00028772894
of O 0 0.00072197133
use O 0 0.0012135167
. O 0 0.0026291946

Over O 0 0.0048086364
the O 0 0.0018349147
period O 0 0.0012732544
1993 O 0 0.0035336488
- O 0 0.0047520124
1996 O 0 0.002012882
, O 0 0.0016723312
551 O 0 0.005079613
cases O 0 0.0010419764
of O 0 0.0008391832
VTE B-Disease 2 0.99916244
were O 0 0.00030644026
identified O 0 0.00017193773
in O 0 0.00025669028
Germany O 0 0.0008281778
and O 0 0.00030931496
the O 0 0.00031201346
UK O 0 0.0020960555
along O 0 0.00050553965
with O 0 0.0008937035
2066 O 0 0.0046834005
controls O 0 0.002229674
. O 0 0.0031482305

Totals O 0 0.19442834
of O 0 0.0030643635
128 O 0 0.0034740765
cases O 0 0.0019416461
and O 0 0.0009822175
650 O 0 0.002070695
controls O 0 0.0006713344
were O 0 0.00032167076
analysed O 0 0.000288033
for O 0 0.00016471765
repeat O 0 0.00015833037
use O 0 0.00017227202
and O 0 0.00026260864
135 O 0 0.0005857169
cases O 0 0.0005131277
and O 0 0.00042586468
622 O 0 0.0015416619
controls O 0 0.00062420464
for O 0 0.00046122406
switching O 0 0.0008272222
patterns O 0 0.0014397351
. O 0 0.0032480345

The O 0 0.0018628876
adjusted O 0 0.0013603591
rate O 0 0.0015002218
ratio O 0 0.0010816567
of O 0 0.001227253
VTE B-Disease 2 0.99862444
for O 0 0.00033547851
repeat O 0 0.00023292101
users O 0 0.0003650321
of O 0 0.00026046197
third O 0 0.00028972438
generation O 0 0.00043222835
OC B-Chemical 0 0.99748755
was O 0 0.00027475657
0 O 0 0.00028432542
. O 0 0.00016326376
6 O 0 0.00012558911
( O 0 0.000276464
95 O 0 0.0003552577
% O 0 0.00039536672
CI O 0 0.0028625436
: O 0 0.00043707914
0 O 0 0.0002389052
. O 0 0.00015975129
3 O 0 0.00015861804
- O 0 0.00071434956
1 O 0 0.00017830462
. O 0 0.00013349025
2 O 0 0.00014236303
) O 0 0.00023085512
relative O 0 8.079448e-05
to O 0 9.2493596e-05
repeat O 0 8.769279e-05
users O 0 0.00016980227
of O 0 0.00012526796
second O 0 0.00011488833
generation O 0 0.00017265351
pills O 0 0.031405438
, O 0 0.0005328275
whereas O 0 0.00022725863
it O 0 0.00029857073
was O 0 0.0001758371
1 O 0 0.00019577584
. O 0 0.00014063789
3 O 0 0.00012706376
( O 0 0.0002514715
95 O 0 0.0003202082
% O 0 0.00035566636
CI O 0 0.002743358
: O 0 0.0003980309
0 O 0 0.00021663346
. O 0 0.00014379156
7 O 0 0.00013331701
- O 0 0.000609381
2 O 0 0.00015332816
. O 0 0.00011343009
4 O 0 9.4695126e-05
) O 0 0.00021127792
for O 0 8.623034e-05
switchers O 0 0.00055871776
from O 0 9.738006e-05
second O 0 8.6782864e-05
to O 0 8.315095e-05
third O 0 0.000110835856
generation O 0 0.00013001918
pills O 0 0.0019028761
relative O 0 0.00011147054
to O 0 0.00014458831
switchers O 0 0.0010863345
from O 0 0.00017357593
third O 0 0.00022181554
to O 0 0.00025453858
second O 0 0.00042335512
generation O 0 0.00095266
pills O 0 0.045379493
. O 0 0.0034573048

We O 0 0.0019987205
conclude O 0 0.0010452041
that O 0 0.0007202193
second O 0 0.00058672373
and O 0 0.0005059617
third O 0 0.0003773583
generation O 0 0.00029226957
agents O 0 0.00060566457
are O 0 0.00016167092
associated O 0 0.00016862122
with O 0 0.00015485991
equivalent O 0 0.00013968775
risks O 0 0.0003064703
of O 0 0.0003225115
VTE B-Disease 2 0.999724
when O 0 9.095761e-05
the O 0 8.2160215e-05
same O 0 6.861261e-05
agent O 0 0.00022591015
is O 0 6.701538e-05
used O 0 6.275794e-05
repeatedly O 0 6.408395e-05
after O 0 3.730228e-05
interruption O 0 8.772707e-05
periods O 0 6.847326e-05
or O 0 6.8355825e-05
when O 0 6.855323e-05
users O 0 0.00020970542
are O 0 0.00010560344
switched O 0 0.00019568458
between O 0 0.00012550518
the O 0 0.00017586861
two O 0 0.00020412955
generations O 0 0.00054557744
of O 0 0.0010627572
pills O 0 0.047455933
. O 0 0.0036251356

These O 0 0.0018961654
analyses O 0 0.0014997192
suggest O 0 0.00057465286
that O 0 0.00053084875
the O 0 0.00047202848
higher O 0 0.00058432424
risk O 0 0.00204525
observed O 0 0.00024632725
for O 0 0.00016998695
the O 0 0.00019200383
newer O 0 0.0017737891
OC B-Chemical 0 0.9976931
in O 0 0.00018384068
other O 0 0.00013485472
studies O 0 0.00019402176
may O 0 0.000105276566
be O 0 0.00010038111
the O 0 7.9400575e-05
result O 0 8.089315e-05
of O 0 0.000109378016
inadequate O 0 0.00017778784
comparisons O 0 0.000104449115
of O 0 0.00014359973
pill O 0 0.003685404
users O 0 0.00035496097
with O 0 0.00021178537
different O 0 0.00016193905
patterns O 0 0.0002599358
of O 0 0.0005890872
pill O 0 0.012161884
use O 0 0.0014955171
. O 0 0.002798853

Differential O 0 0.0027327437
effects O 0 0.0012438962
of O 0 0.0011174834
systemically O 0 0.0020472216
administered O 0 0.0017529131
ketamine B-Chemical 0 0.99991393
and O 0 0.00079510955
lidocaine B-Chemical 0 0.9996394
on O 0 0.00013426719
dynamic O 0 0.00015653693
and O 0 0.00018691743
static O 0 0.00044847376
hyperalgesia B-Disease 0 0.13945772
induced O 0 0.00030507275
by O 0 0.0004218312
intradermal O 0 0.0014282103
capsaicin B-Chemical 0 0.9753019
in O 0 0.0009655805
humans O 0 0.0021460329
. O 0 0.0027224554

We O 0 0.0022242544
have O 0 0.0011678343
examined O 0 0.0006412474
the O 0 0.00044578302
effect O 0 0.0003481081
of O 0 0.0004656987
systemic O 0 0.04850502
administration O 0 0.00058415224
of O 0 0.00038356756
ketamine B-Chemical 0 0.99996316
and O 0 0.00050617853
lidocaine B-Chemical 0 0.9998728
on O 0 0.00011630076
brush O 0 0.0012241651
- O 0 0.0013022261
evoked O 0 0.00034495824
( O 0 0.0002186974
dynamic O 0 0.00013817633
) O 0 0.0004365376
pain B-Disease 0 0.004189535
and O 0 0.00016519107
punctate O 0 0.0001668843
- O 0 0.0010594832
evoked O 0 0.0005134436
( O 0 0.00042422372
static O 0 0.00056259084
) O 0 0.0012720514
hyperalgesia B-Disease 0 0.25593907
induced O 0 0.0007891972
by O 0 0.0015585301
capsaicin B-Chemical 0 0.99614835
. O 0 0.0040483195

In O 0 0.0023116441
a O 0 0.0029832784
randomized O 0 0.0031217574
, O 0 0.001724336
double O 0 0.00090677734
- O 0 0.0053692823
blind O 0 0.025051434
, O 0 0.0012902275
placebo O 0 0.015365673
- O 0 0.0019729787
controlled O 0 0.00038314422
, O 0 0.00057705544
crossover O 0 0.0012504547
study O 0 0.0003530757
, O 0 0.0004089288
we O 0 0.00015451948
studied O 0 0.00039980703
12 O 0 0.00027107628
volunteers O 0 0.00069770485
in O 0 0.0004443149
three O 0 0.00040522576
experiments O 0 0.0009795772
. O 0 0.002857182

Capsaicin B-Chemical 0 0.9987783
100 O 0 0.005799733
micrograms O 0 0.0075862287
was O 0 0.00058140245
injected O 0 0.0003650874
intradermally O 0 0.00036833165
on O 0 0.00016611826
the O 0 0.00023090906
volar O 0 0.018187819
forearm O 0 0.033430506
followed O 0 0.00017582637
by O 0 0.00016067707
an O 0 0.0001869882
i O 0 0.0003169408
. O 0 0.00016175372
v O 0 0.0005481312
. O 0 0.00013606955
infusion O 0 0.00031281498
of O 0 0.0002096035
ketamine B-Chemical 0 0.9999341
( O 0 0.0004119537
bolus O 0 0.0006058508
0 O 0 0.00013810558
. O 0 8.876463e-05
1 O 0 0.00011465949
mg O 0 0.00074382295
kg O 0 0.0003423052
- O 0 0.000552246
1 O 0 0.00010835558
over O 0 6.711259e-05
10 O 0 8.829803e-05
min O 0 0.00012035054
followed O 0 5.989164e-05
by O 0 7.807e-05
infusion O 0 0.00020406533
of O 0 0.00010269707
7 O 0 9.61026e-05
micrograms O 0 0.0006629412
kg O 0 0.00040293788
- O 0 0.0006629412
1 O 0 0.00016388358
min O 0 0.00025787926
- O 0 0.0007004477
1 O 0 0.00018818854
) O 0 0.0003962734
, O 0 0.000494973
lidocaine B-Chemical 0 0.99931467
5 O 0 0.00021760895
mg O 0 0.0014184334
kg O 0 0.0005541252
- O 0 0.00092001643
1 O 0 0.00026749706
or O 0 0.0002484453
saline O 0 0.0008065869
for O 0 0.0004592444
50 O 0 0.0011942692
min O 0 0.0020507153
. O 0 0.0027002257

Infusion O 0 0.026485143
started O 0 0.003895981
15 O 0 0.0022961984
min O 0 0.002161563
after O 0 0.0009796036
injection O 0 0.0015219967
of O 0 0.0034764113
capsaicin B-Chemical 0 0.9818812
. O 0 0.008004812

The O 0 0.0016470444
following O 0 0.00088507426
were O 0 0.00081949466
measured O 0 0.0007688342
: O 0 0.0011535293
spontaneous O 0 0.0013250072
pain B-Disease 0 0.02538748
, O 0 0.00080919743
pain B-Disease 0 0.012580185
evoked O 0 0.0005716368
by O 0 0.00018232643
punctate O 0 0.00014485866
and O 0 0.00017284592
brush O 0 0.00060281757
stimuli O 0 0.0003098167
( O 0 0.0004296782
VAS O 0 0.0014354324
) O 0 0.00042596497
, O 0 0.0002964112
and O 0 0.0001989694
areas O 0 0.00031116238
of O 0 0.00027026338
brush O 0 0.0024579873
- O 0 0.0026847466
evoked O 0 0.0007688427
and O 0 0.0004017326
punctate O 0 0.00048340717
- O 0 0.003225937
evoked O 0 0.002928228
hyperalgesia B-Disease 0 0.4423636
. O 0 0.0032609368

Ketamine B-Chemical 1 0.9994435
reduced O 0 0.0030100886
both O 0 0.0010895951
the O 0 0.0007178067
area O 0 0.00078067573
of O 0 0.0005451836
brush O 0 0.0030297888
- O 0 0.0030145708
evoked O 0 0.0006755727
and O 0 0.00025869018
punctate O 0 0.00021136578
- O 0 0.0014104927
evoked O 0 0.00069165253
hyperalgesia B-Disease 0 0.24139884
significantly O 0 0.00027676203
and O 0 0.00023598703
it O 0 0.00032393856
tended O 0 0.00028660477
to O 0 0.00021219226
reduce O 0 0.0002541077
brush O 0 0.0040139137
- O 0 0.0063963737
evoked O 0 0.0033214078
pain B-Disease 0 0.07373417
. O 0 0.0029844132

Lidocaine B-Chemical 0 0.99926776
reduced O 0 0.004238396
the O 0 0.0018842708
area O 0 0.0019019626
of O 0 0.0013310835
punctate O 0 0.0012166173
- O 0 0.0051231845
evoked O 0 0.0038559441
hyperalgesia B-Disease 0 0.38118184
significantly O 0 0.0035760726
. O 0 0.0048192227

It O 0 0.0049120993
tended O 0 0.0020318755
to O 0 0.000837995
reduce O 0 0.00053764856
VAS O 0 0.0021247515
scores O 0 0.00040539794
of O 0 0.00041916352
spontaneous O 0 0.001325476
pain B-Disease 0 0.044454355
but O 0 0.0004377002
had O 0 0.0003068846
no O 0 0.0002898053
effect O 0 0.00040508542
on O 0 0.0005924637
evoked O 0 0.0034605346
pain B-Disease 0 0.11773367
. O 0 0.0033513275

The O 0 0.001478651
differential O 0 0.0012427084
effects O 0 0.0009160366
of O 0 0.0014322959
ketamine B-Chemical 0 0.9999325
and O 0 0.0013284549
lidocaine B-Chemical 0 0.9997851
on O 0 0.00015430333
static O 0 0.00026395355
and O 0 0.00015127457
dynamic O 0 0.00015790593
hyperalgesia B-Disease 0 0.02552979
suggest O 0 6.093077e-05
that O 0 6.88164e-05
the O 0 7.380541e-05
two O 0 5.8714144e-05
types O 0 8.8525405e-05
of O 0 0.00017239033
hyperalgesia B-Disease 0 0.20351852
are O 0 9.794274e-05
mediated O 0 6.6815905e-05
by O 0 0.000113501614
separate O 0 0.00010676542
mechanisms O 0 0.00014328568
and O 0 0.0002996669
have O 0 0.00033441212
a O 0 0.00074118545
distinct O 0 0.0006756889
pharmacology O 0 0.005165765
. O 0 0.0029644195

Development O 0 0.0073717055
of O 0 0.0060571805
apomorphine B-Chemical 0 0.9999411
- O 0 0.060029116
induced O 0 0.0013249908
aggressive B-Disease 0 0.26727873
behavior I-Disease 0 0.0026672143
: O 0 0.0010332445
comparison O 0 0.00031593922
of O 0 0.00043007304
adult O 0 0.0006536513
male O 0 0.0010375308
and O 0 0.0006930032
female O 0 0.0017549802
Wistar O 0 0.0043141674
rats O 0 0.0026542835
. O 0 0.0030179908

The O 0 0.0024791532
development O 0 0.003012968
of O 0 0.0038779431
apomorphine B-Chemical 0 0.999964
- O 0 0.04429038
induced O 0 0.00075085333
( O 0 0.0009822559
1 O 0 0.00039751272
. O 0 0.00025427635
0 O 0 0.0003160347
mg O 0 0.0013317437
/ O 0 0.0006839812
kg O 0 0.0004719113
s O 0 0.00030860127
. O 0 0.00019794512
c O 0 0.0007119411
. O 0 0.00016272182
once O 0 0.00011053831
daily O 0 0.00021645032
) O 0 0.0005379169
aggressive B-Disease 0 0.03208167
behavior I-Disease 0 0.00064800103
of O 0 0.00019318408
adult O 0 0.0002682922
male O 0 0.000364293
and O 0 0.00014903532
female O 0 0.00032480224
Wistar O 0 0.00064215343
rats O 0 0.00018086469
obtained O 0 8.493584e-05
from O 0 9.657461e-05
the O 0 0.00011408605
same O 0 0.00014651788
breeder O 0 0.00079332007
was O 0 0.00024654952
studied O 0 0.00038522226
in O 0 0.00031692328
two O 0 0.00032111123
consecutive O 0 0.0006669257
sets O 0 0.0011092959
. O 0 0.0025090564

In O 0 0.0019007011
male O 0 0.002830042
animals O 0 0.00092784176
, O 0 0.0015274362
repeated O 0 0.0006765533
apomorphine B-Chemical 0 0.99991393
treatment O 0 0.00044226905
induced O 0 0.00025916714
a O 0 0.00035734547
gradual O 0 0.00027137832
development O 0 0.00025009044
of O 0 0.00028000324
aggressive B-Disease 0 0.26340765
behavior I-Disease 0 0.0012633608
as O 0 0.0001695573
evidenced O 0 0.00024109184
by O 0 0.00012077534
the O 0 9.9196615e-05
increased O 0 0.00016364716
intensity O 0 7.5642245e-05
of O 0 0.00022218257
aggressiveness B-Disease 2 0.99105656
and O 0 0.00021715109
shortened O 0 0.00027725566
latency O 0 0.00035258662
before O 0 9.2126094e-05
the O 0 0.00015681598
first O 0 0.00020654354
attack O 0 0.0020250462
toward O 0 0.00080527907
the O 0 0.0010852618
opponent O 0 0.011184358
. O 0 0.0037615434

In O 0 0.0026565646
female O 0 0.0045472984
rats O 0 0.003155216
, O 0 0.002686594
only O 0 0.0013807288
a O 0 0.001653883
weak O 0 0.0019645365
tendency O 0 0.0028606728
toward O 0 0.002599743
aggressiveness B-Disease 2 0.9925208
was O 0 0.0025189875
found O 0 0.0030485808
. O 0 0.005055607

In O 0 0.0018040171
conclusion O 0 0.0012680894
, O 0 0.0019695596
the O 0 0.00065400376
present O 0 0.0004328802
study O 0 0.00042264163
demonstrates O 0 0.00017943249
gender O 0 0.0005641846
differences O 0 0.00016518604
in O 0 0.00016236272
the O 0 0.00013231904
development O 0 0.00019931213
of O 0 0.00020484628
the O 0 0.00032226287
apomorphine B-Chemical 0 0.9999926
- O 0 0.02643223
induced O 0 0.000231945
aggressive B-Disease 0 0.45356077
behavior I-Disease 0 0.0012993308
and O 0 0.00014622994
indicates O 0 7.3644194e-05
that O 0 7.1299175e-05
the O 0 9.050676e-05
female O 0 0.00032712458
rats O 0 0.00023057596
do O 0 0.000103725455
not O 0 8.6677006e-05
fill O 0 8.971774e-05
the O 0 8.941658e-05
validation O 0 0.00013904071
criteria O 0 0.00017346059
for O 0 0.00015594072
use O 0 0.00027455596
in O 0 0.00044400693
this O 0 0.0008571142
method O 0 0.0016775763
. O 0 0.0028644537

Intracranial B-Disease 0 0.9680453
aneurysms I-Disease 2 0.99970704
and O 0 0.009009894
cocaine B-Disease 2 0.9999237
abuse I-Disease 2 0.9990434
: O 0 0.004052717
analysis O 0 0.0012035593
of O 0 0.0013488438
prognostic O 0 0.0031075426
indicators O 0 0.0025011755
. O 0 0.0046131876

OBJECTIVE O 0 0.020423086
: O 0 0.0038096844
The O 0 0.00075783074
outcome O 0 0.0010371049
of O 0 0.0012305094
subarachnoid B-Disease 0 0.99969256
hemorrhage I-Disease 2 0.99991167
associated O 0 0.0008645513
with O 0 0.0011958838
cocaine B-Disease 2 0.99997044
abuse I-Disease 2 0.99949527
is O 0 0.0010842626
reportedly O 0 0.0030922869
poor O 0 0.0048905318
. O 0 0.003463611

However O 0 0.0029334843
, O 0 0.0032713683
no O 0 0.0012119168
study O 0 0.0010164717
in O 0 0.0005720982
the O 0 0.0004209508
literature O 0 0.00070362695
has O 0 0.00021172501
reported O 0 0.0002452114
the O 0 0.00015325141
use O 0 0.00015749002
of O 0 0.00021234767
a O 0 0.00029200414
statistical O 0 0.0002845296
model O 0 0.00015331895
to O 0 0.00013645076
analyze O 0 9.807182e-05
the O 0 0.00018026521
variables O 0 0.0003185858
that O 0 0.00026975447
influence O 0 0.00047165703
outcome O 0 0.0017322997
. O 0 0.0025843678

METHODS O 0 0.004949855
: O 0 0.0041975854
A O 0 0.0065182857
review O 0 0.0016963498
of O 0 0.0008716173
admissions O 0 0.0014500893
during O 0 0.00032098455
a O 0 0.0004552725
6 O 0 0.00024501322
- O 0 0.00079156895
year O 0 0.0001583628
period O 0 0.00011370484
revealed O 0 0.00015018342
14 O 0 0.00022596872
patients O 0 0.0005128608
with O 0 0.00063007977
cocaine B-Chemical 0 0.99951816
- O 0 0.010630748
related O 0 0.0011519743
aneurysms B-Disease 2 0.99858606
. O 0 0.0042126207

This O 0 0.004227949
group O 0 0.0023909123
was O 0 0.0009515823
compared O 0 0.0005040399
with O 0 0.0005267469
a O 0 0.00054543465
control O 0 0.00033533445
group O 0 0.00040596988
of O 0 0.00030005825
135 O 0 0.0005804291
patients O 0 0.00049712794
with O 0 0.00040309515
ruptured B-Disease 0 0.99415046
aneurysms I-Disease 2 0.999966
and O 0 0.0004251376
no O 0 0.00032695368
history O 0 0.0010062084
of O 0 0.0016658778
cocaine B-Disease 2 0.9999646
abuse I-Disease 2 0.9996081
. O 0 0.00558745

Age O 0 0.012524806
at O 0 0.0018985783
presentation O 0 0.002263989
, O 0 0.0014710809
time O 0 0.000520935
of O 0 0.00075610395
ictus O 0 0.017119583
after O 0 0.0002904426
intoxication O 0 0.9024656
, O 0 0.0008609236
Hunt O 0 0.0022456783
and O 0 0.00038870735
Hess O 0 0.025075398
grade O 0 0.00649234
of O 0 0.00058546884
subarachnoid B-Disease 0 0.9999169
hemorrhage I-Disease 2 0.9999659
, O 0 0.0004917913
size O 0 0.000245181
of O 0 0.00016223395
the O 0 0.00016526307
aneurysm B-Disease 0 0.9964845
, O 0 0.0003137504
location O 0 9.5952324e-05
of O 0 0.00014307653
the O 0 0.00016451329
aneurysm B-Disease 0 0.9962847
, O 0 0.0003753876
and O 0 0.00015165687
the O 0 0.00012826563
Glasgow O 0 0.00042883545
Outcome O 0 0.0002042296
Scale O 0 0.00067612046
score O 0 0.00018521231
were O 0 0.00024355402
assessed O 0 0.0004060746
and O 0 0.0007692024
compared O 0 0.0011205322
. O 0 0.0030298166

RESULTS O 0 0.004229129
: O 0 0.002761752
The O 0 0.0006628866
patients O 0 0.0009994945
in O 0 0.00043233793
the O 0 0.00030987017
study O 0 0.00033974118
group O 0 0.0003612441
were O 0 0.0002019006
significantly O 0 0.0002605131
younger O 0 0.0010468224
than O 0 0.00015137644
the O 0 0.0001325031
patients O 0 0.00028817917
in O 0 0.00013885363
the O 0 0.00013733185
control O 0 0.00021867905
group O 0 0.00043632102
( O 0 0.00069466786
P O 0 0.006723314
< O 0 0.00076671457
0 O 0 0.00078001776
. O 0 0.00094575324
002 O 0 0.006675786
) O 0 0.0043852916
. O 0 0.004086026

In O 0 0.002307978
patients O 0 0.0030862219
in O 0 0.0011732739
the O 0 0.0007829152
study O 0 0.0008290613
group O 0 0.0009294044
, O 0 0.0010935902
all O 0 0.00072310783
aneurysms B-Disease 2 0.9984301
were O 0 0.0005458505
located O 0 0.00041468142
in O 0 0.00048899965
the O 0 0.00071943324
anterior O 0 0.0068009673
circulation O 0 0.009605214
. O 0 0.0034130125

The O 0 0.0017891726
majority O 0 0.0012696618
of O 0 0.001182678
these O 0 0.0010807667
aneurysms B-Disease 2 0.9985732
were O 0 0.00046570066
smaller O 0 0.00039795786
than O 0 0.00021405933
those O 0 0.00021559061
of O 0 0.0001892623
the O 0 0.00014496631
control O 0 0.00018888206
group O 0 0.0003065197
( O 0 0.0003563956
8 O 0 0.00019683021
+ O 0 0.0007239076
/ O 0 0.0012583331
- O 0 0.0010550881
6 O 0 0.00014681589
. O 0 0.00017373121
08 O 0 0.0009771959
mm O 0 0.00052299764
versus O 0 0.0001833185
11 O 0 0.00026105985
+ O 0 0.00083830004
/ O 0 0.0015825704
- O 0 0.0015138772
5 O 0 0.00025282858
. O 0 0.00022060108
4 O 0 0.00021920302
mm O 0 0.00086882664
; O 0 0.00094593345
P O 0 0.006700102
= O 0 0.0016134337
0 O 0 0.0010690338
. O 0 0.0012301973
05 O 0 0.012995266
) O 0 0.0052365093
. O 0 0.00474925

The O 0 0.0019606936
differences O 0 0.0013813869
in O 0 0.0013287695
mortality O 0 0.0030707945
and O 0 0.00095563906
morbidity O 0 0.0030662084
between O 0 0.00041028493
the O 0 0.0004032422
two O 0 0.00036193253
groups O 0 0.0007848173
were O 0 0.0007762264
not O 0 0.0010152067
significant O 0 0.0020459224
. O 0 0.0040066815

Hunt O 0 0.024381885
and O 0 0.0052255862
Hess O 0 0.063898206
grade O 0 0.014888756
( O 0 0.0029831652
P O 0 0.012257614
< O 0 0.0013586836
0 O 0 0.00086191914
. O 0 0.0006046278
005 O 0 0.0022846372
) O 0 0.00084673107
and O 0 0.0003786924
age O 0 0.0005220845
( O 0 0.00060716347
P O 0 0.0038365507
< O 0 0.0004472265
0 O 0 0.00032154354
. O 0 0.0002403001
007 O 0 0.0012556739
) O 0 0.00047081904
were O 0 0.00013309254
significant O 0 0.00010965383
predictors O 0 8.83153e-05
of O 0 0.00014159203
outcome O 0 0.00019782361
for O 0 0.00011771832
the O 0 0.00016612587
patients O 0 0.0005363983
with O 0 0.00059028604
cocaine B-Chemical 0 0.99969923
- O 0 0.012680874
related O 0 0.001000852
aneurysms B-Disease 2 0.99881613
. O 0 0.0037897646

CONCLUSION O 0 0.04141952
: O 0 0.014940993
Cocaine B-Chemical 0 0.99973327
use O 0 0.002324821
predisposed O 0 0.3295951
aneurysmal B-Disease 0 0.99998903
rupture I-Disease 0 0.99951506
at O 0 0.00040972914
a O 0 0.00048058803
significantly O 0 0.00035054883
earlier O 0 0.0003729101
age O 0 0.0005329372
and O 0 0.00042179375
in O 0 0.00049295306
much O 0 0.0008310073
smaller O 0 0.0024139783
aneurysms B-Disease 2 0.9988558
. O 0 0.004633451

Contrary O 0 0.002319508
to O 0 0.0015572032
the O 0 0.0010858472
published O 0 0.0009709658
literature O 0 0.0014592911
, O 0 0.0012436776
this O 0 0.0006628863
group O 0 0.0008456123
did O 0 0.00062567607
reasonably O 0 0.00076336577
well O 0 0.00065908587
with O 0 0.0011627566
aggressive O 0 0.009997035
management O 0 0.002598705
. O 0 0.00352298

Effect O 0 0.0026792646
of O 0 0.0026615062
intravenous O 0 0.14104411
nimodipine B-Chemical 0 0.99997985
on O 0 0.0008658407
blood O 0 0.0046323976
pressure O 0 0.0051433286
and O 0 0.00064984494
outcome O 0 0.00084361754
after O 0 0.0007074366
acute B-Disease 0 0.7223882
stroke I-Disease 0 0.9991485
. O 0 0.0060320552

BACKGROUND O 0 0.009428195
AND O 0 0.0020502624
PURPOSE O 0 0.0023962918
: O 0 0.0015545143
The O 0 0.0005424052
Intravenous O 0 0.042455893
Nimodipine B-Chemical 0 0.99992025
West O 0 0.0009240654
European O 0 0.0006085075
Stroke B-Disease 0 0.041282546
Trial O 0 0.0008044891
( O 0 0.0005709485
INWEST O 0 0.016471349
) O 0 0.00051671336
found O 0 0.0001621186
a O 0 0.00020486054
correlation O 0 0.00013296088
between O 0 0.00023480806
nimodipine B-Chemical 0 0.9999987
- O 0 0.02566894
induced O 0 0.0001638264
reduction B-Disease 0 0.00020799729
in I-Disease 0 0.00015363636
blood I-Disease 0 0.0022031562
pressure I-Disease 0 0.009509568
( O 0 0.0005317998
BP O 0 0.37913337
) O 0 0.00050732144
and O 0 0.00021482892
an O 0 0.00028919586
unfavorable O 0 0.0011002613
outcome O 0 0.0006285773
in O 0 0.0008047816
acute B-Disease 0 0.9467208
stroke I-Disease 0 0.999634
. O 0 0.004784302

We O 0 0.0023766013
sought O 0 0.0015436066
to O 0 0.00073853513
confirm O 0 0.0003080005
this O 0 0.0004224072
correlation O 0 0.00027544794
with O 0 0.00028436934
and O 0 0.00022987023
without O 0 0.00017109468
adjustment O 0 0.00013130058
for O 0 9.1196525e-05
prognostic O 0 0.00025212448
variables O 0 0.00013314055
and O 0 9.7960685e-05
to O 0 6.764203e-05
investigate O 0 4.1838623e-05
outcome O 0 0.0001583749
in O 0 0.00012297441
subgroups O 0 0.000267918
with O 0 0.00021900496
increasing O 0 0.00028573006
levels O 0 0.00040782188
of O 0 0.0010717164
BP B-Disease 0 0.9951846
reduction I-Disease 0 0.007773618
. O 0 0.0033192239

METHODS O 0 0.004023926
: O 0 0.0030777538
Patients O 0 0.0013206776
with O 0 0.0007438793
a O 0 0.000869292
clinical O 0 0.0013237988
diagnosis O 0 0.0010047901
of O 0 0.0009697334
ischemic B-Disease 0 0.9999746
stroke I-Disease 0 0.99995196
( O 0 0.0006863663
within O 0 7.950073e-05
24 O 0 0.00010980639
hours O 0 8.507429e-05
) O 0 0.00020589036
were O 0 8.130552e-05
consecutively O 0 0.000117706535
allocated O 0 9.292307e-05
to O 0 6.818317e-05
receive O 0 9.000885e-05
placebo O 0 0.00060212536
( O 0 0.00018128926
n O 0 0.00014990356
= O 0 0.0004117158
100 O 0 0.0003148525
) O 0 0.00037766492
, O 0 0.00027560946
1 O 0 0.0001935336
mg O 0 0.0016370822
/ O 0 0.0005708247
h O 0 0.00017645821
( O 0 0.00024973872
low O 0 0.00022851976
- O 0 0.0011513376
dose O 0 0.00042384575
) O 0 0.0012102724
nimodipine B-Chemical 0 0.99999523
( O 0 0.00049824564
n O 0 0.00021543854
= O 0 0.000488615
101 O 0 0.00052557734
) O 0 0.0003823679
, O 0 0.0002558015
or O 0 0.00013695419
2 O 0 0.00020404607
mg O 0 0.0018256509
/ O 0 0.00065839675
h O 0 0.00021698841
( O 0 0.00031071686
high O 0 0.00028537665
- O 0 0.0014018421
dose O 0 0.00066027
) O 0 0.0019057264
nimodipine B-Chemical 0 0.9999895
( O 0 0.0014012648
n O 0 0.0007897904
= O 0 0.0018794289
94 O 0 0.0017788521
) O 0 0.0032219973
. O 0 0.0032360076

The O 0 0.0016242872
correlation O 0 0.0010690537
between O 0 0.00077458564
average O 0 0.00082046393
BP O 0 0.12624212
change O 0 0.00048410188
during O 0 0.00023822555
the O 0 0.00019981636
first O 0 0.00014417074
2 O 0 0.00020388057
days O 0 0.00011686473
and O 0 0.00018524111
the O 0 0.00017810226
outcome O 0 0.0003155828
at O 0 0.00024214438
day O 0 0.00031706225
21 O 0 0.00068330794
was O 0 0.0008383539
analyzed O 0 0.0015454391
. O 0 0.0031530783

RESULTS O 0 0.0041705873
: O 0 0.0025909473
Two O 0 0.0008445249
hundred O 0 0.0011052819
sixty O 0 0.0014152512
- O 0 0.0018555112
five O 0 0.00028221053
patients O 0 0.0005521843
were O 0 0.0002365554
included O 0 0.00019595196
in O 0 0.00018920889
this O 0 0.00020403111
analysis O 0 0.000186265
( O 0 0.00028717532
n O 0 0.00022773584
= O 0 0.00051651325
92 O 0 0.00035997384
, O 0 0.00031959274
93 O 0 0.00035225519
, O 0 0.00027545477
and O 0 0.0001563427
80 O 0 0.00019908288
for O 0 0.00011337926
placebo O 0 0.0014469532
, O 0 0.0002792711
low O 0 0.00023761035
dose O 0 0.00039157172
, O 0 0.000374806
and O 0 0.00026036287
high O 0 0.00043713057
dose O 0 0.0008952419
, O 0 0.0012510224
respectively O 0 0.0019274619
) O 0 0.0036683835
. O 0 0.0032014912

Nimodipine B-Chemical 0 0.99992514
treatment O 0 0.002995787
resulted O 0 0.0010327603
in O 0 0.0006719694
a O 0 0.00067475875
statistically O 0 0.00046721555
significant O 0 0.00023952877
reduction B-Disease 0 0.00025096512
in I-Disease 0 0.00018861516
systolic I-Disease 0 0.03984976
BP I-Disease 0 0.34121305
( O 0 0.0003965648
SBP O 0 0.004620766
) O 0 0.00033219418
and O 0 0.00015064495
diastolic O 0 0.14990333
BP O 0 0.41626498
( O 0 0.00042221235
DBP O 0 0.01992598
) O 0 0.00033173527
from O 0 9.007056e-05
baseline O 0 8.97049e-05
compared O 0 8.441052e-05
with O 0 0.00017821198
placebo O 0 0.0015470005
during O 0 0.00016913556
the O 0 0.00021634532
first O 0 0.00024307265
few O 0 0.00041167162
days O 0 0.0007258353
. O 0 0.0022997928

In O 0 0.0017227868
multivariate O 0 0.001686986
analysis O 0 0.0011821795
, O 0 0.0012809534
a O 0 0.0006781538
significant O 0 0.0003245271
correlation O 0 0.00023796903
between O 0 0.00025243187
DBP B-Disease 0 0.86106235
reduction I-Disease 0 0.0010071262
and O 0 0.00027623822
worsening O 0 0.002377971
of O 0 0.00016421049
the O 0 0.00013785415
neurological O 0 0.21341762
score O 0 0.00010745658
was O 0 8.3211875e-05
found O 0 8.3587256e-05
for O 0 6.8900845e-05
the O 0 8.528646e-05
high O 0 0.00018706986
- O 0 0.00096262427
dose O 0 0.00027552462
group O 0 0.00027835934
( O 0 0.0004905693
beta O 0 0.1122164
= O 0 0.0010985323
0 O 0 0.00033047076
. O 0 0.0002263774
49 O 0 0.00038802988
, O 0 0.00062162883
P O 0 0.008608228
= O 0 0.0014212918
0 O 0 0.0008851619
. O 0 0.0010017486
048 O 0 0.008074004
) O 0 0.0039627636
. O 0 0.0037809287

Patients O 0 0.004702747
with O 0 0.0021776336
a O 0 0.002531323
DBP B-Disease 0 0.8060436
reduction I-Disease 0 0.0021560087
of O 0 0.0007063285
> O 0 0.0010477672
or O 0 0.0003576935
= O 0 0.00078930584
20 O 0 0.00025306997
% O 0 0.00032848126
in O 0 0.00013627783
the O 0 0.00011849428
high O 0 0.00022365569
- O 0 0.0010961039
dose O 0 0.00026823618
group O 0 0.0001983568
had O 0 0.00012506651
a O 0 0.00017591708
significantly O 0 0.00014469409
increased O 0 0.00014583378
adjusted O 0 9.006988e-05
OR O 0 0.00067329826
for O 0 7.0238464e-05
the O 0 7.852987e-05
compound O 0 0.00057441165
outcome O 0 0.00017438464
variable O 0 0.000110456866
death B-Disease 0 0.07594413
or O 0 9.844905e-05
dependency O 0 0.00014248485
( O 0 0.00020803379
Barthel O 0 0.00015639699
Index O 0 0.0001068634
< O 0 0.00014890292
60 O 0 0.00014215453
) O 0 0.00029669388
( O 0 0.0002945238
n O 0 0.0003046641
/ O 0 0.0019738155
N O 0 0.9890103
= O 0 0.0015606337
25 O 0 0.00042466412
/ O 0 0.0009770936
26 O 0 0.00035109685
, O 0 0.00045164008
OR O 0 0.0014298507
10 O 0 0.0002517423
. O 0 0.0001998038
16 O 0 0.00023478232
, O 0 0.00036116698
95 O 0 0.00046144813
% O 0 0.00049513415
CI O 0 0.0037425074
1 O 0 0.0002756828
. O 0 0.00022119863
02 O 0 0.0020559633
to O 0 0.00017315702
101 O 0 0.0005405832
. O 0 0.00019539597
74 O 0 0.00031933203
) O 0 0.00043439813
and O 0 0.00025756843
death B-Disease 0 0.096365646
alone O 0 0.00028678408
( O 0 0.00041156763
n O 0 0.00034447628
/ O 0 0.0024444112
N O 0 0.99183744
= O 0 0.0012016211
9 O 0 0.00022032888
/ O 0 0.0007375055
26 O 0 0.00030325662
, O 0 0.00040625987
OR O 0 0.0012371595
4 O 0 0.00020979346
. O 0 0.00023889927
336 O 0 0.0009014235
, O 0 0.00040431728
95 O 0 0.00047077032
% O 0 0.00048656997
CI O 0 0.0033673402
1 O 0 0.00024432712
. O 0 0.00017601054
131 O 0 0.0003476251
16 O 0 0.00019476189
. O 0 0.00017790146
619 O 0 0.0009935531
) O 0 0.00030893364
compared O 0 9.456716e-05
with O 0 0.0001405707
all O 0 0.00015009295
placebo O 0 0.0017198772
patients O 0 0.00033978862
( O 0 0.0003018311
n O 0 0.00029516302
/ O 0 0.0020237658
N O 0 0.98991346
= O 0 0.0015844791
62 O 0 0.0005545753
/ O 0 0.0009745386
92 O 0 0.0005263539
and O 0 0.00032958033
14 O 0 0.00040872715
/ O 0 0.0015777805
92 O 0 0.0012908931
, O 0 0.0015556782
respectively O 0 0.002338993
) O 0 0.0045316336
. O 0 0.0040712226

There O 0 0.0047925757
was O 0 0.0025512592
no O 0 0.0016368717
correlation O 0 0.0013066566
between O 0 0.0014134813
SBP O 0 0.019455656
change O 0 0.0020343212
and O 0 0.0024096027
outcome O 0 0.0040517724
. O 0 0.0057277363

CONCLUSIONS O 0 0.025499227
: O 0 0.0067443564
DBP O 0 0.1845442
, O 0 0.0027024557
but O 0 0.0010448865
not O 0 0.00063327135
SBP O 0 0.03361752
, O 0 0.0009007839
reduction O 0 0.00041605975
was O 0 0.00022943452
associated O 0 0.0002149199
with O 0 0.0002451768
neurological O 0 0.47312462
worsening O 0 0.0011544779
after O 0 4.8415543e-05
the O 0 6.895212e-05
intravenous O 0 0.00044343653
administration O 0 0.00014911621
of O 0 0.00012793533
high O 0 0.00027435448
- O 0 0.002657244
dose O 0 0.0017282554
nimodipine B-Chemical 0 0.99999404
after O 0 0.000718888
acute B-Disease 0 0.9654084
stroke I-Disease 0 0.9996538
. O 0 0.004178349

For O 0 0.0022696739
low O 0 0.0038906257
- O 0 0.013488418
dose O 0 0.009172512
nimodipine B-Chemical 0 0.99998295
, O 0 0.0035092745
the O 0 0.00094182283
results O 0 0.00092893164
were O 0 0.0011353577
not O 0 0.0015139327
conclusive O 0 0.004147303
. O 0 0.005258734

These O 0 0.0025993525
results O 0 0.0020490715
do O 0 0.0016057579
not O 0 0.0010206219
confirm O 0 0.0005180902
or O 0 0.0008080251
exclude O 0 0.0007058151
a O 0 0.0016043748
neuroprotective O 0 0.014655898
property O 0 0.0026130613
of O 0 0.004449668
nimodipine B-Chemical 0 0.9999844
. O 0 0.009012662

Neonatal O 0 0.23231392
pyridoxine B-Chemical 0 0.99991024
responsive O 0 0.006064537
convulsions B-Disease 0 0.9995821
due O 0 0.002282561
to O 0 0.0029067972
isoniazid B-Chemical 1 0.99978906
therapy O 0 0.0064327247
. O 0 0.005006055

A O 0 0.09056173
17 O 0 0.006040707
- O 0 0.0062819314
day O 0 0.001020614
- O 0 0.002795049
old O 0 0.00074722816
infant O 0 0.0010882828
on O 0 0.00038125084
isoniazid B-Chemical 1 0.9999093
therapy O 0 0.00046010173
13 O 0 0.000230788
mg O 0 0.0014545379
/ O 0 0.0005665133
kg O 0 0.0003686211
daily O 0 0.00014805375
from O 0 9.539081e-05
birth O 0 0.00017907083
because O 0 9.2373106e-05
of O 0 0.00018141879
maternal O 0 0.00039684374
tuberculosis B-Disease 0 0.05869681
was O 0 0.00024553752
admitted O 0 0.0004658954
after O 0 0.000110799716
4 O 0 0.00018420319
days O 0 0.00021012676
of O 0 0.0008269432
clonic B-Disease 0 0.99184775
fits I-Disease 0 0.015415879
. O 0 0.0037528547

No O 0 0.007258453
underlying O 0 0.00496314
infective O 0 0.0067348606
or O 0 0.0021010642
biochemical O 0 0.002682682
cause O 0 0.0024434673
could O 0 0.0015982533
be O 0 0.0023334082
found O 0 0.0034541322
. O 0 0.0060987235

The O 0 0.002316608
fits B-Disease 0 0.0033615653
ceased O 0 0.0018081305
within O 0 0.00038574648
4 O 0 0.00034731827
hours O 0 0.00027278325
of O 0 0.00033214668
administering O 0 0.00071346073
intramuscular O 0 0.049120206
pyridoxine B-Chemical 0 0.9999902
, O 0 0.000854802
suggesting O 0 0.00017449606
an O 0 0.000317513
aetiology O 0 0.0116538005
of O 0 0.0018295549
pyridoxine B-Chemical 0 0.9999982
deficiency O 0 0.87818336
secondary O 0 0.0013193191
to O 0 0.0009864375
isoniazid B-Chemical 1 0.9999676
medication O 0 0.06826607
. O 0 0.0024947333

Ketamine B-Chemical 1 0.9993705
sedation O 0 0.041562255
for O 0 0.0009762393
the O 0 0.00068228564
reduction O 0 0.00078128534
of O 0 0.00075992726
children O 0 0.0018645569
' O 0 0.0015332194
s O 0 0.0015964753
fractures B-Disease 2 0.99454284
in O 0 0.0008895415
the O 0 0.0009098228
emergency O 0 0.004360815
department O 0 0.007382691
. O 0 0.0037931183

BACKGROUND O 0 0.015294264
: O 0 0.004049693
There O 0 0.0013894453
recently O 0 0.00092187716
has O 0 0.0005067724
been O 0 0.00050599163
a O 0 0.0006430528
resurgence O 0 0.00051787996
in O 0 0.00023975038
the O 0 0.00018344072
utilization O 0 0.00031939294
of O 0 0.0004272594
ketamine B-Chemical 0 0.99996006
, O 0 0.0005756105
a O 0 0.0002534056
unique O 0 0.00014968518
anesthetic O 0 0.0023120784
, O 0 0.00028403118
for O 0 0.00014200089
emergency O 0 0.0004197177
- O 0 0.0010581557
department O 0 0.00046243117
procedures O 0 0.00035698185
requiring O 0 0.00061809574
sedation O 0 0.006386042
. O 0 0.0022809554

The O 0 0.0015176248
purpose O 0 0.00096725405
of O 0 0.0010174405
the O 0 0.0005850011
present O 0 0.000416781
study O 0 0.0004335048
was O 0 0.00022108454
to O 0 0.00012760516
examine O 0 5.9056125e-05
the O 0 8.472463e-05
safety O 0 9.8974764e-05
and O 0 8.7102395e-05
efficacy O 0 0.00010462625
of O 0 0.00018800399
ketamine B-Chemical 0 0.99993896
for O 0 0.00011369421
sedation O 0 0.0016216665
in O 0 7.9977945e-05
the O 0 7.499033e-05
treatment O 0 0.00011147787
of O 0 0.00017543482
children O 0 0.0007423454
' O 0 0.0006942555
s O 0 0.00082526135
fractures B-Disease 2 0.9976484
in O 0 0.0005122682
the O 0 0.0005677078
emergency O 0 0.0035285503
department O 0 0.006266116
. O 0 0.0028295785

METHODS O 0 0.004193125
: O 0 0.0029210085
One O 0 0.0012555573
hundred O 0 0.0010510985
and O 0 0.0007370642
fourteen O 0 0.0008445683
children O 0 0.0012938097
( O 0 0.00073052035
average O 0 0.00029301364
age O 0 0.00049795554
, O 0 0.00050627673
5 O 0 0.0002283503
. O 0 0.00017590282
3 O 0 0.00013708642
years O 0 0.00018955018
; O 0 0.00025615952
range O 0 0.00014110815
, O 0 0.00018919536
twelve O 0 8.628898e-05
months O 0 4.9306833e-05
to O 0 6.244518e-05
ten O 0 5.7200406e-05
years O 0 0.00010652176
and O 0 7.808444e-05
ten O 0 5.029434e-05
months O 0 4.8608406e-05
) O 0 0.00018434126
who O 0 0.00012436438
underwent O 0 0.000118551456
closed O 0 0.00018189338
reduction O 0 0.00014823001
of O 0 0.00014485687
an O 0 0.00017323729
isolated O 0 0.0002308573
fracture B-Disease 0 0.95889217
or O 0 0.00020748269
dislocation B-Disease 0 0.9303854
in O 0 0.00014728199
the O 0 0.000120745055
emergency O 0 0.0007771112
department O 0 0.0006495202
at O 0 0.000104039565
a O 0 0.00023388729
level O 0 0.00024577504
- O 0 0.004848924
I O 0 0.08079299
trauma B-Disease 0 0.836919
center O 0 0.00068379624
were O 0 0.00048992434
prospectively O 0 0.00095308304
evaluated O 0 0.0011264017
. O 0 0.0023605353

Ketamine B-Chemical 1 0.9999056
hydrochloride I-Chemical 0 0.99884963
was O 0 0.00120401
administered O 0 0.0009237023
intravenously O 0 0.0007805944
( O 0 0.00041671805
at O 0 0.00014651341
a O 0 0.00023043223
dose O 0 0.00023039774
of O 0 0.00013218055
two O 0 9.1605296e-05
milligrams O 0 0.0003557459
per O 0 0.0001139534
kilogram O 0 0.00029564943
of O 0 0.00010079191
body O 0 0.00018189824
weight O 0 0.0002105493
) O 0 0.0002864848
in O 0 0.00011642404
ninety O 0 0.00040023963
- O 0 0.0005686377
nine O 0 8.165695e-05
of O 0 9.72853e-05
the O 0 8.431656e-05
patients O 0 0.000205551
and O 0 0.000110103
intramuscularly O 0 0.00026708806
( O 0 0.00014250385
at O 0 5.6268775e-05
a O 0 0.000114763076
dose O 0 0.00013837885
of O 0 8.82663e-05
four O 0 6.3464315e-05
milligrams O 0 0.0002920186
per O 0 0.00010808449
kilogram O 0 0.00032531234
of O 0 0.00013719586
body O 0 0.00029801668
weight O 0 0.0004007402
) O 0 0.00061245216
in O 0 0.00031471177
the O 0 0.0003970554
other O 0 0.00070572534
fifteen O 0 0.0015574227
. O 0 0.002818608

A O 0 0.041648865
board O 0 0.004768243
- O 0 0.0062899287
certified O 0 0.0010339229
emergency O 0 0.00113745
physician O 0 0.0010567341
skilled O 0 0.00068909343
in O 0 0.00032198432
airway O 0 0.0006633135
management O 0 0.00023665556
supervised O 0 0.00021435873
administration O 0 0.00026169507
of O 0 0.0001729257
the O 0 0.0001570683
anesthetic O 0 0.0041283774
, O 0 0.00031111194
and O 0 0.00017139936
the O 0 0.000155492
patients O 0 0.00037217172
were O 0 0.00019584624
monitored O 0 0.00020543659
by O 0 0.0003734182
a O 0 0.0008968427
registered O 0 0.0014924201
nurse O 0 0.0032837007
. O 0 0.0031290136

Any O 0 0.0046021044
pain B-Disease 0 0.019692369
during O 0 0.0008243988
the O 0 0.0005619914
reduction O 0 0.00056714617
was O 0 0.00033735926
rated O 0 0.0004420176
by O 0 0.00020608008
the O 0 0.00016819827
orthopaedic O 0 0.00039207132
surgeon O 0 0.00036847018
treating O 0 0.00020295831
the O 0 0.000120973236
patient O 0 0.00016275301
according O 0 9.4152354e-05
to O 0 0.000107816944
the O 0 0.00014055609
Children O 0 0.0004441745
' O 0 0.00040815244
s O 0 0.00038712332
Hospital O 0 0.00042236046
of O 0 0.00030544793
Eastern O 0 0.00086272124
Ontario O 0 0.0007336315
Pain B-Disease 0 0.0058243615
Scale O 0 0.0037232845
( O 0 0.0017866555
CHEOPS O 0 0.1215981
) O 0 0.003985967
. O 0 0.0037490358

RESULTS O 0 0.0037661777
: O 0 0.0021936358
The O 0 0.00045427907
average O 0 0.0003466139
time O 0 0.0002441513
from O 0 0.00027043352
intravenous O 0 0.0010703792
administration O 0 0.00038426864
of O 0 0.0003294509
ketamine B-Chemical 0 0.99987113
to O 0 0.00014878725
manipulation O 0 0.00011316357
of O 0 0.00015958548
the O 0 0.00017170621
fracture B-Disease 0 0.9167496
or O 0 0.00020766121
dislocation B-Disease 0 0.85340095
was O 0 0.000119493576
one O 0 8.194331e-05
minute O 0 0.00010282955
and O 0 8.824206e-05
thirty O 0 0.00010851566
- O 0 0.000337858
six O 0 4.3956814e-05
seconds O 0 8.035284e-05
( O 0 0.0001443091
range O 0 9.3682545e-05
, O 0 0.00013735937
twenty O 0 7.6307915e-05
seconds O 0 7.6997494e-05
to O 0 5.706942e-05
five O 0 4.656667e-05
minutes O 0 8.855716e-05
) O 0 0.00022481664
, O 0 0.00016065729
and O 0 8.703224e-05
the O 0 6.0504266e-05
average O 0 5.4020667e-05
time O 0 4.963273e-05
from O 0 7.6857825e-05
intramuscular O 0 0.0003271829
administration O 0 0.00011840822
to O 0 5.264479e-05
manipulation O 0 5.75833e-05
was O 0 6.0943672e-05
four O 0 4.2442658e-05
minutes O 0 7.342836e-05
and O 0 9.952861e-05
forty O 0 0.00022974797
- O 0 0.00042391787
two O 0 7.440856e-05
seconds O 0 0.00013175861
( O 0 0.00024909808
range O 0 0.00018789414
, O 0 0.00034404342
sixty O 0 0.0004305944
seconds O 0 0.00026983858
to O 0 0.00030457348
fifteen O 0 0.00056945824
minutes O 0 0.0008614381
) O 0 0.0028035413
. O 0 0.0029592193

The O 0 0.0017769253
average O 0 0.001231055
score O 0 0.000890926
according O 0 0.00051421573
to O 0 0.00042820064
the O 0 0.00040251363
Children O 0 0.0008283687
' O 0 0.00067794195
s O 0 0.0005291816
Hospital O 0 0.00045690523
of O 0 0.00026557417
Eastern O 0 0.00058910856
Ontario O 0 0.00039866354
Pain B-Disease 0 0.0029573515
Scale O 0 0.0012121928
was O 0 0.00012825511
6 O 0 9.7003045e-05
. O 0 0.00010566337
4 O 0 8.752845e-05
points O 0 0.00011710234
( O 0 0.00024968726
range O 0 0.00016063586
, O 0 0.00023885511
5 O 0 0.00011486654
to O 0 9.034877e-05
10 O 0 0.00011099895
points O 0 0.00013081744
) O 0 0.00040590565
, O 0 0.00030796934
reflecting O 0 0.00022801418
minimal O 0 0.00017047505
or O 0 0.00020003253
no O 0 0.00031731903
pain B-Disease 0 0.019641478
during O 0 0.0006024824
fracture B-Disease 0 0.8803847
reduction O 0 0.002602034
. O 0 0.0031901957

Adequate O 0 0.009338687
fracture B-Disease 0 0.7688247
reduction O 0 0.0033179887
was O 0 0.0017247752
obtained O 0 0.0011608541
in O 0 0.0013413037
111 O 0 0.0030974743
of O 0 0.0018066879
the O 0 0.0020547486
children O 0 0.0069572
. O 0 0.005865939

Ninety O 0 0.009234543
- O 0 0.0064011975
nine O 0 0.0011675067
percent O 0 0.0010433329
( O 0 0.0013341728
sixty O 0 0.0012883346
- O 0 0.0016399745
eight O 0 0.00025721948
) O 0 0.00056904816
of O 0 0.0002547481
the O 0 0.00020350108
sixty O 0 0.00056098955
- O 0 0.0010028835
nine O 0 0.00014754722
parents O 0 0.00036860493
present O 0 9.7725744e-05
during O 0 8.302118e-05
the O 0 9.434972e-05
reduction O 0 0.00016169189
were O 0 0.00012288263
pleased O 0 0.00065467635
with O 0 0.00013158472
the O 0 0.000108137385
sedation O 0 0.002342283
and O 0 0.00012332846
would O 0 9.3692535e-05
allow O 0 0.00010748026
it O 0 0.00021491006
to O 0 0.0001359111
be O 0 0.00015907137
used O 0 0.00017585757
again O 0 0.00027353465
in O 0 0.00034578185
a O 0 0.0007013522
similar O 0 0.00052794925
situation O 0 0.0015827586
. O 0 0.0027806235

Patency O 0 0.009485569
of O 0 0.002264197
the O 0 0.0013075001
airway O 0 0.0023917276
and O 0 0.00085241516
independent O 0 0.00057776924
respiration O 0 0.014141242
were O 0 0.0004907121
maintained O 0 0.00051320996
in O 0 0.0004765168
all O 0 0.00053605664
of O 0 0.00082753086
the O 0 0.001067675
patients O 0 0.0033124685
. O 0 0.0035090614

Blood O 0 0.040648647
pressure O 0 0.024601826
and O 0 0.0054517514
heart O 0 0.024405804
rate O 0 0.005069607
remained O 0 0.0050075585
stable O 0 0.0058920574
. O 0 0.008569055

Minor O 0 0.014518793
side O 0 0.004500276
effects O 0 0.0014333705
included O 0 0.0013554364
nausea B-Disease 0 0.9980629
( O 0 0.0012716443
thirteen O 0 0.0005619775
patients O 0 0.0008116234
) O 0 0.0009037693
, O 0 0.0008134073
emesis B-Disease 0 0.98796844
( O 0 0.00037040247
eight O 0 8.625945e-05
of O 0 0.00012128521
the O 0 9.764946e-05
thirteen O 0 0.00016834974
patients O 0 0.00030010662
with O 0 0.00024731044
nausea B-Disease 0 0.9993262
) O 0 0.0013964641
, O 0 0.0011964643
clumsiness B-Disease 0 0.99989796
( O 0 0.0006975347
evident O 0 0.00021508655
as O 0 0.00031445053
ataxic B-Disease 0 0.99994504
movements I-Disease 0 0.0036504916
in O 0 0.00013228269
ten O 0 9.010511e-05
patients O 0 0.00033475406
) O 0 0.0004801876
, O 0 0.000495637
and O 0 0.0007314329
dysphoric B-Disease 0 0.99999523
reaction I-Disease 0 0.0014923498
( O 0 0.0009438404
one O 0 0.00051122473
patient O 0 0.0010513989
) O 0 0.0027146935
. O 0 0.0027473227

No O 0 0.0047508674
long O 0 0.002700638
- O 0 0.005364815
term O 0 0.0013436448
sequelae O 0 0.0052145254
were O 0 0.0006646332
noted O 0 0.0005989233
, O 0 0.0008411145
and O 0 0.0004909131
no O 0 0.0004958247
patients O 0 0.0015091366
had O 0 0.0015896723
hallucinations B-Disease 0 0.9999801
or O 0 0.003101358
nightmares O 0 0.9766641
. O 0 0.004753747

CONCLUSIONS O 0 0.048024517
: O 0 0.012367752
Ketamine B-Chemical 1 0.9995689
reliably O 0 0.0013080512
, O 0 0.0013161792
safely O 0 0.00075691234
, O 0 0.0006508637
and O 0 0.00030253959
quickly O 0 0.00025692486
provided O 0 0.00012666878
adequate O 0 0.0001854974
sedation O 0 0.0012637645
to O 0 9.852163e-05
effectively O 0 9.13898e-05
facilitate O 0 8.541188e-05
the O 0 0.000108348555
reduction O 0 0.00018080503
of O 0 0.00019895063
children O 0 0.0007635072
' O 0 0.0005651125
s O 0 0.00059712364
fractures B-Disease 2 0.99792683
in O 0 0.0002555704
the O 0 0.000231777
emergency O 0 0.0012214151
department O 0 0.0012906103
at O 0 0.00035058847
our O 0 0.0006354301
institution O 0 0.0021641932
. O 0 0.0028243286

Ketamine B-Chemical 1 0.99954337
should O 0 0.0015007678
only O 0 0.0011923652
be O 0 0.00062788697
used O 0 0.0004026923
in O 0 0.00034466124
an O 0 0.00031214466
environment O 0 0.0002911679
such O 0 0.00019400624
as O 0 0.00019675476
the O 0 0.00018063167
emergency O 0 0.0012027274
department O 0 0.0014428528
, O 0 0.00031767346
where O 0 0.00013042137
proper O 0 0.00011035569
one O 0 0.00013769927
- O 0 0.00082058203
on O 0 0.00010377738
- O 0 0.00069540704
one O 0 8.337765e-05
monitoring O 0 8.2179016e-05
is O 0 6.5460954e-05
used O 0 7.7175835e-05
and O 0 0.00012158964
board O 0 0.00022359706
- O 0 0.00068123563
certified O 0 0.00012156402
physicians O 0 0.00031272642
skilled O 0 0.00026614856
in O 0 0.00014436583
airway O 0 0.000506003
management O 0 0.00017123812
are O 0 9.5058385e-05
directly O 0 8.8720386e-05
involved O 0 0.00014312414
in O 0 0.00020152249
the O 0 0.00022825191
care O 0 0.00043534592
of O 0 0.00056344626
the O 0 0.00072850875
patient O 0 0.0016699712
. O 0 0.0025210069

Cyclosporine B-Chemical 0 0.99935824
and O 0 0.01577121
tacrolimus B-Chemical 0 0.9998493
- O 0 0.20259969
associated O 0 0.012127583
thrombotic B-Disease 0 0.99980384
microangiopathy I-Disease 0 0.9999839
. O 0 0.0148657095

The O 0 0.0028037762
development O 0 0.003550258
of O 0 0.00552405
thrombotic B-Disease 0 0.9999559
microangiopathy I-Disease 0 0.99999905
( O 0 0.12272097
TMA B-Disease 0 0.99568355
) O 0 0.0013513537
associated O 0 0.00030436303
with O 0 0.0002411914
the O 0 0.00018730831
use O 0 0.00024191017
of O 0 0.00062067213
cyclosporine B-Chemical 1 0.99997175
has O 0 0.00045986427
been O 0 0.000598806
well O 0 0.0008585614
documented O 0 0.0021453511
. O 0 0.003067245

Treatments O 0 0.007604624
have O 0 0.0012207051
included O 0 0.0007894781
discontinuation O 0 0.0022865061
or O 0 0.0003353696
reduction O 0 0.00037563406
of O 0 0.00049567106
cyclosporine B-Chemical 1 0.9999825
dose O 0 0.0006769622
with O 0 0.00017029533
or O 0 0.00011799861
without O 0 0.00014373289
concurrent O 0 0.00037060576
plasma O 0 0.0037651954
exchange O 0 0.00022812028
, O 0 0.00031173785
plasma O 0 0.0018200477
infusion O 0 0.0005092662
, O 0 0.00032330945
anticoagulation O 0 0.002106592
, O 0 0.00035676308
and O 0 0.00034151686
intravenous O 0 0.0051852264
immunoglobulin O 0 0.054519434
G O 0 0.6550592
infusion O 0 0.00735607
. O 0 0.0027982912

However O 0 0.0026299586
, O 0 0.0026256396
for O 0 0.00074254104
recipients O 0 0.00051750796
of O 0 0.0005200038
organ O 0 0.000687268
transplantation O 0 0.00050980237
, O 0 0.00043290126
removing O 0 0.0001942713
the O 0 0.00020781768
inciting O 0 0.00080324884
agent O 0 0.0005519741
is O 0 0.000156113
not O 0 0.00014747016
without O 0 0.00017729167
the O 0 0.00016226909
attendant O 0 0.00038210113
risk O 0 0.002708133
of O 0 0.00044982068
precipitating O 0 0.07232745
acute O 0 0.09655218
rejection O 0 0.008455511
and O 0 0.0006145214
graft O 0 0.0017029073
loss O 0 0.0016546517
. O 0 0.0024527863

The O 0 0.0016922525
last O 0 0.0009694287
decade O 0 0.0014220874
has O 0 0.0005525087
seen O 0 0.00052653905
the O 0 0.0003262914
emergence O 0 0.000418097
of O 0 0.0005232186
tacrolimus B-Chemical 0 0.99996316
as O 0 0.0002703289
a O 0 0.0002889787
potent O 0 0.00030731235
immunosuppressive O 0 0.008296046
agent O 0 0.00032793393
with O 0 0.00013128806
mechanisms O 0 9.943318e-05
of O 0 0.00017380115
action O 0 0.0001968437
virtually O 0 0.00017087065
identical O 0 0.00016027843
to O 0 0.00027848035
those O 0 0.00061367423
of O 0 0.0016001399
cyclosporine B-Chemical 1 0.99993813
. O 0 0.0043337727

As O 0 0.002245377
a O 0 0.0024925263
result O 0 0.0011483141
, O 0 0.0014484993
switching O 0 0.0006573306
to O 0 0.0007134699
tacrolimus B-Chemical 0 0.9999486
has O 0 0.00027467273
been O 0 0.00023958954
reported O 0 0.00022302562
to O 0 0.00014185418
be O 0 0.00014000297
a O 0 0.00018482597
viable O 0 0.00012257649
therapeutic O 0 0.00019512414
option O 0 0.00017033807
in O 0 0.00014583435
the O 0 0.0001615675
setting O 0 0.0002918967
of O 0 0.0008676816
cyclosporine B-Chemical 1 0.9999845
- O 0 0.099641554
induced O 0 0.0024595077
TMA B-Disease 0 0.99040073
. O 0 0.0045732046

With O 0 0.0021527912
the O 0 0.001421225
more O 0 0.0013411401
widespread O 0 0.00071749423
application O 0 0.0005517669
of O 0 0.000787824
tacrolimus B-Chemical 0 0.9999281
in O 0 0.00035474342
organ O 0 0.0004904991
transplantation O 0 0.00045292013
, O 0 0.0009588516
tacrolimus B-Chemical 0 0.9999676
- O 0 0.02038221
associated O 0 0.0008757009
TMA B-Disease 0 0.92016685
has O 0 0.00040956473
also O 0 0.0006153669
been O 0 0.0009776335
recognized O 0 0.001638172
. O 0 0.0033038084

However O 0 0.0029952996
, O 0 0.003577471
literature O 0 0.0020113057
regarding O 0 0.0005547162
the O 0 0.00057319796
incidence O 0 0.0009071541
of O 0 0.0004799512
the O 0 0.00038381302
recurrence O 0 0.013419061
of O 0 0.00061500975
TMA B-Disease 0 0.9589409
in O 0 0.00024250643
patients O 0 0.00038152514
exposed O 0 0.00019664859
sequentially O 0 0.00018018685
to O 0 0.00032257423
cyclosporine B-Chemical 1 0.99997365
and O 0 0.0012403765
tacrolimus B-Chemical 0 0.9999324
is O 0 0.0008643644
limited O 0 0.0014842652
. O 0 0.0027845032

We O 0 0.0027848156
report O 0 0.002997679
a O 0 0.001740599
case O 0 0.0008837731
of O 0 0.0006350747
a O 0 0.0006584674
living O 0 0.0005994721
donor O 0 0.0002576215
renal O 0 0.049257766
transplant O 0 0.00027316692
recipient O 0 0.00014336003
who O 0 0.00020318621
developed O 0 0.00034055946
cyclosporine B-Chemical 1 0.9999926
- O 0 0.038878188
induced O 0 0.0003284875
TMA B-Disease 0 0.97150034
that O 0 0.000104322295
responded O 0 0.00017122195
to O 0 7.8161174e-05
the O 0 8.2135215e-05
withdrawal O 0 0.00068563805
of O 0 0.0002267954
cyclosporine B-Chemical 1 0.9999895
in O 0 0.00013976368
conjunction O 0 0.00013151298
with O 0 0.0001727879
plasmapheresis O 0 0.047421627
and O 0 0.00024317559
fresh O 0 0.00063302735
frozen O 0 0.0010191441
plasma O 0 0.0072307917
replacement O 0 0.000878396
therapy O 0 0.0015127582
. O 0 0.0019907393

Introduction O 0 0.0038642865
of O 0 0.0035798294
tacrolimus B-Chemical 0 0.99979156
as O 0 0.0010371365
an O 0 0.00055446615
alternative O 0 0.00027878906
immunosuppressive O 0 0.0032717118
agent O 0 0.0006728778
resulted O 0 0.00025769518
in O 0 0.00024849223
the O 0 0.00025590105
recurrence O 0 0.009358494
of O 0 0.00053923985
TMA B-Disease 0 0.9510449
and O 0 0.00028735856
the O 0 0.00018609424
subsequent O 0 0.00020624285
loss O 0 0.00038234162
of O 0 0.0004498638
the O 0 0.0006251304
renal O 0 0.6950872
allograft O 0 0.015428623
. O 0 0.003017143

Patients O 0 0.0041038212
who O 0 0.0019953696
are O 0 0.0007910479
switched O 0 0.0011215947
from O 0 0.00081404124
cyclosporine B-Chemical 1 0.99995494
to O 0 0.0009129194
tacrolimus B-Chemical 0 0.99998283
or O 0 0.0006150083
vice O 0 0.0645859
versa O 0 0.004166228
should O 0 0.00011335353
be O 0 0.00013476177
closely O 0 0.00010118377
monitored O 0 9.445307e-05
for O 0 0.000110847264
the O 0 0.00017387308
signs O 0 0.0010095306
and O 0 0.000472423
symptoms O 0 0.004582839
of O 0 0.0012678807
recurrent O 0 0.0509745
TMA B-Disease 0 0.98062885
. O 0 0.0041643335

Analgesic O 0 0.35070986
effect O 0 0.0013418032
of O 0 0.0013830581
intravenous O 0 0.10212484
ketamine B-Chemical 0 0.9999347
in O 0 0.0007735795
cancer B-Disease 0 0.8597641
patients O 0 0.0006719227
on O 0 0.0001847955
morphine B-Chemical 0 0.99901545
therapy O 0 0.00034150804
: O 0 0.00030175573
a O 0 0.00022076376
randomized O 0 0.0004338806
, O 0 0.0002608578
controlled O 0 0.0002047717
, O 0 0.0003401101
double O 0 0.00024653308
- O 0 0.003366912
blind O 0 0.036445342
, O 0 0.00084363733
crossover O 0 0.0020950127
, O 0 0.00078340486
double O 0 0.0005611548
- O 0 0.0032459665
dose O 0 0.0016452733
study O 0 0.0017853277
. O 0 0.0027771061

Pain B-Disease 0 0.04788152
not O 0 0.00310862
responsive O 0 0.0019782851
to O 0 0.0027703291
morphine B-Chemical 0 0.99784315
is O 0 0.002495277
often O 0 0.003358648
problematic O 0 0.0049283043
. O 0 0.0061101746

Animal O 0 0.0060661724
and O 0 0.0025244518
clinical O 0 0.002825591
studies O 0 0.0012090644
have O 0 0.00066534936
suggested O 0 0.00058090064
that O 0 0.00080199307
N B-Chemical 0 0.9993556
- I-Chemical 0 0.7142926
methyl I-Chemical 0 0.9979086
- I-Chemical 0 0.62263197
D I-Chemical 0 0.9988992
- I-Chemical 0 0.89761597
aspartate I-Chemical 1 0.9999031
( O 0 0.016468044
NMDA B-Chemical 0 0.9999647
) O 0 0.0028310039
antagonists O 0 0.025470603
, O 0 0.00041652564
such O 0 0.00016031314
as O 0 0.00030076312
ketamine B-Chemical 0 0.99998105
, O 0 0.00056100107
may O 0 9.2706316e-05
be O 0 7.836552e-05
effective O 0 7.20724e-05
in O 0 7.718591e-05
improving O 0 0.00011629599
opioid O 0 0.25601262
analgesia O 0 0.17057814
in O 0 0.00011838992
difficult O 0 0.00018718158
pain B-Disease 0 0.069654144
syndromes O 0 0.23763087
, O 0 0.0005898845
such O 0 0.00039702814
as O 0 0.00089523714
neuropathic B-Disease 0 0.9992072
pain I-Disease 0 0.9689227
. O 0 0.00332266

A O 0 0.018734807
slow O 0 0.0043369383
bolus O 0 0.004756019
of O 0 0.0012461162
subhypnotic O 0 0.9967468
doses O 0 0.0019499745
of O 0 0.0008586052
ketamine B-Chemical 0 0.9999404
( O 0 0.00081334723
0 O 0 0.00029300188
. O 0 0.00017026433
25 O 0 0.00023486516
mg O 0 0.0012739392
/ O 0 0.0005880234
kg O 0 0.00036779075
or O 0 0.00012916935
0 O 0 0.000184575
. O 0 0.00013072304
50 O 0 0.00019270997
mg O 0 0.0013449992
/ O 0 0.00060952216
kg O 0 0.00044784427
) O 0 0.00032859648
was O 0 0.000100734644
given O 0 6.7838795e-05
to O 0 9.4517214e-05
10 O 0 0.00016162962
cancer B-Disease 0 0.6153003
patients O 0 0.0004124602
whose O 0 0.00018338196
pain B-Disease 0 0.0155655015
was O 0 0.00012698708
unrelieved O 0 0.0043960335
by O 0 0.0001740343
morphine B-Chemical 0 0.9995018
in O 0 0.00014554817
a O 0 0.00022235082
randomized O 0 0.00046672527
, O 0 0.00026006444
double O 0 0.0001911411
- O 0 0.0028672214
blind O 0 0.035964586
, O 0 0.0007611535
crossover O 0 0.0020362206
, O 0 0.00072887994
double O 0 0.0005232331
- O 0 0.003174979
dose O 0 0.0015734492
study O 0 0.0017085186
. O 0 0.002670048

Pain B-Disease 0 0.026187787
intensity O 0 0.0012495295
on O 0 0.00079418195
a O 0 0.0010287433
0 O 0 0.0006727518
to O 0 0.00031901192
10 O 0 0.00030361963
numerical O 0 0.0004803199
scale O 0 0.0003975732
; O 0 0.0008084507
nausea B-Disease 0 0.99154836
and O 0 0.00042887186
vomiting B-Disease 0 0.97743386
, O 0 0.0014832208
drowsiness O 0 0.9998981
, O 0 0.001126986
confusion B-Disease 0 0.35530725
, O 0 0.0005823009
and O 0 0.00035748113
dry B-Disease 0 0.5032032
mouth I-Disease 0 0.8635014
, O 0 0.0004262536
using O 0 0.000116881885
a O 0 0.00019927147
scale O 0 0.00016919732
from O 0 0.00010060736
0 O 0 0.00014447517
to O 0 8.573936e-05
3 O 0 9.874662e-05
( O 0 0.00017933086
not O 0 8.8844754e-05
at O 0 8.81208e-05
all O 0 0.00013183377
, O 0 0.00029951468
slight O 0 0.00033733895
, O 0 0.00040808262
a O 0 0.00032270898
lot O 0 0.0004656587
, O 0 0.0006891658
awful O 0 0.017129231
) O 0 0.001063904
; O 0 0.0006639216
Mini O 0 0.0014831609
- O 0 0.0012682755
Mental O 0 0.00035631782
State O 0 0.0002701279
Examination O 0 0.00012591203
( O 0 0.00042723888
MMSE O 0 0.9689947
) O 0 0.00056377443
( O 0 0.00033907834
0 O 0 0.000261142
- O 0 0.00066888327
30 O 0 0.00014194754
) O 0 0.00029459738
; O 0 0.00024434182
and O 0 0.00014314012
arterial O 0 0.023283094
pressure O 0 0.0015171662
were O 0 8.6154716e-05
recorded O 0 7.241334e-05
before O 0 4.2175117e-05
administration O 0 0.0001363752
of O 0 0.00013130296
drugs O 0 0.0025927532
( O 0 0.0003577542
T0 O 0 0.00041958928
) O 0 0.00027334248
and O 0 0.000109562585
after O 0 6.253803e-05
30 O 0 9.814526e-05
minutes O 0 0.00012201055
( O 0 0.0002988338
T30 O 0 0.0034617237
) O 0 0.0004887758
, O 0 0.00029308573
60 O 0 0.00018112114
minutes O 0 0.00016059053
( O 0 0.0003545852
T60 O 0 0.0038386213
) O 0 0.0005322085
, O 0 0.00035163952
120 O 0 0.0002673061
minutes O 0 0.0002301334
( O 0 0.0005687355
T120 O 0 0.077110484
) O 0 0.0009271676
, O 0 0.00061438966
and O 0 0.00042535955
180 O 0 0.00064904493
minutes O 0 0.00061522843
( O 0 0.0015976005
T180 O 0 0.005861847
) O 0 0.0044285147
. O 0 0.0040214257

Ketamine B-Chemical 1 0.99971336
, O 0 0.0075411852
but O 0 0.0018947211
not O 0 0.00090485153
saline O 0 0.0024500696
solution O 0 0.0014970802
, O 0 0.0007553304
significantly O 0 0.0003722106
reduced O 0 0.00032530676
the O 0 0.00023647535
pain B-Disease 0 0.005587121
intensity O 0 0.00012164635
in O 0 0.0001697461
almost O 0 0.00020610014
all O 0 0.00020626052
the O 0 0.00023107928
patients O 0 0.0005543135
at O 0 0.00033645015
both O 0 0.0006515727
doses O 0 0.002595723
. O 0 0.0028784848

This O 0 0.0044042654
effect O 0 0.0017933864
was O 0 0.0014179379
more O 0 0.0012925903
relevant O 0 0.00061655097
in O 0 0.0006688935
patients O 0 0.0011887288
treated O 0 0.0012046254
with O 0 0.0010233943
higher O 0 0.0016211648
doses O 0 0.0045068506
. O 0 0.004047254

Hallucinations B-Disease 0 0.9989942
occurred O 0 0.0026214581
in O 0 0.0012201872
4 O 0 0.00077482004
patients O 0 0.0010687659
, O 0 0.00084898947
and O 0 0.00048446425
an O 0 0.0005276811
unpleasant O 0 0.009034023
sensation O 0 0.0047496785
( O 0 0.0007397167
" O 0 0.0006611332
empty O 0 0.000922956
head O 0 0.0030165394
" O 0 0.0011398878
) O 0 0.0010209087
was O 0 0.00037581348
also O 0 0.00040776082
reported O 0 0.0005997316
by O 0 0.00072438724
2 O 0 0.0012306395
patients O 0 0.0026040704
. O 0 0.0030436635

These O 0 0.002664622
episodes O 0 0.0042048446
reversed O 0 0.002129848
after O 0 0.0006954538
the O 0 0.0007762479
administration O 0 0.0015687295
of O 0 0.0019263981
diazepam B-Chemical 0 0.9999794
1 O 0 0.0024117287
mg O 0 0.012937068
intravenously O 0 0.002953976
. O 0 0.0029637925

Significant O 0 0.0040618
increases O 0 0.002045183
in O 0 0.0019140169
drowsiness O 0 0.999524
were O 0 0.00062684173
reported O 0 0.0003866669
in O 0 0.00023895029
patients O 0 0.00042515484
treated O 0 0.00041615777
with O 0 0.00037590292
ketamine B-Chemical 0 0.99995506
in O 0 0.0001640842
both O 0 0.00010438708
groups O 0 0.00015908184
and O 0 0.00014158177
were O 0 0.00012446595
more O 0 0.00020194317
marked O 0 0.00026543875
with O 0 0.00038129953
ketamine B-Chemical 0 0.99991906
0 O 0 0.00053170853
. O 0 0.00032666832
50 O 0 0.0006103343
mg O 0 0.003933884
/ O 0 0.0029953497
kg O 0 0.0032245312
. O 0 0.002924491

A O 0 0.019932387
significant O 0 0.0021274623
difference O 0 0.0012732502
in O 0 0.0013658277
MMSE O 0 0.98919827
was O 0 0.0005339994
observed O 0 0.00031769773
at O 0 0.00028898145
T30 O 0 0.0050245915
in O 0 0.0002864892
patients O 0 0.00043670952
who O 0 0.00027654442
received O 0 0.00019498466
0 O 0 0.00029074456
. O 0 0.00025427464
50 O 0 0.00045296116
mg O 0 0.0026886452
/ O 0 0.0017954123
kg O 0 0.001763374
of O 0 0.0018950467
ketamine B-Chemical 0 0.99968624
. O 0 0.004782314

Ketamine B-Chemical 1 0.9993394
can O 0 0.0018977372
improve O 0 0.0013992917
morphine B-Chemical 0 0.9993506
analgesia O 0 0.6410429
in O 0 0.0005150543
difficult O 0 0.0005568558
pain B-Disease 0 0.06886787
syndromes O 0 0.23500851
, O 0 0.0010132539
such O 0 0.000643685
as O 0 0.0012928593
neuropathic B-Disease 0 0.9987709
pain I-Disease 0 0.96407884
. O 0 0.004264158

However O 0 0.0031185183
, O 0 0.003473017
the O 0 0.0011447513
occurrence O 0 0.0009559987
of O 0 0.0006808654
central O 0 0.00073990814
adverse O 0 0.0009860139
effects O 0 0.00022089851
should O 0 0.000116576564
be O 0 0.00015031752
taken O 0 0.000120791236
into O 0 0.000105310595
account O 0 0.00019483449
, O 0 0.00037905286
especially O 0 0.00026789753
when O 0 0.0002272465
using O 0 0.00037779348
higher O 0 0.0008890755
doses O 0 0.0028925997
. O 0 0.0028896055

This O 0 0.005145188
observation O 0 0.0018675552
should O 0 0.00090145017
be O 0 0.0009191499
tested O 0 0.0007139702
in O 0 0.0006978804
studies O 0 0.00088940014
of O 0 0.0010632798
prolonged O 0 0.0027999654
ketamine B-Chemical 0 0.9997962
administration O 0 0.006385353
. O 0 0.003821876

Paclitaxel B-Chemical 0 0.9991411
, O 0 0.013182216
cisplatin B-Chemical 0 0.99946123
, O 0 0.0022326112
and O 0 0.0009793442
gemcitabine B-Chemical 0 0.9968136
combination O 0 0.00058713375
chemotherapy O 0 0.0013281164
within O 0 0.00011356591
a O 0 0.00026954597
multidisciplinary O 0 0.00041232223
therapeutic O 0 0.00033594645
approach O 0 0.00031922365
in O 0 0.0005514357
metastatic O 0 0.8029141
nonsmall B-Disease 0 0.9978124
cell I-Disease 0 0.0032597575
lung I-Disease 0 0.4038156
carcinoma I-Disease 0 0.9985669
. O 0 0.0049352613

BACKGROUND O 0 0.022276463
: O 0 0.010492224
Cisplatin B-Chemical 0 0.99965477
- O 0 0.004993757
based O 0 0.00047327264
chemotherapy O 0 0.00086957705
combinations O 0 0.00015093196
improve O 0 0.0001247823
quality O 0 0.00013129193
of O 0 0.00020717173
life O 0 0.00023250165
and O 0 0.00024638412
survival O 0 0.00051586126
in O 0 0.00035859045
advanced O 0 0.013045405
nonsmall B-Disease 0 0.99738485
cell I-Disease 0 0.002087571
lung I-Disease 0 0.397301
carcinoma I-Disease 0 0.9993861
( O 0 0.0102624735
NSCLC B-Disease 0 0.99882776
) O 0 0.0056742616
. O 0 0.0034151587

The O 0 0.0021396047
emergence O 0 0.0020441727
of O 0 0.0012742261
new O 0 0.0010714348
active O 0 0.00089633354
drugs O 0 0.007158812
might O 0 0.00020621395
translate O 0 0.00020120398
into O 0 0.00013192116
more O 0 0.00023546471
effective O 0 0.00016169989
regimens O 0 0.0002376525
for O 0 0.00016219946
the O 0 0.00024097969
treatment O 0 0.00040379132
of O 0 0.00073305983
this O 0 0.0015485163
disease O 0 0.49662918
. O 0 0.003768517

METHODS O 0 0.0035631792
: O 0 0.0021961527
The O 0 0.0005133736
objective O 0 0.0005719427
of O 0 0.000549956
this O 0 0.00046596464
study O 0 0.00039710276
was O 0 0.00021422062
to O 0 0.00012973386
determine O 0 5.2369098e-05
the O 0 8.687825e-05
feasibility O 0 8.415912e-05
, O 0 0.0002263284
response O 0 0.00014322721
rate O 0 0.00025484918
, O 0 0.00032150274
and O 0 0.0002123651
toxicity B-Disease 0 0.16827865
of O 0 0.00024739438
a O 0 0.00056511845
paclitaxel B-Chemical 1 0.9997335
, O 0 0.001737164
cisplatin B-Chemical 0 0.9998981
, O 0 0.0006096235
and O 0 0.00036342753
gemcitabine B-Chemical 0 0.9985605
combination O 0 0.0005251717
to O 0 0.00046718662
treat O 0 0.0025194485
metastatic O 0 0.936454
NSCLC B-Disease 0 0.9989104
. O 0 0.0035300457

Thirty O 0 0.0070558097
- O 0 0.0049608494
five O 0 0.00067639246
consecutive O 0 0.0007390332
chemotherapy O 0 0.0021266371
- O 0 0.0014561836
naive O 0 0.00049386953
patients O 0 0.00065582694
with O 0 0.00048204605
Stage O 0 0.25783384
IV O 0 0.77388436
NSCLC B-Disease 0 0.99859184
and O 0 0.00029291253
an O 0 0.00024393073
Eastern O 0 0.00047596137
Cooperative O 0 0.00039345067
Oncology O 0 0.00017861977
Group O 0 0.0003869147
performance O 0 0.00014456915
status O 0 0.00012484858
of O 0 0.00016095187
0 O 0 0.00025960637
- O 0 0.0007499586
2 O 0 0.00012613458
were O 0 8.6377564e-05
treated O 0 0.00016703364
with O 0 0.00012070326
a O 0 0.00017007385
combination O 0 0.00016660542
of O 0 0.00024382006
paclitaxel B-Chemical 1 0.99950457
( O 0 0.0004812626
135 O 0 0.00042921497
mg O 0 0.0034076108
/ O 0 0.0007987958
m O 0 0.0011121649
( O 0 0.0002780734
2 O 0 0.00013017797
) O 0 0.0001976641
given O 0 6.2334104e-05
intravenously O 0 0.00016477203
in O 0 7.3745396e-05
3 O 0 7.211742e-05
hours O 0 7.6770724e-05
) O 0 0.00019266972
on O 0 7.649982e-05
Day O 0 0.00024597708
1 O 0 0.00019556782
, O 0 0.00044967557
cisplatin B-Chemical 0 0.99942386
( O 0 0.0003987599
120 O 0 0.00023458406
mg O 0 0.0018386635
/ O 0 0.00076014496
m O 0 0.0010714903
( O 0 0.00029881563
2 O 0 0.00014176602
) O 0 0.00021093432
given O 0 6.6086235e-05
intravenously O 0 0.00016725404
in O 0 7.349813e-05
6 O 0 6.2819374e-05
hours O 0 7.597428e-05
) O 0 0.00019336837
on O 0 7.594769e-05
Day O 0 0.00023409922
1 O 0 0.00016566177
, O 0 0.00024415643
and O 0 0.00022668192
gemcitabine B-Chemical 0 0.99789953
( O 0 0.0004764568
800 O 0 0.00058957085
mg O 0 0.0030690082
/ O 0 0.00086465676
m O 0 0.0011521631
( O 0 0.00031412212
2 O 0 0.00015160539
) O 0 0.0002262794
given O 0 7.460594e-05
intravenously O 0 0.00019180549
in O 0 9.555202e-05
30 O 0 9.965511e-05
minutes O 0 0.00011663705
) O 0 0.0002717955
on O 0 0.00012834075
Days O 0 0.00076191814
1 O 0 0.0002851477
and O 0 0.0002751335
8 O 0 0.0003121902
, O 0 0.000579859
every O 0 0.00029918872
4 O 0 0.000552231
weeks O 0 0.000692706
. O 0 0.0024107974

Although O 0 0.001665223
responding O 0 0.0019386312
patients O 0 0.0016134591
were O 0 0.0004691149
scheduled O 0 0.0002243601
to O 0 0.00020494669
receive O 0 0.00021231429
consolidation O 0 0.0011504714
radiotherapy O 0 0.0012596762
and O 0 0.00013539627
24 O 0 0.000116855255
patients O 0 0.00015392742
received O 0 9.397333e-05
preplanned O 0 0.0002979113
second O 0 0.00010043999
- O 0 0.0005395439
line O 0 0.00012655467
chemotherapy O 0 0.00072913774
after O 0 6.7125715e-05
disease O 0 0.04800939
progression O 0 0.00099661
, O 0 0.00022561115
the O 0 8.122749e-05
response O 0 0.00010848514
and O 0 0.0001749841
toxicity B-Disease 0 0.35518804
rates O 0 0.00023406997
reported O 0 0.00019411188
refer O 0 0.0002537823
only O 0 0.00019167039
to O 0 0.00017176518
the O 0 0.00023735312
chemotherapy O 0 0.0013334061
regimen O 0 0.00054040033
given O 0 0.00064026815
. O 0 0.002036612

RESULTS O 0 0.00460585
: O 0 0.0029128194
All O 0 0.000780392
the O 0 0.00070807606
patients O 0 0.0010126719
were O 0 0.00045691087
examined O 0 0.0003594252
for O 0 0.00044571905
toxicity B-Disease 0 0.16309494
; O 0 0.0012370186
34 O 0 0.0006683118
were O 0 0.000521081
examinable O 0 0.0013360094
for O 0 0.00076788163
response O 0 0.0017070198
. O 0 0.0034263262

An O 0 0.0026103558
objective O 0 0.0015799032
response O 0 0.0011191426
was O 0 0.0008108512
observed O 0 0.00058215496
in O 0 0.0005685708
73 O 0 0.00096329086
. O 0 0.0003851294
5 O 0 0.00028949106
% O 0 0.00046009888
of O 0 0.0002749043
the O 0 0.00024255985
patients O 0 0.0005385351
( O 0 0.00044819363
95 O 0 0.00043788523
% O 0 0.0003470034
confidence O 0 0.00047920653
interval O 0 0.00029288235
[ O 0 0.0010138153
CI O 0 0.0067810137
] O 0 0.001008562
, O 0 0.00040084298
55 O 0 0.00027685202
. O 0 0.00017891054
6 O 0 0.00015930102
- O 0 0.0008192194
87 O 0 0.00040113315
. O 0 0.00019694773
1 O 0 0.0002206556
% O 0 0.00039914268
) O 0 0.0004945544
, O 0 0.00034678547
including O 0 0.0001477639
4 O 0 0.00016408763
complete O 0 0.00016746596
responses O 0 0.00028686202
( O 0 0.0006640409
11 O 0 0.0005058643
. O 0 0.00049896707
7 O 0 0.00063784805
% O 0 0.0019176487
) O 0 0.003786547
. O 0 0.003904063

According O 0 0.0026284745
to O 0 0.0019145098
intention O 0 0.004070115
- O 0 0.005769145
to O 0 0.0009074152
- O 0 0.004133741
treat O 0 0.0010455976
, O 0 0.0006804395
the O 0 0.00024823364
overall O 0 0.0002478382
response O 0 0.000264825
rate O 0 0.00041304767
was O 0 0.00027222338
71 O 0 0.0004913346
. O 0 0.00022793114
4 O 0 0.00019749453
% O 0 0.00043615766
( O 0 0.00046230227
95 O 0 0.0005707942
% O 0 0.00063337345
CI O 0 0.004289874
, O 0 0.0006916195
53 O 0 0.0005913298
. O 0 0.0003593214
7 O 0 0.00037655025
- O 0 0.0015432965
85 O 0 0.0009079506
. O 0 0.000673616
4 O 0 0.0008341419
% O 0 0.0023477413
) O 0 0.0043679923
. O 0 0.004466355

After O 0 0.0017710683
154 O 0 0.0031563821
courses O 0 0.0017186006
of O 0 0.0009129333
therapy O 0 0.00088398234
, O 0 0.0006619572
the O 0 0.00024038053
median O 0 0.00017889195
dose O 0 0.00033165308
intensity O 0 0.00013070246
was O 0 0.00019894265
131 O 0 0.0005715158
mg O 0 0.0026044557
/ O 0 0.0010815231
m O 0 0.0013844867
( O 0 0.00044156722
2 O 0 0.00022945159
) O 0 0.00039393915
for O 0 0.00020336977
paclitaxel B-Chemical 1 0.9974722
( O 0 0.0005954496
97 O 0 0.00037020654
. O 0 0.00016571312
3 O 0 0.00014240523
% O 0 0.00032663968
) O 0 0.00043070278
, O 0 0.0003809075
117 O 0 0.00054712064
mg O 0 0.0032226252
/ O 0 0.0011185906
m O 0 0.0014438233
( O 0 0.00042617717
2 O 0 0.00021873537
) O 0 0.00038734224
for O 0 0.00021156156
cisplatin B-Chemical 0 0.99964
( O 0 0.000580819
97 O 0 0.0003517614
. O 0 0.0001596217
3 O 0 0.00014088996
% O 0 0.00033619488
) O 0 0.0004659664
, O 0 0.0004150219
and O 0 0.00036052644
1378 O 0 0.019935584
mg O 0 0.007204445
/ O 0 0.0013325174
m O 0 0.0016044757
( O 0 0.0005059338
2 O 0 0.00028093942
) O 0 0.0004968086
for O 0 0.00030133052
gemcitabine B-Chemical 0 0.9960561
( O 0 0.0010434361
86 O 0 0.00091849105
. O 0 0.0005991191
2 O 0 0.0009101228
% O 0 0.0020765124
) O 0 0.0038727338
. O 0 0.0039053408

World O 0 0.0065237447
Health O 0 0.0024232008
Organization O 0 0.0012960482
Grade O 0 0.0054573026
3 O 0 0.0009322949
- O 0 0.0025326225
4 O 0 0.00061910687
neutropenia B-Disease 0 0.8985489
and O 0 0.0007690504
thrombocytopenia B-Disease 0 0.9989998
occurred O 0 0.0003220101
in O 0 0.0002295702
39 O 0 0.00033116966
. O 0 0.0002030394
9 O 0 0.00017703135
% O 0 0.00035813198
and O 0 0.00024171398
11 O 0 0.00028644383
. O 0 0.00023851602
4 O 0 0.0002446817
% O 0 0.0005826767
of O 0 0.00057018956
patients O 0 0.0014908995
, O 0 0.0020562098
respectively O 0 0.0032514746
. O 0 0.0037337681

There O 0 0.0070544034
was O 0 0.00443327
one O 0 0.003481842
treatment O 0 0.004040502
- O 0 0.011203273
related O 0 0.004098526
death B-Disease 0 0.54240435
. O 0 0.010790143

Nonhematologic O 0 0.8113191
toxicities B-Disease 0 0.65451276
were O 0 0.01335354
mild O 0 0.0850897
. O 0 0.01766518

After O 0 0.0017163514
a O 0 0.0020020239
median O 0 0.0008188445
follow O 0 0.00071638153
- O 0 0.0021543219
up O 0 0.00054905564
of O 0 0.00040619285
22 O 0 0.0004006166
months O 0 0.0001335263
, O 0 0.0002828942
the O 0 0.00013552442
median O 0 0.00013390626
progression O 0 0.0006420602
free O 0 0.00030170308
survival O 0 0.00037184617
rate O 0 0.00023964069
was O 0 0.00012431057
7 O 0 9.137619e-05
months O 0 6.4104126e-05
, O 0 0.00019551991
and O 0 0.0001413949
the O 0 0.00012528876
median O 0 0.00013600106
survival O 0 0.00038822336
time O 0 0.00025082132
was O 0 0.00046557197
16 O 0 0.0007818543
months O 0 0.00064823177
. O 0 0.0021602048

CONCLUSIONS O 0 0.015656175
: O 0 0.0032805402
The O 0 0.00067187974
combination O 0 0.0008482727
of O 0 0.001035954
paclitaxel B-Chemical 1 0.99922407
, O 0 0.0034032057
cisplatin B-Chemical 0 0.99984396
, O 0 0.00087767723
and O 0 0.00042334505
gemcitabine B-Chemical 0 0.9984419
is O 0 0.00017133825
well O 0 0.00016436857
tolerated O 0 0.0003583784
and O 0 0.00018488835
shows O 0 0.0001148718
high O 0 0.0003875334
activity O 0 0.00040335063
in O 0 0.0010421536
metastatic O 0 0.88268244
NSCLC B-Disease 0 0.99864477
. O 0 0.0037673262

This O 0 0.0043057655
treatment O 0 0.0017661443
merits O 0 0.0011633348
further O 0 0.0008163211
comparison O 0 0.0007322074
with O 0 0.000979655
other O 0 0.0013815836
cisplatin B-Chemical 0 0.9995364
- O 0 0.00782411
based O 0 0.0012884365
regimens O 0 0.0024754058
. O 0 0.00364484

Serotonergic B-Chemical 0 0.83196825
antidepressants I-Chemical 0 0.9994715
and O 0 0.013920465
urinary B-Disease 0 0.5117165
incontinence I-Disease 0 0.9323642
. O 0 0.01501546

Many O 0 0.0036353318
new O 0 0.004477868
serotonergic B-Chemical 0 0.7869207
antidepressants I-Chemical 0 0.9998902
have O 0 0.0013164983
been O 0 0.00082166924
introduced O 0 0.0006207938
over O 0 0.0006729994
the O 0 0.0008578757
past O 0 0.0016778263
decade O 0 0.0034441918
. O 0 0.004756726

Although O 0 0.0026571646
urinary B-Disease 0 0.1338124
incontinence I-Disease 0 0.6905395
is O 0 0.00062383915
listed O 0 0.00023964481
as O 0 0.00033750513
one O 0 0.00025269025
side O 0 0.0005582274
effect O 0 0.00019508248
of O 0 0.0002430196
these O 0 0.00020238844
drugs O 0 0.0037367248
in O 0 0.00014720786
their O 0 0.0001270966
package O 0 0.0002102885
inserts O 0 0.00025744544
there O 0 0.00014326164
is O 0 0.00016715981
only O 0 0.0002510637
one O 0 0.0002662991
report O 0 0.0006431356
in O 0 0.0005077409
the O 0 0.0007463483
literature O 0 0.002717163
. O 0 0.0029933823

This O 0 0.0046642884
concerns O 0 0.0023040003
2 O 0 0.0016973383
male O 0 0.0021118897
patients O 0 0.0016469292
who O 0 0.0011412649
experienced O 0 0.0011387375
incontinence B-Disease 0 0.35607353
while O 0 0.0013335572
taking O 0 0.0040562483
venlafaxine B-Chemical 0 0.9998747
. O 0 0.005917943

In O 0 0.0019225504
the O 0 0.0014067462
present O 0 0.0009122651
paper O 0 0.0010980174
the O 0 0.0004123558
authors O 0 0.00032190548
describe O 0 0.0002904988
2 O 0 0.00028888258
female O 0 0.00049035705
patients O 0 0.00041345225
who O 0 0.00024291071
developed O 0 0.00022548836
incontinence B-Disease 0 0.41798067
secondary O 0 0.00017183872
to O 0 9.1065565e-05
the O 0 0.00011255123
selective O 0 0.0008643825
serotonin B-Chemical 0 0.9999894
reuptake O 0 0.99965215
inhibitors O 0 0.0546774
paroxetine B-Chemical 0 0.99999964
and O 0 0.0013659467
sertraline B-Chemical 0 0.9999989
, O 0 0.00042668448
as O 0 0.00010641618
well O 0 9.902045e-05
as O 0 0.00011480566
a O 0 0.0001981009
third O 0 0.00015513094
who O 0 0.00024308934
developed O 0 0.00020558925
this O 0 0.00023941825
side O 0 0.0007934645
effect O 0 0.0005081827
on O 0 0.0011056192
venlafaxine B-Chemical 0 0.9999558
. O 0 0.003865937

In O 0 0.0022963143
2 O 0 0.0020362623
of O 0 0.0012246397
the O 0 0.0007080188
3 O 0 0.0005320302
cases O 0 0.0006296277
the O 0 0.00028223556
patients O 0 0.00046194872
were O 0 0.00019077514
also O 0 0.00019645745
taking O 0 0.0006583661
lithium B-Chemical 0 0.99993396
carbonate I-Chemical 0 0.99464864
and O 0 0.00056942116
beta O 0 0.8935176
- O 0 0.110051766
blockers O 0 0.9553815
, O 0 0.0005767766
both O 0 0.00017890168
of O 0 0.0002527883
which O 0 0.000289111
could O 0 0.00019187572
have O 0 0.00027322417
contributed O 0 0.0005964936
to O 0 0.00054453517
the O 0 0.0009554393
incontinence B-Disease 0 0.7508377
. O 0 0.0030976024

Animal O 0 0.005032015
studies O 0 0.002029671
suggest O 0 0.00077250437
that O 0 0.0009258253
incontinence B-Disease 0 0.73113036
secondary O 0 0.0009966083
to O 0 0.0005827178
serotonergic B-Chemical 0 0.78754246
antidepressants I-Chemical 0 0.9999733
could O 0 0.00022647172
be O 0 0.00018803481
mediated O 0 0.00012553403
by O 0 0.00024690284
the O 0 0.00036751718
5HT4 O 0 0.94043744
receptors O 0 0.0011697308
found O 0 0.0005163552
on O 0 0.00049974915
the O 0 0.0009823495
bladder O 0 0.038130578
. O 0 0.003438628

Further O 0 0.0027974013
research O 0 0.0026449023
is O 0 0.0009849154
needed O 0 0.00058687583
to O 0 0.00041092164
delineate O 0 0.00022784594
the O 0 0.00023160383
frequency O 0 0.00021865402
of O 0 0.00027935818
this O 0 0.00030965902
troubling O 0 0.0009184482
side O 0 0.0006489738
effect O 0 0.00023887923
and O 0 0.00031317543
how O 0 0.00022646373
best O 0 0.000448633
to O 0 0.000630772
treat O 0 0.0019084521
it O 0 0.0026156737
. O 0 0.0033325772

Acute O 0 0.6123665
cocaine B-Chemical 0 0.9994593
- O 0 0.05738534
induced O 0 0.0025983416
seizures B-Disease 0 0.99988484
: O 0 0.0021784315
differential O 0 0.0006763364
sensitivity O 0 0.0007752898
of O 0 0.0006116241
six O 0 0.0004038408
inbred O 0 0.0011492026
mouse O 0 0.00087476603
strains O 0 0.0018057978
. O 0 0.003601359

Mature O 0 0.007405036
male O 0 0.0041546496
and O 0 0.0014582874
female O 0 0.0013930703
mice O 0 0.00027079938
from O 0 0.00032557204
six O 0 0.00021376846
inbred O 0 0.0005650828
stains O 0 0.0005006593
were O 0 0.00020309517
tested O 0 0.00016802097
for O 0 0.00015168679
susceptibility O 0 0.0003309986
to O 0 0.0002277821
behavioral O 0 0.013077904
seizures B-Disease 0 0.9999614
induced O 0 0.00030286165
by O 0 0.00025973414
a O 0 0.00039266792
single O 0 0.0002442277
injection O 0 0.00037581244
of O 0 0.0010939763
cocaine B-Chemical 0 0.9987778
. O 0 0.00339331

Cocaine B-Chemical 0 0.99961853
was O 0 0.002144716
injected O 0 0.0011682488
ip O 0 0.003940751
over O 0 0.00036592648
a O 0 0.00041018697
range O 0 0.0002569376
of O 0 0.00025703854
doses O 0 0.00055882474
( O 0 0.00050315086
50 O 0 0.00037004496
- O 0 0.0011020913
100 O 0 0.00050141296
mg O 0 0.0022977348
/ O 0 0.0008625103
kg O 0 0.0006389326
) O 0 0.00052931474
and O 0 0.00026232234
behavior O 0 0.00042219626
was O 0 0.0003238175
monitored O 0 0.00030827426
for O 0 0.0004273134
20 O 0 0.00085891003
minutes O 0 0.0011653695
. O 0 0.002446429

Seizure B-Disease 2 0.982637
end O 0 0.0011135727
points O 0 0.0009784825
included O 0 0.00068273966
latency O 0 0.0010331636
to O 0 0.00041790176
forelimb O 0 0.0032328763
or O 0 0.00036320757
hindlimb O 0 0.0049820947
clonus O 0 0.9793396
, O 0 0.00065445324
latency O 0 0.0005902883
to O 0 0.0002819064
clonic O 0 0.7920872
running O 0 0.0009340962
seizure B-Disease 0 0.9976694
and O 0 0.0003973383
latency O 0 0.0008145645
to O 0 0.0005013695
jumping O 0 0.0073041567
bouncing O 0 0.035143364
seizure B-Disease 0 0.9988795
. O 0 0.004298168

A O 0 0.016758103
range O 0 0.001998885
of O 0 0.0011333677
strain O 0 0.0005711831
specific O 0 0.00033661886
sensitivities O 0 0.00048549098
was O 0 0.00040418605
documented O 0 0.0004939215
with O 0 0.00046708932
A O 0 0.012347085
/ O 0 0.005196756
J O 0 0.3600354
and O 0 0.0004341882
SJL O 0 0.000919417
mice O 0 8.1840924e-05
being O 0 0.00019157171
most O 0 0.00027116237
sensitive O 0 0.00025818506
and O 0 0.00055411906
C57BL O 0 0.023957249
/ O 0 0.003651928
6J O 0 0.006368291
most O 0 0.001557175
resistant O 0 0.0025102096
. O 0 0.0036752406

DBA O 0 0.9690757
/ O 0 0.03408249
2J O 0 0.2855379
, O 0 0.00524173
BALB O 0 0.0055081686
/ O 0 0.0041546673
cByJ O 0 0.0025836672
and O 0 0.001518412
NZW O 0 0.010678781
/ O 0 0.0040153814
LacJ O 0 0.0023876908
strains O 0 0.0010245264
exhibited O 0 0.0013331579
intermediate O 0 0.0029163626
sensitivity O 0 0.0044052275
. O 0 0.00519508

EEG O 0 0.2553289
recordings O 0 0.0024803833
were O 0 0.0013318692
made O 0 0.0010621373
in O 0 0.0010470893
SJL O 0 0.0033160027
, O 0 0.0015267702
A O 0 0.0074138422
/ O 0 0.005442991
J O 0 0.34333
and O 0 0.00093256583
C57BL O 0 0.049605943
/ O 0 0.002168324
6J O 0 0.0016231386
mice O 0 0.00010499434
revealing O 0 0.00022040306
a O 0 0.00032803023
close O 0 0.00024035669
correspondence O 0 0.00036925203
between O 0 0.00027367473
electrical O 0 0.0008687886
activity O 0 0.00043262154
and O 0 0.0009589087
behavior O 0 0.0025208367
. O 0 0.0035448167

Additionally O 0 0.002733963
, O 0 0.0033864763
levels O 0 0.0012860113
of O 0 0.0017072146
cocaine B-Chemical 0 0.9994011
determined O 0 0.0006047376
in O 0 0.00047593733
hippocampus O 0 0.0029362913
and O 0 0.00039125534
cortex O 0 0.0034036038
were O 0 0.0001942891
not O 0 0.00015368985
different O 0 0.00013815683
between O 0 0.00020694648
sensitive O 0 0.0003469594
and O 0 0.0006599183
resistant O 0 0.0012812351
strains O 0 0.0018795773
. O 0 0.0035038462

Additional O 0 0.0020583028
studies O 0 0.0018153932
of O 0 0.0012410223
these O 0 0.0008548688
murine O 0 0.00092760095
strains O 0 0.00057157606
may O 0 0.00033947357
be O 0 0.00026287365
useful O 0 0.00020737965
for O 0 0.0001726239
investigating O 0 0.00020589368
genetic O 0 0.0004595733
influences O 0 0.00032229515
on O 0 0.00050908054
cocaine B-Chemical 0 0.9996507
- O 0 0.03468828
induced O 0 0.0024998386
seizures B-Disease 0 0.9998647
. O 0 0.005119426

Hypotension B-Disease 2 0.994965
following O 0 0.00093141134
the O 0 0.0006195451
initiation O 0 0.00044512117
of O 0 0.00094998017
tizanidine B-Chemical 0 0.9999734
in O 0 0.00043827758
a O 0 0.00042192327
patient O 0 0.00028275375
treated O 0 0.00040803806
with O 0 0.00034233485
an O 0 0.00077862525
angiotensin B-Chemical 0 0.99998415
converting O 0 0.007271267
enzyme O 0 0.0041821287
inhibitor O 0 0.0029413328
for O 0 0.0007291759
chronic O 0 0.54870903
hypertension B-Disease 2 0.99996257
. O 0 0.0045786607

Centrally O 0 0.034911443
acting O 0 0.0043445015
alpha O 0 0.8421994
- O 0 0.05315288
2 O 0 0.0015550939
adrenergic O 0 0.7966096
agonists O 0 0.0056867506
are O 0 0.00022577535
one O 0 0.00015389339
of O 0 0.00015306259
several O 0 9.391044e-05
pharmacologic O 0 0.00038917307
agents O 0 0.00031492818
used O 0 0.00011149382
in O 0 0.00011089178
the O 0 0.00010251684
treatment O 0 0.00015437104
of O 0 0.0003122908
spasticity B-Disease 0 0.99974924
related O 0 0.00014827414
to O 0 0.00024968968
disorders B-Disease 0 0.9636102
of I-Disease 0 0.00046093337
the I-Disease 0 0.0004145158
central I-Disease 0 0.0011525458
nervous I-Disease 0 0.0048615476
system I-Disease 0 0.0016150329
. O 0 0.0025352933

In O 0 0.0016256673
addition O 0 0.00087783707
to O 0 0.00076382677
their O 0 0.00056281616
effects O 0 0.00056174694
on O 0 0.00062147627
spasticity B-Disease 0 0.9995931
, O 0 0.00093107065
certain O 0 0.0003926316
adverse O 0 0.001375697
cardiorespiratory O 0 0.0018094513
effects O 0 0.00038946743
have O 0 0.0005209146
been O 0 0.00087005063
reported O 0 0.0016820007
. O 0 0.002944401

Adults O 0 0.015914718
chronically O 0 0.008063433
treated O 0 0.0032930123
with O 0 0.0026822838
angiotensin B-Chemical 0 0.99997556
converting O 0 0.023610976
enzyme O 0 0.005039962
inhibitors O 0 0.00097179133
may O 0 0.000220737
have O 0 0.00016217609
a O 0 0.00021995923
limited O 0 0.00013098084
ability O 0 0.0001182331
to O 0 0.00011774526
respond O 0 0.0001223265
to O 0 0.00017773242
hypotension B-Disease 0 0.999746
when O 0 0.00013787992
the O 0 0.00018498763
sympathetic O 0 0.0010900088
response O 0 0.00028363743
is O 0 0.0003537934
simultaneously O 0 0.00070796
blocked O 0 0.0025529054
. O 0 0.0032186115

The O 0 0.00195608
authors O 0 0.0014606215
present O 0 0.001003027
a O 0 0.0012983609
10 O 0 0.0007972574
- O 0 0.002112
year O 0 0.00040622405
- O 0 0.0012680751
old O 0 0.00038281328
boy O 0 0.0009948944
chronically O 0 0.0011935914
treated O 0 0.00053923315
with O 0 0.00051425
lisinopril B-Chemical 0 0.9999957
, O 0 0.0016452607
an O 0 0.0006710312
angiotensin B-Chemical 0 0.9999925
converting O 0 0.0073709902
enzyme O 0 0.0037020047
inhibitor O 0 0.0016568162
, O 0 0.00030666176
to O 0 9.067181e-05
control O 0 0.0002088072
hypertension B-Disease 2 0.9999943
who O 0 0.00044237968
developed O 0 0.00020994713
hypotension B-Disease 0 0.999848
following O 0 4.5606146e-05
the O 0 4.9246974e-05
addition O 0 5.1276766e-05
of O 0 0.00030512543
tizanidine B-Chemical 0 0.99999535
, O 0 0.0007968317
an O 0 0.0003597771
alpha O 0 0.7610327
- O 0 0.010196669
2 O 0 0.0002687679
agonist O 0 0.0019845418
, O 0 0.0004136506
for O 0 0.00019240721
the O 0 0.0002909548
treatment O 0 0.00057266385
of O 0 0.0015960436
spasticity B-Disease 0 0.99939454
. O 0 0.003576331

The O 0 0.0014950586
possible O 0 0.00089311623
interaction O 0 0.00078147737
of O 0 0.0013965126
tizanidine B-Chemical 0 0.99997044
and O 0 0.00053556944
other O 0 0.00028422894
antihypertensive O 0 0.66644263
agents O 0 0.0006063787
should O 0 9.1040034e-05
be O 0 0.00012338081
kept O 0 0.00017226332
in O 0 0.00012414991
mind O 0 0.00028864417
when O 0 8.7321365e-05
prescribing O 0 0.00047258273
therapy O 0 0.00016937958
to O 0 9.855791e-05
treat O 0 0.00031225066
either O 0 0.0003271636
hypertension B-Disease 2 0.9999896
or O 0 0.0009293465
spasticity B-Disease 0 0.99976975
in O 0 0.00052832376
such O 0 0.0006924153
patients O 0 0.0023722053
. O 0 0.0023584364

Two O 0 0.0021161728
mouse O 0 0.0012792904
lines O 0 0.0010589517
selected O 0 0.0005059427
for O 0 0.00034456007
differential O 0 0.0004014064
sensitivities O 0 0.00042634542
to O 0 0.00048586592
beta B-Chemical 0 0.98620284
- I-Chemical 0 0.5532784
carboline I-Chemical 0 0.9996074
- O 0 0.08932744
induced O 0 0.0005381325
seizures B-Disease 0 0.99998176
are O 0 0.00012868766
also O 0 8.2221646e-05
differentially O 0 4.8220492e-05
sensitive O 0 6.9686845e-05
to O 0 7.408062e-05
various O 0 9.540991e-05
pharmacological O 0 0.0002879482
effects O 0 0.00016761389
of O 0 0.00035318933
other O 0 0.00075459905
GABA B-Chemical 0 0.9999609
( O 0 0.0033837445
A O 0 0.10651568
) O 0 0.003515814
receptor O 0 0.004067516
ligands O 0 0.007349631
. O 0 0.0044299276

Two O 0 0.0023205515
mouse O 0 0.0015067238
lines O 0 0.001408411
were O 0 0.000781559
selectively O 0 0.0005630326
bred O 0 0.00075522426
according O 0 0.00026559137
to O 0 0.00020922514
their O 0 0.00020956915
sensitivity O 0 0.00046961417
( O 0 0.000912761
BS O 0 0.8323879
line O 0 0.00031633404
) O 0 0.0005586615
or O 0 0.00019276825
resistance O 0 0.00084734283
( O 0 0.0007126066
BR O 0 0.05514982
line O 0 0.0002739943
) O 0 0.00068997475
to O 0 0.00026490554
seizures B-Disease 0 0.9999678
induced O 0 0.00020215855
by O 0 0.00015109121
a O 0 0.00020379272
single O 0 9.39546e-05
i O 0 0.0002276349
. O 0 0.00010885757
p O 0 0.0001922792
. O 0 0.00010570499
injection O 0 0.00011462439
of O 0 0.00031146064
methyl B-Chemical 0 0.9918682
beta I-Chemical 0 0.9993407
- I-Chemical 0 0.74215573
carboline I-Chemical 0 0.99959
- I-Chemical 0 0.02212645
3 I-Chemical 0 0.0002333794
- I-Chemical 0 0.0024994225
carboxylate I-Chemical 0 0.103380546
( O 0 0.0014052886
beta B-Chemical 0 0.98039925
- I-Chemical 0 0.1444653
CCM I-Chemical 0 0.9513998
) O 0 0.0009212735
, O 0 0.00034702738
an O 0 0.00018535295
inverse O 0 0.00019932144
agonist O 0 0.003489852
of O 0 0.0004468754
the O 0 0.00065517594
GABA B-Chemical 0 0.99995637
( O 0 0.002743653
A O 0 0.1180803
) O 0 0.004464926
receptor O 0 0.021310838
benzodiazepine B-Chemical 0 0.9999515
site O 0 0.0016335944
. O 0 0.0032482322

Our O 0 0.0018447242
aim O 0 0.001105028
was O 0 0.0008688291
to O 0 0.0004589186
characterize O 0 0.00021682959
both O 0 0.0002659895
lines O 0 0.00035586636
' O 0 0.00047414372
sensitivities O 0 0.00022921762
to O 0 0.00014666899
various O 0 0.00013879724
physiological O 0 0.00015575094
effects O 0 0.00014355838
of O 0 0.000211522
other O 0 0.00022205041
ligands O 0 0.0010437673
of O 0 0.00068822916
the O 0 0.0009948934
GABA B-Chemical 0 0.99993694
( O 0 0.004038254
A O 0 0.091657005
) O 0 0.004732376
receptor O 0 0.006054735
. O 0 0.003967769

We O 0 0.003009452
measured O 0 0.0049159145
diazepam B-Chemical 0 0.99998546
- O 0 0.08881727
induced O 0 0.0009803192
anxiolysis O 0 0.9900475
with O 0 0.0004032393
the O 0 0.00021362017
elevated O 0 0.0006633612
plus O 0 0.0002489321
- O 0 0.0014872751
maze O 0 0.26872113
test O 0 0.00051173987
, O 0 0.0015960832
diazepam B-Chemical 0 0.9999982
- O 0 0.006504386
induced O 0 0.00011825702
sedation O 0 0.0013675073
by O 0 6.7827474e-05
recording O 0 6.93122e-05
the O 0 7.755326e-05
vigilance O 0 0.002525123
states O 0 0.00024061395
, O 0 0.00038408095
and O 0 0.00044989726
picrotoxin B-Chemical 0 0.9999931
- O 0 0.14784548
and O 0 0.00074529945
pentylenetetrazol B-Chemical 0 0.99999344
- O 0 0.07250186
induced O 0 0.00051812764
seizures B-Disease 0 0.99994993
after O 0 0.00018992105
i O 0 0.00055022235
. O 0 0.00034795646
p O 0 0.00072324503
. O 0 0.0006263207
injections O 0 0.0010646948
. O 0 0.0021651841

Results O 0 0.002487153
presented O 0 0.0014285028
here O 0 0.0009808906
show O 0 0.00054373883
that O 0 0.00041249875
the O 0 0.00034817233
differential O 0 0.00039677392
sensitivities O 0 0.00043590183
of O 0 0.00066102867
BS O 0 0.9651438
and O 0 0.0005805417
BR O 0 0.06846093
lines O 0 0.00043737478
to O 0 0.0003700938
beta B-Chemical 0 0.9899933
- I-Chemical 0 0.27940723
CCM I-Chemical 0 0.9326298
can O 0 0.00013938146
be O 0 0.0001263109
extended O 0 0.00013617883
to O 0 0.00025609552
diazepam B-Chemical 0 0.9999988
, O 0 0.018581603
picrotoxin B-Chemical 0 0.99999535
, O 0 0.0016735959
and O 0 0.00058081036
pentylenetetrazol B-Chemical 0 0.9999938
, O 0 0.00062026654
suggesting O 0 9.2328104e-05
a O 0 0.00018170754
genetic O 0 0.00018441914
selection O 0 8.788265e-05
of O 0 0.000111356756
a O 0 0.0001533546
general O 0 9.71519e-05
sensitivity O 0 0.00017549608
and O 0 0.00014149702
resistance O 0 0.0003922573
to O 0 0.00011652099
several O 0 0.000110253975
ligands O 0 0.00061291666
of O 0 0.0005106572
the O 0 0.0008228205
GABA B-Chemical 0 0.9999422
( O 0 0.0037699188
A O 0 0.09829128
) O 0 0.004615934
receptor O 0 0.005891638
. O 0 0.0037711847

Propylthiouracil B-Chemical 0 0.9990415
- O 0 0.061888114
induced O 0 0.0023122116
perinuclear O 0 0.0022453268
- O 0 0.008968312
staining O 0 0.0009284936
antineutrophil O 0 0.37328428
cytoplasmic O 0 0.0008584056
autoantibody O 0 0.38003236
- O 0 0.006973031
positive O 0 0.0008941393
vasculitis B-Disease 2 0.9995117
in O 0 0.00068092183
conjunction O 0 0.00088260515
with O 0 0.0016801336
pericarditis B-Disease 0 0.9921515
. O 0 0.003805622

OBJECTIVE O 0 0.01975835
: O 0 0.0036993022
To O 0 0.00065615354
describe O 0 0.0009353447
a O 0 0.0012107027
case O 0 0.0009543124
of O 0 0.0015465858
propylthiouracil B-Chemical 0 0.99997365
- O 0 0.14335315
induced O 0 0.0016809801
vasculitis B-Disease 2 0.99987674
manifesting O 0 0.33604667
with O 0 0.0025602179
pericarditis B-Disease 0 0.99594265
. O 0 0.0040480583

METHODS O 0 0.004186144
: O 0 0.0027486281
We O 0 0.0007441012
present O 0 0.0005179783
the O 0 0.00041062475
first O 0 0.0002823965
case O 0 0.00040741367
report O 0 0.00053948915
of O 0 0.00034330587
a O 0 0.00053940766
woman O 0 0.0014835339
with O 0 0.0006106726
hyperthyroidism B-Disease 0 0.99998677
treated O 0 0.002405116
with O 0 0.0007968936
propylthiouracil B-Chemical 0 0.99999225
in O 0 0.00030325603
whom O 0 0.00046092764
a O 0 0.00042690054
syndrome O 0 0.8088643
of O 0 0.0005506623
pericarditis B-Disease 0 0.99928457
, O 0 0.0029231983
fever B-Disease 0 0.99713624
, O 0 0.0014223901
and O 0 0.0013271178
glomerulonephritis B-Disease 2 0.9999138
developed O 0 0.0031823763
. O 0 0.0030337914

Serologic O 0 0.008455296
testing O 0 0.0018157304
and O 0 0.0014470683
immunologic O 0 0.0022340033
studies O 0 0.0009265583
were O 0 0.0005741899
done O 0 0.0005272452
, O 0 0.00095675956
and O 0 0.00066324265
a O 0 0.0010368421
pericardial O 0 0.0031312527
biopsy O 0 0.0009761494
was O 0 0.0008967987
performed O 0 0.0014414329
. O 0 0.003242047

RESULTS O 0 0.0059795133
: O 0 0.005001501
A O 0 0.0076027126
25 O 0 0.0020275349
- O 0 0.0033115565
year O 0 0.00070935866
- O 0 0.001807445
old O 0 0.00059265766
woman O 0 0.0010721112
with O 0 0.000573264
Graves B-Disease 2 0.97134924
' I-Disease 2 0.0036453942
disease I-Disease 2 0.9537631
had O 0 0.00041449274
a O 0 0.00095425604
febrile B-Disease 0 0.998171
illness I-Disease 0 0.9775249
and O 0 0.00023017511
evidence O 0 0.00017427708
of O 0 0.000427282
pericarditis B-Disease 0 0.99727976
, O 0 0.0008292659
which O 0 0.00041775976
was O 0 0.00037291134
confirmed O 0 0.0004462973
by O 0 0.0008526438
biopsy O 0 0.0018408701
. O 0 0.00245916

Serologic O 0 0.007948309
evaluation O 0 0.0016597416
revealed O 0 0.00092220877
the O 0 0.00073027296
presence O 0 0.0006839246
of O 0 0.00083341886
perinuclear O 0 0.001024919
- O 0 0.00589574
staining O 0 0.0005606632
antineutrophil O 0 0.40308815
cytoplasmic O 0 0.0006069824
autoantibodies O 0 0.050336584
( O 0 0.0018142876
pANCA O 0 0.15993617
) O 0 0.0015347486
against O 0 0.00057843816
myeloperoxidase O 0 0.99458015
( O 0 0.0073547047
MPO O 0 0.99433905
) O 0 0.0072776377
. O 0 0.0041314857

Propylthiouracil B-Chemical 0 0.99802446
therapy O 0 0.0043271915
was O 0 0.0013475764
withdrawn O 0 0.002449171
, O 0 0.0011188916
and O 0 0.0005183376
she O 0 0.00037804997
was O 0 0.00028411084
treated O 0 0.0004951188
with O 0 0.0003049015
a O 0 0.00039188168
1 O 0 0.0002720472
- O 0 0.0006095399
month O 0 9.380312e-05
course O 0 0.00016986445
of O 0 0.0003618435
prednisone B-Chemical 0 0.99957055
, O 0 0.0010063809
which O 0 0.0006896664
alleviated O 0 0.00311226
her O 0 0.0018592735
symptoms O 0 0.013024382
. O 0 0.0032845032

A O 0 0.027360177
literature O 0 0.004326442
review O 0 0.002060851
revealed O 0 0.00061150343
no O 0 0.00044913965
prior O 0 0.0002527314
reports O 0 0.0004163162
of O 0 0.0005533121
pericarditis B-Disease 0 0.9879282
in O 0 0.00043677315
anti O 0 0.0019268153
- O 0 0.23627877
MPO O 0 0.9990509
pANCA O 0 0.7100439
- O 0 0.0051176026
positive O 0 0.00054481765
vasculitis B-Disease 2 0.9997836
associated O 0 0.0005419656
with O 0 0.0006763032
propylthio B-Chemical 0 0.5391737
- I-Chemical 0 0.056182794
uracil I-Chemical 0 0.25517166
therapy O 0 0.0025283725
. O 0 0.0025264928

CONCLUSION O 0 0.035424724
: O 0 0.011535139
Pericarditis B-Disease 0 0.9880163
may O 0 0.00086050935
be O 0 0.00051111873
the O 0 0.0003275524
initial O 0 0.0003117613
manifestation O 0 0.0015166156
of O 0 0.00045373468
drug O 0 0.041224033
- O 0 0.005580159
induced O 0 0.0005762162
vasculitis B-Disease 2 0.9998355
attributable O 0 0.00039081485
to O 0 0.00050075457
propylthio B-Chemical 0 0.38296455
- I-Chemical 0 0.041246608
uracil I-Chemical 0 0.22216475
therapy O 0 0.002535373
. O 0 0.0025649641

Repeated O 0 0.0044341716
transient O 0 0.004534982
anuria B-Disease 0 0.99298006
following O 0 0.0010059179
losartan B-Chemical 1 0.99995184
administration O 0 0.0019013353
in O 0 0.00049345277
a O 0 0.000677815
patient O 0 0.0005682506
with O 0 0.000636979
a O 0 0.0014161612
solitary O 0 0.005559428
kidney O 0 0.070836656
. O 0 0.0040312256

We O 0 0.003026705
report O 0 0.0030285493
the O 0 0.0011777674
case O 0 0.0009959299
of O 0 0.00076643744
a O 0 0.00082587934
70 O 0 0.0006129941
- O 0 0.0015884994
year O 0 0.00029650357
- O 0 0.0011645799
old O 0 0.0004655231
hypertensive B-Disease 0 0.9997706
man O 0 0.008037448
with O 0 0.0002453681
a O 0 0.00034375556
solitary O 0 0.0012907983
kidney O 0 0.016687559
and O 0 0.00021494286
chronic B-Disease 0 0.27887246
renal I-Disease 0 0.98394644
insufficiency I-Disease 0 0.99985254
who O 0 0.0002654537
developed O 0 0.000109716064
two O 0 6.577507e-05
episodes O 0 0.00026700966
of O 0 0.0002036352
transient O 0 0.00097007805
anuria B-Disease 0 0.99776685
after O 0 0.00044742392
losartan B-Chemical 1 0.9999536
administration O 0 0.0049467534
. O 0 0.0024599745

He O 0 0.009545206
was O 0 0.0026326356
hospitalized O 0 0.0055496013
for O 0 0.00093135814
a O 0 0.0021290155
myocardial B-Disease 0 0.99922657
infarction I-Disease 0 0.9999709
with O 0 0.0010475487
pulmonary B-Disease 0 0.8756426
edema I-Disease 0 0.99983954
, O 0 0.0007037356
treated O 0 0.0004849024
with O 0 0.00035183167
high O 0 0.00068409106
- O 0 0.0040894197
dose O 0 0.0023152938
diuretics O 0 0.99492526
. O 0 0.003657135

Due O 0 0.0034878133
to O 0 0.0028654153
severe O 0 0.010327461
systolic B-Disease 0 0.98775524
dysfunction I-Disease 0 0.9991617
losartan B-Chemical 1 0.9999615
was O 0 0.0046697506
prescribed O 0 0.011412354
. O 0 0.0052228547

Surprisingly O 0 0.0021573359
, O 0 0.0028302274
the O 0 0.0008393831
first O 0 0.00046601752
dose O 0 0.00079161976
of O 0 0.00046415464
50 O 0 0.00059323246
mg O 0 0.010052639
of O 0 0.0005608003
losartan B-Chemical 1 0.99998474
resulted O 0 0.00030620105
in O 0 0.00021551868
a O 0 0.0004023588
sudden O 0 0.22260946
anuria B-Disease 0 0.99931085
, O 0 0.00035148318
which O 0 0.0001188232
lasted O 0 6.174403e-05
eight O 0 4.6608744e-05
hours O 0 6.800428e-05
despite O 0 9.7706456e-05
high O 0 0.0002743563
- O 0 0.0022480367
dose O 0 0.001709434
furosemide B-Chemical 0 0.9999819
and O 0 0.0017207584
amine B-Chemical 0 0.9969643
infusion O 0 0.010132295
. O 0 0.0027542503

One O 0 0.003322415
week O 0 0.0013626865
later O 0 0.0011741415
, O 0 0.0016277551
by O 0 0.0008492646
mistake O 0 0.0030287565
, O 0 0.003026672
losartan B-Chemical 1 0.999979
was O 0 0.0005357262
prescribed O 0 0.0013621821
again O 0 0.00017242286
and O 0 0.00013091677
after O 0 6.0668175e-05
the O 0 7.726995e-05
second O 0 8.950838e-05
dose O 0 0.0001900453
of O 0 0.00014187652
50 O 0 0.00024514945
mg O 0 0.0048793224
, O 0 0.00023386898
the O 0 0.0001011853
patient O 0 0.00014885238
developed O 0 0.00014643701
a O 0 0.00018857598
second O 0 0.00012917884
episode O 0 0.00023328974
of O 0 0.00026786153
transient O 0 0.0011457943
anuria B-Disease 0 0.99515
lasting O 0 0.0005746101
10 O 0 0.00060742075
hours O 0 0.0007934444
. O 0 0.0020137783

During O 0 0.0019246788
these O 0 0.0014356729
two O 0 0.0008596845
episodes O 0 0.0018945471
, O 0 0.0013608955
his O 0 0.00088549516
blood O 0 0.0039203963
pressure O 0 0.01299618
diminished O 0 0.0010080078
but O 0 0.0006911409
no O 0 0.0007005472
severe O 0 0.022639379
hypotension B-Disease 0 0.9997454
was O 0 0.0014493053
noted O 0 0.0019701407
. O 0 0.0032851368

Ultimately O 0 0.006536545
, O 0 0.005169053
an O 0 0.00244514
arteriography O 0 0.0075059156
showed O 0 0.0011495805
a O 0 0.0014578887
70 O 0 0.0013041178
- O 0 0.0029824362
80 O 0 0.0014865558
% O 0 0.002469061
renal B-Disease 0 0.8957873
artery I-Disease 0 0.7559016
stenosis I-Disease 0 0.99891233
. O 0 0.0059736725

In O 0 0.0020114207
this O 0 0.0018758294
patient O 0 0.0015567894
, O 0 0.0019377014
renal B-Disease 0 0.9023878
artery I-Disease 0 0.65140486
stenosis I-Disease 0 0.999624
combined O 0 0.00039038446
with O 0 0.00025592686
heart B-Disease 0 0.015201787
failure I-Disease 0 0.0057332763
and O 0 0.0002231715
diuretic O 0 0.99944276
therapy O 0 0.00033658167
certainly O 0 0.00014573731
resulted O 0 0.00010691559
in O 0 0.00011876532
a O 0 0.0001814309
strong O 0 0.00011925466
activation O 0 0.00014762743
of O 0 0.00022899262
the O 0 0.00034305395
renin O 0 0.9981501
- O 0 0.32854527
angiotensin B-Chemical 0 0.9999542
system O 0 0.0015224143
( O 0 0.0026097798
RAS O 0 0.46570972
) O 0 0.0049470444
. O 0 0.0032517337

Under O 0 0.0036141875
such O 0 0.0018037887
conditions O 0 0.002222212
, O 0 0.010173691
angiotensin B-Chemical 1 0.9999825
II I-Chemical 1 0.9935034
receptor O 0 0.013900601
blockade O 0 0.006536362
by O 0 0.00098434
losartan B-Chemical 1 0.9999894
probably O 0 0.00075889815
induced O 0 0.00036982173
a O 0 0.00052478915
critical O 0 0.00029573147
fall O 0 0.0008862937
in O 0 0.0007082829
glomerular O 0 0.9882372
filtration O 0 0.07162147
pressure O 0 0.0312738
. O 0 0.0030932587

This O 0 0.004606643
case O 0 0.002184623
report O 0 0.0018082649
highlights O 0 0.00055568514
the O 0 0.00044234894
fact O 0 0.00030939493
that O 0 0.00033586557
the O 0 0.00075282
angiotensin B-Chemical 1 0.99999595
II I-Chemical 1 0.99889565
receptor O 0 0.2342142
antagonist O 0 0.99281126
losartan B-Chemical 1 0.99999833
can O 0 0.00022347005
cause O 0 0.0002491974
serious O 0 0.00045295464
unexpected O 0 0.00014433183
complications O 0 0.00334496
in O 0 0.00010842969
patients O 0 0.00032166095
with O 0 0.00028271574
renovascular B-Disease 0 0.9999956
disease I-Disease 0 0.9974775
and O 0 0.00017450606
should O 0 6.3978805e-05
be O 0 9.8383825e-05
used O 0 0.00011006795
with O 0 0.00020335794
extreme O 0 0.0004963291
caution O 0 0.00046185323
in O 0 0.000406873
this O 0 0.0007396276
setting O 0 0.0012835794
. O 0 0.002504042

Calcineurin O 0 0.19354557
- O 0 0.02695419
inhibitor O 0 0.0048466534
induced O 0 0.0017483223
pain B-Disease 0 0.7212607
syndrome O 0 0.99064976
( O 0 0.005901664
CIPS B-Disease 0 0.9993781
) O 0 0.0020466323
: O 0 0.0009969069
a O 0 0.000670934
severe O 0 0.0030370092
disabling O 0 0.058401562
complication O 0 0.0020657973
after O 0 0.00031791403
organ O 0 0.0011575366
transplantation O 0 0.0017004901
. O 0 0.0023496891

Bone O 0 0.0106880795
pain B-Disease 0 0.013926226
after O 0 0.00079511444
transplantation O 0 0.001001035
is O 0 0.000509262
a O 0 0.00073494564
frequent O 0 0.0006951135
complication O 0 0.0021084615
that O 0 0.00036700652
can O 0 0.0003645739
be O 0 0.000505187
caused O 0 0.0006401866
by O 0 0.0009087945
several O 0 0.0011604794
diseases O 0 0.12813948
. O 0 0.0045865956

Treatment O 0 0.007437727
strategies O 0 0.0024069701
depend O 0 0.0014581867
on O 0 0.0009459299
the O 0 0.0009622144
correct O 0 0.001265693
diagnosis O 0 0.0019498466
of O 0 0.0015720219
the O 0 0.0019158224
pain B-Disease 0 0.06741694
. O 0 0.005094537

Nine O 0 0.004865621
patients O 0 0.003510324
with O 0 0.0016785898
severe O 0 0.0070949737
pain B-Disease 0 0.038542684
in O 0 0.0005235264
their O 0 0.00047076965
feet O 0 0.0048378184
, O 0 0.0008200009
which O 0 0.00041929298
was O 0 0.0003025197
registered O 0 0.0004095255
after O 0 0.00021407218
transplantation O 0 0.00058898027
, O 0 0.0009930766
were O 0 0.0008269436
investigated O 0 0.0014956468
. O 0 0.0033490225

Bone O 0 0.010268806
scans O 0 0.0041591143
showed O 0 0.0019268116
an O 0 0.001938943
increased O 0 0.0022162178
tracer O 0 0.0073416545
uptake O 0 0.004481112
of O 0 0.0015068852
the O 0 0.0015150375
foot O 0 0.009178547
bones O 0 0.01767757
. O 0 0.0058368333

Magnetic O 0 0.010950788
resonance O 0 0.005663884
imaging O 0 0.0021011732
demonstrated O 0 0.0013661803
bone B-Disease 0 0.0056613893
marrow I-Disease 0 0.07956494
oedema I-Disease 0 0.99892515
in O 0 0.0013508507
the O 0 0.0014175097
painful O 0 0.1568387
bones O 0 0.014341903
. O 0 0.005065484

Pain B-Disease 0 0.09025984
was O 0 0.0020826089
not O 0 0.0011057009
explained O 0 0.00075435423
by O 0 0.0005866911
other O 0 0.0005859472
diseases O 0 0.12024563
causing O 0 0.00087114936
foot O 0 0.008370727
pain B-Disease 0 0.07464196
, O 0 0.00046316482
like O 0 0.00021739512
reflex B-Disease 0 0.013556409
sympathetic I-Disease 0 0.010094369
dystrophy I-Disease 0 0.9943779
, O 0 0.001100099
polyneuropathy B-Disease 0 0.9995034
, O 0 0.00058428844
Morton B-Disease 0 0.0024169842
' I-Disease 0 0.0005284391
s I-Disease 0 0.0006358354
neuralgia I-Disease 0 0.99973255
, O 0 0.0016336085
gout B-Disease 0 0.999969
, O 0 0.0062539442
osteoporosis B-Disease 0 0.9999584
, O 0 0.030058106
avascular B-Disease 0 0.9999802
necrosis I-Disease 2 0.999997
, O 0 0.0011079626
intermittent B-Disease 0 0.0011695191
claudication I-Disease 0 0.83249986
, O 0 0.00028769052
orthopaedic O 0 0.00043071777
foot B-Disease 0 0.0024395913
deformities I-Disease 0 0.631954
, O 0 0.0017245272
stress B-Disease 0 0.9437409
fractures I-Disease 2 0.9999187
, O 0 0.0038322157
and O 0 0.0023102316
hyperparathyroidism B-Disease 0 0.99977547
. O 0 0.0044032247

The O 0 0.0017802209
reduction O 0 0.001881285
of O 0 0.0022188995
cyclosporine B-Chemical 1 0.99996746
- O 0 0.03663872
or O 0 0.0007360036
tacrolimus B-Chemical 0 0.9999614
trough O 0 0.013594134
levels O 0 0.00015940421
and O 0 0.00015734819
the O 0 0.00012749837
administration O 0 0.00032847526
of O 0 0.00034043123
calcium B-Chemical 0 0.9966479
channel O 0 0.010644268
blockers O 0 0.95685846
led O 0 0.00051782624
to O 0 0.0003919166
relief O 0 0.00087790977
of O 0 0.001129161
pain B-Disease 0 0.1253062
. O 0 0.0029433277

The O 0 0.0037009984
Calcineurin O 0 0.021346191
- O 0 0.011237502
inhibitor O 0 0.0040878304
Induced O 0 0.0047997613
Pain B-Disease 0 0.30390087
Syndrome O 0 0.76443076
( O 0 0.0023988434
CIPS B-Disease 0 0.9986259
) O 0 0.0012684241
is O 0 0.00025237072
a O 0 0.0004667386
rare O 0 0.0012339695
but O 0 0.0002897639
severe O 0 0.0009415851
side O 0 0.0003949418
effect O 0 0.00012993689
of O 0 0.00039362756
cyclosporine B-Chemical 1 0.99999654
or O 0 0.00045564392
tacrolimus B-Chemical 0 0.9999914
and O 0 0.0001793319
is O 0 8.999554e-05
accurately O 0 0.00010973625
diagnosed O 0 0.0006257023
by O 0 0.00011062784
its O 0 0.00016569748
typical O 0 0.00016559465
presentation O 0 0.00030057135
, O 0 0.0002938969
magnetic O 0 0.00048672516
resonance O 0 0.00086946675
imaging O 0 0.00044596172
and O 0 0.0005122728
bone O 0 0.0021440613
scans O 0 0.002158952
. O 0 0.0023416304

Incorrect O 0 0.01679651
diagnosis O 0 0.003922194
of O 0 0.0016776345
the O 0 0.0013047929
syndrome O 0 0.8674039
will O 0 0.0005796805
lead O 0 0.0019599018
to O 0 0.00029199966
a O 0 0.00035335924
significant O 0 0.00020933549
reduction O 0 0.00025367632
of O 0 0.00022021902
life O 0 0.00022831763
quality O 0 0.00019792172
in O 0 0.000365417
patients O 0 0.001405199
suffering O 0 0.01835788
from O 0 0.0016392346
CIPS B-Disease 0 0.9977309
. O 0 0.004124495

Brain O 0 0.020848462
natriuretic O 0 0.022412837
peptide O 0 0.001887155
is O 0 0.001121144
a O 0 0.0013527096
predictor O 0 0.0008644048
of O 0 0.0018629245
anthracycline B-Chemical 0 0.9997327
- O 0 0.03351366
induced O 0 0.00353871
cardiotoxicity B-Disease 0 0.99980396
. O 0 0.007173434

Anthracyclines B-Chemical 0 0.9671125
are O 0 0.00168159
effective O 0 0.0013058231
antineoplastic O 0 0.0624767
drugs O 0 0.07158739
, O 0 0.001647248
but O 0 0.0007250379
they O 0 0.0004712676
frequently O 0 0.0005362268
cause O 0 0.00073926034
dose O 0 0.0014982811
- O 0 0.0042998334
related O 0 0.0013551272
cardiotoxicity B-Disease 0 0.99960536
. O 0 0.0052738236

The O 0 0.0027834713
cardiotoxicity B-Disease 0 0.9988563
of O 0 0.0013317474
conventional O 0 0.0011134095
anthracycline B-Chemical 0 0.9997197
therapy O 0 0.00069464435
highlights O 0 0.00018455039
a O 0 0.00028825802
need O 0 0.00014397815
to O 0 0.00011590254
search O 0 0.00011599674
for O 0 8.575776e-05
methods O 0 0.0001122782
that O 0 9.960969e-05
are O 0 0.00011001296
highly O 0 0.00011757295
sensitive O 0 0.00012809291
and O 0 0.00018772222
capable O 0 0.00018171396
of O 0 0.00040910702
predicting O 0 0.0005622735
cardiac B-Disease 0 0.14693317
dysfunction I-Disease 0 0.9949497
. O 0 0.004019167

We O 0 0.002637366
measured O 0 0.0020811597
the O 0 0.0013448097
plasma O 0 0.004791982
level O 0 0.0005913092
of O 0 0.0006515025
brain O 0 0.0015095938
natriuretic O 0 0.008036578
peptide O 0 0.00032461775
( O 0 0.0007188939
BNP O 0 0.39106515
) O 0 0.00046780583
to O 0 9.5021845e-05
determine O 0 3.947796e-05
whether O 0 5.904469e-05
BNP O 0 0.12123175
might O 0 7.165888e-05
serve O 0 0.00011471538
as O 0 0.00010468973
a O 0 0.00014718581
simple O 0 0.000115911054
diagnostic O 0 0.000118103744
indicator O 0 0.000101007354
of O 0 0.00027009778
anthracycline B-Chemical 0 0.9999728
- O 0 0.022979753
induced O 0 0.00028942316
cardiotoxicity B-Disease 0 0.99998546
in O 0 0.00018991344
patients O 0 0.00043154342
with O 0 0.00024440754
acute B-Disease 0 0.9866839
leukemia I-Disease 0 0.9999914
treated O 0 0.0014465372
with O 0 0.00035290007
a O 0 0.0013642319
daunorubicin B-Chemical 0 0.9999896
( O 0 0.0091311075
DNR B-Chemical 0 0.99992025
) O 0 0.002476908
- O 0 0.0019952026
containing O 0 0.0005558192
regimen O 0 0.0012926603
. O 0 0.0021187481

Thirteen O 0 0.007108217
patients O 0 0.004700382
with O 0 0.002908987
acute B-Disease 0 0.98092103
leukemia I-Disease 0 0.99991775
were O 0 0.0011789207
treated O 0 0.0014134094
with O 0 0.0009582384
a O 0 0.002313457
DNR B-Chemical 0 0.9997174
- O 0 0.0067408253
containing O 0 0.0009812845
regimen O 0 0.0018813593
. O 0 0.002887426

Cardiac O 0 0.009912257
functions O 0 0.0020380626
were O 0 0.0015567236
evaluated O 0 0.0012018856
with O 0 0.0013063797
radionuclide O 0 0.0035441332
angiography O 0 0.0038113445
before O 0 0.0011033345
chemotherapies O 0 0.005146791
. O 0 0.0042395312

The O 0 0.002884653
plasma O 0 0.00763199
levels O 0 0.0011606005
of O 0 0.0011705199
atrial O 0 0.022676378
natriuretic O 0 0.018738328
peptide O 0 0.0006461189
( O 0 0.0015476128
ANP O 1 0.99759114
) O 0 0.0014357959
and O 0 0.0004699469
BNP O 0 0.10672509
were O 0 0.00024858845
measured O 0 0.00024016634
at O 0 0.00018246575
the O 0 0.00022733213
time O 0 0.00028624976
of O 0 0.0007124255
radionuclide O 0 0.003998424
angiography O 0 0.0075814305
. O 0 0.0028124282

Three O 0 0.0034104458
patients O 0 0.004338182
developed O 0 0.0033953032
congestive B-Disease 0 0.998464
heart I-Disease 0 0.12215843
failure I-Disease 0 0.0066243573
after O 0 0.00041989496
the O 0 0.0005051098
completion O 0 0.0005464009
of O 0 0.0014022598
chemotherapy O 0 0.006184168
. O 0 0.0034855704

Five O 0 0.0038460828
patients O 0 0.0036132534
were O 0 0.0014620827
diagnosed O 0 0.0030841161
as O 0 0.0007841487
having O 0 0.0008261879
subclinical O 0 0.5319314
heart B-Disease 0 0.06801135
failure I-Disease 0 0.004218487
after O 0 0.00022564793
the O 0 0.00030420927
completion O 0 0.00035896702
of O 0 0.0010119625
chemotherapy O 0 0.0051855347
. O 0 0.002763549

The O 0 0.0027323582
plasma O 0 0.008433811
levels O 0 0.0011398628
of O 0 0.0012570502
BNP O 0 0.4050676
in O 0 0.00044528523
all O 0 0.0002604632
the O 0 0.00019009333
patients O 0 0.0003439557
with O 0 0.00019001433
clinical O 0 0.0005839488
and O 0 0.00022476497
subclinical O 0 0.52590996
heart B-Disease 0 0.08239521
failure I-Disease 0 0.009224358
increased O 0 0.00016550357
above O 0 9.7419266e-05
the O 0 8.139457e-05
normal O 0 0.00017967832
limit O 0 0.00015565727
( O 0 0.00021471873
40 O 0 0.00014648939
pg O 0 0.0018532304
/ O 0 0.0010047876
ml O 0 0.0007162058
) O 0 0.00027121254
before O 0 5.3229873e-05
the O 0 7.722162e-05
detection O 0 9.9685916e-05
of O 0 0.00015902119
clinical O 0 0.0006335437
or O 0 0.00023832345
subclinical O 0 0.4805095
heart B-Disease 0 0.059802283
failure I-Disease 0 0.00620143
by O 0 0.0005278836
radionuclide O 0 0.0030779499
angiography O 0 0.005945751
. O 0 0.0020761972

On O 0 0.002954271
the O 0 0.0016261232
other O 0 0.00124817
hand O 0 0.0018459396
, O 0 0.0034222875
BNP O 0 0.866189
did O 0 0.0006745482
not O 0 0.00030155157
increase O 0 0.00022897996
in O 0 0.00017760503
the O 0 0.00014362314
patients O 0 0.00029869028
without O 0 0.00017577624
heart B-Disease 0 0.012908498
failure I-Disease 0 0.008800009
given O 0 0.00019740681
DNR B-Chemical 0 0.99989486
, O 0 0.00044174702
even O 0 0.00017526429
at O 0 0.000118469536
more O 0 0.00023990544
than O 0 0.00021626464
700 O 0 0.00094595156
mg O 0 0.0044961856
/ O 0 0.0019459558
m O 0 0.0029192704
( O 0 0.0015623226
2 O 0 0.0013358758
) O 0 0.003164589
. O 0 0.0032409625

The O 0 0.0029958964
plasma O 0 0.009914166
level O 0 0.0014780181
of O 0 0.0021251107
ANP O 1 0.99915516
did O 0 0.0011258433
not O 0 0.00046195227
always O 0 0.00046732897
increase O 0 0.00025072953
in O 0 0.00019925967
all O 0 0.00017052528
the O 0 0.00016105932
patients O 0 0.00036907961
with O 0 0.00027759923
clinical O 0 0.0010471905
and O 0 0.00062716624
subclinical O 0 0.7079228
heart B-Disease 0 0.24404633
failure I-Disease 0 0.08869341
. O 0 0.0029667811

These O 0 0.0019419111
preliminary O 0 0.0016642514
results O 0 0.0010074581
suggest O 0 0.00060598593
that O 0 0.0008112534
BNP O 0 0.56045943
may O 0 0.00043730228
be O 0 0.00030001337
useful O 0 0.00024701186
as O 0 0.00025493035
an O 0 0.0002739961
early O 0 0.00035412135
and O 0 0.00024778105
sensitive O 0 0.00020943809
indicator O 0 0.0003070936
of O 0 0.0008219719
anthracycline B-Chemical 0 0.9998803
- O 0 0.033707876
induced O 0 0.0022520125
cardiotoxicity B-Disease 0 0.99988437
. O 0 0.0051989527

Nephrotoxicity B-Disease 0 0.9892201
of O 0 0.005882541
combined O 0 0.0076794527
cephalothin B-Chemical 0 0.9998379
- O 0 0.21099402
gentamicin B-Chemical 0 0.99923563
regimen O 0 0.0058956225
. O 0 0.005933181

Two O 0 0.0028327934
patients O 0 0.0041038757
developed O 0 0.0030982282
acute B-Disease 2 0.98475546
tubular I-Disease 2 0.99984896
necrosis I-Disease 2 0.999998
, O 0 0.007943219
characterized O 0 0.00082729594
clinically O 0 0.0017998788
by O 0 0.00026468464
acute O 0 0.2619574
oliguric B-Disease 0 0.99995255
renal I-Disease 0 0.97324127
failure I-Disease 0 0.031487495
, O 0 0.00023819669
while O 0 8.7147586e-05
they O 0 7.557808e-05
were O 0 7.3633244e-05
receiving O 0 0.00010100773
a O 0 0.00014867735
combination O 0 0.000199468
of O 0 0.00050605676
cephalothin B-Chemical 0 0.99999654
sodium I-Chemical 0 0.9999076
and O 0 0.0026037833
gentamicin B-Chemical 0 0.99998486
sulfate I-Chemical 0 0.99969006
therapy O 0 0.0044868677
. O 0 0.0027350269

Patients O 0 0.004467347
who O 0 0.00207009
are O 0 0.00071813446
given O 0 0.00043091513
this O 0 0.00052874594
drug O 0 0.0027484295
regimen O 0 0.00039938893
should O 0 0.0001450534
be O 0 0.00020731342
observed O 0 0.00020033488
very O 0 0.00031321365
carefully O 0 0.00019351277
for O 0 0.00027452767
early O 0 0.0008293726
signs O 0 0.00334068
of O 0 0.00207103
nephrotoxicity B-Disease 0 0.9998715
. O 0 0.005181035

High O 0 0.00457343
doses O 0 0.0035691585
of O 0 0.0014900038
this O 0 0.0010824931
antibiotic O 0 0.0026255096
combination O 0 0.00072499225
should O 0 0.00029322156
be O 0 0.00040669908
avoided O 0 0.00050154683
especially O 0 0.0007076343
in O 0 0.00096535345
elderly O 0 0.11648197
patients O 0 0.0043013114
. O 0 0.0035145716

Patients O 0 0.0057262816
with O 0 0.00343772
renal B-Disease 0 0.9047087
insufficiency I-Disease 0 0.9956293
should O 0 0.0008019793
not O 0 0.0007933155
be O 0 0.0007764731
given O 0 0.0006458585
this O 0 0.0013209688
regimen O 0 0.0023158784
. O 0 0.0036418263

In O 0 0.001989366
vivo O 0 0.0017539981
protection O 0 0.0014821682
of O 0 0.0014924677
dna O 0 0.1357957
damage O 0 0.1808377
associated O 0 0.0008382553
apoptotic O 0 0.02235308
and O 0 0.00063711894
necrotic B-Disease 0 0.38894427
cell O 0 0.0006051222
deaths O 0 0.059367377
during O 0 0.00026797212
acetaminophen B-Chemical 0 0.9999957
- O 0 0.02366617
induced O 0 0.00027537308
nephrotoxicity B-Disease 0 0.9999894
, O 0 0.004747114
amiodarone B-Chemical 0 0.99999
- O 0 0.014713916
induced O 0 0.00021076626
lung B-Disease 0 0.80839217
toxicity I-Disease 0 0.99819916
and O 0 0.00057559594
doxorubicin B-Chemical 0 0.99997437
- O 0 0.036070835
induced O 0 0.00038810234
cardiotoxicity B-Disease 0 0.99997294
by O 0 0.00034616198
a O 0 0.000555526
novel O 0 0.0006217088
IH636 B-Chemical 0 0.99931455
grape I-Chemical 0 0.9550561
seed I-Chemical 0 0.009894803
proanthocyanidin I-Chemical 0 0.9997466
extract I-Chemical 0 0.1355474
. O 0 0.0045972276

Grape B-Chemical 0 0.90350085
seed I-Chemical 0 0.008012383
extract I-Chemical 0 0.023141766
, O 0 0.0027955992
primarily O 0 0.0008564203
a O 0 0.00086868805
mixture O 0 0.00094276504
of O 0 0.0010085702
proanthocyanidins B-Chemical 0 0.99994457
, O 0 0.0015182745
has O 0 0.00016011989
been O 0 0.0001444727
shown O 0 6.565964e-05
to O 0 8.082793e-05
modulate O 0 4.942448e-05
a O 0 0.00016692869
wide O 0 0.00021893189
- O 0 0.0006167452
range O 0 0.00011193356
of O 0 0.00011707396
biological O 0 0.0001460275
, O 0 0.00026279796
pharmacological O 0 0.00043479496
and O 0 0.00020216568
toxicological O 0 0.0006615174
effects O 0 0.00028923064
which O 0 0.0004919206
are O 0 0.00046549938
mainly O 0 0.0009919121
cytoprotective O 0 0.058260676
. O 0 0.0035328446

This O 0 0.0044084736
study O 0 0.0020273845
assessed O 0 0.0010393397
the O 0 0.00067543075
ability O 0 0.00065610046
of O 0 0.0013378505
IH636 B-Chemical 0 0.9991316
grape I-Chemical 0 0.9194707
seed I-Chemical 0 0.0049438863
proanthocyanidin I-Chemical 0 0.99988246
extract I-Chemical 0 0.1269673
( O 0 0.046988815
GSPE B-Chemical 0 0.9999994
) O 0 0.0040209196
to O 0 0.0001830099
prevent O 0 0.00029994245
acetaminophen B-Chemical 0 0.9999962
( O 0 0.0038836482
AAP B-Chemical 0 0.9964868
) O 0 0.0012570214
- O 0 0.0018078871
induced O 0 0.0002576861
nephrotoxicity B-Disease 0 0.9999864
, O 0 0.0047894926
amiodarone B-Chemical 0 0.99998784
( O 0 0.0036270646
AMI B-Chemical 0 0.99996996
) O 0 0.0012168887
- O 0 0.0016227168
induced O 0 0.0002135051
lung B-Disease 0 0.74129766
toxicity I-Disease 0 0.9974088
, O 0 0.000696754
and O 0 0.00044467763
doxorubicin B-Chemical 0 0.99993944
( O 0 0.0054885433
DOX B-Chemical 1 0.9999424
) O 0 0.0035111592
- O 0 0.004131291
induced O 0 0.00074914115
cardiotoxicity B-Disease 0 0.999881
in O 0 0.0009828903
mice O 0 0.00064059254
. O 0 0.002366556

Experimental O 0 0.005273524
design O 0 0.0026097847
consisted O 0 0.0011867706
of O 0 0.00081048
four O 0 0.00039569585
groups O 0 0.00063771853
: O 0 0.0008329421
control O 0 0.00041214676
( O 0 0.00067275984
vehicle O 0 0.0011582379
alone O 0 0.00049375254
) O 0 0.0014757027
, O 0 0.0022865944
GSPE B-Chemical 0 0.99999726
alone O 0 0.0010715056
, O 0 0.0011081679
drug O 0 0.011289799
alone O 0 0.00074797485
and O 0 0.0017209747
GSPE B-Chemical 0 0.99999464
+ O 0 0.14174289
drug O 0 0.16712156
. O 0 0.003611194

For O 0 0.0017967109
the O 0 0.0018092032
cytoprotection O 0 0.025623014
study O 0 0.0011583919
, O 0 0.00088220986
animals O 0 0.00028749753
were O 0 0.00028377376
orally O 0 0.0005667255
gavaged O 0 0.00288996
100 O 0 0.00061062904
mg O 0 0.0041185627
/ O 0 0.0018705423
Kg O 0 0.018975133
GSPE B-Chemical 0 0.99999475
for O 0 0.00021165518
7 O 0 0.00015434278
- O 0 0.0005235134
10 O 0 9.662628e-05
days O 0 5.3419455e-05
followed O 0 6.662682e-05
by O 0 9.174753e-05
i O 0 0.0002117597
. O 0 0.000108452965
p O 0 0.0001800862
. O 0 8.916506e-05
injections O 0 8.7689856e-05
of O 0 9.6736636e-05
organ O 0 0.00015865723
specific O 0 5.3732947e-05
three O 0 5.6935318e-05
drugs O 0 0.0025306898
( O 0 0.0006238861
AAP B-Chemical 0 0.95993674
: O 0 0.0005774846
500 O 0 0.00048735563
mg O 0 0.0034283083
/ O 0 0.00075694255
Kg O 0 0.0006436654
for O 0 9.1729955e-05
24 O 0 0.00013008516
h O 0 0.00017985042
; O 0 0.0005550764
AMI B-Chemical 0 0.9996307
: O 0 0.00043388247
50 O 0 0.00023854556
mg O 0 0.0016570039
/ O 0 0.0007410827
Kg O 0 0.0008729425
/ O 0 0.0004471621
day O 0 8.4082756e-05
for O 0 8.003296e-05
four O 0 8.107689e-05
days O 0 0.00012417432
; O 0 0.00066633767
DOX B-Chemical 1 0.9993845
: O 0 0.0008093062
20 O 0 0.00035417255
mg O 0 0.0026689665
/ O 0 0.0013712177
Kg O 0 0.0014470841
for O 0 0.00036026808
48 O 0 0.00066951726
h O 0 0.0011544686
) O 0 0.0032208827
. O 0 0.0033828474

Parameters O 0 0.0058616973
of O 0 0.0021130273
study O 0 0.0014445754
included O 0 0.0008064735
analysis O 0 0.00068755285
of O 0 0.0007842223
serum O 0 0.011886627
chemistry O 0 0.0028564648
( O 0 0.0029053448
ALT O 0 0.9985323
, O 0 0.005236882
BUN O 0 0.9999658
and O 0 0.0025256802
CPK O 0 0.99987054
) O 0 0.001533836
, O 0 0.00051490555
and O 0 0.0002685497
orderly O 0 0.0007650732
fragmentation O 0 0.0006104032
of O 0 0.00022527087
genomic O 0 0.00023418562
DNA O 0 0.0012423741
( O 0 0.00029540286
both O 0 0.00011277189
endonuclease O 0 0.0005568728
- O 0 0.0011157332
dependent O 0 7.8296944e-05
and O 0 0.00010734649
independent O 0 8.0656304e-05
) O 0 0.00026673742
in O 0 8.564139e-05
addition O 0 5.433054e-05
to O 0 8.645676e-05
microscopic O 0 0.00016194492
evaluation O 0 0.00011705902
of O 0 0.0001752496
damage O 0 0.009184447
and O 0 0.00025504653
/ O 0 0.0012241319
or O 0 0.00019264237
protection O 0 0.00029146674
in O 0 0.0003321242
corresponding O 0 0.00039609347
PAS O 0 0.084545426
stained O 0 0.0016449803
tissues O 0 0.0024178617
. O 0 0.0029385246

Results O 0 0.0027012648
indicate O 0 0.0013741225
that O 0 0.0023722888
GSPE B-Chemical 0 0.9999906
preexposure O 0 0.011836952
prior O 0 0.00039353062
to O 0 0.0005554871
AAP B-Chemical 0 0.9903887
, O 0 0.0029929155
AMI B-Chemical 0 0.9999317
and O 0 0.0008452752
DOX B-Chemical 1 0.9999161
, O 0 0.00052222254
provided O 0 0.00012313129
near O 0 0.0001675893
complete O 0 0.000100027944
protection O 0 0.00013178009
in O 0 0.000113012604
terms O 0 0.00011546118
of O 0 0.00023082341
serum O 0 0.01160209
chemistry O 0 0.0008872181
changes O 0 0.00037008303
( O 0 0.0012489014
ALT O 0 0.99885786
, O 0 0.0034520335
BUN O 0 0.9999769
and O 0 0.0022019509
CPK O 0 0.9998729
) O 0 0.0017276328
, O 0 0.00071810576
and O 0 0.00048423753
significantly O 0 0.0007945623
reduced O 0 0.0014480148
DNA O 0 0.010970612
fragmentation O 0 0.009896722
. O 0 0.0038155161

Histopathological O 0 0.004433222
examination O 0 0.0014021404
of O 0 0.0014394314
kidney O 0 0.038367335
, O 0 0.0019246009
heart O 0 0.025420997
and O 0 0.00052097364
lung O 0 0.0022145398
sections O 0 0.00019209593
revealed O 0 0.00015771454
moderate O 0 0.000616889
to O 0 0.00019949426
massive O 0 0.0018989487
tissue B-Disease 0 0.07676338
damage I-Disease 0 0.5864912
with O 0 0.00019293444
a O 0 0.00019768765
variety O 0 0.0001144455
of O 0 0.00013387713
morphological O 0 0.0005448883
aberrations O 0 0.1460627
by O 0 0.00010452862
all O 0 7.655157e-05
the O 0 6.089719e-05
three O 0 4.5558725e-05
drugs O 0 0.0010935576
in O 0 0.00011520658
the O 0 0.00011147223
absence O 0 0.00014426316
of O 0 0.0008203158
GSPE B-Chemical 0 0.99999905
preexposure O 0 0.026745552
than O 0 0.0004022524
in O 0 0.00049808115
its O 0 0.0010412842
presence O 0 0.0014412577
. O 0 0.002863984

GSPE B-Chemical 0 0.99996114
+ O 0 0.189636
drug O 0 0.17190026
exposed O 0 0.0017200197
tissues O 0 0.0012584621
exhibited O 0 0.0007580757
minor O 0 0.0010399577
residual O 0 0.0009522879
damage O 0 0.0090407925
or O 0 0.00068893953
near O 0 0.0010450348
total O 0 0.0012497058
recovery O 0 0.002482227
. O 0 0.0032662305

Additionally O 0 0.0032825458
, O 0 0.0046394765
histopathological O 0 0.0053792433
alterations O 0 0.0024633114
mirrored O 0 0.0013487353
both O 0 0.00078996684
serum O 0 0.009562152
chemistry O 0 0.0016579032
changes O 0 0.0006230394
and O 0 0.00056061574
the O 0 0.0004931065
pattern O 0 0.00071438635
of O 0 0.0014726256
DNA O 0 0.009020595
fragmentation O 0 0.009180413
. O 0 0.004335728

Interestingly O 0 0.0026254847
, O 0 0.0034998811
all O 0 0.0012832248
the O 0 0.0009303613
drugs O 0 0.008512921
, O 0 0.0012204731
such O 0 0.0004998044
as O 0 0.0005832195
, O 0 0.0017923947
AAP B-Chemical 0 0.99679214
, O 0 0.0048274808
AMI B-Chemical 0 0.99995255
and O 0 0.0010205067
DOX B-Chemical 1 0.99994254
induced O 0 0.0004744165
apoptotic O 0 0.22526991
death O 0 0.9301457
in O 0 0.00016414256
addition O 0 9.028814e-05
to O 0 0.00025271266
necrosis B-Disease 2 0.9999511
in O 0 0.00017229072
the O 0 0.0001012687
respective O 0 9.855791e-05
organs O 0 0.00036774727
which O 0 0.00022870109
was O 0 0.0002181497
very O 0 0.0004110714
effectively O 0 0.00052481436
blocked O 0 0.0021936274
by O 0 0.0033305283
GSPE B-Chemical 0 0.9999906
. O 0 0.008613845

Since O 0 0.0041409587
AAP B-Chemical 0 0.98800397
, O 0 0.01440241
AMI B-Chemical 0 0.99980265
and O 0 0.0033659888
DOX B-Chemical 1 0.9998679
undergo O 0 0.0008142619
biotransformation O 0 0.81972843
and O 0 0.0003688283
are O 0 0.00017859711
known O 0 0.00017423354
to O 0 0.00016540228
produce O 0 0.00018839697
damaging O 0 0.01061392
radicals O 0 0.96712065
in O 0 0.00022185617
vivo O 0 0.00018522609
, O 0 0.00029153874
the O 0 0.00011860766
protection O 0 0.00022898651
by O 0 0.00047150574
GSPE B-Chemical 0 0.9999994
may O 0 0.00026928395
be O 0 0.00014483655
linked O 0 0.0001117092
to O 0 9.181677e-05
both O 0 0.00010588699
inhibition O 0 0.00022183964
of O 0 0.0003126656
metabolism O 0 0.060498405
and O 0 0.0004416148
/ O 0 0.002888133
or O 0 0.00045536403
detoxification O 0 0.055905987
of O 0 0.0013811311
cytotoxic O 0 0.42760658
radicals O 0 0.9940906
. O 0 0.0048270044

In O 0 0.0019598391
addition O 0 0.0012930348
, O 0 0.0025714443
its O 0 0.0015190549
' O 0 0.0017895834
presumed O 0 0.00074334146
contribution O 0 0.0003043259
to O 0 0.00039637243
DNA O 0 0.0020540154
repair O 0 0.0005301272
may O 0 0.000170693
be O 0 0.00016381203
another O 0 0.00020774081
important O 0 0.00012679494
attribute O 0 0.00026561672
, O 0 0.00047329094
which O 0 0.00031332535
played O 0 0.00040741096
a O 0 0.00040927593
role O 0 0.00018456425
in O 0 0.00042995706
the O 0 0.00062114553
chemoprevention O 0 0.015865853
process O 0 0.0020029112
. O 0 0.0032936384

Additionally O 0 0.003384719
, O 0 0.0044078985
this O 0 0.001654483
may O 0 0.0008437736
have O 0 0.0005603438
been O 0 0.00041577072
the O 0 0.00028079693
first O 0 0.00021961116
report O 0 0.0005964516
on O 0 0.00041832842
AMI B-Chemical 0 0.9999256
- O 0 0.009408385
induced O 0 0.0005143581
apoptotic O 0 0.11319628
death O 0 0.91280437
in O 0 0.0006690711
the O 0 0.00073551876
lung O 0 0.018114228
tissue O 0 0.0049670227
. O 0 0.002890359

Taken O 0 0.0029121423
together O 0 0.0022402043
, O 0 0.0025113549
these O 0 0.00093205855
events O 0 0.0011682293
undoubtedly O 0 0.0009133953
establish O 0 0.0005518542
GSPE B-Chemical 0 0.99999595
' O 0 0.0020812708
s O 0 0.0005266211
abundant O 0 0.00019989106
bioavailability O 0 0.21502714
, O 0 0.00037470058
and O 0 0.00015524696
the O 0 0.000118873184
power O 0 0.0005143486
to O 0 0.00011695213
defend O 0 0.00019537138
multiple O 0 0.00010181209
target O 0 7.892845e-05
organs O 0 0.00030203033
from O 0 0.00015987473
toxic O 0 0.015352439
assaults O 0 0.0111248875
induced O 0 0.00018312022
by O 0 0.00018103188
structurally O 0 0.00026324284
diverse O 0 0.00020281265
and O 0 0.00020516041
functionally O 0 0.00017915723
different O 0 0.00023904533
entities O 0 0.0009293946
in O 0 0.0007589377
vivo O 0 0.0014544126
. O 0 0.0027574701

Antidepressant B-Chemical 0 0.99973255
- O 0 0.067803055
induced O 0 0.003922529
mania B-Disease 0 0.99987674
in O 0 0.0032669213
bipolar B-Disease 2 0.99989057
patients O 0 0.0034863485
: O 0 0.0016400394
identification O 0 0.0007010768
of O 0 0.0012766643
risk O 0 0.0071101827
factors O 0 0.004869085
. O 0 0.0051427963

BACKGROUND O 0 0.012983641
: O 0 0.0036090757
Concerns O 0 0.0014979187
about O 0 0.0007320681
possible O 0 0.00037259114
risks O 0 0.00061738864
of O 0 0.000348886
switching O 0 0.0002855612
to O 0 0.00033028997
mania B-Disease 0 0.99993944
associated O 0 0.00030660155
with O 0 0.00035816472
antidepressants B-Chemical 0 0.9999654
continue O 0 0.00019195917
to O 0 0.00010389442
interfere O 0 9.928973e-05
with O 0 0.00011889053
the O 0 9.4625975e-05
establishment O 0 0.00011359559
of O 0 0.00013946055
an O 0 0.00013682182
optimal O 0 8.0143625e-05
treatment O 0 0.00019516435
paradigm O 0 0.00049762864
for O 0 0.0008142471
bipolar B-Disease 2 0.99995625
depression I-Disease 0 0.9996817
. O 0 0.004115235

METHOD O 0 0.010274701
: O 0 0.0034181394
The O 0 0.0006717159
response O 0 0.00061689183
of O 0 0.00059062766
44 O 0 0.00064249936
patients O 0 0.0005847474
meeting O 0 0.0003490311
DSM O 0 0.0034179804
- O 0 0.0033519457
IV O 0 0.03804036
criteria O 0 0.000319315
for O 0 0.0003015435
bipolar B-Disease 2 0.999982
disorder I-Disease 0 0.99954104
to O 0 0.00019031075
naturalistic O 0 0.0071767867
treatment O 0 0.00012614926
was O 0 8.2326e-05
assessed O 0 7.7453486e-05
for O 0 5.7681562e-05
at O 0 5.5595232e-05
least O 0 6.234362e-05
6 O 0 4.7740246e-05
weeks O 0 3.7539307e-05
using O 0 6.1710474e-05
the O 0 0.00010338516
Montgomery O 0 0.001024409
- O 0 0.0013378537
Asberg O 0 0.009507054
Depression O 0 0.96519244
Rating O 0 0.0020732265
Scale O 0 0.0014232647
and O 0 0.0003113404
the O 0 0.00039593093
Bech O 0 0.0033023688
- O 0 0.0024464256
Rafaelson O 0 0.0017240224
Mania O 0 0.514019
Rating O 0 0.008984648
Scale O 0 0.009521857
. O 0 0.004469047

Patients O 0 0.0046907365
who O 0 0.0025046102
experienced O 0 0.001808764
a O 0 0.0039213896
manic B-Disease 0 0.9999831
or O 0 0.0017435447
hypomanic B-Disease 0 0.9999515
switch O 0 0.00029546375
were O 0 0.00015097944
compared O 0 0.00010449713
with O 0 0.00015921461
those O 0 0.0002016307
who O 0 0.00023849124
did O 0 0.00013506487
not O 0 8.8134504e-05
on O 0 5.8759404e-05
several O 0 5.3963868e-05
variables O 0 0.00010339611
including O 0 7.3262876e-05
age O 0 0.00020041339
, O 0 0.00025061145
sex O 0 0.0003356466
, O 0 0.0003102104
diagnosis O 0 0.00036681606
( O 0 0.00041865138
DSM B-Disease 0 0.0050545204
- I-Disease 0 0.012894095
IV I-Disease 0 0.93546516
bipolar I-Disease 2 0.99999666
I I-Disease 0 0.96509546
vs O 0 0.0012729305
. O 0 0.0007295548
bipolar B-Disease 2 0.99999654
II I-Disease 0 0.9909826
) O 0 0.0011906764
, O 0 0.00028011322
number O 0 9.33111e-05
of O 0 0.00015068088
previous O 0 0.00024751612
manic B-Disease 0 0.9999944
episodes O 0 0.0008378891
, O 0 0.00025244534
type O 0 0.0002425786
of O 0 0.00020593924
antidepressant B-Chemical 0 0.9999006
therapy O 0 0.00016073268
used O 0 6.253898e-05
( O 0 0.00017583575
electroconvulsive O 0 0.03418342
therapy O 0 8.9809684e-05
vs O 0 0.000102655555
. O 0 0.000104787505
antidepressant B-Chemical 0 0.99976605
drugs O 0 0.00939867
and O 0 0.00012833158
, O 0 0.00022528614
more O 0 0.0001614768
particularly O 0 0.00016065546
, O 0 0.0003635819
selective O 0 0.0009512894
serotonin B-Chemical 0 0.99998796
reuptake I-Chemical 0 0.99916995
inhibitors I-Chemical 0 0.002476868
[ O 0 0.037667494
SSRIs B-Chemical 0 0.9998116
] O 0 0.0018505993
) O 0 0.0003709902
, O 0 0.00017516004
use O 0 8.194113e-05
and O 0 0.00011649112
type O 0 0.00030655012
of O 0 0.00035687533
mood O 0 0.99950445
stabilizers O 0 0.94147867
( O 0 0.0011296555
lithium B-Chemical 0 0.9998652
vs O 0 0.0003416036
. O 0 0.00017416562
anticonvulsants O 0 0.99817026
) O 0 0.00059369823
, O 0 0.00027416152
and O 0 0.00017936919
temperament O 0 0.37844858
of O 0 0.00015000624
the O 0 9.951267e-05
patient O 0 0.00014293061
, O 0 0.00016321271
assessed O 0 8.7044275e-05
during O 0 7.556143e-05
a O 0 0.00021710843
normothymic O 0 0.5580165
period O 0 7.960565e-05
using O 0 9.16732e-05
the O 0 0.0001517221
hyperthymia O 0 0.7563971
component O 0 0.000219902
of O 0 0.00026143974
the O 0 0.00028972852
Semi O 0 0.0010166566
- O 0 0.0018210452
structured O 0 0.00071555417
Affective O 0 0.00490568
Temperament O 0 0.01749284
Interview O 0 0.0028356612
. O 0 0.0032445968

RESULTS O 0 0.0054352423
: O 0 0.0044224747
Switches O 0 0.004068412
to O 0 0.001799267
hypomania B-Disease 0 0.9999081
or O 0 0.0014804389
mania B-Disease 0 0.99986815
occurred O 0 0.0005196292
in O 0 0.00030453954
27 O 0 0.00038182188
% O 0 0.00040659192
of O 0 0.0002202917
all O 0 0.00020961968
patients O 0 0.0005344157
( O 0 0.00065392896
N O 0 0.98411536
= O 0 0.0010251123
12 O 0 0.00014354744
) O 0 0.0003460064
( O 0 0.00025694104
and O 0 0.00014456693
in O 0 0.00013096821
24 O 0 0.00014357372
% O 0 0.00021109609
of O 0 0.0001167135
the O 0 9.846378e-05
subgroup O 0 0.00027799912
of O 0 0.00014634641
patients O 0 0.00033307515
treated O 0 0.0003178286
with O 0 0.00030309995
SSRIs B-Chemical 0 0.99956363
[ O 0 0.0014403069
8 O 0 0.00016974755
/ O 0 0.00064456346
33 O 0 0.00031119978
] O 0 0.00072828564
) O 0 0.0004760183
; O 0 0.00036366424
16 O 0 0.00021738828
% O 0 0.00040796102
( O 0 0.0005743379
N O 0 0.975934
= O 0 0.0009857349
7 O 0 0.00017017928
) O 0 0.00046940765
experienced O 0 0.0005428132
manic B-Disease 0 0.9999862
episodes O 0 0.0010755952
, O 0 0.00041869807
and O 0 0.00024813568
11 O 0 0.0003032329
% O 0 0.0005779769
( O 0 0.0008531961
N O 0 0.97914004
= O 0 0.0018256805
5 O 0 0.00046343182
) O 0 0.0011703171
experienced O 0 0.0016185598
hypomanic B-Disease 0 0.99978167
episodes O 0 0.00497313
. O 0 0.00315598

Sex O 0 0.021211473
, O 0 0.005538174
age O 0 0.0031507083
, O 0 0.0027746614
diagnosis O 0 0.0027469192
( O 0 0.0049047186
bipolar B-Disease 2 0.9999739
I I-Disease 0 0.92680967
vs O 0 0.0022717763
. O 0 0.0014681399
bipolar B-Disease 2 0.99999094
II I-Disease 0 0.9883292
) O 0 0.0019140763
, O 0 0.0005502268
and O 0 0.00024854767
additional O 0 0.00016732136
treatment O 0 0.00023597578
did O 0 0.0002783487
not O 0 0.0002569464
affect O 0 0.0002726491
the O 0 0.00043051972
risk O 0 0.0028520527
of O 0 0.0011506245
switching O 0 0.001610851
. O 0 0.0029699379

The O 0 0.0023062462
incidence O 0 0.0035875428
of O 0 0.0025656023
mood O 0 0.99605846
switches O 0 0.0011218053
seemed O 0 0.00060624495
not O 0 0.0003042467
to O 0 0.00021221774
differ O 0 0.00017575343
between O 0 0.00012482668
patients O 0 0.00030352615
receiving O 0 0.0001996366
an O 0 0.0002517776
anticonvulsant O 0 0.96399873
and O 0 0.000246208
those O 0 0.00028645093
receiving O 0 0.00043185725
no O 0 0.0007303105
mood O 0 0.9969459
stabilizer O 0 0.4176622
. O 0 0.0038422935

In O 0 0.0021890441
contrast O 0 0.0030990297
, O 0 0.004900204
mood O 0 0.9864
switches O 0 0.0009580184
were O 0 0.000461934
less O 0 0.0004911766
frequent O 0 0.00037390736
in O 0 0.00022517768
patients O 0 0.00044945357
receiving O 0 0.00045564957
lithium B-Chemical 0 0.9996861
( O 0 0.00053434895
15 O 0 0.00018081107
% O 0 0.00030255344
, O 0 0.0002634281
4 O 0 0.00013951524
/ O 0 0.00055372354
26 O 0 0.0002117892
) O 0 0.00030637597
than O 0 0.000110232526
in O 0 0.00012514454
patients O 0 0.0002794493
not O 0 0.0001371616
treated O 0 0.0004362743
with O 0 0.0005199371
lithium B-Chemical 0 0.9999244
( O 0 0.0007634822
44 O 0 0.00036339118
% O 0 0.0004262292
, O 0 0.0003937071
8 O 0 0.00025783823
/ O 0 0.00085530384
18 O 0 0.00037446027
; O 0 0.00064024195
p O 0 0.0008242362
= O 0 0.0016065087
. O 0 0.0011640876
04 O 0 0.01901712
) O 0 0.0049279276
. O 0 0.004266909

The O 0 0.0018740803
number O 0 0.0012557284
of O 0 0.0014017767
previous O 0 0.0017197741
manic B-Disease 0 0.9999865
episodes O 0 0.0050583472
did O 0 0.00047192455
not O 0 0.00021760126
affect O 0 0.00013497785
the O 0 0.00011933668
probability O 0 0.00013650986
of O 0 0.00014730278
switching O 0 0.0001411624
, O 0 0.0002512165
whereas O 0 0.00012295798
a O 0 0.00015600436
high O 0 0.00012342166
score O 0 8.743951e-05
on O 0 6.578028e-05
the O 0 0.00011562601
hyperthymia O 0 0.75231373
component O 0 0.000115238894
of O 0 0.00010961744
the O 0 0.000100107995
Semistructured O 0 0.0002494389
Affective O 0 0.001196982
Temperament O 0 0.0056976783
Interview O 0 0.00020460735
was O 0 9.9891644e-05
associated O 0 0.00012792181
with O 0 0.00015659753
a O 0 0.00026026834
greater O 0 0.00028383516
risk O 0 0.0011175371
of O 0 0.0002691513
switching O 0 0.00027481758
( O 0 0.00056645955
p O 0 0.00073959335
= O 0 0.0013358084
. O 0 0.00084351836
008 O 0 0.004646422
) O 0 0.0035896199
. O 0 0.0034614473

CONCLUSION O 0 0.014490458
: O 0 0.0031846506
The O 0 0.00062903843
frequency O 0 0.0006322698
of O 0 0.0009240473
mood O 0 0.97194934
switching O 0 0.00039740457
associated O 0 0.00033375825
with O 0 0.00038968207
acute O 0 0.18573098
antidepressant B-Chemical 0 0.999907
therapy O 0 0.00057543244
may O 0 0.00021417282
be O 0 0.0002988854
reduced O 0 0.0005815928
by O 0 0.0010463378
lithium B-Chemical 0 0.99958235
treatment O 0 0.0023367384
. O 0 0.0031353245

Particular O 0 0.0024088027
attention O 0 0.0035044758
should O 0 0.0007429722
be O 0 0.00071247824
paid O 0 0.00080331473
to O 0 0.00040922753
patients O 0 0.0007499454
with O 0 0.00048516275
a O 0 0.001713084
hyperthymic O 0 0.99998057
temperament O 0 0.9655524
, O 0 0.0009181017
who O 0 0.00046316083
have O 0 0.00024754822
a O 0 0.00047696577
greater O 0 0.00063157745
risk O 0 0.004422124
of O 0 0.0016493769
mood O 0 0.995926
switches O 0 0.0027044395
. O 0 0.0034324322

Peritubular O 0 0.7824673
capillary O 0 0.9189143
basement O 0 0.9078309
membrane O 0 0.016259123
reduplication O 0 0.046658374
in O 0 0.00057877484
allografts O 0 0.0011261207
and O 0 0.00040692225
native O 0 0.00048735007
kidney B-Disease 0 0.060139723
disease I-Disease 0 0.2508092
: O 0 0.0007697399
a O 0 0.0004171449
clinicopathologic O 0 0.0011896142
study O 0 0.0004313997
of O 0 0.00050084124
278 O 0 0.0024546457
consecutive O 0 0.0008002163
renal O 0 0.23024239
specimens O 0 0.0019259765
. O 0 0.0028247987

BACKGROUND O 0 0.01579686
: O 0 0.0039522485
An O 0 0.0010761556
association O 0 0.0005504324
has O 0 0.00041318763
been O 0 0.00040070692
found O 0 0.00034700867
between O 0 0.00035696581
transplant B-Disease 0 0.014764106
glomerulopathy I-Disease 0 0.9999727
( O 0 0.0021832637
TG B-Disease 0 0.88937736
) O 0 0.0012283283
and O 0 0.0004701882
reduplication O 0 0.032920867
of O 0 0.000864759
peritubular O 0 0.9634188
capillary O 0 0.9703423
basement O 0 0.93201166
membranes O 0 0.01606813
( O 0 0.002643646
PTCR O 0 0.14284411
) O 0 0.003997173
. O 0 0.0031998039

Although O 0 0.0018947734
such O 0 0.0015330213
an O 0 0.0011710447
association O 0 0.00052039645
is O 0 0.0004219311
of O 0 0.00041389494
practical O 0 0.00036749474
and O 0 0.000320957
theoretical O 0 0.00044047312
importance O 0 0.00021727204
, O 0 0.00051865634
only O 0 0.00030008145
one O 0 0.00026497807
prospective O 0 0.0011993261
study O 0 0.00039288582
has O 0 0.00024497558
tried O 0 0.00059302745
to O 0 0.0005455704
confirm O 0 0.0005657301
it O 0 0.0026606377
. O 0 0.0035552918

METHODS O 0 0.0046865465
: O 0 0.0030750246
We O 0 0.0008978713
examined O 0 0.00072736695
278 O 0 0.002179722
consecutive O 0 0.0006979027
renal O 0 0.07461984
specimens O 0 0.00047426551
( O 0 0.0005172111
from O 0 0.00022681076
135 O 0 0.00045636852
transplants O 0 0.00045278884
and O 0 0.0002569768
143 O 0 0.0005479842
native O 0 0.00035205865
kidneys O 0 0.0014513002
) O 0 0.00093966717
for O 0 0.00037402497
ultrastructural O 0 0.0013873336
evidence O 0 0.0008393511
of O 0 0.0020654693
PTCR O 0 0.3744858
. O 0 0.0043043466

In O 0 0.0017626991
addition O 0 0.0010230166
to O 0 0.001162622
renal O 0 0.32914937
allografts O 0 0.0025416526
with O 0 0.00082869804
TG B-Disease 0 0.8671415
, O 0 0.0006218802
we O 0 0.000119511584
also O 0 0.00014082922
examined O 0 0.00012196681
grafts O 0 0.00034880705
with O 0 0.00018816987
acute O 0 0.009979316
rejection O 0 0.0074060136
, O 0 0.0005170622
recurrent O 0 0.0060824547
glomerulonephritis B-Disease 2 0.999977
, O 0 0.0007538788
chronic B-Disease 0 0.17390339
allograft I-Disease 0 0.09622744
nephropathy I-Disease 0 0.99999714
and O 0 0.00032872777
stable O 0 0.0002329743
grafts O 0 0.00056141504
( O 0 0.00048190186
" O 0 0.0005234416
protocol O 0 0.00040686489
biopsies O 0 0.00072233775
" O 0 0.0017956984
) O 0 0.0034880186
. O 0 0.0034366252

Native O 0 0.01897375
kidney O 0 0.04063217
specimens O 0 0.0014366051
included O 0 0.0007003773
a O 0 0.0006956291
wide O 0 0.00051438337
range O 0 0.0003631079
of O 0 0.00047534725
glomerulopathies B-Disease 0 0.99942964
as O 0 0.00033329465
well O 0 0.00022661906
as O 0 0.0002422243
cases O 0 0.00058281195
of O 0 0.0009987872
thrombotic B-Disease 0 0.99999285
microangiopathy I-Disease 0 0.9999999
, O 0 0.06605225
malignant B-Disease 0 0.99989474
hypertension I-Disease 2 0.9999993
, O 0 0.004074509
acute O 0 0.62711763
interstitial B-Disease 0 0.99711394
nephritis I-Disease 0 0.9999987
, O 0 0.002630658
and O 0 0.0010540618
acute B-Disease 2 0.9768481
tubular I-Disease 2 0.9997665
necrosis I-Disease 2 0.9999926
. O 0 0.0076921373

RESULTS O 0 0.005648121
: O 0 0.0038829527
We O 0 0.0011724014
found O 0 0.0012389998
PTCR O 0 0.01823418
in O 0 0.0005998336
14 O 0 0.00041694596
of O 0 0.0003747597
15 O 0 0.00032184066
cases O 0 0.00045425573
of O 0 0.0004276247
TG B-Disease 0 0.81477153
, O 0 0.0005598419
in O 0 0.00017518307
7 O 0 0.000124984
transplant O 0 0.00021824226
biopsy O 0 0.00015525377
specimens O 0 0.0001414467
without O 0 0.00022582871
TG B-Disease 0 0.7116019
, O 0 0.0005553973
and O 0 0.00024733733
in O 0 0.00021769962
13 O 0 0.0002762153
of O 0 0.0003096844
143 O 0 0.00084751967
native O 0 0.00058804994
kidney O 0 0.012014899
biopsy O 0 0.0013056501
specimens O 0 0.001489679
. O 0 0.0026130192

These O 0 0.0024123874
13 O 0 0.0022840798
included O 0 0.0012972535
cases O 0 0.0019253119
of O 0 0.00187942
malignant B-Disease 0 0.99934703
hypertension I-Disease 2 0.99999785
, O 0 0.22480114
thrombotic B-Disease 0 0.99999
microangiopathy I-Disease 0 0.99999964
, O 0 0.17154355
lupus B-Disease 0 0.9999981
nephritis I-Disease 0 0.9999976
, O 0 0.014327458
Henoch B-Disease 0 0.99987423
- I-Disease 0 0.43314973
Schonlein I-Disease 0 0.9999429
nephritis I-Disease 0 0.99999535
, O 0 0.003113775
crescentic O 0 0.9996915
glomerulonephritis B-Disease 2 0.99999106
, O 0 0.0011250378
and O 0 0.0005067649
cocaine B-Chemical 0 0.9997991
- O 0 0.005330233
related O 0 0.00032060378
acute B-Disease 0 0.04746515
renal I-Disease 0 0.90612394
failure I-Disease 0 0.10977605
. O 0 0.0028783013

Mild O 0 0.94576645
PTCR O 0 0.35621807
in O 0 0.0015941937
allografts O 0 0.002825716
without O 0 0.0012051722
TG B-Disease 0 0.8992789
did O 0 0.0006048944
not O 0 0.00027972067
predict O 0 0.00020222987
renal B-Disease 0 0.61630666
failure I-Disease 0 0.013008803
or O 0 0.00016536396
significant O 0 0.00024163196
proteinuria B-Disease 0 0.9998902
after O 0 9.631765e-05
follow O 0 0.00010401694
- O 0 0.00055667065
up O 0 0.00014007697
periods O 0 0.00012410471
of O 0 0.00015728697
between O 0 0.00014913085
3 O 0 0.00020146891
months O 0 0.00015681
and O 0 0.0004306628
1 O 0 0.00082882756
year O 0 0.0010927177
. O 0 0.002433186

CONCLUSIONS O 0 0.021385584
: O 0 0.003899102
We O 0 0.00082871335
conclude O 0 0.0005172168
that O 0 0.0004333877
in O 0 0.00046495747
transplants O 0 0.000987298
, O 0 0.00052369706
there O 0 0.00019682475
is O 0 0.00017898342
a O 0 0.00023936488
strong O 0 0.00012753802
association O 0 8.9715e-05
between O 0 0.000112746515
well O 0 0.00019038592
- O 0 0.0014883787
developed O 0 0.0003044446
PTCR O 0 0.08383653
and O 0 0.00029088903
TG B-Disease 0 0.86756414
, O 0 0.00036856276
while O 0 0.000119181896
the O 0 9.245162e-05
significance O 0 0.00014619855
of O 0 0.00022675844
mild O 0 0.11712553
PTCR O 0 0.19930361
and O 0 0.00016595016
its O 0 0.00018228473
predictive O 0 0.00032022622
value O 0 0.00018731599
in O 0 0.00016994432
the O 0 0.00018359505
absence O 0 0.00024169394
of O 0 0.00077218417
TG B-Disease 0 0.888891
is O 0 0.00093015295
unclear O 0 0.0011769251
. O 0 0.0029314067

PTCR O 0 0.2873962
also O 0 0.0020563898
occurs O 0 0.0011519449
in O 0 0.0007467388
certain O 0 0.000626398
native O 0 0.0007407438
kidney B-Disease 0 0.13013123
diseases I-Disease 0 0.40674537
, O 0 0.0008542068
though O 0 0.00027397493
the O 0 0.000183064
association O 0 0.0001554674
is O 0 0.00019740757
not O 0 0.0002422781
as O 0 0.00030989884
strong O 0 0.00039316344
as O 0 0.0005217186
that O 0 0.0006203788
for O 0 0.0012764119
TG B-Disease 0 0.9069481
. O 0 0.0046413145

We O 0 0.0021657178
suggest O 0 0.001006706
that O 0 0.0009688155
repeated O 0 0.0009974617
endothelial B-Disease 0 0.9994147
injury I-Disease 0 0.9577319
, O 0 0.0013080536
including O 0 0.00033986184
immunologic B-Disease 0 0.08542117
injury I-Disease 0 0.76804227
, O 0 0.00065326865
may O 0 0.00015833836
be O 0 0.00014384436
the O 0 0.00012454073
cause O 0 0.0001960308
of O 0 0.00019004801
this O 0 0.00022344127
lesion O 0 0.0006369541
both O 0 0.00018130674
in O 0 0.0002449684
allografts O 0 0.00092046574
and O 0 0.0005487551
native O 0 0.0010120741
kidneys O 0 0.006067282
. O 0 0.003100183

Caffeine B-Chemical 0 0.9997894
- O 0 0.089433625
induced O 0 0.0031917319
cardiac B-Disease 0 0.5515029
arrhythmia I-Disease 0 0.9997008
: O 0 0.004293415
an O 0 0.00137652
unrecognised O 0 0.0032952526
danger O 0 0.0019514796
of O 0 0.0017195024
healthfood O 0 0.0083597535
products O 0 0.0032698943
. O 0 0.004354351

We O 0 0.0028493255
describe O 0 0.0020748393
a O 0 0.0022093619
25 O 0 0.001752233
- O 0 0.003282181
year O 0 0.0006347646
- O 0 0.0016755984
old O 0 0.00049732515
woman O 0 0.00075583404
with O 0 0.00028288315
pre O 0 0.0005018811
- O 0 0.0009920624
existing O 0 0.00021297626
mitral B-Disease 0 0.009428858
valve I-Disease 0 0.0010617585
prolapse I-Disease 0 0.083627604
who O 0 0.00023781775
developed O 0 0.00017397158
intractable O 0 0.0033907047
ventricular B-Disease 0 0.25540873
fibrillation I-Disease 0 0.9953284
after O 0 6.8418565e-05
consuming O 0 0.00027563708
a O 0 0.00022995925
" O 0 0.00031031301
natural O 0 0.00032410194
energy O 0 0.00069228665
" O 0 0.0009361428
guarana O 0 0.99762315
health O 0 0.0024417532
drink O 0 0.046745565
containing O 0 0.00022459748
a O 0 0.00040325144
high O 0 0.0004965636
concentration O 0 0.0011933736
of O 0 0.0017676533
caffeine B-Chemical 0 0.999411
. O 0 0.0040634633

This O 0 0.005209931
case O 0 0.002273339
highlights O 0 0.0009863277
the O 0 0.00077191676
need O 0 0.00059260626
for O 0 0.0004536415
adequate O 0 0.0006190021
labelling O 0 0.00061641756
and O 0 0.0005400561
regulation O 0 0.00036580858
of O 0 0.0010008977
such O 0 0.0013440107
products O 0 0.0026106639
. O 0 0.004134021

Conformationally O 0 0.017015351
restricted O 0 0.0020668672
analogs O 0 0.0043198243
of O 0 0.0021127227
BD1008 B-Chemical 0 0.99926454
and O 0 0.0008255383
an O 0 0.00052288675
antisense O 0 0.00085405586
oligodeoxynucleotide B-Chemical 0 0.03506378
targeting O 0 0.00018223154
sigma1 O 0 0.103363164
receptors O 0 0.0009996336
produce O 0 0.00025775758
anti O 0 0.0012283635
- O 0 0.02791986
cocaine B-Chemical 0 0.99889356
effects O 0 0.0006953537
in O 0 0.00077261514
mice O 0 0.00064773124
. O 0 0.002473537

Cocaine B-Chemical 0 0.99965394
' O 0 0.0058804518
s O 0 0.0018516495
ability O 0 0.0006295642
to O 0 0.0004345331
interact O 0 0.00024164
with O 0 0.00045979302
sigma O 0 0.0018066586
receptors O 0 0.0007915236
suggests O 0 0.0001608759
that O 0 0.00016330641
these O 0 0.00020210168
proteins O 0 0.00021189019
mediate O 0 0.00016356948
some O 0 0.0003467891
of O 0 0.0005158999
its O 0 0.0008967752
behavioral O 0 0.0029362538
effects O 0 0.0015892969
. O 0 0.003134414

Therefore O 0 0.0020007896
, O 0 0.0027057168
three O 0 0.00067745434
novel O 0 0.00092617556
sigma O 0 0.004170868
receptor O 0 0.0034410798
ligands O 0 0.0026089228
with O 0 0.00078768434
antagonist O 0 0.1494085
activity O 0 0.0002011631
were O 0 0.00015662635
evaluated O 0 0.00014053263
in O 0 0.00014175035
Swiss O 0 0.00025493762
Webster O 0 0.0005642257
mice O 0 9.112021e-05
: O 0 0.00074327766
BD1018 B-Chemical 0 0.9816845
( O 0 0.0013638901
3S B-Chemical 0 0.16901195
- I-Chemical 0 0.0034821003
1 I-Chemical 0 0.00033707806
- I-Chemical 0 0.0013405692
[ I-Chemical 0 0.00092518213
2 I-Chemical 0 0.00027793713
- I-Chemical 0 0.00095719
( I-Chemical 0 0.00033526702
3 I-Chemical 0 0.00016470824
, I-Chemical 0 0.00032696337
4 I-Chemical 0 0.00023813675
- I-Chemical 0 0.0031129317
dichlorophenyl I-Chemical 0 0.8829594
) I-Chemical 0 0.003941851
ethyl I-Chemical 0 0.99927264
] I-Chemical 0 0.025105482
- I-Chemical 0 0.0034399817
1 I-Chemical 0 0.00024097877
, I-Chemical 0 0.00030444487
4 I-Chemical 0 0.0001836404
- I-Chemical 0 0.0014759409
diazabicyclo I-Chemical 0 0.02170156
[ I-Chemical 0 0.0011518005
4 I-Chemical 0 0.00014964535
. I-Chemical 0 0.00013409035
3 I-Chemical 0 0.00011741429
. I-Chemical 0 0.00014282027
0 I-Chemical 0 0.0002523332
] I-Chemical 0 0.0012135538
nonane I-Chemical 0 0.94869417
) O 0 0.0020676672
, O 0 0.0018207897
BD1063 B-Chemical 0 0.99996006
( O 0 0.0010288146
1 B-Chemical 0 0.00033440482
- I-Chemical 0 0.0013210946
[ I-Chemical 0 0.00087306777
2 I-Chemical 0 0.00025930358
- I-Chemical 0 0.000898258
( I-Chemical 0 0.00031583986
3 I-Chemical 0 0.0001563202
, I-Chemical 0 0.0003125884
4 I-Chemical 0 0.00022841648
- I-Chemical 0 0.0029492246
dichlorophenyl I-Chemical 0 0.86858565
) I-Chemical 0 0.0034962725
ethyl I-Chemical 0 0.9991373
] I-Chemical 0 0.019137602
- I-Chemical 0 0.0032722652
4 I-Chemical 0 0.00023042587
- I-Chemical 0 0.0020449995
methylpiperazine I-Chemical 0 0.015899943
) O 0 0.000857383
, O 0 0.0005459574
and O 0 0.00049507467
LR132 B-Chemical 0 0.9946291
( O 0 0.0023935053
1R O 0 0.9656365
, O 0 0.001619702
2S O 0 0.8763433
- O 0 0.0047532283
( O 0 0.00058534264
+ O 0 0.0011084017
) O 0 0.0008907434
- O 0 0.0020323028
cis O 0 0.0008200516
- O 0 0.026813716
N O 0 0.9990595
- O 0 0.026522519
[ O 0 0.0018278046
2 O 0 0.00031704965
- O 0 0.0010491427
( O 0 0.00034522323
3 O 0 0.00017025623
, O 0 0.00034105498
4 O 0 0.000253716
- O 0 0.0029758855
dichlorophenyl O 0 0.84964234
) O 0 0.0035849186
ethyl O 0 0.9989041
] O 0 0.017276812
- O 0 0.003675941
2 O 0 0.00044798516
- O 0 0.0016821319
( O 0 0.0007622132
1 O 0 0.0006803597
- O 0 0.00478698
pyrrolidinyl O 0 0.58260703
) O 0 0.009099743
cyclohexylamine O 0 0.99853444
) O 0 0.008465985
. O 0 0.0041600703

Competition O 0 0.004374953
binding O 0 0.0013967569
assays O 0 0.0013283378
demonstrated O 0 0.00074767903
that O 0 0.00050396804
all O 0 0.00045423236
three O 0 0.00026475254
compounds O 0 0.0020788456
have O 0 0.00042051027
high O 0 0.0006614342
affinities O 0 0.0010604403
for O 0 0.0009802221
sigma1 O 0 0.17439312
receptors O 0 0.006839196
. O 0 0.004407116

The O 0 0.0016727779
three O 0 0.0009277247
compounds O 0 0.0049858927
vary O 0 0.000904964
in O 0 0.00041258018
their O 0 0.0002944671
affinities O 0 0.00038348843
for O 0 0.00024995
sigma2 O 0 0.006387128
receptors O 0 0.0005346261
and O 0 0.00020420393
exhibit O 0 0.0001744593
negligible O 0 0.00028449815
affinities O 0 0.0004642604
for O 0 0.00043007178
dopamine B-Chemical 0 0.9998733
, O 0 0.002166901
opioid O 0 0.9361199
, O 0 0.004326103
GABA B-Chemical 0 0.9999385
( O 0 0.0025432946
A O 0 0.06986068
) O 0 0.0034428842
and O 0 0.0020538396
NMDA B-Chemical 0 0.99979144
receptors O 0 0.014370551
. O 0 0.004349222

In O 0 0.0020968358
behavioral O 0 0.0040167393
studies O 0 0.0016414039
, O 0 0.0016807095
pre O 0 0.0014729957
- O 0 0.0023931079
treatment O 0 0.0003793448
of O 0 0.00029354548
mice O 0 0.00014132212
with O 0 0.0005171916
BD1018 B-Chemical 0 0.9977963
, O 0 0.0061053876
BD1063 B-Chemical 0 0.99997437
, O 0 0.0013965174
or O 0 0.00041327396
LR132 B-Chemical 0 0.98734003
significantly O 0 0.0005909799
attenuated O 0 0.0014176922
cocaine B-Chemical 0 0.99990416
- O 0 0.04979718
induced O 0 0.0011266196
convulsions B-Disease 0 0.99987686
and O 0 0.0018918116
lethality O 0 0.025915818
. O 0 0.003449784

Moreover O 0 0.0033671132
, O 0 0.003712692
post O 0 0.0015801379
- O 0 0.0043453495
treatment O 0 0.0008860374
with O 0 0.0011322692
LR132 B-Chemical 0 0.9950899
prevented O 0 0.0051402403
cocaine B-Chemical 0 0.99992895
- O 0 0.044073854
induced O 0 0.00048617405
lethality O 0 0.0038447748
in O 0 0.00037897198
a O 0 0.00053163077
significant O 0 0.0004092135
proportion O 0 0.00050644734
of O 0 0.00093615305
animals O 0 0.0011387598
. O 0 0.0028439832

In O 0 0.0019323445
contrast O 0 0.0020258704
to O 0 0.00090484327
the O 0 0.00056226493
protection O 0 0.0004905978
provided O 0 0.000278826
by O 0 0.00026604964
the O 0 0.00019791756
putative O 0 0.00015783579
antagonists O 0 0.008602894
, O 0 0.00050975505
the O 0 0.00017010093
well O 0 0.00022417534
- O 0 0.0026366324
characterized O 0 0.00036764125
sigma O 0 0.0023098148
receptor O 0 0.0020552727
agonist O 0 0.040805887
di B-Chemical 0 0.0009573815
- I-Chemical 0 0.0022696068
o I-Chemical 0 0.0018730584
- I-Chemical 0 0.0021694852
tolylguanidine I-Chemical 0 0.00043442502
( O 0 0.0008254246
DTG B-Chemical 0 0.9987418
) O 0 0.00052726053
and O 0 0.0001341753
the O 0 0.00010363095
novel O 0 0.00015568755
sigma O 0 0.0025033536
receptor O 0 0.0059469603
agonist O 0 0.566755
BD1031 B-Chemical 0 0.999668
( O 0 0.0034165904
3R B-Chemical 0 0.5229129
- I-Chemical 0 0.0029214977
1 I-Chemical 0 0.00026136043
- I-Chemical 0 0.0011418827
[ I-Chemical 0 0.0007926287
2 I-Chemical 0 0.00023418762
- I-Chemical 0 0.0008580167
( I-Chemical 0 0.0002960186
3 I-Chemical 0 0.00014702731
, I-Chemical 0 0.00029800672
4 I-Chemical 0 0.00021899579
- I-Chemical 0 0.003052205
dichlorophenyl I-Chemical 0 0.88807017
) I-Chemical 0 0.0039110696
ethyl I-Chemical 0 0.9993075
] I-Chemical 0 0.025775056
- I-Chemical 0 0.003424186
1 I-Chemical 0 0.00023374014
, I-Chemical 0 0.00029659545
4 I-Chemical 0 0.00017907596
- I-Chemical 0 0.0014601452
diazabicyclo I-Chemical 0 0.021969004
[ I-Chemical 0 0.001144832
4 I-Chemical 0 0.00014777899
. I-Chemical 0 0.0001330351
3 I-Chemical 0 0.000117234384
. I-Chemical 0 0.00014339804
0 I-Chemical 0 0.0002547117
] I-Chemical 0 0.0011516161
nonane I-Chemical 0 0.8856183
) O 0 0.00081504794
each O 0 0.00017919706
worsened O 0 0.0014164032
the O 0 0.00027758494
behavioral O 0 0.0022435798
toxicity B-Disease 0 0.4915219
of O 0 0.001961263
cocaine B-Chemical 0 0.99939644
. O 0 0.0039336076

At O 0 0.0011958526
doses O 0 0.002821031
where O 0 0.0011680283
alone O 0 0.0009752119
, O 0 0.0010437702
they O 0 0.00035353494
produced O 0 0.0002369118
no O 0 0.00020201615
significant O 0 0.00018702366
effects O 0 0.0001952105
on O 0 0.00018101772
locomotion O 0 0.006227918
, O 0 0.001471661
BD1018 B-Chemical 0 0.99865544
, O 0 0.0047794073
BD1063 B-Chemical 0 0.99997985
and O 0 0.00091687223
LR132 B-Chemical 0 0.9959431
significantly O 0 0.00040277847
attenuated O 0 0.00039213785
the O 0 0.0002629002
locomotor O 0 0.003947011
stimulatory O 0 0.00068786263
effects O 0 0.0006422563
of O 0 0.0018890407
cocaine B-Chemical 0 0.9995752
. O 0 0.0038855672

To O 0 0.0011494325
further O 0 0.00093169184
validate O 0 0.00046475325
the O 0 0.00046073057
hypothesis O 0 0.00039271728
that O 0 0.0002848037
the O 0 0.00029256532
anti O 0 0.0010026183
- O 0 0.025005516
cocaine B-Chemical 0 0.9991339
effects O 0 0.00018615421
of O 0 0.00015916121
the O 0 0.00010285132
novel O 0 0.00011417354
ligands O 0 0.00046897336
involved O 0 0.00015775092
antagonism O 0 0.0040167877
of O 0 0.00024156352
sigma O 0 0.0022092033
receptors O 0 0.00069726247
, O 0 0.00031556806
an O 0 0.00015455985
antisense O 0 0.00041483482
oligodeoxynucleotide B-Chemical 0 0.11513808
against O 0 0.00010318572
sigma1 O 0 0.38351935
receptors O 0 0.0008302024
was O 0 0.00011945372
also O 0 8.8279085e-05
shown O 0 5.084864e-05
to O 0 8.2254905e-05
significantly O 0 0.00015947597
attenuate O 0 0.00022842041
the O 0 0.00026784546
convulsive B-Disease 0 0.9998448
and O 0 0.00033690815
locomotor O 0 0.0038003763
stimulatory O 0 0.0005903879
effects O 0 0.00057059847
of O 0 0.0017588756
cocaine B-Chemical 0 0.9996112
. O 0 0.0036833407

Together O 0 0.005278987
, O 0 0.0042096535
the O 0 0.0013043998
data O 0 0.0010104957
suggests O 0 0.00036626952
that O 0 0.00033093803
functional O 0 0.00037812462
antagonism O 0 0.0037290533
of O 0 0.000514754
sigma O 0 0.0026483852
receptors O 0 0.00079924805
is O 0 0.00016252488
capable O 0 0.00012903688
of O 0 0.00023522327
attenuating O 0 0.00039974795
a O 0 0.00040174887
number O 0 0.00024221205
of O 0 0.00064205524
cocaine B-Chemical 0 0.9997199
- O 0 0.007886215
induced O 0 0.00095659733
behaviors O 0 0.0035604683
. O 0 0.0032116706

Ranitidine B-Chemical 0 0.99981564
- O 0 0.068984374
induced O 0 0.003355235
acute O 0 0.6630054
interstitial B-Disease 0 0.9954814
nephritis I-Disease 0 0.99999034
in O 0 0.0015685868
a O 0 0.0016809347
cadaveric O 0 0.004618382
renal O 0 0.56251115
allograft O 0 0.011844797
. O 0 0.004022084

Ranitidine B-Chemical 0 0.9997758
frequently O 0 0.0035325913
is O 0 0.0012754902
used O 0 0.000898006
for O 0 0.00078128383
preventing O 0 0.001469615
peptic O 0 0.99252725
ulceration O 0 0.9099743
after O 0 0.00091818534
renal O 0 0.3451534
transplantation O 0 0.0032281934
. O 0 0.0034230554

This O 0 0.006742176
drug O 0 0.042171415
occasionally O 0 0.0029195673
has O 0 0.0007764432
been O 0 0.00070865324
associated O 0 0.00073516386
with O 0 0.00094014185
acute O 0 0.37008277
interstitial B-Disease 0 0.9938433
nephritis I-Disease 0 0.9999932
in O 0 0.0014420946
native O 0 0.0016268046
kidneys O 0 0.0074531115
. O 0 0.003531576

There O 0 0.004960578
are O 0 0.0025349276
no O 0 0.001965257
similar O 0 0.0014613728
reports O 0 0.002178188
with O 0 0.0028923438
renal O 0 0.6556824
transplantation O 0 0.0058413814
. O 0 0.0055117775

We O 0 0.0027882592
report O 0 0.0030361793
a O 0 0.0019114582
case O 0 0.0012272215
of O 0 0.0018541868
ranitidine B-Chemical 1 0.99999
- O 0 0.06774957
induced O 0 0.0005935922
acute O 0 0.56744796
interstitial B-Disease 0 0.9970874
nephritis I-Disease 0 0.9999988
in O 0 0.00025120523
a O 0 0.00018993932
recipient O 0 0.000115951174
of O 0 0.000108090055
a O 0 0.00017072831
cadaveric O 0 0.0006973944
renal O 0 0.30850795
allograft O 0 0.0012207329
presenting O 0 0.00030307972
with O 0 0.00012017978
acute O 0 0.0064916513
allograft O 0 0.0022483608
dysfunction O 0 0.17425285
within O 0 6.833432e-05
48 O 0 0.00011116673
hours O 0 9.7310076e-05
of O 0 0.00018158217
exposure O 0 0.00030473818
to O 0 0.0003500269
the O 0 0.0006631399
drug O 0 0.010000994
. O 0 0.0027684222

The O 0 0.0023466374
biopsy O 0 0.0021498841
specimen O 0 0.0013772564
showed O 0 0.0010153218
pathognomonic O 0 0.0024617317
features O 0 0.0009845434
, O 0 0.0012203883
including O 0 0.0006727669
eosinophilic O 0 0.68695366
infiltration O 0 0.018865742
of O 0 0.00088732794
the O 0 0.0008911789
interstitial O 0 0.015984572
compartment O 0 0.0025437023
. O 0 0.0031795122

Allograft O 0 0.006522595
function O 0 0.0015467244
improved O 0 0.0018855005
rapidly O 0 0.0011261452
and O 0 0.00082384277
returned O 0 0.00062599423
to O 0 0.00041600442
baseline O 0 0.00043669826
after O 0 0.00038823372
stopping O 0 0.0011954353
the O 0 0.0012921583
drug O 0 0.011340539
. O 0 0.0044267867

Liver B-Disease 0 0.9905033
disease I-Disease 0 0.9810616
caused O 0 0.011784204
by O 0 0.014798075
propylthiouracil B-Chemical 0 0.99955577
. O 0 0.022177475

This O 0 0.0050439565
report O 0 0.003193098
presents O 0 0.0011426236
the O 0 0.00070946105
clinical O 0 0.0015343775
, O 0 0.0008726581
laboratory O 0 0.00049509807
, O 0 0.0005498281
and O 0 0.00030026116
light O 0 0.00041400938
and O 0 0.000283638
electron O 0 0.00166006
microscopic O 0 0.0002517891
observations O 0 0.00014618422
on O 0 9.7427626e-05
a O 0 0.00021710347
patient O 0 0.00017976265
with O 0 0.00017722795
chronic B-Disease 0 0.005187463
active I-Disease 0 0.0003311283
( I-Disease 0 0.00074117276
aggressive I-Disease 0 0.022623336
) I-Disease 0 0.003110169
hepatitis I-Disease 0 0.99995816
caused O 0 0.0005024344
by O 0 0.00035802598
the O 0 0.00036911844
administration O 0 0.0012479608
of O 0 0.0018182574
propylthiouracil B-Chemical 0 0.9999176
. O 0 0.005025628

This O 0 0.0048543666
is O 0 0.0015815361
an O 0 0.0010797149
addition O 0 0.00039948645
to O 0 0.0003864322
the O 0 0.00027113574
list O 0 0.00018362675
of O 0 0.0003191476
drugs O 0 0.004766972
that O 0 0.00018847316
must O 0 0.00013162477
be O 0 0.00018113686
considered O 0 0.00018304653
in O 0 0.00017816169
the O 0 0.00019042201
evaluation O 0 0.00030787484
of O 0 0.00065764145
chronic O 0 0.7024992
liver B-Disease 0 0.99671054
disease I-Disease 0 0.9989072
. O 0 0.004530472

Withdrawal B-Disease 0 0.19900563
- I-Disease 0 0.013918541
emergent I-Disease 0 0.0036318896
rabbit I-Disease 0 0.0072368733
syndrome I-Disease 0 0.96722335
during O 0 0.0010483024
dose O 0 0.0019290026
reduction O 0 0.0018567744
of O 0 0.0037795084
risperidone B-Chemical 0 0.9999722
. O 0 0.0066974363

Rabbit B-Disease 0 0.03994971
syndrome I-Disease 0 0.99688256
( O 0 0.013951072
RS B-Disease 0 0.98234797
) O 0 0.0035896418
is O 0 0.0007737948
a O 0 0.0013305848
rare O 0 0.010139338
extrapyramidal O 0 0.9999145
side O 0 0.0018524878
effect O 0 0.00040109985
caused O 0 0.00050736836
by O 0 0.0006723323
prolonged O 0 0.0032405776
neuroleptic O 0 0.9999862
medication O 0 0.034529213
. O 0 0.0027897763

Here O 0 0.0028490545
we O 0 0.0012145009
present O 0 0.0010848494
a O 0 0.001320875
case O 0 0.00078742614
of O 0 0.00073545054
withdrawal B-Disease 0 0.0073572053
- I-Disease 0 0.0055346373
emergent I-Disease 0 0.0011891536
RS I-Disease 0 0.93528515
, O 0 0.0007195525
which O 0 0.00030518888
is O 0 0.00017732699
the O 0 0.00016490057
first O 0 0.00015177911
of O 0 0.00033436622
its O 0 0.0005333173
kind O 0 0.0007266946
to O 0 0.00067306607
be O 0 0.0010442113
reported O 0 0.001793279
. O 0 0.0030655258

The O 0 0.0032643792
patient O 0 0.0034817215
developed O 0 0.0034201283
RS B-Disease 0 0.5703925
during O 0 0.0012910976
dose O 0 0.0023059852
reduction O 0 0.0022175163
of O 0 0.004374143
risperidone B-Chemical 0 0.99996793
. O 0 0.0075286594

The O 0 0.0029057025
symptom O 0 0.0053873593
was O 0 0.0016907146
treated O 0 0.0022451603
successfully O 0 0.0017066068
with O 0 0.0034971698
trihexyphenidyl B-Chemical 0 0.9999944
anticholinergic O 0 0.9996624
therapy O 0 0.0051419227
. O 0 0.0039237966

The O 0 0.0019391185
underlying O 0 0.0016660818
mechanism O 0 0.00076934684
of O 0 0.0011202375
withdrawal B-Disease 0 0.012739621
- I-Disease 0 0.008300037
emergent I-Disease 0 0.0013275151
RS I-Disease 0 0.87947863
in O 0 0.00025577564
the O 0 0.00016122925
present O 0 0.00014259249
case O 0 0.00019401695
may O 0 0.00011750703
have O 0 0.00010551023
been O 0 9.7067255e-05
related O 0 5.7995232e-05
to O 0 6.559918e-05
the O 0 6.321238e-05
pharmacological O 0 0.00021144842
profile O 0 0.00010719664
of O 0 0.00034823158
risperidone B-Chemical 0 0.9999994
, O 0 0.0012054697
a O 0 0.0012347349
serotonin B-Chemical 0 0.99997604
- O 0 0.8671813
dopamine B-Chemical 0 0.99997425
antagonist O 0 0.5301501
, O 0 0.00034791467
suggesting O 0 7.162765e-05
the O 0 8.5738866e-05
pathophysiologic O 0 0.00035753482
influence O 0 7.951104e-05
of O 0 0.00019110084
the O 0 0.00027136487
serotonin B-Chemical 0 0.9995334
system O 0 0.00033401258
in O 0 0.00028800283
the O 0 0.00034767727
development O 0 0.0008799054
of O 0 0.0017699687
RS B-Disease 0 0.97413707
. O 0 0.0038596257

Pharmacokinetic O 0 0.019105388
/ O 0 0.0058483193
pharmacodynamic O 0 0.005075744
assessment O 0 0.0005198437
of O 0 0.0003795595
the O 0 0.00023813244
effects O 0 0.00028855968
of O 0 0.0006817562
E4031 B-Chemical 0 0.99998975
, O 0 0.012850396
cisapride B-Chemical 0 0.9999912
, O 0 0.009894433
terfenadine B-Chemical 1 0.99999547
and O 0 0.00093191914
terodiline B-Chemical 0 0.99993515
on O 0 0.00017281162
monophasic O 0 0.0009687905
action O 0 0.0001995616
potential O 0 0.00021695325
duration O 0 0.00031575584
in O 0 0.0007151799
dog O 0 0.0022933304
. O 0 0.0028139611

1 O 0 0.059545428
. O 0 0.059476506

Torsades B-Disease 0 0.9922127
de I-Disease 0 0.055621784
pointes I-Disease 0 0.9992225
( O 0 0.031094993
TDP B-Disease 0 0.9990107
) O 0 0.0030233974
is O 0 0.00046581615
a O 0 0.00060413935
potentially O 0 0.00051266525
fatal O 0 0.6286757
ventricular B-Disease 0 0.9979164
tachycardia I-Disease 2 0.99991274
associated O 0 0.00027395194
with O 0 0.00017573185
increases O 0 0.00016703524
in O 0 0.0001950159
QT O 0 0.50933564
interval O 0 0.0001554422
and O 0 0.00014282994
monophasic O 0 0.0005753027
action O 0 0.00017331263
potential O 0 0.00020350418
duration O 0 0.00033051302
( O 0 0.001368888
MAPD O 0 0.020870749
) O 0 0.0038096518
. O 0 0.0031006888

TDP B-Disease 0 0.9958126
is O 0 0.0026610645
a O 0 0.0025005294
side O 0 0.0044948235
- O 0 0.004832835
effect O 0 0.00044667372
that O 0 0.0003074709
has O 0 0.00020696461
led O 0 0.00026217406
to O 0 0.0001991894
withdrawal O 0 0.0008704068
of O 0 0.00016690054
several O 0 0.000108390625
drugs O 0 0.0015004133
from O 0 0.00014075727
the O 0 0.00013770137
market O 0 0.0004182471
( O 0 0.00046768656
e O 0 0.00065414404
. O 0 0.000291836
g O 0 0.0013298898
. O 0 0.00071911066
terfenadine B-Chemical 1 0.99997187
and O 0 0.0026524789
terodiline B-Chemical 0 0.99986553
) O 0 0.0068256417
. O 0 0.0033514237

2 O 0 0.05912018
. O 0 0.06027965

The O 0 0.0020056036
potential O 0 0.0014958448
of O 0 0.0017522948
compounds O 0 0.013357229
to O 0 0.0010282447
cause O 0 0.0019239855
TDP B-Disease 0 0.9982476
was O 0 0.00039261495
evaluated O 0 0.0002563701
by O 0 0.00020754246
monitoring O 0 0.0001985928
their O 0 0.0002075569
effects O 0 0.00032697493
on O 0 0.00047163406
MAPD O 0 0.009983165
in O 0 0.0012049715
dog O 0 0.0030061358
. O 0 0.0034468311

Four O 0 0.0043937042
compounds O 0 0.011692562
known O 0 0.0015838511
to O 0 0.0009383395
increase O 0 0.0008889438
QT O 0 0.63056636
interval O 0 0.00051135337
and O 0 0.0004021293
cause O 0 0.0007011413
TDP B-Disease 0 0.993189
were O 0 0.000287395
investigated O 0 0.00031847952
: O 0 0.002566515
terfenadine B-Chemical 1 0.9999902
, O 0 0.008701207
terodiline B-Chemical 0 0.9999609
, O 0 0.007279912
cisapride B-Chemical 0 0.9999511
and O 0 0.0038346597
E4031 B-Chemical 0 0.99992
. O 0 0.0053240377

On O 0 0.0027488698
the O 0 0.0014597595
basis O 0 0.001039467
that O 0 0.00070773944
only O 0 0.00081331853
free O 0 0.0009958313
drug O 0 0.007332053
in O 0 0.00029534206
the O 0 0.00023718392
systemic O 0 0.07789782
circulation O 0 0.0018914768
will O 0 8.2667255e-05
elicit O 0 5.405303e-05
a O 0 0.00013133576
pharmacological O 0 0.00023322902
response O 0 9.696689e-05
target O 0 8.859002e-05
, O 0 0.00031695774
free O 0 0.0002632358
concentrations O 0 0.00036678897
in O 0 0.00018681728
plasma O 0 0.0030034164
were O 0 0.00011009869
selected O 0 9.2026436e-05
to O 0 0.000112593836
mimic O 0 0.00015797054
the O 0 0.0002193088
free O 0 0.0005952016
drug O 0 0.008232056
exposures O 0 0.0013122639
in O 0 0.0010634034
man O 0 0.011425236
. O 0 0.0032013757

Infusion O 0 0.014262029
regimens O 0 0.0019112063
were O 0 0.0007333233
designed O 0 0.00045762333
that O 0 0.00031556294
rapidly O 0 0.00035227634
achieved O 0 0.00029908435
and O 0 0.00023241366
maintained O 0 0.00022378686
target O 0 0.00017276416
- O 0 0.0016542389
free O 0 0.00028091826
concentrations O 0 0.00027779886
of O 0 0.00015602997
these O 0 0.00014349405
drugs O 0 0.0064595686
in O 0 0.00017679908
plasma O 0 0.0032258187
and O 0 0.00012018896
data O 0 0.000100969984
on O 0 5.2985866e-05
the O 0 5.9936432e-05
relationship O 0 5.5737386e-05
between O 0 9.6911055e-05
free O 0 0.00026625925
concentration O 0 0.00034533383
and O 0 0.00019417948
changes O 0 0.00020689872
in O 0 0.00021975108
MAPD O 0 0.0034313123
were O 0 0.00022923664
obtained O 0 0.00022273489
for O 0 0.00033313804
these O 0 0.00083043426
compounds O 0 0.013972545
. O 0 0.0035589358

3 O 0 0.049031585
. O 0 0.058089748

These O 0 0.0021306076
data O 0 0.001804122
indicate O 0 0.00066056324
that O 0 0.00066943496
the O 0 0.0006862384
free O 0 0.0013752196
ED50 O 0 0.8585949
in O 0 0.0005395884
plasma O 0 0.01529965
for O 0 0.00044519763
terfenadine B-Chemical 1 0.99999106
( O 0 0.0009188057
1 O 0 0.00022304346
. O 0 0.00013919099
9 O 0 0.00013283279
nM O 0 0.0008132999
) O 0 0.0006906218
, O 0 0.0008625132
terodiline B-Chemical 0 0.99991655
( O 0 0.00059094944
76 O 0 0.0004281556
nM O 0 0.0015722307
) O 0 0.0008433974
, O 0 0.0009351938
cisapride B-Chemical 0 0.9999633
( O 0 0.0005659426
11 O 0 0.00022063307
nM O 0 0.0012232956
) O 0 0.00065954105
and O 0 0.00040872657
E4031 B-Chemical 0 0.99998605
( O 0 0.0007627026
1 O 0 0.00019178336
. O 0 0.00012436428
9 O 0 0.00012264312
nM O 0 0.0007723505
) O 0 0.0004404261
closely O 0 0.00013196608
correlate O 0 0.00016186404
with O 0 0.00019703072
the O 0 0.0002069455
free O 0 0.00048054405
concentration O 0 0.0007659062
in O 0 0.00054275064
man O 0 0.009155323
causing O 0 0.0017157503
QT O 0 0.9673158
effects O 0 0.0017137245
. O 0 0.003042205

For O 0 0.0019989898
compounds O 0 0.009329036
that O 0 0.0011370428
have O 0 0.0008875854
shown O 0 0.0006025392
TDP B-Disease 0 0.9946844
in O 0 0.00038255862
the O 0 0.00024591497
clinic O 0 0.0004884136
( O 0 0.0014556394
terfenadine B-Chemical 1 0.999992
, O 0 0.0055478043
terodiline B-Chemical 0 0.99998176
, O 0 0.0033984883
cisapride B-Chemical 0 0.9999857
) O 0 0.0006872834
there O 0 9.731472e-05
is O 0 9.2508686e-05
little O 0 0.00012826527
differentiation O 0 0.00039279897
between O 0 9.403858e-05
the O 0 0.000111930785
dog O 0 0.00038221848
ED50 O 0 0.56898016
and O 0 0.00012119411
the O 0 8.899126e-05
efficacious O 0 0.00018487584
free O 0 0.0002674438
plasma O 0 0.007464401
concentrations O 0 0.00038292274
in O 0 0.00018715764
man O 0 0.0020319538
( O 0 0.00031200604
< O 0 0.00025408127
10 O 0 0.00018101565
- O 0 0.00076559355
fold O 0 0.00028214062
) O 0 0.00062272325
reflecting O 0 0.00036860385
their O 0 0.00030534077
limited O 0 0.0005211798
safety O 0 0.0010096384
margins O 0 0.0062100617
. O 0 0.0028619475

These O 0 0.002142671
data O 0 0.0018186449
underline O 0 0.00083287427
the O 0 0.000634659
need O 0 0.00042655232
to O 0 0.00026578494
maximize O 0 0.00014291439
the O 0 0.00017814859
therapeutic O 0 0.0002665198
ratio O 0 0.00020930414
with O 0 0.00018625683
respect O 0 0.00015605318
to O 0 0.00024821566
TDP B-Disease 0 0.9968471
in O 0 0.00012260338
potential O 0 8.0125814e-05
development O 0 0.00010858863
candidates O 0 5.2126903e-05
and O 0 8.825965e-05
the O 0 6.926773e-05
importance O 0 7.104189e-05
of O 0 0.00013975716
using O 0 0.0001314736
free O 0 0.00031454294
drug O 0 0.0040520243
concentrations O 0 0.00046323964
in O 0 0.00028944798
pharmacokinetic O 0 0.0033112578
/ O 0 0.002175916
pharmacodynamic O 0 0.015192486
studies O 0 0.0014983817
. O 0 0.0022670566

Bladder O 0 0.026079524
retention B-Disease 0 0.00579811
of I-Disease 0 0.0024015263
urine I-Disease 0 0.27303073
as O 0 0.00084321824
a O 0 0.0006771061
result O 0 0.0002922826
of O 0 0.0002788467
continuous O 0 0.00024521048
intravenous O 0 0.0011418946
infusion O 0 0.0006424745
of O 0 0.0005379135
fentanyl B-Chemical 0 0.9997017
: O 0 0.0013463437
2 O 0 0.00068323367
case O 0 0.0008776978
reports O 0 0.001640479
. O 0 0.003036338

Sedation O 0 0.008858695
has O 0 0.0012171228
been O 0 0.0008918836
commonly O 0 0.0006976746
used O 0 0.00039780827
in O 0 0.00033780353
the O 0 0.0002694807
neonate O 0 0.00084006
to O 0 0.00017273834
decrease O 0 0.0001930191
the O 0 0.00014688243
stress O 0 0.0023332126
and O 0 0.0002145669
pain B-Disease 0 0.006181206
from O 0 8.302402e-05
the O 0 6.766008e-05
noxious O 0 0.0001401209
stimuli O 0 0.00011754559
and O 0 9.7292446e-05
invasive O 0 0.00013716238
procedures O 0 7.5208816e-05
in O 0 6.9664326e-05
the O 0 6.674516e-05
neonatal O 0 0.00016437311
intensive O 0 0.00012954792
care O 0 0.00012319388
unit O 0 0.000119640434
, O 0 0.0002233597
as O 0 0.0001228763
well O 0 0.00012371126
as O 0 0.0001344013
to O 0 0.0001156001
facilitate O 0 0.00012852225
synchrony O 0 0.0004058033
between O 0 0.00023042389
ventilator O 0 0.001295103
and O 0 0.0006146968
spontaneous O 0 0.0021993585
breaths O 0 0.006146263
. O 0 0.0024474082

Fentanyl B-Chemical 0 0.99966955
, O 0 0.005950271
an O 0 0.0020867526
opioid O 0 0.5885785
analgesic O 0 0.062305402
, O 0 0.00089768996
is O 0 0.00026597935
frequently O 0 0.00024187857
used O 0 0.00016749087
in O 0 0.00016170298
the O 0 0.00013889918
neonatal O 0 0.0002914412
intensive O 0 0.00022662207
care O 0 0.0002160328
unit O 0 0.00020184035
setting O 0 0.0002336499
for O 0 0.00025967121
these O 0 0.0004927086
very O 0 0.0010564825
purposes O 0 0.0015921716
. O 0 0.0032834727

Various O 0 0.0031012045
reported O 0 0.0018484541
side O 0 0.0020199711
effects O 0 0.00079364784
of O 0 0.0011415738
fentanyl B-Chemical 0 0.9998648
administration O 0 0.00091904076
include O 0 0.00026200392
chest B-Disease 0 0.0011709543
wall I-Disease 0 0.005246578
rigidity I-Disease 0 0.9948891
, O 0 0.0023250964
hypotension B-Disease 0 0.99991894
, O 0 0.0017079314
respiratory B-Disease 0 0.02623512
depression I-Disease 0 0.99919254
, O 0 0.00177424
and O 0 0.0015807977
bradycardia B-Disease 0 0.9958781
. O 0 0.0034962194

Here O 0 0.0039595985
, O 0 0.004323023
2 O 0 0.0018359735
cases O 0 0.0017418208
of O 0 0.0011935049
urinary B-Disease 0 0.4576899
bladder I-Disease 0 0.031723905
retention I-Disease 0 0.0014389169
leading O 0 0.00033655824
to O 0 0.00023979154
renal O 0 0.5959921
pelvocalyceal O 0 0.075689435
dilatation O 0 0.61177844
mimicking O 0 0.00039284013
hydronephrosis B-Disease 0 0.9942027
as O 0 0.00018687395
a O 0 0.00020857062
result O 0 0.000112365386
of O 0 0.00014595313
continuous O 0 0.00016810463
infusion O 0 0.0006141238
of O 0 0.0005487007
fentanyl B-Chemical 0 0.99979275
are O 0 0.0006974359
reported O 0 0.0012115379
. O 0 0.0022357898

Fatal O 0 0.14818682
myeloencephalopathy B-Disease 0 0.98839146
due O 0 0.0013760272
to O 0 0.0009743571
accidental O 0 0.009685325
intrathecal O 0 0.108959846
vincristin B-Chemical 0 0.9997209
administration O 0 0.0014525128
: O 0 0.0010948668
a O 0 0.0007671308
report O 0 0.0009449513
of O 0 0.0008422955
two O 0 0.00087831356
cases O 0 0.0031531428
. O 0 0.0037665674

We O 0 0.0027980346
report O 0 0.0027030995
on O 0 0.0008726906
two O 0 0.0007453375
fatal O 0 0.12535273
cases O 0 0.00089042867
of O 0 0.00047455923
accidental O 0 0.021772223
intrathecal O 0 0.27116606
vincristine B-Chemical 1 0.99997616
instillation O 0 0.00086236733
in O 0 0.00015100076
a O 0 0.00021486313
5 O 0 0.00014388784
- O 0 0.0005610123
year O 0 0.000110781126
old O 0 0.00017849036
girl O 0 0.0005915403
with O 0 0.0002560245
recurrent O 0 0.0069246325
acute B-Disease 0 0.94925207
lymphoblastic I-Disease 0 0.9999665
leucemia I-Disease 0 0.99701786
and O 0 0.00032479857
a O 0 0.00041018485
57 O 0 0.000497064
- O 0 0.00117619
year O 0 0.0002561959
old O 0 0.0005405077
man O 0 0.0056968974
with O 0 0.0028607557
lymphoblastic B-Disease 0 0.9999708
lymphoma I-Disease 0 0.99986374
. O 0 0.0061680158

The O 0 0.0030728679
girl O 0 0.0069077746
died O 0 0.0028148966
seven O 0 0.0007059008
days O 0 0.00050070806
, O 0 0.0009396126
the O 0 0.00048119313
man O 0 0.0015001547
four O 0 0.00020469322
weeks O 0 0.00017311773
after O 0 0.00021992947
intrathecal O 0 0.0014986086
injection O 0 0.00061165733
of O 0 0.0017586908
vincristine B-Chemical 1 0.9996395
. O 0 0.0050421623

Clinically O 0 0.011622138
, O 0 0.0038749436
the O 0 0.0012849665
onset O 0 0.0015312749
was O 0 0.00064518576
characterized O 0 0.0005922737
by O 0 0.0003453531
the O 0 0.00027684332
signs O 0 0.0008685245
of O 0 0.00028738243
opistothonus B-Disease 0 0.0005381041
, I-Disease 0 0.00057972857
sensory I-Disease 0 0.0005255904
and I-Disease 0 0.00033887115
motor I-Disease 0 0.0015560796
dysfunction I-Disease 0 0.26274547
and O 0 0.00097569986
ascending O 0 0.009215567
paralysis B-Disease 0 0.99616003
. O 0 0.0036325038

Histological O 0 0.0053064986
and O 0 0.0027019149
immunohistochemical O 0 0.0019651516
investigations O 0 0.0021722782
( O 0 0.004348619
HE O 0 0.9925101
- O 0 0.17248651
LFB O 0 0.98780733
, O 0 0.0024843628
CD O 0 0.916578
- O 0 0.005667048
68 O 0 0.0008086112
, O 0 0.0009665011
Neurofilament O 0 0.020274987
) O 0 0.0008774394
revealed O 0 0.0002823031
degeneration B-Disease 0 0.5070041
of I-Disease 0 0.00035925885
myelin I-Disease 0 0.0049453406
and I-Disease 0 0.00019954907
axons I-Disease 0 0.00021206767
as O 0 0.000121308345
well O 0 0.00013189878
as O 0 0.00021145184
pseudocystic B-Disease 0 0.729016
transformation I-Disease 0 0.0017627715
in O 0 0.00015315661
areas O 0 0.00022726644
exposed O 0 0.00016963301
to O 0 0.00021933412
vincristine B-Chemical 1 0.99998045
, O 0 0.00070828357
accompanied O 0 0.00038527828
by O 0 0.00021530509
secondary O 0 0.0003386572
changes O 0 0.00032722097
with O 0 0.00041351022
numerous O 0 0.0006610904
prominent O 0 0.002237311
macrophages O 0 0.003599563
. O 0 0.0028540618

The O 0 0.0023812184
clinical O 0 0.0034910913
course O 0 0.0014910302
and O 0 0.00114494
histopathological O 0 0.0019885178
results O 0 0.0006646813
of O 0 0.00075853337
the O 0 0.0006170883
two O 0 0.0005981783
cases O 0 0.0015873776
are O 0 0.0011595997
presented O 0 0.0018650965
. O 0 0.0037562735

A O 0 0.03144629
review O 0 0.0051847324
of O 0 0.0022780814
all O 0 0.0015300987
reported O 0 0.0014679717
cases O 0 0.0017159822
in O 0 0.0009647985
the O 0 0.00095480174
literature O 0 0.002016316
is O 0 0.0013864024
given O 0 0.0017607101
. O 0 0.0042825723

A O 0 0.0132152205
better O 0 0.0021482927
controlled O 0 0.0012898048
regimen O 0 0.00090969197
for O 0 0.0005411779
administering O 0 0.0013989707
vincristine B-Chemical 1 0.9998072
and O 0 0.0010348
intrathecal O 0 0.010923322
chemotherapy O 0 0.0032309394
is O 0 0.00080354704
recommended O 0 0.001514733
. O 0 0.0030855178

Palpebral B-Disease 0 0.99426866
twitching I-Disease 0 0.9860956
in O 0 0.0055721444
a O 0 0.008008151
depressed B-Disease 2 0.99522877
adolescent O 0 0.1872184
on O 0 0.005365932
citalopram B-Chemical 0 0.9999331
. O 0 0.010654822

Current O 0 0.0057033384
estimates O 0 0.0015808858
suggest O 0 0.00070934684
that O 0 0.00064647215
between O 0 0.00059121876
0 O 0 0.0008234477
. O 0 0.00044676126
4 O 0 0.00030174598
% O 0 0.00052151695
and O 0 0.00027800817
8 O 0 0.00023560977
. O 0 0.00020450399
3 O 0 0.00017669945
% O 0 0.00036131006
of O 0 0.00027357475
children O 0 0.00083302264
and O 0 0.0004335862
adolescents O 0 0.0047651664
are O 0 0.00037488673
affected O 0 0.0006123778
by O 0 0.0009451565
major B-Disease 0 0.0046969475
depression I-Disease 0 0.9997507
. O 0 0.00523488

We O 0 0.0026791655
report O 0 0.0028144375
a O 0 0.0016348393
favorable O 0 0.0013280621
response O 0 0.00046197607
to O 0 0.00031716994
treatment O 0 0.00036162432
with O 0 0.00064923544
citalopram B-Chemical 0 0.99999475
by O 0 0.0003062116
a O 0 0.00031661915
15 O 0 0.00018442707
- O 0 0.00070242566
year O 0 0.00014655448
- O 0 0.00066360243
old O 0 0.00021269216
boy O 0 0.00067783927
with O 0 0.00023478142
major B-Disease 0 0.0016516753
depression I-Disease 0 0.9999801
who O 0 0.0009339307
exhibited O 0 0.00059705623
palpebral B-Disease 0 0.9999341
twitching I-Disease 0 0.99459994
during O 0 0.0001843286
his O 0 0.00022848292
first O 0 0.00012592932
2 O 0 0.00024903085
weeks O 0 0.00018521002
of O 0 0.000604154
treatment O 0 0.0012013327
. O 0 0.0025132943

This O 0 0.0052660573
may O 0 0.0018192693
have O 0 0.0011220751
been O 0 0.0008493585
a O 0 0.0009392035
side O 0 0.0013056888
effect O 0 0.000534032
of O 0 0.0015608193
citalopram B-Chemical 0 0.9999968
as O 0 0.00086031924
it O 0 0.0013411146
remitted O 0 0.98144794
with O 0 0.000588404
redistribution O 0 0.00079209555
of O 0 0.0010923696
doses O 0 0.0034831017
. O 0 0.0030793282

The O 0 0.0037412576
3 O 0 0.0036375693
- O 0 0.00913578
week O 0 0.0034242983
sulphasalazine B-Chemical 0 0.9997439
syndrome O 0 0.9793569
strikes O 0 0.015178417
again O 0 0.005927359
. O 0 0.00792309

A O 0 0.02569406
34 O 0 0.0045827716
- O 0 0.0073869824
year O 0 0.0014328456
- O 0 0.0032513726
old O 0 0.0010209953
lady O 0 0.001796474
developed O 0 0.00070557767
a O 0 0.0008615128
constellation O 0 0.0067887297
of O 0 0.0009789291
dermatitis B-Disease 0 0.9996804
, O 0 0.00390648
fever B-Disease 0 0.9989705
, O 0 0.0019664175
lymphadenopathy B-Disease 0 0.99571216
and O 0 0.00060480007
hepatitis B-Disease 0 0.9999757
, O 0 0.00059894647
beginning O 0 9.003485e-05
on O 0 6.914451e-05
the O 0 8.195135e-05
17th O 0 0.00015045317
day O 0 7.039933e-05
of O 0 0.00011687776
a O 0 0.00018262466
course O 0 0.00014926102
of O 0 0.00022806351
oral O 0 0.013146591
sulphasalazine B-Chemical 0 0.99998
for O 0 0.000416032
sero O 0 0.040740225
- O 0 0.012383836
negative O 0 0.0017388593
rheumatoid B-Disease 0 0.99989676
arthritis I-Disease 0 0.99984777
. O 0 0.0054498897

Cervical O 0 0.014897495
and O 0 0.0034975188
inguinal O 0 0.004856883
lymph O 0 0.008735638
node O 0 0.0011252558
biopsies O 0 0.00039232933
showed O 0 0.00023788441
the O 0 0.0001974104
features O 0 0.00029766912
of O 0 0.00033729107
severe O 0 0.008689144
necrotising O 0 0.9983576
lymphadenitis B-Disease 0 0.9994392
, O 0 0.0004308997
associated O 0 0.00016931319
with O 0 0.0002235747
erythrophagocytosis O 0 0.7769816
and O 0 0.00023898677
prominent O 0 0.0015556677
eosinophilic O 0 0.94877946
infiltrates O 0 0.21729378
, O 0 0.00025517106
without O 0 0.00010094813
viral O 0 0.00016246212
inclusion O 0 5.381182e-05
bodies O 0 0.0001782147
, O 0 0.00022669339
suggestive O 0 0.00014497087
of O 0 0.000113842616
an O 0 0.00015228156
adverse B-Disease 0 0.006106863
drug I-Disease 0 0.004344784
reaction I-Disease 0 0.00019337796
. O 0 0.00011651112
A O 0 0.0012033804
week O 0 6.9905494e-05
later O 0 0.00010291922
, O 0 0.0004294962
fulminant O 0 0.9994617
drug B-Disease 0 0.34996292
- I-Disease 0 0.024091763
induced I-Disease 0 0.00039961323
hepatitis I-Disease 0 0.9999919
, O 0 0.0013493963
associated O 0 0.0001694592
with O 0 0.00012238446
the O 0 8.4787345e-05
presence O 0 0.000100459525
of O 0 0.00016615234
anti O 0 0.0008083678
- O 0 0.015854169
nuclear O 0 0.00057597656
autoantibodies O 0 0.123104796
( O 0 0.0005509345
but O 0 0.0001548295
not O 0 8.9630004e-05
with O 0 0.000114489805
other O 0 0.00010948915
markers O 0 0.00029428495
of O 0 0.0002703464
autoimmunity B-Disease 0 0.99290085
) O 0 0.0012905138
, O 0 0.00036897723
and O 0 0.00018852977
accompanied O 0 0.0003018743
by O 0 0.00021935772
multi B-Disease 0 0.0022957996
- I-Disease 0 0.0030716269
organ I-Disease 0 0.00067357486
failure I-Disease 0 0.0085096285
and O 0 0.000847003
sepsis B-Disease 2 0.998059
, O 0 0.0036957029
supervened O 0 0.3109363
. O 0 0.0032848886

She O 0 0.0069025303
subsequently O 0 0.0023959212
died O 0 0.0023508305
some O 0 0.00062585145
5 O 0 0.0003508016
weeks O 0 0.00015133126
after O 0 0.00011830246
the O 0 0.00014815711
commencement O 0 0.0001728403
of O 0 0.00019212598
her O 0 0.00024407521
drug O 0 0.0012811573
therapy O 0 0.0002626532
. O 0 0.00015386169
Post O 0 0.00049485435
- O 0 0.0010115341
mortem O 0 0.00048182489
examination O 0 9.298442e-05
showed O 0 9.442371e-05
evidence O 0 0.000120116994
of O 0 0.0003565295
massive B-Disease 0 0.6395746
hepatocellular I-Disease 0 0.99999905
necrosis I-Disease 2 0.99999976
, O 0 0.026275191
acute O 0 0.8122566
hypersensitivity O 0 0.9956117
myocarditis B-Disease 0 0.9999949
, O 0 0.0010079314
focal O 0 0.0028011163
acute O 0 0.15432003
tubulo O 0 0.7141785
- O 0 0.052982852
interstitial O 0 0.98547333
nephritis B-Disease 0 0.99999905
and O 0 0.0003142033
extensive O 0 0.0002638187
bone B-Disease 0 0.042958487
marrow I-Disease 0 0.3508306
necrosis I-Disease 2 0.9999795
, O 0 0.0007161846
with O 0 0.0002808912
no O 0 0.00029142952
evidence O 0 0.00049066934
of O 0 0.0015687175
malignancy B-Disease 2 0.99802256
. O 0 0.00414007

It O 0 0.0052742744
is O 0 0.001690387
thought O 0 0.0011789394
that O 0 0.0006434157
the O 0 0.00071733276
clinico O 0 0.105754204
- O 0 0.0053434945
pathological O 0 0.0018944677
features O 0 0.00036430356
and O 0 0.00026733216
chronology O 0 0.00062158913
of O 0 0.00023193927
this O 0 0.00021490226
case O 0 0.00022780926
bore O 0 0.0011456667
the O 0 0.00015166079
hallmarks O 0 0.00023243339
of O 0 0.00017493787
the O 0 0.00014019135
so O 0 0.00019375444
- O 0 0.0018131738
called O 0 0.00023768829
" O 0 0.00028227025
3 O 0 0.00013562266
- O 0 0.0007832078
week O 0 0.00016435822
sulphasalazine B-Chemical 0 0.9999813
syndrome O 0 0.9814508
" O 0 0.00073725916
, O 0 0.0005333486
a O 0 0.00050623
rare O 0 0.0019432795
, O 0 0.00061941583
but O 0 0.00040433562
often O 0 0.00062861945
fatal O 0 0.51006925
, O 0 0.0013411185
immunoallergic O 0 0.6769896
reaction O 0 0.0007121415
to O 0 0.001221787
sulphasalazine B-Chemical 0 0.9999052
. O 0 0.0040396927

Intravenous O 0 0.042308494
administration O 0 0.0032956065
of O 0 0.002106969
prochlorperazine B-Chemical 0 0.99987555
by O 0 0.0006421764
15 O 0 0.00041655023
- O 0 0.0008851687
minute O 0 0.00023753628
infusion O 0 0.0003052296
versus O 0 0.00013003778
2 O 0 0.00017901379
- O 0 0.0005712266
minute O 0 0.00018525808
bolus O 0 0.0005604597
does O 0 9.8089484e-05
not O 0 0.00010742984
affect O 0 9.8850156e-05
the O 0 0.00012865837
incidence O 0 0.00039757148
of O 0 0.0004764357
akathisia B-Disease 0 0.9999864
: O 0 0.0009234568
a O 0 0.00044042672
prospective O 0 0.0014398714
, O 0 0.00070979557
randomized O 0 0.0011630651
, O 0 0.0009799793
controlled O 0 0.0010785703
trial O 0 0.0024811255
. O 0 0.0029088587

STUDY O 0 0.007581581
OBJECTIVE O 0 0.014043258
: O 0 0.0025618854
We O 0 0.00055390806
sought O 0 0.0004549946
to O 0 0.0002590614
compare O 0 0.00012526225
the O 0 0.00017646325
rate O 0 0.00030630062
of O 0 0.00035742694
akathisia B-Disease 0 0.999966
after O 0 8.586487e-05
administration O 0 0.00018730937
of O 0 0.00015836039
intravenous O 0 0.021729566
prochlorperazine B-Chemical 0 0.9999527
as O 0 0.00016504529
a O 0 0.0002303806
2 O 0 0.0002038895
- O 0 0.0006194477
minute O 0 0.00021227926
bolus O 0 0.00056537136
or O 0 0.00021117723
15 O 0 0.0003350092
- O 0 0.0013277282
minute O 0 0.0008226535
infusion O 0 0.0021499137
. O 0 0.0022743533

METHODS O 0 0.004594825
: O 0 0.0029786313
We O 0 0.00089585537
conducted O 0 0.00093566574
a O 0 0.0009912569
prospective O 0 0.0018566293
, O 0 0.0009783164
randomized O 0 0.0010981592
, O 0 0.0006093853
double O 0 0.00035739082
- O 0 0.0033810087
blind O 0 0.015204434
study O 0 0.00032421507
in O 0 0.0001993644
the O 0 0.00020282812
emergency O 0 0.0010897155
department O 0 0.0011818694
of O 0 0.0003411701
a O 0 0.00057712314
central O 0 0.000922937
- O 0 0.0031384723
city O 0 0.0015494543
teaching O 0 0.0018035509
hospital O 0 0.0021142724
. O 0 0.002764769

Patients O 0 0.0044009755
aged O 0 0.0026620708
18 O 0 0.0011350818
years O 0 0.0008511186
or O 0 0.0005083658
older O 0 0.001361199
treated O 0 0.00090763747
with O 0 0.00082190026
prochlorperazine B-Chemical 0 0.9999716
for O 0 0.000471804
headache B-Disease 0 0.99779046
, O 0 0.0011753757
nausea B-Disease 0 0.9983038
, O 0 0.00066740735
or O 0 0.0003429238
vomiting B-Disease 0 0.7692015
were O 0 0.0003432329
eligible O 0 0.00045277053
for O 0 0.00044748368
inclusion O 0 0.0007197411
. O 0 0.002343119

Study O 0 0.0062089404
participants O 0 0.001638403
were O 0 0.0008948258
randomized O 0 0.0011081061
to O 0 0.00033302497
receive O 0 0.00027384225
10 O 0 0.00026826
mg O 0 0.0017899547
of O 0 0.00032788768
prochlorperazine B-Chemical 0 0.9999347
administered O 0 0.00031407902
intravenously O 0 0.0002352493
by O 0 8.497812e-05
means O 0 8.550152e-05
of O 0 0.0001342608
2 O 0 0.0001767217
- O 0 0.0005904447
minute O 0 0.00014471356
push O 0 0.0002875183
( O 0 0.00023816015
bolus O 0 0.0005078505
group O 0 0.00017586208
) O 0 0.0002627203
or O 0 9.613752e-05
10 O 0 0.00012632934
mg O 0 0.0012859656
diluted O 0 0.00016861912
in O 0 9.82047e-05
50 O 0 0.00015981252
mL O 0 0.00066748046
of O 0 0.00010842204
normal O 0 0.00020026193
saline O 0 0.0003498678
solution O 0 0.00021766311
administered O 0 0.000112614776
by O 0 5.7972236e-05
means O 0 5.6981055e-05
of O 0 9.526718e-05
intravenous O 0 0.00073619874
infusion O 0 0.0002392462
during O 0 7.566822e-05
a O 0 0.00017972184
15 O 0 0.00015033601
- O 0 0.0005140667
minute O 0 0.0001808785
period O 0 0.00015288607
( O 0 0.00052149437
infusion O 0 0.0009867882
group O 0 0.0011609902
) O 0 0.0030082793
. O 0 0.002894816

The O 0 0.0018516734
main O 0 0.0016155828
outcome O 0 0.0012815892
was O 0 0.0006226455
the O 0 0.00037732776
number O 0 0.00027377545
of O 0 0.0003381473
study O 0 0.00035239494
participants O 0 0.00038924968
experiencing O 0 0.0016165483
akathisia B-Disease 0 0.9999498
within O 0 0.00024151977
60 O 0 0.00039563858
minutes O 0 0.00037479578
of O 0 0.00071197556
administration O 0 0.0019469619
. O 0 0.002563086

Akathisia O 0 0.9996898
was O 0 0.0022802218
defined O 0 0.0010266218
as O 0 0.0007611376
either O 0 0.0005438637
a O 0 0.0006838737
spontaneous O 0 0.000996782
report O 0 0.00062025763
of O 0 0.0004902504
restlessness O 0 0.99714273
or O 0 0.0003342614
agitation B-Disease 2 0.993537
or O 0 0.00017600818
a O 0 0.00021440105
change O 0 0.000114193135
of O 0 0.00011840009
2 O 0 0.00011629776
or O 0 8.000938e-05
more O 0 0.00012317135
in O 0 7.9640115e-05
the O 0 7.763421e-05
patient O 0 0.00015963541
- O 0 0.0010528894
reported O 0 0.00022676383
akathisia B-Disease 0 0.9999801
rating O 0 0.00019090943
scale O 0 0.00014421447
and O 0 0.00010773627
a O 0 0.00015540767
change O 0 9.7961056e-05
of O 0 0.00010652095
at O 0 8.310435e-05
least O 0 0.000109787434
1 O 0 0.00014086241
in O 0 0.000116848794
the O 0 0.00014925319
investigator O 0 0.00069450465
- O 0 0.0018124888
observed O 0 0.0005284965
akathisia B-Disease 0 0.99994516
rating O 0 0.0014089139
scale O 0 0.0017524459
. O 0 0.0024731806

The O 0 0.001894786
intensity O 0 0.001166605
of O 0 0.0018133405
headache B-Disease 0 0.99155104
and O 0 0.0014896018
nausea B-Disease 0 0.9966344
was O 0 0.0005244174
measured O 0 0.00044018246
with O 0 0.00043373936
a O 0 0.0006761476
100 O 0 0.0010290948
- O 0 0.0019999708
mm O 0 0.0018801885
visual O 0 0.0039626313
analog O 0 0.0017831696
scale O 0 0.0023048162
. O 0 0.0032351422

RESULTS O 0 0.0094402395
: O 0 0.007221562
One O 0 0.0039058363
hundred O 0 0.004243203
patients O 0 0.0049492843
were O 0 0.004052823
enrolled O 0 0.008036859
. O 0 0.009037403

One O 0 0.005990963
study O 0 0.0036739681
participant O 0 0.0021912355
was O 0 0.0019087438
excluded O 0 0.0019521354
after O 0 0.0011888704
protocol O 0 0.002285857
violation O 0 0.006995357
. O 0 0.007031371

Seventy O 0 0.01227297
- O 0 0.0067487606
three O 0 0.00087524706
percent O 0 0.0012138439
( O 0 0.001621001
73 O 0 0.001564038
/ O 0 0.0022204246
99 O 0 0.0010489598
) O 0 0.00080196594
of O 0 0.0003081935
the O 0 0.00020984345
study O 0 0.00023879748
participants O 0 0.00021295778
were O 0 0.00017217462
treated O 0 0.00036140255
for O 0 0.00024280953
headache B-Disease 0 0.9623156
and O 0 0.00028710716
70 O 0 0.00032902908
% O 0 0.0005208798
( O 0 0.00054763845
70 O 0 0.00048586758
/ O 0 0.0015457827
99 O 0 0.0012220715
) O 0 0.001610523
for O 0 0.0012011371
nausea B-Disease 0 0.99209094
. O 0 0.0043477

In O 0 0.0020711105
the O 0 0.0017934622
bolus O 0 0.0042094258
group O 0 0.0016566457
, O 0 0.0015190896
26 O 0 0.00089100824
. O 0 0.0005115443
0 O 0 0.00053572666
% O 0 0.00070013705
( O 0 0.0005842413
13 O 0 0.00038589878
/ O 0 0.0010658107
50 O 0 0.00041142662
) O 0 0.0006908103
had O 0 0.00040023105
akathisia B-Disease 0 0.99996066
compared O 0 0.00017821862
with O 0 0.00021225741
32 O 0 0.00026543144
. O 0 0.00014912176
7 O 0 0.00011862927
% O 0 0.00027511147
( O 0 0.00027881458
16 O 0 0.00020569394
/ O 0 0.00064807053
49 O 0 0.00027676046
) O 0 0.00031800228
in O 0 0.00011726826
the O 0 0.0001139884
infusion O 0 0.0003614098
group O 0 0.00024925297
( O 0 0.00037101423
Delta O 0 0.0008525666
= O 0 0.0007766081
- O 0 0.00086046394
6 O 0 0.00013492096
. O 0 0.00015131755
7 O 0 0.0001446465
% O 0 0.00034602176
; O 0 0.00039344165
95 O 0 0.00038819396
% O 0 0.00033429964
confidence O 0 0.00048039632
interval O 0 0.00030690277
[ O 0 0.0010835893
CI O 0 0.008806829
] O 0 0.0015592996
- O 0 0.0013670737
24 O 0 0.00025579857
. O 0 0.0002031769
6 O 0 0.00018242904
% O 0 0.00045186165
to O 0 0.00030204072
11 O 0 0.00051751616
. O 0 0.0005573122
2 O 0 0.0009117246
% O 0 0.002119954
) O 0 0.003966665
. O 0 0.0040099085

The O 0 0.0014908895
difference O 0 0.0009095827
between O 0 0.0006062155
the O 0 0.00053694204
bolus O 0 0.0013650222
and O 0 0.00036487795
infusion O 0 0.0005983305
groups O 0 0.0002570503
in O 0 0.00015150684
the O 0 0.000112498215
percentage O 0 9.9063895e-05
of O 0 0.00015600347
participants O 0 0.0002008283
who O 0 0.00024025748
saw O 0 0.0002494974
a O 0 0.00025432292
50 O 0 0.00021109206
% O 0 0.00027029353
reduction O 0 0.00015452979
in O 0 0.00011464747
their O 0 0.00015599767
headache B-Disease 0 0.93395
intensity O 0 5.575376e-05
within O 0 4.6727215e-05
30 O 0 7.775142e-05
minutes O 0 8.7092834e-05
was O 0 9.6934906e-05
11 O 0 0.00013610836
. O 0 0.000120047844
8 O 0 0.00013645792
% O 0 0.00030505328
( O 0 0.0003422843
95 O 0 0.0004393518
% O 0 0.0005114066
CI O 0 0.0067103337
- O 0 0.0013087541
9 O 0 0.00021478877
. O 0 0.00020676779
6 O 0 0.00018919192
% O 0 0.00047326882
to O 0 0.00032269605
33 O 0 0.0007424254
. O 0 0.0005754184
3 O 0 0.00074342545
% O 0 0.0020644432
) O 0 0.003908577
. O 0 0.0039846334

The O 0 0.0018635651
difference O 0 0.0012763379
in O 0 0.000933028
the O 0 0.00057183346
percentage O 0 0.00040319486
of O 0 0.0005099032
patients O 0 0.000761521
with O 0 0.00034804802
a O 0 0.00042695162
50 O 0 0.00033257698
% O 0 0.00039784616
reduction O 0 0.00022799286
in O 0 0.00017526263
their O 0 0.000241337
nausea B-Disease 0 0.99203485
was O 0 0.00018506474
12 O 0 0.00011728671
. O 0 0.00013058027
6 O 0 0.000118551565
% O 0 0.00031218576
( O 0 0.00035207375
95 O 0 0.00045057622
% O 0 0.000522369
CI O 0 0.0068191313
- O 0 0.0013011768
4 O 0 0.00020379564
. O 0 0.00020586328
6 O 0 0.00018742407
% O 0 0.00046680044
to O 0 0.0003181909
29 O 0 0.0007005448
. O 0 0.00057721854
8 O 0 0.0007938887
% O 0 0.0020994681
) O 0 0.003994273
. O 0 0.0040484946

CONCLUSION O 0 0.024173168
: O 0 0.0063596945
A O 0 0.0103620915
50 O 0 0.0015961827
% O 0 0.0013944262
reduction O 0 0.0005864741
in O 0 0.0003319302
the O 0 0.0002439342
incidence O 0 0.00053085305
of O 0 0.00054479943
akathisia B-Disease 0 0.9999913
when O 0 0.00034279533
prochlorperazine B-Chemical 0 0.9999821
was O 0 0.00014582796
administered O 0 0.0001487715
by O 0 7.62551e-05
means O 0 7.292593e-05
of O 0 0.00010761213
15 O 0 0.00011212316
- O 0 0.0003647997
minute O 0 0.00010786056
intravenous O 0 0.0003505133
infusion O 0 0.00017767209
versus O 0 8.681647e-05
a O 0 0.00018150063
2 O 0 0.00019780021
- O 0 0.0006863915
minute O 0 0.00027760243
intravenous O 0 0.0012739112
push O 0 0.000820523
was O 0 0.0005089384
not O 0 0.0007184857
detected O 0 0.0011664551
. O 0 0.003060465

The O 0 0.001437604
efficacy O 0 0.0014332925
of O 0 0.0019286815
prochlorperazine B-Chemical 0 0.9999274
in O 0 0.00055151636
the O 0 0.000278228
treatment O 0 0.0002888652
of O 0 0.00043055337
headache B-Disease 0 0.9979114
and O 0 0.0005718921
nausea B-Disease 0 0.99965453
likewise O 0 0.0013761156
did O 0 0.00027968996
not O 0 0.00015870143
appear O 0 0.00012231086
to O 0 0.00010242929
be O 0 0.00011036948
affected O 0 0.00012581794
by O 0 0.00010424314
the O 0 9.49483e-05
rate O 0 0.00017622364
of O 0 0.00015974017
administration O 0 0.00038792723
, O 0 0.00032308238
although O 0 0.0001688043
no O 0 0.00019487408
formal O 0 0.00038994814
statistical O 0 0.00062373566
comparisons O 0 0.0005168787
were O 0 0.0006770032
made O 0 0.0012448669
. O 0 0.0027423564

Combined O 0 0.005606739
antiretroviral O 0 0.0044195973
therapy O 0 0.001971825
causes O 0 0.0017991626
cardiomyopathy B-Disease 0 0.99971515
and O 0 0.0020271009
elevates O 0 0.021966698
plasma O 0 0.49338552
lactate B-Chemical 0 0.99114895
in O 0 0.0009591938
transgenic O 0 0.00090460014
AIDS B-Disease 0 0.9771085
mice O 0 0.0010894804
. O 0 0.0033320973

Highly O 0 0.004357857
active O 0 0.0021688968
antiretroviral O 0 0.0026410536
therapy O 0 0.0012638126
( O 0 0.0013790689
HAART O 0 0.008839439
) O 0 0.0008977277
is O 0 0.0002579631
implicated O 0 0.00026313844
in O 0 0.00041000068
cardiomyopathy B-Disease 0 0.99986863
( O 0 0.002183934
CM B-Disease 0 0.94652927
) O 0 0.00084083603
and O 0 0.00023124108
in O 0 0.0002450562
elevated O 0 0.003506653
plasma O 0 0.3106865
lactate B-Chemical 0 0.9982116
( O 0 0.0022036363
LA B-Chemical 0 0.9993936
) O 0 0.0017231781
in O 0 0.00044261105
AIDS B-Disease 0 0.9904118
through O 0 0.00030311727
mechanisms O 0 0.00036947968
of O 0 0.0011986969
mitochondrial B-Disease 0 0.9524294
dysfunction I-Disease 0 0.9992593
. O 0 0.0050418368

To O 0 0.0013814599
determine O 0 0.00083342084
mitochondrial O 0 0.006222283
events O 0 0.0014568939
from O 0 0.0006448688
HAART O 0 0.006371309
in O 0 0.00026788271
vivo O 0 0.00025470732
, O 0 0.00040390872
8 O 0 0.00022117289
- O 0 0.0007027425
week O 0 0.00013554121
- O 0 0.0006318291
old O 0 0.00023293967
hemizygous O 0 0.00028396805
transgenic O 0 0.00015974688
AIDS B-Disease 0 0.93511623
mice O 0 0.000110018416
( O 0 0.0005101237
NL4 O 0 0.0045107566
- O 0 0.0026827813
3Delta O 0 0.001640436
gag O 0 0.0008343517
/ O 0 0.0018001864
pol O 0 0.0012255872
; O 0 0.0010866517
TG O 0 0.7798463
) O 0 0.00063842733
and O 0 0.00019378992
wild O 0 0.00019262749
- O 0 0.0011854864
type O 0 0.00032502285
FVB O 0 0.00030203207
/ O 0 0.0003153795
n O 0 9.0501744e-05
littermates O 0 2.8680544e-05
were O 0 6.928352e-05
treated O 0 0.00015046564
with O 0 0.00010471728
the O 0 9.5897165e-05
HAART O 0 0.0018412145
combination O 0 0.000118206844
of O 0 0.00017816917
zidovudine B-Chemical 0 0.9832529
, O 0 0.0011005566
lamivudine B-Chemical 0 0.99996686
, O 0 0.0004151899
and O 0 0.00022651511
indinavir B-Chemical 0 0.99903107
or O 0 0.00014995877
vehicle O 0 0.0006216297
control O 0 0.00017379982
for O 0 0.00014137752
10 O 0 0.00019306934
days O 0 0.0001381293
or O 0 0.00028056974
35 O 0 0.00058561645
days O 0 0.00062011875
. O 0 0.0020043221

At O 0 0.0012224546
termination O 0 0.0013942808
of O 0 0.0010692374
the O 0 0.0005798775
experiments O 0 0.0003814075
, O 0 0.000521293
mice O 0 0.000121666766
underwent O 0 0.00023490995
echocardiography O 0 0.00037206121
, O 0 0.00032635953
quantitation O 0 0.00022317343
of O 0 0.00018271207
abundance O 0 0.00014589846
of O 0 0.00022599439
molecular O 0 0.00044909082
markers O 0 0.0004716799
of O 0 0.0003692151
CM B-Disease 0 0.93773156
( O 0 0.00056249247
ventricular O 0 0.08117321
mRNA O 0 0.00016264098
encoding O 0 0.000120559256
atrial O 0 0.030106544
natriuretic O 0 0.0695049
factor O 0 0.024933407
[ O 0 0.062177576
ANF O 0 0.9998772
] O 0 0.007942058
and O 0 0.00037712776
sarcoplasmic O 0 0.016005415
calcium B-Chemical 0 0.99614525
ATPase O 0 0.0036735437
[ O 0 0.006018776
SERCA2 O 0 0.21959226
] O 0 0.002303093
) O 0 0.0008515871
, O 0 0.0005809817
and O 0 0.00043990792
determination O 0 0.00082151423
of O 0 0.0012838641
plasma O 0 0.2694918
LA B-Chemical 0 0.99850625
. O 0 0.004939942

Myocardial O 0 0.3376641
histologic O 0 0.0056098048
features O 0 0.0016446608
were O 0 0.0008257287
analyzed O 0 0.0006567658
semiquantitatively O 0 0.00079011405
and O 0 0.0004950477
results O 0 0.00041330876
were O 0 0.0004559322
confirmed O 0 0.00047431255
by O 0 0.00076743355
transmission O 0 0.0010949757
electron O 0 0.0062446916
microscopy O 0 0.0029867
. O 0 0.0038524491

After O 0 0.0018148567
35 O 0 0.0018866541
days O 0 0.00087913364
in O 0 0.0009089694
the O 0 0.0009419978
TG O 0 0.46004066
+ O 0 0.004135527
HAART O 0 0.011098693
cohort O 0 0.00096869556
, O 0 0.0006803643
left O 0 0.00085481175
ventricular O 0 0.03949907
mass O 0 0.00073485886
increased O 0 0.0006500048
160 O 0 0.0012036831
% O 0 0.0011679432
by O 0 0.0009609903
echocardiography O 0 0.0030266661
. O 0 0.0030139904

Molecularly O 0 0.016789299
, O 0 0.015348851
ANF O 0 0.99817264
mRNA O 0 0.003519464
increased O 0 0.00246853
250 O 0 0.0037399763
% O 0 0.0026808223
and O 0 0.0017344888
SERCA2 O 0 0.048046574
mRNA O 0 0.0021936807
decreased O 0 0.003403929
57 O 0 0.004290662
% O 0 0.005445503
. O 0 0.005433618

Biochemically O 0 0.027744025
, O 0 0.012224635
LA B-Chemical 0 0.9952354
was O 0 0.0024149409
elevated O 0 0.004121541
( O 0 0.0017412523
8 O 0 0.0007049022
. O 0 0.0006030923
5 O 0 0.0006131025
+ O 0 0.0018771171
/ O 0 0.00319742
- O 0 0.0034071135
2 O 0 0.001055458
. O 0 0.0010536686
0 O 0 0.0019187625
mM O 0 0.009694636
) O 0 0.0066384175
. O 0 0.005820415

Pathologically O 0 0.11589059
, O 0 0.0065705893
granular O 0 0.006020553
cytoplasmic O 0 0.001058449
changes O 0 0.00078024226
were O 0 0.00048782714
found O 0 0.00041270547
in O 0 0.00040237626
cardiac O 0 0.0013811983
myocytes O 0 0.0010468898
, O 0 0.0009155108
indicating O 0 0.0005213979
enlarged O 0 0.0074810553
, O 0 0.002711553
damaged O 0 0.008916245
mitochondria O 0 0.0116941715
. O 0 0.004390552

Findings O 0 0.01215921
were O 0 0.009808387
confirmed O 0 0.009778559
ultrastructurally O 0 0.023821661
. O 0 0.019756678

No O 0 0.008179922
changes O 0 0.0046074856
were O 0 0.0031031095
found O 0 0.0027321957
in O 0 0.0027318278
other O 0 0.0032612276
cohorts O 0 0.0067591025
. O 0 0.008146179

After O 0 0.0019391977
10 O 0 0.0018357254
days O 0 0.0010672782
, O 0 0.0021589191
only O 0 0.0018549415
ANF O 0 0.9987902
was O 0 0.0010057157
elevated O 0 0.002551235
, O 0 0.0010039681
and O 0 0.00051015406
only O 0 0.0004947048
in O 0 0.0004907706
the O 0 0.0006733304
TG O 0 0.76887137
+ O 0 0.0067089554
HAART O 0 0.03881968
cohort O 0 0.0039880048
. O 0 0.0033618305

Results O 0 0.0026959698
show O 0 0.0013548324
that O 0 0.0010877195
cumulative O 0 0.0014709764
HAART O 0 0.042969435
caused O 0 0.0011170758
mitochondrial O 0 0.15076713
CM B-Disease 0 0.99014986
with O 0 0.0013814298
elevated O 0 0.042086344
LA B-Chemical 0 0.9993167
in O 0 0.0015881192
AIDS B-Disease 0 0.9892117
transgenic O 0 0.0007233746
mice O 0 0.0007687334
. O 0 0.002834394

A O 0 0.034802556
Phase O 0 0.010186707
II O 0 0.016537983
trial O 0 0.00219398
of O 0 0.0016267326
cisplatin B-Chemical 0 0.99939895
plus O 0 0.0016573549
WR B-Chemical 0 0.9612797
- I-Chemical 0 0.066040024
2721 I-Chemical 0 0.9915931
( O 0 0.0019986464
amifostine B-Chemical 0 0.9996137
) O 0 0.0012894615
for O 0 0.0003686833
metastatic O 0 0.77092737
breast B-Disease 0 0.992766
carcinoma I-Disease 0 0.9998486
: O 0 0.0015705902
an O 0 0.00046223067
Eastern O 0 0.00091514195
Cooperative O 0 0.0008934252
Oncology O 0 0.0005870761
Group O 0 0.0017207125
Study O 0 0.001567347
( O 0 0.0015428799
E8188 O 0 0.0045495788
) O 0 0.0049587125
. O 0 0.0042867665

BACKGROUND O 0 0.024750555
: O 0 0.010298507
Cisplatin B-Chemical 0 0.99947876
has O 0 0.0005824086
minimal O 0 0.0004422642
antitumor O 0 0.0018686997
activity O 0 0.00019709066
when O 0 0.00015194592
used O 0 0.00018544098
as O 0 0.00020850562
second O 0 0.00022563718
- O 0 0.001254904
or O 0 0.00019727829
third O 0 0.0002812725
- O 0 0.0012886598
line O 0 0.00034935062
treatment O 0 0.00046662692
of O 0 0.0010767756
metastatic O 0 0.9595452
breast B-Disease 0 0.9973289
carcinoma I-Disease 0 0.9997917
. O 0 0.006177783

Older O 0 0.014292665
reports O 0 0.0019493651
suggest O 0 0.0006973113
an O 0 0.0007779058
objective O 0 0.00054439146
response O 0 0.00042186194
rate O 0 0.00049954664
of O 0 0.00033129408
8 O 0 0.00025424198
% O 0 0.00035889942
when O 0 0.0001380948
60 O 0 0.0002470896
- O 0 0.0007043294
120 O 0 0.0002702227
mg O 0 0.0015397224
/ O 0 0.0009137601
m2 O 0 0.0015168173
of O 0 0.00040783058
cisplatin B-Chemical 0 0.9995902
is O 0 0.0002420846
administered O 0 0.0003314887
every O 0 0.00016397393
3 O 0 0.00031266766
- O 0 0.0011835305
4 O 0 0.0005349686
weeks O 0 0.00063427683
. O 0 0.0022318999

Although O 0 0.0019252481
a O 0 0.002517089
dose O 0 0.002476738
- O 0 0.0032687744
response O 0 0.00046182657
effect O 0 0.00032842671
has O 0 0.0002215864
been O 0 0.00022525132
observed O 0 0.00020050611
with O 0 0.0004064671
cisplatin B-Chemical 0 0.9998666
, O 0 0.00040461493
the O 0 0.00011810431
dose O 0 0.0003210323
- O 0 0.0009442029
limiting O 0 0.00017920883
toxicities B-Disease 0 0.13638246
associated O 0 0.00016705862
with O 0 0.00027044283
cisplatin B-Chemical 0 0.99991715
( O 0 0.0005136183
e O 0 0.00045877733
. O 0 0.00013921011
g O 0 0.0004945787
. O 0 0.00015729251
, O 0 0.000557321
nephrotoxicity B-Disease 0 0.99997854
, O 0 0.0036355082
ototoxicity B-Disease 0 0.9999769
, O 0 0.00074348034
and O 0 0.00033770353
neurotoxicity B-Disease 0 0.99831355
) O 0 0.00063413
have O 0 0.00011246968
limited O 0 0.00013797054
its O 0 0.00020447746
use O 0 0.00016754965
as O 0 0.00022401295
a O 0 0.000460055
treatment O 0 0.00048062214
for O 0 0.0007678929
breast B-Disease 0 0.99097216
carcinoma I-Disease 0 0.99977463
. O 0 0.005715031

WR B-Chemical 0 0.98035
- I-Chemical 0 0.33203635
2721 I-Chemical 0 0.9910273
or O 0 0.0028090281
amifostine B-Chemical 0 0.999509
initially O 0 0.0013516723
was O 0 0.00050832686
developed O 0 0.00047047043
to O 0 0.00029803603
protect O 0 0.0003821028
military O 0 0.0009953134
personnel O 0 0.00072293694
in O 0 0.000421005
the O 0 0.00043679232
event O 0 0.000991736
of O 0 0.0011358405
nuclear O 0 0.0028037599
war O 0 0.0059415814
. O 0 0.0042653433

Amifostine B-Chemical 0 0.9989691
subsequently O 0 0.0030557748
was O 0 0.0011057894
shown O 0 0.0003868511
to O 0 0.00038953012
protect O 0 0.00042350893
normal O 0 0.0006116346
tissues O 0 0.00036418362
from O 0 0.000171655
the O 0 0.00015422008
toxic O 0 0.00115842
effects O 0 0.00014623886
of O 0 0.0002174737
alkylating B-Chemical 0 0.18499494
agents I-Chemical 0 0.0007338636
and O 0 0.00032764647
cisplatin B-Chemical 0 0.99986684
without O 0 0.00020379893
decreasing O 0 0.00019127403
the O 0 0.0001795778
antitumor O 0 0.0014190428
effect O 0 0.0002923077
of O 0 0.0005962523
the O 0 0.0007995752
chemotherapy O 0 0.008243829
. O 0 0.0021366428

Early O 0 0.0055938438
trials O 0 0.0030409964
of O 0 0.002423843
cisplatin B-Chemical 0 0.9997402
and O 0 0.0021812175
amifostine B-Chemical 0 0.9997595
also O 0 0.0003660177
suggested O 0 0.00018903721
that O 0 0.00013682495
the O 0 0.00014953938
incidence O 0 0.00032894377
and O 0 0.00018707734
severity O 0 0.0005638679
of O 0 0.00037215027
cisplatin B-Chemical 0 0.9999436
- O 0 0.014656457
induced O 0 0.00042754583
nephrotoxicity B-Disease 0 0.99998677
, O 0 0.007856974
ototoxicity B-Disease 0 0.99996185
, O 0 0.0013115678
and O 0 0.00084523816
neuropathy B-Disease 0 0.9997867
were O 0 0.0010430387
reduced O 0 0.0017356185
. O 0 0.0028320327

METHODS O 0 0.0053345403
: O 0 0.0046423567
A O 0 0.00808944
Phase O 0 0.0038623249
II O 0 0.0067294817
study O 0 0.0006452297
of O 0 0.00039129652
the O 0 0.00025235006
combination O 0 0.0003464793
of O 0 0.00049624045
cisplatin B-Chemical 0 0.99989784
plus O 0 0.00075086975
amifostine B-Chemical 0 0.999851
was O 0 0.00016466803
conducted O 0 0.00014974613
in O 0 0.00010510152
patients O 0 0.00025419783
with O 0 0.00017455779
progressive O 0 0.02990903
metastatic O 0 0.96663004
breast B-Disease 0 0.998582
carcinoma I-Disease 0 0.9999664
who O 0 0.00042177705
had O 0 9.498145e-05
received O 0 8.9141424e-05
one O 0 8.71436e-05
, O 0 0.00023686257
but O 0 0.00014726189
not O 0 0.000109647546
more O 0 0.00018374514
than O 0 0.000115096125
one O 0 0.00012951852
, O 0 0.00033472406
chemotherapy O 0 0.00093742984
regimen O 0 0.0003233477
for O 0 0.00043363686
metastatic O 0 0.45745912
disease O 0 0.42413142
. O 0 0.0029702752

Patients O 0 0.0057415757
received O 0 0.0036291059
amifostine B-Chemical 0 0.99699056
, O 0 0.003687373
910 O 0 0.006618881
mg O 0 0.011922254
/ O 0 0.0036616449
m2 O 0 0.004077834
intravenously O 0 0.0014884922
over O 0 0.00080622034
15 O 0 0.0011854627
minutes O 0 0.0016761274
. O 0 0.0035021747

After O 0 0.0014758109
completion O 0 0.0010948647
of O 0 0.0012100749
the O 0 0.0011035048
amifostine B-Chemical 0 0.99837387
infusion O 0 0.0029509498
, O 0 0.0014374139
cisplatin B-Chemical 0 0.9991059
120 O 0 0.0006991482
mg O 0 0.0037776933
/ O 0 0.0014150632
m2 O 0 0.0016764171
was O 0 0.0003656071
administered O 0 0.0005222071
over O 0 0.00043451323
30 O 0 0.0006809007
minutes O 0 0.0010997384
. O 0 0.002455504

Intravenous O 0 0.13304523
hydration O 0 0.010455728
and O 0 0.0032780466
mannitol B-Chemical 0 0.9979698
was O 0 0.0013452491
administered O 0 0.0011917306
before O 0 0.0005484312
and O 0 0.0011575316
after O 0 0.0014081146
cisplatin B-Chemical 0 0.9968521
. O 0 0.00584904

Treatment O 0 0.008737587
was O 0 0.0024073871
administered O 0 0.0019444822
every O 0 0.00072477944
3 O 0 0.0007806371
weeks O 0 0.0006269974
until O 0 0.0010871901
disease O 0 0.031117871
progression O 0 0.009527847
. O 0 0.0058926465

RESULTS O 0 0.0048692427
: O 0 0.003695217
Forty O 0 0.0028112167
- O 0 0.0027682434
four O 0 0.00045973895
patients O 0 0.00081684353
were O 0 0.00039228008
enrolled O 0 0.00056108827
in O 0 0.0002862214
the O 0 0.0002580256
study O 0 0.00034934314
of O 0 0.00036038915
which O 0 0.00042254655
7 O 0 0.0003412043
( O 0 0.0006880393
16 O 0 0.00059558806
% O 0 0.0011266806
) O 0 0.0016517484
were O 0 0.0011676957
ineligible O 0 0.0026908848
. O 0 0.0033309208

A O 0 0.0144324405
median O 0 0.0016248749
of O 0 0.0013834627
2 O 0 0.00090861606
cycles O 0 0.00039568948
of O 0 0.00052115053
therapy O 0 0.0006411633
was O 0 0.00040708506
administered O 0 0.0005681268
to O 0 0.0003972487
the O 0 0.000511255
37 O 0 0.0013842243
eligible O 0 0.0013330207
patients O 0 0.0027435303
. O 0 0.0032678777

Six O 0 0.0029677968
partial O 0 0.0023413894
responses O 0 0.0012641377
were O 0 0.0008904524
observed O 0 0.0006201568
for O 0 0.00050289195
an O 0 0.0006221389
overall O 0 0.00053404854
response O 0 0.00065381185
rate O 0 0.0011614099
of O 0 0.0013160112
16 O 0 0.0020274827
% O 0 0.0039208177
. O 0 0.0041845283

Most O 0 0.0067144576
patients O 0 0.005865416
( O 0 0.0040669497
57 O 0 0.0029181656
% O 0 0.0027027153
) O 0 0.002379638
stopped O 0 0.001440226
treatment O 0 0.0010145338
because O 0 0.000924301
of O 0 0.0021461863
disease O 0 0.49989128
progression O 0 0.018180184
. O 0 0.005495148

Neurologic B-Disease 0 0.92685074
toxicity I-Disease 0 0.98416173
was O 0 0.0030899355
reported O 0 0.0021815142
in O 0 0.0016888735
52 O 0 0.0025639567
% O 0 0.003145565
of O 0 0.0027644853
patients O 0 0.0060716923
. O 0 0.0061981836

Seven O 0 0.00403756
different O 0 0.0014335477
life O 0 0.0018162385
- O 0 0.005639683
threatening O 0 0.0023195092
toxicities B-Disease 0 0.18077257
were O 0 0.00055928406
observed O 0 0.00041016995
in O 0 0.0004732316
patients O 0 0.00089546636
while O 0 0.0006334764
receiving O 0 0.0011160823
treatment O 0 0.0016174321
. O 0 0.0031394244

CONCLUSIONS O 0 0.015715057
: O 0 0.0032775388
The O 0 0.00067590334
combination O 0 0.00088982214
of O 0 0.0011957375
cisplatin B-Chemical 0 0.99980026
and O 0 0.0014592827
amifostine B-Chemical 0 0.99978477
in O 0 0.00034535755
this O 0 0.00027083833
study O 0 0.00025291054
resulted O 0 0.00018489383
in O 0 0.00020854974
an O 0 0.00025508011
overall O 0 0.00024574148
response O 0 0.00033914862
rate O 0 0.00068767805
of O 0 0.0008363823
16 O 0 0.0013697728
% O 0 0.002812883
. O 0 0.003063848

Neither O 0 0.003229711
a O 0 0.0052192197
tumor B-Disease 0 0.7937331
- O 0 0.012574282
protective O 0 0.0010367774
effect O 0 0.0004003034
nor O 0 0.00032431152
reduced O 0 0.000649392
toxicity B-Disease 0 0.79215395
to O 0 0.00026875356
normal O 0 0.00047724365
tissues O 0 0.0002658103
was O 0 0.00012437245
observed O 0 0.00010383282
with O 0 0.0001334391
the O 0 0.000108157394
addition O 0 0.00010076185
of O 0 0.00042352936
amifostine B-Chemical 0 0.9998486
to O 0 0.0006044956
cisplatin B-Chemical 0 0.9997925
in O 0 0.000607584
this O 0 0.00088797
trial O 0 0.0020985722
. O 0 0.0024059494

Oral B-Chemical 0 0.31933078
contraceptives I-Chemical 0 0.77881145
and O 0 0.0045656236
the O 0 0.0030954885
risk O 0 0.013676003
of O 0 0.0072109792
myocardial B-Disease 0 0.9991756
infarction I-Disease 0 0.99989176
. O 0 0.011070245

BACKGROUND O 0 0.01389815
: O 0 0.003409801
An O 0 0.00086325646
association O 0 0.00039196483
between O 0 0.00033999016
the O 0 0.00031182877
use O 0 0.0002884095
of O 0 0.00039877268
oral B-Chemical 0 0.0050965897
contraceptives I-Chemical 0 0.55193573
and O 0 0.00029503054
the O 0 0.0002029256
risk O 0 0.002316596
of O 0 0.00070027326
myocardial B-Disease 0 0.99990726
infarction I-Disease 0 0.9999944
has O 0 0.00016533416
been O 0 0.00015104539
found O 0 0.00016510811
in O 0 0.00018674193
some O 0 0.00027037293
, O 0 0.0005812931
but O 0 0.00042779636
not O 0 0.00040853184
all O 0 0.000622684
, O 0 0.0016173011
studies O 0 0.0019432071
. O 0 0.0030631167

We O 0 0.0024285573
investigated O 0 0.0015885487
this O 0 0.0011777298
association O 0 0.00064365123
, O 0 0.0010789812
according O 0 0.00033501972
to O 0 0.00025815086
the O 0 0.00023487545
type O 0 0.0005372111
of O 0 0.0005402855
progestagen B-Chemical 0 0.9998603
included O 0 0.00024767336
in O 0 0.00016814517
third O 0 0.00021446055
- O 0 0.0013187997
generation O 0 0.0001870299
( O 0 0.0003303662
i O 0 0.00033484088
. O 0 0.00016792808
e O 0 0.00040707202
. O 0 0.00017050673
, O 0 0.0005367898
desogestrel B-Chemical 0 0.99996126
or O 0 0.0004023682
gestodene B-Chemical 0 0.9999752
) O 0 0.0007370608
and O 0 0.00015399378
second O 0 0.00014752556
- O 0 0.0011587837
generation O 0 0.00016468405
( O 0 0.00030527497
i O 0 0.0003213495
. O 0 0.0001608388
e O 0 0.00040953682
. O 0 0.0001633871
, O 0 0.00044513945
levonorgestrel B-Chemical 0 0.9992804
) O 0 0.0009736013
oral B-Chemical 0 0.004001148
contraceptives I-Chemical 0 0.46955422
, O 0 0.00027480998
the O 0 0.00010508148
dose O 0 0.00033049693
of O 0 0.00035216505
estrogen B-Chemical 0 0.9998229
, O 0 0.00066540734
and O 0 0.00015773169
the O 0 9.6841126e-05
presence O 0 0.00010317853
or O 0 9.4241106e-05
absence O 0 8.204512e-05
of O 0 0.00021168019
prothrombotic O 0 0.69698066
mutations O 0 0.00017910702
METHODS O 0 0.00025895325
: O 0 0.00013947213
In O 0 4.712203e-05
a O 0 0.00013293137
nationwide O 0 0.00022970288
, O 0 0.0002999084
population O 0 0.00030925305
- O 0 0.0013698263
based O 0 0.00012862684
, O 0 0.0002821513
case O 0 0.00019935887
- O 0 0.001062686
control O 0 0.00014710402
study O 0 0.00017020623
, O 0 0.00018971579
we O 0 5.3878462e-05
identified O 0 7.2142124e-05
and O 0 0.00013744178
enrolled O 0 0.00032915143
248 O 0 0.00053404906
women O 0 0.00035302123
18 O 0 0.00010519658
through O 0 7.063981e-05
49 O 0 0.00013355924
years O 0 0.00010868807
of O 0 0.00010038168
age O 0 0.00019605848
who O 0 0.00017181512
had O 0 0.00010434499
had O 0 0.000111637426
a O 0 0.00019041586
first O 0 0.00013200259
myocardial B-Disease 0 0.99966645
infarction I-Disease 0 0.9999869
between O 0 0.00012409572
1990 O 0 0.0003302459
and O 0 0.000117846575
1995 O 0 0.00032661256
and O 0 0.00014345451
925 O 0 0.0014622874
control O 0 0.00013498054
women O 0 0.0005449057
who O 0 0.0001913417
had O 0 0.00010175589
not O 0 9.529653e-05
had O 0 0.00014714805
a O 0 0.00054550375
myocardial B-Disease 0 0.9998722
infarction I-Disease 0 0.99999464
and O 0 0.00017975681
who O 0 0.00013993158
were O 0 5.7308407e-05
matched O 0 5.0068753e-05
for O 0 5.9337697e-05
age O 0 0.00016771334
, O 0 0.0001851062
calendar O 0 9.126099e-05
year O 0 8.854551e-05
of O 0 0.00011880688
the O 0 0.00012623999
index O 0 0.0002823973
event O 0 0.00047382043
, O 0 0.00063833693
and O 0 0.0005204052
area O 0 0.00087593327
of O 0 0.0010756006
residence O 0 0.0036887059
. O 0 0.0032068654

Subjects O 0 0.0046132295
supplied O 0 0.0033479305
information O 0 0.001257604
on O 0 0.0009149131
oral B-Chemical 0 0.0076646446
- I-Chemical 0 0.004817005
contraceptive I-Chemical 0 0.0045806407
use O 0 0.00066229526
and O 0 0.0007918869
major O 0 0.0010519124
cardiovascular O 0 0.20894952
risk O 0 0.010650149
factors O 0 0.0045934496
. O 0 0.004625576

An O 0 0.0040588267
analysis O 0 0.0026365397
for O 0 0.0022337278
factor O 0 0.3624661
V O 0 0.99629956
Leiden O 0 0.9990897
and O 0 0.0017068424
the O 0 0.0016187392
G20210A O 0 0.999979
mutation O 0 0.00061161624
in O 0 0.00028413816
the O 0 0.00027581112
prothrombin O 0 0.73630524
gene O 0 0.0001620985
was O 0 0.00014172359
conducted O 0 0.00017839082
in O 0 0.00015194417
217 O 0 0.00061250146
patients O 0 0.00028848925
and O 0 0.00016170298
763 O 0 0.0008273279
controls O 0 0.00017440609
RESULTS O 0 0.00021295837
: O 0 0.00015572096
The O 0 4.444526e-05
odds O 0 0.00011377511
ratio O 0 0.00013577742
for O 0 0.0001586002
myocardial B-Disease 0 0.9997011
infarction I-Disease 0 0.99999285
among O 0 0.0002548783
women O 0 0.00057499117
who O 0 0.00013250184
used O 0 6.3352025e-05
any O 0 6.959221e-05
type O 0 0.00017297121
of O 0 0.00011774617
combined O 0 0.00019053009
oral B-Chemical 0 0.0031027736
contraceptive I-Chemical 0 0.0033627315
, O 0 0.00024155891
as O 0 9.325481e-05
compared O 0 7.4768475e-05
with O 0 0.00014607873
nonusers O 0 0.004868198
, O 0 0.00036446567
was O 0 0.00014359877
2 O 0 0.00016012936
. O 0 0.00012735014
0 O 0 0.00017554393
( O 0 0.00022369408
95 O 0 0.0002336185
percent O 0 0.00012878713
confidence O 0 0.00038275376
interval O 0 0.0002409714
, O 0 0.00038240707
1 O 0 0.00027256022
. O 0 0.0002340084
5 O 0 0.00024145162
to O 0 0.0002762111
2 O 0 0.00051329995
. O 0 0.0006195522
8 O 0 0.00096847035
) O 0 0.0029936284
. O 0 0.0033494188

The O 0 0.0020278955
adjusted O 0 0.001424001
odds O 0 0.0017308447
ratio O 0 0.0012126755
was O 0 0.00075322395
2 O 0 0.0006504485
. O 0 0.00043438878
5 O 0 0.00033111064
( O 0 0.0004619289
95 O 0 0.000425913
percent O 0 0.0002126644
confidence O 0 0.0004919164
interval O 0 0.00028279203
, O 0 0.00038744404
1 O 0 0.00022896031
. O 0 0.0001604422
5 O 0 0.00012489037
to O 0 0.00010223168
4 O 0 0.000112359914
. O 0 0.00012301041
1 O 0 0.00014133303
) O 0 0.00025361925
among O 0 0.00015106384
women O 0 0.00041225832
who O 0 0.0001729346
used O 0 9.9974925e-05
second O 0 0.00014160878
- O 0 0.0012785858
generation O 0 0.00019872046
oral B-Chemical 0 0.0067632548
contraceptives I-Chemical 0 0.67063516
and O 0 0.0002264145
1 O 0 0.00018797748
. O 0 0.00012656904
3 O 0 0.000107547516
( O 0 0.00019520437
95 O 0 0.00020104366
percent O 0 0.000105442734
confidence O 0 0.00029990953
interval O 0 0.00017141472
, O 0 0.00024591378
0 O 0 0.00018943202
. O 0 0.00011909193
7 O 0 8.955021e-05
to O 0 9.454697e-05
2 O 0 0.00014193509
. O 0 0.00012105805
5 O 0 0.00011989615
) O 0 0.00026044084
among O 0 0.00016699986
those O 0 0.00020841039
who O 0 0.00025826684
used O 0 0.00020139916
third O 0 0.00039895935
- O 0 0.0024350523
generation O 0 0.00085115747
oral B-Chemical 0 0.019140294
contraceptives I-Chemical 0 0.81461644
. O 0 0.0038228594

Among O 0 0.004032583
women O 0 0.005361661
who O 0 0.0019663116
used O 0 0.0009718969
oral B-Chemical 0 0.00769769
contraceptives I-Chemical 0 0.6715056
, O 0 0.0009961108
the O 0 0.00030305024
odds O 0 0.00044662858
ratio O 0 0.00035975376
was O 0 0.0002579543
2 O 0 0.00026463848
. O 0 0.00019740776
1 O 0 0.00020124942
( O 0 0.00026505612
95 O 0 0.00025706823
percent O 0 0.00013252598
confidence O 0 0.00035428803
interval O 0 0.00020635144
, O 0 0.00029754455
1 O 0 0.00018071887
. O 0 0.00012933438
5 O 0 0.000103447
to O 0 8.6354274e-05
3 O 0 9.894494e-05
. O 0 0.00010834112
0 O 0 0.00015560487
) O 0 0.00024095809
for O 0 9.0374284e-05
those O 0 0.00015126087
without O 0 0.00017448026
a O 0 0.00046503305
prothrombotic O 0 0.87320364
mutation O 0 0.00024769627
and O 0 0.00018968107
1 O 0 0.00017773038
. O 0 0.000119218734
9 O 0 0.00010251234
( O 0 0.00018117401
95 O 0 0.00018862938
percent O 0 9.833017e-05
confidence O 0 0.00028550567
interval O 0 0.00016077192
, O 0 0.00022931882
0 O 0 0.0001737435
. O 0 0.00010578737
6 O 0 7.319535e-05
to O 0 8.1361824e-05
5 O 0 0.000102188314
. O 0 0.00010106438
5 O 0 9.983249e-05
) O 0 0.0002074722
for O 0 8.0261256e-05
those O 0 0.00012888294
with O 0 0.00013709569
a O 0 0.00020927402
mutation O 0 0.00018802601
CONCLUSIONS O 0 0.011692469
: O 0 0.0003048483
The O 0 7.403359e-05
risk O 0 0.0008452434
of O 0 0.00040403946
myocardial B-Disease 0 0.9998859
infarction I-Disease 0 0.9999944
was O 0 0.00017451338
increased O 0 0.00017697987
among O 0 0.00016615726
women O 0 0.0005245339
who O 0 0.00021062001
used O 0 0.00014825349
second O 0 0.00026229632
- O 0 0.0021071928
generation O 0 0.0006990097
oral B-Chemical 0 0.020167809
contraceptives I-Chemical 0 0.82000273
. O 0 0.0033548353

The O 0 0.0017653644
results O 0 0.0012569401
with O 0 0.0010328848
respect O 0 0.00057111337
to O 0 0.00039891902
the O 0 0.0002750732
use O 0 0.00023211469
of O 0 0.00027085797
third O 0 0.00031102297
- O 0 0.001657436
generation O 0 0.00024269149
oral B-Chemical 0 0.003562221
contraceptives I-Chemical 0 0.51835763
were O 0 0.00016269342
inconclusive O 0 0.00042200187
but O 0 0.00016118545
suggested O 0 9.4688534e-05
that O 0 8.7325105e-05
the O 0 0.00011966143
risk O 0 0.0010593089
was O 0 0.0001220954
lower O 0 0.00015370507
than O 0 0.00010601813
the O 0 0.00011917587
risk O 0 0.000981806
associated O 0 0.00022242717
with O 0 0.0002598842
second O 0 0.00033302367
- O 0 0.002679642
generation O 0 0.00072205905
oral B-Chemical 0 0.019535147
contraceptives I-Chemical 0 0.80610645
. O 0 0.00331582

The O 0 0.0026887807
risk O 0 0.009215694
of O 0 0.0035277838
myocardial B-Disease 0 0.9995609
infarction I-Disease 0 0.9999758
was O 0 0.0005200866
similar O 0 0.00018573862
among O 0 0.00026753533
women O 0 0.0006691266
who O 0 0.0002664502
used O 0 0.00016515376
oral B-Chemical 0 0.0023295505
contraceptives I-Chemical 0 0.17244612
whether O 0 8.648438e-05
or O 0 0.00020150385
not O 0 0.00023928839
they O 0 0.00033246476
had O 0 0.0005589973
a O 0 0.0015487125
prothrombotic O 0 0.91439164
mutation O 0 0.002203611
. O 0 0.003014631

End B-Disease 0 0.01863472
- I-Disease 0 0.033018664
stage I-Disease 0 0.020567559
renal I-Disease 0 0.9987134
disease I-Disease 0 0.9973139
( O 0 0.0072058537
ESRD B-Disease 2 0.9999192
) O 0 0.0012109862
after O 0 0.00016888158
orthotopic O 0 0.0015933824
liver O 0 0.003531992
transplantation O 0 0.00032244847
( O 0 0.00034240575
OLTX O 0 0.0022313157
) O 0 0.000320786
using O 0 0.00013992237
calcineurin O 0 0.0009542225
- O 0 0.0010640369
based O 0 0.00019418445
immunotherapy O 0 0.00052420044
: O 0 0.00074663066
risk O 0 0.0018050057
of O 0 0.00056733325
development O 0 0.000879988
and O 0 0.0010293219
treatment O 0 0.0015532456
. O 0 0.0027966641

BACKGROUND O 0 0.013650728
: O 0 0.0036562646
The O 0 0.00087886554
calcineurin O 0 0.0030400497
inhibitors O 0 0.0028663764
cyclosporine B-Chemical 1 0.99997544
and O 0 0.002380675
tacrolimus B-Chemical 0 0.9999602
are O 0 0.0004624572
both O 0 0.00040113236
known O 0 0.00053438055
to O 0 0.0007260771
be O 0 0.0014961432
nephrotoxic B-Disease 0 0.99593157
. O 0 0.004481157

Their O 0 0.0049319835
use O 0 0.0019237429
in O 0 0.0015560278
orthotopic O 0 0.007690212
liver O 0 0.017238397
transplantation O 0 0.0012734273
( O 0 0.0012920253
OLTX O 0 0.0072496324
) O 0 0.0010902004
has O 0 0.0003826346
dramatically O 0 0.0006979256
improved O 0 0.001361702
success O 0 0.0022719295
rates O 0 0.0027688015
. O 0 0.004283223

Recently O 0 0.0040651597
, O 0 0.0048197904
however O 0 0.0022055053
, O 0 0.0018696595
we O 0 0.0004529853
have O 0 0.0004534275
had O 0 0.00038478422
an O 0 0.00032157634
increase O 0 0.00021378804
of O 0 0.00024266558
patients O 0 0.00045678008
who O 0 0.00023634396
are O 0 0.00010742821
presenting O 0 0.00024608054
after O 0 8.4626525e-05
OLTX O 0 0.0014106353
with O 0 0.00014909999
end B-Disease 0 0.00015566588
- I-Disease 0 0.0026321397
stage I-Disease 0 0.0046834364
renal I-Disease 0 0.99936634
disease I-Disease 0 0.9978537
( O 0 0.010550061
ESRD B-Disease 2 0.9999021
) O 0 0.0072332565
. O 0 0.0032862485

This O 0 0.005342713
retrospective O 0 0.008225316
study O 0 0.0015567556
examines O 0 0.0009691645
the O 0 0.00050994067
incidence O 0 0.0007836497
and O 0 0.0003875707
treatment O 0 0.00035586025
of O 0 0.0005901415
ESRD B-Disease 2 0.99994886
and O 0 0.00062972977
chronic B-Disease 0 0.3770729
renal I-Disease 0 0.9605706
failure I-Disease 0 0.6718382
( O 0 0.0025471346
CRF B-Disease 0 0.99968266
) O 0 0.0017276576
in O 0 0.0007392188
OLTX O 0 0.019636324
patients O 0 0.0024164221
. O 0 0.002494496

METHODS O 0 0.0039733453
: O 0 0.0029387453
Patients O 0 0.0012945601
receiving O 0 0.00079912087
an O 0 0.000782571
OLTX O 0 0.004487524
only O 0 0.0004447694
from O 0 0.00032673683
June O 0 0.0003270485
1985 O 0 0.0005464564
through O 0 0.0001968287
December O 0 0.00019333683
of O 0 0.00021143329
1994 O 0 0.00052402663
who O 0 0.00026578925
survived O 0 0.00020640178
6 O 0 9.4137366e-05
months O 0 6.804067e-05
postoperatively O 0 0.00015558516
were O 0 0.0001776887
studied O 0 0.00037071685
( O 0 0.00070468395
n O 0 0.00080722506
= O 0 0.00257712
834 O 0 0.0060909134
) O 0 0.0041175205
. O 0 0.0038371412

Our O 0 0.003341706
prospectively O 0 0.0035768051
collected O 0 0.0020347175
database O 0 0.0017001088
was O 0 0.0013086881
the O 0 0.0011447056
source O 0 0.0013431663
of O 0 0.002274434
information O 0 0.0033722282
. O 0 0.0057288585

Patients O 0 0.003942686
were O 0 0.0013459545
divided O 0 0.00095601607
into O 0 0.0004119806
three O 0 0.00028429859
groups O 0 0.00060456496
: O 0 0.0009868057
Controls O 0 0.0011243322
, O 0 0.0007023089
no O 0 0.0005326985
CRF B-Disease 0 0.9996269
or O 0 0.0006897186
ESRD B-Disease 2 0.9999119
, O 0 0.0006087517
n O 0 0.0003274556
= O 0 0.0008494148
748 O 0 0.0013890034
; O 0 0.0010049936
CRF B-Disease 0 0.99959046
, O 0 0.00062340405
sustained O 0 0.00057162944
serum O 0 0.07299211
creatinine B-Chemical 0 0.99616265
> O 0 0.00065678335
2 O 0 0.00020347626
. O 0 0.00014603778
5 O 0 0.00015833217
mg O 0 0.0013242465
/ O 0 0.00091014535
dl O 0 0.0013683124
, O 0 0.0003941878
n O 0 0.00031958663
= O 0 0.0007355609
41 O 0 0.00058716006
; O 0 0.0007359973
and O 0 0.0007287011
ESRD B-Disease 2 0.99972445
, O 0 0.0015699107
n O 0 0.0011415216
= O 0 0.0026197508
45 O 0 0.0018434427
. O 0 0.002956179

Groups O 0 0.008170851
were O 0 0.0013622442
compared O 0 0.0006275578
for O 0 0.00043710164
preoperative O 0 0.0007193537
laboratory O 0 0.00041570154
variables O 0 0.00036422306
, O 0 0.00047152306
diagnosis O 0 0.0004121764
, O 0 0.00033301988
postoperative O 0 0.0002514904
variables O 0 0.00020844696
, O 0 0.00030746975
survival O 0 0.00037638374
, O 0 0.00038626938
type O 0 0.00045498685
of O 0 0.00052664574
ESRD B-Disease 2 0.9999629
therapy O 0 0.00069512246
, O 0 0.000421596
and O 0 0.00028403717
survival O 0 0.0005914974
from O 0 0.00041699567
onset O 0 0.0011305248
of O 0 0.0020910227
ESRD B-Disease 2 0.9998294
. O 0 0.004887052

RESULTS O 0 0.004225468
: O 0 0.0023687256
At O 0 0.00047678352
13 O 0 0.00083325326
years O 0 0.00069881923
after O 0 0.0003643654
OLTX O 0 0.0035686127
, O 0 0.00063359167
the O 0 0.00027691404
incidence O 0 0.00055085757
of O 0 0.00043083378
severe O 0 0.020604068
renal B-Disease 0 0.99936324
dysfunction I-Disease 0 0.99824595
was O 0 0.0002890958
18 O 0 0.0002193385
. O 0 0.00015857133
1 O 0 0.00019341333
% O 0 0.0004092553
( O 0 0.0006961852
CRF B-Disease 0 0.9991716
8 O 0 0.00024514104
. O 0 0.00017897795
6 O 0 0.00015724904
% O 0 0.00045434386
and O 0 0.00054940826
ESRD B-Disease 2 0.9997807
9 O 0 0.0005696035
. O 0 0.000531596
5 O 0 0.00068430405
% O 0 0.0018059526
) O 0 0.0035097052
. O 0 0.0036056018

Compared O 0 0.002145303
with O 0 0.0017367954
control O 0 0.0014484795
patients O 0 0.0025825347
, O 0 0.0031484284
CRF B-Disease 0 0.999726
and O 0 0.0014673691
ESRD B-Disease 2 0.99995184
patients O 0 0.0007637419
had O 0 0.00015098059
higher O 0 0.00015561808
preoperative O 0 0.00053694565
serum O 0 0.033279706
creatinine B-Chemical 0 0.99198544
levels O 0 0.00014168344
, O 0 0.00022969126
a O 0 0.00014395535
greater O 0 0.00010931057
percentage O 0 6.387761e-05
of O 0 0.00010879675
patients O 0 0.0002808497
with O 0 0.00023779416
hepatorenal B-Disease 0 0.9999838
syndrome I-Disease 0 0.9915631
, O 0 0.00025616662
higher O 0 8.5985565e-05
percentage O 0 4.5671914e-05
requirement O 0 3.401379e-05
for O 0 5.4413922e-05
dialysis O 0 0.00023509524
in O 0 6.395892e-05
the O 0 5.043064e-05
first O 0 3.850814e-05
3 O 0 4.9636754e-05
months O 0 3.355216e-05
postoperatively O 0 8.644357e-05
, O 0 0.00017080664
and O 0 0.00015194954
a O 0 0.00028315434
higher O 0 0.00032471278
1 O 0 0.0004898221
- O 0 0.0019323177
year O 0 0.0006804762
serum O 0 0.034815002
creatinine B-Chemical 0 0.9940235
. O 0 0.0039285365

Multivariate O 0 0.0022214476
stepwise O 0 0.0013129615
logistic O 0 0.00067452824
regression O 0 0.00060477684
analysis O 0 0.00029618238
using O 0 0.00017038711
preoperative O 0 0.00031267124
and O 0 0.00015534737
postoperative O 0 0.00017969785
variables O 0 0.00012699193
identified O 0 6.9695685e-05
that O 0 8.0556e-05
an O 0 0.00013392961
increase O 0 0.00012067633
of O 0 0.00020429895
serum O 0 0.091953844
creatinine B-Chemical 0 0.9952779
compared O 0 8.887373e-05
with O 0 0.00010057522
average O 0 7.54499e-05
at O 0 6.9485985e-05
1 O 0 0.0001052052
year O 0 7.843535e-05
, O 0 0.00012733339
3 O 0 6.115931e-05
months O 0 3.950474e-05
, O 0 0.00011364088
and O 0 7.164672e-05
4 O 0 5.14719e-05
weeks O 0 3.3968634e-05
postoperatively O 0 6.806948e-05
were O 0 5.764797e-05
independent O 0 5.8328525e-05
risk O 0 0.00040014237
factors O 0 0.00020073183
for O 0 9.136957e-05
the O 0 0.000104049286
development O 0 0.00020782718
of O 0 0.0003574741
CRF B-Disease 0 0.9999386
or O 0 0.00037743046
ESRD B-Disease 2 0.99997115
with O 0 0.00016914427
odds O 0 0.00018218775
ratios O 0 0.000120861856
of O 0 0.00014173101
2 O 0 0.00015416025
. O 0 0.00011671283
6 O 0 9.837312e-05
, O 0 0.00024281903
2 O 0 0.0001928002
. O 0 0.00018261578
2 O 0 0.00024137936
, O 0 0.00042686332
and O 0 0.00035440543
1 O 0 0.0004609966
. O 0 0.0004426807
6 O 0 0.00049975986
, O 0 0.0015293086
respectively O 0 0.0026979088
. O 0 0.0035651876

Overall O 0 0.0032916884
survival O 0 0.0027556887
from O 0 0.0009479216
the O 0 0.0005673408
time O 0 0.00039361557
of O 0 0.0006062224
OLTX O 0 0.015305815
was O 0 0.00025439082
not O 0 0.000174725
significantly O 0 0.0001932176
different O 0 0.00010943478
among O 0 0.00018738765
groups O 0 0.0002703732
, O 0 0.00037314318
but O 0 0.00019584438
by O 0 0.00013793516
year O 0 0.00012657762
13 O 0 0.0001396249
, O 0 0.0001798614
the O 0 8.817771e-05
survival O 0 0.00020633293
of O 0 0.00012434187
the O 0 0.00010989606
patients O 0 0.00035366055
who O 0 0.00025934316
had O 0 0.00027227867
ESRD B-Disease 2 0.9999715
was O 0 0.00017862656
only O 0 0.0001463799
28 O 0 0.00013091491
. O 0 0.000104350955
2 O 0 0.00011696719
% O 0 0.00019021389
compared O 0 9.086762e-05
with O 0 0.00017753102
54 O 0 0.00034864663
. O 0 0.00019434206
6 O 0 0.0001692798
% O 0 0.00043266878
in O 0 0.00030829222
the O 0 0.00042081156
control O 0 0.0008891903
group O 0 0.002328293
. O 0 0.0032631024

Patients O 0 0.006683999
developing O 0 0.007444298
ESRD B-Disease 2 0.9997061
had O 0 0.0012802095
a O 0 0.000896492
6 O 0 0.000391092
- O 0 0.0011425811
year O 0 0.00021892521
survival O 0 0.00029369327
after O 0 0.00011208576
onset O 0 0.00030776593
of O 0 0.00038430182
ESRD B-Disease 2 0.99992776
of O 0 0.00030555684
27 O 0 0.00025440828
% O 0 0.00022528808
for O 0 7.013024e-05
the O 0 7.40033e-05
patients O 0 0.00015709197
receiving O 0 0.00011105929
hemodialysis O 0 0.0013740492
versus O 0 9.498752e-05
71 O 0 0.00020086698
. O 0 9.2592614e-05
4 O 0 7.760298e-05
% O 0 0.00016202463
for O 0 7.451692e-05
the O 0 0.000108561915
patients O 0 0.00041281624
developing O 0 0.0009473027
ESRD B-Disease 2 0.99996555
who O 0 0.0006095718
subsequently O 0 0.00032470658
received O 0 0.0004286197
kidney O 0 0.012640122
transplants O 0 0.003047619
. O 0 0.002201446

CONCLUSIONS O 0 0.022139566
: O 0 0.004775557
Patients O 0 0.001831906
who O 0 0.0010276643
are O 0 0.0004510182
more O 0 0.00055789994
than O 0 0.000322953
10 O 0 0.00030262643
years O 0 0.00032459083
post O 0 0.00028874323
- O 0 0.0015561752
OLTX O 0 0.0057810387
have O 0 0.0005087092
CRF B-Disease 0 0.9993647
and O 0 0.0011802146
ESRD B-Disease 2 0.999851
at O 0 0.0005685675
a O 0 0.0010164301
high O 0 0.0013234717
rate O 0 0.0025671632
. O 0 0.0033944515

The O 0 0.002280313
development O 0 0.0025182455
of O 0 0.0026392855
ESRD B-Disease 2 0.99977046
decreases O 0 0.001316929
survival O 0 0.0013379289
, O 0 0.0008619049
particularly O 0 0.00044389413
in O 0 0.00033409602
those O 0 0.00043316834
patients O 0 0.00075609057
treated O 0 0.0008505941
with O 0 0.00082755846
dialysis O 0 0.002715267
only O 0 0.0018545965
. O 0 0.0030704176

Patients O 0 0.0050697834
who O 0 0.002911623
develop O 0 0.0021824974
ESRD B-Disease 2 0.99967325
have O 0 0.00058492966
a O 0 0.00050717685
higher O 0 0.00030944237
preoperative O 0 0.0005114621
and O 0 0.0002608842
1 O 0 0.00029050547
- O 0 0.0009999974
year O 0 0.0002313348
serum O 0 0.0076687983
creatinine B-Chemical 0 0.984539
and O 0 0.00029789624
are O 0 0.00019226655
more O 0 0.00032221279
likely O 0 0.00019967182
to O 0 0.00038402708
have O 0 0.0009008422
hepatorenal B-Disease 0 0.9998048
syndrome I-Disease 0 0.9896734
. O 0 0.004039585

However O 0 0.0031822943
, O 0 0.0036969502
an O 0 0.00152025
increase O 0 0.0008599299
of O 0 0.00097385544
serum O 0 0.07785482
creatinine B-Chemical 0 0.98244447
at O 0 0.00020771228
various O 0 0.00015676815
times O 0 0.00010722413
postoperatively O 0 0.00017521183
is O 0 0.00013046601
more O 0 0.000238541
predictive O 0 0.00039870536
of O 0 0.000291474
the O 0 0.0002993973
development O 0 0.00066931633
of O 0 0.0013708272
CRF B-Disease 0 0.9997819
or O 0 0.0030393072
ESRD B-Disease 2 0.9998518
. O 0 0.0048801973

New O 0 0.0046368344
strategies O 0 0.0018857402
for O 0 0.0012353642
long O 0 0.0014195037
- O 0 0.0037716702
term O 0 0.0010392716
immunosuppression O 0 0.007980018
may O 0 0.000512162
be O 0 0.0004570921
needed O 0 0.0003968464
to O 0 0.0005228036
decrease O 0 0.0008962995
this O 0 0.0013895094
complication O 0 0.010077059
. O 0 0.0037478325

Epileptic B-Disease 0 0.99985087
seizures I-Disease 0 0.9999522
following O 0 0.0014613784
cortical O 0 0.002408047
application O 0 0.00072532566
of O 0 0.00090942846
fibrin O 0 0.21790476
sealants O 0 0.35074794
containing O 0 0.00195522
tranexamic B-Chemical 0 0.9998325
acid I-Chemical 0 0.94901603
in O 0 0.0021981115
rats O 0 0.0037901646
. O 0 0.0035667191

BACKGROUND O 0 0.022341914
: O 0 0.007951363
Fibrin O 0 0.020336628
sealants O 0 0.0389493
( O 0 0.0029242698
FS O 0 0.016149903
) O 0 0.0016424888
derived O 0 0.0003859486
from O 0 0.00044648003
human O 0 0.0006589455
plasma O 0 0.004318455
are O 0 0.00045949555
frequently O 0 0.00056598865
used O 0 0.0006407162
in O 0 0.0011938132
neurosurgery O 0 0.005745164
. O 0 0.0033442334

In O 0 0.002108982
order O 0 0.0013499901
to O 0 0.001106838
increase O 0 0.0010364151
clot O 0 0.02285007
stability O 0 0.00062705384
, O 0 0.0012984409
FS O 0 0.009428204
typically O 0 0.0006146327
contain O 0 0.00037190446
aprotinin O 0 0.9726873
, O 0 0.0014723234
a O 0 0.0014338605
natural O 0 0.003289549
fibrinolysis O 0 0.9989384
inhibitor O 0 0.014031734
. O 0 0.0044831634

Recently O 0 0.003715734
, O 0 0.0046985215
synthetic O 0 0.0026315236
fibrinolysis O 0 0.9980211
inhibitors O 0 0.0023552643
such O 0 0.00096924306
as O 0 0.0021174971
tranexamic B-Chemical 0 0.99994385
acid I-Chemical 0 0.995799
( O 0 0.027153233
tAMCA B-Chemical 1 0.9992606
) O 0 0.0015283085
have O 0 0.0002709804
been O 0 0.00028025292
considered O 0 0.00034900662
as O 0 0.00045101455
substitutes O 0 0.0011427756
for O 0 0.0011150771
aprotinin O 0 0.98452526
. O 0 0.004060022

However O 0 0.0058004255
, O 0 0.012861748
tAMCA B-Chemical 1 0.9929636
has O 0 0.0019213305
been O 0 0.0015563017
shown O 0 0.00089880265
to O 0 0.0016156775
cause O 0 0.0065082423
epileptic B-Disease 0 0.9999614
seizures I-Disease 0 0.9999682
. O 0 0.009356823

We O 0 0.0028756612
wanted O 0 0.0024891542
to O 0 0.0012006853
study O 0 0.0010299017
whether O 0 0.00048031256
tAMCA B-Chemical 1 0.98455054
retains O 0 0.000844479
its O 0 0.001709368
convulsive B-Disease 0 0.99957484
action O 0 0.00056481897
if O 0 0.00036461855
incorporated O 0 0.00058279943
into O 0 0.0006468472
a O 0 0.0023357025
FS O 0 0.02882327
. O 0 0.004033872

METHOD O 0 0.012698533
: O 0 0.0057266047
FS O 0 0.015849674
containing O 0 0.0012810712
aprotinin O 0 0.9679068
or O 0 0.00048467718
different O 0 0.00029128342
concentrations O 0 0.00070849655
of O 0 0.00067833945
tAMCA B-Chemical 1 0.9963296
( O 0 0.00079811143
0 O 0 0.00033400906
. O 0 0.00019533095
5 O 0 0.0001876789
- O 0 0.00069451664
47 O 0 0.00028118808
. O 0 0.00015636119
5 O 0 0.0001649613
mg O 0 0.0013271127
/ O 0 0.00085381704
ml O 0 0.0008373816
) O 0 0.00044420056
were O 0 0.00014168615
applied O 0 0.00014230791
to O 0 0.00015707189
the O 0 0.00024746635
pial O 0 0.9647195
surface O 0 0.000633291
of O 0 0.00032819825
the O 0 0.000320323
cortex O 0 0.0042862357
of O 0 0.0006731267
anaesthetized O 0 0.0049039954
rats O 0 0.0018836943
. O 0 0.002279608

The O 0 0.0017414461
response O 0 0.0012825532
of O 0 0.00094582443
the O 0 0.0004944785
animals O 0 0.00030903556
was O 0 0.0002711792
evaluated O 0 0.00021041831
using O 0 0.00016563285
electroencephalography O 0 0.002248118
and O 0 0.00015191273
by O 0 0.0001123447
monitoring O 0 0.000110767185
the O 0 0.00010916609
clinical O 0 0.00038875782
behaviour O 0 0.00028849172
during O 0 0.00014293852
and O 0 0.00022786009
after O 0 0.00017954562
recovery O 0 0.0005691254
from O 0 0.00068306836
anaesthesia O 0 0.005301115
. O 0 0.0023580247

FINDINGS O 0 0.010428687
: O 0 0.0064305337
FS O 0 0.03124293
containing O 0 0.0019073072
tAMCA B-Chemical 1 0.99683124
caused O 0 0.0016610142
paroxysmal O 0 0.996944
brain O 0 0.002574954
activity O 0 0.000277676
which O 0 0.00037157245
was O 0 0.0003154649
associated O 0 0.00041993003
with O 0 0.0005911898
distinct O 0 0.0008756988
convulsive B-Disease 0 0.9991161
behaviours O 0 0.0041006557
. O 0 0.0032520955

The O 0 0.0026646382
degree O 0 0.0031899863
of O 0 0.002309827
these O 0 0.0025273075
seizures B-Disease 0 0.99985754
increased O 0 0.0019849562
with O 0 0.0010992128
increasing O 0 0.0011303945
concentration O 0 0.0025269922
of O 0 0.003113796
tAMCA B-Chemical 1 0.99394834
. O 0 0.005852016

Thus O 0 0.0032676575
, O 0 0.0056884335
FS O 0 0.017006444
containing O 0 0.0011841203
47 O 0 0.0014593084
. O 0 0.0006278851
5 O 0 0.0005022194
mg O 0 0.003497303
/ O 0 0.0022010657
ml O 0 0.004276952
tAMCA B-Chemical 1 0.9956014
evoked O 0 0.0046223826
generalized B-Disease 0 0.7932601
seizures I-Disease 0 0.99999607
in O 0 0.00026245895
all O 0 0.00012895584
tested O 0 0.00010613344
rats O 0 0.00020140473
( O 0 0.00019463434
n O 0 0.00013711439
= O 0 0.00028142115
6 O 0 7.7733486e-05
) O 0 0.00019144498
while O 0 8.673513e-05
the O 0 8.739476e-05
lowest O 0 0.00018393499
concentration O 0 0.00035949238
of O 0 0.00036525034
tAMCA B-Chemical 1 0.9977575
( O 0 0.00048463215
0 O 0 0.00019475073
. O 0 0.00011274394
5 O 0 0.000115473085
mg O 0 0.0011489858
/ O 0 0.0006556663
ml O 0 0.00063720765
) O 0 0.000326442
only O 0 0.0001281297
evoked O 0 0.00027389007
brief O 0 0.00014077366
episodes O 0 0.00033995043
of O 0 0.0002765178
jerk O 0 0.86956286
- O 0 0.012656926
correlated O 0 0.00047334237
convulsive B-Disease 0 0.99958426
potentials O 0 0.0011381003
in O 0 0.00030171344
1 O 0 0.000402627
of O 0 0.0004868574
6 O 0 0.0005819982
rats O 0 0.0016521903
. O 0 0.0024810492

In O 0 0.0028420552
contrast O 0 0.0037563986
, O 0 0.0046739657
FS O 0 0.039873444
containing O 0 0.001842234
aprotinin O 0 0.99564445
did O 0 0.0013436901
not O 0 0.00088137644
evoke O 0 0.0013086868
any O 0 0.0013508737
paroxysmal O 0 0.935548
activity O 0 0.0018551562
. O 0 0.0037129212

INTERPRETATION O 0 0.05901629
: O 0 0.18469708
Tranexamic B-Chemical 0 0.9992605
acid I-Chemical 0 0.97728306
retains O 0 0.0033676126
its O 0 0.00569248
convulsive B-Disease 0 0.9992644
action O 0 0.0023260466
within O 0 0.0016625046
FS O 0 0.022635452
. O 0 0.0055678356

Thus O 0 0.0024777032
, O 0 0.0033093165
use O 0 0.0012916801
of O 0 0.0013518429
FS O 0 0.026359307
containing O 0 0.0008272424
tAMCA B-Chemical 1 0.9850915
for O 0 0.00030224203
surgery O 0 0.00033122086
within O 0 9.556652e-05
or O 0 0.00013960253
close O 0 0.00017044513
to O 0 0.00017986877
the O 0 0.00023016107
CNS O 0 0.0025363714
may O 0 0.00019730258
pose O 0 0.000290985
a O 0 0.00046576327
substantial O 0 0.00048482156
risk O 0 0.002581523
to O 0 0.0005644329
the O 0 0.0007771478
patient O 0 0.0017060927
. O 0 0.0025187102

Sequential O 0 0.0032440724
observations O 0 0.0022238058
of O 0 0.0025412827
exencephaly B-Disease 0 0.9990701
and O 0 0.0010072096
subsequent O 0 0.00045603068
morphological O 0 0.0008630895
changes O 0 0.00035317754
by O 0 0.00024110079
mouse O 0 0.00020985807
exo O 0 0.0015031262
utero O 0 0.00040435736
development O 0 0.00021978692
system O 0 0.00019168043
: O 0 0.00035464743
analysis O 0 0.00014572646
of O 0 0.00015220608
the O 0 0.00012975487
mechanism O 0 0.00014046913
of O 0 0.00034916538
transformation O 0 0.000838171
from O 0 0.00076743355
exencephaly B-Disease 0 0.99937445
to O 0 0.0020067673
anencephaly B-Disease 0 0.9996412
. O 0 0.004719771

Anencephaly B-Disease 0 0.98431486
has O 0 0.0020442284
been O 0 0.0012761075
suggested O 0 0.000707728
to O 0 0.0005597405
develop O 0 0.000604186
from O 0 0.0005980859
exencephaly B-Disease 0 0.9995135
; O 0 0.0011017969
however O 0 0.00034139722
, O 0 0.00036326266
there O 0 0.00013338287
is O 0 0.0001188691
little O 0 0.00012910152
direct O 0 9.1078335e-05
experimental O 0 0.00014629759
evidence O 0 0.000113754395
to O 0 0.00012272874
support O 0 0.00015303981
this O 0 0.00022217451
, O 0 0.00037633083
and O 0 0.00021066378
the O 0 0.000168457
mechanism O 0 0.00018642971
of O 0 0.0004548576
transformation O 0 0.0008958248
remains O 0 0.00054458453
unclear O 0 0.0010500501
. O 0 0.0027604417

We O 0 0.0023393678
examined O 0 0.0013570556
this O 0 0.0012100092
theory O 0 0.0014620257
using O 0 0.00050308666
the O 0 0.0004327748
exo O 0 0.002838254
utero O 0 0.0006599525
development O 0 0.00029311256
system O 0 0.00018384523
that O 0 0.000103676495
allows O 0 8.624513e-05
direct O 0 8.867327e-05
and O 0 0.00013824919
sequential O 0 0.00014523361
observations O 0 0.00017113365
of O 0 0.000240742
mid O 0 0.00091569714
- O 0 0.0018639723
to O 0 0.00025954723
late O 0 0.0010087576
- O 0 0.002118233
gestation O 0 0.00070502923
mouse O 0 0.0006736693
embryos O 0 0.0015648247
. O 0 0.0030698443

We O 0 0.0029986624
observed O 0 0.0020395324
the O 0 0.001980335
exencephaly B-Disease 0 0.9986889
induced O 0 0.000974254
by O 0 0.0006606533
5 B-Chemical 0 0.00059324235
- I-Chemical 0 0.0056261155
azacytidine I-Chemical 0 0.6100576
at O 0 0.00023244756
embryonic O 0 0.0005103489
day O 0 0.00014280503
13 O 0 0.00020389904
. O 0 0.00016701325
5 O 0 0.00017632516
( O 0 0.0004296778
E13 O 0 0.009034557
. O 0 0.00020856803
5 O 0 0.00018468502
) O 0 0.00046219342
, O 0 0.00040552588
let O 0 0.0005775341
the O 0 0.00017457512
embryos O 0 0.00024282065
develop O 0 0.00026440795
exo O 0 0.0032709313
utero O 0 0.00049610186
until O 0 0.00014878796
E18 O 0 0.005060812
. O 0 0.00016305901
5 O 0 0.00013691305
, O 0 0.0002513962
and O 0 0.00021612697
re O 0 0.0010979464
- O 0 0.0014138994
observed O 0 0.00019942143
the O 0 0.00020332205
same O 0 0.00021351507
embryos O 0 0.000425014
at O 0 0.0005106121
E18 O 0 0.0066536693
. O 0 0.0010619567
5 O 0 0.0014325571
. O 0 0.002710129

We O 0 0.0034809457
confirmed O 0 0.0020767497
several O 0 0.0015130752
cases O 0 0.0025945653
of O 0 0.0018329456
transformation O 0 0.0027525965
from O 0 0.0023022695
exencephaly B-Disease 0 0.99855214
to O 0 0.0042756884
anencephaly B-Disease 0 0.9992086
. O 0 0.007882914

However O 0 0.003414683
, O 0 0.00404165
in O 0 0.0015090837
many O 0 0.0010228027
cases O 0 0.0018052291
, O 0 0.0016174389
the O 0 0.00085975835
exencephalic B-Disease 2 0.99655885
brain O 0 0.005589875
tissue O 0 0.0010191815
was O 0 0.00022646633
preserved O 0 0.00052819814
with O 0 0.00024642452
more O 0 0.0003180729
or O 0 0.00021395303
less O 0 0.0003615011
reduction O 0 0.0004170489
during O 0 0.00034374555
this O 0 0.0007172942
period O 0 0.0009532647
. O 0 0.0024429616

To O 0 0.0013359591
analyze O 0 0.00092645583
the O 0 0.0009459267
transformation O 0 0.0011684892
patterns O 0 0.00053663406
, O 0 0.00075919804
we O 0 0.00021922894
classified O 0 0.0004874936
the O 0 0.00039980267
exencephaly B-Disease 0 0.9994185
by O 0 0.00028581647
size O 0 0.00039790914
and O 0 0.00021986027
shape O 0 0.0002712314
of O 0 0.00025449417
the O 0 0.00028914682
exencephalic B-Disease 2 0.9939659
tissue O 0 0.00065549987
into O 0 8.832751e-05
several O 0 9.000155e-05
types O 0 0.00014121125
at O 0 0.00021169856
E13 O 0 0.016310642
. O 0 0.00034442017
5 O 0 0.00034962536
and O 0 0.00058459106
E18 O 0 0.005411158
. O 0 0.0010702747
5 O 0 0.001476321
. O 0 0.002811388

It O 0 0.0053810365
was O 0 0.0019011897
found O 0 0.0011741202
that O 0 0.00067907816
the O 0 0.0006328687
transformation O 0 0.0011548707
of O 0 0.0011091249
exencephalic B-Disease 2 0.9980519
tissue O 0 0.0021494727
was O 0 0.00024168655
not O 0 0.00017682773
simply O 0 0.00024626058
size O 0 0.0004977591
- O 0 0.0019308341
dependent O 0 0.00013576991
, O 0 0.00029645668
and O 0 0.00016688733
all O 0 0.0001485236
cases O 0 0.0003259926
of O 0 0.00034974804
anencephaly B-Disease 0 0.9999063
at O 0 0.00023285972
E18 O 0 0.023786161
. O 0 0.00014068307
5 O 0 9.7404125e-05
resulted O 0 8.6602886e-05
from O 0 9.8721954e-05
embryos O 0 0.0001490859
with O 0 0.00018811767
a O 0 0.00030471582
large O 0 0.00030009635
amount O 0 0.0001842253
of O 0 0.00064669433
exencephalic B-Disease 2 0.9975642
tissue O 0 0.0029058438
at O 0 0.0005278612
E13 O 0 0.025534583
. O 0 0.0009598579
5 O 0 0.0012750134
. O 0 0.0024154854

Microscopic O 0 0.0052845585
observation O 0 0.0015609732
showed O 0 0.0010053195
the O 0 0.0006811652
configuration O 0 0.00076829625
of O 0 0.0011772043
exencephaly B-Disease 0 0.99955744
at O 0 0.0005473168
E13 O 0 0.11310442
. O 0 0.00029461848
5 O 0 0.00021246151
, O 0 0.00039844358
frequent O 0 0.00045984588
hemorrhaging B-Disease 0 0.9842918
and O 0 0.00034140275
detachment O 0 0.7573997
of O 0 0.00022515752
the O 0 0.00016258455
neural O 0 0.0006670906
plate O 0 0.015441176
from O 0 0.00024508542
surface O 0 0.0010173857
ectoderm O 0 0.19276749
in O 0 0.00018469102
the O 0 0.00021823644
exencephalic B-Disease 2 0.99308324
head O 0 0.0026049935
at O 0 0.00018607615
E15 O 0 0.34958684
. O 0 0.00014219736
5 O 0 0.00010525096
, O 0 0.00016852832
and O 0 0.00010537218
multiple O 0 9.72431e-05
modes O 0 0.00011287367
of O 0 0.00019274416
reduction O 0 0.00030950113
in O 0 0.0002732573
the O 0 0.00040452043
exencephalic B-Disease 2 0.99446267
tissue O 0 0.0021821319
at O 0 0.00047149247
E18 O 0 0.006423107
. O 0 0.00089218066
5 O 0 0.0012250895
. O 0 0.002366912

From O 0 0.003064518
observations O 0 0.0020671568
of O 0 0.0016150976
the O 0 0.0011935845
vasculature O 0 0.07710759
, O 0 0.0013229039
altered O 0 0.00048337696
distribution O 0 0.00020871166
patterns O 0 0.0002908383
of O 0 0.00049512705
vessels O 0 0.03836188
were O 0 0.00039974987
identified O 0 0.00030613187
in O 0 0.0005706789
the O 0 0.00101766
exencephalic B-Disease 2 0.97575957
head O 0 0.017600449
. O 0 0.0046064467

These O 0 0.0020419874
findings O 0 0.0018890909
suggest O 0 0.0008513198
that O 0 0.0010045824
overgrowth O 0 0.043313347
of O 0 0.0009678269
the O 0 0.00085664965
exencephalic B-Disease 2 0.9980411
neural O 0 0.0025954563
tissue O 0 0.0010725571
causes O 0 0.000222097
the O 0 0.00012406376
altered O 0 0.00012849958
distribution O 0 6.0658167e-05
patterns O 0 9.249933e-05
of O 0 0.00017914151
vessels O 0 0.1336553
, O 0 0.00029792974
subsequent O 0 0.00010317459
peripheral O 0 0.0007740474
circulatory B-Disease 0 0.71355677
failure I-Disease 0 0.47600102
and O 0 0.00019292746
/ O 0 0.001498605
or O 0 0.00018477558
hemorrhaging B-Disease 0 0.98972857
in O 0 9.8384946e-05
various O 0 8.6760025e-05
parts O 0 0.00010783258
of O 0 0.00013871308
the O 0 0.00018655615
exencephalic B-Disease 2 0.9965777
head O 0 0.005395598
, O 0 0.00038222285
leading O 0 0.00013819346
to O 0 8.140808e-05
the O 0 7.252565e-05
multiple O 0 8.319553e-05
modes O 0 9.836984e-05
of O 0 0.00018425444
tissue O 0 0.00056150387
reduction O 0 0.00023990819
during O 0 0.00017412094
transformation O 0 0.00053947006
from O 0 0.0005699323
exencephaly B-Disease 0 0.9992342
to O 0 0.0017301233
anencephaly B-Disease 0 0.99965477
. O 0 0.004404671

99mTc B-Chemical 0 0.8796648
- I-Chemical 0 0.22307228
glucarate I-Chemical 0 0.9050813
for O 0 0.0014459415
detection O 0 0.0011711266
of O 0 0.0018635179
isoproterenol B-Chemical 0 0.99978274
- O 0 0.060023427
induced O 0 0.0019125649
myocardial B-Disease 0 0.99959224
infarction I-Disease 0 0.9999553
in O 0 0.0018653894
rats O 0 0.0030955856
. O 0 0.0032664258

Infarct B-Disease 0 0.99795425
- O 0 0.04920295
avid O 0 0.0074318433
radiopharmaceuticals O 0 0.004109621
are O 0 0.000563915
necessary O 0 0.00030166947
for O 0 0.0003239021
rapid O 0 0.0005205704
and O 0 0.00043765386
timely O 0 0.0005392336
diagnosis O 0 0.0010944773
of O 0 0.0011912106
acute O 0 0.9602914
myocardial B-Disease 0 0.9997533
infarction I-Disease 0 0.99997747
. O 0 0.0057946914

The O 0 0.0020008169
animal O 0 0.0016955425
model O 0 0.0010236541
used O 0 0.0007729174
to O 0 0.00064024585
produce O 0 0.0006899507
infarction B-Disease 0 0.9999162
implies O 0 0.00039259228
artery O 0 0.08947116
ligation O 0 0.00042597897
but O 0 0.00032547492
chemical O 0 0.0003319504
induction O 0 0.00023167161
can O 0 0.00022143434
be O 0 0.00030446233
easily O 0 0.00036983154
obtained O 0 0.00047252435
with O 0 0.0014413464
isoproterenol B-Chemical 0 0.9993099
. O 0 0.0045317737

A O 0 0.04098493
new O 0 0.007281167
infarct B-Disease 0 0.9990746
- O 0 0.096330225
avid O 0 0.007989008
radiopharmaceutical O 0 0.005772083
based O 0 0.0006278989
on O 0 0.00071755494
glucaric B-Chemical 0 0.9997681
acid I-Chemical 0 0.96154577
was O 0 0.0005510416
prepared O 0 0.00037248564
in O 0 0.0002843246
the O 0 0.00027684594
hospital O 0 0.00052943226
radiopharmacy O 0 0.0005770975
of O 0 0.0007720679
the O 0 0.0011954621
INCMNSZ O 0 0.23853913
. O 0 0.0034141757

99mTc B-Chemical 0 0.91953784
- I-Chemical 0 0.38295263
glucarate I-Chemical 0 0.96751004
was O 0 0.0016254667
easy O 0 0.0012629835
to O 0 0.0005237128
prepare O 0 0.00043156915
, O 0 0.00068113994
stable O 0 0.0003094341
for O 0 0.0002140534
96 O 0 0.00052042474
h O 0 0.00022769417
and O 0 0.00017258505
was O 0 0.00012665222
used O 0 0.000106722066
to O 0 0.00010851958
study O 0 0.00015075503
its O 0 0.00017857533
biodistribution O 0 0.00063913653
in O 0 0.00014904811
rats O 0 0.0003243746
with O 0 0.00043400886
isoproterenol B-Chemical 0 0.99988186
- O 0 0.020363294
induced O 0 0.0008029749
acute O 0 0.9800616
myocardial B-Disease 0 0.999845
infarction I-Disease 0 0.99998474
. O 0 0.004461352

Histological O 0 0.004419018
studies O 0 0.002280068
demonstrated O 0 0.0010869805
that O 0 0.00071649725
the O 0 0.00064671796
rats O 0 0.0010532611
developed O 0 0.0008190727
an O 0 0.0009325316
infarct B-Disease 0 0.9954379
18 O 0 0.0006484443
h O 0 0.0005860581
after O 0 0.0005309555
isoproterenol B-Chemical 0 0.99669325
administration O 0 0.0037761005
. O 0 0.0031910404

The O 0 0.0022253394
rat O 0 0.002649708
biodistribution O 0 0.0033558954
studies O 0 0.0012459026
showed O 0 0.00079896895
a O 0 0.0011345742
rapid O 0 0.0012007527
blood O 0 0.00621345
clearance O 0 0.003163804
via O 0 0.00077524065
the O 0 0.0011447165
kidneys O 0 0.006059007
. O 0 0.0042797406

Thirty O 0 0.0052732937
minutes O 0 0.001942267
after O 0 0.001105822
99mTc B-Chemical 0 0.13950339
- I-Chemical 0 0.017781321
glucarate I-Chemical 0 0.79740393
administration O 0 0.0009794404
the O 0 0.0002902829
standardised O 0 0.00031205476
heart O 0 0.004769121
uptake O 0 0.001382696
value O 0 0.00043285213
S O 0 0.82575697
( O 0 0.0007187853
h O 0 0.0003481655
) O 0 0.0008550235
UV O 0 0.11542517
was O 0 0.00016620605
4 O 0 0.0001196442
. O 0 0.000114120325
7 O 0 9.579151e-05
in O 0 0.00013957218
infarcted O 0 0.024941502
rat O 0 0.00029380422
heart O 0 0.0026517904
which O 0 0.00014341802
is O 0 8.728723e-05
six O 0 6.721218e-05
times O 0 0.0001027527
more O 0 0.0002940407
than O 0 0.0002708074
in O 0 0.0004418066
normal O 0 0.0012352478
rats O 0 0.0020605882
. O 0 0.002601214

ROIs O 0 0.004668321
drawn O 0 0.002364596
over O 0 0.0011243921
the O 0 0.0009819159
gamma O 0 0.004761715
camera O 0 0.0016441918
images O 0 0.0007696608
showed O 0 0.0005860167
a O 0 0.00085560785
ratio O 0 0.00077135314
of O 0 0.0008920978
4 O 0 0.00089271425
. O 0 0.0011740543
4 O 0 0.0016185627
. O 0 0.0033005893

The O 0 0.0015554545
high O 0 0.0013376386
image O 0 0.00074581645
quality O 0 0.00041477708
suggests O 0 0.0002552991
that O 0 0.00023927631
high O 0 0.0003475076
contrast O 0 0.00034848665
images O 0 0.00027305467
can O 0 0.00013892315
be O 0 0.00013746813
obtained O 0 0.00010788339
in O 0 0.00012726674
humans O 0 0.000209379
and O 0 0.00013673614
the O 0 0.00011250122
96 O 0 0.00031035475
h O 0 0.00013046789
stability O 0 9.589023e-05
makes O 0 0.00011674232
it O 0 0.00019995261
an O 0 0.00014514528
ideal O 0 0.00012568304
agent O 0 0.0003459228
to O 0 0.00015129073
detect O 0 0.0001336715
, O 0 0.00046832967
in O 0 0.00030587424
patients O 0 0.0009021857
, O 0 0.0010217201
early O 0 0.0019243201
cardiac B-Disease 0 0.85851735
infarction I-Disease 0 0.9999801
. O 0 0.0052602906

Bupropion B-Chemical 0 0.9991549
( O 0 0.038341094
Zyban B-Chemical 0 0.9928517
) O 0 0.022989217
toxicity B-Disease 0 0.7098451
. O 0 0.015264848

Bupropion B-Chemical 0 0.9994832
is O 0 0.0039013287
a O 0 0.0054901987
monocyclic O 0 0.984602
antidepressant B-Chemical 0 0.99983656
structurally O 0 0.0027928408
related O 0 0.0013258277
to O 0 0.002790266
amphetamine B-Chemical 1 0.99985015
. O 0 0.0071608764

Zyban B-Chemical 0 0.9945081
, O 0 0.0049335705
a O 0 0.002238033
sustained O 0 0.0020916495
- O 0 0.0055005075
release O 0 0.0012260093
formulation O 0 0.0022825622
of O 0 0.0012855894
bupropion B-Chemical 0 0.99999785
hydrochloride I-Chemical 0 0.9998406
, O 0 0.0008832016
was O 0 0.00021527799
recently O 0 0.00020385804
released O 0 0.0002758048
in O 0 0.0002784403
Ireland O 0 0.0016069878
, O 0 0.000550719
as O 0 0.00034491005
a O 0 0.00071480114
smoking O 0 0.0059421957
cessation O 0 0.0010831464
aid O 0 0.0023286054
. O 0 0.0033034456

In O 0 0.0018790005
the O 0 0.0012741649
initial O 0 0.0007280944
6 O 0 0.0004664348
months O 0 0.00026823184
since O 0 0.0002767821
it O 0 0.0005008195
' O 0 0.00066238263
s O 0 0.00046021727
introduction O 0 0.00020420956
, O 0 0.0005002312
12 O 0 0.0002846341
overdose B-Disease 0 0.9962684
cases O 0 0.0005553981
have O 0 0.0002246632
been O 0 0.00025067985
reported O 0 0.0003060233
to O 0 0.00027016085
The O 0 0.00025649337
National O 0 0.0005745463
Poisons O 0 0.0051973597
Information O 0 0.0007679632
Centre O 0 0.0019539823
. O 0 0.0025374442

8 O 0 0.0071918336
patients O 0 0.007712441
developed O 0 0.0057620984
symptoms O 0 0.015314032
of O 0 0.006904675
toxicity B-Disease 0 0.78395665
. O 0 0.011960518

Common O 0 0.0057337144
features O 0 0.0037127412
included O 0 0.002925651
tachycardia B-Disease 2 0.9963691
, O 0 0.011837689
drowsiness O 0 0.99971
, O 0 0.037075475
hallucinations B-Disease 0 0.999974
and O 0 0.012977732
convulsions B-Disease 0 0.9996251
. O 0 0.008287189

Two O 0 0.0026319341
patients O 0 0.0033205997
developed O 0 0.0018599762
severe O 0 0.0075554494
cardiac B-Disease 0 0.4050006
arrhythmias I-Disease 2 0.99995327
, O 0 0.0013904554
including O 0 0.00025908166
one O 0 0.0002483392
patient O 0 0.000324858
who O 0 0.00035715566
was O 0 0.0002917022
resuscitated O 0 0.0022268188
following O 0 0.00031064486
a O 0 0.0010599243
cardiac B-Disease 0 0.04365954
arrest I-Disease 0 0.14033855
. O 0 0.0038476782

All O 0 0.0065781134
patients O 0 0.008771038
recovered O 0 0.005210458
without O 0 0.006957622
sequelae O 0 0.038314395
. O 0 0.014265516

We O 0 0.0031622506
report O 0 0.0034563602
a O 0 0.0020643058
case O 0 0.0010720647
of O 0 0.0007732733
a O 0 0.00078859203
31 O 0 0.0005515437
year O 0 0.00023274828
old O 0 0.0002601274
female O 0 0.0004048715
who O 0 0.00021564552
required O 0 7.7291465e-05
admission O 0 0.00017930524
to O 0 0.00010272527
the O 0 0.00013491813
Intensive O 0 0.00081033795
Care O 0 0.00027780232
Unit O 0 0.00014985871
for O 0 6.313141e-05
ventilation O 0 0.00022440459
and O 0 9.221671e-05
full O 0 7.858209e-05
supportive O 0 0.00025344107
therapy O 0 0.00022105945
, O 0 0.00024904605
following O 0 0.00013165222
ingestion O 0 0.0014773794
of O 0 0.00037707132
13 O 0 0.0005358745
. O 0 0.00064862904
5g O 0 0.0057230787
bupropion B-Chemical 0 0.9998784
. O 0 0.003659492

Recurrent O 0 0.02652013
seizures B-Disease 0 0.99966645
were O 0 0.0015869455
treated O 0 0.001988816
with O 0 0.0017301118
diazepam B-Chemical 0 0.9999918
and O 0 0.0008260458
broad O 0 0.00064955396
complex O 0 0.0005595984
tachycardia B-Disease 2 0.992442
was O 0 0.00046616056
successfully O 0 0.0005868037
treated O 0 0.0014989468
with O 0 0.0021483907
adenosine B-Chemical 0 0.9982679
. O 0 0.0046390356

Zyban B-Chemical 0 0.99427867
caused O 0 0.0034198817
significant O 0 0.002843207
neurological B-Disease 0 0.83880705
and I-Disease 0 0.0028965825
cardiovascular I-Disease 0 0.9935881
toxicity I-Disease 0 0.9974636
in O 0 0.0043015215
overdose B-Disease 0 0.998968
. O 0 0.005895236

The O 0 0.0019454891
potential O 0 0.0015855137
toxic O 0 0.009073193
effects O 0 0.000834372
should O 0 0.0003771272
be O 0 0.0003981647
considered O 0 0.000327284
when O 0 0.00026504882
prescribing O 0 0.0011521732
it O 0 0.00057539373
as O 0 0.00046195203
a O 0 0.0009109219
smoking O 0 0.0068956213
cessation O 0 0.0012708185
aid O 0 0.0026281157
. O 0 0.0036603296

GLEPP1 O 0 0.78550905
receptor O 0 0.26120132
tyrosine B-Chemical 0 0.89346707
phosphatase O 0 0.6153298
( O 0 0.006907239
Ptpro O 0 0.0067069437
) O 0 0.0045341896
in O 0 0.0024183667
rat O 0 0.008406393
PAN B-Chemical 0 0.99959666
nephrosis B-Disease 2 0.9999163
. O 0 0.011824832

A O 0 0.05376967
marker O 0 0.010623794
of O 0 0.0088427225
acute O 0 0.5914509
podocyte O 0 0.9732721
injury O 0 0.4991726
. O 0 0.011962067

Glomerular O 0 0.98934585
epithelial O 0 0.013847333
protein O 0 0.0024763304
1 O 0 0.0018160638
( O 0 0.0024798901
GLEPP1 O 0 0.015596878
) O 0 0.0016760132
is O 0 0.0004726444
a O 0 0.0010351313
podocyte O 0 0.8827947
receptor O 0 0.013611485
membrane O 0 0.022822652
protein O 0 0.0012432027
tyrosine B-Chemical 0 0.65562326
phosphatase O 0 0.18702005
located O 0 0.00018300816
on O 0 0.00010661262
the O 0 0.00014430277
apical O 0 0.00072998105
cell O 0 0.0005140452
membrane O 0 0.0020309708
of O 0 0.00046629057
visceral O 0 0.06885036
glomerular O 0 0.9984755
epithelial O 0 0.0050934157
cell O 0 0.00088245707
and O 0 0.000813741
foot O 0 0.0054464918
processes O 0 0.0024817854
. O 0 0.002913017

This O 0 0.005836338
receptor O 0 0.00439518
plays O 0 0.00085220276
a O 0 0.001059947
role O 0 0.00033892563
in O 0 0.00043280225
regulating O 0 0.00019768067
the O 0 0.0003508648
structure O 0 0.00044368804
and O 0 0.00052612164
function O 0 0.0005629846
of O 0 0.0012388002
podocyte O 0 0.8132915
foot O 0 0.019873286
process O 0 0.0025501822
. O 0 0.00369942

To O 0 0.0013679039
better O 0 0.0016861053
understand O 0 0.00081526843
the O 0 0.0006044434
utility O 0 0.0004838592
of O 0 0.0008305446
GLEPP1 O 0 0.014147284
as O 0 0.00043370403
a O 0 0.0005031398
marker O 0 0.00045066042
of O 0 0.00059883547
glomerular B-Disease 0 0.9999149
injury I-Disease 0 0.90781134
, O 0 0.0004034968
the O 0 9.944466e-05
amount O 0 6.991723e-05
and O 0 0.00011223077
distribution O 0 7.249335e-05
of O 0 0.00021404095
GLEPP1 O 0 0.015514658
protein O 0 0.0001784805
and O 0 0.0001606979
mRNA O 0 0.00015983402
were O 0 0.00010341316
examined O 0 8.636331e-05
by O 0 0.00011933485
immunohistochemistry O 0 0.00018769233
, O 0 0.00029192865
Western O 0 0.00024154785
blot O 0 0.00012305948
and O 0 0.0002210251
RNase O 0 0.0028982367
protection O 0 0.0002792892
assay O 0 0.00028883823
in O 0 0.00017309595
a O 0 0.0002691643
model O 0 0.00020264294
of O 0 0.00045666442
podocyte O 0 0.90489584
injury O 0 0.09833552
in O 0 0.00060590735
the O 0 0.00069187867
rat O 0 0.0019547998
. O 0 0.0024545335

Puromycin B-Chemical 0 0.99968076
aminonucleoside I-Chemical 0 0.99999344
nephrosis B-Disease 2 0.9999838
was O 0 0.001318477
induced O 0 0.00047702805
by O 0 0.00029751562
single O 0 0.00018803445
intraperitoneal O 0 0.00039389386
injection O 0 0.00018609318
of O 0 0.0003688598
puromycin B-Chemical 0 0.9348189
aminonucleoside I-Chemical 0 0.99999285
( O 0 0.008235047
PAN B-Chemical 0 0.999706
, O 0 0.001186784
20 O 0 0.00062698184
mg O 0 0.0067716204
/ O 0 0.0043898453
100g O 0 0.4259774
BW O 0 0.061294474
) O 0 0.004637209
. O 0 0.0035575645

Tissues O 0 0.0067143976
were O 0 0.0021653406
analyzed O 0 0.0013825984
at O 0 0.00088405935
0 O 0 0.0011432149
, O 0 0.0011850494
5 O 0 0.00059360545
, O 0 0.0007943272
7 O 0 0.00039781642
, O 0 0.0006646227
11 O 0 0.0004483391
, O 0 0.0005719558
21 O 0 0.0003815295
, O 0 0.0004628504
45 O 0 0.00027613473
, O 0 0.00036501815
80 O 0 0.00027363244
and O 0 0.00017242352
126 O 0 0.00028533262
days O 0 9.029898e-05
after O 0 0.00010978052
PAN B-Chemical 0 0.99725515
injection O 0 0.0001509246
so O 0 0.000115752664
as O 0 0.00010832511
to O 0 8.621834e-05
include O 0 8.312408e-05
both O 0 8.001548e-05
the O 0 9.558028e-05
acute O 0 0.00334264
phase O 0 0.0003910877
of O 0 0.00033919248
proteinuria B-Disease 0 0.99998045
associated O 0 0.00023959458
with O 0 0.000177941
foot O 0 0.0018358844
process O 0 0.00018271801
effacement O 0 0.032329895
( O 0 0.00019339417
days O 0 6.002709e-05
5 O 0 9.900147e-05
- O 0 0.00043594438
11 O 0 0.00012494397
) O 0 0.00021656511
and O 0 0.000105966785
the O 0 0.00010319507
chronic O 0 0.0014578709
phase O 0 0.00046415773
of O 0 0.0004464498
proteinuria B-Disease 0 0.9999738
associated O 0 0.00048539447
with O 0 0.00065905345
glomerulosclerosis B-Disease 0 0.99998724
( O 0 0.00082273793
days O 0 0.00021350592
45 O 0 0.0004546129
- O 0 0.0018900223
126 O 0 0.0020247668
) O 0 0.0030301202
. O 0 0.0030551825

At O 0 0.001483072
day O 0 0.001680621
5 O 0 0.0016256185
, O 0 0.0026315514
GLEPP1 O 0 0.0093903905
protein O 0 0.0008450364
and O 0 0.0006494224
mRNA O 0 0.0005564043
were O 0 0.00033582025
reduced O 0 0.00034127323
from O 0 0.00021762202
the O 0 0.00018760556
normal O 0 0.00034105874
range O 0 0.00023931968
( O 0 0.00040441385
265 O 0 0.000753717
. O 0 0.00019575066
2 O 0 0.0002266921
+ O 0 0.0007459198
/ O 0 0.0013777994
- O 0 0.0013648849
79 O 0 0.00032543024
. O 0 0.00015455233
6 O 0 0.00011531794
x O 0 0.00044584312
10 O 0 0.00019168611
( O 0 0.00028090135
6 O 0 0.00014903546
) O 0 0.0005750508
moles O 0 0.083491154
/ O 0 0.0033004072
glomerulus O 0 0.0150387585
and O 0 0.0002628175
100 O 0 0.00044128238
% O 0 0.0004071741
) O 0 0.00036286097
to O 0 0.00012536036
15 O 0 0.00014083124
% O 0 0.00025209083
of O 0 0.00017966874
normal O 0 0.0003589518
( O 0 0.0003481549
41 O 0 0.0002982594
. O 0 0.0001484361
8 O 0 0.00015656513
+ O 0 0.00065155624
/ O 0 0.001272541
- O 0 0.001118003
4 O 0 0.0001499988
. O 0 0.00014030086
8 O 0 0.00014196028
x O 0 0.00048044146
10 O 0 0.00021523611
( O 0 0.0003323361
6 O 0 0.00019087031
) O 0 0.0007172015
moles O 0 0.04752325
/ O 0 0.0030521324
glomerulus O 0 0.007580031
, O 0 0.00071149634
p O 0 0.0006963713
< O 0 0.00074545084
0 O 0 0.0008084406
. O 0 0.000983298
005 O 0 0.0060596033
) O 0 0.0043497668
. O 0 0.0042058825

This O 0 0.004414919
occurred O 0 0.0017040424
in O 0 0.0009223296
association O 0 0.0005016788
with O 0 0.0005942414
an O 0 0.00051259884
increase O 0 0.00035432534
in O 0 0.00037064022
urinary O 0 0.011499245
protein O 0 0.00033440194
content O 0 0.000323344
from O 0 0.00019832485
1 O 0 0.00021386737
. O 0 0.00015634032
8 O 0 0.00016895405
+ O 0 0.0007003239
/ O 0 0.0014784292
- O 0 0.0015037273
1 O 0 0.00022519741
to O 0 0.00015003298
99 O 0 0.00033849146
. O 0 0.00018062153
0 O 0 0.00027011527
+ O 0 0.00077258755
/ O 0 0.0013881503
- O 0 0.0015276653
61 O 0 0.00049779867
mg O 0 0.0024112908
/ O 0 0.00086389465
day O 0 0.00021656077
( O 0 0.00049757055
p O 0 0.0006063793
< O 0 0.00073509174
0 O 0 0.00084145955
. O 0 0.0010511025
001 O 0 0.009223739
) O 0 0.0051423036
. O 0 0.0046169907

In O 0 0.0030274307
contrast O 0 0.0043596015
, O 0 0.005964079
podocalyxin O 0 0.049428515
did O 0 0.0018968676
not O 0 0.0011237876
change O 0 0.0010263309
significantly O 0 0.0011143909
at O 0 0.00089712004
this O 0 0.0014699221
time O 0 0.0017808396
. O 0 0.0042611575

By O 0 0.0027118458
day O 0 0.0022605334
11 O 0 0.002517661
, O 0 0.0035273451
GLEPP1 O 0 0.012346586
protein O 0 0.0012543101
and O 0 0.0010515508
mRNA O 0 0.001038259
had O 0 0.0008183449
begun O 0 0.0011207099
to O 0 0.0007005065
return O 0 0.0010060569
towards O 0 0.0011974289
baseline O 0 0.0018657483
. O 0 0.0036294644

By O 0 0.0023357747
day O 0 0.001837319
45 O 0 0.001915343
- O 0 0.0040694554
126 O 0 0.0017964835
, O 0 0.0010488259
at O 0 0.0003806402
a O 0 0.00048499356
time O 0 0.00024678872
when O 0 0.00033723222
glomerular O 0 0.99648345
scarring O 0 0.49094886
was O 0 0.00022368832
present O 0 0.00017915553
, O 0 0.00059679104
GLEPP1 O 0 0.008988282
was O 0 0.00017718959
absent O 0 0.0001747998
from O 0 0.00017517523
glomerulosclerotic O 0 0.46361837
areas O 0 0.0002829185
although O 0 0.0001283454
the O 0 0.00012988746
total O 0 0.00025850133
glomerular O 0 0.9913189
content O 0 0.0004400167
of O 0 0.00045610065
GLEPP1 O 0 0.020233449
was O 0 0.00031337253
not O 0 0.00030265554
different O 0 0.0003583796
from O 0 0.0007418557
normal O 0 0.0022605762
. O 0 0.0027818826

We O 0 0.002803963
conclude O 0 0.001738875
that O 0 0.0016900097
GLEPP1 O 0 0.01801176
expression O 0 0.0010696194
, O 0 0.0016648838
unlike O 0 0.00076960935
podocalyxin O 0 0.046452567
, O 0 0.0020164691
reflects O 0 0.0010199482
podocyte O 0 0.83679515
injury O 0 0.11253745
induced O 0 0.0016685621
by O 0 0.002952106
PAN B-Chemical 0 0.99903667
. O 0 0.006226997

GLEPP1 O 0 0.09494055
expression O 0 0.0038356797
may O 0 0.002394235
be O 0 0.001912925
a O 0 0.0021086824
useful O 0 0.0014696639
marker O 0 0.0022446937
of O 0 0.0029925427
podocyte O 0 0.90917623
injury O 0 0.36699283
. O 0 0.006931184

Antithymocyte B-Chemical 0 0.1568148
globulin I-Chemical 0 0.8788951
in O 0 0.0020601614
the O 0 0.0011770574
treatment O 0 0.0012015318
of O 0 0.0019732895
D B-Chemical 0 0.99824095
- I-Chemical 0 0.9573609
penicillamine I-Chemical 1 0.9999933
- O 0 0.41101527
induced O 0 0.005001127
aplastic B-Disease 0 0.9998223
anemia I-Disease 0 0.999936
. O 0 0.008422299

A O 0 0.020536838
patient O 0 0.002272828
who O 0 0.0014417663
received O 0 0.00084533484
antithymocyte B-Chemical 0 0.06488077
globulin I-Chemical 0 0.86195505
therapy O 0 0.0012350361
for O 0 0.000706948
aplastic B-Disease 0 0.9998615
anemia I-Disease 0 0.9999776
due O 0 0.00050577853
to O 0 0.0007111958
D B-Chemical 0 0.999124
- I-Chemical 0 0.91275907
penicillamine I-Chemical 1 0.99999356
therapy O 0 0.0023004483
is O 0 0.00084840925
described O 0 0.0012948698
. O 0 0.0028046158

Bone O 0 0.010418196
marrow O 0 0.008782454
recovery O 0 0.0016169308
and O 0 0.00084840925
peripheral O 0 0.0014883775
blood O 0 0.0024603116
recovery O 0 0.00046518556
were O 0 0.00018905776
complete O 0 0.00013659814
1 O 0 0.00014502506
month O 0 6.909659e-05
and O 0 9.459836e-05
3 O 0 7.9343794e-05
months O 0 5.5227458e-05
, O 0 0.00017355275
respectively O 0 0.00021430866
, O 0 0.00019792435
after O 0 6.449397e-05
treatment O 0 0.00012106682
, O 0 0.00022178593
and O 0 0.0001512091
blood O 0 0.0015463207
transfusion O 0 0.00035341064
or O 0 7.506473e-05
other O 0 7.8823825e-05
therapies O 0 0.00015972006
were O 0 9.0027635e-05
not O 0 8.359714e-05
necessary O 0 6.9352e-05
in O 0 0.00012468857
a O 0 0.00021520122
follow O 0 0.00012397543
- O 0 0.00069512875
up O 0 0.00018277549
period O 0 0.0001391049
of O 0 0.0002898263
more O 0 0.0005296973
than O 0 0.00047715424
2 O 0 0.00087731687
years O 0 0.001507776
. O 0 0.0024209458

Use O 0 0.0062344843
of O 0 0.0032155442
antithymocyte B-Chemical 0 0.5821383
globulin I-Chemical 0 0.9638058
may O 0 0.00085302006
be O 0 0.00047767285
the O 0 0.00028157356
optimal O 0 0.00019715288
treatment O 0 0.00041854166
of O 0 0.00089480705
D B-Chemical 0 0.9987382
- I-Chemical 0 0.95429194
penicillamine I-Chemical 1 0.99999607
- O 0 0.38559458
induced O 0 0.003868928
aplastic B-Disease 0 0.9998665
anemia I-Disease 0 0.9999505
. O 0 0.007149491

Metamizol B-Chemical 0 0.9977192
potentiates O 0 0.048451222
morphine B-Chemical 0 0.99986875
antinociception O 0 0.99600047
but O 0 0.0018448049
not O 0 0.0011423837
constipation B-Disease 0 0.98721164
after O 0 0.0007897151
chronic O 0 0.0073296134
treatment O 0 0.0022047625
. O 0 0.0037022296

This O 0 0.0039551896
work O 0 0.0017939917
evaluates O 0 0.00090111827
the O 0 0.00065105193
antinociceptive O 0 0.016850006
and O 0 0.0006431766
constipating B-Disease 0 0.9748905
effects O 0 0.00028503026
of O 0 0.0002511645
the O 0 0.00015677203
combination O 0 0.00021037836
of O 0 0.00017913997
3 O 0 0.00013483659
. O 0 0.0001227525
2 O 0 0.00014725179
mg O 0 0.0008559846
/ O 0 0.0004602866
kg O 0 0.00033164737
s O 0 0.00023382573
. O 0 0.00016594176
c O 0 0.0008950236
. O 0 0.00027728683
morphine B-Chemical 0 0.99906784
with O 0 0.00024852873
177 O 0 0.00058503175
. O 0 0.00012085759
8 O 0 0.000113619644
mg O 0 0.0007602746
/ O 0 0.00043003613
kg O 0 0.00031337581
s O 0 0.00022121318
. O 0 0.00015606359
c O 0 0.0009624728
. O 0 0.00032076275
metamizol B-Chemical 0 0.99997413
in O 0 0.00021999991
acutely O 0 0.0010100626
and O 0 0.00016859005
chronically O 0 0.001066511
treated O 0 0.00041380947
( O 0 0.00032936613
once O 0 0.00011931425
a O 0 0.00021998503
day O 0 0.00012194437
for O 0 0.00015608456
12 O 0 0.00020781212
days O 0 0.00026089564
) O 0 0.001267146
rats O 0 0.00190668
. O 0 0.0027595952

On O 0 0.0030487434
the O 0 0.001707509
13th O 0 0.001993168
day O 0 0.0007993874
, O 0 0.0012567264
antinociceptive O 0 0.0044583133
effects O 0 0.00033832033
were O 0 0.00023033799
assessed O 0 0.00017713215
using O 0 0.0001283208
a O 0 0.00018878268
model O 0 0.00011927945
of O 0 0.00019810828
inflammatory O 0 0.008740706
nociception O 0 0.0012190377
, O 0 0.0003720169
pain B-Disease 0 0.03423781
- O 0 0.0008579018
induced O 0 0.00010035947
functional O 0 0.00012184813
impairment O 0 0.053948477
model O 0 0.0001427311
, O 0 0.0002661826
and O 0 0.00015604202
the O 0 0.00017716172
charcoal B-Chemical 0 0.97830623
meal O 0 0.0014804177
test O 0 0.00028508055
was O 0 0.00015938218
used O 0 0.00014763771
to O 0 0.00016617213
evaluate O 0 0.00015129044
the O 0 0.000448873
intestinal O 0 0.0036227952
transit O 0 0.0038978024
. O 0 0.0028742317

Simultaneous O 0 0.0035109962
administration O 0 0.002904251
of O 0 0.00194076
morphine B-Chemical 0 0.9996927
with O 0 0.002211703
metamizol B-Chemical 0 0.9999825
resulted O 0 0.000388082
in O 0 0.00024317444
a O 0 0.00036312937
markedly O 0 0.0006995455
antinociceptive O 0 0.07256955
potentiation O 0 0.004534056
and O 0 0.00013573327
an O 0 0.000109555476
increasing O 0 8.5565705e-05
of O 0 9.0471454e-05
the O 0 6.0755716e-05
duration O 0 5.0850867e-05
of O 0 8.33534e-05
action O 0 9.4137e-05
after O 0 5.63806e-05
a O 0 0.00015076093
single O 0 9.910566e-05
( O 0 0.00026588555
298 O 0 0.00086327293
+ O 0 0.0009319627
/ O 0 0.0012620937
- O 0 0.00080521
7 O 0 0.000109378336
vs O 0 0.0001850134
. O 0 0.00014705506
139 O 0 0.0003272478
+ O 0 0.00073078944
/ O 0 0.0012510384
- O 0 0.001119632
36 O 0 0.00022454413
units O 0 0.00020710121
area O 0 0.0003692735
( O 0 0.00076288835
ua O 0 0.9869042
) O 0 0.0009850384
; O 0 0.0005451589
P O 0 0.0044716587
< O 0 0.0003224651
0 O 0 0.0002442258
. O 0 0.00019532387
001 O 0 0.0017039533
) O 0 0.00039132207
and O 0 0.0001536491
repeated O 0 0.00010297585
administration O 0 0.00028417827
( O 0 0.0003989605
280 O 0 0.0012161824
+ O 0 0.00097393803
/ O 0 0.0014119523
- O 0 0.0011997226
17 O 0 0.00029001702
vs O 0 0.00030586112
. O 0 0.00025358904
131 O 0 0.0006616425
+ O 0 0.0012390682
/ O 0 0.0024536618
- O 0 0.0034874622
22 O 0 0.0011672532
ua O 0 0.96814984
; O 0 0.0016084648
P O 0 0.009208836
< O 0 0.0010735185
0 O 0 0.0010205621
. O 0 0.0011861178
001 O 0 0.009702367
) O 0 0.0054438277
. O 0 0.004889441

Antinociceptive O 0 0.460162
effect O 0 0.0018610281
of O 0 0.002588969
morphine B-Chemical 0 0.99969876
was O 0 0.00072771637
reduced O 0 0.00051105744
in O 0 0.00032741413
chronically O 0 0.0012242572
treated O 0 0.0004508237
rats O 0 0.00037392427
( O 0 0.00035375255
39 O 0 0.00028501506
+ O 0 0.0007617685
/ O 0 0.0011836179
- O 0 0.00096479204
10 O 0 0.00015946607
vs O 0 0.00020548637
. O 0 0.0001436759
18 O 0 0.00017940956
+ O 0 0.00063435966
/ O 0 0.00124351
- O 0 0.0012970787
5 O 0 0.00018209536
au O 0 0.00061716186
) O 0 0.00031165913
while O 0 0.00010669316
the O 0 9.823327e-05
combination O 0 0.0002242878
- O 0 0.0018428733
induced O 0 0.00019079224
antinociception O 0 0.83087313
was O 0 0.00013444298
remained O 0 0.00015304433
similar O 0 7.96876e-05
as O 0 0.00011388725
an O 0 0.0001665573
acute O 0 0.0029968082
treatment O 0 0.0001723637
( O 0 0.00032322505
298 O 0 0.0010518342
+ O 0 0.0010861399
/ O 0 0.0014913852
- O 0 0.001025207
7 O 0 0.00017226249
vs O 0 0.00032850687
. O 0 0.00033533797
280 O 0 0.0018057182
+ O 0 0.0018991225
/ O 0 0.0034731107
- O 0 0.004376501
17 O 0 0.0018012733
au O 0 0.0048868754
) O 0 0.0045460532
. O 0 0.0040417267

Acute O 0 0.05664093
antinociceptive O 0 0.02483689
effects O 0 0.000981342
of O 0 0.00077093864
the O 0 0.00045410247
combination O 0 0.0005551121
were O 0 0.00033958652
partially O 0 0.0003227542
prevented O 0 0.0005289516
by O 0 0.000306684
3 O 0 0.00024843676
. O 0 0.00024355263
2 O 0 0.00032270467
mg O 0 0.0019009997
/ O 0 0.0014977625
kg O 0 0.0020497055
naloxone B-Chemical 0 0.9994473
s O 0 0.0018873214
. O 0 0.0014210877
c O 0 0.006093064
. O 0 0.0039983774

( O 0 0.00964175
P O 0 0.027521962
< O 0 0.0034894447
0 O 0 0.0020290753
. O 0 0.0013571713
05 O 0 0.009880164
) O 0 0.0019349746
, O 0 0.0009862328
suggesting O 0 0.000314381
the O 0 0.0003144143
partial O 0 0.0004797168
involvement O 0 0.00047518415
of O 0 0.0003750292
the O 0 0.00033742792
opioidergic O 0 0.0051815566
system O 0 0.00044079614
in O 0 0.0004460718
the O 0 0.00057863916
synergism O 0 0.0028176673
observed O 0 0.0017419104
. O 0 0.0035883798

In O 0 0.0017466863
independent O 0 0.0012544673
groups O 0 0.0019792635
, O 0 0.00400318
morphine B-Chemical 0 0.999627
inhibited O 0 0.0016621104
the O 0 0.0005160066
intestinal O 0 0.0019307295
transit O 0 0.0007839264
in O 0 0.0002487888
48 O 0 0.00027440317
+ O 0 0.00085256464
/ O 0 0.0013386701
- O 0 0.0010670059
4 O 0 0.00016045063
% O 0 0.0002822649
and O 0 0.00017512665
38 O 0 0.00029233645
+ O 0 0.0008752436
/ O 0 0.0015977815
- O 0 0.0012219038
4 O 0 0.00013172986
% O 0 0.00021789651
after O 0 7.263361e-05
acute O 0 0.0011723897
and O 0 0.00015259582
chronic O 0 0.0017540816
treatment O 0 0.0001601753
, O 0 0.00027945382
respectively O 0 0.00033215748
, O 0 0.00026913462
suggesting O 0 9.536797e-05
that O 0 0.00012298004
tolerance O 0 0.0016820736
did O 0 0.0002675397
not O 0 0.00020619055
develop O 0 0.00027609602
to O 0 0.00027996663
the O 0 0.00048211572
constipating B-Disease 0 0.9761303
effects O 0 0.0016752554
. O 0 0.0030615036

The O 0 0.0018902168
combination O 0 0.0022235627
inhibited O 0 0.0024943268
intestinal O 0 0.0057076607
transit O 0 0.0016674345
similar O 0 0.0002650551
to O 0 0.00020611902
that O 0 0.00015069927
produced O 0 0.00017500512
by O 0 0.0002786971
morphine B-Chemical 0 0.9994215
regardless O 0 9.4128205e-05
of O 0 0.00012125192
the O 0 7.751452e-05
time O 0 6.509549e-05
of O 0 0.00011883714
treatment O 0 0.00014173237
, O 0 0.00024240473
suggesting O 0 0.00010402021
that O 0 0.00020610465
metamizol B-Chemical 0 0.99998844
did O 0 0.00044768828
not O 0 0.0002827524
potentiate O 0 0.0012074301
morphine B-Chemical 0 0.9998964
- O 0 0.038328353
induced O 0 0.0014371434
constipation B-Disease 0 0.9986675
. O 0 0.0033749535

These O 0 0.0017802472
findings O 0 0.0016583453
show O 0 0.00076395454
a O 0 0.0008710979
significant O 0 0.00041038252
interaction O 0 0.00027971825
between O 0 0.00037000878
morphine B-Chemical 0 0.99978024
and O 0 0.000856131
metamizol B-Chemical 0 0.99998426
in O 0 0.00024418347
chronically O 0 0.0011882053
treated O 0 0.00032153033
rats O 0 0.00028503296
, O 0 0.00023400327
suggesting O 0 7.54463e-05
that O 0 8.2968305e-05
this O 0 0.00013895576
combination O 0 0.00018651914
could O 0 9.8933626e-05
be O 0 0.00012045755
useful O 0 0.00011987705
for O 0 0.00011768735
the O 0 0.00017220041
treatment O 0 0.0003002818
of O 0 0.00062459224
chronic B-Disease 0 0.050990548
pain I-Disease 0 0.24322115
. O 0 0.0027414723

Ifosfamide B-Chemical 1 0.9993562
encephalopathy B-Disease 2 0.9997751
presenting O 0 0.07123532
with O 0 0.015916724
asterixis B-Disease 0 0.9997762
. O 0 0.016274232

CNS O 0 0.056196876
toxic O 0 0.011810777
effects O 0 0.0010340387
of O 0 0.00079044315
the O 0 0.00051009405
antineoplastic O 0 0.02519145
agent O 0 0.0025124121
ifosfamide B-Chemical 0 0.99983037
( O 0 0.0016663767
IFX B-Chemical 0 0.99808633
) O 0 0.0005049442
are O 0 0.0001181923
frequent O 0 0.00016704017
and O 0 0.00013537961
include O 0 0.00012409371
a O 0 0.00021921034
variety O 0 0.0001920238
of O 0 0.00036380644
neurological O 0 0.99836653
symptoms O 0 0.25327796
that O 0 0.00024293897
can O 0 0.0002782898
limit O 0 0.00083640707
drug O 0 0.0072594606
use O 0 0.001358159
. O 0 0.0025743772

We O 0 0.0032223498
report O 0 0.00349246
a O 0 0.002099613
case O 0 0.0011122355
of O 0 0.00083420065
a O 0 0.0009360692
51 O 0 0.0009497237
- O 0 0.0019884678
year O 0 0.00033921268
- O 0 0.0012618725
old O 0 0.00038490974
man O 0 0.0019869872
who O 0 0.00037311364
developed O 0 0.00029614594
severe O 0 0.0020546976
, O 0 0.00067915994
disabling O 0 0.25134984
negative O 0 0.00048840826
myoclonus B-Disease 0 0.99995863
of O 0 0.00018175416
the O 0 0.00010461119
upper O 0 0.00017742188
and O 0 0.00011534256
lower O 0 0.00017388287
extremities O 0 0.0013050578
after O 0 6.957841e-05
the O 0 0.00012634922
infusion O 0 0.00050333154
of O 0 0.00053932617
ifosfamide B-Chemical 0 0.9990833
for O 0 0.0010454492
plasmacytoma B-Disease 0 0.99521977
. O 0 0.0033029465

He O 0 0.008350664
was O 0 0.002282701
awake O 0 0.004609494
, O 0 0.0015120921
revealed O 0 0.0004925334
no O 0 0.00043309113
changes O 0 0.00045311358
of O 0 0.0004900486
mental O 0 0.00702973
status O 0 0.00030878227
and O 0 0.00026193896
at O 0 0.0001845898
rest O 0 0.00032035905
there O 0 0.00021368205
were O 0 0.00028029113
no O 0 0.00034800658
further O 0 0.0005885094
motor O 0 0.0042107324
symptoms O 0 0.0095513575
. O 0 0.00307771

Cranial O 0 0.011614301
magnetic O 0 0.0033199403
resonance O 0 0.0027858166
imaging O 0 0.0009088229
and O 0 0.0005424173
extensive O 0 0.0003986833
laboratory O 0 0.00036898535
studies O 0 0.00033790595
failed O 0 0.00028395778
to O 0 0.0002243834
reveal O 0 0.00020276163
structural B-Disease 0 0.00036944888
lesions I-Disease 0 0.0022831038
of I-Disease 0 0.00041348653
the I-Disease 0 0.0003940956
brain I-Disease 0 0.0017528762
and O 0 0.0010056114
metabolic B-Disease 0 0.62816006
abnormalities I-Disease 0 0.88113207
. O 0 0.0035710875

An O 0 0.0034248093
electroencephalogram O 0 0.034115262
showed O 0 0.0009787034
continuous O 0 0.0007248088
, O 0 0.001227146
generalized O 0 0.0020208585
irregular O 0 0.0014568486
slowing O 0 0.0016734159
with O 0 0.0005975714
admixed O 0 0.0036088766
periodic O 0 0.0010095664
triphasic O 0 0.09445628
waves O 0 0.0019549746
indicating O 0 0.00072998385
symptomatic O 0 0.042884663
encephalopathy B-Disease 2 0.99988985
. O 0 0.0048178895

The O 0 0.0019816293
administration O 0 0.0026645735
of O 0 0.002123738
ifosfamide B-Chemical 0 0.9991001
was O 0 0.00085626397
discontinued O 0 0.0016069546
and O 0 0.00042464485
within O 0 0.00022786681
12 O 0 0.0003137241
h O 0 0.0006052742
the O 0 0.0009830873
asterixis B-Disease 0 0.99988484
resolved O 0 0.0025490567
completely O 0 0.0022849762
. O 0 0.0040411144

In O 0 0.0019864596
the O 0 0.0015950355
patient O 0 0.0014178852
described O 0 0.0007161825
, O 0 0.00094762666
the O 0 0.00038536682
presence O 0 0.00039176064
of O 0 0.00073970784
asterixis B-Disease 0 0.9999769
during O 0 0.0001987572
infusion O 0 0.00054765906
of O 0 0.00025574295
ifosfamide B-Chemical 0 0.9997476
, O 0 0.00029135254
normal O 0 0.00017040173
laboratory O 0 9.3839546e-05
findings O 0 8.17839e-05
and O 0 6.892279e-05
imaging O 0 9.592918e-05
studies O 0 8.916906e-05
and O 0 7.341268e-05
the O 0 5.92799e-05
resolution O 0 0.00019268315
of O 0 0.000121732344
symptoms O 0 0.00076484826
following O 0 4.145485e-05
the O 0 5.8050624e-05
discontinuation O 0 0.0005664001
of O 0 8.187965e-05
the O 0 7.96266e-05
drug O 0 0.0010865512
suggest O 0 6.035697e-05
that O 0 0.00010496111
negative O 0 0.0004589652
myoclonus B-Disease 0 0.9999721
is O 0 0.00019089178
associated O 0 0.00023348622
with O 0 0.00026369852
the O 0 0.00027951616
use O 0 0.00047300136
of O 0 0.0014140683
IFX B-Chemical 0 0.99690574
. O 0 0.0028634516

Antagonism O 0 0.021001767
between O 0 0.0025579105
interleukin O 0 0.96614945
3 O 0 0.0013233714
and O 0 0.0011993495
erythropoietin O 0 0.9734195
in O 0 0.0003486428
mice O 0 0.00014264224
with O 0 0.0005049473
azidothymidine B-Chemical 0 0.99945396
- O 0 0.0333495
induced O 0 0.0007873661
anemia B-Disease 0 0.9999192
and O 0 0.0006571343
in O 0 0.0005652655
bone O 0 0.009160724
marrow O 0 0.114436395
endothelial O 0 0.99125177
cells O 0 0.0034780686
. O 0 0.0037178048

Azidothymidine B-Chemical 0 0.98733807
( O 0 0.018031653
AZT B-Chemical 0 0.99920017
) O 0 0.008508265
- O 0 0.012919913
induced O 0 0.0014086337
anemia B-Disease 0 0.99982613
in O 0 0.00044915618
mice O 0 0.00013249172
can O 0 0.00016571218
be O 0 0.00019794135
reversed O 0 0.00032195885
by O 0 0.00019547535
the O 0 0.00018273648
administration O 0 0.0005649323
of O 0 0.00072825374
IGF O 0 0.99993753
- O 0 0.4541706
IL O 0 0.99253935
- O 0 0.004446023
3 O 0 0.00015635553
( O 0 0.00023163471
fusion O 0 0.00012763668
protein O 0 0.00017005
of O 0 0.00034378635
insulin O 0 0.99395174
- O 0 0.010258192
like O 0 0.0003193229
growth O 0 0.007995374
factor O 0 0.12664668
II O 0 0.86139965
( O 0 0.014128124
IGF O 0 0.9999094
II O 0 0.80310017
) O 0 0.0025764618
and O 0 0.0009831856
interleukin O 0 0.983712
3 O 0 0.0015699927
) O 0 0.0035164072
. O 0 0.003043976

Although O 0 0.004066967
interleukin O 0 0.9085538
3 O 0 0.002962682
( O 0 0.004391198
IL O 0 0.8756565
- O 0 0.006166984
3 O 0 0.0006466213
) O 0 0.001184856
and O 0 0.0007627423
erythropoietin O 0 0.9979942
( O 0 0.0034762118
EPO O 0 0.99960226
) O 0 0.001199814
are O 0 0.00016177888
known O 0 0.00014375949
to O 0 0.00012110447
act O 0 0.00013714968
synergistically O 0 0.00024664684
on O 0 0.00014585645
hematopoietic O 0 0.0073630433
cell O 0 0.0004814489
proliferation O 0 0.03249802
in O 0 0.00016739413
vitro O 0 0.00015635329
, O 0 0.00028302966
injection O 0 0.00016155922
of O 0 0.000469755
IGF O 0 0.9999441
- O 0 0.42237094
IL O 0 0.99373865
- O 0 0.0059012533
3 O 0 0.00014855166
and O 0 0.00025019704
EPO O 0 0.9993592
in O 0 0.0003736782
AZT B-Chemical 0 0.9998221
- O 0 0.0029757253
treated O 0 0.00019852616
mice O 0 3.801259e-05
resulted O 0 8.034794e-05
in O 0 9.907438e-05
a O 0 0.00017049765
reduction O 0 0.00015594876
of O 0 0.00015360193
red O 0 0.0002778603
cells O 0 0.00018340259
and O 0 0.00014497514
an O 0 0.00013747416
increase O 0 0.00011744655
of O 0 0.00024134529
plasma O 0 0.32134697
EPO O 0 0.99976593
levels O 0 0.00012807814
as O 0 9.992727e-05
compared O 0 7.2308314e-05
to O 0 8.704319e-05
animals O 0 0.00011149393
treated O 0 0.000552406
with O 0 0.00097345514
IGF O 0 0.99995065
- O 0 0.58849895
IL O 0 0.9949917
- O 0 0.009937836
3 O 0 0.0005106727
or O 0 0.0007889628
EPO O 0 0.9964323
alone O 0 0.0023327656
. O 0 0.0032781279

We O 0 0.0024850576
tested O 0 0.0014739612
the O 0 0.0008853804
hypothesis O 0 0.00069928553
that O 0 0.0004820946
the O 0 0.00040567433
antagonistic O 0 0.0004609479
effect O 0 0.00042058903
of O 0 0.000924838
IL O 0 0.9928269
- O 0 0.014543157
3 O 0 0.00032056862
and O 0 0.00050819456
EPO O 0 0.99912983
on O 0 0.00037839182
erythroid O 0 0.9069898
cells O 0 0.0006608463
may O 0 0.0003363611
be O 0 0.00035761573
mediated O 0 0.00033785024
by O 0 0.0010008276
endothelial O 0 0.9908708
cells O 0 0.0044794115
. O 0 0.004484215

Bovine O 0 0.2572178
liver O 0 0.85142666
erythroid O 0 0.9663648
cells O 0 0.0016449342
were O 0 0.0006460974
cultured O 0 0.0006857537
on O 0 0.00025484723
monolayers O 0 0.0011797745
of O 0 0.00038290743
human O 0 0.00039727008
bone O 0 0.0046036816
marrow O 0 0.07641707
endothelial O 0 0.98162377
cells O 0 0.0004456959
previously O 0 0.00037371955
treated O 0 0.0009406382
with O 0 0.0011377056
EPO O 0 0.9998093
and O 0 0.003188839
IGF O 0 0.99990904
- O 0 0.536085
IL O 0 0.9914492
- O 0 0.013201951
3 O 0 0.0016834089
. O 0 0.0027250848

There O 0 0.0035899982
was O 0 0.0019113674
a O 0 0.0016007937
significant O 0 0.00083191256
reduction O 0 0.00096827204
of O 0 0.0010824265
thymidine B-Chemical 0 0.86567026
incorporation O 0 0.00065314944
into O 0 0.00018319601
both O 0 0.0003026178
erythroid O 0 0.92566586
and O 0 0.000588976
endothelial O 0 0.9914585
cells O 0 0.00038569444
in O 0 0.0001846685
cultures O 0 0.00023011322
pre O 0 0.00048950803
- O 0 0.0018883377
treated O 0 0.00084717973
with O 0 0.0012933395
IGF O 0 0.99991775
- O 0 0.5566695
IL O 0 0.99364376
- O 0 0.011743304
3 O 0 0.00092722505
and O 0 0.0017897646
EPO O 0 0.9961569
. O 0 0.004586667

Endothelial O 0 0.9933782
cell O 0 0.0043641776
culture O 0 0.0023193846
supernatants O 0 0.0009284291
separated O 0 0.00076229504
by O 0 0.000422829
ultrafiltration O 0 0.004629193
and O 0 0.00032055087
ultracentrifugation O 0 0.00062311185
from O 0 0.0001722845
cells O 0 0.00026361507
treated O 0 0.0005955109
with O 0 0.0006214293
EPO O 0 0.99976
and O 0 0.00067407166
IL O 0 0.99046236
- O 0 0.006201051
3 O 0 0.00012251196
significantly O 0 0.00016891283
reduced O 0 0.00032932407
thymidine B-Chemical 0 0.8350882
incorporation O 0 0.00038804617
into O 0 0.00012764923
erythroid O 0 0.86033857
cells O 0 0.00021643259
as O 0 0.00010521845
compared O 0 6.6176224e-05
to O 0 6.588456e-05
identical O 0 5.0330564e-05
fractions O 0 8.504655e-05
obtained O 0 7.477896e-05
from O 0 9.020844e-05
the O 0 0.00011010878
media O 0 0.0004102114
of O 0 0.00029908234
cells O 0 0.0005398963
cultured O 0 0.0014729131
with O 0 0.0017854363
EPO O 0 0.9994831
alone O 0 0.0027573914
. O 0 0.0032234953

These O 0 0.0019478331
results O 0 0.0013916263
suggest O 0 0.00081844855
that O 0 0.0010658056
endothelial O 0 0.9718553
cells O 0 0.0012472526
treated O 0 0.0013175185
simultaneously O 0 0.00049745315
with O 0 0.00096957735
EPO O 0 0.9996092
and O 0 0.0009379976
IL O 0 0.98211724
- O 0 0.0038307165
3 O 0 0.0001967148
have O 0 0.00015752154
a O 0 0.00028016823
negative O 0 0.00025986394
effect O 0 0.00036167642
on O 0 0.00061555364
erythroid O 0 0.9421037
cell O 0 0.004077055
production O 0 0.004567271
. O 0 0.0042169737

The O 0 0.0016321907
relationship O 0 0.001043475
between O 0 0.0013241619
hippocampal O 0 0.31347358
acetylcholine B-Chemical 1 0.9997328
release O 0 0.002595415
and O 0 0.0006916219
cholinergic O 0 0.10957766
convulsant O 0 0.9888104
sensitivity O 0 0.00048964936
in O 0 0.00025129935
withdrawal O 0 0.019063272
seizure B-Disease 0 0.99968815
- O 0 0.003327179
prone O 0 0.00021177507
and O 0 0.0002485524
withdrawal O 0 0.008826789
seizure B-Disease 0 0.99939275
- O 0 0.003753903
resistant O 0 0.00049823563
selected O 0 0.00039617257
mouse O 0 0.00062255317
lines O 0 0.0016945282
. O 0 0.0029180741

BACKGROUND O 0 0.015658768
: O 0 0.0042864066
The O 0 0.0011079457
septo O 0 0.060089316
- O 0 0.015046408
hippocampal O 0 0.019104393
cholinergic O 0 0.011335456
pathway O 0 0.00024304716
has O 0 0.00016127476
been O 0 0.00019561146
implicated O 0 0.00019041877
in O 0 0.0002511303
epileptogenesis O 0 0.6858747
, O 0 0.0003754214
and O 0 0.00015405238
genetic O 0 0.00021356353
factors O 0 0.00018272098
influence O 0 6.9720416e-05
the O 0 7.941541e-05
response O 0 9.851094e-05
to O 0 0.00010483507
cholinergic O 0 0.002838211
agents O 0 0.00040866423
, O 0 0.00028325315
but O 0 0.00014734098
limited O 0 0.0001275508
data O 0 0.00014365876
are O 0 8.3937666e-05
available O 0 8.6898806e-05
on O 0 0.00011581659
cholinergic O 0 0.0029175705
involvement O 0 0.0004434521
in O 0 0.0004656947
alcohol B-Chemical 0 0.99837935
withdrawal O 0 0.047063094
severity O 0 0.0044578793
. O 0 0.0024213525

Thus O 0 0.0021570686
, O 0 0.0027674483
the O 0 0.00081745087
relationship O 0 0.0004446532
between O 0 0.0004995189
cholinergic O 0 0.005209343
activity O 0 0.00021606103
and O 0 0.00023817652
responsiveness O 0 0.0002533203
and O 0 0.00036366077
alcohol B-Chemical 0 0.99820113
withdrawal O 0 0.0049899206
was O 0 0.00015775076
investigated O 0 0.00014770884
in O 0 0.00017205236
a O 0 0.00029827165
genetic O 0 0.00034992181
animal O 0 0.00025893003
model O 0 0.00028810967
of O 0 0.0007353769
ethanol B-Chemical 0 0.9994241
withdrawal O 0 0.10452679
severity O 0 0.005247539
. O 0 0.002561821

METHODS O 0 0.005607864
: O 0 0.0056506894
Cholinergic O 0 0.02630754
convulsant O 0 0.90531343
sensitivity O 0 0.0011396984
was O 0 0.00050523045
examined O 0 0.0003690152
in O 0 0.000609381
alcohol B-Chemical 0 0.99883264
- O 0 0.259346
na O 0 0.99993944
ve O 0 0.9609492
Withdrawal O 0 0.6163555
Seizure B-Disease 2 0.998604
- O 0 0.0039154445
Prone O 0 0.006672647
( O 0 0.00104281
WSP O 0 0.049471874
) O 0 0.0009789258
and O 0 0.0005929954
- O 0 0.0028441667
Resistant O 0 0.002984818
( O 0 0.0019110044
WSR O 0 0.64754236
) O 0 0.0024771506
mice O 0 0.00093685614
. O 0 0.0033119123

Animals O 0 0.0033062475
were O 0 0.0017351973
administered O 0 0.0026111507
nicotine B-Chemical 0 0.99547714
, O 0 0.0041735466
carbachol B-Chemical 0 0.999559
, O 0 0.0013059
or O 0 0.00047330515
neostigmine B-Chemical 0 0.999843
via O 0 0.00015777184
timed O 0 0.00020323232
tail O 0 0.00012628392
vein O 0 0.005202648
infusion O 0 0.000503349
, O 0 0.00020216047
and O 0 0.00010594678
the O 0 8.7813954e-05
latencies O 0 0.00033966248
to O 0 9.943299e-05
onset O 0 0.00023521205
of O 0 0.00030066966
tremor B-Disease 0 0.9999038
and O 0 0.00037227373
clonus O 0 0.97494966
were O 0 0.00017269072
recorded O 0 0.00018128702
and O 0 0.00022460494
converted O 0 0.00030693374
to O 0 0.00030941292
threshold O 0 0.00056061574
dose O 0 0.0019113926
. O 0 0.0024289305

We O 0 0.002333568
also O 0 0.0014415955
used O 0 0.0010801479
microdialysis O 0 0.004235905
to O 0 0.0004075195
measure O 0 0.0002896219
basal O 0 0.00079746486
and O 0 0.00072659756
potassium B-Chemical 0 0.9996588
- O 0 0.066356085
stimulated O 0 0.00166415
acetylcholine B-Chemical 1 0.9998678
( O 0 0.0053413254
ACh B-Chemical 0 0.9996486
) O 0 0.0014382319
release O 0 0.0006078218
in O 0 0.0002752799
the O 0 0.00033964776
CA1 O 0 0.024700595
region O 0 0.0003205393
of O 0 0.00060614065
the O 0 0.0008816116
hippocampus O 0 0.009450939
. O 0 0.0031307454

Potassium B-Chemical 0 0.9977431
was O 0 0.0032238988
applied O 0 0.0016295431
by O 0 0.0011774714
reverse O 0 0.0014002909
dialysis O 0 0.0018461846
twice O 0 0.0007610041
, O 0 0.0015883158
separated O 0 0.0014103577
by O 0 0.0014210247
75 O 0 0.0028930272
min O 0 0.0035392984
. O 0 0.004376721

Hippocampal O 0 0.9518866
ACh B-Chemical 0 0.997603
also O 0 0.0016054483
was O 0 0.00093320705
measured O 0 0.00072625006
during O 0 0.00044081296
testing O 0 0.0004878357
for O 0 0.00051312434
handling O 0 0.0013576915
- O 0 0.0065674526
induced O 0 0.003154842
convulsions B-Disease 0 0.99955744
. O 0 0.006722225

RESULTS O 0 0.0044359737
: O 0 0.0033226013
Sensitivity O 0 0.0027821653
to O 0 0.00065630523
several O 0 0.0005112041
convulsion B-Disease 0 0.99566
endpoints O 0 0.00036866008
induced O 0 0.0002967137
by O 0 0.00042158252
nicotine B-Chemical 0 0.99875844
, O 0 0.002723025
carbachol B-Chemical 0 0.99978524
, O 0 0.00095652847
and O 0 0.00052110077
neostigmine B-Chemical 0 0.9999318
were O 0 0.0002448362
significantly O 0 0.00027346707
greater O 0 0.00038796512
in O 0 0.0004921713
WSR O 0 0.74954194
versus O 0 0.00081977434
WSP O 0 0.02193256
mice O 0 0.0007048404
. O 0 0.0025175416

In O 0 0.0024547088
microdialysis O 0 0.00920476
experiments O 0 0.0010076314
, O 0 0.0014729692
the O 0 0.00057292485
lines O 0 0.000713288
did O 0 0.00055244734
not O 0 0.00035809097
differ O 0 0.00034015262
in O 0 0.0003030962
basal O 0 0.0007565647
release O 0 0.00078260875
of O 0 0.00061622146
ACh B-Chemical 0 0.9996438
, O 0 0.0006608891
and O 0 0.00027963426
50 O 0 0.00048481813
mM O 0 0.045111276
KCl B-Chemical 0 0.9852291
increased O 0 0.0017043079
ACh B-Chemical 0 0.99923146
output O 0 0.00040750165
in O 0 0.00026754633
both O 0 0.0003073065
lines O 0 0.0006191148
of O 0 0.000875059
mice O 0 0.0007095054
. O 0 0.0026767128

However O 0 0.0031571607
, O 0 0.0035879961
the O 0 0.0012232442
increase O 0 0.0009126476
in O 0 0.0007704874
release O 0 0.0014527204
of O 0 0.001031222
ACh B-Chemical 0 0.99927646
produced O 0 0.00027005194
by O 0 0.00019558478
the O 0 0.00013313851
first O 0 9.858159e-05
application O 0 0.00017205926
of O 0 0.0003024756
KCl B-Chemical 0 0.8714094
was O 0 0.00028863453
2 O 0 0.00031468205
- O 0 0.0010206759
fold O 0 0.00033826724
higher O 0 0.00044379133
in O 0 0.0005949153
WSP O 0 0.06686492
versus O 0 0.0008557856
WSR O 0 0.47956455
mice O 0 0.00076545746
. O 0 0.002574605

When O 0 0.0029875576
hippocampal O 0 0.18022531
ACh B-Chemical 0 0.99846005
was O 0 0.00078852504
measured O 0 0.00045986232
during O 0 0.00022227835
testing O 0 0.00020460188
for O 0 0.00017238194
handling O 0 0.00042088985
- O 0 0.0029712624
induced O 0 0.0005688391
convulsions B-Disease 0 0.99996436
, O 0 0.0023952387
extracellular O 0 0.012262879
ACh B-Chemical 0 0.99971944
was O 0 0.00020873378
significantly O 0 0.00025207206
elevated O 0 0.0009827324
( O 0 0.0004022307
192 O 0 0.0004397046
% O 0 0.0003800803
) O 0 0.0004338918
in O 0 0.00020426215
WSP O 0 0.027228227
mice O 0 7.897249e-05
, O 0 0.00033369302
but O 0 0.00025328866
was O 0 0.00025856297
nonsignificantly O 0 0.22124791
elevated O 0 0.0020239092
( O 0 0.0007020894
59 O 0 0.0005807357
% O 0 0.00080412155
) O 0 0.0011211066
in O 0 0.0008697523
WSR O 0 0.48745868
mice O 0 0.00085458613
. O 0 0.0028095117

CONCLUSIONS O 0 0.016463248
: O 0 0.0031272632
These O 0 0.0006377514
results O 0 0.00049803266
suggest O 0 0.00028665067
that O 0 0.00030243144
differences O 0 0.00028364582
in O 0 0.0003512308
cholinergic O 0 0.004072937
activity O 0 0.00013821718
and O 0 0.00020170031
postsynaptic O 0 0.0015876052
sensitivity O 0 0.00035966342
to O 0 0.00025101178
cholinergic O 0 0.47851396
convulsants B-Disease 0 0.9999521
may O 0 0.00015249908
be O 0 0.000115531024
associated O 0 0.00013903422
with O 0 0.00023852465
ethanol B-Chemical 0 0.9997609
withdrawal O 0 0.021476006
severity O 0 0.0005937644
and O 0 0.0001501837
implicate O 0 0.000120478675
cholinergic O 0 0.0021190504
mechanisms O 0 0.00023902777
in O 0 0.00065162894
alcohol B-Chemical 0 0.99848145
withdrawal O 0 0.07033517
. O 0 0.0027232398

Specifically O 0 0.0035944767
, O 0 0.0059227557
WSP O 0 0.07848921
mice O 0 0.00045606823
may O 0 0.0004399511
have O 0 0.00032064534
lower O 0 0.00037919547
sensitivity O 0 0.00051123305
to O 0 0.00034302226
cholinergic O 0 0.1193966
convulsants B-Disease 0 0.99979764
compared O 0 0.00016109848
with O 0 0.00025749477
WSR O 0 0.9474476
because O 0 0.00011329961
of O 0 0.00019955267
postsynaptic O 0 0.0057065343
receptor O 0 0.00088835653
desensitization O 0 0.000767935
brought O 0 0.00020663335
on O 0 0.000113590395
by O 0 0.00017704943
higher O 0 0.00028808604
activity O 0 0.00028049803
of O 0 0.00074359943
cholinergic O 0 0.03678715
neurons O 0 0.0016040716
. O 0 0.002372737

Capsaicin B-Chemical 0 0.99935144
- O 0 0.08429607
induced O 0 0.0027588997
muscle B-Disease 0 0.55969316
pain I-Disease 0 0.82086724
alters O 0 0.00049747305
the O 0 0.00049568
excitability O 0 0.0019595332
of O 0 0.00052077585
the O 0 0.0004824943
human O 0 0.00090843864
jaw O 0 0.11352794
- O 0 0.008469171
stretch O 0 0.0030482302
reflex O 0 0.030255735
. O 0 0.0040977728

The O 0 0.0024939436
pathophysiology O 0 0.012639037
of O 0 0.0028141125
painful O 0 0.9728361
temporomandibular B-Disease 0 0.99973863
disorders I-Disease 0 0.9998704
is O 0 0.0004671165
not O 0 0.00028849035
fully O 0 0.00024072088
understood O 0 0.00079544866
, O 0 0.00056855555
but O 0 0.00024035279
evidence O 0 0.00014362547
suggests O 0 0.00011932996
that O 0 0.00020553455
muscle B-Disease 0 0.21087305
pain I-Disease 0 0.6786613
modulates O 0 0.00014713938
motor O 0 0.00085638685
function O 0 0.00031397212
in O 0 0.000500656
characteristic O 0 0.00088650064
ways O 0 0.0014830126
. O 0 0.0029293906

This O 0 0.004391409
study O 0 0.0019183059
tested O 0 0.0008703367
the O 0 0.00052821625
hypothesis O 0 0.00043530014
that O 0 0.00031821275
activation O 0 0.00035318613
of O 0 0.0004607205
nociceptive B-Disease 0 0.004712754
muscle I-Disease 0 0.09609103
afferent O 0 0.0007960579
fibers O 0 0.00034818528
would O 0 0.000121168916
be O 0 0.00012632307
linked O 0 0.000119518314
to O 0 0.00010439395
an O 0 0.00014627262
increased O 0 0.00020345568
excitability O 0 0.0008530615
of O 0 0.00012635211
the O 0 0.00010963375
human O 0 0.00020872243
jaw O 0 0.147475
- O 0 0.0034148912
stretch O 0 0.0003051711
reflex O 0 0.0029768818
and O 0 0.00010253434
whether O 0 4.2579846e-05
this O 0 0.0001359676
process O 0 0.00013335592
would O 0 0.000115661416
be O 0 0.00012654164
sensitive O 0 0.00011209999
to O 0 0.00012908773
length O 0 0.0001665624
and O 0 0.00031999184
velocity O 0 0.0011324788
of O 0 0.0006919156
the O 0 0.00084710476
stretch O 0 0.0025458315
. O 0 0.002954389

Capsaicin B-Chemical 0 0.99860257
( O 0 0.0056849173
10 O 0 0.0016864801
micro O 0 0.0033511142
g O 0 0.0028493041
) O 0 0.0011671985
was O 0 0.00032730578
injected O 0 0.00024047658
into O 0 0.0001770214
the O 0 0.0002712539
masseter O 0 0.0016628258
muscle O 0 0.00097550475
to O 0 0.0002090028
induce O 0 0.00024374895
pain B-Disease 0 0.0076385913
in O 0 0.00048625286
11 O 0 0.00078705413
healthy O 0 0.0025438103
volunteers O 0 0.0033431547
. O 0 0.0030384331

Short O 0 0.005494022
- O 0 0.008224623
latency O 0 0.0028237645
reflex O 0 0.005197044
responses O 0 0.0006402642
were O 0 0.00044804497
evoked O 0 0.00073202915
in O 0 0.00029895862
the O 0 0.000269276
masseter O 0 0.001216316
and O 0 0.00025077807
temporalis O 0 0.0010987164
muscles O 0 0.0003626875
by O 0 0.00014336796
a O 0 0.0002037018
stretch O 0 0.0001990508
device O 0 0.00020032647
with O 0 0.00012077649
different O 0 8.648215e-05
velocities O 0 0.0004601131
and O 0 0.00017233905
displacements O 0 0.0006053212
before O 0 0.000112764465
, O 0 0.0003367251
during O 0 0.00018882862
, O 0 0.0005068944
and O 0 0.00038889417
after O 0 0.00032637818
the O 0 0.00080155453
pain B-Disease 0 0.026229408
. O 0 0.0030612391

The O 0 0.0017463587
normalized O 0 0.0010800745
reflex O 0 0.0074674683
amplitude O 0 0.0018090664
increased O 0 0.000752906
with O 0 0.00043626933
an O 0 0.0003366858
increase O 0 0.00020939216
in O 0 0.00018435111
velocity O 0 0.0004950409
at O 0 0.00012613182
a O 0 0.00020687032
given O 0 0.000108385044
displacement O 0 0.00049454096
, O 0 0.0003903104
but O 0 0.00022054705
remained O 0 0.00024139523
constant O 0 0.00023698185
with O 0 0.00021561694
different O 0 0.00018206445
displacements O 0 0.0009807149
at O 0 0.0003065527
a O 0 0.00067007873
given O 0 0.000546787
velocity O 0 0.0032344288
. O 0 0.0028414072

The O 0 0.0017057979
normalized O 0 0.0010490023
reflex O 0 0.0071317838
amplitude O 0 0.0016126712
was O 0 0.0004770278
significantly O 0 0.00041530788
higher O 0 0.0003584474
during O 0 0.0002758737
pain B-Disease 0 0.020663815
, O 0 0.00060616556
but O 0 0.0003309588
only O 0 0.00028079882
at O 0 0.00022350586
faster O 0 0.00041366668
stretches O 0 0.000615066
in O 0 0.00054601824
the O 0 0.0009359091
painful B-Disease 0 0.9275118
muscle I-Disease 0 0.23862608
. O 0 0.003932569

Increased O 0 0.004176701
sensitivity O 0 0.002434074
of O 0 0.0013199998
the O 0 0.0007359458
fusimotor O 0 0.0013893374
system O 0 0.00048217384
during O 0 0.00036586178
acute O 0 0.08741705
muscle B-Disease 0 0.5237615
pain I-Disease 0 0.8481205
could O 0 0.00019433687
be O 0 0.00019556576
one O 0 0.00016799087
likely O 0 0.00013203998
mechanism O 0 0.00018554283
to O 0 0.00032473414
explain O 0 0.0004683725
the O 0 0.00075857464
findings O 0 0.0019910736
. O 0 0.0031038534

Effects O 0 0.0038286315
of O 0 0.0026989882
5 O 0 0.0021235219
- O 0 0.013513434
HT1B O 0 0.15981162
receptor O 0 0.0027399524
ligands O 0 0.0017236951
microinjected O 0 0.00072774896
into O 0 0.00023461739
the O 0 0.00035869045
accumbal O 0 0.95256937
shell O 0 0.0008784114
or O 0 0.00017105747
core O 0 0.00015055304
on O 0 0.00013204727
the O 0 0.00027013538
cocaine B-Chemical 0 0.9997526
- O 0 0.014260803
induced O 0 0.0007136807
locomotor B-Disease 0 0.98225176
hyperactivity I-Disease 2 0.999997
in O 0 0.0016634562
rats O 0 0.0027072125
. O 0 0.0027070965

The O 0 0.001973128
present O 0 0.0013902923
study O 0 0.0012625452
was O 0 0.0006336968
designed O 0 0.0003918277
to O 0 0.0002539527
examine O 0 0.00011959539
the O 0 0.00016982008
effect O 0 0.00017952677
of O 0 0.00029515344
5 O 0 0.00031113272
- O 0 0.004862429
HT1B O 0 0.10768589
receptor O 0 0.00088236795
ligands O 0 0.0006464275
microinjected O 0 0.0002575306
into O 0 7.687483e-05
the O 0 9.278805e-05
subregions O 0 0.00021324001
of O 0 0.00012277008
the O 0 0.00010911489
nucleus O 0 0.00013554147
accumbens O 0 0.0019603334
( O 0 0.00019697775
the O 0 8.8140805e-05
shell O 0 0.0003645866
and O 0 0.0001391248
the O 0 0.00010738949
core O 0 0.00013602714
) O 0 0.00035982425
on O 0 0.00011444572
the O 0 0.0002424401
locomotor B-Disease 0 0.96042717
hyperactivity I-Disease 2 0.9999989
induced O 0 0.0007560044
by O 0 0.00083052675
cocaine B-Chemical 0 0.99946314
in O 0 0.0010263344
rats O 0 0.0021405048
. O 0 0.0024472007

Male O 0 0.008638254
Wistar O 0 0.0054355618
rats O 0 0.0016022424
were O 0 0.0006439258
implanted O 0 0.00083977194
bilaterally O 0 0.0011193287
with O 0 0.00028623996
cannulae O 0 0.00062939496
into O 0 0.00014843016
the O 0 0.00020232052
accumbens O 0 0.0021312311
shell O 0 0.00051131257
or O 0 0.00014570118
core O 0 0.00014696199
, O 0 0.0002724958
and O 0 0.00014792758
then O 0 0.000119225435
were O 0 0.000116842
locally O 0 0.00027926898
injected O 0 0.00013887946
with O 0 0.0003111517
GR B-Chemical 0 0.9601604
55562 I-Chemical 0 0.9876364
( O 0 0.00062262174
an O 0 0.00022335863
antagonist O 0 0.013951662
of O 0 0.00024547012
5 O 0 0.00023622318
- O 0 0.0033027923
HT1B O 0 0.073571846
receptors O 0 0.00085044047
) O 0 0.0009357513
or O 0 0.00042525918
CP B-Chemical 0 0.9998134
93129 I-Chemical 0 0.99983215
( O 0 0.0009475012
an O 0 0.00035335976
agonist O 0 0.0032726417
of O 0 0.000489887
5 O 0 0.00057396985
- O 0 0.0049062786
HT1B O 0 0.089409836
receptors O 0 0.0033741647
) O 0 0.004417126
. O 0 0.0034293837

Given O 0 0.0016990546
alone O 0 0.0023546526
to O 0 0.0015064599
any O 0 0.0016315046
accumbal O 0 0.9935614
subregion O 0 0.006219967
, O 0 0.0025019653
GR B-Chemical 0 0.93706316
55562 I-Chemical 0 0.9659442
( O 0 0.0008912481
0 O 0 0.00035865023
. O 0 0.00021085692
1 O 0 0.00023031232
- O 0 0.0006246012
10 O 0 0.00017408309
microg O 0 0.00034636617
/ O 0 0.0010030088
side O 0 0.00092117034
) O 0 0.0010080591
or O 0 0.00046160913
CP B-Chemical 0 0.9997446
93129 I-Chemical 0 0.9997552
( O 0 0.000707323
0 O 0 0.0002659948
. O 0 0.00015981132
1 O 0 0.00018822137
- O 0 0.00056456146
10 O 0 0.00016116763
microg O 0 0.00034897268
/ O 0 0.0011094189
side O 0 0.001035849
) O 0 0.0009392376
did O 0 0.0003794296
not O 0 0.00036226667
change O 0 0.00057013147
basal O 0 0.0016765877
locomotor O 0 0.0077999826
activity O 0 0.0011665707
. O 0 0.0026237485

Systemic O 0 0.8142378
cocaine B-Chemical 0 0.9988188
( O 0 0.0033745046
10 O 0 0.0011589238
mg O 0 0.004642709
/ O 0 0.0019797508
kg O 0 0.0014163764
) O 0 0.001124713
significantly O 0 0.0005632457
increased O 0 0.00067298044
the O 0 0.00054277596
locomotor O 0 0.0032129346
activity O 0 0.0005662173
of O 0 0.0011988624
rats O 0 0.0028997834
. O 0 0.0034966946

GR B-Chemical 0 0.9888015
55562 I-Chemical 0 0.9858385
( O 0 0.005192769
0 O 0 0.001753923
. O 0 0.00088346744
1 O 0 0.00073425716
- O 0 0.0014516616
10 O 0 0.00037786624
microg O 0 0.00059081207
/ O 0 0.0012393784
side O 0 0.00090586237
) O 0 0.0007604431
, O 0 0.00045412628
administered O 0 0.00038100017
intra O 0 0.0012193461
- O 0 0.003095628
accumbens O 0 0.002324268
shell O 0 0.0003663497
prior O 0 7.756628e-05
to O 0 0.000156886
cocaine B-Chemical 0 0.9991043
, O 0 0.0005556332
dose O 0 0.00074500556
- O 0 0.0077939513
dependently O 0 0.10900931
attenuated O 0 0.0005182442
the O 0 0.00038714142
psychostimulant O 0 0.99814165
- O 0 0.0106712505
induced O 0 0.0011161003
locomotor B-Disease 0 0.98773545
hyperactivity I-Disease 2 0.999995
. O 0 0.0061092363

Such O 0 0.003880219
attenuation O 0 0.0022300633
was O 0 0.0011884401
not O 0 0.00071193534
found O 0 0.00054019847
in O 0 0.00038714457
animals O 0 0.0002675527
which O 0 0.00036067923
had O 0 0.0002839762
been O 0 0.0002605357
injected O 0 0.00032217594
with O 0 0.00068270485
GR B-Chemical 0 0.9284138
55562 I-Chemical 0 0.91923314
into O 0 0.0004512358
the O 0 0.0006934121
accumbens O 0 0.005397415
core O 0 0.0014515311
. O 0 0.0027740863

When O 0 0.0016680665
injected O 0 0.0014695638
into O 0 0.00083557185
the O 0 0.00096186786
accumbens O 0 0.01211057
shell O 0 0.0022286272
( O 0 0.00098318
but O 0 0.00039588643
not O 0 0.00022518887
the O 0 0.00019051193
core O 0 0.00022300945
) O 0 0.00057656725
before O 0 0.00018956391
cocaine B-Chemical 0 0.9996805
, O 0 0.0032029995
CP B-Chemical 0 0.9998078
93129 I-Chemical 0 0.9997552
( O 0 0.00064720574
0 O 0 0.0002393977
. O 0 0.00013989703
1 O 0 0.00015905198
- O 0 0.00047905854
10 O 0 0.0001210622
microg O 0 0.00025122153
/ O 0 0.00075230503
side O 0 0.00058686576
) O 0 0.00043797996
enhanced O 0 0.00014249326
the O 0 0.00011996877
locomotor O 0 0.0012996206
response O 0 0.00011215557
to O 0 0.00013971253
cocaine B-Chemical 0 0.9995165
; O 0 0.00030799667
the O 0 7.381787e-05
maximum O 0 0.00010411955
effect O 0 8.703315e-05
being O 0 0.00012651087
observed O 0 0.00010284014
after O 0 7.927422e-05
10 O 0 0.00016884856
microg O 0 0.00042029988
/ O 0 0.0012872968
side O 0 0.0010077799
of O 0 0.0007047749
the O 0 0.0009228948
agonist O 0 0.04517594
. O 0 0.0035433301

The O 0 0.002095778
later O 0 0.0016242393
enhancement O 0 0.0014496372
was O 0 0.00080154685
attenuated O 0 0.0007926147
after O 0 0.00036072277
intra O 0 0.002028349
- O 0 0.0053605014
accumbens O 0 0.0051431647
shell O 0 0.0010366678
treatment O 0 0.0004173977
with O 0 0.00069060526
GR B-Chemical 0 0.93331105
55562 I-Chemical 0 0.96674234
( O 0 0.0011772156
1 O 0 0.0005953154
microg O 0 0.0010911631
/ O 0 0.0029964934
side O 0 0.003303788
) O 0 0.00492689
. O 0 0.003928768

Our O 0 0.0018554175
findings O 0 0.0016509049
indicate O 0 0.0007160109
that O 0 0.0010269892
cocaine B-Chemical 0 0.99974257
induced O 0 0.002414223
hyperlocomotion B-Disease 0 0.99998105
is O 0 0.00037649914
modified O 0 0.00024223239
by O 0 0.00020871546
5 O 0 0.00025004605
- O 0 0.0030703915
HT1B O 0 0.077606425
receptor O 0 0.0008687919
ligands O 0 0.00070602464
microinjected O 0 0.00030409792
into O 0 9.481766e-05
the O 0 0.00014391144
accumbens O 0 0.0064889975
shell O 0 0.00072930485
, O 0 0.00035500192
but O 0 0.00016855211
not O 0 0.00010671657
core O 0 0.000119699434
, O 0 0.00024050982
this O 0 0.00011193794
modification O 0 9.098077e-05
consisting O 0 8.914279e-05
in O 0 0.00010004235
inhibitory O 0 0.00021576234
and O 0 0.00012362494
facilitatory O 0 0.0007222545
effects O 0 0.00010557082
of O 0 0.00014325604
the O 0 0.00012466978
5 O 0 0.00018885758
- O 0 0.005153669
HT1B O 0 0.2832376
receptor O 0 0.00467228
antagonist O 0 0.72142977
( O 0 0.0061899098
GR B-Chemical 0 0.9890463
55562 I-Chemical 0 0.99381196
) O 0 0.0016085445
and O 0 0.0004264198
agonist O 0 0.04957578
( O 0 0.0040774215
CP B-Chemical 0 0.99966955
93129 I-Chemical 0 0.999648
) O 0 0.003699146
, O 0 0.0021677578
respectively O 0 0.0030026836
. O 0 0.003256114

In O 0 0.0018946787
other O 0 0.0016734765
words O 0 0.0026280242
, O 0 0.0017925749
the O 0 0.0005368991
present O 0 0.0003402421
results O 0 0.00027679684
suggest O 0 0.00018060964
that O 0 0.00024442992
the O 0 0.00040225856
accumbal O 0 0.9845872
shell O 0 0.0016946759
5 O 0 0.0003059871
- O 0 0.0028278788
HT1B O 0 0.026331712
receptors O 0 0.00041617596
play O 0 0.00011813168
a O 0 0.00020089053
permissive O 0 0.00012762219
role O 0 7.869795e-05
in O 0 0.00016430246
the O 0 0.00019195423
behavioural O 0 0.0009113555
response O 0 0.00033193053
to O 0 0.0004354854
the O 0 0.00086148817
psychostimulant O 0 0.9814478
. O 0 0.003021794

Cocaine B-Chemical 0 0.99947554
related O 0 0.002457038
chest B-Disease 0 0.0042877356
pain I-Disease 0 0.034778412
: O 0 0.0020395138
are O 0 0.00061852706
we O 0 0.00046146766
seeing O 0 0.0013335559
the O 0 0.000885699
tip O 0 0.002759637
of O 0 0.0020339293
an O 0 0.0031428165
iceberg O 0 0.10214918
? O 0 0.014837008

The O 0 0.0030933397
recreational O 0 0.0073958556
use O 0 0.0023181327
of O 0 0.0030537858
cocaine B-Chemical 0 0.99818486
is O 0 0.0016370619
on O 0 0.0011891793
the O 0 0.001670576
increase O 0 0.0028378519
. O 0 0.0052850028

The O 0 0.0025055297
emergency O 0 0.0034949703
nurse O 0 0.0029905844
ought O 0 0.0015512694
to O 0 0.0006478278
be O 0 0.00053627003
familiar O 0 0.00089942105
with O 0 0.00044339805
some O 0 0.0003746577
of O 0 0.00039818988
the O 0 0.00037953744
cardiovascular O 0 0.03083845
consequences O 0 0.0007249639
of O 0 0.0012818406
cocaine B-Chemical 0 0.9989146
use O 0 0.0019964923
. O 0 0.003029295

In O 0 0.002006818
particular O 0 0.0014059372
, O 0 0.0020384418
the O 0 0.00078319624
tendency O 0 0.0013307208
of O 0 0.000943088
cocaine B-Chemical 0 0.9994716
to O 0 0.00028341956
produce O 0 0.00016405979
chest B-Disease 0 0.0005869995
pain I-Disease 0 0.014154875
ought O 0 0.00027006454
to O 0 0.00012044113
be O 0 0.000119630386
in O 0 0.00011117987
the O 0 0.000107070264
mind O 0 0.000325822
of O 0 0.00014654764
the O 0 0.0001096534
emergency O 0 0.00023403719
nurse O 0 0.00024120865
when O 0 7.516845e-05
faced O 0 0.0001548546
with O 0 0.00017605553
a O 0 0.00031030265
young O 0 0.001073649
victim O 0 0.00073303224
of O 0 0.00021173974
chest B-Disease 0 0.0007968321
pain I-Disease 0 0.030206565
who O 0 0.00030365554
is O 0 0.00018607295
otherwise O 0 0.00036856785
at O 0 0.00037574975
low O 0 0.0012288942
risk O 0 0.009276139
. O 0 0.0033688706

The O 0 0.0015834558
mechanism O 0 0.0009953603
of O 0 0.0012099083
chest B-Disease 0 0.0021457665
pain I-Disease 0 0.017581182
related O 0 0.00034747942
to O 0 0.0004509582
cocaine B-Chemical 0 0.9978271
use O 0 0.00033824117
is O 0 0.00024077759
discussed O 0 0.0002697177
and O 0 0.00038660612
treatment O 0 0.00051288767
dilemmas O 0 0.0013522354
are O 0 0.0008506743
discussed O 0 0.001533715
. O 0 0.003331529

Finally O 0 0.0032079692
, O 0 0.004379847
moral O 0 0.0057508484
issues O 0 0.0015101891
relating O 0 0.0005741489
to O 0 0.00047308553
the O 0 0.00037503114
testing O 0 0.0003517317
of O 0 0.0004432083
potential O 0 0.0005744677
cocaine B-Chemical 0 0.9992023
users O 0 0.0015044379
will O 0 0.0006265431
be O 0 0.00086620834
addressed O 0 0.0010582313
. O 0 0.0030936159

Crossover O 0 0.009366852
comparison O 0 0.0012263001
of O 0 0.0008975831
efficacy O 0 0.0006350057
and O 0 0.0005090246
preference O 0 0.00042754054
for O 0 0.00044576303
rizatriptan B-Chemical 0 0.9998311
10 O 0 0.00045604652
mg O 0 0.0035942888
versus O 0 0.0006339964
ergotamine B-Chemical 0 0.99998724
/ O 0 0.17528358
caffeine B-Chemical 0 0.9997136
in O 0 0.0032978863
migraine B-Disease 0 0.9998155
. O 0 0.0043537235

Rizatriptan B-Chemical 0 0.99969673
is O 0 0.0024514366
a O 0 0.002054858
selective O 0 0.001408812
5 B-Chemical 0 0.0010518834
- I-Chemical 0 0.006338789
HT I-Chemical 0 0.9694466
( O 0 0.0010162093
1B O 0 0.00048318008
/ O 0 0.0014036509
1D O 0 0.0005764974
) O 0 0.00084173423
receptor O 0 0.0008970675
agonist O 0 0.003458056
with O 0 0.00024878574
rapid O 0 0.00034500542
oral O 0 0.0016126028
absorption O 0 0.013299912
and O 0 0.00015277081
early O 0 0.00022935623
onset O 0 0.00023400415
of O 0 0.00015997933
action O 0 0.00019733135
in O 0 0.0002065268
the O 0 0.00026153572
acute O 0 0.01105901
treatment O 0 0.0006725832
of O 0 0.0017513635
migraine B-Disease 0 0.999833
. O 0 0.003842239

This O 0 0.0044582523
randomized O 0 0.0037003518
double O 0 0.0013521776
- O 0 0.007102001
blind O 0 0.026800493
crossover O 0 0.0028620793
outpatient O 0 0.000748249
study O 0 0.00023327237
assessed O 0 0.00014292817
the O 0 0.00010932453
preference O 0 0.00013036914
for O 0 0.000117014366
1 O 0 0.00025571196
rizatriptan B-Chemical 0 0.99987435
10 O 0 0.00017177747
mg O 0 0.0024687122
tablet O 0 0.01901238
to O 0 0.000121089906
2 O 0 0.0002881396
ergotamine B-Chemical 0 0.9999914
1 O 0 0.00024849983
mg O 0 0.0067491625
/ O 0 0.0023594967
caffeine B-Chemical 0 0.999567
100 O 0 0.0007457592
mg O 0 0.025490412
tablets O 0 0.03767135
in O 0 0.00014721698
439 O 0 0.0010058047
patients O 0 0.00030446783
treating O 0 0.00021420879
a O 0 0.00033013825
single O 0 0.00035419466
migraine B-Disease 0 0.9999429
attack O 0 0.008585835
with O 0 0.0006095187
each O 0 0.00052280456
therapy O 0 0.0014818615
. O 0 0.0019903868

Of O 0 0.0049563763
patients O 0 0.0029432103
expressing O 0 0.00074053946
a O 0 0.0013287828
preference O 0 0.0008442409
( O 0 0.001187541
89 O 0 0.0008976139
. O 0 0.00039032148
1 O 0 0.00033943637
% O 0 0.00052060315
) O 0 0.00054949493
, O 0 0.00035423785
more O 0 0.00022562168
than O 0 0.000117084244
twice O 0 8.709309e-05
as O 0 9.90316e-05
many O 0 9.463203e-05
preferred O 0 0.00019928513
rizatriptan B-Chemical 0 0.99996614
to O 0 0.00039821042
ergotamine B-Chemical 0 0.99999774
/ O 0 0.16637337
caffeine B-Chemical 0 0.99986005
( O 0 0.0005269109
69 O 0 0.00021272784
. O 0 0.0001076997
9 O 0 9.272196e-05
vs O 0 0.0001728474
. O 0 0.00013626015
30 O 0 0.0001297748
. O 0 0.00014857078
1 O 0 0.0001945872
% O 0 0.0003387906
, O 0 0.00035029647
p O 0 0.0004111304
< O 0 0.0004420627
or O 0 0.00034606914
= O 0 0.001199662
0 O 0 0.0009231732
. O 0 0.001060261
001 O 0 0.009701666
) O 0 0.0049209152
. O 0 0.0043551913

Faster O 0 0.017953612
relief O 0 0.004011078
of O 0 0.0027101738
headache B-Disease 0 0.99419194
was O 0 0.0006853503
the O 0 0.00035315732
most O 0 0.00033141667
important O 0 0.00014185013
reason O 0 0.0001238711
for O 0 0.00014897563
preference O 0 0.00023241919
, O 0 0.00044729857
cited O 0 0.00044901553
by O 0 0.0002062104
67 O 0 0.00034995296
. O 0 0.00014429247
3 O 0 0.00010802175
% O 0 0.00020890181
of O 0 0.00014460555
patients O 0 0.00042438088
preferring O 0 0.0019916592
rizatriptan B-Chemical 0 0.9999683
and O 0 0.00021917543
54 O 0 0.00027671663
. O 0 0.00013675701
2 O 0 0.00014919257
% O 0 0.00025379055
of O 0 0.00020093058
patients O 0 0.0005368965
who O 0 0.0005446048
preferred O 0 0.0008293481
ergotamine B-Chemical 0 0.99999
/ O 0 0.38933644
caffeine B-Chemical 0 0.9995517
. O 0 0.0045375163

The O 0 0.002850766
co O 0 0.021232305
- O 0 0.0068038832
primary O 0 0.0008114873
endpoint O 0 0.00058778183
of O 0 0.00056111306
being O 0 0.0006039231
pain B-Disease 0 0.018778967
free O 0 0.0005097575
at O 0 0.0002309304
2 O 0 0.00030467164
h O 0 0.0003123078
was O 0 0.00026614452
also O 0 0.00030204272
in O 0 0.00042882853
favor O 0 0.00090697524
of O 0 0.0021396328
rizatriptan B-Chemical 0 0.9998312
. O 0 0.004120531

Forty O 0 0.00828168
- O 0 0.0060419897
nine O 0 0.0009794282
percent O 0 0.00079468865
of O 0 0.0006787455
patients O 0 0.0009869917
were O 0 0.00041444946
pain B-Disease 0 0.006318483
free O 0 0.00036426765
2 O 0 0.00020383862
h O 0 0.00018191872
after O 0 0.0001285279
rizatriptan B-Chemical 0 0.99983966
, O 0 0.00027480788
compared O 0 9.110058e-05
with O 0 0.00013646143
24 O 0 0.00013789689
. O 0 9.997454e-05
3 O 0 8.740618e-05
% O 0 0.00020976886
treated O 0 0.0003056501
with O 0 0.00054215244
ergotamine B-Chemical 0 0.9999982
/ O 0 0.17955972
caffeine B-Chemical 0 0.9997702
( O 0 0.00034951002
p O 0 0.00021338626
< O 0 0.00016713815
or O 0 0.00010325974
= O 0 0.00035893932
0 O 0 0.00019695821
. O 0 0.00016395672
001 O 0 0.0023943426
) O 0 0.00061279687
, O 0 0.0007295408
rizatriptan B-Chemical 0 0.9999261
being O 0 0.00024290725
superior O 0 0.00033429035
within O 0 0.0001435046
1 O 0 0.00034150382
h O 0 0.00045764187
of O 0 0.0007729565
treatment O 0 0.0013610001
. O 0 0.0027042944

Headache B-Disease 0 0.028855942
relief O 0 0.002960128
at O 0 0.0011729521
2 O 0 0.0010619841
h O 0 0.0008529079
was O 0 0.0005525958
75 O 0 0.0007006574
. O 0 0.00032844173
9 O 0 0.00024431458
% O 0 0.00045112846
for O 0 0.00027780628
rizatriptan B-Chemical 0 0.9998559
and O 0 0.00028805528
47 O 0 0.00033620305
. O 0 0.00015275406
3 O 0 0.00012831957
% O 0 0.00031415268
for O 0 0.00025942278
ergotamine B-Chemical 0 0.9999945
/ O 0 0.069877714
caffeine B-Chemical 0 0.9996439
( O 0 0.00037959852
p O 0 0.00023338296
< O 0 0.00018110388
or O 0 0.000108930355
= O 0 0.00036547935
0 O 0 0.00019171313
. O 0 0.00015041788
001 O 0 0.0019515632
) O 0 0.0004135096
, O 0 0.00027978758
with O 0 0.00026993663
rizatriptan B-Chemical 0 0.9999598
being O 0 0.00017176944
superior O 0 0.0003190046
to O 0 0.00028596987
ergotamine B-Chemical 0 0.9999963
/ O 0 0.08115829
caffeine B-Chemical 0 0.9993431
within O 0 0.00017545155
30 O 0 0.00024833874
min O 0 0.00045549992
of O 0 0.0005911703
dosing O 0 0.0012653265
. O 0 0.0018978835

Almost O 0 0.0047695944
36 O 0 0.0022688445
% O 0 0.0020485919
of O 0 0.00088383834
patients O 0 0.0013020767
taking O 0 0.0013180908
rizatriptan B-Chemical 0 0.99992394
were O 0 0.0003971319
pain B-Disease 0 0.008128167
free O 0 0.00026611405
at O 0 0.000114937546
2 O 0 0.00014629563
h O 0 0.00014014616
and O 0 0.00012662892
had O 0 0.00011522559
no O 0 0.00012110331
recurrence O 0 0.0017967783
or O 0 8.955602e-05
need O 0 7.352617e-05
for O 0 6.315761e-05
additional O 0 6.568232e-05
medication O 0 0.00035602003
within O 0 4.406005e-05
24 O 0 8.177774e-05
h O 0 9.56743e-05
, O 0 0.00014246689
compared O 0 6.481655e-05
to O 0 7.970287e-05
20 O 0 0.00011145417
% O 0 0.00019553014
of O 0 0.0001373058
patients O 0 0.00040047325
on O 0 0.00023553973
ergotamine B-Chemical 0 0.99999714
/ O 0 0.13312891
caffeine B-Chemical 0 0.99971515
( O 0 0.0005103363
p O 0 0.0003553468
< O 0 0.00032396542
or O 0 0.00024761312
= O 0 0.0009305253
0 O 0 0.0007229766
. O 0 0.0008475787
001 O 0 0.00888547
) O 0 0.004224762
. O 0 0.003756588

Rizatriptan B-Chemical 0 0.99970883
was O 0 0.0017832979
also O 0 0.0008505572
superior O 0 0.0012805803
to O 0 0.00097353867
ergotamine B-Chemical 0 0.99999344
/ O 0 0.22530197
caffeine B-Chemical 0 0.9997377
in O 0 0.00021158777
the O 0 0.00010641567
proportions O 0 0.00010675361
of O 0 0.00013251574
patients O 0 0.0002509364
with O 0 0.00012364428
no O 0 0.00018888603
nausea B-Disease 0 0.99990165
, O 0 0.0015497347
vomiting B-Disease 0 0.99969494
, O 0 0.0031702553
phonophobia B-Disease 0 0.9999939
or O 0 0.00026818324
photophobia B-Disease 0 0.9996087
and O 0 0.00011880382
for O 0 7.051765e-05
patients O 0 0.0002093291
with O 0 0.0001006017
normal O 0 0.00016394828
function O 0 7.8617086e-05
2 O 0 0.000103210026
h O 0 9.636064e-05
after O 0 6.130986e-05
drug O 0 0.0008176717
intake O 0 0.0010959922
( O 0 0.0003018156
p O 0 0.00030248796
< O 0 0.00032043204
or O 0 0.00025964473
= O 0 0.00097546325
0 O 0 0.0007669989
. O 0 0.0008984708
001 O 0 0.009186296
) O 0 0.0044102143
. O 0 0.003909071

More O 0 0.012130612
patients O 0 0.004781372
were O 0 0.0015914654
( O 0 0.0019654965
completely O 0 0.0008018157
, O 0 0.0010976604
very O 0 0.0006185424
or O 0 0.00037945437
somewhat O 0 0.0005630417
) O 0 0.0007117476
satisfied O 0 0.0002977997
2 O 0 0.00018469155
h O 0 0.00014154597
after O 0 6.957038e-05
treatment O 0 0.00013167283
with O 0 0.00026670078
rizatriptan B-Chemical 0 0.99995625
( O 0 0.00040015133
69 O 0 0.00020108832
. O 0 0.00011150859
8 O 0 0.00010525819
% O 0 0.00022877524
) O 0 0.000258002
than O 0 8.819402e-05
at O 0 7.363886e-05
2 O 0 0.00010398561
h O 0 9.761109e-05
after O 0 5.4614477e-05
treatment O 0 0.00012844481
with O 0 0.00038506128
ergotamine B-Chemical 0 0.9999975
/ O 0 0.23060122
caffeine B-Chemical 0 0.999866
( O 0 0.0006439249
38 O 0 0.00026927164
. O 0 0.00014190288
6 O 0 0.00011263325
% O 0 0.0002804296
, O 0 0.0003061056
p O 0 0.00037150597
< O 0 0.00040618124
or O 0 0.0003222515
= O 0 0.0011434604
0 O 0 0.0008811346
. O 0 0.0010150955
001 O 0 0.009610341
) O 0 0.004774257
. O 0 0.004221317

Recurrence O 0 0.024525393
rates O 0 0.0028967587
were O 0 0.0015137208
31 O 0 0.0015367937
. O 0 0.0007288265
4 O 0 0.00049158855
% O 0 0.00090826117
with O 0 0.00077022385
rizatriptan B-Chemical 0 0.99983394
and O 0 0.0005149903
15 O 0 0.00034584303
. O 0 0.00029962492
3 O 0 0.0003223203
% O 0 0.00087927276
with O 0 0.0014220678
ergotamine B-Chemical 0 0.99998355
/ O 0 0.3568969
caffeine B-Chemical 0 0.9993839
. O 0 0.0055220984

Both O 0 0.0057467856
active O 0 0.0053668967
treatments O 0 0.0048764707
were O 0 0.003910862
well O 0 0.0044524805
tolerated O 0 0.009425193
. O 0 0.009874013

The O 0 0.0020907996
most O 0 0.0020029643
common O 0 0.0013263683
adverse O 0 0.0023937093
events O 0 0.0010562611
( O 0 0.0009560547
incidence O 0 0.0007222131
> O 0 0.00068862643
or O 0 0.0002553176
= O 0 0.0006209358
5 O 0 0.00017741765
% O 0 0.00026409858
in O 0 0.00011391602
one O 0 0.00010454836
group O 0 0.00019719591
) O 0 0.00034133685
after O 0 0.00011540473
rizatriptan B-Chemical 0 0.99995816
and O 0 0.000590794
ergotamine B-Chemical 0 0.99999774
/ O 0 0.14413276
caffeine B-Chemical 0 0.9998677
, O 0 0.000543387
respectively O 0 0.00040728084
, O 0 0.00035192858
were O 0 0.00020390311
dizziness B-Disease 0 0.9974367
( O 0 0.0003119656
6 O 0 9.059845e-05
. O 0 9.668555e-05
7 O 0 8.062924e-05
and O 0 0.000111313966
5 O 0 0.00011341624
. O 0 0.000109846915
3 O 0 0.00011035138
% O 0 0.00029081668
) O 0 0.0004919906
, O 0 0.0006325759
nausea B-Disease 0 0.99756145
( O 0 0.00047442105
4 O 0 0.00014447627
. O 0 0.00013570907
2 O 0 0.00013792161
and O 0 0.0001311982
8 O 0 0.0001300043
. O 0 0.00012862058
5 O 0 0.00013232787
% O 0 0.00030257506
) O 0 0.00045823382
and O 0 0.00036554152
somnolence B-Disease 0 0.99966884
( O 0 0.00063173124
5 O 0 0.00022895943
. O 0 0.00021494368
5 O 0 0.00022235612
and O 0 0.00030374617
2 O 0 0.0004384859
. O 0 0.0004801333
3 O 0 0.0006603282
% O 0 0.0018899848
) O 0 0.003652711
. O 0 0.0037965993

Severe O 0 0.13189074
ocular B-Disease 0 0.17804138
and I-Disease 0 0.0024600518
orbital I-Disease 0 0.021564074
toxicity I-Disease 0 0.09930612
after O 0 0.00045264343
intracarotid O 0 0.12991482
injection O 0 0.00042310034
of O 0 0.0007313291
carboplatin B-Chemical 0 0.99011886
for O 0 0.00095535856
recurrent O 0 0.011890867
glioblastomas B-Disease 0 0.99720013
. O 0 0.0044896826

BACKGROUND O 0 0.04347826
: O 0 0.021194365
Glioblastoma B-Disease 0 0.9975725
is O 0 0.0017860058
a O 0 0.003429154
malignant B-Disease 0 0.997459
tumor I-Disease 0 0.9899893
that O 0 0.0006490493
occurs O 0 0.00059119903
in O 0 0.000576117
the O 0 0.00066395354
cerebrum O 0 0.007133958
during O 0 0.001111376
adulthood O 0 0.017653948
. O 0 0.003801293

With O 0 0.0017383303
current O 0 0.0013280457
treatment O 0 0.0007355781
regimens O 0 0.00058866345
including O 0 0.0002650096
combined O 0 0.00038680737
surgery O 0 0.00043863308
, O 0 0.00042908386
radiation O 0 0.0006622902
and O 0 0.00020798201
chemotherapy O 0 0.00088591885
, O 0 0.00020684782
the O 0 8.749783e-05
average O 0 8.4592466e-05
life O 0 0.00012043849
expectancy O 0 0.00018757461
of O 0 0.00017472767
the O 0 0.00016717591
patients O 0 0.0004135382
is O 0 0.00018272689
limited O 0 0.0002836277
to O 0 0.00035294984
approximately O 0 0.0007012907
1 O 0 0.00090675964
year O 0 0.0010301404
. O 0 0.0021780098

Therefore O 0 0.0023702257
, O 0 0.00421566
patients O 0 0.0033670415
with O 0 0.0021738615
glioblastoma B-Disease 0 0.9988889
sometimes O 0 0.0016008165
have O 0 0.00044770105
intracarotid O 0 0.4442234
injection O 0 0.0002706319
of O 0 0.00035637658
carcinostatics O 0 0.01435817
added O 0 0.0004627718
to O 0 0.00032874246
the O 0 0.00039999557
treatment O 0 0.00069662055
regimen O 0 0.0014083064
. O 0 0.0023902524

Generally O 0 0.0034778905
, O 0 0.0065383017
carboplatin B-Chemical 0 0.99677366
is O 0 0.0009936487
said O 0 0.0011679878
to O 0 0.00044553596
have O 0 0.00038344544
milder O 0 0.0037137994
side O 0 0.00065583445
effects O 0 0.0002732401
than O 0 0.00039059087
cisplatin B-Chemical 0 0.9998499
, O 0 0.00077626377
whose O 0 0.00043663837
ocular B-Disease 0 0.07879862
and I-Disease 0 0.0004761254
orbital I-Disease 0 0.050134346
toxicity I-Disease 0 0.40361828
are O 0 0.0004891092
well O 0 0.00070185127
known O 0 0.0013688144
. O 0 0.0029746732

However O 0 0.0031277095
, O 0 0.003248058
we O 0 0.0008292217
experienced O 0 0.0011472463
a O 0 0.0010358889
case O 0 0.00060877757
of O 0 0.0005772018
severe O 0 0.004086482
ocular B-Disease 0 0.124257796
and I-Disease 0 0.00037462573
orbital I-Disease 0 0.013836788
toxicity I-Disease 0 0.06691485
after O 0 0.000102551654
intracarotid O 0 0.11748653
injection O 0 0.00013260623
of O 0 0.00026392363
carboplatin B-Chemical 0 0.996554
, O 0 0.00061474787
which O 0 0.00044294013
is O 0 0.00048469496
infrequently O 0 0.0013983531
reported O 0 0.0015514002
. O 0 0.0026707735

CASE O 0 0.42305043
: O 0 0.008049529
A O 0 0.012938388
58 O 0 0.0028319182
- O 0 0.003859717
year O 0 0.0007429952
- O 0 0.0018214589
old O 0 0.000583217
man O 0 0.0014085945
received O 0 0.0002752366
an O 0 0.00028843645
intracarotid O 0 0.13579492
injection O 0 0.00017330155
of O 0 0.00027875503
carboplatin B-Chemical 0 0.9942425
for O 0 0.00025350103
recurrent O 0 0.004166974
glioblastomas B-Disease 0 0.99798137
in O 0 0.00040723893
his O 0 0.0006038343
left O 0 0.0014242092
temporal O 0 0.008680932
lobe O 0 0.41837427
. O 0 0.0034751114

He O 0 0.009619822
complained O 0 0.0061589982
of O 0 0.0019608834
pain B-Disease 0 0.06706106
and I-Disease 0 0.0012848673
visual I-Disease 0 0.40269852
disturbance I-Disease 0 0.7817067
in I-Disease 0 0.0004911307
the I-Disease 0 0.00034874535
ipsilateral I-Disease 0 0.0007204029
eye I-Disease 0 0.0015371097
30 O 0 0.0003147769
h O 0 0.000365924
after O 0 0.00027823806
the O 0 0.000592162
injection O 0 0.001105979
. O 0 0.00266869

Various O 0 0.0052396464
ocular O 0 0.18239574
symptoms O 0 0.010442268
and O 0 0.0014055269
findings O 0 0.0012760351
caused O 0 0.0011231322
by O 0 0.0016663142
carboplatin B-Chemical 0 0.9989249
toxicity B-Disease 0 0.7248097
were O 0 0.0017553143
seen O 0 0.002413618
. O 0 0.003925112

RESULTS O 0 0.0051092454
: O 0 0.0040567494
He O 0 0.0021477155
was O 0 0.0006834877
treated O 0 0.000788548
with O 0 0.0004571823
intravenous O 0 0.0018278256
administration O 0 0.00046309066
of O 0 0.00037237434
corticosteroids O 0 0.9963498
and O 0 0.0005733286
glycerin B-Chemical 0 0.9988424
for O 0 0.00022161302
6 O 0 0.00017009526
days O 0 0.000142487
after O 0 0.00019431725
the O 0 0.00046959452
injection O 0 0.0009373414
. O 0 0.0023268014

Although O 0 0.0018706325
the O 0 0.0017342385
intraocular O 0 0.25717118
pressure O 0 0.053411096
elevation O 0 0.009303651
caused O 0 0.0004926116
by O 0 0.00036008403
secondary O 0 0.00050731003
acute O 0 0.01752075
angle O 0 0.016724713
- O 0 0.011284477
closure O 0 0.00921269
glaucoma B-Disease 0 0.9999832
decreased O 0 0.00075790694
and O 0 0.00033065418
ocular B-Disease 0 0.9793185
pain I-Disease 0 0.930769
diminished O 0 0.00053149165
, O 0 0.0008303179
inexorable O 0 0.25938812
papilledema B-Disease 0 0.9999751
and O 0 0.0011827548
exudative O 0 0.9999006
retinal B-Disease 0 0.9720487
detachment I-Disease 0 0.9468341
continued O 0 0.00032803995
for O 0 0.0002664187
3 O 0 0.00042668064
weeks O 0 0.00048652824
. O 0 0.0017471709

Finally O 0 0.0029743793
, O 0 0.0031435024
6 O 0 0.00093512377
weeks O 0 0.00055158837
later O 0 0.00075144594
, O 0 0.0018072134
diffuse O 0 0.042543594
chorioretinal B-Disease 0 0.9999517
atrophy I-Disease 2 0.9999572
with O 0 0.0014604651
optic B-Disease 0 0.9983365
atrophy I-Disease 2 0.9993832
occurred O 0 0.00022950408
and O 0 0.00017589997
the O 0 0.00016176376
vision O 0 0.0023789634
in O 0 0.0002888991
his O 0 0.00046161906
left O 0 0.001098449
eye O 0 0.0047515184
was O 0 0.0010214634
lost O 0 0.0017691017
. O 0 0.0029757596

CONCLUSION O 0 0.011003193
: O 0 0.0024640851
When O 0 0.0005154612
performing O 0 0.00053895765
intracarotid O 0 0.09387345
injection O 0 0.00040498402
of O 0 0.00055464933
carboplatin B-Chemical 0 0.99662775
, O 0 0.0005392799
we O 0 0.00014003756
must O 0 0.00014789063
be O 0 0.00022742836
aware O 0 0.00028201903
of O 0 0.000373876
its O 0 0.000575325
potentially O 0 0.00067761895
blinding O 0 0.012159695
ocular B-Disease 0 0.9955123
toxicity I-Disease 0 0.997736
. O 0 0.0043695522

It O 0 0.004716151
is O 0 0.0014233114
recommended O 0 0.00092256075
that O 0 0.00048692772
further O 0 0.0004095571
studies O 0 0.00051815377
and O 0 0.00039566288
investigations O 0 0.000392839
are O 0 0.0002037624
undertaken O 0 0.00021807503
in O 0 0.0002009394
the O 0 0.00018720314
effort O 0 0.0002801263
to O 0 0.00020098347
minimize O 0 0.00017493336
such O 0 0.00043507633
severe O 0 0.0026552835
side O 0 0.0021717958
effects O 0 0.0018827182
. O 0 0.003580842

Visual B-Disease 0 0.9887706
hallucinations I-Disease 0 0.999948
associated O 0 0.016374838
with O 0 0.017616656
zonisamide B-Chemical 0 0.9998079
. O 0 0.016667688

Zonisamide B-Chemical 0 0.9991248
is O 0 0.0022807124
a O 0 0.0020859118
broad O 0 0.0016619174
- O 0 0.0045145475
spectrum O 0 0.0015045366
antiepileptic O 0 0.99740475
drug O 0 0.0073211463
used O 0 0.0003506304
to O 0 0.00034973136
treat O 0 0.0007269138
various O 0 0.0005359097
types O 0 0.0007779889
of O 0 0.002481678
seizures B-Disease 0 0.9998221
. O 0 0.0054316134

Although O 0 0.0028922656
visual B-Disease 0 0.9495891
hallucinations I-Disease 0 0.99999475
have O 0 0.0013835534
not O 0 0.00061377103
been O 0 0.0004314449
reported O 0 0.00036310687
as O 0 0.00023288035
an O 0 0.00021808168
adverse O 0 0.0005132843
effect O 0 0.00011766961
of O 0 0.00017299598
this O 0 0.0001799578
agent O 0 0.0004636558
, O 0 0.00022326261
we O 0 4.8755202e-05
describe O 0 7.362237e-05
three O 0 4.1965533e-05
patients O 0 0.00018549581
who O 0 0.00012243234
experienced O 0 0.00011107073
complex O 0 0.00016629024
visual B-Disease 0 0.9665049
hallucinations I-Disease 0 0.99999976
and O 0 0.0003454547
altered O 0 0.00021461847
mental O 0 0.010318399
status O 0 0.00013233341
after O 0 0.000108016284
zonisamide B-Chemical 0 0.99997556
treatment O 0 0.00019794247
was O 0 0.00017287082
begun O 0 0.0003679759
or O 0 0.0003032621
its O 0 0.0007246534
dosage O 0 0.0030935956
increased O 0 0.0019838354
. O 0 0.0026902882

All O 0 0.0019521669
three O 0 0.0009844544
had O 0 0.0012105331
been O 0 0.0009417609
diagnosed O 0 0.0028223242
earlier O 0 0.0008437668
with O 0 0.0012770126
epilepsy B-Disease 0 0.9999788
, O 0 0.0011862828
and O 0 0.00038683027
their O 0 0.0003639098
electroencephalogram O 0 0.11896357
( O 0 0.0010121838
EEG O 0 0.20526119
) O 0 0.0010366545
findings O 0 0.0007628807
were O 0 0.0009699331
abnormal O 0 0.00433686
. O 0 0.0031991696

During O 0 0.0019507217
monitoring O 0 0.0018766222
, O 0 0.0038942117
visual B-Disease 0 0.9515471
hallucinations I-Disease 0 0.9999975
did O 0 0.0014891471
not O 0 0.00044914993
correlate O 0 0.0003419785
with O 0 0.0003662982
EEG O 0 0.36602396
readings O 0 0.00036006598
, O 0 0.00030015496
nor O 0 0.00012191088
did O 0 0.00017647048
video O 0 0.00024757895
recording O 0 0.00021333051
capture O 0 0.00026067285
any O 0 0.00024557402
of O 0 0.00041910302
the O 0 0.0004858569
described O 0 0.0007223309
events O 0 0.0020282732
. O 0 0.0029141337

None O 0 0.004200088
of O 0 0.002321353
the O 0 0.0014121111
patients O 0 0.002020099
had O 0 0.0010157408
experienced O 0 0.0015708385
visual B-Disease 0 0.89471483
hallucinations I-Disease 0 0.9999931
before O 0 0.0011101549
this O 0 0.0018243116
event O 0 0.0035921666
. O 0 0.0041159587

The O 0 0.0020148223
only O 0 0.0017034935
recent O 0 0.001156576
change O 0 0.00077760086
in O 0 0.0005167602
their O 0 0.000404897
treatment O 0 0.00037957504
was O 0 0.00027996878
the O 0 0.00022606505
introduction O 0 0.00020725689
or O 0 0.00033969808
increased O 0 0.00078691763
dosage O 0 0.0035021354
of O 0 0.002429142
zonisamide B-Chemical 0 0.99994016
. O 0 0.004617361

With O 0 0.0020865856
either O 0 0.001685585
discontinuation O 0 0.0055603855
or O 0 0.0007017553
decreased O 0 0.0009881483
dosage O 0 0.0015545763
of O 0 0.00040747906
the O 0 0.00031902044
drug O 0 0.003736991
the O 0 0.00033600937
symptoms O 0 0.003108945
disappeared O 0 0.0005507441
and O 0 0.00057092786
did O 0 0.0008995184
not O 0 0.0013135993
recur O 0 0.009507957
. O 0 0.0030715957

Further O 0 0.0031903689
observations O 0 0.002850472
and O 0 0.0022916016
reports O 0 0.0018490789
will O 0 0.001064337
help O 0 0.0011788505
clarify O 0 0.00069735484
this O 0 0.0015639017
adverse O 0 0.0046406607
effect O 0 0.0025478627
. O 0 0.0051899813

Until O 0 0.003213845
then O 0 0.0022992524
, O 0 0.002732606
clinicians O 0 0.0017609936
need O 0 0.00071128254
to O 0 0.00053145626
be O 0 0.0004653889
aware O 0 0.00044917176
of O 0 0.0004583044
this O 0 0.00043785182
possible O 0 0.0003710197
complication O 0 0.0038770977
associated O 0 0.0010283235
with O 0 0.0024437844
zonisamide B-Chemical 0 0.99995065
. O 0 0.004754672

Anti O 0 0.038638126
- O 0 0.3028265
epileptic B-Disease 0 0.99941635
drugs O 0 0.4701696
- O 0 0.016283799
induced O 0 0.0025689579
de O 0 0.008267199
novo O 0 0.007313595
absence B-Disease 0 0.008028595
seizures I-Disease 0 0.9999471
. O 0 0.010789502

The O 0 0.0017648216
authors O 0 0.0012503065
present O 0 0.0007525746
three O 0 0.00043475727
patients O 0 0.0010935048
with O 0 0.00072319875
de O 0 0.0021475551
novo O 0 0.0015093251
absence B-Disease 0 0.0011712249
epilepsy I-Disease 0 0.9999951
after O 0 0.00028774815
administration O 0 0.0009069947
of O 0 0.0012237547
carbamazepine B-Chemical 1 0.9999956
and O 0 0.004612317
vigabatrin B-Chemical 0 0.9999567
. O 0 0.004096453

Despite O 0 0.0021632276
the O 0 0.0018233351
underlying O 0 0.0022809424
diseases O 0 0.17276771
, O 0 0.0015645124
the O 0 0.0005249713
prognosis O 0 0.036150623
for O 0 0.00033825083
drug O 0 0.026069505
- O 0 0.0036426554
induced O 0 0.00031621408
de O 0 0.0016707971
novo O 0 0.00108174
absence B-Disease 0 0.0006288281
seizure I-Disease 0 0.9999709
is O 0 0.00014843229
good O 0 0.00018202837
because O 0 0.00010185724
it O 0 0.00022800265
subsides O 0 0.00025034233
rapidly O 0 0.00012294922
after O 0 6.97699e-05
discontinuing O 0 0.0003331155
the O 0 0.00012223821
use O 0 0.00018100081
of O 0 0.00035217713
the O 0 0.0005151191
offending O 0 0.011187786
drugs O 0 0.07453976
. O 0 0.0033628435

The O 0 0.0051835277
gamma B-Chemical 0 0.91364574
- I-Chemical 0 0.98105246
aminobutyric I-Chemical 0 0.9999213
acid I-Chemical 0 0.99736565
- O 0 0.11989502
transmitted O 0 0.00042261742
thalamocortical O 0 0.0010172563
circuitry O 0 0.00034040274
accounts O 0 0.00031502038
for O 0 0.00016270057
a O 0 0.00029624926
major O 0 0.00020378923
part O 0 0.00016574709
of O 0 0.00021773658
the O 0 0.00021339867
underlying O 0 0.00044269403
neurophysiology O 0 0.0030390108
of O 0 0.00058973103
the O 0 0.00071808137
absence B-Disease 0 0.0029768818
epilepsy I-Disease 0 0.999984
. O 0 0.006274015

Because O 0 0.0028447662
drug O 0 0.051567003
- O 0 0.012034738
induced O 0 0.0016005314
de O 0 0.00475201
novo O 0 0.0028706808
absence B-Disease 0 0.0016388117
seizure I-Disease 0 0.99993265
is O 0 0.0005645332
rare O 0 0.0023879544
, O 0 0.0007980208
pro O 0 0.0021787735
- O 0 0.0024512024
absence O 0 0.00021219306
drugs O 0 0.008280411
can O 0 0.00023073783
only O 0 0.0003425503
be O 0 0.00034484957
considered O 0 0.00045355325
a O 0 0.00093605084
promoting O 0 0.0011686155
factor O 0 0.018708618
. O 0 0.00443172

The O 0 0.0022118797
underlying O 0 0.0025335124
epileptogenecity O 0 0.0069740084
of O 0 0.0008913904
the O 0 0.00049422757
patients O 0 0.0007150511
or O 0 0.00022682396
the O 0 0.00016263478
synergistic O 0 0.00024695887
effects O 0 0.00018341011
of O 0 0.0002216635
the O 0 0.00016343135
accompanying O 0 0.00032329033
drugs O 0 0.006379882
is O 0 0.00013888965
required O 0 9.3835515e-05
to O 0 0.00016496034
trigger O 0 0.00019466404
the O 0 0.00037541907
de O 0 0.002210085
novo O 0 0.002412711
absence B-Disease 0 0.0029090217
seizure I-Disease 0 0.9998368
. O 0 0.0051426548

The O 0 0.0017035542
possibility O 0 0.0010617013
of O 0 0.0017192304
drug O 0 0.1409427
- O 0 0.015313127
induced O 0 0.0007100046
aggravation O 0 0.12642787
should O 0 0.00016896227
be O 0 0.000180324
considered O 0 0.00015207838
whenever O 0 0.00014334402
an O 0 0.00016793064
unexpected O 0 0.00015192258
increase O 0 0.00014325617
in O 0 0.00020040711
seizure B-Disease 0 0.9972072
frequency O 0 0.00014353744
and O 0 0.00017902932
/ O 0 0.00095653214
or O 0 0.00015831571
new O 0 0.00035065497
seizure B-Disease 0 0.9989109
types O 0 0.00018310502
appear O 0 0.00014860675
following O 0 0.00012170599
a O 0 0.00034091488
change O 0 0.00031970124
in O 0 0.0004766896
drug O 0 0.0058484413
treatment O 0 0.0013667601
. O 0 0.0024198592

By O 0 0.002184884
understanding O 0 0.0019608694
the O 0 0.0011222584
underlying O 0 0.0009943851
mechanism O 0 0.0004882996
of O 0 0.00087340554
absence B-Disease 0 0.0024786578
epilepsy I-Disease 0 0.9999982
, O 0 0.00151913
we O 0 0.00013331295
can O 0 0.00010621859
avoid O 0 9.550112e-05
the O 0 0.00010115791
inappropriate O 0 0.00018088918
use O 0 0.00010155204
of O 0 0.00019482707
anticonvulsants O 0 0.99881786
in O 0 0.00020223412
children O 0 0.001032416
with O 0 0.00052769395
epilepsy B-Disease 0 0.99999094
and O 0 0.00037823853
prevent O 0 0.00030741756
drug O 0 0.08026246
- O 0 0.0075413864
induced O 0 0.00083492114
absence B-Disease 0 0.003540962
seizures I-Disease 0 0.99997926
. O 0 0.005843774

Prenatal O 0 0.14068404
dexamethasone B-Chemical 0 0.99890375
programs O 0 0.0051933895
hypertension B-Disease 2 0.99994993
and O 0 0.0052803014
renal B-Disease 0 0.9984666
injury I-Disease 0 0.81647277
in O 0 0.001432692
the O 0 0.0013736704
rat O 0 0.0032560006
. O 0 0.003970667

Dexamethasone O 0 0.99958545
is O 0 0.002492506
frequently O 0 0.0015653394
administered O 0 0.0012882162
to O 0 0.0006017527
the O 0 0.00055241276
developing O 0 0.0011308468
fetus O 0 0.002069819
to O 0 0.0007583271
accelerate O 0 0.001515995
pulmonary O 0 0.21662432
development O 0 0.0032269382
. O 0 0.0037970562

The O 0 0.0015600089
purpose O 0 0.0010029906
of O 0 0.0010632116
the O 0 0.00062091294
present O 0 0.00045324964
study O 0 0.0004918461
was O 0 0.00026351557
to O 0 0.00016183812
determine O 0 6.962674e-05
if O 0 0.00013824155
prenatal O 0 0.0017692812
dexamethasone B-Chemical 0 0.99980754
programmed O 0 0.0009874466
a O 0 0.00040388125
progressive O 0 0.0013862659
increase B-Disease 0 0.00014416895
in I-Disease 0 0.0001607848
blood I-Disease 0 0.0022423945
pressure I-Disease 0 0.011129987
and O 0 0.0005456962
renal B-Disease 0 0.99508864
injury I-Disease 0 0.5644654
in O 0 0.0008813297
rats O 0 0.0019697582
. O 0 0.0023810624

Pregnant O 0 0.009515022
rats O 0 0.002458241
were O 0 0.00087126973
given O 0 0.00041396634
either O 0 0.0004257762
vehicle O 0 0.0010508554
or O 0 0.00024478533
2 O 0 0.0002070947
daily O 0 0.00016519502
intraperitoneal O 0 0.00022930503
injections O 0 0.00013866747
of O 0 0.00021789275
dexamethasone B-Chemical 0 0.9994911
( O 0 0.00045987303
0 O 0 0.00019165612
. O 0 0.00010946975
2 O 0 0.00012589799
mg O 0 0.0007431375
/ O 0 0.00036931524
kg O 0 0.00024901115
body O 0 0.00017235416
weight O 0 0.00018684131
) O 0 0.00022359664
on O 0 6.578925e-05
gestational O 0 0.00029527055
days O 0 7.288367e-05
11 O 0 0.00011607043
and O 0 0.00011308741
12 O 0 9.549956e-05
, O 0 0.00021022034
13 O 0 0.00015643338
and O 0 0.00014760745
14 O 0 0.00015719535
, O 0 0.00027819403
15 O 0 0.00016357884
and O 0 0.00018868713
16 O 0 0.00026111762
, O 0 0.00041266004
17 O 0 0.00034582865
and O 0 0.00029606212
18 O 0 0.0003975823
, O 0 0.0006634228
or O 0 0.00049173005
19 O 0 0.0009791609
and O 0 0.0011282697
20 O 0 0.0018422394
. O 0 0.0030712162

Offspring O 0 0.005768871
of O 0 0.0017114335
rats O 0 0.0019266871
administered O 0 0.0019120587
dexamethasone B-Chemical 0 0.9978969
on O 0 0.00027820864
days O 0 0.00016906268
15 O 0 0.00017570436
and O 0 0.00015745533
16 O 0 0.00016382952
gestation O 0 0.00018876055
had O 0 0.00014897408
a O 0 0.00021167615
20 O 0 0.00015796979
% O 0 0.00026193846
reduction B-Disease 2 0.00018562851
in I-Disease 2 0.00018283095
glomerular I-Disease 2 0.9789259
number I-Disease 2 9.68173e-05
compared O 0 7.076089e-05
with O 0 9.916928e-05
control O 0 0.00010151176
at O 0 7.059449e-05
6 O 0 6.166131e-05
to O 0 5.81792e-05
9 O 0 6.105454e-05
months O 0 3.969514e-05
of O 0 9.7577504e-05
age O 0 0.00022550598
( O 0 0.000303348
22 O 0 0.00028114973
527 O 0 0.0007302277
+ O 0 0.0008115832
/ O 0 0.001383995
- O 0 0.0014441918
509 O 0 0.0008587475
versus O 0 0.00015866662
28 O 0 0.00022244966
050 O 0 0.0031243286
+ O 0 0.0009166211
/ O 0 0.0016400324
- O 0 0.002414456
561 O 0 0.0027037824
, O 0 0.0004839872
P O 0 0.004517811
< O 0 0.00036355265
0 O 0 0.00028051034
. O 0 0.00023272498
05 O 0 0.004665997
) O 0 0.0005966699
, O 0 0.0003583497
which O 0 0.00019249528
was O 0 0.00012605738
comparable O 0 8.478371e-05
to O 0 9.701211e-05
the O 0 0.00010107344
percent O 0 0.00014687683
reduction O 0 0.00021657399
in O 0 0.00020298114
glomeruli O 0 0.0020023116
measured O 0 0.00024266951
at O 0 0.00016558249
3 O 0 0.00021407279
weeks O 0 0.00020061854
of O 0 0.0006633578
age O 0 0.0020069133
. O 0 0.002799851

Six O 0 0.004148934
- O 0 0.0073310295
to O 0 0.0011502607
9 O 0 0.0008596473
- O 0 0.0016765494
month O 0 0.00023896716
old O 0 0.00030699465
rats O 0 0.0003548769
receiving O 0 0.0002959881
prenatal O 0 0.0011270451
dexamethasone B-Chemical 0 0.9990157
on O 0 0.0001337869
days O 0 9.5407e-05
17 O 0 0.0001610131
and O 0 0.000114028284
18 O 0 0.000114223854
of O 0 0.00010721494
gestation O 0 0.00017731804
had O 0 0.00014058009
a O 0 0.00022019341
17 O 0 0.00020843008
% O 0 0.0002685696
reduction O 0 0.0001898986
in O 0 0.00017914476
glomeruli O 0 0.002975734
( O 0 0.00040628773
23 O 0 0.00030144976
380 O 0 0.00090330996
+ O 0 0.0008761917
/ O 0 0.0017943912
- O 0 0.002834986
587 O 0 0.0026149186
) O 0 0.00041772448
compared O 0 0.00012140022
with O 0 0.00018835514
control O 0 0.00024378378
rats O 0 0.00051494676
( O 0 0.00068820856
P O 0 0.0054216594
< O 0 0.0007638846
0 O 0 0.00078678975
. O 0 0.0009663753
05 O 0 0.012060908
) O 0 0.0045257113
. O 0 0.0040987707

Male O 0 0.0074116806
rats O 0 0.0023908163
that O 0 0.00086585386
received O 0 0.0008491368
prenatal O 0 0.0027368793
dexamethasone B-Chemical 0 0.99879164
on O 0 0.00027706297
days O 0 0.0001737448
15 O 0 0.00019506946
and O 0 0.00019977694
16 O 0 0.00024268917
, O 0 0.0003395849
17 O 0 0.0002458718
and O 0 0.00017547801
18 O 0 0.00019115022
, O 0 0.00025672285
and O 0 0.00015148676
13 O 0 0.00014634893
and O 0 0.0001088721
14 O 0 8.8723165e-05
of O 0 9.525174e-05
gestation O 0 0.00016638158
had O 0 0.0001470046
elevated B-Disease 0 0.0021731209
blood I-Disease 0 0.0023804891
pressures I-Disease 0 0.0012221029
at O 0 6.7644745e-05
6 O 0 5.157139e-05
months O 0 3.651446e-05
of O 0 8.735926e-05
age O 0 0.00020258923
; O 0 0.00026885813
the O 0 0.0001236569
latter O 0 0.00039345963
group O 0 0.00033611158
did O 0 0.00025430814
not O 0 0.00021349677
have O 0 0.0002423867
a O 0 0.00051080494
reduction B-Disease 2 0.0006689216
in I-Disease 2 0.00090444507
glomerular I-Disease 2 0.9934588
number I-Disease 2 0.0015873694
. O 0 0.0026978424

Adult O 0 0.0058547156
rats O 0 0.0027981924
given O 0 0.0011420568
dexamethasone B-Chemical 0 0.99627113
on O 0 0.00040276273
days O 0 0.00024267251
15 O 0 0.00024450355
and O 0 0.00021635542
16 O 0 0.0002169305
of O 0 0.00019035651
gestation O 0 0.00029486322
had O 0 0.00026020408
more O 0 0.00046997226
glomeruli O 0 0.005300904
with O 0 0.0009718631
glomerulosclerosis B-Disease 0 0.9999683
than O 0 0.000725664
control O 0 0.000897624
rats O 0 0.0022471168
. O 0 0.00269644

This O 0 0.0041356334
study O 0 0.0017326527
shows O 0 0.00051472033
that O 0 0.00059492514
prenatal O 0 0.0036963893
dexamethasone B-Chemical 0 0.99963653
in O 0 0.00040210522
rats O 0 0.0004058662
results O 0 0.00016326188
in O 0 0.00016684642
a O 0 0.00025318004
reduction B-Disease 2 0.00024213582
in I-Disease 2 0.00023719681
glomerular I-Disease 2 0.98925894
number I-Disease 2 0.00020244092
, O 0 0.000969611
glomerulosclerosis B-Disease 0 0.9999924
, O 0 0.0007176942
and O 0 0.00031327398
hypertension B-Disease 2 0.9999789
when O 0 0.0001444727
administered O 0 0.00023401841
at O 0 0.000111395086
specific O 0 0.000117929325
points O 0 0.00026911998
during O 0 0.00042428353
gestation O 0 0.0013887547
. O 0 0.002304951

Hypertension B-Disease 0 0.99564004
was O 0 0.002071831
observed O 0 0.0008971786
in O 0 0.00056595553
animals O 0 0.00032695525
that O 0 0.00026738615
had O 0 0.0003020804
a O 0 0.00037397133
reduction O 0 0.00030834868
in O 0 0.00022912213
glomeruli O 0 0.0029813924
as O 0 0.00016381734
well O 0 0.00013106166
as O 0 0.00013376217
in O 0 0.0001311912
a O 0 0.0002202434
group O 0 0.00021787135
that O 0 9.6558404e-05
did O 0 0.0001492912
not O 0 0.000107304324
have O 0 9.9725636e-05
a O 0 0.00017770902
reduction B-Disease 2 0.00017991541
in I-Disease 2 0.00017392664
glomerular I-Disease 2 0.9958817
number I-Disease 2 0.000113954266
, O 0 0.00019934385
suggesting O 0 6.283423e-05
that O 0 7.138469e-05
a O 0 0.00018072593
reduction B-Disease 2 0.00020048927
in I-Disease 2 0.00020153882
glomerular I-Disease 2 0.996691
number I-Disease 2 0.00012754106
is O 0 0.000103230406
not O 0 0.00011448054
the O 0 0.00014182307
sole O 0 0.00054720516
cause O 0 0.00031653556
for O 0 0.00020280568
the O 0 0.0003024591
development O 0 0.00076072325
of O 0 0.001707361
hypertension B-Disease 2 0.9999474
. O 0 0.0046523535

Kidney O 0 0.009022974
function O 0 0.001330009
and O 0 0.0010953769
morphology O 0 0.000990138
after O 0 0.0003011798
short O 0 0.0003632452
- O 0 0.0009965565
term O 0 0.00026653963
combination O 0 0.00029362243
therapy O 0 0.0004076452
with O 0 0.00053587963
cyclosporine B-Chemical 1 0.99999285
A I-Chemical 0 0.7727306
, O 0 0.0036100375
tacrolimus B-Chemical 0 0.9999747
and O 0 0.0010893148
sirolimus B-Chemical 0 0.9997116
in O 0 0.00070910214
the O 0 0.00078382005
rat O 0 0.002196215
. O 0 0.0027093953

BACKGROUND O 0 0.022234475
: O 0 0.008827666
Sirolimus B-Chemical 0 0.9734596
( O 0 0.0062080985
SRL B-Chemical 0 0.99939
) O 0 0.0027694756
may O 0 0.00064620824
supplement O 0 0.0025874006
calcineurin O 0 0.0038216088
inhibitors O 0 0.0011795453
in O 0 0.0007966407
clinical O 0 0.0024668386
organ O 0 0.001978887
transplantation O 0 0.0022300282
. O 0 0.0027696495

These O 0 0.0025127695
are O 0 0.0024803458
nephrotoxic B-Disease 0 0.9971835
, O 0 0.00463794
but O 0 0.0027111454
SRL B-Chemical 0 0.99976426
seems O 0 0.0003653752
to O 0 0.00021686286
act O 0 0.00016983935
differently O 0 0.00010664972
displaying O 0 0.00018678111
only O 0 0.00022579277
minor O 0 0.0004782569
nephrotoxic B-Disease 0 0.99759346
effects O 0 0.00029390867
, O 0 0.0005233416
although O 0 0.00024574876
this O 0 0.00029539247
question O 0 0.00030543396
is O 0 0.0003895101
still O 0 0.0006949459
open O 0 0.0017556719
. O 0 0.0027464647

In O 0 0.0020409324
a O 0 0.0021551996
number O 0 0.00079493487
of O 0 0.0007270734
treatment O 0 0.0005090866
protocols O 0 0.0003808883
where O 0 0.0005861209
SRL B-Chemical 0 0.9995671
was O 0 0.0002651744
combined O 0 0.00024124015
with O 0 0.00022102449
a O 0 0.0003709194
calcineurin O 0 0.0014137162
inhibitor O 0 0.00049472204
indications O 0 0.00017369613
of O 0 0.00024743215
a O 0 0.0004597897
synergistic O 0 0.000943106
nephrotoxic B-Disease 0 0.99898857
effect O 0 0.0007344636
were O 0 0.0009233477
described O 0 0.0011491851
. O 0 0.0023941875

The O 0 0.0016715451
aim O 0 0.0010790259
of O 0 0.0011741561
this O 0 0.0008703148
study O 0 0.00066620845
was O 0 0.00033135567
to O 0 0.00019118177
examine O 0 9.024079e-05
further O 0 0.0001444512
the O 0 0.00017749466
renal O 0 0.21053569
function O 0 0.00015460451
, O 0 0.000263898
including O 0 9.560782e-05
morphological O 0 0.00026385218
analysis O 0 0.000119999655
of O 0 0.00011840687
the O 0 0.000102629514
kidneys O 0 0.0005669489
of O 0 0.00016660176
male O 0 0.00050142995
Sprague O 0 0.21381909
- O 0 0.0013015083
Dawley O 0 0.0020094842
rats O 0 0.00017384886
treated O 0 0.0001753626
with O 0 0.0001304598
either O 0 0.00024978802
cyclosporine B-Chemical 1 0.9999964
A I-Chemical 0 0.7029343
( O 0 0.0016109891
CsA B-Chemical 0 0.9998989
) O 0 0.0013102844
, O 0 0.00095961883
tacrolimus B-Chemical 0 0.9999862
( O 0 0.0023985307
FK506 B-Chemical 0 0.99997306
) O 0 0.0014375097
or O 0 0.00032592734
SRL B-Chemical 0 0.9998012
as O 0 0.000329985
monotherapies O 0 0.02542225
or O 0 0.00029428749
in O 0 0.00037737572
different O 0 0.000457701
combinations O 0 0.000989924
. O 0 0.0025091174

METHODS O 0 0.0039895675
: O 0 0.0024844382
For O 0 0.0005669098
a O 0 0.0008657717
period O 0 0.00039029977
of O 0 0.0004445653
2 O 0 0.00037188941
weeks O 0 0.00020696757
, O 0 0.00070996326
CsA B-Chemical 0 0.9959352
15 O 0 0.0003358798
mg O 0 0.001651757
/ O 0 0.0006893378
kg O 0 0.00048299404
/ O 0 0.0006155261
day O 0 0.0001246037
( O 0 0.00024662595
given O 0 0.000104536695
orally O 0 0.00041393258
) O 0 0.00059342355
, O 0 0.0007467858
FK506 B-Chemical 0 0.9999099
3 O 0 0.00018959427
. O 0 0.00013295139
0 O 0 0.00017787145
mg O 0 0.0009200598
/ O 0 0.00046429047
kg O 0 0.0003523847
/ O 0 0.0004855285
day O 0 9.5452124e-05
( O 0 0.00019858826
given O 0 8.339196e-05
orally O 0 0.00032652292
) O 0 0.00040701323
or O 0 0.00021740301
SRL B-Chemical 0 0.99970394
0 O 0 0.00023804847
. O 0 0.000107180786
4 O 0 9.215448e-05
mg O 0 0.00067916355
/ O 0 0.0003916225
kg O 0 0.00030398028
/ O 0 0.0004201364
day O 0 7.827081e-05
( O 0 0.00015485001
given O 0 5.955334e-05
intraperitoneally O 0 0.00014576846
) O 0 0.00020107988
was O 0 7.538812e-05
administered O 0 0.00011566341
once O 0 5.6760495e-05
a O 0 0.00010260407
day O 0 5.4780765e-05
as O 0 7.091018e-05
these O 0 8.173798e-05
doses O 0 0.00025617878
have O 0 9.361949e-05
earlier O 0 0.00014052326
been O 0 0.00010464631
found O 0 0.00010621353
to O 0 8.976755e-05
achieve O 0 9.408164e-05
a O 0 0.00021306826
significant O 0 0.00019225059
immunosuppressive O 0 0.0027030483
effect O 0 0.00024131352
in O 0 0.00048579834
Sprague O 0 0.3580712
- O 0 0.0063133324
Dawley O 0 0.012604857
rats O 0 0.002281993
. O 0 0.0024970437

In O 0 0.0019329672
the O 0 0.0015919608
' O 0 0.0024000986
conscious O 0 0.0048174695
catheterized O 0 0.0021494832
rat O 0 0.0007718818
' O 0 0.00070945936
model O 0 0.0003278874
, O 0 0.0005997671
the O 0 0.0003597493
glomerular O 0 0.969537
filtration O 0 0.0136201875
rate O 0 0.00053178304
( O 0 0.00083904085
GFR O 0 0.99882454
) O 0 0.0007546523
was O 0 0.00020837682
measured O 0 0.00024870672
as O 0 0.00025271313
the O 0 0.00031833898
clearance O 0 0.002533784
of O 0 0.0013320708
Cr O 0 0.99930096
( O 0 0.0064224433
EDTA O 0 0.99416757
) O 0 0.006953044
. O 0 0.004199709

The O 0 0.0020685343
morphological O 0 0.0026095416
analysis O 0 0.001071545
of O 0 0.0007487715
the O 0 0.00048318057
kidneys O 0 0.001456755
included O 0 0.00033141795
a O 0 0.00041085092
semi O 0 0.00037482244
- O 0 0.0007765567
quantitative O 0 0.0001158841
scoring O 0 0.00012234703
system O 0 0.00012619268
analysing O 0 9.815275e-05
the O 0 0.00010184006
degree O 0 0.00021402177
of O 0 0.00022644537
striped O 0 0.0010774409
fibrosis B-Disease 0 0.9992499
, O 0 0.0010481448
subcapsular O 0 0.8999596
fibrosis B-Disease 0 0.9961063
and O 0 0.00013489227
the O 0 7.573485e-05
number O 0 7.9294034e-05
of O 0 0.00018315374
basophilic O 0 0.1264875
tubules O 0 0.012807076
, O 0 0.0003011482
plus O 0 0.00011573169
an O 0 9.834911e-05
additional O 0 5.8746013e-05
stereological O 0 8.550046e-05
analysis O 0 8.317998e-05
of O 0 0.00010278093
the O 0 0.00010133121
total O 0 0.00016476779
grade O 0 0.0033398739
of O 0 0.00038057394
fibrosis B-Disease 0 0.99697816
in O 0 0.0002996669
the O 0 0.0003005745
cortex O 0 0.016096024
stained O 0 0.00090830185
with O 0 0.0013158632
Sirius O 0 0.9241126
Red O 0 0.026874755
. O 0 0.004087314

RESULTS O 0 0.0073600854
: O 0 0.009029311
CsA B-Chemical 0 0.9982835
, O 0 0.010140495
FK506 B-Chemical 0 0.9998116
and O 0 0.0041086883
SRL B-Chemical 0 0.99949884
all O 0 0.0012497773
significantly O 0 0.0013532971
decreased O 0 0.0023450975
the O 0 0.002321853
GFR O 0 0.99731123
. O 0 0.0061623915

A O 0 0.022682013
further O 0 0.0021027236
deterioration O 0 0.011925104
was O 0 0.00084043795
seen O 0 0.000587075
when O 0 0.00042646736
CsA B-Chemical 0 0.9994085
was O 0 0.0002859748
combined O 0 0.00025625405
with O 0 0.00023871574
either O 0 0.00036949114
FK506 B-Chemical 0 0.9999759
or O 0 0.00058191776
SRL B-Chemical 0 0.9999443
, O 0 0.00045763882
whereas O 0 0.0001451857
the O 0 0.00015043121
GFR O 0 0.9995772
remained O 0 0.00023426242
unchanged O 0 0.00014699493
in O 0 7.877251e-05
the O 0 6.839051e-05
group O 0 0.00014535026
treated O 0 0.00027105614
with O 0 0.00031596152
FK506 B-Chemical 0 0.99998724
plus O 0 0.0006809066
SRL B-Chemical 0 0.9999275
when O 0 8.8821456e-05
compared O 0 8.082716e-05
with O 0 0.00013559175
treatment O 0 0.00016449274
with O 0 0.00020930755
any O 0 0.00021923271
of O 0 0.00038826372
the O 0 0.0004568573
single O 0 0.0007405896
substances O 0 0.075508945
. O 0 0.0030507674

The O 0 0.0043196706
morphological O 0 0.0060461666
changes O 0 0.0037287166
presented O 0 0.0028509055
a O 0 0.0038036248
similar O 0 0.0024734242
pattern O 0 0.004461911
. O 0 0.008124321

The O 0 0.002408677
semi O 0 0.0029296638
- O 0 0.0040471856
quantitative O 0 0.00064475334
scoring O 0 0.0005705881
was O 0 0.0004051321
significantly O 0 0.0004163192
worst O 0 0.0005890894
in O 0 0.00020764062
the O 0 0.0001567136
group O 0 0.00027032112
treated O 0 0.00039773883
with O 0 0.00038187063
CsA B-Chemical 0 0.9998735
plus O 0 0.00068578863
SRL B-Chemical 0 0.99988306
( O 0 0.00053166575
P O 0 0.006944048
< O 0 0.00022045097
0 O 0 0.00015964791
. O 0 0.000117006995
001 O 0 0.00083738915
compared O 0 8.088714e-05
with O 0 0.00012333435
controls O 0 0.00024511624
) O 0 0.00035420142
and O 0 0.00011832717
the O 0 8.47648e-05
analysis O 0 9.272957e-05
of O 0 9.889314e-05
the O 0 8.53815e-05
total O 0 0.00012506603
grade O 0 0.002793922
of O 0 0.00023167185
fibrosis B-Disease 0 0.9967128
also O 0 0.00010613546
showed O 0 7.650201e-05
the O 0 6.0075137e-05
highest O 0 7.861386e-05
proportion O 0 7.3007905e-05
in O 0 7.6339944e-05
the O 0 6.507035e-05
same O 0 6.17518e-05
group O 0 0.00014840864
and O 0 0.00011933361
was O 0 0.000104852465
significantly O 0 0.00013721039
different O 0 9.30049e-05
from O 0 0.00014115742
controls O 0 0.0003300627
( O 0 0.00056570664
P O 0 0.0060128705
< O 0 0.0006783614
0 O 0 0.00071186846
. O 0 0.00088584115
02 O 0 0.013226362
) O 0 0.0040755146
. O 0 0.003670688

The O 0 0.0036167195
FK506 B-Chemical 0 0.99953187
plus O 0 0.0040108035
SRL B-Chemical 0 0.9996333
combination O 0 0.0009999956
showed O 0 0.00040506842
only O 0 0.00036287052
a O 0 0.00041496198
marginally O 0 0.0005468177
higher O 0 0.0002556891
degree O 0 0.00036118625
of O 0 0.00037559503
fibrosis B-Disease 0 0.99264055
as O 0 0.00021305039
compared O 0 0.0001335748
with O 0 0.00022781771
controls O 0 0.00046446177
( O 0 0.0007528314
P O 0 0.019755663
= O 0 0.001348221
0 O 0 0.0008116842
. O 0 0.00092273735
05 O 0 0.0123988995
) O 0 0.0041970033
. O 0 0.003786292

CONCLUSION O 0 0.02213202
: O 0 0.004870869
This O 0 0.001701895
rat O 0 0.0011551535
study O 0 0.00061052566
demonstrated O 0 0.00035607742
a O 0 0.00052789936
synergistic O 0 0.00071043806
nephrotoxic B-Disease 0 0.9962452
effect O 0 0.00031602176
of O 0 0.0006267255
CsA B-Chemical 0 0.99991894
plus O 0 0.0011875808
SRL B-Chemical 0 0.99992657
, O 0 0.0010062946
whereas O 0 0.00060842687
FK506 B-Chemical 0 0.99995065
plus O 0 0.001449629
SRL B-Chemical 0 0.9997316
was O 0 0.0006972951
better O 0 0.0010600772
tolerated O 0 0.0024157935
. O 0 0.0025624158

Evaluation O 0 0.0029735845
of O 0 0.002408943
cardiac O 0 0.008680539
troponin O 0 0.8578371
I O 0 0.08482765
and O 0 0.0010216453
T O 0 0.0047100913
levels O 0 0.00038645839
as O 0 0.00034725058
markers O 0 0.00061838736
of O 0 0.0006690415
myocardial B-Disease 0 0.99991715
damage I-Disease 0 0.9342745
in O 0 0.00046526804
doxorubicin B-Chemical 0 0.99995506
- O 0 0.010313604
induced O 0 0.00023863521
cardiomyopathy B-Disease 0 0.9999217
rats O 0 0.0005312073
, O 0 0.0002629318
and O 0 0.00011825407
their O 0 9.344521e-05
relationship O 0 8.3796505e-05
with O 0 0.00020428553
echocardiographic O 0 0.0007402259
and O 0 0.00048871397
histological O 0 0.0019280914
findings O 0 0.0018153569
. O 0 0.0026611823

BACKGROUND O 0 0.018803187
: O 0 0.0069101043
Cardiac O 0 0.008507159
troponins O 0 0.26590392
I O 0 0.060399853
( O 0 0.002906515
cTnI O 0 0.13368344
) O 0 0.001466418
and O 0 0.0005998122
T O 0 0.0058098454
( O 0 0.0014625443
cTnT O 0 0.7453642
) O 0 0.0009913065
have O 0 0.00020000528
been O 0 0.00017294582
shown O 0 9.264835e-05
to O 0 0.00013485756
be O 0 0.00014570702
highly O 0 0.00012980463
sensitive O 0 0.00014104306
and O 0 0.00021609009
specific O 0 0.00018396447
markers O 0 0.0007158209
of O 0 0.0010205918
myocardial B-Disease 0 0.9993198
cell I-Disease 0 0.0039480645
injury I-Disease 0 0.63070947
. O 0 0.0034916585

We O 0 0.0022071986
investigated O 0 0.0013167735
the O 0 0.00080293056
diagnostic O 0 0.0007419056
value O 0 0.0005996653
of O 0 0.00067287625
cTnI O 0 0.15770133
and O 0 0.0005702668
cTnT O 0 0.31561428
for O 0 0.0001764602
the O 0 0.0001597216
diagnosis O 0 0.0004322827
of O 0 0.00044111768
myocardial B-Disease 0 0.99993753
damage I-Disease 0 0.89462084
in O 0 0.00017937773
a O 0 0.00019476615
rat O 0 0.00015667088
model O 0 9.531552e-05
of O 0 0.00023958267
doxorubicin B-Chemical 0 0.99994504
( O 0 0.003983365
DOX B-Chemical 1 0.999969
) O 0 0.002346874
- O 0 0.0026472781
induced O 0 0.00023253224
cardiomyopathy B-Disease 0 0.99996436
, O 0 0.00049276487
and O 0 0.000105679486
we O 0 4.1769097e-05
examined O 0 5.5336528e-05
the O 0 5.2732725e-05
relationship O 0 4.2259097e-05
between O 0 6.6944864e-05
serial O 0 0.00016130968
cTnI O 0 0.1423618
and O 0 0.0002178508
cTnT O 0 0.53896695
with O 0 0.00013128118
the O 0 8.318712e-05
development O 0 0.00013751976
of O 0 0.00016293405
cardiac B-Disease 0 0.15424608
disorders I-Disease 0 0.9992467
monitored O 0 9.496523e-05
by O 0 9.380322e-05
echocardiography O 0 0.00026488685
and O 0 0.00015630723
histological O 0 0.0005248166
examinations O 0 0.00036682168
in O 0 0.00036985413
this O 0 0.0006972951
model O 0 0.001197502
. O 0 0.0026703023

METHODS O 0 0.0046363063
: O 0 0.00352512
Thirty O 0 0.002531576
- O 0 0.0024675217
five O 0 0.00042676867
Wistar O 0 0.0013895842
rats O 0 0.00059777475
were O 0 0.00027565335
given O 0 0.00017480964
1 O 0 0.00024733238
. O 0 0.00019359047
5 O 0 0.00019999917
mg O 0 0.0011908
/ O 0 0.00094386697
kg O 0 0.0013852194
DOX B-Chemical 1 0.9997483
, O 0 0.0006672795
i O 0 0.00049585296
. O 0 0.00021969894
v O 0 0.0008294216
. O 0 0.00017468918
, O 0 0.00022873534
weekly O 0 0.00010319851
for O 0 7.907611e-05
up O 0 0.00011752989
to O 0 7.95517e-05
8 O 0 7.8162666e-05
weeks O 0 4.8017257e-05
for O 0 7.4576776e-05
a O 0 0.00017080877
total O 0 0.0001442618
cumulative O 0 0.00017942702
dose O 0 0.00032431277
of O 0 0.00028828083
12 O 0 0.00030753834
mg O 0 0.002528392
/ O 0 0.0022238598
kg O 0 0.002661314
BW O 0 0.017183486
. O 0 0.0034934194

Ten O 0 0.004700449
rats O 0 0.0038681342
received O 0 0.0024255624
saline O 0 0.004139638
as O 0 0.0020877775
a O 0 0.0028768543
control O 0 0.0028476513
group O 0 0.0055487165
. O 0 0.00716957

cTnI O 0 0.20599659
was O 0 0.002713817
measured O 0 0.0018443668
with O 0 0.0015044148
Access O 0 0.00257264
( O 0 0.0020599
R O 0 0.86212695
) O 0 0.0017299256
( O 0 0.0008752921
ng O 0 0.0009425823
/ O 0 0.0019703563
ml O 0 0.0015324425
) O 0 0.0006855789
and O 0 0.0002687556
a O 0 0.00035389815
research O 0 0.0003590425
immunoassay O 0 0.0009880066
( O 0 0.00055992143
pg O 0 0.0036926775
/ O 0 0.0017700603
ml O 0 0.0013579463
) O 0 0.00065491284
, O 0 0.00038780004
and O 0 0.00023725808
compared O 0 0.00021823395
with O 0 0.00059748226
cTnT O 0 0.9240337
, O 0 0.0050733634
CK O 0 0.9976646
- O 0 0.2757058
MB O 0 0.99959344
mass O 0 0.0036085972
and O 0 0.0028447136
CK O 0 0.95274824
. O 0 0.004921009

By O 0 0.0016465418
using O 0 0.0010584157
transthoracic O 0 0.0010288341
echocardiography O 0 0.0014163683
, O 0 0.0013179485
anterior O 0 0.0025053667
and O 0 0.00058844837
posterior O 0 0.002150021
wall O 0 0.0017505125
thickness O 0 0.0019305733
, O 0 0.00077820313
LV O 0 0.9612884
diameters O 0 0.0020577663
and O 0 0.00035348107
LV O 0 0.969074
fractional O 0 0.0018399137
shortening O 0 0.0014792236
( O 0 0.0005175561
FS O 0 0.0064644665
) O 0 0.00040122186
were O 0 0.00010862923
measured O 0 0.00011633193
in O 0 9.2740986e-05
all O 0 9.070373e-05
rats O 0 0.0001805647
before O 0 9.902158e-05
DOX B-Chemical 1 0.9997422
or O 0 0.00015550431
saline O 0 0.0005728206
, O 0 0.00020185344
and O 0 9.578009e-05
at O 0 6.187347e-05
weeks O 0 5.0479335e-05
6 O 0 7.012302e-05
and O 0 0.00010557796
9 O 0 0.000108313645
after O 0 8.71633e-05
treatment O 0 0.00020369909
in O 0 0.00029366248
all O 0 0.00047997345
surviving O 0 0.0016880744
rats O 0 0.0023803734
. O 0 0.0027962625

Histology O 0 0.010734221
was O 0 0.0021084195
performed O 0 0.0013840805
in O 0 0.0017365423
DOX B-Chemical 1 0.9996871
- O 0 0.0063891686
rats O 0 0.00061221025
at O 0 0.00020128685
6 O 0 0.0001520749
and O 0 0.00015748762
9 O 0 0.00011954977
weeks O 0 7.52132e-05
after O 0 8.4731175e-05
the O 0 0.00015255202
last O 0 0.00021164144
DOX B-Chemical 1 0.9992447
dose O 0 0.0009737914
and O 0 0.0004977878
in O 0 0.0005638202
all O 0 0.0008515116
controls O 0 0.002138315
. O 0 0.003117232

RESULTS O 0 0.0048862374
: O 0 0.003497213
Eighteen O 0 0.0020876674
of O 0 0.0011010687
the O 0 0.001086051
DOX B-Chemical 1 0.99954826
rats O 0 0.0018741775
died O 0 0.0017957713
prematurely O 0 0.0017883383
of O 0 0.00036164964
general O 0 0.00040073713
toxicity B-Disease 0 0.119704954
during O 0 0.00025293685
the O 0 0.0002898092
9 O 0 0.00040336692
- O 0 0.0013990531
week O 0 0.00045260464
period O 0 0.00086470455
. O 0 0.002508225

End O 0 0.013287097
- O 0 0.012815084
diastolic O 0 0.398677
( O 0 0.0040343436
ED O 0 0.02254329
) O 0 0.0013946035
and O 0 0.00045665205
end O 0 0.00030890093
- O 0 0.0016803576
systolic O 0 0.021478381
( O 0 0.00094731036
ES O 0 0.0020698477
) O 0 0.0010009276
LV O 0 0.96726227
diameters O 0 0.003494801
/ O 0 0.002031599
BW O 0 0.011553073
significantly O 0 0.00029913627
increased O 0 0.00032481152
, O 0 0.00044014805
whereas O 0 0.0003273614
LV O 0 0.9985819
FS O 0 0.051394794
was O 0 0.00015923922
decreased O 0 0.00020098117
after O 0 6.164097e-05
9 O 0 8.198755e-05
weeks O 0 6.0186496e-05
in O 0 0.0001291244
the O 0 0.00023624617
DOX B-Chemical 1 0.9995065
group O 0 0.0005372828
( O 0 0.00052398135
p O 0 0.0005352747
< O 0 0.0005989493
0 O 0 0.0006834984
. O 0 0.0008588383
001 O 0 0.008619952
) O 0 0.0044595646
. O 0 0.003993071

These O 0 0.00437161
parameters O 0 0.0050110337
remained O 0 0.005325773
unchanged O 0 0.0052969833
in O 0 0.004914678
controls O 0 0.008510087
. O 0 0.010616263

Histological O 0 0.0037610123
evaluation O 0 0.0015259426
of O 0 0.0011447716
hearts O 0 0.0013956005
from O 0 0.00050766295
all O 0 0.0003960125
rats O 0 0.00063113606
given O 0 0.0003973807
DOX B-Chemical 1 0.99939823
revealed O 0 0.00031030324
significant O 0 0.0003350446
slight O 0 0.00070522545
degrees O 0 0.014794198
of O 0 0.001038178
perivascular O 0 0.050015565
and O 0 0.0013664971
interstitial O 0 0.93288153
fibrosis B-Disease 0 0.9995654
. O 0 0.0044441163

In O 0 0.0026417105
7 O 0 0.0020243842
of O 0 0.0016307086
the O 0 0.0010940436
18 O 0 0.0011796794
rats O 0 0.0015636806
, O 0 0.002306357
degeneration O 0 0.4603992
and O 0 0.001543492
myocyte O 0 0.2296342
vacuolisation O 0 0.62965965
were O 0 0.0016761633
found O 0 0.00218572
. O 0 0.003944694

Only O 0 0.0036931757
five O 0 0.0012728014
of O 0 0.0013356591
the O 0 0.0008781968
controls O 0 0.0011620192
exhibited O 0 0.00074343395
evidence O 0 0.0006626967
of O 0 0.001082459
very O 0 0.0017567297
slight O 0 0.003957198
perivascular O 0 0.39109454
fibrosis B-Disease 0 0.9970662
. O 0 0.0054120696

A O 0 0.027130457
significant O 0 0.002598261
rise O 0 0.0020034984
in O 0 0.0014457054
cTnT O 0 0.5605429
was O 0 0.00061637117
found O 0 0.00045782386
in O 0 0.0005315757
DOX B-Chemical 1 0.9996753
rats O 0 0.00038879077
after O 0 7.953804e-05
cumulative O 0 0.00012463982
doses O 0 0.00024185023
of O 0 0.00014592978
7 O 0 0.00010680279
. O 0 0.00010298558
5 O 0 8.719265e-05
and O 0 9.6623146e-05
12 O 0 9.163439e-05
mg O 0 0.0007536123
/ O 0 0.00045430963
kg O 0 0.00030283682
in O 0 0.000113982744
comparison O 0 0.00010659981
with O 0 0.00016327621
baseline O 0 0.0001933866
( O 0 0.000393669
p O 0 0.00048657393
< O 0 0.00060209294
0 O 0 0.00071705435
. O 0 0.0009234925
05 O 0 0.012040834
) O 0 0.004441117
. O 0 0.004009316

cTnT O 0 0.79781663
found O 0 0.00229088
in O 0 0.001125994
rats O 0 0.0009843699
after O 0 0.00030986694
12 O 0 0.00032448315
mg O 0 0.001718096
/ O 0 0.0009355267
kg O 0 0.0005938717
were O 0 0.00019308555
significantly O 0 0.00021794967
greater O 0 0.00025278688
than O 0 0.00017467335
that O 0 0.00014629119
found O 0 0.00021130513
after O 0 0.00014851737
7 O 0 0.00022764032
. O 0 0.00030817642
5 O 0 0.0004386149
mg O 0 0.0029240153
/ O 0 0.0032123423
kg O 0 0.0051524076
DOX B-Chemical 1 0.998615
. O 0 0.005307848

Maximal O 0 0.022899218
cTnI O 0 0.19788258
( O 0 0.0044187703
pg O 0 0.01291136
/ O 0 0.00520309
ml O 0 0.003576431
) O 0 0.0015819588
and O 0 0.00066952524
cTnT O 0 0.25760898
levels O 0 0.0002948171
were O 0 0.00022658923
significantly O 0 0.0002647909
increased O 0 0.00033353368
in O 0 0.00032180513
DOX B-Chemical 1 0.99976486
rats O 0 0.00035672486
compared O 0 0.00010837936
with O 0 0.00015873274
controls O 0 0.0002771795
( O 0 0.00035301514
p O 0 0.0004018798
= O 0 0.0006369981
0 O 0 0.00038974482
. O 0 0.00038722204
006 O 0 0.0031903244
, O 0 0.00095579564
0 O 0 0.0009428472
. O 0 0.0010691447
007 O 0 0.006945131
) O 0 0.005042416
. O 0 0.004533032

cTnI O 0 0.22791673
( O 0 0.0066955877
ng O 0 0.005346673
/ O 0 0.008151019
ml O 0 0.0070248386
) O 0 0.004416042
, O 0 0.0046678046
CK O 0 0.99455523
- O 0 0.17972805
MB O 0 0.9995846
mass O 0 0.0015830173
and O 0 0.0009464546
CK O 0 0.91995937
remained O 0 0.0006785696
unchanged O 0 0.0006366143
in O 0 0.0006305772
DOX B-Chemical 1 0.99951744
rats O 0 0.0009680429
compared O 0 0.00044409494
with O 0 0.0009458511
controls O 0 0.002339363
. O 0 0.0032562083

All O 0 0.005751277
markers O 0 0.0075727706
remained O 0 0.0056155296
stable O 0 0.00477897
in O 0 0.0050307405
controls O 0 0.008786914
. O 0 0.010989794

Analysis O 0 0.0038126837
of O 0 0.0019860768
data O 0 0.001377097
revealed O 0 0.0006750115
a O 0 0.0007601858
significant O 0 0.0003850543
correlation O 0 0.00028568538
between O 0 0.00027327499
maximal O 0 0.000713983
cTnT O 0 0.47093725
and O 0 0.00048062007
ED O 0 0.015596557
and O 0 0.0003598342
ES O 0 0.002915417
LV O 0 0.9897759
diameters O 0 0.0037778623
/ O 0 0.0017120455
BW O 0 0.0059523834
( O 0 0.00042566907
r O 0 0.00045472794
= O 0 0.0005535534
0 O 0 0.0002745819
. O 0 0.00020410155
81 O 0 0.00038628484
and O 0 0.0002520341
0 O 0 0.00035213315
. O 0 0.00027669288
65 O 0 0.00039875344
; O 0 0.0005714927
p O 0 0.0006337162
< O 0 0.0007825527
0 O 0 0.00088641455
. O 0 0.0010861441
0001 O 0 0.0071806232
) O 0 0.0052264435
. O 0 0.0048869895

A O 0 0.019074233
significant O 0 0.0018269662
relationship O 0 0.00083698065
was O 0 0.00073285494
observed O 0 0.00044547438
between O 0 0.0003818699
maximal O 0 0.0008678689
cTnT O 0 0.3515347
and O 0 0.00031886474
the O 0 0.0001818027
extent O 0 0.0002018377
of O 0 0.00038322876
myocardial O 0 0.9926286
morphological O 0 0.0006910728
changes O 0 0.00024806286
, O 0 0.00032043294
and O 0 0.00019016638
between O 0 0.00022647367
LV O 0 0.98607767
diameters O 0 0.0057409927
/ O 0 0.0029695707
BW O 0 0.013068447
and O 0 0.0007339916
histological O 0 0.0022807643
findings O 0 0.0020952427
. O 0 0.0030762178

CONCLUSIONS O 0 0.018785704
: O 0 0.004354902
Among O 0 0.0017344763
markers O 0 0.0021186934
of O 0 0.0019418566
ischemic B-Disease 0 0.9998809
injury I-Disease 0 0.8856175
after O 0 0.000426737
DOX B-Chemical 1 0.9997526
in O 0 0.00028538646
rats O 0 0.00045860832
, O 0 0.000567783
cTnT O 0 0.26123497
showed O 0 0.00014827639
the O 0 0.00011020972
greatest O 0 0.00019295928
ability O 0 0.00013500408
to O 0 0.00014918973
detect O 0 0.00016574486
myocardial B-Disease 0 0.9998803
damage I-Disease 0 0.57403374
assessed O 0 0.00017684746
by O 0 0.00014853691
echocardiographic O 0 0.00046380525
detection O 0 0.0002650023
and O 0 0.0004641723
histological O 0 0.002062614
changes O 0 0.001624964
. O 0 0.0025569287

Although O 0 0.0019513497
there O 0 0.0015021861
was O 0 0.0011844198
a O 0 0.0010523449
discrepancy O 0 0.0005576241
between O 0 0.00031634912
the O 0 0.00028286054
amount O 0 0.00021651224
of O 0 0.00045675633
cTnI O 0 0.17919534
and O 0 0.0004749242
cTnT O 0 0.60662663
after O 0 0.00024753335
DOX B-Chemical 1 0.9998951
, O 0 0.0007350942
probably O 0 0.00022328476
due O 0 0.000103109494
to O 0 0.00011402361
heterogeneity O 0 0.00022447457
in O 0 0.00013098109
cross O 0 0.00024056144
- O 0 0.0011705959
reactivities O 0 0.0004324414
of O 0 0.0001460467
mAbs O 0 0.00028468698
to O 0 0.00011786613
various O 0 0.00017912
cTnI O 0 0.16071548
and O 0 0.00025682908
cTnT O 0 0.6546071
forms O 0 0.00017616265
, O 0 0.00035358555
it O 0 0.00021215017
is O 0 9.646913e-05
likely O 0 7.2597046e-05
that O 0 0.00010828887
cTnT O 0 0.34446755
in O 0 0.000122007164
rats O 0 0.00022743206
after O 0 0.000106811756
DOX B-Chemical 1 0.9998554
indicates O 0 0.00012138761
cell O 0 0.00034752087
damage O 0 0.024923872
determined O 0 9.3478004e-05
by O 0 8.081421e-05
the O 0 6.61624e-05
magnitude O 0 9.139005e-05
of O 0 0.0001387537
injury O 0 0.006319024
induced O 0 0.000115683026
and O 0 0.00013903422
that O 0 0.00011823446
cTnT O 0 0.606419
should O 0 6.395928e-05
be O 0 8.548872e-05
a O 0 0.00012220512
useful O 0 8.024441e-05
marker O 0 0.00011495771
for O 0 6.3559826e-05
the O 0 6.777135e-05
prediction O 0 6.633905e-05
of O 0 0.00012923995
experimentally O 0 0.00015141629
induced O 0 0.00036876937
cardiotoxicity B-Disease 0 0.99997115
and O 0 0.00047376918
possibly O 0 0.0004952104
for O 0 0.00039955578
cardioprotective O 0 0.011834972
experiments O 0 0.0010177022
. O 0 0.0025468743

Octreotide B-Chemical 0 0.99869543
- O 0 0.05964072
induced O 0 0.0035125697
hypoxemia B-Disease 0 0.9989907
and O 0 0.003159782
pulmonary B-Disease 2 0.99775106
hypertension I-Disease 2 0.9999906
in O 0 0.0023689824
premature O 0 0.007282008
neonates O 0 0.012163327
. O 0 0.0041277306

The O 0 0.0022597332
authors O 0 0.0019080135
report O 0 0.002388943
2 O 0 0.0012494999
cases O 0 0.0012010548
of O 0 0.0007342712
premature O 0 0.0019017588
neonates O 0 0.0030023952
who O 0 0.0008254286
had O 0 0.00069826894
enterocutaneous O 0 0.9181176
fistula B-Disease 0 0.97408867
complicating O 0 0.3816082
necrotizing B-Disease 0 0.9997422
enterocolitis I-Disease 0 0.99956506
. O 0 0.0055213207

Pulmonary B-Disease 0 0.96457666
hypertension I-Disease 2 0.9999579
developed O 0 0.0015877724
after O 0 0.00037531083
administration O 0 0.0006572599
of O 0 0.00043695542
a O 0 0.0007146472
somatostatin O 0 0.21723033
analogue O 0 0.0014100334
, O 0 0.0012900468
octreotide B-Chemical 0 0.998823
, O 0 0.00069109513
to O 0 0.00024762776
enhance O 0 0.00026069477
resolution O 0 0.0010185048
of O 0 0.00091267325
the O 0 0.0012203099
fistula B-Disease 0 0.84672785
. O 0 0.0038361459

The O 0 0.0018086333
authors O 0 0.0012825453
discuss O 0 0.00084543263
the O 0 0.00054579636
mechanism O 0 0.0003480447
of O 0 0.00044932595
the O 0 0.00028241452
occurrence O 0 0.00029244652
of O 0 0.00023799308
this O 0 0.0002235476
complication O 0 0.0012921324
and O 0 0.00016339909
recommend O 0 0.00014938504
caution O 0 0.00020780579
of O 0 0.00018130499
its O 0 0.00024377753
use O 0 0.00018724153
in O 0 0.00025147267
high O 0 0.00060852896
- O 0 0.0052436823
risk O 0 0.006312704
premature O 0 0.0054491796
neonates O 0 0.013989814
. O 0 0.0032329394

The O 0 0.0025045471
risk O 0 0.0064354744
of O 0 0.0022573264
venous B-Disease 0 0.9642363
thromboembolism I-Disease 0 0.99997544
in O 0 0.0008318923
women O 0 0.0031773928
prescribed O 0 0.076187566
cyproterone B-Chemical 0 0.9999937
acetate I-Chemical 0 0.99691415
in O 0 0.00024512093
combination O 0 0.00028306418
with O 0 0.0004791643
ethinyl B-Chemical 0 0.99998057
estradiol I-Chemical 0 0.99996686
: O 0 0.0010317296
a O 0 0.00025835424
nested O 0 0.00016430214
cohort O 0 0.0003878512
analysis O 0 0.00019927943
and O 0 0.00027884406
case O 0 0.0005056611
- O 0 0.0022912952
control O 0 0.000945397
study O 0 0.0018771886
. O 0 0.0028102773

BACKGROUND O 0 0.05064556
: O 0 0.023666432
Cyproterone B-Chemical 0 0.9998915
acetate I-Chemical 0 0.9970431
combined O 0 0.0018973082
with O 0 0.0019777422
ethinyl B-Chemical 0 0.99996805
estradiol I-Chemical 0 0.99997234
( O 0 0.020200597
CPA B-Chemical 1 0.9998809
/ O 0 0.0767621
EE B-Chemical 0 0.99686015
) O 0 0.00078118406
is O 0 0.00013285657
licensed O 0 0.0002559332
in O 0 0.00013329298
the O 0 0.00012540327
UK O 0 0.0010405009
for O 0 7.5014366e-05
the O 0 7.247164e-05
treatment O 0 9.302645e-05
of O 0 0.00012405797
women O 0 0.0006166968
with O 0 0.00029020512
acne B-Disease 0 0.99839884
and O 0 0.00050258863
hirsutism B-Disease 0 0.9997197
and O 0 0.00020253439
is O 0 9.7593314e-05
also O 0 0.00010005752
a O 0 0.00016889848
treatment O 0 0.00012137002
option O 0 0.00017014182
for O 0 0.0002112439
polycystic B-Disease 0 0.951155
ovary I-Disease 0 0.22866784
syndrome I-Disease 0 0.9906441
( O 0 0.0058233486
PCOS B-Disease 0 0.9994042
) O 0 0.005942877
. O 0 0.0031810168

Previous O 0 0.0021581335
studies O 0 0.002035242
have O 0 0.001019632
demonstrated O 0 0.000739705
an O 0 0.00076196704
increased O 0 0.0008095407
risk O 0 0.002813639
of O 0 0.0007363018
venous B-Disease 0 0.98637044
thromboembolism I-Disease 0 0.99999404
( O 0 0.008071882
VTE B-Disease 2 0.999821
) O 0 0.00076637417
associated O 0 0.00020970267
with O 0 0.00034590022
CPA B-Chemical 1 0.999801
/ O 0 0.016820239
EE B-Chemical 0 0.95213985
compared O 0 0.00011504588
with O 0 0.0001552184
conventional O 0 0.00019710023
combined O 0 0.00067187555
oral B-Chemical 0 0.023431508
contraceptives I-Chemical 0 0.9841164
( O 0 0.0029444962
COCs O 0 0.12919791
) O 0 0.004422886
. O 0 0.0032543303

We O 0 0.002651687
believe O 0 0.001885936
the O 0 0.0010934696
results O 0 0.00080943684
of O 0 0.0008657871
those O 0 0.0008176834
studies O 0 0.00076313515
may O 0 0.00048119313
have O 0 0.00047914532
been O 0 0.0005739242
affected O 0 0.00078566297
by O 0 0.00088805286
residual O 0 0.0014075005
confounding O 0 0.0021240492
. O 0 0.0036709115

METHODS O 0 0.0042639743
: O 0 0.00265519
Using O 0 0.0006959215
the O 0 0.0007695661
General O 0 0.0010091868
Practice O 0 0.0011965494
Research O 0 0.0010892198
Database O 0 0.00062004186
we O 0 0.00014303424
conducted O 0 0.00026682133
a O 0 0.00030955215
cohort O 0 0.00043178786
analysis O 0 0.00015925958
and O 0 0.00016143586
case O 0 0.00020407702
- O 0 0.0008771497
control O 0 0.00013878176
study O 0 0.00013774536
nested O 0 9.503988e-05
within O 0 5.4939595e-05
a O 0 0.00014792349
population O 0 0.00015851298
of O 0 0.00014187381
women O 0 0.00043190416
aged O 0 0.00019792587
between O 0 7.437806e-05
15 O 0 8.8896944e-05
and O 0 9.047645e-05
39 O 0 0.00014099113
years O 0 0.00015137861
with O 0 0.00021909918
acne B-Disease 0 0.994027
, O 0 0.0014572531
hirsutism B-Disease 0 0.99962795
or O 0 0.00041516375
PCOS B-Disease 0 0.9997389
to O 0 0.00015605988
estimate O 0 0.00011023957
the O 0 0.00016544487
risk O 0 0.0021702957
of O 0 0.0006990303
VTE B-Disease 2 0.9997842
associated O 0 0.00075976615
with O 0 0.0013421151
CPA B-Chemical 1 0.99974626
/ O 0 0.2400357
EE B-Chemical 0 0.9945885
. O 0 0.0037254146

RESULTS O 0 0.0046353117
: O 0 0.002985408
The O 0 0.00077705894
age O 0 0.001320016
- O 0 0.002069497
adjusted O 0 0.000439529
incidence O 0 0.0006917293
rate O 0 0.0004891113
ratio O 0 0.00040685013
for O 0 0.00039207115
CPA B-Chemical 1 0.99940777
/ O 0 0.008434628
EE B-Chemical 0 0.9100796
versus O 0 0.0001992781
conventional O 0 0.00021416527
COCs O 0 0.0061669606
was O 0 0.00020903071
2 O 0 0.00021799291
. O 0 0.00017668499
20 O 0 0.00020291746
[ O 0 0.000591811
95 O 0 0.00038327882
% O 0 0.00032038472
confidence O 0 0.00046405417
interval O 0 0.0002881264
( O 0 0.0005026184
CI O 0 0.0045886836
) O 0 0.0007154867
1 O 0 0.00034006828
. O 0 0.00030915314
35 O 0 0.00045956564
- O 0 0.0014257025
3 O 0 0.0005471415
. O 0 0.0008079701
58 O 0 0.0019853238
] O 0 0.0050241956
. O 0 0.0041905213

Using O 0 0.001781428
as O 0 0.0014937075
the O 0 0.00081289664
reference O 0 0.00074870937
group O 0 0.00088992564
women O 0 0.001382222
who O 0 0.0005031504
were O 0 0.00020659476
not O 0 0.00016340314
using O 0 0.00015736843
oral O 0 0.0014356681
contraception O 0 0.0018726855
, O 0 0.000303374
had O 0 0.00011911521
no O 0 0.000100268415
recent O 0 0.00014068549
pregnancy O 0 0.0010178229
or O 0 0.0002449866
menopausal O 0 0.9888347
symptoms O 0 0.34718832
, O 0 0.0002898675
the O 0 0.000105787876
case O 0 0.00017383942
- O 0 0.00088349695
control O 0 0.00013191337
analysis O 0 0.00012214069
gave O 0 0.00012226758
an O 0 0.000103090024
adjusted O 0 7.509588e-05
odds O 0 0.00015477664
ratio O 0 0.0001740695
( O 0 0.00033111725
OR O 0 0.0013634454
( O 0 0.00036495551
adj O 0 0.0016400183
) O 0 0.0004645379
) O 0 0.00037172157
of O 0 0.00018170822
7 O 0 0.00014736796
. O 0 0.00016500581
44 O 0 0.00025541644
( O 0 0.0003207575
95 O 0 0.00038254674
% O 0 0.00039912865
CI O 0 0.0022062317
3 O 0 0.00017116204
. O 0 0.00017681709
67 O 0 0.0003492319
- O 0 0.0007815087
15 O 0 0.00018394059
. O 0 0.0001979455
08 O 0 0.0018729406
) O 0 0.0005647453
for O 0 0.00025314407
CPA B-Chemical 1 0.9994204
/ O 0 0.008592298
EE B-Chemical 0 0.93981916
use O 0 0.00014617752
compared O 0 0.00010363736
with O 0 0.00016693983
an O 0 0.0002245375
OR O 0 0.0017021341
( O 0 0.00042642406
adj O 0 0.0017731534
) O 0 0.00042460463
of O 0 0.00020223489
2 O 0 0.0002219503
. O 0 0.00018449318
58 O 0 0.00030903085
( O 0 0.00034272872
95 O 0 0.0004101125
% O 0 0.0004403174
CI O 0 0.0029702669
1 O 0 0.00024427657
. O 0 0.00018340538
60 O 0 0.0002391682
- O 0 0.00072809344
4 O 0 0.0001791241
. O 0 0.00020474492
18 O 0 0.00026439514
) O 0 0.00048356483
for O 0 0.00023616193
use O 0 0.0003821139
of O 0 0.00075529114
conventional O 0 0.0013535388
COCs O 0 0.05048378
. O 0 0.0041319784

CONCLUSIONS O 0 0.023164758
: O 0 0.004384126
We O 0 0.0009950972
have O 0 0.0006765549
demonstrated O 0 0.0005364239
an O 0 0.0006004777
increased O 0 0.0007098232
risk O 0 0.003736973
of O 0 0.00083530275
VTE B-Disease 2 0.9997669
associated O 0 0.00028905118
with O 0 0.00017526162
the O 0 0.00011771305
use O 0 0.00013683774
of O 0 0.00033525933
CPA B-Chemical 1 0.99985576
/ O 0 0.054074146
EE B-Chemical 0 0.99410784
in O 0 0.00018832568
women O 0 0.0006507253
with O 0 0.00031747975
acne B-Disease 0 0.99811375
, O 0 0.00177732
hirsutism B-Disease 0 0.99970007
or O 0 0.00044208422
PCOS B-Disease 0 0.99984515
although O 0 0.00024557544
residual O 0 0.00024340267
confounding O 0 0.00024380238
by O 0 0.0002499879
indication O 0 0.00028149225
cannot O 0 0.0019958254
be O 0 0.0010121424
excluded O 0 0.0019444729
. O 0 0.0027768456

The O 0 0.001765408
effect O 0 0.0012658185
of O 0 0.0012592096
treatment O 0 0.0009422945
with O 0 0.0009617479
gum B-Chemical 0 0.7566058
Arabic I-Chemical 0 0.0035639093
on O 0 0.00062127586
gentamicin B-Chemical 0 0.99995434
nephrotoxicity B-Disease 0 0.99996305
in O 0 0.00060346257
rats O 0 0.0008674129
: O 0 0.0010967765
a O 0 0.0009097686
preliminary O 0 0.0011240274
study O 0 0.002009207
. O 0 0.0031662453

In O 0 0.0019130337
the O 0 0.0013923217
present O 0 0.00086075166
work O 0 0.0007428068
we O 0 0.0002934906
assessed O 0 0.0003404582
the O 0 0.00022728334
effect O 0 0.00020034978
of O 0 0.0002549819
treatment O 0 0.00020531245
of O 0 0.00019019938
rats O 0 0.00031608986
with O 0 0.00025524967
gum B-Chemical 0 0.65670204
Arabic I-Chemical 0 0.0011413622
on O 0 0.0001526999
acute B-Disease 0 0.028486988
renal I-Disease 0 0.854369
failure I-Disease 0 0.020031134
induced O 0 0.0003303624
by O 0 0.00061365135
gentamicin B-Chemical 0 0.9999335
( O 0 0.004502766
GM B-Chemical 0 0.9897691
) O 0 0.010455333
nephrotoxicity B-Disease 0 0.99985707
. O 0 0.0044449996

Rats O 0 0.007020987
were O 0 0.001985952
treated O 0 0.002025984
with O 0 0.0009922471
the O 0 0.00068624754
vehicle O 0 0.002019775
( O 0 0.0009658723
2 O 0 0.0004994665
mL O 0 0.0015560316
/ O 0 0.0009782391
kg O 0 0.000611176
of O 0 0.00031365833
distilled O 0 0.0008545305
water O 0 0.0012722093
and O 0 0.00025679602
5 O 0 0.00019857386
% O 0 0.0003547776
w O 0 0.00056222925
/ O 0 0.0014834123
v O 0 0.003041728
cellulose O 0 0.4896167
, O 0 0.00051674
10 O 0 0.00018587521
days O 0 0.00011385152
) O 0 0.00042330247
, O 0 0.00047362308
gum B-Chemical 0 0.33171713
Arabic I-Chemical 0 0.0014467589
( O 0 0.00045238523
2 O 0 0.0002573561
mL O 0 0.0010497337
/ O 0 0.0007034024
kg O 0 0.00043644127
of O 0 0.00020311512
a O 0 0.0002690825
10 O 0 0.00018327076
% O 0 0.00031237182
w O 0 0.00048501385
/ O 0 0.0011552006
v O 0 0.0015598441
aqueous O 0 0.01676787
suspension O 0 0.00048042773
of O 0 0.00027007563
gum B-Chemical 0 0.82676
Arabic I-Chemical 0 0.0031456996
powder O 0 0.020726223
, O 0 0.00036592016
orally O 0 0.00029739345
for O 0 7.8614314e-05
10 O 0 9.331662e-05
days O 0 6.384691e-05
) O 0 0.00025244534
, O 0 0.00022633615
or O 0 0.00015499315
gum B-Chemical 0 0.5343924
Arabic I-Chemical 0 0.001612246
concomitantly O 0 0.0005752235
with O 0 0.00033650274
GM B-Chemical 0 0.9824442
( O 0 0.00078254304
80mg O 0 0.9720991
/ O 0 0.00072348176
kg O 0 0.00034872512
/ O 0 0.00043351908
day O 0 8.1531995e-05
intramuscularly O 0 0.00023970834
, O 0 0.00016068165
during O 0 6.702274e-05
the O 0 7.142814e-05
last O 0 5.261398e-05
six O 0 6.2048006e-05
days O 0 8.490459e-05
of O 0 0.00020011705
the O 0 0.00024991544
treatment O 0 0.00043793683
period O 0 0.00062071363
) O 0 0.0027777348
. O 0 0.0028453749

Nephrotoxicity B-Disease 0 0.9946325
was O 0 0.0017378738
assessed O 0 0.00084967335
by O 0 0.0005429408
measuring O 0 0.00038570678
the O 0 0.00030853626
concentrations O 0 0.0005750374
of O 0 0.00056876236
creatinine B-Chemical 0 0.9972235
and O 0 0.00078942394
urea B-Chemical 0 0.99931455
in O 0 0.0003037259
the O 0 0.00023656081
plasma O 0 0.014148096
and O 0 0.00042967062
reduced O 0 0.008938462
glutathione B-Chemical 0 0.9999974
( O 0 0.6001715
GSH B-Chemical 1 0.99999917
) O 0 0.0049587805
in O 0 0.00016635907
the O 0 0.00014603681
kidney O 0 0.048493933
cortex O 0 0.02456398
, O 0 0.00032718913
and O 0 0.00016710085
by O 0 0.0001692004
light O 0 0.0003103142
microscopic O 0 0.00032439223
examination O 0 0.0002686721
of O 0 0.0005699676
kidney O 0 0.020678611
sections O 0 0.0015376477
. O 0 0.0027065338

The O 0 0.001656529
results O 0 0.0011375773
indicated O 0 0.00064909033
that O 0 0.0005496358
concomitant O 0 0.0009870327
treatment O 0 0.0004702765
with O 0 0.00049991393
gum B-Chemical 0 0.8006917
Arabic I-Chemical 0 0.002778371
and O 0 0.00047910193
GM B-Chemical 0 0.9553986
significantly O 0 0.00039457978
increased O 0 0.00061910093
creatinine B-Chemical 0 0.99825186
and O 0 0.000526873
urea B-Chemical 0 0.9992699
by O 0 0.00022426064
about O 0 0.00023977738
183 O 0 0.00061706884
and O 0 0.0001871648
239 O 0 0.00066079054
% O 0 0.0003261359
, O 0 0.00027058003
respectively O 0 0.0002884436
( O 0 0.00024524788
compared O 0 9.7227516e-05
to O 0 0.00013336226
432 O 0 0.00083032943
and O 0 0.00020412916
346 O 0 0.0010975437
% O 0 0.00037455955
, O 0 0.00029943927
respectively O 0 0.00031563392
, O 0 0.00025714983
in O 0 0.00012240629
rats O 0 0.00024934544
treated O 0 0.00034165752
with O 0 0.00028737582
cellulose O 0 0.7197817
and O 0 0.00051878643
GM B-Chemical 0 0.99430263
) O 0 0.0010071107
, O 0 0.00033187922
and O 0 0.00017026693
decreased O 0 0.00030169476
that O 0 0.00013509784
of O 0 0.00039750076
cortical O 0 0.21906777
GSH B-Chemical 1 0.999998
by O 0 0.00030967168
21 O 0 0.00020527252
% O 0 0.00025853512
( O 0 0.00018737584
compared O 0 7.481482e-05
to O 0 9.677695e-05
27 O 0 0.00018424778
% O 0 0.00024151197
in O 0 0.00012190065
the O 0 0.00014878328
cellulose O 0 0.25697866
plus O 0 0.0003691018
GM B-Chemical 0 0.96485114
group O 0 0.00039514102
) O 0 0.0004915569
The O 0 0.00012295706
GM B-Chemical 0 0.9690916
- O 0 0.00402925
induced O 0 0.0002362198
proximal O 0 0.0077409055
tubular B-Disease 0 0.99994767
necrosis I-Disease 2 0.9999989
appeared O 0 0.0002857987
to O 0 0.00010321337
be O 0 9.3060335e-05
slightly O 0 0.00015547987
less O 0 0.00018053457
severe O 0 0.00051368546
in O 0 8.531931e-05
rats O 0 0.0001691091
given O 0 9.6795506e-05
GM B-Chemical 0 0.5851744
together O 0 0.00013484342
with O 0 0.00022135476
gum B-Chemical 0 0.7652235
Arabic I-Chemical 0 0.0014328532
than O 0 0.00019235657
in O 0 0.00023735268
those O 0 0.00040887427
given O 0 0.0004750299
GM B-Chemical 0 0.9120913
and O 0 0.0018965724
cellulose O 0 0.7508654
. O 0 0.004312587

It O 0 0.005754714
could O 0 0.0016605012
be O 0 0.001197648
inferred O 0 0.0007459814
that O 0 0.00062052277
gum B-Chemical 0 0.6940799
Arabic I-Chemical 0 0.0028207344
treatment O 0 0.00038419812
has O 0 0.00017074688
induced O 0 0.0002187658
a O 0 0.00036133162
modest O 0 0.0004277562
amelioration O 0 0.0048106406
of O 0 0.00022807503
some O 0 0.00018745875
of O 0 0.00019993453
the O 0 0.00017192414
histological O 0 0.0006818387
and O 0 0.00028834352
biochemical O 0 0.00048636296
indices O 0 0.00087050215
of O 0 0.0014934307
GM B-Chemical 0 0.9978671
nephrotoxicity B-Disease 0 0.99994063
. O 0 0.0048905197

Further O 0 0.002506312
work O 0 0.002041555
is O 0 0.000909952
warranted O 0 0.0006052159
on O 0 0.00031633646
the O 0 0.0002631309
effect O 0 0.0002254361
of O 0 0.00026729083
the O 0 0.0001705578
treatments O 0 0.00021890643
on O 0 0.00012651885
renal O 0 0.08959921
functional O 0 0.00010445151
aspects O 0 8.9988665e-05
in O 0 9.159595e-05
models O 0 0.000104502506
of O 0 0.0001959895
chronic B-Disease 0 0.2532093
renal I-Disease 0 0.95530266
failure I-Disease 0 0.33392805
, O 0 0.00039566515
and O 0 0.00017797509
on O 0 0.00012711927
the O 0 0.00017925052
mechanism O 0 0.0002515151
( O 0 0.0009160444
s O 0 0.0010992393
) O 0 0.002019875
involved O 0 0.0014540304
. O 0 0.0031518107

Increased O 0 0.0039438144
frequency O 0 0.0016481831
of O 0 0.0018003252
venous B-Disease 0 0.91721576
thromboembolism I-Disease 0 0.99996006
with O 0 0.0005482007
the O 0 0.00021484285
combination O 0 0.0002689381
of O 0 0.0003533663
docetaxel B-Chemical 0 0.99965024
and O 0 0.0005358457
thalidomide B-Chemical 0 0.9999293
in O 0 0.00029344056
patients O 0 0.0007044143
with O 0 0.00052896497
metastatic O 0 0.9547103
androgen O 0 0.998601
- O 0 0.015358691
independent O 0 0.0007769243
prostate B-Disease 0 0.9945215
cancer I-Disease 0 0.99906117
. O 0 0.0052619353

STUDY O 0 0.0070100995
OBJECTIVE O 0 0.009495333
: O 0 0.0017632407
To O 0 0.0002736408
evaluate O 0 0.00020602625
the O 0 0.0002744078
frequency O 0 0.00028360443
of O 0 0.0004894125
venous B-Disease 0 0.9495781
thromboembolism I-Disease 0 0.9999924
( O 0 0.0062238583
VTE B-Disease 2 0.99982446
) O 0 0.00067839696
in O 0 0.00013847389
patients O 0 0.00031503956
with O 0 0.00021701842
advanced O 0 0.036810238
androgen O 0 0.999012
- O 0 0.014389313
independent O 0 0.00017985146
prostate B-Disease 0 0.99681735
cancer I-Disease 0 0.99964345
who O 0 0.00036972403
were O 0 0.00010175288
treated O 0 0.00023182915
with O 0 0.00023741809
docetaxel B-Chemical 0 0.9995117
alone O 0 0.0002418396
or O 0 0.0001911794
in O 0 0.00027087686
combination O 0 0.0006475158
with O 0 0.001461608
thalidomide B-Chemical 0 0.99984133
. O 0 0.004090503

DESIGN O 0 0.006981846
: O 0 0.0061005685
Retrospective O 0 0.00880777
analysis O 0 0.0017653577
of O 0 0.0016484736
a O 0 0.0023550023
randomized O 0 0.0036638288
phase O 0 0.004385575
II O 0 0.044697683
trial O 0 0.0063582924
. O 0 0.00604617

SETTING O 0 0.013337128
: O 0 0.0068294024
National O 0 0.0027860207
Institutes O 0 0.0024612641
of O 0 0.0021716352
Health O 0 0.002353197
clinical O 0 0.0040638065
research O 0 0.0036857596
center O 0 0.00529059
. O 0 0.0073876088

PATIENTS O 0 0.0029089414
: O 0 0.0037738855
Seventy O 0 0.003706226
men O 0 0.0037304284
, O 0 0.0019241396
aged O 0 0.0016529022
50 O 0 0.0011489707
- O 0 0.002265506
80 O 0 0.00078845373
years O 0 0.0006505871
, O 0 0.00087577675
with O 0 0.0008164425
advanced O 0 0.028939368
androgen O 0 0.99772686
- O 0 0.022474447
independent O 0 0.0013962927
prostate B-Disease 0 0.9924596
cancer I-Disease 0 0.9985227
. O 0 0.006981324

INTERVENTION O 0 0.003400789
: O 0 0.0024434936
Each O 0 0.00057303463
patient O 0 0.0005177618
received O 0 0.0003266381
either O 0 0.00030739297
intravenous O 0 0.002168118
docetaxel B-Chemical 0 0.9865389
30 O 0 0.00023199676
mg O 0 0.0014836731
/ O 0 0.00080498296
m2 O 0 0.0012146934
/ O 0 0.00055611535
week O 0 7.762829e-05
for O 0 6.702139e-05
3 O 0 7.144824e-05
consecutive O 0 6.882907e-05
weeks O 0 5.1075505e-05
, O 0 0.00015457164
followed O 0 8.039569e-05
by O 0 9.660077e-05
1 O 0 0.00011270813
week O 0 6.346813e-05
off O 0 0.00012955237
, O 0 0.00018026074
or O 0 8.233518e-05
the O 0 7.03486e-05
combination O 0 0.00010533852
of O 0 0.00010357353
continuous O 0 0.000120850906
oral O 0 0.001712176
thalidomide B-Chemical 0 0.9998925
200 O 0 0.00053591764
mg O 0 0.0023985785
every O 0 8.12233e-05
evening O 0 0.0002596435
plus O 0 0.00018624634
the O 0 0.00022084858
same O 0 0.00039418502
docetaxel B-Chemical 0 0.9942334
regimen O 0 0.0016154159
. O 0 0.0021676507

This O 0 0.0048641292
4 O 0 0.0020409604
- O 0 0.0038640774
week O 0 0.000622165
cycle O 0 0.0006035595
was O 0 0.0004155183
repeated O 0 0.0002279294
until O 0 0.00018068784
there O 0 0.0002142776
was O 0 0.0002520204
evidence O 0 0.00025603693
of O 0 0.0005027988
excessive O 0 0.0028445905
toxicity B-Disease 0 0.78505707
or O 0 0.0011669898
disease O 0 0.5844551
progression O 0 0.014304736
. O 0 0.003503327

MEASUREMENTS O 0 0.007972767
AND O 0 0.0019224772
MAIN O 0 0.00223363
RESULTS O 0 0.0011062651
: O 0 0.00086263276
None O 0 0.0004777582
of O 0 0.00039363562
23 O 0 0.00048337886
patients O 0 0.0004506864
who O 0 0.00030687582
received O 0 0.00026537522
docetaxel B-Chemical 0 0.9973546
alone O 0 0.0003302037
developed O 0 0.00057115505
VTE B-Disease 2 0.99978524
, O 0 0.00049272925
whereas O 0 0.00015925882
9 O 0 0.00011768286
of O 0 0.00013952839
47 O 0 0.0002597685
patients O 0 0.00028323857
( O 0 0.00022131526
19 O 0 0.0001639136
% O 0 0.00023106452
) O 0 0.00025803497
who O 0 0.00016139261
received O 0 0.00016252843
docetaxel B-Chemical 0 0.99822193
plus O 0 0.0004255719
thalidomide B-Chemical 0 0.9999404
developed O 0 0.0011783869
VTE B-Disease 2 0.999676
( O 0 0.00064696796
p O 0 0.0005957505
= O 0 0.00097081036
0 O 0 0.0006573635
. O 0 0.0007763178
025 O 0 0.010151636
) O 0 0.0036485132
. O 0 0.003335285

CONCLUSION O 0 0.014762184
: O 0 0.003208901
The O 0 0.00061297364
addition O 0 0.0004374253
of O 0 0.0010068461
thalidomide B-Chemical 0 0.9998128
to O 0 0.0007222435
docetaxel B-Chemical 0 0.9994254
in O 0 0.0002587627
the O 0 0.00017635037
treatment O 0 0.00024362859
of O 0 0.0005021462
prostate B-Disease 0 0.9984402
cancer I-Disease 0 0.99961936
significantly O 0 0.0007000347
increases O 0 0.00039276414
the O 0 0.00036359942
frequency O 0 0.0006020737
of O 0 0.001824942
VTE B-Disease 2 0.9991147
. O 0 0.00377078

Clinicians O 0 0.006005184
should O 0 0.001247993
be O 0 0.0011037815
aware O 0 0.0008497013
of O 0 0.0006763941
this O 0 0.0004984667
potential O 0 0.0003675676
complication O 0 0.0019038862
when O 0 0.00033223158
adding O 0 0.00075191946
thalidomide B-Chemical 0 0.9997166
to O 0 0.0008585266
chemotherapeutic O 0 0.0071518873
regimens O 0 0.001875156
. O 0 0.0025632686

Ticlopidine B-Chemical 0 0.9993581
- O 0 0.26890695
induced O 0 0.023718007
cholestatic B-Disease 0 0.99991846
hepatitis I-Disease 0 0.99985194
. O 0 0.03427984

OBJECTIVE O 0 0.018942505
: O 0 0.0034858298
To O 0 0.0006344839
report O 0 0.0013421099
2 O 0 0.0007900204
cases O 0 0.0009965113
of O 0 0.0012604035
ticlopidine B-Chemical 0 0.9999956
- O 0 0.18629986
induced O 0 0.0013555315
cholestatic B-Disease 0 0.99999845
hepatitis I-Disease 0 0.99999547
, O 0 0.00096074684
investigate O 0 6.6893306e-05
its O 0 0.00016208258
mechanism O 0 8.848828e-05
, O 0 0.00023268972
and O 0 0.000107453416
compare O 0 4.853106e-05
the O 0 8.440465e-05
observed O 0 9.9422556e-05
main O 0 0.00014399656
characteristics O 0 0.00013860916
with O 0 0.00021005808
those O 0 0.00028955398
of O 0 0.00037564532
the O 0 0.00044126954
published O 0 0.00081310974
cases O 0 0.0024024448
. O 0 0.002883217

CASE O 0 0.5296117
SUMMARIES O 0 0.018778376
: O 0 0.0026302352
Two O 0 0.000673332
patients O 0 0.0009879938
developed O 0 0.000620629
prolonged O 0 0.0014632381
cholestatic B-Disease 0 0.99999285
hepatitis I-Disease 0 0.9999815
after O 0 0.00018177791
receiving O 0 0.00042428798
ticlopidine B-Chemical 0 0.99997735
following O 0 6.269765e-05
percutaneous O 0 0.00015673811
coronary O 0 0.003401964
angioplasty O 0 0.050155096
, O 0 0.00018294899
with O 0 0.000112806854
complete O 0 0.00011724467
remission O 0 0.0013419834
during O 0 0.00011860099
the O 0 0.00018236294
follow O 0 0.0002584284
- O 0 0.0016111787
up O 0 0.0008058889
period O 0 0.00094813784
. O 0 0.0024558872

T O 0 0.05031434
- O 0 0.0121196145
cell O 0 0.0017713694
stimulation O 0 0.0006184955
by O 0 0.0005292959
therapeutic O 0 0.0007229755
concentration O 0 0.00088103174
of O 0 0.0010451607
ticlopidine B-Chemical 0 0.99999523
was O 0 0.00030721308
demonstrated O 0 0.000167745
in O 0 0.00015984804
vitro O 0 0.00016945548
in O 0 0.00016214118
the O 0 0.00017460009
patients O 0 0.0005826606
, O 0 0.0005353594
but O 0 0.00040161502
not O 0 0.00038586088
in O 0 0.0006425642
healthy O 0 0.0033644116
controls O 0 0.0024883458
. O 0 0.0031201434

DISCUSSION O 0 0.01055749
: O 0 0.016149
Cholestatic B-Disease 0 0.9998871
hepatitis I-Disease 0 0.9999311
is O 0 0.0010660549
a O 0 0.0009696771
rare O 0 0.0014037671
complication O 0 0.0015726059
of O 0 0.00023640702
the O 0 0.00020819767
antiplatelet O 0 0.8169634
agent O 0 0.0089511555
ticlopidine B-Chemical 0 0.9999974
; O 0 0.0007953497
several O 0 0.00010851348
cases O 0 0.0002788603
have O 0 0.00013798974
been O 0 0.00017163405
reported O 0 0.00023373836
but O 0 0.00025452813
few O 0 0.00017564958
in O 0 0.00032276375
the O 0 0.00046692195
English O 0 0.0016220122
literature O 0 0.0025775589
. O 0 0.002885742

Our O 0 0.0020610804
patients O 0 0.0029181049
developed O 0 0.0016256844
jaundice B-Disease 0 0.9660838
following O 0 0.00032698366
treatment O 0 0.00038561798
with O 0 0.0006501934
ticlopidine B-Chemical 0 0.9999937
and O 0 0.00028975008
showed O 0 0.00014106793
the O 0 0.00011137832
clinical O 0 0.00036796363
and O 0 0.00012067772
laboratory O 0 0.00013998244
characteristics O 0 0.00012879656
of O 0 0.00043481615
cholestatic B-Disease 0 0.99999785
hepatitis I-Disease 0 0.9999957
, O 0 0.0021889564
which O 0 0.00028745257
resolved O 0 0.00023485305
after O 0 0.00012593484
discontinuation O 0 0.0010850303
of O 0 0.00045172533
the O 0 0.0007029558
drug O 0 0.012967944
. O 0 0.0028430396

Hepatitis B-Disease 0 0.9988996
may O 0 0.0020262364
develop O 0 0.0009475591
weeks O 0 0.00034215936
after O 0 0.0002527642
discontinuation O 0 0.0011388052
of O 0 0.0002948348
the O 0 0.00024267807
drug O 0 0.0026508651
and O 0 0.0002445264
may O 0 0.00014841274
run O 0 0.00019192001
a O 0 0.00021923271
prolonged O 0 0.00021476933
course O 0 0.00018243145
, O 0 0.00031532714
but O 0 0.00020094974
complete O 0 0.00016953016
remission O 0 0.002730807
was O 0 0.00020028581
observed O 0 0.00023081261
in O 0 0.0003613018
all O 0 0.0005344256
reported O 0 0.0009745623
cases O 0 0.002470548
. O 0 0.0029678477

An O 0 0.002211381
objective O 0 0.0013587697
causality O 0 0.001479327
assessment O 0 0.00053525635
revealed O 0 0.00034268262
that O 0 0.0002719606
the O 0 0.00029471904
adverse O 0 0.0014812774
drug O 0 0.0045046965
event O 0 0.0004942424
was O 0 0.00024407078
probably O 0 0.0002668122
related O 0 0.0001611418
to O 0 0.00023660007
the O 0 0.00032173854
use O 0 0.00058513216
of O 0 0.0020342227
ticlopidine B-Chemical 0 0.99995935
. O 0 0.0049258242

The O 0 0.0023853977
mechanisms O 0 0.001931085
of O 0 0.0027620147
this O 0 0.0047282726
ticlopidine B-Chemical 0 0.99998236
- O 0 0.15045892
induced O 0 0.0031914106
cholestasis B-Disease 0 0.99993515
are O 0 0.0023118663
unclear O 0 0.0021133933
. O 0 0.004512795

Immune O 0 0.012387442
mechanisms O 0 0.0016916244
may O 0 0.001188098
be O 0 0.0008110869
involved O 0 0.0005420093
in O 0 0.00048699597
the O 0 0.000415124
drug O 0 0.0035122342
' O 0 0.0010160814
s O 0 0.0011246754
hepatotoxicity B-Disease 0 0.9999536
, O 0 0.0008866847
as O 0 0.00025105293
suggested O 0 0.00018676829
by O 0 0.00023529395
the O 0 0.00028716767
T O 0 0.0064037694
- O 0 0.0026167699
cell O 0 0.00057310343
stimulation O 0 0.00036987403
study O 0 0.00070297625
reported O 0 0.00091938383
here O 0 0.0013951003
. O 0 0.0031661673

CONCLUSIONS O 0 0.13360713
: O 0 0.04177767
Cholestatic B-Disease 0 0.99990916
hepatitis I-Disease 0 0.9999362
is O 0 0.001346511
a O 0 0.0012658498
rare O 0 0.0018325555
adverse O 0 0.0013147001
effect O 0 0.00035348206
of O 0 0.0011202461
ticlopidine B-Chemical 0 0.99999166
that O 0 0.0005247311
may O 0 0.00051716814
be O 0 0.00072564057
immune O 0 0.002455051
mediated O 0 0.0011775569
. O 0 0.0031970872

Patients O 0 0.0036047471
receiving O 0 0.0016515888
the O 0 0.00094583794
drug O 0 0.0040650284
should O 0 0.00029155402
be O 0 0.00029764755
monitored O 0 0.00021185806
with O 0 0.00031237482
liver O 0 0.0045358427
function O 0 0.00024557614
tests O 0 0.00052924687
along O 0 0.00026650302
with O 0 0.00035583036
complete O 0 0.00042685497
blood O 0 0.0033857583
cell O 0 0.0016403211
counts O 0 0.0015632691
. O 0 0.0029435975

This O 0 0.0050368253
complication O 0 0.009189603
will O 0 0.00093542057
be O 0 0.00063322164
observed O 0 0.00042796804
even O 0 0.00049667724
less O 0 0.0005075296
often O 0 0.00034700902
in O 0 0.000207681
the O 0 0.00017069967
future O 0 0.00022014178
as O 0 0.0004307342
ticlopidine B-Chemical 0 0.99999225
is O 0 0.00024541793
being O 0 0.00023338829
replaced O 0 0.00018074988
by O 0 0.00022281095
the O 0 0.00027747487
newer O 0 0.0020429464
antiplatelet O 0 0.85858595
agent O 0 0.009668121
clopidogrel B-Chemical 0 0.99968624
. O 0 0.003695378

Epithelial O 0 0.32498154
sodium B-Chemical 0 0.99726415
channel O 0 0.011942083
( O 0 0.0037356135
ENaC O 0 0.015323584
) O 0 0.00203876
subunit O 0 0.0008778993
mRNA O 0 0.0006357227
and O 0 0.00044806825
protein O 0 0.00036077158
expression O 0 0.00025996205
in O 0 0.00027107887
rats O 0 0.000539203
with O 0 0.00059499696
puromycin B-Chemical 0 0.9776317
aminonucleoside I-Chemical 0 0.99999297
- O 0 0.19278374
induced O 0 0.0028337042
nephrotic B-Disease 0 0.9999943
syndrome I-Disease 0 0.99650395
. O 0 0.0042769713

In O 0 0.0025575818
experimental O 0 0.0062193475
nephrotic B-Disease 0 0.99998367
syndrome I-Disease 0 0.99730563
, O 0 0.0059970547
urinary O 0 0.8216958
sodium B-Chemical 0 0.9997873
excretion O 0 0.9626015
is O 0 0.0003592012
decreased O 0 0.000504385
during O 0 0.00021725569
the O 0 0.00026207036
early O 0 0.00058200565
phase O 0 0.0010258636
of O 0 0.0009618748
the O 0 0.0012794007
disease O 0 0.3600436
. O 0 0.0037810544

The O 0 0.0026711049
molecular O 0 0.0031430197
mechanism O 0 0.0013285617
( O 0 0.0023996965
s O 0 0.0016996322
) O 0 0.0019170884
leading O 0 0.0008024505
to O 0 0.00070024113
salt O 0 0.91026783
retention O 0 0.0016704394
has O 0 0.00047817055
not O 0 0.00063602807
been O 0 0.00091942487
completely O 0 0.0013866804
elucidated O 0 0.0025313208
. O 0 0.004359088

The O 0 0.0025155859
rate O 0 0.003378882
- O 0 0.0058637196
limiting O 0 0.0012559184
constituent O 0 0.0014549644
of O 0 0.0008564521
collecting O 0 0.0022351502
duct O 0 0.97188133
sodium B-Chemical 0 0.9996394
transport O 0 0.0014908576
is O 0 0.00033931114
the O 0 0.0003845268
epithelial O 0 0.010699772
sodium B-Chemical 0 0.998882
channel O 0 0.0061966884
( O 0 0.0026870957
ENaC O 0 0.014359892
) O 0 0.0049702376
. O 0 0.0038551507

We O 0 0.0023503697
examined O 0 0.001299686
the O 0 0.0009407332
abundance O 0 0.00070084876
of O 0 0.0009260248
ENaC O 0 0.00791384
subunit O 0 0.00080128224
mRNAs O 0 0.00044962246
and O 0 0.00040955027
proteins O 0 0.0003875164
in O 0 0.0006103514
puromycin B-Chemical 0 0.97924906
aminonucleoside I-Chemical 0 0.9999933
( O 0 0.019119214
PAN B-Chemical 0 0.9998234
) O 0 0.0049465965
- O 0 0.00825305
induced O 0 0.002327293
nephrotic B-Disease 0 0.9999925
syndrome I-Disease 0 0.99653035
. O 0 0.004811969

The O 0 0.001517249
time O 0 0.0010333734
courses O 0 0.001709928
of O 0 0.0013166781
urinary O 0 0.3219774
sodium B-Chemical 0 0.99960595
excretion O 0 0.9850641
, O 0 0.0026391577
plasma O 0 0.36689678
aldosterone B-Chemical 0 0.9999795
concentration O 0 0.0014776024
and O 0 0.0005074583
proteinuria B-Disease 0 0.99995077
were O 0 0.00020383434
studied O 0 0.00019617405
in O 0 0.00013616729
male O 0 0.00044764922
Sprague O 0 0.12857868
- O 0 0.0013794366
Dawley O 0 0.0023914876
rats O 0 0.00023048231
treated O 0 0.00023163384
with O 0 0.00015758285
a O 0 0.00023247593
single O 0 0.00014318804
dose O 0 0.00038757702
of O 0 0.00038699637
either O 0 0.0007773961
PAN B-Chemical 0 0.9995677
or O 0 0.0013450441
vehicle O 0 0.006643728
. O 0 0.0033478448

The O 0 0.0019520117
relative O 0 0.0012823364
amounts O 0 0.0011444549
of O 0 0.0013418602
alphaENaC O 0 0.010779542
, O 0 0.0015646748
betaENaC O 0 0.009375295
and O 0 0.00060822256
gammaENaC O 0 0.009547009
mRNAs O 0 0.00029119122
were O 0 0.000190448
determined O 0 0.00014417419
in O 0 0.00016093605
kidneys O 0 0.00058636867
from O 0 0.00012655504
these O 0 0.000117629235
rats O 0 0.00019948892
by O 0 0.000120930905
real O 0 0.0001389714
- O 0 0.0005220001
time O 0 9.5773255e-05
quantitative O 0 0.00012870302
TaqMan O 0 0.00021989466
PCR O 0 0.00033669785
, O 0 0.0003191418
and O 0 0.00020690287
the O 0 0.00018891541
amounts O 0 0.00027178123
of O 0 0.00046845552
proteins O 0 0.0006112118
by O 0 0.00096845464
Western O 0 0.001970536
blot O 0 0.0016018532
. O 0 0.0032935117

The O 0 0.002035704
kinetics O 0 0.0020464365
of O 0 0.002136826
urinary O 0 0.53938013
sodium B-Chemical 0 0.9995664
excretion O 0 0.9195699
and O 0 0.000553244
the O 0 0.00030018532
appearance O 0 0.00046551804
of O 0 0.00054541643
proteinuria B-Disease 0 0.99988425
were O 0 0.0003412558
comparable O 0 0.00020617344
with O 0 0.00040467473
those O 0 0.00065156247
reported O 0 0.00095564814
previously O 0 0.0016505393
. O 0 0.0030674431

Sodium B-Chemical 0 0.9986197
retention O 0 0.004591614
occurred O 0 0.0014189801
on O 0 0.0006581289
days O 0 0.0005398117
2 O 0 0.0007701516
, O 0 0.001023156
3 O 0 0.00057032984
and O 0 0.000669516
6 O 0 0.000673886
after O 0 0.000887199
PAN B-Chemical 0 0.98638296
injection O 0 0.002622825
. O 0 0.004316409

A O 0 0.02248721
significant O 0 0.0024373424
up O 0 0.002007943
- O 0 0.0031828617
regulation O 0 0.00036391726
of O 0 0.00069681584
alphaENaC O 0 0.004501819
and O 0 0.0005527318
betaENaC O 0 0.005298989
mRNA O 0 0.00032773422
abundance O 0 0.00016293778
on O 0 0.00012364911
days O 0 0.0001142829
1 O 0 0.00018699674
and O 0 0.0001853897
2 O 0 0.00023738842
preceded O 0 0.0003379385
sodium B-Chemical 0 0.97028697
retention O 0 0.00059509894
on O 0 0.00023232284
days O 0 0.00025695868
2 O 0 0.00057252095
and O 0 0.00083019724
3 O 0 0.0013078519
. O 0 0.0026483194

Conversely O 0 0.0037881986
, O 0 0.0041201496
down O 0 0.0020726093
- O 0 0.0041204253
regulation O 0 0.00044095286
of O 0 0.00084258046
alphaENaC O 0 0.008162899
, O 0 0.0012436304
betaENaC O 0 0.01142298
and O 0 0.0005401112
gammaENaC O 0 0.017348753
mRNA O 0 0.00029901165
expression O 0 0.00014878882
on O 0 9.549584e-05
day O 0 8.574377e-05
3 O 0 8.984076e-05
occurred O 0 9.072883e-05
in O 0 8.1796155e-05
the O 0 7.628318e-05
presence O 0 9.583995e-05
of O 0 0.00015902256
high O 0 0.0005450696
aldosterone B-Chemical 0 0.99998796
concentrations O 0 0.0011956762
, O 0 0.00036458383
and O 0 0.00014635397
was O 0 0.000113870956
followed O 0 9.438517e-05
by O 0 0.0001297639
a O 0 0.00025991915
return O 0 0.00027092284
of O 0 0.0004489489
sodium B-Chemical 0 0.999374
excretion O 0 0.85110825
to O 0 0.00051224424
control O 0 0.0007858468
values O 0 0.0013769416
. O 0 0.0025095528

The O 0 0.0023402004
amounts O 0 0.0019271179
of O 0 0.002127869
alphaENaC O 0 0.013594913
, O 0 0.002332417
betaENaC O 0 0.012366307
and O 0 0.00091848057
gammaENaC O 0 0.010571696
proteins O 0 0.00044913043
were O 0 0.00034723143
not O 0 0.00031896873
increased O 0 0.0005960296
during O 0 0.0006334715
PAN B-Chemical 0 0.99967
- O 0 0.019648591
induced O 0 0.0014422277
sodium B-Chemical 0 0.9977824
retention O 0 0.0058086836
. O 0 0.0038321412

In O 0 0.002071568
conclusion O 0 0.0016258421
, O 0 0.0035132691
ENaC O 0 0.014434482
mRNA O 0 0.0011298391
expression O 0 0.00063027535
, O 0 0.0011101624
especially O 0 0.00066059345
alphaENaC O 0 0.009753562
, O 0 0.0006690536
is O 0 0.00019601567
increased O 0 0.00026134474
in O 0 0.0001529084
the O 0 0.00012399684
very O 0 0.00019133186
early O 0 0.00024361024
phase O 0 0.0003099186
of O 0 0.00015103098
the O 0 9.810708e-05
experimental O 0 0.00012626359
model O 0 0.00013151825
of O 0 0.00040749597
PAN B-Chemical 0 0.99995935
- O 0 0.10873112
induced O 0 0.0007919752
nephrotic B-Disease 0 0.9999995
syndrome I-Disease 0 0.99567235
in O 0 0.00017786025
rats O 0 0.00039530775
, O 0 0.00035732865
but O 0 0.00016810109
appears O 0 8.200264e-05
to O 0 0.00010832893
escape O 0 0.00023412044
from O 0 0.00012483059
the O 0 0.000121766345
regulation O 0 0.00011679131
by O 0 0.0004466407
aldosterone B-Chemical 0 0.9998367
after O 0 0.00040580853
day O 0 0.00051064376
3 O 0 0.0010385877
. O 0 0.0021788753

Sub O 0 0.08054584
- O 0 0.013855275
chronic O 0 0.0085906945
low O 0 0.0017844983
dose O 0 0.0028148284
gamma B-Chemical 0 0.46916533
- I-Chemical 0 0.20629995
vinyl I-Chemical 0 0.95312864
GABA I-Chemical 0 0.9999753
( O 0 0.015065154
vigabatrin B-Chemical 0 0.99999094
) O 0 0.0021117872
inhibits O 0 0.00038116288
cocaine B-Chemical 0 0.9998727
- O 0 0.010898488
induced O 0 0.00033057475
increases O 0 0.00043258158
in O 0 0.0005539557
nucleus O 0 0.00088015443
accumbens O 0 0.20158261
dopamine B-Chemical 0 0.9985959
. O 0 0.0031636024

RATIONALE O 0 0.01652069
: O 0 0.010455583
gamma B-Chemical 0 0.21911061
- I-Chemical 0 0.14293808
Vinyl I-Chemical 0 0.93089575
GABA I-Chemical 0 0.9999132
( O 0 0.11078036
GVG B-Chemical 0 0.99998534
) O 0 0.08938121
irreversibly O 0 0.23973916
inhibits O 0 0.004403676
GABA B-Chemical 0 0.99995756
- O 0 0.94722056
transaminase O 0 0.99975616
. O 0 0.008157838

This O 0 0.0058488324
non O 0 0.0050501106
- O 0 0.014397457
receptor O 0 0.002946196
mediated O 0 0.00060696393
inhibition O 0 0.00095484004
requires O 0 0.00053164724
de O 0 0.0028182059
novo O 0 0.0017237985
synthesis O 0 0.0011595711
for O 0 0.000388564
restoration O 0 0.0007292628
of O 0 0.0009897731
functional O 0 0.002204731
GABA B-Chemical 0 0.99989104
catabolism O 0 0.8229671
. O 0 0.0051851952

OBJECTIVES O 0 0.0033264912
: O 0 0.0024193553
Given O 0 0.00042917737
its O 0 0.00073090126
preclinical O 0 0.0008191754
success O 0 0.00061788573
for O 0 0.0002892935
treating O 0 0.00085774495
substance B-Disease 0 0.99708265
abuse I-Disease 0 0.9995969
and O 0 0.0003601594
the O 0 0.00016416088
increased O 0 0.0002688394
risk O 0 0.001058079
of O 0 0.000200027
visual B-Disease 2 0.018874286
field I-Disease 2 0.00032782764
defects I-Disease 2 0.0018284242
( O 0 0.00093460054
VFD B-Disease 0 0.99973136
) O 0 0.0005604586
associated O 0 0.00011236357
with O 0 9.69864e-05
cumulative O 0 0.00011098837
lifetime O 0 0.00021529071
exposure O 0 0.00013482965
, O 0 0.00015223568
we O 0 4.1872026e-05
explored O 0 7.570315e-05
the O 0 6.0628154e-05
effects O 0 8.511096e-05
of O 0 0.00015175884
sub O 0 0.0011201287
- O 0 0.0025820928
chronic O 0 0.002108044
low O 0 0.000231348
dose O 0 0.0011500765
GVG B-Chemical 0 0.99999356
on O 0 0.00022499182
cocaine B-Chemical 0 0.9999188
- O 0 0.0068380395
induced O 0 0.00013816565
increases O 0 0.00017044951
in O 0 0.00018027294
nucleus O 0 0.00021073129
accumbens O 0 0.0042796587
( O 0 0.000555962
NAcc O 0 0.00095454435
) O 0 0.0018466443
dopamine B-Chemical 0 0.9993549
( O 0 0.0045056436
DA B-Chemical 0 0.9985305
) O 0 0.0055927197
. O 0 0.0034260121

METHODS O 0 0.0038183173
: O 0 0.0023661836
Using O 0 0.000588758
in O 0 0.0006533797
vivo O 0 0.0006758519
microdialysis O 0 0.0039881826
, O 0 0.0005528497
we O 0 0.00014988355
compared O 0 0.00019643703
acute O 0 0.0024361056
exposure O 0 0.000305438
( O 0 0.00044375702
450 O 0 0.0011208203
mg O 0 0.0026980257
/ O 0 0.0007083254
kg O 0 0.0004665687
) O 0 0.00033280725
to O 0 0.0001074949
an O 0 0.0001327167
identical O 0 8.9155794e-05
sub O 0 0.0005722733
- O 0 0.0014353605
chronic O 0 0.001440475
exposure O 0 0.00017227646
( O 0 0.00022618168
150 O 0 0.00018557346
mg O 0 0.0012799205
/ O 0 0.00046574394
kg O 0 0.00027900073
per O 0 8.8432265e-05
day O 0 5.8291822e-05
for O 0 6.4527936e-05
3 O 0 8.5279135e-05
days O 0 7.9168916e-05
) O 0 0.00030545314
, O 0 0.00028524827
followed O 0 0.00015277795
by O 0 0.00022594804
1 O 0 0.00036574964
- O 0 0.0011002226
or O 0 0.00030997832
3 O 0 0.0004254686
- O 0 0.0016105474
day O 0 0.0006271387
washout O 0 0.0020644316
. O 0 0.0027023493

Finally O 0 0.002811999
, O 0 0.0029051597
we O 0 0.0006714705
examined O 0 0.0005570663
the O 0 0.00043898006
low O 0 0.0005319359
dose O 0 0.0005657651
of O 0 0.00031753813
150 O 0 0.00043152168
mg O 0 0.0024085452
/ O 0 0.0008390712
kg O 0 0.0005510663
( O 0 0.00037333852
50 O 0 0.00029029336
mg O 0 0.001501817
/ O 0 0.0006945993
kg O 0 0.00046270393
per O 0 0.00018100566
day O 0 0.000153674
) O 0 0.00046666962
using O 0 0.00023642507
a O 0 0.0004966661
similar O 0 0.00036998058
washout O 0 0.0011078829
period O 0 0.0009507213
. O 0 0.0025064275

RESULTS O 0 0.0060979724
: O 0 0.0060897525
Sub O 0 0.024523815
- O 0 0.01668906
chronic O 0 0.3867293
GVG B-Chemical 0 0.9999814
exposure O 0 0.001151988
inhibited O 0 0.00061405386
the O 0 0.00021582116
effect O 0 0.00020425006
of O 0 0.00041982436
cocaine B-Chemical 0 0.9996319
for O 0 0.00012907443
3 O 0 9.5478346e-05
days O 0 6.6209934e-05
, O 0 0.00018362235
which O 0 0.00013508547
exceeded O 0 0.00014433719
in O 0 0.00012466383
magnitude O 0 0.00015798546
and O 0 0.00019176891
duration O 0 0.00015759005
the O 0 0.00024016909
identical O 0 0.0003262883
acute O 0 0.006912429
dose O 0 0.002417136
. O 0 0.0025385162

CONCLUSIONS O 0 0.026477953
: O 0 0.007287087
Sub O 0 0.022083936
- O 0 0.0063363514
chronic O 0 0.005054756
low O 0 0.0010779564
dose O 0 0.0040201196
GVG B-Chemical 0 0.9999876
potentiates O 0 0.0011961374
and O 0 0.000277216
extends O 0 0.00017817834
the O 0 0.00011871131
inhibition O 0 0.00022619464
of O 0 0.0003868992
cocaine B-Chemical 0 0.9999347
- O 0 0.014409553
induced O 0 0.00016548716
increases O 0 0.00023205827
in O 0 0.00039815195
dopamine B-Chemical 0 0.999871
, O 0 0.000405907
effectively O 0 0.00012468167
reducing O 0 0.0001240303
cumulative O 0 0.00020347917
exposures O 0 0.0004130587
and O 0 0.0003015182
the O 0 0.00036371782
risk O 0 0.0030339414
for O 0 0.0010302995
VFDS O 0 0.14912708
. O 0 0.0034423429

MR O 0 0.03365461
imaging O 0 0.0021949238
with O 0 0.001070541
quantitative O 0 0.0006316551
diffusion O 0 0.0014804623
mapping O 0 0.00037379292
of O 0 0.0007882355
tacrolimus B-Chemical 0 0.99996734
- O 0 0.017263638
induced O 0 0.00071095926
neurotoxicity B-Disease 0 0.995612
in O 0 0.00063226465
organ O 0 0.001206999
transplant O 0 0.0015553894
patients O 0 0.0022069854
. O 0 0.0024959107

Our O 0 0.0018905371
objective O 0 0.0015333572
was O 0 0.00087618496
to O 0 0.0004647426
investigate O 0 0.00022806873
brain O 0 0.0009556117
MR O 0 0.012273575
imaging O 0 0.00026939466
findings O 0 0.00018066354
and O 0 0.00012891181
the O 0 8.657705e-05
utility O 0 8.906156e-05
of O 0 0.00017370954
diffusion O 0 0.001157504
- O 0 0.0008668792
weighted O 0 0.00013083752
( O 0 0.0002958544
DW O 0 0.014139113
) O 0 0.00029623968
imaging O 0 0.0001338382
in O 0 8.735693e-05
organ O 0 0.00016974044
transplant O 0 0.00019923762
patients O 0 0.00021418958
who O 0 0.00018237217
developed O 0 0.00023886625
neurologic O 0 0.36983162
symptoms O 0 0.002889688
during O 0 0.00047279967
tacrolimus B-Chemical 0 0.9998857
therapy O 0 0.0022375197
. O 0 0.0021294004

Brain O 0 0.01611213
MR O 0 0.059624504
studies O 0 0.0018904093
, O 0 0.001527562
including O 0 0.00058419036
DW O 0 0.0125031695
imaging O 0 0.0006137766
, O 0 0.00053309137
were O 0 0.00019321723
prospectively O 0 0.00021481379
performed O 0 0.000116846786
in O 0 0.000111059715
14 O 0 0.00010802905
organ O 0 0.00017035805
transplant O 0 0.0001988808
patients O 0 0.00024144011
receiving O 0 0.00032194654
tacrolimus B-Chemical 0 0.9999182
who O 0 0.00074727705
developed O 0 0.0008819136
neurologic B-Disease 0 0.9920874
complications I-Disease 0 0.7533205
. O 0 0.0031413066

In O 0 0.00187293
each O 0 0.0012370133
patient O 0 0.0012418223
who O 0 0.0010236421
had O 0 0.00058703974
abnormalities O 0 0.002499734
on O 0 0.00021928412
the O 0 0.00020346616
initial O 0 0.00022986805
MR O 0 0.0523106
study O 0 0.00034554407
, O 0 0.00040230688
a O 0 0.0003210488
follow O 0 0.0001864082
- O 0 0.0010014026
up O 0 0.00035403683
MR O 0 0.030515231
study O 0 0.000379634
was O 0 0.00027706297
performed O 0 0.00032144913
1 O 0 0.0005262731
month O 0 0.00042281408
later O 0 0.0010539949
. O 0 0.0025310183

Apparent O 0 0.010383614
diffusion O 0 0.007617291
coefficient O 0 0.0057395506
( O 0 0.0031193488
ADC O 0 0.057883415
) O 0 0.0012095195
values O 0 0.00036738405
on O 0 0.00020818737
the O 0 0.00022032656
initial O 0 0.00026144442
MR O 0 0.025464768
study O 0 0.00037842986
were O 0 0.00024326394
correlated O 0 0.00026871305
with O 0 0.00039360582
reversibility O 0 0.001378409
of O 0 0.00085235626
the O 0 0.0010724283
lesions O 0 0.011396775
. O 0 0.0033643353

Of O 0 0.005561382
the O 0 0.0021082077
14 O 0 0.0016758441
patients O 0 0.002055614
, O 0 0.0015562219
5 O 0 0.0007137807
( O 0 0.0008893959
35 O 0 0.00049869466
. O 0 0.00034350785
7 O 0 0.0002687687
% O 0 0.00057090033
) O 0 0.00064409245
had O 0 0.00031622458
white B-Disease 0 0.00088102
matter I-Disease 0 0.00072329043
abnormalities I-Disease 0 0.12795934
, O 0 0.0006485964
1 O 0 0.0002955139
( O 0 0.0003428071
7 O 0 0.0001470419
. O 0 0.00016068765
1 O 0 0.0001949735
% O 0 0.00036766683
) O 0 0.0005358791
had O 0 0.0003846183
putaminal B-Disease 0 0.9997758
hemorrhage I-Disease 2 0.99993896
, O 0 0.0005064855
and O 0 0.00019271455
8 O 0 0.00017268858
( O 0 0.000307658
57 O 0 0.00028935337
. O 0 0.00016924008
1 O 0 0.00020268872
% O 0 0.00037521438
) O 0 0.00046683516
had O 0 0.00023246309
normal O 0 0.0003934366
findings O 0 0.00035891894
on O 0 0.000293686
initial O 0 0.0006007431
MR O 0 0.07453496
images O 0 0.0021670423
. O 0 0.0031101124

Among O 0 0.003525041
the O 0 0.0016983972
5 O 0 0.0012153641
patients O 0 0.0013095951
with O 0 0.0007462292
white B-Disease 0 0.0017600255
matter I-Disease 0 0.0011587533
abnormalities I-Disease 0 0.10760967
, O 0 0.0006784497
4 O 0 0.00023423006
patients O 0 0.00041651135
( O 0 0.00035111376
80 O 0 0.00026100464
. O 0 0.00015283696
0 O 0 0.00019175574
% O 0 0.00028454507
) O 0 0.0002901481
showed O 0 0.000113141774
higher O 0 0.00015336074
than O 0 0.00013522545
normal O 0 0.00032686148
ADC O 0 0.010491382
values O 0 9.848191e-05
on O 0 5.9254915e-05
initial O 0 8.928741e-05
MR O 0 0.010487147
images O 0 0.00017794574
, O 0 0.0002589177
and O 0 0.00014244246
all O 0 0.000120576486
showed O 0 0.00012866988
complete O 0 0.00014213652
resolution O 0 0.00041777192
on O 0 0.00022177726
follow O 0 0.00031897417
- O 0 0.0018749101
up O 0 0.0009663297
images O 0 0.0016568791
. O 0 0.0028851277

The O 0 0.0023150018
remaining O 0 0.0019068234
1 O 0 0.0015837379
patient O 0 0.0011237208
( O 0 0.0011490281
20 O 0 0.0005422488
. O 0 0.00038324794
0 O 0 0.0004182425
% O 0 0.0005569726
) O 0 0.00051449734
showed O 0 0.00020161914
lower O 0 0.0002719702
than O 0 0.00021938555
normal O 0 0.00050957815
ADC O 0 0.016889734
value O 0 0.0002251822
and O 0 0.00020308918
showed O 0 0.00021519054
incomplete O 0 0.00051650335
resolution O 0 0.0009348627
with O 0 0.00087659917
cortical B-Disease 0 0.042123213
laminar I-Disease 0 0.13716654
necrosis I-Disease 2 0.9999044
. O 0 0.0051722657

Diffusion O 0 0.03057281
- O 0 0.006150534
weighted O 0 0.001016098
imaging O 0 0.0009234191
may O 0 0.00043958097
be O 0 0.00032661695
useful O 0 0.00024837785
in O 0 0.00021273739
predicting O 0 0.00015639758
the O 0 0.00016007866
outcomes O 0 0.0002304966
of O 0 0.00025569226
the O 0 0.00026949047
lesions O 0 0.00280804
of O 0 0.0010149011
tacrolimus B-Chemical 0 0.9999758
- O 0 0.035484113
induced O 0 0.0017834149
neurotoxicity B-Disease 0 0.99825245
. O 0 0.004530468

L B-Chemical 0 0.9934395
- I-Chemical 0 0.63988155
arginine I-Chemical 0 0.34699887
transport O 0 0.004630028
in O 0 0.0016232159
humans O 0 0.0021395383
with O 0 0.0022557804
cortisol B-Chemical 0 0.9986237
- O 0 0.025545953
induced O 0 0.0035720242
hypertension B-Disease 2 0.99988604
. O 0 0.007904823

A O 0 0.057146907
deficient O 0 0.007449
L B-Chemical 0 0.9956267
- I-Chemical 0 0.7938409
arginine I-Chemical 0 0.92134684
- O 0 0.7864898
nitric B-Chemical 0 0.99916506
oxide I-Chemical 0 0.9414777
system O 0 0.00082798646
is O 0 0.00047821546
implicated O 0 0.0005442968
in O 0 0.00094842067
cortisol B-Chemical 0 0.998725
- O 0 0.018358592
induced O 0 0.0025310556
hypertension B-Disease 2 0.99991775
. O 0 0.0063708625

We O 0 0.0023536806
investigate O 0 0.00087438105
whether O 0 0.00081433327
abnormalities O 0 0.02217141
in O 0 0.0022776893
L B-Chemical 0 0.9973182
- I-Chemical 0 0.5940585
arginine I-Chemical 0 0.42956296
uptake O 0 0.011026611
contribute O 0 0.000900874
to O 0 0.0009347845
this O 0 0.0018206413
deficiency O 0 0.11440497
. O 0 0.0049259504

Eight O 0 0.013069836
healthy O 0 0.01824517
men O 0 0.018439898
were O 0 0.008114728
recruited O 0 0.0096743675
. O 0 0.014134908

Hydrocortisone B-Chemical 0 0.99996805
acetate I-Chemical 0 0.99877197
( O 0 0.006179147
50 O 0 0.00200682
mg O 0 0.023055645
) O 0 0.0011338589
was O 0 0.0002813358
given O 0 0.00015575673
orally O 0 0.00030609395
every O 0 7.9358935e-05
6 O 0 8.031645e-05
hours O 0 8.212879e-05
for O 0 8.039285e-05
24 O 0 0.00011235295
hours O 0 8.722541e-05
after O 0 7.1813214e-05
a O 0 0.00019655618
5 O 0 0.0001729092
- O 0 0.00058837346
day O 0 0.00014226434
fixed O 0 0.00034354225
- O 0 0.0031877884
salt O 0 0.8839466
diet O 0 0.0103147905
( O 0 0.0011891931
150 O 0 0.0010587077
mmol O 0 0.17115767
/ O 0 0.0041989107
d O 0 0.002339172
) O 0 0.0044946703
. O 0 0.0037842204

Crossover O 0 0.021787716
studies O 0 0.005457064
were O 0 0.0032057595
performed O 0 0.0025161933
2 O 0 0.0028853402
weeks O 0 0.0020254103
apart O 0 0.0046859635
. O 0 0.008041334

Thirty O 0 0.0064424654
milliliters O 0 0.003964514
of O 0 0.0015123419
blood O 0 0.0037109286
was O 0 0.0005272019
obtained O 0 0.00029093676
for O 0 0.00022256635
isolation O 0 0.0002787213
of O 0 0.00034090577
peripheral O 0 0.0011969716
blood O 0 0.004617986
mononuclear O 0 0.0075846533
cells O 0 0.00041489414
after O 0 0.00020945388
each O 0 0.00028233216
treatment O 0 0.0005657564
period O 0 0.000871176
. O 0 0.0024031743

L B-Chemical 0 0.99469745
- I-Chemical 0 0.7049018
arginine I-Chemical 0 0.4704607
uptake O 0 0.011472739
was O 0 0.00077169325
assessed O 0 0.0004883201
in O 0 0.00041162866
mononuclear O 0 0.004045364
cells O 0 0.00046010874
incubated O 0 0.00049375935
with O 0 0.0006787526
L B-Chemical 0 0.998221
- I-Chemical 0 0.32669502
arginine I-Chemical 0 0.086830355
( O 0 0.0005913363
1 O 0 0.00020195183
to O 0 0.00013708576
300 O 0 0.00044181524
micromol O 0 0.014598615
/ O 0 0.002044062
L O 0 0.5027088
) O 0 0.0008341152
, O 0 0.00034175426
incorporating O 0 0.00016188333
100 O 0 0.00056522235
nmol O 0 0.04658202
/ O 0 0.0048134085
L O 0 0.9064043
[ B-Chemical 0 0.033345316
3H I-Chemical 0 0.95873797
] I-Chemical 0 0.01705772
- I-Chemical 0 0.016242336
l I-Chemical 0 0.123230726
- I-Chemical 0 0.039883852
arginine I-Chemical 0 0.008948715
for O 0 0.00017253518
a O 0 0.00026045824
period O 0 0.00013529664
of O 0 0.00023116742
5 O 0 0.00024182002
minutes O 0 0.00026410387
at O 0 0.00034892926
37 O 0 0.0014437543
degrees O 0 0.020528713
C O 0 0.983845
. O 0 0.006222336

Forearm O 0 0.74194807
[ B-Chemical 0 0.040306024
3H I-Chemical 0 0.93000036
] I-Chemical 0 0.043841027
- I-Chemical 0 0.16250858
L I-Chemical 0 0.99620914
- I-Chemical 0 0.2716236
arginine I-Chemical 0 0.055472903
extraction O 0 0.0011836523
was O 0 0.00024287526
calculated O 0 0.00015003026
after O 0 9.680788e-05
infusion O 0 0.00036143028
of O 0 0.00027481574
[ B-Chemical 0 0.0027927824
3H I-Chemical 0 0.90644085
] I-Chemical 0 0.026294427
- I-Chemical 0 0.084636346
L I-Chemical 0 0.9978607
- I-Chemical 0 0.14085048
arginine I-Chemical 0 0.008499778
into O 0 0.00011902278
the O 0 0.00015734517
brachial O 0 0.51165485
artery O 0 0.017277703
at O 0 0.00011461096
a O 0 0.00021939246
rate O 0 0.0002639911
of O 0 0.00030320516
100 O 0 0.0010542631
nCi O 0 0.62808406
/ O 0 0.0018878308
min O 0 0.00067451026
for O 0 0.00041119588
80 O 0 0.0010772567
minutes O 0 0.0011013751
. O 0 0.0022497547

Deep O 0 0.018218942
forearm O 0 0.23182417
venous O 0 0.2464928
samples O 0 0.0016602237
were O 0 0.00083353365
collected O 0 0.0006515171
for O 0 0.0005842496
determination O 0 0.0011884487
of O 0 0.0018414686
L B-Chemical 0 0.9919373
- I-Chemical 0 0.28785473
arginine I-Chemical 0 0.28984845
extraction O 0 0.011573178
. O 0 0.0055194665

Plasma O 0 0.9259055
cortisol B-Chemical 0 0.998293
concentrations O 0 0.0032200129
were O 0 0.00078773766
significantly O 0 0.00060689857
raised O 0 0.00040892258
during O 0 0.00023886967
the O 0 0.00023802575
active O 0 0.00033419608
phase O 0 0.0006427569
( O 0 0.00072276645
323 O 0 0.0014085545
+ O 0 0.0013051652
/ O 0 0.0018550307
- O 0 0.0016294748
43 O 0 0.0004676964
to O 0 0.00030535186
1082 O 0 0.0052926107
+ O 0 0.0015013524
/ O 0 0.0025085183
- O 0 0.0035172529
245 O 0 0.002729157
mmol O 0 0.3326887
/ O 0 0.004613129
L O 0 0.4195843
, O 0 0.0016179674
P O 0 0.01429599
< O 0 0.001162442
0 O 0 0.0010783611
. O 0 0.0012464451
05 O 0 0.013092264
) O 0 0.0053156684
. O 0 0.0048040426

Systolic O 0 0.23319541
blood O 0 0.013658903
pressure O 0 0.012748237
was O 0 0.0017349387
elevated O 0 0.0027351594
by O 0 0.0010320088
an O 0 0.00097558275
average O 0 0.0007023136
of O 0 0.0010386351
7 O 0 0.0011919308
mm O 0 0.0052393666
Hg O 0 0.6711866
. O 0 0.0064898217

Neither O 0 0.0059199464
L B-Chemical 0 0.9948624
- I-Chemical 0 0.5636897
arginine I-Chemical 0 0.21593627
transport O 0 0.0018714205
into O 0 0.00044447358
mononuclear O 0 0.0048109917
cells O 0 0.00051015866
( O 0 0.0006310723
placebo O 0 0.0018804605
vs O 0 0.00035555603
active O 0 0.00027451984
, O 0 0.00039196893
26 O 0 0.00027310674
. O 0 0.00017561241
3 O 0 0.00017059717
+ O 0 0.0007118135
/ O 0 0.0013257671
- O 0 0.0011424713
3 O 0 0.00015210625
. O 0 0.00012670648
6 O 0 9.424506e-05
vs O 0 0.00018986635
29 O 0 0.00022722244
. O 0 0.00015497839
0 O 0 0.00024389308
+ O 0 0.0007673568
/ O 0 0.0015583587
- O 0 0.0015254326
2 O 0 0.00021857816
. O 0 0.00015667938
1 O 0 0.00017224146
pmol O 0 0.00037500827
/ O 0 0.0007169702
10 O 0 0.00016219636
000 O 0 0.00017013858
cells O 0 0.00015209639
per O 0 0.000115217685
5 O 0 9.771661e-05
minutes O 0 0.00010313171
, O 0 0.00020175223
respectively O 0 0.00024386981
, O 0 0.00024334395
at O 0 0.00012016557
an O 0 0.00025194208
l B-Chemical 0 0.035001438
- I-Chemical 0 0.034456927
arginine I-Chemical 0 0.018436132
concentration O 0 0.00044263917
of O 0 0.00023875991
300 O 0 0.00069206534
micromol O 0 0.072466105
/ O 0 0.0028119362
L O 0 0.700741
) O 0 0.0010392249
nor O 0 0.00027499165
L B-Chemical 0 0.99793625
- I-Chemical 0 0.36938784
arginine I-Chemical 0 0.10324884
extraction O 0 0.0008835794
in O 0 0.00015402287
the O 0 0.00013942107
forearm O 0 0.04190609
( O 0 0.0002342671
at O 0 7.361401e-05
80 O 0 0.00013412899
minutes O 0 9.419116e-05
, O 0 0.00018756425
placebo O 0 0.0007257471
vs O 0 0.00021103711
active O 0 0.00020120494
, O 0 0.0003567842
1 O 0 0.00027866787
868 O 0 0.0020659629
904 O 0 0.0019255823
+ O 0 0.00093830645
/ O 0 0.0015886311
- O 0 0.0018780447
434 O 0 0.00065813644
962 O 0 0.0024491316
vs O 0 0.00031273387
2 O 0 0.000254402
013 O 0 0.0012351265
910 O 0 0.0010098038
+ O 0 0.0009239267
/ O 0 0.0017036345
- O 0 0.002843065
770 O 0 0.0022800374
619 O 0 0.004029284
disintegrations O 0 0.001718045
per O 0 0.00015154688
minute O 0 0.0001756069
) O 0 0.00030273202
was O 0 0.00012742825
affected O 0 0.00017115375
by O 0 0.00022762078
cortisol B-Chemical 0 0.9963356
treatment O 0 0.00023680067
; O 0 0.00035708532
ie O 0 0.00030085916
, O 0 0.0003869352
that O 0 0.00025142758
L B-Chemical 0 0.99853635
- I-Chemical 0 0.6308951
arginine I-Chemical 0 0.45036933
uptake O 0 0.012007232
is O 0 0.00018727618
not O 0 0.00017562078
affected O 0 0.00024884837
by O 0 0.00026187254
short O 0 0.00035647038
- O 0 0.002242405
term O 0 0.0010642726
cortisol B-Chemical 0 0.9967913
treatment O 0 0.0021182017
. O 0 0.003002251

We O 0 0.002296513
conclude O 0 0.001444114
that O 0 0.0016398652
cortisol B-Chemical 0 0.999049
- O 0 0.014773938
induced O 0 0.0004920644
increases B-Disease 0 0.00037402302
in I-Disease 0 0.00030989115
blood I-Disease 0 0.002649519
pressure I-Disease 0 0.0041815965
are O 0 0.00015577783
not O 0 0.00014286835
associated O 0 0.00019741266
with O 0 0.00026540866
abnormalities O 0 0.0053940886
in O 0 0.0003014251
the O 0 0.0003895829
l B-Chemical 0 0.08358837
- I-Chemical 0 0.069140606
arginine I-Chemical 0 0.093879014
transport O 0 0.002418299
system O 0 0.0020714763
. O 0 0.0031073994

Amount O 0 0.010105612
of O 0 0.003885429
bleeding B-Disease 0 0.9055524
and O 0 0.0022677828
hematoma B-Disease 0 0.9950126
size O 0 0.0015585716
in O 0 0.0006380276
the O 0 0.00066360243
collagenase O 0 0.92627996
- O 0 0.0070491214
induced O 0 0.0010579015
intracerebral B-Disease 0 0.9927435
hemorrhage I-Disease 2 0.9997974
rat O 0 0.0021046705
model O 0 0.0015596977
. O 0 0.0030112092

The O 0 0.0032304127
aggravated O 0 0.02334329
risk O 0 0.00923834
on O 0 0.0013588894
intracerebral B-Disease 0 0.9922964
hemorrhage I-Disease 2 0.99992335
( O 0 0.0049908957
ICH B-Disease 0 0.9998747
) O 0 0.0008983389
with O 0 0.00027499083
drugs O 0 0.0022554852
used O 0 0.0002228989
for O 0 0.00028226944
stroke B-Disease 0 0.99149644
patients O 0 0.00087297586
should O 0 0.00023091193
be O 0 0.00045204686
estimated O 0 0.0007521308
carefully O 0 0.0009208869
. O 0 0.0025096878

We O 0 0.0023115946
therefore O 0 0.001478266
established O 0 0.00091861625
sensitive O 0 0.00051092077
quantification O 0 0.00036320844
methods O 0 0.00037709344
and O 0 0.0004068078
provided O 0 0.00032310918
a O 0 0.0006819869
rat O 0 0.0012095108
ICH B-Disease 0 0.99956363
model O 0 0.0003587231
for O 0 0.00030872985
detection O 0 0.0005335362
of O 0 0.0014165315
ICH B-Disease 0 0.99977726
deterioration O 0 0.12140168
. O 0 0.0032454757

In O 0 0.004961661
ICH B-Disease 0 0.9995516
intrastriatally O 0 0.42107984
induced O 0 0.0011515005
by O 0 0.0007923885
0 O 0 0.0008508458
. O 0 0.0005894273
014 O 0 0.0030921253
- O 0 0.0016452498
unit O 0 0.0003676579
, O 0 0.00055038463
0 O 0 0.00040407744
. O 0 0.00031189987
070 O 0 0.0016061156
- O 0 0.0009743465
unit O 0 0.00023102995
, O 0 0.00035487808
and O 0 0.00021447382
0 O 0 0.00025804728
. O 0 0.00017707911
350 O 0 0.00030448148
- O 0 0.0008720937
unit O 0 0.00025573806
collagenase O 0 0.6568241
, O 0 0.00035960495
the O 0 0.00011206471
amount O 0 8.834309e-05
of O 0 0.00021834113
bleeding B-Disease 0 0.81641114
was O 0 0.00011120066
measured O 0 0.000111645626
using O 0 8.824324e-05
a O 0 0.0002491926
hemoglobin O 0 0.6308177
assay O 0 0.0002240403
developed O 0 0.0001394583
in O 0 8.805965e-05
the O 0 7.579785e-05
present O 0 8.231288e-05
study O 0 0.00013296341
and O 0 0.00012650086
was O 0 0.0001177611
compared O 0 0.00010950241
with O 0 0.00020727151
the O 0 0.00023797218
morphologically O 0 0.0006343869
determined O 0 0.0007041247
hematoma B-Disease 0 0.9952461
volume O 0 0.0038462451
. O 0 0.0028363196

The O 0 0.0023185343
blood O 0 0.005608227
amounts O 0 0.0012138515
and O 0 0.0013285642
hematoma B-Disease 0 0.9875004
volumes O 0 0.0011108917
were O 0 0.00033715428
significantly O 0 0.0003328698
correlated O 0 0.00026400192
, O 0 0.0004281362
and O 0 0.00025774114
the O 0 0.00025827938
hematoma B-Disease 0 0.9885922
induced O 0 0.00025909973
by O 0 0.0002293772
0 O 0 0.00032522087
. O 0 0.0002518722
014 O 0 0.002347191
- O 0 0.0013085253
unit O 0 0.00035509805
collagenase O 0 0.50049603
was O 0 0.00032706346
adequate O 0 0.00039409616
to O 0 0.00040931883
detect O 0 0.0006689012
ICH B-Disease 0 0.9997131
deterioration O 0 0.08879399
. O 0 0.0030304445

In O 0 0.004067883
ICH B-Disease 0 0.99826044
induction O 0 0.0012914975
using O 0 0.0007829884
0 O 0 0.000912083
. O 0 0.0006351821
014 O 0 0.002994423
- O 0 0.0019688846
unit O 0 0.00054550765
collagenase O 0 0.8460595
, O 0 0.0015376712
heparin B-Chemical 0 0.9953467
enhanced O 0 0.00037677845
the O 0 0.000275809
hematoma B-Disease 0 0.9954181
volume O 0 0.00045424534
3 O 0 0.00012513678
. O 0 0.00010756761
4 O 0 0.00010154159
- O 0 0.00047915333
fold O 0 0.00013640056
over O 0 9.415792e-05
that O 0 9.172828e-05
seen O 0 0.00015118114
in O 0 0.00014730221
control O 0 0.00030021422
ICH B-Disease 0 0.99987996
animals O 0 0.0001351651
and O 0 0.00019338605
the O 0 0.00022760038
bleeding B-Disease 0 0.520136
7 O 0 0.00025867097
. O 0 0.00033178466
6 O 0 0.00043713622
- O 0 0.0024008364
fold O 0 0.0019483032
. O 0 0.0034284077

Data O 0 0.003578935
suggest O 0 0.0010074351
that O 0 0.0009024613
this O 0 0.000920771
sensitive O 0 0.00076670543
hemoglobin O 0 0.64344037
assay O 0 0.0006919239
is O 0 0.00024080926
useful O 0 0.00022945728
for O 0 0.00028161463
ICH B-Disease 0 0.9998332
detection O 0 0.00022079614
, O 0 0.0003059778
and O 0 0.00015203982
that O 0 0.00010002536
a O 0 0.00018640891
model O 0 0.00011525098
with O 0 0.00017041799
a O 0 0.00031809384
small O 0 0.0006995118
ICH B-Disease 0 0.999954
induced O 0 0.00013755559
with O 0 0.00013482117
a O 0 0.00019243638
low O 0 0.00024356841
- O 0 0.0020982947
dose O 0 0.0004596782
collagenase O 0 0.6935976
should O 0 6.680285e-05
be O 0 8.560668e-05
used O 0 8.080496e-05
for O 0 8.763962e-05
evaluation O 0 0.00015112218
of O 0 0.00025493858
drugs O 0 0.0058458997
that O 0 0.0003655269
may O 0 0.00060189754
affect O 0 0.0012323585
ICH B-Disease 0 0.9996737
. O 0 0.0036916777

Estradiol B-Chemical 0 0.99974793
reduces O 0 0.008370751
seizure B-Disease 0 0.99970514
- O 0 0.12641811
induced O 0 0.001406726
hippocampal B-Disease 0 0.78697616
injury I-Disease 0 0.78051436
in O 0 0.000612177
ovariectomized O 0 0.09278539
female O 0 0.0015095824
but O 0 0.000595843
not O 0 0.0004671243
in O 0 0.0006886277
male O 0 0.0020882555
rats O 0 0.0027207418
. O 0 0.0031276736

Estrogens O 0 0.7510705
protect O 0 0.0032596583
ovariectomized O 0 0.11471339
rats O 0 0.002502113
from O 0 0.0010310714
hippocampal B-Disease 0 0.49855474
injury I-Disease 0 0.7877645
induced O 0 0.0010007303
by O 0 0.0022177729
kainic B-Chemical 0 0.99997747
acid I-Chemical 0 0.99337465
- O 0 0.056341086
induced O 0 0.000634933
status B-Disease 0 0.0011646644
epilepticus I-Disease 0 0.9992378
( O 0 0.002823712
SE B-Disease 0 0.17553481
) O 0 0.004213391
. O 0 0.0033484446

We O 0 0.0021457267
compared O 0 0.0011585094
the O 0 0.00089741155
effects O 0 0.0010375971
of O 0 0.0026809627
17beta B-Chemical 0 0.9999386
- I-Chemical 0 0.96620005
estradiol I-Chemical 0 0.99997914
in O 0 0.00057664915
adult O 0 0.00045787185
male O 0 0.0004867493
and O 0 0.0002122226
ovariectomized O 0 0.005912383
female O 0 0.0004360207
rats O 0 0.00027312757
subjected O 0 0.00014141892
to O 0 0.00032436626
lithium B-Chemical 0 0.99989307
- O 0 0.37460247
pilocarpine B-Chemical 0 0.9999764
- O 0 0.019069532
induced O 0 0.0016309757
SE B-Disease 0 0.490839
. O 0 0.00372092

Rats O 0 0.0050789523
received O 0 0.0016840975
subcutaneous O 0 0.001972574
injections O 0 0.0009420988
of O 0 0.0014607954
17beta B-Chemical 0 0.99982065
- I-Chemical 0 0.81539345
estradiol I-Chemical 0 0.999966
( O 0 0.0015424077
2 O 0 0.00034781283
microg O 0 0.0005123527
/ O 0 0.0010847502
rat O 0 0.0004045544
) O 0 0.00052421197
or O 0 0.0002401645
oil O 0 0.3724782
once O 0 0.00022849406
daily O 0 0.00028571102
for O 0 0.00019251126
four O 0 0.0002302594
consecutive O 0 0.0004974318
days O 0 0.00063892215
. O 0 0.0020700074

SE B-Disease 0 0.49417427
was O 0 0.0024056446
induced O 0 0.0013558741
20 O 0 0.0009822091
h O 0 0.0006897637
following O 0 0.0002956052
the O 0 0.00031743493
second O 0 0.0003326797
injection O 0 0.0003595967
and O 0 0.000508526
terminated O 0 0.00072559086
3 O 0 0.0006883636
h O 0 0.001158776
later O 0 0.0017041373
. O 0 0.0035322977

The O 0 0.002611496
extent O 0 0.0023504747
of O 0 0.0034332972
silver B-Chemical 0 0.99692625
- O 0 0.15952921
stained O 0 0.0031825954
CA3 O 0 0.82818705
and O 0 0.0011402158
CA1 O 0 0.21214356
hippocampal O 0 0.0039558583
neurons O 0 0.0004568079
was O 0 0.00032256992
evaluated O 0 0.00035992483
2 O 0 0.00047816438
days O 0 0.000382876
after O 0 0.00071866845
SE B-Disease 0 0.018515905
. O 0 0.0038701557

17beta B-Chemical 1 0.9997739
- I-Chemical 1 0.9943685
Estradiol I-Chemical 1 0.9999778
did O 0 0.0034875614
not O 0 0.00083545997
alter O 0 0.00045268488
the O 0 0.00032037465
onset O 0 0.00045942175
of O 0 0.00027705403
first O 0 0.00021827577
clonus O 0 0.95282364
in O 0 0.0003216677
ovariectomized O 0 0.025718054
rats O 0 0.00072980236
but O 0 0.00052724977
accelerated O 0 0.0011081968
it O 0 0.0009854115
in O 0 0.0010249156
males O 0 0.0031328981
. O 0 0.0033089514

17beta B-Chemical 1 0.99969494
- I-Chemical 1 0.99092054
Estradiol I-Chemical 1 0.9999664
reduced O 0 0.006241661
the O 0 0.0019341294
argyrophilic O 0 0.66840464
neurons O 0 0.0008083521
in O 0 0.00047711242
the O 0 0.00051935215
CA1 O 0 0.08847769
and O 0 0.000942321
CA3 O 0 0.8800808
- O 0 0.013985045
C O 0 0.9435941
sectors O 0 0.0034412649
of O 0 0.0012682743
ovariectomized O 0 0.0690512
rats O 0 0.0034768374
. O 0 0.0032996514

In O 0 0.0042338627
males O 0 0.009269091
, O 0 0.011371387
estradiol B-Chemical 0 0.9991173
increased O 0 0.0046619046
the O 0 0.0021547659
total O 0 0.0026990946
damage O 0 0.018082932
score O 0 0.0034543504
. O 0 0.0052642664

These O 0 0.0018449464
findings O 0 0.0016030386
suggest O 0 0.00063290785
that O 0 0.00055114453
the O 0 0.00045769446
effects O 0 0.00052871765
of O 0 0.0010988279
estradiol B-Chemical 0 0.99992526
on O 0 0.0005637116
seizure B-Disease 0 0.9995297
threshold O 0 0.00022501028
and O 0 0.00028084137
damage O 0 0.0125850495
may O 0 0.00014540473
be O 0 0.00014227981
altered O 0 0.00017169902
by O 0 0.00017588587
sex O 0 0.00060537946
- O 0 0.0012797082
related O 0 0.00014958145
differences O 0 0.00020332477
in O 0 0.00034442675
the O 0 0.00050800515
hormonal O 0 0.002508708
environment O 0 0.0019531897
. O 0 0.0029062761

Pseudoacromegaly B-Disease 0 0.116060175
induced O 0 0.0033125374
by O 0 0.0021459782
the O 0 0.0014785299
long O 0 0.0016787907
- O 0 0.004041562
term O 0 0.0015259659
use O 0 0.00169218
of O 0 0.0043522683
minoxidil B-Chemical 0 0.99993336
. O 0 0.010260468

Acromegaly B-Disease 0 0.99878377
is O 0 0.0029763482
an O 0 0.0033087344
endocrine B-Disease 0 0.9964684
disorder I-Disease 0 0.9998815
caused O 0 0.0009410318
by O 0 0.00063742505
chronic O 0 0.058312003
excessive O 0 0.004679048
growth O 0 0.022047075
hormone O 0 0.44887942
secretion O 0 0.0034646087
from O 0 0.00047392616
the O 0 0.0005565749
anterior O 0 0.03679423
pituitary O 0 0.6127744
gland O 0 0.03398785
. O 0 0.0034596303

Significant O 0 0.0070218053
disfiguring O 0 0.011291193
changes O 0 0.0016881735
occur O 0 0.0009788391
as O 0 0.0006830286
a O 0 0.00073182094
result O 0 0.0003910042
of O 0 0.0005072738
bone O 0 0.0031078365
, O 0 0.0010266604
cartilage O 0 0.015690574
, O 0 0.00056156015
and O 0 0.00033342463
soft O 0 0.004316655
tissue O 0 0.0014934253
hypertrophy B-Disease 2 0.9980965
, O 0 0.00042682223
including O 0 0.00010738273
the O 0 0.00013044737
thickening O 0 0.043117683
of O 0 0.00019881445
the O 0 0.00017348357
skin O 0 0.00104741
, O 0 0.0005311215
coarsening O 0 0.047706693
of O 0 0.00040021143
facial O 0 0.058720816
features O 0 0.0006575831
, O 0 0.0010515827
and O 0 0.0011788708
cutis B-Disease 0 0.9533949
verticis I-Disease 0 0.8394006
gyrata I-Disease 0 0.9561024
. O 0 0.004038333

Pseudoacromegaly B-Disease 0 0.17432249
, O 0 0.003931463
on O 0 0.00090891484
the O 0 0.0006640257
other O 0 0.00055483356
hand O 0 0.00083133
, O 0 0.001037728
is O 0 0.00029167414
the O 0 0.00021286846
presence O 0 0.00020273532
of O 0 0.00024216934
similar O 0 0.00019330383
acromegaloid O 0 0.7160064
features O 0 0.00025321235
in O 0 0.00012787411
the O 0 0.000100455414
absence O 0 9.759555e-05
of O 0 0.00024968013
elevated O 0 0.0047971653
growth O 0 0.018626811
hormone O 0 0.4246371
or O 0 0.0005250999
insulin O 0 0.9957681
- O 0 0.011635548
like O 0 0.0005407069
growth O 0 0.006802658
factor O 0 0.022243729
levels O 0 0.0019417633
. O 0 0.0033120087

We O 0 0.0023645465
present O 0 0.0014595455
a O 0 0.0017649033
patient O 0 0.0011286761
with O 0 0.00097447366
pseudoacromegaly B-Disease 0 0.88768375
that O 0 0.00029272382
resulted O 0 0.00024649384
from O 0 0.00019126253
the O 0 0.00016295504
long O 0 0.00023152256
- O 0 0.0007788538
term O 0 0.00020231243
use O 0 0.0002053191
of O 0 0.0005412819
minoxidil B-Chemical 0 0.99999094
at O 0 0.00044440277
an O 0 0.0006227461
unusually O 0 0.0021595757
high O 0 0.0012521017
dose O 0 0.002617635
. O 0 0.0027369747

This O 0 0.0048121656
is O 0 0.0015787587
the O 0 0.0009401633
first O 0 0.0005909281
case O 0 0.0008100452
report O 0 0.0011286467
of O 0 0.000966449
pseudoacromegaly B-Disease 0 0.94732976
as O 0 0.00061851734
a O 0 0.00076902803
side O 0 0.0012716231
effect O 0 0.00069985155
of O 0 0.002229587
minoxidil B-Chemical 0 0.99998236
use O 0 0.0029704876
. O 0 0.0036552274

Combined O 0 0.016944507
androgen O 0 0.99454147
blockade O 0 0.041237883
- O 0 0.05268066
induced O 0 0.002928846
anemia B-Disease 0 0.99990296
in O 0 0.0030491406
prostate B-Disease 0 0.99886096
cancer I-Disease 0 0.99948287
patients O 0 0.004069465
without O 0 0.0011517868
bone O 0 0.005655085
involvement O 0 0.0032150352
. O 0 0.00349761

BACKGROUND O 0 0.01217369
: O 0 0.0027224647
To O 0 0.00042276853
determine O 0 0.0002532556
the O 0 0.00039876127
onset O 0 0.000566573
and O 0 0.000312214
extent O 0 0.0002494755
of O 0 0.00035049694
combined O 0 0.00071673625
androgen O 0 0.9940317
blockade O 0 0.0030818118
( O 0 0.00088431174
CAB O 0 0.015776701
) O 0 0.0011965563
- O 0 0.0035189127
induced O 0 0.00057106337
anemia B-Disease 0 0.9999579
in O 0 0.0011612765
prostate B-Disease 0 0.9994073
cancer I-Disease 0 0.99975723
patients O 0 0.0030623656
without O 0 0.00072639016
bone O 0 0.005024286
involvement O 0 0.0024488799
. O 0 0.0026598347

PATIENTS O 0 0.0021795388
AND O 0 0.0014556795
METHODS O 0 0.0013545962
: O 0 0.001328414
Forty O 0 0.0012377034
- O 0 0.0014857003
two O 0 0.0003100265
patients O 0 0.0006296164
with O 0 0.00042602143
biopsy O 0 0.00066970644
- O 0 0.0033524141
proven O 0 0.001153136
prostatic B-Disease 0 0.99980325
adenocarcinoma I-Disease 0 0.99993265
[ O 0 0.0106937075
26 O 0 0.000362363
with O 0 0.0002757569
stage O 0 0.0025655667
C O 0 0.99651176
( O 0 0.0043079704
T3N0M0 O 0 0.9998586
) O 0 0.0009420041
and O 0 0.0002086118
16 O 0 0.00021641627
with O 0 0.00025133483
stage O 0 0.0028117476
D1 O 0 0.9236441
( O 0 0.002444082
T3N1M0 O 0 0.9986545
) O 0 0.0012328036
] O 0 0.0011189646
were O 0 0.00030131132
included O 0 0.00034497268
in O 0 0.00051093515
this O 0 0.0009925523
study O 0 0.0018742818
. O 0 0.0029740564

All O 0 0.0025425144
patients O 0 0.0032525007
received O 0 0.0019240445
CAB O 0 0.023890296
[ O 0 0.029304521
leuprolide B-Chemical 0 0.9991303
acetate I-Chemical 0 0.99918
( O 0 0.009645347
LHRH B-Chemical 0 0.9894817
- I-Chemical 0 0.053216897
A I-Chemical 0 0.1789475
) O 0 0.0009439519
3 O 0 0.00019663978
. O 0 0.00017808203
75 O 0 0.00029318748
mg O 0 0.0015514828
, O 0 0.00030045875
intramuscularly O 0 0.0003241007
, O 0 0.00018345875
every O 0 5.3737353e-05
28 O 0 7.5221586e-05
days O 0 5.1143837e-05
plus O 0 0.000108157394
250 O 0 0.0005142736
mg O 0 0.054702535
flutamide B-Chemical 0 0.99994254
, O 0 0.0014491472
tid O 0 0.9989293
, O 0 0.0004418373
per O 0 0.0002280744
Os O 0 0.7640965
] O 0 0.00072338036
and O 0 0.0001234964
were O 0 8.7707e-05
evaluated O 0 9.9495206e-05
for O 0 0.00012835581
anemia B-Disease 0 0.99977547
by O 0 0.00011199376
physical O 0 0.00015287484
examination O 0 6.590328e-05
and O 0 7.759172e-05
laboratory O 0 0.00010068547
tests O 0 0.00015794329
at O 0 5.769048e-05
baseline O 0 7.527562e-05
and O 0 8.797119e-05
4 O 0 7.2259514e-05
subsequent O 0 7.004468e-05
intervals O 0 0.00010614841
( O 0 0.00023755146
1 O 0 0.00017448125
, O 0 0.00027158126
2 O 0 0.00019898303
, O 0 0.00028455266
3 O 0 0.00015210394
and O 0 0.0001754457
6 O 0 0.00015758029
months O 0 0.00015284338
post O 0 0.00042290075
- O 0 0.0028025217
CAB O 0 0.007238587
) O 0 0.004473013
. O 0 0.003959896

Hb O 0 0.8044848
, O 0 0.01791555
PSA O 0 0.5469675
and O 0 0.00852674
Testosterone B-Chemical 0 0.9989009
measurements O 0 0.003786664
were O 0 0.003306622
recorded O 0 0.0042569367
. O 0 0.0068225553

Patients O 0 0.0052222363
with O 0 0.0028732559
stage O 0 0.015289
D2 O 0 0.99429214
- O 0 0.013851378
3 O 0 0.00073335756
disease O 0 0.07470831
, O 0 0.0009128272
abnormal O 0 0.0023971503
hemoglobin O 0 0.4719605
level O 0 0.00021209291
or O 0 0.00021899474
renal O 0 0.4409513
and O 0 0.00022203346
liver O 0 0.006233229
function O 0 0.00010851379
tests O 0 0.00023511519
that O 0 7.228577e-05
were O 0 8.406784e-05
higher O 0 0.000111927584
than O 0 9.499928e-05
the O 0 0.00010428172
upper O 0 0.00022809961
limits O 0 0.0003231899
were O 0 0.0002372891
excluded O 0 0.0003677755
from O 0 0.00037849552
the O 0 0.0006262903
study O 0 0.0015593747
. O 0 0.0026325427

The O 0 0.0027880007
duration O 0 0.00198372
of O 0 0.002284811
the O 0 0.0017426086
study O 0 0.0019713636
was O 0 0.0015238675
six O 0 0.0011988464
months O 0 0.0016102209
. O 0 0.0047178473

RESULTS O 0 0.004368278
: O 0 0.0027593023
The O 0 0.0007088005
mean O 0 0.00087823224
hemoglobin O 0 0.17812732
( O 0 0.0021538916
Hb O 0 0.32040685
) O 0 0.0010689298
levels O 0 0.00026484902
were O 0 0.0002196566
significantly O 0 0.00025559083
declined O 0 0.00027733098
in O 0 0.00013875344
all O 0 0.00012386755
patients O 0 0.00020702087
from O 0 8.579496e-05
baseline O 0 9.28926e-05
of O 0 0.00012246807
14 O 0 0.00012347732
. O 0 0.0001182728
2 O 0 0.00015069367
g O 0 0.0005059338
/ O 0 0.0009627811
dl O 0 0.0012927995
to O 0 0.00012748476
14 O 0 0.00012860585
. O 0 0.00012205815
0 O 0 0.00019144372
g O 0 0.0005636504
/ O 0 0.001166159
dl O 0 0.0023934927
, O 0 0.00038239014
13 O 0 0.00020434687
. O 0 0.00014529898
5 O 0 0.00014762463
g O 0 0.0005391041
/ O 0 0.0011230947
dl O 0 0.002313226
, O 0 0.00039340006
13 O 0 0.00021130673
. O 0 0.00015048013
2 O 0 0.0001785467
g O 0 0.0005606715
/ O 0 0.0010351968
dl O 0 0.0014927619
and O 0 0.00018477946
12 O 0 0.000112182315
. O 0 0.00012187763
7 O 0 0.00012229092
g O 0 0.00051086553
/ O 0 0.00102845
dl O 0 0.0015311438
at O 0 0.00016728976
1 O 0 0.00024074958
, O 0 0.00034020434
2 O 0 0.0002291241
, O 0 0.0003045384
3 O 0 0.00015354542
and O 0 0.00016671332
6 O 0 0.00014072306
months O 0 0.00012875335
post O 0 0.00033375158
- O 0 0.002112593
CAB O 0 0.004749609
, O 0 0.002338026
respectively O 0 0.0034752355
. O 0 0.0040601473

Severe O 0 0.083381236
and O 0 0.0034034937
clinically O 0 0.007908811
evident O 0 0.0022270405
anemia B-Disease 0 0.9996074
of O 0 0.0012309005
Hb O 0 0.21965207
< O 0 0.00061062694
11 O 0 0.00033321904
g O 0 0.00083283737
/ O 0 0.001385131
dl O 0 0.0022352715
with O 0 0.00027824787
clinical O 0 0.0011151929
symptoms O 0 0.00201799
was O 0 0.0001633662
detected O 0 0.000116419375
in O 0 0.00016764729
6 O 0 0.00016680428
patients O 0 0.0004191795
( O 0 0.00047929148
14 O 0 0.00032807406
. O 0 0.0004123682
3 O 0 0.00058677717
% O 0 0.0017247372
) O 0 0.003418471
. O 0 0.0035332276

This O 0 0.01221618
CAB O 0 0.107589975
- O 0 0.025778813
induced O 0 0.0057468754
anemia B-Disease 0 0.99961805
was O 0 0.0044458546
normochromic O 0 0.26133567
and O 0 0.0043669473
normocytic O 0 0.60206556
. O 0 0.0066307937

At O 0 0.0010401026
six O 0 0.0007891246
months O 0 0.0005926133
post O 0 0.00082094996
- O 0 0.0034182698
CAB O 0 0.005850629
, O 0 0.0010686014
patients O 0 0.0009370208
with O 0 0.00059352425
severe O 0 0.055728327
anemia B-Disease 0 0.9999114
had O 0 0.00040289332
a O 0 0.00050747575
Hb O 0 0.09505852
mean O 0 0.00013323859
value O 0 0.00015096605
of O 0 0.000164213
10 O 0 0.00016405777
. O 0 0.00014233179
2 O 0 0.00018334559
+ O 0 0.00065342616
/ O 0 0.0012799264
- O 0 0.0012688464
0 O 0 0.00026036237
. O 0 0.00016897112
1 O 0 0.0002050667
g O 0 0.00061002315
/ O 0 0.0012131401
dl O 0 0.0030691833
( O 0 0.00080922747
X O 0 0.2594611
+ O 0 0.0018039588
/ O 0 0.003003999
- O 0 0.0057481015
SE O 0 0.35541984
) O 0 0.00068979716
, O 0 0.0003117203
whereas O 0 0.00014145047
the O 0 0.00010569451
other O 0 0.00012848941
patients O 0 0.00042669426
had O 0 0.00024125718
mild O 0 0.51304054
anemia B-Disease 0 0.99995506
with O 0 0.00040413157
Hb O 0 0.32402894
mean O 0 0.00011268224
value O 0 0.00013254432
of O 0 0.00015118734
13 O 0 0.0001825223
. O 0 0.00014804471
2 O 0 0.00020243012
+ O 0 0.00074469496
/ O 0 0.0015270226
- O 0 0.0016356129
0 O 0 0.00041383554
. O 0 0.000326839
17 O 0 0.0005424786
( O 0 0.0010363124
X O 0 0.14551291
+ O 0 0.0036988438
/ O 0 0.007004721
- O 0 0.012707827
SE O 0 0.30232462
) O 0 0.005771561
. O 0 0.004322118

The O 0 0.0023947796
development O 0 0.0025768739
of O 0 0.0022043115
severe O 0 0.081407115
anemia B-Disease 0 0.99963117
at O 0 0.00036145892
6 O 0 0.00018798033
months O 0 0.0001086139
post O 0 0.0001896514
- O 0 0.0011495267
CAB O 0 0.0018037141
was O 0 0.00017762942
predictable O 0 0.00024132918
by O 0 0.00011978587
the O 0 0.000105189065
reduction O 0 0.00017404775
of O 0 0.00020834921
Hb O 0 0.111823305
baseline O 0 0.000110196284
value O 0 0.0001133517
of O 0 0.00012647905
more O 0 0.00018369698
than O 0 0.000113028975
2 O 0 0.00013658042
. O 0 0.00011037211
5 O 0 0.000118033044
g O 0 0.00043402665
/ O 0 0.0007681842
dl O 0 0.00084138464
after O 0 7.7388446e-05
3 O 0 0.00010186977
months O 0 7.595914e-05
of O 0 0.00022103648
CAB O 0 0.0015680821
( O 0 0.0005562532
p O 0 0.00067614176
= O 0 0.0011362047
0 O 0 0.00082150206
. O 0 0.00093874196
01 O 0 0.0051475316
) O 0 0.0041576396
. O 0 0.004019751

The O 0 0.002403293
development O 0 0.0024806205
of O 0 0.0020318823
severe O 0 0.013146597
CAB O 0 0.15641609
- O 0 0.020047756
induced O 0 0.0014070851
anemia B-Disease 0 0.99995005
in O 0 0.0018414669
prostate B-Disease 0 0.999616
cancer I-Disease 0 0.9998741
patients O 0 0.0031137366
did O 0 0.00024750407
not O 0 0.00014140003
correlate O 0 0.00014079486
with O 0 0.00015386756
T O 0 0.0012184887
baseline O 0 0.00011753661
values O 0 0.00012241949
( O 0 0.00023193883
T O 0 0.0007255694
< O 0 0.00020299025
3 O 0 0.00010458127
ng O 0 0.0002704351
/ O 0 0.00065316405
ml O 0 0.0004969074
versus O 0 0.00015163432
T O 0 0.0012259432
> O 0 0.00040369027
or O 0 0.00014959343
= O 0 0.00038463203
3 O 0 0.00012817272
ng O 0 0.00034602653
/ O 0 0.0009881976
ml O 0 0.000939399
) O 0 0.00048212378
, O 0 0.00027488256
with O 0 0.00016801455
age O 0 0.00025791983
( O 0 0.00024718454
< O 0 0.00020495491
76 O 0 0.00020705741
yrs O 0 0.00016295208
versus O 0 0.000105310995
> O 0 0.00027881298
or O 0 0.00015372573
= O 0 0.00047421284
76 O 0 0.00033864912
yrs O 0 0.00031050746
) O 0 0.00042386775
, O 0 0.00035758948
and O 0 0.00027200417
clinical O 0 0.0009304353
stage O 0 0.0014033081
( O 0 0.0010531603
stage O 0 0.0030788719
C O 0 0.97113335
versus O 0 0.0012413705
stage O 0 0.012777502
D1 O 0 0.93405306
) O 0 0.00861229
. O 0 0.0043306095

Severe O 0 0.0967733
and O 0 0.0032337585
clinically O 0 0.009107943
evident O 0 0.0022155324
anemia B-Disease 0 0.9997489
was O 0 0.00054248044
easily O 0 0.0002819295
corrected O 0 0.00026153
by O 0 0.00017840596
subcutaneous O 0 0.00033179537
injections O 0 0.00013362143
( O 0 0.00017474999
3 O 0 7.79819e-05
times O 0 6.9819354e-05
/ O 0 0.00034453016
week O 0 7.7700424e-05
for O 0 8.757261e-05
1 O 0 0.00014529053
month O 0 9.874304e-05
) O 0 0.00034342046
of O 0 0.0002794733
recombinant O 0 0.0006190296
erythropoietin O 0 0.99909604
( O 0 0.0045541483
rHuEPO O 0 0.99150014
- O 0 0.013778241
beta O 0 0.49326825
) O 0 0.007047779
. O 0 0.0040143197

CONCLUSION O 0 0.0161495
: O 0 0.0037986306
Our O 0 0.00096644484
data O 0 0.00097141875
suggest O 0 0.00049358286
that O 0 0.0008327651
rHuEPO O 0 0.9888849
- O 0 0.037326872
beta O 0 0.8259959
correctable O 0 0.6993297
CAB O 0 0.30728304
- O 0 0.015701734
induced O 0 0.0006524399
anemia B-Disease 0 0.9999336
occurs O 0 0.00028480263
in O 0 0.0001827513
14 O 0 0.00015986619
. O 0 0.00013643515
3 O 0 0.00012958264
% O 0 0.00033348822
of O 0 0.00039269394
prostate B-Disease 0 0.9953951
cancer I-Disease 0 0.9993482
patients O 0 0.0008238048
after O 0 0.00013172458
6 O 0 0.00017193593
months O 0 0.00016926334
of O 0 0.000587893
therapy O 0 0.0015254995
. O 0 0.0023617204

Delirium B-Disease 2 0.99556774
during O 0 0.0047274474
clozapine B-Chemical 0 0.9999447
treatment O 0 0.0024448493
: O 0 0.0026782034
incidence O 0 0.0019181634
and O 0 0.0013195453
associated O 0 0.0017632397
risk O 0 0.007581828
factors O 0 0.005538649
. O 0 0.005911069

BACKGROUND O 0 0.017853444
: O 0 0.0052186605
Incidence O 0 0.0030872428
and O 0 0.0011514556
risk O 0 0.0028278248
factors O 0 0.0012197862
for O 0 0.00080259243
delirium B-Disease 0 0.9998735
during O 0 0.0009485323
clozapine B-Chemical 0 0.99998546
treatment O 0 0.00072846405
require O 0 0.0004760265
further O 0 0.0007890911
clarification O 0 0.0022470753
. O 0 0.0032788706

METHODS O 0 0.003968783
: O 0 0.0024283146
We O 0 0.0006586293
used O 0 0.000529991
computerized O 0 0.0010952626
pharmacy O 0 0.0018237298
records O 0 0.0005024035
to O 0 0.00017697465
identify O 0 0.000100012294
all O 0 0.0001756094
adult O 0 0.0004972244
psychiatric B-Disease 2 0.9988906
inpatients O 0 0.011478061
treated O 0 0.00044829038
with O 0 0.0004756323
clozapine B-Chemical 0 0.9999976
( O 0 0.0008306131
1995 O 0 0.0007984556
- O 0 0.0015577533
96 O 0 0.00043747536
) O 0 0.0003502168
, O 0 0.00022472683
reviewed O 0 0.00021023558
their O 0 9.87939e-05
medical O 0 0.0003335636
records O 0 0.00016444743
to O 0 7.4824675e-05
score O 0 9.12703e-05
incidence O 0 0.00019927451
and O 0 0.0001378246
severity O 0 0.00057351985
of O 0 0.00036911474
delirium B-Disease 0 0.99996614
, O 0 0.0005083273
and O 0 0.00018768982
tested O 0 0.00016681541
associations O 0 0.0002249798
with O 0 0.00036766403
potential O 0 0.0005277528
risk O 0 0.0066542584
factors O 0 0.003420751
. O 0 0.0034082164

RESULTS O 0 0.0051117255
: O 0 0.003729443
Subjects O 0 0.0016206686
( O 0 0.001423079
n O 0 0.0009656367
= O 0 0.001557448
139 O 0 0.001082821
) O 0 0.0009912306
were O 0 0.00037863522
72 O 0 0.00045092148
women O 0 0.00068795244
and O 0 0.00034392386
67 O 0 0.00058569986
men O 0 0.0010754137
, O 0 0.0005140373
aged O 0 0.00046376986
40 O 0 0.00025350176
. O 0 0.00018594188
8 O 0 0.00019302059
+ O 0 0.0007343551
/ O 0 0.0013793953
- O 0 0.00126854
12 O 0 0.00014432316
. O 0 0.00015027093
1 O 0 0.00016501729
years O 0 0.00019872462
, O 0 0.00030567285
hospitalized O 0 0.00061484275
for O 0 0.00011110378
24 O 0 0.00014679153
. O 0 0.0001210112
9 O 0 0.00012846882
+ O 0 0.00057762116
/ O 0 0.0012656328
- O 0 0.0013792949
23 O 0 0.00023232748
. O 0 0.000107021464
3 O 0 7.511464e-05
days O 0 6.0009756e-05
, O 0 0.00017002002
and O 0 0.0001361025
given O 0 0.00016556322
clozapine B-Chemical 0 0.99999607
, O 0 0.00064915384
gradually O 0 0.00028095415
increased O 0 0.00016512779
to O 0 8.1734855e-05
an O 0 9.310899e-05
average O 0 6.749879e-05
daily O 0 0.000104760926
dose O 0 0.00014730978
of O 0 0.00014152832
282 O 0 0.0006675867
+ O 0 0.000851635
/ O 0 0.0016499117
- O 0 0.0020905568
203 O 0 0.0010421382
mg O 0 0.0032789472
( O 0 0.00026951308
3 O 0 0.000114712646
. O 0 0.000121515244
45 O 0 0.00015571414
+ O 0 0.00058032735
/ O 0 0.001149427
- O 0 0.0011206395
2 O 0 0.00019670954
. O 0 0.0001472772
45 O 0 0.00017150628
mg O 0 0.0010251353
/ O 0 0.0006356978
kg O 0 0.0004964962
) O 0 0.00040945504
for O 0 0.00015077343
18 O 0 0.00023161044
. O 0 0.0002090646
9 O 0 0.0002482713
+ O 0 0.0010356777
/ O 0 0.0021243866
- O 0 0.0023656576
16 O 0 0.00068443385
. O 0 0.00060594897
4 O 0 0.0007051451
days O 0 0.0008921152
. O 0 0.002745817

Delirium B-Disease 2 0.9965043
was O 0 0.003488536
diagnosed O 0 0.0058640623
in O 0 0.0010254522
14 O 0 0.0007833384
( O 0 0.0010123979
10 O 0 0.00048628717
. O 0 0.00037260962
1 O 0 0.0003645989
% O 0 0.00056732865
incidence O 0 0.00055201125
, O 0 0.00049490127
or O 0 0.00023287747
1 O 0 0.00025769667
. O 0 0.0001861867
48 O 0 0.00019345798
cases O 0 0.00034690334
/ O 0 0.0011266647
person O 0 0.0006174372
- O 0 0.0011687618
years O 0 0.00022797611
of O 0 0.00019325926
exposure O 0 0.00027608944
) O 0 0.0005958868
; O 0 0.00048569927
71 O 0 0.00040472872
. O 0 0.0001928824
4 O 0 0.00017349582
% O 0 0.00039188747
of O 0 0.0003282383
cases O 0 0.0006667169
were O 0 0.00048341366
moderate O 0 0.00168305
or O 0 0.0010759726
severe O 0 0.007653634
. O 0 0.0032077436

Associated O 0 0.005850931
factors O 0 0.0028917345
were O 0 0.0014696374
co O 0 0.012498901
- O 0 0.0041752076
treatment O 0 0.00043398235
with O 0 0.0003071852
other O 0 0.00024180824
centrally O 0 0.00053693925
antimuscarinic O 0 0.8003396
agents O 0 0.00054785336
, O 0 0.00032291457
poor O 0 0.00039975918
clinical O 0 0.0004065198
outcome O 0 0.00019670863
, O 0 0.00024663797
older O 0 0.0005498798
age O 0 0.0002385242
, O 0 0.00020888027
and O 0 0.0001050302
longer O 0 7.061004e-05
hospitalization O 0 0.00022183012
( O 0 0.00020248437
by O 0 0.00011037642
17 O 0 0.00015921461
. O 0 9.1914444e-05
5 O 0 7.393087e-05
days O 0 5.5178916e-05
, O 0 0.00015965156
increasing O 0 0.00011831995
cost O 0 0.0002552667
) O 0 0.0004761658
; O 0 0.0003448208
sex O 0 0.0003343439
, O 0 0.00027446542
diagnosis O 0 0.0002591837
or O 0 0.00012057096
medical O 0 0.000810758
co O 0 0.03439902
- O 0 0.009564941
morbidity O 0 0.009240238
, O 0 0.00025944132
and O 0 0.00015477148
daily O 0 0.00041653158
clozapine B-Chemical 0 0.9999938
dose O 0 0.0006100351
, O 0 0.00034278608
which O 0 0.00023611488
fell O 0 0.00044703597
with O 0 0.00034712284
age O 0 0.00076021807
, O 0 0.0010687307
were O 0 0.0008442996
unrelated O 0 0.0020526338
. O 0 0.0029022028

CONCLUSIONS O 0 0.03906463
: O 0 0.010962167
Delirium B-Disease 2 0.99449253
was O 0 0.0010997427
found O 0 0.0006454724
in O 0 0.0004674878
10 O 0 0.00040567107
% O 0 0.0006463566
of O 0 0.00061963365
clozapine B-Chemical 0 0.999995
- O 0 0.02403472
treated O 0 0.0008422169
inpatients O 0 0.012115089
, O 0 0.00039918534
particularly O 0 0.00022145311
in O 0 0.00019643796
older O 0 0.0010263377
patients O 0 0.0005064242
exposed O 0 0.00030609625
to O 0 0.00028831683
other O 0 0.000485853
central O 0 0.0019805583
anticholinergics O 0 0.9889071
. O 0 0.0029579843

Delirium B-Disease 2 0.9970368
was O 0 0.002584304
inconsistently O 0 0.0036693993
recognized O 0 0.00092522614
clinically O 0 0.002392747
in O 0 0.0005982843
milder O 0 0.016113477
cases O 0 0.00060684385
and O 0 0.00026127326
was O 0 0.00017797187
associated O 0 0.00017019763
with O 0 0.00016007684
increased O 0 0.00020579634
length O 0 0.00015108976
- O 0 0.0010472833
of O 0 0.00021752286
- O 0 0.000978023
stay O 0 0.00016137953
and O 0 0.0001558988
higher O 0 0.00022401338
costs O 0 0.0005235823
, O 0 0.0005681001
and O 0 0.0004540263
inferior O 0 0.003898313
clinical O 0 0.0020463374
outcome O 0 0.0017103292
. O 0 0.002388554

Neuroprotective O 0 0.34818327
action O 0 0.003222999
of O 0 0.004716081
MPEP B-Chemical 1 0.9999845
, O 0 0.005540918
a O 0 0.001449811
selective O 0 0.0015548305
mGluR5 O 0 0.91165185
antagonist O 0 0.49060872
, O 0 0.0012232244
in O 0 0.0005615302
methamphetamine B-Chemical 1 0.99998295
- O 0 0.08247044
induced O 0 0.00031233163
dopaminergic O 0 0.073537424
neurotoxicity B-Disease 0 0.99711466
is O 0 0.00011733258
associated O 0 0.00013146983
with O 0 0.00014465602
a O 0 0.0002582582
decrease O 0 0.00024338248
in O 0 0.0003700298
dopamine B-Chemical 0 0.99987006
outflow O 0 0.967252
and O 0 0.0003125741
inhibition O 0 0.00046290594
of O 0 0.00077529566
hyperthermia B-Disease 0 0.99868065
in O 0 0.00095406605
rats O 0 0.00213725
. O 0 0.0024038933

The O 0 0.0016161652
aim O 0 0.0010380108
of O 0 0.0011236939
this O 0 0.0008289369
study O 0 0.0006330831
was O 0 0.00031813234
to O 0 0.00018735314
examine O 0 9.355907e-05
the O 0 0.00014876427
role O 0 0.00012858427
of O 0 0.00086884893
metabotropic O 0 0.99997544
glutamate B-Chemical 0 0.99995816
receptor O 0 0.008985123
5 O 0 0.00028373318
( O 0 0.0005848238
mGluR5 O 0 0.15559283
) O 0 0.00048194683
in O 0 0.00013534824
the O 0 0.00014099867
toxic O 0 0.0026908517
action O 0 0.00025481978
of O 0 0.00052022736
methamphetamine B-Chemical 1 0.9999585
on O 0 0.00039534445
dopaminergic O 0 0.0044047316
neurones O 0 0.0008059857
in O 0 0.0005928958
rats O 0 0.0017632659
. O 0 0.0023949358

Methamphetamine B-Chemical 1 0.99953747
( O 0 0.0053107664
10 O 0 0.0016184018
mg O 0 0.0052191555
/ O 0 0.0019729517
kg O 0 0.0012976414
sc O 0 0.0014057456
) O 0 0.00072195305
, O 0 0.0004096473
administered O 0 0.00023858332
five O 0 8.8330795e-05
times O 0 0.00010221618
, O 0 0.00027268575
reduced O 0 0.00018651276
the O 0 0.00013687795
levels O 0 0.00017717305
of O 0 0.00050972076
dopamine B-Chemical 0 0.9998356
and O 0 0.00032414246
its O 0 0.00047244917
metabolites O 0 0.5813764
in O 0 0.00035242466
striatal O 0 0.105948016
tissue O 0 0.00045008256
when O 0 0.00010046479
measured O 0 0.00018657198
72 O 0 0.00021924042
h O 0 0.0001963067
after O 0 0.00012995275
the O 0 0.00024627818
last O 0 0.0003217155
injection O 0 0.0008456184
. O 0 0.0021387546

A O 0 0.080801204
selective O 0 0.0064367023
antagonist O 0 0.47405255
of O 0 0.0034999808
mGluR5 O 0 0.85969543
, O 0 0.0027996034
2 B-Chemical 0 0.0013052659
- I-Chemical 0 0.015846672
methyl I-Chemical 0 0.89971656
- I-Chemical 0 0.005269168
6 I-Chemical 0 0.00035406233
- I-Chemical 0 0.0018793716
( I-Chemical 0 0.00078856305
phenylethynyl I-Chemical 0 0.02023758
) I-Chemical 0 0.0037134048
pyridine I-Chemical 0 0.99588335
( O 0 0.009830468
MPEP B-Chemical 1 0.9999918
; O 0 0.0010149324
5 O 0 0.00018501533
mg O 0 0.0012522676
/ O 0 0.0005173184
kg O 0 0.00043150067
ip O 0 0.0020842755
) O 0 0.00029671597
, O 0 0.00015409909
when O 0 5.8267808e-05
administered O 0 0.00010723947
five O 0 3.8187394e-05
times O 0 4.1290332e-05
immediately O 0 4.6395577e-05
before O 0 4.4046184e-05
each O 0 8.63462e-05
methamphetamine B-Chemical 1 0.99965847
injection O 0 0.00014723086
reversed O 0 0.00023249809
the O 0 0.00016248321
above O 0 0.00031943223
- O 0 0.0028189765
mentioned O 0 0.00056138623
methamphetamine B-Chemical 1 0.99966335
effects O 0 0.0020788128
. O 0 0.003165549

A O 0 0.079543136
single O 0 0.004780541
MPEP B-Chemical 1 0.9999325
( O 0 0.0033304398
5 O 0 0.00081256474
mg O 0 0.003476998
/ O 0 0.0012737075
kg O 0 0.0008976806
ip O 0 0.0023820866
) O 0 0.00046856143
injection O 0 0.00015066838
reduced O 0 0.00019997991
the O 0 0.00018622239
basal O 0 0.0008906586
extracellular O 0 0.0058914847
dopamine B-Chemical 0 0.99974376
level O 0 0.0001512763
in O 0 0.00012973373
the O 0 0.00012730826
striatum O 0 0.0014558524
, O 0 0.0002371423
as O 0 0.00011612977
well O 0 0.00014754201
as O 0 0.00033919554
dopamine B-Chemical 0 0.99989545
release O 0 0.0006648622
stimulated O 0 0.00021087441
either O 0 0.000152683
by O 0 0.00022319215
methamphetamine B-Chemical 1 0.9999567
( O 0 0.00042740747
10 O 0 0.00013227461
mg O 0 0.0010367073
/ O 0 0.000429479
kg O 0 0.00035002307
sc O 0 0.0005106601
) O 0 0.000283055
or O 0 0.00011901903
by O 0 0.00019045745
intrastriatally O 0 0.04816999
administered O 0 0.0011695798
veratridine B-Chemical 0 0.99986386
( O 0 0.0020741129
100 O 0 0.002437675
microM O 0 0.27521536
) O 0 0.0050845603
. O 0 0.0032918917

Moreover O 0 0.003714813
, O 0 0.004801422
it O 0 0.0023965759
transiently O 0 0.0019862405
diminished O 0 0.0016358561
the O 0 0.00091092836
methamphetamine B-Chemical 1 0.9998815
( O 0 0.0010760168
10 O 0 0.0003369072
mg O 0 0.0016567404
/ O 0 0.0007758703
kg O 0 0.00063778873
sc O 0 0.0009869254
) O 0 0.00076178886
- O 0 0.0014857095
induced O 0 0.0004692352
hyperthermia B-Disease 0 0.99732447
and O 0 0.0006333707
reduced O 0 0.00083520124
basal O 0 0.0017656938
body O 0 0.0022468688
temperature O 0 0.004092928
. O 0 0.0030795624

MPEP B-Chemical 1 0.9998994
administered O 0 0.004274266
into O 0 0.000749057
the O 0 0.00064338656
striatum O 0 0.0016728075
at O 0 0.00023119873
high O 0 0.0003321334
concentrations O 0 0.00053862826
( O 0 0.0006114481
500 O 0 0.00085869274
microM O 0 0.15564352
) O 0 0.0010505649
increased O 0 0.00052500534
extracellular O 0 0.0053857625
dopamine B-Chemical 0 0.99976903
levels O 0 0.00017851555
, O 0 0.0002789074
while O 0 0.00013032093
lower O 0 0.00020067384
concentrations O 0 0.00039004814
( O 0 0.0004405359
50 O 0 0.0003425174
- O 0 0.001870994
100 O 0 0.0007306366
microM O 0 0.091684185
) O 0 0.00086703047
were O 0 0.00026098694
devoid O 0 0.00021342633
of O 0 0.00054129143
any O 0 0.0007157663
effect O 0 0.0014667014
. O 0 0.003524629

The O 0 0.0018316269
results O 0 0.0013429322
of O 0 0.0012171007
this O 0 0.0008594614
study O 0 0.0005966693
suggest O 0 0.00023264068
that O 0 0.00025742236
the O 0 0.0002963634
blockade O 0 0.0015684232
of O 0 0.0007574427
mGluR5 O 0 0.9188456
by O 0 0.0011855287
MPEP B-Chemical 1 0.9999951
may O 0 0.00043945253
protect O 0 0.00038886792
dopaminergic O 0 0.003776913
neurones O 0 0.0005375773
against O 0 0.00024979824
methamphetamine B-Chemical 1 0.99991226
- O 0 0.032488808
induced O 0 0.0014218403
toxicity B-Disease 0 0.88752335
. O 0 0.0038520268

Neuroprotection O 0 0.5409812
rendered O 0 0.0046723173
by O 0 0.0040148706
MPEP B-Chemical 1 0.9999745
may O 0 0.0009756237
be O 0 0.00046644214
associated O 0 0.000332173
with O 0 0.00024675296
the O 0 0.0001660383
reduction O 0 0.00022815641
of O 0 0.0002253001
the O 0 0.00029862137
methamphetamine B-Chemical 1 0.9999826
- O 0 0.16212608
induced O 0 0.0006159613
dopamine B-Chemical 0 0.99995947
efflux O 0 0.28525785
in O 0 0.00014994689
the O 0 0.00012116926
striatum O 0 0.0010218467
due O 0 6.4934844e-05
to O 0 7.46799e-05
the O 0 9.415495e-05
blockade O 0 0.00064565474
of O 0 0.00044788502
extrastriatal O 0 0.99368423
mGluR5 O 0 0.5361472
, O 0 0.00048250717
and O 0 0.00025813535
with O 0 0.00034902777
a O 0 0.00068541
decrease O 0 0.00078799075
in O 0 0.001311609
hyperthermia B-Disease 0 0.99782
. O 0 0.0034141494

Protective O 0 0.015887741
efficacy O 0 0.0024410263
of O 0 0.0022225017
neuroactive O 0 0.42467356
steroids B-Chemical 0 0.9989151
against O 0 0.0010905557
cocaine B-Chemical 0 0.9998661
kindled O 0 0.99847823
- O 0 0.2736899
seizures B-Disease 0 0.9998062
in O 0 0.0013030339
mice O 0 0.0008614184
. O 0 0.0029747186

Neuroactive O 0 0.732342
steroids B-Chemical 0 0.9920328
demonstrate O 0 0.00069450133
pharmacological O 0 0.0019237833
actions O 0 0.000811922
that O 0 0.00032385363
have O 0 0.00025507112
relevance O 0 0.00019478287
for O 0 0.00023987111
a O 0 0.0004920067
host O 0 0.0004948116
of O 0 0.00070883427
neurological B-Disease 0 0.890388
and I-Disease 0 0.00239199
psychiatric I-Disease 2 0.9999157
disorders I-Disease 0 0.9996488
. O 0 0.0053169085

They O 0 0.0043498427
offer O 0 0.0019089098
protection O 0 0.0014790256
against O 0 0.0009081764
seizures B-Disease 0 0.999879
in O 0 0.00064352667
a O 0 0.0005192544
range O 0 0.0002582922
of O 0 0.00020995752
models O 0 0.00019049922
and O 0 0.0002347859
seem O 0 0.0001892222
to O 0 0.00014469466
inhibit O 0 0.00014626885
certain O 0 0.0002332379
stages O 0 0.00049801654
of O 0 0.00049174554
drug B-Disease 0 0.442714
dependence I-Disease 0 0.0018356555
in O 0 0.0005806687
preclinical O 0 0.0017113163
assessments O 0 0.0013877789
. O 0 0.002290237

The O 0 0.0018371562
present O 0 0.0012694079
study O 0 0.001126823
was O 0 0.0005435448
designed O 0 0.00032291395
to O 0 0.00020024226
evaluate O 0 9.104655e-05
two O 0 0.00010610936
endogenous O 0 0.00011328752
and O 0 0.00017434506
one O 0 0.00013906232
synthetic O 0 0.00018906263
neuroactive O 0 0.28298262
steroid B-Chemical 0 0.9868226
that O 0 0.0001306961
positively O 0 0.00013428357
modulate O 0 6.877127e-05
the O 0 0.00022137247
gamma B-Chemical 0 0.9328303
- I-Chemical 0 0.9739754
aminobutyric I-Chemical 0 0.99998784
acid I-Chemical 0 0.9992993
( O 0 0.19654608
GABA B-Chemical 0 0.999987
( O 0 0.0017496536
A O 0 0.059975084
) O 0 0.0010577182
) O 0 0.00055246596
receptor O 0 0.00030256176
against O 0 5.219385e-05
the O 0 7.893116e-05
increase O 0 8.692002e-05
in O 0 8.001113e-05
sensitivity O 0 0.00015511662
to O 0 8.604421e-05
the O 0 0.00010787722
convulsant O 0 0.9497958
effects O 0 0.00014136995
of O 0 0.00028759567
cocaine B-Chemical 0 0.9998332
engendered O 0 0.00033840176
by O 0 0.00014302005
repeated O 0 0.0001448001
cocaine B-Chemical 0 0.99890435
administration O 0 0.0010872371
( O 0 0.001445397
seizure B-Disease 0 0.9990814
kindling O 0 0.8557761
) O 0 0.003604252
. O 0 0.0025230548

Allopregnanolone B-Chemical 0 0.9992392
( O 0 0.07836986
3alpha B-Chemical 0 0.9972869
- I-Chemical 0 0.9033768
hydroxy I-Chemical 0 0.9998306
- I-Chemical 0 0.70603
5alpha I-Chemical 0 0.9582751
- I-Chemical 0 0.1263261
pregnan I-Chemical 0 0.37139082
- I-Chemical 0 0.004685895
20 I-Chemical 0 0.0004029052
- I-Chemical 0 0.0011908658
one I-Chemical 0 0.00024270167
) O 0 0.0008639168
, O 0 0.0014370208
pregnanolone B-Chemical 0 0.9999747
( O 0 0.016701618
3alpha B-Chemical 0 0.99781203
- I-Chemical 0 0.76814514
hydroxy I-Chemical 0 0.9999416
- I-Chemical 0 0.5627694
5beta I-Chemical 0 0.99249965
- I-Chemical 0 0.1271703
pregnan I-Chemical 0 0.36310357
- I-Chemical 0 0.0035016793
20 I-Chemical 0 0.00019730389
- I-Chemical 0 0.0007368855
one I-Chemical 0 0.00011665363
) O 0 0.00037494858
and O 0 0.00024105827
ganaxolone B-Chemical 0 0.9992292
( O 0 0.0004954098
a O 0 0.00023617475
synthetic O 0 0.00016372176
derivative O 0 0.002693398
of O 0 0.0018097458
allopregnanolone B-Chemical 0 0.9999993
3alpha B-Chemical 0 0.9999263
- I-Chemical 0 0.98660684
hydroxy I-Chemical 0 0.99998295
- I-Chemical 0 0.9221513
3beta I-Chemical 0 0.46781096
- I-Chemical 0 0.25296658
methyl I-Chemical 0 0.99422944
- I-Chemical 0 0.22607182
5alpha I-Chemical 0 0.89407027
- I-Chemical 0 0.08413936
pregnan I-Chemical 0 0.3643102
- I-Chemical 0 0.0038828496
20 I-Chemical 0 0.0001769178
- I-Chemical 0 0.000726984
one I-Chemical 0 9.8216595e-05
) O 0 0.00024942984
were O 0 7.551195e-05
tested O 0 6.8835696e-05
for O 0 6.139604e-05
their O 0 7.2947216e-05
ability O 0 7.81816e-05
to O 0 7.844178e-05
suppress O 0 5.9892558e-05
the O 0 8.319505e-05
expression O 0 0.00011580874
( O 0 0.00047094136
anticonvulsant O 0 0.98588437
effect O 0 0.00012401456
) O 0 0.0004527349
and O 0 0.00013915665
development O 0 0.0002039455
( O 0 0.00036166483
antiepileptogenic O 0 0.12005174
effect O 0 0.00013514914
) O 0 0.0006327661
of O 0 0.00041805237
cocaine B-Chemical 0 0.99994457
- O 0 0.28596216
kindled O 0 0.99700457
seizures B-Disease 0 0.99996567
in O 0 0.0003259637
male O 0 0.00078027963
, O 0 0.0007618172
Swiss O 0 0.0008538361
- O 0 0.0026377786
Webster O 0 0.0024430533
mice O 0 0.0006733092
. O 0 0.0025743344

Kindled O 0 0.99873966
seizures B-Disease 0 0.99985147
were O 0 0.0014798611
induced O 0 0.0007198265
by O 0 0.0005166097
daily O 0 0.0005080309
administration O 0 0.00048078966
of O 0 0.0003398599
60 O 0 0.00042526063
mg O 0 0.0025716897
/ O 0 0.0014797095
kg O 0 0.0016486327
cocaine B-Chemical 0 0.99195474
for O 0 0.0005929973
5 O 0 0.0007774205
days O 0 0.0008234556
. O 0 0.0024940667

All O 0 0.0024854182
of O 0 0.002283935
these O 0 0.0017999389
positive O 0 0.0032096133
GABA B-Chemical 0 0.9998765
( O 0 0.004300237
A O 0 0.045320593
) O 0 0.001472296
modulators O 0 0.00044281344
suppressed O 0 0.000345711
the O 0 0.00020935285
expression O 0 0.00021993912
of O 0 0.00052590226
kindled O 0 0.998755
seizures B-Disease 0 0.99999
, O 0 0.00093903975
whereas O 0 0.0002814388
only O 0 0.00063321134
allopregnanolone B-Chemical 0 0.99999475
and O 0 0.0016236634
ganaxolone B-Chemical 0 0.99985945
inhibited O 0 0.0010359797
the O 0 0.00042235808
development O 0 0.0008362146
of O 0 0.0013528268
kindling O 0 0.82515293
. O 0 0.0030487638

Allopregnanolone B-Chemical 0 0.9992429
and O 0 0.011770968
pregnanolone B-Chemical 0 0.9999385
, O 0 0.006646365
but O 0 0.0014590893
not O 0 0.00094887894
ganaxolone B-Chemical 0 0.9993505
, O 0 0.0013259716
also O 0 0.0004068579
reduced O 0 0.00053355016
cumulative O 0 0.00062285207
lethality O 0 0.0037127482
associated O 0 0.0009410098
with O 0 0.0015552155
kindling O 0 0.7868402
. O 0 0.0035500675

These O 0 0.0016293033
findings O 0 0.0013801699
demonstrate O 0 0.0004983257
that O 0 0.0005624059
some O 0 0.0007755502
neuroactive O 0 0.41698194
steroids B-Chemical 0 0.99964
attenuate O 0 0.0016820286
convulsant O 0 0.99822074
and O 0 0.00023237952
sensitizing O 0 0.00024557262
properties O 0 8.5496875e-05
of O 0 0.00022477483
cocaine B-Chemical 0 0.9997534
and O 0 0.00016419015
add O 0 0.000109264285
to O 0 8.4656625e-05
a O 0 0.00014202092
growing O 0 0.00011063259
literature O 0 0.00019372083
on O 0 5.4480686e-05
their O 0 6.581837e-05
potential O 0 6.6868815e-05
use O 0 8.374721e-05
in O 0 9.1722955e-05
the O 0 8.579873e-05
modulation O 0 9.5701675e-05
of O 0 0.00017189166
effects O 0 0.00024716026
of O 0 0.0005370286
drugs O 0 0.04574301
of O 0 0.0017631172
abuse O 0 0.9854468
. O 0 0.003966105

Effect O 0 0.0028164873
of O 0 0.0024393732
humoral O 0 0.008580041
modulators O 0 0.0018075369
of O 0 0.0021112042
morphine B-Chemical 0 0.9998565
- O 0 0.018671013
induced O 0 0.00055011065
increase B-Disease 0 0.0005008896
in I-Disease 0 0.00057294563
locomotor I-Disease 0 0.0034076367
activity I-Disease 0 0.00048147113
of O 0 0.00090004737
mice O 0 0.0007605127
. O 0 0.0028490624

The O 0 0.0017170182
effect O 0 0.0012653031
of O 0 0.0013632727
humoral O 0 0.005352996
modulators O 0 0.00083111547
on O 0 0.00039251446
the O 0 0.0005753238
morphine B-Chemical 0 0.999826
- O 0 0.0073981727
induced O 0 0.00028673705
increase B-Disease 0 0.0002718644
in I-Disease 0 0.00030583754
locomotor I-Disease 0 0.0021922553
activity I-Disease 0 0.00021438856
of O 0 0.00035683878
mice O 0 0.00024017731
was O 0 0.0007595815
studied O 0 0.001978806
. O 0 0.0030316778

The O 0 0.0019861707
subcutaneous O 0 0.0027538051
administration O 0 0.0013213312
of O 0 0.00073106325
10 O 0 0.0006133199
mg O 0 0.0028659988
/ O 0 0.0012677562
kg O 0 0.0009294194
of O 0 0.0006822118
morphine B-Chemical 0 0.99986696
- O 0 0.29208428
HC1 O 0 0.9993136
produced O 0 0.00034883234
a O 0 0.0004913503
marked O 0 0.00044145843
increase B-Disease 0 0.00030432444
in I-Disease 0 0.0003864659
locomotor I-Disease 0 0.0029555634
activity I-Disease 0 0.00037232204
in O 0 0.00061338267
mice O 0 0.00059790834
. O 0 0.0023930622

The O 0 0.003938947
morphine B-Chemical 0 0.9991683
- O 0 0.052747555
induced O 0 0.0027787993
hyperactivity B-Disease 2 0.9999851
was O 0 0.0015596651
potentiated O 0 0.016935114
by O 0 0.0017767883
scopolamine B-Chemical 0 0.9999939
and O 0 0.0016454956
attenuated O 0 0.0021871855
by O 0 0.002680567
physostigmine B-Chemical 0 0.999889
. O 0 0.0055916985

In O 0 0.0019331347
contrast O 0 0.0023693473
, O 0 0.002459172
both O 0 0.0013480432
methscopolamine B-Chemical 0 0.9998524
and O 0 0.00281088
neostigmine B-Chemical 0 0.9999684
, O 0 0.0014953939
which O 0 0.0003937651
do O 0 0.00024494174
not O 0 0.00021064654
penetrate O 0 0.00047400207
the O 0 0.00017974174
blood O 0 0.008667926
- O 0 0.004843375
brain O 0 0.0009383824
barrier O 0 0.00079074077
, O 0 0.000309098
had O 0 0.00013156551
no O 0 0.00011399144
effect O 0 0.00014941751
on O 0 0.00019717694
the O 0 0.00049568573
hyperactivity B-Disease 2 0.9999883
produced O 0 0.0009466899
by O 0 0.001647758
morphine B-Chemical 0 0.9994305
. O 0 0.0036782066

Pretreatment O 0 0.017211374
of O 0 0.0022324563
mice O 0 0.0008287714
with O 0 0.0019161927
alpha B-Chemical 0 0.9796664
- I-Chemical 0 0.16530912
methyltyrosine I-Chemical 0 0.87022746
( O 0 0.0010870239
20 O 0 0.0004047056
mg O 0 0.002066519
/ O 0 0.00081547984
kg O 0 0.0005138223
i O 0 0.00036595666
. O 0 0.0001818625
p O 0 0.0003051577
. O 0 0.00017150235
, O 0 0.00026115344
one O 0 0.00014256257
hour O 0 0.00020968646
) O 0 0.00045019624
, O 0 0.00036631862
an O 0 0.00027455908
inhibitor O 0 0.0012256685
of O 0 0.0010159352
tyrosine B-Chemical 0 0.90314525
hydroxylase O 0 0.9440543
, O 0 0.0005888217
significantly O 0 0.00025373558
decreased O 0 0.00033070776
the O 0 0.00015165658
activity O 0 0.00017686938
- O 0 0.0011831467
increasing O 0 0.00030304707
effects O 0 0.00054658897
of O 0 0.0017187266
morphine B-Chemical 0 0.99955636
. O 0 0.0037658587

On O 0 0.003030921
the O 0 0.0016617371
other O 0 0.0012479265
hand O 0 0.0016676687
, O 0 0.0022062527
pretreatment O 0 0.0035757092
with O 0 0.00073860516
p B-Chemical 0 0.0022838265
- I-Chemical 0 0.0030481014
chlorophenylalamine I-Chemical 0 0.0010803466
( O 0 0.0007207782
3 O 0 0.0003411374
X O 0 0.052125238
320 O 0 0.0011659876
mg O 0 0.0027175946
/ O 0 0.0007276987
kg O 0 0.00044634874
i O 0 0.00032348675
. O 0 0.00016335389
p O 0 0.00028205718
. O 0 0.00016270057
, O 0 0.000269871
24 O 0 0.00017800851
hr O 0 0.0003102444
) O 0 0.00055610714
, O 0 0.0005932387
a O 0 0.0013707998
serotonin B-Chemical 0 0.99996114
depletor O 0 0.9998479
, O 0 0.0011524848
caused O 0 0.00027080197
no O 0 0.0002488284
significant O 0 0.00034638285
change O 0 0.00043970795
in O 0 0.00060419436
the O 0 0.0012820073
hyperactivity B-Disease 2 0.9999583
. O 0 0.004769619

The O 0 0.0019421987
study O 0 0.0016259754
suggests O 0 0.0005832012
that O 0 0.00047126986
the O 0 0.0004031784
activity O 0 0.00032782488
- O 0 0.0014196073
increasing O 0 0.00021075823
effects O 0 0.00022568966
of O 0 0.0004456315
morphine B-Chemical 0 0.99973243
are O 0 0.00014592754
mediated O 0 8.2604216e-05
by O 0 0.00013821757
the O 0 0.00015864497
release O 0 0.00054655725
of O 0 0.0005679715
catecholamines B-Chemical 0 0.99987936
from O 0 0.00054981816
adrenergic O 0 0.84722394
neurons O 0 0.0004884078
in O 0 0.0004550508
the O 0 0.0007148569
brain O 0 0.003691276
. O 0 0.0025966119

And O 0 0.006559754
the O 0 0.0015598463
results O 0 0.00095074496
are O 0 0.0005944275
consistent O 0 0.00040996145
with O 0 0.00038525293
the O 0 0.0002467346
hypothesis O 0 0.00027452037
that O 0 0.0003227456
morphine B-Chemical 0 0.99964225
acts O 0 0.00026286335
by O 0 0.0002992732
retarding O 0 0.027531182
the O 0 0.0003002623
release O 0 0.000941129
of O 0 0.00070556556
acetylcholine B-Chemical 1 0.99943894
at O 0 0.0003018985
some O 0 0.00046114647
central O 0 0.0011637837
cholinergic O 0 0.011455645
synapses O 0 0.0024443422
. O 0 0.0025740345

It O 0 0.0047598872
is O 0 0.0014259319
also O 0 0.00090826245
suggested O 0 0.00054977654
from O 0 0.00040604998
collected O 0 0.000284003
evidence O 0 0.00018594525
that O 0 0.0001518396
the O 0 0.0001527031
activity O 0 0.00014678246
- O 0 0.00086790574
increasing O 0 0.00011725037
effects O 0 0.000135296
of O 0 0.00029479124
morphine B-Chemical 0 0.99979085
in O 0 0.00010195044
mice O 0 3.2081727e-05
are O 0 4.838706e-05
mediated O 0 3.8109138e-05
by O 0 6.0979764e-05
mechanisms O 0 5.5924163e-05
different O 0 6.412143e-05
from O 0 8.41689e-05
those O 0 0.000110780915
which O 0 9.713245e-05
mediate O 0 5.2521435e-05
the O 0 8.9639245e-05
activity O 0 0.000115704206
- O 0 0.0008582093
increasing O 0 0.00017482448
effects O 0 0.00027823698
of O 0 0.0007758264
morphine B-Chemical 0 0.99961025
in O 0 0.0009931617
rats O 0 0.0020987103
. O 0 0.0023764116

Effects O 0 0.003316849
of O 0 0.0024560203
uninephrectomy O 0 0.22483698
and O 0 0.00096862635
high O 0 0.00075454015
protein O 0 0.0005626756
feeding O 0 0.00081182184
on O 0 0.0005015635
lithium B-Chemical 0 0.99987364
- O 0 0.011970801
induced O 0 0.0005867425
chronic B-Disease 0 0.50429827
renal I-Disease 0 0.9656126
failure I-Disease 0 0.31190032
in O 0 0.0010341767
rats O 0 0.0022756117
. O 0 0.0027144894

Rats O 0 0.009002513
with O 0 0.004711249
lithium B-Chemical 0 0.9996737
- O 0 0.039690875
induced O 0 0.0016418523
nephropathy B-Disease 0 0.9999696
were O 0 0.00045705726
subjected O 0 0.00018446433
to O 0 0.00017486267
high O 0 0.00026930295
protein O 0 0.00028902362
( O 0 0.0006371554
HP O 0 0.011267741
) O 0 0.0006089473
feeding O 0 0.00037379525
, O 0 0.0005425417
uninephrectomy O 0 0.4107944
( O 0 0.0011001576
NX O 0 0.99875
) O 0 0.00053949765
or O 0 0.00011304493
a O 0 0.00016573981
combination O 0 0.00015046465
of O 0 0.00014959057
these O 0 0.00015352432
, O 0 0.00030852537
in O 0 0.00013859027
an O 0 0.00015766821
attempt O 0 0.00015558783
to O 0 0.0001266381
induce O 0 0.00018627495
glomerular O 0 0.9993648
hyperfiltration O 0 0.99992657
and O 0 0.00035796946
further O 0 0.00025078264
progression O 0 0.0014873898
of O 0 0.0008025649
renal B-Disease 0 0.90682596
failure I-Disease 0 0.1281297
. O 0 0.0028236115

Newborn O 0 0.007950433
female O 0 0.0040510893
Wistar O 0 0.0042139553
rats O 0 0.0013276929
were O 0 0.0006063123
fed O 0 0.0011908953
a O 0 0.0013663996
lithium B-Chemical 0 0.999782
- O 0 0.004033077
containing O 0 0.0002746937
diet O 0 0.001975697
( O 0 0.000548313
50 O 0 0.00037220208
mmol O 0 0.098858215
/ O 0 0.0010229738
kg O 0 0.0004960966
) O 0 0.00028952915
for O 0 7.513398e-05
8 O 0 7.66466e-05
weeks O 0 4.6962956e-05
and O 0 9.056268e-05
then O 0 0.00010139103
randomized O 0 0.00030137048
to O 0 0.00011003656
normal O 0 0.0002758106
diet O 0 0.0013931167
, O 0 0.0004999695
HP O 0 0.009626716
diet O 0 0.0020015293
( O 0 0.00034333518
40 O 0 0.00016945727
vs O 0 0.00022018714
. O 0 0.0001609649
19 O 0 0.00024881275
% O 0 0.00043929883
) O 0 0.0007248465
, O 0 0.0009528034
NX O 0 0.9960349
or O 0 0.00052353635
HP O 0 0.053070903
+ O 0 0.0065133814
NX O 0 0.99672264
for O 0 0.00046492065
another O 0 0.00072819536
8 O 0 0.00069494854
weeks O 0 0.00068745855
. O 0 0.0022858253

Corresponding O 0 0.007647267
non O 0 0.007920402
- O 0 0.0659823
lithium B-Chemical 0 0.9990269
pretreated O 0 0.0143365385
groups O 0 0.0034806083
were O 0 0.0025679106
generated O 0 0.0022218407
. O 0 0.005927702

When O 0 0.0015195598
comparing O 0 0.0010084425
all O 0 0.0013903573
lithium B-Chemical 0 0.9988274
treated O 0 0.0012796017
versus O 0 0.0004539984
non O 0 0.0009427646
- O 0 0.03844826
lithium B-Chemical 0 0.9998863
- O 0 0.006671835
treated O 0 0.0005392812
groups O 0 0.0004168645
, O 0 0.001137417
lithium B-Chemical 0 0.9998796
caused O 0 0.00024304277
a O 0 0.0002858434
reduction O 0 0.00023104755
in O 0 0.00020692358
glomerular O 0 0.99461997
filtration O 0 0.027058128
rate O 0 0.00028635157
( O 0 0.00050627865
GFR O 0 0.99962974
) O 0 0.00042904442
without O 0 9.587157e-05
significant O 0 9.3037976e-05
changes O 0 0.000103268016
in O 0 8.9640955e-05
effective O 0 0.0001320702
renal O 0 0.7230578
plasma O 0 0.015851876
flow O 0 0.0021572893
( O 0 0.00026201815
as O 0 9.915216e-05
determined O 0 9.10634e-05
by O 0 0.00012221783
a O 0 0.00022228852
marker O 0 0.00021052806
secreted O 0 0.00018704936
into O 0 0.000116948104
the O 0 0.00018898782
proximal O 0 0.0007585092
tubules O 0 0.0091702165
) O 0 0.0017382776
or O 0 0.0009566438
lithium B-Chemical 0 0.9996087
clearance O 0 0.03662274
. O 0 0.0033054652

Consequently O 0 0.0037575888
, O 0 0.011557867
lithium B-Chemical 0 0.9997124
pretreatment O 0 0.036937084
caused O 0 0.0010779102
a O 0 0.0011024564
fall O 0 0.0009915781
in O 0 0.00041029847
filtration O 0 0.0030646753
fraction O 0 0.00035885855
and O 0 0.00037599824
an O 0 0.00042549436
increase O 0 0.00042625438
in O 0 0.00068183255
fractional O 0 0.008971837
Li B-Chemical 0 0.30254823
excretion O 0 0.9539861
. O 0 0.005026861

Lithium B-Chemical 0 0.9995629
also O 0 0.003398784
caused O 0 0.0029063963
proteinuria B-Disease 0 0.99969065
and O 0 0.00198736
systolic O 0 0.8796384
hypertension B-Disease 2 0.99994123
in O 0 0.0013405125
absence O 0 0.0010803116
of O 0 0.003610048
glomerulosclerosis B-Disease 0 0.99992275
. O 0 0.007266399

HP O 0 0.039370973
failed O 0 0.002241619
to O 0 0.0010779251
accentuante O 0 0.0016219227
progression O 0 0.0023969498
of O 0 0.0007696721
renal B-Disease 0 0.7802775
failure I-Disease 0 0.02096289
and O 0 0.00028170782
in O 0 0.00017084443
fact O 0 0.000118243704
tended O 0 0.00019267047
to O 0 0.00013851786
increase O 0 0.00022688581
GFR O 0 0.99903023
and O 0 0.00027355994
decrease O 0 0.00032956156
plasma O 0 0.03503617
creatinine B-Chemical 0 0.9925021
levels O 0 0.00036574304
in O 0 0.00065253134
lithium B-Chemical 0 0.9997187
pretreated O 0 0.012554037
rats O 0 0.0029558332
. O 0 0.0028274944

NX O 0 0.9956251
caused O 0 0.0032951226
an O 0 0.002030104
additive O 0 0.0028614523
deterioration O 0 0.026031
in O 0 0.0012528738
GFR O 0 0.99919945
which O 0 0.0010235556
, O 0 0.0011311662
however O 0 0.00084215833
, O 0 0.0014044464
was O 0 0.0010225207
ameliorated O 0 0.019682996
by O 0 0.002578308
HP O 0 0.079188325
. O 0 0.0049782107

NX O 0 0.9964025
+ O 0 0.046157986
HP O 0 0.08739453
caused O 0 0.0016849971
a O 0 0.0014193389
further O 0 0.00064735045
rise O 0 0.0007625144
in O 0 0.0006008089
blood O 0 0.0037314063
pressure O 0 0.008748175
in O 0 0.0009839762
Li B-Chemical 0 0.027466869
- O 0 0.008159181
pretreated O 0 0.0055748373
rats O 0 0.003954058
. O 0 0.004210345

The O 0 0.0019278629
results O 0 0.0013693006
indicate O 0 0.0007813121
that O 0 0.0010599606
Li B-Chemical 0 0.07923823
- O 0 0.0182957
induced O 0 0.0014499394
nephropathy B-Disease 0 0.99998987
, O 0 0.0017012696
even O 0 0.00036057387
when O 0 0.00017302828
the O 0 0.00026777497
GFR O 0 0.99946934
is O 0 0.00019167953
only O 0 0.00021224323
modestly O 0 0.00075972156
reduced O 0 0.00030805802
, O 0 0.00042599707
is O 0 0.00015883768
associated O 0 0.00023744594
with O 0 0.00043254363
proteinuria B-Disease 0 0.9999156
and O 0 0.0007195584
arterial O 0 0.7348346
systolic O 0 0.95350003
hypertension B-Disease 2 0.9999331
. O 0 0.0038001016

In O 0 0.0018571243
this O 0 0.0014955578
model O 0 0.0009327337
of O 0 0.0010831273
chronic B-Disease 0 0.37677082
renal I-Disease 0 0.9515826
failure I-Disease 0 0.2648225
the O 0 0.0002629318
decline O 0 0.0006959906
in O 0 0.0003083698
GFR O 0 0.99955827
is O 0 0.00017000154
not O 0 0.00013596968
accompanied O 0 0.00023382706
by O 0 0.00012900234
a O 0 0.00017760164
corresponding O 0 7.359043e-05
fall O 0 0.00021625291
in O 0 9.759164e-05
effective O 0 0.00014153967
renal O 0 0.7627416
plasma O 0 0.028070688
flow O 0 0.004215364
, O 0 0.0003441247
which O 0 0.00015281889
may O 0 9.113124e-05
be O 0 9.366878e-05
the O 0 8.222086e-05
functional O 0 0.000101995654
expression O 0 0.00013402109
of O 0 0.00022816293
the O 0 0.00022704489
formation O 0 0.0005355743
of O 0 0.000556612
nonfiltrating O 0 0.002137794
atubular O 0 0.78779787
glomeruli O 0 0.09414578
. O 0 0.0033057325

The O 0 0.0028111392
fractional O 0 0.012596769
reabsorption O 0 0.8044568
of O 0 0.0020171066
tubular O 0 0.6710046
fluid O 0 0.003018832
by O 0 0.00042162335
the O 0 0.00030561804
proximal O 0 0.0007955825
tubules O 0 0.0034147254
is O 0 0.00025465316
reduced O 0 0.0003465933
, O 0 0.00051486655
leaving O 0 0.0003010796
the O 0 0.00019746066
distal O 0 0.0004587119
delivery O 0 0.0002709569
unchanged O 0 0.0004651423
. O 0 0.00046566583
( O 0 0.001047915
ABSTRACT O 0 0.0058726994
TRUNCATED O 0 0.014621522
AT O 0 0.012967846
250 O 0 0.0060119675
WORDS O 0 0.027800636
) O 0 0.017457979

Treatment O 0 0.008551257
of O 0 0.0038620387
Crohn B-Disease 0 0.8258567
' I-Disease 0 0.0029621103
s I-Disease 0 0.0023219727
disease I-Disease 0 0.69356114
with O 0 0.004391175
fusidic B-Chemical 0 0.9999901
acid I-Chemical 0 0.9830225
: O 0 0.0019898857
an O 0 0.0003752956
antibiotic O 0 0.00097488967
with O 0 0.00031388446
immunosuppressive O 0 0.0029605445
properties O 0 0.0002620134
similar O 0 0.0004112353
to O 0 0.0012572093
cyclosporin B-Chemical 0 0.99991536
. O 0 0.0053627645

Fusidic O 0 0.9999138
acid O 0 0.99396694
is O 0 0.0021376223
an O 0 0.0013989992
antibiotic O 0 0.0029612123
with O 0 0.0008246004
T O 0 0.01587126
- O 0 0.0036933005
cell O 0 0.0005001926
specific O 0 0.00020530655
immunosuppressive O 0 0.0022610703
effects O 0 0.00026915257
similar O 0 0.00024645243
to O 0 0.00039569606
those O 0 0.0008302163
of O 0 0.0020599677
cyclosporin B-Chemical 0 0.99992454
. O 0 0.0058573973

Because O 0 0.0019060475
of O 0 0.001861393
the O 0 0.0009771115
need O 0 0.0006383093
for O 0 0.0004139902
the O 0 0.00034601465
development O 0 0.00038549432
of O 0 0.00028726846
new O 0 0.0002818282
treatments O 0 0.00029658104
for O 0 0.00023958954
Crohn B-Disease 0 0.73268896
' I-Disease 0 0.00053409534
s I-Disease 0 0.00045548583
disease I-Disease 0 0.11839799
, O 0 0.00035016093
a O 0 0.00021448261
pilot O 0 0.00022612457
study O 0 0.0001301987
was O 0 7.9048215e-05
undertaken O 0 7.230327e-05
to O 0 5.2926986e-05
estimate O 0 4.5332286e-05
the O 0 6.586388e-05
pharmacodynamics O 0 0.0017213041
and O 0 0.00010005657
tolerability O 0 0.0006300227
of O 0 0.00060289056
fusidic B-Chemical 0 0.99999607
acid I-Chemical 0 0.96926326
treatment O 0 0.00034241745
in O 0 0.0001959486
chronic O 0 0.005743961
active O 0 0.00030714984
, O 0 0.00054372405
therapy O 0 0.000625812
- O 0 0.00208961
resistant O 0 0.001082005
patients O 0 0.002675478
. O 0 0.0026116895

Eight O 0 0.011438854
Crohn B-Disease 0 0.609108
' I-Disease 0 0.0068450742
s I-Disease 0 0.005186019
disease I-Disease 0 0.11310858
patients O 0 0.004444905
were O 0 0.0025741276
included O 0 0.0032823868
. O 0 0.005995878

Fusidic B-Chemical 0 0.99991906
acid I-Chemical 0 0.99251187
was O 0 0.0019920832
administered O 0 0.0015422639
orally O 0 0.00113539
in O 0 0.0003292211
a O 0 0.0003860202
dose O 0 0.00038757088
of O 0 0.0002693944
500 O 0 0.0006645879
mg O 0 0.004608231
t O 0 0.000963261
. O 0 0.0001784788
d O 0 0.00025475147
. O 0 0.0001754852
s O 0 0.00025193798
. O 0 0.00015995174
and O 0 0.00016250736
the O 0 0.00015118878
treatment O 0 0.00021264552
was O 0 0.00022181023
planned O 0 0.00033049125
to O 0 0.00025384518
last O 0 0.00025187028
8 O 0 0.0005602599
weeks O 0 0.0006303921
. O 0 0.0021899107

The O 0 0.0031205262
disease O 0 0.07355879
activity O 0 0.0011800796
was O 0 0.00096264714
primarily O 0 0.0007772405
measured O 0 0.000777689
by O 0 0.00067902793
a O 0 0.0009755544
modified O 0 0.0006992755
individual O 0 0.0007310336
grading O 0 0.0020947473
score O 0 0.0019361058
. O 0 0.0036300956

Five O 0 0.003844711
of O 0 0.002347717
8 O 0 0.0015557396
patients O 0 0.0018465951
( O 0 0.0014331839
63 O 0 0.0010733912
% O 0 0.0011317472
) O 0 0.0011520052
improved O 0 0.0008975292
during O 0 0.0008606541
fusidic B-Chemical 0 0.9999815
acid I-Chemical 0 0.9371982
treatment O 0 0.0005811673
: O 0 0.00053687557
3 O 0 0.00014163308
at O 0 9.441885e-05
two O 0 9.038014e-05
weeks O 0 0.0001047058
and O 0 0.00023658315
2 O 0 0.00031804078
after O 0 0.00022334883
four O 0 0.00037509014
weeks O 0 0.00067689386
. O 0 0.0023918129

There O 0 0.003162613
were O 0 0.001588594
no O 0 0.0010585701
serious O 0 0.0019540037
clinical O 0 0.0016998716
side O 0 0.0012316813
effects O 0 0.00044876884
, O 0 0.0007785199
but O 0 0.00037087736
dose O 0 0.000457457
reduction O 0 0.00026943986
was O 0 0.0001659587
required O 0 0.00010288389
in O 0 0.00018462271
two O 0 0.00018302018
patients O 0 0.0006132498
because O 0 0.00043367487
of O 0 0.001518112
nausea B-Disease 0 0.9976884
. O 0 0.00392941

Biochemically O 0 0.016731057
, O 0 0.0049488754
an O 0 0.0019536242
increase O 0 0.0012143563
in O 0 0.0013306488
alkaline O 0 0.2768904
phosphatases O 0 0.005055197
was O 0 0.00046990707
noted O 0 0.0003602588
in O 0 0.0002585245
5 O 0 0.00020781273
of O 0 0.00020581027
8 O 0 0.00019526448
cases O 0 0.0003253822
( O 0 0.0003523514
63 O 0 0.00031398862
% O 0 0.00039802789
) O 0 0.00046183472
, O 0 0.00029667807
and O 0 0.00015660022
the O 0 0.00011709396
greatest O 0 0.00021809062
increases O 0 0.00016139953
were O 0 0.00013063844
seen O 0 0.00013888569
in O 0 0.00012483656
those O 0 0.00018151221
who O 0 0.00025448983
had O 0 0.00020618465
elevated O 0 0.00079290016
levels O 0 0.00027906988
prior O 0 0.00024847707
to O 0 0.0005597437
treatment O 0 0.0011971837
. O 0 0.0023895553

All O 0 0.0028960756
reversed O 0 0.003198338
to O 0 0.0015604679
pre O 0 0.0024918625
- O 0 0.003866218
treatment O 0 0.0008355073
levels O 0 0.0006462129
after O 0 0.00052571064
cessation O 0 0.001035395
of O 0 0.0016509206
treatment O 0 0.0025250681
. O 0 0.0044860654

The O 0 0.00186959
results O 0 0.0013660084
of O 0 0.0012347738
this O 0 0.0009229027
pilot O 0 0.001067886
study O 0 0.00060702756
suggest O 0 0.000314304
that O 0 0.0009945087
fusidic B-Chemical 0 0.999995
acid I-Chemical 0 0.993735
may O 0 0.00031998908
be O 0 0.00016233222
of O 0 0.0001368072
benefit O 0 0.00012735429
in O 0 9.8023855e-05
selected O 0 0.00010323572
chronic O 0 0.0020960416
active O 0 0.0003163844
Crohn B-Disease 0 0.8613879
' I-Disease 0 0.00042807823
s I-Disease 0 0.00038385988
disease I-Disease 0 0.14274855
patients O 0 0.0004085028
in O 0 0.00016156334
whom O 0 0.00031572845
conventional O 0 0.00024195676
treatment O 0 0.0003897716
is O 0 0.0006053567
ineffective O 0 0.002834982
. O 0 0.0029786695

Because O 0 0.001916874
there O 0 0.0014889266
seems O 0 0.00093576824
to O 0 0.00066509226
exist O 0 0.00050286495
a O 0 0.00061279687
scientific O 0 0.0006739762
rationale O 0 0.00027419915
for O 0 0.00017977774
the O 0 0.00018198237
use O 0 0.00024751894
of O 0 0.001149415
fusidic B-Chemical 0 0.9999949
acid I-Chemical 0 0.95251346
at O 0 0.00017755083
the O 0 0.00013698553
cytokine O 0 0.0018123481
level O 0 0.00012484309
in O 0 0.00018471251
inflammatory B-Disease 0 0.4878997
bowel I-Disease 0 0.4695752
disease I-Disease 0 0.8660183
, O 0 0.00023186454
we O 0 4.941755e-05
suggest O 0 5.386757e-05
that O 0 7.6394994e-05
the O 0 8.995864e-05
role O 0 6.911926e-05
of O 0 0.00019836646
this O 0 0.00024899788
treatment O 0 0.00025556554
should O 0 0.00018030268
be O 0 0.0003775512
further O 0 0.0005537796
investigated O 0 0.0013181978
. O 0 0.0028450312

Changes O 0 0.005506868
in O 0 0.0050823754
depressive B-Disease 2 0.9996669
status O 0 0.0020398519
associated O 0 0.0016464298
with O 0 0.0019870687
topical O 0 0.66219854
beta O 0 0.9319903
- O 0 0.21829055
blockers O 0 0.98114175
. O 0 0.0079167355

Depression B-Disease 0 0.9974769
and O 0 0.004187798
sexual B-Disease 0 0.36357796
dysfunction I-Disease 0 0.99432737
have O 0 0.00090534944
been O 0 0.00051039946
related O 0 0.00027607023
to O 0 0.00031300916
side O 0 0.00078343204
effects O 0 0.00047902475
of O 0 0.0009526019
topical O 0 0.78826004
beta O 0 0.9522303
- O 0 0.23143195
blockers O 0 0.981444
. O 0 0.0052591255

We O 0 0.0022951523
performed O 0 0.0014435096
a O 0 0.0013843713
preliminary O 0 0.0008308229
study O 0 0.00065789913
in O 0 0.00034638663
order O 0 0.00019221906
to O 0 0.00015924287
determine O 0 6.446065e-05
any O 0 0.00010820483
difference O 0 9.689266e-05
between O 0 0.00010337481
a O 0 0.00022997656
non O 0 0.00028946454
selective O 0 0.00042840076
beta O 0 0.86275965
- O 0 0.12497361
blocker O 0 0.8575751
( O 0 0.005375022
timolol B-Chemical 0 0.99999845
) O 0 0.0010264032
and O 0 0.00017705685
a O 0 0.00025982826
selective O 0 0.0004019921
beta O 0 0.8227224
- O 0 0.10341397
blocker O 0 0.8447662
( O 0 0.005226528
betaxolol B-Chemical 0 0.9999976
) O 0 0.0019716986
regarding O 0 0.0003235796
CNS O 0 0.0044530258
side O 0 0.0017432433
effects O 0 0.001564265
. O 0 0.0031413322

Eight O 0 0.00790058
glaucomatous B-Disease 0 0.9997725
patients O 0 0.0054166936
chronically O 0 0.0057172454
treated O 0 0.0017105539
with O 0 0.0014060629
timolol B-Chemical 0 0.99999404
0 O 0 0.0007390036
. O 0 0.0002613652
5 O 0 0.00020334941
% O 0 0.00043826795
/ O 0 0.0013448609
12h O 0 0.0040277424
, O 0 0.0006038725
suffering O 0 0.0046980805
from O 0 0.0003078217
depression B-Disease 0 0.9993063
diagnosed O 0 0.0040550507
through O 0 0.00038944976
DMS O 0 0.9988341
- O 0 0.04188794
III O 0 0.2806284
- O 0 0.017292688
R O 0 0.9708948
criteria O 0 0.0004938464
, O 0 0.0005617542
were O 0 0.00030115567
included O 0 0.0003486179
in O 0 0.0004988634
the O 0 0.00075995945
study O 0 0.001771904
. O 0 0.0028892194

During O 0 0.0019367168
the O 0 0.0013391802
six O 0 0.0007906021
- O 0 0.0024054616
month O 0 0.00037750634
follow O 0 0.0003146221
up O 0 0.00052183145
, O 0 0.001139515
depression B-Disease 0 0.993612
was O 0 0.00033491178
quantified O 0 0.00026980616
through O 0 0.0002131957
the O 0 0.0002617809
Beck O 0 0.0018897651
and O 0 0.00048613673
Zung O 0 0.0051429938
- O 0 0.0020537397
Conde O 0 0.001980483
scales O 0 0.00057984213
every O 0 0.0003440372
two O 0 0.0005208887
months O 0 0.00082011026
. O 0 0.0027611766

In O 0 0.0022019886
a O 0 0.0025631897
double O 0 0.0014190773
blind O 0 0.023419704
cross O 0 0.0014177016
- O 0 0.002306659
over O 0 0.00026285258
study O 0 0.00025914962
with O 0 0.000200728
control O 0 0.0002053516
group O 0 0.0003055924
, O 0 0.00029650668
the O 0 0.000118033946
patients O 0 0.0002898252
under O 0 0.00017921018
timolol B-Chemical 0 0.99999547
treatment O 0 0.00014442722
presented O 0 8.481815e-05
higher O 0 0.0001573078
depression B-Disease 0 0.9936558
values O 0 0.00011353084
measured O 0 0.00010513822
through O 0 8.53767e-05
the O 0 0.000114488605
Beck O 0 0.000993946
and O 0 0.00016197073
the O 0 0.00018513252
Zung O 0 0.003888911
- O 0 0.0012687794
Conde O 0 0.0011236185
scales O 0 0.00029706187
( O 0 0.00039035818
p O 0 0.00042329362
< O 0 0.0004520389
0 O 0 0.0004505586
. O 0 0.00046061448
001 O 0 0.0030304012
vs O 0 0.0012449612
control O 0 0.0014819679
) O 0 0.004619823
. O 0 0.004275798

These O 0 0.0019403663
results O 0 0.001391896
suggest O 0 0.0008582567
that O 0 0.0014206822
betaxolol B-Chemical 0 0.9999914
could O 0 0.0006795896
be O 0 0.00043728063
less O 0 0.00046160715
of O 0 0.00041879702
a O 0 0.0010372334
depression B-Disease 0 0.9996648
- O 0 0.014507854
inducer O 0 0.0023892086
than O 0 0.0010441984
timolol B-Chemical 0 0.99999404
in O 0 0.001299857
predisposed O 0 0.008184112
patients O 0 0.0033472916
. O 0 0.0028322926

Protection O 0 0.0044758082
against O 0 0.002222365
amphetamine B-Chemical 1 0.999956
- O 0 0.13820006
induced O 0 0.0016106487
neurotoxicity B-Disease 0 0.9993892
toward O 0 0.0024544625
striatal O 0 0.9590388
dopamine B-Chemical 0 0.9998229
neurons O 0 0.0003791649
in O 0 0.0002119391
rodents O 0 0.00041479667
by O 0 0.0004867767
LY274614 B-Chemical 0 0.99986994
, O 0 0.0017731047
an O 0 0.001078975
excitatory O 0 0.48216048
amino B-Chemical 0 0.9954046
acid I-Chemical 0 0.99882
antagonist O 0 0.9900461
. O 0 0.0064204657

LY274614 B-Chemical 0 0.9991942
, O 0 0.014978705
3SR B-Chemical 0 0.03038607
, I-Chemical 0 0.0037716364
4aRS I-Chemical 0 0.0029803778
, I-Chemical 0 0.0030181687
6SR I-Chemical 0 0.06554138
, I-Chemical 0 0.0017328267
8aRS I-Chemical 0 0.0015289859
- I-Chemical 0 0.0027099343
6 I-Chemical 0 0.0004618076
- I-Chemical 0 0.0024336756
[ I-Chemical 0 0.0024522906
phosphonomethyl I-Chemical 0 0.08715856
] I-Chemical 0 0.0013588027
decahydr I-Chemical 0 0.0005381256
oisoquinoline I-Chemical 0 0.00076852983
- I-Chemical 0 0.003932087
3 I-Chemical 0 0.00041212788
- I-Chemical 0 0.060345158
carboxylic I-Chemical 0 0.99934095
acid I-Chemical 0 0.97559834
, O 0 0.0011795919
has O 0 0.00014070855
been O 0 0.0001482368
described O 0 0.0001215209
as O 0 0.0001400445
a O 0 0.00028131754
potent O 0 0.00044658536
antagonist O 0 0.075101465
of O 0 0.00039419738
the O 0 0.00046755528
N B-Chemical 0 0.99979633
- I-Chemical 0 0.7055941
methyl I-Chemical 0 0.99795914
- I-Chemical 0 0.588564
D I-Chemical 0 0.99901795
- I-Chemical 0 0.89679646
aspartate I-Chemical 1 0.9999083
( O 0 0.027108526
NMDA B-Chemical 0 0.9999523
) O 0 0.010460045
subtype O 0 0.027505362
of O 0 0.0027082206
glutamate B-Chemical 0 0.9996469
receptor O 0 0.057436515
. O 0 0.0046958663

Here O 0 0.0028416743
its O 0 0.0021432494
ability O 0 0.00092951686
to O 0 0.0006282164
antagonize O 0 0.00055457663
the O 0 0.00033210934
prolonged O 0 0.00047059736
depletion O 0 0.0002991565
of O 0 0.0007216288
dopamine B-Chemical 0 0.999783
in O 0 0.0002454055
the O 0 0.00019064621
striatum O 0 0.0027109329
by O 0 0.00035078637
amphetamine B-Chemical 1 0.9999893
in O 0 0.0010235659
iprindole B-Chemical 0 0.9999988
- O 0 0.033302303
treated O 0 0.00088193413
rats O 0 0.00087258866
is O 0 0.00066513155
reported O 0 0.0013849098
. O 0 0.0025019606

A O 0 0.024824858
single O 0 0.0021838443
18 O 0 0.0016931252
. O 0 0.00096967525
4 O 0 0.0006847748
mg O 0 0.0030574067
/ O 0 0.0016384254
kg O 0 0.001103088
( O 0 0.00070019544
i O 0 0.00056509284
. O 0 0.00028299537
p O 0 0.00042759292
. O 0 0.00024181564
) O 0 0.00043098125
dose O 0 0.00031200363
of O 0 0.00024243986
( O 0 0.0004916244
+ O 0 0.0011534871
/ O 0 0.0026201722
- O 0 0.00539699
) O 0 0.0019521165
- O 0 0.24234219
amphetamine B-Chemical 1 0.9999976
hemisulfate O 0 0.999959
, O 0 0.0004892853
given O 0 7.122158e-05
to O 0 7.4111704e-05
rats O 0 0.0002043527
pretreated O 0 0.0011550797
with O 0 0.0005398034
iprindole B-Chemical 0 0.9999995
, O 0 0.00071841414
resulted O 0 0.00012158025
in O 0 0.00012123156
persistent O 0 0.00028268178
depletion O 0 0.00017290427
of O 0 0.0005661633
dopamine B-Chemical 0 0.99983203
in O 0 0.00028753586
the O 0 0.0002741244
striatum O 0 0.0017769479
1 O 0 0.0004385632
week O 0 0.000330956
later O 0 0.00082316995
. O 0 0.0020420814

This O 0 0.0042171297
prolonged O 0 0.0025592877
depletion O 0 0.0012916297
of O 0 0.0023479771
dopamine B-Chemical 0 0.99970907
in O 0 0.00061187014
the O 0 0.00038970064
striatum O 0 0.0039482
was O 0 0.00028540715
antagonized O 0 0.0059169224
by O 0 0.0005797559
dizocilpine B-Chemical 0 0.9999902
( O 0 0.012905127
MK B-Chemical 0 0.99834096
- I-Chemical 0 0.07101576
801 I-Chemical 0 0.14973599
, O 0 0.0003921251
a O 0 0.00027164523
non O 0 0.00042604053
- O 0 0.0042316676
competitive O 0 0.0006584774
antagonist O 0 0.3707755
of O 0 0.0013399279
NMDA B-Chemical 0 0.999982
receptors O 0 0.0042601298
) O 0 0.00091002486
or O 0 0.00018974562
by O 0 0.00034974635
LY274614 B-Chemical 0 0.9999248
( O 0 0.0010105949
a O 0 0.00055907597
competitive O 0 0.0009989928
antagonist O 0 0.43238783
of O 0 0.0029599946
NMDA B-Chemical 0 0.9999329
receptors O 0 0.02349936
) O 0 0.006423639
. O 0 0.0034968553

The O 0 0.002070019
protective O 0 0.0023251527
effect O 0 0.0012108738
of O 0 0.0020775502
LY274614 B-Chemical 0 0.9997893
was O 0 0.0007772442
dose O 0 0.0011596058
- O 0 0.0019385775
dependent O 0 0.0002135837
, O 0 0.00042298218
being O 0 0.00023079677
maximum O 0 0.00024878854
at O 0 0.00017260564
10 O 0 0.00027608153
- O 0 0.0010321838
40 O 0 0.0003983672
mgkg O 0 0.05390017
( O 0 0.0007764147
i O 0 0.0008189034
. O 0 0.0005726625
p O 0 0.001231946
. O 0 0.0011778504
) O 0 0.0035533225
. O 0 0.0037057172

A O 0 0.020208122
10 O 0 0.0027051806
mg O 0 0.00891426
/ O 0 0.0027071517
kg O 0 0.0015546444
dose O 0 0.0009373499
of O 0 0.0007529247
LY274614 B-Chemical 0 0.99973947
was O 0 0.00030471408
effective O 0 0.00018414923
in O 0 0.00015974672
antagonizing O 0 0.00025336572
the O 0 0.00014596999
depletion O 0 0.0001890529
of O 0 0.0005759389
dopamine B-Chemical 0 0.9998847
in O 0 0.00017421576
the O 0 0.00012784607
striatum O 0 0.001611016
, O 0 0.00017025882
when O 0 5.7706653e-05
given O 0 5.952405e-05
as O 0 8.506261e-05
long O 0 0.00010142295
as O 0 9.0517104e-05
8 O 0 8.768258e-05
hr O 0 0.00014016997
prior O 0 5.930647e-05
to O 0 0.00017255032
amphetamine B-Chemical 1 0.99998856
but O 0 0.00025383092
not O 0 0.00011923385
when O 0 0.000102091115
given O 0 0.00012535999
24 O 0 0.00022291145
hr O 0 0.00036771482
prior O 0 0.000246258
to O 0 0.0008822103
amphetamine B-Chemical 1 0.9998623
. O 0 0.0036599576

Depletion O 0 0.00454538
of O 0 0.005350524
dopamine B-Chemical 0 0.99948514
in O 0 0.0010981468
the O 0 0.00062426797
striatum O 0 0.0038110097
was O 0 0.0002756765
also O 0 0.00024016909
antagonized O 0 0.004478854
when O 0 0.00031328472
LY274614 B-Chemical 0 0.9999083
was O 0 0.00015718381
given O 0 6.1237515e-05
after O 0 4.1576077e-05
the O 0 6.200673e-05
injection O 0 8.9847534e-05
of O 0 0.0002777819
amphetamine B-Chemical 1 0.99999547
; O 0 0.0077630086
LY274614 B-Chemical 0 0.99994266
protected O 0 0.00013851428
when O 0 6.953769e-05
given O 0 6.5985405e-05
up O 0 0.000104952305
to O 0 7.4653195e-05
4 O 0 7.728572e-05
hr O 0 0.00013260233
after O 0 5.4948192e-05
but O 0 0.00012011998
not O 0 9.883254e-05
when O 0 9.436879e-05
given O 0 0.00011253931
8 O 0 0.00017095573
or O 0 0.00019228214
24 O 0 0.00032682592
hr O 0 0.00067807507
after O 0 0.0006656757
amphetamine B-Chemical 1 0.9997278
. O 0 0.0036823414

The O 0 0.0018577963
prolonged O 0 0.002173348
depletion O 0 0.0012110987
of O 0 0.002209237
dopamine B-Chemical 0 0.9996886
in O 0 0.00054033136
the O 0 0.00030943294
striatum O 0 0.0012309331
in O 0 0.00012781683
mice O 0 5.5298704e-05
, O 0 0.00017656811
given O 0 6.67689e-05
multiple O 0 9.322537e-05
injections O 0 0.00012969712
of O 0 0.00023220411
methamphetamine B-Chemical 1 0.9999471
, O 0 0.0005540002
was O 0 0.00015062166
also O 0 0.00016923234
antagonized O 0 0.007256468
dose O 0 0.0021103062
- O 0 0.03593332
dependently O 0 0.3263606
and O 0 0.0007103426
completely O 0 0.0008631726
by O 0 0.001883913
LY274614 B-Chemical 0 0.9996499
. O 0 0.00474095

The O 0 0.0020864904
data O 0 0.0017813194
strengthen O 0 0.00096688274
the O 0 0.00059572665
evidence O 0 0.0004206829
that O 0 0.00034277677
the O 0 0.00041021864
neurotoxic B-Disease 0 0.8715697
effect O 0 0.00029105024
of O 0 0.00084788434
amphetamine B-Chemical 1 0.9999951
and O 0 0.00033497947
related O 0 0.00012037706
compounds O 0 0.017426899
toward O 0 0.0006988029
nigrostriatal O 0 0.98017615
dopamine B-Chemical 0 0.99987185
neurons O 0 0.00025104027
involves O 0 0.00018778612
NMDA B-Chemical 0 0.9999566
receptors O 0 0.0011047055
and O 0 0.00020669663
that O 0 0.00019596242
LY274614 B-Chemical 0 0.9999621
is O 0 0.00024636718
an O 0 0.00065954204
NMDA B-Chemical 0 0.9999826
receptor O 0 0.016477175
antagonist O 0 0.2282056
with O 0 0.0002597433
long O 0 0.00026799308
- O 0 0.0013333502
lasting O 0 0.00017336385
in O 0 0.0001588254
vivo O 0 0.00023491913
effects O 0 0.00039175447
in O 0 0.00072976854
rats O 0 0.0020886776
. O 0 0.0025412173

Ketoconazole B-Chemical 0 0.9995814
- O 0 0.12861112
induced O 0 0.010963263
neurologic B-Disease 0 0.99384487
sequelae I-Disease 0 0.8925636
. O 0 0.014591941

A O 0 0.032170393
77 O 0 0.008316037
- O 0 0.00952191
y O 0 0.004749327
- O 0 0.0041079447
old O 0 0.00089815113
patient O 0 0.00066670583
developed O 0 0.00072022824
weakness B-Disease 0 0.7780406
of I-Disease 0 0.00065591757
extremities I-Disease 0 0.57005876
, O 0 0.0017360175
legs B-Disease 0 0.9353718
paralysis I-Disease 0 0.9999553
, O 0 0.008329017
dysarthria B-Disease 0 0.9999714
and O 0 0.00087229727
tremor B-Disease 0 0.9999056
1 O 0 0.00018369101
h O 0 0.00010772127
after O 0 5.5336794e-05
ingestion O 0 0.0004938344
of O 0 0.00014418602
200 O 0 0.00046186004
mg O 0 0.16816297
ketoconazole B-Chemical 0 0.99998736
for O 0 0.00016074601
the O 0 0.00013934533
first O 0 0.00012879755
time O 0 0.00020854337
in O 0 0.00045091697
his O 0 0.00096842146
life O 0 0.0014693197
. O 0 0.0027259972

All O 0 0.00580593
complaints O 0 0.014315531
faded O 0 0.009784499
away O 0 0.0041248365
within O 0 0.0023358138
24 O 0 0.0040711234
h O 0 0.0057043685
. O 0 0.008624724

Few O 0 0.0026990974
days O 0 0.0012573327
later O 0 0.0010832936
, O 0 0.001319949
the O 0 0.00049323484
patient O 0 0.00044684153
used O 0 0.0002671866
another O 0 0.0003842571
200 O 0 0.0007692765
mg O 0 0.31418782
ketoconazole B-Chemical 0 0.99999547
tablet O 0 0.91392833
, O 0 0.0004315048
and O 0 0.00013712916
within O 0 6.0904276e-05
an O 0 0.00011210116
hour O 0 0.000109187946
experienced O 0 0.00011740556
a O 0 0.00015241026
similar O 0 8.8898974e-05
clinical O 0 0.0004460695
picture O 0 0.00033161385
, O 0 0.0004598976
which O 0 0.00031405207
resolved O 0 0.00038059085
again O 0 0.00036222555
spontaneously O 0 0.0009237816
within O 0 0.00036667308
hours O 0 0.0008441789
. O 0 0.0021218208

Laboratory O 0 0.009516821
evaluations O 0 0.003468341
, O 0 0.0039261994
including O 0 0.0018254302
head O 0 0.005373167
CT O 0 0.009598703
scan O 0 0.002963874
, O 0 0.0033841243
were O 0 0.002378943
normal O 0 0.0047707013
. O 0 0.005966343

This O 0 0.004580643
case O 0 0.0019048135
illustrates O 0 0.0007614532
the O 0 0.00054964685
need O 0 0.00040526228
for O 0 0.00030239482
close O 0 0.00038349116
vigilance O 0 0.0040984266
in O 0 0.00036875255
adverse B-Disease 0 0.004338069
drug I-Disease 0 0.0050166305
reactions I-Disease 0 0.00080283225
, O 0 0.0007209229
particularly O 0 0.0005487138
in O 0 0.0006118964
the O 0 0.0009838698
elderly O 0 0.116106175
. O 0 0.0035958742

Development O 0 0.0069604423
of O 0 0.006411495
levodopa B-Chemical 0 0.9999745
- O 0 0.1591154
induced O 0 0.002264027
dyskinesias B-Disease 0 0.99997866
in O 0 0.0014365132
parkinsonian B-Disease 2 0.9999447
monkeys O 0 0.0002853087
may O 0 0.00014692823
depend O 0 0.00011452716
upon O 0 9.3013856e-05
rate O 0 0.00022903628
of O 0 0.00022487387
symptom O 0 0.00088669866
onset O 0 0.00033987142
and O 0 0.0002779459
/ O 0 0.0010492266
or O 0 0.0002918811
duration O 0 0.0003385452
of O 0 0.00097363937
symptoms O 0 0.009673213
. O 0 0.0028924868

Levodopa B-Chemical 0 0.9998888
- O 0 0.20585832
induced O 0 0.004656374
dyskinesias B-Disease 0 0.99995995
( O 0 0.008765837
LIDs B-Disease 0 0.99467456
) O 0 0.001102371
present O 0 0.00023188174
a O 0 0.00033091783
major O 0 0.00019990576
problem O 0 0.00022426149
for O 0 0.00012366008
the O 0 0.00013236949
long O 0 0.00020180091
- O 0 0.0007444708
term O 0 0.0001997217
management O 0 0.00028006942
of O 0 0.0004762402
Parkinson B-Disease 0 0.99783844
' I-Disease 0 0.0010240478
s I-Disease 0 0.00097348535
disease I-Disease 0 0.4278948
( O 0 0.0030192668
PD B-Disease 0 0.99838626
) O 0 0.003399831
patients O 0 0.0031885842
. O 0 0.002984565

Due O 0 0.002359006
to O 0 0.001410687
the O 0 0.0008898536
interdependence O 0 0.0010541119
of O 0 0.0008756967
risk O 0 0.0032283328
factors O 0 0.0008231236
in O 0 0.00037227036
clinical O 0 0.0010181421
populations O 0 0.00036403522
, O 0 0.00046771936
it O 0 0.00027342592
is O 0 0.00012715042
difficult O 0 0.00013855353
to O 0 0.000105092804
independently O 0 7.999565e-05
examine O 0 6.369605e-05
factors O 0 0.0002953618
that O 0 0.0001629757
may O 0 0.00018666005
influence O 0 0.00020573965
the O 0 0.00037529814
development O 0 0.0009445299
of O 0 0.0019380056
LIDs B-Disease 0 0.98958987
. O 0 0.0034976585

Using O 0 0.0014947703
macaque O 0 0.00090010575
monkeys O 0 0.0007785117
with O 0 0.0006197391
different O 0 0.00036915104
types O 0 0.00045424877
of O 0 0.0012002621
MPTP B-Chemical 0 0.9999864
- O 0 0.0669861
induced O 0 0.0007607521
parkinsonism B-Disease 2 0.9999924
, O 0 0.0005233199
the O 0 0.00011333765
current O 0 0.00013753629
study O 0 0.00012079319
evaluated O 0 8.991705e-05
the O 0 7.684133e-05
degree O 0 0.00015788003
to O 0 9.327338e-05
which O 0 0.00012096781
rate O 0 0.00015237322
of O 0 0.0001368979
symptom O 0 0.0009171579
progression O 0 0.00088067126
, O 0 0.00029717287
symptom O 0 0.0007484187
severity O 0 0.0004005244
, O 0 0.00017601255
and O 0 8.568688e-05
response O 0 7.446378e-05
to O 0 6.3148575e-05
and O 0 7.9413745e-05
duration O 0 7.163401e-05
of O 0 0.0002790252
levodopa B-Chemical 0 0.9999927
therapy O 0 0.00032915772
may O 0 0.000113840884
be O 0 0.00014736768
involved O 0 0.00017009462
in O 0 0.00026042468
the O 0 0.0003430043
development O 0 0.0008766275
of O 0 0.0018423935
LIDs B-Disease 0 0.9896778
. O 0 0.003435334

Monkeys O 0 0.011884387
with O 0 0.0030248868
acute O 0 0.022044318
( O 0 0.0019197727
short O 0 0.0007497879
- O 0 0.0025010959
term O 0 0.00070900074
) O 0 0.0037288708
MPTP B-Chemical 0 0.9999584
exposure O 0 0.0004510721
, O 0 0.00037908525
rapid O 0 0.0002526295
symptom O 0 0.00054996595
onset O 0 0.00017296478
and O 0 9.296722e-05
short O 0 7.721617e-05
symptom O 0 0.00019856099
duration O 0 4.15214e-05
prior O 0 3.2973523e-05
to O 0 5.2657142e-05
initiation O 0 6.4657106e-05
of O 0 0.0002405096
levodopa B-Chemical 0 0.9999926
therapy O 0 0.00035802156
developed O 0 0.00033095755
dyskinesia B-Disease 0 0.9999949
between O 0 0.00011461467
11 O 0 0.00013949037
and O 0 0.00011620887
24 O 0 0.00012311322
days O 0 9.009436e-05
of O 0 0.00027645373
daily O 0 0.0010028644
levodopa B-Chemical 0 0.999923
administration O 0 0.002498151
. O 0 0.002194174

In O 0 0.002057026
contrast O 0 0.0023533357
, O 0 0.0020176882
monkeys O 0 0.00079689664
with O 0 0.00066821906
long O 0 0.00067638507
- O 0 0.0032344242
term O 0 0.00086007005
MPTP B-Chemical 0 0.9999604
exposure O 0 0.00043977457
, O 0 0.00042046755
slow O 0 0.00047595412
symptom O 0 0.0007797911
progression O 0 0.00056279515
and O 0 0.00015221303
/ O 0 0.00063279265
or O 0 8.719315e-05
long O 0 9.587157e-05
symptom O 0 0.00020624188
duration O 0 3.768885e-05
prior O 0 2.9160869e-05
to O 0 4.62866e-05
initiation O 0 5.6122364e-05
of O 0 0.00020449657
levodopa B-Chemical 0 0.9999925
therapy O 0 0.00019767295
were O 0 7.0424445e-05
more O 0 0.00012065275
resistant O 0 0.00013710366
to O 0 0.00010933433
developing O 0 0.0006853319
LIDs B-Disease 0 0.9901102
( O 0 0.0003642805
e O 0 0.0004190976
. O 0 0.0001396028
g O 0 0.0005892593
. O 0 0.00017897181
, O 0 0.0008555639
dyskinesia B-Disease 0 0.99999654
developed O 0 0.0002250416
no O 0 0.00013025917
sooner O 0 0.00037052963
than O 0 0.00013223264
146 O 0 0.00033021913
days O 0 0.00010752351
of O 0 0.0003149582
chronic O 0 0.13783397
levodopa B-Chemical 0 0.9999769
administration O 0 0.0024958884
) O 0 0.0029752927
. O 0 0.002469817

All O 0 0.0017060775
animals O 0 0.0010656203
were O 0 0.00083259697
similarly O 0 0.00060875696
symptomatic O 0 0.0012077913
at O 0 0.00025025738
the O 0 0.00020814608
start O 0 0.00017131309
of O 0 0.00050957914
levodopa B-Chemical 0 0.999979
treatment O 0 0.00027437147
and O 0 0.00020748269
had O 0 0.00018204695
similar O 0 0.00014063479
therapeutic O 0 0.00034131145
responses O 0 0.00034562402
to O 0 0.0004698074
the O 0 0.00083839067
drug O 0 0.01457357
. O 0 0.0031571954

These O 0 0.0020414384
data O 0 0.0016809347
suggest O 0 0.0005964619
distinct O 0 0.000526385
differences O 0 0.00041654627
in O 0 0.00039060108
the O 0 0.000285763
propensity O 0 0.00042918514
to O 0 0.00023608112
develop O 0 0.00038554208
LIDs B-Disease 0 0.9460924
in O 0 0.000120274715
monkeys O 0 9.767656e-05
with O 0 9.254257e-05
different O 0 6.045698e-05
rates O 0 0.00010514925
of O 0 0.00012180003
symptom O 0 0.00061539153
progression O 0 0.00041445895
or O 0 7.4156735e-05
symptom O 0 0.00021369857
durations O 0 5.6984103e-05
prior O 0 4.33435e-05
to O 0 0.00012809732
levodopa B-Chemical 0 0.9999865
and O 0 9.290111e-05
demonstrate O 0 3.648619e-05
the O 0 6.841974e-05
value O 0 0.00010481029
of O 0 0.00011030677
these O 0 9.9653975e-05
models O 0 0.00010904488
for O 0 0.00010597537
further O 0 0.0001509587
studying O 0 0.00027608892
the O 0 0.00038045063
pathophysiology O 0 0.010840556
of O 0 0.0019603297
LIDs B-Disease 0 0.9922346
. O 0 0.0032612884

A O 0 0.043913137
diet O 0 0.02043699
promoting O 0 0.0024756452
sugar B-Disease 0 0.81596714
dependency I-Disease 0 0.0044093365
causes O 0 0.0011066145
behavioral B-Disease 0 0.0033617872
cross I-Disease 0 0.0008185714
- I-Disease 0 0.0019425008
sensitization I-Disease 0 0.00040554983
to O 0 0.0002528968
a O 0 0.00048748573
low O 0 0.00065831747
dose O 0 0.0014521491
of O 0 0.0021609496
amphetamine B-Chemical 1 0.9999248
. O 0 0.00500792

Previous O 0 0.002361583
research O 0 0.0024895724
in O 0 0.0012050499
this O 0 0.00089120056
laboratory O 0 0.0007226738
has O 0 0.00026490353
shown O 0 0.00014754751
that O 0 0.00016542562
a O 0 0.00032644015
diet O 0 0.0011685147
of O 0 0.00026048877
intermittent O 0 0.0009236979
excessive O 0 0.0009924566
sugar O 0 0.055996165
consumption O 0 0.006414549
produces O 0 0.000148761
a O 0 0.00023177367
state O 0 0.00017676991
with O 0 0.00019515821
neurochemical O 0 0.0021860297
and O 0 0.00022834071
behavioral O 0 0.00078636064
similarities O 0 0.00028225788
to O 0 0.00051513116
drug B-Disease 0 0.3063846
dependency I-Disease 0 0.0055475463
. O 0 0.0032348605

The O 0 0.0018102437
present O 0 0.0011975949
study O 0 0.0009681484
examined O 0 0.0003955141
whether O 0 0.00018402023
female O 0 0.00066717964
rats O 0 0.000373393
on O 0 0.00012107364
various O 0 0.00013728654
regimens O 0 0.00021562846
of O 0 0.00020921895
sugar O 0 0.0048129945
access O 0 0.00020640217
would O 0 0.00013323568
show O 0 0.00011648878
behavioral B-Disease 0 0.00080542563
cross I-Disease 0 0.00031569443
- I-Disease 0 0.0011070984
sensitization I-Disease 0 0.00022435133
to O 0 0.00015237016
a O 0 0.00033489228
low O 0 0.00049002684
dose O 0 0.0011715184
of O 0 0.0017894384
amphetamine B-Chemical 1 0.99994266
. O 0 0.004295717

After O 0 0.0019613162
a O 0 0.0025473551
30 O 0 0.0013234521
- O 0 0.0024465024
min O 0 0.0007356836
baseline O 0 0.00028768007
measure O 0 0.00019702547
of O 0 0.000338903
locomotor O 0 0.0019294792
activity O 0 0.00017217905
( O 0 0.00032129744
day O 0 0.00012337611
0 O 0 0.00022387334
) O 0 0.00035003977
, O 0 0.0002245041
animals O 0 9.179104e-05
were O 0 0.00010377699
maintained O 0 0.00012523477
on O 0 9.1905415e-05
a O 0 0.00022424568
cyclic O 0 0.00042517815
diet O 0 0.0012860768
of O 0 0.00017791027
12 O 0 0.00011853543
- O 0 0.0006205479
h O 0 0.00014558205
deprivation O 0 0.00038526268
followed O 0 8.2929226e-05
by O 0 9.592287e-05
12 O 0 9.124907e-05
- O 0 0.00041311045
h O 0 0.00011317587
access O 0 0.000105567386
to O 0 0.00010119997
10 O 0 0.00013834256
% O 0 0.00035936624
sucrose B-Chemical 0 0.8896779
solution O 0 0.00052627816
and O 0 0.0001578635
chow O 0 0.002181678
pellets O 0 0.0004922002
( O 0 0.00020369675
12 O 0 6.027857e-05
h O 0 7.684594e-05
access O 0 7.490135e-05
starting O 0 5.636684e-05
4 O 0 7.2804054e-05
h O 0 9.962071e-05
after O 0 6.286839e-05
onset O 0 0.00018215303
of O 0 0.00016413833
the O 0 0.00016257633
dark O 0 0.00023250963
period O 0 0.00020803121
) O 0 0.00068553834
for O 0 0.0003869568
21 O 0 0.0008181165
days O 0 0.000763993
. O 0 0.0023501676

Locomotor O 0 0.08522001
activity O 0 0.0015458292
was O 0 0.0010959328
measured O 0 0.00083702616
again O 0 0.0005423201
for O 0 0.00032993717
30 O 0 0.0003103062
min O 0 0.00035908222
at O 0 0.0001567834
the O 0 0.00015691665
beginning O 0 0.00015235708
of O 0 0.00025365263
days O 0 0.00019790551
1 O 0 0.00036260352
and O 0 0.0004177751
21 O 0 0.00063197786
of O 0 0.0009161818
sugar O 0 0.011994211
access O 0 0.0027273772
. O 0 0.0041622203

Beginning O 0 0.005609917
on O 0 0.001794991
day O 0 0.0014115368
22 O 0 0.0018377658
, O 0 0.0015545588
all O 0 0.000736511
rats O 0 0.000970411
were O 0 0.0005608314
maintained O 0 0.00061523257
on O 0 0.0005539173
ad O 0 0.002366493
libitum O 0 0.04622987
chow O 0 0.014168064
. O 0 0.0049205963

Nine O 0 0.0035413203
days O 0 0.0011854237
later O 0 0.0010943698
locomotor O 0 0.00363101
activity O 0 0.00037851484
was O 0 0.00032802526
measured O 0 0.0002973781
in O 0 0.00020489414
response O 0 0.00018373094
to O 0 0.00015209726
a O 0 0.00022231374
single O 0 0.00011551548
low O 0 0.00022570904
dose O 0 0.0004432032
of O 0 0.00051618984
amphetamine B-Chemical 1 0.99998343
( O 0 0.00083106477
0 O 0 0.0003742133
. O 0 0.00027049024
5 O 0 0.00034923173
mg O 0 0.0022794984
/ O 0 0.0021685997
kg O 0 0.0024142014
) O 0 0.0035170887
. O 0 0.003373113

The O 0 0.0016347949
animals O 0 0.0010680682
that O 0 0.0007864842
had O 0 0.00077585597
experienced O 0 0.00088067586
cyclic O 0 0.0023525255
sucrose B-Chemical 0 0.9739507
and O 0 0.0004717898
chow O 0 0.0068085175
were O 0 0.0002572261
hyperactive B-Disease 0 0.22634375
in O 0 0.00013255139
response O 0 0.00013257893
to O 0 0.0001825726
amphetamine B-Chemical 1 0.99997747
compared O 0 9.231631e-05
with O 0 9.019898e-05
four O 0 4.8393842e-05
control O 0 8.515627e-05
groups O 0 0.00013488789
( O 0 0.00019164279
ad O 0 0.00029804456
libitum O 0 0.011763693
10 O 0 0.00013008168
% O 0 0.00025371672
sucrose B-Chemical 0 0.5325928
and O 0 0.00013839574
chow O 0 0.0012578586
followed O 0 8.753655e-05
by O 0 0.00015273762
amphetamine B-Chemical 1 0.9999777
injection O 0 0.00012755212
, O 0 0.00019697004
cyclic O 0 0.00025931693
chow O 0 0.0015357938
followed O 0 8.423442e-05
by O 0 0.00014186623
amphetamine B-Chemical 1 0.9999709
injection O 0 9.9931465e-05
, O 0 0.00014297926
ad O 0 0.00025198917
libitum O 0 0.027085556
chow O 0 0.0036489123
with O 0 0.00033442295
amphetamine B-Chemical 1 0.99998856
, O 0 0.00045766265
or O 0 0.00014429014
cyclic O 0 0.0004053465
10 O 0 0.00018286773
% O 0 0.0004391186
sucrose B-Chemical 0 0.84649354
and O 0 0.00027363584
chow O 0 0.0021707441
with O 0 0.000307468
a O 0 0.0005282095
saline O 0 0.001152443
injection O 0 0.0006187836
) O 0 0.002180797
. O 0 0.0022680268

These O 0 0.0018794322
results O 0 0.0012573716
suggest O 0 0.0006417677
that O 0 0.0006192526
a O 0 0.0009065252
diet O 0 0.0024912779
comprised O 0 0.00049672107
of O 0 0.00033537587
alternating O 0 0.0004967788
deprivation O 0 0.00084709865
and O 0 0.0001675968
access O 0 0.00014608653
to O 0 0.00012873775
a O 0 0.00026828275
sugar O 0 0.0087726675
solution O 0 0.00054395164
and O 0 0.00016273439
chow O 0 0.0034378504
produces O 0 0.00014823496
bingeing O 0 0.9872673
on O 0 0.0001080376
sugar O 0 0.0108331395
that O 0 9.156356e-05
leads O 0 9.483139e-05
to O 0 8.246239e-05
a O 0 0.00013446706
long O 0 8.523101e-05
lasting O 0 8.062932e-05
state O 0 8.542498e-05
of O 0 9.1806265e-05
increased O 0 0.00014865863
sensitivity O 0 0.00027582163
to O 0 0.0002692329
amphetamine B-Chemical 1 0.999995
, O 0 0.0006038615
possibly O 0 0.00019846049
due O 0 9.2678296e-05
to O 0 0.000118587086
a O 0 0.0002461155
lasting O 0 0.00021734247
alteration O 0 0.00031322768
in O 0 0.00037308305
the O 0 0.0007140427
dopamine B-Chemical 0 0.99883777
system O 0 0.0019978664
. O 0 0.0027119415

Reversible O 0 0.32543513
dilated B-Disease 0 0.99712425
cardiomyopathy I-Disease 0 0.9998586
related O 0 0.0027830733
to O 0 0.0031606264
amphotericin B-Chemical 0 0.9994382
B I-Chemical 0 0.8186722
therapy O 0 0.0076948754
. O 0 0.0060850275

We O 0 0.0024201365
describe O 0 0.001695478
a O 0 0.0016905619
patient O 0 0.0009946182
who O 0 0.0008613486
developed O 0 0.0008352001
dilated B-Disease 0 0.99842876
cardiomyopathy I-Disease 0 0.99998903
and O 0 0.0007611826
clinical O 0 0.008371012
congestive O 0 0.9997328
heart B-Disease 0 0.06665674
failure I-Disease 0 0.0017498061
after O 0 5.089502e-05
2 O 0 7.2976574e-05
months O 0 3.6367215e-05
of O 0 8.665998e-05
therapy O 0 0.0001800673
with O 0 0.0002783033
amphotericin B-Chemical 0 0.9999039
B I-Chemical 0 0.8876689
( O 0 0.004262837
AmB B-Chemical 1 0.9996877
) O 0 0.0027276909
for O 0 0.000871303
disseminated O 0 0.7202982
coccidioidomycosis B-Disease 0 0.9991561
. O 0 0.0036457824

His O 0 0.0040754336
echocardiographic O 0 0.0040864954
abnormalities O 0 0.010473715
and O 0 0.0014757531
heart B-Disease 0 0.019813772
failure I-Disease 0 0.008607178
resolved O 0 0.00087016006
after O 0 0.0005274998
posaconazole B-Chemical 0 0.99960905
was O 0 0.0009168884
substituted O 0 0.0016479319
for O 0 0.001759383
AmB B-Chemical 1 0.99745375
. O 0 0.005412914

It O 0 0.005379187
is O 0 0.0017040628
important O 0 0.0009269742
to O 0 0.00078890804
recognize O 0 0.0005620503
the O 0 0.00073745596
rare O 0 0.0020994733
and O 0 0.000790096
potentially O 0 0.00092879176
reversible O 0 0.0048840563
toxicity B-Disease 0 0.71520567
of O 0 0.0038495297
AmB B-Chemical 1 0.99901664
. O 0 0.00594512

NO B-Chemical 0 0.9968901
- O 0 0.15917622
induced O 0 0.0047642803
migraine B-Disease 0 0.9999268
attack O 0 0.09514261
: O 0 0.0014624783
strong O 0 0.00037169392
increase O 0 0.00032038838
in O 0 0.00034907283
plasma O 0 0.01149009
calcitonin B-Chemical 0 0.01745407
gene I-Chemical 0 0.00021695737
- I-Chemical 0 0.0012483264
related I-Chemical 0 0.000120371544
peptide I-Chemical 0 0.0002057887
( O 0 0.0008966543
CGRP B-Chemical 1 0.99132735
) O 0 0.000768085
concentration O 0 0.00036806625
and O 0 0.00021890081
negative O 0 0.00025455048
correlation O 0 0.0003400106
with O 0 0.0011358134
platelet O 0 0.9983259
serotonin B-Chemical 0 0.99984396
release O 0 0.010321579
. O 0 0.0034768686

The O 0 0.0016073274
aim O 0 0.0010091483
of O 0 0.0010223823
the O 0 0.0005994812
present O 0 0.00043424204
study O 0 0.00046041692
was O 0 0.0002445152
to O 0 0.00015267602
investigate O 0 8.0201724e-05
changes O 0 0.00018726582
in O 0 0.00016059911
the O 0 0.00017734391
plasma O 0 0.008037152
calcitonin B-Chemical 0 0.013897973
gene I-Chemical 0 0.0001581544
- I-Chemical 0 0.0010890098
related I-Chemical 0 9.264031e-05
peptide I-Chemical 0 0.00016257245
( O 0 0.0007958498
CGRP B-Chemical 1 0.99438065
) O 0 0.00084053085
concentration O 0 0.0004991162
and O 0 0.0004869094
platelet O 0 0.99757487
serotonin B-Chemical 0 0.9999039
( O 0 0.00058022584
5 B-Chemical 0 0.00015589225
- I-Chemical 0 0.0006247769
hydroxytriptamine I-Chemical 0 0.00025882636
, O 0 0.0003252925
5 B-Chemical 0 0.00019715363
- I-Chemical 0 0.0026133547
HT I-Chemical 0 0.98338324
) O 0 0.0005039476
content O 0 0.00015301951
during O 0 8.21154e-05
the O 0 0.00010284858
immediate O 0 0.0003446925
headache B-Disease 0 0.9783545
and O 0 0.00017217101
the O 0 0.00015572482
delayed O 0 0.00093157473
genuine O 0 0.0012388704
migraine B-Disease 0 0.99996924
attack O 0 0.11193173
provoked O 0 0.0064167683
by O 0 0.0025103302
nitroglycerin B-Chemical 0 0.9999654
. O 0 0.0044709602

Fifteen O 0 0.0070419624
female O 0 0.0114592
migraineurs B-Disease 0 0.998458
( I-Disease 0 0.004290446
without I-Disease 0 0.0024892006
aura I-Disease 0 0.99987686
) I-Disease 0 0.0023617696
and O 0 0.0005849595
eight O 0 0.00036693393
controls O 0 0.00086760434
participated O 0 0.0017480985
in O 0 0.0009016735
the O 0 0.001135866
study O 0 0.0023512747
. O 0 0.0036104925

Sublingual O 0 0.98772043
nitroglycerin B-Chemical 0 0.9998828
( O 0 0.0062882453
0 O 0 0.0023323526
. O 0 0.0014347839
5 O 0 0.0014085919
mg O 0 0.0059914067
) O 0 0.003068527
was O 0 0.0019891486
administered O 0 0.0036727812
. O 0 0.005199567

Blood O 0 0.02279794
was O 0 0.0019185314
collected O 0 0.0009920818
from O 0 0.00060803123
the O 0 0.0005134336
antecubital O 0 0.003960404
vein O 0 0.002803247
four O 0 0.00014730768
times O 0 0.00013358639
: O 0 0.00032612655
60 O 0 0.00017366232
min O 0 0.00017473068
before O 0 5.9516213e-05
and O 0 0.00010265566
after O 0 7.045017e-05
the O 0 0.00016687157
nitroglycerin B-Chemical 0 0.9999734
application O 0 0.00020039335
, O 0 0.00024218667
and O 0 0.00012598529
60 O 0 0.00012147665
and O 0 9.932875e-05
120 O 0 0.00012453622
min O 0 0.00012302097
after O 0 4.199596e-05
the O 0 6.19965e-05
beginning O 0 7.3062496e-05
of O 0 0.00016305855
the O 0 0.00027098792
migraine B-Disease 0 0.99995947
attack O 0 0.0064207003
( O 0 0.00038691916
mean O 0 0.00017158086
344 O 0 0.001416798
and O 0 0.00029453
404 O 0 0.00094751385
min O 0 0.0005298447
; O 0 0.0007163668
12 O 0 0.00041345303
subjects O 0 0.0012114719
) O 0 0.0028750792
. O 0 0.003091587

In O 0 0.0019546538
those O 0 0.0021348277
subjects O 0 0.0021640921
who O 0 0.001434001
had O 0 0.0008019407
no O 0 0.0010454132
migraine B-Disease 0 0.9999312
attack O 0 0.03589551
( O 0 0.00091726315
11 O 0 0.00037851484
subjects O 0 0.00049349776
) O 0 0.0006072865
a O 0 0.00037368713
similar O 0 0.00019870719
time O 0 0.00026817812
schedule O 0 0.0004931994
was O 0 0.00077742117
used O 0 0.0013385753
. O 0 0.0030844822

Plasma O 0 0.931449
CGRP B-Chemical 1 0.9958889
concentration O 0 0.00384878
increased O 0 0.0015386781
significantly O 0 0.00097249896
( O 0 0.0011628224
P O 0 0.0076967827
< O 0 0.00063506677
0 O 0 0.00042115978
. O 0 0.0003017782
01 O 0 0.0012832943
) O 0 0.00054166926
during O 0 0.00018656006
the O 0 0.00033534117
migraine B-Disease 0 0.99993503
attack O 0 0.0060767955
and O 0 0.00023624841
returned O 0 0.00017054903
to O 0 0.00010884937
baseline O 0 0.00012034193
after O 0 9.0004294e-05
the O 0 0.00017142322
cessation O 0 0.0003513425
of O 0 0.00068270223
the O 0 0.0013806025
migraine B-Disease 0 0.9997229
. O 0 0.0040981947

In O 0 0.0018664241
addition O 0 0.0011616573
, O 0 0.0019724502
both O 0 0.00076152536
change O 0 0.00061115704
and O 0 0.0005215783
peak O 0 0.00051927817
, O 0 0.0005220628
showed O 0 0.00021549525
significant O 0 0.00020993054
positive O 0 0.00024506368
correlations O 0 0.0003184294
with O 0 0.0008986886
migraine B-Disease 0 0.9999962
headache B-Disease 0 0.99988174
intensity O 0 0.00023754511
( O 0 0.0005984802
P O 0 0.005313173
< O 0 0.00070016115
0 O 0 0.00072162185
. O 0 0.00087887567
001 O 0 0.008737983
) O 0 0.0044946126
. O 0 0.004024903

However O 0 0.003955005
, O 0 0.008093528
plasma O 0 0.38961637
CGRP B-Chemical 1 0.9971744
concentrations O 0 0.0017849366
failed O 0 0.0005137113
to O 0 0.00028251472
change O 0 0.00023842709
during O 0 0.00017220205
immediate O 0 0.0005020399
headache B-Disease 0 0.9690317
and O 0 0.00024479185
in O 0 0.00019773196
the O 0 0.00021206119
subjects O 0 0.00055505097
with O 0 0.00057187
no O 0 0.0012723226
migraine B-Disease 0 0.9998884
attack O 0 0.12487605
. O 0 0.003980389

Basal O 0 0.50185114
CGRP B-Chemical 1 0.9945754
concentration O 0 0.0032958994
was O 0 0.0009113038
significantly O 0 0.0007260017
higher O 0 0.0006391984
and O 0 0.00076057785
platelet O 0 0.7164545
5 B-Chemical 0 0.000517635
- I-Chemical 0 0.0064787045
HT I-Chemical 0 0.98562753
content O 0 0.00037987006
tended O 0 0.00025534775
to O 0 0.0001412708
be O 0 0.00014514444
lower O 0 0.00019599064
in O 0 0.00018957998
subjects O 0 0.00046370688
who O 0 0.00048533067
experienced O 0 0.0006510076
a O 0 0.002283005
migraine B-Disease 0 0.999877
attack O 0 0.09215584
. O 0 0.003824167

Platelet O 0 0.99819106
serotonin B-Chemical 0 0.9993142
content O 0 0.0030153794
decreased O 0 0.0020817234
significantly O 0 0.0010201902
( O 0 0.0011668075
P O 0 0.007974316
< O 0 0.00059720356
0 O 0 0.00038361165
. O 0 0.0002676568
01 O 0 0.0010977476
) O 0 0.00050559227
after O 0 0.0001798072
nitroglycerin B-Chemical 0 0.99996054
in O 0 0.00020588016
subjects O 0 0.00030664596
with O 0 0.00019520437
no O 0 0.00034806246
migraine B-Disease 0 0.99998486
attack O 0 0.05057916
but O 0 0.00024696125
no O 0 0.00013846306
consistent O 0 0.000134107
change O 0 0.00015919626
was O 0 0.00015579625
observed O 0 0.00017638081
in O 0 0.00028935086
patients O 0 0.0010992838
with O 0 0.0013896682
migraine B-Disease 0 0.99991775
attack O 0 0.11981268
. O 0 0.0035387285

In O 0 0.0018423594
conclusion O 0 0.0013222181
, O 0 0.002113175
the O 0 0.0007349383
fact O 0 0.00049341633
that O 0 0.0005776269
plasma O 0 0.21669383
CGRP B-Chemical 1 0.99788445
concentration O 0 0.0007168941
correlates O 0 0.00021987496
with O 0 0.00015316128
the O 0 9.364797e-05
timing O 0 7.220254e-05
and O 0 0.00014302073
severity O 0 0.00046727635
of O 0 0.00024862876
a O 0 0.0019531539
migraine B-Disease 0 0.99999857
headache B-Disease 0 0.9999473
suggests O 0 0.00012775467
a O 0 0.00023335023
direct O 0 0.00012293443
relationship O 0 0.00018338212
between O 0 0.00053437473
CGRP B-Chemical 1 0.99643624
and O 0 0.002967825
migraine B-Disease 0 0.99982363
. O 0 0.004133647

In O 0 0.0023948958
contrast O 0 0.00389106
, O 0 0.009567881
serotonin B-Chemical 0 0.999645
release O 0 0.0052801967
from O 0 0.00093563716
platelets O 0 0.36620668
does O 0 0.00033176693
not O 0 0.0003492314
provoke O 0 0.0026941139
migraine B-Disease 0 0.999977
, O 0 0.0010199691
it O 0 0.00034057995
may O 0 0.00013783538
even O 0 0.00019222236
counteract O 0 0.00021090012
the O 0 0.000251024
headache B-Disease 0 0.99276966
and O 0 0.00024803253
the O 0 0.00023846552
concomitant O 0 0.002032645
CGRP B-Chemical 1 0.9969694
release O 0 0.0012352525
in O 0 0.00052848365
this O 0 0.0008444806
model O 0 0.0013117841
. O 0 0.0027948483

Hyperbaric O 0 0.99933064
oxygen B-Chemical 1 0.99876416
therapy O 0 0.0026920622
for O 0 0.00072441483
control O 0 0.0007836883
of O 0 0.0011231975
intractable O 0 0.2369921
cyclophosphamide B-Chemical 0 0.999777
- O 0 0.020315528
induced O 0 0.0025961255
hemorrhagic B-Disease 2 0.9996458
cystitis I-Disease 0 0.99933285
. O 0 0.0060725925

We O 0 0.0031337393
report O 0 0.0034141885
a O 0 0.0021389388
case O 0 0.0012665119
of O 0 0.0013430453
intractable O 0 0.5667748
hemorrhagic B-Disease 2 0.99980325
cystitis I-Disease 0 0.9993024
due O 0 0.0003515247
to O 0 0.0004095579
cyclophosphamide B-Chemical 0 0.9993007
therapy O 0 0.0006411973
for O 0 0.0004434401
Wegener B-Disease 0 0.035642117
' I-Disease 0 0.0017913166
s I-Disease 0 0.0024496545
granulomatosis I-Disease 0 0.74311405
. O 0 0.003628923

Conservative O 0 0.013291817
treatment O 0 0.0023873479
, O 0 0.0021247165
including O 0 0.00075098674
bladder O 0 0.0050569577
irrigation O 0 0.0011660024
with O 0 0.00035169383
physiological O 0 0.0003523645
saline O 0 0.00073204
and O 0 0.00029588433
instillation O 0 0.0008776455
of O 0 0.0010933534
prostaglandin B-Chemical 0 0.999998
F2 I-Chemical 0 0.9987424
alpha I-Chemical 0 0.9980525
, O 0 0.0016237693
failed O 0 0.0005222801
to O 0 0.00051414757
totally O 0 0.0016768833
control O 0 0.0022376156
hemorrhage B-Disease 2 0.99967325
. O 0 0.0041702464

We O 0 0.0030581944
then O 0 0.0022985481
used O 0 0.0026449813
hyperbaric O 0 0.9990884
oxygen B-Chemical 1 0.9991763
at O 0 0.00044825108
an O 0 0.0003658473
absolute O 0 0.00035730668
pressure O 0 0.001995026
of O 0 0.00034744944
2 O 0 0.00037614538
atm O 0 0.059533823
, O 0 0.00047940025
5 O 0 0.0001869939
days O 0 0.00012081657
a O 0 0.0002674073
week O 0 0.00016663452
for O 0 0.00023595509
8 O 0 0.000415915
consecutive O 0 0.00057632604
weeks O 0 0.00070371863
. O 0 0.0024366619

The O 0 0.0036512078
bleeding B-Disease 0 0.95739084
ceased O 0 0.0034761652
completely O 0 0.00091895415
by O 0 0.0005402625
the O 0 0.00032283392
end O 0 0.00021937363
of O 0 0.00035465418
treatment O 0 0.00032568816
and O 0 0.0003136308
the O 0 0.00027615816
patient O 0 0.00044731091
remained O 0 0.0006056054
free O 0 0.0009758914
of O 0 0.0013988029
hematuria B-Disease 0 0.9966558
thereafter O 0 0.0024426281
. O 0 0.0033106345

No O 0 0.005925786
side O 0 0.0058637653
effect O 0 0.0018999504
was O 0 0.0015584506
noted O 0 0.0012019393
during O 0 0.0007812455
the O 0 0.0008713752
course O 0 0.0012442654
of O 0 0.0018668365
therapy O 0 0.003454904
. O 0 0.004350826

In O 0 0.0023847735
future O 0 0.0021660207
, O 0 0.0025101297
this O 0 0.0010521074
form O 0 0.00066964614
of O 0 0.0005842505
therapy O 0 0.0005855131
can O 0 0.00019307487
offer O 0 0.00022831174
a O 0 0.0002924181
safe O 0 0.0002289258
alternative O 0 0.00010852135
in O 0 0.00015230347
the O 0 0.00016567376
treatment O 0 0.00026394852
of O 0 0.0006024879
cyclophosphamide B-Chemical 0 0.99986064
- O 0 0.021085866
induced O 0 0.0017738641
hemorrhagic B-Disease 2 0.9997849
cystitis I-Disease 0 0.99952567
. O 0 0.0046748244

Acute B-Disease 0 0.990862
psychosis I-Disease 0 0.9999217
due O 0 0.0017142219
to O 0 0.0010393397
treatment O 0 0.0011097477
with O 0 0.0020090914
phenytoin B-Chemical 0 0.99998593
in O 0 0.0016102387
a O 0 0.002926577
nonepileptic O 0 0.98724395
patient O 0 0.0028034563
. O 0 0.0033626296

The O 0 0.0020107918
development O 0 0.0022156525
of O 0 0.0022377968
psychosis B-Disease 0 0.9998222
related O 0 0.00049598556
to O 0 0.00049110496
antiepileptic O 0 0.9988846
drug O 0 0.022866644
treatment O 0 0.00023624324
is O 0 0.00014128009
usually O 0 0.00018270007
attributed O 0 0.00011281888
to O 0 0.00010019729
the O 0 9.4008006e-05
interaction O 0 9.798749e-05
between O 0 0.00014470569
the O 0 0.0003359466
epileptic B-Disease 0 0.99991095
brain O 0 0.0025791787
substratum O 0 0.006079054
and O 0 0.00045356512
the O 0 0.00060083816
antiepileptic O 0 0.9980556
drugs O 0 0.0968314
. O 0 0.0029400785

The O 0 0.0020635712
case O 0 0.001832732
of O 0 0.0014168418
a O 0 0.0020444763
nonepileptic O 0 0.9935523
patient O 0 0.0006976117
who O 0 0.000555755
developed O 0 0.00062194915
psychosis B-Disease 0 0.9999074
following O 0 0.00044686432
phenytoin B-Chemical 0 0.9999939
treatment O 0 0.00038409742
for O 0 0.00029650275
trigeminal B-Disease 0 0.0022735407
neuralgia I-Disease 0 0.9953584
is O 0 0.00069179956
described O 0 0.0010853714
. O 0 0.0024998826

This O 0 0.0046448195
case O 0 0.0019301313
suggests O 0 0.00072988955
that O 0 0.0007338284
the O 0 0.0015686629
psychotic B-Disease 0 0.99999857
symptoms I-Disease 0 0.8408587
that O 0 0.00022630593
occur O 0 0.00021530243
following O 0 0.00018947535
phenytoin B-Chemical 0 0.99999595
treatment O 0 0.0002194433
in O 0 0.00014357644
some O 0 0.0002948908
epileptic B-Disease 0 0.99993896
patients O 0 0.0005059251
may O 0 9.506299e-05
be O 0 9.6586584e-05
the O 0 8.423482e-05
direct O 0 8.678891e-05
result O 0 0.00014729548
of O 0 0.0002892312
medication O 0 0.003978843
, O 0 0.0009668994
unrelated O 0 0.0011939006
to O 0 0.0015051701
seizures B-Disease 0 0.99984705
. O 0 0.004194955

Risks O 0 0.009921896
of O 0 0.0040128008
the O 0 0.002848212
consumption O 0 0.007990118
of O 0 0.0033551522
beverages O 0 0.5900666
containing O 0 0.00508128
quinine B-Chemical 0 0.99900013
. O 0 0.0085729975

Although O 0 0.0021749227
the O 0 0.00181013
United O 0 0.002008966
States O 0 0.0019111743
Food O 0 0.003166131
and O 0 0.00086526125
Drug O 0 0.13305788
Administration O 0 0.0012098835
banned O 0 0.0005946969
its O 0 0.0002725207
use O 0 0.0001749032
for O 0 0.00020817107
nocturnal B-Disease 0 0.77954304
leg I-Disease 0 0.5005013
cramps I-Disease 0 0.99955326
due O 0 0.000103849365
to O 0 7.869427e-05
lack O 0 6.695719e-05
of O 0 8.672603e-05
safety O 0 9.2661416e-05
and O 0 8.938248e-05
efficacy O 0 0.0001440769
, O 0 0.00063186523
quinine B-Chemical 0 0.99986064
is O 0 0.0001308218
widely O 0 0.0001189022
available O 0 0.00010153016
in O 0 0.00016747043
beverages O 0 0.07386973
including O 0 0.0002471047
tonic O 0 0.0015388275
water O 0 0.004039182
and O 0 0.0012493742
bitter O 0 0.729926
lemon O 0 0.9957009
. O 0 0.0053828442

Numerous O 0 0.0030798698
anecdotal O 0 0.004391575
reports O 0 0.0012104806
suggest O 0 0.00044686263
that O 0 0.0004395026
products O 0 0.00062096096
containing O 0 0.0006488813
quinine B-Chemical 0 0.999863
may O 0 0.0002720259
produce O 0 0.00021665926
neurological B-Disease 0 0.99386334
complications I-Disease 0 0.61594915
, O 0 0.0004539073
including O 0 0.00016054304
confusion B-Disease 0 0.24633545
, O 0 0.0004915672
altered O 0 0.00027357502
mental O 0 0.018590579
status O 0 0.00029778492
, O 0 0.0012074508
seizures B-Disease 0 0.999966
, O 0 0.0010068197
and O 0 0.00064340956
coma B-Disease 0 0.999819
, O 0 0.0010230537
particularly O 0 0.00055746443
in O 0 0.00063139445
older O 0 0.0042828396
women O 0 0.0048988136
. O 0 0.0029978144

Psychologists O 0 0.006697871
need O 0 0.0018358234
to O 0 0.0012051527
inquire O 0 0.0017726439
about O 0 0.000965055
consumption O 0 0.0042518727
of O 0 0.0012283658
quinine B-Chemical 0 0.99986756
- O 0 0.007954391
containing O 0 0.00040301486
beverages O 0 0.13737106
as O 0 0.00043843137
part O 0 0.0003723518
of O 0 0.0005501654
an O 0 0.0007788405
evaluation O 0 0.0009148097
process O 0 0.0015702237
. O 0 0.0030679463

Transient O 0 0.025222827
platypnea B-Disease 0 0.9070088
- I-Disease 0 0.17124975
orthodeoxia I-Disease 0 0.99796534
- I-Disease 0 0.014652437
like I-Disease 0 0.00086053443
syndrome I-Disease 0 0.78118277
induced O 0 0.00062077807
by O 0 0.0010907328
propafenone B-Chemical 0 0.9999969
overdose B-Disease 0 0.9999012
in O 0 0.00038704733
a O 0 0.00052225345
young O 0 0.0013889109
woman O 0 0.0012387673
with O 0 0.00066945923
Ebstein B-Disease 0 0.27109215
' I-Disease 0 0.0020775998
s I-Disease 0 0.0024398747
anomaly I-Disease 0 0.72662026
. O 0 0.004086674

In O 0 0.002285647
this O 0 0.0021039867
report O 0 0.0018135431
we O 0 0.00049651565
describe O 0 0.00056581147
the O 0 0.0004190818
case O 0 0.00043479996
of O 0 0.00039223654
a O 0 0.0005303212
37 O 0 0.00072416745
- O 0 0.0013911128
year O 0 0.00020578614
- O 0 0.0006897999
old O 0 0.00021125356
white O 0 0.00030076655
woman O 0 0.0005240161
with O 0 0.00024780162
Ebstein B-Disease 0 0.17217179
' I-Disease 0 0.0005111351
s I-Disease 0 0.00043450043
anomaly I-Disease 0 0.5772564
, O 0 0.00043169857
who O 0 0.00023722668
developed O 0 0.00017689115
a O 0 0.00030862482
rare O 0 0.0025137437
syndrome O 0 0.94205683
called O 0 0.0005590488
platypnea B-Disease 0 0.93054014
- I-Disease 0 0.06599033
orthodeoxia I-Disease 0 0.99856025
, O 0 0.0003932671
characterized O 0 0.00019124302
by O 0 0.00013491248
massive O 0 0.00052067183
right O 0 0.00061834673
- O 0 0.0014153906
to O 0 0.00014227805
- O 0 0.0009011479
left O 0 0.00045516467
interatrial O 0 0.042010073
shunting O 0 0.10133782
with O 0 0.00031452463
transient O 0 0.0009712036
profound O 0 0.008955146
hypoxia B-Disease 2 0.998276
and O 0 0.0026591404
cyanosis B-Disease 0 0.9977816
. O 0 0.00318103

This O 0 0.004972415
shunt O 0 0.007743427
of O 0 0.0016486242
blood O 0 0.0040013874
via O 0 0.0005916396
a O 0 0.0009709825
patent B-Disease 0 0.09526132
foramen I-Disease 0 0.9621465
ovale I-Disease 0 0.98705006
occurred O 0 0.0003415642
in O 0 0.00018147136
the O 0 0.00013586612
presence O 0 0.00014586882
of O 0 0.00018878377
a O 0 0.0002785473
normal O 0 0.00035195495
pulmonary O 0 0.030193355
artery O 0 0.10532444
pressure O 0 0.0070612375
, O 0 0.0003697974
and O 0 0.00021012896
was O 0 0.0002172681
probably O 0 0.00033349617
precipitated O 0 0.0007029849
by O 0 0.0006374904
a O 0 0.0031311263
propafenone B-Chemical 0 0.9999883
overdose B-Disease 0 0.9997242
. O 0 0.004019713

This O 0 0.005850787
drug O 0 0.023059985
caused O 0 0.0018232889
biventricular B-Disease 0 0.9336295
dysfunction I-Disease 0 0.9983469
, O 0 0.0016288497
due O 0 0.00027407132
to O 0 0.00022531641
its O 0 0.00030867808
negative O 0 0.00029394787
inotropic O 0 0.4357151
effect O 0 0.00022067767
, O 0 0.0005944292
and O 0 0.0005090437
hypotension B-Disease 0 0.9999249
, O 0 0.00065119966
due O 0 0.00018598781
to O 0 0.00025293685
its O 0 0.0005771764
peripheral O 0 0.0028886783
vasodilatory O 0 0.7720031
effect O 0 0.0014718552
. O 0 0.0030190041

These O 0 0.0018846994
effects O 0 0.0016551905
gave O 0 0.0014500858
rise O 0 0.000893409
to O 0 0.0004526607
an O 0 0.00040297318
increase O 0 0.00024365229
in O 0 0.00018671648
the O 0 0.00014697867
right O 0 0.0003994316
atrial O 0 0.0065930006
pressure O 0 0.0024649317
and O 0 0.00016091303
a O 0 0.0001870135
decrease O 0 0.00013249161
in O 0 9.853629e-05
the O 0 8.785114e-05
left O 0 0.00025156356
one O 0 9.973363e-05
with O 0 0.00013138186
a O 0 0.00021058186
consequent O 0 0.00023547727
stretching O 0 0.0003643173
of O 0 0.00014006536
the O 0 0.00014873433
foramen O 0 0.8229427
ovale O 0 0.79680026
and O 0 0.000178143
the O 0 0.00010998285
creation O 0 0.00016443236
of O 0 0.00021164083
massive O 0 0.00078506756
right O 0 0.0010275473
- O 0 0.0024187788
to O 0 0.00045883478
- O 0 0.0027612937
left O 0 0.0022529918
shunting O 0 0.2659901
. O 0 0.0031294434

In O 0 0.00235387
our O 0 0.002013292
case O 0 0.0017731544
this O 0 0.0014683343
interatrial O 0 0.03508165
shunt O 0 0.005895259
was O 0 0.00062530645
very O 0 0.00065004494
accurately O 0 0.00045928903
detected O 0 0.00038244846
at O 0 0.0005196861
bubble O 0 0.0028838343
contrast O 0 0.0017690792
echocardiography O 0 0.004253813
. O 0 0.003484676

Noxious O 0 0.021070072
chemical O 0 0.0022552202
stimulation O 0 0.00091963384
of O 0 0.0010279905
rat O 0 0.0016445903
facial O 0 0.14957914
mucosa O 0 0.0070828814
increases O 0 0.000398092
intracranial O 0 0.60866934
blood O 0 0.0032273126
flow O 0 0.0010609834
through O 0 0.00014264674
a O 0 0.00028654194
trigemino O 0 0.0025514413
- O 0 0.002720562
parasympathetic O 0 0.07249658
reflex O 0 0.020158915
- O 0 0.0024376486
- O 0 0.0009786871
an O 0 0.00016841012
experimental O 0 0.00017026466
model O 0 0.00019939156
for O 0 0.00034693064
vascular B-Disease 0 0.9992281
dysfunctions I-Disease 0 0.9980856
in O 0 0.0010803846
cluster B-Disease 0 0.0021662288
headache I-Disease 0 0.99532145
. O 0 0.003000803

Cluster B-Disease 0 0.93110234
headache I-Disease 0 0.99927
is O 0 0.0017162723
characterized O 0 0.001331682
by O 0 0.0007396994
typical O 0 0.00083508145
autonomic O 0 0.02722738
dysfunctions O 0 0.17219238
including O 0 0.000499676
facial O 0 0.026750157
and O 0 0.0011899887
intracranial B-Disease 0 0.9951102
vascular I-Disease 0 0.9922701
disturbances I-Disease 0 0.9831579
. O 0 0.0039573577

Both O 0 0.0028413094
the O 0 0.001957818
trigeminal O 0 0.0030581686
and O 0 0.0010565284
the O 0 0.0008065857
cranial O 0 0.022822535
parasympathetic O 0 0.040345527
systems O 0 0.00056933373
may O 0 0.00038079786
be O 0 0.00038799102
involved O 0 0.00037912623
in O 0 0.00048544168
mediating O 0 0.00044303384
these O 0 0.0013396133
dysfunctions O 0 0.39509237
. O 0 0.004454068

An O 0 0.0027775788
experimental O 0 0.0016800953
model O 0 0.0010322162
was O 0 0.0007756689
developed O 0 0.0006687686
in O 0 0.00038328065
the O 0 0.0002689509
rat O 0 0.00034983305
to O 0 0.0001507839
measure O 0 0.000115112925
changes O 0 0.00018885921
in O 0 0.00021217708
lacrimation O 0 0.54340905
and O 0 0.00024311067
intracranial O 0 0.53659844
blood O 0 0.0025013715
flow O 0 0.00083974714
following O 0 0.0001033081
noxious O 0 0.0002762901
chemical O 0 0.00024253048
stimulation O 0 0.00025209517
of O 0 0.0007772149
facial O 0 0.2674884
mucosa O 0 0.07123063
. O 0 0.0032160336

Blood O 0 0.037869833
flow O 0 0.008051889
was O 0 0.0012830212
monitored O 0 0.00067859935
in O 0 0.00071606174
arteries O 0 0.107239634
of O 0 0.000565788
the O 0 0.0003783752
exposed O 0 0.00064584805
cranial O 0 0.074044414
dura O 0 0.086427726
mater O 0 0.0063260077
and O 0 0.00034250823
the O 0 0.00035026894
parietal O 0 0.26510137
cortex O 0 0.0033156325
using O 0 0.00050570985
laser O 0 0.00221645
Doppler O 0 0.0056458395
flowmetry O 0 0.009640846
. O 0 0.0028252366

Capsaicin B-Chemical 0 0.9986387
( O 0 0.007032343
0 O 0 0.0025100398
. O 0 0.0014468511
01 O 0 0.0045454646
- O 0 0.0027958625
1 O 0 0.00061211165
mm O 0 0.0012343446
) O 0 0.0008067083
applied O 0 0.0002788082
to O 0 0.0002428322
oral O 0 0.0008807149
or O 0 0.00024389772
nasal O 0 0.0008042809
mucosa O 0 0.0019057029
induced O 0 0.00019677183
increases B-Disease 0 0.00023138309
in I-Disease 0 0.00028188515
dural I-Disease 0 0.702095
and I-Disease 0 0.00035075867
cortical I-Disease 0 0.0012547217
blood I-Disease 0 0.004625023
flow I-Disease 0 0.0036976612
and O 0 0.00086818286
provoked O 0 0.0048322617
lacrimation O 0 0.96392393
. O 0 0.0034407955

These O 0 0.0020008744
responses O 0 0.0017563885
were O 0 0.0012788554
blocked O 0 0.001395196
by O 0 0.0008136565
systemic O 0 0.017759675
pre O 0 0.0011576915
- O 0 0.002741934
administration O 0 0.0009774446
of O 0 0.0012085382
hexamethonium B-Chemical 0 0.9999957
chloride I-Chemical 0 0.9999225
( O 0 0.0019842698
20 O 0 0.0007479759
mg O 0 0.00442756
/ O 0 0.0027810517
kg O 0 0.0027949482
) O 0 0.0038589141
. O 0 0.003640116

The O 0 0.002031286
evoked O 0 0.0030681929
increases B-Disease 0 0.0011861806
in I-Disease 0 0.001020723
dural I-Disease 0 0.7459041
blood I-Disease 0 0.008412123
flow I-Disease 0 0.0024153867
were O 0 0.00022817617
also O 0 0.00016720747
abolished O 0 0.00021098704
by O 0 0.00018691119
topical O 0 0.015027799
pre O 0 0.00039341502
- O 0 0.0011260395
administration O 0 0.00034534044
of O 0 0.0003539481
atropine B-Chemical 0 0.99996316
( O 0 0.0005520978
1 O 0 0.00019094802
mm O 0 0.0005879864
) O 0 0.00045519485
and O 0 0.00025120116
[ O 0 0.0016092906
Lys1 O 0 0.0010885498
, O 0 0.0007163198
Pro2 O 0 0.0013064158
, O 0 0.0004928185
5 O 0 0.0002385076
, O 0 0.0004995524
Arg3 O 0 0.002719667
, O 0 0.00048223775
4 O 0 0.00021193708
, O 0 0.00048364062
Tyr6 O 0 0.002814095
] O 0 0.0028385401
- O 0 0.0050761197
VIP O 0 0.10786709
( O 0 0.00047049104
0 O 0 0.0002406665
. O 0 0.00014623189
1 O 0 0.00015930604
mm O 0 0.00052742613
) O 0 0.00046656886
, O 0 0.00033506055
a O 0 0.00031076182
vasoactive O 0 0.0026840651
intestinal O 0 0.0016880205
polypeptide O 0 0.00076773704
( O 0 0.0011423886
VIP O 0 0.48714286
) O 0 0.0019145134
antagonist O 0 0.0787143
, O 0 0.00081426
onto O 0 0.00045562067
the O 0 0.00049689156
exposed O 0 0.0013371379
dura O 0 0.24839322
mater O 0 0.0996678
. O 0 0.0034796523

We O 0 0.0021059816
conclude O 0 0.0010948046
that O 0 0.0007950458
noxious O 0 0.0011335694
stimulation O 0 0.00040458853
of O 0 0.0006269908
facial O 0 0.124172024
mucosa O 0 0.007889155
increases O 0 0.0003829406
intracranial O 0 0.7098267
blood O 0 0.0058100545
flow O 0 0.0023086688
and O 0 0.00038176763
lacrimation O 0 0.50502765
via O 0 0.0002725186
a O 0 0.00069094036
trigemino O 0 0.0069077886
- O 0 0.007955534
parasympathetic O 0 0.19265065
reflex O 0 0.029508185
. O 0 0.0030648382

The O 0 0.0024789572
blood O 0 0.0076757837
flow O 0 0.00509374
responses O 0 0.0009849136
seem O 0 0.00066435704
to O 0 0.0004006722
be O 0 0.00033580937
mediated O 0 0.00021454501
by O 0 0.00032880958
the O 0 0.00034931587
release O 0 0.0010510084
of O 0 0.0010207959
acetylcholine B-Chemical 1 0.99961877
and O 0 0.0010115877
VIP O 0 0.13004392
within O 0 0.0004585825
the O 0 0.00095655816
meninges O 0 0.014453897
. O 0 0.0029558123

Similar O 0 0.002453344
mechanisms O 0 0.0019885236
may O 0 0.0016978872
be O 0 0.0013351049
involved O 0 0.001025122
in O 0 0.001041432
the O 0 0.0009918752
pathogenesis O 0 0.001976027
of O 0 0.0019812237
cluster B-Disease 0 0.0040238113
headache I-Disease 0 0.99465203
. O 0 0.005620908

Organophosphate B-Chemical 0 0.9992494
- O 0 0.13200386
induced O 0 0.0059626517
convulsions B-Disease 0 0.9996402
and O 0 0.0030117591
prevention O 0 0.003330636
of O 0 0.003986005
neuropathological B-Disease 0 0.9901008
damages I-Disease 0 0.97556216
. O 0 0.008141761

Such O 0 0.011408638
organophosphorus B-Chemical 0 0.9995678
( O 0 0.017284773
OP B-Chemical 0 0.998553
) O 0 0.0065604253
compounds O 0 0.057022247
as O 0 0.001751707
diisopropylfluorophosphate B-Chemical 0 0.99987614
( O 0 0.03532147
DFP B-Chemical 0 0.9999472
) O 0 0.0037566877
, O 0 0.0016615695
sarin B-Chemical 0 0.9997174
and O 0 0.0007683599
soman B-Chemical 0 0.9991861
are O 0 0.00016795514
potent O 0 0.0002633789
inhibitors O 0 0.00039944533
of O 0 0.0004342526
acetylcholinesterases O 0 0.26276663
( O 0 0.0012503832
AChEs O 0 0.0022238598
) O 0 0.001164632
and O 0 0.00064106064
butyrylcholinesterases O 0 0.24347256
( O 0 0.002743014
BChEs O 0 0.007348887
) O 0 0.0043219808
. O 0 0.003334488

The O 0 0.0026593807
acute O 0 0.08805683
toxicity B-Disease 0 0.68719214
of O 0 0.0015478435
OPs B-Chemical 0 0.32542202
is O 0 0.00037996768
the O 0 0.00024368642
result O 0 0.00020434843
of O 0 0.0002521783
their O 0 0.00025109795
irreversible O 0 0.0017378562
binding O 0 0.00013398044
with O 0 0.00026045676
AChEs O 0 0.0010748589
in O 0 0.00015844846
the O 0 0.00013477476
central O 0 0.00033156647
nervous O 0 0.0013782632
system O 0 0.00021621745
( O 0 0.00049732794
CNS O 0 0.0035259621
) O 0 0.0006363422
, O 0 0.0004982198
which O 0 0.00048114793
elevates O 0 0.021024955
acetylcholine B-Chemical 1 0.9998354
( O 0 0.0064022103
ACh B-Chemical 0 0.999087
) O 0 0.0030129834
levels O 0 0.0015873099
. O 0 0.0030955132

The O 0 0.0019149347
protective O 0 0.0020379673
action O 0 0.0010936685
of O 0 0.00087714056
subcutaneously O 0 0.00079747883
( O 0 0.0009961909
SC O 0 0.0033589208
) O 0 0.0007773297
administered O 0 0.00041927662
antidotes O 0 0.0031226822
or O 0 0.00016923735
their O 0 0.00014432204
combinations O 0 0.00016992357
in O 0 0.0004023636
DFP B-Chemical 0 0.9998882
( O 0 0.00053934875
2 O 0 0.00017706965
. O 0 0.00012505065
0 O 0 0.00018246436
mg O 0 0.0009769844
/ O 0 0.0005499825
kg O 0 0.0005146632
BW O 0 0.010904703
) O 0 0.0009594154
intoxication O 0 0.9501812
was O 0 0.000191044
studied O 0 0.0002313103
in O 0 0.00015935968
9 O 0 0.00017950572
- O 0 0.00075162825
10 O 0 0.00019916585
- O 0 0.0006143422
weeks O 0 0.00014254163
- O 0 0.000947949
old O 0 0.00056119205
Han O 0 0.0032816473
- O 0 0.0033075083
Wistar O 0 0.003146356
male O 0 0.002238593
rats O 0 0.0026787757
. O 0 0.0031885034

The O 0 0.002064015
rats O 0 0.0029646463
received O 0 0.002184044
AChE O 0 0.29494303
reactivator O 0 0.5069516
pralidoxime B-Chemical 0 0.999169
- I-Chemical 0 0.010324653
2 I-Chemical 0 0.000702053
- I-Chemical 0 0.008642396
chloride I-Chemical 0 0.9990897
( O 0 0.0020552315
2PAM B-Chemical 0 0.9688702
) O 0 0.0009348841
( O 0 0.00040352368
30 O 0 0.00015567271
. O 0 0.00014125921
0 O 0 0.00020931472
mg O 0 0.0009889053
/ O 0 0.0005900909
kg O 0 0.0005361499
BW O 0 0.00620193
) O 0 0.00078143534
, O 0 0.0009167324
anticonvulsant O 0 0.9997745
diazepam B-Chemical 0 0.99999833
( O 0 0.0008515396
2 O 0 0.00018742174
. O 0 0.000127557
0 O 0 0.00018733136
mg O 0 0.0009815759
/ O 0 0.00056151435
kg O 0 0.0005167215
BW O 0 0.0051181754
) O 0 0.00064305705
, O 0 0.0004915136
A O 0 0.004023112
( O 0 0.0005734671
1 O 0 0.00030500503
) O 0 0.0009967348
- O 0 0.026735561
adenosine B-Chemical 0 0.9992207
receptor O 0 0.0075580208
agonist O 0 0.34398568
N B-Chemical 0 0.99955124
( I-Chemical 0 0.0008569056
6 I-Chemical 0 0.00017719028
) I-Chemical 0 0.000873426
- I-Chemical 0 0.03017905
cyclopentyl I-Chemical 0 0.99966013
adenosine I-Chemical 0 0.9998933
( O 0 0.006916027
CPA B-Chemical 1 0.9998834
) O 0 0.0013810826
( O 0 0.00035271051
2 O 0 0.00015284221
. O 0 0.000115459974
0 O 0 0.00017428008
mg O 0 0.0009552175
/ O 0 0.0005471655
kg O 0 0.00052283844
BW O 0 0.012521113
) O 0 0.0010858822
, O 0 0.0016618897
NMDA B-Chemical 0 0.999969
- O 0 0.29760984
receptor O 0 0.024622224
antagonist O 0 0.99215466
dizocilpine B-Chemical 0 0.9999993
maleate I-Chemical 0 0.99999964
( O 0 0.019375503
+ O 0 0.07112034
- O 0 0.8421039
MK801 O 0 0.99999976
hydrogen O 0 0.99999475
maleate O 0 0.99999964
) O 0 0.010323163
( O 0 0.00035487604
2 O 0 0.00012440898
. O 0 8.980454e-05
0 O 0 0.00013536154
mg O 0 0.00076234544
/ O 0 0.00041316307
kg O 0 0.00036197598
BW O 0 0.003555052
) O 0 0.000273574
or O 0 7.276429e-05
their O 0 6.7623456e-05
combinations O 0 8.261422e-05
with O 0 0.0002677974
cholinolytic O 0 0.9997708
drug O 0 0.95942533
atropine B-Chemical 0 0.9999989
sulfate I-Chemical 0 0.9999536
( O 0 0.00078881485
50 O 0 0.0001993167
. O 0 0.00011229437
0 O 0 0.00016324912
mg O 0 0.0010575253
/ O 0 0.0004994753
kg O 0 0.00043840212
BW O 0 0.0044377204
) O 0 0.0003549454
immediately O 0 9.0484136e-05
or O 0 0.0001073687
30 O 0 0.00011898307
min O 0 0.00018551067
after O 0 8.590614e-05
the O 0 0.00015849287
single O 0 0.00025137057
SC O 0 0.002166169
injection O 0 0.0005856418
of O 0 0.0017322707
DFP B-Chemical 0 0.999275
. O 0 0.00419418

The O 0 0.0016767395
control O 0 0.0015062598
rats O 0 0.002165584
received O 0 0.0022922494
atropine B-Chemical 0 0.9999865
sulfate I-Chemical 0 0.9998441
, O 0 0.002095461
but O 0 0.000490248
also O 0 0.0002845269
saline O 0 0.00095891964
and O 0 0.0003475285
olive O 0 0.09960578
oil O 0 0.8734596
instead O 0 0.0002961445
of O 0 0.00033543963
other O 0 0.00038796364
antidotes O 0 0.120809145
and O 0 0.0016910414
DFP B-Chemical 0 0.99974924
, O 0 0.0029563776
respectively O 0 0.0031527695
. O 0 0.0031838072

All O 0 0.002456698
rats O 0 0.0028435139
were O 0 0.0013266613
terminated O 0 0.0011544087
either O 0 0.00071531115
24 O 0 0.00063168374
h O 0 0.0005411335
or O 0 0.00036663812
3 O 0 0.00033641452
weeks O 0 0.00025676863
after O 0 0.0003840348
the O 0 0.0010707501
DFP B-Chemical 0 0.99682045
injection O 0 0.002203086
. O 0 0.0037301213

The O 0 0.0021630567
rats O 0 0.0030507352
treated O 0 0.0033818858
with O 0 0.0033820807
DFP B-Chemical 0 0.99990845
- O 0 0.6082526
atropine B-Chemical 0 0.999946
showed O 0 0.0009727636
severe O 0 0.006200331
typical O 0 0.0012651952
OP B-Chemical 0 0.99894065
- O 0 0.016229678
induced O 0 0.0012410441
toxicity B-Disease 0 0.88676924
signs O 0 0.025579244
. O 0 0.0037059672

When O 0 0.004326627
CPA B-Chemical 1 0.99919504
, O 0 0.056265153
diazepam B-Chemical 0 0.99999225
or O 0 0.0022461272
2PAM B-Chemical 0 0.9832412
was O 0 0.0003798317
given O 0 0.0001691983
immediately O 0 0.00016012539
after O 0 0.00020501608
DFP B-Chemical 0 0.999876
- O 0 0.13997127
atropine B-Chemical 0 0.999962
, O 0 0.00047826878
these O 0 0.00014701596
treatments O 0 0.00022021902
prevented O 0 0.000359107
, O 0 0.00048629203
delayed O 0 0.00068513665
or O 0 0.00017878486
shortened O 0 0.0002935908
the O 0 0.0001746204
occurrence O 0 0.0002818591
of O 0 0.00040195227
serious O 0 0.0018244036
signs O 0 0.006117949
of O 0 0.0021553484
poisoning B-Disease 2 0.9996859
. O 0 0.004612378

Atropine B-Chemical 0 0.9999672
- O 0 0.98833734
MK801 B-Chemical 0 0.9999896
did O 0 0.0033380268
not O 0 0.0009946196
offer O 0 0.00078887114
any O 0 0.0005902607
additional O 0 0.00052020286
protection O 0 0.0009729012
against O 0 0.001138784
DFP B-Chemical 0 0.99970764
toxicity B-Disease 0 0.9707791
. O 0 0.0054532196

In O 0 0.002123826
conclusion O 0 0.0018498906
, O 0 0.007154797
CPA B-Chemical 1 0.99967945
, O 0 0.051617775
diazepam B-Chemical 0 0.99999654
and O 0 0.002120315
2PAM B-Chemical 0 0.98826563
in O 0 0.00028646106
combination O 0 0.0003450952
with O 0 0.0005619651
atropine B-Chemical 0 0.9999839
prevented O 0 0.0005917591
the O 0 0.00014223832
occurrence O 0 0.00016621208
of O 0 0.00016978689
serious O 0 0.0007122732
signs O 0 0.0020165585
of O 0 0.00040353907
poisoning B-Disease 2 0.9999218
and O 0 0.0002656922
thus O 0 0.00020265898
reduced O 0 0.00029702732
the O 0 0.00031596093
toxicity B-Disease 0 0.8327155
of O 0 0.0017302238
DFP B-Chemical 0 0.99986386
in O 0 0.0012293531
rat O 0 0.0024073182
. O 0 0.002581071

A O 0 0.9405703
pyridoxine B-Chemical 0 0.9999484
- O 0 0.21585953
dependent O 0 0.002886574
behavioral B-Disease 0 0.7312416
disorder I-Disease 0 0.9997508
unmasked O 0 0.33214906
by O 0 0.005873368
isoniazid B-Chemical 1 0.9998084
. O 0 0.008178421

A O 0 0.025453778
3 O 0 0.002969064
- O 0 0.006212702
year O 0 0.0012723779
- O 0 0.003065031
old O 0 0.00092493533
girl O 0 0.0018329499
had O 0 0.00054371037
behavioral B-Disease 0 0.041111074
deterioration I-Disease 0 0.48536143
, O 0 0.0008502634
with O 0 0.00070007466
hyperkinesis B-Disease 0 0.9999819
, O 0 0.0062649846
irritability B-Disease 0 0.99997115
, O 0 0.00075364934
and O 0 0.00032641148
sleeping B-Disease 0 0.24184315
difficulties I-Disease 0 0.0066666096
after O 0 0.00012157179
the O 0 0.00017751192
therapeutic O 0 0.00045195638
administration O 0 0.0009266028
of O 0 0.0015692828
isoniazid B-Chemical 1 0.9999051
. O 0 0.004266956

The O 0 0.001758731
administration O 0 0.0020541952
of O 0 0.0011865693
pharmacologic O 0 0.0032914316
doses O 0 0.0038201278
of O 0 0.004425022
pyridoxine B-Chemical 0 0.9999981
hydrochloride I-Chemical 0 0.9998456
led O 0 0.0010107486
to O 0 0.00057228963
a O 0 0.0010459766
disappearance O 0 0.0017059897
of O 0 0.0014443265
symptoms O 0 0.014554203
. O 0 0.00331412

After O 0 0.0018109159
discontinuing O 0 0.014731472
isoniazid B-Chemical 1 0.9998419
therapy O 0 0.0015238349
a O 0 0.0006596577
similar O 0 0.00024848487
pattern O 0 0.00027966252
of O 0 0.00037485387
behavior O 0 0.0005844117
was O 0 0.0003605825
noted O 0 0.00037678494
that O 0 0.00032551403
was O 0 0.00055345555
controlled O 0 0.0011585013
by O 0 0.0024225402
pyridoxine B-Chemical 0 0.99994683
. O 0 0.0065999087

A O 0 0.050752435
placebo O 0 0.045115646
had O 0 0.001549917
no O 0 0.00093251956
effect O 0 0.000972942
, O 0 0.0028529412
but O 0 0.0031046828
niacinamide B-Chemical 0 0.9999702
was O 0 0.0013711118
as O 0 0.0010005159
effective O 0 0.0013342281
as O 0 0.0030262894
pyridoxine B-Chemical 0 0.9999443
. O 0 0.0082694935

Periodic O 0 0.008321589
withdrawal O 0 0.019274896
of O 0 0.0062299217
pyridoxine B-Chemical 0 0.9999584
was O 0 0.0018779159
associated O 0 0.0012183818
with O 0 0.001093854
return O 0 0.001271399
of O 0 0.0014835225
the O 0 0.0023519772
hyperkinesis B-Disease 0 0.99957067
. O 0 0.0066924514

The O 0 0.0027789895
level O 0 0.0028087103
of O 0 0.0057543344
pyridoxal B-Chemical 0 0.9997888
in O 0 0.0013726889
the O 0 0.0007846705
blood O 0 0.00460404
was O 0 0.0005178097
normal O 0 0.0006455167
during O 0 0.00030873428
the O 0 0.0003963696
periods O 0 0.00066712464
of O 0 0.0014737506
relapse O 0 0.06119133
. O 0 0.003756138

Metabolic O 0 0.03698484
studies O 0 0.0032545496
suggested O 0 0.0015689266
a O 0 0.0018638036
block O 0 0.0012402363
in O 0 0.0011944057
the O 0 0.0016003762
kynurenine B-Chemical 0 0.9996871
pathway O 0 0.0015493939
of O 0 0.0032468955
tryptophan B-Chemical 0 0.99642193
metabolism O 0 0.75612205
. O 0 0.0061942283

The O 0 0.0021084754
patient O 0 0.0018712013
has O 0 0.0007024528
been O 0 0.0005407783
followed O 0 0.00031409517
for O 0 0.00021159342
six O 0 0.00014707007
years O 0 0.00025612654
and O 0 0.00018628116
has O 0 0.000107718195
required O 0 0.00010066253
pharmacologic O 0 0.0007462095
doses O 0 0.0009841645
of O 0 0.0010543701
pyridoxine B-Chemical 0 0.9999889
to O 0 0.0006259716
control O 0 0.00071972463
her O 0 0.0011689467
behavior O 0 0.002250395
. O 0 0.003076582

Recurrent O 0 0.011805502
excitation O 0 0.012540928
in O 0 0.0018932311
the O 0 0.0014069095
dentate O 0 0.013876256
gyrus O 0 0.6488976
of O 0 0.0009895355
a O 0 0.0009337154
murine O 0 0.0006960366
model O 0 0.00054578646
of O 0 0.0010214831
temporal B-Disease 0 0.13135014
lobe I-Disease 0 0.98057806
epilepsy I-Disease 0 0.9999584
. O 0 0.00581373

Similar O 0 0.0018755542
to O 0 0.0014665965
rats O 0 0.0021001825
, O 0 0.0025317397
systemic O 0 0.6918384
pilocarpine B-Chemical 0 0.99996316
injection O 0 0.00041692008
causes O 0 0.00034568147
status B-Disease 0 0.00043745388
epilepticus I-Disease 0 0.99939024
( O 0 0.00076594314
SE B-Disease 0 0.16039068
) O 0 0.0004800237
and O 0 0.00015619879
the O 0 0.00012460416
eventual O 0 0.0003708001
development O 0 0.00022522191
of O 0 0.00024109366
spontaneous O 0 0.0047411704
seizures B-Disease 0 0.9999794
and O 0 0.00041940532
mossy O 0 0.2483583
fiber O 0 0.001973376
sprouting O 0 0.5500203
in O 0 0.00023829554
C57BL O 0 0.034093138
/ O 0 0.0006272957
6 O 0 8.220511e-05
and O 0 0.00011238092
CD1 O 0 0.0007283731
mice O 0 5.684131e-05
, O 0 0.00023883801
but O 0 0.00015073203
the O 0 0.0001029467
physiological O 0 0.00015800414
correlates O 0 0.00014990027
of O 0 0.00015737413
these O 0 0.00015576491
events O 0 0.00030102732
have O 0 0.00018357878
not O 0 0.00022252178
been O 0 0.00030593784
identified O 0 0.00031884984
in O 0 0.00061113085
mice O 0 0.0005853628
. O 0 0.0023329796

Population O 0 0.0044653816
responses O 0 0.0018885981
in O 0 0.00150515
granule O 0 0.004323409
cells O 0 0.00095168833
of O 0 0.0006970257
the O 0 0.00051295705
dentate O 0 0.017197786
gyrus O 0 0.6716098
were O 0 0.00022181596
examined O 0 0.00013036306
in O 0 0.00015125972
transverse O 0 0.00047084974
slices O 0 0.00021873662
of O 0 0.00016620701
the O 0 0.00015610659
ventral O 0 0.0005657619
hippocampus O 0 0.0019420385
from O 0 0.00035626517
pilocarpine B-Chemical 0 0.99997544
- O 0 0.005656705
treated O 0 0.00070916774
and O 0 0.00055285264
untreated O 0 0.0011533255
mice O 0 0.0006305772
. O 0 0.0024152386

In O 0 0.004859068
Mg B-Chemical 0 0.99526334
( O 0 0.0046785977
2 O 0 0.001785387
+ O 0 0.0035245635
) O 0 0.0025848667
- O 0 0.0043230047
free O 0 0.0008611287
bathing O 0 0.0020930276
medium O 0 0.002491188
containing O 0 0.00052399316
bicuculline B-Chemical 1 0.9999751
, O 0 0.0006928754
conditions O 0 0.00017946327
designed O 0 0.00012099042
to O 0 0.000107643136
increase O 0 0.00012716302
excitability O 0 0.0006461361
in O 0 8.537645e-05
the O 0 7.507697e-05
slices O 0 0.00015559125
, O 0 0.00018520984
electrical O 0 0.00018817704
stimulation O 0 5.841291e-05
of O 0 9.7405326e-05
the O 0 9.883028e-05
hilus O 0 0.0029704534
resulted O 0 9.672097e-05
in O 0 9.0009016e-05
a O 0 0.00013338502
single O 0 6.467184e-05
population O 0 0.000133573
spike O 0 0.00012368412
in O 0 0.00010485857
granule O 0 0.0009330165
cells O 0 0.00014554983
from O 0 8.490231e-05
control O 0 9.030957e-05
mice O 0 4.978907e-05
and O 0 0.00028386412
pilocarpine B-Chemical 0 0.9999887
- O 0 0.005227366
treated O 0 0.00032088906
mice O 0 8.3860294e-05
that O 0 0.00018976066
did O 0 0.00046403168
not O 0 0.00066749036
experience O 0 0.003340818
SE B-Disease 0 0.4600221
. O 0 0.0035463346

In O 0 0.0030470137
SE B-Disease 0 0.27091002
survivors O 0 0.004060296
, O 0 0.0015857809
similar O 0 0.00041242776
stimulation O 0 0.00031942094
resulted O 0 0.0003063409
in O 0 0.00027692725
a O 0 0.00036014858
population O 0 0.00029230016
spike O 0 0.00021134743
followed O 0 0.00012540421
, O 0 0.00023253623
at O 0 0.000100046265
a O 0 0.00018185974
variable O 0 0.00011848908
latency O 0 0.0003204953
, O 0 0.0002570758
by O 0 0.00012540756
negative O 0 0.00017700352
DC O 0 0.003612203
shifts O 0 0.00021987243
and O 0 0.0001603928
repetitive O 0 0.00016062007
afterdischarges O 0 0.012540437
of O 0 0.00012395474
3 O 0 0.00011350984
- O 0 0.00041671805
60 O 0 0.000107257976
s O 0 0.0001300482
duration O 0 8.177759e-05
, O 0 0.00025522267
which O 0 0.00021712706
were O 0 0.00023498408
blocked O 0 0.00069051416
by O 0 0.00086844095
ionotropic O 0 0.99768126
glutamate B-Chemical 0 0.99987876
receptor O 0 0.13503845
antagonists O 0 0.6523567
. O 0 0.004713307

Focal O 0 0.60161906
glutamate B-Chemical 0 0.9980336
photostimulation O 0 0.0030611982
of O 0 0.0010784689
the O 0 0.00069099176
granule O 0 0.0037020817
cell O 0 0.00079831487
layer O 0 0.0008367007
at O 0 0.00017476965
sites O 0 0.0001594959
distant O 0 0.0007262086
from O 0 0.000116509786
the O 0 8.875668e-05
recording O 0 0.000113153976
pipette O 0 0.00064492057
resulted O 0 0.00010696393
in O 0 0.00010652339
population O 0 0.00015709318
responses O 0 0.00012174163
of O 0 0.00016226721
1 O 0 0.00019322145
- O 0 0.00050554716
30 O 0 8.9631205e-05
s O 0 0.000120474884
duration O 0 6.710555e-05
in O 0 0.00010784492
slices O 0 0.000235555
from O 0 0.0002454612
SE B-Disease 0 0.10565557
survivors O 0 0.0011161657
but O 0 0.00052905804
not O 0 0.00051019987
other O 0 0.00083212694
groups O 0 0.0020889123
. O 0 0.0032842641

These O 0 0.0023501306
data O 0 0.0020271856
support O 0 0.0010769643
the O 0 0.00072002306
hypothesis O 0 0.0006806532
that O 0 0.0006993802
SE B-Disease 0 0.6473783
- O 0 0.006165757
induced O 0 0.0005491938
mossy O 0 0.29803512
fiber O 0 0.0041451436
sprouting O 0 0.71319693
and O 0 0.0003186338
synaptic O 0 0.0004417346
reorganization O 0 0.00016520669
are O 0 6.995644e-05
relevant O 0 6.224524e-05
characteristics O 0 8.827656e-05
of O 0 0.00019889977
seizure B-Disease 0 0.9990089
development O 0 0.00023394726
in O 0 0.00011333603
these O 0 0.00011217205
murine O 0 0.00019042002
strains O 0 0.00017582218
, O 0 0.00038538149
resembling O 0 0.0002810219
rat O 0 0.0002791332
models O 0 0.0001931415
of O 0 0.00033748563
human O 0 0.0006197432
temporal B-Disease 0 0.2237417
lobe I-Disease 0 0.98843
epilepsy I-Disease 0 0.9999765
. O 0 0.0042497977

Urinary B-Disease 0 0.9725841
bladder I-Disease 0 0.97314745
cancer I-Disease 0 0.998159
in O 0 0.0031317396
Wegener B-Disease 0 0.18393409
' I-Disease 0 0.0020820175
s I-Disease 0 0.0016569005
granulomatosis I-Disease 0 0.4621089
: O 0 0.0013417215
risks O 0 0.0009247388
and O 0 0.0006702907
relation O 0 0.00065689505
to O 0 0.001664581
cyclophosphamide B-Chemical 0 0.9985085
. O 0 0.0049788384

OBJECTIVE O 0 0.017235303
: O 0 0.0030127345
To O 0 0.0004635981
assess O 0 0.00035515561
and O 0 0.00051995023
characterise O 0 0.00031881643
the O 0 0.00035761987
risk O 0 0.00238857
of O 0 0.0007856581
bladder B-Disease 0 0.9798972
cancer I-Disease 0 0.99960524
, O 0 0.0008670634
and O 0 0.00023724316
its O 0 0.0002161484
relation O 0 0.00012019469
to O 0 0.00024478955
cyclophosphamide B-Chemical 0 0.9997409
, O 0 0.00052916293
in O 0 0.00025900462
patients O 0 0.00061879394
with O 0 0.0006040749
Wegener B-Disease 0 0.14403488
' I-Disease 0 0.001771462
s I-Disease 0 0.0023237527
granulomatosis I-Disease 0 0.8092089
. O 0 0.0033338729

METHODS O 0 0.0037512274
: O 0 0.002394805
In O 0 0.0006424834
the O 0 0.0006468422
population O 0 0.00077004876
based O 0 0.00048422487
, O 0 0.00077906536
nationwide O 0 0.00067731424
Swedish O 0 0.0005839497
Inpatient O 0 0.0011311754
Register O 0 0.00027236438
a O 0 0.00029422855
cohort O 0 0.0005043869
of O 0 0.00035692877
1065 O 0 0.044238538
patients O 0 0.0005217895
with O 0 0.00034644743
Wegener B-Disease 0 0.06845742
' I-Disease 0 0.0006498843
s I-Disease 0 0.0006941024
granulomatosis I-Disease 0 0.7334349
, O 0 0.00094466767
1969 O 0 0.0018935672
- O 0 0.002721227
95 O 0 0.0012536902
, O 0 0.0011912385
was O 0 0.00092830125
identified O 0 0.0012527609
. O 0 0.0033203978

Through O 0 0.00436613
linkage O 0 0.0038431976
with O 0 0.0016685701
the O 0 0.0010695593
Swedish O 0 0.0014935895
Cancer B-Disease 0 0.005135634
Register O 0 0.00058117585
, O 0 0.00058524206
all O 0 0.00029204754
subjects O 0 0.00047158301
in O 0 0.00027303724
this O 0 0.00035667347
cohort O 0 0.0011576866
diagnosed O 0 0.0032028698
with O 0 0.0009798602
bladder B-Disease 0 0.9608453
cancer I-Disease 0 0.9987809
were O 0 0.0013520932
identified O 0 0.0012302205
. O 0 0.0029203724

Nested O 0 0.0052860756
within O 0 0.001072317
the O 0 0.0010342139
cohort O 0 0.001784281
, O 0 0.0011600063
a O 0 0.0006764037
matched O 0 0.00032714673
case O 0 0.00042253223
- O 0 0.0013651502
control O 0 0.00024195493
study O 0 0.000223551
was O 0 0.00012984178
performed O 0 0.000101813835
to O 0 8.250173e-05
estimate O 0 6.384557e-05
the O 0 7.033109e-05
association O 0 6.8936926e-05
between O 0 0.00014621725
cyclophosphamide B-Chemical 0 0.9998611
and O 0 0.00045233182
bladder B-Disease 0 0.9121661
cancer I-Disease 0 0.9978923
using O 0 0.0001811638
odds O 0 0.000300163
ratios O 0 0.00024945766
( O 0 0.0004647718
ORs O 0 0.00042345442
) O 0 0.0008061312
as O 0 0.00050976843
relative O 0 0.0007434573
risk O 0 0.008984623
. O 0 0.0037543646

In O 0 0.0019490682
the O 0 0.001561779
cohort O 0 0.0020103152
the O 0 0.00068425905
cumulative O 0 0.0007330169
risk O 0 0.003091978
of O 0 0.00093036785
bladder B-Disease 0 0.9177715
cancer I-Disease 0 0.99758065
after O 0 0.00025251176
Wegener B-Disease 0 0.06500491
' I-Disease 0 0.00044510385
s I-Disease 0 0.00040852439
granulomatosis I-Disease 0 0.63742095
, O 0 0.00028137822
and O 0 0.00012186277
the O 0 8.241586e-05
relative O 0 7.784371e-05
prevalence O 0 0.00016946228
of O 0 0.00015517001
a O 0 0.00024711245
history O 0 0.00037061438
of O 0 0.00033849408
bladder B-Disease 0 0.9717561
cancer I-Disease 0 0.9992073
at O 0 0.0001177976
the O 0 8.619367e-05
time O 0 7.445498e-05
of O 0 0.0001457423
diagnosis O 0 0.00033502353
of O 0 0.00029429593
Wegener B-Disease 0 0.12785098
' I-Disease 0 0.00065160805
s I-Disease 0 0.00071655086
granulomatosis I-Disease 0 0.7483027
, O 0 0.0008628157
were O 0 0.0005007099
also O 0 0.0007201623
estimated O 0 0.0015423829
. O 0 0.0027550124

RESULTS O 0 0.0037302123
: O 0 0.0021103767
The O 0 0.0004312402
median O 0 0.00032291116
cumulative O 0 0.00039629726
doses O 0 0.00071283785
of O 0 0.00061274815
cyclophosphamide B-Chemical 0 0.9996327
among O 0 0.00044885886
cases O 0 0.00050679606
( O 0 0.0003782259
n O 0 0.00025727635
= O 0 0.00051246205
11 O 0 0.00020710674
) O 0 0.00031910196
and O 0 0.00016722741
controls O 0 0.00026698902
( O 0 0.00033611
n O 0 0.00026551468
= O 0 0.00058832497
25 O 0 0.00033693915
) O 0 0.0004916928
were O 0 0.0002520418
113 O 0 0.00069638557
g O 0 0.0009365817
and O 0 0.0004953701
25 O 0 0.000871322
g O 0 0.0021073
, O 0 0.002044525
respectively O 0 0.003091033
. O 0 0.0036688994

The O 0 0.0028923657
risk O 0 0.009572917
of O 0 0.0033650082
bladder B-Disease 0 0.97436076
cancer I-Disease 0 0.9986565
doubled O 0 0.0011387119
for O 0 0.00030319765
every O 0 0.00016785235
10 O 0 0.00022382315
g O 0 0.0005133584
increment O 0 0.00029800134
in O 0 0.000293029
cyclophosphamide B-Chemical 0 0.99932444
( O 0 0.0006048858
OR O 0 0.0017234193
= O 0 0.0007113073
2 O 0 0.0002339948
. O 0 0.00018525896
0 O 0 0.00025472287
, O 0 0.00034720657
95 O 0 0.00040906746
% O 0 0.00035858786
confidence O 0 0.00051543367
interval O 0 0.00030737772
( O 0 0.00051570346
CI O 0 0.0046410635
) O 0 0.000674554
0 O 0 0.0003626915
. O 0 0.0002609867
8 O 0 0.00026392387
to O 0 0.0002918839
4 O 0 0.00042619283
. O 0 0.000647908
9 O 0 0.0009805845
) O 0 0.0031516221
. O 0 0.0035515537

Treatment O 0 0.004362846
duration O 0 0.00090827723
longer O 0 0.0005877559
than O 0 0.0005879163
1 O 0 0.00054890965
year O 0 0.00034411257
was O 0 0.0002770622
associated O 0 0.00029042794
with O 0 0.00029925493
an O 0 0.00035444024
eightfold O 0 0.00088013767
increased O 0 0.0005016721
risk O 0 0.0025251615
( O 0 0.00066832005
OR O 0 0.0021718822
= O 0 0.00074267806
7 O 0 0.0001849432
. O 0 0.00019334164
7 O 0 0.00018852546
, O 0 0.00043788127
95 O 0 0.0006235285
% O 0 0.0007155041
CI O 0 0.003759789
0 O 0 0.00057637575
. O 0 0.00042448158
9 O 0 0.00045622888
to O 0 0.00064103043
69 O 0 0.0017693408
) O 0 0.003746508
. O 0 0.003854336

The O 0 0.0022774562
absolute O 0 0.002676033
risk O 0 0.0074018654
for O 0 0.0015254369
bladder B-Disease 0 0.9469325
cancer I-Disease 0 0.9984888
in O 0 0.00056789967
the O 0 0.00031459687
cohort O 0 0.0006769554
reached O 0 0.00029701428
10 O 0 0.0001938594
% O 0 0.0002684836
16 O 0 0.00013923827
years O 0 0.000121405195
after O 0 5.937438e-05
diagnosis O 0 0.00018845087
of O 0 0.00019273258
Wegener B-Disease 0 0.03749178
' I-Disease 0 0.00038318618
s I-Disease 0 0.00038043575
granulomatosis I-Disease 0 0.75663704
, O 0 0.0003042952
and O 0 0.00015094117
a O 0 0.00022299583
history O 0 0.0003444438
of O 0 0.00034206803
bladder B-Disease 0 0.9768365
cancer I-Disease 0 0.9996742
was O 0 0.00024121691
( O 0 0.0003520125
non O 0 0.00030033418
- O 0 0.0015289866
significantly O 0 0.00017321862
) O 0 0.00030390813
twice O 0 8.044644e-05
as O 0 0.000104999344
common O 0 0.00013483943
as O 0 0.00011477129
expected O 0 8.572145e-05
at O 0 8.7525696e-05
the O 0 0.00010003882
time O 0 0.00010881573
of O 0 0.00024365577
diagnosis O 0 0.00061482715
of O 0 0.0006500652
Wegener B-Disease 0 0.19224599
' I-Disease 0 0.0018288862
s I-Disease 0 0.0023614417
granulomatosis I-Disease 0 0.8289298
. O 0 0.0033140727

CONCLUSION O 0 0.014949647
: O 0 0.0031616616
The O 0 0.0005818119
results O 0 0.00046441483
indicate O 0 0.00028297649
a O 0 0.0005882165
dose O 0 0.0007049754
- O 0 0.0009643565
response O 0 0.00015181166
relationship O 0 0.00010204576
between O 0 0.00019131142
cyclophosphamide B-Chemical 0 0.9996449
and O 0 0.00022124038
the O 0 0.00015425008
risk O 0 0.0016371602
of O 0 0.0004203213
bladder B-Disease 0 0.98131484
cancer I-Disease 0 0.9997093
, O 0 0.000486801
high O 0 0.00016309136
cumulative O 0 0.00012390509
risks O 0 0.000185073
in O 0 8.2511484e-05
the O 0 6.8463596e-05
entire O 0 7.459975e-05
cohort O 0 0.00032683247
, O 0 0.00020699066
and O 0 0.00010883255
also O 0 8.7914996e-05
the O 0 7.655778e-05
possibility O 0 7.1116374e-05
of O 0 0.0001948018
risk O 0 0.0016102814
factors O 0 0.00039999306
operating O 0 0.00028731558
even O 0 0.0002778823
before O 0 0.00024167064
Wegener B-Disease 0 0.034874868
' I-Disease 0 0.0013904407
s I-Disease 0 0.0019787005
granulomatosis I-Disease 0 0.7541468
. O 0 0.0031062593

Differential O 0 0.004260615
modulation O 0 0.001939794
by O 0 0.002516761
estrogen B-Chemical 0 0.9985624
of O 0 0.0029226686
alpha2 O 0 0.96155876
- O 0 0.21448399
adrenergic O 0 0.9514323
and O 0 0.0010507931
I1 O 0 0.9921773
- O 0 0.3690359
imidazoline B-Chemical 0 0.9999217
receptor O 0 0.012353704
- O 0 0.0071632224
mediated O 0 0.000457559
hypotension B-Disease 0 0.9997366
in O 0 0.0008538723
female O 0 0.0022270924
rats O 0 0.00265744
. O 0 0.002927067

We O 0 0.0023840454
have O 0 0.0014674796
recently O 0 0.0010828463
shown O 0 0.00051891897
that O 0 0.0007084537
estrogen B-Chemical 0 0.9989304
negatively O 0 0.0003999437
modulates O 0 0.00013905941
the O 0 0.00022807004
hypotensive B-Disease 0 0.97600424
effect O 0 0.00018425673
of O 0 0.00046191041
clonidine B-Chemical 0 0.99998474
( O 0 0.000793229
mixed O 0 0.0006880062
alpha2 O 0 0.65381026
- O 0 0.02013047
/ O 0 0.012004058
I1 O 0 0.9897682
- O 0 0.02861763
receptor O 0 0.0013263241
agonist O 0 0.02000866
) O 0 0.0005935644
in O 0 0.00012940668
female O 0 0.00032499526
rats O 0 0.00023314898
and O 0 0.00013356384
implicates O 0 0.00011626474
the O 0 0.00016065867
cardiovascular O 0 0.127744
autonomic O 0 0.010174162
control O 0 0.00031433036
in O 0 0.00039772442
this O 0 0.0006821673
interaction O 0 0.0010180121
. O 0 0.002614691

The O 0 0.0017980686
present O 0 0.0012192345
study O 0 0.0010422951
investigated O 0 0.0005135887
whether O 0 0.00021823311
this O 0 0.00042554695
effect O 0 0.0003816039
of O 0 0.0008630101
estrogen B-Chemical 0 0.99941206
involves O 0 0.00029450585
interaction O 0 0.0002463653
with O 0 0.0005286724
alpha2 O 0 0.60808367
- O 0 0.0048454376
and O 0 0.0005268533
/ O 0 0.0025091807
or O 0 0.0008634465
I1 O 0 0.91396934
- O 0 0.013264966
receptors O 0 0.0044961255
. O 0 0.0038887777

Changes O 0 0.003123016
evoked O 0 0.0030264708
by O 0 0.0010072418
a O 0 0.0008350834
single O 0 0.00032931592
intraperitoneal O 0 0.0005596053
injection O 0 0.00024344536
of O 0 0.00040783116
rilmenidine B-Chemical 0 0.9999647
( O 0 0.0006544951
600 O 0 0.00049393444
microg O 0 0.00034134206
/ O 0 0.0006864016
kg O 0 0.0005135591
) O 0 0.00048472732
or O 0 0.00025885305
alpha B-Chemical 0 0.9671725
- I-Chemical 0 0.6012754
methyldopa I-Chemical 0 0.9999995
( O 0 0.0010294988
100 O 0 0.00046850022
mg O 0 0.002241153
/ O 0 0.00057207583
kg O 0 0.00040706852
) O 0 0.00037153947
, O 0 0.00028503622
selective O 0 0.00034987493
I1 O 0 0.9231485
- O 0 0.0059676957
and O 0 0.0003572244
alpha2 O 0 0.6988458
- O 0 0.017965343
receptor O 0 0.0010249151
agonists O 0 0.010063701
, O 0 0.0004504072
respectively O 0 0.00037240508
, O 0 0.00025289584
in O 0 0.00011714923
blood O 0 0.0013182289
pressure O 0 0.0036841792
, O 0 0.0002559427
hemodynamic O 0 0.0011363995
variability O 0 0.00015245228
, O 0 0.00019038409
and O 0 0.00012559953
locomotor O 0 0.000991519
activity O 0 6.2028674e-05
were O 0 6.802717e-05
assessed O 0 7.5295786e-05
in O 0 9.11468e-05
radiotelemetered O 0 0.0007940922
sham O 0 0.00018043871
- O 0 0.00081186014
operated O 0 0.00038203652
and O 0 0.0001704253
ovariectomized O 0 0.019088697
( O 0 0.0006132687
Ovx O 0 0.45761895
) O 0 0.00078145287
Sprague O 0 0.1681427
- O 0 0.0016961899
Dawley O 0 0.0038593449
female O 0 0.00035333465
rats O 0 0.00023614752
with O 0 0.00016237186
or O 0 0.00015717962
without O 0 0.00023346595
12 O 0 0.00026086802
- O 0 0.0013957248
wk O 0 0.0005616704
estrogen B-Chemical 0 0.9937629
replacement O 0 0.002831668
. O 0 0.0033112182

Three O 0 0.0018168878
time O 0 0.00089381257
domain O 0 0.0005798526
indexes O 0 0.0009333302
of O 0 0.00059039105
hemodynamic O 0 0.0021509943
variability O 0 0.00035471283
were O 0 0.0001751951
employed O 0 0.00017707456
: O 0 0.0002643598
the O 0 9.40219e-05
standard O 0 0.00011148478
deviation O 0 0.00019285869
of O 0 0.000101321064
mean O 0 9.8578865e-05
arterial O 0 0.022424782
pressure O 0 0.0018815438
as O 0 0.0001107676
a O 0 0.00012555308
measure O 0 6.0751834e-05
of O 0 0.00011781626
blood O 0 0.0013445145
pressure O 0 0.002470192
variability O 0 0.0001355478
and O 0 8.143837e-05
the O 0 6.240488e-05
standard O 0 9.316546e-05
deviation O 0 0.00021616324
of O 0 0.00015455131
beat O 0 0.000622512
- O 0 0.0017141837
to O 0 0.00015862077
- O 0 0.0010836791
beat O 0 0.00033194537
intervals O 0 0.0001422009
( O 0 0.0003565285
SDRR O 0 0.06548218
) O 0 0.0003035589
and O 0 0.00011423998
the O 0 9.399447e-05
root O 0 0.0003001736
mean O 0 0.0001067182
square O 0 0.00028595462
of O 0 0.00013052027
successive O 0 0.000108911234
differences O 0 0.000114208495
in O 0 0.00022949993
R O 0 0.9808592
- O 0 0.0062610996
wave O 0 0.0021443223
- O 0 0.0018871659
to O 0 0.00024195976
- O 0 0.0048682857
R O 0 0.98583776
- O 0 0.0031066432
wave O 0 0.0007619362
intervals O 0 0.00017629674
as O 0 0.00017989226
measures O 0 0.00023406617
of O 0 0.0004966079
heart O 0 0.009498077
rate O 0 0.0014062183
variability O 0 0.0019974085
. O 0 0.002673535

In O 0 0.001980298
sham O 0 0.002538813
- O 0 0.0050152265
operated O 0 0.0022368045
rats O 0 0.0014708743
, O 0 0.0024629612
rilmenidine B-Chemical 0 0.99997246
or O 0 0.0012088433
alpha B-Chemical 0 0.9969735
- I-Chemical 0 0.85105634
methyldopa I-Chemical 0 0.9999994
elicited O 0 0.00028005446
similar O 0 0.00018210335
hypotension B-Disease 0 0.99980515
that O 0 8.94983e-05
lasted O 0 6.906577e-05
at O 0 5.786293e-05
least O 0 7.760919e-05
5 O 0 8.217933e-05
h O 0 0.000101544494
and O 0 0.00010213318
was O 0 9.474968e-05
associated O 0 0.00011226075
with O 0 0.00012262429
reductions O 0 0.00015645559
in O 0 0.00013144652
standard O 0 0.0001838375
deviation O 0 0.00040194156
of O 0 0.00033488753
mean O 0 0.00048192663
arterial O 0 0.1763248
pressure O 0 0.029084725
. O 0 0.0029577902

SDRR O 0 0.49121317
was O 0 0.004995587
reduced O 0 0.0043143807
only O 0 0.0039929533
by O 0 0.005130369
alpha B-Chemical 0 0.98782164
- I-Chemical 0 0.8867287
methyldopa I-Chemical 0 0.99998116
. O 0 0.016286397

Ovx O 0 0.85486627
significantly O 0 0.002747324
enhanced O 0 0.0014289572
the O 0 0.0009919434
hypotensive B-Disease 0 0.98285055
response O 0 0.0005945102
to O 0 0.0005874411
alpha B-Chemical 0 0.99087536
- I-Chemical 0 0.84493077
methyldopa I-Chemical 0 0.9999994
, O 0 0.0013336266
in O 0 0.00024303696
contrast O 0 0.00029401208
to O 0 0.00019179727
no O 0 0.00023167669
effect O 0 0.00038842935
on O 0 0.00091726054
rilmenidine B-Chemical 0 0.9999883
hypotension B-Disease 0 0.9999362
. O 0 0.0041968436

The O 0 0.0028869924
enhanced O 0 0.004123749
alpha B-Chemical 0 0.9925217
- I-Chemical 0 0.9608614
methyldopa I-Chemical 0 0.99999917
hypotension B-Disease 0 0.99997354
in O 0 0.0009225612
Ovx O 0 0.66708416
rats O 0 0.0005976392
was O 0 0.00022350179
paralleled O 0 0.00026748
with O 0 0.00019206427
further O 0 0.00016928496
reduction O 0 0.00033865075
in O 0 0.00035546234
SDRR O 0 0.17273039
and O 0 0.0003873177
a B-Disease 0 0.0006425624
reduced I-Disease 0 0.0008886046
locomotor I-Disease 0 0.008616423
activity I-Disease 0 0.0011939086
. O 0 0.0027005172

Estrogen O 0 0.99942577
replacement O 0 0.009119853
( O 0 0.025561485
17beta B-Chemical 0 0.9998
- I-Chemical 0 0.8827106
estradiol I-Chemical 0 0.99995005
subcutaneous O 0 0.006189141
pellet O 0 0.0008096752
, O 0 0.0005083888
14 O 0 0.00020897851
. O 0 0.00016855726
2 O 0 0.0001749886
microg O 0 0.00030040345
/ O 0 0.0005847418
day O 0 0.00012111359
, O 0 0.00021944016
12 O 0 8.5346015e-05
wk O 0 8.361827e-05
) O 0 0.00027199535
of O 0 0.00019310525
Ovx O 0 0.22476429
rats O 0 0.0003140832
restored O 0 0.00017475683
the O 0 0.0001109363
hemodynamic O 0 0.0009905116
and O 0 0.00015670268
locomotor O 0 0.0008773349
effects O 0 0.00015826982
of O 0 0.0004167282
alpha B-Chemical 0 0.99476504
- I-Chemical 0 0.7432545
methyldopa I-Chemical 0 0.9999989
to O 0 0.00045328983
sham O 0 0.0005946054
- O 0 0.0025351355
operated O 0 0.0018075135
levels O 0 0.0013036174
. O 0 0.002737477

These O 0 0.0020190505
findings O 0 0.0019511017
suggest O 0 0.00096849666
that O 0 0.0014394411
estrogen B-Chemical 0 0.99948764
downregulates O 0 0.0026770923
alpha2 O 0 0.97831583
- O 0 0.060620565
but O 0 0.00056261284
not O 0 0.00040712283
I1 O 0 0.9665317
- O 0 0.018142728
receptor O 0 0.0013991465
- O 0 0.0024966565
mediated O 0 0.00015681927
hypotension B-Disease 0 0.99983335
and O 0 0.00015544367
highlight O 0 6.54436e-05
a O 0 0.00013402237
role O 0 4.8397862e-05
for O 0 7.83242e-05
the O 0 0.00010600297
cardiac O 0 0.0007020215
autonomic O 0 0.0026005395
control O 0 0.00020650336
in O 0 0.0003832092
alpha B-Chemical 0 0.9920161
- I-Chemical 0 0.9184102
methyldopa I-Chemical 0 0.9999995
- O 0 0.8380102
estrogen B-Chemical 0 0.9992624
interaction O 0 0.0018974941
. O 0 0.0032908078

Severe O 0 0.046954725
reversible O 0 0.0048717796
left B-Disease 0 0.0025830716
ventricular I-Disease 0 0.063763455
systolic I-Disease 0 0.053351432
and I-Disease 0 0.00082872243
diastolic I-Disease 0 0.9855144
dysfunction I-Disease 0 0.9833461
due O 0 0.00047737584
to O 0 0.00056508475
accidental O 0 0.03671887
iatrogenic O 0 0.5996919
epinephrine B-Chemical 0 0.99985015
overdose B-Disease 0 0.9994254
. O 0 0.00410958

Catecholamine B-Chemical 0 0.99929416
- O 0 0.060055654
induced O 0 0.0026621998
cardiomyopathy B-Disease 0 0.99972564
due O 0 0.00064733805
to O 0 0.00046087356
chronic O 0 0.008727236
excess O 0 0.0005756856
of O 0 0.00035428043
endogenous O 0 0.00035087237
catecholamines B-Chemical 0 0.99982697
has O 0 0.00018871702
been O 0 0.00018734172
recognized O 0 0.00019028736
for O 0 0.00020348787
decades O 0 0.0006186674
as O 0 0.000480569
a O 0 0.0010715472
clinical O 0 0.0032991655
phenomenon O 0 0.0052850056
. O 0 0.003135046

In O 0 0.0023170745
contrast O 0 0.002842273
, O 0 0.0029098154
reports O 0 0.001609512
of O 0 0.0021665548
myocardial B-Disease 0 0.999814
dysfunction I-Disease 0 0.99847764
due O 0 0.0006133485
to O 0 0.0005981714
acute O 0 0.08603335
iatrogenic O 0 0.30509743
overdose B-Disease 0 0.99930894
are O 0 0.0013273691
rare O 0 0.0048329495
. O 0 0.0031695687

A O 0 0.024673846
35 O 0 0.0040293876
- O 0 0.00686659
year O 0 0.0013573852
- O 0 0.003329965
old O 0 0.0010135372
woman O 0 0.0019075839
whose O 0 0.00080557296
cervix O 0 0.02385957
uteri O 0 0.004803847
was O 0 0.00023814151
inadvertently O 0 0.00035761815
injected O 0 0.00013619091
with O 0 0.0001399755
8 O 0 0.00014304911
mg O 0 0.0019096998
of O 0 0.00026095583
epinephrine B-Chemical 0 0.99980813
developed O 0 0.00040523254
myocardial B-Disease 0 0.9983486
stunning I-Disease 0 0.04698858
that O 0 8.288567e-05
was O 0 9.768792e-05
characterized O 0 0.00014236235
by O 0 0.000107822285
severe O 0 0.000835888
hemodynamic O 0 0.0019396214
compromise O 0 0.00018542558
, O 0 0.00025903032
profound O 0 0.00056151807
, O 0 0.0003213379
albeit O 0 0.00030640457
transient O 0 0.00025957517
, O 0 0.0001932712
left B-Disease 0 0.0002292882
ventricular I-Disease 0 0.03003578
systolic I-Disease 0 0.020670872
and I-Disease 0 0.00013400025
diastolic I-Disease 0 0.99099827
dysfunction I-Disease 0 0.9935874
, O 0 0.00042314635
and O 0 0.00017326833
only O 0 0.00022027027
modestly O 0 0.0010959113
elevated O 0 0.0018289335
biochemical O 0 0.0007489553
markers O 0 0.0013212847
of O 0 0.0024344157
myocardial B-Disease 0 0.99994636
necrosis I-Disease 2 0.99998224
. O 0 0.0064805555

Our O 0 0.002225206
case O 0 0.001795402
illustrates O 0 0.00077672733
the O 0 0.0006341904
serious O 0 0.0011375693
consequences O 0 0.00052277563
of O 0 0.0005146857
medical O 0 0.0018045178
errors O 0 0.001175863
that O 0 0.00019679921
can O 0 0.00014738888
be O 0 0.00015860716
avoided O 0 0.00016727588
through O 0 0.00016318951
improved O 0 0.00039893496
medication O 0 0.0012742328
labeling O 0 0.00040023887
and O 0 0.00061504083
staff O 0 0.0016013136
supervision O 0 0.0032145614
. O 0 0.0031999832

Cardioprotective O 0 0.19542126
effect O 0 0.0026451284
of O 0 0.0036590344
tincture B-Chemical 0 0.99596465
of I-Chemical 0 0.002677334
Crataegus I-Chemical 0 0.99603194
on O 0 0.001446799
isoproterenol B-Chemical 0 0.9999099
- O 0 0.09905828
induced O 0 0.0015387653
myocardial B-Disease 0 0.99969304
infarction I-Disease 0 0.9999647
in O 0 0.0015691657
rats O 0 0.0026895094
. O 0 0.0028780522

Tincture B-Chemical 0 0.98631895
of I-Chemical 0 0.0067306263
Crataegus I-Chemical 0 0.9893015
( O 0 0.0070998063
TCR B-Chemical 0 0.078771554
) O 0 0.0032285983
, O 0 0.0014690092
an O 0 0.0009160519
alcoholic B-Chemical 0 0.99868256
extract I-Chemical 0 0.0025928197
of I-Chemical 0 0.0004399658
the I-Chemical 0 0.00031489396
berries I-Chemical 0 0.27099007
of I-Chemical 0 0.0005730003
hawthorn I-Chemical 0 0.9847447
( O 0 0.0024615969
Crataegus B-Chemical 0 0.99552095
oxycantha I-Chemical 0 0.93324405
) O 0 0.0016156513
, O 0 0.00048053006
is O 0 0.00018062895
used O 0 0.00021679072
in O 0 0.0003589513
herbal O 0 0.24767964
and O 0 0.001048621
homeopathic O 0 0.15886463
medicine O 0 0.040804785
. O 0 0.0037556028

The O 0 0.002007626
present O 0 0.0014364559
study O 0 0.0013437707
was O 0 0.00069667073
done O 0 0.00044294054
to O 0 0.0002847508
investigate O 0 0.00014039883
the O 0 0.00023334155
protective O 0 0.00040296762
effect O 0 0.00026172827
of O 0 0.00046576923
TCR B-Chemical 0 0.014074573
on O 0 0.000227748
experimentally O 0 0.00032315846
induced O 0 0.00082117773
myocardial B-Disease 0 0.999741
infarction I-Disease 0 0.9999733
in O 0 0.0012866588
rats O 0 0.0022944761
. O 0 0.0024767134

Pretreatment O 0 0.031037217
of O 0 0.0039839027
TCR B-Chemical 0 0.029786862
, O 0 0.0021964964
at O 0 0.000645868
a O 0 0.00080701977
dose O 0 0.00071363064
of O 0 0.0004032118
0 O 0 0.00041724293
. O 0 0.0002469935
5 O 0 0.00022158238
mL O 0 0.0010248672
/ O 0 0.0007714597
100 O 0 0.00039244228
g O 0 0.00064704573
bodyweight O 0 0.0014246005
per O 0 0.000109143184
day O 0 7.566418e-05
, O 0 0.00018393989
orally O 0 0.0001990508
for O 0 7.2116665e-05
30 O 0 7.952105e-05
days O 0 6.147178e-05
, O 0 0.00019155437
prevented O 0 0.00020551184
the O 0 0.00012903061
increase O 0 0.000176402
in O 0 0.00030392027
lipid O 0 0.9883321
peroxidation O 0 0.9999962
and O 0 0.00028370178
activity O 0 8.505668e-05
of O 0 0.00013152904
marker O 0 0.00020859271
enzymes O 0 0.0006204699
observed O 0 0.00014861909
in O 0 0.0002702333
isoproterenol B-Chemical 0 0.99994576
- O 0 0.0051739565
induced O 0 0.00012074908
rats O 0 0.00025143957
( O 0 0.00024509057
85 O 0 0.00020799175
mg O 0 0.0011576661
kg O 0 0.00036887766
( O 0 0.0003455324
- O 0 0.0008357438
1 O 0 0.00019430096
) O 0 0.000342204
s O 0 0.00026453656
. O 0 0.00019387604
c O 0 0.0007777128
. O 0 0.00017362193
for O 0 0.000114835224
2 O 0 0.00015802913
days O 0 9.188473e-05
at O 0 0.00013028948
an O 0 0.00024226884
interval O 0 0.00030783462
of O 0 0.00044657683
24 O 0 0.00067769195
h O 0 0.0011146925
) O 0 0.0031310786
. O 0 0.00318623

TCR B-Chemical 0 0.095757194
prevented O 0 0.0052347975
the O 0 0.002703871
isoproterenol B-Chemical 0 0.9998091
- O 0 0.04094032
induced O 0 0.0006231178
decrease O 0 0.00064134033
in O 0 0.0005991262
antioxidant O 0 0.99428755
enzymes O 0 0.0020695957
in O 0 0.0002302908
the O 0 0.00017275677
heart O 0 0.0050761634
and O 0 0.00017025866
increased O 0 0.00020314843
the O 0 0.00013974744
rate O 0 0.00035416006
of O 0 0.0006947002
ADP B-Chemical 0 0.9999169
- O 0 0.21532151
stimulated O 0 0.0022609257
oxygen B-Chemical 1 0.9999205
uptake O 0 0.053804763
and O 0 0.00070288044
respiratory O 0 0.002787254
coupling O 0 0.00088444405
ratio O 0 0.0014839133
. O 0 0.0026222412

TCR B-Chemical 0 0.050244868
protected O 0 0.00276639
against O 0 0.0012315388
pathological O 0 0.005718365
changes O 0 0.0013515113
induced O 0 0.0012166816
by O 0 0.0018115022
isoproterenol B-Chemical 0 0.99937445
in O 0 0.001967991
rat O 0 0.0034703624
heart O 0 0.04383869
. O 0 0.004399075

The O 0 0.001911944
results O 0 0.0013862295
show O 0 0.0008846973
that O 0 0.00081449276
pretreatment O 0 0.0048545073
with O 0 0.0010852629
TCR B-Chemical 0 0.0491286
may O 0 0.00034385064
be O 0 0.00024067018
useful O 0 0.00019775306
in O 0 0.00019831255
preventing O 0 0.0002230779
the O 0 0.00027491216
damage O 0 0.010530388
induced O 0 0.00045096636
by O 0 0.0007554466
isoproterenol B-Chemical 0 0.99970895
in O 0 0.0010158984
rat O 0 0.0020687112
heart O 0 0.040960476
. O 0 0.0029029576

Treatment O 0 0.0071877483
of O 0 0.0028738133
tinnitus B-Disease 2 0.98601156
by O 0 0.0013648785
intratympanic O 0 0.9597641
instillation O 0 0.0018520065
of O 0 0.0010203458
lignocaine B-Chemical 0 0.99993825
( O 0 0.002869158
lidocaine B-Chemical 0 0.99979097
) O 0 0.0010656924
2 O 0 0.00038332632
per O 0 0.00032104788
cent O 0 0.00064633694
through O 0 0.0005122884
ventilation O 0 0.0022081335
tubes O 0 0.0039435914
. O 0 0.0032919354

Idiopathic B-Disease 0 0.9440144
subjective I-Disease 0 0.017647209
tinnitus I-Disease 2 0.9991191
( O 0 0.0067393216
IST B-Disease 0 0.8179336
) O 0 0.0019166139
is O 0 0.0005139866
one O 0 0.0004604617
of O 0 0.0005851756
the O 0 0.00056756014
most O 0 0.0010429034
obscure O 0 0.0026486758
otological O 0 0.13928612
pathologies O 0 0.03758172
. O 0 0.0043521198

This O 0 0.0049043396
paper O 0 0.0029522844
presents O 0 0.0010350647
the O 0 0.0005555321
results O 0 0.00043174363
of O 0 0.00051729515
treating O 0 0.0008227544
IST B-Disease 0 0.31334656
by O 0 0.00030527145
intratympanic O 0 0.91705877
instillation O 0 0.00070854963
of O 0 0.00043605562
lignocaine B-Chemical 0 0.9999683
( O 0 0.0016604165
lidocaine B-Chemical 0 0.99989355
) O 0 0.00056244474
2 O 0 0.00016596216
per O 0 0.00012650859
cent O 0 0.00023959548
through O 0 0.00013632304
a O 0 0.00032272097
grommet O 0 0.001964739
, O 0 0.0004717105
for O 0 0.00023824147
five O 0 0.00028474454
weekly O 0 0.0005946517
courses O 0 0.0016656574
. O 0 0.0024160703

Fifty O 0 0.010375675
- O 0 0.007381643
two O 0 0.00097307493
patients O 0 0.0020765974
suffering O 0 0.007659327
from O 0 0.00056079467
intractable O 0 0.04867625
tinnitus B-Disease 2 0.99589086
entered O 0 0.00057232176
this O 0 0.00024804697
therapeutic O 0 0.00035955783
trial O 0 0.00048163114
, O 0 0.00051986956
but O 0 0.0003502599
only O 0 0.00033648088
nine O 0 0.0003257574
finished O 0 0.0005484894
all O 0 0.0004948739
five O 0 0.00053659466
courses O 0 0.0019198614
. O 0 0.002635687

In O 0 0.0020802827
one O 0 0.0017490523
patient O 0 0.0016192149
, O 0 0.0016846313
the O 0 0.00086945354
tinnitus B-Disease 2 0.9976528
was O 0 0.0005772466
almost O 0 0.00042023955
completely O 0 0.00035521248
abolished O 0 0.000518181
, O 0 0.00074202014
but O 0 0.0003058419
in O 0 0.0001709321
all O 0 0.00013197678
the O 0 0.000105100924
nine O 0 0.00012098673
patients O 0 0.00028969895
the O 0 0.00021161039
decompensated O 0 0.99977475
tinnitus B-Disease 2 0.9995653
changed O 0 0.00052421546
to O 0 0.00039976242
a O 0 0.0009569182
compensated O 0 0.0021930325
one O 0 0.0014922523
. O 0 0.0028367739

We O 0 0.002092645
suggest O 0 0.00091560243
this O 0 0.0009289512
mode O 0 0.0006528361
of O 0 0.0005517464
treatment O 0 0.00038735056
for O 0 0.00022454734
patients O 0 0.00041046998
that O 0 0.00013545321
were O 0 0.00014952954
previously O 0 0.00017907459
treated O 0 0.0003323266
by O 0 0.00020050725
drugs O 0 0.0037069286
, O 0 0.0004825233
acupuncture O 0 0.0010816153
and O 0 0.00032446676
biofeedback O 0 0.0023887132
, O 0 0.0007119688
with O 0 0.00066322245
disappointing O 0 0.0017443399
results O 0 0.0014209496
. O 0 0.003114021

Patients O 0 0.0046463995
should O 0 0.0011425541
be O 0 0.0011217016
warned O 0 0.0015717437
about O 0 0.0006679975
the O 0 0.00038176728
side O 0 0.00085578277
effects O 0 0.0003721616
of O 0 0.0008256767
vertigo B-Disease 0 0.99997604
and O 0 0.0008214144
vomiting B-Disease 0 0.99305856
, O 0 0.0005246271
which O 0 0.00022780534
subsides O 0 0.00031718382
gradually O 0 0.00018091884
with O 0 0.00010507447
every O 0 5.5079083e-05
new O 0 0.00011575145
instillation O 0 0.00030796204
, O 0 0.00020869018
and O 0 0.00011290574
that O 0 8.654957e-05
the O 0 0.00016327777
tinnitus B-Disease 2 0.99919087
may O 0 0.00014367973
not O 0 0.0001455179
disappear O 0 0.00039733262
but O 0 0.00017604629
will O 0 9.56173e-05
be O 0 0.00012251922
alleviated O 0 0.00061923754
, O 0 0.00029885545
enabling O 0 0.00015131064
them O 0 0.0002035395
to O 0 0.00012637007
cope O 0 0.00036167106
more O 0 0.00023676998
easily O 0 0.00013503834
with O 0 0.00016957492
the O 0 0.00020127227
disease O 0 0.17209041
and O 0 0.0003811251
lead O 0 0.0023185671
a O 0 0.00077690725
more O 0 0.0008628659
normal O 0 0.0013407544
life O 0 0.0014543842
. O 0 0.002486862

The O 0 0.0038594862
alpha3 O 0 0.5404329
and O 0 0.0070278225
beta4 O 0 0.9983708
nicotinic O 0 0.999876
acetylcholine B-Chemical 1 0.9999198
receptor O 0 0.0052290773
subunits O 0 0.0005722869
are O 0 0.00023714502
necessary O 0 0.00016115748
for O 0 0.00029449095
nicotine B-Chemical 0 0.99717927
- O 0 0.013519532
induced O 0 0.0008397703
seizures B-Disease 0 0.99996984
and O 0 0.0018405197
hypolocomotion B-Disease 0 0.99950457
in O 0 0.0009641544
mice O 0 0.0006453367
. O 0 0.0023628732

Binding O 0 0.0033660508
of O 0 0.0036726908
nicotine B-Chemical 0 0.9987369
to O 0 0.0038479266
nicotinic O 0 0.99979955
acetylcholine B-Chemical 1 0.9999199
receptors O 0 0.0065340754
( O 0 0.0015732739
nAChRs O 0 0.06010623
) O 0 0.000559335
elicits O 0 0.00012727195
a O 0 0.00020100645
series O 0 0.0001645249
of O 0 0.00014977569
dose O 0 0.00038031282
- O 0 0.00090524764
dependent O 0 8.146516e-05
behaviors O 0 0.00024101508
that O 0 9.710669e-05
go O 0 0.0002141181
from O 0 0.00012275673
altered O 0 0.00016315372
exploration O 0 0.00033922217
, O 0 0.0003763574
sedation O 0 0.0043796515
, O 0 0.00046543064
and O 0 0.00048420223
tremors B-Disease 2 0.99908483
, O 0 0.0012924548
to O 0 0.0008784487
seizures B-Disease 0 0.9999218
and O 0 0.0023708348
death B-Disease 0 0.87622064
. O 0 0.0037763908

nAChRs O 0 0.19072992
are O 0 0.0027647715
pentameric O 0 0.0031280455
ion O 0 0.005888093
channels O 0 0.0023835748
usually O 0 0.0013717277
composed O 0 0.0011330929
of O 0 0.0017644454
alpha O 0 0.37535417
and O 0 0.003115078
beta O 0 0.49188343
subunits O 0 0.0059258137
. O 0 0.0068768696

A O 0 0.02724724
gene O 0 0.002883549
cluster O 0 0.0022708157
comprises O 0 0.0014442467
the O 0 0.0011895286
alpha3 O 0 0.42217463
, O 0 0.003271671
alpha5 O 0 0.9459487
and O 0 0.0014210822
beta4 O 0 0.66617876
subunits O 0 0.00102985
, O 0 0.0012617715
which O 0 0.00064830494
coassemble O 0 0.0009683139
to O 0 0.0005408291
form O 0 0.00075177074
functional O 0 0.0011143576
receptors O 0 0.0040737805
. O 0 0.0041006478

We O 0 0.0022367684
examined O 0 0.0011711523
the O 0 0.00075387163
role O 0 0.00039074948
of O 0 0.00067838695
the O 0 0.00058903475
beta4 O 0 0.44276482
subunits O 0 0.0007462049
in O 0 0.0006415818
nicotine B-Chemical 0 0.99926907
- O 0 0.029256925
induced O 0 0.00058541156
seizures B-Disease 0 0.99998605
and O 0 0.0010207284
hypolocomotion B-Disease 0 0.99988174
in O 0 0.00032611287
beta4 O 0 0.3722192
homozygous O 0 0.00016874944
null O 0 0.00010222116
( O 0 0.00061297393
beta4 O 0 0.7815736
- O 0 0.014546513
/ O 0 0.0038041382
- O 0 0.0033975178
) O 0 0.00074122153
and O 0 0.00037978933
alpha3 O 0 0.046850134
heterozygous O 0 0.0004540131
( O 0 0.00093025446
+ O 0 0.0021072659
/ O 0 0.0040233075
- O 0 0.0043396163
) O 0 0.002163663
mice O 0 0.0008635642
. O 0 0.0030999014

beta4 O 0 0.9172212
- O 0 0.042372365
/ O 0 0.009831299
- O 0 0.0038559316
mice O 0 0.00030706372
were O 0 0.00037676102
less O 0 0.0003988677
sensitive O 0 0.00019750396
to O 0 0.000156326
the O 0 0.0001242538
effects O 0 0.00015457372
of O 0 0.00027012583
nicotine B-Chemical 0 0.9785759
both O 0 0.000109895846
at O 0 7.2457195e-05
low O 0 0.00013567673
doses O 0 0.00027663013
, O 0 0.00021155187
measured O 0 0.00012311779
as O 0 0.00011033885
decreased O 0 0.00022377515
exploration O 0 0.0002532498
in O 0 9.698454e-05
an O 0 0.000107568645
open O 0 0.00012618364
field O 0 0.00015927826
, O 0 0.00018476642
and O 0 9.611067e-05
at O 0 6.853447e-05
high O 0 0.0001378196
doses O 0 0.0003230149
, O 0 0.00027431027
measured O 0 0.00017841907
as O 0 0.00017406585
sensitivity O 0 0.00043283176
to O 0 0.00047497993
nicotine B-Chemical 0 0.998637
- O 0 0.028316436
induced O 0 0.0021124773
seizures B-Disease 0 0.99989533
. O 0 0.0046160393

Using O 0 0.0022925856
in O 0 0.002098092
situ O 0 0.0018824331
hybridization O 0 0.0006898784
probes O 0 0.00053827127
for O 0 0.00038433788
the O 0 0.00047505324
alpha3 O 0 0.19861573
and O 0 0.00073065364
alpha5 O 0 0.88617504
subunits O 0 0.0005655058
, O 0 0.0004832662
we O 0 0.00010556477
showed O 0 0.00016905462
that O 0 0.00018127129
alpha5 O 0 0.9123689
mRNA O 0 0.00031621408
levels O 0 0.00015450004
are O 0 0.00012002517
unchanged O 0 0.00021602519
, O 0 0.00034799744
whereas O 0 0.00023994935
alpha3 O 0 0.2559086
mRNA O 0 0.00023384913
levels O 0 0.00013184722
are O 0 9.995223e-05
selectively O 0 0.00011387291
decreased O 0 0.00022848227
in O 0 0.00011529077
the O 0 0.000118615695
mitral O 0 0.033067584
cell O 0 0.0002846452
layer O 0 0.0004264094
of O 0 0.0001549698
the O 0 0.00013552725
olfactory O 0 0.0008450695
bulb O 0 0.05100972
, O 0 0.00024990877
and O 0 0.000121023426
the O 0 0.00010591667
inferior O 0 0.001083771
and O 0 0.00013806517
the O 0 0.00011883465
superior O 0 0.0003269955
colliculus O 0 0.000536722
of O 0 0.00045740764
beta4 O 0 0.7165651
- O 0 0.01838853
/ O 0 0.0070109917
- O 0 0.0070087113
brains O 0 0.0024891107
. O 0 0.0032669539

alpha3 O 0 0.5177147
+ O 0 0.016147517
/ O 0 0.010694473
- O 0 0.004318801
mice O 0 0.00035418553
were O 0 0.0004449753
partially O 0 0.00040567358
resistant O 0 0.0005499261
to O 0 0.00046615128
nicotine B-Chemical 0 0.998245
- O 0 0.013342959
induced O 0 0.0005736264
seizures B-Disease 0 0.99994016
when O 0 0.00022665835
compared O 0 0.00020520538
to O 0 0.0002770482
wild O 0 0.00047514267
- O 0 0.002887198
type O 0 0.0014119213
littermates O 0 0.00061501213
. O 0 0.0027649952

mRNA O 0 0.0045237886
levels O 0 0.0019903658
for O 0 0.0013416888
the O 0 0.0013843747
alpha5 O 0 0.7168585
and O 0 0.0011649282
the O 0 0.0007657245
beta4 O 0 0.20442526
subunits O 0 0.00080375915
were O 0 0.0005255357
unchanged O 0 0.000707406
in O 0 0.0007266533
alpha3 O 0 0.124185964
+ O 0 0.0051685595
/ O 0 0.0073790406
- O 0 0.007863199
brains O 0 0.003207018
. O 0 0.004173936

Together O 0 0.0054016765
, O 0 0.0039971923
these O 0 0.0013044563
results O 0 0.0007757579
suggest O 0 0.0004346268
that O 0 0.0004842484
the O 0 0.0006094025
beta4 O 0 0.5652464
and O 0 0.0005858031
the O 0 0.0003810027
alpha3 O 0 0.072826505
subunits O 0 0.00039173567
are O 0 0.00021931487
mediators O 0 0.00055584096
of O 0 0.000615725
nicotine B-Chemical 0 0.9990388
- O 0 0.030901203
induced O 0 0.0013084064
seizures B-Disease 0 0.999959
and O 0 0.0041038077
hypolocomotion B-Disease 0 0.99960464
. O 0 0.004287355

The O 0 0.0026689032
effects O 0 0.002694539
of O 0 0.004105472
sevoflurane B-Chemical 0 0.9996859
on O 0 0.0030331006
lidocaine B-Chemical 0 0.9997782
- O 0 0.04281549
induced O 0 0.0043973434
convulsions B-Disease 0 0.9995146
. O 0 0.00758909

The O 0 0.0020630579
influence O 0 0.001473884
of O 0 0.0025959427
sevoflurane B-Chemical 0 0.9997582
on O 0 0.001681534
lidocaine B-Chemical 0 0.99989486
- O 0 0.03283606
induced O 0 0.0013861549
convulsions B-Disease 0 0.9998093
was O 0 0.000997142
studied O 0 0.0012714026
in O 0 0.0012646382
cats O 0 0.0036368074
. O 0 0.0035976886

The O 0 0.004350107
convulsive B-Disease 0 0.9954255
threshold O 0 0.0014326745
( O 0 0.0016584701
mean O 0 0.00078717706
+ O 0 0.002385652
/ O 0 0.0037497752
- O 0 0.0053028553
SD O 0 0.013414883
) O 0 0.0012446411
was O 0 0.00044166256
41 O 0 0.0007003386
. O 0 0.00038392114
4 O 0 0.0003802643
+ O 0 0.0014054098
/ O 0 0.0024235316
- O 0 0.0024400835
6 O 0 0.0006008535
. O 0 0.0008583402
5 O 0 0.0013231692
mg O 0 0.0075098276
. O 0 0.0038873446

l O 0 0.021290358
( O 0 0.007527422
- O 0 0.008321757
1 O 0 0.0014502212
) O 0 0.0016956395
with O 0 0.00095827214
lidocaine B-Chemical 0 0.99945754
infusion O 0 0.0015443461
( O 0 0.0004902677
6 O 0 0.00019115678
mg O 0 0.0010821723
. O 0 0.00020027606
kg O 0 0.00048370674
( O 0 0.0005150757
- O 0 0.0011299729
1 O 0 0.0002776654
) O 0 0.00044848848
. O 0 0.0002125713
min O 0 0.0003536939
( O 0 0.00047916637
- O 0 0.0011237304
1 O 0 0.00025864728
) O 0 0.00048855104
) O 0 0.0004940232
, O 0 0.00034676495
increasing O 0 0.00020387745
significantly O 0 0.0002636598
to O 0 0.00019850457
66 O 0 0.00036197252
. O 0 0.00020759823
6 O 0 0.00020179438
+ O 0 0.00095081603
/ O 0 0.0019659577
- O 0 0.002249727
10 O 0 0.0005983929
. O 0 0.0006675441
9 O 0 0.0010016924
mg O 0 0.006987872
. O 0 0.0032040975

l O 0 0.022750374
( O 0 0.008210485
- O 0 0.009288565
1 O 0 0.0016029533
) O 0 0.0015532196
when O 0 0.00044541195
the O 0 0.0004238312
end O 0 0.00040761603
- O 0 0.0025947117
tidal O 0 0.0046159653
concentration O 0 0.00094376586
of O 0 0.000919456
sevoflurane B-Chemical 0 0.9998368
was O 0 0.0007088481
0 O 0 0.000798521
. O 0 0.00068703195
8 O 0 0.000976683
% O 0 0.0026130278
. O 0 0.0033483477

However O 0 0.0036508818
, O 0 0.003976364
the O 0 0.001363761
threshold O 0 0.0010180796
( O 0 0.0015673618
61 O 0 0.0010282863
. O 0 0.0005012746
6 O 0 0.00037040425
+ O 0 0.0012984007
/ O 0 0.0020261693
- O 0 0.0017329825
8 O 0 0.00029218956
. O 0 0.00023844595
7 O 0 0.00021346418
mg O 0 0.0014087611
. O 0 0.0002685379
l O 0 0.0011754133
( O 0 0.0007352038
- O 0 0.0016316646
1 O 0 0.0002955088
) O 0 0.0005054011
) O 0 0.00042010957
during O 0 0.00013396946
1 O 0 0.00018528578
. O 0 0.00013680394
6 O 0 0.00011829525
% O 0 0.00046142502
sevoflurane B-Chemical 0 0.99985754
was O 0 0.00017082554
not O 0 0.00011266129
significant O 0 0.00012639994
from O 0 0.00011254886
that O 0 9.3734634e-05
during O 0 0.00011184447
0 O 0 0.00022326453
. O 0 0.0001618196
8 O 0 0.00019142784
% O 0 0.00066368503
sevoflurane B-Chemical 0 0.99982065
, O 0 0.00085005764
indicating O 0 0.0003712302
a O 0 0.0010358781
celling O 0 0.0029205002
effect O 0 0.0017138133
. O 0 0.0036853345

There O 0 0.0039576734
was O 0 0.0020281177
no O 0 0.0012267692
significant O 0 0.0009771717
difference O 0 0.0007515047
in O 0 0.00078360195
the O 0 0.0009032807
convulsive B-Disease 0 0.99802196
threshold O 0 0.00060252205
between O 0 0.00089740695
sevoflurane B-Chemical 0 0.999762
and O 0 0.0040786746
enflurane B-Chemical 0 0.9999082
. O 0 0.0052647167

The O 0 0.0018995382
rise O 0 0.0016788001
in O 0 0.001051383
blood O 0 0.0039100647
pressure O 0 0.0077373646
became O 0 0.00067322905
less O 0 0.00040538592
marked O 0 0.0002930642
when O 0 0.00012869503
higher O 0 0.00020402837
concentrations O 0 0.00034884547
of O 0 0.00035201904
sevoflurane B-Chemical 0 0.99996674
or O 0 0.00034808303
enflurane B-Chemical 0 0.99999
were O 0 0.0001135291
administered O 0 0.00011038674
and O 0 7.196471e-05
the O 0 6.923385e-05
blood O 0 0.0010068787
pressure O 0 0.00527721
at O 0 0.00016225221
convulsions B-Disease 0 0.9999182
decreased O 0 0.00042912338
significantly O 0 0.00019918085
in O 0 0.00012993751
1 O 0 0.00014311665
. O 0 0.0001004173
6 O 0 8.916055e-05
% O 0 0.00037946072
sevoflurane B-Chemical 0 0.99989986
, O 0 0.0004277419
and O 0 0.0001800347
in O 0 0.00016630958
0 O 0 0.00025202255
. O 0 0.0001763677
8 O 0 0.0001890841
% O 0 0.00040804452
and O 0 0.0003226979
1 O 0 0.00044119422
. O 0 0.0004579059
6 O 0 0.0006000003
% O 0 0.0026991447
enflurane B-Chemical 0 0.99978656
. O 0 0.0049592205

However O 0 0.003016737
, O 0 0.0032896865
there O 0 0.0010354617
was O 0 0.0007429937
no O 0 0.00045756382
significant O 0 0.00036923846
difference O 0 0.00027184392
in O 0 0.0002771341
the O 0 0.00032143807
lidocaine B-Chemical 0 0.9997453
concentrations O 0 0.00043730854
measured O 0 0.00017867309
when O 0 0.000110324225
the O 0 0.00016857171
systolic O 0 0.027071787
blood O 0 0.003512224
pressure O 0 0.0053261365
became O 0 0.0009595608
70 O 0 0.0011123647
mmHg O 0 0.0046854834
. O 0 0.0029242297

Apamin B-Chemical 0 0.9986187
, O 0 0.0069023473
a O 0 0.0026869639
selective O 0 0.0020470219
blocker O 0 0.6200257
of O 0 0.00181301
calcium B-Chemical 0 0.99924904
- O 0 0.09270352
dependent O 0 0.0004286977
potassium B-Chemical 0 0.99929976
channels O 0 0.0007723225
, O 0 0.0003628577
was O 0 0.000134363
administered O 0 0.00021542437
intracerebroventricularly O 0 0.0023134244
in O 0 9.1142974e-05
rats O 0 0.0001524405
anesthetized O 0 0.00032842203
with O 0 0.00010756905
0 O 0 0.00014610298
. O 0 0.000103001585
8 O 0 0.00011721271
% O 0 0.0003750837
sevoflurane B-Chemical 0 0.9996581
to O 0 0.00012549094
investigate O 0 6.316478e-05
the O 0 0.0001362361
mechanism O 0 0.0001682897
of O 0 0.00045106185
the O 0 0.00071797235
anticonvulsive O 0 0.9991592
effects O 0 0.0019941926
. O 0 0.0032753507

Apamin B-Chemical 0 0.998147
( O 0 0.0061029075
10 O 0 0.0017261122
ng O 0 0.0022889234
) O 0 0.0019501604
had O 0 0.0006005996
a O 0 0.0006637517
tendency O 0 0.0006902457
to O 0 0.00027856295
decrease O 0 0.0003390324
the O 0 0.00032860713
convulsive B-Disease 0 0.99932384
threshold O 0 0.00018817149
( O 0 0.00031660014
21 O 0 0.00017827588
. O 0 0.00012866131
6 O 0 0.00012046456
+ O 0 0.0006147303
/ O 0 0.0013886224
- O 0 0.0015383895
2 O 0 0.00022240682
. O 0 0.00015655663
2 O 0 0.00014926471
to O 0 0.00011475081
19 O 0 0.00019602294
. O 0 0.00013839219
9 O 0 0.00014747157
+ O 0 0.00064704387
/ O 0 0.0013538296
- O 0 0.0013710904
2 O 0 0.00021619476
. O 0 0.00016284848
5 O 0 0.00016981296
mg O 0 0.0011632275
. O 0 0.00020743918
l O 0 0.0010341683
( O 0 0.00068500737
- O 0 0.0016961608
1 O 0 0.00034970551
) O 0 0.0007045852
) O 0 0.0007566891
but O 0 0.00042072777
this O 0 0.00044154952
was O 0 0.00046843995
not O 0 0.0005811177
statistically O 0 0.0014272735
significant O 0 0.0018133282
. O 0 0.0033219948

It O 0 0.005144024
is O 0 0.0016371812
suggested O 0 0.0010792604
that O 0 0.0010702799
sevoflurane B-Chemical 0 0.99982196
reduces O 0 0.0006298248
the O 0 0.0005773619
convulsive B-Disease 0 0.99951255
effect O 0 0.00027770142
of O 0 0.0006849248
lidocaine B-Chemical 0 0.9999776
toxicity B-Disease 0 0.95625246
but O 0 0.00035823832
carries O 0 0.00022750818
some O 0 0.00031581213
risk O 0 0.0021648472
due O 0 0.00034555234
to O 0 0.0006588876
circulatory O 0 0.476504
depression B-Disease 0 0.9991291
. O 0 0.00331337

Cardiac B-Disease 0 0.51407444
toxicity I-Disease 0 0.9703177
observed O 0 0.0011476061
in O 0 0.0006314568
association O 0 0.0003361872
with O 0 0.0004251372
high O 0 0.00057506916
- O 0 0.002305304
dose O 0 0.0011481517
cyclophosphamide B-Chemical 0 0.99963
- O 0 0.002280747
based O 0 0.00035241022
chemotherapy O 0 0.0020490678
for O 0 0.0005990735
metastatic O 0 0.7506138
breast B-Disease 0 0.9917223
cancer I-Disease 0 0.99885976
. O 0 0.005935378

INTRODUCTION O 0 0.024675556
: O 0 0.011092992
Cyclophosphamide B-Chemical 0 0.9989427
is O 0 0.0009872743
an O 0 0.0008983346
alkylating O 0 0.07589445
agent O 0 0.0009506072
given O 0 0.0002556018
frequently O 0 0.00033246604
as O 0 0.00030062548
a O 0 0.00045076114
component O 0 0.00034667042
of O 0 0.00043143463
many O 0 0.0004507932
conditioning O 0 0.0008394306
regimens O 0 0.0014946322
. O 0 0.0024607163

In O 0 0.0020111622
high O 0 0.0023321274
doses O 0 0.0032271498
, O 0 0.0023223315
its O 0 0.0015645527
nonhematological O 0 0.27791318
dose O 0 0.0023522612
- O 0 0.004733387
limiting O 0 0.0014084565
toxicity B-Disease 0 0.57048666
is O 0 0.0023583937
cardiomyopathy B-Disease 0 0.9995571
. O 0 0.006115268

STUDY O 0 0.005869121
DESIGN O 0 0.0025496448
: O 0 0.0017806074
We O 0 0.0005717907
combined O 0 0.0009381245
paclitaxel B-Chemical 1 0.99738795
, O 0 0.0021658787
melphalan B-Chemical 1 0.9997751
and O 0 0.00033105002
high O 0 0.0003222967
- O 0 0.0013122376
dose O 0 0.0005859936
cyclophosphamide B-Chemical 0 0.9997336
, O 0 0.00081052247
thiotepa B-Chemical 0 0.99981326
, O 0 0.00039643535
and O 0 0.00023263335
carboplatin B-Chemical 0 0.9969062
in O 0 0.00011598435
a O 0 0.00014461024
triple O 0 0.0001231831
sequential O 0 0.00010485157
high O 0 0.00017466405
- O 0 0.0007304187
dose O 0 0.0002076426
regimen O 0 0.00015635195
for O 0 0.00013587622
patients O 0 0.00060127774
with O 0 0.00077182037
metastatic O 0 0.95339316
breast B-Disease 0 0.9968893
cancer I-Disease 0 0.99933344
. O 0 0.0052264417

Analysis O 0 0.0037411116
was O 0 0.0014832243
performed O 0 0.0008389201
on O 0 0.00051310234
61 O 0 0.00083734206
women O 0 0.00097516045
with O 0 0.0004701958
chemotherapy O 0 0.003410206
- O 0 0.001671794
responsive O 0 0.00025500692
metastatic O 0 0.53935564
breast B-Disease 0 0.97580624
cancer I-Disease 0 0.99811256
receiving O 0 0.00035427065
96 O 0 0.00048642952
- O 0 0.0006784108
h O 0 0.00017665954
infusional O 0 0.87675005
cyclophosphamide B-Chemical 0 0.9995814
as O 0 0.00010248048
part O 0 7.380218e-05
of O 0 9.444469e-05
a O 0 0.00013222417
triple O 0 0.00011104955
sequential O 0 8.903702e-05
high O 0 0.00014398158
- O 0 0.00068282615
dose O 0 0.00013363137
regimen O 0 7.3576884e-05
to O 0 4.0188093e-05
assess O 0 2.5132707e-05
association O 0 3.9866503e-05
between O 0 5.4539945e-05
presence O 0 8.4459956e-05
of O 0 0.00014463066
peritransplant O 0 0.028291047
congestive B-Disease 0 0.9998128
heart I-Disease 0 0.19481426
failure I-Disease 0 0.061431
( O 0 0.0010131611
CHF B-Disease 2 0.9999702
) O 0 0.00046862976
and O 0 8.9438756e-05
the O 0 6.099006e-05
following O 0 5.370159e-05
pretreatment O 0 0.0003938691
characteristics O 0 9.655813e-05
: O 0 0.00020820065
presence O 0 9.01602e-05
of O 0 0.00013724639
electrocardiogram O 0 0.0049696765
( O 0 0.00028153652
EKG O 0 0.019699952
) O 0 0.00034705055
abnormalities O 0 0.002314515
, O 0 0.00023041399
age O 0 0.00024108677
, O 0 0.00049621606
hypertension B-Disease 2 0.9999846
, O 0 0.00032866353
prior O 0 5.926147e-05
cardiac O 0 0.00042089907
history O 0 0.00023417175
, O 0 0.00029185938
smoking O 0 0.013441868
, O 0 0.0010633153
diabetes B-Disease 0 0.99996257
mellitus I-Disease 0 0.9999851
, O 0 0.0005485948
prior O 0 7.544184e-05
use O 0 0.00011958341
of O 0 0.000283519
anthracyclines B-Chemical 0 0.9997402
, O 0 0.0005989565
and O 0 0.0003437539
left O 0 0.0011532548
- O 0 0.004499819
sided O 0 0.101943895
chest O 0 0.002576783
irradiation O 0 0.0025038715
. O 0 0.0024386086

RESULTS O 0 0.00497078
: O 0 0.003238736
Six O 0 0.0011871792
of O 0 0.0011058778
61 O 0 0.0014211296
women O 0 0.0018048013
( O 0 0.0010302543
10 O 0 0.00047636736
% O 0 0.00074560434
) O 0 0.00075402186
developed O 0 0.00038906364
clinically O 0 0.0011956156
reversible O 0 0.0009208183
grade O 0 0.0026837436
3 O 0 0.00022585005
CHF B-Disease 2 0.9995109
following O 0 0.00012274877
infusional O 0 0.87014955
cyclophosphamide B-Chemical 0 0.99935454
with O 0 0.00012875335
a O 0 0.0001418458
median O 0 7.5461125e-05
percent O 0 0.00013998778
decline O 0 0.00038702207
in O 0 0.00024851642
ejection O 0 0.020948568
fraction O 0 0.00052859576
of O 0 0.0008183234
31 O 0 0.0016233231
% O 0 0.0025894393
. O 0 0.0027869043

Incidence O 0 0.0069790464
of O 0 0.0024428058
transient O 0 0.005585519
cyclophosphamide B-Chemical 0 0.99980515
- O 0 0.012576384
related O 0 0.00049898465
cardiac B-Disease 0 0.076041386
toxicity I-Disease 0 0.98602444
( O 0 0.00093122246
10 O 0 0.00033488558
% O 0 0.0005331394
) O 0 0.0005426342
is O 0 0.00019899842
comparable O 0 0.00018875119
to O 0 0.00029377002
previous O 0 0.00045463175
recorded O 0 0.000944431
literature O 0 0.0026734127
. O 0 0.0032941017

Older O 0 0.020150553
age O 0 0.0031915726
was O 0 0.0012727899
significantly O 0 0.0009988144
correlated O 0 0.0006266028
with O 0 0.00058921246
the O 0 0.0006302047
CHF B-Disease 2 0.9998865
development O 0 0.000563184
; O 0 0.00041403063
with O 0 0.0001414053
median O 0 8.569979e-05
ages O 0 0.00016503003
for O 0 8.3305e-05
the O 0 8.6120795e-05
entire O 0 8.618545e-05
group O 0 0.00017534937
and O 0 0.00014219357
for O 0 0.00012816097
patients O 0 0.0005045679
developing O 0 0.0009593697
CHF B-Disease 2 0.9998981
of O 0 0.00044846194
45 O 0 0.00038231944
and O 0 0.0004311978
59 O 0 0.0008776104
, O 0 0.0014480636
respectively O 0 0.0024062993
. O 0 0.002994074

No O 0 0.006084139
association O 0 0.0024714766
was O 0 0.0023321097
found O 0 0.0019868219
with O 0 0.0021338214
other O 0 0.002275575
pretreatment O 0 0.009480894
characteristics O 0 0.0038129794
. O 0 0.006172001

CONCLUSIONS O 0 0.023364574
: O 0 0.00468196
As O 0 0.0009230786
a O 0 0.0012029231
result O 0 0.00057900604
of O 0 0.0005364305
these O 0 0.00040690438
findings O 0 0.0005088994
, O 0 0.00068367296
oncologists O 0 0.00074020575
should O 0 0.00015010941
carefully O 0 0.0001600402
monitor O 0 0.00022264232
fluid O 0 0.00090508815
balance O 0 0.00066031335
in O 0 0.0006944233
older O 0 0.003556275
patients O 0 0.0032371152
. O 0 0.0030423063

Routine O 0 0.0030525825
EKG O 0 0.009207552
monitoring O 0 0.0012436361
during O 0 0.0011436037
infusional O 0 0.90532684
cyclophosphamide B-Chemical 0 0.99922085
did O 0 0.0013153164
not O 0 0.0010452056
predict O 0 0.0014243718
CHF B-Disease 2 0.99955744
development O 0 0.0049337856
. O 0 0.0048535326

Tremor B-Disease 0 0.87737197
side O 0 0.0061950684
effects O 0 0.0021279077
of O 0 0.0029111218
salbutamol B-Chemical 0 0.99931705
, O 0 0.0026059374
quantified O 0 0.0011057124
by O 0 0.001008796
a O 0 0.0016928972
laser O 0 0.0036448438
pointer O 0 0.0031130945
technique O 0 0.0031374074
. O 0 0.0045354897

OBJECTIVE O 0 0.01670709
: O 0 0.0031590825
To O 0 0.00061551353
study O 0 0.0014590687
tremor B-Disease 0 0.9991817
side O 0 0.0015675983
effects O 0 0.000434936
of O 0 0.0007059799
salbutamol B-Chemical 0 0.9997433
an O 0 0.00036136364
easily O 0 0.000189612
applicable O 0 0.00015305776
, O 0 0.00031015478
quick O 0 0.0003686028
and O 0 0.00031214763
low O 0 0.00064489036
- O 0 0.004073541
priced O 0 0.013740344
method O 0 0.0008789484
is O 0 0.0008390145
needed O 0 0.001386384
. O 0 0.0033582023

A O 0 0.020792652
new O 0 0.003058631
method O 0 0.0017549618
using O 0 0.0009715061
a O 0 0.0011800145
commercially O 0 0.001230779
available O 0 0.0006167249
, O 0 0.0013615257
pen O 0 0.003454741
- O 0 0.0043240883
shaped O 0 0.0017954055
laser O 0 0.0034879197
pointer O 0 0.002435467
was O 0 0.0015996859
developed O 0 0.0027417645
. O 0 0.004152762

Aim O 0 0.007899813
of O 0 0.002156162
the O 0 0.0011126848
study O 0 0.00091329875
was O 0 0.00045344734
to O 0 0.00025572124
determine O 0 0.00010768431
sensitivity O 0 0.00035658714
, O 0 0.0004143096
reproducibility O 0 0.00029760614
, O 0 0.00039117175
reference O 0 0.00022314792
values O 0 0.0002235975
and O 0 0.0002606271
the O 0 0.0002623639
agreement O 0 0.0005821269
with O 0 0.0006699695
a O 0 0.0013751502
questionnaire O 0 0.001241846
. O 0 0.0026240242

METHODS O 0 0.007916679
: O 0 0.0081221545
Tremor B-Disease 0 0.14557111
was O 0 0.0019252202
measured O 0 0.0016697324
using O 0 0.0013289959
a O 0 0.0024740864
laser O 0 0.0051000454
pointer O 0 0.004528329
technique O 0 0.004468876
. O 0 0.006292833

To O 0 0.0010766571
determine O 0 0.00053011905
sensitivity O 0 0.0010127536
we O 0 0.00043660507
assessed O 0 0.0008746394
tremor B-Disease 0 0.9997029
in O 0 0.0004014579
44 O 0 0.00043037467
patients O 0 0.00047725663
with O 0 0.00037462593
obstructive B-Disease 0 0.99972445
lung I-Disease 0 0.07731974
disease I-Disease 0 0.4482203
after O 0 9.503689e-05
administration O 0 0.00024455856
of O 0 0.00021252493
cumulative O 0 0.00032335354
doses O 0 0.0010248438
of O 0 0.0014175868
salbutamol B-Chemical 0 0.9989936
. O 0 0.003314296

Subjects O 0 0.0038243998
were O 0 0.0014002648
asked O 0 0.00075600547
to O 0 0.00048181452
aim O 0 0.00034217662
at O 0 0.00031079623
the O 0 0.00030834868
centre O 0 0.0004821302
of O 0 0.00034875216
a O 0 0.00041676871
target O 0 0.00022390364
, O 0 0.0006132115
subdivided O 0 0.0009443972
in O 0 0.00036814943
concentric O 0 0.0024044411
circles O 0 0.00050014677
, O 0 0.0008686305
from O 0 0.000556011
5 O 0 0.00079687155
m O 0 0.003316332
distance O 0 0.0027386579
. O 0 0.0037435812

The O 0 0.0025598237
circle O 0 0.0039249593
in O 0 0.0015102798
which O 0 0.0011682643
the O 0 0.0006872552
participant O 0 0.0006232285
succeeded O 0 0.0012060932
to O 0 0.00042865402
aim O 0 0.00040619963
was O 0 0.0005332134
recorded O 0 0.0006986797
in O 0 0.0009464239
millimetres O 0 0.0041439882
radius O 0 0.012067773
. O 0 0.0048497478

In O 0 0.0020170123
another O 0 0.0019382455
series O 0 0.0011640398
of O 0 0.00067571184
measurements O 0 0.0004176154
, O 0 0.00053047895
reproducibility O 0 0.00031175002
and O 0 0.00024332007
reference O 0 0.00020234057
values O 0 0.00018150236
of O 0 0.00021956029
the O 0 0.00027336722
tremor B-Disease 0 0.9997944
was O 0 0.00016433002
assessed O 0 0.00012319999
in O 0 0.00011340598
65 O 0 0.00016841364
healthy O 0 0.00036248946
subjects O 0 0.00016594351
in O 0 7.3389856e-05
three O 0 4.1642263e-05
sessions O 0 9.6237774e-05
, O 0 0.00017492737
at O 0 8.370339e-05
9 O 0 0.00010961033
a O 0 0.00018815964
. O 0 0.00015930163
m O 0 0.0008105936
. O 0 0.00017229072
, O 0 0.00023501838
4 O 0 0.0001146031
p O 0 0.00024183822
. O 0 0.00016128599
m O 0 0.00075047376
. O 0 0.00018060759
and O 0 0.0001782018
9 O 0 0.00016895437
a O 0 0.00028379704
. O 0 0.00025020298
m O 0 0.0011862727
. O 0 0.0003433468
, O 0 0.00062751543
respectively O 0 0.00078922906
, O 0 0.000948371
1 O 0 0.0007199647
week O 0 0.00055869983
later O 0 0.0012654022
. O 0 0.0029136601

Postural O 0 0.8420071
tremor B-Disease 0 0.99928564
was O 0 0.0014970517
measured O 0 0.0008248172
with O 0 0.00052291097
the O 0 0.00034917353
arm O 0 0.00062511256
horizontally O 0 0.0014239955
outstretched O 0 0.03940516
rest O 0 0.0011151269
tremor B-Disease 0 0.9997644
with O 0 0.00024059515
the O 0 0.00013726024
arm O 0 0.0002484129
supported O 0 0.00019137563
by O 0 0.00015636864
an O 0 0.00022745115
armrest O 0 0.012658577
and O 0 0.00029168103
finally O 0 0.0008776559
tremor B-Disease 0 0.99987006
was O 0 0.00016422803
measured O 0 0.00014016034
after O 0 7.853421e-05
holding O 0 0.00029892617
a O 0 0.00033277934
2 O 0 0.0003152947
- O 0 0.0009786941
kg O 0 0.00073899695
weight O 0 0.0007363608
until O 0 0.0006346221
exhaustion O 0 0.0069034426
. O 0 0.0030703286

Inter O 0 0.013345224
- O 0 0.011607072
observer O 0 0.0045968695
variability O 0 0.0015991643
was O 0 0.000915653
measured O 0 0.0008337069
in O 0 0.00068184745
a O 0 0.0009576867
series O 0 0.0008804607
of O 0 0.00091334304
10 O 0 0.0011426825
healthy O 0 0.0033584773
subjects O 0 0.0033892067
. O 0 0.0039274846

Tremor B-Disease 0 0.89678985
was O 0 0.004060439
measured O 0 0.0027765078
simultaneously O 0 0.0019447191
by O 0 0.0018899839
two O 0 0.0014760814
independent O 0 0.00196558
observers O 0 0.0066054408
. O 0 0.007461014

RESULTS O 0 0.0057586846
: O 0 0.007360277
Salbutamol B-Chemical 0 0.9993043
significantly O 0 0.0019014549
increased O 0 0.0024981177
tremor B-Disease 0 0.9998036
severity O 0 0.002588245
in O 0 0.00043055913
patients O 0 0.0006860331
in O 0 0.00036973003
a O 0 0.00070620026
dose O 0 0.0012027383
- O 0 0.002655996
dependent O 0 0.00078985665
way O 0 0.0018603251
. O 0 0.003793311

Within O 0 0.0019502633
healthy O 0 0.0056738905
adults O 0 0.0035363282
no O 0 0.0009846096
age O 0 0.0015590756
- O 0 0.0034295616
dependency O 0 0.0006419093
could O 0 0.0003208741
be O 0 0.00034075405
found O 0 0.00035189776
( O 0 0.0006185601
b O 0 0.000706342
= O 0 0.00088585506
0 O 0 0.00037274568
. O 0 0.0002646425
262 O 0 0.00065878034
mm O 0 0.0009824071
/ O 0 0.0012948137
year O 0 0.00041211964
; O 0 0.0009031236
P O 0 0.007104846
= O 0 0.0016240667
0 O 0 0.0009966814
. O 0 0.0009962432
72 O 0 0.0018098278
) O 0 0.0040120673
. O 0 0.0043065837

There O 0 0.0032380987
was O 0 0.0015462738
no O 0 0.0008853269
agreement O 0 0.0008665072
between O 0 0.00041078296
the O 0 0.00038297914
questionnaire O 0 0.0003444003
and O 0 0.0006199854
tremor B-Disease 0 0.9995202
severity O 0 0.0014991537
( O 0 0.0005990997
r O 0 0.0006551744
= O 0 0.0007919273
0 O 0 0.00043188193
. O 0 0.00038851143
093 O 0 0.0017763019
; O 0 0.00095250923
P O 0 0.006835431
= O 0 0.0016150252
0 O 0 0.0010095786
. O 0 0.0010329452
53 O 0 0.002322117
) O 0 0.0043229638
. O 0 0.004504801

Postural O 0 0.89562774
tremor B-Disease 0 0.99949455
showed O 0 0.00139356
no O 0 0.0006841805
significant O 0 0.00047644635
difference O 0 0.00030403415
between O 0 0.00024143067
the O 0 0.00022555201
first O 0 0.0001641335
and O 0 0.0002451095
third O 0 0.00025999077
session O 0 0.00032902815
( O 0 0.0007699504
P O 0 0.007850226
= O 0 0.0015223076
0 O 0 0.0009607341
. O 0 0.001052745
07 O 0 0.0046079224
) O 0 0.004665284
. O 0 0.0044661956

Support O 0 0.0047174664
of O 0 0.002150226
the O 0 0.0013548066
arm O 0 0.0022064184
decreased O 0 0.0040358384
tremor B-Disease 0 0.9997609
severity O 0 0.005969308
, O 0 0.0018901809
exhaustion O 0 0.016044468
increased O 0 0.0025301545
tremor B-Disease 0 0.99972624
severity O 0 0.0062653194
significantly O 0 0.0025073267
. O 0 0.0035482086

A O 0 0.016678626
good O 0 0.0027009014
agreement O 0 0.0020029997
was O 0 0.00087635696
found O 0 0.0005531705
between O 0 0.00035292306
two O 0 0.0002726504
independent O 0 0.00026933633
observers O 0 0.00079147343
( O 0 0.00083006994
interclass O 0 0.0015425899
correlation O 0 0.00044330274
coefficient O 0 0.001433595
0 O 0 0.0009828766
. O 0 0.00097438676
72 O 0 0.0017607722
) O 0 0.0039068437
. O 0 0.004197966

DISCUSSION O 0 0.006200267
: O 0 0.003907571
Quantifying O 0 0.0020407673
tremor B-Disease 0 0.9984446
by O 0 0.0007028389
using O 0 0.00038099327
an O 0 0.00039382424
inexpensive O 0 0.00076479255
laser O 0 0.0012642768
pointer O 0 0.00066193996
is O 0 0.00022479714
, O 0 0.00038405127
with O 0 0.00020834047
the O 0 0.00014985226
exception O 0 0.0001567535
of O 0 0.00022005785
children O 0 0.00062937936
( O 0 0.00034049555
< O 0 0.00026789625
12 O 0 0.00013131986
years O 0 0.0002497847
) O 0 0.0005019174
a O 0 0.00042217513
sensitive O 0 0.0003405478
and O 0 0.0006049382
reproducible O 0 0.00090079335
method O 0 0.001694416
. O 0 0.0031224135

Safety O 0 0.0052452497
and O 0 0.0018479808
adverse O 0 0.0025562707
effects O 0 0.00081909023
associated O 0 0.0008706328
with O 0 0.0010804377
raloxifene B-Chemical 0 0.9993431
: O 0 0.0014651575
multiple O 0 0.0004486463
outcomes O 0 0.0006093938
of O 0 0.0010798213
raloxifene B-Chemical 0 0.9984652
evaluation O 0 0.002479999
. O 0 0.0032092244

OBJECTIVE O 0 0.016977582
: O 0 0.002760746
To O 0 0.00039729476
examine O 0 0.00026846898
the O 0 0.00033724704
effect O 0 0.00033139106
of O 0 0.00063847634
raloxifene B-Chemical 0 0.9995592
on O 0 0.0002087624
major O 0 0.00021534653
adverse O 0 0.00072482706
events O 0 0.00024858347
that O 0 0.00012753948
occur O 0 0.00020111978
with O 0 0.00041423732
postmenopausal O 0 0.90289366
estrogen B-Chemical 0 0.9995958
therapy O 0 0.0018818885
or O 0 0.0010622359
tamoxifen B-Chemical 1 0.997156
. O 0 0.003592148

METHODS O 0 0.0041461294
: O 0 0.0026358876
The O 0 0.00068735244
Multiple O 0 0.00086039666
Outcomes O 0 0.0006436193
of O 0 0.00082804443
Raloxifene B-Chemical 1 0.99688786
Evaluation O 0 0.00047450452
, O 0 0.0006119154
a O 0 0.00055207836
multicenter O 0 0.023699299
, O 0 0.0006167003
randomized O 0 0.0007546407
, O 0 0.0004067375
double O 0 0.00025731462
- O 0 0.0024272301
blind O 0 0.01326404
trial O 0 0.00057854236
, O 0 0.0004971443
enrolled O 0 0.00048696066
7 O 0 0.0002597242
, O 0 0.0006953786
705 O 0 0.0021021464
postmenopausal O 0 0.11264886
women O 0 0.0029031525
with O 0 0.0021887347
osteoporosis B-Disease 0 0.9992161
. O 0 0.0053724307

Women O 0 0.006352331
were O 0 0.0016425794
randomly O 0 0.0007217219
assigned O 0 0.0006933873
to O 0 0.00074562524
raloxifene B-Chemical 0 0.9958651
60 O 0 0.0008771882
mg O 0 0.0049904124
/ O 0 0.0012650917
d O 0 0.00052344735
or O 0 0.0003447166
120 O 0 0.00061651866
mg O 0 0.0032167397
/ O 0 0.0017761497
d O 0 0.0011052217
or O 0 0.0011276675
placebo O 0 0.0102732945
. O 0 0.0035622327

Outcomes O 0 0.003820694
included O 0 0.002726583
venous B-Disease 0 0.7922525
thromboembolism I-Disease 0 0.99994624
, O 0 0.02859468
cataracts B-Disease 2 0.9999409
, O 0 0.013858004
gallbladder B-Disease 2 0.9988527
disease I-Disease 2 0.9978637
, O 0 0.0025573168
and O 0 0.001436789
endometrial B-Disease 0 0.9646825
hyperplasia I-Disease 0 0.9992015
or I-Disease 0 0.0025595517
cancer I-Disease 0 0.9740426
. O 0 0.0050241044

RESULTS O 0 0.00444739
: O 0 0.0027185613
During O 0 0.0007366138
a O 0 0.0009814515
mean O 0 0.00052828854
follow O 0 0.00043557055
- O 0 0.0015842672
up O 0 0.00041208055
of O 0 0.00032467442
3 O 0 0.00023075301
. O 0 0.00019293242
3 O 0 0.00015417626
years O 0 0.00024890318
, O 0 0.0005451677
raloxifene B-Chemical 0 0.9986773
was O 0 0.00021731514
associated O 0 0.00017991524
with O 0 0.0001651473
an O 0 0.00017975339
increased O 0 0.00024383585
risk O 0 0.0012326592
for O 0 0.00018094285
venous B-Disease 0 0.95639634
thromboembolism I-Disease 0 0.999992
( O 0 0.0005424287
relative O 0 0.0001351976
risk O 0 0.0029440203
[ O 0 0.0035997939
RR O 0 0.17949228
] O 0 0.0012416488
2 O 0 0.00020554237
. O 0 0.00015424832
1 O 0 0.00017993961
; O 0 0.00029415087
95 O 0 0.00030435144
% O 0 0.00027679658
confidence O 0 0.0004316621
interval O 0 0.0002928793
[ O 0 0.0011014442
CI O 0 0.0076722577
] O 0 0.0011416416
1 O 0 0.00034134483
. O 0 0.000295639
2 O 0 0.00042222807
- O 0 0.0012883414
3 O 0 0.0004793934
. O 0 0.00067109906
8 O 0 0.0010481527
) O 0 0.0032165714
. O 0 0.003627606

The O 0 0.0028589934
excess O 0 0.0034001751
event O 0 0.0025713937
rate O 0 0.0017027931
was O 0 0.00080625416
1 O 0 0.0006672515
. O 0 0.00041993384
8 O 0 0.00033039707
per O 0 0.00028944688
1 O 0 0.00032948295
, O 0 0.000494087
000 O 0 0.0004620985
woman O 0 0.00096863834
- O 0 0.0014020717
years O 0 0.0003947479
( O 0 0.0004762616
95 O 0 0.0005366192
% O 0 0.000573487
CI O 0 0.0064008515
- O 0 0.0014312576
0 O 0 0.0002996972
. O 0 0.00019578928
5 O 0 0.00019301321
- O 0 0.0006949297
4 O 0 0.00014939488
. O 0 0.00016137844
1 O 0 0.0001939626
) O 0 0.00038257084
, O 0 0.00028824236
and O 0 0.00016480187
the O 0 0.00012005952
number O 0 0.00010743805
needed O 0 0.00011276264
to O 0 0.00014304325
treat O 0 0.0003322943
to O 0 0.00015529552
cause O 0 0.0002491717
1 O 0 0.0002108973
event O 0 0.00027073175
was O 0 0.0001823167
170 O 0 0.00045443588
( O 0 0.0003697965
95 O 0 0.00042571063
% O 0 0.00046605617
CI O 0 0.003964363
100 O 0 0.0008035988
- O 0 0.002028916
582 O 0 0.0018650804
) O 0 0.00072882057
over O 0 0.0003084698
3 O 0 0.00041170677
. O 0 0.0005578836
3 O 0 0.0007849659
years O 0 0.0017026804
. O 0 0.0029401248

Risk O 0 0.0075200414
in O 0 0.0018219667
the O 0 0.0014122336
raloxifene B-Chemical 0 0.99866605
group O 0 0.0011180425
was O 0 0.0003457878
higher O 0 0.00028311546
than O 0 0.00016924331
in O 0 0.00013904575
the O 0 0.0001277749
placebo O 0 0.0013614892
group O 0 0.00017870206
for O 0 8.093992e-05
the O 0 7.9161444e-05
first O 0 6.596874e-05
2 O 0 0.00012407938
years O 0 0.00015841053
, O 0 0.00023488217
but O 0 0.00016907009
decreased O 0 0.00024752886
to O 0 0.00012005368
about O 0 0.00016530075
the O 0 0.000120994584
same O 0 0.000116482115
rate O 0 0.00026517492
as O 0 0.00020183885
in O 0 0.00023445571
the O 0 0.00031671606
placebo O 0 0.004197719
group O 0 0.001125528
thereafter O 0 0.0014180581
. O 0 0.002453692

Raloxifene B-Chemical 1 0.9994475
did O 0 0.00399007
not O 0 0.0015858792
increase O 0 0.0012042943
risk O 0 0.006402571
for O 0 0.0011257522
cataracts B-Disease 2 0.99991024
( O 0 0.0029434424
RR O 0 0.0792616
0 O 0 0.00047412748
. O 0 0.0002461223
9 O 0 0.00020821753
; O 0 0.00041184257
95 O 0 0.00045518726
% O 0 0.0004798593
CI O 0 0.0024692924
0 O 0 0.00031427195
. O 0 0.00020381954
8 O 0 0.00021937572
- O 0 0.00088493124
1 O 0 0.00025260542
. O 0 0.00021065597
1 O 0 0.000266079
) O 0 0.00062521733
, O 0 0.0008599127
gallbladder B-Disease 2 0.9936453
disease I-Disease 2 0.99578565
( O 0 0.0014856544
RR O 0 0.08498245
1 O 0 0.000286923
. O 0 0.0001859025
0 O 0 0.00024723666
; O 0 0.00035950364
95 O 0 0.0003940092
% O 0 0.0004179197
CI O 0 0.002384624
0 O 0 0.00028278364
. O 0 0.00018213739
7 O 0 0.00017462307
- O 0 0.0007958418
1 O 0 0.00023075497
. O 0 0.0001859931
3 O 0 0.00019204504
) O 0 0.0005979237
, O 0 0.0008301365
endometrial B-Disease 0 0.83584654
hyperplasia I-Disease 0 0.9994235
( O 0 0.0015250592
RR O 0 0.08059529
1 O 0 0.0002770403
. O 0 0.00017148582
3 O 0 0.00015227574
; O 0 0.00032322624
95 O 0 0.0003663897
% O 0 0.00039772253
CI O 0 0.0023219096
0 O 0 0.00027083678
. O 0 0.00017218168
4 O 0 0.00016675085
- O 0 0.00070771074
5 O 0 0.00017526679
. O 0 0.00017807644
1 O 0 0.00023032613
) O 0 0.00050613226
, O 0 0.0005011719
or O 0 0.00042883097
endometrial B-Disease 2 0.99755764
cancer I-Disease 2 0.99966824
( O 0 0.0020428326
RR O 0 0.09502588
0 O 0 0.00035710487
. O 0 0.00019633834
9 O 0 0.00018159306
; O 0 0.00039167027
95 O 0 0.00046783884
% O 0 0.00052949693
CI O 0 0.0028488636
0 O 0 0.00043498757
. O 0 0.00032375485
3 O 0 0.00038007906
- O 0 0.0014649649
2 O 0 0.00068523234
. O 0 0.0007663994
7 O 0 0.0010505309
) O 0 0.0034706788
. O 0 0.0039558336

CONCLUSION O 0 0.05790361
: O 0 0.01576498
Raloxifene B-Chemical 1 0.99928266
was O 0 0.001044367
associated O 0 0.000636401
with O 0 0.00046650218
an O 0 0.00041001805
increased O 0 0.00045226215
risk O 0 0.0016624316
for O 0 0.00027164962
venous B-Disease 0 0.97180444
thromboembolism I-Disease 0 0.99999475
, O 0 0.0009907737
but O 0 0.0001967341
there O 0 0.0001045364
was O 0 0.00011878592
no O 0 0.00012609357
increased O 0 0.00028355527
risk O 0 0.0028584579
for O 0 0.00033943815
cataracts B-Disease 2 0.99998224
, O 0 0.008620311
gallbladder B-Disease 2 0.9996101
disease I-Disease 2 0.9993488
, O 0 0.004753124
endometrial B-Disease 0 0.9903493
hyperplasia I-Disease 0 0.999706
, O 0 0.0023088877
or O 0 0.0011599361
endometrial B-Disease 2 0.99819857
cancer I-Disease 2 0.9993374
. O 0 0.005312009

LEVEL O 0 0.07501072
OF O 0 0.03780758
EVIDENCE O 0 0.091062404
: O 0 0.04163058
I O 0 0.14841133

Optimization O 0 0.015664155
of O 0 0.01893359
levodopa B-Chemical 0 0.9995906
therapy O 0 0.01981997
. O 0 0.015261078

While O 0 0.0019483811
there O 0 0.0013165239
is O 0 0.00082619657
no O 0 0.00054468494
single O 0 0.00031742247
correct O 0 0.00030071838
starting O 0 0.00016321334
dose O 0 0.00037522495
for O 0 0.00025424318
levodopa B-Chemical 0 0.9999809
therapy O 0 0.0003547585
, O 0 0.00024419418
many O 0 0.000113444476
individuals O 0 0.00026868537
can O 0 8.98813e-05
be O 0 0.00010239335
started O 0 0.00010962298
on O 0 6.875658e-05
either O 0 9.793452e-05
the O 0 0.000100929545
25 O 0 0.00019841753
/ O 0 0.00066140114
100 O 0 0.00025174927
or O 0 9.953079e-05
controlled O 0 0.00019171313
- O 0 0.0014358973
release O 0 0.00033279648
formula O 0 0.0006666756
, O 0 0.000222972
following O 0 6.457853e-05
the O 0 8.12329e-05
general O 0 0.00011082232
rule O 0 0.00016210468
not O 0 9.774849e-05
to O 0 9.174246e-05
attempt O 0 0.00013916538
to O 0 0.00013114931
titrate O 0 0.00092500396
carbidopa B-Chemical 0 0.9999989
- O 0 0.6776848
levodopa B-Chemical 0 0.99999297
to O 0 0.00010148409
the O 0 7.871078e-05
point O 0 8.703697e-05
of O 0 0.0001952846
" O 0 0.00054412894
normality O 0 0.003120621
, O 0 0.00069090346
" O 0 0.0006872837
which O 0 0.00045620996
can O 0 0.00039414066
lead O 0 0.0028783986
to O 0 0.0011665195
toxicity B-Disease 0 0.7866735
. O 0 0.003716401

The O 0 0.0022144935
physician O 0 0.0032094212
should O 0 0.00058139965
also O 0 0.000462243
determine O 0 0.00016210576
the O 0 0.0002262175
proper O 0 0.00018956626
use O 0 0.00017281393
of O 0 0.00019179507
any O 0 0.00014999908
adjunctive O 0 0.001111284
medications O 0 0.0012334395
; O 0 0.0002810452
such O 0 0.000110447065
combined O 0 0.00018651204
therapy O 0 0.000254468
has O 0 0.000118472024
become O 0 0.00024627184
the O 0 0.00019942087
standard O 0 0.00030121248
approach O 0 0.0004180916
to O 0 0.00060649315
treatment O 0 0.0013188834
. O 0 0.0026561057

Following O 0 0.0015889027
the O 0 0.0009781563
initial O 0 0.00055270543
period O 0 0.000368816
of O 0 0.00044911075
therapy O 0 0.0005502591
, O 0 0.00050067797
emerging O 0 0.00025115444
difficulties O 0 0.0007078899
require O 0 0.00015851646
a O 0 0.00025107185
reassessment O 0 0.00025214226
of O 0 0.00014113143
therapeutic O 0 0.00019296443
approaches O 0 0.00017702983
, O 0 0.00027750182
such O 0 0.00014077767
as O 0 0.0001723696
dosage O 0 0.0006396131
adjustment O 0 0.00016774565
or O 0 0.00015681912
introduction O 0 0.00018137053
of O 0 0.00054992764
a O 0 0.0026725584
dopamine B-Chemical 0 0.99975365
agonist O 0 0.30396345
. O 0 0.0037162916

Other O 0 0.0029433249
possible O 0 0.0012444331
adverse O 0 0.0026570319
effects O 0 0.0010361624
- O 0 0.0075785103
- O 0 0.0029350757
such O 0 0.00038162898
as O 0 0.0005484978
gastrointestinal B-Disease 0 0.988197
disorders I-Disease 0 0.9998989
, O 0 0.00811571
orthostatic B-Disease 0 0.99996674
hypotension I-Disease 0 0.9999975
, O 0 0.023543663
levodopa B-Chemical 0 0.9999969
- O 0 0.013341973
induced O 0 0.0003246391
psychosis B-Disease 0 0.9999862
, O 0 0.0024512704
sleep B-Disease 0 0.9925971
disturbances I-Disease 0 0.9941332
or O 0 0.0002866485
parasomnias B-Disease 0 0.9998783
, O 0 0.0003406186
or O 0 0.00012474504
drug O 0 0.0016260032
interactions O 0 0.0002063711
- O 0 0.0032731052
- O 0 0.0012045761
also O 0 0.00016383156
require O 0 0.00014162282
carefully O 0 0.00016433987
monitored O 0 0.0002676609
individual O 0 0.00047763117
treatment O 0 0.0010791102
. O 0 0.0022962226

Nonpharmacologic O 0 0.0056766244
concerns O 0 0.0019762327
can O 0 0.00091927685
help O 0 0.0009919961
the O 0 0.00094174576
Parkinson B-Disease 0 0.99631435
' I-Disease 0 0.00112716
s I-Disease 0 0.0007299727
disease I-Disease 0 0.068074994
patient O 0 0.00019155254
achieve O 0 8.26891e-05
and O 0 0.00010211896
maintain O 0 6.533946e-05
optimal O 0 5.4993798e-05
functioning O 0 0.0002708025
, O 0 0.00019240318
including O 0 8.1768776e-05
daily O 0 0.0001453044
exercise O 0 0.00025593783
, O 0 0.00022105503
physical O 0 0.00024766556
therapy O 0 0.0002650056
, O 0 0.00034586265
and O 0 0.0002841853
involvement O 0 0.0005506809
with O 0 0.0005810734
support O 0 0.0008612912
groups O 0 0.0019880373
. O 0 0.0031705722

Long O 0 0.009034437
term O 0 0.0039204583
audiological O 0 0.005961868
evaluation O 0 0.0023637952
of O 0 0.0034518403
beta B-Disease 0 0.97733283
- I-Disease 0 0.5357617
thalassemic I-Disease 0 0.9989247
patients O 0 0.013726534
. O 0 0.0070052277

OBJECTIVE O 0 0.01846691
: O 0 0.0032092626
The O 0 0.0005753409
objective O 0 0.0005941998
of O 0 0.00053680595
this O 0 0.0004463068
study O 0 0.0003880835
was O 0 0.00021540323
to O 0 0.00014228551
identify O 0 8.322227e-05
the O 0 0.00012710254
incidence O 0 0.0002778084
and O 0 0.00013070896
to O 0 8.733077e-05
monitor O 0 7.5240954e-05
the O 0 9.305812e-05
progression O 0 0.00049026724
of O 0 0.00017002181
hearing B-Disease 0 0.16805053
loss I-Disease 0 0.00022337142
in O 0 0.00014393532
children O 0 0.00050797855
and O 0 0.00021926573
young O 0 0.0012409472
adults O 0 0.0017887854
with O 0 0.0007992915
beta B-Disease 0 0.99365175
- I-Disease 0 0.7019188
thalassemia I-Disease 0 0.9999633
major O 0 0.0030544389
. O 0 0.003391166

METHODS O 0 0.0044276696
: O 0 0.0031010674
One O 0 0.0013350918
hundred O 0 0.0010880855
and O 0 0.00069486187
four O 0 0.00040940466
( O 0 0.0008729446
104 O 0 0.00084140024
) O 0 0.00092021504
patients O 0 0.0006074329
aged O 0 0.00051279773
6 O 0 0.0002382101
- O 0 0.0007764036
35 O 0 0.00026384564
years O 0 0.0002858385
( O 0 0.00036888858
mean O 0 0.00021460476
17 O 0 0.0003709615
, O 0 0.00048700106
2 O 0 0.00037701507
years O 0 0.00051158597
) O 0 0.0010250024
participated O 0 0.0013469536
in O 0 0.00078089896
the O 0 0.0010442059
study O 0 0.0022426343
. O 0 0.0034928783

All O 0 0.0022513757
patients O 0 0.0026108725
were O 0 0.00090096326
on O 0 0.00048858376
a O 0 0.0006960379
regular O 0 0.0005026516
transfusion O 0 0.0014889629
- O 0 0.0033070117
chelation O 0 0.0040139095
program O 0 0.00021101962
maintaining O 0 0.0001679244
a O 0 0.00033568326
mean O 0 0.00025705743
hemoglobin O 0 0.10303693
level O 0 0.00029163854
of O 0 0.00039123648
9 O 0 0.00036692902
. O 0 0.0004175219
5 O 0 0.0005776079
gr O 0 0.0031440284
/ O 0 0.004826794
dl O 0 0.011078991
. O 0 0.0042948565

Subjects O 0 0.003953056
were O 0 0.0019782155
receiving O 0 0.0036852956
desferrioxamine B-Chemical 0 0.99995184
( O 0 0.063132815
DFO B-Chemical 0 0.999979
) O 0 0.007596366
chelation O 0 0.03198834
treatment O 0 0.0002371301
with O 0 0.0001766085
a O 0 0.0001957122
mean O 0 0.00010585973
daily O 0 0.00014059362
dose O 0 0.00017616097
of O 0 0.0001406388
50 O 0 0.0002236314
- O 0 0.0006833942
60 O 0 0.00016893313
mg O 0 0.0011567537
/ O 0 0.00053288764
kg O 0 0.00038606214
, O 0 0.00025531003
5 O 0 0.00013120734
- O 0 0.000383264
6 O 0 5.894214e-05
days O 0 4.5472392e-05
a O 0 9.5955715e-05
week O 0 4.8975893e-05
during O 0 4.9412934e-05
the O 0 5.543884e-05
first O 0 4.4968627e-05
six O 0 4.5410165e-05
years O 0 0.00010492769
of O 0 0.0001013228
the O 0 9.857078e-05
study O 0 0.0001677909
, O 0 0.00026126602
which O 0 0.00015601418
was O 0 0.000114073744
then O 0 0.00010764293
reduced O 0 0.00015191939
to O 0 0.000121246936
40 O 0 0.00019639246
- O 0 0.0007609766
50 O 0 0.00024014115
mg O 0 0.0016833583
/ O 0 0.0006701349
kg O 0 0.00043574185
for O 0 0.0001634117
the O 0 0.0002163449
following O 0 0.0002473953
eight O 0 0.000442295
years O 0 0.0013687994
. O 0 0.0023275146

Patients O 0 0.007163463
were O 0 0.003027199
followed O 0 0.0019846172
for O 0 0.0018456726
8 O 0 0.0025419716
- O 0 0.0062520397
14 O 0 0.003073511
years O 0 0.0048178234
. O 0 0.007111721

RESULTS O 0 0.005113123
: O 0 0.003562062
Overall O 0 0.0016369685
, O 0 0.0018752419
21 O 0 0.0009458208
out O 0 0.00050215813
of O 0 0.00053950713
104 O 0 0.00090668147
patients O 0 0.00085989217
( O 0 0.0005930323
20 O 0 0.00028425985
. O 0 0.00021241978
2 O 0 0.00021512614
% O 0 0.00035542046
) O 0 0.00035978586
presented O 0 0.00013039711
with O 0 0.00015318012
high O 0 0.0002281951
frequency O 0 0.0003011459
sensorineural B-Disease 0 0.99986804
hearing I-Disease 0 0.8324588
loss I-Disease 0 0.0017310452
( O 0 0.0027340907
SNHL B-Disease 0 0.99998343
) O 0 0.001936069
, O 0 0.00073114753
either O 0 0.000490667
unilateral O 0 0.012118822
or O 0 0.0009294992
bilateral O 0 0.008068248
. O 0 0.0027254347

No O 0 0.010422066
ototoxic B-Disease 0 0.9981938
factor O 0 0.045428615
, O 0 0.0030135363
other O 0 0.0012343581
than O 0 0.001829771
DFO B-Chemical 0 0.999946
, O 0 0.0021415155
was O 0 0.0005555236
present O 0 0.00040773556
in O 0 0.00049560965
any O 0 0.0005204662
of O 0 0.00086601765
the O 0 0.001082702
patients O 0 0.0033769137
. O 0 0.00336938

Patients O 0 0.0057480247
with O 0 0.0038752106
SNHL B-Disease 0 0.999861
presented O 0 0.00088383956
with O 0 0.0005886483
relatively O 0 0.00065830955
lower O 0 0.00074494485
serum O 0 0.14495666
ferritin O 0 0.9947178
levels O 0 0.00023341634
than O 0 0.0001583995
those O 0 0.00017425681
with O 0 0.00018513745
normal O 0 0.00045032505
hearing O 0 0.16849202
, O 0 0.00048084877
however O 0 0.00028998166
, O 0 0.00040056198
no O 0 0.00022437956
statistically O 0 0.00044422198
significant O 0 0.00037541604
difference O 0 0.000456483
was O 0 0.00078701583
observed O 0 0.001292911
. O 0 0.0029949483

Subjects O 0 0.007627159
with O 0 0.006511209
SNHL B-Disease 0 0.9997706
were O 0 0.0021654537
submitted O 0 0.0015359255
to O 0 0.0017809456
DFO B-Chemical 0 0.9998216
reduction O 0 0.0021792557
or O 0 0.0014220448
temporary O 0 0.004833014
withdrawal O 0 0.011417897
. O 0 0.0044439263

Following O 0 0.0024189143
intervention O 0 0.0026360317
, O 0 0.0023359947
7 O 0 0.00082803966
out O 0 0.00058337266
of O 0 0.0006126156
21 O 0 0.00060119154
affected O 0 0.00047905487
patients O 0 0.000708398
recovered O 0 0.00032251398
, O 0 0.0006121706
10 O 0 0.00034912722
remained O 0 0.0004252308
stable O 0 0.00042896875
and O 0 0.00052665255
4 O 0 0.0005814914
demonstrated O 0 0.00097647274
aggravation O 0 0.05495338
. O 0 0.003630311

CONCLUSION O 0 0.016294742
: O 0 0.0037611912
The O 0 0.0007975169
findings O 0 0.000987744
are O 0 0.00064705126
indicative O 0 0.0006964015
of O 0 0.0014096535
DFO B-Chemical 0 0.99994504
' O 0 0.0019798505
s O 0 0.0006886612
contributing O 0 0.0003543828
role O 0 0.00015796468
in O 0 0.00029605647
the O 0 0.00031927906
development O 0 0.0006127984
of O 0 0.0009667464
hearing B-Disease 0 0.63752204
impairment I-Disease 0 0.8117273
. O 0 0.0042271214

Regular O 0 0.004582032
audiologic O 0 0.0053190296
evaluation O 0 0.001035439
is O 0 0.0005729003
imperative O 0 0.00049945293
in O 0 0.00045382357
all O 0 0.0005423385
thalassemic B-Disease 0 0.9969478
patients O 0 0.00086593354
so O 0 0.00019020881
that O 0 0.00013760189
early O 0 0.000322784
changes O 0 0.00019781757
may O 0 0.00011752675
be O 0 0.00011521977
recognized O 0 0.00011170292
and O 0 0.00014205032
treatment O 0 0.00014212294
may O 0 9.8791075e-05
be O 0 0.00010504122
judiciously O 0 0.00014578749
adjusted O 0 0.00010265869
in O 0 0.00011761229
order O 0 0.00010410904
to O 0 0.00015586193
prevent O 0 0.00021719521
or O 0 0.00034646163
reverse O 0 0.001045251
hearing B-Disease 0 0.66749215
impairment I-Disease 0 0.8126663
. O 0 0.0036164015

Individual O 0 0.0030665959
differences O 0 0.0015283063
in O 0 0.0016902995
renal O 0 0.85828036
ACE O 0 0.95766246
activity O 0 0.0004544307
in O 0 0.00040022156
healthy O 0 0.0009971538
rats O 0 0.0004349409
predict O 0 0.00018784702
susceptibility O 0 0.00051382545
to O 0 0.0005974464
adriamycin B-Chemical 0 0.9999578
- O 0 0.045894977
induced O 0 0.0014951184
renal B-Disease 0 0.99884975
damage I-Disease 0 0.9717947
. O 0 0.0043495456

BACKGROUND O 0 0.014294014
: O 0 0.0039920923
In O 0 0.0011006208
man O 0 0.00511046
, O 0 0.0015123563
differences O 0 0.0006125581
in O 0 0.0010952845
angiotensin B-Chemical 0 0.99996626
- O 0 0.20087515
converting O 0 0.0018380941
enzyme O 0 0.002533654
( O 0 0.0015359255
ACE O 0 0.964782
) O 0 0.0009363662
levels O 0 0.0002204354
, O 0 0.00038978274
related O 0 0.00014970373
to O 0 0.00026702823
ACE O 0 0.9087524
( O 0 0.001105633
I O 0 0.05501178
/ O 0 0.014212027
D O 0 0.96006674
) O 0 0.0018674557
genotype O 0 0.00059322396
, O 0 0.0006318535
are O 0 0.00028880825
associated O 0 0.00048537643
with O 0 0.0009205509
renal O 0 0.9086703
prognosis O 0 0.61717194
. O 0 0.0036282698

This O 0 0.0035440188
raises O 0 0.00071196747
the O 0 0.00070130837
hypothesis O 0 0.00056340784
that O 0 0.00038516225
individual O 0 0.00031288268
differences O 0 0.00027398329
in O 0 0.00041687564
renal O 0 0.8716783
ACE O 0 0.94906735
activity O 0 0.00022367616
are O 0 0.00018572091
involved O 0 0.0002171428
in O 0 0.00038006663
renal O 0 0.5251811
susceptibility O 0 0.0011141733
to O 0 0.000835696
inflicted O 0 0.06801149
damage O 0 0.21941553
. O 0 0.00378808

Therefore O 0 0.0021980947
, O 0 0.0030130965
we O 0 0.0007623589
studied O 0 0.0010046097
the O 0 0.00046080595
predictive O 0 0.000674869
effect O 0 0.00031101675
of O 0 0.0005676224
renal O 0 0.97774017
ACE O 0 0.98096955
activity O 0 0.00014522378
for O 0 0.000105952946
the O 0 0.00012134676
severity O 0 0.0005405964
of O 0 0.00032660353
renal B-Disease 0 0.99934226
damage I-Disease 0 0.82844025
induced O 0 0.00020556022
by O 0 0.00016706198
a O 0 0.00023741403
single O 0 0.00013339559
injection O 0 0.00019425704
of O 0 0.0005482004
adriamycin B-Chemical 0 0.999856
in O 0 0.001018288
rats O 0 0.0021397073
. O 0 0.0024265666

METHODS O 0 0.005779405
: O 0 0.0057014
Renal O 0 0.016493704
ACE O 0 0.3641455
activity O 0 0.0008587328
( O 0 0.0016017801
Hip B-Chemical 0 0.003359403
- I-Chemical 0 0.004093964
His I-Chemical 0 0.0009900371
- I-Chemical 0 0.0049848612
Leu I-Chemical 0 0.02036662
cleavage O 0 0.00042558892
by O 0 0.00036346077
cortical O 0 0.0013408477
homogenates O 0 0.0005733911
) O 0 0.00056451384
was O 0 0.00017723184
determined O 0 0.00016177764
by O 0 0.00025632884
renal O 0 0.2808074
biopsy O 0 0.0003891115
in O 0 0.0002506337
27 O 0 0.00044713105
adult O 0 0.00054952427
male O 0 0.0012276869
Wistar O 0 0.0031617938
rats O 0 0.0022384503
. O 0 0.0026682357

After O 0 0.0017152799
1 O 0 0.0016011258
week O 0 0.00072968606
of O 0 0.0008326619
recovery O 0 0.0011548932
, O 0 0.0019591209
proteinuria B-Disease 0 0.9997843
was O 0 0.0005010807
induced O 0 0.00037458527
by O 0 0.0005664039
adriamycin B-Chemical 0 0.9999665
[ O 0 0.004750932
1 O 0 0.00024179579
. O 0 0.00013905954
5 O 0 0.00012862585
mg O 0 0.00071404607
/ O 0 0.00044997167
kg O 0 0.00036352142
intravenously O 0 0.00031291906
( O 0 0.00026596137
i O 0 0.0003021369
. O 0 0.00018595908
v O 0 0.00066852005
. O 0 0.00018805866
) O 0 0.00032790017
n O 0 0.000215516
= O 0 0.00045089654
18 O 0 0.00019955305
; O 0 0.0003193652
controls O 0 0.00029195176
, O 0 0.00044649618
saline O 0 0.00075806334
i O 0 0.00056512625
. O 0 0.00033645303
v O 0 0.0010860433
. O 0 0.00041853785
n O 0 0.00063465117
= O 0 0.0015983772
9 O 0 0.0010342721
] O 0 0.0040251995
. O 0 0.003521552

Proteinuria B-Disease 0 0.9980995
was O 0 0.0068446393
measured O 0 0.0044945423
every O 0 0.002488715
2 O 0 0.0037406
weeks O 0 0.0030694837
. O 0 0.007994035

After O 0 0.0018456691
12 O 0 0.0013783546
weeks O 0 0.0008513778
, O 0 0.0015913561
rats O 0 0.001206045
were O 0 0.0006800369
sacrificed O 0 0.0005530057
and O 0 0.0008934184
their O 0 0.0010697916
kidneys O 0 0.0037901215
harvested O 0 0.0023411827
. O 0 0.004776605

RESULTS O 0 0.0045721885
: O 0 0.0030486246
As O 0 0.0007296437
anticipated O 0 0.00085387717
, O 0 0.002495189
adriamycin B-Chemical 0 0.9998449
elicited O 0 0.0014379668
nephrotic B-Disease 0 0.9999926
range O 0 0.0012729098
proteinuria B-Disease 0 0.9999362
, O 0 0.0024247158
renal B-Disease 0 0.99240595
interstitial I-Disease 0 0.2675759
damage I-Disease 0 0.34606317
and O 0 0.0009955951
mild O 0 0.36910397
focal B-Disease 0 0.8740282
glomerulosclerosis I-Disease 0 0.9999896
. O 0 0.006540225

Baseline O 0 0.0053327596
renal O 0 0.9020911
ACE O 0 0.97354126
positively O 0 0.0010627047
correlated O 0 0.00055121764
with O 0 0.000408219
the O 0 0.00025711724
relative O 0 0.00020344599
rise O 0 0.00032165358
in O 0 0.00033965908
proteinuria B-Disease 0 0.9998585
after O 0 0.00025899746
adriamycin B-Chemical 0 0.9999007
( O 0 0.00051538256
r O 0 0.00043468436
= O 0 0.00047544128
0 O 0 0.00021754505
. O 0 0.00015632853
62 O 0 0.00026286513
, O 0 0.00032354443
P O 0 0.002730663
< O 0 0.00032585496
0 O 0 0.00025695842
. O 0 0.00021182232
01 O 0 0.0011442455
) O 0 0.000606854
, O 0 0.00060369185
renal O 0 0.6972122
interstitial O 0 0.20462798
alpha O 0 0.81603914
- O 0 0.013602875
smooth O 0 0.0021352586
muscle O 0 0.0018339438
actin O 0 0.00044901273
( O 0 0.00037419779
r O 0 0.00041634028
= O 0 0.00048203528
0 O 0 0.00021820335
. O 0 0.00015358053
49 O 0 0.00024174855
, O 0 0.0003400025
P O 0 0.003322543
< O 0 0.00034782328
0 O 0 0.00028348985
. O 0 0.0002461169
05 O 0 0.004704618
) O 0 0.00071739434
, O 0 0.0005877788
interstitial O 0 0.016203621
macrophage O 0 0.013518298
influx O 0 0.0026865427
( O 0 0.00040381055
r O 0 0.00042571937
= O 0 0.0004915965
0 O 0 0.00022774193
. O 0 0.00016263449
56 O 0 0.00024653776
, O 0 0.0003534765
P O 0 0.0030741768
< O 0 0.0003699109
0 O 0 0.00030146964
. O 0 0.00026403466
05 O 0 0.0041505774
) O 0 0.000765483
, O 0 0.00068675267
interstitial O 0 0.03800553
collagen O 0 0.8523125
III O 0 0.13541068
( O 0 0.00059193006
r O 0 0.00053623243
= O 0 0.0005855313
0 O 0 0.00026299927
. O 0 0.00018531759
53 O 0 0.00029962807
, O 0 0.00037395564
P O 0 0.0030241723
< O 0 0.0003773065
0 O 0 0.0003063368
. O 0 0.00026841092
05 O 0 0.0045336257
) O 0 0.0008711137
, O 0 0.0009898276
glomerular O 0 0.99825543
alpha O 0 0.8931429
- O 0 0.017822284
smooth O 0 0.002473816
muscle O 0 0.0020594832
actin O 0 0.00050229457
( O 0 0.00041292032
r O 0 0.0004510455
= O 0 0.0005162046
0 O 0 0.00023617722
. O 0 0.00016830672
74 O 0 0.0002866425
, O 0 0.00035440543
P O 0 0.0029209892
< O 0 0.00035693898
0 O 0 0.00028645832
. O 0 0.0002420105
01 O 0 0.0013502885
) O 0 0.0007036404
and O 0 0.0004952604
glomerular O 0 0.9966273
desmin O 0 0.050987225
( O 0 0.00062975497
r O 0 0.0006083165
= O 0 0.0006851664
0 O 0 0.00034509602
. O 0 0.00026449066
48 O 0 0.0003318153
, O 0 0.0006857922
P O 0 0.0042237868
< O 0 0.0010030203
0 O 0 0.0010317705
. O 0 0.0012479596
05 O 0 0.013485608
) O 0 0.0054335822
. O 0 0.004883176

Baseline O 0 0.006597755
renal O 0 0.93227327
ACE O 0 0.98465997
did O 0 0.001777684
not O 0 0.0008859256
correlate O 0 0.00078130956
with O 0 0.0010239709
focal B-Disease 0 0.57175595
glomerulosclerosis I-Disease 0 0.9999945
( O 0 0.0019283795
r O 0 0.0011038366
= O 0 0.0011092306
0 O 0 0.0006271268
. O 0 0.00058960594
22 O 0 0.0011763725
, O 0 0.002436256
NS O 0 0.75679034
) O 0 0.006854377
. O 0 0.0050794706

In O 0 0.0025910705
controls O 0 0.0034720795
, O 0 0.002803588
no O 0 0.0011911558
predictive O 0 0.0017117888
values O 0 0.0009660798
for O 0 0.0008875507
renal O 0 0.10383199
parameters O 0 0.0016138339
were O 0 0.0014616956
observed O 0 0.0020056362
. O 0 0.004294769

CONCLUSION O 0 0.014441526
: O 0 0.0035176086
Individual O 0 0.0011201185
differences O 0 0.0006330243
in O 0 0.0007940287
renal O 0 0.7365392
ACE O 0 0.90361387
activity O 0 0.00023830254
predict O 0 0.0001419516
the O 0 0.00017868348
severity O 0 0.0006592475
of O 0 0.0005513689
adriamycin B-Chemical 0 0.9999852
- O 0 0.06057206
induced O 0 0.0005638981
renal B-Disease 0 0.99951017
damage I-Disease 0 0.9031308
in O 0 0.00041554566
this O 0 0.00047439666
outbred O 0 0.00083529437
rat O 0 0.0010028443
strain O 0 0.0010189364
. O 0 0.0025347471

This O 0 0.0042094076
supports O 0 0.0014428528
the O 0 0.0008679748
assumption O 0 0.0005673728
that O 0 0.00040128743
differences O 0 0.00037542268
in O 0 0.0005649649
renal O 0 0.92890435
ACE O 0 0.97809905
activity O 0 0.00029364062
predispose O 0 0.00061561714
to O 0 0.00021628074
a O 0 0.00038612692
less O 0 0.00041564507
favourable O 0 0.00072314224
course O 0 0.00051732623
of O 0 0.0011251523
renal B-Disease 0 0.99761677
damage I-Disease 0 0.9462936
. O 0 0.0041901474

Recurrent O 0 0.023807075
acute O 0 0.58285993
interstitial B-Disease 0 0.99066263
nephritis I-Disease 0 0.99996364
induced O 0 0.0060172696
by O 0 0.006169357
azithromycin B-Chemical 0 0.9991467
. O 0 0.008435415

A O 0 0.024221208
14 O 0 0.0034043384
- O 0 0.0067575495
year O 0 0.0014206951
- O 0 0.0035155667
old O 0 0.0010911647
girl O 0 0.002003732
is O 0 0.00044588523
reported O 0 0.00049064757
with O 0 0.000534242
recurrent O 0 0.0034181771
, O 0 0.0017608468
azithromycin B-Chemical 0 0.99985707
- O 0 0.0071395705
induced O 0 0.00068497803
, O 0 0.002211461
acute O 0 0.5954994
interstitial B-Disease 0 0.9965299
nephritis I-Disease 0 0.9999887
. O 0 0.006600797

The O 0 0.0017948416
second O 0 0.0013768419
episode O 0 0.0013725777
was O 0 0.00072064705
more O 0 0.0008341879
severe O 0 0.0015598827
than O 0 0.0002421144
the O 0 0.00016526906
first O 0 0.00013152277
; O 0 0.0003635944
and O 0 0.0001683632
although O 0 0.00013101305
both O 0 0.00011092255
were O 0 0.00011260908
treated O 0 0.0002031281
with O 0 0.00015280723
intensive O 0 0.00032353392
corticosteroid O 0 0.9815167
therapy O 0 0.00039265296
, O 0 0.00049654656
renal O 0 0.17125876
function O 0 0.00048410922
remained O 0 0.0012181923
impaired O 0 0.0052453494
. O 0 0.003097595

Although O 0 0.0020918655
most O 0 0.0023298452
cases O 0 0.0020487285
of O 0 0.0010370135
antibiotic O 0 0.003269635
induced O 0 0.00077051634
acute O 0 0.56586426
interstitial B-Disease 0 0.9973465
nephritis I-Disease 0 0.9999987
are O 0 0.00041442728
benign O 0 0.13457972
and O 0 0.00019060733
self O 0 0.00073483086
- O 0 0.0012796328
limited O 0 0.00018515933
, O 0 0.0003249441
some O 0 0.00019417539
patients O 0 0.0003706436
are O 0 0.00014768024
at O 0 0.0001806255
risk O 0 0.001300543
for O 0 0.00043106463
permanent O 0 0.0071329954
renal B-Disease 0 0.99828064
injury I-Disease 0 0.92212754
. O 0 0.0035974088

Spironolactone B-Chemical 0 0.9998115
- O 0 0.069752775
induced O 0 0.002531038
renal B-Disease 0 0.9732823
insufficiency I-Disease 0 0.99904436
and O 0 0.0022114927
hyperkalemia B-Disease 0 0.9999039
in O 0 0.00083644374
patients O 0 0.0013226037
with O 0 0.0010459223
heart B-Disease 0 0.055988215
failure I-Disease 0 0.047597326
. O 0 0.0035950593

BACKGROUND O 0 0.016300032
: O 0 0.0045596445
A O 0 0.005471282
previous O 0 0.0006838545
randomized O 0 0.0010277119
controlled O 0 0.00038335082
trial O 0 0.000339804
evaluating O 0 0.000107759595
the O 0 0.0001179851
use O 0 0.00013683226
of O 0 0.00030314445
spironolactone B-Chemical 0 0.9999883
in O 0 0.00031185197
heart B-Disease 0 0.070069864
failure I-Disease 0 0.015368501
patients O 0 0.0003400957
reported O 0 0.000121843594
a O 0 0.00016284088
low O 0 0.00021464568
risk O 0 0.0019268146
of O 0 0.00042860518
hyperkalemia B-Disease 0 0.9999795
( O 0 0.0006848599
2 O 0 0.0002142537
% O 0 0.00035633022
) O 0 0.0004636483
and O 0 0.0003334631
renal B-Disease 0 0.86143357
insufficiency I-Disease 0 0.9978636
( O 0 0.0013354898
0 O 0 0.0009372173
% O 0 0.001696642
) O 0 0.0030738234
. O 0 0.0030146039

Because O 0 0.0015771346
treatments O 0 0.001869154
for O 0 0.0010127943
heart B-Disease 0 0.029604971
failure I-Disease 0 0.012962286
have O 0 0.0003426608
changed O 0 0.00027683697
since O 0 0.00011854016
the O 0 0.00010935832
benefits O 0 0.00012173618
of O 0 0.00032309128
spironolactone B-Chemical 0 0.99998784
were O 0 0.00025142447
reported O 0 0.00018909868
, O 0 0.00023012595
the O 0 0.00010355951
prevalence O 0 0.00018406166
of O 0 0.00016860741
these O 0 0.00018347029
complications O 0 0.003648976
may O 0 0.00018211585
differ O 0 0.00022987461
in O 0 0.0002760289
current O 0 0.0005585675
clinical O 0 0.0020745827
practice O 0 0.0018906568
. O 0 0.0024981224

We O 0 0.0024871244
therefore O 0 0.001544019
sought O 0 0.0010024671
to O 0 0.00047859183
determine O 0 0.00016114056
the O 0 0.0002407193
prevalence O 0 0.00033101026
and O 0 0.00023558777
clinical O 0 0.0004369552
associations O 0 0.00015739212
of O 0 0.0003079121
hyperkalemia B-Disease 0 0.99995875
and O 0 0.00047350168
renal B-Disease 0 0.9686817
insufficiency I-Disease 0 0.99875546
in O 0 0.00025187028
heart B-Disease 0 0.020098574
failure I-Disease 0 0.0075058765
patients O 0 0.00068378483
treated O 0 0.00084530987
with O 0 0.0014479097
spironolactone B-Chemical 0 0.9999639
. O 0 0.0044791303

METHODS O 0 0.0042880923
: O 0 0.0027519448
We O 0 0.00076653156
performed O 0 0.00061577663
a O 0 0.00073963957
case O 0 0.0004560991
control O 0 0.0003598582
study O 0 0.00035211854
of O 0 0.00033984578
heart B-Disease 0 0.01621023
failure I-Disease 0 0.009292854
patients O 0 0.00058944244
treated O 0 0.000525362
with O 0 0.00058254006
spironolactone B-Chemical 0 0.99998045
in O 0 0.0005789318
our O 0 0.0005455787
clinical O 0 0.0023252987
practice O 0 0.001979971
. O 0 0.0025488967

Cases O 0 0.008466877
were O 0 0.0020458468
patients O 0 0.0023589064
who O 0 0.0015654213
developed O 0 0.0016203006
hyperkalemia B-Disease 0 0.9998765
( O 0 0.005336792
K B-Chemical 0 0.9991804
( O 0 0.0018204048
+ O 0 0.0018757248
) O 0 0.0008507622
> O 0 0.0006252552
5 O 0 0.00023174827
. O 0 0.00020819668
0 O 0 0.00035331308
mEq O 0 0.2004992
/ O 0 0.001898609
L O 0 0.3595025
) O 0 0.00095702935
or O 0 0.00029141398
renal B-Disease 0 0.8457086
insufficiency I-Disease 0 0.9990889
( O 0 0.0018127649
Cr B-Chemical 0 0.99868304
> O 0 0.0005305242
or O 0 0.00016133873
= O 0 0.00044029913
2 O 0 0.00015793937
. O 0 0.00012185824
5 O 0 0.00013394111
mg O 0 0.0011960376
/ O 0 0.0010054441
dL O 0 0.01194386
) O 0 0.0005975885
, O 0 0.00032836007
and O 0 0.00017465405
they O 0 0.00013832356
were O 0 0.0001278363
compared O 0 0.00010702351
to O 0 0.00013898026
2 O 0 0.00019981922
randomly O 0 0.00012778465
selected O 0 0.00023576643
controls O 0 0.0006585088
per O 0 0.0007592255
case O 0 0.0015011908
. O 0 0.0027710418

Clinical O 0 0.0055741128
characteristics O 0 0.0016319683
, O 0 0.0023192305
medications O 0 0.0054899277
, O 0 0.0015425466
and O 0 0.0007911141
serum O 0 0.004330531
chemistries O 0 0.0008442272
at O 0 0.00022838404
baseline O 0 0.00023235138
and O 0 0.0002696994
follow O 0 0.00023406462
- O 0 0.0010150616
up O 0 0.00035784286
time O 0 0.00028346764
periods O 0 0.0005386244
were O 0 0.0007872116
compared O 0 0.0011116501
. O 0 0.0029899918

RESULTS O 0 0.0052177496
: O 0 0.0040606507
Sixty O 0 0.0033822076
- O 0 0.003365632
seven O 0 0.0006887534
of O 0 0.00093099795
926 O 0 0.13929899
patients O 0 0.0013746421
( O 0 0.0006995841
7 O 0 0.00024782715
. O 0 0.00022438212
2 O 0 0.00022121865
% O 0 0.0003484481
) O 0 0.00033072956
required O 0 9.906787e-05
discontinuation O 0 0.0012690484
of O 0 0.00032951753
spironolactone B-Chemical 0 0.9999846
due O 0 0.00020511872
to O 0 0.00024172758
hyperkalemia B-Disease 0 0.99992716
( O 0 0.00043373174
n O 0 0.0002168424
= O 0 0.00048244465
33 O 0 0.00029030917
) O 0 0.00039159582
or O 0 0.00022044338
renal B-Disease 0 0.29775023
failure I-Disease 0 0.006593656
( O 0 0.0007100495
n O 0 0.00059332233
= O 0 0.0015196436
34 O 0 0.0012852125
) O 0 0.0030090513
. O 0 0.00309558

Patients O 0 0.0044798534
who O 0 0.0024994335
developed O 0 0.0020440961
hyperkalemia B-Disease 0 0.99979156
were O 0 0.0007466862
older O 0 0.0016333244
and O 0 0.00034899177
more O 0 0.00032249952
likely O 0 0.00011768219
to O 0 0.00014211956
have O 0 0.00020041568
diabetes B-Disease 0 0.99966455
, O 0 0.0004436304
had O 0 0.00012441515
higher O 0 0.00013231448
baseline O 0 0.000155044
serum O 0 0.06372151
potassium B-Chemical 0 0.9993765
levels O 0 0.00010542485
and O 0 9.6882686e-05
lower O 0 0.00011849021
baseline O 0 0.00013864394
potassium B-Chemical 0 0.99771667
supplement O 0 0.0012598286
doses O 0 0.00045244565
, O 0 0.00024029278
and O 0 0.00011582178
were O 0 9.188482e-05
more O 0 0.00012825096
likely O 0 5.595841e-05
to O 0 7.590932e-05
be O 0 9.876235e-05
treated O 0 0.00025408904
with O 0 0.0002742167
beta O 0 0.8583837
- O 0 0.06369431
blockers O 0 0.8618026
than O 0 0.0002560816
controls O 0 0.0004306453
( O 0 0.0006099034
n O 0 0.000587349
= O 0 0.0017282406
134 O 0 0.0022988585
) O 0 0.0031366749
. O 0 0.0030571816

Patients O 0 0.0040297243
who O 0 0.002084703
developed O 0 0.0014247862
renal B-Disease 0 0.7867548
insufficiency I-Disease 0 0.9944583
had O 0 0.00031319994
lower O 0 0.00019236522
baseline O 0 0.00010832356
body O 0 0.00015938202
weight O 0 0.00015043309
and O 0 9.4795505e-05
higher O 0 0.00010731948
baseline O 0 0.00012841666
serum O 0 0.011130344
creatinine B-Chemical 0 0.9880817
, O 0 0.00018865797
required O 0 4.2768756e-05
higher O 0 9.030974e-05
doses O 0 0.0001956361
of O 0 0.00010952654
loop O 0 0.00014879805
diuretics O 0 0.99818796
, O 0 0.0003742326
and O 0 0.00013293645
were O 0 9.945291e-05
more O 0 0.00013558437
likely O 0 6.0434322e-05
to O 0 8.41718e-05
be O 0 0.000115661096
treated O 0 0.00031808869
with O 0 0.00051019253
thiazide B-Chemical 0 0.99999523
diuretics O 0 0.9997714
than O 0 0.0009889788
controls O 0 0.0019887737
. O 0 0.00257022

CONCLUSIONS O 0 0.052879695
: O 0 0.015524558
Spironolactone B-Chemical 0 0.9998685
- O 0 0.029652702
induced O 0 0.0012630973
hyperkalemia B-Disease 0 0.99992347
and O 0 0.0010760936
renal B-Disease 0 0.97008777
insufficiency I-Disease 0 0.9985684
are O 0 0.00020760516
more O 0 0.00023962514
common O 0 0.00017773344
in O 0 0.00014888149
our O 0 0.0001807728
clinical O 0 0.0007178721
experience O 0 0.00067008636
than O 0 0.00043301063
reported O 0 0.0008324557
previously O 0 0.0015494898
. O 0 0.0029504392

This O 0 0.004385003
difference O 0 0.0016226666
is O 0 0.0010113751
explained O 0 0.00076129934
by O 0 0.0006354476
patient O 0 0.00072960445
comorbidities O 0 0.00581959
and O 0 0.000523873
more O 0 0.00062327395
frequent O 0 0.0005813869
use O 0 0.00048609063
of O 0 0.0010727451
beta O 0 0.7913158
- O 0 0.16983745
blockers O 0 0.9803067
. O 0 0.0059500197

Acute O 0 0.853299
reserpine B-Chemical 0 0.9999517
and O 0 0.005588669
subchronic O 0 0.9996865
haloperidol B-Chemical 1 0.9999981
treatments O 0 0.0020965952
change O 0 0.00086888333
synaptosomal O 0 0.8918681
brain O 0 0.07193434
glutamate B-Chemical 0 0.99973387
uptake O 0 0.011278902
and O 0 0.0004297038
elicit O 0 0.000394564
orofacial B-Disease 0 0.99580956
dyskinesia I-Disease 0 0.9999975
in O 0 0.0012554515
rats O 0 0.0023495078
. O 0 0.002601591

Reserpine B-Chemical 1 0.9998938
- O 0 0.34173384
and O 0 0.0069920816
haloperidol B-Chemical 1 0.9999963
- O 0 0.31463188
induced O 0 0.001651562
orofacial B-Disease 0 0.99923456
dyskinesia I-Disease 0 0.9999993
are O 0 0.00020966667
putative O 0 8.8986846e-05
animal O 0 0.00015221813
models O 0 0.0001735852
of O 0 0.0007251505
tardive B-Disease 0 0.9999981
dyskinesia I-Disease 0 0.9999995
( O 0 0.0070213233
TD B-Disease 0 0.9999484
) O 0 0.0012351961
whose O 0 0.00027734737
pathophysiology O 0 0.0035659026
has O 0 0.00011156794
been O 0 0.00015062281
related O 0 0.00013145767
to O 0 0.00024422418
free O 0 0.0007806333
radical O 0 0.05127795
generation O 0 0.0006758638
and O 0 0.0011179567
oxidative O 0 0.5499298
stress O 0 0.23372366
. O 0 0.0039924355

In O 0 0.0019378269
the O 0 0.0014566142
present O 0 0.0009959167
study O 0 0.0010842206
, O 0 0.0010686723
the O 0 0.0004139922
authors O 0 0.00043875873
induced O 0 0.0009204456
orofacial B-Disease 0 0.9993418
dyskinesia I-Disease 0 0.9999995
by O 0 0.0007689541
acute O 0 0.80691147
reserpine B-Chemical 0 0.99999475
and O 0 0.0012686338
subchronic O 0 0.9997409
haloperidol B-Chemical 1 0.999998
administration O 0 0.001314282
to O 0 0.00053977384
rats O 0 0.00152492
. O 0 0.002052364

Reserpine B-Chemical 1 0.9997398
injection O 0 0.0025847882
( O 0 0.0020462607
one O 0 0.00064592063
dose O 0 0.00079220766
of O 0 0.00047595208
1 O 0 0.0004840873
mg O 0 0.0022316407
/ O 0 0.00093286746
kg O 0 0.00060267735
s O 0 0.00038139205
. O 0 0.00024252078
c O 0 0.0008963549
. O 0 0.0002121524
) O 0 0.00031457347
every O 0 6.5971195e-05
other O 0 8.1862236e-05
day O 0 7.015191e-05
for O 0 6.892477e-05
3 O 0 7.715163e-05
days O 0 5.6693847e-05
caused O 0 9.2456474e-05
a O 0 0.00015887493
significant O 0 0.00011708469
increase O 0 0.00012273694
in O 0 0.00016339956
vacuous O 0 0.54213196
chewing O 0 0.59079945
, O 0 0.00070790196
tongue O 0 0.0104120765
protrusion O 0 0.0037728855
and O 0 0.00012738972
duration O 0 9.17296e-05
of O 0 0.00022506995
facial O 0 0.12806511
twitching O 0 0.3374897
, O 0 0.0005975176
compared O 0 0.0002510343
to O 0 0.00037769336
the O 0 0.00060954044
control O 0 0.0014013228
. O 0 0.0028965096

Haloperidol B-Chemical 1 0.9999713
administration O 0 0.008047239
( O 0 0.0020730284
one O 0 0.0005729243
dose O 0 0.00065991865
of O 0 0.0003670494
12 O 0 0.0002588923
mg O 0 0.0016996476
/ O 0 0.0008010383
kg O 0 0.0004761953
once O 0 0.00013897299
a O 0 0.00021076828
week O 0 0.000111226436
s O 0 0.00024817
. O 0 0.0001922176
c O 0 0.00081965595
. O 0 0.0001952872
) O 0 0.00030921414
for O 0 8.476415e-05
4 O 0 7.935182e-05
weeks O 0 5.2586238e-05
caused O 0 9.2717986e-05
an O 0 0.00012827566
increase O 0 0.00011990083
in O 0 0.00016631733
vacuous O 0 0.5053475
chewing O 0 0.58729106
, O 0 0.00074109406
tongue O 0 0.01119702
protrusion O 0 0.0040801507
and O 0 0.00012827138
duration O 0 9.062784e-05
of O 0 0.00021905093
facial O 0 0.12779337
twitching O 0 0.2165082
observed O 0 0.00024621453
in O 0 0.0002680304
four O 0 0.00023392965
weekly O 0 0.0004510358
evaluations O 0 0.0009031412
. O 0 0.0019483633

After O 0 0.0015416918
the O 0 0.0013386687
treatments O 0 0.0013975484
and O 0 0.0011002738
behavioral O 0 0.002887915
observation O 0 0.0008808936
, O 0 0.0037813887
glutamate B-Chemical 0 0.99950886
uptake O 0 0.011053437
by O 0 0.00049149484
segments O 0 0.00050914777
of O 0 0.00054387667
the O 0 0.0005669905
brain O 0 0.001876489
was O 0 0.0009950867
analyzed O 0 0.0015614869
. O 0 0.002971702

A O 0 0.43344107
decreased O 0 0.0664512
glutamate B-Chemical 0 0.99961
uptake O 0 0.059801154
was O 0 0.00074550445
observed O 0 0.000385145
in O 0 0.0003070558
the O 0 0.0002615008
subcortical O 0 0.006651382
parts O 0 0.00017249456
of O 0 0.00014139235
animals O 0 0.00011291339
treated O 0 0.00042388352
with O 0 0.0006254286
reserpine B-Chemical 0 0.9999957
and O 0 0.00263635
haloperidol B-Chemical 1 0.99999845
, O 0 0.00086637586
compared O 0 0.00024425704
to O 0 0.0003544573
the O 0 0.0005749944
control O 0 0.0013400294
. O 0 0.0028027175

Importantly O 0 0.0023517958
, O 0 0.0042650984
a O 0 0.0026059526
decrease O 0 0.0017766579
in O 0 0.0019129569
glutamate B-Chemical 0 0.99960166
uptake O 0 0.023014663
correlates O 0 0.00053126627
negatively O 0 0.0002961245
with O 0 0.00031373664
an O 0 0.00031533977
increase O 0 0.00024973231
in O 0 0.0002713838
the O 0 0.00032122212
incidence O 0 0.0010806029
of O 0 0.0014090657
orofacial B-Disease 0 0.9889024
diskinesia I-Disease 0 0.99849904
. O 0 0.0040350906

These O 0 0.0018048451
results O 0 0.0012503832
indicate O 0 0.0006469221
that O 0 0.0007022655
early O 0 0.0013236928
changes O 0 0.0009992069
in O 0 0.0012284045
glutamate B-Chemical 0 0.99969447
transport O 0 0.001617419
may O 0 0.00024134367
be O 0 0.00018804701
related O 0 0.000115524184
to O 0 0.0001446818
the O 0 0.00016336542
development O 0 0.0003057329
of O 0 0.0004336631
vacuous O 0 0.5802182
chewing O 0 0.3611657
movements O 0 0.0018976894
in O 0 0.0009664872
rats O 0 0.0022270333
. O 0 0.0027064541

Ceftriaxone B-Chemical 0 0.99744284
- O 0 0.026628336
associated O 0 0.004156901
biliary B-Disease 0 0.9976332
pseudolithiasis I-Disease 0 0.99949896
in O 0 0.0022140783
paediatric O 0 0.0029380482
surgical O 0 0.00288874
patients O 0 0.004090289
. O 0 0.004508076

It O 0 0.0053350786
is O 0 0.001805267
well O 0 0.0013713705
known O 0 0.0011599058
that O 0 0.0011556861
ceftriaxone B-Chemical 0 0.99977976
leads O 0 0.00088341784
to O 0 0.00087811344
pseudolithiasis B-Disease 0 0.98535395
in O 0 0.0010812681
some O 0 0.0014745024
patients O 0 0.0035364137
. O 0 0.0036253037

Clinical O 0 0.005847166
and O 0 0.0016549181
experimental O 0 0.0010841433
studies O 0 0.0008147283
also O 0 0.0004073253
suggest O 0 0.00021007689
that O 0 0.00023710185
situations O 0 0.0005286744
causing O 0 0.00088537065
gallbladder B-Disease 0 0.9974884
dysfunction I-Disease 0 0.9989654
, O 0 0.0007042771
such O 0 0.00017977774
as O 0 0.00022557414
fasting O 0 0.25741917
, O 0 0.0004247463
may O 0 0.00013958976
have O 0 0.00013488134
a O 0 0.00021462869
role O 0 0.00010007421
for O 0 0.00019330677
the O 0 0.000313912
development O 0 0.00075423886
of O 0 0.0014816003
pseudolithiasis B-Disease 0 0.9968887
. O 0 0.00393899

In O 0 0.002104122
this O 0 0.0019095897
study O 0 0.0013987168
, O 0 0.0011210932
we O 0 0.0002893349
prospectively O 0 0.00045829234
evaluated O 0 0.0002469909
the O 0 0.00017690295
incidence O 0 0.0003270167
and O 0 0.00016402193
clinical O 0 0.00031665238
importance O 0 8.5385414e-05
of O 0 0.00019418706
pseudolithiasis B-Disease 0 0.99362046
in O 0 0.000121522295
paediatric O 0 0.00019125815
surgical O 0 0.00013443656
patients O 0 0.00014539974
receiving O 0 0.00016158138
ceftriaxone B-Chemical 0 0.99992406
treatment O 0 0.00013354399
, O 0 0.00022991738
who O 0 0.00019299185
often O 0 0.00014500458
had O 0 0.000120234334
to O 0 0.00011503941
fast O 0 0.00022308259
in O 0 0.000172107
the O 0 0.00019453675
post O 0 0.0002993071
- O 0 0.0014387838
operative O 0 0.0008757392
period O 0 0.0008392555
. O 0 0.0022625152

Fifty O 0 0.0095411455
children O 0 0.005426575
who O 0 0.0020691415
were O 0 0.00095243356
given O 0 0.0007903641
ceftriaxone B-Chemical 0 0.9991604
were O 0 0.0006036651
evaluated O 0 0.00050538837
by O 0 0.0005847569
serial O 0 0.00087809557
abdominal O 0 0.0023033188
sonograms O 0 0.0052682087
. O 0 0.0036418561

Of O 0 0.008787776
those O 0 0.005002821
, O 0 0.0051320777
13 O 0 0.003003946
( O 0 0.0032511589
26 O 0 0.0024203574
% O 0 0.0031932613
) O 0 0.0037289152
developed O 0 0.0031245633
biliary O 0 0.7975659
pathology O 0 0.018276785
. O 0 0.007068459

Comparison O 0 0.0016739959
of O 0 0.0015702785
the O 0 0.0009378613
patients O 0 0.0012648193
with O 0 0.0005416483
or O 0 0.0003760696
without O 0 0.0004813982
pseudolithiasis B-Disease 0 0.99402076
revealed O 0 0.00019515524
no O 0 0.00014651538
significant O 0 0.00014099208
difference O 0 0.00011171666
with O 0 0.00013602129
respect O 0 0.000106727566
to O 0 0.00012047592
age O 0 0.00026680657
, O 0 0.00030032243
sex O 0 0.00036155246
, O 0 0.00028193675
duration O 0 0.00011960759
of O 0 0.00021138188
the O 0 0.00022485286
treatment O 0 0.00036408816
and O 0 0.0005940041
starvation O 0 0.002032481
variables O 0 0.0020907917
. O 0 0.0027904224

After O 0 0.0016970299
cessation O 0 0.0018916279
of O 0 0.0013225784
the O 0 0.00088402326
treatment O 0 0.0009787488
, O 0 0.001985664
pseudolithiasis B-Disease 0 0.99238
resolved O 0 0.0011266974
spontaneously O 0 0.0012597926
within O 0 0.00035744056
a O 0 0.0009045743
short O 0 0.0008398848
period O 0 0.0012159924
. O 0 0.0031287593

The O 0 0.003379457
incidence O 0 0.004954641
of O 0 0.0037204074
pseudolithiasis B-Disease 0 0.9930841
is O 0 0.0018573375
not O 0 0.0016250018
affected O 0 0.0022395283
by O 0 0.0031479616
fasting O 0 0.3213478
. O 0 0.006285081

Coronary B-Disease 0 0.6251744
aneurysm I-Disease 0 0.9914479
after O 0 0.0014111961
implantation O 0 0.001624881
of O 0 0.0016324098
a O 0 0.003055653
paclitaxel B-Chemical 1 0.9968664
- O 0 0.011800695
eluting O 0 0.006970747
stent O 0 0.008183275
. O 0 0.005335932

Formation O 0 0.011742431
of O 0 0.0032000928
coronary B-Disease 0 0.30553374
aneurysm I-Disease 0 0.9939803
is O 0 0.0006777614
a O 0 0.0007419444
rare O 0 0.001060247
complication O 0 0.0010857035
of O 0 0.00023365945
stenting O 0 0.0017580002
with O 0 0.00021374565
bare O 0 0.00094246113
metal O 0 0.0012644965
stents O 0 0.0013401109
, O 0 0.0003390806
but O 0 0.00015497218
based O 0 8.759951e-05
on O 0 6.548156e-05
experimental O 0 0.00011914872
studies O 0 0.00019225208
drug O 0 0.005360842
- O 0 0.0014891117
eluting O 0 0.00071261503
stents O 0 0.00070921937
may O 0 8.413729e-05
induce O 0 8.104774e-05
toxic O 0 0.0019802067
effects O 0 0.00010834484
on O 0 7.8401696e-05
the O 0 0.00010966272
vessel O 0 0.03320494
wall O 0 0.0016377447
with O 0 0.00013522054
incomplete O 0 0.00020986906
stent O 0 0.00051869394
apposition O 0 0.0006559491
, O 0 0.0004648788
aneurysm B-Disease 0 0.9984334
formation O 0 0.00037517096
and O 0 0.00014776053
with O 0 0.00014238567
the O 0 0.00011402883
potential O 0 0.00014235881
of O 0 0.00032399755
stent O 0 0.006358917
thrombosis B-Disease 0 0.99989915
or O 0 0.0012657377
vessel B-Disease 0 0.9913833
rupture I-Disease 0 0.99942845
. O 0 0.0042829663

We O 0 0.0027907381
present O 0 0.0017517478
a O 0 0.0021517016
43 O 0 0.002019874
- O 0 0.0036222395
year O 0 0.00067829347
- O 0 0.002049992
old O 0 0.0006288892
man O 0 0.0023986422
who O 0 0.00046949985
developed O 0 0.00030655507
a O 0 0.00042972903
coronary B-Disease 0 0.12642792
aneurysm I-Disease 0 0.9906442
in O 0 0.00015540425
the O 0 0.00010621241
right O 0 0.00032455125
coronary O 0 0.0067910897
artery O 0 0.0027390015
6 O 0 6.6831715e-05
months O 0 4.2052103e-05
after O 0 6.0688435e-05
receiving O 0 0.00020033201
a O 0 0.0005973379
paclitaxel B-Chemical 1 0.9974371
- O 0 0.0058995723
eluting O 0 0.0037110148
stent O 0 0.0049680835
. O 0 0.0029349544

The O 0 0.002481951
patient O 0 0.002383086
was O 0 0.0014313557
asymptomatic O 0 0.0030352948
and O 0 0.0009869033
the O 0 0.0008823806
aneurysm B-Disease 0 0.9907075
was O 0 0.0007508404
detected O 0 0.0004473668
in O 0 0.0006307815
a O 0 0.001119348
routine O 0 0.0008703318
control O 0 0.0018883016
. O 0 0.0038455238

Angiography O 0 0.0054998198
and O 0 0.0017159103
intracoronary O 0 0.006978386
ultrasound O 0 0.000988642
demonstrated O 0 0.00037285977
lack O 0 0.00028138224
of O 0 0.00031077903
contact O 0 0.00030579788
between O 0 0.00019123591
stent O 0 0.0008510298
and O 0 0.0003233619
vessel O 0 0.016172657
wall O 0 0.0020480342
in O 0 0.00021470973
a O 0 0.0002705173
15 O 0 0.00017408357
- O 0 0.0006018833
mm O 0 0.00045447814
long O 0 0.00016055346
segment O 0 0.00020110885
with O 0 0.00020188482
maximal O 0 0.0004592072
aneurysm B-Disease 0 0.9923224
diameter O 0 0.0041918224
of O 0 0.00043642212
6 O 0 0.00033842676
. O 0 0.00049598387
0 O 0 0.001013323
mm O 0 0.0035675038
. O 0 0.0031958309

The O 0 0.0032799242
patient O 0 0.0031575542
was O 0 0.0019416545
successfully O 0 0.0018969652
treated O 0 0.002574889
with O 0 0.0019225021
a O 0 0.002820646
graft O 0 0.0045720674
stent O 0 0.007901219
. O 0 0.0056068

Causes O 0 0.009381598
of O 0 0.005411528
acute O 0 0.92654115
thrombotic B-Disease 0 0.9999504
microangiopathy I-Disease 0 0.99999714
in O 0 0.0016016611
patients O 0 0.001788495
receiving O 0 0.0011303686
kidney O 0 0.013325945
transplantation O 0 0.0027867015
. O 0 0.0031151224

OBJECTIVES O 0 0.006402025
: O 0 0.013402707
Thrombotic B-Disease 0 0.99851435
microangiopathy I-Disease 0 0.9999914
is O 0 0.00096250133
a O 0 0.00090273295
well O 0 0.0005414751
- O 0 0.0023943705
known O 0 0.00037934043
problem O 0 0.00053295883
in O 0 0.000444248
patients O 0 0.00087414024
following O 0 0.00047770378
renal O 0 0.25499594
transplantation O 0 0.0022782385
. O 0 0.0025544027

In O 0 0.0030551215
postrenal O 0 0.39156336
transplantation O 0 0.0038941607
, O 0 0.0074042263
thrombotic B-Disease 0 0.9999199
microangiopathy I-Disease 0 0.9999975
is O 0 0.00093955075
often O 0 0.0008156632
a O 0 0.0009388672
reflection O 0 0.0015033323
of O 0 0.0026111233
hemolytic B-Disease 0 0.9999628
uremic I-Disease 0 0.99997926
syndrome I-Disease 0 0.99911445
. O 0 0.005756479

We O 0 0.0023313896
aimed O 0 0.0015239952
to O 0 0.00084935164
determine O 0 0.000299887
the O 0 0.00046600285
causes O 0 0.0006741304
of O 0 0.0015849656
thrombotic B-Disease 0 0.9999869
microangiopathy I-Disease 0 0.99999964
in O 0 0.00042785486
a O 0 0.00033110337
population O 0 0.00024815463
of O 0 0.00021939412
renal O 0 0.18949062
transplantation O 0 0.0002628636
recipients O 0 0.00013991997
and O 0 0.00023550447
discuss O 0 0.00035412342
the O 0 0.00063551706
literature O 0 0.0024971315
. O 0 0.0029609303

MATERIALS O 0 0.0029890025
AND O 0 0.0012699345
METHODS O 0 0.0012548252
: O 0 0.0011455738
We O 0 0.0004153203
investigated O 0 0.00041391223
the O 0 0.0003999235
causes O 0 0.00061723683
of O 0 0.0014600444
thrombotic B-Disease 0 0.999984
microangiopathy I-Disease 0 0.9999995
during O 0 0.0003293891
a O 0 0.00037173607
1 O 0 0.00023085797
- O 0 0.0006039217
year O 0 0.00010358164
period O 0 8.941863e-05
, O 0 0.0002402811
from O 0 0.00014784919
June O 0 0.00017302085
2003 O 0 0.00023823236
to O 0 0.00013462333
June O 0 0.00016761165
2004 O 0 0.00027166438
, O 0 0.00025967442
at O 0 0.00012328393
the O 0 0.00017162046
King O 0 0.0009429771
Fahad O 0 0.0005196446
National O 0 0.00016407965
Guard O 0 0.00026613637
Hospital O 0 0.0002697629
in O 0 0.00015561035
Riyadh O 0 0.00031196946
, O 0 0.00035252885
Saudi O 0 0.00047720794
Arabia O 0 0.00039243704
, O 0 0.0002680107
by O 0 0.00014215778
reviewing O 0 0.00021851421
the O 0 0.00014388715
slides O 0 0.00037107433
of O 0 0.00015284003
all O 0 0.00012581193
transplant O 0 0.0002267366
biopsies O 0 0.00014071903
( O 0 0.00022454777
n O 0 0.00021520369
= O 0 0.00055200513
25 O 0 0.00035445188
) O 0 0.000539735
performed O 0 0.00028928026
during O 0 0.00035903958
this O 0 0.00083223125
interval O 0 0.0014999127
. O 0 0.002606431

Pre O 0 0.014134967
- O 0 0.010583903
and O 0 0.002693053
posttransplant O 0 0.003946891
crossmatching O 0 0.0026066394
was O 0 0.0014775024
done O 0 0.0014403171
when O 0 0.0016334568
possible O 0 0.0028087369
. O 0 0.006342587

RESULTS O 0 0.008005743
: O 0 0.006028448
Five O 0 0.0031880627
cases O 0 0.0044219983
of O 0 0.0059431926
thrombotic B-Disease 0 0.9998609
microangiopathy I-Disease 0 0.999992
were O 0 0.0043102857
found O 0 0.003751931
. O 0 0.0056745955

Three O 0 0.002789284
of O 0 0.002072
these O 0 0.0013488809
cases O 0 0.0015542945
were O 0 0.0005778435
from O 0 0.00036943515
the O 0 0.00028144364
25 O 0 0.00036344904
transplantations O 0 0.00039614883
performed O 0 0.00017781057
at O 0 0.00018131969
King O 0 0.0008899078
Fahad O 0 0.0005620346
National O 0 0.00018529216
Guard O 0 0.00030178335
Hospital O 0 0.00032330945
, O 0 0.00025508864
while O 0 0.00013254468
the O 0 0.00010931725
other O 0 0.00011569538
2 O 0 0.00014998621
transplantations O 0 0.00025570832
had O 0 0.00011056372
been O 0 0.000104346975
performed O 0 0.00011957713
abroad O 0 0.00040028396
and O 0 0.00019272283
were O 0 0.00017635355
referred O 0 0.00025575637
to O 0 0.00020496018
us O 0 0.00038791634
for O 0 0.00032791236
follow O 0 0.0005154116
- O 0 0.003249903
up O 0 0.0019832198
. O 0 0.003157749

Three O 0 0.0030240028
cases O 0 0.0030781063
were O 0 0.001152129
related O 0 0.0006625897
to O 0 0.0010054627
cyclosporine B-Chemical 1 0.99994624
, O 0 0.0015541739
and O 0 0.0005263396
1 O 0 0.00042709778
case O 0 0.00033287486
was O 0 0.00027236072
secondary O 0 0.00038773738
to O 0 0.00034556436
both O 0 0.00069939316
cyclosporine B-Chemical 1 0.9999424
and O 0 0.0032341164
tacrolimus B-Chemical 0 0.9998745
. O 0 0.004327239

The O 0 0.0021789062
fifth O 0 0.0023161178
case O 0 0.0014898437
had O 0 0.0009906571
features O 0 0.0011435879
of O 0 0.0020965682
thrombotic B-Disease 0 0.9999778
microangiopathy I-Disease 0 0.9999993
related O 0 0.0003449852
to O 0 0.00027854543
an O 0 0.00061385613
antiphospholipid B-Disease 0 0.9999541
syndrome I-Disease 0 0.962953
in O 0 0.0002911046
a O 0 0.00047647703
patient O 0 0.0005011055
with O 0 0.0009730101
systemic B-Disease 0 0.9988431
lupus I-Disease 0 0.9999982
erythematosus I-Disease 0 0.99999785
. O 0 0.007060796

CONCLUSIONS O 0 0.016650323
: O 0 0.003434064
In O 0 0.0007658566
the O 0 0.000753983
literature O 0 0.0011932696
, O 0 0.0009440225
the O 0 0.00039837332
most O 0 0.0005822265
- O 0 0.0025017108
frequent O 0 0.00042158415
cause O 0 0.00039728204
of O 0 0.00092488417
hemolytic B-Disease 0 0.99999297
uremic I-Disease 0 0.99999726
syndrome I-Disease 0 0.9996432
in O 0 0.00020575378
patients O 0 0.00032261424
following O 0 8.859475e-05
renal O 0 0.1706602
transplantation O 0 0.00025337757
is O 0 0.00014093751
recurrence O 0 0.0017551916
of O 0 0.00039532824
the O 0 0.0009202917
hemolytic B-Disease 0 0.9999759
uremic I-Disease 0 0.9999865
syndrome I-Disease 0 0.99931383
. O 0 0.004492183

Other O 0 0.0037699956
causes O 0 0.0023342497
include O 0 0.0014427043
drug O 0 0.017232472
- O 0 0.0041135666
related O 0 0.00045446103
( O 0 0.0016913844
cyclosporine B-Chemical 1 0.99996746
, O 0 0.0042174817
tacrolimus B-Chemical 0 0.99997807
) O 0 0.004222331
toxicity B-Disease 0 0.85760295
, O 0 0.001978933
procoagulant O 0 0.9270863
status O 0 0.00038395042
, O 0 0.0006544112
and O 0 0.00046225777
antibody O 0 0.0009011479
- O 0 0.002935397
mediated O 0 0.0007641645
rejection O 0 0.012299088
. O 0 0.0036724359

We O 0 0.0026845844
found O 0 0.001782573
that O 0 0.0009996726
the O 0 0.00086575904
most O 0 0.0011668513
- O 0 0.004216369
frequent O 0 0.0007543254
cause O 0 0.00066314527
of O 0 0.0012682803
thrombotic B-Disease 0 0.99998355
microangiopathy I-Disease 0 0.9999995
was O 0 0.0006942823
drug O 0 0.012531825
related O 0 0.00022275826
, O 0 0.0006064284
secondary O 0 0.0005848146
mainly O 0 0.0007158052
to O 0 0.0012248864
cyclosporine B-Chemical 1 0.9999038
. O 0 0.0042613135

In O 0 0.0018972217
the O 0 0.0014537984
current O 0 0.001341917
study O 0 0.0010573686
, O 0 0.0010130666
the O 0 0.00039775818
frequency O 0 0.00041891003
of O 0 0.0011767199
thrombotic B-Disease 0 0.99998295
microangiopathy I-Disease 0 0.9999995
was O 0 0.0003243282
similar O 0 0.00010988096
to O 0 0.0001089476
the O 0 0.00010953072
percentage O 0 0.00012234435
reported O 0 0.00021138047
in O 0 0.00020677192
the O 0 0.0002593612
literature O 0 0.00080362975
( O 0 0.0009937359
20 O 0 0.0008191422
% O 0 0.0018882675
) O 0 0.003505175
. O 0 0.003344963

Comparison O 0 0.0017508133
of O 0 0.0019037122
developmental O 0 0.0034708406
toxicity B-Disease 0 0.39667475
of O 0 0.00077237666
selective O 0 0.0006719713
and O 0 0.00047902658
non O 0 0.0008947921
- O 0 0.008043643
selective O 0 0.001320392
cyclooxygenase O 0 0.99983597
- O 0 0.026840942
2 O 0 0.00029233895
inhibitors O 0 0.00034323847
in O 0 0.00029297118
CRL O 0 0.20816845
: O 0 0.00089251983
( O 0 0.0005450368
WI O 0 0.0014585896
) O 0 0.0011012644
WUBR O 0 0.009884759
Wistar O 0 0.0017481917
rats O 0 0.00084092654
- O 0 0.005435472
- O 0 0.02670151
DFU B-Chemical 0 0.99993587
and O 0 0.0029959364
piroxicam B-Chemical 0 0.9999411
study O 0 0.004042581
. O 0 0.003610213

BACKGROUND O 0 0.062111206
: O 0 0.019281054
Cyclooxygenase O 0 0.9982672
( O 0 0.01798359
COX O 0 0.9995976
) O 0 0.0038722774
inhibitors O 0 0.0010711602
are O 0 0.0003451655
one O 0 0.00027893792
of O 0 0.00032811973
the O 0 0.00028221324
most O 0 0.0004528204
often O 0 0.0005829358
ingested O 0 0.0041115712
drugs O 0 0.0077838646
during O 0 0.00086360524
pregnancy O 0 0.0045248754
. O 0 0.003218284

Unlike O 0 0.002104945
general O 0 0.0028105942
toxicity B-Disease 0 0.39652738
data O 0 0.0015573233
, O 0 0.0014143545
their O 0 0.00063739833
prenatal O 0 0.001999869
toxic O 0 0.0071226764
effects O 0 0.0005371023
were O 0 0.0004952227
not O 0 0.0004966602
extensively O 0 0.00077193376
studied O 0 0.0013399943
before O 0 0.0010671725
. O 0 0.0031757138

The O 0 0.0016007569
aim O 0 0.0009907061
of O 0 0.0009754183
the O 0 0.00054485607
experiment O 0 0.00034070268
was O 0 0.0002972418
to O 0 0.00017603723
evaluate O 0 9.0776586e-05
the O 0 0.00015753867
developmental O 0 0.000614092
toxicity B-Disease 0 0.2044533
of O 0 0.0001963361
the O 0 0.00013450696
non O 0 0.00035264378
- O 0 0.001923853
selective O 0 0.0003456708
( O 0 0.0012383081
piroxicam B-Chemical 0 0.9999894
) O 0 0.0013454068
and O 0 0.00022097518
selective O 0 0.0004086782
( O 0 0.0015465984
DFU B-Chemical 0 0.9999815
; O 0 0.0008692681
5 B-Chemical 0 0.00019392929
, I-Chemical 0 0.00034272546
5 I-Chemical 0 0.00025015837
- I-Chemical 0 0.004292323
dimethyl I-Chemical 0 0.9816534
- I-Chemical 0 0.0039899624
3 I-Chemical 0 0.00021026086
- I-Chemical 0 0.0009847095
( I-Chemical 0 0.00034044165
3 I-Chemical 0 0.0002017909
- I-Chemical 0 0.0018008093
fluorophenyl I-Chemical 0 0.16898943
) I-Chemical 0 0.0010208329
- I-Chemical 0 0.001345347
4 I-Chemical 0 0.00019979865
- I-Chemical 0 0.00093275245
( I-Chemical 0 0.0003724844
4 I-Chemical 0 0.00022846396
- I-Chemical 0 0.0026502549
methylsulphonyl I-Chemical 0 0.7979615
) I-Chemical 0 0.0026958634
phenyl I-Chemical 0 0.9895622
- I-Chemical 0 0.0069799814
2 I-Chemical 0 0.00037104194
( I-Chemical 0 0.00059183297
5H I-Chemical 0 0.005815748
) I-Chemical 0 0.0010477183
- I-Chemical 0 0.0020122651
furanon I-Chemical 0 0.001269588
) O 0 0.004954359
COX O 0 0.9995258
- O 0 0.019892251
2 O 0 0.0016212055
inhibitors O 0 0.0028093727
. O 0 0.003988001

METHODS O 0 0.004469768
: O 0 0.0036440333
Drugs O 0 0.004944383
were O 0 0.00067302235
separately O 0 0.0003995384
, O 0 0.00073279726
orally O 0 0.00064084167
once O 0 0.00021612202
daily O 0 0.00029344924
dosed O 0 0.00067691156
to O 0 0.00016397751
pregnant O 0 0.0004757931
rats O 0 0.00027456958
from O 0 0.00014723522
day O 0 0.00012639379
8 O 0 0.00017729032
to O 0 0.00020168224
21 O 0 0.000401145
( O 0 0.0008014193
GD1 O 0 0.0041475315
= O 0 0.0019829941
plug O 0 0.002731385
day O 0 0.00096917467
) O 0 0.0037045223
. O 0 0.0037091505

Doses O 0 0.0115192905
were O 0 0.0019338467
set O 0 0.0010932309
at O 0 0.0007702792
0 O 0 0.0009607341
. O 0 0.00057072163
3 O 0 0.00040833064
, O 0 0.0006154311
3 O 0 0.00029660086
. O 0 0.00026915592
0 O 0 0.00029071386
and O 0 0.00022615194
30 O 0 0.00020571492
. O 0 0.00025509787
0mg O 0 0.27378216
/ O 0 0.0011834669
kg O 0 0.0007070016
for O 0 0.00028990643
piroxicam B-Chemical 0 0.99996245
and O 0 0.00036828086
0 O 0 0.00032388326
. O 0 0.00019169872
2 O 0 0.00020714152
, O 0 0.00031898514
2 O 0 0.00021972322
. O 0 0.00018867778
0 O 0 0.00025793436
and O 0 0.00025139833
20 O 0 0.00033433942
. O 0 0.00045888053
0mg O 0 0.50180894
/ O 0 0.0032416866
kg O 0 0.002498605
for O 0 0.0017373676
DFU B-Chemical 0 0.9997054
. O 0 0.005645912

Fetuses O 0 0.014356877
were O 0 0.0029179829
delivered O 0 0.0020698614
on O 0 0.0019782456
GD O 0 0.41912147
21 O 0 0.002346751
and O 0 0.0018815803
routinely O 0 0.0018319705
examined O 0 0.0027725522
. O 0 0.0060219634

Comprehensive O 0 0.010951015
clinical O 0 0.0075071193
and O 0 0.0036171284
developmental O 0 0.004738246
measurements O 0 0.0027023584
were O 0 0.0029615895
done O 0 0.0039267605
. O 0 0.0072625647

The O 0 0.002111996
pooled O 0 0.0016428077
statistical O 0 0.0017056153
analysis O 0 0.0008044534
for O 0 0.0005713821
ventricular B-Disease 0 0.11547215
septal I-Disease 0 0.03618636
( I-Disease 0 0.0013169064
VSD I-Disease 0 0.7215652
) I-Disease 0 0.0008875241
and I-Disease 0 0.0003168429
midline I-Disease 0 0.0010659605
( I-Disease 0 0.0007993532
MD I-Disease 0 0.9277066
) I-Disease 0 0.0008774749
defects I-Disease 0 0.00046509758
was O 0 0.00013456415
performed O 0 0.000101972226
for O 0 8.8856614e-05
rat O 0 0.00020788368
fetuses O 0 0.0006225953
exposed O 0 0.00017747907
to O 0 0.00020281457
piroxicam B-Chemical 0 0.99998784
, O 0 0.00050233025
selective O 0 0.0002103651
and O 0 0.00017336269
non O 0 0.00045237556
- O 0 0.008378167
selective O 0 0.001183619
COX O 0 0.99992895
- O 0 0.043094654
2 O 0 0.0002971913
inhibitor O 0 0.0005128266
based O 0 0.00019336726
on O 0 0.00019206993
present O 0 0.00033053313
and O 0 0.0007466545
historic O 0 0.004182484
data O 0 0.0020096959
. O 0 0.0030459403

RESULTS O 0 0.004939487
: O 0 0.004148794
Maternal O 0 0.0032234339
toxicity B-Disease 0 0.52275723
, O 0 0.0036351439
intrauterine B-Disease 0 0.9361399
growth I-Disease 0 0.9812066
retardation I-Disease 0 0.9999871
, O 0 0.0019635698
and O 0 0.00032868327
increase B-Disease 0 0.00019127567
of I-Disease 0 0.00019752204
external I-Disease 0 0.0002822493
and I-Disease 0 0.00021181689
skeletal I-Disease 0 0.0006061696
variations I-Disease 0 0.00011518825
were O 0 9.432527e-05
found O 0 9.908809e-05
in O 0 0.00011005556
rats O 0 0.00023505963
treated O 0 0.00030032586
with O 0 0.0002063294
the O 0 0.00019641586
highest O 0 0.00036406924
dose O 0 0.0010815164
of O 0 0.001712678
piroxicam B-Chemical 0 0.9999355
. O 0 0.0048396876

Decrease O 0 0.011253381
of O 0 0.0029248483
fetal O 0 0.0092740925
length O 0 0.0007721857
was O 0 0.00054966385
the O 0 0.0003571926
only O 0 0.00039735946
signs O 0 0.0011923619
of O 0 0.00037060733
the O 0 0.000487275
DFU B-Chemical 0 0.99998677
developmental O 0 0.008285988
toxicity B-Disease 0 0.8183496
observed O 0 0.00019597738
in O 0 0.00017214262
pups O 0 0.00021079158
exposed O 0 0.0002446248
to O 0 0.00020468816
the O 0 0.0002645121
highest O 0 0.0005462007
compound O 0 0.0049496624
dose O 0 0.0030311388
. O 0 0.0026975805

Lack O 0 0.005743255
of O 0 0.004836749
teratogenicity O 0 0.99766684
was O 0 0.0019234897
found O 0 0.0014332421
in O 0 0.0019964497
piroxicam B-Chemical 0 0.9999627
and O 0 0.006627286
DFU B-Chemical 0 0.9999628
- O 0 0.03470409
exposed O 0 0.0020700959
groups O 0 0.0029141242
. O 0 0.0041934275

Prenatal O 0 0.014383688
exposure O 0 0.0023724092
to O 0 0.0011794963
non O 0 0.0019914156
- O 0 0.011899671
selective O 0 0.0025143295
COX O 0 0.9997359
inhibitors O 0 0.0015745906
increases O 0 0.00039364165
the O 0 0.00026304013
risk O 0 0.0020766063
of O 0 0.00042992114
VSD O 0 0.9639276
and O 0 0.00037878373
MD O 0 0.8967795
when O 0 0.00011113473
compared O 0 0.00010152512
to O 0 0.00012638597
historic O 0 0.00075077027
control O 0 0.00022268669
but O 0 0.0002828834
not O 0 0.00023529933
with O 0 0.00048512392
selective O 0 0.0026243574
COX O 0 0.99985194
- O 0 0.05879334
2 O 0 0.0012673964
inhibitors O 0 0.0022762301
. O 0 0.0031931615

CONCLUSION O 0 0.014616645
: O 0 0.0033906694
Both O 0 0.000944472
selective O 0 0.001026972
and O 0 0.00084896083
non O 0 0.0014174011
- O 0 0.009449215
selective O 0 0.0023522147
COX O 0 0.999863
- O 0 0.034392036
2 O 0 0.00035284454
inhibitors O 0 0.0003780028
were O 0 0.00022609091
toxic O 0 0.0018051742
for O 0 0.00013336455
rats O 0 0.00030875695
fetuses O 0 0.0006820071
when O 0 0.00014436005
administered O 0 0.00033692375
in O 0 0.0002653717
the O 0 0.00034493502
highest O 0 0.0007485443
dose O 0 0.0021642265
. O 0 0.0025412778

Unlike O 0 0.006225321
DFU B-Chemical 0 0.99985063
, O 0 0.07809931
piroxicam B-Chemical 0 0.9999484
was O 0 0.0022134758
also O 0 0.0012373127
highly O 0 0.0011823345
toxic O 0 0.0077710887
to O 0 0.0011772683
the O 0 0.0015513847
dams O 0 0.006034334
. O 0 0.004804273

Prenatal O 0 0.017787172
exposure O 0 0.0028878872
to O 0 0.0015501878
selective O 0 0.0040941993
COX O 0 0.9997929
- O 0 0.078186765
2 O 0 0.000627667
inhibitors O 0 0.0005950782
does O 0 0.00022410763
not O 0 0.00019899917
increase O 0 0.00018366385
the O 0 0.0001617687
risk O 0 0.0010588795
of O 0 0.00025019393
ventricular B-Disease 0 0.5794693
septal I-Disease 0 0.054517325
and I-Disease 0 0.00020505734
midline I-Disease 0 0.010607853
defects I-Disease 0 0.0017586965
in O 0 0.00011728068
rat O 0 0.00014949034
when O 0 6.280542e-05
compared O 0 7.8207995e-05
to O 0 0.000116803225
non O 0 0.000364218
- O 0 0.0017130204
selective O 0 0.0004747868
drugs O 0 0.008030772
and O 0 0.0007608076
historic O 0 0.003739282
control O 0 0.0017318107
. O 0 0.0031378772

Lone O 0 0.02304828
atrial B-Disease 0 0.55470055
fibrillation I-Disease 0 0.9984118
associated O 0 0.005897931
with O 0 0.009308008
creatine B-Chemical 1 0.9998118
monohydrate O 0 0.99956197
supplementation O 0 0.95110464
. O 0 0.009700054

Atrial B-Disease 0 0.28551662
fibrillation I-Disease 0 0.9991333
in O 0 0.0025343709
young O 0 0.0048751724
patients O 0 0.0021399865
without O 0 0.0010627876
structural O 0 0.0015986039
heart B-Disease 0 0.180228
disease I-Disease 0 0.40045008
is O 0 0.0019664443
rare O 0 0.007624136
. O 0 0.0043944954

Therefore O 0 0.0022713924
, O 0 0.0033916167
when O 0 0.0011097335
the O 0 0.0011830498
arrhythmia B-Disease 0 0.99271023
is O 0 0.0005136031
present O 0 0.0003330761
in O 0 0.0003447082
this O 0 0.0003931123
population O 0 0.00064450694
, O 0 0.000927658
reversible O 0 0.0015239569
causes O 0 0.00045917608
must O 0 0.0002637448
be O 0 0.0004246471
identified O 0 0.00044417768
and O 0 0.0010752588
resolved O 0 0.0021227743
. O 0 0.0031218226

Thyroid B-Disease 0 0.9846756
disorders I-Disease 0 0.99901724
, O 0 0.0064888475
illicit O 0 0.95504737
drug O 0 0.047908098
or O 0 0.0006189142
stimulant O 0 0.4403798
use O 0 0.0003735662
, O 0 0.0006686011
and O 0 0.0005326521
acute B-Disease 0 0.8195418
alcohol I-Disease 0 0.99976665
intoxication I-Disease 0 0.99972445
are O 0 0.00051883265
among O 0 0.00069109775
these O 0 0.0008811396
causes O 0 0.0018297064
. O 0 0.00316591

We O 0 0.0030357116
report O 0 0.003031718
the O 0 0.0011807977
case O 0 0.000995576
of O 0 0.0007650483
a O 0 0.00081402296
30 O 0 0.00045148082
- O 0 0.0013301426
year O 0 0.0002981821
- O 0 0.0010331884
old O 0 0.00039701606
Caucasian O 0 0.004412415
man O 0 0.0034603027
who O 0 0.00042016624
came O 0 0.00024007614
to O 0 0.00014870825
the O 0 0.0001700547
emergency O 0 0.0010209953
department O 0 0.0010822214
in O 0 0.00024989806
atrial B-Disease 0 0.05945109
fibrillation I-Disease 0 0.9971181
with O 0 0.0004985059
rapid O 0 0.0009144315
ventricular O 0 0.21104841
response O 0 0.001409228
. O 0 0.0024112724

His O 0 0.0054658204
medical O 0 0.006019811
history O 0 0.0028580308
was O 0 0.0011729543
unremarkable O 0 0.0023046567
, O 0 0.001303583
except O 0 0.0005108005
for O 0 0.0004928502
minor O 0 0.0012953965
fractures B-Disease 2 0.9926076
of O 0 0.0009241975
the O 0 0.000735372
fingers O 0 0.0025560122
and O 0 0.0019603015
foot O 0 0.011354752
. O 0 0.00443981

Thyroid O 0 0.5032296
- O 0 0.039058886
stimulating O 0 0.0059160814
hormone O 0 0.6842339
, O 0 0.008578398
magnesium B-Chemical 1 0.99966
, O 0 0.0026371726
and O 0 0.0009787296
potassium B-Chemical 0 0.9989955
levels O 0 0.00027924927
were O 0 0.00016224076
within O 0 8.382744e-05
normal O 0 0.00022799264
limits O 0 0.00031172833
, O 0 0.00048285828
urine O 0 0.013782805
drug O 0 0.0024195332
screen O 0 0.00020120206
was O 0 0.00019610372
negative O 0 0.00027012505
, O 0 0.00061912066
and O 0 0.0005715401
alcohol B-Chemical 0 0.9891502
use O 0 0.000829044
was O 0 0.0010625912
denied O 0 0.0031223616
. O 0 0.003335759

However O 0 0.002955711
, O 0 0.003178961
when O 0 0.0009317643
the O 0 0.00074827037
patient O 0 0.00068703754
was O 0 0.0003762641
questioned O 0 0.0004023705
about O 0 0.0002963753
use O 0 0.0002152041
of O 0 0.0003014676
herbal O 0 0.1302295
products O 0 0.0003502006
and O 0 0.00034294295
supplements O 0 0.13775714
, O 0 0.0006569004
the O 0 0.00025956033
use O 0 0.0003782775
of O 0 0.0013769343
creatine B-Chemical 1 0.9999238
monohydrate O 0 0.99961853
was O 0 0.0015177116
revealed O 0 0.0015499184
. O 0 0.0030104362

The O 0 0.0022474509
patient O 0 0.0021337192
was O 0 0.001159745
admitted O 0 0.0016410868
to O 0 0.0004167677
the O 0 0.0003239892
hospital O 0 0.00048829237
, O 0 0.0005202921
anticoagulated O 0 0.0014364737
with O 0 0.00023284795
unfractionated O 0 0.011120314
heparin B-Chemical 0 0.9958268
, O 0 0.00033041372
and O 0 0.0001181292
given O 0 8.351371e-05
intravenous O 0 0.008965931
diltiazem B-Chemical 1 0.9999925
for O 0 9.820985e-05
rate O 0 0.00014289287
control O 0 0.000111458
and O 0 0.00017191758
intravenous O 0 0.0111660315
amiodarone B-Chemical 0 0.9998443
for O 0 0.00019262602
rate O 0 0.00041887013
and O 0 0.00046850066
rhythm O 0 0.0012362871
control O 0 0.001231119
. O 0 0.002545629

When O 0 0.0020499697
discharged O 0 0.0038668644
less O 0 0.0013650768
than O 0 0.00064393505
24 O 0 0.000505644
hours O 0 0.00032439624
later O 0 0.00030664683
, O 0 0.0005203563
he O 0 0.00032896575
was O 0 0.00021645776
receiving O 0 0.00056772056
metoprolol B-Chemical 1 0.999998
and O 0 0.00086138805
aspirin B-Chemical 0 0.99993527
, O 0 0.00049497414
with O 0 0.0001813662
follow O 0 0.0001230956
- O 0 0.00067284063
up O 0 0.00014400452
plans O 0 0.00014950958
for O 0 9.817614e-05
echocardiography O 0 0.0003223237
and O 0 0.00020938498
nuclear O 0 0.00038586932
imaging O 0 0.00043343022
to O 0 0.00035176423
assess O 0 0.00041705725
perfusion O 0 0.018606592
. O 0 0.0026621341

Exogenous O 0 0.5228407
creatine B-Chemical 1 0.9991786
is O 0 0.0020006085
used O 0 0.001199084
by O 0 0.0010862723
athletes O 0 0.0022033446
to O 0 0.0007630297
theoretically O 0 0.00094775035
improve O 0 0.0008964122
exercise O 0 0.0026810453
performance O 0 0.0030803839
. O 0 0.004438246

Vegetarians O 0 0.1407027
may O 0 0.002591582
also O 0 0.0018100213
take O 0 0.0018628796
creatine B-Chemical 1 0.9991103
to O 0 0.0005740238
replace O 0 0.00037317982
what O 0 0.00050378655
they O 0 0.0002730586
are O 0 0.00020734387
not O 0 0.00022948331
consuming O 0 0.0006369887
from O 0 0.0003530639
meat O 0 0.0025191323
, O 0 0.0008966893
fish O 0 0.0017262954
, O 0 0.0009544143
and O 0 0.0005721276
other O 0 0.000617682
animal O 0 0.0012157914
products O 0 0.002060347
. O 0 0.0032021638

Previous O 0 0.0033680252
anecdotal O 0 0.0068965903
reports O 0 0.0027903176
have O 0 0.001974694
linked O 0 0.0028957755
creatine B-Chemical 1 0.99912924
to O 0 0.0011981187
the O 0 0.0010034733
development O 0 0.0017102348
of O 0 0.0027798899
arrhythmia B-Disease 0 0.996198
. O 0 0.005900817

Clinicians O 0 0.005060774
must O 0 0.0010335083
be O 0 0.00080193527
diligent O 0 0.0007869532
when O 0 0.0003640125
interviewing O 0 0.0009815744
patients O 0 0.00054704683
about O 0 0.00025431952
their O 0 0.00019261426
drug O 0 0.0015326419
therapy O 0 0.00023748103
histories O 0 0.00022929761
and O 0 0.0001283317
include O 0 0.00010359962
questions O 0 0.00015131972
about O 0 0.00015549912
their O 0 0.0001343065
use O 0 0.00016129784
of O 0 0.0003126772
herbal O 0 0.18809262
products O 0 0.0006693539
and O 0 0.00086783955
dietary O 0 0.049461484
supplements O 0 0.72335523
. O 0 0.0043860413

In O 0 0.0019364504
addition O 0 0.0012714771
, O 0 0.0025201365
it O 0 0.0012566695
is O 0 0.00045915556
important O 0 0.00025436978
to O 0 0.00024091583
report O 0 0.0003905929
adverse O 0 0.00056851713
effects O 0 0.0001463862
associated O 0 0.00016970774
with O 0 0.00017042318
frequently O 0 0.0001917561
consumed O 0 0.0014786073
supplements O 0 0.10513918
and O 0 0.00023846302
herbal O 0 0.16004469
products O 0 0.00019831993
to O 0 0.00012804066
the O 0 0.00015489622
Food O 0 0.0013071372
and O 0 0.00033270734
Drug O 0 0.24147856
Administration O 0 0.0009859772
and O 0 0.00036833534
in O 0 0.00045095262
the O 0 0.0006877506
literature O 0 0.002553351
. O 0 0.0029292833

Seizures B-Disease 0 0.998552
induced O 0 0.0041547776
by O 0 0.0029821866
the O 0 0.0033890924
cocaine B-Chemical 0 0.9997981
metabolite O 0 0.9976666
benzoylecgonine B-Chemical 0 0.99998367
in O 0 0.0036723712
rats O 0 0.0048193736
. O 0 0.0046057887

The O 0 0.0022075654
half O 0 0.001898225
- O 0 0.0046437676
life O 0 0.001218906
( O 0 0.0016081893
t1 O 0 0.002134442
/ O 0 0.0018986344
2 O 0 0.0005213085
) O 0 0.0007871595
of O 0 0.00048324527
cocaine B-Chemical 0 0.9990268
is O 0 0.00022131104
relatively O 0 0.00026674074
short O 0 0.00017721594
, O 0 0.0003458823
but O 0 0.00018648802
some O 0 0.00013827148
of O 0 0.00014125463
the O 0 0.000103443344
consequences O 0 0.0001466023
of O 0 0.00016642174
its O 0 0.00020389457
use O 0 0.0001465851
, O 0 0.00030751666
such O 0 0.00018351874
as O 0 0.00040116863
seizures B-Disease 0 0.99997604
and O 0 0.0009255021
strokes B-Disease 0 0.9986291
, O 0 0.0009017937
can O 0 0.00022718542
occur O 0 0.00028798418
hours O 0 0.00029657508
after O 0 0.0003559549
exposure O 0 0.0012188305
. O 0 0.0023456528

This O 0 0.005391081
led O 0 0.002445123
us O 0 0.0016234678
to O 0 0.00068875303
hypothesize O 0 0.00048648907
that O 0 0.00044851692
a O 0 0.0011526331
metabolite O 0 0.6198285
of O 0 0.0011015198
cocaine B-Chemical 0 0.9998646
may O 0 0.00027218342
be O 0 0.00019607102
responsible O 0 0.00015109811
for O 0 0.00016381688
some O 0 0.0002845117
of O 0 0.00044341304
those O 0 0.0007302068
delayed O 0 0.002682321
sequelae O 0 0.026448999
. O 0 0.0033561639

We O 0 0.002268115
evaluated O 0 0.0013996982
the O 0 0.0008043254
potential O 0 0.0005748146
of O 0 0.00066161633
the O 0 0.00049354
major O 0 0.000669206
metabolite O 0 0.35169694
of O 0 0.00128094
cocaine B-Chemical 0 0.99991965
, O 0 0.026338387
benzoylecgonine B-Chemical 0 0.99999607
( O 0 0.010152109
BE B-Chemical 0 0.9926005
) O 0 0.0019040148
, O 0 0.0011201805
to O 0 0.00081687974
cause O 0 0.0028706465
seizures B-Disease 0 0.99981064
. O 0 0.0051354826

Two O 0 0.002378704
separate O 0 0.0015880353
equimolar O 0 0.004100975
doses O 0 0.0027087538
( O 0 0.0015191828
0 O 0 0.00072602584
. O 0 0.0003895064
2 O 0 0.0003197192
and O 0 0.00027211205
0 O 0 0.00032519887
. O 0 0.00021816009
4 O 0 0.00020599051
mumol O 0 0.0015460021
) O 0 0.00047242397
of O 0 0.00024306294
either O 0 0.0003480132
cocaine B-Chemical 0 0.999585
or O 0 0.00043741195
BE B-Chemical 0 0.9097405
were O 0 0.00022816076
injected O 0 0.00023101321
ventricularly O 0 0.0014674432
in O 0 0.00039060295
unanesthetized O 0 0.0048712622
juvenile O 0 0.018607134
rats O 0 0.0025134305
. O 0 0.0026737598

Treated O 0 0.026345653
rats O 0 0.002738977
were O 0 0.0009823565
then O 0 0.0005854456
evaluated O 0 0.0004494838
for O 0 0.00033240998
incidence O 0 0.000720336
, O 0 0.0006939251
latency O 0 0.000847672
, O 0 0.00067319017
and O 0 0.00047925362
seizure B-Disease 0 0.99789643
pattern O 0 0.00023054893
or O 0 0.00019547498
for O 0 0.00019760153
locomotor O 0 0.0020162142
activity O 0 0.00019136704
in O 0 0.00029317208
animals O 0 0.0004029398
without O 0 0.0015413307
seizures B-Disease 0 0.9998252
. O 0 0.004234275

BE B-Chemical 0 0.99271214
- O 0 0.17686531
Induced O 0 0.019766387
seizures B-Disease 0 0.99988675
occurred O 0 0.0010294934
more O 0 0.0007180332
frequently O 0 0.00034728422
and O 0 0.00025448206
had O 0 0.00019272669
significantly O 0 0.00018489332
longer O 0 0.00010905965
latencies O 0 0.00047413583
than O 0 0.0001603454
those O 0 0.00021942134
induced O 0 0.00025465095
by O 0 0.00038832365
equimolar O 0 0.0022549992
amounts O 0 0.00086029916
of O 0 0.002155444
cocaine B-Chemical 0 0.99942005
. O 0 0.004252761

Whereas O 0 0.005054113
cocaine B-Chemical 0 0.9994055
- O 0 0.069110304
induced O 0 0.0020075468
seizures B-Disease 0 0.9999094
were O 0 0.0004645074
best O 0 0.00029726187
characterized O 0 0.00035621188
as O 0 0.00023637166
brief O 0 0.00027376186
, O 0 0.00051948114
generalized O 0 0.0013099774
, O 0 0.0004358393
and O 0 0.00021612369
tonic O 0 0.00068035454
and O 0 0.0001675666
resulted O 0 0.00014775108
in O 0 0.00021567201
death B-Disease 0 0.70644915
, O 0 0.0004298599
those O 0 0.00017336021
induced O 0 0.00014814369
by O 0 0.00022482479
BE B-Chemical 0 0.9621691
were O 0 0.00013387701
prolonged O 0 0.00018179334
, O 0 0.00021510522
often O 0 0.00013556228
multiple O 0 0.00011225486
and O 0 0.00014808027
mixed O 0 0.00031000224
in O 0 0.00021610472
type O 0 0.0005907355
, O 0 0.0006768845
and O 0 0.00045232792
rarely O 0 0.00071455253
resulted O 0 0.00066915684
in O 0 0.0013226885
death B-Disease 0 0.80133766
. O 0 0.0038865844

Electrical O 0 0.007316386
recordings O 0 0.0018551418
from O 0 0.0010566073
the O 0 0.000810748
hippocampus O 0 0.0027982793
showed O 0 0.00049101625
a O 0 0.0006635528
rhythmic O 0 0.00096435373
progression O 0 0.0012822438
in O 0 0.0003764295
EEG O 0 0.18393265
frequency O 0 0.00024319041
and O 0 0.00031555328
voltage O 0 0.0012681517
with O 0 0.00061398686
clinical O 0 0.004697367
seizure B-Disease 0 0.99717903
expression O 0 0.0018321893
. O 0 0.0032562145

BE B-Chemical 0 0.9893231
- O 0 0.0333037
Injected O 0 0.0038684497
rats O 0 0.0015981398
that O 0 0.0005818534
did O 0 0.0006299492
not O 0 0.00044678184
have O 0 0.0005658859
seizures B-Disease 0 0.9999517
had O 0 0.00035020814
significantly O 0 0.00029479436
more O 0 0.00033580122
locomotor O 0 0.0015705699
activity O 0 0.00012275451
than O 0 0.00022319023
cocaine B-Chemical 0 0.99901974
- O 0 0.0019360798
injected O 0 0.00027628537
animals O 0 0.00034980575
without O 0 0.0013417571
seizures B-Disease 0 0.9998068
. O 0 0.00399364

The O 0 0.002076293
finding O 0 0.0019027739
that O 0 0.0016401792
cocaine B-Chemical 0 0.99956554
- O 0 0.047703207
and O 0 0.0013543468
BE B-Chemical 0 0.9950362
- O 0 0.019112904
induced O 0 0.0007251791
seizures B-Disease 0 0.9999747
differ O 0 0.0002933709
in O 0 0.0001302983
several O 0 8.118326e-05
respects O 0 0.00021883383
suggests O 0 7.431609e-05
more O 0 0.00015404931
than O 0 8.247451e-05
one O 0 6.8909845e-05
mechanism O 0 6.814878e-05
for O 0 0.00015290313
cocaine B-Chemical 0 0.9998858
- O 0 0.020301886
induced O 0 0.0003450913
seizures B-Disease 0 0.9999783
and O 0 0.00022181978
emphasizes O 0 0.00015812274
the O 0 0.00012290818
importance O 0 0.00014639639
of O 0 0.00039168578
a O 0 0.0016381191
cocaine B-Chemical 0 0.99987984
metabolite O 0 0.9678835
, O 0 0.0075774067
BE B-Chemical 0 0.9914419
. O 0 0.0039600222

The O 0 0.0022597031
selective O 0 0.0025854632
5 O 0 0.0019645316
- O 0 0.015893484
HT6 O 0 0.7072077
receptor O 0 0.008712595
antagonist O 0 0.7233771
Ro4368554 B-Chemical 1 0.99158317
restores O 0 0.00039779287
memory O 0 0.10782535
performance O 0 0.0005704739
in O 0 0.00028898587
cholinergic O 0 0.0045483843
and O 0 0.00022169334
serotonergic O 0 0.001650912
models O 0 0.00018303885
of O 0 0.00041557793
memory B-Disease 0 0.9917891
deficiency I-Disease 0 0.97469884
in O 0 0.00089498097
the O 0 0.0008809612
rat O 0 0.00232888
. O 0 0.0026649386

Antagonists O 0 0.049278967
at O 0 0.0040027313
serotonin B-Chemical 0 0.998055
type O 0 0.0027196722
6 O 0 0.0008074625
( O 0 0.001192434
5 B-Chemical 0 0.0006920102
- I-Chemical 0 0.0037956524
HT I-Chemical 0 0.93885356
( O 0 0.00079800386
6 O 0 0.00026742238
) O 0 0.0006796829
) O 0 0.0006822372
receptors O 0 0.00049721706
show O 0 0.000182866
activity O 0 0.00018912446
in O 0 0.00024996838
models O 0 0.00031276845
of O 0 0.00055421994
learning O 0 0.0021273203
and O 0 0.0014367704
memory O 0 0.28733522
. O 0 0.004506859

Although O 0 0.0020862503
the O 0 0.0016461005
underlying O 0 0.0014099301
mechanism O 0 0.0007086282
( O 0 0.0013557868
s O 0 0.000947373
) O 0 0.000975929
are O 0 0.00025571513
not O 0 0.00023321834
well O 0 0.0002679167
understood O 0 0.00066932145
, O 0 0.00048480977
these O 0 0.00020080533
effects O 0 0.00021506587
may O 0 0.00018849435
involve O 0 0.00021341677
an O 0 0.00028574094
increase O 0 0.0003178589
in O 0 0.0006414592
acetylcholine B-Chemical 1 0.9996582
( O 0 0.0046711867
ACh B-Chemical 0 0.9988728
) O 0 0.002985906
levels O 0 0.0016162321
. O 0 0.0031560324

The O 0 0.0019000317
present O 0 0.0013018543
study O 0 0.0011337354
sought O 0 0.0006877184
to O 0 0.00038961202
characterize O 0 0.00021410118
the O 0 0.0003663343
cognitive O 0 0.821665
- O 0 0.0017176127
enhancing O 0 0.0001617443
effects O 0 0.00016919135
of O 0 0.00021803388
the O 0 0.0001828278
5 B-Chemical 0 0.00024927934
- I-Chemical 0 0.0030217494
HT I-Chemical 0 0.9783301
( O 0 0.00042988404
6 O 0 0.00014335127
) O 0 0.0005855645
antagonist O 0 0.11085134
Ro4368554 B-Chemical 1 0.9879291
( O 0 0.00074507325
3 B-Chemical 0 0.0002513545
- I-Chemical 0 0.0035719634
benzenesulfonyl I-Chemical 0 0.6616046
- I-Chemical 0 0.002195653
7 I-Chemical 0 0.0001948975
- I-Chemical 0 0.0009944504
( I-Chemical 0 0.00039210086
4 I-Chemical 0 0.00024196922
- I-Chemical 0 0.0044632712
methyl I-Chemical 0 0.94022125
- I-Chemical 0 0.08669366
piperazin I-Chemical 0 0.8437802
- I-Chemical 0 0.010109099
1 I-Chemical 0 0.00044208378
- I-Chemical 0 0.005241693
yl I-Chemical 0 0.9383096
) I-Chemical 0 0.0022770825
1H I-Chemical 0 0.5303591
- I-Chemical 0 0.06801536
indole I-Chemical 0 0.7362266
) O 0 0.0008444746
in O 0 0.00013448526
a O 0 0.00017853003
rat O 0 0.00016182793
object O 0 0.00022375319
recognition O 0 0.000109183056
task O 0 0.0002953018
employing O 0 0.000113174036
a O 0 0.00031365504
cholinergic O 0 0.042682905
( O 0 0.0015122462
scopolamine B-Chemical 0 0.99999857
pretreatment O 0 0.024357744
) O 0 0.00058729795
and O 0 0.00015614367
a O 0 0.00031798953
serotonergic O 0 0.07144672
- O 0 0.008553962
( O 0 0.0010953163
tryptophan B-Chemical 0 0.9837638
( O 0 0.0018492136
TRP B-Chemical 0 0.9987344
) O 0 0.00058841833
depletion O 0 0.00012146959
) O 0 0.00031234056
deficient O 0 9.8702185e-05
model O 0 0.000102980965
, O 0 0.00021695117
and O 0 0.00011438909
compared O 0 8.282175e-05
its O 0 0.00014120438
pattern O 0 0.00010466487
of O 0 0.00014802493
action O 0 0.00017643534
with O 0 0.00020347275
that O 0 0.00017189233
of O 0 0.00040489313
the O 0 0.00065730524
acetylcholinesterase O 0 0.9982054
inhibitor O 0 0.338277
metrifonate B-Chemical 0 0.999962
. O 0 0.005010284

Initial O 0 0.0031611116
testing O 0 0.0014532681
in O 0 0.0009841669
a O 0 0.0009589023
time O 0 0.0004939759
- O 0 0.002036681
dependent O 0 0.00030588853
forgetting O 0 0.013243761
task O 0 0.00062525587
employing O 0 0.00019759116
a O 0 0.00029971832
24 O 0 0.00020685788
- O 0 0.0005477956
h O 0 0.00012583376
delay O 0 0.00014122028
between O 0 6.910931e-05
training O 0 0.00010519939
and O 0 0.00010304913
testing O 0 8.8264875e-05
showed O 0 0.00010275075
that O 0 0.00014562075
metrifonate B-Chemical 0 0.9999734
improved O 0 0.00034229018
object O 0 0.0004163363
recognition O 0 0.00016632875
( O 0 0.00024149446
at O 0 7.756924e-05
10 O 0 9.608711e-05
and O 0 9.9032346e-05
30 O 0 0.00010936279
mg O 0 0.0007785696
/ O 0 0.00047877073
kg O 0 0.0003718773
, O 0 0.00029462238
p O 0 0.000361272
. O 0 0.00023967134
o O 0 0.00114908
. O 0 0.00040817133
) O 0 0.0009902172
, O 0 0.00096467393
whereas O 0 0.00095192
Ro4368554 B-Chemical 1 0.9470563
was O 0 0.001604236
inactive O 0 0.002885211
. O 0 0.0036602912

Both O 0 0.004511664
, O 0 0.007962089
Ro4368554 B-Chemical 1 0.92710125
( O 0 0.002774799
3 O 0 0.00074125925
and O 0 0.000600002
10 O 0 0.0005301883
mg O 0 0.0023166551
/ O 0 0.0011264688
kg O 0 0.00075248716
, O 0 0.0005034167
intraperitoneally O 0 0.00037770596
( O 0 0.0003945049
i O 0 0.00036689424
. O 0 0.0001943117
p O 0 0.00033651665
. O 0 0.00020935624
) O 0 0.0005002019
) O 0 0.0005963592
and O 0 0.00044809404
metrifonate B-Chemical 0 0.99995327
( O 0 0.00053700426
10 O 0 0.00019463526
mg O 0 0.0013742212
/ O 0 0.0005331371
kg O 0 0.00036063368
, O 0 0.00024605964
p O 0 0.00027705642
. O 0 0.0001560758
o O 0 0.00072614517
. O 0 0.0001806551
, O 0 0.00028946373
respectively O 0 0.00036237217
) O 0 0.00050697144
reversed O 0 0.00047838068
memory B-Disease 0 0.99372125
deficits I-Disease 0 0.9990766
induced O 0 0.00034318416
by O 0 0.0005567993
scopolamine B-Chemical 0 0.99999905
and O 0 0.00079827756
TRP B-Chemical 0 0.9977209
depletion O 0 0.0001540675
( O 0 0.00026031226
10 O 0 0.00013514141
mg O 0 0.0012061645
/ O 0 0.00050266145
kg O 0 0.00036380297
, O 0 0.0002518321
i O 0 0.00027328465
. O 0 0.00014349597
p O 0 0.00026117513
. O 0 0.0001501761
, O 0 0.00024785782
and O 0 0.00016954745
3 O 0 0.0001778565
mg O 0 0.0013944334
/ O 0 0.0007331493
kg O 0 0.000557631
, O 0 0.00045659716
p O 0 0.0005614841
. O 0 0.0004064208
o O 0 0.0017082447
. O 0 0.0007593398
, O 0 0.0015804718
respectively O 0 0.0024167337
) O 0 0.0045171846
. O 0 0.003950087

In O 0 0.0020085895
conclusion O 0 0.0015641111
, O 0 0.0033882211
although O 0 0.0019392291
Ro4368554 B-Chemical 1 0.98436975
did O 0 0.0008442441
not O 0 0.00032911223
improve O 0 0.00019934138
a O 0 0.00030817438
time O 0 0.00017239837
- O 0 0.0011446292
related O 0 0.00013060766
retention O 0 0.0024630046
deficit O 0 0.9733093
, O 0 0.0007743716
it O 0 0.0003341374
reversed O 0 0.00041383947
a O 0 0.00044786642
cholinergic O 0 0.0119036995
and O 0 0.0001473931
a O 0 0.00027933312
serotonergic O 0 0.07333991
memory B-Disease 0 0.9920012
deficit I-Disease 0 0.9968395
, O 0 0.00044387253
suggesting O 0 6.697245e-05
that O 0 5.7065612e-05
both O 0 6.604553e-05
mechanisms O 0 6.7957015e-05
may O 0 7.933366e-05
be O 0 8.160689e-05
involved O 0 6.9645066e-05
in O 0 7.911216e-05
the O 0 7.451927e-05
facilitation O 0 0.00036317576
of O 0 0.0001268005
object O 0 0.00057696656
memory O 0 0.33956796
by O 0 0.00032621395
Ro4368554 B-Chemical 1 0.97482806
and O 0 0.00026483284
, O 0 0.00037287327
possibly O 0 0.00025275984
, O 0 0.0003432108
other O 0 0.00020674332
5 B-Chemical 0 0.0003260669
- I-Chemical 0 0.0037282882
HT I-Chemical 0 0.97813326
( O 0 0.0008798829
6 O 0 0.0004021968
) O 0 0.0014154876
receptor O 0 0.0031239693
antagonists O 0 0.12209935
. O 0 0.004643108

Evaluation O 0 0.0029431623
of O 0 0.0019797734
the O 0 0.001273864
anticocaine O 0 0.0022920845
monoclonal O 0 0.0019890112
antibody O 0 0.0018542451
GNC92H2 B-Chemical 0 0.41335827
as O 0 0.0008599135
an O 0 0.0008317683
immunotherapy O 0 0.0014748407
for O 0 0.0013750257
cocaine B-Disease 0 0.99991894
overdose I-Disease 0 0.9998994
. O 0 0.0064126477

The O 0 0.0023081892
illicit O 0 0.21795051
use O 0 0.0013294213
of O 0 0.0015970196
cocaine B-Chemical 0 0.999456
continues O 0 0.0006678948
in O 0 0.00040978854
epidemic O 0 0.00058308506
proportions O 0 0.00025437097
and O 0 0.00029549192
treatment O 0 0.00033977875
for O 0 0.0005091085
cocaine B-Disease 0 0.99996173
overdose I-Disease 0 0.9999348
remains O 0 0.00093268004
elusive O 0 0.0022705053
. O 0 0.003190065

Current O 0 0.007211822
protein O 0 0.0030971474
- O 0 0.005633619
based O 0 0.00076897745
technology O 0 0.0007386488
offers O 0 0.0003973496
a O 0 0.00052845397
new O 0 0.0003682986
therapeutic O 0 0.0004255277
venue O 0 0.00046119743
by O 0 0.00022408282
which O 0 0.00022667348
antibodies O 0 0.00020897693
bind O 0 9.1021204e-05
the O 0 0.00017236681
drug O 0 0.00233188
in O 0 0.00019296094
the O 0 0.00019607475
blood O 0 0.0026776856
stream O 0 0.00085226895
, O 0 0.00071473705
inactivating O 0 0.0005063957
its O 0 0.0009898333
toxic O 0 0.015401959
effects O 0 0.0019066527
. O 0 0.0035493302

The O 0 0.0017779912
therapeutic O 0 0.001791084
potential O 0 0.0008228743
of O 0 0.00087454426
the O 0 0.00061327306
anticocaine O 0 0.0014865757
antibody O 0 0.0012121017
GNC92H2 B-Chemical 0 0.55379903
was O 0 0.00040452296
examined O 0 0.00026251073
using O 0 0.0002818795
a O 0 0.0005440924
model O 0 0.0005291185
of O 0 0.0017412571
cocaine B-Disease 0 0.9999598
overdose I-Disease 0 0.9999348
. O 0 0.005496931

Swiss O 0 0.004392626
albino O 0 0.002718039
mice O 0 0.0004733692
prepared O 0 0.00061568926
with O 0 0.0005942578
intrajugular O 0 0.022356104
catheters O 0 0.0012754872
were O 0 0.00021049594
tested O 0 0.0001615766
in O 0 0.00018344667
photocell O 0 0.0015027799
cages O 0 0.0004744498
after O 0 7.734632e-05
administration O 0 0.00017827468
of O 0 0.00014306589
93 O 0 0.00032541098
mg O 0 0.0016387914
/ O 0 0.0006075658
kg O 0 0.00046453194
( O 0 0.00041210948
LD50 O 0 0.038897093
) O 0 0.00043824248
of O 0 0.00025971976
cocaine B-Chemical 0 0.99946135
and O 0 0.00034517844
GNC92H2 B-Chemical 0 0.53510857
infusions O 0 0.00066971313
ranging O 0 0.00024167202
from O 0 0.00014707848
30 O 0 0.00017706443
to O 0 0.0002444264
190 O 0 0.0013094778
mg O 0 0.0047981422
/ O 0 0.0031611011
kg O 0 0.0033294049
. O 0 0.0030064918

GNC92H2 B-Chemical 0 0.534186
was O 0 0.0024868432
delivered O 0 0.0012621502
30 O 0 0.00090378907
min O 0 0.00095492275
before O 0 0.00037430268
, O 0 0.0009675726
concomitantly O 0 0.0009801503
or O 0 0.0004779051
3 O 0 0.0004784158
min O 0 0.0008040254
after O 0 0.00057499716
cocaine B-Chemical 0 0.9846015
treatment O 0 0.002184861
. O 0 0.0034333444

Significant O 0 0.004395976
blockade O 0 0.005942917
of O 0 0.0029242043
cocaine B-Chemical 0 0.99983156
toxicity B-Disease 0 0.94262546
was O 0 0.0004130654
observed O 0 0.00021119797
with O 0 0.00019764714
the O 0 0.00013457084
higher O 0 0.00018044474
dose O 0 0.00030813
of O 0 0.00025279436
GNC92H2 B-Chemical 0 0.57222736
( O 0 0.00047244193
190 O 0 0.0006553286
mg O 0 0.0022565103
/ O 0 0.0006146811
kg O 0 0.0004459322
) O 0 0.00039659356
, O 0 0.0002748252
where O 0 0.00018445343
premorbid O 0 0.65046436
behaviors O 0 0.00043294582
were O 0 0.00014012237
reduced O 0 0.00017069251
up O 0 0.00017104378
to O 0 0.00013188671
40 O 0 0.0002089566
% O 0 0.00045795218
, O 0 0.00084797613
seizures B-Disease 0 0.99991775
up O 0 0.00036439093
to O 0 0.00023971383
77 O 0 0.0006273728
% O 0 0.0006752025
and O 0 0.0005939767
death B-Disease 0 0.257977
by O 0 0.0009999899
72 O 0 0.0015943176
% O 0 0.0028787693
. O 0 0.0031866904

Importantly O 0 0.003946126
, O 0 0.01029446
GNC92H2 B-Chemical 0 0.9091897
prevented O 0 0.007854633
death B-Disease 0 0.79440695
even O 0 0.0023299716
post O 0 0.0017517179
- O 0 0.01299561
cocaine B-Chemical 0 0.9970843
injection O 0 0.0027969738
. O 0 0.004278631

The O 0 0.001917177
results O 0 0.0013662069
support O 0 0.0010535718
the O 0 0.0007321485
important O 0 0.0004667266
potential O 0 0.00050837983
of O 0 0.0009094527
GNC92H2 B-Chemical 0 0.57840455
as O 0 0.0006205337
a O 0 0.00068492
therapeutic O 0 0.0006677528
tool O 0 0.0006613623
against O 0 0.0008554937
cocaine B-Disease 0 0.9999466
overdose I-Disease 0 0.9999311
. O 0 0.006169135

Electrocardiographic O 0 0.018536568
evidence O 0 0.0024984754
of O 0 0.0038478805
myocardial B-Disease 0 0.99952054
injury I-Disease 0 0.951468
in O 0 0.00256498
psychiatrically O 0 0.99793977
hospitalized O 0 0.45069942
cocaine B-Chemical 0 0.99968743
abusers O 0 0.9975297
. O 0 0.0052546947

The O 0 0.0025135763
electrocardiograms O 0 0.007804825
( O 0 0.0031004518
ECG O 0 0.01013926
) O 0 0.0016780603
of O 0 0.0007424717
99 O 0 0.0018647914
cocaine B-Chemical 0 0.9995906
- O 0 0.02513069
abusing O 0 0.18184271
patients O 0 0.000628153
were O 0 0.00019198241
compared O 0 0.0001458922
with O 0 0.0002411208
the O 0 0.00026860955
ECGs O 0 0.0010771332
of O 0 0.0005792364
50 O 0 0.0016451777
schizophrenic B-Disease 0 0.9998803
controls O 0 0.0039588464
. O 0 0.0035101804

Eleven O 0 0.0053374656
of O 0 0.0021224017
the O 0 0.0017633286
cocaine B-Chemical 0 0.9997223
abusers O 0 0.99839514
and O 0 0.0005410227
none O 0 0.00031987927
of O 0 0.0002569562
the O 0 0.00017886263
controls O 0 0.00031019826
had O 0 0.00020438177
ECG O 0 0.002970494
evidence O 0 0.00010896069
of O 0 0.00017416611
significant O 0 0.00034509687
myocardial B-Disease 0 0.99991035
injury I-Disease 0 0.8065349
defined O 0 0.00021251987
as O 0 0.00034321522
myocardial B-Disease 0 0.99980706
infarction I-Disease 0 0.9999937
, O 0 0.0036267184
ischemia B-Disease 0 0.9997837
, O 0 0.0008438716
and O 0 0.00046892467
bundle B-Disease 0 0.0029331686
branch I-Disease 0 0.0022345062
block I-Disease 0 0.0023228067
. O 0 0.0029944899

Behavioral O 0 0.014462504
effects O 0 0.0034938115
of O 0 0.005130291
urotensin B-Chemical 0 0.99851626
- I-Chemical 0 0.3648341
II I-Chemical 0 0.6372135
centrally O 0 0.0029950936
administered O 0 0.0018807764
in O 0 0.0014105217
mice O 0 0.0012213046
. O 0 0.004201029

Urotensin B-Chemical 0 0.79641294
- I-Chemical 0 0.12871435
II I-Chemical 0 0.6590784
( O 0 0.008360956
U B-Chemical 0 0.97609293
- I-Chemical 0 0.17438288
II I-Chemical 0 0.6972624
) O 0 0.0030052683
receptors O 0 0.001399613
are O 0 0.00043449755
widely O 0 0.00042910455
distributed O 0 0.00037927262
in O 0 0.00046996374
the O 0 0.00057495246
central O 0 0.0014550097
nervous O 0 0.004737439
system O 0 0.0023291649
. O 0 0.003615204

Intracerebroventricular O 0 0.50204813
( O 0 0.00614432
i O 0 0.0033539045
. O 0 0.0015152228
c O 0 0.003080211
. O 0 0.00081622065
v O 0 0.0018389347
. O 0 0.0004780826
) O 0 0.000663061
injection O 0 0.00027143006
of O 0 0.00048006768
U B-Chemical 0 0.9432972
- I-Chemical 0 0.07630384
II I-Chemical 0 0.57285464
causes O 0 0.0009134415
hypertension B-Disease 2 0.99998856
and O 0 0.000901433
bradycardia B-Disease 0 0.99862003
and O 0 0.00046768656
stimulates O 0 0.0005564067
prolactin O 0 0.99579865
and O 0 0.0023429939
thyrotropin O 0 0.99888104
secretion O 0 0.041861556
. O 0 0.0038172544

However O 0 0.0031484535
, O 0 0.0034526207
the O 0 0.0012035129
behavioral O 0 0.0020214766
effects O 0 0.0006760683
of O 0 0.00074052287
centrally O 0 0.0010987676
administered O 0 0.0013270044
U B-Chemical 0 0.89083314
- I-Chemical 0 0.021816626
II I-Chemical 0 0.10826178
have O 0 0.0006056475
received O 0 0.0006899918
little O 0 0.0011627676
attention O 0 0.0058827666
. O 0 0.0041719815

In O 0 0.0020146105
the O 0 0.0015205598
present O 0 0.001041972
study O 0 0.001109075
, O 0 0.0010067506
we O 0 0.0002680616
tested O 0 0.0003073235
the O 0 0.00023703788
effects O 0 0.0002650943
of O 0 0.00035689457
i O 0 0.0006844449
. O 0 0.0002923144
c O 0 0.0010460613
. O 0 0.00021784913
v O 0 0.0006702806
. O 0 0.00015957636
injections O 0 0.00016104642
of O 0 0.00027425302
U B-Chemical 0 0.9336696
- I-Chemical 0 0.03821075
II I-Chemical 0 0.19573598
on O 0 0.00018650848
behavioral O 0 0.0012430304
, O 0 0.00063072244
metabolic O 0 0.0058323387
, O 0 0.00064003846
and O 0 0.0004377805
endocrine O 0 0.015251959
responses O 0 0.0005501372
in O 0 0.00065177085
mice O 0 0.0005858626
. O 0 0.0022974669

Administration O 0 0.0075840247
of O 0 0.0022349206
graded O 0 0.0023305714
doses O 0 0.002267692
of O 0 0.0016044177
U B-Chemical 0 0.9752206
- I-Chemical 0 0.14379248
II I-Chemical 0 0.61413693
( O 0 0.0012742449
1 O 0 0.0005051399
- O 0 0.0011431169
10 O 0 0.00025501056
, O 0 0.0003474182
000 O 0 0.000282754
ng O 0 0.00050100754
/ O 0 0.0010393319
mouse O 0 0.0002135399
) O 0 0.0005605798
provoked O 0 0.0006477294
: O 0 0.0005861958
( O 0 0.00038588
1 O 0 0.00019781267
) O 0 0.00031419317
a O 0 0.0002081673
dose O 0 0.0003357599
- O 0 0.0008203576
dependent O 0 9.084752e-05
reduction O 0 0.00015636014
in O 0 0.000111742986
the O 0 9.2782466e-05
number O 0 9.259879e-05
of O 0 0.00017085111
head O 0 0.0012766197
dips O 0 0.0035330227
in O 0 0.0001411313
the O 0 0.00013872949
hole O 0 0.0049018553
- O 0 0.0019843867
board O 0 0.0002451955
test O 0 0.00023818128
; O 0 0.00037559323
( O 0 0.00026629682
2 O 0 0.00014576915
) O 0 0.0002592124
a O 0 0.00017479363
dose O 0 0.00029798233
- O 0 0.00078513124
dependent O 0 7.691919e-05
reduction O 0 0.00013433724
in O 0 9.2721784e-05
the O 0 7.374272e-05
number O 0 6.8135065e-05
of O 0 0.000105398205
entries O 0 0.00016239478
in O 0 8.647664e-05
the O 0 7.572482e-05
white O 0 0.00017543667
chamber O 0 0.0008172021
in O 0 9.322466e-05
the O 0 8.174725e-05
black O 0 0.0001942513
- O 0 0.0012249307
and O 0 0.00016425546
- O 0 0.001018488
white O 0 0.00020228562
compartment O 0 0.00017199053
test O 0 0.00018842447
, O 0 0.00023808112
and O 0 0.00011611594
in O 0 9.089543e-05
the O 0 7.3183975e-05
number O 0 6.863146e-05
of O 0 0.00010814377
entries O 0 0.00017123633
in O 0 8.998352e-05
the O 0 7.3297255e-05
central O 0 0.00013663343
platform O 0 0.00011799928
and O 0 9.425134e-05
open O 0 0.00012069624
arms O 0 0.00020307387
in O 0 8.191878e-05
the O 0 7.854972e-05
plus O 0 0.00014053988
- O 0 0.0011520755
maze O 0 0.2419448
test O 0 0.00032372982
; O 0 0.00033427123
and O 0 0.00014072291
( O 0 0.00022166922
3 O 0 9.973211e-05
) O 0 0.00022968426
a O 0 0.00016396298
dose O 0 0.000285857
- O 0 0.00074253965
dependent O 0 7.580725e-05
increase O 0 9.128021e-05
in O 0 8.3596744e-05
the O 0 7.005584e-05
duration O 0 7.0317205e-05
of O 0 0.0001607713
immobility O 0 0.071286425
in O 0 0.00015997124
the O 0 0.00016508842
forced O 0 0.0011609643
- O 0 0.0030774216
swimming O 0 0.005069184
test O 0 0.0005052747
and O 0 0.00042657918
tail O 0 0.00052925496
suspension O 0 0.001660936
test O 0 0.0022293155
. O 0 0.0030085223

Intracerebroventricular O 0 0.09905212
injection O 0 0.0022303627
of O 0 0.002517563
U B-Chemical 0 0.9804292
- I-Chemical 0 0.20540917
II I-Chemical 0 0.5000558
also O 0 0.0005255452
caused O 0 0.0003709771
an O 0 0.00031384794
increase O 0 0.00020433559
in O 0 0.00018539184
: O 0 0.00037168173
food O 0 0.00039689307
intake O 0 0.00095773995
at O 0 9.649894e-05
doses O 0 0.00025359486
of O 0 0.00016125801
100 O 0 0.00030912983
and O 0 0.00014963366
1 O 0 0.00015303105
, O 0 0.00020272913
000 O 0 0.00016711728
ng O 0 0.0003259758
/ O 0 0.0007325403
mouse O 0 0.0001274974
, O 0 0.00027611892
water O 0 0.00087340345
intake O 0 0.0011031543
at O 0 8.67933e-05
doses O 0 0.00023413268
of O 0 0.00015906456
100 O 0 0.00041376415
- O 0 0.0008500171
10 O 0 0.00012854137
, O 0 0.00018557294
000 O 0 0.00015803592
ng O 0 0.00031862163
/ O 0 0.00073192664
mouse O 0 0.00012021027
, O 0 0.00022333478
and O 0 0.00014117586
horizontal O 0 0.00029796557
locomotion O 0 0.0010070091
activity O 0 0.000100806625
at O 0 0.000105450075
a O 0 0.00023343947
dose O 0 0.00031412154
of O 0 0.00025986717
10 O 0 0.00031388982
, O 0 0.0005858056
000 O 0 0.00064509135
ng O 0 0.0014453446
/ O 0 0.0034960783
mouse O 0 0.0014750971
. O 0 0.0029536167

Whatever O 0 0.008595034
was O 0 0.0021031396
the O 0 0.0011570294
dose O 0 0.0015180815
, O 0 0.001043222
the O 0 0.00038519493
central O 0 0.00054156675
administration O 0 0.0005670138
of O 0 0.0005158084
U B-Chemical 0 0.9770065
- I-Chemical 0 0.10759332
II I-Chemical 0 0.36381045
had O 0 0.00019131471
no O 0 0.0001078189
effect O 0 0.00010133159
on O 0 9.5465235e-05
body O 0 0.00029889026
temperature O 0 0.0005453348
, O 0 0.00035697504
nociception O 0 0.0015713457
, O 0 0.0010441382
apomorphine B-Chemical 0 0.9999881
- O 0 0.00832808
induced O 0 0.00019957834
penile B-Disease 0 0.18548867
erection I-Disease 0 0.48257068
and O 0 0.00022625417
climbing O 0 0.0011530404
behavior O 0 0.00037036627
, O 0 0.0004810718
and O 0 0.0003685668
stress O 0 0.034357265
- O 0 0.0079385545
induced O 0 0.00085840846
plasma O 0 0.44328701
corticosterone B-Chemical 0 0.999551
level O 0 0.0021556036
. O 0 0.003192142

Taken O 0 0.0027708258
together O 0 0.0021471032
, O 0 0.00240175
the O 0 0.00074270985
present O 0 0.0004830613
study O 0 0.00046269398
demonstrates O 0 0.00018036732
that O 0 0.00017738655
the O 0 0.00017963859
central O 0 0.00029041243
injection O 0 0.00016787174
of O 0 0.00030646066
U B-Chemical 0 0.9433637
- I-Chemical 0 0.030886251
II I-Chemical 0 0.1071929
at O 0 0.00013347242
doses O 0 0.0003139051
of O 0 0.00018454298
1 O 0 0.0002196721
- O 0 0.0006922335
10 O 0 0.00013742066
, O 0 0.00020396283
000 O 0 0.00017757792
ng O 0 0.00035691226
/ O 0 0.0007998034
mouse O 0 0.00014024871
induces O 0 0.0001743311
anxiogenic O 0 0.83695513
- O 0 0.0059360927
and O 0 0.00047080536
depressant O 0 0.9974783
- O 0 0.0035841353
like O 0 0.00033834195
effects O 0 0.0005297314
in O 0 0.0008639485
mouse O 0 0.0013097529
. O 0 0.0027414593

These O 0 0.0027072534
data O 0 0.0024366782
suggest O 0 0.0011508657
that O 0 0.0017337854
U B-Chemical 0 0.9850309
- I-Chemical 0 0.36161286
II I-Chemical 0 0.68479764
may O 0 0.0006590022
be O 0 0.00046577677
involved O 0 0.00036519478
in O 0 0.0004099669
some O 0 0.0005097451
aspects O 0 0.00070375705
of O 0 0.002312358
psychiatric B-Disease 2 0.9998884
disorders I-Disease 0 0.9996232
. O 0 0.00692177

Learning O 0 0.016124131
of O 0 0.0042593246
rats O 0 0.004827836
under O 0 0.0037688785
amnesia B-Disease 0 0.99810225
caused O 0 0.0039361683
by O 0 0.005112643
pentobarbital B-Chemical 0 0.998417
. O 0 0.008693939

Dissociated O 0 0.009458856
learning O 0 0.0042201425
of O 0 0.0013241853
rats O 0 0.0013212608
in O 0 0.0005441642
the O 0 0.00037853429
normal O 0 0.0005938779
state O 0 0.00033357154
and O 0 0.00025093445
the O 0 0.00018775409
state O 0 0.00027987672
of O 0 0.00041242127
amnesia B-Disease 0 0.9997106
produced O 0 0.00023492989
by O 0 0.00030557552
pentobarbital B-Chemical 0 0.99954814
( O 0 0.00044193884
15 O 0 0.00019089413
mg O 0 0.0011538316
/ O 0 0.0007509019
kg O 0 0.00068216206
, O 0 0.0007187319
ip O 0 0.004263962
) O 0 0.0011281688
was O 0 0.0005982513
carried O 0 0.00081017497
out O 0 0.0015040933
. O 0 0.0033307767

Rats O 0 0.007058981
were O 0 0.0019870081
trained O 0 0.0015721994
to O 0 0.00092100835
approach O 0 0.00093463657
a O 0 0.0012756232
shelf O 0 0.002353054
where O 0 0.0007723222
they O 0 0.0007179233
received O 0 0.00094748853
food O 0 0.0025479537
reinforcement O 0 0.0037624885
. O 0 0.0041208006

In O 0 0.0025830409
Group O 0 0.0071635614
1 O 0 0.0013028379
the O 0 0.000595484
rats O 0 0.00072145485
were O 0 0.00033751607
trained O 0 0.00031697887
under O 0 0.00019736314
the O 0 0.00015551172
influence O 0 0.00013982781
of O 0 0.0003512221
pentobarbital B-Chemical 0 0.99938774
to O 0 0.00019852501
run O 0 0.00020365111
to O 0 0.00013580435
the O 0 0.00014516231
same O 0 0.00016671777
shelf O 0 0.0010342776
as O 0 0.00033439652
in O 0 0.00040533356
the O 0 0.0005486419
normal O 0 0.0015860262
state O 0 0.0019882056
. O 0 0.003020046

In O 0 0.0027307903
Group O 0 0.0069707204
2 O 0 0.0014280038
the O 0 0.0007092677
rats O 0 0.0008886381
were O 0 0.0004569793
trained O 0 0.00046143908
to O 0 0.00032206965
approach O 0 0.0003745495
different O 0 0.00035802275
shelves O 0 0.002469513
in O 0 0.0006951661
different O 0 0.0007674606
drug O 0 0.008126315
states O 0 0.0031765911
. O 0 0.003913719

It O 0 0.006133777
was O 0 0.0023003027
shown O 0 0.0010332499
that O 0 0.0013193191
memory B-Disease 0 0.8101109
dissociation I-Disease 0 0.012124835
occurred O 0 0.0014190807
in O 0 0.001209585
both O 0 0.001479718
groups O 0 0.003090106
. O 0 0.004807644

Differences O 0 0.0025712654
in O 0 0.0015081255
the O 0 0.00086388766
parameters O 0 0.00078181195
of O 0 0.00059842947
training O 0 0.0004702187
under O 0 0.000298115
the O 0 0.00022456105
influence O 0 0.00019583876
of O 0 0.00046097641
pentobarbital B-Chemical 0 0.9981325
between O 0 0.00035387653
Groups O 0 0.0015490303
1 O 0 0.00049161294
and O 0 0.0004917985
2 O 0 0.0006912446
were O 0 0.00077119074
revealed O 0 0.0013128284
. O 0 0.0031879279

These O 0 0.0019290136
findings O 0 0.0018235284
show O 0 0.0008502104
that O 0 0.0006588318
the O 0 0.0006767438
brain O 0 0.0032169782
- O 0 0.0036439707
dissociated O 0 0.00043333232
state O 0 0.00029475585
induced O 0 0.00022844567
by O 0 0.00033027865
pentobarbital B-Chemical 0 0.9997359
is O 0 0.00017164959
formed O 0 0.00018163548
with O 0 0.00016360628
the O 0 0.00013068019
participation O 0 0.00019706156
of O 0 0.00020855093
the O 0 0.00018617569
mechanisms O 0 0.00023704919
of O 0 0.00055369193
information O 0 0.0008985222
perception O 0 0.0032061297
. O 0 0.0029414447

The O 0 0.0016884602
effects O 0 0.0013811298
of O 0 0.0013026702
short O 0 0.0010147309
- O 0 0.0034735496
term O 0 0.0010134971
raloxifene B-Chemical 0 0.9988618
therapy O 0 0.0011836529
on O 0 0.0005019103
fibrinolysis O 0 0.9974718
markers O 0 0.0017711637
: O 0 0.005098149
TAFI O 0 0.9995628
, O 0 0.0027837113
tPA O 0 0.93758094
, O 0 0.001553057
and O 0 0.0013754953
PAI O 0 0.3000707
- O 0 0.006316911
1 O 0 0.0023282797
. O 0 0.0032714286

BACKGROUND O 0 0.020817053
: O 0 0.0069471006
Markers O 0 0.006995195
of O 0 0.0025593925
fibrinolysis O 0 0.9981476
, O 0 0.0045250454
thrombin O 0 0.92898506
- O 0 0.061761502
activatable O 0 0.017637134
fibrinolysis O 0 0.9995389
inhibitor O 0 0.0075997394
( O 0 0.004416275
TAFI O 0 0.9997861
) O 0 0.0016520959
, O 0 0.0007249718
tissue O 0 0.0013816078
- O 0 0.004085692
type O 0 0.001282284
plasminogen O 0 0.995131
activator O 0 0.0019014576
( O 0 0.0012724136
tPA O 0 0.966819
) O 0 0.0007592128
, O 0 0.0004534735
and O 0 0.00041673618
plasminogen O 0 0.9945305
activator O 0 0.0017456498
inhibitor O 0 0.0025717302
- O 0 0.005798
1 O 0 0.0002545767
( O 0 0.00050589396
PAI O 0 0.1525852
- O 0 0.0012349273
1 O 0 0.00014948093
) O 0 0.00023180198
levels O 0 8.6872285e-05
were O 0 8.9071844e-05
studied O 0 0.000118932585
for O 0 6.423839e-05
the O 0 6.9106405e-05
evaluation O 0 8.54522e-05
of O 0 0.00010627897
short O 0 0.00011954066
- O 0 0.00056641526
term O 0 0.00013990328
effects O 0 0.0001767979
of O 0 0.00046894295
raloxifene B-Chemical 0 0.9998066
administration O 0 0.00214283
in O 0 0.00073787104
postmenopausal O 0 0.522157
women O 0 0.0056482255
. O 0 0.002730733

METHODS O 0 0.0042872266
: O 0 0.00328293
Thirty O 0 0.0025085825
- O 0 0.0031405136
nine O 0 0.0007951023
postmenopausal O 0 0.04238527
women O 0 0.0019412311
with O 0 0.00093447004
osteopenia B-Disease 0 0.9997975
or O 0 0.0007733171
osteoporosis B-Disease 0 0.9996437
were O 0 0.00029496106
included O 0 0.0002037255
in O 0 0.00021091884
this O 0 0.00031917164
prospective O 0 0.0015192239
, O 0 0.00084909546
controlled O 0 0.0008143127
clinical O 0 0.0026058361
study O 0 0.00190772
. O 0 0.0028230825

Twenty O 0 0.006597499
- O 0 0.0061984393
five O 0 0.0008499966
women O 0 0.001856027
were O 0 0.0006318204
given O 0 0.000532712
raloxifene B-Chemical 0 0.99961215
hydrochloride I-Chemical 0 0.99678314
( O 0 0.0008490118
60 O 0 0.00034490039
mg O 0 0.002002607
/ O 0 0.0007270413
day O 0 0.00017587464
) O 0 0.0005550295
plus O 0 0.0004306262
calcium B-Chemical 0 0.9537795
( O 0 0.001315629
500 O 0 0.0015136302
mg O 0 0.007995302
/ O 0 0.002546649
day O 0 0.0008813605
) O 0 0.0033702608
. O 0 0.0034498968

Age O 0 0.028887248
- O 0 0.010182828
matched O 0 0.0016552936
controls O 0 0.0019199582
( O 0 0.0018583207
n O 0 0.0012253317
= O 0 0.0018902123
14 O 0 0.0008469311
) O 0 0.001536629
were O 0 0.0008326275
given O 0 0.00085478975
only O 0 0.0023102083
calcium B-Chemical 0 0.9679588
. O 0 0.007065819

Plasma O 0 0.96579814
TAFI O 0 0.99860495
, O 0 0.010828123
tPA O 0 0.9573621
, O 0 0.0026449438
and O 0 0.0015136142
PAI O 0 0.42011806
- O 0 0.004477132
1 O 0 0.00045153973
antigen O 0 0.00074423564
levels O 0 0.00019453415
were O 0 0.00015324878
measured O 0 0.00014265394
at O 0 8.9175264e-05
baseline O 0 0.00010274036
and O 0 0.000108554465
after O 0 6.208903e-05
3 O 0 8.7649816e-05
months O 0 6.372106e-05
of O 0 0.00015357339
treatment O 0 0.00022097075
by O 0 0.00030057106
commercially O 0 0.00095366576
available O 0 0.0008043645
ELISA O 0 0.10074644
kits O 0 0.012792796
. O 0 0.004022224

Variations O 0 0.0065911827
of O 0 0.0035032653
individuals O 0 0.0033990035
were O 0 0.001649677
assessed O 0 0.001372266
by O 0 0.0014711398
Wilcoxon O 0 0.002703956
' O 0 0.003283532
s O 0 0.0034586706
test O 0 0.0046942104
. O 0 0.0063689826

Relationship O 0 0.0033925246
between O 0 0.0020610255
those O 0 0.0023765946
markers O 0 0.0025071974
and O 0 0.0016153114
demographic O 0 0.0017507998
characteristics O 0 0.0014754046
were O 0 0.001868834
investigated O 0 0.0028911612
. O 0 0.0057905614

RESULTS O 0 0.0037699097
: O 0 0.0022332922
Three O 0 0.0006435638
months O 0 0.00039346566
of O 0 0.00074870227
raloxifene B-Chemical 0 0.9980393
treatment O 0 0.0005333254
was O 0 0.00027517625
associated O 0 0.00024619672
with O 0 0.0002235847
a O 0 0.0002737778
significant O 0 0.0001770128
decrease O 0 0.00020781708
in O 0 0.00018306712
the O 0 0.0002497211
plasma O 0 0.4080373
TAFI O 0 0.9998801
antigen O 0 0.0038901302
concentrations O 0 0.00056108506
( O 0 0.00034643122
16 O 0 0.00016761485
% O 0 0.000241239
change O 0 0.00013127468
, O 0 0.000272542
P O 0 0.0037245105
< O 0 0.00025761782
0 O 0 0.00020303862
. O 0 0.0001661799
01 O 0 0.0010380065
) O 0 0.00046020767
, O 0 0.00031025714
and O 0 0.00018530645
a O 0 0.0002411438
significant O 0 0.00017702748
increase O 0 0.00020124043
in O 0 0.00031507717
tPA O 0 0.9639571
antigen O 0 0.001882639
concentrations O 0 0.0006287834
( O 0 0.00049071846
25 O 0 0.00032346547
% O 0 0.0004196759
change O 0 0.00026715582
, O 0 0.00060449296
P O 0 0.0058103683
< O 0 0.0008074544
0 O 0 0.0008251541
. O 0 0.0009957484
05 O 0 0.0130254105
) O 0 0.004580565
. O 0 0.0040965388

A O 0 0.0195504
significant O 0 0.0019384339
correlation O 0 0.0010728443
was O 0 0.00071342767
found O 0 0.00049162534
between O 0 0.00040113064
baseline O 0 0.0008461455
TAFI O 0 0.9993048
antigen O 0 0.0021955944
concentrations O 0 0.00049951964
and O 0 0.00019471899
the O 0 0.00011982345
duration O 0 0.00011066699
of O 0 0.00025848288
amenorrhea B-Disease 0 0.73111445
( O 0 0.0005735753
P O 0 0.0071568363
< O 0 0.00040678747
0 O 0 0.00033884405
. O 0 0.00031217802
05 O 0 0.0031874175
; O 0 0.00075125153
r O 0 0.0008995423
= O 0 0.0012514944
0 O 0 0.00087779266
. O 0 0.0009263835
33 O 0 0.002111578
) O 0 0.0041765007
. O 0 0.004318373

CONCLUSION O 0 0.018331291
: O 0 0.00387416
We O 0 0.000828143
suggest O 0 0.00043511795
that O 0 0.00044367395
the O 0 0.0004376768
increased O 0 0.00067363906
risk O 0 0.002816743
of O 0 0.0006491987
venous B-Disease 0 0.990307
thromboembolism I-Disease 0 0.99999404
due O 0 0.00021608596
to O 0 0.00022970309
raloxifene B-Chemical 0 0.9997875
treatment O 0 0.00022640932
may O 0 0.000108319015
be O 0 0.00011002324
related O 0 8.380339e-05
to O 0 0.00015020004
increased O 0 0.0005269548
tPA O 0 0.9386065
levels O 0 0.00036219726
, O 0 0.0009365973
but O 0 0.0008500151
not O 0 0.0012924334
TAFI O 0 0.99884206
levels O 0 0.0021436736
. O 0 0.0034191194

Valproate B-Chemical 0 0.99958175
- O 0 0.24698563
induced O 0 0.022571743
encephalopathy B-Disease 2 0.9994543
. O 0 0.026527854

Valproate B-Chemical 0 0.9999058
- O 0 0.19422197
induced O 0 0.0039637717
encephalopathy B-Disease 2 0.999933
is O 0 0.0011157676
a O 0 0.0014996384
rare O 0 0.00708052
syndrome O 0 0.8942133
that O 0 0.00035021917
may O 0 0.00036945048
manifest O 0 0.0016600058
in O 0 0.00047249286
otherwise O 0 0.0009340392
normal O 0 0.0030408201
epileptic B-Disease 0 0.99960643
individuals O 0 0.003796098
. O 0 0.0030686755

It O 0 0.005121639
may O 0 0.0016107806
even O 0 0.001290402
present O 0 0.0006793642
in O 0 0.00062582636
patients O 0 0.0009959994
who O 0 0.0005651938
have O 0 0.00030978365
tolerated O 0 0.00068991067
this O 0 0.00044997895
medicine O 0 0.0028464778
well O 0 0.000596031
in O 0 0.00071198575
the O 0 0.0009225145
past O 0 0.0020475986
. O 0 0.003379136

It O 0 0.007914136
is O 0 0.0031509416
usually O 0 0.0032279447
but O 0 0.0025419486
not O 0 0.0018547951
necessarily O 0 0.0023650771
associated O 0 0.0026752553
with O 0 0.0052535012
hyperammonemia B-Disease 0 0.999741
. O 0 0.009635746

The O 0 0.0033861734
EEG O 0 0.13575214
shows O 0 0.0008804489
characteristic O 0 0.0012928217
triphasic O 0 0.032481376
waves O 0 0.0023518952
in O 0 0.00071470335
most O 0 0.0008817721
patients O 0 0.0012388363
with O 0 0.00095332507
this O 0 0.0015442211
complication O 0 0.011693544
. O 0 0.00397141

A O 0 0.034619473
case O 0 0.0054631
of O 0 0.0065860613
valproate B-Chemical 0 0.99994695
- O 0 0.14475682
induced O 0 0.004245194
encephalopathy B-Disease 2 0.9998603
is O 0 0.00294629
presented O 0 0.0030008173
. O 0 0.0048873466

The O 0 0.0030267672
problems O 0 0.006649032
in O 0 0.0022188514
diagnosing O 0 0.002549777
this O 0 0.0016856132
condition O 0 0.0024520492
are O 0 0.00148554
subsequently O 0 0.0020716647
discussed O 0 0.002705381
. O 0 0.005068143

Recurrent O 0 0.05450053
dysphonia B-Disease 0 0.99197525
and O 0 0.025261674
acitretin B-Chemical 0 0.99928755
. O 0 0.025238987

We O 0 0.0029720834
report O 0 0.0029959904
the O 0 0.0011918826
case O 0 0.0010533951
of O 0 0.00089355715
a O 0 0.0012211493
woman O 0 0.002676816
complaining O 0 0.0016638173
of O 0 0.000818031
dysphonia B-Disease 0 0.99820125
while O 0 0.00052150403
she O 0 0.00052103255
was O 0 0.00057561597
treated O 0 0.0017208568
by O 0 0.0023036464
acitretin B-Chemical 0 0.99988985
. O 0 0.0054994933

Her O 0 0.007843849
symptoms O 0 0.0154137
totally O 0 0.0033366848
regressed O 0 0.002552774
after O 0 0.0005816887
drug O 0 0.0054807425
withdrawal O 0 0.0031286434
and O 0 0.0007856712
reappeared O 0 0.001596121
when O 0 0.0010074856
acitretin B-Chemical 0 0.9998574
was O 0 0.0021430328
reintroduced O 0 0.003634389
. O 0 0.0039986274

To O 0 0.0016151544
our O 0 0.0018247197
knowledge O 0 0.0021548038
, O 0 0.0022947
this O 0 0.0009581845
is O 0 0.0005316933
the O 0 0.0004076454
first O 0 0.00033281808
case O 0 0.00066966505
of O 0 0.0014511537
acitretin B-Chemical 0 0.999969
- O 0 0.08267185
induced O 0 0.0026895797
dysphonia B-Disease 0 0.99822396
. O 0 0.004644139

This O 0 0.0046525677
effect O 0 0.0018024362
may O 0 0.0011729163
be O 0 0.0007763374
related O 0 0.0003939472
to O 0 0.00037334277
the O 0 0.00032815503
pharmacological O 0 0.0007647073
effect O 0 0.00036319444
of O 0 0.0006022778
this O 0 0.00081459794
drug O 0 0.021624621
on O 0 0.00093046186
mucous O 0 0.32124123
membranes O 0 0.011193406
. O 0 0.0035456035

Nitro B-Chemical 0 0.42824
- I-Chemical 0 0.562161
L I-Chemical 0 0.99672604
- I-Chemical 0 0.94784206
arginine I-Chemical 0 0.986452
methyl I-Chemical 0 0.99900776
ester I-Chemical 0 0.9983699
: O 0 0.005314206
a O 0 0.001431404
potential O 0 0.0008336393
protector O 0 0.0048682718
against O 0 0.0014067702
gentamicin B-Chemical 0 0.99991477
ototoxicity B-Disease 0 0.99988115
. O 0 0.006516109

The O 0 0.0071366094
nitric B-Chemical 0 0.9960747
oxide I-Chemical 0 0.98962176
( O 0 0.02063369
NO B-Chemical 0 0.99805486
) O 0 0.01275912
inhibitor O 0 0.0461114
nitro B-Chemical 0 0.9992418
- I-Chemical 0 0.80521065
L I-Chemical 0 0.99937266
- I-Chemical 0 0.931081
arginine I-Chemical 0 0.97431445
methyl I-Chemical 0 0.9995603
ester I-Chemical 0 0.9995254
( O 0 0.030282231
L B-Chemical 0 0.9994398
- I-Chemical 0 0.8628244
NAME I-Chemical 0 0.99996436
) O 0 0.0015215048
may O 0 0.000128573
act O 0 0.00011971474
as O 0 0.00012902323
an O 0 0.00015809668
otoprotectant O 0 0.0007825222
against O 0 6.2674866e-05
high B-Disease 0 0.00021023517
- I-Disease 0 0.0012722161
frequency I-Disease 0 0.00012254341
hearing I-Disease 0 0.12833726
loss I-Disease 0 0.00019844816
caused O 0 0.0001360742
by O 0 0.00024391724
gentamicin B-Chemical 0 0.999982
, O 0 0.0005342879
but O 0 0.00013292833
further O 0 7.42369e-05
studies O 0 0.00012031268
are O 0 5.989084e-05
needed O 0 5.211333e-05
to O 0 5.4619166e-05
confirm O 0 3.7016343e-05
this O 0 0.000118627795
. O 0 0.00016550388
Aminoglycoside B-Chemical 0 0.9941718
antibiotics O 0 0.034658253
are O 0 7.886969e-05
still O 0 7.933684e-05
widely O 0 9.64317e-05
used O 0 9.712893e-05
by O 0 0.0001263503
virtue O 0 0.00025428217
of O 0 0.00020235234
their O 0 0.00019691503
efficacy O 0 0.00031205954
and O 0 0.0004921814
low O 0 0.001121318
cost O 0 0.0023042986
. O 0 0.0029099097

Their O 0 0.013702926
ototoxicity B-Disease 0 0.99952257
is O 0 0.0014052436
a O 0 0.001350426
serious O 0 0.0016212635
health O 0 0.0012581504
problem O 0 0.0005339579
and O 0 0.00037698683
, O 0 0.0005016683
as O 0 0.00022856506
their O 0 0.00024628875
ototoxic B-Disease 0 0.98425585
mechanism O 0 0.0001208992
involves O 0 0.00012850435
the O 0 0.00015064984
production O 0 0.00035704873
of O 0 0.0005723512
NO B-Chemical 0 0.999271
, O 0 0.00045237943
we O 0 6.676088e-05
need O 0 8.338678e-05
to O 0 6.868122e-05
assess O 0 4.2191812e-05
the O 0 7.9851285e-05
use O 0 0.0001140954
of O 0 0.0002960065
NO B-Chemical 0 0.99763703
inhibitors O 0 0.0004634744
for O 0 0.00012058247
the O 0 0.00012897994
prevention O 0 0.0002976921
of O 0 0.0004565885
aminoglycoside B-Chemical 0 0.9996049
- O 0 0.024309507
induced O 0 0.0009028594
sensorineural B-Disease 0 0.99989855
hearing I-Disease 0 0.9469221
loss I-Disease 0 0.0053780596
. O 0 0.0029863776

In O 0 0.002380016
this O 0 0.0020546175
experimental O 0 0.0014691708
study O 0 0.0009791342
we O 0 0.00038525404
used O 0 0.0004676917
30 O 0 0.00050160225
Sprague O 0 0.022910986
- O 0 0.0020634632
Dawley O 0 0.0037417803
rats O 0 0.0005083823
, O 0 0.0004550536
27 O 0 0.00032190085
of O 0 0.0002497968
which O 0 0.00032812756
had O 0 0.0004629929
gentamicin B-Chemical 0 0.999843
instilled O 0 0.0040976736
into O 0 0.00029903106
the O 0 0.0004990752
middle O 0 0.002186755
ear O 0 0.005784386
. O 0 0.0032763926

The O 0 0.00475836
otoprotectant O 0 0.07004176
L B-Chemical 0 0.9945748
- I-Chemical 0 0.73444474
NAME I-Chemical 0 0.9996146
was O 0 0.0015657151
administered O 0 0.0016023169
topically O 0 0.012843412
to O 0 0.00066964555
12 O 0 0.000671899
/ O 0 0.0024763048
27 O 0 0.0017318967
animals O 0 0.0014852412
. O 0 0.003848462

Its O 0 0.011460944
effect O 0 0.0017029576
was O 0 0.0011401485
determined O 0 0.000603981
in O 0 0.00043470736
terms O 0 0.00028832097
of O 0 0.00031808627
attenuation O 0 0.00032756932
of O 0 0.00034327508
hearing B-Disease 0 0.102996655
loss I-Disease 0 0.0004046834
, O 0 0.0004181219
measured O 0 0.0002334506
by O 0 0.00019517567
shifts O 0 0.00027402904
in O 0 0.0002290699
the O 0 0.0002603753
auditory O 0 0.0015871888
brainstem O 0 0.0013833973
response O 0 0.00058903696
threshold O 0 0.0009965849
. O 0 0.00238112

L B-Chemical 0 0.99388325
- I-Chemical 0 0.87860477
NAME I-Chemical 0 0.9997274
reduced O 0 0.00862311
gentamicin B-Chemical 0 0.9999497
- O 0 0.030086642
induced O 0 0.0005248755
hearing B-Disease 0 0.18651588
loss I-Disease 0 0.00038298772
in O 0 0.00017720732
the O 0 0.00013746052
high O 0 0.00024384912
- O 0 0.0008659834
frequency O 0 0.00012818849
range O 0 0.00017427244
, O 0 0.00030457872
but O 0 0.0002024977
gave O 0 0.00019075006
no O 0 0.0001559752
protection O 0 0.00023377802
in O 0 0.00022356253
the O 0 0.0002464757
middle O 0 0.0009292211
or O 0 0.00046197075
low O 0 0.0009893167
frequencies O 0 0.0012221042
. O 0 0.002734707

Safety O 0 0.004321876
profile O 0 0.0013453863
of O 0 0.0012542532
a O 0 0.001980925
nicotine B-Chemical 0 0.9987212
lozenge O 0 0.97245336
compared O 0 0.00024762753
with O 0 0.00023752406
that O 0 0.00015647021
of O 0 0.00037211317
nicotine B-Chemical 0 0.9993807
gum O 0 0.8839667
in O 0 0.00020589976
adult O 0 0.00028370583
smokers O 0 0.0005452098
with O 0 0.00013191941
underlying O 0 0.00017162372
medical O 0 0.00037942835
conditions O 0 0.00015520405
: O 0 0.0003363874
a O 0 0.00020693266
12 O 0 0.000113771544
- O 0 0.0004548816
week O 0 0.00010765833
, O 0 0.00034038586
randomized O 0 0.0006824436
, O 0 0.0006709199
open O 0 0.00077440124
- O 0 0.0032508841
label O 0 0.0027532286
study O 0 0.0022402531
. O 0 0.0032292998

BACKGROUND O 0 0.03560886
: O 0 0.016703466
Nicotine B-Chemical 0 0.99975497
polacrilex O 0 0.9973889
lozenges O 0 0.8784925
deliver O 0 0.0004530864
25 O 0 0.0005450841
% O 0 0.0005302944
to O 0 0.00020481818
27 O 0 0.0003231218
% O 0 0.00043016794
more O 0 0.00037689216
nicotine B-Chemical 0 0.897074
compared O 0 0.00014971416
with O 0 0.00019594056
equivalent O 0 0.00021653186
doses O 0 0.00072468177
of O 0 0.00079364027
nicotine B-Chemical 0 0.9990245
polacrilex O 0 0.9985348
gum O 0 0.9407704
. O 0 0.0042415825

The O 0 0.0022090382
increased O 0 0.0031339582
nicotine B-Chemical 0 0.98505396
exposure O 0 0.0011036595
from O 0 0.0004828311
the O 0 0.00043595707
lozenge O 0 0.56051105
has O 0 0.00020150116
raised O 0 0.00022366316
questions O 0 0.00023959661
about O 0 0.00021713991
the O 0 0.00015305776
relative O 0 0.00015057372
safety O 0 0.00027931557
of O 0 0.0003984003
the O 0 0.00059003854
lozenge O 0 0.86555046
and O 0 0.0020102705
gum O 0 0.68328047
. O 0 0.004597568

OBJECTIVE O 0 0.0181973
: O 0 0.0031623484
The O 0 0.0005646379
objective O 0 0.0005776525
of O 0 0.0005147417
this O 0 0.000416446
study O 0 0.0003455998
was O 0 0.00018202959
to O 0 0.00011278888
compare O 0 5.7383495e-05
the O 0 8.034487e-05
safety O 0 0.00010049393
profiles O 0 7.887277e-05
of O 0 0.00011426645
the O 0 9.939621e-05
4 O 0 0.0001277303
- O 0 0.0015811207
mg O 0 0.040718246
nicotine B-Chemical 0 0.99743503
lozenge O 0 0.92242837
and O 0 0.00016666693
4 O 0 0.00013681791
- O 0 0.0016862137
mg O 0 0.039607048
nicotine B-Chemical 0 0.99536884
gum O 0 0.51228946
in O 0 0.0002313412
smokers O 0 0.0007562292
with O 0 0.00025526964
selected O 0 0.00028332262
label O 0 0.0016259033
- O 0 0.0040020095
restricted O 0 0.0010030722
diseases O 0 0.168994
. O 0 0.0035806124

METHODS O 0 0.0047524157
: O 0 0.003597918
This O 0 0.0015818261
was O 0 0.000834889
a O 0 0.0010675208
multicenter O 0 0.010523434
, O 0 0.000966933
randomized O 0 0.0010452541
, O 0 0.00058806455
open O 0 0.00045655167
- O 0 0.0017166276
label O 0 0.00060862006
study O 0 0.00021454276
in O 0 0.00014481916
adult O 0 0.00024852448
smokers O 0 0.0005731704
with O 0 0.00021600853
heart B-Disease 0 0.089008786
disease I-Disease 0 0.48353365
, O 0 0.0009437253
hypertension B-Disease 2 0.99998426
not O 0 0.00017083385
controlled O 0 0.00019539989
by O 0 0.00017431597
medication O 0 0.0012484821
, O 0 0.00046563672
and O 0 0.00041477667
/ O 0 0.0026674059
or O 0 0.0012251548
diabetes B-Disease 0 0.9998349
mellitus I-Disease 0 0.9999206
. O 0 0.0067802174

Patients O 0 0.004563986
were O 0 0.0018333904
randomized O 0 0.002417613
in O 0 0.0008952249
a O 0 0.0010090614
1 O 0 0.0006518569
: O 0 0.00074177195
1 O 0 0.00031610252
ratio O 0 0.00024429127
to O 0 0.0001625043
receive O 0 0.00015579938
the O 0 0.0001382123
4 O 0 0.00019304449
- O 0 0.0016174028
mg O 0 0.03364969
nicotine B-Chemical 0 0.99652654
lozenge O 0 0.9074005
or O 0 0.00034644612
4 O 0 0.0004124695
- O 0 0.0035269507
mg O 0 0.07911909
nicotine B-Chemical 0 0.9952421
gum O 0 0.81770766
. O 0 0.0044423467

Safety O 0 0.0047242353
assessments O 0 0.0015324055
were O 0 0.00085505936
made O 0 0.00061725423
at O 0 0.0004028568
baseline O 0 0.0003853613
and O 0 0.00038548236
at O 0 0.00028041677
2 O 0 0.0003788923
, O 0 0.0004936149
4 O 0 0.00024783023
, O 0 0.00040111208
6 O 0 0.00019069204
, O 0 0.0003440252
and O 0 0.00020583776
12 O 0 0.00013550864
weeks O 0 0.000102304344
after O 0 0.00012673474
the O 0 0.00023080339
start O 0 0.00028084702
of O 0 0.00071379973
product O 0 0.0012353595
use O 0 0.0016672591
. O 0 0.0034574957

RESULTS O 0 0.0042060167
: O 0 0.0028313352
Nine O 0 0.0014521269
hundred O 0 0.00096431974
one O 0 0.0005186425
patients O 0 0.0006995801
were O 0 0.00031500927
randomized O 0 0.0005344776
to O 0 0.00018515493
treatment O 0 0.0002232939
, O 0 0.00039792983
447 O 0 0.00083232124
who O 0 0.00022756265
received O 0 0.0001388339
the O 0 0.000155252
lozenge O 0 0.47936204
and O 0 0.00024895513
454 O 0 0.00047823138
who O 0 0.0002704387
received O 0 0.00018711909
the O 0 0.00023862656
gum O 0 0.0760263
( O 0 0.0009356889
safety O 0 0.0006754781
population O 0 0.0013602698
) O 0 0.0035466836
. O 0 0.003086154

The O 0 0.0032501689
majority O 0 0.002742169
were O 0 0.0026257182
women O 0 0.0050485437
( O 0 0.0036774778
52 O 0 0.0028919976
. O 0 0.0020081534
7 O 0 0.0021048347
% O 0 0.0050042905
) O 0 0.008235727
. O 0 0.008167536

Patients O 0 0.004703769
' O 0 0.0029745968
mean O 0 0.0010908102
age O 0 0.0012751265
was O 0 0.0006624498
53 O 0 0.0007921329
. O 0 0.0003641069
9 O 0 0.00025282594
years O 0 0.00029672642
, O 0 0.00032024452
their O 0 0.00015463121
mean O 0 0.00014855889
weight O 0 0.00028249537
was O 0 0.00019347866
193 O 0 0.0005599454
. O 0 0.00016297912
9 O 0 0.00013187212
pounds O 0 0.00030695836
, O 0 0.00026028496
and O 0 0.00016246957
they O 0 0.00015969783
smoked O 0 0.0006945053
a O 0 0.00022341506
mean O 0 0.00013407617
of O 0 0.00020449208
25 O 0 0.00030416524
. O 0 0.00020724008
2 O 0 0.00025348293
cigarettes O 0 0.0005811099
per O 0 0.00025742897
day O 0 0.00024367828
at O 0 0.00043862598
baseline O 0 0.0010304624
. O 0 0.0024084155

Five O 0 0.0034560252
hundred O 0 0.0026886717
fifty O 0 0.0022736832
- O 0 0.0030039714
three O 0 0.00041053924
patients O 0 0.0009582571
, O 0 0.00085279334
264 O 0 0.0012679591
taking O 0 0.00043649809
the O 0 0.00029538205
lozenge O 0 0.6032887
and O 0 0.00031741313
289 O 0 0.0008513165
taking O 0 0.00024656078
the O 0 0.00017117723
gum O 0 0.13141981
, O 0 0.0003676551
used O 0 0.00012579131
the O 0 0.00011186643
study O 0 0.00014364507
product O 0 0.00012406672
for O 0 8.776222e-05
> O 0 0.00027556875
or O 0 0.00011268783
= O 0 0.00029562094
4 O 0 7.155781e-05
days O 0 4.8722108e-05
per O 0 6.768035e-05
week O 0 5.2268864e-05
during O 0 6.5260385e-05
the O 0 9.063206e-05
first O 0 9.461794e-05
2 O 0 0.00018675068
weeks O 0 0.00013987755
( O 0 0.00056866993
evaluable O 0 0.000989535
population O 0 0.0011137293
) O 0 0.0031102977
. O 0 0.0030945954

The O 0 0.0030593637
nicotine B-Chemical 0 0.9971712
lozenge O 0 0.99217355
and O 0 0.0021095355
nicotine B-Chemical 0 0.9987134
gum O 0 0.7724087
were O 0 0.00035269352
equally O 0 0.0002665531
well O 0 0.00022416445
tolerated O 0 0.00054040883
, O 0 0.0004418967
despite O 0 0.00027570676
increased O 0 0.0007861834
nicotine B-Chemical 0 0.99206287
exposure O 0 0.00073177216
from O 0 0.00059882714
the O 0 0.001020233
lozenge O 0 0.8264375
. O 0 0.0037162176

The O 0 0.0020206342
incidence O 0 0.0025123965
of O 0 0.0011993725
adverse O 0 0.0024887044
events O 0 0.00082056917
in O 0 0.00034493965
the O 0 0.0002303494
2 O 0 0.0002378506
groups O 0 0.00022309025
was O 0 0.00013630875
similar O 0 8.4557956e-05
during O 0 7.9602076e-05
the O 0 7.987727e-05
first O 0 6.1056235e-05
2 O 0 9.075911e-05
weeks O 0 4.6868954e-05
of O 0 9.450063e-05
product O 0 0.000118777105
use O 0 0.00010355181
( O 0 0.00021305424
evaluation O 0 0.00012441266
population O 0 0.00020563081
: O 0 0.00035202978
55 O 0 0.00020287221
. O 0 0.00012606062
3 O 0 0.0001215296
% O 0 0.0003875064
lozenge O 0 0.56786317
, O 0 0.00043264503
54 O 0 0.00030838803
. O 0 0.00014362356
7 O 0 0.00011849993
% O 0 0.0003536661
gum O 0 0.11822034
) O 0 0.000759946
, O 0 0.0003525846
as O 0 0.00014992601
well O 0 0.00012879705
as O 0 0.00012435798
during O 0 8.6366446e-05
the O 0 8.945489e-05
entire O 0 8.760502e-05
study O 0 0.00013736592
( O 0 0.00019417205
safety O 0 0.000135512
population O 0 0.00022337186
: O 0 0.00040670158
63 O 0 0.0003010064
. O 0 0.00016328118
8 O 0 0.00016517218
% O 0 0.00034516797
and O 0 0.00026161576
58 O 0 0.00047746912
. O 0 0.0003087982
6 O 0 0.00031020623
% O 0 0.0009030363
, O 0 0.0013887812
respectively O 0 0.0022590335
) O 0 0.0044945935
. O 0 0.0040283394

Stratification O 0 0.0146237
of O 0 0.0024137914
patients O 0 0.0024383652
by O 0 0.0009134023
sex O 0 0.0014764188
, O 0 0.001035663
age O 0 0.0006934065
, O 0 0.00053779513
extent O 0 0.00023110241
of O 0 0.00027466146
concurrent O 0 0.0005102793
smoking O 0 0.008451979
, O 0 0.0003498541
extent O 0 0.00013842729
of O 0 0.00016228593
product O 0 0.00015761322
use O 0 0.00011541838
, O 0 0.00023025498
and O 0 0.00013515221
severity O 0 0.00033251327
of O 0 0.00012478526
adverse O 0 0.00054056104
events O 0 0.00015933081
revealed O 0 8.565044e-05
no O 0 0.00011801695
clinically O 0 0.00051594985
significant O 0 0.00013664516
differences O 0 0.0001283962
between O 0 0.0002004281
the O 0 0.0004425195
lozenge O 0 0.8456694
and O 0 0.0016709436
gum O 0 0.67941904
. O 0 0.0040538046

The O 0 0.0020676563
most O 0 0.001970499
common O 0 0.0013084244
adverse O 0 0.0023309716
events O 0 0.0011122497
were O 0 0.00074378896
nausea B-Disease 0 0.9952376
( O 0 0.0010243162
17 O 0 0.00048761794
. O 0 0.00027360453
2 O 0 0.0002765966
% O 0 0.0004348603
and O 0 0.00026779308
16 O 0 0.0003089978
. O 0 0.0002453012
1 O 0 0.0002735148
% O 0 0.0004514847
; O 0 0.00048099976
95 O 0 0.0005050768
% O 0 0.00054546096
CI O 0 0.005222499
, O 0 0.00068640587
- O 0 0.0013273249
3 O 0 0.000186421
. O 0 0.00015978281
7 O 0 0.000115844414
to O 0 0.000111652545
6 O 0 0.00011765077
. O 0 0.00015420139
0 O 0 0.00024772433
) O 0 0.000527946
, O 0 0.00064326974
hiccups B-Disease 0 0.80989575
( O 0 0.00053709303
10 O 0 0.00021007888
. O 0 0.00016002539
7 O 0 0.00013233315
% O 0 0.00028443194
and O 0 0.00017460741
6 O 0 0.00013634996
. O 0 0.000156138
6 O 0 0.00013841926
% O 0 0.00035440712
; O 0 0.0004190948
95 O 0 0.00046070738
% O 0 0.00050185167
CI O 0 0.0043373876
, O 0 0.00045975298
0 O 0 0.0002857121
. O 0 0.00017275529
5 O 0 0.00013349764
to O 0 0.00011058924
7 O 0 0.00011863493
. O 0 0.00013725017
8 O 0 0.00015262145
) O 0 0.00039919274
, O 0 0.00038348092
and O 0 0.00036319252
headache B-Disease 0 0.98760194
( O 0 0.0004537972
8 O 0 0.00017010466
. O 0 0.00014688061
7 O 0 0.00012740078
% O 0 0.0002846886
and O 0 0.00018517647
9 O 0 0.00017182971
. O 0 0.00017556318
9 O 0 0.00017815932
% O 0 0.0004030911
; O 0 0.0004990688
95 O 0 0.00062755006
% O 0 0.0010454775
Cl O 0 0.9995809
, O 0 0.0014755452
- O 0 0.002326961
5 O 0 0.0003353124
. O 0 0.0003084645
0 O 0 0.00042104637
to O 0 0.00035570844
2 O 0 0.0006053469
. O 0 0.00068922585
6 O 0 0.00089588703
) O 0 0.003166581
. O 0 0.0036330393

Serious O 0 0.008278278
adverse O 0 0.005861353
events O 0 0.002193474
were O 0 0.0009864442
reported O 0 0.0007985918
in O 0 0.0005604546
11 O 0 0.000583611
and O 0 0.00049440766
13 O 0 0.00058821816
patients O 0 0.0008028449
in O 0 0.0005222335
the O 0 0.00061710534
respective O 0 0.00086655625
groups O 0 0.0023989207
. O 0 0.0039506946

Fewer O 0 0.008157762
than O 0 0.0018046827
6 O 0 0.0010071838
% O 0 0.0014936279
of O 0 0.00071780564
patients O 0 0.0009168971
in O 0 0.00034013967
either O 0 0.00028560832
group O 0 0.0003826279
were O 0 0.00018821833
considered O 0 0.00016048644
by O 0 0.00013915014
the O 0 0.00013433045
investigator O 0 0.0003448183
to O 0 0.00011077553
have O 0 0.00011328644
a O 0 0.00022602196
worsening O 0 0.0014694568
of O 0 0.00016220487
their O 0 0.00015347163
overall O 0 0.0002479791
disease O 0 0.05636723
condition O 0 0.0006343651
during O 0 0.00036167313
the O 0 0.0006201648
study O 0 0.0014755769
. O 0 0.002383755

The O 0 0.0020569703
majority O 0 0.0015202087
of O 0 0.0015136906
patients O 0 0.001991392
( O 0 0.001389469
> O 0 0.0012408451
60 O 0 0.0005880452
% O 0 0.0007766492
) O 0 0.00070872076
experienced O 0 0.00034654303
no O 0 0.00026442055
change O 0 0.00030232852
in O 0 0.00031098293
their O 0 0.00043005685
disease O 0 0.023830634
status O 0 0.0006431591
from O 0 0.00075539085
baseline O 0 0.0012967024
. O 0 0.0027048537

CONCLUSION O 0 0.015142315
: O 0 0.0035287833
The O 0 0.0007512841
4 O 0 0.00081941346
- O 0 0.0038968492
mg O 0 0.05855215
nicotine B-Chemical 0 0.9971635
lozenge O 0 0.9310088
and O 0 0.00035565943
4 O 0 0.0002448166
- O 0 0.0020208238
mg O 0 0.03262995
nicotine B-Chemical 0 0.9930184
gum O 0 0.30243587
had O 0 0.00013639977
comparable O 0 6.766737e-05
safety O 0 0.00010347245
profiles O 0 8.797219e-05
in O 0 0.00011485897
these O 0 0.00014702954
patients O 0 0.0003751917
with O 0 0.0002836315
label O 0 0.0015266722
- O 0 0.0028399795
restricted O 0 0.0004863066
medical O 0 0.0019278371
conditions O 0 0.0015333463
. O 0 0.00286007

Pharmacological O 0 0.025790326
modulation O 0 0.0015800806
of O 0 0.0018049215
pain B-Disease 0 0.33149272
- O 0 0.007059064
related O 0 0.00038905398
brain O 0 0.0010034546
activity O 0 0.00022125452
during O 0 0.00022107843
normal O 0 0.0004973749
and O 0 0.00036142685
central O 0 0.00059940986
sensitization O 0 0.0006388273
states O 0 0.00084173784
in O 0 0.0009281699
humans O 0 0.0023434046
. O 0 0.0031393855

Abnormal O 0 0.007484537
processing O 0 0.0015021136
of O 0 0.0013200458
somatosensory O 0 0.003292931
inputs O 0 0.00054254394
in O 0 0.00035401506
the O 0 0.00028325885
central O 0 0.00052699976
nervous O 0 0.0015592151
system O 0 0.0002518494
( O 0 0.000364715
central O 0 0.00025558594
sensitization O 0 0.00022120558
) O 0 0.0002832313
is O 0 7.5111064e-05
the O 0 6.565695e-05
mechanism O 0 6.122058e-05
accounting O 0 0.00014655196
for O 0 7.126104e-05
the O 0 8.114619e-05
enhanced O 0 0.00013754192
pain B-Disease 0 0.008071072
sensitivity O 0 0.00022633163
in O 0 0.00014208948
the O 0 0.00016033194
skin O 0 0.0011466962
surrounding O 0 0.0003488027
tissue B-Disease 0 0.019539742
injury I-Disease 0 0.6634869
( O 0 0.0013100409
secondary B-Disease 0 0.0033924584
hyperalgesia I-Disease 0 0.9914159
) O 0 0.0044442173
. O 0 0.0027206382

Secondary B-Disease 0 0.009394383
hyperalgesia I-Disease 0 0.94190377
shares O 0 0.002258493
clinical O 0 0.002233612
characteristics O 0 0.0006264691
with O 0 0.0009644769
neurogenic B-Disease 0 0.9788598
hyperalgesia I-Disease 0 0.9892463
in O 0 0.00061776856
patients O 0 0.0013132992
with O 0 0.0012788457
neuropathic B-Disease 0 0.99868566
pain I-Disease 0 0.9379323
. O 0 0.0036753945

Abnormal O 0 0.010789051
brain O 0 0.0034601104
responses O 0 0.0008635679
to O 0 0.00054203876
somatosensory O 0 0.0015336674
stimuli O 0 0.00044882591
have O 0 0.00022613579
been O 0 0.00019700085
found O 0 0.00018682033
in O 0 0.00017972082
patients O 0 0.00036186454
with O 0 0.00021425329
hyperalgesia B-Disease 0 0.19073409
as O 0 0.00015911234
well O 0 0.00014079311
as O 0 0.00016085073
in O 0 0.0001841568
normal O 0 0.00040969305
subjects O 0 0.0004116838
during O 0 0.00022412193
experimental O 0 0.00049436965
central O 0 0.001170453
sensitization O 0 0.0016749686
. O 0 0.0022741896

The O 0 0.0016170879
aim O 0 0.0010333586
of O 0 0.0011139058
this O 0 0.0008092021
study O 0 0.00060232077
was O 0 0.0002908488
to O 0 0.00016240358
assess O 0 7.82953e-05
the O 0 0.00010693925
effects O 0 0.00014869789
of O 0 0.00034995447
gabapentin B-Chemical 0 0.9999473
, O 0 0.00047974242
a O 0 0.00025176562
drug O 0 0.0021872784
effective O 0 0.000116265175
in O 0 0.00016965566
neuropathic B-Disease 0 0.99928766
pain I-Disease 0 0.89671516
patients O 0 0.00038381593
, O 0 0.00019104345
on O 0 7.525933e-05
brain O 0 0.00031832198
processing O 0 9.025362e-05
of O 0 0.0001338696
nociceptive O 0 0.00020234809
information O 0 0.00012739653
in O 0 0.00016480312
normal O 0 0.00039815615
and O 0 0.00034715366
central O 0 0.0007406072
sensitization O 0 0.0009633684
states O 0 0.001648257
. O 0 0.0023942955

Using O 0 0.0014109309
functional O 0 0.001074852
magnetic O 0 0.0017346183
resonance O 0 0.0018865445
imaging O 0 0.000724234
( O 0 0.0007959233
fMRI O 0 0.0012929147
) O 0 0.0005982461
in O 0 0.00021890685
normal O 0 0.000371212
volunteers O 0 0.00047875638
, O 0 0.00026239187
we O 0 7.857999e-05
studied O 0 0.00021476544
the O 0 0.00020705661
gabapentin B-Chemical 0 0.999949
- O 0 0.002795586
induced O 0 0.00010433752
modulation O 0 8.8994486e-05
of O 0 0.00015157547
brain O 0 0.000536474
activity O 0 6.3157e-05
in O 0 7.0041875e-05
response O 0 7.268107e-05
to O 0 6.563766e-05
nociceptive O 0 0.00010688246
mechanical O 0 8.024671e-05
stimulation O 0 5.6230092e-05
of O 0 0.00012909684
normal O 0 0.00039704217
skin O 0 0.0009976887
and O 0 0.00040109755
capsaicin B-Chemical 0 0.99884295
- O 0 0.009807348
induced O 0 0.00073029654
secondary B-Disease 0 0.01024881
hyperalgesia I-Disease 0 0.9970898
. O 0 0.0036129185

The O 0 0.0021299133
dose O 0 0.0030721524
of O 0 0.0023363184
gabapentin B-Chemical 0 0.9996338
was O 0 0.00094116485
1 O 0 0.0007059123
, O 0 0.0008829541
800 O 0 0.0012985348
mg O 0 0.00440206
per O 0 0.00053325837
os O 0 0.004999627
, O 0 0.00085115386
in O 0 0.00055296463
a O 0 0.0010269607
single O 0 0.0008688996
administration O 0 0.0025672193
. O 0 0.0032069266

We O 0 0.00265923
found O 0 0.0018039562
that O 0 0.0011016898
( O 0 0.0018389297
i O 0 0.001781155
) O 0 0.0036357276
gabapentin B-Chemical 0 0.999793
reduced O 0 0.0004740194
the O 0 0.00021915809
activations O 0 0.00054095074
in O 0 0.00015150843
the O 0 0.00013738974
bilateral O 0 0.0017392152
operculoinsular O 0 0.0014797997
cortex O 0 0.0050053783
, O 0 0.00021521455
independently O 0 7.06547e-05
of O 0 0.00010773987
the O 0 8.758138e-05
presence O 0 9.9854486e-05
of O 0 0.00013269074
central O 0 0.00022656654
sensitization O 0 0.00019089013
; O 0 0.00024609553
( O 0 0.00018989189
ii O 0 0.00018821814
) O 0 0.0010720764
gabapentin B-Chemical 0 0.99991286
reduced O 0 0.00016494728
the O 0 8.42869e-05
activation O 0 9.656246e-05
in O 0 9.141376e-05
the O 0 9.4091694e-05
brainstem O 0 0.0011403734
, O 0 0.00018017051
only O 0 9.0239075e-05
during O 0 6.361184e-05
central O 0 0.0001542548
sensitization O 0 0.00015251507
; O 0 0.00021627433
( O 0 0.00017704909
iii O 0 0.00020818181
) O 0 0.00092622195
gabapentin B-Chemical 0 0.99988747
suppressed O 0 0.00016249376
stimulus O 0 0.00027206927
- O 0 0.0018389288
induced O 0 0.00014324389
deactivations O 0 0.052011374
, O 0 0.0002596717
only O 0 0.000103026156
during O 0 6.794808e-05
central O 0 0.00016009074
sensitization O 0 0.00015290781
; O 0 0.00018581444
this O 0 8.6402855e-05
effect O 0 8.8062e-05
was O 0 0.000120015444
more O 0 0.00017049033
robust O 0 9.269703e-05
than O 0 0.00012748379
the O 0 0.00014829577
effect O 0 0.00024838565
on O 0 0.00040349772
brain O 0 0.0023279695
activation O 0 0.0013991426
. O 0 0.0025059078

The O 0 0.0022667763
observed O 0 0.0020135257
drug O 0 0.029112382
- O 0 0.005359258
induced O 0 0.0006199231
effects O 0 0.00054190087
were O 0 0.00043055543
not O 0 0.00031878875
due O 0 0.00023912032
to O 0 0.0002635221
changes O 0 0.00033376843
in O 0 0.0003012791
the O 0 0.00033137525
baseline O 0 0.00053733273
fMRI O 0 0.0021144382
signal O 0 0.0009530939
. O 0 0.002563781

These O 0 0.0015911064
findings O 0 0.0014458692
indicate O 0 0.00061637
that O 0 0.0008642313
gabapentin B-Chemical 0 0.99983406
has O 0 0.0003543213
a O 0 0.00046290772
measurable O 0 0.00032447913
antinociceptive O 0 0.0042887377
effect O 0 0.0001262017
and O 0 0.00015695272
a O 0 0.00019719404
stronger O 0 0.00015190436
antihyperalgesic O 0 0.026986128
effect O 0 0.00010401774
most O 0 0.00016264999
evident O 0 0.00011203894
in O 0 8.8375455e-05
the O 0 8.136601e-05
brain O 0 0.00033544554
areas O 0 0.00012126602
undergoing O 0 8.23428e-05
deactivation O 0 0.00013631291
, O 0 0.000116958145
thus O 0 6.2878826e-05
supporting O 0 5.610374e-05
the O 0 6.614216e-05
concept O 0 0.00013467147
that O 0 0.0001159116
gabapentin B-Chemical 0 0.9999441
is O 0 0.00010413286
more O 0 0.0001407562
effective O 0 8.7542314e-05
in O 0 8.765608e-05
modulating O 0 6.675146e-05
nociceptive O 0 0.00022036606
transmission O 0 0.000114567796
when O 0 0.00012652848
central O 0 0.00044330044
sensitization O 0 0.00052667706
is O 0 0.0004858625
present O 0 0.000934788
. O 0 0.002430226

Investigation O 0 0.008253534
of O 0 0.0035489271
mitochondrial O 0 0.018675111
involvement O 0 0.0018975555
in O 0 0.00076243473
the O 0 0.00048346707
experimental O 0 0.0005486005
model O 0 0.0005764032
of O 0 0.0014659927
epilepsy B-Disease 0 0.9999577
induced O 0 0.0019777385
by O 0 0.003143078
pilocarpine B-Chemical 0 0.99990904
. O 0 0.0056322063

Mitochondrial B-Disease 0 0.99407154
abnormalities I-Disease 0 0.88640136
have O 0 0.0013273597
been O 0 0.00071349565
associated O 0 0.0005041989
with O 0 0.0003405327
several O 0 0.0001759518
aspects O 0 0.00022285576
of O 0 0.00039207953
epileptogenesis O 0 0.65752614
, O 0 0.00049425894
such O 0 0.00018104551
as O 0 0.00020038037
energy O 0 0.00045578272
generation O 0 0.00021508553
, O 0 0.0003399798
control O 0 0.00019184974
of O 0 0.00027239963
cell O 0 0.0008671708
death B-Disease 0 0.973138
, O 0 0.0021510506
neurotransmitter O 0 0.30282184
synthesis O 0 0.0012907977
, O 0 0.0008207892
and O 0 0.0004983931
free O 0 0.0011194642
radical O 0 0.1260246
( O 0 0.0021118603
FR O 0 0.21191648
) O 0 0.0030468337
production O 0 0.0026410948
. O 0 0.0035744642

Increased O 0 0.006530346
production O 0 0.0037355744
of O 0 0.0026265825
FRs O 0 0.0100413365
may O 0 0.0009971643
cause O 0 0.001474197
mtDNA O 0 0.064324945
damage O 0 0.078335665
leading O 0 0.00043171112
to O 0 0.00022464627
decreased O 0 0.00039967787
activities O 0 0.0002296205
of O 0 0.00040019563
oxidative O 0 0.10174206
phosphorylation O 0 0.00034117303
complexes O 0 0.00044103488
containing O 0 0.00051036204
mtDNA O 0 0.02165307
- O 0 0.004361601
encoded O 0 0.0005581035
subunits O 0 0.0019199518
. O 0 0.0034648378

In O 0 0.0022090464
this O 0 0.0020575097
study O 0 0.0015568036
, O 0 0.0012708899
we O 0 0.00031000286
investigated O 0 0.00031776045
whether O 0 0.00014665151
increased O 0 0.00043291447
generation O 0 0.00029077093
of O 0 0.00035344547
FR O 0 0.15210934
during O 0 0.00017228286
status B-Disease 0 0.00032663625
epilepticus I-Disease 0 0.99951684
would O 0 0.00012511207
be O 0 9.6595424e-05
sufficient O 0 6.846203e-05
to O 0 0.00010206484
provoke O 0 0.00033602762
abnormalities O 0 0.017698491
in O 0 0.00018900656
mtDNA O 0 0.004655152
and O 0 0.0001461307
in O 0 9.828929e-05
the O 0 8.0199046e-05
expression O 0 9.564183e-05
and O 0 0.00014634056
activity O 0 0.0001364203
of O 0 0.00054830016
cytochrome O 0 0.9997619
c O 0 0.9017864
oxidase O 0 0.9999074
( O 0 0.01025676
CCO O 0 0.9945215
) O 0 0.0007038491
, O 0 0.00029010582
complex O 0 0.00019073804
IV O 0 0.060099788
of O 0 0.00017469833
the O 0 0.00013137147
respiratory O 0 0.0007676668
chain O 0 0.00013142446
, O 0 0.00024794604
in O 0 0.00011324172
the O 0 0.00011289229
chronic O 0 0.0017017475
phase O 0 0.00039173997
of O 0 0.0002501214
the O 0 0.00031555328
pilocarpine B-Chemical 0 0.99996185
model O 0 0.0003379928
of O 0 0.0005621743
temporal B-Disease 0 0.2042481
lobe I-Disease 0 0.985113
epilepsy I-Disease 0 0.99997556
. O 0 0.003990686

DNA O 0 0.011408574
analysis O 0 0.0019322664
revealed O 0 0.00093147357
low O 0 0.0010276292
amounts O 0 0.0006056239
of O 0 0.00061457383
a O 0 0.0006238293
4 O 0 0.00027411655
. O 0 0.00022242738
8 O 0 0.00018841657
kb O 0 0.00028725422
mtDNA O 0 0.0016026284
deletion O 0 0.00017953038
but O 0 0.00019202674
with O 0 0.00014883422
no O 0 0.000114017625
differences O 0 9.6713586e-05
in O 0 0.00011542718
frequency O 0 0.00011772561
or O 0 0.000124257
quantity O 0 0.00012218485
in O 0 0.00018417313
the O 0 0.00020368588
control O 0 0.00034218904
and O 0 0.00054123846
experimental O 0 0.0009099633
groups O 0 0.0018541637
. O 0 0.0029508206

We O 0 0.0030952492
did O 0 0.002222896
not O 0 0.0011080877
find O 0 0.0007727584
abnormalities O 0 0.010565656
in O 0 0.00044191862
the O 0 0.00026045798
expression O 0 0.00021782212
and O 0 0.00022714188
distribution O 0 0.0001240601
of O 0 0.0002629609
an O 0 0.00039168302
mtDNA O 0 0.009219157
- O 0 0.001977629
encoded O 0 0.00011966611
subunit O 0 0.00036259092
of O 0 0.0005916012
CCO O 0 0.9940187
( O 0 0.0018720665
CCO O 0 0.9897333
- O 0 0.009148249
I O 0 0.017109124
) O 0 0.00059465907
or O 0 0.00014217269
a O 0 0.00019671574
relative O 0 0.00011138193
decrease O 0 0.00021366272
in O 0 0.00028591458
CCO O 0 0.9873684
- O 0 0.0061720647
I O 0 0.0036624451
when O 0 0.00010749399
compared O 0 0.0001144442
with O 0 0.00020899363
nuclear O 0 0.0005182501
- O 0 0.0016991736
encoded O 0 0.00012713393
subunits O 0 0.00041155564
( O 0 0.0015782883
CCO O 0 0.9876936
- O 0 0.018398512
IV O 0 0.28972402
and O 0 0.0014020089
SDH O 0 0.98041874
- O 0 0.047584906
fp O 0 0.85158914
) O 0 0.0057083042
. O 0 0.0038158477

No O 0 0.009156942
abnormality O 0 0.026083697
in O 0 0.0045469017
CCO O 0 0.9088847
activity O 0 0.0017018853
was O 0 0.001661204
observed O 0 0.00161978
through O 0 0.0023878715
histochemistry O 0 0.006023873
. O 0 0.0062751956

Although O 0 0.0018414003
evidences O 0 0.0020365124
of O 0 0.0026849
mitochondrial B-Disease 0 0.90314037
abnormalities I-Disease 0 0.9382435
were O 0 0.000493478
found O 0 0.00027900923
in O 0 0.00019908667
previously O 0 0.00019925377
published O 0 0.00015727406
studies O 0 0.00020360046
, O 0 0.0002704281
our O 0 0.00012068416
results O 0 0.00011934772
do O 0 0.00013466415
not O 0 0.00010974902
suggest O 0 7.1851835e-05
that O 0 0.000101058795
the O 0 0.0001437026
FRs O 0 0.0011321149
, O 0 0.00020226729
generated O 0 4.882294e-05
during O 0 6.9206784e-05
the O 0 9.828516e-05
acute O 0 0.0031149185
phase O 0 0.00038306147
, O 0 0.00028770423
determined O 0 0.00010864176
important O 0 0.000114428694
abnormalities O 0 0.007989143
in O 0 0.0002458254
mtDNA O 0 0.0062740957
, O 0 0.0004334391
in O 0 0.00018149994
expression O 0 0.000219104
of O 0 0.0006004597
CCO O 0 0.99497104
- O 0 0.02142508
I O 0 0.033445142
, O 0 0.0011832695
and O 0 0.0007813341
in O 0 0.0011845523
CCO O 0 0.90425926
activity O 0 0.0016145918
. O 0 0.0031859085

Adverse O 0 0.0033805873
effect O 0 0.0011880281
of O 0 0.0012738759
the O 0 0.0011338487
calcium B-Chemical 0 0.9964604
channel O 0 0.07247306
blocker O 0 0.9969891
nitrendipine B-Chemical 0 0.9999988
on O 0 0.0016666347
nephrosclerosis B-Disease 0 0.9999969
in O 0 0.00073731923
rats O 0 0.001131294
with O 0 0.001593835
renovascular B-Disease 0 0.9999721
hypertension I-Disease 2 0.9999913
. O 0 0.005894029

The O 0 0.0017834929
effect O 0 0.0012773033
of O 0 0.0012395012
a O 0 0.0010779441
6 O 0 0.00045753678
- O 0 0.0012004771
week O 0 0.00016853941
treatment O 0 0.00018570694
with O 0 0.0002079382
the O 0 0.00024747275
calcium B-Chemical 0 0.9959021
channel O 0 0.033367172
blocker O 0 0.9952118
nitrendipine B-Chemical 0 0.9999995
or O 0 0.0004009179
the O 0 0.0003129549
angiotensin B-Chemical 0 0.9999927
converting O 0 0.0051034093
enzyme O 0 0.004410572
inhibitor O 0 0.018309588
enalapril B-Chemical 1 0.9999982
on O 0 0.00011960338
blood O 0 0.0037578407
pressure O 0 0.02418953
, O 0 0.000666304
albuminuria B-Disease 2 0.9999831
, O 0 0.0008949797
renal O 0 0.9069423
hemodynamics O 0 0.9401293
, O 0 0.00026838994
and O 0 0.000101769096
morphology O 0 0.00019058243
of O 0 0.00011514136
the O 0 0.00010975237
nonclipped O 0 0.24054436
kidney O 0 0.024781872
was O 0 0.00010551285
studied O 0 0.00013031981
in O 0 8.636471e-05
rats O 0 0.00016345175
with O 0 0.00012758523
two O 0 0.000120854595
- O 0 0.0017435447
kidney O 0 0.010631143
, O 0 0.00061105686
one O 0 0.00039780102
clip O 0 0.009394706
renovascular B-Disease 0 0.99997973
hypertension I-Disease 2 0.99999297
. O 0 0.0058269217

Six O 0 0.002059584
weeks O 0 0.00088610454
after O 0 0.0006489744
clipping O 0 0.0025818753
of O 0 0.00072417606
one O 0 0.00059241377
renal O 0 0.31838444
artery O 0 0.2043898
, O 0 0.0011426258
hypertensive B-Disease 0 0.9991334
rats O 0 0.0006012961
( O 0 0.00047988034
178 O 0 0.00072041736
+ O 0 0.00083626236
/ O 0 0.0011304257
- O 0 0.0008383448
4 O 0 0.00013404626
mm O 0 0.00059975276
Hg O 0 0.64186174
) O 0 0.00042579367
were O 0 9.920438e-05
randomly O 0 5.5768705e-05
assigned O 0 6.919794e-05
to O 0 6.461242e-05
three O 0 4.584471e-05
groups O 0 0.00014024269
: O 0 0.00029550117
untreated O 0 0.00043924293
hypertensive B-Disease 0 0.9996464
controls O 0 0.00030358523
( O 0 0.00022439583
n O 0 0.00014746509
= O 0 0.00031875347
8 O 0 0.0001206593
) O 0 0.00035658563
, O 0 0.00062103226
enalapril B-Chemical 1 0.9999944
- O 0 0.005798908
treated O 0 0.000383132
( O 0 0.0002869996
n O 0 0.00019349692
= O 0 0.0004122892
8 O 0 0.00015211989
) O 0 0.00037856537
, O 0 0.00039296356
or O 0 0.00040679076
nitrendipine B-Chemical 0 0.99999714
- O 0 0.030518843
treated O 0 0.00091411755
( O 0 0.00081748056
n O 0 0.00068651116
= O 0 0.0017060011
10 O 0 0.0010807151
) O 0 0.0029081642
. O 0 0.0030514214

Sham O 0 0.02114653
- O 0 0.010758414
operated O 0 0.0036508576
rats O 0 0.0017787623
served O 0 0.001447983
as O 0 0.00089543394
normotensive O 0 0.742479
controls O 0 0.00096747425
( O 0 0.0009114107
128 O 0 0.0010281297
+ O 0 0.0015841435
/ O 0 0.0020245844
- O 0 0.0015915822
3 O 0 0.00037902797
mm O 0 0.0013731531
Hg O 0 0.22969297
, O 0 0.001267012
n O 0 0.0010055422
= O 0 0.0021941527
8 O 0 0.0014655524
) O 0 0.0039543174
. O 0 0.0042876867

After O 0 0.0013520734
6 O 0 0.00094223354
weeks O 0 0.0005323643
of O 0 0.0006978811
treatment O 0 0.00066358916
, O 0 0.0011927981
renal O 0 0.5027191
hemodynamics O 0 0.8838662
( O 0 0.0012578635
glomerular O 0 0.96952313
filtration O 0 0.0062879
rate O 0 0.00034325582
and O 0 0.00029021123
renal O 0 0.5880074
plasma O 0 0.008700026
flow O 0 0.0020582618
) O 0 0.0005529818
were O 0 0.00019291641
measured O 0 0.00024877148
in O 0 0.00027581348
the O 0 0.00038791835
anesthetized O 0 0.0018614277
rats O 0 0.0017472169
. O 0 0.00233602

Renal O 0 0.10134117
tissue O 0 0.005746188
was O 0 0.0015887454
obtained O 0 0.0009348957
for O 0 0.0008240764
determination O 0 0.001377497
of O 0 0.0017552166
glomerular O 0 0.98539126
size O 0 0.003643263
and O 0 0.0036243636
sclerosis O 0 0.9931114
. O 0 0.0052769217

Enalapril B-Chemical 0 0.9999335
but O 0 0.009415681
not O 0 0.0055010295
nitrendipine B-Chemical 0 0.9999784
reduced O 0 0.006207711
blood O 0 0.05637984
pressure O 0 0.06253845
significantly O 0 0.0045121997
. O 0 0.0057135117

After O 0 0.0014245345
6 O 0 0.001011672
weeks O 0 0.0005951814
of O 0 0.0008481902
therapy O 0 0.0011598505
, O 0 0.00166321
glomerular O 0 0.971067
filtration O 0 0.020059027
rate O 0 0.000715915
was O 0 0.0003481119
not O 0 0.00029467125
different O 0 0.00027848087
among O 0 0.00056523393
the O 0 0.0006341971
studied O 0 0.0014270194
groups O 0 0.0022727805
. O 0 0.0036372617

Renal O 0 0.13892671
plasma O 0 0.01896076
flow O 0 0.0073380764
increased O 0 0.0017954627
, O 0 0.0021218532
but O 0 0.0017362764
albumin O 0 0.9977835
excretion O 0 0.9730551
and O 0 0.0017775696
glomerulosclerosis B-Disease 0 0.9999838
did O 0 0.00073532824
not O 0 0.00038672853
change O 0 0.0004675236
after O 0 0.00052022835
enalapril B-Chemical 1 0.99994195
treatment O 0 0.002209875
. O 0 0.0029518593

In O 0 0.0020940886
contrast O 0 0.0025558001
, O 0 0.0024560369
in O 0 0.0010418359
the O 0 0.0011876621
nitrendipine B-Chemical 0 0.99999547
- O 0 0.06253083
treated O 0 0.00105555
group O 0 0.0010249242
albuminuria B-Disease 2 0.9999608
increased O 0 0.00048174176
from O 0 0.00015853989
12 O 0 0.000106168154
. O 0 0.00011774594
8 O 0 0.00013836974
+ O 0 0.00058539485
/ O 0 0.0012156379
- O 0 0.001237331
2 O 0 0.0001998061
progressively O 0 0.0001980148
to O 0 0.00013564256
163 O 0 0.0004512467
+ O 0 0.0007537162
/ O 0 0.0012341712
- O 0 0.0010329925
55 O 0 0.00019753468
compared O 0 9.765104e-05
with O 0 0.00016284802
19 O 0 0.00023677449
. O 0 0.00015962445
2 O 0 0.00019892937
+ O 0 0.0006706642
/ O 0 0.001220636
- O 0 0.0012158266
9 O 0 0.00023652586
mg O 0 0.002259611
/ O 0 0.00093842275
24 O 0 0.0002949301
hr O 0 0.00043751454
in O 0 0.00036958614
the O 0 0.000653809
hypertensive B-Disease 0 0.99859816
controls O 0 0.003027426
. O 0 0.0031644173

Furthermore O 0 0.003970676
, O 0 0.0090411585
glomerulosclerosis B-Disease 0 0.99989974
index O 0 0.0018027442
was O 0 0.0005909266
significantly O 0 0.00047406074
increased O 0 0.00042359272
in O 0 0.00026707991
the O 0 0.00036843523
nitrendipine B-Chemical 0 0.9999981
- O 0 0.022745522
treated O 0 0.0003685431
group O 0 0.00019635333
compared O 0 8.70569e-05
with O 0 0.00013299106
the O 0 0.0001572018
hypertensive B-Disease 0 0.9997565
controls O 0 0.00038632296
( O 0 0.00029496895
0 O 0 0.00017877293
. O 0 0.00012490014
38 O 0 0.00021774467
+ O 0 0.00070644764
/ O 0 0.0014858602
- O 0 0.0014837839
0 O 0 0.0002679887
. O 0 0.00016275703
1 O 0 0.0001628578
versus O 0 0.00014159904
0 O 0 0.00025158562
. O 0 0.00022365933
13 O 0 0.0003490477
+ O 0 0.0011879563
/ O 0 0.0024316786
- O 0 0.0029710636
0 O 0 0.0011246385
. O 0 0.0012217328
04 O 0 0.019135114
) O 0 0.004965547
. O 0 0.004285159

In O 0 0.0019799825
addition O 0 0.0013953502
, O 0 0.0038781862
glomerular O 0 0.9846843
size O 0 0.0013586506
was O 0 0.00043589683
higher O 0 0.0003702512
in O 0 0.00030131073
the O 0 0.00042401918
nitrendipine B-Chemical 0 0.9999974
- O 0 0.02659525
treated O 0 0.00053914066
group O 0 0.000346682
( O 0 0.0003363752
14 O 0 0.00014550127
. O 0 0.00013156075
9 O 0 0.00014102206
+ O 0 0.0006267841
/ O 0 0.0013321907
- O 0 0.0014141524
0 O 0 0.00026599178
. O 0 0.00016762556
17 O 0 0.00020262902
10 O 0 0.0001564125
( O 0 0.0002998544
- O 0 0.00062013644
3 O 0 0.00012984165
) O 0 0.00030818055
mm2 O 0 0.00045918924
) O 0 0.0003821015
but O 0 0.00015837912
lower O 0 0.00016041116
in O 0 0.00013791477
the O 0 0.00022035051
enalapril B-Chemical 1 0.99999654
- O 0 0.010033126
treated O 0 0.00038603836
group O 0 0.00028620608
( O 0 0.00030909388
11 O 0 0.00015797777
. O 0 0.0001199897
5 O 0 0.0001314766
+ O 0 0.0005621621
/ O 0 0.001205108
- O 0 0.0012605379
0 O 0 0.00023488553
. O 0 0.0001423664
15 O 0 0.00012496792
10 O 0 0.0001378481
( O 0 0.0002748118
- O 0 0.00056755584
3 O 0 0.00012288497
) O 0 0.00027844164
mm2 O 0 0.0003672235
) O 0 0.0002717146
compared O 0 8.508394e-05
with O 0 0.00013659865
the O 0 0.00016717208
hypertensive B-Disease 0 0.9996942
controls O 0 0.00041216167
( O 0 0.00029829924
12 O 0 9.9162935e-05
. O 0 0.00012117874
1 O 0 0.0001747225
+ O 0 0.00062868185
/ O 0 0.0013024098
- O 0 0.0014021505
0 O 0 0.00029588686
. O 0 0.0001988645
17 O 0 0.00025726017
10 O 0 0.00021413219
( O 0 0.00043350834
- O 0 0.00091213087
3 O 0 0.0002562861
) O 0 0.0006370809
mm2 O 0 0.0009635042
) O 0 0.0009879494
. O 0 0.0005515721
( O 0 0.0012003039
ABSTRACT O 0 0.005971323
TRUNCATED O 0 0.014736774
AT O 0 0.013991452
250 O 0 0.006774308
WORDS O 0 0.030064464
) O 0 0.019269543

Ketoconazole B-Chemical 0 0.99969363
induced O 0 0.007981445
torsades B-Disease 0 0.9990595
de I-Disease 0 0.027995126
pointes I-Disease 0 0.99420494
without O 0 0.0010091922
concomitant O 0 0.0012071719
use O 0 0.0005128539
of O 0 0.00080682285
QT O 0 0.8082128
interval O 0 0.00084932486
- O 0 0.0023588731
prolonging O 0 0.0011910645
drug O 0 0.010390393
. O 0 0.0037422935

Ketoconazole B-Chemical 0 0.99979836
is O 0 0.0024975708
not O 0 0.0013164086
known O 0 0.0008460165
to O 0 0.00056863064
be O 0 0.0005399153
proarrhythmic O 0 0.026760314
without O 0 0.0004072591
concomitant O 0 0.0006455215
use O 0 0.00033280978
of O 0 0.00058337516
QT O 0 0.7965161
interval O 0 0.00067947817
- O 0 0.001984264
prolonging O 0 0.0010029237
drugs O 0 0.012254993
. O 0 0.0036116983

We O 0 0.0029575638
report O 0 0.003313405
a O 0 0.0021878488
woman O 0 0.0025390775
with O 0 0.0008827775
coronary B-Disease 0 0.12112716
artery I-Disease 0 0.55003786
disease I-Disease 0 0.32329166
who O 0 0.00044943174
developed O 0 0.00026363414
a O 0 0.0003274157
markedly O 0 0.0005647326
prolonged B-Disease 0 0.00087478803
QT I-Disease 0 0.8240759
interval I-Disease 0 0.00032654815
and O 0 0.00028080068
torsades B-Disease 0 0.9975637
de I-Disease 0 0.0021188708
pointes I-Disease 0 0.9928342
( O 0 0.0011326829
TdP B-Disease 2 0.99692935
) O 0 0.0003795508
after O 0 8.4295985e-05
taking O 0 0.00041704372
ketoconazole B-Chemical 0 0.99998236
for O 0 0.0002944828
treatment O 0 0.00042339246
of O 0 0.0007784717
fungal B-Disease 0 0.018781582
infection I-Disease 0 0.5225662
. O 0 0.0040427865

Her O 0 0.0112033365
QT O 0 0.51663494
interval O 0 0.0025317783
returned O 0 0.0015359853
to O 0 0.0010421794
normal O 0 0.001618502
upon O 0 0.0010127806
withdrawal O 0 0.005525527
of O 0 0.0043684295
ketoconazole B-Chemical 0 0.9999181
. O 0 0.009158508

Genetic O 0 0.011439388
study O 0 0.003348717
did O 0 0.0018150597
not O 0 0.0009163504
find O 0 0.00058898644
any O 0 0.000537448
mutation O 0 0.0005675112
in O 0 0.0003913596
her O 0 0.00041205544
genes O 0 0.00028923532
that O 0 0.00024804013
encode O 0 0.00027870454
cardiac O 0 0.00363263
IKr O 0 0.66811705
channel O 0 0.003269346
proteins O 0 0.0019407304
. O 0 0.0035848848

We O 0 0.0027451226
postulate O 0 0.0026521005
that O 0 0.0010481327
by O 0 0.00090261473
virtue O 0 0.0010840725
of O 0 0.00060290867
its O 0 0.00048342173
direct O 0 0.00020381916
blocking O 0 0.00029300162
action O 0 0.0002907097
on O 0 0.00024920213
IKr O 0 0.91211087
, O 0 0.002652666
ketoconazole B-Chemical 0 0.9999931
alone O 0 0.00052124786
may O 0 0.0002459607
prolong O 0 0.0003425647
QT O 0 0.6864675
interval O 0 0.0004687852
and O 0 0.00056918967
induce O 0 0.000983591
TdP B-Disease 2 0.99572647
. O 0 0.003507374

This O 0 0.0040944056
calls O 0 0.002056521
for O 0 0.0008734571
attention O 0 0.0019775613
when O 0 0.0008223781
ketoconazole B-Chemical 0 0.99998426
is O 0 0.0004139474
administered O 0 0.00042739484
to O 0 0.0001982549
patients O 0 0.00039929262
with O 0 0.00027063626
risk O 0 0.0013726085
factors O 0 0.0005764798
for O 0 0.00035303665
acquired O 0 0.0012572273
long B-Disease 0 0.0020371135
QT I-Disease 0 0.9948074
syndrome I-Disease 0 0.9911596
. O 0 0.0034508528

Cerebral B-Disease 0 0.9950793
vasculitis I-Disease 2 0.9997365
following O 0 0.0014830492
oral O 0 0.023286577
methylphenidate B-Chemical 1 0.999964
intake O 0 0.023457883
in O 0 0.00060813705
an O 0 0.0006535264
adult O 0 0.00089018006
: O 0 0.0014846735
a O 0 0.0013476843
case O 0 0.0015360035
report O 0 0.0035407196
. O 0 0.0041450546

Methylphenidate B-Chemical 0 0.9997633
is O 0 0.0037442164
structurally O 0 0.0030692795
and O 0 0.001978386
functionally O 0 0.0014209975
similar O 0 0.0016105566
to O 0 0.0035094281
amphetamine B-Chemical 1 0.9997907
. O 0 0.008834176

Cerebral B-Disease 0 0.9970714
vasculitis I-Disease 2 0.9998828
associated O 0 0.0028747155
with O 0 0.0041640173
amphetamine B-Disease 1 0.9999981
abuse I-Disease 0 0.9997737
is O 0 0.00037857873
well O 0 0.00025670376
documented O 0 0.00037331393
, O 0 0.00043396436
and O 0 0.00025136553
in O 0 0.00027579375
rare O 0 0.0024509346
cases O 0 0.003505743
ischaemic B-Disease 0 0.9999944
stroke I-Disease 0 0.99995863
has O 0 0.00018970927
been O 0 0.00018824363
reported O 0 0.00024185576
after O 0 0.00022579535
methylphenidate B-Chemical 1 0.9999716
intake O 0 0.02507457
in O 0 0.00085919973
children O 0 0.0034387424
. O 0 0.0025665285

We O 0 0.0030694664
report O 0 0.0030744546
the O 0 0.001203737
case O 0 0.0010273698
of O 0 0.0008071132
a O 0 0.00091752195
63 O 0 0.0009432579
- O 0 0.0018716467
year O 0 0.000311907
- O 0 0.0009698596
old O 0 0.0002751954
female O 0 0.00045693154
who O 0 0.00027876167
was O 0 0.00015731456
treated O 0 0.0004066206
with O 0 0.0005387861
methylphenidate B-Chemical 1 0.99999297
due O 0 0.00022195729
to O 0 0.00036580456
hyperactivity B-Disease 2 0.9999931
and O 0 0.0006793215
suffered O 0 0.002392006
from O 0 0.00050765544
multiple O 0 0.0014061206
ischaemic B-Disease 0 0.9999528
strokes I-Disease 0 0.9997018
. O 0 0.0050885566

We O 0 0.002522602
consider O 0 0.0016110506
drug O 0 0.0399011
- O 0 0.012778802
induced O 0 0.0016157358
cerebral B-Disease 0 0.999866
vasculitis I-Disease 2 0.99998593
as O 0 0.00047405984
the O 0 0.00020866471
most O 0 0.0002432913
likely O 0 0.00011601677
cause O 0 0.00023826779
of O 0 0.00033343036
recurrent O 0 0.15182912
ischaemic B-Disease 0 0.99999595
strokes I-Disease 0 0.9999621
in O 0 0.00021708052
the O 0 0.0001030296
absence O 0 8.0456426e-05
of O 0 0.00014852347
any O 0 0.00013273655
pathological O 0 0.0011184893
findings O 0 0.00019066148
during O 0 0.00012444482
the O 0 0.00018806368
diagnostic O 0 0.00044292535
work O 0 0.00069210486
- O 0 0.003261152
up O 0 0.0018038875
. O 0 0.0028716687

We O 0 0.00211498
conclude O 0 0.0013076969
that O 0 0.0015932831
methylphenidate B-Chemical 1 0.9999722
mediated O 0 0.0008969684
vasculitis B-Disease 2 0.99983895
should O 0 0.0002121963
be O 0 0.00019188305
considered O 0 0.00016077653
in O 0 0.00015313338
patients O 0 0.00038103317
with O 0 0.0003259031
neurological O 0 0.99778736
symptoms O 0 0.2424808
and O 0 0.00029078036
a O 0 0.0004508175
history O 0 0.0007820276
of O 0 0.0011413759
methylphenidate B-Chemical 1 0.99997425
therapy O 0 0.0033357937
. O 0 0.0023587078

This O 0 0.0039569875
potential O 0 0.0016663902
side O 0 0.0048445426
- O 0 0.006036821
effect O 0 0.00071431557
, O 0 0.0012897821
though O 0 0.00056137895
very O 0 0.0006986131
rare O 0 0.001980888
, O 0 0.00056662154
represents O 0 0.00020218092
one O 0 0.00015821973
more O 0 0.000207743
reason O 0 0.00010714604
to O 0 0.0001544246
be O 0 0.00018570552
very O 0 0.00028806133
restrictive O 0 0.00046890206
in O 0 0.00026949638
the O 0 0.00030499804
use O 0 0.00053500995
of O 0 0.0017850207
methylphenidate B-Chemical 1 0.9999461
. O 0 0.0044232663

MDMA B-Chemical 0 0.9999875
polydrug O 0 0.99983823
users O 0 0.0036277834
show O 0 0.0006095884
process O 0 0.00062122406
- O 0 0.0018427742
specific O 0 0.00022347558
central O 0 0.0005845039
executive O 0 0.16726285
impairments O 0 0.27829656
coupled O 0 0.00026620185
with O 0 0.00029940787
impaired B-Disease 0 0.0011380775
social I-Disease 0 0.005227555
and I-Disease 0 0.00074272434
emotional I-Disease 0 0.017239064
judgement I-Disease 0 0.004081186
processes I-Disease 0 0.0027283498
. O 0 0.0033796723

In O 0 0.0016558036
recent O 0 0.0015564812
years O 0 0.0015676485
working O 0 0.002652893
memory B-Disease 0 0.9772037
deficits I-Disease 0 0.9962463
have O 0 0.00052887044
been O 0 0.0003407813
reported O 0 0.00031036185
in O 0 0.00024848158
users O 0 0.0005772711
of O 0 0.0008818536
MDMA B-Chemical 0 0.99999833
( O 0 0.0011380143
3 B-Chemical 0 0.00027616316
, I-Chemical 0 0.0005106501
4 I-Chemical 0 0.00042599076
- I-Chemical 0 0.00785496
methylenedioxymethamphetamine I-Chemical 0 0.99994993
, O 0 0.011811629
ecstasy B-Chemical 1 0.99993885
) O 0 0.01144387
. O 0 0.003972511

The O 0 0.0018827074
current O 0 0.0016854441
study O 0 0.001037275
aimed O 0 0.0005919171
to O 0 0.00035290682
assess O 0 0.00016299215
the O 0 0.00020452525
impact O 0 0.0001945453
of O 0 0.0006524389
MDMA B-Chemical 0 0.99999833
use O 0 0.00019493984
on O 0 7.522051e-05
three O 0 4.656067e-05
separate O 0 7.6695505e-05
central O 0 0.00021481111
executive O 0 0.024769692
processes O 0 0.00022122794
( O 0 0.00020093843
set O 0 8.530011e-05
shifting O 0 0.00016645202
, O 0 0.00024065113
inhibition O 0 0.00017399315
and O 0 0.00017568292
memory O 0 0.11801471
updating O 0 0.00045501866
) O 0 0.00043329268
and O 0 0.00013567983
also O 0 0.000117784686
on O 0 0.00012456995
" O 0 0.00057183346
prefrontal O 0 0.3458292
" O 0 0.00042519008
mediated O 0 0.00017168267
social O 0 0.0033604025
and O 0 0.0006814788
emotional O 0 0.026259359
judgement O 0 0.004371855
processes O 0 0.002684203
. O 0 0.0032615147

Fifteen O 0 0.009610047
polydrug O 0 0.9995883
ecstasy B-Chemical 1 0.9999269
users O 0 0.0025412005
and O 0 0.00071788713
15 O 0 0.0005736248
polydrug O 0 0.9987722
non O 0 0.0010442098
- O 0 0.018426742
ecstasy B-Chemical 1 0.99995613
user O 0 0.0002996338
controls O 0 0.0002447284
completed O 0 0.00016573114
a O 0 0.00016616518
general O 0 0.00012568424
drug O 0 0.0006134166
use O 0 9.656908e-05
questionnaire O 0 9.130408e-05
, O 0 0.00018918436
the O 0 0.00012580965
Brixton O 0 0.0021245475
Spatial O 0 0.0006011591
Anticipation O 0 0.0012400172
task O 0 0.00040606258
( O 0 0.00026649007
set O 0 0.00011870146
shifting O 0 0.00022325687
) O 0 0.00044282022
, O 0 0.0003845332
Backward O 0 0.0022376261
Digit O 0 0.9887882
Span O 0 0.90243715
procedure O 0 0.0001683064
( O 0 0.00032760116
memory O 0 0.012695346
updating O 0 0.00044715914
) O 0 0.0005940896
, O 0 0.0003576219
Inhibition O 0 0.00022877437
of O 0 0.00021957495
Return O 0 0.00047702217
( O 0 0.00037230356
inhibition O 0 0.00027333308
) O 0 0.0005731663
, O 0 0.00035188094
an O 0 0.00023152652
emotional O 0 0.009792061
intelligence O 0 0.025438795
scale O 0 0.00029609085
, O 0 0.0002984153
the O 0 0.00015807708
Tromso O 0 0.00083648396
Social O 0 0.00047872166
Intelligence O 0 0.0005561032
Scale O 0 0.001119091
and O 0 0.0002509967
the O 0 0.00033632616
Dysexecutive O 0 0.08024576
Questionnaire O 0 0.0009351595
( O 0 0.0019712471
DEX O 0 0.9960783
) O 0 0.0063954373
. O 0 0.004256979

Compared O 0 0.0033054731
with O 0 0.0061013694
MDMA B-Chemical 0 0.9999925
- O 0 0.14836092
free O 0 0.0021889878
polydrug O 0 0.9996648
controls O 0 0.0017343699
, O 0 0.0040507372
MDMA B-Chemical 0 0.9999993
polydrug O 0 0.9999597
users O 0 0.00061599124
showed O 0 0.00016652141
impairments O 0 0.06058275
in O 0 0.00010909127
set O 0 8.7752764e-05
shifting O 0 0.00015664802
and O 0 0.00016195203
memory O 0 0.058136374
updating O 0 0.00042241122
, O 0 0.0003376374
and O 0 0.00018084557
also O 0 0.0001749981
in O 0 0.00024764217
social O 0 0.0035638295
and O 0 0.0006123047
emotional O 0 0.020456636
judgement O 0 0.003922332
processes O 0 0.0025193673
. O 0 0.0031060246

The O 0 0.002257206
latter O 0 0.002949906
two O 0 0.0010991311
deficits O 0 0.14028363
remained O 0 0.0011158468
significant O 0 0.0005613177
after O 0 0.00029603613
controlling O 0 0.00031522135
for O 0 0.0004862037
other O 0 0.000875622
drug O 0 0.0064353156
use O 0 0.002053291
. O 0 0.003763783

These O 0 0.00245804
data O 0 0.0023109843
lend O 0 0.0018032711
further O 0 0.0007605608
support O 0 0.0006370203
to O 0 0.00044585415
the O 0 0.0003481008
proposal O 0 0.0004959647
that O 0 0.00029219457
cognitive O 0 0.6555001
processes O 0 0.0004200579
mediated O 0 0.0001458171
by O 0 0.00023133258
the O 0 0.00029287566
prefrontal O 0 0.6905814
cortex O 0 0.008293593
may O 0 0.00019602857
be O 0 0.0002381506
impaired O 0 0.00081457
by O 0 0.00057292375
recreational O 0 0.016629508
ecstasy B-Chemical 1 0.9998903
use O 0 0.0022497731
. O 0 0.0030953046

Phase O 0 0.0144477375
II O 0 0.021294577
study O 0 0.0021720994
of O 0 0.0015029195
the O 0 0.0015334979
amsacrine B-Chemical 0 0.999848
analogue O 0 0.006203752
CI B-Chemical 0 0.42396212
- I-Chemical 0 0.021085136
921 I-Chemical 0 0.025189167
( O 0 0.001449586
NSC B-Chemical 0 0.6088814
343499 I-Chemical 0 0.11932251
) O 0 0.0012026756
in O 0 0.00044891195
non B-Disease 2 0.001004739
- I-Disease 2 0.0040219678
small I-Disease 2 0.0016418672
cell I-Disease 2 0.0037516498
lung I-Disease 2 0.96719944
cancer I-Disease 2 0.99897647
. O 0 0.0066842083

CI B-Chemical 0 0.3817861
- I-Chemical 0 0.067279406
921 I-Chemical 0 0.06671769
( O 0 0.006345199
NSC B-Chemical 0 0.67035115
343499 I-Chemical 0 0.10714263
; O 0 0.002231218
9 B-Chemical 0 0.00081982696
- I-Chemical 0 0.0028523267
[ I-Chemical 0 0.0024115841
[ I-Chemical 0 0.0022159119
2 I-Chemical 0 0.00071296014
- I-Chemical 0 0.0050369357
methoxy I-Chemical 0 0.9739792
- I-Chemical 0 0.0044689546
4 I-Chemical 0 0.00034319886
- I-Chemical 0 0.0018143954
[ I-Chemical 0 0.0017110646
( I-Chemical 0 0.0010052723
methylsulphonyl I-Chemical 0 0.8921909
) I-Chemical 0 0.0032528236
amino I-Chemical 0 0.60758334
] I-Chemical 0 0.075703405
phenyl I-Chemical 0 0.99862134
] I-Chemical 0 0.091718465
amino I-Chemical 0 0.6921579
] I-Chemical 0 0.032535158
- I-Chemical 0 0.05298564
N I-Chemical 0 0.9983955
, I-Chemical 0 0.0009650628
5 I-Chemical 0 0.0003352606
- I-Chemical 0 0.0072914558
dimethyl I-Chemical 0 0.9861704
- I-Chemical 0 0.0044611804
4 I-Chemical 0 0.00020342348
- I-Chemical 0 0.001504435
acridinecarboxamide I-Chemical 0 0.0035613836
) O 0 0.0006017527
is O 0 0.0001864619
a O 0 0.0005236242
topoisomerase O 0 0.72635156
II O 0 0.5048478
poison O 0 0.015135618
with O 0 0.0004331572
high O 0 0.0005891743
experimental O 0 0.0008318923
antitumour O 0 0.07824308
activity O 0 0.0012487291
. O 0 0.002789738

It O 0 0.0046988693
was O 0 0.0017133517
administered O 0 0.0013816811
by O 0 0.0006536062
15 O 0 0.00047248925
min O 0 0.00051595573
infusion O 0 0.00049434416
to O 0 0.0001656872
16 O 0 0.00019949996
evaluable O 0 0.00031480208
patients O 0 0.00023085313
with O 0 0.00017071758
non B-Disease 2 0.00041845167
- I-Disease 2 0.0023712688
small I-Disease 2 0.00052677654
cell I-Disease 2 0.0011547926
lung I-Disease 2 0.9813752
cancer I-Disease 2 0.9998729
( O 0 0.008734379
NSCLC B-Disease 0 0.9997942
) O 0 0.0008092954
( O 0 0.0002340345
7 O 0 7.216614e-05
with O 0 7.914551e-05
no O 0 7.066042e-05
prior O 0 5.0543204e-05
treatment O 0 0.00010199166
, O 0 0.00017965607
9 O 0 8.816164e-05
patients O 0 0.00016633193
in O 0 8.99504e-05
relapse O 0 0.0018724645
following O 0 5.4943474e-05
surgery O 0 0.00014250563
/ O 0 0.0004599647
radiotherapy O 0 0.0012582649
) O 0 0.00019510146
at O 0 6.4878965e-05
a O 0 0.000144445
dose O 0 0.0002327827
( O 0 0.00029696446
648 O 0 0.0020202114
mg O 0 0.0028013184
/ O 0 0.00068441295
m2 O 0 0.0007911982
divided O 0 0.00012305971
over O 0 7.030849e-05
3 O 0 7.300846e-05
days O 0 5.8352663e-05
, O 0 0.0001512192
repeated O 0 6.459467e-05
every O 0 6.0696362e-05
3 O 0 9.753806e-05
weeks O 0 9.601027e-05
) O 0 0.00041536108
determined O 0 0.00026965674
by O 0 0.0005123864
phase O 0 0.0019098386
I O 0 0.0369908
trial O 0 0.0044491696
. O 0 0.003883272

Patients O 0 0.0042065303
had O 0 0.0015171098
a O 0 0.0011433925
median O 0 0.00046273562
performance O 0 0.0006565214
status O 0 0.00052485743
of O 0 0.00059050554
1 O 0 0.0006218239
( O 0 0.000823454
WHO O 0 0.00070278696
) O 0 0.0008424697
, O 0 0.0006199222
and O 0 0.00038266016
median O 0 0.00032689015
age O 0 0.00083077815
of O 0 0.0009763616
61 O 0 0.0020260727
years O 0 0.0023853725
. O 0 0.0035267195

The O 0 0.0030719272
histology O 0 0.008230025
comprised O 0 0.0053160316
squamous B-Disease 0 0.9969669
carcinoma I-Disease 0 0.9996327
( O 0 0.003243055
11 O 0 0.0009614112
) O 0 0.0015443447
, O 0 0.0015323062
adenocarcinoma B-Disease 0 0.99236286
( O 0 0.0011518998
1 O 0 0.00042413012
) O 0 0.0006438243
, O 0 0.00046778264
mixed O 0 0.0005041091
histology O 0 0.0014272043
( O 0 0.00052393175
2 O 0 0.00028343932
) O 0 0.00056585413
, O 0 0.0005566178
bronchio B-Disease 0 0.003373626
- I-Disease 0 0.019235356
alveolar I-Disease 0 0.6772093
carcinoma I-Disease 0 0.99903786
( O 0 0.000913193
1 O 0 0.00031058505
) O 0 0.0005102438
and O 0 0.0002905894
large O 0 0.00057227246
cell O 0 0.001473802
undifferentiated B-Disease 0 0.8993239
carcinoma I-Disease 0 0.9998795
( O 0 0.004062541
1 O 0 0.0016068883
) O 0 0.0033090708
. O 0 0.003047241

Neutropenia B-Disease 0 0.99619746
grade O 0 0.016072497
greater O 0 0.0016776607
than O 0 0.0007314357
or O 0 0.0004942311
equal O 0 0.00045130096
to O 0 0.0002894
3 O 0 0.00023848441
was O 0 0.0001977329
seen O 0 0.0002005581
in O 0 0.00016555218
15 O 0 0.0001729826
patients O 0 0.00033283074
, O 0 0.0003756516
infections B-Disease 0 0.0028525395
with O 0 0.00021435301
recovery O 0 0.00028439646
in O 0 0.00016641426
3 O 0 0.00017723403
, O 0 0.00038596737
and O 0 0.00040410418
grand O 0 0.010438849
mal O 0 0.9997867
seizures B-Disease 0 0.9999876
in O 0 0.0011237251
1 O 0 0.0011823175
patient O 0 0.0015317773
. O 0 0.0023393957

Grade O 0 0.022230316
less O 0 0.0027928702
than O 0 0.0011246315
or O 0 0.0007305879
equal O 0 0.0006405388
to O 0 0.00044676932
2 O 0 0.0006242185
nausea B-Disease 0 0.9867143
and O 0 0.0005126196
vomiting B-Disease 0 0.7659889
occurred O 0 0.00023407867
in O 0 0.0001792659
66 O 0 0.0003007706
% O 0 0.00034178296
courses O 0 0.0003347764
and O 0 0.00032492803
phlebitis B-Disease 0 0.99759644
in O 0 0.00025630585
the O 0 0.00023467086
infusion O 0 0.00073508825
arm O 0 0.0006290894
in O 0 0.00063300563
37 O 0 0.001920194
% O 0 0.0028740428
. O 0 0.0031017235

1 O 0 0.005151161
patient O 0 0.003219978
with O 0 0.0028835395
squamous B-Disease 0 0.9110358
cell I-Disease 0 0.0047561973
carcinoma I-Disease 0 0.99877316
achieved O 0 0.0013670789
a O 0 0.0010741767
partial O 0 0.00083891494
response O 0 0.0005920353
lasting O 0 0.0007279164
5 O 0 0.0007989271
months O 0 0.0007795647
. O 0 0.0025851286

Further O 0 0.0025157675
testing O 0 0.0017424079
in O 0 0.0012394075
this O 0 0.0010042781
and O 0 0.00086760597
other O 0 0.00078654545
tumour B-Disease 0 0.4067024
types O 0 0.00044126532
using O 0 0.00032464316
multiple O 0 0.00037434802
daily O 0 0.00049184094
schedules O 0 0.000538666
is O 0 0.0006765929
warranted O 0 0.0013501452
. O 0 0.0030005288

Pharmacokinetics O 0 0.85686785
of O 0 0.013474928
desipramine B-Chemical 0 0.9999964
HCl I-Chemical 0 0.9997515
when O 0 0.0015718342
administered O 0 0.0026220244
with O 0 0.0032704538
cinacalcet B-Chemical 1 0.9999074
HCl I-Chemical 0 0.999443
. O 0 0.007985381

OBJECTIVE O 0 0.02154457
: O 0 0.0035666109
In O 0 0.00073595636
vitro O 0 0.00077045435
work O 0 0.0006645765
has O 0 0.00032411123
demonstrated O 0 0.00035357813
that O 0 0.0004512726
cinacalcet B-Chemical 1 0.99985266
is O 0 0.00039317954
a O 0 0.0005420984
strong O 0 0.00043059274
inhibitor O 0 0.0034540452
of O 0 0.00359977
cytochrome O 0 0.99992514
P450 O 0 0.9999864
isoenzyme O 0 0.99985576
( O 0 0.33422753
CYP O 0 0.99997425
) O 0 0.34209612
2D6 O 0 0.9997385
. O 0 0.005921844

The O 0 0.0015789459
purpose O 0 0.0010315345
of O 0 0.0011581503
this O 0 0.00083313975
study O 0 0.00061467174
was O 0 0.00029835184
to O 0 0.00016868814
evaluate O 0 8.190167e-05
the O 0 0.000121374185
effect O 0 0.00015122972
of O 0 0.00042064115
cinacalcet B-Chemical 1 0.9999571
on O 0 0.00031061168
CYP2D6 O 0 0.998454
activity O 0 0.00014833748
, O 0 0.00039851276
using O 0 0.00029423164
desipramine B-Chemical 0 0.99999845
as O 0 0.0003094911
a O 0 0.0003591558
probe O 0 0.00022550276
substrate O 0 0.0005132276
, O 0 0.0008273582
in O 0 0.00060291495
healthy O 0 0.0032234937
subjects O 0 0.0025933464
. O 0 0.002718291

METHODS O 0 0.0039506857
: O 0 0.0028861742
Seventeen O 0 0.0022145335
subjects O 0 0.0011972352
who O 0 0.00080821186
were O 0 0.00046100782
genotyped O 0 0.00068501197
as O 0 0.00060561555
CYP2D6 O 0 0.99454945
extensive O 0 0.0005120555
metabolizers O 0 0.9867259
were O 0 0.0001702929
enrolled O 0 0.00022134017
in O 0 0.00010237265
this O 0 0.00013015763
randomized O 0 0.0003952344
, O 0 0.0002541496
open O 0 0.00023679482
- O 0 0.0013268756
label O 0 0.00052976445
, O 0 0.000323657
crossover O 0 0.00072255393
study O 0 0.00012790559
to O 0 7.5101896e-05
receive O 0 8.015485e-05
a O 0 0.00011249242
single O 0 6.7701396e-05
oral O 0 0.0003819959
dose O 0 0.00023863929
of O 0 0.0003285332
desipramine B-Chemical 0 0.9999994
( O 0 0.0007231168
50 O 0 0.00022150108
mg O 0 0.0039734566
) O 0 0.00018179456
on O 0 3.9415998e-05
two O 0 3.7092246e-05
separate O 0 5.2405365e-05
occasions O 0 0.00014838304
, O 0 0.00016750797
once O 0 6.3689055e-05
alone O 0 9.37737e-05
and O 0 8.773829e-05
once O 0 5.524737e-05
after O 0 3.9735478e-05
multiple O 0 7.9041274e-05
doses O 0 0.0002538992
of O 0 0.0002784517
cinacalcet B-Chemical 1 0.9998915
( O 0 0.0005851157
90 O 0 0.0002919735
mg O 0 0.0014469876
for O 0 0.00022421831
7 O 0 0.0003356767
days O 0 0.00043256156
) O 0 0.0022591723
. O 0 0.0026810465

Blood O 0 0.027663337
samples O 0 0.0031808123
were O 0 0.0016510417
obtained O 0 0.0013053013
predose O 0 0.012111278
and O 0 0.0011001434
up O 0 0.001106799
to O 0 0.0009536162
72 O 0 0.0015768103
h O 0 0.0020086323
postdose O 0 0.0056142784
. O 0 0.0041969856

RESULTS O 0 0.0070685595
: O 0 0.005444033
Fourteen O 0 0.003681434
subjects O 0 0.0026924002
completed O 0 0.0021173088
both O 0 0.0019034294
treatment O 0 0.0028579195
arms O 0 0.00732489
. O 0 0.007881559

Relative O 0 0.0036293955
to O 0 0.0034241844
desipramine B-Chemical 0 0.9999845
alone O 0 0.0015415781
, O 0 0.0010810508
mean O 0 0.0004258653
AUC O 0 0.001184025
and O 0 0.00044755917
C O 0 0.7690685
( O 0 0.0009370217
max O 0 0.0028734105
) O 0 0.0009863192
of O 0 0.0007138919
desipramine B-Chemical 0 0.9999988
increased O 0 0.0005684055
3 O 0 0.0001650582
. O 0 0.00013486629
6 O 0 0.00011609689
- O 0 0.0005776783
and O 0 0.00017194214
1 O 0 0.00019699614
. O 0 0.00016720062
8 O 0 0.00019827869
- O 0 0.0007984141
fold O 0 0.0003381206
when O 0 0.00036466008
coadministered O 0 0.25353605
with O 0 0.0021902577
cinacalcet B-Chemical 1 0.99978894
. O 0 0.00442178

The O 0 0.003377527
t O 0 0.008176866
( O 0 0.00324617
1 O 0 0.0014694948
/ O 0 0.002435927
2 O 0 0.0007276103
, O 0 0.00084138184
z O 0 0.0015502041
) O 0 0.001240032
of O 0 0.00088698394
desipramine B-Chemical 0 0.9999976
was O 0 0.00027576217
longer O 0 0.0001212274
when O 0 0.00022065833
desipramine B-Chemical 0 0.99999833
was O 0 0.000300327
coadministered O 0 0.22958292
with O 0 0.0004194527
cinacalcet B-Chemical 1 0.99994373
( O 0 0.00057173567
21 O 0 0.00021910858
. O 0 0.0001570659
0 O 0 0.00022675995
versus O 0 0.00021333029
43 O 0 0.0005159778
. O 0 0.00045805806
3 O 0 0.00069643237
hs O 0 0.006867065
) O 0 0.0038823977
. O 0 0.003483141

The O 0 0.004157912
t O 0 0.009209348
( O 0 0.0048328647
max O 0 0.007320314
) O 0 0.0033400392
was O 0 0.0011848272
similar O 0 0.00078860665
between O 0 0.0010531915
the O 0 0.0016562783
regimens O 0 0.0034103647
. O 0 0.005068431

Fewer O 0 0.0077102734
subjects O 0 0.0028439139
reported O 0 0.0011000654
adverse O 0 0.0014891089
events O 0 0.0005231144
following O 0 0.00017069658
treatment O 0 0.00024795922
with O 0 0.0004837912
desipramine B-Chemical 0 0.9999987
alone O 0 0.00027028273
than O 0 9.891173e-05
when O 0 8.100663e-05
receiving O 0 0.00051291945
desipramine B-Chemical 0 0.9999993
with O 0 0.0007101257
cinacalcet B-Chemical 1 0.9999701
( O 0 0.00036981783
33 O 0 0.00016272414
versus O 0 8.328983e-05
86 O 0 0.00018553612
% O 0 0.0002482597
) O 0 0.00031911719
, O 0 0.00020465536
the O 0 9.168763e-05
most O 0 0.00014211169
frequent O 0 0.0001494691
of O 0 0.0001267548
which O 0 0.00018910696
( O 0 0.0006203493
nausea B-Disease 0 0.99909854
and O 0 0.00034016347
headache B-Disease 0 0.9980124
) O 0 0.00044894486
have O 0 9.1565125e-05
been O 0 9.746275e-05
reported O 0 0.00011553003
for O 0 9.113628e-05
patients O 0 0.00032450142
treated O 0 0.0003849583
with O 0 0.00037253147
either O 0 0.0010349301
desipramine B-Chemical 0 0.99999845
or O 0 0.0027959715
cinacalcet B-Chemical 1 0.9998779
. O 0 0.003602884

CONCLUSION O 0 0.021233046
: O 0 0.0051924954
This O 0 0.0019555616
study O 0 0.0010758272
demonstrates O 0 0.00053413864
that O 0 0.0008596718
cinacalcet B-Chemical 1 0.9996749
is O 0 0.0008533615
a O 0 0.0011925107
strong O 0 0.0010098341
inhibitor O 0 0.0044390387
of O 0 0.004316995
CYP2D6 O 0 0.99841416
. O 0 0.0057384055

These O 0 0.0019776772
data O 0 0.001617483
suggest O 0 0.0005597752
that O 0 0.0004894247
during O 0 0.00038560017
concomitant O 0 0.0007573478
treatment O 0 0.00036266577
with O 0 0.0004970765
cinacalcet B-Chemical 1 0.9999306
, O 0 0.00064342614
dose O 0 0.00034361516
adjustment O 0 0.0001267814
may O 0 8.184475e-05
be O 0 7.9288664e-05
necessary O 0 5.3777803e-05
for O 0 8.259594e-05
drugs O 0 0.0010617453
that O 0 8.073826e-05
demonstrate O 0 6.146088e-05
a O 0 0.00021989067
narrow O 0 0.00034283655
therapeutic O 0 0.00028476736
index O 0 0.00032586863
and O 0 0.00038814827
are O 0 0.000512201
metabolized O 0 0.14192334
by O 0 0.0019873288
CYP2D6 O 0 0.9969584
. O 0 0.0038194708

Case O 0 0.02966371
report O 0 0.009809187
: O 0 0.010772371
acute O 0 0.30362257
unintentional O 0 0.84355915
carbachol B-Chemical 0 0.99958414
intoxication O 0 0.99819475
. O 0 0.011740687

INTRODUCTION O 0 0.024414012
: O 0 0.008474474
Intoxications O 0 0.20103356
with O 0 0.0030622168
carbachol B-Chemical 0 0.9995117
, O 0 0.004678844
a O 0 0.0034538223
muscarinic O 0 0.9921395
cholinergic O 0 0.39004633
receptor O 0 0.0061718663
agonist O 0 0.06278244
are O 0 0.0016414813
rare O 0 0.006753159
. O 0 0.0038137545

We O 0 0.0036754294
report O 0 0.0038306292
an O 0 0.0018445344
interesting O 0 0.00085187884
case O 0 0.0010957437
investigating O 0 0.00087858795
a O 0 0.0017476043
( O 0 0.0022497613
near O 0 0.0020493935
) O 0 0.0061963773
fatal O 0 0.9038698
poisoning B-Disease 2 0.99929965
. O 0 0.0072519663

METHODS O 0 0.0049053966
: O 0 0.0033948584
The O 0 0.00096590776
son O 0 0.002034693
of O 0 0.0009072647
an O 0 0.0008003257
84 O 0 0.0010658898
- O 0 0.0020152626
year O 0 0.00039532295
- O 0 0.0011517281
old O 0 0.00035563536
male O 0 0.00054596993
discovered O 0 0.0003004765
a O 0 0.00036607654
newspaper O 0 0.00046200294
report O 0 0.0003913816
stating O 0 0.00034477562
clinical O 0 0.0006829268
success O 0 0.00045414816
with O 0 0.00036640576
plant O 0 0.0011590896
extracts O 0 0.0009751069
in O 0 0.0012377293
Alzheimer B-Disease 0 0.99991024
' I-Disease 0 0.0033984706
s I-Disease 0 0.002599204
disease I-Disease 0 0.40124002
. O 0 0.003455352

The O 0 0.0017543689
mode O 0 0.0014926582
of O 0 0.0012435942
action O 0 0.0010170635
was O 0 0.0006945583
said O 0 0.00088353356
to O 0 0.00031072364
be O 0 0.00022809985
comparable O 0 0.00013470744
to O 0 0.00014099074
that O 0 0.00012300009
of O 0 0.00019397
the O 0 0.00016692566
synthetic O 0 0.00022485264
compound O 0 0.0041887825
' O 0 0.001774931
carbamylcholin B-Chemical 0 0.6114043
' O 0 0.0019750916
; O 0 0.0011459176
that O 0 0.0004411194
is O 0 0.00078141526
, O 0 0.00366334
carbachol B-Chemical 0 0.9988927
. O 0 0.0051498488

He O 0 0.011658498
bought O 0 0.009575458
25 O 0 0.0028577836
g O 0 0.004379612
of O 0 0.0016733196
carbachol B-Chemical 0 0.99929965
as O 0 0.0008645505
pure O 0 0.0018819539
substance O 0 0.46153685
in O 0 0.0003933312
a O 0 0.0005440517
pharmacy O 0 0.002226157
, O 0 0.00050005433
and O 0 0.00025909502
the O 0 0.00022419523
father O 0 0.00058715564
was O 0 0.00029722162
administered O 0 0.0005453328
400 O 0 0.001070235
to O 0 0.0005911478
500 O 0 0.0023407836
mg O 0 0.012663386
. O 0 0.002994783

Carbachol B-Chemical 0 0.99951124
concentrations O 0 0.007285083
in O 0 0.0019108852
serum O 0 0.021060638
and O 0 0.0010567468
urine O 0 0.009080072
on O 0 0.00024977635
day O 0 0.00020740714
1 O 0 0.00025819565
and O 0 0.00021640678
2 O 0 0.0002219139
of O 0 0.00022278332
hospital O 0 0.00033627372
admission O 0 0.00033644517
were O 0 0.0002487041
analysed O 0 0.000406117
by O 0 0.0006070423
HPLC O 0 0.13599634
- O 0 0.003999526
mass O 0 0.002055614
spectrometry O 0 0.0030800367
. O 0 0.0031399466

RESULTS O 0 0.0046448563
: O 0 0.0036544914
Minutes O 0 0.0066621085
after O 0 0.00060855976
oral O 0 0.00163636
administration O 0 0.0008593746
, O 0 0.00067916675
the O 0 0.00029199495
patient O 0 0.00040128568
developed O 0 0.00057931134
nausea B-Disease 0 0.9984573
, O 0 0.0021063215
sweating O 0 0.9969103
and O 0 0.0010290282
hypotension B-Disease 0 0.999846
, O 0 0.0014737359
and O 0 0.00090198766
finally O 0 0.0019921174
collapsed O 0 0.005202584
. O 0 0.0035328935

Bradycardia B-Disease 0 0.99744874
, O 0 0.015462182
cholinergic O 0 0.16998291
symptoms O 0 0.027441213
and O 0 0.0050859405
asystole B-Disease 0 0.98009825
occurred O 0 0.0053060083
. O 0 0.0070969188

Initial O 0 0.0026052683
cardiopulmonary O 0 0.001856458
resuscitation O 0 0.0011986501
and O 0 0.0005981196
immediate O 0 0.000642461
treatment O 0 0.0005040867
with O 0 0.00089198985
adrenaline B-Chemical 0 0.9999583
( O 0 0.0051154373
epinephrine B-Chemical 0 0.99980205
) O 0 0.0020817462
, O 0 0.0018047598
atropine B-Chemical 0 0.99993205
and O 0 0.002041074
furosemide B-Chemical 0 0.99996614
was O 0 0.0014477555
successful O 0 0.0018017337
. O 0 0.0028962658

On O 0 0.0033232914
hospital O 0 0.0030944191
admission O 0 0.0021301433
, O 0 0.001795831
blood O 0 0.0032567964
pressure O 0 0.003843829
of O 0 0.0005567725
the O 0 0.00039951783
intubated O 0 0.001430203
, O 0 0.00084815506
bradyarrhythmic O 0 0.006153846
patient O 0 0.00055817177
was O 0 0.0004986309
100 O 0 0.001259091
/ O 0 0.0027514228
65 O 0 0.0018111502
mmHg O 0 0.006245081
. O 0 0.0037528474

Further O 0 0.0030643912
signs O 0 0.007458867
were O 0 0.0024246557
hyperhidrosis B-Disease 0 0.9972439
, O 0 0.0050152983
hypersalivation B-Disease 0 0.99973637
, O 0 0.0033777165
bronchorrhoea B-Disease 0 0.9159995
, O 0 0.001070135
and O 0 0.00055662234
severe O 0 0.020966226
miosis B-Disease 0 0.9999089
; O 0 0.0008056222
the O 0 0.00021907013
electrocardiographic O 0 0.0026701319
finding O 0 0.00030746916
was O 0 0.00040413445
atrio B-Disease 0 0.022177702
- I-Disease 0 0.0054849656
ventricular I-Disease 0 0.3054946
dissociation I-Disease 0 0.003395336
. O 0 0.002958292

High O 0 0.0049137925
doses O 0 0.004938147
of O 0 0.0032112221
atropine B-Chemical 0 0.9998996
( O 0 0.0022651204
up O 0 0.000606749
to O 0 0.00033838145
50 O 0 0.00049855304
mg O 0 0.0022503329
per O 0 0.0002275314
24 O 0 0.00021429498
hours O 0 0.00022083448
) O 0 0.00080249377
, O 0 0.0015365889
adrenaline B-Chemical 0 0.9999157
and O 0 0.0021371779
dopamine B-Chemical 0 0.99915624
were O 0 0.0011273598
necessary O 0 0.0010757386
. O 0 0.002939602

The O 0 0.004563139
patient O 0 0.004580747
was O 0 0.003258348
extubated O 0 0.004299082
1 O 0 0.0026463957
week O 0 0.0019904966
later O 0 0.0037180912
. O 0 0.007365177

However O 0 0.0053915256
, O 0 0.008027318
increased O 0 0.0065406435
dyspnoea B-Disease 0 0.9765038
and O 0 0.0049379123
bronchospasm B-Disease 0 0.997832
necessitated O 0 0.0053543956
reintubation O 0 0.019872062
. O 0 0.0055306726

Respiratory B-Disease 0 0.8560091
insufficiency I-Disease 0 0.99862266
was O 0 0.0021481581
further O 0 0.0013277738
worsened O 0 0.015404781
by O 0 0.0018761723
Proteus B-Disease 0 0.9916597
mirabilis I-Disease 0 0.41417336
infection I-Disease 0 0.066105984
and O 0 0.002450609
severe O 0 0.046253234
bronchoconstriction O 0 0.9937596
. O 0 0.00520583

One O 0 0.003417503
week O 0 0.0013996237
later O 0 0.0011888258
, O 0 0.0015332687
the O 0 0.0006231148
patient O 0 0.0006193972
was O 0 0.00036131422
again O 0 0.00033248597
extubated O 0 0.00048255545
and O 0 0.00020888167
3 O 0 0.00016330143
days O 0 0.00012702099
later O 0 0.0002061697
was O 0 0.00027666497
transferred O 0 0.00045224646
to O 0 0.00043698933
a O 0 0.001088006
peripheral O 0 0.0028321552
ward O 0 0.0024469085
. O 0 0.0032244145

On O 0 0.0032077178
the O 0 0.0016244636
next O 0 0.00077672803
day O 0 0.00093692937
he O 0 0.0014455135
died O 0 0.0021077155
, O 0 0.0014594273
probably O 0 0.00089392375
as O 0 0.00073360396
a O 0 0.0010614875
result O 0 0.0007998557
of O 0 0.0014763463
heart B-Disease 0 0.11567429
failure I-Disease 0 0.08854445
. O 0 0.0044120043

Serum O 0 0.26811418
samples O 0 0.0027130803
from O 0 0.001057291
the O 0 0.00060360297
first O 0 0.00034891645
and O 0 0.00039751138
second O 0 0.0002625686
days O 0 0.00016730667
contained O 0 0.00014928622
3 O 0 0.00019577939
. O 0 0.00019127803
6 O 0 0.00014992472
and O 0 0.00021840545
1 O 0 0.00027433535
. O 0 0.00025190436
9 O 0 0.0003131563
mg O 0 0.0027671838
/ O 0 0.0025639639
l O 0 0.01002098
carbachol B-Chemical 0 0.99907315
, O 0 0.003809516
respectively O 0 0.0039439825
. O 0 0.0038608832

The O 0 0.0027237593
corresponding O 0 0.0020470347
urine O 0 0.017715603
concentrations O 0 0.0028055229
amounted O 0 0.0026933555
to O 0 0.0012107481
374 O 0 0.0044516097
and O 0 0.001538002
554 O 0 0.0053631742
mg O 0 0.013227052
/ O 0 0.007550781
l O 0 0.010845343
. O 0 0.0064216405

CONCLUSION O 0 0.020782877
: O 0 0.004674893
This O 0 0.0016551707
case O 0 0.0008585879
started O 0 0.0006169695
with O 0 0.0004844936
a O 0 0.00056882505
media O 0 0.00078419544
report O 0 0.0005135393
in O 0 0.00021338198
a O 0 0.00029438233
popular O 0 0.0003069522
newspaper O 0 0.0003890848
, O 0 0.00029995848
initiated O 0 0.00015063144
by O 0 0.00014152561
published O 0 0.00016880689
, O 0 0.0003896897
peer O 0 0.00603688
- O 0 0.0020822692
reviewed O 0 0.00033045316
research O 0 0.0001818065
on O 0 0.00010397511
herbals O 0 0.22631891
, O 0 0.00043018538
and O 0 0.00016814661
involved O 0 0.00012497186
human O 0 0.00018901809
failure O 0 0.005279846
in O 0 0.00015089595
a O 0 0.00022865616
case O 0 0.00018564265
history O 0 0.0003646015
, O 0 0.00041324913
medical O 0 0.0007249194
examination O 0 0.0002801263
and O 0 0.00047179905
clinical O 0 0.0018708878
treatment O 0 0.0013080599
. O 0 0.0024786475

For O 0 0.0014991708
the O 0 0.0011775504
first O 0 0.00064678123
time O 0 0.0005648465
, O 0 0.00097244437
an O 0 0.00049291574
analytical O 0 0.00069909357
method O 0 0.0003065653
for O 0 0.0001917199
the O 0 0.00021308311
determination O 0 0.00040568152
of O 0 0.00055869215
carbachol B-Chemical 0 0.99963236
in O 0 0.0006083895
plasma O 0 0.024959845
and O 0 0.0006340248
urine O 0 0.04039441
has O 0 0.00048246235
been O 0 0.00086643005
developed O 0 0.0018480986
. O 0 0.0029546109

The O 0 0.0024533346
analysed O 0 0.0037196286
carbachol B-Chemical 0 0.9988912
concentration O 0 0.0022499368
exceeded O 0 0.00073287234
the O 0 0.00040072988
supposed O 0 0.0005750854
serum O 0 0.0043843137
level O 0 0.00025183137
resulting O 0 0.00020620863
from O 0 0.00017768634
a O 0 0.00027281605
therapeutic O 0 0.000316768
dose O 0 0.00042668104
by O 0 0.0002953877
a O 0 0.00063787145
factor O 0 0.0025275801
of O 0 0.0007997799
130 O 0 0.0017370047
to O 0 0.0010890035
260 O 0 0.0066390424
. O 0 0.003345688

Especially O 0 0.005396811
in O 0 0.001993722
old O 0 0.0018156492
patients O 0 0.0018296667
, O 0 0.0011894372
intensivists O 0 0.00084707444
should O 0 0.00022571637
consider O 0 0.00030377047
intoxications O 0 0.99271625
( O 0 0.00096649776
with O 0 0.0004887499
cholinergics O 0 0.82183355
) O 0 0.00095863524
as O 0 0.00030405767
a O 0 0.00049813214
cause O 0 0.0005318525
of O 0 0.0007611212
acute B-Disease 0 0.72992915
cardiovascular I-Disease 0 0.85774314
failure I-Disease 0 0.59832597
. O 0 0.0033384708

Pharmacological O 0 0.035626605
evidence O 0 0.001757997
for O 0 0.0010663623
the O 0 0.0007709031
potential O 0 0.00064012234
of O 0 0.0009950085
Daucus O 0 0.0036833666
carota O 0 0.08238265
in O 0 0.0006905954
the O 0 0.00054738147
management O 0 0.0009102485
of O 0 0.0014279723
cognitive B-Disease 0 0.9789363
dysfunctions I-Disease 0 0.8849586
. O 0 0.004766474

The O 0 0.0019054435
present O 0 0.0013166617
study O 0 0.0011531875
was O 0 0.00054889685
aimed O 0 0.0003944805
at O 0 0.00024549774
investigating O 0 0.00019445147
the O 0 0.00017160934
effects O 0 0.00020371347
of O 0 0.0003339693
Daucus O 0 0.0015999357
carota O 0 0.117419064
seeds O 0 0.0008213995
on O 0 0.00018205614
cognitive O 0 0.62122303
functions O 0 0.00018484323
, O 0 0.00041078686
total O 0 0.00028986004
serum O 0 0.15434855
cholesterol B-Chemical 0 0.9998486
levels O 0 0.00038145916
and O 0 0.0004970443
brain O 0 0.008323159
cholinesterase O 0 0.99454135
activity O 0 0.00035905157
in O 0 0.00054809614
mice O 0 0.00051984395
. O 0 0.0021409416

The O 0 0.003302436
ethanolic O 0 0.39737892
extract B-Chemical 0 0.005085144
of I-Chemical 0 0.0016593996
Daucus I-Chemical 0 0.0053413655
carota I-Chemical 0 0.16095822
seeds I-Chemical 0 0.0022293525
( O 0 0.0012950919
DCE B-Chemical 0 0.615123
) O 0 0.00067430234
was O 0 0.00015963329
administered O 0 0.00020970368
orally O 0 0.00023329485
in O 0 8.668114e-05
three O 0 5.3831624e-05
doses O 0 0.000260728
( O 0 0.00029303264
100 O 0 0.00031008353
, O 0 0.00027780418
200 O 0 0.00027886295
, O 0 0.00029619902
400 O 0 0.00051199674
mg O 0 0.0019887555
/ O 0 0.00060123904
kg O 0 0.00039974606
) O 0 0.00027344207
for O 0 7.8312325e-05
seven O 0 7.482831e-05
successive O 0 8.052289e-05
days O 0 6.6676264e-05
to O 0 9.402853e-05
different O 0 0.00010884802
groups O 0 0.00026208535
of O 0 0.00037057462
young O 0 0.0013701877
and O 0 0.0006686921
aged O 0 0.0013827579
mice O 0 0.0006454718
. O 0 0.002421055

Elevated O 0 0.014873449
plus O 0 0.0024738864
maze O 0 0.113745004
and O 0 0.0010007337
passive O 0 0.0008046776
avoidance O 0 0.001145131
apparatus O 0 0.000824096
served O 0 0.00069806067
as O 0 0.0003771578
the O 0 0.00033039923
exteroceptive O 0 0.0022607504
behavioral O 0 0.00094035186
models O 0 0.00037774377
for O 0 0.00045967582
testing O 0 0.00095558754
memory O 0 0.078896336
. O 0 0.0042351573

Diazepam B-Chemical 0 0.9999654
- O 0 0.55007917
, O 0 0.024630193
scopolamine B-Chemical 0 0.9999912
- O 0 0.11078046
and O 0 0.0012500559
ageing O 0 0.022369385
- O 0 0.005746591
induced O 0 0.0008650627
amnesia B-Disease 0 0.9996966
served O 0 0.001258254
as O 0 0.0005322669
the O 0 0.00054673955
interoceptive O 0 0.01004955
behavioral O 0 0.0026915336
models O 0 0.001496666
. O 0 0.0029924402

DCE B-Chemical 0 0.5568223
( O 0 0.0055635683
200 O 0 0.0029263422
, O 0 0.002219318
400 O 0 0.002416182
mg O 0 0.0053654965
/ O 0 0.001820612
kg O 0 0.0010977617
, O 0 0.00068697386
p O 0 0.0006586908
. O 0 0.00035810977
o O 0 0.001201252
. O 0 0.00032441976
) O 0 0.00047987554
showed O 0 0.00016193998
significant O 0 0.00017068225
improvement O 0 0.0002377275
in O 0 0.00019753033
memory O 0 0.0076814154
scores O 0 0.0003393713
of O 0 0.00040255007
young O 0 0.0013438974
and O 0 0.00067505066
aged O 0 0.00138928
mice O 0 0.0006623394
. O 0 0.0024738451

The O 0 0.0018588586
extent O 0 0.0013753321
of O 0 0.001327323
memory O 0 0.019002642
improvement O 0 0.00097404106
evoked O 0 0.0010389116
by O 0 0.00045960222
DCE B-Chemical 0 0.13600138
was O 0 0.00027793
23 O 0 0.00030403098
% O 0 0.0002807576
at O 0 9.772593e-05
the O 0 0.0001056406
dose O 0 0.00020807047
of O 0 0.00016083388
200 O 0 0.00034451965
mg O 0 0.0022834504
/ O 0 0.000593419
kg O 0 0.00033846663
and O 0 0.00013410239
35 O 0 0.00013798263
% O 0 0.00018624458
at O 0 7.1232505e-05
the O 0 8.4091414e-05
dose O 0 0.0001840055
of O 0 0.00015604768
400 O 0 0.00057587796
mg O 0 0.0024873896
/ O 0 0.0006636239
kg O 0 0.0004191565
in O 0 0.00017483199
young O 0 0.0004746712
mice O 0 0.00010998139
using O 0 0.00027289407
elevated O 0 0.0015087819
plus O 0 0.0011922494
maze O 0 0.5237594
. O 0 0.004096105

Similarly O 0 0.0030608608
, O 0 0.002896924
significant O 0 0.0010210741
improvements O 0 0.0007766867
in O 0 0.0006089235
memory O 0 0.008681578
scores O 0 0.00047024692
were O 0 0.0002758734
observed O 0 0.00021614715
using O 0 0.00021016244
passive O 0 0.00039237287
avoidance O 0 0.0008439903
apparatus O 0 0.000841822
and O 0 0.0007497986
aged O 0 0.0015621991
mice O 0 0.00078832824
. O 0 0.0028607624

Furthermore O 0 0.003949233
, O 0 0.0060287854
DCE B-Chemical 0 0.6820674
reversed O 0 0.002847275
the O 0 0.001329772
amnesia B-Disease 0 0.99964905
induced O 0 0.0008787685
by O 0 0.0011590542
scopolamine B-Chemical 0 0.99999654
( O 0 0.0012061209
0 O 0 0.0003118169
. O 0 0.00015750715
4 O 0 0.00013738922
mg O 0 0.000934605
/ O 0 0.0005766312
kg O 0 0.00044363312
, O 0 0.00031932382
i O 0 0.00032860652
. O 0 0.00017349268
p O 0 0.00031206492
. O 0 0.00019788719
) O 0 0.00052059494
and O 0 0.00048688965
diazepam B-Chemical 0 0.9999939
( O 0 0.0009126707
1 O 0 0.00033858782
mg O 0 0.0020580483
/ O 0 0.00094878796
kg O 0 0.00075851823
, O 0 0.0006541817
i O 0 0.0008148751
. O 0 0.0005880525
p O 0 0.0012645959
. O 0 0.0012028979
) O 0 0.003602442
. O 0 0.0037481242

Daucus B-Chemical 0 0.09094062
carota I-Chemical 0 0.5768726
extract I-Chemical 0 0.026613703
( O 0 0.0034239988
200 O 0 0.0017703291
, O 0 0.0013132128
400 O 0 0.0015184279
mg O 0 0.0037036655
/ O 0 0.0011948621
kg O 0 0.0007349646
, O 0 0.00047026575
p O 0 0.000472826
. O 0 0.00026155912
o O 0 0.0010547368
. O 0 0.00027641552
) O 0 0.00052435667
reduced O 0 0.00024838326
significantly O 0 0.0002783137
the O 0 0.00022391535
brain O 0 0.0042566843
acetylcholinesterase O 0 0.9422823
activity O 0 0.000165233
and O 0 0.0003617135
cholesterol B-Chemical 0 0.99963963
levels O 0 0.0003635665
in O 0 0.0003680559
young O 0 0.0014020215
and O 0 0.00059886166
aged O 0 0.0012351961
mice O 0 0.0005743305
. O 0 0.0022088005

The O 0 0.0018085393
extent O 0 0.001359402
of O 0 0.001257828
inhibition O 0 0.0012424375
of O 0 0.0011151226
brain O 0 0.01745429
cholinesterase O 0 0.9973183
activity O 0 0.00021151817
evoked O 0 0.00046949537
by O 0 0.00019597851
DCE B-Chemical 0 0.06181625
at O 0 0.0001003926
the O 0 9.415082e-05
dose O 0 0.00018875192
of O 0 0.00015611599
400 O 0 0.00055738474
mg O 0 0.0023342294
/ O 0 0.00065660645
kg O 0 0.0004170123
was O 0 0.00016349679
22 O 0 0.00025894583
% O 0 0.00033636607
in O 0 0.00021571727
young O 0 0.0008081229
and O 0 0.00037706233
19 O 0 0.00055200676
% O 0 0.000766886
in O 0 0.0005490755
aged O 0 0.0013737037
mice O 0 0.0007130342
. O 0 0.0026698415

There O 0 0.003722998
was O 0 0.0020230338
a O 0 0.0017435106
remarkable O 0 0.0010758907
reduction O 0 0.00088848063
in O 0 0.0005778931
total O 0 0.0007187261
cholesterol B-Chemical 0 0.99926823
level O 0 0.00038433148
as O 0 0.0002851007
well O 0 0.0002303683
, O 0 0.000375756
to O 0 0.00014648757
the O 0 0.00012490324
extent O 0 0.00014197518
of O 0 0.00020382072
23 O 0 0.00029565563
% O 0 0.0003301307
in O 0 0.00016116838
young O 0 0.00058766396
and O 0 0.00019570046
21 O 0 0.000206354
% O 0 0.00028556693
in O 0 0.00015286493
aged O 0 0.0003156129
animals O 0 0.00015163705
with O 0 0.00029872783
this O 0 0.00047272307
dose O 0 0.0011011034
of O 0 0.0014475032
DCE B-Chemical 0 0.7685686
. O 0 0.0034559646

Therefore O 0 0.0029498036
, O 0 0.0061725047
DCE B-Chemical 0 0.5992641
may O 0 0.0010898224
prove O 0 0.00079644227
to O 0 0.00044184155
be O 0 0.00034327607
a O 0 0.00035799577
useful O 0 0.00019497778
remedy O 0 0.00034198715
for O 0 0.00012846907
the O 0 0.00012487441
management O 0 0.00019550743
of O 0 0.00024386006
cognitive B-Disease 0 0.95790905
dysfunctions I-Disease 0 0.35918015
on O 0 8.1866456e-05
account O 0 9.116157e-05
of O 0 0.00010660713
its O 0 0.00014447462
multifarious O 0 0.00020129819
beneficial O 0 0.00011157677
effects O 0 9.231394e-05
such O 0 0.00010107055
as O 0 0.00012517878
, O 0 0.0002972797
memory O 0 0.03345386
improving O 0 0.00018805885
property O 0 0.00039501916
, O 0 0.0009110278
cholesterol B-Chemical 0 0.99973613
lowering O 0 0.011002985
property O 0 0.0008888562
and O 0 0.0008815482
anticholinesterase O 0 0.9851436
activity O 0 0.0011888806
. O 0 0.0025120704

Valproic B-Chemical 0 0.9999778
acid I-Chemical 0 0.9977858
induced O 0 0.018149488
encephalopathy B-Disease 2 0.99998534
- O 0 0.51829225
- O 0 0.0074044336
19 O 0 0.00057531835
new O 0 0.00037295165
cases O 0 0.00046402944
in O 0 0.00025623257
Germany O 0 0.00071399903
from O 0 0.00018064237
1994 O 0 0.0004151792
to O 0 0.00016603514
2003 O 0 0.00042292455
- O 0 0.0019584266
- O 0 0.0012436872
a O 0 0.00025630754
side O 0 0.00043073026
effect O 0 0.00017235382
associated O 0 0.00031186207
to O 0 0.00045083053
VPA B-Chemical 1 0.99999547
- O 0 0.03007104
therapy O 0 0.00041965046
not O 0 0.00022969367
only O 0 0.00040741928
in O 0 0.0006032964
young O 0 0.003915028
children O 0 0.005227436
. O 0 0.002935637

Valproic B-Chemical 0 0.9999784
acid I-Chemical 0 0.9987459
( O 0 0.45334673
VPA B-Chemical 1 0.9999845
) O 0 0.005583758
is O 0 0.00055324216
a O 0 0.0006668414
broad O 0 0.0006473659
- O 0 0.0022332063
spectrum O 0 0.0008055999
antiepileptic O 0 0.99764025
drug O 0 0.009339269
and O 0 0.00036651053
is O 0 0.000305925
usually O 0 0.0005373429
well O 0 0.00066207116
- O 0 0.0042470424
tolerated O 0 0.0029597525
. O 0 0.0030553814

Rare O 0 0.035933852
serious O 0 0.007668868
complications O 0 0.03160999
may O 0 0.00090429373
occur O 0 0.0005802566
in O 0 0.00037607437
some O 0 0.00036563564
patients O 0 0.0006932007
, O 0 0.00058247737
including O 0 0.00036971873
haemorrhagic O 0 0.9998765
pancreatitis B-Disease 0 0.9999864
, O 0 0.0024187027
bone B-Disease 0 0.10260309
marrow I-Disease 0 0.5839099
suppression I-Disease 0 0.0057702363
, O 0 0.004554505
VPA B-Chemical 1 0.99999666
- O 0 0.110514134
induced O 0 0.0007763592
hepatotoxicity B-Disease 0 0.99999046
and O 0 0.007315029
VPA B-Chemical 1 0.99999535
- O 0 0.2517878
induced O 0 0.002458821
encephalopathy B-Disease 2 0.99994993
. O 0 0.0049470444

The O 0 0.0023024827
typical O 0 0.0023986152
signs O 0 0.006572289
of O 0 0.003690243
VPA B-Chemical 1 0.9999901
- O 0 0.25629056
induced O 0 0.001317309
encephalopathy B-Disease 2 0.999985
are O 0 0.00049409835
impaired B-Disease 0 0.16804492
consciousness I-Disease 0 0.997393
, O 0 0.00069317454
sometimes O 0 0.00050724746
marked O 0 0.00036956693
EEG O 0 0.38543573
background O 0 0.00012710085
slowing O 0 0.00067234796
, O 0 0.00044125228
increased O 0 0.0005528487
seizure B-Disease 0 0.99879813
frequency O 0 0.0003007316
, O 0 0.0005836466
with O 0 0.00044119777
or O 0 0.0005980545
without O 0 0.0018391345
hyperammonemia B-Disease 0 0.99989784
. O 0 0.004832656

There O 0 0.0035204513
is O 0 0.0016041199
still O 0 0.0010248632
no O 0 0.0007272578
proof O 0 0.0006000052
of O 0 0.0006349041
causative O 0 0.00064788
effect O 0 0.00040193196
of O 0 0.0014541306
VPA B-Chemical 1 0.99999607
in O 0 0.00047637214
patients O 0 0.0009766171
with O 0 0.00052592164
encephalopathy B-Disease 2 0.9999912
, O 0 0.0010189936
but O 0 0.00025014955
only O 0 0.00018780529
of O 0 0.00020237571
an O 0 0.00021667396
association O 0 0.00015202796
with O 0 0.00033034035
an O 0 0.00047312156
assumed O 0 0.000527916
causal O 0 0.00094185746
relation O 0 0.0010474998
. O 0 0.0029313257

We O 0 0.0028863512
report O 0 0.0031680549
19 O 0 0.0020616897
patients O 0 0.0023781916
with O 0 0.0023170875
VPA B-Chemical 1 0.99999046
- O 0 0.20995183
associated O 0 0.0012287999
encephalopathy B-Disease 2 0.9999689
in O 0 0.00038278132
Germany O 0 0.00078748056
from O 0 0.00013785691
the O 0 0.00012202416
years O 0 0.00020627884
1994 O 0 0.0003651043
to O 0 0.0001526846
2003 O 0 0.00032348585
, O 0 0.00033322859
none O 0 0.00024837285
of O 0 0.00034037544
whom O 0 0.0006846876
had O 0 0.0004486159
been O 0 0.0005525013
published O 0 0.0008294714
previously O 0 0.0016605004
. O 0 0.0030722313

Cerebral B-Disease 0 0.9968526
haemorrhage I-Disease 0 0.9998367
induced O 0 0.002562469
by O 0 0.002041933
warfarin B-Chemical 0 0.99895716
- O 0 0.004639934
the O 0 0.00044819064
influence O 0 0.00038103334
of O 0 0.0008703902
drug O 0 0.027409913
- O 0 0.008420272
drug O 0 0.009367048
interactions O 0 0.002136466
. O 0 0.003888547

PURPOSE O 0 0.006135027
: O 0 0.0023391298
To O 0 0.00035991656
evaluate O 0 0.0002557654
the O 0 0.0003274347
frequency O 0 0.00032159378
, O 0 0.00059070875
severity O 0 0.00067460176
and O 0 0.0002634299
preventability O 0 0.0064346544
of O 0 0.0004575852
warfarin B-Chemical 0 0.99978095
- O 0 0.017194008
induced O 0 0.00042292092
cerebral B-Disease 0 0.9999578
haemorrhages I-Disease 0 0.9999896
due O 0 0.000116701245
to O 0 0.00012939544
warfarin B-Chemical 0 0.99869883
and O 0 0.0002460857
warfarin B-Chemical 0 0.9996099
- O 0 0.003548379
drug O 0 0.0015766579
interactions O 0 0.00010233927
in O 0 0.00012445408
patients O 0 0.00035865008
living O 0 0.0003250386
in O 0 0.00016727477
the O 0 0.00018834973
county O 0 0.0006149055
of O 0 0.00039725722
Osterg O 0 0.00080959965
tland O 0 0.0015148484
, O 0 0.0024831742
Sweden O 0 0.005386128
. O 0 0.0032742536

METHODS O 0 0.0039553884
: O 0 0.0025825715
All O 0 0.000761791
patients O 0 0.0012192903
with O 0 0.0007742813
a O 0 0.0012768947
diagnosed O 0 0.04493585
cerebral B-Disease 0 0.9998448
haemorrhage I-Disease 0 0.9999757
at O 0 0.0002166444
three O 0 0.00010069076
hospitals O 0 0.00031167694
during O 0 0.00013153203
the O 0 0.00016653792
period O 0 0.0002204398
2000 O 0 0.00081569667
- O 0 0.0018645845
2002 O 0 0.0012549304
were O 0 0.00083099346
identified O 0 0.0011301796
. O 0 0.0030987747

Medical O 0 0.0052445875
records O 0 0.00270639
were O 0 0.0010117182
studied O 0 0.0008762209
retrospectively O 0 0.00058151555
to O 0 0.00022314642
evaluate O 0 0.0001091691
whether O 0 0.00013441873
warfarin B-Chemical 0 0.9968058
and O 0 0.0006182395
warfarin B-Chemical 0 0.9995752
- O 0 0.007856238
drug O 0 0.0032247733
interactions O 0 0.00024385306
could O 0 0.00021224952
have O 0 0.00030850447
caused O 0 0.0005537437
the O 0 0.0012399264
cerebral B-Disease 0 0.9997634
haemorrhage I-Disease 0 0.9999572
. O 0 0.004664184

The O 0 0.0022603965
proportion O 0 0.0017913388
of O 0 0.0018360286
possibly O 0 0.0019200452
avoidable O 0 0.003231174
cases O 0 0.0016062311
due O 0 0.0005967563
to O 0 0.00071349
drug O 0 0.00457254
interactions O 0 0.0010257688
was O 0 0.0013805446
estimated O 0 0.0022846763
. O 0 0.0037699637

RESULTS O 0 0.0049148924
: O 0 0.0036710803
Among O 0 0.001991522
593 O 0 0.0087737655
patients O 0 0.0021193991
with O 0 0.0016691571
cerebral B-Disease 0 0.9997321
haemorrhage I-Disease 0 0.99997747
, O 0 0.0014887672
59 O 0 0.00060745206
( O 0 0.0004983793
10 O 0 0.00026188852
% O 0 0.00045850888
) O 0 0.00050531904
were O 0 0.00021629085
assessed O 0 0.0002544316
as O 0 0.0003085595
related O 0 0.00031447425
to O 0 0.0007457408
warfarin B-Chemical 0 0.99516857
treatment O 0 0.0019411192
. O 0 0.0029916582

This O 0 0.005635032
imply O 0 0.0016864914
an O 0 0.0020262422
incidence O 0 0.0022183012
of O 0 0.0012517392
1 O 0 0.0010512201
. O 0 0.0007139576
7 O 0 0.0006248698
/ O 0 0.0021213393
100 O 0 0.0015105745
, O 0 0.0015245491
000 O 0 0.0013955941
treatment O 0 0.001320626
years O 0 0.002587377
. O 0 0.00399544

Of O 0 0.006327123
the O 0 0.0025706282
59 O 0 0.0029548553
cases O 0 0.0024124
, O 0 0.0018720404
26 O 0 0.001153331
( O 0 0.0011059863
44 O 0 0.0007651734
% O 0 0.00091786555
) O 0 0.0008650762
had O 0 0.0003487231
a O 0 0.0005469736
fatal O 0 0.056021452
outcome O 0 0.00034153997
, O 0 0.00030977596
compared O 0 0.00012734966
to O 0 0.00015858101
136 O 0 0.0004729881
( O 0 0.00032708715
25 O 0 0.00023883344
% O 0 0.0003344931
) O 0 0.0003466465
among O 0 0.00017662653
the O 0 0.00016110294
non O 0 0.0004805482
- O 0 0.008431821
warfarin B-Chemical 0 0.9979044
patients O 0 0.00064708607
( O 0 0.00044817504
p O 0 0.00049883605
< O 0 0.00058615196
0 O 0 0.00067812164
. O 0 0.00083608396
01 O 0 0.0048817866
) O 0 0.0039554974
. O 0 0.0038240259

A O 0 0.41119125
warfarin B-Chemical 0 0.99916565
- O 0 0.05768105
drug O 0 0.012506042
interaction O 0 0.00055984565
could O 0 0.00036283315
have O 0 0.00033044274
contributed O 0 0.0004967708
to O 0 0.00027951004
the O 0 0.00035911606
haemorrhage B-Disease 0 0.99972767
in O 0 0.0002306771
24 O 0 0.00019187186
( O 0 0.00025772883
41 O 0 0.00025357187
% O 0 0.000289649
) O 0 0.00030398404
of O 0 0.00015305763
the O 0 0.00018028548
warfarin B-Chemical 0 0.99898344
patients O 0 0.00044645873
and O 0 0.00013249615
in O 0 0.00010825645
7 O 0 8.810896e-05
of O 0 0.00011454136
these O 0 0.00012525245
( O 0 0.00023528136
12 O 0 9.477805e-05
% O 0 0.00024108955
) O 0 0.0003139
the O 0 0.00015799659
bleeding B-Disease 0 0.68601334
complication O 0 0.0023108218
was O 0 0.00019965619
considered O 0 0.00023937487
being O 0 0.00030514898
possible O 0 0.000324632
to O 0 0.00060140126
avoid O 0 0.0011284746
. O 0 0.0028392787

CONCLUSIONS O 0 0.04410968
: O 0 0.014246177
Warfarin B-Chemical 0 0.9990293
- O 0 0.018051716
induced O 0 0.0019141765
cerebral B-Disease 0 0.9997739
haemorrhages I-Disease 0 0.9999516
are O 0 0.00042190935
a O 0 0.00043649558
major O 0 0.00029233226
clinical O 0 0.0006851393
problem O 0 0.00042471391
with O 0 0.00046056858
a O 0 0.0008532982
high O 0 0.0012940408
fatality O 0 0.8421713
rate O 0 0.0032616435
. O 0 0.0033852775

Almost O 0 0.005252771
half O 0 0.0019935474
of O 0 0.0017503118
the O 0 0.0011700679
cases O 0 0.0016059215
was O 0 0.0007095787
related O 0 0.00044628582
to O 0 0.0006155648
a O 0 0.001653905
warfarin B-Chemical 0 0.9983987
- O 0 0.010145495
drug O 0 0.008355791
interaction O 0 0.0018166568
. O 0 0.0039043801

A O 0 0.01742809
significant O 0 0.0018801078
proportion O 0 0.0012150283
of O 0 0.0017596848
warfarin B-Chemical 0 0.99956864
- O 0 0.03954432
related O 0 0.0005889171
cerebral B-Disease 0 0.9998728
haemorrhages I-Disease 0 0.9999771
might O 0 0.00015018455
have O 0 0.00013531031
been O 0 0.00012887863
prevented O 0 0.00020216973
if O 0 8.791298e-05
greater O 0 0.00018287994
caution O 0 0.00018708628
had O 0 0.00010657511
been O 0 9.16774e-05
taken O 0 8.154257e-05
when O 0 8.630125e-05
prescribing O 0 0.00072357483
drugs O 0 0.004014562
known O 0 0.00023301896
to O 0 0.00024501554
interact O 0 0.00027027214
with O 0 0.0012108273
warfarin B-Chemical 0 0.99837387
. O 0 0.0032276579

Antipsychotic O 0 0.99882287
- O 0 0.015076324
like O 0 0.0013911361
profile O 0 0.0012254677
of O 0 0.0021320689
thioperamide B-Chemical 0 0.9998766
, O 0 0.004005923
a O 0 0.0015207712
selective O 0 0.0015701297
H3 O 0 0.005562017
- O 0 0.05322626
receptor O 0 0.0062620314
antagonist O 0 0.20769149
in O 0 0.0013799202
mice O 0 0.000938091
. O 0 0.0032141015

Experimental O 0 0.0051161437
and O 0 0.0020688078
clinical O 0 0.0020226373
evidence O 0 0.00057910645
points O 0 0.00054818916
to O 0 0.00040111705
a O 0 0.00047329545
role O 0 0.00018010475
of O 0 0.00042271096
central O 0 0.00079287076
histaminergic O 0 0.0026589795
system O 0 0.00035363896
in O 0 0.00034602027
the O 0 0.00043057816
pathogenesis O 0 0.0014088819
of O 0 0.002446514
schizophrenia B-Disease 2 0.9999268
. O 0 0.0053565367

The O 0 0.0019526538
present O 0 0.0013707236
study O 0 0.0012410831
was O 0 0.0006323598
designed O 0 0.0004145431
to O 0 0.00032199413
study O 0 0.00033077397
the O 0 0.00020567571
effect O 0 0.0002723446
of O 0 0.0010187795
histamine B-Chemical 0 0.99994636
H O 0 0.99996233
( O 0 0.0019305088
3 O 0 0.00022972761
) O 0 0.0006392654
- O 0 0.0016007122
receptor O 0 0.0005132811
ligands O 0 0.00074941997
on O 0 0.00035554075
neuroleptic O 0 0.9999988
- O 0 0.0620383
induced O 0 0.0005650656
catalepsy B-Disease 0 0.999997
, O 0 0.017995697
apomorphine B-Chemical 0 0.9999939
- O 0 0.005870735
induced O 0 0.00014465574
climbing O 0 0.001374997
behavior O 0 0.00042315683
and O 0 0.00062308507
amphetamine B-Chemical 1 0.9999938
- O 0 0.018710572
induced O 0 0.00037214335
locomotor O 0 0.0040932815
activities O 0 0.00039762736
in O 0 0.0005538297
mice O 0 0.0005294248
. O 0 0.0021539961

Catalepsy B-Disease 0 0.99892175
was O 0 0.0027029004
induced O 0 0.0016372504
by O 0 0.002066879
haloperidol B-Chemical 1 0.99999094
( O 0 0.0016723027
2 O 0 0.00051688286
mg O 0 0.0019563017
/ O 0 0.0008083713
kg O 0 0.0005249577
p O 0 0.00042383585
. O 0 0.00024265493
o O 0 0.00094846985
. O 0 0.0002972698
) O 0 0.000655537
, O 0 0.0005402312
while O 0 0.0005112099
apomorphine B-Chemical 0 0.99997807
( O 0 0.0007103457
1 O 0 0.0002041718
. O 0 0.00013189424
5 O 0 0.0001309421
mg O 0 0.00079382746
/ O 0 0.00048547273
kg O 0 0.00036152004
s O 0 0.0002573117
. O 0 0.00018113566
c O 0 0.0007867219
. O 0 0.00021610265
) O 0 0.0005265353
and O 0 0.00039199714
amphetamine B-Chemical 1 0.99997914
( O 0 0.0005239861
2 O 0 0.00020169416
mg O 0 0.0011532997
/ O 0 0.00049974513
kg O 0 0.00034860426
s O 0 0.00024314776
. O 0 0.00016848011
c O 0 0.00070591195
. O 0 0.00018044663
) O 0 0.00030766736
were O 0 0.000102706465
used O 0 9.202626e-05
for O 0 9.7205004e-05
studying O 0 0.0001789353
climbing O 0 0.0009891046
behavior O 0 0.00046478375
and O 0 0.00046542534
locomotor O 0 0.0035817043
activities O 0 0.000594395
, O 0 0.0016499966
respectively O 0 0.0026443992
. O 0 0.0030713666

( B-Chemical 0 0.017682573
R I-Chemical 0 0.9811513
) I-Chemical 0 0.017716123
- I-Chemical 0 0.11458747
alpha I-Chemical 0 0.942868
- I-Chemical 0 0.5885413
methylhistamine I-Chemical 0 0.99954045
( O 0 0.0120793525
RAMH B-Chemical 0 0.99989617
) O 0 0.002423768
( O 0 0.0006750267
5 O 0 0.00025653737
microg O 0 0.00041734643
i O 0 0.00047335136
. O 0 0.00026717162
c O 0 0.0009826935
. O 0 0.0002692334
v O 0 0.001117706
. O 0 0.0002844762
) O 0 0.0007470392
and O 0 0.000584255
thioperamide B-Chemical 0 0.99993646
( O 0 0.013842131
THP B-Chemical 0 0.99995387
) O 0 0.0016152366
( O 0 0.00041117566
15 O 0 0.00018146636
mg O 0 0.0011762148
/ O 0 0.0005768033
kg O 0 0.00040382074
i O 0 0.00032780546
. O 0 0.00018383014
p O 0 0.00035714457
. O 0 0.00025356413
) O 0 0.0006725944
, O 0 0.0006873207
per O 0 0.00047968596
se O 0 0.0014012882
did O 0 0.00075355853
not O 0 0.0009631132
cause O 0 0.0039500264
catalepsy B-Disease 0 0.99993706
. O 0 0.0057678325

Administration O 0 0.01628994
of O 0 0.0071304534
THP B-Chemical 0 0.99961793
( O 0 0.0040991977
3 O 0 0.00094483595
. O 0 0.0007166656
75 O 0 0.00083793706
, O 0 0.0006976072
7 O 0 0.00030513824
. O 0 0.00027428594
5 O 0 0.00021390711
and O 0 0.00021943368
15 O 0 0.00023343878
mg O 0 0.0012624699
/ O 0 0.00071225927
kg O 0 0.0004837725
i O 0 0.00035831757
. O 0 0.00017969408
p O 0 0.00031028167
. O 0 0.00017764128
) O 0 0.00034097923
1 O 0 0.00014975328
h O 0 0.00012885159
prior O 0 7.2826e-05
to O 0 0.00019204998
haloperidol B-Chemical 1 0.9999958
resulted O 0 0.00016395703
in O 0 0.00012653066
a O 0 0.0002142137
dose O 0 0.0003686968
- O 0 0.0009394627
dependent O 0 9.6525815e-05
increase O 0 0.00013758718
in O 0 0.00017376951
the O 0 0.0002775373
catalepsy B-Disease 0 0.99995565
times O 0 0.00023356815
( O 0 0.0005760921
P O 0 0.0051772264
< O 0 0.0006598312
0 O 0 0.0006932059
. O 0 0.00086256664
05 O 0 0.011993679
) O 0 0.0041907066
. O 0 0.003781852

However O 0 0.0035009172
, O 0 0.005492777
pretreatment O 0 0.015239223
with O 0 0.0037350846
RAMH B-Chemical 0 0.9999193
significantly O 0 0.0016339367
reversed O 0 0.0009943087
such O 0 0.00036450368
an O 0 0.00034987176
effect O 0 0.00030998304
of O 0 0.0008599681
THP B-Chemical 0 0.9999093
( O 0 0.0011066014
15 O 0 0.0003389862
mg O 0 0.0020871137
/ O 0 0.0010298776
kg O 0 0.000794727
i O 0 0.0007614894
. O 0 0.0005470601
p O 0 0.0011949666
. O 0 0.0011673266
) O 0 0.0035342388
. O 0 0.003732176

RAMH B-Chemical 0 0.9996111
per O 0 0.0046952288
se O 0 0.004150302
showed O 0 0.0007493972
significant O 0 0.0005651448
reduction O 0 0.00059525354
in O 0 0.00040418623
locomotor O 0 0.0019255318
time O 0 0.00017850839
, O 0 0.00039277668
distance O 0 0.00034611928
traveled O 0 0.00075639464
and O 0 0.00018917426
average O 0 0.00015645425
speed O 0 0.00068528485
but O 0 0.0006865718
THP B-Chemical 0 0.9998747
( O 0 0.00063542766
15 O 0 0.00019512173
mg O 0 0.0012825661
/ O 0 0.00055619545
kg O 0 0.00037531334
i O 0 0.00029387814
. O 0 0.0001581707
p O 0 0.0003019667
. O 0 0.00020010656
) O 0 0.0004996027
per O 0 0.0002523955
se O 0 0.0006140536
had O 0 0.00024141524
no O 0 0.00024262437
effect O 0 0.00033839306
on O 0 0.00043874828
these O 0 0.0008565761
parameters O 0 0.0018868273
. O 0 0.0030019444

On O 0 0.009163391
amphetamine B-Chemical 1 0.99993384
- O 0 0.22363539
induced O 0 0.004223147
hyperactivity B-Disease 2 0.99999225
, O 0 0.08977428
THP B-Chemical 0 0.99993503
( O 0 0.001740673
3 O 0 0.00032159564
. O 0 0.00025430208
75 O 0 0.00031344098
and O 0 0.0001862625
7 O 0 0.00014628923
. O 0 0.00015614336
5 O 0 0.00016579957
mg O 0 0.0009837609
/ O 0 0.0005973453
kg O 0 0.00042209122
i O 0 0.00032513254
. O 0 0.0001680769
p O 0 0.0003007075
. O 0 0.00018331448
) O 0 0.00040316916
reduced O 0 0.00026540106
locomotor O 0 0.0015327483
time O 0 0.00014747748
, O 0 0.00037369708
distance O 0 0.00036309575
traveled O 0 0.00083179324
and O 0 0.00023184264
average O 0 0.00020259465
speed O 0 0.00067852077
( O 0 0.0007889971
P O 0 0.006043015
< O 0 0.00084920146
0 O 0 0.0008595039
. O 0 0.0010438006
05 O 0 0.012436176
) O 0 0.004781
. O 0 0.004319546

Pretreatment O 0 0.09479622
with O 0 0.0067581707
RAMH B-Chemical 0 0.9996792
( O 0 0.0032820173
5 O 0 0.0008353489
microg O 0 0.0010448388
i O 0 0.00094261457
. O 0 0.00048387327
c O 0 0.0014713871
. O 0 0.00039616483
v O 0 0.0014141955
. O 0 0.00032931936
) O 0 0.00052633305
could O 0 0.00013970507
partially O 0 0.00017561091
reverse O 0 0.00025216193
such O 0 0.00015730692
effects O 0 0.0002390681
of O 0 0.000689351
THP B-Chemical 0 0.9999492
( O 0 0.00088820263
3 O 0 0.00019738931
. O 0 0.00019181446
75 O 0 0.0003583762
mg O 0 0.0015615151
/ O 0 0.00094627246
kg O 0 0.0007665638
i O 0 0.00075083895
. O 0 0.00054148416
p O 0 0.0011867009
. O 0 0.0011553129
) O 0 0.0035085147
. O 0 0.003693597

Climbing O 0 0.01885364
behavior O 0 0.0041222554
induced O 0 0.0023048532
by O 0 0.002906692
apomorphine B-Chemical 0 0.9999242
was O 0 0.0011529471
reduced O 0 0.0009031291
in O 0 0.00067047507
animals O 0 0.0006685328
treated O 0 0.002336985
with O 0 0.0035556804
THP B-Chemical 0 0.99957854
. O 0 0.0074541774

Such O 0 0.0052529876
an O 0 0.0028071285
effect O 0 0.0016505686
was O 0 0.0016595599
, O 0 0.0024010818
however O 0 0.001626598
, O 0 0.002298475
reversed O 0 0.0021187207
in O 0 0.0014579658
presence O 0 0.0019266916
of O 0 0.004653981
RAMH B-Chemical 0 0.99961036
. O 0 0.008793166

THP B-Chemical 0 0.9991259
exhibited O 0 0.002989136
an O 0 0.0022200805
antipsychotic O 0 0.99876595
- O 0 0.0040970584
like O 0 0.00030308755
profile O 0 0.00027457273
by O 0 0.000333328
potentiating O 0 0.03398669
haloperidol B-Chemical 1 0.9999994
- O 0 0.23131673
induced O 0 0.0006833812
catalepsy B-Disease 0 0.9999944
, O 0 0.0010735298
reducing O 0 0.0003959157
amphetamine B-Chemical 1 0.99999607
- O 0 0.054607518
induced O 0 0.0004359064
hyperactivity B-Disease 2 0.9999968
and O 0 0.00049004203
reducing O 0 0.00052749855
apomorphine B-Chemical 0 0.9999881
- O 0 0.009878466
induced O 0 0.0004581823
climbing O 0 0.0025140094
in O 0 0.0006966444
mice O 0 0.0005882846
. O 0 0.0023014697

Such O 0 0.0039635403
effects O 0 0.0025055981
of O 0 0.0040360834
THP B-Chemical 0 0.9997682
were O 0 0.0013695309
reversed O 0 0.0016560165
by O 0 0.0011178049
RAMH B-Chemical 0 0.9998418
indicating O 0 0.00039443007
the O 0 0.0003297268
involvement O 0 0.0007756393
of O 0 0.0012781
histamine B-Chemical 0 0.99988604
H O 0 0.9998939
( O 0 0.0036075586
3 O 0 0.00079601695
) O 0 0.0020652756
- O 0 0.0046476787
receptors O 0 0.0037945835
. O 0 0.0039117085

Findings O 0 0.0026932426
suggest O 0 0.0011842098
a O 0 0.0017346991
potential O 0 0.00095028576
for O 0 0.0012004742
H O 0 0.999276
( O 0 0.002389924
3 O 0 0.00057861925
) O 0 0.0014488118
- O 0 0.0035893947
receptor O 0 0.0013737265
antagonists O 0 0.008797062
in O 0 0.00036253908
improving O 0 0.00034166503
the O 0 0.00042141776
refractory O 0 0.003140287
cases O 0 0.0015171871
of O 0 0.0025064442
schizophrenia B-Disease 2 0.9999294
. O 0 0.005625043

Cauda B-Disease 0 0.96841574
equina I-Disease 0 0.12538505
syndrome I-Disease 0 0.7587859
after O 0 0.0009552035
epidural O 0 0.012684652
steroid B-Chemical 0 0.6885162
injection O 0 0.00097397517
: O 0 0.0018525347
a O 0 0.0015939706
case O 0 0.0017660223
report O 0 0.0039137383
. O 0 0.0046260282

OBJECTIVE O 0 0.015263197
: O 0 0.0029920067
Conventional O 0 0.0010046479
treatment O 0 0.00050485105
methods O 0 0.0003597841
of O 0 0.000406963
lumbusacral O 0 0.0009717182
radiculopathy B-Disease 0 0.98907185
are O 0 0.00019164023
physical O 0 0.00027652862
therapy O 0 0.00024483667
, O 0 0.0003236382
epidural O 0 0.004760682
steroid B-Chemical 0 0.57213855
injections O 0 0.00021423449
, O 0 0.00031364156
oral O 0 0.00070720306
medications O 0 0.0013353798
, O 0 0.00047074832
and O 0 0.00037154372
spinal O 0 0.0007223612
manipulative O 0 0.0024990218
therapy O 0 0.0019022414
. O 0 0.0025094836

Cauda B-Disease 0 0.9810158
equina I-Disease 0 0.32280686
syndrome I-Disease 0 0.93862754
is O 0 0.0015537093
a O 0 0.0019942874
rare O 0 0.003245786
complication O 0 0.004197807
of O 0 0.0016566521
epidural O 0 0.022146266
anesthesia O 0 0.01149225
. O 0 0.0037421943

The O 0 0.001871899
following O 0 0.0010647285
case O 0 0.0011646005
is O 0 0.0006728557
a O 0 0.0008906016
report O 0 0.0009846954
of O 0 0.0008646057
cauda B-Disease 0 0.74460095
equina I-Disease 0 0.11404326
syndrome I-Disease 0 0.94423676
possibly O 0 0.0003226093
caused O 0 0.0002034681
by O 0 0.00022756524
epidural O 0 0.0024085026
injection O 0 0.00024753215
of O 0 0.0006378681
triamcinolone B-Chemical 0 0.99990714
and O 0 0.0023527853
bupivacaine B-Chemical 0 0.99986625
. O 0 0.003051629

CLINICAL O 0 0.0047062924
FEATURES O 0 0.0038582233
: O 0 0.0034315994
A O 0 0.006536908
50 O 0 0.0014803958
- O 0 0.0028512687
year O 0 0.0005499749
- O 0 0.0015639539
old O 0 0.00046293222
woman O 0 0.00075761275
with O 0 0.0002678153
low B-Disease 0 0.00033861413
back I-Disease 0 0.00028802507
and I-Disease 0 0.0002307233
right I-Disease 0 0.0005899525
leg I-Disease 0 0.0014013962
pain I-Disease 0 0.0053022164
was O 0 0.00018837972
scheduled O 0 0.0001394248
for O 0 0.00024923205
epidural O 0 0.0060027675
steroid B-Chemical 0 0.5784761
injection O 0 0.0011897525
. O 0 0.00230115

INTERVENTION O 0 0.0038647323
AND O 0 0.0020743853
OUTCOME O 0 0.002420055
: O 0 0.0015335009
An O 0 0.00064176705
18 O 0 0.0006610586
- O 0 0.0014147224
gauge O 0 0.0008729654
Touhy O 0 0.000973298
needle O 0 0.0004024856
was O 0 0.00024194615
inserted O 0 0.00022397496
until O 0 0.00015215643
loss O 0 0.00028266775
of O 0 0.00029910915
resistance O 0 0.0007502296
occurred O 0 0.00031552862
at O 0 0.00025934266
the O 0 0.00041474582
L4 O 0 0.0031033652
- O 0 0.0030913213
5 O 0 0.0009761156
level O 0 0.0014651156
. O 0 0.0033172383

Spread O 0 0.009078767
of O 0 0.0025055357
the O 0 0.0014374015
contrast O 0 0.0020474049
medium O 0 0.003689006
within O 0 0.00043206208
the O 0 0.000527309
epidural O 0 0.003373934
space O 0 0.00069224375
was O 0 0.0004399574
determined O 0 0.00042953013
by O 0 0.0006776664
radiographic O 0 0.0019249795
imaging O 0 0.0023184458
. O 0 0.003277246

After O 0 0.0017420788
verifying O 0 0.0013627574
the O 0 0.0014042056
epidural O 0 0.0064402134
space O 0 0.0018234452
, O 0 0.0035347673
bupivacaine B-Chemical 0 0.99988186
and O 0 0.004164682
triamcinolone B-Chemical 1 0.9999759
diacetate I-Chemical 1 0.99920017
were O 0 0.0016541769
injected O 0 0.0016483949
. O 0 0.0031397196

After O 0 0.0019796367
the O 0 0.0018088156
injection O 0 0.001470126
, O 0 0.002000839
there O 0 0.00092256156
was O 0 0.0010176712
a O 0 0.0014289941
reduction O 0 0.0014788616
in O 0 0.0017767042
radicular O 0 0.83973205
symptoms O 0 0.022522705
. O 0 0.0044702766

Three O 0 0.0028119253
hours O 0 0.0019625311
later O 0 0.0015714759
, O 0 0.002232058
she O 0 0.001237272
complained O 0 0.0023196617
of O 0 0.0011611393
perineal O 0 0.004515182
numbness B-Disease 0 0.77844
and O 0 0.0012709402
lower B-Disease 0 0.0028608197
extremity I-Disease 0 0.07807505
weakness I-Disease 0 0.94395924
. O 0 0.0049726483

The O 0 0.0022469352
neurologic O 0 0.061860178
evaluation O 0 0.0009455263
revealed O 0 0.00058154156
loss B-Disease 0 0.0009895882
of I-Disease 0 0.00065246783
sensation I-Disease 0 0.020315528
in O 0 0.000380656
the O 0 0.0003224906
saddle O 0 0.002537344
area O 0 0.0005391178
and O 0 0.0003996426
medial O 0 0.001867031
aspect O 0 0.0004907685
of O 0 0.0006203505
her O 0 0.0009865006
right O 0 0.0024253537
leg O 0 0.006573233
. O 0 0.0037839762

There O 0 0.0051967013
was O 0 0.0031250296
a O 0 0.0030111633
decrease O 0 0.0018018606
in O 0 0.0012657858
the O 0 0.0010892204
perception O 0 0.002219509
of O 0 0.0020471194
pinprick O 0 0.007146009
test O 0 0.0038207592
. O 0 0.0049688136

Deep O 0 0.02350562
- O 0 0.02351784
tendon O 0 0.028012032
reflexes O 0 0.024833027
were O 0 0.0014895088
decreased O 0 0.0017987936
especially O 0 0.0012353436
in O 0 0.0011156678
the O 0 0.0012701082
right O 0 0.0038453664
leg O 0 0.009098865
. O 0 0.0055322708

She O 0 0.017188039
was O 0 0.0077355998
unable O 0 0.006125963
to O 0 0.008015383
urinate O 0 0.030731564
. O 0 0.016553495

The O 0 0.002463722
patient O 0 0.002423445
' O 0 0.002653486
s O 0 0.0019178314
symptoms O 0 0.003945877
improved O 0 0.0011324714
slightly O 0 0.00089637033
over O 0 0.00051962177
the O 0 0.00049934606
next O 0 0.00041605494
few O 0 0.0007878461
hours O 0 0.0016003731
. O 0 0.003712096

She O 0 0.006885192
had O 0 0.0024418624
a O 0 0.0020697895
gradual O 0 0.0013101895
return O 0 0.00087591034
of O 0 0.00065430114
motor O 0 0.0013153414
function O 0 0.000395549
and O 0 0.00049125805
ability O 0 0.00052862347
of O 0 0.001008184
feeling O 0 0.008069416
Foley O 0 0.005618752
catheter O 0 0.0040683676
. O 0 0.003690364

All O 0 0.002631749
of O 0 0.0023935193
the O 0 0.0016905159
symptoms O 0 0.0069393218
were O 0 0.00099456
completely O 0 0.0008102889
resolved O 0 0.0008461068
over O 0 0.00050066743
the O 0 0.0005140232
next O 0 0.00045782866
8 O 0 0.0010672561
hours O 0 0.0014785018
. O 0 0.003464342

CONCLUSION O 0 0.017678596
: O 0 0.005198336
Complications O 0 0.0027871125
associated O 0 0.0013136206
with O 0 0.0014291342
epidural O 0 0.020674828
steroid B-Chemical 0 0.8156441
injections O 0 0.0016942999
are O 0 0.0015373931
rare O 0 0.0056291306
. O 0 0.00437851

Clinical O 0 0.0047889017
examination O 0 0.0012140162
and O 0 0.0010320339
continued O 0 0.00081826135
vigilance O 0 0.0050241714
for O 0 0.00054232473
neurologic B-Disease 0 0.9515074
deterioration I-Disease 0 0.06884339
after O 0 0.0002671423
epidural O 0 0.006296647
steroid B-Chemical 0 0.53880674
injections O 0 0.00061855157
is O 0 0.0005924645
important O 0 0.00096566393
. O 0 0.0025968824

High O 0 0.009022377
- O 0 0.020656126
dose O 0 0.008558884
testosterone B-Chemical 0 0.9989157
is O 0 0.0014820511
associated O 0 0.0014226366
with O 0 0.0020340125
atherosclerosis B-Disease 0 0.999757
in O 0 0.0027993373
postmenopausal O 0 0.7342999
women O 0 0.0098902015
. O 0 0.0047107018

OBJECTIVES O 0 0.003643382
: O 0 0.002498026
To O 0 0.00049197057
study O 0 0.00072420575
the O 0 0.00045109063
long O 0 0.00053564063
- O 0 0.001476068
term O 0 0.00037147378
effects O 0 0.00038835662
of O 0 0.0007919427
androgen O 0 0.99078184
treatment O 0 0.00060672325
on O 0 0.00052624126
atherosclerosis B-Disease 0 0.99984777
in O 0 0.0015826374
postmenopausal O 0 0.76474583
women O 0 0.007832072
. O 0 0.003304435

METHODS O 0 0.0038991207
: O 0 0.0025542206
In O 0 0.0007435491
a O 0 0.0012274261
population O 0 0.0011504152
- O 0 0.0025191463
based O 0 0.00042110574
study O 0 0.0004568103
in O 0 0.00038517968
513 O 0 0.001915014
naturally O 0 0.0005783637
postmenopausal O 0 0.09526963
women O 0 0.0009627416
aged O 0 0.00049558724
54 O 0 0.00041648018
- O 0 0.00097183813
67 O 0 0.00028488738
years O 0 0.00018453348
, O 0 0.00019463545
we O 0 6.4851185e-05
studied O 0 0.00014492193
the O 0 7.7292054e-05
association O 0 6.02341e-05
between O 0 8.270802e-05
self O 0 0.00063611806
- O 0 0.0012028704
reported O 0 0.00012516086
intramuscularly O 0 0.00021344707
administered O 0 0.00012526833
high O 0 0.00015990154
- O 0 0.0015987494
dose O 0 0.0009393328
estrogen B-Chemical 0 0.9998368
- O 0 0.28420222
testosterone B-Chemical 0 0.99989796
therapy O 0 0.0012317096
( O 0 0.0013279577
estradiol B-Chemical 0 0.99994886
- I-Chemical 0 0.16663945
and I-Chemical 0 0.0012514782
testosterone I-Chemical 0 0.9999416
esters I-Chemical 0 0.9959132
) O 0 0.0045349216
and O 0 0.001239992
aortic O 0 0.85310364
atherosclerosis B-Disease 0 0.9998336
. O 0 0.0046313624

Aortic O 0 0.5803271
atherosclerosis B-Disease 0 0.99953043
was O 0 0.002080235
diagnosed O 0 0.0032417327
by O 0 0.0004950737
radiographic O 0 0.00073515554
detection O 0 0.0003063479
of O 0 0.00042544983
calcified O 0 0.08785515
deposits O 0 0.0032531917
in O 0 0.00017429852
the O 0 0.00014739984
abdominal O 0 0.0005642747
aorta O 0 0.008649954
, O 0 0.00042602042
which O 0 0.00024328899
have O 0 0.00019587875
been O 0 0.0002390091
shown O 0 0.0001855163
to O 0 0.0004196165
reflect O 0 0.00094191794
intima O 0 0.9975561
atherosclerosis B-Disease 0 0.99981636
. O 0 0.0050614006

Hormone O 0 0.25018984
therapy O 0 0.0049531558
users O 0 0.003458286
were O 0 0.0017296062
compared O 0 0.0013424552
with O 0 0.0022521978
never O 0 0.004091319
users O 0 0.0063708625
. O 0 0.0070740194

RESULTS O 0 0.0049797054
: O 0 0.0047254195
Intramuscular O 0 0.011817596
hormone O 0 0.011377193
therapy O 0 0.0009101957
use O 0 0.00038703572
for O 0 0.0003000334
1 O 0 0.00038398063
year O 0 0.00026363818
or O 0 0.00024038053
longer O 0 0.00023562193
was O 0 0.00042650723
reported O 0 0.0006249752
by O 0 0.0008381108
25 O 0 0.0018169717
women O 0 0.0044705933
. O 0 0.00380971

In O 0 0.0020424866
almost O 0 0.0016885606
half O 0 0.00093995826
of O 0 0.00091234985
these O 0 0.00074780587
women O 0 0.0030411351
severe O 0 0.022672731
atherosclerosis B-Disease 0 0.9998747
of O 0 0.0005014314
the O 0 0.00025628973
aorta O 0 0.008569473
was O 0 0.00015127283
present O 0 0.000108238375
( O 0 0.00022081699
n O 0 0.00016876197
= O 0 0.00038622375
11 O 0 0.0001576416
) O 0 0.00030496664
, O 0 0.00022421982
while O 0 0.00012584504
in O 0 0.00014569645
women O 0 0.00065618614
without O 0 0.00021240926
hormone O 0 0.05411883
use O 0 0.00019728168
severe O 0 0.012627166
atherosclerosis B-Disease 0 0.99995255
of O 0 0.00022666139
the O 0 0.00012802138
aorta O 0 0.016336435
was O 0 9.544084e-05
present O 0 7.219593e-05
in O 0 9.561949e-05
less O 0 0.00015544961
than O 0 0.00010980796
20 O 0 0.00014658355
% O 0 0.0003028954
( O 0 0.0003295518
OR O 0 0.0010486366
3 O 0 0.00015532292
. O 0 0.00015319092
1 O 0 0.00018470545
; O 0 0.00031553255
95 O 0 0.00036185177
% O 0 0.00041490205
CI O 0 0.00404434
, O 0 0.00043362053
1 O 0 0.00023311473
. O 0 0.00018143385
1 O 0 0.00021738622
- O 0 0.00065868266
8 O 0 0.00014276674
. O 0 0.0001280398
5 O 0 0.00011273297
, O 0 0.000172655
adjusted O 0 8.8652625e-05
for O 0 9.409905e-05
age O 0 0.00023419052
, O 0 0.0002807814
years O 0 0.00021335958
since O 0 0.00014289137
menopause O 0 0.004577891
, O 0 0.00059529406
smoking O 0 0.004325768
, O 0 0.00064567017
and O 0 0.00043422385
body O 0 0.00085261953
mass O 0 0.0010558441
index O 0 0.0013747114
) O 0 0.003345065
. O 0 0.003221801

The O 0 0.0016127373
association O 0 0.00097687
remained O 0 0.0010078378
after O 0 0.0003653778
additional O 0 0.00031285227
adjustment O 0 0.00035355566
for O 0 0.00041508957
diabetes B-Disease 0 0.9994704
, O 0 0.0022650256
cholesterol B-Chemical 0 0.9993476
level O 0 0.0003877285
, O 0 0.0006403884
systolic O 0 0.09674362
blood O 0 0.004930562
pressure O 0 0.007976735
, O 0 0.0010356057
or O 0 0.0007823966
alcohol B-Chemical 0 0.9703091
use O 0 0.0020499902
. O 0 0.0033102164

No O 0 0.004833564
association O 0 0.001823893
was O 0 0.0016261613
found O 0 0.0013104865
for O 0 0.0010873895
hormone O 0 0.017457576
use O 0 0.0010430112
less O 0 0.0013923316
than O 0 0.0010848194
1 O 0 0.0016812875
year O 0 0.0018867789
. O 0 0.003755717

CONCLUSION O 0 0.014111548
: O 0 0.003041919
Our O 0 0.0006835923
results O 0 0.00051633205
suggest O 0 0.00030179546
that O 0 0.00034463182
high O 0 0.0006789565
- O 0 0.0061394796
dose O 0 0.0018678271
testosterone B-Chemical 0 0.9997929
therapy O 0 0.0006900099
may O 0 0.00014606537
adversely O 0 0.00030164703
affect O 0 0.00019134681
atherosclerosis B-Disease 0 0.9999442
in O 0 0.00034379322
postmenopausal O 0 0.5142503
women O 0 0.00070560566
and O 0 0.00012677196
indicate O 0 7.44344e-05
that O 0 0.00016880287
androgen O 0 0.9899358
replacement O 0 0.00031968506
in O 0 0.00020197705
these O 0 0.0002623251
women O 0 0.0010664185
may O 0 0.00034190028
not O 0 0.00051944697
be O 0 0.0009761872
harmless O 0 0.0035045922
. O 0 0.0030707887

Optimising O 0 0.010456793
stroke B-Disease 0 0.9815953
prevention O 0 0.004282324
in O 0 0.0022914296
non O 0 0.0036998559
- O 0 0.013154903
valvular O 0 0.2603012
atrial B-Disease 0 0.57897604
fibrillation I-Disease 0 0.99773633
. O 0 0.00678458

Atrial B-Disease 0 0.36871624
fibrillation I-Disease 0 0.99912935
is O 0 0.0022536574
associated O 0 0.001713571
with O 0 0.001504717
substantial O 0 0.0018783398
morbidity O 0 0.016683232
and O 0 0.0025467942
mortality O 0 0.009434864
. O 0 0.0050963014

Pooled O 0 0.004131429
data O 0 0.0013794302
from O 0 0.0006204397
trials O 0 0.00064173434
comparing O 0 0.00023909935
antithrombotic O 0 0.02078847
treatment O 0 0.00024121646
with O 0 0.00023827598
placebo O 0 0.005668884
have O 0 0.00012344118
shown O 0 7.1017574e-05
that O 0 0.00012909339
warfarin B-Chemical 0 0.997042
reduces O 0 0.00013145503
the O 0 0.00013594594
risk O 0 0.0016460997
of O 0 0.0003231184
stroke B-Disease 0 0.99762136
by O 0 0.00019109795
62 O 0 0.00028825886
% O 0 0.00029523397
, O 0 0.00024977635
and O 0 0.00016653158
that O 0 0.00019158378
aspirin B-Chemical 0 0.99987876
alone O 0 0.00040292248
reduces O 0 0.00028016636
the O 0 0.0003883581
risk O 0 0.0036768368
by O 0 0.00083535525
22 O 0 0.0015942605
% O 0 0.0025948489
. O 0 0.0027989883

Overall O 0 0.004017026
, O 0 0.0037104224
in O 0 0.0014583493
high O 0 0.001665854
- O 0 0.008089979
risk O 0 0.0049614026
patients O 0 0.0015250642
, O 0 0.0012802375
warfarin B-Chemical 0 0.9974356
is O 0 0.00020967728
superior O 0 0.0003764232
to O 0 0.00023491174
aspirin B-Chemical 0 0.999813
in O 0 0.00023432208
preventing O 0 0.00030475477
strokes B-Disease 0 0.99673516
, O 0 0.00068523467
with O 0 0.00028110927
a O 0 0.00037351012
relative O 0 0.00023083067
risk O 0 0.0020743902
reduction O 0 0.00066333247
of O 0 0.0008115828
36 O 0 0.0012347561
% O 0 0.0024761208
. O 0 0.002687855

Ximelagatran B-Chemical 0 0.99770135
, O 0 0.0055916593
an O 0 0.0020408079
oral O 0 0.0041439803
direct O 0 0.0012080929
thrombin O 0 0.9434314
inhibitor O 0 0.04396286
, O 0 0.0011373049
was O 0 0.00027700965
found O 0 0.0002054217
to O 0 0.00014840708
be O 0 0.0001390378
as O 0 0.00012772519
efficient O 0 0.00011616787
as O 0 0.00045060067
vitamin B-Chemical 0 0.9999937
K I-Chemical 0 0.999995
antagonist O 0 0.9837721
drugs O 0 0.31653702
in O 0 0.00015122928
the O 0 9.661596e-05
prevention O 0 0.00017781887
of O 0 0.00019511001
embolic B-Disease 0 0.9100928
events I-Disease 0 0.0024567214
, O 0 0.00042908857
but O 0 0.00018299071
has O 0 8.897684e-05
been O 0 0.00012936733
recently O 0 0.00017236402
withdrawn O 0 0.0006207293
because O 0 0.00016346875
of O 0 0.000395608
abnormal B-Disease 0 0.019289173
liver I-Disease 0 0.07283459
function I-Disease 0 0.0012512625
tests O 0 0.0031591558
. O 0 0.0026621618

The O 0 0.004055164
ACTIVE O 0 0.20490001
- O 0 0.024901563
W O 0 0.8263087
( O 0 0.0036108133
Atrial B-Disease 0 0.014436769
Fibrillation I-Disease 0 0.0053283954
Clopidogrel B-Chemical 0 0.9963134
Trial O 0 0.0009539602
with O 0 0.0004740244
Irbesartan B-Chemical 0 0.9997414
for O 0 0.0002116586
Prevention O 0 0.00028878782
of O 0 0.00034124815
Vascular O 0 0.9754029
Events O 0 0.0007288758
) O 0 0.00036703525
study O 0 0.00013031073
has O 0 6.361184e-05
demonstrated O 0 8.848271e-05
that O 0 0.00011914735
warfarin B-Chemical 0 0.99676204
is O 0 0.000101253165
superior O 0 0.00020562395
to O 0 0.00012053902
platelet O 0 0.48363373
therapy O 0 0.00029077008
( O 0 0.00049144303
clopidogrel B-Chemical 0 0.9998671
plus O 0 0.000430663
aspirin B-Chemical 0 0.99992967
) O 0 0.0010702473
in O 0 0.00024551738
the O 0 0.00028836247
prevention O 0 0.0009989615
af O 0 0.2135328
embolic B-Disease 0 0.9128351
events I-Disease 0 0.0072180154
. O 0 0.0029580265

Idraparinux B-Chemical 0 0.95074236
, O 0 0.010918377
a O 0 0.00985683
Factor O 0 0.9937272
Xa O 0 0.93924004
inhibitor O 0 0.004195672
, O 0 0.0014404777
is O 0 0.000467414
being O 0 0.00046858637
evaluated O 0 0.00042831476
in O 0 0.0004777905
patients O 0 0.0010575333
with O 0 0.001036342
atrial B-Disease 0 0.31991598
fibrillation I-Disease 0 0.9983234
. O 0 0.004155089

Angiotensin B-Chemical 0 0.9999021
- O 0 0.32879114
converting O 0 0.0060576536
enzyme O 0 0.0048618545
inhibitors O 0 0.0029140092
and O 0 0.003000951
angiotensin B-Chemical 1 0.99999356
II I-Chemical 1 0.9964644
receptor O 0 0.021760456
- O 0 0.0075345077
blocking O 0 0.00039285698
drugs O 0 0.0052898275
hold O 0 0.00034945045
promise O 0 0.0002661077
in O 0 0.00033692215
atrial B-Disease 0 0.1115097
fibrillation I-Disease 0 0.99839944
through O 0 0.0007606978
cardiac B-Disease 0 0.056151893
remodelling I-Disease 0 0.029865628
. O 0 0.0031345678

Preliminary O 0 0.003523835
studies O 0 0.00206847
suggest O 0 0.00087177055
that O 0 0.0011371239
statins B-Chemical 0 0.99764
could O 0 0.0006419411
interfere O 0 0.00052285864
with O 0 0.00052584143
the O 0 0.00043809315
risk O 0 0.0022266665
of O 0 0.00066840026
recurrence O 0 0.0042466256
after O 0 0.00038786087
electrical O 0 0.0014908114
cardioversion O 0 0.0016334001
. O 0 0.0021788066

Finally O 0 0.0023706576
, O 0 0.0024949354
percutaneous O 0 0.0013744796
methods O 0 0.00062950986
for O 0 0.00039349194
the O 0 0.000333445
exclusion O 0 0.00030620367
of O 0 0.00034490763
left O 0 0.00082141947
atrial O 0 0.020377344
appendage O 0 0.0018956494
are O 0 0.00019665722
under O 0 0.00019805347
investigation O 0 0.0003263732
in O 0 0.00033421704
high O 0 0.0008106708
- O 0 0.0051894025
risk O 0 0.0073074983
patients O 0 0.004045506
. O 0 0.0033482967

Anti O 0 0.03550303
- O 0 0.10767729
oxidant O 0 0.68947
effects O 0 0.0014729286
of O 0 0.0022085388
atorvastatin B-Chemical 0 0.9999777
in O 0 0.0022167598
dexamethasone B-Chemical 0 0.99989784
- O 0 0.06101363
induced O 0 0.0011623374
hypertension B-Disease 2 0.9999665
in O 0 0.0011665106
the O 0 0.0010157166
rat O 0 0.002542453
. O 0 0.0029878204

1 O 0 0.059545428
. O 0 0.059476506

Dexamethasone B-Chemical 0 0.99967575
( O 0 0.025508925
Dex B-Chemical 1 0.9991887
) O 0 0.011391442
- O 0 0.011273513
induced O 0 0.0011060154
hypertension B-Disease 2 0.99997795
is O 0 0.0004999962
characterized O 0 0.00054830674
by O 0 0.0004255966
endothelial O 0 0.9978473
dysfunction O 0 0.9803388
associated O 0 0.00058547326
with O 0 0.000829941
nitric B-Chemical 0 0.9997253
oxide I-Chemical 0 0.9965971
( O 0 0.0054851603
NO B-Chemical 0 0.99925774
) O 0 0.0035601805
deficiency O 0 0.12687346
and O 0 0.0007206443
increased O 0 0.005734622
superoxide B-Chemical 1 0.99998355
( O 0 0.10361657
O2 B-Chemical 0 0.9999691
- I-Chemical 0 0.08071335
) O 0 0.0028838695
production O 0 0.0024680875
. O 0 0.0033726387

Atorvastatin B-Chemical 0 0.99970454
( O 0 0.012966578
Ato B-Chemical 0 0.8103635
) O 0 0.0029253752
possesses O 0 0.00054295943
pleiotropic O 0 0.0007370846
properties O 0 0.00024934256
that O 0 0.00021790502
have O 0 0.00021581848
been O 0 0.00020414706
reported O 0 0.00019981238
to O 0 0.00012730279
improve O 0 0.00014009995
endothelial O 0 0.8851657
function O 0 0.00015769001
through O 0 0.00012681478
increased O 0 0.0002112765
availability O 0 0.00017564154
of O 0 0.00042663675
NO B-Chemical 0 0.9983645
and O 0 0.00054906745
reduced O 0 0.0016143573
O2 B-Chemical 0 0.9999908
- I-Chemical 0 0.053298667
production O 0 0.00041489513
in O 0 0.00027100937
various O 0 0.0003459032
forms O 0 0.0005460099
of O 0 0.0017262544
hypertension B-Disease 2 0.9999436
. O 0 0.0048936466

In O 0 0.0020068209
the O 0 0.0015079739
present O 0 0.0010239347
study O 0 0.0010702539
, O 0 0.0009400115
we O 0 0.00023920742
investigated O 0 0.00025929912
whether O 0 0.0001314874
50 O 0 0.00043629302
mg O 0 0.0031875474
/ O 0 0.0008309171
kg O 0 0.00044913386
per O 0 0.00014289682
day O 0 0.000104245824
, O 0 0.00025574391
p O 0 0.00033770886
. O 0 0.00021323432
o O 0 0.0010896942
. O 0 0.00032259885
, O 0 0.0008188421
Ato B-Chemical 0 0.63459533
could O 0 0.00025735906
prevent O 0 0.00056561525
endothelial O 0 0.9998622
NO B-Chemical 0 0.9999552
synthase O 0 0.8661338
( O 0 0.0034206375
eNOS O 0 0.14984606
) O 0 0.00066521013
downregulation O 0 0.00016168096
and O 0 0.00016916814
the O 0 0.00014404187
increase O 0 0.0002221402
in O 0 0.00049041427
O2 B-Chemical 0 0.9999746
- I-Chemical 0 0.0072289705
in O 0 0.00025574636
Sprague O 0 0.12056016
- O 0 0.0019766563
Dawley O 0 0.0052439463
( O 0 0.00054259074
SD O 0 0.0032308395
) O 0 0.00056258735
rats O 0 0.00044774564
, O 0 0.00054853025
thereby O 0 0.00040111918
reducing O 0 0.0006417331
blood O 0 0.010970824
pressure O 0 0.057256743
. O 0 0.0036429984

2 O 0 0.05912018
. O 0 0.06027965

Male O 0 0.0126537625
SD O 0 0.016986867
rats O 0 0.0024070195
( O 0 0.0017010941
n O 0 0.000961921
= O 0 0.0013223019
30 O 0 0.00045173694
) O 0 0.0007049079
were O 0 0.00029788943
treated O 0 0.0005193908
with O 0 0.0004777086
Ato B-Chemical 0 0.39159244
( O 0 0.00065297674
50 O 0 0.00036761127
mg O 0 0.0022248174
/ O 0 0.00069754856
kg O 0 0.0004092763
per O 0 0.00013725933
day O 0 0.00010303411
in O 0 0.0001742372
drinking O 0 0.0018950792
water O 0 0.002130788
) O 0 0.00079148856
or O 0 0.00032435203
tap O 0 0.0015013088
water O 0 0.0017714081
for O 0 0.00047843246
15 O 0 0.0007048377
days O 0 0.000732599
. O 0 0.0022701316

Dexamethasone B-Chemical 0 0.999408
( O 0 0.005565867
10 O 0 0.0015661713
microg O 0 0.0016405103
/ O 0 0.0021997415
kg O 0 0.0012151129
per O 0 0.00039176384
day O 0 0.00026001432
, O 0 0.000526641
s O 0 0.0004893041
. O 0 0.00032257175
c O 0 0.0011037119
. O 0 0.00027356905
) O 0 0.00044327654
or O 0 0.0001660326
saline O 0 0.00047115888
was O 0 0.00012259051
started O 0 0.00011032538
after O 0 5.2756663e-05
4 O 0 7.181725e-05
days O 0 6.338718e-05
in O 0 0.00014531105
Ato B-Chemical 0 0.2313299
- O 0 0.0016371289
treated O 0 0.00033739256
and O 0 0.00019486684
non O 0 0.00038283586
- O 0 0.0016100745
treated O 0 0.00037507867
rats O 0 0.00034198552
and O 0 0.00022410677
continued O 0 0.00023889543
for O 0 0.00025429044
11 O 0 0.00054394413
- O 0 0.0016807648
13 O 0 0.0008178561
days O 0 0.00075027667
. O 0 0.002318426

Systolic O 0 0.15331477
blood O 0 0.010304317
pressure O 0 0.009938591
( O 0 0.0025175882
SBP O 0 0.01602995
) O 0 0.0016379396
was O 0 0.0004837591
measured O 0 0.0004041227
on O 0 0.00023076092
alternate O 0 0.0002704998
days O 0 0.00021183303
using O 0 0.00027851624
the O 0 0.00038632058
tail O 0 0.000670996
- O 0 0.003238243
cuff O 0 0.003488884
method O 0 0.002452446
. O 0 0.003920559

Endothelial O 0 0.98083705
function O 0 0.001965431
was O 0 0.0012837963
assessed O 0 0.0009958636
by O 0 0.001277099
acetylcholine B-Chemical 1 0.99945253
- O 0 0.0133108925
induced O 0 0.00083571876
vasorelaxation O 0 0.9997063
and O 0 0.0020561402
phenylephrine B-Chemical 0 0.9999765
- O 0 0.03145289
induced O 0 0.0007784483
vasoconstriction O 0 0.9992085
in O 0 0.0010371815
aortic O 0 0.104143485
segments O 0 0.0019974045
. O 0 0.002707717

Vascular O 0 0.9941322
eNOS O 0 0.31381541
mRNA O 0 0.0031119818
was O 0 0.0014386565
assessed O 0 0.0010117028
by O 0 0.0008946697
semi O 0 0.0012196894
- O 0 0.0022544994
quantitative O 0 0.00056278176
reverse O 0 0.0010108396
transcription O 0 0.00094813557
- O 0 0.0049622264
polymerase O 0 0.0030973847
chain O 0 0.0020182934
reaction O 0 0.0028354404
. O 0 0.0046290127

3 O 0 0.049031585
. O 0 0.058089748

In O 0 0.0019174088
rats O 0 0.0027604564
treated O 0 0.0025102582
with O 0 0.0016960438
Dex B-Chemical 1 0.9986682
alone O 0 0.0010430466
, O 0 0.0010667793
SBP O 0 0.029114792
was O 0 0.00030368337
increased O 0 0.00030198196
from O 0 0.00019999134
109 O 0 0.0004570764
+ O 0 0.0009962587
/ O 0 0.0015880897
- O 0 0.0012626263
2 O 0 0.00022194332
to O 0 0.00016272446
133 O 0 0.00052977056
+ O 0 0.0008466883
/ O 0 0.0012767306
- O 0 0.001017142
2 O 0 0.00020110156
mmHg O 0 0.00061441923
on O 0 0.00013162187
Days O 0 0.00055510894
4 O 0 0.00015577486
and O 0 0.00018924748
Day O 0 0.00036789014
14 O 0 0.00024496418
, O 0 0.000462778
respectively O 0 0.00057861675
( O 0 0.0007918152
P O 0 0.0050310027
< O 0 0.0009380807
0 O 0 0.00094499125
. O 0 0.001128633
001 O 0 0.009781206
) O 0 0.0053433497
. O 0 0.004762843

In O 0 0.0027628096
the O 0 0.0030196155
Ato B-Chemical 0 0.57260984
+ O 0 0.016451424
Dex B-Chemical 1 0.99845254
group O 0 0.0018665671
, O 0 0.0013513654
SBP O 0 0.0253438
was O 0 0.0003964316
increased O 0 0.0003926288
from O 0 0.00026594513
113 O 0 0.00074229355
+ O 0 0.0012047669
/ O 0 0.0017894965
- O 0 0.001351825
2 O 0 0.00022989392
to O 0 0.00015868811
119 O 0 0.0004324201
+ O 0 0.0008295607
/ O 0 0.0012749832
- O 0 0.001032355
2 O 0 0.00019515616
mmHg O 0 0.00060918415
on O 0 0.000121861834
Days O 0 0.0005225749
4 O 0 0.00012776832
to O 0 0.00011209068
14 O 0 0.00014077405
, O 0 0.00026110964
respectively O 0 0.00030826722
( O 0 0.00036546297
P O 0 0.0033200476
< O 0 0.00029874378
0 O 0 0.00023463753
. O 0 0.0001958171
001 O 0 0.003145266
) O 0 0.0006400025
, O 0 0.00038409798
but O 0 0.00020042963
was O 0 0.00012649255
significantly O 0 0.00014681561
lower O 0 0.00014977169
than O 0 0.00011555228
SBP O 0 0.0060605453
in O 0 0.00012077925
the O 0 0.000104133054
group O 0 0.00022442792
treated O 0 0.00041394797
with O 0 0.0004314071
Dex B-Chemical 1 0.9994411
alone O 0 0.00060296414
( O 0 0.0008422927
P O 0 0.014948533
< O 0 0.0007073247
0 O 0 0.0007023856
. O 0 0.000848322
05 O 0 0.012189975
) O 0 0.0040665134
. O 0 0.0036606758

Endothelial O 0 0.9953087
- O 0 0.021663403
dependent O 0 0.0014265369
relaxation O 0 0.0058625666
and O 0 0.0013388813
eNOS O 0 0.030846432
mRNA O 0 0.0006030035
expression O 0 0.00030370566
were O 0 0.00023868025
greater O 0 0.00027380988
in O 0 0.00020587859
the O 0 0.00025600108
Dex B-Chemical 1 0.9990208
+ O 0 0.007831264
Ato B-Chemical 0 0.6716347
group O 0 0.00034342354
than O 0 0.00014413694
in O 0 0.00015054672
the O 0 0.00020342774
Dex B-Chemical 1 0.9987734
only O 0 0.00029419546
group O 0 0.0003437256
( O 0 0.00042156404
P O 0 0.0064263702
< O 0 0.00031826037
0 O 0 0.0002607412
. O 0 0.00022595363
05 O 0 0.002161167
and O 0 0.00032503955
P O 0 0.004032409
< O 0 0.0005722115
0 O 0 0.00052205485
. O 0 0.00053699245
0001 O 0 0.0035139401
, O 0 0.0018133344
respectively O 0 0.0026071093
) O 0 0.0049563437
. O 0 0.0044365046

Aortic O 0 0.97536045
superoxide B-Chemical 1 0.99980754
production O 0 0.003036498
was O 0 0.0009318037
lower O 0 0.00073586346
in O 0 0.00046801346
the O 0 0.0004960241
Dex B-Chemical 1 0.9988838
+ O 0 0.008973989
Ato B-Chemical 0 0.58596647
group O 0 0.00035338654
compared O 0 0.00012626768
with O 0 0.00016085655
the O 0 0.00013525716
group O 0 0.00027793396
treated O 0 0.00048305068
with O 0 0.00047164355
Dex B-Chemical 1 0.9994356
alone O 0 0.0006146694
( O 0 0.00084170816
P O 0 0.012871591
< O 0 0.00068714813
0 O 0 0.0006633141
. O 0 0.0007734406
0001 O 0 0.005966349
) O 0 0.003985922
. O 0 0.0037431598

4 O 0 0.04741095
. O 0 0.057336286

Treatment O 0 0.008406381
with O 0 0.003463489
Ato B-Chemical 0 0.70987886
improved O 0 0.003959217
endothelial O 0 0.9822766
function O 0 0.0010992765
, O 0 0.0026408152
reduced O 0 0.003369665
superoxide B-Chemical 1 0.99996567
production O 0 0.0010132539
and O 0 0.00043479705
reduced O 0 0.00053706643
SBP O 0 0.1603346
in O 0 0.000823188
Dex B-Chemical 1 0.9990767
- O 0 0.013969411
treated O 0 0.0023443655
SD O 0 0.036027964
rats O 0 0.0031830207
. O 0 0.0033658955

Severe O 0 0.5690475
citrate B-Chemical 0 0.90261364
toxicity B-Disease 0 0.9173858
complicating O 0 0.07751885
volunteer O 0 0.008494716
apheresis O 0 0.047850583
platelet O 0 0.8941648
donation O 0 0.008269575
. O 0 0.006665246

We O 0 0.0032447327
report O 0 0.0035946954
a O 0 0.0022754685
case O 0 0.0013470883
of O 0 0.0013207964
severe O 0 0.0324852
citrate B-Chemical 0 0.82864106
toxicity B-Disease 0 0.60314167
during O 0 0.00044551984
volunteer O 0 0.0010574794
donor O 0 0.0007366303
apheresis O 0 0.0060362224
platelet O 0 0.60309887
collection O 0 0.0023416704
. O 0 0.0034689642

The O 0 0.0023765573
donor O 0 0.0018615403
was O 0 0.0013380329
a O 0 0.001420725
40 O 0 0.0010561686
- O 0 0.0023946865
year O 0 0.0005791741
- O 0 0.001553898
old O 0 0.00058767316
female O 0 0.0009420966
, O 0 0.0008187119
first O 0 0.00039947085
- O 0 0.0019672802
time O 0 0.00064481224
apheresis O 0 0.006648499
platelet O 0 0.5918918
donor O 0 0.0023311246
. O 0 0.0039410056

Past O 0 0.0141012715
medical O 0 0.0076682544
history O 0 0.0033470606
was O 0 0.0013372512
remarkable O 0 0.0013345515
for O 0 0.001340797
hypertension B-Disease 2 0.9999466
, O 0 0.016946333
hyperlipidemia B-Disease 0 0.9999708
, O 0 0.006845223
and O 0 0.0034552405
depression B-Disease 0 0.99833834
. O 0 0.0053955573

Reported O 0 0.004496813
medications O 0 0.011117142
included O 0 0.0038623216
bumetanide B-Chemical 0 0.9999429
, O 0 0.041152306
pravastatin B-Chemical 0 0.9999622
, O 0 0.010482862
and O 0 0.006490911
paroxetine B-Chemical 0 0.99996006
. O 0 0.008389232

Thirty O 0 0.005176365
minutes O 0 0.0016756934
from O 0 0.00083159906
the O 0 0.0005296483
start O 0 0.0003287732
of O 0 0.0004176427
the O 0 0.00029650104
procedure O 0 0.00026305343
, O 0 0.00045142698
the O 0 0.00020870032
donor O 0 0.00024036929
noted O 0 0.0003419904
tingling O 0 0.0036967094
around O 0 0.00035287987
the O 0 0.0003452782
mouth O 0 0.009119427
, O 0 0.0011314135
hands O 0 0.0014661086
, O 0 0.001906484
and O 0 0.0018529852
feet O 0 0.018333457
. O 0 0.0046065934

She O 0 0.006888646
then O 0 0.0023678942
very O 0 0.0021692459
rapidly O 0 0.0014821063
developed O 0 0.0013581028
acute O 0 0.016326744
onset O 0 0.001276424
of O 0 0.00092378334
severe O 0 0.0061747627
facial O 0 0.08198844
and O 0 0.0017674858
extremity O 0 0.1646524
tetany B-Disease 0 0.9982198
. O 0 0.0045903265

Empirical O 0 0.004503698
treatment O 0 0.0016127657
with O 0 0.0014106083
intravenous O 0 0.056639038
calcium B-Chemical 0 0.99790454
gluconate I-Chemical 0 0.9112607
was O 0 0.00043403488
initiated O 0 0.0003615811
, O 0 0.00062431465
and O 0 0.00046864757
muscle B-Disease 0 0.13114858
contractions I-Disease 0 0.45146874
slowly O 0 0.00093626947
subsided O 0 0.0007551105
over O 0 0.00021327396
approximately O 0 0.00036917388
10 O 0 0.0003660301
to O 0 0.00039809386
15 O 0 0.0006739522
minutes O 0 0.0010065688
. O 0 0.002225426

The O 0 0.001978034
events O 0 0.0023683726
are O 0 0.0009564871
consistent O 0 0.0006669107
with O 0 0.00071899453
a O 0 0.00096991734
severe O 0 0.0022830095
reaction O 0 0.00040823317
to O 0 0.00042092678
calcium B-Chemical 0 0.99791354
chelation O 0 0.47322252
by O 0 0.00068916613
sodium B-Chemical 0 0.9998995
citrate I-Chemical 0 0.9967483
anticoagulant O 0 0.9635021
resulting O 0 0.00036142787
in O 0 0.00047721295
symptomatic O 0 0.006688288
systemic O 0 0.819971
hypocalcemia B-Disease 0 0.9997371
. O 0 0.003797045

Upon O 0 0.0025672193
additional O 0 0.0017050641
retrospective O 0 0.0052542887
analysis O 0 0.0010760931
, O 0 0.0013431406
it O 0 0.0007872859
was O 0 0.00042365066
noted O 0 0.00042971407
that O 0 0.00045855631
bumetanide B-Chemical 0 0.9999865
is O 0 0.00044117947
a O 0 0.00057699136
loop B-Chemical 0 0.00063902023
diuretic I-Chemical 0 0.9997758
that O 0 0.00043592657
may O 0 0.0004723917
cause O 0 0.0009922197
significant O 0 0.001853271
hypocalcemia B-Disease 0 0.9996697
. O 0 0.004700732

We O 0 0.0019338919
conclude O 0 0.00096733065
that O 0 0.00062726816
careful O 0 0.0005120111
screening O 0 0.00037032302
for O 0 0.00026343417
medications O 0 0.0017746142
and O 0 0.00027194762
underlying O 0 0.00026668908
conditions O 0 0.00025613487
predisposing O 0 0.0019496405
to O 0 0.00031077903
hypocalcemia B-Disease 0 0.9998977
is O 0 0.00017302316
recommended O 0 0.0001490295
to O 0 0.00012605738
help O 0 0.00020933988
prevent O 0 0.0002489708
severe O 0 0.00236456
reactions O 0 0.00049432326
due O 0 0.00033626411
to O 0 0.0007099958
citrate B-Chemical 0 0.69449395
toxicity B-Disease 0 0.8952048
. O 0 0.0034990245

Laboratory O 0 0.0056835613
measurement O 0 0.0014933341
of O 0 0.0013654238
pre O 0 0.0019864975
- O 0 0.0035934523
procedure O 0 0.00069915055
serum O 0 0.030184735
calcium B-Chemical 0 0.9828211
levels O 0 0.0004457815
in O 0 0.00031906788
selected O 0 0.00024332355
donors O 0 0.0003532888
may O 0 0.00021591851
identify O 0 0.00018578059
cases O 0 0.000690941
requiring O 0 0.000656942
heightened O 0 0.0031219847
vigilance O 0 0.074860744
. O 0 0.0033007418

The O 0 0.0019569925
case O 0 0.0016147139
also O 0 0.0008191929
illustrates O 0 0.00043257457
the O 0 0.0003225607
importance O 0 0.00022840672
of O 0 0.00030523163
maintaining O 0 0.00022027321
preparedness O 0 0.0003380508
for O 0 0.00019828344
managing O 0 0.0006005753
rare O 0 0.0014163149
but O 0 0.00037169483
serious O 0 0.00078362436
reactions O 0 0.00042369848
in O 0 0.0003461719
volunteer O 0 0.0011328559
apheresis O 0 0.0040103165
blood O 0 0.0061769634
donors O 0 0.002007672
. O 0 0.0027952138

Sirolimus B-Chemical 0 0.99039906
- O 0 0.037232712
associated O 0 0.00694345
proteinuria B-Disease 0 0.9995178
and O 0 0.008370984
renal B-Disease 0 0.9967901
dysfunction I-Disease 0 0.9965238
. O 0 0.010721077

Sirolimus B-Chemical 0 0.9665223
is O 0 0.0015187338
a O 0 0.0012612008
novel O 0 0.0006810068
immunosuppressant O 0 0.1116008
with O 0 0.0005225691
potent O 0 0.00072340557
antiproliferative O 0 0.034878477
actions O 0 0.00050499063
through O 0 0.000198779
its O 0 0.00024625845
ability O 0 0.00015004656
to O 0 0.00014527625
inhibit O 0 0.00014155138
the O 0 0.00020416401
raptor O 0 0.0023322927
- O 0 0.0021160117
containing O 0 0.00016524749
mammalian O 0 0.00017491053
target O 0 0.00022472769
of O 0 0.00067732297
rapamycin B-Chemical 0 0.5264372
protein O 0 0.0024487437
kinase O 0 0.008556345
. O 0 0.0038585295

Sirolimus B-Chemical 0 0.9656494
represents O 0 0.0019143914
a O 0 0.0014951725
major O 0 0.0007404347
therapeutic O 0 0.00076967035
advance O 0 0.00056364393
in O 0 0.00033162272
the O 0 0.00025077807
prevention O 0 0.00039656216
of O 0 0.00038826745
acute O 0 0.049526915
renal O 0 0.69759923
allograft O 0 0.003392663
rejection O 0 0.0037721812
and O 0 0.00057522405
chronic O 0 0.13078241
allograft O 0 0.18904455
nephropathy B-Disease 0 0.9999765
. O 0 0.005568818

Its O 0 0.008723474
role O 0 0.0010501826
in O 0 0.0010848427
the O 0 0.00072348735
therapy O 0 0.00097315013
of O 0 0.0010278446
glomerulonephritis B-Disease 2 0.99992573
, O 0 0.0030459347
autoimmunity B-Disease 0 0.9846581
, O 0 0.0019650355
cystic B-Disease 0 0.9223925
renal I-Disease 0 0.9877564
diseases I-Disease 0 0.9348706
and O 0 0.0011222402
renal B-Disease 0 0.99936825
cancer I-Disease 0 0.99905926
is O 0 0.00074728025
under O 0 0.00084614067
investigation O 0 0.0018375027
. O 0 0.002640226

Because O 0 0.0030078297
sirolimus B-Chemical 0 0.99911743
does O 0 0.0011085232
not O 0 0.00064384635
share O 0 0.0005759801
the O 0 0.00044793647
vasomotor O 0 0.8177985
renal O 0 0.6088236
adverse O 0 0.0008102989
effects O 0 0.0001256321
exhibited O 0 0.00015271794
by O 0 0.00016573428
calcineurin O 0 0.0016834633
inhibitors O 0 0.0004952042
, O 0 0.00054188276
it O 0 0.00028194507
has O 0 0.000109412555
been O 0 0.00014416197
designated O 0 0.0001629078
a O 0 0.00038564354
' O 0 0.00076252024
non O 0 0.0010313876
- O 0 0.02373114
nephrotoxic B-Disease 0 0.9992131
drug O 0 0.16367123
' O 0 0.0048536058
. O 0 0.0034705373

However O 0 0.0029816292
, O 0 0.003739424
clinical O 0 0.002732974
reports O 0 0.0008959195
suggest O 0 0.0003542948
that O 0 0.00039237642
, O 0 0.0006976544
under O 0 0.0002735221
some O 0 0.0002672343
circumstances O 0 0.00040083245
, O 0 0.0010412744
sirolimus B-Chemical 0 0.99974805
is O 0 0.000261139
associated O 0 0.00032070742
with O 0 0.0005939928
proteinuria B-Disease 0 0.99994934
and O 0 0.0013768234
acute B-Disease 0 0.939232
renal I-Disease 0 0.9993388
dysfunction I-Disease 0 0.99945885
. O 0 0.004272668

A O 0 0.07063231
common O 0 0.0051175198
risk O 0 0.04487469
factor O 0 0.014340136
appears O 0 0.0007474123
to O 0 0.0005760127
be O 0 0.00047660852
presence O 0 0.0004141767
of O 0 0.0005579389
pre O 0 0.0011605838
- O 0 0.0032771495
existing O 0 0.0011214666
chronic B-Disease 0 0.6702717
renal I-Disease 0 0.99888164
damage I-Disease 0 0.9941403
. O 0 0.0052840277

The O 0 0.0015984473
mechanisms O 0 0.0012550666
of O 0 0.002150109
sirolimus B-Chemical 0 0.9997875
- O 0 0.040740028
associated O 0 0.0011378472
proteinuria B-Disease 0 0.99991286
are O 0 0.00042055798
multifactorial O 0 0.0040088343
and O 0 0.00026026808
may O 0 0.00015815307
be O 0 0.00014834243
due O 0 0.00010502579
to O 0 0.00012257871
an O 0 0.00017238606
increase O 0 0.00016412191
in O 0 0.00025674416
glomerular O 0 0.99471635
capillary O 0 0.59577066
pressure O 0 0.013369048
following O 0 0.00026399185
calcineurin O 0 0.0022659593
inhibitor O 0 0.0030384373
withdrawal O 0 0.015108361
. O 0 0.0029059418

It O 0 0.0048290845
has O 0 0.0013080616
also O 0 0.0010023438
been O 0 0.000722875
suggested O 0 0.00046750446
that O 0 0.00048782647
sirolimus B-Chemical 0 0.99966013
directly O 0 0.00025516865
causes O 0 0.00037484025
increased O 0 0.00076898036
glomerular O 0 0.9994099
permeability O 0 0.95428663
/ O 0 0.015222367
injury O 0 0.03980599
, O 0 0.00041523163
but O 0 0.00018366754
evidence O 0 0.00013300515
for O 0 0.00015040167
this O 0 0.00024820378
mechanism O 0 0.00023597444
is O 0 0.00041975832
currently O 0 0.00079596124
inconclusive O 0 0.0036811256
. O 0 0.0030135636

The O 0 0.0027737075
acute B-Disease 0 0.7987731
renal I-Disease 0 0.9987924
dysfunction I-Disease 0 0.9993612
associated O 0 0.0009987605
with O 0 0.00082651194
sirolimus B-Chemical 0 0.999853
( O 0 0.00062724215
such O 0 0.00016121371
as O 0 0.00015135508
in O 0 0.00014125921
delayed O 0 0.00039144987
graft O 0 0.0003805941
function O 0 0.00014883265
) O 0 0.0004685783
may O 0 0.00011446067
be O 0 0.00011165861
due O 0 8.123793e-05
to O 0 9.8883625e-05
suppression O 0 0.00015555088
of O 0 0.00022620932
compensatory O 0 0.0007310664
renal O 0 0.8686896
cell O 0 0.0007331175
proliferation O 0 0.026329339
and O 0 0.00046205512
survival O 0 0.001090177
/ O 0 0.0026670736
repair O 0 0.001400735
processes O 0 0.0020244217
. O 0 0.0026834563

Although O 0 0.0016446013
these O 0 0.001404326
adverse O 0 0.0025478364
effects O 0 0.0006765511
occur O 0 0.0004942924
in O 0 0.00031948125
some O 0 0.00031619237
patients O 0 0.000605331
, O 0 0.00039892548
their O 0 0.00017955607
occurrence O 0 0.00020862493
could O 0 0.00011033917
be O 0 0.0001260598
minimised O 0 0.00015050195
by O 0 0.00011185183
knowledge O 0 0.00016431606
of O 0 0.00012995127
the O 0 9.2166345e-05
molecular O 0 0.00018316387
effects O 0 0.000118078184
of O 0 0.00024363278
sirolimus B-Chemical 0 0.9999132
on O 0 8.2666615e-05
the O 0 9.323097e-05
kidney O 0 0.014430888
, O 0 0.00019515895
the O 0 6.126398e-05
use O 0 6.934346e-05
of O 0 0.00015301515
sirolimus B-Chemical 0 0.99988616
in O 0 8.8059816e-05
appropriate O 0 5.6984103e-05
patient O 0 8.577484e-05
populations O 0 8.789137e-05
, O 0 0.00012427168
close O 0 6.556879e-05
monitoring O 0 7.6778786e-05
of O 0 0.00015616213
proteinuria B-Disease 0 0.9999597
and O 0 0.00021539789
renal O 0 0.33810294
function O 0 9.171325e-05
, O 0 0.0001730697
use O 0 9.173468e-05
of O 0 0.0002891967
angiotensin B-Chemical 0 0.9999939
- O 0 0.23305343
converting O 0 0.0007985606
enzyme O 0 0.0011196679
inhibitors O 0 0.00077109376
or O 0 0.00063105486
angiotensin B-Chemical 1 0.99999845
II I-Chemical 1 0.99840325
receptor O 0 0.04297979
blockers O 0 0.99238425
if O 0 0.0003964913
proteinuria B-Disease 0 0.9999784
occurs O 0 0.0004006191
and O 0 0.00042450186
withdrawal O 0 0.0016973554
if O 0 0.00046940142
needed O 0 0.00096435094
. O 0 0.0024629906

Further O 0 0.002433368
long O 0 0.002237044
- O 0 0.0040854593
term O 0 0.00087005936
analysis O 0 0.0005285691
of O 0 0.00049971865
renal O 0 0.10269112
allograft O 0 0.0014018834
studies O 0 0.00030118838
using O 0 0.0002274728
sirolimus B-Chemical 0 0.9996092
as O 0 0.00027158513
de O 0 0.0008060291
novo O 0 0.00049693603
immunosuppression O 0 0.0061858627
along O 0 0.000117732685
with O 0 0.0001417444
clinical O 0 0.00046081629
and O 0 0.00014371327
laboratory O 0 0.00017988781
studies O 0 0.00019405322
will O 0 0.00014002461
refine O 0 0.00032013524
these O 0 0.00033231583
issues O 0 0.0005870831
in O 0 0.0005278793
the O 0 0.0007035224
future O 0 0.0013710394
. O 0 0.0027643864

Proteinuria B-Disease 0 0.9986047
after O 0 0.0025053571
conversion O 0 0.0029668317
to O 0 0.0018605659
sirolimus B-Chemical 0 0.9983096
in O 0 0.0017214114
renal O 0 0.23359339
transplant O 0 0.0025630225
recipients O 0 0.0016963037
. O 0 0.0035496003

Sirolimus B-Chemical 0 0.99053824
( O 0 0.018579071
SRL B-Chemical 0 0.9990325
) O 0 0.00579612
is O 0 0.0014323144
a O 0 0.0018430057
new O 0 0.001665142
, O 0 0.0025965797
potent O 0 0.0030862982
immunosuppressive O 0 0.06459169
agent O 0 0.007814162
. O 0 0.006049801

More O 0 0.011150217
recently O 0 0.0031857844
, O 0 0.0068158284
proteinuria B-Disease 0 0.999803
has O 0 0.00077828247
been O 0 0.0005429794
reported O 0 0.00044926128
as O 0 0.0003030589
a O 0 0.000354089
consequence O 0 0.00018499664
of O 0 0.00041186143
sirolimus B-Chemical 0 0.99982965
therapy O 0 0.0006053047
, O 0 0.000416901
although O 0 0.00022689879
the O 0 0.00022105439
mechanism O 0 0.00026134052
has O 0 0.00039427142
remained O 0 0.0010866108
unclear O 0 0.001254592
. O 0 0.0030925614

We O 0 0.0024369333
retrospectively O 0 0.0019577062
examined O 0 0.00077738415
the O 0 0.0005919205
records O 0 0.0007667011
of O 0 0.00047919786
25 O 0 0.00058899313
renal O 0 0.13959786
transplant O 0 0.0005791048
patients O 0 0.00043791844
, O 0 0.00035877354
who O 0 0.00028095362
developed O 0 0.00023421396
or O 0 0.00020363345
displayed O 0 0.00028397157
increased O 0 0.0011389642
proteinuria B-Disease 0 0.99992275
after O 0 0.0010130164
SRL B-Chemical 0 0.9995351
conversion O 0 0.0034689312
. O 0 0.0028847074

The O 0 0.0023469343
patient O 0 0.0023496351
cohort O 0 0.002601836
( O 0 0.0016410335
14 O 0 0.00074385764
men O 0 0.001931598
, O 0 0.00091485475
11 O 0 0.00050968333
women O 0 0.0009309669
) O 0 0.0006793752
was O 0 0.00024512186
treated O 0 0.0005035506
with O 0 0.00052330235
SRL B-Chemical 0 0.9998752
as O 0 0.00028781948
conversion O 0 0.00033051427
therapy O 0 0.00024935088
, O 0 0.00023099383
due O 0 9.573508e-05
to O 0 0.00013862674
chronic B-Disease 0 0.05032264
allograft I-Disease 0 0.0893976
nephropathy I-Disease 0 0.999998
( O 0 0.0023018573
CAN B-Disease 0 0.95509684
) O 0 0.0006038199
( O 0 0.00025795875
n O 0 0.00018068888
= O 0 0.00042027104
15 O 0 0.00016673749
) O 0 0.000557572
neoplasia B-Disease 0 0.95017934
( O 0 0.00034574678
n O 0 0.00021962938
= O 0 0.0004772334
8 O 0 0.00019175628
) O 0 0.0005925467
; O 0 0.0010835016
Kaposi B-Disease 0 0.98511976
' I-Disease 0 0.0007042603
s I-Disease 0 0.0007771449
sarcoma I-Disease 0 0.9991934
, O 0 0.00055459724
Four O 0 0.0002690112
skin B-Disease 0 0.0592936
cancers I-Disease 0 0.9989084
, O 0 0.00078421144
One O 0 0.00036487865
intestinal B-Disease 0 0.29633787
tumors I-Disease 0 0.9982287
, O 0 0.00075198966
One O 0 0.00031855848
renal B-Disease 0 0.90768915
cell I-Disease 0 0.000497171
carsinom I-Disease 0 0.0015663399
) O 0 0.0012304601
or O 0 0.0004586944
BK O 0 0.9637108
virus O 0 0.01625885
nephropathy B-Disease 0 0.9999856
( O 0 0.0015211913
n O 0 0.00074968004
= O 0 0.0016956249
2 O 0 0.0011396174
) O 0 0.00278851
. O 0 0.002921689

SRL B-Chemical 0 0.99845195
was O 0 0.0030100285
started O 0 0.0016141873
at O 0 0.000773214
a O 0 0.00090651395
mean O 0 0.00048728453
of O 0 0.00059173716
78 O 0 0.00108085
+ O 0 0.0019069874
/ O 0 0.0028210871
- O 0 0.002517491
42 O 0 0.0006370467
( O 0 0.00066717586
15 O 0 0.00034443132
to O 0 0.0003224952
163 O 0 0.0009326026
) O 0 0.0008370756
months O 0 0.00030442054
after O 0 0.0004909225
transplantation O 0 0.0017385025
. O 0 0.0030195809

Mean O 0 0.0028438438
follow O 0 0.0018946022
- O 0 0.0045853723
up O 0 0.0013877762
on O 0 0.000997065
SRL B-Chemical 0 0.99821645
therapy O 0 0.0010637809
was O 0 0.00047477006
20 O 0 0.0005222674
+ O 0 0.0014934117
/ O 0 0.002369288
- O 0 0.0020457434
12 O 0 0.0003588883
( O 0 0.0006350831
6 O 0 0.0003484667
to O 0 0.00047367506
43 O 0 0.0011810118
) O 0 0.0019526714
months O 0 0.0010385248
. O 0 0.0031775334

Proteinuria B-Disease 0 0.99934
increased O 0 0.004288536
from O 0 0.0015657434
0 O 0 0.0015061835
. O 0 0.00096592057
445 O 0 0.002764418
( O 0 0.0009635436
0 O 0 0.0005270894
to O 0 0.00028941105
1 O 0 0.00033488558
. O 0 0.00024623802
5 O 0 0.00022230866
) O 0 0.00047748417
g O 0 0.00071872264
/ O 0 0.0008278124
d O 0 0.00031763868
before O 0 0.00012289552
conversion O 0 0.00026040457
to O 0 0.00013179568
3 O 0 0.00013582844
. O 0 0.00014096238
2 O 0 0.00018043735
g O 0 0.0005647528
/ O 0 0.0012064162
dL O 0 0.009656074
( O 0 0.00047949236
0 O 0 0.000283469
. O 0 0.00017889503
2 O 0 0.00017407812
to O 0 0.00013515865
12 O 0 0.00014387727
) O 0 0.00036380297
after O 0 0.00014690706
conversion O 0 0.00044067303
( O 0 0.0007250358
P O 0 0.008542348
= O 0 0.0015174025
0 O 0 0.00095520564
. O 0 0.0010701279
001 O 0 0.009459107
) O 0 0.0049655847
. O 0 0.0044285655

Before O 0 0.0038475809
conversion O 0 0.0037163307
8 O 0 0.0016709357
( O 0 0.0019045877
32 O 0 0.0012396972
% O 0 0.0014261594
) O 0 0.0013259016
patients O 0 0.0008784612
had O 0 0.0004529842
no O 0 0.00062242034
proteinuria B-Disease 0 0.9999045
, O 0 0.0016190668
whereas O 0 0.0005963919
afterwards O 0 0.00091749616
all O 0 0.00058156543
patients O 0 0.0015629594
had O 0 0.0017389595
proteinuria B-Disease 0 0.99969566
. O 0 0.0051807

In O 0 0.0022527806
28 O 0 0.0022121842
% O 0 0.0024137166
of O 0 0.0012577303
patients O 0 0.0035082712
proteinuria B-Disease 0 0.9998271
remained O 0 0.0013750362
unchanged O 0 0.0008889476
, O 0 0.0009253761
whereas O 0 0.0004916965
it O 0 0.000663382
increased O 0 0.00068271364
in O 0 0.00057234877
68 O 0 0.0010985761
% O 0 0.0013815166
of O 0 0.0013304042
patients O 0 0.003600627
. O 0 0.0035691063

In O 0 0.0033889683
40 O 0 0.003801116
% O 0 0.0043844385
it O 0 0.0026258794
increased O 0 0.002159216
by O 0 0.0016532775
more O 0 0.0022787526
than O 0 0.0018756142
100 O 0 0.0043942137
% O 0 0.0059124245
. O 0 0.0059589813

Twenty O 0 0.0066517754
- O 0 0.00569706
eight O 0 0.0008769058
percent O 0 0.00092944776
of O 0 0.00085900695
patients O 0 0.0012615306
showed O 0 0.0007004143
increased O 0 0.0017077602
proteinuria B-Disease 0 0.9998354
to O 0 0.0011760589
the O 0 0.0016715076
nephrotic B-Disease 0 0.9999614
range O 0 0.002906685
. O 0 0.003248368

Biopsies O 0 0.0032549484
performed O 0 0.0013578455
in O 0 0.00092257344
five O 0 0.00052191457
patients O 0 0.000948371
revealed O 0 0.00043725202
new O 0 0.0006521767
pathological O 0 0.0023577623
changes O 0 0.0006367736
: O 0 0.0014115388
One O 0 0.0015476362
membranoproliferative B-Disease 0 0.99998605
glomerulopathy I-Disease 0 0.9999907
and O 0 0.0054829237
interstitial B-Disease 0 0.9967603
nephritis I-Disease 0 0.99998784
. O 0 0.006760495

These O 0 0.0038869164
patients O 0 0.0054190992
showed O 0 0.0028076102
persistently O 0 0.0060213436
good O 0 0.003507854
graft O 0 0.005559552
function O 0 0.003984039
. O 0 0.0074847704

Serum O 0 0.844246
creatinine B-Chemical 0 0.9913265
values O 0 0.0020171604
did O 0 0.0011896539
not O 0 0.00067536545
change O 0 0.0005722015
significantly O 0 0.0006141452
: O 0 0.0008904108
1 O 0 0.00039405932
. O 0 0.00028584557
98 O 0 0.0005438572
+ O 0 0.0010632278
/ O 0 0.0016634767
- O 0 0.001417117
0 O 0 0.00028597098
. O 0 0.00017064628
8 O 0 0.00017211275
mg O 0 0.0013359757
/ O 0 0.0009695168
dL O 0 0.0041427603
before O 0 0.00017736033
SRL B-Chemical 0 0.9993685
therapy O 0 0.00032708995
and O 0 0.00017007401
2 O 0 0.00018113358
. O 0 0.00015813421
53 O 0 0.0002884051
+ O 0 0.00075959344
/ O 0 0.00151279
- O 0 0.0014718496
1 O 0 0.00021517045
. O 0 0.0001520526
9 O 0 0.00015762493
mg O 0 0.0014501591
/ O 0 0.00095637323
dL O 0 0.0023708413
at O 0 0.00013903846
last O 0 0.000112593305
follow O 0 0.00018777307
- O 0 0.0010177547
up O 0 0.00045054485
( O 0 0.000873937
P O 0 0.0097576985
= O 0 0.0017651158
. O 0 0.0008716774
14 O 0 0.0011982728
) O 0 0.0035220042
. O 0 0.0038337505

Five O 0 0.004418921
grafts O 0 0.004388516
were O 0 0.0017895595
lost O 0 0.001580262
and O 0 0.0013182284
the O 0 0.0011071544
patients O 0 0.0020578043
returned O 0 0.0014507861
to O 0 0.0015786579
dialysis O 0 0.004868113
. O 0 0.0047450876

Five O 0 0.006786579
patients O 0 0.0070771687
displayed O 0 0.0041659116
CAN B-Disease 0 0.93094295
and O 0 0.00811175
Kaposi B-Disease 0 0.99256575
' I-Disease 0 0.008129106
s I-Disease 0 0.008316745
sarcoma I-Disease 0 0.994888
. O 0 0.008530229

Mean O 0 0.0029665863
urinary O 0 0.010647326
protein O 0 0.0013864316
of O 0 0.0010164165
patients O 0 0.0014326028
who O 0 0.0007104018
returned O 0 0.00034905004
to O 0 0.00023285128
dialysis O 0 0.00059077516
was O 0 0.000216744
1 O 0 0.00023230577
. O 0 0.00018098374
26 O 0 0.00023957263
( O 0 0.00031303096
0 O 0 0.00023220811
. O 0 0.00015398026
5 O 0 0.00012497437
to O 0 0.00010617514
3 O 0 0.00012136782
. O 0 0.00013045358
5 O 0 0.00013359135
) O 0 0.00032393454
g O 0 0.00053684635
/ O 0 0.00064978737
d O 0 0.00024069034
before O 0 8.887559e-05
and O 0 0.00016029067
4 O 0 0.0001342247
. O 0 0.00013559083
7 O 0 0.00011700711
( O 0 0.00022407106
3 O 0 0.00011481386
to O 0 0.000112202855
12 O 0 0.00012755663
) O 0 0.0003843333
g O 0 0.00064699916
/ O 0 0.0008289009
d O 0 0.00039397445
after O 0 0.00019363144
conversion O 0 0.00054195063
( O 0 0.00086403167
P O 0 0.012501962
= O 0 0.0020095243
. O 0 0.0011195611
01 O 0 0.00579937
) O 0 0.0043666214
. O 0 0.0041399286

Mean O 0 0.0035328479
serum O 0 0.033233944
creatinine B-Chemical 0 0.95799494
level O 0 0.0009414676
before O 0 0.00047535152
conversion O 0 0.00077231776
was O 0 0.00037655653
2 O 0 0.0003603261
. O 0 0.00027646136
21 O 0 0.0003413995
mg O 0 0.0022061854
/ O 0 0.0015069211
dL O 0 0.0061306376
and O 0 0.00033677393
thereafter O 0 0.00030435898
, O 0 0.0004464487
4 O 0 0.0002283699
. O 0 0.00026733777
93 O 0 0.00061969686
mg O 0 0.0028649305
/ O 0 0.001974133
dL O 0 0.007861893
( O 0 0.0014174416
P O 0 0.016683193
= O 0 0.0026491531
. O 0 0.0015230507
02 O 0 0.017289998
) O 0 0.0053827316
. O 0 0.0047662314

Heavy O 0 0.5212983
proteinuria B-Disease 0 0.9995431
was O 0 0.0019862698
common O 0 0.0009857969
after O 0 0.00037175487
the O 0 0.00039368082
use O 0 0.00044318358
of O 0 0.0008626344
SRL B-Chemical 0 0.9993861
as O 0 0.0005691129
rescue O 0 0.00044628343
therapy O 0 0.00075112557
for O 0 0.00062637887
renal O 0 0.32107466
transplantation O 0 0.002686242
. O 0 0.0028886853

Therefore O 0 0.002711388
, O 0 0.0048383926
conversion O 0 0.002338946
should O 0 0.0005709548
be O 0 0.00056292745
considered O 0 0.00043211997
for O 0 0.00032895664
patients O 0 0.0007526883
who O 0 0.0005053794
have O 0 0.00029505248
not O 0 0.0003696335
developed O 0 0.0007825613
advanced O 0 0.0109368125
CAN B-Disease 0 0.98300534
and O 0 0.0035368858
proteinuria B-Disease 0 0.9998287
. O 0 0.005628098

The O 0 0.002082936
possibility O 0 0.0013855286
of O 0 0.002290764
de O 0 0.0059234076
novo O 0 0.0055470513
glomerular O 0 0.998033
pathology O 0 0.0054156943
under O 0 0.00068906567
SRL B-Chemical 0 0.99949336
treatment O 0 0.00037393338
requires O 0 0.0001943391
further O 0 0.0003211627
investigation O 0 0.00069368636
by O 0 0.0008760088
renal O 0 0.5499508
biopsy O 0 0.0026011083
. O 0 0.002820619

Long O 0 0.010317844
- O 0 0.007923456
term O 0 0.0016212797
follow O 0 0.0008739812
- O 0 0.002599026
up O 0 0.0006858573
of O 0 0.0008981477
ifosfamide B-Chemical 0 0.99986815
renal B-Disease 0 0.99948066
toxicity I-Disease 0 0.99700254
in O 0 0.00032302568
children O 0 0.00089445495
treated O 0 0.000548874
for O 0 0.00031112085
malignant B-Disease 0 0.99680007
mesenchymal I-Disease 0 0.9518886
tumors I-Disease 0 0.9993919
: O 0 0.00072943873
an O 0 0.000235681
International O 0 0.00018929568
Society O 0 0.00025586295
of O 0 0.00037733704
Pediatric O 0 0.0005162937
Oncology O 0 0.0010505514
report O 0 0.0019477941
. O 0 0.0029144334

The O 0 0.00244073
renal O 0 0.09463342
function O 0 0.0010019152
of O 0 0.00094940106
74 O 0 0.0012874238
children O 0 0.001865433
with O 0 0.0009866689
malignant B-Disease 0 0.9980124
mesenchymal I-Disease 0 0.97330314
tumors I-Disease 0 0.9994797
in O 0 0.00018934025
complete O 0 0.00011597583
remission O 0 0.0015177056
and O 0 0.00010166191
who O 0 0.00012047994
have O 0 6.1658844e-05
received O 0 6.9178874e-05
the O 0 6.401872e-05
same O 0 9.224362e-05
ifosfamide B-Chemical 0 0.998987
chemotherapy O 0 0.0006760728
protocol O 0 8.314468e-05
( O 0 0.0001445052
International O 0 7.6431286e-05
Society O 0 9.396867e-05
of O 0 0.00012065092
Pediatric O 0 0.00014042133
Oncology O 0 0.00031189542
Malignant B-Disease 0 0.10727302
Mesenchymal I-Disease 0 0.0026606205
Tumor I-Disease 0 0.97444576
Study O 0 0.0007124802
84 O 0 0.00034685718
[ O 0 0.00085543917
SIOP O 0 0.0008507886
MMT O 0 0.005380858
84 O 0 0.00033451128
] O 0 0.00066965446
) O 0 0.00042547006
were O 0 0.00016364263
studied O 0 0.00024732813
1 O 0 0.0002104574
year O 0 0.00015063949
after O 0 0.00011178838
the O 0 0.00021018706
completion O 0 0.00028286615
of O 0 0.00078175444
treatment O 0 0.001447441
. O 0 0.002893923

Total O 0 0.0043787826
cumulative O 0 0.0018190301
doses O 0 0.001971717
were O 0 0.0007167765
36 O 0 0.0005815616
or O 0 0.0003503663
60 O 0 0.00041272645
g O 0 0.00090808474
/ O 0 0.0012650663
m2 O 0 0.0017962672
of O 0 0.00047130042
ifosfamide B-Chemical 0 0.99913055
( O 0 0.00038029347
six O 0 8.656813e-05
or O 0 0.00011115677
10 O 0 0.000120736186
cycles O 0 8.350447e-05
of O 0 0.00024562134
ifosfamide B-Chemical 0 0.9992312
, I-Chemical 0 0.0012526839
vincristine I-Chemical 1 0.99993825
, I-Chemical 0 0.0010721168
and I-Chemical 0 0.0008311376
dactinomycin I-Chemical 0 0.9989115
[ O 0 0.2520691
IVA B-Chemical 0 0.99997795
] O 0 0.052237146
) O 0 0.0055563734
. O 0 0.0036652891

None O 0 0.006970938
of O 0 0.0044104443
them O 0 0.0043624174
had O 0 0.0033519107
received O 0 0.004290045
cisplatin B-Chemical 0 0.998235
chemotherapy O 0 0.03387202
. O 0 0.006552518

Ages O 0 0.010126253
ranged O 0 0.0028660083
from O 0 0.0012132312
4 O 0 0.00074173306
months O 0 0.0003985636
to O 0 0.0004902516
17 O 0 0.00073178334
years O 0 0.0006928486
; O 0 0.0010008749
58 O 0 0.00089733
patients O 0 0.0009153704
were O 0 0.0006027136
males O 0 0.001292117
and O 0 0.0012104651
42 O 0 0.0021399455
females O 0 0.0044888854
. O 0 0.0047022896

The O 0 0.0028635361
most O 0 0.003047015
common O 0 0.0022846586
primary O 0 0.001995891
tumor B-Disease 0 0.11967992
site O 0 0.0009424422
was O 0 0.0011015544
the O 0 0.0011122412
head O 0 0.0043404945
and O 0 0.0028186268
neck O 0 0.02856699
. O 0 0.0059407707

Renal O 0 0.019204393
function O 0 0.0014010959
was O 0 0.0009137879
investigated O 0 0.0005980756
by O 0 0.0005105912
measuring O 0 0.00049287366
plasma O 0 0.0035809132
and O 0 0.00048084464
urinary O 0 0.039667204
electrolytes O 0 0.5240673
, O 0 0.0015548703
glucosuria B-Disease 0 0.99992085
, O 0 0.0040623266
proteinuria B-Disease 0 0.9999808
, O 0 0.012216951
aminoaciduria B-Disease 0 0.9999937
, O 0 0.003039736
urinary O 0 0.29978615
pH O 0 0.034313627
, O 0 0.00074863876
osmolarity O 0 0.2419534
, O 0 0.0011910575
creatinine B-Chemical 0 0.99768114
clearance O 0 0.0071129506
, O 0 0.00103928
phosphate B-Chemical 0 0.8948593
tubular O 0 0.98780257
reabsorption O 0 0.9925804
, O 0 0.0016173612
beta O 0 0.3179068
2 O 0 0.0008635066
microglobulinuria O 0 0.15609483
, O 0 0.0016647665
and O 0 0.0016352563
lysozymuria O 0 0.9428463
. O 0 0.0041355584

Fifty O 0 0.011492478
- O 0 0.00793985
eight O 0 0.0012026837
patients O 0 0.0019541364
( O 0 0.0015348684
78 O 0 0.0012764107
% O 0 0.001185609
) O 0 0.001073199
had O 0 0.00044569952
normal O 0 0.0008054206
renal O 0 0.33882356
tests O 0 0.00097064674
, O 0 0.0005792116
whereas O 0 0.00030734725
16 O 0 0.00036546143
patients O 0 0.00056619727
( O 0 0.00059263484
22 O 0 0.00056608074
% O 0 0.00086501846
) O 0 0.0013781145
had O 0 0.0012050845
renal B-Disease 0 0.9947291
abnormalities I-Disease 0 0.9258248
. O 0 0.004492132

Two O 0 0.0020341063
subsets O 0 0.0014936493
of O 0 0.0012572794
patients O 0 0.0014317591
were O 0 0.00045069502
identified O 0 0.00024998313
from O 0 0.0002670038
this O 0 0.00029489023
latter O 0 0.00054687326
group O 0 0.00038574063
: O 0 0.00038808573
the O 0 0.00010838577
first O 0 7.276151e-05
included O 0 9.291864e-05
four O 0 7.106195e-05
patients O 0 0.00024018214
( O 0 0.00021205716
5 O 0 0.00010263069
% O 0 0.00017602548
of O 0 0.00010413901
the O 0 8.844542e-05
total O 0 0.00012074298
population O 0 0.00021760292
) O 0 0.00039672968
who O 0 0.0001796403
developed O 0 0.00013695445
major O 0 0.00015491513
toxicity B-Disease 0 0.27475998
resulting O 0 0.00015458859
in O 0 0.00021393181
Fanconi B-Disease 0 0.77538365
' I-Disease 0 0.0004928615
s I-Disease 0 0.00050576474
syndrome I-Disease 0 0.95908123
( O 0 0.0014205166
TDFS B-Disease 0 0.9932724
) O 0 0.00082754664
; O 0 0.0002929019
and O 0 0.00010319073
the O 0 7.232935e-05
second O 0 7.6774246e-05
group O 0 0.00013063994
included O 0 7.9448815e-05
five O 0 5.9456757e-05
patients O 0 0.00021820585
with O 0 0.00018592413
elevated O 0 0.0020702789
beta O 0 0.51410097
2 O 0 0.0005299137
microglobulinuria O 0 0.16616821
and O 0 0.00053649134
low O 0 0.0014020329
phosphate B-Chemical 0 0.9443761
reabsorption O 0 0.9840971
. O 0 0.0039566755

The O 0 0.002786018
remaining O 0 0.0023293777
seven O 0 0.0018056674
patients O 0 0.0029219221
had O 0 0.0018655362
isolated O 0 0.0024515744
beta O 0 0.32549566
2 O 0 0.0048274375
microglobulinuria O 0 0.30977112
. O 0 0.0070244954

Severe O 0 0.33761317
toxicity B-Disease 0 0.6830298
was O 0 0.0012118412
correlated O 0 0.0006116486
with O 0 0.0004218175
the O 0 0.00025061026
higher O 0 0.00025045074
cumulative O 0 0.00021325995
dose O 0 0.00026654548
of O 0 0.00016822682
60 O 0 0.00019035868
g O 0 0.000499601
/ O 0 0.0007735563
m2 O 0 0.0012640854
of O 0 0.00029555673
ifosfamide B-Chemical 0 0.9996245
, O 0 0.00037484386
a O 0 0.00025513556
younger O 0 0.0010222396
age O 0 0.0002810645
( O 0 0.0002535813
less O 0 0.00017328437
than O 0 0.00011875331
2 O 0 0.00015450623
1 O 0 0.00016691105
/ O 0 0.00045535644
2 O 0 0.00016178751
years O 0 0.00018175069
old O 0 0.00023167559
) O 0 0.0004801949
, O 0 0.000415695
and O 0 0.0003102379
a O 0 0.0005238279
predominance O 0 0.00075825804
of O 0 0.0008656456
vesicoprostatic O 0 0.09054855
tumor B-Disease 0 0.76321393
involvement O 0 0.0041862256
. O 0 0.0034827485

This O 0 0.00479692
low O 0 0.002621416
percentage O 0 0.0012966974
( O 0 0.001924699
5 O 0 0.00083343714
% O 0 0.0013135805
) O 0 0.0013830996
of O 0 0.00084590813
TDFS O 0 0.9371872
must O 0 0.00021433871
be O 0 0.00019689852
evaluated O 0 0.00016164225
with O 0 0.0001526862
respect O 0 0.00010576347
to O 0 9.449612e-05
the O 0 8.512493e-05
efficacy O 0 0.0001333512
of O 0 0.00026110566
ifosfamide B-Chemical 0 0.9996086
in O 0 0.00018382593
the O 0 0.00016360098
treatment O 0 0.00026982545
of O 0 0.0005754928
mesenchymal B-Disease 0 0.8906548
tumors I-Disease 0 0.9971559
in O 0 0.0013138897
children O 0 0.005138265
. O 0 0.0027797245

Progressive O 0 0.11001559
myopathy B-Disease 0 0.9982597
with O 0 0.002778686
up O 0 0.0018711666
- O 0 0.003092935
regulation O 0 0.00043395732
of O 0 0.0009960629
MHC O 0 0.010869894
- O 0 0.009888643
I O 0 0.014045719
associated O 0 0.0011673765
with O 0 0.0015323902
statin B-Chemical 1 0.9922707
therapy O 0 0.003912385
. O 0 0.003579687

Statins B-Chemical 0 0.9970669
can O 0 0.0025226527
cause O 0 0.0024199444
a O 0 0.0030890605
necrotizing O 0 0.9990927
myopathy B-Disease 0 0.9998971
and O 0 0.0021418391
hyperCKaemia B-Disease 0 0.9897928
which O 0 0.00058935117
is O 0 0.00030993277
reversible O 0 0.00086456945
on O 0 0.00025189837
cessation O 0 0.00045485242
of O 0 0.0007006493
the O 0 0.0010048652
drug O 0 0.019260623
. O 0 0.0034371417

What O 0 0.006632115
is O 0 0.0018329753
less O 0 0.001719897
well O 0 0.00088345894
known O 0 0.00065964926
is O 0 0.00044996053
a O 0 0.0006845447
phenomenon O 0 0.0013587084
whereby O 0 0.00045845838
statins B-Chemical 0 0.9986933
may O 0 0.0002685169
induce O 0 0.0002027912
a O 0 0.0009889096
myopathy B-Disease 0 0.9998634
, O 0 0.0008916711
which O 0 0.00026985147
persists O 0 0.0001806496
or O 0 0.00018211167
may O 0 0.00019136193
progress O 0 0.00041094216
after O 0 0.00021241046
stopping O 0 0.00075865194
the O 0 0.00080880086
drug O 0 0.011572333
. O 0 0.0031144444

We O 0 0.0039286786
investigated O 0 0.002944243
the O 0 0.0026184178
muscle O 0 0.009355334
pathology O 0 0.004879915
in O 0 0.0016864634
8 O 0 0.001683546
such O 0 0.0020034476
cases O 0 0.0049973456
. O 0 0.006080403

All O 0 0.0046884394
had O 0 0.0064527784
myofibre O 0 0.9607161
necrosis B-Disease 2 0.99981123
but O 0 0.0029337585
only O 0 0.0014001267
3 O 0 0.0009783789
had O 0 0.0010820276
an O 0 0.0017611948
inflammatory O 0 0.01825574
infiltrate O 0 0.016489241
. O 0 0.004595216

In O 0 0.002297188
all O 0 0.0019887611
cases O 0 0.0020984556
there O 0 0.00083287514
was O 0 0.0008336842
diffuse O 0 0.0023074932
or O 0 0.00047605098
multifocal O 0 0.027546577
up O 0 0.00042204696
- O 0 0.0008970675
regulation O 0 0.0001230956
of O 0 0.0003595974
MHC O 0 0.007052784
- O 0 0.0076976134
I O 0 0.0117317345
expression O 0 0.00040168452
even O 0 0.00057119457
in O 0 0.0005852841
non O 0 0.0017084635
- O 0 0.022305427
necrotic B-Disease 0 0.5172548
fibres O 0 0.009528261
. O 0 0.0035826676

Progressive O 0 0.011188593
improvement O 0 0.0024659918
occurred O 0 0.0011497193
in O 0 0.0006732768
7 O 0 0.00043930678
cases O 0 0.0005014942
after O 0 0.0001764185
commencement O 0 0.00028043147
of O 0 0.00049248274
prednisolone B-Chemical 0 0.99984884
and O 0 0.0011190568
methotrexate B-Chemical 0 0.9999572
, O 0 0.0011408388
and O 0 0.00049440644
in O 0 0.00048869266
one O 0 0.00060914375
case O 0 0.0012196974
spontaneously O 0 0.0038420656
. O 0 0.0031818165

These O 0 0.0019042866
observations O 0 0.0016100361
suggest O 0 0.0007735972
that O 0 0.0009939948
statins B-Chemical 0 0.9975228
may O 0 0.00054514385
initiate O 0 0.00027725776
an O 0 0.00045487835
immune O 0 0.0019426107
- O 0 0.0029440583
mediated O 0 0.00021653806
myopathy B-Disease 0 0.9993637
that O 0 0.00015479702
persists O 0 0.0001322387
after O 0 8.278684e-05
withdrawal O 0 0.0005345527
of O 0 0.00017143335
the O 0 0.00017557807
drug O 0 0.0025577105
and O 0 0.00029283742
responds O 0 0.0002941893
to O 0 0.00045019368
immunosuppressive O 0 0.014142165
therapy O 0 0.0017657351
. O 0 0.0022462609

The O 0 0.001830089
mechanism O 0 0.0012367148
of O 0 0.0016901909
this O 0 0.0022228835
myopathy B-Disease 0 0.9996505
is O 0 0.00067692646
uncertain O 0 0.0006943564
but O 0 0.00040664573
may O 0 0.00017890272
involve O 0 0.0001542945
the O 0 0.00012088687
induction O 0 0.00012808132
by O 0 0.00022149051
statins B-Chemical 0 0.99717027
of O 0 0.00037138502
an O 0 0.00037797214
endoplasmic O 0 0.0022179245
reticulum O 0 0.014871974
stress O 0 0.0035115618
response O 0 0.00011987213
with O 0 0.00012373451
associated O 0 0.00013654082
up O 0 0.00016306539
- O 0 0.00052885956
regulation O 0 6.7968685e-05
of O 0 0.00023221942
MHC O 0 0.008505595
- O 0 0.009155125
I O 0 0.014395875
expression O 0 0.00031344037
and O 0 0.00043861152
antigen O 0 0.002131568
presentation O 0 0.0013584456
by O 0 0.0008913326
muscle O 0 0.0068144994
fibres O 0 0.0061493656
. O 0 0.0031348295

Use O 0 0.0075657866
of O 0 0.0034881914
chromosome O 0 0.0056276703
substitution O 0 0.0021234027
strains O 0 0.0010202252
to O 0 0.00073515554
identify O 0 0.0006409171
seizure B-Disease 0 0.99737155
susceptibility O 0 0.0016957169
loci O 0 0.0013627146
in O 0 0.000979955
mice O 0 0.00082478614
. O 0 0.0029616177

Seizure B-Disease 2 0.99459153
susceptibility O 0 0.007121267
varies O 0 0.003551432
among O 0 0.0032369033
inbred O 0 0.004445439
mouse O 0 0.0027775168
strains O 0 0.004567165
. O 0 0.007856495

Chromosome O 0 0.031947114
substitution O 0 0.0039686398
strains O 0 0.0021231307
( O 0 0.0035725266
CSS O 0 0.7418363
) O 0 0.002230401
, O 0 0.0010171885
in O 0 0.00041046584
which O 0 0.00039763117
a O 0 0.00040774545
single O 0 0.00020218497
chromosome O 0 0.00053956214
from O 0 0.0001336812
one O 0 0.00012085402
inbred O 0 0.00023779848
strain O 0 0.00010982158
( O 0 0.00025847548
donor O 0 0.00014119482
) O 0 0.00033699872
has O 0 8.31841e-05
been O 0 0.00010778221
transferred O 0 0.00015140156
onto O 0 0.00012255416
a O 0 0.0001613629
second O 0 9.729319e-05
strain O 0 0.0001042337
( O 0 0.00028849914
host O 0 0.00019436896
) O 0 0.0003234987
by O 0 0.00010398264
repeated O 0 7.8705074e-05
backcrossing O 0 0.00015192997
, O 0 0.00022686203
may O 0 9.9543606e-05
be O 0 0.00010198136
used O 0 9.081789e-05
to O 0 8.551628e-05
identify O 0 6.336495e-05
quantitative O 0 0.0001309666
trait O 0 0.0011871046
loci O 0 0.00036714878
( O 0 0.0004605484
QTLs O 0 0.0007185901
) O 0 0.0005706329
that O 0 0.00021267454
contribute O 0 0.00039751234
to O 0 0.00078638684
seizure B-Disease 0 0.99853015
susceptibility O 0 0.0038868187
. O 0 0.003180708

QTLs O 0 0.0076658526
for O 0 0.001686852
susceptibility O 0 0.0022052787
to O 0 0.0016146608
pilocarpine B-Chemical 0 0.9999795
- O 0 0.07895876
induced O 0 0.0009786312
seizures B-Disease 0 0.9999683
, O 0 0.0008430744
a O 0 0.00029963066
model O 0 0.00015132954
of O 0 0.00025084167
temporal B-Disease 0 0.13134971
lobe I-Disease 0 0.991442
epilepsy I-Disease 0 0.9999981
, O 0 0.0005846508
have O 0 0.0001149427
not O 0 0.00010722659
been O 0 0.00013131899
reported O 0 0.00018043097
, O 0 0.00031619775
and O 0 0.00024946406
CSS O 0 0.5950967
have O 0 0.00013399425
not O 0 0.0001292789
previously O 0 0.00019749266
been O 0 0.00017753475
used O 0 0.0001823906
to O 0 0.00022637608
localize O 0 0.00021008289
seizure B-Disease 0 0.99610007
susceptibility O 0 0.0016612513
genes O 0 0.001508677
. O 0 0.0027466698

We O 0 0.0031435979
report O 0 0.0033906726
QTLs O 0 0.0028792296
identified O 0 0.00065940345
using O 0 0.0006161727
a O 0 0.0010256759
B6 O 0 0.0038811497
( O 0 0.0009015116
host O 0 0.0005203105
) O 0 0.00087339303
x O 0 0.0016496668
A O 0 0.010356597
/ O 0 0.004593624
J O 0 0.41553256
( O 0 0.0007165765
donor O 0 0.0002639058
) O 0 0.00075106084
CSS O 0 0.14385705
panel O 0 0.00014935556
to O 0 0.000113100024
localize O 0 5.6353187e-05
genes O 0 0.00014275436
involved O 0 0.00016319402
in O 0 0.00023674832
susceptibility O 0 0.0006074216
to O 0 0.00067894196
pilocarpine B-Chemical 0 0.99998164
- O 0 0.06281051
induced O 0 0.00217675
seizures B-Disease 0 0.9998832
. O 0 0.004517926

Three O 0 0.003040349
hundred O 0 0.0029976717
fifty O 0 0.0026373996
- O 0 0.0034766989
five O 0 0.00057394395
adult O 0 0.00095697754
male O 0 0.0015525292
CSS O 0 0.06834119
mice O 0 0.00021233491
, O 0 0.0006502052
58 O 0 0.0006951483
B6 O 0 0.0022308442
, O 0 0.0006367335
and O 0 0.00036794101
39 O 0 0.0005689657
A O 0 0.0059929457
/ O 0 0.0039629308
J O 0 0.27281395
were O 0 0.00029439753
tested O 0 0.0002198716
for O 0 0.0002183047
susceptibility O 0 0.00062536215
to O 0 0.000724196
pilocarpine B-Chemical 0 0.9999777
- O 0 0.056501318
induced O 0 0.0022750727
seizures B-Disease 0 0.99987066
. O 0 0.0046824804

Highest O 0 0.017181952
stage O 0 0.0072587775
reached O 0 0.0023159117
and O 0 0.0013909717
latency O 0 0.0016674687
to O 0 0.0006106342
each O 0 0.0004391998
stage O 0 0.0012541732
were O 0 0.0005469345
recorded O 0 0.00058253837
for O 0 0.0005477223
all O 0 0.0009000912
mice O 0 0.0008819291
. O 0 0.003307458

B6 O 0 0.012275478
mice O 0 0.0011392761
were O 0 0.00127479
resistant O 0 0.0013837103
to O 0 0.0011486161
seizures B-Disease 0 0.999841
and O 0 0.00077729457
slower O 0 0.00069826323
to O 0 0.00034653724
reach O 0 0.00046040615
stages O 0 0.00063386624
compared O 0 0.0003883218
to O 0 0.000644242
A O 0 0.009866286
/ O 0 0.0078548705
J O 0 0.20011252
mice O 0 0.0013352374
. O 0 0.0039047718

The O 0 0.0037713714
CSS O 0 0.39702314
for O 0 0.001834817
Chromosomes O 0 0.015433099
10 O 0 0.00081298535
and O 0 0.0005616808
18 O 0 0.0005123096
progressed O 0 0.00067529496
to O 0 0.00024176903
the O 0 0.00023559833
most O 0 0.0003990069
severe O 0 0.0014790875
stages O 0 0.00073061645
, O 0 0.00091526314
diverging O 0 0.0013230551
dramatically O 0 0.0005707725
from O 0 0.00055121025
the O 0 0.00076305773
B6 O 0 0.0064290743
phenotype O 0 0.0028724761
. O 0 0.003812248

Latencies O 0 0.051957097
to O 0 0.002375574
stages O 0 0.0025687618
were O 0 0.0011237294
also O 0 0.00083238597
significantly O 0 0.00088917295
shorter O 0 0.00071009627
for O 0 0.00079473987
CSS10 O 0 0.0035613314
and O 0 0.0020586583
CSS18 O 0 0.014421876
mice O 0 0.0015222396
. O 0 0.0045934925

CSS O 0 0.6241056
mapping O 0 0.0026628482
suggests O 0 0.0019164335
seizure B-Disease 0 0.99722785
susceptibility O 0 0.0023944175
loci O 0 0.0014170253
on O 0 0.00060210784
mouse O 0 0.0008797884
Chromosomes O 0 0.0109877875
10 O 0 0.0011433302
and O 0 0.0013719896
18 O 0 0.0022698683
. O 0 0.0035190834

This O 0 0.0038327693
approach O 0 0.0015573233
provides O 0 0.0006826424
a O 0 0.00094225456
framework O 0 0.00047877894
for O 0 0.00030935009
identifying O 0 0.00026602577
potentially O 0 0.00027723954
novel O 0 0.00022732583
homologous O 0 0.0001449175
candidate O 0 0.00018119716
genes O 0 0.00029559562
for O 0 0.00033015525
human O 0 0.00077292003
temporal B-Disease 0 0.14187646
lobe I-Disease 0 0.98289305
epilepsy I-Disease 0 0.99996746
. O 0 0.0050018462

In O 0 0.0019037114
vitro O 0 0.0015661952
characterization O 0 0.00095036544
of O 0 0.0011117798
parasympathetic O 0 0.05427561
and O 0 0.0006398524
sympathetic O 0 0.001498229
responses O 0 0.0003629679
in O 0 0.0005424594
cyclophosphamide B-Chemical 0 0.9997435
- O 0 0.006756599
induced O 0 0.0008518179
cystitis B-Disease 0 0.9983247
in O 0 0.0009979408
the O 0 0.0010570593
rat O 0 0.0028134286
. O 0 0.0033011013

In O 0 0.0035092284
cyclophosphamide B-Chemical 0 0.99935347
- O 0 0.02550272
induced O 0 0.0016706779
cystitis B-Disease 0 0.99821186
in O 0 0.00062221446
the O 0 0.0003571379
rat O 0 0.0006357463
, O 0 0.0007957909
detrusor O 0 0.5108248
function O 0 0.00018626696
is O 0 0.00016320306
impaired O 0 0.0005667752
and O 0 0.0001979772
the O 0 0.00014037821
expression O 0 0.0001629064
and O 0 0.00024152805
effects O 0 0.00034007235
of O 0 0.0009136895
muscarinic O 0 0.97230184
receptors O 0 0.004239129
altered O 0 0.002284772
. O 0 0.0031649875

Whether O 0 0.0025996084
or O 0 0.0022011872
not O 0 0.0014850971
the O 0 0.0011322708
neuronal O 0 0.0020488661
transmission O 0 0.0006697777
may O 0 0.00046170288
be O 0 0.0005000808
affected O 0 0.0006724115
by O 0 0.0009371235
cystitis B-Disease 0 0.995395
was O 0 0.001092699
presently O 0 0.0015999806
investigated O 0 0.0020524804
. O 0 0.0039386516

Responses O 0 0.0028913578
of O 0 0.0021974465
urinary O 0 0.009149542
strip O 0 0.0014807039
preparations O 0 0.0005766962
from O 0 0.00031736834
control O 0 0.00033944155
and O 0 0.0005406041
cyclophosphamide B-Chemical 0 0.99986196
- O 0 0.005337405
pretreated O 0 0.00085078937
rats O 0 0.00024159302
to O 0 9.51967e-05
electrical O 0 0.0002042263
field O 0 0.00011197284
stimulation O 0 6.16137e-05
and O 0 9.1126814e-05
to O 0 8.438018e-05
agonists O 0 0.00102131
were O 0 9.576248e-05
assessed O 0 8.853233e-05
in O 0 8.4051644e-05
the O 0 7.610908e-05
absence O 0 7.631519e-05
and O 0 0.00015098217
presence O 0 0.0001768672
of O 0 0.0004561644
muscarinic O 0 0.9860665
, O 0 0.0024231777
adrenergic O 0 0.9684796
and O 0 0.0008338192
purinergic O 0 0.28105223
receptor O 0 0.0076048295
antagonists O 0 0.31243536
. O 0 0.0039423513

Generally O 0 0.0037760322
, O 0 0.009692563
atropine B-Chemical 0 0.9998467
reduced O 0 0.002787957
contractions O 0 0.11938858
, O 0 0.0016446325
but O 0 0.0005368975
in O 0 0.0002817132
contrast O 0 0.0003307349
to O 0 0.0001962152
controls O 0 0.00039335393
, O 0 0.00041747547
it O 0 0.00022826671
also O 0 0.00011994257
reduced O 0 0.00014312865
responses O 0 0.000114417235
to O 0 9.4960975e-05
low O 0 0.00015715952
electrical O 0 0.0002547425
field O 0 0.00014345342
stimulation O 0 8.669552e-05
intensity O 0 8.947611e-05
( O 0 0.00030855273
1 O 0 0.00025961874
- O 0 0.0008239249
5 O 0 0.00026054264
Hz O 0 0.0016767131
) O 0 0.000974664
in O 0 0.00062464946
inflamed O 0 0.0030628752
preparations O 0 0.0018435367
. O 0 0.0029466513

In O 0 0.0020480305
both O 0 0.0017589326
types O 0 0.0015723745
, O 0 0.0033363234
purinoceptor O 0 0.86048186
desensitization O 0 0.0057094065
with O 0 0.001183902
alpha B-Chemical 0 0.7581726
, I-Chemical 0 0.0033719013
beta I-Chemical 0 0.9682653
- I-Chemical 0 0.5955932
methylene I-Chemical 0 0.99161947
adenosine I-Chemical 0 0.99965596
- I-Chemical 0 0.005912832
5 I-Chemical 0 0.00022621664
' I-Chemical 0 0.0006181723
- I-Chemical 0 0.004064
triphosphate I-Chemical 0 0.04815366
( O 0 0.0012674025
alpha B-Chemical 0 0.6100134
, I-Chemical 0 0.0016980409
beta I-Chemical 0 0.95764333
- I-Chemical 0 0.55403626
meATP I-Chemical 0 0.9997243
) O 0 0.001428167
caused O 0 0.00017523138
further O 0 0.00012917735
reductions O 0 0.00018730956
at O 0 0.00012117862
low O 0 0.00024328945
frequencies O 0 0.00023105725
( O 0 0.00058246794
< O 0 0.0006800923
10 O 0 0.0006690249
Hz O 0 0.003918537
) O 0 0.0034308853
. O 0 0.0031823912

The O 0 0.0037870798
muscarinic O 0 0.97182685
receptor O 0 0.0422054
antagonists O 0 0.9267412
atropine B-Chemical 0 0.9999684
, O 0 0.0023399936
4 B-Chemical 0 0.0005208297
- I-Chemical 0 0.0017737452
diphenylacetoxy I-Chemical 0 0.0009385121
- I-Chemical 0 0.017102653
N I-Chemical 0 0.99879116
- I-Chemical 0 0.07672071
methylpiperidine I-Chemical 0 0.66200155
( O 0 0.0008738296
4 B-Chemical 0 0.00034839124
- I-Chemical 0 0.0047388845
DAMP I-Chemical 0 0.9962554
) O 0 0.0014692624
( O 0 0.0007671794
' O 0 0.0011846195
M O 0 0.60794276
( O 0 0.00083229074
1 O 0 0.00036565377
) O 0 0.0007349418
/ O 0 0.0020561179
M O 0 0.32785827
( O 0 0.0005977591
3 O 0 0.00023179202
) O 0 0.00060469494
/ O 0 0.0017209616
M O 0 0.29552388
( O 0 0.00054991036
5 O 0 0.00021005186
) O 0 0.00049251225
- O 0 0.0008931175
selective O 0 0.00026751417
' O 0 0.0006185666
) O 0 0.0010179911
, O 0 0.001126383
methoctramine B-Chemical 0 0.99988246
( O 0 0.0013433996
' O 0 0.0013335515
M O 0 0.7267427
( O 0 0.00058529497
2 O 0 0.00022669272
) O 0 0.0004664773
- O 0 0.00082635676
selective O 0 0.00022710268
' O 0 0.00052423344
) O 0 0.0008490612
and O 0 0.00062957586
pirenzepine B-Chemical 0 0.99999666
( O 0 0.0016256502
' O 0 0.0014273714
M O 0 0.8283765
( O 0 0.0006010895
1 O 0 0.00021519506
) O 0 0.0004524187
- O 0 0.0008889198
selective O 0 0.00021644331
' O 0 0.0005487138
) O 0 0.00085151615
antagonized O 0 0.0028265342
the O 0 0.00014963967
tonic O 0 0.0005006326
component O 0 0.00010905455
of O 0 0.00010840705
the O 0 8.606998e-05
electrical O 0 0.0002248173
field O 0 0.00013135569
stimulation O 0 9.684399e-05
- O 0 0.0009246067
evoked O 0 0.0004744525
contractile O 0 0.004015052
response O 0 0.0001848397
more O 0 0.0003400976
potently O 0 0.0006830292
than O 0 0.00032381597
the O 0 0.00044477807
phasic O 0 0.003174146
component O 0 0.0013225651
. O 0 0.0024749176

4 B-Chemical 0 0.0060160947
- I-Chemical 0 0.16739197
DAMP I-Chemical 0 0.9975702
inhibited O 0 0.0028153386
the O 0 0.00089007325
tonic O 0 0.0028102787
contractions O 0 0.006526715
in O 0 0.00041149175
controls O 0 0.00065685844
more O 0 0.0006838613
potently O 0 0.0017280342
than O 0 0.0009863569
methoctramine B-Chemical 0 0.9998779
and O 0 0.008595573
pirenzepine B-Chemical 0 0.9999821
. O 0 0.0068159574

In O 0 0.0023455948
inflamed O 0 0.006020956
preparations O 0 0.0017253055
, O 0 0.0020324227
the O 0 0.00094612374
muscarinic O 0 0.9591805
receptor O 0 0.0038251304
antagonism O 0 0.005281038
on O 0 0.00017407697
the O 0 0.00016665278
phasic O 0 0.0008234947
component O 0 0.00012617378
of O 0 0.00011878977
the O 0 9.0570626e-05
electrical O 0 0.00022134779
field O 0 0.00012615131
stimulation O 0 8.668651e-05
- O 0 0.00077041576
evoked O 0 0.00033843922
contraction O 0 0.001520725
was O 0 0.00010690998
decreased O 0 0.00021449859
and O 0 0.00015407545
the O 0 0.00023194413
pirenzepine B-Chemical 0 0.999997
and O 0 0.0002961502
4 B-Chemical 0 0.00019492333
- I-Chemical 0 0.01865586
DAMP I-Chemical 0 0.9992717
antagonism O 0 0.0064414404
on O 0 9.275682e-05
the O 0 0.00010824024
tonic O 0 0.00046339334
component O 0 0.00014418161
was O 0 0.00014111676
much O 0 0.00017682182
less O 0 0.00027362487
efficient O 0 0.0001912133
than O 0 0.00036366493
in O 0 0.00066946686
controls O 0 0.0019383009
. O 0 0.0028459297

In O 0 0.0018909744
contrast O 0 0.0020193907
to O 0 0.0010829902
controls O 0 0.0017434203
, O 0 0.002894461
methoctramine B-Chemical 0 0.99974984
increased O 0 0.0021787402
- O 0 0.010808772
- O 0 0.0019333408
instead O 0 0.0002590288
of O 0 0.0003500523
decreased O 0 0.0009179067
- O 0 0.005993639
- O 0 0.0018254084
the O 0 0.00025373657
tonic O 0 0.0006914535
responses O 0 0.00033742376
at O 0 0.0003807825
high O 0 0.00093006354
frequencies O 0 0.0012876935
. O 0 0.002975092

While O 0 0.0026637716
contractions O 0 0.023833413
to O 0 0.0024986998
carbachol B-Chemical 0 0.9996214
and O 0 0.0029930135
ATP B-Chemical 0 0.99779665
were O 0 0.00040373355
the O 0 0.00020195972
same O 0 0.00014580626
in O 0 0.00019154303
inflamed O 0 0.0008066045
and O 0 0.00014429439
in O 0 0.000109344546
control O 0 0.000128677
strips O 0 0.00031485944
when O 0 7.807e-05
related O 0 7.271219e-05
to O 0 0.00010109426
a O 0 0.00021847106
reference O 0 0.00025123206
potassium B-Chemical 0 0.99809986
response O 0 0.00030151935
, O 0 0.0011935448
isoprenaline B-Chemical 0 0.9999602
- O 0 0.016035022
induced O 0 0.00037952926
relaxations O 0 0.94242954
were O 0 0.000357841
smaller O 0 0.00054454687
in O 0 0.00061715127
inflamed O 0 0.0037051998
strips O 0 0.0031193143
. O 0 0.0025768492

Thus O 0 0.0031422519
, O 0 0.005319166
in O 0 0.0028869223
cystitis B-Disease 0 0.9945972
substantial O 0 0.0015934532
changes O 0 0.0010067783
of O 0 0.00084386277
the O 0 0.00068378117
efferent O 0 0.0021051802
functional O 0 0.0007909265
responses O 0 0.0012833078
occur O 0 0.0020025144
. O 0 0.0036146683

While O 0 0.0048000873
postjunctional O 0 0.9888826
beta O 0 0.9846816
- O 0 0.66299427
adrenoceptor O 0 0.9995409
- O 0 0.03474369
mediated O 0 0.00043614602
relaxations O 0 0.8919938
are O 0 0.00028534106
reduced O 0 0.00033448255
, O 0 0.00046975169
effects O 0 0.00029719953
by O 0 0.0004932175
prejunctional O 0 0.95948815
inhibitory O 0 0.007895503
muscarinic O 0 0.9888676
receptors O 0 0.002672248
may O 0 0.00066018
be O 0 0.0009438809
increased O 0 0.0021413602
. O 0 0.0030383908

Direct O 0 0.004101409
inhibition O 0 0.0024796475
of O 0 0.0018264054
cardiac O 0 0.008371225
hyperpolarization O 0 0.56492734
- O 0 0.0073251254
activated O 0 0.0007505335
cyclic B-Chemical 0 0.0030177126
nucleotide I-Chemical 0 0.0073684477
- O 0 0.0035422412
gated O 0 0.0007095338
pacemaker O 0 0.001060298
channels O 0 0.0012690538
by O 0 0.0016760158
clonidine B-Chemical 0 0.9997265
. O 0 0.004875286

BACKGROUND O 0 0.017668847
: O 0 0.00447576
Inhibition O 0 0.0014800068
of O 0 0.0009387955
cardiac O 0 0.0027036448
sympathetic O 0 0.0032347022
tone O 0 0.0043242774
represents O 0 0.00023591417
an O 0 0.00017711679
important O 0 8.4663654e-05
strategy O 0 9.740653e-05
for O 0 9.3451985e-05
treatment O 0 0.00013612924
of O 0 0.00020500454
cardiovascular B-Disease 0 0.48100448
disease I-Disease 0 0.41210997
, O 0 0.00038225017
including O 0 0.00015925123
arrhythmia B-Disease 0 0.99447787
, O 0 0.0006220233
coronary B-Disease 0 0.18995458
heart I-Disease 0 0.06375864
disease I-Disease 0 0.16679138
, O 0 0.00061009347
and O 0 0.00046666563
chronic O 0 0.022819906
heart B-Disease 0 0.13844344
failure I-Disease 0 0.06633334
. O 0 0.002781667

Activation O 0 0.004584619
of O 0 0.0031055978
presynaptic O 0 0.042224016
alpha2 O 0 0.9367934
- O 0 0.22017299
adrenoceptors O 0 0.98220843
is O 0 0.0003411587
the O 0 0.00021732654
most O 0 0.0002478165
widely O 0 0.00015994502
accepted O 0 0.000160752
mechanism O 0 7.383026e-05
of O 0 0.00012579419
action O 0 0.0001363311
of O 0 0.00014893585
the O 0 0.00014544549
antisympathetic O 0 0.46128055
drug O 0 0.46275058
clonidine B-Chemical 0 0.9999918
; O 0 0.000555633
however O 0 0.00014586173
, O 0 0.00017820299
other O 0 7.548048e-05
target O 0 6.654383e-05
proteins O 0 0.00011631806
have O 0 0.00011804205
been O 0 0.00013017896
postulated O 0 0.00017054674
to O 0 0.000111793284
contribute O 0 0.00012483465
to O 0 0.00012471364
the O 0 0.00013734968
in O 0 0.00018760073
vivo O 0 0.0002966266
actions O 0 0.00079625286
of O 0 0.0017569278
clonidine B-Chemical 0 0.9999205
. O 0 0.004017976

METHODS O 0 0.0031385256
AND O 0 0.0012858546
RESULTS O 0 0.0011053554
: O 0 0.0007892197
To O 0 0.00019320728
test O 0 0.000410845
whether O 0 0.00019756913
clonidine B-Chemical 0 0.99984336
elicits O 0 0.00021067905
pharmacological O 0 0.00042748122
effects O 0 0.00015342672
independent O 0 0.00012674948
of O 0 0.00034516666
alpha2 O 0 0.8937811
- O 0 0.16125022
adrenoceptors O 0 0.98762274
, O 0 0.00029644958
we O 0 5.5724264e-05
have O 0 6.585674e-05
generated O 0 3.6480207e-05
mice O 0 3.4228582e-05
with O 0 0.00010153316
a O 0 0.0001530896
targeted O 0 6.226252e-05
deletion O 0 0.00010205822
of O 0 0.00015102235
all O 0 0.0001622867
3 O 0 0.00022548836
alpha2 O 0 0.25360906
- O 0 0.021558028
adrenoceptor O 0 0.99638534
subtypes O 0 0.0011143761
( O 0 0.0008510805
alpha2ABC O 0 0.0011748889
- O 0 0.0046981247
/ O 0 0.005291313
- O 0 0.0072698365
) O 0 0.0044786367
. O 0 0.0037650182

Alpha2ABC O 0 0.007761818
- O 0 0.016538791
/ O 0 0.008565944
- O 0 0.004178084
mice O 0 0.0003409838
were O 0 0.00042379423
completely O 0 0.00034224172
unresponsive O 0 0.00039899166
to O 0 0.00016822714
the O 0 0.00015536557
analgesic O 0 0.0019049854
and O 0 0.00021593334
hypnotic O 0 0.9360632
effects O 0 0.00016680095
of O 0 0.00037906156
clonidine B-Chemical 0 0.99998844
; O 0 0.0007732589
however O 0 0.00024314453
, O 0 0.0008250601
clonidine B-Chemical 0 0.99998295
significantly O 0 0.00034541168
lowered O 0 0.0016081601
heart O 0 0.018199045
rate O 0 0.00022738543
in O 0 0.00014720013
alpha2ABC O 0 0.00043893023
- O 0 0.0019274397
/ O 0 0.0013938758
- O 0 0.00097027695
mice O 0 0.000108354965
by O 0 0.00026900735
up O 0 0.00044600852
to O 0 0.00049252727
150 O 0 0.0012282928
bpm O 0 0.003707059
. O 0 0.0027969505

Clonidine B-Chemical 0 0.9999455
- O 0 0.12221097
induced O 0 0.0021832422
bradycardia B-Disease 0 0.99381965
in O 0 0.00082513527
conscious O 0 0.0041166423
alpha2ABC O 0 0.0011395236
- O 0 0.0030114844
/ O 0 0.0019218634
- O 0 0.0011987396
mice O 0 0.00011049005
was O 0 0.0001976464
32 O 0 0.00028898782
. O 0 0.00017975611
3 O 0 0.00015031063
% O 0 0.0003087387
( O 0 0.00027774007
10 O 0 0.00015976302
microg O 0 0.00029027706
/ O 0 0.0006883849
kg O 0 0.00053419865
) O 0 0.00042723416
and O 0 0.00019002793
26 O 0 0.00022665488
. O 0 0.00014273857
6 O 0 0.00011154368
% O 0 0.00027585475
( O 0 0.00028549042
100 O 0 0.00030877872
microg O 0 0.0003583649
/ O 0 0.0007991601
kg O 0 0.0005855394
) O 0 0.00044899626
of O 0 0.00021619847
the O 0 0.00018508114
effect O 0 0.000255433
in O 0 0.00042383157
wild O 0 0.0006415641
- O 0 0.0045396816
type O 0 0.0018465617
mice O 0 0.0008643
. O 0 0.003029263

A O 0 0.034574986
similar O 0 0.0023266287
bradycardic O 0 0.99042624
effect O 0 0.0009198026
of O 0 0.0016131118
clonidine B-Chemical 0 0.99997354
was O 0 0.00043896056
observed O 0 0.00021213906
in O 0 0.00018438292
isolated O 0 0.00020156227
spontaneously O 0 0.0004900276
beating O 0 0.0005015874
right O 0 0.00042138525
atria O 0 0.001693122
from O 0 0.00015826497
alpha2ABC O 0 0.00037886034
- O 0 0.00082715525
knockout O 0 0.0001681832
and O 0 0.00039688588
wild O 0 0.0006002737
- O 0 0.004086004
type O 0 0.0018737376
mice O 0 0.00090226735
. O 0 0.0031548163

Clonidine B-Chemical 0 0.9999423
inhibited O 0 0.0059833415
the O 0 0.0013146645
native O 0 0.0010628833
pacemaker O 0 0.0012646327
current O 0 0.000696915
( O 0 0.0011154785
I O 0 0.007919646
( O 0 0.00088946614
f O 0 0.00082790275
) O 0 0.0009764877
) O 0 0.00066974707
in O 0 0.00021181183
isolated O 0 0.00027034536
sinoatrial O 0 0.09660333
node O 0 0.00036267357
pacemaker O 0 0.00023570168
cells O 0 0.00015277867
and O 0 0.00015991084
the O 0 0.00016596976
I O 0 0.0063897376
( O 0 0.00049053534
f O 0 0.0005171202
) O 0 0.00074081897
- O 0 0.0011402119
generating O 0 0.00012082418
hyperpolarization O 0 0.12762478
- O 0 0.0020536506
activated O 0 0.00022966738
cyclic B-Chemical 0 0.0014768371
nucleotide I-Chemical 0 0.007684636
- O 0 0.0031965722
gated O 0 0.00036665908
( O 0 0.00062985404
HCN O 0 0.042887036
) O 0 0.00064908765
2 O 0 0.00024934352
and O 0 0.0002795852
HCN4 O 0 0.0023730733
channels O 0 0.00064221397
in O 0 0.0004461926
transfected O 0 0.0010136241
HEK293 O 0 0.01968686
cells O 0 0.0036380829
. O 0 0.004472701

As O 0 0.002415451
a O 0 0.0026215368
consequence O 0 0.0010752243
of O 0 0.0012250667
blocking O 0 0.0014236543
I O 0 0.04231645
( O 0 0.0014515456
f O 0 0.0011757016
) O 0 0.0015068708
, O 0 0.0013911693
clonidine B-Chemical 0 0.9999441
reduced O 0 0.0003160715
the O 0 0.00014109496
slope O 0 0.00048717862
of O 0 0.00012424182
the O 0 9.945879e-05
diastolic O 0 0.44091988
depolarization O 0 0.0036111462
and O 0 0.000100034056
the O 0 6.475398e-05
frequency O 0 7.077999e-05
of O 0 0.000103631144
pacemaker O 0 0.0002204682
potentials O 0 0.00037135993
in O 0 0.0001341185
sinoatrial O 0 0.05218538
node O 0 0.00027098172
cells O 0 0.00014937793
from O 0 0.00013880529
wild O 0 0.0002155791
- O 0 0.0019273655
type O 0 0.0005887219
and O 0 0.0004339176
alpha2ABC O 0 0.0009801475
- O 0 0.001972512
knockout O 0 0.000494136
mice O 0 0.00067766197
. O 0 0.0026965956

CONCLUSIONS O 0 0.019626038
: O 0 0.004235851
Direct O 0 0.0015616845
inhibition O 0 0.0011072608
of O 0 0.00090868527
cardiac O 0 0.0049735545
HCN O 0 0.10664634
pacemaker O 0 0.0007507295
channels O 0 0.00037590988
contributes O 0 0.00011754962
to O 0 0.00013150471
the O 0 0.00015895675
bradycardic O 0 0.9465344
effects O 0 0.00015607683
of O 0 0.00033632503
clonidine B-Chemical 0 0.99998224
gene O 0 0.00017853429
- O 0 0.0007565078
targeted O 0 4.313987e-05
mice O 0 3.15812e-05
in O 0 7.479579e-05
vivo O 0 0.00010688369
, O 0 0.0002137475
and O 0 0.00012813497
thus O 0 0.00017137108
, O 0 0.00092854013
clonidine B-Chemical 0 0.9999862
- O 0 0.0051134136
like O 0 0.00015297577
drugs O 0 0.002360176
represent O 0 0.00014639067
novel O 0 0.0001620835
structures O 0 0.00023857695
for O 0 0.0002673699
future O 0 0.0005408443
HCN O 0 0.14254493
channel O 0 0.0040625236
inhibitors O 0 0.0033508295
. O 0 0.0037266763

Granulomatous B-Disease 0 0.39500642
hepatitis I-Disease 0 0.9994709
due O 0 0.002147321
to O 0 0.0013547614
combination B-Chemical 0 0.0017977365
of I-Chemical 0 0.0029250989
amoxicillin I-Chemical 0 0.9998652
and I-Chemical 0 0.015293243
clavulanic I-Chemical 0 0.9999647
acid I-Chemical 0 0.9939791
. O 0 0.010049137

We O 0 0.002802219
report O 0 0.0027881756
the O 0 0.0010741011
case O 0 0.00090820837
of O 0 0.00071207975
a O 0 0.00081630313
patient O 0 0.0006377277
with O 0 0.0009779306
amoxicillin B-Chemical 0 0.9999715
- I-Chemical 0 0.96732324
clavulanic I-Chemical 0 0.9999963
acid I-Chemical 0 0.99793494
- O 0 0.33435196
induced O 0 0.0012255663
hepatitis B-Disease 0 0.99996686
with O 0 0.0016722502
histologic O 0 0.013983449
multiple O 0 0.0014064962
granulomas B-Disease 0 0.26893124
. O 0 0.0030350778

This O 0 0.0051435037
type O 0 0.0035288737
of O 0 0.00172501
lesion O 0 0.0032103502
broadens O 0 0.0017161529
the O 0 0.00046147298
spectrum O 0 0.0007051259
of O 0 0.00058827084
liver B-Disease 0 0.96848273
injury I-Disease 0 0.75831735
due O 0 0.00016494807
to O 0 0.0001388118
this O 0 0.00018772187
drug O 0 0.0020080407
combination O 0 0.0002856963
, O 0 0.00042166852
mainly O 0 0.00026446846
represented O 0 0.0002705225
by O 0 0.00044273533
a O 0 0.0018518638
benign O 0 0.99401665
cholestatic B-Disease 0 0.9999962
syndrome I-Disease 0 0.9996737
. O 0 0.005280893

The O 0 0.002633479
association O 0 0.001917532
of O 0 0.0028404223
granulomas B-Disease 0 0.25317216
and O 0 0.0030852687
eosinophilia B-Disease 0 0.98579425
favor O 0 0.0022728452
an O 0 0.002437492
immunoallergic O 0 0.40092766
mechanism O 0 0.0022693023
. O 0 0.0048599606

As O 0 0.0036910323
penicillin B-Chemical 1 0.999813
derivatives O 0 0.07085411
and O 0 0.0025184182
amoxicillin B-Chemical 0 0.99985254
alone O 0 0.0007182966
are O 0 0.00025609578
known O 0 0.0002061752
to O 0 0.00014645419
induce O 0 0.000105720515
such O 0 0.0001196547
types O 0 0.00012075392
of O 0 0.00020174531
lesions O 0 0.0038465231
, O 0 0.00035808704
the O 0 0.00017188725
amoxicillin B-Chemical 0 0.99985456
component O 0 0.00016587593
, O 0 0.00023625427
with O 0 0.00012754057
or O 0 0.00010377253
without O 0 0.00013468598
a O 0 0.00025584098
potentiating O 0 0.0007514617
effect O 0 0.00029856275
of O 0 0.006396898
clavulanic B-Chemical 0 0.9999988
acid I-Chemical 0 0.9978677
, O 0 0.0018791944
might O 0 0.00020168588
have O 0 0.00030831102
a O 0 0.00063508947
major O 0 0.00062038715
role O 0 0.000705986
. O 0 0.0024621165

Dobutamine B-Chemical 0 0.98539335
stress O 0 0.01235474
echocardiography O 0 0.0025742464
: O 0 0.0015114234
a O 0 0.0006201621
sensitive O 0 0.00026419075
indicator O 0 0.00023684428
of O 0 0.000303796
diminished O 0 0.0006446998
myocardial O 0 0.97615564
function O 0 0.00019090324
in O 0 0.00020510718
asymptomatic O 0 0.0042501166
doxorubicin B-Chemical 0 0.99991524
- O 0 0.0056824866
treated O 0 0.00045481639
long O 0 0.0003076618
- O 0 0.0012700314
term O 0 0.00039981067
survivors O 0 0.0012398012
of O 0 0.0011713315
childhood O 0 0.76155925
cancer B-Disease 0 0.99500704
. O 0 0.005131347

Doxorubicin B-Chemical 0 0.99957556
is O 0 0.0019915618
an O 0 0.0012069109
effective O 0 0.00078210584
anticancer O 0 0.0076035447
chemotherapeutic O 0 0.006591301
agent O 0 0.0012296934
known O 0 0.0004597146
to O 0 0.00042942227
cause O 0 0.00081680896
acute O 0 0.03339721
and O 0 0.0012730482
chronic O 0 0.3018388
cardiomyopathy B-Disease 0 0.99978167
. O 0 0.005063127

To O 0 0.0013719858
develop O 0 0.001603087
a O 0 0.001281018
more O 0 0.00073106296
sensitive O 0 0.0003080407
echocardiographic O 0 0.00057263416
screening O 0 0.00023249057
test O 0 0.0003068267
for O 0 0.00020962028
cardiac B-Disease 0 0.037455764
damage I-Disease 0 0.32529178
due O 0 0.00014428874
to O 0 0.00019769593
doxorubicin B-Chemical 0 0.9998716
, O 0 0.00040776763
a O 0 0.00019969541
cohort O 0 0.00026836921
study O 0 9.556096e-05
was O 0 5.9295617e-05
performed O 0 5.6271132e-05
using O 0 7.029535e-05
dobutamine B-Chemical 0 0.9901929
infusion O 0 0.00030868337
to O 0 6.3180974e-05
differentiate O 0 0.00012282899
asymptomatic O 0 0.0004323363
long O 0 0.00012775259
- O 0 0.00060138694
term O 0 0.00012917268
survivors O 0 0.00039106363
of O 0 0.00024336879
childhood O 0 0.5489048
cancer B-Disease 0 0.9896563
treated O 0 0.0011960692
with O 0 0.0006279581
doxorubicin B-Chemical 0 0.9999199
from O 0 0.0004525917
healthy O 0 0.0017701405
control O 0 0.0007522412
subjects O 0 0.0022184693
. O 0 0.0023482842

Echocardiographic O 0 0.008044572
data O 0 0.0022227513
from O 0 0.00094141864
the O 0 0.0006002002
experimental O 0 0.0005951883
group O 0 0.00064080715
of O 0 0.00043126728
21 O 0 0.0003948108
patients O 0 0.00043225382
( O 0 0.00031361045
mean O 0 0.00014434505
age O 0 0.00025769643
16 O 0 0.00024160638
+ O 0 0.00075025647
/ O 0 0.0013021841
- O 0 0.0011476136
5 O 0 0.00016497404
years O 0 0.00020309209
) O 0 0.00036008368
treated O 0 0.00030861745
from O 0 0.00015764115
1 O 0 0.00018007109
. O 0 0.00011862113
6 O 0 7.844881e-05
to O 0 8.168725e-05
14 O 0 0.000100224046
. O 0 9.269986e-05
3 O 0 8.145623e-05
years O 0 0.00012117851
( O 0 0.00015429936
median O 0 6.889874e-05
5 O 0 9.7747004e-05
. O 0 9.780071e-05
3 O 0 9.2792114e-05
) O 0 0.000200543
before O 0 5.799159e-05
this O 0 0.00011435878
study O 0 0.00013645896
with O 0 0.00013970907
27 O 0 0.00019751056
to O 0 0.00013833147
532 O 0 0.007335014
mg O 0 0.0037612407
/ O 0 0.0008041422
m2 O 0 0.0011964815
of O 0 0.0002537056
doxorubicin B-Chemical 0 0.99980754
( O 0 0.00035173603
mean O 0 0.000110940644
196 O 0 0.00040446842
) O 0 0.00022902753
were O 0 7.102102e-05
compared O 0 5.515503e-05
with O 0 9.001339e-05
echocardiographic O 0 0.00027152768
data O 0 0.00013746288
from O 0 0.00011096159
12 O 0 0.000111922665
normal O 0 0.000276609
age O 0 0.00043517316
- O 0 0.0011513053
matched O 0 0.00036902542
control O 0 0.000811294
subjects O 0 0.002498676
. O 0 0.002933163

Graded O 0 0.012557986
dobutamine B-Chemical 0 0.9913379
infusions O 0 0.0038502098
of O 0 0.0010326486
0 O 0 0.0009213414
. O 0 0.00053724286
5 O 0 0.00042226788
, O 0 0.0006392734
2 O 0 0.00040394336
. O 0 0.00031259318
5 O 0 0.00027352604
, O 0 0.00043120436
5 O 0 0.000243263
and O 0 0.00026800533
10 O 0 0.00033255224
micrograms O 0 0.0014434556
/ O 0 0.0012014227
kg O 0 0.0009041388
per O 0 0.00046185742
min O 0 0.0008016125
were O 0 0.0007726528
administered O 0 0.0016865651
. O 0 0.002704622

Echocardiographic O 0 0.0064865053
Doppler O 0 0.0058266926
studies O 0 0.0012413712
were O 0 0.0005791073
performed O 0 0.00037367124
before O 0 0.00023741245
infusion O 0 0.00063751714
and O 0 0.00029646797
after O 0 0.00017311708
15 O 0 0.0002681945
min O 0 0.00039924358
of O 0 0.00038306587
infusion O 0 0.00085279165
at O 0 0.000445602
each O 0 0.0006167661
rate O 0 0.0020590152
. O 0 0.0032184068

Dobutamine B-Chemical 0 0.97776616
infusion O 0 0.004034596
at O 0 0.00077025214
10 O 0 0.0007131748
micrograms O 0 0.0022322768
/ O 0 0.0013125526
kg O 0 0.0007617003
per O 0 0.0002572305
min O 0 0.00031249665
was O 0 0.00016024377
discontinued O 0 0.00032666736
after O 0 6.514472e-05
six O 0 6.888442e-05
studies O 0 0.0001665184
secondary O 0 0.0002192494
to O 0 0.00017956493
a O 0 0.00034768402
50 O 0 0.00035502765
% O 0 0.00051844085
incidence O 0 0.00057021814
rate O 0 0.000571825
of O 0 0.0007231829
adverse O 0 0.0067489194
symptoms O 0 0.011668666
. O 0 0.0026834423

The O 0 0.0017925397
most O 0 0.001558292
important O 0 0.00062715524
findings O 0 0.0006936722
were O 0 0.00037604535
that O 0 0.00021532642
compared O 0 0.00017535925
with O 0 0.00021022656
values O 0 0.00017799054
in O 0 0.00013856859
control O 0 0.00015520124
subjects O 0 0.00025965317
, O 0 0.00020389262
end O 0 8.773662e-05
- O 0 0.00067046005
systolic O 0 0.009562185
left O 0 0.0004476319
ventricular O 0 0.109940976
posterior O 0 0.0013756754
wall O 0 0.00056462927
dimension O 0 0.0002410647
and O 0 9.750969e-05
percent O 0 8.986159e-05
of O 0 0.00010699841
left O 0 0.00034082387
ventricular O 0 0.22951186
posterior O 0 0.002437717
wall O 0 0.0013496019
thickening O 0 0.14509992
in O 0 0.00018328703
doxorubicin B-Chemical 0 0.99995065
- O 0 0.0079332
treated O 0 0.00026919387
patients O 0 0.00021934666
were O 0 6.347817e-05
decreased O 0 0.00010310655
at O 0 4.6077934e-05
baseline O 0 6.265974e-05
study O 0 8.148559e-05
and O 0 8.13948e-05
these O 0 8.988044e-05
findings O 0 0.00015416893
were O 0 0.00013222809
more O 0 0.00022222238
clearly O 0 0.00016128091
delineated O 0 0.00043418075
with O 0 0.0006206157
dobutamine B-Chemical 0 0.99624556
stimulation O 0 0.0010075461
. O 0 0.0021355492

End O 0 0.010950237
- O 0 0.00903323
systolic O 0 0.024961146
left O 0 0.0028689015
ventricular O 0 0.1849989
posterior O 0 0.0036973432
wall O 0 0.0012939684
dimension O 0 0.00046302422
at O 0 0.00013403552
baseline O 0 0.00012586245
for O 0 0.00011265688
the O 0 0.00020013365
doxorubicin B-Chemical 0 0.99977833
- O 0 0.003343167
treated O 0 0.00036669263
group O 0 0.00025073407
was O 0 0.00015214515
11 O 0 0.00020144353
+ O 0 0.0007351881
/ O 0 0.0015853144
- O 0 0.0014719244
1 O 0 0.00018060912
. O 0 0.00011390103
9 O 0 9.40934e-05
mm O 0 0.00029452634
versus O 0 0.00012145615
13 O 0 0.000161114
. O 0 0.00014056265
1 O 0 0.00019137416
+ O 0 0.0006970748
/ O 0 0.0015257725
- O 0 0.0015736812
1 O 0 0.0002067875
. O 0 0.00013208177
5 O 0 0.000110085464
mm O 0 0.0003083848
for O 0 0.000105423744
control O 0 0.0001693883
subjects O 0 0.00035089624
( O 0 0.0003820347
p O 0 0.0004202199
less O 0 0.0003837611
than O 0 0.0003455675
0 O 0 0.0007229031
. O 0 0.000869205
01 O 0 0.0049504684
) O 0 0.003900807
. O 0 0.0037387593

End O 0 0.011291237
- O 0 0.0093712695
systolic O 0 0.026874144
left O 0 0.003100261
ventricular O 0 0.22278957
posterior O 0 0.0045361314
wall O 0 0.0016427177
dimension O 0 0.0006100952
at O 0 0.00018216397
the O 0 0.00016448193
5 O 0 0.00019707056
- O 0 0.0007545286
micrograms O 0 0.0009050782
/ O 0 0.00050801993
kg O 0 0.00029276987
per O 0 0.000104921186
min O 0 0.00018432367
dobutamine B-Chemical 0 0.8847473
infusion O 0 0.00023933518
for O 0 6.620571e-05
the O 0 0.00012499961
doxorubicin B-Chemical 0 0.9998709
- O 0 0.0040501505
treated O 0 0.0003126418
group O 0 0.00021280251
was O 0 0.00011658268
14 O 0 0.000112906826
. O 0 0.000112350055
1 O 0 0.00015427408
+ O 0 0.0005820018
/ O 0 0.0012606407
- O 0 0.0012180575
2 O 0 0.00016561156
. O 0 0.00010796613
4 O 0 8.590983e-05
mm O 0 0.00028305934
versus O 0 0.000115970746
19 O 0 0.00017521417
. O 0 0.0001230211
3 O 0 0.0001305026
+ O 0 0.0005971401
/ O 0 0.0012610189
- O 0 0.0012466209
2 O 0 0.00017455313
. O 0 0.00010948279
6 O 0 7.613557e-05
mm O 0 0.00026149358
for O 0 8.80788e-05
control O 0 0.00013700107
subjects O 0 0.0002741304
( O 0 0.00027440494
p O 0 0.00028339744
less O 0 0.00022867754
than O 0 0.0001787617
0 O 0 0.0003291251
. O 0 0.0003176953
01 O 0 0.0017472019
) O 0 0.0009262299
. O 0 0.0005249778
( O 0 0.0011590902
ABSTRACT O 0 0.005817745
TRUNCATED O 0 0.01448291
AT O 0 0.013852902
250 O 0 0.006703552
WORDS O 0 0.029877707
) O 0 0.019102937

Influence O 0 0.0073133013
of O 0 0.0063623195
smoking B-Chemical 0 0.02448382
on O 0 0.0037686168
developing O 0 0.007636809
cochlea O 0 0.018781925
. O 0 0.010627484

Does O 0 0.0046624956
smoking B-Chemical 0 0.013196592
during O 0 0.0011740577
pregnancy O 0 0.002328016
affect O 0 0.0005276489
the O 0 0.0004835883
amplitudes O 0 0.0010017176
of O 0 0.0006209734
transient O 0 0.0011576274
evoked O 0 0.00231182
otoacoustic O 0 0.6769668
emissions O 0 0.0049066017
in O 0 0.0012462176
newborns O 0 0.005269598
? O 0 0.0075395587

OBJECTIVE O 0 0.029070806
: O 0 0.0059384904
Maternal O 0 0.0031632595
tobacco O 0 0.0027730586
smoking B-Chemical 0 0.007885479
has O 0 0.0006726915
negative O 0 0.00080406264
effects O 0 0.0010573828
on O 0 0.0013635277
fetal O 0 0.06790672
growth O 0 0.019658532
. O 0 0.0058009587

The O 0 0.001489033
influence O 0 0.00092338555
of O 0 0.0011659208
smoking B-Chemical 0 0.007718278
during O 0 0.00042957277
pregnancy O 0 0.0011586491
on O 0 0.00019935222
the O 0 0.00020509721
developing O 0 0.000489462
cochlea O 0 0.0011518055
has O 0 0.000113598624
not O 0 0.0001239992
been O 0 0.00013743587
estimated O 0 0.00018214608
, O 0 0.00031519763
although O 0 0.00018468696
smoking B-Chemical 0 0.007132853
has O 0 0.00012312837
been O 0 0.000163773
positively O 0 0.00019397258
associated O 0 0.0002525125
with O 0 0.0003790191
hearing B-Disease 0 0.21753731
loss I-Disease 0 0.00092628424
in O 0 0.0009284587
adults O 0 0.0049326397
. O 0 0.0029610628

The O 0 0.0016023254
objective O 0 0.0013732212
of O 0 0.001097171
this O 0 0.0007907851
study O 0 0.00060457736
was O 0 0.00030210635
to O 0 0.00017225789
determine O 0 6.686594e-05
the O 0 0.00011299578
effects O 0 0.00013910476
of O 0 0.0001933171
maternal O 0 0.00029003943
smoking B-Chemical 0 0.0034238524
on O 0 0.00012504576
transient O 0 0.00036021898
evoked O 0 0.0007833541
otoacoustic O 0 0.6117643
emissions O 0 0.0020157986
( O 0 0.00048722883
TEOAEs O 0 0.0024252671
) O 0 0.00075522246
of O 0 0.0006499354
healthy O 0 0.0033906628
neonates O 0 0.0067238747
. O 0 0.0031129054

METHODS O 0 0.004455426
: O 0 0.0033910708
This O 0 0.0015143724
study O 0 0.0008848903
was O 0 0.00051340414
undertaken O 0 0.00040729484
as O 0 0.00032785896
part O 0 0.00023194456
of O 0 0.00025443063
neonatal O 0 0.00039469925
screening O 0 0.0001762243
for O 0 0.00017114166
hearing B-Disease 0 0.22095133
impairment I-Disease 0 0.2600555
and O 0 0.00031123712
involved O 0 0.00023544922
both O 0 0.0003308241
ears O 0 0.0027736642
of O 0 0.00088535517
200 O 0 0.0021664454
newborns O 0 0.004920372
. O 0 0.0030694488

Newborns O 0 0.033057425
whose O 0 0.0025502376
mothers O 0 0.0028922777
reported O 0 0.001101736
smoking B-Chemical 0 0.0041701156
during O 0 0.00035885084
pregnancy O 0 0.0009616443
( O 0 0.00047767008
n O 0 0.00029881275
= O 0 0.00059505185
200 O 0 0.00037791397
ears O 0 0.0015364512
) O 0 0.00044613137
were O 0 0.000121813966
compared O 0 8.740842e-05
to O 0 0.00010081316
a O 0 0.00017473017
control O 0 0.00013992129
group O 0 0.00021697847
of O 0 0.00018643877
newborns O 0 0.0006198912
( O 0 0.0002712084
n O 0 0.00019252356
= O 0 0.00047764985
200 O 0 0.0003574324
ears O 0 0.002039317
) O 0 0.00070839666
, O 0 0.00050161994
whose O 0 0.00041286694
mothers O 0 0.0008869518
were O 0 0.0005024138
non O 0 0.0012365745
- O 0 0.0058056796
smokers O 0 0.00478292
. O 0 0.0032740796

Exposure O 0 0.007000092
to O 0 0.001797112
tobacco O 0 0.0023728441
was O 0 0.0008987195
characterized O 0 0.00079375674
as O 0 0.00047457576
low O 0 0.00054165063
( O 0 0.00060743815
< O 0 0.00041952147
5 O 0 0.00020993191
cigarettes O 0 0.00043661773
per O 0 0.00014355264
day O 0 0.00010778375
, O 0 0.00024955475
n O 0 0.00022979268
= O 0 0.0005378418
88 O 0 0.0004430845
ears O 0 0.0019849553
) O 0 0.00066625734
, O 0 0.00041808665
moderate O 0 0.0006369417
( O 0 0.00031822882
5 O 0 0.00012197368
< O 0 0.00017305173
or O 0 0.0001081875
= O 0 0.00037011833
cigarettes O 0 0.00036729476
per O 0 9.843571e-05
day O 0 7.167117e-05
< O 0 0.0001693862
10 O 0 0.00011800423
, O 0 0.00019186657
n O 0 0.00018182262
= O 0 0.00044900973
76 O 0 0.00031280663
) O 0 0.00032629794
or O 0 0.0001299286
high O 0 0.0002210112
( O 0 0.00036133334
> O 0 0.00041357186
or O 0 0.00018556071
= O 0 0.00054858875
10 O 0 0.00021435546
cigarettes O 0 0.0004851903
per O 0 0.00018978401
day O 0 0.00017580423
, O 0 0.0005388452
n O 0 0.00063614873
= O 0 0.0017145494
36 O 0 0.0013547938
) O 0 0.0032231414
. O 0 0.0033841243

RESULTS O 0 0.004172574
: O 0 0.0026129447
In O 0 0.00069834216
exposed O 0 0.0009967255
neonates O 0 0.001871245
, O 0 0.0008585855
TEOAEs O 0 0.0016792292
mean O 0 0.00021093995
response O 0 0.00020893148
( O 0 0.00032374248
across O 0 0.00014758467
frequency O 0 0.00014664087
) O 0 0.0003131832
and O 0 0.00013245358
mean O 0 0.00011322131
amplitude O 0 0.00027478748
at O 0 0.00013870408
4000Hz O 0 0.04430434
was O 0 0.00017184675
significantly O 0 0.000201194
lower O 0 0.00023692669
than O 0 0.00020050802
in O 0 0.000291594
non O 0 0.00082035176
- O 0 0.0034046846
exposed O 0 0.0013235026
neonates O 0 0.0068339705
. O 0 0.0030356913

Comparisons O 0 0.0022084697
between O 0 0.0017687744
exposed O 0 0.0023790807
newborns O 0 0.004092691
' O 0 0.0027119128
subgroups O 0 0.0018423192
revealed O 0 0.0010137812
no O 0 0.0012248706
significant O 0 0.0018070051
differences O 0 0.00240315
. O 0 0.005120094

However O 0 0.0029469174
, O 0 0.0031314404
by O 0 0.0010315194
comparing O 0 0.00045106525
each O 0 0.000373882
subgroup O 0 0.0006976117
to O 0 0.00025617806
control O 0 0.00029045867
group O 0 0.0004295908
, O 0 0.00039026426
we O 0 0.000106080624
found O 0 0.00017594008
statistically O 0 0.00026329004
significant O 0 0.00016470351
decreases B-Disease 0 0.00020104961
of I-Disease 0 0.00022469815
TEOAEs I-Disease 0 0.0026935989
amplitudes I-Disease 0 0.00044542766
at O 0 0.00021398402
4000Hz O 0 0.015831493
for O 0 0.00029843466
all O 0 0.0004061758
three O 0 0.00038417068
groups O 0 0.001452528
. O 0 0.002746065

Mean O 0 0.0021071536
TEOAEs O 0 0.005015474
responses O 0 0.00091855414
of O 0 0.00074086204
highly O 0 0.0004738907
exposed O 0 0.0005702872
newborns O 0 0.0010754884
were O 0 0.00025628484
also O 0 0.00021249025
significantly O 0 0.00028720134
lower O 0 0.000311682
in O 0 0.00024642472
comparison O 0 0.00024200937
to O 0 0.00030897776
our O 0 0.00047403388
control O 0 0.00094917
group O 0 0.0024429802
. O 0 0.0033719586

CONCLUSION O 0 0.015189785
: O 0 0.0035016728
In O 0 0.00083831965
utero O 0 0.0013813233
, O 0 0.0011058969
exposure O 0 0.0005774491
to O 0 0.00036562624
tobacco O 0 0.0008868563
smoking B-Chemical 0 0.0067397617
seems O 0 0.00024213053
to O 0 0.00023052144
have O 0 0.00023649157
a O 0 0.0004211726
small O 0 0.0004855625
impact O 0 0.00033369017
on O 0 0.00054162764
outer O 0 0.018672174
hair O 0 0.20271271
cells O 0 0.0034710125
. O 0 0.0042448514

These O 0 0.0021584097
effects O 0 0.0019363296
seem O 0 0.0014319993
to O 0 0.00079514517
be O 0 0.00061029353
equally O 0 0.0005311883
true O 0 0.0004785139
for O 0 0.00026292301
all O 0 0.00029059217
exposed O 0 0.00042095283
newborns O 0 0.0011281902
, O 0 0.0005508775
regardless O 0 0.0002079715
of O 0 0.0004380627
the O 0 0.0004495847
degree O 0 0.0010809586
of O 0 0.0013489973
exposure O 0 0.0023007824
. O 0 0.0033131815

Further O 0 0.0024132517
studies O 0 0.002142623
are O 0 0.00094093307
needed O 0 0.0005950859
in O 0 0.00047204178
order O 0 0.00026201815
to O 0 0.00022001882
establish O 0 0.00013626613
a O 0 0.00025543253
potential O 0 0.00013249728
negative O 0 0.00016175419
effect O 0 0.0001521959
of O 0 0.00024327994
maternal O 0 0.00039456718
smoking B-Chemical 0 0.005113118
on O 0 0.00017577372
the O 0 0.00024766155
neonate O 0 0.0012899239
' O 0 0.0010255959
s O 0 0.0012197341
hearing O 0 0.42591375
acuity O 0 0.9632334
. O 0 0.0035180133

Simvastatin B-Chemical 0 0.99988675
- O 0 0.06463518
induced O 0 0.0023747277
bilateral O 0 0.014158708
leg O 0 0.008697766
compartment B-Disease 0 0.009921826
syndrome I-Disease 0 0.9980884
and O 0 0.0024896432
myonecrosis B-Disease 0 0.99925584
associated O 0 0.0019276096
with O 0 0.003333322
hypothyroidism B-Disease 0 0.9998932
. O 0 0.006388978

A O 0 0.029490616
54 O 0 0.0059282975
- O 0 0.007407017
year O 0 0.0013471273
- O 0 0.0033315984
old O 0 0.0011884623
hypothyroid B-Disease 0 0.99095154
male O 0 0.0019485321
taking O 0 0.001405467
thyroxine B-Chemical 0 0.9997147
and O 0 0.0010958894
simvastatin B-Chemical 1 0.99998283
presented O 0 0.00035472805
with O 0 0.00036226874
bilateral O 0 0.00435503
leg O 0 0.0027301407
compartment B-Disease 0 0.004615891
syndrome I-Disease 0 0.9980312
and O 0 0.0028792843
myonecrosis B-Disease 0 0.9991417
. O 0 0.003867634

Urgent O 0 0.0077858767
fasciotomies O 0 0.010108034
were O 0 0.0010409238
performed O 0 0.0006520998
and O 0 0.00060779194
the O 0 0.00042304714
patient O 0 0.0004570309
made O 0 0.00033568693
an O 0 0.00037339833
uneventful O 0 0.00053095096
recovery O 0 0.0004326531
with O 0 0.00040230725
the O 0 0.0005084252
withdrawal O 0 0.0037971786
of O 0 0.0024286383
simvastatin B-Chemical 1 0.99993217
. O 0 0.006206837

It O 0 0.004933353
is O 0 0.0014520482
likely O 0 0.0006932885
that O 0 0.0005550809
this O 0 0.0006407547
complication O 0 0.0034546934
will O 0 0.00027020054
be O 0 0.00023421264
seen O 0 0.0002320191
more O 0 0.00026121645
often O 0 0.00018846741
with O 0 0.00014446952
the O 0 0.00011143355
increased O 0 0.0001885481
worldwide O 0 0.0002510723
use O 0 0.00011869274
of O 0 0.00016557491
this O 0 0.00022224252
drug O 0 0.0049824826
and O 0 0.00025355976
its O 0 0.0003364243
approval O 0 0.00032792173
for O 0 0.00025272273
all O 0 0.00067452044
arteriopathic B-Disease 0 0.99936146
patients O 0 0.0041755047
. O 0 0.0026696012

Neuroinflammation B-Disease 0 0.86581796
and O 0 0.003121283
behavioral B-Disease 0 0.060310885
abnormalities I-Disease 0 0.21398336
after O 0 0.00047884075
neonatal O 0 0.0016519622
terbutaline B-Chemical 0 0.9997559
treatment O 0 0.00050088984
in O 0 0.000373716
rats O 0 0.00072718126
: O 0 0.001065956
implications O 0 0.00086519826
for O 0 0.0015199793
autism B-Disease 0 0.99857724
. O 0 0.0051416354

Autism B-Disease 0 0.99787474
is O 0 0.0026617427
a O 0 0.004399511
neurodevelopmental B-Disease 0 0.9994618
disorder I-Disease 0 0.9998754
presenting O 0 0.0018022963
before O 0 0.00015808824
3 O 0 0.00016108711
years O 0 0.00018064392
of O 0 0.00015593195
age O 0 0.00025892854
with O 0 0.00023206536
deficits B-Disease 0 0.086176835
in I-Disease 0 0.00023603877
communication I-Disease 0 0.00054211
and I-Disease 0 0.0003363701
social I-Disease 0 0.0039068884
skills I-Disease 0 0.003781624
and O 0 0.00087414024
repetitive B-Disease 0 0.0017850249
behaviors I-Disease 0 0.00774742
. O 0 0.0035953475

In O 0 0.0017949012
addition O 0 0.0010146459
to O 0 0.00096193526
genetic O 0 0.0011513897
influences O 0 0.0005124723
, O 0 0.00078875845
recent O 0 0.0003581108
studies O 0 0.0003264756
suggest O 0 0.00014858862
that O 0 0.00020665504
prenatal O 0 0.001133785
drug O 0 0.0069788215
or O 0 0.00024153774
chemical O 0 0.00035782548
exposures O 0 0.00057206757
are O 0 0.00030729684
risk O 0 0.0017891234
factors O 0 0.0013635877
for O 0 0.0014471137
autism B-Disease 0 0.9993625
. O 0 0.004339233

Terbutaline B-Chemical 0 0.9992854
, O 0 0.007872043
a O 0 0.004734998
beta2 O 0 0.9744684
- O 0 0.40930653
adrenoceptor O 0 0.9994136
agonist O 0 0.0551508
used O 0 0.00032905483
to O 0 0.000266652
arrest O 0 0.0036950307
preterm B-Disease 0 0.93191504
labor I-Disease 0 0.415069
, O 0 0.0005932206
has O 0 0.00012857141
been O 0 0.00015580963
associated O 0 0.00018987794
with O 0 0.00021589836
increased O 0 0.00035106775
concordance O 0 0.00057560555
for O 0 0.0004654648
autism B-Disease 0 0.99941146
in O 0 0.0011357465
dizygotic O 0 0.8574222
twins O 0 0.4390856
. O 0 0.0041219676

We O 0 0.002294604
studied O 0 0.0018274523
the O 0 0.00079024053
effects O 0 0.0007429672
of O 0 0.0012738294
terbutaline B-Chemical 0 0.9999155
on O 0 0.00041100386
microglial O 0 0.0033887366
activation O 0 0.00023077149
in O 0 0.00016880914
different O 0 0.00013207675
brain O 0 0.00042991154
regions O 0 0.00012292249
and O 0 0.00018842895
behavioral O 0 0.00064047135
outcomes O 0 0.00035167555
in O 0 0.0004170805
developing O 0 0.0012186784
rats O 0 0.002238692
. O 0 0.0026708941

Newborn O 0 0.006347258
rats O 0 0.002609678
were O 0 0.0011372957
given O 0 0.0008276863
terbutaline B-Chemical 0 0.999446
( O 0 0.0011197419
10 O 0 0.00042785384
mg O 0 0.0020951838
/ O 0 0.00091532466
kg O 0 0.0006363322
) O 0 0.00047854058
daily O 0 0.00019201537
on O 0 9.784753e-05
postnatal O 0 0.00023566281
days O 0 0.000120701414
( O 0 0.0003992411
PN O 0 0.0033916007
) O 0 0.0004562489
2 O 0 0.00016775796
to O 0 0.000111959074
5 O 0 0.00012817772
or O 0 0.00013796317
PN O 0 0.0015575903
11 O 0 0.00014026837
to O 0 8.569309e-05
14 O 0 9.701136e-05
and O 0 0.000103301696
examined O 0 9.411537e-05
24 O 0 0.00013060903
h O 0 0.00012725618
after O 0 7.000717e-05
the O 0 0.00011003321
last O 0 0.000114559385
dose O 0 0.00042077168
and O 0 0.0004319198
at O 0 0.0005729992
PN O 0 0.0055422164
30 O 0 0.0013512765
. O 0 0.0024840767

Immunohistochemical O 0 0.0029386545
studies O 0 0.0017860415
showed O 0 0.00087319507
that O 0 0.00057059195
administration O 0 0.0010838432
of O 0 0.00091408
terbutaline B-Chemical 0 0.99990296
on O 0 0.0003532508
PN O 0 0.0075394483
2 O 0 0.00020840422
to O 0 0.00011510754
5 O 0 0.00011286387
produced O 0 9.13647e-05
a O 0 0.00016414115
robust O 0 8.434744e-05
increase O 0 0.0001275778
in O 0 0.00015032497
microglial O 0 0.0013107524
activation O 0 0.00013240054
on O 0 0.0001027
PN O 0 0.002079293
30 O 0 9.863257e-05
in O 0 9.453588e-05
the O 0 0.00013848288
cerebral O 0 0.9578257
cortex O 0 0.02244392
, O 0 0.00032244757
as O 0 0.00015387402
well O 0 0.00017402369
as O 0 0.000247684
in O 0 0.00040125797
cerebellar O 0 0.2510957
and O 0 0.00091749046
cerebrocortical O 0 0.85496885
white O 0 0.0022605504
matter O 0 0.002561749
. O 0 0.0027430034

None O 0 0.0036863026
of O 0 0.0018886809
these O 0 0.001046515
effects O 0 0.0008204882
occurred O 0 0.0006728749
in O 0 0.00045816528
animals O 0 0.00036448872
given O 0 0.0004990779
terbutaline B-Chemical 0 0.99954826
on O 0 0.00065776246
PN O 0 0.006038182
11 O 0 0.0008877897
to O 0 0.000841916
14 O 0 0.0015418181
. O 0 0.002909167

In O 0 0.0020336169
behavioral O 0 0.004379824
tests O 0 0.0023027675
, O 0 0.0012504666
animals O 0 0.0004360714
treated O 0 0.0009247318
with O 0 0.00079099386
terbutaline B-Chemical 0 0.9999107
on O 0 0.00030634206
PN O 0 0.0060812933
2 O 0 0.00018256388
to O 0 0.00010038695
5 O 0 9.7561875e-05
showed O 0 8.365471e-05
consistent O 0 8.204058e-05
patterns O 0 0.00010118377
of O 0 0.00024656832
hyper O 0 0.53099823
- O 0 0.0035588886
reactivity O 0 0.0002969327
to O 0 9.8887205e-05
novelty O 0 0.0013257804
and O 0 0.00011150806
aversive O 0 0.00029352587
stimuli O 0 0.00011069093
when O 0 5.7306603e-05
assessed O 0 8.925549e-05
in O 0 9.2343245e-05
a O 0 0.00014306357
novel O 0 9.735871e-05
open O 0 0.00016663276
field O 0 0.00023452255
, O 0 0.0003083851
as O 0 0.00016782644
well O 0 0.00017726058
as O 0 0.00021447771
in O 0 0.00024789022
the O 0 0.00031454413
acoustic O 0 0.002452021
startle O 0 0.6847243
response O 0 0.0009375312
test O 0 0.0019656678
. O 0 0.00278832

Our O 0 0.0018887646
findings O 0 0.0016613306
indicate O 0 0.0007352137
that O 0 0.0010200416
beta2 O 0 0.9752484
- O 0 0.54880786
adrenoceptor O 0 0.9997004
overstimulation O 0 0.40923262
during O 0 0.00019467928
an O 0 0.000186129
early O 0 0.00018107884
critical O 0 7.2666095e-05
period O 0 6.976584e-05
results O 0 8.9868365e-05
in O 0 0.00013003443
microglial O 0 0.0013362654
activation O 0 0.0001227654
associated O 0 0.00012221596
with O 0 0.00013406324
innate O 0 0.0005060814
neuroinflammatory O 0 0.060196187
pathways O 0 0.00010739922
and O 0 0.00016671729
behavioral B-Disease 0 0.05529279
abnormalities I-Disease 0 0.6422149
, O 0 0.0003991703
similar O 0 0.00013143936
to O 0 0.0002012456
those O 0 0.0003937443
described O 0 0.00048312734
in O 0 0.0012080537
autism B-Disease 0 0.99928063
. O 0 0.0039054707

This O 0 0.004489433
study O 0 0.0019301781
provides O 0 0.0007054472
a O 0 0.00097368663
useful O 0 0.00048667873
animal O 0 0.00046764777
model O 0 0.00033521684
for O 0 0.00027567334
understanding O 0 0.00039334942
the O 0 0.00040370488
neuropathological O 0 0.023993598
processes O 0 0.0010924195
underlying O 0 0.0022661833
autism B-Disease 0 0.9998815
spectrum I-Disease 0 0.008982092
disorders I-Disease 0 0.9981669
. O 0 0.0045739273

Upregulation O 0 0.007105586
of O 0 0.0028018223
brain O 0 0.0032866984
expression O 0 0.00089156616
of O 0 0.0011382657
P O 0 0.45834246
- O 0 0.032250114
glycoprotein O 0 0.057249688
in O 0 0.00085399434
MRP2 O 0 0.9996525
- O 0 0.020312302
deficient O 0 0.00043525113
TR O 0 0.3838661
( O 0 0.0009436121
- O 0 0.0019518688
) O 0 0.0004974083
rats O 0 0.000350548
resembles O 0 0.0002780108
seizure B-Disease 0 0.99931264
- O 0 0.0024898779
induced O 0 0.00016912668
up O 0 0.00023663999
- O 0 0.00074420485
regulation O 0 7.5032534e-05
of O 0 0.00020692023
this O 0 0.00035124933
drug O 0 0.11673598
efflux O 0 0.43236256
transporter O 0 0.022622574
in O 0 0.00062187266
normal O 0 0.0013955814
rats O 0 0.0019911202
. O 0 0.0024196436

PURPOSE O 0 0.008670066
: O 0 0.0044810725
The O 0 0.0011640637
multidrug O 0 0.056333706
resistance O 0 0.0021780254
protein O 0 0.0007238504
2 O 0 0.0006598362
( O 0 0.0013419637
MRP2 O 0 0.9986577
) O 0 0.0013256257
is O 0 0.00021633727
a O 0 0.00042754118
drug O 0 0.061080832
efflux O 0 0.31517926
transporter O 0 0.006958617
that O 0 9.631324e-05
is O 0 8.289698e-05
expressed O 0 5.8590198e-05
predominantly O 0 8.6258544e-05
at O 0 6.882533e-05
the O 0 8.576535e-05
apical O 0 0.00036144943
domain O 0 8.160938e-05
of O 0 0.00018613893
hepatocytes O 0 0.028074265
but O 0 0.0002482412
seems O 0 8.324363e-05
also O 0 8.427492e-05
to O 0 7.590924e-05
be O 0 7.3299634e-05
expressed O 0 4.6633333e-05
at O 0 6.4465385e-05
the O 0 9.379418e-05
apical O 0 0.00061539
membrane O 0 0.0009513412
of O 0 0.00022740473
brain O 0 0.0034566675
capillary O 0 0.95077175
endothelial O 0 0.99779993
cells O 0 0.0003121694
that O 0 0.00012087915
form O 0 0.00016332432
the O 0 0.00019492704
blood O 0 0.016514052
- O 0 0.0066652335
brain O 0 0.0021162168
barrier O 0 0.0033038883
( O 0 0.0028411434
BBB O 0 0.99586797
) O 0 0.004995425
. O 0 0.0030509618

MRP2 O 0 0.99770004
is O 0 0.0029319713
absent O 0 0.0017999987
in O 0 0.0010229151
the O 0 0.0007642574
transport O 0 0.0014517509
- O 0 0.0027626161
deficient O 0 0.00052817626
( O 0 0.0011152969
TR O 0 0.20935905
( O 0 0.0012303003
- O 0 0.002586975
) O 0 0.0007563378
) O 0 0.0005981988
Wistar O 0 0.0009857486
rat O 0 0.0002658052
mutant O 0 0.00010344541
, O 0 0.0002820849
so O 0 0.00013476948
that O 0 0.000104105464
this O 0 0.0001553373
rat O 0 0.00021328594
strain O 0 9.144201e-05
was O 0 0.00010657339
very O 0 0.0001394341
helpful O 0 0.00013670497
in O 0 8.64805e-05
defining O 0 7.461562e-05
substrates O 0 0.00012849136
of O 0 0.0002833731
MRP2 O 0 0.99967396
by O 0 0.00015122206
comparing O 0 6.9533184e-05
tissue O 0 0.0003288146
concentrations O 0 0.00016807514
or O 0 6.588116e-05
functional O 0 6.257215e-05
activities O 0 7.800921e-05
of O 0 0.00014659208
compounds O 0 0.011536923
in O 0 0.00037434537
MRP2 O 0 0.99989367
- O 0 0.016765568
deficient O 0 0.00014451568
rats O 0 0.00024576305
with O 0 0.0001795081
those O 0 0.00022910073
in O 0 0.00025013307
transport O 0 0.0007071219
- O 0 0.0017154628
competent O 0 0.0005441131
Wistar O 0 0.0028759607
rats O 0 0.0020495865
. O 0 0.0024657324

By O 0 0.0019884536
using O 0 0.0013694422
this O 0 0.0009889446
strategy O 0 0.00059969496
to O 0 0.00045827098
study O 0 0.0004402355
the O 0 0.00026667025
involvement O 0 0.0004942655
of O 0 0.0005908301
MRP2 O 0 0.9994721
in O 0 0.00032350738
brain O 0 0.00051585335
access O 0 0.00013626562
of O 0 0.00020102889
antiepileptic O 0 0.99739504
drugs O 0 0.020257065
( O 0 0.00044179836
AEDs O 0 0.043961093
) O 0 0.000377138
, O 0 0.00019149738
we O 0 6.242172e-05
recently O 0 0.00013812917
reported O 0 0.00022426085
that O 0 0.00027574322
phenytoin B-Chemical 0 0.99999774
is O 0 0.0002875707
a O 0 0.00046388834
substrate O 0 0.00054928544
for O 0 0.000525677
MRP2 O 0 0.9991775
in O 0 0.0012017711
the O 0 0.0015051758
BBB O 0 0.9957487
. O 0 0.0037412576

However O 0 0.0028863046
, O 0 0.0030915283
one O 0 0.0009953437
drawback O 0 0.00071523647
of O 0 0.0006137833
such O 0 0.00041324695
studies O 0 0.00048322842
in O 0 0.00030540657
genetically O 0 0.00032827366
deficient O 0 0.00022627143
rats O 0 0.0003630714
is O 0 0.00013912041
the O 0 0.000118280695
fact O 0 0.000102045466
that O 0 0.00012321057
compensatory O 0 0.00032828772
changes O 0 0.00021660478
with O 0 0.00022826997
upregulation O 0 0.00028939615
of O 0 0.0003880097
other O 0 0.0004893013
transporters O 0 0.0049611577
can O 0 0.00075135136
occur O 0 0.001329786
. O 0 0.0024599885

This O 0 0.0050637713
prompted O 0 0.0020821127
us O 0 0.0016305534
to O 0 0.00076577987
study O 0 0.0006967929
the O 0 0.00041428156
brain O 0 0.00085146824
expression O 0 0.00026774485
of O 0 0.00043514042
P O 0 0.40634868
- O 0 0.021969577
glycoprotein O 0 0.09069324
( O 0 0.0015794699
Pgp O 0 0.9884248
) O 0 0.0010841173
, O 0 0.00038620955
a O 0 0.00026186855
major O 0 0.00021772245
drug O 0 0.06882643
efflux O 0 0.3799079
transporter O 0 0.010925454
in O 0 0.000128478
many O 0 0.0001004578
tissues O 0 0.00020548205
, O 0 0.00023406617
including O 0 0.00010676257
the O 0 0.00019337372
BBB O 0 0.9973067
, O 0 0.00048162835
in O 0 0.00021143026
TR O 0 0.22944646
( O 0 0.0006019882
- O 0 0.0012104668
) O 0 0.00032515673
rats O 0 0.00020595084
compared O 0 0.00011734221
with O 0 0.00025866457
nonmutant O 0 0.0055571953
( O 0 0.0006910223
wild O 0 0.00042160624
- O 0 0.003495186
type O 0 0.0013198747
) O 0 0.002075103
Wistar O 0 0.004183384
rats O 0 0.00252404
. O 0 0.0028452142

METHODS O 0 0.0042087217
: O 0 0.0027766742
The O 0 0.0007142945
expression O 0 0.0007889674
of O 0 0.0014086965
MRP2 O 0 0.9991265
and O 0 0.0021446752
Pgp O 0 0.99311066
in O 0 0.0005244709
brain O 0 0.0011342237
and O 0 0.0002929653
liver O 0 0.00628902
sections O 0 0.00017773003
of O 0 0.0002550446
TR O 0 0.26001963
( O 0 0.00070025417
- O 0 0.0015571853
) O 0 0.0003545825
rats O 0 0.00020596183
and O 0 0.00012671758
normal O 0 0.00020447123
Wistar O 0 0.0004964733
rats O 0 0.00016494177
was O 0 7.792615e-05
determined O 0 7.02739e-05
with O 0 0.00011379941
immunohistochemistry O 0 0.0001635567
, O 0 0.00021425677
by O 0 0.000100907215
using O 0 9.046351e-05
a O 0 0.00017170033
novel O 0 0.00012385384
, O 0 0.00028044192
highly O 0 0.00012846196
selective O 0 0.00027228385
monoclonal O 0 0.001043906
MRP2 O 0 0.9996923
antibody O 0 0.0006318697
and O 0 0.0002819889
the O 0 0.00025158442
monoclonal O 0 0.0012488682
Pgp O 0 0.9756994
antibody O 0 0.001439097
C219 O 0 0.044076294
, O 0 0.0023642492
respectively O 0 0.0028266418
. O 0 0.0030522498

RESULTS O 0 0.004713226
: O 0 0.003556946
Immunofluorescence O 0 0.0014589347
staining O 0 0.00085447053
with O 0 0.00078631716
the O 0 0.0008086255
MRP2 O 0 0.9991542
antibody O 0 0.00092314766
was O 0 0.00029295724
found O 0 0.00020952716
to O 0 0.00016779012
label O 0 0.0005107655
a O 0 0.00023597848
high O 0 0.00017649101
number O 0 0.000112278525
of O 0 0.0002145301
microvessels O 0 0.20922427
throughout O 0 9.675518e-05
the O 0 0.00010405167
brain O 0 0.000368994
in O 0 9.78872e-05
normal O 0 0.00019243931
Wistar O 0 0.0005251431
rats O 0 0.00020929555
, O 0 0.00021343854
whereas O 0 0.00012734748
such O 0 0.00013244072
labeling O 0 0.00018309508
was O 0 0.00020905424
absent O 0 0.00030288327
in O 0 0.00043219083
TR O 0 0.3074683
( O 0 0.001801664
- O 0 0.0039937007
) O 0 0.0022269855
rats O 0 0.0024648155
. O 0 0.0031051564

TR O 0 0.6518791
( O 0 0.008472383
- O 0 0.010247818
) O 0 0.002483715
rats O 0 0.0011475334
exhibited O 0 0.0005667312
a O 0 0.00057827495
significant O 0 0.00034191462
up O 0 0.00040842238
- O 0 0.001080241
regulation O 0 0.00013218887
of O 0 0.00043819824
Pgp O 0 0.9750269
in O 0 0.00039998812
brain O 0 0.0029021697
capillary O 0 0.8645642
endothelial O 0 0.99138534
cells O 0 0.00040374184
compared O 0 0.00020025086
with O 0 0.0003486285
wild O 0 0.00050734275
- O 0 0.0049619717
type O 0 0.0020332024
controls O 0 0.0027824184
. O 0 0.0033484797

No O 0 0.0053624543
such O 0 0.0023551458
obvious O 0 0.001676406
upregulation O 0 0.0019609139
of O 0 0.0027027756
Pgp O 0 0.9866708
was O 0 0.0013737364
observed O 0 0.0010475721
in O 0 0.0014610131
liver O 0 0.042437084
sections O 0 0.0025569566
. O 0 0.0041003013

A O 0 0.018946268
comparable O 0 0.0016997771
overexpression O 0 0.0012630058
of O 0 0.0020462614
Pgp O 0 0.9873061
in O 0 0.0008510132
the O 0 0.00066137366
BBB O 0 0.99088144
was O 0 0.00029616372
obtained O 0 0.00018940527
after O 0 0.00021384718
pilocarpine B-Chemical 0 0.9999646
- O 0 0.009803756
induced O 0 0.00059515564
seizures B-Disease 0 0.99993896
in O 0 0.00048169494
wild O 0 0.00051493745
- O 0 0.0037775824
type O 0 0.0015845366
Wistar O 0 0.0048643486
rats O 0 0.0025763456
. O 0 0.0028015373

Experiments O 0 0.0028262336
with O 0 0.0019475457
systemic O 0 0.034094993
administration O 0 0.0013263696
of O 0 0.0005971939
the O 0 0.0005553563
Pgp O 0 0.99400723
substrate O 0 0.003520032
phenobarbital B-Chemical 0 0.99999845
and O 0 0.00039255957
the O 0 0.00017119845
selective O 0 0.0005452904
Pgp O 0 0.9975647
inhibitor O 0 0.035268597
tariquidar B-Chemical 0 0.9999808
in O 0 0.0003556862
TR O 0 0.678969
( O 0 0.0006644637
- O 0 0.0015777166
) O 0 0.000342038
rats O 0 0.0002496354
substantiated O 0 0.00041459585
that O 0 0.00016595078
Pgp O 0 0.95779294
is O 0 0.00013088221
functional O 0 0.00011456266
and O 0 0.00013863586
compensates O 0 9.71317e-05
for O 0 0.000115271316
the O 0 0.00016456992
lack O 0 0.00025785025
of O 0 0.0007844298
MRP2 O 0 0.9992519
in O 0 0.0013807721
the O 0 0.0016734637
BBB O 0 0.9960601
. O 0 0.0039492934

CONCLUSIONS O 0 0.020055437
: O 0 0.0042813662
The O 0 0.00090655533
data O 0 0.0010058753
on O 0 0.0006677935
TR O 0 0.114338495
( O 0 0.0017061951
- O 0 0.002898536
) O 0 0.0007287848
rats O 0 0.0003687156
indicate O 0 0.00013056048
that O 0 0.00023063357
Pgp O 0 0.80979866
plays O 0 0.0001339033
an O 0 0.00017592129
important O 0 9.052574e-05
role O 0 7.736535e-05
in O 0 0.00016634398
the O 0 0.00019317154
compensation O 0 0.0005798087
of O 0 0.0008642639
MRP2 O 0 0.9997819
deficiency O 0 0.7030496
in O 0 0.0011910594
the O 0 0.001620964
BBB O 0 0.9962127
. O 0 0.004014613

Because O 0 0.0019034549
such O 0 0.0017135456
a O 0 0.0018495083
compensatory O 0 0.001319861
mechanism O 0 0.00045367438
most O 0 0.0006089456
likely O 0 0.00023304985
occurs O 0 0.00023281
to O 0 0.00016763403
reduce O 0 0.000136793
injury B-Disease 0 0.0024437483
to I-Disease 0 0.000133477
the I-Disease 0 0.00012424466
brain I-Disease 0 0.00045904785
from O 0 0.00012810453
cytotoxic O 0 0.0043705264
compounds O 0 0.011552044
, O 0 0.00034172137
the O 0 9.7038945e-05
present O 0 8.804403e-05
data O 0 0.00012151002
substantiate O 0 0.0001047957
the O 0 0.00012270361
concept O 0 0.0002565655
that O 0 0.00022977909
MRP2 O 0 0.9994301
performs O 0 0.00036632808
a O 0 0.00050457806
protective O 0 0.00050779607
role O 0 0.00024930717
in O 0 0.0006799929
the O 0 0.0013070834
BBB O 0 0.99536276
. O 0 0.003902483

Furthermore O 0 0.0036134282
, O 0 0.003866606
our O 0 0.0013785646
data O 0 0.00109218
suggest O 0 0.0004698112
that O 0 0.0006314092
TR O 0 0.39701715
( O 0 0.0018280073
- O 0 0.0033840053
) O 0 0.0006858076
rats O 0 0.00034435446
are O 0 0.00012946357
an O 0 0.00012664076
interesting O 0 6.696696e-05
tool O 0 0.000110250294
to O 0 9.679016e-05
study O 0 0.00012646554
consequences O 0 0.00012816367
of O 0 0.00015289731
overexpression O 0 0.00013690247
of O 0 0.00040518158
Pgp O 0 0.9949911
in O 0 0.00020758875
the O 0 0.00017147814
BBB O 0 0.9890667
on O 0 6.5591994e-05
access O 0 8.65206e-05
of O 0 0.000121479556
drugs O 0 0.0043865247
in O 0 0.00011385521
the O 0 0.00010693292
brain O 0 0.0006082613
, O 0 0.00020451899
without O 0 9.642986e-05
the O 0 7.7827375e-05
need O 0 8.735843e-05
of O 0 0.00014910311
inducing O 0 0.0003908639
seizures B-Disease 0 0.99998295
or O 0 0.00023131273
other O 0 0.00029293937
Pgp O 0 0.9926819
- O 0 0.003346186
enhancing O 0 0.00023013078
events O 0 0.00043098454
for O 0 0.00030755388
this O 0 0.0006419952
purpose O 0 0.0009648045
. O 0 0.0024874534

Role O 0 0.0076021557
of O 0 0.028844008
xanthine B-Chemical 0 0.99998903
oxidase O 0 0.9997341
in O 0 0.006792152
dexamethasone B-Chemical 0 0.9998872
- O 0 0.11981621
induced O 0 0.0021116955
hypertension B-Disease 2 0.9999404
in O 0 0.0023081473
rats O 0 0.0037150788
. O 0 0.0037592617

1 O 0 0.059545428
. O 0 0.059476506

Glucocorticoid O 0 0.989997
- O 0 0.024320344
induced O 0 0.0032889533
hypertension B-Disease 2 0.9999356
( O 0 0.0074227033
GC O 0 0.22113694
- O 0 0.0855472
HT B-Disease 0 0.9966472
) O 0 0.0014824818
in O 0 0.0003232164
the O 0 0.00026550126
rat O 0 0.00048377342
is O 0 0.00029149372
associated O 0 0.00052075565
with O 0 0.00119967
nitric B-Chemical 0 0.999445
oxide I-Chemical 0 0.9968092
- O 0 0.10227318
redox O 0 0.010027815
imbalance O 0 0.005232059
. O 0 0.0034318664

2 O 0 0.05912018
. O 0 0.06027965

We O 0 0.0028390894
studied O 0 0.0024965592
the O 0 0.0012546829
role O 0 0.00094691006
of O 0 0.010846807
xanthine B-Chemical 0 0.9999982
oxidase O 0 0.9999645
( O 0 0.815944
XO O 0 0.9999964
) O 0 0.009420906
, O 0 0.00073436287
which O 0 0.00026997805
is O 0 0.00015278276
implicated O 0 0.0001529514
in O 0 0.00016257928
the O 0 0.0001682374
production O 0 0.00041728013
of O 0 0.00073228875
reactive O 0 0.9560068
oxygen O 1 0.9999454
species O 0 0.0007183011
, O 0 0.00056095776
in O 0 0.00033582043
dexamethasone B-Chemical 0 0.9998598
- O 0 0.018579334
induced O 0 0.0006547509
hypertension B-Disease 2 0.99999
( O 0 0.028914737
dex B-Chemical 0 0.99991226
- O 0 0.3996172
HT B-Disease 0 0.9973115
) O 0 0.0058001312
. O 0 0.0032468813

3 O 0 0.049031585
. O 0 0.058089748

Thirty O 0 0.008213915
male O 0 0.0060765767
Sprague O 0 0.19348706
- O 0 0.006110947
Dawley O 0 0.007684029
rats O 0 0.00075430574
were O 0 0.00027581374
divided O 0 0.00023105548
randomly O 0 9.554064e-05
into O 0 8.2739185e-05
four O 0 7.8416946e-05
treatment O 0 0.00012331741
groups O 0 0.00019455179
: O 0 0.00039358946
saline O 0 0.0007298499
, O 0 0.0006881685
dexamethasone B-Chemical 0 0.99973816
( O 0 0.0025321576
dex B-Chemical 0 0.99990714
) O 0 0.0024000828
, O 0 0.0013977215
allopurinol B-Chemical 0 0.99998736
plus O 0 0.00042842605
saline O 0 0.0014342428
, O 0 0.00076052453
and O 0 0.00091794436
allopurinol B-Chemical 0 0.9999782
plus O 0 0.0037924193
dex B-Chemical 0 0.9996563
. O 0 0.004928213

4 O 0 0.04741095
. O 0 0.057336286

Systolic O 0 0.16124159
blood O 0 0.010221445
pressures O 0 0.005713126
( O 0 0.0029263855
SBP O 0 0.015431556
) O 0 0.0022423335
and O 0 0.0010503028
bodyweights O 0 0.004178151
were O 0 0.00074285077
recorded O 0 0.0007536723
each O 0 0.00061033276
alternate O 0 0.0010807799
day O 0 0.001500014
. O 0 0.0039436948

Thymus O 0 0.016480358
weight O 0 0.0033304254
was O 0 0.001229314
used O 0 0.0007692677
as O 0 0.0007003249
a O 0 0.0008200258
marker O 0 0.00069589727
of O 0 0.00067678327
glucocorticoid O 0 0.22901341
activity O 0 0.00039242205
, O 0 0.00096566847
and O 0 0.0008085512
serum O 0 0.37390238
urate B-Chemical 0 0.9990953
to O 0 0.0010589064
assess O 0 0.0010913486
XO O 0 0.9999318
inhibition O 0 0.0068147085
. O 0 0.004484479

5 O 0 0.052639987
. O 0 0.05837286

Dex B-Chemical 1 0.99655294
increased B-Disease 0 0.015479314
SBP I-Disease 0 0.8705148
( O 0 0.0036524017
110 O 0 0.0025771093
+ O 0 0.0032246108
/ O 0 0.0037302633
- O 0 0.0030079044
2 O 0 0.00071931735
- O 0 0.001659756
126 O 0 0.000977546
+ O 0 0.0014651497
/ O 0 0.0018455744
- O 0 0.0013462809
3 O 0 0.000256128
mmHg O 0 0.001019891
; O 0 0.00058582524
P O 0 0.0025764166
< O 0 0.00043262032
0 O 0 0.00034235086
. O 0 0.0002850928
001 O 0 0.0025565627
) O 0 0.00065546826
and O 0 0.00029406647
decreased B-Disease 0 0.00046641243
thymus I-Disease 0 0.0005512754
( I-Disease 0 0.0005620967
P I-Disease 0 0.0047477703
< I-Disease 0 0.00038996447
0 I-Disease 0 0.00030624162
. I-Disease 0 0.00026205537
001 I-Disease 0 0.0022412466
) I-Disease 0 0.00064657786
and I-Disease 0 0.00037430105
bodyweights I-Disease 0 0.004147636
( O 0 0.0008910639
P O 0 0.008048034
" O 0 0.00092785864
< O 0 0.00093025493
0 O 0 0.0009910917
. O 0 0.001155504
01 O 0 0.005986228
) O 0 0.0048892135
. O 0 0.0046682125

Allopurinol B-Chemical 0 0.9999193
decreased O 0 0.030760866
serum O 0 0.7265656
urate B-Chemical 0 0.9978301
from O 0 0.0010981766
76 O 0 0.0014958169
+ O 0 0.00218999
/ O 0 0.0026074154
- O 0 0.0017791578
5 O 0 0.00028197412
to O 0 0.00020410522
30 O 0 0.00024343585
+ O 0 0.0008177287
/ O 0 0.0014024095
- O 0 0.0014225799
3 O 0 0.00030747885
micromol O 0 0.0066847275
/ O 0 0.0019961863
L O 0 0.27610314
( O 0 0.000784124
P O 0 0.0072792475
< O 0 0.00038066434
0 O 0 0.00027475762
. O 0 0.00021636658
001 O 0 0.0019541208
) O 0 0.0004570309
in O 0 0.0001766769
saline O 0 0.0004491696
and O 0 0.00017530407
from O 0 0.00015487011
84 O 0 0.00034658602
+ O 0 0.0008210149
/ O 0 0.0013507889
- O 0 0.0010888075
13 O 0 0.0001980803
to O 0 0.00012964233
28 O 0 0.00020004246
+ O 0 0.0007175342
/ O 0 0.0013871783
- O 0 0.0015430395
2 O 0 0.00034567935
micromol O 0 0.013741441
/ O 0 0.002595545
L O 0 0.63181305
in O 0 0.0007627444
dex B-Chemical 0 0.9998766
- O 0 0.010258749
treated O 0 0.00077631226
( O 0 0.0007544552
P O 0 0.0077161756
< O 0 0.00064939266
0 O 0 0.0005965463
. O 0 0.00063584204
01 O 0 0.0032796827
) O 0 0.0023931514
groups O 0 0.0024198014
. O 0 0.004013761

6 O 0 0.044867903
. O 0 0.05719148

Allopurinol B-Chemical 0 0.9998056
did O 0 0.009947218
not O 0 0.0055776825
prevent O 0 0.007597693
dex B-Chemical 0 0.9994324
- O 0 0.6786108
HT B-Disease 0 0.99402314
. O 0 0.012440223

This O 0 0.0047593177
, O 0 0.002890573
together O 0 0.0010219413
with O 0 0.00075669744
our O 0 0.0004318739
previous O 0 0.00032177195
findings O 0 0.00048393966
that O 0 0.00044702683
allopurinol B-Chemical 0 0.999992
failed O 0 0.0004692448
to O 0 0.0002296135
prevent O 0 0.0003226985
adrenocorticotrophic O 0 0.9972583
hormone O 0 0.72301763
induced O 0 0.000655269
hypertension B-Disease 2 0.99999714
, O 0 0.0011765385
suggests O 0 0.00013437196
that O 0 0.00034549323
XO O 0 0.9999951
activity O 0 0.00018208494
is O 0 0.00012273273
not O 0 0.0001271594
a O 0 0.0002291988
major O 0 0.00016850486
determinant O 0 0.00013435724
of O 0 0.00042565016
GC O 0 0.13169567
- O 0 0.07520853
HT B-Disease 0 0.99367577
in O 0 0.0007037534
the O 0 0.0007927419
rat O 0 0.0022352855
. O 0 0.0027412064

Side O 0 0.013746567
effects O 0 0.0015810288
of O 0 0.0011117498
postoperative O 0 0.0010349739
administration O 0 0.00089488114
of O 0 0.0007412476
methylprednisolone B-Chemical 0 0.99985635
and O 0 0.00079828134
gentamicin B-Chemical 0 0.9997936
into O 0 0.00023378314
the O 0 0.0003000328
posterior O 0 0.0034139354
sub O 0 0.0025362233
- O 0 0.00759001
Tenon O 0 0.15015401
' O 0 0.00169893
s O 0 0.0017297651
space O 0 0.0025357865
. O 0 0.0034256557

PURPOSE O 0 0.006293981
: O 0 0.0024439748
To O 0 0.00038216583
assess O 0 0.00028280442
the O 0 0.0003489048
incidence O 0 0.00053066126
of O 0 0.0002905595
postoperative O 0 0.0004501971
emetic O 0 0.0074937805
side O 0 0.00034086712
effects O 0 0.0001045374
after O 0 5.4141918e-05
the O 0 7.1893926e-05
administration O 0 0.00018085557
of O 0 0.00019155309
methylprednisolone B-Chemical 0 0.9999418
and O 0 0.0002779822
gentamicin B-Chemical 0 0.99991167
into O 0 8.321306e-05
the O 0 0.000109557775
posterior O 0 0.002344678
sub O 0 0.0013192282
- O 0 0.0061110896
Tenon O 0 0.16169806
' O 0 0.00034072122
s O 0 0.00023978195
space O 0 0.00019967278
at O 0 0.00010810068
the O 0 0.00012609633
end O 0 0.00014570939
of O 0 0.00040350755
routine O 0 0.00060076534
cataract B-Disease 2 0.99409616
surgery O 0 0.002568128
. O 0 0.002429112

SETTING O 0 0.05508134
: O 0 0.04316296
St O 0 0.0505429
. O 0 0.03350646

Luke O 0 0.030478513
' O 0 0.0144073935
s O 0 0.009905362
Hospital O 0 0.008826828
, O 0 0.0090396255
Gwardamangia O 0 0.015464752
, O 0 0.012025823
Malta O 0 0.018862883
. O 0 0.012245323

METHODS O 0 0.0049620406
: O 0 0.004182554
A O 0 0.006175652
double O 0 0.0013733701
- O 0 0.0054887384
blind O 0 0.009688253
double O 0 0.00077589287
- O 0 0.003753204
armed O 0 0.0023816887
prospective O 0 0.001529714
study O 0 0.00031391977
comprised O 0 0.00026921774
40 O 0 0.0002143757
patients O 0 0.00026878557
who O 0 0.00016115562
had O 0 9.941859e-05
uneventful O 0 0.00017423372
sutureless O 0 0.00038875482
phacoemulsification O 0 0.002436392
under O 0 0.00015845208
sub O 0 0.00084714714
- O 0 0.0038398579
Tenon O 0 0.12720612
' O 0 0.00046115287
s O 0 0.00034391452
local O 0 0.00029309498
infiltration O 0 0.0020414295
of O 0 0.0003395508
3 O 0 0.00036298987
mL O 0 0.001846133
of O 0 0.000879072
plain O 0 0.019668939
lignocaine B-Chemical 0 0.99977475
. O 0 0.003937959

At O 0 0.0012970428
the O 0 0.0012804772
end O 0 0.0007820265
of O 0 0.0009467684
the O 0 0.0006075384
procedure O 0 0.00051755214
, O 0 0.0010255944
Group O 0 0.0029543638
A O 0 0.0036388158
( O 0 0.00064923795
n O 0 0.00037902937
= O 0 0.0006667277
20 O 0 0.00025233513
) O 0 0.00041419073
had O 0 0.00019232942
20 O 0 0.00023336224
mg O 0 0.002204534
/ O 0 0.0007785622
0 O 0 0.00023719613
. O 0 0.00014225933
5 O 0 0.00013521564
mL O 0 0.00067162816
of O 0 0.00023761783
methylprednisolone B-Chemical 0 0.99976844
and O 0 0.00020071938
10 O 0 0.00017809901
mg O 0 0.0019692462
/ O 0 0.0005945284
0 O 0 0.00017934198
. O 0 0.00010886369
5 O 0 0.00010732347
mL O 0 0.0005706169
of O 0 0.00018779328
gentamicin B-Chemical 0 0.9998029
injected O 0 0.00011531156
into O 0 6.7112334e-05
the O 0 0.0001089928
posterior O 0 0.0018188208
sub O 0 0.0012278493
- O 0 0.004975249
Tenon O 0 0.12536253
' O 0 0.0003157456
s O 0 0.00022025159
space O 0 0.0001990508
and O 0 0.00018234989
Group O 0 0.0015565731
B O 0 0.008502708
( O 0 0.0003392552
n O 0 0.00019383151
= O 0 0.00040770156
20 O 0 0.00014327175
) O 0 0.0002514065
had O 0 9.9224046e-05
the O 0 7.720947e-05
same O 0 7.040759e-05
combination O 0 0.00012870056
injected O 0 0.000108983964
into O 0 9.8922676e-05
the O 0 0.00019056225
anterior O 0 0.0032970132
sub O 0 0.0020960234
- O 0 0.0071115056
Tenon O 0 0.17810072
' O 0 0.0015015231
s O 0 0.0015481196
space O 0 0.0023103107
. O 0 0.003126364

Postoperatively O 0 0.0055333646
, O 0 0.003258713
all O 0 0.0011722785
patients O 0 0.0012904888
were O 0 0.0004906495
assessed O 0 0.0003931226
for O 0 0.00035401015
symptoms O 0 0.0022744602
of O 0 0.0008789272
nausea B-Disease 0 0.9996588
, I-Disease 0 0.0036238006
vomiting I-Disease 0 0.9976261
, O 0 0.0025492425
and O 0 0.002358206
headache B-Disease 0 0.9941407
. O 0 0.004455439

A O 0 0.053833444
chi O 0 0.3382212
- O 0 0.01498033
square O 0 0.003682494
test O 0 0.001478513
was O 0 0.00070692616
used O 0 0.00048263758
to O 0 0.00039003813
assess O 0 0.00025658947
the O 0 0.00044625258
statistical O 0 0.0009205562
significance O 0 0.0009616846
of O 0 0.0014500052
results O 0 0.0020325603
. O 0 0.0041468325

RESULTS O 0 0.004517289
: O 0 0.0031391047
Sixty O 0 0.002021854
percent O 0 0.00085140986
in O 0 0.00069304905
Group O 0 0.0028519565
A O 0 0.003398572
developed O 0 0.00052586244
postoperative B-Disease 0 0.0011909998
emetic I-Disease 0 0.12524825
symptoms I-Disease 0 0.08530122
, O 0 0.0011299446
headache B-Disease 0 0.9944759
, O 0 0.0005268814
or O 0 0.0002071526
both O 0 0.00023023391
; O 0 0.0005638755
1 O 0 0.00031668047
patient O 0 0.00033063965
in O 0 0.00039237755
Group O 0 0.0034705272
B O 0 0.036712646
developed O 0 0.0020918667
symptoms O 0 0.015301941
. O 0 0.003380816

CONCLUSIONS O 0 0.014687296
: O 0 0.0030141568
The O 0 0.0006156033
administration O 0 0.0009801441
of O 0 0.0009090305
methylprednisolone B-Chemical 0 0.99983764
and O 0 0.0009885662
gentamicin B-Chemical 0 0.9998895
in O 0 0.00028749698
the O 0 0.00020450866
posterior O 0 0.0027966963
sub O 0 0.001620154
- O 0 0.0065603233
Tenon O 0 0.15044162
' O 0 0.00035292696
s O 0 0.00023611239
space O 0 0.00018817758
was O 0 0.00010066771
related O 0 6.358965e-05
to O 0 8.4180225e-05
a O 0 0.00015172485
high O 0 0.0001475219
incidence O 0 0.00023020669
of O 0 0.00013261485
side O 0 0.00037655188
effects O 0 0.00018250594
including O 0 0.00029699557
nausea B-Disease 0 0.9998567
, I-Disease 0 0.0022186108
vomiting I-Disease 0 0.99811745
, O 0 0.0015642875
and O 0 0.0015897145
headache B-Disease 0 0.99544734
. O 0 0.0032871435

All O 0 0.0040667756
adverse O 0 0.006485719
effects O 0 0.0030451743
were O 0 0.003317981
self O 0 0.008767282
- O 0 0.013801899
limiting O 0 0.006716777
. O 0 0.0089352345

Assessment O 0 0.003621589
of O 0 0.0020460335
a O 0 0.0018077759
new O 0 0.0011743517
non O 0 0.0013747009
- O 0 0.0027640169
invasive O 0 0.0005825998
index O 0 0.00036495915
of O 0 0.00029374368
cardiac O 0 0.0007255946
performance O 0 0.00028716738
for O 0 0.00017032717
detection O 0 0.00023722374
of O 0 0.0005057903
dobutamine B-Chemical 0 0.9992524
- O 0 0.00795517
induced O 0 0.0013343125
myocardial B-Disease 0 0.99924445
ischemia I-Disease 0 0.9996505
. O 0 0.0040945145

BACKGROUND O 0 0.015536667
: O 0 0.004714801
Electrocardiography O 0 0.0039414945
has O 0 0.000602448
a O 0 0.00077348296
very O 0 0.0005925258
low O 0 0.000550275
sensitivity O 0 0.0006207409
in O 0 0.00041978192
detecting O 0 0.00048470538
dobutamine B-Chemical 0 0.99872226
- O 0 0.0076289605
induced O 0 0.0015665286
myocardial B-Disease 0 0.99907506
ischemia I-Disease 0 0.9995987
. O 0 0.0046047834

OBJECTIVES O 0 0.0035664395
: O 0 0.0023384152
To O 0 0.00039244714
assess O 0 0.00030101498
the O 0 0.00036770853
added O 0 0.00043521135
diagnostic O 0 0.0003466506
value O 0 0.00027294873
of O 0 0.00024928813
a O 0 0.00029128118
new O 0 0.0002109299
cardiac O 0 0.00046967997
performance O 0 0.00018795003
index O 0 0.00020791561
( O 0 0.00031669583
dP O 0 0.002306482
/ O 0 0.0006810172
dtejc O 0 0.0003291646
) O 0 0.00036041168
measurement O 0 0.000119627766
, O 0 0.00021276742
based O 0 0.00010160377
on O 0 0.00010593718
brachial O 0 0.48568657
artery O 0 0.08402832
flow O 0 0.0011448158
changes O 0 0.00014126136
, O 0 0.0001907846
as O 0 8.927005e-05
compared O 0 6.6503795e-05
to O 0 7.900737e-05
standard O 0 0.00011219825
12 O 0 0.000100893856
- O 0 0.0007314708
lead O 0 0.0007524645
ECG O 0 0.008504561
, O 0 0.00019056571
for O 0 7.273189e-05
detecting O 0 0.0001090507
dobutamine B-Chemical 0 0.9988593
- O 0 0.0023932308
induced O 0 0.00024078587
myocardial B-Disease 0 0.99947137
ischemia I-Disease 0 0.9998802
, O 0 0.00038825744
using O 0 0.00014574357
Tc99m B-Chemical 0 0.8487032
- I-Chemical 0 0.0029455533
Sestamibi I-Chemical 0 0.7248415
single O 0 0.00010330465
- O 0 0.00051254896
photon O 0 0.00039177915
emission O 0 0.0004370706
computed O 0 8.533714e-05
tomography O 0 0.00019075006
as O 0 8.396897e-05
the O 0 9.024545e-05
gold O 0 0.02682905
standard O 0 0.00013396997
of O 0 0.00012637272
comparison O 0 0.000102581376
to O 0 0.0001029519
assess O 0 7.585621e-05
the O 0 0.00016511172
presence O 0 0.000257608
or O 0 0.0003374789
absence O 0 0.0004804016
of O 0 0.001958478
ischemia B-Disease 0 0.9995372
. O 0 0.004077205

METHODS O 0 0.004226184
: O 0 0.0027064157
The O 0 0.0006969177
study O 0 0.00081669097
group O 0 0.0008124235
comprised O 0 0.0006905523
40 O 0 0.000561399
patients O 0 0.0006777327
undergoing O 0 0.0006139737
Sestamibi B-Chemical 0 0.21429649
- O 0 0.0033940324
SPECT O 0 0.29528135
/ O 0 0.005670416
dobutamine B-Chemical 0 0.99649894
stress O 0 0.017791262
test O 0 0.00325584
. O 0 0.0038280387

Simultaneous O 0 0.0042902036
measurements O 0 0.0019415598
of O 0 0.0018591479
ECG O 0 0.008791949
and O 0 0.0011937199
brachial O 0 0.24035683
artery O 0 0.03353837
dP O 0 0.0069051133
/ O 0 0.0016231046
dtejc O 0 0.00075979583
were O 0 0.0003926035
performed O 0 0.0003629072
at O 0 0.00041625457
each O 0 0.00062672666
dobutamine B-Chemical 0 0.94251186
level O 0 0.0019292304
. O 0 0.0035425269

In O 0 0.002397643
19 O 0 0.002595192
of O 0 0.001384881
the O 0 0.0008577763
40 O 0 0.0009020301
patients O 0 0.001207935
perfusion O 0 0.007879814
defects O 0 0.0011185473
compatible O 0 0.0005797595
with O 0 0.00088012597
ischemia B-Disease 0 0.9990227
were O 0 0.0006705639
detected O 0 0.00052736886
on O 0 0.00094233226
SPECT O 0 0.45123917
. O 0 0.003636467

The O 0 0.0020386504
increase O 0 0.00150858
in O 0 0.0012069897
dP O 0 0.006725374
/ O 0 0.0020722868
dtejc O 0 0.00071569846
during O 0 0.0002722239
infusion O 0 0.0006351192
of O 0 0.00032556307
dobutamine B-Chemical 0 0.9948201
in O 0 0.00019103834
this O 0 0.00017194936
group O 0 0.0002536894
was O 0 0.00018300886
severely O 0 0.0011253192
impaired O 0 0.00070013606
as O 0 0.00018848898
compared O 0 0.00014494624
to O 0 0.00019832786
the O 0 0.00029337144
non O 0 0.0010841313
- O 0 0.022100445
ischemic O 0 0.9983821
group O 0 0.0028733308
. O 0 0.003004139

dP O 0 0.029421508
/ O 0 0.007285297
dtejc O 0 0.0024587929
outcome O 0 0.0012760217
was O 0 0.00061191746
combined O 0 0.0005594949
with O 0 0.00043065683
the O 0 0.00033708868
ECG O 0 0.0038841628
results O 0 0.00023180794
, O 0 0.00041432085
giving O 0 0.00027985324
an O 0 0.0003453941
ECG O 0 0.01865924
- O 0 0.0011374891
enhanced O 0 0.00024167642
value O 0 0.00029904017
, O 0 0.0004977562
and O 0 0.00035096434
compared O 0 0.0003346526
to O 0 0.0006400527
ECG O 0 0.020512875
alone O 0 0.0017552191
. O 0 0.0029932118

RESULTS O 0 0.0044195927
: O 0 0.0027943128
The O 0 0.0006623545
sensitivity O 0 0.0009835801
improved O 0 0.0010120431
dramatically O 0 0.00061842037
from O 0 0.00040253435
16 O 0 0.0004325168
% O 0 0.00052451313
to O 0 0.00021288329
79 O 0 0.00038216964
% O 0 0.00043835485
, O 0 0.0003268674
positive O 0 0.00018993877
predictive O 0 0.00034403126
value O 0 0.00020007888
increased O 0 0.0002307781
from O 0 0.00014325645
60 O 0 0.00017560973
% O 0 0.00024623214
to O 0 0.00011048815
68 O 0 0.00021308454
% O 0 0.00024013106
and O 0 0.00012109107
negative O 0 0.00012726152
predictive O 0 0.00027907838
value O 0 0.00016476196
from O 0 0.00013816643
54 O 0 0.0002720716
% O 0 0.00029192644
to O 0 0.00013991236
78 O 0 0.00033903596
% O 0 0.00037300342
, O 0 0.0003321822
and O 0 0.00022187307
specificity O 0 0.00041492298
decreased O 0 0.0005807412
from O 0 0.00034229312
90 O 0 0.0004853769
% O 0 0.0008705901
to O 0 0.00066582544
67 O 0 0.0019815904
% O 0 0.0029687532
. O 0 0.0033523026

CONCLUSIONS O 0 0.020868417
: O 0 0.0042217057
If O 0 0.0010342648
ECG O 0 0.0069804806
alone O 0 0.0006977025
is O 0 0.00033776186
used O 0 0.00025622916
for O 0 0.00020070598
specificity O 0 0.00037636064
, O 0 0.00038135302
the O 0 0.00014206061
combination O 0 0.00019016223
with O 0 0.00020473986
dP O 0 0.007555156
/ O 0 0.00082770677
dtejc O 0 0.00027840445
improved O 0 0.00019693044
the O 0 8.964266e-05
sensitivity O 0 0.00017556168
of O 0 0.00013714524
the O 0 0.00010313929
test O 0 0.0001853243
and O 0 0.00013387905
could O 0 7.987186e-05
be O 0 0.00010225587
a O 0 0.0001716902
cost O 0 0.00023506345
- O 0 0.00084829814
savings O 0 0.0002814158
alternative O 0 4.4616227e-05
to O 0 5.7012097e-05
cardiac O 0 0.00023515218
imaging O 0 0.00010691397
or O 0 8.0220154e-05
perfusion O 0 0.0018453274
studies O 0 0.00013134653
to O 0 9.342427e-05
detect O 0 0.00012025476
myocardial B-Disease 0 0.99943346
ischemia I-Disease 0 0.99990904
, O 0 0.0005363464
especially O 0 0.00022468655
in O 0 0.00021816694
patients O 0 0.0005098678
unable O 0 0.0003126528
to O 0 0.0006848406
exercise O 0 0.0026856433
. O 0 0.0023449233

Cocaine B-Chemical 0 0.999782
- O 0 0.1370109
induced O 0 0.0049253404
myocardial B-Disease 0 0.9992514
infarction I-Disease 0 0.999951
: O 0 0.004056786
clinical O 0 0.0020879672
observations O 0 0.0009286405
and O 0 0.0012295439
pathogenetic O 0 0.004966799
considerations O 0 0.0029390233
. O 0 0.004306798

Clinical O 0 0.006183726
and O 0 0.0017954652
experimental O 0 0.001205733
data O 0 0.00086901296
published O 0 0.0004568382
to O 0 0.00026635572
date O 0 0.00017455597
suggest O 0 0.0001243395
several O 0 0.00012660238
possible O 0 0.0001267282
mechanisms O 0 0.000164123
by O 0 0.00028507592
which O 0 0.0006141613
cocaine B-Chemical 0 0.99964666
may O 0 0.0003385552
result O 0 0.00036034983
in O 0 0.0006768464
acute B-Disease 0 0.93943936
myocardial I-Disease 0 0.99977666
infarction I-Disease 0 0.9999808
. O 0 0.004631248

In O 0 0.0021274881
individuals O 0 0.002909233
with O 0 0.0015517547
preexisting O 0 0.0033171184
, O 0 0.0014013889
high O 0 0.00086772547
- O 0 0.0033755794
grade O 0 0.004435984
coronary O 0 0.04479915
arterial O 0 0.22077
narrowing O 0 0.007882149
, O 0 0.0009276258
acute B-Disease 0 0.90869224
myocardial I-Disease 0 0.9999181
infarction I-Disease 0 0.9999975
may O 0 0.00015660976
result O 0 9.674374e-05
from O 0 8.919066e-05
an O 0 0.00011996111
increase O 0 0.00012096966
in O 0 0.00023160779
myocardial O 0 0.9997459
oxygen B-Chemical 1 0.99992156
demand O 0 0.000503719
associated O 0 0.00017645316
with O 0 0.00028421
cocaine B-Chemical 0 0.9998795
- O 0 0.003822324
induced O 0 0.00018694931
increase O 0 0.00022416018
in O 0 0.00029995161
rate O 0 0.0007721265
- O 0 0.0036885098
pressure O 0 0.011923109
product O 0 0.0018158926
. O 0 0.0026323248

In O 0 0.001853368
other O 0 0.0016233502
individuals O 0 0.0019751703
with O 0 0.00096766336
no O 0 0.0007507048
underlying O 0 0.0018519317
atherosclerotic B-Disease 0 0.9998945
obstruction I-Disease 0 0.9959791
, O 0 0.0012744749
coronary B-Disease 0 0.14589055
occlusion I-Disease 0 0.48943204
may O 0 0.00019728715
be O 0 0.00019594803
due O 0 0.00019242447
to O 0 0.00043492432
spasm B-Disease 0 0.99975806
, O 0 0.0025691593
thrombus B-Disease 0 0.99941015
, O 0 0.0019283043
or O 0 0.00094855524
both O 0 0.0014980962
. O 0 0.003110265

With O 0 0.0023578764
regard O 0 0.0015513654
to O 0 0.0019243887
spasm B-Disease 0 0.9993444
, O 0 0.0015382818
the O 0 0.00041963827
clinical O 0 0.0008254781
findings O 0 0.00035258342
are O 0 0.00019819592
largely O 0 0.0002133423
circumstantial O 0 0.0005158541
, O 0 0.0005026783
and O 0 0.00025490555
the O 0 0.0001943065
locus O 0 0.00022518585
of O 0 0.0004934554
cocaine B-Chemical 0 0.9998103
- O 0 0.015396495
induced O 0 0.00078471977
vasoconstriction O 0 0.9988393
remains O 0 0.0008463309
speculative O 0 0.0034038334
. O 0 0.003164476

Although O 0 0.001726819
certain O 0 0.0016126944
clinical O 0 0.0021066945
and O 0 0.0006963259
experimental O 0 0.0005027185
findings O 0 0.0004293787
support O 0 0.00027935524
the O 0 0.000222754
hypothesis O 0 0.0002767507
that O 0 0.0003481451
spasm B-Disease 0 0.9996916
involves O 0 0.00022172905
the O 0 0.00021029053
epicardial O 0 0.006479116
, O 0 0.00053590874
medium O 0 0.0015619382
- O 0 0.0027823616
size O 0 0.0006720213
vessels O 0 0.13463672
, O 0 0.00066737743
other O 0 0.00033502578
data O 0 0.00053435814
suggest O 0 0.00055153447
intramural O 0 0.29596955
vasoconstriction O 0 0.99919575
. O 0 0.0046618935

Diffuse O 0 0.17913339
intramural O 0 0.46304452
vasoconstriction O 0 0.9986299
is O 0 0.0012331047
not O 0 0.0007321809
consistent O 0 0.0005379815
with O 0 0.00064785156
reports O 0 0.00077108276
of O 0 0.0009725458
segmental O 0 0.007432762
, O 0 0.0027164754
discrete O 0 0.0027137138
infarction B-Disease 0 0.99979275
. O 0 0.0055754874

Whereas O 0 0.0026501084
certain O 0 0.0017467618
in O 0 0.001046676
vivo O 0 0.0007379266
data O 0 0.00055245816
suggest O 0 0.00021228819
that O 0 0.0002224293
these O 0 0.00024386284
effects O 0 0.00030114903
are O 0 0.00033979822
alpha O 0 0.4237833
- O 0 0.0033415505
mediated O 0 0.00017608222
, O 0 0.00046586516
other O 0 0.00024836906
in O 0 0.0002989216
vitro O 0 0.00037428644
data O 0 0.00045785678
suggest O 0 0.00034595432
the O 0 0.0007897893
opposite O 0 0.0022579536
. O 0 0.0035571777

The O 0 0.0020092374
finding O 0 0.0019012295
of O 0 0.002501016
cocaine B-Chemical 0 0.99974257
- O 0 0.052310467
induced O 0 0.00090209715
vasoconstriction O 0 0.9992747
in O 0 0.00032672967
segments O 0 0.00026282403
of O 0 0.00025725822
( O 0 0.0005327173
noninnervated O 0 0.0017266447
) O 0 0.00036386002
human O 0 0.00013798763
umbilical O 0 0.001827548
artery O 0 0.095334835
suggests O 0 7.219428e-05
that O 0 7.373056e-05
the O 0 8.8611225e-05
presence O 0 0.00010391076
or O 0 9.565851e-05
absence O 0 7.713272e-05
of O 0 0.00015753703
intact O 0 0.00021638429
innervation O 0 0.0005668198
is O 0 7.907249e-05
not O 0 7.5483e-05
sufficient O 0 6.485737e-05
to O 0 8.396305e-05
explain O 0 8.451265e-05
the O 0 9.42287e-05
discrepant O 0 0.00022054413
data O 0 0.00014151887
involving O 0 0.00014221255
the O 0 0.00012026921
possibility O 0 0.00014758705
of O 0 0.0005958348
alpha O 0 0.802989
- O 0 0.00753177
mediated O 0 0.00054729875
effects O 0 0.0014974858
. O 0 0.0032182198

Finally O 0 0.0029976915
, O 0 0.0033397041
the O 0 0.0010611336
contribution O 0 0.0006343521
of O 0 0.0008779072
a O 0 0.0009891876
primary O 0 0.0006627201
, O 0 0.0015078281
thrombotic B-Disease 0 0.99144214
effect O 0 0.0004263009
of O 0 0.0009190566
cocaine B-Chemical 0 0.99966586
has O 0 0.00051234604
not O 0 0.00064071955
been O 0 0.001045742
excluded O 0 0.0021251866
. O 0 0.0030530656

Proteomic O 0 0.0076322355
analysis O 0 0.002705901
of O 0 0.002364803
striatal O 0 0.03067861
proteins O 0 0.0008398423
in O 0 0.000627898
the O 0 0.0004762532
rat O 0 0.00073408056
model O 0 0.00055375736
of O 0 0.0013802614
L B-Chemical 0 0.9984687
- I-Chemical 0 0.9779243
DOPA I-Chemical 0 0.9999801
- O 0 0.22626047
induced O 0 0.0042462684
dyskinesia B-Disease 0 0.9999788
. O 0 0.006082369

L B-Chemical 0 0.99679524
- I-Chemical 0 0.9914574
DOPA I-Chemical 0 0.999956
- O 0 0.3937166
induced O 0 0.004728071
dyskinesia B-Disease 0 0.9999963
( O 0 0.028842548
LID B-Disease 0 0.9996859
) O 0 0.0012239149
is O 0 0.00018125003
among O 0 0.00019706962
the O 0 0.00015402405
motor O 0 0.0006650865
complications O 0 0.0014364744
that O 0 0.00010770782
arise O 0 0.00012309066
in O 0 0.000221857
Parkinson B-Disease 0 0.99522984
' I-Disease 0 0.00051161496
s I-Disease 0 0.00047213788
disease I-Disease 0 0.3633588
( O 0 0.0012560016
PD B-Disease 0 0.9992586
) O 0 0.0006399201
patients O 0 0.00029194535
after O 0 9.001751e-05
a O 0 0.0002666319
prolonged O 0 0.00037929977
treatment O 0 0.0004408539
with O 0 0.0012042479
L B-Chemical 0 0.99830985
- I-Chemical 0 0.95751446
DOPA I-Chemical 0 0.9999372
. O 0 0.006047356

To O 0 0.0013684011
this O 0 0.0015183309
day O 0 0.00087687233
, O 0 0.00116794
transcriptome O 0 0.00044682852
analysis O 0 0.00043317248
has O 0 0.00022594418
been O 0 0.00023606827
performed O 0 0.00020649114
in O 0 0.00021422697
a O 0 0.0003092218
rat O 0 0.00028891864
model O 0 0.00019191197
of O 0 0.00046825013
LID B-Disease 0 0.9995433
[ O 0 0.007953932
Neurobiol O 0 0.21207407
. O 0 0.0002821134
Dis O 0 0.0058301
. O 0 0.00025332853
, O 0 0.00039159655
17 O 0 0.00030202256
( O 0 0.00036017402
2004 O 0 0.00040054426
) O 0 0.0005385795
, O 0 0.0004581314
219 O 0 0.000988482
] O 0 0.0009539375
but O 0 0.00024607164
information O 0 0.00018682264
regarding O 0 0.0001456534
the O 0 0.0002585679
proteome O 0 0.0005161475
is O 0 0.00044923986
still O 0 0.0007008019
lacking O 0 0.00094428874
. O 0 0.0030239508

In O 0 0.0019419341
the O 0 0.0014485519
present O 0 0.0009770669
study O 0 0.0010283205
, O 0 0.00092517765
we O 0 0.00024181377
investigated O 0 0.00030077487
the O 0 0.00023641041
changes O 0 0.00024974535
occurring O 0 0.00018864684
at O 0 0.00010510805
the O 0 0.00011397807
protein O 0 0.00015585167
level O 0 0.00015106067
in O 0 0.00021404095
striatal O 0 0.012308164
samples O 0 0.0001349894
obtained O 0 7.447252e-05
from O 0 7.9409816e-05
the O 0 9.393748e-05
unilaterally O 0 0.0011008884
6 B-Chemical 0 0.00011120257
- I-Chemical 0 0.0014801393
hydroxydopamine I-Chemical 0 0.32065278
- O 0 0.0017516793
lesion O 0 0.00042077873
rat O 0 0.00015452037
model O 0 9.306549e-05
of O 0 0.0002211284
PD B-Disease 0 0.9988135
treated O 0 0.0003820549
with O 0 0.00020557357
saline O 0 0.001953455
, O 0 0.0013117709
L B-Chemical 0 0.9994821
- I-Chemical 0 0.975474
DOPA I-Chemical 0 0.99999464
or O 0 0.00054108177
bromocriptine B-Chemical 0 0.9999814
using O 0 0.00012709394
two O 0 9.89172e-05
- O 0 0.0006348417
dimensional O 0 0.0002554469
difference O 0 0.0002099129
gel O 0 0.0023458402
electrophoresis O 0 0.0018875657
and O 0 0.00036835694
mass O 0 0.00073875405
spectrometry O 0 0.0012365722
( O 0 0.0020573195
MS O 0 0.8951859
) O 0 0.0046067964
. O 0 0.0034591767

Rats O 0 0.009016717
treated O 0 0.005441272
with O 0 0.004445526
L B-Chemical 0 0.9981382
- I-Chemical 0 0.975311
DOPA I-Chemical 0 0.9999565
were O 0 0.00062099664
allocated O 0 0.00038426113
to O 0 0.00019281564
two O 0 0.00014367166
groups O 0 0.00027422007
based O 0 0.00020636049
on O 0 0.00018861373
the O 0 0.00027047787
presence O 0 0.00040453242
or O 0 0.0005201128
absence O 0 0.00073886174
of O 0 0.002930448
LID B-Disease 0 0.9988325
. O 0 0.005089355

Among O 0 0.0038206321
the O 0 0.0019369943
2000 O 0 0.0022634012
spots O 0 0.0010736919
compared O 0 0.00043834944
for O 0 0.00035615923
statistical O 0 0.00058947306
difference O 0 0.00032356416
, O 0 0.00061001565
67 O 0 0.00051198766
spots O 0 0.0002886703
were O 0 0.00017161867
significantly O 0 0.00020610998
changed O 0 0.00018246383
in O 0 0.00013178198
abundance O 0 0.00010767578
and O 0 0.00013986982
identified O 0 9.4712996e-05
using O 0 0.00013467892
matrix O 0 0.0008563118
- O 0 0.001163623
assisted O 0 0.00033703313
laser O 0 0.0010686945
desorption O 0 0.0028902735
/ O 0 0.0008047275
ionization O 0 0.00047958308
time O 0 0.000116493786
- O 0 0.00076862023
of O 0 0.000249564
- O 0 0.0018308426
flight O 0 0.00061395625
MS O 0 0.94205236
, O 0 0.0005822617
atmospheric O 0 0.024828093
pressure O 0 0.005580026
matrix O 0 0.0012753024
- O 0 0.0011620148
assisted O 0 0.00037221285
laser O 0 0.0011865755
desorption O 0 0.003587413
/ O 0 0.0012545766
ionization O 0 0.00096735166
and O 0 0.00034264376
HPLC O 0 0.036190186
coupled O 0 0.00035070124
tandem O 0 0.000438742
MS O 0 0.82299685
( O 0 0.0014724741
LC O 0 0.05653847
/ O 0 0.013423296
MS O 0 0.9915378
/ O 0 0.045794938
MS O 0 0.9878748
) O 0 0.0061206077
. O 0 0.0038609128

Out O 0 0.0072374223
of O 0 0.0027568566
these O 0 0.0016503092
67 O 0 0.0021831775
proteins O 0 0.0011063985
, O 0 0.0038668555
LID B-Disease 0 0.9994628
significantly O 0 0.0007569247
changed O 0 0.00037162128
the O 0 0.000184368
expression O 0 0.00015659783
level O 0 0.00014474186
of O 0 0.00016653349
five O 0 9.485002e-05
proteins O 0 0.00016412442
: O 0 0.0005105521
alphabeta O 0 0.003089351
- O 0 0.0019888075
crystalin O 0 0.00054021314
, O 0 0.0008425051
gamma O 0 0.3742579
- O 0 0.13106272
enolase O 0 0.41614935
, O 0 0.0018188164
guanidoacetate O 0 0.6966051
methyltransferase O 0 0.0031759732
, O 0 0.0012060716
vinculin O 0 0.0052339607
, O 0 0.0010804429
and O 0 0.00069884746
proteasome O 0 0.006239884
alpha O 0 0.8950722
- O 0 0.017917586
2 O 0 0.0014100509
subunit O 0 0.0023725496
. O 0 0.0036290388

Complementary O 0 0.002664139
techniques O 0 0.0016199359
such O 0 0.0011030029
as O 0 0.0009518425
western O 0 0.0010386024
immunoblotting O 0 0.00039592225
and O 0 0.000405517
immunohistochemistry O 0 0.0003382007
were O 0 0.00018356775
performed O 0 0.00013525832
to O 0 0.00010545289
investigate O 0 6.228341e-05
the O 0 0.00012245137
validity O 0 0.00024259338
of O 0 0.00021685458
the O 0 0.00019398735
data O 0 0.0002778354
obtained O 0 0.00022666571
using O 0 0.00028652584
the O 0 0.00045854234
proteomic O 0 0.0011927123
approach O 0 0.00158208
. O 0 0.002950093

In O 0 0.002068032
conclusion O 0 0.0015329111
, O 0 0.0025458774
this O 0 0.0011006383
study O 0 0.00076652033
provides O 0 0.00032047727
new O 0 0.00048689175
insights O 0 0.00039179856
into O 0 0.00030593522
the O 0 0.00042128164
protein O 0 0.0006479924
changes O 0 0.0008982996
occurring O 0 0.0012166665
in O 0 0.002012081
LID B-Disease 0 0.9970931
. O 0 0.0046764393

Cardiac O 0 0.010285127
Angiography O 0 0.004576744
in O 0 0.0014923214
Renally O 0 0.007028555
Impaired O 0 0.0045557464
Patients O 0 0.0008463249
( O 0 0.0007523821
CARE O 0 0.0014330988
) O 0 0.00069953647
study O 0 0.00032058332
: O 0 0.00046519312
a O 0 0.00032422616
randomized O 0 0.00049873476
double O 0 0.00021100233
- O 0 0.0016732934
blind O 0 0.0055096946
trial O 0 0.00035596505
of O 0 0.00020254424
contrast O 0 0.00040346984
- O 0 0.004182601
induced O 0 0.000510034
nephropathy B-Disease 0 0.99999344
in O 0 0.00048276113
patients O 0 0.0009036642
with O 0 0.00055805425
chronic B-Disease 0 0.53172
kidney I-Disease 0 0.70410675
disease I-Disease 0 0.96983474
. O 0 0.0032201845

BACKGROUND O 0 0.014953707
: O 0 0.0037423936
No O 0 0.001228611
direct O 0 0.00046719355
comparisons O 0 0.00043702454
exist O 0 0.0002996803
of O 0 0.00030328723
the O 0 0.000239191
renal O 0 0.079316325
tolerability O 0 0.00046642573
of O 0 0.00014325316
the O 0 0.00011414861
low O 0 0.00028090592
- O 0 0.0031339824
osmolality O 0 0.093744114
contrast B-Chemical 0 0.00042287697
medium I-Chemical 0 0.007605419
iopamidol B-Chemical 1 0.99923384
with O 0 0.00016884487
that O 0 9.1826405e-05
of O 0 0.00016416104
the O 0 0.00020810141
iso O 0 0.9391216
- O 0 0.024359342
osmolality O 0 0.19401513
contrast B-Chemical 0 0.0005106143
medium I-Chemical 0 0.006865179
iodixanol B-Chemical 1 0.99822146
in O 0 0.00036731284
high O 0 0.0007221368
- O 0 0.0054410757
risk O 0 0.007089698
patients O 0 0.0034494163
. O 0 0.002767631

METHODS O 0 0.0033796642
AND O 0 0.0014423006
RESULTS O 0 0.0013420659
: O 0 0.0010870409
The O 0 0.0003104906
present O 0 0.00033250218
study O 0 0.00042153586
is O 0 0.0002803943
a O 0 0.00052034965
multicenter O 0 0.022803817
, O 0 0.0005747018
randomized O 0 0.0006660767
, O 0 0.00032355398
double O 0 0.00018201812
- O 0 0.001479337
blind O 0 0.0028104284
comparison O 0 0.000109646084
of O 0 0.00018599807
iopamidol B-Chemical 1 0.9987357
and O 0 0.00022237161
iodixanol B-Chemical 1 0.99641305
in O 0 0.000113470225
patients O 0 0.00022675649
with O 0 0.00014512244
chronic B-Disease 0 0.2615878
kidney I-Disease 0 0.5020464
disease I-Disease 0 0.953635
( O 0 0.0003960593
estimated O 0 0.00021482892
glomerular O 0 0.9951015
filtration O 0 0.026594555
rate O 0 0.00024275071
, O 0 0.00023514792
20 O 0 0.00011725004
to O 0 9.383659e-05
59 O 0 0.00021559226
mL O 0 0.0008900469
/ O 0 0.00062506896
min O 0 0.00026782707
) O 0 0.00031224109
who O 0 0.0001736431
underwent O 0 0.00016562828
cardiac O 0 0.00040481845
angiography O 0 0.0007172351
or O 0 0.00021685935
percutaneous O 0 0.00060798175
coronary O 0 0.0047838665
interventions O 0 0.00097525335
. O 0 0.0021646752

Serum O 0 0.7922087
creatinine B-Chemical 0 0.99322164
( O 0 0.0057939063
SCr O 0 0.10805204
) O 0 0.0017409133
levels O 0 0.00048771926
and O 0 0.000517416
estimated O 0 0.00060935545
glomerular O 0 0.9582493
filtration O 0 0.007875447
rate O 0 0.00032670386
were O 0 0.00013652442
assessed O 0 0.000117127565
at O 0 9.4884585e-05
baseline O 0 0.00012816708
and O 0 0.00016542342
2 O 0 0.00018110147
to O 0 0.00013546832
5 O 0 0.00015691994
days O 0 0.00012380081
after O 0 0.00018400233
receiving O 0 0.00063137553
medications O 0 0.0036399984
. O 0 0.0026552684

The O 0 0.0018774986
primary O 0 0.001481017
outcome O 0 0.0013239533
was O 0 0.00075931597
a O 0 0.000953787
postdose O 0 0.002349935
SCr O 0 0.0076688644
increase O 0 0.00029029365
> O 0 0.0005370657
or O 0 0.00024993357
= O 0 0.00063939096
0 O 0 0.00031203817
. O 0 0.00021239548
5 O 0 0.00022922723
mg O 0 0.0016624603
/ O 0 0.0013699926
dL O 0 0.006201145
( O 0 0.00065768877
44 O 0 0.00048077633
. O 0 0.0003467868
2 O 0 0.0005140158
micromol O 0 0.0073711756
/ O 0 0.0034567006
L O 0 0.31649652
) O 0 0.002338679
over O 0 0.00093600986
baseline O 0 0.0015422805
. O 0 0.0031639873

Secondary O 0 0.0030910494
outcomes O 0 0.0018677714
were O 0 0.001120379
a O 0 0.0013201116
postdose O 0 0.0027341219
SCr O 0 0.007276019
increase O 0 0.00036049756
> O 0 0.00061969744
or O 0 0.0002813868
= O 0 0.0007007449
25 O 0 0.0003562774
% O 0 0.00044226166
, O 0 0.00037616654
a O 0 0.000327913
postdose O 0 0.0008181565
estimated O 0 0.00025065616
glomerular O 0 0.9213188
filtration O 0 0.0046532652
rate O 0 0.00024236867
decrease O 0 0.00016073805
of O 0 0.00017202545
> O 0 0.0003996203
or O 0 0.00017454551
= O 0 0.0005666067
25 O 0 0.00028362556
% O 0 0.0003847644
, O 0 0.00034748873
and O 0 0.0002238821
the O 0 0.00020617952
mean O 0 0.00027593633
peak O 0 0.0005316693
change O 0 0.0006200773
in O 0 0.0011398233
SCr O 0 0.21703702
. O 0 0.0034396707

In O 0 0.0029317178
414 O 0 0.008740454
patients O 0 0.0030146055
, O 0 0.0018713332
contrast O 0 0.0011032062
volume O 0 0.0012401982
, O 0 0.00094336306
presence O 0 0.00043757545
of O 0 0.0008072893
diabetes B-Disease 0 0.9999224
mellitus I-Disease 0 0.9999727
, O 0 0.0010422223
use O 0 0.0002444968
of O 0 0.00050975726
N B-Chemical 0 0.9998716
- I-Chemical 0 0.37607744
acetylcysteine I-Chemical 0 0.9998399
, O 0 0.0003027655
mean O 0 9.3873365e-05
baseline O 0 0.00012846074
SCr O 0 0.013446182
, O 0 0.0002508479
and O 0 0.00016493202
estimated O 0 0.00026890758
glomerular O 0 0.98357004
filtration O 0 0.012181951
rate O 0 0.00032240764
were O 0 0.00017720615
comparable O 0 0.0001576395
in O 0 0.00029327438
the O 0 0.00042751056
2 O 0 0.0008736682
groups O 0 0.0015637483
. O 0 0.0027846668

SCr O 0 0.16939662
increases O 0 0.0025383278
> O 0 0.0030010429
or O 0 0.0010887727
= O 0 0.0018745627
0 O 0 0.0007622285
. O 0 0.00044960098
5 O 0 0.00040273296
mg O 0 0.0026863685
/ O 0 0.0018764632
dL O 0 0.0075017717
occurred O 0 0.00031486817
in O 0 0.00022549438
4 O 0 0.0001848464
. O 0 0.00017294366
4 O 0 0.00014564369
% O 0 0.00030991595
( O 0 0.00027107654
9 O 0 0.0001281446
of O 0 0.00016307177
204 O 0 0.00047423612
patients O 0 0.00031737197
) O 0 0.00031118613
after O 0 0.00010460879
iopamidol B-Chemical 1 0.97904074
and O 0 0.00017371567
6 O 0 0.000105724954
. O 0 0.00011393253
7 O 0 0.00010136899
% O 0 0.00023856717
( O 0 0.00022464113
14 O 0 0.00011714063
of O 0 0.00014729954
210 O 0 0.00042686614
patients O 0 0.00030559066
) O 0 0.00029311646
after O 0 0.000100645455
iodixanol B-Chemical 1 0.95993733
( O 0 0.00042871386
P O 0 0.011935322
= O 0 0.0005089439
0 O 0 0.00019429243
. O 0 0.00013031694
39 O 0 0.00020349876
) O 0 0.00037458632
, O 0 0.00027458215
whereas O 0 0.0001569837
rates O 0 0.0001977744
of O 0 0.0002526823
SCr O 0 0.13294351
increases O 0 0.00018218844
> O 0 0.00037390375
or O 0 0.00015750235
= O 0 0.0005018931
25 O 0 0.00023109207
% O 0 0.00027921278
were O 0 0.00012017727
9 O 0 0.00011514553
. O 0 0.00011852887
8 O 0 0.00012513486
% O 0 0.00025336284
and O 0 0.00016294057
12 O 0 0.00012753655
. O 0 0.00015424301
4 O 0 0.00016015912
% O 0 0.00039337567
, O 0 0.00046467877
respectively O 0 0.0005958198
( O 0 0.0008273989
P O 0 0.011127149
= O 0 0.0014765109
0 O 0 0.00085389346
. O 0 0.00084170135
44 O 0 0.0017783584
) O 0 0.0037902945
. O 0 0.0039404887

In O 0 0.0023046143
patients O 0 0.0037886563
with O 0 0.0026415507
diabetes B-Disease 0 0.9995365
, O 0 0.004294133
SCr O 0 0.2690966
increases O 0 0.00050443376
> O 0 0.00079118466
or O 0 0.00029891304
= O 0 0.0007065153
0 O 0 0.00030884997
. O 0 0.00019726832
5 O 0 0.00020167185
mg O 0 0.001564146
/ O 0 0.0011766404
dL O 0 0.0047692666
were O 0 0.00020724979
5 O 0 0.00017704083
. O 0 0.00016458766
1 O 0 0.00018761861
% O 0 0.00031111817
( O 0 0.00026491162
4 O 0 0.000116840216
of O 0 0.00015082447
78 O 0 0.00030137852
patients O 0 0.00032411123
) O 0 0.00036967683
with O 0 0.0002467793
iopamidol B-Chemical 1 0.99795425
and O 0 0.00021800496
13 O 0 0.00018875803
. O 0 0.0001341107
0 O 0 0.00018013737
% O 0 0.0002679854
( O 0 0.00022354271
12 O 0 8.582951e-05
of O 0 0.00012636332
92 O 0 0.00027749472
patients O 0 0.0003008824
) O 0 0.0003340164
with O 0 0.0002254363
iodixanol B-Chemical 1 0.9957799
( O 0 0.0005177714
P O 0 0.023024492
= O 0 0.00054078654
0 O 0 0.00019802424
. O 0 0.00013152628
11 O 0 0.000160987
) O 0 0.00034046065
, O 0 0.000295308
whereas O 0 0.00022102344
SCr O 0 0.0573471
increases O 0 0.00018328808
> O 0 0.0003811331
or O 0 0.00016433456
= O 0 0.0005179297
25 O 0 0.00024175821
% O 0 0.00029625974
were O 0 0.00013269555
10 O 0 0.00014294834
. O 0 0.00012539417
3 O 0 0.00012093021
% O 0 0.00026363414
and O 0 0.00017844561
15 O 0 0.00017849478
. O 0 0.00017676991
2 O 0 0.00022426192
% O 0 0.00042322738
, O 0 0.00048364548
respectively O 0 0.0006139293
( O 0 0.0008488799
P O 0 0.011666483
= O 0 0.0015418483
0 O 0 0.0009058559
. O 0 0.0009188302
37 O 0 0.0023900021
) O 0 0.0042042555
. O 0 0.004153878

Mean O 0 0.0022744809
post O 0 0.0019123425
- O 0 0.0064427066
SCr O 0 0.025274146
increases O 0 0.00061397196
were O 0 0.00038748796
significantly O 0 0.00037978386
less O 0 0.00041495368
with O 0 0.00044523683
iopamidol B-Chemical 1 0.99765235
( O 0 0.0005476632
all O 0 0.00019600913
patients O 0 0.0003777737
: O 0 0.00037346367
0 O 0 0.00023401798
. O 0 0.0001634993
07 O 0 0.00045642487
versus O 0 0.00013040619
0 O 0 0.00018466778
. O 0 0.0001329197
12 O 0 0.00012129411
mg O 0 0.0012130268
/ O 0 0.0010771173
dL O 0 0.006800047
, O 0 0.00038767012
6 O 0 0.00013807767
. O 0 0.00014046046
2 O 0 0.00013919684
versus O 0 0.00011875943
10 O 0 0.00014747803
. O 0 0.00014311487
6 O 0 0.00015396441
micromol O 0 0.003166539
/ O 0 0.0016080077
L O 0 0.31118315
, O 0 0.00082025054
P O 0 0.038516622
= O 0 0.0007852135
0 O 0 0.00028566684
. O 0 0.00021124007
03 O 0 0.0014037645
; O 0 0.0004033658
patients O 0 0.00036696615
with O 0 0.00033455627
diabetes B-Disease 0 0.99970514
: O 0 0.00094178243
0 O 0 0.00029326463
. O 0 0.00016595237
07 O 0 0.00045541747
versus O 0 0.00012041586
0 O 0 0.00017508172
. O 0 0.00013293872
16 O 0 0.00019112854
mg O 0 0.0017861623
/ O 0 0.0011941832
dL O 0 0.007938888
, O 0 0.00038882488
6 O 0 0.00014061895
. O 0 0.00014615704
2 O 0 0.00015049592
versus O 0 0.00013304473
14 O 0 0.000175138
. O 0 0.00021540794
1 O 0 0.00035612597
micromol O 0 0.0054534553
/ O 0 0.0024917973
L O 0 0.33569974
, O 0 0.0016177002
P O 0 0.04210064
= O 0 0.0019243372
0 O 0 0.0010678966
. O 0 0.0011227877
01 O 0 0.0056706923
) O 0 0.004616206
. O 0 0.004452081

CONCLUSIONS O 0 0.018843953
: O 0 0.0038684905
The O 0 0.0007908801
rate O 0 0.0010170131
of O 0 0.00072512554
contrast O 0 0.0010155874
- O 0 0.005702059
induced O 0 0.0009172335
nephropathy B-Disease 0 0.9999914
, O 0 0.001109008
defined O 0 0.00017408343
by O 0 0.00012415655
multiple O 0 9.68186e-05
end O 0 6.496365e-05
points O 0 0.00012682541
, O 0 0.00025288473
is O 0 9.085099e-05
not O 0 8.183539e-05
statistically O 0 0.00011911828
different O 0 4.4761164e-05
after O 0 3.1678326e-05
the O 0 4.972174e-05
intraarterial O 0 0.0012158944
administration O 0 0.00012262944
of O 0 0.00011530463
iopamidol B-Chemical 1 0.9957119
or O 0 0.00013550385
iodixanol B-Chemical 1 0.98741597
to O 0 0.000107674765
high O 0 0.00023247236
- O 0 0.0024000441
risk O 0 0.002003093
patients O 0 0.00057833345
, O 0 0.0004080744
with O 0 0.00031390123
or O 0 0.00041080898
without O 0 0.0013277193
diabetes B-Disease 0 0.99990654
mellitus I-Disease 0 0.99994624
. O 0 0.0068253637

Any O 0 0.0042574084
true O 0 0.0021457798
difference O 0 0.00090900925
between O 0 0.0006443209
the O 0 0.00059802894
agents O 0 0.0012802812
is O 0 0.0004832501
small O 0 0.0007778384
and O 0 0.0005571733
not O 0 0.00042577094
likely O 0 0.00033226103
to O 0 0.000506347
be O 0 0.0007851447
clinically O 0 0.0026912712
significant O 0 0.0017799166
. O 0 0.0033608463

A O 0 0.028405273
novel O 0 0.003350194
compound O 0 0.011680172
, O 0 0.0032105318
maltolyl B-Chemical 0 0.00867857
p I-Chemical 0 0.0033396897
- I-Chemical 0 0.05427863
coumarate I-Chemical 0 0.56783503
, O 0 0.0017630047
attenuates O 0 0.003414054
cognitive B-Disease 2 0.9997962
deficits I-Disease 2 0.99796486
and O 0 0.0002751222
shows O 0 8.722025e-05
neuroprotective O 0 0.00093331194
effects O 0 0.00017063326
in O 0 0.0001923476
vitro O 0 0.00023809816
and O 0 0.0003105578
in O 0 0.00039936745
vivo O 0 0.0010311165
dementia B-Disease 0 0.9998721
models O 0 0.0020627566
. O 0 0.003120823

To O 0 0.001452892
develop O 0 0.0016974404
a O 0 0.001350659
novel O 0 0.0006482638
and O 0 0.0005821444
effective O 0 0.00047196329
drug O 0 0.0039625526
that O 0 0.00020325907
could O 0 0.00015226066
enhance O 0 0.00017692438
cognitive O 0 0.6072567
function O 0 0.00017625875
and O 0 0.00022081721
neuroprotection O 0 0.0025024905
, O 0 0.00028450412
we O 0 8.12473e-05
newly O 0 0.00026463796
synthesized O 0 0.00025768095
maltolyl B-Chemical 0 0.0043988824
p I-Chemical 0 0.0012199548
- I-Chemical 0 0.020907141
coumarate I-Chemical 0 0.28866822
by O 0 0.0003711191
the O 0 0.00041160593
esterification O 0 0.98489136
of O 0 0.0016988647
maltol B-Chemical 0 0.9999726
and O 0 0.0014874558
p B-Chemical 0 0.00691308
- I-Chemical 0 0.5534289
coumaric I-Chemical 0 0.9998958
acid I-Chemical 0 0.99738425
. O 0 0.009940046

In O 0 0.0020040274
the O 0 0.0015040395
present O 0 0.0010201534
study O 0 0.0010684223
, O 0 0.00093952485
we O 0 0.0002412121
investigated O 0 0.00026868843
whether O 0 0.0001465556
maltolyl B-Chemical 0 0.003136043
p I-Chemical 0 0.0014926746
- I-Chemical 0 0.023603018
coumarate I-Chemical 0 0.14928927
could O 0 0.00014685497
improve O 0 0.00015089108
cognitive B-Disease 0 0.87079567
decline I-Disease 0 0.0010050922
in O 0 0.00035201703
scopolamine B-Chemical 0 0.999998
- O 0 0.003426354
injected O 0 0.000107457396
rats O 0 0.00018896026
and O 0 0.00016201723
in O 0 0.0002496987
amyloid B-Chemical 0 0.83760077
beta I-Chemical 0 0.5925226
peptide I-Chemical 0 0.0003448884
( I-Chemical 0 0.0006380952
1 I-Chemical 0 0.00039229527
- I-Chemical 0 0.0012631748
42 I-Chemical 0 0.00052489474
) I-Chemical 0 0.0011017092
- O 0 0.0025150487
infused O 0 0.002898711
rats O 0 0.0024142172
. O 0 0.0029423046

Maltolyl B-Chemical 0 0.016293868
p I-Chemical 0 0.009763003
- I-Chemical 0 0.13625269
coumarate I-Chemical 0 0.48656166
was O 0 0.00093380344
found O 0 0.00053847
to O 0 0.00038107787
attenuate O 0 0.0008962247
cognitive B-Disease 2 0.99965227
deficits I-Disease 2 0.9969897
in O 0 0.00020973044
both O 0 0.00011389266
rat O 0 0.00014703529
models O 0 7.621403e-05
using O 0 6.474607e-05
passive O 0 0.00011805297
avoidance O 0 0.0002921481
test O 0 0.0001701775
and O 0 0.00012401173
to O 0 9.7689226e-05
reduce O 0 0.000101133795
apoptotic O 0 0.014786485
cell O 0 0.0008719266
death O 0 0.90700656
observed O 0 0.00015364135
in O 0 0.00012949185
the O 0 0.00012466217
hippocampus O 0 0.0014207371
of O 0 0.00020355657
the O 0 0.00024817308
amyloid B-Chemical 0 0.91798156
beta I-Chemical 0 0.68798417
peptide I-Chemical 0 0.00033133454
( I-Chemical 0 0.00061122904
1 I-Chemical 0 0.0003737003
- I-Chemical 0 0.0012202715
42 I-Chemical 0 0.0005038833
) I-Chemical 0 0.0010658873
- O 0 0.0024575884
infused O 0 0.0028412002
rats O 0 0.0023640415
. O 0 0.0028851316

We O 0 0.002497015
also O 0 0.001496887
examined O 0 0.0009138402
the O 0 0.00076488254
neuroprotective O 0 0.002470192
effects O 0 0.00052587944
of O 0 0.0006638649
maltolyl B-Chemical 0 0.007101476
p I-Chemical 0 0.0021217968
- I-Chemical 0 0.020614639
coumarate I-Chemical 0 0.2173225
in O 0 0.0005761928
vitro O 0 0.0006749202
using O 0 0.0009844908
SH O 0 0.99948835
- O 0 0.3022691
SY5Y O 0 0.9974275
cells O 0 0.004825562
. O 0 0.0049252207

Cells O 0 0.007895944
were O 0 0.0024322856
pretreated O 0 0.004107412
with O 0 0.00137362
maltolyl B-Chemical 0 0.00654506
p I-Chemical 0 0.002845115
- I-Chemical 0 0.028528024
coumarate I-Chemical 0 0.29338628
, O 0 0.00093040423
before O 0 0.00021038216
exposed O 0 0.00041766837
to O 0 0.0004437338
amyloid B-Chemical 0 0.8377263
beta I-Chemical 0 0.58487105
peptide I-Chemical 0 0.00047177888
( I-Chemical 0 0.00081801624
1 I-Chemical 0 0.00050404086
- I-Chemical 0 0.0017563491
42 I-Chemical 0 0.0007148958
) I-Chemical 0 0.0017861879
, O 0 0.0032605785
glutamate B-Chemical 0 0.9991301
or O 0 0.0047942135
H2O2 B-Chemical 0 0.99959046
. O 0 0.0074321213

We O 0 0.0027956234
found O 0 0.0019206117
that O 0 0.0012488824
maltolyl B-Chemical 0 0.00676173
p I-Chemical 0 0.0037988992
- I-Chemical 0 0.0726614
coumarate I-Chemical 0 0.5243695
significantly O 0 0.0010281571
decreased O 0 0.0014739737
apoptotic O 0 0.04848588
cell O 0 0.001669534
death O 0 0.95544803
and O 0 0.00068849843
reduced O 0 0.0014171278
reactive O 0 0.9749039
oxygen O 1 0.9999522
species O 0 0.0022134737
, O 0 0.0030830824
cytochrome O 0 0.99882823
c O 0 0.08864251
release O 0 0.0018707702
, O 0 0.0010066853
and O 0 0.0007232495
caspase O 0 0.011442029
3 O 0 0.00092071266
activation O 0 0.0013211789
. O 0 0.0025176709

Taking O 0 0.0022789768
these O 0 0.0015655616
in O 0 0.0010727798
vitro O 0 0.0007724465
and O 0 0.0005901755
in O 0 0.00036498875
vivo O 0 0.00028725175
results O 0 0.00021433012
together O 0 0.00024433577
, O 0 0.00042000448
our O 0 0.00018261524
study O 0 0.00020266943
suggests O 0 9.54931e-05
that O 0 0.00013356395
maltolyl B-Chemical 0 0.002623994
p I-Chemical 0 0.0012161135
- I-Chemical 0 0.03537859
coumarate I-Chemical 0 0.31461588
is O 0 0.00014541582
a O 0 0.00017539668
potentially O 0 9.274638e-05
effective O 0 7.793834e-05
candidate O 0 7.013037e-05
against O 0 0.00012017566
Alzheimer B-Disease 0 0.9999716
' I-Disease 0 0.00086735765
s I-Disease 0 0.00046966568
disease I-Disease 0 0.18824705
that O 0 9.4408046e-05
is O 0 0.000100483485
characterized O 0 0.0001810155
by O 0 0.00014454062
wide O 0 0.00034494096
spread O 0 0.0005511204
neuronal B-Disease 0 0.0219797
death I-Disease 0 0.99209774
and O 0 0.00039924623
progressive O 0 0.0037358105
decline B-Disease 0 0.0010563034
of I-Disease 0 0.0007351566
cognitive I-Disease 0 0.863045
function I-Disease 0 0.0013715809
. O 0 0.0025428107

Attenuation O 0 0.010626671
of O 0 0.006040129
methamphetamine B-Chemical 1 0.9999043
- O 0 0.24535431
induced O 0 0.0021297326
nigrostriatal O 0 0.87894666
dopaminergic O 0 0.086053714
neurotoxicity B-Disease 0 0.98991853
in O 0 0.00057358656
mice O 0 0.00032980446
by O 0 0.0013049989
lipopolysaccharide B-Chemical 0 0.99940586
pretreatment O 0 0.16449377
. O 0 0.005096874

Immunological O 0 0.011852406
activation O 0 0.0020687722
has O 0 0.00092548184
been O 0 0.0007291899
proposed O 0 0.00049072824
to O 0 0.00037847838
play O 0 0.00029137867
a O 0 0.0004582749
role O 0 0.00022740041
in O 0 0.0007129642
methamphetamine B-Chemical 1 0.99993396
- O 0 0.051844906
induced O 0 0.0011203992
dopaminergic B-Disease 0 0.18190527
terminal I-Disease 0 0.0039854203
damage I-Disease 0 0.54282504
. O 0 0.0041871998

In O 0 0.0021598397
this O 0 0.002006013
study O 0 0.0015168706
, O 0 0.0012371672
we O 0 0.00031274583
examined O 0 0.00029987041
the O 0 0.00025235247
roles O 0 0.00020004551
of O 0 0.0006672795
lipopolysaccharide B-Chemical 0 0.9997501
, O 0 0.0011071865
a O 0 0.00057530164
pro O 0 0.0024089955
- O 0 0.0069191554
inflammatory O 0 0.009788141
and O 0 0.00026664563
inflammatory O 0 0.026855092
factor O 0 0.0024889256
, O 0 0.00033638388
treatment O 0 0.00013853768
in O 0 0.00011478967
modulating O 0 9.405086e-05
the O 0 0.00029847363
methamphetamine B-Chemical 1 0.9999722
- O 0 0.12629746
induced O 0 0.0011503444
nigrostriatal O 0 0.9909514
dopamine B-Chemical 0 0.999881
neurotoxicity B-Disease 0 0.99910635
. O 0 0.0036218835

Lipopolysaccharide B-Chemical 0 0.99961567
pretreatment O 0 0.1798114
did O 0 0.0021522648
not O 0 0.0008600741
affect O 0 0.00047764048
the O 0 0.00043225219
basal O 0 0.0007924221
body O 0 0.0007052869
temperature O 0 0.001034185
or O 0 0.00048685484
methamphetamine B-Chemical 1 0.99989414
- O 0 0.0060716458
elicited O 0 0.0004538285
hyperthermia B-Disease 0 0.959478
three O 0 0.0002821925
days O 0 0.0004197687
later O 0 0.0010752486
. O 0 0.0024870557

Such O 0 0.0062027876
systemic O 0 0.8684195
lipopolysaccharide B-Chemical 0 0.99948174
treatment O 0 0.0020664483
mitigated O 0 0.016965456
methamphetamine B-Chemical 1 0.9999801
- O 0 0.29775345
induced O 0 0.00094313925
striatal O 0 0.8955521
dopamine B-Chemical 0 0.999762
and O 0 0.00029845058
3 B-Chemical 0 0.00020093135
, I-Chemical 0 0.00050322193
4 I-Chemical 0 0.0004951217
- I-Chemical 0 0.9218618
dihydroxyphenylacetic I-Chemical 0 0.99999964
acid I-Chemical 0 0.99529135
depletions O 0 0.010826259
in O 0 0.00032292807
a O 0 0.0005332276
dose O 0 0.00089644245
- O 0 0.0021274218
dependent O 0 0.0005789318
manner O 0 0.0013750807
. O 0 0.0029508627

As O 0 0.0019194868
the O 0 0.0014414155
most O 0 0.0013783606
potent O 0 0.0012651592
dose O 0 0.0013148298
( O 0 0.0009464523
1 O 0 0.00047965505
mg O 0 0.0023365293
/ O 0 0.0009980762
kg O 0 0.00074458
) O 0 0.0006578897
of O 0 0.00041032463
lipopolysaccharide B-Chemical 0 0.99954826
was O 0 0.00018208772
administered O 0 0.00014964835
two O 0 4.8326012e-05
weeks O 0 4.5884382e-05
, O 0 0.00012643418
one O 0 6.0237373e-05
day O 0 4.6025583e-05
before O 0 3.552524e-05
or O 0 5.6130284e-05
after O 0 4.1263364e-05
the O 0 8.7513356e-05
methamphetamine B-Chemical 1 0.9997049
dosing O 0 0.00018466549
regimen O 0 0.00014160796
, O 0 0.000448347
methamphetamine B-Chemical 1 0.9999747
- O 0 0.06461685
induced O 0 0.00039683483
striatal O 0 0.8838908
dopamine B-Chemical 0 0.999821
and O 0 0.00022974052
3 B-Chemical 0 0.00017515285
, I-Chemical 0 0.00048384097
4 I-Chemical 0 0.0004988986
- I-Chemical 0 0.8872864
dihydroxyphenylacetic I-Chemical 0 0.9999995
acid I-Chemical 0 0.99679863
depletions O 0 0.052166473
remained O 0 0.0016414828
unaltered O 0 0.001906623
. O 0 0.0028553293

Moreover O 0 0.0041631907
, O 0 0.007926321
systemic O 0 0.9501788
lipopolysaccharide B-Chemical 0 0.99976283
pretreatment O 0 0.05812067
( O 0 0.0013801566
1 O 0 0.000502898
mg O 0 0.0024800154
/ O 0 0.0008969008
kg O 0 0.0006141898
) O 0 0.00049206085
attenuated O 0 0.00029277126
local O 0 0.00036428726
methamphetamine B-Chemical 1 0.9999143
infusion O 0 0.0055921897
- O 0 0.003524922
produced O 0 0.00022966738
dopamine B-Chemical 0 0.99948406
and O 0 0.00019438693
3 B-Chemical 0 0.0001411531
, I-Chemical 0 0.00039372907
4 I-Chemical 0 0.00039495557
- I-Chemical 0 0.9645796
dihydroxyphenylacetic I-Chemical 0 0.9999999
acid I-Chemical 0 0.9976659
depletions O 0 0.017871305
in O 0 0.00014515096
the O 0 0.00011693317
striatum O 0 0.0017718558
, O 0 0.00017848951
indicating O 0 5.9469352e-05
that O 0 5.8036894e-05
the O 0 7.32735e-05
protective O 0 0.00017846773
effect O 0 0.00013000131
of O 0 0.00056939374
lipopolysaccharide B-Chemical 0 0.99996483
is O 0 0.00017475699
less O 0 0.00018845142
likely O 0 6.740391e-05
due O 0 7.4337775e-05
to O 0 0.0001068033
interrupted O 0 0.00029270956
peripheral O 0 0.00049733033
distribution O 0 0.00014323815
or O 0 0.00035987364
metabolism O 0 0.043386072
of O 0 0.0021134615
methamphetamine B-Chemical 1 0.9998783
. O 0 0.0042777415

We O 0 0.0023851956
concluded O 0 0.001669986
a O 0 0.0012441936
critical O 0 0.00040479298
time O 0 0.00028368857
window O 0 0.00037945004
for O 0 0.00036883884
systemic O 0 0.7819723
lipopolysaccharide B-Chemical 0 0.99989367
pretreatment O 0 0.012758755
in O 0 0.00021575595
exerting O 0 0.00034413722
effective O 0 0.0001773407
protection O 0 0.00024024466
against O 0 0.00022066338
methamphetamine B-Chemical 1 0.9999769
- O 0 0.22068113
induced O 0 0.0013787603
nigrostriatal O 0 0.9928712
dopamine B-Chemical 0 0.99988365
neurotoxicity B-Disease 0 0.9991093
. O 0 0.0037048105

Acute O 0 0.66195804
myocarditis B-Disease 0 0.99855083
associated O 0 0.010423757
with O 0 0.013743898
clozapine B-Chemical 0 0.99989295
. O 0 0.016716901

OBJECTIVE O 0 0.037887294
: O 0 0.0069117085
A O 0 0.011966628
case O 0 0.0012899548
of O 0 0.0010878693
acute O 0 0.39775383
myocarditis B-Disease 0 0.99987113
associated O 0 0.00044452757
with O 0 0.00022224146
the O 0 0.00013841911
commencement O 0 0.00016966987
of O 0 0.0003410901
clozapine B-Chemical 0 0.99999535
is O 0 0.00018590162
described O 0 0.00013474264
, O 0 0.00023061487
highlighting O 0 0.00010502499
the O 0 0.00016160402
onset O 0 0.00038305015
, O 0 0.00044209202
course O 0 0.00031805108
and O 0 0.00038123922
possible O 0 0.0004169002
contributing O 0 0.0011400317
factors O 0 0.002928828
. O 0 0.0034784754

There O 0 0.003947686
is O 0 0.0019264248
an O 0 0.0015191856
urgent O 0 0.0011559383
need O 0 0.00057356246
to O 0 0.0004395537
raise O 0 0.00038844178
awareness O 0 0.0009426542
about O 0 0.0005348468
this O 0 0.00046985646
potentially O 0 0.0005848695
fatal O 0 0.23708208
complication O 0 0.008413121
of O 0 0.0016774884
clozapine B-Chemical 0 0.99997973
use O 0 0.0022498467
. O 0 0.0031158382

RESULTS O 0 0.0060248096
: O 0 0.004999219
A O 0 0.0072836173
20 O 0 0.0015645855
- O 0 0.003061431
year O 0 0.00068818947
- O 0 0.0016836773
old O 0 0.0005486706
male O 0 0.00095611304
with O 0 0.00086019374
schizophrenia B-Disease 2 0.99997044
developed O 0 0.0006829238
a O 0 0.00060692575
sudden O 0 0.02588009
onset O 0 0.00065230345
of O 0 0.0005359031
myocarditis B-Disease 0 0.99954945
after O 0 0.00030518742
commencement O 0 0.00057649415
of O 0 0.0015650077
clozapine B-Chemical 0 0.9999641
. O 0 0.0044304403

The O 0 0.0037907572
patient O 0 0.0036779114
recovered O 0 0.0023594173
with O 0 0.002698612
intensive O 0 0.003658972
medical O 0 0.006806583
support O 0 0.0048208563
. O 0 0.008012963

The O 0 0.002535328
symptoms O 0 0.007065996
occurred O 0 0.0012137961
around O 0 0.0008316641
2 O 0 0.0005336071
weeks O 0 0.00023845756
after O 0 0.00025137322
starting O 0 0.0004909173
clozapine B-Chemical 0 0.9999305
in O 0 0.0008878244
an O 0 0.0010568928
inpatient O 0 0.0026075032
setting O 0 0.0017412315
. O 0 0.00321796

Possible O 0 0.0047397036
contributing O 0 0.0028010295
factors O 0 0.0024493318
may O 0 0.0009975757
have O 0 0.0007241501
been O 0 0.0007050386
concomitant O 0 0.0020236203
antidepressant B-Chemical 0 0.99957496
use O 0 0.00062824436
and O 0 0.0007678556
unaccustomed O 0 0.0019751592
physical O 0 0.0016583358
activity O 0 0.0014163014
. O 0 0.0033708103

CONCLUSIONS O 0 0.052251797
: O 0 0.011960828
Myocarditis B-Disease 0 0.9880654
is O 0 0.0010031402
an O 0 0.00077386777
increasingly O 0 0.0005774449
recognized O 0 0.00046361293
complication O 0 0.002046085
associated O 0 0.00049098255
with O 0 0.0004846012
the O 0 0.00047370273
use O 0 0.00075297133
of O 0 0.0023449142
clozapine B-Chemical 0 0.999967
. O 0 0.0056350133

It O 0 0.007915952
can O 0 0.0027853413
be O 0 0.0027347824
fatal O 0 0.12638326
if O 0 0.0010727083
not O 0 0.0011468934
recognized O 0 0.0012481938
and O 0 0.0017947168
treated O 0 0.0037593192
early O 0 0.0052825217
. O 0 0.0057133352

Considering O 0 0.0015663519
that O 0 0.0021157882
clozapine B-Chemical 0 0.99995553
remains O 0 0.00061482633
the O 0 0.00047445
gold O 0 0.101290785
standard O 0 0.0003116879
in O 0 0.00018917552
treatment O 0 0.00018358386
of O 0 0.00022716484
resistant O 0 0.00076593616
psychosis B-Disease 0 0.99997246
, O 0 0.00053974945
there O 0 0.0001213956
is O 0 0.00011164435
an O 0 0.00013293377
urgent O 0 0.00014634976
need O 0 8.116135e-05
to O 0 7.872558e-05
raise O 0 8.6237575e-05
awareness O 0 0.00032393454
among O 0 0.00019396073
medical O 0 0.00068951363
and O 0 0.00019468558
paramedical O 0 0.0017580304
staff O 0 0.000420658
involved O 0 0.00017981714
in O 0 0.00021259788
the O 0 0.00022929936
care O 0 0.0004321496
of O 0 0.0005687033
these O 0 0.00086703047
patients O 0 0.0026972662
. O 0 0.0026777748

There O 0 0.003326945
are O 0 0.0015159805
also O 0 0.0009801455
implications O 0 0.000809056
for O 0 0.00055807264
recommendations O 0 0.00066481275
and O 0 0.00056035444
regulations O 0 0.00067146856
regarding O 0 0.00036295905
the O 0 0.00057827437
use O 0 0.00093889225
of O 0 0.0028340786
clozapine B-Chemical 0 0.99995875
. O 0 0.0067108776

Severe O 0 0.7694173
rhabdomyolysis B-Disease 0 0.99979967
and O 0 0.0028331464
acute B-Disease 0 0.28156307
renal I-Disease 0 0.9350423
failure I-Disease 0 0.034916393
secondary O 0 0.0004633536
to O 0 0.00022601098
concomitant O 0 0.00041679948
use O 0 0.00024224991
of O 0 0.0006291995
simvastatin B-Chemical 1 0.9999881
, O 0 0.0107082445
amiodarone B-Chemical 0 0.9999496
, O 0 0.0021484133
and O 0 0.0015806285
atazanavir B-Chemical 0 0.99604475
. O 0 0.0031735303

OBJECTIVE O 0 0.01860156
: O 0 0.003336246
To O 0 0.00060216035
report O 0 0.0012912147
a O 0 0.0008764029
case O 0 0.00050603726
of O 0 0.0004165373
a O 0 0.0005198355
severe O 0 0.0009210492
interaction O 0 0.00016239617
between O 0 0.0002796617
simvastatin B-Chemical 1 0.99999213
, O 0 0.0054035718
amiodarone B-Chemical 0 0.99997807
, O 0 0.00066313654
and O 0 0.0003109738
atazanavir B-Chemical 0 0.9953088
resulting O 0 0.00022652095
in O 0 0.00038800543
rhabdomyolysis B-Disease 0 0.999933
and O 0 0.0007319555
acute B-Disease 0 0.20100632
renal I-Disease 0 0.9516229
failure I-Disease 0 0.13806374
. O 0 0.0027106905

BACKGROUND O 0 0.020846147
: O 0 0.0066102115
A O 0 0.010282981
72 O 0 0.0019589618
- O 0 0.003247275
year O 0 0.0006878896
- O 0 0.001757294
old O 0 0.00056325074
white O 0 0.00081695255
man O 0 0.0034333575
with O 0 0.00050486816
underlying O 0 0.0008656196
human B-Disease 0 0.0030587777
immunodeficiency I-Disease 0 0.9998934
virus I-Disease 0 0.022073101
, O 0 0.00067789096
atrial B-Disease 0 0.13811016
fibrillation I-Disease 0 0.99908686
, O 0 0.00042894259
coronary B-Disease 0 0.053045016
artery I-Disease 0 0.30641752
disease I-Disease 0 0.19204636
, O 0 0.0002889845
and O 0 0.00022043055
hyperlipidemia B-Disease 0 0.9999895
presented O 0 0.00016283653
with O 0 0.00017279532
generalized O 0 0.0018745316
pain B-Disease 0 0.12913354
, O 0 0.0006293092
fatigue B-Disease 0 0.9107705
, O 0 0.00047413647
and O 0 0.0002921456
dark O 0 0.00040906217
orange O 0 0.0029945269
urine O 0 0.028828569
for O 0 0.00041912158
3 O 0 0.0005919357
days O 0 0.0006714458
. O 0 0.0020783858

The O 0 0.0019708327
patient O 0 0.0017259645
was O 0 0.0009017122
taking O 0 0.00092975504
80 O 0 0.0011205599
mg O 0 0.12086318
simvastatin B-Chemical 1 0.99995315
at O 0 0.00039748393
bedtime O 0 0.5883352
( O 0 0.00041729744
initiated O 0 0.00015542249
27 O 0 0.0001733951
days O 0 7.8346246e-05
earlier O 0 0.00017138333
) O 0 0.00047635872
; O 0 0.00064615026
amiodarone B-Chemical 0 0.99982136
at O 0 0.00010567021
a O 0 0.00016089385
dose O 0 0.00018324808
of O 0 0.00012421637
400 O 0 0.00048938394
mg O 0 0.00214705
daily O 0 9.409707e-05
for O 0 4.6532405e-05
7 O 0 5.0719635e-05
days O 0 4.4160086e-05
, O 0 0.00012918845
then O 0 8.472939e-05
200 O 0 0.00023960325
mg O 0 0.0021966684
daily O 0 0.00013629317
( O 0 0.0001533445
initiated O 0 8.2441635e-05
19 O 0 0.00010707701
days O 0 5.3294283e-05
earlier O 0 0.00012540063
) O 0 0.00030829955
; O 0 0.0002538152
and O 0 0.000146096
400 O 0 0.00062385754
mg O 0 0.021633744
atazanavir B-Chemical 0 0.9858795
daily O 0 0.00021274896
( O 0 0.00023864977
initiated O 0 0.00014402896
at O 0 0.00014018679
least O 0 0.0002273529
2 O 0 0.00038906737
years O 0 0.0006078896
previously O 0 0.0009062773
) O 0 0.0030506775
. O 0 0.0030172323

Laboratory O 0 0.007911362
evaluation O 0 0.0023416658
revealed O 0 0.0015654184
66 O 0 0.0025210008
, O 0 0.0028026483
680 O 0 0.0097081745
U O 0 0.5343042
/ O 0 0.07706367
L O 0 0.99651957
creatine B-Chemical 1 0.9998982
kinase O 0 0.0034733848
, O 0 0.00088475517
93 O 0 0.0008744201
mg O 0 0.009122861
/ O 0 0.0034858948
dL O 0 0.36881846
blood B-Chemical 1 0.9391563
urea I-Chemical 1 0.99997187
nitrogen I-Chemical 1 0.9999218
, O 0 0.0009900931
4 O 0 0.00018705775
. O 0 0.00015032009
6 O 0 0.00013442733
mg O 0 0.0011827702
/ O 0 0.0012602131
dL O 0 0.04961519
creatinine B-Chemical 0 0.989687
, O 0 0.0013397536
1579 O 0 0.0672166
U O 0 0.7826169
/ O 0 0.20848113
L O 0 0.9991679
aspartate B-Chemical 1 0.9999629
aminotransferase O 0 0.99912804
, O 0 0.0013974013
and O 0 0.0007825107
738 O 0 0.00925591
U O 0 0.64125675
/ O 0 0.09955366
L O 0 0.9948212
alanine B-Chemical 0 0.9974458
aminotransferase O 0 0.99786144
. O 0 0.006039522

Simvastatin B-Chemical 0 0.99991286
, O 0 0.041032694
amiodarone B-Chemical 0 0.99989796
, O 0 0.0026953265
and O 0 0.0007112008
the O 0 0.00039653704
patient O 0 0.00045452037
' O 0 0.0007083667
s O 0 0.00070898153
human B-Disease 0 0.0014884865
immunodeficiency I-Disease 0 0.9997936
virus I-Disease 0 0.008238493
medications O 0 0.0044692163
were O 0 0.00011833857
all O 0 0.000104070416
temporarily O 0 0.00029255613
discontinued O 0 0.00048747874
and O 0 0.00011535214
the O 0 9.767954e-05
patient O 0 0.00015249444
was O 0 0.00011981362
given O 0 0.00012627947
forced O 0 0.0016143018
alkaline O 0 0.18709633
diuresis O 0 0.9950393
and O 0 0.0005171283
started O 0 0.0005379708
on O 0 0.0005557744
dialysis O 0 0.0027865584
. O 0 0.002550985

Nine O 0 0.003973332
days O 0 0.0013274981
later O 0 0.0010914599
the O 0 0.0008529458
patient O 0 0.0010467436
' O 0 0.001804092
s O 0 0.002605313
creatine B-Chemical 1 0.9997118
kinase O 0 0.0022030682
had O 0 0.00046745592
dropped O 0 0.0008300814
to O 0 0.0004342261
1695 O 0 0.047672953
U O 0 0.4656894
/ O 0 0.009669577
L O 0 0.8021447
and O 0 0.0008551034
creatinine B-Chemical 0 0.9881572
was O 0 0.00037642894
3 O 0 0.00030524997
. O 0 0.00036459105
3 O 0 0.0005187691
mg O 0 0.003782657
/ O 0 0.00443819
dL O 0 0.018687718
. O 0 0.0044171237

The O 0 0.0021771572
patient O 0 0.002049172
was O 0 0.0011305033
discharged O 0 0.001577881
and O 0 0.00051914953
continued O 0 0.00041006538
outpatient O 0 0.0006860017
dialysis O 0 0.0005907858
for O 0 0.00019658486
1 O 0 0.00026342185
month O 0 0.00015359343
until O 0 0.000199503
his O 0 0.0006167655
renal O 0 0.061650928
function O 0 0.0009893002
recovered O 0 0.0015950568
. O 0 0.0033070082

DISCUSSION O 0 0.006095072
: O 0 0.0032651313
The O 0 0.00086783664
risk O 0 0.0034469885
of O 0 0.0016668997
rhabdomyolysis B-Disease 0 0.9999112
is O 0 0.0004996772
increased O 0 0.00049166824
in O 0 0.00025241956
the O 0 0.00019245969
presence O 0 0.00021637068
of O 0 0.00031688128
concomitant O 0 0.0009191197
drugs O 0 0.023866324
that O 0 0.00047452102
inhibit O 0 0.0013397015
simvastatin B-Chemical 1 0.99998724
metabolism O 0 0.96178377
. O 0 0.004913505

Simvastatin B-Chemical 0 0.9996878
is O 0 0.017205583
metabolized O 0 0.88010645
by O 0 0.017419089
CYP3A4 O 0 0.9984647
. O 0 0.018922994

Amiodarone B-Chemical 1 0.9993573
and O 0 0.009246868
atazanavir B-Chemical 0 0.99580693
are O 0 0.0031187113
recognized O 0 0.004396398
CYP3A4 O 0 0.9987595
inhibitors O 0 0.012563019
. O 0 0.009087308

CONCLUSIONS O 0 0.019496158
: O 0 0.004883767
Pharmacokinetic O 0 0.0049697356
differences O 0 0.0006287618
in O 0 0.0007099122
statins B-Chemical 0 0.97693175
are O 0 0.00035115794
an O 0 0.00028023985
important O 0 0.00013473662
consideration O 0 0.00012494481
for O 0 0.00013182976
assessing O 0 0.00015819876
the O 0 0.00024290771
risk O 0 0.0012919588
of O 0 0.00053270685
potential O 0 0.0006611278
drug O 0 0.010366704
interactions O 0 0.0017642815
. O 0 0.0032716868

In O 0 0.0017741573
patients O 0 0.0022417756
requiring O 0 0.0007834616
the O 0 0.0004702001
concurrent O 0 0.00058053085
use O 0 0.00032338587
of O 0 0.00051781954
statins B-Chemical 0 0.9991072
and O 0 0.0014701412
CYP3A4 O 0 0.99994755
inhibitors O 0 0.0020958132
, O 0 0.004187518
pravastatin B-Chemical 0 0.9999975
, O 0 0.020110607
fluvastatin B-Chemical 0 0.99999774
, O 0 0.0011540591
and O 0 0.0003502048
rosuvastatin B-Chemical 0 0.9999901
carry O 0 0.000113634924
the O 0 8.058427e-05
lowest O 0 0.00015060489
risk O 0 0.0007736017
of O 0 0.00013877462
drug O 0 0.0033487708
interactions O 0 0.00013791464
; O 0 0.0009670467
atorvastatin B-Chemical 0 0.99999046
carries O 0 0.00017904521
moderate O 0 0.0012276623
risk O 0 0.006110302
, O 0 0.0004453761
whereas O 0 0.00036323702
simvastatin B-Chemical 1 0.99999774
and O 0 0.0013777154
lovastatin B-Chemical 1 0.9999958
have O 0 0.00015078377
the O 0 8.387213e-05
highest O 0 0.00013055687
risk O 0 0.0013383675
and O 0 0.00012794619
should O 0 6.135921e-05
be O 0 9.999494e-05
avoided O 0 0.00012938003
in O 0 0.0001663738
patients O 0 0.0005583812
taking O 0 0.0005978828
concomitant O 0 0.0043044817
CYP3A4 O 0 0.99981934
inhibitors O 0 0.0066032168
. O 0 0.0035653692

Interaction O 0 0.0064698644
between O 0 0.004306919
warfarin B-Chemical 0 0.9950944
and O 0 0.005972443
levofloxacin B-Chemical 1 0.99931633
: O 0 0.0064359885
case O 0 0.0033828926
series O 0 0.0048563406
. O 0 0.0065116966

Warfarin B-Chemical 0 0.9982792
is O 0 0.0018260123
the O 0 0.0009839587
most O 0 0.00088139233
widely O 0 0.00052770093
used O 0 0.0004809198
oral O 0 0.0030198537
anticoagulant O 0 0.5580244
and O 0 0.00038155043
is O 0 0.00024601415
indicated O 0 0.00021450144
for O 0 0.0003068738
many O 0 0.0004988021
clinical O 0 0.0018607714
conditions O 0 0.0016726641
. O 0 0.0031903244

Levofloxacin B-Chemical 0 0.9985519
, O 0 0.0059691016
a O 0 0.0036390491
fluoroquinolone B-Chemical 0 0.9989391
, O 0 0.0015440043
is O 0 0.00033282756
one O 0 0.0002285533
of O 0 0.00022421875
the O 0 0.0001561742
most O 0 0.00019738686
commonly O 0 0.0001850725
prescribed O 0 0.0006936434
antibiotics O 0 0.0031418996
in O 0 0.00011726111
clinical O 0 0.00037959134
practice O 0 0.00017294977
and O 0 0.00011959699
is O 0 9.192085e-05
effective O 0 0.00011686139
against O 0 0.00011140975
Gram O 0 0.0022177892
- O 0 0.0023150237
positive O 0 0.00040136796
, O 0 0.0010151941
Gram O 0 0.003815991
- O 0 0.0027561958
negative O 0 0.0005838875
, O 0 0.0012585561
and O 0 0.0011695158
atypical O 0 0.018797312
bacteria O 0 0.0072776587
. O 0 0.0041474015

While O 0 0.00227615
small O 0 0.0028950763
prospective O 0 0.004135635
studies O 0 0.0011079062
have O 0 0.0004980616
not O 0 0.00034094072
revealed O 0 0.0002400457
any O 0 0.00020421308
significant O 0 0.00024831647
drug O 0 0.0144678755
- O 0 0.002382848
drug O 0 0.0012151257
interaction O 0 8.442969e-05
between O 0 0.000120551435
warfarin B-Chemical 0 0.9989802
and O 0 0.0003119965
levofloxacin B-Chemical 1 0.9999484
, O 0 0.00024454203
several O 0 5.8746296e-05
case O 0 9.452948e-05
reports O 0 0.00010453371
have O 0 7.458147e-05
indicated O 0 7.075502e-05
that O 0 0.00014256977
levofloxacin B-Chemical 1 0.9999566
may O 0 0.00014912587
significantly O 0 0.0002101452
potentiate O 0 0.00023716333
the O 0 0.00020252743
anticoagulation O 0 0.0035175902
effect O 0 0.00038756224
of O 0 0.0013894199
warfarin B-Chemical 0 0.99901783
. O 0 0.003275885

We O 0 0.0028938525
report O 0 0.0029493507
3 O 0 0.0011829907
cases O 0 0.0013425727
of O 0 0.0008136472
serious O 0 0.0030169324
bleeding B-Disease 0 0.9743766
complications O 0 0.026540352
that O 0 0.00022633464
appear O 0 0.00019230488
to O 0 0.00015688421
be O 0 0.0001564817
the O 0 0.0001306114
result O 0 0.00014315732
of O 0 0.0001966876
the O 0 0.00017516738
interaction O 0 0.00022011617
between O 0 0.00046650466
warfarin B-Chemical 0 0.99871576
and O 0 0.0020741068
levofloxacin B-Chemical 1 0.99969447
. O 0 0.0036007192

Physicians O 0 0.004560869
should O 0 0.0011488688
be O 0 0.0010186567
aware O 0 0.00076675334
of O 0 0.00058969954
this O 0 0.00039255415
potential O 0 0.00022793654
interaction O 0 0.00019548877
and O 0 0.0002336648
use O 0 0.00018386045
caution O 0 0.00026118485
when O 0 0.00017308835
prescribing O 0 0.002340815
levofloxacin B-Chemical 1 0.9997669
to O 0 0.00039521503
patients O 0 0.0011491042
taking O 0 0.0014976321
warfarin B-Chemical 0 0.99631435
. O 0 0.003180114

Mutations O 0 0.0039181127
associated O 0 0.002330945
with O 0 0.0026504868
lamivudine B-Chemical 0 0.9998287
- O 0 0.009082312
resistance O 0 0.0013561175
in O 0 0.0004501297
therapy O 0 0.0010178487
- O 0 0.041282535
na B-Chemical 0 0.999969
ve O 0 0.99918526
hepatitis B-Disease 2 0.99999845
B I-Disease 2 0.99967897
virus I-Disease 0 0.05639508
( I-Disease 0 0.0019143425
HBV I-Disease 0 0.6028175
) I-Disease 0 0.0007010414
infected I-Disease 0 0.00016029403
patients O 0 0.00028212176
with O 0 0.00013597902
and O 0 0.00016165427
without O 0 0.00024566584
HIV B-Disease 0 0.23684712
co I-Disease 0 0.20233734
- I-Disease 0 0.014797144
infection I-Disease 0 0.0011437561
: O 0 0.00025212998
implications O 0 9.652139e-05
for O 0 8.617707e-05
antiretroviral O 0 0.00044277104
therapy O 0 0.00020638939
in O 0 0.0001831225
HBV B-Disease 0 0.24388795
and I-Disease 0 0.00051472447
HIV I-Disease 0 0.18400544
co I-Disease 0 0.10116502
- I-Disease 0 0.005382341
infected I-Disease 0 0.00062170386
South O 0 0.0015960154
African O 0 0.0024074155
patients O 0 0.0029025492
. O 0 0.002741479

This O 0 0.0049189897
was O 0 0.0019283125
an O 0 0.0013895577
exploratory O 0 0.0018088835
study O 0 0.0005987119
to O 0 0.00033664826
investigate O 0 0.00028370612
lamivudine B-Chemical 0 0.9999416
- O 0 0.10523572
resistant O 0 0.004047061
hepatitis B-Disease 2 0.9999976
B I-Disease 2 0.99965847
virus O 0 0.0658881
( O 0 0.0019431795
HBV O 0 0.5242104
) O 0 0.00055432087
strains O 0 0.00013746918
in O 0 0.00013387432
selected O 0 0.00021774115
lamivudine B-Chemical 0 0.99996674
- O 0 0.25103056
na B-Chemical 0 0.99998283
ve O 0 0.98135835
HBV O 0 0.85231996
carriers O 0 0.00056287483
with O 0 0.00019153993
and O 0 0.0001996446
without O 0 0.00028686394
human B-Disease 0 0.0023452311
immunodeficiency I-Disease 0 0.9999323
virus I-Disease 0 0.09688447
( I-Disease 0 0.0016554063
HIV I-Disease 0 0.18076693
) I-Disease 0 0.0017918856
co I-Disease 0 0.058341123
- I-Disease 0 0.010303139
infection I-Disease 0 0.0024186682
in O 0 0.0005588604
South O 0 0.0015520126
African O 0 0.0024080672
patients O 0 0.0028939203
. O 0 0.002708084

Thirty O 0 0.008875087
- O 0 0.009123258
five O 0 0.0018350527
lamivudine B-Chemical 0 0.9998067
- O 0 0.47381112
na B-Chemical 0 0.99993753
ve O 0 0.99109733
HBV B-Disease 0 0.9971957
infected I-Disease 0 0.0016013188
patients O 0 0.0007697693
with O 0 0.00025805418
or O 0 0.00020973824
without O 0 0.00034081706
HIV B-Disease 0 0.20976083
co I-Disease 0 0.2017757
- I-Disease 0 0.015986966
infection I-Disease 0 0.0012449031
were O 0 0.0001498254
studied O 0 0.00021586707
: O 0 0.000343409
15 O 0 0.0001633821
chronic O 0 0.0030784868
HBV B-Disease 0 0.43364638
mono I-Disease 0 0.04604277
- I-Disease 0 0.0032245496
infected I-Disease 0 0.00021214815
patients O 0 0.00043146653
and O 0 0.0002545913
20 O 0 0.00038944793
HBV B-Disease 0 0.5646988
- I-Disease 0 0.03083311
HIV I-Disease 0 0.15535468
co I-Disease 0 0.08128947
- I-Disease 0 0.0065379576
infected I-Disease 0 0.0011579606
patients O 0 0.0031485255
. O 0 0.002936498

The O 0 0.0025261464
latter O 0 0.0035154982
group O 0 0.0019626962
was O 0 0.00088632276
further O 0 0.0006414955
sub O 0 0.0020838294
- O 0 0.0023767191
divided O 0 0.00042561934
into O 0 0.00023453264
13 O 0 0.00046181906
occult O 0 0.014042327
HBV O 0 0.5548245
( O 0 0.0019813888
HBsAg B-Chemical 0 0.997531
- O 0 0.0038756744
negative O 0 0.00032235717
) O 0 0.00067300035
and O 0 0.00031559213
7 O 0 0.00033086797
overt O 0 0.064596504
HBV O 0 0.6959873
( O 0 0.0030262836
HBsAg B-Chemical 0 0.99741626
- O 0 0.006994635
positive O 0 0.0010322817
) O 0 0.0026241401
patients O 0 0.0032158087
. O 0 0.0032392778

HBsAg B-Chemical 0 0.9925513
, O 0 0.00997155
anti O 0 0.008344257
- O 0 0.09215802
HBs O 0 0.91175884
, O 0 0.002968429
anti O 0 0.0026930647
- O 0 0.012113606
HBc O 0 0.031991422
, O 0 0.0012377211
and O 0 0.0005516809
anti O 0 0.0013800977
- O 0 0.014831817
HIV O 0 0.028539749
1 O 0 0.00037356923
/ O 0 0.00080637634
2 O 0 0.0001894909
were O 0 0.000116270836
determined O 0 0.0001044292
as O 0 0.00012261832
part O 0 0.00010814212
of O 0 0.0001340128
routine O 0 0.00011125369
diagnosis O 0 0.00028627214
using O 0 0.0001701637
Axsym O 0 0.0027479406
assays O 0 0.000292398
( O 0 0.0006290036
Abbott O 0 0.006773548
Laboratories O 0 0.004452745
, O 0 0.0009703341
North O 0 0.001163746
Chicago O 0 0.002808016
, O 0 0.0031973594
IL O 0 0.87709486
) O 0 0.0074810167
. O 0 0.004687118

Serum O 0 0.15983322
samples O 0 0.0033128192
were O 0 0.001526116
PCR O 0 0.0016000423
amplified O 0 0.0005407247
with O 0 0.00081310084
HBV O 0 0.08864004
reverse O 0 0.0008441443
transcriptase O 0 0.00095406873
( O 0 0.0007681377
RT O 0 0.00095507834
) O 0 0.00041088066
primers O 0 0.00014840327
, O 0 0.00026467684
followed O 0 0.00011113834
by O 0 0.000112776186
direct O 0 9.538161e-05
sequencing O 0 0.00015090575
across O 0 0.00017090698
the O 0 0.00026501116
tyrosine B-Chemical 0 0.25038126
- O 0 0.4090508
methionine B-Chemical 0 0.99970967
- O 0 0.9489283
aspartate B-Chemical 1 0.99997175
- O 0 0.9023311
aspartate B-Chemical 1 0.99990046
( O 0 0.002022131
YMDD O 0 0.2306921
) O 0 0.00040339908
motif O 0 9.19247e-05
of O 0 0.00013926574
the O 0 0.00012206327
major O 0 0.00016642078
catalytic O 0 0.00024685296
region O 0 0.000130845
in O 0 0.00018008758
the O 0 0.000253055
C O 0 0.8956155
domain O 0 0.00031987682
of O 0 0.00057745544
the O 0 0.0007661519
HBV O 0 0.7721457
RT O 0 0.015466153
enzyme O 0 0.005891739
. O 0 0.003340677

HBV O 0 0.58617604
viral O 0 0.0048301616
load O 0 0.0022056273
was O 0 0.0010569798
performed O 0 0.0007369694
with O 0 0.00090631435
Amplicor O 0 0.0038901563
HBV O 0 0.12274608
Monitor O 0 0.0018668461
test O 0 0.0007476976
v2 O 0 0.0016641549
. O 0 0.00041456558
0 O 0 0.0005514845
( O 0 0.0008699508
Roche O 0 0.0019771305
Diagnostics O 0 0.00246151
, O 0 0.0019173211
Penzberg O 0 0.010817427
, O 0 0.002759078
Germany O 0 0.005075036
) O 0 0.0052951872
. O 0 0.0046722707

HBV O 0 0.98539126
lamivudine B-Chemical 0 0.9998795
- O 0 0.03851603
resistant O 0 0.0013147371
strains O 0 0.00065021357
were O 0 0.00041560185
detected O 0 0.0002383828
in O 0 0.00025156763
3 O 0 0.00020445175
of O 0 0.00023324146
15 O 0 0.00024424284
mono O 0 0.0025561734
- O 0 0.002860028
infected O 0 0.0004597586
chronic O 0 0.9532169
hepatitis B-Disease 2 0.9999982
B I-Disease 2 0.99980944
patients O 0 0.002958007
and O 0 0.00025755222
10 O 0 0.00020703845
of O 0 0.00024888394
20 O 0 0.00039849142
HBV B-Disease 0 0.5005824
- I-Disease 0 0.024578298
HIV I-Disease 0 0.13157904
co I-Disease 0 0.07164081
- I-Disease 0 0.0063325996
infected I-Disease 0 0.001169961
patients O 0 0.00316296
. O 0 0.0029694706

To O 0 0.0012671829
the O 0 0.0011437855
best O 0 0.0009017578
of O 0 0.000823691
our O 0 0.0005614079
knowledge O 0 0.00077417877
, O 0 0.0008691768
this O 0 0.00035512206
constitutes O 0 0.00022548254
the O 0 0.00015359036
first O 0 0.00012334023
report O 0 0.00037061336
of O 0 0.0003861501
HBV O 0 0.97817403
lamivudine B-Chemical 0 0.9999856
- O 0 0.005902392
resistant O 0 0.00021048752
strains O 0 0.00015106169
in O 0 0.00018183961
therapy O 0 0.00056465215
- O 0 0.016405072
na B-Chemical 0 0.9999565
ve O 0 0.9866895
HBV B-Disease 0 0.9821697
- I-Disease 0 0.10783718
HIV I-Disease 0 0.20370564
co I-Disease 0 0.0804913
- I-Disease 0 0.0064865174
infected I-Disease 0 0.0012159015
patients O 0 0.003216828
. O 0 0.0030568182

The O 0 0.003424497
HBV O 0 0.13823743
viral O 0 0.0022871557
loads O 0 0.0011350092
for O 0 0.0006740999
mono O 0 0.009330825
- O 0 0.004052124
infected O 0 0.00042786548
and O 0 0.0004564364
co O 0 0.015574381
- O 0 0.003139372
infected O 0 0.00026326466
patients O 0 0.00039237775
ranged O 0 0.00018510745
from O 0 0.00011513641
3 O 0 0.00011622882
. O 0 0.00012505792
32 O 0 0.00018968053
x O 0 0.00050460227
10 O 0 0.0001913282
( O 0 0.00028386657
2 O 0 0.00017967388
) O 0 0.00029424933
to O 0 0.000113355054
3 O 0 0.00012109245
. O 0 0.0001319623
82 O 0 0.00024992452
x O 0 0.00047909873
10 O 0 0.00017653915
( O 0 0.0002428174
7 O 0 0.00011701994
) O 0 0.00026135048
and O 0 0.00014597012
< O 0 0.00025356727
200 O 0 0.00025449684
to O 0 0.00012772469
4 O 0 0.00013319477
. O 0 0.00014607761
40 O 0 0.0001875047
x O 0 0.0005671951
10 O 0 0.00025177083
( O 0 0.00038488235
3 O 0 0.0002389797
) O 0 0.0005810269
copies O 0 0.00037991244
/ O 0 0.002022031
ml O 0 0.0027566103
, O 0 0.0022795235
respectively O 0 0.003306083
. O 0 0.0037933653

It O 0 0.0047025546
remains O 0 0.001249194
to O 0 0.0009391579
be O 0 0.0006389469
seen O 0 0.0004100529
whether O 0 0.00014446773
such O 0 0.0002780535
pre O 0 0.00065462483
- O 0 0.0017669927
existing O 0 0.00027093783
antiviral O 0 0.00072281633
mutations O 0 0.00029996273
could O 0 0.00012064251
result O 0 0.00013160103
in O 0 0.00013424762
widespread O 0 0.00015961197
emergence O 0 0.00019710098
of O 0 0.00021214774
HBV O 0 0.36086032
resistant O 0 0.00022034421
strains O 0 0.0001187404
when O 0 0.00013749537
lamivudine B-Chemical 0 0.99998164
- O 0 0.004258653
containing O 0 8.139022e-05
highly O 0 7.5875294e-05
active O 0 0.00011952059
antiretroviral O 0 0.0005142206
( O 0 0.00023592178
ARV O 0 0.0046444195
) O 0 0.00023727167
treatment O 0 0.000100343015
( O 0 0.00022617693
HAART O 0 0.0026331036
) O 0 0.00020271867
regimens O 0 0.00012192077
become O 0 0.00011166469
widely O 0 8.7390086e-05
applied O 0 9.843787e-05
in O 0 0.0001257167
South O 0 0.0003679303
Africa O 0 0.000260314
, O 0 0.00022250692
as O 0 0.00011226524
this O 0 0.0001251679
is O 0 8.60287e-05
likely O 0 5.9992355e-05
to O 0 7.4374235e-05
have O 0 6.945697e-05
potential O 0 7.217789e-05
implications O 0 0.00011866694
in O 0 0.00012777539
the O 0 0.00013364629
management O 0 0.00027224026
of O 0 0.0004423243
HBV B-Disease 0 0.91385305
- I-Disease 0 0.11222216
HIV I-Disease 0 0.29576784
co I-Disease 0 0.12117485
- I-Disease 0 0.00708951
infected I-Disease 0 0.0011082201
patients O 0 0.0030402653
. O 0 0.0028137765

Rabbit B-Disease 0 0.030325253
syndrome I-Disease 0 0.9954951
, O 0 0.010481581
antidepressant B-Chemical 0 0.9993886
use O 0 0.0015060217
, O 0 0.0019990276
and O 0 0.0014663668
cerebral O 0 0.87163436
perfusion O 0 0.06056934
SPECT O 0 0.23528661
scan O 0 0.0018502129
findings O 0 0.002065302
. O 0 0.0033352738

The O 0 0.0030051344
rabbit B-Disease 0 0.0132916495
syndrome I-Disease 0 0.9936748
is O 0 0.0013793447
an O 0 0.0018510127
extrapyramidal O 0 0.9998642
side O 0 0.002153829
effect O 0 0.0004905805
associated O 0 0.00068611547
with O 0 0.0009909071
chronic O 0 0.54793066
neuroleptic O 0 0.9999864
therapy O 0 0.0033794635
. O 0 0.0026557054

Its O 0 0.0144248195
occurrence O 0 0.0022233403
in O 0 0.001118768
a O 0 0.0010702258
patient O 0 0.0006219388
being O 0 0.00041404547
treated O 0 0.0008473267
with O 0 0.0010829191
imipramine B-Chemical 0 0.99999833
is O 0 0.0002854191
described O 0 0.00016353423
, O 0 0.00025062438
representing O 0 0.000116917116
the O 0 9.5895615e-05
first O 0 8.442389e-05
reported O 0 0.00016383841
case O 0 0.00018416559
of O 0 0.00024717982
this O 0 0.000450987
syndrome O 0 0.8375913
in O 0 0.00042639094
conjunction O 0 0.0006719153
with O 0 0.0015152632
antidepressants B-Chemical 0 0.999858
. O 0 0.0038914334

Repeated O 0 0.006037496
cerebral O 0 0.73953646
perfusion O 0 0.024173863
SPECT O 0 0.13136363
scans O 0 0.0008128646
revealed O 0 0.00030088873
decreased B-Disease 0 0.0006033769
basal I-Disease 0 0.0007306366
ganglia I-Disease 0 0.000981812
perfusion I-Disease 0 0.0053487117
while O 0 0.0001432794
the O 0 0.00012996947
movement B-Disease 0 0.00070658635
disorder I-Disease 0 0.9947942
was O 0 0.00015216484
present O 0 0.00011723237
, O 0 0.00027854784
and O 0 0.00016812338
a O 0 0.00024579096
return O 0 0.00018827882
to O 0 0.00013529549
normal O 0 0.00036687392
perfusion O 0 0.005173733
when O 0 0.0001939648
the O 0 0.00035858498
rabbit B-Disease 0 0.004488572
syndrome I-Disease 0 0.99461937
resolved O 0 0.0025100687
. O 0 0.0027624755

Estrogen O 0 0.9997403
prevents O 0 0.05652415
cholesteryl B-Chemical 0 0.99987423
ester I-Chemical 0 0.99942845
accumulation O 0 0.002652387
in O 0 0.0009454146
macrophages O 0 0.0015467259
induced O 0 0.0005917385
by O 0 0.0006254137
the O 0 0.000744336
HIV O 0 0.12398124
protease O 0 0.004905713
inhibitor O 0 0.030294355
ritonavir B-Chemical 0 0.99965096
. O 0 0.005159234

Individuals O 0 0.010737421
with O 0 0.003370797
HIV O 0 0.028866922
can O 0 0.0006677719
now O 0 0.0005635755
live O 0 0.0005462327
long O 0 0.00041663845
lives O 0 0.00091217604
with O 0 0.00036010516
drug O 0 0.0038742663
therapy O 0 0.00035193178
that O 0 0.00015357706
often O 0 0.00029848528
includes O 0 0.0002781142
protease O 0 0.0007959214
inhibitors O 0 0.0008179219
such O 0 0.00077526545
as O 0 0.0016135912
ritonavir B-Chemical 0 0.9995043
. O 0 0.004279011

Many O 0 0.0031941633
patients O 0 0.0043342193
, O 0 0.0028373282
however O 0 0.0014497276
, O 0 0.0014939678
develop O 0 0.0006514876
negative O 0 0.0005260836
long O 0 0.0005870437
- O 0 0.0018432024
term O 0 0.00047692982
side O 0 0.0009745405
effects O 0 0.0005804753
such O 0 0.0007819974
as O 0 0.0013820732
premature B-Disease 0 0.54796165
atherosclerosis I-Disease 0 0.99995923
. O 0 0.009164478

We O 0 0.0021738124
have O 0 0.0012552973
previously O 0 0.00096292334
demonstrated O 0 0.00058311014
that O 0 0.00055452326
ritonavir B-Chemical 0 0.9996092
treatment O 0 0.0005502591
increases O 0 0.00062961667
atherosclerotic B-Disease 0 0.9999392
lesion I-Disease 0 0.19005917
formation O 0 0.00040604186
in O 0 0.0001416998
male O 0 0.0002513866
mice O 0 5.0774554e-05
to O 0 0.00010713358
a O 0 0.0002280546
greater O 0 0.00024395817
extent O 0 0.00024246251
than O 0 0.0003048585
in O 0 0.00045949404
female O 0 0.0013444583
mice O 0 0.0006348453
. O 0 0.0023618126

Furthermore O 0 0.0032895426
, O 0 0.004156658
peripheral O 0 0.004444987
blood O 0 0.012521092
monocytes O 0 0.028662212
isolated O 0 0.0007194867
from O 0 0.000667074
ritonavir B-Chemical 0 0.9996506
- O 0 0.007289347
treated O 0 0.0011330848
females O 0 0.0017453565
had O 0 0.0009790339
less O 0 0.0031848988
cholesteryl B-Chemical 0 0.99973196
ester I-Chemical 0 0.998928
accumulation O 0 0.0062232385
. O 0 0.0045817043

In O 0 0.0019659111
the O 0 0.0014747783
present O 0 0.0010026705
study O 0 0.0010639126
, O 0 0.0009681401
we O 0 0.0002578982
have O 0 0.0002671105
investigated O 0 0.00023381079
the O 0 0.00018916343
molecular O 0 0.00031859797
mechanisms O 0 0.00013701373
by O 0 0.00017276945
which O 0 0.0002209126
female O 0 0.0006103221
hormones O 0 0.014777706
influence O 0 0.00026258486
cholesterol B-Chemical 0 0.9999443
metabolism O 0 0.574502
in O 0 0.00023901367
macrophages O 0 0.00049143046
in O 0 0.00014262646
response O 0 0.00016070847
to O 0 0.0001871498
the O 0 0.00031362183
HIV O 0 0.09354526
protease O 0 0.0034901875
inhibitor O 0 0.02893441
ritonavir B-Chemical 0 0.9997551
. O 0 0.0040089604

We O 0 0.0025775575
have O 0 0.0014836856
utilized O 0 0.0009894005
the O 0 0.00090420636
human O 0 0.0011792943
monocyte O 0 0.39700207
cell O 0 0.001272947
line O 0 0.00096755597
, O 0 0.0039439043
THP O 0 0.9999367
- O 0 0.028168585
1 O 0 0.0004771179
as O 0 0.0003055618
a O 0 0.0004244741
model O 0 0.00030007973
to O 0 0.00032728587
address O 0 0.00028590174
this O 0 0.0009559787
question O 0 0.0015307969
. O 0 0.0032430242

Briefly O 0 0.0034478924
, O 0 0.003938382
cells O 0 0.0019244462
were O 0 0.0011012385
differentiated O 0 0.0015177174
for O 0 0.0004212029
72 O 0 0.00048381512
h O 0 0.00036302189
with O 0 0.0003474225
100 O 0 0.0008694415
nM O 0 0.008556992
PMA O 0 0.9748942
to O 0 0.00019430133
obtain O 0 0.000114173105
a O 0 0.00037933287
macrophage O 0 0.028257348
- O 0 0.0031515772
like O 0 0.00014075391
phenotype O 0 0.0002021277
in O 0 0.00012380212
the O 0 0.00010187696
presence O 0 0.000113116315
or O 0 0.00010474953
absence O 0 9.124028e-05
of O 0 0.00020838021
1 O 0 0.00035223822
nM O 0 0.095490925
17beta B-Chemical 0 0.9999703
- I-Chemical 0 0.94433796
estradiol I-Chemical 0 0.99999404
( O 0 0.037287157
E2 B-Chemical 0 0.9998061
) O 0 0.0030805843
, O 0 0.0006638535
100 O 0 0.0009599974
nM O 0 0.054311816
progesterone B-Chemical 0 0.9999075
or O 0 0.00039376438
vehicle O 0 0.002034792
( O 0 0.00071455014
0 O 0 0.0005003804
. O 0 0.00046452528
01 O 0 0.0031391063
% O 0 0.002127385
ethanol B-Chemical 0 0.9951675
) O 0 0.0069830357
. O 0 0.0038652539

Cells O 0 0.007078221
were O 0 0.0018463333
then O 0 0.0010786838
treated O 0 0.0012054674
with O 0 0.0006113962
30 O 0 0.0004302526
ng O 0 0.00081748405
/ O 0 0.0020707382
ml O 0 0.0032942519
ritonavir B-Chemical 0 0.9993266
or O 0 0.0002921272
vehicle O 0 0.00091296027
in O 0 0.00023597354
the O 0 0.00021073331
presence O 0 0.00029037643
of O 0 0.000534635
aggregated O 0 0.0010877645
LDL O 0 0.9993224
for O 0 0.0007565038
24 O 0 0.0010553624
h O 0 0.0015475057
. O 0 0.002621406

Cell O 0 0.021969259
extracts O 0 0.0041772937
were O 0 0.0017820953
harvested O 0 0.001250428
, O 0 0.002216588
and O 0 0.0015718648
lipid O 0 0.060543787
or O 0 0.0013046942
total O 0 0.0015488777
RNA O 0 0.0039031566
was O 0 0.0019057628
isolated O 0 0.0027513665
. O 0 0.004452379

E2 B-Chemical 0 0.99681795
decreased O 0 0.008988299
the O 0 0.002588458
accumulation O 0 0.0026976536
of O 0 0.004500866
cholesteryl B-Chemical 0 0.99980325
esters I-Chemical 0 0.9976278
in O 0 0.0013264491
macrophages O 0 0.0021914083
following O 0 0.00088383496
ritonavir B-Chemical 0 0.99840266
treatment O 0 0.0021125525
. O 0 0.0031495658

Ritonavir B-Chemical 0 0.99844897
increased O 0 0.0032621657
the O 0 0.0011631283
expression O 0 0.00087751757
of O 0 0.0011294419
the O 0 0.0013411515
scavenger O 0 0.99935
receptor O 0 0.04073642
, O 0 0.004621968
CD36 O 0 0.9699905
mRNA O 0 0.0010076065
, O 0 0.0010222903
responsible O 0 0.00040594858
for O 0 0.0004428031
the O 0 0.000743373
uptake O 0 0.0062742117
of O 0 0.0034991277
LDL O 0 0.99931335
. O 0 0.0063008047

Additionally O 0 0.002880633
, O 0 0.005958009
ritonavir B-Chemical 0 0.99931014
treatment O 0 0.0010031441
selectively O 0 0.00047819104
increased O 0 0.00045393495
the O 0 0.00021205634
relative O 0 0.00016890895
levels O 0 0.0002166027
of O 0 0.00037021394
PPARgamma O 0 0.043802004
mRNA O 0 0.0004899164
, O 0 0.00060536683
a O 0 0.0003794589
transcription O 0 0.00022939949
factor O 0 0.0020785965
responsible O 0 0.00018350894
for O 0 0.00016012616
the O 0 0.0001942089
regulation O 0 0.0001926523
of O 0 0.0008627737
CD36 O 0 0.90512127
mRNA O 0 0.0018895474
expression O 0 0.0020113755
. O 0 0.0037246519

Treatment O 0 0.013376906
with O 0 0.0060348413
E2 B-Chemical 0 0.99841
, O 0 0.0052990965
however O 0 0.0017981371
, O 0 0.0016869063
failed O 0 0.00070332905
to O 0 0.00045293607
prevent O 0 0.00041312896
these O 0 0.00045280572
increases O 0 0.0005114412
at O 0 0.00047375134
the O 0 0.00067418505
mRNA O 0 0.0013955336
level O 0 0.0020564173
. O 0 0.004130668

E2 B-Chemical 0 0.99785906
did O 0 0.0060951584
, O 0 0.0046730954
however O 0 0.0020775376
, O 0 0.0022977642
significantly O 0 0.0012130389
suppress O 0 0.0008535009
CD36 O 0 0.8734227
protein O 0 0.0009727608
levels O 0 0.0006731315
as O 0 0.00072571664
measured O 0 0.00093530875
by O 0 0.0011361797
fluorescent O 0 0.0023131047
immunocytochemistry O 0 0.0023717382
. O 0 0.003768359

This O 0 0.005451583
data O 0 0.00258557
suggests O 0 0.0010515262
that O 0 0.0013212557
E2 B-Chemical 0 0.9980996
modifies O 0 0.0007860186
the O 0 0.00042426193
expression O 0 0.00036457845
of O 0 0.0006048832
CD36 O 0 0.83722514
at O 0 0.00017548604
the O 0 0.00013014385
level O 0 0.00012577175
of O 0 0.00017423522
protein O 0 0.0001825787
expression O 0 0.00017123338
in O 0 0.0002750118
monocyte O 0 0.8671
- O 0 0.0035673974
derived O 0 0.00011588762
macrophages O 0 0.00044887324
resulting O 0 0.0001968388
in O 0 0.00030605542
reduced O 0 0.0014875719
cholesteryl B-Chemical 0 0.9999517
ester I-Chemical 0 0.9995939
accumulation O 0 0.0010601701
following O 0 0.00052842044
ritonavir B-Chemical 0 0.9994186
treatment O 0 0.0014001009
. O 0 0.0021505093

Acute O 0 0.8679751
hepatitis B-Disease 0 0.99961096
attack O 0 0.068646185
after O 0 0.0022209128
exposure O 0 0.0032371138
to O 0 0.0036619306
telithromycin B-Chemical 1 0.99381155
. O 0 0.007961181

INTRODUCTION O 0 0.034090415
: O 0 0.013738198
Antibiotic O 0 0.11439459
- O 0 0.01705868
associated O 0 0.0053324155
hepatotoxicity B-Disease 0 0.9996062
is O 0 0.004901251
rare O 0 0.013554152
. O 0 0.007334479

With O 0 0.0021351958
widespread O 0 0.0015355335
use O 0 0.0008934047
of O 0 0.0008240843
antimicrobial O 0 0.0014726984
agents O 0 0.0014752994
, O 0 0.0009304056
however O 0 0.0005875811
, O 0 0.0014523135
hepatic B-Disease 0 0.99960095
injury I-Disease 0 0.9227948
occurs O 0 0.00022147255
frequently O 0 0.00016518857
, O 0 0.00021700496
and O 0 0.00012602327
among O 0 0.0001772418
adverse B-Disease 0 0.0039973594
drug I-Disease 0 0.0042686136
reactions I-Disease 0 0.0005332169
, O 0 0.0005225826
idiosyncratic O 0 0.0038328771
reactions O 0 0.00036898567
are O 0 0.00025349983
the O 0 0.00037330948
most O 0 0.0009767718
serious O 0 0.003138423
. O 0 0.0028891962

CASE O 0 0.2340576
SUMMARY O 0 0.0073592183
: O 0 0.004325218
A O 0 0.0076431395
25 O 0 0.0016596768
- O 0 0.002854799
year O 0 0.0005626973
- O 0 0.0014311743
old O 0 0.00044000708
male O 0 0.00066369865
patient O 0 0.00034948005
, O 0 0.00037929506
with O 0 0.00022672364
a O 0 0.00029766798
height O 0 0.00044978014
of O 0 0.00022051699
175 O 0 0.00046720245
cm O 0 0.00049726205
and O 0 0.00014308703
weight O 0 0.00019148587
of O 0 0.00014367781
72 O 0 0.00016970531
kg O 0 0.0002802457
presented O 0 0.00012385349
to O 0 0.00016159231
Marmara O 0 0.00417736
University O 0 0.00035460782
Hospital O 0 0.0003084754
Emergency O 0 0.0002820631
Department O 0 0.00024064287
, O 0 0.00032372796
Istanbul O 0 0.0006980817
, O 0 0.00046028462
Turkey O 0 0.0008961099
, O 0 0.00030146647
with O 0 0.00014836492
5 O 0 0.0001091663
days O 0 7.188103e-05
' O 0 0.0002517812
history O 0 0.00031148738
of O 0 0.00034895173
jaundice B-Disease 0 0.99860954
, O 0 0.0028691795
malaise O 0 0.99682367
, O 0 0.0018860139
nausea B-Disease 0 0.9985428
, O 0 0.0017926131
and O 0 0.0015934563
vomiting B-Disease 0 0.96860117
. O 0 0.003454899

He O 0 0.0077206306
had O 0 0.0020355259
been O 0 0.0013011948
prescribed O 0 0.00570929
telithromycin B-Chemical 1 0.99793446
400 O 0 0.0025982636
mg O 0 0.009706211
/ O 0 0.0017293821
d O 0 0.0008349426
PO O 0 0.51933956
to O 0 0.0002780689
treat O 0 0.0004965958
an O 0 0.00032308916
upper B-Disease 0 0.0004991131
respiratory I-Disease 0 0.0012618179
tract I-Disease 0 0.00047308416
infection I-Disease 0 0.0009840948
7 O 0 0.00038601688
days O 0 0.00037689955
prior O 0 0.00069117616
. O 0 0.0024165015

Admission O 0 0.0061698896
laboratory O 0 0.0023754702
tests O 0 0.002360076
were O 0 0.0009889333
as O 0 0.0008472927
follows O 0 0.0009884216
: O 0 0.0036945164
alanine B-Chemical 0 0.94219214
aminotransferase O 0 0.99143773
, O 0 0.0013619757
67 O 0 0.001102745
U O 0 0.11573271
/ O 0 0.004728504
L O 0 0.47191313
( O 0 0.0007410845
reference O 0 0.00027858603
range O 0 0.00026832597
, O 0 0.00043218647
10 O 0 0.0003085813
- O 0 0.0011315213
37 O 0 0.0007208318
U O 0 0.14304696
/ O 0 0.008909118
L O 0 0.9398639
) O 0 0.008846532
; O 0 0.01183462
aspartate B-Chemical 1 0.99986756
aminotransferase O 0 0.99742645
, O 0 0.000979201
98 O 0 0.00096463575
U O 0 0.20448086
/ O 0 0.005127109
L O 0 0.61511904
( O 0 0.0008181082
10 O 0 0.00032235688
- O 0 0.0009869387
40 O 0 0.00034724778
U O 0 0.06193509
/ O 0 0.0050814226
L O 0 0.8623967
) O 0 0.0032271838
; O 0 0.0020849938
alkaline O 0 0.21817954
phosphatase O 0 0.15107195
, O 0 0.0012281875
513 O 0 0.0039861794
U O 0 0.36565712
/ O 0 0.006276463
L O 0 0.6242929
( O 0 0.000901123
0 O 0 0.0005045701
- O 0 0.0014688686
270 O 0 0.0011885251
U O 0 0.09203421
/ O 0 0.00454
L O 0 0.701758
) O 0 0.0021065562
; O 0 0.0014458388
gamma O 0 0.24848422
- O 0 0.12410783
glutamyltransferase O 0 0.99894375
, O 0 0.0011049985
32 O 0 0.000667519
U O 0 0.15244411
/ O 0 0.0047343443
L O 0 0.5406082
( O 0 0.00080372236
7 O 0 0.0002816396
- O 0 0.0010774949
49 O 0 0.00053628435
U O 0 0.079501115
/ O 0 0.0053778933
L O 0 0.80938524
) O 0 0.0025116666
; O 0 0.0015196537
amylase O 0 0.6395232
, O 0 0.00090952025
46 O 0 0.000731557
U O 0 0.21213256
/ O 0 0.0057657217
L O 0 0.64338315
( O 0 0.0008906518
0 O 0 0.00048800456
- O 0 0.0014372233
220 O 0 0.0010981713
U O 0 0.12516554
/ O 0 0.0048264777
L O 0 0.73746806
) O 0 0.0015470713
; O 0 0.00076576567
total O 0 0.00045869968
bilirubin B-Chemical 0 0.99986935
, O 0 0.0007580167
20 O 0 0.00024026344
. O 0 0.00017709956
1 O 0 0.00021766643
mg O 0 0.0017531359
/ O 0 0.0011532471
dL O 0 0.007818914
( O 0 0.0004319206
0 O 0 0.000262683
. O 0 0.00017996672
2 O 0 0.00021906137
- O 0 0.0007111751
1 O 0 0.00018409235
. O 0 0.00014675558
0 O 0 0.00022941438
mg O 0 0.0015965786
/ O 0 0.0011479246
dL O 0 0.010040418
) O 0 0.0006735364
; O 0 0.00045377942
direct O 0 0.00022520342
bilirubin B-Chemical 0 0.9998441
, O 0 0.0006336832
14 O 0 0.00018654832
. O 0 0.00014837355
8 O 0 0.00015908897
mg O 0 0.0014810797
/ O 0 0.0010784657
dL O 0 0.0067766635
( O 0 0.00043737856
0 O 0 0.0003054418
- O 0 0.0007684207
0 O 0 0.00021567346
. O 0 0.00014210682
3 O 0 0.00014748085
mg O 0 0.001306384
/ O 0 0.0010932198
dL O 0 0.009750182
) O 0 0.0007564177
; O 0 0.0005629666
and O 0 0.00037626945
albumin O 0 0.9614738
, O 0 0.0005002029
4 O 0 0.00016347934
. O 0 0.000151572
7 O 0 0.00014986728
mg O 0 0.0014362705
/ O 0 0.0011884375
dL O 0 0.0070493584
( O 0 0.00048171033
3 O 0 0.0002074196
. O 0 0.00022442579
5 O 0 0.00025621057
- O 0 0.0008669164
5 O 0 0.0002854401
. O 0 0.0003261141
4 O 0 0.00044500388
mg O 0 0.0034026853
/ O 0 0.003807043
dL O 0 0.01760128
) O 0 0.0054437504
. O 0 0.0045258254

No O 0 0.008939096
toxin O 0 0.06460795
, O 0 0.010576968
alcohol B-Chemical 0 0.9974317
, O 0 0.0041893898
or O 0 0.0014037791
other O 0 0.0014448616
drugs O 0 0.014585045
were O 0 0.0021553985
reported O 0 0.003014644
. O 0 0.004777156

The O 0 0.0023423263
patient O 0 0.0023583116
had O 0 0.001497657
suffered O 0 0.0029798427
a O 0 0.00087144447
previous O 0 0.0004037432
episode O 0 0.0005807539
of O 0 0.0005383703
" O 0 0.0019153439
acute O 0 0.99414366
hepatitis B-Disease 0 0.9999951
of O 0 0.0010296666
unknown O 0 0.0005116784
origin O 0 0.0005356268
, O 0 0.00060733827
" O 0 0.0005050845
that O 0 0.00022742013
occurred O 0 0.00038326363
after O 0 0.00040261418
telithromycin B-Chemical 1 0.98785734
usage O 0 0.0014573295
. O 0 0.002753835

Both O 0 0.006654161
incidents O 0 0.009144041
occurred O 0 0.004476095
within O 0 0.0028305063
a O 0 0.0062078433
year O 0 0.00559238
. O 0 0.009062207

DISCUSSION O 0 0.0066428296
: O 0 0.005022384
Telithromycin B-Chemical 0 0.4207602
is O 0 0.000614744
the O 0 0.00036835694
first O 0 0.00023217135
of O 0 0.00032353887
the O 0 0.00027199354
ketolide O 0 0.003727206
antibacterials O 0 0.21638483
to O 0 0.00024386634
receive O 0 0.0002657639
US O 0 0.0016378274
Food O 0 0.0017261484
and O 0 0.0004284171
Drug O 0 0.16533971
Administration O 0 0.0010913974
approval O 0 0.00042381318
for O 0 0.00033833596
clinical O 0 0.0015084997
use O 0 0.0012470781
. O 0 0.0027074222

It O 0 0.005513003
has O 0 0.0016228264
been O 0 0.0012972263
associated O 0 0.0011058811
with O 0 0.001018488
infrequent O 0 0.001755647
and O 0 0.00092489604
usually O 0 0.0011676213
reversible O 0 0.0046640863
severe O 0 0.04704748
hepatic B-Disease 0 0.9991855
dysfunction I-Disease 0 0.99873596
. O 0 0.0060197716

Based O 0 0.003791207
on O 0 0.0012402583
a O 0 0.0013395303
score O 0 0.00060894794
of O 0 0.00047540636
8 O 0 0.00030636543
on O 0 0.0001705155
the O 0 0.00020099095
Naranjo O 0 0.0009784988
adverse B-Disease 0 0.0023926094
drug I-Disease 0 0.0017529015
reaction I-Disease 0 0.00019175101
probability O 0 0.00014182633
scale O 0 0.00024035464
, O 0 0.0004787399
telithromycin B-Chemical 1 0.99867225
was O 0 0.00014099033
the O 0 0.00011096021
probable O 0 0.00035094577
cause O 0 0.00023741403
of O 0 0.00040971645
acute O 0 0.9987937
hepatitis B-Disease 0 0.9999988
in O 0 0.0003749809
this O 0 0.0002020903
patient O 0 0.00019093291
, O 0 0.00023008775
and O 0 0.00015910446
pathological O 0 0.0012237115
findings O 0 0.00026550583
suggested O 0 0.00025773206
drug O 0 0.054501876
- O 0 0.018417627
induced O 0 0.0015730463
toxic B-Disease 0 0.9975478
hepatitis I-Disease 0 0.99998856
. O 0 0.0151336845

Recurrence O 0 0.12777573
of O 0 0.007213007
hepatitis B-Disease 0 0.9999144
attack O 0 0.24658525
might O 0 0.00050957646
have O 0 0.00040248365
been O 0 0.00029250345
avoided O 0 0.00023209456
if O 0 0.00013050235
the O 0 0.00013607123
initial O 0 0.00013664647
incident O 0 0.00043505413
had O 0 0.00015672197
been O 0 0.00013459317
communicated O 0 0.00017327859
to O 0 9.02741e-05
the O 0 9.419385e-05
attending O 0 0.00019237382
physician O 0 0.0005067245
who O 0 0.0003455937
prescribed O 0 0.0016972165
telithromycin B-Chemical 1 0.99203354
the O 0 0.00038981397
second O 0 0.0005513581
time O 0 0.00089796755
. O 0 0.0025136315

CONCLUSION O 0 0.015466669
: O 0 0.0036773311
Here O 0 0.0011994672
we O 0 0.00066840695
report O 0 0.0013698557
a O 0 0.0010497196
case O 0 0.0007457297
of O 0 0.0011065428
acute O 0 0.9979481
hepatitis B-Disease 0 0.9999964
probably O 0 0.001530178
associated O 0 0.0004507609
with O 0 0.00037272542
the O 0 0.0003560455
administration O 0 0.000979375
of O 0 0.001327992
telithromycin B-Chemical 1 0.99833906
. O 0 0.003330411

A O 0 0.023064723
study O 0 0.0023244868
on O 0 0.000777449
the O 0 0.00055077247
effect O 0 0.00041302916
of O 0 0.00043390028
the O 0 0.00025683595
duration O 0 0.00019385203
of O 0 0.00034320867
subcutaneous O 0 0.001136968
heparin B-Chemical 0 0.9395025
injection O 0 0.0003383142
on O 0 0.00040183484
bruising B-Disease 0 0.8851968
and O 0 0.0014146501
pain B-Disease 0 0.11228481
. O 0 0.003087939

AIM O 0 0.4864425
: O 0 0.0064543304
This O 0 0.0021530977
study O 0 0.0010854325
was O 0 0.00056042895
carried O 0 0.00037553185
out O 0 0.00025564985
to O 0 0.00016216435
determine O 0 6.0917464e-05
the O 0 9.526663e-05
effect O 0 9.0859394e-05
of O 0 0.00011857883
injection O 0 8.364546e-05
duration O 0 6.55975e-05
on O 0 9.290536e-05
bruising B-Disease 0 0.84816766
and O 0 0.00016802033
pain B-Disease 0 0.0041553043
following O 0 6.040522e-05
the O 0 8.309388e-05
administration O 0 0.00020058184
of O 0 0.00016682845
the O 0 0.00018449599
subcutaneous O 0 0.0005508258
injection O 0 0.00029271544
of O 0 0.00085700076
heparin B-Chemical 0 0.9902154
. O 0 0.0031776996

BACKGROUND O 0 0.013026497
: O 0 0.002974769
Although O 0 0.00053313863
different O 0 0.00040265368
methods O 0 0.00042181468
to O 0 0.00035552995
prevent O 0 0.00044424145
bruising B-Disease 0 0.96264446
and O 0 0.00034682284
pain B-Disease 0 0.005540574
following O 0 7.012823e-05
the O 0 7.704892e-05
subcutaneous O 0 0.00018565186
injection O 0 6.6415705e-05
of O 0 0.00013111527
heparin B-Chemical 0 0.9896265
have O 0 0.00010442262
been O 0 9.0839814e-05
widely O 0 9.4312934e-05
studied O 0 0.00014937934
and O 0 0.00011093164
described O 0 8.514701e-05
, O 0 0.00014490605
the O 0 5.8963327e-05
effect O 0 6.292021e-05
of O 0 9.164155e-05
injection O 0 6.715741e-05
duration O 0 5.0165243e-05
on O 0 5.4243978e-05
the O 0 8.539746e-05
occurrence O 0 0.00017517572
of O 0 0.00034076202
bruising B-Disease 0 0.9884779
and O 0 0.00048362173
pain B-Disease 0 0.042220566
is O 0 0.00039166785
little O 0 0.00080126815
documented O 0 0.002133585
. O 0 0.0029166427

DESIGN O 0 0.0054992037
: O 0 0.004223813
This O 0 0.0018564749
study O 0 0.0010891923
was O 0 0.0006521658
designed O 0 0.0005246879
as O 0 0.00053722796
within O 0 0.0003742368
- O 0 0.001989755
subject O 0 0.00050461286
, O 0 0.0013043637
quasi O 0 0.002557543
- O 0 0.003797824
experimental O 0 0.0017144113
research O 0 0.003199419
. O 0 0.004357416

METHOD O 0 0.010975719
: O 0 0.0038300594
The O 0 0.00082148437
sample O 0 0.00094459835
for O 0 0.00043360543
the O 0 0.0003738612
study O 0 0.00039655005
consisted O 0 0.0003195251
of O 0 0.00035110893
50 O 0 0.00044630427
patients O 0 0.0005086877
to O 0 0.00027384146
whom O 0 0.0007282967
subcutaneous O 0 0.0016319
heparin B-Chemical 0 0.9494894
was O 0 0.0009696512
administered O 0 0.0019011751
. O 0 0.0025638759

Heparin B-Chemical 1 0.9978042
was O 0 0.001955114
injected O 0 0.0009167198
over O 0 0.00048243036
10 O 0 0.00038370106
seconds O 0 0.00026908633
on O 0 0.00015606137
the O 0 0.00017695085
right O 0 0.0004253162
abdominal O 0 0.00043683732
site O 0 0.00012966865
and O 0 0.00020516489
30 O 0 0.00017995265
seconds O 0 0.00019033272
on O 0 0.00017516573
the O 0 0.0003032884
left O 0 0.0010627026
abdominal O 0 0.0017149623
site O 0 0.0010180839
. O 0 0.0029103316

Injections O 0 0.00730341
areas O 0 0.0026051519
were O 0 0.0009681212
assessed O 0 0.0006536261
for O 0 0.00043422467
the O 0 0.00041326153
presence O 0 0.00045936593
of O 0 0.00072756485
bruising B-Disease 0 0.9151849
at O 0 0.00030616103
48 O 0 0.00032595373
and O 0 0.0003060011
72 O 0 0.00036826282
hours O 0 0.0002602882
after O 0 0.00026457565
each O 0 0.00047059404
injection O 0 0.0010009424
. O 0 0.0025317157

Dimensions O 0 0.009657597
of O 0 0.0029007872
the O 0 0.0020212133
bruising B-Disease 0 0.8556368
on O 0 0.0006608655
the O 0 0.0007106619
heparin B-Chemical 0 0.9809193
applied O 0 0.00051251287
areas O 0 0.0005671008
were O 0 0.00028813796
measured O 0 0.00033815182
using O 0 0.00032805683
transparent O 0 0.0011038001
millimetric O 0 0.0021724426
measuring O 0 0.0010860608
paper O 0 0.0026994979
. O 0 0.003356261

The O 0 0.0020022315
visual O 0 0.005016076
analog O 0 0.0018243949
scale O 0 0.0011594027
( O 0 0.0012164272
VAS O 0 0.0026024997
) O 0 0.0007302107
was O 0 0.00021225032
used O 0 0.0001553973
to O 0 0.00013786611
measure O 0 0.00012921385
pain B-Disease 0 0.0018600624
intensity O 0 0.000101016405
and O 0 0.00017166891
a O 0 0.0002828775
stop O 0 0.0003312262
- O 0 0.00162087
watch O 0 0.00036735568
was O 0 0.00020257996
used O 0 0.0001837208
to O 0 0.00020488378
time O 0 0.00024015305
the O 0 0.0004628638
pain B-Disease 0 0.0072729927
period O 0 0.0010245402
. O 0 0.0024824184

Data O 0 0.005037547
were O 0 0.0020984535
analysed O 0 0.0016711145
using O 0 0.0011170576
chi O 0 0.016727371
- O 0 0.004166428
square O 0 0.0016737187
test O 0 0.0009957042
, O 0 0.0013723025
Mann O 0 0.0057698777
- O 0 0.004913827
Whitney O 0 0.10489148
U O 0 0.13822329
, O 0 0.0012987797
Wilcoxon O 0 0.0011648084
signed O 0 0.0009552334
ranks O 0 0.0011407427
tests O 0 0.0017389049
and O 0 0.0014417388
correlation O 0 0.0020202114
. O 0 0.004262746

RESULTS O 0 0.004592747
: O 0 0.002946825
The O 0 0.0007029605
percentage O 0 0.00067200395
of O 0 0.0011486356
bruising B-Disease 0 0.93716466
occurrence O 0 0.00064620393
was O 0 0.0003300753
64 O 0 0.00037934174
% O 0 0.0003813079
with O 0 0.00016796523
the O 0 0.00011836757
injection O 0 0.00011037948
of O 0 0.00012940902
10 O 0 0.00011216862
seconds O 0 9.415487e-05
duration O 0 7.756909e-05
and O 0 0.00015065975
42 O 0 0.0002451441
% O 0 0.0003667909
in O 0 0.00022135644
the O 0 0.00026608055
30 O 0 0.00039339217
- O 0 0.0014418659
second O 0 0.00064579723
injection O 0 0.0010760347
. O 0 0.002496285

It O 0 0.0051603373
was O 0 0.0018151056
determined O 0 0.0009750094
that O 0 0.0006448209
the O 0 0.0005856761
size O 0 0.00087469426
of O 0 0.0006387444
the O 0 0.0006000244
bruising B-Disease 0 0.930719
was O 0 0.0004001359
smaller O 0 0.00045138336
in O 0 0.0003272912
the O 0 0.00033226705
30 O 0 0.00044811628
- O 0 0.001506125
second O 0 0.0006852363
injection O 0 0.0011232328
. O 0 0.0026065002

Pain B-Disease 0 0.02214251
intensity O 0 0.0010498066
and O 0 0.0010469203
pain B-Disease 0 0.0045203413
period O 0 0.00033726133
were O 0 0.00028394477
statistically O 0 0.00035884316
significantly O 0 0.00025540084
lower O 0 0.00022717328
for O 0 0.00013081307
the O 0 0.00013849119
30 O 0 0.00015785385
- O 0 0.00047348836
second O 0 0.000111627734
injection O 0 0.00011865235
than O 0 0.00012792107
for O 0 0.0001445209
the O 0 0.00023608674
10 O 0 0.00042597938
- O 0 0.0014567015
second O 0 0.00061913487
injection O 0 0.0010288934
. O 0 0.002388534

CONCLUSIONS O 0 0.024243552
: O 0 0.004922772
It O 0 0.0016446961
was O 0 0.0005983437
determined O 0 0.000331796
that O 0 0.00021873577
injection O 0 0.00019413205
duration O 0 0.00013838822
had O 0 0.00016397142
an O 0 0.00016260674
effect O 0 0.00014471536
on O 0 0.00019720475
bruising B-Disease 0 0.9587169
and O 0 0.00029939876
pain B-Disease 0 0.006912429
following O 0 0.00011701079
the O 0 0.00018809507
subcutaneous O 0 0.00063323794
administration O 0 0.0006499338
of O 0 0.0010396953
heparin B-Chemical 0 0.9933316
. O 0 0.0034616233

This O 0 0.0070142425
study O 0 0.003480876
should O 0 0.0013751965
be O 0 0.0014931216
repeated O 0 0.000988129
on O 0 0.0011238504
a O 0 0.0025138215
larger O 0 0.0034625942
sample O 0 0.005125854
. O 0 0.0060834875

RELEVANCE O 0 0.010121096
TO O 0 0.0060656006
CLINICAL O 0 0.0012491415
PRACTICE O 0 0.00041895197
: O 0 0.00066326227
When O 0 0.0002085533
administering O 0 0.00049610186
subcutaneous O 0 0.0011229609
heparin B-Chemical 0 0.9651571
injections O 0 0.0003599821
, O 0 0.00043040933
it O 0 0.00028876387
is O 0 0.00014958615
important O 0 0.00012313951
to O 0 0.00015081282
extend O 0 0.00016600934
the O 0 0.00018908661
duration O 0 0.00021976429
of O 0 0.0004850578
the O 0 0.0006440667
injection O 0 0.0011042646
. O 0 0.0024517924

Acute B-Disease 0 0.7177907
liver I-Disease 0 0.40477842
failure I-Disease 0 0.20269491
in O 0 0.000720587
two O 0 0.0003537944
patients O 0 0.00066921354
with O 0 0.0003897805
regular O 0 0.0005179714
alcohol B-Chemical 0 0.9970169
consumption O 0 0.0992706
ingesting O 0 0.546778
paracetamol B-Chemical 0 0.99989796
at O 0 0.0005806659
therapeutic O 0 0.0013090182
dosage O 0 0.0038983058
. O 0 0.002702799

BACKGROUND O 0 0.013932833
: O 0 0.003217758
The O 0 0.0005745687
possible O 0 0.00039014968
role O 0 0.00028366558
of O 0 0.000706522
alcohol B-Chemical 0 0.99594706
in O 0 0.00037564946
the O 0 0.0002105118
development O 0 0.00029161738
of O 0 0.00037449485
hepatotoxicity B-Disease 0 0.999969
associated O 0 0.00021718732
with O 0 0.00013550968
therapeutic O 0 0.00021545972
doses O 0 0.00042473257
of O 0 0.00046276583
paracetamol B-Chemical 0 0.99998367
( O 0 0.005889326
acetaminophen B-Chemical 0 0.9999894
) O 0 0.001785773
is O 0 0.00042063132
currently O 0 0.00071129063
debated O 0 0.0024866327
. O 0 0.0026904754

CASE O 0 0.042150952
REPORT O 0 0.00279329
: O 0 0.002624834
We O 0 0.00071176526
describe O 0 0.0006191901
2 O 0 0.00059786224
patients O 0 0.0006778263
who O 0 0.00038685903
were O 0 0.00018476941
regular O 0 0.00019068166
consumers O 0 0.0007752414
of O 0 0.00034774074
alcohol B-Chemical 0 0.99763656
and O 0 0.00029137172
who O 0 0.00029215423
developed O 0 0.00021572571
liver B-Disease 0 0.060295723
failure I-Disease 0 0.0065419106
within O 0 5.600971e-05
3 O 0 8.011267e-05
- O 0 0.00029340415
5 O 0 4.9066213e-05
days O 0 2.8765187e-05
after O 0 3.0074516e-05
hospitalization O 0 0.0001041414
and O 0 9.001099e-05
stopping O 0 0.00031783496
alcohol B-Chemical 0 0.9968316
consumption O 0 0.0071055563
while O 0 0.00016029434
being O 0 0.00017741392
treated O 0 0.00034960202
with O 0 0.0002741244
4 O 0 0.0003314053
g O 0 0.0028366551
paracetamol B-Chemical 0 0.99982303
/ O 0 0.0046450216
day O 0 0.0009791843
. O 0 0.0023355135

A O 0 0.748529
paracetamol B-Chemical 0 0.99989545
serum O 0 0.10121568
level O 0 0.0009547836
obtained O 0 0.0005354622
in O 0 0.00043852458
one O 0 0.00034150382
of O 0 0.00039329
these O 0 0.00038358878
patients O 0 0.00074907666
was O 0 0.00036507435
not O 0 0.00038492418
in O 0 0.00054283784
the O 0 0.0007684163
toxic O 0 0.010874806
range O 0 0.0021164322
. O 0 0.0030465962

Possible O 0 0.0049694316
risk O 0 0.0075577814
factors O 0 0.0020566892
for O 0 0.0007244356
the O 0 0.00055012194
development O 0 0.00067268894
of O 0 0.00080156064
hepatotoxicity B-Disease 0 0.99995446
in O 0 0.00038086195
patients O 0 0.00050526124
treated O 0 0.00034376702
with O 0 0.0002213332
therapeutic O 0 0.00039887495
doses O 0 0.00084154226
of O 0 0.0009223468
paracetamol B-Chemical 0 0.9999114
are O 0 0.0009015133
discussed O 0 0.0012298836
. O 0 0.0025268293

CONCLUSION O 0 0.014796838
: O 0 0.003398367
In O 0 0.0008100847
patients O 0 0.0013979746
with O 0 0.00080552266
risk O 0 0.0028474862
factors O 0 0.0010468215
, O 0 0.0010072341
e O 0 0.0010769684
. O 0 0.00031762748
g O 0 0.00075109804
. O 0 0.00018727368
regular O 0 0.00017842469
consumption O 0 0.0010532327
of O 0 0.0003551292
alcohol B-Chemical 0 0.99901867
, O 0 0.0012364615
liver B-Disease 0 0.2113106
failure I-Disease 0 0.014234444
is O 0 0.00013867805
possible O 0 0.00011179456
when O 0 0.00015040496
therapeutic O 0 0.00048307833
doses O 0 0.001041247
are O 0 0.0007576914
ingested O 0 0.0071284035
. O 0 0.002836221

We O 0 0.002188162
propose O 0 0.001221527
that O 0 0.00098681
the O 0 0.0012266933
paracetamol B-Chemical 0 0.9999001
dose O 0 0.0013298714
should O 0 0.00017905375
not O 0 0.00020341223
exceed O 0 0.00025396748
2 O 0 0.0002002119
g O 0 0.00051834696
/ O 0 0.000546812
day O 0 8.973879e-05
in O 0 9.714514e-05
such O 0 0.00010142932
patients O 0 0.00024087769
and O 0 0.00011366449
that O 0 8.087404e-05
their O 0 0.00013002116
liver O 0 0.01133419
function O 0 0.000113824375
should O 0 6.542675e-05
be O 0 9.8784476e-05
monitored O 0 9.0150315e-05
closely O 0 0.00011252634
while O 0 0.00018294882
being O 0 0.0003384597
treated O 0 0.0010656725
with O 0 0.0018748475
paracetamol B-Chemical 0 0.9998988
. O 0 0.004005365

Associations O 0 0.0022701705
between O 0 0.0010616239
use O 0 0.0009628646
of O 0 0.0012684604
benzodiazepines B-Chemical 1 0.99988055
or O 0 0.0005057041
related O 0 0.00023229425
drugs O 0 0.0035056216
and O 0 0.00029129896
health O 0 0.0006385892
, O 0 0.00037287647
physical O 0 0.0003125223
abilities O 0 0.0012169372
and O 0 0.00029964262
cognitive O 0 0.48589277
function O 0 0.00017837925
: O 0 0.00040969675
a O 0 0.00026995363
non O 0 0.00037896872
- O 0 0.0015693188
randomised O 0 0.0008167007
clinical O 0 0.0007661314
study O 0 0.00041629793
in O 0 0.00047259266
the O 0 0.0008393
elderly O 0 0.12560782
. O 0 0.0033185738

OBJECTIVE O 0 0.016510407
: O 0 0.0027032283
To O 0 0.00040964692
describe O 0 0.00046673484
associations O 0 0.00033219607
between O 0 0.00023961601
the O 0 0.00021734143
use O 0 0.00021256425
of O 0 0.00037304944
benzodiazepines B-Chemical 1 0.99993527
or O 0 0.00020970864
related O 0 0.00012359736
drugs O 0 0.006967265
( O 0 0.0008427913
BZDs B-Chemical 0 0.99966
/ O 0 0.0018139507
RDs O 0 0.00073418726
) O 0 0.00035127124
and O 0 0.00015204621
health O 0 0.00040853786
, O 0 0.00027925728
functional O 0 0.00015110329
abilities O 0 0.0015809353
and O 0 0.00045423364
cognitive O 0 0.7112835
function O 0 0.00039279897
in O 0 0.00053931173
the O 0 0.0008410276
elderly O 0 0.110625826
. O 0 0.0030830253

METHODS O 0 0.0049828608
: O 0 0.0041909153
A O 0 0.006509032
non O 0 0.002060602
- O 0 0.004192468
randomised O 0 0.0015646524
clinical O 0 0.0009798448
study O 0 0.00036828246
of O 0 0.00030846274
patients O 0 0.00052773015
aged O 0 0.0004742538
> O 0 0.00047860213
or O 0 0.0002069887
= O 0 0.0005884582
65 O 0 0.00028563364
years O 0 0.00027391096
admitted O 0 0.00046168195
to O 0 0.00022674934
acute O 0 0.004223494
hospital O 0 0.0005827606
wards O 0 0.00071866397
during O 0 0.00039009014
1 O 0 0.00080402923
month O 0 0.00073448394
. O 0 0.0021619885

164 O 0 0.008990407
patients O 0 0.0040762406
( O 0 0.0022656089
mean O 0 0.0008837238
age O 0 0.0012720004
+ O 0 0.0023007537
/ O 0 0.0026402096
- O 0 0.0019581546
standard O 0 0.00048403823
deviation O 0 0.0009018032
[ O 0 0.0017833029
SD O 0 0.0067499075
] O 0 0.0013277383
81 O 0 0.00064613397
. O 0 0.0002828352
6 O 0 0.00024052382
+ O 0 0.0009912777
/ O 0 0.0017517569
- O 0 0.001613973
6 O 0 0.00029665657
. O 0 0.00034811624
8 O 0 0.00041095074
years O 0 0.00073107297
) O 0 0.0015965862
were O 0 0.0012789079
admitted O 0 0.0038699005
. O 0 0.003810799

Of O 0 0.0056663333
these O 0 0.0024639503
, O 0 0.0027202205
nearly O 0 0.0011752016
half O 0 0.0006636407
( O 0 0.000960427
n O 0 0.00061303144
= O 0 0.0010288516
78 O 0 0.0006430072
) O 0 0.00059425615
had O 0 0.00024743215
used O 0 0.00029625153
BZDs B-Chemical 0 0.99923134
/ O 0 0.0017164911
RDs O 0 0.0005715521
before O 0 9.194785e-05
admission O 0 0.00022908564
, O 0 0.00026026485
and O 0 0.00017033367
the O 0 0.00015102208
remainder O 0 0.0002536376
( O 0 0.00038400115
n O 0 0.0003242877
= O 0 0.00075883424
86 O 0 0.00061496
) O 0 0.00079711835
were O 0 0.0004746542
non O 0 0.0011815109
- O 0 0.004384214
users O 0 0.0030807399
. O 0 0.0036772024

Cognitive O 0 0.5154351
ability O 0 0.0023655072
was O 0 0.0016137618
assessed O 0 0.0011328727
by O 0 0.00097064633
the O 0 0.0009052149
Mini O 0 0.003800488
- O 0 0.0039270143
Mental O 0 0.0016627712
State O 0 0.0015087347
Examination O 0 0.0008947192
( O 0 0.0028992072
MMSE O 0 0.94362074
) O 0 0.0068683326
. O 0 0.0056807925

Patients O 0 0.004274588
scoring O 0 0.0017362804
> O 0 0.0022295562
or O 0 0.00088791316
= O 0 0.0016547107
20 O 0 0.0006885976
MMSE O 0 0.64098513
sum O 0 0.00026602883
points O 0 0.00020673781
were O 0 0.00019058715
interviewed O 0 0.00033176347
( O 0 0.00029585385
n O 0 0.00021440166
= O 0 0.00043446108
79 O 0 0.00025863692
) O 0 0.000304102
and O 0 0.00013847137
questioned O 0 0.00017086332
regarding O 0 9.544685e-05
symptoms O 0 0.0009842269
and O 0 0.00015226385
functional O 0 0.00014269695
abilities O 0 0.0010204318
during O 0 0.00016711616
the O 0 0.00017770547
week O 0 0.00015848092
prior O 0 0.00019234851
to O 0 0.0005096887
admission O 0 0.001557089
. O 0 0.0022342901

Data O 0 0.0033960359
on O 0 0.0010723011
use O 0 0.0009885469
of O 0 0.0013546168
BZDs B-Chemical 0 0.99928963
/ O 0 0.0037394136
RDs O 0 0.0010065588
before O 0 0.00014721249
admission O 0 0.00028415228
, O 0 0.00028250183
current O 0 0.00019954887
medications O 0 0.00081034604
and O 0 0.0002081316
discharge O 0 0.00025665332
diagnoses O 0 0.00043306203
were O 0 0.00024145578
collected O 0 0.00030934124
from O 0 0.000474697
medical O 0 0.0021157274
records O 0 0.0025938174
. O 0 0.0030498884

Health O 0 0.0035275256
, O 0 0.002965825
physical O 0 0.0019542205
abilities O 0 0.0040597175
and O 0 0.0011435612
cognitive O 0 0.39060935
function O 0 0.0003255233
were O 0 0.00023003732
compared O 0 0.00016497796
between O 0 0.00027872846
BZD O 0 0.9995414
/ O 0 0.016351076
RD O 0 0.998064
users O 0 0.00051267876
and O 0 0.00021816487
non O 0 0.00037510408
- O 0 0.0013634539
users O 0 0.0003635273
, O 0 0.0003420571
and O 0 0.00019756971
adjustments O 0 0.00018730189
were O 0 0.00019352826
made O 0 0.00025228338
for O 0 0.00031619656
confounding O 0 0.0007495575
variables O 0 0.001600062
. O 0 0.0025822092

The O 0 0.0027508407
residual O 0 0.0032111697
serum O 0 0.015757129
concentrations O 0 0.0041646296
of O 0 0.0064309505
oxazepam B-Chemical 0 0.9999989
, O 0 0.4075293
temazepam B-Chemical 0 0.99999905
and O 0 0.009316608
zopiclone B-Chemical 0 0.9999945
were O 0 0.0019142483
analysed O 0 0.0021343608
. O 0 0.0030712776

RESULTS O 0 0.004937479
: O 0 0.003024355
The O 0 0.000773832
mean O 0 0.00086435245
+ O 0 0.002468232
/ O 0 0.0033000377
- O 0 0.0035254965
SD O 0 0.004493947
duration O 0 0.0003592464
of O 0 0.0007718653
BZD O 0 0.99957603
/ O 0 0.020615526
RD O 0 0.99494004
use O 0 0.0003154709
was O 0 0.00023817582
7 O 0 0.00022537938
+ O 0 0.0008761386
/ O 0 0.0014659264
- O 0 0.0012908949
7 O 0 0.0002545369
years O 0 0.00038470593
( O 0 0.0006040242
range O 0 0.0005283346
1 O 0 0.0008285353
- O 0 0.0027764088
31 O 0 0.0021025327
) O 0 0.00394673
. O 0 0.0040614894

Two O 0 0.0025146334
or O 0 0.0017333884
three O 0 0.0011246948
BZDs B-Chemical 0 0.99781007
/ O 0 0.005177708
RDs O 0 0.0020781267
were O 0 0.0004782204
concomitantly O 0 0.0006836825
taken O 0 0.0002956827
by O 0 0.00030883527
26 O 0 0.00044993564
% O 0 0.0005982358
of O 0 0.00042880236
users O 0 0.00079350907
( O 0 0.00098072
n O 0 0.0008792308
= O 0 0.0020722896
20 O 0 0.001431721
) O 0 0.0036165442
. O 0 0.003772984

Long O 0 0.0096571
- O 0 0.007139645
term O 0 0.0013173141
use O 0 0.00072550785
of O 0 0.0006459514
these O 0 0.00050486164
drugs O 0 0.0077509293
was O 0 0.00031272494
associated O 0 0.00025241813
with O 0 0.00022614848
female O 0 0.00048534642
sex O 0 0.00035931112
and O 0 0.00013347103
use O 0 9.528072e-05
of O 0 0.00012116846
a O 0 0.00016401772
higher O 0 0.00011609611
number O 0 7.698993e-05
of O 0 0.00012443746
drugs O 0 0.002531334
with O 0 0.00012065011
effects O 0 0.00011212349
on O 0 9.671986e-05
the O 0 0.0001547411
CNS O 0 0.008730652
, O 0 0.00037579323
which O 0 0.00021113612
tended O 0 0.00023550245
to O 0 0.00017726328
be O 0 0.00022719995
related O 0 0.00023083155
to O 0 0.00058508554
diagnosed O 0 0.07756559
dementia B-Disease 0 0.99990296
. O 0 0.004916988

After O 0 0.001353809
adjustment O 0 0.001166947
for O 0 0.0006341118
these O 0 0.0005094198
variables O 0 0.0004824138
as O 0 0.00031251035
confounders O 0 0.00031064544
, O 0 0.00047599766
use O 0 0.0002466986
of O 0 0.00045062645
BZDs B-Chemical 0 0.99965405
/ O 0 0.0030393158
RDs O 0 0.00085677
was O 0 0.00016049255
not O 0 0.0001377325
associated O 0 0.00019438508
with O 0 0.00028188084
cognitive O 0 0.53681004
function O 0 0.00026742084
as O 0 0.0003251003
measured O 0 0.00047196914
by O 0 0.00062116067
the O 0 0.0010983355
MMSE O 0 0.992272
. O 0 0.0034334587

However O 0 0.0028981694
, O 0 0.003222561
use O 0 0.0013302426
of O 0 0.001714803
BZDs B-Chemical 0 0.9994856
/ O 0 0.006310922
RDs O 0 0.001625117
was O 0 0.00029263282
associated O 0 0.00028344415
with O 0 0.00042460766
dizziness B-Disease 0 0.99935454
, O 0 0.00056766346
inability B-Disease 0 0.0002650273
to I-Disease 0 0.00016747012
sleep I-Disease 0 0.13488145
after O 0 7.9071586e-05
awaking O 0 0.026466364
at O 0 7.1525064e-05
night O 0 0.00022649375
and O 0 0.00018729476
tiredness B-Disease 0 0.97410685
in O 0 0.000107288775
the O 0 9.111673e-05
mornings O 0 0.00086821796
during O 0 4.8654692e-05
the O 0 4.6597594e-05
week O 0 3.4587152e-05
prior O 0 2.8661627e-05
to O 0 5.0404862e-05
admission O 0 0.00010875464
and O 0 8.2534534e-05
with O 0 0.00013122709
stronger O 0 0.00051574036
depressive B-Disease 2 0.9999989
symptoms I-Disease 0 0.48560986
measured O 0 0.0001763963
at O 0 0.0001045688
the O 0 0.00012739823
beginning O 0 0.0001562594
of O 0 0.00034587338
the O 0 0.0004387713
hospital O 0 0.0011174675
stay O 0 0.0012907259
. O 0 0.0022791894

Use O 0 0.0067881825
of O 0 0.0039707213
BZDs B-Chemical 0 0.9992385
/ O 0 0.011484702
RDs O 0 0.003164285
tended O 0 0.00066643994
to O 0 0.00030800255
be O 0 0.00025400502
associated O 0 0.00023964024
with O 0 0.00022925848
a O 0 0.00029259603
reduced O 0 0.00019915123
ability O 0 0.0001444629
to O 0 0.00014783522
walk O 0 0.0005040058
and O 0 0.00013377058
shorter O 0 0.000115967654
night O 0 0.0003484428
- O 0 0.00082436146
time O 0 0.00013684049
sleep O 0 0.0036443293
during O 0 0.00012147979
the O 0 0.00014623329
week O 0 0.00014595091
prior O 0 0.00018767997
to O 0 0.0005077503
admission O 0 0.0015630971
. O 0 0.0022731253

A O 0 0.024097908
higher O 0 0.002805044
residual O 0 0.0022236682
serum O 0 0.020691412
concentration O 0 0.002200271
of O 0 0.002371527
temazepam B-Chemical 0 0.9999993
correlated O 0 0.00049166026
with O 0 0.00027886828
a O 0 0.00031972345
lower O 0 0.0003286087
MMSE O 0 0.9249722
sum O 0 0.0001673113
score O 0 0.00013478413
after O 0 0.00010155204
adjustment O 0 0.00020917546
for O 0 0.0002730643
confounding O 0 0.0006872381
variables O 0 0.0015451426
. O 0 0.002601361

CONCLUSIONS O 0 0.023180248
: O 0 0.0053355414
Long O 0 0.0035989785
- O 0 0.0031373117
term O 0 0.0006650935
use O 0 0.00041274438
and O 0 0.0004063377
concomitant O 0 0.00053128984
use O 0 0.00022906205
of O 0 0.00026371915
more O 0 0.0003344902
than O 0 0.00021244568
one O 0 0.00031126206
BZD O 0 0.9997235
/ O 0 0.029849587
RD O 0 0.9987472
were O 0 0.00020987347
common O 0 0.00018920959
in O 0 0.00020083616
elderly O 0 0.06291116
patients O 0 0.0009955814
hospitalised O 0 0.011412575
because O 0 0.00027894165
of O 0 0.00073571893
acute O 0 0.16660167
illnesses O 0 0.5049952
. O 0 0.0034860934

Long O 0 0.009754576
- O 0 0.007455945
term O 0 0.0013269584
use O 0 0.00073431147
was O 0 0.0005273125
associated O 0 0.00043160288
with O 0 0.00039994693
daytime O 0 0.0024124
and O 0 0.0002800502
night O 0 0.00054941664
- O 0 0.00097532535
time O 0 0.0001167785
symptoms O 0 0.00081877026
indicative O 0 0.000113476504
of O 0 0.00014928805
poorer O 0 0.000493893
health O 0 0.00048790942
and O 0 0.00016899772
potentially O 0 0.00015457533
caused O 0 0.00015388736
by O 0 0.00016549567
the O 0 0.00017197641
adverse O 0 0.00069460593
effects O 0 0.00029378288
of O 0 0.00057585654
these O 0 0.00093067955
drugs O 0 0.035315238
. O 0 0.0030105168

Acute O 0 0.13613503
vocal B-Disease 0 0.021791901
fold I-Disease 0 0.01175885
palsy I-Disease 0 0.9999052
after O 0 0.0031254205
acute O 0 0.8751806
disulfiram B-Chemical 0 0.99996424
intoxication O 0 0.99897575
. O 0 0.009908996

Acute O 0 0.27903754
peripheral B-Disease 0 0.4964479
neuropathy I-Disease 0 0.9999417
caused O 0 0.0014568722
by O 0 0.00090085645
a O 0 0.0032791966
disulfiram B-Chemical 0 0.9999957
overdose B-Disease 0 0.99994195
is O 0 0.00031364575
very O 0 0.0003788504
rare O 0 0.00086575403
and O 0 0.00018556019
there O 0 0.00013290627
is O 0 0.00014393586
no O 0 0.00018652591
report O 0 0.00044522394
of O 0 0.00035226863
it O 0 0.00055718445
leading O 0 0.0005160093
to O 0 0.00058092276
vocal B-Disease 0 0.006040023
fold I-Disease 0 0.0042008674
palsy I-Disease 0 0.99995995
. O 0 0.00500172

A O 0 0.030450387
49 O 0 0.0054941727
- O 0 0.0077825906
year O 0 0.0013879912
- O 0 0.003345849
old O 0 0.00096068636
woman O 0 0.001421059
was O 0 0.00036931454
transferred O 0 0.0003618026
to O 0 0.00018657946
our O 0 0.00018239113
department O 0 0.00037419243
because O 0 0.00015184293
of O 0 0.00041927863
quadriparesis B-Disease 0 0.9995437
, O 0 0.00095621834
lancinating O 0 0.08930418
pain B-Disease 0 0.04018573
, O 0 0.0004861194
sensory B-Disease 0 0.0015586169
loss I-Disease 0 0.00076882506
, O 0 0.00061818206
and O 0 0.0005179099
paresthesia B-Disease 0 0.9617444
of O 0 0.0005760419
the O 0 0.00058992405
distal O 0 0.0023179234
limbs O 0 0.021770557
. O 0 0.0032163789

One O 0 0.0031649137
month O 0 0.0012260041
previously O 0 0.0012288586
, O 0 0.0014722134
she O 0 0.0006168872
had O 0 0.00040721954
taken O 0 0.0002709218
a O 0 0.00032621305
single O 0 0.00015350178
high O 0 0.00024583432
dose O 0 0.00045269114
of O 0 0.0004830859
disulfiram B-Chemical 0 0.99998534
( O 0 0.00088683935
130 O 0 0.0005441339
tablets O 0 0.008633592
of O 0 0.00027279468
ALCOHOL B-Chemical 0 0.008067767
STOP O 0 0.0006877882
TAB O 0 0.092746094
, O 0 0.0006885214
Shin O 0 0.0017213563
- O 0 0.0121988375
Poong O 0 0.6922071
Pharm O 0 0.9607842
. O 0 0.0006314541
Co O 0 0.6758431
. O 0 0.0004586243
, O 0 0.000843803
Ansan O 0 0.01389911
, O 0 0.0009010058
Korea O 0 0.0008961068
) O 0 0.0011777433
in O 0 0.0006720107
a O 0 0.0016615211
suicide O 0 0.16234906
attempt O 0 0.0027996928
. O 0 0.0038332716

She O 0 0.018336315
was O 0 0.008757309
not O 0 0.008071017
an O 0 0.012262909
alcoholic O 0 0.9935133
. O 0 0.02069793

For O 0 0.001447253
the O 0 0.0010864416
first O 0 0.0005406742
few O 0 0.00036870243
days O 0 0.0003037407
after O 0 0.00027164083
ingestion O 0 0.002549207
, O 0 0.0007179778
she O 0 0.00032040788
was O 0 0.00025156522
in O 0 0.00026614804
a O 0 0.000519653
confused O 0 0.0015237601
state O 0 0.0003286908
and O 0 0.0003025367
had O 0 0.00035983813
mild O 0 0.013618265
to O 0 0.00049179385
moderate O 0 0.0277361
ataxia B-Disease 0 0.9999608
and O 0 0.0048172274
giddiness B-Disease 0 0.99966013
. O 0 0.0046571875

She O 0 0.00796681
noticed O 0 0.0049546277
hoarseness B-Disease 2 0.96022177
and O 0 0.0017654728
distally O 0 0.00609755
accentuated O 0 0.0052216756
motor O 0 0.0021162783
and O 0 0.0004364165
sensory O 0 0.00073934457
dysfunction O 0 0.06563404
after O 0 0.00019679942
she O 0 0.00030430764
had O 0 0.00033918244
recovered O 0 0.0003937124
from O 0 0.00059141184
this O 0 0.0011392512
state O 0 0.0022439235
. O 0 0.0034790225

A O 0 0.08995142
nerve O 0 0.080507465
conduction O 0 0.009437074
study O 0 0.0018233472
was O 0 0.0010238659
consistent O 0 0.00082497287
with O 0 0.0012898687
severe O 0 0.008111705
sensorimotor O 0 0.13202684
axonal O 0 0.046586823
polyneuropathy B-Disease 0 0.9980392
. O 0 0.005319012

Laryngeal O 0 0.024272427
electromyography O 0 0.026705217
( O 0 0.005561382
thyroarytenoid O 0 0.009548867
muscle O 0 0.006425841
) O 0 0.0031536405
showed O 0 0.0015065516
ample O 0 0.003068463
denervation O 0 0.17438477
potentials O 0 0.009556338
. O 0 0.006112764

Laryngoscopy O 0 0.016521744
revealed O 0 0.003410185
asymmetric O 0 0.0037252977
vocal O 0 0.006704822
fold O 0 0.0031739466
movements O 0 0.0047192317
during O 0 0.0030600228
phonation O 0 0.026866036
. O 0 0.0070208847

Her O 0 0.0073772
vocal O 0 0.0073073185
change O 0 0.002002935
and O 0 0.0019272299
weakness O 0 0.3365179
began O 0 0.000973489
to O 0 0.0005076431
improve O 0 0.00042063333
spontaneously O 0 0.001054361
about O 0 0.0005725569
3 O 0 0.00044508773
weeks O 0 0.00034922824
after O 0 0.00057852746
transfer O 0 0.0017075682
. O 0 0.0034284536

This O 0 0.0054462673
was O 0 0.0022285616
a O 0 0.0019920669
case O 0 0.0012204185
of O 0 0.001348851
acute O 0 0.8766949
palsy B-Disease 0 0.99999213
of O 0 0.0006816835
the O 0 0.00033960547
recurrent O 0 0.002946007
laryngeal O 0 0.020631367
nerve O 0 0.0054492694
and O 0 0.00017277226
superimposed O 0 0.00027397939
severe O 0 0.0024383015
acute O 0 0.08172693
sensorimotor O 0 0.15820988
axonal O 0 0.012383785
polyneuropathy B-Disease 0 0.99929976
caused O 0 0.00020623892
by O 0 0.00021843462
high O 0 0.0005231176
- O 0 0.007223484
dose O 0 0.0049062967
disulfiram B-Chemical 0 0.99998224
intoxication O 0 0.9992488
. O 0 0.004236845

Encephalopathy B-Disease 0 0.99549073
induced O 0 0.005864171
by O 0 0.006186073
levetiracetam B-Chemical 0 0.9998541
added O 0 0.006483332
to O 0 0.0054813176
valproate B-Chemical 0 0.99980825
. O 0 0.009685769

BACKGROUND O 0 0.017073631
: O 0 0.004384942
We O 0 0.0011113028
report O 0 0.0013300013
on O 0 0.0005157642
the O 0 0.00055887696
manifestation O 0 0.0023840328
of O 0 0.00071800756
a O 0 0.0019750388
levetiracetam B-Chemical 0 0.99998105
( O 0 0.0071573756
LEV B-Chemical 0 0.9998578
) O 0 0.003171956
- O 0 0.0055079097
induced O 0 0.0022464092
encephalopathy B-Disease 2 0.9998864
. O 0 0.0061526624

FINDINGS O 0 0.010525704
: O 0 0.0060162293
A O 0 0.008902687
28 O 0 0.0016795084
- O 0 0.0035537903
year O 0 0.0007654381
- O 0 0.0023584487
old O 0 0.00078890764
man O 0 0.0065563056
suffering O 0 0.029094556
from O 0 0.0006075059
idiopathic B-Disease 0 0.99990463
epilepsy I-Disease 0 0.9999993
with O 0 0.0018796257
generalized O 0 0.9472537
seizures B-Disease 0 0.99999785
was O 0 0.00024756262
treated O 0 0.0004229868
with O 0 0.0003664054
LEV B-Chemical 0 0.9999403
( O 0 0.0004388524
3000 O 0 0.0006521658
mg O 0 0.00262996
) O 0 0.00034926357
added O 0 0.00023941758
to O 0 0.00035924057
valproate B-Chemical 0 0.99998784
( O 0 0.010477373
VPA B-Chemical 1 0.9999881
) O 0 0.0032777444
( O 0 0.0013346049
2000 O 0 0.0017725974
mg O 0 0.01172066
) O 0 0.0034505902
. O 0 0.0030815217

Frequency O 0 0.0045961887
of O 0 0.0028205349
generalized O 0 0.008006122
tonic B-Disease 0 0.029202083
- I-Disease 0 0.446203
clonic I-Disease 0 0.9998504
seizures I-Disease 0 0.9999944
increased O 0 0.0011357946
from O 0 0.000294737
one O 0 0.00021963629
per O 0 0.00019070439
6 O 0 0.00013723526
months O 0 0.000109533445
to O 0 0.00021181628
two O 0 0.00029831578
per O 0 0.00062661926
month O 0 0.0007823738
. O 0 0.0023733745

Neuropsychological O 0 0.15659393
testing O 0 0.0017848569
showed O 0 0.0012700236
impaired B-Disease 0 0.002961205
word I-Disease 0 0.0054843435
fluency I-Disease 0 0.9993826
, I-Disease 0 0.00619066
psychomotor I-Disease 0 0.9989618
speed I-Disease 0 0.0031748158
and I-Disease 0 0.0014252701
working I-Disease 0 0.0036129137
memory I-Disease 0 0.24419741
. O 0 0.005575191

The O 0 0.0029673113
interictal O 0 0.6598697
electroencephalogram O 0 0.43209124
( O 0 0.0029120063
EEG O 0 0.47014946
) O 0 0.0012578862
showed O 0 0.00036001726
a O 0 0.000524896
generalized O 0 0.0012109885
slowing O 0 0.0008810305
to O 0 0.0001803909
5 O 0 0.00016151868
per O 0 0.0001300497
second O 0 0.00014031788
theta O 0 0.002631898
rhythms O 0 0.00037604893
with O 0 0.00024281461
bilateral O 0 0.0017566325
generalized O 0 0.0010558678
high O 0 0.000668294
- O 0 0.0032506862
amplitude O 0 0.0021945531
discharges O 0 0.004159375
. O 0 0.002501084

OUTCOME O 0 0.0057969643
: O 0 0.0026713258
Following O 0 0.0007535567
discontinuation O 0 0.0028271743
of O 0 0.0012313207
LEV B-Chemical 0 0.9996487
, O 0 0.0015891902
EEG O 0 0.35130867
and O 0 0.0004868161
neuropsychological O 0 0.11803036
findings O 0 0.00043681654
improved O 0 0.0006630973
and O 0 0.0008452715
seizure B-Disease 0 0.9959125
frequency O 0 0.0012178145
decreased O 0 0.0031972863
. O 0 0.0034509017

Norepinephrine B-Chemical 0 0.99926764
signaling O 0 0.0026876046
through O 0 0.0021592705
beta O 0 0.91454387
- O 0 0.3971073
adrenergic O 0 0.97172654
receptors O 0 0.0016191971
is O 0 0.00032497448
critical O 0 0.00022510662
for O 0 0.00024247706
expression O 0 0.00037074092
of O 0 0.0009614757
cocaine B-Chemical 0 0.99973017
- O 0 0.025168018
induced O 0 0.0019326562
anxiety B-Disease 0 0.996591
. O 0 0.0041867383

BACKGROUND O 0 0.038855843
: O 0 0.015627591
Cocaine B-Chemical 0 0.9997578
is O 0 0.0011611163
a O 0 0.0011824978
widely O 0 0.000805907
abused O 0 0.49857274
psychostimulant O 0 0.98878133
that O 0 0.0003395584
has O 0 0.00024830017
both O 0 0.00035340287
rewarding O 0 0.0014790621
and O 0 0.00075265643
aversive O 0 0.002269648
properties O 0 0.0011943978
. O 0 0.003053996

While O 0 0.0017808039
the O 0 0.0011960161
mechanisms O 0 0.00087732944
underlying O 0 0.0017969871
cocaine B-Chemical 0 0.99928516
' O 0 0.001354301
s O 0 0.0005484704
rewarding O 0 0.00073878886
effects O 0 0.00017672557
have O 0 0.00014559785
been O 0 0.00014478643
studied O 0 0.00022200997
extensively O 0 0.00017687175
, O 0 0.00030361008
less O 0 0.00021571337
attention O 0 0.00050955074
has O 0 9.031069e-05
been O 0 0.00011260211
paid O 0 0.0001924054
to O 0 0.0001069417
the O 0 0.00012817113
unpleasant O 0 0.0072881673
behavioral O 0 0.00076770195
states O 0 0.00025950643
induced O 0 0.00023225172
by O 0 0.00045051155
cocaine B-Chemical 0 0.9995788
, O 0 0.0011830076
such O 0 0.0006428788
as O 0 0.0012805606
anxiety B-Disease 0 0.99526864
. O 0 0.0036557105

METHODS O 0 0.003774065
: O 0 0.0024277905
In O 0 0.0006693103
this O 0 0.00078699185
study O 0 0.0007024551
, O 0 0.00067028304
we O 0 0.00019394353
evaluated O 0 0.00025380455
the O 0 0.00020822865
performance O 0 0.00045515073
of O 0 0.00087949476
dopamine B-Chemical 0 0.9999281
beta O 0 0.9935221
- O 0 0.40268156
hydroxylase O 0 0.2709623
knockout O 0 0.00013090293
( O 0 0.00042193691
Dbh O 0 0.0007223947
- O 0 0.0020124314
/ O 0 0.0015474344
- O 0 0.0014147843
) O 0 0.00031788132
mice O 0 6.110014e-05
, O 0 0.00026545828
which O 0 0.00021878853
lack O 0 0.00031793254
norepinephrine B-Chemical 0 0.99997985
( O 0 0.003628009
NE B-Chemical 0 0.9998178
) O 0 0.0009874378
, O 0 0.00027820677
in O 0 0.00011021908
the O 0 0.000101077785
elevated O 0 0.0004482686
plus O 0 0.00018928305
maze O 0 0.69496655
( O 0 0.001543852
EPM O 0 0.99905556
) O 0 0.00037590202
to O 0 7.0963484e-05
examine O 0 3.9176353e-05
the O 0 7.66371e-05
contribution O 0 8.640121e-05
of O 0 0.0002463714
noradrenergic O 0 0.029570162
signaling O 0 0.00019584772
to O 0 0.0003733912
cocaine B-Chemical 0 0.9997415
- O 0 0.017380167
induced O 0 0.0014064285
anxiety B-Disease 0 0.99734914
. O 0 0.0033789948

RESULTS O 0 0.004523862
: O 0 0.002947816
We O 0 0.0007945679
found O 0 0.00071223144
that O 0 0.0006462778
cocaine B-Chemical 0 0.9992198
dose O 0 0.003314309
- O 0 0.024595361
dependently O 0 0.2276456
increased O 0 0.0009922609
anxiety B-Disease 0 0.99907863
- O 0 0.0021685676
like O 0 0.00013862713
behavior O 0 0.0002244521
in O 0 0.00014494943
control O 0 0.00018678095
( O 0 0.00039390926
Dbh O 0 0.000574133
+ O 0 0.0009929265
/ O 0 0.0016783462
- O 0 0.0014998006
) O 0 0.0003579132
mice O 0 7.322578e-05
, O 0 0.00029363277
as O 0 0.00019302827
measured O 0 0.00025107616
by O 0 0.0002524097
a O 0 0.00043487042
decrease O 0 0.00038644322
in O 0 0.00039901485
open O 0 0.00071769865
arm O 0 0.0012837264
exploration O 0 0.002448287
. O 0 0.0029046086

The O 0 0.0028738105
Dbh O 0 0.006425846
- O 0 0.009811578
/ O 0 0.005451588
- O 0 0.0027577246
mice O 0 0.00023532734
had O 0 0.0003360044
normal O 0 0.00039775704
baseline O 0 0.00019657025
performance O 0 0.00027753992
in O 0 0.00023017378
the O 0 0.000315356
EPM O 0 0.9986714
but O 0 0.0003664828
were O 0 0.00019035088
completely O 0 0.00018728904
resistant O 0 0.00028113043
to O 0 0.00020861617
the O 0 0.0002896981
anxiogenic O 0 0.2279563
effects O 0 0.00065573945
of O 0 0.0017686136
cocaine B-Chemical 0 0.99943954
. O 0 0.0040125754

Cocaine B-Chemical 0 0.999861
- O 0 0.14226072
induced O 0 0.002644174
anxiety B-Disease 0 0.9968887
was O 0 0.0007193705
also O 0 0.00041657247
attenuated O 0 0.00052606297
in O 0 0.00034374226
Dbh O 0 0.00088868174
+ O 0 0.0012588905
/ O 0 0.0013680394
- O 0 0.00070959196
mice O 0 5.5518936e-05
following O 0 8.1214006e-05
administration O 0 0.00030369204
of O 0 0.00047067972
disulfiram B-Chemical 0 0.9999908
, O 0 0.0029814637
a O 0 0.0032090293
dopamine B-Chemical 0 0.9999424
beta O 0 0.99652207
- O 0 0.784458
hydroxylase O 0 0.95754516
( O 0 0.005020383
DBH O 0 0.9811137
) O 0 0.003664255
inhibitor O 0 0.005123015
. O 0 0.0038727338

In O 0 0.0015878524
experiments O 0 0.0011437975
using O 0 0.0009263724
specific O 0 0.00074274954
adrenergic O 0 0.95367897
antagonists O 0 0.14407825
, O 0 0.0008699159
we O 0 0.00015772808
found O 0 0.0002233938
that O 0 0.00016918879
pretreatment O 0 0.0013213998
with O 0 0.00026221684
the O 0 0.00025847767
beta O 0 0.95306486
- O 0 0.5532819
adrenergic O 0 0.99588376
receptor O 0 0.02233958
antagonist O 0 0.9813996
propranolol B-Chemical 0 0.9999994
blocked O 0 0.031679217
cocaine B-Chemical 0 0.99997854
- O 0 0.035611965
induced O 0 0.00023252204
anxiety B-Disease 0 0.99939525
- O 0 0.0018187334
like O 0 9.291509e-05
behavior O 0 0.00017777343
in O 0 0.0001314058
Dbh O 0 0.00047661606
+ O 0 0.00089273887
/ O 0 0.0015122159
- O 0 0.0011567137
and O 0 0.00016122818
wild O 0 0.00017551212
- O 0 0.0013753126
type O 0 0.00040173967
C57BL6 O 0 0.00057235075
/ O 0 0.0010381523
J O 0 0.042030185
mice O 0 7.7942575e-05
, O 0 0.00027916412
while O 0 0.00016341342
the O 0 0.00020085245
alpha O 0 0.42965722
( O 0 0.0006773107
1 O 0 0.00026219856
) O 0 0.0009394022
antagonist O 0 0.680942
prazosin B-Chemical 0 0.9999975
and O 0 0.00046027012
the O 0 0.0002659066
alpha O 0 0.50240314
( O 0 0.0007625383
2 O 0 0.0003382874
) O 0 0.0013407033
antagonist O 0 0.76868314
yohimbine B-Chemical 1 0.99999404
had O 0 0.0010578935
no O 0 0.0008015232
effect O 0 0.0014639524
. O 0 0.003391388

CONCLUSIONS O 0 0.01687188
: O 0 0.0032553975
These O 0 0.0006906889
results O 0 0.0005698019
indicate O 0 0.00035144918
that O 0 0.0004741123
noradrenergic O 0 0.013142146
signaling O 0 0.00031436962
via O 0 0.00037191834
beta O 0 0.879076
- O 0 0.2850213
adrenergic O 0 0.9560954
receptors O 0 0.00068627996
is O 0 0.00015091366
required O 0 0.000112367845
for O 0 0.0002721878
cocaine B-Chemical 0 0.99969923
- O 0 0.009219357
induced O 0 0.00071017543
anxiety B-Disease 0 0.9906859
in O 0 0.0008474042
mice O 0 0.00064926833
. O 0 0.0024498599

Hypothalamic O 0 0.92309475
prolactin O 0 0.9988243
receptor O 0 0.61446756
messenger O 0 0.52138513
ribonucleic B-Chemical 0 0.9994822
acid I-Chemical 0 0.9981166
levels O 0 0.0014445961
, O 0 0.002912818
prolactin O 0 0.97294676
signaling O 0 0.00032362092
, O 0 0.00056612917
and O 0 0.00039082678
hyperprolactinemic B-Disease 0 0.9995505
inhibition O 0 0.00044095246
of O 0 0.0003488576
pulsatile O 0 0.020156315
luteinizing O 0 0.72184265
hormone O 0 0.6534131
secretion O 0 0.0036732384
are O 0 0.00036602345
dependent O 0 0.00040519336
on O 0 0.0009032333
estradiol B-Chemical 0 0.99955493
. O 0 0.004975136

Hyperprolactinemia B-Disease 0 0.99894327
can O 0 0.0059177214
reduce O 0 0.0040514474
fertility O 0 0.011775291
and O 0 0.007906357
libido O 0 0.86930907
. O 0 0.012718744

Although O 0 0.0025364356
central O 0 0.0051345327
prolactin O 0 0.9607091
actions O 0 0.0020469334
are O 0 0.0006795925
thought O 0 0.00054118515
to O 0 0.00034926424
contribute O 0 0.00032946788
to O 0 0.00031479134
this O 0 0.0004153243
, O 0 0.00065070426
the O 0 0.0003343321
mechanisms O 0 0.00042204815
are O 0 0.0007119458
poorly O 0 0.0020594385
understood O 0 0.0038181164
. O 0 0.004141321

We O 0 0.0020211122
first O 0 0.00094888255
tested O 0 0.00075312855
whether O 0 0.00039891747
chronic O 0 0.36367318
hyperprolactinemia B-Disease 0 0.9999745
inhibited O 0 0.0012736953
two O 0 0.00023624052
neuroendocrine O 0 0.0060176495
parameters O 0 0.00019471045
necessary O 0 8.413199e-05
for O 0 0.000111301546
female O 0 0.0004234088
fertility O 0 0.00079365313
: O 0 0.00066578726
pulsatile O 0 0.0039666723
LH O 0 0.94810516
secretion O 0 0.0024015515
and O 0 0.00048725598
the O 0 0.00061926973
estrogen B-Chemical 0 0.9997093
- O 0 0.08246107
induced O 0 0.0018310919
LH O 0 0.99282736
surge O 0 0.11142402
. O 0 0.004088759

Chronic O 0 0.48378313
hyperprolactinemia B-Disease 0 0.99983907
induced O 0 0.002034031
by O 0 0.0013089783
the O 0 0.0017770765
dopamine B-Chemical 0 0.99995506
antagonist O 0 0.9983286
sulpiride B-Chemical 0 0.9999994
caused O 0 0.0006225704
a O 0 0.00044749214
40 O 0 0.0002299073
% O 0 0.00033692262
reduction O 0 0.000273754
LH O 0 0.6296335
pulse O 0 0.0002650574
frequency O 0 9.6199234e-05
in O 0 0.00010951129
ovariectomized O 0 0.013756196
rats O 0 0.00035601816
, O 0 0.00030762897
but O 0 0.00016401084
only O 0 0.00014306807
in O 0 0.00012449514
the O 0 0.0001174714
presence O 0 0.00015835617
of O 0 0.00028070592
chronic O 0 0.006219386
low O 0 0.0006453887
levels O 0 0.0006561073
of O 0 0.0020227404
estradiol B-Chemical 0 0.9997644
. O 0 0.005409957

Sulpiride B-Chemical 0 0.99996567
did O 0 0.0041709673
not O 0 0.0011978557
affect O 0 0.0005593006
the O 0 0.00041764847
magnitude O 0 0.0004097229
of O 0 0.0005031403
a O 0 0.0010234154
steroid B-Chemical 0 0.9909769
- O 0 0.02041106
induced O 0 0.0005557807
LH O 0 0.98926383
surge O 0 0.006786466
or O 0 0.00018556214
the O 0 0.00013714838
percentage O 0 0.00013974623
of O 0 0.00028735993
GnRH O 0 0.000966252
neurons O 0 0.00035533137
activated O 0 0.00037359825
during O 0 0.00041773028
the O 0 0.00087111414
surge O 0 0.007687713
. O 0 0.003346636

Estradiol B-Chemical 0 0.99976295
is O 0 0.0025902868
known O 0 0.0011793706
to O 0 0.0005591527
influence O 0 0.00031402515
expression O 0 0.00032119144
of O 0 0.0003444863
the O 0 0.00023386632
long O 0 0.00027202695
form O 0 0.00026495304
of O 0 0.0005028
prolactin O 0 0.9937558
receptors O 0 0.0041119815
( O 0 0.0038194673
PRL O 0 0.9999455
- O 0 0.22913188
R O 0 0.9950145
) O 0 0.0010086077
and O 0 0.0002549916
components O 0 0.00025862313
of O 0 0.0005970226
prolactin O 0 0.9689237
' O 0 0.001628649
s O 0 0.0010297422
signaling O 0 0.00076309993
pathway O 0 0.0012657256
. O 0 0.0029401276

To O 0 0.0014784356
test O 0 0.002050808
the O 0 0.0009617158
hypothesis O 0 0.0009340691
that O 0 0.0010775785
estrogen B-Chemical 0 0.99961746
increases O 0 0.004506065
PRL O 0 0.99996936
- O 0 0.49307516
R O 0 0.99365705
expression O 0 0.00024253535
and O 0 0.00020941973
sensitivity O 0 0.00035581613
to O 0 0.000251331
prolactin O 0 0.9789411
, O 0 0.00033038575
we O 0 6.1789804e-05
next O 0 5.9363392e-05
demonstrated O 0 0.00015177982
that O 0 0.00025752574
estradiol B-Chemical 0 0.9999416
greatly O 0 0.003360706
augments O 0 0.0065288334
prolactin O 0 0.999252
- O 0 0.036938705
induced O 0 0.0009692366
STAT5 O 0 0.010244027
activation O 0 0.0018707837
. O 0 0.0029401304

Lastly O 0 0.004021848
, O 0 0.004334036
we O 0 0.0014561247
measured O 0 0.003474697
PRL O 0 0.99976236
- O 0 0.39875656
R O 0 0.99446553
and O 0 0.0009609666
suppressor O 0 0.0008895865
of O 0 0.00047672895
cytokine O 0 0.004371646
signaling O 0 0.00034575092
( O 0 0.00088212115
SOCS O 0 0.00714808
- O 0 0.0029908433
1 O 0 0.00023816583
and O 0 0.00021115728
- O 0 0.00090076245
3 O 0 0.00014744498
and O 0 0.00023015754
CIS O 0 0.25703412
, O 0 0.0003893061
which O 0 0.00017358089
reflect O 0 0.0001072769
the O 0 0.00010221433
level O 0 0.00013521333
of O 0 0.0003108321
prolactin O 0 0.9620125
signaling O 0 0.00023116654
) O 0 0.0005402387
mRNAs O 0 0.00019118378
in O 0 0.00021583948
response O 0 0.00035001087
to O 0 0.0007903366
sulpiride B-Chemical 0 0.99999654
and O 0 0.005436882
estradiol B-Chemical 0 0.9997944
. O 0 0.005330878

Sulpiride B-Chemical 0 0.99994147
induced O 0 0.004327313
only O 0 0.0032425711
SOCS O 0 0.057199426
- O 0 0.011452693
1 O 0 0.00071121135
in O 0 0.00038418992
the O 0 0.000351487
medial O 0 0.0050087725
preoptic O 0 0.0006704591
area O 0 0.00030781084
, O 0 0.00033177232
where O 0 0.0001923375
GnRH O 0 0.00050605263
neurons O 0 0.00016255588
are O 0 8.98155e-05
regulated O 0 6.363648e-05
, O 0 0.0003258816
but O 0 0.00022485564
in O 0 0.00017120989
the O 0 0.00017775073
arcuate O 0 0.0007526206
nucleus O 0 0.00017109468
and O 0 0.0003464149
choroid O 0 0.99553764
plexus O 0 0.3056944
, O 0 0.0017328843
PRL O 0 0.9999187
- O 0 0.18708496
R O 0 0.99682546
, O 0 0.0015413096
SOCS O 0 0.01166617
- O 0 0.002844359
3 O 0 0.00024732176
, O 0 0.0004688898
and O 0 0.00044251088
CIS O 0 0.22228263
mRNA O 0 0.00056199194
levels O 0 0.000498625
were O 0 0.00061540114
also O 0 0.00084454496
induced O 0 0.0017157526
. O 0 0.0035772047

Estradiol B-Chemical 0 0.9993142
enhanced O 0 0.004778432
these O 0 0.002311081
effects O 0 0.0019508296
on O 0 0.0018321258
SOCS O 0 0.0150674675
- O 0 0.009454912
3 O 0 0.0021726731
and O 0 0.0034116583
CIS O 0 0.24774057
. O 0 0.0069717364

Interestingly O 0 0.004169474
, O 0 0.012094306
estradiol B-Chemical 0 0.9994349
also O 0 0.0029103912
induced O 0 0.004050354
PRL O 0 0.9998988
- O 0 0.5994842
R O 0 0.99724776
, O 0 0.0033744308
SOCS O 0 0.014087124
- O 0 0.0041298084
3 O 0 0.00053247897
, O 0 0.00096768094
and O 0 0.0009271371
CIS O 0 0.1747267
mRNA O 0 0.001313745
levels O 0 0.0013149525
independently O 0 0.0017332622
. O 0 0.0039205737

These O 0 0.0022311779
data O 0 0.0019904738
show O 0 0.0008460133
that O 0 0.00069200725
GnRH O 0 0.001642689
pulse O 0 0.0008382122
frequency O 0 0.00035730566
is O 0 0.00028571702
inhibited O 0 0.0005552965
by O 0 0.00048346134
chronic O 0 0.2974535
hyperprolactinemia B-Disease 0 0.99996674
in O 0 0.0006890653
a O 0 0.0014334283
steroid B-Chemical 0 0.9870956
- O 0 0.0078143915
dependent O 0 0.0007189367
manner O 0 0.001517921
. O 0 0.0030814414

They O 0 0.0039633694
also O 0 0.0013574879
provide O 0 0.0007090586
evidence O 0 0.00073483086
for O 0 0.0010036405
estradiol B-Chemical 0 0.99986804
- O 0 0.042431552
dependent O 0 0.00030587104
and O 0 0.0003494213
brain O 0 0.00074001815
region O 0 0.00017073777
- O 0 0.0006862541
specific O 0 9.608675e-05
regulation O 0 0.00011084219
of O 0 0.00059757737
PRL O 0 0.99993575
- O 0 0.2277952
R O 0 0.98779476
expression O 0 0.00035380622
and O 0 0.00037779243
signaling O 0 0.00037102448
responses O 0 0.0007168005
by O 0 0.0014762818
prolactin O 0 0.9809764
. O 0 0.004335814

Clonidine B-Chemical 0 0.9998122
for O 0 0.0037049057
attention B-Disease 0 0.009471468
- I-Disease 0 0.02057041
deficit I-Disease 0 0.58954835
/ I-Disease 0 0.34621617
hyperactivity I-Disease 2 0.9999863
disorder I-Disease 0 0.9995066
: O 0 0.014853572
II O 0 0.14665852
. O 0 0.0066954764

ECG O 0 0.049538143
changes O 0 0.0058046146
and O 0 0.004843483
adverse O 0 0.008738629
events O 0 0.006354463
analysis O 0 0.0058321976
. O 0 0.0084145805

OBJECTIVE O 0 0.015288081
: O 0 0.0024359191
To O 0 0.00033400522
examine O 0 0.0002100258
the O 0 0.00024055365
safety O 0 0.00023501659
and O 0 0.0001996008
tolerability O 0 0.00047704147
of O 0 0.00031738018
clonidine B-Chemical 0 0.9999535
used O 0 0.00014688453
alone O 0 0.00015048645
or O 0 0.00012183569
with O 0 0.00032607684
methylphenidate B-Chemical 1 0.99999464
in O 0 0.00017249456
children O 0 0.00045125405
with O 0 0.00016889801
attention B-Disease 0 0.0014459271
- I-Disease 0 0.0065653627
deficit I-Disease 0 0.55718666
/ I-Disease 0 0.2646789
hyperactivity I-Disease 2 0.9999981
disorder I-Disease 0 0.999889
( O 0 0.040904418
ADHD B-Disease 0 0.9999734
) O 0 0.006976961
. O 0 0.0031584275

METHOD O 0 0.010559214
: O 0 0.0036943445
In O 0 0.00090268964
a O 0 0.0012705722
16 O 0 0.00091823825
- O 0 0.0017624844
week O 0 0.0003598366
multicenter O 0 0.0050632567
, O 0 0.0006347952
double O 0 0.00035909144
- O 0 0.0028786515
blind O 0 0.013567854
trial O 0 0.00060297275
, O 0 0.00048211296
122 O 0 0.00067256554
children O 0 0.0007526829
with O 0 0.0005136543
ADHD B-Disease 0 0.99999034
were O 0 0.00014322721
randomly O 0 6.198272e-05
assigned O 0 8.708303e-05
to O 0 0.00014065382
clonidine B-Chemical 0 0.99990416
( O 0 0.00029582652
n O 0 0.00016622474
= O 0 0.000396102
31 O 0 0.00022488394
) O 0 0.0004060328
, O 0 0.0005833508
methylphenidate B-Chemical 1 0.9999765
( O 0 0.00034819025
n O 0 0.00018036699
= O 0 0.00041413587
29 O 0 0.00023938948
) O 0 0.00044246114
, O 0 0.00063536625
clonidine B-Chemical 0 0.99996746
and O 0 0.0006240047
methylphenidate B-Chemical 1 0.99998903
( O 0 0.00040773768
n O 0 0.00020535845
= O 0 0.00044912382
32 O 0 0.00025082828
) O 0 0.000402036
, O 0 0.0003416505
or O 0 0.00023622702
placebo O 0 0.002085324
( O 0 0.00066736847
n O 0 0.0006166638
= O 0 0.0015499879
30 O 0 0.00091455696
) O 0 0.0027332923
. O 0 0.0030247045

Doses O 0 0.011087291
were O 0 0.0017094283
flexibly O 0 0.001463976
titrated O 0 0.0009992808
up O 0 0.00062097516
to O 0 0.0003491392
0 O 0 0.00040702993
. O 0 0.0002355532
6 O 0 0.00017926368
mg O 0 0.0011641874
/ O 0 0.0005992831
day O 0 0.00013273706
for O 0 0.000187885
clonidine B-Chemical 0 0.99985754
and O 0 0.00022966956
60 O 0 0.0002133423
mg O 0 0.0015353323
/ O 0 0.0005259109
day O 0 0.00011671405
for O 0 0.00021441557
methylphenidate B-Chemical 1 0.99997234
( O 0 0.00054357667
both O 0 0.00021090456
with O 0 0.00034764595
divided O 0 0.0006070833
dosing O 0 0.0010327544
) O 0 0.002376075
. O 0 0.0024910318

Groups O 0 0.007892321
were O 0 0.0013017221
compared O 0 0.00060164207
regarding O 0 0.00037941986
adverse O 0 0.0011903747
events O 0 0.000561249
and O 0 0.00032713832
changes O 0 0.00025182273
from O 0 0.00016793801
baseline O 0 0.00015615826
to O 0 0.00014293798
week O 0 0.00013516459
16 O 0 0.00025022874
in O 0 0.00028676004
electrocardiograms O 0 0.0019424676
and O 0 0.0007063393
vital O 0 0.0020679417
signs O 0 0.005481034
. O 0 0.0032177519

RESULTS O 0 0.004379026
: O 0 0.0029197326
There O 0 0.0011163503
were O 0 0.00071008474
more O 0 0.00075018057
incidents O 0 0.0009442078
of O 0 0.00053770567
bradycardia B-Disease 0 0.98540986
in O 0 0.00023402445
subjects O 0 0.00034368443
treated O 0 0.00036172278
with O 0 0.00031606818
clonidine B-Chemical 0 0.99997425
compared O 0 0.00010504723
with O 0 0.00012037809
those O 0 0.00012711502
not O 0 9.805189e-05
treated O 0 0.0003456138
with O 0 0.00042945685
clonidine B-Chemical 0 0.9999901
( O 0 0.0006298282
17 O 0 0.00019061042
. O 0 9.94055e-05
5 O 0 8.762942e-05
% O 0 0.00016290361
versus O 0 8.934294e-05
3 O 0 9.509636e-05
. O 0 0.00010102034
4 O 0 9.6093616e-05
% O 0 0.00022131739
; O 0 0.00024601087
p O 0 0.00027890233
= O 0 0.00051299087
. O 0 0.0002144442
02 O 0 0.008651597
) O 0 0.00056726974
, O 0 0.0003361375
but O 0 0.00017623589
no O 0 0.00011739861
other O 0 0.000113985785
significant O 0 0.00013731443
group O 0 0.00019399328
differences O 0 0.00010360386
regarding O 0 0.000112205744
electrocardiogram O 0 0.0015255503
and O 0 0.0002770123
other O 0 0.0004082262
cardiovascular O 0 0.055920437
outcomes O 0 0.0016209694
. O 0 0.0024259663

There O 0 0.0032652153
were O 0 0.0016153499
no O 0 0.0009778347
suggestions O 0 0.0008840346
of O 0 0.00069652393
interactions O 0 0.0005863154
between O 0 0.00076234405
clonidine B-Chemical 0 0.99993277
and O 0 0.001964007
methylphenidate B-Chemical 1 0.9999589
regarding O 0 0.0006917276
cardiovascular O 0 0.08196911
outcomes O 0 0.001992776
. O 0 0.0029183351

Moderate O 0 0.048477158
or O 0 0.0021804504
severe O 0 0.004442053
adverse O 0 0.00238046
events O 0 0.0007635921
were O 0 0.00032722906
more O 0 0.0003581118
common O 0 0.00024164276
in O 0 0.00018850029
subjects O 0 0.00036858823
on O 0 0.00022240724
clonidine B-Chemical 0 0.99995387
( O 0 0.0006127394
79 O 0 0.0002994507
. O 0 0.00013500448
4 O 0 0.0001055375
% O 0 0.0002144303
versus O 0 0.00012421803
49 O 0 0.00022893367
. O 0 0.00014828361
2 O 0 0.00016389467
% O 0 0.00028114516
; O 0 0.00029484832
p O 0 0.00032219436
= O 0 0.00057384407
. O 0 0.00022903607
0006 O 0 0.0024614257
) O 0 0.00065060967
but O 0 0.00023674607
not O 0 0.00016436151
associated O 0 0.00021030495
with O 0 0.000231348
higher O 0 0.00030134115
rates O 0 0.00038144604
of O 0 0.0004782635
early O 0 0.0010216511
study O 0 0.0012256035
withdrawal O 0 0.0057541323
. O 0 0.0027419117

Drowsiness B-Disease 0 0.99588144
was O 0 0.002726547
common O 0 0.0018362051
on O 0 0.0013679098
clonidine B-Chemical 0 0.9999201
, O 0 0.0027623074
but O 0 0.0009615994
generally O 0 0.0007214046
resolved O 0 0.0006863438
by O 0 0.0004891269
6 O 0 0.00042422308
to O 0 0.000516793
8 O 0 0.0008038741
weeks O 0 0.00086495053
. O 0 0.002844985

CONCLUSIONS O 0 0.07017232
: O 0 0.01908238
Clonidine B-Chemical 0 0.9999387
, O 0 0.0022562088
used O 0 0.000556262
alone O 0 0.00052149507
or O 0 0.0004026979
with O 0 0.0008442783
methylphenidate B-Chemical 1 0.9999877
, O 0 0.0008163067
appears O 0 0.00017400262
safe O 0 0.000300321
and O 0 0.0002747052
well O 0 0.00034996716
tolerated O 0 0.0010593579
in O 0 0.0010473072
childhood O 0 0.90366095
ADHD B-Disease 0 0.99996555
. O 0 0.0059231916

Physicians O 0 0.0054711266
prescribing O 0 0.015513119
clonidine B-Chemical 0 0.9997789
should O 0 0.00042643523
monitor O 0 0.00030730094
for O 0 0.000325465
bradycardia B-Disease 0 0.9669827
and O 0 0.00034456336
advise O 0 0.0006254247
patients O 0 0.00046541466
about O 0 0.00025638187
the O 0 0.00020606298
high O 0 0.0003676535
likelihood O 0 0.0004328006
of O 0 0.00073334255
initial O 0 0.0013244641
drowsiness B-Disease 0 0.9994072
. O 0 0.0037277672

Renal B-Disease 0 0.9779261
Fanconi I-Disease 0 0.9984547
syndrome I-Disease 0 0.9992544
and O 0 0.003934701
myopathy B-Disease 0 0.99902153
after O 0 0.0006627024
liver O 0 0.020006254
transplantation O 0 0.001148021
: O 0 0.0014736215
drug O 0 0.009009847
- O 0 0.0047717877
related O 0 0.0010621666
mitochondrial B-Disease 0 0.20788099
cytopathy I-Disease 0 0.99906236
? O 0 0.027890384

Advances O 0 0.003991859
in O 0 0.0016780716
the O 0 0.0009177672
field O 0 0.00093702663
of O 0 0.0005379415
transplantation O 0 0.00044894766
provide O 0 0.00016670855
a O 0 0.00025802536
better O 0 0.00018542966
quality O 0 0.000120641365
of O 0 0.00017200611
life O 0 0.0001757563
and O 0 0.00015445318
allow O 0 0.00012335034
more O 0 0.0002353527
favorable O 0 0.00034950505
conditions O 0 0.00020442407
for O 0 0.0002238569
growth O 0 0.0014270718
and O 0 0.0005350018
development O 0 0.0008321552
in O 0 0.000972133
children O 0 0.0042904853
. O 0 0.0030321016

However O 0 0.002776715
, O 0 0.00277325
combinations O 0 0.00092370634
of O 0 0.00081911177
different O 0 0.00043332114
therapeutic O 0 0.00062589464
regimens O 0 0.0005096635
require O 0 0.00027015028
consideration O 0 0.000294473
of O 0 0.0005337302
potential O 0 0.0007104364
adverse O 0 0.0039001356
reactions O 0 0.002363442
. O 0 0.003221694

We O 0 0.0030355311
describe O 0 0.0021806995
a O 0 0.0022121177
15 O 0 0.0012705046
- O 0 0.0028751227
yr O 0 0.00095677876
- O 0 0.0018725361
old O 0 0.000623503
girl O 0 0.0013617505
who O 0 0.0005523878
had O 0 0.0003582815
orthotopic O 0 0.0042759804
liver O 0 0.015790831
transplantation O 0 0.0005025474
because O 0 0.00024349669
of O 0 0.0005582128
Wilson B-Disease 0 0.0052005854
' I-Disease 0 0.0022548942
s I-Disease 0 0.0026271786
disease I-Disease 0 0.32308996
. O 0 0.0039593824

Tacrolimus B-Chemical 0 0.9992061
, O 0 0.02840499
MMF B-Chemical 0 0.9997708
, O 0 0.005484463
and O 0 0.0026255483
steroids B-Chemical 0 0.98203367
were O 0 0.0015179544
given O 0 0.0010701875
as O 0 0.0020624932
immunosuppressant O 0 0.20838651
. O 0 0.005788926

Lamivudine B-Chemical 1 0.99805295
was O 0 0.0027219465
added O 0 0.0019049185
because O 0 0.0009495445
of O 0 0.0014931975
de O 0 0.009082341
nova O 0 0.9716337
hepatitis B-Disease 2 0.99999726
B I-Disease 2 0.9993326
infection I-Disease 0 0.39310083
during O 0 0.00065717724
her O 0 0.0008946174
follow O 0 0.0007181693
- O 0 0.003870547
up O 0 0.0024692193
. O 0 0.0038617696

Three O 0 0.0022679307
yr O 0 0.0017828929
after O 0 0.0006037249
transplantation O 0 0.00088642206
she O 0 0.00062333397
developed O 0 0.001003916
renal B-Disease 0 0.99786526
Fanconi I-Disease 0 0.99974185
syndrome I-Disease 0 0.99981433
with O 0 0.0011008233
severe O 0 0.15520899
metabolic B-Disease 2 0.99631363
acidosis I-Disease 2 0.99999666
, O 0 0.110440016
hypophosphatemia B-Disease 0 0.99998605
, O 0 0.011043601
glycosuria B-Disease 2 0.99993265
, O 0 0.0040189875
and O 0 0.0028468692
aminoaciduria B-Disease 0 0.9999399
. O 0 0.0064804056

Although O 0 0.0036866162
tacrolimus B-Chemical 0 0.9998103
was O 0 0.0019729713
suspected O 0 0.0028417204
to O 0 0.0004839872
be O 0 0.00034078115
the O 0 0.00023437077
cause O 0 0.00028765405
of O 0 0.00023479083
late O 0 0.0004892197
post O 0 0.0001989969
- O 0 0.0012741284
transplant O 0 0.00057286426
renal O 0 0.91162103
acidosis B-Disease 0 0.9999188
and O 0 0.0002786522
was O 0 0.0001548109
replaced O 0 0.00014337506
by O 0 0.00028204295
sirolimus B-Chemical 0 0.99990106
, O 0 0.002778234
acidosis B-Disease 0 0.9999379
, O 0 0.0013905772
and O 0 0.0005917425
electrolyte O 0 0.1393055
imbalance O 0 0.002151243
got O 0 0.001688321
worse O 0 0.0035041177
. O 0 0.0029657264

Proximal O 0 0.13474047
muscle B-Disease 0 0.07991389
weakness I-Disease 0 0.71754
has O 0 0.0016394742
developed O 0 0.0017045529
during O 0 0.0011314789
her O 0 0.0018056106
follow O 0 0.0015164346
- O 0 0.0065099937
up O 0 0.0042389836
. O 0 0.006207117

Fanconi B-Disease 0 0.9978927
syndrome I-Disease 0 0.9978192
, O 0 0.0044536344
as O 0 0.0012498237
well O 0 0.00087544176
as O 0 0.0012217679
myopathy B-Disease 0 0.9996426
, O 0 0.0014010279
is O 0 0.00026712246
well O 0 0.00022075238
recognized O 0 0.00021414302
in O 0 0.00023693121
patients O 0 0.00070127094
with O 0 0.0005501301
mitochondrial B-Disease 0 0.975453
disorders I-Disease 0 0.9999286
and O 0 0.0006508047
caused O 0 0.00043523664
by O 0 0.0004986692
depletion O 0 0.00072165014
of O 0 0.0017633472
mtDNA O 0 0.06816405
. O 0 0.003990223

We O 0 0.0022391481
suggest O 0 0.0010126892
that O 0 0.0008816133
our O 0 0.0007915459
patient O 0 0.00087931997
' O 0 0.0012900713
s O 0 0.0014109274
tubular B-Disease 0 0.99793327
dysfunction I-Disease 0 0.9994456
and O 0 0.0017297122
myopathy B-Disease 0 0.9998436
may O 0 0.00022030558
have O 0 0.0001428501
resulted O 0 0.000156099
from O 0 0.00023494355
mitochondrial B-Disease 0 0.8436481
dysfunction I-Disease 0 0.9991721
which O 0 0.00031305186
is O 0 0.00012936325
triggered O 0 0.00015527435
by O 0 0.00034554375
tacrolimus B-Chemical 0 0.99995553
and O 0 0.0006038613
augmented O 0 0.0014369873
by O 0 0.001570295
lamivudine B-Chemical 0 0.99974734
. O 0 0.0036462743

Higher O 0 0.005254946
optical O 0 0.004980268
density O 0 0.0021457288
of O 0 0.0012759196
an O 0 0.001045598
antigen O 0 0.002330783
assay O 0 0.0008068053
predicts O 0 0.00054258335
thrombosis B-Disease 0 0.9998078
in O 0 0.00050911284
patients O 0 0.0009553118
with O 0 0.0007892212
heparin B-Chemical 0 0.9988274
- O 0 0.030660428
induced O 0 0.0021914179
thrombocytopenia B-Disease 0 0.99950016
. O 0 0.0040815

OBJECTIVES O 0 0.0035874199
: O 0 0.0025065872
To O 0 0.000494777
correlate O 0 0.0006871514
optical O 0 0.0011718592
density O 0 0.00061550067
and O 0 0.00035912378
percent O 0 0.00029569736
inhibition O 0 0.00030918675
of O 0 0.0002614983
a O 0 0.00030858276
two O 0 0.00015446334
- O 0 0.0014206342
step O 0 0.00026701475
heparin B-Chemical 0 0.9986436
- O 0 0.012965986
induced O 0 0.00043813762
thrombocytopenia B-Disease 0 0.9999243
( O 0 0.0027738288
HIT B-Disease 2 0.9997944
) O 0 0.0012340712
antigen O 0 0.0011995108
assay O 0 0.00029232778
with O 0 0.00031972132
thrombosis B-Disease 0 0.9999653
; O 0 0.0005091551
the O 0 9.328049e-05
assay O 0 0.00013762077
utilizes O 0 6.088639e-05
reaction O 0 0.000117114054
inhibition O 0 0.00018869739
characteristics O 0 0.00017124416
of O 0 0.00028569956
a O 0 0.0006328988
high O 0 0.0012025222
heparin B-Chemical 0 0.99778134
concentration O 0 0.0050001657
. O 0 0.0031467911

PATIENTS O 0 0.0019059533
AND O 0 0.0012651248
METHODS O 0 0.0011759032
: O 0 0.0011585342
Patients O 0 0.00062268786
with O 0 0.0004069397
more O 0 0.0004970199
than O 0 0.0003100915
50 O 0 0.0004111424
% O 0 0.00054047373
decrease O 0 0.00030271965
in O 0 0.00031531363
platelet O 0 0.55133075
count O 0 0.000305932
or O 0 0.00026926553
thrombocytopenia B-Disease 0 0.99908316
( O 0 0.00032145987
< O 0 0.00021395281
150 O 0 0.00018112305
x O 0 0.0004833699
10 O 0 0.00016810495
( O 0 0.00023796993
9 O 0 0.00013513469
) O 0 0.000392388
/ O 0 0.0011882811
L O 0 0.36736512
) O 0 0.00050552306
after O 0 7.432615e-05
exposure O 0 0.00014421035
to O 0 0.00015189654
heparin B-Chemical 0 0.9938024
, O 0 0.00042720707
who O 0 0.00022424503
had O 0 0.00011524494
a O 0 0.00016304875
positive O 0 0.00012734736
two O 0 9.921403e-05
- O 0 0.0009730111
step O 0 0.00013737139
antigen O 0 0.0007411996
assay O 0 0.00030466527
[ O 0 0.0009124385
optical O 0 0.00051817804
density O 0 0.00031104227
( O 0 0.0005223615
OD O 0 0.17430681
) O 0 0.0005602094
> O 0 0.0003813517
0 O 0 0.0001921476
. O 0 0.0001061719
4 O 0 8.072071e-05
and O 0 0.00010817801
> O 0 0.00028008493
50 O 0 0.00016992196
inhibition O 0 0.00015656916
with O 0 0.000151703
high O 0 0.00023230554
concentration O 0 0.00043713517
of O 0 0.0004262178
heparin B-Chemical 0 0.9989286
] O 0 0.0024934786
were O 0 0.00025771142
included O 0 0.00027466565
in O 0 0.00039396298
the O 0 0.00061998516
study O 0 0.0015055111
. O 0 0.0024963336

RESULTS O 0 0.0055211554
: O 0 0.0040961984
Forty O 0 0.002766009
of O 0 0.0014595411
94 O 0 0.0025588302
HIT B-Disease 2 0.99630296
patients O 0 0.0017942181
had O 0 0.00075775455
thrombosis B-Disease 0 0.9995946
at O 0 0.00034141363
diagnosis O 0 0.0006557354
; O 0 0.0006406505
54 O 0 0.00056037476
/ O 0 0.0011719826
94 O 0 0.0005800707
had O 0 0.00042528313
isolated O 0 0.0007899401
- O 0 0.019601453
HIT B-Disease 2 0.9985769
without O 0 0.003259672
thrombosis B-Disease 0 0.99975246
. O 0 0.00540162

Eight O 0 0.0038756337
of O 0 0.002135206
the O 0 0.0013333368
isolated O 0 0.0016077725
- O 0 0.052565295
HIT B-Disease 2 0.999027
patients O 0 0.0018239418
developed O 0 0.0007910015
thrombosis B-Disease 0 0.9997929
within O 0 0.00013079176
the O 0 0.000111199166
next O 0 6.772187e-05
30 O 0 0.00012345459
d O 0 0.00023335044
; O 0 0.00033757254
thus O 0 0.00018755066
, O 0 0.00035194925
a O 0 0.00028332582
total O 0 0.00020487655
of O 0 0.00024434042
48 O 0 0.000285058
patients O 0 0.0005427816
had O 0 0.00046682224
thrombosis B-Disease 0 0.99927896
at O 0 0.0004888395
day O 0 0.0005314744
30 O 0 0.0010418141
. O 0 0.0021582586

At O 0 0.0013753164
diagnosis O 0 0.002397944
there O 0 0.0008960142
was O 0 0.0007005943
no O 0 0.00047029645
significant O 0 0.00041677762
difference O 0 0.00034836755
in O 0 0.00044977135
OD O 0 0.07704444
between O 0 0.00047677034
HIT B-Disease 2 0.9991008
patients O 0 0.0010786374
with O 0 0.00055255863
thrombosis B-Disease 0 0.9998801
and O 0 0.0004974669
those O 0 0.0004641011
with O 0 0.00061665324
isolated O 0 0.0013185586
- O 0 0.04179281
HIT B-Disease 2 0.99793786
. O 0 0.0043616556

However O 0 0.003697087
, O 0 0.006197823
OD O 0 0.34397215
was O 0 0.0011442183
significantly O 0 0.0008146329
higher O 0 0.00056530803
in O 0 0.00036453322
all O 0 0.000299443
patients O 0 0.0005393966
with O 0 0.0004094168
thrombosis B-Disease 0 0.9997875
( O 0 0.00051482534
n O 0 0.00024815436
= O 0 0.0004840827
48 O 0 0.00018254109
, O 0 0.00027022528
1 O 0 0.00017485752
. O 0 0.00014312236
34 O 0 0.00021383716
+ O 0 0.0007288244
/ O 0 0.0014323455
- O 0 0.00142586
0 O 0 0.00025891716
. O 0 0.00016356356
89 O 0 0.00029563112
) O 0 0.0003846441
, O 0 0.00026488357
including O 0 0.00012689448
isolated O 0 0.00028959513
- O 0 0.025681227
HIT B-Disease 2 0.99962854
patients O 0 0.00072815025
who O 0 0.00022540086
later O 0 0.00011871595
developed O 0 0.0002581558
thrombosis B-Disease 0 0.9998375
within O 0 7.575862e-05
30 O 0 8.644588e-05
d O 0 0.00014628854
( O 0 0.00018981133
n O 0 0.0001529905
= O 0 0.00034703666
8 O 0 0.00012862094
, O 0 0.000228736
1 O 0 0.00015934616
. O 0 0.00013827268
84 O 0 0.00027096568
+ O 0 0.00071460113
/ O 0 0.0013942277
- O 0 0.0013632365
0 O 0 0.0002376262
. O 0 0.0001442179
64 O 0 0.00020142779
) O 0 0.00028763374
as O 0 0.00011550788
compared O 0 9.356772e-05
to O 0 0.00012697751
isolated O 0 0.00028429128
- O 0 0.034333747
HIT B-Disease 2 0.9997212
patients O 0 0.0009986113
who O 0 0.00029159346
did O 0 0.00017041572
not O 0 0.00015339497
develop O 0 0.00035789254
thrombosis B-Disease 0 0.9999436
( O 0 0.0005592585
0 O 0 0.00022169437
. O 0 0.00014889498
96 O 0 0.0004072581
+ O 0 0.0007983354
/ O 0 0.0015222431
- O 0 0.0014387529
0 O 0 0.00028608495
. O 0 0.00019754427
75 O 0 0.00033244258
; O 0 0.00047114567
P O 0 0.00504111
= O 0 0.00078433775
0 O 0 0.00040319527
. O 0 0.00036365885
011 O 0 0.004004747
and O 0 0.0005825237
P O 0 0.010725737
= O 0 0.0016582948
0 O 0 0.0010025807
. O 0 0.0010931591
008 O 0 0.0052616308
) O 0 0.004527338
. O 0 0.0044140113

The O 0 0.0035581545
Receiver O 0 0.013704365
Operative O 0 0.003199129
Characteristic O 0 0.0015915836
Curve O 0 0.0043078433
showed O 0 0.0005084218
that O 0 0.0004794242
OD O 0 0.080046445
> O 0 0.0013106163
1 O 0 0.00044047268
. O 0 0.0002719313
27 O 0 0.0002931626
in O 0 0.000173287
the O 0 0.0001713211
isolated O 0 0.00032075448
- O 0 0.00976322
HIT B-Disease 2 0.99888045
group O 0 0.00039799864
had O 0 0.00018364724
a O 0 0.0002469287
significantly O 0 0.00021372794
higher O 0 0.0002275802
chance O 0 0.0003650982
of O 0 0.00039650852
developing O 0 0.0018675019
thrombosis B-Disease 0 0.99985147
by O 0 0.0006991996
day O 0 0.00055497483
30 O 0 0.0010179407
. O 0 0.002048634

None O 0 0.0045914003
of O 0 0.00255644
these O 0 0.0016334155
groups O 0 0.0016531966
showed O 0 0.0010184743
significant O 0 0.000983218
difference O 0 0.00092614966
in O 0 0.0012473625
percent O 0 0.0018779875
inhibition O 0 0.003712646
. O 0 0.0053854645

Multivariate O 0 0.003673031
analysis O 0 0.0020940236
showed O 0 0.0013346296
a O 0 0.0015484706
2 O 0 0.00097191636
. O 0 0.00067763706
8 O 0 0.0006307894
- O 0 0.0019582931
fold O 0 0.00077630667
increased O 0 0.0010941521
risk O 0 0.004921011
of O 0 0.001979812
thrombosis B-Disease 0 0.9997681
in O 0 0.0022082597
females O 0 0.0053968905
. O 0 0.00412021

Similarly O 0 0.0060045635
, O 0 0.011555535
thrombotic B-Disease 0 0.9970034
risk O 0 0.014756616
increased O 0 0.0022122704
with O 0 0.0016189474
age O 0 0.0023853795
and O 0 0.0022663395
OD O 0 0.086235024
values O 0 0.0034687202
. O 0 0.0051928703

CONCLUSION O 0 0.01794213
: O 0 0.0049826433
Higher O 0 0.003065624
OD O 0 0.089223415
is O 0 0.0006925868
associated O 0 0.00055804336
with O 0 0.00043206167
significant O 0 0.00039332878
risk O 0 0.0018267357
of O 0 0.00034229897
subsequent O 0 0.0003369056
thrombosis B-Disease 0 0.9999181
in O 0 0.00024289821
patients O 0 0.00038132136
with O 0 0.00019020682
isolated O 0 0.00032711396
- O 0 0.020067614
HIT B-Disease 2 0.9993075
; O 0 0.00060379197
percent O 0 0.0002320222
inhibition O 0 0.00039484916
, O 0 0.00069181307
however O 0 0.00058405264
, O 0 0.0009870072
was O 0 0.0006261479
not O 0 0.000865444
predictive O 0 0.0033217014
. O 0 0.003265982

Thalidomide B-Chemical 0 0.9991398
has O 0 0.0016852738
limited O 0 0.0011680959
single O 0 0.0007815452
- O 0 0.0031397361
agent O 0 0.0008949042
activity O 0 0.00028151314
in O 0 0.00037660933
relapsed O 0 0.08034314
or O 0 0.00025232215
refractory O 0 0.0023365517
indolent O 0 0.03244288
non B-Disease 0 0.00059111643
- I-Disease 0 0.0135474205
Hodgkin I-Disease 0 0.8976954
lymphomas I-Disease 0 0.92371875
: O 0 0.00066110335
a O 0 0.00039283506
phase O 0 0.0007354007
II O 0 0.02038727
trial O 0 0.00060175563
of O 0 0.00041151434
the O 0 0.0005101626
Cancer B-Disease 0 0.05077478
and O 0 0.0015704272
Leukemia B-Disease 0 0.9984794
Group O 0 0.06845475
B O 0 0.25346306
. O 0 0.0051163984

Thalidomide B-Chemical 0 0.999265
is O 0 0.0020809716
an O 0 0.001391531
immunomodulatory O 0 0.0024274336
agent O 0 0.001316243
with O 0 0.0004940534
demonstrated O 0 0.00031535904
activity O 0 0.00025014763
in O 0 0.00034225656
multiple B-Disease 0 0.0005852936
myeloma I-Disease 0 0.9980215
, O 0 0.0018646333
mantle B-Disease 0 0.22113699
cell I-Disease 0 0.0029359928
lymphoma I-Disease 0 0.99967813
and O 0 0.0038008492
lymphoplasmacytic B-Disease 0 0.9993358
lymphoma I-Disease 0 0.9995752
. O 0 0.0046106507

Its O 0 0.016782532
activity O 0 0.00183006
is O 0 0.0012113202
believed O 0 0.0009717858
to O 0 0.000545345
be O 0 0.0004040624
due O 0 0.00023650016
modulation O 0 0.00022252135
of O 0 0.00033989214
the O 0 0.00034844744
tumour B-Disease 0 0.7566673
milieu O 0 0.0005294871
, O 0 0.00047025408
including O 0 0.00019406655
downregulation O 0 0.00034736635
of O 0 0.000727422
angiogenesis O 0 0.92357355
and O 0 0.0014245401
inflammatory O 0 0.13710517
cytokines O 0 0.21374018
. O 0 0.0039600255

Between O 0 0.007923063
July O 0 0.0032943552
2001 O 0 0.0029122238
and O 0 0.0013914646
April O 0 0.00096620177
2004 O 0 0.001115571
, O 0 0.00088525465
24 O 0 0.00044159355
patients O 0 0.0005280819
with O 0 0.00039178738
relapsed O 0 0.1363799
/ O 0 0.0019349885
refractory O 0 0.004869594
indolent O 0 0.21726933
lymphomas B-Disease 0 0.8937906
received O 0 0.00025136795
thalidomide B-Chemical 0 0.9999149
200 O 0 0.000594871
mg O 0 0.009816196
daily O 0 0.000119995646
with O 0 9.4310235e-05
escalation O 0 0.00038845936
by O 0 8.36994e-05
100 O 0 0.00025804012
mg O 0 0.0020015503
daily O 0 0.00010072515
every O 0 4.617576e-05
1 O 0 0.000104665174
- O 0 0.00031634577
2 O 0 8.146866e-05
weeks O 0 4.79978e-05
as O 0 0.00010619175
tolerated O 0 0.0003072696
, O 0 0.00030629916
up O 0 0.00022280797
to O 0 0.00018525419
a O 0 0.00036357547
maximum O 0 0.0003829479
of O 0 0.0005314142
800 O 0 0.0020245924
mg O 0 0.009641316
daily O 0 0.0015247836
. O 0 0.0022111142

Patients O 0 0.0042969263
had O 0 0.0016421363
received O 0 0.0010453775
a O 0 0.00097558275
median O 0 0.00045075789
of O 0 0.0006101497
2 O 0 0.00062953687
( O 0 0.00080669305
range O 0 0.0005274953
, O 0 0.00088922377
1 O 0 0.0007109518
- O 0 0.0017032502
4 O 0 0.00056905596
) O 0 0.0012237506
prior O 0 0.00063433
regimens O 0 0.0019970909
. O 0 0.003471873

Of O 0 0.004723971
24 O 0 0.0020879218
evaluable O 0 0.002197452
patients O 0 0.0012431862
, O 0 0.00076891587
two O 0 0.0002497823
achieved O 0 0.00035856105
a O 0 0.000370175
complete O 0 0.00020230433
remission O 0 0.0018593266
and O 0 0.0001567281
one O 0 0.00011121423
achieved O 0 0.00015406926
a O 0 0.00019890565
partial O 0 0.00021698323
remission O 0 0.0014273897
for O 0 7.671489e-05
an O 0 0.00010703872
overall O 0 9.774886e-05
response O 0 0.00011875037
rate O 0 0.00020420198
of O 0 0.00016973396
12 O 0 0.00011824122
. O 0 0.00013362321
5 O 0 0.00013812719
% O 0 0.0002904559
( O 0 0.00029972117
95 O 0 0.0003367209
% O 0 0.0002962086
confidence O 0 0.0004420366
interval O 0 0.00025768363
: O 0 0.00042728774
2 O 0 0.00024785192
. O 0 0.00022591098
6 O 0 0.00024144909
- O 0 0.0010957379
32 O 0 0.000610297
. O 0 0.00053566665
4 O 0 0.00069611846
% O 0 0.0020275447
) O 0 0.0038875772
. O 0 0.004007399

Eleven O 0 0.015869047
patients O 0 0.011003473
progressed O 0 0.00976685
during O 0 0.0050855805
therapy O 0 0.009060635
. O 0 0.011018864

Grade O 0 0.023602065
3 O 0 0.0024507036
- O 0 0.004058561
4 O 0 0.00069278193
adverse O 0 0.0010635433
effects O 0 0.00042549742
included O 0 0.0005620362
myelosuppression B-Disease 0 0.99826604
, O 0 0.0015680686
fatigue B-Disease 0 0.9575712
, O 0 0.0023460803
somnolence B-Disease 0 0.99991107
/ O 0 0.3240507
depressed B-Disease 2 0.9999492
mood I-Disease 0 0.99992776
, O 0 0.006155089
neuropathy B-Disease 0 0.999851
and O 0 0.0027073938
dyspnea B-Disease 0 0.9792047
. O 0 0.0032011517

Of O 0 0.0073822783
concern O 0 0.0040111807
was O 0 0.0023385715
the O 0 0.0016396318
occurrence O 0 0.001824151
of O 0 0.0018985783
four O 0 0.00175417
thromboembolic B-Disease 0 0.9928035
events O 0 0.0061752773
. O 0 0.0056793

Our O 0 0.0020435164
results O 0 0.0014225249
failed O 0 0.001089839
to O 0 0.0005517293
demonstrate O 0 0.00024863493
an O 0 0.00037099756
important O 0 0.0001787259
response O 0 0.00021003342
rate O 0 0.00027203836
to O 0 0.00013620403
single O 0 0.00013077754
agent O 0 0.000983935
thalidomide B-Chemical 0 0.9999553
in O 0 0.00044651772
indolent O 0 0.8167127
lymphomas B-Disease 0 0.9743124
and O 0 0.0001284502
contrast O 0 0.00014360191
with O 0 0.000107842454
the O 0 7.597667e-05
higher O 0 0.00010723159
activity O 0 7.013787e-05
level O 0 9.586316e-05
reported O 0 0.00013981968
with O 0 0.00013965764
the O 0 0.00012553728
second O 0 0.00016161066
generation O 0 0.0002741675
immunomodulatory O 0 0.0021167065
agent O 0 0.002250527
, O 0 0.003859079
lenalidomide B-Chemical 0 0.9993469
. O 0 0.0036699732

Sex O 0 0.01909948
differences O 0 0.0025052333
in O 0 0.0034067817
NMDA B-Chemical 0 0.999859
antagonist O 0 0.6167187
enhancement O 0 0.001182607
of O 0 0.0009716724
morphine B-Chemical 0 0.9999162
antihyperalgesia O 0 0.636098
in O 0 0.00023965236
a O 0 0.00040626354
capsaicin B-Chemical 0 0.9735388
model O 0 0.00013092402
of O 0 0.00016247887
persistent O 0 0.00039091767
pain B-Disease 0 0.013244528
: O 0 0.0003190627
comparisons O 0 0.00012914694
to O 0 0.00011834026
two O 0 0.00012347742
models O 0 0.0002777062
of O 0 0.0007146107
acute B-Disease 0 0.1299766
pain I-Disease 0 0.25235406
. O 0 0.0028706698

In O 0 0.002873767
acute B-Disease 0 0.0293061
pain I-Disease 0 0.038057204
models O 0 0.0016002343
, O 0 0.0046055084
N B-Chemical 0 0.9990476
- I-Chemical 0 0.6508139
methyl I-Chemical 0 0.99714416
- I-Chemical 0 0.6086891
D I-Chemical 0 0.9987281
- I-Chemical 0 0.9083155
aspartate I-Chemical 1 0.999894
( O 0 0.021147685
NMDA B-Chemical 0 0.9999633
) O 0 0.0026137473
antagonists O 0 0.006675954
enhance O 0 0.000119051496
the O 0 0.00012845265
antinociceptive O 0 0.0036778343
effects O 0 0.00015758045
of O 0 0.00035084356
morphine B-Chemical 0 0.9997905
to O 0 0.00018244938
a O 0 0.00026529277
greater O 0 0.00024425332
extent O 0 0.00023433974
in O 0 0.00035024757
males O 0 0.0009575658
than O 0 0.00073637976
females O 0 0.0027716295
. O 0 0.0027804198

The O 0 0.0015992924
purpose O 0 0.0010478653
of O 0 0.0011722049
this O 0 0.00083776144
investigation O 0 0.0006966139
was O 0 0.00033895439
to O 0 0.00020837165
extend O 0 0.00016094679
these O 0 0.0001564292
findings O 0 0.00020023997
to O 0 0.0001363393
a O 0 0.00024945813
persistent O 0 0.0003859499
pain B-Disease 0 0.0139961615
model O 0 0.00011734411
which O 0 0.0001457526
could O 0 7.900089e-05
be O 0 9.812364e-05
distinguished O 0 0.00012205477
from O 0 0.00010894158
acute B-Disease 0 0.010692505
pain I-Disease 0 0.0071588247
models O 0 7.20425e-05
on O 0 5.134243e-05
the O 0 6.1822386e-05
basis O 0 7.5331416e-05
of O 0 0.0001110934
the O 0 9.813422e-05
nociceptive O 0 0.00020847023
fibers O 0 0.00021052203
activated O 0 0.00013724939
, O 0 0.0003183757
neurochemical O 0 0.001790442
substrates O 0 0.0001893695
, O 0 0.0003340801
and O 0 0.00019573871
duration O 0 0.00016060584
of O 0 0.00032790925
the O 0 0.0004075838
nociceptive O 0 0.0010085487
stimulus O 0 0.0014585839
. O 0 0.0023788842

To O 0 0.0012811846
this O 0 0.0013459513
end O 0 0.0007292252
, O 0 0.0015227984
persistent O 0 0.0013980577
hyperalgesia B-Disease 0 0.3105309
was O 0 0.00028966885
induced O 0 0.00020339379
by O 0 0.00019046689
administration O 0 0.00040432886
of O 0 0.00030690452
capsaicin B-Chemical 0 0.9954331
in O 0 0.00014552512
the O 0 9.252748e-05
tail O 0 9.894617e-05
of O 0 0.00015094188
gonadally O 0 0.00052036176
intact O 0 0.00015817703
F344 O 0 0.0062299157
rats O 0 0.00020558394
, O 0 0.00015447204
following O 0 5.2232237e-05
which O 0 8.97619e-05
the O 0 7.2392904e-05
tail O 0 9.641119e-05
was O 0 0.00012242673
immersed O 0 0.0003773851
in O 0 0.00013431355
a O 0 0.00027796684
mildly O 0 0.01676954
noxious O 0 0.00031177737
thermal O 0 0.00020853066
stimulus O 0 0.00021036793
, O 0 0.00032164928
and O 0 0.00023119432
tail O 0 0.0003127193
- O 0 0.0022455766
withdrawal O 0 0.0022034338
latencies O 0 0.0021148399
measured O 0 0.0014946166
. O 0 0.0026126886

For O 0 0.0016493809
comparison O 0 0.0015563723
, O 0 0.002151853
tests O 0 0.0016607936
were O 0 0.0005905598
conducted O 0 0.00050619186
in O 0 0.00030528312
two O 0 0.00022731174
acute B-Disease 0 0.0049113072
pain I-Disease 0 0.005882056
models O 0 0.00023046145
, O 0 0.00039594303
the O 0 0.00021687525
hotplate O 0 0.0021256197
and O 0 0.0003443197
warm O 0 0.001104805
water O 0 0.0017911361
tail O 0 0.0005463239
- O 0 0.003004263
withdrawal O 0 0.0026669542
procedures O 0 0.0013644497
. O 0 0.002637278

In O 0 0.002311679
males O 0 0.003961574
, O 0 0.002489885
the O 0 0.0009770208
non O 0 0.0019318968
- O 0 0.030379465
competitive O 0 0.008046007
NMDA B-Chemical 0 0.9999827
antagonist O 0 0.99758613
dextromethorphan B-Chemical 0 0.999998
enhanced O 0 0.00038946295
the O 0 0.00014056936
antihyperalgesic O 0 0.008807778
effect O 0 8.719165e-05
of O 0 0.00011816695
low O 0 0.00015261998
to O 0 8.684702e-05
moderate O 0 0.0003788325
doses O 0 0.0003482279
of O 0 0.00024323494
morphine B-Chemical 0 0.99966836
in O 0 0.00016058546
a O 0 0.0002484264
dose O 0 0.00041522764
- O 0 0.0009914861
and O 0 0.00025390912
time O 0 0.00028925657
- O 0 0.0021009312
dependent O 0 0.0005928594
manner O 0 0.0014077531
. O 0 0.0029788224

Across O 0 0.004057231
the O 0 0.001680248
doses O 0 0.002406557
and O 0 0.0011830701
pretreatment O 0 0.002379837
times O 0 0.00045688654
examined O 0 0.00048364318
, O 0 0.00101154
enhancement O 0 0.00077566
was O 0 0.0005690294
not O 0 0.00059069856
observed O 0 0.0008019976
in O 0 0.0014266892
females O 0 0.004727254
. O 0 0.00428415

Enhancement O 0 0.0068318383
of O 0 0.0039054411
morphine B-Chemical 0 0.99976844
antinociception O 0 0.9957842
by O 0 0.001862111
dextromethorphan B-Chemical 0 0.9999902
was O 0 0.00044483916
seen O 0 0.00024624367
in O 0 0.00014939829
both O 0 0.00013255203
males O 0 0.00031948858
and O 0 0.00017429538
females O 0 0.00038258225
in O 0 0.00012561845
the O 0 0.00012079469
acute B-Disease 0 0.009265225
pain I-Disease 0 0.010012456
models O 0 0.000117974865
, O 0 0.00022459748
with O 0 0.00013272504
the O 0 0.00010659696
magnitude O 0 0.00014445781
of O 0 0.00019397959
this O 0 0.00021137683
effect O 0 0.00023163958
being O 0 0.00042414846
greater O 0 0.0007164105
in O 0 0.00087803026
males O 0 0.0027077002
. O 0 0.0027918238

These O 0 0.00186038
findings O 0 0.0016561174
demonstrate O 0 0.0006783129
a O 0 0.0015150548
sexually O 0 0.0019005997
- O 0 0.0049713985
dimorphic O 0 0.00039182696
interaction O 0 0.00026795734
between O 0 0.00045334987
NMDA B-Chemical 0 0.99995863
antagonists O 0 0.517699
and O 0 0.00083038636
morphine B-Chemical 0 0.9998833
in O 0 0.00020437338
a O 0 0.0002448656
persistent O 0 0.0003279477
pain B-Disease 0 0.0074117715
model O 0 0.000101009755
that O 0 8.9222216e-05
can O 0 9.382335e-05
be O 0 0.00012971529
distinguished O 0 0.00017370174
from O 0 0.00015589404
those O 0 0.00023515108
observed O 0 0.00023854055
in O 0 0.0004344124
acute B-Disease 0 0.047841825
pain I-Disease 0 0.055506963
models O 0 0.0012713833
. O 0 0.002529828

Development O 0 0.0055004032
of O 0 0.003263707
proteinuria B-Disease 0 0.9991217
after O 0 0.00063908513
switch O 0 0.00061875174
to O 0 0.0006122911
sirolimus B-Chemical 0 0.9996228
- O 0 0.0033960459
based O 0 0.0003014929
immunosuppression O 0 0.0028324432
in O 0 0.000282826
long O 0 0.00038464926
- O 0 0.0013463662
term O 0 0.0005159154
cardiac O 0 0.0018194305
transplant O 0 0.0015194209
patients O 0 0.00224239
. O 0 0.0026171906

Calcineurin O 0 0.17789939
- O 0 0.027355889
inhibitor O 0 0.0052794707
therapy O 0 0.0020636125
can O 0 0.0007416992
lead O 0 0.0029436704
to O 0 0.0009013566
renal B-Disease 0 0.99779534
dysfunction I-Disease 0 0.99653804
in O 0 0.0009963784
heart O 0 0.018633554
transplantation O 0 0.0015034011
patients O 0 0.0022540425
. O 0 0.0025663597

The O 0 0.0022417202
novel O 0 0.0021312118
immunosuppressive O 0 0.01421186
( O 0 0.0024993487
IS O 0 0.005986893
) O 0 0.001761374
drug O 0 0.004653932
sirolmus B-Chemical 0 0.00310571
( O 0 0.0011691872
Srl B-Chemical 0 0.05348537
) O 0 0.00061159726
lacks O 0 0.00015695542
nephrotoxic B-Disease 0 0.96794975
effects O 0 0.0002715163
; O 0 0.0005855665
however O 0 0.00032537192
, O 0 0.0009433284
proteinuria B-Disease 0 0.9999503
associated O 0 0.00037955167
with O 0 0.00035608487
Srl B-Chemical 0 0.12497759
has O 0 0.0001581161
been O 0 0.00022217409
reported O 0 0.00031584437
following O 0 0.00032824956
renal O 0 0.2751717
transplantation O 0 0.0018839982
. O 0 0.0021345457

In O 0 0.0022940408
cardiac O 0 0.005041923
transplantation O 0 0.0020752018
, O 0 0.0016743283
the O 0 0.00074247277
incidence O 0 0.0013951873
of O 0 0.0013632688
proteinuria B-Disease 0 0.9998653
associated O 0 0.001415413
with O 0 0.0013886462
Srl B-Chemical 0 0.14411396
is O 0 0.0012414663
unknown O 0 0.0023041999
. O 0 0.0036861026

In O 0 0.002101286
this O 0 0.0019419352
study O 0 0.0015162503
, O 0 0.0014871816
long O 0 0.00078717887
- O 0 0.0018316251
term O 0 0.00042519032
cardiac O 0 0.00092989596
transplant O 0 0.0004817358
patients O 0 0.00038648193
were O 0 0.00020489414
switched O 0 0.00040692848
from O 0 0.00043959604
cyclosporine B-Chemical 1 0.99991345
to O 0 0.00082382205
Srl B-Chemical 0 0.259385
- O 0 0.0035365666
based O 0 0.0012036659
IS O 0 0.008079345
. O 0 0.003469014

Concomitant O 0 0.011550787
IS O 0 0.010574948
consisted O 0 0.0026073647
of O 0 0.0037449598
mycophenolate B-Chemical 0 0.9999198
mofetil I-Chemical 0 0.9999677
+ O 0 0.031585526
/ O 0 0.020664964
- O 0 0.03808621
steroids B-Chemical 0 0.9936293
. O 0 0.007920597

Proteinuria O 0 0.99952674
increased O 0 0.0038614315
significantly O 0 0.0014780344
from O 0 0.0006827784
a O 0 0.00065206195
median O 0 0.0002778227
of O 0 0.00036870575
0 O 0 0.00041795472
. O 0 0.0002570606
13 O 0 0.0002756665
g O 0 0.0006367283
/ O 0 0.0007145018
day O 0 0.00015717812
( O 0 0.00030952442
range O 0 0.00019799572
0 O 0 0.0002885968
- O 0 0.0007601395
5 O 0 0.00016225685
. O 0 0.00014629787
7 O 0 0.00013631603
) O 0 0.00038953722
preswitch O 0 0.0009426326
to O 0 0.00015515802
0 O 0 0.00023241567
. O 0 0.00016040319
23 O 0 0.00024417532
g O 0 0.00052694726
/ O 0 0.0006523183
day O 0 0.00014452587
( O 0 0.00033936097
0 O 0 0.00030271875
- O 0 0.00081284787
9 O 0 0.00016366308
. O 0 0.00016763755
88 O 0 0.000337611
) O 0 0.00033123157
at O 0 0.000118566495
24 O 0 0.00015382735
months O 0 9.738322e-05
postswitch O 0 0.00047038138
( O 0 0.0004798799
p O 0 0.0006385487
= O 0 0.0011370591
0 O 0 0.0008795647
. O 0 0.0010501017
0024 O 0 0.010061664
) O 0 0.0047065066
. O 0 0.0041878037

Before O 0 0.0030996983
the O 0 0.0021052577
switch O 0 0.0017742468
, O 0 0.002147415
11 O 0 0.0010187551
. O 0 0.000588976
5 O 0 0.0004061847
% O 0 0.0005908118
of O 0 0.00033545084
patients O 0 0.00052068726
had O 0 0.0002581698
high O 0 0.0004347902
- O 0 0.0053853365
grade O 0 0.11497143
proteinuria B-Disease 0 0.9999583
( O 0 0.00091324863
> O 0 0.0005710408
1 O 0 0.00021145184
. O 0 0.00014416238
0 O 0 0.00019902231
g O 0 0.0004759838
/ O 0 0.0006156569
day O 0 0.00014298677
) O 0 0.0004567694
; O 0 0.00038353904
this O 0 0.00019744107
increased O 0 0.00026152426
to O 0 0.00018044216
22 O 0 0.00029495516
. O 0 0.00017203647
9 O 0 0.00016514368
% O 0 0.0003773572
postswitch O 0 0.00068426615
( O 0 0.0005388534
p O 0 0.0006611404
= O 0 0.0011276036
0 O 0 0.00084360916
. O 0 0.0010049639
006 O 0 0.008291936
) O 0 0.004303612
. O 0 0.004081213

ACE B-Chemical 0 0.9959033
inhibitor I-Chemical 0 0.11020375
and O 0 0.0073281284
angiotensin B-Chemical 0 0.9999621
- I-Chemical 0 0.3865274
releasing I-Chemical 0 0.0031795062
blocker I-Chemical 0 0.9090453
( O 0 0.008247085
ARB B-Chemical 0 0.9999515
) O 0 0.003653483
therapy O 0 0.0013537349
reduced O 0 0.0018033439
proteinuria B-Disease 0 0.9997991
development O 0 0.0048692008
. O 0 0.004335979

Patients O 0 0.0050391844
without O 0 0.0030213355
proteinuria B-Disease 0 0.99964774
had O 0 0.0012897237
increased O 0 0.0010685532
renal O 0 0.28822538
function O 0 0.00030996266
( O 0 0.00040999186
median O 0 0.00013847243
42 O 0 0.00023169481
. O 0 0.00015832175
5 O 0 0.00014035172
vs O 0 0.00023285972
. O 0 0.00017651406
64 O 0 0.00024985257
. O 0 0.00017242221
1 O 0 0.00017959182
, O 0 0.00025588003
p O 0 0.00031126387
= O 0 0.00047131992
0 O 0 0.0002223646
. O 0 0.00015344033
25 O 0 0.00021459594
) O 0 0.00037217632
, O 0 0.00026928497
whereas O 0 0.00015366683
patients O 0 0.00029907748
who O 0 0.00017686195
developed O 0 0.00013972718
high O 0 0.0002337847
- O 0 0.0056574102
grade O 0 0.112638
proteinuria B-Disease 0 0.99997747
showed O 0 0.00022698274
decreased O 0 0.001293026
renal O 0 0.66071534
function O 0 0.00012840245
at O 0 5.7191897e-05
the O 0 5.3754884e-05
end O 0 4.8580972e-05
of O 0 0.000110885325
follow O 0 9.700119e-05
- O 0 0.00067785085
up O 0 0.00014248538
( O 0 0.00018110388
median O 0 7.404015e-05
39 O 0 0.00015785867
. O 0 0.00010985267
6 O 0 9.175987e-05
vs O 0 0.00020927582
. O 0 0.00018379805
29 O 0 0.00030504688
. O 0 0.00021762865
2 O 0 0.00026984734
, O 0 0.00047309612
p O 0 0.00066249503
= O 0 0.0011380304
0 O 0 0.00081403734
. O 0 0.000887338
125 O 0 0.002990148
) O 0 0.004198941
. O 0 0.004081988

Thus O 0 0.0030455855
, O 0 0.009355298
proteinuria B-Disease 0 0.99974865
may O 0 0.0010752758
develop O 0 0.0006182624
in O 0 0.00035792135
cardiac O 0 0.0008960399
transplant O 0 0.00039409086
patients O 0 0.00025779643
after O 0 7.780846e-05
switch O 0 0.00014148648
to O 0 0.00017958344
Srl B-Chemical 0 0.06776795
, O 0 0.00037978607
which O 0 0.00019016783
may O 0 0.00011667522
have O 0 0.00011281685
an O 0 0.00015399231
adverse O 0 0.00042102448
effect O 0 0.00013235373
on O 0 0.00017948587
renal O 0 0.32019058
function O 0 0.000341276
in O 0 0.0004608727
these O 0 0.0007419134
patients O 0 0.0023090544
. O 0 0.0023192598

Srl B-Chemical 0 0.110367544
should O 0 0.0013374246
be O 0 0.0010015344
used O 0 0.0006734777
with O 0 0.0009458317
ACEi B-Chemical 0 0.998701
/ O 0 0.052580364
ARB B-Chemical 0 0.9999553
therapy O 0 0.0007353272
and O 0 0.00026241038
patients O 0 0.0003754697
monitored O 0 0.00017650262
for O 0 0.00029905443
proteinuria B-Disease 0 0.99983406
and O 0 0.0008436425
increased O 0 0.001790069
renal B-Disease 0 0.9984487
dysfunction I-Disease 0 0.9980975
. O 0 0.0043700417

Ginsenoside B-Chemical 0 0.9992712
Rg1 I-Chemical 0 0.99980944
restores O 0 0.0020681492
the O 0 0.0012032521
impairment B-Disease 0 0.72748137
of I-Disease 0 0.00083365594
learning I-Disease 0 0.0034857688
induced O 0 0.0004939844
by O 0 0.00057707133
chronic O 0 0.10306056
morphine B-Chemical 0 0.99962175
administration O 0 0.0016224101
in O 0 0.0008648888
rats O 0 0.0021046484
. O 0 0.0026927423

Rg1 B-Chemical 0 0.9988079
, O 0 0.0101279635
as O 0 0.0030997102
a O 0 0.00475077
ginsenoside B-Chemical 0 0.9998116
extracted O 0 0.0021637648
from O 0 0.000836323
Panax O 0 0.060893297
ginseng O 0 0.61608064
, O 0 0.0015038836
could O 0 0.00044498718
ameliorate O 0 0.0016053681
spatial O 0 0.0035374237
learning B-Disease 0 0.31739992
impairment I-Disease 0 0.99254394
. O 0 0.0047994903

Previous O 0 0.0021292
studies O 0 0.0020487653
have O 0 0.0010730716
demonstrated O 0 0.00086667686
that O 0 0.00096334727
Rg1 B-Chemical 0 0.9997148
might O 0 0.00035050494
be O 0 0.00029850806
a O 0 0.00030394955
useful O 0 0.00016713703
agent O 0 0.0003411389
for O 0 0.000118809716
the O 0 0.00012706447
prevention O 0 0.00022853215
and O 0 0.0001861274
treatment O 0 0.00018450743
of O 0 0.0002175046
the O 0 0.00022116338
adverse O 0 0.0010177027
effects O 0 0.00050030206
of O 0 0.0015424615
morphine B-Chemical 0 0.99949455
. O 0 0.003615548

The O 0 0.0016414007
aim O 0 0.0010546272
of O 0 0.0011439197
this O 0 0.0008399223
study O 0 0.0006349927
was O 0 0.0003107278
to O 0 0.00017637358
investigate O 0 8.2013124e-05
the O 0 0.00013193753
effect O 0 0.00015871442
of O 0 0.00040525052
Rg1 B-Chemical 0 0.9998996
on O 0 0.0001895274
learning B-Disease 0 0.08164626
impairment I-Disease 0 0.98219126
by O 0 0.00022746371
chronic O 0 0.090984546
morphine B-Chemical 0 0.999828
administration O 0 0.0003610203
and O 0 0.00013005576
the O 0 0.000106370026
mechanism O 0 0.00012371196
responsible O 0 0.00021700993
for O 0 0.00031595005
this O 0 0.00071812596
effect O 0 0.0012499653
. O 0 0.0030647393

Male O 0 0.006334478
rats O 0 0.0020460687
were O 0 0.0007894096
subcutaneously O 0 0.00059642654
injected O 0 0.0004272592
with O 0 0.000603341
morphine B-Chemical 0 0.99878377
( O 0 0.00070425426
10 O 0 0.0002737919
mg O 0 0.0015547696
/ O 0 0.0006777959
kg O 0 0.00047362602
) O 0 0.00033949575
twice O 0 9.731964e-05
a O 0 0.000149917
day O 0 7.1978706e-05
at O 0 6.610016e-05
12 O 0 6.222934e-05
hour O 0 7.4648495e-05
intervals O 0 6.0634684e-05
for O 0 5.7616697e-05
10 O 0 8.478047e-05
days O 0 6.681629e-05
, O 0 0.00022722008
and O 0 0.00026511075
Rg1 B-Chemical 0 0.9996325
( O 0 0.00048814807
30 O 0 0.00014347257
mg O 0 0.001086471
/ O 0 0.00046505895
kg O 0 0.00032333596
) O 0 0.00023762166
was O 0 7.8803154e-05
intraperitoneally O 0 0.00010519698
injected O 0 6.303264e-05
2 O 0 6.914418e-05
hours O 0 4.7066205e-05
after O 0 3.439316e-05
the O 0 5.4456224e-05
second O 0 7.303686e-05
injection O 0 0.0001019066
of O 0 0.00023351694
morphine B-Chemical 0 0.99912363
once O 0 0.00019068494
a O 0 0.00031311216
day O 0 0.00018475743
for O 0 0.00028420074
10 O 0 0.00058164523
days O 0 0.0006329568
. O 0 0.0020139397

Spatial O 0 0.011320199
learning O 0 0.007220516
capacity O 0 0.003822765
was O 0 0.00176484
assessed O 0 0.0014071908
in O 0 0.0013710428
the O 0 0.0015904618
Morris O 0 0.011523722
water O 0 0.016226795
maze O 0 0.6520422
. O 0 0.007820261

The O 0 0.0017334389
results O 0 0.0012057901
showed O 0 0.0008182182
that O 0 0.0005315828
rats O 0 0.00096413033
treated O 0 0.0012446832
with O 0 0.0013118045
Morphine B-Chemical 0 0.99996996
/ O 0 0.19157057
Rg1 B-Chemical 0 0.99991333
decreased O 0 0.0011707051
escape O 0 0.00051897526
latency O 0 0.00048551318
and O 0 0.00017833064
increased O 0 0.00019182508
the O 0 0.00010678416
time O 0 0.00010328534
spent O 0 0.00022363481
in O 0 0.00020598383
platform O 0 0.00039919672
quadrant O 0 0.0007783218
and O 0 0.00055267586
entering O 0 0.0010243312
frequency O 0 0.0012601118
. O 0 0.0026909309

By O 0 0.0016728959
implantation O 0 0.001627339
of O 0 0.0010341406
electrodes O 0 0.001649516
and O 0 0.00052468263
electrophysiological O 0 0.0006929047
recording O 0 0.00025261025
in O 0 0.00020784403
vivo O 0 0.00022145607
, O 0 0.00034162233
the O 0 0.00013844443
results O 0 0.00013914378
showed O 0 0.00018219644
that O 0 0.00024046372
Rg1 B-Chemical 0 0.9998847
restored O 0 0.00041964467
the O 0 0.00015402875
long O 0 0.00020006075
- O 0 0.0008434922
term O 0 0.00017937465
potentiation O 0 0.002745664
( O 0 0.00064163585
LTP O 0 0.8514216
) O 0 0.00069740013
impaired O 0 0.0007711415
by O 0 0.00028375754
morphine B-Chemical 0 0.99945873
in O 0 0.00020371075
both O 0 0.00017670906
freely O 0 0.00038996874
moving O 0 0.00056876394
and O 0 0.00059205305
anaesthetised O 0 0.0054531656
rats O 0 0.0017134642
. O 0 0.0021748098

The O 0 0.0016046619
electrophysiological O 0 0.002200155
recording O 0 0.00086257287
in O 0 0.0006263744
vitro O 0 0.00053030095
showed O 0 0.00047159047
that O 0 0.00054180325
Rg1 B-Chemical 0 0.99981743
restored O 0 0.0009137975
the O 0 0.00039025868
LTP O 0 0.8047242
in O 0 0.00016603942
slices O 0 0.00018434477
from O 0 8.493081e-05
the O 0 7.356068e-05
rats O 0 0.00017727764
treated O 0 0.00028716575
with O 0 0.00031960677
morphine B-Chemical 0 0.99992895
, O 0 0.0006314928
but O 0 0.00019033437
not O 0 0.00012270841
changed O 0 0.00024795378
LTP O 0 0.7909924
in O 0 0.000100282756
the O 0 6.7761786e-05
slices O 0 0.000119204065
from O 0 7.4725554e-05
normal O 0 0.00018233444
saline O 0 0.00051217346
- O 0 0.0009215552
or O 0 0.00016563476
morphine B-Chemical 0 0.999821
/ O 0 0.06487481
Rg1 B-Chemical 0 0.99996245
- O 0 0.01849941
treated O 0 0.00037213395
rats O 0 0.00032016085
; O 0 0.0003069557
this O 0 0.00012740844
restoration O 0 0.00016591945
could O 0 0.00010237147
be O 0 0.00016153287
inhibited O 0 0.0004163015
by O 0 0.0005608519
N B-Chemical 0 0.99979776
- I-Chemical 0 0.7320616
methyl I-Chemical 0 0.9981171
- I-Chemical 0 0.61522186
D I-Chemical 0 0.9990638
- I-Chemical 0 0.90921474
aspartate I-Chemical 1 0.999912
( O 0 0.037559625
NMDA B-Chemical 0 0.9999573
) O 0 0.021749364
receptor O 0 0.046462066
antagonist O 0 0.99216145
MK801 B-Chemical 0 0.9999924
. O 0 0.010191607

We O 0 0.0024340032
conclude O 0 0.0015589079
that O 0 0.0017960295
Rg1 B-Chemical 0 0.9996276
may O 0 0.0007405458
significantly O 0 0.00046431014
improve O 0 0.00019041149
the O 0 0.00017142405
spatial O 0 0.000464435
learning O 0 0.00079085
capacity O 0 0.00044420944
impaired O 0 0.0007121317
by O 0 0.00022996058
chonic O 0 0.12806831
morphine B-Chemical 0 0.9996364
administration O 0 0.0004322794
and O 0 0.00018894927
restore O 0 0.00020235332
the O 0 0.00043276718
morphine B-Chemical 0 0.9997259
- O 0 0.027769182
inhibited O 0 0.0033644135
LTP O 0 0.97685164
. O 0 0.0042096577

This O 0 0.011020647
effect O 0 0.0066015217
is O 0 0.00905286
NMDA B-Chemical 0 0.9994579
receptor O 0 0.05306614
dependent O 0 0.006856744
. O 0 0.010818974

Synthesis O 0 0.011751
of O 0 0.007025514
N B-Chemical 0 0.9970906
- I-Chemical 0 0.18560106
pyrimidinyl I-Chemical 0 0.6034002
- I-Chemical 0 0.016458198
2 I-Chemical 0 0.0014379901
- I-Chemical 0 0.005308183
phenoxyacetamides I-Chemical 0 0.0067072012
as O 0 0.0021746464
adenosine B-Chemical 0 0.9995722
A2A O 0 0.9986584
receptor O 0 0.049536996
antagonists O 0 0.51774204
. O 0 0.006386971

A O 0 0.023363769
series O 0 0.004580182
of O 0 0.0042239274
N B-Chemical 0 0.99766254
- I-Chemical 0 0.1642615
pyrimidinyl I-Chemical 0 0.5928009
- I-Chemical 0 0.01628645
2 I-Chemical 0 0.0011067035
- I-Chemical 0 0.0079623265
phenoxyacetamide I-Chemical 0 0.5268341
adenosine B-Chemical 0 0.99918705
A O 0 0.1504994
( O 0 0.0016608561
2A O 0 0.0009777144
) O 0 0.0019136827
antagonists O 0 0.014401044
is O 0 0.0013175111
described O 0 0.0018336392
. O 0 0.0036663066

SAR O 0 0.1418629
studies O 0 0.003194704
led O 0 0.001682768
to O 0 0.00091992394
compound O 0 0.002551808
14 O 0 0.0004475344
with O 0 0.0003313244
excellent O 0 0.00047244737
potency O 0 0.0010283648
( O 0 0.0014907802
K O 0 0.999064
( O 0 0.0010334409
i O 0 0.00064525555
) O 0 0.00066712213
= O 0 0.00061925524
0 O 0 0.00025005106
. O 0 0.0001572183
4 O 0 0.00014934017
nM O 0 0.00084380823
) O 0 0.00059500965
, O 0 0.00041801692
selectivity O 0 0.0005785542
( O 0 0.00072902866
A O 0 0.0059343423
( O 0 0.0006211048
1 O 0 0.0003062165
) O 0 0.000613229
/ O 0 0.0014181067
A O 0 0.0052578435
( O 0 0.0005770423
2A O 0 0.00031655125
) O 0 0.00049882015
> O 0 0.0005078377
100 O 0 0.00046388392
) O 0 0.00046754614
, O 0 0.00027925568
and O 0 0.00015623435
efficacy O 0 0.00019929615
( O 0 0.0004890034
MED O 0 0.056800794
10 O 0 0.00017394821
mg O 0 0.001038357
/ O 0 0.00044600593
kg O 0 0.00030822787
p O 0 0.0002610111
. O 0 0.00014969817
o O 0 0.00073495763
. O 0 0.00019487536
) O 0 0.0003754107
in O 0 0.00013963396
the O 0 0.00016196376
rat O 0 0.0012160278
haloperidol B-Chemical 1 0.9999987
- O 0 0.035571266
induced O 0 0.00051879307
catalepsy B-Disease 0 0.9999753
model O 0 0.0004145723
for O 0 0.00050944753
Parkinson B-Disease 0 0.9965779
' I-Disease 0 0.0018096183
s I-Disease 0 0.00206122
disease I-Disease 0 0.28822285
. O 0 0.003316291

Evidence O 0 0.0043491824
for O 0 0.0015555123
an O 0 0.0014467783
involvement O 0 0.0015811161
of O 0 0.0017707455
D1 O 0 0.9684668
and O 0 0.0041453047
D2 O 0 0.9995977
dopamine B-Chemical 0 0.99989295
receptors O 0 0.0015058661
in O 0 0.00030714396
mediating O 0 0.0002458636
nicotine B-Chemical 0 0.99790657
- O 0 0.018351398
induced O 0 0.0011856331
hyperactivity B-Disease 2 0.9999838
in O 0 0.0017091517
rats O 0 0.0029785675
. O 0 0.0030145708

Previous O 0 0.0021053846
studies O 0 0.0019711065
have O 0 0.00093033386
suggested O 0 0.0005436448
that O 0 0.00034489034
repeated O 0 0.0002262382
exposure O 0 0.00029037584
of O 0 0.00023252072
rats O 0 0.0003135435
to O 0 0.00013992663
the O 0 0.00013841357
drug O 0 0.0016838409
or O 0 0.00011800109
to O 0 9.435071e-05
the O 0 9.112099e-05
experimental O 0 0.00013457226
environment O 0 0.00017786263
is O 0 0.000107485386
necessary O 0 8.659423e-05
to O 0 0.00015147521
observe O 0 0.0002352872
nicotine B-Chemical 0 0.9984232
- O 0 0.009431864
induced O 0 0.0007030713
locomotor O 0 0.008699069
stimulation O 0 0.0010434107
. O 0 0.0023440914

In O 0 0.0017726218
the O 0 0.0012733992
present O 0 0.00078905956
study O 0 0.0006918767
the O 0 0.00032126036
role O 0 0.00017499877
of O 0 0.0003645861
habituation O 0 0.0028460056
to O 0 0.00016554017
the O 0 0.00012091996
experimental O 0 0.00014615119
environment O 0 0.00016755956
on O 0 9.7701326e-05
the O 0 0.00014531298
stimulant O 0 0.25964522
effect O 0 0.00022294736
of O 0 0.00052927615
nicotine B-Chemical 0 0.9970431
in O 0 0.000480791
rats O 0 0.0008341962
was O 0 0.0006673125
examined O 0 0.0009847095
. O 0 0.002441427

In O 0 0.0017246689
addition O 0 0.0010507602
, O 0 0.0017375826
the O 0 0.00059301365
role O 0 0.0003515135
of O 0 0.0012198838
dopamine B-Chemical 0 0.9997615
receptors O 0 0.001344213
in O 0 0.00023304141
mediating O 0 0.00015079758
nicotine B-Chemical 0 0.9985201
- O 0 0.006428499
induced O 0 0.00017557121
locomotor O 0 0.0019459208
stimulation O 0 7.2576484e-05
was O 0 7.054368e-05
investigated O 0 6.7178415e-05
by O 0 6.3988446e-05
examining O 0 4.321786e-05
the O 0 5.9950267e-05
effects O 0 9.328548e-05
of O 0 0.00018859038
selective O 0 0.00081599044
D1 O 0 0.98749465
and O 0 0.0028012826
D2 O 0 0.99988985
dopamine B-Chemical 0 0.9999757
receptor O 0 0.008385476
antagonists O 0 0.046305865
on O 0 0.00021174295
activity O 0 0.00026696842
induced O 0 0.0006061057
by O 0 0.0014264922
nicotine B-Chemical 0 0.9977366
. O 0 0.0038350676

Locomotor O 0 0.083490536
activity O 0 0.0020802796
was O 0 0.0015353288
assessed O 0 0.0011269809
in O 0 0.0010456603
male O 0 0.0023514656
Sprague O 0 0.13762636
- O 0 0.004730885
Dawley O 0 0.0073206713
rats O 0 0.0012128333
tested O 0 0.0008298133
in O 0 0.0012570705
photocell O 0 0.010754595
cages O 0 0.007527284
. O 0 0.004871211

Nicotine B-Chemical 0 0.9994265
( O 0 0.0063980655
1 O 0 0.0017810531
. O 0 0.00095462525
0 O 0 0.0009233363
mg O 0 0.0034408444
/ O 0 0.0016444292
kg O 0 0.0011779092
) O 0 0.0008392091
caused O 0 0.0002848184
a O 0 0.0003509153
significant O 0 0.00021178233
increase B-Disease 0 0.00018433036
in I-Disease 0 0.00018808432
locomotor I-Disease 0 0.0018475358
activity I-Disease 0 8.1601065e-05
in O 0 8.9728004e-05
rats O 0 0.00015477517
that O 0 6.651559e-05
were O 0 8.5027335e-05
habituated O 0 0.00022752488
to O 0 6.623343e-05
the O 0 6.612002e-05
test O 0 0.0001324609
environment O 0 0.000168761
, O 0 0.00028578838
but O 0 0.00015514989
had O 0 0.00011316099
only O 0 0.00012396302
a O 0 0.00018037732
weak O 0 0.00020787257
and O 0 0.00015014388
delayed O 0 0.00074110995
stimulant O 0 0.7080287
action O 0 0.00015315207
in O 0 0.00011605471
rats O 0 0.00021879187
that O 0 0.0001139334
were O 0 0.00017900049
unfamiliar O 0 0.001027592
with O 0 0.00037130507
the O 0 0.00040522654
test O 0 0.0009835976
environment O 0 0.0017942463
. O 0 0.0027144302

The O 0 0.0021103383
stimulant O 0 0.41966292
action O 0 0.001514069
of O 0 0.0015434097
nicotine B-Chemical 0 0.9986242
was O 0 0.0006181911
blocked O 0 0.00071689783
by O 0 0.0002894455
the O 0 0.00027048457
central O 0 0.0022117295
nicotinic O 0 0.99979514
antagonist O 0 0.99503326
mecamylamine B-Chemical 0 0.99999845
but O 0 0.0005421175
not O 0 0.00013078464
by O 0 0.00012400559
the O 0 0.00014343236
peripheral O 0 0.023406306
nicotinic O 0 0.9998165
blocker O 0 0.998626
hexamethonium B-Chemical 0 0.99999857
, O 0 0.0008899121
indicating O 0 9.781366e-05
that O 0 8.363069e-05
the O 0 0.00010298912
response O 0 0.00015014273
is O 0 0.00015461617
probably O 0 0.00025643467
mediated O 0 0.00019568327
by O 0 0.00053443806
central O 0 0.0028733925
nicotinic O 0 0.9968803
receptors O 0 0.008181454
. O 0 0.0035449837

Nicotine B-Chemical 0 0.9997166
- O 0 0.14474776
induced O 0 0.00385156
hyperactivity B-Disease 2 0.9999852
was O 0 0.0012333273
blocked O 0 0.0010488814
by O 0 0.00037575996
the O 0 0.00031073135
selective O 0 0.0011610886
D1 O 0 0.9943077
antagonist O 0 0.996549
SCH B-Chemical 0 0.9999963
23390 I-Chemical 0 0.9999881
, O 0 0.0012359646
the O 0 0.00022324517
selective O 0 0.0010212638
D2 O 0 0.9992292
antagonist O 0 0.98840964
raclopride B-Chemical 0 0.99999785
and O 0 0.00091996207
the O 0 0.00062864856
D1 O 0 0.9792358
/ O 0 0.4289257
D2 O 0 0.9993081
antagonist O 0 0.9966047
fluphenazine B-Chemical 0 0.99999654
. O 0 0.005840999

Pretreatment O 0 0.032085493
with O 0 0.0030245504
the O 0 0.002528933
D2 O 0 0.9968845
agonist O 0 0.8542043
PHNO B-Chemical 0 0.9999497
enhanced O 0 0.0016158567
nicotine B-Chemical 0 0.99949396
- O 0 0.03558793
induced O 0 0.0007297682
hyperactivity B-Disease 2 0.9999964
, O 0 0.001622957
whereas O 0 0.00040393067
the O 0 0.00052135094
D1 O 0 0.9960807
agonist O 0 0.9912236
SKF B-Chemical 0 0.9999956
38393 I-Chemical 0 0.99999857
had O 0 0.001216022
no O 0 0.00075202587
effect O 0 0.0013400088
. O 0 0.0031371226

The O 0 0.0016112576
results O 0 0.0010898287
indicate O 0 0.000572582
that O 0 0.00070558913
acute O 0 0.11346826
nicotine B-Chemical 0 0.99619377
injection O 0 0.00037913726
induces O 0 0.00023387323
a O 0 0.00054201676
pronounced O 0 0.0014496109
hyperactivity B-Disease 2 0.9999908
in O 0 0.00037386673
rats O 0 0.00053460797
habituated O 0 0.0007109488
to O 0 0.0002866266
the O 0 0.00038426512
test O 0 0.0009649166
environment O 0 0.0018167961
. O 0 0.0028625776

The O 0 0.0018525928
effect O 0 0.0013320129
appears O 0 0.00077157846
to O 0 0.00058955065
be O 0 0.0004308512
mediated O 0 0.00024167642
by O 0 0.00036116698
central O 0 0.0009719881
nicotine B-Chemical 0 0.99773455
receptors O 0 0.001410032
, O 0 0.00052500557
possibly O 0 0.00025321526
located O 0 0.00013701897
on O 0 0.000107283144
dopaminergic O 0 0.0009521065
neurons O 0 0.00015443521
, O 0 0.0002186803
and O 0 0.00012723946
also O 0 0.00010327452
requires O 0 7.772785e-05
the O 0 0.000120696925
activation O 0 0.00017575696
of O 0 0.00029491127
both O 0 0.00048799615
D1 O 0 0.9499878
and O 0 0.003289385
D2 O 0 0.99938107
dopamine B-Chemical 0 0.99982774
receptors O 0 0.009628367
. O 0 0.0035488904

Central O 0 0.0077264295
retinal B-Disease 0 0.22063664
vein I-Disease 0 0.1402086
occlusion I-Disease 0 0.7392314
associated O 0 0.0018529879
with O 0 0.002490631
clomiphene B-Chemical 0 0.99981683
- O 0 0.028263425
induced O 0 0.0028699355
ovulation O 0 0.3498827
. O 0 0.0061360183

OBJECTIVE O 0 0.019050827
: O 0 0.0035676241
To O 0 0.0006657439
report O 0 0.0014304604
a O 0 0.0010023611
case O 0 0.0006079887
of O 0 0.0005305682
central O 0 0.00086842687
retinal B-Disease 0 0.3057403
vein I-Disease 0 0.16371784
occlusion I-Disease 0 0.71901625
associated O 0 0.00050230534
with O 0 0.000966728
clomiphene B-Chemical 0 0.9999685
citrate I-Chemical 0 0.9863622
( O 0 0.004282092
CC B-Chemical 0 0.83043635
) O 0 0.0056169066
. O 0 0.0037184532

DESIGN O 0 0.022424052
: O 0 0.024212072
Case O 0 0.031046659
study O 0 0.016231643
. O 0 0.020085054

SETTING O 0 0.014717103
: O 0 0.008695439
Ophthalmology O 0 0.006767869
clinic O 0 0.003366944
of O 0 0.0028383539
an O 0 0.0033532097
academic O 0 0.00810938
hospital O 0 0.006794493
. O 0 0.0075588035

PATIENT O 0 0.009208813
( O 0 0.008931622
S O 0 0.77114177
) O 0 0.0057514296
: O 0 0.0032602407
A O 0 0.0062071485
36 O 0 0.0011118768
- O 0 0.0023782277
year O 0 0.00052995863
- O 0 0.001640718
old O 0 0.00058613514
woman O 0 0.0011526922
referred O 0 0.00049828214
from O 0 0.00034081933
the O 0 0.00046133573
infertility B-Disease 0 0.7930484
clinic O 0 0.0011267253
for O 0 0.000852492
blurred B-Disease 0 0.5874262
vision I-Disease 0 0.8028577
. O 0 0.0048187147

INTERVENTION O 0 0.009155135
( O 0 0.010218584
S O 0 0.5894602
) O 0 0.007050369
: O 0 0.0042582443
Ophthalmic O 0 0.0029723607
examination O 0 0.0013210763
after O 0 0.0013926035
CC B-Chemical 0 0.05367116
therapy O 0 0.0051909145
. O 0 0.0061037377

MAIN O 0 0.011237052
OUTCOME O 0 0.0057002883
MEASURE O 0 0.0037048778
( O 0 0.0032053445
S O 0 0.3281107
) O 0 0.0030334364
: O 0 0.0018502815
Central O 0 0.0010925266
retinal B-Disease 0 0.04213605
vein I-Disease 0 0.03478652
occlusion I-Disease 0 0.26746166
after O 0 0.00039506628
ovulation O 0 0.005501439
induction O 0 0.00081161415
with O 0 0.0019114116
CC B-Chemical 0 0.74308115
. O 0 0.004811385

RESULT O 0 0.014497666
( O 0 0.009149949
S O 0 0.77455646
) O 0 0.0055611073
: O 0 0.0031265363
A O 0 0.0058361166
36 O 0 0.0010549024
- O 0 0.0021904234
year O 0 0.00048037435
- O 0 0.001393126
old O 0 0.00050579227
Chinese O 0 0.0012466066
woman O 0 0.0012436748
developed O 0 0.00044578683
central O 0 0.0006577323
retinal B-Disease 0 0.2234401
vein I-Disease 0 0.07286485
occlusion I-Disease 0 0.16605294
after O 0 0.00017401771
eight O 0 0.00024011343
courses O 0 0.0008095692
of O 0 0.0013522394
CC B-Chemical 0 0.5434939
. O 0 0.004203603

A O 0 0.020482376
search O 0 0.0022196814
of O 0 0.0014022327
the O 0 0.0008050481
literature O 0 0.0010408147
on O 0 0.0003441297
the O 0 0.00043571836
thromboembolic B-Disease 0 0.9983944
complications O 0 0.051749226
of O 0 0.0005294243
CC B-Chemical 0 0.91896164
does O 0 0.00016662879
not O 0 0.00012603529
include O 0 0.000112279165
this O 0 0.00014809892
severe O 0 0.00097107963
ophthalmic O 0 0.050177965
complication O 0 0.0034288152
, O 0 0.00030015782
although O 0 0.00018438415
mild O 0 0.06538324
visual B-Disease 0 0.5720099
disturbance I-Disease 0 0.78226006
after O 0 0.00021782088
CC B-Chemical 0 0.58099073
intake O 0 0.008504087
is O 0 0.0005145616
not O 0 0.0008629794
uncommon O 0 0.006665624
. O 0 0.0028559242

CONCLUSION O 0 0.0346043
( O 0 0.009506089
S O 0 0.891069
) O 0 0.0054173977
: O 0 0.002506339
This O 0 0.0009436211
is O 0 0.00036977816
the O 0 0.00027809828
first O 0 0.00021093813
reported O 0 0.00032688046
case O 0 0.00030746858
of O 0 0.0003384879
central O 0 0.0006790561
retinal B-Disease 0 0.29676464
vein I-Disease 0 0.1089986
occlusion I-Disease 0 0.3041856
after O 0 0.00023665083
treatment O 0 0.00049433904
with O 0 0.0011872273
CC B-Chemical 0 0.6422942
. O 0 0.0039002688

Extra O 0 0.01176799
caution O 0 0.0028468051
is O 0 0.001023061
warranted O 0 0.0007471599
in O 0 0.0006210627
treating O 0 0.0011305554
infertility B-Disease 0 0.916642
patients O 0 0.0012468542
with O 0 0.0005110306
CC B-Chemical 0 0.87416637
, O 0 0.0006578524
and O 0 0.00024700857
patients O 0 0.0003638007
should O 0 8.005578e-05
be O 0 0.000121516285
well O 0 0.00013060766
informed O 0 0.00021211315
of O 0 0.00017653526
this O 0 0.00020676579
side O 0 0.0004917397
effect O 0 0.00022560684
before O 0 0.00020482109
commencement O 0 0.00044944993
of O 0 0.0008144881
therapy O 0 0.0018250108
. O 0 0.0024255705

Acute O 0 0.052696116
bronchodilating O 0 0.76165366
effects O 0 0.001500845
of O 0 0.0024279198
ipratropium B-Chemical 0 0.99997115
bromide I-Chemical 0 0.99947757
and O 0 0.0023556117
theophylline B-Chemical 0 0.9999503
in O 0 0.0010481017
chronic B-Disease 0 0.21915492
obstructive I-Disease 0 0.99915016
pulmonary I-Disease 0 0.9199091
disease I-Disease 0 0.6753184
. O 0 0.003285524

The O 0 0.0019685472
bronchodilator O 0 0.010461511
effects O 0 0.00085682434
of O 0 0.0007365707
a O 0 0.0006610933
single O 0 0.00028163748
dose O 0 0.00053759397
of O 0 0.00054440706
ipratropium B-Chemical 0 0.99997056
bromide I-Chemical 0 0.9976035
aerosol O 0 0.0007005041
( O 0 0.0002761521
36 O 0 0.0001617943
micrograms O 0 0.0008426347
) O 0 0.00025215908
and O 0 0.000109087116
short O 0 0.00011940896
- O 0 0.0010378199
acting O 0 0.00029382322
theophylline B-Chemical 0 0.9999831
tablets O 0 0.64015216
( O 0 0.00035966205
dose O 0 0.0002233776
titrated O 0 0.00013443938
to O 0 8.398682e-05
produce O 0 8.836745e-05
serum O 0 0.00212771
levels O 0 0.000116268835
of O 0 0.00015528753
10 O 0 0.00016622632
- O 0 0.0006393534
20 O 0 0.00013472902
micrograms O 0 0.0010469253
/ O 0 0.0008072459
mL O 0 0.0013693541
) O 0 0.0002770902
were O 0 7.7559176e-05
compared O 0 6.200152e-05
in O 0 8.843033e-05
a O 0 0.00015995234
double O 0 0.00014422547
- O 0 0.0021340095
blind O 0 0.024192397
, O 0 0.00045875195
placebo O 0 0.010712419
- O 0 0.001018384
controlled O 0 0.0001703176
crossover O 0 0.00068263005
study O 0 0.00015579833
in O 0 0.00011774179
21 O 0 0.00016323822
patients O 0 0.00024962515
with O 0 0.00018190534
stable O 0 0.00028417638
, O 0 0.00082111586
chronic B-Disease 0 0.11073009
obstructive I-Disease 0 0.99930346
pulmonary I-Disease 0 0.9376962
disease I-Disease 0 0.7355535
. O 0 0.0029063246

Mean O 0 0.0028369871
peak O 0 0.0025503614
forced O 0 0.0035139383
expiratory O 0 0.0061555617
volume O 0 0.0010556742
in O 0 0.00043833378
1 O 0 0.00037352237
second O 0 0.00025942104
( O 0 0.00054982025
FEV1 O 0 0.0027658856
) O 0 0.00037103327
increases O 0 0.0001234593
over O 0 8.831294e-05
baseline O 0 9.7711854e-05
and O 0 0.00010501818
the O 0 8.171373e-05
proportion O 0 9.350244e-05
of O 0 0.00014052285
patients O 0 0.0002964414
attaining O 0 0.0002845627
at O 0 8.376055e-05
least O 0 0.00010383054
a O 0 0.00017045927
15 O 0 0.000114442664
% O 0 0.00019472268
increase O 0 9.8455144e-05
in O 0 0.000103808765
the O 0 0.00012291779
FEV1 O 0 0.0025907601
( O 0 0.0002350352
responders O 0 0.0002977997
) O 0 0.00032082424
were O 0 0.0001257841
31 O 0 0.00020133446
% O 0 0.00023515376
and O 0 0.00013804516
90 O 0 0.00016153071
% O 0 0.0002923537
, O 0 0.00028780382
respectively O 0 0.0003240182
, O 0 0.0003235379
for O 0 0.00019877977
ipratropium B-Chemical 0 0.9997203
and O 0 0.00026676184
17 O 0 0.00028600558
% O 0 0.0003508404
and O 0 0.0002362779
50 O 0 0.0003730141
% O 0 0.0006255047
, O 0 0.00073805003
respectively O 0 0.0010331265
, O 0 0.0015419833
for O 0 0.0014858999
theophylline B-Chemical 0 0.9998068
. O 0 0.005154995

The O 0 0.002069622
average O 0 0.0017367557
FEV1 O 0 0.007498378
increases O 0 0.0007149146
during O 0 0.0003926683
the O 0 0.0003358643
6 O 0 0.00029986326
- O 0 0.00094895397
hour O 0 0.0002431306
observation O 0 0.00015122005
period O 0 0.00013901062
were O 0 0.00017963447
18 O 0 0.0002349722
% O 0 0.00039917883
for O 0 0.0002868962
ipratropium B-Chemical 0 0.99883944
and O 0 0.00051302556
8 O 0 0.0005110335
% O 0 0.0011939825
for O 0 0.0012634805
theophylline B-Chemical 0 0.99969375
. O 0 0.004963634

The O 0 0.0015305533
mean O 0 0.0010151389
duration O 0 0.0006173842
of O 0 0.0007038973
action O 0 0.0006169898
was O 0 0.00042957132
3 O 0 0.00029783035
. O 0 0.00023844595
8 O 0 0.0001870019
hours O 0 0.00017885648
with O 0 0.0003521291
ipratropium B-Chemical 0 0.99931824
and O 0 0.00039719403
2 O 0 0.0003510207
. O 0 0.00029076508
4 O 0 0.0003086763
hours O 0 0.0004691596
with O 0 0.0015189968
theophylline B-Chemical 0 0.99966335
. O 0 0.0048739556

While O 0 0.0021657622
side O 0 0.0037153987
effects O 0 0.0013740157
were O 0 0.0011084757
rare O 0 0.002425327
, O 0 0.00091905263
those O 0 0.0004405712
experienced O 0 0.0004145261
after O 0 0.00027824522
theophylline B-Chemical 0 0.99987185
use O 0 0.00033119018
did O 0 0.00032944654
involve O 0 0.00028999994
the O 0 0.00034915155
cardiovascular B-Disease 0 0.07598195
and I-Disease 0 0.0008852775
gastrointestinal I-Disease 0 0.038955428
systems I-Disease 0 0.0018441395
. O 0 0.0029714531

These O 0 0.0017803395
results O 0 0.0012587251
show O 0 0.0007999422
that O 0 0.0008779746
ipratropium B-Chemical 0 0.9996903
is O 0 0.00044878275
a O 0 0.00048556685
more O 0 0.00037371172
potent O 0 0.0004031015
bronchodilator O 0 0.028991312
than O 0 0.00022966781
oral O 0 0.004298102
theophylline B-Chemical 0 0.999946
in O 0 0.00033390752
patients O 0 0.000682181
with O 0 0.00054842856
chronic B-Disease 0 0.34637925
airflow I-Disease 0 0.44850665
obstruction I-Disease 0 0.85157317
. O 0 0.0026380143

Methamphetamine B-Chemical 1 0.9998235
- O 0 0.15747865
induced O 0 0.0030690955
neurotoxicity B-Disease 0 0.9981053
and O 0 0.0015867159
microglial O 0 0.007887733
activation O 0 0.0005304112
are O 0 0.00033339602
not O 0 0.00034658503
mediated O 0 0.0003575212
by O 0 0.000964843
fractalkine O 0 0.9537322
receptor O 0 0.0076092673
signaling O 0 0.0024848967
. O 0 0.004232363

Methamphetamine B-Chemical 1 0.99977785
( O 0 0.08510005
METH B-Chemical 0 0.99991417
) O 0 0.05114234
damages O 0 0.9351893
dopamine B-Chemical 0 0.9998833
( O 0 0.012753663
DA B-Chemical 0 0.99969006
) O 0 0.002971343
nerve O 0 0.03344265
endings O 0 0.0014149514
by O 0 0.00019915977
a O 0 0.00026687578
process O 0 0.00016021656
that O 0 0.00011844468
has O 0 0.000110221496
been O 0 0.00015044141
linked O 0 0.00015672899
to O 0 0.00015336456
microglial O 0 0.0027231793
activation O 0 0.00014816107
but O 0 0.00013582791
the O 0 8.066623e-05
signaling O 0 8.1392864e-05
pathways O 0 9.569657e-05
that O 0 8.202884e-05
mediate O 0 8.236322e-05
this O 0 0.00019071676
response O 0 0.00022899326
have O 0 0.00025944383
not O 0 0.00036183678
yet O 0 0.0006729952
been O 0 0.00096462196
delineated O 0 0.002341002
. O 0 0.0029255173

Cardona O 0 0.06269387
et O 0 0.03631945
al O 0 0.038003955
. O 0 0.036195364

[ O 0 0.017428638
Nat O 0 0.00811068
. O 0 0.0030701887
Neurosci O 0 0.10912983
. O 0 0.0014202022
9 O 0 0.0008253755
( O 0 0.0011422194
2006 O 0 0.0010414647
) O 0 0.0013193872
, O 0 0.0011166475
917 O 0 0.0049478333
] O 0 0.0011988882
recently O 0 0.00025070633
identified O 0 0.00016747043
the O 0 0.00024266326
microglial O 0 0.0076793726
- O 0 0.0031201523
specific O 0 0.00018469807
fractalkine O 0 0.95746624
receptor O 0 0.003633533
( O 0 0.0013267808
CX3CR1 O 0 0.6788892
) O 0 0.00075226097
as O 0 0.00017253369
an O 0 0.00017741257
important O 0 0.00012605786
mediator O 0 0.0003482663
of O 0 0.0009790685
MPTP B-Chemical 0 0.99999166
- O 0 0.06895743
induced O 0 0.00084815914
neurodegeneration B-Disease 0 0.99721056
of O 0 0.002998139
DA B-Chemical 0 0.9994635
neurons O 0 0.0026927688
. O 0 0.0028185064

Because O 0 0.0026184046
the O 0 0.0031429986
CNS B-Disease 0 0.79974943
damage I-Disease 0 0.76064706
caused O 0 0.0012179727
by O 0 0.0015125789
METH B-Chemical 0 0.99997663
and O 0 0.0030730155
MPTP B-Chemical 0 0.9999869
is O 0 0.00020922255
highly O 0 0.00013079937
selective O 0 0.00018584881
for O 0 0.00013250348
the O 0 0.00026154442
DA B-Chemical 0 0.9997031
neuronal O 0 0.0005149672
system O 0 0.00013197162
in O 0 9.317115e-05
mouse O 0 7.516336e-05
models O 0 9.719156e-05
of O 0 0.00023462588
neurotoxicity B-Disease 0 0.9985184
, O 0 0.00031412454
we O 0 5.585066e-05
hypothesized O 0 8.2693114e-05
that O 0 9.3024326e-05
the O 0 0.00015390335
CX3CR1 O 0 0.21835051
plays O 0 8.967789e-05
a O 0 0.00018768087
role O 0 9.210018e-05
in O 0 0.00039362966
METH B-Chemical 0 0.99997723
- O 0 0.030082176
induced O 0 0.0006025137
neurotoxicity B-Disease 0 0.99864453
and O 0 0.001133622
microglial O 0 0.022277627
activation O 0 0.0016811723
. O 0 0.0026786635

Mice O 0 0.0017073603
in O 0 0.0017464194
which O 0 0.0014951148
the O 0 0.0010913906
CX3CR1 O 0 0.25790367
gene O 0 0.0005827794
has O 0 0.00028824044
been O 0 0.0002772855
deleted O 0 0.00020986107
and O 0 0.00022944415
replaced O 0 0.00016881074
with O 0 0.00020817228
a O 0 0.00027182268
cDNA O 0 0.00017877191
encoding O 0 0.00012788472
enhanced O 0 0.00024247613
green O 0 0.00039641134
fluorescent O 0 0.00041705507
protein O 0 0.00024649405
( O 0 0.00046325423
eGFP O 0 0.00030155818
) O 0 0.00040380188
were O 0 0.00015797128
treated O 0 0.00041861943
with O 0 0.0005676826
METH B-Chemical 0 0.9999472
and O 0 0.0004715437
examined O 0 0.0003601424
for O 0 0.00064612995
striatal O 0 0.4195423
neurotoxicity B-Disease 0 0.9973537
. O 0 0.0036117842

METH B-Chemical 0 0.99981433
depleted O 0 0.007660798
DA B-Chemical 0 0.9995492
, O 0 0.0037030773
caused O 0 0.0010202213
microglial O 0 0.00724307
activation O 0 0.00045846362
, O 0 0.00057381677
and O 0 0.0002651972
increased O 0 0.000302289
body O 0 0.00041611944
temperature O 0 0.0005653905
in O 0 0.00018199885
CX3CR1 O 0 0.020309873
knockout O 0 6.720129e-05
mice O 0 4.0993014e-05
to O 0 7.595812e-05
the O 0 7.85698e-05
same O 0 6.9339825e-05
extent O 0 9.528263e-05
and O 0 0.00011968345
over O 0 8.6698914e-05
the O 0 8.6762346e-05
same O 0 7.953804e-05
time O 0 9.655233e-05
course O 0 0.00020177918
seen O 0 0.00025894385
in O 0 0.00030680973
wild O 0 0.0005105523
- O 0 0.0045349943
type O 0 0.0021327885
controls O 0 0.00293502
. O 0 0.003539273

The O 0 0.0018912816
effects O 0 0.0019015407
of O 0 0.0033140662
METH B-Chemical 0 0.9999081
in O 0 0.0012314392
CX3CR1 O 0 0.100585155
knockout O 0 0.00021027208
mice O 0 0.00011803957
were O 0 0.00020107451
not O 0 0.00021821604
gender O 0 0.0008885009
- O 0 0.0018405189
dependent O 0 0.00021504493
and O 0 0.00032837913
did O 0 0.000378639
not O 0 0.00033593888
extend O 0 0.00039689004
beyond O 0 0.0006620305
the O 0 0.0010562596
striatum O 0 0.008113165
. O 0 0.0031868992

Striatal O 0 0.9435861
microglia O 0 0.0056211287
expressing O 0 0.0008156862
eGFP O 0 0.0012585501
constitutively O 0 0.00037496394
show O 0 0.00042924815
morphological O 0 0.0010268213
changes O 0 0.0006400854
after O 0 0.00047879425
METH B-Chemical 0 0.9997055
that O 0 0.00048184578
are O 0 0.00045920783
characteristic O 0 0.0007209122
of O 0 0.0010859361
activation O 0 0.0018466497
. O 0 0.0034187112

This O 0 0.0041194884
response O 0 0.0016750817
was O 0 0.0010222372
restricted O 0 0.0006043478
to O 0 0.00043863663
the O 0 0.0003941846
striatum O 0 0.0018174854
and O 0 0.00031162254
contrasted O 0 0.00062814314
sharply O 0 0.00039280197
with O 0 0.00023661203
unresponsive O 0 0.00043187453
eGFP O 0 0.00044120263
- O 0 0.0023174887
microglia O 0 0.00091200566
in O 0 0.00021145468
surrounding O 0 0.0002739149
brain O 0 0.00073866395
areas O 0 0.00034405882
that O 0 0.00018328932
are O 0 0.0002670509
not O 0 0.00048773948
damaged O 0 0.004120371
by O 0 0.0022248344
METH B-Chemical 0 0.99977356
. O 0 0.0047986247

We O 0 0.002255141
conclude O 0 0.0012191208
from O 0 0.00097574736
these O 0 0.00076603214
studies O 0 0.00087028695
that O 0 0.0006132425
CX3CR1 O 0 0.37594023
signaling O 0 0.00049431785
does O 0 0.00035339713
not O 0 0.00040782383
modulate O 0 0.00043673805
METH B-Chemical 0 0.99997246
neurotoxicity B-Disease 0 0.99947757
or O 0 0.0011373677
microglial O 0 0.013821493
activation O 0 0.0018697173
. O 0 0.0029816676

Furthermore O 0 0.003870516
, O 0 0.0050130044
it O 0 0.0023351936
appears O 0 0.00081506494
that O 0 0.0007848694
striatal O 0 0.17231853
- O 0 0.0062465495
resident O 0 0.0006564479
microglia O 0 0.0011462081
respond O 0 0.0002276542
to O 0 0.0003118065
METH B-Chemical 0 0.9999316
with O 0 0.00025225116
an O 0 0.0001711841
activation O 0 0.00012696844
cascade O 0 0.0001324195
and O 0 0.00012852655
then O 0 0.00011867248
return O 0 0.00015547467
to O 0 0.00011104054
a O 0 0.0002345711
surveying O 0 0.00038458107
state O 0 0.00025071445
without O 0 0.00028166865
undergoing O 0 0.0005813049
apoptosis O 0 0.10527617
or O 0 0.001020029
migration O 0 0.005927536
. O 0 0.003171211

Nicotine B-Chemical 0 0.9994294
- O 0 0.0776052
induced O 0 0.0056300513
nystagmus B-Disease 0 0.99921525
correlates O 0 0.00452266
with O 0 0.003855704
midpontine O 0 0.047478743
activation O 0 0.003831777
. O 0 0.0057147928

The O 0 0.003276919
pathomechanism O 0 0.015358634
of O 0 0.00397656
nicotine B-Chemical 0 0.9984078
- O 0 0.0457909
induced O 0 0.0024582222
nystagmus B-Disease 0 0.9997689
( O 0 0.009752365
NIN B-Disease 0 0.77698267
) O 0 0.003555897
is O 0 0.0015726493
unknown O 0 0.002953148
. O 0 0.0046698875

The O 0 0.0017693401
aim O 0 0.0011651092
of O 0 0.0012858937
this O 0 0.0009926647
study O 0 0.00080868875
was O 0 0.00045923804
to O 0 0.00032790238
delineate O 0 0.00025854819
brain O 0 0.0008933069
structures O 0 0.00035239913
that O 0 0.0003023204
are O 0 0.0003815741
involved O 0 0.00056989543
in O 0 0.0011803966
NIN B-Disease 0 0.32029143
generation O 0 0.002540693
. O 0 0.003837462

Eight O 0 0.0037165706
healthy O 0 0.004990337
volunteers O 0 0.0037110676
inhaled O 0 0.18765704
nicotine B-Chemical 0 0.9915207
in O 0 0.0005377362
darkness O 0 0.0012368566
during O 0 0.00016678823
a O 0 0.0002105485
functional O 0 0.00011672151
magnetic O 0 0.00030810447
resonance O 0 0.0004801924
imaging O 0 0.00021369063
( O 0 0.00028301723
fMRI O 0 0.0005493205
) O 0 0.0002961733
experiment O 0 0.00012414707
; O 0 0.00042647813
eye O 0 0.0011688188
movements O 0 0.000490937
were O 0 0.00024553048
registered O 0 0.00037611742
using O 0 0.00031631536
video O 0 0.0010060818
- O 0 0.0055269552
oculography O 0 0.12864202
. O 0 0.0034698185

NIN B-Disease 0 0.6537819
correlated O 0 0.0031091722
with O 0 0.002605368
blood O 0 0.123987734
oxygen B-Chemical 1 0.9991541
level O 0 0.0009545766
- O 0 0.0034717838
dependent O 0 0.00036981713
( O 0 0.00091628666
BOLD O 0 0.00589766
) O 0 0.00054127566
activity O 0 0.00015168331
levels O 0 0.00019864543
in O 0 0.00026586957
a O 0 0.00054415147
midpontine O 0 0.0035596732
site O 0 0.00018884518
in O 0 0.00031153788
the O 0 0.0004106657
posterior O 0 0.0026843143
basis O 0 0.00095040264
pontis O 0 0.0017171105
. O 0 0.002411247

NIN B-Disease 0 0.9609829
- O 0 0.04657138
induced O 0 0.002557944
midpontine O 0 0.05151395
activation O 0 0.0007363562
may O 0 0.0003620381
correspond O 0 0.00019487129
to O 0 0.00019693871
activation O 0 0.00021320504
of O 0 0.0002618401
the O 0 0.0002587763
dorsomedial O 0 0.0052426327
pontine O 0 0.006142623
nuclei O 0 0.00019252909
and O 0 0.00014333104
the O 0 0.00012245149
nucleus O 0 0.00014864163
reticularis O 0 0.00043682693
tegmenti O 0 4.5303586e-05
pontis O 0 9.375814e-05
, O 0 0.00013348006
structures O 0 0.00010586972
known O 0 0.000118483316
to O 0 0.000109394605
participate O 0 0.00011094773
in O 0 0.000113828835
the O 0 0.0001101843
generation O 0 0.0001555813
of O 0 0.00024237398
multidirectional O 0 0.0074843103
saccades O 0 0.02420246
and O 0 0.0005116148
smooth O 0 0.0024354302
pursuit O 0 0.004052292
eye O 0 0.0076362165
movements O 0 0.0035094449
. O 0 0.0030169324

Acute O 0 0.017668407
effects O 0 0.0026727708
of O 0 0.0034717333
N B-Chemical 0 0.99742174
- I-Chemical 0 0.026672455
( I-Chemical 0 0.0016221837
2 I-Chemical 0 0.00073173305
- I-Chemical 0 0.001880678
propylpentanoyl I-Chemical 0 0.000990039
) I-Chemical 0 0.0029150276
urea I-Chemical 0 0.9989629
on O 0 0.00058291387
hippocampal O 0 0.35792598
amino B-Chemical 0 0.99632543
acid I-Chemical 0 0.9988834
neurotransmitters O 0 0.79780954
in O 0 0.0013694245
pilocarpine B-Chemical 0 0.9999912
- O 0 0.04272959
induced O 0 0.0008450392
seizure B-Disease 0 0.99856097
in O 0 0.0010596558
rats O 0 0.0023281479
. O 0 0.002632058

The O 0 0.0017506883
present O 0 0.0011566983
study O 0 0.0009448338
aimed O 0 0.0005458047
to O 0 0.00032860934
investigate O 0 0.00015358157
the O 0 0.00030996147
anticonvulsant O 0 0.9881015
activity O 0 0.00016041727
as O 0 0.00015078549
well O 0 0.00012395403
as O 0 0.00011481047
the O 0 8.399083e-05
effects O 0 9.9887824e-05
on O 0 8.000297e-05
the O 0 9.8331104e-05
level O 0 0.0001355518
of O 0 0.00037990592
hippocampal O 0 0.59691364
amino B-Chemical 0 0.9987558
acid I-Chemical 0 0.99966145
neurotransmitters O 0 0.973097
( O 0 0.05967138
glutamate B-Chemical 0 0.9999573
, O 0 0.057608355
aspartate B-Chemical 1 0.9999534
, O 0 0.013685087
glycine B-Chemical 0 0.9986066
and O 0 0.0017261517
GABA B-Chemical 0 0.99997246
) O 0 0.0016665561
of O 0 0.00046430485
N B-Chemical 0 0.999418
- I-Chemical 0 0.017024891
( I-Chemical 0 0.00041259726
2 I-Chemical 0 0.000205533
- I-Chemical 0 0.00076380273
propylpentanoyl I-Chemical 0 0.0004341332
) I-Chemical 0 0.0016663481
urea I-Chemical 0 0.9995913
( O 0 0.0020866205
VPU B-Chemical 0 0.9946838
) O 0 0.00067563617
in O 0 0.00014328021
comparison O 0 0.00012211032
to O 0 0.000150133
its O 0 0.00033629156
parent O 0 0.0008035904
compound O 0 0.089247994
, O 0 0.07803397
valproic B-Chemical 0 0.9999975
acid I-Chemical 0 0.9990563
( O 0 0.40023366
VPA B-Chemical 1 0.9999857
) O 0 0.021009503
. O 0 0.0037791815

VPU B-Chemical 0 0.9871133
was O 0 0.0027064814
more O 0 0.0021746205
potent O 0 0.0019598755
than O 0 0.0016507511
VPA B-Chemical 1 0.99998176
, O 0 0.0014113003
exhibiting O 0 0.00036869632
the O 0 0.00015359445
median O 0 0.00010709885
effective O 0 0.0001504348
dose O 0 0.00036371418
( O 0 0.0004981651
ED O 0 0.0174309
( O 0 0.00039160103
50 O 0 0.00023960622
) O 0 0.00038346578
) O 0 0.00031163858
of O 0 0.00015251712
49 O 0 0.00026311434
mg O 0 0.0024655599
/ O 0 0.0006299606
kg O 0 0.0003530582
in O 0 0.0001075472
protecting O 0 0.00015805115
rats O 0 0.00025484286
against O 0 0.00013199415
pilocarpine B-Chemical 0 0.9999926
- O 0 0.02817365
induced O 0 0.0002910758
seizure B-Disease 0 0.9995467
whereas O 0 0.00017309314
the O 0 0.00010536705
corresponding O 0 8.989784e-05
value O 0 0.00022477849
for O 0 0.00034291254
VPA B-Chemical 1 0.999974
was O 0 0.00069330964
322 O 0 0.0026348713
mg O 0 0.0076067112
/ O 0 0.003159007
kg O 0 0.0031727098
. O 0 0.0028234422

In O 0 0.0016936492
vivo O 0 0.0016448504
microdialysis O 0 0.0064198216
demonstrated O 0 0.00045261192
that O 0 0.00026770402
an O 0 0.0003029133
intraperitoneal O 0 0.0005407118
administration O 0 0.00046135663
of O 0 0.00042879253
pilocarpine B-Chemical 0 0.99998176
induced O 0 0.00023387837
a O 0 0.00028757672
pronounced O 0 0.0002824288
increment O 0 0.00028812475
of O 0 0.00031702756
hippocampal O 0 0.61812377
glutamate B-Chemical 0 0.9999423
and O 0 0.001584403
aspartate B-Chemical 1 0.99988353
whereas O 0 0.0002027357
no O 0 0.00011322995
significant O 0 0.00013286622
change O 0 0.00013242064
was O 0 0.00011411217
observed O 0 0.00011167449
on O 0 0.000111933885
the O 0 0.00018000088
level O 0 0.00033208082
of O 0 0.0011483053
glycine B-Chemical 0 0.99798787
and O 0 0.0074680196
GABA B-Chemical 0 0.9998716
. O 0 0.005241521

Pretreatment O 0 0.0386754
with O 0 0.0032393364
either O 0 0.0026567183
VPU B-Chemical 0 0.99134386
( O 0 0.002144551
50 O 0 0.0007861599
and O 0 0.00048108463
100 O 0 0.00079656445
mg O 0 0.003199077
/ O 0 0.0011360733
kg O 0 0.00083583023
) O 0 0.0007931156
or O 0 0.00045588939
VPA B-Chemical 1 0.99998176
( O 0 0.0007754431
300 O 0 0.0004016625
and O 0 0.00019011165
600 O 0 0.0005372948
mg O 0 0.0021846883
/ O 0 0.00073895266
kg O 0 0.0005698201
) O 0 0.0005224603
completely O 0 0.00022558468
abolished O 0 0.00080592313
pilocarpine B-Chemical 0 0.9999914
- O 0 0.028133437
evoked O 0 0.0008957859
increases O 0 0.00036367466
in O 0 0.0005744743
extracellular O 0 0.02158521
glutamate B-Chemical 0 0.9997435
and O 0 0.0056062173
aspartate B-Chemical 1 0.99944276
. O 0 0.0053020306

In O 0 0.0019300947
addition O 0 0.0012287151
, O 0 0.0023070134
a O 0 0.0012935109
statistically O 0 0.00087146816
significant O 0 0.00044099832
reduction O 0 0.0004513887
was O 0 0.00024078265
also O 0 0.00017052137
observed O 0 0.00013892249
on O 0 0.000102426064
the O 0 0.00012759496
level O 0 0.00019026686
of O 0 0.0008297236
GABA B-Chemical 0 0.99998534
and O 0 0.0013311635
glycine B-Chemical 0 0.99599564
but O 0 0.00036793062
less O 0 0.00026706772
than O 0 0.00015846793
a O 0 0.00029993415
drastic O 0 0.0003893768
reduction O 0 0.00061503623
of O 0 0.0013948738
glutamate B-Chemical 0 0.9998486
and O 0 0.0041152984
aspartate B-Chemical 1 0.9994842
level O 0 0.0023773094
. O 0 0.0034968955

Based O 0 0.0040488406
on O 0 0.0013342147
the O 0 0.001062819
finding O 0 0.0010446665
that O 0 0.0009920307
VPU B-Chemical 0 0.9985275
and O 0 0.004837773
VPA B-Chemical 1 0.99999356
could O 0 0.0003178783
protect O 0 0.0002230779
the O 0 0.00012882211
animals O 0 0.00010994605
against O 0 0.00014510985
pilocarpine B-Chemical 0 0.99999344
- O 0 0.0515277
induced O 0 0.0003374781
seizure B-Disease 0 0.999816
it O 0 0.00028816873
is O 0 8.522589e-05
suggested O 0 6.96096e-05
that O 0 6.3103005e-05
the O 0 8.457843e-05
reduction O 0 0.00019236008
of O 0 0.00029267024
inhibitory O 0 0.011780573
amino B-Chemical 0 0.999131
acid I-Chemical 0 0.9995958
neurotransmitters O 0 0.60389584
was O 0 0.00017317964
comparatively O 0 0.0003832485
minor O 0 0.00023324235
and O 0 0.00014284778
offset O 0 0.0002489034
by O 0 0.00017218431
a O 0 0.0003420204
pronounced O 0 0.0005051442
reduction O 0 0.0006558063
of O 0 0.0014693085
glutamate B-Chemical 0 0.99980634
and O 0 0.006003789
aspartate B-Chemical 1 0.9995511
. O 0 0.004955302

Therefore O 0 0.002697578
, O 0 0.0056178356
like O 0 0.003991051
VPA B-Chemical 1 0.9999708
, O 0 0.0031356274
the O 0 0.00059672707
finding O 0 0.00056169636
that O 0 0.00048351966
VPU B-Chemical 0 0.9950588
could O 0 0.00030765915
drastically O 0 0.0006216292
reduce O 0 0.00036107094
pilocarpine B-Chemical 0 0.99999523
- O 0 0.038173147
induced O 0 0.00020263056
increases O 0 0.00028287317
in O 0 0.0005320165
glutamate B-Chemical 0 0.9999174
and O 0 0.0014307759
aspartate B-Chemical 1 0.9997782
should O 0 8.595875e-05
account O 0 0.000110523346
, O 0 0.00016887482
at O 0 6.593233e-05
least O 0 8.4893654e-05
partly O 0 0.00012799537
, O 0 0.00019654605
for O 0 9.121801e-05
its O 0 0.00026424514
anticonvulsant O 0 0.9921623
activity O 0 0.00011377533
observed O 0 0.00016061073
in O 0 0.0004415239
pilocarpine B-Chemical 0 0.99999344
- O 0 0.04374554
induced O 0 0.0005593027
seizure B-Disease 0 0.99909675
in O 0 0.00052502274
experimental O 0 0.0007364005
animals O 0 0.00089295075
. O 0 0.0023084283

Some O 0 0.003167272
other O 0 0.0014899451
mechanism O 0 0.00094547303
than O 0 0.0009880377
those O 0 0.0010169026
being O 0 0.00083782733
reported O 0 0.0007858756
herein O 0 0.0008470469
should O 0 0.0004939302
be O 0 0.00084662176
further O 0 0.0010809365
investigated O 0 0.0022116757
. O 0 0.0043963017

Protective O 0 0.023477979
effect O 0 0.0029074687
of O 0 0.0052090446
verapamil B-Chemical 0 0.9999771
on O 0 0.0034865143
gastric B-Disease 0 0.9986431
hemorrhagic I-Disease 2 0.99998176
ulcers B-Disease 0 0.9998721
in O 0 0.002024593
severe O 0 0.06528284
atherosclerotic B-Disease 0 0.99755234
rats O 0 0.004183425
. O 0 0.0034570945

Studies O 0 0.005078541
concerning O 0 0.0017193353
with O 0 0.0017834242
pathogenesis O 0 0.002597767
of O 0 0.0022934822
gastric B-Disease 0 0.9976484
hemorrhage I-Disease 2 0.9999888
and O 0 0.0017147787
mucosal O 0 0.11173192
ulceration O 0 0.95976937
produced O 0 0.00042503365
in O 0 0.00062641443
atherosclerotic B-Disease 0 0.99491465
rats O 0 0.0011694913
are O 0 0.00060936273
lacking O 0 0.00075457565
. O 0 0.0025384475

The O 0 0.0016609944
aim O 0 0.0010745958
of O 0 0.0011710782
this O 0 0.0008686967
study O 0 0.00066101825
is O 0 0.00030103652
to O 0 0.00020137247
examine O 0 9.967127e-05
the O 0 0.00014895988
role O 0 0.000114635535
of O 0 0.00041876634
gastric O 0 0.48050287
acid O 0 0.7952406
back O 0 0.000854758
- O 0 0.007946899
diffusion O 0 0.0032870204
, O 0 0.00087511534
mast O 0 0.17987436
cell O 0 0.0027783
histamine B-Chemical 0 0.99993014
release O 0 0.005807216
, O 0 0.0028314309
lipid O 0 0.9936854
peroxide O 0 0.9999778
( O 0 0.24419957
LPO O 0 0.99999905
) O 0 0.001727823
generation O 0 0.00015997034
and O 0 0.00019444403
mucosal O 0 0.02283378
microvascular O 0 0.9972326
permeability O 0 0.86583644
in O 0 0.00016240761
modulating O 0 0.00011753348
gastric B-Disease 0 0.9948723
hemorrhage I-Disease 2 0.9999969
and O 0 0.0005097152
ulcer B-Disease 0 0.99701095
in O 0 0.00012710168
rats O 0 0.00025909848
with O 0 0.00027006274
atherosclerosis B-Disease 0 0.99994457
induced O 0 0.00028049003
by O 0 0.00032132963
coadministration O 0 0.73915064
of O 0 0.0018958584
vitamin B-Chemical 0 0.99998856
D2 I-Chemical 0 0.99980813
and O 0 0.0049223565
cholesterol B-Chemical 0 0.999688
. O 0 0.005163403

Additionally O 0 0.0033519235
, O 0 0.00395661
the O 0 0.0013757475
protective O 0 0.0016139507
effect O 0 0.00096067094
of O 0 0.002178645
verapamil B-Chemical 0 0.99998343
on O 0 0.00097091025
this O 0 0.0014507633
ulcer B-Disease 0 0.99241865
model O 0 0.0010147562
was O 0 0.0012115223
evaluated O 0 0.0018618939
. O 0 0.0034172076

Male O 0 0.008394259
Wistar O 0 0.005329561
rats O 0 0.0014785769
were O 0 0.000548838
challenged O 0 0.0004110879
intragastrically O 0 0.0012467128
once O 0 0.00022719757
daily O 0 0.00023659487
for O 0 0.00012165633
9 O 0 0.0001253093
days O 0 8.947791e-05
with O 0 0.00015914209
1 O 0 0.00018996448
. O 0 0.00014623343
0 O 0 0.00019959967
ml O 0 0.00045321073
/ O 0 0.0006034859
kg O 0 0.00046897714
of O 0 0.00032431833
corn O 0 0.8697336
oil O 0 0.99459743
containing O 0 0.0015128446
vitamin B-Chemical 0 0.99999297
D2 I-Chemical 0 0.99986565
and O 0 0.002007435
cholesterol B-Chemical 0 0.99975973
to O 0 0.0009863639
induce O 0 0.0013090862
atherosclerosis B-Disease 0 0.99981767
. O 0 0.0051160147

Control O 0 0.011131426
rats O 0 0.008153826
received O 0 0.006935931
corn O 0 0.80456495
oil O 0 0.97031355
only O 0 0.01037655
. O 0 0.010925603

After O 0 0.0025688903
gastric O 0 0.017355567
surgery O 0 0.0026124439
, O 0 0.0018671108
rat O 0 0.0012702545
stomachs O 0 0.0023403675
were O 0 0.00055545644
irrigated O 0 0.0020164521
for O 0 0.00022867405
3 O 0 0.00021836613
h O 0 0.00026593907
with O 0 0.00026198642
either O 0 0.00028723176
simulated O 0 0.00039882242
gastric O 0 0.10033304
juice O 0 0.9854645
or O 0 0.0010062528
normal O 0 0.0022157645
saline O 0 0.0043879664
. O 0 0.0029997146

Gastric O 0 0.25496548
acid O 0 0.6765165
back O 0 0.005231404
- O 0 0.021447672
diffusion O 0 0.012261476
, O 0 0.004621959
mucosal O 0 0.7397873
LPO O 0 0.9999938
generation O 0 0.001548989
, O 0 0.0036445768
histamine B-Chemical 0 0.9996675
concentration O 0 0.0017434632
, O 0 0.0014256204
microvascular O 0 0.9971481
permeability O 0 0.9639056
, O 0 0.0016994147
luminal B-Chemical 0 0.8314809
hemoglobin O 0 0.9624758
content O 0 0.00072385825
and O 0 0.0008045136
ulcer B-Disease 0 0.99557835
areas O 0 0.0012988694
were O 0 0.00078649924
determined O 0 0.001118833
. O 0 0.002608085

Elevated O 0 0.15921672
atherosclerotic B-Disease 0 0.98868424
parameters O 0 0.002093456
, O 0 0.0018473398
such O 0 0.00075305137
as O 0 0.00087048806
serum O 0 0.07838383
calcium B-Chemical 0 0.995516
, O 0 0.0013679268
total O 0 0.0006045921
cholesterol B-Chemical 0 0.9993144
and O 0 0.00045702257
low O 0 0.00057300273
- O 0 0.003168255
density O 0 0.0007448746
lipoprotein O 0 0.98827505
concentration O 0 0.00082155183
were O 0 0.00030741608
obtained O 0 0.00031784497
in O 0 0.00069488137
atherosclerotic B-Disease 0 0.98834175
rats O 0 0.002851131
. O 0 0.002763599

Severe O 0 0.5317222
gastric O 0 0.83771884
ulcers B-Disease 0 0.99939024
accompanied O 0 0.0026862551
with O 0 0.0010362728
increased O 0 0.0013369946
ulcerogenic O 0 0.9796663
factors O 0 0.0011030834
, O 0 0.00083211076
including O 0 0.00033057158
gastric O 0 0.39438987
acid O 0 0.75618136
back O 0 0.00084109564
- O 0 0.011622395
diffusion O 0 0.008067004
, O 0 0.0021506862
histamine B-Chemical 0 0.9998406
release O 0 0.0051252074
, O 0 0.011339449
LPO O 0 0.999998
generation O 0 0.00043353066
and O 0 0.00036590116
luminal B-Chemical 0 0.8333914
hemoglobin O 0 0.96755475
content O 0 0.00041676732
were O 0 0.00021664647
also O 0 0.00022211287
observed O 0 0.0002850403
in O 0 0.0004532674
these O 0 0.00074343215
rats O 0 0.0019931423
. O 0 0.0025262476

Moreover O 0 0.0035433115
, O 0 0.0040174797
a O 0 0.0020104311
positive O 0 0.0010764427
correlation O 0 0.0008138543
of O 0 0.0015637708
histamine B-Chemical 0 0.99960214
to O 0 0.0012805191
gastric B-Disease 0 0.99792707
hemorrhage I-Disease 2 0.99999094
and O 0 0.00068240106
to O 0 0.00046255882
ulcer B-Disease 0 0.9949875
was O 0 0.00037488816
found O 0 0.00038392114
in O 0 0.0005185004
those O 0 0.0011671515
atherosclerotic B-Disease 0 0.99470574
rats O 0 0.0031544818
. O 0 0.0028765982

This O 0 0.013544147
hemorrhagic B-Disease 2 0.9992859
ulcer B-Disease 0 0.99830806
and O 0 0.0014204489
various O 0 0.0008477628
ulcerogenic O 0 0.78951925
parameters O 0 0.00054534915
were O 0 0.00035678726
dose O 0 0.00091066415
- O 0 0.005945867
dependently O 0 0.16313559
ameliorated O 0 0.020535288
by O 0 0.00067083427
daily O 0 0.0012566178
intragastric O 0 0.19635046
verapamil B-Chemical 0 0.9999355
. O 0 0.0048739812

Atherosclerosis B-Disease 0 0.9689284
could O 0 0.00247343
produce O 0 0.0022679805
gastric B-Disease 0 0.9948179
hemorrhagic I-Disease 2 0.9999703
ulcer B-Disease 0 0.99964356
via O 0 0.0006855508
aggravation O 0 0.27337816
of O 0 0.0008177918
gastric O 0 0.6889264
acid O 0 0.8504813
back O 0 0.0010033745
- O 0 0.015990587
diffusion O 0 0.014750316
, O 0 0.006579297
LPO O 0 0.99999774
generation O 0 0.0007688836
, O 0 0.0026827175
histamine B-Chemical 0 0.99982494
release O 0 0.0011935738
and O 0 0.0003926196
microvascular O 0 0.99814916
permeability O 0 0.89553624
that O 0 0.00016242974
could O 0 0.0001453177
be O 0 0.0002553721
ameliorated O 0 0.020284139
by O 0 0.00094234344
verapamil B-Chemical 0 0.9999814
in O 0 0.0014227993
rats O 0 0.0025465845
. O 0 0.0026090476

Lamivudine B-Chemical 1 0.9978695
for O 0 0.0019382483
the O 0 0.0013076918
prevention O 0 0.0020551083
of O 0 0.0037608908
hepatitis B-Disease 2 0.99999475
B I-Disease 2 0.99955803
virus O 0 0.069417045
reactivation O 0 0.0026012694
in O 0 0.00088791194
hepatitis B-Chemical 0 0.99998
- I-Chemical 0 0.38266838
B I-Chemical 0 0.50395906
surface I-Chemical 0 0.0016326436
antigen I-Chemical 0 0.0070136553
( O 0 0.0020603028
HBSAG B-Chemical 0 0.9976726
) O 0 0.00236097
seropositive O 0 0.0035370272
cancer B-Disease 0 0.88637537
patients O 0 0.0011649117
undergoing O 0 0.0007417447
cytotoxic O 0 0.010735977
chemotherapy O 0 0.011515419
. O 0 0.0024070402

Hepatitis B-Disease 0 0.99981946
B I-Disease 0 0.99565804
virus O 0 0.059614897
( O 0 0.008739859
HBV O 0 0.68924713
) O 0 0.0026074725
is O 0 0.00048028806
one O 0 0.00036215875
of O 0 0.00039488327
the O 0 0.0003145351
major O 0 0.00039097716
causes O 0 0.0005254789
of O 0 0.0008939599
chronic O 0 0.86657643
liver B-Disease 0 0.99770784
disease I-Disease 0 0.999071
worldwide O 0 0.008255186
. O 0 0.003824126

Cancer B-Disease 0 0.14285585
patients O 0 0.004806964
who O 0 0.0020371685
are O 0 0.0008011024
chronic O 0 0.0053560636
carriers O 0 0.0012609512
of O 0 0.00070858776
HBV O 0 0.35636377
have O 0 0.00026394374
a O 0 0.0003181475
higher O 0 0.00031082795
hepatic B-Disease 0 0.99814296
complication I-Disease 0 0.28003493
rate O 0 0.0001992228
while O 0 9.836609e-05
receiving O 0 0.00014938063
cytotoxic O 0 0.0019417512
chemotherapy O 0 0.0019406695
( O 0 0.00027063832
CT O 0 0.0026421752
) O 0 0.00041082484
and O 0 0.00016724224
this O 0 0.00019603866
has O 0 0.00015077487
mainly O 0 0.00028790592
been O 0 0.0003333223
attributed O 0 0.00045020808
to O 0 0.0008046025
HBV O 0 0.67018336
reactivation O 0 0.004581447
. O 0 0.0031620024

In O 0 0.002250684
this O 0 0.0022082818
study O 0 0.0019962168
, O 0 0.0030648997
cancer B-Disease 0 0.9097824
patients O 0 0.0019039714
who O 0 0.00061475165
have O 0 0.00024284911
solid O 0 0.0010440089
and O 0 0.0004610867
hematological B-Disease 0 0.99559903
malignancies I-Disease 0 0.999683
with O 0 0.00046906367
chronic O 0 0.32709393
HBV B-Disease 0 0.99796426
infection I-Disease 0 0.12104053
received O 0 0.00010003901
the O 0 6.2994965e-05
antiviral O 0 0.00031764715
agent O 0 0.0009793182
lamivudine B-Chemical 0 0.99994123
prior O 0 4.9737628e-05
and O 0 7.503789e-05
during O 0 6.0835668e-05
CT O 0 0.0008098083
compared O 0 6.579465e-05
with O 0 0.000114959796
historical O 0 0.00059558294
control O 0 0.00017973779
group O 0 0.00037066333
who O 0 0.00041594036
did O 0 0.00035682466
not O 0 0.00046795837
receive O 0 0.001141577
lamivudine B-Chemical 0 0.99964476
. O 0 0.0031273926

The O 0 0.0015688633
objectives O 0 0.0012406942
were O 0 0.00074960105
to O 0 0.00039204798
assess O 0 0.00017653275
the O 0 0.00021321134
efficacy O 0 0.00027787435
of O 0 0.0004891274
lamivudine B-Chemical 0 0.9999155
in O 0 0.00022268796
reducing O 0 0.0001455984
the O 0 0.00015092993
incidence O 0 0.00044086884
of O 0 0.00033869952
HBV O 0 0.73237014
reactivation O 0 0.0007760644
, O 0 0.0004267876
and O 0 0.0002299952
diminishing O 0 0.0004442601
morbidity O 0 0.006917013
and O 0 0.0004618429
mortality O 0 0.001927572
during O 0 0.0007203501
CT O 0 0.012182605
. O 0 0.0027124083

Two O 0 0.0044833254
groups O 0 0.0045305886
were O 0 0.0028892127
compared O 0 0.0021717101
in O 0 0.0028860508
this O 0 0.0040067527
study O 0 0.0059494586
. O 0 0.008105024

The O 0 0.0021453367
prophylactic O 0 0.0033918684
lamivudin B-Chemical 0 0.5962305
group O 0 0.0013142414
consisted O 0 0.0006790564
of O 0 0.0006135058
37 O 0 0.0009602271
patients O 0 0.00077092036
who O 0 0.00055016624
received O 0 0.00049262826
prophylactic O 0 0.0015720655
lamivudine B-Chemical 0 0.99942017
treatment O 0 0.0020866194
. O 0 0.003201287

The O 0 0.0023559255
historical O 0 0.0044733398
controls O 0 0.0017947578
consisted O 0 0.0009585137
of O 0 0.0007739113
50 O 0 0.0007230558
consecutive O 0 0.0004376981
patients O 0 0.00064870605
who O 0 0.0005113393
underwent O 0 0.0005488835
CT O 0 0.0024175406
without O 0 0.0008318408
prophylactic O 0 0.0031159134
lamivudine B-Chemical 0 0.99943465
. O 0 0.0043909564

They O 0 0.005580132
were O 0 0.0022477135
followed O 0 0.0013239501
up O 0 0.0012868121
during O 0 0.000741243
and O 0 0.00087326526
for O 0 0.0006545378
8 O 0 0.0007943412
weeks O 0 0.00062101387
after O 0 0.0010756206
CT O 0 0.008984474
. O 0 0.0052056746

The O 0 0.0031255882
outcomes O 0 0.0032037243
were O 0 0.0022811887
compared O 0 0.0016775556
for O 0 0.0019182651
both O 0 0.0028613897
groups O 0 0.005618523
. O 0 0.008393961

Of O 0 0.005042805
our O 0 0.0019891916
control O 0 0.0015914243
group O 0 0.0016931342
( O 0 0.001547984
n O 0 0.00096904166
= O 0 0.0015976226
50 O 0 0.0008036466
) O 0 0.0011155275
, O 0 0.0008430359
21 O 0 0.000582737
patients O 0 0.0008033347
( O 0 0.0008531428
42 O 0 0.0007515269
% O 0 0.0012218166
) O 0 0.0016761243
were O 0 0.0010839744
established O 0 0.0023750258
hepatitis B-Disease 0 0.99962974
. O 0 0.008773819

Twelve O 0 0.00932293
( O 0 0.0055694235
24 O 0 0.0025609047
% O 0 0.0031596455
) O 0 0.0026075023
of O 0 0.0013012331
them O 0 0.0015084357
were O 0 0.0010877169
evaluated O 0 0.0012742631
as O 0 0.0020459166
severe O 0 0.06537848
hepatitis B-Disease 0 0.99974114
. O 0 0.010963686

In O 0 0.0018309595
the O 0 0.0015977991
prophylactic O 0 0.0037908216
lamivudine B-Chemical 0 0.9998392
group O 0 0.002849778
severe O 0 0.17936474
hepatitis B-Disease 0 0.9999641
were O 0 0.00046820153
observed O 0 0.00022687414
only O 0 0.00023727416
in O 0 0.00019542633
1 O 0 0.0002222743
patient O 0 0.00021225214
( O 0 0.0002871734
2 O 0 0.00017959473
. O 0 0.00014782774
7 O 0 0.00013856635
% O 0 0.00034638235
) O 0 0.00043946027
of O 0 0.0002793009
37 O 0 0.00057209
patients O 0 0.0005453
( O 0 0.0005063646
p O 0 0.00057610794
< O 0 0.0006874635
0 O 0 0.00079355785
. O 0 0.0010044622
006 O 0 0.008476766
) O 0 0.004433533
. O 0 0.004177024

Comparison O 0 0.0017357655
of O 0 0.0016135029
the O 0 0.000986511
mean O 0 0.00095984066
ALT O 0 0.88529366
values O 0 0.0004690436
revealed O 0 0.00026632243
significantly O 0 0.00034114145
higher O 0 0.00036933162
mean O 0 0.0004264314
alanine B-Chemical 0 0.954195
aminotransferase O 0 0.9985868
( O 0 0.0019331806
ALT O 0 0.9930782
) O 0 0.00048048564
values O 0 0.00012296831
in O 0 9.24377e-05
the O 0 7.8396755e-05
control O 0 0.000105616935
group O 0 0.00016622807
than O 0 9.8082564e-05
the O 0 0.000107067615
prophylactic O 0 0.00047344167
lamivudine B-Chemical 0 0.9998493
group O 0 0.00041232674
; O 0 0.00051526073
154 O 0 0.00056694564
: O 0 0.00044261044
64 O 0 0.00033266706
( O 0 0.00039944894
p O 0 0.0004693327
< O 0 0.0005719284
0 O 0 0.0006408741
. O 0 0.00072623073
32 O 0 0.001595698
) O 0 0.0036076612
. O 0 0.0037793145

Our O 0 0.0020847975
study O 0 0.0017088328
suggests O 0 0.00062665716
that O 0 0.00060634955
prophylactic O 0 0.0024204336
lamivudine B-Chemical 0 0.9999174
significantly O 0 0.00056831015
decreases O 0 0.00032792988
the O 0 0.00019354414
incidence O 0 0.00047238992
of O 0 0.0003261925
HBV O 0 0.58531153
reactivation O 0 0.000442969
and O 0 0.00015445039
overall O 0 0.00016295005
morbidity O 0 0.007613363
in O 0 0.00023317299
cancer B-Disease 0 0.8831644
patients O 0 0.00054601306
during O 0 0.00015259524
and O 0 0.00026747925
after O 0 0.00025545736
immunosuppressive O 0 0.006109295
therapy O 0 0.0015793962
. O 0 0.0021390805

Further O 0 0.0022426408
studies O 0 0.0019342795
are O 0 0.00081317127
needed O 0 0.00048068698
to O 0 0.00032276745
determine O 0 0.00012242603
the O 0 0.00020145354
most O 0 0.00025460531
appropriate O 0 0.00018068147
nucleoside B-Chemical 0 0.020117834
or O 0 0.00019528811
nucleotide B-Chemical 0 0.0009138724
analogue O 0 0.00038657253
for O 0 9.302096e-05
antiviral O 0 0.00030036885
prophylaxis O 0 0.00013234011
during O 0 7.2300514e-05
CT O 0 0.0010607778
and O 0 9.796021e-05
the O 0 6.1803534e-05
optimal O 0 4.6081095e-05
duration O 0 7.6457676e-05
of O 0 0.0001651602
administration O 0 0.0003193844
after O 0 0.00015615975
completion O 0 0.000274629
of O 0 0.00088498066
CT O 0 0.011154612
. O 0 0.0029077122

Recovery O 0 0.008527487
of O 0 0.004137983
tacrolimus B-Chemical 0 0.99990094
- O 0 0.02679507
associated O 0 0.0013406294
brachial B-Disease 0 0.99895453
neuritis I-Disease 0 0.9999229
after O 0 0.00020413169
conversion O 0 0.0003087269
to O 0 0.00017853224
everolimus B-Chemical 0 0.96494174
in O 0 0.00014889867
a O 0 0.0002104277
pediatric O 0 0.00037059566
renal O 0 0.07936777
transplant O 0 0.00026109198
recipient O 0 0.00019224291
- O 0 0.0012403753
- O 0 0.0009371346
case O 0 0.00023560732
report O 0 0.00042665194
and O 0 0.00035997026
review O 0 0.0007583665
of O 0 0.0006558257
the O 0 0.0008613551
literature O 0 0.0031171432
. O 0 0.0032458927

TAC B-Chemical 0 0.84633726
has O 0 0.0018755221
been O 0 0.0011687841
shown O 0 0.00046093622
to O 0 0.00046864248
be O 0 0.00042204495
a O 0 0.00054449996
potent O 0 0.00060017477
immunosuppressive O 0 0.006853397
agent O 0 0.00073353713
for O 0 0.00028484475
solid O 0 0.0012431584
organ O 0 0.0008980844
transplantation O 0 0.0008425813
in O 0 0.0008565149
pediatrics O 0 0.00545731
. O 0 0.00310473

Neurotoxicity B-Disease 0 0.9928027
is O 0 0.0046124063
a O 0 0.0047554546
potentially O 0 0.0034079237
serious O 0 0.008209895
toxic O 0 0.03921717
effect O 0 0.00525103
. O 0 0.008905289

It O 0 0.0063001504
is O 0 0.0023744465
characterized O 0 0.0026224237
by O 0 0.0026150192
encephalopathy B-Disease 2 0.99994385
, O 0 0.02132126
headaches B-Disease 0 0.99974746
, O 0 0.011023739
seizures B-Disease 0 0.99993503
, O 0 0.003081509
or O 0 0.001555536
neurological B-Disease 0 0.9967822
deficits I-Disease 0 0.9952614
. O 0 0.0053249947

Here O 0 0.0039517377
, O 0 0.0036113241
we O 0 0.00090671174
describe O 0 0.0009491149
an O 0 0.0008052154
eight O 0 0.00047472867
- O 0 0.002229327
and O 0 0.00057486177
- O 0 0.0021229761
a O 0 0.0006004786
- O 0 0.0013430989
half O 0 0.00025136938
- O 0 0.0011959044
yr O 0 0.0003777398
- O 0 0.0008225622
old O 0 0.00031458127
male O 0 0.00065059046
renal O 0 0.08694576
transplant O 0 0.0006468804
recipient O 0 0.0004722974
with O 0 0.00076951215
right O 0 0.0034907947
BN O 0 0.91411304
. O 0 0.0040455977

MRI O 0 0.012974134
demonstrated O 0 0.001896512
hyperintense O 0 0.0043032356
T2 O 0 0.0023342585
signals O 0 0.00037393568
in O 0 0.0003749012
the O 0 0.00032536883
cervical O 0 0.001259825
cord O 0 0.00086242944
and O 0 0.0002843753
right O 0 0.0008974394
brachial O 0 0.9446188
plexus O 0 0.0358392
roots O 0 0.0006245432
indicative O 0 0.00020168781
of O 0 0.00028513544
both O 0 0.00045114872
myelitis B-Disease 0 0.99965835
and O 0 0.00069366064
right O 0 0.0028729131
brachial B-Disease 0 0.9984189
plexitis I-Disease 0 0.95514154
. O 0 0.003056865

Symptoms O 0 0.0061431937
persisted O 0 0.00105881
for O 0 0.0005139692
three O 0 0.00024853298
months O 0 0.00021847106
despite O 0 0.00032137617
TAC B-Chemical 0 0.048937567
dose O 0 0.0005693099
reduction O 0 0.0003384857
, O 0 0.00043696605
administration O 0 0.00040906726
of O 0 0.0003336288
IVIG O 0 0.63234484
and O 0 0.00019304983
four O 0 0.00012163313
doses O 0 0.00046984057
of O 0 0.0005932935
methylprednisolone B-Chemical 0 0.9995943
pulse O 0 0.001708052
therapy O 0 0.0016762087
. O 0 0.0021612202

Improvement O 0 0.007826101
and O 0 0.0022849804
eventually O 0 0.0019532254
full O 0 0.0006773423
recovery O 0 0.0008478787
only O 0 0.00048797877
occurred O 0 0.00037484936
after O 0 0.0002498454
TAC B-Chemical 0 0.15600157
was O 0 0.0003552538
completely O 0 0.00035647652
discontinued O 0 0.0012308375
and O 0 0.0004568423
successfully O 0 0.00059666054
replaced O 0 0.0007049006
by O 0 0.0015748888
everolimus B-Chemical 0 0.993418
. O 0 0.00428046

Omitting O 0 0.016904289
fentanyl B-Chemical 0 0.9995664
reduces O 0 0.002039416
nausea B-Disease 0 0.99885654
and O 0 0.0014306388
vomiting B-Disease 0 0.97302103
, O 0 0.0009114327
without O 0 0.00039432035
increasing O 0 0.00045180455
pain B-Disease 0 0.023784906
, O 0 0.0007261127
after O 0 0.00033796811
sevoflurane B-Chemical 0 0.99934846
for O 0 0.0005284691
day O 0 0.00059970666
surgery O 0 0.0015688923
. O 0 0.0023298396

BACKGROUND O 0 0.008265806
AND O 0 0.0018205055
OBJECTIVE O 0 0.0042396844
: O 0 0.0009811065
Despite O 0 0.00021621333
advantages O 0 0.00014979953
of O 0 0.0002805256
induction O 0 0.0002067518
and O 0 0.0002401242
maintenance O 0 0.00023542027
of O 0 0.00023520913
anaesthesia O 0 0.0018455232
with O 0 0.00032277085
sevoflurane B-Chemical 0 0.99990237
, O 0 0.00057377986
postoperative B-Disease 0 0.00061741425
nausea I-Disease 0 0.9904033
and I-Disease 0 0.0005999031
vomiting I-Disease 0 0.8979114
occurs O 0 0.00082179066
frequently O 0 0.0014500658
. O 0 0.0025332717

Fentanyl B-Chemical 0 0.9995921
is O 0 0.0022036652
a O 0 0.0017752977
commonly O 0 0.0009006655
used O 0 0.00054810423
supplement O 0 0.0017302098
that O 0 0.0003455041
may O 0 0.0002919159
contribute O 0 0.00027834286
to O 0 0.00026853304
this O 0 0.00037371065
, O 0 0.00067304034
although O 0 0.00038723717
it O 0 0.0005816915
may O 0 0.0003805685
also O 0 0.00052765897
improve O 0 0.00080401235
analgesia O 0 0.29398465
. O 0 0.003129442

METHODS O 0 0.0042279325
: O 0 0.003194201
This O 0 0.0014150727
double O 0 0.00091736286
- O 0 0.004108675
blind O 0 0.007960676
study O 0 0.00046853482
examined O 0 0.00020957674
the O 0 0.0001887825
incidence O 0 0.00035654224
and O 0 0.00017945026
severity O 0 0.00035749492
of O 0 0.00013922619
postoperative B-Disease 0 0.00037759542
nausea I-Disease 0 0.99538416
and I-Disease 0 0.00021649637
vomiting I-Disease 0 0.9304654
and O 0 0.0001731357
pain B-Disease 0 0.01129812
in O 0 9.107051e-05
the O 0 6.972554e-05
first O 0 5.7492438e-05
24 O 0 9.490504e-05
h O 0 0.000107422056
after O 0 9.145832e-05
sevoflurane B-Chemical 0 0.9997576
anaesthesia O 0 0.0022072268
in O 0 0.00017728593
216 O 0 0.0005741801
adult O 0 0.00031520452
day O 0 0.0002624712
surgery O 0 0.000758347
patients O 0 0.0016363248
. O 0 0.00222101

Patients O 0 0.0038139122
were O 0 0.0011932289
randomly O 0 0.0005363012
allocated O 0 0.0006320272
to O 0 0.0003531533
either O 0 0.00031626076
receive O 0 0.00025177182
or O 0 0.00019070275
not O 0 0.00017519061
receive O 0 0.00018058538
1 O 0 0.00021112911
1 O 0 0.00027133408
fentanyl B-Chemical 0 0.9996025
, O 0 0.000322625
while O 0 0.00013700839
a O 0 0.00020020807
third O 0 0.00015712643
group O 0 0.00028922677
received O 0 0.00034220776
dexamethasone B-Chemical 0 0.9990994
in O 0 0.00040296625
addition O 0 0.00033413965
to O 0 0.001085689
fentanyl B-Chemical 0 0.9997497
. O 0 0.003301019

RESULTS O 0 0.00509365
: O 0 0.0043591214
Omission O 0 0.004373356
of O 0 0.0019168612
fentanyl B-Chemical 0 0.99985874
did O 0 0.0007877553
not O 0 0.0002853495
reduce O 0 0.00014872187
the O 0 0.00014215398
overall O 0 0.00014833988
incidence O 0 0.00024955664
of O 0 0.00015109897
postoperative B-Disease 0 0.00044484445
nausea I-Disease 0 0.9975988
and I-Disease 0 0.00030533146
vomiting I-Disease 0 0.9890137
, O 0 0.00049503456
but O 0 0.00020265473
did O 0 0.0001403374
reduce O 0 6.985778e-05
the O 0 9.19781e-05
incidence O 0 0.00027499004
of O 0 0.00019485084
vomiting B-Disease 0 0.9622471
and O 0 0.00015671793
/ O 0 0.00097389764
or O 0 0.00010650207
moderate O 0 0.00048403797
to O 0 0.00012209354
severe O 0 0.0060719308
nausea B-Disease 0 0.99634224
prior O 0 4.7193535e-05
to O 0 6.284094e-05
discharge O 0 9.486477e-05
from O 0 6.432028e-05
20 O 0 8.854044e-05
% O 0 0.00016197552
and O 0 9.977206e-05
17 O 0 0.00013667617
% O 0 0.00019944027
with O 0 0.00019255256
fentanyl B-Chemical 0 0.9999356
and O 0 0.00043643775
fentanyl B-Chemical 0 0.99997973
- O 0 0.09071698
dexamethasone B-Chemical 0 0.99981564
, O 0 0.00059187814
respectively O 0 0.00044792323
, O 0 0.00034538124
to O 0 0.00016940203
5 O 0 0.0002139373
% O 0 0.00045949404
( O 0 0.00060478406
P O 0 0.008508156
= O 0 0.0013333515
0 O 0 0.0008454468
. O 0 0.00097269454
013 O 0 0.0072248653
) O 0 0.004250617
. O 0 0.0039339624

Antiemetic O 0 0.09396032
requirements O 0 0.0016166585
were O 0 0.0012830469
reduced O 0 0.0011465532
from O 0 0.0007422776
24 O 0 0.0007349947
% O 0 0.000974924
and O 0 0.00055568514
31 O 0 0.00073606224
% O 0 0.0007567703
to O 0 0.0003492524
7 O 0 0.00038175308
% O 0 0.00086493156
( O 0 0.0010885426
P O 0 0.008891243
= O 0 0.002093638
0 O 0 0.0013356023
. O 0 0.0015205613
0012 O 0 0.017876906
) O 0 0.00605691
. O 0 0.005434557

Dexamethasone B-Chemical 0 0.9996573
had O 0 0.0025051509
no O 0 0.0009770745
significant O 0 0.0006337759
effect O 0 0.00043308575
on O 0 0.0003017992
the O 0 0.00030525637
incidence O 0 0.00058896624
or O 0 0.00028278204
severity O 0 0.00069927087
of O 0 0.00040792083
postoperative B-Disease 0 0.001178094
nausea I-Disease 0 0.99424076
and I-Disease 0 0.0015540983
vomiting I-Disease 0 0.9581027
. O 0 0.0033107558

Combining O 0 0.0018207862
the O 0 0.0011833676
two O 0 0.0009373227
fentanyl B-Chemical 0 0.9995377
groups O 0 0.00071575405
revealed O 0 0.00023268083
further O 0 0.00015654798
significant O 0 0.00014137535
benefits O 0 0.00010573473
from O 0 0.000101986116
the O 0 8.834174e-05
avoidance O 0 0.00029581948
of O 0 0.00015737594
opioids O 0 0.08340373
, O 0 0.0001975134
reducing O 0 7.739207e-05
postoperative B-Disease 0 0.0003038974
nausea I-Disease 0 0.9957896
and I-Disease 0 0.00020142931
vomiting I-Disease 0 0.9589514
and O 0 0.00021258063
nausea B-Disease 0 0.99387425
prior O 0 5.5579858e-05
to O 0 7.517383e-05
discharge O 0 0.000113427595
from O 0 8.030994e-05
35 O 0 0.0001241691
% O 0 0.00022245327
and O 0 0.00014651565
33 O 0 0.00025218312
% O 0 0.00027935472
to O 0 0.00012895657
22 O 0 0.00022993886
% O 0 0.00028029596
and O 0 0.00016782594
19 O 0 0.00024007523
% O 0 0.0003524094
( O 0 0.00037698753
P O 0 0.010603699
= O 0 0.00062408356
0 O 0 0.00025175072
. O 0 0.0001895086
049 O 0 0.0023471753
and O 0 0.00022054644
P O 0 0.009889217
= O 0 0.0005926893
0 O 0 0.00023861609
. O 0 0.0001885242
035 O 0 0.002804264
) O 0 0.0004020722
, O 0 0.0002922314
respectively O 0 0.00035090928
, O 0 0.000363133
while O 0 0.00025752033
nausea B-Disease 0 0.9974389
in O 0 0.00015331514
the O 0 0.00010000114
first O 0 7.8225676e-05
24 O 0 0.00012752731
h O 0 0.00013930279
was O 0 0.00012492931
decreased O 0 0.00024634416
from O 0 0.00015657811
42 O 0 0.00024850218
% O 0 0.00034078147
to O 0 0.00018720546
27 O 0 0.00037151872
% O 0 0.00056062295
( O 0 0.0007068107
P O 0 0.010142152
= O 0 0.0014700608
0 O 0 0.00091278285
. O 0 0.0010501491
034 O 0 0.011655932
) O 0 0.004288037
. O 0 0.0039245756

Pain B-Disease 0 0.07445409
severity O 0 0.004662896
and O 0 0.0015374281
analgesic O 0 0.0046908963
requirements O 0 0.0006150789
were O 0 0.00067285245
unaffected O 0 0.0010254884
by O 0 0.0007417652
the O 0 0.0007858928
omission O 0 0.0020914136
of O 0 0.0027576261
fentanyl B-Chemical 0 0.9995969
. O 0 0.005486099

Fentanyl B-Chemical 0 0.9997024
did O 0 0.0025586232
reduce O 0 0.00075498887
minor O 0 0.0009092543
intraoperative O 0 0.0008069701
movement O 0 0.0008778212
but O 0 0.00040472797
had O 0 0.00027639393
no O 0 0.00036798802
sevoflurane B-Chemical 0 0.999956
- O 0 0.008353093
sparing O 0 0.00044856584
effect O 0 0.00014582266
and O 0 0.00024314174
increased O 0 0.00052390323
respiratory B-Disease 0 0.02702818
depression I-Disease 0 0.99963593
, O 0 0.0026746488
hypotension B-Disease 0 0.99985564
and O 0 0.0017645143
bradycardia B-Disease 0 0.99669087
. O 0 0.0029794914

CONCLUSION O 0 0.013700736
: O 0 0.003565103
As O 0 0.0009410591
fentanyl B-Chemical 0 0.99937195
exacerbated O 0 0.0015809234
postoperative B-Disease 0 0.00115819
nausea I-Disease 0 0.9972274
and I-Disease 0 0.00043712996
vomiting I-Disease 0 0.8480161
without O 0 0.00016657189
an O 0 0.00013529819
improvement O 0 0.000140837
in O 0 0.00010265634
postoperative B-Disease 0 0.00077378855
pain I-Disease 0 0.27673435
and O 0 0.0001068844
also O 0 8.069923e-05
had O 0 9.52839e-05
adverse O 0 0.00053707516
cardiorespiratory O 0 0.0009786369
effects O 0 0.00010289979
, O 0 0.00027814019
it O 0 0.000179414
appears O 0 7.151688e-05
to O 0 8.780407e-05
be O 0 0.000100108766
an O 0 0.00012031738
unnecessary O 0 0.00013309064
and O 0 0.00013975702
possibly O 0 0.00021420041
detrimental O 0 0.00031205537
supplement O 0 0.0018153785
to O 0 0.00048038235
sevoflurane B-Chemical 0 0.9999013
in O 0 0.00054319855
day O 0 0.000468575
surgery O 0 0.0012569694
. O 0 0.0018312949

Valvular B-Disease 0 0.81898904
heart I-Disease 0 0.52337265
disease I-Disease 0 0.82018447
in O 0 0.0012490972
patients O 0 0.0018205123
with O 0 0.0013541746
Parkinson B-Disease 0 0.99657756
' I-Disease 0 0.0016994656
s I-Disease 0 0.0014160379
disease I-Disease 0 0.17577727
treated O 0 0.002604379
with O 0 0.0034677412
pergolide B-Chemical 0 0.999943
. O 0 0.005168361

Course O 0 0.022110617
following O 0 0.006352418
treatment O 0 0.008222181
modifications O 0 0.010314908
. O 0 0.016309055

Valvular B-Disease 0 0.7551693
heart I-Disease 0 0.27840483
abnormalities I-Disease 0 0.22973137
have O 0 0.00084038184
been O 0 0.0005751243
reported O 0 0.00048926845
in O 0 0.00035992017
patients O 0 0.0007202358
with O 0 0.00061499747
Parkinson B-Disease 0 0.996506
' I-Disease 0 0.0009360063
s I-Disease 0 0.00082447776
disease I-Disease 0 0.30504256
( O 0 0.0020722426
PD B-Disease 0 0.99862874
) O 0 0.0019057428
treated O 0 0.0017433754
with O 0 0.002784912
pergolide B-Chemical 0 0.9999496
. O 0 0.0046228347

However O 0 0.0031313628
, O 0 0.0035689876
the O 0 0.0012246713
incidence O 0 0.0016037044
and O 0 0.00074175146
severity O 0 0.0011286105
of O 0 0.0003627979
these O 0 0.00029504515
abnormalities O 0 0.0052277604
vary O 0 0.00023490032
from O 0 0.0001205935
study O 0 0.00013079488
to O 0 9.0705464e-05
study O 0 0.00012317687
and O 0 0.000107422464
their O 0 9.807209e-05
course O 0 0.00013060217
after O 0 9.45046e-05
drug O 0 0.0024419343
withdrawal O 0 0.0013782214
has O 0 0.00017865161
not O 0 0.0002837172
been O 0 0.00044723484
systematically O 0 0.00065480336
assessed O 0 0.001380857
. O 0 0.0026722422

OBJECTIVES O 0 0.003378179
: O 0 0.0022435787
To O 0 0.00037962262
estimate O 0 0.00035649413
the O 0 0.00031212805
frequency O 0 0.00027459185
and O 0 0.00031278396
severity O 0 0.00063371466
of O 0 0.0003363145
valvular B-Disease 0 0.68792397
heart I-Disease 0 0.11511763
abnormality I-Disease 0 0.052992903
and O 0 0.00016182869
its O 0 0.00015035796
possible O 0 8.485739e-05
reversibility O 0 0.0003835738
after O 0 9.034825e-05
drug O 0 0.002231324
withdrawal O 0 0.0011078898
in O 0 0.00021985691
a O 0 0.00044436427
case O 0 0.0005264758
- O 0 0.0023316692
control O 0 0.00092748046
study O 0 0.0018420928
. O 0 0.0027629358

METHODS O 0 0.0044621974
: O 0 0.0032675068
All O 0 0.0013148935
PD B-Disease 0 0.9677922
patients O 0 0.0014347757
in O 0 0.0005133998
the O 0 0.00043770854
Amiens O 0 0.0028479034
area O 0 0.00046997832
treated O 0 0.00060029025
with O 0 0.0006494924
pergolide B-Chemical 0 0.99998367
were O 0 0.00022702475
invited O 0 0.00021843564
to O 0 0.00013754259
attend O 0 0.00024253558
a O 0 0.00028883823
cardiologic O 0 0.0006747726
assessment O 0 0.00022172146
including O 0 0.00024148362
transthoracic O 0 0.00066877657
echocardiography O 0 0.0018219929
. O 0 0.0020819928

Thirty O 0 0.026022043
PD B-Disease 0 0.9934635
patients O 0 0.00979078
participated O 0 0.008091748
in O 0 0.0034326168
the O 0 0.0035256506
study O 0 0.0058524627
. O 0 0.007959178

A O 0 0.013932934
second O 0 0.0017853698
echocardiography O 0 0.001991723
was O 0 0.00072182727
performed O 0 0.0004623902
( O 0 0.00058476947
median O 0 0.0002077856
interval O 0 0.0002953539
: O 0 0.00041797146
13 O 0 0.00022128024
months O 0 0.00011995767
) O 0 0.00043258446
after O 0 0.00023903644
pergolide B-Chemical 0 0.99991214
withdrawal O 0 0.0021513146
( O 0 0.0006159475
n O 0 0.00050692697
= O 0 0.0011945638
10 O 0 0.0007120889
patients O 0 0.0016384277
) O 0 0.0032153085
. O 0 0.003303846

Controls O 0 0.007481675
were O 0 0.002090782
age O 0 0.0024317708
- O 0 0.0039392947
and O 0 0.0009797936
sex O 0 0.0017004182
- O 0 0.0027125282
matched O 0 0.00048678642
non O 0 0.0011855281
- O 0 0.025767572
PD B-Disease 0 0.9986394
patients O 0 0.0013842097
referred O 0 0.0006476331
to O 0 0.00046954904
the O 0 0.0006871022
cardiology O 0 0.0033912656
department O 0 0.003357513
. O 0 0.003321329

RESULTS O 0 0.0041364916
: O 0 0.0027050776
Compared O 0 0.00080214744
to O 0 0.0006975111
controls O 0 0.001075449
, O 0 0.0015473402
aortic B-Disease 0 0.74569553
regurgitation I-Disease 0 0.99139273
( O 0 0.0013597226
OR O 0 0.003104786
: O 0 0.0007387473
3 O 0 0.00025753357
. O 0 0.00024591145
1 O 0 0.00027462823
; O 0 0.00044553302
95 O 0 0.0004937626
% O 0 0.00056579453
IC O 0 0.0043109166
: O 0 0.00055962056
1 O 0 0.00026484445
. O 0 0.00020559375
1 O 0 0.00024230838
- O 0 0.00066994876
8 O 0 0.0001571113
. O 0 0.00014294016
8 O 0 0.00014406933
) O 0 0.00032923336
and O 0 0.00024244866
mitral B-Disease 0 0.55080146
regurgitation I-Disease 0 0.97505957
( O 0 0.0006609165
OR O 0 0.0019583139
: O 0 0.00049275835
10 O 0 0.00019336099
. O 0 0.0001549172
7 O 0 0.0001390541
; O 0 0.00032201596
95 O 0 0.00038606836
% O 0 0.00045620673
IC O 0 0.0036222672
: O 0 0.00046123704
2 O 0 0.00022424142
. O 0 0.00018707592
1 O 0 0.00023890792
- O 0 0.00080252363
53 O 0 0.00033444658
) O 0 0.0004041096
were O 0 0.00017515602
more O 0 0.00029161462
frequent O 0 0.00035816882
in O 0 0.00042031813
PD B-Disease 0 0.99675024
patients O 0 0.0012242672
( O 0 0.001169508
tricuspid O 0 0.24710906
: O 0 0.003658772
NS O 0 0.9097003
) O 0 0.0052493517
. O 0 0.0037250712

The O 0 0.0022272428
number O 0 0.0014859226
of O 0 0.0014845923
affected O 0 0.0012588324
valves O 0 0.0034313432
( O 0 0.0011511534
n O 0 0.0006477679
= O 0 0.0009871502
2 O 0 0.0003542867
. O 0 0.00025438934
4 O 0 0.00023324703
+ O 0 0.0008885514
/ O 0 0.0015958059
- O 0 0.0015894445
0 O 0 0.00032269882
. O 0 0.00018520365
7 O 0 0.00014166912
) O 0 0.00030294596
and O 0 0.00014127835
the O 0 0.00010581955
sum O 0 0.00012458314
of O 0 0.00017426346
regurgitation O 0 0.09916008
grades O 0 0.0008280768
( O 0 0.00029201305
n O 0 0.00020222583
= O 0 0.00040845136
2 O 0 0.000158503
. O 0 0.00012848193
8 O 0 0.00014839068
+ O 0 0.0006359615
/ O 0 0.0014244805
- O 0 0.0016713412
1 O 0 0.00025193175
. O 0 0.00020775509
09 O 0 0.0012461494
) O 0 0.0004084146
were O 0 0.0001368414
higher O 0 0.00017215069
( O 0 0.00028575293
p O 0 0.00031814174
= O 0 0.00046967666
0 O 0 0.00023509905
. O 0 0.00017563299
008 O 0 0.00059578114
and O 0 0.00017924164
p O 0 0.00035413724
= O 0 0.0005609826
0 O 0 0.00031894472
. O 0 0.0002855607
006 O 0 0.0023219592
, O 0 0.000595482
respectively O 0 0.0007214497
) O 0 0.0010346659
in O 0 0.0005950785
the O 0 0.0010966194
pergolide B-Chemical 0 0.99991775
group O 0 0.0036678242
. O 0 0.0036163796

Severity O 0 0.004219674
of O 0 0.0025653446
regurgitation O 0 0.20212184
was O 0 0.001365351
not O 0 0.0009643004
correlated O 0 0.0010674257
with O 0 0.001957153
pergolide B-Chemical 0 0.99989986
cumulative O 0 0.0023044115
dose O 0 0.00385721
. O 0 0.0038331642

A O 0 0.024084175
restrictive O 0 0.0035722586
pattern O 0 0.0012085255
of O 0 0.0013605224
valvular B-Disease 0 0.9270439
regurgitation I-Disease 0 0.9963966
, O 0 0.001138159
suggestive O 0 0.00038843323
of O 0 0.00021704883
the O 0 0.0001418416
role O 0 0.00010639801
of O 0 0.0005327625
pergolide B-Chemical 0 0.9999919
, O 0 0.0006359869
was O 0 0.00016190975
observed O 0 0.00012851306
in O 0 0.00013947705
12 O 0 0.00011876804
/ O 0 0.00047313847
30 O 0 0.00013795738
( O 0 0.00023547323
40 O 0 0.00017724941
% O 0 0.00033034696
) O 0 0.00043058518
patients O 0 0.00034457142
including O 0 0.00016951043
two O 0 0.00022841997
with O 0 0.0006998258
heart B-Disease 0 0.063175805
failure I-Disease 0 0.06228449
. O 0 0.0031947829

Pergolide B-Chemical 0 0.99973625
was O 0 0.0024147388
discontinued O 0 0.0034934792
in O 0 0.0006046466
10 O 0 0.00045022502
patients O 0 0.0005491873
with O 0 0.00040184768
valvular B-Disease 0 0.6788881
heart I-Disease 0 0.38193628
disease I-Disease 0 0.8966384
, O 0 0.0004238714
resulting O 0 0.00013065849
in O 0 0.00011797521
a O 0 0.0001765282
lower O 0 0.0001794034
regurgitation O 0 0.18425108
grade O 0 0.002121601
( O 0 0.00023494064
p O 0 0.00023147797
= O 0 0.00035019845
0 O 0 0.00016825375
. O 0 0.00012528947
01 O 0 0.0006191765
) O 0 0.00021177385
at O 0 5.8619822e-05
the O 0 5.427389e-05
second O 0 5.2166128e-05
transthoracic O 0 7.626979e-05
echocardiography O 0 0.00013516277
and O 0 7.504676e-05
the O 0 6.1808e-05
two O 0 6.148339e-05
patients O 0 0.00021194821
with O 0 0.00016993217
heart B-Disease 0 0.019010557
failure I-Disease 0 0.0068169786
returned O 0 0.00021574381
to O 0 0.0001754365
nearly O 0 0.00032827584
normal O 0 0.000737398
clinical O 0 0.001553298
examination O 0 0.000966344
. O 0 0.0020035175

This O 0 0.0040593278
study O 0 0.0017586338
supports O 0 0.0007550875
the O 0 0.00050378055
high O 0 0.00048224878
frequency O 0 0.00028348767
of O 0 0.0002989754
restrictive O 0 0.00055510836
valve B-Disease 0 0.012823182
regurgitation I-Disease 0 0.9822222
in O 0 0.0003471182
PD B-Disease 0 0.9991148
patients O 0 0.00048380363
treated O 0 0.0003847677
with O 0 0.00045361574
pergolide B-Chemical 0 0.9999956
and O 0 0.00016673366
reveals O 0 7.708382e-05
that O 0 6.660356e-05
a O 0 0.00013131673
significant O 0 8.684993e-05
improvement O 0 0.00011904821
is O 0 6.524234e-05
usual O 0 0.000116724965
when O 0 6.067819e-05
the O 0 8.595089e-05
treatment O 0 0.00012436794
is O 0 0.00011673453
converted O 0 0.00019404046
to O 0 0.00020071842
non O 0 0.0010742627
- O 0 0.34770533
ergot O 0 0.9999541
dopamine B-Chemical 0 0.9999038
agonists O 0 0.38252184
. O 0 0.0036873063

Adriamycin B-Chemical 0 0.9998355
- O 0 0.11073836
induced O 0 0.002378816
autophagic O 0 0.016451186
cardiomyocyte O 0 0.30022752
death B-Disease 0 0.7707619
plays O 0 0.00028444442
a O 0 0.00046995567
pathogenic O 0 0.00026349572
role O 0 0.00014460638
in O 0 0.00029868743
a O 0 0.00051221246
rat O 0 0.00054897135
model O 0 0.00042978776
of O 0 0.00091869273
heart B-Disease 0 0.063585296
failure I-Disease 0 0.059290692
. O 0 0.0035267803

BACKGROUND O 0 0.013333675
: O 0 0.0033116199
The O 0 0.0006442125
mechanisms O 0 0.0005905829
underlying O 0 0.0010288483
heart B-Disease 0 0.024427364
failure I-Disease 0 0.010431561
induced O 0 0.00051751663
by O 0 0.00073665066
adriamycin B-Chemical 0 0.99993443
are O 0 0.00044020114
very O 0 0.0005988477
complicated O 0 0.0011243466
and O 0 0.00069973315
still O 0 0.00085562
unclear O 0 0.0013263822
. O 0 0.0033632144

The O 0 0.0016495881
aim O 0 0.0010627173
of O 0 0.0011585663
this O 0 0.0008567705
study O 0 0.000656285
was O 0 0.00032272618
to O 0 0.00018302385
investigate O 0 8.237343e-05
whether O 0 9.10839e-05
autophagy O 0 0.0015894662
was O 0 0.00018310416
involved O 0 0.0001229063
in O 0 0.000121715624
the O 0 0.00010831281
progression O 0 0.00053182966
of O 0 0.00017462639
heart B-Disease 0 0.025181906
failure I-Disease 0 0.0066198995
induced O 0 0.0001547861
by O 0 0.00028640646
adriamycin B-Chemical 0 0.9999876
, O 0 0.0005919032
so O 0 0.00012970787
that O 0 8.793068e-05
we O 0 7.1918264e-05
can O 0 9.974676e-05
develop O 0 0.00016726043
a O 0 0.00023577856
novel O 0 0.00016738648
treatment O 0 0.00021801204
strategy O 0 0.000275043
for O 0 0.00047063304
heart B-Disease 0 0.058825612
failure I-Disease 0 0.06163882
. O 0 0.0029790434

METHODS O 0 0.005236042
: O 0 0.0040727365
3 B-Chemical 0 0.001883419
- I-Chemical 0 0.007318131
methyladenine I-Chemical 0 0.020984167
( O 0 0.00442656
3MA B-Chemical 0 0.99916637
) O 0 0.0034493315
, O 0 0.0010388572
a O 0 0.0005337702
specific O 0 0.00020125057
inhibitor O 0 0.0007029045
on O 0 0.00020343084
autophagy O 0 0.0017554371
was O 0 0.00019946953
used O 0 0.00015344779
in O 0 0.00017577506
a O 0 0.00033823244
heart B-Disease 0 0.008692139
failure I-Disease 0 0.002210789
model O 0 0.0001981672
of O 0 0.00030678487
rats O 0 0.0006501209
induced O 0 0.0006890344
by O 0 0.0016775379
adriamycin B-Chemical 0 0.99983
. O 0 0.0046270466

Neonatal O 0 0.009789679
cardiomyocytes O 0 0.0050820303
were O 0 0.0012759361
isolated O 0 0.00087067805
from O 0 0.00070988754
Sprague O 0 0.11817822
- O 0 0.0037285856
Dawley O 0 0.0065649394
rat O 0 0.00039849733
hearts O 0 0.00033262678
and O 0 0.0001434392
randomly O 0 7.176281e-05
divided O 0 0.00011748988
into O 0 7.9436846e-05
controls O 0 0.00022484126
, O 0 0.00034302534
an O 0 0.00037039665
adriamycin B-Chemical 0 0.99996674
- O 0 0.006346419
treated O 0 0.00044408604
group O 0 0.00035615888
, O 0 0.00044132376
and O 0 0.0003129925
a O 0 0.00086255017
3MA B-Chemical 0 0.9995134
plus O 0 0.0021860185
adriamycin B-Chemical 0 0.99997544
- O 0 0.044801738
treated O 0 0.0020123378
group O 0 0.0022898328
. O 0 0.002908879

We O 0 0.0025769374
then O 0 0.0015700847
examined O 0 0.00094300986
the O 0 0.0007964001
morphology O 0 0.0013718387
, O 0 0.001132534
expression O 0 0.00046502217
of O 0 0.000661997
beclin O 0 0.089027986
1 O 0 0.00054652855
gene O 0 0.00031566163
, O 0 0.00087939337
mitochondrial O 0 0.041654978
permeability O 0 0.88259226
transition O 0 0.0012015615
( O 0 0.0017411229
MPT O 0 0.9997999
) O 0 0.0011001203
, O 0 0.0004969811
and O 0 0.00043510078
Na O 0 0.99516356
+ O 0 0.008825467
- O 0 0.049214236
K B-Chemical 0 0.9995161
+ O 0 0.018316986
ATPase O 0 0.0022922363
activity O 0 0.0005574745
in O 0 0.0009308906
vivo O 0 0.0017410069
. O 0 0.003226584

We O 0 0.0027163865
also O 0 0.0018084549
assessed O 0 0.0015044035
cell O 0 0.002157036
viability O 0 0.0073276777
, O 0 0.003245749
mitochondrial O 0 0.060207166
membrane O 0 0.0024531714
potential O 0 0.0002837075
changes O 0 0.00032851502
and O 0 0.00032793864
counted O 0 0.0003642687
autophagic O 0 0.0020449688
vacuoles O 0 0.0013569662
in O 0 0.0007265318
cultured O 0 0.001888368
cardiomyocytes O 0 0.0060428237
. O 0 0.0035428316

In O 0 0.001973789
addition O 0 0.0012152622
, O 0 0.0019192374
we O 0 0.00051665946
analyzed O 0 0.00058856694
the O 0 0.0003834855
expression O 0 0.00035366928
of O 0 0.000493012
autophagy O 0 0.003030921
associated O 0 0.00040399423
gene O 0 0.00027939893
, O 0 0.0006802369
beclin O 0 0.023033261
1 O 0 0.00033119746
using O 0 0.00020185344
RT O 0 0.0009851283
- O 0 0.0011892397
PCR O 0 0.00044921116
and O 0 0.00030047708
Western O 0 0.00050440687
blotting O 0 0.00046608926
in O 0 0.00041053476
an O 0 0.00062792463
animal O 0 0.0009004878
model O 0 0.0014447564
. O 0 0.0030571234

RESULTS O 0 0.007409225
: O 0 0.008833158
3MA B-Chemical 0 0.99388874
significantly O 0 0.0018861494
improved O 0 0.0017176275
cardiac O 0 0.0026500933
function O 0 0.0008315234
and O 0 0.0013162175
reduced O 0 0.0026067358
mitochondrial O 0 0.88107485
injury O 0 0.9668273
. O 0 0.005974029

Furthermore O 0 0.004184381
, O 0 0.01045298
adriamycin B-Chemical 0 0.9998307
induced O 0 0.0014617833
the O 0 0.00074762746
formation O 0 0.0009892917
of O 0 0.00064500526
autophagic O 0 0.0035743196
vacuoles O 0 0.0014004557
, O 0 0.0008508632
and O 0 0.00062099757
3MA B-Chemical 0 0.9997327
strongly O 0 0.00032913918
downregulated O 0 0.00018983358
the O 0 0.0001283143
expression O 0 0.0001358094
of O 0 0.0002442589
beclin O 0 0.10105504
1 O 0 0.00028509743
in O 0 0.00027058416
adriamycin B-Chemical 0 0.99998283
- O 0 0.008079112
induced O 0 0.0001767566
failing O 0 0.0009906145
heart O 0 0.04294567
and O 0 0.00027577954
inhibited O 0 0.0005028932
the O 0 0.00034684528
formation O 0 0.0009084369
of O 0 0.0009932172
autophagic O 0 0.010008448
vacuoles O 0 0.0053535323
. O 0 0.003196279

CONCLUSION O 0 0.035430912
: O 0 0.010055966
Autophagic O 0 0.1670869
cardiomyocyte O 0 0.08296478
death B-Disease 0 0.44383496
plays O 0 0.00031827128
an O 0 0.00033726456
important O 0 0.0001526175
role O 0 0.000113350834
in O 0 0.00020274286
the O 0 0.00019815698
pathogenesis O 0 0.00042843726
of O 0 0.00035584767
heart B-Disease 0 0.033165727
failure I-Disease 0 0.0072054444
in O 0 0.00034061342
rats O 0 0.00065995636
induced O 0 0.00069322315
by O 0 0.0016715403
adriamycin B-Chemical 0 0.9998036
. O 0 0.0047066854

Mitochondrial O 0 0.8906247
injury O 0 0.14618593
may O 0 0.0013027336
be O 0 0.000763949
involved O 0 0.0004855574
in O 0 0.0004274401
the O 0 0.00034966436
progression O 0 0.0011530382
of O 0 0.0004626554
heart B-Disease 0 0.0349516
failure I-Disease 0 0.0118978
caused O 0 0.0004070047
by O 0 0.0006337234
adriamycin B-Chemical 0 0.99990606
via O 0 0.0005447707
the O 0 0.0006382181
autophagy O 0 0.0044846786
pathway O 0 0.00157645
. O 0 0.0032047965

mToR O 0 0.036844157
inhibitors O 0 0.007800097
- O 0 0.017520357
induced O 0 0.0029102983
proteinuria B-Disease 0 0.99976546
: O 0 0.0029633627
mechanisms O 0 0.0007868854
, O 0 0.0015806585
significance O 0 0.0012151847
, O 0 0.0022328512
and O 0 0.00191453
management O 0 0.0032540036
. O 0 0.00470757

Massive O 0 0.02764056
urinary O 0 0.40647766
protein O 0 0.016461527
excretion O 0 0.996664
has O 0 0.0005500884
been O 0 0.00036189522
observed O 0 0.00022834922
after O 0 0.00013739878
conversion O 0 0.0002998873
from O 0 0.00016180755
calcineurin O 0 0.0008417362
inhibitors O 0 0.00025938224
to O 0 0.00010755059
mammalian O 0 8.908025e-05
target O 0 8.49569e-05
of O 0 0.000206671
rapamycin B-Chemical 0 0.41512296
( O 0 0.00082930474
mToR O 0 0.006129073
) O 0 0.0005257539
inhibitors O 0 0.0002973157
, O 0 0.00038811122
especially O 0 0.00034041502
sirolimus B-Chemical 0 0.99989974
, O 0 0.00039826546
in O 0 0.00016105734
renal O 0 0.14030252
transplant O 0 0.0002820911
recipients O 0 0.00013695812
with O 0 0.0003113505
chronic B-Disease 0 0.07996575
allograft I-Disease 0 0.17841832
nephropathy I-Disease 0 0.99998116
. O 0 0.005126841

Because O 0 0.0032405946
proteinuria B-Disease 0 0.9993986
is O 0 0.0014641085
a O 0 0.0012237617
major O 0 0.00061920716
predictive O 0 0.0009883157
factor O 0 0.0016621697
of O 0 0.0003001736
poor O 0 0.00051997753
transplantation O 0 0.00024404682
outcome O 0 0.00018078124
, O 0 0.00019739327
many O 0 9.48153e-05
studies O 0 0.00015227328
focused O 0 0.00013501555
on O 0 0.00012101016
this O 0 0.0002265944
adverse O 0 0.00096365885
event O 0 0.00039738146
during O 0 0.00023039115
the O 0 0.00036536963
past O 0 0.0008268755
years O 0 0.0016416695
. O 0 0.0024280583

Whether O 0 0.0038133527
proteinuria B-Disease 0 0.99955267
was O 0 0.0016149392
due O 0 0.0006398075
to O 0 0.00064548315
sirolimus B-Chemical 0 0.9996221
or O 0 0.00032361443
only O 0 0.00024810445
a O 0 0.00025490214
consequence O 0 0.0001099145
of O 0 0.00019663417
calcineurin O 0 0.0016663522
inhibitors O 0 0.00039804704
withdrawal O 0 0.0032205428
remained O 0 0.00019402176
unsolved O 0 0.00018699639
until O 0 5.4294134e-05
high O 0 0.0001248225
range O 0 0.00019280608
proteinuria B-Disease 0 0.9999418
has O 0 7.645673e-05
been O 0 7.415398e-05
observed O 0 6.896381e-05
during O 0 8.996344e-05
sirolimus B-Chemical 0 0.99975437
therapy O 0 0.00017950093
in O 0 8.474652e-05
islet O 0 0.0008054636
transplantation O 0 0.0001944644
and O 0 0.00011351892
in O 0 0.00012680872
patients O 0 0.0003517212
who O 0 0.00034909564
received O 0 0.000498698
sirolimus B-Chemical 0 0.99955505
de O 0 0.005603199
novo O 0 0.0039111194
. O 0 0.0029958081

Podocyte O 0 0.8935503
injury O 0 0.07374075
and O 0 0.0023294662
focal O 0 0.031662013
segmental O 0 0.26754636
glomerulosclerosis B-Disease 0 0.99999297
have O 0 0.00048608714
been O 0 0.00024586054
related O 0 0.00013795265
to O 0 0.00019226142
mToR O 0 0.0019103978
inhibition O 0 0.00028160604
in O 0 0.000178107
some O 0 0.00020993732
patients O 0 0.0005327282
, O 0 0.00040004382
but O 0 0.00023951642
the O 0 0.00017637006
pathways O 0 0.00023308516
underlying O 0 0.00043089502
these O 0 0.00046924682
lesions O 0 0.003784091
remain O 0 0.0007982422
hypothetic O 0 0.002668893
. O 0 0.002725624

We O 0 0.0025096852
discuss O 0 0.0016110222
herein O 0 0.0014692554
the O 0 0.0006976045
possible O 0 0.00041502406
mechanisms O 0 0.0003784562
and O 0 0.00047872827
the O 0 0.00033953736
significance O 0 0.0004780687
of O 0 0.0007070922
mToR O 0 0.008523875
blockade O 0 0.0056918273
- O 0 0.009940303
induced O 0 0.0025421386
proteinuria B-Disease 0 0.9998442
. O 0 0.0065141525

Neuropsychiatric O 0 0.6646676
side O 0 0.006236086
effects O 0 0.0021512348
after O 0 0.0012559557
the O 0 0.001501461
use O 0 0.0019780356
of O 0 0.0044402545
mefloquine B-Chemical 0 0.99883956
. O 0 0.008576699

This O 0 0.005058028
study O 0 0.0028566604
describes O 0 0.0027921745
neuropsychiatric O 0 0.9892169
side O 0 0.002054725
effects O 0 0.0006274293
in O 0 0.0005669144
patients O 0 0.00085328997
after O 0 0.00031875077
treatment O 0 0.0007082138
with O 0 0.0017814542
mefloquine B-Chemical 0 0.9992855
. O 0 0.004710174

Reactions O 0 0.0050702277
consisted O 0 0.002086556
mainly O 0 0.0016274436
of O 0 0.0021931096
seizures B-Disease 0 0.9999193
, O 0 0.0052750446
acute O 0 0.8954791
psychoses B-Disease 0 0.99999
, O 0 0.042499036
anxiety B-Disease 0 0.9999765
neurosis I-Disease 0 0.9999912
, O 0 0.0014137365
and O 0 0.0004119926
major O 0 0.00045763445
disturbances B-Disease 0 0.18223815
of I-Disease 0 0.00085305504
sleep I-Disease 0 0.24339603
- I-Disease 0 0.0045770435
wake I-Disease 0 0.0021633974
rhythm I-Disease 0 0.0029715241
. O 0 0.0028898723

Side O 0 0.019313233
effects O 0 0.0018626251
occurred O 0 0.0010399044
after O 0 0.00038412522
both O 0 0.00038514
therapeutic O 0 0.00052814424
and O 0 0.00038897785
prophylactic O 0 0.0005968297
intake O 0 0.0022180218
and O 0 0.0003913342
were O 0 0.0003275615
graded O 0 0.0006631115
from O 0 0.00045654952
moderate O 0 0.0015872598
to O 0 0.001092294
severe O 0 0.0071479543
. O 0 0.0033504409

In O 0 0.002238312
a O 0 0.002906877
risk O 0 0.0047253044
analysis O 0 0.00094041514
of O 0 0.0010239107
neuropsychiatric O 0 0.9943844
side O 0 0.001156434
effects O 0 0.00031165316
in O 0 0.00030974703
Germany O 0 0.0012979759
, O 0 0.00045295164
it O 0 0.0002627762
is O 0 0.00013137322
estimated O 0 0.00015935239
that O 0 0.000101912134
one O 0 0.00012626793
of O 0 0.00018303555
8 O 0 0.00019221264
, O 0 0.0003960895
000 O 0 0.0005505242
mefloquine B-Chemical 0 0.99954295
users O 0 0.0008932157
suffers O 0 0.0009454911
from O 0 0.00049392175
such O 0 0.00077786285
reactions O 0 0.0018744014
. O 0 0.0028662945

The O 0 0.0020130954
incidence O 0 0.002361462
calculation O 0 0.0008005744
revealed O 0 0.00051160477
that O 0 0.00036725344
one O 0 0.00033702073
of O 0 0.00038109242
215 O 0 0.00089934055
therapeutic O 0 0.00034890513
users O 0 0.00034476773
had O 0 0.00018043304
reactions O 0 0.00021558958
, O 0 0.00024319506
compared O 0 9.298247e-05
with O 0 0.00013069873
one O 0 0.000106649924
of O 0 0.0001420032
13 O 0 0.00016124433
, O 0 0.00020420198
000 O 0 0.00013312722
in O 0 7.486793e-05
the O 0 6.799864e-05
prophylaxis O 0 0.00011551625
group O 0 0.00014878796
, O 0 0.00019941154
making O 0 0.00012563942
the O 0 0.00011020742
risk O 0 0.0013573742
of O 0 0.00028972464
neuropsychiatric O 0 0.9980373
reactions O 0 0.00017076901
after O 0 7.719018e-05
mefloquine B-Chemical 0 0.9993782
treatment O 0 0.000120510515
60 O 0 0.000114143266
times O 0 7.865217e-05
higher O 0 0.00019833013
than O 0 0.00024114612
after O 0 0.00029084468
prophylaxis O 0 0.0010491227
. O 0 0.0019534233

Therefore O 0 0.0021001175
, O 0 0.0030117533
certain O 0 0.001141452
limitations O 0 0.0008338022
for O 0 0.0007966392
malaria B-Disease 0 0.1000365
prophylaxis O 0 0.00068843906
and O 0 0.00046883256
treatment O 0 0.0005372564
with O 0 0.0010430177
mefloquine B-Chemical 0 0.99950254
are O 0 0.0010938023
recommended O 0 0.001569221
. O 0 0.002910665

Prenatal O 0 0.024718499
protein O 0 0.0035094214
deprivation O 0 0.01018402
alters O 0 0.0015957276
dopamine B-Chemical 0 0.99967384
- O 0 0.006846711
mediated O 0 0.0003321236
behaviors O 0 0.0011409824
and O 0 0.00079838594
dopaminergic O 0 0.0058253477
and O 0 0.0009641396
glutamatergic O 0 0.03731779
receptor O 0 0.0033048103
binding O 0 0.0017091826
. O 0 0.004093157

Epidemiological O 0 0.007467865
evidence O 0 0.0016200413
indicates O 0 0.0010197782
that O 0 0.0008991054
prenatal O 0 0.0030068161
nutritional O 0 0.0046761823
deprivation O 0 0.00373074
may O 0 0.00053384417
increase O 0 0.00055389357
the O 0 0.0006657416
risk O 0 0.005531691
of O 0 0.0034612387
schizophrenia B-Disease 2 0.9999218
. O 0 0.006245415

The O 0 0.001854868
goal O 0 0.0016263361
of O 0 0.0011529514
these O 0 0.0007369435
studies O 0 0.00071012334
was O 0 0.00037857456
to O 0 0.00023787466
use O 0 0.00020064306
an O 0 0.00020132448
animal O 0 0.00016181341
model O 0 0.0001130236
to O 0 8.484161e-05
examine O 0 4.3907297e-05
the O 0 7.5659846e-05
effects O 0 0.00010235196
of O 0 0.00015863862
prenatal O 0 0.0006666566
protein O 0 0.00018735797
deprivation O 0 0.00085494533
on O 0 9.2445276e-05
behaviors O 0 0.00037427575
and O 0 0.0002264605
receptor O 0 0.0005873686
binding O 0 0.00018310659
with O 0 0.00036022393
relevance O 0 0.00042034773
to O 0 0.0012424149
schizophrenia B-Disease 2 0.99992883
. O 0 0.0041409293

We O 0 0.003106481
report O 0 0.0034718963
that O 0 0.001575311
prenatally O 0 0.35022745
protein O 0 0.0010996206
deprived O 0 0.001897713
( O 0 0.0024067115
PD O 0 0.9987412
) O 0 0.0010138222
female O 0 0.0005367374
rats O 0 0.00032855765
showed O 0 0.00015607713
an O 0 0.00019092725
increased O 0 0.00030892363
stereotypic O 0 0.2899671
response O 0 0.0001890365
to O 0 0.00024679833
apomorphine B-Chemical 0 0.99997234
and O 0 0.00022215757
an O 0 0.00019893696
increased O 0 0.00030261892
locomotor O 0 0.002363876
response O 0 0.00027535183
to O 0 0.00050231826
amphetamine B-Chemical 1 0.99996233
in O 0 0.001221278
adulthood O 0 0.06280318
. O 0 0.002798202

These O 0 0.0039352407
differences O 0 0.00313442
were O 0 0.0029697854
not O 0 0.0025988037
observed O 0 0.0027224685
during O 0 0.003657773
puberty O 0 0.09457896
. O 0 0.009373598

No O 0 0.0051896735
changes O 0 0.0030570128
in O 0 0.0037248004
haloperidol B-Chemical 1 0.9999924
- O 0 0.18653144
induced O 0 0.0021304605
catalepsy B-Disease 0 0.99998224
or O 0 0.0017863968
MK B-Chemical 0 0.9976665
- I-Chemical 0 0.13291956
801 I-Chemical 0 0.4235049
- O 0 0.0032711148
induced O 0 0.0004962828
locomotion O 0 0.0037085067
were O 0 0.0006116179
seen O 0 0.000831323
following O 0 0.0010702544
PD O 0 0.9918426
. O 0 0.0039109117

In O 0 0.0023208172
addition O 0 0.0016970064
, O 0 0.0054397243
PD O 0 0.99767977
female O 0 0.0024218585
rats O 0 0.0010418836
showed O 0 0.00045290974
increased O 0 0.0005904715
( O 0 0.00071081595
3 O 0 0.00037499538
) O 0 0.0017312072
H B-Chemical 0 0.9997625
- O 0 0.5169089
MK B-Chemical 0 0.9983425
- I-Chemical 0 0.093994685
801 I-Chemical 0 0.09143033
binding O 0 0.00017138268
in O 0 0.00020566669
the O 0 0.00021827745
striatum O 0 0.0020378288
and O 0 0.00032240825
hippocampus O 0 0.0037683195
, O 0 0.0006874448
but O 0 0.0004481654
not O 0 0.00041088182
in O 0 0.0006193857
the O 0 0.0009717224
cortex O 0 0.027187943
. O 0 0.0032497547

PD O 0 0.9968304
female O 0 0.0060002585
rats O 0 0.0022559008
also O 0 0.0008220303
showed O 0 0.0006218872
increased O 0 0.000773602
( O 0 0.000878797
3 O 0 0.00043487002
) O 0 0.0019421921
H B-Chemical 0 0.9997968
- O 0 0.77617
haloperidol B-Chemical 1 0.99999774
binding O 0 0.00036475935
and O 0 0.00058712316
decreased O 0 0.004600237
dopamine B-Chemical 0 0.999895
transporter O 0 0.043994315
binding O 0 0.0005764798
in O 0 0.0011635543
striatum O 0 0.0093065165
. O 0 0.00285836

No O 0 0.004183625
statistically O 0 0.0023079345
significant O 0 0.0010699359
changes O 0 0.0008019888
in O 0 0.0005184636
behavior O 0 0.00069937814
or O 0 0.00039096357
receptor O 0 0.00088438386
binding O 0 0.00020184112
were O 0 0.0002149953
found O 0 0.00022487687
in O 0 0.00032726902
PD O 0 0.9989214
males O 0 0.00047810216
with O 0 0.00017207515
the O 0 0.00012111117
exception O 0 0.00013516728
of O 0 0.00020013307
increased O 0 0.0003461112
( O 0 0.00050433015
3 O 0 0.00029510734
) O 0 0.0016325891
H B-Chemical 0 0.9997906
- O 0 0.58087933
MK B-Chemical 0 0.9981408
- I-Chemical 0 0.10105043
801 I-Chemical 0 0.1402862
binding O 0 0.00063279114
in O 0 0.0012841295
cortex O 0 0.030904545
. O 0 0.0036362924

This O 0 0.0046429806
animal O 0 0.0020890087
model O 0 0.0011686384
may O 0 0.00069560955
be O 0 0.00045752805
useful O 0 0.0003028423
to O 0 0.00020865814
explore O 0 0.00013128895
the O 0 0.00013779751
mechanisms O 0 0.00012431851
by O 0 0.00017318444
which O 0 0.00023054321
prenatal O 0 0.0012902077
nutritional B-Disease 0 0.21601374
deficiency I-Disease 0 0.894017
enhances O 0 0.00018702778
risk O 0 0.013778306
for O 0 0.00030515043
schizophrenia B-Disease 2 0.99999547
in O 0 0.00019612709
humans O 0 0.00023229735
and O 0 0.0001070478
may O 0 6.576641e-05
also O 0 6.803003e-05
have O 0 6.237918e-05
implications O 0 8.2622806e-05
for O 0 8.0823535e-05
developmental O 0 0.00033521364
processes O 0 0.00022840039
leading O 0 0.00015778086
to O 0 0.000118730546
differential O 0 0.00020598482
sensitivity O 0 0.00039177222
to O 0 0.00034773245
drugs O 0 0.012624954
of O 0 0.0014692112
abuse O 0 0.97577125
. O 0 0.003821286

Adverse O 0 0.004159932
effects O 0 0.0019917144
of O 0 0.0026430427
topical O 0 0.80362207
papaverine B-Chemical 0 0.99988294
on O 0 0.0014746126
auditory O 0 0.007492964
nerve O 0 0.012206942
function O 0 0.002232985
. O 0 0.0043160035

BACKGROUND O 0 0.047412895
: O 0 0.01990157
Papaverine B-Chemical 0 0.99972886
hydrochloride I-Chemical 0 0.9988141
is O 0 0.00073535484
a O 0 0.0006793661
direct O 0 0.00034164256
- O 0 0.0024137835
acting O 0 0.0005212918
vasodilator O 0 0.9431429
used O 0 0.00031668047
to O 0 0.0003326087
manage O 0 0.0013038942
vasospasm B-Disease 2 0.9999794
during O 0 0.0004228955
various O 0 0.00056176516
neurosurgical O 0 0.001691597
operations O 0 0.0016982389
. O 0 0.002423904

Transient O 0 0.030161858
cranial B-Disease 0 0.85720795
nerve I-Disease 0 0.4282913
dysfunction I-Disease 0 0.96531284
has O 0 0.0007137004
been O 0 0.00057493796
described O 0 0.00041017737
in O 0 0.00041194487
a O 0 0.0006213943
few O 0 0.00036610462
cases O 0 0.0010718687
with O 0 0.0014354193
topical O 0 0.9304795
papaverine B-Chemical 0 0.9999205
. O 0 0.005667669

This O 0 0.0039827446
study O 0 0.0017518579
supports O 0 0.0007904763
previous O 0 0.0005812219
reports O 0 0.00058760296
and O 0 0.00040077802
provides O 0 0.00020539509
neurophysiological O 0 0.0007843117
evidence O 0 0.00022713927
of O 0 0.00032577573
an O 0 0.00036466616
adverse O 0 0.0008818594
effect O 0 0.00027696212
on O 0 0.00032703197
the O 0 0.0005980828
auditory O 0 0.006864961
nerve O 0 0.024794148
. O 0 0.0028482922

METHODS O 0 0.004465933
: O 0 0.0029050424
We O 0 0.00087562075
conducted O 0 0.0009256353
a O 0 0.0009866745
retrospective O 0 0.0022962475
review O 0 0.00068467396
of O 0 0.00033536452
70 O 0 0.00031705925
consecutive O 0 0.00025380842
microvascular O 0 0.5754098
decompression O 0 0.0015343825
operations O 0 0.00021911068
and O 0 0.0001438187
studied O 0 0.00020011705
those O 0 0.00018624084
patients O 0 0.00033820845
who O 0 0.00029145117
received O 0 0.0003383252
topical O 0 0.6045897
papaverine B-Chemical 0 0.9999664
for O 0 0.0022147284
vasospasm B-Disease 2 0.99997175
. O 0 0.004055886

Topical O 0 0.9923544
papaverine B-Chemical 0 0.9998803
was O 0 0.0015078512
used O 0 0.0006763371
as O 0 0.000518447
a O 0 0.00048698758
direct O 0 0.00022142207
therapeutic O 0 0.00041656752
action O 0 0.00034623808
to O 0 0.0003626011
manage O 0 0.0015735548
vasospasm B-Disease 2 0.9999871
in O 0 0.00054400164
a O 0 0.00064801617
total O 0 0.0005103435
of O 0 0.00074277783
11 O 0 0.0011657354
patients O 0 0.0024033866
. O 0 0.0026908335

The O 0 0.0016151259
timing O 0 0.0010731698
of O 0 0.0019115873
papaverine B-Chemical 0 0.9998578
application O 0 0.0007131671
and O 0 0.0004044545
ongoing O 0 0.0002656836
operative O 0 0.00035866394
events O 0 0.00034869084
was O 0 0.00023159632
reviewed O 0 0.00039628285
relative O 0 0.00018861608
to O 0 0.00025934167
changes O 0 0.0003995287
in O 0 0.00048136536
neurophysiological O 0 0.0019977477
recordings O 0 0.0013939304
. O 0 0.0022985227

Brainstem O 0 0.012652673
auditory O 0 0.004700431
evoked O 0 0.0021203635
potentials O 0 0.0020357692
( O 0 0.0013300863
BAEPs O 0 0.0095410785
) O 0 0.00085713505
were O 0 0.00024863207
routinely O 0 0.00017227037
used O 0 0.0001799305
to O 0 0.00019150322
monitor O 0 0.00022469
cochlear O 0 0.0013158984
nerve O 0 0.002266384
function O 0 0.00032773297
during O 0 0.0003987194
these O 0 0.00080347934
operations O 0 0.002030238
. O 0 0.0029091726

FINDINGS O 0 0.009847471
: O 0 0.005508853
A O 0 0.008615255
temporal O 0 0.002622734
relationship O 0 0.00047751758
was O 0 0.00044776808
found O 0 0.0003510557
between O 0 0.00036769835
topical O 0 0.7031621
papaverine B-Chemical 0 0.9999728
and O 0 0.0007468581
BAEP O 0 0.5285724
changes O 0 0.00032339577
leading O 0 0.00031798592
to O 0 0.00030744102
complete O 0 0.00044361703
waveform O 0 0.0013517044
loss O 0 0.0018458939
. O 0 0.002795711

The O 0 0.0018397927
average O 0 0.0013883184
temporal O 0 0.002840929
delay O 0 0.0015291782
between O 0 0.00091088936
papaverine B-Chemical 0 0.999905
and O 0 0.0006740119
the O 0 0.0003485243
onset O 0 0.0005191141
of O 0 0.00037382325
an O 0 0.00046849708
adverse O 0 0.0021399213
BAEP O 0 0.1881883
change O 0 0.00046310673
was O 0 0.0005389493
5 O 0 0.0007990379
min O 0 0.0017516187
. O 0 0.0025258774

In O 0 0.0025933525
10 O 0 0.0022098792
of O 0 0.0015720392
11 O 0 0.0013883698
patients O 0 0.0015933303
, O 0 0.0016550809
BAEP O 0 0.16719785
waves O 0 0.0025521903
II O 0 0.044088453
/ O 0 0.0077473545
III O 0 0.38680416
- O 0 0.049120832
V O 0 0.7905998
completely O 0 0.00048491886
disappeared O 0 0.00043286823
within O 0 0.00018474915
2 O 0 0.00034051537
to O 0 0.00030741197
25 O 0 0.0006386738
min O 0 0.00092708727
after O 0 0.0008428608
papaverine B-Chemical 0 0.99944574
. O 0 0.004431278

Eight O 0 0.004101635
of O 0 0.0022073407
these O 0 0.001387874
10 O 0 0.0011258636
patients O 0 0.001201609
had O 0 0.00055614504
complete O 0 0.00043029652
loss O 0 0.00063488225
of O 0 0.0007381137
BAEP O 0 0.12111702
waveforms O 0 0.0010456105
within O 0 0.00044537586
10 O 0 0.0009972451
min O 0 0.0020633787
. O 0 0.002944632

One O 0 0.0038684758
patient O 0 0.0020432663
showed O 0 0.00095638924
no O 0 0.0007282891
recovery O 0 0.00088935014
of O 0 0.0005957431
later O 0 0.00049732794
waves O 0 0.0013701101
and O 0 0.00057398056
a O 0 0.00083872746
delayed O 0 0.002055203
profound O 0 0.008387763
sensorineural B-Disease 0 0.99982053
hearing I-Disease 0 0.92166716
loss I-Disease 0 0.0060343263
. O 0 0.0037447782

The O 0 0.0018490595
average O 0 0.0012691601
recovery O 0 0.001194519
time O 0 0.00055300054
of O 0 0.0007585877
BAEP O 0 0.022567997
waveforms O 0 0.00068983895
to O 0 0.00032743628
pre O 0 0.0008185113
- O 0 0.00470295
papaverine B-Chemical 0 0.9997695
baseline O 0 0.00054308545
values O 0 0.00053768104
was O 0 0.0006866791
39 O 0 0.0014593814
min O 0 0.0023547502
. O 0 0.0031087175

CONCLUSIONS O 0 0.027336549
: O 0 0.008266201
Topical O 0 0.96631217
papaverine B-Chemical 0 0.9998933
for O 0 0.0005554971
the O 0 0.0003465389
treatment O 0 0.0003719761
of O 0 0.0006803101
vasospasm B-Disease 2 0.9999932
was O 0 0.00025867592
associated O 0 0.00016559355
with O 0 0.00013285039
the O 0 0.00010228678
onset O 0 0.00019418466
of O 0 0.00013484599
a O 0 0.0002211771
transient O 0 0.00038193364
disturbance O 0 0.0135321235
in O 0 0.00012188449
neurophysiological O 0 0.0004359143
function O 0 0.000110581954
of O 0 0.00017793386
the O 0 0.00019198516
ascending O 0 0.0010514796
auditory O 0 0.0028331326
brainstem O 0 0.0021318884
pathway O 0 0.0008444858
. O 0 0.0021375928

The O 0 0.0019833785
complete O 0 0.0014672651
disappearance O 0 0.0020286273
of O 0 0.001029852
BAEP O 0 0.1314842
waveforms O 0 0.00079494546
with O 0 0.00036544047
a O 0 0.00040114459
consistent O 0 0.00021564345
temporal O 0 0.00092778134
delay O 0 0.0004089891
suggests O 0 0.00012780244
a O 0 0.00025798427
possible O 0 0.00014574217
adverse B-Disease 0 0.0006180736
effect I-Disease 0 0.0001992853
on I-Disease 0 0.0002330552
the I-Disease 0 0.00039504893
proximal I-Disease 0 0.0015353786
eighth I-Disease 0 0.0030428418
nerve I-Disease 0 0.054870572
. O 0 0.0032166005

Recommendations O 0 0.0026615062
to O 0 0.0016632755
avoid O 0 0.0012067017
potential O 0 0.0013999277
cranial B-Disease 0 0.37927
nerve I-Disease 0 0.16229585
deficits I-Disease 0 0.93873584
from O 0 0.0021018402
papaverine B-Chemical 0 0.9997898
are O 0 0.0017042509
provided O 0 0.001921301
. O 0 0.0041237255

Simvastatin B-Chemical 0 0.9999522
- I-Chemical 0 0.96305877
ezetimibe I-Chemical 0 0.9999665
- O 0 0.15184705
induced O 0 0.0021816927
hepatic B-Disease 0 0.97495914
failure I-Disease 0 0.13349202
necessitating O 0 0.0018244992
liver O 0 0.041649494
transplantation O 0 0.0031834973
. O 0 0.003346916

Abstract O 0 0.16924334
Serum O 0 0.9581828
aminotransferase O 0 0.9918502
elevations O 0 0.009280359
are O 0 0.00070648803
a O 0 0.0007389719
commonly O 0 0.0004561919
known O 0 0.00029801554
adverse O 0 0.00071892946
effect O 0 0.00021374362
of O 0 0.00035223403
3 O 0 0.00042277537
- O 0 0.029594054
hydroxy O 0 0.9997545
- O 0 0.049333606
3 O 0 0.00045697254
- O 0 0.023156375
methylglutaryl O 0 0.9412482
coenzyme O 0 0.99997556
A O 0 0.9920806
reductase O 0 0.9990361
inhibitor O 0 0.037016153
( O 0 0.003309307
statin B-Chemical 1 0.99725443
) O 0 0.003219095
therapy O 0 0.002055574
. O 0 0.0024464373

However O 0 0.0035716358
, O 0 0.0072563514
hepatotoxic B-Disease 0 0.9987684
events O 0 0.0023845877
have O 0 0.0005770835
not O 0 0.00038915657
been O 0 0.00031029762
widely O 0 0.00025849004
published O 0 0.00024903394
with O 0 0.00043290725
ezetimibe B-Chemical 0 0.9999312
or O 0 0.00030523192
the O 0 0.00024825116
combination O 0 0.0005966136
agent O 0 0.014877885
simvastatin B-Chemical 1 0.99999607
- I-Chemical 0 0.9489386
ezetimibe I-Chemical 0 0.99997425
. O 0 0.005948142

We O 0 0.0028560518
describe O 0 0.0020514699
a O 0 0.0021029576
70 O 0 0.0014845867
- O 0 0.0029887464
year O 0 0.0006167346
- O 0 0.001726196
old O 0 0.0005935112
Hispanic O 0 0.012392058
woman O 0 0.0016939807
who O 0 0.0005883508
developed O 0 0.00064108946
fulminant B-Disease 2 0.9999181
hepatic I-Disease 2 0.9988551
failure I-Disease 2 0.7345566
necessitating O 0 0.00023767471
liver O 0 0.009308883
transplantation O 0 0.00013322118
10 O 0 5.190834e-05
weeks O 0 2.7030788e-05
after O 0 3.4533496e-05
conversion O 0 0.00012241202
from O 0 0.00012847187
simvastatin B-Chemical 1 0.9999745
40 O 0 0.00026879762
mg O 0 0.004554853
/ O 0 0.00050927274
day O 0 8.8291374e-05
to O 0 0.00017330734
simvastatin B-Chemical 1 0.9999763
10 I-Chemical 0 0.00041527083
mg I-Chemical 0 0.03521202
- I-Chemical 0 0.0063235443
ezetimibe I-Chemical 0 0.99986684
40 I-Chemical 0 0.00081496045
mg I-Chemical 0 0.008809426
/ O 0 0.002633433
day O 0 0.00096197514
. O 0 0.002415759

The O 0 0.002220991
patient O 0 0.0021829875
' O 0 0.0024207064
s O 0 0.0017137717
lipid O 0 0.035415057
panel O 0 0.0004912222
had O 0 0.0003649858
been O 0 0.0002470856
maintained O 0 0.0002933541
with O 0 0.00047510146
simvastatin B-Chemical 1 0.9999796
for O 0 0.00018066802
18 O 0 0.00015122799
months O 0 5.9221926e-05
before O 0 6.9156515e-05
the O 0 0.00015181022
conversion O 0 0.00035254736
without O 0 0.00033683845
evidence O 0 0.0005744877
of O 0 0.0020974323
hepatotoxicity B-Disease 0 0.99992263
. O 0 0.005541833

A O 0 0.017555397
routine O 0 0.0018779928
laboratory O 0 0.0018512398
work O 0 0.0015024692
- O 0 0.003024263
up O 0 0.00069300714
10 O 0 0.00040940507
weeks O 0 0.0002138333
after O 0 0.00024525466
conversion O 0 0.0006437684
revealed O 0 0.00060245086
elevated O 0 0.006558763
serum O 0 0.50469744
aminotransferase O 0 0.9935121
levels O 0 0.0028316164
. O 0 0.004265266

Simvastatinezetimibe B-Chemical 0 0.011161373
and O 0 0.005092884
escitalopram B-Chemical 0 0.9999125
( O 0 0.0027215737
which O 0 0.0007390751
she O 0 0.00041542682
was O 0 0.00027998374
taking O 0 0.00034831674
for O 0 0.0002829177
depression B-Disease 0 0.99836856
) O 0 0.0007700283
were O 0 0.00019885125
discontinued O 0 0.0006457231
, O 0 0.00031637744
and O 0 0.00018949884
other O 0 0.00017607618
potential O 0 0.00023352809
causes O 0 0.0005119648
of O 0 0.0011770799
hepatotoxicity B-Disease 0 0.99995184
were O 0 0.0014011706
excluded O 0 0.0018905804
. O 0 0.002479289

A O 0 0.022308767
repeat O 0 0.002241607
work O 0 0.002039764
- O 0 0.004359291
up O 0 0.0007806557
revealed O 0 0.00040141883
further O 0 0.00039963957
elevations O 0 0.005750445
in O 0 0.00063425745
aminotransferase O 0 0.954385
levels O 0 0.00028199886
, O 0 0.0004696384
and O 0 0.00028093002
liver O 0 0.011158378
biopsy O 0 0.00022554985
revealed O 0 0.000102693535
evidence O 0 0.00012719553
of O 0 0.0002664055
moderate O 0 0.0017851329
- O 0 0.003521112
to O 0 0.00043646875
- O 0 0.0066543124
severe O 0 0.01383466
drug B-Disease 0 0.8674936
toxicity I-Disease 0 0.997062
. O 0 0.004205278

She O 0 0.007497072
underwent O 0 0.0039763413
liver O 0 0.014337954
transplantation O 0 0.002183167
with O 0 0.0013926247
an O 0 0.0014478491
uneventful O 0 0.0020424896
postoperative O 0 0.0021587517
course O 0 0.0026765675
. O 0 0.004777086

Her O 0 0.014209188
aminotransferase O 0 0.9518063
levels O 0 0.0015917821
returned O 0 0.0010753705
to O 0 0.0005548489
normal O 0 0.00066509855
by O 0 0.0003211627
postoperative O 0 0.0003930737
day O 0 0.00020072875
23 O 0 0.00037670758
, O 0 0.00042868464
and O 0 0.00028055423
her O 0 0.000323205
2 O 0 0.00032388017
- O 0 0.00095092785
year O 0 0.00021974689
follow O 0 0.00019981143
- O 0 0.0010628544
up O 0 0.00039305555
showed O 0 0.0003942955
no O 0 0.0006213765
adverse O 0 0.0030975596
events O 0 0.002488274
. O 0 0.0031649559

Ezetimibe B-Chemical 0 0.9989298
undergoes O 0 0.0022629953
extensive O 0 0.0027159203
glucuronidation O 0 0.9987797
by O 0 0.002318362
uridine B-Chemical 0 0.9995578
diphosphate I-Chemical 0 0.98573095
glucoronosyltransferases O 0 0.142933
( O 0 0.0024539838
UGT O 0 0.9608987
) O 0 0.0008857847
in O 0 0.00016765257
the O 0 0.00014822776
intestine O 0 0.0011247338
and O 0 0.00025006657
liver O 0 0.04905477
and O 0 0.00019173801
may O 0 0.000106860854
have O 0 0.00011184159
inhibited O 0 0.0003015866
the O 0 0.0003110574
glucuronidation O 0 0.99981743
of O 0 0.021588383
simvastatin B-Chemical 1 0.9999999
hydroxy I-Chemical 0 0.99999833
acid I-Chemical 0 0.9998822
, O 0 0.0028239794
resulting O 0 0.0002004214
in O 0 0.0002041101
increased O 0 0.0007380222
simvastatin B-Chemical 1 0.9999857
exposure O 0 0.00068767613
and O 0 0.0005821859
subsequent O 0 0.0009988034
hepatotoxicity B-Disease 0 0.9998903
. O 0 0.003626951

To O 0 0.0014295337
our O 0 0.0015712976
knowledge O 0 0.0018360732
, O 0 0.0019087001
this O 0 0.0007241467
is O 0 0.00036109865
the O 0 0.00024392144
first O 0 0.00016859357
case O 0 0.0002793984
report O 0 0.00053065363
of O 0 0.0008488536
simvastatin B-Chemical 1 0.9999988
- I-Chemical 0 0.9666109
ezetimibe I-Chemical 0 0.99999785
- O 0 0.117945164
induced O 0 0.00035467718
liver B-Disease 0 0.32435206
failure I-Disease 0 0.031276893
that O 0 0.0002226835
resulted O 0 0.00033346916
in O 0 0.0005649391
liver O 0 0.070160195
transplantation O 0 0.0021490923
. O 0 0.0021570534

We O 0 0.0027396975
postulate O 0 0.0025002013
that O 0 0.0009009555
the O 0 0.000590834
mechanism O 0 0.0003668727
of O 0 0.0004863411
the O 0 0.0003682986
simvastatinezetimibe B-Chemical 0 0.0052620852
- O 0 0.0077088983
induced O 0 0.0005576499
hepatotoxicity B-Disease 0 0.9999713
is O 0 0.00023816788
the O 0 0.00018646315
increased O 0 0.0006440323
simvastatin B-Chemical 1 0.9999877
exposure O 0 0.0006333747
by O 0 0.000528625
ezetimibe B-Chemical 0 0.9999598
inhibition O 0 0.0017499577
of O 0 0.001981697
UGT O 0 0.9930482
enzymes O 0 0.024223655
. O 0 0.0037528204

Clinicians O 0 0.0055745356
should O 0 0.0011008338
be O 0 0.00093313423
aware O 0 0.0006937386
of O 0 0.000589388
potential O 0 0.00062458514
hepatotoxicity B-Disease 0 0.9999697
with O 0 0.0043368274
simvastatin B-Chemical 1 0.99999917
- I-Chemical 0 0.9504384
ezetimibe I-Chemical 0 0.99999654
especially O 0 0.00039723562
in O 0 0.00017441707
elderly O 0 0.08288979
patients O 0 0.0002870081
and O 0 8.855961e-05
should O 0 4.26556e-05
carefully O 0 5.7398483e-05
monitor O 0 0.00011344891
serum O 0 0.1414199
aminotransferase O 0 0.9743794
levels O 0 0.000120272874
when O 0 8.849858e-05
starting O 0 0.00010736665
therapy O 0 0.00027955987
and O 0 0.0003027176
titrating O 0 0.0007101528
the O 0 0.0006949353
dosage O 0 0.0042213527
. O 0 0.0025755097

Massive O 0 0.050580624
proteinuria B-Disease 0 0.99961555
and O 0 0.0028075008
acute B-Disease 0 0.13015667
renal I-Disease 0 0.76821285
failure I-Disease 0 0.00763957
after O 0 0.0002164107
oral O 0 0.0015966699
bisphosphonate B-Chemical 0 0.99510324
( O 0 0.0011424947
alendronate B-Chemical 0 0.9995283
) O 0 0.0008003647
administration O 0 0.0003932823
in O 0 0.0002125608
a O 0 0.0003876836
patient O 0 0.00039926334
with O 0 0.0005793767
focal B-Disease 0 0.033645693
segmental I-Disease 0 0.4329001
glomerulosclerosis I-Disease 0 0.9999802
. O 0 0.0051122545

A O 0 0.030182011
61 O 0 0.0059692035
- O 0 0.007424949
year O 0 0.001425099
- O 0 0.0031523006
old O 0 0.0010203968
Japanese O 0 0.0019172335
man O 0 0.008595956
with O 0 0.0021954116
nephrotic B-Disease 0 0.99999774
syndrome I-Disease 0 0.9926179
due O 0 0.0002452745
to O 0 0.0002510838
focal B-Disease 0 0.012968048
segmental I-Disease 0 0.1607361
glomerulosclerosis I-Disease 0 0.9999963
was O 0 0.00028875342
initially O 0 0.00027873323
responding O 0 0.00030462723
well O 0 0.0003002552
to O 0 0.0005037512
steroid B-Chemical 0 0.86684245
therapy O 0 0.0023412472
. O 0 0.0023206836

The O 0 0.0018996161
amount O 0 0.0011777449
of O 0 0.0014571387
daily O 0 0.0017420314
urinary O 0 0.0129399225
protein O 0 0.0008345429
decreased O 0 0.0010088567
from O 0 0.00046980515
15 O 0 0.00042310255
. O 0 0.00035467552
6 O 0 0.00029454878
to O 0 0.0003796941
2 O 0 0.0006615987
. O 0 0.0007768561
8 O 0 0.001196706
g O 0 0.0040505813
. O 0 0.00382095

Within O 0 0.0014010186
14 O 0 0.0012161516
days O 0 0.00060951756
of O 0 0.0006817851
the O 0 0.0005692846
oral O 0 0.003412398
bisphosphonate B-Chemical 0 0.9983719
( O 0 0.0033993104
alendronate B-Chemical 0 0.99995136
sodium I-Chemical 0 0.9998473
) O 0 0.0012858589
administration O 0 0.0004015819
, O 0 0.00024191846
the O 0 8.8974135e-05
amount O 0 7.181664e-05
of O 0 0.00015762508
daily O 0 0.000289098
urinary O 0 0.010322666
protein O 0 0.00019647469
increased O 0 0.00027478143
rapidly O 0 0.00020894581
up O 0 0.00017316858
to O 0 0.00011848162
12 O 0 0.00010673235
. O 0 0.00013576666
8 O 0 0.00017529337
g O 0 0.00061569654
with O 0 0.00046968355
acute B-Disease 0 0.048548073
renal I-Disease 0 0.9069186
failure I-Disease 0 0.1114374
. O 0 0.0030644974

After O 0 0.0016628752
discontinuing O 0 0.0037311495
the O 0 0.0011458205
oral O 0 0.0059277075
alendronate B-Chemical 0 0.999127
, O 0 0.0010642203
the O 0 0.0002963583
patient O 0 0.00027660507
underwent O 0 0.00020338781
six O 0 8.688836e-05
cycles O 0 9.762599e-05
of O 0 0.00022158575
hemodialysis O 0 0.002174945
and O 0 0.00029648864
four O 0 0.00021725772
cycles O 0 0.0003192955
of O 0 0.0012097447
LDL O 0 0.99911064
apheresis O 0 0.036186572
. O 0 0.003538352

Urinary O 0 0.1021361
volume O 0 0.004321696
and O 0 0.0022359171
serum O 0 0.08939313
creatinine B-Chemical 0 0.9899788
levels O 0 0.0005192846
recovered O 0 0.0003122024
to O 0 0.00022693709
the O 0 0.00020454417
normal O 0 0.00036448316
range O 0 0.00025232596
, O 0 0.0004178902
with O 0 0.00036032748
urinary O 0 0.026120603
protein O 0 0.0005705435
disappearing O 0 0.0015888672
completely O 0 0.00046745528
within O 0 0.00034450862
40 O 0 0.0008041565
days O 0 0.0007502575
. O 0 0.0022517648

This O 0 0.004743079
report O 0 0.002710188
demonstrates O 0 0.00067208626
that O 0 0.00055527507
not O 0 0.00050057535
only O 0 0.0005489458
intravenous O 0 0.005103318
, O 0 0.00066451
but O 0 0.00034253896
also O 0 0.00029274423
oral O 0 0.0036264395
bisphosphonates B-Chemical 0 0.99888843
can O 0 0.00036691365
aggravate O 0 0.17503516
proteinuria B-Disease 0 0.9999521
and O 0 0.0010986709
acute B-Disease 0 0.2363413
renal I-Disease 0 0.947777
failure I-Disease 0 0.12355122
. O 0 0.0029139896

Serum O 0 0.6512378
- O 0 0.028967481
and O 0 0.0040292316
glucocorticoid O 0 0.74738175
- O 0 0.015910452
inducible O 0 0.0019587798
kinase O 0 0.0025429137
1 O 0 0.00094893586
in O 0 0.0010327927
doxorubicin B-Chemical 0 0.9996867
- O 0 0.04959945
induced O 0 0.003636099
nephrotic B-Disease 0 0.9999908
syndrome I-Disease 0 0.99632
. O 0 0.005534758

Doxorubicin B-Chemical 0 0.99981874
- O 0 0.16470145
induced O 0 0.004075484
nephropathy B-Disease 0 0.99996436
leads O 0 0.0011890817
to O 0 0.00069042295
epithelial O 0 0.022791576
sodium B-Chemical 0 0.99919766
channel O 0 0.0035315491
( O 0 0.0010789097
ENaC O 0 0.0059283874
) O 0 0.0012182082
- O 0 0.0016653909
dependent O 0 0.00029530207
volume B-Disease 0 0.0017500917
retention I-Disease 0 0.0031009335
and O 0 0.0013553383
renal O 0 0.95780474
fibrosis B-Disease 0 0.9975957
. O 0 0.0041779685

The O 0 0.0044443356
aldosterone B-Chemical 0 0.99972934
- O 0 0.030657995
sensitive O 0 0.0012936236
serum O 0 0.04049658
- O 0 0.009232751
and O 0 0.000938826
glucocorticoid O 0 0.72814465
- O 0 0.019416487
inducible O 0 0.0009675333
kinase O 0 0.0038585733
SGK1 O 0 0.09421662
has O 0 0.00014540556
been O 0 0.0001334498
shown O 0 6.341772e-05
to O 0 8.570306e-05
participate O 0 8.3538966e-05
in O 0 7.987901e-05
the O 0 6.957549e-05
stimulation O 0 7.362433e-05
of O 0 0.00015582776
ENaC O 0 0.0022136706
and O 0 0.00015281918
to O 0 0.00011451307
mediate O 0 0.00012739676
renal O 0 0.9257012
fibrosis B-Disease 0 0.9991523
following O 0 0.00041681
mineralocorticoid O 0 0.99756706
and O 0 0.0013966564
salt O 0 0.9882614
excess O 0 0.0046970854
. O 0 0.0033025385

The O 0 0.0019965682
present O 0 0.0014195889
study O 0 0.0013115442
was O 0 0.0006842401
performed O 0 0.0004353352
to O 0 0.00029000128
elucidate O 0 0.00013831409
the O 0 0.00019833146
role O 0 0.0001455165
of O 0 0.0004290677
SGK1 O 0 0.010277707
in O 0 0.00028051704
the O 0 0.00024073788
volume B-Disease 0 0.001358073
retention I-Disease 0 0.0020426053
and O 0 0.00068769377
fibrosis B-Disease 0 0.997166
during O 0 0.0015619895
nephrotic B-Disease 0 0.9999913
syndrome I-Disease 0 0.9920614
. O 0 0.0037685363

To O 0 0.0014560082
this O 0 0.0015822562
end O 0 0.0009803496
, O 0 0.0029813629
doxorubicin B-Chemical 0 0.9994661
( O 0 0.0013312439
15 O 0 0.00040134616
mug O 0 0.00062263274
/ O 0 0.001010208
g O 0 0.000694833
body O 0 0.00029089377
wt O 0 0.00015333766
) O 0 0.00032794362
was O 0 0.00010641597
injected O 0 9.928178e-05
intravenously O 0 0.00017165908
into O 0 6.305433e-05
gene O 0 0.00010673184
- O 0 0.0004354581
targeted O 0 5.732863e-05
mice O 0 4.9295453e-05
lacking O 0 0.00010409553
SGK1 O 0 0.005198179
( O 0 0.00051327306
sgk1 O 0 0.00057736464
( O 0 0.0006179561
- O 0 0.00227779
/ O 0 0.0019855062
- O 0 0.0022646668
) O 0 0.00056799996
) O 0 0.00040818032
and O 0 0.00016858106
their O 0 0.000155966
wild O 0 0.00021311764
- O 0 0.0011005716
type O 0 0.00034998602
littermates O 0 0.00010485867
( O 0 0.0005561138
sgk1 O 0 0.00085576763
( O 0 0.0010818946
+ O 0 0.0022547161
/ O 0 0.003900836
+ O 0 0.004136419
) O 0 0.003866047
) O 0 0.0049356264
. O 0 0.004248448

Doxorubicin B-Chemical 0 0.99965525
treatment O 0 0.0026319819
resulted O 0 0.0011303265
in O 0 0.00095586985
heavy O 0 0.0068065515
proteinuria B-Disease 0 0.99988055
( O 0 0.0014645088
> O 0 0.0009867027
100 O 0 0.0007437624
mg O 0 0.0028737083
protein O 0 0.000314047
/ O 0 0.0017902233
mg O 0 0.023543587
crea O 0 0.040542092
) O 0 0.0005092153
in O 0 0.00017367971
15 O 0 0.00018220009
/ O 0 0.0005534123
44 O 0 0.00024313733
of O 0 0.00020127381
sgk1 O 0 0.00047602467
( O 0 0.00049932173
+ O 0 0.00096663676
/ O 0 0.0013838132
+ O 0 0.0010658223
) O 0 0.0004973976
and O 0 0.00019589237
15 O 0 0.0001777875
/ O 0 0.00055142207
44 O 0 0.00022841997
of O 0 0.00019136668
sgk1 O 0 0.00052016263
( O 0 0.0006165378
- O 0 0.002393032
/ O 0 0.0019375926
- O 0 0.0017128272
) O 0 0.00032853853
mice O 0 5.6464105e-05
leading O 0 0.00015209262
to O 0 0.00018268875
severe O 0 0.07323446
nephrotic B-Disease 0 0.9999989
syndrome I-Disease 0 0.9939067
with O 0 0.0006301906
ascites B-Disease 0 0.99974686
, O 0 0.0040366435
lipidemia B-Disease 0 0.99996984
, O 0 0.0014477279
and O 0 0.00070093985
hypoalbuminemia B-Disease 0 0.9996865
in O 0 0.00062601245
both O 0 0.0007319936
genotypes O 0 0.0018973949
. O 0 0.0027937628

Plasma O 0 0.94432205
aldosterone B-Chemical 0 0.9998105
levels O 0 0.0018294872
increased O 0 0.0016399651
in O 0 0.0012478158
nephrotic B-Disease 0 0.9999758
mice O 0 0.00015687448
of O 0 0.00023236024
both O 0 0.00017841566
genotypes O 0 0.00027500157
and O 0 0.00021098643
was O 0 0.00016278467
followed O 0 0.00013252233
by O 0 0.00018621865
increased O 0 0.00043760793
SGK1 O 0 0.012401538
protein O 0 0.00028662366
expression O 0 0.00024274077
in O 0 0.0003200519
sgk1 O 0 0.00088119577
( O 0 0.00097140524
+ O 0 0.0019083022
/ O 0 0.0029917804
+ O 0 0.0026897872
) O 0 0.0020867127
mice O 0 0.0008145339
. O 0 0.0029605418

Urinary O 0 0.8813285
sodium B-Chemical 0 0.99890757
excretion O 0 0.9312896
reached O 0 0.0020232308
signficantly O 0 0.027534572
lower O 0 0.0005839118
values O 0 0.00037029447
in O 0 0.00032917655
sgk1 O 0 0.0007086772
( O 0 0.00070495356
+ O 0 0.0012071702
/ O 0 0.0014963176
+ O 0 0.0010437593
) O 0 0.00046680335
mice O 0 9.3628514e-05
( O 0 0.00031873284
15 O 0 0.00020347296
+ O 0 0.00068838854
/ O 0 0.0011844807
- O 0 0.0011459187
5 O 0 0.00022186355
mumol O 0 0.0016678799
/ O 0 0.0011760029
mg O 0 0.008047228
crea O 0 0.020775864
) O 0 0.00043479062
than O 0 0.00013851338
in O 0 0.00016987498
sgk1 O 0 0.00051451754
( O 0 0.00063081644
- O 0 0.0021570432
/ O 0 0.0016877017
- O 0 0.0013877617
) O 0 0.00035050375
mice O 0 7.070876e-05
( O 0 0.00025629194
35 O 0 0.00020282075
+ O 0 0.0006776332
/ O 0 0.0011800335
- O 0 0.0011230712
5 O 0 0.0001924208
mumol O 0 0.0017047281
/ O 0 0.0011778808
mg O 0 0.014442402
crea O 0 0.053878833
) O 0 0.00041110476
and O 0 0.00013291121
was O 0 0.000104469145
associated O 0 0.00011399449
with O 0 0.00011528825
a O 0 0.00015699178
significantly O 0 0.0001170704
higher O 0 0.00010657979
body O 0 0.00016199776
weight B-Disease 0 0.00015183758
gain I-Disease 0 0.0001245183
in O 0 0.00011443754
sgk1 O 0 0.0003155446
( O 0 0.00034432986
+ O 0 0.0007020696
/ O 0 0.0010300521
+ O 0 0.0007705942
) O 0 0.00034412605
compared O 0 9.9902965e-05
with O 0 0.00018071647
sgk1 O 0 0.0005538965
( O 0 0.0006441889
- O 0 0.00246724
/ O 0 0.0017867906
- O 0 0.0014581296
) O 0 0.0003426387
mice O 0 7.011493e-05
( O 0 0.00029269815
+ O 0 0.0004797452
6 O 0 0.00011808889
. O 0 0.00012929394
6 O 0 0.00012418107
+ O 0 0.000603699
/ O 0 0.0012176093
- O 0 0.0012255219
0 O 0 0.00025726878
. O 0 0.00014971473
7 O 0 0.00011932825
vs O 0 0.0002368522
. O 0 0.00021125072
+ O 0 0.0005946873
4 O 0 0.00020638722
. O 0 0.00024045962
1 O 0 0.0003416466
+ O 0 0.0011004941
/ O 0 0.002050316
- O 0 0.0021853342
0 O 0 0.00072983006
. O 0 0.00061800744
8 O 0 0.00084779836
g O 0 0.0028975965
) O 0 0.004007403
. O 0 0.003940964

During O 0 0.0019333701
the O 0 0.0014685314
course O 0 0.0015239285
of O 0 0.0027977137
nephrotic B-Disease 0 0.9999939
syndrome I-Disease 0 0.99840087
, O 0 0.0043386086
serum O 0 0.6650512
urea B-Chemical 0 0.99980646
concentrations O 0 0.0011761043
increased O 0 0.0003664367
significantly O 0 0.00023383398
faster O 0 0.00020428826
in O 0 0.00017186101
sgk1 O 0 0.0004788499
( O 0 0.00054132985
- O 0 0.0019107895
/ O 0 0.0014890507
- O 0 0.0012423616
) O 0 0.00027655074
mice O 0 4.992814e-05
than O 0 9.803582e-05
in O 0 0.00013452041
sgk1 O 0 0.00038758418
( O 0 0.00042453295
+ O 0 0.0008771538
/ O 0 0.00127066
+ O 0 0.0008779984
) O 0 0.0003260215
mice O 0 5.311933e-05
leading O 0 0.00015487763
to O 0 0.00020856723
uremia B-Disease 0 0.99995685
and O 0 0.00021763198
a O 0 0.00018575668
reduced O 0 0.00011736694
median O 0 7.330313e-05
survival O 0 0.00020502448
in O 0 0.00013211151
sgk1 O 0 0.00043433538
( O 0 0.00054142217
- O 0 0.002244228
/ O 0 0.0017433122
- O 0 0.0014799209
) O 0 0.00032462983
mice O 0 6.263341e-05
( O 0 0.00023856922
29 O 0 0.0002112624
vs O 0 0.00021287943
. O 0 0.00013982167
40 O 0 0.0001467111
days O 0 9.8820376e-05
in O 0 0.00019559468
sgk1 O 0 0.00060886313
( O 0 0.00080552156
+ O 0 0.0016548375
/ O 0 0.0025963231
+ O 0 0.002334081
) O 0 0.0016954917
mice O 0 0.00061431207
) O 0 0.003551287
. O 0 0.0037607963

In O 0 0.0020058076
conclusion O 0 0.0014779584
, O 0 0.0025231664
gene O 0 0.001076287
- O 0 0.0024459092
targeted O 0 0.00025235728
mice O 0 0.00015604976
lacking O 0 0.00022568966
SGK1 O 0 0.0060513155
showed O 0 0.00035324204
blunted O 0 0.0058716307
volume B-Disease 0 0.0036582195
retention I-Disease 0 0.0037543043
, O 0 0.00052782265
yet O 0 0.00020086794
were O 0 0.00014765278
not O 0 0.00013622532
protected O 0 0.00016687682
against O 0 0.0001582045
renal O 0 0.8846836
fibrosis B-Disease 0 0.9975902
during O 0 0.00049966265
experimental O 0 0.0019633456
nephrotic B-Disease 0 0.9999927
syndrome I-Disease 0 0.9939126
. O 0 0.0036492986

Severe O 0 0.78266376
thrombocytopenia B-Disease 0 0.9994442
and O 0 0.0075589838
haemolytic B-Disease 0 0.999571
anaemia I-Disease 0 0.9999454
associated O 0 0.0015832162
with O 0 0.0015864907
ciprofloxacin B-Chemical 0 0.9999789
: O 0 0.0018206233
a O 0 0.0006566628
case O 0 0.0005120219
report O 0 0.000935557
with O 0 0.0010669957
fatal O 0 0.36494678
outcome O 0 0.0026107559
. O 0 0.0029758585

Haematological O 0 0.25107506
adverse O 0 0.0068060094
reactions O 0 0.0016734127
associated O 0 0.0009596344
with O 0 0.00094344746
fatal O 0 0.10142749
outcome O 0 0.0007352768
are O 0 0.00039958928
rare O 0 0.0010750679
during O 0 0.00039431694
treatment O 0 0.0007670595
with O 0 0.0019546666
ciprofloxacin B-Chemical 0 0.9998677
. O 0 0.0050168633

A O 0 0.023049276
30 O 0 0.002804644
- O 0 0.0046902425
year O 0 0.0008980125
old O 0 0.0010222401
Caucasian O 0 0.00599323
man O 0 0.0039482745
reported O 0 0.00043041815
with O 0 0.00032717042
abdominal B-Disease 0 0.0009153848
pain I-Disease 0 0.01276001
and O 0 0.000260571
jaundice B-Disease 0 0.8986574
after O 0 8.460215e-05
3 O 0 0.00011060031
- O 0 0.00038706246
day O 0 7.2924326e-05
administration O 0 0.00017900439
of O 0 0.00019084792
oral O 0 0.003945834
ciprofloxacin B-Chemical 0 0.9999685
for O 0 0.00021852025
a O 0 0.00043750784
suspect O 0 0.0007911021
of O 0 0.000734472
urinary B-Disease 0 0.15631099
tract I-Disease 0 0.001739795
infection I-Disease 0 0.0063202675
. O 0 0.003211106

Clinical O 0 0.0067890966
evaluations O 0 0.0020847975
suggested O 0 0.0012303512
an O 0 0.0011736596
initial O 0 0.0007976115
diagnosis O 0 0.0015823068
of O 0 0.0014770017
severe O 0 0.08430923
thrombocytopenia B-Disease 0 0.9996519
and O 0 0.0051566986
haemolysis B-Disease 0 0.9997588
. O 0 0.0072670314

The O 0 0.002727076
patient O 0 0.0028378384
progressively O 0 0.0024207872
developed O 0 0.0023204167
petechiae B-Disease 0 0.8672748
and O 0 0.002323503
purpura B-Disease 0 0.9993142
on O 0 0.0007273035
thorax O 0 0.0029105751
and O 0 0.0012017287
lower O 0 0.0019966967
limbs O 0 0.015989186
. O 0 0.0044520474

Despite O 0 0.0019400296
pharmacological O 0 0.0034437762
and O 0 0.0012832163
supportive O 0 0.0013682903
interventions O 0 0.0006160449
, O 0 0.000822217
laboratory O 0 0.0004639914
parameters O 0 0.00046307058
worsened O 0 0.002245595
and O 0 0.00035539153
the O 0 0.0002789342
patient O 0 0.00044032958
died O 0 0.00071268156
17 O 0 0.00048274893
hours O 0 0.00035606534
after O 0 0.0004469512
admission O 0 0.0016267906
. O 0 0.0025715893

An O 0 0.0040983
accurate O 0 0.0029050077
autopsy O 0 0.006991917
revealed O 0 0.0014558743
most O 0 0.0018778562
organs O 0 0.0027152188
with O 0 0.0024568967
diffuse O 0 0.0311209
petechial O 0 0.7741928
haemorrhages B-Disease 0 0.99853134
. O 0 0.005843777

No O 0 0.008049174
signs O 0 0.0102331685
of O 0 0.0043287184
bone B-Disease 0 0.05748766
marrow I-Disease 0 0.26893014
depression I-Disease 0 0.9990177
were O 0 0.0032155
found O 0 0.0037285076
. O 0 0.006285022

No O 0 0.009221289
thrombi B-Disease 0 0.9915684
or O 0 0.00282715
signs O 0 0.007756843
of O 0 0.0032665501
microangiopathies B-Disease 0 0.9999112
were O 0 0.001391568
observed O 0 0.0009876244
in O 0 0.001501138
arterial O 0 0.5788385
vessels O 0 0.35469556
. O 0 0.0049285195

Blood O 0 0.07390816
and O 0 0.0053300234
urine O 0 0.053029034
cultures O 0 0.002422593
did O 0 0.0018955067
not O 0 0.0013331235
show O 0 0.001157654
any O 0 0.0017282332
bacterial O 0 0.0054176445
growth O 0 0.020633226
. O 0 0.0067884815

This O 0 0.004458917
case O 0 0.0020810505
report O 0 0.0017115712
shows O 0 0.00044090732
that O 0 0.00072959677
ciprofloxacin B-Chemical 0 0.99996364
may O 0 0.0004359008
precipitate O 0 0.0009966912
life O 0 0.00038635172
- O 0 0.003911501
threatening O 0 0.0020306208
thrombocytopenia B-Disease 0 0.9998709
and O 0 0.0009910144
haemolytic B-Disease 0 0.99991167
anaemia I-Disease 0 0.99999213
, O 0 0.001231024
even O 0 0.00023803234
in O 0 0.00013275124
the O 0 0.00010507007
early O 0 0.00020135751
phases O 0 0.00023436923
of O 0 0.00020727784
treatment O 0 0.00022139672
and O 0 0.0002582087
without O 0 0.00033566405
apparent O 0 0.00050612935
previous O 0 0.0006612394
exposures O 0 0.0022527326
. O 0 0.0026014708

Alpha B-Chemical 0 0.97208124
- I-Chemical 0 0.9927366
lipoic I-Chemical 0 0.9999753
acid I-Chemical 0 0.99830014
prevents O 0 0.011241211
mitochondrial B-Disease 0 0.9961863
damage I-Disease 0 0.99252325
and O 0 0.002031717
neurotoxicity B-Disease 0 0.99624497
in O 0 0.00072964304
experimental O 0 0.0010679174
chemotherapy O 0 0.024453763
neuropathy B-Disease 0 0.99919695
. O 0 0.0039939107

The O 0 0.0024195183
study O 0 0.0023731398
investigates O 0 0.0018033432
if O 0 0.0016455677
alpha B-Chemical 1 0.99720615
- I-Chemical 1 0.99716884
lipoic I-Chemical 1 0.99999654
acid I-Chemical 1 0.9984458
is O 0 0.0005888489
neuroprotective O 0 0.006846144
against O 0 0.000115558665
chemotherapy O 0 0.004118972
induced O 0 0.00026498086
neurotoxicity B-Disease 0 0.99944764
, O 0 0.000824363
if O 0 0.0001887393
mitochondrial B-Disease 0 0.9192815
damage I-Disease 0 0.8879494
plays O 0 7.6506025e-05
a O 0 0.00013088496
critical O 0 5.43049e-05
role O 0 4.904764e-05
in O 0 0.00016668788
toxic B-Disease 0 0.63985455
neurodegenerative I-Disease 0 0.9812371
cascade I-Disease 0 0.00034359092
, O 0 0.00027158385
and O 0 0.00012774882
if O 0 9.481639e-05
neuroprotective O 0 0.001421732
effects O 0 0.0002456804
of O 0 0.000910838
alpha B-Chemical 1 0.99910283
- I-Chemical 1 0.99640155
lipoic I-Chemical 1 0.99999774
acid I-Chemical 1 0.9983931
depend O 0 0.00078769104
on O 0 0.00056938856
mitochondria O 0 0.004933896
protection O 0 0.0020038702
. O 0 0.0027377307

We O 0 0.0023722064
used O 0 0.0014781273
an O 0 0.0011487582
in O 0 0.0006093645
vitro O 0 0.0004168182
model O 0 0.00029539078
of O 0 0.00036507312
chemotherapy O 0 0.0022648836
induced O 0 0.00027762091
peripheral B-Disease 0 0.2776383
neuropathy I-Disease 0 0.9999924
that O 0 0.0001684093
closely O 0 0.000109390334
mimic O 0 9.372472e-05
the O 0 8.1474085e-05
in O 0 8.480393e-05
vivo O 0 9.586718e-05
condition O 0 0.000212795
by O 0 0.00010457279
exposing O 0 0.0001872653
primary O 0 0.00011548024
cultures O 0 0.0001344704
of O 0 0.00016350164
dorsal O 0 0.00041108124
root O 0 0.00075815764
ganglion O 0 0.016741052
( O 0 0.00034724447
DRG O 0 0.00078209763
) O 0 0.00028930703
sensory O 0 0.0001839613
neurons O 0 0.000101590114
to O 0 0.00011281416
paclitaxel B-Chemical 1 0.9985669
and O 0 0.00037994666
cisplatin B-Chemical 0 0.9999106
, O 0 0.00033421835
two O 0 8.38149e-05
widely O 0 0.00012145487
used O 0 0.00013493872
and O 0 0.0002145579
highly O 0 0.00024600804
effective O 0 0.0004389794
chemotherapeutic O 0 0.0055055916
drugs O 0 0.028024916
. O 0 0.003122838

This O 0 0.0037206833
approach O 0 0.0015151688
allowed O 0 0.00093120866
investigating O 0 0.00052150676
the O 0 0.00043194165
efficacy O 0 0.0005573656
of O 0 0.0011426182
alpha B-Chemical 1 0.9977241
- I-Chemical 1 0.9969484
lipoic I-Chemical 1 0.9999982
acid I-Chemical 1 0.9990306
in O 0 0.00072386966
preventing O 0 0.0005174535
axonal B-Disease 0 0.81130075
damage I-Disease 0 0.92010504
and O 0 0.00031923765
apoptosis O 0 0.11659403
and O 0 0.00013865253
the O 0 7.4439515e-05
function O 0 8.552158e-05
and O 0 0.00014338436
ultrastructural O 0 0.00060674525
morphology O 0 0.0003692197
of O 0 0.000205753
mitochondria O 0 0.0007652154
after O 0 7.340539e-05
exposure O 0 0.00015448796
to O 0 0.00015503025
toxic O 0 0.004118364
agents O 0 0.0014485663
and O 0 0.0011185954
alpha B-Chemical 1 0.99441904
- I-Chemical 1 0.9754117
lipoic I-Chemical 1 0.9999871
acid I-Chemical 1 0.9985024
. O 0 0.0102971755

Our O 0 0.0018160309
results O 0 0.0011212481
demonstrate O 0 0.00050733157
that O 0 0.00059017265
both O 0 0.00086557097
cisplatin B-Chemical 0 0.9997961
and O 0 0.0012291471
paclitaxel B-Chemical 1 0.9997346
cause O 0 0.00074000587
early O 0 0.0011480553
mitochondrial B-Disease 0 0.9249079
impairment I-Disease 0 0.99691904
with O 0 0.0003112686
loss O 0 0.00024702714
of O 0 0.00019703561
membrane O 0 0.000630099
potential O 0 0.00012741148
and O 0 0.00018376301
induction O 0 0.00018823809
of O 0 0.00043839292
autophagic O 0 0.0038725496
vacuoles O 0 0.0017450025
in O 0 0.00084988197
neurons O 0 0.0015073925
. O 0 0.0022830768

Alpha B-Chemical 0 0.9688046
- I-Chemical 0 0.991767
lipoic I-Chemical 0 0.9999751
acid I-Chemical 0 0.99297756
exerts O 0 0.001414236
neuroprotective O 0 0.015644
effects O 0 0.00032148432
against O 0 0.00015637954
chemotherapy O 0 0.004478012
induced O 0 0.00028243475
neurotoxicity B-Disease 0 0.9977366
in O 0 0.00020292948
sensory O 0 0.00036940377
neurons O 0 0.00016625803
: O 0 0.00031833624
it O 0 0.00020142047
rescues O 0 0.00018640484
the O 0 0.00024631553
mitochondrial B-Disease 0 0.9603028
toxicity I-Disease 0 0.9994758
and O 0 0.00021854044
induces O 0 9.0386515e-05
the O 0 9.687141e-05
expression O 0 0.00012998025
of O 0 0.00034809412
frataxin O 0 0.90939885
, O 0 0.0006408875
an O 0 0.00021963085
essential O 0 0.0001819782
mitochondrial O 0 0.012890792
protein O 0 0.00031258783
with O 0 0.00040289233
anti O 0 0.0026311795
- O 0 0.12590286
oxidant O 0 0.970884
and O 0 0.000794294
chaperone O 0 0.0012717509
properties O 0 0.001182833
. O 0 0.0027815374

In O 0 0.0022721943
conclusion O 0 0.0022486781
mitochondrial B-Disease 0 0.9503604
toxicity I-Disease 0 0.998321
is O 0 0.00076882436
an O 0 0.0005592446
early O 0 0.00053679314
common O 0 0.00034512466
event O 0 0.00042597408
both O 0 0.0002635751
in O 0 0.00046834323
paclitaxel B-Chemical 1 0.99902546
and O 0 0.001448398
cisplatin B-Chemical 0 0.9998117
induced O 0 0.0024861358
neurotoxicity B-Disease 0 0.99869233
. O 0 0.0045010503

Alpha B-Chemical 0 0.97267085
- I-Chemical 0 0.99321073
lipoic I-Chemical 0 0.9999783
acid I-Chemical 0 0.99677974
protects O 0 0.002332758
sensory O 0 0.0018588629
neurons O 0 0.00049266795
through O 0 0.00028429614
its O 0 0.0005057814
anti O 0 0.0015389712
- O 0 0.10540323
oxidant O 0 0.9696786
and O 0 0.0004806478
mitochondrial O 0 0.00439509
regulatory O 0 0.00016440824
functions O 0 0.00020272718
, O 0 0.0004956311
possibly O 0 0.00035622597
inducing O 0 0.00035825867
the O 0 0.00039716825
expression O 0 0.0006816152
of O 0 0.0019309885
frataxin O 0 0.8947166
. O 0 0.0045154435

These O 0 0.0021652128
findings O 0 0.0021117649
suggest O 0 0.0011156023
that O 0 0.0018501353
alpha B-Chemical 1 0.99765897
- I-Chemical 1 0.9979494
lipoic I-Chemical 1 0.999997
acid I-Chemical 1 0.9983347
might O 0 0.00031172653
reduce O 0 0.00017837007
the O 0 0.00019325317
risk O 0 0.0015380769
of O 0 0.00022502101
developing O 0 0.0005582029
peripheral B-Disease 0 0.017795661
nerve I-Disease 0 0.12247203
toxicity I-Disease 0 0.824067
in O 0 0.000113809285
patients O 0 0.00020688216
undergoing O 0 0.00014161471
chemotherapy O 0 0.00057315535
and O 0 0.00014415041
encourage O 0 0.00028204377
further O 0 0.0002940592
confirmatory O 0 0.002204882
clinical O 0 0.002359811
trials O 0 0.0021568984
. O 0 0.0024894136

Toxicity B-Disease 0 0.055994283
in O 0 0.0013822713
rhesus O 0 0.00053197413
monkeys O 0 0.00047241585
following O 0 0.00026042195
administration O 0 0.00047983343
of O 0 0.00031327698
the O 0 0.00024751187
8 B-Chemical 0 0.00032531205
- I-Chemical 0 0.0019877611
aminoquinoline I-Chemical 0 0.021964299
8 B-Chemical 0 0.0003046499
- I-Chemical 0 0.0014228818
[ I-Chemical 0 0.0010354083
( I-Chemical 0 0.00044102268
4 I-Chemical 0 0.00024387236
- I-Chemical 0 0.0020866303
amino I-Chemical 0 0.09460132
- I-Chemical 0 0.008195853
l I-Chemical 0 0.009006058
- I-Chemical 0 0.027907714
methylbutyl I-Chemical 0 0.41567913
) I-Chemical 0 0.0022053404
amino I-Chemical 0 0.25083137
] I-Chemical 0 0.0047060023
- I-Chemical 0 0.002159104
5 I-Chemical 0 0.00024122128
- I-Chemical 0 0.00096876343
( I-Chemical 0 0.00045378963
l I-Chemical 0 0.0019811152
- I-Chemical 0 0.004816344
hexyloxy I-Chemical 0 0.113068596
) I-Chemical 0 0.0013659481
- I-Chemical 0 0.0020205488
6 I-Chemical 0 0.00030457813
- I-Chemical 0 0.0036657802
methoxy I-Chemical 0 0.981006
- I-Chemical 0 0.0063916324
4 I-Chemical 0 0.0005630224
- I-Chemical 0 0.00335977
methylquinoline I-Chemical 0 0.013870729
( O 0 0.004223165
WR242511 B-Chemical 0 0.9971193
) O 0 0.0070655746
. O 0 0.004213829

INTRODUCTION O 0 0.01743388
: O 0 0.005110547
Many O 0 0.0018036658
substances O 0 0.015047617
that O 0 0.0013562763
form O 0 0.0025684678
methemoglobin O 0 0.99990714
( O 0 0.008992301
MHb O 0 0.84491265
) O 0 0.0018716897
effectively O 0 0.0008180958
counter O 0 0.0064930785
cyanide O 0 0.9998771
( O 0 0.014842947
CN O 0 0.9857028
) O 0 0.0078762
toxicity B-Disease 0 0.7005028
. O 0 0.0047351327

Although O 0 0.0036113688
MHb O 0 0.802861
formers O 0 0.255523
are O 0 0.0009953281
generally O 0 0.0007266828
applied O 0 0.00046939653
as O 0 0.00040513734
treatments O 0 0.00052272883
for O 0 0.0005103117
CN O 0 0.99798965
poisoning B-Disease 2 0.99994755
, O 0 0.0012219194
it O 0 0.00035849918
has O 0 0.00011935216
been O 0 0.00013406428
proposed O 0 0.00011791605
that O 0 0.000108615866
a O 0 0.00023923459
stable O 0 0.00019394094
, O 0 0.0003589287
long O 0 0.00028116448
- O 0 0.00209034
acting O 0 0.00044515877
MHb O 0 0.57049835
former O 0 0.0011119678
could O 0 0.000284525
serve O 0 0.0005319957
as O 0 0.0007230485
a O 0 0.002354348
CN O 0 0.97795206
pretreatment O 0 0.049313854
. O 0 0.004315468

Using O 0 0.0019003882
this O 0 0.0016868584
rationale O 0 0.001337552
, O 0 0.001713332
the O 0 0.00070933293
8 B-Chemical 0 0.0008208174
- I-Chemical 0 0.011883453
aminoquinoline I-Chemical 0 0.8554553
WR242511 B-Chemical 0 0.999508
, O 0 0.00093138486
a O 0 0.00040717973
potent O 0 0.00034833947
long O 0 0.00030037574
- O 0 0.0021436284
lasting O 0 0.00032628488
MHb O 0 0.3353678
former O 0 0.0005678266
in O 0 0.00014150821
rodents O 0 0.00021418263
and O 0 0.00016142368
beagle O 0 0.0008239916
dogs O 0 0.00036433002
, O 0 0.00024657845
was O 0 0.00011241405
studied O 0 0.00016111445
in O 0 0.00010026879
the O 0 8.347869e-05
rhesus O 0 6.782573e-05
monkey O 0 0.00017977018
for O 0 0.00014520716
advanced O 0 0.0010984485
development O 0 0.00040592096
as O 0 0.00038563454
a O 0 0.00083329977
potential O 0 0.0010137743
CN O 0 0.97913617
pretreatment O 0 0.053373925
. O 0 0.00392968

METHODS O 0 0.003918399
: O 0 0.0025451027
In O 0 0.00072100904
this O 0 0.0009105075
study O 0 0.001007872
, O 0 0.0018758096
WR242511 B-Chemical 0 0.99292177
was O 0 0.0004158151
administered O 0 0.00046280358
intravenously O 0 0.0005951146
( O 0 0.0005381425
IV O 0 0.032902014
) O 0 0.00055535213
in O 0 0.0001676796
2 O 0 0.00018090816
female O 0 0.0002971154
and O 0 0.00013730304
4 O 0 9.4324896e-05
male O 0 0.00016817066
rhesus O 0 5.1241324e-05
monkeys O 0 8.0554e-05
in O 0 8.9513924e-05
doses O 0 0.00022155132
of O 0 0.00013653899
3 O 0 0.00011162976
. O 0 0.000105601015
5 O 0 9.551387e-05
and O 0 0.00012649872
/ O 0 0.0005182304
or O 0 0.00011493371
7 O 0 9.794349e-05
. O 0 0.00010814563
0 O 0 0.00017186381
mg O 0 0.001082574
/ O 0 0.00054296304
kg O 0 0.0004116342
; O 0 0.0002869542
a O 0 0.00017266865
single O 0 9.533115e-05
male O 0 0.00026646137
also O 0 0.0001442768
received O 0 0.0002668076
WR242511 B-Chemical 0 0.9980919
orally O 0 0.0012738062
( O 0 0.00072888203
PO O 0 0.5000564
) O 0 0.0005271173
at O 0 0.00016940542
7 O 0 0.00021353665
. O 0 0.00031240488
0 O 0 0.00065280346
mg O 0 0.0036078172
/ O 0 0.0032997064
kg O 0 0.0036562039
. O 0 0.0033697642

Health O 0 0.0051265736
status O 0 0.0033799915
and O 0 0.0037206495
MHb O 0 0.18153922
levels O 0 0.0015648848
were O 0 0.0013315412
monitored O 0 0.0011187211
following O 0 0.001223211
exposure O 0 0.003025855
. O 0 0.0050408994

RESULTS O 0 0.0041687614
: O 0 0.0025389001
The O 0 0.00057518244
selected O 0 0.00053798174
doses O 0 0.0012559791
of O 0 0.001157504
WR242511 B-Chemical 0 0.9992017
, O 0 0.0012231453
which O 0 0.00038909775
produced O 0 0.00024374244
significant O 0 0.0006055091
methemoglobinemia B-Disease 0 0.9999877
in O 0 0.000264643
beagle O 0 0.0011072841
dogs O 0 0.0002680465
in O 0 8.958565e-05
earlier O 0 0.00011448458
studies O 0 0.0001344686
conducted O 0 0.00016509899
elsewhere O 0 0.00023114892
, O 0 0.00024504217
produced O 0 0.00011897399
very O 0 0.0002343089
little O 0 0.00030997331
MHb O 0 0.4787977
( O 0 0.00029715282
mean O 0 0.00012387394
< O 0 0.00025145852
2 O 0 0.00019549065
. O 0 0.00018889649
0 O 0 0.0003156333
% O 0 0.00056471216
) O 0 0.0007352252
in O 0 0.00039690256
the O 0 0.0004750197
rhesus O 0 0.0005791669
monkey O 0 0.0020599372
. O 0 0.003219479

Furthermore O 0 0.004019858
, O 0 0.0064799814
transient O 0 0.012242331
hemoglobinuria B-Disease 0 0.9996793
was O 0 0.0008734497
noted O 0 0.00045446446
approximately O 0 0.00034322144
60 O 0 0.00023471675
minutes O 0 0.00016912313
postinjection O 0 0.00032359097
of O 0 0.0003039449
WR242511 B-Chemical 0 0.99372804
( O 0 0.0004782854
3 O 0 0.00014862958
. O 0 0.00013081955
5 O 0 0.0001073899
or O 0 9.5533724e-05
7 O 0 9.813047e-05
. O 0 0.00011725329
0 O 0 0.00019014228
mg O 0 0.0010881699
/ O 0 0.00061977986
kg O 0 0.0005113405
) O 0 0.00047777823
, O 0 0.00031982924
and O 0 0.00019729053
2 O 0 0.00024012374
lethalities O 0 0.028811898
occurred O 0 0.00020111806
( O 0 0.00032605787
one O 0 0.0001720645
IV O 0 0.033795517
and O 0 0.00022471571
one O 0 0.0002311412
PO O 0 0.65152717
) O 0 0.00045600804
following O 0 0.000101668404
the O 0 0.00013636856
7 O 0 0.00016368962
. O 0 0.00022624662
0 O 0 0.00044421668
mg O 0 0.0023952785
/ O 0 0.0019154559
kg O 0 0.001982044
dose O 0 0.0023642336
. O 0 0.0028759402

Myoglobinuria B-Disease 0 0.99648476
was O 0 0.0027394525
also O 0 0.0013488097
observed O 0 0.0008424782
following O 0 0.00049009116
the O 0 0.00052616926
7 O 0 0.0005092716
. O 0 0.0005895141
0 O 0 0.00093433214
mg O 0 0.0037300775
/ O 0 0.0030853238
kg O 0 0.0030628708
dose O 0 0.0034684532
. O 0 0.0041352226

Histopathology O 0 0.008792372
analyses O 0 0.0019763475
in O 0 0.0009688294
the O 0 0.0005716379
2 O 0 0.00047462666
animals O 0 0.00024743448
that O 0 0.00024723454
died O 0 0.00064780243
revealed O 0 0.00024575484
liver B-Disease 0 0.03415712
and I-Disease 0 0.0003890306
kidney I-Disease 0 0.16732971
toxicity I-Disease 0 0.7605152
, O 0 0.00042175598
with O 0 0.00018690762
greater O 0 0.00026694834
severity O 0 0.0005753348
in O 0 0.00019425093
the O 0 0.0002348853
orally O 0 0.00102473
- O 0 0.002411519
treated O 0 0.0013599097
animal O 0 0.0017308661
. O 0 0.002920778

CONCLUSIONS O 0 0.019291751
: O 0 0.0039861114
These O 0 0.00092226535
data O 0 0.0008815327
demonstrate O 0 0.00035354996
direct O 0 0.00047686213
and O 0 0.000809391
/ O 0 0.0026140236
or O 0 0.00068286917
indirect O 0 0.001514061
drug O 0 0.042445503
- O 0 0.007903795
induced O 0 0.0019946215
toxicity B-Disease 0 0.83625394
. O 0 0.0052160835

It O 0 0.0055958233
is O 0 0.00188466
concluded O 0 0.0017115606
that O 0 0.0014268373
WR242511 B-Chemical 0 0.99832124
should O 0 0.00042005372
not O 0 0.00039055233
be O 0 0.00034547676
pursued O 0 0.00063529745
as O 0 0.0003116368
a O 0 0.000503019
pretreatment O 0 0.0027663352
for O 0 0.0004067989
CN O 0 0.9987361
poisoning B-Disease 2 0.99994814
unless O 0 0.000256943
the O 0 0.00014922216
anti O 0 0.0006681325
- O 0 0.021121006
CN O 0 0.8664455
characteristics O 0 0.00014599045
of O 0 0.00016702073
this O 0 0.00021881482
compound O 0 0.0021918267
can O 0 0.0001273074
be O 0 0.00014397388
successfully O 0 0.00018360067
dissociated O 0 0.00026299726
from O 0 0.00022263595
those O 0 0.00036424663
producing O 0 0.0005241826
undesirable O 0 0.0040802476
toxicity B-Disease 0 0.8251358
. O 0 0.0035341007

Repetitive O 0 0.0030955607
transcranial O 0 0.0022725794
magnetic O 0 0.0017559354
stimulation O 0 0.00068681943
for O 0 0.0010734642
levodopa B-Chemical 0 0.99997294
- O 0 0.023755196
induced O 0 0.0014257847
dyskinesias B-Disease 0 0.99995124
in O 0 0.0016910946
Parkinson B-Disease 0 0.99788684
' I-Disease 0 0.002644086
s I-Disease 0 0.0027293635
disease I-Disease 0 0.28417227
. O 0 0.004000808

In O 0 0.0021976724
a O 0 0.003082625
placebo O 0 0.020852853
- O 0 0.004529737
controlled O 0 0.00085326185
, O 0 0.00094667287
single O 0 0.00040263336
- O 0 0.002046055
blinded O 0 0.0007121158
, O 0 0.00055524707
crossover O 0 0.0010934352
study O 0 0.00027010913
, O 0 0.00027150466
we O 0 7.93447e-05
assessed O 0 0.00012441326
the O 0 0.00010120673
effect O 0 0.00011607718
of O 0 0.00019227937
" O 0 0.0002775193
real O 0 0.00011393253
" O 0 0.00018398093
repetitive O 0 8.301642e-05
transcranial O 0 0.00015690604
magnetic O 0 0.00015911918
stimulation O 0 7.234769e-05
( O 0 0.00020867266
rTMS O 0 0.0030848798
) O 0 0.00021418244
versus O 0 8.5647254e-05
" O 0 0.00016335686
sham O 0 0.00013379788
" O 0 0.000256893
rTMS O 0 0.009455104
( O 0 0.0002836296
placebo O 0 0.0014307043
) O 0 0.0002509541
on O 0 7.532114e-05
peak O 0 0.0001829551
dose O 0 0.0007455777
dyskinesias B-Disease 0 0.99995303
in O 0 0.00018198635
patients O 0 0.00045219448
with O 0 0.0004125322
Parkinson B-Disease 0 0.99807715
' I-Disease 0 0.0009877486
s I-Disease 0 0.0010330337
disease I-Disease 0 0.48918274
( O 0 0.0038895977
PD B-Disease 0 0.9981781
) O 0 0.0050297836
. O 0 0.0032407406

Ten O 0 0.0039508203
patients O 0 0.003982094
with O 0 0.002700638
PD B-Disease 0 0.99825424
and O 0 0.0015835131
prominent O 0 0.009438762
dyskinesias B-Disease 0 0.99995255
had O 0 0.00059810077
rTMS O 0 0.07396813
( O 0 0.0004941164
1 O 0 0.00023329373
, O 0 0.0002981969
800 O 0 0.00035597628
pulses O 0 0.00021377539
; O 0 0.00030099374
1 O 0 0.00016542405
Hz O 0 0.0006988136
rate O 0 0.0002056071
) O 0 0.0002487549
delivered O 0 8.249228e-05
over O 0 7.66868e-05
the O 0 9.851019e-05
motor O 0 0.00063668226
cortex O 0 0.0014518399
for O 0 6.0771417e-05
4 O 0 5.1810857e-05
consecutive O 0 4.7186513e-05
days O 0 3.3622884e-05
twice O 0 4.6070905e-05
, O 0 0.00011392493
once O 0 4.8727685e-05
real O 0 5.720772e-05
stimuli O 0 0.00011580521
and O 0 8.286638e-05
once O 0 5.0723498e-05
sham O 0 7.38466e-05
stimulation O 0 4.971316e-05
were O 0 5.892275e-05
used O 0 6.4077656e-05
; O 0 0.00015075445
evaluations O 0 7.543522e-05
were O 0 5.876703e-05
done O 0 5.5785782e-05
at O 0 4.9290804e-05
the O 0 5.8237645e-05
baseline O 0 7.633077e-05
and O 0 9.392118e-05
1 O 0 9.845928e-05
day O 0 5.540533e-05
after O 0 4.83669e-05
the O 0 7.930689e-05
end O 0 9.0935835e-05
of O 0 0.00021758715
each O 0 0.00017950023
of O 0 0.00035835427
the O 0 0.00042572807
treatment O 0 0.00076389255
series O 0 0.0017496463
. O 0 0.0026471245

Direct O 0 0.002723284
comparison O 0 0.0010129012
between O 0 0.0006477855
sham O 0 0.0007396071
and O 0 0.0004929228
real O 0 0.00038695458
rTMS O 0 0.0052695284
effects O 0 0.0002660471
showed O 0 0.0002271252
no O 0 0.0002008804
significant O 0 0.00022887824
difference O 0 0.00022601442
in O 0 0.0003331228
clinician O 0 0.001487227
- O 0 0.004110735
assessed O 0 0.001410791
dyskinesia B-Disease 0 0.9999825
severity O 0 0.010521537
. O 0 0.0032072635

However O 0 0.0026019006
, O 0 0.0027650702
comparison O 0 0.0008643025
with O 0 0.000694557
the O 0 0.0003977208
baseline O 0 0.00033041276
showed O 0 0.00028875726
small O 0 0.0004743883
but O 0 0.00032391012
significant O 0 0.00024050593
reduction O 0 0.00039558197
in O 0 0.00052863156
dyskinesia B-Disease 0 0.9999964
severity O 0 0.0009413972
following O 0 0.00012539297
real O 0 0.00023486739
rTMS O 0 0.01902689
but O 0 0.00057091913
not O 0 0.0007541246
placebo O 0 0.011350526
. O 0 0.002722567

The O 0 0.0038019684
major O 0 0.0034536712
effect O 0 0.002751406
was O 0 0.0033555063
on O 0 0.0039382963
dystonia B-Disease 0 0.99983835
subscore O 0 0.040615786
. O 0 0.007583038

Similarly O 0 0.0032042647
, O 0 0.0033201987
in O 0 0.0011731817
patient O 0 0.0009242478
diaries O 0 0.0007394735
, O 0 0.000684765
although O 0 0.00027250563
both O 0 0.00020175955
treatments O 0 0.000273032
caused O 0 0.00018587841
reduction O 0 0.0002480465
in O 0 0.0001914187
subjective O 0 0.002964301
dyskinesia B-Disease 0 0.9999957
scores O 0 0.000119809745
during O 0 5.0526723e-05
the O 0 5.069874e-05
days O 0 4.22972e-05
of O 0 8.301975e-05
intervention O 0 0.00013947852
, O 0 0.000174755
the O 0 7.5288895e-05
effect O 0 8.849065e-05
was O 0 0.000106113
sustained O 0 0.00016322375
for O 0 6.8245485e-05
3 O 0 6.748855e-05
days O 0 4.439138e-05
after O 0 4.6544832e-05
the O 0 8.76112e-05
intervention O 0 0.00017855914
for O 0 0.00015810468
the O 0 0.00026490883
real O 0 0.0005330754
rTMS O 0 0.031138029
only O 0 0.0016293585
. O 0 0.0027524761

Following O 0 0.0023347905
rTMS O 0 0.05233058
, O 0 0.0018970536
no O 0 0.0006605057
side O 0 0.0011834049
effects O 0 0.0004181566
and O 0 0.0003636112
no O 0 0.00024149031
adverse O 0 0.00063575624
effects O 0 0.00018322676
on O 0 0.00016155952
motor O 0 0.0007115232
function O 0 0.00027563813
and O 0 0.00072764046
PD B-Disease 0 0.99892575
symptoms O 0 0.009600072
were O 0 0.00084288634
noted O 0 0.0014820263
. O 0 0.0027943777

The O 0 0.0017759298
results O 0 0.0011751038
suggest O 0 0.0005952748
the O 0 0.00057659
existence O 0 0.00044433353
of O 0 0.00047731484
residual O 0 0.0004285519
beneficial O 0 0.00040963365
clinical O 0 0.00097308145
aftereffects O 0 0.0035480692
of O 0 0.00017586527
consecutive O 0 0.000119292876
daily O 0 0.00011154262
applications O 0 8.8735695e-05
of O 0 0.00014199832
low O 0 0.00029485254
- O 0 0.0011935026
frequency O 0 0.0002770746
rTMS O 0 0.045302603
on O 0 0.0005783271
dyskinesias B-Disease 0 0.9999025
in O 0 0.002151378
PD B-Disease 0 0.9980627
. O 0 0.0037791403

The O 0 0.0026637195
effects O 0 0.0023757513
may O 0 0.0017052069
be O 0 0.0012843558
further O 0 0.00093245966
exploited O 0 0.0011240483
for O 0 0.0008714507
potential O 0 0.001138373
therapeutic O 0 0.0024151467
uses O 0 0.0023398018
. O 0 0.0049318876

Intracavernous O 0 0.8239156
epinephrine B-Chemical 0 0.99910563
: O 0 0.0044123684
a O 0 0.001652085
minimally O 0 0.0010208631
invasive O 0 0.0009624687
treatment O 0 0.0006336648
for O 0 0.0007307717
priapism B-Disease 0 0.9972747
in O 0 0.0009330875
the O 0 0.0010004196
emergency O 0 0.0051663173
department O 0 0.008594102
. O 0 0.0040286034

Priapism B-Disease 0 0.98507154
is O 0 0.002028577
the O 0 0.0011812301
prolonged O 0 0.0014496585
erection O 0 0.0069779623
of O 0 0.00084664393
the O 0 0.00063585903
penis O 0 0.0033770697
in O 0 0.0005388126
the O 0 0.00046416788
absence O 0 0.0005216806
of O 0 0.0013251157
sexual O 0 0.01476518
arousal O 0 0.58683264
. O 0 0.0042281933

A O 0 0.02461772
45 O 0 0.003833851
- O 0 0.0066509973
year O 0 0.0014032673
- O 0 0.003505928
old O 0 0.0011653946
man O 0 0.0043726983
, O 0 0.0010567579
an O 0 0.0005613241
admitted O 0 0.0012643532
frequent O 0 0.0007129322
cocaine B-Chemical 0 0.9992099
user O 0 0.000346196
, O 0 0.00033644694
presented O 0 0.00013248566
to O 0 0.00011046877
the O 0 0.00012286271
Emergency O 0 0.00031391825
Department O 0 0.0002640251
( O 0 0.00035867214
ED O 0 0.0074273003
) O 0 0.00028687433
on O 0 6.476812e-05
two O 0 5.9973252e-05
separate O 0 8.20905e-05
occasions O 0 0.0001998232
with O 0 0.00018513571
a O 0 0.0003284186
history O 0 0.0005199294
of O 0 0.00058630167
priapism B-Disease 0 0.9993259
after O 0 0.00051149307
cocaine B-Chemical 0 0.99840444
use O 0 0.0015456091
. O 0 0.0025664016

The O 0 0.001868263
management O 0 0.0017777475
options O 0 0.0013871677
in O 0 0.00084214745
the O 0 0.00071707304
ED O 0 0.04495775
, O 0 0.00088635826
as O 0 0.0003378343
exemplified O 0 0.00031113627
by O 0 0.00018533492
four O 0 0.00010254685
individual O 0 0.00012061559
case O 0 0.00016870679
reports O 0 0.00019394427
, O 0 0.0002764851
in O 0 0.00012472506
particular O 0 8.199162e-05
the O 0 8.988824e-05
use O 0 0.00010145119
of O 0 0.00014900234
a O 0 0.00022474397
minimally O 0 0.00018110492
invasive O 0 0.00019847146
method O 0 0.00015514219
of O 0 0.00025053145
intracorporal O 0 0.011989109
epinephrine B-Chemical 0 0.99963677
instillation O 0 0.0013981136
, O 0 0.00093701587
are O 0 0.00061196816
discussed O 0 0.0011471222
. O 0 0.002607119

Prophylactic O 0 0.009430113
use O 0 0.0020056295
of O 0 0.0023971058
lamivudine B-Chemical 0 0.9996158
with O 0 0.00129987
chronic O 0 0.017668275
immunosuppressive O 0 0.027735328
therapy O 0 0.0011436271
for O 0 0.0009817629
rheumatologic B-Disease 0 0.9886253
disorders I-Disease 0 0.9989844
. O 0 0.0053921905

The O 0 0.0015513188
objective O 0 0.0013205983
of O 0 0.0010473852
this O 0 0.00075252587
study O 0 0.0005798087
was O 0 0.00031093255
to O 0 0.00022211604
report O 0 0.00034327313
our O 0 0.00015195417
experience O 0 0.0002571422
concerning O 0 9.240721e-05
the O 0 7.960132e-05
effectiveness O 0 7.964384e-05
of O 0 0.00010935999
the O 0 8.9698224e-05
prophylactic O 0 0.00020200382
administration O 0 0.00027558082
of O 0 0.00036362372
lamivudine B-Chemical 0 0.99998367
in O 0 0.0012691154
hepatitis B-Chemical 2 0.9999988
B I-Chemical 2 0.99975556
virus I-Chemical 0 0.06304059
surface I-Chemical 0 0.0017644337
antigen I-Chemical 0 0.010678449
( O 0 0.001855618
HBs B-Chemical 0 0.98995775
Ag I-Chemical 0 0.02913746
) O 0 0.0008708531
positive O 0 0.000375491
patients O 0 0.00096774776
with O 0 0.0010769228
rheumatologic B-Disease 0 0.99526775
disease I-Disease 0 0.9864492
. O 0 0.0036113844

From O 0 0.004993904
June O 0 0.0031426535
2004 O 0 0.0027501187
to O 0 0.0011641385
October O 0 0.0010118117
2006 O 0 0.0012701651
, O 0 0.0012702158
11 O 0 0.00093624095
HBs B-Chemical 0 0.8112419
Ag I-Chemical 0 0.0050204187
positive O 0 0.00040350444
patients O 0 0.0006277293
with O 0 0.00042644783
rheumatologic B-Disease 0 0.992831
diseases I-Disease 0 0.96034896
, O 0 0.0005166982
who O 0 0.00021444769
were O 0 8.26407e-05
on O 0 5.850216e-05
both O 0 9.4295305e-05
immunosuppressive O 0 0.001582633
and O 0 0.00017028788
prophylactic O 0 0.000599643
lamivudine B-Chemical 0 0.99980205
therapies O 0 0.0005291541
, O 0 0.0006080153
were O 0 0.00043099688
retrospectively O 0 0.0009010933
assessed O 0 0.0011243263
. O 0 0.002374642

Liver O 0 0.1903161
function O 0 0.0027527418
tests O 0 0.0066260234
, O 0 0.015062346
hepatitis B-Disease 2 0.9999844
B I-Disease 2 0.9989041
virus O 0 0.0591103
( O 0 0.0038704386
HBV O 0 0.6581276
) O 0 0.0016406648
serologic O 0 0.0009761815
markers O 0 0.00059436203
, O 0 0.0006031342
and O 0 0.00042503892
HBV O 0 0.5737578
DNA O 0 0.0020606548
levels O 0 0.0001560856
of O 0 0.00016096733
the O 0 0.00012145233
patients O 0 0.0002524169
during O 0 9.560007e-05
follow O 0 0.00011855428
- O 0 0.00074369716
up O 0 0.00021441352
were O 0 0.0001776279
obtained O 0 0.00018785706
from O 0 0.0002932635
hospital O 0 0.00062749087
file O 0 0.00054560386
records O 0 0.0019214473
. O 0 0.0026182288

Eleven O 0 0.007088543
patients O 0 0.003834718
( O 0 0.0020163427
six O 0 0.00055694394
male O 0 0.0012642966
) O 0 0.000970355
with O 0 0.000346659
median O 0 0.0002113436
age O 0 0.00039184903
47 O 0 0.00039621643
years O 0 0.00028294307
( O 0 0.00033631222
range O 0 0.00021911276
27 O 0 0.0003342958
- O 0 0.00090757955
73 O 0 0.00041837987
) O 0 0.00041117842
, O 0 0.00026181687
median O 0 0.00011956197
disease O 0 0.0027026215
duration O 0 8.817593e-05
50 O 0 0.00013156526
months O 0 5.7566605e-05
( O 0 0.00015854971
range O 0 0.00011413544
9 O 0 0.00012533535
- O 0 0.0006303291
178 O 0 0.00045203697
) O 0 0.0002612972
and O 0 0.00010428858
median O 0 7.438381e-05
follow O 0 9.099153e-05
- O 0 0.0005148676
up O 0 0.00012486619
period O 0 8.145374e-05
of O 0 0.00014519496
patients O 0 0.00029921983
13 O 0 0.00015028211
. O 0 0.00010052384
8 O 0 8.508808e-05
months O 0 5.7831545e-05
( O 0 0.00018562107
range O 0 0.00015632302
5 O 0 0.00019081606
- O 0 0.0007647645
27 O 0 0.00037624995
) O 0 0.00057848886
were O 0 0.00031983413
enrolled O 0 0.0006845532
in O 0 0.0005643966
this O 0 0.0010718784
study O 0 0.0020201728
. O 0 0.0031966406

Lamivudine B-Chemical 1 0.99810284
therapy O 0 0.0034872135
was O 0 0.0011342434
started O 0 0.0008649485
3 O 0 0.00059489574
- O 0 0.0013076912
7 O 0 0.00026134375
days O 0 0.00016737512
prior O 0 0.00015981786
to O 0 0.00029963235
immunosuppressive O 0 0.002655252
therapy O 0 0.00072264386
in O 0 0.00061735534
all O 0 0.0010191576
patients O 0 0.0029829592
. O 0 0.0033135717

Baseline O 0 0.003847029
, O 0 0.003839517
liver O 0 0.009286663
function O 0 0.0007879922
tests O 0 0.0013256257
were O 0 0.0004852155
elevated O 0 0.0009553681
in O 0 0.00026071758
two O 0 0.00017707136
patients O 0 0.00048104432
( O 0 0.0004356505
fourth O 0 0.0003471089
patient O 0 0.00037943124
: O 0 0.0009581489
ALT O 0 0.9711981
: O 0 0.00079183554
122 O 0 0.0008450827
IU O 0 0.011811411
/ O 0 0.0013703653
l O 0 0.002084712
, O 0 0.0011705814
AST O 0 0.99888736
: O 0 0.0008647499
111 O 0 0.00088700384
IU O 0 0.0140502835
/ O 0 0.001207007
l O 0 0.0013500032
, O 0 0.00048594867
tenth O 0 0.00035438617
patient O 0 0.0003742044
: O 0 0.0009257901
ALT O 0 0.9725303
: O 0 0.0007721445
294 O 0 0.001116763
IU O 0 0.017581157
/ O 0 0.0013546215
l O 0 0.0020428726
, O 0 0.0011063351
AST O 0 0.99905723
: O 0 0.0008562212
274 O 0 0.0013203832
IU O 0 0.01854364
/ O 0 0.001183602
l O 0 0.0013305373
, O 0 0.00040642757
with O 0 0.00020580477
minimal O 0 0.00018563752
changes O 0 0.00023637751
in O 0 0.00022345642
the O 0 0.0002752125
liver O 0 0.017128823
biopsy O 0 0.0006094176
in O 0 0.00047778437
both O 0 0.0008008113
) O 0 0.003106869
. O 0 0.0030005318

Shortly O 0 0.004218279
after O 0 0.0009579681
treatment O 0 0.0008672468
their O 0 0.0005651346
tests O 0 0.0008156085
normalized O 0 0.00022685445
and O 0 0.00030029638
during O 0 0.00019752167
follow O 0 0.00019238189
- O 0 0.0008111147
up O 0 0.0001910921
period O 0 0.00011487629
none O 0 0.00018033397
of O 0 0.0002225241
the O 0 0.00022281475
patients O 0 0.00062811375
had O 0 0.00042971692
abnormal B-Disease 0 0.007716051
liver I-Disease 0 0.048685793
function I-Disease 0 0.0014097809
tests O 0 0.0034901262
. O 0 0.0029775426

In O 0 0.002374939
four O 0 0.0018389313
patients O 0 0.0045230803
HBV O 0 0.36740133
DNA O 0 0.004521775
levels O 0 0.0007218846
were O 0 0.0005707257
higher O 0 0.00064039545
than O 0 0.0005956874
normal O 0 0.0011028302
at O 0 0.00085123983
baseline O 0 0.0015724635
. O 0 0.003335017

Two O 0 0.0033868079
of O 0 0.0027158982
these O 0 0.0018257918
normalized O 0 0.0010500535
and O 0 0.0015367696
the O 0 0.0014238008
others O 0 0.0031172347
increased O 0 0.0034113117
later O 0 0.003573148
. O 0 0.0059141186

In O 0 0.0019886883
three O 0 0.00113398
additional O 0 0.0012321379
patients O 0 0.0026156278
, O 0 0.002947464
HBV O 0 0.51304626
DNA O 0 0.0045109577
levels O 0 0.00062409183
were O 0 0.00053395843
increased O 0 0.0007047921
during O 0 0.00051978027
follow O 0 0.0007431651
- O 0 0.003888625
up O 0 0.002563959
. O 0 0.004007881

None O 0 0.0045830463
of O 0 0.0026002303
the O 0 0.0016174444
patients O 0 0.0022641327
had O 0 0.0010518072
significant O 0 0.0010367053
clinical O 0 0.0029759717
sings O 0 0.0036501535
of O 0 0.002292979
HBV O 0 0.51679987
activation O 0 0.003568989
. O 0 0.004789538

Lamivudine B-Chemical 1 0.9975278
was O 0 0.0025823994
well O 0 0.0016027977
tolerated O 0 0.0024448622
and O 0 0.0011992279
was O 0 0.0009961972
continued O 0 0.0010582745
in O 0 0.0012069506
all O 0 0.0016670582
patients O 0 0.0040837056
. O 0 0.004443133

Prophylactic O 0 0.010619148
administration O 0 0.0030457373
of O 0 0.0019400693
lamivudine B-Chemical 0 0.99984205
in O 0 0.00052784005
patients O 0 0.0006293662
who O 0 0.00027437095
required O 0 0.00010540806
immunosuppressive O 0 0.0028923536
therapy O 0 0.00024223812
seems O 0 9.4950476e-05
to O 0 0.00010695261
be O 0 0.00012528374
safe O 0 0.00019414983
, O 0 0.00026249344
well O 0 0.00017201366
tolerated O 0 0.00044495388
and O 0 0.0002635442
effective O 0 0.00032271142
in O 0 0.00047105766
preventing O 0 0.0009663818
HBV O 0 0.7751789
reactivation O 0 0.005842885
. O 0 0.0035408842

Effect O 0 0.0036750992
of O 0 0.0036709793
green B-Chemical 1 0.0083858995
tea I-Chemical 1 0.99809736
and O 0 0.009779476
vitamin B-Chemical 0 0.99997556
E I-Chemical 0 0.9998987
combination O 0 0.0040425714
in O 0 0.0014140111
isoproterenol B-Chemical 0 0.99987304
induced O 0 0.002400704
myocardial B-Disease 0 0.99981374
infarction I-Disease 0 0.9999722
in O 0 0.001455957
rats O 0 0.0025037297
. O 0 0.0026902808

The O 0 0.0019081951
present O 0 0.00132829
study O 0 0.0011783678
was O 0 0.0005668292
aimed O 0 0.00040410072
to O 0 0.00024490626
investigate O 0 0.00010797498
the O 0 0.00016195033
combined O 0 0.00021173467
effects O 0 0.00019713202
of O 0 0.0003442655
green B-Chemical 1 0.0015849009
tea I-Chemical 1 0.99943393
and O 0 0.00278685
vitamin B-Chemical 0 0.99999416
E I-Chemical 0 0.9999584
on O 0 0.00022694403
heart O 0 0.01749684
weight O 0 0.00026085583
, O 0 0.00021196356
body O 0 0.00020705347
weight O 0 0.00026365076
, O 0 0.0003900195
serum O 0 0.0069285156
marker O 0 0.00038283385
enzymes O 0 0.0021230024
, O 0 0.0026997123
lipid O 0 0.9970241
peroxidation O 0 0.99999774
, O 0 0.0026143317
endogenous O 0 0.00022269452
antioxidants O 0 0.99925774
and O 0 0.0004132308
membrane O 0 0.0018516119
bound O 0 0.00013932858
ATPases O 0 0.0019000218
in O 0 0.00031848528
isoproterenol B-Chemical 0 0.9998907
( O 0 0.0018803969
ISO B-Chemical 0 0.97553545
) O 0 0.0012403971
- O 0 0.002682155
induced O 0 0.0006743049
myocardial B-Disease 0 0.9997204
infarction I-Disease 0 0.9999745
in O 0 0.0012300337
rats O 0 0.0022641756
. O 0 0.002435707

Adult O 0 0.0071201883
male O 0 0.00414573
albino O 0 0.00306701
rats O 0 0.0016019326
, O 0 0.0013925968
treated O 0 0.0011618629
with O 0 0.0008568832
ISO B-Chemical 0 0.8820568
( O 0 0.0008156629
200 O 0 0.00061923225
mg O 0 0.0026764043
/ O 0 0.0009334157
kg O 0 0.0006239164
, O 0 0.00042735864
s O 0 0.00037412124
. O 0 0.00025109726
c O 0 0.0009958214
. O 0 0.00023386632
) O 0 0.00036575404
for O 0 0.000107300446
2 O 0 0.00012665524
days O 0 6.381527e-05
at O 0 7.479772e-05
an O 0 0.00011435147
interval O 0 0.00012300526
of O 0 0.00013053296
24 O 0 0.00014163039
h O 0 0.00014950786
caused O 0 0.0001339282
a O 0 0.0002142092
significant O 0 0.00017009591
( O 0 0.00035156126
P O 0 0.0057046087
< O 0 0.0002658906
0 O 0 0.0002079967
. O 0 0.00017367027
05 O 0 0.0039464748
) O 0 0.00047823772
elevation O 0 0.0011013057
of O 0 0.00019088776
heart O 0 0.0048725177
weight O 0 0.00038139403
, O 0 0.00047930016
serum O 0 0.008747564
marker O 0 0.00041110083
enzymes O 0 0.0019462327
, O 0 0.002136581
lipid O 0 0.993386
peroxidation O 0 0.9999963
and O 0 0.0015981711
Ca B-Chemical 0 0.9997758
+ O 0 0.0048331404
2 O 0 0.00022610472
ATPase O 0 0.000381665
level O 0 0.000102045364
whereas O 0 0.0001238867
there O 0 0.000103104576
was O 0 0.00013074836
a O 0 0.00019466145
significant O 0 0.00015281816
( O 0 0.00032227702
P O 0 0.006365534
< O 0 0.00024530635
0 O 0 0.00019236888
. O 0 0.00015914119
05 O 0 0.0031393182
) O 0 0.00034749156
decrease O 0 0.0001429493
in O 0 0.00011886694
body O 0 0.00024921092
weight O 0 0.0003060741
, O 0 0.0003785089
endogenous O 0 0.00023178672
antioxidants O 0 0.99734324
, O 0 0.0029936798
Na B-Chemical 0 0.9990608
+ O 0 0.009631223
/ O 0 0.023027733
K B-Chemical 0 0.9996488
+ O 0 0.019045558
ATPase O 0 0.0026123382
and O 0 0.0009953794
Mg B-Chemical 0 0.99943525
+ O 0 0.00537773
2 O 0 0.0011808589
ATPase O 0 0.0024242797
levels O 0 0.0017247283
. O 0 0.003499893

Administration O 0 0.011039065
of O 0 0.003728222
green B-Chemical 1 0.0065810494
tea I-Chemical 1 0.9940209
( O 0 0.0029232774
100 O 0 0.0016956958
mg O 0 0.0058152103
/ O 0 0.0014085572
kg O 0 0.00086344854
/ O 0 0.0009498124
day O 0 0.00020271965
, O 0 0.00039687715
p O 0 0.0004562711
. O 0 0.0002681746
o O 0 0.0010813918
. O 0 0.0003299589
) O 0 0.00080422114
and O 0 0.0006683054
vitamin B-Chemical 0 0.9999747
E I-Chemical 0 0.9999286
( O 0 0.0019182466
100 O 0 0.00070569094
mg O 0 0.0033751475
/ O 0 0.0006454416
kg O 0 0.00041427265
/ O 0 0.0005196614
day O 0 0.00010562852
, O 0 0.00023345504
p O 0 0.0002903753
. O 0 0.00016394064
o O 0 0.0007623131
. O 0 0.0001757062
) O 0 0.00027519805
together O 0 9.5120486e-05
for O 0 7.201743e-05
30 O 0 6.9385336e-05
consecutive O 0 5.6977475e-05
days O 0 4.046016e-05
and O 0 7.4378986e-05
challenged O 0 8.976977e-05
with O 0 0.00018265464
ISO B-Chemical 0 0.63739735
on O 0 7.389844e-05
the O 0 7.622588e-05
day O 0 7.342486e-05
29th O 0 0.00019858296
and O 0 0.00014262184
30th O 0 0.0002722182
, O 0 0.00029165274
showed O 0 0.0001463975
a O 0 0.0002246056
significant O 0 0.00017246744
( O 0 0.0003565902
P O 0 0.0070555992
< O 0 0.00026063307
0 O 0 0.00020087427
. O 0 0.00016489714
05 O 0 0.0032576013
) O 0 0.00036831072
decrease O 0 0.00015580398
in O 0 0.0001469729
heart O 0 0.0030816216
weight O 0 0.00036866148
, O 0 0.00048334312
serum O 0 0.008678733
marker O 0 0.00042641387
enzymes O 0 0.0020058143
, O 0 0.002254863
lipid O 0 0.99464536
peroxidation O 0 0.9999969
, O 0 0.01768157
Ca B-Chemical 0 0.99977165
+ O 0 0.005200097
2 O 0 0.00023369935
ATPase O 0 0.00040896764
and O 0 0.0001191994
a O 0 0.0001496094
significant O 0 9.877091e-05
increase O 0 9.112656e-05
in O 0 8.238207e-05
the O 0 7.59112e-05
body O 0 0.0001891443
weight O 0 0.00023360645
, O 0 0.00028824457
endogenous O 0 0.00017160214
antioxidants O 0 0.9975431
, O 0 0.0024000963
Na B-Chemical 0 0.99925405
+ O 0 0.008447424
/ O 0 0.021142296
K B-Chemical 0 0.9997789
+ O 0 0.01779482
ATPase O 0 0.0015718917
and O 0 0.00043813136
Mg B-Chemical 0 0.9997898
+ O 0 0.0025275382
2 O 0 0.00021666857
ATPase O 0 0.00030398404
when O 0 6.7747125e-05
compared O 0 8.554384e-05
with O 0 0.00019783266
ISO B-Chemical 0 0.8720686
treated O 0 0.00040362292
group O 0 0.0003180875
and O 0 0.00030098457
green B-Chemical 1 0.001254414
tea I-Chemical 1 0.9991074
or O 0 0.0018267983
vitamin B-Chemical 0 0.99998856
E I-Chemical 0 0.9999323
alone O 0 0.0026931248
treated O 0 0.0030944983
groups O 0 0.002326653
. O 0 0.0030467904

These O 0 0.0018438796
findings O 0 0.0016307257
indicate O 0 0.00064964587
the O 0 0.0006937849
synergistic O 0 0.000977439
protective O 0 0.0009298858
effect O 0 0.0004842505
of O 0 0.0008246872
green B-Chemical 1 0.0038558212
tea I-Chemical 1 0.9995135
and O 0 0.006641349
vitamin B-Chemical 0 0.9999924
E I-Chemical 0 0.999961
during O 0 0.001247167
ISO B-Chemical 0 0.99512225
induced O 0 0.0011315758
myocardial B-Disease 0 0.9997546
infarction I-Disease 0 0.9999716
in O 0 0.0012484364
rats O 0 0.0022690683
. O 0 0.0024769702

Irreversible O 0 0.32977936
damage O 0 0.032647237
to O 0 0.0016299187
the O 0 0.0013082243
medullary O 0 0.22933707
interstitium O 0 0.020681983
in O 0 0.00061021355
experimental O 0 0.0008063218
analgesic O 0 0.16665837
nephropathy B-Disease 0 0.99995315
in O 0 0.0016236302
F344 O 0 0.06790321
rats O 0 0.0032006023
. O 0 0.003212678

Renal B-Disease 0 0.9655713
papillary I-Disease 0 0.9963141
necrosis I-Disease 2 0.9999777
( O 0 0.040132225
RPN B-Disease 0 0.9990398
) O 0 0.0022853492
and O 0 0.0005017711
a O 0 0.0005706452
decreased O 0 0.00078885874
urinary O 0 0.048690844
concentrating O 0 0.0016675218
ability O 0 0.0001519594
developed O 0 0.00015682555
during O 0 7.325463e-05
continuous O 0 8.6243985e-05
long O 0 0.00012347756
- O 0 0.00049923727
term O 0 0.00012790094
treatment O 0 0.00014921336
with O 0 0.00031174708
aspirin B-Chemical 0 0.99993265
and O 0 0.0009481848
paracetamol B-Chemical 0 0.9999616
in O 0 0.000454238
female O 0 0.0011789224
Fischer O 0 0.0026395856
344 O 0 0.0058171297
rats O 0 0.0018883483
. O 0 0.002284348

Renal O 0 0.03365299
structure O 0 0.002080921
and O 0 0.0016109372
concentrating O 0 0.003420925
ability O 0 0.000547533
were O 0 0.00036448264
examined O 0 0.00020818142
after O 0 0.00013060468
a O 0 0.00024723596
recovery O 0 0.00020434085
period O 0 9.482037e-05
of O 0 0.00013766342
up O 0 0.00014039039
to O 0 8.711486e-05
18 O 0 9.371113e-05
weeks O 0 4.843785e-05
, O 0 0.00012936053
when O 0 6.060729e-05
no O 0 0.000102642734
analgesics O 0 0.003693053
were O 0 9.878165e-05
given O 0 7.1617884e-05
, O 0 0.0001706492
to O 0 7.097459e-05
investigate O 0 3.9815815e-05
whether O 0 5.356065e-05
the O 0 0.00017711916
analgesic O 0 0.020562414
- O 0 0.002068717
induced O 0 0.0003981645
changes O 0 0.0007078565
were O 0 0.0008805265
reversible O 0 0.0038183373
. O 0 0.0027149143

There O 0 0.0035101837
was O 0 0.0017048246
no O 0 0.00095309847
evidence O 0 0.0006720457
of O 0 0.00077901746
repair O 0 0.0008694639
to O 0 0.00035722458
the O 0 0.00036516783
damaged O 0 0.0038945563
medullary O 0 0.54256177
interstitial O 0 0.07833988
matrix O 0 0.0020267128
, O 0 0.00042024397
or O 0 0.00016919377
proliferation O 0 0.0030822263
of O 0 0.00019988383
remaining O 0 0.00019948036
undamaged O 0 0.0015610349
type O 0 0.00049626484
1 O 0 0.00028305664
medullary O 0 0.10725126
interstitial O 0 0.0040984303
cells O 0 0.00015046593
after O 0 6.462196e-05
the O 0 9.6685915e-05
recovery O 0 0.0001910052
period O 0 0.00013373028
following O 0 0.00021006007
analgesic O 0 0.0029570211
treatment O 0 0.0010272607
. O 0 0.0021348973

The O 0 0.0018799262
recovery O 0 0.0022131663
of O 0 0.0016379388
urinary O 0 0.06701695
concentrating O 0 0.005293141
ability O 0 0.00046202162
was O 0 0.0003206906
related O 0 0.00015169417
to O 0 0.00014018975
the O 0 0.00011315591
length O 0 0.000108447166
of O 0 0.00017848679
analgesic O 0 0.0022501769
treatment O 0 0.00015426362
and O 0 0.00014984011
the O 0 0.00012817491
extent O 0 0.00017290888
of O 0 0.00027982015
the O 0 0.00028983294
resulting O 0 0.00050817925
inner O 0 0.10828987
medullary O 0 0.6181774
structural O 0 0.0018190902
damage O 0 0.09295181
. O 0 0.0032406682

During O 0 0.0018794923
the O 0 0.0013728784
early O 0 0.0014720248
stages O 0 0.0012394988
of O 0 0.0007049214
analgesic O 0 0.009100654
treatment O 0 0.00038141824
, O 0 0.00043657632
the O 0 0.000173831
changes O 0 0.0002145759
in O 0 0.00021855898
urinary O 0 0.026582172
concentrating O 0 0.0016929809
ability O 0 0.00016349275
were O 0 0.0001718207
reversible O 0 0.00065968477
, O 0 0.00026792308
but O 0 0.000120277466
after O 0 5.294713e-05
prolonged O 0 0.00014650713
analgesic O 0 0.0012174038
treatment O 0 0.00014326519
, O 0 0.000297643
maximum O 0 0.00032670662
urinary O 0 0.037038203
concentrating O 0 0.00223173
ability O 0 0.00040234483
failed O 0 0.00067909685
to O 0 0.000822375
recover O 0 0.0016397255
. O 0 0.0027136274

This O 0 0.003901651
study O 0 0.0015594087
shows O 0 0.00043252797
that O 0 0.00042717243
prolonged O 0 0.00066139444
analgesic O 0 0.003812027
treatment O 0 0.00028490392
in O 0 0.00021693711
Fischer O 0 0.0008418442
344 O 0 0.0017767127
rats O 0 0.00031705113
causes O 0 0.0002347512
progressive O 0 0.001849526
and O 0 0.0002727843
irreversible O 0 0.0033141607
damage O 0 0.0067324275
to O 0 0.00013235184
the O 0 0.00014366794
interstitial O 0 0.008404216
matrix O 0 0.001077578
and O 0 0.0002530193
type O 0 0.0005324175
1 O 0 0.00040496225
interstitial O 0 0.0044521615
cells O 0 0.00059883855
leading O 0 0.0008647004
to O 0 0.00136503
RPN B-Disease 0 0.9973054
. O 0 0.003689898

The O 0 0.002342914
associated O 0 0.0027242866
urinary O 0 0.07987794
concentrating O 0 0.012998736
defect O 0 0.0018188979
is O 0 0.0006058413
reversible O 0 0.0016472418
only O 0 0.0003736839
during O 0 0.00020792669
the O 0 0.00021745732
early O 0 0.0004289389
stages O 0 0.00056770997
of O 0 0.00045612606
structural O 0 0.0006370413
damage O 0 0.014384133
to O 0 0.00058359106
the O 0 0.0008374889
inner O 0 0.08285707
medulla O 0 0.2713483
. O 0 0.0032292348

Testosterone B-Chemical 0 0.9997131
- O 0 0.08916207
dependent O 0 0.0021904714
hypertension B-Disease 2 0.9998839
and O 0 0.0012504017
upregulation O 0 0.00076560234
of O 0 0.0009392934
intrarenal O 0 0.98318994
angiotensinogen O 0 0.96608835
in O 0 0.0011579815
Dahl O 0 0.8365654
salt B-Chemical 0 0.9877679
- O 0 0.0078495
sensitive O 0 0.001115961
rats O 0 0.0027085799
. O 0 0.003429731

Blood O 0 0.030003322
pressure O 0 0.021579474
( O 0 0.0052229594
BP O 0 0.46265233
) O 0 0.0029042899
is O 0 0.0008216942
more O 0 0.0013220492
salt B-Chemical 0 0.70686316
sensitive O 0 0.0006533749
in O 0 0.0006557804
men O 0 0.0022946978
than O 0 0.0007251912
in O 0 0.0011409535
premenopausal O 0 0.08976767
women O 0 0.006739203
. O 0 0.0044545084

In O 0 0.0040339334
Dahl O 0 0.7883927
salt B-Chemical 0 0.98558193
- O 0 0.011373027
sensitive O 0 0.00089571706
rats O 0 0.0014770691
( O 0 0.0019111651
DS O 0 0.85444283
) O 0 0.0017642268
, O 0 0.00093039236
high O 0 0.0008198203
- O 0 0.014264894
salt B-Chemical 0 0.9805884
( O 0 0.0023842824
HS O 0 0.6403678
) O 0 0.0011750488
diet O 0 0.0020509486
increases O 0 0.000467858
BP O 0 0.5463337
more O 0 0.000631634
in O 0 0.00046611147
males O 0 0.0011342333
than O 0 0.000907397
females O 0 0.0032338735
. O 0 0.0033358557

In O 0 0.0018760095
contrast O 0 0.0020025822
to O 0 0.0010441601
the O 0 0.0009808542
systemic O 0 0.6975771
renin O 0 0.9989786
- O 0 0.52138335
angiotensin B-Chemical 0 0.9999695
system O 0 0.00070876774
, O 0 0.0006851106
which O 0 0.00026960508
is O 0 0.00015088185
suppressed O 0 0.00019891912
in O 0 0.0001611541
response O 0 0.00017129545
to O 0 0.0001955514
HS O 0 0.2853538
in O 0 0.00021479453
male O 0 0.0010402724
DS O 0 0.9827524
, O 0 0.001018616
intrarenal O 0 0.9886246
angiotensinogen O 0 0.93452734
expression O 0 0.0001809677
is O 0 0.00013421317
increased O 0 0.00024814776
, O 0 0.00035619145
and O 0 0.00026729747
intrarenal O 0 0.7792092
levels O 0 0.0003761877
of O 0 0.0009476818
ANG O 0 0.99982893
II O 0 0.4745791
are O 0 0.00066421425
not O 0 0.000843239
suppressed O 0 0.0021069287
. O 0 0.0037321332

In O 0 0.0021949594
this O 0 0.0020662725
study O 0 0.0016155236
, O 0 0.0014450393
the O 0 0.00049335684
hypothesis O 0 0.00043619133
was O 0 0.00036298865
tested O 0 0.0002628912
that O 0 0.00018297954
there O 0 0.00018605981
is O 0 0.00019876535
a O 0 0.00037755855
sexual O 0 0.0016412226
dimorphism O 0 0.0007835856
in O 0 0.00030889537
HS O 0 0.723278
- O 0 0.0020476524
induced O 0 0.00013706525
upregulation O 0 0.00017391006
of O 0 0.0002774918
intrarenal O 0 0.9939168
angiotensinogen O 0 0.9711339
mediated O 0 0.00013830196
by O 0 0.0002954975
testosterone B-Chemical 0 0.99979967
that O 0 0.00016138305
also O 0 0.00016761149
causes O 0 0.00024212914
increases O 0 0.0002806816
in O 0 0.00041210532
BP O 0 0.78671753
and O 0 0.0010951409
renal B-Disease 0 0.9968027
injury I-Disease 0 0.86689615
. O 0 0.0032762866

On O 0 0.004190259
a O 0 0.0041402555
low O 0 0.0038805816
- O 0 0.03454247
salt B-Chemical 0 0.9650684
( O 0 0.0031806007
LS O 0 0.008904825
) O 0 0.0015677154
diet O 0 0.0029281096
, O 0 0.0009962678
male O 0 0.0015739572
DS O 0 0.88542634
had O 0 0.00035097118
higher O 0 0.0003169514
levels O 0 0.00030015555
of O 0 0.00061924406
intrarenal O 0 0.98495877
angiotensinogen O 0 0.96363187
mRNA O 0 0.0013148267
than O 0 0.001068239
females O 0 0.0035545945
. O 0 0.0033125263

HS O 0 0.67560136
diet O 0 0.010398113
for O 0 0.0009968622
4 O 0 0.0005869279
wk O 0 0.00040145253
increased O 0 0.00077373686
renal O 0 0.5075794
cortical O 0 0.0034927155
angiotensinogen O 0 0.7245238
mRNA O 0 0.0004935502
and O 0 0.00032717982
protein O 0 0.00030456303
only O 0 0.00031346368
in O 0 0.00033157627
male O 0 0.0016972077
DS O 0 0.97895604
, O 0 0.0011536749
which O 0 0.00057718577
was O 0 0.0005638411
prevented O 0 0.0013923316
by O 0 0.0016481556
castration O 0 0.075534075
. O 0 0.0039582974

Ovariectomy O 0 0.867041
of O 0 0.0038525846
female O 0 0.008489127
DS O 0 0.9477732
had O 0 0.00093822955
no O 0 0.00050295336
effect O 0 0.00047320436
on O 0 0.0005663065
intrarenal O 0 0.969375
angiotensinogen O 0 0.9167446
expression O 0 0.000715868
on O 0 0.0005979799
either O 0 0.0011489901
diet O 0 0.009832753
. O 0 0.0038625193

Radiotelemetric O 0 0.023662664
BP O 0 0.30420026
was O 0 0.0017629535
similar O 0 0.0008132229
between O 0 0.00083827646
males O 0 0.0018960084
and O 0 0.0013395522
castrated O 0 0.009223019
rats O 0 0.0019989298
on O 0 0.001277949
LS O 0 0.009231277
diet O 0 0.012210771
. O 0 0.0056939623

HS O 0 0.7465231
diet O 0 0.0125263985
for O 0 0.0010828299
4 O 0 0.0006263312
wk O 0 0.00038710743
caused O 0 0.00043630652
a O 0 0.00064024556
progressive O 0 0.0016154911
increase O 0 0.0002735388
in O 0 0.00028882665
BP O 0 0.39590836
, O 0 0.0005201022
protein O 0 0.00027763785
and O 0 0.00046926318
albumin O 0 0.99846905
excretion O 0 0.94983536
, O 0 0.00076924823
and O 0 0.00056798634
glomerular B-Disease 2 0.9999485
sclerosis I-Disease 2 0.99994636
in O 0 0.00028600995
male O 0 0.000986807
DS O 0 0.92634726
rats O 0 0.00063521846
, O 0 0.0005364653
which O 0 0.00037242495
were O 0 0.00038730088
attenuated O 0 0.0008795512
by O 0 0.0012134486
castration O 0 0.035098985
. O 0 0.0034385596

Testosterone B-Chemical 0 0.9995634
replacement O 0 0.0054069
in O 0 0.0025695257
castrated O 0 0.23753384
DS O 0 0.94491315
rats O 0 0.001546128
increased O 0 0.0009972213
BP O 0 0.75112545
, O 0 0.0015787514
renal B-Disease 0 0.9949275
injury I-Disease 0 0.6318303
, O 0 0.0006195232
and O 0 0.0002687853
upregulation O 0 0.00030359736
of O 0 0.0005199123
renal O 0 0.9562618
angiotensinogen O 0 0.9503728
associated O 0 0.0009751581
with O 0 0.0012712501
HS O 0 0.78193617
diet O 0 0.03798878
. O 0 0.003606383

Testosterone B-Chemical 0 0.9995796
contributes O 0 0.0018516328
to O 0 0.0010173911
the O 0 0.0006317158
development O 0 0.0007165416
of O 0 0.00087548065
hypertension B-Disease 2 0.99997973
and O 0 0.0013266148
renal B-Disease 0 0.9990381
injury I-Disease 0 0.72843903
in O 0 0.00025308176
male O 0 0.00077190757
DS O 0 0.83575827
rats O 0 0.0003441956
on O 0 0.00013986528
HS O 0 0.2634187
diet O 0 0.0022784125
possibly O 0 0.00021894986
through O 0 0.0001305382
upregulation O 0 0.00019372822
of O 0 0.00026890452
the O 0 0.00037543284
intrarenal O 0 0.9966007
renin O 0 0.99935704
- O 0 0.4190608
angiotensin B-Chemical 0 0.99990666
system O 0 0.0033465943
. O 0 0.0033745046

Explicit O 0 0.012442689
episodic O 0 0.85017955
memory O 0 0.0944601
for O 0 0.0008522904
sensory O 0 0.0013317855
- O 0 0.0017390553
discriminative O 0 0.00049415766
components O 0 0.00029008425
of O 0 0.0005502137
capsaicin B-Chemical 0 0.998466
- O 0 0.005411515
induced O 0 0.00043220154
pain B-Disease 0 0.037791777
: O 0 0.0008566411
immediate O 0 0.0006194406
and O 0 0.0006602935
delayed O 0 0.0021983488
ratings O 0 0.0027359712
. O 0 0.002983616

Pain B-Disease 0 0.22472046
memory O 0 0.1620951
is O 0 0.0014264467
thought O 0 0.00091733533
to O 0 0.0004943218
affect O 0 0.00033767987
future O 0 0.00039354857
pain B-Disease 0 0.0052820104
sensitivity O 0 0.00050934317
and O 0 0.00034630095
thus O 0 0.00032488402
contribute O 0 0.00033330638
to O 0 0.00042274714
clinical O 0 0.0019617567
pain B-Disease 0 0.0139488345
conditions O 0 0.001601312
. O 0 0.0029730587

Systematic O 0 0.006441584
investigations O 0 0.0023652148
of O 0 0.0014678108
the O 0 0.00089825166
human O 0 0.00084230996
capacity O 0 0.0011190263
to O 0 0.00052659854
remember O 0 0.0013811627
sensory O 0 0.0008242559
features O 0 0.00052266027
of O 0 0.0005349686
experimental O 0 0.00083574856
pain B-Disease 0 0.01873944
are O 0 0.0009941113
sparse O 0 0.0021413309
. O 0 0.0033781982

In O 0 0.0017411932
order O 0 0.0010051983
to O 0 0.000661811
address O 0 0.00030443326
long O 0 0.0005854906
- O 0 0.0017813762
term O 0 0.00046040726
pain B-Disease 0 0.02013751
memory O 0 0.061343156
, O 0 0.00050049135
nine O 0 0.00016822794
healthy O 0 0.00048312917
male O 0 0.00029218732
volunteers O 0 0.00024897367
received O 0 8.914754e-05
intradermal O 0 0.00012626672
injections O 0 6.2307365e-05
of O 0 6.142116e-05
three O 0 3.8677957e-05
doses O 0 0.00021670021
of O 0 0.00022877546
capsaicin B-Chemical 0 0.99748456
( O 0 0.0004628102
0 O 0 0.00022737567
. O 0 0.00016638332
05 O 0 0.004972875
, O 0 0.00026808126
1 O 0 0.00013778437
and O 0 0.00011598026
20 O 0 0.00012858132
microg O 0 0.00024883862
, O 0 0.00024697208
separated O 0 0.00016668282
by O 0 0.00010936926
15 O 0 0.00011200199
min O 0 0.0001805012
breaks O 0 0.0002680401
) O 0 0.00031885138
, O 0 0.00017477667
each O 0 5.5820794e-05
given O 0 4.6076e-05
three O 0 3.5944082e-05
times O 0 5.641524e-05
in O 0 9.903792e-05
a O 0 0.00017856085
balanced O 0 0.00022524125
design O 0 0.00020537157
across O 0 0.00011830246
three O 0 7.103891e-05
sessions O 0 0.00015287369
at O 0 0.00016263773
one O 0 0.00026664615
week O 0 0.00034141899
intervals O 0 0.0007971218
. O 0 0.0020425345

Pain B-Disease 0 0.02256725
rating O 0 0.001867134
was O 0 0.0008527828
performed O 0 0.0005140412
using O 0 0.0003605563
a O 0 0.00047217763
computerized O 0 0.0007074494
visual O 0 0.0017952379
analogue O 0 0.0006261186
scale O 0 0.00037551337
( O 0 0.00042666314
0 O 0 0.00032908586
- O 0 0.0009795121
100 O 0 0.0003690495
) O 0 0.0003591409
digitized O 0 0.00033287072
at O 0 0.00012572149
1 O 0 0.00018796671
/ O 0 0.000531664
s O 0 0.00025660955
, O 0 0.00025818162
either O 0 0.00012486083
immediately O 0 9.164916e-05
online O 0 0.00013924835
or O 0 0.000118863994
one O 0 0.00013205897
hour O 0 0.00018496311
or O 0 0.00016623647
one O 0 0.00021047647
day O 0 0.00023840643
after O 0 0.0003359062
injection O 0 0.00086640526
. O 0 0.0022155137

Subjects O 0 0.0061765066
also O 0 0.003155713
recalled O 0 0.0049358746
their O 0 0.002572841
pains B-Disease 0 0.046646297
one O 0 0.0022571622
week O 0 0.0019014006
later O 0 0.0033476967
. O 0 0.0063717496

Capsaicin B-Chemical 0 0.99837697
injection O 0 0.0019372081
reliably O 0 0.0009618981
induced O 0 0.0006999049
a O 0 0.00091363426
dose O 0 0.0011797352
- O 0 0.0023009598
dependent O 0 0.00031225957
flare O 0 0.014704021
( O 0 0.00047272918
p O 0 0.00038466393
< O 0 0.0003445696
0 O 0 0.00030107182
. O 0 0.00026457667
001 O 0 0.0028199647
) O 0 0.00064332585
without O 0 0.00027213074
any O 0 0.00022987681
difference O 0 0.00023796517
within O 0 0.00021382557
or O 0 0.00042091796
across O 0 0.00072329934
sessions O 0 0.0013331034
. O 0 0.0025307296

The O 0 0.0027552797
strong O 0 0.0028675867
burning O 0 0.019672848
pain B-Disease 0 0.23588255
decayed O 0 0.006915866
exponentially O 0 0.0015357732
within O 0 0.00074203074
a O 0 0.0015838781
few O 0 0.0011518114
minutes O 0 0.0021833656
. O 0 0.0041597704

Subjects O 0 0.004000417
were O 0 0.0013890219
able O 0 0.0007202468
to O 0 0.00051900255
reliably O 0 0.00039091086
discriminate O 0 0.0002716442
pain B-Disease 0 0.002913401
magnitude O 0 0.00019908953
and O 0 0.00016375487
duration O 0 0.00010720022
across O 0 0.0001810184
capsaicin B-Chemical 0 0.955561
doses O 0 0.0004308987
( O 0 0.00022169163
both O 0 9.191086e-05
p O 0 0.00020453909
< O 0 0.0001995011
0 O 0 0.00018080883
. O 0 0.00015680194
001 O 0 0.0023073128
) O 0 0.00044018117
, O 0 0.00022457328
regardless O 0 6.610495e-05
of O 0 9.9196994e-05
whether O 0 4.158924e-05
first O 0 8.233259e-05
- O 0 0.00051501626
time O 0 7.305567e-05
ratings O 0 0.00018423812
were O 0 0.00010044698
requested O 0 0.00012418035
immediately O 0 9.0552836e-05
, O 0 0.00021299902
after O 0 8.545856e-05
one O 0 0.00015128496
hour O 0 0.0002308102
or O 0 0.00022846267
after O 0 0.00024123164
one O 0 0.0005510201
day O 0 0.0008780131
. O 0 0.0025125796

Pain B-Disease 0 0.03268689
recall O 0 0.0035772894
after O 0 0.0006714246
one O 0 0.00056940597
week O 0 0.0003695773
was O 0 0.00035097238
similarly O 0 0.00028729008
precise O 0 0.00025788712
( O 0 0.00052245357
magnitude O 0 0.00029775288
: O 0 0.00052750355
p O 0 0.00044855647
< O 0 0.00041594947
0 O 0 0.00035885084
. O 0 0.00030319215
01 O 0 0.0011348779
, O 0 0.0004956038
duration O 0 0.00025036428
: O 0 0.00069096143
p O 0 0.0007535463
< O 0 0.0009039229
0 O 0 0.0010167679
. O 0 0.0012636363
05 O 0 0.013206773
) O 0 0.005520435
. O 0 0.004979098

Correlation O 0 0.0017391589
with O 0 0.0012792891
rating O 0 0.0009791809
recall O 0 0.001154444
after O 0 0.00023366725
one O 0 0.0002195779
week O 0 0.00014432604
was O 0 0.00013771883
best O 0 0.00012910459
when O 0 0.00010243749
first O 0 0.00011021309
- O 0 0.0005512778
time O 0 8.856375e-05
ratings O 0 0.0002019807
were O 0 0.00010760947
requested O 0 0.00012955915
as O 0 0.00012226804
late O 0 0.0003102027
as O 0 0.00012407644
one O 0 8.996259e-05
day O 0 6.756466e-05
after O 0 5.8474598e-05
injection O 0 0.00012145082
( O 0 0.0004194445
R O 0 0.91044235
( O 0 0.00046870654
2 O 0 0.00019453675
) O 0 0.00034587504
= O 0 0.00040935105
0 O 0 0.00019410838
. O 0 0.00013541215
79 O 0 0.00022689642
) O 0 0.00028778324
indicating O 0 9.634209e-05
that O 0 0.0001043034
both O 0 0.00014617629
rating O 0 0.0002546024
retrievals O 0 0.00037072305
utilized O 0 0.00025039318
similar O 0 0.00039283003
memory O 0 0.035539735
traces O 0 0.0030439051
. O 0 0.0034034727

These O 0 0.0018674823
results O 0 0.0012839057
indicate O 0 0.0006720856
a O 0 0.001079029
reliable O 0 0.00062072277
memory O 0 0.008888944
for O 0 0.00039221882
magnitude O 0 0.00039345308
and O 0 0.00038821594
duration O 0 0.00028879804
of O 0 0.00052455533
experimentally O 0 0.0006743239
induced O 0 0.0014429663
pain B-Disease 0 0.1447561
. O 0 0.003918317

The O 0 0.0021015191
data O 0 0.0017209764
further O 0 0.0007652708
suggest O 0 0.0004254307
that O 0 0.00040925058
the O 0 0.00039645293
consolidation O 0 0.0025765796
of O 0 0.00036932845
this O 0 0.000348805
memory O 0 0.0675987
is O 0 0.00022526659
an O 0 0.00022113517
important O 0 0.00014359766
interim O 0 0.0004420046
stage O 0 0.0009626344
, O 0 0.00058058405
and O 0 0.00032188182
may O 0 0.0002500735
take O 0 0.00027493053
up O 0 0.00045531418
to O 0 0.00045165129
one O 0 0.0006875985
day O 0 0.00097604626
. O 0 0.0026558342

Severe O 0 0.025632104
and O 0 0.0019373529
long O 0 0.0011990063
lasting O 0 0.0012755442
cholestasis B-Disease 0 0.9998117
after O 0 0.00032879325
high O 0 0.00053491455
- O 0 0.0023723927
dose O 0 0.0008010666
co B-Chemical 0 0.1690707
- I-Chemical 0 0.012617438
trimoxazole I-Chemical 0 0.038946163
treatment O 0 0.00024126386
for O 0 0.00020423662
Pneumocystis B-Disease 0 0.29818782
pneumonia I-Disease 0 0.9996333
in O 0 0.00037687688
HIV B-Disease 0 0.57661486
- I-Disease 0 0.0036450513
infected I-Disease 0 0.0003944075
patients O 0 0.0008685506
- O 0 0.0031410095
- O 0 0.0019052594
a O 0 0.00056183717
report O 0 0.00074243953
of O 0 0.0006692532
two O 0 0.0007130889
cases O 0 0.0027512931
. O 0 0.0032255154

Pneumocystis B-Disease 0 0.8279325
pneumonia I-Disease 0 0.9989743
( O 0 0.012119999
PCP B-Disease 0 0.9974433
) O 0 0.0034890946
, O 0 0.0012380596
a O 0 0.0007224022
common O 0 0.0004907926
opportunistic B-Disease 0 0.001320135
infection I-Disease 0 0.0030006918
in O 0 0.00045393148
HIV B-Disease 0 0.7235149
- I-Disease 0 0.007361671
infected I-Disease 0 0.0003717506
individuals O 0 0.00044747302
, O 0 0.0003447516
is O 0 0.00013255164
generally O 0 0.00018110784
treated O 0 0.00032140498
with O 0 0.00023436677
high O 0 0.00038791468
doses O 0 0.0009955894
of O 0 0.0009119848
co B-Chemical 0 0.5982897
- I-Chemical 0 0.08212435
trimoxazole I-Chemical 0 0.38711694
. O 0 0.0038577851

However O 0 0.004227673
, O 0 0.005294873
treatment O 0 0.002391467
is O 0 0.0015405172
often O 0 0.0017469282
limited O 0 0.0015082239
by O 0 0.0017724176
adverse O 0 0.004695209
effects O 0 0.0030703302
. O 0 0.0056680073

Here O 0 0.0037653777
, O 0 0.0035541465
we O 0 0.00092035264
report O 0 0.0014158328
two O 0 0.0005095517
cases O 0 0.0010010459
of O 0 0.0006946731
severely O 0 0.024394125
immunocompromised O 0 0.5360505
HIV B-Disease 0 0.7912608
- I-Disease 0 0.0049477583
infected I-Disease 0 0.00031708283
patients O 0 0.00038793002
who O 0 0.00022235421
developed O 0 0.00021576419
severe O 0 0.0058352146
intrahepatic B-Disease 0 0.9998723
cholestasis I-Disease 0 0.99999964
, O 0 0.0018353732
and O 0 0.00017429056
in O 0 0.00010648907
one O 0 9.350708e-05
patient O 0 0.00016280268
lesions O 0 0.0015066456
mimicking O 0 0.00024291026
liver B-Disease 0 0.21178405
abscess I-Disease 0 0.62676454
formation O 0 0.0001866896
on O 0 6.55256e-05
radiologic O 0 0.00037470632
exams O 0 0.00023368109
, O 0 0.00030300807
during O 0 0.00021167858
co B-Chemical 0 0.15318854
- I-Chemical 0 0.019271135
trimoxazole I-Chemical 0 0.1016099
treatment O 0 0.00081014715
for O 0 0.0010835006
PCP B-Disease 0 0.99100703
. O 0 0.003957132

Whereas O 0 0.0030902252
patient O 0 0.0024529067
1 O 0 0.0013723896
showed O 0 0.0008052821
lesions O 0 0.0027421908
of O 0 0.0005339574
up O 0 0.0004181869
to O 0 0.00023985235
1 O 0 0.0002661011
cm O 0 0.0005874262
readily O 0 0.00012706885
detectable O 0 8.296008e-05
on O 0 6.9833135e-05
magnetic O 0 0.00023806976
resonance O 0 0.00038158207
imaging O 0 0.00014739239
under O 0 0.00010386571
prolonged O 0 0.0002507666
co B-Chemical 0 0.06871263
- I-Chemical 0 0.0071956953
trimoxazole I-Chemical 0 0.027755229
treatment O 0 0.00021519177
, O 0 0.0003342279
therapy O 0 0.00028011433
of O 0 0.00025476195
patient O 0 0.00038076704
2 O 0 0.0004075611
was O 0 0.00046746928
switched O 0 0.0011964389
early O 0 0.002287677
. O 0 0.0030012366

Bradykinin B-Chemical 0 0.99976355
receptors O 0 0.067764156
antagonists O 0 0.7763702
and O 0 0.0072527523
nitric B-Chemical 0 0.9996729
oxide I-Chemical 0 0.99811965
synthase O 0 0.21693036
inhibitors O 0 0.0013138615
in O 0 0.00064138457
vincristine B-Chemical 1 0.9999796
and O 0 0.00063482113
streptozotocin B-Chemical 0 0.9999473
induced O 0 0.00038241496
hyperalgesia B-Disease 0 0.4227232
in O 0 0.00024412177
chemotherapy O 0 0.0022776015
and O 0 0.0005689768
diabetic B-Disease 2 0.9999721
neuropathy I-Disease 0 0.99998796
rat O 0 0.0026351465
model O 0 0.0013773338
. O 0 0.0025332922

PURPOSE O 0 0.0076381746
: O 0 0.0034706476
The O 0 0.0006851468
influence O 0 0.00054527295
of O 0 0.00083349907
an O 0 0.0009414447
irreversible O 0 0.0057877237
inhibitor O 0 0.0019422375
of O 0 0.00071020005
constitutive O 0 0.00092315604
NO B-Chemical 0 0.9996076
synthase O 0 0.4585803
( O 0 0.0029372775
L O 0 0.9740778
- O 0 0.07369204
NOArg O 0 0.030767087
; O 0 0.0005106815
1 O 0 0.00018071232
. O 0 0.00012596727
0 O 0 0.00017884608
mg O 0 0.0009425041
/ O 0 0.0005205011
kg O 0 0.00047274466
ip O 0 0.002330701
) O 0 0.00041007026
, O 0 0.00026752616
a O 0 0.00022241891
relatively O 0 0.00024377428
selective O 0 0.00032754868
inhibitor O 0 0.0009572721
of O 0 0.00044453033
inducible O 0 0.002751139
NO B-Chemical 0 0.99985003
synthase O 0 0.6009725
( O 0 0.0028745926
L O 0 0.97764117
- O 0 0.065222986
NIL O 0 0.13267882
; O 0 0.000495458
1 O 0 0.00015806351
. O 0 0.00010894417
0 O 0 0.00015778012
mg O 0 0.000900911
/ O 0 0.00047577967
kg O 0 0.00042665418
ip O 0 0.0020384167
) O 0 0.00031525985
and O 0 0.0001289182
a O 0 0.00019196521
relatively O 0 0.00020054357
specific O 0 0.00010973122
inhibitor O 0 0.00079822325
of O 0 0.0004928523
neuronal O 0 0.02134896
NO B-Chemical 0 0.9998054
synthase O 0 0.27473357
( O 0 0.00068007933
7 O 0 0.00018015712
- O 0 0.0016255435
NI O 0 0.030860977
; O 0 0.000332115
0 O 0 0.00016752168
. O 0 0.00010925168
1 O 0 0.00013289662
mg O 0 0.000820817
/ O 0 0.0004518052
kg O 0 0.00040142133
ip O 0 0.001869227
) O 0 0.00030629974
, O 0 0.0001751709
on O 0 7.204711e-05
antihyperalgesic O 0 0.003314829
action O 0 0.00012991992
of O 0 0.00015239703
selective O 0 0.00031485854
antagonists O 0 0.0455354
of O 0 0.00060509366
B2 O 0 0.9961792
and O 0 0.0008179995
B1 O 0 0.9931137
receptors O 0 0.002816727
: O 0 0.0020767753
D O 0 0.98442924
- O 0 0.074074544
Arg O 0 0.0429101
- O 0 0.012206827
[ O 0 0.0033163477
Hyp3 O 0 0.17249088
, O 0 0.00082356617
Thi5 O 0 0.3460743
, O 0 0.0009228719
D O 0 0.8746271
- O 0 0.0042616003
Tic7 O 0 0.0004796439
, O 0 0.0008791328
Oic8 O 0 0.9777043
] O 0 0.04157149
bradykinin B-Chemical 0 0.99993074
( O 0 0.0020174964
HOE B-Chemical 0 0.99937254
140 I-Chemical 0 0.0006317067
; O 0 0.00034595004
70 O 0 0.00019680317
nmol O 0 0.0029214418
/ O 0 0.0007547414
kg O 0 0.0005413306
ip O 0 0.002306975
) O 0 0.0003467286
or O 0 0.0001416898
des B-Chemical 0 0.00047166666
Arg10 I-Chemical 0 0.061980154
HOE I-Chemical 0 0.99946815
140 I-Chemical 0 0.00062511704
( O 0 0.00029667013
70 O 0 0.00018693651
nmol O 0 0.002607403
/ O 0 0.0006909496
kg O 0 0.0004977773
ip O 0 0.002238785
) O 0 0.00034644906
respectively O 0 0.00024530213
, O 0 0.00021167837
in O 0 0.0001026442
model O 0 0.000115073315
of O 0 0.0002744319
diabetic B-Disease 2 0.9998348
( I-Disease 0 0.0025441635
streptozotocin I-Disease 0 0.9999776
- I-Disease 0 0.010325559
induced I-Disease 0 0.0002042635
) I-Disease 0 0.00056186685
and I-Disease 0 0.00027054315
toxic I-Disease 0 0.025189968
( I-Disease 0 0.0018442713
vincristine I-Disease 1 0.9999795
- I-Disease 0 0.011980657
induced I-Disease 0 0.0005374072
) I-Disease 0 0.0037458886
neuropathy I-Disease 0 0.9997733
was O 0 0.0011178028
investigated O 0 0.0014792454
. O 0 0.0029084643

METHODS O 0 0.0037634613
: O 0 0.002437595
The O 0 0.0005816403
changes O 0 0.0006252817
in O 0 0.0005074999
pain B-Disease 0 0.0026144276
thresholds O 0 0.0003123206
were O 0 0.00019580236
determined O 0 0.00013665181
using O 0 0.00012135891
mechanical O 0 0.00020352939
stimuli O 0 0.0003538376
- O 0 0.002081525
- O 0 0.0010133561
the O 0 0.00013119045
modification O 0 0.0001421708
of O 0 0.00019062441
the O 0 0.00019008662
classic O 0 0.0014946987
paw O 0 0.004097539
withdrawal O 0 0.0013438866
test O 0 0.0004117415
described O 0 0.00032099616
by O 0 0.0005569739
Randall O 0 0.002540161
- O 0 0.010140606
Selitto O 0 0.18924043
. O 0 0.0039910045

RESULTS O 0 0.004308948
: O 0 0.0026738604
The O 0 0.0006009005
results O 0 0.000549148
of O 0 0.0005992316
this O 0 0.0004901801
paper O 0 0.00048185405
confirm O 0 0.00013215319
that O 0 0.00020137573
inhibition O 0 0.0004955499
of O 0 0.0009780956
bradykinin B-Chemical 0 0.99996984
receptors O 0 0.0059401006
and O 0 0.00057067187
inducible O 0 0.0030863273
NO B-Chemical 0 0.9998864
synthase O 0 0.70787454
but O 0 0.0007781312
not O 0 0.00043199107
neuronal O 0 0.011839535
NO B-Chemical 0 0.9996631
synthase O 0 0.19623984
activity O 0 0.000496086
reduces O 0 0.0011371629
diabetic B-Disease 2 0.99996865
hyperalgesia I-Disease 0 0.9992887
. O 0 0.0042374106

Pretreatment O 0 0.037652113
with O 0 0.00549947
L O 0 0.9417773
- O 0 0.098689444
NOArg O 0 0.055824067
and O 0 0.0017593981
L O 0 0.93185043
- O 0 0.07586795
NIL O 0 0.15317756
but O 0 0.00059584074
not O 0 0.00030810712
7 O 0 0.00030236773
- O 0 0.0024502
NI O 0 0.04641841
, O 0 0.00044665372
significantly O 0 0.00024053805
increases O 0 0.00022340528
antihyperalgesic O 0 0.024169916
activity O 0 0.00017947098
both O 0 0.00031686106
HOE B-Chemical 0 0.99859077
140 I-Chemical 0 0.001084727
and O 0 0.00057785626
des B-Chemical 0 0.0018556822
Arg10 I-Chemical 0 0.18855022
HOE I-Chemical 0 0.9990711
140 I-Chemical 0 0.006242768
. O 0 0.003619986

It O 0 0.0048823236
was O 0 0.0016479887
also O 0 0.00090400997
shown O 0 0.00038571082
that O 0 0.00034654053
both O 0 0.0003512875
products O 0 0.00046168658
of O 0 0.0005665543
inducible O 0 0.002232709
NO B-Chemical 0 0.99972636
synthase O 0 0.5149631
and O 0 0.00096845144
neuronal O 0 0.013821096
NO B-Chemical 0 0.9996468
synthase O 0 0.07640741
activation O 0 0.00023322632
as O 0 0.00017068422
well O 0 0.00018788392
as O 0 0.00035852258
bradykinin B-Chemical 0 0.99986815
are O 0 0.00022933084
involved O 0 0.00021190515
in O 0 0.00035004463
hyperalgesia B-Disease 0 0.18057342
produced O 0 0.00059873407
by O 0 0.0015112206
vincristine B-Chemical 1 0.99982977
. O 0 0.004355125

Moreover O 0 0.0053940117
, O 0 0.009520178
L O 0 0.92147326
- O 0 0.081623994
NOArg O 0 0.026351461
and O 0 0.001113454
7 O 0 0.0007847805
- O 0 0.0044916305
NI O 0 0.05247342
but O 0 0.0006116979
not O 0 0.0004978293
L O 0 0.8855022
- O 0 0.05167287
NIL O 0 0.124771744
intensify O 0 0.000557753
antihyperalgesic O 0 0.034878172
activity O 0 0.00017551547
of O 0 0.00037978875
HOE B-Chemical 0 0.9990907
140 I-Chemical 0 0.00071003265
or O 0 0.00024306733
des B-Chemical 0 0.00065824593
- I-Chemical 0 0.0014958198
Arg10HOE I-Chemical 0 0.00062028953
140 I-Chemical 0 0.0009286614
in O 0 0.0010365818
toxic B-Disease 0 0.9234362
neuropathy I-Disease 0 0.99994624
. O 0 0.0062394077

CONCLUSIONS O 0 0.015510608
: O 0 0.0033741437
Results O 0 0.00094922434
of O 0 0.0007489741
these O 0 0.00052519573
studies O 0 0.00052640354
suggest O 0 0.0002687956
that O 0 0.00045370092
B1 O 0 0.9793291
and O 0 0.0015121519
B2 O 0 0.99519086
receptors O 0 0.0016862522
are O 0 0.00020523768
engaged O 0 0.00029354045
in O 0 0.00017422772
transmission O 0 0.00013833925
of O 0 0.0001634862
nociceptive O 0 0.00023258568
stimuli O 0 0.000244977
in O 0 0.00023098876
both O 0 0.0004262747
diabetic B-Disease 2 0.99954873
and I-Disease 0 0.0022955297
toxic I-Disease 0 0.9913635
neuropathy I-Disease 0 0.99997246
. O 0 0.005659167

In O 0 0.003367382
streptozotocin B-Chemical 0 0.9996778
- O 0 0.04349193
induced O 0 0.0014606444
hyperalgesia B-Disease 0 0.8669633
, O 0 0.0024210934
inducible O 0 0.0027459997
NO B-Chemical 0 0.9996244
synthase O 0 0.14454408
participates O 0 0.00022396108
in O 0 0.00018726564
pronociceptive O 0 0.00053064915
activity O 0 0.00011555812
of O 0 0.00032486484
bradykinin B-Chemical 0 0.9999268
, O 0 0.0006006483
whereas O 0 0.0002019576
in O 0 0.00033182072
vincristine B-Chemical 1 0.99999094
- O 0 0.03546918
induced O 0 0.00037238165
hyperalgesia B-Disease 0 0.9946802
bradykinin B-Chemical 0 0.99995697
seemed O 0 0.00043568708
to O 0 0.00024932405
activate O 0 0.0002504247
neuronal O 0 0.005781938
NO B-Chemical 0 0.9991405
synthase O 0 0.25023183
pathway O 0 0.0018281762
. O 0 0.0032262623

Therefore O 0 0.0018757881
, O 0 0.002973381
concomitant O 0 0.0019733682
administration O 0 0.0012399417
of O 0 0.00056506775
small O 0 0.00070897915
doses O 0 0.0015296872
of O 0 0.0010918322
bradykinin B-Chemical 0 0.9999703
receptor O 0 0.053158257
antagonists O 0 0.6727644
and O 0 0.0021485148
NO B-Chemical 0 0.9998901
synthase O 0 0.47623587
inhibitors O 0 0.0008444083
can O 0 0.00010989899
be O 0 0.00010403788
effective O 0 9.839433e-05
in O 0 0.00011611803
alleviation O 0 0.0005256833
of O 0 0.0003883968
neuropathic B-Disease 0 0.9996716
pain I-Disease 0 0.950822
, O 0 0.00072531495
even O 0 0.00047943223
in O 0 0.00054232887
hospital O 0 0.0011887159
care O 0 0.0016102891
. O 0 0.0024995534

Confusion B-Disease 0 0.79753447
, O 0 0.004825832
a O 0 0.0020950127
rather O 0 0.0010753359
serious O 0 0.0024105336
adverse O 0 0.024103235
drug O 0 0.030059645
reaction O 0 0.0011785631
with O 0 0.0025363064
valproic B-Chemical 0 0.99999714
acid I-Chemical 0 0.9895225
: O 0 0.0025385113
a O 0 0.00061846967
review O 0 0.0005865588
of O 0 0.0004074929
the O 0 0.00048510128
French O 0 0.0018376872
Pharmacovigilance O 0 0.0048264023
database O 0 0.0015231784
. O 0 0.0025466862

INTRODUCTION O 0 0.0258321
: O 0 0.009087209
Confusion B-Disease 0 0.26492828
is O 0 0.0011927946
an O 0 0.0011597904
adverse O 0 0.0069216257
drug O 0 0.008465288
reaction O 0 0.001012492
frequently O 0 0.00076936156
observed O 0 0.0008888392
with O 0 0.004069067
valproic B-Chemical 0 0.9999862
acid I-Chemical 0 0.9959908
. O 0 0.009131616

Some O 0 0.0034439988
case O 0 0.0019878678
reports O 0 0.0013248206
are O 0 0.000653585
published O 0 0.0005212814
in O 0 0.0003973004
the O 0 0.00033109772
literature O 0 0.0006664292
but O 0 0.00034036636
no O 0 0.00023024908
systematic O 0 0.00034665523
study O 0 0.00029123094
from O 0 0.00021962037
a O 0 0.0004001134
sample O 0 0.00044211224
of O 0 0.00044458947
patients O 0 0.0009467883
has O 0 0.00041699846
been O 0 0.00080523646
published O 0 0.0014165996
. O 0 0.0028709562

We O 0 0.0024599265
performed O 0 0.0015648536
this O 0 0.0012422545
study O 0 0.0009198609
in O 0 0.0004979522
order O 0 0.00029194172
to O 0 0.00027684568
describe O 0 0.00027126115
the O 0 0.00023298897
main O 0 0.0002987321
characteristics O 0 0.00027277338
of O 0 0.00042348955
this O 0 0.0006672365
adverse O 0 0.014897642
drug O 0 0.01296819
reaction O 0 0.0024076
. O 0 0.002978756

METHODS O 0 0.0039336076
: O 0 0.0024415695
Using O 0 0.0006380462
the O 0 0.0007458054
French O 0 0.0016107438
Pharmacovigilance O 0 0.0025005282
database O 0 0.00045508007
, O 0 0.00049637957
we O 0 0.00015559496
selected O 0 0.00020166954
the O 0 0.00023075234
cases O 0 0.00052422495
of O 0 0.0004879469
confusion B-Disease 0 0.3047488
reported O 0 0.0005510132
since O 0 0.00039384185
1985 O 0 0.0029874241
with O 0 0.0039916486
valproic B-Chemical 0 0.9999895
acid I-Chemical 0 0.9964418
. O 0 0.008386059

RESULTS O 0 0.005621896
: O 0 0.0046107364
272 O 0 0.004591627
cases O 0 0.0020443741
of O 0 0.0013470401
confusion B-Disease 0 0.10622087
were O 0 0.0008343029
reported O 0 0.0009619911
with O 0 0.0024553905
valproic B-Chemical 0 0.9999949
acid I-Chemical 0 0.990564
: O 0 0.004639407
153 O 0 0.0021237594
women O 0 0.0017457753
and O 0 0.0009795817
119 O 0 0.0026310408
men O 0 0.005668271
. O 0 0.0038643435

Confusion B-Disease 0 0.74110675
mostly O 0 0.0025419595
occurred O 0 0.0011151104
during O 0 0.0005118725
the O 0 0.00036341677
two O 0 0.00022289548
first O 0 0.00020179476
weeks O 0 0.0002333053
following O 0 0.0005147823
valproic B-Chemical 0 0.9999888
acid I-Chemical 0 0.9341743
exposure O 0 0.0011581867
( O 0 0.0010450418
39 O 0 0.00072682335
. O 0 0.0005428202
7 O 0 0.0006335488
% O 0 0.0018614251
) O 0 0.0036564087
. O 0 0.0038013363

It O 0 0.0062251147
was O 0 0.0025759314
" O 0 0.0031505632
serious O 0 0.0029734727
" O 0 0.001646222
for O 0 0.00053989195
almost O 0 0.0005492949
2 O 0 0.000525372
/ O 0 0.0011298202
3 O 0 0.00024029416
of O 0 0.00023618893
the O 0 0.00020350903
patients O 0 0.00047571684
( O 0 0.00041069402
62 O 0 0.00032594134
. O 0 0.0001642188
5 O 0 0.00014620594
% O 0 0.0002984025
) O 0 0.00033978588
and O 0 0.00016279475
its O 0 0.00020558905
outcome O 0 0.00026028795
favourable O 0 0.0004022227
in O 0 0.00019077623
most O 0 0.000283075
of O 0 0.00031595668
the O 0 0.0003463236
cases O 0 0.0009383233
( O 0 0.0012652364
82 O 0 0.0016655806
% O 0 0.0021814604
) O 0 0.0037746513
. O 0 0.0035532352

The O 0 0.0023070911
occurrence O 0 0.0022209128
of O 0 0.0018253468
this O 0 0.002297092
ADR O 0 0.99978966
was O 0 0.0007726759
more O 0 0.000685445
frequent O 0 0.0004931441
in O 0 0.00031995826
patients O 0 0.0005975233
aged O 0 0.00060587295
between O 0 0.00036552048
61 O 0 0.0008879729
and O 0 0.00081488246
80 O 0 0.0016582191
years O 0 0.0021961117
. O 0 0.0032881577

CONCLUSION O 0 0.020706266
: O 0 0.0046613025
This O 0 0.0016166184
work O 0 0.00083288975
shows O 0 0.00033496984
that O 0 0.0005400741
confusion B-Disease 0 0.6556656
with O 0 0.008835735
valproic B-Chemical 0 0.99999857
acid I-Chemical 0 0.9954971
is O 0 0.00044954204
a O 0 0.00055726897
serious O 0 0.0009594347
, O 0 0.00048731192
rather O 0 0.00025573734
frequent O 0 0.0004637411
but O 0 0.00047781997
reversible O 0 0.0021022463
adverse O 0 0.020278899
drug O 0 0.010988864
reaction O 0 0.0020470337
. O 0 0.0025958242

It O 0 0.004897482
occurs O 0 0.0017557907
especially O 0 0.0013103562
in O 0 0.0009284012
older O 0 0.002568678
patients O 0 0.001073179
and O 0 0.0004338918
during O 0 0.0002620679
the O 0 0.00025697143
first O 0 0.00020970046
two O 0 0.00025219418
weeks O 0 0.00031976402
of O 0 0.00094229623
treatment O 0 0.0017032194
. O 0 0.0033371258

Reversible O 0 0.0487285
inferior B-Disease 0 0.12727435
colliculus I-Disease 0 0.004766336
lesion I-Disease 0 0.005733877
in O 0 0.0012450378
metronidazole B-Chemical 0 0.99988997
- O 0 0.0074485065
induced O 0 0.0005993847
encephalopathy B-Disease 2 0.99991846
: O 0 0.000625428
magnetic O 0 0.00042886677
resonance O 0 0.0005469027
findings O 0 0.00017380247
on O 0 0.00011768668
diffusion O 0 0.0009179678
- O 0 0.0009621107
weighted O 0 0.00018572377
and O 0 0.00026769072
fluid O 0 0.0009443005
attenuated O 0 0.0006587831
inversion O 0 0.001588849
recovery O 0 0.0011077727
imaging O 0 0.0016008026
. O 0 0.002322566

OBJECTIVE O 0 0.037833467
: O 0 0.005690613
This O 0 0.00179132
is O 0 0.0006403979
to O 0 0.00045137282
present O 0 0.00038831087
reversible O 0 0.0016467432
inferior B-Disease 0 0.06756021
colliculus I-Disease 0 0.0011452445
lesions I-Disease 0 0.01040362
in O 0 0.00037668672
metronidazole B-Chemical 0 0.9999627
- O 0 0.011729739
induced O 0 0.00039470656
encephalopathy B-Disease 2 0.99998784
, O 0 0.00055760896
to O 0 0.00011285246
focus O 0 0.00013441977
on O 0 6.889066e-05
the O 0 9.5372794e-05
diffusion O 0 0.00067409826
- O 0 0.0005007478
weighted O 0 8.855446e-05
imaging O 0 0.00016039095
( O 0 0.00029660112
DWI O 0 0.18766977
) O 0 0.0004691741
and O 0 0.00020370803
fluid O 0 0.000660421
attenuated O 0 0.00039603404
inversion O 0 0.0009465015
recovery O 0 0.00059003016
( O 0 0.0009455668
FLAIR O 0 0.10562036
) O 0 0.0018623795
imaging O 0 0.0017006545
. O 0 0.0024597323

MATERIALS O 0 0.0035313615
AND O 0 0.0015297455
METHODS O 0 0.0015429042
: O 0 0.0015480446
From O 0 0.00077706785
November O 0 0.00070472894
2005 O 0 0.00086470536
to O 0 0.00045936528
September O 0 0.00043025037
2007 O 0 0.00063526694
, O 0 0.0005684692
8 O 0 0.00029514867
patients O 0 0.00046893468
( O 0 0.00040336137
5 O 0 0.00019917611
men O 0 0.0005613126
and O 0 0.00018903901
3 O 0 0.00015998025
women O 0 0.00046986385
) O 0 0.0004074671
were O 0 0.0001591961
diagnosed O 0 0.0006564298
as O 0 0.00017933053
having O 0 0.00042726938
metronidazole B-Chemical 0 0.999977
- O 0 0.0218145
induced O 0 0.00047970147
encephalopathy B-Disease 2 0.99998116
( O 0 0.00080134673
age O 0 0.00038674253
range O 0 0.00029618546
; O 0 0.0005994976
43 O 0 0.00068057666
- O 0 0.001810305
78 O 0 0.0013021802
years O 0 0.0013488284
) O 0 0.0032587722
. O 0 0.003425566

They O 0 0.0047101895
had O 0 0.0020527344
been O 0 0.0013742428
taking O 0 0.0023964993
metronidazole B-Chemical 0 0.99976236
( O 0 0.0013429021
total O 0 0.00049580005
dosage O 0 0.0012251764
, O 0 0.00054791174
45 O 0 0.000313461
- O 0 0.0008117135
120 O 0 0.00027251002
g O 0 0.00050864206
; O 0 0.0002897807
duration O 0 0.000105744104
, O 0 0.00023100131
30 O 0 0.00010784883
days O 0 6.928213e-05
to O 0 9.300951e-05
2 O 0 0.00013153328
months O 0 8.07064e-05
) O 0 0.00031176727
to O 0 0.00018111304
treat O 0 0.0004672955
the O 0 0.00032958476
infection B-Disease 0 0.0017546678
in O 0 0.0006481523
various O 0 0.000990765
organs O 0 0.0029704282
. O 0 0.0030872354

Initial O 0 0.003513623
brain O 0 0.00286198
magnetic O 0 0.0019605213
resonance O 0 0.0019522728
imaging O 0 0.0007337004
( O 0 0.00079390116
MRI O 0 0.0021714712
) O 0 0.00057867804
were O 0 0.00016583625
obtained O 0 0.00011313886
after O 0 7.891264e-05
the O 0 0.000118177995
hospitalization O 0 0.00025579933
, O 0 0.0002558322
including O 0 0.00015184468
DWI O 0 0.19864821
( O 0 0.00039504346
8 O 0 0.00017394406
/ O 0 0.00055852573
8 O 0 0.00017458628
) O 0 0.00038322803
, O 0 0.00030992925
apparent O 0 0.00022099668
diffusion O 0 0.0009890957
coefficient O 0 0.0012790674
( O 0 0.0007069878
ADC O 0 0.07927303
) O 0 0.00048345423
map O 0 0.00016722853
( O 0 0.0002961194
4 O 0 0.00015670792
/ O 0 0.0005532506
8 O 0 0.00018589347
) O 0 0.0004072888
, O 0 0.0004174228
FLAIR O 0 0.05835683
( O 0 0.0004124262
7 O 0 0.00017194968
/ O 0 0.00058297615
8 O 0 0.00020924308
) O 0 0.00045032593
, O 0 0.00039722203
and O 0 0.00031723283
T2 O 0 0.0013296094
- O 0 0.0011348979
weighted O 0 0.0002803585
image O 0 0.00037895064
( O 0 0.0008516204
8 O 0 0.0006641288
/ O 0 0.0023349007
8 O 0 0.0013138722
) O 0 0.003567209
. O 0 0.0037795533

Follow O 0 0.008540595
- O 0 0.0077159083
up O 0 0.0017586723
MRIs O 0 0.0018774424
were O 0 0.00052740827
performed O 0 0.00035122372
on O 0 0.00024367317
5 O 0 0.00028734733
patients O 0 0.00039174999
from O 0 0.00018534074
third O 0 0.00020253439
to O 0 0.00016861576
14th O 0 0.0003021245
days O 0 0.00013547194
after O 0 0.00016239617
discontinuation O 0 0.0014521311
of O 0 0.0009514295
metronidazole B-Chemical 0 0.9997009
administration O 0 0.0039998237
. O 0 0.0029986978

Findings O 0 0.0025772045
of O 0 0.0016298875
initial O 0 0.000903922
and O 0 0.00085570087
follow O 0 0.00051916385
- O 0 0.0016315816
up O 0 0.00042141575
MRIs O 0 0.0006066444
were O 0 0.00018512404
retrospectively O 0 0.000222778
evaluated O 0 0.00014330591
by O 0 0.00014059804
2 O 0 0.00017231291
neuroradiologists O 0 0.00044569976
by O 0 0.00011447204
consensus O 0 7.809576e-05
, O 0 0.00022520772
to O 0 9.711633e-05
analyze O 0 6.134652e-05
the O 0 9.79377e-05
presence O 0 0.0001150856
of O 0 0.00015862154
abnormal O 0 0.0004995001
signal O 0 6.528689e-05
intensities O 0 5.5017135e-05
, O 0 0.00017124612
their O 0 0.000100741665
locations O 0 0.00012389306
, O 0 0.00026524373
and O 0 0.00016726075
signal O 0 0.0001152822
changes O 0 0.00021090094
on O 0 0.00019170603
follow O 0 0.00030539287
- O 0 0.0018303198
up O 0 0.0009827923
images O 0 0.0016900501
. O 0 0.002948755

RESULTS O 0 0.004020595
: O 0 0.0026358573
Initial O 0 0.001136831
MRIs O 0 0.0014340968
showed O 0 0.00050296437
abnormal O 0 0.00095189776
high O 0 0.00034789878
signal O 0 0.00015066449
intensities O 0 0.00010534977
on O 0 0.0001441636
DWI O 0 0.03434053
and O 0 0.00028169222
FLAIR O 0 0.10256771
( O 0 0.00035650365
or O 0 0.00015231581
T2 O 0 0.00072596676
- O 0 0.00060969876
weighted O 0 0.00011293536
image O 0 0.000134524
) O 0 0.00032792173
at O 0 0.00011268139
the O 0 0.00014889556
dentate O 0 0.0015705109
nucleus O 0 0.00016450357
( O 0 0.00026888066
8 O 0 0.00014600702
/ O 0 0.00049190567
8 O 0 0.00015947474
) O 0 0.00036476093
, O 0 0.00032769892
inferior O 0 0.0015054625
colliculus O 0 0.0004519592
( O 0 0.0002645633
6 O 0 0.00012548652
/ O 0 0.00049423304
8 O 0 0.00018348097
) O 0 0.00042110737
, O 0 0.00039794514
corpus O 0 0.00061757484
callosum O 0 0.13365023
( O 0 0.0004293275
2 O 0 0.00023448638
/ O 0 0.000659652
8 O 0 0.00020968507
) O 0 0.00052113284
, O 0 0.00054969394
pons O 0 0.009095199
( O 0 0.00038121414
2 O 0 0.0002286627
/ O 0 0.0006596162
8 O 0 0.00021710678
) O 0 0.0005555101
, O 0 0.0006083173
medulla O 0 0.016400388
( O 0 0.0004394737
1 O 0 0.00024219541
/ O 0 0.00063049525
8 O 0 0.00020262187
) O 0 0.00044270226
, O 0 0.0003840943
and O 0 0.00031510988
bilateral O 0 0.0037318212
cerebral O 0 0.8977377
white O 0 0.0007776016
matter O 0 0.00073223986
( O 0 0.00086224126
1 O 0 0.0007328734
/ O 0 0.0022267576
8 O 0 0.0011547398
) O 0 0.0031539
. O 0 0.0033205426

High O 0 0.006271581
- O 0 0.0067116274
signal O 0 0.00083328027
intensity O 0 0.00053367176
lesions O 0 0.0018264132
on O 0 0.0003853999
DWI O 0 0.26021296
tended O 0 0.0003993916
to O 0 0.00017311262
show O 0 0.00012288803
low O 0 0.00020593355
signal O 0 0.00010045005
intensity O 0 8.9576526e-05
on O 0 0.00013304714
ADC O 0 0.016007157
map O 0 0.00015755145
( O 0 0.0002638011
3 O 0 0.00013012832
/ O 0 0.000514129
4 O 0 0.00013049749
) O 0 0.00035643842
, O 0 0.00027970332
but O 0 0.0001662222
in O 0 0.000119328375
one O 0 0.000108618355
patient O 0 0.00014973815
, O 0 0.00018183405
high O 0 0.00012467228
signal O 0 6.451772e-05
intensity O 0 5.8613e-05
was O 0 8.4886444e-05
shown O 0 5.5041328e-05
at O 0 9.8084805e-05
bilateral O 0 0.001531127
dentate O 0 0.0022535245
nuclei O 0 0.00022228788
on O 0 0.00012358792
not O 0 0.00019674236
only O 0 0.00044072804
DWI O 0 0.71262205
but O 0 0.0008191637
also O 0 0.00092532404
ADC O 0 0.09346481
map O 0 0.0015709029
. O 0 0.0027073591

All O 0 0.002520688
the O 0 0.0020246913
lesions O 0 0.005970604
in O 0 0.0012611805
dentate O 0 0.0072906855
, O 0 0.0014899543
inferior O 0 0.0061820033
colliculus O 0 0.0014418097
, O 0 0.0009336277
pons O 0 0.0229487
, O 0 0.00050852087
and O 0 0.00031161035
medullas O 0 0.0045289733
had O 0 0.00021522236
been O 0 0.00017028999
resolved O 0 0.00020341648
completely O 0 0.00012439747
on O 0 9.152339e-05
follow O 0 0.00010697577
- O 0 0.0006715286
up O 0 0.00015783745
MRIs O 0 0.0003401179
in O 0 0.000110007495
5 O 0 0.000121932266
patients O 0 0.0002709337
, O 0 0.0002913984
but O 0 0.00020685315
in O 0 0.0001785903
1 O 0 0.00022300008
patient O 0 0.00021290603
of O 0 0.00024000792
them O 0 0.00046952357
, O 0 0.0009351621
corpus O 0 0.0018068899
callosal B-Disease 0 0.63739055
lesion I-Disease 0 0.016760381
persisted O 0 0.0014025498
. O 0 0.0025224723

CONCLUSIONS O 0 0.0315555
: O 0 0.00766269
Reversible O 0 0.01707703
inferior B-Disease 0 0.10782392
colliculus I-Disease 0 0.0031901367
lesions I-Disease 0 0.008609315
could O 0 0.0002797337
be O 0 0.0002486074
considered O 0 0.00021361995
as O 0 0.000184771
the O 0 0.00015638654
characteristic O 0 0.00023616057
for O 0 0.0002767726
metronidazole B-Chemical 0 0.9999615
- O 0 0.016407665
induced O 0 0.0005384594
encephalopathy B-Disease 2 0.9999808
, O 0 0.0007111466
next O 0 0.00013134528
to O 0 0.00025184816
the O 0 0.00037307682
dentate O 0 0.0043076244
nucleus O 0 0.0007869102
involvement O 0 0.0020367624
. O 0 0.0026197934

Clinically O 0 0.009111816
significant O 0 0.0028912013
proteinuria B-Disease 0 0.99942315
following O 0 0.0006239991
the O 0 0.0004927865
administration O 0 0.00081338786
of O 0 0.00078835647
sirolimus B-Chemical 0 0.9992556
to O 0 0.00068750966
renal O 0 0.235281
transplant O 0 0.0014728912
recipients O 0 0.0010255475
. O 0 0.0023237881

BACKGROUND O 0 0.019860957
: O 0 0.0064223646
Sirolimus B-Chemical 0 0.8290922
is O 0 0.00063993287
the O 0 0.0004034325
latest O 0 0.00052043813
immunosuppressive O 0 0.0044235014
agent O 0 0.0005858534
used O 0 0.00019158672
to O 0 0.00015862138
prevent O 0 0.00017309083
rejection O 0 0.0041681123
, O 0 0.00040791693
and O 0 0.00017353421
may O 0 0.0001133516
have O 0 0.00012297476
less O 0 0.00033184286
nephrotoxicity B-Disease 0 0.99994254
than O 0 0.00027420753
calcineurin O 0 0.0024011391
inhibitor O 0 0.0018405741
( O 0 0.0021914449
CNI O 0 0.9992872
) O 0 0.0017371038
- O 0 0.002138151
based O 0 0.00066555577
regimens O 0 0.0015954723
. O 0 0.0025442238

To O 0 0.0011931004
date O 0 0.001004827
there O 0 0.0008229457
has O 0 0.0005421193
been O 0 0.00047371903
little O 0 0.00041403834
documentation O 0 0.00050865766
of O 0 0.00043710435
clinically O 0 0.0017868229
significant O 0 0.00057458924
proteinuria B-Disease 0 0.9999255
linked O 0 0.00045704265
with O 0 0.00040428486
the O 0 0.0003644908
use O 0 0.0005563974
of O 0 0.0015297038
sirolimus B-Chemical 0 0.9994136
. O 0 0.00396301

We O 0 0.002538399
have O 0 0.0014846679
encountered O 0 0.0013184388
several O 0 0.0006648283
patients O 0 0.0012895457
who O 0 0.0008658407
developed O 0 0.0007062564
substantial O 0 0.0010481547
proteinuria B-Disease 0 0.9998698
associated O 0 0.0013191045
with O 0 0.0015981786
sirolimus B-Chemical 0 0.9993187
use O 0 0.0020389995
. O 0 0.0032080333

In O 0 0.0018999379
each O 0 0.0012793592
patient O 0 0.0012848121
, O 0 0.0011495481
the O 0 0.00041901792
close O 0 0.00037316454
temporal O 0 0.0008087912
association O 0 0.00014805855
between O 0 0.00012654442
the O 0 0.0001246208
commencement O 0 0.00014090688
of O 0 0.00020857778
sirolimus B-Chemical 0 0.99961144
therapy O 0 0.0003396521
and O 0 0.00025218335
proteinuria B-Disease 0 0.99995124
implicated O 0 0.00037874028
sirolimus B-Chemical 0 0.9998653
as O 0 0.0002054411
the O 0 0.00015608873
most O 0 0.00025941414
likely O 0 0.00018926879
etiology O 0 0.0021819873
of O 0 0.0007468844
the O 0 0.0012881333
proteinuria B-Disease 0 0.9998599
. O 0 0.004455753

METHODS O 0 0.004073905
: O 0 0.0026373672
We O 0 0.0007361692
analyzed O 0 0.00060974323
the O 0 0.0004341696
clinical O 0 0.00085387885
and O 0 0.00032450823
laboratory O 0 0.00027066903
information O 0 0.00016441169
available O 0 0.00011081038
for O 0 0.000101889986
all O 0 0.00012458563
119 O 0 0.00028557674
patients O 0 0.00023321388
transplanted O 0 0.00024844505
at O 0 8.475323e-05
the O 0 0.000107207576
Washington O 0 0.00037619146
Hospital O 0 0.00025955538
Center O 0 0.00016934825
between O 0 0.00010721147
1999 O 0 0.00039885
- O 0 0.0008787948
2003 O 0 0.00024472934
for O 0 0.00012647506
whom O 0 0.0005184621
sirolimus B-Chemical 0 0.9996331
was O 0 0.00022661105
a O 0 0.00029680648
component O 0 0.00023002218
of O 0 0.00032847247
their O 0 0.00047490312
immunosuppressant O 0 0.102287665
regimen O 0 0.0016182949
. O 0 0.0023042238

In O 0 0.0019440396
these O 0 0.001735555
patients O 0 0.0022180006
, O 0 0.0013126456
the O 0 0.0004586713
magnitude O 0 0.00044524472
of O 0 0.0006881415
proteinuria B-Disease 0 0.9998894
was O 0 0.00028008333
assessed O 0 0.00017154259
on O 0 0.00012743748
morning O 0 0.00073752244
urine O 0 0.008246816
samples O 0 0.00018293697
by O 0 0.00014399283
turbidometric O 0 0.004356531
measurement O 0 0.00010994783
or O 0 0.00012180258
random O 0 0.00029335465
urine O 0 0.020267118
protein O 0 0.00023937921
: O 0 0.0007804005
creatinine B-Chemical 0 0.9700493
ratios O 0 0.00021658081
, O 0 0.0002991046
an O 0 0.00017503316
estimate O 0 0.00012420723
of O 0 0.00028295952
grams O 0 0.00093701185
of O 0 0.0009113194
proteinuria B-Disease 0 0.9998839
/ O 0 0.009740915
day O 0 0.0012395125
. O 0 0.002688337

Laboratory O 0 0.0066418047
results O 0 0.0017311991
were O 0 0.0011092769
compared O 0 0.00063001434
between O 0 0.0005660607
prior O 0 0.00046811294
, O 0 0.0010802889
during O 0 0.00054096675
and O 0 0.0008528502
following O 0 0.0009308077
sirolimus B-Chemical 0 0.99715024
use O 0 0.002392104
. O 0 0.0039418964

RESULTS O 0 0.0048874808
: O 0 0.0036861643
Twenty O 0 0.0022491044
- O 0 0.0026604405
eight O 0 0.0004960241
patients O 0 0.00092800276
( O 0 0.0007618745
24 O 0 0.00039624248
% O 0 0.00059764175
) O 0 0.00060747546
developed O 0 0.00034009956
increased O 0 0.00057353027
proteinuria B-Disease 0 0.9998437
from O 0 0.0002283357
baseline O 0 0.00016686377
during O 0 0.00013784641
their O 0 0.00021439348
post O 0 0.00033415432
- O 0 0.0016044177
transplantation O 0 0.000996896
course O 0 0.0013985124
. O 0 0.0026837206

In O 0 0.002193087
21 O 0 0.0022871024
patients O 0 0.0018438463
an O 0 0.00078120717
alternative O 0 0.00038821503
cause O 0 0.0006540947
of O 0 0.00086823234
proteinuria B-Disease 0 0.9999391
was O 0 0.00045896802
either O 0 0.00026090757
obvious O 0 0.00019429966
or O 0 0.00021196938
insufficient O 0 0.00030753072
data O 0 0.0003474486
was O 0 0.00029475472
available O 0 0.00030156135
to O 0 0.0004832625
be O 0 0.00085633947
conclusive O 0 0.002419171
. O 0 0.0031934395

In O 0 0.0020620066
7 O 0 0.0014940446
of O 0 0.0011383801
the O 0 0.0006978519
28 O 0 0.00066203903
patients O 0 0.00069451664
there O 0 0.00027524686
was O 0 0.00028298944
a O 0 0.00034233503
striking O 0 0.00022600322
temporal O 0 0.00069294276
association O 0 0.000104712
between O 0 9.8697856e-05
the O 0 0.00010662572
initiation O 0 0.00010679077
of O 0 0.00027546842
sirolimus B-Chemical 0 0.9997279
and O 0 0.00025649898
the O 0 0.00019125486
development O 0 0.00042060547
of O 0 0.0010403611
nephrotic B-Disease 0 0.99999523
- O 0 0.040724423
range O 0 0.0018002273
proteinuria B-Disease 0 0.9997323
. O 0 0.00389113

Proteinuria B-Disease 0 0.9994748
correlated O 0 0.002381119
most O 0 0.0013932601
strongly O 0 0.00076164363
with O 0 0.0008542915
sirolimus B-Chemical 0 0.99948716
therapy O 0 0.00053002656
when O 0 0.00016314111
compared O 0 0.00016655699
to O 0 0.00019981922
other O 0 0.00025948958
demographic O 0 0.0005299869
and O 0 0.00064321957
clinical O 0 0.0020000907
variables O 0 0.0017612467
. O 0 0.0026810684

In O 0 0.001997493
most O 0 0.0022112853
patients O 0 0.002294379
, O 0 0.0017318536
discontinuation O 0 0.0045575537
of O 0 0.00090257137
sirolimus B-Chemical 0 0.99968266
resulted O 0 0.00041857036
in O 0 0.00033262014
a O 0 0.0004923996
decrease O 0 0.0004186091
, O 0 0.00067140284
but O 0 0.00044732288
not O 0 0.00040980647
resolution O 0 0.0014868396
, O 0 0.001958449
of O 0 0.0024299023
proteinuria B-Disease 0 0.9998275
. O 0 0.0055938284

CONCLUSIONS O 0 0.02931411
: O 0 0.007197879
Sirolimus B-Chemical 0 0.83284473
induces O 0 0.0007835008
or O 0 0.0007053182
aggravates O 0 0.0045749545
pre O 0 0.0013007004
- O 0 0.003475992
existing O 0 0.00068049174
proteinuria B-Disease 0 0.9998758
in O 0 0.00043716808
an O 0 0.0003825557
unpredictable O 0 0.00059386034
subset O 0 0.00028270116
of O 0 0.0005516428
renal O 0 0.37770334
allograft O 0 0.004713088
recipients O 0 0.0012108912
. O 0 0.0024080696

Proteinuria B-Disease 0 0.9993395
may O 0 0.0030052357
improve O 0 0.0016731116
, O 0 0.0029172099
but O 0 0.0014929638
does O 0 0.0007493072
not O 0 0.0007062837
resolve O 0 0.00064818846
, O 0 0.0014455774
when O 0 0.0010147924
sirolimus B-Chemical 0 0.99910694
is O 0 0.00182884
withdrawn O 0 0.0056218677
. O 0 0.0040130313

Components O 0 0.009996554
of O 0 0.0052178185
lemon O 0 0.96664643
essential O 0 0.0031677494
oil O 0 0.9914076
attenuate O 0 0.017815767
dementia B-Disease 0 0.99995434
induced O 0 0.0036690577
by O 0 0.005430931
scopolamine B-Chemical 0 0.999977
. O 0 0.008424664

The O 0 0.0027669272
anti O 0 0.0058469386
- O 0 0.108345106
dementia B-Disease 0 0.9996983
effects O 0 0.001083533
of O 0 0.0009907004
s B-Chemical 0 0.00269123
- I-Chemical 0 0.03980142
limonene I-Chemical 0 0.99947065
and O 0 0.0005697901
s B-Chemical 0 0.00080161676
- I-Chemical 0 0.02608747
perillyl I-Chemical 0 0.99966025
alcohol I-Chemical 0 0.9998503
were O 0 0.00019889028
observed O 0 0.000102994614
using O 0 8.0311926e-05
the O 0 8.019545e-05
passive O 0 0.00014987527
avoidance O 0 0.00039707174
test O 0 0.0003064928
( O 0 0.0006108854
PA O 0 0.68238914
) O 0 0.0005548447
and O 0 0.00017860936
the O 0 0.00014896372
open O 0 0.00027400942
field O 0 0.00045165862
habituation O 0 0.0032882986
test O 0 0.0009750215
( O 0 0.0022276794
OFH O 0 0.9004608
) O 0 0.005008466
. O 0 0.0035601198

These O 0 0.00317676
lemon O 0 0.9237726
essential O 0 0.0016763788
oils O 0 0.5121359
showed O 0 0.0006082347
strong O 0 0.00033216318
ability O 0 0.00024192287
to O 0 0.00019860984
improve O 0 0.00019427057
memory B-Disease 0 0.9252818
impaired I-Disease 0 0.18235174
by O 0 0.0007277018
scopolamine B-Chemical 0 0.99999785
; O 0 0.0009081955
however O 0 0.00022253662
, O 0 0.00033300373
s B-Chemical 0 0.00042434648
- I-Chemical 0 0.020995386
perillyl I-Chemical 0 0.9997863
alcohol I-Chemical 0 0.9999368
relieved O 0 0.0012523355
the O 0 0.0001475226
deficit B-Disease 0 0.061213102
of I-Disease 0 0.00023098062
associative I-Disease 0 0.04828663
memory I-Disease 0 0.42034325
in O 0 0.00032227518
PA O 0 0.910725
only O 0 0.00023895942
, O 0 0.00032123618
and O 0 0.00016085763
did O 0 0.00015939343
not O 0 0.00012416708
improve O 0 0.0001294958
non O 0 0.00046827027
- O 0 0.0032862704
associative O 0 0.02100525
memory O 0 0.24746007
significantly O 0 0.0013260336
in O 0 0.0015811056
OFH O 0 0.9538501
. O 0 0.0036920232

Analysis O 0 0.0041559217
of O 0 0.0027233467
neurotransmitter O 0 0.12849548
concentration O 0 0.0017609147
in O 0 0.0005517356
some O 0 0.00043264235
brain O 0 0.00071366405
regions O 0 0.00013248996
on O 0 8.7425935e-05
the O 0 9.48977e-05
test O 0 0.00015836643
day O 0 8.71485e-05
showed O 0 0.00012549237
that O 0 0.0001695216
dopamine B-Chemical 0 0.9997321
concentration O 0 0.000333651
of O 0 0.00012079654
the O 0 9.8076394e-05
vehicle O 0 0.0021133912
/ O 0 0.10856079
scopolamine B-Chemical 0 0.99999905
group O 0 0.0003524136
was O 0 8.1381215e-05
significantly O 0 9.593458e-05
lower O 0 9.591985e-05
than O 0 5.955601e-05
that O 0 4.8709844e-05
of O 0 8.810013e-05
the O 0 8.7372675e-05
vehicle O 0 0.0008104016
/ O 0 0.0015686033
vehicle O 0 0.0012796725
group O 0 0.0003230596
, O 0 0.00035303112
but O 0 0.00017363897
this O 0 0.00015860535
phenomenon O 0 0.00060897623
was O 0 0.0001265845
reversed O 0 0.00022455206
when O 0 0.00012549729
s B-Chemical 0 0.00088927126
- I-Chemical 0 0.02835075
limonene I-Chemical 0 0.99970454
or O 0 0.00022584508
s B-Chemical 0 0.00047310055
- I-Chemical 0 0.020877626
perillyl I-Chemical 0 0.99965084
alcohol I-Chemical 0 0.9998343
were O 0 0.000207058
administered O 0 0.000204605
before O 0 8.698386e-05
the O 0 0.00018254979
injection O 0 0.00035059432
of O 0 0.0013082256
scopolamine B-Chemical 0 0.9999784
. O 0 0.0043107974

Simultaneously O 0 0.007020186
, O 0 0.0037549676
we O 0 0.00084144715
found O 0 0.0008384387
that O 0 0.00047880018
these O 0 0.00045551034
two O 0 0.00037832436
lemon O 0 0.93419063
essential O 0 0.0005087993
oil O 0 0.9386532
components O 0 0.0003127118
could O 0 0.00020247741
inhibit O 0 0.00032099892
acetylcholinesterase O 0 0.97680867
activity O 0 0.00022714381
in O 0 0.00026859727
vitro O 0 0.00036169728
using O 0 0.00041307954
the O 0 0.0007785547
Ellman O 0 0.27454907
method O 0 0.0021400524
. O 0 0.0032473984

Attentional O 0 0.098750375
modulation O 0 0.001570321
of O 0 0.001457841
perceived O 0 0.0020326998
pain B-Disease 0 0.018075766
intensity O 0 0.0005712585
in O 0 0.0009794901
capsaicin B-Chemical 0 0.99720323
- O 0 0.011181368
induced O 0 0.0014708665
secondary O 0 0.0106421225
hyperalgesia B-Disease 0 0.9954751
. O 0 0.0054143616

Perceived O 0 0.011897066
pain B-Disease 0 0.022237862
intensity O 0 0.002262836
is O 0 0.0020810054
modulated O 0 0.001841879
by O 0 0.0038239968
attention O 0 0.01134761
. O 0 0.009513265

However O 0 0.0034064078
, O 0 0.004489919
it O 0 0.0020805756
is O 0 0.0007773156
not O 0 0.0005347194
known O 0 0.00036519323
that O 0 0.00021300145
how O 0 0.00018611657
pain B-Disease 0 0.0037024156
intensity O 0 0.00011439062
ratings O 0 0.00025360595
are O 0 0.0001294137
affected O 0 0.00018990909
by O 0 0.00021821771
attention O 0 0.0010786447
in O 0 0.00053786876
capsaicin B-Chemical 0 0.9988985
- O 0 0.010664373
induced O 0 0.0008736606
secondary O 0 0.009126719
hyperalgesia B-Disease 0 0.99638784
. O 0 0.0039648945

Here O 0 0.0023612273
we O 0 0.0009298623
show O 0 0.00068503816
that O 0 0.0005338536
perceived O 0 0.0011176228
pain B-Disease 0 0.025335869
intensity O 0 0.00021143671
in O 0 0.0002628887
secondary O 0 0.0013191841
hyperalgesia B-Disease 0 0.982362
is O 0 0.00017125004
decreased O 0 0.00027589264
when O 0 0.00011418814
attention O 0 0.00074264023
is O 0 0.00017822048
distracted O 0 0.004505821
away O 0 0.00021938304
from O 0 0.00014656315
the O 0 0.00017709483
painful O 0 0.018217186
pinprick O 0 0.00093332573
stimulus O 0 0.00031859372
with O 0 0.00040250574
a O 0 0.00087603217
visual O 0 0.0051299557
task O 0 0.0038877695
. O 0 0.0031213036

Furthermore O 0 0.0036655155
, O 0 0.0046238154
it O 0 0.002105542
was O 0 0.0008562351
found O 0 0.0005269934
that O 0 0.0002833137
the O 0 0.00023408784
magnitude O 0 0.00023943788
of O 0 0.00029879512
attentional O 0 0.12856014
modulation O 0 0.00017990102
in O 0 0.00019915123
secondary O 0 0.0012523261
hyperalgesia B-Disease 0 0.983214
is O 0 0.0001328619
very O 0 0.00015889858
similar O 0 8.414644e-05
to O 0 0.0001061302
that O 0 0.00012384416
of O 0 0.00038480846
capsaicin B-Chemical 0 0.9990626
- O 0 0.008686623
untreated O 0 0.00094469875
, O 0 0.0010427018
control O 0 0.00090160005
condition O 0 0.002966386
. O 0 0.003110413

Our O 0 0.0019353935
findings O 0 0.0019492501
, O 0 0.0018390504
showing O 0 0.00055890495
no O 0 0.00038476184
interaction O 0 0.00027256957
between O 0 0.0003228456
capsaicin B-Chemical 0 0.9931189
treatment O 0 0.00027403297
and O 0 0.000208688
attentional O 0 0.035556097
modulation O 0 0.00010619904
suggest O 0 7.189523e-05
that O 0 0.00014831756
capsaicin B-Chemical 0 0.99947613
- O 0 0.014621824
induced O 0 0.00019750773
secondary O 0 0.002652551
hyperalgesia B-Disease 0 0.9959501
and O 0 0.00022771802
attention O 0 0.0005739731
might O 0 8.152274e-05
affect O 0 0.00012087707
mechanical O 0 0.00032822142
pain B-Disease 0 0.003196666
through O 0 0.00028723644
independent O 0 0.00036902117
mechanisms O 0 0.0008754043
. O 0 0.0025363604

Cardioprotective O 0 0.49356604
effect O 0 0.0048135864
of O 0 0.059088428
salvianolic B-Chemical 1 0.99999905
acid I-Chemical 1 0.9998777
A I-Chemical 1 0.9973392
on O 0 0.0020674695
isoproterenol B-Chemical 0 0.99993026
- O 0 0.09245479
induced O 0 0.0013796134
myocardial B-Disease 0 0.99966455
infarction I-Disease 0 0.9999629
in O 0 0.00148771
rats O 0 0.0025921871
. O 0 0.0028061217

The O 0 0.0019617802
present O 0 0.0013792817
study O 0 0.0012421759
was O 0 0.0006253935
designed O 0 0.00039028024
to O 0 0.00026211186
evaluate O 0 0.00014166196
the O 0 0.0002526389
cardioprotective O 0 0.004940392
potential O 0 0.00043994188
of O 0 0.005855432
salvianolic B-Chemical 1 0.9999999
acid I-Chemical 1 0.99995494
A I-Chemical 1 0.9985851
on O 0 0.0009829038
isoproterenol B-Chemical 0 0.99996316
- O 0 0.0766115
induced O 0 0.0008428286
myocardial B-Disease 0 0.99977845
infarction I-Disease 0 0.99997485
in O 0 0.0011176714
rats O 0 0.0020745874
. O 0 0.0022902722

Hemodynamic O 0 0.018213723
parameters O 0 0.0032961594
and O 0 0.00272722
lead O 0 0.007694292
II O 0 0.04141687
electrocardiograph O 0 0.01248539
were O 0 0.0008729932
monitored O 0 0.0006681593
and O 0 0.0010449871
recorded O 0 0.0014650145
continuously O 0 0.0025210525
. O 0 0.004310617

Cardiac O 0 0.0155695565
marker O 0 0.0037660294
enzymes O 0 0.004742545
and O 0 0.002299154
antioxidative O 0 0.8628916
parameters O 0 0.0014169733
in O 0 0.0010007294
serum O 0 0.011486991
and O 0 0.0011603965
heart O 0 0.018860694
tissues O 0 0.0014362683
were O 0 0.0011682849
measured O 0 0.0019682702
. O 0 0.0034527585

Assay O 0 0.030222397
for O 0 0.002628892
mitochondrial O 0 0.017559657
respiratory O 0 0.0041878973
function O 0 0.0005551483
and O 0 0.00057174277
histopathological O 0 0.0012549589
examination O 0 0.0004186677
of O 0 0.00065258413
heart O 0 0.008942603
tissues O 0 0.0011834623
were O 0 0.00096666586
performed O 0 0.0013943872
. O 0 0.003014273

Isoproterenol B-Chemical 0 0.99986374
- O 0 0.063371226
treated O 0 0.002452
rats O 0 0.00122363
showed O 0 0.0004389292
significant O 0 0.00034991815
increases O 0 0.0002988065
in O 0 0.0002349579
the O 0 0.00019415205
levels O 0 0.00025566714
of O 0 0.0008410227
lactate B-Chemical 0 0.9997491
dehydrogenase O 0 0.9911255
, O 0 0.14768302
aspartate B-Chemical 1 0.9999869
transaminase O 0 0.9999939
, O 0 0.12056311
creatine B-Chemical 1 0.99997604
kinase O 0 0.016783891
and O 0 0.0026711912
malondialdehyde B-Chemical 1 0.9999999
and O 0 0.0004183344
significant O 0 0.0001555258
decreases O 0 0.0001607385
in O 0 0.000116396724
the O 0 0.000119802426
activities O 0 0.00027062956
of O 0 0.0066028135
superoxide B-Chemical 1 0.9999993
dismutase O 0 0.99999976
, O 0 0.791705
catalase O 0 0.99998355
and O 0 0.06411116
glutathione B-Chemical 0 0.9999949
peroxidase O 0 0.99832183
in O 0 0.0009621557
serum O 0 0.07017118
and O 0 0.0014247219
heart O 0 0.072329536
. O 0 0.0028467418

These O 0 0.0017950158
rats O 0 0.0021047045
also O 0 0.000868772
showed O 0 0.00060599
declines O 0 0.000725873
in O 0 0.00030990475
left O 0 0.000562348
ventricular O 0 0.018119825
systolic O 0 0.026567416
pressure O 0 0.0028862413
, O 0 0.00030142252
maximum O 0 0.00015565073
and O 0 0.00011825092
minimum O 0 9.504215e-05
rate O 0 0.00015924318
of O 0 0.00012744733
developed O 0 0.00014869717
left O 0 0.00034308175
ventricular O 0 0.13201112
pressure O 0 0.005234249
, O 0 0.00027214809
and O 0 0.00014516618
elevation O 0 0.00091830955
of O 0 0.00014022665
left O 0 0.00033356677
ventricular O 0 0.015948595
end O 0 0.00011842367
- O 0 0.00094277674
diastolic O 0 0.18650773
pressure O 0 0.0064569246
and O 0 0.0007816107
ST O 0 0.25340274
- O 0 0.0045573656
segment O 0 0.0021712543
. O 0 0.0029673693

In O 0 0.0021002986
addition O 0 0.0015149243
, O 0 0.0047797933
mitochondrial O 0 0.31050554
respiratory B-Disease 0 0.9009423
dysfunction I-Disease 0 0.9987262
characterized O 0 0.00090534304
by O 0 0.00032311812
decreased O 0 0.00057267264
respiratory O 0 0.0010909287
control O 0 0.00020742415
ratio O 0 0.00033416483
and O 0 0.0006739839
ADP B-Chemical 0 0.99982256
/ O 0 0.18093811
O O 0 0.9994362
was O 0 0.00051434047
observed O 0 0.00034980878
in O 0 0.0006371572
isoproterenol B-Chemical 0 0.9997589
- O 0 0.012775596
treated O 0 0.001865965
rats O 0 0.0025190613
. O 0 0.0028445798

Administration O 0 0.056871727
of O 0 0.073290884
salvianolic B-Chemical 1 0.9999987
acid I-Chemical 1 0.99982363
A I-Chemical 1 0.98776764
for O 0 0.00060985977
a O 0 0.00045998284
period O 0 0.00014233655
of O 0 0.00015680553
8 O 0 0.00011643481
days O 0 7.615083e-05
significantly O 0 0.00017202465
attenuated O 0 0.00052107277
isoproterenol B-Chemical 0 0.99991906
- O 0 0.012624301
induced O 0 0.00023052144
cardiac B-Disease 0 0.22426662
dysfunction I-Disease 0 0.9978289
and O 0 0.0007937934
myocardial B-Disease 0 0.999928
injury I-Disease 0 0.8317397
and O 0 0.00039139314
improved O 0 0.0007624661
mitochondrial O 0 0.01858763
respiratory O 0 0.0054784426
function O 0 0.0010458988
. O 0 0.0021635406

The O 0 0.0025081118
protective O 0 0.0031151727
role O 0 0.001437787
of O 0 0.013417186
salvianolic B-Chemical 1 0.9999994
acid I-Chemical 1 0.9999006
A I-Chemical 1 0.9969951
against O 0 0.00090302946
isoproterenol B-Chemical 0 0.999964
- O 0 0.15228863
induced O 0 0.0008261994
myocardial B-Disease 0 0.99993587
damage I-Disease 0 0.8932326
was O 0 0.0002959385
further O 0 0.00021965493
confirmed O 0 0.00028242852
by O 0 0.00048359705
histopathological O 0 0.0023559749
examination O 0 0.0012016337
. O 0 0.0023103247

The O 0 0.0018868526
results O 0 0.0013836378
of O 0 0.0012418729
our O 0 0.00086465344
study O 0 0.0008980013
suggest O 0 0.0005203025
that O 0 0.0021198532
salvianolic B-Chemical 1 0.99999976
acid I-Chemical 1 0.9999651
A I-Chemical 1 0.99946564
possessing O 0 0.0068746917
antioxidant O 0 0.9991667
activity O 0 0.00021011413
has O 0 0.00011210372
a O 0 0.00020442953
significant O 0 0.0001452044
protective O 0 0.00026223934
effect O 0 0.00019081897
against O 0 0.0002645784
isoproterenol B-Chemical 0 0.9999348
- O 0 0.11390337
induced O 0 0.001624881
myocardial B-Disease 0 0.9997807
infarction I-Disease 0 0.9999685
. O 0 0.0042579453

Long O 0 0.016680457
- O 0 0.03182897
term O 0 0.005790521
glutamate B-Chemical 0 0.9994135
supplementation O 0 0.71291625
failed O 0 0.0013294637
to O 0 0.0006890945
protect O 0 0.00069968315
against O 0 0.00052734895
peripheral B-Disease 0 0.20403342
neurotoxicity I-Disease 0 0.9997063
of O 0 0.0047014235
paclitaxel B-Chemical 1 0.9992055
. O 0 0.005363115

Toxic O 0 0.5823104
peripheral B-Disease 0 0.58996356
neuropathy I-Disease 0 0.99993956
is O 0 0.0010072456
still O 0 0.0005400762
a O 0 0.0006070536
significant O 0 0.00033772996
limiting O 0 0.00040929092
factor O 0 0.0013186774
for O 0 0.00017556502
chemotherapy O 0 0.0013400185
with O 0 0.0002514691
paclitaxel B-Chemical 1 0.99948514
( O 0 0.0012544619
PAC B-Chemical 0 0.99679345
) O 0 0.0012342704
, O 0 0.0005532288
although O 0 0.00040131784
glutamate B-Chemical 0 0.999496
and O 0 0.00031960307
its O 0 0.00033282407
closely O 0 0.00020290937
related O 0 0.0002768734
amino B-Chemical 0 0.9966468
acid I-Chemical 0 0.9997743
glutamine B-Chemical 0 0.9999536
were O 0 0.0006494199
claimed O 0 0.00078460015
to O 0 0.0004935986
ameliorate O 0 0.008509082
PAC B-Chemical 0 0.9991948
neurotoxicity B-Disease 0 0.99924016
. O 0 0.0039613876

This O 0 0.004188977
pilot O 0 0.0024924348
trial O 0 0.0013895418
aimed O 0 0.0005763972
to O 0 0.00032716172
evaluate O 0 0.00014609196
the O 0 0.00019445884
role O 0 0.00014532199
of O 0 0.0006515874
glutamate B-Chemical 0 0.99980336
supplementation O 0 0.46984977
for O 0 0.0001927719
preventing O 0 0.00030754157
PAC B-Chemical 0 0.99893755
- O 0 0.008947523
induced O 0 0.00020356901
peripheral B-Disease 0 0.25377357
neuropathy I-Disease 0 0.9999924
in O 0 0.00017344025
a O 0 0.00020949761
randomized O 0 0.0004113641
, O 0 0.00025574613
placebo O 0 0.0033489142
- O 0 0.00080558064
controlled O 0 0.00016706962
, O 0 0.00026290872
double O 0 0.0001829258
- O 0 0.0014906205
blinded O 0 0.00050682813
clinical O 0 0.0007116982
and O 0 0.00039562763
electro O 0 0.0028019221
- O 0 0.0021792713
diagnostic O 0 0.0010110986
study O 0 0.001586811
. O 0 0.0026421114

Forty O 0 0.010187231
- O 0 0.00995929
three O 0 0.0013269811
ovarian B-Disease 0 0.97532505
cancer I-Disease 0 0.9986701
patients O 0 0.002018057
were O 0 0.0002878398
available O 0 0.00014947765
for O 0 0.0001189825
analysis O 0 0.00011422189
following O 0 5.8286983e-05
six O 0 4.86334e-05
cycles O 0 5.2446012e-05
of O 0 9.659782e-05
the O 0 9.54911e-05
same O 0 0.0001239525
PAC B-Chemical 0 0.9715029
- O 0 0.0010515598
containing O 0 8.799938e-05
regimen O 0 0.00014412348
: O 0 0.0002496275
23 O 0 0.0001733414
had O 0 0.00011387019
been O 0 0.00014119766
supplemented O 0 0.0057320995
by O 0 0.00032544453
glutamate B-Chemical 0 0.99943167
all O 0 0.00011896038
along O 0 7.822538e-05
the O 0 5.7173795e-05
treatment O 0 6.4769665e-05
period O 0 5.0831484e-05
, O 0 0.00012278424
at O 0 5.528837e-05
a O 0 0.0001138602
daily O 0 9.864855e-05
dose O 0 0.00010972504
of O 0 6.6511275e-05
three O 0 3.482715e-05
times O 0 6.0126953e-05
500 O 0 0.00031020152
mg O 0 0.002584294
( O 0 0.0002832062
group O 0 0.00032014106
G O 0 0.3445519
) O 0 0.00089482963
, O 0 0.0003538821
and O 0 0.00018261177
20 O 0 0.000169202
had O 0 0.00014942235
received O 0 0.00018264662
a O 0 0.00038905474
placebo O 0 0.0028342702
( O 0 0.00087485975
group O 0 0.001131538
P O 0 0.06116458
) O 0 0.0040382906
. O 0 0.0032864127

Patients O 0 0.0039567864
were O 0 0.0013843105
evaluated O 0 0.0009246828
by O 0 0.00083649595
neurological O 0 0.0349754
examinations O 0 0.00062154414
, O 0 0.0006762967
questionnaires O 0 0.0003850479
and O 0 0.00043452255
sensory O 0 0.0010066825
- O 0 0.0026777757
motor O 0 0.0025210094
nerve O 0 0.008141626
conduction O 0 0.0041828877
studies O 0 0.0022091307
. O 0 0.0034727345

There O 0 0.0033620796
was O 0 0.001618912
no O 0 0.00090232154
significant O 0 0.00064833893
difference O 0 0.00041716523
in O 0 0.00032509377
the O 0 0.00021284512
frequency O 0 0.0001876882
of O 0 0.00023481634
signs O 0 0.00092796516
or O 0 0.0001505166
symptoms O 0 0.00063425716
between O 0 7.179424e-05
the O 0 7.086178e-05
two O 0 5.825159e-05
groups O 0 0.00015351584
although O 0 0.00019215676
neurotoxicity B-Disease 0 0.9976871
symptoms O 0 0.0044251904
presented O 0 9.8873454e-05
mostly O 0 0.000116004485
with O 0 0.0001292004
lower O 0 0.00019155692
scores O 0 0.00019897036
of O 0 0.00031038345
severity O 0 0.0010843928
in O 0 0.00063683547
group O 0 0.001897684
G O 0 0.6884677
. O 0 0.004319603

However O 0 0.0031437548
, O 0 0.003523467
this O 0 0.0012681106
difference O 0 0.0006954564
reached O 0 0.0007138406
statistical O 0 0.00067647523
significance O 0 0.00038097234
only O 0 0.00030535273
with O 0 0.00024536482
regard O 0 0.00015773348
to O 0 0.0002041823
reported O 0 0.00033499286
pain B-Disease 0 0.01108276
sensation O 0 0.0030797955
( O 0 0.0008042472
P O 0 0.01307458
= O 0 0.0015008749
0 O 0 0.00093977724
. O 0 0.001098617
011 O 0 0.018984262
) O 0 0.0050844005
. O 0 0.0043409434

Also O 0 0.002742393
the O 0 0.0013370081
frequency O 0 0.0009205223
of O 0 0.00094273675
abnormal O 0 0.0026831846
electro O 0 0.004232576
- O 0 0.0016979882
diagnostic O 0 0.0002735255
findings O 0 0.00022877328
showed O 0 0.00015491188
similarity O 0 0.00014455702
between O 0 0.00012849332
the O 0 0.00013913368
two O 0 0.00012317875
groups O 0 0.00031548474
( O 0 0.00067306095
G O 0 0.14807437
: O 0 0.00069508277
7 O 0 0.00021114903
/ O 0 0.00071988587
23 O 0 0.00034574594
= O 0 0.00051354984
30 O 0 0.00018203844
. O 0 0.00017955997
4 O 0 0.00018561329
% O 0 0.00046480368
; O 0 0.0006560169
P O 0 0.0051379167
: O 0 0.0007776465
6 O 0 0.0003502803
/ O 0 0.0012711835
20 O 0 0.00063035404
= O 0 0.0014213867
30 O 0 0.00085500977
% O 0 0.0021534204
) O 0 0.0040789125
. O 0 0.0042581414

This O 0 0.004672455
pilot O 0 0.002971103
study O 0 0.0014180816
leads O 0 0.00067624095
to O 0 0.0004315815
the O 0 0.00032043725
conclusion O 0 0.00027210583
that O 0 0.0004854035
glutamate B-Chemical 0 0.9997694
supplementation O 0 0.3700386
at O 0 0.00016353767
the O 0 0.0001176179
chosen O 0 0.000114590744
regimen O 0 0.00017043894
fails O 0 0.00013423826
to O 0 0.00016558124
protect O 0 0.0002621251
against O 0 0.000259642
peripheral B-Disease 0 0.29746056
neurotoxicity I-Disease 0 0.99983025
of O 0 0.004097747
PAC B-Chemical 0 0.9974445
. O 0 0.0041952557

Development O 0 0.0058716754
of O 0 0.003555738
ocular B-Disease 0 0.94907796
myasthenia I-Disease 0 0.9994635
during O 0 0.0014744533
pegylated B-Chemical 0 0.997262
interferon I-Chemical 0 0.99986124
and O 0 0.001627524
ribavirin B-Chemical 0 0.9983827
treatment O 0 0.00075802323
for O 0 0.00084239146
chronic B-Disease 0 0.9585376
hepatitis I-Disease 0 0.99998915
C I-Disease 0 0.9999058
. O 0 0.014147552

A O 0 0.032049946
63 O 0 0.006136472
- O 0 0.00764701
year O 0 0.0013276257
- O 0 0.0028027443
old O 0 0.00077193853
male O 0 0.0010519035
experienced O 0 0.0006631188
sudden O 0 0.09247598
diplopia B-Disease 0 0.99758244
after O 0 0.00010941787
9 O 0 9.4065486e-05
weeks O 0 5.554245e-05
of O 0 0.000116668096
administration O 0 0.00026001234
of O 0 0.00032925376
pegylated B-Chemical 0 0.9972619
interferon I-Chemical 0 0.99996805
( I-Chemical 0 0.021889465
IFN I-Chemical 0 0.9999702
) I-Chemical 0 0.014008598
alpha I-Chemical 0 0.83162856
- I-Chemical 0 0.0050721527
2b I-Chemical 0 0.00029637048
and O 0 0.00033666828
ribavirin B-Chemical 0 0.9965289
for O 0 0.00046602864
chronic B-Disease 0 0.9697146
hepatitis I-Disease 0 0.9999969
C I-Disease 0 0.9999757
( O 0 0.24779983
CHC B-Disease 0 0.9987286
) O 0 0.0104226265
. O 0 0.0037631805

Ophthalmologic O 0 0.016604418
examinations O 0 0.0022700734
showed O 0 0.0013707789
ptosis B-Disease 0 0.5888934
on I-Disease 0 0.00042371
the I-Disease 0 0.0003408523
right I-Disease 0 0.0007632755
upper I-Disease 0 0.00060255674
lid I-Disease 0 0.0016530835
and O 0 0.00027927486
restricted B-Disease 0 0.00021713534
right I-Disease 0 0.00070303644
eye I-Disease 0 0.0033579043
movement I-Disease 0 0.00070452614
without O 0 0.0003667549
any O 0 0.0003851971
other O 0 0.00071059004
neurological O 0 0.7698091
signs O 0 0.0094516
. O 0 0.0029366952

A O 0 0.026433334
brain O 0 0.005007043
imaging O 0 0.0017576681
study O 0 0.0011069356
and O 0 0.00079718675
repetitive O 0 0.0007342041
nerve O 0 0.0031221004
stimulation O 0 0.00047357165
test O 0 0.0008509779
indicated O 0 0.00062703114
no O 0 0.0014104611
abnormality O 0 0.02225205
. O 0 0.004633781

The O 0 0.0043008905
acetylcholine B-Chemical 1 0.99917334
receptor O 0 0.007719308
antibody O 0 0.0014114012
titer O 0 0.0010309855
and O 0 0.00048245385
response O 0 0.00036074666
to O 0 0.0003761461
acetylcholinesterase O 0 0.92195374
inhibitors O 0 0.0005099268
were O 0 0.00019454492
negative O 0 0.00020869097
, O 0 0.00034996917
and O 0 0.00019123736
the O 0 0.00014967246
results O 0 0.00018213948
of O 0 0.00035923847
thyroid O 0 0.014493291
function O 0 0.00043807836
tests O 0 0.0013455745
were O 0 0.00084427063
normal O 0 0.0020717552
. O 0 0.002540463

The O 0 0.0020639726
patient O 0 0.0019335008
' O 0 0.0019890477
s O 0 0.0013692563
ophthalmological O 0 0.0066817203
symptoms O 0 0.0030486665
improved O 0 0.00050036685
rapidly O 0 0.00025561862
3 O 0 0.00013867753
weeks O 0 8.142066e-05
after O 0 0.00010124689
discontinuation O 0 0.00074166665
of O 0 0.00049683306
pegylated B-Chemical 0 0.9849038
IFN I-Chemical 0 0.99994373
alpha I-Chemical 0 0.98270744
- I-Chemical 0 0.023629662
2b I-Chemical 0 0.0012253748
and O 0 0.0016243305
ribavirin B-Chemical 0 0.9951526
. O 0 0.003826606

The O 0 0.0028671436
ocular B-Disease 0 0.9025006
myasthenia I-Disease 0 0.99915266
associated O 0 0.0009414218
with O 0 0.00048877456
combination O 0 0.0004518502
therapy O 0 0.0005040706
of O 0 0.0005478068
pegylated B-Chemical 0 0.9968412
IFN I-Chemical 0 0.99998
alpha I-Chemical 0 0.99059206
- I-Chemical 0 0.020466411
2b I-Chemical 0 0.00028452394
and O 0 0.00027314553
ribavirin B-Chemical 0 0.9974456
for O 0 0.00022232837
CHC B-Disease 0 0.9953915
is O 0 0.00016911006
very O 0 0.00023926672
rarely O 0 0.00026892938
reported O 0 0.00019282888
; O 0 0.0003112582
therefore O 0 0.00012764435
, O 0 0.00020295697
we O 0 5.876658e-05
present O 0 9.254265e-05
this O 0 0.00014012773
case O 0 0.00015308331
with O 0 0.0001673863
a O 0 0.00027239678
review O 0 0.00031443735
of O 0 0.00017735761
the O 0 0.00016105165
various O 0 0.00026672267
eye O 0 0.0037227096
complications O 0 0.013631809
of O 0 0.0013617001
IFN B-Chemical 0 0.9997763
therapy O 0 0.0046210596
. O 0 0.0027816999

Learning B-Disease 0 0.012445656
and I-Disease 0 0.0030748844
memory I-Disease 0 0.9355245
deficits I-Disease 0 0.9957896
in O 0 0.0020762961
ecstasy B-Chemical 1 0.99995935
users O 0 0.0015337924
and O 0 0.00042029223
their O 0 0.00029541415
neural O 0 0.00058336137
correlates O 0 0.00034420218
during O 0 0.00027895044
a O 0 0.00068278355
face O 0 0.0012579334
- O 0 0.0037284864
learning O 0 0.003048019
task O 0 0.0046427934
. O 0 0.0040187202

It O 0 0.004830194
has O 0 0.0013312274
been O 0 0.0009804206
consistently O 0 0.00065460015
shown O 0 0.0003409417
that O 0 0.00051115267
ecstasy B-Chemical 1 0.99991894
users O 0 0.0011283935
display O 0 0.0003490795
impairments B-Disease 0 0.09282498
in I-Disease 0 0.0004194139
learning I-Disease 0 0.0012048996
and I-Disease 0 0.0007935287
memory I-Disease 0 0.047222998
performance O 0 0.0031366379
. O 0 0.0034223848

In O 0 0.0016079969
addition O 0 0.0009923234
, O 0 0.0018899848
working O 0 0.0019250263
memory O 0 0.061205298
processing O 0 0.00056658534
in O 0 0.00068185205
ecstasy B-Chemical 1 0.99997675
users O 0 0.001164052
has O 0 0.00014486059
been O 0 0.00013690599
shown O 0 6.9805305e-05
to O 0 0.000100289835
be O 0 0.000111244044
associated O 0 0.00013131148
with O 0 0.00015293303
neural O 0 0.000409022
alterations O 0 0.00031929978
in O 0 0.00013423698
hippocampal O 0 0.0017249425
and O 0 0.00016793754
/ O 0 0.0008236227
or O 0 0.00012275521
cortical O 0 0.0003680414
regions O 0 8.735009e-05
as O 0 0.0001042668
measured O 0 0.00012985143
by O 0 0.00012050097
functional O 0 0.00014006763
magnetic O 0 0.0005048265
resonance O 0 0.0009819454
imaging O 0 0.0005857749
( O 0 0.0010504778
fMRI O 0 0.0027450963
) O 0 0.002719368
. O 0 0.0027431324

Using O 0 0.001421921
functional O 0 0.0011146584
imaging O 0 0.0011680174
and O 0 0.0008308703
a O 0 0.0008826021
face O 0 0.0010784083
- O 0 0.0024566557
learning O 0 0.0010035163
task O 0 0.0008101766
, O 0 0.00042934902
we O 0 0.0001065559
investigated O 0 0.00016749375
neural O 0 0.00035919604
correlates O 0 0.00015732192
of O 0 0.00013780856
encoding O 0 0.00010692671
and O 0 0.00019391265
recalling O 0 0.0012829859
face O 0 0.00046183582
- O 0 0.0011587671
name O 0 0.00013493151
associations O 0 9.903877e-05
in O 0 0.00010463154
20 O 0 0.00012989204
recreational O 0 0.00074409484
drug O 0 0.0017250328
users O 0 0.00027561394
whose O 0 0.0001978121
predominant O 0 0.00022607605
drug O 0 0.0022422727
use O 0 0.00025542325
was O 0 0.0004793413
ecstasy B-Chemical 1 0.99993825
and O 0 0.0009541565
20 O 0 0.0009226657
controls O 0 0.0017229731
. O 0 0.0025481025

To O 0 0.0009817905
address O 0 0.0005548458
the O 0 0.0005588804
potential O 0 0.00037410686
confounding O 0 0.00037229434
effects O 0 0.00029700238
of O 0 0.00033672235
the O 0 0.00029358047
cannabis B-Chemical 0 0.9994355
use O 0 0.00019378087
of O 0 0.00018897197
the O 0 0.00020729603
ecstasy B-Chemical 1 0.99997604
using O 0 0.00015530027
group O 0 0.00022713278
, O 0 0.00023067558
a O 0 0.00014857065
second O 0 7.994058e-05
analysis O 0 8.161834e-05
included O 0 7.089788e-05
14 O 0 7.8083256e-05
previously O 0 0.00010176278
tested O 0 0.00015810512
cannabis B-Chemical 0 0.99977726
users O 0 0.00073812564
( O 0 0.00057091913
Nestor O 0 0.0024442982
, O 0 0.00061429566
L O 0 0.5085402
. O 0 0.00032490882
, O 0 0.00054354116
Roberts O 0 0.0017709689
, O 0 0.0009721048
G O 0 0.47170657
. O 0 0.00046163646
, O 0 0.0009606122
Garavan O 0 0.70934993
, O 0 0.0018214977
H O 0 0.9997316
. O 0 0.0006457157
, O 0 0.0009200076
Hester O 0 0.0062804823
, O 0 0.0010854314
R O 0 0.9817645
. O 0 0.000366137
, O 0 0.00042912114
2008 O 0 0.000445516
. O 0 0.00020409182
Deficits B-Disease 0 0.0016009614
in I-Disease 0 0.00013050645
learning I-Disease 0 0.00037418422
and I-Disease 0 0.00019724031
memory I-Disease 0 0.12160969
: O 0 0.003219871
parahippocampal O 0 0.99955946
hyperactivity B-Disease 2 0.999998
and O 0 0.0009106303
frontocortical O 0 0.9960517
hypoactivity O 0 0.99981433
in O 0 0.00029533982
cannabis B-Chemical 0 0.99973196
users O 0 0.00068736624
. O 0 0.00031746854
Neuroimage O 0 0.0028690621
40 O 0 0.0004884448
, O 0 0.0011584035
1328 O 0 0.009615644
- O 0 0.007993294
1339 O 0 0.5975456
) O 0 0.0051232674
. O 0 0.0038360257

Ecstasy B-Chemical 0 0.99914145
users O 0 0.003912943
performed O 0 0.0009918006
significantly O 0 0.0008119213
worse O 0 0.0010316682
in O 0 0.00041254042
learning O 0 0.0008991594
and O 0 0.0004240149
memory O 0 0.007662408
compared O 0 0.00030025086
to O 0 0.00034121386
controls O 0 0.00079368416
and O 0 0.0011648434
cannabis B-Chemical 0 0.999203
users O 0 0.0050413776
. O 0 0.0036798215

A O 0 0.019142717
conjunction O 0 0.00223351
analysis O 0 0.0010681013
of O 0 0.0006818972
the O 0 0.0003655548
encode O 0 0.00019130485
and O 0 0.00031235276
recall O 0 0.0006147021
phases O 0 0.00033846276
of O 0 0.00021117723
the O 0 0.00014942976
task O 0 0.00047751938
revealed O 0 0.0003073358
ecstasy B-Chemical 1 0.9999896
- O 0 0.03058893
specific O 0 0.0001894078
hyperactivity B-Disease 2 0.9999927
in O 0 0.00024016885
bilateral O 0 0.0041879495
frontal O 0 0.08100124
regions O 0 9.115723e-05
, O 0 0.00017988626
left O 0 0.00026204338
temporal O 0 0.00078139844
, O 0 0.00033021692
right O 0 0.0005784952
parietal O 0 0.6337165
, O 0 0.0004299972
bilateral O 0 0.0013477895
temporal O 0 0.001132213
, O 0 0.0005144292
and O 0 0.0003990141
bilateral O 0 0.0077318023
occipital O 0 0.92760545
brain O 0 0.00244484
regions O 0 0.0009817699
. O 0 0.0020986025

Ecstasy B-Chemical 0 0.9996815
- O 0 0.14164367
specific O 0 0.0018138731
hypoactivity O 0 0.9990681
was O 0 0.00078230596
evident O 0 0.00044330233
in O 0 0.0002975738
the O 0 0.0002429487
right O 0 0.00069531694
dorsal O 0 0.0008423722
anterior O 0 0.017134603
cingulated O 0 0.9987482
cortex O 0 0.029400628
( O 0 0.00076736993
ACC O 0 0.0029081793
) O 0 0.0007201747
and O 0 0.00042077713
left O 0 0.0014683226
posterior O 0 0.05702627
cingulated O 0 0.99863523
cortex O 0 0.11696051
. O 0 0.0034452588

In O 0 0.002044313
both O 0 0.0026288219
ecstasy B-Chemical 1 0.9998766
and O 0 0.002803032
cannabis B-Chemical 0 0.9997242
groups O 0 0.0012269163
brain O 0 0.0012513185
activation O 0 0.0002484645
was O 0 0.0001939023
decreased O 0 0.00029559364
in O 0 0.00015303193
the O 0 0.00014099383
right O 0 0.0005483366
medial O 0 0.009469938
frontal O 0 0.5604358
gyrus O 0 0.68819255
, O 0 0.000558626
left O 0 0.0009609785
parahippocampal O 0 0.98534864
gyrus O 0 0.8079613
, O 0 0.0006148609
left O 0 0.00072554336
dorsal O 0 0.0010841747
cingulate O 0 0.9974251
gyrus O 0 0.7032132
, O 0 0.0010910797
and O 0 0.00074434804
left O 0 0.0024146421
caudate O 0 0.055260826
. O 0 0.0032218765

These O 0 0.0022666545
results O 0 0.0020900697
elucidated O 0 0.0032343105
ecstasy B-Chemical 1 0.99994683
- O 0 0.055913556
related O 0 0.00059533125
deficits O 0 0.43361455
, O 0 0.0010160368
only O 0 0.00040180993
some O 0 0.00033651973
of O 0 0.00037922058
which O 0 0.00039518136
might O 0 0.0002116253
be O 0 0.00036716313
attributed O 0 0.00045171715
to O 0 0.00081713276
cannabis B-Chemical 0 0.9990415
use O 0 0.0022184437
. O 0 0.0033157284

These O 0 0.0042314827
ecstasy B-Chemical 1 0.9998573
- O 0 0.022977764
specific O 0 0.0005999425
effects O 0 0.00060791976
may O 0 0.0004144277
be O 0 0.00031666536
related O 0 0.00017950195
to O 0 0.00020117806
the O 0 0.00022062866
vulnerability O 0 0.0021377138
of O 0 0.0005786739
isocortical O 0 0.9603361
and O 0 0.00043018683
allocortical O 0 0.011324687
regions O 0 0.0001695258
to O 0 0.00019278917
the O 0 0.0003044292
neurotoxic B-Disease 0 0.6864663
effects O 0 0.0007769132
of O 0 0.0023687321
ecstasy B-Chemical 1 0.9999479
. O 0 0.0056214225

Disulfiram B-Chemical 0 0.999848
- O 0 0.16070916
like O 0 0.0030912845
syndrome O 0 0.9714965
after O 0 0.0014443555
hydrogen B-Chemical 0 0.9998628
cyanamide I-Chemical 0 0.99989986
professional O 0 0.0034700655
skin O 0 0.0020487653
exposure O 0 0.000498135
: O 0 0.00067251717
two O 0 0.00026797364
case O 0 0.0005552738
reports O 0 0.0008709436
in O 0 0.0013434706
France O 0 0.008209492
. O 0 0.0037600477

Hydrogen B-Chemical 0 0.99774194
cyanamide I-Chemical 0 0.9994178
is O 0 0.0023820004
a O 0 0.0022951127
plant O 0 0.002622457
growth O 0 0.0029114955
regulator O 0 0.00035575405
used O 0 0.00040345194
in O 0 0.00048275926
agriculture O 0 0.0041300966
to O 0 0.0004107193
induce O 0 0.0004177466
bud O 0 0.009319561
break O 0 0.0011330805
in O 0 0.0011180559
fruit O 0 0.0070479163
trees O 0 0.0038160908
. O 0 0.004337799

Contact O 0 0.016948327
with O 0 0.0027187604
the O 0 0.0015403265
skin O 0 0.0026244621
can O 0 0.00041458852
result O 0 0.00031105356
in O 0 0.00027278689
percutaneous O 0 0.0005259607
absorption O 0 0.0054967003
of O 0 0.00027404702
the O 0 0.00025410482
substance O 0 0.3973217
that O 0 0.00028432297
inhibits O 0 0.0007970598
aldehyde B-Chemical 0 0.99997485
dehydrogenase O 0 0.9839443
and O 0 0.00057676126
can O 0 0.00023691678
induce O 0 0.0004759745
acetaldehyde B-Chemical 0 0.99999213
syndrome O 0 0.99728703
in O 0 0.00044412946
case O 0 0.00053550146
of O 0 0.00090998935
alcohol B-Chemical 0 0.9968798
use O 0 0.0018620348
. O 0 0.0028289654

The O 0 0.0016383382
purpose O 0 0.0010963796
of O 0 0.0012730627
this O 0 0.000987282
report O 0 0.0011057989
is O 0 0.000358772
to O 0 0.0002521192
describe O 0 0.00022464928
two O 0 0.00015932063
cases O 0 0.0003940642
of O 0 0.0003313415
a O 0 0.0013407231
disulfiram B-Chemical 0 0.9999945
- O 0 0.056659494
like O 0 0.0003461021
syndrome O 0 0.6727462
following O 0 0.00019684987
occupational O 0 0.000661554
exposure O 0 0.00065333437
to O 0 0.0010799118
hydrogen B-Chemical 0 0.9997459
cyanamide I-Chemical 0 0.9998228
. O 0 0.0063970434

The O 0 0.0019775662
first O 0 0.0012317031
case O 0 0.0012944752
involved O 0 0.00082356617
a O 0 0.0010933164
59 O 0 0.0010491018
- O 0 0.002179961
year O 0 0.0004217329
- O 0 0.0014179352
old O 0 0.00046106495
man O 0 0.0019384705
who O 0 0.00041653117
used O 0 0.00026764223
Dormex B-Chemical 0 0.07557446
, O 0 0.0006712026
which O 0 0.00037877492
contains O 0 0.00040484412
hydrogen B-Chemical 0 0.99996936
cyanamide I-Chemical 0 0.9999752
, O 0 0.0010230946
without O 0 0.00017872488
protection O 0 0.0001549277
after O 0 8.0788166e-05
consuming O 0 0.00034818062
a O 0 0.0002820182
large O 0 0.00027883184
amount O 0 0.00017576081
of O 0 0.0005119021
alcohol B-Chemical 0 0.9945798
during O 0 0.00063130574
a O 0 0.0015619328
meal O 0 0.0055042543
. O 0 0.002959806

In O 0 0.0019540417
less O 0 0.0022512635
than O 0 0.0010420821
1 O 0 0.00078667136
hour O 0 0.0004877869
after O 0 0.00020882873
the O 0 0.00028612342
ingestion O 0 0.0019041292
of O 0 0.00052632554
alcohol B-Chemical 0 0.998321
, O 0 0.0010307502
he O 0 0.00043513376
developed O 0 0.0004500929
malaise O 0 0.9560992
with O 0 0.00033351395
flushing B-Disease 0 0.058219623
of I-Disease 0 0.00028011887
the I-Disease 0 0.0002471591
face I-Disease 0 0.0007941282
, O 0 0.0014543855
tachycardia B-Disease 2 0.9981774
, O 0 0.0018067884
and O 0 0.0016074721
dyspnea B-Disease 0 0.9591939
. O 0 0.0031120293

Manifestations O 0 0.022725532
regressed O 0 0.00955522
spontaneously O 0 0.0054227575
under O 0 0.0019429742
surveillance O 0 0.0015360805
in O 0 0.0019109743
the O 0 0.0023628406
hospital O 0 0.004964056
. O 0 0.006237557

The O 0 0.002272298
second O 0 0.0017838343
case O 0 0.001534889
occurred O 0 0.0009993203
in O 0 0.00074999727
a O 0 0.0009571544
55 O 0 0.00090620597
- O 0 0.0020143536
year O 0 0.0005046124
- O 0 0.0016649074
old O 0 0.0006991519
farmer O 0 0.0020355182
following O 0 0.000514103
cutaneous O 0 0.004523982
contact O 0 0.0012596895
with O 0 0.001927304
Dormex B-Chemical 0 0.15062687
. O 0 0.004664996

Five O 0 0.0028550564
hours O 0 0.001416
after O 0 0.000700103
exposure O 0 0.0010181823
, O 0 0.0013297074
he O 0 0.0009544675
developed O 0 0.0013700404
disulfiram B-Chemical 0 0.99998593
- O 0 0.056644883
like O 0 0.00046009623
syndrome O 0 0.8781587
with O 0 0.00048806833
flushing B-Disease 0 0.544337
, O 0 0.0009932739
tachycardia B-Disease 2 0.9985593
, O 0 0.00051662227
and O 0 0.00031459177
arterial B-Disease 0 0.9970995
hypotension I-Disease 0 0.9999771
after O 0 0.00015979836
consuming O 0 0.00047921567
three O 0 0.00022011112
glasses O 0 0.0026227678
of O 0 0.0017310936
wine O 0 0.86902773
. O 0 0.0041520046

The O 0 0.0025274386
patient O 0 0.0023654555
recovered O 0 0.0013361055
spontaneously O 0 0.002124932
in O 0 0.0007552325
3 O 0 0.0005587901
hours O 0 0.00047840236
under O 0 0.00052064355
surveillance O 0 0.0005731455
in O 0 0.0008741557
the O 0 0.0012653145
hospital O 0 0.0031019268
. O 0 0.004113835

These O 0 0.0021612265
cases O 0 0.0022563708
confirm O 0 0.00050494244
the O 0 0.000528595
necessity O 0 0.00047331306
of O 0 0.00047009863
avoiding O 0 0.00053017307
alcohol B-Chemical 0 0.9986358
consumption O 0 0.015660724
as O 0 0.0002292541
recommended O 0 0.00015966235
in O 0 0.00012547983
the O 0 0.000106855565
instructions O 0 0.0001595975
for O 0 9.0978516e-05
use O 0 0.00012667288
of O 0 0.00024692732
Dormex B-Chemical 0 0.029552646
and O 0 0.0002793057
of O 0 0.00032044703
preventing O 0 0.00042682444
cutaneous O 0 0.006983849
contact O 0 0.00066583336
during O 0 0.00056522124
use O 0 0.0011715172
. O 0 0.0025800266

Sulpiride B-Chemical 0 0.9998921
- O 0 0.568732
induced O 0 0.028225759
tardive B-Disease 0 0.9999467
dystonia I-Disease 0 0.999936
. O 0 0.023014985

Sulpiride B-Chemical 0 0.9999379
is O 0 0.0032231917
a O 0 0.0031860236
selective O 0 0.004260702
D2 O 0 0.9974032
- O 0 0.094483756
receptor O 0 0.0050474997
antagonist O 0 0.23194717
with O 0 0.0014959536
antipsychotic O 0 0.9991936
and O 0 0.0015599503
antidepressant B-Chemical 0 0.999286
properties O 0 0.0015365266
. O 0 0.0031150454

Although O 0 0.0022145165
initially O 0 0.002581422
thought O 0 0.0013011314
to O 0 0.0007139569
be O 0 0.0005858821
free O 0 0.00074127095
of O 0 0.00080399704
extrapyramidal O 0 0.99991345
side O 0 0.0016386469
effects O 0 0.00046192433
, O 0 0.0066792206
sulpiride B-Chemical 0 0.9999994
- O 0 0.3139214
induced O 0 0.0013230722
tardive B-Disease 0 0.9999987
dyskinesia I-Disease 0 0.9999995
and O 0 0.002553709
parkinsonism B-Disease 2 0.99999034
have O 0 0.0004542847
been O 0 0.00052123395
reported O 0 0.00092117547
occasionally O 0 0.0023929735
. O 0 0.00264772

We O 0 0.0031720581
studied O 0 0.0029944102
a O 0 0.0024033333
37 O 0 0.0026327558
- O 0 0.0038930618
year O 0 0.0007109071
- O 0 0.0021096836
old O 0 0.00065945584
man O 0 0.0026129496
who O 0 0.00052432786
developed O 0 0.00036348976
persistent O 0 0.00074433844
segmental O 0 0.08558683
dystonia B-Disease 0 0.9999821
within O 0 0.00014072507
2 O 0 0.00017867683
months O 0 8.9039306e-05
after O 0 0.00014028922
starting O 0 0.00042932507
sulpiride B-Chemical 0 0.99997246
therapy O 0 0.0034229204
. O 0 0.002732419

We O 0 0.0031634339
could O 0 0.0016356885
not O 0 0.0011805191
find O 0 0.0007344959
any O 0 0.0006224245
previous O 0 0.00054330495
reports O 0 0.0008910745
of O 0 0.0022040703
sulpiride B-Chemical 0 0.99999774
- O 0 0.49962944
induced O 0 0.005423876
tardive B-Disease 0 0.99999034
dystonia I-Disease 0 0.9999831
. O 0 0.0067649013

Comparative O 0 0.005181273
cognitive O 0 0.5052631
and O 0 0.0013539069
subjective O 0 0.0015004255
side O 0 0.0010983318
effects O 0 0.0004048142
of O 0 0.0004615124
immediate O 0 0.0007997478
- O 0 0.005628893
release O 0 0.0014089999
oxycodone B-Chemical 1 0.99977595
in O 0 0.00032783486
healthy O 0 0.0011476274
middle O 0 0.001203111
- O 0 0.0023290883
aged O 0 0.00092032243
and O 0 0.00074727705
older O 0 0.0038576862
adults O 0 0.0057938537
. O 0 0.0034917514

This O 0 0.0034795334
study O 0 0.0015253753
measured O 0 0.0007911605
the O 0 0.0003941549
objective O 0 0.00037024464
and O 0 0.00033837292
subjective O 0 0.0007743813
neurocognitive O 0 0.07136088
effects O 0 0.00017806522
of O 0 0.00019530657
a O 0 0.00022755873
single O 0 0.00010677601
10 O 0 0.00014670241
- O 0 0.0007602257
mg O 0 0.0012531123
dose O 0 0.00016585697
of O 0 0.00011491694
immediate O 0 0.0002748063
- O 0 0.0027552508
release O 0 0.00080300926
oxycodone B-Chemical 1 0.9998827
in O 0 0.0001782035
healthy O 0 0.00084530865
, O 0 0.0003353002
older O 0 0.0007600171
( O 0 0.00030113783
> O 0 0.00032241925
65 O 0 0.0001838275
years O 0 0.0001779157
) O 0 0.00031884952
, O 0 0.00024754752
and O 0 0.00017449308
middle O 0 0.0007551972
- O 0 0.001719215
aged O 0 0.0003750592
( O 0 0.00025934982
35 O 0 0.000132584
to O 0 9.272108e-05
55 O 0 0.00016186187
years O 0 0.00017604796
) O 0 0.0003599656
adults O 0 0.0005582184
who O 0 0.00024344119
were O 0 0.00013636024
not O 0 0.00017047847
suffering O 0 0.0033038694
from O 0 0.00022027278
chronic O 0 0.002711139
or O 0 0.00029262784
significant O 0 0.0004923311
daily O 0 0.0010944741
pain B-Disease 0 0.028991392
. O 0 0.0023076886

Seventy O 0 0.011782105
- O 0 0.0073683076
one O 0 0.0010167253
participants O 0 0.0007970895
completed O 0 0.00057680823
2 O 0 0.0003467319
separate O 0 0.0001838098
study O 0 0.00020592845
days O 0 0.00011536224
and O 0 0.0001771879
were O 0 0.00017183021
blind O 0 0.0018346965
to O 0 0.00016275798
medication O 0 0.00073645276
condition O 0 0.00037997073
( O 0 0.00050693366
placebo O 0 0.0026991207
, O 0 0.0005848606
10 O 0 0.0004677142
- O 0 0.0032908125
mg O 0 0.09416279
oxycodone B-Chemical 1 0.99938285
) O 0 0.0044072685
. O 0 0.0030293586

Plasma O 0 0.8683088
oxycodone B-Chemical 1 0.9995821
concentration O 0 0.0024834152
peaked O 0 0.00093292573
between O 0 0.0003895632
60 O 0 0.0004094318
and O 0 0.0002635286
90 O 0 0.00023656803
minutes O 0 0.00020248264
postdose O 0 0.0005299248
( O 0 0.0003183514
P O 0 0.001642384
< O 0 0.000332806
. O 0 0.0002180106
01 O 0 0.0010204605
) O 0 0.0004708105
and O 0 0.00023464378
pupil O 0 0.0016955045
size O 0 0.0003964172
, O 0 0.00032211206
an O 0 0.0001286429
indication O 0 6.338779e-05
of O 0 0.000102266975
physiological O 0 0.000114397815
effects O 0 9.6790245e-05
of O 0 0.00012899016
the O 0 0.000109808694
medication O 0 0.0011715022
, O 0 0.0002300461
peaked O 0 0.00017158168
at O 0 9.080621e-05
approximately O 0 0.00014013948
90 O 0 0.000116976786
to O 0 9.0848385e-05
120 O 0 0.00016568167
minutes O 0 0.00015689782
postdose O 0 0.000571825
( O 0 0.0004563459
P O 0 0.002576875
< O 0 0.0008510517
. O 0 0.0008550512
01 O 0 0.0048227296
) O 0 0.0040656943
. O 0 0.0039822566

Significant O 0 0.004185345
declines B-Disease 0 0.002749192
in I-Disease 0 0.0010072836
simple I-Disease 0 0.0008195095
and I-Disease 0 0.00057407306
sustained I-Disease 0 0.00071222463
attention I-Disease 0 0.0011380223
, I-Disease 0 0.0006228238
working I-Disease 0 0.0007649357
memory I-Disease 0 0.09695809
, I-Disease 0 0.00056098186
and I-Disease 0 0.0002578517
verbal I-Disease 0 0.088513754
memory I-Disease 0 0.0754814
were O 0 0.00013157756
observed O 0 7.9717465e-05
at O 0 6.221878e-05
1 O 0 8.4909596e-05
hour O 0 7.55726e-05
postdose O 0 0.00016708285
compared O 0 3.463422e-05
to O 0 3.9981172e-05
baseline O 0 4.974161e-05
for O 0 4.4279594e-05
both O 0 6.124481e-05
age O 0 0.00013638599
groups O 0 0.00012788436
with O 0 0.00012985924
a O 0 0.00020225457
trend O 0 0.00023906241
toward O 0 0.00018655935
return O 0 0.00020300284
to O 0 0.00013770965
baseline O 0 0.00018725653
by O 0 0.0002570672
5 O 0 0.0003619123
hours O 0 0.0005210735
postdose O 0 0.0026785373
. O 0 0.00206193

For O 0 0.0016694455
almost O 0 0.0016974242
all O 0 0.0012474866
cognitive O 0 0.28992933
measures O 0 0.0005857409
, O 0 0.0006549069
there O 0 0.00023381056
were O 0 0.0002022077
no O 0 0.00017490269
medication O 0 0.00065532303
by O 0 0.00015661395
age O 0 0.0002988931
- O 0 0.0006591071
interaction O 0 9.7172655e-05
effects O 0 0.00015516498
, O 0 0.00035777912
which O 0 0.00017036195
indicates O 0 8.775193e-05
that O 0 8.53399e-05
the O 0 9.8506236e-05
2 O 0 0.00012746472
age O 0 0.00016206881
groups O 0 0.00014248755
exhibited O 0 0.00013230716
similar O 0 0.00010630867
responses O 0 0.00018999349
to O 0 0.0002324121
the O 0 0.00035574997
medication O 0 0.0020903083
challenge O 0 0.00091081427
. O 0 0.002207807

This O 0 0.004497225
study O 0 0.0019023744
suggests O 0 0.0006319435
that O 0 0.00051627425
for O 0 0.0004792193
healthy O 0 0.0023755583
older O 0 0.0026957581
adults O 0 0.0017277694
who O 0 0.00039373996
are O 0 0.00013953558
not O 0 0.00015854502
suffering O 0 0.0022652894
from O 0 0.00014097878
chronic B-Disease 0 0.006278572
pain I-Disease 0 0.0678728
, O 0 0.00038892718
neurocognitive O 0 0.37863752
and O 0 0.0001242243
pharmacodynamic O 0 0.0028227537
changes O 0 8.982534e-05
in O 0 6.505354e-05
response O 0 7.034605e-05
to O 0 6.889086e-05
a O 0 0.0001364928
10 O 0 0.000111995585
- O 0 0.00067279924
mg O 0 0.0011637803
dose O 0 0.00013785624
of O 0 9.7229284e-05
immediate O 0 0.00024713625
- O 0 0.002828726
release O 0 0.0007384796
oxycodone B-Chemical 1 0.9998641
are O 0 9.428191e-05
similar O 0 6.741323e-05
to O 0 9.7221025e-05
those O 0 0.00016148835
observed O 0 0.00015769784
for O 0 0.00022432118
middle O 0 0.0015391199
- O 0 0.004365154
aged O 0 0.0020743932
adults O 0 0.0044073043
. O 0 0.0029257957

PERSPECTIVE O 0 0.010926742
: O 0 0.0043409164
Study O 0 0.002348194
findings O 0 0.00074019266
indicate O 0 0.00030819408
that O 0 0.0003492085
the O 0 0.00043200425
metabolism O 0 0.0274628
, O 0 0.0010078129
neurocognitive O 0 0.37680826
effects O 0 0.00019447407
, O 0 0.0002969783
and O 0 0.00014094637
physical O 0 0.0001991759
side O 0 0.00026523307
effects O 0 0.000116869196
of O 0 0.00019656781
oral O 0 0.004811677
oxycodone B-Chemical 1 0.9998054
are O 0 9.0932364e-05
similar O 0 6.5963206e-05
for O 0 0.00010228434
healthy O 0 0.0006955174
middle O 0 0.0009990566
- O 0 0.0022149528
aged O 0 0.0008050473
and O 0 0.00064734946
older O 0 0.0036930651
adults O 0 0.0055426215
. O 0 0.003171184

Therefore O 0 0.0021190122
, O 0 0.0033854207
clinicians O 0 0.0019207889
should O 0 0.00043448634
not O 0 0.00037837974
avoid O 0 0.00028230148
prescribing O 0 0.0011713242
oral O 0 0.0013051627
opioids O 0 0.044724062
to O 0 0.00015726883
older O 0 0.00083034957
adults O 0 0.0005584315
based O 0 9.8673576e-05
on O 0 7.079444e-05
the O 0 9.178552e-05
belief O 0 0.00031653073
that O 0 0.00011467393
older O 0 0.0011746248
adults O 0 0.00071003364
are O 0 9.205225e-05
at O 0 8.173197e-05
higher O 0 0.000164265
risk O 0 0.0007636226
for O 0 0.00015391363
side O 0 0.00056912866
effects O 0 0.00037292816
than O 0 0.0005673965
younger O 0 0.00884692
adults O 0 0.0065335548
. O 0 0.002849011

The O 0 0.0045856507
glycine B-Chemical 0 0.9948413
transporter O 0 0.48792976
- O 0 0.039386448
1 O 0 0.0011931651
inhibitor O 0 0.0031840953
SSR103800 B-Chemical 0 0.9947588
displays O 0 0.00027146787
a O 0 0.00036088753
selective O 0 0.0002599566
and O 0 0.00019957246
specific O 0 0.00015752981
antipsychotic O 0 0.9978321
- O 0 0.0015618779
like O 0 0.00017386778
profile O 0 0.00022434106
in O 0 0.00029168496
normal O 0 0.0006050466
and O 0 0.0004671735
transgenic O 0 0.00043125497
mice O 0 0.0005987778
. O 0 0.002443482

Schizophrenia B-Disease 0 0.9959914
has O 0 0.0021770266
been O 0 0.0015609501
initially O 0 0.0015379142
associated O 0 0.0012076498
with O 0 0.0014957543
dysfunction O 0 0.9114898
in O 0 0.0035916397
dopamine B-Chemical 0 0.99961
neurotransmission O 0 0.414801
. O 0 0.0046096398

However O 0 0.003052665
, O 0 0.0034430332
the O 0 0.0011386371
observation O 0 0.0007990919
that O 0 0.0006408533
antagonists O 0 0.023014173
of O 0 0.001142886
the O 0 0.0013777816
glutamate B-Chemical 0 0.99990916
N B-Chemical 0 0.9999167
- I-Chemical 0 0.87398577
methyl I-Chemical 0 0.9982516
- I-Chemical 0 0.5943008
D I-Chemical 0 0.99894196
- I-Chemical 0 0.89012194
aspartate I-Chemical 1 0.9999145
( O 0 0.0184271
NMDA B-Chemical 0 0.99996936
) O 0 0.0031181655
receptor O 0 0.00121869
produce O 0 0.00029065728
schizophrenic B-Disease 0 0.99999523
- O 0 0.028978994
like O 0 0.00016466834
symptoms O 0 0.0024484457
in O 0 0.00012416436
humans O 0 0.00020636992
has O 0 7.208359e-05
led O 0 0.00011307263
to O 0 9.075374e-05
the O 0 8.567986e-05
idea O 0 0.00011547506
of O 0 0.00018225414
a O 0 0.0004031991
dysfunctioning O 0 0.22019571
of O 0 0.00025181746
the O 0 0.00022222409
glutamatergic O 0 0.0050422675
system O 0 0.00034379962
via O 0 0.00042871365
its O 0 0.0021016502
NMDA B-Chemical 0 0.99986076
receptor O 0 0.037063554
. O 0 0.004161653

As O 0 0.0024094929
a O 0 0.0027712819
result O 0 0.001284612
, O 0 0.0015333317
there O 0 0.0005396074
is O 0 0.00042637833
a O 0 0.0005185441
growing O 0 0.00030194048
interest O 0 0.00018933971
in O 0 0.0001537196
the O 0 0.00011459392
development O 0 0.00014757115
of O 0 0.00012078213
pharmacological O 0 0.0003175351
agents O 0 0.0002835542
with O 0 0.00010632733
potential O 0 0.00010043692
antipsychotic O 0 0.9923137
properties O 0 5.6742094e-05
that O 0 5.0896964e-05
enhance O 0 5.7399524e-05
the O 0 7.668344e-05
activity O 0 7.7002194e-05
of O 0 0.00014439158
the O 0 0.00014613
glutamatergic O 0 0.0029670235
system O 0 0.00015382882
via O 0 0.00013236924
a O 0 0.000294798
modulation O 0 0.00023547413
of O 0 0.0005838953
the O 0 0.0011514665
NMDA B-Chemical 0 0.9998673
receptor O 0 0.040100258
. O 0 0.0040906314

Among O 0 0.004554016
them O 0 0.0043966565
are O 0 0.0026912163
glycine B-Chemical 0 0.9953099
transporter O 0 0.3854888
- O 0 0.023151845
1 O 0 0.0008344201
( O 0 0.0012240089
GlyT1 O 0 0.042054914
) O 0 0.0007915285
inhibitors O 0 0.0004163049
such O 0 0.00025590055
as O 0 0.0004292248
SSR103800 B-Chemical 0 0.99925107
, O 0 0.0008323125
which O 0 0.00025431468
indirectly O 0 0.00019106404
enhance O 0 0.0002440596
NMDA B-Chemical 0 0.9999647
receptor O 0 0.001518086
function O 0 0.0001428554
by O 0 0.0001339738
increasing O 0 0.00017066467
the O 0 0.00021259078
glycine B-Chemical 0 0.9763014
( O 0 0.0006428034
a O 0 0.00039906416
co O 0 0.05817459
- O 0 0.017865675
agonist O 0 0.007800758
for O 0 0.00020480371
the O 0 0.00042825172
NMDA B-Chemical 0 0.9999523
receptor O 0 0.006106692
) O 0 0.0012782101
levels O 0 0.0004048854
in O 0 0.00054563844
the O 0 0.00076866936
synapse O 0 0.00295604
. O 0 0.002953215

This O 0 0.0037705079
study O 0 0.0015324499
aimed O 0 0.0007739501
at O 0 0.00043568687
investigating O 0 0.00031358955
the O 0 0.00026526419
potential O 0 0.00030639113
antipsychotic O 0 0.9984664
- O 0 0.001902618
like O 0 0.00013980448
properties O 0 0.00012073791
of O 0 0.00034138287
SSR103800 B-Chemical 0 0.9990964
, O 0 0.0005545832
with O 0 0.00018513534
a O 0 0.00019672715
particular O 0 7.237378e-05
focus O 0 0.00011195032
on O 0 5.817959e-05
models O 0 0.000100546546
of O 0 0.00033407213
hyperactivity B-Disease 2 0.9999974
, O 0 0.00060074736
involving O 0 0.00014733043
either O 0 0.00011213011
drug O 0 0.0015181827
challenge O 0 9.147184e-05
( O 0 0.00023610923
ie O 0 0.00031649903
, O 0 0.0009963509
amphetamine B-Chemical 1 0.99999225
and O 0 0.0008141075
MK B-Chemical 0 0.99814796
- I-Chemical 0 0.07664124
801 I-Chemical 0 0.14662771
) O 0 0.00035405692
or O 0 8.4721476e-05
transgenic O 0 6.0060414e-05
mice O 0 5.6679688e-05
( O 0 0.0003043427
ie O 0 0.00047523828
, O 0 0.0012857681
NMDA B-Chemical 0 0.9999124
Nr1 O 0 0.00672633
( O 0 0.00061998423
neo O 0 0.0012062426
- O 0 0.0028977322
/ O 0 0.0024567002
- O 0 0.0030630524
) O 0 0.001006263
and O 0 0.00066580763
DAT O 0 0.90994596
( O 0 0.0016153399
- O 0 0.0045757885
/ O 0 0.004833174
- O 0 0.0064142393
) O 0 0.003693595
) O 0 0.0048074047
. O 0 0.0042319936

Results O 0 0.003072564
showed O 0 0.0020355766
that O 0 0.001786891
SSR103800 B-Chemical 0 0.99135137
( O 0 0.002128345
10 O 0 0.000744497
- O 0 0.0014929282
30 O 0 0.00033850854
mg O 0 0.001407788
/ O 0 0.000755307
kg O 0 0.0005150892
p O 0 0.00042059785
. O 0 0.00023875856
o O 0 0.00103145
. O 0 0.00030338354
) O 0 0.0008732482
blocked O 0 0.0013772853
hyperactivity B-Disease 2 0.99999464
induced O 0 0.00030296363
by O 0 0.00018287262
the O 0 0.00015447794
non O 0 0.00053587963
- O 0 0.01896342
competitive O 0 0.0028131478
NMDA B-Chemical 0 0.9999833
receptor O 0 0.06953576
antagonist O 0 0.8660072
, O 0 0.006949377
MK B-Chemical 0 0.9993175
- I-Chemical 0 0.20522751
801 I-Chemical 0 0.23715594
and O 0 0.00019783927
partially O 0 0.000175217
reversed O 0 0.0005619842
spontaneous O 0 0.023149436
hyperactivity B-Disease 2 0.9999974
of O 0 0.0028869756
NMDA B-Chemical 0 0.9999665
Nr1 O 0 0.020560604
( O 0 0.0008943271
neo O 0 0.0017556719
- O 0 0.0038940457
/ O 0 0.003465708
- O 0 0.003751058
) O 0 0.0019217363
mice O 0 0.00077751535
. O 0 0.0028618781

In O 0 0.0023283039
contrast O 0 0.003352403
, O 0 0.0056085475
SSR103800 B-Chemical 0 0.9958281
failed O 0 0.000988543
to O 0 0.00052216783
affect O 0 0.0005648408
hyperactivity B-Disease 2 0.99999034
induced O 0 0.0005999843
by O 0 0.00067895424
amphetamine B-Chemical 1 0.99999225
or O 0 0.0002887435
naturally O 0 0.0002961513
observed O 0 0.00019256063
in O 0 0.00044571096
dopamine B-Chemical 0 0.99992454
transporter O 0 0.10471589
( O 0 0.001304121
DAT O 0 0.946755
( O 0 0.00062116096
- O 0 0.002027917
/ O 0 0.0017225122
- O 0 0.0018581216
) O 0 0.0004548576
) O 0 0.00029213275
knockout O 0 7.9040066e-05
mice O 0 7.098561e-05
( O 0 0.00030871987
10 O 0 0.00021992654
- O 0 0.0007170936
30 O 0 0.00021111239
mg O 0 0.0012053956
/ O 0 0.00084324385
kg O 0 0.0007219349
p O 0 0.00074685446
. O 0 0.000610268
o O 0 0.002672922
. O 0 0.0015519068
) O 0 0.0041727624
. O 0 0.00393824

Importantly O 0 0.0020410914
, O 0 0.00312217
both O 0 0.0012361717
classical O 0 0.0017197242
( O 0 0.004806976
haloperidol B-Chemical 1 0.99999404
) O 0 0.0024308295
and O 0 0.0004723055
atypical O 0 0.0048946217
( O 0 0.0016536139
olanzapine B-Chemical 1 0.9999975
, O 0 0.0030960434
clozapine B-Chemical 0 0.99999666
and O 0 0.0007508354
aripiprazole B-Chemical 0 0.9999957
) O 0 0.0013881656
antipsychotics O 0 0.98748535
were O 0 0.00012536967
effective O 0 0.00012088664
in O 0 0.000148783
all O 0 0.00019195075
these O 0 0.0002702603
models O 0 0.0004948779
of O 0 0.0017900127
hyperactivity B-Disease 2 0.9999683
. O 0 0.0052147503

However O 0 0.0032313126
, O 0 0.003660768
unlike O 0 0.0012131996
these O 0 0.0012448984
latter O 0 0.0032226988
, O 0 0.00434418
SSR103800 B-Chemical 0 0.9989127
did O 0 0.0008083251
not O 0 0.00039328833
produce O 0 0.00043297178
catalepsy B-Disease 0 0.99997914
( O 0 0.0006762793
retention O 0 0.0002907995
on O 0 0.00010179171
the O 0 0.00013381166
bar O 0 0.00073204836
test O 0 0.00036900854
) O 0 0.00051951903
up O 0 0.00022240363
to O 0 0.00017662351
30 O 0 0.0002424981
mg O 0 0.001493679
/ O 0 0.0011101728
kg O 0 0.0010146904
p O 0 0.0011444647
. O 0 0.001079138
o O 0 0.0052520283
. O 0 0.004065019

Together O 0 0.0038731166
these O 0 0.0018045994
findings O 0 0.0014905091
show O 0 0.00070080825
that O 0 0.0005981363
the O 0 0.00077201903
GlyT1 O 0 0.5283234
inhibitor O 0 0.004517965
, O 0 0.0025000763
SSR103800 B-Chemical 0 0.9991379
, O 0 0.0007946403
produces O 0 0.00025284325
antipsychotic O 0 0.99927694
- O 0 0.0016568389
like O 0 9.943489e-05
effects O 0 0.00012838923
, O 0 0.00031344275
which O 0 0.00016009883
differ O 0 0.000111160574
from O 0 8.096964e-05
those O 0 0.00010497312
observed O 0 8.086664e-05
with O 0 0.0001333236
compounds O 0 0.0035512315
primarily O 0 0.00010599134
targeting O 0 4.0554798e-05
the O 0 9.344993e-05
dopaminergic O 0 0.0008656897
system O 0 0.000115363895
, O 0 0.00021354336
and O 0 0.000117816926
has O 0 7.4638745e-05
a O 0 0.00017593705
reduced O 0 0.00018828294
side O 0 0.0009279179
- O 0 0.0013393327
effect O 0 0.00012213475
potential O 0 0.00014741307
as O 0 0.0001944811
compared O 0 0.00018767265
with O 0 0.00039195473
these O 0 0.00059047743
latter O 0 0.0024393382
drugs O 0 0.06960514
. O 0 0.0031610832

Pyrrolidine B-Chemical 0 0.9988821
dithiocarbamate I-Chemical 0 0.99901366
protects O 0 0.0035174447
the O 0 0.0016771785
piriform O 0 0.5176703
cortex O 0 0.019880245
in O 0 0.0006944503
the O 0 0.00088875333
pilocarpine B-Chemical 0 0.9999138
status B-Disease 0 0.002167916
epilepticus I-Disease 0 0.9973731
model O 0 0.0019556158
. O 0 0.0032658672

Pyrrolidine B-Chemical 0 0.9991487
dithiocarbamate I-Chemical 0 0.9996755
( O 0 0.6383502
PDTC B-Chemical 1 0.9999933
) O 0 0.00842729
has O 0 0.00038095983
a O 0 0.00043282536
dual O 0 0.00025669223
mechanism O 0 0.00014237821
of O 0 0.00023627904
action O 0 0.00027945143
as O 0 0.00027775276
an O 0 0.00046882898
antioxidant O 0 0.986665
and O 0 0.00038631284
an O 0 0.00034105108
inhibitor O 0 0.0007682476
of O 0 0.00034365343
the O 0 0.00031283018
transcription O 0 0.0004924346
factor O 0 0.017450346
kappa O 0 0.13885221
- O 0 0.04696179
beta O 0 0.66216016
. O 0 0.00473638

Both O 0 0.0041447436
, O 0 0.005911534
production O 0 0.003693404
of O 0 0.0040954202
reactive O 0 0.9530398
oxygen B-Chemical 1 0.999783
species O 0 0.0011970514
as O 0 0.00040032968
well O 0 0.0002700012
as O 0 0.00025865223
activation O 0 0.0002833439
of O 0 0.0006028889
NF O 0 0.9979546
- O 0 0.12197476
kappaB O 0 0.05627182
have O 0 0.00018361115
been O 0 0.00015581082
implicated O 0 0.00014938547
in O 0 0.00019669323
severe O 0 0.0066724755
neuronal B-Disease 0 0.019205347
damage I-Disease 0 0.4872069
in O 0 0.00012771643
different O 0 9.0695e-05
sub O 0 0.0005885726
- O 0 0.00085970294
regions O 0 8.551049e-05
of O 0 0.00012661479
the O 0 0.00013444823
hippocampus O 0 0.0013254515
as O 0 0.00018248819
well O 0 0.00020019567
as O 0 0.00026137318
in O 0 0.00034269554
the O 0 0.00046622148
surrounding O 0 0.0010566114
cortices O 0 0.083729506
. O 0 0.0028060272

The O 0 0.0022493354
effect O 0 0.0021281948
of O 0 0.00484289
PDTC B-Chemical 1 0.999985
on O 0 0.00096941565
status B-Disease 0 0.0013379067
epilepticus I-Disease 0 0.99981457
- O 0 0.0063942014
associated O 0 0.0002811602
cell O 0 0.00033466026
loss O 0 0.00026511322
in O 0 0.00016200502
the O 0 0.000158427
hippocampus O 0 0.002090018
and O 0 0.0002756092
piriform O 0 0.1668557
cortex O 0 0.0029390473
was O 0 0.0001332161
evaluated O 0 0.00014185392
in O 0 0.00016623632
the O 0 0.0002140234
rat O 0 0.0006435783
fractionated O 0 0.0017840584
pilocarpine B-Chemical 0 0.99982965
model O 0 0.0015528603
. O 0 0.0025524753

Treatment O 0 0.0063114185
with O 0 0.002073059
150 O 0 0.0022284852
mg O 0 0.018644918
/ O 0 0.00561815
kg O 0 0.013944724
PDTC B-Chemical 1 0.999984
before O 0 0.00028287803
and O 0 0.0002852826
following O 0 0.00015895964
status B-Disease 0 0.0003650954
epilepticus I-Disease 0 0.99878484
significantly O 0 0.00033934007
increased O 0 0.0003438047
the O 0 0.00025812897
mortality O 0 0.0013330501
rate O 0 0.00067016145
to O 0 0.00060238916
100 O 0 0.0019925227
% O 0 0.0028621627
. O 0 0.0029831778

Administration O 0 0.0081817545
of O 0 0.002535981
50 O 0 0.0024238613
mg O 0 0.019844977
/ O 0 0.0057413965
kg O 0 0.014502788
PDTC B-Chemical 1 0.99998724
( O 0 0.001825565
low O 0 0.00069828326
- O 0 0.002994091
dose O 0 0.00059481827
) O 0 0.0005924634
did O 0 0.00019612988
not O 0 0.00013073812
exert O 0 0.00013245623
major O 0 0.00013022663
effects O 0 0.00012428554
on O 0 9.724662e-05
the O 0 0.000118598844
development O 0 0.00020638683
of O 0 0.0002176764
a O 0 0.0003930057
status B-Disease 0 0.00046658557
epilepticus I-Disease 0 0.9990509
or O 0 0.00034437742
the O 0 0.00042356318
mortality O 0 0.0026834093
rate O 0 0.0020184452
. O 0 0.0026827124

In O 0 0.002430515
vehicle O 0 0.008645719
- O 0 0.008090175
treated O 0 0.0018584782
rats O 0 0.0014447413
, O 0 0.0012870927
status B-Disease 0 0.0008816065
epilepticus I-Disease 0 0.9994615
caused O 0 0.00048095238
pronounced O 0 0.0010427638
neuronal B-Disease 0 0.03386512
damage I-Disease 0 0.6351329
in O 0 0.00024850242
the O 0 0.00022185658
piriform O 0 0.116111085
cortex O 0 0.0029922542
comprising O 0 0.00024907623
both O 0 0.00026568002
pyramidal O 0 0.002988609
cells O 0 0.0007253962
and O 0 0.0011120463
interneurons O 0 0.0041522803
. O 0 0.0028172624

Low O 0 0.019661302
- O 0 0.07724205
dose O 0 0.051063962
PDTC B-Chemical 1 0.9999825
treatment O 0 0.0023339377
almost O 0 0.0009313981
completely O 0 0.0006502499
protected O 0 0.00057669973
from O 0 0.0005687336
lesions O 0 0.003205107
in O 0 0.0006980138
the O 0 0.00093132886
piriform O 0 0.18847342
cortex O 0 0.022054695
. O 0 0.0034681205

A O 0 0.028153548
significant O 0 0.0024194415
decrease O 0 0.0016946726
in O 0 0.0009900031
neuronal O 0 0.0013461438
density O 0 0.000730472
of O 0 0.0004590024
the O 0 0.00034932385
hippocampal O 0 0.01199403
hilar O 0 0.704867
formation O 0 0.00039016103
was O 0 0.0001360807
identified O 0 9.56597e-05
in O 0 0.00017218858
vehicle O 0 0.0018688242
- O 0 0.012791434
and O 0 0.0011034859
PDTC B-Chemical 1 0.9999974
- O 0 0.09013565
treated O 0 0.00080397865
rats O 0 0.0006197158
following O 0 0.00035266095
status B-Disease 0 0.0011893853
epilepticus I-Disease 0 0.9976544
. O 0 0.0029576763

In O 0 0.0024472985
conclusion O 0 0.001965303
, O 0 0.0038921412
the O 0 0.0023536
NF O 0 0.9959936
- O 0 0.323857
kappaB O 0 0.45813712
inhibitor O 0 0.01799519
and O 0 0.0035513071
antioxidant O 0 0.9999263
PDTC B-Chemical 1 0.99999917
protected O 0 0.0009869763
the O 0 0.00039768766
piriform O 0 0.6474115
cortex O 0 0.03445261
, O 0 0.000458858
whereas O 0 0.00024677292
it O 0 0.00038881894
did O 0 0.00034752832
not O 0 0.00035509025
affect O 0 0.0005226282
hilar O 0 0.91360873
neuronal B-Disease 0 0.030526668
loss I-Disease 0 0.004985008
. O 0 0.0030804412

These O 0 0.0022775887
data O 0 0.0019477997
might O 0 0.00064382615
indicate O 0 0.000440487
that O 0 0.00047497038
the O 0 0.00049527996
generation O 0 0.0006401312
of O 0 0.0012234638
reactive O 0 0.9328576
oxygen B-Chemical 1 0.9998858
species O 0 0.0005996653
and O 0 0.0002506648
activation O 0 0.00021978922
of O 0 0.0004320141
NF O 0 0.9963264
- O 0 0.04608213
kappaB O 0 0.012693172
plays O 0 9.51252e-05
a O 0 0.00021569464
more O 0 0.000176164
central O 0 0.00016351396
role O 0 5.94482e-05
in O 0 0.00020108468
seizure B-Disease 0 0.9997273
- O 0 0.014898642
associated O 0 0.0002753169
neuronal B-Disease 0 0.012332498
damage I-Disease 0 0.523612
in O 0 0.000158472
the O 0 0.00013226629
temporal O 0 0.0014475342
cortex O 0 0.0056865215
as O 0 0.00018579743
compared O 0 0.00016245517
to O 0 0.00026923933
the O 0 0.00048609366
hippocampal O 0 0.010736873
hilus O 0 0.035042685
. O 0 0.0030230398

However O 0 0.0032525552
, O 0 0.0035873777
future O 0 0.0013136319
investigations O 0 0.0010873179
are O 0 0.00047436813
necessary O 0 0.00026294787
to O 0 0.00026166163
exactly O 0 0.00018891522
analyze O 0 0.0001145312
the O 0 0.00015703743
biochemical O 0 0.000243116
mechanisms O 0 0.00016083174
by O 0 0.00029753635
which O 0 0.0010930727
PDTC B-Chemical 1 0.9999968
exerted O 0 0.0010282339
its O 0 0.00046870162
beneficial O 0 0.0003686373
effects O 0 0.00032116516
in O 0 0.00043726852
the O 0 0.00064672256
piriform O 0 0.36248013
cortex O 0 0.03030055
. O 0 0.0025934908

Anaesthetists O 0 0.015919684
' O 0 0.007616044
nightmare O 0 0.017683864
: O 0 0.0077399025
masseter B-Disease 0 0.744191
spasm I-Disease 0 0.9998068
after O 0 0.00042469671
induction O 0 0.00039752846
in O 0 0.0004853337
an O 0 0.0007162825
undiagnosed O 0 0.010937132
case O 0 0.0010212618
of O 0 0.0020468866
myotonia B-Disease 0 0.9997178
congenita I-Disease 0 0.18300116
. O 0 0.0042555244

We O 0 0.002983009
report O 0 0.0033573348
an O 0 0.001910656
undiagnosed O 0 0.019523876
case O 0 0.0009525779
of O 0 0.0011845147
myotonia B-Disease 0 0.9998658
congenita I-Disease 0 0.027308468
in O 0 0.00025407306
a O 0 0.00032540542
24 O 0 0.00021432809
- O 0 0.0007641307
year O 0 0.00013503397
- O 0 0.00052303635
old O 0 0.00014623706
previously O 0 0.0001521515
healthy O 0 0.0008166724
primigravida O 0 0.0053864857
, O 0 0.00032014473
who O 0 0.00019781322
developed O 0 0.00014268102
life O 0 0.0001715766
threatening O 0 0.0008961671
masseter B-Disease 0 0.6202286
spasm I-Disease 0 0.9999616
following O 0 7.774533e-05
a O 0 0.00012836572
standard O 0 9.835239e-05
dose O 0 0.00017663276
of O 0 0.00017918219
intravenous O 0 0.0096282
suxamethonium B-Chemical 0 0.99753344
for O 0 0.00019065294
induction O 0 0.0002913162
of O 0 0.00080354745
anaesthesia O 0 0.010286432
. O 0 0.0021808862

Neither O 0 0.0023189643
the O 0 0.0016127962
patient O 0 0.0012861848
nor O 0 0.0005896602
the O 0 0.00053828926
anaesthetist O 0 0.0010833694
was O 0 0.00037220953
aware O 0 0.00033342908
of O 0 0.00032417272
the O 0 0.00025624255
diagnosis O 0 0.00048223132
before O 0 0.00016473401
this O 0 0.0003471288
potentially O 0 0.0004931291
lethal O 0 0.0012247331
complication O 0 0.005859225
occurred O 0 0.0016464908
. O 0 0.00284253

Twin O 0 0.019491365
preterm O 0 0.07673382
neonates O 0 0.0064970604
with O 0 0.0016986785
cardiac B-Disease 0 0.12750405
toxicity I-Disease 0 0.967839
related O 0 0.0006075201
to O 0 0.00088219845
lopinavir B-Chemical 0 0.995893
/ I-Chemical 0 0.049856246
ritonavir I-Chemical 0 0.9997681
therapy O 0 0.0035909147
. O 0 0.0029728368

We O 0 0.0030287623
report O 0 0.0039530424
twin O 0 0.054596815
neonates O 0 0.0075864117
who O 0 0.0012852448
were O 0 0.000524134
born O 0 0.0010671918
prematurely O 0 0.0010942334
at O 0 0.00015923481
32 O 0 0.00020180129
weeks O 0 8.097922e-05
of O 0 0.00014749322
gestation O 0 0.00024727482
to O 0 0.00020368354
a O 0 0.00045354935
mother O 0 0.0009213564
with O 0 0.00078802335
human B-Disease 0 0.0047781733
immunodeficiency I-Disease 0 0.99977964
virus I-Disease 0 0.21750721
infection I-Disease 0 0.059169684
. O 0 0.004056936

One O 0 0.0037644587
of O 0 0.002033609
the O 0 0.001282491
twins O 0 0.014321708
developed O 0 0.000838106
complete O 0 0.00042141636
heart B-Disease 0 0.004767664
block I-Disease 0 0.00031125464
and O 0 0.00042247708
dilated B-Disease 0 0.99859065
cardiomyopathy I-Disease 0 0.9999895
related O 0 0.00016473446
to O 0 0.00018894316
lopinavir B-Chemical 0 0.9962698
/ I-Chemical 0 0.02011832
ritonavir I-Chemical 0 0.99995136
therapy O 0 0.0003017589
, O 0 0.00020566158
a O 0 0.0001787024
boosted O 0 0.00019432133
protease O 0 0.0007669634
- O 0 0.0046458575
inhibitor O 0 0.00083457155
agent O 0 0.00081033254
, O 0 0.0004371073
while O 0 0.00020159592
the O 0 0.00020320268
other O 0 0.0003330313
twin O 0 0.08911197
developed O 0 0.0016072624
mild O 0 0.6338815
bradycardia B-Disease 0 0.9986505
. O 0 0.003289996

We O 0 0.0024663669
recommend O 0 0.0017305012
caution O 0 0.001503514
in O 0 0.0007351933
the O 0 0.00049146323
use O 0 0.00047694918
of O 0 0.00084111566
lopinavir B-Chemical 0 0.9981851
/ I-Chemical 0 0.08354812
ritonavir I-Chemical 0 0.9998927
in O 0 0.00050988456
the O 0 0.0003834597
immediate O 0 0.0007669188
neonatal O 0 0.0012705612
period O 0 0.0010325911
. O 0 0.00255082

When O 0 0.0025673355
drugs O 0 0.037426945
disappear O 0 0.002712861
from O 0 0.0008616663
the O 0 0.000634208
patient O 0 0.00073200685
: O 0 0.00095014134
elimination O 0 0.0005816874
of O 0 0.00058935763
intravenous O 0 0.0030598568
medication O 0 0.0020814794
by O 0 0.0011225584
hemodiafiltration O 0 0.027714264
. O 0 0.0032068577

Twenty O 0 0.0058582053
- O 0 0.004654902
three O 0 0.0005096933
hours O 0 0.00051015505
after O 0 0.00031201824
heart O 0 0.0022220837
transplantation O 0 0.00049123843
, O 0 0.0004654366
life O 0 0.00033658586
- O 0 0.0016545178
threatening O 0 0.00064700533
acute O 0 0.011130554
right B-Disease 0 0.0023089335
heart I-Disease 0 0.0903307
failure I-Disease 0 0.13255851
was O 0 0.00018722491
diagnosed O 0 0.0007869015
in O 0 0.00012920151
a O 0 0.00019253697
patient O 0 0.00014228837
requiring O 0 0.00011089601
continuous O 0 0.00015575733
venovenous O 0 0.00094291515
hemodiafiltration O 0 0.004433163
( O 0 0.0010823146
CVVHDF O 0 0.04383179
) O 0 0.002527954
. O 0 0.002556378

Increasing O 0 0.0028728542
doses O 0 0.0044319006
of O 0 0.0028175684
catecholamines B-Chemical 0 0.9995259
, O 0 0.00330906
sedatives O 0 0.93105114
, O 0 0.0010040844
and O 0 0.00048681704
muscle O 0 0.0027139476
relaxants O 0 0.051036734
administered O 0 0.0003681491
through O 0 0.000220587
a O 0 0.00044970002
central O 0 0.0006571854
venous O 0 0.041050076
catheter O 0 0.001155685
were O 0 0.00072274375
ineffective O 0 0.002248349
. O 0 0.002838323

However O 0 0.0030456926
, O 0 0.0036206378
a O 0 0.002177939
bolus O 0 0.004146783
of O 0 0.0013325333
epinephrine B-Chemical 0 0.9986859
injected O 0 0.00044604827
through O 0 0.00028888063
an O 0 0.00031880307
alternative O 0 0.00021594694
catheter O 0 0.0008215495
provoked O 0 0.0015685383
a O 0 0.0022794497
hypertensive B-Disease 0 0.99953234
crisis O 0 0.18166552
. O 0 0.0045442083

Thus O 0 0.0027676458
, O 0 0.0041537303
interference O 0 0.0021911615
with O 0 0.0012747949
the O 0 0.000793458
central O 0 0.0011921795
venous O 0 0.07774943
infusion O 0 0.0011008694
by O 0 0.00035820814
the O 0 0.0003537652
dialysis O 0 0.00097331835
catheter O 0 0.0012917072
was O 0 0.001091657
suspected O 0 0.0041659474
. O 0 0.0034430134

The O 0 0.0022735968
catheters O 0 0.0051079583
were O 0 0.0015153758
changed O 0 0.0013247132
, O 0 0.0016349334
and O 0 0.0010743533
hemodynamics O 0 0.38625014
stabilized O 0 0.0014170604
at O 0 0.00084877276
lower O 0 0.0021239358
catecholamine B-Chemical 0 0.9988263
doses O 0 0.0068080216
. O 0 0.0040994566

When O 0 0.0015618779
the O 0 0.0011734555
effects O 0 0.0009799872
of O 0 0.0012127749
IV O 0 0.26870325
drugs O 0 0.017520191
are O 0 0.000260647
inadequate O 0 0.000322649
in O 0 0.00016643984
patients O 0 0.0002739284
receiving O 0 0.00021457141
CVVHDF O 0 0.03248578
, O 0 0.00022669815
interference O 0 0.00017098621
with O 0 0.00014301842
adjacent O 0 0.00014986198
catheters O 0 0.00057673926
resulting O 0 0.00011472795
in O 0 0.00012131841
elimination O 0 0.00019417577
of O 0 0.00018654155
the O 0 0.00020226014
drug O 0 0.0034206505
by O 0 0.000421222
CVVHDF O 0 0.057535693
should O 0 0.00029728338
be O 0 0.0007668505
suspected O 0 0.0036601352
. O 0 0.002856254

Less O 0 0.08418454
frequent O 0 0.01014424
lithium B-Chemical 0 0.99875414
administration O 0 0.005483845
and O 0 0.002657747
lower O 0 0.0034526994
urine O 0 0.040782657
volume O 0 0.0071585984
. O 0 0.0065537067

OBJECTIVE O 0 0.031340435
: O 0 0.0053006327
This O 0 0.0017687844
study O 0 0.0008717747
was O 0 0.00043363892
designed O 0 0.00027295758
to O 0 0.00017321217
determine O 0 6.086334e-05
whether O 0 6.3016174e-05
patients O 0 0.00025369084
maintained O 0 0.000130072
on O 0 7.775201e-05
a O 0 0.00015571264
regimen O 0 0.0001591424
of O 0 0.00021983552
lithium B-Chemical 0 0.999828
on O 0 0.00010829257
a O 0 0.00019856989
once O 0 0.00010713185
- O 0 0.0008200602
per O 0 0.00010472767
- O 0 0.00033504938
day O 0 4.8090034e-05
schedule O 0 6.0648046e-05
have O 0 6.804728e-05
lower O 0 0.00014674467
urine O 0 0.003535933
volumes O 0 0.00023001757
than O 0 0.000103079896
do O 0 0.00012037751
patients O 0 0.0002587341
receiving O 0 0.0001936887
multiple O 0 0.0002289699
doses O 0 0.0006923205
per O 0 0.0005380956
day O 0 0.00067417417
. O 0 0.0019876265

METHOD O 0 0.014381626
: O 0 0.0058095837
This O 0 0.0022038342
was O 0 0.0010838076
a O 0 0.0012194535
cross O 0 0.0011764264
- O 0 0.003803392
sectional O 0 0.0043658903
study O 0 0.00041099582
of O 0 0.00031913177
85 O 0 0.0004592989
patients O 0 0.000449254
from O 0 0.00022297924
a O 0 0.0006074642
lithium B-Chemical 0 0.9996598
clinic O 0 0.0005167368
who O 0 0.0003716592
received O 0 0.0002589661
different O 0 0.00028445775
dose O 0 0.0009937746
schedules O 0 0.0012757987
. O 0 0.0024029592

Patients O 0 0.0047308044
were O 0 0.0017693908
admitted O 0 0.0022374187
to O 0 0.0005845302
the O 0 0.00041689843
hospital O 0 0.00047144076
for O 0 0.00021169311
measurement O 0 0.00023322945
of O 0 0.00045834476
lithium B-Chemical 0 0.9995473
level O 0 0.0004135646
, O 0 0.0012254016
creatinine B-Chemical 0 0.9963612
clearance O 0 0.0053019146
, O 0 0.0009885757
urine O 0 0.013599371
volume O 0 0.00096518476
, O 0 0.0009799867
and O 0 0.0008155276
maximum O 0 0.0016348269
osmolality O 0 0.20826827
. O 0 0.0036460648

RESULTS O 0 0.0043821265
: O 0 0.0029601338
Multiple O 0 0.0013359904
daily O 0 0.0009992655
doses O 0 0.0013546731
of O 0 0.0012088048
lithium B-Chemical 0 0.99937576
were O 0 0.0006966651
associated O 0 0.00063236494
with O 0 0.0007510486
higher O 0 0.0013160725
urine O 0 0.037900303
volumes O 0 0.0039052777
. O 0 0.0038129885

The O 0 0.0015053492
dosing O 0 0.0013825813
schedule O 0 0.00071942905
, O 0 0.00084075745
duration O 0 0.0003413718
of O 0 0.000656645
lithium B-Chemical 0 0.9996228
treatment O 0 0.00042754074
, O 0 0.00042491156
and O 0 0.00021234808
daily O 0 0.0002444588
dose O 0 0.00035262393
of O 0 0.0003977286
lithium B-Chemical 0 0.9998795
did O 0 0.0003705169
not O 0 0.00021788113
affect O 0 0.00021541001
maximum O 0 0.0005513431
osmolality O 0 0.20475033
or O 0 0.0008320358
creatinine B-Chemical 0 0.99262154
clearance O 0 0.010808533
. O 0 0.0029074631

CONCLUSIONS O 0 0.035395455
: O 0 0.0085552195
Urine O 0 0.03421471
volume O 0 0.0018489221
can O 0 0.0005195143
be O 0 0.00043714972
reduced O 0 0.00044060286
by O 0 0.00035143725
giving O 0 0.00057755917
lithium B-Chemical 0 0.99971753
once O 0 0.00023412133
daily O 0 0.00026460594
and O 0 0.00022936582
/ O 0 0.00084235176
or O 0 0.00020705326
by O 0 0.00024952737
lowering O 0 0.00085718406
the O 0 0.00035016274
total O 0 0.0005752197
daily O 0 0.00095900614
dose O 0 0.0019400887
. O 0 0.0024195795

Lithium B-Chemical 0 0.999828
- O 0 0.17203534
induced O 0 0.0031866932
polyuria B-Disease 0 0.9983864
seems O 0 0.0007706812
to O 0 0.0004887228
be O 0 0.0003855746
related O 0 0.00025234814
to O 0 0.00039388565
extrarenal O 0 0.43925393
as O 0 0.00045574232
well O 0 0.00041122077
as O 0 0.0005235775
to O 0 0.00073675177
renal O 0 0.41776606
effects O 0 0.0020862662
. O 0 0.003570884

Antibacterial O 0 0.013774282
medication O 0 0.005322369
use O 0 0.0009543416
during O 0 0.000641561
pregnancy O 0 0.0017960737
and O 0 0.0007338826
risk O 0 0.0021986116
of O 0 0.0006524619
birth B-Disease 0 0.001006814
defects I-Disease 0 0.0014196477
: O 0 0.0014641182
National O 0 0.0008095435
Birth B-Disease 0 0.0025062712
Defects I-Disease 0 0.0035622413
Prevention O 0 0.0024658954
Study O 0 0.005021262
. O 0 0.0039312993

OBJECTIVE O 0 0.018118931
: O 0 0.0031339582
To O 0 0.0004966458
estimate O 0 0.00045582338
the O 0 0.000391778
association O 0 0.00028490773
between O 0 0.00036423968
antibacterial O 0 0.0026152781
medications O 0 0.003429648
and O 0 0.0006736317
selected O 0 0.00067110994
birth B-Disease 0 0.0017679199
defects I-Disease 0 0.003915402
. O 0 0.003836334

DESIGN O 0 0.0056006704
, O 0 0.003951008
SETTING O 0 0.0030841846
, O 0 0.0015918995
AND O 0 0.0008000859
PARTICIPANTS O 0 0.0011558712
: O 0 0.001030272
Population O 0 0.00078725733
- O 0 0.0014323095
based O 0 0.00031915127
, O 0 0.00059322256
multisite O 0 0.00072485924
, O 0 0.0005481145
case O 0 0.00032046472
- O 0 0.0011514117
control O 0 0.00018346819
study O 0 0.00018810207
of O 0 0.00018286232
women O 0 0.0007648009
who O 0 0.00025962768
had O 0 0.00015074827
pregnancies O 0 0.0068336506
affected O 0 0.00016071124
by O 0 0.000113917544
1 O 0 0.00011532947
of O 0 9.667301e-05
more O 0 0.00012566567
than O 0 6.95869e-05
30 O 0 6.237948e-05
eligible O 0 7.358425e-05
major O 0 7.065201e-05
birth B-Disease 0 0.00013654304
defects I-Disease 0 0.00019408729
identified O 0 5.7951947e-05
via O 0 6.9303605e-05
birth B-Disease 0 0.0001761608
defect I-Disease 0 0.00017057374
surveillance O 0 7.3618714e-05
programs O 0 9.3175506e-05
in O 0 0.00010839197
10 O 0 0.00011767568
states O 0 0.00015093425
( O 0 0.00018765513
n O 0 0.00014371726
= O 0 0.00032395122
13 O 0 0.00013727763
155 O 0 0.00026709877
) O 0 0.0002446318
and O 0 0.00011211664
control O 0 0.00013287432
women O 0 0.00036105956
randomly O 0 7.107401e-05
selected O 0 9.271754e-05
from O 0 0.00011301487
the O 0 0.00012307143
same O 0 0.00013556356
geographical O 0 0.00031888936
regions O 0 0.00021849982
( O 0 0.0005607116
n O 0 0.0006245605
= O 0 0.002014905
4941 O 0 0.00444846
) O 0 0.0034752258
. O 0 0.0032668873

MAIN O 0 0.00836344
EXPOSURE O 0 0.003916142
: O 0 0.002250271
Reported O 0 0.000721583
maternal O 0 0.00054221775
use O 0 0.0003598853
of O 0 0.00048211918
antibacterials O 0 0.33486816
( O 0 0.00063260517
1 O 0 0.00021372201
month O 0 8.790344e-05
before O 0 7.8864345e-05
pregnancy O 0 0.0003674972
through O 0 0.00014415798
the O 0 0.00014703909
end O 0 0.0001494979
of O 0 0.00033358808
the O 0 0.0003557361
first O 0 0.00047564274
trimester O 0 0.0049942117
) O 0 0.0041613136
. O 0 0.0034347167

MAIN O 0 0.0085348915
OUTCOME O 0 0.0038660767
MEASURE O 0 0.0020609766
: O 0 0.0012973504
Odds O 0 0.00077228463
ratios O 0 0.000490747
( O 0 0.00064785534
ORs O 0 0.00046427478
) O 0 0.00057213334
measuring O 0 0.00019516492
the O 0 0.0001436348
association O 0 0.000109133085
between O 0 0.0001391979
antibacterial O 0 0.00083946827
use O 0 0.00016812932
and O 0 0.00019196136
selected O 0 0.0001638317
birth B-Disease 0 0.00034784485
defects I-Disease 0 0.0004704608
adjusted O 0 0.00023514187
for O 0 0.0002741296
potential O 0 0.0005007156
confounders O 0 0.0012698541
. O 0 0.0026530745

RESULTS O 0 0.0042898287
: O 0 0.0027330762
The O 0 0.00063900166
reported O 0 0.00065031176
use O 0 0.0004513106
of O 0 0.00058140024
antibacterials O 0 0.22461513
increased O 0 0.00058191665
during O 0 0.00028272814
pregnancy O 0 0.001250097
, O 0 0.0007215187
peaking O 0 0.0010342395
during O 0 0.00032517963
the O 0 0.00043281275
third O 0 0.0007658007
month O 0 0.0008924148
. O 0 0.002520067

Sulfonamides B-Chemical 0 0.99505436
were O 0 0.0028701401
associated O 0 0.001895661
with O 0 0.0019677617
anencephaly B-Disease 0 0.99904484
( O 0 0.0015650354
adjusted O 0 0.0005108653
OR O 0 0.0032223845
[ O 0 0.002416729
AOR O 0 0.046791103
] O 0 0.0016779804
= O 0 0.00085189514
3 O 0 0.00022888175
. O 0 0.00021025645
4 O 0 0.00018591314
; O 0 0.000382127
95 O 0 0.00038693353
% O 0 0.00034141622
confidence O 0 0.00047529693
interval O 0 0.0003090556
[ O 0 0.001078449
CI O 0 0.008203666
] O 0 0.0011876328
, O 0 0.00043868006
1 O 0 0.00023372364
. O 0 0.00016988
3 O 0 0.00016032827
- O 0 0.0005892315
8 O 0 0.00014616456
. O 0 0.00014018906
8 O 0 0.00015180964
) O 0 0.00040507148
, O 0 0.00048513402
hypoplastic B-Disease 0 0.80308187
left I-Disease 0 0.0010340258
heart I-Disease 0 0.14097457
syndrome I-Disease 0 0.8861974
( O 0 0.00063941657
AOR O 0 0.04739669
= O 0 0.0006815529
3 O 0 0.00015262376
. O 0 0.00015060816
2 O 0 0.00018263755
; O 0 0.00032575428
95 O 0 0.00037888222
% O 0 0.00043535468
CI O 0 0.0038850135
, O 0 0.0004421512
1 O 0 0.00023314319
. O 0 0.00017138121
3 O 0 0.00016272864
- O 0 0.00059197686
7 O 0 0.00012659849
. O 0 0.00013143435
6 O 0 0.00011569803
) O 0 0.00034134515
, O 0 0.0003704189
coarctation B-Disease 0 0.43629193
of I-Disease 0 0.00025376197
the I-Disease 0 0.00020456132
aorta I-Disease 0 0.010807707
( O 0 0.00055960636
AOR O 0 0.02289221
= O 0 0.00071533024
2 O 0 0.00021329835
. O 0 0.00016048933
7 O 0 0.00014613138
; O 0 0.0003411903
95 O 0 0.00040924846
% O 0 0.00047559198
CI O 0 0.004032363
, O 0 0.00048152258
1 O 0 0.0002558803
. O 0 0.00019045909
3 O 0 0.00018434724
- O 0 0.00070597086
5 O 0 0.00016734145
. O 0 0.00015485444
6 O 0 0.00014021114
) O 0 0.0004469156
, O 0 0.00056485884
choanal B-Disease 0 0.72409993
atresia I-Disease 0 0.9503312
( O 0 0.0009433068
AOR O 0 0.04682284
= O 0 0.00080281
8 O 0 0.00020025659
. O 0 0.00018219261
0 O 0 0.00025839437
; O 0 0.0003902897
95 O 0 0.0004382335
% O 0 0.00048617058
CI O 0 0.003464661
, O 0 0.00045680415
2 O 0 0.00024576564
. O 0 0.00019116206
7 O 0 0.00018042082
- O 0 0.0007903584
23 O 0 0.00030079464
. O 0 0.00018912446
5 O 0 0.00018672342
) O 0 0.0004621793
, O 0 0.00048127133
transverse B-Disease 0 0.0033945001
limb I-Disease 0 0.0512593
deficiency I-Disease 0 0.3524459
( O 0 0.000862662
AOR O 0 0.07729124
= O 0 0.00091531547
2 O 0 0.00023948244
. O 0 0.0001773067
5 O 0 0.00017163961
; O 0 0.00034422858
95 O 0 0.00040238144
% O 0 0.00046128346
CI O 0 0.0038317062
, O 0 0.00046170817
1 O 0 0.0002477359
. O 0 0.00019344875
0 O 0 0.0002823615
- O 0 0.0007836949
5 O 0 0.00016485923
. O 0 0.00015124572
9 O 0 0.00015310242
) O 0 0.00041173346
, O 0 0.0004112598
and O 0 0.00042590144
diaphragmatic B-Disease 0 0.99484396
hernia I-Disease 0 0.9925383
( O 0 0.0008358314
AOR O 0 0.048598573
= O 0 0.00082465226
2 O 0 0.00023809611
. O 0 0.0001798319
4 O 0 0.00017203334
; O 0 0.00039901998
95 O 0 0.00048371256
% O 0 0.00057769543
CI O 0 0.004189324
, O 0 0.00068970944
1 O 0 0.00043111006
. O 0 0.00038882636
1 O 0 0.0005482263
- O 0 0.0015998656
5 O 0 0.000589288
. O 0 0.00073584344
4 O 0 0.0010442636
) O 0 0.003398364
. O 0 0.003805219

Nitrofurantoins B-Chemical 0 0.31862673
were O 0 0.002910243
associated O 0 0.0021947809
with O 0 0.0028908246
anophthalmia B-Disease 0 0.9998822
or O 0 0.0021796362
microphthalmos B-Disease 0 0.999853
( O 0 0.0022882244
AOR O 0 0.100660555
= O 0 0.0010984667
3 O 0 0.00024052038
. O 0 0.00021395527
7 O 0 0.00018866031
; O 0 0.00042038542
95 O 0 0.0004889474
% O 0 0.00055669184
CI O 0 0.004115728
, O 0 0.00055184023
1 O 0 0.0002963996
. O 0 0.0002271096
1 O 0 0.00026359898
- O 0 0.0007180151
12 O 0 0.00013768929
. O 0 0.00016050845
2 O 0 0.00020261685
) O 0 0.00045357528
, O 0 0.00052342156
hypoplastic B-Disease 0 0.7989499
left I-Disease 0 0.0010678844
heart I-Disease 0 0.14020793
syndrome I-Disease 0 0.8854629
( O 0 0.0006545756
AOR O 0 0.04814885
= O 0 0.0006930427
4 O 0 0.0001513245
. O 0 0.00015256568
2 O 0 0.00018470036
; O 0 0.00032906927
95 O 0 0.00038228775
% O 0 0.00043782263
CI O 0 0.0037747156
, O 0 0.00044256402
1 O 0 0.00023576013
. O 0 0.00017813721
9 O 0 0.0001780503
- O 0 0.0007047262
9 O 0 0.00016241103
. O 0 0.0001706458
1 O 0 0.00021434507
) O 0 0.00045573903
, O 0 0.00046027472
atrial B-Disease 0 0.11748588
septal I-Disease 0 0.020066386
defects I-Disease 0 0.0014382927
( O 0 0.00057653425
AOR O 0 0.034656532
= O 0 0.00081988994
1 O 0 0.00022636895
. O 0 0.00016289708
9 O 0 0.00015612491
; O 0 0.00033491655
95 O 0 0.0003962527
% O 0 0.00045834304
CI O 0 0.004165002
, O 0 0.00047882844
1 O 0 0.00026011575
. O 0 0.00020405502
1 O 0 0.0002457694
- O 0 0.0007285678
3 O 0 0.00015396676
. O 0 0.00015756994
4 O 0 0.00015647932
) O 0 0.00045787927
, O 0 0.0004670662
and O 0 0.0004488334
cleft B-Disease 0 0.27131826
lip I-Disease 0 0.6315972
with O 0 0.0007577431
cleft B-Disease 0 0.60390526
palate I-Disease 0 0.7887176
( O 0 0.000825753
AOR O 0 0.056706704
= O 0 0.0008578765
2 O 0 0.0002462277
. O 0 0.00019601661
1 O 0 0.00023822872
; O 0 0.00041675463
95 O 0 0.00049021357
% O 0 0.0005739426
CI O 0 0.0041405577
, O 0 0.0006666633
1 O 0 0.0004122283
. O 0 0.0003656137
2 O 0 0.00050700916
- O 0 0.0014938647
3 O 0 0.0005452065
. O 0 0.0007441566
9 O 0 0.0010878313
) O 0 0.003419056
. O 0 0.0038397599

Other O 0 0.0033841466
antibacterial O 0 0.0054235314
agents O 0 0.0021679096
that O 0 0.0005531249
showed O 0 0.00044678376
associations O 0 0.00041454288
included O 0 0.0005091856
erythromycins B-Chemical 0 0.9946144
( O 0 0.0009490579
2 O 0 0.00033026293
defects O 0 0.0006068841
) O 0 0.0008020022
, O 0 0.00080527243
penicillins B-Chemical 0 0.99935144
( O 0 0.0006402236
1 O 0 0.0002473208
defect O 0 0.00038128134
) O 0 0.0007611488
, O 0 0.0009268099
cephalosporins B-Chemical 1 0.99981564
( O 0 0.0007057189
1 O 0 0.0002785887
defect O 0 0.00042890685
) O 0 0.00075052486
, O 0 0.00063735276
and O 0 0.0006056631
quinolones B-Chemical 0 0.9968309
( O 0 0.0016876961
1 O 0 0.00097328925
defect O 0 0.0018376565
) O 0 0.0039422037
. O 0 0.0034995682

CONCLUSIONS O 0 0.020344526
: O 0 0.0050543626
Reassuringly O 0 0.0027222314
, O 0 0.00302976
penicillins B-Chemical 0 0.9989189
, O 0 0.0033147468
erythromycins B-Chemical 0 0.9980532
, O 0 0.0016779694
and O 0 0.00085378566
cephalosporins B-Chemical 1 0.9998728
, O 0 0.00073082466
although O 0 0.00019994956
used O 0 0.00016420643
commonly O 0 0.00021498979
by O 0 0.00019008298
pregnant O 0 0.0010453111
women O 0 0.0009470101
, O 0 0.00041880703
were O 0 0.00019323788
not O 0 0.00019799023
associated O 0 0.0003069019
with O 0 0.00040016318
many O 0 0.00049015746
birth B-Disease 0 0.0014072565
defects I-Disease 0 0.0032362046
. O 0 0.0031060083

Sulfonamides B-Chemical 0 0.9971125
and O 0 0.0042577577
nitrofurantoins B-Chemical 0 0.57601976
were O 0 0.0010286778
associated O 0 0.0006617368
with O 0 0.0004664317
several O 0 0.00028245896
birth B-Disease 0 0.00062050007
defects I-Disease 0 0.00091827847
, O 0 0.0007305058
indicating O 0 0.00031693446
a O 0 0.00062471884
need O 0 0.0004395778
for O 0 0.00049358356
additional O 0 0.0007579149
scrutiny O 0 0.0025611727
. O 0 0.003167662

Differential O 0 0.004012219
impact O 0 0.0015455665
of O 0 0.0019230611
immune O 0 0.0049370225
escape O 0 0.002152314
mutations O 0 0.0016374858
G145R O 0 0.72132355
and O 0 0.00078713923
P120T O 0 0.026490923
on O 0 0.00018773996
the O 0 0.00018352698
replication O 0 0.00042429427
of O 0 0.0006069832
lamivudine B-Chemical 0 0.999977
- O 0 0.08051661
resistant O 0 0.0025628826
hepatitis B-Chemical 2 0.9999975
B I-Chemical 2 0.9995042
virus I-Chemical 0 0.032869928
e I-Chemical 0 0.0032155197
antigen I-Chemical 0 0.0046551586
- O 0 0.003221737
positive O 0 0.00043252218
and O 0 0.000599803
- O 0 0.0027522645
negative O 0 0.0009943784
strains O 0 0.0017597232
. O 0 0.0032876516

Immune O 0 0.02086193
escape O 0 0.004201691
variants O 0 0.0015596086
of O 0 0.0018205757
the O 0 0.0024935626
hepatitis B-Disease 2 0.99999106
B I-Disease 2 0.9993316
virus O 0 0.06855192
( O 0 0.0029913536
HBV O 0 0.5504418
) O 0 0.00085074885
represent O 0 0.0001621285
an O 0 0.00016066694
emerging O 0 0.00013850175
clinical O 0 0.00039624362
challenge O 0 0.00012046019
, O 0 0.0002676558
because O 0 0.000105996296
they O 0 0.000129845
can O 0 9.8458346e-05
be O 0 0.00012335081
associated O 0 0.00014768729
with O 0 0.00016690469
vaccine O 0 0.00020649508
escape O 0 0.0005638545
, O 0 0.0009455393
HBV O 0 0.59372115
reactivation O 0 0.0008323097
, O 0 0.0005625188
and O 0 0.0003743796
failure O 0 0.0036745686
of O 0 0.0006408283
diagnostic O 0 0.0011270231
tests O 0 0.0028475213
. O 0 0.0027888466

Recent O 0 0.0037847147
data O 0 0.0021971017
suggest O 0 0.0008126252
a O 0 0.0012269947
preferential O 0 0.0006405632
selection O 0 0.00049297704
of O 0 0.0005583368
immune O 0 0.0014734349
escape O 0 0.00052705425
mutants O 0 0.00017509326
in O 0 0.00022513668
distinct O 0 0.00019678457
peripheral O 0 0.0009810653
blood O 0 0.005716652
leukocyte O 0 0.031016305
compartments O 0 0.00045921333
of O 0 0.00064866897
infected O 0 0.0010350784
individuals O 0 0.002964452
. O 0 0.0031328711

We O 0 0.00225777
therefore O 0 0.0013848606
systematically O 0 0.0007873564
analyzed O 0 0.0005987881
the O 0 0.0003305634
functional O 0 0.00024058734
impact O 0 0.00018112357
of O 0 0.00027566517
the O 0 0.00021547265
most O 0 0.00032341672
prevalent O 0 0.00045393797
immune O 0 0.0008278389
escape O 0 0.00032880894
variants O 0 0.00014439943
, O 0 0.00031805714
the O 0 0.00015276003
sG145R O 0 0.001999122
and O 0 0.0001851161
sP120T O 0 0.00041626644
mutants O 0 8.783958e-05
, O 0 0.00022299966
on O 0 7.271656e-05
the O 0 8.489195e-05
viral O 0 0.00018593034
replication O 0 0.00016656303
efficacy O 0 0.00010411152
and O 0 0.00010191525
antiviral O 0 0.00042203369
drug O 0 0.005843098
susceptibility O 0 0.00020349855
of O 0 0.00011623026
common O 0 0.00012801345
treatment O 0 0.00013729911
- O 0 0.000859115
associated O 0 9.41854e-05
mutants O 0 5.969287e-05
with O 0 0.0001403235
resistance O 0 0.0007094536
to O 0 0.0002909201
lamivudine B-Chemical 0 0.99996567
( O 0 0.0021942516
LAM B-Chemical 0 0.9996686
) O 0 0.0009941999
and O 0 0.0004401394
/ O 0 0.002723525
or O 0 0.0010445208
HBeAg B-Chemical 0 0.9995208
negativity O 0 0.6182185
. O 0 0.0038974448

Replication O 0 0.012137538
- O 0 0.013886797
competent O 0 0.0021406738
HBV O 0 0.13099872
strains O 0 0.00111361
with O 0 0.000986615
sG145R O 0 0.004958832
or O 0 0.0005237909
sP120T O 0 0.0013784268
and O 0 0.00071699417
LAM B-Chemical 0 0.9993297
resistance O 0 0.001842084
( O 0 0.00079464976
rtM204I O 0 0.03592692
or O 0 0.00022795438
rtL180M O 0 0.17867295
/ O 0 0.0025183342
rtM204V O 0 0.01809629
) O 0 0.00034594
were O 0 8.737334e-05
generated O 0 4.9495564e-05
on O 0 8.707814e-05
an O 0 0.00027684701
HBeAg B-Chemical 0 0.9997732
- O 0 0.005099076
positive O 0 0.00019643047
and O 0 0.00020514318
an O 0 0.00036448074
HBeAg B-Chemical 0 0.99982136
- O 0 0.0046299114
negative O 0 0.00017307134
background O 0 0.00012712702
with O 0 0.00025864583
precore O 0 0.010402496
( O 0 0.0011226091
PC O 0 0.311406
) O 0 0.0009623679
and O 0 0.0003307286
basal O 0 0.00061616616
core O 0 0.00034451915
promoter O 0 0.00037101793
( O 0 0.0015203087
BCP O 0 0.023530938
) O 0 0.0025312065
mutants O 0 0.0013572668
. O 0 0.0036089246

The O 0 0.0029678422
sG145R O 0 0.01293896
mutation O 0 0.002072479
strongly O 0 0.0013171779
reduced O 0 0.001900977
HBsAg B-Chemical 0 0.9977048
levels O 0 0.00057139195
and O 0 0.0004284904
was O 0 0.000246285
able O 0 0.00015611881
to O 0 0.0001527529
fully O 0 0.0001217919
restore O 0 0.000121844874
the O 0 0.00013787979
impaired O 0 0.0006676793
replication O 0 0.0004619573
of O 0 0.0005661848
LAM B-Chemical 0 0.9999299
- O 0 0.01828029
resistant O 0 0.00036415705
HBV O 0 0.12430233
mutants O 0 8.7228815e-05
to O 0 9.4637355e-05
the O 0 9.072398e-05
levels O 0 0.00010844675
of O 0 0.00018038625
wild O 0 0.00024076934
- O 0 0.007020586
type O 0 0.0010949727
HBV O 0 0.7709874
, O 0 0.0009330551
and O 0 0.00045946665
PC O 0 0.29523805
or O 0 0.00042039584
BCP O 0 0.025733825
mutations O 0 0.0004960478
further O 0 0.00037873845
enhanced O 0 0.0007849023
viral O 0 0.001989223
replication O 0 0.003721286
. O 0 0.0034629034

Although O 0 0.0022308042
the O 0 0.0020609766
sP120T O 0 0.004264232
substitution O 0 0.002035129
also O 0 0.0010200965
impaired O 0 0.011697854
HBsAg B-Chemical 0 0.9990596
secretion O 0 0.019832712
, O 0 0.0014846375
it O 0 0.0006307209
did O 0 0.00036294642
not O 0 0.00024205369
enhance O 0 0.00020941734
the O 0 0.00029876374
replication O 0 0.0008432062
of O 0 0.001275916
LAM B-Chemical 0 0.9996958
- O 0 0.009323019
resistant O 0 0.001349413
clones O 0 0.0015240111
. O 0 0.0031582399

However O 0 0.0035123473
, O 0 0.0040668533
the O 0 0.0015103696
concomitant O 0 0.0021611184
occurrence O 0 0.0012247505
of O 0 0.001517726
HBeAg B-Chemical 0 0.99970895
negativity O 0 0.39946896
( O 0 0.0020668802
PC O 0 0.2820221
/ O 0 0.0062483107
BCP O 0 0.05159621
) O 0 0.001095441
, O 0 0.00061679457
sP120T O 0 0.0009362123
, O 0 0.0005780424
and O 0 0.000479225
LAM B-Chemical 0 0.99963427
resistance O 0 0.0010192187
resulted O 0 0.00016028226
in O 0 0.00013941669
the O 0 0.00011952948
restoration O 0 0.00019966972
of O 0 0.00020799927
replication O 0 0.00036071744
to O 0 0.00020052063
levels O 0 0.00024651663
of O 0 0.00044857332
wild O 0 0.0006811136
- O 0 0.011247349
type O 0 0.0041532433
HBV O 0 0.840718
. O 0 0.004794359

In O 0 0.0018875874
all O 0 0.0014368978
clones O 0 0.0009460174
with O 0 0.0009028014
combined O 0 0.0009627701
immune O 0 0.002115317
escape O 0 0.0009588069
and O 0 0.0007470171
LAM B-Chemical 0 0.9995443
resistance O 0 0.0013867167
mutations O 0 0.00033231013
, O 0 0.0003579838
the O 0 0.00015375433
nucleotide B-Chemical 0 0.0017242151
analogues O 0 0.047272686
adefovir B-Chemical 0 0.99998355
and O 0 0.0004955345
tenofovir B-Chemical 0 0.9997843
remained O 0 0.00025320222
effective O 0 0.0001546026
in O 0 0.0001798885
suppressing O 0 0.0002720228
viral O 0 0.0008778362
replication O 0 0.0012624448
in O 0 0.00088288344
vitro O 0 0.0014900643
. O 0 0.002626986

These O 0 0.0019847448
findings O 0 0.0018127615
reveal O 0 0.00084537984
the O 0 0.0006107946
differential O 0 0.0005750103
impact O 0 0.00032117372
of O 0 0.00050491845
immune O 0 0.0015412229
escape O 0 0.00047059666
variants O 0 0.00015136287
on O 0 0.00010799187
the O 0 0.00012698467
replication O 0 0.00028815938
and O 0 0.0002053949
drug O 0 0.0055051213
susceptibility O 0 0.00028122694
of O 0 0.00017637374
complex O 0 0.00021977938
HBV O 0 0.2832959
mutants O 0 9.4439296e-05
, O 0 0.00021464199
supporting O 0 7.651507e-05
the O 0 7.3964424e-05
need O 0 7.341709e-05
of O 0 9.3789e-05
close O 0 8.625032e-05
surveillance O 0 6.8088964e-05
and O 0 9.058445e-05
treatment O 0 9.151807e-05
adjustment O 0 8.945113e-05
in O 0 8.967729e-05
response O 0 0.00011425326
to O 0 0.0001202481
the O 0 0.00014280896
selection O 0 0.00020998977
of O 0 0.00036522056
distinct O 0 0.00040005636
mutational O 0 0.0008589202
patterns O 0 0.001206923
. O 0 0.00271614

Hemolytic B-Disease 0 0.9954165
anemia I-Disease 0 0.9997968
associated O 0 0.004722478
with O 0 0.0026347258
the O 0 0.0018647007
use O 0 0.0022318251
of O 0 0.005005779
omeprazole B-Chemical 0 0.99962974
. O 0 0.009206148

Omeprazole B-Chemical 0 0.9997696
is O 0 0.002023789
the O 0 0.0009486602
first O 0 0.00055141153
drug O 0 0.0030357963
designed O 0 0.00035668572
to O 0 0.00026133432
block O 0 0.0002698993
the O 0 0.00020708799
final O 0 0.00028353956
step O 0 0.0002524901
in O 0 0.00029740075
the O 0 0.00037687473
acid O 0 0.4342173
secretory O 0 0.0014558524
process O 0 0.00037860253
within O 0 0.0002553054
the O 0 0.00060453964
parietal O 0 0.42716852
cell O 0 0.0029614586
. O 0 0.0032808303

It O 0 0.0052035614
has O 0 0.0014170442
been O 0 0.0010064878
shown O 0 0.00040991628
to O 0 0.00042038818
be O 0 0.00037480777
extremely O 0 0.00056673336
effective O 0 0.00022647151
in O 0 0.00018631812
the O 0 0.00016197459
treatment O 0 0.00023295429
of O 0 0.0005561684
peptic B-Disease 0 0.9997956
ulcer I-Disease 0 0.99981135
disease I-Disease 0 0.99359554
, O 0 0.0024008912
reflux B-Disease 0 0.99312466
esophagitis I-Disease 0 0.99633956
, O 0 0.000682986
and O 0 0.00037951642
the O 0 0.00049041846
Zollinger B-Disease 0 0.36101663
- I-Disease 0 0.012354363
Ellison I-Disease 0 0.006906405
syndrome I-Disease 0 0.89643484
. O 0 0.0041616033

Although O 0 0.0017646705
clinical O 0 0.003553814
experience O 0 0.0023170523
with O 0 0.0017613992
omeprazole B-Chemical 0 0.99992585
is O 0 0.00041269875
still O 0 0.0002621666
limited O 0 0.0002741364
, O 0 0.00038187174
many O 0 0.00014366658
controlled O 0 0.00020084708
studies O 0 0.00021013076
have O 0 0.00013910317
established O 0 0.00016719615
the O 0 0.00015516719
short O 0 0.00021754859
- O 0 0.0009174354
term O 0 0.0003233939
safety O 0 0.00042000043
of O 0 0.00066040055
this O 0 0.0012912349
drug O 0 0.032054354
. O 0 0.0035265454

We O 0 0.0026875162
report O 0 0.0025853536
the O 0 0.0009051412
first O 0 0.000514579
case O 0 0.0006027156
of O 0 0.0005064201
a O 0 0.00060115196
serious O 0 0.00079523603
short O 0 0.0002931858
- O 0 0.0011275735
term O 0 0.0002570753
adverse O 0 0.00069487875
reaction O 0 0.00018298895
with O 0 0.000199519
the O 0 0.00018412941
use O 0 0.00028255244
of O 0 0.0009780984
omeprazole B-Chemical 0 0.9999734
: O 0 0.27021405
hemolytic B-Disease 0 0.9999814
anemia I-Disease 0 0.9999753
. O 0 0.007357672

The O 0 0.0023778433
patient O 0 0.0025244972
developed O 0 0.0025266667
weakness O 0 0.84440863
, O 0 0.0050339447
lethargy B-Disease 0 0.9987583
, O 0 0.0017717268
and O 0 0.00080908445
shortness B-Disease 0 0.42582983
of I-Disease 0 0.00046179266
breath I-Disease 0 0.004972557
2 O 0 0.00025318825
days O 0 0.000114597955
after O 0 0.000118127406
starting O 0 0.00020551086
therapy O 0 0.00069807697
with O 0 0.0014579041
omeprazole B-Chemical 0 0.99970156
. O 0 0.0046487884

Two O 0 0.0016540106
weeks O 0 0.00076658715
after O 0 0.00046396884
the O 0 0.00043336433
initiation O 0 0.00032125055
of O 0 0.00044847437
therapy O 0 0.00061500043
, O 0 0.0006355209
her O 0 0.0004961253
hematocrit O 0 0.39796546
had O 0 0.00031041127
decreased O 0 0.00043449545
from O 0 0.00020848076
44 O 0 0.00031573809
. O 0 0.0001785142
1 O 0 0.00017940065
% O 0 0.00026204862
to O 0 0.000119212025
20 O 0 0.00014896669
. O 0 0.000121892976
4 O 0 0.000109116445
% O 0 0.00026085682
, O 0 0.00025450584
and O 0 0.0001645337
she O 0 0.00015524725
had O 0 0.00014921706
a O 0 0.00022871722
positive O 0 0.0001978287
direct O 0 0.00021257698
Coombs O 0 0.92618454
antiglobulin O 0 0.9696409
test O 0 0.00072959956
and O 0 0.0004781076
an O 0 0.0006684838
elevated O 0 0.0042327247
indirect O 0 0.004546957
bilirubin B-Chemical 0 0.9997882
. O 0 0.0052674664

After O 0 0.0019451402
she O 0 0.0022109507
discontinued O 0 0.0042976025
the O 0 0.0016460511
omeprazole B-Chemical 0 0.9998566
, O 0 0.002385629
her O 0 0.0012598303
hemoglobin O 0 0.5526948
and O 0 0.0012162194
hematocrit O 0 0.7861243
gradually O 0 0.0016038595
returned O 0 0.0009945765
to O 0 0.0010618485
normal O 0 0.0029395812
. O 0 0.003611108

The O 0 0.0017744579
mechanism O 0 0.0011972694
by O 0 0.0014161195
which O 0 0.0022511724
omeprazole B-Chemical 0 0.99990976
caused O 0 0.0006543329
the O 0 0.00036022533
patient O 0 0.0004599366
' O 0 0.00095389166
s O 0 0.0023915728
hemolytic B-Disease 0 0.99999404
anemia I-Disease 0 0.99999535
is O 0 0.0003260681
uncertain O 0 0.00039780576
, O 0 0.00049274194
but O 0 0.0002728925
physicians O 0 0.0005961108
should O 0 0.00011772629
be O 0 0.00020230973
alerted O 0 0.00045144075
to O 0 0.00023497244
this O 0 0.00034644708
possible O 0 0.00037641943
adverse O 0 0.0022336035
effect O 0 0.00123362
. O 0 0.0029533613

Phenylephrine B-Chemical 0 0.9997768
but O 0 0.0053170095
not O 0 0.002774045
ephedrine B-Chemical 0 0.9998745
reduces B-Disease 0 0.0014155039
frontal I-Disease 0 0.81926155
lobe I-Disease 0 0.49784207
oxygenation I-Disease 0 0.14295754
following O 0 0.00031418027
anesthesia O 0 0.0025361604
- O 0 0.0023987165
induced O 0 0.0014428514
hypotension B-Disease 0 0.9994141
. O 0 0.0042023063

BACKGROUND O 0 0.017033169
: O 0 0.005443298
Vasopressor O 0 0.0063976925
agents O 0 0.0018671642
are O 0 0.0006435679
used O 0 0.00054441974
to O 0 0.00054688315
correct O 0 0.0008906798
anesthesia O 0 0.0064174677
- O 0 0.0046062698
induced O 0 0.0022709535
hypotension B-Disease 0 0.9993748
. O 0 0.005521326

We O 0 0.002258809
describe O 0 0.0014347879
the O 0 0.00087772496
effect O 0 0.00075199537
of O 0 0.0015061336
phenylephrine B-Chemical 0 0.9999429
and O 0 0.0018421568
ephedrine B-Chemical 0 0.9999565
on O 0 0.00041495447
frontal O 0 0.7147011
lobe O 0 0.62244034
oxygenation O 0 0.6459508
( O 0 0.000911501
S O 0 0.7719362
( O 0 0.0009651212
c O 0 0.0028599943
) O 0 0.0021147323
O O 0 0.9978435
( O 0 0.0011209662
2 O 0 0.00036691054
) O 0 0.00058234576
) O 0 0.0005296605
following O 0 0.00022823861
anesthesia O 0 0.002566853
- O 0 0.0025525882
induced O 0 0.0014610668
hypotension B-Disease 0 0.99954045
. O 0 0.0041811224

METHODS O 0 0.0035839973
: O 0 0.0022077563
Following O 0 0.0005496618
induction O 0 0.00048264494
of O 0 0.00062420225
anesthesia O 0 0.0028849614
by O 0 0.0006262672
fentanyl B-Chemical 0 0.9997545
( O 0 0.0006941824
0 O 0 0.00029898572
. O 0 0.00017623203
15 O 0 0.00016938846
mg O 0 0.00088859315
kg O 0 0.0004691833
( O 0 0.00044646792
- O 0 0.0009705261
1 O 0 0.00024053255
) O 0 0.00043606764
) O 0 0.00045099691
and O 0 0.00030932264
propofol B-Chemical 0 0.9997509
( O 0 0.0005067644
2 O 0 0.00017749735
. O 0 0.00012687985
0 O 0 0.00018366562
mg O 0 0.00092914246
kg O 0 0.0004147836
( O 0 0.00039141718
- O 0 0.0009261382
1 O 0 0.00021494794
) O 0 0.00040519974
) O 0 0.00039712602
, O 0 0.00026995386
13 O 0 0.00017113512
patients O 0 0.00027392767
received O 0 0.00022678892
phenylephrine B-Chemical 0 0.9999174
( O 0 0.0004296964
0 O 0 0.0001871596
. O 0 0.00011286182
1 O 0 0.00013406159
mg O 0 0.00091975386
iv O 0 0.00020742533
) O 0 0.00024087884
and O 0 9.647391e-05
12 O 0 6.892003e-05
patients O 0 0.00016983823
received O 0 0.0001685465
ephedrine B-Chemical 0 0.9999249
( O 0 0.00040526
10 O 0 0.00016696325
mg O 0 0.0015732342
iv O 0 0.00028671217
) O 0 0.0003356348
to O 0 0.0001263238
restore O 0 0.00015923589
mean O 0 0.00026288093
arterial O 0 0.089217804
pressure O 0 0.019998224
( O 0 0.0023936408
MAP O 0 0.3737107
) O 0 0.004398018
. O 0 0.0034811273

Heart O 0 0.015461405
rate O 0 0.0053189993
( O 0 0.0051133316
HR O 0 0.028417766
) O 0 0.0041046515
, O 0 0.003152506
MAP O 0 0.5354923
, O 0 0.0025826944
stroke B-Disease 0 0.987938
volume O 0 0.0017001462
( O 0 0.0013763856
SV O 0 0.06628014
) O 0 0.0010593145
, O 0 0.00059046445
cardiac O 0 0.0009919078
output O 0 0.00041426532
( O 0 0.0009823969
CO O 0 0.9972475
) O 0 0.0011792531
, O 0 0.0005570607
and O 0 0.00040426909
frontal O 0 0.5573819
lobe O 0 0.58559966
oxygenation O 0 0.6601043
( O 0 0.0010523902
S O 0 0.7765862
( O 0 0.0012172323
c O 0 0.0035786936
) O 0 0.002746603
O O 0 0.99712014
( O 0 0.0019178275
2 O 0 0.0007840068
) O 0 0.0014138131
) O 0 0.0016429705
were O 0 0.001085929
registered O 0 0.0023718474
. O 0 0.0034535646

RESULTS O 0 0.0046566613
: O 0 0.0031469301
Induction O 0 0.0011771988
of O 0 0.00097124063
anesthesia O 0 0.0029556016
was O 0 0.00046403584
followed O 0 0.00029645808
by O 0 0.00031653797
a B-Disease 0 0.0004774716
decrease I-Disease 0 0.00040047782
in I-Disease 0 0.00044600636
MAP I-Disease 0 0.40234083
, I-Disease 0 0.00093819376
HR I-Disease 0 0.033130914
, I-Disease 0 0.00093168125
SV I-Disease 0 0.11790843
, I-Disease 0 0.00080511335
and I-Disease 0 0.00056572683
CO I-Disease 0 0.99882907
concomitant O 0 0.0010416275
with O 0 0.00035394827
an O 0 0.00043523623
elevation O 0 0.009313765
in O 0 0.0005594733
S O 0 0.9423834
( O 0 0.0020244143
c O 0 0.006763922
) O 0 0.0043580723
O O 0 0.9969009
( O 0 0.0037243017
2 O 0 0.001860867
) O 0 0.003810591
. O 0 0.0036063606

After O 0 0.0019933074
administration O 0 0.0034528472
of O 0 0.0030827732
phenylephrine B-Chemical 0 0.9998448
, O 0 0.0047858595
MAP O 0 0.5648856
increased O 0 0.00089538435
( O 0 0.0008639625
51 O 0 0.00069452025
+ O 0 0.0013718095
/ O 0 0.0018779669
- O 0 0.0013479064
12 O 0 0.00018790863
to O 0 0.00018966552
81 O 0 0.00051091344
+ O 0 0.0009785439
/ O 0 0.0014522631
- O 0 0.0012262762
13 O 0 0.00031373152
mmHg O 0 0.0011118228
; O 0 0.0006176823
P O 0 0.002792643
< O 0 0.0005058026
0 O 0 0.00042638567
. O 0 0.00039158313
001 O 0 0.0023712441
; O 0 0.00089462154
mean O 0 0.0005439726
+ O 0 0.0022668217
/ O 0 0.0047820597
- O 0 0.00868122
SD O 0 0.025928004
) O 0 0.0063885264
. O 0 0.0051648906

However O 0 0.0042257565
, O 0 0.005068188
a O 0 0.0027259092
14 O 0 0.0014195577
% O 0 0.0018779499
( O 0 0.0012555227
from O 0 0.0005518979
70 O 0 0.0007251881
+ O 0 0.0016957095
/ O 0 0.002349755
- O 0 0.0018219035
8 O 0 0.0003341629
% O 0 0.00047223957
to O 0 0.00021854875
60 O 0 0.00032905952
+ O 0 0.00096585386
/ O 0 0.0015728801
- O 0 0.0013680839
7 O 0 0.00022716832
% O 0 0.00048126926
) O 0 0.0005817383
reduction O 0 0.00039110894
in O 0 0.0004464398
S O 0 0.92080814
( O 0 0.0014781675
c O 0 0.0047849994
) O 0 0.0027801357
O O 0 0.99835867
( O 0 0.0011075237
2 O 0 0.000322109
) O 0 0.0004862698
( O 0 0.00039233343
P O 0 0.002963732
< O 0 0.00032831213
0 O 0 0.00025870695
. O 0 0.0002118615
05 O 0 0.0030079973
) O 0 0.0004141765
followed O 0 0.0001260747
with O 0 0.00016510212
no O 0 0.0001716131
change O 0 0.00023347196
in O 0 0.00033613303
CO O 0 0.99837685
( O 0 0.00049904466
3 O 0 0.00014127781
. O 0 0.00012867406
7 O 0 0.00012838433
+ O 0 0.0006291977
/ O 0 0.0015405503
- O 0 0.0019050345
1 O 0 0.00024434182
. O 0 0.00016852928
1 O 0 0.00016047253
to O 0 0.00011264141
3 O 0 0.00012824363
. O 0 0.00014243879
4 O 0 0.00015823693
+ O 0 0.0006888125
/ O 0 0.0013422972
- O 0 0.001403159
0 O 0 0.00036430047
. O 0 0.0002501512
9 O 0 0.000262521
l O 0 0.0011094635
min O 0 0.0008103418
( O 0 0.001146801
- O 0 0.0025820334
1 O 0 0.001167082
) O 0 0.0026257755
) O 0 0.0040683835
. O 0 0.004039197

The O 0 0.0020437953
administration O 0 0.0030530945
of O 0 0.0025556935
ephedrine B-Chemical 0 0.99989474
led O 0 0.0010371123
to O 0 0.00045057107
a O 0 0.00052373926
similar O 0 0.00022633553
increase O 0 0.00039060423
in O 0 0.00039120065
MAP O 0 0.7710053
( O 0 0.0005786719
53 O 0 0.00043646726
+ O 0 0.00094849383
/ O 0 0.0014975999
- O 0 0.0011346693
9 O 0 0.00016349446
to O 0 0.00014131982
79 O 0 0.00032349073
+ O 0 0.0007680759
/ O 0 0.0011564714
- O 0 0.0009178646
8 O 0 0.00018083143
mmHg O 0 0.00079754915
; O 0 0.00044578066
P O 0 0.0023822326
< O 0 0.0003583806
0 O 0 0.00029947952
. O 0 0.00026725468
001 O 0 0.0031763327
) O 0 0.00088234857
, O 0 0.0006968858
restored O 0 0.0008251384
CO O 0 0.9988029
( O 0 0.0007478897
3 O 0 0.00020174493
. O 0 0.00018137001
2 O 0 0.00022339483
+ O 0 0.0007793089
/ O 0 0.0016654996
- O 0 0.0018589356
1 O 0 0.0002574506
. O 0 0.00017282498
2 O 0 0.00016147141
to O 0 0.00011934578
5 O 0 0.00014094557
. O 0 0.00014752893
0 O 0 0.00024271786
+ O 0 0.0007651501
/ O 0 0.0015678447
- O 0 0.0015890412
1 O 0 0.0002452598
. O 0 0.0001670564
3 O 0 0.00015520376
l O 0 0.0006584759
min O 0 0.00041288725
( O 0 0.0005137086
- O 0 0.0011370112
1 O 0 0.00030828366
) O 0 0.00060089474
) O 0 0.0006798078
, O 0 0.0006050971
and O 0 0.0005206267
preserved O 0 0.002626594
S O 0 0.96182626
( O 0 0.0028392635
c O 0 0.008336385
) O 0 0.0052375323
O O 0 0.9963182
( O 0 0.004250143
2 O 0 0.0021555917
) O 0 0.0042915805
. O 0 0.004064988

CONCLUSIONS O 0 0.018880283
: O 0 0.0037423668
The O 0 0.0007633715
utilization O 0 0.0010822729
of O 0 0.0011795547
phenylephrine B-Chemical 0 0.9998747
to O 0 0.00041556288
correct O 0 0.000516119
hypotension B-Disease 0 0.9997969
induced O 0 0.0002237903
by O 0 0.000181273
anesthesia O 0 0.0012671321
has O 0 8.5517095e-05
a O 0 0.00015663398
negative O 0 0.00012119595
impact O 0 0.000113650094
on O 0 0.00019386828
S O 0 0.93352187
( O 0 0.0011424489
c O 0 0.004506052
) O 0 0.0023024313
O O 0 0.99894446
( O 0 0.0008430696
2 O 0 0.0002231111
) O 0 0.00040178464
while O 0 0.0002507276
ephedrine B-Chemical 0 0.9999486
maintains O 0 0.00032509066
frontal O 0 0.8268706
lobe O 0 0.6471392
oxygenation O 0 0.31849736
potentially O 0 0.00018011231
related O 0 0.00012917318
to O 0 0.00022981217
an O 0 0.0004708338
increase O 0 0.0006587178
in O 0 0.0014884417
CO O 0 0.99680054
. O 0 0.0042900695

Prolonged O 0 0.007355234
elevation O 0 0.011876605
of O 0 0.002157039
plasma O 0 0.21639374
argatroban B-Chemical 0 0.9995233
in O 0 0.00038762463
a O 0 0.00038572444
cardiac O 0 0.00073300785
transplant O 0 0.00033400144
patient O 0 0.00017526795
with O 0 0.00016350194
a O 0 0.00029863903
suspected O 0 0.00078740786
history O 0 0.00050083693
of O 0 0.00052607805
heparin B-Chemical 0 0.99953103
- O 0 0.046567954
induced O 0 0.0010865828
thrombocytopenia B-Disease 0 0.99980944
with O 0 0.0029554467
thrombosis B-Disease 0 0.9998572
. O 0 0.0042285887

BACKGROUND O 0 0.01981243
: O 0 0.005991401
Direct O 0 0.003991391
thrombin O 0 0.5041381
inhibitors O 0 0.003149648
( O 0 0.0014724811
DTIs O 0 0.0014149869
) O 0 0.00054237
provide O 0 0.00013060342
an O 0 0.00015229346
alternative O 0 7.78951e-05
method O 0 0.00012877166
of O 0 0.00015901194
anticoagulation O 0 0.0020829113
for O 0 9.275222e-05
patients O 0 0.00022566644
with O 0 0.00012443248
a O 0 0.00019888498
history O 0 0.00029771708
of O 0 0.00030627666
heparin B-Chemical 0 0.9996648
- O 0 0.035283875
induced O 0 0.00044536803
thrombocytopenia B-Disease 0 0.99994195
( O 0 0.0027409482
HIT B-Disease 2 0.99976355
) O 0 0.0012443129
or O 0 0.00030646008
HIT B-Disease 2 0.9995147
with O 0 0.00067934376
thrombosis B-Disease 0 0.9999752
( O 0 0.0032746568
HITT B-Disease 0 0.99966717
) O 0 0.00057150406
undergoing O 0 0.00024679906
cardiopulmonary O 0 0.00036514938
bypass O 0 0.00046056398
( O 0 0.00097125175
CPB O 0 0.008843008
) O 0 0.002779143
. O 0 0.0027364893

In O 0 0.0020028327
the O 0 0.0014672672
following O 0 0.000835274
report O 0 0.0015163291
, O 0 0.0013004896
a O 0 0.00085691136
65 O 0 0.00072748685
- O 0 0.0017150359
year O 0 0.0003281244
- O 0 0.0012005022
old O 0 0.00038563582
critically B-Disease 0 0.0013752392
ill I-Disease 0 0.9089173
patient O 0 0.00033327844
with O 0 0.00020040615
a O 0 0.0003072863
suspected O 0 0.000747615
history O 0 0.00036875863
of O 0 0.0003252398
HITT B-Disease 0 0.9997441
was O 0 0.00018175432
administered O 0 0.00044080516
argatroban B-Chemical 0 0.9989687
for O 0 0.00011517979
anticoagulation O 0 0.0010479819
on O 0 0.00011214979
bypass O 0 0.00030317364
during O 0 0.0002815913
heart O 0 0.005460181
transplantation O 0 0.0015635386
. O 0 0.002001197

The O 0 0.0020621284
patient O 0 0.0017226369
required O 0 0.00069616997
massive O 0 0.0018128061
transfusion O 0 0.0013231585
support O 0 0.00044015728
( O 0 0.0006734096
55 O 0 0.0003923106
units O 0 0.00025628632
of O 0 0.00029654292
red O 0 0.0005537666
blood O 0 0.0027450465
cells O 0 0.00034893642
, O 0 0.00040295185
42 O 0 0.00021905635
units O 0 0.00015337947
of O 0 0.00020439598
fresh O 0 0.00063167076
- O 0 0.003170762
frozen O 0 0.00069073564
plasma O 0 0.0042289123
, O 0 0.00027342068
40 O 0 0.00013580163
units O 0 0.00012278624
of O 0 0.00021252877
cryoprecipitate O 0 0.80994153
, O 0 0.00026602097
40 O 0 0.00012920029
units O 0 0.00011695525
of O 0 0.00019621858
platelets O 0 0.09921231
, O 0 0.00027322132
and O 0 0.00011312548
three O 0 5.7074754e-05
doses O 0 0.0002760242
of O 0 0.00023589708
recombinant O 0 0.00060724537
Factor O 0 0.9979456
VIIa O 0 0.9961396
) O 0 0.000685935
for O 0 0.00017885954
severe O 0 0.0008268601
intraoperative B-Disease 0 0.00045425052
and I-Disease 0 0.00044455065
postoperative I-Disease 0 0.0013769638
bleeding I-Disease 0 0.66855437
. O 0 0.0025472897

STUDY O 0 0.00576547
DESIGN O 0 0.0024413746
AND O 0 0.0011426689
METHODS O 0 0.0012219884
: O 0 0.0015506174
Plasma O 0 0.003495515
samples O 0 0.0004333393
from O 0 0.00023191671
before O 0 0.00013363533
and O 0 0.00019835378
after O 0 0.0001270692
CPB O 0 0.0015645078
were O 0 0.00011240053
analyzed O 0 0.00010377065
postoperatively O 0 0.00013319096
for O 0 0.00014306398
argatroban B-Chemical 0 0.9972363
concentration O 0 0.00030320112
using O 0 0.00014035453
a O 0 0.00028884978
modified O 0 0.00028133448
ecarin O 0 0.019520475
clotting O 0 0.06387562
time O 0 0.0002973248
( O 0 0.001273762
ECT O 0 0.63791335
) O 0 0.0022062461
assay O 0 0.0021693963
. O 0 0.002972503

RESULTS O 0 0.0038814005
: O 0 0.0026046543
Unexpectedly O 0 0.0009376442
high O 0 0.0009452249
concentrations O 0 0.0011713743
of O 0 0.0009825017
argatroban B-Chemical 0 0.99936706
were O 0 0.00028762416
measured O 0 0.00023264313
in O 0 0.00017014069
these O 0 0.00016908604
samples O 0 0.00021558609
( O 0 0.00028761895
range O 0 0.00017471617
, O 0 0.0002797337
0 O 0 0.00024582492
- O 0 0.00061041274
32 O 0 0.00021522708
microg O 0 0.00033758365
/ O 0 0.0010476022
mL O 0 0.0020891768
) O 0 0.000497694
, O 0 0.00028471416
and O 0 0.00016188904
a O 0 0.0002361455
prolonged O 0 0.00034114145
plasma O 0 0.02902375
argatroban B-Chemical 0 0.99936813
half O 0 0.00010415451
life O 0 0.00015178592
( O 0 0.00030555247
t O 0 0.0008870291
( O 0 0.00033917563
1 O 0 0.00019741322
/ O 0 0.0005902812
2 O 0 0.00018844243
) O 0 0.00035459807
) O 0 0.00033293513
of O 0 0.00019005401
514 O 0 0.0012357144
minutes O 0 0.00013922938
was O 0 0.00010767702
observed O 0 0.00011339007
( O 0 0.00024714493
published O 0 0.00013886967
elimination O 0 0.00023916434
t O 0 0.001059892
( O 0 0.00038150136
1 O 0 0.00021693092
/ O 0 0.0006529845
2 O 0 0.00019995586
) O 0 0.00032451382
is O 0 0.00012637621
39 O 0 0.0002567238
- O 0 0.00067800854
51 O 0 0.00023787306
minutes O 0 0.00014876669
[ O 0 0.00043033715
< O 0 0.00024644422
or O 0 0.000164542
= O 0 0.000559879
181 O 0 0.0006325371
minutes O 0 0.00028122615
with O 0 0.00055463874
hepatic B-Disease 0 0.9983658
impairment I-Disease 0 0.9961372
] O 0 0.013089627
) O 0 0.0045084287
. O 0 0.0032236564

CONCLUSIONS O 0 0.015398229
: O 0 0.0035234469
Correlation O 0 0.00093092874
of O 0 0.0011514708
plasma O 0 0.03540783
argatroban B-Chemical 0 0.99925166
concentration O 0 0.0005646849
versus O 0 0.00020039946
the O 0 0.00015341473
patient O 0 0.00020605572
' O 0 0.0003358529
s O 0 0.00034653427
coagulation O 0 0.090524845
variables O 0 0.00013511034
and O 0 9.914006e-05
clinical O 0 0.00023673117
course O 0 8.147455e-05
suggest O 0 4.2328717e-05
that O 0 6.430581e-05
prolonged O 0 0.00018337915
elevated O 0 0.00055280316
levels O 0 0.00012736314
of O 0 0.00027755369
plasma O 0 0.34374818
argatroban B-Chemical 0 0.9998945
may O 0 0.00012262487
have O 0 0.00011331019
contributed O 0 0.00022267163
to O 0 0.00015756211
the O 0 0.00019366063
patient O 0 0.0003705019
' O 0 0.00078618195
s O 0 0.0009956355
extended O 0 0.0013418824
coagulopathy B-Disease 0 0.99897766
. O 0 0.003779302

Because O 0 0.0023121983
DTIs O 0 0.004901343
do O 0 0.0011428326
not O 0 0.0006801759
have O 0 0.00043829516
reversal O 0 0.00057863054
agents O 0 0.00089211855
, O 0 0.0005816688
surgical O 0 0.00038779876
teams O 0 0.00025431518
and O 0 0.00020987786
transfusion O 0 0.00045783716
services O 0 0.00021441598
should O 0 7.4076386e-05
remain O 0 9.590778e-05
aware O 0 0.00012982865
of O 0 0.0001382098
the O 0 9.803722e-05
possibility O 0 8.157734e-05
of O 0 0.0002013191
massive O 0 0.00074847584
transfusion O 0 0.0005713573
events O 0 0.00025964598
during O 0 0.00017640991
anticoagulation O 0 0.0025360808
with O 0 0.00040765764
these O 0 0.0006486909
agents O 0 0.0027557213
. O 0 0.0026561802

This O 0 0.0044428585
is O 0 0.0014063462
the O 0 0.0008117932
first O 0 0.00049537985
report O 0 0.0008218799
to O 0 0.00036952615
measure O 0 0.00035431405
plasma O 0 0.05955634
argatroban B-Chemical 0 0.9997098
concentration O 0 0.0005776101
in O 0 0.00021544799
the O 0 0.0001724171
context O 0 0.00015392978
of O 0 0.0004937838
CPB O 0 0.01591182
and O 0 0.0007641715
extended O 0 0.0013857953
coagulopathy B-Disease 0 0.99865085
. O 0 0.0041177813

The O 0 0.0014125326
effects O 0 0.0011131687
of O 0 0.000976853
the O 0 0.0006712506
adjunctive O 0 0.039455816
bupropion B-Chemical 0 0.99996746
on O 0 0.00026433085
male O 0 0.0011338984
sexual B-Disease 0 0.2326527
dysfunction I-Disease 0 0.99510914
induced O 0 0.00024627068
by O 0 0.00018936915
a O 0 0.00037571104
selective B-Chemical 0 0.0010105468
serotonin I-Chemical 0 0.9999585
reuptake I-Chemical 0 0.9985727
inhibitor I-Chemical 0 0.0010114348
: O 0 0.00046300722
a O 0 0.00023074575
double O 0 0.00018229708
- O 0 0.002655685
blind O 0 0.051177796
placebo O 0 0.027056282
- O 0 0.0015646897
controlled O 0 0.00041181096
and O 0 0.00056529377
randomized O 0 0.0019116766
study O 0 0.0015400478
. O 0 0.0024511232

OBJECTIVE O 0 0.016108261
: O 0 0.0025595715
To O 0 0.00035247588
determine O 0 0.000185824
the O 0 0.00024253257
safety O 0 0.00023532353
and O 0 0.00018501568
efficacy O 0 0.00017855217
of O 0 0.00024271414
adjunctive O 0 0.031291038
bupropion B-Chemical 0 0.9999845
sustained O 0 0.0009562087
- O 0 0.0043991753
release O 0 0.00053181365
( O 0 0.00048638147
SR O 0 0.028258355
) O 0 0.00035885602
on O 0 8.7871e-05
male O 0 0.0004977406
sexual B-Disease 0 0.13846393
dysfunction I-Disease 0 0.9973007
( O 0 0.00089480233
SD B-Disease 0 0.031958982
) O 0 0.00035611037
induced O 0 0.000105213636
by O 0 0.00012640368
a O 0 0.00030646092
selective B-Chemical 0 0.00097033556
serotonin I-Chemical 0 0.9999672
reuptake I-Chemical 0 0.9992781
inhibitor I-Chemical 0 0.0024913135
( O 0 0.0019707426
SSRI B-Chemical 0 0.99998903
) O 0 0.0008451053
, O 0 0.00029297508
as O 0 0.00015807798
SD B-Disease 0 0.010752759
is O 0 0.000104063874
a O 0 0.00017131816
common O 0 0.0001403425
side O 0 0.0005796186
- O 0 0.0011308437
effect O 0 0.000109074215
of O 0 0.00027153257
SSRIs B-Chemical 0 0.99957436
and O 0 0.00016537737
the O 0 0.000108159446
most O 0 0.00016029357
effective O 0 0.00014253687
treatments O 0 0.00024682892
have O 0 0.0002384455
yet O 0 0.00037928493
to O 0 0.00045079942
be O 0 0.0007604971
determined O 0 0.0011544955
. O 0 0.0027132812

PATIENTS O 0 0.0021160035
AND O 0 0.0013958784
METHODS O 0 0.0012378201
: O 0 0.001024584
The O 0 0.00033785152
randomized O 0 0.0007342309
sample O 0 0.0004782084
consisted O 0 0.0003634537
of O 0 0.00046596464
234 O 0 0.0034921498
euthymic O 0 0.9950112
men O 0 0.0015110624
who O 0 0.00039605759
were O 0 0.00023499821
receiving O 0 0.00034059293
some O 0 0.00048147576
type O 0 0.0014099025
of O 0 0.0025589275
SSRI B-Chemical 0 0.999876
. O 0 0.0048474153

The O 0 0.0022633336
men O 0 0.0046756803
were O 0 0.0009962253
randomly O 0 0.0004559442
assigned O 0 0.00047914078
to O 0 0.0006219915
bupropion B-Chemical 0 0.99995375
SR O 0 0.172133
( O 0 0.00054652337
150 O 0 0.00031353632
mg O 0 0.0013000632
twice O 0 0.00011629111
daily O 0 0.00018138488
, O 0 0.00027194375
117 O 0 0.00035522046
) O 0 0.000348588
or O 0 0.00015949742
placebo O 0 0.001574221
( O 0 0.0003397713
twice O 0 0.00015535582
daily O 0 0.00029427907
, O 0 0.0005234064
117 O 0 0.00077807304
) O 0 0.0007958015
for O 0 0.0003937276
12 O 0 0.0005443429
weeks O 0 0.00069720834
. O 0 0.0024291005

Efficacy O 0 0.0037990867
was O 0 0.0015073058
evaluated O 0 0.0009247648
using O 0 0.0005842608
the O 0 0.0005363324
Clinical O 0 0.0011739357
Global O 0 0.0008703364
Impression O 0 0.0017194197
- O 0 0.0014542768
Sexual O 0 0.00099097
Function O 0 0.00058896514
( O 0 0.0006170598
CGI O 0 0.0025595983
- O 0 0.0022891304
SF O 0 0.019408321
; O 0 0.0004896249
the O 0 0.00013970281
primary O 0 0.00014285867
outcome O 0 0.00018863496
measure O 0 0.00011429074
) O 0 0.00038358694
, O 0 0.0002564305
the O 0 0.00010941955
International O 0 0.00011093017
Index O 0 0.00013764139
of O 0 0.00013255228
Erectile O 0 0.00017774904
Function O 0 0.00023269327
( O 0 0.00025903792
IIEF O 0 0.0003512909
) O 0 0.00035440476
, O 0 0.0003331415
Arizona O 0 0.00048037939
Sexual O 0 0.0007359945
Experience O 0 0.0011057546
Scale O 0 0.0024020679
( O 0 0.00061395945
ASEX O 0 0.7107214
) O 0 0.0005643473
, O 0 0.0003500009
and O 0 0.00023554533
Erectile B-Disease 0 0.00043374227
Dysfunction I-Disease 0 0.0006375685
Inventory O 0 0.00048291025
of O 0 0.00019625448
Treatment O 0 0.00044767844
Satisfaction O 0 0.00054297707
( O 0 0.00053219654
EDITS O 0 0.0026299674
) O 0 0.0008013945
( O 0 0.0006891503
secondary O 0 0.00062956626
outcome O 0 0.00092921365
measures O 0 0.0011052227
) O 0 0.003695984
. O 0 0.0037309157

Participants O 0 0.0045760707
were O 0 0.0026494004
followed O 0 0.0018551985
biweekly O 0 0.0025419304
during O 0 0.0016674552
study O 0 0.0027627647
period O 0 0.0028620374
. O 0 0.0065147267

RESULTS O 0 0.0041131373
: O 0 0.0022816858
After O 0 0.00047433603
12 O 0 0.0004110771
weeks O 0 0.0002657421
of O 0 0.00040409723
treatment O 0 0.00038188574
, O 0 0.0004833581
the O 0 0.00020237107
mean O 0 0.00019369941
( O 0 0.00036947776
sd O 0 0.00048631057
) O 0 0.000385335
scores O 0 0.00016688352
for O 0 0.00016136197
CGI O 0 0.0024039447
- O 0 0.0020890017
SF O 0 0.01486057
were O 0 0.00015801529
significantly O 0 0.00018077469
lower O 0 0.00021834549
, O 0 0.0003304698
i O 0 0.0003689945
. O 0 0.00017716138
e O 0 0.00038548955
. O 0 0.00012750311
better O 0 0.00015597134
, O 0 0.0002591607
in O 0 0.00013891958
patients O 0 0.0003636942
on O 0 0.00018399619
bupropion B-Chemical 0 0.9999894
SR O 0 0.38067335
, O 0 0.00034027212
at O 0 0.00010344778
2 O 0 0.00014538615
. O 0 0.00011350172
4 O 0 0.0001021551
( O 0 0.00021310365
1 O 0 0.00013874272
. O 0 0.00011344317
2 O 0 0.00013647275
) O 0 0.00028185156
, O 0 0.00021262445
than O 0 0.0001004219
in O 0 0.00010383144
the O 0 0.00011395862
placebo O 0 0.0019248283
group O 0 0.00025062964
, O 0 0.00026978788
at O 0 0.000110755136
3 O 0 0.0001333222
. O 0 0.00014536978
9 O 0 0.00015186553
( O 0 0.00032069517
1 O 0 0.00023826372
. O 0 0.00022229974
1 O 0 0.00030323808
) O 0 0.0006447453
( O 0 0.0007407177
P O 0 0.007328968
= O 0 0.0015267346
0 O 0 0.000970477
. O 0 0.0010715226
01 O 0 0.005578984
) O 0 0.004552021
. O 0 0.004390735

Men O 0 0.030620843
who O 0 0.003607252
received O 0 0.0023706416
bupropion B-Chemical 0 0.9999236
had O 0 0.00083355035
a O 0 0.0006119979
significant O 0 0.00031101913
increase O 0 0.00024020138
in O 0 0.00018786584
the O 0 0.00015002425
total O 0 0.00018634407
IIEF O 0 0.00035443294
score O 0 0.00015140243
( O 0 0.0002829905
54 O 0 0.0002743194
. O 0 0.00015584318
4 O 0 0.00013368552
% O 0 0.00028963463
vs O 0 0.00027606657
1 O 0 0.00022217366
. O 0 0.0001768001
2 O 0 0.0002045317
% O 0 0.00037400427
; O 0 0.00047022948
P O 0 0.005581175
= O 0 0.00069840334
0 O 0 0.00031073432
. O 0 0.00024825186
003 O 0 0.0014874698
) O 0 0.00056839734
, O 0 0.00040557687
and O 0 0.00024543967
in O 0 0.00020811115
the O 0 0.00017816269
five O 0 0.0001391837
different O 0 0.00018096338
domains O 0 0.00026174702
of O 0 0.00063876656
the O 0 0.00092771684
IIEF O 0 0.0030699742
. O 0 0.00272711

Total O 0 0.0070422897
ASEX O 0 0.80518097
scores O 0 0.0012783093
were O 0 0.00071356574
significantly O 0 0.00066669437
lower O 0 0.0006790063
, O 0 0.0008787215
i O 0 0.0007959707
. O 0 0.00036951053
e O 0 0.0006351231
. O 0 0.00020476113
better O 0 0.00021570349
, O 0 0.0003140545
among O 0 0.00020967587
men O 0 0.0007877436
who O 0 0.00024690144
received O 0 0.00021364335
bupropion B-Chemical 0 0.9999651
than O 0 0.00015986862
placebo O 0 0.0028494801
, O 0 0.00023614797
at O 0 9.63566e-05
15 O 0 0.00012191658
. O 0 0.00011532959
5 O 0 0.000114398696
( O 0 0.00020185865
4 O 0 0.000103840735
. O 0 0.0001126614
3 O 0 0.000112219765
) O 0 0.0002759105
vs O 0 0.00023802395
21 O 0 0.00021379109
. O 0 0.00017498944
5 O 0 0.00017953003
( O 0 0.00032559564
4 O 0 0.00018243634
. O 0 0.00021467065
7 O 0 0.00022931948
) O 0 0.0006614203
( O 0 0.00080756785
P O 0 0.0073109097
= O 0 0.0016904315
0 O 0 0.0010977853
. O 0 0.0012440977
002 O 0 0.0076882555
) O 0 0.0051805237
. O 0 0.004810321

The O 0 0.0025156636
EDITS O 0 0.00806161
scores O 0 0.001377663
were O 0 0.0009430844
67 O 0 0.0013163496
. O 0 0.00060915947
4 O 0 0.00042671175
( O 0 0.0006804042
10 O 0 0.00035532206
. O 0 0.0002802425
2 O 0 0.00027836784
) O 0 0.0004411419
for O 0 0.00017592566
the O 0 0.00029147897
bupropion B-Chemical 0 0.9999505
and O 0 0.00030438745
36 O 0 0.00024146544
. O 0 0.00015863242
3 O 0 0.00013660347
( O 0 0.0002599095
11 O 0 0.00017009153
. O 0 0.00013325652
7 O 0 0.00011780951
) O 0 0.0002701382
for O 0 0.00011412653
the O 0 0.00016510622
placebo O 0 0.0015145434
group O 0 0.0004534847
( O 0 0.00074609864
P O 0 0.012495429
= O 0 0.0014040932
0 O 0 0.0008633836
. O 0 0.00096800085
001 O 0 0.0089875525
) O 0 0.00462489
. O 0 0.004139156

The O 0 0.0035118202
ASEX O 0 0.4520368
score O 0 0.001653843
and O 0 0.0016303438
CGI O 0 0.007169231
- O 0 0.0049714595
SF O 0 0.010132468
score O 0 0.00067200715
were O 0 0.00054619915
correlated O 0 0.00061491894
( O 0 0.0012966532
P O 0 0.009798138
= O 0 0.0023168053
0 O 0 0.001428858
. O 0 0.0015474727
003 O 0 0.007594389
) O 0 0.005637293
. O 0 0.0054868306

In O 0 0.0017162991
linear O 0 0.0014901386
regression O 0 0.0012979567
analyses O 0 0.00081361894
the O 0 0.0006024649
CGI O 0 0.004935802
- O 0 0.0035718668
SF O 0 0.014531454
score O 0 0.00030384812
was O 0 0.00021987327
not O 0 0.00019308094
affected O 0 0.00024596913
significantly O 0 0.00024862614
by O 0 0.0001613626
the O 0 0.0001240375
duration O 0 0.000119555014
of O 0 0.00027680476
SD B-Disease 0 0.009248602
, O 0 0.00063483295
type O 0 0.0007367746
of O 0 0.00091590604
SSRI B-Chemical 0 0.99992645
used O 0 0.00072526035
and O 0 0.0010789725
age O 0 0.0024947005
. O 0 0.0029640107

CONCLUSIONS O 0 0.07185045
: O 0 0.01587789
Bupropion B-Chemical 0 0.9994599
is O 0 0.00109131
an O 0 0.00078926294
effective O 0 0.00053017057
treatment O 0 0.0005189447
for O 0 0.00048285828
male O 0 0.0017358449
SD B-Disease 0 0.011193969
induced O 0 0.0012985861
by O 0 0.002455783
SSRIs B-Chemical 0 0.99738055
. O 0 0.0052999742

These O 0 0.0021238218
results O 0 0.0014951277
provide O 0 0.00095372077
empirical O 0 0.0013237447
support O 0 0.0007965766
for O 0 0.00061333104
conducting O 0 0.00071621937
a O 0 0.0010181182
further O 0 0.0007620799
study O 0 0.0014518336
of O 0 0.0028517449
bupropion B-Chemical 0 0.9998815
. O 0 0.0061440933

Prevention O 0 0.0053297626
of O 0 0.004458485
seizures B-Disease 0 0.99983644
and O 0 0.001532391
reorganization O 0 0.0008951536
of O 0 0.0005385418
hippocampal O 0 0.002001216
functions O 0 0.00021027308
by O 0 0.00020465729
transplantation O 0 0.0002906271
of O 0 0.00023149211
bone O 0 0.0012747512
marrow O 0 0.0023191352
cells O 0 0.0002809378
in O 0 0.00022280755
the O 0 0.00024889107
acute O 0 0.005191626
phase O 0 0.0009801601
of O 0 0.0009147401
experimental O 0 0.0025805668
epilepsy B-Disease 0 0.9999378
. O 0 0.004558805

In O 0 0.0021943685
this O 0 0.0020356402
study O 0 0.001535715
, O 0 0.0012535529
we O 0 0.0003178877
investigated O 0 0.00035165242
the O 0 0.00025857726
therapeutic O 0 0.0003333541
potential O 0 0.00018121462
of O 0 0.00029623572
bone O 0 0.0022273469
marrow O 0 0.0075532906
mononuclear O 0 0.00869634
cells O 0 0.00030017988
( O 0 0.00046845217
BMCs O 0 0.0009371044
) O 0 0.00041225713
in O 0 0.0001451479
a O 0 0.00022876501
model O 0 0.0001894909
of O 0 0.00059242634
epilepsy B-Disease 0 0.9999862
induced O 0 0.0007143611
by O 0 0.001079754
pilocarpine B-Chemical 0 0.99996126
in O 0 0.0011941264
rats O 0 0.002237492
. O 0 0.0024661126

BMCs O 0 0.0099506
obtained O 0 0.0018758142
from O 0 0.0014058715
green O 0 0.0018314909
fluorescent O 0 0.0015528676
protein O 0 0.00082935486
( O 0 0.001129387
GFP O 0 0.0008224294
) O 0 0.0005855271
transgenic O 0 0.00012221596
mice O 0 7.4313895e-05
or O 0 0.00013042796
rats O 0 0.0002355945
were O 0 0.00013740611
transplanted O 0 0.00031206015
intravenously O 0 0.00022899306
after O 0 7.5161646e-05
induction O 0 0.00014195648
of O 0 0.0003502539
status B-Disease 0 0.00081281643
epilepticus I-Disease 0 0.9990496
( O 0 0.0026417684
SE B-Disease 0 0.19060783
) O 0 0.0041727503
. O 0 0.0032782976

Spontaneous B-Disease 0 0.026678756
recurrent I-Disease 0 0.19782402
seizures I-Disease 0 0.99992335
( O 0 0.007582012
SRS B-Disease 0 0.6131915
) O 0 0.0015872484
were O 0 0.00047020998
monitored O 0 0.00035814822
using O 0 0.00044088735
Racine O 0 0.0021526394
' O 0 0.001574197
s O 0 0.0020457767
seizure B-Disease 0 0.9966485
severity O 0 0.004863894
scale O 0 0.0027580527
. O 0 0.003577738

All O 0 0.0021048016
of O 0 0.0016697356
the O 0 0.0009181162
rats O 0 0.0010652564
in O 0 0.0004990929
the O 0 0.0003877638
saline O 0 0.0015523502
- O 0 0.0027297176
treated O 0 0.0011741063
epileptic B-Disease 0 0.9997408
control O 0 0.0002494905
group O 0 0.00032338465
developed O 0 0.00034305625
SRS B-Disease 0 0.48513162
, O 0 0.00027604445
whereas O 0 0.00012359358
none O 0 0.00013386487
of O 0 0.00015774537
the O 0 0.00018063874
BMC O 0 0.7313661
- O 0 0.009003195
treated O 0 0.0011730817
epileptic B-Disease 0 0.99992347
animals O 0 0.00012349393
had O 0 0.00025739218
seizures B-Disease 0 0.9999672
in O 0 0.00012164473
the O 0 7.737185e-05
short O 0 7.989235e-05
term O 0 0.0001201461
( O 0 0.00018644589
15 O 0 8.086432e-05
days O 0 4.981101e-05
after O 0 5.9211816e-05
transplantation O 0 0.00021037154
) O 0 0.0004155429
, O 0 0.00039007273
regardless O 0 0.00020472288
of O 0 0.00056886347
the O 0 0.00082724984
BMC O 0 0.21612136
source O 0 0.0017855605
. O 0 0.0032865456

Over O 0 0.004471177
the O 0 0.0017560732
long O 0 0.0015942386
- O 0 0.0035531574
term O 0 0.0008595171
chronic O 0 0.004044618
phase O 0 0.0009847663
( O 0 0.00059211254
120 O 0 0.00025423593
days O 0 9.809098e-05
after O 0 8.651902e-05
transplantation O 0 0.00023320742
) O 0 0.00039765358
, O 0 0.00031699246
only O 0 0.00020189637
25 O 0 0.0002604508
% O 0 0.00034599623
of O 0 0.00027888583
BMC O 0 0.6545408
- O 0 0.008304776
treated O 0 0.0013431968
epileptic B-Disease 0 0.99991417
animals O 0 0.00014613237
had O 0 0.0003226622
seizures B-Disease 0 0.9999844
, O 0 0.0005479384
but O 0 0.00015871729
with O 0 0.0001245431
a O 0 0.00016096061
lower O 0 0.00011872207
frequency O 0 8.343356e-05
and O 0 0.000100478406
duration O 0 8.064407e-05
compared O 0 0.000110882786
to O 0 0.00020253516
the O 0 0.00044710614
epileptic B-Disease 0 0.99955124
control O 0 0.0009516081
group O 0 0.0020362362
. O 0 0.0026873031

The O 0 0.0022943954
density O 0 0.0026771533
of O 0 0.0018479878
hippocampal O 0 0.008532879
neurons O 0 0.0007966233
in O 0 0.0004081441
the O 0 0.00030095645
brains O 0 0.0003884351
of O 0 0.0002948441
animals O 0 0.00024213445
treated O 0 0.00067971065
with O 0 0.00063707214
BMCs O 0 0.002587861
was O 0 0.0008598144
markedly O 0 0.002742377
preserved O 0 0.005908839
. O 0 0.0039480873

At O 0 0.0021553636
hippocampal O 0 0.011247615
Schaeffer O 0 0.01016626
collateral O 0 0.41457862
- O 0 0.01894371
CA1 O 0 0.08777432
synapses O 0 0.001145624
, O 0 0.0007611172
long O 0 0.00043360007
- O 0 0.0013827453
term O 0 0.00034539922
potentiation O 0 0.0020490931
was O 0 0.0002821707
preserved O 0 0.0007163102
in O 0 0.00036226542
BMC O 0 0.35904363
- O 0 0.0021914553
transplanted O 0 0.0006240972
rats O 0 0.00044374942
compared O 0 0.00031088572
to O 0 0.0007542669
epileptic B-Disease 0 0.9993005
controls O 0 0.0028077262
. O 0 0.0030500176

The O 0 0.0026083428
donor O 0 0.0024361773
- O 0 0.00516383
derived O 0 0.0008954893
GFP O 0 0.0017398371
( O 0 0.001680364
+ O 0 0.0026018855
) O 0 0.0013664034
cells O 0 0.0006111416
were O 0 0.00041943952
rarely O 0 0.000501653
found O 0 0.00033523215
in O 0 0.00032223735
the O 0 0.0003223735
brains O 0 0.00058465573
of O 0 0.000754776
transplanted O 0 0.0049506673
epileptic B-Disease 0 0.9994281
rats O 0 0.0031031836
. O 0 0.002943914

In O 0 0.0018900172
conclusion O 0 0.0013637793
, O 0 0.0023417326
treatment O 0 0.001049857
with O 0 0.00091228675
BMCs O 0 0.002553656
can O 0 0.0002765352
prevent O 0 0.00023738299
the O 0 0.0002090038
development O 0 0.00031202866
of O 0 0.00037326204
chronic O 0 0.47913432
seizures B-Disease 0 0.99998915
, O 0 0.00083327555
reduce O 0 0.00015494617
neuronal B-Disease 0 0.005100578
loss I-Disease 0 0.00084233563
, O 0 0.0003615023
and O 0 0.00016323448
influence O 0 0.00011531365
the O 0 0.00017349515
reorganization O 0 0.00033231074
of O 0 0.0003496597
the O 0 0.00042868627
hippocampal O 0 0.0076196776
neuronal O 0 0.0021191484
network O 0 0.0016341242
. O 0 0.0027538144

Normalizing O 0 0.0044962047
effects O 0 0.002337908
of O 0 0.0035266844
modafinil B-Chemical 0 0.9999206
on O 0 0.001456095
sleep O 0 0.12144092
in O 0 0.0012872657
chronic O 0 0.083475076
cocaine B-Chemical 0 0.9990029
users O 0 0.0053432686
. O 0 0.0041133016

OBJECTIVE O 0 0.019132484
: O 0 0.0032351145
The O 0 0.0005518429
purpose O 0 0.00041901154
of O 0 0.00050919555
the O 0 0.00032752904
present O 0 0.00026118133
study O 0 0.0003048585
was O 0 0.00016755491
to O 0 0.00010425517
determine O 0 4.3627566e-05
the O 0 7.9599195e-05
effect O 0 9.541882e-05
of O 0 0.00018889467
morning O 0 0.0012556255
- O 0 0.0042776093
dosed O 0 0.013118603
modafinil B-Chemical 0 0.99997926
on O 0 0.00013762733
sleep O 0 0.030594409
and O 0 0.00024154902
daytime B-Disease 0 0.39203706
sleepiness I-Disease 0 0.9975721
in O 0 0.00041466244
chronic O 0 0.042112265
cocaine B-Chemical 0 0.99924505
users O 0 0.0031051696
. O 0 0.0025079085

METHOD O 0 0.010575935
: O 0 0.0047528036
Twenty O 0 0.0036962824
cocaine B-Chemical 0 0.99883527
- O 0 0.004810239
dependent O 0 0.0003029815
participants O 0 0.0003002526
were O 0 0.00017346573
randomly O 0 9.532624e-05
assigned O 0 0.00011510578
to O 0 0.00013185023
receive O 0 0.0002464386
modafinil B-Chemical 0 0.9999597
, O 0 0.00058356876
400 O 0 0.0008882974
mg O 0 0.00795905
( O 0 0.00058621226
N O 0 0.9791875
= O 0 0.00096025126
10 O 0 0.00018517928
) O 0 0.00033401063
, O 0 0.00024824048
or O 0 0.0001547852
placebo O 0 0.00374539
( O 0 0.0006343733
N O 0 0.99147063
= O 0 0.0010728094
10 O 0 0.0001678922
) O 0 0.00025471774
every O 0 6.86473e-05
morning O 0 0.00022132436
at O 0 8.289564e-05
7 O 0 0.00010021813
: O 0 0.00023029606
30 O 0 0.000113030925
a O 0 0.00017640907
. O 0 0.00014815768
m O 0 0.00065710326
. O 0 0.00013274085
for O 0 8.729322e-05
16 O 0 0.00012818641
days O 0 7.445633e-05
in O 0 0.0001251629
an O 0 0.00021088366
inpatient O 0 0.00070973224
, O 0 0.0004703796
double O 0 0.00038649223
- O 0 0.0032775982
blind O 0 0.02705243
randomized O 0 0.0034175778
trial O 0 0.0026324864
. O 0 0.002907484

Participants O 0 0.00247103
underwent O 0 0.0019066102
polysomnographic O 0 0.0062470697
sleep O 0 0.0050248057
recordings O 0 0.00040060133
on O 0 0.00020612292
days O 0 0.00018245532
1 O 0 0.00025776323
to O 0 0.00017829186
3 O 0 0.00019005309
, O 0 0.00031302232
7 O 0 0.0001463559
to O 0 0.00013475238
9 O 0 0.00015692668
, O 0 0.00027209288
and O 0 0.00017196788
14 O 0 0.00014808621
to O 0 0.00012527849
16 O 0 0.00018926735
( O 0 0.00025356413
first O 0 0.00010964357
, O 0 0.000311179
second O 0 0.0001920725
, O 0 0.00039354217
and O 0 0.00024961543
third O 0 0.00026949815
weeks O 0 0.00021703808
of O 0 0.0006711553
abstinence O 0 0.0066948035
) O 0 0.0034970848
. O 0 0.0031377904

The O 0 0.00317255
Multiple O 0 0.0037235692
Sleep O 0 0.009044296
Latency O 0 0.0050812177
Test O 0 0.0024235246
was O 0 0.0005164798
performed O 0 0.00036165467
at O 0 0.0003063602
11 O 0 0.00042333573
: O 0 0.00060484454
30 O 0 0.00028300536
a O 0 0.0003909246
. O 0 0.00032558106
m O 0 0.0012212856
. O 0 0.00034023012
, O 0 0.0004818412
2 O 0 0.00031002384
: O 0 0.0004883964
00 O 0 0.0007690936
p O 0 0.0004323029
. O 0 0.00025288016
m O 0 0.0010018431
. O 0 0.00026706312
, O 0 0.00037607583
and O 0 0.0002241854
4 O 0 0.00017939381
: O 0 0.00033303958
30 O 0 0.00015396148
p O 0 0.00029069526
. O 0 0.00020897272
m O 0 0.0007909046
. O 0 0.00021975819
on O 0 0.00015288082
days O 0 0.00018138108
2 O 0 0.0003864377
, O 0 0.00072625146
8 O 0 0.00058540376
, O 0 0.0012676946
and O 0 0.0013195097
15 O 0 0.0019339216
. O 0 0.0033647907

For O 0 0.001513607
comparison O 0 0.0013765233
of O 0 0.001521849
sleep O 0 0.031467915
architecture O 0 0.0008748527
variables O 0 0.00050336006
, O 0 0.00047922938
12 O 0 0.00017029178
healthy O 0 0.00037137483
comparison O 0 0.00011417201
participants O 0 0.00014690566
underwent O 0 0.00016349586
a O 0 0.00016561219
single O 0 9.447396e-05
night O 0 0.00021211982
of O 0 0.00014380144
experimental O 0 0.00018016175
polysomnography O 0 0.0004092806
that O 0 0.00011400046
followed O 0 0.00015581722
1 O 0 0.00028680346
night O 0 0.00051161577
of O 0 0.00059180346
accommodation O 0 0.0038816421
polysomnography O 0 0.0039904476
. O 0 0.002425385

RESULTS O 0 0.0044488944
: O 0 0.0035588075
Progressive O 0 0.004177231
abstinence O 0 0.006068772
from O 0 0.00091074436
cocaine B-Chemical 0 0.9979856
was O 0 0.000473946
associated O 0 0.00036700073
with O 0 0.0003699948
worsening O 0 0.0022013264
of O 0 0.00034537382
all O 0 0.0003241684
measured O 0 0.00053044304
polysomnographic O 0 0.008552865
sleep O 0 0.009707394
outcomes O 0 0.0014658064
. O 0 0.0024295046

Compared O 0 0.0019230766
with O 0 0.0018685209
placebo O 0 0.03150314
, O 0 0.0038109443
modafinil B-Chemical 0 0.99995816
decreased O 0 0.0017423664
nighttime O 0 0.010004465
sleep O 0 0.03327203
latency O 0 0.0004809746
and O 0 0.00021416873
increased O 0 0.00030278167
slow O 0 0.0006849336
- O 0 0.0022227394
wave O 0 0.0017709571
sleep O 0 0.014797416
time O 0 0.00020512048
in O 0 0.00045775814
cocaine B-Chemical 0 0.9992687
- O 0 0.004501888
dependent O 0 0.0006322776
participants O 0 0.0015922139
. O 0 0.002710175

The O 0 0.001510435
effect O 0 0.0012167408
of O 0 0.0019448929
modafinil B-Chemical 0 0.99995315
interacted O 0 0.00048158635
with O 0 0.00034962036
the O 0 0.00020167955
abstinence O 0 0.0011270606
week O 0 9.4225106e-05
and O 0 0.0001217219
was O 0 0.00010675045
associated O 0 0.00011592353
with O 0 0.00010912539
longer O 0 7.466473e-05
total O 0 0.00014771786
sleep O 0 0.0029979297
time O 0 7.947874e-05
and O 0 0.00014413474
shorter O 0 0.00022032257
REM O 0 0.99921787
sleep O 0 0.070652336
latency O 0 0.0003874263
in O 0 0.00015457047
the O 0 0.00015515757
third O 0 0.00024992615
week O 0 0.00025590297
of O 0 0.0007522172
abstinence O 0 0.0075609796
. O 0 0.0026426364

Comparison O 0 0.002083748
of O 0 0.0023719706
slow O 0 0.0041279383
- O 0 0.008458198
wave O 0 0.005033544
sleep O 0 0.025066122
time O 0 0.00033817132
, O 0 0.0006059712
total O 0 0.00035484592
sleep O 0 0.004879885
time O 0 0.00014957403
, O 0 0.00033867548
and O 0 0.00023415992
sleep O 0 0.018310865
latency O 0 0.0004314157
in O 0 0.00021762618
cocaine B-Chemical 0 0.99969995
- O 0 0.0019600352
dependent O 0 7.5978554e-05
and O 0 0.00011143185
healthy O 0 0.00037437084
participants O 0 0.00011079855
revealed O 0 7.753862e-05
a O 0 0.00014433911
normalizing O 0 0.00010369548
effect O 0 0.00013288092
of O 0 0.0005147004
modafinil B-Chemical 0 0.9999926
in O 0 0.00081477064
cocaine B-Chemical 0 0.9998149
- O 0 0.0061793667
dependent O 0 0.0005177914
participants O 0 0.0013546809
. O 0 0.0022986312

Modafinil B-Chemical 0 0.9995788
was O 0 0.0021786282
associated O 0 0.0011433379
with O 0 0.00081248354
increased O 0 0.00097397383
daytime O 0 0.01277885
sleep O 0 0.04826784
latency O 0 0.0007049781
, O 0 0.00042867562
as O 0 0.00019783645
measured O 0 0.00020331102
by O 0 0.00016697153
the O 0 0.00016117824
Multiple O 0 0.0002937274
Sleep O 0 0.0017748905
Latency O 0 0.0011337067
Test O 0 0.00077368686
, O 0 0.000297733
and O 0 0.00019077277
a O 0 0.00027314163
nearly O 0 0.00022169692
significant O 0 0.00023170166
decrease O 0 0.00032836696
in O 0 0.00038412327
subjective O 0 0.0020513975
daytime B-Disease 0 0.46843347
sleepiness I-Disease 0 0.99651307
. O 0 0.0029915955

CONCLUSIONS O 0 0.022968663
: O 0 0.005922905
Morning O 0 0.007830228
- O 0 0.00961984
dosed O 0 0.02758789
modafinil B-Chemical 0 0.99993384
promotes O 0 0.00058533263
nocturnal O 0 0.3230489
sleep O 0 0.23398617
, O 0 0.00079433934
normalizes O 0 0.0031811588
sleep O 0 0.037306968
architecture O 0 0.0003671264
, O 0 0.00033046448
and O 0 0.00020377988
decreases O 0 0.0003581371
daytime B-Disease 0 0.48811492
sleepiness I-Disease 0 0.9984579
in O 0 0.00060699595
abstinent O 0 0.7981581
cocaine B-Chemical 0 0.99864393
users O 0 0.0029140008
. O 0 0.002649064

These O 0 0.0023941235
effects O 0 0.002122052
may O 0 0.0014446636
be O 0 0.0010420384
relevant O 0 0.0006721884
in O 0 0.0006927595
the O 0 0.00065059017
treatment O 0 0.00089760666
of O 0 0.001721395
cocaine B-Chemical 0 0.998524
dependence O 0 0.004733439
. O 0 0.0046743406

Safety O 0 0.0048184046
of O 0 0.0017515252
transesophageal O 0 0.0020322432
echocardiography O 0 0.0018465775
in O 0 0.0009966595
adults O 0 0.0024470019
: O 0 0.001792253
study O 0 0.0010050131
in O 0 0.0009216435
a O 0 0.0018032454
multidisciplinary O 0 0.0033850104
hospital O 0 0.0035743804
. O 0 0.004259887

BACKGROUND O 0 0.014711629
: O 0 0.00472537
TEE O 0 0.0054896935
is O 0 0.0009061249
a O 0 0.0010376193
semi O 0 0.0009303139
- O 0 0.0020625647
invasive O 0 0.0004667442
tool O 0 0.00024029735
broadly O 0 0.00017290344
used O 0 0.0001703051
and O 0 0.00021372527
its O 0 0.00025701255
utilization O 0 0.00027710738
associated O 0 0.0002064707
to O 0 0.0001900058
sedatives O 0 0.8162052
drugs O 0 0.0048964387
might O 0 0.00012954396
to O 0 0.00019603998
affect O 0 0.00022541247
the O 0 0.00034272575
procedure O 0 0.00051602063
safety O 0 0.001172566
. O 0 0.0022704527

OBJECTIVE O 0 0.023154834
: O 0 0.003673596
to O 0 0.00079890917
analyze O 0 0.00033117473
aspects O 0 0.00037543892
of O 0 0.00043316442
TEE O 0 0.0014837076
safety O 0 0.00028888314
associated O 0 0.00021508594
to O 0 0.00014301637
the O 0 0.00013208958
use O 0 0.00015627683
of O 0 0.00030584537
Midazolan B-Chemical 0 0.68940544
( O 0 0.0012720162
MZ B-Chemical 1 0.99940646
) O 0 0.0014428941
and O 0 0.00057342096
Flumazenil B-Chemical 0 0.9999927
( O 0 0.0018209873
FL B-Chemical 0 0.97390455
) O 0 0.0005893035
and O 0 0.0001453213
the O 0 9.6351454e-05
influence O 0 8.755742e-05
of O 0 0.00016862026
the O 0 0.00016025065
clinical O 0 0.0005431338
variables O 0 0.00028413007
on O 0 0.00021093192
the O 0 0.00039386985
event O 0 0.001256323
rate O 0 0.0021771714
. O 0 0.0029357749

METHOD O 0 0.01143031
: O 0 0.0048805936
prospective O 0 0.0038542466
study O 0 0.00117632
with O 0 0.00083205366
137 O 0 0.0012208318
patients O 0 0.0007283831
that O 0 0.0002966427
underwent O 0 0.000510963
TEE O 0 0.001969195
with O 0 0.00071882876
MZ B-Chemical 1 0.9957118
associated O 0 0.00082291657
to O 0 0.0007001017
moderate O 0 0.0031486782
sedation O 0 0.024596838
. O 0 0.0029517664

We O 0 0.0022868381
analyzed O 0 0.0014100658
the O 0 0.00071926665
following O 0 0.0003906115
events O 0 0.00072094856
: O 0 0.00088258146
complications O 0 0.001956071
related O 0 0.0001667095
with O 0 0.00022445897
the O 0 0.00021103228
topical O 0 0.042164836
anesthesia O 0 0.0029834756
, O 0 0.0004353369
with O 0 0.00039575153
MZ B-Chemical 1 0.9963909
use O 0 0.00037675977
and O 0 0.00043805662
with O 0 0.00058874034
the O 0 0.00071169855
procedure O 0 0.0011541392
. O 0 0.0025849827

Uni O 0 0.710518
- O 0 0.010156781
and O 0 0.0013312191
multivariate O 0 0.00084221445
analyses O 0 0.0006138664
were O 0 0.00033851436
used O 0 0.0002429642
to O 0 0.00020137132
test O 0 0.00026435428
the O 0 0.00013370249
influence O 0 0.00010138541
of O 0 0.00016196471
the O 0 0.00012858573
clinical O 0 0.00037455632
variables O 0 0.00018896621
: O 0 0.0002980252
age O 0 0.00025404448
, O 0 0.0003138994
sex O 0 0.00049979077
, O 0 0.00075388025
stroke B-Disease 0 0.9979114
, O 0 0.002309562
myocardiopathy B-Disease 0 0.99998164
( O 0 0.0038934834
MP B-Disease 0 0.99483705
) O 0 0.0006772061
, O 0 0.00022053464
duration O 0 7.853998e-05
of O 0 0.00012399732
the O 0 0.00011783006
test O 0 0.00026175723
, O 0 0.0005361915
mitral B-Disease 0 0.8430246
regurgitation I-Disease 0 0.9849834
( O 0 0.00093958084
MR B-Disease 0 0.20227478
) O 0 0.001008809
and O 0 0.00053288916
the O 0 0.00079689134
MZ B-Chemical 1 0.99628264
dose O 0 0.004313778
. O 0 0.0031229747

RESULTS O 0 0.0055768336
: O 0 0.0036968219
All O 0 0.0011575404
patients O 0 0.0018622032
( O 0 0.001701364
65 O 0 0.0013002655
+ O 0 0.002454787
/ O 0 0.0031935591
- O 0 0.0026476723
16 O 0 0.00070935965
yrs O 0 0.00081424596
; O 0 0.0009529169
58 O 0 0.0008857491
% O 0 0.0011348175
males O 0 0.0013633124
) O 0 0.0018081976
finished O 0 0.0014113763
the O 0 0.0012412019
examination O 0 0.0019777634
. O 0 0.003993625

The O 0 0.0019625272
mean O 0 0.0015590221
doses O 0 0.002562096
of O 0 0.0020339747
MZ B-Chemical 1 0.99801105
and O 0 0.0017816018
FL B-Chemical 0 0.9366801
were O 0 0.00046628417
4 O 0 0.00027613947
. O 0 0.00024162758
3 O 0 0.00022977711
+ O 0 0.0008735158
/ O 0 0.0016413617
- O 0 0.001706317
1 O 0 0.0002844485
. O 0 0.00019755706
9 O 0 0.00018894424
mg O 0 0.0010978705
and O 0 0.00021155611
0 O 0 0.00027269928
. O 0 0.00020778242
28 O 0 0.00027123553
+ O 0 0.0009688893
/ O 0 0.001899606
- O 0 0.0020422281
0 O 0 0.00059135794
. O 0 0.00047644228
2 O 0 0.0007254778
mg O 0 0.0040751933
, O 0 0.0020528918
respectively O 0 0.003130412
. O 0 0.0038895244

The O 0 0.0015673505
duration O 0 0.0009633601
of O 0 0.0009145187
the O 0 0.0005267145
examination O 0 0.00038009792
and O 0 0.00035276334
the O 0 0.00023856193
mean O 0 0.00024063139
ejection O 0 0.004885197
fraction O 0 0.00036839308
( O 0 0.0007479574
EF O 0 0.2780142
) O 0 0.0006772962
were O 0 0.00017959953
16 O 0 0.00019554095
. O 0 0.0001518325
4 O 0 0.00015467513
+ O 0 0.0006616057
/ O 0 0.0012346501
- O 0 0.0011301178
6 O 0 0.00015760779
. O 0 0.00016611858
1 O 0 0.00017780904
minutes O 0 0.00015658527
and O 0 0.00021082173
60 O 0 0.00033256112
+ O 0 0.0010745218
/ O 0 0.0019849895
- O 0 0.002182197
9 O 0 0.0006362955
% O 0 0.0014404468
, O 0 0.0021400964
respectively O 0 0.0034095354
. O 0 0.0041382425

Mild O 0 0.98830926
hypoxia B-Disease 2 0.99632543
( O 0 0.011107067
SO2 O 0 0.9882494
< O 0 0.0016156558
90 O 0 0.0007762767
% O 0 0.0010219724
) O 0 0.0008951323
was O 0 0.0003102802
the O 0 0.00023757729
most O 0 0.0003152998
common O 0 0.00028500988
event O 0 0.00041831745
( O 0 0.00043020345
11 O 0 0.00023703968
patients O 0 0.00037730398
) O 0 0.00044186178
; O 0 0.0003284643
3 O 0 0.00013736945
patients O 0 0.00026938977
( O 0 0.00025694692
2 O 0 0.00016427285
% O 0 0.0003000111
) O 0 0.00037097107
presented O 0 0.00015313046
transient O 0 0.00059409696
hypoxia B-Disease 2 0.9811965
due O 0 0.00011602484
to O 0 0.00010438847
upper O 0 0.00020456444
airway B-Disease 0 0.0004992004
obstruction I-Disease 0 0.010787578
by O 0 8.759825e-05
probe O 0 7.4575495e-05
introduction O 0 6.913436e-05
and O 0 0.0001280497
8 O 0 0.00013790741
( O 0 0.00024561855
5 O 0 0.00013232735
. O 0 0.0001352284
8 O 0 0.00015914178
% O 0 0.0003930406
) O 0 0.00054943725
due O 0 0.00024019016
to O 0 0.0004684859
hypoxia B-Disease 2 0.97710615
caused O 0 0.0009441003
by O 0 0.0014320359
MZ B-Chemical 1 0.9977458
use O 0 0.0022879045
. O 0 0.0033725293

Transient O 0 0.043445423
hypotension B-Disease 0 0.99944717
( O 0 0.0058961306
SAP O 0 0.21726152
< O 0 0.0017400018
90mmHg O 0 0.0088441195
) O 0 0.0015248255
occurred O 0 0.000568386
in O 0 0.0004991193
1 O 0 0.0006061392
patient O 0 0.00061678875
( O 0 0.00091409794
0 O 0 0.0007953997
. O 0 0.00072384556
7 O 0 0.0008889181
% O 0 0.0025115113
) O 0 0.0046974425
. O 0 0.0048513794

The O 0 0.0018937772
multivariate O 0 0.0017250158
analysis O 0 0.0011644375
showed O 0 0.00077715935
that O 0 0.00067305897
severe O 0 0.0040423716
MR B-Disease 0 0.5571085
, O 0 0.002271936
MP B-Disease 0 0.9711131
( O 0 0.0010476714
EF O 0 0.07030871
< O 0 0.00042314592
45 O 0 0.00021759565
% O 0 0.0003404832
) O 0 0.000350829
and O 0 0.00016173768
high O 0 0.00021320504
doses O 0 0.00047532143
of O 0 0.00040005505
MZ B-Chemical 1 0.9993801
( O 0 0.00087216176
> O 0 0.0010940832
5mg O 0 0.73353094
) O 0 0.0005308681
were O 0 0.00014859768
associated O 0 0.00016749007
with O 0 0.0001976739
events O 0 0.0003636514
( O 0 0.00047005108
p O 0 0.0005226026
< O 0 0.00060019904
0 O 0 0.00068714254
. O 0 0.0008625518
001 O 0 0.008537894
) O 0 0.004465819
. O 0 0.004004523

The O 0 0.0036369301
EF O 0 0.14766121
was O 0 0.0018356065
40 O 0 0.0013722198
% O 0 0.0016157752
, O 0 0.0010203049
in O 0 0.00042813862
the O 0 0.00032768268
group O 0 0.0005472969
with O 0 0.00057240087
MP B-Disease 0 0.96746504
and O 0 0.00034563948
44 O 0 0.0003333668
% O 0 0.00032359437
in O 0 0.00012419753
the O 0 0.000108740845
group O 0 0.00020853283
with O 0 0.00020865933
severe O 0 0.002054762
MR B-Disease 0 0.48311275
and O 0 0.00023282462
it O 0 0.00024035212
can O 0 0.00010275251
be O 0 0.00014124681
a O 0 0.00029090096
factor O 0 0.0016711543
associated O 0 0.000218179
with O 0 0.0002264091
clinical O 0 0.00077236455
events O 0 0.0003878777
in O 0 0.00027114272
the O 0 0.00031295847
last O 0 0.0003701388
group O 0 0.0015462073
. O 0 0.002480277

CONCLUSION O 0 0.015528587
: O 0 0.004823959
TEE O 0 0.0055519175
with O 0 0.0014762037
sedation O 0 0.005035655
presents O 0 0.00092940615
a O 0 0.0011713427
low O 0 0.0012902691
rate O 0 0.0017714746
of O 0 0.0020231495
events O 0 0.0041793953
. O 0 0.005017602

There O 0 0.0036448229
were O 0 0.0019351689
no O 0 0.0013898409
severe O 0 0.0033730422
events O 0 0.0012076028
and O 0 0.0006647073
there O 0 0.00044407565
was O 0 0.00046614124
no O 0 0.00043167383
need O 0 0.00047902978
to O 0 0.0005464546
interrupt O 0 0.00082539784
the O 0 0.0009353581
examinations O 0 0.0021469279
. O 0 0.0032844904

Effect O 0 0.0021375825
of O 0 0.0014711061
direct O 0 0.0008269862
intracoronary O 0 0.03280617
administration O 0 0.00124511
of O 0 0.00086253945
methylergonovine B-Chemical 0 0.9997888
in O 0 0.0005252233
patients O 0 0.0008003028
with O 0 0.0004758035
and O 0 0.0006543903
without O 0 0.0011383921
variant B-Disease 2 0.00726892
angina I-Disease 2 0.9999697
. O 0 0.005596802

The O 0 0.001337536
effects O 0 0.0010590006
of O 0 0.0010735935
intracoronary O 0 0.046972528
administration O 0 0.0010328051
of O 0 0.00065401435
methylergonovine B-Chemical 0 0.9998282
were O 0 0.0002651297
studied O 0 0.00024832215
in O 0 0.00014557135
21 O 0 0.00017352692
patients O 0 0.0002644859
with O 0 0.0001929569
variant B-Disease 2 0.0009989804
angina I-Disease 2 0.99999595
and O 0 0.0002296249
22 O 0 0.00019379733
patients O 0 0.00019641191
with O 0 0.00011625897
atypical O 0 0.0012989386
chest B-Disease 0 0.00042740174
pain I-Disease 0 0.0066786576
and O 0 0.00012981454
in O 0 0.00014577067
others O 0 0.000522022
without O 0 0.00089483726
angina B-Disease 0 0.9999925
pectoris I-Disease 0 0.9999223
( O 0 0.00090348895
control O 0 0.000549596
group O 0 0.00132946
) O 0 0.003241414
. O 0 0.002804133

Methylergonovine B-Chemical 0 0.7580652
was O 0 0.002239599
administered O 0 0.0016540793
continuously O 0 0.0008468783
at O 0 0.00049197953
a O 0 0.0007090417
rate O 0 0.0006338188
of O 0 0.00051220757
10 O 0 0.0005602129
micrograms O 0 0.00284557
/ O 0 0.0017716418
min O 0 0.0008235548
up O 0 0.000642589
to O 0 0.00067855924
50 O 0 0.0016823938
micrograms O 0 0.007982568
. O 0 0.0035128887

In O 0 0.001999358
all O 0 0.0017732118
patients O 0 0.0023105203
with O 0 0.0014072981
variant B-Disease 2 0.004625951
angina I-Disease 2 0.9999894
, O 0 0.0070754304
coronary B-Disease 2 0.998162
spasm I-Disease 2 0.99997795
was O 0 0.00033284407
provoked O 0 0.0004605684
at O 0 0.0001224662
a O 0 0.00018567524
mean O 0 0.00011218006
dose O 0 0.00020681786
of O 0 0.00016954602
28 O 0 0.00022109509
+ O 0 0.0007867339
/ O 0 0.001449266
- O 0 0.0014033014
13 O 0 0.0003493658
micrograms O 0 0.0013519395
( O 0 0.0005076523
mean O 0 0.00034774208
+ O 0 0.0016448589
/ O 0 0.0038199264
- O 0 0.0074693626
SD O 0 0.025212895
) O 0 0.0053461483
. O 0 0.0043446417

In O 0 0.0022593185
the O 0 0.0017982646
control O 0 0.0016222486
group O 0 0.00199132
neither O 0 0.0018338094
ischemic O 0 0.9991841
ST O 0 0.7673244
change O 0 0.000939584
nor O 0 0.0007403955
localized O 0 0.0012193333
spasm B-Disease 0 0.998741
occurred O 0 0.0028405169
. O 0 0.0039102226

The O 0 0.0023754768
basal O 0 0.0033392513
tone O 0 0.006952109
of O 0 0.0009222171
the O 0 0.000501148
right O 0 0.0010975385
coronary O 0 0.030309366
artery O 0 0.03005249
was O 0 0.00023986312
significantly O 0 0.0002449866
lower O 0 0.00026682287
than O 0 0.00020130856
that O 0 0.00019996463
of O 0 0.0003918759
the O 0 0.00046949627
left O 0 0.0019382088
coronary O 0 0.12336955
artery O 0 0.14643295
. O 0 0.0030984725

The O 0 0.0018349523
percentage O 0 0.0013272439
of O 0 0.0017791621
vasoconstriction O 0 0.99634945
of O 0 0.0007281344
the O 0 0.0003457229
right O 0 0.0008029106
coronary O 0 0.026246231
artery O 0 0.02558085
was O 0 0.00018633464
significantly O 0 0.00019913811
higher O 0 0.00021163902
than O 0 0.0001784953
that O 0 0.00017897523
of O 0 0.0003586506
the O 0 0.0004334585
left O 0 0.0018413874
coronary O 0 0.12888788
artery O 0 0.15009531
. O 0 0.0029604277

These O 0 0.0019204571
results O 0 0.001342496
suggest O 0 0.00079005305
that O 0 0.0011384587
spasm B-Disease 0 0.9996222
provocation O 0 0.025388498
tests O 0 0.0010456383
, O 0 0.00049822475
which O 0 0.0002037624
use O 0 0.00012613315
an O 0 0.00015060215
intracoronary O 0 0.0027223858
injection O 0 7.7250574e-05
of O 0 8.9798465e-05
a O 0 0.0001294574
relatively O 0 0.00012526022
low O 0 0.0001471701
dose O 0 0.0002491686
of O 0 0.00022437358
methylergonovine B-Chemical 0 0.99994206
, O 0 0.00032150213
have O 0 8.094949e-05
a O 0 0.00012279807
high O 0 0.00011471122
sensitivity O 0 0.00020930395
in O 0 0.00015995356
variant B-Disease 2 0.0010588362
angina I-Disease 2 0.99999726
and O 0 0.0001998699
the O 0 0.00013565499
vasoreactivity O 0 0.99958485
of O 0 0.00012448172
the O 0 7.420873e-05
right O 0 0.00029750456
coronary O 0 0.04304241
artery O 0 0.03795839
may O 0 8.2463026e-05
be O 0 8.847149e-05
greater O 0 0.00014376195
than O 0 0.000119281605
that O 0 0.00012506008
of O 0 0.00026676236
the O 0 0.00031275835
other O 0 0.00061430625
coronary O 0 0.22150347
arteries O 0 0.78659225
. O 0 0.0029285941

Oral O 0 0.055048827
manifestations O 0 0.043811712
of O 0 0.0043048495
" O 0 0.009797037
meth B-Disease 2 0.99926454
mouth I-Disease 2 0.98595977
" O 0 0.0057915337
: O 0 0.003891004
a O 0 0.002713088
case O 0 0.0026317413
report O 0 0.005175817
. O 0 0.0058495724

AIM O 0 0.22055113
: O 0 0.0037655407
The O 0 0.00064184656
aim O 0 0.00047277848
of O 0 0.00053732627
the O 0 0.00034900295
documentation O 0 0.00041695827
of O 0 0.00032065116
this O 0 0.0003022219
clinical O 0 0.00081451447
case O 0 0.00022253918
is O 0 0.00012630344
to O 0 0.000115367526
make O 0 0.00013659305
clinicians O 0 0.00035810602
aware O 0 0.00020580321
of O 0 0.00030676823
" O 0 0.0017031222
meth B-Disease 2 0.9999039
mouth I-Disease 2 0.99426395
" O 0 0.0007403507
and O 0 0.00020386811
the O 0 0.00016028028
medical O 0 0.0007242954
risks O 0 0.00044925464
associated O 0 0.0003218996
with O 0 0.00040541767
this O 0 0.000645139
serious O 0 0.0022773491
condition O 0 0.0030664732
. O 0 0.003050814

BACKGROUND O 0 0.040981986
: O 0 0.015175388
Methamphetamine B-Chemical 1 0.9996774
is O 0 0.0009381254
a O 0 0.0009648831
very O 0 0.0008529299
addictive O 0 0.59820753
, O 0 0.000682848
powerful O 0 0.00047071688
stimulant O 0 0.60551953
that O 0 0.00015712896
increases O 0 0.00023082472
wakefulness O 0 0.30939868
and O 0 0.00014114489
physical O 0 0.00018611587
activity O 0 7.502094e-05
and O 0 0.00010667719
can O 0 6.2705956e-05
produce O 0 5.747358e-05
other O 0 7.242839e-05
effects O 0 0.0001012299
such O 0 0.00012286317
as O 0 0.00019227424
cardiac B-Disease 0 0.3066964
dysrhythmias I-Disease 0 0.9999833
, O 0 0.006090746
hypertension B-Disease 2 0.9999949
, O 0 0.03699079
hallucinations B-Disease 0 0.9999964
, O 0 0.0022478804
and O 0 0.0011023652
violent B-Disease 0 0.9280528
behavior I-Disease 0 0.021749659
. O 0 0.0038128

Dental O 0 0.010341804
patients O 0 0.008952987
abusing O 0 0.9454937
methamphetamine B-Chemical 1 0.99987376
can O 0 0.0005771885
present O 0 0.00032470442
with O 0 0.0003743892
poor O 0 0.0009349083
oral O 0 0.0012687335
hygiene O 0 0.0006635468
, O 0 0.0012015959
xerostomia B-Disease 0 0.9985663
, O 0 0.0014303671
rampant O 0 0.034327973
caries B-Disease 0 0.99902713
( O 0 0.0022865366
" O 0 0.0023499036
meth B-Disease 2 0.9997956
mouth I-Disease 2 0.99113363
" O 0 0.0019329588
) O 0 0.0014549894
, O 0 0.0009923181
and O 0 0.0007913321
excessive O 0 0.0030617567
tooth B-Disease 0 0.023668459
wear I-Disease 0 0.009947975
. O 0 0.004071951

Oral O 0 0.025593512
rehabilitation O 0 0.005947527
of O 0 0.0027437506
patients O 0 0.003864355
using O 0 0.0021921187
methamphetamine B-Chemical 1 0.99951434
can O 0 0.0018396947
be O 0 0.0020597726
challenging O 0 0.003387313
. O 0 0.005072894

CASE O 0 0.19650318
DESCRIPTION O 0 0.007886565
: O 0 0.00425649
A O 0 0.006400767
30 O 0 0.0010119765
- O 0 0.0022497657
year O 0 0.0005240532
- O 0 0.0014430988
old O 0 0.00053698634
Caucasian O 0 0.0029931846
woman O 0 0.00094711315
presented O 0 0.00022888719
with O 0 0.0002824889
dental O 0 0.0009388756
pain B-Disease 0 0.065799505
, O 0 0.0008522766
bad B-Disease 0 0.043420725
breath I-Disease 0 0.34765044
, O 0 0.0009028891
and O 0 0.00048112407
self O 0 0.0021405038
- O 0 0.0042539528
reported O 0 0.0009689119
poor O 0 0.0030762558
esthetics O 0 0.050296657
. O 0 0.0041022976

A O 0 0.013980851
comprehensive O 0 0.0014322121
examination O 0 0.000834469
including O 0 0.0005466007
her O 0 0.0007251767
medical O 0 0.0013257343
history O 0 0.00083335256
, O 0 0.00071436557
panoramic O 0 0.0037228544
radiograph O 0 0.001041504
, O 0 0.0004244229
and O 0 0.0002024143
intraoral O 0 0.00037767482
examination O 0 0.00012291122
revealed O 0 0.00014157298
19 O 0 0.000438217
carious B-Disease 0 0.9841524
lesions I-Disease 0 0.45379204
, O 0 0.0005619028
which O 0 0.00023514971
is O 0 0.0001532574
not O 0 0.00018271749
very O 0 0.0003351526
common O 0 0.00035428852
for O 0 0.00032613278
a O 0 0.00097491895
healthy O 0 0.0031448384
adult O 0 0.00224205
. O 0 0.002886763

She O 0 0.006126511
reported O 0 0.002105049
her O 0 0.0013295414
use O 0 0.00076249806
of O 0 0.0010606541
methamphetamine B-Chemical 1 0.9998
for O 0 0.00030457028
five O 0 0.00015229941
years O 0 0.0002493274
and O 0 0.00018940256
had O 0 0.00017107347
not O 0 0.00015030632
experienced O 0 0.00023108545
any O 0 0.00017974789
major O 0 0.0003420323
carious B-Disease 0 0.98434526
episodes I-Disease 0 0.004914277
before O 0 0.00013709084
she O 0 0.00024901092
started O 0 0.00033469853
using O 0 0.00038585902
the O 0 0.00075045123
drug O 0 0.012265977
. O 0 0.0030152316

SUMMARY O 0 0.007129654
: O 0 0.0033363344
The O 0 0.0007463492
patient O 0 0.00085923285
' O 0 0.0010505255
s O 0 0.0007524728
medical O 0 0.0010284564
and O 0 0.0003384508
dental O 0 0.0005388247
histories O 0 0.00037072322
along O 0 0.00014781591
with O 0 0.0001483085
radiographic O 0 0.00032141813
and O 0 0.000153981
clinical O 0 0.00043364058
findings O 0 0.00020142547
lead O 0 0.0007125244
to O 0 0.00012068416
a O 0 0.00022087555
diagnosis O 0 0.00034101933
of O 0 0.00022545652
" O 0 0.0013934426
meth B-Disease 2 0.9999323
mouth I-Disease 2 0.99573046
. O 0 0.0002162956
" O 0 0.00018708358
Although O 0 3.9931565e-05
three O 0 3.209856e-05
different O 0 4.741901e-05
dental O 0 0.00015329935
treatment O 0 7.468937e-05
modalities O 0 0.00014113507
( O 0 0.00016277458
either O 0 7.29027e-05
conventional O 0 8.065745e-05
or O 0 9.3228045e-05
implant O 0 0.00038367326
- O 0 0.0012410566
supported O 0 0.00019723298
) O 0 0.00039270456
have O 0 0.00010596234
been O 0 0.0001072453
offered O 0 0.00014390924
to O 0 0.000102032915
the O 0 0.00010620867
patient O 0 0.00015635433
since O 0 9.3442715e-05
August O 0 0.00017173932
2007 O 0 0.00028662497
, O 0 0.0002958612
the O 0 0.00015834709
patient O 0 0.00025189956
has O 0 0.00014897577
yet O 0 0.00026152027
to O 0 0.0002728345
initiate O 0 0.00031467638
any O 0 0.0006742615
treatment O 0 0.0013733061
. O 0 0.0026556992

CLINICAL O 0 0.0037303502
SIGNIFICANCE O 0 0.003209876
: O 0 0.0023085775
This O 0 0.0009986047
clinical O 0 0.0010477514
case O 0 0.00040187524
showing O 0 0.00028293038
oral O 0 0.001618495
manifestations O 0 0.024289291
of O 0 0.000628778
meth B-Disease 2 0.9999056
mouth I-Disease 2 0.98782504
was O 0 0.00020679815
presented O 0 0.00011143195
to O 0 8.824181e-05
help O 0 0.0001356436
dental O 0 0.00036429215
practitioners O 0 0.00037575368
recognize O 0 0.000101890764
and O 0 0.00020023042
manage O 0 0.0003670398
patients O 0 0.0006803121
who O 0 0.0004716658
may O 0 0.00036556838
be O 0 0.00081476994
abusing O 0 0.8611149
methamphetamines B-Chemical 0 0.99993
. O 0 0.0063748844

Dental O 0 0.008444364
practitioners O 0 0.0045413407
also O 0 0.0012233782
may O 0 0.00069454836
be O 0 0.00052620744
skeptical O 0 0.0008152277
about O 0 0.0003724743
the O 0 0.00020217108
reliability O 0 0.00026282604
of O 0 0.00023654885
appointment O 0 0.00026633564
keeping O 0 0.00018534003
by O 0 0.00015630871
these O 0 0.00017594344
patients O 0 0.00044242863
, O 0 0.00034325648
as O 0 0.00017970472
they O 0 0.00017700368
frequently O 0 0.00022752878
miss O 0 0.00039384243
their O 0 0.00024608948
appointments O 0 0.0006906237
without O 0 0.00044943258
reasonable O 0 0.00053623854
justification O 0 0.0018518849
. O 0 0.0030409386

Antituberculosis B-Chemical 0 0.9385769
therapy O 0 0.0052371994
- O 0 0.0076914676
induced O 0 0.0013277865
acute B-Disease 0 0.6036779
liver I-Disease 0 0.42965364
failure I-Disease 0 0.32220998
: O 0 0.00090741215
magnitude O 0 0.00031344814
, O 0 0.00050319097
profile O 0 0.00031739258
, O 0 0.0007680401
prognosis O 0 0.042858664
, O 0 0.00075699243
and O 0 0.0004391646
predictors O 0 0.0004186093
of O 0 0.0009748431
outcome O 0 0.0021954442
. O 0 0.0030577146

Antituberculosis B-Chemical 0 0.8261972
therapy O 0 0.0039058437
( O 0 0.0027673142
ATT O 0 0.0025734783
) O 0 0.002638717
- O 0 0.0037346268
associated O 0 0.00083917077
acute B-Disease 0 0.2101335
liver I-Disease 0 0.17537272
failure I-Disease 0 0.22959942
( O 0 0.0009258734
ATT O 0 0.0012787665
- O 0 0.009390407
ALF B-Disease 0 0.99971265
) O 0 0.001177317
is O 0 0.00023462744
the O 0 0.00027437622
commonest O 0 0.0033994073
drug O 0 0.042446796
- O 0 0.0058376137
induced O 0 0.0010582745
ALF B-Disease 0 0.99972373
in O 0 0.0015189457
South O 0 0.003142921
Asia O 0 0.0042899284
. O 0 0.003191932

Prospective O 0 0.019995406
studies O 0 0.005027493
on O 0 0.0031212128
ATT O 0 0.009239602
- O 0 0.03155887
ALF B-Disease 0 0.9973149
are O 0 0.0040458078
lacking O 0 0.0033432087
. O 0 0.008241865

The O 0 0.0017935187
current O 0 0.0016116167
study O 0 0.0010847816
prospectively O 0 0.0008057035
evaluated O 0 0.00041810595
the O 0 0.0002934162
magnitude O 0 0.00033373345
, O 0 0.0005836299
clinical O 0 0.0006778554
course O 0 0.00029609283
, O 0 0.00043735153
outcome O 0 0.0003748292
, O 0 0.00048333465
and O 0 0.00036071005
prognostic O 0 0.0009228719
factors O 0 0.00090985757
in O 0 0.0008682614
ATT O 0 0.0040303697
- O 0 0.023386981
ALF B-Disease 0 0.9989644
. O 0 0.005975677

From O 0 0.0051769908
January O 0 0.0028349117
1986 O 0 0.004399517
to O 0 0.0012758819
January O 0 0.00089873496
2009 O 0 0.0013073917
, O 0 0.0013642552
1223 O 0 0.0033909143
consecutive O 0 0.00067678327
ALF B-Disease 0 0.9991677
patients O 0 0.0007667467
were O 0 0.0002008785
evaluated O 0 0.00019883872
: O 0 0.00042641224
ATT O 0 0.0004447421
alone O 0 0.00023362652
was O 0 0.00019543266
the O 0 0.0001871298
cause O 0 0.0003089466
in O 0 0.0002613627
70 O 0 0.00037835448
( O 0 0.00050858594
5 O 0 0.00029033466
. O 0 0.00032390706
7 O 0 0.00039285736
% O 0 0.0011585801
) O 0 0.002195069
patients O 0 0.0031068486
. O 0 0.0035218198

Another O 0 0.0059507866
15 O 0 0.003250232
( O 0 0.003333773
1 O 0 0.0015994033
. O 0 0.0010423607
2 O 0 0.0009449746
% O 0 0.0014147345
) O 0 0.0014528559
had O 0 0.00074642006
ATT O 0 0.0016087696
and O 0 0.0011231289
simultaneous O 0 0.0029036037
hepatitis B-Disease 0 0.9999492
virus I-Disease 0 0.195511
infection I-Disease 0 0.40521348
. O 0 0.006141586

In O 0 0.0030817504
44 O 0 0.0039965007
( O 0 0.0032365648
62 O 0 0.002074554
. O 0 0.00090674503
8 O 0 0.0006609767
% O 0 0.001097905
) O 0 0.0011312767
patients O 0 0.00083979504
, O 0 0.0007405074
ATT O 0 0.0008164148
was O 0 0.00035337845
prescribed O 0 0.0009439825
empirically O 0 0.0004368836
without O 0 0.00038795182
definitive O 0 0.0006102086
evidence O 0 0.0007211046
of O 0 0.001848646
tuberculosis B-Disease 0 0.29023352
. O 0 0.0048056575

ATT O 0 0.016106961
- O 0 0.0983549
ALF B-Disease 0 0.99887365
patients O 0 0.004322159
were O 0 0.0011464952
younger O 0 0.0032259019
( O 0 0.0012079823
32 O 0 0.00072251
. O 0 0.00045693328
87 O 0 0.0007959328
[ O 0 0.0014430651
+ O 0 0.0015618555
/ O 0 0.0022848565
- O 0 0.001846182
15 O 0 0.00028198567
. O 0 0.00021992109
8 O 0 0.00021385105
] O 0 0.00065328577
years O 0 0.0003551857
) O 0 0.0005986094
, O 0 0.0004904897
and O 0 0.00034175182
49 O 0 0.0005325066
( O 0 0.0005987541
70 O 0 0.00045763052
% O 0 0.0007607754
) O 0 0.0009473757
of O 0 0.0006723378
them O 0 0.0011912379
were O 0 0.0012915578
women O 0 0.004481223
. O 0 0.0037492781

Most O 0 0.0049421405
had O 0 0.0026664548
hyperacute O 0 0.012614064
presentation O 0 0.0021154094
; O 0 0.0013615529
the O 0 0.00045023143
median O 0 0.00051145506
icterus B-Disease 0 0.9995629
encephalopathy B-Disease 2 0.9999553
interval O 0 0.0005525016
was O 0 0.00024840317
4 O 0 0.0002087638
. O 0 0.00023521564
5 O 0 0.00026329406
( O 0 0.00054981286
0 O 0 0.0006114055
- O 0 0.001636398
30 O 0 0.0006709753
) O 0 0.0016594896
days O 0 0.0010815397
. O 0 0.0031146724

The O 0 0.0016522525
median O 0 0.0010319556
duration O 0 0.0008270693
of O 0 0.0010910768
ATT O 0 0.0019859776
before O 0 0.0008312929
ALF B-Disease 0 0.997908
was O 0 0.00092704076
30 O 0 0.0006543426
( O 0 0.0010075916
7 O 0 0.0006702853
- O 0 0.0023533136
350 O 0 0.001717261
) O 0 0.0026782532
days O 0 0.0015869515
. O 0 0.004181023

At O 0 0.0016311
presentation O 0 0.0037803089
, O 0 0.0038896536
advanced O 0 0.04890273
encephalopathy B-Disease 2 0.9999471
and O 0 0.0027511246
cerebral B-Disease 0 0.99900776
edema I-Disease 0 0.9998462
were O 0 0.00029672362
present O 0 0.00016918266
in O 0 0.0002039778
51 O 0 0.00037176907
( O 0 0.00039488342
76 O 0 0.00041129816
% O 0 0.0004604933
) O 0 0.0005190854
and O 0 0.00028463328
29 O 0 0.00046330946
( O 0 0.0005297412
41 O 0 0.0005315535
. O 0 0.000297932
4 O 0 0.00029945583
% O 0 0.00077269424
) O 0 0.00122795
patients O 0 0.0014527148
, O 0 0.0020919621
respectively O 0 0.003342497
. O 0 0.0039689583

Gastrointestinal B-Disease 0 0.35648593
bleed I-Disease 0 0.45230338
, O 0 0.012235396
seizures B-Disease 0 0.99991
, O 0 0.0043707136
infection B-Disease 0 0.005618049
, O 0 0.0011089604
and O 0 0.00053396786
acute B-Disease 0 0.053867016
renal I-Disease 0 0.8512924
failure I-Disease 0 0.015763745
were O 0 0.00017313076
documented O 0 0.00019654962
in O 0 0.00012499437
seven O 0 0.00011894166
( O 0 0.00026457894
10 O 0 0.00016221197
% O 0 0.00032276622
) O 0 0.00040543426
, O 0 0.00028017894
five O 0 0.00011022853
( O 0 0.00029662403
7 O 0 0.00014187179
. O 0 0.00016211922
1 O 0 0.00020322748
% O 0 0.00038355184
) O 0 0.0005104683
, O 0 0.0004181861
26 O 0 0.0003375872
( O 0 0.0004384999
37 O 0 0.00045909645
. O 0 0.00022786441
1 O 0 0.00025125628
% O 0 0.00044988113
) O 0 0.0005710362
, O 0 0.0004407207
and O 0 0.0002817223
seven O 0 0.00025018628
( O 0 0.00055791304
10 O 0 0.00038647547
% O 0 0.0007999605
) O 0 0.0012296728
patients O 0 0.0014148018
, O 0 0.0019950715
respectively O 0 0.003196025
. O 0 0.0037887567

Compared O 0 0.004685412
with O 0 0.010686864
hepatitis B-Disease 0 0.9999838
E I-Disease 0 0.9999461
virus O 0 0.28576005
( O 0 0.007862455
HEV O 0 0.6812038
) O 0 0.0014386371
and O 0 0.0004388955
non O 0 0.0007095017
- O 0 0.0031419322
A O 0 0.0061327536
non O 0 0.0011016536
- O 0 0.044320922
E O 0 0.9993412
- O 0 0.03218465
induced O 0 0.0005829953
ALF B-Disease 0 0.99991
, O 0 0.00109303
ATT O 0 0.0013245019
- O 0 0.019954074
ALF B-Disease 0 0.99987197
patients O 0 0.0006364553
had O 0 0.00012441966
nearly O 0 0.00011340111
similar O 0 7.281426e-05
presentations O 0 0.00019188342
except O 0 8.654346e-05
for O 0 9.637221e-05
older O 0 0.0005713489
age O 0 0.00031687735
and O 0 0.00025385004
less O 0 0.00048148766
elevation O 0 0.00483007
of O 0 0.000954653
liver O 0 0.23869492
enzymes O 0 0.008737637
. O 0 0.0035778042

The O 0 0.0022848586
mortality O 0 0.0047573894
rate O 0 0.0016169115
among O 0 0.0009902705
patients O 0 0.0012118857
with O 0 0.0006929179
ATT O 0 0.0021065422
- O 0 0.018873915
ALF B-Disease 0 0.99958307
was O 0 0.00045242088
high O 0 0.00045754114
( O 0 0.00062358414
67 O 0 0.0004889887
. O 0 0.0002229648
1 O 0 0.00022184578
% O 0 0.00033827336
, O 0 0.0003112155
n O 0 0.00026787582
= O 0 0.00062504364
47 O 0 0.00041429498
) O 0 0.0005316325
, O 0 0.0003882291
and O 0 0.00024477832
only O 0 0.00027140733
23 O 0 0.00039286262
( O 0 0.00040726026
32 O 0 0.00029836808
. O 0 0.00019297456
9 O 0 0.00018757748
% O 0 0.0004435929
) O 0 0.00061960414
patients O 0 0.0005618329
recovered O 0 0.0003476254
with O 0 0.00067773234
medical O 0 0.0028503686
treatment O 0 0.0017339044
. O 0 0.0030243506

In O 0 0.0016944984
multivariate O 0 0.0016335928
analysis O 0 0.0010966815
, O 0 0.0010581677
three O 0 0.00027863256
factors O 0 0.000557141
independently O 0 0.00024034752
predicted O 0 0.0002148107
mortality O 0 0.0019038536
: O 0 0.0013781524
serum O 0 0.23828688
bilirubin B-Chemical 0 0.9999335
( O 0 0.0008493245
> O 0 0.00050524995
or O 0 0.00017528869
= O 0 0.00047215383
10 O 0 0.00015099354
. O 0 0.0001230774
8 O 0 0.00014168683
mg O 0 0.0012747815
/ O 0 0.0010853093
dL O 0 0.012529348
) O 0 0.0008169627
, O 0 0.0006673017
prothrombin O 0 0.495152
time O 0 0.00017466754
( O 0 0.0005196089
PT O 0 0.004511859
) O 0 0.0005179242
prolongation O 0 0.0005315616
( O 0 0.00030673953
> O 0 0.00034054826
or O 0 0.00015900814
= O 0 0.00044589798
26 O 0 0.00021880565
seconds O 0 0.000185725
) O 0 0.00044793947
, O 0 0.00042233773
and O 0 0.0003783366
grade O 0 0.007840294
III O 0 0.16228753
/ O 0 0.01642727
IV O 0 0.8814697
encephalopathy B-Disease 2 0.9999125
at O 0 0.0012350661
presentation O 0 0.0031782372
. O 0 0.0031702078

CONCLUSION O 0 0.02101887
: O 0 0.0068709874
ATT O 0 0.0063128364
- O 0 0.024417737
ALF B-Disease 0 0.9988918
constituted O 0 0.0024295417
5 O 0 0.0007436383
. O 0 0.0004800482
7 O 0 0.00034741123
% O 0 0.0006992188
of O 0 0.000634356
ALF B-Disease 0 0.99916923
at O 0 0.0003340801
our O 0 0.00029242228
center O 0 0.00044499754
and O 0 0.00041208803
had O 0 0.0004385622
a O 0 0.00075467356
high O 0 0.0010238537
mortality O 0 0.0043297624
rate O 0 0.0027547833
. O 0 0.003396943

Because O 0 0.0019349563
the O 0 0.0017843642
mortality O 0 0.0041749305
rate O 0 0.0013045514
is O 0 0.0005199024
so O 0 0.0004539769
high O 0 0.0005733859
, O 0 0.0006799326
determining O 0 0.00020978483
which O 0 0.00036297497
factors O 0 0.00052995107
are O 0 0.00028739555
predictors O 0 0.00031604286
is O 0 0.0005187725
less O 0 0.0011826397
important O 0 0.0012965358
. O 0 0.00317556

A O 0 0.018701082
high O 0 0.0024761658
proportion O 0 0.0011765995
of O 0 0.0010945936
patients O 0 0.0014395536
had O 0 0.00069920893
consumed O 0 0.0024457066
ATT O 0 0.0013224744
empirically O 0 0.00074173167
, O 0 0.0009788879
which O 0 0.0006814406
could O 0 0.00053384545
have O 0 0.00081807666
been O 0 0.0013583453
prevented O 0 0.0040037544
. O 0 0.005106156

Design O 0 0.012382403
and O 0 0.0024264324
analysis O 0 0.0012509783
of O 0 0.00088295
the O 0 0.0006053388
HYPREN O 0 0.002226228
- O 0 0.0023362627
trial O 0 0.00052497926
: O 0 0.00044686196
safety O 0 0.00023793681
of O 0 0.00041341857
enalapril B-Chemical 1 0.9999964
and O 0 0.0016300458
prazosin B-Chemical 0 0.9999968
in O 0 0.00021968824
the O 0 0.00010565602
initial O 0 9.584926e-05
treatment O 0 0.00013042522
phase O 0 0.00031044413
of O 0 0.00027994715
patients O 0 0.00075132924
with O 0 0.00074337405
congestive B-Disease 0 0.99959916
heart I-Disease 0 0.37890315
failure I-Disease 0 0.08834417
. O 0 0.0027199916

Since O 0 0.0016672728
the O 0 0.0013676864
introduction O 0 0.0009613485
of O 0 0.002105457
angiotensin B-Chemical 0 0.9999609
converting I-Chemical 0 0.01953595
enzyme I-Chemical 0 0.009552877
( I-Chemical 0 0.0025969034
ACE I-Chemical 0 0.9837938
) I-Chemical 0 0.0009186827
inhibitors I-Chemical 0 0.00025629657
into O 0 8.5057734e-05
the O 0 9.8963246e-05
adjunctive O 0 0.0006596947
treatment O 0 9.79676e-05
of O 0 0.00011649956
patients O 0 0.00031557376
with O 0 0.0002494617
congestive B-Disease 0 0.999819
heart I-Disease 0 0.23018904
failure I-Disease 0 0.026855594
, O 0 0.00028900898
cases O 0 0.00021944058
of O 0 0.00017002485
severe O 0 0.01993072
hypotension B-Disease 0 0.9999653
, O 0 0.00030639698
especially O 0 0.00010177462
on O 0 5.3891617e-05
the O 0 6.198118e-05
first O 0 5.598221e-05
day O 0 7.5300246e-05
of O 0 0.00016117332
treatment O 0 0.00024373522
, O 0 0.0005305672
have O 0 0.0003529751
occasionally O 0 0.0009787063
been O 0 0.00085239846
reported O 0 0.001580989
. O 0 0.00271435

To O 0 0.0010721697
assess O 0 0.00064995734
the O 0 0.0006534984
safety O 0 0.00063531136
of O 0 0.00058591005
the O 0 0.000587042
ACE B-Chemical 0 0.9968533
inhibitor I-Chemical 0 0.15946124
enalapril B-Chemical 1 0.999997
a O 0 0.0012586435
multicenter O 0 0.23526883
, O 0 0.00052874995
randomized O 0 0.0010467976
, O 0 0.0011250506
prazosin B-Chemical 0 0.9999968
- O 0 0.010410554
controlled O 0 0.00017625841
trial O 0 0.00019348455
was O 0 7.414429e-05
designed O 0 6.224756e-05
that O 0 5.404901e-05
compared O 0 6.20454e-05
the O 0 7.936695e-05
incidence O 0 0.00022669425
and O 0 0.0001330224
severity O 0 0.0004291115
of O 0 0.000190456
symptomatic O 0 0.0064886874
hypotension B-Disease 0 0.9998312
on O 0 0.00012046984
the O 0 0.00013529716
first O 0 0.00014716446
day O 0 0.00023662894
of O 0 0.00065742404
treatment O 0 0.0012447146
. O 0 0.0024145069

Trial O 0 0.009456828
medication O 0 0.0071223085
was O 0 0.0015168375
2 O 0 0.0011902445
. O 0 0.00085809815
5 O 0 0.0008709041
mg O 0 0.03071781
enalapril B-Chemical 1 0.9999405
or O 0 0.0010328385
0 O 0 0.0012626395
. O 0 0.0011981187
5 O 0 0.0020958523
prazosin B-Chemical 0 0.9998142
. O 0 0.006736874

Subjects O 0 0.0055758897
were O 0 0.003153759
1210 O 0 0.45644253
inpatients O 0 0.00724041
with O 0 0.001141881
New O 0 0.0013301395
York O 0 0.0015996797
Heart O 0 0.001720547
Association O 0 0.00055232673
( O 0 0.0009980919
NYHA O 0 0.013661794
) O 0 0.0011937625
functional O 0 0.000678983
class O 0 0.0020941533
II O 0 0.026523164
and O 0 0.0032267377
III O 0 0.11312326
. O 0 0.0064761336

Patients O 0 0.0036686987
who O 0 0.0020494782
received O 0 0.0015517878
enalapril B-Chemical 1 0.99997807
experienced O 0 0.0012096852
clinically O 0 0.0017210599
and O 0 0.00028552883
statistically O 0 0.0003354625
significantly O 0 0.0002516662
less O 0 0.00032738634
symptomatic O 0 0.0034235434
hypotension B-Disease 0 0.9998771
( O 0 0.00042523872
5 O 0 0.0001286721
. O 0 0.00010962267
2 O 0 0.00012537051
% O 0 0.00023012683
) O 0 0.00026007314
than O 0 9.738712e-05
the O 0 0.00010500996
patients O 0 0.0003070889
who O 0 0.000294292
received O 0 0.00039696178
prazosin B-Chemical 0 0.9999889
( O 0 0.0010729582
12 O 0 0.00028834076
. O 0 0.000378491
9 O 0 0.00053404114
% O 0 0.0015666278
) O 0 0.003191981
. O 0 0.0032940325

All O 0 0.014440786
patients O 0 0.02075463
recovered O 0 0.016002636
. O 0 0.02392606

It O 0 0.0045524817
was O 0 0.0015011416
concluded O 0 0.00095506746
that O 0 0.00051397143
treatment O 0 0.00058188365
with O 0 0.0008541824
enalapril B-Chemical 1 0.9999924
was O 0 0.0003500396
well O 0 0.00021093493
tolerated O 0 0.00046287262
and O 0 0.00020593277
it O 0 0.0002782105
is O 0 0.00016063385
, O 0 0.00036785228
therefore O 0 0.00020877118
, O 0 0.00044785513
unreasonable O 0 0.00044205342
to O 0 0.000114959905
restrict O 0 0.00010216289
the O 0 0.000109551926
initiation O 0 0.00010408541
of O 0 0.00020097716
treatment O 0 0.00028891533
with O 0 0.0007226546
enalapril B-Chemical 1 0.9999887
to O 0 0.0013393135
inpatients O 0 0.047545142
. O 0 0.0026133943

Central B-Disease 0 0.0058228844
nervous I-Disease 0 0.0068889717
system I-Disease 0 0.0014533913
complications I-Disease 0 0.0041372715
during O 0 0.00051797286
treatment O 0 0.0005668344
of O 0 0.00086698943
acute B-Disease 0 0.9579449
lymphoblastic I-Disease 0 0.99995756
leukemia I-Disease 0 0.999966
in O 0 0.00084284105
a O 0 0.000892935
single O 0 0.000543529
pediatric O 0 0.0017558543
institution O 0 0.0023710625
. O 0 0.0027900722

Central B-Disease 0 0.0068993247
nervous I-Disease 0 0.010248262
system I-Disease 0 0.0020810706
( I-Disease 0 0.002780966
CNS I-Disease 0 0.006496408
) I-Disease 0 0.00138135
complications I-Disease 0 0.0021100433
during O 0 0.00023888425
treatment O 0 0.000277978
of O 0 0.00039980764
childhood O 0 0.35609043
acute B-Disease 0 0.99031126
lymphoblastic I-Disease 0 0.99997723
leukemia I-Disease 0 0.9999869
( O 0 0.008919015
ALL B-Disease 0 0.99678636
) O 0 0.0010354539
remain O 0 0.00025914764
a O 0 0.0005422333
challenging O 0 0.00068420754
clinical O 0 0.002149666
problem O 0 0.0020886373
. O 0 0.003090172

Outcome O 0 0.002553086
improvement O 0 0.0013501201
with O 0 0.0008729251
more O 0 0.0008605779
intensive O 0 0.0007613012
chemotherapy O 0 0.0018136003
has O 0 0.00020687071
significantly O 0 0.0003193369
increased O 0 0.00038363747
the O 0 0.00025846882
incidence O 0 0.0005983889
and O 0 0.0004259603
severity O 0 0.0010848215
of O 0 0.0007315012
adverse O 0 0.0034100974
events O 0 0.0021898295
. O 0 0.0027532985

This O 0 0.0042205974
study O 0 0.0019489522
analyzed O 0 0.000990715
the O 0 0.00060981006
incidence O 0 0.0010064979
of O 0 0.0007292864
neurological B-Disease 0 0.99558157
complications I-Disease 0 0.5805036
during O 0 0.00029420276
ALL B-Disease 0 0.98041415
treatment O 0 0.0001870499
in O 0 0.00012042023
a O 0 0.00017206663
single O 0 9.4045754e-05
pediatric O 0 0.00027976942
institution O 0 0.00023157179
, O 0 0.0002325522
focusing O 0 0.00017790908
on O 0 0.00012783437
clinical O 0 0.0006900363
, O 0 0.00047629743
radiological O 0 0.0007508103
, O 0 0.00065130735
and O 0 0.0005392138
electrophysiological O 0 0.0017558174
findings O 0 0.0016766351
. O 0 0.002662586

Exclusion O 0 0.006085806
criteria O 0 0.0021064288
included O 0 0.0014584019
CNS O 0 0.026943527
leukemic B-Disease 0 0.9896431
infiltration I-Disease 0 0.014299997
at O 0 0.0002702057
diagnosis O 0 0.0004750646
, O 0 0.00041553535
therapy O 0 0.00038405808
- O 0 0.0010093434
related O 0 0.00015366258
peripheral B-Disease 0 0.052756183
neuropathy I-Disease 0 0.99998724
, O 0 0.0010243478
late O 0 0.0014135762
- O 0 0.0076652365
onset O 0 0.0011273673
encephalopathy B-Disease 2 0.9999697
, O 0 0.00069317553
or O 0 0.0002441513
long O 0 0.0004107271
- O 0 0.0023262282
term O 0 0.0010224655
neurocognitive B-Disease 0 0.9939209
defects I-Disease 0 0.044145823
. O 0 0.0037599602

During O 0 0.0024452377
a O 0 0.0027418141
9 O 0 0.0014068848
- O 0 0.0028374281
year O 0 0.00052482536
period O 0 0.0003165217
, O 0 0.00052309793
we O 0 0.00017817291
retrospectively O 0 0.0003563219
collected O 0 0.0002322493
27 O 0 0.0003715143
neurological O 0 0.05280726
events O 0 0.00035077045
( O 0 0.0003477041
11 O 0 0.00019267634
% O 0 0.00031355425
) O 0 0.0003306258
in O 0 0.0001293635
as O 0 0.00013192242
many O 0 0.00012581481
patients O 0 0.0003645935
, O 0 0.00030408634
from O 0 0.00017374945
253 O 0 0.00078874454
children O 0 0.00060175906
enrolled O 0 0.00041600325
in O 0 0.00025181938
the O 0 0.0003899931
ALL B-Disease 0 0.9646511
front O 0 0.0015978821
- O 0 0.003783419
line O 0 0.001077639
protocol O 0 0.0016530085
. O 0 0.0029984456

CNS O 0 0.03316194
complications O 0 0.018180056
included O 0 0.0016189527
posterior O 0 0.01073338
reversible O 0 0.007217318
leukoencephalopathy B-Disease 0 0.9979481
syndrome O 0 0.90264785
( O 0 0.00066021556
n O 0 0.00033972805
= O 0 0.0006428819
10 O 0 0.0002342821
) O 0 0.0004993963
, O 0 0.00053158385
stroke B-Disease 0 0.93585736
( O 0 0.00040830538
n O 0 0.00023426041
= O 0 0.00047887227
5 O 0 0.00016078632
) O 0 0.00037834924
, O 0 0.00038915157
temporal B-Disease 0 0.017903337
lobe I-Disease 0 0.93455595
epilepsy I-Disease 0 0.9999937
( O 0 0.0004202197
n O 0 0.00017882392
= O 0 0.00035161787
2 O 0 0.00013645948
) O 0 0.00025178312
, O 0 0.00020265163
high O 0 0.00019962022
- O 0 0.0014457426
dose O 0 0.00079502125
methotrexate B-Chemical 0 0.9999778
toxicity B-Disease 0 0.6667874
( O 0 0.00029731914
n O 0 0.00016679474
= O 0 0.00038379783
2 O 0 0.00014858322
) O 0 0.00034616247
, O 0 0.00039747692
syndrome O 0 0.5988558
of O 0 0.0002634126
inappropriate B-Disease 0 0.0011942601
antidiuretic I-Disease 0 0.9923683
hormone I-Disease 0 0.38143095
secretion I-Disease 0 0.0016239054
( O 0 0.00035427435
n O 0 0.00019636042
= O 0 0.00046482144
1 O 0 0.00017559483
) O 0 0.00033157313
, O 0 0.0002672552
and O 0 0.00018533951
other O 0 0.00021433443
unclassified O 0 0.0016829146
events O 0 0.00058191305
( O 0 0.0007157111
n O 0 0.0006404802
= O 0 0.0015542362
7 O 0 0.0008628305
) O 0 0.0027790728
. O 0 0.0030644727

In O 0 0.0020268888
conclusion O 0 0.0015681118
, O 0 0.0033845163
CNS O 0 0.010705144
complications O 0 0.0069869454
are O 0 0.00037566238
frequent O 0 0.00038637163
events O 0 0.00038459996
during O 0 0.00025212351
ALL B-Disease 0 0.9357416
therapy O 0 0.00041366392
, O 0 0.00031408112
and O 0 0.00017453951
require O 0 0.00012104236
rapid O 0 0.00022625136
detection O 0 0.00016892508
and O 0 0.00022127539
prompt O 0 0.00047875088
treatment O 0 0.00030498116
to O 0 0.00034481587
limit O 0 0.0010235226
permanent O 0 0.005442679
damage O 0 0.11665381
. O 0 0.00346727

Cocaine B-Chemical 0 0.9997093
causes O 0 0.0036800315
memory B-Disease 0 0.14870757
and I-Disease 0 0.0011533062
learning I-Disease 0 0.0025490676
impairments I-Disease 0 0.17782979
in O 0 0.0003656196
rats O 0 0.0004968563
: O 0 0.0005366461
involvement O 0 0.0003569492
of O 0 0.0003221658
nuclear O 0 0.00068710156
factor O 0 0.008448558
kappa O 0 0.05388209
B O 0 0.3476958
and O 0 0.0007773864
oxidative O 0 0.49093327
stress O 0 0.06878875
, O 0 0.0009799629
and O 0 0.00054682454
prevention O 0 0.0011391622
by O 0 0.0018956077
topiramate B-Chemical 0 0.99997556
. O 0 0.0047414377

Different O 0 0.0023415345
mechanisms O 0 0.0012255091
have O 0 0.0009595141
been O 0 0.0006706128
suggested O 0 0.00044485737
for O 0 0.0005176809
cocaine B-Chemical 0 0.99979275
toxicity B-Disease 0 0.81456006
including O 0 0.0001939025
an O 0 0.0002186307
increase O 0 0.000176027
in O 0 0.00023716039
oxidative O 0 0.29209334
stress O 0 0.044751406
but O 0 0.00020311183
the O 0 8.687833e-05
association O 0 6.968784e-05
between O 0 0.00011010457
oxidative O 0 0.04738711
status O 0 0.00015714965
in O 0 0.00012395262
the O 0 0.00012414258
brain O 0 0.00067777495
and O 0 0.00028629453
cocaine B-Chemical 0 0.9994985
induced O 0 0.0004008655
- O 0 0.0036579762
behaviour O 0 0.00083395146
is O 0 0.0005476124
poorly O 0 0.0016730193
understood O 0 0.0030883602
. O 0 0.0032657632

Nuclear O 0 0.02334119
factor O 0 0.021740945
kappa O 0 0.052735936
B O 0 0.35927117
( O 0 0.004407972
NFkappaB O 0 0.0068075513
) O 0 0.0016608181
is O 0 0.00037824613
a O 0 0.00047678937
sensor O 0 0.00030490328
of O 0 0.000435589
oxidative O 0 0.18691319
stress O 0 0.018516365
and O 0 0.00024820617
participates O 0 0.00013809056
in O 0 0.000186965
memory O 0 0.1671097
formation O 0 0.00044547862
that O 0 0.000120639976
could O 0 0.00010837419
be O 0 0.0001448135
involved O 0 0.00015844528
in O 0 0.00029926948
drug O 0 0.67786777
toxicity B-Disease 0 0.99375796
and O 0 0.0009875726
addiction O 0 0.4117606
mechanisms O 0 0.0012984525
. O 0 0.0027899158

Therefore O 0 0.003154873
NFkappaB O 0 0.01006356
activity O 0 0.0016616754
, O 0 0.0042288923
oxidative O 0 0.5728899
stress O 0 0.31801707
, O 0 0.0047805435
neuronal O 0 0.029444598
nitric B-Chemical 0 0.99972314
oxide I-Chemical 0 0.99828017
synthase O 0 0.39814842
( O 0 0.001426626
nNOS O 0 0.0021049108
) O 0 0.00046225206
activity O 0 0.00010523712
, O 0 0.00022514118
spatial O 0 0.00032049805
learning O 0 0.0005563845
and O 0 0.00017030313
memory O 0 0.035800386
as O 0 0.00013378092
well O 0 9.362682e-05
as O 0 8.468869e-05
the O 0 6.70591e-05
effect O 0 9.356362e-05
of O 0 0.00039881162
topiramate B-Chemical 0 0.99999905
, O 0 0.0004716467
a O 0 0.00015593373
previously O 0 8.994525e-05
proposed O 0 6.650272e-05
therapy O 0 0.00014534888
for O 0 0.00012021278
cocaine B-Disease 0 0.9999864
addiction I-Disease 0 0.9991386
, O 0 0.00037436886
were O 0 9.308626e-05
evaluated O 0 9.214112e-05
in O 0 9.468248e-05
an O 0 0.00012155336
experimental O 0 0.0001348294
model O 0 0.0001640526
of O 0 0.000426074
cocaine B-Chemical 0 0.9995732
administration O 0 0.0013203827
in O 0 0.00067307055
rats O 0 0.0017716095
. O 0 0.0022483156

NFkappaB O 0 0.0144743845
activity O 0 0.0015414227
was O 0 0.001177363
decreased O 0 0.0012891139
in O 0 0.0005737358
the O 0 0.00048273653
frontal O 0 0.3562214
cortex O 0 0.0134156635
of O 0 0.00041124254
cocaine B-Chemical 0 0.9993293
treated O 0 0.00051235704
rats O 0 0.0003425471
, O 0 0.0003111876
as O 0 0.00016127998
well O 0 0.00023240192
as O 0 0.0009188395
GSH B-Chemical 1 0.99999917
concentration O 0 0.16729684
and O 0 0.02297267
glutathione B-Chemical 0 0.99999774
peroxidase O 0 0.997658
activity O 0 0.00014833959
in O 0 0.00012683122
the O 0 0.00012799489
hippocampus O 0 0.0032453616
, O 0 0.00040151013
whereas O 0 0.00023710389
nNOS O 0 0.0012608598
activity O 0 0.00017727865
in O 0 0.00026566483
the O 0 0.00035948123
hippocampus O 0 0.0036185274
was O 0 0.0008244455
increased O 0 0.0018600011
. O 0 0.0026657751

Memory O 0 0.1551523
retrieval O 0 0.0028567265
of O 0 0.0012748021
experiences O 0 0.0021694668
acquired O 0 0.00093427236
prior O 0 0.00022391365
to O 0 0.00032513036
cocaine B-Chemical 0 0.9987362
administration O 0 0.0005959805
was O 0 0.0001855871
impaired O 0 0.0005280459
and O 0 0.00020799531
negatively O 0 0.00018235634
correlated O 0 0.00021740074
with O 0 0.00033136198
NFkappaB O 0 0.0017701891
activity O 0 0.0002699554
in O 0 0.00041381302
the O 0 0.0006396183
frontal O 0 0.5553489
cortex O 0 0.05813888
. O 0 0.002951236

In O 0 0.0020329338
contrast O 0 0.0024117266
, O 0 0.0022988194
learning O 0 0.0020268422
of O 0 0.0007180218
new O 0 0.0006068531
tasks O 0 0.001323517
was O 0 0.00033850034
enhanced O 0 0.00029023114
and O 0 0.00025842374
correlated O 0 0.000196891
with O 0 0.00019568496
the O 0 0.00015834032
increase O 0 0.0001898182
of O 0 0.00029363114
nNOS O 0 0.001437704
activity O 0 0.0001960998
and O 0 0.00031523642
the O 0 0.0003544264
decrease O 0 0.00090826635
of O 0 0.003439975
glutathione B-Chemical 0 0.99996996
peroxidase O 0 0.99788636
. O 0 0.005846179

These O 0 0.0018321258
results O 0 0.0012176584
provide O 0 0.00068715663
evidence O 0 0.000618709
for O 0 0.0005075952
a O 0 0.0006240684
possible O 0 0.0002507728
mechanistic O 0 0.00029109794
role O 0 0.00018479303
of O 0 0.00057525944
oxidative O 0 0.40042034
and O 0 0.00094645954
nitrosative O 0 0.9973278
stress O 0 0.15333775
and O 0 0.0005804371
NFkappaB O 0 0.0024963738
in O 0 0.00029371452
the O 0 0.00028416392
alterations O 0 0.00077419897
induced O 0 0.0006567524
by O 0 0.0014844
cocaine B-Chemical 0 0.9991881
. O 0 0.0040039103

Topiramate B-Chemical 0 0.99992204
prevented O 0 0.006934102
all O 0 0.0017711415
the O 0 0.001117953
alterations O 0 0.0016563617
observed O 0 0.00081436004
, O 0 0.0014111566
showing O 0 0.0007634534
novel O 0 0.0011674666
neuroprotective O 0 0.008309222
properties O 0 0.0020247214
. O 0 0.0044323155

Efficacy O 0 0.0028911517
and O 0 0.001365552
safety O 0 0.0010606541
of O 0 0.0013229216
asenapine B-Chemical 1 0.9999652
in O 0 0.0005046875
a O 0 0.00057683024
placebo O 0 0.01185607
- O 0 0.0026996236
and O 0 0.00057060935
haloperidol B-Chemical 1 0.9999975
- O 0 0.0044315807
controlled O 0 0.00023657548
trial O 0 0.00030488698
in O 0 0.00018210405
patients O 0 0.0004410412
with O 0 0.0003693417
acute O 0 0.058992736
exacerbation O 0 0.03740986
of O 0 0.001962006
schizophrenia B-Disease 2 0.99994123
. O 0 0.00424291

Asenapine B-Chemical 0 0.99863774
is O 0 0.002730154
approved O 0 0.002262371
by O 0 0.00084228744
the O 0 0.0006066218
Food O 0 0.0024057422
and O 0 0.000536687
Drugs O 0 0.004452309
Administration O 0 0.00083626393
in O 0 0.00020861319
adults O 0 0.0005633045
for O 0 0.00013611042
acute O 0 0.0028256571
treatment O 0 0.00017790197
of O 0 0.0003396202
schizophrenia B-Disease 2 0.9999896
or O 0 0.00023529978
of O 0 0.0005338747
manic B-Disease 0 0.99999607
or O 0 0.00014775728
mixed O 0 0.00027970705
episodes O 0 0.00046006244
associated O 0 0.00020713698
with O 0 0.0008020145
bipolar B-Disease 2 0.9999994
I I-Disease 0 0.99951196
disorder I-Disease 0 0.9999517
with O 0 0.0006247632
or O 0 0.00048354964
without O 0 0.0014820844
psychotic B-Disease 0 0.9999794
features O 0 0.0032636672
. O 0 0.0028398659

In O 0 0.002368836
a O 0 0.0028337284
double O 0 0.0016961527
- O 0 0.0069909957
blind O 0 0.0094452
6 O 0 0.0005332266
- O 0 0.0012913757
week O 0 0.00021752514
trial O 0 0.00042755704
, O 0 0.00055208826
458 O 0 0.0015414908
patients O 0 0.00044091846
with O 0 0.0002852853
acute O 0 0.3477886
schizophrenia B-Disease 2 0.99998796
were O 0 0.00013288877
randomly O 0 5.116384e-05
assigned O 0 6.0437258e-05
to O 0 6.3991014e-05
fixed O 0 0.00012228974
- O 0 0.00058307225
dose O 0 0.00014785228
treatment O 0 8.591105e-05
with O 0 0.00016578691
asenapine B-Chemical 1 0.99999106
at O 0 7.347529e-05
5 O 0 7.741436e-05
mg O 0 0.00049928733
twice O 0 4.9285216e-05
daily O 0 9.743376e-05
( O 0 0.00021480312
BID O 0 0.39336613
) O 0 0.0004887396
, O 0 0.00050141034
asenapine B-Chemical 1 0.999985
at O 0 9.169218e-05
10 O 0 0.00011922954
mg O 0 0.0026195291
BID O 0 0.41025624
, O 0 0.00029844776
placebo O 0 0.0027811192
, O 0 0.00030280475
or O 0 0.00023145591
haloperidol B-Chemical 1 0.99999595
at O 0 0.00014042683
4 O 0 0.00015484293
mg O 0 0.0037479922
BID O 0 0.32105622
( O 0 0.00039309243
to O 0 0.00017457046
verify O 0 0.00014146407
assay O 0 0.00075667445
sensitivity O 0 0.0017283666
) O 0 0.003997294
. O 0 0.0031358937

With O 0 0.0020613903
last O 0 0.0009984857
observations O 0 0.0010629842
carried O 0 0.00074845756
forward O 0 0.0010556222
( O 0 0.0014927476
LOCF O 0 0.006023656
) O 0 0.0007500748
, O 0 0.00042907486
mean O 0 0.00020249962
Positive O 0 0.00040729562
and O 0 0.00024379122
Negative O 0 0.00078539905
Syndrome O 0 0.056450758
Scale O 0 0.0011859242
total O 0 0.00011539614
score O 0 8.946383e-05
reductions O 0 0.00010158924
from O 0 6.8613655e-05
baseline O 0 6.7099216e-05
to O 0 5.691877e-05
endpoint O 0 7.834206e-05
were O 0 6.8414585e-05
significantly O 0 9.7601325e-05
greater O 0 0.00013895099
with O 0 0.00023200075
asenapine B-Chemical 1 0.99998987
at O 0 9.316795e-05
5 O 0 0.000110815025
mg O 0 0.0022643588
BID O 0 0.4053883
( O 0 0.00036629644
- O 0 0.00074806466
16 O 0 0.00014424666
. O 0 0.00011063818
2 O 0 0.00013598758
) O 0 0.0003419591
and O 0 0.00033749643
haloperidol B-Chemical 1 0.9999976
( O 0 0.0009418552
- O 0 0.0011712044
15 O 0 0.00012127585
. O 0 9.482514e-05
4 O 0 8.434784e-05
) O 0 0.00021468193
than O 0 0.00011364349
placebo O 0 0.0017254765
( O 0 0.00041566926
- O 0 0.0009871427
10 O 0 0.00015884417
. O 0 0.00012341977
7 O 0 0.00010358064
; O 0 0.00021786781
both O 0 0.00013007746
P O 0 0.0026428413
< O 0 0.00029121398
0 O 0 0.00023591954
. O 0 0.00019765543
05 O 0 0.0033841212
) O 0 0.00047078694
; O 0 0.00029293823
using O 0 0.00010475333
mixed O 0 0.00018486615
model O 0 9.448675e-05
for O 0 7.318788e-05
repeated O 0 6.180512e-05
measures O 0 0.00010182277
( O 0 0.00027964494
MMRM O 0 0.004462148
) O 0 0.00031096727
, O 0 0.00018863029
changes O 0 9.733336e-05
at O 0 6.315767e-05
day O 0 6.195329e-05
42 O 0 0.000106772146
were O 0 7.028731e-05
significantly O 0 9.850304e-05
greater O 0 0.00014248429
with O 0 0.0002450095
asenapine B-Chemical 1 0.9999912
at O 0 8.852727e-05
5 O 0 7.881548e-05
and O 0 8.634595e-05
10 O 0 0.000119775475
mg O 0 0.0025885748
BID O 0 0.48587444
( O 0 0.0004090678
- O 0 0.0008371031
21 O 0 0.00014941864
. O 0 0.00010348923
3 O 0 9.3329356e-05
and O 0 0.00014873449
- O 0 0.00077717163
19 O 0 0.00019356093
. O 0 0.000115468676
4 O 0 9.769109e-05
, O 0 0.00021339885
respectively O 0 0.0003000405
) O 0 0.0005165475
and O 0 0.00043534263
haloperidol B-Chemical 1 0.999998
( O 0 0.0011083616
- O 0 0.0013634226
20 O 0 0.00015226645
. O 0 0.00011636322
0 O 0 0.00016054335
) O 0 0.00026479468
than O 0 0.00013407809
placebo O 0 0.001830027
( O 0 0.00046098718
- O 0 0.00095720135
14 O 0 0.0001897516
. O 0 0.00017725685
6 O 0 0.00016280515
; O 0 0.00041335885
all O 0 0.00030546598
P O 0 0.0035304467
< O 0 0.0008306221
0 O 0 0.00087842275
. O 0 0.0010797791
05 O 0 0.012752497
) O 0 0.004911135
. O 0 0.0044214358

On O 0 0.0030410935
the O 0 0.0018001847
Positive O 0 0.002388894
and O 0 0.0011477376
Negative O 0 0.0025332863
Syndrome O 0 0.098560564
Scale O 0 0.0028230222
positive O 0 0.00034553636
subscale O 0 0.00065468415
, O 0 0.00038351386
all O 0 0.00016812081
treatments O 0 0.00019591962
were O 0 0.00012420038
superior O 0 0.00019427
to O 0 0.00010598942
placebo O 0 0.000844269
with O 0 0.00015766836
LOCF O 0 0.0020045443
and O 0 0.00014087194
MMRM O 0 0.0060724486
; O 0 0.0004983202
asenapine B-Chemical 1 0.99997246
at O 0 8.22451e-05
5 O 0 9.710428e-05
mg O 0 0.0015296697
BID O 0 0.11746435
was O 0 7.273619e-05
superior O 0 0.00011572296
to O 0 6.128946e-05
placebo O 0 0.00047664403
on O 0 4.3113716e-05
the O 0 5.2320476e-05
negative O 0 8.589942e-05
subscale O 0 0.00025568227
with O 0 0.00013600769
MMRM O 0 0.0042691017
and O 0 0.00010086355
on O 0 7.05488e-05
the O 0 0.00010686299
general O 0 0.00023327727
psychopathology O 0 0.97337794
subscale O 0 0.0009024686
with O 0 0.00049162627
LOCF O 0 0.0064181304
and O 0 0.0010026423
MMRM O 0 0.011348328
. O 0 0.0025494618

Treatment O 0 0.010824573
- O 0 0.0077204187
related O 0 0.00095065037
adverse O 0 0.0022341467
events O 0 0.0010751738
( O 0 0.0010400219
AEs O 0 0.001066759
) O 0 0.000760944
occurred O 0 0.00028281388
in O 0 0.00024211853
44 O 0 0.00036956585
% O 0 0.00043155684
and O 0 0.00024880373
52 O 0 0.0003641371
% O 0 0.00048020383
, O 0 0.0004429025
57 O 0 0.0004144099
% O 0 0.00045975906
, O 0 0.0003700876
and O 0 0.00022195451
41 O 0 0.00036336432
% O 0 0.00033956664
of O 0 0.00018935507
the O 0 0.00023526947
asenapine B-Chemical 1 0.9999856
at O 0 0.00011766782
5 O 0 0.000101884536
and O 0 0.00010986377
10 O 0 0.00015277023
mg O 0 0.00363857
BID O 0 0.739103
, O 0 0.0014004948
haloperidol B-Chemical 1 0.9999958
, O 0 0.00076454005
and O 0 0.0003846177
placebo O 0 0.0034707766
groups O 0 0.00078610616
, O 0 0.00166917
respectively O 0 0.0026267974
. O 0 0.0030260447

Extrapyramidal B-Disease 0 0.9992384
symptoms I-Disease 0 0.5842686
reported O 0 0.0017920448
as O 0 0.00093937863
AEs O 0 0.0013958724
occurred O 0 0.00048027112
in O 0 0.00035287347
15 O 0 0.00031820635
% O 0 0.00047958354
and O 0 0.00027071085
18 O 0 0.00029046313
% O 0 0.00045539666
, O 0 0.0004041421
34 O 0 0.0003059355
% O 0 0.00045543592
, O 0 0.00036511023
and O 0 0.00020891357
10 O 0 0.00018645923
% O 0 0.00028733883
of O 0 0.00017574073
the O 0 0.00022289506
asenapine B-Chemical 1 0.9999845
at O 0 0.00011513675
5 O 0 0.00010055528
and O 0 0.00010891446
10 O 0 0.0001519636
mg O 0 0.0036009487
BID O 0 0.7373113
, O 0 0.0013968819
haloperidol B-Chemical 1 0.9999958
, O 0 0.0007637663
and O 0 0.00038435587
placebo O 0 0.0034696169
groups O 0 0.0007857598
, O 0 0.0016686097
respectively O 0 0.0026261029
. O 0 0.0030252251

Across O 0 0.0044021164
all O 0 0.0019242164
groups O 0 0.0018603507
, O 0 0.0017343416
no O 0 0.00074526435
more O 0 0.0008665109
than O 0 0.00046420816
5 O 0 0.00041005737
% O 0 0.0006512607
of O 0 0.00043256817
patients O 0 0.0008127484
had O 0 0.0004874625
clinically O 0 0.0013570115
significant O 0 0.000675554
weight O 0 0.001565177
change O 0 0.0017168018
. O 0 0.0030748246

Post O 0 0.00614716
hoc O 0 0.004846302
analyses O 0 0.0009915219
indicated O 0 0.0003594482
that O 0 0.0002729823
efficacy O 0 0.0003084045
was O 0 0.00022582957
similar O 0 0.00015839272
with O 0 0.00044765687
asenapine B-Chemical 1 0.9999945
and O 0 0.0009521232
haloperidol B-Chemical 1 0.9999982
; O 0 0.000608719
greater O 0 0.00020321527
contrasts O 0 0.0002478921
were O 0 0.00013772672
seen O 0 0.00016741327
in O 0 0.0001924872
AEs O 0 0.00062931824
, O 0 0.0007544276
especially O 0 0.0013734644
extrapyramidal B-Disease 0 0.99997306
symptoms I-Disease 0 0.809903
. O 0 0.003342875

Salvage O 0 0.007105727
therapy O 0 0.0024313407
with O 0 0.0016848367
nelarabine B-Chemical 0 0.5997581
, O 0 0.0026524311
etoposide B-Chemical 0 0.9996233
, O 0 0.001245606
and O 0 0.00070278003
cyclophosphamide B-Chemical 0 0.9996327
in O 0 0.0005103518
relapsed O 0 0.19296269
/ O 0 0.0017282703
refractory O 0 0.0017906365
paediatric O 0 0.0008020901
T B-Disease 0 0.007562196
- I-Disease 0 0.0073664663
cell I-Disease 0 0.00320568
lymphoblastic I-Disease 0 0.9999275
leukaemia I-Disease 0 0.9999256
and I-Disease 0 0.008076784
lymphoma I-Disease 0 0.9983368
. O 0 0.0044366647

A O 0 0.019800222
combination O 0 0.0027229334
of O 0 0.0015062253
5 O 0 0.00086836354
d O 0 0.00092113216
of O 0 0.00079491554
nelarabine B-Chemical 0 0.6151384
( O 0 0.0010198209
AraG B-Chemical 0 0.010864158
) O 0 0.0006206456
with O 0 0.00022123425
5 O 0 0.00017120173
d O 0 0.00027000354
of O 0 0.0003664005
etoposide B-Chemical 0 0.9998727
( O 0 0.0011613755
VP B-Chemical 0 0.90191466
) O 0 0.0005867998
and O 0 0.00027374385
cyclophosphamide B-Chemical 0 0.9998448
( O 0 0.0008303017
CPM B-Chemical 0 0.9877643
) O 0 0.00032993528
and O 0 0.000102428705
prophylactic O 0 0.00017344093
intrathecal O 0 0.0013172069
chemotherapy O 0 0.0005495447
was O 0 5.856635e-05
used O 0 6.0835086e-05
as O 0 8.576486e-05
salvage O 0 0.00027799967
therapy O 0 0.000119464654
in O 0 7.3156196e-05
seven O 0 8.18059e-05
children O 0 0.0003301911
with O 0 0.00018558798
refractory O 0 0.0016056218
or O 0 0.0002687405
relapsed O 0 0.35945886
T B-Disease 0 0.01839218
- I-Disease 0 0.009854048
cell I-Disease 0 0.0024626928
leukaemia I-Disease 0 0.99985456
or I-Disease 0 0.0031016085
lymphoma I-Disease 0 0.99809605
. O 0 0.0039616227

The O 0 0.0020782345
most O 0 0.0020246587
common O 0 0.0013172163
side O 0 0.0018383494
effects O 0 0.0006273315
attributable O 0 0.00038619133
to O 0 0.00030742076
the O 0 0.0003068618
AraG B-Chemical 0 0.0068744374
included O 0 0.000274028
Grade O 0 0.0022077255
2 O 0 0.00021777852
and O 0 0.00017093062
3 O 0 0.00016038652
sensory O 0 0.00033703732
and O 0 0.0003374958
motor O 0 0.047109008
neuropathy B-Disease 0 0.9999504
and O 0 0.0013792699
musculoskeletal B-Disease 0 0.009156742
pain I-Disease 0 0.062772766
. O 0 0.0027786435

Haematological B-Disease 0 0.99131495
toxicity I-Disease 0 0.9766228
was O 0 0.0010894196
greater O 0 0.00069918856
for O 0 0.00029266495
the O 0 0.00023010027
combination O 0 0.00029921383
than O 0 0.00024096062
AraG B-Chemical 0 0.0069514834
alone O 0 0.00024188457
, O 0 0.0002836304
although O 0 0.000110189554
median O 0 7.2097064e-05
time O 0 8.096184e-05
to O 0 0.00014269722
neutrophil O 0 0.008364428
and O 0 0.0003410073
platelet O 0 0.7595104
recovery O 0 0.00036545531
was O 0 0.00018360956
consistent O 0 0.00018231566
with O 0 0.00030527817
other O 0 0.00043883087
salvage O 0 0.0017911921
therapies O 0 0.0015335681
. O 0 0.0023144963

All O 0 0.0021546162
patients O 0 0.0026759463
had O 0 0.0009308205
some O 0 0.00057738915
response O 0 0.00039431168
to O 0 0.0002524877
the O 0 0.00018791258
combined O 0 0.00024077162
therapy O 0 0.00024587766
and O 0 0.00013366807
five O 0 7.4257936e-05
of O 0 0.00012517556
the O 0 9.963743e-05
seven O 0 9.426824e-05
went O 0 0.00017576701
into O 0 6.388328e-05
complete O 0 9.2389404e-05
remission O 0 0.00077550486
after O 0 5.613184e-05
one O 0 9.029468e-05
or O 0 0.000110345696
two O 0 0.00012200042
courses O 0 0.0004193212
of O 0 0.00055489445
AraG B-Chemical 0 0.0780563
/ O 0 0.014829899
VP B-Chemical 0 0.9835634
/ O 0 0.052288834
CPM B-Chemical 0 0.9929979
. O 0 0.004401657

Our O 0 0.002138317
experience O 0 0.0024756123
supports O 0 0.0008533058
the O 0 0.0005559074
safety O 0 0.0005090706
of O 0 0.00043526237
giving O 0 0.00048544494
AraG B-Chemical 0 0.01204346
as O 0 0.00025779987
salvage O 0 0.00052865193
therapy O 0 0.00020172684
in O 0 0.00011375743
synchrony O 0 0.00029382712
with O 0 0.00030775482
etoposide B-Chemical 0 0.99989605
and O 0 0.0005549412
cyclophosphamide B-Chemical 0 0.99993014
, O 0 0.0007552997
although O 0 0.0004544697
neurological B-Disease 0 0.9991135
toxicity I-Disease 0 0.9938
must O 0 0.00030248507
be O 0 0.00045948874
closely O 0 0.0005412483
monitored O 0 0.0008690663
. O 0 0.002184571

Effect O 0 0.0032417327
of O 0 0.0039431197
adriamycin B-Chemical 0 0.9997472
combined O 0 0.0017345928
with O 0 0.000906726
whole O 0 0.00076726614
body O 0 0.0017439746
hyperthermia B-Disease 0 0.9962404
on O 0 0.0006534293
tumor B-Disease 0 0.31867936
and O 0 0.0012073725
normal O 0 0.0021987967
tissues O 0 0.0027185716
. O 0 0.003428113

Thermal O 0 0.006861395
enhancement O 0 0.0025939457
of O 0 0.0026740106
Adriamycin B-Chemical 0 0.99991584
- O 0 0.0074816183
mediated O 0 0.0002981133
antitumor O 0 0.0022873657
activity O 0 0.00021106933
and O 0 0.00028795778
normal O 0 0.0005403197
tissue O 0 0.0008118419
toxicities B-Disease 0 0.09732975
by O 0 0.00015624345
whole O 0 0.00017785007
body O 0 0.0004988045
hyperthermia B-Disease 0 0.9854139
were O 0 0.00016982137
compared O 0 0.00013196746
using O 0 0.00020427481
a O 0 0.00061075616
F344 O 0 0.011655263
rat O 0 0.0012080962
model O 0 0.0011907591
. O 0 0.0025252888

Antitumor O 0 0.029322911
activity O 0 0.002420696
was O 0 0.0020228145
studied O 0 0.0021292758
using O 0 0.0014163358
a O 0 0.002970363
tumor B-Disease 0 0.5799423
growth O 0 0.012097205
delay O 0 0.0049987137
assay O 0 0.004980665
. O 0 0.0053666066

Acute O 0 0.10156773
normal O 0 0.0050459406
tissue O 0 0.0046095983
toxicities B-Disease 0 0.34506258
( O 0 0.0016691412
i O 0 0.0011241758
. O 0 0.0005243139
e O 0 0.0009944405
. O 0 0.00041137723
, O 0 0.001043798
leukopenia B-Disease 0 0.9996872
and O 0 0.0007028258
thrombocytopenia B-Disease 0 0.9997565
) O 0 0.0007431619
and O 0 0.00020154729
late O 0 0.0005832954
normal O 0 0.00048566016
tissue O 0 0.0007816405
toxicities B-Disease 0 0.2553689
( O 0 0.0003300561
i O 0 0.00030542377
. O 0 0.00015423744
e O 0 0.00041580794
. O 0 0.00016275317
, O 0 0.00043388995
myocardial B-Disease 0 0.9912066
and I-Disease 0 0.00030445535
kidney I-Disease 0 0.8766188
injury I-Disease 0 0.71610373
) O 0 0.00045261343
were O 0 9.1014255e-05
evaluated O 0 9.2030125e-05
by O 0 0.00010250267
functional O 0 0.00014130445
/ O 0 0.00078585354
physiological O 0 0.0002882308
assays O 0 0.00031634822
and O 0 0.0003969031
by O 0 0.0005231166
morphological O 0 0.0015407621
techniques O 0 0.001641757
. O 0 0.0028906264

Whole O 0 0.007788049
body O 0 0.006212661
hyperthermia B-Disease 0 0.9923654
( O 0 0.0023748905
120 O 0 0.0010034508
min O 0 0.0007585005
at O 0 0.00033086547
41 O 0 0.00062047644
. O 0 0.00033337637
5 O 0 0.00031953974
degrees O 0 0.003662976
C O 0 0.9470828
) O 0 0.001214398
enhanced O 0 0.0003537529
both O 0 0.00044551346
Adriamycin B-Chemical 0 0.9999571
- O 0 0.0035050367
mediated O 0 0.00018701599
antitumor O 0 0.0021782564
activity O 0 0.0003039559
and O 0 0.000634993
toxic O 0 0.022742998
side O 0 0.0030880356
effects O 0 0.0020537125
. O 0 0.0037393211

The O 0 0.0024273596
thermal O 0 0.002682809
enhancement O 0 0.0015194411
ratio O 0 0.0010528308
calculated O 0 0.0006632269
for O 0 0.00058121525
antitumor O 0 0.003150118
activity O 0 0.0006429241
was O 0 0.0008664535
1 O 0 0.0011618652
. O 0 0.0012063253
6 O 0 0.0015182752
. O 0 0.0033539138

Thermal O 0 0.006944594
enhancement O 0 0.002181239
ratios O 0 0.0012306096
estimated O 0 0.00086794293
for O 0 0.0005330665
" O 0 0.0011736277
acute O 0 0.014927636
" O 0 0.0010964518
hematological O 0 0.058353756
changes O 0 0.0002859306
were O 0 0.00018064099
1 O 0 0.00018435111
. O 0 0.00013032465
3 O 0 0.00011179648
, O 0 0.00021388999
whereas O 0 0.00013813429
those O 0 0.00015925913
estimated O 0 0.00015453759
for O 0 0.0001205473
" O 0 0.00035170792
late O 0 0.0006443989
" O 0 0.0006165098
damage O 0 0.013763192
( O 0 0.0003380271
based O 0 9.888465e-05
on O 0 8.00457e-05
morphological O 0 0.00031692148
cardiac B-Disease 0 0.0010993488
and I-Disease 0 0.00028023022
renal I-Disease 0 0.9975858
lesions I-Disease 0 0.44512394
) O 0 0.0005275968
varied O 0 0.00017688372
between O 0 0.00012895116
2 O 0 0.00022673122
. O 0 0.00019992157
4 O 0 0.00020865674
and O 0 0.00033748307
4 O 0 0.00044284348
. O 0 0.0007107671
3 O 0 0.0011557131
. O 0 0.0024975901

Thus O 0 0.0023118122
, O 0 0.0032442252
while O 0 0.0012493428
whole O 0 0.0009983948
body O 0 0.0017902921
hyperthermia B-Disease 0 0.9967445
enhances O 0 0.0007375877
Adriamycin B-Chemical 0 0.9999722
- O 0 0.0043124002
mediated O 0 0.00013109103
antitumor O 0 0.0013231647
effect O 0 0.00018691759
, O 0 0.00059501786
normal O 0 0.0006577887
tissue O 0 0.0013281937
toxicity B-Disease 0 0.41654414
is O 0 0.00010259605
also O 0 0.00010175162
increased O 0 0.00019026705
, O 0 0.0002244155
and O 0 0.00010415917
the O 0 7.040416e-05
potential O 0 7.4992975e-05
therapeutic O 0 0.00015798306
gain O 0 0.00014885367
of O 0 0.00015712163
the O 0 0.00014484345
combined O 0 0.00026929498
modality O 0 0.00051339436
treatment O 0 0.0005413368
is O 0 0.00088047906
eroded O 0 0.013785513
. O 0 0.0031103906

Permeability O 0 0.2523108
, O 0 0.005484516
ultrastructural O 0 0.0041631195
changes O 0 0.0012893087
, O 0 0.0012770102
and O 0 0.0005225064
distribution O 0 0.00022910882
of O 0 0.0003425298
novel O 0 0.0002848146
proteins O 0 0.00030877106
in O 0 0.0003439968
the O 0 0.00042374496
glomerular O 0 0.9965006
barrier O 0 0.0026344801
in O 0 0.000520246
early O 0 0.0017781231
puromycin B-Chemical 0 0.9929472
aminonucleoside I-Chemical 0 0.9999927
nephrosis B-Disease 2 0.9999796
. O 0 0.0070058783

BACKGROUND O 0 0.02180212
/ O 0 0.012517559
AIMS O 0 0.014010806
: O 0 0.0025041944
It O 0 0.0010737276
is O 0 0.00044424375
still O 0 0.00040603263
unclear O 0 0.00035748555
what O 0 0.0007550638
happens O 0 0.00065793167
in O 0 0.0005082575
the O 0 0.0005858227
glomerulus O 0 0.014029854
when O 0 0.0011849388
proteinuria B-Disease 0 0.9997482
starts O 0 0.0035220108
. O 0 0.004202395

Using O 0 0.003775731
puromycin B-Chemical 0 0.98659116
aminonucleoside I-Chemical 0 0.9999876
nephrosis B-Disease 2 0.9999893
( O 0 0.08202946
PAN O 0 0.999811
) O 0 0.0020135466
rats O 0 0.0006205621
, O 0 0.00040854636
we O 0 0.000116551775
studied O 0 0.00029200857
early O 0 0.00039668885
ultrastructural O 0 0.00093039894
and O 0 0.0003071346
permeability O 0 0.46730828
changes O 0 0.0001851396
in O 0 9.5108335e-05
relation O 0 6.147676e-05
to O 0 7.603813e-05
the O 0 7.5247845e-05
expression O 0 9.066258e-05
of O 0 0.00015034419
the O 0 0.00017039133
podocyte O 0 0.8721921
- O 0 0.006906264
associated O 0 0.00019828098
molecules O 0 0.0004003971
nephrin O 0 0.96930325
, O 0 0.0009379463
a O 0 0.0005690172
- O 0 0.007381349
actinin O 0 0.051642094
, O 0 0.0005909486
dendrin O 0 0.0013293453
, O 0 0.00039397576
and O 0 0.00020579458
plekhh2 O 0 0.0010830346
, O 0 0.00027061818
the O 0 9.254195e-05
last O 0 5.893247e-05
two O 0 7.8611316e-05
of O 0 0.00017424983
which O 0 0.00023986105
were O 0 0.00021580223
only O 0 0.00031159964
recently O 0 0.00042400157
discovered O 0 0.00085322006
in O 0 0.0013063205
podocytes O 0 0.5332248
. O 0 0.004242756

METHODS O 0 0.004361531
: O 0 0.0028879712
Using O 0 0.00083703094
immune O 0 0.0020718134
stainings O 0 0.0011675484
, O 0 0.0010140191
semiquantitative O 0 0.00037801737
measurement O 0 0.00043895573
was O 0 0.00047560647
performed O 0 0.0004962622
under O 0 0.0006487787
the O 0 0.0009674324
electron O 0 0.005695574
microscope O 0 0.0043102144
. O 0 0.004178832

Permeability O 0 0.06123639
was O 0 0.0027795618
assessed O 0 0.0017717486
using O 0 0.0013022448
isolated O 0 0.0017276206
kidney O 0 0.020631744
perfusion O 0 0.03927949
with O 0 0.002871972
tracers O 0 0.007955308
. O 0 0.0051283105

Possible O 0 0.007090739
effects O 0 0.0047710086
of O 0 0.006601131
ACE O 0 0.9686642
inhibition O 0 0.006246455
were O 0 0.004113217
tested O 0 0.004765008
. O 0 0.008094067

RESULTS O 0 0.004605544
: O 0 0.0027669377
By O 0 0.0008687128
day O 0 0.00083420624
2 O 0 0.0009799518
, O 0 0.0012144626
some O 0 0.00076154387
patchy O 0 0.0016214425
foot O 0 0.0034293432
process O 0 0.00087368226
effacement O 0 0.08209807
, O 0 0.0012937875
but O 0 0.0009294389
no O 0 0.0013129995
proteinuria B-Disease 0 0.9998115
, O 0 0.004790595
appeared O 0 0.0025752613
. O 0 0.0041402197

The O 0 0.002473858
amount O 0 0.0017151778
of O 0 0.0025943308
nephrin O 0 0.82805926
was O 0 0.0014174922
reduced O 0 0.0011683294
in O 0 0.0008175447
both O 0 0.0008403258
diseased O 0 0.0033418427
and O 0 0.0013651878
normal O 0 0.0025773528
areas O 0 0.0034861567
. O 0 0.003980143

The O 0 0.0020546291
other O 0 0.0015759337
proteins O 0 0.0012545293
showed O 0 0.00091409095
few O 0 0.0006018551
changes O 0 0.0008648158
, O 0 0.0012675992
which O 0 0.0007748123
were O 0 0.00060394424
limited O 0 0.00075408083
to O 0 0.0010143471
diseased O 0 0.005086775
areas O 0 0.0035194792
. O 0 0.0038251684

By O 0 0.002219752
day O 0 0.0016668211
4 O 0 0.0013119933
, O 0 0.0019856943
foot O 0 0.0037692185
process O 0 0.0009849868
effacement O 0 0.017471561
was O 0 0.0004067834
complete O 0 0.00030554927
and O 0 0.00057569135
proteinuria B-Disease 0 0.9998808
appeared O 0 0.0003928699
in O 0 0.00028268932
parallel O 0 0.00042196328
with O 0 0.0004399484
signs O 0 0.0018287767
of O 0 0.0006835258
size O 0 0.0016930536
barrier O 0 0.008187662
damage O 0 0.1488342
. O 0 0.003631807

Nephrin O 0 0.013575353
decreased O 0 0.003767058
further O 0 0.0014593299
, O 0 0.002103355
while O 0 0.00097585283
dendrin O 0 0.0026614035
and O 0 0.00082648714
plekhh2 O 0 0.0024366353
also O 0 0.0005342853
decreased O 0 0.0010483575
but O 0 0.00083849573
a O 0 0.0013609943
- O 0 0.006776157
actinin O 0 0.03693124
remained O 0 0.002410816
unchanged O 0 0.003254299
. O 0 0.0040706536

ACE O 0 0.9817945
inhibition O 0 0.006962717
had O 0 0.0035054984
no O 0 0.0024954195
significant O 0 0.002853535
protective O 0 0.005162272
effect O 0 0.0048129745
. O 0 0.008684381

CONCLUSIONS O 0 0.07167947
: O 0 0.017142128
PAN O 0 0.9993618
glomeruli O 0 0.047283836
already O 0 0.00077265856
showed O 0 0.0004815728
significant O 0 0.00047226076
pathology O 0 0.0011320286
by O 0 0.0003140958
day O 0 0.00023041708
4 O 0 0.00028849914
, O 0 0.0006183764
despite O 0 0.0005096737
relatively O 0 0.0017652097
mild O 0 0.66950977
proteinuria B-Disease 0 0.9998627
. O 0 0.0060390406

This O 0 0.0054745995
was O 0 0.0022287003
preceded O 0 0.0016780187
by O 0 0.0012117692
altered O 0 0.001463572
nephrin O 0 0.73031217
expression O 0 0.0007842156
, O 0 0.0010075178
supporting O 0 0.00040600743
its O 0 0.00061209704
pivotal O 0 0.0005473141
role O 0 0.0004149309
in O 0 0.0011861483
podocyte O 0 0.71336466
morphology O 0 0.007400338
. O 0 0.004798415

The O 0 0.0019753848
novel O 0 0.0015935731
proteins O 0 0.0013736816
dendrin O 0 0.0035338015
and O 0 0.0010048833
plekhh2 O 0 0.0024617843
were O 0 0.00038293857
both O 0 0.00028228128
reduced O 0 0.000396119
, O 0 0.00050814153
suggesting O 0 0.00017652247
roles O 0 0.00019411874
in O 0 0.00059416046
PAN O 0 0.99964607
, O 0 0.001359681
whereas O 0 0.00061220437
a O 0 0.0012609275
- O 0 0.007024735
actinin O 0 0.03474839
was O 0 0.0014811087
unchanged O 0 0.0026442069
. O 0 0.0036063078

A O 0 0.021612095
novel O 0 0.0027751678
, O 0 0.002835478
multiple O 0 0.0011689322
symptom O 0 0.001956909
model O 0 0.0006883075
of O 0 0.0016266635
obsessive B-Disease 0 0.99996376
- I-Disease 0 0.47098783
compulsive I-Disease 0 0.9999145
- I-Disease 0 0.008263141
like I-Disease 0 0.0006865109
behaviors I-Disease 0 0.0015666971
in O 0 0.0011502858
animals O 0 0.0014565102
. O 0 0.0035902506

BACKGROUND O 0 0.0149387885
: O 0 0.0042614867
Current O 0 0.0020104714
animal O 0 0.00090936007
models O 0 0.000770041
of O 0 0.0017256455
obsessive B-Disease 0 0.99997175
- I-Disease 0 0.70713943
compulsive I-Disease 0 0.99997973
disorder I-Disease 0 0.9998516
( O 0 0.021354502
OCD B-Disease 2 0.9999964
) O 0 0.0013064215
typically O 0 0.00025675248
involve O 0 0.00017745623
acute O 0 0.005475835
, O 0 0.00046682134
drug O 0 0.012771788
- O 0 0.001805609
induced O 0 0.00017365637
symptom O 0 0.0010740429
provocation O 0 0.0014815362
or O 0 0.00014712886
a O 0 0.0002685824
genetic O 0 0.00035819958
association O 0 0.00022912996
with O 0 0.0010043245
stereotypies O 0 0.99995935
or O 0 0.002148561
anxiety B-Disease 0 0.99798054
. O 0 0.003351742

None O 0 0.004499943
of O 0 0.0024404284
these O 0 0.0014675647
current O 0 0.0012411919
models O 0 0.0008762806
demonstrate O 0 0.0006448065
multiple O 0 0.0022961285
OCD B-Disease 2 0.999972
- O 0 0.014145023
like O 0 0.0018611345
behaviors O 0 0.0052248645
. O 0 0.0052657807

METHODS O 0 0.0040288963
: O 0 0.0028725388
Neonatal O 0 0.0017192379
rats O 0 0.00082079944
were O 0 0.00040986508
treated O 0 0.0005593987
with O 0 0.00034932984
the O 0 0.00038607224
tricyclic O 0 0.9998264
antidepressant B-Chemical 0 0.9999951
clomipramine B-Chemical 0 0.99999964
or O 0 0.00020186289
vehicle O 0 0.000428739
between O 0 7.4966934e-05
days O 0 5.985298e-05
9 O 0 7.4359334e-05
and O 0 9.154444e-05
16 O 0 0.00011655333
twice O 0 8.8010296e-05
daily O 0 0.00017573418
and O 0 0.00022653736
behaviorally O 0 0.0011746696
tested O 0 0.00046078005
in O 0 0.0008771907
adulthood O 0 0.028804453
. O 0 0.0031855267

RESULTS O 0 0.00569088
: O 0 0.008517696
Clomipramine B-Chemical 0 0.99988866
exposure O 0 0.0012491571
in O 0 0.0005427302
immature O 0 0.00083702337
rats O 0 0.0004884078
produced O 0 0.00018666522
significant O 0 0.00020556943
behavioral O 0 0.00070118875
and O 0 0.00016872931
biochemical O 0 0.00019894776
changes O 0 0.00012427797
that O 0 7.642479e-05
include O 0 0.00010288369
enhanced O 0 0.00020575909
anxiety B-Disease 0 0.99548966
( O 0 0.00033328417
elevated O 0 0.00042191785
plus O 0 0.0001467721
maze O 0 0.32550067
and O 0 0.00026613436
marble O 0 0.003339172
burying O 0 0.04571853
) O 0 0.0011891241
, O 0 0.0005842516
behavioral B-Disease 0 0.24768774
inflexibility I-Disease 0 0.99549294
( O 0 0.0022370182
perseveration O 0 0.9997677
in O 0 0.00011383393
the O 0 7.359506e-05
spontaneous O 0 0.00024645502
alternation O 0 0.0005359999
task O 0 0.00025993105
and O 0 0.00010843787
impaired O 0 0.0003201261
reversal O 0 0.00018797048
learning O 0 0.00052153564
) O 0 0.0003793804
, O 0 0.00025043378
working O 0 0.0006109719
memory B-Disease 2 0.9886791
impairment I-Disease 2 0.99687344
( O 0 0.0006647399
e O 0 0.0005219812
. O 0 0.00016088726
g O 0 0.0004960653
. O 0 0.00016354719
, O 0 0.00030884528
win O 0 0.00037193618
- O 0 0.0011203133
shift O 0 0.00027234826
paradigm O 0 0.00041065845
) O 0 0.0010784526
, O 0 0.0013808208
hoarding B-Disease 0 0.9990662
, O 0 0.0017159767
and O 0 0.0012348503
corticostriatal B-Disease 0 0.70650434
dysfunction I-Disease 0 0.9943077
. O 0 0.0044858474

Dopamine B-Chemical 0 0.9998142
D2 O 0 0.99667776
receptors O 0 0.0057743164
were O 0 0.0011021768
elevated O 0 0.0019826402
in O 0 0.000489718
the O 0 0.00040521668
striatum O 0 0.0037949765
, O 0 0.00075789826
whereas O 0 0.0005687207
serotonin B-Chemical 0 0.9996275
2C O 0 0.0005401626
, O 0 0.0006160097
but O 0 0.0003535793
not O 0 0.00035183554
serotonin B-Chemical 0 0.9996753
1A O 0 0.0005669905
, O 0 0.0005420395
receptors O 0 0.0005820418
were O 0 0.00026739787
elevated O 0 0.0009367344
in O 0 0.00035532494
the O 0 0.00049414585
orbital O 0 0.051161077
frontal O 0 0.681493
cortex O 0 0.05081944
. O 0 0.0029793524

CONCLUSIONS O 0 0.028063627
: O 0 0.005232432
This O 0 0.0017183536
is O 0 0.0006025433
the O 0 0.00038021567
first O 0 0.00023390824
demonstration O 0 0.0002562189
of O 0 0.00032453577
multiple O 0 0.00032114433
symptoms O 0 0.001664776
consistent O 0 0.00022912974
with O 0 0.0003864963
an O 0 0.0011167697
OCD B-Disease 2 0.99999404
- O 0 0.0061678397
like O 0 0.00042679635
profile O 0 0.00055882736
in O 0 0.00079950056
animals O 0 0.001120634
. O 0 0.0028767828

Moreover O 0 0.003209287
, O 0 0.0033808285
these O 0 0.0012798589
behaviors O 0 0.0020196873
are O 0 0.0006838307
accompanied O 0 0.0008289562
by O 0 0.00043383284
biochemical O 0 0.0005603902
changes O 0 0.00037754164
in O 0 0.0003069349
brain O 0 0.000696359
regions O 0 0.0001929729
previously O 0 0.00026282403
identified O 0 0.00023442823
as O 0 0.00043312725
relevant O 0 0.00065141346
to O 0 0.0018421211
OCD B-Disease 2 0.99994886
. O 0 0.004928662

This O 0 0.0040321904
novel O 0 0.0016822072
model O 0 0.001352559
of O 0 0.0026709945
OCD B-Disease 2 0.99998367
demonstrates O 0 0.00037922294
that O 0 0.00029395826
drug O 0 0.0035995047
exposure O 0 0.00026338646
during O 0 0.00011920759
a O 0 0.00018202106
sensitive O 0 8.96377e-05
period O 0 7.910959e-05
can O 0 8.032541e-05
program O 0 0.00015983966
disease O 0 0.23793
- O 0 0.0018902437
like O 0 0.000116703144
systems O 0 0.00018410798
permanently O 0 0.00055608945
, O 0 0.0003506971
which O 0 0.00014630442
could O 0 6.928543e-05
have O 0 7.082219e-05
implications O 0 8.705789e-05
for O 0 7.532768e-05
current O 0 0.00012595032
and O 0 0.00011423932
future O 0 0.000100387806
therapeutic O 0 0.00016122032
strategies O 0 0.00013435967
for O 0 0.00015681957
this O 0 0.0003147091
and O 0 0.00051131425
other O 0 0.0011821673
psychiatric B-Disease 2 0.9999398
disorders I-Disease 0 0.9997533
. O 0 0.0049535036

Elevation O 0 0.031828035
of O 0 0.005689515
ADAM10 O 0 0.46309504
, O 0 0.009184829
ADAM17 O 0 0.7768646
, O 0 0.00915253
MMP O 0 0.9980544
- O 0 0.01809956
2 O 0 0.0007720353
and O 0 0.0008036807
MMP O 0 0.99200624
- O 0 0.0033578512
9 O 0 0.00020506397
expression O 0 0.00015270861
with O 0 0.00022885465
media O 0 0.0009814065
degeneration O 0 0.682988
features O 0 0.0006517836
CaCl2 B-Chemical 0 0.993979
- O 0 0.0026883343
induced O 0 0.00024571034
thoracic B-Disease 0 0.0024421888
aortic I-Disease 0 0.4908848
aneurysm I-Disease 0 0.9995734
in O 0 0.00054815336
a O 0 0.0008773516
rat O 0 0.0011649561
model O 0 0.0012808632
. O 0 0.002718692

PURPOSE O 0 0.008864063
: O 0 0.00474391
This O 0 0.0017584723
study O 0 0.00092380086
was O 0 0.00048298432
designed O 0 0.00032625158
to O 0 0.00024086761
establish O 0 0.00015568399
a O 0 0.0003217002
rat O 0 0.0002577952
model O 0 0.00013165249
of O 0 0.00018473117
thoracic B-Disease 0 0.0011417369
aortic I-Disease 0 0.261237
aneurysm I-Disease 0 0.99976164
( O 0 0.0009488798
TAA B-Disease 0 0.14847475
) O 0 0.00087997335
by O 0 0.00035734498
calcium B-Chemical 0 0.9993197
chloride I-Chemical 0 0.99991345
( O 0 0.0031934408
CaCl B-Chemical 0 0.99631506
( I-Chemical 0 0.0005312557
2 I-Chemical 0 0.00020368918
) I-Chemical 0 0.00040959776
) O 0 0.000482469
- O 0 0.00095897727
induced O 0 0.00019507876
arterial B-Disease 0 0.99440056
injury I-Disease 0 0.6533849
and O 0 0.00014135218
to O 0 7.125507e-05
explore O 0 4.8875492e-05
the O 0 5.965042e-05
potential O 0 5.9310256e-05
role O 0 4.907351e-05
of O 0 0.0001568094
a O 0 0.00039411476
disintegrin O 0 0.4574703
and O 0 0.00046591315
metalloproteinase O 0 0.9751002
( O 0 0.001447583
ADAM O 0 0.8350734
) O 0 0.0012375844
, O 0 0.0006375903
matrix O 0 0.010082864
metalloproteinases O 0 0.9989875
( O 0 0.0015970456
MMPs O 0 0.8461789
) O 0 0.00064320053
and O 0 0.00016344163
their O 0 0.00013754364
endogenous O 0 0.00015120144
inhibitors O 0 0.00068775157
( O 0 0.0017392988
TIMPs O 0 0.7231249
) O 0 0.0018047633
in O 0 0.0009246348
TAA B-Disease 0 0.2304136
formation O 0 0.0037698613
. O 0 0.0036431213

METHODS O 0 0.005174931
: O 0 0.004030975
Thoracic O 0 0.0025313112
aorta O 0 0.0044868616
of O 0 0.0010582253
male O 0 0.0019347545
Sprague O 0 0.13482973
- O 0 0.0037387735
Dawley O 0 0.006078392
rats O 0 0.0006079626
was O 0 0.00027678526
exposed O 0 0.00030699113
to O 0 0.00024400729
0 O 0 0.00043485328
. O 0 0.00044451738
5M O 0 0.4835794
CaCl B-Chemical 0 0.98769546
( I-Chemical 0 0.0008253963
2 I-Chemical 0 0.0003801153
) I-Chemical 0 0.00060918415
or O 0 0.00031635215
normal O 0 0.0007740519
saline O 0 0.0017519438
( O 0 0.0019787655
NaCl B-Chemical 0 0.4818327
) O 0 0.0057222075
. O 0 0.004110872

After O 0 0.0019762048
12weeks O 0 0.0033922913
, O 0 0.0018323489
animals O 0 0.00064170535
were O 0 0.0005864679
euthanized O 0 0.0005233041
, O 0 0.00087720784
and O 0 0.0007521373
CaCl B-Chemical 0 0.95175666
( I-Chemical 0 0.0009983
2 I-Chemical 0 0.00045911525
) I-Chemical 0 0.0008651274
- O 0 0.0016162783
treated O 0 0.0007337364
, O 0 0.0011345752
CaCl B-Chemical 0 0.9886507
( I-Chemical 0 0.00075033394
2 I-Chemical 0 0.0003052735
) I-Chemical 0 0.0005716714
- O 0 0.0009130551
untreated O 0 0.0003369859
( O 0 0.00029895522
n O 0 0.00020678947
= O 0 0.00039222662
12 O 0 0.00010970821
) O 0 0.00027961453
and O 0 0.00020810837
NaCl B-Chemical 0 0.55938816
- O 0 0.002199687
treated O 0 0.0004349797
aortic O 0 0.013030016
segments O 0 0.00020914435
( O 0 0.00025199758
n O 0 0.00018461706
= O 0 0.00037528097
12 O 0 0.00011903254
) O 0 0.0003000972
were O 0 0.00015118446
collected O 0 0.0001752633
for O 0 0.00020540331
histological O 0 0.00093967794
and O 0 0.00068837416
molecular O 0 0.0016495232
assessments O 0 0.0016919127
. O 0 0.0027364865

MMP O 0 0.9965675
- O 0 0.5398518
TIMP O 0 0.99215287
and O 0 0.0029731747
ADAM O 0 0.30653468
mRNAs O 0 0.0010047457
were O 0 0.00065456156
semi O 0 0.00081704406
- O 0 0.0017348875
quantitatively O 0 0.0003845297
analyzed O 0 0.00037269344
and O 0 0.00039625363
protein O 0 0.0004444528
expressions O 0 0.00063443766
were O 0 0.0006039358
determined O 0 0.0006456507
by O 0 0.0011381909
immunohistochemistry O 0 0.0022789498
. O 0 0.0035170675

RESULTS O 0 0.0043592746
: O 0 0.0026915937
Despite O 0 0.0007319981
similar O 0 0.000600248
external O 0 0.0009889962
diameters O 0 0.0029382603
among O 0 0.0011670414
CaCl B-Chemical 0 0.98278934
( I-Chemical 0 0.001069921
2 I-Chemical 0 0.00045516161
) I-Chemical 0 0.00081993005
- O 0 0.0013975705
treated O 0 0.00056819804
, O 0 0.00060678023
non O 0 0.00073610054
- O 0 0.01166792
CaCl B-Chemical 0 0.9912451
( I-Chemical 0 0.00064945174
2 I-Chemical 0 0.00026031895
) I-Chemical 0 0.00051744014
- O 0 0.00094794057
treated O 0 0.00034908802
and O 0 0.00028802315
NaCl B-Chemical 0 0.88084966
- O 0 0.0035285049
treated O 0 0.00037798224
segments O 0 0.00021426105
, O 0 0.0002997046
aneurymal O 0 0.00031363856
alteration O 0 0.00021220157
( O 0 0.00025942922
n O 0 0.00018167567
= O 0 0.00036179158
6 O 0 0.000102381724
, O 0 0.00022262661
50 O 0 0.00020133215
% O 0 0.00035095634
) O 0 0.00046894723
, O 0 0.0003724828
media O 0 0.0008873144
degeneration O 0 0.6721453
with O 0 0.00020343297
regional O 0 0.00030275137
disruption O 0 0.00013568137
, O 0 0.0002804189
fragmentation O 0 0.0004141856
of O 0 0.00018646439
elastic O 0 0.00081290933
fiber O 0 0.0007028543
, O 0 0.00036635075
and O 0 0.00020572003
increased O 0 0.00043781076
collagen O 0 0.75510514
deposition O 0 0.00064842356
( O 0 0.00027387307
n O 0 0.00017381871
= O 0 0.00035710607
12 O 0 9.920646e-05
, O 0 0.00023542813
100 O 0 0.00032304943
% O 0 0.00039413484
) O 0 0.00043676072
were O 0 0.00017015623
demonstrated O 0 0.0001998739
in O 0 0.0003963148
CaCl B-Chemical 0 0.9806889
( I-Chemical 0 0.0010268096
2 I-Chemical 0 0.000582476
) I-Chemical 0 0.0012846029
- O 0 0.0025999881
treated O 0 0.0017168394
segments O 0 0.0021634703
. O 0 0.0033978664

MMP O 0 0.9932989
- O 0 0.040203456
2 O 0 0.004174684
, O 0 0.0061347475
MMP O 0 0.9898065
- O 0 0.008758717
9 O 0 0.0009387947
, O 0 0.0016395155
ADAM O 0 0.35323933
- O 0 0.00377699
10 O 0 0.0004570405
and O 0 0.0004929608
ADAM O 0 0.37055507
- O 0 0.0032239074
17 O 0 0.00037653017
mRNA O 0 0.00024633546
levels O 0 0.00018682441
were O 0 0.00019336099
increased O 0 0.00030032874
in O 0 0.00030988763
CaCl B-Chemical 0 0.98386484
( I-Chemical 0 0.0005569033
2 I-Chemical 0 0.00023660074
) I-Chemical 0 0.0004893862
- O 0 0.00087870186
treated O 0 0.00028481023
segments O 0 0.00019194289
( O 0 0.00024733852
all O 0 0.00011034801
p O 0 0.00021762699
< O 0 0.00021323087
0 O 0 0.00019270611
. O 0 0.000164794
01 O 0 0.000962848
) O 0 0.00043459053
, O 0 0.0002842208
with O 0 0.0001720604
trends O 0 0.00021038117
of O 0 0.00025690524
elevation O 0 0.00724886
in O 0 0.00032403955
CaCl B-Chemical 0 0.99058086
( I-Chemical 0 0.0004948723
2 I-Chemical 0 0.00020872401
) I-Chemical 0 0.00043432732
- O 0 0.00079453515
untreated O 0 0.00029527477
segments O 0 0.00023014547
, O 0 0.00035642178
as O 0 0.00020193201
compared O 0 0.0002024641
with O 0 0.00055218145
NaCl B-Chemical 0 0.9131936
- O 0 0.008959345
treated O 0 0.001975979
segments O 0 0.0021000109
. O 0 0.0030949397

Immunohistochemistry O 0 0.0049860254
displayed O 0 0.0016793692
significantly O 0 0.0015422726
increased O 0 0.0013379742
expressions O 0 0.0012200326
of O 0 0.001824791
MMP O 0 0.9979634
- O 0 0.016770184
2 O 0 0.0007623763
, O 0 0.0014475762
MMP O 0 0.9883569
- O 0 0.0039116004
9 O 0 0.00034478825
, O 0 0.0007413339
ADAM O 0 0.3451851
- O 0 0.002615334
10 O 0 0.0002858358
and O 0 0.00034108575
ADAM O 0 0.3677267
- O 0 0.0024862941
17 O 0 0.0003038881
( O 0 0.00026268227
all O 0 0.00012439236
p O 0 0.00024553097
< O 0 0.00024919404
0 O 0 0.00022750862
. O 0 0.00019759833
01 O 0 0.0010852055
) O 0 0.0005225871
in O 0 0.0002840986
intima O 0 0.8846745
and O 0 0.00032484345
media O 0 0.0006855305
for O 0 0.0003880811
CaCl B-Chemical 0 0.9803136
( I-Chemical 0 0.0010587904
2 I-Chemical 0 0.0006025979
) I-Chemical 0 0.0013162557
- O 0 0.0026460635
treated O 0 0.0017612467
segments O 0 0.002219996
. O 0 0.0034847488

TIMP O 0 0.9912628
mRNA O 0 0.004802051
and O 0 0.0027190358
tissue O 0 0.0035770363
levels O 0 0.0009789108
did O 0 0.00093853805
not O 0 0.00065203157
differ O 0 0.0006628499
obviously O 0 0.0012152587
among O 0 0.0007353545
the O 0 0.0005690337
three O 0 0.00050307176
aortic O 0 0.011625891
segments O 0 0.0023852577
. O 0 0.0034371058

CONCLUSION O 0 0.021469552
: O 0 0.005136866
This O 0 0.0019053093
study O 0 0.0010311134
establishes O 0 0.00061773293
a O 0 0.0010488454
TAA B-Disease 0 0.022189017
model O 0 0.0004794247
by O 0 0.0005571903
periarterial O 0 0.43995816
CaCl B-Chemical 0 0.99436647
( I-Chemical 0 0.0007200539
2 I-Chemical 0 0.00025783453
) I-Chemical 0 0.00036210418
exposure O 0 0.0001669994
in O 0 0.00012964616
rats O 0 0.0002610509
, O 0 0.00027414347
and O 0 0.00014282245
demonstrates O 0 8.476043e-05
a O 0 0.00021091744
significant O 0 0.00017955671
elevation O 0 0.0021104065
of O 0 0.00019207945
expression O 0 0.00019131252
of O 0 0.0005360952
MMP O 0 0.9992144
- O 0 0.016632792
2 O 0 0.00032099584
, O 0 0.0007652383
MMP O 0 0.9938963
- O 0 0.0037291807
9 O 0 0.00022373698
, O 0 0.00054992456
ADAM10 O 0 0.0793165
and O 0 0.00058583246
ADAM17 O 0 0.18404761
in O 0 0.00037854223
the O 0 0.00036318507
pathogenesis O 0 0.0010154707
of O 0 0.0011507028
vascular O 0 0.95583963
remodeling O 0 0.006420216
. O 0 0.003276604

Suxamethonium B-Chemical 0 0.9800648
induced O 0 0.0031959934
prolonged O 0 0.0044956175
apnea B-Disease 0 0.9975973
in O 0 0.0011387921
a O 0 0.0011722043
patient O 0 0.00090834935
receiving O 0 0.0011389614
electroconvulsive O 0 0.1170762
therapy O 0 0.0024232883
. O 0 0.0031001493

Suxamethonium B-Chemical 0 0.9845502
causes O 0 0.003089422
prolonged O 0 0.003447152
apnea B-Disease 0 0.9985643
in O 0 0.0008099639
patients O 0 0.0011864213
in O 0 0.0005452517
whom O 0 0.003157584
pseudocholinesterase O 0 0.9997769
enzyme O 0 0.0037765505
gets O 0 0.00092455465
deactivated O 0 0.003094107
by O 0 0.0011231654
organophosphorus B-Chemical 0 0.99990094
( I-Chemical 0 0.010133443
OP I-Chemical 0 0.99856097
) I-Chemical 0 0.007844236
poisons I-Chemical 0 0.4058076
. O 0 0.0048880815

Here O 0 0.0036996717
, O 0 0.0034548494
we O 0 0.00084587705
present O 0 0.0007815958
a O 0 0.0009642641
similar O 0 0.0003998905
incident O 0 0.0010706543
in O 0 0.00040385002
a O 0 0.0007220285
severely O 0 0.0098389145
depressed B-Disease 2 0.99284995
patient O 0 0.0003947771
who O 0 0.00031619417
received O 0 0.00028264726
electroconvulsive O 0 0.052643333
therapy O 0 0.00070118514
( O 0 0.0013827024
ECT O 0 0.4276964
) O 0 0.0034114528
. O 0 0.003026347

Prolonged O 0 0.012204005
apnea B-Disease 0 0.99663097
in O 0 0.0014019608
our O 0 0.0007839115
case O 0 0.0007761924
ensued O 0 0.0014388264
because O 0 0.0002980826
the O 0 0.00026880682
information O 0 0.000325932
about O 0 0.0006689882
suicidal O 0 0.99959
attempt O 0 0.0006017774
by O 0 0.00058403704
OP B-Chemical 0 0.9996032
compound I-Chemical 0 0.08113184
was O 0 0.00049737585
concealed O 0 0.0015041957
from O 0 0.00045242347
the O 0 0.00055518403
treating O 0 0.0012845418
team O 0 0.0020400712
. O 0 0.0032895363

Curcumin B-Chemical 0 0.9998585
ameliorates O 0 0.9875087
cognitive B-Disease 0 0.9985964
dysfunction I-Disease 0 0.9894315
and O 0 0.002307673
oxidative O 0 0.7114671
damage O 0 0.27501577
in O 0 0.0013564054
phenobarbitone B-Chemical 0 0.99999547
and O 0 0.0041513126
carbamazepine B-Chemical 1 0.99999464
administered O 0 0.0026568864
rats O 0 0.0023206053
. O 0 0.0026354475

The O 0 0.0026284044
antiepileptic O 0 0.9961153
drugs O 0 0.3718071
, O 0 0.012862111
phenobarbitone B-Chemical 0 0.99999607
and O 0 0.008758133
carbamazepine B-Chemical 1 0.9999982
are O 0 0.00035058695
well O 0 0.00023422179
known O 0 0.00022596528
to O 0 0.00024066238
cause O 0 0.00056905247
cognitive B-Disease 0 0.9502218
impairment I-Disease 0 0.350439
on O 0 0.00053624954
chronic O 0 0.006289002
use O 0 0.0013507323
. O 0 0.0025701444

The O 0 0.002287909
increase O 0 0.0019135561
in O 0 0.0016130706
free O 0 0.0024139485
radical O 0 0.052301385
generation O 0 0.0006352938
has O 0 0.00027863443
been O 0 0.00028096134
implicated O 0 0.00023004369
as O 0 0.00021379396
one O 0 0.00016386733
of O 0 0.00018718762
the O 0 0.00013352043
important O 0 0.00010570741
mechanisms O 0 0.00014804937
of O 0 0.00042098414
cognitive B-Disease 0 0.9657439
impairment I-Disease 0 0.6290299
by O 0 0.001075743
antiepileptic O 0 0.9985885
drugs O 0 0.09957116
. O 0 0.0030234735

Curcumin B-Chemical 0 0.9997559
has O 0 0.0031131066
shown O 0 0.0016879956
antioxidant O 0 0.98628217
, O 0 0.0034371447
anti O 0 0.00327506
- O 0 0.016479123
inflammatory O 0 0.015791347
and O 0 0.0011367319
neuro O 0 0.075739525
- O 0 0.0059765805
protective O 0 0.002220165
properties O 0 0.0018362936
. O 0 0.0041663335

Therefore O 0 0.002334976
, O 0 0.0033853883
the O 0 0.001132726
present O 0 0.0007572659
study O 0 0.000761064
was O 0 0.0004099276
carried O 0 0.0002832918
out O 0 0.00019612988
to O 0 0.00012966483
investigate O 0 6.108926e-05
the O 0 9.858705e-05
effect O 0 0.00011197669
of O 0 0.0002332775
chronic O 0 0.17437537
curcumin B-Chemical 0 0.9999703
administration O 0 0.0017113513
on O 0 0.00022251626
phenobarbitone B-Chemical 0 0.99999905
- O 0 0.18741524
and O 0 0.0008115488
carbamazepine B-Chemical 1 0.9999994
- O 0 0.038707532
induced O 0 0.00032368512
cognitive B-Disease 0 0.99318236
impairment I-Disease 0 0.84139836
and O 0 0.00074071524
oxidative O 0 0.44792178
stress O 0 0.04413052
in O 0 0.0009183589
rats O 0 0.002071351
. O 0 0.0023420402

Pharmacokinetic O 0 0.016298676
interactions O 0 0.0024622972
of O 0 0.0033628915
curcumin B-Chemical 0 0.9998135
with O 0 0.015270181
phenobarbitone B-Chemical 0 0.9999969
and O 0 0.022129292
carbamazepine B-Chemical 1 0.9999951
were O 0 0.0013842916
also O 0 0.0012185287
studied O 0 0.002557286
. O 0 0.0035762035

Vehicle O 0 0.2596412
/ O 0 0.011206226
drugs O 0 0.012353554
were O 0 0.0011760583
administered O 0 0.0011568535
daily O 0 0.0007971252
for O 0 0.000556559
21days O 0 0.002812154
to O 0 0.0007335067
male O 0 0.0019639744
Wistar O 0 0.004456649
rats O 0 0.0031697436
. O 0 0.0036778378

Passive O 0 0.005751618
avoidance O 0 0.0035282718
paradigm O 0 0.0016799064
and O 0 0.0011468907
elevated O 0 0.0019756667
plus O 0 0.0008281119
maze O 0 0.13464484
test O 0 0.00085020834
were O 0 0.0003981914
used O 0 0.0003387058
to O 0 0.00039117792
assess O 0 0.00043302836
cognitive O 0 0.28178558
function O 0 0.0018891611
. O 0 0.0035937065

At O 0 0.0010872802
the O 0 0.0010275107
end O 0 0.00060598797
of O 0 0.0007648968
study O 0 0.00063050183
period O 0 0.00039071296
, O 0 0.0012523213
serum O 0 0.4321233
phenobarbitone B-Chemical 0 0.999998
and O 0 0.008393485
carbamazepine B-Chemical 1 0.99999917
, O 0 0.0023847462
whole O 0 0.00078034186
brain O 0 0.37497765
malondialdehyde B-Chemical 1 0.99999976
and O 0 0.0031178836
reduced O 0 0.0121736275
glutathione B-Chemical 0 0.9999757
levels O 0 0.0010964756
were O 0 0.0009350508
estimated O 0 0.0014716744
. O 0 0.0024649762

The O 0 0.0017852342
administration O 0 0.002812253
of O 0 0.0028436235
phenobarbitone B-Chemical 0 0.9999943
and O 0 0.008205999
carbamazepine B-Chemical 1 0.9999981
for O 0 0.00042895405
21days O 0 0.009866505
caused O 0 0.00018632594
a O 0 0.000241093
significant O 0 0.00019164114
impairment B-Disease 0 0.45801374
of I-Disease 0 0.00022634328
learning I-Disease 0 0.0017227943
and I-Disease 0 0.00024509756
memory I-Disease 0 0.05091095
as O 0 0.0002853805
well O 0 0.00027529645
as O 0 0.00036888823
an O 0 0.00066898024
increased O 0 0.0015319649
oxidative O 0 0.6096848
stress O 0 0.26620072
. O 0 0.004057909

Concomitant O 0 0.04684139
curcumin B-Chemical 0 0.99969506
administration O 0 0.0064259074
prevented O 0 0.0017933658
the O 0 0.00077099557
cognitive B-Disease 0 0.9759142
impairment I-Disease 0 0.5687986
and O 0 0.00045105754
decreased O 0 0.0005584273
the O 0 0.00026881296
increased O 0 0.0006436093
oxidative O 0 0.25345007
stress O 0 0.019966293
induced O 0 0.00043727813
by O 0 0.0004921203
these O 0 0.00082766137
antiepileptic O 0 0.99818665
drugs O 0 0.09942928
. O 0 0.0030832158

Curcumin B-Chemical 0 0.99984133
co O 0 0.85625947
- O 0 0.1525975
administration O 0 0.0033036561
did O 0 0.0008810448
not O 0 0.00045860242
cause O 0 0.00047963433
any O 0 0.00023119035
significant O 0 0.00023594046
alteration O 0 0.0002673301
in O 0 0.00018155895
the O 0 0.0001825712
serum O 0 0.004375863
concentrations O 0 0.00048247867
of O 0 0.00031968203
both O 0 0.00051586225
phenobarbitone B-Chemical 0 0.9999939
as O 0 0.0007277812
well O 0 0.00078684033
as O 0 0.0019698422
carbamazepine B-Chemical 1 0.9999882
. O 0 0.005200307

These O 0 0.0018635846
results O 0 0.0013922614
show O 0 0.00093596795
that O 0 0.0010722015
curcumin B-Chemical 0 0.99980503
has O 0 0.00040082386
beneficial O 0 0.000401402
effect O 0 0.00021023478
in O 0 0.0001991214
mitigating O 0 0.000266094
the O 0 0.00013996335
deterioration B-Disease 0 0.0031358479
of I-Disease 0 0.00021881756
cognitive I-Disease 0 0.78096616
functions I-Disease 0 0.00014049861
and O 0 0.00023403605
oxidative O 0 0.2834701
damage O 0 0.020450925
in O 0 9.154959e-05
rats O 0 0.00017061294
treated O 0 0.00026955624
with O 0 0.00039672456
phenobarbitone B-Chemical 0 0.9999993
and O 0 0.0030509387
carbamazepine B-Chemical 1 0.9999994
without O 0 0.00035706063
significantly O 0 0.00035812822
altering O 0 0.00030589526
their O 0 0.00054212473
serum O 0 0.0423524
concentrations O 0 0.003456799
. O 0 0.0028294176

The O 0 0.0018615277
findings O 0 0.0017667278
suggest O 0 0.00085360144
that O 0 0.0013007349
curcumin B-Chemical 0 0.9998716
can O 0 0.0005633048
be O 0 0.00034723867
considered O 0 0.00023994662
as O 0 0.00018054488
a O 0 0.00019584662
potential O 0 0.000101233854
safe O 0 0.00015643369
and O 0 0.000113810696
effective O 0 0.00011656467
adjuvant O 0 0.0006549119
to O 0 0.00021059411
phenobarbitone B-Chemical 0 0.99999845
and O 0 0.0016399903
carbamazepine B-Chemical 1 0.9999993
therapy O 0 0.00044749046
in O 0 0.00012326486
preventing O 0 0.00021217282
cognitive B-Disease 0 0.9762021
impairment I-Disease 0 0.56567746
associated O 0 0.00047596294
with O 0 0.000535922
these O 0 0.00082505814
drugs O 0 0.026670163
. O 0 0.002719244

Can O 0 0.022053093
angiogenesis O 0 0.78223616
be O 0 0.0020153788
a O 0 0.001500665
target O 0 0.0006143322
of O 0 0.00082850293
treatment O 0 0.0008313036
for O 0 0.0009765872
ribavirin B-Chemical 0 0.9986243
associated O 0 0.0081542665
hemolytic B-Disease 0 0.9999572
anemia I-Disease 0 0.99996126
? O 0 0.11078559

BACKGROUND O 0 0.018366208
/ O 0 0.010210621
AIMS O 0 0.010619384
: O 0 0.0019028643
Recently O 0 0.00083110435
ribavirin B-Chemical 0 0.9953825
has O 0 0.0003396244
been O 0 0.0002897183
found O 0 0.00025238827
to O 0 0.00020912559
inhibit O 0 0.0002453952
angiogenesis O 0 0.8000776
and O 0 0.00024301148
a O 0 0.00023056078
number O 0 0.0001071902
of O 0 0.00021185828
angiogenesis O 0 0.72972834
inhibitors O 0 0.00032106962
such O 0 0.00014750446
as O 0 0.00024862922
sunitinib B-Chemical 0 0.9998128
and O 0 0.00043890558
sorafenib B-Chemical 0 0.9996582
have O 0 0.00021591583
been O 0 0.00022026985
found O 0 0.00029429508
to O 0 0.00040609995
cause O 0 0.0013485316
acute O 0 0.80449766
hemolysis B-Disease 0 0.9998229
. O 0 0.0046505183

We O 0 0.002156876
aimed O 0 0.0013525742
to O 0 0.00070079794
investigate O 0 0.00024415084
whether O 0 0.00017953482
there O 0 0.00028407964
is O 0 0.00024694143
a O 0 0.0003016407
relation O 0 0.00013755808
between O 0 0.00022942488
hemoglobin O 0 0.89104825
, O 0 0.0020999266
haptoglobin O 0 0.9915535
and O 0 0.00064077263
angiogenesis O 0 0.9696184
soluble O 0 0.0033503182
markers O 0 0.0005258933
which O 0 0.00021088768
are O 0 0.00012156819
modifiable O 0 0.0003175996
and O 0 0.00018478333
can O 0 0.0001295604
help O 0 0.00023708896
in O 0 0.00027011067
developing O 0 0.000613946
strategies O 0 0.00059835677
against O 0 0.00091773
anemia B-Disease 0 0.99970645
. O 0 0.0049379687

METHODS O 0 0.004207981
: O 0 0.0031671247
Fourteen O 0 0.0020828438
patients O 0 0.0015948481
chronically B-Disease 0 0.002541923
infected I-Disease 0 0.0009335774
with I-Disease 0 0.0022044017
hepatitis I-Disease 0 0.99999475
C I-Disease 0 0.9999335
virus I-Disease 0 0.013636251
were O 0 0.00044762704
treated O 0 0.0007288841
by O 0 0.000619293
pegylated B-Chemical 0 0.99703574
interferon I-Chemical 0 0.99993217
alpha I-Chemical 0 0.92195517
2a I-Chemical 0 0.0015069355
and O 0 0.0017986798
ribavirin B-Chemical 0 0.99616927
. O 0 0.0037243739

Serum O 0 0.8555988
hemoglobin O 0 0.9664293
, O 0 0.012680301
haptoglobin O 0 0.9828452
and O 0 0.0022438124
angiogenesis O 0 0.8648457
markers O 0 0.0017898967
of O 0 0.0012214594
vascular O 0 0.99817073
endothelial O 0 0.99964404
growth O 0 0.15084851
factor O 0 0.03631238
and O 0 0.0005483901
angiopoetin O 0 0.17403324
- O 0 0.0032732517
2 O 0 0.00023672667
were O 0 0.00014937592
investigated O 0 0.00016987986
before O 0 0.00015796527
and O 0 0.00040360718
after O 0 0.0004317918
therapy O 0 0.0015293013
. O 0 0.0023837632

RESULTS O 0 0.005040827
: O 0 0.00334332
We O 0 0.0009148578
observed O 0 0.0007249121
a O 0 0.0008910448
significant O 0 0.0005650367
decrease O 0 0.0006409672
in O 0 0.0006325187
haptoglobin O 0 0.8574561
levels O 0 0.00032092427
at O 0 0.00021155429
the O 0 0.00020491486
end O 0 0.0001979657
of O 0 0.00043353127
the O 0 0.00047733236
treatment O 0 0.00077178475
period O 0 0.0010644911
. O 0 0.0027304005

Hemoglobin O 0 0.99349207
levels O 0 0.0045348783
also O 0 0.0033740397
decreased O 0 0.005140699
but O 0 0.004306892
insignificantly O 0 0.09832263
by O 0 0.0036548178
treatment O 0 0.0042465543
. O 0 0.0066923625

In O 0 0.0019004336
contrast O 0 0.0020623934
with O 0 0.001288885
the O 0 0.00084788393
literature O 0 0.0015587171
, O 0 0.0014616457
serum O 0 0.008342482
levels O 0 0.00041856355
of O 0 0.00060660124
angiogenesis O 0 0.8716851
factors O 0 0.0007844993
did O 0 0.0003224067
not O 0 0.00020469577
change O 0 0.00022453217
significantly O 0 0.0003174346
by O 0 0.00044738085
pegylated B-Chemical 0 0.9930496
interferon I-Chemical 0 0.999871
and O 0 0.001846335
ribavirin B-Chemical 0 0.9983236
therapy O 0 0.002512283
. O 0 0.0024251265

We O 0 0.0028217994
found O 0 0.0019040954
no O 0 0.0012795207
correlation O 0 0.001108906
of O 0 0.001684115
angiogenesis O 0 0.9294493
soluble O 0 0.0066328063
markers O 0 0.0016931324
with O 0 0.0009911432
either O 0 0.0012439194
hemoglobin O 0 0.90534174
or O 0 0.0024904986
haptoglobin O 0 0.97848105
. O 0 0.005406787

CONCLUSION O 0 0.022338293
: O 0 0.004811794
This O 0 0.0016049417
is O 0 0.0005696844
the O 0 0.00036995427
first O 0 0.00024282598
study O 0 0.000324893
in O 0 0.00021318227
the O 0 0.00017707709
literature O 0 0.000330409
investigating O 0 0.0001395304
a O 0 0.00022198436
link O 0 0.000114772265
between O 0 0.00019763038
angiogenesis O 0 0.91270304
soluble O 0 0.0026069216
markers O 0 0.00059798564
and O 0 0.00038645652
ribavirin B-Chemical 0 0.9995883
induced O 0 0.00052302115
anemia B-Disease 0 0.9999684
in O 0 0.00029465754
patients O 0 0.0012734223
with O 0 0.0011386339
hepatitis B-Disease 0 0.9999989
C I-Disease 0 0.99997437
and O 0 0.00071665156
we O 0 0.00015743775
could O 0 0.00019757627
not O 0 0.00028523116
find O 0 0.00037748064
any O 0 0.0006563772
relation O 0 0.0009819055
. O 0 0.0027603772

Future O 0 0.0038152188
research O 0 0.0025738678
with O 0 0.0014357851
larger O 0 0.0012647513
number O 0 0.00053681177
of O 0 0.00059375446
patients O 0 0.00081075035
is O 0 0.00023074441
needed O 0 0.00017713993
to O 0 0.00016759377
find O 0 0.00014988326
out O 0 0.00017937808
modifiable O 0 0.00042514654
factors O 0 0.0003554093
that O 0 0.00015052491
will O 0 0.00013762011
improve O 0 0.00013383554
the O 0 0.00018453173
safety O 0 0.00034335646
of O 0 0.00070163223
ribavirin B-Chemical 0 0.9949744
therapy O 0 0.0023257192
. O 0 0.0024085715

Reduction O 0 0.0039512427
in O 0 0.0015956014
injection O 0 0.0011735164
pain B-Disease 0 0.01117243
using O 0 0.00076057133
buffered O 0 0.0027324215
lidocaine B-Chemical 0 0.9994049
as O 0 0.0005209836
a O 0 0.0005866561
local O 0 0.0004995213
anesthetic O 0 0.0021270493
before O 0 0.0003338916
cardiac O 0 0.0019259948
catheterization O 0 0.0029300118
. O 0 0.0025147635

Previous O 0 0.0020213164
reports O 0 0.0017925696
have O 0 0.00090210664
suggested O 0 0.0005877309
that O 0 0.00049016584
pain B-Disease 0 0.019003995
associated O 0 0.0003700266
with O 0 0.0002547724
the O 0 0.00017433891
injection O 0 0.00018725243
of O 0 0.000372019
lidocaine B-Chemical 0 0.9998418
is O 0 0.00019834453
related O 0 0.00013881775
to O 0 0.00021569918
the O 0 0.00032806027
acidic O 0 0.0020211344
pH O 0 0.008149369
of O 0 0.0009110868
the O 0 0.001014787
solution O 0 0.0040030284
. O 0 0.003504539

To O 0 0.0011934413
determine O 0 0.00056778116
if O 0 0.0005957845
the O 0 0.00050381944
addition O 0 0.0002953618
of O 0 0.00051349297
a O 0 0.0007300301
buffering O 0 0.003508316
solution O 0 0.00074354094
to O 0 0.00014754047
adjust O 0 0.00010281758
the O 0 0.00014623189
pH O 0 0.0032007564
of O 0 0.00029752924
lidocaine B-Chemical 0 0.9998419
into O 0 7.071941e-05
the O 0 7.0075424e-05
physiologic O 0 0.00016399441
range O 0 8.1794045e-05
would O 0 5.5565975e-05
reduce O 0 5.5539167e-05
pain B-Disease 0 0.0017791026
during O 0 5.7770794e-05
injection O 0 7.196505e-05
, O 0 0.00012497007
we O 0 4.3127904e-05
performed O 0 8.079895e-05
a O 0 0.00016866336
blinded O 0 0.00030335004
randomized O 0 0.00040805654
study O 0 0.00017512616
in O 0 0.00017407529
patients O 0 0.00044118913
undergoing O 0 0.0004240135
cardiac O 0 0.0016865492
catheterization O 0 0.0025727933
. O 0 0.001970917

Twenty O 0 0.00507936
patients O 0 0.0027212957
were O 0 0.00084780727
asked O 0 0.0004702532
to O 0 0.00030991237
quantify O 0 0.00016651918
the O 0 0.00021355049
severity O 0 0.0004921518
of O 0 0.00021128537
pain B-Disease 0 0.0018915982
after O 0 6.437041e-05
receiving O 0 0.00012893554
standard O 0 0.00019190427
lidocaine B-Chemical 0 0.9996216
in O 0 0.00014286685
one O 0 0.00013064677
femoral O 0 0.0027305551
area O 0 0.00028593908
and O 0 0.00025499988
buffered O 0 0.0013256914
lidocaine B-Chemical 0 0.9996013
in O 0 0.0002921272
the O 0 0.00030538006
opposite O 0 0.00078527635
femoral O 0 0.018267622
area O 0 0.0022662068
. O 0 0.002530348

The O 0 0.0015167493
mean O 0 0.0012307438
pain B-Disease 0 0.00592421
score O 0 0.0006364486
for O 0 0.00048919383
buffered O 0 0.002153036
lidocaine B-Chemical 0 0.99964225
was O 0 0.00023043135
significantly O 0 0.00018598408
lower O 0 0.0001597653
than O 0 9.160059e-05
the O 0 7.179993e-05
mean O 0 7.320227e-05
score O 0 8.306045e-05
for O 0 8.717685e-05
standard O 0 0.00022416744
lidocaine B-Chemical 0 0.9996978
( O 0 0.00037444886
2 O 0 0.00015567506
. O 0 0.00011873723
7 O 0 0.00011965778
+ O 0 0.0005877063
/ O 0 0.0013604304
- O 0 0.0014780421
1 O 0 0.00020577808
. O 0 0.00013605437
9 O 0 0.00011513851
vs O 0 0.00020098138
. O 0 0.0001453684
3 O 0 0.00013038059
. O 0 0.00015345846
8 O 0 0.00019157099
+ O 0 0.00078460097
/ O 0 0.001608099
- O 0 0.0017124562
2 O 0 0.00035924857
. O 0 0.0002960542
2 O 0 0.00037253805
, O 0 0.0007443098
P O 0 0.0070164916
= O 0 0.0016470152
0 O 0 0.001052733
. O 0 0.0011836111
03 O 0 0.007021104
) O 0 0.0047347955
. O 0 0.004576105

The O 0 0.0026160842
pH O 0 0.008243253
adjustment O 0 0.0011371229
of O 0 0.0010118247
standard O 0 0.0012915847
lidocaine B-Chemical 0 0.99972636
can O 0 0.00031440498
be O 0 0.00023156714
accomplished O 0 0.00023117602
easily O 0 0.00014684096
in O 0 0.00010800897
the O 0 8.290299e-05
catheterization O 0 0.00024784458
laboratory O 0 8.945343e-05
before O 0 3.9288218e-05
injection O 0 6.3214306e-05
and O 0 8.146632e-05
results O 0 7.718363e-05
in O 0 0.00010324359
a O 0 0.00017952027
reduction O 0 0.00017037414
of O 0 0.00016699206
the O 0 0.00016612856
pain B-Disease 0 0.016580818
occurring O 0 0.00020246835
during O 0 0.00015712762
the O 0 0.00029248753
infiltration O 0 0.006939088
of O 0 0.0009901206
tissues O 0 0.0022106846
. O 0 0.0027353882

Effect O 0 0.004937069
of O 0 0.0057793395
L B-Chemical 0 0.94542176
- I-Chemical 0 0.31583232
alpha I-Chemical 0 0.9588207
- I-Chemical 0 0.5233609
glyceryl I-Chemical 0 0.9998816
- I-Chemical 0 0.13738565
phosphorylcholine I-Chemical 0 0.05310986
on O 0 0.0011111865
amnesia B-Disease 0 0.9996419
caused O 0 0.0020272397
by O 0 0.0036627653
scopolamine B-Chemical 0 0.9999782
. O 0 0.007418103

The O 0 0.0021655702
present O 0 0.0015647344
study O 0 0.0014710774
was O 0 0.00078947283
carried O 0 0.00053230586
out O 0 0.0003775837
to O 0 0.00028402335
test O 0 0.00035565824
the O 0 0.00019400401
effects O 0 0.00025417842
of O 0 0.00053709897
L B-Chemical 0 0.96300715
- I-Chemical 0 0.21763021
alpha I-Chemical 0 0.9371711
- I-Chemical 0 0.1581701
glycerylphosphorylcholine I-Chemical 0 0.97380924
( O 0 0.0017541567
L B-Chemical 0 0.9485704
- I-Chemical 0 0.10869956
alpha I-Chemical 0 0.87986636
- I-Chemical 0 0.1304291
GFC I-Chemical 0 0.99869126
) O 0 0.0009293092
on O 0 0.00021947759
memory B-Disease 2 0.9719367
impairment I-Disease 2 0.99633515
induced O 0 0.0008618206
by O 0 0.0015412596
scopolamine B-Chemical 0 0.99999356
in O 0 0.0022443496
man O 0 0.03233548
. O 0 0.0033744643

Thirty O 0 0.008573649
- O 0 0.0070627956
two O 0 0.0011503345
healthy O 0 0.0031919258
young O 0 0.002614686
volunteers O 0 0.0015233627
were O 0 0.00048733657
randomly O 0 0.000294122
allocated O 0 0.00048147002
to O 0 0.00042290258
four O 0 0.0004216816
different O 0 0.0007210544
groups O 0 0.0021070936
. O 0 0.0037152076

They O 0 0.004292673
were O 0 0.0015353669
given O 0 0.0007168565
a O 0 0.00082365755
ten O 0 0.00034238023
day O 0 0.00033541597
pretreatment O 0 0.0012080537
with O 0 0.00044675783
either O 0 0.00053789484
L B-Chemical 0 0.93476224
- I-Chemical 0 0.14790782
alpha I-Chemical 0 0.9053443
- I-Chemical 0 0.12055488
GFC I-Chemical 0 0.99764097
or O 0 0.00025521245
placebo O 0 0.0029959423
, O 0 0.0003128105
p O 0 0.0003295584
. O 0 0.00017444766
o O 0 0.00085623545
. O 0 0.00019451411
, O 0 0.0002660146
and O 0 0.00014140502
on O 0 9.044134e-05
the O 0 0.00011686931
eleventh O 0 0.0003555501
day O 0 0.0001456752
either O 0 0.0003687026
scopolamine B-Chemical 0 0.99999475
or O 0 0.00050239323
placebo O 0 0.011793275
, O 0 0.00097603275
i O 0 0.001351471
. O 0 0.0011231258
m O 0 0.00566285
. O 0 0.003277389

Before O 0 0.0035607724
and O 0 0.0030676154
0 O 0 0.0024057054
. O 0 0.001333944
5 O 0 0.000934524
, O 0 0.0012730318
1 O 0 0.0007561741
, O 0 0.00087610475
2 O 0 0.00051169645
, O 0 0.0005964562
3 O 0 0.00028257212
, O 0 0.00040939922
and O 0 0.00021561282
6 O 0 0.00013402723
h O 0 0.00015516911
after O 0 7.938876e-05
injection O 0 0.00011381624
the O 0 0.00013103554
subjects O 0 0.00029053484
were O 0 0.00019081606
given O 0 0.0001891149
attention O 0 0.0008905898
and O 0 0.00077723525
mnemonic O 0 0.00903757
tests O 0 0.0038115543
. O 0 0.0032668218

The O 0 0.0017618571
findings O 0 0.0016828792
of O 0 0.0011827237
this O 0 0.0008022713
study O 0 0.0005527667
indicate O 0 0.00020260699
that O 0 0.00023125342
the O 0 0.00027224078
drug O 0 0.004902355
is O 0 0.00016510102
able O 0 0.000121866724
to O 0 0.00014173008
antagonize O 0 0.00025916565
impairment B-Disease 0 0.16437007
of I-Disease 0 0.0003307667
attention I-Disease 0 0.0012905248
and I-Disease 0 0.00044261062
memory I-Disease 0 0.18826208
induced O 0 0.0010205155
by O 0 0.0022729416
scopolamine B-Chemical 0 0.999985
. O 0 0.0049971323

Safety O 0 0.015431563
of O 0 0.010193027
capecitabine B-Chemical 1 0.99449027
: O 0 0.011982198
a O 0 0.008482595
review O 0 0.010667607
. O 0 0.011034725

IMPORTANCE O 0 0.0073710633
OF O 0 0.0040948316
THE O 0 0.002708947
FIELD O 0 0.032902554
: O 0 0.0027706218
Fluoropyrimidines B-Chemical 0 0.45420748
, O 0 0.0010729486
in O 0 0.00038834164
particular O 0 0.0002538002
5 B-Chemical 0 0.00036745938
- I-Chemical 0 0.002867535
fluorouracil I-Chemical 0 0.99953365
( O 0 0.0005890038
5 B-Chemical 0 0.00024967588
- I-Chemical 0 0.0015393154
FU I-Chemical 0 0.18456659
) O 0 0.0005562135
, O 0 0.00029959975
have O 0 0.00011989912
been O 0 0.00011076316
the O 0 9.67645e-05
mainstay O 0 0.00020593748
of O 0 0.0001276821
treatment O 0 0.000114567905
for O 0 7.890219e-05
several O 0 8.950471e-05
solid O 0 0.0010367202
tumors B-Disease 0 0.6507314
, O 0 0.00044279994
including O 0 0.00018416347
colorectal B-Disease 0 0.84158975
, I-Disease 0 0.00084592303
breast I-Disease 0 0.10466585
and I-Disease 0 0.0003156315
head I-Disease 0 0.0016799162
and I-Disease 0 0.0004755743
neck I-Disease 0 0.123071715
cancers I-Disease 0 0.96351
, O 0 0.000887508
for O 0 0.00040301314
> O 0 0.0014297562
40 O 0 0.0010791606
years O 0 0.001690466
. O 0 0.0025873294

AREAS O 0 0.008315245
COVERED O 0 0.008244979
IN O 0 0.007215077
THIS O 0 0.0069628092
REVIEW O 0 0.004608435
: O 0 0.0015526806
This O 0 0.00067121576
article O 0 0.00053094816
reviews O 0 0.000387808
the O 0 0.00019616321
pharmacology O 0 0.00062760065
and O 0 0.00020033258
efficacy O 0 0.00021577942
of O 0 0.00037342196
capecitabine B-Chemical 1 0.99928313
with O 0 0.00033163792
a O 0 0.000413961
special O 0 0.00032778297
emphasis O 0 0.000630415
on O 0 0.00040600743
its O 0 0.0010511857
safety O 0 0.0015959425
. O 0 0.0026620605

WHAT O 0 0.012151291
THE O 0 0.006191459
READER O 0 0.5433237
WILL O 0 0.111754045
GAIN O 0 0.07861896
: O 0 0.0016448274
The O 0 0.00038228536
reader O 0 0.0023058557
will O 0 0.00022436671
gain O 0 0.00022849884
better O 0 0.0001838971
insight O 0 0.00013672754
into O 0 8.0966325e-05
the O 0 8.8919325e-05
safety O 0 0.00012649872
of O 0 0.00020254115
capecitabine B-Chemical 1 0.99877053
in O 0 0.00011623968
special O 0 0.00011108683
populations O 0 0.00014041892
such O 0 0.00010900122
as O 0 0.00013530682
patients O 0 0.0003214617
with O 0 0.00020916268
advanced O 0 0.0017650014
age O 0 0.000571533
, O 0 0.0008587246
renal B-Disease 0 0.65112436
and I-Disease 0 0.0009901337
kidney I-Disease 0 0.29185542
disease I-Disease 0 0.6913821
. O 0 0.003341106

We O 0 0.0027422912
also O 0 0.0015679753
explore O 0 0.00084178126
different O 0 0.00071869144
dosing O 0 0.00095922215
and O 0 0.0007640619
schedules O 0 0.0009423327
of O 0 0.0016590331
capecitabine B-Chemical 1 0.99671715
administration O 0 0.0045134076
. O 0 0.0041444683

TAKE O 0 0.06696292
HOME O 0 0.2494424
MESSAGE O 0 0.0276949
: O 0 0.005857203
Capecitabine B-Chemical 0 0.99694556
is O 0 0.0005743442
an O 0 0.0005577976
oral O 0 0.0016337833
prodrug O 0 0.00458849
of O 0 0.0003053632
5 B-Chemical 0 0.00028027056
- I-Chemical 0 0.0021296232
FU I-Chemical 0 0.16604584
and O 0 0.00018287734
was O 0 0.00012820376
developed O 0 0.00014234008
to O 0 8.662842e-05
fulfill O 0 7.571543e-05
the O 0 8.1372295e-05
need O 0 8.375704e-05
for O 0 8.0370235e-05
a O 0 0.00016653126
more O 0 0.00015000794
convenient O 0 0.00012496089
therapy O 0 0.00015662276
and O 0 0.000110827175
provide O 0 9.55523e-05
an O 0 0.00019282925
improved O 0 0.0003252113
safety O 0 0.00036691123
/ O 0 0.0013455809
efficacy O 0 0.0007323627
profile O 0 0.0012965136
. O 0 0.0027266522

It O 0 0.0041523264
has O 0 0.000997035
shown O 0 0.00043745217
promising O 0 0.00045605697
results O 0 0.00034100862
alone O 0 0.00037502794
or O 0 0.00023954498
in O 0 0.00019001089
combination O 0 0.0002120802
with O 0 0.00016807915
other O 0 0.00014920681
chemotherapeutic O 0 0.0014927178
agents O 0 0.00053925626
in O 0 0.00026546788
colorectal B-Disease 0 0.8492224
, I-Disease 0 0.00093002623
breast I-Disease 0 0.1616411
, I-Disease 0 0.0007922031
pancreaticobiliary I-Disease 0 0.45258945
, I-Disease 0 0.0010461005
gastric I-Disease 0 0.08497999
, I-Disease 0 0.0009819864
renal I-Disease 0 0.69580466
cell I-Disease 0 0.0007966092
and I-Disease 0 0.0006054536
head I-Disease 0 0.0030616017
and I-Disease 0 0.0012898736
neck I-Disease 0 0.20881873
cancers I-Disease 0 0.9798418
. O 0 0.0042917607

The O 0 0.0020270206
most O 0 0.0020403264
commonly O 0 0.0014213867
reported O 0 0.0009956842
toxic O 0 0.0035483222
effects O 0 0.00046003592
of O 0 0.0007557397
capecitabine B-Chemical 1 0.9996685
are O 0 0.00037691605
diarrhea B-Disease 0 0.8985741
, O 0 0.0016252564
nausea B-Disease 0 0.9998311
, O 0 0.0022220628
vomiting B-Disease 0 0.9989924
, O 0 0.0016064796
stomatitis B-Disease 0 0.93238664
and O 0 0.0006443786
hand B-Disease 2 0.0012026299
- I-Disease 2 0.036361057
foot I-Disease 2 0.10004254
syndrome I-Disease 2 0.9737375
. O 0 0.004199178

Capecitabine B-Chemical 0 0.99703574
has O 0 0.0015643262
a O 0 0.0015081621
well O 0 0.000821652
- O 0 0.0022301332
established O 0 0.00036602397
safety O 0 0.0003075659
profile O 0 0.00024926555
and O 0 0.00026395207
can O 0 0.0001487857
be O 0 0.00015361335
given O 0 0.00010477371
safely O 0 0.00019541087
to O 0 0.00012334176
patients O 0 0.00029225787
with O 0 0.00021631003
advanced O 0 0.0014478934
age O 0 0.0006162378
, O 0 0.00095798087
hepatic B-Disease 0 0.88542926
and I-Disease 0 0.0012955556
renal I-Disease 0 0.95251995
dysfunctions I-Disease 0 0.84008235
. O 0 0.0033538565

Levodopa B-Chemical 0 0.99989676
- O 0 0.18930471
induced O 0 0.0036621075
dyskinesias B-Disease 0 0.9999236
in O 0 0.00091155735
patients O 0 0.0012566749
with O 0 0.0008044036
Parkinson B-Disease 0 0.9968472
' I-Disease 0 0.0008958785
s I-Disease 0 0.0006785091
disease I-Disease 0 0.0593666
: O 0 0.00069029105
filling O 0 0.0009504609
the O 0 0.00031772346
bench O 0 0.0013471524
- O 0 0.0022405367
to O 0 0.0006005787
- O 0 0.0030129505
bedside O 0 0.0026533825
gap O 0 0.0028400251
. O 0 0.003657792

Levodopa B-Chemical 0 0.9997712
is O 0 0.0021105048
the O 0 0.0011015481
most O 0 0.001009071
effective O 0 0.00070649706
drug O 0 0.0029135186
for O 0 0.00038072892
the O 0 0.0003983416
treatment O 0 0.0005676294
of O 0 0.0011609792
Parkinson B-Disease 0 0.9957741
' I-Disease 0 0.0027569707
s I-Disease 0 0.0029080051
disease I-Disease 0 0.26823014
. O 0 0.0042501735

However O 0 0.0030197622
, O 0 0.0033354799
the O 0 0.0011680779
long O 0 0.0011071459
- O 0 0.0025230343
term O 0 0.0005445546
use O 0 0.00039832754
of O 0 0.00057729945
this O 0 0.0011801348
dopamine B-Chemical 0 0.9998348
precursor O 0 0.0011733857
is O 0 0.00028811075
complicated O 0 0.00075143634
by O 0 0.0003256506
highly O 0 0.00041636088
disabling O 0 0.07545364
fluctuations O 0 0.0010785599
and O 0 0.0019299282
dyskinesias B-Disease 0 0.9998216
. O 0 0.0037764793

Although O 0 0.0016059002
preclinical O 0 0.002383451
and O 0 0.0010526284
clinical O 0 0.0012302891
findings O 0 0.00044027143
suggest O 0 0.00018836232
pulsatile O 0 0.000958258
stimulation O 0 0.00021248296
of O 0 0.0003927012
striatal O 0 0.0873415
postsynaptic O 0 0.0043309634
receptors O 0 0.0004355409
as O 0 0.00014912915
a O 0 0.00018676367
key O 0 9.1076254e-05
mechanism O 0 0.000120399105
underlying O 0 0.0010975678
levodopa B-Chemical 0 0.999997
- O 0 0.041933253
induced O 0 0.00057679036
dyskinesias B-Disease 0 0.9999831
, O 0 0.0007140835
their O 0 0.00028363205
pathogenesis O 0 0.00064327836
is O 0 0.00038047877
still O 0 0.0006160152
unclear O 0 0.0010327573
. O 0 0.002722049

In O 0 0.001957874
recent O 0 0.0018672718
years O 0 0.0017020556
, O 0 0.0013100085
evidence O 0 0.00047171477
from O 0 0.00038492403
animal O 0 0.00036917988
models O 0 0.00031722436
of O 0 0.00059939787
Parkinson B-Disease 0 0.99834764
' I-Disease 0 0.000758631
s I-Disease 0 0.0005190293
disease I-Disease 0 0.06280933
has O 0 8.683129e-05
provided O 0 7.429626e-05
important O 0 6.648388e-05
information O 0 9.119148e-05
to O 0 7.508886e-05
understand O 0 6.4764536e-05
the O 0 7.661094e-05
effect O 0 8.886271e-05
of O 0 0.00014459563
specific O 0 9.1211405e-05
receptor O 0 0.00044563855
and O 0 0.00016979886
post O 0 0.00016335375
- O 0 0.0015256874
receptor O 0 0.00046049393
molecular O 0 0.00034532824
mechanisms O 0 0.00017032215
underlying O 0 0.00037526665
the O 0 0.00029092593
development O 0 0.0007534465
of O 0 0.0018851829
dyskinetic B-Disease 0 0.9999857
movements I-Disease 0 0.124508984
. O 0 0.0034863635

Recent O 0 0.003307815
preclinical O 0 0.0031397943
and O 0 0.0013762709
clinical O 0 0.0017970984
data O 0 0.0005527033
from O 0 0.00027415235
promising O 0 0.0002465768
lines O 0 0.00029957577
of O 0 0.0002786158
research O 0 0.00031004244
focus O 0 0.00020353872
on O 0 8.738293e-05
the O 0 8.5946296e-05
differential O 0 0.000109829845
role O 0 5.2358966e-05
of O 0 0.00014083956
presynaptic O 0 0.0005776673
versus O 0 0.00010402111
postsynaptic O 0 0.00073782465
mechanisms O 0 0.00012642719
, O 0 0.0016056837
dopamine B-Chemical 0 0.99992216
receptor O 0 0.0043660724
subtypes O 0 0.0013504782
, O 0 0.0012593182
ionotropic O 0 0.9706296
and O 0 0.0018286268
metabotropic O 0 0.99998677
glutamate B-Chemical 0 0.9999639
receptors O 0 0.002810923
, O 0 0.00041755932
and O 0 0.00018062895
non O 0 0.00049657427
- O 0 0.020834712
dopaminergic O 0 0.008102397
neurotransmitter O 0 0.0051527056
systems O 0 0.00015238902
in O 0 0.00014327776
the O 0 0.00017627068
pathophysiology O 0 0.0070575667
of O 0 0.0011444035
levodopa B-Chemical 0 0.99999285
- O 0 0.050173137
induced O 0 0.0020402174
dyskinesias B-Disease 0 0.99992
. O 0 0.0038134595

Effects O 0 0.004305839
of O 0 0.0039945785
pallidal O 0 0.79406947
neurotensin B-Chemical 0 0.99496895
on O 0 0.0017631708
haloperidol B-Chemical 1 0.99999774
- O 0 0.30367965
induced O 0 0.0027729506
parkinsonian B-Disease 2 0.999998
catalepsy I-Disease 0 0.9999982
: O 0 0.003270403
behavioral O 0 0.0018503589
and O 0 0.00061515084
electrophysiological O 0 0.0017027127
studies O 0 0.001603744
. O 0 0.0026694771

OBJECTIVE O 0 0.02904441
: O 0 0.0062741404
The O 0 0.0015950334
globus O 0 0.00835017
pallidus O 0 0.008263348
plays O 0 0.0005134536
a O 0 0.0008645843
critical O 0 0.00045853798
role O 0 0.0004428736
in O 0 0.0009914945
movement O 0 0.0024363534
regulation O 0 0.0014974517
. O 0 0.0044253096

Previous O 0 0.0020071713
studies O 0 0.0018444159
have O 0 0.0008791692
indicated O 0 0.00050064217
that O 0 0.00046032763
the O 0 0.0005639999
globus O 0 0.013721429
pallidus O 0 0.017657049
receives O 0 0.00020795107
neurotensinergic O 0 0.00038503594
innervation O 0 0.0003949177
from O 0 0.000121156445
the O 0 0.00013316202
striatum O 0 0.0010175732
, O 0 0.0002586298
and O 0 0.00016753655
systemic O 0 0.019141458
administration O 0 0.0003274475
of O 0 0.00021251073
a O 0 0.0005724369
neurotensin B-Chemical 0 0.98838216
analog O 0 0.0006479568
could O 0 0.0002547583
produce O 0 0.00041511148
antiparkinsonian O 0 0.939984
effects O 0 0.0013285181
. O 0 0.0026554489

The O 0 0.0018749145
present O 0 0.0012597003
study O 0 0.0010404285
aimed O 0 0.0006095036
to O 0 0.00036307465
investigate O 0 0.00016084874
the O 0 0.00024009672
effects O 0 0.0003164951
of O 0 0.0006487716
pallidal O 0 0.7238067
neurotensin B-Chemical 0 0.9918206
on O 0 0.0006905911
haloperidol B-Chemical 1 0.9999982
- O 0 0.13973778
induced O 0 0.0021343406
parkinsonian B-Disease 2 0.9999856
symptoms I-Disease 0 0.8754295
. O 0 0.0033667022

METHODS O 0 0.004803961
: O 0 0.0036441458
Behavioral O 0 0.0027854512
experiments O 0 0.0005814803
and O 0 0.00064025837
electrophysiological O 0 0.0009327804
recordings O 0 0.0005311271
were O 0 0.00042047395
performed O 0 0.00043136143
in O 0 0.0005660537
the O 0 0.0006992215
present O 0 0.0011055472
study O 0 0.0025407812
. O 0 0.003970065

RESULTS O 0 0.004370747
: O 0 0.003345992
Bilateral O 0 0.003189072
infusions O 0 0.0018768705
of O 0 0.00090593373
neurotensin B-Chemical 0 0.80893797
into O 0 0.00033262582
the O 0 0.00043647978
globus O 0 0.01640121
pallidus O 0 0.12009606
reversed O 0 0.0033504344
haloperidol B-Chemical 1 0.99999857
- O 0 0.23850653
induced O 0 0.0025943762
parkinsonian B-Disease 2 0.99999726
catalepsy I-Disease 0 0.9999962
in O 0 0.0017577677
rats O 0 0.0027651412
. O 0 0.0027694886

Electrophysiological O 0 0.005234889
recordings O 0 0.0014400594
showed O 0 0.0007805441
that O 0 0.00051833934
microinjection O 0 0.0007678597
of O 0 0.0008065685
neurotensin B-Chemical 0 0.9800426
induced O 0 0.000568204
excitation O 0 0.010931731
of O 0 0.00053660694
pallidal O 0 0.112015665
neurons O 0 0.00024526706
in O 0 0.00017199217
the O 0 0.00017928472
presence O 0 0.0002837394
of O 0 0.0006851804
systemic O 0 0.9547166
haloperidol B-Chemical 1 0.99999535
administration O 0 0.005903928
. O 0 0.0024933908

The O 0 0.0035763783
neurotensin B-Chemical 0 0.982415
type I-Chemical 0 0.007631073
- I-Chemical 0 0.049106926
1 I-Chemical 0 0.0015371162
receptor I-Chemical 0 0.00931219
antagonist I-Chemical 0 0.9741072
SR48692 B-Chemical 0 0.99998796
blocked O 0 0.0022066308
both O 0 0.0002820271
the O 0 0.00021000119
behavioral O 0 0.00072314224
and O 0 0.00020738994
the O 0 0.00017083417
electrophysiological O 0 0.00053272006
effects O 0 0.0003479455
induced O 0 0.00069132634
by O 0 0.0015541259
neurotensin B-Chemical 0 0.99192387
. O 0 0.0042824904

CONCLUSION O 0 0.019698482
: O 0 0.0051950873
Activation O 0 0.0020188102
of O 0 0.0018294399
pallidal O 0 0.7050686
neurotensin B-Chemical 0 0.99433064
receptors O 0 0.0022853306
may O 0 0.00039902396
be O 0 0.00034869733
involved O 0 0.00034540464
in O 0 0.0006090361
neurotensin B-Chemical 0 0.9912914
- O 0 0.009494463
induced O 0 0.0010410359
antiparkinsonian O 0 0.975752
effects O 0 0.0019050763
. O 0 0.003439344

Carmofur B-Chemical 0 0.97095495
- O 0 0.04174092
induced O 0 0.0092226155
organic B-Disease 0 0.9893706
mental I-Disease 0 0.9373925
disorders I-Disease 0 0.99784124
. O 0 0.0156817

Organic B-Disease 0 0.9927699
mental I-Disease 0 0.933443
disorder I-Disease 0 0.99945277
was O 0 0.0013688175
observed O 0 0.00064520445
in O 0 0.0005139751
a O 0 0.0006539621
29 O 0 0.00067421264
- O 0 0.0014825976
year O 0 0.00027378512
- O 0 0.00091204385
old O 0 0.00026741318
female O 0 0.00040238223
in O 0 0.00016139678
the O 0 0.00013028551
prognostic O 0 0.00029355666
period O 0 9.749407e-05
after O 0 8.460643e-05
the O 0 0.00015560427
onset O 0 0.0004337886
of O 0 0.00068973866
carmofur B-Chemical 0 0.9998078
- O 0 0.013426019
induced O 0 0.0015984032
leukoencephalopathy B-Disease 0 0.9965229
. O 0 0.0039850953

Symptoms O 0 0.0078009716
such O 0 0.0018595239
as O 0 0.0021022041
euphoria O 0 0.9982193
, O 0 0.0027562734
emotional O 0 0.1319514
lability O 0 0.33925828
and O 0 0.00062424503
puerile O 0 0.01508342
attitude O 0 0.0052779983
noted O 0 0.0003012978
in O 0 0.00018421825
the O 0 0.00014311363
patient O 0 0.00018933935
were O 0 0.00013986355
diagnosed O 0 0.0007988502
as O 0 0.0002618653
organic B-Disease 0 0.99561006
personality I-Disease 0 0.9998392
syndrome I-Disease 0 0.9984769
according O 0 0.00013025594
to O 0 9.9464574e-05
the O 0 0.000100223384
criteria O 0 0.00016014646
defined O 0 0.00015433718
in O 0 0.00022971688
the O 0 0.0003627631
DSM O 0 0.007821141
- O 0 0.00882131
III O 0 0.25239688
- O 0 0.046040453
R O 0 0.98484993
. O 0 0.0059071616

It O 0 0.0078109126
is O 0 0.003067388
referred O 0 0.0030617178
to O 0 0.0018679048
as O 0 0.0021862346
a O 0 0.004164002
frontal B-Disease 0 0.95456964
lobe I-Disease 0 0.8907712
syndrome I-Disease 0 0.9897339
. O 0 0.0072836764

Brain O 0 0.015765786
CT O 0 0.009937061
revealed O 0 0.0012504333
a O 0 0.0015143012
periventricular O 0 0.0025890241
low O 0 0.0005847365
density O 0 0.00055890594
area O 0 0.00041561932
in O 0 0.00020704555
the O 0 0.00020131872
frontal O 0 0.054280795
white O 0 0.0003756666
matter O 0 0.0002698453
and O 0 0.00016058149
moderate O 0 0.000569698
dilatation O 0 0.14837809
of O 0 0.00021044076
the O 0 0.00016448647
lateral O 0 0.0014322754
ventricles O 0 0.0074679777
especially O 0 0.00022771847
at O 0 0.00017710682
the O 0 0.00030407644
bilateral O 0 0.003363499
anterior O 0 0.008389121
horns O 0 0.007678352
. O 0 0.0029859885

Consequently O 0 0.0035199998
, O 0 0.009593532
carmofur B-Chemical 0 0.9996357
- O 0 0.036963556
induced O 0 0.0015167689
leukoencephalopathy B-Disease 0 0.9970907
may O 0 0.0007101987
uncommonly O 0 0.010922255
result O 0 0.0003762534
in O 0 0.0005561035
organic B-Disease 0 0.9929709
personality I-Disease 0 0.99956447
syndrome I-Disease 0 0.99688524
in O 0 0.00063249725
the O 0 0.0006012723
residual O 0 0.0012127449
state O 0 0.002061775
. O 0 0.003131766

It O 0 0.0073584234
may O 0 0.0025720543
be O 0 0.001788319
attributed O 0 0.0011883038
to O 0 0.0009011316
the O 0 0.00081223814
structural B-Disease 0 0.0011790381
damage I-Disease 0 0.00800725
to I-Disease 0 0.0009316519
the I-Disease 0 0.0012176514
frontal I-Disease 0 0.38573742
lobe I-Disease 0 0.26490998
. O 0 0.004565121

Butyrylcholinesterase O 0 0.030365825
gene O 0 0.0020515008
mutations O 0 0.0016590545
in O 0 0.00092527026
patients O 0 0.0012310838
with O 0 0.0006512529
prolonged O 0 0.0011596229
apnea B-Disease 0 0.9960603
after O 0 0.000458364
succinylcholine B-Chemical 1 0.9975184
for O 0 0.00066891423
electroconvulsive O 0 0.13043247
therapy O 0 0.0018131367
. O 0 0.002398955

BACKGROUND O 0 0.0129143195
: O 0 0.0034651172
patients O 0 0.0016294376
undergoing O 0 0.0009074178
electroconvulsive O 0 0.055666108
therapy O 0 0.00072323944
( O 0 0.0008632256
ECT O 0 0.34733808
) O 0 0.0007296427
often O 0 0.00034925024
receive O 0 0.0003752994
succinylcholine B-Chemical 1 0.99811614
as O 0 0.00033475022
part O 0 0.00029322438
of O 0 0.00045147046
the O 0 0.00057244016
anesthetic O 0 0.0060937083
procedure O 0 0.0011992834
. O 0 0.0025132154

The O 0 0.0015010765
duration O 0 0.00095572916
of O 0 0.0009953361
action O 0 0.00080165156
may O 0 0.00044957272
be O 0 0.00034895688
prolonged O 0 0.00040765453
in O 0 0.00024280327
patients O 0 0.00042376964
with O 0 0.00021215543
genetic O 0 0.00032266896
variants O 0 0.00014771531
of O 0 0.00024980586
the O 0 0.00030397996
butyrylcholinesterase O 0 0.8981008
enzyme O 0 0.005021665
( O 0 0.0020731895
BChE O 0 0.94919634
) O 0 0.0007817433
, O 0 0.00029974803
the O 0 0.00012493825
most O 0 0.0001929523
common O 0 0.0001971384
being O 0 0.00023054806
the O 0 0.0003379765
K O 0 0.9995048
- O 0 0.0130877355
and O 0 0.0005364969
the O 0 0.0005804919
A O 0 0.019959176
- O 0 0.0067278408
variants O 0 0.0015073372
. O 0 0.0032008137

The O 0 0.0016535351
aim O 0 0.001048261
of O 0 0.0010843606
the O 0 0.00067569345
study O 0 0.0006197128
was O 0 0.00032166555
to O 0 0.00018971814
assess O 0 9.777011e-05
the O 0 0.00014549932
clinical O 0 0.00037529832
significance O 0 0.00017400659
of O 0 0.0001934993
genetic O 0 0.00033480895
variants O 0 0.00016315185
in O 0 0.0002638771
butyrylcholinesterase O 0 0.4508357
gene O 0 0.00022808179
( O 0 0.0010740791
BCHE O 0 0.75330406
) O 0 0.0005173879
in O 0 0.00012421803
patients O 0 0.00027276584
with O 0 0.00013731509
a O 0 0.0002236653
suspected O 0 0.00043921362
prolonged O 0 0.00015791347
duration O 0 8.4383806e-05
of O 0 0.0001688188
action O 0 0.00028608172
of O 0 0.0006598507
succinylcholine B-Chemical 1 0.999554
after O 0 0.0007087211
ECT O 0 0.5219894
. O 0 0.002320761

METHODS O 0 0.004728555
: O 0 0.0034117491
a O 0 0.0016995334
total O 0 0.0009492686
of O 0 0.00078091724
13 O 0 0.00073393574
patients O 0 0.0007918069
were O 0 0.000351641
referred O 0 0.0003993684
to O 0 0.00026342363
the O 0 0.00033199755
Danish O 0 0.0010692674
Cholinesterase O 0 0.946652
Research O 0 0.001353319
Unit O 0 0.00058583217
after O 0 0.00025074268
ECT O 0 0.030905638
during O 0 0.0004023586
38 O 0 0.000970815
months O 0 0.00070494687
. O 0 0.0023426064

We O 0 0.0028226099
determined O 0 0.0018635667
the O 0 0.0017418937
BChE O 0 0.71574056
activity O 0 0.00060787133
and O 0 0.00063938054
the O 0 0.0005362572
BCHE O 0 0.25582847
genotype O 0 0.00043315388
using O 0 0.00018680429
molecular O 0 0.0003598335
genetic O 0 0.00029966375
methods O 0 0.00015242858
, O 0 0.0002351161
the O 0 9.329072e-05
duration O 0 8.847326e-05
of O 0 0.00022706436
apnea B-Disease 0 0.99906343
, O 0 0.00028943445
time O 0 7.620131e-05
to O 0 8.379411e-05
sufficient O 0 8.0764745e-05
spontaneous O 0 0.00032819636
ventilation O 0 0.00043149368
and O 0 0.00014563368
whether O 0 9.592342e-05
neuromuscular O 0 0.003115721
monitoring O 0 0.00041114513
was O 0 0.0005652778
used O 0 0.0009967681
. O 0 0.0024084875

The O 0 0.0018922581
duration O 0 0.0013784308
of O 0 0.0020593412
apnea B-Disease 0 0.9949262
was O 0 0.0008175857
compared O 0 0.00044209434
with O 0 0.0005835359
published O 0 0.00057669316
data O 0 0.0007009646
on O 0 0.00062900066
normal O 0 0.001992265
subjects O 0 0.0033185016
. O 0 0.0037791887

RESULTS O 0 0.00501198
: O 0 0.0035214715
in O 0 0.0012732804
11 O 0 0.001162013
patients O 0 0.0013094622
, O 0 0.0010557692
mutations O 0 0.0006442465
were O 0 0.00038459006
found O 0 0.00035970216
in O 0 0.00035809353
the O 0 0.0004133748
BCHE O 0 0.19745813
gene O 0 0.0003295703
, O 0 0.00067521416
the O 0 0.00049121544
K O 0 0.99949336
- O 0 0.014046038
variant O 0 0.00045540684
being O 0 0.0005286706
the O 0 0.0005785134
most O 0 0.0012780743
frequent O 0 0.0021655487
. O 0 0.0029740594

The O 0 0.0019317238
duration O 0 0.0014041977
of O 0 0.002107916
apnea B-Disease 0 0.9960278
was O 0 0.0008723563
5 O 0 0.000580472
- O 0 0.0012480832
15 O 0 0.00028496125
min O 0 0.00032555062
compared O 0 0.00015864316
with O 0 0.00025934362
3 O 0 0.00029473114
- O 0 0.0010497201
5 O 0 0.00028057297
. O 0 0.00027596205
3 O 0 0.000299463
min O 0 0.00056453055
from O 0 0.0005018452
the O 0 0.0008144341
literature O 0 0.0027948325
. O 0 0.003596455

Severe O 0 0.2786161
distress O 0 0.5123404
was O 0 0.0019340256
noted O 0 0.0012686055
in O 0 0.0008881929
the O 0 0.00073592126
recovery O 0 0.0011372356
phase O 0 0.0015235294
in O 0 0.0010463105
two O 0 0.0010913324
patients O 0 0.0036236888
. O 0 0.0041095954

Neuromuscular O 0 0.01704316
monitoring O 0 0.0035030858
was O 0 0.0026135473
used O 0 0.0021355595
in O 0 0.0023771261
two O 0 0.002423779
patients O 0 0.0067342254
. O 0 0.0075234273

CONCLUSION O 0 0.01609453
: O 0 0.0036011965
eleven O 0 0.0011608459
of O 0 0.0008528847
13 O 0 0.0007053511
patients O 0 0.00067803304
with O 0 0.0003044475
a O 0 0.00030423483
prolonged O 0 0.00020502978
duration O 0 9.0275564e-05
of O 0 0.00013146896
action O 0 0.00016816138
of O 0 0.0003224537
succinylcholine B-Chemical 1 0.999876
had O 0 0.00020389436
mutations O 0 0.00024608924
in O 0 0.00024785617
BCHE O 0 0.75483793
, O 0 0.0003297768
indicating O 0 9.2668575e-05
that O 0 9.1970025e-05
this O 0 0.00014405257
is O 0 0.00010032416
the O 0 9.166822e-05
possible O 0 8.189237e-05
reason O 0 9.645138e-05
for O 0 0.0001497587
a O 0 0.00036668932
prolonged O 0 0.00043616578
period O 0 0.0003716303
of O 0 0.0012724458
apnea B-Disease 0 0.9982679
. O 0 0.0034774835

We O 0 0.0027469138
recommend O 0 0.0019597749
objective O 0 0.0018545398
neuromuscular O 0 0.006991562
monitoring O 0 0.0010636055
during O 0 0.0008520298
the O 0 0.0011625759
first O 0 0.0016894451
ECT O 0 0.46109173
. O 0 0.0052328883

Perhexiline B-Chemical 0 0.9997178
maleate I-Chemical 0 0.999961
and O 0 0.028301876
peripheral B-Disease 0 0.86172324
neuropathy I-Disease 0 0.9997812
. O 0 0.018549463

Peripheral B-Disease 0 0.9602098
neuropathy I-Disease 0 0.9998969
has O 0 0.0013119789
been O 0 0.00074474147
noted O 0 0.00052559364
as O 0 0.00036734028
a O 0 0.00042864302
complication O 0 0.001251309
of O 0 0.00025490168
therapy O 0 0.00049599144
with O 0 0.00097094727
perhexiline B-Chemical 0 0.99999964
maleate I-Chemical 0 0.99999976
, O 0 0.0023866459
a O 0 0.00036348682
drug O 0 0.0031431154
widely O 0 0.00010132221
used O 0 8.588632e-05
in O 0 0.0001184098
France O 0 0.000944777
( O 0 0.00020699148
and O 0 9.689636e-05
in O 0 9.1297465e-05
clinical O 0 0.00030982523
trials O 0 0.00018556195
in O 0 0.00010081441
the O 0 0.00010102198
United O 0 0.00020279677
States O 0 0.00026482047
) O 0 0.00030436827
for O 0 0.00011229812
the O 0 0.00015964349
prophylactic O 0 0.00042691518
treatment O 0 0.00045903958
of O 0 0.0017745947
angina B-Disease 0 0.9999771
pectoris I-Disease 0 0.999835
. O 0 0.003538913

In O 0 0.0019651244
24 O 0 0.0018181362
patients O 0 0.0016077642
with O 0 0.00075760443
this O 0 0.00063925266
complication O 0 0.0030309025
, O 0 0.0006565342
the O 0 0.00024089769
marked O 0 0.00038230413
slowing O 0 0.0008260538
of O 0 0.00029626876
motor O 0 0.0015217043
nerve O 0 0.004464445
conduction O 0 0.00081667706
velocity O 0 0.00042985723
and O 0 0.00016283155
the O 0 0.0001527191
electromyographic O 0 0.0008022296
changes O 0 0.00021423449
imply O 0 0.00016080918
mainly O 0 0.0004797673
a O 0 0.0017094178
demyelinating B-Disease 0 0.9982175
disorder I-Disease 0 0.9997186
. O 0 0.0047007767

Improvement O 0 0.01266387
was O 0 0.003837123
noted O 0 0.0029305986
with O 0 0.0027159124
cessation O 0 0.002971931
of O 0 0.0037710597
therapy O 0 0.005996068
. O 0 0.0069993692

In O 0 0.0022641046
a O 0 0.0024975662
few O 0 0.0009425855
cases O 0 0.0014268061
the O 0 0.0005713242
presence O 0 0.00049297704
of O 0 0.00054505625
active O 0 0.00070755533
denervation O 0 0.41700238
signified O 0 0.001949842
a O 0 0.0006385335
poor O 0 0.0014179061
prognosis O 0 0.11125294
, O 0 0.000889567
with O 0 0.00058606616
only O 0 0.0007894818
slight O 0 0.0017235414
improvement O 0 0.002307006
. O 0 0.0028888257

The O 0 0.0020615228
underlying O 0 0.001881533
mechanism O 0 0.000878632
causing O 0 0.001431905
the O 0 0.0009735456
neuropathy B-Disease 0 0.99987507
is O 0 0.00044242927
not O 0 0.0002864021
yet O 0 0.00026268428
fully O 0 0.00017678001
known O 0 0.00021492933
, O 0 0.00040603767
although O 0 0.00017606124
some O 0 0.00016671586
evidence O 0 0.00014608249
indicates O 0 0.00015291334
that O 0 0.00020449208
it O 0 0.00048205018
may O 0 0.00030995495
be O 0 0.0004376077
a O 0 0.0010471995
lipid O 0 0.27753982
storage O 0 0.0032473567
process O 0 0.0018337413
. O 0 0.002888298

A O 0 0.037254
phase O 0 0.010035249
I O 0 0.026309641
study O 0 0.002693179
of O 0 0.0018849828
4 B-Chemical 0 0.0015329997
' I-Chemical 0 0.003300078
- I-Chemical 0 0.0063928925
0 I-Chemical 0 0.003077941
- I-Chemical 0 0.008943655
tetrahydropyranyladriamycin I-Chemical 0 0.045341846
. O 0 0.0068873544

Clinical O 0 0.022392016
pharmacology O 0 0.023596022
and O 0 0.013320564
pharmacokinetics O 0 0.34588456
. O 0 0.017718503

A O 0 0.03431598
Phase O 0 0.009449831
I O 0 0.011417527
study O 0 0.0013389864
of O 0 0.00094026903
intravenous O 0 0.004115539
( O 0 0.0011800111
IV O 0 0.014983601
) O 0 0.00085825875
bolus O 0 0.0009102294
4 B-Chemical 0 0.00020856207
' I-Chemical 0 0.0004953803
- I-Chemical 0 0.0011089963
0 I-Chemical 0 0.00036430723
- I-Chemical 0 0.0014390764
tetrahydropyranyladriamycin I-Chemical 0 0.017218826
( O 0 0.0008344873
Pirarubicin B-Chemical 0 0.9504089
) O 0 0.0004892818
was O 0 0.00012784594
done O 0 0.00011521824
in O 0 0.00012981887
55 O 0 0.00020020256
patients O 0 0.00023022118
in O 0 0.00012372942
good O 0 0.00021579544
performance O 0 0.0003391706
status O 0 0.00042521342
with O 0 0.000847426
refractory O 0 0.017584963
tumors B-Disease 0 0.70319736
. O 0 0.0036859922

Twenty O 0 0.006428721
- O 0 0.005700964
six O 0 0.0006626165
had O 0 0.000599106
minimal O 0 0.0003754611
prior O 0 0.00022302328
therapy O 0 0.0004384581
( O 0 0.00045281154
good O 0 0.00037348663
risk O 0 0.0019619723
) O 0 0.0008695915
, O 0 0.0004709144
23 O 0 0.00029245406
had O 0 0.00014281945
extensive O 0 0.000122058846
prior O 0 6.785768e-05
therapy O 0 0.00018757353
( O 0 0.00026049846
poor O 0 0.0004971839
risk O 0 0.0016342339
) O 0 0.0006154425
, O 0 0.00032738695
and O 0 0.00017132453
six O 0 0.00010741366
had O 0 0.00024564404
renal B-Disease 0 0.30550182
and I-Disease 0 0.0005087291
/ I-Disease 0 0.002885144
or I-Disease 0 0.0009238449
hepatic I-Disease 0 0.99920267
dysfunction I-Disease 0 0.9989134
. O 0 0.0045386427

A O 0 0.020928053
total O 0 0.0029296079
of O 0 0.0018406565
167 O 0 0.0020200864
courses O 0 0.0011657099
at O 0 0.0004993208
doses O 0 0.00091215596
of O 0 0.00057008956
15 O 0 0.00045451778
to O 0 0.00037928816
70 O 0 0.0006979576
mg O 0 0.003638854
/ O 0 0.0026747603
m2 O 0 0.0039279866
were O 0 0.0013527289
evaluable O 0 0.0031910068
. O 0 0.003158303

Maximum O 0 0.007019655
tolerated O 0 0.0037109815
dose O 0 0.0017614245
in O 0 0.00074885384
good O 0 0.0009681295
- O 0 0.003906881
risk O 0 0.0023666855
patients O 0 0.00070051453
was O 0 0.00026108275
70 O 0 0.00033113526
mg O 0 0.0026434397
/ O 0 0.0012265146
m2 O 0 0.0018771045
, O 0 0.000412355
and O 0 0.00023385382
in O 0 0.00024439144
poor O 0 0.0009670629
- O 0 0.002449468
risk O 0 0.0020483308
patients O 0 0.0008861151
, O 0 0.0008545305
60 O 0 0.0007963918
mg O 0 0.006800243
/ O 0 0.004503136
m2 O 0 0.009133993
. O 0 0.0035939403

The O 0 0.0029559596
dose O 0 0.005134903
- O 0 0.009281648
limiting O 0 0.0022555678
toxic O 0 0.010512898
effect O 0 0.0011918611
was O 0 0.0014634298
transient O 0 0.004314684
noncumulative O 0 0.56249654
granulocytopenia B-Disease 0 0.999226
. O 0 0.0051966473

Granulocyte O 0 0.9940479
nadir O 0 0.0054133194
was O 0 0.001460559
on O 0 0.00074138254
day O 0 0.0006646252
14 O 0 0.0007907264
( O 0 0.0012612812
range O 0 0.0009251204
, O 0 0.0016248178
4 O 0 0.0012406281
- O 0 0.004384859
22 O 0 0.0031675117
) O 0 0.005603985
. O 0 0.005658687

Less O 0 0.055708155
frequent O 0 0.0044103037
toxic O 0 0.010713419
effects O 0 0.0011972009
included O 0 0.00141083
thrombocytopenia B-Disease 0 0.9996731
, O 0 0.005959893
anemia B-Disease 0 0.9999107
, O 0 0.0051604793
nausea B-Disease 0 0.9996105
, O 0 0.002849729
mild O 0 0.7745104
alopecia B-Disease 0 0.9998988
, O 0 0.005692942
phlebitis B-Disease 0 0.9997192
, O 0 0.0026564053
and O 0 0.002009599
mucositis B-Disease 2 0.9980509
. O 0 0.0040729805

Myelosuppression B-Disease 0 0.99736834
was O 0 0.0041112863
more O 0 0.0033544411
in O 0 0.0021266222
patients O 0 0.0036265308
with O 0 0.0035335296
hepatic B-Disease 0 0.99817836
dysfunction I-Disease 0 0.99803644
. O 0 0.009230544

Pharmacokinetic O 0 0.015794357
analyses O 0 0.0020206987
in O 0 0.0011061361
21 O 0 0.0010176934
patients O 0 0.0010901683
revealed O 0 0.0006859141
Pirarubicin B-Chemical 0 0.96490043
plasma O 0 0.012391088
T O 0 0.004548253
1 O 0 0.00049585506
/ O 0 0.0012229461
2 O 0 0.00041745504
alpha O 0 0.0156252
( O 0 0.0007190686
+ O 0 0.0013020259
/ O 0 0.0023745187
- O 0 0.0040849317
SE O 0 0.16273113
) O 0 0.00063576107
of O 0 0.0002411484
2 O 0 0.00023019926
. O 0 0.00017521651
5 O 0 0.00018022224
+ O 0 0.00068495155
/ O 0 0.0013067996
- O 0 0.0012951411
0 O 0 0.00027793343
. O 0 0.00017480215
85 O 0 0.00025694692
minutes O 0 0.00018845734
, O 0 0.00043321084
T O 0 0.0037131594
beta O 0 0.23542972
1 O 0 0.0004178844
/ O 0 0.0009165652
2 O 0 0.00020663296
of O 0 0.00018033123
25 O 0 0.00023279512
. O 0 0.00014592448
6 O 0 0.00012803882
+ O 0 0.0006035206
/ O 0 0.0011569803
- O 0 0.0010275694
6 O 0 0.00013133326
. O 0 0.0001345067
5 O 0 0.00012352585
minutes O 0 0.00013960706
, O 0 0.00028016343
and O 0 0.0002451291
T O 0 0.001907554
1 O 0 0.0003539211
/ O 0 0.00097514974
2 O 0 0.0003148129
gamma O 0 0.0024593752
of O 0 0.0003130584
23 O 0 0.00038643475
. O 0 0.00022710918
6 O 0 0.0002175131
+ O 0 0.000992669
/ O 0 0.0019409374
- O 0 0.0019953158
7 O 0 0.00046344197
. O 0 0.0005738544
6 O 0 0.0006736834
hours O 0 0.0011842827
. O 0 0.003029707

The O 0 0.0025447553
area O 0 0.0024097462
under O 0 0.001040601
the O 0 0.00075593306
curve O 0 0.00086053484
was O 0 0.0006374281
537 O 0 0.002596328
+ O 0 0.0017889275
/ O 0 0.0022146853
- O 0 0.0019043066
149 O 0 0.00082513446
ng O 0 0.0006691968
/ O 0 0.0011910655
ml O 0 0.0008669833
x O 0 0.00076488184
hours O 0 0.0001951048
, O 0 0.00031817541
volume O 0 0.00027758547
of O 0 0.00017519061
distribution O 0 0.00012160148
( O 0 0.00046609013
Vd O 0 0.0063119065
) O 0 0.00064685487
3504 O 0 0.003995715
+ O 0 0.0008313403
/ O 0 0.0012795797
- O 0 0.0015998977
644 O 0 0.0014555736
l O 0 0.0013146405
/ O 0 0.001610546
m2 O 0 0.00210545
, O 0 0.0003845622
and O 0 0.00021737212
total O 0 0.00025731462
clearance O 0 0.0015360978
( O 0 0.000750844
ClT O 0 0.21576934
) O 0 0.0005310202
was O 0 0.00022062128
204 O 0 0.0006423759
+ O 0 0.00072114856
39 O 0 0.00038993347
. O 0 0.00028542348
3 O 0 0.00032144636
l O 0 0.0014511523
/ O 0 0.0021762694
hour O 0 0.0010856848
/ O 0 0.0041419263
m2 O 0 0.008556491
. O 0 0.0040093064

Adriamycinol B-Chemical 0 0.76926005
, O 0 0.0119636515
doxorubicin B-Chemical 0 0.9996809
, O 0 0.0055626375
adriamycinone B-Chemical 0 0.7598421
, O 0 0.0013209136
and O 0 0.0004894261
tetrahydropyranyladriamycinol B-Chemical 0 0.0018033448
were O 0 0.00029409226
the O 0 0.00024438187
metabolites O 0 0.04555709
detected O 0 0.00015690573
in O 0 0.00020169994
plasma O 0 0.0020631806
and O 0 0.00013130422
the O 0 8.597638e-05
amount O 0 7.783488e-05
of O 0 0.0002515993
doxorubicin B-Chemical 0 0.9999124
was O 0 0.0001752942
less O 0 0.00018151758
than O 0 0.000106221116
or O 0 0.00011151731
equal O 0 0.00016558029
to O 0 0.00017078889
10 O 0 0.0002479238
% O 0 0.0004677316
of O 0 0.0004074195
the O 0 0.0005374772
total O 0 0.0012632669
metabolites O 0 0.45863095
. O 0 0.004005991

Urinary O 0 0.5627554
excretion O 0 0.75239265
of O 0 0.0029178204
Pirarubicin B-Chemical 0 0.9644902
in O 0 0.0006012225
the O 0 0.0003197579
first O 0 0.00020681963
24 O 0 0.000271703
hours O 0 0.00020306923
was O 0 0.00022963082
less O 0 0.00035602308
than O 0 0.0002794845
or O 0 0.0003418721
equal O 0 0.00055802974
to O 0 0.00069932913
10 O 0 0.0012116618
% O 0 0.0028388991
. O 0 0.0033060214

Activity O 0 0.005917629
was O 0 0.0027487562
noted O 0 0.0022664494
in O 0 0.0023338886
mesothelioma B-Disease 0 0.7915334
, O 0 0.0051193438
leiomyosarcoma B-Disease 0 0.9963727
, O 0 0.003074709
and O 0 0.0018730939
basal B-Disease 0 0.0065806564
cell I-Disease 0 0.0071239644
carcinoma I-Disease 0 0.99892884
. O 0 0.008548645

The O 0 0.0018124905
recommended O 0 0.0013164086
starting O 0 0.0007163051
dose O 0 0.0011072503
for O 0 0.0005828331
Phase O 0 0.0018128692
II O 0 0.0043548085
trials O 0 0.00062401156
is O 0 0.00030436885
60 O 0 0.0004371012
mg O 0 0.0025864805
/ O 0 0.0016641389
m2 O 0 0.003168403
IV O 0 0.013941465
bolus O 0 0.0015023241
every O 0 0.00033323304
3 O 0 0.00057266554
weeks O 0 0.0007039949
. O 0 0.0024802736

Ocular B-Disease 0 0.11144205
and I-Disease 0 0.0037508134
auditory I-Disease 0 0.010091605
toxicity I-Disease 0 0.43171537
in O 0 0.0022660636
hemodialyzed O 0 0.998095
patients O 0 0.0052632634
receiving O 0 0.0045220926
desferrioxamine B-Chemical 0 0.99977237
. O 0 0.007533791

During O 0 0.00232452
an O 0 0.0020703461
18 O 0 0.0014482787
- O 0 0.0021777258
month O 0 0.00030340033
period O 0 0.00023585478
of O 0 0.0003323421
study O 0 0.00038407164
41 O 0 0.00074070913
hemodialyzed O 0 0.9973425
patients O 0 0.00083762454
receiving O 0 0.0006642744
desferrioxamine B-Chemical 0 0.9999759
( O 0 0.0006657423
10 O 0 0.00020249073
- O 0 0.0006230073
40 O 0 0.00016304394
mg O 0 0.0009865579
/ O 0 0.0004746859
kg O 0 0.0003939119
BW O 0 0.0027719212
/ O 0 0.0004978037
3 O 0 8.0081125e-05
times O 0 5.6323363e-05
weekly O 0 8.760536e-05
) O 0 0.0001939602
for O 0 7.1127164e-05
the O 0 7.813643e-05
first O 0 6.727695e-05
time O 0 8.928085e-05
were O 0 0.00013057045
monitored O 0 0.00012722514
for O 0 0.00016846278
detection O 0 0.00032136726
of O 0 0.0007342411
audiovisual B-Disease 0 0.18026835
toxicity I-Disease 0 0.99396354
. O 0 0.0040862784

6 O 0 0.0029637443
patients O 0 0.003165248
presented O 0 0.0014671714
clinical O 0 0.0026670976
symptoms O 0 0.0039392537
of O 0 0.001200125
visual B-Disease 0 0.004856961
or I-Disease 0 0.0014105076
auditory I-Disease 0 0.009321252
toxicity I-Disease 0 0.4710542
. O 0 0.0047961823

Moreover O 0 0.0029889003
, O 0 0.0028613354
detailed O 0 0.00079085113
ophthalmologic O 0 0.0027792754
and O 0 0.0007729443
audiologic O 0 0.002216473
studies O 0 0.0006340994
disclosed O 0 0.0007689965
abnormalities O 0 0.005366854
in O 0 0.00051932444
7 O 0 0.0004969889
more O 0 0.0009909316
asymptomatic O 0 0.0035353703
patients O 0 0.0031826727
. O 0 0.0032521791

Visual B-Disease 0 0.9507697
toxicity I-Disease 0 0.98934305
was O 0 0.0016729906
of O 0 0.0012944579
retinal O 0 0.40300125
origin O 0 0.00087090285
and O 0 0.00042398114
was O 0 0.0002815784
characterized O 0 0.0003206805
by O 0 0.00024636107
a O 0 0.0006288856
tritan O 0 0.99965525
- O 0 0.045897134
type O 0 0.0009586991
dyschromatopsy B-Disease 0 0.61794186
, O 0 0.00057988666
sometimes O 0 0.0004344677
associated O 0 0.00018308878
with O 0 0.0001793454
a B-Disease 0 0.00025961926
loss I-Disease 0 0.00022852607
of I-Disease 0 0.00025344736
visual I-Disease 0 0.0067281625
acuity I-Disease 0 0.9742278
and O 0 0.0014580707
pigmentary B-Disease 0 0.9994012
retinal I-Disease 0 0.97624654
deposits I-Disease 0 0.5353788
. O 0 0.0030918473

Auditory B-Disease 0 0.88412017
toxicity I-Disease 0 0.9793413
was O 0 0.0015740568
characterized O 0 0.0011124165
by O 0 0.00062123704
a O 0 0.0007944048
mid O 0 0.0012709893
- O 0 0.0018276107
to O 0 0.00022589743
high O 0 0.000375255
- O 0 0.0018786732
frequency O 0 0.00033179886
neurosensorial B-Disease 0 0.9990969
hearing I-Disease 0 0.4514563
loss I-Disease 0 0.00057154335
and O 0 0.00023946073
the O 0 0.00021403441
lesion O 0 0.00078811496
was O 0 0.00030009003
of O 0 0.00043884365
the O 0 0.0005660149
cochlear O 0 0.0036065918
type O 0 0.0028226112
. O 0 0.0030910908

Desferrioxamine B-Chemical 0 0.99969804
withdrawal O 0 0.048452802
resulted O 0 0.0010970582
in O 0 0.0006435632
a O 0 0.0005864657
complete O 0 0.00025166862
recovery O 0 0.00031314316
of O 0 0.00021988439
visual O 0 0.001020028
function O 0 0.00014957089
in O 0 0.00014747931
1 O 0 0.00015413672
patient O 0 0.00012537505
and O 0 0.00010412869
partial O 0 0.00015708836
recovery O 0 0.00016163608
in O 0 0.000101210586
3 O 0 0.00010192847
, O 0 0.00018883112
and O 0 0.0001187438
a O 0 0.00015434733
complete O 0 8.836391e-05
reversal O 0 0.00017818803
of O 0 0.00018337337
hearing B-Disease 0 0.16098908
loss I-Disease 0 0.00025149112
in O 0 0.0001491681
3 O 0 0.00015045519
patients O 0 0.0003049233
and O 0 0.00024081845
partial O 0 0.00046877714
recovery O 0 0.0006505346
in O 0 0.00068689376
3 O 0 0.0011469213
. O 0 0.0022681225

This O 0 0.006335456
toxicity B-Disease 0 0.5277449
appeared O 0 0.0010179174
in O 0 0.00056117785
patients O 0 0.0006428589
receiving O 0 0.00028522653
the O 0 0.00016087774
higher O 0 0.00022459404
doses O 0 0.000638602
of O 0 0.0006356972
desferrioxamine B-Chemical 0 0.9999871
or O 0 0.00028367102
coincided O 0 0.00026737517
with O 0 0.0001866946
the O 0 0.00015693715
normalization O 0 0.0001926264
of O 0 0.00050499087
ferritin O 0 0.9975235
or O 0 0.0011583467
aluminium B-Chemical 0 0.99907047
serum O 0 0.26214772
levels O 0 0.0020537456
. O 0 0.003339036

The O 0 0.0019591611
data O 0 0.0016347754
indicate O 0 0.00062131224
that O 0 0.00076898845
audiovisual B-Disease 0 0.11674329
toxicity I-Disease 0 0.9906125
is O 0 0.00045154642
not O 0 0.00031859678
an O 0 0.00036472056
infrequent O 0 0.0006853535
complication O 0 0.002252366
in O 0 0.0005168831
hemodialyzed O 0 0.9989531
patients O 0 0.0026027225
receiving O 0 0.0023923956
desferrioxamine B-Chemical 0 0.99988115
. O 0 0.0047367048

Periodical O 0 0.0038832866
audiovisual O 0 0.0038816382
monitoring O 0 0.00093342544
should O 0 0.0003826487
be O 0 0.00037726964
performed O 0 0.00028701164
on O 0 0.00027097188
hemodialyzed O 0 0.9947448
patients O 0 0.00055762887
receiving O 0 0.00021065054
the O 0 0.0001466557
drug O 0 0.0016962012
in O 0 0.00013882437
order O 0 9.452208e-05
to O 0 0.0001164327
detect O 0 0.00010209373
adverse O 0 0.0005851288
effects O 0 0.00025437292
as O 0 0.00038896853
early O 0 0.0009030798
as O 0 0.0008239861
possible O 0 0.0011801043
. O 0 0.0029946265

Serial O 0 0.012705662
epilepsy B-Disease 0 0.9998197
caused O 0 0.0030062718
by O 0 0.0040097483
levodopa B-Chemical 0 0.99999475
/ I-Chemical 0 0.8500147
carbidopa I-Chemical 0 0.9999969
administration O 0 0.0018915882
in O 0 0.00041108005
two O 0 0.0003183596
patients O 0 0.000925056
on O 0 0.00072478707
hemodialysis O 0 0.017386187
. O 0 0.0031527218

Two O 0 0.0022389241
patients O 0 0.0024653347
with O 0 0.0009781083
similar O 0 0.0004961644
clinical O 0 0.0010563105
features O 0 0.00044886058
are O 0 0.00021538496
presented O 0 0.00019661295
: O 0 0.00035131534
both O 0 0.00014673613
patients O 0 0.00032965705
had O 0 0.0001834759
chronic B-Disease 0 0.101061374
renal I-Disease 0 0.9103399
failure I-Disease 0 0.20961305
, O 0 0.00022805721
on O 0 6.64641e-05
hemodialysis O 0 0.0018618345
for O 0 5.8322403e-05
many O 0 6.585353e-05
years O 0 0.00012757281
but O 0 0.000110007284
recently O 0 9.573964e-05
begun O 0 0.0001660011
on O 0 7.552289e-05
a O 0 0.00017601826
high O 0 0.00022493006
- O 0 0.0018757613
flux O 0 0.0007933485
dialyzer O 0 0.34337687
; O 0 0.0002738146
both O 0 7.523838e-05
had O 0 8.478015e-05
been O 0 8.757412e-05
receiving O 0 0.00018795829
a O 0 0.0010108579
carbidopa B-Chemical 0 0.9999994
/ I-Chemical 0 0.7352278
levodopa I-Chemical 0 0.9999988
preparation O 0 0.00022818967
; O 0 0.00026876587
and O 0 9.443146e-05
both O 0 7.7386234e-05
had O 0 9.259932e-05
the O 0 9.03417e-05
onset O 0 0.00027822613
of O 0 0.00045767092
hallucinosis B-Disease 0 0.99999785
and O 0 0.0007080217
recurrent O 0 0.099215075
seizures B-Disease 0 0.999979
, O 0 0.0007496107
which O 0 0.00033288216
were O 0 0.0003266752
refractory O 0 0.001789091
to O 0 0.00074153306
anticonvulsants O 0 0.996657
. O 0 0.0030422285

The O 0 0.0018041604
first O 0 0.0011551005
patient O 0 0.0014511814
died O 0 0.001613871
without O 0 0.000579733
a O 0 0.00070774485
diagnosis O 0 0.0007988255
; O 0 0.000563817
the O 0 0.00018174255
second O 0 0.00018047796
patient O 0 0.00023503811
had O 0 0.00017546762
a O 0 0.00025455438
dramatic O 0 0.00021241492
recovery O 0 0.00026465105
following O 0 0.00012785825
the O 0 0.00022434341
administration O 0 0.0007693718
of O 0 0.0013104624
vitamin B-Chemical 0 0.9998802
B6 I-Chemical 0 0.76673704
. O 0 0.004684694

Neither O 0 0.002584638
patient O 0 0.0023266198
was O 0 0.0010763545
considered O 0 0.0007164918
to O 0 0.00049475743
have O 0 0.0004351676
a O 0 0.0008203451
renal O 0 0.5577489
state O 0 0.0005761017
sufficiently O 0 0.0005204607
severe O 0 0.0017352889
enough O 0 0.00039352235
to O 0 0.00037017127
explain O 0 0.0004864478
their O 0 0.000864249
presentation O 0 0.0027807096
. O 0 0.0030808996

Randomized O 0 0.010420664
, O 0 0.004944852
double O 0 0.0026172553
- O 0 0.009720808
blind O 0 0.02605547
trial O 0 0.003705152
of O 0 0.0041129966
mazindol B-Chemical 0 0.99997926
in O 0 0.010725322
Duchenne B-Disease 0 0.99904054
dystrophy I-Disease 0 0.9995105
. O 0 0.008450948

There O 0 0.0037294396
is O 0 0.0017733485
evidence O 0 0.0012926955
that O 0 0.0012812462
growth O 0 0.027658978
hormone O 0 0.5433315
may O 0 0.0006267312
be O 0 0.0004043651
related O 0 0.00022742165
to O 0 0.00027278558
the O 0 0.00033357917
progression O 0 0.0015850338
of O 0 0.0010199356
weakness B-Disease 0 0.8579748
in O 0 0.0023763867
Duchenne B-Disease 0 0.9986627
dystrophy I-Disease 0 0.99957937
. O 0 0.006213126

We O 0 0.0027288608
conducted O 0 0.0021246315
a O 0 0.0015692605
12 O 0 0.0006861508
- O 0 0.0015018884
month O 0 0.00024545347
controlled O 0 0.00034919035
trial O 0 0.0005842168
of O 0 0.00077547267
mazindol B-Chemical 0 0.9999938
, O 0 0.0014163324
a O 0 0.000484205
putative O 0 0.00020583029
growth O 0 0.008679004
hormone O 0 0.59938574
secretion O 0 0.013163169
inhibitor O 0 0.0034713254
, O 0 0.0008582122
in O 0 0.0004103387
83 O 0 0.0010841422
boys O 0 0.0047461097
with O 0 0.0021335122
Duchenne B-Disease 0 0.99885106
dystrophy I-Disease 0 0.99962294
. O 0 0.0055373306

Muscle O 0 0.030646523
strength O 0 0.0033980964
, O 0 0.0056073554
contractures O 0 0.9948197
, O 0 0.0016231185
functional O 0 0.00041726461
ability O 0 0.00032567975
and O 0 0.00038427065
pulmonary O 0 0.015450572
function O 0 0.00017081723
were O 0 0.00012420393
tested O 0 9.623173e-05
at O 0 8.116654e-05
baseline O 0 0.00011086186
, O 0 0.00019838104
and O 0 0.00011246026
6 O 0 7.262086e-05
and O 0 7.9972764e-05
12 O 0 5.1362167e-05
months O 0 3.5002886e-05
after O 0 4.457506e-05
treatment O 0 0.00012326169
with O 0 0.0003495724
mazindol B-Chemical 0 0.9999924
( O 0 0.00087314966
3 O 0 0.0002712376
mg O 0 0.002574742
/ O 0 0.0011415738
d O 0 0.00070401607
) O 0 0.0012870951
or O 0 0.0008664741
placebo O 0 0.009695141
. O 0 0.002983443

The O 0 0.0022470485
study O 0 0.001986645
was O 0 0.0010003147
designed O 0 0.0006387438
to O 0 0.00047100554
have O 0 0.00036672465
a O 0 0.0005006579
power O 0 0.00091104425
of O 0 0.00028500392
greater O 0 0.00030158088
than O 0 0.00018095959
0 O 0 0.00023411932
. O 0 0.00013861855
90 O 0 0.0001295063
to O 0 9.199055e-05
detect O 0 7.7035176e-05
a O 0 0.00021834008
slowing O 0 0.000492344
to O 0 0.00012845559
25 O 0 0.00020085437
% O 0 0.00024453245
of O 0 0.00013089094
the O 0 0.00010364595
expected O 0 9.854776e-05
rate O 0 0.00021340924
of O 0 0.00020785572
progression O 0 0.0011672738
of O 0 0.00035838629
weakness B-Disease 0 0.39284652
at O 0 0.00022895768
P O 0 0.011575981
less O 0 0.00048765948
than O 0 0.0004048659
0 O 0 0.00087980024
. O 0 0.0011302733
05 O 0 0.01649274
. O 0 0.0034423359

Mazindol B-Chemical 0 0.9989906
did O 0 0.0038500144
not O 0 0.0014888806
benefit O 0 0.0011120177
strength O 0 0.00095803296
at O 0 0.00064123975
any O 0 0.00063968357
point O 0 0.0006596237
in O 0 0.0010235556
the O 0 0.0013498372
study O 0 0.0027213062
. O 0 0.00411686

Side O 0 0.026561808
effects O 0 0.0024304315
attributable O 0 0.0014370695
to O 0 0.0017002482
mazindol B-Chemical 0 0.99998605
included O 0 0.0010641984
decreased B-Disease 0 0.007515103
appetite I-Disease 0 0.91649616
( O 0 0.00082324166
36 O 0 0.00035760878
% O 0 0.00056107435
) O 0 0.00075774087
, O 0 0.0008257814
dry B-Disease 0 0.24876261
mouth I-Disease 0 0.7591345
( O 0 0.00065902557
10 O 0 0.0002296884
% O 0 0.00039978093
) O 0 0.00047767648
, O 0 0.00035911283
behavioral O 0 0.0006838985
change O 0 0.00019225336
( O 0 0.00032113912
22 O 0 0.00025067243
% O 0 0.00035026993
) O 0 0.00045395506
, O 0 0.00036555127
and O 0 0.00031323815
gastrointestinal B-Disease 0 0.9110572
symptoms I-Disease 0 0.22196478
( O 0 0.00042387546
18 O 0 0.00020765646
% O 0 0.0004047785
) O 0 0.0007445676
; O 0 0.001692624
mazindol B-Chemical 0 0.9999938
dosage O 0 0.0060364776
was O 0 0.00026640497
reduced O 0 0.00035742915
in O 0 0.00038160538
43 O 0 0.0007816733
% O 0 0.001041449
of O 0 0.0010431539
patients O 0 0.0030536652
. O 0 0.0029757933

The O 0 0.0018742899
effect O 0 0.0016961527
of O 0 0.003685374
mazindol B-Chemical 0 0.99998903
on O 0 0.0016918755
GH O 0 0.9989422
secretion O 0 0.0036527172
was O 0 0.0002926312
estimated O 0 0.00021706105
indirectly O 0 0.00014310367
by O 0 0.00012880823
comparing O 0 9.900685e-05
the O 0 0.00026186107
postabsorptive O 0 0.9953335
IGF O 0 0.9999527
- O 0 0.11069567
I O 0 0.019373855
levels O 0 0.00013913169
obtained O 0 9.2414964e-05
following O 0 6.74919e-05
3 O 0 9.565132e-05
, O 0 0.00017811584
6 O 0 8.762875e-05
, O 0 0.00018348674
9 O 0 0.00010396786
, O 0 0.00017420563
and O 0 0.000102121296
12 O 0 6.4807595e-05
months O 0 4.7389352e-05
in O 0 0.00010149966
the O 0 0.0002148949
mazindol B-Chemical 0 0.9999919
treated O 0 0.0009135477
to O 0 0.00021946988
those O 0 0.00029007372
in O 0 0.00028600995
the O 0 0.00041113966
placebo O 0 0.004928325
groups O 0 0.0016020896
. O 0 0.0025752417

Although O 0 0.003975733
mazindol B-Chemical 0 0.99997234
- O 0 0.06476991
treated O 0 0.0017077804
patients O 0 0.00089882774
gained O 0 0.0003914719
less O 0 0.00029710602
weight O 0 0.00028717177
and O 0 0.00016926962
height O 0 0.00035355013
than O 0 0.0001579103
placebo O 0 0.0029184127
- O 0 0.0011638192
treated O 0 0.00036570922
patients O 0 0.00042849366
, O 0 0.00028169627
no O 0 0.00014521519
significant O 0 0.00020009014
effect O 0 0.00029480617
on O 0 0.00059613417
IGF O 0 0.99992275
- O 0 0.31736183
I O 0 0.098544754
levels O 0 0.0008666637
was O 0 0.0010237347
observed O 0 0.001445755
. O 0 0.0031077303

Mazindol B-Chemical 0 0.9985141
doses O 0 0.00868068
not O 0 0.0020092586
slow O 0 0.002757095
the O 0 0.0011981889
progression O 0 0.0037415968
of O 0 0.0021555994
weakness B-Disease 0 0.8700279
in O 0 0.0040160683
Duchenne B-Disease 0 0.99817884
dystrophy I-Disease 0 0.9993988
. O 0 0.008274351

Facilitation O 0 0.009877897
of O 0 0.0024833796
memory O 0 0.027936446
retrieval O 0 0.0015805899
by O 0 0.00063780573
pre O 0 0.0010287199
- O 0 0.0025381865
test O 0 0.0008366899
morphine B-Chemical 0 0.9993844
and O 0 0.0003498254
its O 0 0.0002919696
state O 0 0.00022304986
dependency O 0 0.0002162191
in O 0 0.00015940893
the O 0 0.00014197774
step O 0 0.00018827702
- O 0 0.00088775327
through O 0 0.00016277534
type O 0 0.00036416436
passive O 0 0.0003560835
avoidance O 0 0.0008874328
learning O 0 0.0012027811
test O 0 0.00079635606
in O 0 0.00072069064
mice O 0 0.0006515771
. O 0 0.0025088165

Amnesia B-Disease 0 0.97474754
produced O 0 0.0027777846
by O 0 0.003690501
scopolamine B-Chemical 0 0.99999285
and O 0 0.005712466
cycloheximide B-Chemical 0 0.99986875
were O 0 0.0006164211
reversed O 0 0.00068760145
by O 0 0.00038221668
morphine B-Chemical 0 0.99903035
given O 0 0.00011532815
30 O 0 9.8798984e-05
min O 0 0.00012003182
before O 0 4.3120584e-05
the O 0 6.692547e-05
test O 0 0.00013671698
trial O 0 0.00020512733
( O 0 0.00022890966
pre O 0 0.00026855172
- O 0 0.00073625025
test O 0 0.00022622786
) O 0 0.00038766846
, O 0 0.0002409799
and O 0 0.00014467725
pre O 0 0.00032237227
- O 0 0.0013097023
test O 0 0.0003794491
morphine B-Chemical 0 0.9995363
also O 0 0.00012312015
facilitated O 0 0.00014073325
the O 0 0.000111807894
memory O 0 0.047152996
retrieval O 0 0.0003202033
in O 0 0.0001038858
the O 0 8.1469436e-05
animals O 0 9.751211e-05
administered O 0 0.00043797726
naloxone B-Chemical 0 0.999721
during O 0 0.00023716764
the O 0 0.00030802545
training O 0 0.00067437044
trial O 0 0.001821158
. O 0 0.0023012285

Similarly O 0 0.0034255008
, O 0 0.004090818
pre O 0 0.003651822
- O 0 0.011409623
test O 0 0.0038813893
scopolamine B-Chemical 0 0.9999933
partially O 0 0.00096498925
reversed O 0 0.0012675197
the O 0 0.00084956933
scopolamine B-Chemical 0 0.99999857
- O 0 0.15012561
induced O 0 0.0005741325
amnesia B-Disease 0 0.9999428
, O 0 0.0008302977
but O 0 0.00023490502
not O 0 0.0001372919
significantly O 0 0.00021145264
; O 0 0.00033211187
and O 0 0.000167015
pre O 0 0.00039187644
- O 0 0.0018983278
test O 0 0.00062968244
cycloheximide B-Chemical 0 0.9997687
failed O 0 0.00044147778
to O 0 0.00027352705
reverse O 0 0.0005965511
the O 0 0.0006334486
cycloheximide B-Chemical 0 0.9998541
- O 0 0.18860964
induced O 0 0.0024826697
amnesia B-Disease 0 0.99970657
. O 0 0.004732017

These O 0 0.0018341728
results O 0 0.0012196157
suggest O 0 0.00061171444
that O 0 0.00055464613
the O 0 0.00048774548
facilitation O 0 0.0013770963
of O 0 0.00047958488
memory O 0 0.03973533
retrieval O 0 0.0005698155
by O 0 0.00021923271
pre O 0 0.00044221952
- O 0 0.0015397238
test O 0 0.00046464955
morphine B-Chemical 0 0.9994241
might O 0 8.445319e-05
be O 0 9.024226e-05
the O 0 6.856167e-05
direct O 0 6.592001e-05
action O 0 0.00015158269
of O 0 0.00032215627
morphine B-Chemical 0 0.9997223
rather O 0 0.00028044297
than O 0 0.00025832342
a O 0 0.00050014246
state O 0 0.00053648726
dependent O 0 0.00049259915
effect O 0 0.0012294926
. O 0 0.003084946

Naloxone B-Chemical 0 0.99975353
reverses O 0 0.015011913
the O 0 0.0030112006
antihypertensive O 0 0.7488391
effect O 0 0.0026591124
of O 0 0.005993878
clonidine B-Chemical 0 0.99983
. O 0 0.009455961

In O 0 0.0022445975
unanesthetized O 0 0.011492635
, O 0 0.0027043829
spontaneously O 0 0.0032821747
hypertensive B-Disease 0 0.99897385
rats O 0 0.00078526145
the O 0 0.00022702257
decrease O 0 0.00022961154
in O 0 0.00018572199
blood O 0 0.001338746
pressure O 0 0.002787017
and O 0 0.00020687899
heart O 0 0.0028138247
rate O 0 0.00017928095
produced O 0 9.290784e-05
by O 0 0.00014075285
intravenous O 0 0.02615869
clonidine B-Chemical 0 0.9999682
, O 0 0.00031258783
5 O 0 9.189525e-05
to O 0 7.0723254e-05
20 O 0 0.00011167651
micrograms O 0 0.00077693094
/ O 0 0.0005788904
kg O 0 0.0004347428
, O 0 0.00028901285
was O 0 0.00014759916
inhibited O 0 0.00030640807
or O 0 0.00020542485
reversed O 0 0.0005042018
by O 0 0.00036405068
nalozone B-Chemical 0 0.695537
, O 0 0.00072171225
0 O 0 0.00038349407
. O 0 0.00024230791
2 O 0 0.00027146115
to O 0 0.00026740044
2 O 0 0.0005761931
mg O 0 0.0033679025
/ O 0 0.0030897285
kg O 0 0.0034316597
. O 0 0.0031935743

The O 0 0.0028703338
hypotensive B-Disease 0 0.92184347
effect O 0 0.0011464362
of O 0 0.0011279731
100 O 0 0.0018227916
mg O 0 0.011769654
/ O 0 0.0028026695
kg O 0 0.0032180087
alpha B-Chemical 0 0.9831344
- I-Chemical 0 0.7179562
methyldopa I-Chemical 0 0.99999857
was O 0 0.0007466349
also O 0 0.0004773492
partially O 0 0.0006412712
reversed O 0 0.001818169
by O 0 0.0023386958
naloxone B-Chemical 0 0.99981326
. O 0 0.005417105

Naloxone B-Chemical 0 0.99987173
alone O 0 0.0053989715
did O 0 0.0021809705
not O 0 0.0010628384
affect O 0 0.00070527213
either O 0 0.0008898938
blood O 0 0.0058809626
pressure O 0 0.011313963
or O 0 0.001306964
heart O 0 0.013974764
rate O 0 0.00341904
. O 0 0.004135309

In O 0 0.002716717
brain O 0 0.0060483795
membranes O 0 0.004337717
from O 0 0.00085859245
spontaneously O 0 0.0025482858
hypertensive B-Disease 0 0.99954623
rats O 0 0.0031637526
clonidine B-Chemical 0 0.99994636
, O 0 0.000810789
10 O 0 0.0002887727
( O 0 0.0004619767
- O 0 0.00089928915
8 O 0 0.0001889291
) O 0 0.00034686117
to O 0 0.00014638716
10 O 0 0.00020061435
( O 0 0.00039939844
- O 0 0.0009951266
5 O 0 0.00021625045
) O 0 0.000726357
M O 0 0.4289586
, O 0 0.0005686025
did O 0 0.00022371222
not O 0 0.00014673991
influence O 0 0.00012995387
stereoselective O 0 0.0010703094
binding O 0 0.0001335804
of O 0 0.0003098403
[ B-Chemical 0 0.013003471
3H I-Chemical 0 0.9791998
] I-Chemical 0 0.0525427
- I-Chemical 0 0.106478274
naloxone I-Chemical 0 0.99996257
( O 0 0.00045684905
8 O 0 0.00014061763
nM O 0 0.0008633807
) O 0 0.00050559896
, O 0 0.0003711656
and O 0 0.0003522641
naloxone B-Chemical 0 0.99995196
, O 0 0.00063673954
10 O 0 0.00020653685
( O 0 0.00035357964
- O 0 0.00075885473
8 O 0 0.00014010073
) O 0 0.00027019024
to O 0 0.000114144794
10 O 0 0.00016160742
( O 0 0.00033174732
- O 0 0.00082406786
4 O 0 0.00016146601
) O 0 0.0006147865
M O 0 0.34815568
, O 0 0.00046124696
did O 0 0.00018984138
not O 0 0.00014394602
influence O 0 0.00021498854
clonidine B-Chemical 0 0.99999
- O 0 0.07051511
suppressible O 0 0.0028942858
binding O 0 0.000153922
of O 0 0.0003807084
[ B-Chemical 0 0.013793334
3H I-Chemical 0 0.9793352
] I-Chemical 0 0.064720735
- I-Chemical 0 0.08549303
dihydroergocryptine I-Chemical 0 0.9976922
( O 0 0.0014796638
1 O 0 0.00093107065
nM O 0 0.0041801133
) O 0 0.0039680554
. O 0 0.0032691797

These O 0 0.0017907539
findings O 0 0.0015832132
indicate O 0 0.0006107003
that O 0 0.0005937471
in O 0 0.0006312467
spontaneously O 0 0.0021522003
hypertensive B-Disease 0 0.9993455
rats O 0 0.00049774226
the O 0 0.00014700614
effects O 0 0.00016999732
of O 0 0.00028082987
central O 0 0.0008348595
alpha O 0 0.8250003
- O 0 0.064178064
adrenoceptor O 0 0.9933287
stimulation O 0 0.00021276702
involve O 0 0.00025409463
activation O 0 0.00037824232
of O 0 0.00095316704
opiate O 0 0.9950492
receptors O 0 0.0059283148
. O 0 0.003246556

As O 0 0.0034506884
naloxone B-Chemical 0 0.9997917
and O 0 0.007102694
clonidine B-Chemical 0 0.99996793
do O 0 0.00096003135
not O 0 0.0004008552
appear O 0 0.00022656588
to O 0 0.00014558094
interact O 0 8.519005e-05
with O 0 0.00015827207
the O 0 0.00012276106
same O 0 0.00010843207
receptor O 0 0.00035977297
site O 0 9.2917755e-05
, O 0 0.00023758702
the O 0 9.1972746e-05
observed O 0 9.2888346e-05
functional O 0 0.000114166134
antagonism O 0 0.0012733695
suggests O 0 7.067828e-05
the O 0 9.5745854e-05
release O 0 0.0002456183
of O 0 0.00012249433
an O 0 0.00013245146
endogenous O 0 0.0001109418
opiate O 0 0.99450845
by O 0 0.000289098
clonidine B-Chemical 0 0.9999896
or O 0 0.00035042237
alpha B-Chemical 0 0.9976914
- I-Chemical 0 0.87519175
methyldopa I-Chemical 0 0.99999976
and O 0 0.0002075175
the O 0 7.0719754e-05
possible O 0 5.108193e-05
role O 0 4.4761637e-05
of O 0 0.00013988795
the O 0 0.00018159323
opiate O 0 0.9747683
in O 0 0.00018408551
the O 0 0.00016500533
central O 0 0.00037038658
control O 0 0.0003374588
of O 0 0.0006781349
sympathetic O 0 0.0073905713
tone O 0 0.029596042
. O 0 0.0027945

Neurotoxicity B-Disease 0 0.9943474
of O 0 0.005617098
halogenated B-Chemical 0 0.886846
hydroxyquinolines I-Chemical 0 0.95994544
: O 0 0.0035384863
clinical O 0 0.0021253312
analysis O 0 0.00072021416
of O 0 0.0008186287
cases O 0 0.001470455
reported O 0 0.0011908835
outside O 0 0.0013911042
Japan O 0 0.005022849
. O 0 0.0041866647

An O 0 0.0032657182
analysis O 0 0.0017782155
is O 0 0.0009613658
presented O 0 0.0007627324
of O 0 0.00082481094
220 O 0 0.0018922816
cases O 0 0.0008635547
of O 0 0.00049689884
possible O 0 0.00043609153
neurotoxic B-Disease 0 0.9502066
reactions O 0 0.0006952596
to O 0 0.00044661883
halogenated B-Chemical 0 0.78494304
hydroxyquinolines I-Chemical 0 0.9385719
reported O 0 0.0007456132
from O 0 0.0005791473
outside O 0 0.0008747956
Japan O 0 0.0035508722
. O 0 0.003025856

In O 0 0.0022009131
80 O 0 0.0027872887
cases O 0 0.0018617618
insufficient O 0 0.00081936235
information O 0 0.00050636387
was O 0 0.00032785424
available O 0 0.00019041567
for O 0 0.00016655873
adequate O 0 0.0002549481
comment O 0 0.0005106871
and O 0 0.00023342231
in O 0 0.00019853826
29 O 0 0.00029279583
a O 0 0.00020881876
relationship O 0 0.00010144781
to O 0 0.00015162172
the O 0 0.00019775383
administration O 0 0.0006997622
of O 0 0.0009650862
clioquinol B-Chemical 0 0.9999651
could O 0 0.00072016986
be O 0 0.0009932512
excluded O 0 0.0018440902
. O 0 0.0026566528

Of O 0 0.0052599385
the O 0 0.002066643
remainder O 0 0.0020318485
, O 0 0.0019911865
a O 0 0.0010959463
relationship O 0 0.0005088717
to O 0 0.0009844595
clioquinol B-Chemical 0 0.9999603
was O 0 0.0005658498
considered O 0 0.0003985805
probable O 0 0.0006423631
in O 0 0.00033306752
42 O 0 0.0004659236
and O 0 0.00038823762
possible O 0 0.00038433587
in O 0 0.00075143774
69 O 0 0.0017270959
cases O 0 0.002831544
. O 0 0.0034431245

In O 0 0.0017306866
six O 0 0.0010215519
of O 0 0.0011565523
the O 0 0.0007881355
probable O 0 0.0013542868
cases O 0 0.0009962773
the O 0 0.0004980376
neurological B-Disease 0 0.99754035
disturbance I-Disease 0 0.7717391
consisted O 0 0.00026464654
of O 0 0.0002225065
an O 0 0.00027921997
acute O 0 0.11086852
reversible O 0 0.02445145
encephalopathy B-Disease 2 0.99999106
usually O 0 0.00022883416
related O 0 5.9880447e-05
to O 0 7.148088e-05
the O 0 8.5981876e-05
ingestion O 0 0.000935143
of O 0 0.00013125227
a O 0 0.00018893955
high O 0 0.0002040276
dose O 0 0.0004477941
of O 0 0.0005166277
clioquinol B-Chemical 0 0.9999651
over O 0 0.0003782504
a O 0 0.00063945184
short O 0 0.00053488225
period O 0 0.0007841285
. O 0 0.0020997731

The O 0 0.0025171428
most O 0 0.0026814674
common O 0 0.0021715518
manifestation O 0 0.0075831236
, O 0 0.0017995429
observed O 0 0.0006672687
in O 0 0.00059228926
15 O 0 0.0005001976
further O 0 0.00043238202
cases O 0 0.0010378279
, O 0 0.0012374547
was O 0 0.0008578619
isolated O 0 0.0016597448
optic B-Disease 0 0.98815197
atrophy I-Disease 2 0.9982816
. O 0 0.0049275584

This O 0 0.0047601014
was O 0 0.0018798888
most O 0 0.0014764307
frequently O 0 0.0008791813
found O 0 0.0005869033
in O 0 0.0005071962
children O 0 0.0012087784
, O 0 0.00057581323
many O 0 0.00021726913
of O 0 0.0002948292
whom O 0 0.00048413879
had O 0 0.0003073748
received O 0 0.00054505625
clioquinol B-Chemical 0 0.9999517
as O 0 0.0005297142
treatment O 0 0.000603445
for O 0 0.00087544596
acrodermatitis B-Disease 0 0.91962796
enteropathica I-Disease 0 0.9997274
. O 0 0.0055003306

In O 0 0.0020331668
the O 0 0.0015514895
remaining O 0 0.0012523273
cases O 0 0.0016453358
, O 0 0.0011996883
a O 0 0.00070273236
combination O 0 0.0005525521
of O 0 0.00080184056
myelopathy B-Disease 0 0.99993145
, O 0 0.0015308834
visual B-Disease 0 0.57285583
disturbance I-Disease 0 0.9048386
, O 0 0.00070184155
and O 0 0.00038620218
peripheral B-Disease 0 0.1398966
neuropathy I-Disease 0 0.9999776
was O 0 0.0004483265
the O 0 0.00034392503
most O 0 0.0006737919
common O 0 0.0010342036
manifestation O 0 0.008005194
. O 0 0.0029545745

Isolated O 0 0.016976077
myelopathy B-Disease 0 0.9994667
or O 0 0.00248095
peripheral B-Disease 0 0.32339725
neuropathy I-Disease 0 0.9999646
, O 0 0.0020593482
or O 0 0.0005082987
these O 0 0.0005034685
manifestations O 0 0.0060638585
occurring O 0 0.00057183515
together O 0 0.0006104518
, O 0 0.0014566614
were O 0 0.0011596031
infrequent O 0 0.0031873567
. O 0 0.003321354

The O 0 0.0022665618
onset O 0 0.0025488555
of O 0 0.0013443973
all O 0 0.0010266467
manifestations O 0 0.019059742
( O 0 0.0014335007
except O 0 0.0006094086
toxic O 0 0.305682
encephalopathy B-Disease 2 0.99997926
) O 0 0.002543996
was O 0 0.00036636245
usually O 0 0.00052060984
subacute O 0 0.6918916
, O 0 0.000783203
with O 0 0.00048443905
subsequent O 0 0.0005377095
partial O 0 0.0012943593
recovery O 0 0.002038138
. O 0 0.002676565

Older O 0 0.02860048
subjects O 0 0.005712602
tended O 0 0.003064885
to O 0 0.0017887214
display O 0 0.0016282698
more O 0 0.0029143794
side O 0 0.005170011
effects O 0 0.004513275
. O 0 0.00767712

The O 0 0.0020636125
full O 0 0.0018856738
syndrome O 0 0.518619
of O 0 0.0016767476
subacute O 0 0.98316896
myelo B-Disease 0 0.22848302
- I-Disease 0 0.23210233
optic I-Disease 0 0.9997738
neuropathy I-Disease 0 0.99999154
was O 0 0.0003347569
more O 0 0.00029129314
frequent O 0 0.0002262382
in O 0 0.00015414614
women O 0 0.000686559
, O 0 0.00037185586
but O 0 0.00020779451
they O 0 0.00014928679
tended O 0 0.00019938643
to O 0 0.0001336752
have O 0 0.00013822246
taken O 0 0.0001576305
greater O 0 0.00030301846
quantities O 0 0.00041901515
of O 0 0.00063065044
the O 0 0.0008794176
drug O 0 0.017939406
. O 0 0.0030664704

Prazosin B-Chemical 0 0.99983716
- O 0 0.34248754
induced O 0 0.014137539
stress B-Disease 0 0.9641575
incontinence I-Disease 0 0.9954277
. O 0 0.018787693

A O 0 0.027939102
case O 0 0.0029384505
of O 0 0.0019444126
genuine O 0 0.0024924066
stress B-Disease 0 0.94060796
incontinence I-Disease 0 0.998623
due O 0 0.0006180816
to O 0 0.0007946845
prazosin B-Chemical 0 0.9999914
, O 0 0.0014500997
a O 0 0.0006076064
common O 0 0.0005102259
antihypertensive O 0 0.86281747
drug O 0 0.016417002
, O 0 0.0013366923
is O 0 0.0008358855
presented O 0 0.0014032058
. O 0 0.0028786832

Prazosin B-Chemical 0 0.99990845
exerts O 0 0.0021467675
its O 0 0.0017106184
antihypertensive O 0 0.762771
effects O 0 0.00059772946
through O 0 0.0006007007
vasodilatation O 0 0.999406
caused O 0 0.00036620794
by O 0 0.000262528
selective O 0 0.00039790155
blockade O 0 0.001065462
of O 0 0.0005717253
postsynaptic O 0 0.059883058
alpha O 0 0.895073
- O 0 0.045786917
1 O 0 0.0014741282
adrenergic O 0 0.764026
receptors O 0 0.0040708026
. O 0 0.0033037248

As O 0 0.002854739
an O 0 0.0038332245
alpha O 0 0.8022474
- O 0 0.14619334
blocker O 0 0.8100489
, O 0 0.0021012872
it O 0 0.00077010936
also O 0 0.0003526273
exerts O 0 0.00032452182
a O 0 0.00053048454
significant O 0 0.00040595012
relaxant O 0 0.053062256
effect O 0 0.00024813143
on O 0 0.00024945504
the O 0 0.00043292396
bladder O 0 0.02758697
neck O 0 0.03332215
and O 0 0.0016442357
urethra O 0 0.037923113
. O 0 0.003551976

The O 0 0.0020663915
patient O 0 0.0019402243
' O 0 0.0019661319
s O 0 0.0012154673
clinical O 0 0.0012034039
course O 0 0.00042964297
is O 0 0.00023627163
described O 0 0.00018389622
and O 0 0.00018781693
correlated O 0 0.00014566939
with O 0 0.00013512929
initial O 0 0.00010512258
urodynamic O 0 0.0003356453
studies O 0 0.00015296016
while O 0 0.00015187495
on O 0 0.0002210736
prazosin B-Chemical 0 0.9999912
and O 0 0.00037525824
subsequent O 0 0.0002292696
studies O 0 0.00041965386
while O 0 0.0005723294
taking O 0 0.0024136466
verapamil B-Chemical 0 0.99995685
. O 0 0.0050676065

Her O 0 0.012689771
incontinence B-Disease 0 0.5457611
resolved O 0 0.003966457
with O 0 0.0023361784
the O 0 0.0017964083
change O 0 0.0020173236
of O 0 0.00296377
medication O 0 0.0120716
. O 0 0.006295523

The O 0 0.0019254044
restoration O 0 0.0018974997
of O 0 0.0014423734
continence O 0 0.0034272578
was O 0 0.0007332684
accompanied O 0 0.0008056348
by O 0 0.00042174812
a O 0 0.00050826377
substantial O 0 0.00032061324
rise O 0 0.0002812712
in O 0 0.00018611994
maximum O 0 0.00024758058
urethral O 0 0.00077888975
pressure O 0 0.0017942702
, O 0 0.00035665225
maximum O 0 0.00026376793
urethral O 0 0.00087119464
closure O 0 0.00095082325
pressure O 0 0.0031385587
, O 0 0.0006542273
and O 0 0.00046095726
functional O 0 0.00059608533
urethral O 0 0.0027058467
length O 0 0.0013248539
. O 0 0.003072018

Patients O 0 0.004095893
who O 0 0.0019140188
present O 0 0.0007710654
with O 0 0.0010994799
stress B-Disease 0 0.86391777
incontinence I-Disease 0 0.99870753
while O 0 0.00054427964
taking O 0 0.0014642305
prazosin B-Chemical 0 0.99999416
should O 0 0.00010171796
change O 0 9.191883e-05
their O 0 8.017801e-05
antihypertensive O 0 0.26486894
medication O 0 0.00039402684
before O 0 3.5746678e-05
considering O 0 5.829771e-05
surgery O 0 0.00015029844
, O 0 0.00016154982
because O 0 7.9295096e-05
their O 0 0.00015948509
incontinence B-Disease 0 0.46040094
may O 0 0.00012572593
resolve O 0 0.0001230346
spontaneously O 0 0.00046974537
with O 0 0.0002414081
a O 0 0.00040406064
change O 0 0.00033760228
in O 0 0.0004876902
drug O 0 0.0066446145
therapy O 0 0.0018635553
. O 0 0.0022159638

Myocardial B-Disease 0 0.99657464
infarction I-Disease 0 0.9999062
following O 0 0.0028446012
sublingual O 0 0.8969387
administration O 0 0.005185286
of O 0 0.009180707
isosorbide B-Chemical 0 0.9999989
dinitrate I-Chemical 0 0.9999968
. O 0 0.012403599

A O 0 0.03198467
78 O 0 0.007309301
- O 0 0.008112839
year O 0 0.0015046943
- O 0 0.0033007714
old O 0 0.0009580731
with O 0 0.0008777541
healed O 0 0.010994033
septal O 0 0.6896004
necrosis B-Disease 2 0.9999436
suffered O 0 0.027369035
a O 0 0.00089806516
recurrent O 0 0.031090455
myocardial B-Disease 0 0.99977475
infarction I-Disease 0 0.9999877
of O 0 0.00025145157
the O 0 0.00013631603
anterior O 0 0.0017506024
wall O 0 0.0005981914
following O 0 7.055203e-05
the O 0 0.0001049587
administration O 0 0.00042831578
of O 0 0.0013554888
isosorbide B-Chemical 0 0.9999999
dinitrate I-Chemical 0 0.99999964
5 O 0 0.0012458925
mg O 0 0.05938957
sublingually O 0 0.89891815
. O 0 0.0022410483

After O 0 0.0015358041
detailing O 0 0.0016011656
the O 0 0.0009051929
course O 0 0.00078519294
of O 0 0.0006404637
events O 0 0.0008014628
, O 0 0.000618929
we O 0 0.0001506507
discuss O 0 0.00017384953
the O 0 0.00013466056
role O 0 8.8541194e-05
of O 0 0.0002433767
paradoxical O 0 0.013359031
coronary O 2 0.9975777
spasm B-Disease 2 0.99998975
and O 0 0.00061492913
hypotension B-Disease 0 0.99996805
- O 0 0.006136059
mediated O 0 0.00012202254
myocardial B-Disease 0 0.9994425
ischemia I-Disease 0 0.99988663
occurring O 0 0.00011370635
downstream O 0 3.6571713e-05
to O 0 5.6674606e-05
significant O 0 0.00011166735
coronary B-Disease 0 0.29401755
arterial I-Disease 0 0.6695272
stenosis I-Disease 0 0.9997603
in O 0 0.000172808
the O 0 0.00017217347
pathophysiology O 0 0.0026498742
of O 0 0.0005585686
acute B-Disease 0 0.73140407
coronary I-Disease 0 0.83980745
insufficiency I-Disease 0 0.9992354
. O 0 0.0030519424

Comparison O 0 0.0018877384
of O 0 0.001820632
the O 0 0.001122929
respiratory O 0 0.0022169962
effects O 0 0.0005455922
of O 0 0.00056914904
i O 0 0.0008457481
. O 0 0.00036749232
v O 0 0.0010273693
. O 0 0.000261611
infusions O 0 0.00054788386
of O 0 0.0003817691
morphine B-Chemical 0 0.99900997
and O 0 0.0004273822
regional O 0 0.0008656939
analgesia O 0 0.12101823
by O 0 0.00069076684
extradural O 0 0.117223635
block O 0 0.0014774032
. O 0 0.0027132481

The O 0 0.0019782428
incidence O 0 0.0023869162
of O 0 0.0011521176
postoperative O 0 0.0015146689
respiratory O 0 0.008044393
apnoea B-Disease 0 0.99830914
was O 0 0.00021790835
compared O 0 9.750402e-05
between O 0 8.336413e-05
five O 0 7.049096e-05
patients O 0 0.00017732615
receiving O 0 0.000113973394
a O 0 0.00013104381
continuous O 0 9.198485e-05
i O 0 0.00022021272
. O 0 0.00012129747
v O 0 0.00047912617
. O 0 0.00011611604
infusion O 0 0.00030268295
of O 0 0.00018887271
morphine B-Chemical 0 0.9995003
( O 0 0.00026535674
mean O 0 8.695302e-05
73 O 0 0.00018978165
. O 0 8.558595e-05
6 O 0 7.331375e-05
mg O 0 0.0008799117
) O 0 0.00019807236
and O 0 7.658099e-05
five O 0 4.5705678e-05
patients O 0 0.00012720814
receiving O 0 8.334943e-05
a O 0 0.00010230493
continuous O 0 8.6078355e-05
extradural O 0 0.02996268
infusion O 0 0.00024572934
of O 0 9.9808225e-05
0 O 0 0.00014314121
. O 0 0.00010036417
25 O 0 0.0001612211
% O 0 0.00043752513
bupivacaine B-Chemical 0 0.9999254
( O 0 0.0002384071
mean O 0 9.642259e-05
192 O 0 0.00033461844
mg O 0 0.0022770108
) O 0 0.00031003976
in O 0 0.000117522715
the O 0 0.000121453486
24 O 0 0.0001877736
- O 0 0.00056213845
h O 0 0.00017285482
period O 0 0.00012891267
following O 0 0.00016876149
upper O 0 0.0005669008
abdominal O 0 0.0012170601
surgery O 0 0.0013660294
. O 0 0.0020307002

Monitoring O 0 0.0036046696
consisted O 0 0.0018835426
of O 0 0.0016887856
airflow O 0 0.011271604
detection O 0 0.00064284506
by O 0 0.00058035605
a O 0 0.0011341273
carbon B-Chemical 0 0.9843127
dioxide I-Chemical 0 0.9995921
analyser O 0 0.033704083
, O 0 0.00054368883
chest O 0 0.0005142246
wall O 0 0.00096550427
movement O 0 0.00035655737
detected O 0 0.00010575238
by O 0 0.0001442955
pneumatic O 0 0.0010914213
capsules O 0 0.001349645
, O 0 0.0002939577
and O 0 0.00015137327
continuous O 0 0.00014766474
electrocardiograph O 0 0.0013356501
recorded O 0 0.00018758606
with O 0 0.00023777397
a O 0 0.0005004835
Holter O 0 0.0015270516
ambulatory O 0 0.0009408097
monitor O 0 0.00078503386
. O 0 0.0021647236

Both O 0 0.004879125
obstructive B-Disease 0 0.98875964
( I-Disease 0 0.0046142433
P I-Disease 0 0.043760784
less I-Disease 0 0.0012642093
than I-Disease 0 0.00061447866
0 I-Disease 0 0.0007292013
. I-Disease 0 0.0005404848
05 I-Disease 0 0.0052281125
) I-Disease 0 0.0008800253
and I-Disease 0 0.0003767002
central I-Disease 0 0.0007518244
apnoea I-Disease 0 0.99822706
( O 0 0.0006749019
P O 0 0.011335894
less O 0 0.00027183356
than O 0 0.0001583489
0 O 0 0.00024843676
. O 0 0.000206316
05 O 0 0.0039365473
) O 0 0.00044160782
occurred O 0 0.00017280041
more O 0 0.00023506994
frequently O 0 0.00018508696
in O 0 0.0001842671
patients O 0 0.00046532086
who O 0 0.00039634484
had O 0 0.00039776615
a O 0 0.0012385501
morphine B-Chemical 0 0.999258
infusion O 0 0.0062860493
. O 0 0.0024770468

There O 0 0.0036375192
was O 0 0.0018795594
also O 0 0.001136064
a O 0 0.0011815588
higher O 0 0.0007338717
incidence O 0 0.0009602618
of O 0 0.0006490134
tachyarrhythmias B-Disease 0 0.99921286
( O 0 0.0010214654
P O 0 0.02530719
less O 0 0.00031558733
than O 0 0.00017445265
0 O 0 0.0002648374
. O 0 0.00021575658
05 O 0 0.0032719914
) O 0 0.00044457123
and O 0 0.00021354927
ventricular B-Disease 0 0.23561971
ectopic I-Disease 0 0.00043296537
beats I-Disease 0 0.037433267
( O 0 0.000496951
P O 0 0.009974483
less O 0 0.00025164487
than O 0 0.00016189384
0 O 0 0.0002831225
. O 0 0.00026071558
05 O 0 0.0041585555
) O 0 0.00064598845
in O 0 0.0003142219
the O 0 0.0004913822
morphine B-Chemical 0 0.9984054
infusion O 0 0.0031698472
group O 0 0.0019629493
. O 0 0.002699088

Effects O 0 0.004284191
of O 0 0.0043821577
aminophylline B-Chemical 0 0.99985576
on O 0 0.0007172644
the O 0 0.00043987078
threshold O 0 0.00032753308
for O 0 0.000301986
initiating O 0 0.00045610606
ventricular B-Disease 0 0.3147472
fibrillation I-Disease 0 0.9975708
during O 0 0.00075634633
respiratory B-Disease 0 0.0047613373
failure I-Disease 0 0.016823709
. O 0 0.003181647

Cardiac B-Disease 0 0.6317656
arrhythmias I-Disease 2 0.9996747
have O 0 0.0022179363
frequently O 0 0.0014315137
been O 0 0.0009164836
reported O 0 0.0008334713
in O 0 0.00064719183
association O 0 0.00060702785
with O 0 0.0013706106
respiratory B-Disease 0 0.009070578
failure I-Disease 0 0.042966865
. O 0 0.0043838015

The O 0 0.0016226704
possible O 0 0.00095766474
additive O 0 0.0012813689
role O 0 0.00033028272
of O 0 0.0005282512
pharmacologic O 0 0.0015375995
agents O 0 0.0011721792
in O 0 0.00038824373
precipitating O 0 0.056925554
cardiac B-Disease 0 0.41542986
disturbances I-Disease 0 0.9898788
in O 0 0.00023013561
patients O 0 0.00042660642
with O 0 0.00022826954
respiratory B-Disease 0 0.001938002
failure I-Disease 0 0.0045170155
has O 0 0.00018594631
only O 0 0.0003600758
recently O 0 0.00051943806
been O 0 0.00080580026
emphasized O 0 0.0015766353
. O 0 0.0030218472

The O 0 0.0016837647
effects O 0 0.0015889927
of O 0 0.0024111345
aminophylline B-Chemical 0 0.99990845
on O 0 0.00045050876
the O 0 0.00035365816
ventricular B-Disease 0 0.37694117
fibrillation I-Disease 0 0.9982815
threshold O 0 0.00018856699
during O 0 0.00016204317
normal O 0 0.00075308763
acid O 0 0.5915346
- O 0 0.006606443
base O 0 0.00024338992
conditions O 0 0.00014175927
and O 0 0.00014142712
during O 0 0.000110870526
respiratory B-Disease 0 0.000866477
failure I-Disease 0 0.0017376512
were O 0 0.00013853371
studied O 0 0.00020336802
in O 0 0.0001918258
anesthetized O 0 0.0008031938
open O 0 0.00048104225
chest O 0 0.0011749862
dogs O 0 0.0018484752
. O 0 0.0022670554

The O 0 0.0023397272
ventricular B-Disease 0 0.19579972
fibrillation I-Disease 0 0.9944401
threshold O 0 0.0006882711
was O 0 0.0004435424
measured O 0 0.00036067716
by O 0 0.0002588471
passing O 0 0.00031124544
a O 0 0.00026330838
gated O 0 0.00021249635
train O 0 0.00015646289
of O 0 0.0001528536
12 O 0 9.468411e-05
constant O 0 0.00012604694
current O 0 0.0001296563
pulses O 0 0.00015111842
through O 0 0.0001057782
the O 0 0.0001375174
ventricular O 0 0.123112746
myocardium O 0 0.011705668
during O 0 0.00011817957
the O 0 0.00013061725
vulnerable O 0 0.0002600369
period O 0 0.00016916958
of O 0 0.00035366495
the O 0 0.00047999586
cardiac O 0 0.002637332
cycle O 0 0.0015408531
. O 0 0.0027593446

During O 0 0.0017741887
the O 0 0.0014248942
infusion O 0 0.0028110405
of O 0 0.0017270927
aminophylline B-Chemical 0 0.9999429
, O 0 0.0012324179
the O 0 0.00033648088
ventricular B-Disease 0 0.33321318
fibrillation I-Disease 0 0.99771994
threshold O 0 0.0001701913
was O 0 0.00013993999
reduced O 0 0.00016361191
by O 0 0.00012445384
30 O 0 9.829285e-05
to O 0 7.378402e-05
40 O 0 9.6932774e-05
percent O 0 8.5296044e-05
of O 0 9.887994e-05
the O 0 8.5691136e-05
control O 0 0.00012219102
when O 0 0.00011794742
pH O 0 0.0025889406
and O 0 0.00018119112
partial O 0 0.0002626577
pressures O 0 0.0011446553
of O 0 0.00055475265
oxygen B-Chemical 1 0.9998404
( O 0 0.004511913
PO2 B-Chemical 0 0.99997663
) O 0 0.0012633059
and O 0 0.0004570359
carbon B-Chemical 0 0.9925488
dioxide I-Chemical 0 0.99983644
( O 0 0.0046693156
CO2 B-Chemical 0 0.9994023
) O 0 0.0010703595
were O 0 0.0002971423
kept O 0 0.000435621
within O 0 0.00031330503
normal O 0 0.0011869859
limits O 0 0.0023649076
. O 0 0.0029641658

When O 0 0.00271292
respiratory B-Disease 0 0.010509654
failure I-Disease 0 0.018988194
was O 0 0.0010329759
produced O 0 0.00070116704
by O 0 0.0011009119
hypoventilation B-Disease 0 0.99987733
( O 0 0.0019471303
pH O 0 0.005055624
7 O 0 0.00029909718
. O 0 0.0003087764
05 O 0 0.0023449413
to O 0 0.00020402798
7 O 0 0.00018611268
. O 0 0.00021476626
25 O 0 0.00032832718
; O 0 0.0005716714
PC02 O 0 0.00992044
70 O 0 0.00024328295
to O 0 0.00013874921
100 O 0 0.00030944357
mm O 0 0.0008186111
Hg O 0 0.75226516
: O 0 0.00077476323
P02 O 0 0.01032942
20 O 0 0.00014695106
to O 0 8.5979744e-05
40 O 0 0.000120209574
mm O 0 0.0004620401
Hg O 0 0.50611407
) O 0 0.00043778654
, O 0 0.00025832886
infusion O 0 0.000449664
of O 0 0.00029900455
aminophylline B-Chemical 0 0.9999819
resulted O 0 0.0001529889
in O 0 0.0001138689
an O 0 0.00012176473
even O 0 0.0001210172
greater O 0 0.00014792364
decrease O 0 0.00013436211
in O 0 0.00013113604
ventricular B-Disease 0 0.33262452
fibrillation I-Disease 0 0.99547416
threshold O 0 0.00011109658
to O 0 0.000110628054
60 O 0 0.00017172293
percent O 0 0.00018061136
of O 0 0.00028031625
the O 0 0.00035098125
control O 0 0.0007204376
level O 0 0.0013499344
. O 0 0.0029230814

These O 0 0.0016834819
experiments O 0 0.001038444
suggest O 0 0.0006031385
that O 0 0.0005901614
although O 0 0.00055603613
many O 0 0.00038664922
factors O 0 0.00066819263
may O 0 0.00025309552
contribute O 0 0.0002007944
to O 0 0.0001541401
the O 0 0.00013664765
increased O 0 0.00022791354
incidence O 0 0.0003470861
of O 0 0.00026445359
ventricular B-Disease 0 0.9984201
arrhythmias I-Disease 2 0.9999865
in O 0 0.0002320233
respiratory B-Disease 0 0.0015772773
failure I-Disease 0 0.0028908753
, O 0 0.00021448651
pharmacologic O 0 0.00045497945
agents O 0 0.0004973562
, O 0 0.00048821306
particularly O 0 0.00071814744
aminophylline B-Chemical 0 0.99998534
, O 0 0.00077648385
may O 0 0.00023231041
play O 0 0.00024960827
a O 0 0.00059907977
significant O 0 0.0006315717
role O 0 0.00076565554
. O 0 0.0026293292

Pentoxifylline B-Chemical 0 0.9998299
( O 0 0.05844963
Trental B-Chemical 0 0.99973136
) O 0 0.004845658
does O 0 0.0005875816
not O 0 0.0004840894
inhibit O 0 0.0005967723
dipyridamole B-Chemical 0 0.99994624
- O 0 0.010722788
induced O 0 0.00041479786
coronary O 0 0.5361118
hyperemia B-Disease 0 0.99936837
: O 0 0.00045226453
implications O 0 0.00020409182
for O 0 0.00029282653
dipyridamole B-Chemical 0 0.99991846
- O 0 0.09117916
thallium B-Chemical 0 0.9995932
- O 0 0.01040806
201 O 0 0.004220663
myocardial O 0 0.9255679
imaging O 0 0.00209664
. O 0 0.0025080135

Dipyridamole B-Chemical 0 0.9996464
- O 0 0.39768788
thallium B-Chemical 0 0.998901
- O 0 0.010212283
201 O 0 0.0019687759
imaging O 0 0.0005773591
is O 0 0.00028396834
often O 0 0.00030724236
performed O 0 0.00021515322
in O 0 0.00023005181
patients O 0 0.00039069063
unable O 0 0.00016988876
to O 0 0.00023449506
exercise O 0 0.0006061308
because O 0 0.00027556508
of O 0 0.0006991049
peripheral B-Disease 0 0.03924425
vascular I-Disease 0 0.99237293
disease I-Disease 0 0.9783066
. O 0 0.0039283163

Many O 0 0.002387791
of O 0 0.0017990891
these O 0 0.0011487216
patients O 0 0.0014702588
are O 0 0.00056364015
taking O 0 0.0013167784
pentoxifylline B-Chemical 1 0.9999598
( O 0 0.007289367
Trental B-Chemical 0 0.9998505
) O 0 0.0023495278
, O 0 0.0010900268
a O 0 0.001673592
methylxanthine B-Chemical 0 0.99993646
derivative O 0 0.0082596885
which O 0 0.00055217696
may O 0 0.00035634296
improve O 0 0.00046471687
intermittent B-Disease 0 0.0029826146
claudication I-Disease 0 0.8619814
. O 0 0.002458517

Whether O 0 0.0036462082
pentoxifylline B-Chemical 1 0.9998869
inhibits O 0 0.0030189783
dipyridamole B-Chemical 0 0.9999596
- O 0 0.044219583
induced O 0 0.0006198496
coronary O 0 0.7298401
hyperemia B-Disease 0 0.99961925
like O 0 0.00019810731
other O 0 0.000228861
methylxanthines B-Chemical 0 0.9998011
such O 0 0.00022316047
as O 0 0.00036106558
theophylline B-Chemical 0 0.99998474
and O 0 0.00022177746
should O 0 7.115837e-05
be O 0 0.000102073005
stopped O 0 0.00014781914
prior O 0 7.9197154e-05
to O 0 0.00022356508
dipyridamole B-Chemical 0 0.9999466
- O 0 0.08129676
thallium B-Chemical 0 0.9996438
- O 0 0.004150834
201 O 0 0.0013165759
imaging O 0 0.0006155516
is O 0 0.0006109163
unknown O 0 0.0014805617
. O 0 0.0027219013

Therefore O 0 0.0022304135
, O 0 0.003085629
we O 0 0.00082926673
studied O 0 0.0012454926
the O 0 0.0007662482
hyperemic O 0 0.83568513
response O 0 0.00034777707
to O 0 0.00031684563
dipyridamole B-Chemical 0 0.9997943
in O 0 0.0001765297
seven O 0 0.00010569058
open O 0 0.00017396228
- O 0 0.00049785065
chest O 0 0.00020207182
anesthetized O 0 0.00030686148
dogs O 0 0.00016037033
after O 0 5.268678e-05
pretreatment O 0 0.0004138971
with O 0 0.0001648245
either O 0 0.00029464657
pentoxifylline B-Chemical 1 0.99998975
( O 0 0.0007784428
0 O 0 0.00023784245
, O 0 0.00022868015
7 O 0 9.7357595e-05
. O 0 0.000103845596
5 O 0 0.00010028907
, O 0 0.00017558444
or O 0 0.00010427217
15 O 0 0.00013534991
mg O 0 0.0010490568
/ O 0 0.00054204086
kg O 0 0.0003855996
i O 0 0.00032105797
. O 0 0.00018052597
v O 0 0.0007769583
. O 0 0.00021219792
) O 0 0.000503271
or O 0 0.00030715685
theophylline B-Chemical 0 0.9999386
( O 0 0.0006142201
3 O 0 0.00023333999
mg O 0 0.0017542028
/ O 0 0.00094785966
kg O 0 0.00078202237
i O 0 0.0008107265
. O 0 0.00062125747
v O 0 0.002540421
. O 0 0.0013483473
) O 0 0.0037063144
. O 0 0.0036366463

Baseline O 0 0.0052273264
circumflex O 0 0.7979197
coronary O 0 0.13409416
blood O 0 0.008192403
flows O 0 0.004698452
did O 0 0.0008994661
not O 0 0.0006181363
differ O 0 0.0006524603
significantly O 0 0.0008055096
among O 0 0.0010689304
treatment O 0 0.0013465809
groups O 0 0.0025193482
. O 0 0.004033868

Dipyridamole B-Chemical 0 0.99950504
significantly O 0 0.0028409746
increased O 0 0.0019157287
coronary O 0 0.09999772
blood O 0 0.0040912027
flow O 0 0.0015981635
before O 0 0.00015889705
and O 0 0.00021085348
after O 0 0.00011403339
7 O 0 0.0001493205
. O 0 0.00015585464
5 O 0 0.00013241117
or O 0 0.00011860823
15 O 0 0.0001421033
mm O 0 0.00047690418
/ O 0 0.0007083241
kg O 0 0.0005002679
i O 0 0.0004153892
. O 0 0.00024585635
v O 0 0.001107704
. O 0 0.0004364313
pentoxifylline B-Chemical 1 0.9999237
( O 0 0.0007422443
p O 0 0.00054798444
less O 0 0.0004322366
than O 0 0.00037008128
0 O 0 0.0007640113
. O 0 0.0009376934
002 O 0 0.0066493903
) O 0 0.0042109024
. O 0 0.0038917416

Neither O 0 0.0019646091
dose O 0 0.0029603154
of O 0 0.002220374
pentoxifylline B-Chemical 1 0.9999559
significantly O 0 0.0012692265
decreased O 0 0.0010410259
the O 0 0.0005193027
dipyridamole B-Chemical 0 0.99996614
- O 0 0.024027193
induced O 0 0.0004035698
hyperemia B-Disease 0 0.9998072
, O 0 0.0003465895
while O 0 0.0001191218
peak O 0 0.00018204121
coronary O 0 0.017075142
blood O 0 0.001336444
flow O 0 0.0008526118
was O 0 9.635908e-05
significantly O 0 0.00012257334
lower O 0 0.00015423038
after O 0 0.000121463454
theophylline B-Chemical 0 0.9999025
( O 0 0.00045016984
p O 0 0.00037068647
less O 0 0.00030730388
than O 0 0.00027563656
0 O 0 0.00059826806
. O 0 0.0007271608
01 O 0 0.0045082644
) O 0 0.0034253297
. O 0 0.0032821638

We O 0 0.0022928035
conclude O 0 0.0012869438
that O 0 0.0010648835
pentoxyifylline B-Chemical 0 0.0049590864
does O 0 0.0007113625
not O 0 0.00060370594
inhibit O 0 0.00076318136
dipyridamole B-Chemical 0 0.9999503
- O 0 0.019485414
induced O 0 0.0006274801
coronary O 0 0.6874563
hyperemia B-Disease 0 0.9992466
even O 0 0.0005316234
at O 0 0.0003859043
high O 0 0.0009653235
doses O 0 0.002751657
. O 0 0.0028835093

Cause O 0 0.0095113525
of O 0 0.0035171206
death B-Disease 0 0.43168107
among O 0 0.0015155394
patients O 0 0.001930012
with O 0 0.0012270794
Parkinson B-Disease 0 0.9967681
' I-Disease 0 0.0012658396
s I-Disease 0 0.0009643679
disease I-Disease 0 0.13217701
: O 0 0.0010864456
a O 0 0.00072107575
rare O 0 0.0017956363
mortality O 0 0.0020925556
due O 0 0.00050397456
to O 0 0.0012208219
cerebral B-Disease 0 0.999624
haemorrhage I-Disease 0 0.99994147
. O 0 0.00495302

Causes O 0 0.0076526958
of O 0 0.0037547322
death B-Disease 0 0.6478986
, O 0 0.0021526662
with O 0 0.0007462572
special O 0 0.000529033
reference O 0 0.00049380574
to O 0 0.00054635823
cerebral B-Disease 0 0.99982125
haemorrhage I-Disease 0 0.9999876
, O 0 0.0006045114
among O 0 0.00020296933
240 O 0 0.00029595854
patients O 0 0.00026281652
with O 0 0.00016986494
pathologically O 0 0.030297931
verified O 0 0.00018355095
Parkinson B-Disease 0 0.996811
' I-Disease 0 0.0004095915
s I-Disease 0 0.00032647184
disease I-Disease 0 0.040868286
were O 0 9.954494e-05
investigated O 0 8.988293e-05
using O 0 8.683833e-05
the O 0 0.00011541376
Annuals O 0 0.0010634824
of O 0 0.00018914032
the O 0 0.00019198626
Pathological O 0 0.0056573274
Autopsy O 0 0.005959077
Cases O 0 0.00062910677
in O 0 0.0002618186
Japan O 0 0.00083231606
from O 0 0.0004678268
1981 O 0 0.0016808409
to O 0 0.0009533318
1985 O 0 0.0039855167
. O 0 0.0032064933

The O 0 0.0024984146
leading O 0 0.002364832
causes O 0 0.0017756814
of O 0 0.0017173935
death B-Disease 0 0.8039384
were O 0 0.0009898499
pneumonia B-Disease 0 0.98251766
and O 0 0.00081664586
bronchitis B-Disease 0 0.9969103
( O 0 0.0008222661
44 O 0 0.00039322625
. O 0 0.00021702544
1 O 0 0.00023526455
% O 0 0.00044523942
) O 0 0.0006916169
, O 0 0.00082271046
malignant O 0 0.8527213
neoplasms B-Disease 0 0.98286057
( O 0 0.0005505492
11 O 0 0.00019800666
. O 0 0.00012930406
6 O 0 0.00010500475
% O 0 0.00029551328
) O 0 0.00045636288
, O 0 0.00047137676
heart B-Disease 0 0.03498821
diseases I-Disease 0 0.13345692
( O 0 0.0004837799
4 O 0 0.00015325959
. O 0 0.0001510899
1 O 0 0.00018179283
% O 0 0.0003637376
) O 0 0.00061479356
, O 0 0.00089268107
cerebral B-Disease 0 0.99875796
infarction I-Disease 0 0.99998784
( O 0 0.0006390184
3 O 0 0.000150412
. O 0 0.0001364479
7 O 0 0.00013062486
% O 0 0.00035995324
) O 0 0.00057840254
and O 0 0.00046687035
septicaemia B-Disease 0 0.98720086
( O 0 0.00091787864
3 O 0 0.0004010738
. O 0 0.00047332907
3 O 0 0.0006296566
% O 0 0.0017903518
) O 0 0.0034720183
. O 0 0.003592172

Cerebral B-Disease 0 0.99732566
haemorrhage I-Disease 0 0.9998567
was O 0 0.0017202392
the O 0 0.00075673853
11th O 0 0.0010211724
most O 0 0.0006534436
frequent O 0 0.0005921366
cause O 0 0.00047098464
of O 0 0.00049509405
death B-Disease 0 0.74885076
, O 0 0.00069407263
accounting O 0 0.0003398466
for O 0 0.00013197967
only O 0 0.00017275068
0 O 0 0.00020190736
. O 0 0.00011731928
8 O 0 0.00010441365
% O 0 0.00021058568
of O 0 0.00015765017
deaths B-Disease 0 0.0040419376
among O 0 0.00016079891
the O 0 0.00011855699
patients O 0 0.00039010838
, O 0 0.00027728206
whereas O 0 0.00014855505
it O 0 0.00019306142
was O 0 0.00010518436
the O 0 8.970952e-05
5th O 0 0.00015608247
most O 0 0.0001612231
common O 0 0.00016344039
cause O 0 0.00021592903
of O 0 0.0002829946
death B-Disease 0 0.6125223
among O 0 0.00033515325
the O 0 0.0002461972
Japanese O 0 0.00078662817
general O 0 0.0004446901
population O 0 0.00082932634
in O 0 0.0009776986
1985 O 0 0.0039435443
. O 0 0.002848583

The O 0 0.0021109602
low O 0 0.0024912958
incidence O 0 0.003028333
of O 0 0.0027347836
cerebral B-Disease 0 0.99986136
haemorrhage I-Disease 0 0.9999863
as O 0 0.00065829925
a O 0 0.00053258124
cause O 0 0.0003467742
of O 0 0.00032331285
death B-Disease 0 0.5300921
in O 0 0.00019077987
patients O 0 0.00040693878
with O 0 0.0002946946
Parkinson B-Disease 0 0.9988758
' I-Disease 0 0.0004969555
s I-Disease 0 0.00039354255
disease I-Disease 0 0.1372142
may O 0 8.963719e-05
reflect O 0 7.670494e-05
the O 0 9.535206e-05
hypotensive B-Disease 0 0.9726792
effect O 0 0.000116083495
of O 0 0.0004668563
levodopa B-Chemical 0 0.9999969
and O 0 0.00021222421
a O 0 0.00034630758
hypotensive B-Disease 0 0.99124664
mechanism O 0 8.200436e-05
due O 0 9.295968e-05
to O 0 0.00015779516
reduced O 0 0.0007497322
noradrenaline B-Chemical 1 0.9999845
levels O 0 0.00040475032
in O 0 0.00045176194
the O 0 0.0008490728
parkinsonian B-Disease 2 0.9998845
brain O 0 0.0066007716
. O 0 0.0023713817

Possible O 0 0.008284258
intramuscular O 0 0.07423814
midazolam B-Chemical 0 0.99992406
- O 0 0.049595058
associated O 0 0.002960252
cardiorespiratory B-Disease 0 0.33905298
arrest I-Disease 0 0.12066394
and O 0 0.0043320535
death B-Disease 0 0.73635453
. O 0 0.0071859015

Midazolam B-Chemical 0 0.999961
hydrochloride I-Chemical 0 0.99904317
is O 0 0.0018947626
commonly O 0 0.0012823041
used O 0 0.0007507499
for O 0 0.00066730933
dental O 0 0.0015986238
or O 0 0.0009578431
endoscopic O 0 0.0017577091
procedures O 0 0.0020797185
. O 0 0.004050876

Although O 0 0.0015760498
generally O 0 0.0013690719
consisted O 0 0.00081985514
safe O 0 0.00068090006
when O 0 0.00029178677
given O 0 0.0002445686
intramuscularly O 0 0.0006144395
, O 0 0.0004755684
intravenous O 0 0.0013597497
administration O 0 0.0003879764
is O 0 0.00018015265
known O 0 0.0002236896
to O 0 0.0002647803
cause O 0 0.0005781565
respiratory B-Disease 0 0.0036539463
and I-Disease 0 0.0011260204
cardiovascular I-Disease 0 0.9969579
depression I-Disease 0 0.999869
. O 0 0.0043841037

This O 0 0.0051944223
report O 0 0.0033412834
describes O 0 0.0014168662
the O 0 0.0005831729
first O 0 0.00035039085
published O 0 0.00039891427
case O 0 0.00041194036
of O 0 0.0005118394
cardiorespiratory B-Disease 0 0.48894683
arrest I-Disease 0 0.10459654
and O 0 0.00053743005
death B-Disease 0 0.36991322
associated O 0 0.00035039018
with O 0 0.00038086704
intramuscular O 0 0.0016555594
administration O 0 0.00093099975
of O 0 0.0014780689
midazolam B-Chemical 0 0.99993217
. O 0 0.0037221964

Information O 0 0.0021239878
regarding O 0 0.0015872734
midazolam B-Chemical 0 0.9997925
use O 0 0.0010692313
is O 0 0.0006366161
reviewed O 0 0.0009224711
to O 0 0.0004016598
provide O 0 0.00034458234
recommendation O 0 0.0006718656
for O 0 0.0006065319
safe O 0 0.0015612191
administration O 0 0.0029330573
. O 0 0.0037285024

Myasthenia B-Disease 0 0.9839113
gravis I-Disease 0 0.99845564
presenting O 0 0.0142322555
as O 0 0.0036325662
weakness O 0 0.690628
after O 0 0.0022250072
magnesium B-Chemical 1 0.99673283
administration O 0 0.010086753
. O 0 0.0066293012

We O 0 0.0025399837
studied O 0 0.0023882953
a O 0 0.0016429902
patient O 0 0.00084892043
with O 0 0.00046381511
no O 0 0.00028997887
prior O 0 0.00016957962
history O 0 0.0004757917
of O 0 0.0004533568
neuromuscular B-Disease 0 0.97409445
disease I-Disease 0 0.9946365
who O 0 0.00066083815
became O 0 0.00034846173
virtually O 0 0.0002496837
quadriplegic B-Disease 0 0.9965199
after O 0 0.0001795475
parenteral O 0 0.0027437874
magnesium B-Chemical 1 0.99924797
administration O 0 0.0023144898
for O 0 0.0012178492
preeclampsia B-Disease 0 0.99986315
. O 0 0.0043367217

The O 0 0.0040620356
serum O 0 0.22052467
magnesium B-Chemical 1 0.99877673
concentration O 0 0.0033136094
was O 0 0.00086981483
3 O 0 0.00054735376
. O 0 0.0005073715
0 O 0 0.0007762419
mEq O 0 0.2467655
/ O 0 0.00367636
L O 0 0.39135343
, O 0 0.0016222857
which O 0 0.0008286913
is O 0 0.0006400906
usually O 0 0.0010365034
well O 0 0.0012046908
tolerated O 0 0.0033773792
. O 0 0.0038097678

The O 0 0.0047470895
magnesium B-Chemical 1 0.9954203
was O 0 0.002606974
stopped O 0 0.0022669446
and O 0 0.0013449884
she O 0 0.0010397488
recovered O 0 0.0007859378
over O 0 0.0007986291
a O 0 0.0014313769
few O 0 0.0010271125
days O 0 0.0015177737
. O 0 0.0040964084

While O 0 0.002738038
she O 0 0.0023822575
was O 0 0.0014522604
weak O 0 0.0017755124
, O 0 0.0015887823
2 O 0 0.00078532234
- O 0 0.0018712833
Hz O 0 0.0015174631
repetitive O 0 0.00020414453
stimulation O 0 0.000120523044
revealed O 0 0.00013013254
a O 0 0.00025361078
decrement O 0 0.0006777456
without O 0 0.00013688605
significant O 0 0.00013303738
facilitation O 0 0.00047245165
at O 0 9.2520066e-05
rapid O 0 0.00016571723
rates O 0 0.00015074093
or O 0 0.000117679716
after O 0 9.7982345e-05
exercise O 0 0.00045944712
, O 0 0.00047867675
suggesting O 0 0.00033909606
postsynaptic B-Disease 0 0.12842163
neuromuscular I-Disease 0 0.89478505
blockade I-Disease 0 0.5907169
. O 0 0.003907352

After O 0 0.0018071987
her O 0 0.0020605675
strength O 0 0.0013689146
returned O 0 0.00107511
, O 0 0.0010688555
repetitive O 0 0.0004677505
stimulation O 0 0.00031972988
was O 0 0.00038235073
normal O 0 0.0006681869
, O 0 0.00066195946
but O 0 0.00039548698
single O 0 0.0002849955
fiber O 0 0.0012227328
EMG O 0 0.0076798666
revealed O 0 0.00034454543
increased O 0 0.0007375825
jitter O 0 0.0028680488
and O 0 0.0011277292
blocking O 0 0.0020651352
. O 0 0.0034508002

Her O 0 0.026605058
acetylcholine B-Chemical 1 0.9987185
receptor O 0 0.015352651
antibody O 0 0.00409006
level O 0 0.0026543871
was O 0 0.003059992
markedly O 0 0.0074811014
elevated O 0 0.016029749
. O 0 0.008151455

Although O 0 0.0030274994
paralysis B-Disease 0 0.9947884
after O 0 0.0012766843
magnesium B-Chemical 1 0.99884665
administration O 0 0.0020036194
has O 0 0.0002849072
been O 0 0.00025082994
described O 0 0.00017467569
in O 0 0.00016784901
patients O 0 0.00032028573
with O 0 0.00018356231
known O 0 0.00025600474
myasthenia B-Disease 0 0.9996382
gravis I-Disease 0 0.9996424
, O 0 0.00080395536
it O 0 0.00026248724
has O 0 8.6007945e-05
not O 0 0.000107296655
previously O 0 0.00017204236
been O 0 0.00014158635
reported O 0 0.00015353267
to O 0 0.00010212928
be O 0 0.000106981264
the O 0 9.520887e-05
initial O 0 0.00011877506
or O 0 0.00017343712
only O 0 0.0003368903
manifestation O 0 0.0026445135
of O 0 0.00070649304
the O 0 0.0010157253
disease O 0 0.50503325
. O 0 0.0032479882

Patients O 0 0.004829873
who O 0 0.0024689636
are O 0 0.0009775464
unusually O 0 0.0019878186
sensitive O 0 0.00043856888
to O 0 0.00032916776
the O 0 0.0002887501
neuromuscular O 0 0.003044468
effects O 0 0.00028517732
of O 0 0.00056764646
magnesium B-Chemical 1 0.99963784
should O 0 0.00017338434
be O 0 0.00021061399
suspected O 0 0.00062453275
of O 0 0.00022617521
having O 0 0.0002544151
an O 0 0.00036368732
underlying O 0 0.0008123763
disorder B-Disease 0 0.99718297
of I-Disease 0 0.0011312487
neuromuscular I-Disease 0 0.116210885
transmission I-Disease 0 0.0013796699
. O 0 0.0024240213

No O 0 0.0050031273
enhancement O 0 0.0032773674
by O 0 0.0029595217
phenobarbital B-Chemical 0 0.99998224
of O 0 0.0016305279
the O 0 0.0008665126
hepatocarcinogenicity O 0 0.97908396
of O 0 0.0010879282
a O 0 0.0026298284
choline B-Chemical 0 0.99970764
- O 0 0.010530597
devoid O 0 0.0003411758
diet O 0 0.0027973517
in O 0 0.00076487457
the O 0 0.0009678662
rat O 0 0.002670881
. O 0 0.0032049427

An O 0 0.0025215046
experiment O 0 0.0011028964
was O 0 0.00084474706
performed O 0 0.00051181816
to O 0 0.00033915945
test O 0 0.00034133668
whether O 0 0.00010509911
inclusion O 0 0.00015536413
of O 0 0.0005839288
phenobarbital B-Chemical 0 0.9999974
in O 0 0.0006821852
a O 0 0.0018968876
choline B-Chemical 0 0.9998442
- O 0 0.0107131265
devoid O 0 0.00014148999
diet O 0 0.0015427398
would O 0 0.00021435198
increase O 0 0.00027593132
the O 0 0.00035649806
hepatocarcinogenicity O 0 0.91497123
of O 0 0.00083337753
the O 0 0.00085574895
diet O 0 0.008754503
. O 0 0.0030008769

Groups O 0 0.01131145
of O 0 0.0027431636
5 O 0 0.001714497
- O 0 0.0027909097
week O 0 0.0004963732
old O 0 0.0006677388
male O 0 0.0010121892
Fischer O 0 0.001797863
- O 0 0.001999657
344 O 0 0.0016206214
rats O 0 0.0003763348
were O 0 0.00017628666
fed O 0 0.0003165241
for O 0 0.000139399
7 O 0 0.00016283202
- O 0 0.00062621833
25 O 0 0.00019865946
months O 0 0.00010640837
semipurified O 0 0.01376797
choline B-Chemical 0 0.9996414
- O 0 0.009341503
devoid O 0 0.00015111294
or O 0 0.0004067233
choline B-Chemical 0 0.99982834
- O 0 0.054983743
supplemented O 0 0.008312194
diets O 0 0.01769714
, O 0 0.00052127545
containing O 0 0.00020031558
or O 0 0.00022334905
not O 0 0.00027738596
0 O 0 0.0005599278
. O 0 0.00058982684
06 O 0 0.008570851
% O 0 0.004425011
phenobarbital B-Chemical 0 0.99996567
. O 0 0.0056598443

No O 0 0.010058088
hepatic O 0 0.9921806
preneoplastic O 0 0.9844678
nodules O 0 0.6119125
or O 0 0.0019930238
hepatocellular B-Disease 0 0.99997044
carcinomas I-Disease 0 0.9956567
developed O 0 0.00047465783
in O 0 0.00018106175
rats O 0 0.0002721463
fed O 0 0.00037274638
the O 0 0.00018958794
plain O 0 0.017807659
choline B-Chemical 0 0.9998472
- O 0 0.03528925
supplemented O 0 0.005756113
diet O 0 0.0063051144
, O 0 0.0004115231
while O 0 0.00017612385
one O 0 0.00022059983
preneoplastic O 0 0.88175267
nodule O 0 0.21024144
and O 0 0.000262528
one O 0 0.00032539578
hepatocellular B-Disease 0 0.99999523
carcinoma I-Disease 0 0.99998105
developed O 0 0.0003345148
in O 0 0.00010691386
two O 0 7.261089e-05
rats O 0 0.00021116938
fed O 0 0.00033309424
the O 0 0.00018083747
same O 0 0.00023996699
diet O 0 0.0035353063
containing O 0 0.001446062
phenobarbital B-Chemical 0 0.9999871
. O 0 0.0049263192

The O 0 0.0027709166
incidence O 0 0.0042060628
of O 0 0.002807311
preneoplastic O 0 0.8704051
nodules O 0 0.19944492
and O 0 0.0010139153
of O 0 0.001455532
hepatocellular B-Disease 0 0.99998105
carcinomas I-Disease 0 0.99800724
was O 0 0.00037010454
10 O 0 0.00022272745
% O 0 0.0003086095
and O 0 0.0001732776
37 O 0 0.00033533797
% O 0 0.00035303028
, O 0 0.00030675123
respectively O 0 0.00032252597
, O 0 0.00026207784
in O 0 0.000121918565
rats O 0 0.00022574219
fed O 0 0.00034670281
the O 0 0.00018239424
plain O 0 0.02607342
choline B-Chemical 0 0.99985003
- O 0 0.007936027
devoid O 0 0.00010453261
diet O 0 0.0017397659
, O 0 0.00036819925
and O 0 0.00018406096
17 O 0 0.00021797544
% O 0 0.00025244677
and O 0 0.00013599407
30 O 0 0.00012134837
% O 0 0.00024172667
, O 0 0.00021627579
in O 0 0.000121944606
rats O 0 0.00026053717
fed O 0 0.0005234553
the O 0 0.00045231584
phenobarbital B-Chemical 0 0.99999833
- O 0 0.16136882
containing O 0 0.00084507954
choline B-Chemical 0 0.9996648
- O 0 0.016772622
devoid O 0 0.00070718053
diet O 0 0.009452795
. O 0 0.0033444671

The O 0 0.0022173075
results O 0 0.00195944
evinced O 0 0.008319401
no O 0 0.0010099713
enhancement O 0 0.0010124351
of O 0 0.0007432295
the O 0 0.0006403594
hepatocarcinogenicity O 0 0.96228224
of O 0 0.0008947771
the O 0 0.00087798835
choline B-Chemical 0 0.99961436
- O 0 0.010895322
devoid O 0 0.00046205378
diet O 0 0.007824547
by O 0 0.0026460988
phenobarbital B-Chemical 0 0.99998224
. O 0 0.0067227026

Sporadic O 0 0.72310185
neoplastic O 0 0.39426646
lesions O 0 0.013752238
were O 0 0.0007848244
observed O 0 0.00044190933
in O 0 0.00036139842
organs O 0 0.00053911546
other O 0 0.0002332428
than O 0 0.00020577731
the O 0 0.00020308122
liver O 0 0.007262822
of O 0 0.00024114682
some O 0 0.00019161117
of O 0 0.00019531997
the O 0 0.00015451685
animals O 0 0.00016074954
, O 0 0.00040745427
irrespective O 0 0.00020435623
of O 0 0.00045282926
the O 0 0.0005771536
diet O 0 0.0052982024
fed O 0 0.0039826822
. O 0 0.003556003

On O 0 0.0027634192
two O 0 0.0015008528
paradoxical O 0 0.0059593283
side O 0 0.004336004
- O 0 0.0042324257
effects O 0 0.0005792122
of O 0 0.00094550283
prednisolone B-Chemical 0 0.9998946
in O 0 0.0004312566
rats O 0 0.0007090349
, O 0 0.0008653969
ribosomal O 0 0.0019089017
RNA O 0 0.0049237274
biosyntheses O 0 0.08527298
, O 0 0.0010392091
and O 0 0.00048462916
a O 0 0.0006370033
mechanism O 0 0.00043414644
of O 0 0.0010894092
action O 0 0.002067853
. O 0 0.0035182291

Liver B-Disease 0 0.99137455
enlargement I-Disease 0 0.64365363
and O 0 0.003526076
muscle B-Disease 0 0.32246244
wastage I-Disease 0 0.2144739
occurred O 0 0.0006620219
in O 0 0.0004121713
Wistar O 0 0.0011966912
rats O 0 0.00042104954
following O 0 0.00017012317
the O 0 0.00026069427
subcutaneous O 0 0.0007333746
administration O 0 0.0008216477
of O 0 0.0014200277
prednisolone B-Chemical 0 0.99948716
. O 0 0.0040192795

In O 0 0.002124301
the O 0 0.0018980362
liver O 0 0.0125585785
both O 0 0.00077863596
the O 0 0.0005410538
content O 0 0.00061534985
of O 0 0.00054644264
RNA O 0 0.0014327276
and O 0 0.0003799215
the O 0 0.00025658263
biosynthesis O 0 0.0008606767
of O 0 0.00039023967
ribosomal O 0 0.0018265749
RNA O 0 0.0017832663
increased O 0 0.0003284684
while O 0 0.00014748548
both O 0 0.00012576576
the O 0 0.00014581572
RNA O 0 0.00069966115
content O 0 0.0003217956
and O 0 0.00032731114
ribosomal O 0 0.001833991
RNA O 0 0.0039049163
biosynthesis O 0 0.0018963161
were O 0 0.00031972284
reduced O 0 0.0004260636
in O 0 0.0004535297
the O 0 0.00064985023
gastrocnemius O 0 0.0034663526
muscle O 0 0.0062805326
. O 0 0.0027417073

It O 0 0.004930133
is O 0 0.0014973489
suggested O 0 0.0008757802
that O 0 0.00059952587
the O 0 0.0005982279
drug O 0 0.009613878
acted O 0 0.00091940473
in O 0 0.00034119876
a O 0 0.0004258572
selective O 0 0.00035965262
and O 0 0.00031629516
tissue O 0 0.0010560226
- O 0 0.0011780799
specific O 0 8.628051e-05
manner O 0 0.000121083445
to O 0 0.00012221631
enhance O 0 0.00014733101
ribosomal O 0 0.0013529286
RNA O 0 0.0032269077
synthesis O 0 0.000941708
in O 0 0.00021404831
the O 0 0.00020406513
liver O 0 0.059582308
and O 0 0.00040619168
depress O 0 0.003894266
such O 0 0.00038582113
synthesis O 0 0.0011023113
in O 0 0.00067669456
the O 0 0.0009568285
muscle O 0 0.008502045
. O 0 0.0029938703

This O 0 0.004204581
view O 0 0.0021767819
supports O 0 0.0011816805
the O 0 0.0008409386
contention O 0 0.00094556145
that O 0 0.00050101685
the O 0 0.000559589
liver O 0 0.03742061
and O 0 0.0006481329
muscle O 0 0.0017792255
are O 0 0.00024976445
independent O 0 0.00021051259
sites O 0 0.0003357335
of O 0 0.0011135648
prednisolone B-Chemical 0 0.9996
action O 0 0.0026821052
. O 0 0.003561243

Differential O 0 0.004470981
effects O 0 0.0025799812
of O 0 0.003446446
gamma B-Chemical 0 0.9353824
- I-Chemical 0 0.55751455
hexachlorocyclohexane I-Chemical 0 0.9997242
( O 0 0.016546177
lindane B-Chemical 0 0.99983263
) O 0 0.0031903381
on O 0 0.00065024215
pharmacologically O 0 0.084684215
- O 0 0.012153695
induced O 0 0.0030551313
seizures B-Disease 0 0.99982566
. O 0 0.0062198364

Gamma B-Chemical 0 0.45704272
- I-Chemical 0 0.28137276
hexachlorocyclohexane I-Chemical 0 0.99882954
( O 0 0.011635444
gamma B-Chemical 0 0.903439
- I-Chemical 0 0.24410212
HCH I-Chemical 0 0.9969332
) O 0 0.0025931562
, O 0 0.000774036
the O 0 0.00025930878
active O 0 0.00033155255
ingredient O 0 0.002247104
of O 0 0.0003164628
the O 0 0.00031589885
insecticide O 0 0.9497657
lindane B-Chemical 0 0.99998367
, O 0 0.0011649495
has O 0 0.00010781079
been O 0 0.000109620574
shown O 0 5.8086232e-05
to O 0 9.668131e-05
decrease O 0 0.0002231196
seizure B-Disease 0 0.9976307
threshold O 0 0.000118494165
to O 0 0.00015365086
pentylenetrazol O 0 0.8713202
( O 0 0.0020488573
PTZ B-Chemical 0 0.9999969
) O 0 0.0006736867
3 O 0 8.4722764e-05
h O 0 8.339084e-05
after O 0 4.4963053e-05
exposure O 0 0.00011359798
to O 0 0.00014094208
gamma B-Chemical 0 0.5934544
- I-Chemical 0 0.10938997
HCH I-Chemical 0 0.9971853
and O 0 0.00026287665
conversely O 0 0.00069451664
increase O 0 0.00012556769
threshold O 0 0.00012051914
to O 0 0.0002680309
PTZ B-Chemical 0 0.999998
- O 0 0.06848494
induced O 0 0.00038068826
seizures B-Disease 0 0.9999696
24 O 0 0.00017702815
h O 0 0.00011729142
after O 0 6.194738e-05
exposure O 0 0.00016305559
to O 0 0.00022192003
gamma B-Chemical 0 0.4877688
- I-Chemical 0 0.070893064
HCH I-Chemical 0 0.99597424
( O 0 0.001532755
Vohland O 0 0.0023465077
et O 0 0.0008646173
al O 0 0.0010409476
. O 0 0.0010052185
1981 O 0 0.003740817
) O 0 0.004635184
. O 0 0.0041181874

In O 0 0.002124878
this O 0 0.0019904275
study O 0 0.001550128
, O 0 0.0014282757
the O 0 0.00054364634
severity O 0 0.0009748483
of O 0 0.00033283897
response O 0 0.00024506927
to O 0 0.00020125826
other O 0 0.0003036637
seizure B-Disease 0 0.9996189
- O 0 0.003949393
inducing O 0 0.00017419003
agents O 0 0.00047657947
was O 0 0.0001249454
tested O 0 0.00010128724
in O 0 9.353837e-05
mice O 0 4.3350195e-05
1 O 0 0.000105084684
and O 0 9.3743845e-05
24 O 0 9.0481204e-05
h O 0 8.562562e-05
after O 0 5.0723593e-05
intraperitoneal O 0 0.00019509923
administration O 0 0.00020745261
of O 0 0.0002076626
80 O 0 0.00045406303
mg O 0 0.0032394826
/ O 0 0.0019208695
kg O 0 0.002343645
gamma B-Chemical 0 0.58379936
- I-Chemical 0 0.08550306
HCH I-Chemical 0 0.992481
. O 0 0.0055203466

One O 0 0.0033016345
hour O 0 0.0016835884
after O 0 0.00060520845
the O 0 0.00062631204
administration O 0 0.0010223901
of O 0 0.0009483791
gamma B-Chemical 0 0.820698
- I-Chemical 0 0.22108902
HCH I-Chemical 0 0.9973103
, O 0 0.0008175525
the O 0 0.00019040877
activity O 0 0.00015021049
of O 0 0.0003705448
seizure B-Disease 0 0.9997018
- O 0 0.003925517
inducing O 0 0.00015946472
agents O 0 0.0004642179
was O 0 0.00013579373
increased O 0 0.00020197472
, O 0 0.00020997434
regardless O 0 6.163409e-05
of O 0 0.00011336748
their O 0 9.6035175e-05
mechanism O 0 8.8076275e-05
, O 0 0.00025979627
while O 0 0.00014551498
24 O 0 0.00016246307
h O 0 0.00018080711
after O 0 0.00014659768
gamma B-Chemical 0 0.26392707
- I-Chemical 0 0.03510659
HCH I-Chemical 0 0.98702973
a O 0 0.0007285376
differential O 0 0.0005384814
response O 0 0.00059758424
was O 0 0.0008255946
observed O 0 0.001293317
. O 0 0.0029436438

Seizure B-Disease 2 0.99618953
activity O 0 0.0020048115
due O 0 0.0012880961
to O 0 0.0017777578
PTZ B-Chemical 0 0.99999094
and O 0 0.0055707516
picrotoxin B-Chemical 0 0.99999034
( O 0 0.018731913
PTX B-Chemical 0 0.99973303
) O 0 0.0015414072
was O 0 0.00021169575
significantly O 0 0.00025455144
decreased O 0 0.00044494346
; O 0 0.00052521453
however O 0 0.0002994156
, O 0 0.0008098903
seizure B-Disease 0 0.9990138
activity O 0 0.00013675257
due O 0 0.00011313487
to O 0 0.00015448825
3 B-Chemical 0 0.00028105752
- I-Chemical 0 0.08204035
mercaptopropionic I-Chemical 0 0.99721175
acid I-Chemical 0 0.98447245
( O 0 0.03900621
MPA B-Chemical 0 0.99998283
) O 0 0.0054322607
, O 0 0.002237047
bicuculline B-Chemical 1 0.99998915
( O 0 0.023680408
BCC B-Chemical 0 0.99987423
) O 0 0.003143607
, O 0 0.0010665212
methyl B-Chemical 0 0.71629614
6 I-Chemical 0 0.00019937655
, I-Chemical 0 0.0003513599
7 I-Chemical 0 0.00021186634
- I-Chemical 0 0.0035502512
dimethoxy I-Chemical 0 0.9732055
- I-Chemical 0 0.009415492
4 I-Chemical 0 0.00030840392
- I-Chemical 0 0.007141385
ethyl I-Chemical 0 0.99903405
- I-Chemical 0 0.10743499
B I-Chemical 0 0.6434458
- I-Chemical 0 0.15632088
carboline I-Chemical 0 0.9916831
- I-Chemical 0 0.010726607
3 I-Chemical 0 0.0002621961
- I-Chemical 0 0.0037076666
carboxylate I-Chemical 0 0.28390908
( O 0 0.0045337267
DMCM B-Chemical 0 0.9999912
) O 0 0.002418621
, O 0 0.0007285317
or O 0 0.000499076
strychnine B-Chemical 0 0.99997294
( O 0 0.004464746
STR B-Chemical 0 0.9498385
) O 0 0.0008787333
was O 0 0.00027560553
not O 0 0.00029022753
different O 0 0.0003468364
from O 0 0.0006842724
control O 0 0.0014695163
. O 0 0.0030333933

In O 0 0.0027518715
vitro O 0 0.003045719
, O 0 0.005518957
gamma B-Chemical 0 0.866031
- I-Chemical 0 0.4979776
HCH I-Chemical 0 0.99908733
, O 0 0.029874925
pentylenetetrazol B-Chemical 0 0.9999902
and O 0 0.0044300607
picrotoxin B-Chemical 0 0.99998856
were O 0 0.0003686188
shown O 0 0.00011270899
to O 0 0.00017292652
inhibit O 0 0.00033549307
3H B-Chemical 1 0.99954224
- I-Chemical 1 0.83170825
TBOB I-Chemical 1 0.9992735
binding O 0 0.00015622095
in O 0 0.00014217242
mouse O 0 0.0001123582
whole O 0 0.00015096461
brain O 0 0.0005545872
, O 0 0.00024671224
with O 0 0.0001754544
IC50 O 0 0.03302436
values O 0 0.00014560812
of O 0 0.00014983697
4 O 0 0.00012496376
. O 0 0.00012891734
6 O 0 0.00011669691
, O 0 0.0003188684
404 O 0 0.00068562594
and O 0 0.0002550952
9 O 0 0.00026002253
. O 0 0.00033100173
4 O 0 0.00046542397
microM O 0 0.012219062
, O 0 0.0022893785
respectively O 0 0.0032549514
. O 0 0.003627089

MPA B-Chemical 0 0.9995484
, O 0 0.08469639
BCC B-Chemical 0 0.9992692
, O 0 0.047632366
DMCM B-Chemical 0 0.99997056
, O 0 0.003779399
and O 0 0.0012152656
STR B-Chemical 0 0.6834598
showed O 0 0.00034043385
no O 0 0.0002946415
inhibition O 0 0.00056569284
of O 0 0.0010029551
3H B-Chemical 1 0.9994147
- I-Chemical 1 0.7140253
TBOB I-Chemical 1 0.99908864
( O 0 0.0016622023
t B-Chemical 0 0.013900182
- I-Chemical 0 0.07060464
butyl I-Chemical 0 0.99929154
bicyclo I-Chemical 0 0.9942054
- I-Chemical 0 0.1450459
orthobenzoate I-Chemical 0 0.12682046
) O 0 0.00078271463
binding O 0 0.00018994784
at O 0 0.00025986985
concentrations O 0 0.00079324475
of O 0 0.0009217172
100 O 0 0.0027903437
micron O 0 0.022548445
. O 0 0.003288261

The O 0 0.0018536327
pharmacological O 0 0.0028291862
challenge O 0 0.0008459915
data O 0 0.0007068699
suggest O 0 0.00028836165
that O 0 0.0003497572
tolerance O 0 0.0024825328
may O 0 0.0002893553
occur O 0 0.0002558537
to O 0 0.00025296138
seizure B-Disease 0 0.99780065
activity O 0 0.00014616708
induced O 0 0.000201128
by O 0 0.0004361121
PTZ B-Chemical 0 0.99999714
and O 0 0.0008114057
PTX B-Chemical 0 0.9992835
24 O 0 0.0001920683
h O 0 0.00014659586
after O 0 9.913911e-05
gamma B-Chemical 0 0.3199137
- I-Chemical 0 0.06340044
HCH I-Chemical 0 0.9967374
, O 0 0.00045596217
since O 0 9.019846e-05
the O 0 9.432922e-05
response O 0 0.00011529462
to O 0 0.000110218876
only O 0 0.0001485382
these O 0 0.00015502493
two O 0 0.00019202307
seizure B-Disease 0 0.9989378
- O 0 0.003232179
inducing O 0 0.00043121795
agents O 0 0.001493189
is O 0 0.00082104426
decreased O 0 0.0026999945
. O 0 0.003156028

The O 0 0.002049802
in O 0 0.0015741399
vitro O 0 0.0010849278
data O 0 0.0007828548
suggest O 0 0.00029408385
that O 0 0.00029022864
the O 0 0.00025161056
site O 0 0.00016606823
responsible O 0 0.00017358089
for O 0 0.00014642124
the O 0 0.00015733752
decrease O 0 0.00023063776
in O 0 0.00025600303
seizure B-Disease 0 0.99659306
activity O 0 0.00012343928
24 O 0 0.00014029298
h O 0 0.00014935456
after O 0 0.000117303614
gamma B-Chemical 0 0.30680656
- I-Chemical 0 0.062922284
HCH I-Chemical 0 0.99503183
may O 0 0.00027067369
be O 0 0.00027832933
the O 0 0.00045544028
GABA B-Chemical 0 0.9999484
- O 0 0.101991974
A O 0 0.14601974
receptor O 0 0.010321802
- O 0 0.03077714
linked O 0 0.0014640534
chloride O 0 0.9992536
channel O 0 0.018494504
. O 0 0.004054827

Tolerance O 0 0.009797579
and O 0 0.0022727826
antiviral O 0 0.0023615328
effect O 0 0.0009965736
of O 0 0.0016205104
ribavirin B-Chemical 0 0.9981693
in O 0 0.0009898522
patients O 0 0.0017829015
with O 0 0.001425266
Argentine B-Disease 0 0.015359736
hemorrhagic I-Disease 2 0.9996412
fever I-Disease 0 0.99899524
. O 0 0.005144024

Tolerance O 0 0.008861483
and O 0 0.0018906855
antiviral O 0 0.0019230482
effect O 0 0.0007204431
of O 0 0.0011514776
ribavirin B-Chemical 0 0.9987872
was O 0 0.0004218386
studied O 0 0.00037837864
in O 0 0.00019298615
6 O 0 0.00014401386
patients O 0 0.00031076628
with O 0 0.00027688767
Argentine B-Disease 0 0.00377522
hemorrhagic I-Disease 2 0.9999131
fever I-Disease 0 0.9998597
( O 0 0.0048539797
AHF B-Disease 0 0.99997795
) O 0 0.00080964254
of O 0 0.0002460512
more O 0 0.00032399816
than O 0 0.0002148744
8 O 0 0.00025666045
days O 0 0.00023516093
of O 0 0.0006911894
evolution O 0 0.0014914249
. O 0 0.0027972576

Administration O 0 0.010054119
of O 0 0.0037291879
ribavirin B-Chemical 0 0.9972982
resulted O 0 0.001082009
in O 0 0.00074779626
a O 0 0.0009455866
neutralization O 0 0.0014885984
of O 0 0.0007083589
viremia B-Disease 0 0.16612595
and O 0 0.0004727902
a O 0 0.00062665716
drop O 0 0.0008959439
of O 0 0.0007059722
endogenous O 0 0.0009707276
interferon O 0 0.99952936
titers O 0 0.0059812935
. O 0 0.0041888584

The O 0 0.0037887788
average O 0 0.0030234638
time O 0 0.0026060669
of O 0 0.0045015393
death B-Disease 0 0.39493316
was O 0 0.0049388637
delayed O 0 0.010951301
. O 0 0.008712434

A O 0 0.36090502
reversible O 0 0.29347986
anemia B-Disease 0 0.9995579
was O 0 0.0023760914
the O 0 0.0013181857
only O 0 0.001491586
adverse O 0 0.0034358806
effect O 0 0.0016058291
observed O 0 0.0026506444
. O 0 0.0052334345

From O 0 0.0029205529
these O 0 0.0016109761
results O 0 0.0010972761
, O 0 0.0013022076
we O 0 0.00034215217
conclude O 0 0.00036042262
that O 0 0.0004416708
ribavirin B-Chemical 0 0.9976615
has O 0 0.00021256483
an O 0 0.00023297674
antiviral O 0 0.00040451792
effect O 0 0.00015710156
in O 0 0.00021601285
advanced O 0 0.0027135785
cases O 0 0.0005907431
of O 0 0.0006953889
AHF B-Disease 0 0.99999106
, O 0 0.0006332313
and O 0 0.00021885302
that O 0 0.00023010443
anemia B-Disease 0 0.9999504
, O 0 0.00066946016
the O 0 0.00016497073
only O 0 0.00022392777
secondary O 0 0.00031118287
reaction O 0 0.00025236688
observed O 0 0.00027587762
, O 0 0.0006751424
can O 0 0.00032864156
be O 0 0.00054575445
easily O 0 0.00086460076
managed O 0 0.0024086183
. O 0 0.0029380356

The O 0 0.001800542
possible O 0 0.0010999644
beneficial O 0 0.0012059003
effect O 0 0.00078802294
of O 0 0.0012765847
ribavirin B-Chemical 0 0.9973551
during O 0 0.00039091473
the O 0 0.0003084745
initial O 0 0.00031047195
days O 0 0.0003517547
of O 0 0.0012640564
AHF B-Disease 0 0.99979967
is O 0 0.0013071147
discussed O 0 0.0017810125
. O 0 0.003444208

Is O 0 0.011043199
the O 0 0.0062861564
treatment O 0 0.0064803557
of O 0 0.009244334
scabies B-Disease 0 0.89546686
hazardous O 0 0.02938017
? O 0 0.024074102

Treatment O 0 0.009840294
for O 0 0.0027605558
scabies B-Disease 0 0.7472813
is O 0 0.0009179404
usually O 0 0.0007610131
initiated O 0 0.00044906428
by O 0 0.00035083087
general O 0 0.0003774515
practitioners O 0 0.0009028165
; O 0 0.0006959716
most O 0 0.00039306076
consider O 0 0.00037845565
lindane B-Chemical 0 0.9998894
( O 0 0.010434963
gamma B-Chemical 0 0.9960736
benzene I-Chemical 0 0.99998724
hexachloride I-Chemical 0 0.9999763
) O 0 0.005733173
the O 0 0.0004629796
treatment O 0 0.00054337253
of O 0 0.0008778028
choice O 0 0.0014341582
. O 0 0.0028736156

Lindane B-Chemical 0 0.9993192
is O 0 0.002257134
also O 0 0.0011586386
widely O 0 0.00074177975
used O 0 0.00050764455
as O 0 0.00047833082
an O 0 0.00049084495
agricultural O 0 0.0016593671
and O 0 0.00040525728
industrial O 0 0.0024065236
pesticide O 0 0.032461658
, O 0 0.00058595446
and O 0 0.0002573502
as O 0 0.00021498301
a O 0 0.00029895295
result O 0 0.00017769955
the O 0 0.00019626047
toxic O 0 0.0035199814
profile O 0 0.00025873928
of O 0 0.00036633588
this O 0 0.00057028467
insecticide O 0 0.18447413
is O 0 0.0006147106
well O 0 0.0009259643
understood O 0 0.0032346162
. O 0 0.0034190365

Evidence O 0 0.005396924
is O 0 0.0019284978
accumulating O 0 0.001650237
that O 0 0.0014562156
lindane B-Chemical 0 0.9998099
can O 0 0.0007322936
be O 0 0.0006064088
toxic B-Disease 0 0.0082251765
to I-Disease 0 0.00027567544
the I-Disease 0 0.00023722781
central I-Disease 0 0.00049605634
nervous I-Disease 0 0.0016199973
system I-Disease 0 0.00026834646
and O 0 0.00028173416
may O 0 0.00024210839
be O 0 0.0003420449
associated O 0 0.00062939344
with O 0 0.0017555243
aplastic B-Disease 0 0.9997826
anaemia I-Disease 0 0.9998754
. O 0 0.005958551

Preparations O 0 0.009831652
containing O 0 0.0031683755
lindane B-Chemical 0 0.99952984
continue O 0 0.0013209593
to O 0 0.0006042208
be O 0 0.0004898413
sold O 0 0.0014324262
over O 0 0.00025283676
the O 0 0.00022843434
counter O 0 0.00052854035
and O 0 0.00032240764
may O 0 0.0002204762
represent O 0 0.00022922875
a O 0 0.0004114317
hazard O 0 0.00064912165
to O 0 0.00040289597
poorly O 0 0.0010898131
informed O 0 0.0013647042
patients O 0 0.0023847779
. O 0 0.0027526869

This O 0 0.0046760975
literature O 0 0.0033536844
review O 0 0.0018041125
suggests O 0 0.0004442014
that O 0 0.00037964978
general O 0 0.00043230702
practitioners O 0 0.0007955707
should O 0 0.00016860258
prescribe O 0 0.0012090488
scabicides O 0 0.06458914
with O 0 0.00020612117
increased O 0 0.00023521384
caution O 0 0.00019473866
for O 0 9.37131e-05
certain O 0 0.00013275654
at O 0 0.0001283776
- O 0 0.0012491852
risk O 0 0.0009941728
groups O 0 0.00027488987
, O 0 0.00035620405
and O 0 0.00020005846
give O 0 0.00019047307
adequate O 0 0.0002820018
warnings O 0 0.0004659953
regarding O 0 0.00025779323
potential O 0 0.0007577105
toxicity B-Disease 0 0.6352726
. O 0 0.003601349

Mouse O 0 0.00612625
strain O 0 0.0024414998
- O 0 0.005749458
dependent O 0 0.0008216175
effect O 0 0.00081528246
of O 0 0.0016075096
amantadine B-Chemical 1 0.9996793
on O 0 0.0008839406
motility O 0 0.016754452
and O 0 0.0019812144
brain O 0 0.02770423
biogenic O 0 0.99224234
amines B-Chemical 0 0.9946892
. O 0 0.006205093

The O 0 0.0017911812
effect O 0 0.001575341
of O 0 0.0031428493
amantadine B-Chemical 1 0.99995863
hydrochloride I-Chemical 0 0.9997259
, O 0 0.0014507916
injected O 0 0.00034698335
i O 0 0.0004983245
. O 0 0.0002119888
p O 0 0.00031312855
. O 0 0.00014055047
in O 0 0.0001034178
6 O 0 8.24014e-05
increments O 0 0.00014779449
of O 0 0.00013780172
100 O 0 0.00032505937
mg O 0 0.0017731274
/ O 0 0.0004898104
kg O 0 0.0002532133
each O 0 6.027357e-05
over O 0 6.491974e-05
30 O 0 7.9654325e-05
hr O 0 0.00014850193
, O 0 0.0001598389
on O 0 6.636885e-05
mouse O 0 9.724551e-05
motility O 0 0.00087281526
and O 0 0.00016055009
whole O 0 0.00015683124
brain O 0 0.00045552058
content O 0 0.00015090259
of O 0 0.00015694898
selected O 0 0.00020798817
biogenic O 0 0.985105
amines B-Chemical 0 0.98909354
and O 0 0.000329434
major O 0 0.0003055487
metabolites O 0 0.26018524
was O 0 0.0002459682
studied O 0 0.0003320932
in O 0 0.00024057059
4 O 0 0.00025367778
strains O 0 0.00037305657
of O 0 0.00066666293
mice O 0 0.0006015188
. O 0 0.0023955149

These O 0 0.0028108025
were O 0 0.0020713976
the O 0 0.0014216398
albino O 0 0.0030797864
Sprague O 0 0.07851579
- O 0 0.004244313
Dawley O 0 0.007419311
ICR O 0 0.0012367165
and O 0 0.00051356107
BALB O 0 0.0016579016
/ O 0 0.0027202785
C O 0 0.85946834
, O 0 0.000986807
the O 0 0.0003555035
black O 0 0.0006675545
C57BL O 0 0.017703963
/ O 0 0.0013590343
6 O 0 0.00025487493
and O 0 0.00034395108
the O 0 0.00042939873
brown O 0 0.0016168763
CDF O 0 0.17336267
- O 0 0.011675438
I O 0 0.0159368
mouse O 0 0.0013214081
strains O 0 0.002235864
. O 0 0.0039822035

Amantadine B-Chemical 0 0.9992949
treatment O 0 0.0037172397
produced O 0 0.0018536714
a O 0 0.0023865553
biphasic O 0 0.0026864402
effect O 0 0.0011016206
on O 0 0.0011394849
mouse O 0 0.0018591664
motility O 0 0.015584926
. O 0 0.006388757

The O 0 0.0015045698
initial O 0 0.0010978329
dose O 0 0.0018557548
of O 0 0.0017638701
amantadine B-Chemical 1 0.9999423
depressed B-Disease 2 0.9997509
locomotor O 0 0.09899887
activity O 0 0.00019309013
in O 0 0.00016920298
all O 0 0.00013998471
mouse O 0 0.00011924204
strains O 0 0.00015406485
studied O 0 0.00023337983
with O 0 0.00021007768
the O 0 0.00022671671
BALB O 0 0.0013767836
/ O 0 0.0021206967
C O 0 0.7435502
mice O 0 0.00019443086
being O 0 0.00043762088
the O 0 0.00050295383
most O 0 0.0010768601
sensitive O 0 0.001396056
. O 0 0.0030422022

Subsequent O 0 0.0031033428
amantadine B-Chemical 1 0.9983292
treatments O 0 0.001584602
produced O 0 0.00059311965
enhancement O 0 0.000671464
of O 0 0.0005123895
motility O 0 0.002767901
from O 0 0.00023365789
corresponding O 0 0.00012434756
control O 0 0.00018150355
in O 0 0.00015735657
all O 0 0.0001361282
mouse O 0 0.00011680357
strains O 0 0.00014742542
with O 0 0.00019207617
the O 0 0.00021345483
BALB O 0 0.0012776945
/ O 0 0.0020199441
C O 0 0.72753704
mice O 0 0.0001864354
being O 0 0.00040940018
the O 0 0.00045534497
least O 0 0.0007358003
sensitive O 0 0.0012906564
. O 0 0.0029258663

The O 0 0.0023445303
locomotor O 0 0.009224803
activity O 0 0.0007982004
was O 0 0.0006453278
decreased O 0 0.0007375867
from O 0 0.00028659328
corresponding O 0 0.00016557839
controls O 0 0.00032183944
in O 0 0.00018165229
all O 0 0.0001536913
strains O 0 0.00017617104
studied O 0 0.00027507398
, O 0 0.00030219738
except O 0 0.00011182495
for O 0 9.2101145e-05
the O 0 0.00010601025
ICR O 0 0.0002590088
mice O 0 4.4684268e-05
, O 0 0.00016969672
during O 0 8.47403e-05
an O 0 0.00014946141
overnight O 0 0.00025248338
drug O 0 0.006715129
- O 0 0.0014838757
free O 0 0.00022498968
period O 0 0.00011261392
following O 0 0.00012482144
the O 0 0.00025592346
fourth O 0 0.0009466421
amantadine B-Chemical 1 0.99933016
treatment O 0 0.0018892956
. O 0 0.0027452584

Readministration O 0 0.06989063
of O 0 0.0041791075
amantadine B-Chemical 1 0.9995347
, O 0 0.002084109
after O 0 0.00039896087
a O 0 0.00078315363
drug O 0 0.015816974
- O 0 0.0028792731
free O 0 0.00033927299
overnight O 0 0.00022466536
period O 0 0.000113457456
, O 0 0.00026528645
increased O 0 0.0002228783
motility O 0 0.00090932014
from O 0 0.00010542837
respective O 0 8.080619e-05
saline O 0 0.0003349782
control O 0 0.00010478731
in O 0 9.2233066e-05
all O 0 8.6906424e-05
strains O 0 0.000101970574
with O 0 0.00012511517
exception O 0 0.00011927114
of O 0 0.00016351599
the O 0 0.00017807815
BALB O 0 0.0012189078
/ O 0 0.0019408336
C O 0 0.78382933
mice O 0 0.00013870832
where O 0 0.0003134861
suppression B-Disease 0 0.00069767656
of I-Disease 0 0.0009058413
motility I-Disease 0 0.09463074
occurred O 0 0.0021858632
. O 0 0.0031425445

Treatment O 0 0.010518942
with O 0 0.0043792357
amantadine B-Chemical 1 0.9997638
did O 0 0.0016283488
not O 0 0.00060303276
alter O 0 0.0004341299
whole O 0 0.0005980019
brain O 0 0.020933826
dopamine B-Chemical 0 0.99971944
levels O 0 0.0002245694
but O 0 0.0002333814
decreased O 0 0.00027212867
the O 0 0.00011633948
amounts O 0 0.00012762779
of O 0 0.00018784667
3 B-Chemical 0 0.00017847115
, I-Chemical 0 0.00048338046
4 I-Chemical 0 0.00046331697
- I-Chemical 0 0.9268955
dihydroxyphenylacetic I-Chemical 0 0.99999964
acid I-Chemical 0 0.97897047
in O 0 0.00035292644
the O 0 0.00023798467
BALB O 0 0.0012584926
/ O 0 0.0015860074
C O 0 0.52207243
mice O 0 0.00013765018
compared O 0 0.00023261494
to O 0 0.0004225651
saline O 0 0.0017996791
control O 0 0.001470163
. O 0 0.002856724

Conversely O 0 0.004418575
, O 0 0.00816101
brain O 0 0.1683183
normetanephrine B-Chemical 0 0.9999784
concentration O 0 0.0022527464
was O 0 0.0004565852
increased O 0 0.0004154983
from O 0 0.00025010685
saline O 0 0.00068720506
control O 0 0.0003134652
by O 0 0.00045949532
amantadine B-Chemical 1 0.9991416
in O 0 0.00052480685
the O 0 0.00055624446
BALB O 0 0.0027335575
/ O 0 0.004449484
C O 0 0.76833177
mice O 0 0.0012360341
. O 0 0.003600996

The O 0 0.0017819571
results O 0 0.0012133169
suggest O 0 0.0006793063
a O 0 0.0011296006
strain O 0 0.000621463
- O 0 0.0024353305
dependent O 0 0.0002434029
effect O 0 0.000256751
of O 0 0.000588611
amantadine B-Chemical 1 0.9998673
on O 0 0.00021324978
motility O 0 0.0024674279
and O 0 0.00017871175
indicate O 0 7.7038334e-05
a O 0 0.00019239291
differential O 0 0.00016077147
response O 0 0.00013550192
to O 0 0.00012530536
the O 0 0.00015131582
acute O 0 0.002316563
and O 0 0.0002241903
multiple O 0 0.00024458047
dose O 0 0.00053572515
regimens O 0 0.0006528921
used O 0 0.0008856496
. O 0 0.00225946

The O 0 0.0032236304
BALB O 0 0.009148342
/ O 0 0.012644674
C O 0 0.93376285
mouse O 0 0.000989287
was O 0 0.0005701312
the O 0 0.0003519927
most O 0 0.0003696546
sensitive O 0 0.0002119569
strain O 0 0.00018942657
and O 0 0.00024111415
could O 0 0.0001439035
serve O 0 0.00019719364
as O 0 0.00016205522
the O 0 0.00012152102
strain O 0 0.00011034148
of O 0 0.00015610109
choice O 0 0.00013551251
for O 0 0.00010909876
evaluating O 0 0.00011371459
the O 0 0.00019700573
side O 0 0.00075000763
effects O 0 0.00066023535
of O 0 0.0020588036
amantadine B-Chemical 1 0.999731
. O 0 0.0045644604

The O 0 0.0020902597
biochemical O 0 0.0021563773
results O 0 0.0012804557
of O 0 0.001684743
brain O 0 0.015392035
biogenic O 0 0.9901731
amines B-Chemical 0 0.97888184
of O 0 0.00087990955
BALB O 0 0.0037218465
/ O 0 0.004383471
C O 0 0.93459094
mouse O 0 0.00020935423
strain O 0 0.00012082152
suggest O 0 9.249748e-05
a O 0 0.00027600786
probable O 0 0.00042457992
decrease O 0 0.00024996646
of O 0 0.0004727868
catecholamine B-Chemical 0 0.99992096
turnover O 0 0.00065265916
rate O 0 0.00024006698
and O 0 0.00017455463
/ O 0 0.0014854104
or O 0 0.0002233135
metabolism O 0 0.28448024
by O 0 0.0009972659
monoamine O 0 0.9999888
oxidase O 0 0.9998312
and O 0 0.00028065266
a O 0 0.00021895822
resulting O 0 0.00010335382
increase O 0 0.00012711732
in O 0 0.00023293255
O O 0 0.9997445
- O 0 0.13223197
methylation O 0 0.000476331
of O 0 0.00054176577
norepinephrine B-Chemical 0 0.9999882
which O 0 0.0002018754
may O 0 7.436671e-05
account O 0 8.2040264e-05
for O 0 7.8168334e-05
a O 0 0.0002876491
behavioral B-Disease 0 0.4441095
depression I-Disease 0 0.9999709
caused O 0 0.00031236888
by O 0 0.00041078316
amantadine B-Chemical 1 0.99978465
in O 0 0.00038786215
the O 0 0.00041114082
BALB O 0 0.0024240247
/ O 0 0.0039661904
C O 0 0.8209761
mice O 0 0.0009849548
. O 0 0.0029835477

Chloroacetaldehyde B-Chemical 0 0.9856963
and O 0 0.0030003064
its O 0 0.0017581072
contribution O 0 0.000747194
to O 0 0.0009882513
urotoxicity O 0 0.9887476
during O 0 0.0005193361
treatment O 0 0.0006108836
with O 0 0.0010554191
cyclophosphamide B-Chemical 0 0.99934775
or O 0 0.0020877148
ifosfamide B-Chemical 0 0.9986058
. O 0 0.0041785184

An O 0 0.007684509
experimental O 0 0.006169012
study O 0 0.0065633724
/ O 0 0.012436791
short O 0 0.0058048484
communication O 0 0.01271793
. O 0 0.012473283

Based O 0 0.0039663347
on O 0 0.0014497925
clinical O 0 0.002820905
data O 0 0.0011661386
, O 0 0.001241536
indicating O 0 0.00048566665
that O 0 0.0006653195
chloroacetaldehyde B-Chemical 0 0.9998628
( O 0 0.0032785705
CAA B-Chemical 0 0.18920718
) O 0 0.0007929199
is O 0 0.00015821129
an O 0 0.00018256616
important O 0 0.00013784222
metabolite O 0 0.07425721
of O 0 0.00037189596
oxazaphosphorine O 0 0.9553239
cytostatics O 0 0.9869774
, O 0 0.00039419555
an O 0 0.00013898914
experimental O 0 0.0001314845
study O 0 0.00014022598
was O 0 9.654634e-05
carried O 0 9.1584785e-05
out O 0 9.161963e-05
in O 0 9.2847964e-05
order O 0 6.603187e-05
to O 0 7.4678406e-05
elucidate O 0 4.2897012e-05
the O 0 8.516586e-05
role O 0 7.644236e-05
of O 0 0.00028579382
CAA B-Chemical 0 0.046150733
in O 0 0.00028200127
the O 0 0.00028860095
development O 0 0.00068691367
of O 0 0.0015478928
hemorrhagic B-Disease 2 0.999782
cystitis I-Disease 0 0.9995098
. O 0 0.004165532

The O 0 0.0022922363
data O 0 0.0019111054
demonstrate O 0 0.00071299885
that O 0 0.00095624337
CAA B-Chemical 0 0.010551658
after O 0 0.00045230074
i O 0 0.0010048064
. O 0 0.000539894
v O 0 0.0017070344
. O 0 0.00045037564
administration O 0 0.0006340605
does O 0 0.0003163714
not O 0 0.0004162906
contribute O 0 0.0006177097
to O 0 0.0010752958
bladder B-Disease 0 0.79504174
damage I-Disease 0 0.8727993
. O 0 0.004656922

When O 0 0.0020090826
instilled O 0 0.006096463
directly O 0 0.0007376454
into O 0 0.00051437604
the O 0 0.00061147986
bladder O 0 0.0066378666
, O 0 0.0012578069
CAA B-Chemical 0 0.031229826
exerts O 0 0.00050116715
urotoxic O 0 0.833482
effects O 0 0.00042040503
, O 0 0.00078814756
it O 0 0.0004464615
is O 0 0.00024117551
, O 0 0.0005262493
however O 0 0.0004152712
, O 0 0.00066723843
susceptible O 0 0.00044077093
to O 0 0.0005463853
detoxification O 0 0.06014463
with O 0 0.0024780699
mesna B-Chemical 0 0.99960226
. O 0 0.0038745408

Source O 0 0.011065792
of O 0 0.0034386034
pain B-Disease 0 0.051849194
and O 0 0.002072192
primitive O 0 0.008370988
dysfunction O 0 0.90286857
in O 0 0.0027731746
migraine B-Disease 0 0.99985576
: O 0 0.0031270834
an O 0 0.0012334489
identical O 0 0.00084454333
site O 0 0.0015204961
? O 0 0.0076577286

Twenty O 0 0.0062183957
common O 0 0.003749677
migraine B-Disease 0 0.99962604
patients O 0 0.0020178652
received O 0 0.0005436917
a O 0 0.0005569315
one O 0 0.00038036905
sided O 0 0.5101909
frontotemporal O 0 0.99937975
application O 0 0.0002809777
of O 0 0.00043952226
nitroglycerin B-Chemical 0 0.99999166
( O 0 0.0005614462
10 O 0 0.00014568411
patients O 0 0.00022842085
) O 0 0.00026444072
or O 0 0.00013258513
placebo O 0 0.0145468265
ointment O 0 0.99663734
( O 0 0.00041406954
10 O 0 0.00018850011
patients O 0 0.00038224232
) O 0 0.0004952264
in O 0 0.0002725181
a O 0 0.0005720851
double O 0 0.0006337541
blind O 0 0.058616582
study O 0 0.0023717405
. O 0 0.002993765

Early O 0 0.010799782
onset O 0 0.013401515
migraine B-Disease 0 0.9998734
attacks O 0 0.29143882
were O 0 0.00069189945
induced O 0 0.0005228399
by O 0 0.00074398424
nitroglycerin B-Chemical 0 0.99998164
in O 0 0.00030548463
seven O 0 0.0001461194
out O 0 0.00012528745
of O 0 0.00016477783
10 O 0 0.00016211612
patients O 0 0.00023272875
versus O 0 0.00012594371
no O 0 0.00016559765
patient O 0 0.0002844887
in O 0 0.00028218227
the O 0 0.0004388472
placebo O 0 0.005990535
group O 0 0.0020050271
. O 0 0.00276813

Subsequently O 0 0.003791904
20 O 0 0.004058715
migraine B-Disease 0 0.99970716
patients O 0 0.0033827235
, O 0 0.0013214584
who O 0 0.0007059116
developed O 0 0.00041087143
an O 0 0.00032063067
early O 0 0.00043455427
onset O 0 0.0005497731
attack O 0 0.0028910555
with O 0 0.00069330103
frontotemporal O 0 0.9999627
nitroglycerin B-Chemical 0 0.9999956
, O 0 0.00040663916
received O 0 0.000116100986
the O 0 0.00010314273
drug O 0 0.0013935441
in O 0 0.0001402954
a O 0 0.00020930835
second O 0 0.0001318481
induction O 0 0.00015201273
test O 0 0.00032422648
at O 0 0.0002401487
other O 0 0.0004252815
body O 0 0.0014408214
areas O 0 0.0021488268
. O 0 0.0025127586

No O 0 0.0111398855
early O 0 0.010421309
onset O 0 0.017353412
migraine B-Disease 0 0.9992506
was O 0 0.006204549
observed O 0 0.0055688373
. O 0 0.009352846

Thus O 0 0.002438023
the O 0 0.0033143216
migraine B-Disease 0 0.99985397
- O 0 0.01618521
inducing O 0 0.0006383826
effect O 0 0.00047554434
of O 0 0.0012517953
nitroglycerin B-Chemical 0 0.99999404
seems O 0 0.00023410413
to O 0 0.0001344109
depend O 0 8.603066e-05
on O 0 5.5579647e-05
direct O 0 5.292058e-05
stimulation O 0 6.422277e-05
of O 0 0.00010141037
the O 0 9.108807e-05
habitual O 0 0.0008791446
site O 0 6.389504e-05
of O 0 0.0001522502
pain B-Disease 0 0.040294588
, O 0 0.00022664842
suggesting O 0 7.0066664e-05
that O 0 8.332487e-05
the O 0 0.00017237947
frontotemporal O 0 0.99953043
region O 0 8.478031e-05
is O 0 7.1656206e-05
of O 0 9.790979e-05
crucial O 0 6.631672e-05
importance O 0 9.902385e-05
in O 0 0.00016520762
the O 0 0.00019142857
development O 0 0.00041299922
of O 0 0.0006428598
a O 0 0.0028631752
migraine B-Disease 0 0.99991035
crisis O 0 0.2942466
. O 0 0.00373714

This O 0 0.0063272724
is O 0 0.00234106
not O 0 0.0016782592
consistent O 0 0.0012556585
with O 0 0.0015321136
a O 0 0.0023422632
CNS O 0 0.010118473
origin O 0 0.0021819347
of O 0 0.0034210584
migraine B-Disease 0 0.99981445
attack O 0 0.13628906
. O 0 0.0059081605

Hypersensitivity B-Disease 0 0.32509166
to O 0 0.0042406507
carbamazepine B-Chemical 1 0.9999875
presenting O 0 0.005049432
with O 0 0.00091337005
a O 0 0.0011399568
leukemoid B-Disease 0 0.02252501
reaction I-Disease 0 0.0005814532
, O 0 0.0016249237
eosinophilia B-Disease 0 0.9961132
, O 0 0.002702403
erythroderma B-Disease 0 0.9959966
, O 0 0.0014190024
and O 0 0.0011465296
renal B-Disease 0 0.85990703
failure I-Disease 0 0.12714261
. O 0 0.0037157198

We O 0 0.0027058828
report O 0 0.002963802
a O 0 0.0017398638
patient O 0 0.0009353461
in O 0 0.00052328984
whom O 0 0.0009147226
hypersensitivity B-Disease 0 0.016400201
to O 0 0.0005309418
carbamazepine B-Chemical 1 0.9999975
presented O 0 0.00029298489
with O 0 0.00031583867
generalized O 0 0.0130913025
erythroderma B-Disease 0 0.99902105
, O 0 0.0005769916
a O 0 0.0004270817
severe O 0 0.0030095177
leukemoid B-Disease 0 0.033767607
reaction I-Disease 0 0.0002663308
, O 0 0.00096489786
eosinophilia B-Disease 0 0.99780136
, O 0 0.0018194623
hyponatremia B-Disease 2 0.99983716
, O 0 0.0013729341
and O 0 0.0009231304
renal B-Disease 0 0.8893283
failure I-Disease 0 0.123323575
. O 0 0.003046679

This O 0 0.005395219
is O 0 0.0018663912
the O 0 0.0011756674
first O 0 0.00079989043
report O 0 0.0014589402
of O 0 0.0009763285
such O 0 0.0008487529
an O 0 0.0011489098
unusual O 0 0.0020746537
reaction O 0 0.0013678004
to O 0 0.0024700626
carbamazepine B-Chemical 1 0.9999734
. O 0 0.0065198485

Fluoxetine B-Chemical 0 0.9999329
- O 0 0.14275046
induced O 0 0.005573632
akathisia B-Disease 0 0.99993587
: O 0 0.0062143384
clinical O 0 0.003563748
and O 0 0.0016994987
theoretical O 0 0.0029515182
implications O 0 0.0034256312
. O 0 0.0059346855

Five O 0 0.0028761453
patients O 0 0.0028993299
receiving O 0 0.002426585
fluoxetine B-Chemical 0 0.99995553
for O 0 0.0004620886
the O 0 0.00032534028
treatment O 0 0.000415759
of O 0 0.0012112032
obsessive B-Disease 0 0.99999666
compulsive I-Disease 0 0.9999927
disorder I-Disease 0 0.9999161
or O 0 0.0007833708
major B-Disease 0 0.003599515
depression I-Disease 0 0.9999207
developed O 0 0.0073565994
akathisia B-Disease 0 0.9999548
. O 0 0.0044107856

The O 0 0.0024357764
typical O 0 0.004384511
fluoxetine B-Chemical 0 0.9999795
- O 0 0.03299601
induced O 0 0.0007768772
symptoms O 0 0.0067215436
of O 0 0.00071007526
restlessness O 0 0.99277896
, O 0 0.0005254231
constant O 0 0.0002530181
pacing O 0 0.0008672882
, O 0 0.0005102137
purposeless O 0 0.26564962
movements O 0 0.00039210453
of O 0 0.00017075517
the O 0 0.00014169926
feet O 0 0.0020860406
and O 0 0.00022880579
legs O 0 0.0026851606
, O 0 0.00033790496
and O 0 0.00019228562
marked O 0 0.0004154587
anxiety B-Disease 0 0.98787224
were O 0 0.00013485011
indistinguishable O 0 6.600895e-05
from O 0 0.00012938102
those O 0 0.00027443503
of O 0 0.00080597616
neuroleptic O 0 0.999995
- O 0 0.040787376
induced O 0 0.002041831
akathisia B-Disease 0 0.9999578
. O 0 0.0043565948

Three O 0 0.002434602
patients O 0 0.0028098458
who O 0 0.0015316723
had O 0 0.00084190955
experienced O 0 0.0019016088
neuroleptic O 0 0.99999523
- O 0 0.053054452
induced O 0 0.00067548
akathisia B-Disease 0 0.99998903
in O 0 0.00022127348
the O 0 0.00011747778
past O 0 0.00014059804
reported O 0 0.00012144018
that O 0 7.34706e-05
the O 0 0.000107758984
symptoms O 0 0.001910274
of O 0 0.0004458019
fluoxetine B-Chemical 0 0.9999982
- O 0 0.05827643
induced O 0 0.00048554214
akathisia B-Disease 0 0.99999034
were O 0 0.000268394
identical O 0 0.0001739424
, O 0 0.000591853
although O 0 0.0005643347
somewhat O 0 0.0018354633
milder O 0 0.07717512
. O 0 0.0032714538

Akathisia B-Disease 0 0.99976236
appeared O 0 0.0024079818
to O 0 0.0010227653
be O 0 0.00067824277
a O 0 0.0006773188
common O 0 0.00040992117
side O 0 0.0007121609
effect O 0 0.00026627953
of O 0 0.00072513527
fluoxetine B-Chemical 0 0.9999969
and O 0 0.00030903233
generally O 0 0.00017485334
responded O 0 0.00017426812
well O 0 9.012333e-05
to O 0 8.148808e-05
treatment O 0 0.00010709783
with O 0 0.00013718395
the O 0 0.00018642776
beta O 0 0.9126088
- O 0 0.4768365
adrenergic O 0 0.9977652
antagonist O 0 0.96441144
propranolol B-Chemical 0 0.9999975
, O 0 0.0014044624
dose O 0 0.0007282489
reduction O 0 0.0005429977
, O 0 0.00093746564
or O 0 0.00068356685
both O 0 0.0012226222
. O 0 0.0026802206

The O 0 0.0016526033
authors O 0 0.0011915092
suggest O 0 0.0007080295
that O 0 0.0012732599
fluoxetine B-Chemical 0 0.9999944
- O 0 0.2926892
induced O 0 0.00141305
akathisia B-Disease 0 0.9999939
may O 0 0.00028714634
be O 0 0.00017096585
caused O 0 0.0001453709
by O 0 0.00016114918
serotonergically O 0 0.009036671
mediated O 0 8.0681304e-05
inhibition O 0 0.00021691788
of O 0 0.00026064154
dopaminergic O 0 0.015443565
neurotransmission O 0 0.006538515
and O 0 9.27722e-05
that O 0 5.725078e-05
the O 0 8.387357e-05
pathophysiology O 0 0.0042063366
of O 0 0.00042141194
fluoxetine B-Chemical 0 0.9999989
- O 0 0.056282002
induced O 0 0.0003340658
akathisia B-Disease 0 0.9999963
and O 0 0.00060189556
tricyclic O 0 0.99991524
antidepressant B-Chemical 0 0.9999844
- O 0 0.013530087
induced O 0 0.00032869267
" O 0 0.0022038175
jitteriness O 0 0.9996629
" O 0 0.0013195806
may O 0 0.00052067183
be O 0 0.0007619779
identical O 0 0.0008711905
. O 0 0.0024485828

Effect O 0 0.0033307339
of O 0 0.0030624964
converting O 0 0.0044469903
enzyme O 0 0.0037463831
inhibition O 0 0.0012046708
on O 0 0.00050002785
the O 0 0.0005064905
course O 0 0.0007461146
of O 0 0.0014887253
adriamycin B-Chemical 0 0.99993217
- O 0 0.08648998
induced O 0 0.003533728
nephropathy B-Disease 0 0.9999472
. O 0 0.0077165253

The O 0 0.0018180911
effect O 0 0.001364024
of O 0 0.0014123854
the O 0 0.00097109255
converting O 0 0.0021642004
enzyme O 0 0.003456485
inhibitor O 0 0.0043890243
( O 0 0.0029342286
CEI O 0 0.99893993
) O 0 0.00554023
enalapril B-Chemical 1 0.99998987
was O 0 0.0002984904
assessed O 0 0.0002158473
in O 0 0.00024106748
Munich O 0 0.0009636328
- O 0 0.0012338755
Wistar O 0 0.0009881242
rats O 0 0.00048427383
with O 0 0.00051422504
established O 0 0.0014669653
adriamycin B-Chemical 0 0.9999598
nephrosis B-Disease 2 0.9999728
. O 0 0.006634051

Rats O 0 0.0056394106
were O 0 0.0013745616
given O 0 0.0006174218
a O 0 0.0007312204
single O 0 0.0003343461
dose O 0 0.0006053264
of O 0 0.0005640193
adriamycin B-Chemical 0 0.9999404
and O 0 0.0002743592
one O 0 0.000118718664
month O 0 6.470471e-05
later O 0 7.210009e-05
divided O 0 8.975694e-05
into O 0 5.1237024e-05
four O 0 5.213923e-05
groups O 0 0.000117223
matched O 0 0.00010045196
for O 0 0.00017147521
albuminuria B-Disease 2 0.9999423
, O 0 0.0008568124
blood O 0 0.004694919
pressure O 0 0.014688236
, O 0 0.0008446902
and O 0 0.00072613516
plasma O 0 0.08034392
albumin O 0 0.99277365
concentration O 0 0.004383032
. O 0 0.0032313985

Groups O 0 0.012866388
1 O 0 0.0026117307
and O 0 0.0014432555
3 O 0 0.0009047174
remained O 0 0.0009852655
untreated O 0 0.0011617279
while O 0 0.0006631573
groups O 0 0.00084556686
2 O 0 0.00074412394
and O 0 0.00070802815
4 O 0 0.0008302819
received O 0 0.0016993644
enalapril B-Chemical 1 0.99982893
. O 0 0.0058519854

Groups O 0 0.014982075
1 O 0 0.0035947773
and O 0 0.0021405362
2 O 0 0.0016658714
underwent O 0 0.0015014294
micropuncture O 0 0.0031697315
studies O 0 0.0014343482
after O 0 0.0009523982
10 O 0 0.0017448448
days O 0 0.0018301378
. O 0 0.0049146507

These O 0 0.0019892098
short O 0 0.0017915486
- O 0 0.003719623
term O 0 0.00086907955
studies O 0 0.0007148348
showed O 0 0.00047047806
that O 0 0.0005156666
enalapril B-Chemical 1 0.99998784
reduced O 0 0.0008318241
arterial O 0 0.58895576
blood O 0 0.0040404196
pressure O 0 0.0036856844
( O 0 0.00042993898
101 O 0 0.00060099206
+ O 0 0.0007951697
/ O 0 0.0011544065
- O 0 0.000947132
2 O 0 0.00018604526
vs O 0 0.0002277204
. O 0 0.00017080485
124 O 0 0.00042883688
+ O 0 0.00078713475
/ O 0 0.0011541322
- O 0 0.0008733776
3 O 0 0.00014696382
mm O 0 0.00061706535
Hg O 0 0.5028529
, O 0 0.00037920306
group O 0 0.0002355532
2 O 0 0.00017303818
vs O 0 0.00022611873
. O 0 0.00015576625
1 O 0 0.00017639797
, O 0 0.00030338034
P O 0 0.0043375827
less O 0 0.00024277388
than O 0 0.0001521077
0 O 0 0.00024764996
. O 0 0.00021172845
05 O 0 0.0036164464
) O 0 0.0005124051
and O 0 0.00029509267
glomerular O 0 0.9807765
capillary O 0 0.33906898
pressure O 0 0.007523316
( O 0 0.00039414628
54 O 0 0.00031892557
+ O 0 0.00072797405
/ O 0 0.0011990097
- O 0 0.0010400946
1 O 0 0.00018800938
vs O 0 0.00022294564
. O 0 0.0001627558
61 O 0 0.0002797623
+ O 0 0.0007016811
/ O 0 0.0011388747
- O 0 0.00094853004
2 O 0 0.0001939256
mm O 0 0.00066327426
Hg O 0 0.59571743
, O 0 0.0004959739
P O 0 0.0075152386
less O 0 0.00024644026
than O 0 0.00014845945
0 O 0 0.00023814356
. O 0 0.00019959356
05 O 0 0.0033279082
) O 0 0.0004056548
without O 0 0.00017580156
reducing O 0 0.0002549442
albuminuria B-Disease 2 0.9999591
( O 0 0.0011801954
617 O 0 0.0023202067
+ O 0 0.0010546233
/ O 0 0.0013937245
- O 0 0.0010773938
50 O 0 0.00022518713
vs O 0 0.00026155438
. O 0 0.00022189929
570 O 0 0.004972552
+ O 0 0.0010730844
/ O 0 0.001514392
- O 0 0.0014424949
47 O 0 0.00040444508
mg O 0 0.0022051444
/ O 0 0.0006658397
day O 0 0.00014209653
) O 0 0.0004372656
or O 0 0.00026606384
GFR O 0 0.9990682
( O 0 0.00060387625
1 O 0 0.00024322055
. O 0 0.00021166184
03 O 0 0.0013704383
+ O 0 0.00090030767
/ O 0 0.0014868731
- O 0 0.0014767507
0 O 0 0.00033805208
. O 0 0.00025399725
04 O 0 0.0027474258
vs O 0 0.00038420875
. O 0 0.00024597195
1 O 0 0.00028081247
. O 0 0.000309623
04 O 0 0.0044367085
+ O 0 0.0015112524
/ O 0 0.0022068396
- O 0 0.0020560257
0 O 0 0.00059385836
. O 0 0.00046385828
11 O 0 0.0006496214
ml O 0 0.0018516232
/ O 0 0.0031382872
min O 0 0.002340096
) O 0 0.0042134193
. O 0 0.0039108596

Groups O 0 0.010719703
3 O 0 0.001811159
and O 0 0.0012332833
4 O 0 0.00068248395
were O 0 0.00048302626
studied O 0 0.00046772423
at O 0 0.00021697991
four O 0 0.00014473344
and O 0 0.00018175226
at O 0 0.0001075465
six O 0 6.847986e-05
months O 0 5.6220764e-05
to O 0 6.955393e-05
assess O 0 4.8499594e-05
the O 0 8.502044e-05
effect O 0 0.00012623843
of O 0 0.00041022312
enalapril B-Chemical 1 0.99999535
on O 0 0.00024320386
progression O 0 0.0017573694
of O 0 0.0005703288
renal B-Disease 0 0.99904114
injury I-Disease 0 0.94825846
in O 0 0.0018390968
adriamycin B-Chemical 0 0.99997604
nephrosis B-Disease 2 0.99997795
. O 0 0.005227619

Chronic O 0 0.31307182
enalapril B-Chemical 1 0.99995565
treatment O 0 0.002034154
reduced O 0 0.0012920094
blood O 0 0.0057604597
pressure O 0 0.007997818
without O 0 0.0007319694
reducing O 0 0.00090957625
albuminuria B-Disease 2 0.99985707
in O 0 0.0013762644
group O 0 0.0018728354
4 O 0 0.0017091548
. O 0 0.003033881

Untreated O 0 0.045853946
group O 0 0.0028521286
3 O 0 0.0010537525
rats O 0 0.0011230953
exhibited O 0 0.00064827094
a O 0 0.000839996
progressive O 0 0.0021246276
reduction O 0 0.00054239744
in O 0 0.00050048495
GFR O 0 0.9991372
( O 0 0.0006839709
0 O 0 0.00029856074
. O 0 0.00018676936
35 O 0 0.00023278425
+ O 0 0.0007793341
/ O 0 0.0014601757
- O 0 0.0015142838
0 O 0 0.00033986574
. O 0 0.00025010612
08 O 0 0.0020454533
ml O 0 0.0009436795
/ O 0 0.000835103
min O 0 0.0002681715
at O 0 9.94769e-05
4 O 0 0.00010006448
months O 0 7.286685e-05
, O 0 0.00023270435
0 O 0 0.0002303973
. O 0 0.0001949642
27 O 0 0.0003299856
+ O 0 0.0009193158
/ O 0 0.0017165599
- O 0 0.0017421484
0 O 0 0.0004420484
. O 0 0.00034364546
07 O 0 0.0012203482
ml O 0 0.0012033501
/ O 0 0.0013100598
min O 0 0.0005971973
at O 0 0.00032407665
6 O 0 0.00041347826
months O 0 0.00048576525
) O 0 0.0025588798
. O 0 0.0032573815

Enalapril B-Chemical 0 0.99995065
treatment O 0 0.00613838
blunted O 0 0.09416449
but O 0 0.0016643909
did O 0 0.00080450287
not O 0 0.00041908503
prevent O 0 0.00033681086
reduction O 0 0.00049560796
in O 0 0.000449769
GFR O 0 0.99934274
in O 0 0.00026446392
group O 0 0.0002846585
4 O 0 0.00015829639
( O 0 0.00027058623
0 O 0 0.00020433441
. O 0 0.00015721109
86 O 0 0.00031657904
+ O 0 0.00079021533
/ O 0 0.0014815868
- O 0 0.0014367221
0 O 0 0.00027886403
. O 0 0.00017056106
15 O 0 0.00016098145
ml O 0 0.0004941501
/ O 0 0.0006175887
min O 0 0.00022724563
at O 0 8.640154e-05
4 O 0 8.7483226e-05
months O 0 6.280224e-05
, O 0 0.0001985303
0 O 0 0.00019118395
. O 0 0.0001528874
69 O 0 0.00026123243
+ O 0 0.0007757964
/ O 0 0.0014940057
- O 0 0.0014636352
0 O 0 0.00027786585
. O 0 0.00017026077
13 O 0 0.00019665722
ml O 0 0.0005282709
/ O 0 0.0006161271
min O 0 0.00021462051
at O 0 7.8539684e-05
6 O 0 7.0942166e-05
months O 0 5.593029e-05
, O 0 0.00017772801
both O 0 0.00014368807
P O 0 0.0037793736
less O 0 0.00029332892
than O 0 0.00020087043
0 O 0 0.00034448024
. O 0 0.00031555147
05 O 0 0.0028977268
vs O 0 0.0006268648
. O 0 0.00051573466
group O 0 0.00093982124
3 O 0 0.0011148948
) O 0 0.0033708087
. O 0 0.0035373531

Reduction O 0 0.005905566
in O 0 0.0032563042
GFR O 0 0.9970636
was O 0 0.0010805571
associated O 0 0.00064177444
with O 0 0.00045352627
the O 0 0.0003193451
development O 0 0.00048238077
of O 0 0.0007699956
glomerular B-Disease 2 0.99993694
sclerosis I-Disease 2 0.9999367
in O 0 0.00023702838
both O 0 0.00016469661
treated O 0 0.00036444585
and O 0 0.0002521168
untreated O 0 0.0005283555
rats O 0 0.0005933529
. O 0 0.00041917112
( O 0 0.0009169351
ABSTRACT O 0 0.00512814
TRUNCATED O 0 0.012702503
AT O 0 0.011500005
250 O 0 0.0053748386
WORDS O 0 0.025476296
) O 0 0.01601192

Clotiazepam B-Chemical 0 0.97049475
- O 0 0.08117245
induced O 0 0.015586274
acute O 0 0.99317825
hepatitis B-Disease 0 0.99986136
. O 0 0.03624987

We O 0 0.0028445986
report O 0 0.002861447
the O 0 0.0010962945
case O 0 0.0009329373
of O 0 0.0007267832
a O 0 0.00082100515
patient O 0 0.0005505759
who O 0 0.0005576124
developed O 0 0.0006622984
acute O 0 0.99317414
hepatitis B-Disease 0 0.9999974
with O 0 0.0030635463
extensive B-Disease 0 0.038985964
hepatocellular I-Disease 0 0.99999857
necrosis I-Disease 2 0.9999995
, O 0 0.0008181838
7 O 0 7.503717e-05
months O 0 3.2642412e-05
after O 0 3.354525e-05
the O 0 6.4099964e-05
onset O 0 0.00015585509
of O 0 0.00015696768
administration O 0 0.00046292317
of O 0 0.00065699965
clotiazepam B-Chemical 0 0.9999844
, O 0 0.002409213
a O 0 0.002256285
thienodiazepine B-Chemical 0 0.9989753
derivative O 0 0.048794903
. O 0 0.00373632

Clotiazepam B-Chemical 0 0.9008342
withdrawal O 0 0.01903573
was O 0 0.003338614
followed O 0 0.0022067209
by O 0 0.0027435094
prompt O 0 0.005337395
recovery O 0 0.0061638574
. O 0 0.007417794

The O 0 0.0016828728
administration O 0 0.0020313845
of O 0 0.001095706
several O 0 0.0007834877
benzodiazepines B-Chemical 1 0.99992216
, O 0 0.0018298232
chemically O 0 0.0013053158
related O 0 0.00025086082
to O 0 0.00047959562
clotiazepam B-Chemical 0 0.99998903
, O 0 0.001031065
did O 0 0.00025731462
not O 0 0.0001556108
interfere O 0 0.00015036094
with O 0 0.00019913963
recovery O 0 0.00032285298
and O 0 0.00022813855
did O 0 0.00026050565
not O 0 0.00022772368
induce O 0 0.00024950143
any O 0 0.00052992837
relapse O 0 0.22292443
of O 0 0.002356253
hepatitis B-Disease 0 0.9998964
. O 0 0.006768145

This O 0 0.004072373
observation O 0 0.0014210735
shows O 0 0.00067628996
that O 0 0.0011861755
clotiazepam B-Chemical 0 0.99996424
can O 0 0.00057711976
induce O 0 0.0005265147
acute O 0 0.9975309
hepatitis B-Disease 0 0.99999714
and O 0 0.0006287388
suggests O 0 0.00012182617
that O 0 0.00011122346
there O 0 0.00012234271
is O 0 0.00013709816
no O 0 0.00019002594
cross O 0 0.00059711875
hepatotoxicity B-Disease 0 0.99996185
between O 0 0.00065419887
clotiazepam B-Chemical 0 0.99997735
and O 0 0.0008426054
several O 0 0.00080778834
benzodiazepines B-Chemical 1 0.9997918
. O 0 0.0033251934

5 B-Chemical 0 0.0060554645
- I-Chemical 0 0.027406203
azacytidine I-Chemical 0 0.8149748
potentiates O 0 0.0029015637
initiation B-Disease 0 0.00093160087
induced I-Disease 0 0.0011217839
by I-Disease 0 0.0013415898
carcinogens I-Disease 0 0.07446828
in O 0 0.0017219237
rat O 0 0.0035166931
liver O 0 0.13497104
. O 0 0.0051586293

To O 0 0.0013067262
test O 0 0.0017175495
the O 0 0.0007736964
validity O 0 0.00081337197
of O 0 0.0005092633
the O 0 0.00030105287
hypothesis O 0 0.00030787484
that O 0 0.00029481965
hypomethylation O 0 0.0022483852
of O 0 0.00033956586
DNA O 0 0.0011403022
plays O 0 9.2515394e-05
an O 0 0.00012537147
important O 0 6.233791e-05
role O 0 4.8617585e-05
in O 0 9.5437295e-05
the O 0 8.8303255e-05
initiation B-Disease 0 9.1661575e-05
of I-Disease 0 0.00021174681
carcinogenic I-Disease 0 0.38867307
process I-Disease 0 0.00020894203
, O 0 0.0003664414
5 B-Chemical 0 0.00019999134
- I-Chemical 0 0.0022750716
azacytidine I-Chemical 0 0.694819
( O 0 0.0005498299
5 B-Chemical 0 0.00020493694
- I-Chemical 0 0.0018445872
AzC I-Chemical 0 0.02840138
) O 0 0.00046745816
( O 0 0.0002591128
10 O 0 0.0001447802
mg O 0 0.0011154133
/ O 0 0.0005570342
kg O 0 0.00045449397
) O 0 0.00043390028
, O 0 0.00030534982
an O 0 0.00020918941
inhibitor O 0 0.0006229045
of O 0 0.00033159676
DNA O 0 0.0051929536
methylation O 0 0.00044917452
, O 0 0.00030611435
was O 0 8.940729e-05
given O 0 5.1545678e-05
to O 0 5.9631086e-05
rats O 0 0.00011834704
during O 0 5.3130327e-05
the O 0 6.553528e-05
phase O 0 0.00021185058
of O 0 0.00016086729
repair O 0 0.0003230602
synthesis O 0 0.00032147695
induced O 0 0.0001213647
by O 0 0.00011304472
the O 0 9.292015e-05
three O 0 7.270054e-05
carcinogens O 0 0.028066969
, O 0 0.0007979643
benzo B-Chemical 0 0.99515224
[ I-Chemical 0 0.0055393837
a I-Chemical 0 0.00040927826
] I-Chemical 0 0.0020191655
- I-Chemical 0 0.004033163
pyrene I-Chemical 0 0.26316968
( O 0 0.0003960895
200 O 0 0.00034547693
mg O 0 0.001985925
/ O 0 0.00070208375
kg O 0 0.000578779
) O 0 0.0006971784
, O 0 0.000992973
N B-Chemical 0 0.99926454
- I-Chemical 0 0.3716894
methyl I-Chemical 0 0.9946075
- I-Chemical 0 0.37253556
N I-Chemical 0 0.99967647
- I-Chemical 0 0.20394172
nitrosourea I-Chemical 0 0.99705863
( O 0 0.00041356025
60 O 0 0.00019324008
mg O 0 0.0012493606
/ O 0 0.0005842296
kg O 0 0.00045619454
) O 0 0.00040029196
and O 0 0.0001943595
1 B-Chemical 0 0.00023123268
, I-Chemical 0 0.00037084412
2 I-Chemical 0 0.00033107467
- I-Chemical 0 0.0031152586
dimethylhydrazine I-Chemical 0 0.7371154
( O 0 0.00065751356
1 B-Chemical 0 0.00031908794
, I-Chemical 0 0.000466822
2 I-Chemical 0 0.0004119531
- I-Chemical 0 0.0023571677
DMH I-Chemical 0 0.076955535
) O 0 0.0009869604
( O 0 0.00079929986
100 O 0 0.001098658
mg O 0 0.005039297
/ O 0 0.0029706652
kg O 0 0.0029545152
) O 0 0.004011038
. O 0 0.0037250125

The O 0 0.0022409395
initiated O 0 0.0021209812
hepatocytes O 0 0.0066634626
in O 0 0.0009832474
the O 0 0.0006783711
liver O 0 0.014216537
were O 0 0.0003827857
assayed O 0 0.00028560887
as O 0 0.0002772752
the O 0 0.00031423717
gamma O 0 0.2825876
- O 0 0.23105973
glutamyltransferase O 0 0.9995751
( O 0 0.0017555901
gamma O 0 0.216383
- O 0 0.022029772
GT O 0 0.31013778
) O 0 0.00059193117
positive O 0 0.00017406286
foci O 0 0.00016277395
formed O 0 0.00014842351
following O 0 7.805049e-05
a O 0 0.00016779076
2 O 0 0.00013250728
- O 0 0.00033250407
week O 0 4.4782977e-05
selection O 0 5.745725e-05
regimen O 0 9.31461e-05
consisting O 0 8.471598e-05
of O 0 0.00016495846
dietary O 0 0.0025986452
0 O 0 0.00030826402
. O 0 0.00021394179
02 O 0 0.005666234
% O 0 0.00044372785
2 B-Chemical 0 0.0002963976
- I-Chemical 0 0.0022847936
acetylaminofluorene I-Chemical 0 0.37778315
coupled O 0 0.0002883534
with O 0 0.00036550654
a O 0 0.00085846207
necrogenic O 0 0.52674395
dose O 0 0.0021710494
of O 0 0.002432716
CCl4 B-Chemical 0 0.9999223
. O 0 0.005216314

The O 0 0.0016746034
results O 0 0.0011527676
obtained O 0 0.00069632824
indicate O 0 0.00035966033
that O 0 0.00037293084
with O 0 0.0004205542
all O 0 0.00027766038
three O 0 0.00015128698
carcinogens O 0 0.0055565266
, O 0 0.00045085372
administration O 0 0.00033102065
of O 0 0.00020107087
5 B-Chemical 0 0.00020730552
- I-Chemical 0 0.0018799022
AzC I-Chemical 0 0.014291482
during O 0 0.00011467688
repair O 0 0.00026769275
synthesis O 0 0.00031247697
increased O 0 0.0001867188
the O 0 0.00010221132
incidence O 0 0.00026058266
of O 0 0.00014753175
initiated O 0 0.00017161996
hepatocytes O 0 0.006269608
, O 0 0.00033335885
for O 0 9.262476e-05
example O 0 0.00012134907
10 O 0 0.00015206345
- O 0 0.0005944878
20 O 0 0.00011428224
foci O 0 0.0001353658
/ O 0 0.0007026869
cm2 O 0 0.0012219021
in O 0 0.00013343644
5 B-Chemical 0 0.0001544878
- I-Chemical 0 0.0014838319
AzC I-Chemical 0 0.02533108
and O 0 0.00023446958
carcinogen O 0 0.6745311
- O 0 0.002016592
treated O 0 0.00023511653
rats O 0 0.00017851606
compared O 0 7.6306605e-05
with O 0 0.0001238536
3 O 0 0.00013281581
- O 0 0.00056236115
5 O 0 0.00011766715
foci O 0 0.00016282396
/ O 0 0.00078782206
cm2 O 0 0.0012799533
in O 0 0.00020809667
rats O 0 0.0004572246
treated O 0 0.00076012214
with O 0 0.0008740512
carcinogen O 0 0.7427954
only O 0 0.0022144525
. O 0 0.0029730615

Administration O 0 0.010506804
of O 0 0.0041707
[ B-Chemical 0 0.020019595
3H I-Chemical 0 0.9373827
] I-Chemical 0 0.016378326
- I-Chemical 0 0.0067986837
5 I-Chemical 0 0.0006228321
- I-Chemical 0 0.0024583286
azadeoxycytidine I-Chemical 0 0.0022171268
during O 0 0.00020904905
the O 0 0.00021154057
repair O 0 0.00043945486
synthesis O 0 0.00048711576
induced O 0 0.00022511113
by O 0 0.00023340453
1 B-Chemical 0 0.00027359408
, I-Chemical 0 0.00039227845
2 I-Chemical 0 0.00029097142
- I-Chemical 0 0.0021393124
DMH I-Chemical 0 0.030746853
further O 0 0.00011884575
showed O 0 0.00012684887
that O 0 0.000109882116
0 O 0 0.00023066833
. O 0 0.00018039571
019 O 0 0.0011134217
mol O 0 0.07829776
% O 0 0.0006349346
of O 0 0.00036471448
cytosine B-Chemical 0 0.8506187
residues O 0 0.00032007543
in O 0 0.00020562747
DNA O 0 0.001286744
were O 0 0.00012784338
substituted O 0 0.00018438767
by O 0 0.00010639872
the O 0 0.00010845927
analogue O 0 0.00039221696
, O 0 0.00029989728
indicating O 0 0.00010706649
that O 0 0.00012228904
incorporation O 0 0.00032617507
of O 0 0.00030078087
5 B-Chemical 0 0.0003378538
- I-Chemical 0 0.0035845952
AzC I-Chemical 0 0.032359097
occurs O 0 0.00037420547
during O 0 0.00041572494
repair O 0 0.001380446
synthesis O 0 0.0030199601
. O 0 0.0030293956

In O 0 0.0021053697
the O 0 0.001545278
absence O 0 0.000919729
of O 0 0.0010926478
the O 0 0.00088548247
carcinogen O 0 0.6897036
, O 0 0.0012881774
5 B-Chemical 0 0.00046658822
- I-Chemical 0 0.0025507084
AzC I-Chemical 0 0.006106278
given O 0 0.00010758905
after O 0 7.005538e-05
a O 0 0.00013693277
two O 0 6.7517074e-05
thirds O 0 0.00019706643
partial O 0 0.0002727344
hepatectomy O 0 0.7876389
, O 0 0.0002841062
when O 0 9.2930866e-05
its O 0 0.00020562827
incorporation O 0 0.00023618061
should O 0 7.6667646e-05
be O 0 0.00012141446
maximum O 0 0.000191378
, O 0 0.00029744982
failed O 0 0.00018923015
to O 0 0.00017490485
induce O 0 0.00019664597
any O 0 0.00040969675
gamma O 0 0.2982043
- O 0 0.04558331
GT O 0 0.31259894
positive O 0 0.0013242791
foci O 0 0.0019224213
. O 0 0.003029747

The O 0 0.0021238269
results O 0 0.0015393449
suggest O 0 0.0009295212
that O 0 0.0011698473
hypomethylation O 0 0.0054267193
of O 0 0.0012665245
DNA O 0 0.007193481
per O 0 0.0008565047
se O 0 0.0015811521
may O 0 0.00038156135
not O 0 0.00039052122
be O 0 0.0004374366
sufficient O 0 0.00041120098
for O 0 0.0006852582
initiation O 0 0.0012133827
. O 0 0.003150732

Perhaps O 0 0.0024895533
two O 0 0.0012397385
events O 0 0.0016090093
might O 0 0.00048519258
be O 0 0.0004390924
necessary O 0 0.00022142884
for O 0 0.00022594784
initiation O 0 0.00021545704
, O 0 0.00043714078
the O 0 0.00017896395
first O 0 0.00013757787
caused O 0 0.00021266864
by O 0 0.00023941028
the O 0 0.0002751078
carcinogen O 0 0.4035897
and O 0 0.00038406614
a O 0 0.00048171997
second O 0 0.00034787355
involving O 0 0.0007049351
hypomethylation O 0 0.004175289
of O 0 0.001493721
DNA O 0 0.010932888
. O 0 0.0035575966

Antihypertensive O 0 0.98279345
drugs O 0 0.24238771
and O 0 0.00809797
depression B-Disease 0 0.9975629
: O 0 0.010291835
a O 0 0.0073158178
reappraisal O 0 0.11509722
. O 0 0.009587047

Eighty O 0 0.010368558
- O 0 0.007470512
nine O 0 0.0012503404
new O 0 0.0012404125
referral O 0 0.002109174
hypertensive B-Disease 0 0.99927706
out O 0 0.0005837907
- O 0 0.0026129535
patients O 0 0.00052070536
and O 0 0.00022988865
46 O 0 0.00028181635
new O 0 0.00020410462
referral O 0 0.0003485092
non O 0 0.0003926376
- O 0 0.008790581
hypertensive B-Disease 0 0.99988127
chronically O 0 0.00567068
physically O 0 0.0003480797
ill O 0 0.10017289
out O 0 0.00016138461
- O 0 0.0012064019
patients O 0 0.00025599523
completed O 0 0.00015230478
a O 0 0.00027480343
mood O 0 0.9126087
rating O 0 0.00018739587
scale O 0 0.0001700581
at O 0 0.000106439526
regular O 0 0.00016547485
intervals O 0 0.00020484744
for O 0 0.00027137058
one O 0 0.0005464936
year O 0 0.0010362333
. O 0 0.0022941325

The O 0 0.0017281575
results O 0 0.001249885
showed O 0 0.0009327604
a O 0 0.0010054974
high O 0 0.0007041855
prevalence O 0 0.00073292886
of O 0 0.0007386988
depression B-Disease 0 0.9991346
in O 0 0.00024911374
both O 0 0.00016290424
groups O 0 0.00023407512
of O 0 0.00023422917
patients O 0 0.0005162863
, O 0 0.00037359007
with O 0 0.00024569372
no O 0 0.00027477986
preponderance O 0 0.0010845409
in O 0 0.0004724469
the O 0 0.00073740043
hypertensive B-Disease 0 0.99944574
group O 0 0.0029127363
. O 0 0.0028981832

Hypertensive B-Disease 0 0.99933547
patients O 0 0.0060766465
with O 0 0.0023498992
psychiatric B-Disease 2 0.9979327
histories O 0 0.0015342092
had O 0 0.00048045014
a O 0 0.000501768
higher O 0 0.00038042036
prevalence O 0 0.0005364969
of O 0 0.00069237634
depression B-Disease 0 0.9986003
than O 0 0.00045583482
the O 0 0.00045250927
comparison O 0 0.0007135297
patients O 0 0.002548407
. O 0 0.002817071

This O 0 0.005163369
was O 0 0.0020119166
accounted O 0 0.0014539396
for O 0 0.00067659613
by O 0 0.0006313385
a O 0 0.0007028543
significant O 0 0.00041670434
number O 0 0.0003576485
of O 0 0.0009074554
depressions B-Disease 0 0.99982905
occurring O 0 0.0011516662
in O 0 0.0012511886
methyl B-Chemical 0 0.9998084
dopa I-Chemical 0 0.9999881
treated O 0 0.0032793214
patients O 0 0.0018909806
with O 0 0.001222461
psychiatric B-Disease 2 0.9987606
histories O 0 0.004563587
. O 0 0.0030906969

Chronic B-Disease 0 0.41330573
active I-Disease 0 0.011154718
hepatitis I-Disease 0 0.9998611
associated O 0 0.005916406
with O 0 0.008407657
diclofenac B-Chemical 0 0.99998903
sodium I-Chemical 0 0.99964607
therapy O 0 0.009844282
. O 0 0.0056344634

Diclofenac B-Chemical 0 0.9998673
sodium I-Chemical 0 0.99944884
( O 0 0.018226936
Voltarol B-Chemical 0 0.9991111
, O 0 0.005728861
Geigy O 0 0.9913833
Pharmaceuticals O 0 0.023249475
) O 0 0.0011370839
is O 0 0.00031118313
a O 0 0.0005078454
non O 0 0.0007742115
- O 0 0.0053662197
steroidal O 0 0.29259098
anti O 0 0.004113542
- O 0 0.11957327
inflammatory O 0 0.3024517
derivative O 0 0.029844515
of O 0 0.0073606954
phenylacetic B-Chemical 0 0.99997437
acid I-Chemical 0 0.99894685
. O 0 0.010788332

Although O 0 0.0018545408
generally O 0 0.0018274393
well O 0 0.0013356685
- O 0 0.005140333
tolerated O 0 0.0017933488
, O 0 0.0011359525
asymptomatic O 0 0.0027048949
abnormalities B-Disease 0 0.011305425
of I-Disease 0 0.00039840487
liver I-Disease 0 0.024768807
function I-Disease 0 0.00018079676
have O 0 0.00013658406
been O 0 0.00012961267
recorded O 0 0.00015198723
and O 0 0.00017906656
, O 0 0.00035675932
less O 0 0.0003292977
commonly O 0 0.00038652023
, O 0 0.0009811177
severe O 0 0.04259497
hepatitis B-Disease 0 0.9999436
induced O 0 0.0020176212
by O 0 0.0032566788
diclofenac B-Chemical 0 0.99997747
. O 0 0.0052842703

The O 0 0.0020069804
patient O 0 0.0018557053
described O 0 0.0009122725
developed O 0 0.0011143757
chronic B-Disease 0 0.18021171
active I-Disease 0 0.0014131927
hepatitis I-Disease 0 0.99995613
after O 0 0.00013680759
six O 0 6.72869e-05
months O 0 5.6691624e-05
therapy O 0 0.00016094156
with O 0 0.0003252776
diclofenac B-Chemical 0 0.99999905
sodium I-Chemical 0 0.99995434
which O 0 0.00037935676
progressed O 0 0.00045370567
despite O 0 0.000103141254
the O 0 0.00011287302
withdrawal O 0 0.00070725335
of O 0 0.0001628671
the O 0 0.00016888819
drug O 0 0.0069648963
, O 0 0.0005386349
a O 0 0.00042910987
finding O 0 0.00039063944
not O 0 0.00048098675
previously O 0 0.0010248896
reported O 0 0.0017946314
. O 0 0.002890716

Arterial O 0 0.9109072
hypertension B-Disease 2 0.9997702
as O 0 0.0029271531
a O 0 0.0023711403
complication O 0 0.0049797557
of O 0 0.0017243399
prolonged O 0 0.0046273367
ketoconazole B-Chemical 0 0.9999441
treatment O 0 0.0044542053
. O 0 0.0049038953

Two O 0 0.0023613942
of O 0 0.0018129814
14 O 0 0.0012296512
patients O 0 0.0015043719
with O 0 0.0011259913
Cushing B-Disease 0 0.98603094
' I-Disease 0 0.001236981
s I-Disease 0 0.00089680427
syndrome I-Disease 0 0.56544125
treated O 0 0.0005448667
on O 0 0.00015831873
a O 0 0.0003007296
long O 0 0.00025612413
- O 0 0.00092230627
term O 0 0.0002278866
basis O 0 0.00025476777
with O 0 0.0007847141
ketoconazole B-Chemical 0 0.9999894
developed O 0 0.0019789066
sustained O 0 0.005813386
hypertension B-Disease 2 0.99995065
. O 0 0.0046259277

In O 0 0.001869841
both O 0 0.0016771434
cases O 0 0.0024814846
normal O 0 0.0022137405
plasma O 0 0.011421941
and O 0 0.00081979414
urinary O 0 0.10206668
free O 0 0.0013159405
cortisol B-Chemical 0 0.9987111
levels O 0 0.00021377254
had O 0 0.00014971159
been O 0 0.00010502509
achieved O 0 0.00013215042
following O 0 0.00011768948
ketoconazole B-Chemical 0 0.9999924
therapy O 0 0.00034830993
, O 0 0.00017624868
yet O 0 8.059226e-05
continuous O 0 7.5053846e-05
blood O 0 0.0006436359
pressure O 0 0.0011653407
monitoring O 0 9.544393e-05
demonstrated O 0 0.00013944766
hypertension B-Disease 2 0.99998045
31 O 0 0.00042565545
( O 0 0.00028191658
patient O 0 0.00015549334
1 O 0 0.0001428873
) O 0 0.00025440342
and O 0 0.0001385715
52 O 0 0.0002033936
weeks O 0 0.000103693405
( O 0 0.00036515528
patient O 0 0.00033508358
2 O 0 0.00040597026
) O 0 0.00086103764
after O 0 0.00045323386
treatment O 0 0.0012693113
. O 0 0.0028025177

In O 0 0.002676048
patient O 0 0.00291444
1 O 0 0.0020463374
, O 0 0.0025011206
plasma O 0 0.0053720735
levels O 0 0.0008893467
of O 0 0.0017083447
deoxycorticosterone B-Chemical 0 0.9999788
and O 0 0.0017507651
11 B-Chemical 0 0.0014735296
- I-Chemical 0 0.010426365
deoxycortisol I-Chemical 0 0.9836627
were O 0 0.0018566656
elevated O 0 0.0061544357
. O 0 0.004105825

In O 0 0.0022774485
patient O 0 0.002328848
2 O 0 0.001428228
, O 0 0.0013517591
in O 0 0.00051681703
addition O 0 0.00025558448
to O 0 0.00029281146
an O 0 0.0003067852
increase O 0 0.00021550554
in O 0 0.00021363443
both O 0 0.00031949708
deoxycorticosterone B-Chemical 0 0.9999902
and O 0 0.00042074884
11 B-Chemical 0 0.00034606317
- I-Chemical 0 0.0055742715
deoxycortisol I-Chemical 0 0.9860569
levels O 0 0.00022373036
, O 0 0.0006854276
plasma O 0 0.13775764
aldosterone B-Chemical 0 0.9999708
values O 0 0.00022034251
were O 0 0.00012651148
raised O 0 0.0001588092
, O 0 0.00029016307
with O 0 0.00022035092
a O 0 0.00039634938
concomitant O 0 0.00066120067
suppression O 0 0.000540735
of O 0 0.0011037724
renin O 0 0.9868307
levels O 0 0.0020546468
. O 0 0.003177423

Our O 0 0.0019003077
findings O 0 0.0016802945
show O 0 0.0007464564
that O 0 0.0005555853
long O 0 0.0006603222
- O 0 0.0018558229
term O 0 0.00031569475
treatment O 0 0.00021896134
with O 0 0.00019091034
high O 0 0.00025421748
doses O 0 0.00069172634
of O 0 0.0006601645
ketoconazole B-Chemical 0 0.999997
may O 0 0.0002546
induce O 0 0.00016660686
enzyme O 0 0.0011782442
blockade O 0 0.0018399067
leading O 0 0.00042607886
to O 0 0.0005012375
mineralocorticoid O 0 0.9992029
- O 0 0.028963404
related O 0 0.0009990699
hypertension B-Disease 2 0.99991775
. O 0 0.004152032

Effects O 0 0.003496437
of O 0 0.0023531858
an O 0 0.001897814
inhibitor O 0 0.004094985
of O 0 0.0024898446
angiotensin B-Chemical 0 0.99998116
converting O 0 0.0267795
enzyme O 0 0.014358252
( O 0 0.0057110684
Captopril B-Chemical 0 0.9999906
) O 0 0.0011197078
on O 0 0.00015394768
pulmonary B-Disease 0 0.032217804
and I-Disease 0 0.0003250318
renal I-Disease 0 0.897695
insufficiency I-Disease 0 0.9972519
due O 0 0.0002391315
to O 0 0.00036910744
intravascular B-Disease 0 0.96984386
coagulation I-Disease 0 0.9925553
in O 0 0.0005330878
the O 0 0.00064856233
rat O 0 0.0019123016
. O 0 0.0024205649

Induction O 0 0.0040843287
of O 0 0.0036897422
intravascular B-Disease 0 0.9769408
coagulation I-Disease 0 0.99428755
and O 0 0.00080667145
inhibition O 0 0.0006940385
of O 0 0.00072849257
fibrinolysis O 0 0.9978345
by O 0 0.00022272213
injection O 0 0.00017726277
of O 0 0.0003300344
thrombin O 0 0.8680269
and O 0 0.0012204975
tranexamic B-Chemical 0 0.9999689
acid I-Chemical 0 0.9930906
( O 0 0.029683702
AMCA B-Chemical 0 0.99989414
) O 0 0.0009985646
in O 0 0.00011801279
the O 0 8.943757e-05
rat O 0 0.00015416907
gives O 0 7.870793e-05
rise O 0 0.000104553845
to O 0 8.592007e-05
pulmonary B-Disease 0 0.03812541
and I-Disease 0 0.00020288247
renal I-Disease 0 0.9532066
insufficiency I-Disease 0 0.99925226
resembling O 0 0.00029494672
that O 0 0.00010052633
occurring O 0 0.0001713046
after O 0 0.00013669286
trauma B-Disease 0 0.450884
or O 0 0.0005634016
sepsis B-Disease 2 0.99716276
in O 0 0.0013461142
man O 0 0.025357047
. O 0 0.0032281934

Injection O 0 0.01344751
of O 0 0.0056248936
Captopril B-Chemical 0 0.99992335
( O 0 0.0030913872
1 O 0 0.0009526537
mg O 0 0.003778828
/ O 0 0.0014427936
kg O 0 0.001011537
) O 0 0.00083304767
, O 0 0.00055120816
an O 0 0.00035631747
inhibitor O 0 0.0010230088
of O 0 0.0009012209
angiotensin B-Chemical 0 0.99998975
converting O 0 0.0124394735
enzyme O 0 0.006014846
( O 0 0.0016854623
ACE O 0 0.9822267
) O 0 0.00093583594
, O 0 0.0003355505
reduced O 0 0.00019221449
both O 0 0.00017378242
pulmonary B-Disease 0 0.08196773
and I-Disease 0 0.0003803636
renal I-Disease 0 0.9427842
insufficiency I-Disease 0 0.998212
in O 0 0.00043716974
this O 0 0.0005429638
rat O 0 0.0010138932
model O 0 0.0011267886
. O 0 0.002425168

The O 0 0.0023640504
lung O 0 0.004796567
weights O 0 0.0011310263
were O 0 0.00074686337
lower O 0 0.0007762165
and O 0 0.0008279347
PaO2 O 0 0.706097
was O 0 0.00038033165
improved O 0 0.0004291931
in O 0 0.00027403244
rats O 0 0.0004693222
given O 0 0.00025832542
this O 0 0.00054018095
enzyme O 0 0.0020638844
- O 0 0.0049278345
blocking O 0 0.0015418461
agent O 0 0.004697926
. O 0 0.003954186

The O 0 0.0025289115
contents O 0 0.0039423835
of O 0 0.0026233217
albumin O 0 0.9775555
in O 0 0.00076809456
the O 0 0.0004248113
lungs O 0 0.0006868702
were O 0 0.0002607514
not O 0 0.00021518134
changed O 0 0.00029863615
, O 0 0.00045988048
indicating O 0 0.00021095987
that O 0 0.00038100834
Captopril B-Chemical 0 0.9999895
did O 0 0.00054754474
not O 0 0.0002669445
influence O 0 0.00024976133
the O 0 0.0004769951
extravasation O 0 0.065964185
of O 0 0.0010468683
protein O 0 0.0017954609
. O 0 0.0031996001

Renal B-Disease 0 0.94674903
damage I-Disease 0 0.5870224
as O 0 0.0018633805
reflected O 0 0.0010307512
by O 0 0.00069076486
an O 0 0.00062616164
increase O 0 0.00046674084
in O 0 0.00058432954
serum O 0 0.20674232
urea B-Chemical 0 0.9994856
and O 0 0.000592747
in O 0 0.00041195843
kidney O 0 0.010780748
weight O 0 0.00090123713
was O 0 0.0005911297
prevented O 0 0.0015893423
by O 0 0.0026360257
Captopril B-Chemical 0 0.9999391
. O 0 0.0060596205

The O 0 0.0018955374
amount O 0 0.0012014585
of O 0 0.0016209949
fibrin O 0 0.06423695
in O 0 0.000575546
the O 0 0.00037222297
kidneys O 0 0.0013402003
was O 0 0.00024416205
also O 0 0.00018137244
considerably O 0 0.00026986276
lower O 0 0.00022275271
than O 0 0.00014306411
in O 0 0.00014374961
animals O 0 0.00014564229
which O 0 0.00031806715
received O 0 0.00048972876
thrombin O 0 0.419849
and O 0 0.0014573983
AMCA B-Chemical 0 0.99829715
alone O 0 0.0027155096
. O 0 0.0034980436

It O 0 0.0050273095
is O 0 0.0014955918
suggested O 0 0.0008346908
that O 0 0.00051976077
the O 0 0.00042374214
effects O 0 0.000487462
of O 0 0.0010828237
Captopril B-Chemical 0 0.9999869
on O 0 0.00024784388
the O 0 0.00018958106
lungs O 0 0.0004415693
may O 0 0.00012415535
be O 0 0.00011000121
attributable O 0 8.313066e-05
to O 0 0.00010026038
a O 0 0.00025487735
vasodilatory O 0 0.49836174
effect O 0 0.00010573422
due O 0 8.001869e-05
to O 0 8.890305e-05
a O 0 0.0001633673
reduction O 0 0.00013922923
in O 0 9.297182e-05
the O 0 8.8101224e-05
circulating O 0 0.00043679983
level O 0 0.000113432354
of O 0 0.00024742883
Angiotension B-Chemical 0 0.66074836
II I-Chemical 0 0.45959562
and O 0 0.00019443996
an O 0 0.00017232227
increase O 0 0.00017314282
in O 0 0.00039795996
prostacyclin B-Chemical 0 0.9999958
( O 0 0.0016056892
secondary O 0 0.00034874683
to O 0 0.0002126954
an O 0 0.00034369412
increase O 0 0.00042513557
in O 0 0.00095328107
bradykinin B-Chemical 0 0.99972457
) O 0 0.0071429573
. O 0 0.0031281598

Captopril B-Chemical 0 0.99988544
may O 0 0.0030323435
, O 0 0.0026226307
by O 0 0.000826653
the O 0 0.0004703238
same O 0 0.000288222
mechanism O 0 0.00024171651
, O 0 0.00051538233
reduce O 0 0.0001645624
the O 0 0.00017828404
increase O 0 0.00019750434
in O 0 0.00025371116
glomerular O 0 0.9945458
filtration O 0 0.02335947
that O 0 0.000103680846
is O 0 9.463915e-05
known O 0 9.8813594e-05
to O 0 8.3276966e-05
occur O 0 7.616847e-05
after O 0 3.8414837e-05
an O 0 7.7087934e-05
injection O 0 7.466986e-05
of O 0 0.00016120695
thrombin O 0 0.4907004
, O 0 0.0002599353
thereby O 0 0.00010526783
diminishing O 0 0.0001906622
the O 0 0.000114821196
aggregation O 0 0.0008433511
of O 0 0.00021273637
fibrin O 0 0.2253075
monomers O 0 0.00021237746
in O 0 0.00011273802
the O 0 0.00011156432
glomeruli O 0 0.00940237
, O 0 0.00025758147
with O 0 0.000114471266
the O 0 8.2777384e-05
result O 0 8.628693e-05
that O 0 8.678494e-05
less O 0 0.00027453658
fibrin O 0 0.08217522
will O 0 0.00010606696
be O 0 0.00012567513
deposited O 0 0.00027223557
and O 0 0.00017563031
thus O 0 0.00023969897
less O 0 0.0006331939
kidney B-Disease 0 0.9293511
damage I-Disease 0 0.80355775
will O 0 0.0005581564
be O 0 0.00073551876
produced O 0 0.0010880376
. O 0 0.0025707944

Stroke B-Disease 0 0.5954075
associated O 0 0.008688551
with O 0 0.009324246
cocaine B-Chemical 0 0.99615943
use O 0 0.009237717
. O 0 0.011705502

We O 0 0.0020978604
describe O 0 0.0013045401
eight O 0 0.00074124825
patients O 0 0.0012478908
in O 0 0.0005771267
whom O 0 0.0012718042
cocaine B-Chemical 0 0.9985268
use O 0 0.00031896567
was O 0 0.00022363011
related O 0 0.00015088185
to O 0 0.00026408018
stroke B-Disease 0 0.9661755
and O 0 0.00038943937
review O 0 0.0006166679
39 O 0 0.0005291473
cases O 0 0.00067268027
from O 0 0.0005111758
the O 0 0.0007846353
literature O 0 0.0028154748
. O 0 0.0032708924

Among O 0 0.003992866
these O 0 0.0022163233
47 O 0 0.0024749504
patients O 0 0.0014689532
the O 0 0.00056938094
mean O 0 0.00052220887
( O 0 0.0010261373
+ O 0 0.0018494222
/ O 0 0.002971592
- O 0 0.004115329
SD O 0 0.010133352
) O 0 0.0008501278
age O 0 0.0004461922
was O 0 0.00024781414
32 O 0 0.00032881962
. O 0 0.00022272639
5 O 0 0.00022981151
+ O 0 0.0008275085
/ O 0 0.0015112025
- O 0 0.0014032077
12 O 0 0.00019514016
. O 0 0.00021297077
1 O 0 0.0002503008
years O 0 0.00031702602
; O 0 0.0005334737
76 O 0 0.0005811119
% O 0 0.0006757015
( O 0 0.00071663246
34 O 0 0.0006686226
/ O 0 0.0017884847
45 O 0 0.0008500511
) O 0 0.0017444653
were O 0 0.0013154853
men O 0 0.005610744
. O 0 0.0043469034

Stroke B-Disease 0 0.4687456
followed O 0 0.0026919432
cocaine B-Chemical 0 0.99516284
use O 0 0.0009843563
by O 0 0.0007418256
inhalation O 0 0.0017699146
, O 0 0.0008616794
intranasal O 0 0.0005862514
, O 0 0.0008776316
intravenous O 0 0.002337401
, O 0 0.0011511205
and O 0 0.0010526219
intramuscular O 0 0.003270956
routes O 0 0.0027315994
. O 0 0.003625225

Intracranial B-Disease 0 0.9478055
aneurysms I-Disease 2 0.9996232
or O 0 0.0028861964
arteriovenous B-Disease 0 0.995008
malformations I-Disease 0 0.9997737
were O 0 0.0005056925
present O 0 0.00024503237
in O 0 0.00023838642
17 O 0 0.00027746905
of O 0 0.00019398217
32 O 0 0.00026187903
patients O 0 0.00033233926
studied O 0 0.0002890768
angiographically O 0 0.7662495
or O 0 0.0001569656
at O 0 0.0001543338
autopsy O 0 0.004816041
; O 0 0.0015518131
cerebral B-Disease 0 0.99980026
vasculitis I-Disease 2 0.99997866
was O 0 0.00036718065
present O 0 0.000264091
in O 0 0.0003941234
two O 0 0.0004911825
patients O 0 0.0021522013
. O 0 0.002429788

Cerebral B-Disease 0 0.9980921
infarction I-Disease 0 0.99995935
occurred O 0 0.0023019167
in O 0 0.0009853378
10 O 0 0.00073713734
patients O 0 0.0009022081
( O 0 0.00076685415
22 O 0 0.0005752592
% O 0 0.00073716755
) O 0 0.0009442173
, O 0 0.0010377982
intracerebral B-Disease 0 0.9645278
hemorrhage I-Disease 2 0.9998473
in O 0 0.00032004
22 O 0 0.00036666048
( O 0 0.00036987933
49 O 0 0.00032722254
% O 0 0.00047105429
) O 0 0.0006257634
, O 0 0.0005558383
and O 0 0.00058375736
subarachnoid B-Disease 0 0.9998161
hemorrhage I-Disease 2 0.99989784
in O 0 0.0004816878
13 O 0 0.0005489745
( O 0 0.0008949349
29 O 0 0.0011204031
% O 0 0.0019477884
) O 0 0.0036060126
. O 0 0.003550705

These O 0 0.0022703141
data O 0 0.0019476365
indicate O 0 0.0007352056
that O 0 0.0008149784
( O 0 0.0014884524
1 O 0 0.00070432003
) O 0 0.00086071977
the O 0 0.00026554737
apparent O 0 0.000288982
incidence O 0 0.00048913417
of O 0 0.00037222548
stroke B-Disease 0 0.99445206
related O 0 0.00013839403
to O 0 0.00018451306
cocaine B-Chemical 0 0.99887997
use O 0 0.00012918918
is O 0 9.23909e-05
increasing O 0 0.00013296278
; O 0 0.00034206215
( O 0 0.0002663481
2 O 0 0.00016817854
) O 0 0.0006481575
cocaine B-Chemical 0 0.9997042
- O 0 0.005550348
associated O 0 0.0002547617
stroke B-Disease 0 0.9921904
occurs O 0 0.00013776835
primarily O 0 0.00011810329
in O 0 0.00012473718
young O 0 0.0008850261
adults O 0 0.0011374793
; O 0 0.0004099589
( O 0 0.00026594158
3 O 0 0.00012464338
) O 0 0.00051635597
stroke B-Disease 0 0.97294825
may O 0 9.6062824e-05
follow O 0 6.0949187e-05
any O 0 7.0295275e-05
route O 0 0.00011676046
of O 0 0.00017037835
cocaine B-Chemical 0 0.99964345
administration O 0 0.0005393452
; O 0 0.00030254677
( O 0 0.0001943732
4 O 0 8.955056e-05
) O 0 0.0003359304
stroke B-Disease 0 0.9325956
after O 0 8.200757e-05
cocaine B-Chemical 0 0.99762625
use O 0 9.559788e-05
is O 0 7.240885e-05
frequently O 0 9.1571244e-05
associated O 0 0.000104391955
with O 0 0.00018184083
intracranial B-Disease 0 0.9994129
aneurysms I-Disease 2 0.9999862
and O 0 0.0004018684
arteriovenous B-Disease 0 0.9984308
malformations I-Disease 0 0.99996233
; O 0 0.000583976
and O 0 0.00013534246
( O 0 0.0002235525
5 O 0 0.000103906896
) O 0 0.00026779974
in O 0 0.00016923314
cocaine B-Chemical 0 0.9997594
- O 0 0.006532459
associated O 0 0.00027749524
stroke B-Disease 0 0.99302965
, O 0 0.00032786862
the O 0 0.000109183056
frequency O 0 0.00014190342
of O 0 0.00038073052
intracranial B-Disease 0 0.9997565
hemorrhage I-Disease 2 0.99998856
exceeds O 0 0.0004256912
that O 0 0.0003362199
of O 0 0.0012319038
cerebral B-Disease 0 0.99921083
infarction I-Disease 0 0.99996233
. O 0 0.003906896

A O 0 0.02239595
randomized O 0 0.0053699925
comparison O 0 0.0017622875
of O 0 0.0033615015
labetalol B-Chemical 0 0.99999225
and O 0 0.009120537
nitroprusside B-Chemical 0 0.99997485
for O 0 0.0016662903
induced O 0 0.002895957
hypotension B-Disease 0 0.9995295
. O 0 0.005856781

In O 0 0.002041724
a O 0 0.0025751817
randomized O 0 0.0027727461
study O 0 0.0013601965
, O 0 0.003662814
labetalol B-Chemical 0 0.99999666
- O 0 0.075440735
induced O 0 0.00072878134
hypotension B-Disease 0 0.99994874
and O 0 0.0016915881
nitroprusside B-Chemical 0 0.9999974
- O 0 0.015909849
induced O 0 0.0002645033
hypotension B-Disease 0 0.9998692
were O 0 0.000115922536
compared O 0 7.1157156e-05
in O 0 9.537725e-05
20 O 0 0.00012497876
patients O 0 0.0002444082
( O 0 0.00021416917
10 O 0 0.00011136196
in O 0 9.573946e-05
each O 0 8.59363e-05
group O 0 0.00022392327
) O 0 0.00037544427
scheduled O 0 0.00012916037
for O 0 0.00019251512
major O 0 0.0004390564
orthopedic O 0 0.0013646815
procedures O 0 0.0011670331
. O 0 0.0023834533

Each O 0 0.0021469186
patient O 0 0.0016498953
was O 0 0.00075496803
subjected O 0 0.00038390266
to O 0 0.000327534
an O 0 0.0003050597
identical O 0 0.00015900253
anesthetic O 0 0.0010894996
protocol O 0 0.00015090633
and O 0 0.00014497267
similar O 0 0.00011694365
drug O 0 0.0034055598
- O 0 0.0010742439
induced O 0 0.00012362235
reductions B-Disease 0 0.00014820884
in I-Disease 0 0.00010491168
mean I-Disease 0 0.00011981614
arterial I-Disease 0 0.047335304
blood I-Disease 0 0.002091359
pressure I-Disease 0 0.0054886
( O 0 0.00066134473
BP O 0 0.34454325
) O 0 0.00083615445
( O 0 0.0005831779
50 O 0 0.00046360385
to O 0 0.00040356367
55 O 0 0.0009578742
mmHg O 0 0.004031109
) O 0 0.0036570008
. O 0 0.0035004816

Nitroprusside O 0 0.9995956
infusion O 0 0.009264901
was O 0 0.0010900716
associated O 0 0.00071323366
with O 0 0.00053416286
a O 0 0.00054369273
significant O 0 0.00032134217
( O 0 0.00046745103
p O 0 0.00040689198
less O 0 0.00027117506
than O 0 0.00017352676
0 O 0 0.00026558051
. O 0 0.00021580634
05 O 0 0.003451481
) O 0 0.00042216663
increase B-Disease 0 0.00014536119
in I-Disease 0 0.0001585237
heart I-Disease 0 0.0027739832
rate I-Disease 0 0.00021090133
and I-Disease 0 0.00014262863
cardiac I-Disease 0 0.00050860614
output I-Disease 0 0.00016585617
; O 0 0.000374846
rebound O 0 0.0024622479
hypertension B-Disease 2 0.9999838
was O 0 0.00017875078
observed O 0 0.00011179925
in O 0 0.000111783265
three O 0 7.337027e-05
patients O 0 0.0002823209
after O 0 0.00015660754
discontinuation O 0 0.0023888063
of O 0 0.0014363027
nitroprusside B-Chemical 0 0.99996185
. O 0 0.003986013

Labetalol B-Chemical 0 0.9998665
administration O 0 0.008807669
was O 0 0.0018238775
not O 0 0.0011528487
associated O 0 0.0011381106
with O 0 0.0010774292
any O 0 0.0009201659
of O 0 0.0013063654
these O 0 0.0015830518
findings O 0 0.0030482074
. O 0 0.0045288554

Arterial O 0 0.96928495
PO2 B-Chemical 0 0.99918884
decreased O 0 0.010271801
in O 0 0.00465566
both O 0 0.0045488267
groups O 0 0.0077031767
. O 0 0.010870914

It O 0 0.0066703935
was O 0 0.0027067966
concluded O 0 0.0023145636
that O 0 0.0022231892
labetalol B-Chemical 0 0.9999509
offers O 0 0.0014632932
advantages O 0 0.0010059841
over O 0 0.0027486023
nitroprusside B-Chemical 0 0.9998085
. O 0 0.007924121

Sodium B-Chemical 0 0.99734795
status O 0 0.0037206763
influences O 0 0.002639862
chronic O 0 0.19911878
amphotericin B-Chemical 0 0.9998416
B I-Chemical 0 0.99283785
nephrotoxicity B-Disease 0 0.9999188
in O 0 0.00349213
rats O 0 0.005109311
. O 0 0.005064684

The O 0 0.0027593353
nephrotoxic B-Disease 0 0.93592536
potential O 0 0.0012147761
of O 0 0.0017353912
amphotericin B-Chemical 0 0.99988616
B I-Chemical 0 0.84691274
( O 0 0.0012348114
5 O 0 0.0003395739
mg O 0 0.0018925626
/ O 0 0.0006771739
kg O 0 0.00037871624
per O 0 0.000113214504
day O 0 7.343277e-05
intraperitoneally O 0 0.00012067542
for O 0 6.397234e-05
3 O 0 7.304341e-05
weeks O 0 5.9211194e-05
) O 0 0.00022789139
has O 0 7.905605e-05
been O 0 0.00011482558
investigated O 0 0.00015517327
in O 0 0.00026408143
salt O 0 0.9864433
- O 0 0.008837484
depleted O 0 0.00022525799
, O 0 0.00066012243
normal O 0 0.0009785644
- O 0 0.01219418
salt O 0 0.97079796
, O 0 0.0014408166
and O 0 0.0008748089
salt O 0 0.9838463
- O 0 0.014836177
loaded O 0 0.0020082223
rats O 0 0.00270508
. O 0 0.0030508514

In O 0 0.0035203777
salt O 0 0.9435811
- O 0 0.009542101
depleted O 0 0.00087110745
rats O 0 0.0014040199
, O 0 0.0020657573
amphotericin B-Chemical 0 0.9998703
B I-Chemical 0 0.85638857
decreased O 0 0.003657316
creatinine B-Chemical 0 0.9988223
clearance O 0 0.003143985
linearly O 0 0.00026651524
with O 0 0.00018356566
time O 0 0.0001513242
, O 0 0.00039492676
with O 0 0.0002861035
an O 0 0.0003569917
85 O 0 0.00052727864
% O 0 0.0006197565
reduction O 0 0.0005158544
by O 0 0.00056070276
week O 0 0.0005717858
3 O 0 0.0011728465
. O 0 0.0024841474

In O 0 0.002228029
contrast O 0 0.0027507595
, O 0 0.0027146316
in O 0 0.0011878771
normal O 0 0.0020866948
- O 0 0.011197252
salt O 0 0.9318643
rats O 0 0.0025946514
creatinine B-Chemical 0 0.9978549
clearance O 0 0.0029715947
was O 0 0.00022505427
decreased O 0 0.00037271902
but O 0 0.00022167894
to O 0 0.00014185256
a O 0 0.0002474812
lesser O 0 0.0005329715
extent O 0 0.00011928422
at O 0 8.0832244e-05
week O 0 6.563522e-05
2 O 0 9.852079e-05
and O 0 9.691484e-05
3 O 0 9.57035e-05
, O 0 0.00019201683
and O 0 0.00014206808
in O 0 0.0001895097
salt O 0 0.96190333
- O 0 0.0054191556
loaded O 0 0.00034288722
rats O 0 0.0005870521
creatinine B-Chemical 0 0.9978284
clearance O 0 0.0022864945
did O 0 0.00014785398
not O 0 9.97245e-05
change O 0 0.000101745405
for O 0 7.484737e-05
2 O 0 0.000103755825
weeks O 0 5.7503185e-05
and O 0 0.00013008888
was O 0 0.00016470869
decreased O 0 0.00037031417
by O 0 0.0002947345
43 O 0 0.00055822503
% O 0 0.00065784075
at O 0 0.0003741216
week O 0 0.0004897782
3 O 0 0.0010843741
. O 0 0.0024010865

All O 0 0.0020765767
rats O 0 0.0024283966
in O 0 0.0012415277
the O 0 0.0011452335
sodium B-Chemical 0 0.9977743
- O 0 0.0060978215
depleted O 0 0.00034164434
group O 0 0.00049913046
had O 0 0.00027369504
histopathological O 0 0.00072075723
evidence O 0 0.00017462723
of O 0 0.00030166085
patchy O 0 0.0018860032
tubular O 0 0.919338
cytoplasmic O 0 0.00047586698
degeneration O 0 0.9067539
in O 0 0.00019156223
tubules O 0 0.0026356268
that O 0 0.000105891835
was O 0 0.00011840224
not O 0 0.000109226174
observed O 0 0.00012452768
in O 0 0.00015896736
any O 0 0.0001881618
normal O 0 0.0007896361
- O 0 0.011856868
salt O 0 0.973736
or O 0 0.00081746845
salt O 0 0.9939406
- O 0 0.030306982
loaded O 0 0.0020142454
rat O 0 0.002608889
. O 0 0.0028477043

Concentrations O 0 0.013757937
of O 0 0.0044008
amphotericin B-Chemical 0 0.9998153
B I-Chemical 0 0.9199729
in O 0 0.0014309407
plasma O 0 0.014072596
were O 0 0.00033245972
not O 0 0.00022050246
significantly O 0 0.00023435964
different O 0 0.00012876857
among O 0 0.0001885625
the O 0 0.00012903947
three O 0 8.322664e-05
groups O 0 0.00021297667
at O 0 0.00016037919
any O 0 0.00019991014
time O 0 0.00023200428
during O 0 0.0003689463
the O 0 0.0007027686
study O 0 0.0016803129
. O 0 0.0027701

However O 0 0.003068267
, O 0 0.0031569747
at O 0 0.00089870533
the O 0 0.00055317336
end O 0 0.00032446923
of O 0 0.00039810716
3 O 0 0.00025062796
weeks O 0 0.00016762588
, O 0 0.000661408
amphotericin B-Chemical 0 0.99980813
B I-Chemical 0 0.4374038
levels O 0 0.00023982333
in O 0 0.00017038255
the O 0 0.0001358936
kidneys O 0 0.0008892832
and O 0 0.0002053475
liver O 0 0.016393024
were O 0 0.000109801986
significantly O 0 0.00012319282
higher O 0 0.00013977755
in O 0 0.00017162913
salt O 0 0.9837127
- O 0 0.005515323
depleted O 0 0.000109877605
and O 0 0.00017240545
normal O 0 0.00050654204
- O 0 0.005556853
salt O 0 0.8758532
rats O 0 0.00030990003
than O 0 9.997959e-05
those O 0 0.00013116708
in O 0 0.00015409132
salt O 0 0.96256727
- O 0 0.004135303
loaded O 0 0.00025791593
rats O 0 0.00024410246
, O 0 0.00024385213
with O 0 0.0001813268
plasma O 0 0.008622963
/ O 0 0.0015323486
kidney O 0 0.0058201584
ratios O 0 0.00013854442
of O 0 0.00013926986
21 O 0 0.0001551184
, O 0 0.00019875682
14 O 0 0.00011125072
, O 0 0.0001907415
and O 0 0.00012840061
8 O 0 0.00013084638
in O 0 0.00018053767
salt O 0 0.9493869
- O 0 0.0044906097
depleted O 0 0.00019310894
, O 0 0.00057990523
normal O 0 0.00087024306
- O 0 0.01236244
salt O 0 0.97236675
, O 0 0.0011077136
and O 0 0.0006118436
salt O 0 0.9828781
- O 0 0.009091838
loaded O 0 0.0010027036
rats O 0 0.0011867287
, O 0 0.001781372
respectively O 0 0.0026409319
. O 0 0.003078247

In O 0 0.0016476733
conclusion O 0 0.0011516004
, O 0 0.0019271747
reductions O 0 0.0010182469
in O 0 0.00085598335
creatinine B-Chemical 0 0.98633796
clearance O 0 0.002773245
and O 0 0.000455892
renal O 0 0.8867662
amphotericin B-Chemical 0 0.9999534
B I-Chemical 0 0.54100466
accumulation O 0 0.00022809005
after O 0 9.0146015e-05
chronic O 0 0.010944759
amphotericin B-Chemical 0 0.9999572
B I-Chemical 0 0.69335943
administration O 0 0.00054489874
were O 0 0.00011806052
enhanced O 0 0.00014469617
by O 0 0.0001944496
salt O 0 0.94053686
depletion O 0 0.00026524143
and O 0 0.0003043033
attenuated O 0 0.00053803535
by O 0 0.0005229194
sodium B-Chemical 0 0.99667716
loading O 0 0.00068466744
in O 0 0.0008115503
rats O 0 0.0020894432
. O 0 0.0025349064

Flestolol B-Chemical 0 0.8887288
: O 0 0.0068518226
an O 0 0.0026216006
ultra O 0 0.008763756
- O 0 0.005312089
short O 0 0.0012009699
- O 0 0.0043845596
acting O 0 0.0016112354
beta O 0 0.81688195
- O 0 0.20769288
adrenergic O 0 0.94075435
blocking O 0 0.002880007
agent O 0 0.0066582537
. O 0 0.0052011777

Flestolol B-Chemical 0 0.9726443
( O 0 0.0101692155
ACC B-Chemical 0 0.06573091
- I-Chemical 0 0.012293181
9089 I-Chemical 0 0.0064556794
) O 0 0.0019154222
is O 0 0.00048937084
a O 0 0.00070892076
nonselective O 0 0.0059946906
, O 0 0.0007587438
competitive O 0 0.0005608193
, O 0 0.00065983995
ultra O 0 0.0037077386
- O 0 0.0017447486
short O 0 0.00025142205
- O 0 0.0014496923
acting O 0 0.0003742269
beta O 0 0.8326683
- O 0 0.19265871
adrenergic O 0 0.92088425
blocking O 0 0.00038679963
agent O 0 0.0008895403
, O 0 0.0006091929
without O 0 0.00036126233
any O 0 0.0004145731
intrinsic O 0 0.0010151564
sympathomimetic O 0 0.9844178
activity O 0 0.0013066479
. O 0 0.002754436

Flestolol B-Chemical 0 0.9834224
is O 0 0.0038275826
metabolized O 0 0.49901518
by O 0 0.0018568768
plasma O 0 0.16683571
esterases O 0 0.41087946
and O 0 0.00058652216
has O 0 0.00024782337
an O 0 0.00030822522
elimination O 0 0.00033712437
half O 0 0.00023699447
- O 0 0.0011522977
life O 0 0.0003069566
of O 0 0.0003646947
approximately O 0 0.0005005892
6 O 0 0.00037500827
. O 0 0.00053109165
5 O 0 0.00073475664
minutes O 0 0.0011375044
. O 0 0.0025100566

This O 0 0.004449727
agent O 0 0.0033452304
was O 0 0.0010492927
well O 0 0.0007163996
tolerated O 0 0.0011800275
in O 0 0.00045977396
healthy O 0 0.00127635
volunteers O 0 0.00069353706
at O 0 0.00022057584
doses O 0 0.0005118269
up O 0 0.00033712582
to O 0 0.00029411807
100 O 0 0.0008357557
micrograms O 0 0.0026691216
/ O 0 0.002176728
kg O 0 0.0020233018
/ O 0 0.003761797
min O 0 0.0028663874
. O 0 0.0033561413

In O 0 0.0018335109
long O 0 0.0018608263
- O 0 0.0032499232
term O 0 0.0008138046
infusion O 0 0.0012015485
studies O 0 0.00059714384
, O 0 0.0009889435
flestolol B-Chemical 0 0.9853092
was O 0 0.00026853482
well O 0 0.00018724134
tolerated O 0 0.0003196482
at O 0 0.00010738908
the O 0 0.00012597434
effective O 0 0.00020604767
beta O 0 0.33183524
- O 0 0.0034020708
blocking O 0 0.00023465072
dose O 0 0.0003608015
( O 0 0.0002909251
5 O 0 0.000153622
micrograms O 0 0.0007939927
/ O 0 0.0006364277
kg O 0 0.00053057075
/ O 0 0.00088485243
min O 0 0.00045027136
) O 0 0.00053230056
for O 0 0.00022243652
up O 0 0.00040175897
to O 0 0.0004014267
seven O 0 0.00055885344
days O 0 0.00077516935
. O 0 0.002385503

Flestolol B-Chemical 0 0.97528267
blood O 0 0.022204623
concentrations O 0 0.0021662782
increased O 0 0.0009718002
linearly O 0 0.0005058424
with O 0 0.00028578838
increasing O 0 0.00022144805
dose O 0 0.00031133802
and O 0 0.00014596205
good O 0 0.00015390849
correlation O 0 0.00010534344
exists O 0 0.00010023735
between O 0 0.00014135569
blood O 0 0.0019978257
concentrations O 0 0.0005376032
of O 0 0.0005221534
flestolol B-Chemical 0 0.99870217
and O 0 0.0010944115
beta O 0 0.9277265
- O 0 0.262498
adrenergic O 0 0.96902776
blockade O 0 0.008639913
. O 0 0.00331844

Flestolol B-Chemical 0 0.85519433
produced O 0 0.0026415498
a O 0 0.002709782
dose O 0 0.0027330827
- O 0 0.0037605425
dependent O 0 0.00061362126
attenuation O 0 0.0009845337
of O 0 0.0016662459
isoproterenol B-Chemical 0 0.99969685
- O 0 0.035080127
induced O 0 0.0027410814
tachycardia B-Disease 2 0.9979317
. O 0 0.0055043357

Electrophysiologic O 0 0.016426906
and O 0 0.0019480721
hemodynamic O 0 0.0033514204
effects O 0 0.0007843456
of O 0 0.0010517356
flestolol B-Chemical 0 0.9938626
are O 0 0.00043588644
similar O 0 0.00027292816
to O 0 0.00034112603
those O 0 0.00052638975
of O 0 0.0007326883
other O 0 0.0011795689
beta O 0 0.8747947
blockers O 0 0.9950185
. O 0 0.0066108406

In O 0 0.0018381579
contrast O 0 0.0020395208
with O 0 0.0013703717
other O 0 0.0012111635
beta O 0 0.8734201
blockers O 0 0.99676126
, O 0 0.0058844266
flestolol B-Chemical 0 0.9995702
- O 0 0.006002079
induced O 0 0.00021642949
effects O 0 0.00021557539
reverse O 0 0.00036867714
rapidly O 0 0.00024464415
( O 0 0.0002451513
within O 0 5.7967758e-05
30 O 0 7.959661e-05
minutes O 0 8.524401e-05
) O 0 0.0001810122
following O 0 7.018317e-05
discontinuation O 0 0.0004856097
because O 0 0.00010682775
of O 0 0.00022716375
its O 0 0.00037650738
short O 0 0.00035697687
half O 0 0.0005056384
- O 0 0.0031406125
life O 0 0.0017086911
. O 0 0.0029387788

Flestolol B-Chemical 0 0.94802547
effectively O 0 0.003522218
reduced O 0 0.0032486827
heart O 0 0.05091726
rate O 0 0.0020154084
in O 0 0.0011782842
patients O 0 0.0022954578
with O 0 0.0023684357
supraventricular B-Disease 0 0.9988586
tachyarrhythmia I-Disease 0 0.99944514
. O 0 0.0067416425

In O 0 0.002187222
patients O 0 0.0037966226
with O 0 0.0023942832
unstable B-Disease 0 0.65572804
angina I-Disease 0 0.9999864
, O 0 0.0037637074
flestolol B-Chemical 0 0.9983347
infusion O 0 0.0018735791
was O 0 0.00023083661
found O 0 0.00019087976
to O 0 0.00016048292
be O 0 0.00017407266
safe O 0 0.00024897177
and O 0 0.0002233054
effective O 0 0.00025224514
in O 0 0.0003244522
controlling O 0 0.00039107443
chest B-Disease 0 0.0022571234
pain I-Disease 0 0.028859293
. O 0 0.0029602183

It O 0 0.0048346375
is O 0 0.0015463384
concluded O 0 0.0012852858
that O 0 0.00096203655
flestolol B-Chemical 0 0.99467564
is O 0 0.00057653093
a O 0 0.00065895804
potent O 0 0.0005757112
, O 0 0.00059196894
well O 0 0.00031687735
- O 0 0.001669007
tolerated O 0 0.0006043185
, O 0 0.0005251802
ultra O 0 0.00324349
- O 0 0.0018410014
short O 0 0.0003334081
- O 0 0.0019463327
acting O 0 0.00064707006
beta O 0 0.8285987
- O 0 0.19946347
adrenergic O 0 0.9378667
blocking O 0 0.0017684292
agent O 0 0.0046969135
. O 0 0.0037056028

Use O 0 0.006813575
of O 0 0.0036741025
flestolol B-Chemical 0 0.99272436
in O 0 0.0013163616
the O 0 0.0006972695
critical O 0 0.00047884465
care O 0 0.00069532753
setting O 0 0.00055287004
is O 0 0.0005224194
currently O 0 0.0007157717
undergoing O 0 0.0013261207
investigation O 0 0.0024065021
. O 0 0.0036661392

Immunohistochemical O 0 0.0052273073
, O 0 0.0054517696
electron O 0 0.008104138
microscopic O 0 0.0016146831
and O 0 0.0009241152
morphometric O 0 0.001177043
studies O 0 0.00091578957
of O 0 0.0013339313
estrogen B-Chemical 0 0.99969935
- O 0 0.04272379
induced O 0 0.0007198928
rat O 0 0.002481297
prolactinomas B-Disease 0 0.9998185
after O 0 0.000957179
bromocriptine B-Chemical 0 0.9999082
treatment O 0 0.0022542784
. O 0 0.0030041116

To O 0 0.0011335306
clarify O 0 0.0006883676
the O 0 0.0007043895
effects O 0 0.000756608
of O 0 0.0016780762
bromocriptine B-Chemical 0 0.99998605
on O 0 0.000901089
prolactinoma B-Disease 2 0.9999702
cells O 0 0.0006197518
in O 0 0.00023201975
vivo O 0 0.00021371672
, O 0 0.00036841238
immunohistochemical O 0 0.00020979704
, O 0 0.0003252987
ultrastructural O 0 0.00047309385
and O 0 0.00016458594
morphometrical O 0 0.00038147444
analyses O 0 0.0001356008
were O 0 9.4297735e-05
applied O 0 0.00011713214
to O 0 0.00020506475
estrogen B-Chemical 0 0.9998254
- O 0 0.03423946
induced O 0 0.00023766972
rat O 0 0.0016964434
prolactinoma B-Disease 2 0.999982
cells O 0 0.00034467634
1 O 0 0.0001527912
h O 0 0.00010259683
and O 0 7.7760546e-05
6 O 0 5.1552022e-05
h O 0 6.8420915e-05
after O 0 4.046062e-05
injection O 0 8.252415e-05
of O 0 0.00023275826
bromocriptine B-Chemical 0 0.99996614
( O 0 0.00047557184
3 O 0 0.00018612332
mg O 0 0.0014243394
/ O 0 0.00075908616
kg O 0 0.0005848232
of O 0 0.0004028812
body O 0 0.0009625766
weight O 0 0.001563336
) O 0 0.003270345
. O 0 0.0030070778

One O 0 0.0046321535
h O 0 0.0028691604
after O 0 0.0013076712
treatment O 0 0.0019288724
, O 0 0.004056225
serum O 0 0.15165688
prolactin O 0 0.98867875
levels O 0 0.0026646762
decreased O 0 0.0053930753
markedly O 0 0.009318237
. O 0 0.006713602

Electron O 0 0.011795788
microscopy O 0 0.003108265
disclosed O 0 0.0018004691
many O 0 0.00096815487
secretory O 0 0.0021096508
granules O 0 0.0016476786
, O 0 0.0011987757
slightly O 0 0.00088053284
distorted O 0 0.0016781153
rough O 0 0.0011047676
endoplasmic O 0 0.0027175609
reticulum O 0 0.009451175
, O 0 0.00058647856
and O 0 0.00029982405
partially O 0 0.0003737288
dilated O 0 0.6462135
Golgi O 0 0.0010682559
cisternae O 0 0.0015786971
in O 0 0.0005162066
the O 0 0.00092276646
prolactinoma B-Disease 2 0.999759
cells O 0 0.0038697491
. O 0 0.004079984

Morphometric O 0 0.0079762405
analysis O 0 0.0018484121
revealed O 0 0.0008737722
that O 0 0.0005858367
the O 0 0.00051626517
volume O 0 0.0008150428
density O 0 0.0006278097
of O 0 0.0004949746
secretory O 0 0.0010605818
granules O 0 0.0007335165
increased O 0 0.00044071546
, O 0 0.0004811571
while O 0 0.00023925895
the O 0 0.00023253799
volume O 0 0.00055622053
density O 0 0.0005725897
of O 0 0.00057528436
cytoplasmic O 0 0.0007253862
microtubules O 0 0.002381042
decreased O 0 0.0038332609
. O 0 0.003670252

These O 0 0.0017841094
findings O 0 0.0016130313
suggest O 0 0.0007104831
that O 0 0.00085237256
lowered O 0 0.016333897
serum O 0 0.6788712
prolactin O 0 0.99677163
levels O 0 0.00035710674
in O 0 0.00021249555
the O 0 0.00014562436
early O 0 0.00026928037
phase O 0 0.00048747368
of O 0 0.0005320216
bromocriptine B-Chemical 0 0.99999213
treatment O 0 0.00024437468
may O 0 9.545204e-05
result O 0 9.150786e-05
from O 0 9.943109e-05
an O 0 0.00015898541
impaired O 0 0.0008804203
secretion O 0 0.0021164413
of O 0 0.0005915714
prolactin O 0 0.99410206
due O 0 0.0001721958
to O 0 0.00016842053
decreasing O 0 0.00025277433
numbers O 0 0.00026596565
of O 0 0.0005736636
cytoplasmic O 0 0.0008762263
microtubules O 0 0.0033276265
. O 0 0.0033035271

At O 0 0.0012152675
6 O 0 0.0011397515
h O 0 0.0010441417
after O 0 0.00047079189
injection O 0 0.0006376
, O 0 0.0015177954
serum O 0 0.044731293
prolactin O 0 0.96113694
levels O 0 0.00044386028
were O 0 0.0003164378
still O 0 0.00029256367
considerably O 0 0.0005477262
lower O 0 0.0005903818
than O 0 0.00055757497
in O 0 0.00090016867
controls O 0 0.002366976
. O 0 0.0034303893

The O 0 0.0043583433
prolactinoma B-Disease 2 0.9994093
cells O 0 0.002170172
at O 0 0.00074578443
this O 0 0.00057015
time O 0 0.00032259946
were O 0 0.0003451842
well O 0 0.00036995142
granulated O 0 0.005711843
, O 0 0.00088332186
with O 0 0.0006187285
vesiculated O 0 0.030284382
rough O 0 0.00093929796
endoplasmic O 0 0.0023617337
reticulum O 0 0.008040075
and O 0 0.0006497567
markedly O 0 0.0023426209
dilated O 0 0.88922036
Golgi O 0 0.003075908
cisternae O 0 0.0058527705
. O 0 0.003028025

Electron O 0 0.01495812
microscopical O 0 0.00513219
immunohistochemistry O 0 0.0016248951
revealed O 0 0.0007289383
positive O 0 0.0006796839
reaction O 0 0.0004975921
products O 0 0.00044285736
noted O 0 0.00032313136
on O 0 0.00019995414
the O 0 0.00026298218
secretory O 0 0.0008663317
granules O 0 0.0007944174
, O 0 0.0006787351
Golgi O 0 0.00062006165
cisternae O 0 0.001248233
, O 0 0.0005235204
and O 0 0.00035474176
endoplasmic O 0 0.0014510314
reticulum O 0 0.003442686
of O 0 0.00033313423
the O 0 0.0003227988
untreated O 0 0.0012357893
rat O 0 0.0031879565
prolactinoma B-Disease 2 0.9998611
cells O 0 0.003974264
. O 0 0.0039005508

However O 0 0.0033730601
, O 0 0.004394691
only O 0 0.0019894682
secretory O 0 0.0028432652
granules O 0 0.0014391284
showed O 0 0.0004270825
the O 0 0.0002880094
positive O 0 0.0002975857
reaction O 0 0.00024758838
products O 0 0.000268742
for O 0 0.00022475833
prolactin O 0 0.72962207
6 O 0 0.00016475003
h O 0 0.00021020933
after O 0 0.00017797746
bromocriptine B-Chemical 0 0.99987423
treatment O 0 0.00041819664
of O 0 0.00054673955
the O 0 0.0008536608
adenoma B-Disease 0 0.99882287
cells O 0 0.0037189089
. O 0 0.003915066

An O 0 0.0030208586
increase O 0 0.0015520169
in O 0 0.0010031516
the O 0 0.00066484447
volume O 0 0.00095251296
density O 0 0.00069875154
of O 0 0.0005303121
secretory O 0 0.0010645863
granules O 0 0.0006321791
and O 0 0.0002519644
a O 0 0.00029191087
decrease O 0 0.00018760306
in O 0 0.00013040843
the O 0 0.00011074964
volume O 0 0.00023988073
densities O 0 0.00016065223
of O 0 0.00020320131
rough O 0 0.0004335408
endoplasmic O 0 0.001625483
reticulum O 0 0.0056830454
and O 0 0.00014900419
microtubules O 0 0.0002696529
was O 0 9.838794e-05
determined O 0 7.472698e-05
by O 0 8.700386e-05
morphometric O 0 0.00021211982
analysis O 0 0.00011232907
, O 0 0.00019254506
suggesting O 0 8.0941085e-05
that O 0 0.00016102169
bromocriptine B-Chemical 0 0.9999926
inhibits O 0 0.0001821155
protein O 0 0.00026642502
synthesis O 0 0.0006485447
as O 0 0.00015595456
well O 0 0.0001355478
as O 0 0.0001518751
bringing O 0 0.00029722162
about O 0 0.00032763116
a O 0 0.0006280151
disturbance O 0 0.047572564
of O 0 0.0006101801
the O 0 0.00082748715
prolactin O 0 0.99235654
secretion O 0 0.028234288
. O 0 0.0036926866

Sulfasalazine B-Chemical 0 0.9990305
- O 0 0.47472367
induced O 0 0.048503023
lupus B-Disease 0 0.99994993
erythematosus I-Disease 0 0.9999478
. O 0 0.024922285

Pneumonitis B-Disease 0 0.91222465
, O 0 0.0050110784
bilateral O 0 0.007442636
pleural B-Disease 0 0.0076154023
effusions I-Disease 0 0.024065455
, O 0 0.00056466454
echocardiographic O 0 0.00045416932
evidence O 0 0.00017151526
of O 0 0.00024342566
cardiac B-Disease 0 0.0013016738
tamponade I-Disease 0 0.22064622
, O 0 0.0003624964
and O 0 0.00016793578
positive O 0 0.00020591037
autoantibodies O 0 0.00402458
developed O 0 0.00023135265
in O 0 0.00014660873
a O 0 0.00024481892
43 O 0 0.00029879794
- O 0 0.0008988351
year O 0 0.00014182388
- O 0 0.00072222145
old O 0 0.00022566816
man O 0 0.0015677776
, O 0 0.00030454565
who O 0 0.00018840525
was O 0 9.5862524e-05
receiving O 0 0.00012972359
long O 0 0.00015836749
- O 0 0.00096153206
term O 0 0.0003647385
sulfasalazine B-Chemical 0 0.9999769
therapy O 0 0.00084822584
for O 0 0.00042783024
chronic O 0 0.57040626
ulcerative B-Disease 0 0.9999379
colitis I-Disease 0 0.9998864
. O 0 0.0055716024

After O 0 0.0013929636
cessation O 0 0.0015864122
of O 0 0.0011921189
the O 0 0.0011081463
sulfasalazine B-Chemical 0 0.999938
and O 0 0.00053578767
completion O 0 0.00019075151
of O 0 0.00022366764
a O 0 0.00024692825
six O 0 0.000100768666
- O 0 0.00046530773
week O 0 7.416367e-05
course O 0 0.00011450685
of O 0 0.00018890838
corticosteroids O 0 0.99163604
, O 0 0.0003510135
these O 0 0.00015325083
problems O 0 0.00070070714
resolved O 0 0.00020841455
over O 0 0.00011687274
a O 0 0.00020479983
period O 0 0.00012098177
of O 0 0.00021034386
four O 0 0.000163415
to O 0 0.000271646
six O 0 0.000312772
months O 0 0.0005160152
. O 0 0.001868405

It O 0 0.0049795564
is O 0 0.0014977418
suggested O 0 0.00085786683
that O 0 0.0005637084
the O 0 0.00050973444
patient O 0 0.0006749186
had O 0 0.0008109548
sulfasalazine B-Chemical 0 0.99998844
- O 0 0.10740933
induced O 0 0.00097251753
lupus B-Disease 0 0.9999951
, O 0 0.0014525881
which O 0 0.00033898812
manifested O 0 0.0012936494
with O 0 0.0004254236
serositis B-Disease 0 0.9998764
and O 0 0.00027889595
pulmonary O 0 0.29643586
parenchymal O 0 0.16733135
involvement O 0 0.00031860825
in O 0 0.00016094955
the O 0 0.0001629656
absence O 0 0.00021472243
of O 0 0.00063538586
joint O 0 0.0040846406
symptoms O 0 0.015659913
. O 0 0.0026257497

Physicians O 0 0.004072241
who O 0 0.002413145
use O 0 0.00156215
sulfasalazine B-Chemical 0 0.99991906
to O 0 0.00067555817
treat O 0 0.0009810079
patients O 0 0.0007678951
with O 0 0.00045194154
inflammatory B-Disease 0 0.59921116
bowel I-Disease 0 0.56294817
disease I-Disease 0 0.79980296
should O 0 0.00010598993
be O 0 0.00013736055
aware O 0 0.0001569207
of O 0 0.00019167458
the O 0 0.00019485866
signs O 0 0.0016656938
of O 0 0.00090390485
sulfasalazine B-Chemical 0 0.9999926
- O 0 0.33401635
induced O 0 0.0047156694
lupus B-Disease 0 0.99999726
syndrome I-Disease 0 0.99974245
. O 0 0.005379493

Chronic O 0 0.74249244
carbamazepine B-Chemical 1 0.99998534
treatment O 0 0.001725633
in O 0 0.00064658554
the O 0 0.00040185766
rat O 0 0.00055339996
: O 0 0.00056566164
efficacy O 0 0.00030640722
, O 0 0.0006624953
toxicity B-Disease 0 0.24499798
, O 0 0.00056851684
and O 0 0.00025854915
effect O 0 0.00024436138
on O 0 0.00032455742
plasma O 0 0.01790971
and O 0 0.0009388672
tissue O 0 0.010796935
folate B-Chemical 0 0.99947196
concentrations O 0 0.0072422307
. O 0 0.0035584623

Folate B-Chemical 0 0.999861
depletion O 0 0.0032652805
has O 0 0.0011988066
often O 0 0.0011567423
been O 0 0.0006632092
a O 0 0.00074775855
problem O 0 0.00064713176
in O 0 0.0005487977
chronic O 0 0.028577637
antiepileptic O 0 0.99906975
drug O 0 0.055202905
( O 0 0.0020090546
AED O 0 0.61771286
) O 0 0.0025865885
therapy O 0 0.0021219947
. O 0 0.0027877723

Carbamazepine B-Chemical 0 0.9999517
( O 0 0.25345543
CBZ B-Chemical 0 0.9999894
) O 0 0.0073928316
, O 0 0.0018918512
a O 0 0.0010072438
commonly O 0 0.00064499973
used O 0 0.0005685453
AED O 0 0.697369
, O 0 0.00090208
has O 0 0.00028541425
been O 0 0.0003657664
implicated O 0 0.00039287534
in O 0 0.0005045179
some O 0 0.00079409714
clinical O 0 0.0024129017
studies O 0 0.0021221633
. O 0 0.0032872765

A O 0 0.037217245
rat O 0 0.0034387521
model O 0 0.0012299629
was O 0 0.0008089053
developed O 0 0.0006034577
to O 0 0.00027553854
examine O 0 0.00012679832
the O 0 0.00018241927
effects O 0 0.00023869482
of O 0 0.00047666856
chronic O 0 0.64993036
CBZ B-Chemical 0 0.9999988
treatment O 0 0.00054978154
on O 0 0.00036602517
folate B-Chemical 0 0.99952984
concentrations O 0 0.0017277941
in O 0 0.0006647795
the O 0 0.0007975818
rat O 0 0.0022463237
. O 0 0.0027013612

In O 0 0.0019366891
the O 0 0.0014727728
course O 0 0.001246302
of O 0 0.0009803112
developing O 0 0.0011527165
this O 0 0.0005250521
model O 0 0.00038892883
, O 0 0.00068545307
a O 0 0.00048877695
common O 0 0.000390476
vehicle O 0 0.0034702518
, O 0 0.0026799936
propylene B-Chemical 0 0.9998286
glycol I-Chemical 0 0.9605111
, O 0 0.0006408316
by O 0 0.00015794992
itself O 0 0.000155937
in O 0 0.00010998894
high O 0 0.00017158152
doses O 0 0.00044746022
, O 0 0.00030238504
was O 0 0.000116191906
found O 0 0.00011305367
to O 0 9.927458e-05
exhibit O 0 0.00011959379
protective O 0 0.00020419224
properties O 0 0.00010111914
against O 0 0.00010987677
induced O 0 0.00054957735
seizures B-Disease 0 0.99997723
and O 0 0.00073579117
inhibited O 0 0.00111693
weight B-Disease 0 0.0017456183
gain I-Disease 0 0.0018887051
. O 0 0.0026406655

Seizures B-Disease 0 0.998987
induced O 0 0.0040422515
by O 0 0.0033538917
hexafluorodiethyl B-Chemical 0 0.99588615
ether I-Chemical 0 0.99871206
( O 0 0.003925299
HFDE B-Chemical 0 0.1109177
) O 0 0.0014082453
were O 0 0.00028436663
also O 0 0.00020770496
found O 0 0.00020401942
to O 0 0.00016539407
be O 0 0.00016490812
a O 0 0.00023002634
more O 0 0.00018746321
sensitive O 0 0.000100629615
measure O 0 8.966249e-05
of O 0 0.00017292339
protection O 0 0.00028423138
by O 0 0.0005993761
CBZ B-Chemical 0 0.9999988
than O 0 0.0007538889
seizures B-Disease 0 0.99995625
induced O 0 0.00040876144
by O 0 0.00044629344
maximal O 0 0.0012845228
electroshock O 0 0.9979462
( O 0 0.0035300993
MES O 0 0.8650336
) O 0 0.004953081
. O 0 0.0032394934

Oral O 0 0.02860443
administration O 0 0.005499459
of O 0 0.005108186
CBZ B-Chemical 0 0.9999925
as O 0 0.001256216
an O 0 0.00078845565
aqueous O 0 0.01578625
suspension O 0 0.00060894503
every O 0 0.00011920554
8 O 0 0.00012941951
h O 0 0.00013426617
at O 0 9.097314e-05
a O 0 0.00017116222
dose O 0 0.00019994368
of O 0 0.00014997591
250 O 0 0.0004896261
mg O 0 0.0024316504
/ O 0 0.0006316665
kg O 0 0.0003624406
was O 0 0.00011099927
continuously O 0 0.00013185464
protective O 0 0.00019488542
against O 0 9.659248e-05
HFDE B-Chemical 0 0.14003053
- O 0 0.012455663
induced O 0 0.00042690092
seizures B-Disease 0 0.9999827
and O 0 0.00028191012
was O 0 0.00015908109
minimally O 0 0.000220632
toxic O 0 0.00202137
as O 0 0.0001334017
measured O 0 0.0001467651
by O 0 0.00012817419
weight B-Disease 0 0.00023462008
gain I-Disease 0 0.00020075748
over O 0 0.00015347003
8 O 0 0.00020529328
weeks O 0 0.00018153196
of O 0 0.0006034936
treatment O 0 0.0012127736
. O 0 0.002560576

The O 0 0.005253845
CBZ B-Chemical 0 0.9999616
levels O 0 0.0016292011
measured O 0 0.0011951898
in O 0 0.0008570718
plasma O 0 0.005767329
and O 0 0.0005149205
brain O 0 0.000834891
of O 0 0.00025032088
these O 0 0.00018776824
animals O 0 0.00016296124
, O 0 0.0004075428
however O 0 0.00032014534
, O 0 0.00047276585
were O 0 0.00023884713
below O 0 0.00027488623
those O 0 0.00043829472
normally O 0 0.0005210529
considered O 0 0.0008931217
protective O 0 0.002582115
. O 0 0.0034080544

This O 0 0.004406547
treatment O 0 0.0023766928
with O 0 0.0035940292
CBZ B-Chemical 0 0.9999943
had O 0 0.0007781794
no O 0 0.00032830026
apparent O 0 0.00029504712
adverse O 0 0.0007491576
effect O 0 0.00017865075
on O 0 0.00023954429
folate B-Chemical 0 0.999777
concentrations O 0 0.0008210893
in O 0 0.00015442079
the O 0 0.000114727074
rat O 0 0.00023850099
, O 0 0.0002474864
and O 0 0.00014748998
, O 0 0.00026191748
indeed O 0 0.00013929457
, O 0 0.00040447593
the O 0 0.00025923143
folate B-Chemical 0 0.9998661
concentration O 0 0.0009816152
increased O 0 0.00028428045
in O 0 0.00013964192
liver O 0 0.0063005
after O 0 4.333858e-05
6 O 0 4.2337153e-05
weeks O 0 3.3341577e-05
of O 0 8.274471e-05
treatment O 0 0.000116899384
and O 0 0.00015879436
in O 0 0.000203595
plasma O 0 0.0015898796
at O 0 0.0001624671
8 O 0 0.00021119333
weeks O 0 0.00017870018
of O 0 0.00059024553
treatment O 0 0.0011848779
. O 0 0.0025000668

Dipyridamole B-Chemical 0 0.99920017
- O 0 0.14361063
induced O 0 0.013981081
myocardial B-Disease 0 0.9975062
ischemia I-Disease 0 0.99895597
. O 0 0.016445035

Angina B-Disease 0 0.9900658
and O 0 0.004369449
ischemic O 0 0.99769294
electrocardiographic O 0 0.023372287
changes O 0 0.00043808832
occurred O 0 0.0002343853
after O 0 0.00011461707
administration O 0 0.00027591712
of O 0 0.00024760654
oral O 0 0.002341334
dipyridamole B-Chemical 0 0.9998419
in O 0 0.00019207103
four O 0 0.00011658613
patients O 0 0.00039248602
awaiting O 0 0.00073501404
urgent O 0 0.0008185246
myocardial O 0 0.9732781
revascularization O 0 0.0049551516
procedures O 0 0.0011246026
. O 0 0.0021499002

To O 0 0.0013724692
our O 0 0.0015014252
knowledge O 0 0.0017731577
, O 0 0.0019008422
this O 0 0.00072335737
has O 0 0.00031785588
not O 0 0.00029497402
previously O 0 0.00033445068
been O 0 0.00023481344
reported O 0 0.00022258224
as O 0 0.00015379715
a O 0 0.00020002338
side O 0 0.0002841333
effect O 0 8.978227e-05
of O 0 0.00013370618
preoperative O 0 0.00085289445
dipyridamole B-Chemical 0 0.99994195
therapy O 0 0.00027180713
, O 0 0.00023023148
although O 0 0.00021793513
dipyridamole B-Chemical 0 0.9999821
- O 0 0.031082295
induced O 0 0.0003107358
myocardial B-Disease 0 0.99988544
ischemia I-Disease 0 0.99996114
has O 0 9.080533e-05
been O 0 8.605791e-05
demonstrated O 0 7.98797e-05
to O 0 8.662577e-05
occur O 0 9.739176e-05
in O 0 9.023245e-05
animals O 0 9.161229e-05
and O 0 0.00018751812
humans O 0 0.0003672566
with O 0 0.0004828976
coronary B-Disease 0 0.16066703
artery I-Disease 0 0.4724652
disease I-Disease 0 0.41450468
. O 0 0.0027260284

Epicardial O 0 0.013266033
coronary O 0 0.081521
collateral O 0 0.14233968
vessels O 0 0.05303575
were O 0 0.00059036544
demonstrated O 0 0.0003496707
in O 0 0.0002967646
all O 0 0.00023404653
four O 0 0.00016022405
patients O 0 0.0004449613
; O 0 0.00047446153
a O 0 0.0004102513
coronary O 0 0.030167228
" O 0 0.00069546374
steal O 0 0.05874659
" O 0 0.0007918081
phenomenon O 0 0.0010456976
may O 0 0.00017110004
be O 0 0.00014801337
the O 0 0.000114985436
mechanism O 0 0.00011805253
of O 0 0.00028979313
the O 0 0.00047476287
dipyridamole B-Chemical 0 0.9999602
- O 0 0.036239386
induced O 0 0.0012213611
ischemia B-Disease 0 0.99956757
observed O 0 0.0018709735
. O 0 0.0030168202

Inhibition O 0 0.0070108394
of O 0 0.004545779
sympathoadrenal O 0 0.07589316
activity O 0 0.0013545176
by O 0 0.0015590873
atrial O 0 0.059970528
natriuretic O 0 0.10324641
factor O 0 0.011306102
in O 0 0.0022706946
dogs O 0 0.005264636
. O 0 0.0047700354

In O 0 0.0018014009
six O 0 0.001187919
conscious O 0 0.0049784956
, O 0 0.0015413808
trained O 0 0.0008146255
dogs O 0 0.0010628878
, O 0 0.0006785046
maintained O 0 0.00033495293
on O 0 0.00020288421
a O 0 0.00044247188
normal O 0 0.00086369296
sodium B-Chemical 0 0.9975032
intake O 0 0.006023639
of O 0 0.00021564242
2 O 0 0.00015859173
to O 0 9.612552e-05
4 O 0 0.00012433452
mEq O 0 0.037305687
/ O 0 0.00049641414
kg O 0 0.0003591803
/ O 0 0.0005282709
day O 0 0.00010460559
, O 0 0.00026041947
sympathetic O 0 0.0005846084
activity O 0 7.573637e-05
was O 0 8.750793e-05
assessed O 0 9.772537e-05
as O 0 0.00010300631
the O 0 0.00010257413
release O 0 0.0003111885
rate O 0 0.00026892527
of O 0 0.00042474383
norepinephrine B-Chemical 0 0.99998415
and O 0 0.00045502494
epinephrine B-Chemical 0 0.99970704
during O 0 9.606759e-05
15 O 0 0.00011686853
- O 0 0.00045845358
minute O 0 0.00013184294
i O 0 0.0002218187
. O 0 0.00013867646
v O 0 0.00056313915
. O 0 0.00017008715
infusions O 0 0.00041113904
of O 0 0.0002676305
human O 0 0.0005008281
alpha O 0 0.5969024
- O 0 0.020717427
atrial O 0 0.21906348
natriuretic O 0 0.1455705
factor O 0 0.022206303
. O 0 0.0035006444

Mean O 0 0.0028089029
arterial O 0 0.030672327
pressure O 0 0.010425965
( O 0 0.0018879941
as O 0 0.00068250997
a O 0 0.0006238855
percentage O 0 0.0002918808
of O 0 0.00036953093
control O 0 0.00041316423
+ O 0 0.0014892833
/ O 0 0.0019946804
- O 0 0.001716719
SEM O 0 0.0005762453
) O 0 0.0003517562
during O 0 0.00011715348
randomized O 0 0.00036534766
infusions O 0 0.0003435242
of O 0 0.00017643483
0 O 0 0.00025969575
. O 0 0.00020813577
03 O 0 0.0016240753
, O 0 0.0003525159
0 O 0 0.00026004037
. O 0 0.00017987563
1 O 0 0.00019894152
, O 0 0.000295319
0 O 0 0.00023666774
. O 0 0.00015831164
3 O 0 0.00013935966
, O 0 0.0002658853
or O 0 0.00015373585
1 O 0 0.00019598858
. O 0 0.00016157751
0 O 0 0.00025218094
microgram O 0 0.002210016
/ O 0 0.00075992686
kg O 0 0.0005419452
/ O 0 0.00076114805
min O 0 0.00031910988
was O 0 0.00017640504
99 O 0 0.0004081762
+ O 0 0.00086794706
/ O 0 0.0015076459
- O 0 0.0014096979
1 O 0 0.00026041004
, O 0 0.00034640843
95 O 0 0.0004558003
+ O 0 0.00083748816
/ O 0 0.0014608885
- O 0 0.0013555473
1 O 0 0.00022147065
( O 0 0.00026440393
p O 0 0.00026797902
less O 0 0.00021064111
than O 0 0.00015383174
0 O 0 0.00026144966
. O 0 0.0002319879
05 O 0 0.0032745462
) O 0 0.00055596116
, O 0 0.00040397266
93 O 0 0.00050698064
+ O 0 0.0010722496
/ O 0 0.0018841435
- O 0 0.0016032106
1 O 0 0.00022922635
( O 0 0.00026563142
p O 0 0.00026365276
less O 0 0.00020273957
than O 0 0.00014465532
0 O 0 0.00023925077
. O 0 0.00020234636
01 O 0 0.001067963
) O 0 0.000480539
, O 0 0.00032943586
or O 0 0.0001804771
79 O 0 0.00037076196
+ O 0 0.00092931767
/ O 0 0.0014866253
- O 0 0.0010912655
6 O 0 0.00013702079
% O 0 0.00027818425
( O 0 0.00024510387
p O 0 0.00024957853
less O 0 0.00018979289
than O 0 0.00013199239
0 O 0 0.00021423571
. O 0 0.0001797695
001 O 0 0.0024046951
) O 0 0.0005117962
, O 0 0.00034048452
respectively O 0 0.0003906925
, O 0 0.00035293266
but O 0 0.00018975523
no O 0 0.00017284822
tachycardia B-Disease 2 0.9937264
and O 0 0.0001538042
no O 0 0.00011175097
augmentation O 0 0.00045229687
of O 0 0.00018642793
the O 0 0.00027701812
norepinephrine B-Chemical 0 0.9999814
release O 0 0.00068643474
rate O 0 0.00026180962
( O 0 0.00025774282
up O 0 0.00012255242
to O 0 8.79685e-05
0 O 0 0.0001441177
. O 0 9.630433e-05
3 O 0 0.00010075954
microgram O 0 0.0013461487
/ O 0 0.0005158573
kg O 0 0.00038428383
/ O 0 0.0006365281
min O 0 0.00027518545
) O 0 0.00031187697
were O 0 0.000102655555
observed O 0 0.00010809346
, O 0 0.00025435546
which O 0 0.00015224221
is O 0 9.911567e-05
in O 0 0.00011119503
contrast O 0 0.00017829305
to O 0 0.0001364133
comparable O 0 0.00018800526
hypotension B-Disease 0 0.99980634
induced O 0 0.0004525343
by O 0 0.0010465791
hydralazine B-Chemical 0 0.9999968
or O 0 0.004665851
nitroglycerin B-Chemical 0 0.99997425
. O 0 0.004014802

The O 0 0.002681613
release O 0 0.0036314584
rate O 0 0.0022994603
of O 0 0.00208831
epinephrine B-Chemical 0 0.99957436
( O 0 0.0014570553
control O 0 0.0005143118
, O 0 0.0006412935
6 O 0 0.00023373836
. O 0 0.00023063357
7 O 0 0.00021103934
+ O 0 0.0008212614
/ O 0 0.0014474383
- O 0 0.0013168287
0 O 0 0.00026861214
. O 0 0.0001450274
6 O 0 0.00010317292
ng O 0 0.00027312
/ O 0 0.0006027767
kg O 0 0.0004743838
/ O 0 0.0007236934
min O 0 0.00030650332
) O 0 0.00032524165
declined O 0 0.00015373541
immediately O 0 6.197196e-05
during O 0 6.399626e-05
infusions O 0 0.00021397589
of O 0 0.00013318106
atrial O 0 0.0101069175
natriuretic O 0 0.02075169
factor O 0 0.0014793355
to O 0 0.00010814275
a O 0 0.00015253006
minimum O 0 8.531378e-05
of O 0 0.00013182423
49 O 0 0.00025262832
+ O 0 0.00076186395
/ O 0 0.0014192684
- O 0 0.0010895132
5 O 0 0.00012011276
% O 0 0.00018976934
of O 0 0.00011466583
control O 0 0.0001355712
( O 0 0.00023939954
p O 0 0.00023239461
less O 0 0.00016384138
than O 0 0.000113444476
0 O 0 0.00019240427
. O 0 0.00016110047
001 O 0 0.0020963547
) O 0 0.00035421492
during O 0 0.00010603451
0 O 0 0.00019235584
. O 0 0.00014146906
1 O 0 0.00018632042
microgram O 0 0.0018205503
/ O 0 0.0006557619
kg O 0 0.00046970285
/ O 0 0.0006668786
min O 0 0.00025944898
and O 0 0.00014652628
to O 0 0.00013101219
63 O 0 0.00030268932
+ O 0 0.0007851633
/ O 0 0.0014649384
- O 0 0.0013347726
5 O 0 0.00017733562
% O 0 0.0003218278
( O 0 0.00028473124
0 O 0 0.00019353916
. O 0 0.00012029375
1 O 0 0.00011427635
greater O 0 0.00012062928
than O 0 9.3314135e-05
p O 0 0.00019937483
greater O 0 0.000166259
than O 0 0.0001353093
0 O 0 0.00023304764
. O 0 0.00019812978
05 O 0 0.0028524052
) O 0 0.00039224292
or O 0 0.00015709197
95 O 0 0.00040350255
+ O 0 0.0007796521
/ O 0 0.0014459022
- O 0 0.0014444935
13 O 0 0.00024687414
% O 0 0.0003827419
( O 0 0.00031499425
not O 0 0.00014332068
significant O 0 0.00019322829
) O 0 0.00045253383
during O 0 0.00013699755
0 O 0 0.00024435742
. O 0 0.000161284
3 O 0 0.00014198925
or O 0 0.00016344257
1 O 0 0.00026036735
. O 0 0.00026989158
0 O 0 0.00051302527
microgram O 0 0.0040863752
/ O 0 0.002237688
kg O 0 0.0020904455
/ O 0 0.0038842463
min O 0 0.002939879
. O 0 0.0034163368

Steady O 0 0.026829123
state O 0 0.0037192747
arterial O 0 0.39966893
plasma O 0 0.010990404
concentrations O 0 0.0011254465
of O 0 0.0006457403
atrial O 0 0.025088655
natriuretic O 0 0.027556796
factor O 0 0.0020867854
were O 0 0.00024098107
39 O 0 0.00033695472
+ O 0 0.0008619915
/ O 0 0.0013128483
- O 0 0.0011859043
10 O 0 0.000232335
pg O 0 0.0018321762
/ O 0 0.0010141636
ml O 0 0.0006905852
( O 0 0.0002606162
n O 0 0.00016740036
= O 0 0.00030177587
6 O 0 8.344104e-05
) O 0 0.00017997874
during O 0 7.10194e-05
infusions O 0 0.0002177208
of O 0 0.00012769306
saline O 0 0.0003735201
and O 0 0.0001715053
284 O 0 0.00060895487
+ O 0 0.00075882336
/ O 0 0.0012241377
- O 0 0.0011446909
24 O 0 0.00022067703
pg O 0 0.0016889514
/ O 0 0.00095502194
ml O 0 0.00067779754
( O 0 0.0002809137
n O 0 0.00019268994
= O 0 0.0003705909
6 O 0 0.0001225426
) O 0 0.0003263667
and O 0 0.00024468545
1520 O 0 0.0035473646
+ O 0 0.0009847409
/ O 0 0.0014863547
- O 0 0.0015551901
300 O 0 0.0005411875
pg O 0 0.0031258438
/ O 0 0.0012349983
ml O 0 0.0007905061
( O 0 0.00029893868
n O 0 0.00019995414
= O 0 0.00039980345
9 O 0 0.00013412349
) O 0 0.00026909736
during O 0 0.00010577609
0 O 0 0.00021552402
. O 0 0.00017975098
03 O 0 0.0009920889
and O 0 0.000176852
0 O 0 0.0002242363
. O 0 0.00016448883
1 O 0 0.00021367188
microgram O 0 0.0018046999
/ O 0 0.0006976264
kg O 0 0.0005031504
/ O 0 0.0007262954
min O 0 0.00034454363
infusions O 0 0.0004527936
of O 0 0.00025599718
the O 0 0.00029715593
factor O 0 0.0023633274
. O 0 0.00056500966
( O 0 0.0011671263
ABSTRACT O 0 0.006677759
TRUNCATED O 0 0.015361972
AT O 0 0.012532285
250 O 0 0.0056618275
WORDS O 0 0.026299687
) O 0 0.016527394

Inhibition O 0 0.0051915795
of O 0 0.003369234
immunoreactive O 0 0.005119062
corticotropin O 0 0.9996215
- O 0 0.08475412
releasing O 0 0.0015737271
factor O 0 0.0070413924
secretion O 0 0.0017753871
into O 0 0.00026377448
the O 0 0.0003742948
hypophysial O 0 0.57029575
- O 0 0.004172623
portal O 0 0.07540079
circulation O 0 0.0038572631
by O 0 0.0005113705
delayed O 0 0.0021843244
glucocorticoid O 0 0.22764605
feedback O 0 0.0022395176
. O 0 0.0031029063

Nitroprusside B-Chemical 0 0.99977595
- O 0 0.10765185
induced O 0 0.0031048893
hypotension B-Disease 0 0.99991107
evokes O 0 0.06788147
ACTH O 0 0.9999685
secretion O 0 0.0133019015
which O 0 0.0004421209
is O 0 0.00017111424
primarily O 0 0.0001507786
mediated O 0 8.984351e-05
by O 0 0.00014874044
enhanced O 0 0.00021385247
secretion O 0 0.0010815978
of O 0 0.00039654382
immunoreactive O 0 0.001043616
corticotropin O 0 0.9998859
- O 0 0.03464353
releasing O 0 0.0005618059
factor O 0 0.0112684425
( O 0 0.0011952139
irCRF O 0 0.6094562
) O 0 0.00062684115
into O 0 0.00017341512
the O 0 0.00036065961
hypophysial O 0 0.47844636
- O 0 0.0063232174
portal O 0 0.17953385
circulation O 0 0.01623478
. O 0 0.0027660038

Portal O 0 0.64873385
plasma O 0 0.048434068
concentrations O 0 0.002503638
of O 0 0.0011467655
neither O 0 0.0010360745
arginine B-Chemical 0 0.13376506
vasopressin I-Chemical 0 0.99961096
nor O 0 0.00076002505
oxytocin B-Chemical 0 0.9958961
are O 0 0.0004029878
significantly O 0 0.00052490894
altered O 0 0.0005775369
in O 0 0.0006095477
this O 0 0.001024996
paradigm O 0 0.0024280488
. O 0 0.0033768772

Application O 0 0.0036341993
of O 0 0.0020711848
a O 0 0.0018573842
delayed O 0 0.0019418094
feedback O 0 0.0007232791
signal O 0 0.00036150625
, O 0 0.0006977285
in O 0 0.00030026547
the O 0 0.00022385712
form O 0 0.00022062067
of O 0 0.00024671154
a O 0 0.00033866998
2 O 0 0.00025419588
- O 0 0.0009086204
h O 0 0.00024309674
systemic O 0 0.17421009
corticosterone B-Chemical 0 0.99957365
infusion O 0 0.0007844286
in O 0 0.000119403485
urethane B-Chemical 0 0.77107257
- O 0 0.0007718988
anesthetized O 0 0.00026710413
rats O 0 9.9837824e-05
with O 0 7.330522e-05
pharmacological O 0 0.0003108724
blockade O 0 0.0005477455
of O 0 0.00025463058
glucocorticoid O 0 0.794021
synthesis O 0 0.0009873182
, O 0 0.00030439033
is O 0 6.8889676e-05
without O 0 7.213352e-05
effect O 0 6.576554e-05
on O 0 6.143276e-05
the O 0 8.5396656e-05
resting O 0 0.00040041504
secretion O 0 0.0012684786
of O 0 0.0004026226
arginine B-Chemical 0 0.1924435
vasopressin I-Chemical 0 0.9998803
and O 0 0.0005933145
oxytocin B-Chemical 0 0.99424803
at O 0 0.00020192718
any O 0 0.00033345833
corticosterone B-Chemical 0 0.9992348
feedback O 0 0.0007573658
dose O 0 0.0012239798
tested O 0 0.0011123139
. O 0 0.002448031

Resting O 0 0.114104554
irCRF O 0 0.6095494
levels O 0 0.0012933618
are O 0 0.0007097001
suppressed O 0 0.0006543928
only O 0 0.00044242397
at O 0 0.00024399658
the O 0 0.0002305109
highest O 0 0.00040144048
corticosterone B-Chemical 0 0.99932516
infusion O 0 0.001550957
rate O 0 0.00033344055
, O 0 0.0003477492
which O 0 0.00019856666
resulted O 0 0.00017837569
in O 0 0.00028840097
systemic O 0 0.6740785
corticosterone B-Chemical 0 0.9996044
levels O 0 0.00033180235
of O 0 0.00043017123
40 O 0 0.0006548018
micrograms O 0 0.005784641
/ O 0 0.0045771007
dl O 0 0.010393978
. O 0 0.0031227712

Suppression O 0 0.00472376
of O 0 0.003682938
irCRF O 0 0.7886057
secretion O 0 0.0043241503
in O 0 0.00067567796
response O 0 0.00053705287
to O 0 0.00072509446
nitroprusside B-Chemical 0 0.99999404
- O 0 0.02394227
induced O 0 0.00042154393
hypotension B-Disease 0 0.999907
is O 0 0.00016505236
observed O 0 0.00012888134
and O 0 0.00015923315
occurs O 0 0.00013438977
at O 0 0.00012890346
a O 0 0.00041412638
plasma O 0 0.06331244
corticosterone B-Chemical 0 0.9992841
level O 0 0.00020628651
between O 0 0.00018975124
8 O 0 0.0003083636
- O 0 0.0011151317
12 O 0 0.00037608517
micrograms O 0 0.0027317475
/ O 0 0.003942996
dl O 0 0.009384798
. O 0 0.0035476508

These O 0 0.001876489
studies O 0 0.0016334001
provide O 0 0.00066165987
further O 0 0.00053014327
evidence O 0 0.0004295381
for O 0 0.0003560499
a O 0 0.0004973619
strong O 0 0.0002685256
central O 0 0.00038219444
component O 0 0.00019762435
of O 0 0.00019055988
the O 0 0.0001547616
delayed O 0 0.0004955137
feedback O 0 0.00022037867
process O 0 0.00019300953
which O 0 0.00022742902
is O 0 0.00016297773
mediated O 0 0.0001493349
by O 0 0.00030894188
modulation O 0 0.00042834645
of O 0 0.0012350407
irCRF O 0 0.84168476
release O 0 0.005233626
. O 0 0.0034431804

Noradrenergic O 0 0.07761145
involvement O 0 0.0056683333
in O 0 0.0046774712
catalepsy B-Disease 0 0.9998697
induced O 0 0.002589675
by O 0 0.002146068
delta B-Chemical 0 0.022728242
9 I-Chemical 0 0.0025984526
- I-Chemical 0 0.024657762
tetrahydrocannabinol I-Chemical 0 0.9993261
. O 0 0.007955821

In O 0 0.0018717083
order O 0 0.0011137755
to O 0 0.0007304539
elucidate O 0 0.0002926948
the O 0 0.0003272962
role O 0 0.00018311568
of O 0 0.00034759523
the O 0 0.0002637375
catecholaminergic O 0 0.0008736615
system O 0 0.00019638646
in O 0 0.00016498551
the O 0 0.00018492485
cataleptogenic O 0 0.991122
effect O 0 0.00016692486
of O 0 0.00026303812
delta B-Chemical 0 0.019885868
9 I-Chemical 0 0.00029134282
- I-Chemical 0 0.030739386
tetrahydrocannabinol I-Chemical 0 0.99997056
( O 0 0.013016121
THC B-Chemical 0 0.999997
) O 0 0.0016314742
, O 0 0.0002548331
the O 0 8.1164064e-05
effect O 0 9.288568e-05
of O 0 0.00017666696
pretreatment O 0 0.0015162583
with O 0 0.00018519747
6 B-Chemical 0 0.00013229897
- I-Chemical 0 0.0017697065
hydroxydopamine I-Chemical 0 0.13438374
( O 0 0.00027108664
6 B-Chemical 0 0.00010858645
- I-Chemical 0 0.0012037542
OHDA I-Chemical 0 0.5675176
) O 0 0.00047177865
or O 0 0.00013661037
with O 0 0.00042508048
desipramine B-Chemical 0 0.99999905
and O 0 0.00029151567
6 B-Chemical 0 0.00014897053
- I-Chemical 0 0.0017611058
OHDA I-Chemical 0 0.47275558
and O 0 0.00022382701
lesions O 0 0.001403473
of O 0 0.00021207737
the O 0 0.00019305627
locus O 0 0.00026973107
coeruleus O 0 0.000768831
were O 0 0.00021492278
investigated O 0 0.00034166616
in O 0 0.0006664044
rats O 0 0.0019905185
. O 0 0.0026265413

The O 0 0.0030912785
cataleptogenic O 0 0.9950104
effect O 0 0.001738601
of O 0 0.0038731417
THC B-Chemical 0 0.9999908
was O 0 0.00081352395
significantly O 0 0.00046964572
reduced O 0 0.00030724824
in O 0 0.00018829101
rats O 0 0.0003069174
treated O 0 0.00030973935
with O 0 0.0001749197
6 B-Chemical 0 0.0001436115
- I-Chemical 0 0.0016191046
OHDA I-Chemical 0 0.40015265
and O 0 0.00014421338
in O 0 0.00010231303
rats O 0 0.00019369369
with O 0 0.00014646367
lesions O 0 0.0013263456
of O 0 0.00013842201
the O 0 0.00011032874
locus O 0 0.00014768404
coeruleus O 0 0.0006797628
but O 0 9.4836185e-05
not O 0 7.001624e-05
in O 0 8.374234e-05
rats O 0 0.0002095873
treated O 0 0.00037095498
with O 0 0.0005179482
desipramine B-Chemical 0 0.99999917
and O 0 0.00030683077
6 B-Chemical 0 0.00017001128
- I-Chemical 0 0.0019173822
OHDA I-Chemical 0 0.51774985
, O 0 0.0004657939
as O 0 0.00023446087
compared O 0 0.00022947128
with O 0 0.00050310756
control O 0 0.0008879212
rats O 0 0.0024702298
. O 0 0.0028107732

On O 0 0.0028684798
the O 0 0.001647452
contrary O 0 0.0016236053
, O 0 0.002069959
the O 0 0.00089980254
cataleptogenic O 0 0.9982761
effect O 0 0.0005445744
of O 0 0.0015738087
haloperidol B-Chemical 1 0.99999905
was O 0 0.00031459928
significantly O 0 0.00021089171
reduced O 0 0.00015835132
in O 0 0.00011104817
rats O 0 0.00023706001
treated O 0 0.00038245576
with O 0 0.0005116728
desipramine B-Chemical 0 0.9999994
and O 0 0.0002778516
6 B-Chemical 0 0.00013580099
- I-Chemical 0 0.0032380805
OHDA I-Chemical 0 0.8176912
but O 0 0.00017750193
not O 0 9.2739385e-05
in O 0 9.723215e-05
rats O 0 0.00020632289
treated O 0 0.00024291719
with O 0 0.00014886445
6 B-Chemical 0 0.0001318447
- I-Chemical 0 0.0016707797
OHDA I-Chemical 0 0.4037717
or O 0 0.00014232882
in O 0 0.00014599922
rats O 0 0.0003140964
with O 0 0.0003027626
lesions O 0 0.0022724452
of O 0 0.0004885547
the O 0 0.0005512993
locus O 0 0.0009568381
coeruleus O 0 0.0035789043
. O 0 0.002034945

These O 0 0.0017728902
results O 0 0.0012529894
indicate O 0 0.0006772213
that O 0 0.0008335571
noradrenergic O 0 0.08097855
neurons O 0 0.0004976903
have O 0 0.00022614765
an O 0 0.0002066237
important O 0 0.000101138234
role O 0 7.753951e-05
in O 0 0.00015097915
the O 0 0.00016588891
manifestation O 0 0.0028755357
of O 0 0.00063246075
catalepsy B-Disease 0 0.99999297
induced O 0 0.00042708105
by O 0 0.0006843614
THC B-Chemical 0 0.99999785
, O 0 0.0015414351
whereas O 0 0.00028248728
dopaminergic O 0 0.0019593209
neurons O 0 0.00016569543
are O 0 0.000114555674
important O 0 0.00015028927
in O 0 0.00046752073
catalepsy B-Disease 0 0.99996436
induced O 0 0.0011026138
by O 0 0.0023432283
haloperidol B-Chemical 1 0.9999894
. O 0 0.004595641

Reversibility O 0 0.0200255
of O 0 0.0053304504
captopril B-Chemical 0 0.99995875
- O 0 0.07231258
induced O 0 0.0010305783
renal B-Disease 0 0.9411128
insufficiency I-Disease 0 0.99486095
after O 0 0.0001843599
prolonged O 0 0.0002883971
use O 0 0.00019095822
in O 0 0.00023957672
an O 0 0.00037359772
unusual O 0 0.0008031444
case O 0 0.00063834427
of O 0 0.0016597369
renovascular B-Disease 0 0.99997973
hypertension I-Disease 2 0.9999937
. O 0 0.0072822594

We O 0 0.0028627014
report O 0 0.0031003293
a O 0 0.0018436838
case O 0 0.0010020307
of O 0 0.0009136547
severe O 0 0.033203717
hypertension B-Disease 2 0.99997735
with O 0 0.00055772456
an O 0 0.0003503835
occluded O 0 0.011369441
renal O 0 0.7000226
artery O 0 0.13528691
to O 0 0.00012870939
a O 0 0.00023260097
solitary O 0 0.0009390778
kidney O 0 0.016591087
, O 0 0.00032384836
who O 0 0.00020548597
developed O 0 0.00017635693
sudden B-Disease 0 0.015528668
deterioration I-Disease 0 0.008312991
of I-Disease 0 0.0002331481
renal I-Disease 0 0.39208964
function I-Disease 0 0.00017110232
following O 0 0.00015844966
treatment O 0 0.00038361366
with O 0 0.0011495552
captopril B-Chemical 0 0.9999293
. O 0 0.0038559386

His O 0 0.0055008256
renal O 0 0.32513705
function O 0 0.0011543307
remained O 0 0.001337636
impaired O 0 0.0023167226
but O 0 0.00054397207
stable O 0 0.0002832937
during O 0 0.00015939905
2 O 0 0.00019152387
years O 0 0.00019110124
' O 0 0.00028908643
treatment O 0 0.00017913416
with O 0 0.0003399636
captopril B-Chemical 0 0.99998677
but O 0 0.00034377768
returned O 0 0.00015795023
to O 0 0.000108348555
pre O 0 0.00028254488
- O 0 0.000787397
treatment O 0 0.00015286001
levels O 0 0.00014667682
soon O 0 0.00020421502
after O 0 0.00014438538
cessation O 0 0.0003450699
of O 0 0.00059114577
the O 0 0.00089751417
drug O 0 0.016812572
. O 0 0.003253133

This O 0 0.003946111
indicates O 0 0.0013060798
reversibility O 0 0.0038242075
in O 0 0.001652863
captopril B-Chemical 0 0.9999788
- O 0 0.046092045
induced O 0 0.0005025235
renal B-Disease 0 0.8792526
failure I-Disease 0 0.02114637
even O 0 0.00019018885
after O 0 6.7976594e-05
its O 0 0.00013312849
prolonged O 0 0.00014317944
use O 0 9.073532e-05
and O 0 0.00011159274
suggests O 0 6.9720416e-05
that O 0 0.00010023419
no O 0 0.00022225671
organic O 0 0.8235108
damage O 0 0.10452248
occurs O 0 0.00023895234
to O 0 0.00027869974
glomerular O 0 0.9990578
arterioles O 0 0.9849584
following O 0 0.00030465744
chronic O 0 0.020777725
ACE O 0 0.937246
inhibition O 0 0.0025521195
. O 0 0.0029897855

HMG O 0 0.9935474
CoA O 0 0.9988444
reductase O 0 0.99512416
inhibitors O 0 0.09518041
. O 0 0.026854783

Current O 0 0.031130059
clinical O 0 0.02803181
experience O 0 0.027078874
. O 0 0.025811324

Lovastatin B-Chemical 0 0.99978846
and O 0 0.009728489
simvastatin B-Chemical 1 0.99995065
are O 0 0.0009438224
the O 0 0.00046777815
2 O 0 0.00040816338
best O 0 0.00035218065
- O 0 0.0014708008
known O 0 0.000249914
members O 0 0.00026637246
of O 0 0.00025182153
the O 0 0.00019681404
class O 0 0.0004655347
of O 0 0.00046175043
hypolipidaemic O 0 0.99731404
agents O 0 0.0037374988
known O 0 0.0007579806
as O 0 0.0016091589
HMG O 0 0.9989512
CoA O 0 0.99994636
reductase O 0 0.9993573
inhibitors O 0 0.037722144
. O 0 0.0049464153

Clinical O 0 0.0070763114
experience O 0 0.003644802
with O 0 0.0025592162
lovastatin B-Chemical 1 0.9999051
includes O 0 0.0007046201
over O 0 0.00037448254
5000 O 0 0.0009921086
patients O 0 0.00057912664
, O 0 0.00044312296
700 O 0 0.000556486
of O 0 0.0002087837
whom O 0 0.00030263077
have O 0 0.00012064988
been O 0 0.0001217768
treated O 0 0.00023379852
for O 0 9.204514e-05
2 O 0 0.000120663215
years O 0 0.00011925601
or O 0 8.262069e-05
more O 0 0.00014984325
, O 0 0.00019774912
and O 0 0.00012260243
experience O 0 0.00029183546
with O 0 0.00027702548
simvastatin B-Chemical 1 0.9999907
includes O 0 0.00015811867
over O 0 0.00010993064
3500 O 0 0.0010036717
patients O 0 0.00024245489
, O 0 0.00018448615
of O 0 0.00013608615
whom O 0 0.00027264233
350 O 0 0.00023831482
have O 0 0.00012371385
been O 0 0.00015296205
treated O 0 0.00033568518
for O 0 0.00018557222
18 O 0 0.0003004473
months O 0 0.00019124192
or O 0 0.0005003667
more O 0 0.0015850774
. O 0 0.0025978743

Lovastatin B-Chemical 0 0.999634
has O 0 0.0029257734
been O 0 0.0020108789
marketed O 0 0.0055720457
in O 0 0.0010154273
the O 0 0.00074001984
United O 0 0.0010201578
States O 0 0.0010305116
for O 0 0.0005210077
over O 0 0.00062977
6 O 0 0.0008047467
months O 0 0.00094418036
. O 0 0.0031169783

Both O 0 0.0021973492
agents O 0 0.002796264
show O 0 0.0007585703
substantial O 0 0.00074012956
clinical O 0 0.0011040326
efficacy O 0 0.00040776454
, O 0 0.0005055592
with O 0 0.00026142228
reductions O 0 0.0002739556
in O 0 0.00020886815
total O 0 0.0003101734
cholesterol B-Chemical 0 0.99878365
of O 0 0.00027720886
over O 0 0.00014673627
30 O 0 0.00015046952
% O 0 0.00029192615
and O 0 0.00022961372
in O 0 0.00043953734
LDL O 0 0.99987483
- O 0 0.15676022
cholesterol B-Chemical 0 0.9995683
of O 0 0.000593134
40 O 0 0.0005035438
% O 0 0.0007349236
in O 0 0.0005097509
clinical O 0 0.0018477284
studies O 0 0.0017005428
. O 0 0.0027490687

Modest O 0 0.029358415
increases O 0 0.004197826
in O 0 0.0044505238
HDL O 0 0.9994081
- O 0 0.32451913
cholesterol B-Chemical 0 0.9991097
levels O 0 0.00096750754
of O 0 0.0008381567
about O 0 0.00085430685
10 O 0 0.0007611644
% O 0 0.0012019961
are O 0 0.0006654625
also O 0 0.0010768381
reported O 0 0.0021663464
. O 0 0.0038389752

Clinical O 0 0.004592671
tolerability O 0 0.0024501486
of O 0 0.0008916788
both O 0 0.0005447455
agents O 0 0.0010701208
has O 0 0.00026849922
been O 0 0.00024923825
good O 0 0.00032382336
, O 0 0.00040655042
with O 0 0.00020957873
fewer O 0 0.00019387937
than O 0 0.000135633
3 O 0 0.00012321632
% O 0 0.00023855467
of O 0 0.00016244725
patients O 0 0.00036782
withdrawn O 0 0.00044659196
from O 0 0.00014301609
treatment O 0 0.00017837109
because O 0 0.00017194066
of O 0 0.00041632814
clinical O 0 0.002018741
adverse O 0 0.004035432
experiences O 0 0.0044258875
. O 0 0.0027630301

Ophthalmological O 0 0.005728658
examinations O 0 0.001864021
in O 0 0.00095442246
over O 0 0.000648156
1100 O 0 0.002073505
patients O 0 0.0007477507
treated O 0 0.0005435896
with O 0 0.0002779175
one O 0 0.00018140771
or O 0 0.00014503612
the O 0 0.00011705411
other O 0 0.00012687767
agent O 0 0.000343983
have O 0 0.00011035337
revealed O 0 9.126839e-05
no O 0 9.815855e-05
evidence O 0 0.00010181151
of O 0 0.00015339936
significant O 0 0.000155365
short O 0 0.00014610325
term O 0 0.00022722503
( O 0 0.00039790003
up O 0 0.00026013757
to O 0 0.0002239662
2 O 0 0.00037555955
years O 0 0.00058325625
) O 0 0.0015097678
cataractogenic O 0 0.22218288
potential O 0 0.0016047263
. O 0 0.0032042384

One O 0 0.0040665693
to O 0 0.0017377547
2 O 0 0.0014147485
% O 0 0.0015213578
of O 0 0.00071156595
patients O 0 0.00094643835
have O 0 0.000376441
elevations O 0 0.002468301
of O 0 0.0006322275
serum O 0 0.31248495
transaminases O 0 0.99812824
to O 0 0.00021850316
greater O 0 0.00023869367
than O 0 0.00014481336
3 O 0 0.00013133025
times O 0 0.00011527572
the O 0 0.00020035743
upper O 0 0.00048980856
limit O 0 0.00069770153
of O 0 0.0010853667
normal O 0 0.002870719
. O 0 0.0031993946

These O 0 0.0028305587
episodes O 0 0.0045550843
are O 0 0.0016711599
asymptomatic O 0 0.0041059926
and O 0 0.0014294256
reversible O 0 0.0025480287
when O 0 0.00086931436
therapy O 0 0.0017066197
is O 0 0.0014802795
discontinued O 0 0.006043238
. O 0 0.004523896

Minor O 0 0.03343887
elevations O 0 0.03573694
of O 0 0.007571126
creatine B-Chemical 1 0.9997205
kinase O 0 0.0055183126
levels O 0 0.00076897227
are O 0 0.00055078167
reported O 0 0.000603565
in O 0 0.00052003644
about O 0 0.0007391187
5 O 0 0.0007471922
% O 0 0.0014487712
of O 0 0.0014609839
patients O 0 0.0038071119
. O 0 0.0039492445

Myopathy B-Disease 0 0.99501246
, O 0 0.005611579
associated O 0 0.0017190211
in O 0 0.0009414433
some O 0 0.00079587323
cases O 0 0.0013273717
with O 0 0.0013719401
myoglobinuria B-Disease 0 0.9999474
, O 0 0.0010372587
and O 0 0.00028825915
in O 0 0.00019443959
2 O 0 0.00019489099
cases O 0 0.00023651008
with O 0 0.00016138506
transient O 0 0.0005020141
renal B-Disease 0 0.902766
failure I-Disease 0 0.057669934
, O 0 0.000321799
has O 0 7.339853e-05
been O 0 0.0001009592
rarely O 0 0.00017189559
reported O 0 0.00014810555
with O 0 0.00029464433
lovastatin B-Chemical 1 0.9999937
, O 0 0.0008397631
especially O 0 0.0001745172
in O 0 0.00011837152
patients O 0 0.00031450932
concomitantly O 0 0.00038481524
treated O 0 0.0005161795
with O 0 0.0007866162
cyclosporin B-Chemical 0 0.9999949
, O 0 0.085575804
gemfibrozil B-Chemical 0 0.99999535
or O 0 0.007337438
niacin B-Chemical 0 0.99999046
. O 0 0.006649901

Lovastatin B-Chemical 0 0.99980515
and O 0 0.008656773
simvastatin B-Chemical 1 0.9999548
are O 0 0.0007654363
both O 0 0.00038293676
effective O 0 0.0003048204
and O 0 0.00029804112
well O 0 0.00028307742
- O 0 0.0013315233
tolerated O 0 0.00046346203
agents O 0 0.00048141176
for O 0 0.00022174955
lowering O 0 0.0015051888
elevated O 0 0.0019511749
levels O 0 0.00060932984
of O 0 0.0013718675
serum O 0 0.569776
cholesterol B-Chemical 0 0.9995983
. O 0 0.006138337

As O 0 0.0017163048
wider O 0 0.0019920925
use O 0 0.0008272463
confirms O 0 0.00040339868
their O 0 0.0003589253
safety O 0 0.0003456067
profile O 0 0.00028872094
, O 0 0.00044906983
they O 0 0.00017720782
will O 0 0.00012282337
gain O 0 0.00016946744
increasing O 0 0.0001312743
importance O 0 0.00010314303
in O 0 0.00013547917
the O 0 0.00012772201
therapeutic O 0 0.00024954736
approach O 0 0.00024107345
to O 0 0.00041724474
hypercholesterolaemia B-Disease 0 0.9999548
and O 0 0.0010764705
its O 0 0.0013590745
consequences O 0 0.0020008085
. O 0 0.003169174

Hepatic O 0 0.8544288
reactions O 0 0.0048445268
associated O 0 0.0028584376
with O 0 0.0037629248
ketoconazole B-Chemical 0 0.999941
in O 0 0.0023093016
the O 0 0.0017154431
United O 0 0.0030357696
Kingdom O 0 0.0051283054
. O 0 0.0050578527

Ketoconazole B-Chemical 0 0.99952626
was O 0 0.0041007726
introduced O 0 0.0020633964
in O 0 0.0018789282
the O 0 0.0016670448
United O 0 0.0026416727
Kingdom O 0 0.0036420536
in O 0 0.0028733981
1981 O 0 0.008867168
. O 0 0.006849993

By O 0 0.003207687
November O 0 0.00280446
1984 O 0 0.003512376
the O 0 0.0010088811
Committee O 0 0.000859902
on O 0 0.0003860312
Safety O 0 0.00064128585
of O 0 0.00034875947
Medicines O 0 0.00075419253
had O 0 0.00020670115
received O 0 0.00018258358
82 O 0 0.00029928377
reports O 0 0.00018324389
of O 0 0.00020179803
possible O 0 0.00024442197
hepatotoxicity B-Disease 0 0.99996984
associated O 0 0.00038376474
with O 0 0.00027393468
the O 0 0.00026068432
drug O 0 0.0054774717
, O 0 0.0007067224
including O 0 0.00038502074
five O 0 0.00057748024
deaths B-Disease 0 0.01493928
. O 0 0.002897467

An O 0 0.0031425955
analysis O 0 0.0017117034
of O 0 0.0012314257
the O 0 0.00080935674
75 O 0 0.0011531623
cases O 0 0.0008016519
that O 0 0.00029199215
had O 0 0.00032405008
been O 0 0.00024633357
adequately O 0 0.0002583998
followed O 0 0.00014189289
up O 0 0.00017183037
suggested O 0 0.00011006134
that O 0 0.00010652766
16 O 0 0.00018151429
, O 0 0.00022991453
including O 0 9.690513e-05
three O 0 8.749858e-05
deaths B-Disease 0 0.003952928
, O 0 0.00038492822
were O 0 0.00017027829
probably O 0 0.00020094936
related O 0 0.000127873
to O 0 0.00020383939
treatment O 0 0.00033404888
with O 0 0.00054895267
the O 0 0.00084852
drug O 0 0.019250693
. O 0 0.0030819848

Of O 0 0.0050462442
the O 0 0.0019495914
remainder O 0 0.0018849722
, O 0 0.0018097906
48 O 0 0.0007698816
were O 0 0.0004446598
possibly O 0 0.00041886853
related O 0 0.00019439991
to O 0 0.0002135238
treatment O 0 0.0002558571
, O 0 0.0003634795
five O 0 0.00012786972
were O 0 0.00016410532
unlikely O 0 0.00012100185
to O 0 0.0001869151
be O 0 0.00024383982
so O 0 0.00030226022
, O 0 0.00067356403
and O 0 0.00051307667
six O 0 0.00043611295
were O 0 0.0010803167
unclassifiable O 0 0.12052688
. O 0 0.003495716

The O 0 0.0017661091
mean O 0 0.0013281013
age O 0 0.0015186511
of O 0 0.0009738926
patients O 0 0.0012236951
in O 0 0.0004826001
the O 0 0.00037282117
16 O 0 0.00047433242
probable O 0 0.00066827546
cases O 0 0.00054373575
was O 0 0.00026794098
57 O 0 0.0004083383
. O 0 0.00020620096
9 O 0 0.00018454879
, O 0 0.0003962011
with O 0 0.000489341
hepatotoxicity B-Disease 0 0.99995196
being O 0 0.0006550907
more O 0 0.0006931663
common O 0 0.0006854985
in O 0 0.0009057705
women O 0 0.0039765835
. O 0 0.0029954307

The O 0 0.0016981976
average O 0 0.0011129779
duration O 0 0.0006963385
of O 0 0.00079736835
treatment O 0 0.00060574745
before O 0 0.00032428215
the O 0 0.00046749203
onset O 0 0.0009261377
of O 0 0.0010232462
jaundice B-Disease 0 0.97639334
was O 0 0.0011725533
61 O 0 0.0017511976
days O 0 0.0010897897
. O 0 0.0029685332

None O 0 0.0037600368
of O 0 0.001968536
these O 0 0.0011317246
well O 0 0.000795654
validated O 0 0.0005860436
cases O 0 0.00092815445
occurred O 0 0.00043068643
within O 0 0.00021027047
the O 0 0.0002691002
first O 0 0.00024253558
10 O 0 0.0003828225
days O 0 0.0003002978
after O 0 0.00046086896
treatment O 0 0.0013268623
. O 0 0.0030013737

The O 0 0.0020663885
results O 0 0.0016730967
of O 0 0.0019695107
serum O 0 0.03126126
liver O 0 0.06495926
function O 0 0.0006250378
tests O 0 0.0014971821
suggested O 0 0.0007105772
hepatocellular B-Disease 0 0.99996865
injury I-Disease 0 0.9507089
in O 0 0.00036494478
10 O 0 0.0002728951
( O 0 0.000384337
63 O 0 0.00037306704
% O 0 0.00048656628
) O 0 0.0006328497
; O 0 0.00055520626
the O 0 0.00027656657
rest O 0 0.0005457435
showed O 0 0.0005133041
a O 0 0.0011385573
mixed O 0 0.0018895818
pattern O 0 0.0019378195
. O 0 0.0036966302

In O 0 0.002252594
contrast O 0 0.0026602142
, O 0 0.0022616955
the O 0 0.0007402988
results O 0 0.00053473207
of O 0 0.0005828392
histological O 0 0.0011039969
examination O 0 0.0003418758
of O 0 0.00040178312
the O 0 0.00040540023
liver O 0 0.027198978
often O 0 0.00064034475
showed O 0 0.00049163896
evidence O 0 0.0007571064
of O 0 0.0025686605
cholestasis B-Disease 0 0.9999391
. O 0 0.007308657

The O 0 0.0020649226
characteristics O 0 0.0015367299
of O 0 0.0014253814
the O 0 0.0009687685
48 O 0 0.0010049113
patients O 0 0.0012004742
in O 0 0.00062322314
the O 0 0.0005741891
possible O 0 0.00064560864
cases O 0 0.0016887585
were O 0 0.0012878248
similar O 0 0.0015045265
. O 0 0.003768864

Allergic O 0 0.07660224
manifestations O 0 0.022874689
such O 0 0.0025536604
as O 0 0.0030117936
rash B-Disease 0 0.94647855
and O 0 0.0034610082
eosinophilia B-Disease 0 0.9882505
were O 0 0.0030110062
rare O 0 0.0080456305
. O 0 0.0052313693

Hepatitis B-Disease 0 0.9991609
was O 0 0.0034387459
usually O 0 0.0020363533
reversible O 0 0.0022145102
when O 0 0.00041051774
treatment O 0 0.0004337392
was O 0 0.00030813998
stopped O 0 0.00041774084
, O 0 0.0004288252
with O 0 0.00020532889
the O 0 0.00013399667
results O 0 0.00012772079
of O 0 0.00020526117
liver O 0 0.012853029
function O 0 0.00016369992
tests O 0 0.00046927843
returning O 0 0.00020784621
to O 0 0.00011133233
normal O 0 0.00021104336
after O 0 8.068315e-05
an O 0 0.00016944758
average O 0 0.00015690664
of O 0 0.00029193866
3 O 0 0.0003341199
. O 0 0.0004296053
1 O 0 0.00066705316
months O 0 0.000587412
. O 0 0.0020474244

In O 0 0.0016768737
two O 0 0.0010631218
of O 0 0.0010435007
the O 0 0.00059007056
three O 0 0.00033195864
deaths B-Disease 0 0.00674093
probably O 0 0.00040594858
associated O 0 0.00031060283
with O 0 0.00051041215
ketoconazole B-Chemical 0 0.9999949
treatment O 0 0.0003080002
the O 0 0.00014548156
drug O 0 0.0042589083
had O 0 0.00013426668
been O 0 9.997635e-05
continued O 0 9.676746e-05
after O 0 5.665958e-05
the O 0 9.555212e-05
onset O 0 0.00024076979
of O 0 0.00027706617
jaundice B-Disease 0 0.98837435
and O 0 0.00039479538
other O 0 0.00044461322
symptoms O 0 0.013431925
of O 0 0.0020993096
hepatitis B-Disease 0 0.9999037
. O 0 0.0069903005

Clinical O 0 0.0060521187
and O 0 0.0016722947
biochemical O 0 0.0011221108
monitoring O 0 0.0005104854
at O 0 0.00028775554
regular O 0 0.0002620691
intervals O 0 0.00019951556
for O 0 0.00014557774
evidence O 0 0.0001841252
of O 0 0.00050348573
hepatitis B-Disease 0 0.9999646
is O 0 0.0002710396
advised O 0 0.0002612548
during O 0 8.57705e-05
long O 0 0.00011172903
term O 0 0.00013881564
treatment O 0 0.00017796083
with O 0 0.0004355861
ketoconazole B-Chemical 0 0.99999404
to O 0 0.00031484233
prevent O 0 0.0002788114
possible O 0 0.00038616188
serious O 0 0.007118509
hepatic B-Disease 0 0.9995646
injury I-Disease 0 0.98506236
. O 0 0.0036279266

Glyburide B-Chemical 0 0.99921715
- O 0 0.29918432
induced O 0 0.024150006
hepatitis B-Disease 0 0.99917525
. O 0 0.033930022

Drug O 0 0.9275112
- O 0 0.03299002
induced O 0 0.0034416248
hepatotoxicity B-Disease 0 0.9999279
, O 0 0.0033904973
although O 0 0.0007903407
common O 0 0.00072742894
, O 0 0.00092813367
has O 0 0.00032014167
been O 0 0.00042068385
reported O 0 0.0005429949
only O 0 0.00068160455
infrequently O 0 0.0014659173
with O 0 0.0019489242
sulfonylureas B-Chemical 0 0.9995665
. O 0 0.0049940604

For O 0 0.0034750076
glyburide B-Chemical 0 0.99974185
, O 0 0.0040309383
a O 0 0.0016910174
second O 0 0.00091739604
- O 0 0.0042128963
generation O 0 0.0009706579
sulfonylurea B-Chemical 0 0.9998418
, O 0 0.0011168007
only O 0 0.00038773773
two O 0 0.00023520399
brief O 0 0.00042774045
reports O 0 0.0006595216
of O 0 0.0014327187
hepatotoxicity B-Disease 0 0.9998716
exist O 0 0.002711958
. O 0 0.0037342154

Two O 0 0.0027145606
patients O 0 0.003225822
with O 0 0.0017815535
type B-Disease 0 0.0034405896
II I-Disease 0 0.7182297
diabetes I-Disease 0 0.9999237
mellitus I-Disease 0 0.9999684
developed O 0 0.0016189913
an O 0 0.0010026208
acute B-Disease 0 0.996268
hepatitis I-Disease 0 0.9999976
- I-Disease 0 0.29636872
like I-Disease 0 0.00041363
syndrome I-Disease 0 0.7408745
soon O 0 0.00025597372
after O 0 0.0001334737
initiation O 0 0.00024127123
of O 0 0.0009138855
glyburide B-Chemical 0 0.9999163
therapy O 0 0.0034105594
. O 0 0.0026000398

There O 0 0.0036420808
was O 0 0.0018547889
no O 0 0.001158637
serologic O 0 0.0016861461
evidence O 0 0.0005698642
of O 0 0.00082793715
viral B-Disease 0 0.008809294
infection I-Disease 0 0.28952843
, O 0 0.0009668082
and O 0 0.00034971
a O 0 0.00047437497
liver O 0 0.024274403
biopsy O 0 0.00027805933
sample O 0 0.00020340699
showed O 0 0.00014174292
a O 0 0.00026192548
histologic O 0 0.0008061789
pattern O 0 0.0001979723
consistent O 0 0.00022606333
with O 0 0.00046784754
drug B-Disease 0 0.06680099
- I-Disease 0 0.013813866
induced I-Disease 0 0.0021025785
hepatitis I-Disease 0 0.99990225
. O 0 0.007761135

Both O 0 0.00253549
patients O 0 0.0028262092
recovered O 0 0.00090161903
quickly O 0 0.00074770226
after O 0 0.00031589466
stopping O 0 0.001127028
glyburide B-Chemical 0 0.9999347
therapy O 0 0.0006132608
and O 0 0.00022982292
have O 0 0.00016296886
remained O 0 0.00023639308
well O 0 0.0001735852
for O 0 0.00015919657
a O 0 0.0003355479
follow O 0 0.00020859808
- O 0 0.0010533028
up O 0 0.00034960234
period O 0 0.0002924856
of O 0 0.0006475214
1 O 0 0.0010726252
year O 0 0.0012516492
. O 0 0.0025884716

Glyburide B-Chemical 0 0.9995821
can O 0 0.0028430931
produce O 0 0.0017167691
an O 0 0.0027546498
acute B-Disease 0 0.9945749
hepatitis I-Disease 0 0.99999034
- I-Disease 0 0.3872074
like I-Disease 0 0.0013537953
illness I-Disease 0 0.38391608
in O 0 0.0012168665
some O 0 0.0017127376
persons O 0 0.0047057434
. O 0 0.004129658

Intracranial O 0 0.030947832
pressure O 0 0.014215108
increases O 0 0.0026962443
during O 0 0.002738646
alfentanil B-Chemical 0 0.9997917
- O 0 0.024831945
induced O 0 0.004239958
rigidity B-Disease 0 0.94082886
. O 0 0.008721161

Intracranial O 0 0.039161943
pressure O 0 0.023186825
( O 0 0.0053642984
ICP O 0 0.77634865
) O 0 0.0022073365
was O 0 0.00065820134
measured O 0 0.0006632155
during O 0 0.00073215755
alfentanil B-Chemical 0 0.9999044
- O 0 0.009529566
induced O 0 0.0011757588
rigidity B-Disease 0 0.7976606
in O 0 0.0016982113
rats O 0 0.0034858263
. O 0 0.003881513

Ten O 0 0.0039091567
rats O 0 0.0032460098
had O 0 0.0019420682
arterial O 0 0.10504084
, O 0 0.0019514479
central O 0 0.0013961756
venous O 0 0.12263283
( O 0 0.0014681638
CVP O 0 0.9306829
) O 0 0.0011567853
, O 0 0.00068000134
and O 0 0.0005182991
subdural O 0 0.6783746
cannulae O 0 0.001357744
inserted O 0 0.0005654495
under O 0 0.00092531164
halothane B-Chemical 0 0.9994981
anesthesia O 0 0.029476216
. O 0 0.0029992783

The O 0 0.001953771
animals O 0 0.0013084784
were O 0 0.0011455041
mechanically O 0 0.0021454818
ventilated O 0 0.0017701463
to O 0 0.00033329945
achieve O 0 0.00029481426
normocarbia O 0 0.0024662542
( O 0 0.0009985057
PCO2 O 0 0.9820228
= O 0 0.0010273972
42 O 0 0.00046235518
+ O 0 0.0010716389
/ O 0 0.0016465441
- O 0 0.0015098541
1 O 0 0.0004095753
mmHg O 0 0.0012903449
, O 0 0.0007196259
mean O 0 0.0005194621
+ O 0 0.0022791345
/ O 0 0.0050884937
- O 0 0.010450011
SE O 0 0.2367854
) O 0 0.006549623
. O 0 0.004984206

Following O 0 0.0023534994
instrumentation O 0 0.005124393
, O 0 0.005472834
halothane B-Chemical 0 0.99967825
was O 0 0.0009936676
discontinued O 0 0.0019314336
and O 0 0.00070521404
alfentanil B-Chemical 0 0.9999143
( O 0 0.00089399907
125 O 0 0.0008462528
mu O 0 0.0028341138
/ O 0 0.000995331
kg O 0 0.0006191177
) O 0 0.0005001504
administered O 0 0.0003105578
iv O 0 0.00039769715
during O 0 0.0002454191
emergence O 0 0.0005862902
from O 0 0.00085678196
halothane B-Chemical 0 0.99971956
anesthesia O 0 0.056365702
. O 0 0.0028079948

In O 0 0.0018003919
the O 0 0.0012174948
five O 0 0.0006391417
rats O 0 0.001039218
that O 0 0.00049136905
developed O 0 0.00083111424
somatic B-Disease 0 0.0038805115
rigidity I-Disease 0 0.9983297
, O 0 0.0020148174
ICP O 0 0.9664656
and O 0 0.00040416582
CVP O 0 0.9790886
increased O 0 0.00026410312
significantly O 0 0.00016376111
above O 0 0.00013808557
baseline O 0 0.00016138938
( O 0 0.0003955769
delta O 0 0.005429276
ICP O 0 0.8907468
7 O 0 0.00014410121
. O 0 0.00012958956
5 O 0 0.00014294684
+ O 0 0.0005983094
/ O 0 0.0012931431
- O 0 0.0013540334
1 O 0 0.00021232966
. O 0 0.00015069812
0 O 0 0.00021019188
mmHg O 0 0.00090209977
, O 0 0.0004838064
delta O 0 0.003479277
CVP O 0 0.97043633
5 O 0 0.00026018423
. O 0 0.00020288149
9 O 0 0.00022918615
+ O 0 0.0009496097
/ O 0 0.0019730483
- O 0 0.0022025304
1 O 0 0.0005762779
. O 0 0.0005137427
3 O 0 0.00066246116
mmHg O 0 0.00361706
) O 0 0.0038821045
. O 0 0.0039046735

These O 0 0.0020847647
variables O 0 0.0020327342
returned O 0 0.001314439
to O 0 0.0007670483
baseline O 0 0.0007475469
when O 0 0.00080202403
rigidity B-Disease 0 0.58308405
was O 0 0.0013122476
abolished O 0 0.0019703659
with O 0 0.003612364
metocurine B-Chemical 0 0.99960464
. O 0 0.0063785217

In O 0 0.0018643928
five O 0 0.0011763609
rats O 0 0.001788089
that O 0 0.0007985568
did O 0 0.0008736273
not O 0 0.00060700614
become O 0 0.00075675367
rigid O 0 0.0011033213
, O 0 0.0015458394
ICP O 0 0.91254807
and O 0 0.00076800055
CVP O 0 0.97358954
did O 0 0.0005847614
not O 0 0.0004577527
change O 0 0.00066422246
following O 0 0.00093374564
alfentanil B-Chemical 0 0.9997038
. O 0 0.0038702327

These O 0 0.0019688958
observations O 0 0.0016804
suggest O 0 0.0008048817
that O 0 0.0010055834
rigidity B-Disease 0 0.82872826
should O 0 0.00037224856
be O 0 0.0003652714
prevented O 0 0.00051620614
when O 0 0.00035378378
alfentanil B-Chemical 0 0.9999796
, O 0 0.00075668807
and O 0 0.00024445995
, O 0 0.00036859966
presumably O 0 0.00021811308
, O 0 0.00033826067
other O 0 0.00021047346
opiates O 0 0.97835505
, O 0 0.00039419893
are O 0 0.00010451347
used O 0 0.000103343664
in O 0 0.00012279292
the O 0 0.00013712197
anesthetic O 0 0.0018006449
management O 0 0.00025372228
of O 0 0.0003098551
patients O 0 0.00087847287
with O 0 0.0009577018
ICP O 0 0.98074603
problems O 0 0.010356172
. O 0 0.0031683156

Verapamil B-Chemical 0 0.9998957
withdrawal O 0 0.095353864
as O 0 0.0016749646
a O 0 0.0012475876
possible O 0 0.0005220922
cause O 0 0.00080959
of O 0 0.001113096
myocardial B-Disease 0 0.9997478
infarction I-Disease 0 0.9999858
in O 0 0.0005090231
a O 0 0.0008873677
hypertensive B-Disease 0 0.9998301
woman O 0 0.0019827047
with O 0 0.00044317704
a O 0 0.0008100673
normal O 0 0.0014170023
coronary O 0 0.07382929
angiogram O 0 0.08069361
. O 0 0.0026220889

Verapamil B-Chemical 0 0.99979895
is O 0 0.003072158
an O 0 0.0018919846
effective O 0 0.0011416302
and O 0 0.0012109759
relatively O 0 0.001686864
- O 0 0.004726841
safe O 0 0.0022739042
antihypertensive O 0 0.7618563
drug O 0 0.03322551
. O 0 0.005270088

Serious O 0 0.0068125622
adverse O 0 0.004426497
effects O 0 0.0011140996
are O 0 0.00079597224
uncommon O 0 0.002262909
and O 0 0.00045748448
mainly O 0 0.00033513567
have O 0 0.00020377795
been O 0 0.00017347516
related O 0 0.000107520646
to O 0 0.00013366883
the O 0 0.00018038145
depression B-Disease 0 0.99645716
of O 0 0.00021236346
cardiac O 0 0.0014470345
contractility O 0 0.18907413
and O 0 0.00017859472
conduction O 0 0.0010613187
, O 0 0.00020515003
especially O 0 0.00011059714
when O 0 7.857024e-05
the O 0 0.00012834296
drug O 0 0.0018281274
is O 0 0.00016135244
combined O 0 0.00030711378
with O 0 0.0005236167
beta O 0 0.78154194
- O 0 0.015841749
blocking O 0 0.0012356786
agents O 0 0.004296131
. O 0 0.0031010571

We O 0 0.0029557224
report O 0 0.0033265466
a O 0 0.0020417182
case O 0 0.0011207445
in O 0 0.00078501896
which O 0 0.001346052
myocardial B-Disease 0 0.999665
infarction I-Disease 0 0.9999856
coincided O 0 0.0004580347
with O 0 0.00016945161
the O 0 9.7921824e-05
introduction O 0 8.127482e-05
of O 0 0.00023653283
captopril B-Chemical 0 0.99998343
and O 0 0.00020682694
the O 0 0.00011904821
withdrawal O 0 0.0012968922
of O 0 0.00034663588
verapamil B-Chemical 0 0.9999949
in O 0 0.00028508817
a O 0 0.00035871353
previously O 0 0.00032180265
asymptomatic O 0 0.0034959402
woman O 0 0.0019361121
with O 0 0.000879287
severe O 0 0.16502908
hypertension B-Disease 2 0.9999633
. O 0 0.004501708

Possible O 0 0.0032795768
mechanisms O 0 0.0013510025
that O 0 0.0010479415
involve O 0 0.0011017428
a O 0 0.0027525784
verapamil B-Chemical 0 0.99998784
- O 0 0.033174418
related O 0 0.00027206875
increase O 0 0.00030071838
in O 0 0.00037115498
platelet O 0 0.55421025
and O 0 0.00038731162
/ O 0 0.0020822808
or O 0 0.00040091638
vascular O 0 0.97564596
alpha O 0 0.8509647
2 O 0 0.0007118725
- O 0 0.02279894
adrenoreceptor O 0 0.99793774
affinity O 0 0.00079548015
for O 0 0.0006228669
catecholamines B-Chemical 0 0.9993494
are O 0 0.00087180117
discussed O 0 0.0012454184
. O 0 0.0025812085

Haemolytic B-Disease 0 0.6418362
- I-Disease 0 0.19752018
uraemic I-Disease 0 0.9987576
syndrome I-Disease 0 0.8820254
after O 0 0.0015147857
treatment O 0 0.0022187203
with O 0 0.0043331147
metronidazole B-Chemical 0 0.99938905
. O 0 0.008235662

This O 0 0.004995942
paper O 0 0.003121262
describes O 0 0.0014057128
the O 0 0.00066904334
clinical O 0 0.0011374099
features O 0 0.00048278458
of O 0 0.00032514744
six O 0 0.00017529889
children O 0 0.0006645416
who O 0 0.00034934515
developed O 0 0.00028756494
the O 0 0.00031439
haemolytic B-Disease 0 0.9519793
- I-Disease 0 0.14802687
uraemic I-Disease 0 0.9998728
syndrome I-Disease 0 0.91390604
after O 0 0.0002516432
treatment O 0 0.00055328786
with O 0 0.0014962488
metronidazole B-Chemical 0 0.9997775
. O 0 0.0038043172

These O 0 0.0022398024
children O 0 0.0040227585
were O 0 0.001215011
older O 0 0.0023566966
and O 0 0.00066334417
were O 0 0.00040523734
more O 0 0.0004189464
likely O 0 0.0001582585
to O 0 0.0001616854
have O 0 0.0001429482
undergone O 0 0.00018063874
recent O 0 0.00019077095
bowel O 0 0.0036753698
surgery O 0 0.00028194347
than O 0 0.00014273939
are O 0 0.00014835516
other O 0 0.00023895668
children O 0 0.0009626954
with O 0 0.00063167466
this O 0 0.0010347427
condition O 0 0.0030105794
. O 0 0.0032951366

While O 0 0.0019393704
the O 0 0.0014646372
involvement O 0 0.0017774394
of O 0 0.0018137343
metronidazole B-Chemical 0 0.9998647
in O 0 0.00052175287
the O 0 0.0003087425
aetiology O 0 0.0017341014
of O 0 0.00031901526
the O 0 0.00033570454
haemolytic B-Disease 0 0.98359686
- I-Disease 0 0.34116703
uraemic I-Disease 0 0.9999589
syndrome I-Disease 0 0.98868513
is O 0 0.00012762804
not O 0 0.000103112936
established O 0 0.00013137686
firmly O 0 0.000209494
, O 0 0.00021123422
the O 0 7.6272045e-05
action O 0 0.000102285514
of O 0 0.00012393536
this O 0 0.00015905016
drug O 0 0.0079752635
in O 0 0.00012536871
sensitizing O 0 0.00038050034
tissues O 0 0.00026814902
to O 0 0.00016264083
oxidation O 0 0.7019023
injury O 0 0.020303452
and O 0 0.00010448717
the O 0 6.8071626e-05
reported O 0 9.051745e-05
evidence O 0 8.160689e-05
of O 0 0.00023268483
oxidation O 0 0.61116576
changes O 0 0.00016187469
in O 0 0.00011103599
the O 0 0.00014969603
haemolytic B-Disease 0 0.9744099
- I-Disease 0 0.20260347
uraemic I-Disease 0 0.9999546
syndrome I-Disease 0 0.9435544
suggest O 0 6.407442e-05
a O 0 0.0001382368
possible O 0 5.8056165e-05
link O 0 6.617294e-05
between O 0 0.00014588525
metronidazole B-Chemical 0 0.9999598
treatment O 0 0.0001856508
and O 0 0.00015518999
some O 0 0.00018591882
cases O 0 0.0003808885
of O 0 0.0003496717
the O 0 0.00054681435
haemolytic B-Disease 0 0.98927456
- I-Disease 0 0.4177516
uraemic I-Disease 0 0.9998566
syndrome I-Disease 0 0.99360496
. O 0 0.0038040928

Adverse O 0 0.0035544797
cardiac O 0 0.0025475428
effects O 0 0.00072060997
during O 0 0.00045627417
induction O 0 0.000438631
chemotherapy O 0 0.0016923993
treatment O 0 0.00038412306
with O 0 0.00050302857
cis B-Chemical 0 0.0021193328
- I-Chemical 0 0.016779747
platin I-Chemical 0 0.9040819
and O 0 0.0008816166
5 B-Chemical 0 0.0010280639
- I-Chemical 0 0.0074659633
fluorouracil I-Chemical 0 0.9986966
. O 0 0.004214159

Survival O 0 0.0053293835
for O 0 0.0015386444
patients O 0 0.002080918
with O 0 0.0011338411
advanced O 0 0.004256035
head B-Disease 0 0.0033186434
and I-Disease 0 0.00093169103
neck I-Disease 0 0.13747889
carcinoma I-Disease 0 0.9984854
and O 0 0.001072578
esophageal B-Disease 0 0.9776938
carcinoma I-Disease 0 0.99976736
is O 0 0.00033260332
poor O 0 0.0007314682
with O 0 0.0004070045
radiotherapy O 0 0.003689013
and O 0 0.0005165888
/ O 0 0.0020069287
or O 0 0.0008581214
surgery O 0 0.0018476775
. O 0 0.0024755024

Obviously O 0 0.006011059
, O 0 0.006130798
there O 0 0.002403853
is O 0 0.0019995796
a O 0 0.0024125504
need O 0 0.0014830542
for O 0 0.001417564
effective O 0 0.0024483954
chemotherapy O 0 0.009266744
. O 0 0.0053451005

In O 0 0.0021671506
the O 0 0.0016798985
present O 0 0.0012264373
study O 0 0.0014752685
, O 0 0.0019510943
cis B-Chemical 0 0.0035427827
- I-Chemical 0 0.03167538
platin I-Chemical 0 0.9572684
( O 0 0.0009225866
80 O 0 0.0005440279
- O 0 0.0010890814
120 O 0 0.00035620847
mg O 0 0.0016794195
/ O 0 0.00077736046
m2BSA O 0 0.00044312357
) O 0 0.0004895705
and O 0 0.00022223976
5 B-Chemical 0 0.00022703168
- I-Chemical 0 0.0012431584
FU I-Chemical 0 0.06523615
( O 0 0.00035216272
1000 O 0 0.00040663514
mg O 0 0.0016264677
/ O 0 0.0005172616
m2BSA O 0 0.00025094763
daily O 0 0.00014939545
as O 0 9.4277326e-05
a O 0 0.00012528924
continuous O 0 8.54113e-05
infusion O 0 0.00020452445
during O 0 6.117646e-05
5 O 0 7.5639065e-05
days O 0 6.0007464e-05
) O 0 0.00020913438
were O 0 9.555613e-05
given O 0 7.987384e-05
to O 0 0.00012928851
76 O 0 0.00034561084
patients O 0 0.00035847235
before O 0 0.00018819518
radiotherapy O 0 0.0018593125
and O 0 0.0007464503
surgery O 0 0.0015612355
. O 0 0.00223643

The O 0 0.0016854409
aim O 0 0.0010781433
of O 0 0.0011274478
the O 0 0.00071658025
study O 0 0.000677982
was O 0 0.0003670004
to O 0 0.00022898236
clarify O 0 0.00012305759
the O 0 0.00019257514
incidence O 0 0.0004159103
and O 0 0.0002474083
severity O 0 0.0005563547
of O 0 0.00025111114
adverse O 0 0.0010109836
cardiac O 0 0.00077374757
effects O 0 0.00028433435
to O 0 0.00038728942
this O 0 0.0007771434
treatment O 0 0.0012748945
. O 0 0.0024443096

Before O 0 0.0024269277
treatment O 0 0.001841091
all O 0 0.0011093298
patients O 0 0.0014011213
had O 0 0.0005852916
a O 0 0.0006272045
cardiac O 0 0.0010215363
evaluation O 0 0.00026793103
and O 0 0.00023966286
during O 0 0.00018125642
treatment O 0 0.00026138814
serial O 0 0.0003730139
ECG O 0 0.002995774
recordings O 0 0.00054603704
were O 0 0.00062411895
performed O 0 0.0010858756
. O 0 0.0026437906

In O 0 0.0019674723
the O 0 0.0015978994
pre O 0 0.002400441
- O 0 0.0035884853
treatment O 0 0.00066529954
evaluation O 0 0.000505411
, O 0 0.0008094481
signs O 0 0.0014014157
of O 0 0.00055257365
cardiovascular B-Disease 0 0.6054713
disease I-Disease 0 0.3847068
were O 0 0.00028702206
found O 0 0.00026643494
in O 0 0.00030672576
33 O 0 0.0006298209
patients O 0 0.000839453
( O 0 0.001002077
43 O 0 0.0012660633
% O 0 0.0021121067
) O 0 0.0038068877
. O 0 0.0036650838

During O 0 0.0021198683
treatment O 0 0.0019734108
, O 0 0.00222526
adverse O 0 0.0025905408
cardiac O 0 0.0018016597
effects O 0 0.0005199264
were O 0 0.00042896572
observed O 0 0.0003574552
in O 0 0.00041145252
14 O 0 0.00048797668
patients O 0 0.0009403497
( O 0 0.0011709433
18 O 0 0.0010922534
% O 0 0.0023158665
) O 0 0.0042051002
. O 0 0.0041930433

The O 0 0.0017899001
mean O 0 0.0013373463
age O 0 0.0014736411
of O 0 0.0008686549
these O 0 0.00066052354
patients O 0 0.0009808143
was O 0 0.0003813261
the O 0 0.00027782243
same O 0 0.00023387323
as O 0 0.00028307096
for O 0 0.00023697688
the O 0 0.00029106773
entire O 0 0.0003516551
group O 0 0.00082461763
, O 0 0.0014281309
64 O 0 0.001678717
years O 0 0.0021093495
. O 0 0.0031291086

The O 0 0.0021876355
incidence O 0 0.00324736
of O 0 0.0023939689
cardiotoxicity B-Disease 0 0.99988306
was O 0 0.0006742663
not O 0 0.00031705506
higher O 0 0.00030353022
in O 0 0.00021709768
patients O 0 0.00037025948
with O 0 0.00018178363
signs O 0 0.0007363053
of O 0 0.0002255763
cardiovascular B-Disease 0 0.5641165
disease I-Disease 0 0.3087329
than O 0 0.00012591948
in O 0 0.00011800671
those O 0 0.00015447749
without O 0 0.00015666027
in O 0 0.00017861924
the O 0 0.00021716185
pre O 0 0.0006479859
- O 0 0.0018666942
treatment O 0 0.00068770855
evaluation O 0 0.0011943751
. O 0 0.0023657405

The O 0 0.0022750488
most O 0 0.0022623106
common O 0 0.0015991896
signs O 0 0.003263729
of O 0 0.0014096161
cardiotoxicity B-Disease 0 0.999814
were O 0 0.00059157336
chest B-Disease 0 0.0011197991
pain I-Disease 0 0.013055386
, O 0 0.0010602768
ST O 0 0.25123608
- O 0 0.0036953907
T O 0 0.00425427
wave O 0 0.0023764283
changes O 0 0.00073840463
and O 0 0.0010267161
atrial B-Disease 0 0.20680012
fibrillation I-Disease 0 0.9978096
. O 0 0.003961064

This O 0 0.0048356475
was O 0 0.0018474665
followed O 0 0.0010157813
by O 0 0.0010258646
ventricular B-Disease 0 0.39235398
fibrillation I-Disease 0 0.99852103
in O 0 0.0006024215
one O 0 0.0004443541
patient O 0 0.00063819066
and O 0 0.0008507242
sudden B-Disease 0 0.9301823
death I-Disease 0 0.99716824
in O 0 0.0019104023
another O 0 0.0030646168
. O 0 0.0037791978

It O 0 0.0051243682
is O 0 0.0015773808
concluded O 0 0.001179819
that O 0 0.00066601485
patients O 0 0.0010065036
on O 0 0.00033074818
5 B-Chemical 0 0.00042512667
- I-Chemical 0 0.002661562
FU I-Chemical 0 0.16103177
treatment O 0 0.00020210572
should O 0 8.114503e-05
be O 0 0.00010700474
under O 0 9.282671e-05
close O 0 0.000110815556
supervision O 0 0.0002644899
and O 0 0.00013485563
that O 0 8.653661e-05
the O 0 0.000100183446
treatment O 0 0.000121510726
should O 0 6.615767e-05
be O 0 0.00012085113
discontinued O 0 0.0003904434
if O 0 0.00011247815
chest B-Disease 0 0.000584339
pain I-Disease 0 0.010476874
or O 0 0.00041430545
tachyarrhythmia B-Disease 0 0.9700455
is O 0 0.0007572478
observed O 0 0.0012533523
. O 0 0.002864047

Death B-Disease 0 0.09854396
from O 0 0.0051098582
chemotherapy O 0 0.010670839
in O 0 0.0033632705
gestational B-Disease 0 0.015822366
trophoblastic I-Disease 0 0.9549004
disease I-Disease 0 0.75273675
. O 0 0.0088243745

Multiple O 0 0.004391682
cytotoxic O 0 0.013490956
drug O 0 0.02193746
administration O 0 0.0014804545
is O 0 0.00037871985
the O 0 0.0002765937
generally O 0 0.0003067284
accepted O 0 0.00031311874
treatment O 0 0.00020717114
of O 0 0.00024161769
patients O 0 0.00046206918
with O 0 0.00028127522
a O 0 0.0004749679
high O 0 0.00064987777
- O 0 0.0051104235
risk O 0 0.005457584
stage O 0 0.0047223656
of O 0 0.0030532104
choriocarcinoma B-Disease 0 0.9997044
. O 0 0.005987701

Based O 0 0.0043464024
on O 0 0.0014597302
this O 0 0.0012728815
principle O 0 0.0009795476
a O 0 0.0011157729
27 O 0 0.0009599929
- O 0 0.0018946715
year O 0 0.0003073033
old O 0 0.0003849636
woman O 0 0.00086426473
, O 0 0.00045931357
classified O 0 0.0003210399
as O 0 0.00019895726
being O 0 0.00018698997
in O 0 0.00014629745
the O 0 0.00013158422
high O 0 0.00027960652
- O 0 0.0020103967
risk O 0 0.00121676
group O 0 0.00032669044
( O 0 0.00042482204
Goldstein O 0 0.0022314338
and O 0 0.00022764097
Berkowitz O 0 0.0030481827
score O 0 0.00019628763
: O 0 0.00040312955
11 O 0 0.00025385682
) O 0 0.0004874569
, O 0 0.00042239996
was O 0 0.00026703
treated O 0 0.0005919495
with O 0 0.0005423263
multiple O 0 0.00079221255
cytotoxic O 0 0.026952343
drugs O 0 0.11879472
. O 0 0.003627346

The O 0 0.0021452673
multiple O 0 0.0018647094
drug O 0 0.0056862948
schema O 0 0.0016936064
consisted O 0 0.0007594425
of O 0 0.0008525349
: O 0 0.003153477
Etoposide B-Chemical 0 0.99988115
16 O 0 0.00062316493
. O 0 0.00038176528
213 O 0 0.0010845105
, O 0 0.001226382
Methotrexate B-Chemical 0 0.99957186
, O 0 0.0025987912
Cyclophosphamide B-Chemical 0 0.9997731
, O 0 0.002106099
Actomycin B-Chemical 0 0.40751728
- I-Chemical 0 0.05431735
D I-Chemical 0 0.99010617
, O 0 0.004502873
and O 0 0.0034510314
Cisplatin B-Chemical 0 0.99969923
. O 0 0.005575849

On O 0 0.002649475
the O 0 0.0012851183
first O 0 0.00065263297
day O 0 0.0005043446
of O 0 0.0004950086
the O 0 0.000327133
schedule O 0 0.0003091744
, O 0 0.00050251227
moderate O 0 0.0006139094
high O 0 0.00034811875
doses O 0 0.00075352227
of O 0 0.00074449065
Methotrexate B-Chemical 0 0.99989045
, O 0 0.00452702
Etoposide B-Chemical 0 0.99995196
and O 0 0.0014698276
Cyclophosphamide B-Chemical 0 0.999549
were O 0 0.00090271543
administered O 0 0.0016169602
. O 0 0.002305721

Within O 0 0.0013276525
8 O 0 0.0011266469
hours O 0 0.00062464055
after O 0 0.00030006457
initiation O 0 0.00027577823
of O 0 0.00036842292
therapy O 0 0.00042082364
the O 0 0.00020891275
patient O 0 0.00029031996
died O 0 0.0004184367
with O 0 0.00018595642
a O 0 0.0002775011
clinical O 0 0.000577429
picture O 0 0.0002992869
resembling O 0 0.00033730248
massive O 0 0.00155735
pulmonary B-Disease 0 0.99221957
obstruction I-Disease 0 0.9806614
due O 0 0.00011153433
to O 0 0.000114576105
choriocarcinomic O 0 0.0003493335
tissue O 0 0.00078470976
plugs O 0 0.0010686697
, O 0 0.0005053067
probably O 0 0.00034622752
originating O 0 0.00031721892
from O 0 0.00042235124
the O 0 0.00074148783
uterus O 0 0.0046509583
. O 0 0.003129281

Formation O 0 0.011968826
of O 0 0.0024785295
these O 0 0.0015428667
plugs O 0 0.00365135
was O 0 0.000817041
probably O 0 0.0006429259
due O 0 0.0003222343
to O 0 0.00034117937
extensive O 0 0.00062262826
tumor B-Disease 0 0.96356565
necrosis B-Disease 2 0.9999329
at O 0 0.00017280683
the O 0 0.00011171241
level O 0 0.000104420826
of O 0 0.00014175764
the O 0 0.0001257882
walls O 0 0.0022677202
of O 0 0.00016095293
the O 0 0.0001078038
major O 0 0.00015649723
uterine O 0 0.0063587357
veins O 0 0.88893026
, O 0 0.00032503923
which O 0 0.00012722185
resulted O 0 9.089024e-05
in O 0 9.822081e-05
an O 0 0.00012201369
open O 0 0.00014585408
exchange O 0 0.00015723944
of O 0 0.000170277
tumor B-Disease 0 0.42019302
plugs O 0 0.0009931112
to O 0 0.00010756495
the O 0 0.00013051555
vascular O 0 0.809348
spaces O 0 0.0014680617
; O 0 0.00036399136
decrease O 0 0.00014750051
in O 0 0.00015760012
tumor B-Disease 0 0.4654363
tissue O 0 0.0006468447
coherence O 0 0.0010889859
secondary O 0 0.00016941981
to O 0 0.000109146196
chemotherapy O 0 0.0008552106
may O 0 7.928798e-05
have O 0 8.9598725e-05
further O 0 0.000117405325
contributed O 0 0.00030666997
to O 0 0.00022152574
the O 0 0.00028920305
formation O 0 0.00085039384
of O 0 0.0012176887
tumor B-Disease 0 0.9700483
emboli O 0 0.9968618
. O 0 0.003596568

In O 0 0.0017510584
view O 0 0.0017942351
of O 0 0.0011790948
the O 0 0.0005963214
close O 0 0.00042089645
time O 0 0.00022973001
association O 0 0.00016681271
between O 0 0.00016048613
the O 0 0.00015274982
start O 0 0.00010798013
of O 0 0.0002001453
chemotherapy O 0 0.0010128833
and O 0 0.00014434737
the O 0 0.00012899212
acute O 0 0.0035355447
onset O 0 0.00027371017
of O 0 0.00019355466
massive O 0 0.0020105268
embolism B-Disease 0 0.99994445
other O 0 0.00011985362
explanations O 0 0.00010907837
, O 0 0.0002848396
such O 0 0.00016505693
as O 0 0.00027447744
spontaneous O 0 0.013418606
necrosis B-Disease 2 0.9999653
, O 0 0.0011027829
must O 0 0.00020605177
be O 0 0.00033038858
considered O 0 0.0004683825
less O 0 0.00091389415
likely O 0 0.0009165398
. O 0 0.0025175752

Patients O 0 0.0043846257
with O 0 0.0020715364
large O 0 0.0022451868
pelvic B-Disease 0 0.08953379
tumor I-Disease 0 0.9728521
loads O 0 0.0008692108
are O 0 0.00036670367
, O 0 0.00051851454
according O 0 0.00017443119
to O 0 0.00014883648
existing O 0 0.00018135409
classifications O 0 0.00026199842
, O 0 0.00032131217
at O 0 0.00014604893
high O 0 0.00031045533
risk O 0 0.0015709896
to O 0 0.00026946372
die O 0 0.00057771994
and O 0 0.00035834027
to O 0 0.00037531115
develop O 0 0.00075187965
drug O 0 0.011739575
resistance O 0 0.0050751707
. O 0 0.0032382356

Notwithstanding O 0 0.002597116
these O 0 0.0016520952
facts O 0 0.002385645
our O 0 0.0007124083
findings O 0 0.0006159754
suggest O 0 0.00024347671
that O 0 0.00024664827
these O 0 0.0002696511
patients O 0 0.00043996915
might O 0 8.5353335e-05
benefit O 0 0.00014467533
from O 0 0.000119898315
relatively O 0 0.00024201212
mild O 0 0.0054456783
initial O 0 0.00010926304
treatment O 0 0.00013690247
, O 0 0.00023804346
especially O 0 0.00015145398
true O 0 0.00017205827
for O 0 0.00012433961
patients O 0 0.0003693438
not O 0 0.00017651709
previously O 0 0.00029759904
exposed O 0 0.000444709
to O 0 0.00047526747
this O 0 0.0010496735
drug O 0 0.024260718
. O 0 0.002892143

Close O 0 0.006335102
observation O 0 0.0016006206
of O 0 0.0011486051
the O 0 0.0006003598
response O 0 0.0004574234
status O 0 0.0003791295
both O 0 0.00030536
clinically O 0 0.0009085762
and O 0 0.0002929237
with O 0 0.0004199204
beta O 0 0.9070606
- O 0 0.24846175
hCG O 0 0.9742318
values O 0 0.00018690868
may O 0 7.739679e-05
indicate O 0 4.032584e-05
whether O 0 3.5637113e-05
and O 0 0.00010761317
when O 0 8.703697e-05
more O 0 0.00024368944
agressive O 0 0.008192558
combination O 0 0.0002408575
chemotherapy O 0 0.001083994
should O 0 8.752353e-05
be O 0 0.0001765144
started O 0 0.00028349846
. O 0 0.00036244112
( O 0 0.00089705846
ABSTRACT O 0 0.005644116
TRUNCATED O 0 0.014581995
AT O 0 0.012051304
250 O 0 0.005342103
WORDS O 0 0.025537632
) O 0 0.015730442

Pulmonary O 0 0.021621998
shunt O 0 0.0082723955
and O 0 0.0016883822
cardiovascular O 0 0.010927
responses O 0 0.00080058735
to O 0 0.00075945596
CPAP O 0 0.30120423
during O 0 0.0011814462
nitroprusside B-Chemical 0 0.9999707
- O 0 0.015976228
induced O 0 0.0024831623
hypotension B-Disease 0 0.99952424
. O 0 0.0052797985

The O 0 0.0015258829
effects O 0 0.001173929
of O 0 0.00097439834
continuous O 0 0.00058282976
positive O 0 0.00056513835
airway O 0 0.0012851977
pressure O 0 0.004245639
( O 0 0.00084916555
CPAP O 0 0.12310053
) O 0 0.0005227619
on O 0 0.00014640336
cardiovascular O 0 0.004080608
dynamics O 0 0.00016486757
and O 0 0.00023257616
pulmonary O 0 0.031492814
shunt O 0 0.0033090238
( O 0 0.0005290701
QS O 0 0.010216014
/ O 0 0.0026148686
QT O 0 0.9527627
) O 0 0.00041063808
were O 0 9.0394096e-05
investigated O 0 8.2896266e-05
in O 0 8.207828e-05
12 O 0 6.0194532e-05
dogs O 0 0.00012391787
before O 0 4.142711e-05
and O 0 9.687012e-05
during O 0 0.00013932792
sodium B-Chemical 1 0.99991214
nitroprusside I-Chemical 1 0.99999845
infusion O 0 0.0008389297
that O 0 7.9416095e-05
decreased O 0 0.00018665577
mean O 0 0.00013629926
arterial O 0 0.0771623
blood O 0 0.0025512765
pressure O 0 0.0046463995
40 O 0 0.00047683576
- O 0 0.0015382452
50 O 0 0.0007526141
per O 0 0.00078987086
cent O 0 0.0022601117
. O 0 0.0026305176

Before O 0 0.0057911323
nitroprusside B-Chemical 0 0.9998536
infusion O 0 0.006875525
, O 0 0.0018226989
5 O 0 0.00078178465
cm O 0 0.002896902
H2O B-Chemical 0 0.99289703
CPAP O 0 0.47562733
significantly O 0 0.0005009305
, O 0 0.0006297373
P O 0 0.01034962
less O 0 0.00037011865
than O 0 0.0002171281
. O 0 0.00025438648
05 O 0 0.0037131328
, O 0 0.00039681423
decreased O 0 0.0003839909
arterial O 0 0.281072
blood O 0 0.00639808
pressure O 0 0.024051921
, O 0 0.0005134932
but O 0 0.00023442734
did O 0 0.00018664297
not O 0 0.0001391378
significantly O 0 0.00021603507
alter O 0 0.00016747761
heart O 0 0.008323733
rate O 0 0.00029115516
, O 0 0.0003357977
cardiac O 0 0.0006882875
output O 0 0.00024998694
, O 0 0.0005562103
systemic O 0 0.22171114
vascular O 0 0.9141485
resistance O 0 0.0024975627
, O 0 0.001157483
or O 0 0.0008057949
QS O 0 0.08929735
/ O 0 0.019021658
QT O 0 0.9840635
. O 0 0.0035805334

Ten O 0 0.0044614663
cm O 0 0.0112129655
H2O B-Chemical 0 0.994156
CPAP O 0 0.6867956
before O 0 0.0008491501
nitroprusside B-Chemical 0 0.9999542
infusion O 0 0.0015362634
produced O 0 0.00021672128
a O 0 0.00026853045
further O 0 0.0001373088
decrease B-Disease 0 0.00018208129
in I-Disease 0 0.0001615022
arterial I-Disease 0 0.15834329
blood I-Disease 0 0.0023515408
pressure I-Disease 0 0.0028207465
and O 0 0.00014803837
significantly O 0 0.00017201104
increased O 0 0.00026449925
heart O 0 0.0069753556
rate O 0 0.000296275
and O 0 0.00025182226
decreased B-Disease 0 0.00086769153
cardiac I-Disease 0 0.0016603834
output I-Disease 0 0.00076878583
and O 0 0.0008439899
QS O 0 0.06117918
/ O 0 0.015970545
QT O 0 0.9827739
. O 0 0.0036270288

Nitroprusside B-Chemical 0 0.9996486
caused O 0 0.0021955331
significant O 0 0.0010618404
decreases B-Disease 0 0.0008193283
in I-Disease 0 0.0005411849
arterial I-Disease 0 0.1544179
blood I-Disease 0 0.0031941812
pressure I-Disease 0 0.0036763912
and O 0 0.00032360025
systemic O 0 0.11128591
vascular O 0 0.79179424
resistance O 0 0.00078306295
and O 0 0.00017086837
increases O 0 0.00015164139
in O 0 0.0001726815
heart O 0 0.01569195
rate O 0 0.000359312
, O 0 0.00045351955
but O 0 0.00026306923
did O 0 0.00024150552
not O 0 0.00021152927
change O 0 0.00029052293
cardiac O 0 0.001117493
output O 0 0.00050664827
or O 0 0.00065019465
QS O 0 0.041002024
/ O 0 0.014375469
QT O 0 0.9806793
. O 0 0.0035946937

Five O 0 0.0050815507
cm O 0 0.014603863
H2O B-Chemical 0 0.9963064
CPAP O 0 0.9269996
during O 0 0.0020599146
nitroprusside B-Chemical 0 0.99997735
did O 0 0.00094704906
not O 0 0.00039787593
further O 0 0.00031288568
alter O 0 0.0003103808
any O 0 0.00028493436
of O 0 0.0003853646
the O 0 0.00036563445
above O 0 0.0006235068
- O 0 0.0026796316
mentioned O 0 0.0007588884
variables O 0 0.0017474681
. O 0 0.0029064794

However O 0 0.0038487671
, O 0 0.004580245
10 O 0 0.0022024852
cm O 0 0.0064934846
H2O B-Chemical 0 0.9926104
CPAP O 0 0.5271204
decreased O 0 0.0014488919
arterial O 0 0.14102603
blood O 0 0.004030904
pressure O 0 0.0050871205
, O 0 0.0009991485
cardiac O 0 0.0015277002
output O 0 0.0007503945
, O 0 0.0013343964
and O 0 0.001436397
QS O 0 0.048109118
/ O 0 0.017953197
QT O 0 0.97729295
. O 0 0.0050735925

These O 0 0.0018792158
data O 0 0.0016016953
indicate O 0 0.0006370233
that O 0 0.00100646
nitroprusside B-Chemical 0 0.9999721
infusion O 0 0.0023792314
rates O 0 0.0003179668
that O 0 0.00014588553
decrease O 0 0.00018363392
mean O 0 0.0001578078
arterial O 0 0.04281387
blood O 0 0.0017257786
pressure O 0 0.0021514378
by O 0 0.00017051876
40 O 0 0.00022307812
- O 0 0.0008353692
50 O 0 0.00023108986
per O 0 0.0001679031
cent O 0 0.00033225247
do O 0 0.00017808152
not O 0 0.00019680429
change O 0 0.00028767216
cardiac O 0 0.001069022
output O 0 0.0005431367
or O 0 0.0007053656
QS O 0 0.038468394
/ O 0 0.014683104
QT O 0 0.9800884
. O 0 0.0038153785

During O 0 0.0034885295
nitroprusside B-Chemical 0 0.9998721
infusion O 0 0.00404752
low O 0 0.0008700067
levels O 0 0.000443859
of O 0 0.0006106775
CPAP O 0 0.59171
do O 0 0.00034594408
not O 0 0.00025322154
markedly O 0 0.00067402987
alter O 0 0.00022950122
cardiovascular O 0 0.0910492
dynamics O 0 0.00019395519
, O 0 0.00037898932
but O 0 0.00017589478
high O 0 0.00016972117
levels O 0 0.00013035086
of O 0 0.00023105284
CPAP O 0 0.3326609
( O 0 0.00031509818
10 O 0 0.00016075843
cm O 0 0.0010063555
H2O B-Chemical 0 0.9936381
) O 0 0.0007081098
, O 0 0.00030337746
while O 0 0.00016709097
decreasing O 0 0.00028991612
QS O 0 0.049276862
/ O 0 0.0062042256
QT O 0 0.9771185
, O 0 0.00038134534
produce O 0 0.00012032793
marked O 0 0.00024847657
decreases B-Disease 0 0.00024157183
in I-Disease 0 0.00025323362
arterial I-Disease 0 0.30782908
blood I-Disease 0 0.004996215
pressure I-Disease 0 0.006052747
and I-Disease 0 0.00064992026
cardiac I-Disease 0 0.00234829
output I-Disease 0 0.0015206835
. O 0 0.002399504

Systolic O 0 0.13724898
pressure O 0 0.013379732
variation O 0 0.0014598652
is O 0 0.0006473017
greater O 0 0.00073938264
during O 0 0.0005976435
hemorrhage B-Disease 2 0.9994547
than O 0 0.0004271307
during O 0 0.0004787753
sodium B-Chemical 1 0.9998785
nitroprusside I-Chemical 1 0.999998
- O 0 0.038818043
induced O 0 0.0008282626
hypotension B-Disease 0 0.9997204
in O 0 0.0009269932
ventilated O 0 0.0051643467
dogs O 0 0.0027561996
. O 0 0.00264968

The O 0 0.0019130337
systolic O 0 0.0153185185
pressure O 0 0.01050108
variation O 0 0.0014711489
( O 0 0.0019354692
SPV O 0 0.45082796
) O 0 0.001726201
, O 0 0.0007851731
which O 0 0.00034701565
is O 0 0.0001746214
the O 0 0.00013050956
difference O 0 0.00010691539
between O 0 9.755323e-05
the O 0 0.00010909689
maximal O 0 0.00016836256
and O 0 0.00010595253
minimal O 0 8.2062805e-05
values O 0 8.6770284e-05
of O 0 9.012161e-05
the O 0 8.0890844e-05
systolic O 0 0.018475277
blood O 0 0.0015979207
pressure O 0 0.0024573924
( O 0 0.0002841322
SBP O 0 0.008479395
) O 0 0.00026668093
after O 0 5.690835e-05
one O 0 8.9823196e-05
positive O 0 0.0001737922
- O 0 0.0012272315
pressure O 0 0.0065661836
breath O 0 0.004042172
, O 0 0.00042121415
was O 0 0.00018631882
studied O 0 0.00027365016
in O 0 0.00023603791
ventilated O 0 0.0012115614
dogs O 0 0.00058754714
subjected O 0 0.00034205988
to O 0 0.0008797227
hypotension B-Disease 0 0.9993333
. O 0 0.0030868924

Mean O 0 0.002697275
arterial O 0 0.032772627
pressure O 0 0.008483838
was O 0 0.00092236476
decreased O 0 0.0008695762
to O 0 0.00037687473
50 O 0 0.00044804133
mm O 0 0.0010841634
Hg O 0 0.28054652
for O 0 0.00020249576
30 O 0 0.00016872963
minutes O 0 0.00015482462
either O 0 0.00017581598
by O 0 0.0003365637
hemorrhage B-Disease 2 0.9998323
( O 0 0.0018477557
HEM B-Disease 0 0.9997631
, O 0 0.00039323527
n O 0 0.00021160372
= O 0 0.00038236243
7 O 0 0.00010948706
) O 0 0.00022732171
or O 0 9.1301285e-05
by O 0 9.859335e-05
continuous O 0 0.00012429965
infusion O 0 0.000499179
of O 0 0.00047212842
sodium B-Chemical 1 0.99993336
nitroprusside I-Chemical 1 0.9999982
( O 0 0.0022908037
SNP B-Chemical 0 0.0120327985
, O 0 0.0007994469
n O 0 0.00069121044
= O 0 0.0016452278
7 O 0 0.0009144826
) O 0 0.0029142504
. O 0 0.003199929

During O 0 0.0052525396
HEM B-Disease 0 0.9993881
- O 0 0.025921704
induced O 0 0.0016479366
hypotension B-Disease 0 0.9996581
the O 0 0.00047531666
cardiac O 0 0.0011473561
output O 0 0.00025625454
was O 0 0.00015207203
significantly O 0 0.0001730001
lower O 0 0.00019419611
and O 0 0.00021767723
systemic O 0 0.12614888
vascular O 0 0.799243
resistance O 0 0.0006575192
higher O 0 0.00018279241
compared O 0 0.00012267436
with O 0 0.00021705545
that O 0 0.00021443378
in O 0 0.00039137306
the O 0 0.0006152305
SNP B-Chemical 0 0.026783688
group O 0 0.002365784
. O 0 0.002885748

The O 0 0.0030495813
systemic O 0 0.042825986
, O 0 0.0030149193
central O 0 0.0019987521
venous O 0 0.17685579
, O 0 0.0014289675
pulmonary O 0 0.07822808
capillary O 0 0.34972686
wedge O 0 0.86022675
pressures O 0 0.0026259904
, O 0 0.00056585687
and O 0 0.00031627284
heart O 0 0.0037432697
rates O 0 0.00035843046
, O 0 0.0004989305
were O 0 0.00025191062
similar O 0 0.00021060514
in O 0 0.0003471616
the O 0 0.00043759673
two O 0 0.00058386836
groups O 0 0.001813659
. O 0 0.0031982425

Analysis O 0 0.0039367215
of O 0 0.002080235
the O 0 0.001303942
respiratory O 0 0.0030482693
changes O 0 0.0006399677
in O 0 0.00040544217
the O 0 0.00035063011
arterial O 0 0.029010983
pressure O 0 0.00305344
waveform O 0 0.0005960475
enabled O 0 0.00040695097
differentiation O 0 0.0008360469
between O 0 0.00039557274
the O 0 0.00053160335
two O 0 0.00065841596
groups O 0 0.0019618883
. O 0 0.003410955

The O 0 0.003472639
SPV O 0 0.3037369
during O 0 0.0022731773
hypotension B-Disease 0 0.99917126
was O 0 0.00091481063
15 O 0 0.00052043167
. O 0 0.00036570764
7 O 0 0.00030882997
+ O 0 0.0010653113
/ O 0 0.0016883516
- O 0 0.0013601758
6 O 0 0.00018704258
. O 0 0.00017073369
7 O 0 0.0001421201
mm O 0 0.0006356121
Hg O 0 0.39005396
in O 0 0.00026919207
the O 0 0.00030293124
HEM B-Disease 0 0.999701
group O 0 0.0004057664
, O 0 0.00030470217
compared O 0 0.00011296917
with O 0 0.00016580241
9 O 0 0.0001482532
. O 0 0.00014853367
1 O 0 0.00019335582
+ O 0 0.000676889
/ O 0 0.0013357946
- O 0 0.0012239412
2 O 0 0.00018850729
. O 0 0.00013315439
0 O 0 0.00017878914
mm O 0 0.00061291375
Hg O 0 0.40678295
in O 0 0.00021581953
the O 0 0.00020428884
SNP B-Chemical 0 0.0028092861
group O 0 0.00042770055
( O 0 0.00061625865
P O 0 0.010361138
less O 0 0.00050202245
than O 0 0.00039355233
0 O 0 0.0008045641
. O 0 0.0009894511
02 O 0 0.014420927
) O 0 0.004226644
. O 0 0.0037656445

The O 0 0.0028505938
delta O 0 0.011413329
down O 0 0.0020471038
, O 0 0.0022236216
which O 0 0.0008660655
is O 0 0.0003857864
the O 0 0.00025987084
measure O 0 0.0001766823
of O 0 0.00025252427
decrease O 0 0.00024585635
of O 0 0.00024926628
SBP O 0 0.009441854
after O 0 0.0001135774
a O 0 0.00023255109
mechanical O 0 0.0002662303
breath O 0 0.0015390277
, O 0 0.00035414263
was O 0 0.00015266436
20 O 0 0.0001530277
. O 0 0.0001254827
3 O 0 0.0001287837
+ O 0 0.0005701694
/ O 0 0.0011452881
- O 0 0.001132185
8 O 0 0.00015546978
. O 0 0.00012840294
4 O 0 0.000103596256
and O 0 0.00013481293
10 O 0 0.0001482962
. O 0 0.00014225974
1 O 0 0.00018899646
+ O 0 0.0006427936
/ O 0 0.0011924173
- O 0 0.0010113361
3 O 0 0.00013327951
. O 0 0.00011450226
8 O 0 0.00011155145
mm O 0 0.0005166728
Hg O 0 0.45892048
in O 0 0.0002281677
the O 0 0.00028026119
HEM B-Disease 0 0.9997688
and O 0 0.0003256444
SNP B-Chemical 0 0.0058287783
groups O 0 0.00026660113
, O 0 0.00035613426
respectively O 0 0.00038029545
, O 0 0.00036435723
during O 0 0.00022351906
hypotension B-Disease 0 0.99974996
( O 0 0.0007241975
P O 0 0.012555458
less O 0 0.0004344669
than O 0 0.00034579769
0 O 0 0.00072664017
. O 0 0.00090261054
02 O 0 0.0142287975
) O 0 0.0039691785
. O 0 0.0035386106

It O 0 0.0050987056
is O 0 0.0015902057
concluded O 0 0.0012041074
that O 0 0.00066211465
increases O 0 0.0006355888
in O 0 0.0004929439
the O 0 0.0004313668
SPV O 0 0.29793495
and O 0 0.00034209655
the O 0 0.00022416573
delta O 0 0.0022086473
down O 0 0.0002471327
are O 0 0.00015435043
characteristic O 0 0.00018843902
of O 0 0.00022178868
a O 0 0.0005602241
hypotensive B-Disease 0 0.99703634
state O 0 0.00031589315
due O 0 0.000164838
to O 0 0.000225939
a O 0 0.00049788144
predominant O 0 0.00053254445
decrease O 0 0.0007506912
in O 0 0.0011121861
preload O 0 0.72750294
. O 0 0.0034296464

They O 0 0.004827829
are O 0 0.0017015589
thus O 0 0.0013692856
more O 0 0.0013006098
important O 0 0.00055900373
during O 0 0.0005477306
absolute O 0 0.0011523833
hypovolemia B-Disease 0 0.9985039
than O 0 0.0008791396
during O 0 0.0009129985
deliberate O 0 0.017199922
hypotension B-Disease 0 0.9995246
. O 0 0.005194969

Ventricular B-Disease 0 0.91568077
tachyarrhythmias I-Disease 0 0.99917287
during O 0 0.0011658253
cesarean O 0 0.0008940102
section O 0 0.00048377598
after O 0 0.0004195811
ritodrine B-Chemical 0 0.99790984
therapy O 0 0.0011263497
: O 0 0.0011801723
interaction O 0 0.0007021788
with O 0 0.0017664789
anesthetics O 0 0.65535414
. O 0 0.0046106707

This O 0 0.0039733243
case O 0 0.0015606618
illustrates O 0 0.00059314957
that O 0 0.00042454753
patients O 0 0.0007701581
receiving O 0 0.00063171465
ritodrine B-Chemical 0 0.9997873
for O 0 0.00031432346
preterm B-Disease 0 0.8800751
labor I-Disease 0 0.24044609
may O 0 0.00016840448
risk O 0 0.0006940008
interactions O 0 9.607584e-05
between O 0 7.632371e-05
the O 0 8.507981e-05
residual O 0 0.00014215168
betamimetic O 0 0.016412651
effects O 0 0.000113323375
of O 0 0.00024258878
ritodrine B-Chemical 0 0.9999261
and O 0 0.00017032961
the O 0 9.8784e-05
effects O 0 0.00014515678
of O 0 0.00029322295
anesthetics O 0 0.21652442
during O 0 0.00029699842
cesarean O 0 0.0005956917
section O 0 0.0007616269
. O 0 0.0018460011

Such O 0 0.0040401993
interactions O 0 0.0020114053
may O 0 0.0011591454
result O 0 0.0007943537
in O 0 0.00071213034
serious O 0 0.0022359043
cardiovascular B-Disease 0 0.95880795
complications I-Disease 0 0.4000985
even O 0 0.0003838522
after O 0 0.00014968647
cessation O 0 0.0002633882
of O 0 0.00034586515
an O 0 0.00052698486
infusion O 0 0.0014541653
of O 0 0.0015148888
ritodrine B-Chemical 0 0.9995604
. O 0 0.0041073286

Preoperative O 0 0.0042168614
assessment O 0 0.0016820079
should O 0 0.0008194213
focus O 0 0.0012118511
on O 0 0.00083239505
cardiovascular O 0 0.03585315
status O 0 0.0012800058
and O 0 0.0018635076
serum O 0 0.26058087
potassium B-Chemical 0 0.99836963
level O 0 0.0039646723
. O 0 0.005529401

Delaying O 0 0.005296378
induction O 0 0.0020925617
of O 0 0.0022956294
anesthesia O 0 0.006506205
should O 0 0.0008700901
be O 0 0.0011339211
considered O 0 0.0012592018
whenever O 0 0.0017600482
possible O 0 0.0024457634
. O 0 0.0055688974

Careful O 0 0.002697524
fluid O 0 0.003972739
administration O 0 0.0019217335
and O 0 0.00094561366
cautious O 0 0.001175467
use O 0 0.00049257523
of O 0 0.0005688955
titrated O 0 0.00079817604
doses O 0 0.0015383594
of O 0 0.0015992259
ephedrine B-Chemical 0 0.9998647
are O 0 0.0015991452
advised O 0 0.0029659576
. O 0 0.0036057814

After O 0 0.0015487936
delivery O 0 0.0014550684
of O 0 0.0012032279
the O 0 0.0008068456
infant O 0 0.001875583
, O 0 0.00087942765
there O 0 0.00027452715
should O 0 0.00015440446
be O 0 0.0001694382
no O 0 0.00013323873
contraindication O 0 0.00013193274
to O 0 0.00010305317
the O 0 9.67146e-05
use O 0 0.00011156752
of O 0 0.00018362429
an O 0 0.00033584764
alpha O 0 0.8233492
- O 0 0.11183301
adrenergic O 0 0.93475145
vasopressor O 0 0.20807636
such O 0 0.00015703803
as O 0 0.00028027457
phenylephrine B-Chemical 0 0.9999441
to O 0 0.0003046264
treat O 0 0.0012287479
hypotensive B-Disease 0 0.9984382
patients O 0 0.0017071066
with O 0 0.0012559036
tachycardia B-Disease 2 0.99838185
. O 0 0.0030713857

Verapamil B-Chemical 0 0.9997819
- O 0 0.53486025
induced O 0 0.028663367
carbamazepine B-Chemical 1 0.9999809
neurotoxicity B-Disease 0 0.9991398
. O 0 0.017928137

A O 0 0.05182715
report O 0 0.014214506
of O 0 0.008658619
two O 0 0.0065844823
cases O 0 0.014401187
. O 0 0.01500874

Two O 0 0.002237477
patients O 0 0.0026338138
with O 0 0.0012632207
signs O 0 0.004850742
of O 0 0.0024844015
carbamazepine B-Chemical 1 0.9999989
neurotoxicity B-Disease 0 0.9994246
after O 0 0.0001295777
combined O 0 0.00018399218
treatment O 0 0.00016358258
with O 0 0.00030360834
verapamil B-Chemical 0 0.9999924
showed O 0 0.00018121306
complete O 0 0.00010430679
recovery O 0 0.00015697742
after O 0 7.528624e-05
discontinuation O 0 0.00076463184
of O 0 0.00025107161
the O 0 0.00039279877
calcium B-Chemical 0 0.9895224
entry O 0 0.0018360242
blocker O 0 0.76171786
. O 0 0.0038670355

Use O 0 0.0063091014
of O 0 0.0039406293
verapamil B-Chemical 0 0.99995565
in O 0 0.00120827
combination O 0 0.0011236687
with O 0 0.0019162074
carbamazepine B-Chemical 1 0.99999845
should O 0 0.0001849416
either O 0 0.00016988454
be O 0 0.0001193361
avoided O 0 0.00011108589
or O 0 0.00010063778
prescribed O 0 0.00044117155
only O 0 9.236474e-05
with O 0 8.219468e-05
appropriate O 0 5.6952264e-05
adjustment O 0 7.338531e-05
of O 0 0.00010340064
the O 0 0.00018230714
carbamazepine B-Chemical 1 0.99999857
dose O 0 0.00068080897
( O 0 0.0002707392
usually O 0 0.00013388135
reduction O 0 0.00015220462
of O 0 0.00019396037
the O 0 0.00035236904
carbamazepine B-Chemical 1 0.99999774
dose O 0 0.0010986186
by O 0 0.00034828982
one O 0 0.00041691813
half O 0 0.00065631996
) O 0 0.002864079
. O 0 0.00268693

Paracetamol B-Chemical 0 0.99979085
- O 0 0.15673886
associated O 0 0.005792989
coma B-Disease 0 0.99962294
, O 0 0.012314976
metabolic B-Disease 2 0.9905205
acidosis I-Disease 2 0.99997866
, O 0 0.011946545
renal B-Disease 0 0.9383139
and I-Disease 0 0.0022250419
hepatic I-Disease 0 0.96691304
failure I-Disease 0 0.21394666
. O 0 0.004264858

A O 0 0.034978013
case O 0 0.003756295
of O 0 0.0036453477
metabolic B-Disease 2 0.99047893
acidosis I-Disease 2 0.99998415
, O 0 0.008183473
acute B-Disease 0 0.41437638
renal I-Disease 0 0.93334746
failure I-Disease 0 0.031631324
and I-Disease 0 0.00042571672
hepatic I-Disease 0 0.888829
failure I-Disease 0 0.033982076
following O 0 0.000355048
paracetamol B-Chemical 0 0.9999007
ingestion O 0 0.009827433
is O 0 0.0006482926
presented O 0 0.0010537324
. O 0 0.0022478686

The O 0 0.0032392237
diagnostic O 0 0.0033630482
difficulty O 0 0.0044449973
at O 0 0.0024872122
presentation O 0 0.0042585726
is O 0 0.0028994428
highlighted O 0 0.0035435236
. O 0 0.007874929

Continuous O 0 0.004888963
arteriovenous O 0 0.7638515
haemofiltration O 0 0.64664066
proved O 0 0.0014540337
a O 0 0.00092098245
valuable O 0 0.00047870365
means O 0 0.00046686298
of O 0 0.00060144224
maintaining O 0 0.0006368436
fluid O 0 0.0026113382
and O 0 0.001493987
electrolyte O 0 0.056380026
balance O 0 0.0039266823
. O 0 0.004530511

The O 0 0.013068909
patient O 0 0.015843568
recovered O 0 0.015043059
. O 0 0.023111733

Sexual B-Disease 0 0.3067016
dysfunction I-Disease 0 0.9763484
among O 0 0.0074485
patients O 0 0.00983303
with O 0 0.007843448
arthritis B-Disease 0 0.9932614
. O 0 0.012729525

The O 0 0.0016251024
relationship O 0 0.0010757928
of O 0 0.0018834566
arthritis B-Disease 0 0.99771774
and O 0 0.0015952915
sexual B-Disease 0 0.48097932
dysfunction I-Disease 0 0.9968761
was O 0 0.0003310737
investigated O 0 0.00018931807
among O 0 0.00022405248
169 O 0 0.00051754026
patients O 0 0.00043860523
with O 0 0.0004093602
rheumatoid B-Disease 0 0.9999645
arthritis I-Disease 0 0.99997556
, O 0 0.0039886227
osteoarthritis B-Disease 0 0.99952066
and O 0 0.0005103207
spondyloarthropathy B-Disease 0 0.9998385
, O 0 0.00057785236
130 O 0 0.00038495957
of O 0 0.0002020254
whom O 0 0.0003499802
were O 0 0.00020264392
pair O 0 0.00028973128
- O 0 0.0013558799
matched O 0 0.00038703514
to O 0 0.00065985764
controls O 0 0.0020075247
. O 0 0.0029481873

Assessments O 0 0.0027124109
of O 0 0.0019479397
marital O 0 0.0051983832
happiness O 0 0.12952773
and O 0 0.0032118126
depressed B-Disease 2 0.99988055
mood I-Disease 0 0.9998155
were O 0 0.00048532142
also O 0 0.00026606937
made O 0 0.00025449684
using O 0 0.000229052
the O 0 0.0003458686
CES O 0 0.6980269
- O 0 0.0055974973
D O 0 0.4413033
and O 0 0.00047934084
the O 0 0.00040927512
Azrin O 0 0.0034487678
Marital O 0 0.019278375
Happiness O 0 0.009394733
Scale O 0 0.011492559
( O 0 0.0030254466
AMHS O 0 0.32000214
) O 0 0.0055632386
. O 0 0.0047293636

Sexual B-Disease 0 0.45962697
dysfunctions I-Disease 0 0.9801282
were O 0 0.0016334505
found O 0 0.0008685981
to O 0 0.000498206
be O 0 0.00037213534
common O 0 0.00032409822
among O 0 0.00030771844
patients O 0 0.00045673456
and O 0 0.00021681657
controls O 0 0.00032424196
, O 0 0.00032658613
the O 0 0.00013039637
majority O 0 0.00012842719
in O 0 0.00014169846
both O 0 0.000149602
groups O 0 0.00027216732
reporting O 0 0.0003176499
one O 0 0.00030363587
or O 0 0.00048294343
more O 0 0.001459954
dysfunctions O 0 0.47620636
. O 0 0.0034276783

Impotence B-Disease 2 0.9493439
was O 0 0.0021823717
more O 0 0.0015861887
common O 0 0.0008079874
among O 0 0.0006204498
male O 0 0.0010117693
patients O 0 0.00063028635
than O 0 0.00021724387
controls O 0 0.0003295172
and O 0 0.0002370121
was O 0 0.0001815148
found O 0 0.00016974239
to O 0 0.00014318789
be O 0 0.00015238325
associated O 0 0.00018788392
with O 0 0.00027171208
co O 0 0.03139022
- O 0 0.00833801
morbidity O 0 0.0050085783
and O 0 0.00030482217
the O 0 0.0003063514
taking O 0 0.00072563475
of O 0 0.0016285582
methotrexate B-Chemical 0 0.99985063
. O 0 0.004211334

Depressed B-Disease 0 0.9998018
mood I-Disease 0 0.9995129
was O 0 0.0018815787
more O 0 0.001281225
common O 0 0.00066929363
among O 0 0.00055484654
patients O 0 0.0007588757
and O 0 0.00032949145
was O 0 0.0002471513
associated O 0 0.00025812502
with O 0 0.0002661785
certain O 0 0.0003197256
sexual O 0 0.0019478375
difficulties O 0 0.0031766365
, O 0 0.0010591203
but O 0 0.00070877955
not O 0 0.00074166805
with O 0 0.0018525477
impotence B-Disease 0 0.9633649
. O 0 0.004474854

Marital O 0 0.58305764
unhappiness O 0 0.93066597
, O 0 0.0040709553
as O 0 0.001242995
indicated O 0 0.0006234867
by O 0 0.0008728336
AMHS O 0 0.52189845
scores O 0 0.00049520965
, O 0 0.00058143213
was O 0 0.00024229474
not O 0 0.00019820122
associated O 0 0.00025822295
with O 0 0.0004088316
arthritis B-Disease 0 0.99921286
but O 0 0.00037276506
was O 0 0.0001707384
associated O 0 0.00019190849
with O 0 0.000270036
sexual B-Disease 0 0.29071465
dysfunction I-Disease 0 0.9987476
, O 0 0.00120109
sexual O 0 0.003116177
dissatisfaction O 0 0.004312197
and O 0 0.00063205016
being O 0 0.0009039953
female O 0 0.0029245687
. O 0 0.003032681

Does O 0 0.015161354
paracetamol B-Chemical 0 0.9997664
cause O 0 0.01982916
urothelial B-Disease 0 0.99881065
cancer I-Disease 0 0.99902165
or O 0 0.006463581
renal B-Disease 2 0.9986627
papillary I-Disease 2 0.9982948
necrosis I-Disease 2 0.9999639
? O 0 0.090381294

The O 0 0.0025966056
risk O 0 0.0070402985
of O 0 0.0020834012
developing O 0 0.0065650507
renal B-Disease 2 0.9993006
papillary I-Disease 2 0.9994816
necrosis I-Disease 2 0.999997
or O 0 0.0011089763
cancer B-Disease 0 0.9302139
of I-Disease 0 0.00029936538
the I-Disease 0 0.00019639001
renal I-Disease 0 0.5714496
pelvis I-Disease 0 0.010335081
, I-Disease 0 0.00037739967
ureter I-Disease 0 0.0024887577
or I-Disease 0 0.00012910865
bladder I-Disease 0 0.0017222678
associated O 0 0.000117055555
with O 0 0.00012745438
consumption O 0 0.0012984977
of O 0 0.00017199971
either O 0 0.00032276622
phenacetin B-Chemical 0 0.999998
or O 0 0.00047237554
paracetamol B-Chemical 0 0.9999807
was O 0 0.00011183433
calculated O 0 7.718937e-05
from O 0 7.870095e-05
data O 0 0.00011917246
acquired O 0 0.0002199387
by O 0 0.00013002439
questionnaire O 0 0.00013362792
from O 0 0.00020734327
381 O 0 0.0011877222
cases O 0 0.00080763915
and O 0 0.00089083763
808 O 0 0.019803857
controls O 0 0.0025879177
. O 0 0.003266317

The O 0 0.0027568645
risk O 0 0.00864636
of O 0 0.0034995733
renal B-Disease 2 0.998836
papillary I-Disease 2 0.99924004
necrosis I-Disease 2 0.9999944
was O 0 0.0007278398
increased O 0 0.00047287694
nearly O 0 0.00028572298
20 O 0 0.00025574784
- O 0 0.0009091079
fold O 0 0.00020166628
by O 0 0.00018009513
consumption O 0 0.002493885
of O 0 0.00061463745
phenacetin B-Chemical 0 0.99999774
, O 0 0.0009242922
which O 0 0.00017352692
also O 0 0.00010838163
increased O 0 0.00017384357
the O 0 0.00011375017
risk O 0 0.0012143378
for O 0 0.00015290329
cancer B-Disease 0 0.83047336
of I-Disease 0 0.00020746527
the I-Disease 0 0.00016871885
renal I-Disease 0 0.7370766
pelvis I-Disease 0 0.018764103
and I-Disease 0 0.00031901922
bladder I-Disease 0 0.009651032
but O 0 0.00038145517
not O 0 0.0003828676
for O 0 0.0007026461
ureteric B-Disease 0 0.9761253
cancer I-Disease 0 0.9991381
. O 0 0.005574092

By O 0 0.002389461
contrast O 0 0.0028112342
, O 0 0.0022741433
we O 0 0.00056194555
were O 0 0.00052447466
unable O 0 0.00031335166
to O 0 0.00026778414
substantiate O 0 0.00025424053
an O 0 0.00031549978
increased O 0 0.00039571134
risk O 0 0.002401419
from O 0 0.00036154693
paracetamol B-Chemical 0 0.9999739
consumption O 0 0.016658416
for O 0 0.00023830347
renal B-Disease 2 0.99931026
papillary I-Disease 2 0.99951804
necrosis I-Disease 2 0.9999987
or O 0 0.00020267387
any O 0 0.00010131468
of O 0 0.00013929165
these O 0 0.00019070548
cancers B-Disease 0 0.9595657
although O 0 0.00014341295
there O 0 9.96496e-05
was O 0 0.00013182635
a O 0 0.00022211201
suggestion O 0 0.0002510221
of O 0 0.00020658688
an O 0 0.00023619276
association O 0 0.00018260707
with O 0 0.0005602866
cancer B-Disease 0 0.9407989
of I-Disease 0 0.0010158472
the I-Disease 0 0.0010354103
ureter I-Disease 0 0.047953855
. O 0 0.0031336902

Dapsone B-Chemical 0 0.99912685
- O 0 0.03429918
associated O 0 0.0032760066
Heinz O 0 0.2966904
body O 0 0.03146104
hemolytic B-Disease 0 0.9999794
anemia I-Disease 0 0.99998236
in O 0 0.0014223637
a O 0 0.0015801793
Cambodian O 0 0.0035681396
woman O 0 0.0037108506
with O 0 0.0018488219
hemoglobin O 0 0.99284303
E O 0 0.99919206
trait O 0 0.42222947
. O 0 0.0054197414

A O 0 0.060358357
Cambodian O 0 0.012005807
woman O 0 0.008099325
with O 0 0.0028600576
hemoglobin O 0 0.98913974
E O 0 0.99940526
trait O 0 0.18021445
( O 0 0.0021927652
AE O 0 0.36316213
) O 0 0.0012471415
and O 0 0.0005203883
leprosy B-Disease 0 0.9680236
developed O 0 0.00038414318
a O 0 0.00052735733
Heinz O 0 0.18131189
body O 0 0.00827573
hemolytic B-Disease 0 0.99999595
anemia I-Disease 0 0.9999957
while O 0 0.00027112747
taking O 0 0.00023961694
a O 0 0.00021593685
dose O 0 0.00031313303
of O 0 0.00032695994
dapsone B-Chemical 0 0.9999825
( O 0 0.00050294807
50 O 0 0.00025166143
mg O 0 0.0033757973
/ O 0 0.0006621245
day O 0 0.0001299297
) O 0 0.0004138126
not O 0 0.00020249191
usually O 0 0.0003573007
associated O 0 0.00044854323
with O 0 0.0008556405
clinical O 0 0.024555972
hemolysis B-Disease 0 0.99965656
. O 0 0.004491078

Her O 0 0.0075584967
red O 0 0.0052717007
blood O 0 0.009172921
cells O 0 0.002076393
( O 0 0.0025857007
RBCs O 0 0.004499221
) O 0 0.0014089554
had O 0 0.00044815944
increased O 0 0.0005297554
incubated O 0 0.0006145311
Heinz O 0 0.029801508
body O 0 0.00079816725
formation O 0 0.00071449525
, O 0 0.00091911224
decreased O 0 0.001595053
reduced O 0 0.017775917
glutathione B-Chemical 0 0.9999949
( O 0 0.63395333
GSH B-Chemical 1 0.99999774
) O 0 0.023033133
, O 0 0.0015553967
and O 0 0.0010906319
decreased O 0 0.010214364
GSH B-Chemical 1 0.99997985
stability O 0 0.0039044286
. O 0 0.0042728474

The O 0 0.0045193005
pentose B-Chemical 0 0.77888244
phosphate I-Chemical 0 0.90844417
shunt O 0 0.010485152
activity O 0 0.0006487617
of O 0 0.000742889
the O 0 0.00090118434
dapsone B-Chemical 0 0.9999645
- O 0 0.017841892
exposed O 0 0.00078187924
AE O 0 0.35370365
RBCs O 0 0.0023499506
was O 0 0.0003340011
increased O 0 0.00046835816
compared O 0 0.00034992583
to O 0 0.00063324155
normal O 0 0.0021746163
RBCs O 0 0.007406834
. O 0 0.0035409012

Although O 0 0.00233753
the O 0 0.0024427152
AE O 0 0.375172
RBCs O 0 0.0051388433
from O 0 0.00057615526
an O 0 0.00044128657
individual O 0 0.00024934256
not O 0 0.00027396868
taking O 0 0.0008239547
dapsone B-Chemical 0 0.9999546
had O 0 0.0002900223
increased O 0 0.0003281444
incubated O 0 0.00040771204
Heinz O 0 0.044171236
body O 0 0.0006474349
formation O 0 0.00063323556
, O 0 0.00092155655
the O 0 0.00082049216
GSH B-Chemical 1 0.99999595
content O 0 0.003909959
and O 0 0.0034454179
GSH B-Chemical 1 0.9999925
stability O 0 0.0012263183
were O 0 0.0010725934
normal O 0 0.0023064043
. O 0 0.0025754697

The O 0 0.004446992
pentose B-Chemical 0 0.78943044
phosphate I-Chemical 0 0.9113807
shunt O 0 0.009734555
activity O 0 0.0005690155
of O 0 0.00054889085
the O 0 0.00042383868
non O 0 0.0011390091
- O 0 0.11213174
dapsone B-Chemical 0 0.99997544
- O 0 0.015599836
exposed O 0 0.0006646956
AE O 0 0.35258165
RBCs O 0 0.00227054
was O 0 0.00031764474
decreased O 0 0.000563064
compared O 0 0.00034676908
to O 0 0.000617788
normal O 0 0.002138593
RBCs O 0 0.007360911
. O 0 0.0034483776

Thus O 0 0.0034485708
, O 0 0.007821556
AE O 0 0.77164406
RBCs O 0 0.011023807
appear O 0 0.0007214005
to O 0 0.00041238824
have O 0 0.00030466728
an O 0 0.00032028055
increased O 0 0.00034979507
sensitivity O 0 0.00049411214
to O 0 0.00034767427
oxidant O 0 0.9707473
stress O 0 0.022884201
both O 0 0.00014419248
in O 0 0.00011784265
vitro O 0 0.00011556704
and O 0 0.000120928016
in O 0 0.000108373366
vivo O 0 0.00014728212
, O 0 0.00037970862
since O 0 0.00020799055
dapsone B-Chemical 0 0.9999869
does O 0 0.00019074805
not O 0 0.00023675238
cause O 0 0.002636384
hemolytic B-Disease 0 0.99999774
anemia I-Disease 0 0.99999654
at O 0 0.00023200097
this O 0 0.00027736666
dose O 0 0.0005955929
in O 0 0.0004103151
hematologically O 0 0.29594636
normal O 0 0.0014410733
individuals O 0 0.0021785381
. O 0 0.0024537013

Given O 0 0.0016568287
the O 0 0.0019325018
influx O 0 0.005548265
of O 0 0.0012801149
Southeast O 0 0.0016911814
Asians O 0 0.004073355
into O 0 0.00027333648
the O 0 0.00027539593
United O 0 0.00044494154
States O 0 0.0005971074
, O 0 0.00082608644
oxidant O 0 0.8317702
medications O 0 0.003740508
should O 0 7.877137e-05
be O 0 9.407814e-05
used O 0 8.662585e-05
with O 0 0.0001331639
caution O 0 0.0002215038
, O 0 0.00026510973
especially O 0 0.0001390602
if O 0 8.5850625e-05
an O 0 0.00017644811
infection B-Disease 0 0.0009184963
is O 0 9.885337e-05
present O 0 9.7642944e-05
, O 0 0.00024390654
in O 0 0.00011586099
individuals O 0 0.00024127742
of O 0 0.00016126539
ethnic O 0 0.0015988301
backgrounds O 0 0.00019762227
that O 0 0.0001244631
have O 0 0.00016270088
an O 0 0.00026719327
increased O 0 0.00044271213
prevalence O 0 0.00078020536
of O 0 0.0014521892
hemoglobin O 0 0.9947901
E O 0 0.9991736
. O 0 0.006608891

Severe O 0 0.023213169
complications O 0 0.009443816
of O 0 0.0015283034
antianginal O 0 0.99286216
drug O 0 0.031218302
therapy O 0 0.00057888374
in O 0 0.0002203545
a O 0 0.00029010721
patient O 0 0.00019086321
identified O 0 9.808003e-05
as O 0 0.00015352287
a O 0 0.00030399882
poor O 0 0.0012614562
metabolizer O 0 0.9783252
of O 0 0.00079446274
metoprolol B-Chemical 1 0.99999905
, O 0 0.022231834
propafenone B-Chemical 0 0.9999956
, O 0 0.01309842
diltiazem B-Chemical 1 0.9999949
, O 0 0.0043649534
and O 0 0.002565812
sparteine B-Chemical 0 0.9998635
. O 0 0.0048123715

A O 0 0.031912323
47 O 0 0.0063483324
- O 0 0.007687364
year O 0 0.0013598416
- O 0 0.0030307425
old O 0 0.00084629474
patient O 0 0.00071047497
suffering O 0 0.0025281922
from O 0 0.0003630854
coronary B-Disease 0 0.029332943
artery I-Disease 0 0.30021536
disease I-Disease 0 0.1648883
was O 0 0.00030597867
admitted O 0 0.0006308549
to O 0 0.0002286357
the O 0 0.00031589402
CCU O 0 0.0019291935
in O 0 0.00063523813
shock B-Disease 0 0.6272451
with O 0 0.0021610167
III O 0 0.32225862
. O 0 0.004316421

AV B-Disease 0 0.9724113
block I-Disease 0 0.00955005
, O 0 0.007034324
severe O 0 0.06495247
hypotension B-Disease 0 0.9997117
, O 0 0.0030405268
and O 0 0.0013839818
impairment B-Disease 0 0.104220405
of I-Disease 0 0.0018204768
ventricular I-Disease 0 0.27053538
function I-Disease 0 0.00232755
. O 0 0.0040656566

One O 0 0.0026684764
week O 0 0.00091458927
prior O 0 0.00045315825
to O 0 0.00044188643
admission O 0 0.0005458393
a O 0 0.00039279446
therapy O 0 0.00029063594
with O 0 0.0001797719
standard O 0 0.00018723938
doses O 0 0.0004542198
of O 0 0.00051577255
metoprolol B-Chemical 1 0.99999857
( O 0 0.0010448556
100 O 0 0.00058659987
mg O 0 0.0059750094
t O 0 0.000882576
. O 0 0.00014450122
i O 0 0.000255183
. O 0 0.00013420946
d O 0 0.0002080197
. O 0 0.00013593702
and O 0 0.00013753315
then O 0 0.00014553497
100 O 0 0.00044641344
mg O 0 0.0033170476
b O 0 0.000456073
. O 0 0.00021152281
i O 0 0.00040692926
. O 0 0.0002523746
d O 0 0.0004613879
. O 0 0.00042395163
) O 0 0.0010195
had O 0 0.00065402116
been O 0 0.0009288475
initiated O 0 0.001737772
. O 0 0.0033121437

Two O 0 0.0017694983
days O 0 0.00094535144
before O 0 0.00068069866
admission O 0 0.0021682903
diltiazem B-Chemical 1 0.9999528
( O 0 0.0017004276
60 O 0 0.00067406043
mg O 0 0.0033141216
b O 0 0.00077312114
. O 0 0.00036008918
i O 0 0.000579833
. O 0 0.0003380709
d O 0 0.00053535687
. O 0 0.00044198622
) O 0 0.00092161144
was O 0 0.00052490865
prescribed O 0 0.0016098361
in O 0 0.0008327568
addition O 0 0.0010653469
. O 0 0.0034154737

Analyses O 0 0.0029036836
of O 0 0.0018787562
a O 0 0.0018751883
blood O 0 0.004396832
sample O 0 0.0008652927
revealed O 0 0.00040025185
unusually O 0 0.0014052384
high O 0 0.0005443393
plasma O 0 0.005305842
concentrations O 0 0.00056420127
of O 0 0.00057383976
metoprolol B-Chemical 1 0.99999845
( O 0 0.00058524456
greater O 0 0.00019630839
than O 0 0.00013360818
3000 O 0 0.0003997335
ng O 0 0.000392731
/ O 0 0.0010094796
ml O 0 0.0009900851
) O 0 0.00068392395
and O 0 0.00054138736
diltiazem B-Chemical 1 0.9999883
( O 0 0.0017741277
526 O 0 0.0031577884
ng O 0 0.001635434
/ O 0 0.003962929
ml O 0 0.00459387
) O 0 0.0041921414
. O 0 0.0035043827

The O 0 0.0023416728
patient O 0 0.0020356462
recovered O 0 0.00096150883
within O 0 0.000482963
1 O 0 0.00061800383
week O 0 0.00033070054
following O 0 0.0003382966
discontinuation O 0 0.0016618856
of O 0 0.0011188425
antianginal O 0 0.9305591
therapy O 0 0.0031055636
. O 0 0.0034007712

Three O 0 0.001931572
months O 0 0.00087977207
later O 0 0.0007907064
the O 0 0.0005787974
patient O 0 0.0005825487
was O 0 0.00033118168
exposed O 0 0.00031828435
to O 0 0.0001901062
a O 0 0.00024702834
single O 0 0.00012356801
dose O 0 0.0003087955
of O 0 0.00042658485
metoprolol B-Chemical 1 0.9999993
, O 0 0.021128634
diltiazem B-Chemical 1 0.99999917
, O 0 0.02380483
propafenone B-Chemical 0 0.9999975
( O 0 0.00054730236
since O 0 7.835745e-05
he O 0 0.00012874746
had O 0 8.6394786e-05
received O 0 9.284132e-05
this O 0 0.000118683005
drug O 0 0.0017534539
in O 0 9.711781e-05
the O 0 8.329627e-05
past O 0 0.00014723887
) O 0 0.0004247202
, O 0 0.00034754424
and O 0 0.00036409995
sparteine B-Chemical 0 0.9999757
( O 0 0.00054619525
as O 0 0.0001303136
a O 0 0.00016894811
probe O 0 0.00010188717
for O 0 0.0001247265
the O 0 0.00035626141
debrisoquine B-Chemical 0 0.99999666
/ O 0 0.5517816
sparteine B-Chemical 0 0.9999833
type O 0 0.0012390739
polymorphism O 0 0.00058999297
of O 0 0.0006980391
oxidative O 0 0.7679176
drug O 0 0.47391406
metabolism O 0 0.44838285
) O 0 0.0052535064
. O 0 0.0027675957

It O 0 0.005251408
was O 0 0.0018669217
found O 0 0.0011832509
that O 0 0.00071808486
he O 0 0.00088949635
was O 0 0.0004667364
a O 0 0.0006385201
poor O 0 0.0016083774
metabolizer O 0 0.8628659
of O 0 0.00021622714
all O 0 0.00013519707
four O 0 9.520351e-05
drugs O 0 0.002001121
, O 0 0.00032577603
indicating O 0 0.00012253663
that O 0 0.00013997684
their O 0 0.00026004386
metabolism O 0 0.012562192
is O 0 0.0002495276
under O 0 0.0002595712
the O 0 0.00030220486
same O 0 0.0003979419
genetic O 0 0.0012948265
control O 0 0.0015962548
. O 0 0.0030662548

Therefore O 0 0.0020438577
, O 0 0.0033160844
patients O 0 0.0019451948
belonging O 0 0.0006377398
to O 0 0.00045941447
the O 0 0.00040776646
poor O 0 0.001679147
- O 0 0.0152676655
metabolizer O 0 0.9422495
phenotype O 0 0.00046269177
of O 0 0.00074778625
sparteine B-Chemical 0 0.99999166
/ O 0 0.85646486
debrisoquine B-Chemical 0 0.99999785
polymorphism O 0 0.0006330871
in O 0 0.00021190353
drug O 0 0.06413208
metabolism O 0 0.101672955
, O 0 0.00037217172
which O 0 0.00014045335
constitutes O 0 9.5167394e-05
6 O 0 6.983726e-05
. O 0 7.583516e-05
4 O 0 6.6144305e-05
% O 0 0.00014081784
of O 0 8.916489e-05
the O 0 8.3294595e-05
German O 0 0.00015984804
population O 0 0.00018650207
, O 0 0.00023176108
may O 0 8.686781e-05
experience O 0 0.0002708753
adverse B-Disease 0 0.0034298613
drug I-Disease 0 0.0024688414
reactions I-Disease 0 0.00019782814
when O 0 6.147231e-05
treated O 0 0.00019132857
with O 0 0.00012058914
standard O 0 0.00013427384
doses O 0 0.00030876134
of O 0 0.00019982932
one O 0 0.0001976688
of O 0 0.0003433532
these O 0 0.0005195779
drugs O 0 0.01577628
alone O 0 0.0017477158
. O 0 0.0027785802

Moreover O 0 0.003164279
, O 0 0.0035170137
the O 0 0.0013250716
coadministration O 0 0.11272214
of O 0 0.0006971884
these O 0 0.0004092876
frequently O 0 0.0003300608
used O 0 0.000246684
drugs O 0 0.004109131
is O 0 0.000189744
expected O 0 0.00014342746
to O 0 0.00016730509
be O 0 0.00020316897
especially O 0 0.0002966645
harmful O 0 0.0010135063
in O 0 0.00033527406
this O 0 0.00049204816
subgroup O 0 0.0013459629
of O 0 0.001150163
patients O 0 0.0033780152
. O 0 0.0028633522

Clinical O 0 0.009087463
experiences O 0 0.006076105
in O 0 0.001999712
an O 0 0.0016370057
open O 0 0.0014706277
and O 0 0.001235801
a O 0 0.0016302677
double O 0 0.0015133108
- O 0 0.008154522
blind O 0 0.042763222
trial O 0 0.00591409
. O 0 0.005523478

A O 0 0.01849513
total O 0 0.0022821384
of O 0 0.0014475308
sixty O 0 0.0018798528
patients O 0 0.0012069346
were O 0 0.00049112557
trated O 0 0.0050522243
with O 0 0.0008336488
bromperidol B-Chemical 0 0.99999416
first O 0 0.00016037215
in O 0 0.00014123064
open O 0 0.00016176421
conditions O 0 0.00014814637
( O 0 0.00027468897
20 O 0 0.00014863213
patients O 0 0.00027882413
) O 0 0.00033901623
, O 0 0.00022314792
then O 0 0.000102352154
on O 0 8.166677e-05
a O 0 0.00017805437
double O 0 0.00013868148
blind O 0 0.008100137
basis O 0 0.00017356136
( O 0 0.0003328095
40 O 0 0.00019307838
patients O 0 0.00037909916
) O 0 0.0005617796
with O 0 0.0005888411
haloperidol B-Chemical 1 0.9999956
as O 0 0.0005928543
the O 0 0.0005403861
reference O 0 0.0011642327
substance O 0 0.35783386
. O 0 0.0034411158

The O 0 0.0019854768
open O 0 0.001970242
study O 0 0.0011101601
lasted O 0 0.0004984675
for O 0 0.0002989156
four O 0 0.00020844874
weeks O 0 0.00020121185
; O 0 0.0005294651
the O 0 0.00027097034
drug O 0 0.0019000083
was O 0 0.00031436243
administrated O 0 0.0009174096
in O 0 0.0002720311
the O 0 0.00026636207
form O 0 0.00038020773
of O 0 0.0006469689
1 O 0 0.0011350217
mg O 0 0.018274797
tablets O 0 0.073221326
. O 0 0.0034503376

The O 0 0.0018308756
daily O 0 0.0018543915
dose O 0 0.0015898083
( O 0 0.0010982004
initial O 0 0.00040808786
dose O 0 0.00069967855
: O 0 0.000709811
1 O 0 0.00035860034
mg O 0 0.0015509932
; O 0 0.00031752998
mean O 0 0.00012237723
dose O 0 0.0001930583
at O 0 8.56582e-05
the O 0 8.493729e-05
end O 0 7.5849406e-05
of O 0 0.00014970316
the O 0 0.00013695275
trial O 0 0.00030623283
: O 0 0.00033966397
4 O 0 0.00013082492
. O 0 0.00014699914
47 O 0 0.00030314646
mg O 0 0.002330111
) O 0 0.00044881908
was O 0 0.00019059188
always O 0 0.0002944289
administered O 0 0.0003832792
in O 0 0.000305351
one O 0 0.00039188
single O 0 0.000583487
dose O 0 0.0020149145
. O 0 0.0025485863

Nineteen O 0 0.00881675
patients O 0 0.003601664
finished O 0 0.0017968434
the O 0 0.0008976985
trial O 0 0.0012995932
, O 0 0.0010784941
and O 0 0.0005295358
in O 0 0.0003909602
18 O 0 0.0003928628
cases O 0 0.0004242395
the O 0 0.0002101452
therapeutic O 0 0.0003699638
result O 0 0.00024576424
was O 0 0.000275444
considered O 0 0.00033519155
very O 0 0.00053978927
good O 0 0.00078356534
to O 0 0.00083647715
good O 0 0.0021773456
. O 0 0.0033100524

These O 0 0.0044742003
results O 0 0.003931146
were O 0 0.0034639176
confirmed O 0 0.0028412081
by O 0 0.0036982042
statistical O 0 0.006271498
analysis O 0 0.005799595
. O 0 0.008414242

Nine O 0 0.004814669
patients O 0 0.003541327
exhibited O 0 0.0014886701
mild O 0 0.02648952
to O 0 0.00074910297
moderate O 0 0.02094312
extrapyramidal B-Disease 0 0.999985
concomitant I-Disease 0 0.0035146717
symptoms I-Disease 0 0.10226364
; O 0 0.00058896875
no O 0 0.00023840893
other O 0 0.0003033127
side O 0 0.0010224251
effects O 0 0.00071425905
were O 0 0.0009558562
observed O 0 0.001367366
. O 0 0.0030094832

The O 0 0.0016847942
results O 0 0.0011460007
of O 0 0.00090193213
detailed O 0 0.00039169288
laboratory O 0 0.00055187417
tests O 0 0.00065516075
and O 0 0.00028910572
evaluations O 0 0.00021190959
of O 0 0.00018255187
various O 0 0.0001417475
quantitative O 0 0.00011335862
and O 0 0.00014893388
qualitative O 0 0.0002501438
tolerability O 0 0.0003424449
parameters O 0 0.00021950544
were O 0 0.0002026184
not O 0 0.00023971131
indicative O 0 0.00038146568
of O 0 0.00078979705
toxic O 0 0.019742176
effects O 0 0.0019458985
. O 0 0.0035491162

In O 0 0.0017130923
the O 0 0.0012766928
double O 0 0.0010909095
blind O 0 0.018848361
study O 0 0.0010473811
with O 0 0.0013893029
haloperidol B-Chemical 1 0.9999974
, O 0 0.0012271099
both O 0 0.00027161572
substances O 0 0.01703495
were O 0 0.00017338485
found O 0 0.0001384933
to O 0 0.00010837419
be O 0 0.00010135585
highly O 0 8.0883045e-05
effective O 0 8.6757216e-05
in O 0 9.009574e-05
the O 0 9.394806e-05
treatment O 0 0.000163374
of O 0 0.0005035045
psychotic B-Disease 0 0.9999975
syndromes I-Disease 0 0.8103841
belonging I-Disease 0 0.00022876261
predominantly I-Disease 0 0.0002556062
to I-Disease 0 0.00030985952
the I-Disease 0 0.00069386617
schizophrenia I-Disease 2 0.999938
group I-Disease 0 0.0032758631
. O 0 0.002895577

Certain O 0 0.004686874
clues O 0 0.0022000922
, O 0 0.002486771
including O 0 0.000777599
the O 0 0.0006561413
onset O 0 0.0008688755
of O 0 0.0005352127
action O 0 0.0005845168
, O 0 0.00091017655
seem O 0 0.00038177782
to O 0 0.00027669498
be O 0 0.0002835201
indicative O 0 0.00027364652
of O 0 0.00037609378
the O 0 0.00040617326
superiority O 0 0.0010670536
of O 0 0.0025199924
bromperidol B-Chemical 0 0.9999831
. O 0 0.005600707

No O 0 0.0042812624
differences O 0 0.0016385284
were O 0 0.0012096311
observed O 0 0.00079540425
with O 0 0.00075245847
respect O 0 0.000531481
to O 0 0.0005178783
side O 0 0.0011862138
effects O 0 0.0007032657
and O 0 0.0009824105
general O 0 0.0013168085
tolerability O 0 0.0038666641
. O 0 0.0033950002

Prolonged O 0 0.023136884
cholestasis B-Disease 0 0.999775
after O 0 0.005640518
troleandomycin B-Chemical 0 0.9999784
- O 0 0.44030488
induced O 0 0.00613649
acute O 0 0.9965389
hepatitis B-Disease 0 0.99995494
. O 0 0.018616304

We O 0 0.002829396
report O 0 0.002841908
the O 0 0.001097224
case O 0 0.00093599025
of O 0 0.00073264015
a O 0 0.00081176806
patient O 0 0.0005267863
in O 0 0.0003888141
whom O 0 0.002138663
troleandomycin B-Chemical 0 0.99999714
- O 0 0.30129227
induced O 0 0.0009839063
hepatitis B-Disease 0 0.9999672
was O 0 0.0005951889
followed O 0 0.00032809435
by O 0 0.00051641307
prolonged O 0 0.0021357362
anicteric O 0 0.99968076
cholestasis B-Disease 0 0.9999769
. O 0 0.007318727

Jaundice B-Disease 0 0.95476717
occurred O 0 0.0018193704
after O 0 0.0006853744
administration O 0 0.0013333852
of O 0 0.0012680514
troleandomycin B-Chemical 0 0.99998105
for O 0 0.0004916664
7 O 0 0.0002993865
days O 0 0.00020646991
and O 0 0.00038450828
was O 0 0.0004912405
associated O 0 0.00087551895
with O 0 0.001957518
hypereosinophilia B-Disease 0 0.9984994
. O 0 0.004451679

Jaundice B-Disease 0 0.9892643
disappeared O 0 0.0025060102
within O 0 0.00056531123
3 O 0 0.00047973308
months O 0 0.00025450438
but O 0 0.00036629714
was O 0 0.0002550057
followed O 0 0.00019266423
by O 0 0.00024060869
prolonged O 0 0.00075956923
anicteric O 0 0.9998425
cholestasis B-Disease 0 0.9999956
marked O 0 0.0014594389
by O 0 0.0004341415
pruritus B-Disease 0 0.9986487
and O 0 0.00021981563
high O 0 0.00026094288
levels O 0 0.00024878193
of O 0 0.0006429054
alkaline O 0 0.61990273
phosphatase O 0 0.47286117
and O 0 0.0013504595
gammaglutamyltransferase O 0 0.29679
activities O 0 0.0018116435
. O 0 0.0030642892

Finally O 0 0.0037846589
, O 0 0.009475835
pruritus B-Disease 0 0.99799085
disappeared O 0 0.001324239
within O 0 0.0003333118
19 O 0 0.0004701407
months O 0 0.00018558143
, O 0 0.00046105747
and O 0 0.00035788948
liver O 0 0.008788737
tests O 0 0.0007302246
returned O 0 0.00026727247
to O 0 0.00018102152
normal O 0 0.00032617507
27 O 0 0.0002541465
months O 0 0.000102520746
after O 0 0.00013794319
the O 0 0.00032815535
onset O 0 0.0010955001
of O 0 0.002118502
hepatitis B-Disease 0 0.99979645
. O 0 0.0076520885

This O 0 0.0044224747
observation O 0 0.0015607896
demonstrates O 0 0.0007995288
that O 0 0.0008663412
prolonged O 0 0.0026013264
cholestasis B-Disease 0 0.99995184
can O 0 0.0009348605
follow O 0 0.0009857434
troleandomycin B-Chemical 0 0.99999154
- O 0 0.25905266
induced O 0 0.002626088
acute O 0 0.997326
hepatitis B-Disease 0 0.9999771
. O 0 0.012731337

Serial O 0 0.004663053
studies O 0 0.002839424
of O 0 0.0025095171
auditory B-Disease 0 0.4378271
neurotoxicity I-Disease 0 0.999337
in O 0 0.0013813331
patients O 0 0.0024025342
receiving O 0 0.0025038847
deferoxamine B-Chemical 0 0.999747
therapy O 0 0.004818706
. O 0 0.003925293

Visual B-Disease 0 0.06931328
and I-Disease 0 0.0036955206
auditory I-Disease 0 0.6125297
neurotoxicity I-Disease 0 0.99956363
was O 0 0.0007678769
previously O 0 0.00051708467
documented O 0 0.0004522372
in O 0 0.00023213352
42 O 0 0.0002548715
of O 0 0.00018434283
89 O 0 0.00031071002
patients O 0 0.0002732505
with O 0 0.0001653378
transfusion O 0 0.0007475704
- O 0 0.0016141175
dependent O 0 0.00018327235
anemia B-Disease 0 0.9998796
who O 0 0.0003451217
were O 0 0.00013730096
receiving O 0 0.00036231914
iron B-Chemical 0 0.9997961
chelation O 0 0.10746178
therapy O 0 0.000366349
with O 0 0.00033011308
daily O 0 0.0008102275
subcutaneous O 0 0.0042684637
deferoxamine B-Chemical 0 0.99973017
. O 0 0.0032259568

Twenty O 0 0.0066881804
- O 0 0.006490895
two O 0 0.00086012576
patients O 0 0.0013334183
in O 0 0.0004978853
the O 0 0.00033994802
affected O 0 0.00036433002
group O 0 0.00041430682
had O 0 0.00024275048
abnormal B-Disease 0 0.0008391588
audiograms I-Disease 0 0.015767902
with I-Disease 0 0.00021967587
deficits I-Disease 0 0.2558597
mostly I-Disease 0 0.00016753623
in I-Disease 0 9.271666e-05
the I-Disease 0 7.2508694e-05
high I-Disease 0 0.00010710559
frequency I-Disease 0 8.17914e-05
range I-Disease 0 0.000102047896
of I-Disease 0 0.000108560984
4 I-Disease 0 9.795769e-05
, I-Disease 0 0.00018388448
000 I-Disease 0 0.00013786768
to I-Disease 0 8.201038e-05
8 I-Disease 0 0.000101166006
, I-Disease 0 0.00018356636
000 I-Disease 0 0.00017031353
Hz I-Disease 0 0.00077121065
and O 0 0.00014161391
in O 0 0.00012210892
the O 0 0.00013404613
hearing O 0 0.011571389
threshold O 0 0.00017349847
levels O 0 0.00020903748
of O 0 0.0003446476
30 O 0 0.000348161
to O 0 0.00043211482
100 O 0 0.0015288818
decibels O 0 0.0050544734
. O 0 0.0026789487

When O 0 0.0034274566
deferoxamine B-Chemical 0 0.99967754
therapy O 0 0.0025429283
was O 0 0.00070343254
discontinued O 0 0.0011899689
and O 0 0.00029837975
serial O 0 0.00022597174
studies O 0 0.00023525512
were O 0 0.00014939644
performed O 0 0.00014134827
, O 0 0.0003066419
audiograms O 0 0.004432711
in O 0 0.00013961931
seven O 0 0.00011627328
cases O 0 0.00029226398
reverted O 0 0.0003376606
to O 0 0.0001242275
normal O 0 0.00026227333
or O 0 0.000106587715
near O 0 0.00014717795
normal O 0 0.00016117362
within O 0 4.0063424e-05
two O 0 4.2158306e-05
to O 0 5.105515e-05
three O 0 3.440359e-05
weeks O 0 5.009808e-05
, O 0 0.00016763403
and O 0 0.00012280533
nine O 0 0.00012136284
of O 0 0.00018560498
13 O 0 0.0002626096
patients O 0 0.00047922228
with O 0 0.00043954488
symptoms O 0 0.0057170717
became O 0 0.0015253441
asymptomatic O 0 0.0074753007
. O 0 0.00289017

Audiograms O 0 0.011759066
from O 0 0.0017264368
15 O 0 0.0012188338
patients O 0 0.0013443136
remained O 0 0.00086236285
abnormal O 0 0.001417356
and O 0 0.00039075062
four O 0 0.00020653014
patients O 0 0.00045159057
required O 0 0.00020022412
hearing O 0 0.01939851
aids O 0 0.00097252446
because O 0 0.00051551353
of O 0 0.0012053766
permanent B-Disease 0 0.15177779
disability I-Disease 0 0.8609869
. O 0 0.004384597

Since O 0 0.002003732
18 O 0 0.0019507683
of O 0 0.0011842969
the O 0 0.00071965746
22 O 0 0.0008473849
patients O 0 0.000668444
were O 0 0.00026370757
initially O 0 0.0003386132
receiving O 0 0.00059685216
deferoxamine B-Chemical 0 0.9999521
doses O 0 0.0009825764
in O 0 0.00017203596
excess O 0 0.00022262194
of O 0 0.0001341185
the O 0 9.6096e-05
commonly O 0 0.00012107537
recommended O 0 9.463915e-05
50 O 0 0.00014510611
mg O 0 0.0012131815
/ O 0 0.00040381405
kg O 0 0.0002459867
per O 0 8.313321e-05
dose O 0 0.00014751682
, O 0 0.00016388953
therapy O 0 0.00013817936
was O 0 8.55547e-05
restarted O 0 0.00025945343
with O 0 9.4776246e-05
lower O 0 0.00013260498
doses O 0 0.0003046586
, O 0 0.0002293232
usually O 0 0.00013102355
50 O 0 0.00015109508
mg O 0 0.00132134
/ O 0 0.00040467357
kg O 0 0.00024379378
per O 0 7.8828634e-05
dose O 0 0.00012981625
or O 0 7.408577e-05
less O 0 0.00012497365
depending O 0 0.00011326537
on O 0 5.8368805e-05
the O 0 7.059254e-05
degree O 0 0.00016614869
of O 0 0.00019067712
auditory B-Disease 0 0.3116259
abnormality I-Disease 0 0.45884588
, O 0 0.00028341092
and O 0 0.00011526022
with O 0 0.00011426241
the O 0 9.0801695e-05
exception O 0 0.000104186496
of O 0 0.00014090701
two O 0 0.0001129262
cases O 0 0.00033613894
no O 0 0.00023450445
further O 0 0.0003900145
toxicity B-Disease 0 0.6281641
was O 0 0.0009157856
demonstrated O 0 0.0012764095
. O 0 0.0026754222

Auditory O 0 0.023020182
deterioration O 0 0.007451458
and O 0 0.0010262805
improvement O 0 0.00081214606
, O 0 0.0007252275
demonstrated O 0 0.000256692
serially O 0 0.00020490352
in O 0 0.00015411602
individual O 0 0.0001141939
patients O 0 0.00021443644
receiving O 0 0.00012449396
and O 0 0.00010953354
not O 0 0.000114233226
receiving O 0 0.00044327293
deferoxamine B-Chemical 0 0.999979
, O 0 0.00053780666
respectively O 0 0.00034586893
, O 0 0.00020691805
provided O 0 7.166557e-05
convincing O 0 0.00010644176
evidence O 0 9.114889e-05
for O 0 0.00010447342
a O 0 0.00026432832
cause O 0 0.00029976378
- O 0 0.0018554722
and O 0 0.00021300573
- O 0 0.0008296406
effect O 0 0.00013336683
relation O 0 0.00015699373
between O 0 0.00040737228
deferoxamine B-Chemical 0 0.99995875
administration O 0 0.0035600185
and O 0 0.0017819952
ototoxicity B-Disease 0 0.9997781
. O 0 0.0036589839

Based O 0 0.0041946503
on O 0 0.0014172444
these O 0 0.0012466634
data O 0 0.0012219779
, O 0 0.0013464798
a O 0 0.000822734
plan O 0 0.00060656347
of O 0 0.00041526527
management O 0 0.00042457122
was O 0 0.00025092112
developed O 0 0.00026242665
that O 0 0.0001493725
allows O 0 0.00015596153
effective O 0 0.0002565132
yet O 0 0.00035201784
safe O 0 0.00063083175
administration O 0 0.0012875134
of O 0 0.0021913636
deferoxamine B-Chemical 0 0.9998456
. O 0 0.005502921

A O 0 0.022155015
dose O 0 0.0040437835
of O 0 0.0018357204
50 O 0 0.0018112384
mg O 0 0.008755273
/ O 0 0.0025042393
kg O 0 0.0013927917
is O 0 0.000435637
recommended O 0 0.0004564257
in O 0 0.0004949919
those O 0 0.0007519964
without O 0 0.0011529614
audiogram O 0 0.21567969
abnormalities O 0 0.075592026
. O 0 0.0042354385

With O 0 0.0037962117
mild O 0 0.34824446
toxicity B-Disease 0 0.8690384
, O 0 0.0024516059
a O 0 0.0009965232
reduction O 0 0.0005299895
to O 0 0.0002563635
30 O 0 0.00019137708
or O 0 0.00014715886
40 O 0 0.000204511
mg O 0 0.0012291546
/ O 0 0.00057651615
kg O 0 0.00037810442
per O 0 0.00013031086
dose O 0 0.00018230591
should O 0 6.163967e-05
result O 0 9.79773e-05
in O 0 0.00012152797
a O 0 0.0002064896
reversal O 0 0.00023098786
of O 0 0.00017876917
the O 0 0.00015927902
abnormal O 0 0.00069049874
results O 0 0.00016590711
to O 0 0.00020009434
normal O 0 0.00042548263
within O 0 0.0001965485
four O 0 0.00031028903
weeks O 0 0.0005331468
. O 0 0.001912531

Moderate O 0 0.10732947
abnormalities O 0 0.025387092
require O 0 0.0011892471
a O 0 0.0014103907
reduction O 0 0.0011000433
of O 0 0.0013867061
deferoxamine B-Chemical 0 0.9999045
to O 0 0.00049304706
25 O 0 0.0005913104
mg O 0 0.003006386
/ O 0 0.00104599
kg O 0 0.0006938993
per O 0 0.0003093778
dose O 0 0.00051868457
with O 0 0.00050500146
careful O 0 0.0008038683
monitoring O 0 0.0014282396
. O 0 0.0028263754

In O 0 0.0018642392
those O 0 0.0019215049
with O 0 0.0013852601
symptoms O 0 0.0050620534
of O 0 0.00084554753
hearing B-Disease 0 0.26904443
loss I-Disease 0 0.0007070569
, O 0 0.0006320345
the O 0 0.00024303187
drug O 0 0.0026249615
should O 0 9.4966774e-05
be O 0 0.00011663906
stopped O 0 0.00014092353
for O 0 6.654415e-05
four O 0 4.9728995e-05
weeks O 0 5.2953746e-05
, O 0 0.00015923422
and O 0 0.000100002
when O 0 7.278941e-05
the O 0 0.00011058291
audiogram O 0 0.025881367
is O 0 8.9440975e-05
stable O 0 0.00010033478
or O 0 9.370684e-05
improved O 0 0.00020199304
, O 0 0.0002567786
therapy O 0 0.00018903973
should O 0 6.9780144e-05
be O 0 0.00013829971
restarted O 0 0.00038484877
at O 0 0.00011818823
10 O 0 0.00016308171
to O 0 0.00016053648
25 O 0 0.0003859381
mg O 0 0.0022294144
/ O 0 0.0013776735
kg O 0 0.0012073629
per O 0 0.00076361344
dose O 0 0.0018872452
. O 0 0.002562818

Serial O 0 0.0044104443
audiograms O 0 0.014010527
should O 0 0.000632595
be O 0 0.0004881404
performed O 0 0.00027859668
every O 0 0.00012986701
six O 0 9.040427e-05
months O 0 7.858748e-05
in O 0 0.00011591062
those O 0 0.00015209218
without O 0 0.00015364648
problems O 0 0.0006798779
and O 0 0.00019581785
more O 0 0.0002285485
frequently O 0 0.00014247805
in O 0 0.00012050592
young O 0 0.00055707985
patients O 0 0.00031784526
with O 0 0.00017682368
normal O 0 0.00056534493
serum O 0 0.10808383
ferritin O 0 0.9946391
values O 0 0.00024166142
and O 0 0.0002113966
in O 0 0.00022087639
those O 0 0.00035621677
with O 0 0.0006234635
auditory B-Disease 0 0.31668714
dysfunction I-Disease 0 0.99274397
. O 0 0.0034058772

Lidocaine B-Chemical 0 0.9991308
- O 0 0.06443062
induced O 0 0.010797383
cardiac B-Disease 0 0.6631692
asystole I-Disease 0 0.9977162
. O 0 0.016433332

Intravenous O 0 0.038899876
administration O 0 0.0026294133
of O 0 0.0011008441
a O 0 0.00092878344
single O 0 0.00040509985
50 O 0 0.0005929229
- O 0 0.0018053519
mg O 0 0.0032140987
bolus O 0 0.001128474
of O 0 0.0003695572
lidocaine B-Chemical 0 0.99971324
in O 0 0.00020911582
a O 0 0.00027679288
67 O 0 0.00037034738
- O 0 0.0008843265
year O 0 0.00016085195
- O 0 0.0008209062
old O 0 0.00025110153
man O 0 0.0013878773
resulted O 0 0.0001570761
in O 0 0.00019510277
profound O 0 0.0025857943
depression B-Disease 0 0.99965143
of O 0 0.00022617997
the O 0 0.00013014111
activity O 0 0.00011759098
of O 0 0.00021829303
the O 0 0.000259878
sinoatrial O 0 0.16337328
and O 0 0.0005577496
atrioventricular O 0 0.58209306
nodal O 0 0.015547773
pacemakers O 0 0.003460252
. O 0 0.0023045966

The O 0 0.0020370432
patient O 0 0.0019238144
had O 0 0.0009896457
no O 0 0.0006209781
apparent O 0 0.000548548
associated O 0 0.00040664498
conditions O 0 0.00034796906
which O 0 0.00032881583
might O 0 0.00013849251
have O 0 0.00020952319
predisposed O 0 0.001466941
him O 0 0.00033349555
to O 0 0.00013002861
the O 0 0.000120798955
development O 0 0.000204589
of O 0 0.00027092078
bradyarrhythmias B-Disease 0 0.99914956
; O 0 0.00052307744
and O 0 0.0001856692
, O 0 0.00032128213
thus O 0 0.0002021998
, O 0 0.00040978735
this O 0 0.00024964538
probably O 0 0.00030130212
represented O 0 0.00027128702
a O 0 0.00056766043
true O 0 0.0007995569
idiosyncrasy O 0 0.68246585
to O 0 0.0016477619
lidocaine B-Chemical 0 0.9996711
. O 0 0.0034965684

Flurbiprofen B-Chemical 0 0.999501
in O 0 0.0043714214
the O 0 0.0024620136
treatment O 0 0.0025383723
of O 0 0.0041501955
juvenile B-Disease 0 0.99205935
rheumatoid I-Disease 0 0.9998702
arthritis I-Disease 0 0.99986124
. O 0 0.012376689

Thirty O 0 0.00787784
- O 0 0.0067372816
four O 0 0.0008264958
patients O 0 0.0016165845
with O 0 0.0012335934
juvenile B-Disease 0 0.98823345
rheumatoid I-Disease 0 0.99997425
arthritis I-Disease 0 0.9999858
, O 0 0.0015083279
who O 0 0.00037237382
were O 0 0.00014219491
treated O 0 0.0003157528
with O 0 0.00033547275
flurbiprofen B-Chemical 0 0.99999
at O 0 0.000117659176
a O 0 0.00015103501
maximum O 0 0.00011685381
dose O 0 0.00014887098
of O 0 9.539736e-05
4 O 0 9.2097456e-05
mg O 0 0.0008664359
/ O 0 0.00039865522
kg O 0 0.0003089422
/ O 0 0.0004714457
day O 0 8.57863e-05
, O 0 0.00019794775
had O 0 0.000105877705
statistically O 0 0.0001601382
significant O 0 0.00010260251
decreases O 0 0.0001230983
from O 0 8.644423e-05
baseline O 0 9.3614944e-05
in O 0 0.000104450315
6 O 0 0.00012597928
arthritis B-Disease 0 0.73322684
indices O 0 0.00027794138
after O 0 0.0001088039
12 O 0 0.00015073548
weeks O 0 0.00016737786
of O 0 0.00058339135
treatment O 0 0.0012002336
. O 0 0.0025560593

Improvements O 0 0.0030992182
were O 0 0.0017588907
seen O 0 0.0012291213
in O 0 0.000719713
the O 0 0.0004701954
number O 0 0.00035817377
of O 0 0.0005316951
tender B-Disease 0 0.0044942903
joints I-Disease 0 0.027510377
, O 0 0.00061022345
the O 0 0.00021606433
severity O 0 0.00065795676
of O 0 0.00032029947
swelling B-Disease 0 0.5246685
and O 0 0.00032167014
tenderness B-Disease 0 0.23937005
, O 0 0.00027807712
the O 0 9.3625924e-05
time O 0 8.340698e-05
of O 0 0.0001713077
walk O 0 0.000714208
50 O 0 0.00025431564
feet O 0 0.0015523193
, O 0 0.0002251474
the O 0 8.5769934e-05
duration O 0 8.3319625e-05
of O 0 0.0001988505
morning B-Disease 0 0.0062696114
stiffness I-Disease 0 0.44389275
and O 0 0.0002628511
the O 0 0.00021328249
circumference O 0 0.0013667411
of O 0 0.0004472464
the O 0 0.0005186126
left O 0 0.0020886164
knee O 0 0.007887185
. O 0 0.0028864571

The O 0 0.0021263773
most O 0 0.0021135854
frequently O 0 0.0012326668
observed O 0 0.0007252369
side O 0 0.0014858226
effect O 0 0.0005453559
was O 0 0.00063755474
fecal B-Disease 0 0.02181682
occult I-Disease 0 0.10693712
blood I-Disease 0 0.087262996
( O 0 0.0005541043
25 O 0 0.00027559084
% O 0 0.00031525505
of O 0 0.00019099157
patients O 0 0.00046524737
) O 0 0.0005106966
; O 0 0.0003726558
however O 0 0.00020617206
, O 0 0.00027290735
there O 0 0.00011308666
was O 0 0.0001226161
no O 0 0.00010939127
other O 0 0.00011567201
evidence O 0 0.00014199548
of O 0 0.00031960677
gastrointestinal B-Disease 0 0.22031392
( I-Disease 0 0.00093258184
GI I-Disease 0 0.041557014
) I-Disease 0 0.0016043199
bleeding I-Disease 0 0.75197965
in O 0 0.0005285431
these O 0 0.00081365224
patients O 0 0.0026018433
. O 0 0.0025746576

One O 0 0.004277439
patient O 0 0.0025350654
was O 0 0.0014919013
prematurely O 0 0.004284162
discontinued O 0 0.001990856
from O 0 0.00042316652
the O 0 0.00034740262
study O 0 0.00045213223
for O 0 0.00040747423
severe O 0 0.005471929
headache B-Disease 0 0.9845696
and O 0 0.0010062056
abdominal B-Disease 0 0.0030650324
pain I-Disease 0 0.036670033
. O 0 0.0031377804

Most O 0 0.005093437
side O 0 0.0051361546
effects O 0 0.0020639973
were O 0 0.0018340887
mild O 0 0.019211952
and O 0 0.0011884521
related O 0 0.0006959504
to O 0 0.0009152718
the O 0 0.0012924819
GI O 0 0.012060078
tract O 0 0.0034191278
. O 0 0.0043133157

Hyperkalemia B-Disease 0 0.9974323
associated O 0 0.010377594
with O 0 0.012628628
sulindac B-Chemical 1 0.99988914
therapy O 0 0.022879565
. O 0 0.011322392

Hyperkalemia B-Disease 0 0.9985184
has O 0 0.0016329754
recently O 0 0.0010855458
been O 0 0.0006833086
recognized O 0 0.00048375703
as O 0 0.00041034806
a O 0 0.00050621014
complication O 0 0.0015177587
of O 0 0.00041997005
nonsteroidal O 0 0.9977639
antiinflammatory O 0 0.7528643
agents O 0 0.0040594083
( O 0 0.0027809064
NSAID O 0 0.999951
) O 0 0.0026911
such O 0 0.00081600604
as O 0 0.0018319677
indomethacin B-Chemical 0 0.99994206
. O 0 0.0070634806

Several O 0 0.0019638482
recent O 0 0.0016839129
studies O 0 0.001414022
have O 0 0.00077648606
stressed O 0 0.0011584836
the O 0 0.00056767644
renal O 0 0.51191604
sparing O 0 0.0012029507
features O 0 0.00047375224
of O 0 0.00078471046
sulindac B-Chemical 1 0.9999962
, O 0 0.0012983739
owing O 0 0.0002431313
to O 0 0.00017530807
its O 0 0.00024527826
lack O 0 0.00017607232
of O 0 0.00031073403
interference O 0 0.0006730564
with O 0 0.001268154
renal O 0 0.998638
prostacyclin B-Chemical 0 0.9999906
synthesis O 0 0.11177656
. O 0 0.0042417236

We O 0 0.002469279
describe O 0 0.001635378
4 O 0 0.0010603868
patients O 0 0.001306689
in O 0 0.00062028976
whom O 0 0.0014847415
hyperkalemia B-Disease 0 0.9998703
ranging O 0 0.0007081044
from O 0 0.00020348383
6 O 0 0.0001493507
. O 0 0.00015998741
1 O 0 0.0001554265
to O 0 0.00010625192
6 O 0 0.000104973515
. O 0 0.00013355812
9 O 0 0.00017144284
mEq O 0 0.094404966
/ O 0 0.0010063694
l O 0 0.0010449338
developed O 0 0.00024473446
within O 0 0.00010060649
3 O 0 0.00014304461
to O 0 0.00014334457
8 O 0 0.00020144931
days O 0 0.00021108442
of O 0 0.0009041452
sulindac B-Chemical 1 0.9999629
administration O 0 0.009681119
. O 0 0.0035603244

In O 0 0.0021062505
all O 0 0.001759492
of O 0 0.0015402223
them O 0 0.0018447688
normal O 0 0.0029805496
serum O 0 0.34540725
potassium B-Chemical 0 0.99935406
levels O 0 0.0005537252
reached O 0 0.00047885536
within O 0 0.00017994785
2 O 0 0.00028091422
to O 0 0.00020332535
4 O 0 0.00023580305
days O 0 0.00023961555
of O 0 0.000751941
stopping O 0 0.0039619994
sulindac B-Chemical 1 0.9999471
. O 0 0.0070756176

As O 0 0.0015657935
no O 0 0.0011763234
other O 0 0.0009499906
medications O 0 0.005267094
known O 0 0.00053926784
to O 0 0.0003475424
effect O 0 0.00044598215
serum O 0 0.58407295
potassium B-Chemical 0 0.99982846
had O 0 0.00033192008
been O 0 0.00016340143
given O 0 0.000105800995
concomitantly O 0 0.00039706813
, O 0 0.00026650328
this O 0 0.00012366124
course O 0 0.000118837714
of O 0 0.00012948766
events O 0 0.00022265995
is O 0 0.00010904488
suggestive O 0 0.00017378358
of O 0 0.00015287135
a O 0 0.00026961486
cause O 0 0.0002964434
- O 0 0.0016934614
and O 0 0.00022354654
- O 0 0.0008275837
effect O 0 0.0001550533
relationship O 0 0.00020002681
between O 0 0.0006454311
sulindac B-Chemical 1 0.99999213
and O 0 0.00800111
hyperkalemia B-Disease 0 0.99994063
. O 0 0.004848075

These O 0 0.0017930603
observations O 0 0.0014668319
indicate O 0 0.0006031328
that O 0 0.0005916096
initial O 0 0.00057773566
hopes O 0 0.0016000507
that O 0 0.000865336
sulindac B-Chemical 1 0.99999547
may O 0 0.00045544768
not O 0 0.00023217291
be O 0 0.00017495839
associated O 0 0.00016007196
with O 0 0.00014310818
the O 0 0.0001199245
adverse O 0 0.00082225504
renal O 0 0.10159571
effects O 0 0.00015348423
of O 0 0.00023313919
other O 0 0.00037973243
NSAID O 0 0.9999523
are O 0 0.0004360481
probably O 0 0.000617954
not O 0 0.00072603585
justified O 0 0.0026413158
. O 0 0.0030258235

Drug O 0 0.8756822
- O 0 0.024916595
induced O 0 0.0056088027
arterial O 0 0.96852624
spasm B-Disease 0 0.9995931
relieved O 0 0.01510026
by O 0 0.0061698603
lidocaine B-Chemical 0 0.999057
. O 0 0.009371827

Case O 0 0.08776306
report O 0 0.046542004
. O 0 0.042901542

Following O 0 0.0022121766
major O 0 0.0022479766
intracranial O 0 0.25440285
surgery O 0 0.0013022781
in O 0 0.0005259504
a O 0 0.00063338486
35 O 0 0.00052092207
- O 0 0.0014024322
year O 0 0.00034531488
- O 0 0.0012309016
old O 0 0.0004921237
man O 0 0.0034284387
, O 0 0.0014487195
sodium B-Chemical 0 0.9996785
pentothal I-Chemical 0 0.999169
was O 0 0.00036861477
intravenously O 0 0.00061712274
infused O 0 0.0009160824
to O 0 0.0003572907
minimize O 0 0.0005798048
cerebral B-Disease 0 0.99945754
ischaemia I-Disease 0 0.999951
. O 0 0.004760323

Intense O 0 0.019218182
vasospasm B-Disease 2 0.99988544
with O 0 0.0045220717
threatened O 0 0.021941949
gangrene B-Disease 0 0.99901724
arose O 0 0.00089425175
in O 0 0.00053539657
the O 0 0.00044399992
arm O 0 0.00073631975
used O 0 0.00050438446
for O 0 0.00059664436
the O 0 0.001038182
infusion O 0 0.0036531875
. O 0 0.0034048897

Since O 0 0.0017980532
the O 0 0.0016672788
cranial O 0 0.009290265
condition O 0 0.0011834207
precluded O 0 0.0005815566
use O 0 0.00032683
of O 0 0.00032695712
more O 0 0.00035235475
usual O 0 0.00030797845
methods O 0 0.00022314557
, O 0 0.00070515485
lidocaine B-Chemical 0 0.99966764
was O 0 0.00016677806
given O 0 9.992279e-05
intra O 0 0.0005909984
- O 0 0.001137779
arterially O 0 0.0010811503
, O 0 0.00023605498
with O 0 0.0001464447
careful O 0 0.00019367725
cardiovascular O 0 0.01746647
monitoring O 0 0.0002847915
, O 0 0.00054459623
to O 0 0.00037417462
counteract O 0 0.0008909047
the O 0 0.0018444652
vasospasm B-Disease 2 0.9999602
. O 0 0.0046539432

The O 0 0.006335138
treatment O 0 0.006447702
was O 0 0.0059465403
rapidly O 0 0.006964976
successful O 0 0.008498974
. O 0 0.012171094

Regional O 0 0.0034056297
localization O 0 0.00095354894
of O 0 0.0012650898
the O 0 0.0009501214
antagonism O 0 0.009128043
of O 0 0.0024097497
amphetamine B-Chemical 1 0.9999887
- O 0 0.09718745
induced O 0 0.0013374933
hyperactivity B-Disease 2 0.9999881
by O 0 0.0015120237
intracerebral O 0 0.9451317
calcitonin B-Chemical 0 0.05476532
injections O 0 0.0014748499
. O 0 0.0023375722

Calcitonin B-Chemical 0 0.09542694
receptors O 0 0.0053027244
are O 0 0.0011797599
found O 0 0.0008780931
in O 0 0.00064671953
the O 0 0.0005112996
brain O 0 0.0013142808
, O 0 0.00065490097
and O 0 0.00041265963
intracerebral O 0 0.38024735
infusions O 0 0.001079466
of O 0 0.00043582616
calcitonin B-Chemical 0 0.0075103645
can O 0 0.0003020951
produce O 0 0.00040341602
behavioral O 0 0.0022027262
effects O 0 0.001543559
. O 0 0.0031760265

Among O 0 0.0029289352
these O 0 0.0015483925
behavioral O 0 0.002395308
effects O 0 0.0006904052
are O 0 0.00044022963
decreases O 0 0.00044716382
in O 0 0.00033220812
food O 0 0.00084079197
intake O 0 0.0028547228
and O 0 0.00037218575
decreases O 0 0.0004970635
in O 0 0.0007912819
amphetamine B-Chemical 1 0.99998295
- O 0 0.019318355
induced O 0 0.0009154214
locomotor O 0 0.010147396
activity O 0 0.00127273
. O 0 0.0028175104

In O 0 0.0015818644
previous O 0 0.0010782254
experiments O 0 0.00065153145
we O 0 0.00039040824
found O 0 0.00046940765
that O 0 0.00029503953
decreases O 0 0.00037578092
in O 0 0.00026215057
food O 0 0.0006920138
intake O 0 0.002341755
were O 0 0.00014126083
induced O 0 0.0001193698
by O 0 0.000119654476
local O 0 0.00014528277
administration O 0 0.00023561338
of O 0 0.00017181085
calcitonin B-Chemical 0 0.0031299875
into O 0 8.505644e-05
several O 0 0.00010358993
hypothalamic O 0 0.00035392292
sites O 0 0.00012821928
and O 0 0.00022607153
into O 0 0.00021449756
the O 0 0.00043021003
nucleus O 0 0.0008057415
accumbens O 0 0.007662219
. O 0 0.0023723543

In O 0 0.0016218069
the O 0 0.0011513085
present O 0 0.0007294897
experiment O 0 0.0006230711
calcitonin B-Chemical 0 0.033834416
decreased O 0 0.0012392246
locomotor O 0 0.0054468075
activity O 0 0.00015591008
when O 0 0.00012897895
locally O 0 0.00035060433
injected O 0 0.00012632366
into O 0 8.8829926e-05
the O 0 0.00011910885
same O 0 0.00011925601
sites O 0 0.00015861186
where O 0 0.00029998363
it O 0 0.00055489154
decreases O 0 0.00074242114
food O 0 0.0025574807
intake O 0 0.020138223
. O 0 0.0032991043

The O 0 0.0021497817
areas O 0 0.0026850074
where O 0 0.0014118367
calcitonin B-Chemical 0 0.012537851
is O 0 0.00044633515
most O 0 0.00040968307
effective O 0 0.00025471047
in O 0 0.00022208008
decreasing O 0 0.00028167453
locomotor O 0 0.0026444332
activity O 0 0.00011437392
are O 0 0.00010041884
located O 0 0.00010083527
in O 0 0.000103957056
the O 0 0.00011299794
hypothalamus O 0 0.00037619146
and O 0 0.00015198012
nucleus O 0 0.00013614222
accumbens O 0 0.0022756767
, O 0 0.00017020883
suggesting O 0 5.67481e-05
that O 0 6.124113e-05
these O 0 9.2868955e-05
areas O 0 0.00016581459
are O 0 6.20641e-05
the O 0 5.8460166e-05
major O 0 7.2572475e-05
sites O 0 5.7877056e-05
of O 0 0.00010705883
action O 0 0.00014637155
of O 0 0.00023239483
calcitonin B-Chemical 0 0.04932099
in O 0 0.00024979253
inhibiting O 0 0.0006798863
amphetamine B-Chemical 1 0.9999944
- O 0 0.063029185
induced O 0 0.0007875073
locomotor O 0 0.016581185
activity O 0 0.0010731386
. O 0 0.002419546

The O 0 0.001903473
hematologic O 0 0.01221179
effects O 0 0.0010203546
of O 0 0.0013843008
cefonicid B-Chemical 0 0.9989297
and O 0 0.0013370176
cefazedone B-Chemical 1 0.9997626
in O 0 0.0003698182
the O 0 0.00024150597
dog O 0 0.00047616215
: O 0 0.0005200075
a O 0 0.00029932283
potential O 0 0.00018965466
model O 0 0.00031206728
of O 0 0.0009575594
cephalosporin B-Chemical 0 0.99988675
hematotoxicity B-Disease 0 0.9998976
in O 0 0.0020387338
man O 0 0.03822458
. O 0 0.0037334813

Cephalosporin B-Chemical 0 0.9921004
antibiotics O 0 0.1838607
cause O 0 0.0018891429
a O 0 0.0011375595
variety O 0 0.0005922413
of O 0 0.0007574049
hematologic B-Disease 0 0.9927538
disturbances I-Disease 0 0.9924442
in O 0 0.00051780575
man O 0 0.005020924
, O 0 0.0005182146
the O 0 0.00021638718
pathogeneses O 0 0.0015854352
and O 0 0.00033776797
hematopathology O 0 0.00070629484
of O 0 0.00039477562
which O 0 0.00051944645
remain O 0 0.0005319754
poorly O 0 0.0016335113
characterized O 0 0.0020973333
. O 0 0.0030928236

There O 0 0.003913779
is O 0 0.0019078846
a O 0 0.0017683969
need O 0 0.00077499513
for O 0 0.00053764984
a O 0 0.0007690339
well O 0 0.0004993758
- O 0 0.0018458271
defined O 0 0.0002603038
animal O 0 0.0002920715
model O 0 0.0002512539
in O 0 0.00029300805
which O 0 0.0004082295
these O 0 0.0005374059
blood B-Disease 0 0.7905604
dyscrasias I-Disease 0 0.9994418
can O 0 0.0006721584
be O 0 0.0009808008
studied O 0 0.0021316325
. O 0 0.003142119

In O 0 0.0017016511
four O 0 0.0013206293
subacute O 0 0.823163
toxicity B-Disease 0 0.38306516
studies O 0 0.0007028922
, O 0 0.0005517795
the O 0 0.00020760299
intravenous O 0 0.0011739195
administration O 0 0.00030867336
of O 0 0.00025782076
cefonicid B-Chemical 0 0.9985875
or O 0 0.00028573466
cefazedone B-Chemical 1 0.9998374
to O 0 0.00015396441
beagle O 0 0.0008511377
dogs O 0 0.00026267272
caused O 0 0.00010314184
a O 0 0.00018839912
dose O 0 0.00034161698
- O 0 0.00095104653
dependent O 0 9.094607e-05
incidence O 0 0.00034778868
of O 0 0.00043684276
anemia B-Disease 0 0.99997234
, O 0 0.0027352415
neutropenia B-Disease 0 0.99909043
, O 0 0.00060825556
and O 0 0.0003780437
thrombocytopenia B-Disease 0 0.99947816
after O 0 0.0001252595
1 O 0 0.0002645033
- O 0 0.000741644
3 O 0 0.00020339982
months O 0 0.0001678767
of O 0 0.0005583493
treatment O 0 0.0011650427
. O 0 0.0025452238

A O 0 0.3598528
nonregenerative O 0 0.60058385
anemia B-Disease 0 0.99964416
was O 0 0.0011480538
the O 0 0.00052054605
most O 0 0.00049781887
compromising O 0 0.0004069469
of O 0 0.00034797503
the O 0 0.00034129876
cytopenias B-Disease 0 0.9985795
and O 0 0.00025565762
occurred O 0 0.00016621144
in O 0 0.00013088658
approximately O 0 0.00017092965
50 O 0 0.00016570158
% O 0 0.00019668367
of O 0 0.000108961416
dogs O 0 0.00021713079
receiving O 0 0.0001475008
400 O 0 0.00042213788
- O 0 0.0007388727
500 O 0 0.00035194925
mg O 0 0.0016962497
/ O 0 0.0006919878
kg O 0 0.00075626705
cefonicid B-Chemical 0 0.9661715
or O 0 0.00029067032
540 O 0 0.0037395656
- O 0 0.0025161626
840 O 0 0.004805967
mg O 0 0.006776946
/ O 0 0.0031960038
kg O 0 0.0048122
cefazedone B-Chemical 1 0.9987263
. O 0 0.0043992754

All O 0 0.0021007243
three O 0 0.0013822418
cytopenias B-Disease 0 0.99452955
were O 0 0.00089777546
completely O 0 0.00055078586
reversible O 0 0.0009020061
following O 0 0.00014906956
cessation O 0 0.00019544926
of O 0 0.00018345314
treatment O 0 0.00018091575
; O 0 0.0002573274
the O 0 8.085692e-05
time O 0 6.190977e-05
required O 0 5.1560273e-05
for O 0 7.6969816e-05
recovery O 0 0.00016145031
of O 0 0.00013807294
the O 0 0.00016276976
erythron O 0 0.93987626
( O 0 0.00032191927
approximately O 0 0.00013109429
1 O 0 9.230012e-05
month O 0 4.9764483e-05
) O 0 0.0001632516
was O 0 7.0102964e-05
considerably O 0 0.000108362925
longer O 0 5.3100193e-05
than O 0 7.242936e-05
that O 0 6.863512e-05
of O 0 0.00014342048
the O 0 0.00017337773
granulocytes O 0 0.16929674
and O 0 0.0003720406
platelets O 0 0.17107002
( O 0 0.00043323482
hours O 0 0.00017000527
to O 0 0.00020326664
a O 0 0.00042391522
few O 0 0.00030552305
days O 0 0.0005011353
) O 0 0.0025353853
. O 0 0.0028111099

Upon O 0 0.0028363008
rechallenge O 0 0.0048291353
with O 0 0.0013310455
either O 0 0.0013609864
cephalosporin B-Chemical 0 0.9993242
, O 0 0.0013888943
the O 0 0.0005204893
hematologic B-Disease 0 0.9959818
syndrome I-Disease 0 0.99879175
was O 0 0.0002597668
reproduced O 0 0.00020499459
in O 0 0.00013953504
most O 0 0.00017169247
dogs O 0 0.00028216638
tested O 0 0.00014398652
; O 0 0.0006783963
cefonicid B-Chemical 0 0.9982608
( O 0 0.0003908376
but O 0 0.0001935384
not O 0 0.0002180507
cefazedone B-Chemical 1 0.9999311
) O 0 0.001740464
- O 0 0.0021811456
treated O 0 0.000301486
dogs O 0 0.0003124028
showed O 0 0.000109487475
a O 0 0.00017386611
substantially O 0 0.0001235904
reduced O 0 0.00012197693
induction O 0 7.9016485e-05
period O 0 8.017725e-05
( O 0 0.00019408099
15 O 0 0.00011000215
+ O 0 0.000456939
/ O 0 0.0008813672
- O 0 0.0006930361
5 O 0 8.20268e-05
days O 0 5.2457315e-05
) O 0 0.0001682512
compared O 0 6.290078e-05
to O 0 7.467762e-05
that O 0 7.2169096e-05
of O 0 0.00012083823
the O 0 9.3521514e-05
first O 0 7.4859934e-05
exposure O 0 0.00014524705
to O 0 0.00011464932
the O 0 0.00015252599
drug O 0 0.002266513
( O 0 0.00049786206
61 O 0 0.0004838324
+ O 0 0.0011854967
/ O 0 0.002184568
- O 0 0.0022357372
24 O 0 0.00064312515
days O 0 0.0005623354
) O 0 0.0026180767
. O 0 0.002995408

This O 0 0.00423418
observation O 0 0.0016568238
, O 0 0.0018872917
along O 0 0.0007287223
with O 0 0.0005773426
the O 0 0.00035894
rapid O 0 0.00045887855
rate O 0 0.00041775397
of O 0 0.00030341742
decline O 0 0.0006736664
in O 0 0.00021571029
red O 0 0.0003357847
cell O 0 0.00026962953
mass O 0 0.00024097945
parameters O 0 0.00015378073
of O 0 0.00015187393
affected O 0 0.00017871789
dogs O 0 0.0004161133
, O 0 0.00025032446
suggests O 0 7.236888e-05
that O 0 0.000107333595
a O 0 0.0005989625
hemolytic B-Disease 0 0.99986064
component O 0 0.00022858511
complicated O 0 0.00055129535
the O 0 0.00013187212
red O 0 0.00032320962
cell O 0 0.00031538008
production O 0 0.00027571016
problem O 0 0.00024498586
and O 0 0.0001665284
that O 0 0.000112325106
multiple O 0 0.00018124381
toxicologic O 0 0.000986532
mechanisms O 0 0.00020834903
contributed O 0 0.0005979266
to O 0 0.0005702879
the O 0 0.0011945167
cytopenia B-Disease 0 0.9994369
. O 0 0.003563044

We O 0 0.0018986145
conclude O 0 0.00095225114
that O 0 0.0006264995
the O 0 0.00047312042
administration O 0 0.00061634067
of O 0 0.00029825402
high O 0 0.00030596528
doses O 0 0.0005807567
of O 0 0.00038319585
cefonicid B-Chemical 0 0.9993062
or O 0 0.00033364497
cefazedone B-Chemical 1 0.9998648
to O 0 0.00015340054
dogs O 0 0.00031934906
can O 0 7.6997865e-05
induce O 0 0.00010707528
hematotoxicity B-Disease 0 0.9998166
similar O 0 7.9469195e-05
to O 0 8.280311e-05
the O 0 0.00014266699
cephalosporin B-Chemical 0 0.9998853
- O 0 0.0072527314
induced O 0 0.00019333848
blood B-Disease 0 0.9561242
dyscrasias I-Disease 0 0.99993527
described O 0 0.00013439989
in O 0 0.0001317217
man O 0 0.0020113538
and O 0 0.0001247252
thus O 0 0.00010080451
provides O 0 6.13326e-05
a O 0 0.00014175467
useful O 0 9.203144e-05
model O 0 0.00010029156
for O 0 0.00010594839
studying O 0 0.0001731166
the O 0 0.0001794034
mechanisms O 0 0.00025337323
of O 0 0.0006687247
these O 0 0.00132379
disorders O 0 0.9905923
. O 0 0.0037889043

Cerebral O 0 0.5745591
blood O 0 0.014524041
flow O 0 0.007133725
and O 0 0.0013645898
metabolism O 0 0.010480607
during O 0 0.00066873356
isoflurane B-Chemical 1 0.9996376
- O 0 0.007857231
induced O 0 0.00048294573
hypotension B-Disease 0 0.999808
in O 0 0.0002879666
patients O 0 0.00039048196
subjected O 0 0.00015564925
to O 0 0.00024179442
surgery O 0 0.00054246467
for O 0 0.00064066215
cerebral B-Disease 0 0.9988427
aneurysms I-Disease 2 0.9998714
. O 0 0.0045378846

Cerebral O 0 0.5137802
blood O 0 0.013203318
flow O 0 0.006883187
and O 0 0.0015633904
cerebral O 0 0.94469786
metabolic O 0 0.0112301335
rate O 0 0.0006847774
for O 0 0.0003789517
oxygen B-Chemical 1 0.9985862
were O 0 0.00019812734
measured O 0 0.00016748064
during O 0 0.00015653111
isoflurane B-Chemical 1 0.9995869
- O 0 0.003513409
induced O 0 0.00023887015
hypotension B-Disease 0 0.999881
in O 0 0.00014723733
10 O 0 0.00011969761
patients O 0 0.00016158693
subjected O 0 7.120474e-05
to O 0 0.000116979565
craniotomy O 0 0.0013645275
for O 0 0.00015343184
clipping O 0 0.0014498393
of O 0 0.00055246206
a O 0 0.00196301
cerebral B-Disease 0 0.9995498
aneurysm I-Disease 0 0.99980944
. O 0 0.004464509

Flow O 0 0.059733313
and O 0 0.003735225
metabolism O 0 0.013429214
were O 0 0.001017456
measured O 0 0.0007605216
5 O 0 0.000544039
- O 0 0.0011831784
13 O 0 0.00027439845
days O 0 0.00012840588
after O 0 0.00012202672
the O 0 0.00029396696
subarachnoid B-Disease 0 0.9999535
haemorrhage I-Disease 0 0.99998343
by O 0 0.00024461103
a O 0 0.000233549
modification O 0 0.00012463292
of O 0 0.00014817943
the O 0 0.00013140881
classical O 0 0.00029380896
Kety O 0 0.015648363
- O 0 0.00094465545
Schmidt O 0 0.00049819605
technique O 0 0.00017422358
using O 0 0.00016956717
xenon B-Chemical 0 0.9012905
- O 0 0.0021802546
133 O 0 0.0004791234
i O 0 0.000311012
. O 0 0.00016562686
v O 0 0.00071070285
. O 0 0.00018966841
Anaesthesia O 0 0.003050483
was O 0 9.8331104e-05
maintained O 0 0.00011771674
with O 0 0.00014086644
an O 0 0.00020313333
inspired O 0 0.0025996973
isoflurane B-Chemical 1 0.9998479
concentration O 0 0.00048528946
of O 0 0.00017657835
0 O 0 0.0002081028
. O 0 0.00012882482
75 O 0 0.00020391012
% O 0 0.00025423494
( O 0 0.00024808693
plus O 0 0.0001793921
67 O 0 0.0004494872
% O 0 0.0010970206
nitrous B-Chemical 0 0.9998292
oxide I-Chemical 0 0.9801451
in O 0 0.0006498261
oxygen B-Chemical 1 0.99987316
) O 0 0.0013735429
, O 0 0.00034604833
during O 0 0.00013723237
which O 0 0.00033061634
CBF O 0 0.9637698
and O 0 0.0005347673
CMRO2 O 0 0.99984956
were O 0 0.00016426407
34 O 0 0.00015424832
. O 0 0.00010714462
3 O 0 0.00011394275
+ O 0 0.00053022266
/ O 0 0.0011422345
- O 0 0.0012411424
2 O 0 0.00020104059
. O 0 0.00015299371
1 O 0 0.00018083211
ml O 0 0.0005051384
/ O 0 0.0006955917
100 O 0 0.00038781244
g O 0 0.0006586629
min O 0 0.0003870584
- O 0 0.0008731072
1 O 0 0.00016913361
and O 0 0.00014263898
2 O 0 0.00016069927
. O 0 0.00014407236
32 O 0 0.00023985808
+ O 0 0.0007244742
/ O 0 0.0013655246
- O 0 0.0013243726
0 O 0 0.00026980258
. O 0 0.00017046025
16 O 0 0.00020514162
ml O 0 0.00058042107
/ O 0 0.00077862525
100 O 0 0.00042748163
g O 0 0.00070051616
min O 0 0.00040362772
- O 0 0.0008305023
1 O 0 0.00017834474
at O 0 0.000142498
PaCO2 O 0 0.26508522
4 O 0 0.00015575362
. O 0 0.00015631663
1 O 0 0.00021659382
+ O 0 0.0007230619
/ O 0 0.0013862671
- O 0 0.0014556567
0 O 0 0.0003722986
. O 0 0.00025962718
1 O 0 0.0003299265
kPa O 0 0.0020580825
( O 0 0.0006514237
mean O 0 0.00043563946
+ O 0 0.0018620577
/ O 0 0.0037034312
- O 0 0.0054668607
SEM O 0 0.0036345914
) O 0 0.004723605
. O 0 0.0045174155

Controlled O 0 0.008987539
hypotension B-Disease 0 0.9985297
to O 0 0.001538323
an O 0 0.0010761034
average O 0 0.00071647984
MAP O 0 0.08082859
of O 0 0.00052723766
50 O 0 0.00056226924
- O 0 0.0011654245
55 O 0 0.00031531544
mm O 0 0.0008688402
Hg B-Chemical 0 0.60815334
was O 0 0.00019171972
induced O 0 0.00014240047
by O 0 0.0001298606
increasing O 0 0.00012633536
the O 0 0.00010994385
dose O 0 0.00025103815
of O 0 0.00023146077
isoflurane B-Chemical 1 0.999716
, O 0 0.00037025296
and O 0 0.00013114279
maintained O 0 0.00013386221
at O 0 0.00010142894
an O 0 0.0001828899
inspired O 0 0.0007949853
concentration O 0 0.00039364782
of O 0 0.00024813143
2 O 0 0.00025636866
. O 0 0.00020915552
2 O 0 0.00029027872
+ O 0 0.0010170013
/ O 0 0.0020665086
- O 0 0.0023658492
0 O 0 0.00080822693
. O 0 0.000737954
2 O 0 0.0012049864
% O 0 0.00279967
. O 0 0.0034328029

This O 0 0.0053448677
resulted O 0 0.0020739725
in O 0 0.0014498911
a O 0 0.0014498712
significant O 0 0.0008514958
decrease O 0 0.0009616251
in O 0 0.0011410596
CMRO2 O 0 0.9998179
( O 0 0.0010214736
to O 0 0.0002575552
1 O 0 0.00027693092
. O 0 0.00022063729
73 O 0 0.00044816648
+ O 0 0.0009145187
/ O 0 0.0015447668
- O 0 0.0014584513
0 O 0 0.00032688797
. O 0 0.00021048049
16 O 0 0.00025484772
ml O 0 0.0006937142
/ O 0 0.0009371235
100 O 0 0.000554934
g O 0 0.0009087268
min O 0 0.0005925199
- O 0 0.0014039482
1 O 0 0.00041857196
) O 0 0.00081736525
, O 0 0.00087175186
while O 0 0.0008885745
CBF O 0 0.8378589
was O 0 0.0013780771
unchanged O 0 0.0024080374
. O 0 0.0034647877

After O 0 0.0017882175
the O 0 0.0017186209
clipping O 0 0.005056593
of O 0 0.0011932696
the O 0 0.00094171515
aneurysm B-Disease 0 0.99162066
the O 0 0.00089157134
isoflurane B-Chemical 1 0.999468
concentration O 0 0.0011542164
was O 0 0.00040952314
reduced O 0 0.0004985421
to O 0 0.0004584381
0 O 0 0.0008420107
. O 0 0.00082637294
75 O 0 0.0017980319
% O 0 0.0029990484
. O 0 0.0035583167

There O 0 0.0043073315
was O 0 0.0023775774
a O 0 0.002054029
significant O 0 0.0010981257
increase O 0 0.00091716356
in O 0 0.001041564
CBF O 0 0.95525444
, O 0 0.0015655704
although O 0 0.0008937665
CMRO2 O 0 0.9997106
was O 0 0.0003950676
unchanged O 0 0.00038879926
, O 0 0.00044898214
compared O 0 0.00021580819
with O 0 0.00044181815
pre O 0 0.0012779434
- O 0 0.007899313
hypotensive B-Disease 0 0.9899277
values O 0 0.0020413091
. O 0 0.0031379028

These O 0 0.0024843581
changes O 0 0.0019985482
might O 0 0.0008148522
offer O 0 0.00097117765
protection O 0 0.0009429066
to O 0 0.00073562155
brain O 0 0.0021161302
tissue O 0 0.0011312023
during O 0 0.00034775652
periods O 0 0.0005235927
of O 0 0.00092562556
induced O 0 0.0020277114
hypotension B-Disease 0 0.9996195
. O 0 0.005064581

Triazolam B-Chemical 0 0.99995124
- O 0 0.04379534
induced O 0 0.0016768042
brief O 0 0.0013180301
episodes O 0 0.002004098
of O 0 0.0010615876
secondary O 0 0.0024048816
mania B-Disease 0 0.9998789
in O 0 0.0014370024
a O 0 0.0029244267
depressed B-Disease 2 0.99223995
patient O 0 0.0033785484
. O 0 0.0036835559

Large O 0 0.008078879
doses O 0 0.005914185
of O 0 0.004800123
triazolam B-Chemical 0 0.9999964
repeatedly O 0 0.0010777356
induced O 0 0.0005290676
brief O 0 0.00051406893
episodes O 0 0.0010783242
of O 0 0.00086579035
mania B-Disease 0 0.999905
in O 0 0.000832418
a O 0 0.002091847
depressed B-Disease 2 0.9982845
elderly O 0 0.7645285
woman O 0 0.010487859
. O 0 0.003776

Features O 0 0.011340587
of O 0 0.0056973
organic B-Disease 0 0.9889177
mental I-Disease 0 0.9356252
disorder I-Disease 0 0.9997267
( O 0 0.016925398
delirium B-Disease 0 0.99981815
) O 0 0.004052259
were O 0 0.001221958
not O 0 0.0013545968
present O 0 0.0021335771
. O 0 0.004726204

Manic B-Disease 0 0.994321
excitement O 0 0.029772857
was O 0 0.0023775876
coincident O 0 0.0016137239
with O 0 0.0009891994
the O 0 0.0006499815
duration O 0 0.0005368572
of O 0 0.0009410657
action O 0 0.0015735734
of O 0 0.0046578944
triazolam B-Chemical 0 0.99999094
. O 0 0.009142274

The O 0 0.0017917482
possible O 0 0.001043476
contribution O 0 0.0007462472
of O 0 0.0010125523
the O 0 0.0008590582
triazolo B-Chemical 0 0.9761294
group O 0 0.0011936198
to O 0 0.0004646004
changes O 0 0.0005578269
in O 0 0.0006650669
affective O 0 0.86244076
status O 0 0.0008518033
is O 0 0.0009222803
discussed O 0 0.0016336885
. O 0 0.0034363442

The O 0 0.0020388374
correlation O 0 0.0016633192
between O 0 0.0018418061
neurotoxic B-Disease 0 0.99675447
esterase O 0 0.78335917
inhibition O 0 0.002311336
and O 0 0.0024300732
mipafox B-Chemical 0 0.99991715
- O 0 0.10293029
induced O 0 0.0013408911
neuropathic B-Disease 0 0.99942625
damage I-Disease 0 0.82694113
in O 0 0.0014016505
rats O 0 0.0028187258
. O 0 0.0031489308

The O 0 0.0016837864
correlation O 0 0.001293148
between O 0 0.0013545688
neuropathic B-Disease 0 0.99867827
damage I-Disease 0 0.76556677
and O 0 0.0007281812
inhibition O 0 0.00073140295
of O 0 0.0009512215
neurotoxic B-Disease 0 0.9991738
esterase O 0 0.7516596
or O 0 0.00047001746
neuropathy B-Disease 0 0.9999417
target O 0 0.000218266
enzyme O 0 0.0019056214
( O 0 0.0013044787
NTE O 0 0.76907635
) O 0 0.0005544487
was O 0 0.00010338921
examined O 0 8.0349935e-05
in O 0 0.00010732397
rats O 0 0.00026215983
acutely O 0 0.0007398422
exposed O 0 0.0002014322
to O 0 0.00022999124
Mipafox B-Chemical 0 0.99923265
( O 0 0.0014786841
N B-Chemical 0 0.9984529
, I-Chemical 0 0.0021703916
N I-Chemical 0 0.99842787
' I-Chemical 0 0.002185044
- I-Chemical 0 0.0033558477
diisopropylphosphorodiamidofluoridate I-Chemical 0 0.00084066094
) O 0 0.00155816
, O 0 0.0014680176
a O 0 0.0025932204
neurotoxic B-Disease 0 0.9982009
organophosphate B-Chemical 0 0.9999031
. O 0 0.006198833

Brain O 0 0.015726544
and O 0 0.002476355
spinal O 0 0.0023768968
cord O 0 0.0043971455
NTE O 0 0.13824077
activities O 0 0.0004431834
were O 0 0.00033570264
measured O 0 0.0003359365
in O 0 0.0003074237
Long O 0 0.0010717823
- O 0 0.0025216858
Evans O 0 0.007202164
male O 0 0.0005049675
rats O 0 0.0002955105
1 O 0 0.00016358789
hr O 0 0.00018516798
post O 0 0.000119963974
- O 0 0.0004738405
exposure O 0 0.00012813618
to O 0 8.8194945e-05
various O 0 0.00012399246
dosages O 0 0.00088486006
of O 0 0.00037896814
Mipafox B-Chemical 0 0.9992399
( O 0 0.0009101692
ip O 0 0.007036959
, O 0 0.00052490394
1 O 0 0.0003754214
- O 0 0.0010794793
15 O 0 0.0004189478
mg O 0 0.002468187
/ O 0 0.002281355
kg O 0 0.0024996956
) O 0 0.003615704
. O 0 0.0034543439

These O 0 0.0022117125
data O 0 0.0020966958
were O 0 0.0011187649
correlated O 0 0.00081607065
with O 0 0.0008447039
histologically O 0 0.005325065
scored O 0 0.0009916864
cervical O 0 0.0043063047
cord B-Disease 0 0.07070982
damage I-Disease 0 0.35156196
in O 0 0.00021112368
a O 0 0.00021654199
separate O 0 9.857031e-05
group O 0 0.00016958399
of O 0 0.0001367896
similarly O 0 0.00013908898
dosed O 0 0.0006985205
rats O 0 0.0002350641
sampled O 0 0.00014131525
14 O 0 0.00018574785
- O 0 0.00062722183
21 O 0 0.00024424447
days O 0 0.00017874618
post O 0 0.00042556904
- O 0 0.0023368215
exposure O 0 0.001729541
. O 0 0.0029921515

Those O 0 0.0051757926
dosages O 0 0.007190376
( O 0 0.0021574814
greater O 0 0.00096998014
than O 0 0.0004913231
or O 0 0.00034796144
equal O 0 0.00032653505
to O 0 0.0002292163
10 O 0 0.00026677074
mg O 0 0.0017113634
/ O 0 0.000751588
kg O 0 0.00053660944
) O 0 0.00039330832
that O 0 0.00011727811
inhibited O 0 0.00030007743
mean O 0 0.00022677249
NTE O 0 0.36225206
activity O 0 0.00010716557
in O 0 0.00010217409
the O 0 8.5316555e-05
spinal O 0 0.0001607871
cord O 0 0.0002636892
greater O 0 0.00011191615
than O 0 7.608761e-05
or O 0 7.580443e-05
equal O 0 0.000103719416
to O 0 9.5472526e-05
73 O 0 0.00024362812
% O 0 0.00021929333
and O 0 0.000116466465
brain O 0 0.0003276424
greater O 0 0.00012350004
than O 0 7.806293e-05
or O 0 7.4902346e-05
equal O 0 9.977055e-05
to O 0 8.839027e-05
67 O 0 0.00018483425
% O 0 0.00016403742
of O 0 8.684868e-05
control O 0 9.526509e-05
values O 0 0.00010413574
produced O 0 0.00010015661
severe O 0 0.00088963326
( O 0 0.00022059014
greater O 0 0.00013458624
than O 0 8.7968925e-05
or O 0 8.623519e-05
equal O 0 0.00011757586
to O 0 0.00010644481
3 O 0 0.00013053883
) O 0 0.00038320373
cervical O 0 0.00080725475
cord O 0 0.0007545225
pathology O 0 0.0007177944
in O 0 0.0002651886
85 O 0 0.0005412447
% O 0 0.00067123846
of O 0 0.00056822
the O 0 0.0007485781
rats O 0 0.0022943725
. O 0 0.0029042112

In O 0 0.0019674376
contrast O 0 0.0023592361
, O 0 0.002494221
dosages O 0 0.005953459
of O 0 0.0015324734
Mipafox B-Chemical 0 0.9992906
( O 0 0.0011209281
less O 0 0.00040360447
than O 0 0.00018868857
or O 0 0.00015024241
equal O 0 0.00016524103
to O 0 0.00012764399
5 O 0 0.00015066391
mg O 0 0.0011473098
/ O 0 0.00056803046
kg O 0 0.00044633984
) O 0 0.00037746836
which O 0 0.00016166785
inhibited O 0 0.0002545699
mean O 0 0.00018830359
NTE O 0 0.32698295
activity O 0 9.4676885e-05
in O 0 0.00010158149
spinal O 0 0.00017513566
cord O 0 0.00030468067
less O 0 0.000118475975
than O 0 7.3624964e-05
or O 0 7.441921e-05
equal O 0 0.00010207125
to O 0 9.200836e-05
61 O 0 0.00018206863
% O 0 0.00021535557
and O 0 0.000121050885
brain O 0 0.0003804842
less O 0 0.0001332485
than O 0 7.713941e-05
or O 0 7.5461554e-05
equal O 0 0.000101490084
to O 0 8.992151e-05
60 O 0 0.00012875421
% O 0 0.00019248041
produced O 0 8.690808e-05
this O 0 0.00013827796
degree O 0 0.00029708448
of O 0 0.00040417508
cord B-Disease 0 0.19686973
damage I-Disease 0 0.6727473
in O 0 0.0002562531
only O 0 0.0002721318
9 O 0 0.0002562428
% O 0 0.0005258474
of O 0 0.0004569266
the O 0 0.000575481
animals O 0 0.0009337261
. O 0 0.0025545645

These O 0 0.0020286872
data O 0 0.0017044262
indicate O 0 0.00060074794
that O 0 0.00058053277
a O 0 0.00073474087
critical O 0 0.00030522203
percentage O 0 0.0002950584
of O 0 0.00060544326
NTE O 0 0.79491353
inhibition O 0 0.00052205584
in O 0 0.00025098378
brain O 0 0.0007218554
and O 0 0.0001542698
spinal O 0 0.00020519736
cord O 0 0.0003327108
sampled O 0 9.1130285e-05
shortly O 0 0.0001169247
after O 0 9.085142e-05
Mipafox B-Chemical 0 0.9914077
exposure O 0 0.0002086675
can O 0 0.000102946404
predict O 0 0.00015164631
neuropathic B-Disease 0 0.9986468
damage I-Disease 0 0.4432231
in O 0 0.00026011324
rats O 0 0.0003958381
several O 0 0.00022815292
weeks O 0 0.0002911346
later O 0 0.0008711444
. O 0 0.0021293173

Allergic B-Disease 0 0.36038294
reaction I-Disease 0 0.006691615
to O 0 0.0032355185
5 B-Chemical 0 0.0035681156
- I-Chemical 0 0.013618196
fluorouracil I-Chemical 0 0.9972771
infusion O 0 0.011457828
. O 0 0.00708485

An O 0 0.0054374696
allergic B-Disease 0 0.99294925
reaction I-Disease 0 0.0028031014
consisting O 0 0.0010670293
of O 0 0.0029161267
angioneurotic B-Disease 0 0.99998236
edema I-Disease 0 0.99998534
secondary O 0 0.0004911523
to O 0 0.00012828178
continuous O 0 0.000109036555
infusion O 0 0.00028403662
5 B-Chemical 0 0.00013093126
- I-Chemical 0 0.0014243583
fluorouracil I-Chemical 0 0.9996518
occurred O 0 0.00013167584
in O 0 0.00010160639
a O 0 0.00017417294
patient O 0 0.00014958544
with O 0 0.00016381124
recurrent O 0 0.0032536758
carcinoma B-Disease 0 0.9916099
of I-Disease 0 0.00018217975
the I-Disease 0 0.0001215106
oral I-Disease 0 0.00075204915
cavity I-Disease 0 0.00028371369
, O 0 0.0005731903
cirrhosis B-Disease 0 0.99998057
, O 0 0.00088437623
and O 0 0.0005202809
cisplatin B-Chemical 0 0.9999231
- O 0 0.009144905
induced O 0 0.000483616
impaired B-Disease 0 0.031308386
renal I-Disease 0 0.91328174
function I-Disease 0 0.0022322428
. O 0 0.0027645968

This O 0 0.0051769046
reaction O 0 0.0021189756
occurred O 0 0.0012815313
during O 0 0.0007262746
the O 0 0.00069328886
sixth O 0 0.0011570432
and O 0 0.0007606283
seventh O 0 0.0010925042
courses O 0 0.0013477985
of O 0 0.0015138952
infusional O 0 0.7675564
chemotherapy O 0 0.007823051
. O 0 0.0034193764

Oral O 0 0.7954093
diphenhydramine B-Chemical 0 0.99997556
and O 0 0.004793067
prednisone B-Chemical 0 0.99962604
were O 0 0.00082451274
ineffective O 0 0.0011072889
in O 0 0.00044902408
preventing O 0 0.00044756473
the O 0 0.0005224723
recurrence O 0 0.005274152
of O 0 0.000913016
the O 0 0.0012549417
allergic B-Disease 0 0.9973797
reaction I-Disease 0 0.0046858415
. O 0 0.0038047472

Discontinuance O 0 0.0166804
of O 0 0.0019891113
effective O 0 0.0012954769
chemotherapy O 0 0.0038539318
in O 0 0.0005308831
this O 0 0.0004619014
patient O 0 0.00040840133
during O 0 0.00023551704
partial O 0 0.0005192128
remission O 0 0.0036149293
resulted O 0 0.00043218213
in O 0 0.0007871362
fatal O 0 0.73090726
disease O 0 0.6967011
progression O 0 0.015450331
. O 0 0.0035429478

Myasthenia B-Disease 0 0.98980284
gravis I-Disease 0 0.9990088
caused O 0 0.0036957366
by O 0 0.003776933
penicillamine B-Chemical 1 0.9999722
and O 0 0.0038327347
chloroquine B-Chemical 1 0.9994785
therapy O 0 0.002589263
for O 0 0.0015687228
rheumatoid B-Disease 0 0.99973625
arthritis I-Disease 0 0.9996966
. O 0 0.006896395

We O 0 0.002619477
have O 0 0.0015425597
described O 0 0.00095564267
a O 0 0.000985067
unique O 0 0.0004889756
patient O 0 0.00054465514
who O 0 0.0004820091
had O 0 0.00028018988
reversible O 0 0.0006590352
and O 0 0.0002454254
dose O 0 0.00049024087
- O 0 0.001117122
related O 0 0.00016614632
myasthenia B-Disease 0 0.9976763
gravis I-Disease 0 0.9982583
after O 0 0.0002930986
penicillamine B-Chemical 1 0.9999893
and O 0 0.00097560923
chloroquine B-Chemical 1 0.9996762
therapy O 0 0.0012168967
for O 0 0.0007903535
rheumatoid B-Disease 0 0.9998753
arthritis I-Disease 0 0.99983466
. O 0 0.004958136

Although O 0 0.0044129677
acetylcholine B-Chemical 1 0.9992131
receptor O 0 0.008710652
antibodies O 0 0.0014773464
were O 0 0.0007027465
not O 0 0.00047186905
detectable O 0 0.000352364
, O 0 0.00059400557
the O 0 0.00024190117
time O 0 0.00020867883
course O 0 0.00034286777
was O 0 0.00032191313
consistent O 0 0.00035091882
with O 0 0.0006487231
an O 0 0.0012693419
autoimmune O 0 0.4781837
process O 0 0.0022321695
. O 0 0.0035028209

On O 0 0.002788157
the O 0 0.0014162044
mechanisms O 0 0.0008909175
of O 0 0.0009741172
the O 0 0.0005941967
development O 0 0.00064022787
of O 0 0.0005143277
tolerance O 0 0.0017669937
to O 0 0.0003312764
the O 0 0.0004083293
muscular B-Disease 0 0.36710954
rigidity I-Disease 0 0.9004334
produced O 0 0.0005018179
by O 0 0.00084887753
morphine B-Chemical 0 0.9992073
in O 0 0.0012084242
rats O 0 0.0024841405
. O 0 0.0028446687

The O 0 0.0022124462
development O 0 0.00213791
of O 0 0.0014989625
tolerance O 0 0.003317462
to O 0 0.000704929
the O 0 0.0007341004
muscular B-Disease 0 0.4316377
rigidity I-Disease 0 0.9065218
produced O 0 0.0005512354
by O 0 0.00079776085
morphine B-Chemical 0 0.99941707
was O 0 0.0007206659
studied O 0 0.00093896827
in O 0 0.00096960686
rats O 0 0.002480452
. O 0 0.0031276692

Saline O 0 0.9350456
- O 0 0.01603728
pretreated O 0 0.0040935962
controls O 0 0.0011568217
given O 0 0.00038372597
a O 0 0.00051836524
test O 0 0.00044081738
dose O 0 0.00053586834
of O 0 0.00043988062
morphine B-Chemical 0 0.9994717
( O 0 0.0005318665
20 O 0 0.00021206563
mg O 0 0.001332338
/ O 0 0.0005546961
kg O 0 0.00036580002
i O 0 0.00027541484
. O 0 0.00014066859
p O 0 0.0002555692
. O 0 0.00015339234
) O 0 0.00032389502
showed O 0 0.00015558308
a O 0 0.0003267365
pronounced O 0 0.0005913115
rigidity B-Disease 0 0.7901196
recorded O 0 0.00030934624
as O 0 0.000263395
tonic O 0 0.0008588302
activity O 0 0.00029071854
in O 0 0.0005324658
the O 0 0.00089954276
electromyogram O 0 0.022130372
. O 0 0.0027783685

Rats O 0 0.0065146033
treated O 0 0.0026068126
for O 0 0.0007684123
11 O 0 0.0006625585
days O 0 0.0003239123
with O 0 0.0005788584
morphine B-Chemical 0 0.9986318
and O 0 0.0004115243
withdrawn O 0 0.0006244959
for O 0 0.00014845918
36 O 0 0.00022530762
- O 0 0.00065145787
40 O 0 0.00014215994
h O 0 0.0001256333
showed O 0 9.3008006e-05
differences O 0 8.0911756e-05
in O 0 9.7266944e-05
the O 0 8.781965e-05
development O 0 0.00013702903
of O 0 0.00013557766
tolerance O 0 0.000948511
: O 0 0.0002840003
about O 0 0.00010997551
half O 0 6.691066e-05
of O 0 8.715399e-05
the O 0 6.4060856e-05
animals O 0 5.8969905e-05
showed O 0 9.4247574e-05
a O 0 0.00022913938
rigidity B-Disease 0 0.40285
after O 0 4.5103916e-05
the O 0 5.5024848e-05
test O 0 0.000113556816
dose O 0 0.00020029685
of O 0 0.00018255536
morphine B-Chemical 0 0.9997913
that O 0 8.149243e-05
was O 0 8.211595e-05
not O 0 7.593068e-05
significantly O 0 0.00012875385
less O 0 0.00014877094
than O 0 8.940388e-05
in O 0 9.6468946e-05
the O 0 0.00010718243
controls O 0 0.00026288218
and O 0 0.00028148553
were O 0 0.00042576506
akinetic B-Disease 2 0.99717027
( O 0 0.0012566084
A O 0 0.0072221607
group O 0 0.0018681668
) O 0 0.003887598
. O 0 0.0032041473

The O 0 0.0017188934
other O 0 0.0013055986
rats O 0 0.0015955209
showed O 0 0.0007111958
a O 0 0.00074179855
strong O 0 0.0003889917
decrease O 0 0.00040589832
in O 0 0.0002938801
the O 0 0.0002901747
rigidity B-Disease 0 0.6442233
and O 0 0.00025478308
the O 0 0.00015330607
occurrence O 0 0.00020979985
of O 0 0.00027875768
stereotyped O 0 0.11426439
( O 0 0.00089063396
S O 0 0.9428273
) O 0 0.0011552272
licking O 0 0.004460513
and O 0 0.00022263976
/ O 0 0.0012983227
or O 0 0.00019997609
gnawing O 0 0.7682706
in O 0 0.00016971404
presence O 0 0.00016201985
of O 0 0.00037213624
akinetic B-Disease 2 0.9997534
or O 0 0.0005074745
hyperkinetic B-Disease 0 0.99999154
( O 0 0.0023162786
K O 0 0.9996753
) O 0 0.0013755916
behaviour O 0 0.00060181273
( O 0 0.00070656993
AS O 0 0.13796419
/ O 0 0.016023854
KS O 0 0.9921691
group O 0 0.000643504
) O 0 0.00088070234
, O 0 0.00052906055
suggesting O 0 0.00026078423
signs O 0 0.0019982774
of O 0 0.0008752537
dopaminergic O 0 0.0071403375
activation O 0 0.0014591076
. O 0 0.0026588065

The O 0 0.0034840303
rigidity B-Disease 0 0.680234
was O 0 0.0018891224
considerably O 0 0.0017376894
decreased O 0 0.0014029385
in O 0 0.0006025571
both O 0 0.00046049638
groups O 0 0.0005909281
after O 0 0.00032617195
20 O 0 0.00056097994
days O 0 0.00048953894
' O 0 0.0019231866
treatment O 0 0.0020522852
. O 0 0.0039355326

In O 0 0.002325892
a O 0 0.0024037128
further O 0 0.0009933145
series O 0 0.0010163941
of O 0 0.00068816554
experiments O 0 0.0005399053
, O 0 0.0031933617
haloperidol B-Chemical 1 0.99999607
( O 0 0.0011764445
0 O 0 0.00035727298
. O 0 0.00019097133
2 O 0 0.00020672363
mg O 0 0.001074338
/ O 0 0.0005848143
kg O 0 0.00040418952
i O 0 0.00030839685
. O 0 0.0001571038
p O 0 0.00028020298
. O 0 0.00016313334
) O 0 0.0003200208
was O 0 0.00011499531
used O 0 0.00010088183
in O 0 0.00010177239
order O 0 7.282919e-05
to O 0 8.9190406e-05
block O 0 0.00011607474
the O 0 0.00010994259
dopaminergic O 0 0.00077050907
activation O 0 8.91274e-05
and O 0 9.2425005e-05
to O 0 6.882776e-05
estimate O 0 5.8000816e-05
the O 0 6.894015e-05
real O 0 8.2721665e-05
degree O 0 0.00018010338
of O 0 0.0001541019
the O 0 0.0001311733
tolerance O 0 0.0010197889
to O 0 0.00017002263
the O 0 0.00024449048
rigidity B-Disease 0 0.8405796
without O 0 0.0005033198
any O 0 0.0005904552
dopaminergic O 0 0.006503558
interference O 0 0.0019758437
. O 0 0.0027762621

Haloperidol B-Chemical 1 0.99993956
enhanced O 0 0.0074195215
the O 0 0.0041816127
rigidity B-Disease 0 0.81226104
in O 0 0.0029713742
the O 0 0.0027440733
A O 0 0.018434461
group O 0 0.006718975
. O 0 0.007409005

However O 0 0.0034749366
, O 0 0.0038671345
the O 0 0.0013158895
level O 0 0.0009634785
in O 0 0.00085351686
the O 0 0.0008073077
AS O 0 0.12893416
/ O 0 0.020945866
KS O 0 0.98548234
group O 0 0.0007284411
remained O 0 0.00050021
considerably O 0 0.0005204356
lower O 0 0.00045864636
than O 0 0.00036377588
in O 0 0.00048340627
the O 0 0.00072090945
A O 0 0.008988729
group O 0 0.0031296057
. O 0 0.0037289683

The O 0 0.0018602933
results O 0 0.0013182523
suggest O 0 0.00078403816
that O 0 0.0010693606
rigidity B-Disease 0 0.9554537
, O 0 0.0022100285
which O 0 0.00067658105
is O 0 0.00030283016
assumed O 0 0.00026762794
to O 0 0.00018785312
be O 0 0.00015858917
due O 0 9.855114e-05
to O 0 0.00010148874
an O 0 0.0001292126
action O 0 0.00014653453
of O 0 0.0002917798
morphine B-Chemical 0 0.99983597
in O 0 0.00018860314
the O 0 0.00015332391
striatum O 0 0.003495206
, O 0 0.00029311422
can O 0 9.1812224e-05
be O 0 0.00013804858
antagonized O 0 0.0020924609
by O 0 0.00019038228
another O 0 0.00026255153
process O 0 0.00019019503
leading O 0 0.00024492817
to O 0 0.00023838595
dopaminergic O 0 0.0019110852
activation O 0 0.000316452
in O 0 0.0004482827
the O 0 0.00074625964
striatum O 0 0.0066551855
. O 0 0.0025062084

Nevertheless O 0 0.003889461
, O 0 0.004771611
there O 0 0.0018108055
occurs O 0 0.0015239293
some O 0 0.0013316566
real O 0 0.0012367847
tolerance O 0 0.0036862919
to O 0 0.0012794415
this O 0 0.0017782407
effect O 0 0.0025308318
. O 0 0.0053735953

The O 0 0.0020460316
rapid O 0 0.0023150425
alternations O 0 0.0039688884
of O 0 0.0015409221
rigidity B-Disease 0 0.8670863
and O 0 0.000671344
the O 0 0.00035141245
signs O 0 0.001513499
of O 0 0.00036400484
dopaminergic O 0 0.0019824007
activation O 0 0.00015353662
observed O 0 0.0001154264
in O 0 0.00010907046
the O 0 8.613007e-05
animals O 0 7.894901e-05
of O 0 0.00014686506
the O 0 0.00017865638
AS O 0 0.24586928
/ O 0 0.04442399
KS O 0 0.9970583
group O 0 0.0003310661
might O 0 7.438019e-05
be O 0 0.000101322024
due O 0 7.428492e-05
to O 0 9.15833e-05
rapid O 0 0.0001706764
shifts O 0 0.00016946212
in O 0 0.00013218446
the O 0 0.00013889879
predominance O 0 0.000354771
of O 0 0.00037260464
various O 0 0.0007979848
DA O 0 0.99949586
- O 0 0.010770236
innervated O 0 0.0017134054
structures O 0 0.0014398687
. O 0 0.0028196776

A O 0 0.032466065
case O 0 0.0048702084
of O 0 0.0040082466
massive O 0 0.022054497
rhabdomyolysis B-Disease 0 0.99986386
following O 0 0.004042057
molindone B-Chemical 0 0.9999907
administration O 0 0.01734738
. O 0 0.0054332777

Rhabdomyolysis B-Disease 0 0.9978339
is O 0 0.0024422505
a O 0 0.002148338
potentially O 0 0.0012850215
lethal O 0 0.0028394947
syndrome O 0 0.9263312
that O 0 0.001045258
psychiatric B-Disease 2 0.99946207
patients O 0 0.0031611042
seem O 0 0.0009316107
predisposed O 0 0.0031993676
to O 0 0.0011109445
develop O 0 0.002089499
. O 0 0.0035240597

The O 0 0.002190458
clinical O 0 0.0039337156
signs O 0 0.00415161
and O 0 0.0012071604
symptoms O 0 0.0054260115
, O 0 0.0010162146
typical O 0 0.0004924332
laboratory O 0 0.00046394096
features O 0 0.0005003971
, O 0 0.00068883185
and O 0 0.0005142123
complications O 0 0.006135414
of O 0 0.0013927858
rhabdomyolysis B-Disease 0 0.999861
are O 0 0.0011625362
presented O 0 0.0014633308
. O 0 0.002824061

The O 0 0.002150543
case O 0 0.0019964296
of O 0 0.0017061066
a O 0 0.0038025316
schizophrenic B-Disease 0 0.99996686
patient O 0 0.0010397577
is O 0 0.00029487812
reported O 0 0.00027039796
to O 0 0.00016861127
illustrate O 0 0.00017083695
massive O 0 0.0027342571
rhabdomyolysis B-Disease 0 0.99995744
and O 0 0.000311962
subsequent O 0 0.00021589405
acute B-Disease 0 0.043345388
renal I-Disease 0 0.8596705
failure I-Disease 0 0.04357641
following O 0 0.00057732937
molindone B-Chemical 0 0.99999547
administration O 0 0.0053065694
. O 0 0.0023512568

Physicians O 0 0.0068102465
who O 0 0.0058031618
prescribe O 0 0.07693148
molindone B-Chemical 0 0.9999896
should O 0 0.0013641337
be O 0 0.0012764107
aware O 0 0.0013481529
of O 0 0.0016805737
this O 0 0.0022349749
reaction O 0 0.0030618617
. O 0 0.0049895514

Compression B-Disease 0 0.17757125
neuropathy I-Disease 0 0.9989415
of I-Disease 0 0.0026801033
the I-Disease 0 0.0014912814
radial I-Disease 0 0.015249931
nerve I-Disease 0 0.022006216
due O 0 0.0007185106
to O 0 0.001183229
pentazocine B-Chemical 0 0.99998045
- O 0 0.08713817
induced O 0 0.002742338
fibrous B-Disease 0 0.9915953
myopathy I-Disease 0 0.99986064
. O 0 0.0076072593

Fibrous B-Disease 0 0.98734844
myopathy I-Disease 0 0.9996803
is O 0 0.0020850543
a O 0 0.0017837136
common O 0 0.0010267309
, O 0 0.001230312
well O 0 0.0006671765
- O 0 0.0028238825
known O 0 0.00047364386
side O 0 0.0010176334
effect O 0 0.00046563562
of O 0 0.000783157
repeated O 0 0.0008517961
pentazocine B-Chemical 0 0.99994814
injection O 0 0.0019522152
. O 0 0.0028417432

However O 0 0.0034755906
, O 0 0.0058317524
compression B-Disease 0 0.4011941
neuropathy I-Disease 0 0.9999454
due O 0 0.000933385
to O 0 0.0006812776
fibrotic O 0 0.050419677
muscle O 0 0.0034645973
affected O 0 0.00044301464
by O 0 0.00062716566
pentazocine B-Chemical 0 0.999995
- O 0 0.08428271
induced O 0 0.0007513994
myopathy B-Disease 0 0.9997266
has O 0 0.00036490092
not O 0 0.000431642
previously O 0 0.0007605354
been O 0 0.0009967929
reported O 0 0.0017853895
. O 0 0.00292375

In O 0 0.0025854316
a O 0 0.003335664
37 O 0 0.0034588268
- O 0 0.004648107
year O 0 0.0008792073
- O 0 0.0022236693
old O 0 0.0006531927
woman O 0 0.0011032778
with O 0 0.00047392503
documented O 0 0.0016199372
pentazocine B-Chemical 0 0.99999607
- O 0 0.09713036
induced O 0 0.000580068
fibrous B-Disease 0 0.99085194
myopathy I-Disease 0 0.999974
of O 0 0.0005430257
triceps O 0 0.23495828
and O 0 0.00023327883
deltoid O 0 0.083119504
muscles O 0 0.00031926204
bilaterally O 0 0.0005579386
and O 0 8.962539e-05
a O 0 0.0001066245
three O 0 4.4179626e-05
- O 0 0.00034866805
week O 0 5.0317845e-05
history O 0 0.00011734333
of O 0 9.516731e-05
right O 0 0.00029485478
wrist O 0 0.0014705185
drop O 0 0.00029497093
, O 0 0.00021975317
electrodiagnostic O 0 0.00090258813
examination O 0 6.998354e-05
showed O 0 8.437358e-05
a O 0 0.00020947363
severe O 0 0.0011240558
but O 0 0.00014653004
partial O 0 0.00018215129
lesion O 0 0.0003523645
of O 0 0.00010549674
the O 0 8.7159395e-05
right O 0 0.00040721372
radial O 0 0.0126458835
nerve O 0 0.010814933
distal O 0 0.00024070848
to O 0 8.0328704e-05
the O 0 8.6583415e-05
branches O 0 0.00030993694
to O 0 0.00012680351
the O 0 0.00017887898
triceps O 0 0.03317258
, O 0 0.00037639934
in O 0 0.00019246612
addition O 0 0.00017329527
to O 0 0.0004191683
the O 0 0.00094439444
fibrous B-Disease 0 0.98134375
myopathy I-Disease 0 0.9998895
. O 0 0.005294507

Surgery O 0 0.0060586613
revealed O 0 0.0016019599
the O 0 0.0012140688
right O 0 0.00260732
radial O 0 0.019226525
nerve O 0 0.02022911
to O 0 0.00049186585
be O 0 0.0004512033
severely O 0 0.0016055369
compressed O 0 0.00090704777
by O 0 0.00035775045
the O 0 0.00035106525
densely O 0 0.00074490055
fibrotic O 0 0.007223604
lateral O 0 0.0023928313
head O 0 0.0021050093
of O 0 0.0010769931
the O 0 0.0013902368
triceps O 0 0.06656599
. O 0 0.0036588502

Decompression O 0 0.01863989
and O 0 0.0033379886
neurolysis O 0 0.017215269
were O 0 0.0009952546
performed O 0 0.00066852255
with O 0 0.0007128854
good O 0 0.00089715683
subsequent O 0 0.00073291
recovery O 0 0.0013235869
of O 0 0.0014586227
function O 0 0.0021535156
. O 0 0.0045017162

Recurrent O 0 0.01791565
reversible O 0 0.015224074
acute B-Disease 0 0.20065859
renal I-Disease 0 0.89258295
failure I-Disease 0 0.09240715
from O 0 0.0044572325
amphotericin B-Chemical 0 0.9976694
. O 0 0.008506094

A O 0 0.042043667
patient O 0 0.0035285268
with O 0 0.0031790377
cryptogenic O 0 0.9998988
cirrhosis B-Disease 0 0.99998844
and O 0 0.0031968243
disseminated O 0 0.92058265
sporotrichosis B-Disease 0 0.9996686
developed O 0 0.00045908202
acute B-Disease 0 0.053641792
renal I-Disease 0 0.80612975
failure I-Disease 0 0.00453819
immediately O 0 6.890794e-05
following O 0 5.0590126e-05
the O 0 7.725985e-05
administration O 0 0.00021912194
of O 0 0.00031204414
amphotericin B-Chemical 0 0.9998871
B I-Chemical 0 0.34614238
on O 0 0.00030562503
four O 0 0.00028076055
separate O 0 0.00051344093
occasions O 0 0.0016571293
. O 0 0.0024499227

The O 0 0.0026006694
abruptness O 0 0.008317643
of O 0 0.0014894635
the O 0 0.0009865541
renal B-Disease 0 0.68610597
failure I-Disease 0 0.023566473
and O 0 0.00040478836
its O 0 0.00033382603
reversibility O 0 0.0005230012
within O 0 8.257058e-05
days O 0 7.724821e-05
suggests O 0 7.3104944e-05
that O 0 9.935944e-05
there O 0 0.00013661414
was O 0 0.00019302846
a O 0 0.0002945446
functional O 0 0.00020163145
component O 0 0.00028678082
to O 0 0.00034313952
the O 0 0.0006833877
renal B-Disease 0 0.9977016
dysfunction I-Disease 0 0.9979924
. O 0 0.0041872873

We O 0 0.0021480832
propose O 0 0.0012817956
that O 0 0.0013705924
amphotericin B-Chemical 0 0.99947315
, O 0 0.0017688744
in O 0 0.0004194391
the O 0 0.00024393956
setting O 0 0.00022057712
of O 0 0.00022769805
reduced O 0 0.00024634792
effective O 0 0.0002242769
arterial O 0 0.17737816
volume O 0 0.00049805664
, O 0 0.0003240902
may O 0 0.000116620824
activate O 0 9.712986e-05
tubuloglomerular O 0 0.7360919
feedback O 0 0.00034098103
, O 0 0.0004454684
thereby O 0 0.00026451788
contributing O 0 0.00045087398
to O 0 0.00048806577
acute B-Disease 0 0.10444037
renal I-Disease 0 0.9368293
failure I-Disease 0 0.12470046
. O 0 0.0030271483

Cerebral B-Disease 0 0.9973138
infarction I-Disease 0 0.99993503
with O 0 0.0036691832
a O 0 0.0024773816
single O 0 0.0011559295
oral O 0 0.0034654469
dose O 0 0.0026458672
of O 0 0.0036859678
phenylpropanolamine B-Chemical 0 0.99995375
. O 0 0.007493681

Phenylpropanolamine B-Chemical 0 0.999361
( O 0 0.025076948
PPA B-Chemical 1 0.9996768
) O 0 0.0042374847
, O 0 0.0013920094
a O 0 0.00075556146
synthetic O 0 0.0004918923
sympathomimetic O 0 0.9761855
that O 0 0.00022245306
is O 0 0.00017840308
structurally O 0 0.00025139572
similar O 0 0.00014176144
to O 0 0.0002877846
amphetamine B-Chemical 1 0.99998987
, O 0 0.00049397285
is O 0 9.925148e-05
available O 0 7.6341836e-05
over O 0 7.895074e-05
the O 0 9.601357e-05
counter O 0 0.00031652563
in O 0 0.00026207586
anorectics O 0 0.97883236
, O 0 0.0006856923
nasal O 0 0.00074124197
congestants O 0 0.0006285339
, O 0 0.00085481297
and O 0 0.00074203
cold O 0 0.0024331016
preparations O 0 0.0021140901
. O 0 0.0030865152

Its O 0 0.011516191
prolonged O 0 0.0023999938
use O 0 0.001110287
or O 0 0.0009382313
overuse O 0 0.0077056815
has O 0 0.0003527223
been O 0 0.0003454247
associated O 0 0.00041203303
with O 0 0.0007353124
seizures B-Disease 0 0.99996567
, O 0 0.0024850694
intracerebral B-Disease 0 0.9961726
hemorrhage I-Disease 2 0.9999647
, O 0 0.0034321358
neuropsychiatric B-Disease 0 0.99991274
symptoms I-Disease 0 0.47715983
, O 0 0.000972353
and O 0 0.0009849163
nonhemorrhagic O 0 0.9992995
cerebral B-Disease 0 0.99936515
infarction I-Disease 0 0.9999536
. O 0 0.0038788107

We O 0 0.002909059
report O 0 0.002918807
the O 0 0.0011374397
case O 0 0.0009843694
of O 0 0.00080615585
a O 0 0.00106938
young O 0 0.003296302
woman O 0 0.0025647383
who O 0 0.00080994953
suffered O 0 0.0022007716
a O 0 0.0009645633
cerebral B-Disease 0 0.99885464
infarction I-Disease 0 0.9999765
after O 0 0.00014004597
taking O 0 0.00024287736
a O 0 0.0003035638
single O 0 0.000228332
oral O 0 0.001166424
dose O 0 0.0010464764
of O 0 0.0017043111
PPA B-Chemical 1 0.9995683
. O 0 0.004045233

Remission O 0 0.08053193
induction O 0 0.0021933352
of O 0 0.0032409227
meningeal B-Disease 0 0.99912137
leukemia I-Disease 0 0.999913
with O 0 0.0015051514
high O 0 0.0013764591
- O 0 0.0044023567
dose O 0 0.0021105695
intravenous O 0 0.041163355
methotrexate B-Chemical 0 0.99956435
. O 0 0.004367341

Twenty O 0 0.0060322783
children O 0 0.0050496217
with O 0 0.0024199616
acute B-Disease 0 0.9763193
lymphoblastic I-Disease 0 0.99995613
leukemia I-Disease 0 0.99998105
who O 0 0.0027473122
developed O 0 0.0009766142
meningeal B-Disease 0 0.9997695
disease I-Disease 0 0.98751885
were O 0 0.00014158702
treated O 0 0.00020685335
with O 0 0.000106885826
a O 0 0.00013624299
high O 0 0.00013380962
- O 0 0.0005965212
dose O 0 0.00017837246
intravenous O 0 0.003434694
methotrexate B-Chemical 0 0.9999285
regimen O 0 0.000106615065
that O 0 4.660141e-05
was O 0 5.982046e-05
designed O 0 5.5512526e-05
to O 0 5.5047207e-05
achieve O 0 5.8769383e-05
and O 0 0.000109093664
maintain O 0 0.00013616275
CSF O 0 0.88118833
methotrexate B-Chemical 0 0.9999815
concentrations O 0 0.00042002788
of O 0 0.00017635021
10 O 0 0.00017308127
( O 0 0.00033068695
- O 0 0.00079343
5 O 0 0.00016343057
) O 0 0.0005015645
mol O 0 0.09428879
/ O 0 0.005638037
L O 0 0.6291467
without O 0 0.0003058722
the O 0 0.00019470914
need O 0 0.00020940116
for O 0 0.00024745337
concomitant O 0 0.0009799378
intrathecal O 0 0.008340412
dosing O 0 0.0015264046
. O 0 0.001966917

The O 0 0.003234152
methotrexate B-Chemical 0 0.9995103
was O 0 0.0012881978
administered O 0 0.0009910304
as O 0 0.00044731243
a O 0 0.00043449525
loading O 0 0.00026070568
dose O 0 0.00036211216
of O 0 0.00020140839
6 O 0 0.00013643879
, O 0 0.00026301102
000 O 0 0.00024121531
mg O 0 0.0017526202
/ O 0 0.0007930468
m2 O 0 0.0008794268
for O 0 9.324591e-05
a O 0 0.00013934546
period O 0 6.878701e-05
of O 0 0.000103731974
one O 0 9.0481204e-05
hour O 0 0.000108689426
followed O 0 7.120874e-05
by O 0 9.098719e-05
an O 0 0.0001321551
infusion O 0 0.00030410982
of O 0 0.00015648619
1 O 0 0.00019218188
, O 0 0.0003039559
200 O 0 0.00041951585
mg O 0 0.0031768507
/ O 0 0.0013845828
m2 O 0 0.0024402784
/ O 0 0.0014162131
h O 0 0.0005383165
for O 0 0.00048100183
23 O 0 0.0012254821
hours O 0 0.0011671863
. O 0 0.0027653724

Leucovorin B-Chemical 0 0.9993181
rescue O 0 0.0022707821
was O 0 0.001054126
initiated O 0 0.00060526555
12 O 0 0.00029453507
hours O 0 0.0002089307
after O 0 0.000113914284
the O 0 0.0001222571
end O 0 9.750068e-05
of O 0 0.00016181126
the O 0 0.00013091766
infusion O 0 0.00034309304
with O 0 0.0001252632
a O 0 0.00014741812
loading O 0 9.753685e-05
dose O 0 0.00016817822
of O 0 0.0001178304
200 O 0 0.00027375613
mg O 0 0.0029696403
/ O 0 0.0006691559
m2 O 0 0.00073459244
followed O 0 7.042841e-05
by O 0 7.5307136e-05
12 O 0 7.411107e-05
mg O 0 0.00089904317
/ O 0 0.0004982594
m2 O 0 0.0005094645
every O 0 3.6154794e-05
three O 0 2.550765e-05
hours O 0 4.1690975e-05
for O 0 3.839513e-05
six O 0 3.5274315e-05
doses O 0 0.00013150081
and O 0 7.691545e-05
then O 0 5.7354606e-05
every O 0 3.230674e-05
six O 0 3.0172561e-05
hours O 0 4.7599144e-05
until O 0 4.4832937e-05
the O 0 9.587175e-05
plasma O 0 0.02904777
methotrexate B-Chemical 0 0.9999708
level O 0 0.00014478105
decreased O 0 0.00027584183
to O 0 0.00012990429
less O 0 0.00023354832
than O 0 0.0001884401
1 O 0 0.00035182582
X O 0 0.071514204
10 O 0 0.00035233633
( O 0 0.00065063016
- O 0 0.0014569348
7 O 0 0.00049103546
) O 0 0.0017449396
mol O 0 0.11716338
/ O 0 0.019193223
L O 0 0.855164
. O 0 0.0064010094

The O 0 0.0018543581
mean O 0 0.0014763759
steady O 0 0.0017518121
- O 0 0.004411541
state O 0 0.0010919934
plasma O 0 0.0058444277
and O 0 0.0008220389
CSF O 0 0.8355788
methotrexate B-Chemical 0 0.999956
concentrations O 0 0.00072904455
achieved O 0 0.00030967346
were O 0 0.00020983265
1 O 0 0.00024362045
. O 0 0.00021122153
1 O 0 0.00030274878
X O 0 0.024392784
10 O 0 0.00025330705
( O 0 0.00042930254
- O 0 0.0008836498
3 O 0 0.00021176456
) O 0 0.00064426585
mol O 0 0.07295447
/ O 0 0.005554587
L O 0 0.6430212
and O 0 0.00039893156
3 O 0 0.00024280905
. O 0 0.00023556373
6 O 0 0.00024213515
X O 0 0.014096426
10 O 0 0.0003605553
( O 0 0.0006553077
- O 0 0.0014251575
5 O 0 0.0004698401
) O 0 0.0013395317
mol O 0 0.07709991
/ O 0 0.010764989
L O 0 0.7526226
, O 0 0.0043650363
respectively O 0 0.004579741
. O 0 0.004448924

All O 0 0.0023424937
20 O 0 0.001994074
patients O 0 0.0019053329
responded O 0 0.0011082169
to O 0 0.0005036951
this O 0 0.00047872486
regimen O 0 0.00051884196
, O 0 0.00064286654
16 O 0 0.0004424763
/ O 0 0.0011190035
20 O 0 0.00032206473
( O 0 0.0004226126
80 O 0 0.00034461883
% O 0 0.00042900437
) O 0 0.00042228118
achieved O 0 0.00022907427
a O 0 0.00028086465
complete O 0 0.00019743918
remission O 0 0.0026923541
, O 0 0.00041863782
and O 0 0.00028679232
20 O 0 0.0003306063
% O 0 0.00056563434
obtained O 0 0.0003397423
a O 0 0.000830752
partial O 0 0.0014607063
remission O 0 0.013457788
. O 0 0.0027996462

The O 0 0.0019978173
most O 0 0.0020075953
common O 0 0.0015493659
toxicities B-Disease 0 0.15366378
encountered O 0 0.0010492832
were O 0 0.00064104394
transient O 0 0.0019796723
serum O 0 0.7466429
transaminase O 0 0.9999361
and O 0 0.00188085
bilirubin B-Chemical 0 0.9999316
elevations O 0 0.13388851
, O 0 0.0022609956
neutropenia B-Disease 0 0.99293077
, O 0 0.0019438065
and O 0 0.0019171267
mucositis B-Disease 2 0.9976968
. O 0 0.004299286

One O 0 0.0051111053
patient O 0 0.0032861533
had O 0 0.002487811
focal O 0 0.022315612
seizures B-Disease 0 0.9999099
and O 0 0.002874367
transient B-Disease 0 0.2656497
hemiparesis I-Disease 0 0.9999472
but O 0 0.0025233293
recovered O 0 0.0016011915
completely O 0 0.0025391006
. O 0 0.0045310073

High O 0 0.005056358
- O 0 0.0070184316
dose O 0 0.0023633838
intravenous O 0 0.049653854
methotrexate B-Chemical 0 0.99987423
is O 0 0.0003699668
an O 0 0.00027382426
effective O 0 0.00018139284
treatment O 0 0.0001661807
for O 0 0.00011108365
the O 0 0.00011567378
induction O 0 0.00012201695
of O 0 0.00022003979
remission O 0 0.0032496448
after O 0 0.00016299837
meningeal O 0 0.7359117
relapse O 0 0.08037842
in O 0 0.0006963713
acute B-Disease 0 0.9418698
lymphoblastic I-Disease 0 0.9999107
leukemia I-Disease 0 0.9999237
. O 0 0.006262862

Interaction O 0 0.010014143
of O 0 0.010330906
cyclosporin B-Chemical 0 0.9998574
A I-Chemical 0 0.5993578
with O 0 0.006111003
antineoplastic O 0 0.26026335
agents O 0 0.012792029
. O 0 0.008319437

A O 0 0.01778907
synergistic O 0 0.0028329715
effect O 0 0.0013400179
of O 0 0.002302935
etoposide B-Chemical 0 0.99988663
and O 0 0.0039060644
cyclosporin B-Chemical 0 0.99999523
A I-Chemical 0 0.8147414
was O 0 0.00039846046
observed O 0 0.0002281453
in O 0 0.00022716723
a O 0 0.0003481489
patient O 0 0.00028875342
with O 0 0.00032952256
acute B-Disease 0 0.0369262
T I-Disease 0 0.07770929
- I-Disease 0 0.100632645
lymphocytic I-Disease 0 0.99849546
leukemia I-Disease 0 0.9998035
in O 0 0.0019954504
relapse O 0 0.26546153
. O 0 0.0030173035

The O 0 0.0018580237
concomitant O 0 0.0025250185
administration O 0 0.0020288418
of O 0 0.0016508122
etoposide B-Chemical 0 0.9998286
and O 0 0.0026203464
cyclosporin B-Chemical 0 0.9999939
A I-Chemical 0 0.6724073
resulted O 0 0.00038832458
in O 0 0.00029213916
eradication O 0 0.00047653838
of O 0 0.00034997836
hitherto O 0 0.0012148155
refractory O 0 0.042254493
leukemic B-Disease 0 0.99786085
infiltration I-Disease 0 0.1390197
of O 0 0.00106404
bone O 0 0.00883684
marrow O 0 0.020870656
. O 0 0.0027904967

Severe O 0 0.036323786
side O 0 0.0041615386
effects O 0 0.0011017863
in O 0 0.0007138943
terms O 0 0.0004719808
of O 0 0.0006880751
mental O 0 0.1279178
confusion B-Disease 0 0.4125515
and O 0 0.00054108223
progressive O 0 0.06818012
hyperbilirubinemia B-Disease 0 0.9999658
, O 0 0.0007320971
however O 0 0.00024529744
, O 0 0.00025961976
point O 0 8.9975285e-05
to O 0 9.558986e-05
an O 0 0.000120794
enhancement O 0 0.00013906934
not O 0 8.972133e-05
only O 0 0.00011640605
of O 0 0.00015605944
antineoplastic O 0 0.021998098
effects O 0 0.00017720682
but O 0 0.00025116428
also O 0 0.0002152357
of O 0 0.00044780242
toxicity B-Disease 0 0.75831336
in O 0 0.00066424813
normal O 0 0.001604271
tissues O 0 0.0020192366
. O 0 0.0024837353

This O 0 0.0044321236
report O 0 0.0024722775
demonstrates O 0 0.0005768992
for O 0 0.0004365686
the O 0 0.00030524182
first O 0 0.00017127456
time O 0 0.00014553539
that O 0 0.00013074673
the O 0 0.00014474709
pharmacodynamic O 0 0.0014135048
properties O 0 0.00014018452
of O 0 0.0005171862
cyclosporin B-Chemical 0 0.9999975
A I-Chemical 0 0.89992476
may O 0 0.0002363401
not O 0 0.00016712205
be O 0 0.00015885523
confined O 0 0.00015344282
strictly O 0 0.000117654134
to O 0 0.00013735727
suppression O 0 0.00023624954
of O 0 0.00038404507
normal O 0 0.0010832533
T O 0 0.016057037
- O 0 0.0048297355
cell O 0 0.0015505266
functions O 0 0.0016570173
. O 0 0.0033223834

Incidence O 0 0.009578398
of O 0 0.0036025897
neoplasms B-Disease 0 0.9393186
in O 0 0.0013580439
patients O 0 0.0023180114
with O 0 0.0017715557
rheumatoid B-Disease 0 0.99989367
arthritis I-Disease 0 0.99985456
exposed O 0 0.00092879974
to O 0 0.00043012179
different O 0 0.00039618957
treatment O 0 0.00075090694
regimens O 0 0.001600245
. O 0 0.002609765

Immunosuppressive O 0 0.39277533
drugs O 0 0.048730597
have O 0 0.0011121925
been O 0 0.0006329248
used O 0 0.0003818443
during O 0 0.00024637094
the O 0 0.00019982341
last O 0 0.00012415987
30 O 0 0.0001714672
years O 0 0.0002090018
in O 0 0.0001664922
treatment O 0 0.0002139322
of O 0 0.00032465276
patients O 0 0.00087411155
with O 0 0.00088982045
severe O 0 0.22692986
rheumatoid B-Disease 0 0.99991095
arthritis I-Disease 0 0.9998479
. O 0 0.0058354465

The O 0 0.0020071045
drugs O 0 0.0077464315
commonly O 0 0.0011658131
used O 0 0.0006292588
are O 0 0.00061659206
cyclophosphamide B-Chemical 0 0.9992126
and O 0 0.000871611
chlorambucil B-Chemical 0 0.99992657
( O 0 0.0010790783
alkylating B-Chemical 0 0.08036525
agents I-Chemical 0 0.0008104924
) O 0 0.00088450266
, O 0 0.0011534767
azathioprine B-Chemical 0 0.9999839
( O 0 0.0024243004
purine B-Chemical 0 0.9752651
analogue O 0 0.0016806906
) O 0 0.0011792717
, O 0 0.0007309086
and O 0 0.00090049254
methotrexate B-Chemical 0 0.9999871
( O 0 0.11724504
folic B-Chemical 0 0.9999796
acid I-Chemical 0 0.9971365
analogue O 0 0.07752266
) O 0 0.009170844
. O 0 0.003595548

There O 0 0.0032835635
is O 0 0.0014078591
evidence O 0 0.0008512654
that O 0 0.00059009955
all O 0 0.00048971287
four O 0 0.00032010014
immunosuppressive O 0 0.0075446093
drugs O 0 0.007498818
can O 0 0.00022285384
reduce O 0 0.00024190855
synovitis B-Disease 0 0.9958431
, O 0 0.0010084723
but O 0 0.0004984126
disease O 0 0.2098305
activity O 0 0.00019592786
almost O 0 0.00027914334
always O 0 0.0004610825
recurs O 0 0.0010795606
after O 0 0.00019664616
therapy O 0 0.00056517497
is O 0 0.00061857933
stopped O 0 0.0019399696
. O 0 0.0030640443

Since O 0 0.0018660983
adverse O 0 0.0045348057
reactions O 0 0.0014287573
are O 0 0.00061044045
frequent O 0 0.0006987206
, O 0 0.0006936008
less O 0 0.00043173291
than O 0 0.00023438418
50 O 0 0.00026748562
percent O 0 0.00019199046
of O 0 0.00021610204
patients O 0 0.00038479874
are O 0 0.000119109645
able O 0 0.00010816089
to O 0 0.00013533329
continue O 0 0.00017633391
a O 0 0.00026120673
particular O 0 0.00015401508
drug O 0 0.0018606422
for O 0 0.00022046063
more O 0 0.00046858637
than O 0 0.00039409634
one O 0 0.00059948815
year O 0 0.0010729573
. O 0 0.0022966964

Since O 0 0.0022489307
it O 0 0.0023394309
takes O 0 0.000729821
three O 0 0.000343518
to O 0 0.00033469853
12 O 0 0.00020307019
months O 0 0.00010793422
to O 0 0.000119245
achieve O 0 0.00011353819
maximal O 0 0.00021155752
effects O 0 0.00017449708
, O 0 0.00037166063
those O 0 0.00022668148
patients O 0 0.00037932402
who O 0 0.00021182152
are O 0 9.078387e-05
unable O 0 8.776457e-05
to O 0 0.00011942239
continue O 0 0.00015815155
the O 0 0.00016415822
drug O 0 0.0017692661
receive O 0 0.00022826997
little O 0 0.0003079027
benefit O 0 0.0005651268
from O 0 0.0007762975
it O 0 0.0021505675
. O 0 0.0030290384

Patients O 0 0.004144206
treated O 0 0.0026524402
with O 0 0.0014233271
alkylating B-Chemical 0 0.18299519
agents I-Chemical 0 0.0016049109
have O 0 0.00036678932
an O 0 0.0003653712
increased O 0 0.00042775355
risk O 0 0.0015714114
of O 0 0.00025404952
development O 0 0.0002841127
of O 0 0.0003267415
acute B-Disease 0 0.9377751
nonlymphocytic I-Disease 0 0.9999566
leukemia I-Disease 0 0.999982
, O 0 0.00046172095
and O 0 0.000115621486
both O 0 9.6443655e-05
alkylating B-Chemical 0 0.05892887
agents I-Chemical 0 0.0004981077
and O 0 0.0002853707
azathioprine B-Chemical 0 0.9999858
are O 0 0.0001201139
associated O 0 0.00013076133
with O 0 0.0001405128
the O 0 0.0001337544
development O 0 0.0002528898
of O 0 0.00032464936
non B-Disease 0 0.00096114835
- I-Disease 0 0.015762316
Hodgkin I-Disease 0 0.55712324
' I-Disease 0 0.0019316615
s I-Disease 0 0.0027370017
lymphoma I-Disease 0 0.9933925
. O 0 0.003879708

Cyclophosphamide B-Chemical 0 0.9985411
therapy O 0 0.0044705058
increases O 0 0.0017826902
the O 0 0.001440401
risk O 0 0.0059550763
of O 0 0.0025221412
carcinoma B-Disease 0 0.99382025
of I-Disease 0 0.002670696
the I-Disease 0 0.0023297833
bladder I-Disease 0 0.04976941
. O 0 0.0053481795

There O 0 0.0033088666
have O 0 0.0015975306
been O 0 0.00094149855
several O 0 0.00048409423
long O 0 0.00061352126
- O 0 0.0015605154
term O 0 0.00032366626
studies O 0 0.0002998444
of O 0 0.00026942778
patients O 0 0.0006154305
with O 0 0.00049675634
rheumatoid B-Disease 0 0.99995923
arthritis I-Disease 0 0.999956
treated O 0 0.0010773127
with O 0 0.0004333267
azathioprine B-Chemical 0 0.99999166
and O 0 0.0003994053
cyclophosphamide B-Chemical 0 0.99990714
and O 0 0.00014691912
the O 0 9.91532e-05
incidence O 0 0.0002551195
of O 0 0.00016050479
most O 0 0.0002112165
of O 0 0.00022085616
the O 0 0.00023729749
common O 0 0.0005767513
cancers B-Disease 0 0.93757266
is O 0 0.00056242757
not O 0 0.0007817019
increased O 0 0.00217608
. O 0 0.0030064832

Data O 0 0.0037325663
on O 0 0.0011319257
the O 0 0.00083523476
possible O 0 0.00058240554
increased O 0 0.0009772498
risk O 0 0.0043662176
of O 0 0.00094594114
malignancy B-Disease 2 0.99909616
in O 0 0.0011179503
rheumatoid B-Disease 0 0.9999732
arthritis I-Disease 0 0.99995863
are O 0 0.00015473033
still O 0 0.00010576338
being O 0 0.00012673982
collected O 0 0.00011190185
, O 0 0.00020154958
and O 0 0.00010560616
until O 0 5.4939806e-05
further O 0 6.7282344e-05
information O 0 9.069794e-05
is O 0 6.863106e-05
available O 0 6.594277e-05
, O 0 0.00013828508
the O 0 5.7412715e-05
use O 0 6.378205e-05
of O 0 0.00010915557
immunosuppressive O 0 0.01227509
drugs O 0 0.011469354
, O 0 0.00029523793
particularly O 0 0.00018754546
alkylating B-Chemical 0 0.15374969
agents I-Chemical 0 0.0005600597
, O 0 0.00023428141
in O 0 8.582197e-05
the O 0 7.649355e-05
treatment O 0 0.00012888233
of O 0 0.00035063227
rheumatoid B-Disease 0 0.9999862
arthritis I-Disease 0 0.9999759
should O 0 8.6513086e-05
be O 0 9.4507486e-05
reserved O 0 0.00014698245
for O 0 6.9108115e-05
patients O 0 0.0002296641
with O 0 0.00016866336
severe O 0 0.0026210607
progressive O 0 0.010825564
disease O 0 0.20063014
or O 0 0.00025426332
life O 0 0.00047921107
- O 0 0.0031310949
threatening O 0 0.0020023687
complications O 0 0.025003253
. O 0 0.0027706283

Warfarin B-Chemical 0 0.99866784
- O 0 0.035015013
induced O 0 0.0039778603
iliopsoas O 0 0.29803032
hemorrhage B-Disease 2 0.999413
with O 0 0.002066336
subsequent O 0 0.001788581
femoral B-Disease 0 0.5486767
nerve I-Disease 0 0.8835472
palsy I-Disease 0 0.9999418
. O 0 0.007825917

We O 0 0.0025856737
present O 0 0.0014836554
the O 0 0.0010765438
case O 0 0.0009421079
of O 0 0.00073032617
a O 0 0.0007811319
28 O 0 0.00052278687
- O 0 0.0015554486
year O 0 0.00029758853
- O 0 0.0010553307
old O 0 0.00031190226
man O 0 0.0010761034
on O 0 0.00014177118
chronic O 0 0.0146117825
warfarin B-Chemical 0 0.99910444
therapy O 0 0.0002908688
who O 0 0.0001701152
sustained O 0 0.00020008099
a O 0 0.00024080377
minor O 0 0.0004100779
muscle B-Disease 0 0.3513688
tear I-Disease 0 0.9602628
and O 0 0.00019171223
developed O 0 0.00017149646
increasing O 0 0.00017190921
pain B-Disease 0 0.013788424
and O 0 0.00022769111
a O 0 0.00052300043
flexure O 0 0.78702277
contracture B-Disease 0 0.9989054
of O 0 0.00056773546
the O 0 0.0005177478
right O 0 0.002134119
hip O 0 0.050022155
. O 0 0.0029616868

Surgical O 0 0.007051645
exploration O 0 0.0034097394
revealed O 0 0.0013338756
an O 0 0.0015273001
iliopsoas O 0 0.019396715
hematoma B-Disease 0 0.9904418
and O 0 0.00084052037
femoral O 0 0.067502856
nerve B-Disease 0 0.9134857
entrapment I-Disease 0 0.9589509
, O 0 0.0006872146
resulting O 0 0.00024195446
in O 0 0.0002569322
a O 0 0.00056223676
femoral B-Disease 0 0.4686955
nerve I-Disease 0 0.8074944
palsy I-Disease 0 0.9999944
and O 0 0.00047861628
partial B-Disease 0 0.0005512354
loss I-Disease 0 0.0005837264
of I-Disease 0 0.0008178303
quadriceps I-Disease 0 0.0072079413
functions I-Disease 0 0.0013596792
. O 0 0.002861654

Anticoagulant O 0 0.7041362
- O 0 0.016177844
induced O 0 0.0023019493
femoral B-Disease 0 0.76248354
nerve I-Disease 0 0.96680886
palsy I-Disease 0 0.99999404
represents O 0 0.00051356474
the O 0 0.00024168608
most O 0 0.00027311844
common O 0 0.00021916017
form O 0 0.0001838943
of O 0 0.0003429124
warfarin B-Chemical 0 0.9997328
- O 0 0.007110119
induced O 0 0.0002312307
peripheral B-Disease 0 0.47204337
neuropathy I-Disease 0 0.99999666
; O 0 0.0013113368
it O 0 0.00021848691
is O 0 9.551915e-05
characterized O 0 0.00016476527
by O 0 0.0001373041
severe O 0 0.0020862997
pain B-Disease 0 0.023579305
in O 0 9.990287e-05
the O 0 9.218981e-05
inguinal O 0 0.00023559853
region O 0 5.6415563e-05
, O 0 0.00013334802
varying O 0 0.000106103085
degrees O 0 0.0017004585
of O 0 0.00020008328
motor B-Disease 0 0.0007289709
and I-Disease 0 0.00015436734
sensory I-Disease 0 0.0003984479
impairment I-Disease 0 0.05475442
, O 0 0.0004923161
and O 0 0.0003863313
flexure O 0 0.7715307
contracture B-Disease 0 0.9988883
of O 0 0.00061459607
the O 0 0.00052960846
involved O 0 0.00092142395
extremity O 0 0.014952767
. O 0 0.002749746

Pneumonitis O 0 0.79640007
with O 0 0.0030525052
pleural B-Disease 0 0.0064937924
and I-Disease 0 0.0013247927
pericardial I-Disease 0 0.0045831986
effusion I-Disease 0 0.009025644
and O 0 0.0010828638
neuropathy B-Disease 0 0.99942505
during O 0 0.001380594
amiodarone B-Chemical 0 0.99968326
therapy O 0 0.0034689843
. O 0 0.0032035322

A O 0 0.0528613
patient O 0 0.003432731
with O 0 0.0024033126
sinuatrial B-Disease 0 0.9515576
disease I-Disease 0 0.93649644
and O 0 0.0005310739
implanted O 0 0.00059294415
pacemaker O 0 0.00040985763
was O 0 0.00015810631
treated O 0 0.0003099186
with O 0 0.00030762458
amiodarone B-Chemical 0 0.9999455
( O 0 0.00033692585
maximum O 0 0.00013845804
dose O 0 0.00020922335
1000 O 0 0.00032048216
mg O 0 0.0013472948
, O 0 0.00015683273
maintenance O 0 0.0001073899
dose O 0 0.00019625878
800 O 0 0.0003669231
mg O 0 0.0016052963
daily O 0 0.00014524191
) O 0 0.00020964307
for O 0 7.8676254e-05
10 O 0 0.000110250614
months O 0 7.084645e-05
, O 0 0.00024384797
for O 0 0.00017692352
control O 0 0.0004185492
of O 0 0.0012268849
supraventricular B-Disease 0 0.9995148
tachyarrhythmias I-Disease 0 0.99989283
. O 0 0.004671918

He O 0 0.011369017
developed O 0 0.0052126083
pneumonitis B-Disease 0 0.99235594
, O 0 0.0033178108
pleural B-Disease 0 0.0053892937
and I-Disease 0 0.00083793385
pericardial I-Disease 0 0.004717053
effusions I-Disease 0 0.07533393
, O 0 0.0008229288
and O 0 0.0004943343
a O 0 0.00075765746
predominantly O 0 0.00070365716
proximal B-Disease 0 0.0047321245
motor I-Disease 0 0.5288231
neuropathy I-Disease 0 0.9999548
. O 0 0.0060862047

Immediate O 0 0.005675591
but O 0 0.0022757354
gradual O 0 0.0014177812
improvement O 0 0.0010038126
followed O 0 0.0006052828
withdrawal O 0 0.0021662435
of O 0 0.0010514531
amiodarone B-Chemical 0 0.99979275
and O 0 0.0009734528
treatment O 0 0.0009776466
with O 0 0.0020906662
prednisolone B-Chemical 0 0.99963355
. O 0 0.0049183457

Review O 0 0.0058184913
of O 0 0.0021290663
this O 0 0.001325935
and O 0 0.0009843084
previously O 0 0.00078623474
reported O 0 0.0005933156
cases O 0 0.0005843491
indicates O 0 0.000170536
the O 0 0.00015290169
need O 0 0.00013053496
for O 0 0.00010887552
early O 0 0.00023800124
diagnosis O 0 0.000361583
of O 0 0.00033425787
amiodarone B-Chemical 0 0.99998736
pneumonitis B-Disease 0 0.9995297
, O 0 0.0003371641
immediate O 0 0.0002088098
withdrawal O 0 0.0009770357
of O 0 0.00025414067
amiodarone B-Chemical 0 0.99997485
, O 0 0.0004059728
and O 0 0.00015669044
prompt O 0 0.00036092947
but O 0 0.00021789879
continued O 0 0.00026680736
steroid B-Chemical 0 0.8523764
therapy O 0 0.0004054839
to O 0 0.00019337685
ensure O 0 0.00018279642
full O 0 0.00052286114
recovery O 0 0.0016697905
. O 0 0.002366546

Amiodarone B-Chemical 1 0.9993327
- O 0 0.077338934
induced O 0 0.009634243
sinoatrial B-Disease 0 0.48931944
block I-Disease 0 0.010090943
. O 0 0.012998655

We O 0 0.0027919833
observed O 0 0.002007693
sinoatrial B-Disease 0 0.1253758
block I-Disease 0 0.0008639588
due O 0 0.0003996988
to O 0 0.00039245407
chronic O 0 0.036677275
amiodarone B-Chemical 0 0.99994063
administration O 0 0.00069530925
in O 0 0.00018156104
a O 0 0.0002497223
5 O 0 0.00016935341
- O 0 0.00067492656
year O 0 0.00015473225
- O 0 0.0006812801
old O 0 0.0002389093
boy O 0 0.0007005312
with O 0 0.00026574897
primary B-Disease 0 0.0014989052
cardiomyopathy I-Disease 0 0.99999
, O 0 0.004525366
Wolff B-Disease 0 0.7177157
- I-Disease 0 0.112802014
Parkinson I-Disease 0 0.9992987
- I-Disease 0 0.005134025
White I-Disease 0 0.0035594702
syndrome I-Disease 0 0.90235364
and O 0 0.0017476161
supraventricular B-Disease 0 0.99956065
tachycardia I-Disease 2 0.99979764
. O 0 0.0044959057

Reduction O 0 0.0043544965
in O 0 0.00161682
the O 0 0.0010425106
dosage O 0 0.0029645883
of O 0 0.0012150307
amiodarone B-Chemical 0 0.99990535
resulted O 0 0.00042381603
in O 0 0.0002701686
the O 0 0.00020811016
disappearance O 0 0.0004688
of O 0 0.00022347792
the O 0 0.00019869601
sinoatrial B-Disease 0 0.050794356
block I-Disease 0 0.00018396307
and O 0 0.00019237492
the O 0 0.00017951718
persistence O 0 0.00034624158
of O 0 0.0005993519
asymptomatic O 0 0.0129904235
sinus B-Disease 0 0.8824082
bradycardia I-Disease 0 0.9995154
. O 0 0.0035812962

Desipramine B-Chemical 0 0.9999448
- O 0 0.17713435
induced O 0 0.0036080643
delirium B-Disease 0 0.9997199
at O 0 0.0011227
" O 0 0.0022096669
subtherapeutic O 0 0.7440437
" O 0 0.0016449897
concentrations O 0 0.0015716613
: O 0 0.002053771
a O 0 0.0016787746
case O 0 0.001787153
report O 0 0.0038868682
. O 0 0.0044840532

An O 0 0.0032456948
elderly O 0 0.032918982
patient O 0 0.001295502
treated O 0 0.001079614
with O 0 0.00054236175
low O 0 0.00080824876
dose O 0 0.0051480494
Desipramine B-Chemical 0 0.99999213
developed O 0 0.00072045065
a O 0 0.000967975
delirium B-Disease 0 0.9999459
while O 0 0.0002913848
her O 0 0.00033989293
plasma O 0 0.002490977
level O 0 0.00019154012
was O 0 0.00021800102
in O 0 0.0002465817
the O 0 0.00031940633
" O 0 0.001138705
subtherapeutic O 0 0.65606934
" O 0 0.0017627715
range O 0 0.0016425187
. O 0 0.002691151

Delirium B-Disease 2 0.9979286
, O 0 0.0064789685
which O 0 0.0019047325
may O 0 0.0007933752
be O 0 0.0005578852
induced O 0 0.00046429224
by O 0 0.0005595866
tricyclic O 0 0.9982772
drug O 0 0.03215581
therapy O 0 0.0003980679
in O 0 0.00016754134
the O 0 0.00019170585
elderly O 0 0.07739261
, O 0 0.00047554934
can O 0 0.00013609446
be O 0 0.00016686998
caused O 0 0.0002024724
by O 0 0.0003405442
tricyclics O 0 0.9988341
with O 0 0.0005881263
low O 0 0.0014774392
anticholinergic O 0 0.9991691
potency O 0 0.005840955
. O 0 0.0031126223

Therapeutic O 0 0.0064659305
ranges O 0 0.0015888807
for O 0 0.0011664658
antidepressants B-Chemical 0 0.9995999
that O 0 0.0005487778
have O 0 0.00037581637
been O 0 0.00028321592
derived O 0 0.00016185678
from O 0 0.00017875178
general O 0 0.00021208545
adult O 0 0.00030606944
population O 0 0.0003143085
studies O 0 0.00029388544
may O 0 0.00019703466
not O 0 0.00022646783
be O 0 0.00026730512
appropriate O 0 0.00026595982
for O 0 0.00039687147
the O 0 0.0008564496
elderly O 0 0.0812579
. O 0 0.0034298382

Further O 0 0.0020884909
studies O 0 0.0018778695
of O 0 0.001214991
specifically O 0 0.00071972806
elderly O 0 0.104150884
patients O 0 0.0010475069
are O 0 0.00022903715
now O 0 0.00021037756
required O 0 0.00010911915
to O 0 0.00013985155
establish O 0 0.00011237492
safer O 0 0.00031197094
and O 0 0.00023762281
more O 0 0.000307405
appropriate O 0 0.00020243574
guidelines O 0 0.00031610852
for O 0 0.0004299521
drug O 0 0.0052431896
therapy O 0 0.0021351855
. O 0 0.0026199624

Indomethacin B-Chemical 0 0.9998908
- O 0 0.13302383
induced O 0 0.004270111
renal B-Disease 0 0.97502
insufficiency I-Disease 0 0.9982811
: O 0 0.0063373656
recurrence O 0 0.010476681
on O 0 0.0016462095
rechallenge O 0 0.0058396477
. O 0 0.0043773656

We O 0 0.00274144
have O 0 0.0016975469
reported O 0 0.0013902937
a O 0 0.0011879253
case O 0 0.00071567047
of O 0 0.0007318956
acute O 0 0.49421638
oliguric O 0 0.9999455
renal B-Disease 0 0.98245287
failure I-Disease 0 0.06305399
with O 0 0.00041687142
hyperkalemia B-Disease 0 0.9999622
in O 0 0.0001896753
a O 0 0.00022926916
patient O 0 0.0001823226
with O 0 0.0002734676
cirrhosis B-Disease 0 0.99998903
, O 0 0.0029987982
ascites B-Disease 0 0.9994831
, O 0 0.0012217142
and O 0 0.0009176837
cor B-Disease 0 0.9999677
pulmonale I-Disease 0 0.9999938
after O 0 0.00087465637
indomethacin B-Chemical 0 0.99995303
therapy O 0 0.004124609
. O 0 0.0025093763

Prompt O 0 0.010893908
restoration O 0 0.0022694815
of O 0 0.0015322105
renal O 0 0.19996195
function O 0 0.00049081206
followed O 0 0.00036543404
drug O 0 0.004199393
withdrawal O 0 0.001841964
, O 0 0.00042469607
while O 0 0.00022533876
re O 0 0.0010447318
- O 0 0.0011550125
exposure O 0 0.0001818145
to O 0 0.00011658202
a O 0 0.00019013467
single O 0 0.00011462658
dose O 0 0.00035248007
of O 0 0.00045733573
indomethacin B-Chemical 0 0.99998796
caused O 0 0.00074519403
recurrence O 0 0.09537518
of O 0 0.00079118164
acute O 0 0.38153204
reversible O 0 0.06692197
oliguria B-Disease 0 0.99958485
. O 0 0.0033451635

Our O 0 0.0021981804
case O 0 0.0017896923
supports O 0 0.0008795609
the O 0 0.0005776468
hypothesis O 0 0.00048478297
that O 0 0.0003691447
endogenous O 0 0.00045404528
renal O 0 0.9923125
prostaglandins B-Chemical 0 0.9999082
play O 0 0.00023715
a O 0 0.00022957764
role O 0 6.6300854e-05
in O 0 0.000111428446
the O 0 9.916408e-05
maintenance O 0 0.00015644857
of O 0 0.00021988082
renal O 0 0.6881919
blood O 0 0.008153234
flow O 0 0.0019482465
when O 0 0.00020644825
circulating O 0 0.0021390927
plasma O 0 0.014752145
volume O 0 0.0010790891
is O 0 0.00066602405
diminished O 0 0.0020349217
. O 0 0.002768022

Since O 0 0.0023805231
nonsteroidal O 0 0.99721473
anti O 0 0.008048188
- O 0 0.057759836
inflammatory O 0 0.021686643
agents O 0 0.0013739512
interfere O 0 0.00033110086
with O 0 0.00032337697
this O 0 0.00028572543
compensatory O 0 0.00036734238
mechanism O 0 0.00013544329
and O 0 0.00021819543
may O 0 0.00015448427
cause O 0 0.00029451062
acute B-Disease 0 0.10367542
renal I-Disease 0 0.95302427
failure I-Disease 0 0.06305886
, O 0 0.00033862895
they O 0 0.00011399568
should O 0 7.297985e-05
be O 0 0.00012471079
used O 0 0.00014669304
with O 0 0.00027309445
caution O 0 0.0004940088
in O 0 0.00045352237
such O 0 0.0007497268
patients O 0 0.0026307993
. O 0 0.0026868938

Patterns O 0 0.011968443
of O 0 0.008275183
hepatic B-Disease 0 0.9965479
injury I-Disease 0 0.92174757
induced O 0 0.00557535
by O 0 0.008577526
methyldopa B-Chemical 0 0.99995947
. O 0 0.013770695

Twelve O 0 0.0066444823
patients O 0 0.0044956007
with O 0 0.0027438642
liver B-Disease 0 0.97971076
disease I-Disease 0 0.98574907
related O 0 0.0006959497
to O 0 0.0010799422
methyldopa B-Chemical 0 0.9999933
were O 0 0.0007872882
seen O 0 0.00061545626
between O 0 0.0006192907
1967 O 0 0.0025878919
and O 0 0.0018099113
1977 O 0 0.006931052
. O 0 0.0044580535

Illness O 0 0.013515685
occurred O 0 0.0019164963
within O 0 0.0007998286
1 O 0 0.0011889016
- O 0 0.0030311702
- O 0 0.0015386642
9 O 0 0.00023966264
weeks O 0 0.00012031922
of O 0 0.00018303258
commencement O 0 0.00017562028
of O 0 0.00018759142
therapy O 0 0.0002491755
in O 0 0.00013614314
9 O 0 0.00013510507
patients O 0 0.00026615313
, O 0 0.00020483884
the O 0 8.670942e-05
remaining O 0 9.708763e-05
3 O 0 8.762792e-05
patients O 0 0.00015105461
having O 0 8.089439e-05
received O 0 8.4103995e-05
the O 0 8.330843e-05
drug O 0 0.0009323335
for O 0 7.896196e-05
13 O 0 0.000106136475
months O 0 5.0438288e-05
, O 0 0.0001496381
15 O 0 8.953757e-05
months O 0 5.7253015e-05
and O 0 0.00012904267
7 O 0 0.00015225426
years O 0 0.00028296758
before O 0 0.0002408931
experiencing O 0 0.0014164026
symptoms O 0 0.0074457647
. O 0 0.002917708

Jaundice B-Disease 0 0.980313
with O 0 0.0034532445
tender O 0 0.008144312
hepatomegaly B-Disease 0 0.99878997
, O 0 0.002213082
usually O 0 0.0006503245
preceded O 0 0.00039867626
by O 0 0.00032026254
symptoms O 0 0.002449953
of O 0 0.0004941767
malaise O 0 0.99495184
, O 0 0.001899088
anorexia B-Disease 0 0.99987733
, O 0 0.0016871336
nausea B-Disease 0 0.9994159
and O 0 0.00037836365
vomiting B-Disease 0 0.97246426
, O 0 0.00031171314
and O 0 0.00013229203
associated O 0 0.0001298165
with O 0 0.00013778056
upper O 0 0.00024829662
abdominal B-Disease 0 0.0005324249
pain I-Disease 0 0.009991104
, O 0 0.00033402786
was O 0 0.000194041
an O 0 0.0003089133
invariable O 0 0.0015266517
finding O 0 0.00043970917
in O 0 0.00051394233
all O 0 0.00080465316
patients O 0 0.0024950916
. O 0 0.0025506248

Biochemical O 0 0.014867644
liver O 0 0.034675457
function O 0 0.0012999391
tests O 0 0.0027242764
indicated O 0 0.0012741247
hepatocellular O 0 0.99999
necrosis B-Disease 2 0.99999607
and O 0 0.00085799093
correlated O 0 0.00025158204
with O 0 0.00020706709
histopathological O 0 0.0006600655
evidence O 0 0.00014261532
of O 0 0.00033516437
hepatic B-Disease 0 0.9997601
injury I-Disease 0 0.9497567
, O 0 0.0003934846
the O 0 0.0001058775
spectrum O 0 0.00019042748
of O 0 0.00013611808
which O 0 0.000179629
ranged O 0 0.00024378057
from O 0 0.00029026487
fatty B-Disease 0 0.99983215
change I-Disease 0 0.001672146
and O 0 0.00064066704
focal O 0 0.21855253
hepatocellular O 0 0.9999962
necrosis B-Disease 2 0.9999968
to O 0 0.0013984591
massive B-Disease 0 0.04741956
hepatic I-Disease 0 0.99917233
necrosis I-Disease 2 0.9999356
. O 0 0.0045569376

Most O 0 0.00468575
patients O 0 0.0037525888
showed O 0 0.0013703391
moderate O 0 0.0031170628
to O 0 0.0009995688
severe O 0 0.05452531
acute B-Disease 0 0.9970579
hepatitis I-Disease 0 0.9999945
or O 0 0.001639155
chronic B-Disease 0 0.79684716
active I-Disease 0 0.0026220966
hepatitis I-Disease 0 0.9999776
with O 0 0.0028122675
associated O 0 0.0040204036
cholestasis B-Disease 0 0.999948
. O 0 0.005866854

The O 0 0.0024607612
drug O 0 0.010041162
was O 0 0.001212396
withdrawn O 0 0.0016132448
on O 0 0.00037331766
presentation O 0 0.00066214945
to O 0 0.00028981303
hospital O 0 0.00040247253
in O 0 0.00023191627
11 O 0 0.0002848879
patients O 0 0.0004261461
, O 0 0.00041529618
with O 0 0.00031333254
rapid O 0 0.00053658517
clinical O 0 0.001196861
improvement O 0 0.0007555481
in O 0 0.00079151074
9 O 0 0.0012853042
. O 0 0.0024918977

One O 0 0.004106455
patient O 0 0.0026531199
died O 0 0.0029084368
, O 0 0.0014162213
having O 0 0.00060745375
presented O 0 0.0004261506
in O 0 0.00044712552
hepatic B-Disease 0 0.9153735
failure I-Disease 0 0.08725174
, O 0 0.0005618733
and O 0 0.00021955276
another O 0 0.00025025496
, O 0 0.0003225613
who O 0 0.00021684634
had O 0 0.00012026393
been O 0 0.00013037786
taking O 0 0.00048288977
methyldopa B-Chemical 0 0.99999785
for O 0 0.00011299794
7 O 0 8.093776e-05
years O 0 0.00011431015
, O 0 0.00015061104
showed O 0 9.3249735e-05
slower O 0 0.00019712844
clinical O 0 0.00040456557
and O 0 0.00013602934
biochemical O 0 0.00019838348
resolution O 0 0.0003371517
over O 0 0.00015587977
a O 0 0.00027990845
period O 0 0.00018123342
of O 0 0.00036121692
several O 0 0.00039969274
months O 0 0.00055704516
. O 0 0.0019103321

The O 0 0.0019138514
remaining O 0 0.001546683
patient O 0 0.001253636
in O 0 0.0006618961
the O 0 0.00048026926
series O 0 0.00073838455
developed O 0 0.001425154
fulminant B-Disease 0 0.99997735
hepatitis I-Disease 0 0.999997
when O 0 0.00037950373
the O 0 0.00025462717
drug O 0 0.010705103
was O 0 0.00020821435
accidentally O 0 0.00063135347
recommenced O 0 0.0029382603
1 O 0 0.00016477675
year O 0 9.24325e-05
after O 0 5.932321e-05
a O 0 0.0001598084
prior O 0 9.488703e-05
episode O 0 0.00033706464
of O 0 0.00088080385
methyldopa B-Chemical 0 0.9999976
- O 0 0.24022664
induced O 0 0.002801284
hepatitis B-Disease 0 0.99991345
. O 0 0.008141611

In O 0 0.0022034023
this O 0 0.0021757237
latter O 0 0.002794855
patient O 0 0.0012997343
, O 0 0.0011691862
and O 0 0.00053767744
in O 0 0.00037819092
2 O 0 0.00036541876
others O 0 0.00047516465
, O 0 0.0003811051
the O 0 0.00014015954
causal O 0 0.00016206139
relationship O 0 0.000103168786
between O 0 0.00026013138
methyldopa B-Chemical 0 0.9999989
and O 0 0.0011622937
hepatic B-Disease 0 0.9998932
dysfunction I-Disease 0 0.99952304
was O 0 0.00020315191
proved O 0 0.00017302581
with O 0 0.00013002538
the O 0 0.00012513415
recurrence O 0 0.0073468173
of O 0 0.0003232922
hepatitis B-Disease 0 0.99995315
within O 0 0.000108988745
2 O 0 0.00013051355
weeks O 0 6.6101544e-05
of O 0 0.00018331045
re O 0 0.00096097204
- O 0 0.0013034833
exposure O 0 0.00041224656
to O 0 0.00043113824
the O 0 0.0007817034
drug O 0 0.011423012
. O 0 0.0030871609

Suxamethonium B-Chemical 0 0.97281545
infusion O 0 0.013739282
rate O 0 0.0060110725
and O 0 0.004810225
observed O 0 0.0062329955
fasciculations B-Disease 0 0.9964998
. O 0 0.012274021

A O 0 0.050356083
dose O 0 0.016686566
- O 0 0.02008008
response O 0 0.007701694
study O 0 0.010315093
. O 0 0.01308797

Suxamethonium B-Chemical 0 0.99907076
chloride I-Chemical 0 0.99970263
( O 0 0.04778284
Sch B-Chemical 0 0.999946
) O 0 0.004194507
was O 0 0.0005997985
administered O 0 0.0006307401
i O 0 0.00067537796
. O 0 0.0003352747
v O 0 0.0010285921
. O 0 0.00022618427
to O 0 0.00014927141
36 O 0 0.00019270499
adult O 0 0.0002108742
males O 0 0.0002529691
at O 0 9.942076e-05
six O 0 8.122671e-05
rates O 0 0.00019252743
: O 0 0.00038494347
0 O 0 0.00025907648
. O 0 0.00019177038
25 O 0 0.00030765327
mg O 0 0.0016126619
s O 0 0.00046613993
- O 0 0.0011366376
1 O 0 0.00031976524
to O 0 0.0002691769
20 O 0 0.00049498124
mg O 0 0.0028197768
s O 0 0.0013086143
- O 0 0.0037291418
1 O 0 0.0020947591
. O 0 0.003148741

The O 0 0.0018407931
infusion O 0 0.0032436207
was O 0 0.000974767
discontinued O 0 0.001778803
either O 0 0.00037961663
when O 0 0.00022641731
there O 0 0.00022940147
was O 0 0.00024763274
no O 0 0.0002649126
muscular O 0 0.01451277
response O 0 0.00020499557
to O 0 0.00020065872
tetanic B-Disease 0 0.5624154
stimulation O 0 0.0001205781
of O 0 0.00017969991
the O 0 0.00020949481
ulnar O 0 0.43826208
nerve O 0 0.006471373
or O 0 0.00022406444
when O 0 0.00034070562
Sch B-Chemical 0 0.9999416
120 O 0 0.0014059131
mg O 0 0.008545082
was O 0 0.00081900676
exceeded O 0 0.0014927626
. O 0 0.0026161266

Six O 0 0.0028241295
additional O 0 0.0015130285
patients O 0 0.0019260452
received O 0 0.0009716146
a O 0 0.0011413461
30 O 0 0.00080266123
- O 0 0.0028800482
mg O 0 0.004696792
i O 0 0.0012121957
. O 0 0.0007387765
v O 0 0.0021745358
. O 0 0.0010700127
bolus O 0 0.0033475617
dose O 0 0.00293209
. O 0 0.0035288685

Fasciculations B-Disease 0 0.29090008
in O 0 0.001854035
six O 0 0.00076868874
areas O 0 0.0010678576
of O 0 0.0005885939
the O 0 0.00039601536
body O 0 0.0006295456
were O 0 0.000313658
scored O 0 0.00038234965
from O 0 0.00021747308
0 O 0 0.0002896694
to O 0 0.00017555582
3 O 0 0.00019763772
and O 0 0.00026962152
summated O 0 0.000430951
as O 0 0.0003674177
a O 0 0.0007983445
total O 0 0.0010589896
fasciculation B-Disease 0 0.5572452
score O 0 0.0020778743
. O 0 0.0034431212

The O 0 0.0017844645
times O 0 0.0011372209
to O 0 0.0009519523
first O 0 0.00078594906
fasciculation B-Disease 0 0.59574264
, O 0 0.0020859048
twitch B-Disease 0 0.6747905
suppression O 0 0.0005474031
and O 0 0.0005368682
tetanus B-Disease 0 0.37242392
suppression O 0 0.00038066762
were O 0 0.0002589829
inversely O 0 0.00023801326
related O 0 0.00017566349
to O 0 0.00028865653
the O 0 0.0004607451
infusion O 0 0.0016922993
rates O 0 0.0017010365
. O 0 0.0028952966

Fasciculations B-Disease 0 0.3544467
in O 0 0.0019333242
the O 0 0.0009331445
six O 0 0.0004961328
areas O 0 0.0008019781
and O 0 0.00046742897
the O 0 0.00034762424
total O 0 0.00047968983
fasciculation B-Disease 0 0.29419434
score O 0 0.0003201581
were O 0 0.0002284838
related O 0 0.00016152054
directly O 0 0.00018428713
to O 0 0.00027710185
the O 0 0.00037167853
rate O 0 0.0008532656
of O 0 0.001181735
infusion O 0 0.0040526134
. O 0 0.003011099

Total O 0 0.0076211845
fasciculation B-Disease 0 0.44238707
scores O 0 0.0015309259
in O 0 0.0008035486
the O 0 0.0005315773
30 O 0 0.0005088887
- O 0 0.0016563492
mg O 0 0.002526192
bolus O 0 0.0009229045
group O 0 0.00030495823
and O 0 0.00020717074
the O 0 0.00016907282
5 O 0 0.00022273998
- O 0 0.0010424148
mg O 0 0.0018285678
s O 0 0.00037564803
- O 0 0.00090229826
1 O 0 0.0001914793
and O 0 0.00017011732
20 O 0 0.00021856252
- O 0 0.0009674573
mg O 0 0.0016578946
s O 0 0.00036952706
- O 0 0.00087706826
1 O 0 0.00023820986
infusion O 0 0.00041796864
groups O 0 0.00031868304
were O 0 0.0003104666
not O 0 0.0004221922
significantly O 0 0.0009050761
different O 0 0.0011497681
. O 0 0.0028865614

Treatment O 0 0.02073543
of O 0 0.012605842
psoriasis B-Disease 0 0.99536264
with O 0 0.016496086
azathioprine B-Chemical 0 0.9996075
. O 0 0.016612804

Azathioprine B-Chemical 0 0.99876153
treatment O 0 0.004069786
benefited O 0 0.0069796406
19 O 0 0.0020226722
( O 0 0.0017434019
66 O 0 0.0013071906
% O 0 0.0013325232
) O 0 0.0011643282
out O 0 0.00045312132
of O 0 0.00059932587
29 O 0 0.0010138114
patients O 0 0.0015832222
suffering O 0 0.009388159
from O 0 0.001164408
severe O 0 0.03782753
psoriasis B-Disease 0 0.9982663
. O 0 0.0047848723

Haematological O 0 0.25206944
complications O 0 0.013571849
were O 0 0.001304503
not O 0 0.0008893518
troublesome O 0 0.0023225283
and O 0 0.0005701195
results O 0 0.00040456632
of O 0 0.0005441313
biochemical O 0 0.00090795534
liver O 0 0.016709507
function O 0 0.0006715916
tests O 0 0.0018359717
remained O 0 0.001749777
normal O 0 0.0032563321
. O 0 0.0034194295

Minimal O 0 0.019986687
cholestasis B-Disease 0 0.9998652
was O 0 0.0022509324
seen O 0 0.0010864255
in O 0 0.0005665049
two O 0 0.00035082336
cases O 0 0.0007238676
and O 0 0.0005644611
portal O 0 0.2806244
fibrosis B-Disease 0 0.99668676
of O 0 0.0007449807
a O 0 0.0009434556
reversible O 0 0.0017902588
degree O 0 0.0011621353
in O 0 0.0010163207
eight O 0 0.0011664619
. O 0 0.0027966283

Liver O 0 0.4364603
biopsies O 0 0.0020177644
should O 0 0.0006280542
be O 0 0.0005339671
undertaken O 0 0.00034558182
at O 0 0.00019715533
regular O 0 0.00019114731
intervals O 0 0.00016502797
if O 0 0.0001802934
azathioprine B-Chemical 0 0.99991226
therapy O 0 0.0003496382
is O 0 0.000115532675
continued O 0 0.0001405301
so O 0 0.00014332683
that O 0 0.0001417659
structural O 0 0.00045991052
liver B-Disease 2 0.9949143
damage I-Disease 2 0.9580883
may O 0 0.00021056538
be O 0 0.00016399207
detected O 0 0.00011662872
at O 0 0.00015787249
an O 0 0.00031932382
early O 0 0.0006203117
and O 0 0.0007493761
reversible O 0 0.0037065975
stage O 0 0.006319369
. O 0 0.0037055712

Angiosarcoma B-Disease 0 0.24822831
of I-Disease 0 0.005538037
the I-Disease 0 0.0039843023
liver I-Disease 0 0.08861663
associated O 0 0.0048067067
with O 0 0.006954895
diethylstilbestrol B-Chemical 0 0.9993086
. O 0 0.012529129

Angiosarcoma B-Disease 0 0.27828383
of I-Disease 0 0.002670203
the I-Disease 0 0.001534614
liver I-Disease 0 0.030143084
occurred O 0 0.0007488393
in O 0 0.0004653623
a O 0 0.000589837
76 O 0 0.00073826173
- O 0 0.0013949982
year O 0 0.00026803397
- O 0 0.001064772
old O 0 0.000341716
man O 0 0.0018692199
who O 0 0.00032583383
had O 0 0.00016461074
been O 0 0.00014788231
treated O 0 0.0002961733
for O 0 0.00012759301
a O 0 0.00026951617
well O 0 0.0002273787
- O 0 0.0053830254
differentiated O 0 0.002543682
adenocarcinoma B-Disease 0 0.99785393
of I-Disease 0 0.0003790299
the I-Disease 0 0.0002921818
liver I-Disease 0 0.18352659
with O 0 0.0009313639
diethylstilbestrol B-Chemical 0 0.9998437
for O 0 0.0006308062
13 O 0 0.00097647274
years O 0 0.0014057537
. O 0 0.0021373425

Angiosarcoma B-Disease 0 0.2855831
was O 0 0.0028896441
also O 0 0.0016686852
present O 0 0.0012257098
within O 0 0.0010275113
pulmonary O 0 0.031803325
and O 0 0.0027322008
renal O 0 0.8277371
arteries O 0 0.89178795
. O 0 0.006207793

The O 0 0.0018165774
possibility O 0 0.0010481038
that O 0 0.0010023
the O 0 0.0010746968
intraarterial B-Disease 0 0.8299372
lesions I-Disease 0 0.07207325
might O 0 0.00034016912
represent O 0 0.00039391866
independent O 0 0.00037495248
primary O 0 0.00081808056
tumors B-Disease 0 0.21902584
is O 0 0.0012222334
considered O 0 0.001978673
. O 0 0.0034765236

Galanthamine B-Chemical 0 0.9991696
hydrobromide I-Chemical 0 0.99973446
, O 0 0.0039996114
a O 0 0.0011048601
longer O 0 0.0003632431
acting O 0 0.00062307913
anticholinesterase O 0 0.9891459
drug O 0 0.04056497
, O 0 0.00055437366
in O 0 0.00018624724
the O 0 0.00014459025
treatment O 0 0.0001668089
of O 0 0.00018436658
the O 0 0.00016384185
central O 0 0.00032754056
effects O 0 0.0003178101
of O 0 0.0011849134
scopolamine B-Chemical 0 0.9999964
( O 0 0.02068304
Hyoscine B-Chemical 0 0.9992674
) O 0 0.005060553
. O 0 0.0030086425

Galanthamine B-Chemical 0 0.9991417
hydrobromide I-Chemical 0 0.9997435
, O 0 0.0056478265
an O 0 0.00167369
anticholinesterase O 0 0.98832405
drug O 0 0.00768743
capable O 0 0.00022914265
of O 0 0.00037960178
penetrating O 0 0.04313595
the O 0 0.00022818118
blood O 0 0.011833644
- O 0 0.005418061
brain O 0 0.00094228506
barrier O 0 0.000769278
, O 0 0.00028662063
was O 0 0.00010670578
used O 0 9.421181e-05
in O 0 0.00011095514
a O 0 0.00017934215
patient O 0 0.00013019038
demonstrating O 0 7.6081364e-05
central O 0 0.00020557786
effects O 0 0.00021264632
of O 0 0.00091303594
scopolamine B-Chemical 0 0.99999845
( O 0 0.11608483
hyoscine B-Chemical 0 0.9999962
) O 0 0.10444572
overdosage B-Disease 0 0.999691
. O 0 0.003592445

It O 0 0.0038525609
is O 0 0.0011054913
longer O 0 0.000616817
acting O 0 0.000840937
than O 0 0.0009995959
physostigmine B-Chemical 0 0.999938
and O 0 0.00054889504
is O 0 0.0002270568
used O 0 0.0001928333
in O 0 0.00021782253
anaesthesia O 0 0.0011007315
to O 0 0.00016254859
reverse O 0 0.00028030504
the O 0 0.00023327662
non O 0 0.0006646952
- O 0 0.0032234679
depolarizing O 0 0.0031979003
neuromuscular O 0 0.014917333
block O 0 0.001632621
. O 0 0.0030047859

However O 0 0.0029396971
, O 0 0.003261496
studies O 0 0.0014198809
into O 0 0.00062715966
the O 0 0.0006164364
dose O 0 0.000873952
necessary O 0 0.00033682867
to O 0 0.0005253474
combating O 0 0.0016998241
scopolamine B-Chemical 0 0.9999951
intoxication O 0 0.9990693
are O 0 0.0013198985
indicated O 0 0.0012689062
. O 0 0.0032014896

Comparison O 0 0.0014369274
of O 0 0.0012938317
the O 0 0.00074364577
subjective O 0 0.001073199
effects O 0 0.0004873584
and O 0 0.0006016894
plasma O 0 0.0049760994
concentrations O 0 0.00048212975
following O 0 0.0001543541
oral O 0 0.000615503
and O 0 0.00020671221
i O 0 0.00039872894
. O 0 0.00023860882
m O 0 0.001054701
. O 0 0.00028343714
administration O 0 0.0006155619
of O 0 0.0010167888
flunitrazepam B-Chemical 0 0.9999937
in O 0 0.001722035
volunteers O 0 0.004470349
. O 0 0.0028966814

Flunitrazepam B-Chemical 0 0.999749
0 O 0 0.004917356
. O 0 0.001786999
5 O 0 0.0010567452
, O 0 0.001309239
1 O 0 0.0006904796
. O 0 0.00044685896
0 O 0 0.00043067057
or O 0 0.00026043638
2 O 0 0.0002882858
. O 0 0.00022924297
0 O 0 0.00030760255
mg O 0 0.001391847
was O 0 0.00014454778
given O 0 9.278849e-05
by O 0 0.00012568424
the O 0 0.00013337066
oral O 0 0.00052659924
or O 0 0.00014205724
i O 0 0.0003313563
. O 0 0.00018546026
m O 0 0.0008012025
. O 0 0.00015446807
routes O 0 0.00018873751
to O 0 0.000120564655
groups O 0 0.00021109085
of O 0 0.0002583737
volunteers O 0 0.00069025916
and O 0 0.00037330575
its O 0 0.0005512664
effects O 0 0.0007023293
compared O 0 0.0010857591
. O 0 0.0027397054

Plasma O 0 0.1532543
concentrations O 0 0.0033530917
of O 0 0.0014692021
the O 0 0.00090448384
drug O 0 0.0043395786
were O 0 0.00046767428
estimated O 0 0.00041681877
by O 0 0.0003954583
gas O 0 0.015050982
- O 0 0.0025640076
liquid O 0 0.0010355505
chromatography O 0 0.0030590743
, O 0 0.0005901424
in O 0 0.0003040898
a O 0 0.00049615034
smaller O 0 0.0004932128
number O 0 0.0003775447
of O 0 0.00066194317
the O 0 0.0008467771
subjects O 0 0.002583198
. O 0 0.0030305812

The O 0 0.001808461
most O 0 0.0015933015
striking O 0 0.00088186364
effect O 0 0.00059322227
was O 0 0.0005471327
sedation O 0 0.0050848788
which O 0 0.00033377606
increased O 0 0.00028307768
with O 0 0.00019475425
the O 0 0.0001511144
dose O 0 0.00033628847
, O 0 0.00031578864
2 O 0 0.00020908813
mg O 0 0.0017091517
producing O 0 0.00017226003
deep O 0 0.0009046432
sleep O 0 0.028422795
although O 0 0.00018737835
the O 0 0.00018957563
subjects O 0 0.0004741164
could O 0 0.0002745426
still O 0 0.00053227175
be O 0 0.0010246675
aroused O 0 0.0037673048
. O 0 0.0032295594

The O 0 0.0017518621
effects O 0 0.0014668521
of O 0 0.0014032819
i O 0 0.0017392789
. O 0 0.00076482457
m O 0 0.0021631964
. O 0 0.00039249426
administration O 0 0.0004390106
were O 0 0.00019580536
apparent O 0 0.0001935384
earlier O 0 0.00021978273
and O 0 0.00020821832
sometimes O 0 0.00033920768
lasted O 0 0.00012847531
longer O 0 0.00010551154
than O 0 0.00017795456
those O 0 0.000297502
following O 0 0.00030303004
oral O 0 0.0018816466
administration O 0 0.0019650403
. O 0 0.002472669

Dizziness B-Disease 0 0.9874013
was O 0 0.0025274565
less O 0 0.001935448
marked O 0 0.001450938
than O 0 0.00088759855
sedation O 0 0.0062034614
, O 0 0.0014855185
but O 0 0.0009714322
increased O 0 0.001140299
with O 0 0.0011589185
the O 0 0.001338748
dose O 0 0.0035836347
. O 0 0.003924063

There O 0 0.0037444367
was O 0 0.0022729589
pain B-Disease 0 0.011289554
on O 0 0.0006932532
i O 0 0.0011436234
. O 0 0.00055782613
m O 0 0.0015463413
. O 0 0.0003244872
injection O 0 0.0002588392
of O 0 0.00062157
flunitrazepam B-Chemical 0 0.99999726
significantly O 0 0.00077138696
more O 0 0.0004961755
often O 0 0.00038466943
than O 0 0.00031071418
with O 0 0.00059526745
isotonic O 0 0.0040625487
saline O 0 0.003450682
. O 0 0.0025896376

Plasma O 0 0.15868133
concentrations O 0 0.0031104055
varied O 0 0.0013427101
with O 0 0.0008257522
dose O 0 0.0009593401
and O 0 0.00049188227
route O 0 0.00046631877
and O 0 0.00036163756
corresponded O 0 0.0002637838
qualitatively O 0 0.00031012465
with O 0 0.00048636203
the O 0 0.0005561116
subjective O 0 0.001674538
effects O 0 0.0016368204
. O 0 0.0034780109

The O 0 0.0025116715
drug O 0 0.010269775
was O 0 0.0011225707
still O 0 0.00066399336
present O 0 0.00048822854
in O 0 0.00046115488
measurable O 0 0.00046963213
quantities O 0 0.00034908915
after O 0 0.00018401217
24 O 0 0.00029681157
h O 0 0.0003424103
even O 0 0.00041778584
with O 0 0.00051892665
the O 0 0.00059363566
smallest O 0 0.001400777
dose O 0 0.0029559964
. O 0 0.0031682581

Possible O 0 0.02468111
teratogenicity O 0 0.99326354
of O 0 0.031583592
sulphasalazine B-Chemical 0 0.9996381
. O 0 0.02630385

Three O 0 0.0030854987
infants O 0 0.005048062
, O 0 0.0026394853
born O 0 0.0018234382
of O 0 0.00057658704
two O 0 0.00030312449
mothers O 0 0.0008102237
with O 0 0.00048415147
inflammatory B-Disease 0 0.37289298
bowel I-Disease 0 0.28997603
disease I-Disease 0 0.67005235
who O 0 0.00020816392
received O 0 9.822989e-05
treatment O 0 0.000112404705
with O 0 0.000246135
sulphasalazine B-Chemical 0 0.99998474
throughout O 0 0.00015120751
pregnancy O 0 0.00096496125
, O 0 0.00036466442
were O 0 0.00016552977
found O 0 0.00019943037
to O 0 0.00024370385
have O 0 0.0003808814
major O 0 0.0009341612
congenital B-Disease 0 0.97066826
anomalies I-Disease 0 0.99687874
. O 0 0.004252521

In O 0 0.0019017922
the O 0 0.0015671604
singleton O 0 0.0029687423
pregnancy O 0 0.003569712
, O 0 0.0013577524
the O 0 0.00051811774
mother O 0 0.0013766058
had O 0 0.0011235254
ulcerative B-Disease 0 0.99996066
colitis I-Disease 0 0.9999658
, O 0 0.0012919446
and O 0 0.00029005684
the O 0 0.00019306842
infant O 0 0.0007285011
, O 0 0.00040012447
a O 0 0.0002996906
male O 0 0.0004965317
, O 0 0.00036292098
had O 0 0.00021711775
coarctation B-Disease 0 0.7329146
of I-Disease 0 0.0002696395
the I-Disease 0 0.0002315338
aorta I-Disease 0 0.008242184
and O 0 0.00043023803
a O 0 0.00088328484
ventricular B-Disease 0 0.8718775
septal I-Disease 0 0.0665014
defect I-Disease 0 0.0041744863
. O 0 0.0029378415

In O 0 0.002779845
the O 0 0.0027201727
twin O 0 0.021407662
pregnancy O 0 0.0071214964
, O 0 0.002724836
the O 0 0.0012187689
mother O 0 0.0027676458
had O 0 0.0020827667
Crohn B-Disease 0 0.8129265
' I-Disease 0 0.0037979702
s I-Disease 0 0.0040518013
disease I-Disease 0 0.2658923
. O 0 0.005587927

The O 0 0.002323262
first O 0 0.0017503584
twin O 0 0.016976165
, O 0 0.0026861005
a O 0 0.0015457843
female O 0 0.0018322809
, O 0 0.0011157123
had O 0 0.00048135596
a O 0 0.00058050686
left O 0 0.0009868236
Potter B-Disease 0 0.0024821844
- I-Disease 0 0.0035762324
type I-Disease 0 0.0012249845
IIa I-Disease 0 0.48019934
polycystic I-Disease 0 0.9800473
kidney I-Disease 0 0.08998109
and O 0 0.0005341127
a O 0 0.0007301835
rudimentary B-Disease 0 0.0019127303
left I-Disease 0 0.0023834195
uterine I-Disease 0 0.020051755
cornu I-Disease 0 0.10378775
. O 0 0.0037174148

The O 0 0.0024551046
second O 0 0.002276229
twin O 0 0.020670552
, O 0 0.0026416404
a O 0 0.0014842099
male O 0 0.0017519797
, O 0 0.001003541
had O 0 0.00039590473
some O 0 0.00031965887
features O 0 0.00038175145
of O 0 0.00037577323
Potter B-Disease 0 0.0014001362
' I-Disease 0 0.0008334728
s I-Disease 0 0.00080022274
facies I-Disease 0 0.9638089
, O 0 0.0016710819
hypoplastic B-Disease 0 0.99944955
lungs I-Disease 0 0.0064728726
, O 0 0.0006049417
absent B-Disease 0 0.0003093946
kidneys I-Disease 0 0.0012372173
and I-Disease 0 0.0005213542
ureters I-Disease 0 0.028847372
, O 0 0.0016163274
and O 0 0.0018788538
talipes B-Disease 0 0.9994592
equinovarus I-Disease 0 0.999696
. O 0 0.007870721

Despite O 0 0.0023099026
reports O 0 0.002228113
to O 0 0.0012038506
the O 0 0.0009273342
contrary O 0 0.0011567413
, O 0 0.0018129065
it O 0 0.0010968675
is O 0 0.0005609353
suggested O 0 0.0005856669
that O 0 0.000978009
sulphasalazine B-Chemical 0 0.99994826
may O 0 0.0016298356
be O 0 0.0022329055
teratogenic O 0 0.9944031
. O 0 0.0052805124

Thrombotic B-Disease 0 0.9987185
microangiopathy I-Disease 0 0.9999831
and O 0 0.0054014768
renal B-Disease 0 0.9026526
failure I-Disease 0 0.035095643
associated O 0 0.0013911042
with O 0 0.0015669664
antineoplastic O 0 0.09380068
chemotherapy O 0 0.011671682
. O 0 0.0036451244

Five O 0 0.0038008888
patients O 0 0.00407529
with O 0 0.0025766287
carcinoma B-Disease 0 0.9970709
developed O 0 0.009329044
thrombotic B-Disease 0 0.9999838
microangiopathy I-Disease 0 0.9999995
( O 0 0.0028609543
characterized O 0 0.0004005508
by O 0 0.00026727197
renal B-Disease 0 0.9567406
insufficiency I-Disease 0 0.9997216
, O 0 0.006401695
microangiopathic B-Disease 0 0.9999368
hemolytic I-Disease 0 0.9999988
anemia I-Disease 0 0.9999993
, O 0 0.0014112748
and O 0 0.00024596913
usually O 0 0.00038233944
thrombocytopenia B-Disease 0 0.99964297
) O 0 0.00028216638
after O 0 5.1495317e-05
treatment O 0 0.00011248823
with O 0 0.00026909713
cisplatin B-Chemical 0 0.9998994
, O 0 0.0020188775
bleomycin B-Chemical 0 0.99941707
, O 0 0.0009926482
and O 0 0.0006484566
a O 0 0.002032479
vinca B-Chemical 0 0.9987018
alkaloid I-Chemical 0 0.9976419
. O 0 0.005041296

One O 0 0.0044259457
patient O 0 0.0029771547
had O 0 0.0029183878
thrombotic B-Disease 0 0.9997181
thrombocytopenic I-Disease 0 0.9999453
purpura I-Disease 0 0.99995685
, O 0 0.001082046
three O 0 0.00019958061
the O 0 0.00046999555
hemolytic B-Disease 0 0.999895
- I-Disease 0 0.6684277
uremic I-Disease 0 0.99999034
syndrome I-Disease 0 0.99603623
, O 0 0.0006617337
and O 0 0.00021928454
one O 0 0.0001649273
an O 0 0.00024298877
apparent O 0 0.00039036787
forme O 0 0.8830542
fruste O 0 0.99973863
of O 0 0.00058096595
one O 0 0.0004318834
of O 0 0.00075686764
these O 0 0.0013933628
disorders O 0 0.99108
. O 0 0.0038385817

Histologic O 0 0.0038260878
examination O 0 0.0013551641
of O 0 0.0012153214
the O 0 0.00096925127
renal O 0 0.5808538
tissue O 0 0.0013923991
showed O 0 0.0002962535
evidence O 0 0.00025693318
of O 0 0.00055204233
intravascular B-Disease 0 0.9888526
coagulation I-Disease 0 0.99838424
, O 0 0.0006028072
primarily O 0 0.00022177768
affecting O 0 0.00026072652
the O 0 0.00020576734
small O 0 0.0006571975
arteries O 0 0.9114537
, O 0 0.001905663
arterioles O 0 0.96998894
, O 0 0.001572817
and O 0 0.0012566635
glomeruli O 0 0.014778908
. O 0 0.0034183282

Because O 0 0.0019258765
each O 0 0.0014332181
patient O 0 0.0015925174
was O 0 0.001220893
tumor B-Disease 0 0.56469786
- O 0 0.009466887
free O 0 0.00071977027
or O 0 0.00031195575
had O 0 0.00027625955
only O 0 0.00027762383
a O 0 0.00040445008
small O 0 0.0005331918
tumor B-Disease 0 0.25488886
at O 0 0.00013271708
the O 0 0.000119127486
onset O 0 0.00022497636
of O 0 0.00017664726
this O 0 0.00030800662
syndrome O 0 0.9262157
, O 0 0.00083214487
the O 0 0.0005899424
thrombotic B-Disease 0 0.99999166
microangiopathy I-Disease 0 0.99999976
may O 0 0.00038959476
have O 0 0.00025280518
been O 0 0.0003130471
induced O 0 0.000488755
by O 0 0.0009490688
chemotherapy O 0 0.0076876436
. O 0 0.0022187098

Diagnosis O 0 0.0116192885
of O 0 0.0022720215
this O 0 0.001440711
potentially O 0 0.0012839875
fatal O 0 0.5605555
complication O 0 0.010913007
may O 0 0.00027960277
be O 0 0.00022631328
delayed O 0 0.0005290174
or O 0 0.0001580094
missed O 0 0.00016296793
if O 0 0.00014716953
renal O 0 0.8305057
tissue O 0 0.0006813035
or O 0 9.902139e-05
the O 0 8.786539e-05
peripheral O 0 0.00053155835
blood O 0 0.0020484535
smear O 0 0.0001199746
is O 0 7.31099e-05
not O 0 8.080558e-05
examined O 0 9.358753e-05
, O 0 0.00027618554
because O 0 0.000120391975
renal B-Disease 0 0.86025685
failure I-Disease 0 0.030129666
may O 0 9.79306e-05
be O 0 9.132411e-05
ascribed O 0 0.00011162243
to O 0 0.0001639661
cisplatin B-Chemical 0 0.99997544
nephrotoxicity B-Disease 0 0.9999918
and O 0 0.0002809739
the O 0 0.00024063852
anemia B-Disease 0 0.99995327
and O 0 0.00052917656
thrombocytopenia B-Disease 0 0.999814
to O 0 0.00022359836
drug O 0 0.033818442
- O 0 0.0038094164
induced O 0 0.00050165155
bone B-Disease 0 0.106693566
marrow I-Disease 0 0.6094435
suppression I-Disease 0 0.009121904
. O 0 0.0030468425

International O 0 0.0065126163
mexiletine B-Chemical 0 0.9993253
and O 0 0.0033818637
placebo O 0 0.0215916
antiarrhythmic O 0 0.53637093
coronary O 0 0.043599427
trial O 0 0.0032354787
: O 0 0.0052980687
I O 0 0.026643947
. O 0 0.0074102744

Report O 0 0.015001424
on O 0 0.0053410865
arrhythmia B-Disease 0 0.9676895
and O 0 0.00521824
other O 0 0.004463494
findings O 0 0.0077171824
. O 0 0.010574844

Impact O 0 0.024246883
Research O 0 0.037548207
Group O 0 0.048260495
. O 0 0.029973427

The O 0 0.0019817236
antiarrhythmic O 0 0.061270252
effects O 0 0.0009554574
of O 0 0.00079063146
the O 0 0.00048021416
sustained O 0 0.0007899101
release O 0 0.00076756405
form O 0 0.00031522257
of O 0 0.00058215443
mexiletine B-Chemical 0 0.99998295
( O 0 0.0015952445
Mexitil B-Chemical 0 0.23453268
- I-Chemical 0 0.0056736968
Perlongets I-Chemical 0 0.0038015926
) O 0 0.00040450887
were O 0 9.9455e-05
evaluated O 0 9.6233925e-05
in O 0 9.8138895e-05
a O 0 0.0001637644
double O 0 0.00014131093
- O 0 0.0016490198
blind O 0 0.017384874
placebo O 0 0.006288647
trial O 0 0.00031103365
in O 0 0.0001881209
630 O 0 0.0016225924
patients O 0 0.00042714598
with O 0 0.0002905099
recent O 0 0.00052913843
documented O 0 0.0021592744
myocardial B-Disease 0 0.9996381
infarction I-Disease 0 0.9999616
. O 0 0.004477217

The O 0 0.001723928
primary O 0 0.0012754402
response O 0 0.00084573764
variable O 0 0.00053291663
was O 0 0.0003733084
based O 0 0.00024018329
on O 0 0.00016237076
central O 0 0.00029756216
reading O 0 0.00036406663
of O 0 0.0001539697
24 O 0 0.0001151485
hour O 0 8.807485e-05
ambulatory O 0 0.00013590527
electrocardiographic O 0 0.00038789376
recordings O 0 7.438061e-05
and O 0 7.699801e-05
was O 0 7.335949e-05
defined O 0 7.663863e-05
as O 0 8.939774e-05
the O 0 8.062563e-05
occurrence O 0 0.00011515816
of O 0 0.000113554976
30 O 0 8.738184e-05
or O 0 7.3037554e-05
more O 0 0.000117698124
single O 0 7.0357324e-05
premature O 0 0.00034021327
ventricular O 0 0.16291623
complexes O 0 0.00012746484
in O 0 7.9205005e-05
any O 0 5.656796e-05
two O 0 3.986985e-05
consecutive O 0 5.884463e-05
30 O 0 5.1614395e-05
minute O 0 6.3151165e-05
blocks O 0 5.5512264e-05
or O 0 6.2365856e-05
one O 0 6.630218e-05
or O 0 7.6610646e-05
more O 0 0.00013118444
runs O 0 0.00013009334
of O 0 9.5773255e-05
two O 0 6.2702784e-05
or O 0 9.467201e-05
more O 0 0.0001839725
premature O 0 0.0005065099
ventricular O 0 0.14764258
complexes O 0 0.00019211828
in O 0 0.00014389401
the O 0 0.00013418937
entire O 0 0.0001574367
24 O 0 0.00026035839
hour O 0 0.00034853976
electrocardiographic O 0 0.0022751845
recording O 0 0.00081188953
. O 0 0.0017804183

Large O 0 0.007469487
differences O 0 0.0019143416
, O 0 0.0026212565
regarded O 0 0.0014891117
as O 0 0.0007136691
statistically O 0 0.00069846696
significant O 0 0.00038936659
, O 0 0.0004896769
between O 0 0.0002010542
the O 0 0.0003047693
mexiletine B-Chemical 0 0.9999579
and O 0 0.0002750013
placebo O 0 0.0034396725
groups O 0 0.0001808766
were O 0 0.00010408084
noted O 0 0.000102798476
in O 0 8.091422e-05
that O 0 5.5618188e-05
end O 0 4.990096e-05
point O 0 6.494662e-05
at O 0 6.61963e-05
months O 0 5.3242773e-05
1 O 0 0.0001056661
and O 0 0.00011328093
4 O 0 0.00012227797
, O 0 0.00027581744
but O 0 0.00021350208
only O 0 0.00021817422
trends O 0 0.00028418313
were O 0 0.00024512535
observed O 0 0.00026081657
at O 0 0.00033254086
month O 0 0.0004225528
12 O 0 0.00082029856
. O 0 0.0020614709

These O 0 0.0017665252
differences O 0 0.0012189198
were O 0 0.00091902993
observed O 0 0.0006109262
even O 0 0.0006435313
though O 0 0.00047011249
the O 0 0.00041291185
serum O 0 0.19867188
mexiletine B-Chemical 0 0.9999802
levels O 0 0.00020321818
obtained O 0 0.000114811795
in O 0 0.00010671026
this O 0 0.00011466277
study O 0 0.00011614329
were O 0 7.570156e-05
generally O 0 8.81476e-05
lower O 0 0.00010760075
than O 0 8.036081e-05
those O 0 0.00010418391
observed O 0 8.38763e-05
in O 0 0.000101168705
studies O 0 0.00014468112
that O 0 9.35596e-05
have O 0 0.00011661938
used O 0 0.00013506062
the O 0 0.00016507205
regular O 0 0.00025460898
form O 0 0.00034528942
of O 0 0.00060939667
the O 0 0.0008862147
drug O 0 0.023104953
. O 0 0.003126159

There O 0 0.0037764802
were O 0 0.002209631
more O 0 0.0024261659
deaths B-Disease 0 0.010618713
in O 0 0.00079026056
the O 0 0.0007688778
mexiletine B-Chemical 0 0.99993086
group O 0 0.0009065669
( O 0 0.0005726088
7 O 0 0.00018339297
. O 0 0.00016029312
6 O 0 0.00012234341
% O 0 0.00029857043
) O 0 0.0003373147
than O 0 0.00012447758
in O 0 0.00012648363
the O 0 0.00013817172
placebo O 0 0.0019158917
group O 0 0.0002992886
( O 0 0.0003322943
4 O 0 0.00014046046
. O 0 0.0001454921
8 O 0 0.00015934237
% O 0 0.00037494893
) O 0 0.0005315099
; O 0 0.0004674626
the O 0 0.0002206638
difference O 0 0.0002795487
was O 0 0.00041492932
not O 0 0.0005531776
statistically O 0 0.0014004564
significant O 0 0.001821164
. O 0 0.0033720264

The O 0 0.0028188613
incidence O 0 0.0036024645
of O 0 0.002293434
coronary O 0 0.023657084
events O 0 0.001717033
was O 0 0.0009410487
similar O 0 0.0006854966
in O 0 0.0010394789
both O 0 0.0014398955
groups O 0 0.0031393615
. O 0 0.004952446

Previously O 0 0.0028451164
recognized O 0 0.0016680396
side O 0 0.0026674338
effects O 0 0.0010169221
, O 0 0.0018725378
particularly O 0 0.0015058237
tremor B-Disease 0 0.9998851
and O 0 0.0008210423
gastrointestinal B-Disease 0 0.9357541
problems I-Disease 0 0.065912254
, O 0 0.00051295635
were O 0 0.00016515706
more O 0 0.00021769339
frequent O 0 0.00019346556
in O 0 0.0001393913
the O 0 0.00020714726
mexiletine B-Chemical 0 0.99994206
group O 0 0.00040184328
than O 0 0.00021119797
in O 0 0.00026981183
the O 0 0.00040909648
placebo O 0 0.0052634156
group O 0 0.0018621589
. O 0 0.0026174071

Changes O 0 0.0038608082
in O 0 0.0024050632
heart O 0 0.011316555
size O 0 0.0015273759
during O 0 0.0006341813
long O 0 0.0008259285
- O 0 0.0030608065
term O 0 0.0013652574
timolol B-Chemical 0 0.9999788
treatment O 0 0.001339866
after O 0 0.0010083895
myocardial B-Disease 0 0.99826896
infarction I-Disease 0 0.99988735
. O 0 0.0056588454

The O 0 0.001638197
effect O 0 0.0011769845
of O 0 0.0012024151
long O 0 0.0010740049
- O 0 0.004284793
term O 0 0.0011084059
timolol B-Chemical 0 0.99999106
treatment O 0 0.00045433777
on O 0 0.0001935314
heart O 0 0.004582322
size O 0 0.0003800881
after O 0 0.00017477901
myocardial B-Disease 0 0.9990791
infarction I-Disease 0 0.99997866
was O 0 0.00018276926
evaluated O 0 0.0001541407
by O 0 0.00022411958
X O 0 0.75929517
- O 0 0.0085775815
ray O 0 0.0030136928
in O 0 0.00013643515
a O 0 0.00019728715
double O 0 0.00015643873
- O 0 0.00182787
blind O 0 0.0073065083
study O 0 0.0001820077
including O 0 0.00012021256
241 O 0 0.0006446587
patients O 0 0.00040254393
( O 0 0.00046396087
placebo O 0 0.002955416
126 O 0 0.0012823964
, O 0 0.0023164107
timolol B-Chemical 0 0.9999801
115 O 0 0.0064438637
) O 0 0.0040184804
. O 0 0.0032161816

The O 0 0.0039194487
follow O 0 0.0032029934
- O 0 0.0074894866
up O 0 0.0025299531
period O 0 0.0015530909
was O 0 0.0018796005
12 O 0 0.0017818103
months O 0 0.0018809359
. O 0 0.0055122296

The O 0 0.004287583
timolol B-Chemical 0 0.99997044
- O 0 0.051177736
treated O 0 0.0021500732
patients O 0 0.0013134491
showed O 0 0.0004186404
a O 0 0.0005637253
small O 0 0.00053651
but O 0 0.00031272584
significant O 0 0.00019716604
increase O 0 0.00016882074
in O 0 0.00017064124
heart O 0 0.0040337113
size O 0 0.00021583702
from O 0 9.5971096e-05
baseline O 0 9.731871e-05
in O 0 0.00010532456
contrast O 0 0.00019021262
to O 0 0.00016168773
a O 0 0.00032789455
decrease O 0 0.0002980562
in O 0 0.00030581857
the O 0 0.00043177468
placebo O 0 0.005967636
group O 0 0.0018724629
. O 0 0.0026015479

These O 0 0.0022831378
differences O 0 0.0016298457
may O 0 0.0011727789
be O 0 0.0009259678
caused O 0 0.00083904166
by O 0 0.00140124
timolol B-Chemical 0 0.9999964
- O 0 0.06264972
induced O 0 0.00059205305
bradycardia B-Disease 0 0.9970386
and O 0 0.00040109447
a O 0 0.00043682964
compensatory O 0 0.00044933878
increase O 0 0.00025277142
in O 0 0.00026753332
end O 0 0.00031363376
- O 0 0.0027786884
diastolic O 0 0.42037988
volume O 0 0.0034001863
. O 0 0.0031267088

The O 0 0.0046897144
timolol B-Chemical 0 0.9999702
- O 0 0.02471865
related O 0 0.0006749163
increase O 0 0.00058311125
in O 0 0.0005309863
heart O 0 0.010281321
size O 0 0.00060188235
was O 0 0.00025771093
observed O 0 0.00019765204
only O 0 0.00023799964
in O 0 0.00022530483
patients O 0 0.00047556276
with O 0 0.0003202726
normal O 0 0.0006986028
and O 0 0.00070191984
borderline O 0 0.68239903
heart O 0 0.09212291
size O 0 0.003145511
. O 0 0.0032287426

In O 0 0.002277622
patients O 0 0.0036439814
with O 0 0.0023004944
cardiomegaly B-Disease 0 0.99896026
, O 0 0.0019833415
the O 0 0.0005185251
increase O 0 0.00045448873
in O 0 0.00048134173
heart O 0 0.0076163714
size O 0 0.0007205643
was O 0 0.00040243188
similar O 0 0.00031999947
in O 0 0.0005502423
both O 0 0.00084566145
groups O 0 0.002053732
. O 0 0.0034382148

After O 0 0.0029124229
re O 0 0.012489423
- O 0 0.16724637
infarction B-Disease 0 0.99988234
, O 0 0.003377354
heart O 0 0.035267532
size O 0 0.0008040181
increased O 0 0.00044388144
in O 0 0.00022259433
the O 0 0.00018819087
placebo O 0 0.0016638426
group O 0 0.00030894778
and O 0 0.00025471824
remained O 0 0.00039395245
unchanged O 0 0.0005076426
in O 0 0.00049718196
the O 0 0.000958012
timolol B-Chemical 0 0.9999782
group O 0 0.003965412
. O 0 0.0033226567

Vitamin B-Chemical 0 0.99989736
D3 I-Chemical 0 0.9997198
toxicity B-Disease 0 0.991831
in O 0 0.010373824
dairy O 0 0.07562873
cows O 0 0.021625824
. O 0 0.011534269

Large O 0 0.008227035
parenteral O 0 0.007043879
doses O 0 0.005111187
of O 0 0.00458332
vitamin B-Chemical 0 0.99997175
D3 I-Chemical 0 0.9999583
( O 0 0.0035936844
15 O 0 0.0004602809
to O 0 0.00025227328
17 O 0 0.00032117617
. O 0 0.00018357545
5 O 0 0.00015899586
x O 0 0.00045838082
10 O 0 0.00018865905
( O 0 0.00026470763
6 O 0 0.00014407016
) O 0 0.0007049986
IU O 0 0.73024815
vitamin B-Chemical 0 0.9999865
D3 I-Chemical 0 0.9999807
) O 0 0.0023968846
were O 0 0.00014954891
associated O 0 0.00013077517
with O 0 0.00015076179
prolonged O 0 0.00057824305
hypercalcemia B-Disease 0 0.99997354
, O 0 0.0050098253
hyperphosphatemia B-Disease 0 0.9999974
, O 0 0.00066037476
and O 0 0.00015844997
large O 0 0.00020415623
increases O 0 0.00018404235
of O 0 0.00069933577
vitamin B-Chemical 0 0.99999666
D3 I-Chemical 0 0.9999927
and O 0 0.00063333457
its O 0 0.0004887499
metabolites O 0 0.30241257
in O 0 0.00016752568
the O 0 0.00014926001
blood O 0 0.006616803
plasma O 0 0.0053770216
of O 0 0.00031522135
nonlactating O 0 0.06302442
nonpregnant O 0 0.0049323672
and O 0 0.0005497684
pregnant O 0 0.0026301288
Jersey O 0 0.0044192234
cows O 0 0.004154288
. O 0 0.002782401

Calcium B-Chemical 0 0.99674004
concentrations O 0 0.004170571
1 O 0 0.0012018031
day O 0 0.000490933
postpartum O 0 0.0006744964
were O 0 0.0002979744
higher O 0 0.00030245507
in O 0 0.00026951462
cows O 0 0.00091397297
treated O 0 0.0007665798
with O 0 0.0011010388
vitamin B-Chemical 0 0.9999914
D3 I-Chemical 0 0.999979
about O 0 0.0005986488
32 O 0 0.000294544
days O 0 0.000107045664
prepartum O 0 0.001054472
( O 0 0.00024147281
8 O 0 0.000112138776
. O 0 0.00010673051
8 O 0 0.00012483489
mg O 0 0.0011530926
/ O 0 0.0006732316
100 O 0 0.00038616353
ml O 0 0.0006865672
) O 0 0.00038325615
than O 0 0.00012630066
in O 0 0.00014166169
control O 0 0.0002171078
cows O 0 0.0008622388
( O 0 0.00046314782
5 O 0 0.00022535553
. O 0 0.00023945021
5 O 0 0.00032316925
mg O 0 0.0023413529
/ O 0 0.0020058097
100 O 0 0.0017884583
ml O 0 0.0037030105
) O 0 0.004043781
. O 0 0.0035784794

None O 0 0.0035999222
of O 0 0.0019343236
the O 0 0.001172675
cows O 0 0.0030742532
treated O 0 0.0022138194
with O 0 0.0028800208
vitamin B-Chemical 0 0.9999895
D3 I-Chemical 0 0.99998116
showed O 0 0.0010275157
signs O 0 0.013108378
of O 0 0.000886613
milk B-Disease 2 0.99783367
fever I-Disease 2 0.999879
during O 0 0.00014986556
the O 0 0.00013180045
peripartal O 0 0.0035902066
period O 0 0.00010352969
; O 0 0.00028267235
however O 0 0.00017680245
, O 0 0.00028565922
22 O 0 0.00021049113
% O 0 0.00022858838
of O 0 0.0001230353
the O 0 0.00010215422
control O 0 0.0001562278
cows O 0 0.0006197689
developed O 0 0.00024091768
clinical O 0 0.00097344775
signs O 0 0.0021372775
of O 0 0.00070871
milk B-Disease 2 0.9947173
fever I-Disease 2 0.9997696
during O 0 0.0004795086
this O 0 0.00076881406
period O 0 0.00090986193
. O 0 0.0022482954

Signs O 0 0.27447036
of O 0 0.0135899205
vitamin B-Chemical 0 0.9999659
D3 I-Chemical 0 0.99996984
toxicity B-Disease 0 0.99624556
were O 0 0.0007539342
not O 0 0.00035041803
observed O 0 0.00026667916
in O 0 0.0003081488
nonlactating O 0 0.020708289
nonpregnant O 0 0.003610664
cows O 0 0.00089490076
; O 0 0.0004076524
however O 0 0.00022135263
, O 0 0.00037510265
pregnant O 0 0.0007400407
cows O 0 0.0006771048
commonly O 0 0.00019711566
developed O 0 0.00022463835
severe O 0 0.0014396562
signs O 0 0.0022638158
of O 0 0.0010043882
vitamin B-Chemical 0 0.9999958
D3 I-Chemical 0 0.9999944
toxicity B-Disease 0 0.9962637
and O 0 0.0005360751
10 O 0 0.0003826272
of O 0 0.00048473608
17 O 0 0.00092474325
cows O 0 0.0024496012
died O 0 0.002918124
. O 0 0.0025947727

There O 0 0.0055557154
was O 0 0.0037150243
widespread O 0 0.004099873
metastatic O 0 0.76887566
calcification O 0 0.9960975
in O 0 0.0016110368
the O 0 0.0012692387
cows O 0 0.0034684234
that O 0 0.0017326832
died O 0 0.0055950144
. O 0 0.004956998

Because O 0 0.001855914
of O 0 0.0019056504
the O 0 0.0012268838
extreme O 0 0.0025518588
toxicity B-Disease 0 0.8178309
of O 0 0.004058418
vitamin B-Chemical 0 0.9999908
D3 I-Chemical 0 0.9999819
in O 0 0.0009200098
pregnant O 0 0.002686384
Jersey O 0 0.0012211041
cows O 0 0.0005417322
and O 0 0.00013286647
the O 0 9.2405884e-05
low O 0 0.00016353658
margin O 0 0.0005210087
of O 0 9.31287e-05
safety O 0 8.3303494e-05
between O 0 7.054839e-05
doses O 0 0.0004299429
of O 0 0.00070762075
vitamin B-Chemical 0 0.9999969
D3 I-Chemical 0 0.99999356
that O 0 0.00032155853
prevent O 0 0.00045539206
milk B-Disease 2 0.9991316
fever I-Disease 2 0.9999534
and O 0 0.00023957125
doses O 0 0.00047729275
that O 0 0.00010149358
induce O 0 0.00019315918
milk B-Disease 2 0.99830675
fever I-Disease 2 0.9999552
, O 0 0.00046069265
we O 0 7.226013e-05
concluded O 0 0.0002162422
that O 0 0.0003710287
vitamin B-Chemical 0 0.99999785
D3 I-Chemical 0 0.9999969
cannot O 0 0.09794283
be O 0 0.00020942172
used O 0 0.00013998566
practically O 0 0.00023824282
to O 0 0.00018102083
prevent O 0 0.00035356125
milk B-Disease 2 0.9931987
fever I-Disease 2 0.9997695
when O 0 0.00021851984
injected O 0 0.00025924426
several O 0 0.00025828747
weeks O 0 0.00038442618
prepartum O 0 0.0047541624
. O 0 0.0024013447

Diseases B-Disease 0 0.004950874
of I-Disease 0 0.0033954163
peripheral I-Disease 0 0.005614776
nerves I-Disease 0 0.007723137
as O 0 0.0018191229
seen O 0 0.0016671466
in O 0 0.0015775582
the O 0 0.0018865875
Nigerian O 0 0.0051512006
African O 0 0.007448662
. O 0 0.0063741053

The O 0 0.0018755739
anatomical O 0 0.0020677291
and O 0 0.0013595483
aetiological O 0 0.003761175
diagnoses O 0 0.0017407682
of O 0 0.0006643969
peripheral B-Disease 0 0.017151153
nerve I-Disease 0 0.27600792
disease I-Disease 0 0.8213604
excluding O 0 0.000295886
its O 0 0.0003076797
primary O 0 0.00031508435
benign O 0 0.36133933
and O 0 0.00041255244
malignant O 0 0.9442511
disorders O 0 0.9959461
, O 0 0.00066936604
as O 0 0.00028186906
seen O 0 0.00037104762
in O 0 0.00047224996
358 O 0 0.0035802787
Nigerians O 0 0.0046224506
are O 0 0.0007328301
presented O 0 0.0012016742
. O 0 0.0026079363

There O 0 0.004200648
is O 0 0.0021683772
a O 0 0.0023775003
male O 0 0.0027361857
preponderance O 0 0.0024150996
and O 0 0.00085576606
the O 0 0.00058156543
peak O 0 0.0007958502
incidence O 0 0.0009901649
is O 0 0.0004994196
in O 0 0.0006207988
the O 0 0.0007732596
fourth O 0 0.0017784449
decade O 0 0.0032232793
. O 0 0.004291333

Sensori B-Disease 0 0.01548635
- I-Disease 0 0.038344517
motor I-Disease 0 0.46929398
neuropathy I-Disease 0 0.99987006
was O 0 0.0018443
the O 0 0.0011371522
commonest O 0 0.004417038
presentation O 0 0.0021959883
( O 0 0.0022333113
50 O 0 0.0020159916
% O 0 0.0034505837
) O 0 0.0055258228
. O 0 0.0051994957

Guillain B-Disease 0 0.99109215
- I-Disease 0 0.21898104
Barr I-Disease 0 0.4053601
syndrome I-Disease 0 0.9486668
was O 0 0.0011351912
the O 0 0.0007401553
commonest O 0 0.005840171
identifiable O 0 0.0011047774
cause O 0 0.0005644724
( O 0 0.0005825851
15 O 0 0.0002323288
. O 0 0.00017719365
6 O 0 0.00014052112
% O 0 0.00036370935
) O 0 0.00047892664
, O 0 0.00037606742
accounting O 0 0.00028605634
for O 0 0.00015633526
half O 0 0.00018094422
of O 0 0.00030671552
the O 0 0.00033386197
cases O 0 0.0009019614
with O 0 0.0011239767
motor B-Disease 0 0.5640049
neuropathy I-Disease 0 0.9999404
. O 0 0.00514981

Peripheral B-Disease 0 0.9433113
neuropathy I-Disease 0 0.9998709
due O 0 0.0015388951
to O 0 0.0010790757
nutritional B-Disease 0 0.1996457
deficiency I-Disease 0 0.9767213
of O 0 0.0051088505
thiamine B-Chemical 0 0.99998915
and O 0 0.007938749
riboflavin B-Chemical 0 0.9999882
was O 0 0.00040003294
common O 0 0.00028238012
( O 0 0.00035862738
10 O 0 0.00015971763
. O 0 0.00013143447
1 O 0 0.00015165731
% O 0 0.00026965007
) O 0 0.0003145606
and O 0 0.00015907804
presented O 0 0.0001486589
mainly O 0 0.0001953438
as O 0 0.00022253662
sensory O 0 0.0005542429
and O 0 0.00047950103
sensori B-Disease 0 0.017681273
- I-Disease 0 0.01842225
motor I-Disease 0 0.42953256
neuropathy I-Disease 0 0.9999193
. O 0 0.005182746

Diabetes B-Disease 0 0.99743575
mellitus I-Disease 0 0.9998468
was O 0 0.0035960516
the O 0 0.0017527754
major O 0 0.001718864
cause O 0 0.0021822366
of O 0 0.0031567765
autonomic B-Disease 0 0.9854242
neuropathy I-Disease 0 0.99989164
. O 0 0.008515074

Isoniazid B-Chemical 0 0.9993536
was O 0 0.0028617422
the O 0 0.0013983973
most O 0 0.0014210254
frequent O 0 0.0013138935
agent O 0 0.0018133431
in O 0 0.0011622189
drug O 0 0.025193684
- O 0 0.009106255
induced O 0 0.0029716357
neuropathy B-Disease 0 0.9995659
. O 0 0.0070372024

Migraine B-Disease 0 0.9975865
( O 0 0.0066394233
20 O 0 0.0022016899
% O 0 0.002599021
) O 0 0.0019902666
was O 0 0.0006276174
not O 0 0.00047012567
an O 0 0.0005678196
uncommon O 0 0.001780727
cause O 0 0.00041061302
of O 0 0.00048218347
cranial B-Disease 0 0.99060166
neuropathy I-Disease 0 0.9999944
although O 0 0.00057062827
malignancies B-Disease 0 0.9606831
arising O 0 0.00013746865
from O 0 9.96342e-05
the O 0 0.000113378075
reticuloendothelial O 0 0.10919002
system O 0 0.00012490347
or O 0 8.694125e-05
related O 0 6.2349805e-05
structures O 0 0.000108900116
of O 0 0.00015325258
the O 0 0.00014982081
head O 0 0.00092794007
and O 0 0.00028933102
neck O 0 0.004899216
were O 0 0.00024386354
more O 0 0.00039515985
frequent O 0 0.0005044028
( O 0 0.0008310561
26 O 0 0.00091808155
% O 0 0.0017898764
) O 0 0.0033890037
. O 0 0.0033535394

In O 0 0.0029275585
26 O 0 0.0033966464
. O 0 0.0017433836
5 O 0 0.0011256557
% O 0 0.0014739372
of O 0 0.0007366953
all O 0 0.0005529965
the O 0 0.0004795881
cases O 0 0.0008883604
, O 0 0.0008475924
the O 0 0.00044635576
aetiology O 0 0.0025945834
of O 0 0.0007565511
the O 0 0.00096292247
neuropathy B-Disease 0 0.9996953
was O 0 0.0018421989
undetermined O 0 0.0048848237
. O 0 0.003344191

Heredofamilial O 0 0.72580594
and O 0 0.01334417
connective B-Disease 0 0.9327351
tissue I-Disease 0 0.025702927
disorders I-Disease 0 0.9955224
were O 0 0.0062576085
rare O 0 0.014188716
. O 0 0.008743376

Some O 0 0.003529932
of O 0 0.0020116773
the O 0 0.0011092469
factors O 0 0.0012562051
related O 0 0.00043107575
to O 0 0.00037072288
the O 0 0.0003144032
clinical O 0 0.00079338544
presentation O 0 0.0005593347
and O 0 0.0003347132
pathogenesis O 0 0.00053815154
of O 0 0.0004332588
the O 0 0.00057087716
neuropathies B-Disease 0 0.9994073
are O 0 0.0007228911
briefly O 0 0.0013115117
discussed O 0 0.0016060217
. O 0 0.003161645

Reduction O 0 0.012753471
in O 0 0.00920783
caffeine B-Chemical 0 0.99886477
toxicity B-Disease 0 0.98261386
by O 0 0.011441151
acetaminophen B-Chemical 0 0.99985325
. O 0 0.014034321

A O 0 0.03320008
patient O 0 0.0030828288
who O 0 0.0022813354
allegedly O 0 0.003053533
consumed O 0 0.0045512766
100 O 0 0.0015002483
tablets O 0 0.027964313
of O 0 0.00035223452
an O 0 0.00026796604
over O 0 0.00018350036
- O 0 0.0009084775
the O 0 0.00015769679
- O 0 0.0009306325
counter O 0 0.00038239214
analgesic O 0 0.014688464
containing O 0 0.0003251406
sodium B-Chemical 0 0.9999722
acetylsalicylate I-Chemical 0 0.9999962
, O 0 0.008566796
caffeine B-Chemical 0 0.9999342
, O 0 0.00089077227
and O 0 0.00042207973
acetaminophen B-Chemical 0 0.9999962
displayed O 0 0.00013600003
no O 0 9.9389385e-05
significant O 0 0.00013505045
CNS O 0 0.0015316037
stimulation O 0 6.530919e-05
despite O 0 7.61294e-05
the O 0 8.797773e-05
presence O 0 0.00012307729
of O 0 0.00021802972
175 O 0 0.00091795484
micrograms O 0 0.004145141
of O 0 0.00053281453
caffeine B-Chemical 0 0.9993204
per O 0 0.00070223195
mL O 0 0.0039398614
of O 0 0.0012652917
serum O 0 0.05815218
. O 0 0.0035151024

Because O 0 0.0031930082
salicylates O 0 0.9994382
have O 0 0.0015519194
been O 0 0.0008220389
reported O 0 0.00055688503
to O 0 0.00027425773
augment O 0 0.00024785308
the O 0 0.00018203791
stimulatory O 0 0.00035645135
effects O 0 0.00023705009
of O 0 0.00050812506
caffeine B-Chemical 0 0.99982446
on O 0 0.0001438825
the O 0 0.00015071507
CNS O 0 0.005246389
, O 0 0.00027368098
attention O 0 0.0003880968
was O 0 8.708063e-05
focused O 0 7.817027e-05
on O 0 5.6844452e-05
the O 0 6.2857725e-05
possibility O 0 5.3736017e-05
that O 0 7.617522e-05
the O 0 9.881332e-05
presence O 0 0.0001443807
of O 0 0.00040938513
acetaminophen B-Chemical 0 0.9999945
( O 0 0.0007224672
52 O 0 0.000308244
micrograms O 0 0.0020381818
/ O 0 0.0012898521
mL O 0 0.0024985978
) O 0 0.0006267677
reduced O 0 0.0003593892
the O 0 0.00040380898
CNS O 0 0.02732673
toxicity B-Disease 0 0.71392065
of O 0 0.0022809706
caffeine B-Chemical 0 0.99942786
. O 0 0.0043598125

Studies O 0 0.008694091
in O 0 0.0046038176
DBA O 0 0.95366144
/ O 0 0.013378484
2J O 0 0.06300845
mice O 0 0.00032696087
showed O 0 0.0004076452
that O 0 0.00033414795
: O 0 0.0008129509
1 O 0 0.00039720154
) O 0 0.00069564895
pretreatment O 0 0.00137618
with O 0 0.00057233183
acetaminophen B-Chemical 0 0.9999906
( O 0 0.0008275297
100 O 0 0.00046266595
mg O 0 0.0024369322
/ O 0 0.0005924275
kg O 0 0.00039155697
) O 0 0.0002888096
increased O 0 0.00012631451
the O 0 6.634379e-05
interval O 0 7.866365e-05
between O 0 5.3725773e-05
the O 0 7.392438e-05
administration O 0 0.0002138594
of O 0 0.00023420772
caffeine B-Chemical 0 0.9997342
( O 0 0.00045051222
300 O 0 0.0002603897
to O 0 0.00010359468
450 O 0 0.00077031157
mg O 0 0.0020895675
/ O 0 0.00054635043
kg O 0 0.00040676867
IP O 0 0.0006016885
) O 0 0.00030861038
and O 0 0.000114834125
the O 0 9.9953366e-05
onset O 0 0.00025293685
of O 0 0.00030246575
fatal O 0 0.96672577
convulsions B-Disease 0 0.99996793
by O 0 0.00020284127
a O 0 0.0003147616
factor O 0 0.0014238552
of O 0 0.00014842974
about O 0 0.00014081394
two O 0 8.05686e-05
; O 0 0.00024715438
and O 0 0.000119008946
2 O 0 0.00014009794
) O 0 0.00033241027
pretreatment O 0 0.0008899579
with O 0 0.0003613476
acetaminophen B-Chemical 0 0.9999944
( O 0 0.0005985495
75 O 0 0.00026101957
mg O 0 0.0016039351
/ O 0 0.000497839
kg O 0 0.00036271018
) O 0 0.00030027406
reduced O 0 0.00013705203
the O 0 0.00011021792
incidence O 0 0.00038034384
of O 0 0.00045521042
audiogenic O 0 0.99990046
seizures B-Disease 0 0.9999889
produced O 0 0.00014049218
in O 0 0.00011434406
the O 0 9.936474e-05
presence O 0 0.00014115944
of O 0 0.00036294435
caffeine B-Chemical 0 0.9998343
( O 0 0.0005666961
12 O 0 0.00012028424
. O 0 0.00013033919
5 O 0 0.00013484817
to O 0 0.00016361377
75 O 0 0.0004963601
mg O 0 0.0025030714
/ O 0 0.0018426568
kg O 0 0.001949762
IP O 0 0.0036229969
) O 0 0.0037597283
. O 0 0.0033052643

The O 0 0.0019502094
frequency O 0 0.0015279658
of O 0 0.001532955
sound O 0 0.0039420314
- O 0 0.0100885155
induced O 0 0.0012346086
seizures B-Disease 0 0.99990463
after O 0 0.00024368294
12 O 0 0.00018271506
. O 0 0.00016937165
5 O 0 0.0001381148
or O 0 0.00013279136
25 O 0 0.00026030105
mg O 0 0.0017825186
/ O 0 0.0010501217
kg O 0 0.0013629119
caffeine B-Chemical 0 0.99880624
was O 0 0.00027534345
reduced O 0 0.0003031482
from O 0 0.0002529395
50 O 0 0.00039124637
to O 0 0.0002953694
5 O 0 0.00044870356
% O 0 0.0011397515
by O 0 0.0015069598
acetaminophen B-Chemical 0 0.99989855
. O 0 0.0051773055

In O 0 0.0019713035
the O 0 0.0015027755
absence O 0 0.0010264635
of O 0 0.0020230436
caffeine B-Chemical 0 0.999785
, O 0 0.020522682
acetaminophen B-Chemical 0 0.99999094
( O 0 0.0012603819
up O 0 0.0002757751
to O 0 0.00016523614
300 O 0 0.00040781507
mg O 0 0.0021750324
/ O 0 0.00078888325
kg O 0 0.0006046278
) O 0 0.0004968795
did O 0 0.0001844981
not O 0 0.00013684061
modify O 0 0.00014241664
the O 0 0.00025652468
seizures B-Disease 0 0.99997306
induced O 0 0.00020566687
by O 0 0.00016757203
maximal O 0 0.0005000283
electroshock O 0 0.99903667
and O 0 0.000210012
did O 0 0.00016007668
not O 0 0.00010396142
alter O 0 0.00010060457
the O 0 0.00013148012
convulsant O 0 0.9836014
dose O 0 0.00029344813
of O 0 0.0001226099
pentylenetetrezol B-Chemical 0 0.0007496489
in O 0 0.00010264499
mice O 0 4.925143e-05
( O 0 0.00020977145
tests O 0 0.00026711583
performed O 0 0.00014461258
by O 0 0.00020582067
the O 0 0.00034836138
Anticonvulsant O 0 0.9977149
Screening O 0 0.0008675737
Project O 0 0.0019427328
of O 0 0.0013566808
NINCDS O 0 0.7057039
) O 0 0.0047343485
. O 0 0.0034153906

Acetaminophen B-Chemical 0 0.99981374
( O 0 0.0056716343
up O 0 0.0015342562
to O 0 0.0007514731
150 O 0 0.0010246735
micrograms O 0 0.0045048376
/ O 0 0.0030720735
mL O 0 0.005335449
) O 0 0.0010843566
did O 0 0.00038238466
not O 0 0.00031728364
retard O 0 0.028245255
the O 0 0.0002731679
incorporation O 0 0.0004999402
of O 0 0.00047337782
radioactive O 0 0.017309014
adenosine B-Chemical 0 0.999318
into O 0 0.00036820368
ATP B-Chemical 0 0.99526054
in O 0 0.0003587643
slices O 0 0.0005443842
of O 0 0.00055888493
rat O 0 0.0016505339
cerebral O 0 0.9793473
cortex O 0 0.08128749
. O 0 0.002771971

Thus O 0 0.0018071359
the O 0 0.0013063132
mechanism O 0 0.0008119855
by O 0 0.0010114907
which O 0 0.0017373262
acetaminophen B-Chemical 0 0.99997544
antagonizes O 0 0.00075884716
the O 0 0.00035254244
actions O 0 0.00065827003
of O 0 0.0008992043
caffeine B-Chemical 0 0.99964154
in O 0 0.00065363763
the O 0 0.0005862363
CNS O 0 0.0047424575
remains O 0 0.0006538672
unknown O 0 0.0017200819
. O 0 0.0028952495

A O 0 0.025511185
double O 0 0.0030137156
- O 0 0.011602435
blind O 0 0.013451141
study O 0 0.000744805
of O 0 0.00038991132
the O 0 0.00021527347
efficacy O 0 0.00021467742
and O 0 0.0002115123
safety O 0 0.00028389363
of O 0 0.0008671998
dothiepin B-Chemical 0 0.9999999
hydrochloride I-Chemical 0 0.9997694
in O 0 0.00028758112
the O 0 0.00020114181
treatment O 0 0.00028474943
of O 0 0.000532074
major O 0 0.0017204414
depressive B-Disease 2 0.99998
disorder I-Disease 0 0.9991999
. O 0 0.0039734566

In O 0 0.0021829822
a O 0 0.0023938597
6 O 0 0.001064772
- O 0 0.0023408206
week O 0 0.00039990214
double O 0 0.00047673716
- O 0 0.0024032441
blind O 0 0.004317483
parallel O 0 0.00042647263
treatment O 0 0.00027253837
study O 0 0.00033539618
, O 0 0.0014969356
dothiepin B-Chemical 0 0.9999995
and O 0 0.0013586784
amitriptyline B-Chemical 0 0.9999989
were O 0 0.00014837907
compared O 0 7.738055e-05
to O 0 0.000102730366
placebo O 0 0.001185115
in O 0 0.00013911577
the O 0 0.00015145093
treatment O 0 0.00025104312
of O 0 0.00048606683
33 O 0 0.0017134447
depressed B-Disease 2 0.9967891
outpatients O 0 0.15403867
. O 0 0.002964714

Dothiepin B-Chemical 0 0.99948007
and O 0 0.008879019
amitriptyline B-Chemical 0 0.9999939
were O 0 0.0008547864
equally O 0 0.00045294387
effective O 0 0.00027870748
in O 0 0.00024451286
alleviating O 0 0.00047745364
the O 0 0.0002297055
symptoms O 0 0.004467686
of O 0 0.0010128466
depressive B-Disease 2 0.9999989
illness I-Disease 0 0.9984699
, O 0 0.00067047286
and O 0 0.00022236227
both O 0 0.00017755455
were O 0 0.00020346462
significantly O 0 0.00031972528
superior O 0 0.00067047443
to O 0 0.0006371068
placebo O 0 0.007164193
. O 0 0.0024817123

The O 0 0.001737647
overall O 0 0.001414721
incidence O 0 0.0016083913
of O 0 0.00075896515
side O 0 0.0012591303
effects O 0 0.0003925171
and O 0 0.00032537535
the O 0 0.00017604881
frequency O 0 0.00015915102
and O 0 0.00019554954
severity O 0 0.0005140824
of O 0 0.00026334825
blurred B-Disease 0 0.69775134
vision I-Disease 0 0.8620341
, O 0 0.0013981902
dry B-Disease 0 0.646915
mouth I-Disease 0 0.9106768
, O 0 0.0006065487
and O 0 0.0003401837
drowsiness O 0 0.99980503
were O 0 0.00014913385
significantly O 0 0.00017893991
less O 0 0.000278897
with O 0 0.00060072273
dothiepin B-Chemical 0 0.9999988
than O 0 0.00071288843
with O 0 0.00199291
amitriptyline B-Chemical 0 0.99999344
. O 0 0.0040435046

Dothiepin B-Chemical 0 0.9982374
also O 0 0.0038466835
produced O 0 0.0024285987
fewer O 0 0.0029870209
CNS O 0 0.011342924
and O 0 0.0027325046
cardiovascular O 0 0.0593035
effects O 0 0.0038587824
. O 0 0.0063595944

There O 0 0.004742714
were O 0 0.0027348122
no O 0 0.0020981012
clinically O 0 0.0038501003
important O 0 0.0011225032
changes O 0 0.0014831977
in O 0 0.0015006862
laboratory O 0 0.0023026941
parameters O 0 0.003405552
. O 0 0.0053691315

Dothiepin B-Chemical 0 0.9991652
thus O 0 0.0025611974
was O 0 0.0011558805
found O 0 0.0006769864
to O 0 0.0004010547
be O 0 0.00030449277
an O 0 0.0002771787
effective O 0 0.00030764157
antidepressant B-Chemical 0 0.9998253
drug O 0 0.011147524
associated O 0 0.00016014889
with O 0 0.00012499855
fewer O 0 0.00012800928
side O 0 0.00032533158
effects O 0 0.00018082486
than O 0 0.00037455896
amitriptyline B-Chemical 0 0.99999857
in O 0 0.00026178366
the O 0 0.00020350418
treatment O 0 0.00034228558
of O 0 0.00086486357
depressed B-Disease 2 0.9983505
outpatients O 0 0.26360998
. O 0 0.0028721332

Behavioral O 0 0.010420162
effects O 0 0.0021566665
of O 0 0.0038241423
diazepam B-Chemical 0 0.9999914
and O 0 0.0058978675
propranolol B-Chemical 0 0.9999882
in O 0 0.00095905125
patients O 0 0.0015740604
with O 0 0.0014885091
panic B-Disease 0 0.9999716
disorder I-Disease 0 0.9996208
and O 0 0.0072435704
agoraphobia B-Disease 0 0.99999523
. O 0 0.0072158896

The O 0 0.0014506673
effects O 0 0.0011791638
of O 0 0.0011437648
oral O 0 0.0026390709
doses O 0 0.0015995259
of O 0 0.0011806609
diazepam B-Chemical 0 0.9999956
( O 0 0.00087023934
single O 0 0.00013895032
dose O 0 0.00022832678
of O 0 0.00014120802
10 O 0 0.00014812476
mg O 0 0.0010580296
and O 0 9.35102e-05
a O 0 0.00010373128
median O 0 5.3827003e-05
dose O 0 0.00012581085
of O 0 9.904707e-05
30 O 0 0.00010442541
mg O 0 0.0011454384
/ O 0 0.00035841475
day O 0 5.6761357e-05
for O 0 5.425578e-05
2 O 0 7.9047764e-05
weeks O 0 4.874711e-05
) O 0 0.00023828371
and O 0 0.00022590024
propranolol B-Chemical 0 0.9999912
( O 0 0.00038905826
single O 0 7.534335e-05
dose O 0 0.00015187814
of O 0 0.0001018826
80 O 0 0.00018694949
mg O 0 0.0013881795
and O 0 7.8385616e-05
a O 0 8.803076e-05
median O 0 4.5882545e-05
dose O 0 0.0001115822
of O 0 9.42535e-05
240 O 0 0.00022974753
mg O 0 0.0018976504
/ O 0 0.00037129904
day O 0 5.2931377e-05
for O 0 4.919374e-05
2 O 0 6.822461e-05
weeks O 0 3.7626036e-05
) O 0 0.00013084988
on O 0 4.8001188e-05
psychological O 0 0.00025305286
performance O 0 0.0001145655
of O 0 0.00011384371
patients O 0 0.00032574285
with O 0 0.00034380995
panic B-Disease 0 0.9999937
disorders I-Disease 0 0.99959594
and O 0 0.0010235992
agoraphobia B-Disease 0 0.99999976
were O 0 0.00018069129
investigated O 0 0.00011545271
in O 0 0.00012363037
a O 0 0.00022505427
double O 0 0.00021005287
- O 0 0.0028658817
blind O 0 0.026057767
, O 0 0.0008246797
randomized O 0 0.0011997878
and O 0 0.0006775699
crossover O 0 0.0036647497
design O 0 0.0025627569
. O 0 0.0030922783

Both O 0 0.0029068964
drugs O 0 0.018306186
impaired B-Disease 0 0.004103987
immediate I-Disease 0 0.001701082
free I-Disease 0 0.0012833189
recall I-Disease 0 0.0019119332
but O 0 0.00058715005
the O 0 0.00033077147
decrease O 0 0.00040091886
was O 0 0.0003414371
greater O 0 0.0005699739
for O 0 0.0007749936
diazepam B-Chemical 0 0.9999882
than O 0 0.0031740656
propranolol B-Chemical 0 0.9999583
. O 0 0.005312077

Delayed B-Disease 0 0.017190447
free I-Disease 0 0.003824169
recall I-Disease 0 0.003740824
was I-Disease 0 0.0010843555
also I-Disease 0 0.00080507266
impaired I-Disease 0 0.0020097317
but O 0 0.0008000032
the O 0 0.00049423275
two O 0 0.0004811702
drugs O 0 0.006782572
did O 0 0.0012437304
not O 0 0.0013376353
differ O 0 0.0021860986
. O 0 0.003968244

Patients O 0 0.0048140255
tapped O 0 0.0063187517
faster O 0 0.0016793814
after O 0 0.0009798439
propranolol B-Chemical 0 0.99997056
than O 0 0.0020175327
diazepam B-Chemical 0 0.99999285
and O 0 0.00059171737
they O 0 0.00027922183
were O 0 0.00025064612
more O 0 0.00042138287
sedated O 0 0.003128427
after O 0 0.00042802602
diazepam B-Chemical 0 0.99997413
than O 0 0.002254497
propranolol B-Chemical 0 0.99994636
. O 0 0.005018742

After O 0 0.0015929647
2 O 0 0.0014329986
weeks O 0 0.00059885625
of O 0 0.0007612196
treatment O 0 0.0006802149
, O 0 0.0009529246
patients O 0 0.0007540495
tested O 0 0.00031276367
5 O 0 0.00031075976
- O 0 0.0008494921
8 O 0 0.00015473888
h O 0 0.00014061655
after O 0 6.431279e-05
the O 0 8.0151425e-05
last O 0 6.56914e-05
dose O 0 0.00021372896
of O 0 0.00019258083
medication O 0 0.0013364988
did O 0 0.00024620656
not O 0 0.00020664834
show O 0 0.00021350531
any O 0 0.0003614084
decrement O 0 0.0020358914
of O 0 0.00091793865
performance O 0 0.0020870895
. O 0 0.0027837695

These O 0 0.0022625516
results O 0 0.0017275936
are O 0 0.0011519832
similar O 0 0.0007561007
to O 0 0.0007787743
those O 0 0.00096800865
previously O 0 0.0009242151
found O 0 0.0009799807
in O 0 0.0013064102
healthy O 0 0.005035155
subjects O 0 0.0042019603
. O 0 0.004413701

Accumulation O 0 0.006669275
of O 0 0.003290706
drugs O 0 0.022538744
was O 0 0.0015536139
not O 0 0.0010711229
reflected O 0 0.0010817064
in O 0 0.0011036383
prolonged O 0 0.0022841261
behavioral B-Disease 0 0.13397771
impairment I-Disease 0 0.9796489
. O 0 0.006243418

Comparison O 0 0.0019901937
of O 0 0.002058532
i O 0 0.0024120465
. O 0 0.0011841315
v O 0 0.0036437546
. O 0 0.0013640149
glycopyrrolate B-Chemical 0 0.99998665
and O 0 0.0014986654
atropine B-Chemical 0 0.99995315
in O 0 0.00028077178
the O 0 0.00015538099
prevention O 0 0.00025484432
of O 0 0.00028361633
bradycardia B-Disease 0 0.99659014
and O 0 0.000313789
arrhythmias B-Disease 2 0.99901736
following O 0 0.00010423529
repeated O 0 0.000101734455
doses O 0 0.00043725246
of O 0 0.0005806803
suxamethonium B-Chemical 0 0.99932384
in O 0 0.00085570454
children O 0 0.0032533589
. O 0 0.0024641505

The O 0 0.0014273348
effectiveness O 0 0.0009988454
of O 0 0.0010271966
administration O 0 0.0014418418
of O 0 0.0012254537
glycopyrrolate B-Chemical 0 0.9999827
5 O 0 0.0003681277
and O 0 0.00021921328
10 O 0 0.00019940107
micrograms O 0 0.0009338079
kg O 0 0.0005627459
- O 0 0.0009480091
1 O 0 0.00019304006
and O 0 0.00024992498
atropine B-Chemical 0 0.9998498
10 O 0 0.00017468784
and O 0 0.000121581186
20 O 0 0.00013372595
micrograms O 0 0.000790372
kg O 0 0.00045009158
- O 0 0.0007648705
1 O 0 0.00014568745
i O 0 0.00023448991
. O 0 0.0001364557
v O 0 0.0005817117
. O 0 0.00010740383
immediately O 0 5.5248525e-05
before O 0 3.969393e-05
the O 0 5.891848e-05
induction O 0 6.954784e-05
of O 0 0.00013613132
anaesthesia O 0 0.0028848695
, O 0 0.00020436772
to O 0 8.436867e-05
prevent O 0 0.00012339106
arrhythmia B-Disease 0 0.99527043
and O 0 0.00021348456
bradycardia B-Disease 0 0.9673671
following O 0 5.3957385e-05
repeated O 0 5.4449523e-05
doses O 0 0.00024518147
of O 0 0.00030487304
suxamethonium B-Chemical 0 0.9996013
in O 0 0.00032712927
children O 0 0.0011972818
, O 0 0.0009666294
was O 0 0.0007944559
studied O 0 0.0019104795
. O 0 0.0027946772

A O 0 0.019680802
control O 0 0.002245455
group O 0 0.0017609164
was O 0 0.0007031371
included O 0 0.00040006478
for O 0 0.00025375787
comparison O 0 0.00022634394
with O 0 0.00026027925
the O 0 0.00020625128
lower O 0 0.0003085233
dose O 0 0.00046424405
range O 0 0.00040012447
of O 0 0.0008662587
glycopyrrolate B-Chemical 0 0.9999776
and O 0 0.0032379262
atropine B-Chemical 0 0.99984026
. O 0 0.0045642634

A O 0 0.021620242
frequency O 0 0.0022366852
of O 0 0.0021381339
bradycardia B-Disease 0 0.99329424
of O 0 0.0010113396
50 O 0 0.00081709697
% O 0 0.00081867946
was O 0 0.00026575275
noted O 0 0.00022658793
in O 0 0.00016736427
the O 0 0.00013704797
control O 0 0.00019053154
group O 0 0.0003653994
, O 0 0.00046336377
but O 0 0.000239077
this O 0 0.00018203877
was O 0 0.00013792438
not O 0 0.00012139606
significantly O 0 0.00016884487
different O 0 0.000103225575
from O 0 0.0001305372
the O 0 0.00013824314
frequency O 0 0.00019616395
with O 0 0.00034519806
the O 0 0.00043970247
active O 0 0.001117905
drugs O 0 0.031458143
. O 0 0.0031700013

Bradycardia B-Disease 0 0.997442
( O 0 0.0043011825
defined O 0 0.0011022656
as O 0 0.00086519535
a O 0 0.00088805787
decrease O 0 0.000560593
in O 0 0.00042789176
heart O 0 0.0067809047
rate O 0 0.00037463807
to O 0 0.00016988115
less O 0 0.00024081799
than O 0 0.00015599099
50 O 0 0.00023662874
beat O 0 0.00046596953
min O 0 0.00046069306
- O 0 0.0013163666
1 O 0 0.00020612961
) O 0 0.00033746086
was O 0 0.00012928653
prevented O 0 0.00020846922
when O 0 0.00010881397
the O 0 0.00013815117
larger O 0 0.00027326558
dose O 0 0.0003668748
of O 0 0.0002501357
either O 0 0.0002989444
active O 0 0.000588463
drug O 0 0.0060192323
was O 0 0.00081489567
used O 0 0.0011808723
. O 0 0.0026099214

It O 0 0.00456891
is O 0 0.0013952531
recommended O 0 0.00096604764
that O 0 0.0006078717
either O 0 0.00096670364
glycopyrrolate B-Chemical 0 0.9999702
10 O 0 0.0005558832
micrograms O 0 0.0021742387
kg O 0 0.0008110714
- O 0 0.0011216523
1 O 0 0.00021899954
or O 0 0.00021476996
atropine B-Chemical 0 0.99974495
20 O 0 0.00024370385
micrograms O 0 0.0012337568
kg O 0 0.0005368141
- O 0 0.0008527559
1 O 0 0.00016319979
i O 0 0.0002613971
. O 0 0.00015548489
v O 0 0.00067264796
. O 0 0.00012599683
should O 0 5.6000692e-05
immediately O 0 7.142583e-05
precede O 0 0.00017803772
induction O 0 8.011084e-05
of O 0 0.00014748295
anaesthesia O 0 0.002715494
, O 0 0.0002480952
in O 0 0.00013334396
children O 0 0.0004953097
, O 0 0.00024202598
if O 0 9.067036e-05
the O 0 0.00011799568
repeated O 0 0.00011908467
administration O 0 0.00042068248
of O 0 0.00061062846
suxamethonium B-Chemical 0 0.9992336
is O 0 0.00066381495
anticipated O 0 0.0010663454
. O 0 0.0023935519

Veno B-Disease 0 0.07178261
- I-Disease 0 0.08947921
occlusive I-Disease 0 0.99800164
liver I-Disease 0 0.9811693
disease I-Disease 0 0.9340401
after O 0 0.0008378213
dacarbazine B-Chemical 0 0.99919194
therapy O 0 0.0015762128
( O 0 0.0027462114
DTIC B-Chemical 0 0.9998511
) O 0 0.003718118
for O 0 0.0018812437
melanoma B-Disease 0 0.996033
. O 0 0.0056580408

A O 0 0.020880062
case O 0 0.0026896119
of O 0 0.0019011996
veno B-Disease 0 0.023179524
- I-Disease 0 0.035092063
occlusive I-Disease 0 0.9989392
disease I-Disease 0 0.34504396
of I-Disease 0 0.00039490455
the I-Disease 0 0.00026552076
liver I-Disease 0 0.019885745
with O 0 0.0003239549
fatal O 0 0.0369692
outcome O 0 0.0002159424
after O 0 0.00012711309
dacarbazine B-Chemical 0 0.99959916
( O 0 0.0013768419
DTIC B-Chemical 0 0.9999629
) O 0 0.0009589951
therapy O 0 0.00049633696
for O 0 0.00044269065
melanoma B-Disease 0 0.99673504
is O 0 0.0010167365
reported O 0 0.0017973763
. O 0 0.0029207165

There O 0 0.004693863
was O 0 0.0029320745
a O 0 0.0038138144
fulminant O 0 0.9954189
clinical O 0 0.0030764255
course O 0 0.00077115285
from O 0 0.0004934673
start O 0 0.0004106273
of O 0 0.0009373298
symptoms O 0 0.00569325
until O 0 0.001353796
death B-Disease 0 0.54895204
. O 0 0.005100406

At O 0 0.0020952336
autopsy O 0 0.009395021
the O 0 0.0018945453
liver O 0 0.030307207
was O 0 0.0012760254
enlarged O 0 0.0040369905
and O 0 0.0009992822
firm O 0 0.0035682754
with O 0 0.0011300058
signs O 0 0.004337807
of O 0 0.002242021
venous B-Disease 0 0.99592006
congestion I-Disease 0 0.99231124
. O 0 0.004832264

Small O 0 0.017767007
- O 0 0.016294068
and O 0 0.003404267
medium O 0 0.0079417275
- O 0 0.009423525
sized O 0 0.0028106796
hepatic O 0 0.96247315
veins O 0 0.9159518
were O 0 0.0015316352
blocked O 0 0.0025247938
by O 0 0.0030227723
thrombosis B-Disease 0 0.99921405
. O 0 0.0066854875

Eosinophilic O 0 0.036872752
infiltrations O 0 0.032926437
were O 0 0.0034505671
found O 0 0.0029885932
around O 0 0.003714382
the O 0 0.0040801195
vessels O 0 0.09918819
. O 0 0.009894298

Published O 0 0.009053856
cases O 0 0.004188029
from O 0 0.0015970127
the O 0 0.0012059169
literature O 0 0.0018356014
are O 0 0.00088585087
reviewed O 0 0.0015445263
and O 0 0.0011009511
pertinent O 0 0.0012265146
features O 0 0.002185468
discussed O 0 0.0026622685
. O 0 0.005038733

Maternal O 0 0.014805488
lithium B-Chemical 0 0.9983468
and O 0 0.002455086
neonatal O 0 0.0028330805
Ebstein B-Disease 0 0.08841276
' I-Disease 0 0.0017738701
s I-Disease 0 0.001342161
anomaly I-Disease 0 0.14952733
: O 0 0.0012486767
evaluation O 0 0.00052507233
with O 0 0.0006974419
cross O 0 0.0013633
- O 0 0.0049429014
sectional O 0 0.011045986
echocardiography O 0 0.0044579264
. O 0 0.0035542245

Cross O 0 0.01197027
- O 0 0.012746676
sectional O 0 0.007492255
echocardiography O 0 0.0017749412
was O 0 0.00059906376
used O 0 0.00035683048
to O 0 0.0002528334
evaluate O 0 0.00014048253
two O 0 0.00022052182
neonates O 0 0.0011642193
whose O 0 0.0005694971
mothers O 0 0.0017772254
ingested O 0 0.091031805
lithium B-Chemical 0 0.99966455
during O 0 0.0012193589
pregnancy O 0 0.005834979
. O 0 0.0034481839

In O 0 0.0026764532
one O 0 0.0024290134
infant O 0 0.0042579942
, O 0 0.0033205585
Ebstein B-Disease 0 0.079720035
' I-Disease 0 0.0022260798
s I-Disease 0 0.0016286201
anomaly I-Disease 0 0.102890484
of O 0 0.00085252314
the O 0 0.00073511107
tricuspid O 0 0.087930456
valve O 0 0.0030523965
was O 0 0.0011122433
identified O 0 0.0013181084
. O 0 0.0033814975

In O 0 0.002011145
the O 0 0.0015296487
other O 0 0.001226017
infant O 0 0.0024809525
cross O 0 0.0013535576
- O 0 0.00331561
sectional O 0 0.0026832279
echocardiography O 0 0.00060622045
provided O 0 0.00022352589
reassurance O 0 0.0006667207
that O 0 0.00021446015
the O 0 0.00027824522
infant O 0 0.0009926396
did O 0 0.00044568934
not O 0 0.00040957629
have O 0 0.0005860872
Ebstein B-Disease 0 0.13828166
' I-Disease 0 0.0021459626
s I-Disease 0 0.0025385828
anomaly I-Disease 0 0.6783973
. O 0 0.0042551784

Cross O 0 0.010724492
- O 0 0.011644715
sectional O 0 0.006422599
echocardiographic O 0 0.0015646152
screening O 0 0.00053781207
of O 0 0.000516242
newborns O 0 0.0013480027
exposed O 0 0.0004410435
to O 0 0.00034347302
lithium B-Chemical 0 0.9996952
during O 0 0.00013992717
gestation O 0 0.00018575191
can O 0 7.162301e-05
provide O 0 6.2330306e-05
highly O 0 7.944676e-05
accurate O 0 0.000101985635
, O 0 0.000175668
noninvasive O 0 0.00019069911
assessment O 0 0.00010261532
of O 0 0.0001280723
the O 0 0.00011959961
presence O 0 0.00015414906
or O 0 0.00016651727
absence O 0 0.00018774533
of O 0 0.0007581482
lithium B-Chemical 0 0.999936
- O 0 0.034553956
induced O 0 0.0011642216
cardiac B-Disease 0 0.8223378
malformations I-Disease 0 0.9999331
. O 0 0.0052668448

Effects O 0 0.0034576056
of O 0 0.0020939661
training O 0 0.0013706927
on O 0 0.0006768094
the O 0 0.0005912084
extent O 0 0.00058846804
of O 0 0.00083596766
experimental O 0 0.0017083423
myocardial B-Disease 0 0.99956924
infarction I-Disease 0 0.9999671
in O 0 0.0015802424
aging O 0 0.010269591
rats O 0 0.0030418218
. O 0 0.0031699724

The O 0 0.0015910001
effects O 0 0.0012794097
of O 0 0.0011865292
exercise O 0 0.0014405134
on O 0 0.0003504204
the O 0 0.00034245074
severity O 0 0.0010362401
of O 0 0.0006832389
isoproterenol B-Chemical 0 0.99991703
- O 0 0.04807528
induced O 0 0.00055194047
myocardial B-Disease 0 0.99986565
infarction I-Disease 0 0.9999925
were O 0 0.00019064493
studied O 0 0.00017032766
in O 0 0.00010497012
female O 0 0.00028969426
albino O 0 0.00034033245
rats O 0 0.00018689032
of O 0 0.00014769418
20 O 0 0.0001691128
, O 0 0.00028230148
40 O 0 0.0002173829
, O 0 0.00033604683
60 O 0 0.0002448112
and O 0 0.0002523842
80 O 0 0.00042442817
weeks O 0 0.0002479999
of O 0 0.00076931686
age O 0 0.0022312286
. O 0 0.002997287

The O 0 0.0020262618
rats O 0 0.002325989
were O 0 0.0010703084
trained O 0 0.0009882315
to O 0 0.0007107821
swim O 0 0.010615437
for O 0 0.00041760944
a O 0 0.0005175581
specific O 0 0.00020641557
duration O 0 0.00024116035
and O 0 0.00040374455
for O 0 0.0004051379
a O 0 0.0009140266
particular O 0 0.0006907952
period O 0 0.0012141509
. O 0 0.0030650657

The O 0 0.0034575495
occurrence O 0 0.0037927148
of O 0 0.004366933
infarcts B-Disease 0 0.99930334
were O 0 0.0019170127
confirmed O 0 0.0012417204
by O 0 0.0016026603
histological O 0 0.004203278
methods O 0 0.003030649
. O 0 0.005361791

Elevations O 0 0.034028437
in O 0 0.0029333811
the O 0 0.0024743786
serum O 0 0.6989746
GOT O 0 0.99990785
and O 0 0.0047244015
GPT O 0 0.9983315
were O 0 0.0004638722
maximum O 0 0.00035155355
in O 0 0.00021336082
the O 0 0.00019817361
sedentary O 0 0.00071834977
- O 0 0.0013926134
isoproterenols B-Chemical 0 0.001075092
and O 0 0.0003087817
minimum O 0 0.00025072068
in O 0 0.00032867954
the O 0 0.00044014194
exercise O 0 0.0016023942
- O 0 0.003509785
controls O 0 0.0023068136
. O 0 0.0032770776

These O 0 0.002279455
changes O 0 0.0020570408
in O 0 0.0014063563
the O 0 0.0012528354
serum O 0 0.21355824
transaminases O 0 0.99764
were O 0 0.0005167715
associated O 0 0.00036082006
with O 0 0.00030725173
corresponding O 0 0.00021522543
depletions O 0 0.000885197
in O 0 0.0003756312
the O 0 0.00052868424
cardiac O 0 0.02917399
GOT O 0 0.9998461
and O 0 0.0058828476
GPT O 0 0.99757546
. O 0 0.0054999446

However O 0 0.00330681
, O 0 0.004137749
age O 0 0.0024138521
was O 0 0.0010236125
seen O 0 0.00073899346
to O 0 0.0004275387
interfere O 0 0.00035848105
with O 0 0.00034926922
the O 0 0.00025039533
responses O 0 0.00029395212
exhibited O 0 0.00034652074
by O 0 0.00035662553
the O 0 0.00039322494
young O 0 0.0015131185
and O 0 0.0008028062
old O 0 0.0013426502
rats O 0 0.0025332214
. O 0 0.0031784638

Studies O 0 0.006565692
dealing O 0 0.003931949
with O 0 0.0041432856
myocardial B-Disease 0 0.99929655
infarction I-Disease 0 0.99995613
are O 0 0.0009187195
more O 0 0.0009129316
informative O 0 0.00068462134
when O 0 0.00051379955
dealt O 0 0.0015578269
with O 0 0.0015271185
age O 0 0.0035460265
. O 0 0.0041853553

Effect O 0 0.005449996
of O 0 0.0065548713
polyethylene B-Chemical 0 0.9944687
glycol I-Chemical 0 0.9888341
400 I-Chemical 0 0.03786477
on O 0 0.0021931871
adriamycin B-Chemical 0 0.9998621
toxicity B-Disease 0 0.8279121
in O 0 0.0017959533
mice O 0 0.0011883406
. O 0 0.0038662236

The O 0 0.0019645102
effect O 0 0.0014866733
of O 0 0.0015784815
a O 0 0.0015336688
widely O 0 0.00079985755
used O 0 0.0007725298
organic O 0 0.6536528
solvent O 0 0.3065912
, O 0 0.0037343604
polyethylene B-Chemical 0 0.9984059
glycol I-Chemical 0 0.9885346
400 I-Chemical 0 0.015538147
( O 0 0.0008641901
PEG B-Chemical 0 0.31765798
400 I-Chemical 0 0.0009636584
) O 0 0.00050023524
, O 0 0.00026040385
on O 0 9.549101e-05
the O 0 0.00013166566
toxic O 0 0.002200717
action O 0 0.00016700417
of O 0 0.00017294432
an O 0 0.00020313507
acute O 0 0.0065449513
or O 0 0.00012738827
chronic O 0 0.001883168
treatment O 0 0.00017542898
with O 0 0.00038629922
adriamycin B-Chemical 0 0.99998486
( O 0 0.007467539
ADR B-Chemical 0 0.99993706
) O 0 0.0011608762
was O 0 0.00029982548
evaluated O 0 0.00037545216
in O 0 0.00053963653
mice O 0 0.00053967274
. O 0 0.0022117777

PEG B-Chemical 0 0.77649647
400 I-Chemical 0 0.010658578
impressively O 0 0.008734615
decreased O 0 0.0016848112
both O 0 0.00069183187
acute O 0 0.0060193925
high O 0 0.00068045506
- O 0 0.0019716413
dose O 0 0.00047130242
and O 0 0.0002869345
chronic O 0 0.0018926043
low O 0 0.0005527963
- O 0 0.0029607632
dose O 0 0.001374394
- O 0 0.03511375
ADR B-Chemical 0 0.99985325
- O 0 0.015093821
associated O 0 0.0015224817
lethality O 0 0.010182165
. O 0 0.0037496025

Light O 0 0.009822275
microscopic O 0 0.0034193778
analysis O 0 0.001523116
showed O 0 0.00095009373
a O 0 0.0010787958
significant O 0 0.0006414851
protection O 0 0.00074266916
against O 0 0.0006267928
ADR B-Chemical 0 0.9998671
- O 0 0.016360696
induced O 0 0.00095997227
cardiac B-Disease 0 0.018997544
morphological I-Disease 0 0.0036018947
alterations I-Disease 0 0.008501682
. O 0 0.0037514286

Such O 0 0.0044225
treatment O 0 0.0023869413
did O 0 0.001527266
not O 0 0.0008744335
diminish O 0 0.000805606
the O 0 0.000882394
ADR B-Chemical 0 0.9998167
antitumor O 0 0.023790115
activity O 0 0.00041130502
in O 0 0.00091962074
L1210 B-Disease 0 0.9999273
leukemia I-Disease 0 0.9999808
and O 0 0.0018749393
in O 0 0.00170368
Ehrlich B-Disease 0 0.9971564
ascites I-Disease 0 0.99966073
tumor I-Disease 0 0.9968665
. O 0 0.0052935467

Sublingual O 0 0.84663206
absorption O 0 0.075562276
of O 0 0.0025089397
the O 0 0.0018031759
quaternary B-Chemical 0 0.03656897
ammonium I-Chemical 0 0.9996903
antiarrhythmic O 0 0.9859331
agent O 0 0.006077689
, O 0 0.0051211896
UM B-Chemical 0 0.9462906
- I-Chemical 0 0.020011825
272 I-Chemical 0 0.0107058305
. O 0 0.0052835187

UM B-Chemical 0 0.96700794
- I-Chemical 0 0.031905357
272 I-Chemical 0 0.012339283
( O 0 0.0067425743
N B-Chemical 0 0.9931532
, I-Chemical 0 0.007937806
N I-Chemical 0 0.9984913
- I-Chemical 0 0.066511184
dimethylpropranolol I-Chemical 0 0.024732776
) O 0 0.001659312
, O 0 0.00077507703
a O 0 0.00052512664
quaternary O 0 0.0012265713
antiarrhythmic O 0 0.52955693
agent O 0 0.0006437794
, O 0 0.00036811872
was O 0 0.0001659283
administered O 0 0.00035887051
sublingually O 0 0.82459164
to O 0 0.0001658361
dogs O 0 0.0005018852
with O 0 0.0006050175
ouabain B-Chemical 0 0.99997056
- O 0 0.03972806
induced O 0 0.001105861
ventricular B-Disease 0 0.99752814
tachycardias I-Disease 0 0.99810815
. O 0 0.0035932628

Both O 0 0.0035160983
anti O 0 0.0056724143
- O 0 0.014896612
arrhythmic O 0 0.34225678
efficacy O 0 0.001008212
and O 0 0.0009538161
bioavailability O 0 0.082296796
were O 0 0.00060803414
compared O 0 0.00047310372
to O 0 0.0007997627
oral O 0 0.0040813056
drug O 0 0.012915579
. O 0 0.003977766

Sublingual O 0 0.96255445
UM B-Chemical 0 0.9754567
- I-Chemical 0 0.02017927
272 I-Chemical 0 0.006323161
converted O 0 0.002046572
ventricular B-Disease 0 0.9723335
tachycardia I-Disease 2 0.9995085
to O 0 0.0008380629
sinus O 0 0.0038290408
rhythm O 0 0.0010594381
in O 0 0.0005852038
all O 0 0.0007497322
5 O 0 0.001099432
dogs O 0 0.0027884275
. O 0 0.0034286408

The O 0 0.0022732983
area O 0 0.0022361947
under O 0 0.0009967824
the O 0 0.0008214598
plasma O 0 0.0036057692
concentration O 0 0.0005818052
time O 0 0.00020342153
curve O 0 0.00025694937
at O 0 0.00013169984
90 O 0 0.0001782334
min O 0 0.00022104639
was O 0 0.00011392917
4 O 0 0.00010742923
- O 0 0.000330862
12 O 0 5.4847307e-05
times O 0 4.5544348e-05
greater O 0 0.000100431265
than O 0 7.998741e-05
for O 0 8.486969e-05
oral O 0 0.0006245221
drug O 0 0.0025589042
, O 0 0.000227539
suggesting O 0 6.748952e-05
the O 0 7.425453e-05
existence O 0 8.383024e-05
of O 0 0.00014365684
an O 0 0.0002315972
absorption O 0 0.13538073
- O 0 0.001898488
limiting O 0 0.0001474274
process O 0 0.00010770371
in O 0 0.00010468354
the O 0 0.000113563096
intestine O 0 0.0010333109
, O 0 0.0002789342
and O 0 0.00013140819
providing O 0 0.00011269084
an O 0 0.00016252021
alternate O 0 0.00014268987
form O 0 0.0001780102
of O 0 0.0002930058
administration O 0 0.000693161
for O 0 0.00047129206
quaternary O 0 0.0038321214
drugs O 0 0.100511506
. O 0 0.0034777713

Early O 0 0.01751561
adjuvant O 0 0.048971243
adriamycin B-Chemical 0 0.9995401
in O 0 0.006305634
superficial O 0 0.043257613
bladder B-Disease 0 0.3706436
carcinoma I-Disease 0 0.9938352
. O 0 0.011371923

A O 0 0.043380696
multicenter O 0 0.089646064
study O 0 0.0018837022
was O 0 0.000846934
performed O 0 0.00056502066
in O 0 0.0005406623
110 O 0 0.0010525248
patients O 0 0.0008659389
with O 0 0.0006018933
superficial O 0 0.0038314844
transitional O 0 0.0048133307
cell O 0 0.002070821
carcinoma B-Disease 0 0.9966107
of I-Disease 0 0.0016038694
the I-Disease 0 0.0014700657
bladder I-Disease 0 0.05289283
. O 0 0.0038805597

Adriamycin B-Chemical 0 0.9996039
( O 0 0.0064793495
50 O 0 0.0026326615
mg O 0 0.013441458
/ O 0 0.002958565
50 O 0 0.0008738767
ml O 0 0.0015019401
) O 0 0.00074699934
was O 0 0.00024580339
administered O 0 0.000323587
intravesically O 0 0.0006565687
within O 0 8.795919e-05
24 O 0 0.00013656661
h O 0 0.00014126972
after O 0 9.314469e-05
transurethral O 0 0.00043957657
resection O 0 0.00081841106
of O 0 0.0003795262
TA O 0 0.037245378
- O 0 0.0044937143
T1 O 0 0.004384501
( O 0 0.002204321
O O 0 0.9982487
- O 0 0.11447893
A O 0 0.115569554
) O 0 0.008006357
bladder B-Disease 0 0.9118866
tumors I-Disease 0 0.99424756
. O 0 0.005865233

Instillation O 0 0.06567848
was O 0 0.0013512006
repeated O 0 0.0004989269
twice O 0 0.00035281744
during O 0 0.00023656871
the O 0 0.00019626309
first O 0 0.00013743325
week O 0 0.00014033393
, O 0 0.00028367803
then O 0 0.00014054806
weekly O 0 0.0001242417
during O 0 8.938299e-05
the O 0 0.00010030513
first O 0 9.2282164e-05
month O 0 0.00011345615
and O 0 0.00023380342
afterwards O 0 0.00046804958
monthly O 0 0.0003348958
for O 0 0.00040558944
1 O 0 0.00091481063
year O 0 0.0011384261
. O 0 0.0024710288

The O 0 0.0022718073
tolerance O 0 0.004650194
was O 0 0.0010829958
evaluated O 0 0.00069468544
in O 0 0.0005009611
these O 0 0.00043507325
110 O 0 0.0008576616
patients O 0 0.0006799887
, O 0 0.0005285529
and O 0 0.00032569253
29 O 0 0.00046695778
patients O 0 0.0004956045
presented O 0 0.00026430917
with O 0 0.0004032522
local O 0 0.00065899314
side O 0 0.0021734515
- O 0 0.005065984
effects O 0 0.0019041706
. O 0 0.0036674056

In O 0 0.0021324635
24 O 0 0.0018433094
of O 0 0.0011902953
these O 0 0.0008826563
patients O 0 0.0014832639
chemical O 0 0.001358716
cystitis B-Disease 0 0.99867684
was O 0 0.0006340375
severe O 0 0.0020891111
enough O 0 0.00030854304
for O 0 0.00022596506
them O 0 0.0004062869
to O 0 0.00031033935
drop O 0 0.000727195
out O 0 0.0004265328
of O 0 0.0007056742
the O 0 0.0008838505
study O 0 0.0018992667
. O 0 0.0029183128

No O 0 0.010619368
systemic O 0 0.119995736
side O 0 0.012117845
- O 0 0.011764004
effects O 0 0.0032198403
were O 0 0.0034788044
observed O 0 0.0041193143
. O 0 0.007716036

Recurrence O 0 0.027418558
was O 0 0.0021259382
studied O 0 0.0016561537
in O 0 0.00086478976
82 O 0 0.0011615134
evaluable O 0 0.00093304215
patients O 0 0.00047342046
after O 0 0.00014326902
1 O 0 0.00022106431
year O 0 0.00015799027
of O 0 0.00018653658
follow O 0 0.00016420658
- O 0 0.0009404209
up O 0 0.00021792993
and O 0 0.00018990657
in O 0 0.00017096683
72 O 0 0.00021944853
patients O 0 0.00025334614
followed O 0 0.00011154974
for O 0 0.00012875875
2 O 0 0.00024944078
- O 0 0.0007246724
3 O 0 0.00019144609
years O 0 0.00029042433
( O 0 0.00044106407
mean O 0 0.00031120155
32 O 0 0.00067159417
months O 0 0.00050741015
) O 0 0.002617203
. O 0 0.0032193277

Of O 0 0.005600341
the O 0 0.0022265331
82 O 0 0.0029739242
patients O 0 0.0018975249
studied O 0 0.0009967226
after O 0 0.00040025474
1 O 0 0.0005880713
year O 0 0.00045406132
, O 0 0.0007808544
23 O 0 0.0007009375
had O 0 0.00047511625
primary O 0 0.0005645281
and O 0 0.0008784554
59 O 0 0.0018610205
recurrent O 0 0.006805352
disease O 0 0.21853079
. O 0 0.0043141143

Of O 0 0.00538362
the O 0 0.0021044202
82 O 0 0.0027858801
evaluable O 0 0.0023736344
patients O 0 0.0015152582
, O 0 0.0011751418
50 O 0 0.00074353593
did O 0 0.00046256895
not O 0 0.00028864114
show O 0 0.00020503231
any O 0 0.00023977508
recurrence O 0 0.002036772
after O 0 0.00010269442
1 O 0 0.0001710565
year O 0 0.00013741909
( O 0 0.00025899697
61 O 0 0.00025851736
% O 0 0.00036212886
) O 0 0.00044801075
, O 0 0.000312053
while O 0 0.00017354761
32 O 0 0.00024887398
presented O 0 0.0001451396
with O 0 0.0001888628
one O 0 0.00018853588
or O 0 0.00024465466
more O 0 0.0005520505
recurrences O 0 0.0029553669
( O 0 0.00095259416
39 O 0 0.0010487086
% O 0 0.0019327941
) O 0 0.0034771797
. O 0 0.0033612791

Of O 0 0.0059657805
these O 0 0.0028518708
recurrences O 0 0.008169185
, O 0 0.0024286658
27 O 0 0.0014560588
were O 0 0.0008250495
T1 O 0 0.0040970896
tumors B-Disease 0 0.14832409
while O 0 0.00048470142
five O 0 0.00030269567
progressed O 0 0.00090966164
to O 0 0.00043705205
more O 0 0.00080986513
highly O 0 0.0007655534
invasive O 0 0.0019067825
lesions O 0 0.007437128
. O 0 0.0035866855

In O 0 0.0021847384
patients O 0 0.0030073894
that O 0 0.0009864072
were O 0 0.0008428021
free O 0 0.0009122308
of O 0 0.000627125
recurrence O 0 0.0034611926
during O 0 0.00019870416
the O 0 0.000159965
first O 0 0.00012247833
year O 0 0.00017707152
, O 0 0.0003222017
80 O 0 0.00030865514
% O 0 0.0004554114
remained O 0 0.0004753905
tumor B-Disease 0 0.775297
- O 0 0.0060946527
free O 0 0.000311899
during O 0 0.00012858206
the O 0 0.00014897705
2 O 0 0.00023846098
- O 0 0.00071886915
to O 0 0.00016418638
3 O 0 0.00021896343
- O 0 0.00085050974
year O 0 0.0002659322
follow O 0 0.00030104283
- O 0 0.001665862
up O 0 0.00097301614
period O 0 0.0011513645
. O 0 0.0029376964

Of O 0 0.0045251804
the O 0 0.0017522958
patients O 0 0.0023908324
developing O 0 0.0013067474
one O 0 0.0004907748
or O 0 0.00038187337
more O 0 0.0005149412
recurrences O 0 0.0013737051
during O 0 0.00013344966
the O 0 0.000117917174
first O 0 9.7659235e-05
year O 0 0.0001522335
, O 0 0.0002763254
only O 0 0.00019024855
50 O 0 0.00024810704
% O 0 0.00031884018
presented O 0 0.00013901366
with O 0 0.00017935396
further O 0 0.00020384442
recurrence O 0 0.0028156985
once O 0 0.00021979342
the O 0 0.00030821757
instillations O 0 0.0011537601
were O 0 0.000707159
stopped O 0 0.0016891748
. O 0 0.0026854873

The O 0 0.0017527462
beneficial O 0 0.0016969515
effect O 0 0.0011282144
of O 0 0.0024767783
Adriamycin B-Chemical 0 0.99996924
appears O 0 0.0004221554
obvious O 0 0.000274372
and O 0 0.00027442718
might O 0 0.00011933838
be O 0 0.00014971672
related O 0 9.476812e-05
to O 0 0.00012148315
the O 0 0.00014812745
drug O 0 0.0034792256
itself O 0 0.00024189123
, O 0 0.00030849685
the O 0 0.0001328624
early O 0 0.00023909275
and O 0 0.00017291745
repeated O 0 0.00012936708
instillations O 0 0.0005156023
after O 0 0.00021757097
TUR O 0 0.06921738
, O 0 0.0009353988
or O 0 0.00072673644
both O 0 0.0013486011
. O 0 0.003023852

D B-Chemical 0 0.99499255
- I-Chemical 0 0.9748623
penicillamine I-Chemical 1 0.9999627
- O 0 0.57322663
induced O 0 0.011274862
angiopathy B-Disease 0 0.9999484
in O 0 0.0051252707
rats O 0 0.007046241
. O 0 0.0066586006

The O 0 0.0016312576
effect O 0 0.0011646342
of O 0 0.001192747
high O 0 0.0013222728
dose O 0 0.004127517
D B-Chemical 0 0.99883443
- I-Chemical 0 0.8729587
penicillamine I-Chemical 1 0.9999938
treatment O 0 0.00050044985
on O 0 0.00021822585
aortic O 0 0.17346182
permeability O 0 0.7095668
to O 0 0.00039870763
albumin O 0 0.97562194
and O 0 0.00030205454
on O 0 0.00019645783
the O 0 0.000313228
ultrastructure O 0 0.0017110596
of O 0 0.0008954901
the O 0 0.0011397001
vessel O 0 0.15696818
. O 0 0.0038903686

Male O 0 0.015539751
Sprague O 0 0.217332
- O 0 0.008414797
Dawley O 0 0.009789744
rats O 0 0.0013208643
were O 0 0.0006265431
treated O 0 0.0009963817
with O 0 0.0010784011
D B-Chemical 0 0.99829954
- I-Chemical 0 0.90216744
penicillamine I-Chemical 1 0.99999607
( O 0 0.008417187
D B-Chemical 0 0.9973152
- I-Chemical 0 0.028663727
pen I-Chemical 0 0.0066012996
) O 0 0.00095327373
500 O 0 0.000694191
mg O 0 0.002587653
/ O 0 0.0008882233
kg O 0 0.0006533599
/ O 0 0.0008577948
day O 0 0.00020524669
for O 0 0.00025207785
10 O 0 0.00042431368
or O 0 0.00048633994
42 O 0 0.0010176803
days O 0 0.0008950509
. O 0 0.0026654645

Pair O 0 0.034819484
fed O 0 0.012374691
rats O 0 0.008894697
served O 0 0.008552191
as O 0 0.006398032
controls O 0 0.010235889
. O 0 0.012734254

Changes O 0 0.0036402335
in O 0 0.002311741
aortic O 0 0.020258382
morphology O 0 0.0018988141
were O 0 0.0006853617
examined O 0 0.00045286005
by O 0 0.0005489204
light O 0 0.0010203933
- O 0 0.0023633027
and O 0 0.00059876207
transmission O 0 0.00063127984
- O 0 0.0032482538
electron O 0 0.0038128544
microscopy O 0 0.0013682069
( O 0 0.0022988522
TEM O 0 0.010290282
) O 0 0.0053864038
. O 0 0.00450574

In O 0 0.0019466662
addition O 0 0.0012980766
, O 0 0.0027869972
the O 0 0.0014232423
endothelial O 0 0.9961416
permeability O 0 0.91389483
and O 0 0.0005584347
the O 0 0.0002555748
penetration O 0 0.00080638786
through O 0 0.00014532157
the O 0 0.00015051888
aortic O 0 0.01533173
wall O 0 0.001962035
of O 0 0.00034727727
albumin O 0 0.98040444
were O 0 0.00014304325
studied O 0 0.00015499996
10 O 0 0.00010238231
minutes O 0 9.1262125e-05
, O 0 0.00015705316
24 O 0 9.224697e-05
and O 0 8.327394e-05
48 O 0 8.4161686e-05
hours O 0 6.545508e-05
after O 0 5.438035e-05
i O 0 0.000211522
. O 0 0.0001414576
v O 0 0.0005168009
. O 0 0.0001410015
injection O 0 0.00012076728
of O 0 0.00020630244
human O 0 0.0003770386
serum O 0 0.1770835
131I O 0 0.9981396
- O 0 0.04210405
albumin O 0 0.99325377
( O 0 0.0033360822
131I O 0 0.9904668
- O 0 0.019259598
HSA O 0 0.9101417
) O 0 0.005372089
. O 0 0.0036011862

TEM O 0 0.023792993
revealed O 0 0.002480439
extensive O 0 0.002513636
elastolysis O 0 0.21534446
in O 0 0.00072220253
the O 0 0.00053408666
arterial O 0 0.10926182
wall O 0 0.0031725925
of O 0 0.0007755103
D B-Chemical 0 0.99521893
- I-Chemical 0 0.046318308
pen I-Chemical 0 0.02255686
- O 0 0.0033792031
treated O 0 0.00048586176
rats O 0 0.0004330977
, O 0 0.00039099134
consistent O 0 0.00017503081
with O 0 0.00025479525
an O 0 0.00033310123
inhibitory O 0 0.00053038914
effect O 0 0.00040592844
on O 0 0.0005821702
crosslink O 0 0.0035441027
formation O 0 0.0039463937
. O 0 0.0035920301

In O 0 0.0018357788
experimental O 0 0.0016949446
animals O 0 0.0009968427
excess O 0 0.0015337946
deposition O 0 0.001679641
of O 0 0.0010169598
collagen O 0 0.89558274
and O 0 0.00095005543
glycoaminoglycans O 0 0.26415688
was O 0 0.00028421648
observed O 0 0.00018280846
in O 0 0.00018421141
the O 0 0.00019917269
subendothelial O 0 0.08097929
and O 0 0.00022950977
medial O 0 0.0023110327
layer O 0 0.0003443735
of O 0 0.0001341423
the O 0 0.00012442654
aortic O 0 0.039520424
wall O 0 0.0020666558
, O 0 0.0002952185
together O 0 0.0001403133
with O 0 0.00023128801
prominent O 0 0.0011180372
basal O 0 0.0010660111
membrane O 0 0.0039626933
substance O 0 0.4043079
around O 0 0.0006169201
aortic O 0 0.22861916
smooth O 0 0.0061052484
muscle O 0 0.0050744056
cells O 0 0.0020150784
. O 0 0.0030470479

The O 0 0.0031618855
aorta O 0 0.025447747
/ O 0 0.0112040695
serum O 0 0.02600827
- O 0 0.00476875
ratio O 0 0.00076357235
and O 0 0.0005315162
the O 0 0.0003912253
radioactive O 0 0.0011719525
build O 0 0.00047308978
- O 0 0.0016368242
up O 0 0.00023335335
24 O 0 0.00015357221
and O 0 0.00011504807
48 O 0 9.891512e-05
hours O 0 6.839547e-05
after O 0 5.123771e-05
injection O 0 9.56442e-05
of O 0 0.0002496166
131I O 0 0.987359
- O 0 0.017582342
HSA O 0 0.8892072
was O 0 0.00014167007
reduced O 0 0.00013573882
in O 0 9.554802e-05
animals O 0 8.327093e-05
treated O 0 0.00029993043
with O 0 0.00033168215
D B-Chemical 0 0.9984497
- I-Chemical 0 0.047085833
pen I-Chemical 0 0.0030932266
for O 0 9.9308105e-05
42 O 0 0.0001298612
days O 0 6.147166e-05
, O 0 0.00016644981
indicating O 0 8.593138e-05
an O 0 0.00016788131
impeded O 0 0.00048159735
transmural O 0 0.5143726
transport O 0 0.00047094136
of O 0 0.00023205961
tracer O 0 0.0021582188
which O 0 0.00018760609
may O 0 0.000114672286
be O 0 0.00013300311
caused O 0 0.00015736783
by O 0 0.00020474942
a O 0 0.00038902578
steric O 0 0.000672678
exclusion O 0 0.0002963261
effect O 0 0.00036546664
of O 0 0.00093394535
abundant O 0 0.0016255133
hyaluronate B-Chemical 0 0.99984884
. O 0 0.0051295613

The O 0 0.0040459177
endothelial O 0 0.9665832
ultrastructure O 0 0.011091328
was O 0 0.0013993398
unaffected O 0 0.0016548573
by O 0 0.0011646155
D B-Chemical 0 0.9948213
- I-Chemical 0 0.054970227
pen I-Chemical 0 0.012620427
, O 0 0.0007113293
and O 0 0.00025462694
no O 0 0.00017013939
differences O 0 0.00015240314
in O 0 0.00024672895
aortic O 0 0.32645744
131I O 0 0.99716175
- O 0 0.021335227
HSA O 0 0.93523926
radioactivity O 0 0.0037970631
or O 0 0.00015766866
aorta O 0 0.015479047
/ O 0 0.002116257
serum O 0 0.014052273
- O 0 0.001037867
ratio O 0 0.000118746066
were O 0 6.9750204e-05
recorded O 0 6.38149e-05
between O 0 4.8537906e-05
experimental O 0 8.367753e-05
and O 0 8.570837e-05
control O 0 8.929967e-05
groups O 0 0.000116600924
10 O 0 7.837575e-05
minutes O 0 5.815002e-05
after O 0 3.838649e-05
tracer O 0 0.000277739
injection O 0 6.89671e-05
, O 0 0.00013396985
indicating O 0 6.050917e-05
that O 0 7.1156814e-05
the O 0 0.00012205395
permeability O 0 0.40084165
of O 0 0.00025054006
the O 0 0.00022290953
endothelial O 0 0.99727947
barrier O 0 0.006466402
to O 0 0.00028863948
albumin O 0 0.99165475
remained O 0 0.00049615535
unaffected O 0 0.00070462073
by O 0 0.00072074775
D B-Chemical 0 0.9959637
- I-Chemical 0 0.081581816
pen I-Chemical 0 0.021949474
treatment O 0 0.0019539795
. O 0 0.0029307883

These O 0 0.001845119
observations O 0 0.0015338968
support O 0 0.00090884895
the O 0 0.00056481385
hypothesis O 0 0.00044603954
that O 0 0.00030499717
treatment O 0 0.00030507104
with O 0 0.00025824367
high O 0 0.0003188489
doses O 0 0.0007116174
of O 0 0.00054958975
D B-Chemical 0 0.99875426
- I-Chemical 0 0.14336488
pen I-Chemical 0 0.016382229
may O 0 0.00015760915
induce O 0 0.00011408941
a O 0 0.0003323767
fibroproliferative O 0 0.07219698
response O 0 0.00011646413
in O 0 0.000108581684
rat O 0 0.00024207284
aorta O 0 0.013684701
, O 0 0.0002865425
possibly O 0 0.00016084766
by O 0 0.0001159869
an O 0 0.00014911592
inhibitory O 0 0.00021071984
effect O 0 0.00012162919
on O 0 0.00012571899
the O 0 0.00018767407
cross O 0 0.00044751924
- O 0 0.0018000227
linking O 0 0.00036301688
of O 0 0.00093394046
collagen O 0 0.9051284
and O 0 0.002657819
elastin O 0 0.6869788
. O 0 0.0040763314

Effect O 0 0.003683906
of O 0 0.0043769935
aspirin B-Chemical 0 0.99952173
on O 0 0.0021239119
N B-Chemical 0 0.99842286
- I-Chemical 0 0.046500772
[ I-Chemical 0 0.0032211705
4 I-Chemical 0 0.00052143296
- I-Chemical 0 0.0018004819
( I-Chemical 0 0.0007340701
5 I-Chemical 0 0.0004665131
- I-Chemical 0 0.0045035267
nitro I-Chemical 0 0.9692677
- I-Chemical 0 0.006168147
2 I-Chemical 0 0.000554786
- I-Chemical 0 0.0035200363
furyl I-Chemical 0 0.20818037
) I-Chemical 0 0.0018325035
- I-Chemical 0 0.0031343813
2 I-Chemical 0 0.0004601118
- I-Chemical 0 0.0038609128
thiazolyl I-Chemical 0 0.22150114
] I-Chemical 0 0.010052126
- I-Chemical 0 0.031459045
formamide I-Chemical 0 0.6662609
- O 0 0.0047386377
induced O 0 0.0002502297
epithelial O 0 0.0071512684
proliferation O 0 0.048983585
in O 0 0.00025469373
the O 0 0.00024896796
urinary O 0 0.09218002
bladder O 0 0.0396795
and O 0 0.000612714
forestomach O 0 0.6680182
of O 0 0.0009557693
the O 0 0.00089417706
rat O 0 0.0024004218
. O 0 0.0027433645

The O 0 0.0029531743
co O 0 0.018465608
- O 0 0.009049267
administration O 0 0.002156291
of O 0 0.0015386158
aspirin B-Chemical 0 0.99979645
with O 0 0.0020438684
N B-Chemical 0 0.9993173
- I-Chemical 0 0.043876085
[ I-Chemical 0 0.0021078896
4 I-Chemical 0 0.0003163841
- I-Chemical 0 0.0012578039
( I-Chemical 0 0.00051838055
5 I-Chemical 0 0.00034247947
- I-Chemical 0 0.0038739939
nitro I-Chemical 0 0.9715306
- I-Chemical 0 0.0059348517
2 I-Chemical 0 0.00048304425
- I-Chemical 0 0.0033586782
furyl I-Chemical 0 0.22150722
) I-Chemical 0 0.0017958124
- I-Chemical 0 0.0031562562
2 I-Chemical 0 0.0004513489
- I-Chemical 0 0.003982049
thiazolyl I-Chemical 0 0.23930842
] I-Chemical 0 0.0102077285
- I-Chemical 0 0.028519714
formamide I-Chemical 0 0.65228224
( O 0 0.0021710384
FANFT B-Chemical 0 0.99991643
) O 0 0.0009034493
to O 0 0.00012305807
rats O 0 0.00022042786
resulted O 0 0.000114420945
in O 0 0.00012558444
a O 0 0.00021527245
reduced O 0 0.00020639038
incidence O 0 0.00053320144
of O 0 0.0005911678
FANFT B-Chemical 0 0.9999776
- O 0 0.12216327
induced O 0 0.0004510732
bladder B-Disease 0 0.98011726
carcinomas I-Disease 0 0.99555415
but O 0 0.00053053966
a O 0 0.00051240996
concomitant O 0 0.00076808105
induction O 0 0.00044948226
of O 0 0.0015845502
forestomach B-Disease 0 0.9994266
tumors I-Disease 0 0.9991872
. O 0 0.0048214025

An O 0 0.0036176457
autoradiographic O 0 0.003434552
study O 0 0.0013837616
was O 0 0.0006921187
performed O 0 0.00045848923
on O 0 0.00034761216
male O 0 0.0011579006
F O 0 0.34707642
- O 0 0.004172326
344 O 0 0.001990453
rats O 0 0.0003741015
fed O 0 0.0005001144
diet O 0 0.002035467
containing O 0 0.00034336123
FANFT B-Chemical 0 0.9998254
at O 0 0.00017858112
a O 0 0.00023223445
level O 0 0.00012524815
of O 0 0.00017203973
0 O 0 0.00021777894
. O 0 0.0001257678
2 O 0 0.00012821844
% O 0 0.00021737046
and O 0 0.00015229957
/ O 0 0.00092446216
or O 0 0.0002260381
aspirin B-Chemical 0 0.99981683
at O 0 0.0001274714
a O 0 0.00019162854
level O 0 0.00010754792
of O 0 0.00015207288
0 O 0 0.00019548318
. O 0 0.00010586195
5 O 0 8.444966e-05
% O 0 0.00013574996
to O 0 5.1442898e-05
evaluate O 0 3.1865457e-05
the O 0 6.0561473e-05
effect O 0 8.975163e-05
of O 0 0.000282709
aspirin B-Chemical 0 0.999941
on O 0 0.00011408038
the O 0 0.00012119203
increased O 0 0.00027928577
cell O 0 0.0004948378
proliferation O 0 0.092910774
induced O 0 0.00039882128
by O 0 0.0006670042
FANFT B-Chemical 0 0.9999274
in O 0 0.00060469494
the O 0 0.00056598894
forestomach O 0 0.83612394
and O 0 0.001661518
bladder O 0 0.07967875
. O 0 0.0029972587

FANFT B-Chemical 0 0.9995566
- O 0 0.1212924
induced O 0 0.0021274693
cell O 0 0.002653415
proliferation O 0 0.06729368
in O 0 0.00064870855
the O 0 0.0004200449
bladder O 0 0.006931735
was O 0 0.00024199233
significantly O 0 0.0002642943
suppressed O 0 0.00028448406
by O 0 0.00038629517
aspirin B-Chemical 0 0.999949
co O 0 0.25901273
- O 0 0.0044583115
administration O 0 0.00027049746
after O 0 7.1109804e-05
4 O 0 0.00010082239
weeks O 0 8.665593e-05
but O 0 0.00022043499
not O 0 0.00024304808
after O 0 0.00024464884
12 O 0 0.00043844324
weeks O 0 0.0005967851
. O 0 0.0021500639

In O 0 0.0025987579
the O 0 0.0027150705
forestomach O 0 0.75243473
, O 0 0.0026598587
and O 0 0.0008908241
also O 0 0.00051611656
in O 0 0.00043716014
the O 0 0.00041700655
liver O 0 0.18237361
, O 0 0.0027859702
aspirin B-Chemical 0 0.9999267
did O 0 0.00047067297
not O 0 0.00023675372
affect O 0 0.00022069807
the O 0 0.00044491037
FANFT B-Chemical 0 0.99992156
- O 0 0.014814025
induced O 0 0.00039410839
increase O 0 0.00043865293
in O 0 0.00054577895
labeling O 0 0.0008624976
index O 0 0.0019085974
. O 0 0.0027516151

The O 0 0.0017296325
present O 0 0.001120293
results O 0 0.0008388394
are O 0 0.0005546142
consistent O 0 0.0003938691
with O 0 0.00039528793
the O 0 0.00030030124
carcinogenicity O 0 0.086473316
experiment O 0 0.00014357535
suggesting O 0 9.8553865e-05
that O 0 8.372766e-05
different O 0 7.558241e-05
mechanisms O 0 9.025465e-05
are O 0 0.00010953584
involved O 0 0.00014157635
in O 0 0.00035556618
FANFT B-Chemical 0 0.99996436
carcinogenesis B-Disease 0 0.94120085
in O 0 0.00019654419
the O 0 0.00014927099
bladder O 0 0.01484172
and O 0 0.00025615832
forestomach O 0 0.81849724
, O 0 0.0003996643
and O 0 0.00015022753
that O 0 0.00013701753
aspirin B-Chemical 0 0.9998758
' O 0 0.00051465194
s O 0 0.00022006393
effect O 0 0.00012287349
on O 0 0.00019547965
FANFT B-Chemical 0 0.9999485
in O 0 0.0002711024
the O 0 0.0002103571
forestomach O 0 0.87149245
is O 0 0.00014265421
not O 0 0.000114229515
due O 0 9.547953e-05
to O 0 0.00012818383
an O 0 0.00024017092
irritant O 0 0.09437641
effect O 0 0.00018666503
associated O 0 0.00033612773
with O 0 0.00047434485
increased O 0 0.0010477962
cell O 0 0.002373089
proliferation O 0 0.35889992
. O 0 0.003884517

Also O 0 0.0044398145
, O 0 0.0041130595
there O 0 0.0013213961
appears O 0 0.00079215714
to O 0 0.0006507402
be O 0 0.0005281213
an O 0 0.00046370618
adaptation O 0 0.0004324785
by O 0 0.00028957275
the O 0 0.00024162413
rats O 0 0.00042906075
to O 0 0.00026466144
the O 0 0.00034790093
chronic O 0 0.0057201493
ingestion O 0 0.011913478
of O 0 0.0020825844
aspirin B-Chemical 0 0.9996698
. O 0 0.0044879373

A O 0 0.04694451
case O 0 0.007091172
of O 0 0.0118861245
tardive B-Disease 0 0.9999802
dyskinesia I-Disease 0 0.9999918
caused O 0 0.006036034
by O 0 0.0064247292
metoclopramide B-Chemical 0 0.99990475
. O 0 0.009386744

Abnormal B-Disease 0 0.1274141
involuntary I-Disease 0 0.91658133
movements I-Disease 0 0.08471992
appeared O 0 0.0012630149
in O 0 0.00076358696
the O 0 0.00063193694
mouth O 0 0.029181087
, O 0 0.0013927136
tongue O 0 0.0086712465
, O 0 0.0008257794
neck O 0 0.002952582
and O 0 0.00026414968
abdomen O 0 0.0006045437
of O 0 0.0002029225
a O 0 0.0002657591
64 O 0 0.00028799623
- O 0 0.0008539261
year O 0 0.00014547144
- O 0 0.00055408943
old O 0 0.0001559443
male O 0 0.00026249094
patient O 0 0.00012497995
after O 0 5.5990437e-05
he O 0 0.00015085224
took O 0 0.00022439027
metoclopramide B-Chemical 0 0.9999871
for O 0 0.00024457768
gastrointestinal B-Disease 0 0.99467975
disorder I-Disease 0 0.9999176
in O 0 0.00013228053
a O 0 0.0001490204
regimen O 0 0.00011061834
of O 0 0.000101925936
30 O 0 0.000111304835
mg O 0 0.00094147294
per O 0 9.489508e-05
day O 0 7.435295e-05
for O 0 0.000110929635
a O 0 0.0003001581
total O 0 0.00029910175
of O 0 0.0004575979
about O 0 0.00083493703
260 O 0 0.0039257556
days O 0 0.0009553336
. O 0 0.002467646

The O 0 0.0037631195
symptoms O 0 0.013229295
exacerbated O 0 0.004537178
to O 0 0.0018297754
a O 0 0.002345212
maximum O 0 0.0018709253
in O 0 0.001617466
a O 0 0.0027404255
month O 0 0.0019056703
. O 0 0.0044819145

When O 0 0.001991939
the O 0 0.0025969825
metoclopramide B-Chemical 0 0.9999056
administration O 0 0.0029022398
was O 0 0.0006837753
discontinued O 0 0.0018040877
, O 0 0.0007103409
the O 0 0.0003656008
abnormal B-Disease 0 0.00968602
movements I-Disease 0 0.003166352
gradually O 0 0.00078799634
improved O 0 0.00066617166
to O 0 0.00045500632
a O 0 0.0009228258
considerable O 0 0.00094289763
extent O 0 0.001677126
. O 0 0.0034759904

Attention O 0 0.06493228
to O 0 0.001592552
the O 0 0.00083849934
possible O 0 0.00049419515
induction O 0 0.00045721588
of O 0 0.00064906816
specific O 0 0.0007261117
tardive B-Disease 0 0.99999595
dyskinesia I-Disease 0 0.99999857
is O 0 0.00036815664
called O 0 0.0003523773
for O 0 0.00018709875
in O 0 0.000238241
the O 0 0.00024701658
use O 0 0.00034792096
of O 0 0.00067141245
this O 0 0.0012906323
drug O 0 0.02975782
. O 0 0.0034645475

Intra O 0 0.025768314
- O 0 0.017455354
arterial O 0 0.8153573
BCNU B-Chemical 0 0.9999049
chemotherapy O 0 0.006197091
for O 0 0.0004509801
treatment O 0 0.0005722127
of O 0 0.001078585
malignant B-Disease 0 0.9988055
gliomas I-Disease 0 0.99981624
of O 0 0.0009714882
the O 0 0.000670071
central O 0 0.0015426949
nervous O 0 0.0052919053
system O 0 0.002070089
. O 0 0.0031797406

Because O 0 0.002046957
of O 0 0.0020612923
the O 0 0.0012677102
rapid O 0 0.0016578812
systemic O 0 0.11640296
clearance O 0 0.005445831
of O 0 0.0013910658
BCNU B-Chemical 0 0.999972
( O 0 0.0011402871
1 B-Chemical 0 0.00037470917
, I-Chemical 0 0.00046698024
3 I-Chemical 0 0.0003080704
- I-Chemical 0 0.0026212416
bis I-Chemical 0 0.35967568
- I-Chemical 0 0.003931114
( I-Chemical 0 0.00064236793
2 I-Chemical 0 0.00039901203
- I-Chemical 0 0.0033924987
chloroethyl I-Chemical 0 0.6720152
) I-Chemical 0 0.0014857124
- I-Chemical 0 0.002283037
1 I-Chemical 0 0.00032645604
- I-Chemical 0 0.0028962106
nitrosourea I-Chemical 0 0.9865703
) O 0 0.00059571303
, O 0 0.0003153999
intra O 0 0.0007001598
- O 0 0.0013234258
arterial O 0 0.082042865
administration O 0 0.00019467667
should O 0 4.1580435e-05
provide O 0 5.087949e-05
a O 0 0.00011281008
substantial O 0 8.211227e-05
advantage O 0 5.8781712e-05
over O 0 8.3934385e-05
intravenous O 0 0.0006938054
administration O 0 0.0001972213
for O 0 0.000112394206
the O 0 0.00018518811
treatment O 0 0.00039604606
of O 0 0.0012001329
malignant B-Disease 0 0.99905866
gliomas I-Disease 0 0.99980575
. O 0 0.004188301

Thirty O 0 0.007869034
- O 0 0.0062181386
six O 0 0.00077985605
patients O 0 0.0012574933
were O 0 0.00056685513
treated O 0 0.00096639735
with O 0 0.0010077448
BCNU B-Chemical 0 0.99996495
every O 0 0.00015427274
6 O 0 0.000103590624
to O 0 8.431431e-05
8 O 0 8.590369e-05
weeks O 0 5.836513e-05
, O 0 0.00016085732
either O 0 9.0720176e-05
by O 0 9.081737e-05
transfemoral O 0 0.00022698492
catheterization O 0 0.00021232844
of O 0 8.4262225e-05
the O 0 6.894672e-05
internal O 0 0.000124675
carotid O 0 0.012661581
or O 0 0.00011310682
vertebral O 0 0.014872211
artery O 0 0.051440623
or O 0 8.366604e-05
through O 0 6.732849e-05
a O 0 0.000108534274
fully O 0 5.709218e-05
implantable O 0 0.0001839643
intracarotid O 0 0.4391324
drug O 0 0.0008125916
delivery O 0 7.5587595e-05
system O 0 0.000100734746
, O 0 0.00017070844
beginning O 0 7.5562944e-05
with O 0 0.00013135053
a O 0 0.00021472879
dose O 0 0.00027438588
of O 0 0.00022010294
200 O 0 0.0005948075
mg O 0 0.007355823
/ O 0 0.0020397236
sq O 0 0.0059584873
m O 0 0.0023463604
body O 0 0.0012797851
surface O 0 0.0018064592
area O 0 0.0022221853
. O 0 0.0028121343

Twelve O 0 0.0062544043
patients O 0 0.003688419
with O 0 0.0020493318
Grade O 0 0.021145888
III O 0 0.046611108
or O 0 0.0011616118
IV O 0 0.7072811
astrocytomas B-Disease 0 0.99957246
were O 0 0.0003969701
treated O 0 0.00042039863
after O 0 0.00013880715
partial O 0 0.0003445868
resection O 0 0.0011170587
of O 0 0.00029326405
the O 0 0.00032136636
tumor B-Disease 0 0.13780168
without O 0 0.000491233
prior O 0 0.00036824384
radiation O 0 0.0024032143
therapy O 0 0.0016192179
. O 0 0.0022020724

After O 0 0.0014798498
two O 0 0.0009925409
to O 0 0.00072131003
seven O 0 0.0004409319
cycles O 0 0.00027318826
of O 0 0.00039532446
chemotherapy O 0 0.0015254545
, O 0 0.0004013764
nine O 0 0.00018787174
patients O 0 0.00034535394
showed O 0 0.00016796555
a O 0 0.00028255593
decrease O 0 0.00023927745
in O 0 0.00024593793
tumor B-Disease 0 0.39182624
size O 0 0.0005015845
and O 0 0.00026957446
surrounding O 0 0.00037325296
edema B-Disease 0 0.99919945
on O 0 0.00016447078
contrast O 0 0.0003748185
- O 0 0.0012808541
enhanced O 0 0.00041606074
computerized O 0 0.001209175
tomography O 0 0.0020969172
scans O 0 0.0022421884
. O 0 0.002294402

In O 0 0.0016666744
the O 0 0.0011408553
nine O 0 0.0007691416
responders O 0 0.0011147218
, O 0 0.0006265395
median O 0 0.00019152387
duration O 0 0.0001586704
of O 0 0.00024348902
chemotherapy O 0 0.0008096775
response O 0 0.00013944952
from O 0 0.000113074464
the O 0 9.34461e-05
time O 0 8.3502324e-05
of O 0 0.00013796528
operation O 0 0.00013327124
was O 0 0.00010979005
25 O 0 0.00014256094
weeks O 0 6.787659e-05
( O 0 0.00019858484
range O 0 0.00013980088
12 O 0 0.00011090046
to O 0 0.00014957089
more O 0 0.00034089113
than O 0 0.00033425275
91 O 0 0.0009338738
weeks O 0 0.0005149372
) O 0 0.0026100308
. O 0 0.0030137885

The O 0 0.001334195
median O 0 0.0007787911
duration O 0 0.00057754206
of O 0 0.00068629044
survival O 0 0.0008986502
in O 0 0.00037158604
the O 0 0.0002556091
12 O 0 0.00019286752
patients O 0 0.00031243794
was O 0 0.00014437092
54 O 0 0.00020086372
weeks O 0 7.713183e-05
( O 0 0.00019854601
range O 0 0.00012530836
21 O 0 0.00012922911
to O 0 9.180924e-05
more O 0 0.00015943186
than O 0 0.00011146437
156 O 0 0.00023995667
weeks O 0 8.795986e-05
) O 0 0.0003442176
, O 0 0.00030040432
with O 0 0.0002138119
an O 0 0.00025793264
18 O 0 0.00028044192
- O 0 0.00076618505
month O 0 0.0001599859
survival O 0 0.00049875927
rate O 0 0.0006370388
of O 0 0.0008573241
42 O 0 0.0016457605
% O 0 0.0031229313
. O 0 0.0034324864

Twenty O 0 0.0069453474
- O 0 0.006502058
four O 0 0.00092141004
patients O 0 0.0015172246
with O 0 0.0009331355
recurrent O 0 0.0035976667
Grade O 0 0.020312538
I O 0 0.018774154
to O 0 0.0006056224
IV O 0 0.85414314
astrocytomas B-Disease 0 0.99987733
, O 0 0.000754158
whose O 0 0.00028454207
resection O 0 0.0011032093
and O 0 0.00014854697
irradiation O 0 0.00026579355
therapy O 0 0.00015582435
had O 0 9.583346e-05
failed O 0 0.000120929755
, O 0 0.00020843346
received O 0 0.00010052604
two O 0 6.2802e-05
to O 0 8.5051084e-05
eight O 0 8.896684e-05
courses O 0 0.00025560058
of O 0 0.00028465904
intra O 0 0.0015355685
- O 0 0.0048951674
arterial O 0 0.90695447
BCNU B-Chemical 0 0.9999248
therapy O 0 0.0027167003
. O 0 0.0024327405

Seventeen O 0 0.007437178
of O 0 0.0020603193
these O 0 0.0011738731
had O 0 0.00085496774
a O 0 0.0007712274
response O 0 0.00039869017
or O 0 0.00029123592
were O 0 0.00021418816
stable O 0 0.00018485803
for O 0 0.00012682493
a O 0 0.00019516786
median O 0 9.4809155e-05
of O 0 0.00014232026
20 O 0 0.00013603763
weeks O 0 8.032541e-05
( O 0 0.00022894065
range O 0 0.00015580904
6 O 0 0.00012659634
to O 0 0.00016743706
more O 0 0.00036481238
than O 0 0.00034400486
66 O 0 0.0007936641
weeks O 0 0.0005266906
) O 0 0.0026928766
. O 0 0.0031188047

The O 0 0.0017664135
catheterization O 0 0.0027183509
procedure O 0 0.0008858893
is O 0 0.000635508
safe O 0 0.0008650457
, O 0 0.00093965814
with O 0 0.00052238966
no O 0 0.00043994273
immediate O 0 0.00075514044
complication O 0 0.0022937658
in O 0 0.00065397535
111 O 0 0.0020112444
infusions O 0 0.0024193758
of O 0 0.0026734052
BCNU B-Chemical 0 0.99979
. O 0 0.005204018

A O 0 0.02689605
delayed O 0 0.005855415
complication O 0 0.007775119
in O 0 0.00079548394
nine O 0 0.0005443315
patients O 0 0.00084141473
has O 0 0.0002598404
been O 0 0.0003467269
unilateral O 0 0.0074118907
loss B-Disease 0 0.0006832678
of I-Disease 0 0.00045301465
vision I-Disease 0 0.08278119
secondary O 0 0.0007670453
to O 0 0.00059402315
a O 0 0.001817054
retinal B-Disease 0 0.95535886
vasculitis I-Disease 2 0.9997346
. O 0 0.0042455182

The O 0 0.0018136641
frequency O 0 0.0014296937
of O 0 0.0015169054
visual B-Disease 0 0.06886633
loss I-Disease 0 0.002244338
decreased O 0 0.0009576643
after O 0 0.0002705947
the O 0 0.00034098607
concentration O 0 0.00068135635
of O 0 0.0005861161
the O 0 0.0007303495
ethanol B-Chemical 0 0.9988071
diluent O 0 0.040293436
was O 0 0.0014748612
lowered O 0 0.0063929656
. O 0 0.0036200888

Provocation O 0 0.04439219
of O 0 0.0051308973
postural O 0 0.9793043
hypotension B-Disease 0 0.99994755
by O 0 0.0055590826
nitroglycerin B-Chemical 0 0.99996936
in O 0 0.0045481226
diabetic B-Disease 2 0.9998808
autonomic I-Disease 0 0.9981286
neuropathy I-Disease 0 0.9999651
? O 0 0.026575413

The O 0 0.0016684479
effect O 0 0.0013848897
of O 0 0.0023157685
nitroglycerin B-Chemical 0 0.9999578
on O 0 0.00056461745
heart O 0 0.008135973
rate O 0 0.0003584515
and O 0 0.0002093702
systolic O 0 0.02080989
blood O 0 0.0019835974
pressure O 0 0.0019383414
was O 0 0.00011869263
compared O 0 7.890678e-05
in O 0 9.909243e-05
5 O 0 0.00010340339
normal O 0 0.00017643937
subjects O 0 0.00020359851
, O 0 0.00021170967
12 O 0 0.00011534839
diabetic B-Disease 2 0.99635065
subjects O 0 0.00041374794
without O 0 0.00025030941
autonomic B-Disease 0 0.9524837
neuropathy I-Disease 0 0.9999893
, O 0 0.0006130218
and O 0 0.00023699696
5 O 0 0.00028374998
diabetic B-Disease 2 0.99842846
subjects O 0 0.0010762911
with O 0 0.00093957095
autonomic B-Disease 0 0.9742547
neuropathy I-Disease 0 0.9999428
. O 0 0.0039071925

The O 0 0.0017247283
magnitude O 0 0.0012846793
and O 0 0.0009009504
time O 0 0.0004568216
course O 0 0.0004906413
of O 0 0.0003861976
the O 0 0.0002559979
increase O 0 0.00023643635
in O 0 0.00023521137
heart O 0 0.0048482153
rate O 0 0.00023895259
and O 0 0.00012525736
the O 0 8.231862e-05
decrease O 0 9.8340955e-05
in O 0 8.4176536e-05
systolic O 0 0.015180741
blood O 0 0.0013471022
pressure O 0 0.002050682
after O 0 9.366092e-05
nitroglycerin B-Chemical 0 0.99998045
were O 0 8.911227e-05
similar O 0 4.7752223e-05
in O 0 6.366422e-05
the O 0 6.697187e-05
normal O 0 0.00017771343
and O 0 0.00015897737
diabetic B-Disease 2 0.99971145
subjects O 0 0.0004952649
without O 0 0.0002088753
autonomic B-Disease 0 0.97935176
neuropathy I-Disease 0 0.9999956
, O 0 0.0004875252
whereas O 0 0.00012759956
a O 0 0.00019495211
lesser O 0 0.000660388
increase O 0 0.00011093926
in O 0 0.000107571206
heart O 0 0.005692937
rate O 0 0.0001406364
and O 0 8.7667875e-05
a O 0 0.000114737144
greater O 0 0.00010150149
decrease O 0 8.804487e-05
in O 0 7.941404e-05
systolic O 0 0.035190053
blood O 0 0.0019314057
pressure O 0 0.002318532
occurred O 0 0.00013146382
in O 0 0.00013082566
the O 0 0.0002115908
diabetic B-Disease 2 0.99940073
subjects O 0 0.0013635812
with O 0 0.0010229493
autonomic B-Disease 0 0.9836289
neuropathy I-Disease 0 0.99995065
. O 0 0.00387301

It O 0 0.005023218
is O 0 0.0015297002
therefore O 0 0.0010570744
suggested O 0 0.0005960043
that O 0 0.0004231935
caution O 0 0.0005283872
should O 0 0.00017457345
be O 0 0.0002237103
exercised O 0 0.0006646481
when O 0 0.00014946098
prescribing O 0 0.0012812049
vasodilator O 0 0.96797246
drugs O 0 0.019921737
in O 0 0.00031133718
diabetic B-Disease 2 0.999783
patients O 0 0.0013383259
, O 0 0.0004990099
particularly O 0 0.00034404176
those O 0 0.00044957397
with O 0 0.00092621933
autonomic B-Disease 0 0.98028654
neuropathy I-Disease 0 0.99994767
. O 0 0.0041926587

Blood O 0 0.020125037
pressure O 0 0.008611314
response O 0 0.0012122694
to O 0 0.000790844
chronic O 0 0.0033135407
low O 0 0.0010267877
- O 0 0.0036353527
dose O 0 0.0016129615
intrarenal O 0 0.9922369
noradrenaline B-Chemical 1 0.9999579
infusion O 0 0.0029045702
in O 0 0.00070086314
conscious O 0 0.00518412
rats O 0 0.0023840899
. O 0 0.002802118

Sodium B-Chemical 0 0.9998449
chloride I-Chemical 0 0.99967027
solution O 0 0.013785248
( O 0 0.0025129418
0 O 0 0.00096015935
. O 0 0.000485429
9 O 0 0.000355742
% O 0 0.0007137953
) O 0 0.0009169171
or O 0 0.0005163043
noradrenaline B-Chemical 1 0.9999329
in O 0 0.00028657142
doses O 0 0.00047207734
of O 0 0.00020182903
4 O 0 0.00014280326
, O 0 0.00021763673
12 O 0 8.60041e-05
and O 0 0.00011208886
36 O 0 0.00015643414
micrograms O 0 0.0007363689
h O 0 0.00019452136
- O 0 0.00059271447
1 O 0 0.00014858521
kg O 0 0.00035286203
- O 0 0.00063143484
1 O 0 0.00012631716
was O 0 9.061124e-05
infused O 0 0.00027874546
for O 0 5.5420336e-05
five O 0 4.148823e-05
consecutive O 0 6.368542e-05
days O 0 5.3658805e-05
, O 0 0.00017373917
either O 0 0.00014944914
intrarenally O 0 0.23813145
( O 0 0.00030276144
by O 0 0.00011738138
a O 0 0.00017272598
new O 0 0.00014200184
technique O 0 0.00017178353
) O 0 0.00032277114
or O 0 0.00012515062
intravenously O 0 0.0002563088
into O 0 0.00010207612
rats O 0 0.00032051417
with O 0 0.0003443735
one O 0 0.00048389775
kidney O 0 0.0134354085
removed O 0 0.001529519
. O 0 0.0027417853

Intrarenal O 0 0.81386846
infusion O 0 0.0101805
of O 0 0.0033799582
noradrenaline B-Chemical 1 0.99994946
caused O 0 0.0017022678
hypertension B-Disease 2 0.9999757
at O 0 0.00041078177
doses O 0 0.00094233546
which O 0 0.00037330325
did O 0 0.0003237709
not O 0 0.00026470964
do O 0 0.00031736653
so O 0 0.0003722283
when O 0 0.00045923717
infused O 0 0.003469983
intravenously O 0 0.002535285
. O 0 0.0022837012

Intrarenal O 0 0.247761
compared O 0 0.001060309
with O 0 0.0008858286
intravenous O 0 0.003347051
infusion O 0 0.001570466
of O 0 0.0007916334
noradrenaline B-Chemical 1 0.99996436
caused O 0 0.00038800194
higher O 0 0.000601272
plasma O 0 0.63262177
noradrenaline B-Chemical 1 0.9999908
concentrations O 0 0.0005826062
and O 0 0.00015085065
a O 0 0.00017901396
shift O 0 0.00014456308
of O 0 0.00013010089
the O 0 0.00015975587
plasma O 0 0.33047363
noradrenaline B-Chemical 1 0.9999908
concentration O 0 0.00089863944
- O 0 0.0022395945
blood O 0 0.0014056788
pressure O 0 0.0014192963
effect O 0 0.00011859794
curve O 0 0.00022950889
towards O 0 0.00026586853
lower O 0 0.0007858569
plasma O 0 0.46286097
noradrenaline B-Chemical 1 0.9999471
levels O 0 0.0018762265
. O 0 0.002798238

These O 0 0.0016465002
results O 0 0.0011001697
suggest O 0 0.00060185423
that O 0 0.0008020973
hypertension B-Disease 2 0.9999057
after O 0 0.00039250453
chronic O 0 0.07495959
intrarenal O 0 0.9987338
noradrenaline B-Chemical 1 0.9999893
infusion O 0 0.0013323607
is O 0 8.34529e-05
produced O 0 7.0121816e-05
by O 0 8.565746e-05
relatively O 0 0.00014247042
higher O 0 0.0001333409
levels O 0 0.00011848321
of O 0 0.00025828503
circulating O 0 0.053613428
noradrenaline B-Chemical 1 0.9999907
and O 0 0.00026453633
by O 0 0.00015837926
triggering O 0 0.00016444239
of O 0 0.00024895728
an O 0 0.00035139036
additional O 0 0.00035580425
intrarenal O 0 0.9191897
pressor O 0 0.2896764
mechanism O 0 0.0009995773
. O 0 0.0023841066

Characterization O 0 0.0038917733
of O 0 0.006504155
estrogen B-Chemical 0 0.99938655
- O 0 0.2696541
induced O 0 0.003593625
adenohypophyseal B-Disease 0 0.99677986
tumors I-Disease 0 0.997163
in O 0 0.0012459952
the O 0 0.0009823092
Fischer O 0 0.0041117608
344 O 0 0.009478449
rat O 0 0.0032630279
. O 0 0.0037424252

Pituitary B-Disease 0 0.9784048
tumors I-Disease 0 0.9920696
were O 0 0.0016622744
induced O 0 0.00091076776
in O 0 0.00071249384
F344 O 0 0.01579633
female O 0 0.0009017453
rats O 0 0.00047327424
by O 0 0.00024288733
chronic O 0 0.001733414
treatment O 0 0.0002653912
with O 0 0.00044061066
diethylstilbestrol B-Chemical 0 0.99993086
( O 0 0.0025681402
DES B-Chemical 0 0.9979087
, O 0 0.00053029845
8 O 0 0.00022009182
- O 0 0.0007801493
10 O 0 0.00021704986
mg O 0 0.0012625265
) O 0 0.00043375263
implanted O 0 0.0003986987
subcutaneously O 0 0.00032188703
in O 0 0.0004413227
silastic O 0 0.0038139797
capsules O 0 0.006544992
. O 0 0.003163894

Over O 0 0.0051494217
a O 0 0.0028764051
range O 0 0.0013811286
of O 0 0.0010603963
1 O 0 0.0009133749
- O 0 0.0016553623
150 O 0 0.0004385541
days O 0 0.0002029914
of O 0 0.0003875792
DES B-Chemical 0 0.9629135
treatment O 0 0.0003180247
, O 0 0.00035476324
pairs O 0 0.00018171674
of O 0 0.00018086779
control O 0 0.0002044993
and O 0 0.00033059999
DES B-Chemical 0 0.99840206
- O 0 0.0025729649
treated O 0 0.00026954777
rats O 0 0.00019246538
were O 0 8.216623e-05
sacrificed O 0 7.3082505e-05
, O 0 0.00019317264
and O 0 0.00013169821
their O 0 0.00014646843
pituitaries O 0 0.00087246404
dissociated O 0 0.00033213655
enzymatically O 0 0.0005437852
into O 0 0.00019758532
single O 0 0.00035372935
- O 0 0.0022710457
cell O 0 0.001385922
preparations O 0 0.0020985883
. O 0 0.0031108104

The O 0 0.0021483726
cell O 0 0.0023519055
populations O 0 0.0013242156
were O 0 0.0006066395
examined O 0 0.00033006837
regarding O 0 0.00022179016
total O 0 0.00033629747
cell O 0 0.0004564993
recovery O 0 0.00041940052
correlated O 0 0.00021403708
with O 0 0.00025356945
gland O 0 0.002131355
weight O 0 0.0005391582
, O 0 0.0006100786
intracellular O 0 0.0007497253
prolactin O 0 0.9983193
( O 0 0.006466427
PRL O 0 0.9999486
) O 0 0.001288124
content O 0 0.00020599994
and O 0 0.00014032697
subsequent O 0 0.00011088025
release O 0 0.00028543928
in O 0 0.00011100975
primary O 0 0.00013660465
culture O 0 0.0003198137
, O 0 0.00044372553
immunocytochemical O 0 0.00044689688
PRL O 0 0.99992394
staining O 0 0.00026129145
, O 0 0.00031214466
density O 0 0.00022238518
and O 0 0.00017175403
/ O 0 0.00085259666
or O 0 0.00011144672
size O 0 0.00020311338
alterations O 0 0.00020373329
via O 0 7.063186e-05
separation O 0 0.00014079151
on O 0 8.579677e-05
Ficoll O 0 0.11041499
- O 0 0.004114575
Hypaque O 0 0.9806717
and O 0 0.00013107515
by O 0 0.00010021125
unit O 0 0.00013544303
gravity O 0 0.0009998531
sedimentation O 0 0.0015259818
, O 0 0.00033109772
and O 0 0.00017677243
cell O 0 0.0002873046
cycle O 0 0.00021322619
analysis O 0 0.00022200236
, O 0 0.00045012456
after O 0 0.00024143158
acriflavine B-Chemical 0 0.9998386
DNA O 0 0.007276157
staining O 0 0.0004532503
, O 0 0.0007711974
by O 0 0.00057460595
laser O 0 0.0025798413
flow O 0 0.0043249507
cytometry O 0 0.0023338543
. O 0 0.0030756122

Total O 0 0.0061668614
cell O 0 0.0033524656
yields O 0 0.0019302048
from O 0 0.0015593481
DES B-Chemical 0 0.99777347
- O 0 0.015906392
treated O 0 0.0014618501
pituitaries O 0 0.0030510563
increased O 0 0.0005012192
from O 0 0.00022301475
1 O 0 0.00021168625
. O 0 0.00012455975
3 O 0 8.30698e-05
times O 0 6.2091574e-05
control O 0 0.000102257036
yields O 0 0.00012129828
at O 0 7.734927e-05
8 O 0 8.531565e-05
days O 0 5.7522488e-05
of O 0 0.00011093863
treatment O 0 0.00013222659
to O 0 0.00012717975
58 O 0 0.00026417864
. O 0 0.0001389894
9 O 0 0.00011588928
times O 0 0.00010399017
control O 0 0.00022926916
values O 0 0.00034942495
by O 0 0.0004839669
day O 0 0.00059772265
150 O 0 0.0018899721
. O 0 0.0028684146

Intracellular O 0 0.01991533
PRL O 0 0.99902916
content O 0 0.0030409547
ranged O 0 0.0013597731
from O 0 0.0006293644
1 O 0 0.00056311855
. O 0 0.00034172332
9 O 0 0.0002240574
to O 0 0.00016951674
9 O 0 0.00016287332
. O 0 0.00013473893
4 O 0 9.368986e-05
times O 0 7.568901e-05
control O 0 0.0001390024
levels O 0 0.00017412195
, O 0 0.0005294611
and O 0 0.00059418194
PRL O 0 0.99994004
release O 0 0.0010976881
in O 0 0.00014445272
vitro O 0 0.00012292694
was O 0 9.586736e-05
significantly O 0 0.0001207028
and O 0 9.8594945e-05
consistently O 0 8.744935e-05
higher O 0 0.00011989409
than O 0 0.000100934456
controls O 0 0.00020408638
, O 0 0.00022987441
after O 0 7.343649e-05
at O 0 0.000105216845
least O 0 0.00015571859
8 O 0 0.00020268331
days O 0 0.00020100722
of O 0 0.0007330012
DES B-Chemical 0 0.9568861
exposure O 0 0.0022152974
. O 0 0.0029901054

Beyond O 0 0.0037351432
8 O 0 0.0018606645
days O 0 0.000990173
of O 0 0.001473227
DES B-Chemical 0 0.97469
exposure O 0 0.00116832
, O 0 0.0012716812
the O 0 0.0006797243
immunochemically O 0 0.37710458
PRL O 0 0.999926
- O 0 0.011555119
positive O 0 0.00028013298
proportion O 0 0.00019027322
of O 0 0.00024128454
cells O 0 0.0003129916
increased O 0 0.00034458435
to O 0 0.00019159893
over O 0 0.00019591273
50 O 0 0.0003732029
% O 0 0.0005480259
of O 0 0.00042309792
the O 0 0.0004925376
total O 0 0.00094878796
population O 0 0.0021974964
. O 0 0.003169183

Increased O 0 0.004837451
density O 0 0.0029438732
and O 0 0.0018590011
/ O 0 0.0042238147
or O 0 0.000829824
size O 0 0.0012651429
and O 0 0.0012862526
PRL O 0 0.99976355
content O 0 0.000608155
were O 0 0.00020292058
indicated O 0 0.00010478281
for O 0 0.00010736369
the O 0 0.00011728907
majority O 0 0.00013753315
of O 0 0.00024927314
the O 0 0.00038400898
PRL O 0 0.9998851
cell O 0 0.0008369559
population O 0 0.0004955733
in O 0 0.00024642074
both O 0 0.00023442062
types O 0 0.00030180754
of O 0 0.000581907
separation O 0 0.0012552752
protocols O 0 0.0012254185
. O 0 0.00262228

All O 0 0.00224499
these O 0 0.0016258716
effects O 0 0.0014207519
of O 0 0.002032189
DES B-Chemical 0 0.99424237
were O 0 0.00093893777
more O 0 0.0009892931
pronounced O 0 0.0009918861
among O 0 0.0008730856
previously O 0 0.001123582
ovariectomized O 0 0.019110141
animals O 0 0.001681382
. O 0 0.0034926494

The O 0 0.0020457786
data O 0 0.0017218441
extend O 0 0.00083946827
the O 0 0.00058709964
findings O 0 0.000610418
of O 0 0.00047209556
other O 0 0.00034604635
investigators O 0 0.00042036537
, O 0 0.0004841152
further O 0 0.00018645283
establishing O 0 0.00021158898
the O 0 0.00030503178
DES B-Chemical 0 0.9986552
- O 0 0.007197862
induced O 0 0.0003353015
tumor B-Disease 0 0.5549226
as O 0 0.0002554442
a O 0 0.00028254543
model O 0 0.00016954294
for O 0 0.0001879038
study O 0 0.00041723106
of O 0 0.0008541066
PRL O 0 0.99976295
cellular O 0 0.0018130997
control O 0 0.0009883558
mechanisms O 0 0.0013041674
. O 0 0.0029976415

Age O 0 0.03219989
and O 0 0.009875239
renal O 0 0.7875857
clearance O 0 0.034205653
of O 0 0.012352408
cimetidine B-Chemical 0 0.99984026
. O 0 0.017660044

In O 0 0.0023970043
35 O 0 0.0025644177
patients O 0 0.0024269498
( O 0 0.0016285373
ages O 0 0.000978432
20 O 0 0.00050125236
to O 0 0.00028823494
86 O 0 0.00046206676
yr O 0 0.0003413082
) O 0 0.0005344111
receiving O 0 0.0005527913
cimetidine B-Chemical 0 0.99998724
therapeutically O 0 0.0011569473
two O 0 0.00014122123
serum O 0 0.0041401586
samples O 0 0.00020329143
and O 0 0.00015315879
all O 0 0.00015591246
urine O 0 0.013095308
formed O 0 0.00015995433
in O 0 0.00010456352
the O 0 9.136209e-05
interim O 0 0.00018637515
were O 0 7.538078e-05
collected O 0 6.9610796e-05
for O 0 6.3923195e-05
analysis O 0 0.00011317737
of O 0 0.00027396082
cimetidine B-Chemical 0 0.9999925
by O 0 0.00023381056
high O 0 0.0003412134
- O 0 0.0017235817
pressure O 0 0.004352285
liquid O 0 0.0010302886
chromatography O 0 0.0024470622
and O 0 0.00056621776
for O 0 0.00084003754
creatinine B-Chemical 0 0.9853478
. O 0 0.0034230095

Cimetidine B-Chemical 0 0.99950504
clearance O 0 0.07690458
decreased O 0 0.010699602
with O 0 0.007384089
age O 0 0.011477169
. O 0 0.011994431

The O 0 0.0022079716
extrapolated O 0 0.0018754043
6 O 0 0.0010715867
- O 0 0.0032439553
hr O 0 0.0013439249
serum O 0 0.0050289747
concentration O 0 0.001013558
of O 0 0.0008915437
cimetidine B-Chemical 0 0.99998796
per O 0 0.00029574835
unit O 0 0.000184888
dose O 0 0.00027295915
, O 0 0.0002445525
after O 0 0.00010941318
intravenous O 0 0.015297344
cimetidine B-Chemical 0 0.9999883
, O 0 0.00072182
increased O 0 0.00038638266
with O 0 0.00035360493
age O 0 0.00064027024
of O 0 0.0005906597
the O 0 0.0007554928
patients O 0 0.002631081
. O 0 0.0026711382

The O 0 0.0020501611
ratio O 0 0.0023056758
of O 0 0.0030981768
cimetidine B-Chemical 0 0.999979
clearance O 0 0.030368842
to O 0 0.0007896692
creatinine B-Chemical 0 0.9920879
clearance O 0 0.0037091218
( O 0 0.00088175444
Rc O 0 0.05463733
) O 0 0.0005128525
averaged O 0 0.00015490332
4 O 0 0.0001403457
. O 0 0.00015502567
8 O 0 0.00018381541
+ O 0 0.00072404393
/ O 0 0.0014539701
- O 0 0.0015739707
2 O 0 0.00029839284
. O 0 0.00023912922
0 O 0 0.00033703732
, O 0 0.00047577042
indicating O 0 0.00030157226
net O 0 0.0012250224
tubular O 0 0.8414242
secretion O 0 0.024790943
for O 0 0.0024892571
cimetidine B-Chemical 0 0.99997044
. O 0 0.0059586056

Rc O 0 0.7237979
seemed O 0 0.0028136815
to O 0 0.0010675756
be O 0 0.0006232342
independent O 0 0.00031416919
of O 0 0.00038363377
age O 0 0.000492188
and O 0 0.00030080843
decreased O 0 0.00040812598
with O 0 0.00025336354
increasing O 0 0.00027894482
serum O 0 0.019406078
concentration O 0 0.0007735069
of O 0 0.0007820335
cimetidine B-Chemical 0 0.99999774
, O 0 0.0008402378
suggesting O 0 0.00013826726
that O 0 0.00017088141
secretion O 0 0.002377282
of O 0 0.0016505764
cimetidine B-Chemical 0 0.9999958
is O 0 0.0008227865
a O 0 0.0016020357
saturable O 0 0.054415043
process O 0 0.0018545451
. O 0 0.0029050093

There O 0 0.003580297
was O 0 0.0018881309
only O 0 0.0012649344
one O 0 0.0007748706
case O 0 0.00081593415
of O 0 0.0013057882
dementia B-Disease 0 0.9999713
possibly O 0 0.00093162095
due O 0 0.00026194495
to O 0 0.00043086254
cimetidine B-Chemical 0 0.99999547
( O 0 0.00083725905
with O 0 0.00021432032
a O 0 0.0002972868
drug O 0 0.0024292597
level O 0 0.0001246693
of O 0 0.00016493391
1 O 0 0.00016637349
. O 0 0.000116483
9 O 0 0.00012079607
microgram O 0 0.0030628094
/ O 0 0.00071552175
ml O 0 0.0004112651
6 O 0 7.021375e-05
hr O 0 0.00011480939
after O 0 4.6245255e-05
a O 0 0.00012895682
dose O 0 0.0002089006
) O 0 0.00026138863
in O 0 9.619025e-05
a O 0 0.0001523209
group O 0 0.0001566017
of O 0 0.00012158768
13 O 0 0.00013834838
patients O 0 0.00021911402
without O 0 0.00012724065
liver B-Disease 0 0.048231248
or I-Disease 0 0.00016719152
kidney I-Disease 0 0.23773977
disease I-Disease 0 0.65210235
who O 0 0.00041588867
had O 0 0.0003410979
cimetidine B-Chemical 0 0.9999943
levels O 0 0.00025930483
above O 0 0.00027937657
1 O 0 0.0003511131
. O 0 0.0003426813
25 O 0 0.00072391867
microgram O 0 0.013183836
/ O 0 0.0043948293
ml O 0 0.005253257
. O 0 0.0031034152

Thus O 0 0.002946825
, O 0 0.005629897
high O 0 0.0060886038
cimetidine B-Chemical 0 0.9999721
levels O 0 0.0018375367
alone O 0 0.0015006898
do O 0 0.0011211878
not O 0 0.001132928
always O 0 0.0020361326
induce O 0 0.002376667
dementia B-Disease 0 0.9998067
. O 0 0.0076650837

Further O 0 0.0026860212
observations O 0 0.002116952
on O 0 0.0010671578
the O 0 0.00096865307
electrophysiologic O 0 0.00248941
effects O 0 0.00091286417
of O 0 0.0014884509
oral O 0 0.016012888
amiodarone B-Chemical 0 0.9997178
therapy O 0 0.004461121
. O 0 0.0038304469

A O 0 0.030799171
case O 0 0.0027507974
is O 0 0.0011346953
presented O 0 0.0007784672
of O 0 0.00073440553
a O 0 0.0009139262
reversible O 0 0.0017632557
intra B-Disease 0 0.0021362384
- I-Disease 0 0.0028900907
Hisian I-Disease 0 0.0011303384
block I-Disease 0 0.00018005425
occurring O 0 0.00017344869
under O 0 0.00018039347
amiodarone B-Chemical 0 0.99986625
treatment O 0 0.00018033742
for O 0 0.0001416775
atrial B-Disease 0 0.88886815
tachycardia I-Disease 2 0.99987364
in O 0 0.0002177318
a O 0 0.0002931237
patient O 0 0.00023860495
without O 0 0.00023807249
clear O 0 0.00036652558
intraventricular B-Disease 0 0.97026247
conduction I-Disease 0 0.019590346
abnormalities I-Disease 0 0.21298994
. O 0 0.0025192914

His O 0 0.0043359464
bundle O 0 0.0036745456
recordings O 0 0.0013529601
showed O 0 0.0008342591
an O 0 0.00094742724
atrial B-Disease 0 0.85451406
tachycardia I-Disease 2 0.99975735
with O 0 0.0005443292
intermittent O 0 0.0008635
exit O 0 0.0003502751
block O 0 0.0002007326
and O 0 0.00022505663
greatly O 0 0.00037946107
prolonged O 0 0.00050272327
BH O 0 0.06937515
and O 0 0.00028655885
HV O 0 0.01228968
intervals O 0 0.00019966591
( O 0 0.00032217285
40 O 0 0.00022277184
and O 0 0.0002627053
100 O 0 0.000645624
msec O 0 0.0017736405
, O 0 0.001304652
respectively O 0 0.0019060966
) O 0 0.003782312
. O 0 0.003523239

Thirty O 0 0.0041088504
days O 0 0.0011266426
after O 0 0.0009359194
amiodarone B-Chemical 0 0.99949527
discontinuation O 0 0.010963371
, O 0 0.00090602954
His O 0 0.0004899767
bundle O 0 0.0007537316
electrograms O 0 0.0012585027
showed O 0 0.0002705785
atrial B-Disease 0 0.0052613816
flutter I-Disease 0 0.010505515
without O 0 0.00028964374
intra O 0 0.0011887272
- O 0 0.002089672
Hisian O 0 0.0015751566
or O 0 0.00043916714
infra O 0 0.001994369
- O 0 0.0037482362
Hisian O 0 0.004569164
delay O 0 0.0031001905
. O 0 0.003562922

Amiodarone B-Chemical 1 0.9995639
should O 0 0.0013229864
be O 0 0.00086717657
used O 0 0.0005038046
with O 0 0.00047159113
caution O 0 0.00044153378
during O 0 0.00020149001
long O 0 0.00027731646
- O 0 0.00091493357
term O 0 0.00023105637
oral O 0 0.0006592919
therapy O 0 0.00025680338
in O 0 0.00015834333
patients O 0 0.0003507297
with O 0 0.0002247204
or O 0 0.00022705572
without O 0 0.00033634735
clear O 0 0.00044980162
intraventricular O 0 0.78618824
conduction O 0 0.008420738
defects O 0 0.0030988043
. O 0 0.0027153392

Development O 0 0.0073181386
of O 0 0.0036141323
clear B-Disease 0 0.00283285
cell I-Disease 0 0.0053325365
adenocarcinoma I-Disease 0 0.9990594
in O 0 0.003233322
DES B-Chemical 0 0.9986817
- O 0 0.012414568
exposed O 0 0.001417028
offspring O 0 0.002318102
under O 0 0.0013906644
observation O 0 0.002006858
. O 0 0.0040510623

Two O 0 0.0031318422
cases O 0 0.0036837799
of O 0 0.0018516626
clear B-Disease 0 0.0014898437
cell I-Disease 0 0.003057228
adenocarcinoma I-Disease 0 0.99945194
of I-Disease 0 0.0008964895
the I-Disease 0 0.00041830252
vagina I-Disease 0 0.0016559118
detected O 0 0.00015689468
at O 0 0.00014161039
follow O 0 0.00014961854
- O 0 0.00087361323
up O 0 0.00021311277
in O 0 0.00019635409
young O 0 0.0009046071
women O 0 0.0008131601
exposed O 0 0.00031736653
in O 0 0.00029512536
utero O 0 0.0006935899
to O 0 0.00062720175
diethylstilbestrol B-Chemical 0 0.999739
are O 0 0.0010932517
reported O 0 0.0016822658
. O 0 0.0027345184

One O 0 0.0045606312
patient O 0 0.0027867653
, O 0 0.002660222
aged O 0 0.0020990327
23 O 0 0.0013523784
, O 0 0.0011175787
had O 0 0.000487872
been O 0 0.0003238212
followed O 0 0.00020977504
for O 0 0.00016911878
2 O 0 0.0002192517
years O 0 0.0002188071
before O 0 0.0001326762
carcinoma B-Disease 0 0.9299316
was O 0 0.00025936269
diagnosed O 0 0.001361457
; O 0 0.00032339792
the O 0 0.00010582147
second O 0 0.00011721808
patient O 0 0.00018167948
, O 0 0.00026706926
aged O 0 0.0003347515
22 O 0 0.00024962207
, O 0 0.0002753652
had O 0 0.00015506987
been O 0 0.00014507887
seen O 0 0.00016120572
on O 0 0.000107708125
a O 0 0.00022714771
regular O 0 0.00016162115
basis O 0 0.00016365403
for O 0 0.00018072732
5 O 0 0.00027605364
years O 0 0.0004304147
, O 0 0.0007329282
8 O 0 0.0006074894
months O 0 0.0006159648
. O 0 0.0021417802

In O 0 0.0019376
both O 0 0.0015545157
instances O 0 0.001225624
, O 0 0.0018825408
suspicion O 0 0.0026287544
of O 0 0.0006780056
the O 0 0.00039626894
presence O 0 0.00039135866
of O 0 0.0006625749
carcinoma B-Disease 0 0.9976217
was O 0 0.00037631343
aroused O 0 0.0005586061
by O 0 0.0001714958
the O 0 0.00014395617
palpation O 0 0.00039613753
of O 0 0.0002467532
a O 0 0.00042840219
small O 0 0.00068317703
nodule O 0 0.02889094
in O 0 0.0004806769
the O 0 0.00052084855
vaginal O 0 0.0014267911
fornix O 0 0.029426295
. O 0 0.0027700958

Hysterosalpingography O 0 0.005622348
was O 0 0.0014999704
performed O 0 0.00078479864
on O 0 0.00044499178
both O 0 0.00046479263
patients O 0 0.0008541576
and O 0 0.00046310498
, O 0 0.0006544888
in O 0 0.000298117
1 O 0 0.00029016167
instance O 0 0.00022717091
, O 0 0.00039571433
an O 0 0.0002561036
abnormal O 0 0.0008633355
x O 0 0.0017796616
- O 0 0.0034120993
ray O 0 0.0024893803
film O 0 0.00036357116
was O 0 0.00016290454
reflected O 0 0.00015164545
by O 0 0.00013523034
the O 0 0.00013620507
gross O 0 0.00041340062
appearance O 0 0.00024281509
of O 0 0.0001876959
the O 0 0.00018108645
uterine O 0 0.0018636244
cavity O 0 0.00040497998
found O 0 0.0002787513
in O 0 0.00033886405
the O 0 0.0004470897
surgical O 0 0.0011760298
specimen O 0 0.0014723121
. O 0 0.0025639383

Neurologic O 0 0.013365764
effects O 0 0.0016742883
of O 0 0.0017563875
subarachnoid O 0 0.9971818
administration O 0 0.0013602087
of O 0 0.0005453528
2 B-Chemical 0 0.0006070229
- I-Chemical 0 0.0063704364
chloroprocaine I-Chemical 0 0.99944323
- I-Chemical 0 0.012790687
CE I-Chemical 0 0.99622333
, O 0 0.0021936796
bupivacaine B-Chemical 0 0.9999577
, O 0 0.0007096565
and O 0 0.00033091308
low O 0 0.0005956692
pH O 0 0.0075914287
normal O 0 0.0010893621
saline O 0 0.0016711194
in O 0 0.0009226125
dogs O 0 0.00263533
. O 0 0.0028541964

The O 0 0.0015816665
purpose O 0 0.0010338898
of O 0 0.0011603163
this O 0 0.0008355674
study O 0 0.0006194766
was O 0 0.00030261345
to O 0 0.00017482381
evaluate O 0 9.041996e-05
the O 0 0.00016799023
neurologic O 0 0.053824525
consequences O 0 0.00018892225
of O 0 0.00021312883
deliberate O 0 0.0028960593
subarachnoid O 0 0.99886286
injection O 0 0.00012819604
of O 0 0.00012543677
large O 0 0.00018238991
volumes O 0 0.00026221684
of O 0 0.0002182325
2 B-Chemical 0 0.0003475394
- I-Chemical 0 0.006673977
chloroprocaine I-Chemical 0 0.999566
- I-Chemical 0 0.009569007
CE I-Chemical 0 0.97276944
in O 0 0.00058616535
experimental O 0 0.0008423477
animals O 0 0.0010569888
. O 0 0.0027355314

The O 0 0.0017195562
possible O 0 0.0009653216
role O 0 0.0005761426
of O 0 0.00097135536
low O 0 0.0012759974
pH O 0 0.0076220427
as O 0 0.0004881798
well O 0 0.0003390143
as O 0 0.0003187927
total O 0 0.0003202781
volume O 0 0.0004952635
as O 0 0.000245619
potential O 0 0.00023001034
factors O 0 0.00064623804
in O 0 0.00051878864
causing O 0 0.0014021491
neurotoxicity B-Disease 0 0.996525
was O 0 0.0011700914
evaluated O 0 0.0015449808
. O 0 0.002774247

The O 0 0.0021959215
65 O 0 0.0022971095
dogs O 0 0.0018518418
in O 0 0.0006628531
the O 0 0.00041322171
study O 0 0.00039271166
received O 0 0.0002648775
injections O 0 0.00024168633
in O 0 0.00019503097
the O 0 0.00022514032
subarachnoid O 0 0.99611205
space O 0 0.00031967624
as O 0 0.00015017424
follows O 0 0.00016208428
: O 0 0.0002793739
6 O 0 9.0793124e-05
to O 0 9.020087e-05
8 O 0 0.00012535018
ml O 0 0.00044952446
of O 0 0.00033542828
bupivacaine B-Chemical 0 0.9999585
( O 0 0.0009797567
N O 0 0.9867754
= O 0 0.0009581078
15 O 0 0.00018479496
) O 0 0.0003660388
, O 0 0.00033155223
2 B-Chemical 0 0.0002989253
- I-Chemical 0 0.0042876233
chloroprocaine I-Chemical 0 0.99957865
- I-Chemical 0 0.011208857
CE I-Chemical 0 0.99541855
( O 0 0.0011566927
N O 0 0.9927254
= O 0 0.0012497689
20 O 0 0.00022740518
) O 0 0.0004108321
, O 0 0.00032200458
low O 0 0.0003305533
pH O 0 0.0054014153
normal O 0 0.0005293488
saline O 0 0.0009852285
( O 0 0.0004997115
pH O 0 0.0018915354
3 O 0 0.00017110739
. O 0 0.00016764905
0 O 0 0.00025404085
) O 0 0.00051318767
( O 0 0.000636136
N O 0 0.965134
= O 0 0.001265997
20 O 0 0.00030544557
) O 0 0.00054609426
, O 0 0.00043741026
or O 0 0.0002714094
normal O 0 0.00065641286
saline O 0 0.0015400434
( O 0 0.0015250333
N O 0 0.97207546
= O 0 0.003578408
10 O 0 0.0014212616
) O 0 0.00334967
. O 0 0.0033633935

Of O 0 0.0046194238
the O 0 0.0015660445
20 O 0 0.001020512
animals O 0 0.00047146998
that O 0 0.00038961277
received O 0 0.00050518033
subarachnoid O 0 0.9745448
injection O 0 0.00028984126
of O 0 0.000299132
2 B-Chemical 0 0.00040790177
- I-Chemical 0 0.0045985626
chloroprocaine I-Chemical 0 0.9994043
- I-Chemical 0 0.0056400443
CE I-Chemical 0 0.95297074
seven O 0 0.00024785002
( O 0 0.00043728543
35 O 0 0.0003148447
% O 0 0.00057507853
) O 0 0.0007868336
developed O 0 0.00062841794
hind O 0 0.0032169842
- O 0 0.010066091
limb O 0 0.19552831
paralysis B-Disease 0 0.996467
. O 0 0.0045705955

None O 0 0.0032795987
of O 0 0.001576718
the O 0 0.000743896
animals O 0 0.00044793222
that O 0 0.00039540138
received O 0 0.0007137759
bupivacaine B-Chemical 0 0.99992967
, O 0 0.0007709226
normal O 0 0.00047184137
saline O 0 0.00070972415
, O 0 0.0003125023
or O 0 0.00014568481
normal O 0 0.00028992028
saline O 0 0.00048730354
titrated O 0 0.00021270555
to O 0 0.00015199881
a O 0 0.0003502781
pH O 0 0.0023271511
3 O 0 0.000215686
. O 0 0.000217166
0 O 0 0.00033276476
developed O 0 0.00045069674
hind O 0 0.0022964212
- O 0 0.007365836
limb O 0 0.14951447
paralysis B-Disease 0 0.9961707
. O 0 0.0043105436

Of O 0 0.0047167325
the O 0 0.0016946435
15 O 0 0.0011835684
spinal O 0 0.0010068048
cords O 0 0.00096282095
of O 0 0.00040434254
the O 0 0.00023692692
animals O 0 0.00017187004
that O 0 0.0001693447
received O 0 0.00024139225
2 B-Chemical 0 0.00036589737
- I-Chemical 0 0.004801848
chloroprocaine I-Chemical 0 0.9995455
- I-Chemical 0 0.011392768
CE I-Chemical 0 0.99178374
, O 0 0.0006524296
13 O 0 0.0003396372
showed O 0 0.00045394272
subpial B-Disease 0 0.9929624
necrosis I-Disease 2 0.9999906
; O 0 0.0015536929
the O 0 0.00026267025
nerve O 0 0.011151962
roots O 0 0.0010762705
and O 0 0.0006485503
subarachnoid O 0 0.9994191
vessels O 0 0.38838804
were O 0 0.000929554
normal O 0 0.0019424474
. O 0 0.0024034302

The O 0 0.0019375649
spinal O 0 0.002076722
cords O 0 0.0017711434
of O 0 0.0006563059
the O 0 0.00034798816
animals O 0 0.00023701503
that O 0 0.00023766134
received O 0 0.00048679265
bupivacaine B-Chemical 0 0.9999356
, O 0 0.0006530208
low O 0 0.0004274238
pH O 0 0.006324164
normal O 0 0.00053225673
saline O 0 0.00095662934
( O 0 0.00048789917
pH O 0 0.0018520983
3 O 0 0.00015907745
. O 0 0.00015265665
0 O 0 0.00022263447
) O 0 0.00040229785
, O 0 0.0003334825
or O 0 0.00020266575
normal O 0 0.00049188203
saline O 0 0.0009424942
did O 0 0.00036681903
not O 0 0.00035192608
show O 0 0.00046429312
abnormal O 0 0.003093234
findings O 0 0.0020373904
. O 0 0.002928515

Procainamide B-Chemical 0 0.99911684
- O 0 0.068786286
induced O 0 0.008518493
polymorphous O 0 0.61138463
ventricular B-Disease 0 0.9957058
tachycardia I-Disease 2 0.99930096
. O 0 0.014249024

Seven O 0 0.0073377015
cases O 0 0.006159816
of O 0 0.0054647503
procainamide B-Chemical 0 0.9999
- O 0 0.057576615
induced O 0 0.0021059006
polymorphous O 0 0.4645603
ventricular B-Disease 0 0.99722725
tachycardia I-Disease 2 0.99961084
are O 0 0.0016775571
presented O 0 0.0019260949
. O 0 0.0036032146

In O 0 0.001878312
four O 0 0.0013185462
patients O 0 0.002639862
, O 0 0.00259769
polymorphous O 0 0.12137847
ventricular B-Disease 0 0.9943376
tachycardia I-Disease 2 0.99978286
appeared O 0 0.00024958042
after O 0 9.820816e-05
intravenous O 0 0.0005866622
administration O 0 0.0001811246
of O 0 0.00012506008
200 O 0 0.0002068494
to O 0 0.000112107555
400 O 0 0.00051333575
mg O 0 0.0033272153
of O 0 0.00031347477
procainamide B-Chemical 0 0.99991727
for O 0 0.00016048505
the O 0 0.00016204965
treatment O 0 0.00023833437
of O 0 0.00042218497
sustained O 0 0.0016003266
ventricular B-Disease 0 0.99764013
tachycardia I-Disease 2 0.9997482
. O 0 0.003696223

In O 0 0.0016536084
the O 0 0.0011418957
remaining O 0 0.00075781305
three O 0 0.00038519673
patients O 0 0.0012105128
, O 0 0.0017113261
procainamide B-Chemical 0 0.9999013
was O 0 0.00030673106
administered O 0 0.00030970332
orally O 0 0.0003030254
for O 0 0.000102360544
treatment O 0 0.00014548739
of O 0 0.00021835884
chronic O 0 0.0055329157
premature B-Disease 0 0.0051649413
ventricular I-Disease 0 0.69995534
contractions I-Disease 0 0.08035494
or O 0 0.0006269606
atrial B-Disease 0 0.073792614
flutter I-Disease 0 0.12678435
. O 0 0.0025072286

These O 0 0.0031701305
patients O 0 0.0048214784
had O 0 0.002839512
Q B-Disease 0 0.41769615
- I-Disease 0 0.013841305
T I-Disease 0 0.009810493
prolongation I-Disease 0 0.002922098
and O 0 0.0010441352
recurrent O 0 0.019357428
syncope B-Disease 0 0.999653
due O 0 0.0005846861
to O 0 0.0008574348
polymorphous O 0 0.23892643
ventricular B-Disease 0 0.9966273
tachycardia I-Disease 2 0.9995963
. O 0 0.004699012

In O 0 0.0018848034
four O 0 0.0012968582
patients O 0 0.0023006706
, O 0 0.0017182635
the O 0 0.000839122
arrhythmia B-Disease 0 0.9931156
was O 0 0.0005392002
rapidly O 0 0.00048594427
diagnosed O 0 0.0014871167
and O 0 0.00028959793
treated O 0 0.0005066318
with O 0 0.00033160025
disappearance O 0 0.0006690188
of O 0 0.00031437082
further O 0 0.00030793267
episodes O 0 0.0010444154
of O 0 0.0007192865
the O 0 0.0011148581
arrhythmia B-Disease 0 0.9963839
. O 0 0.003588627

In O 0 0.001962971
two O 0 0.00145948
patients O 0 0.0025827016
, O 0 0.001960913
the O 0 0.0010053641
arrhythmia B-Disease 0 0.9963761
degenerated O 0 0.0019925532
into O 0 0.00036355265
irreversible O 0 0.002937744
ventricular B-Disease 0 0.6108508
fibrillation I-Disease 0 0.9982969
and O 0 0.00063382543
both O 0 0.0006200124
patients O 0 0.001987309
died O 0 0.0031930765
. O 0 0.0029371602

In O 0 0.0021293133
the O 0 0.0017098399
seventh O 0 0.0020994213
patient O 0 0.0014053356
, O 0 0.0013835317
a O 0 0.0008971923
permanent O 0 0.0016344402
ventricular O 0 0.08952485
pacemaker O 0 0.0005104958
was O 0 0.00015064696
inserted O 0 0.00014221852
and O 0 0.00016285128
, O 0 0.0002552115
despite O 0 0.00013922127
continuation O 0 0.00048288127
of O 0 0.0004832229
procainamide B-Chemical 0 0.99996793
therapy O 0 0.000930395
, O 0 0.0008785475
polymorphous O 0 0.24380961
ventricular B-Disease 0 0.9982558
tachycardia I-Disease 2 0.9998754
did O 0 0.001075797
not O 0 0.0010159425
reoccur O 0 0.0036194576
. O 0 0.0024586618

These O 0 0.0021005934
seven O 0 0.0015210927
cases O 0 0.0017949509
demonstrate O 0 0.00055963575
that O 0 0.0010691986
procainamide B-Chemical 0 0.9999118
can O 0 0.00045280528
produce O 0 0.00028539027
an O 0 0.00039319304
acquired O 0 0.00067224103
prolonged B-Disease 0 0.0007779481
Q I-Disease 0 0.47240055
- I-Disease 0 0.014086946
T I-Disease 0 0.051709663
syndrome I-Disease 0 0.9442033
with O 0 0.0013709142
polymorphous O 0 0.66362023
ventricular B-Disease 0 0.9982639
tachycardia I-Disease 2 0.9997137
. O 0 0.004019272

Phenobarbitone B-Chemical 0 0.9999242
- O 0 0.076219045
induced O 0 0.0018036024
enlargement B-Disease 0 0.010511783
of I-Disease 0 0.00088135124
the I-Disease 0 0.00057254115
liver I-Disease 0 0.026342483
in O 0 0.00036636315
the O 0 0.00026263113
rat O 0 0.00045867392
: O 0 0.0005415572
its O 0 0.00031093374
relationship O 0 0.00022367104
to O 0 0.0005739563
carbon B-Chemical 0 0.997943
tetrachloride I-Chemical 0 0.99999464
- O 0 0.38596788
induced O 0 0.0027440023
cirrhosis B-Disease 0 0.999933
. O 0 0.006099837

The O 0 0.0023205932
yield O 0 0.0024351256
of O 0 0.0019186749
severe O 0 0.04200944
cirrhosis B-Disease 0 0.9999515
of I-Disease 0 0.0010233057
the I-Disease 0 0.00047186343
liver I-Disease 0 0.07847029
( O 0 0.00058657
defined O 0 0.00018120788
as O 0 0.0001998846
a O 0 0.00040780343
shrunken O 0 0.00588258
finely O 0 0.00051398907
nodular O 0 0.9378139
liver O 0 0.17757207
with O 0 0.00038897095
micronodular O 0 0.997584
histology O 0 0.0076168766
, O 0 0.000466418
ascites B-Disease 0 0.97848207
greater O 0 0.00016641793
than O 0 8.872512e-05
30 O 0 9.531734e-05
ml O 0 0.00044639685
, O 0 0.00036085775
plasma O 0 0.022350607
albumin O 0 0.9805635
less O 0 0.0002090654
than O 0 9.970683e-05
2 O 0 0.00011636455
. O 0 9.436961e-05
2 O 0 0.00012169764
g O 0 0.0004283895
/ O 0 0.0010262039
dl O 0 0.004246266
, O 0 0.00065245293
splenomegaly B-Disease 0 0.99171937
2 O 0 0.00022236163
- O 0 0.0005587113
3 O 0 7.5307136e-05
times O 0 6.1234416e-05
normal O 0 0.00020289951
, O 0 0.00026053918
and O 0 0.00022476004
testicular O 0 0.58685374
atrophy B-Disease 2 0.9992901
approximately O 0 0.0001689486
half O 0 6.840617e-05
normal O 0 0.00014051014
weight O 0 0.00014270974
) O 0 0.00016379531
after O 0 3.5912537e-05
12 O 0 4.84178e-05
doses O 0 0.00015289147
of O 0 0.00019508379
carbon B-Chemical 0 0.99702054
tetrachloride I-Chemical 0 0.9999976
given O 0 0.00014571492
intragastrically O 0 0.0012518209
in O 0 0.00010461188
the O 0 0.00017563785
phenobarbitone B-Chemical 0 0.99999833
- O 0 0.0128652435
primed O 0 0.00013608018
rat O 0 0.00019489489
was O 0 9.6747615e-05
increased O 0 0.00014474902
from O 0 9.854908e-05
25 O 0 0.00015847609
% O 0 0.00020012028
to O 0 8.8432265e-05
56 O 0 0.0001605599
% O 0 0.00019524549
by O 0 8.940413e-05
giving O 0 0.00010674139
the O 0 8.022176e-05
initial O 0 8.783799e-05
" O 0 0.00018470001
calibrating O 0 0.00010269373
" O 0 0.00023622654
dose O 0 0.0002868404
of O 0 0.00031805714
carbon B-Chemical 0 0.99840957
tetrachloride I-Chemical 0 0.99999666
at O 0 0.00018230661
the O 0 0.000118689
peak O 0 0.0001723979
of O 0 0.00018811732
the O 0 0.00035408832
phenobarbitone B-Chemical 0 0.9999976
- O 0 0.04198632
induced O 0 0.00044913366
enlargement B-Disease 0 0.01730483
of I-Disease 0 0.00077362556
the I-Disease 0 0.0009315055
liver I-Disease 0 0.1922498
. O 0 0.0033207654

At O 0 0.001486078
this O 0 0.0018672958
point O 0 0.0011600791
it O 0 0.001500622
was O 0 0.00079528836
assumed O 0 0.0006561758
that O 0 0.000532783
the O 0 0.0010522908
cytochrome O 0 0.9996376
P450 O 0 0.99995923
/ O 0 0.9594544
CCl4 B-Chemical 0 0.9999964
toxic O 0 0.4423164
state O 0 0.0005084368
was O 0 0.00031644324
both O 0 0.00034535822
maximal O 0 0.000765584
and O 0 0.00091469125
stable O 0 0.0016498859
. O 0 0.0029174497

The O 0 0.0016558052
optimal O 0 0.0008885243
rat O 0 0.0015781724
size O 0 0.0012151545
to O 0 0.0006160399
begin O 0 0.0011393738
phenobarbitone B-Chemical 0 0.99999166
was O 0 0.00043113102
determined O 0 0.00021378131
as O 0 0.00022201083
100 O 0 0.00047589128
g O 0 0.00086594303
, O 0 0.00033203652
and O 0 0.00016633034
this O 0 0.00015959948
size O 0 0.000253753
as O 0 0.00014347039
a O 0 0.00020008557
group O 0 0.00019147711
had O 0 0.00010847841
a O 0 0.00013065289
mean O 0 7.314518e-05
maximum O 0 0.0001041422
relative O 0 8.266962e-05
liver O 0 0.005038953
weight O 0 0.00022543955
increase O 0 0.00011151752
47 O 0 0.00019446366
% O 0 0.00020191581
greater O 0 0.00014892181
than O 0 0.0001222522
normal O 0 0.00025721284
rats O 0 0.00028878398
of O 0 0.00025205425
the O 0 0.0002509656
same O 0 0.0003207233
body O 0 0.0011245474
weight O 0 0.001948215
. O 0 0.0025081327

The O 0 0.0015096024
optimal O 0 0.0007108576
time O 0 0.00063695316
for O 0 0.0005054643
the O 0 0.00042866505
initial O 0 0.0003881175
dose O 0 0.00080789684
of O 0 0.00084406865
carbon B-Chemical 0 0.9968631
tetrachloride I-Chemical 0 0.99998975
was O 0 0.00061445666
after O 0 0.00021759835
14 O 0 0.00033048965
days O 0 0.00033320888
on O 0 0.0009469403
phenobarbitone B-Chemical 0 0.9999167
. O 0 0.0055146534

Triamterene B-Chemical 0 0.9980584
nephrolithiasis B-Disease 0 0.9995864
complicating O 0 0.7830878
dyazide B-Chemical 0 0.9307221
therapy O 0 0.014113851
. O 0 0.01135289

A O 0 0.03317894
case O 0 0.0039383224
of O 0 0.0076555656
triamterene B-Chemical 0 0.99999917
nephrolithiasis B-Disease 0 0.9999832
is O 0 0.00093521865
reported O 0 0.00056228426
in O 0 0.00032857456
a O 0 0.00048904214
man O 0 0.0012332504
after O 0 0.000106458196
4 O 0 0.00013958335
years O 0 0.00024043395
of O 0 0.0005042696
hydrochlorothiazide B-Chemical 0 0.999998
- I-Chemical 0 0.8677678
triamterene I-Chemical 0 0.9999994
therapy O 0 0.0038205981
for O 0 0.0012038756
hypertension B-Disease 2 0.9999031
. O 0 0.004482661

The O 0 0.0029074205
stone O 0 0.060851265
passed O 0 0.0025797968
spontaneously O 0 0.0027815674
and O 0 0.0008392035
was O 0 0.00050809287
found O 0 0.00040313767
to O 0 0.0003327146
contain O 0 0.00030391593
a O 0 0.002610093
triamterene B-Chemical 0 0.9999994
metabolite O 0 0.9985921
admixed O 0 0.62090796
with O 0 0.03086952
uric B-Chemical 0 0.99999535
acid I-Chemical 0 0.9991629
salts I-Chemical 0 0.99922216
. O 0 0.008144461

Factors O 0 0.029194439
affecting O 0 0.019804506
triamterene B-Chemical 0 0.99999785
nephrolithiasis B-Disease 0 0.99995756
are O 0 0.0011825394
discussed O 0 0.0006671036
and O 0 0.0006399012
2 O 0 0.000652563
previously O 0 0.00064791454
reported O 0 0.0008385369
cases O 0 0.001514462
are O 0 0.0011737418
reviewed O 0 0.0033877299
. O 0 0.0040060002

Busulfan B-Chemical 0 0.99671555
- O 0 0.071914196
induced O 0 0.015026896
hemorrhagic B-Disease 2 0.9987331
cystitis I-Disease 0 0.99831223
. O 0 0.0188619

A O 0 0.026407834
case O 0 0.0037521594
of O 0 0.002729832
a O 0 0.0043422086
busulfan B-Chemical 0 0.9994618
- O 0 0.03192175
induced O 0 0.0028214897
hemorrhage B-Disease 2 0.9999018
cystitis I-Disease 0 0.99932396
is O 0 0.0020269512
reported O 0 0.0028239782
. O 0 0.004256555

Spontaneous O 0 0.0076290946
resolution O 0 0.0046253675
occurred O 0 0.0019933025
following O 0 0.0010727746
cessation O 0 0.001619844
of O 0 0.0020149383
the O 0 0.0024698372
drug O 0 0.020342357
. O 0 0.006455702

The O 0 0.001714107
similarity O 0 0.0011976035
between O 0 0.0007794189
the O 0 0.00067977613
histologic O 0 0.0017468502
appearances O 0 0.0011145385
of O 0 0.0008089369
busulfan B-Chemical 0 0.999861
cystitis B-Disease 0 0.9990865
and O 0 0.00027267018
both O 0 0.00017003331
radiation O 0 0.00077485474
and O 0 0.000303041
cyclophosphamide B-Chemical 0 0.9998722
- O 0 0.0042401915
induced O 0 0.00033102822
cystitis B-Disease 0 0.9988372
is O 0 0.00023730788
discussed O 0 0.0002329108
and O 0 0.00032427258
the O 0 0.00038583606
world O 0 0.001522041
literature O 0 0.002108057
reviewed O 0 0.0032348514
. O 0 0.0032054512

In O 0 0.0017940634
view O 0 0.0019046166
of O 0 0.0013545725
the O 0 0.00078216696
known O 0 0.00063436845
tendency O 0 0.0010671422
of O 0 0.0008137604
busulfan B-Chemical 0 0.99970335
to O 0 0.0002672659
induce O 0 0.00018163721
cellular O 0 0.0006055916
atypia O 0 0.19196029
and O 0 0.0004510971
carcinoma B-Disease 0 0.9962004
in O 0 0.00015468591
other O 0 0.000105502884
sites O 0 0.0001036668
, O 0 0.00033673458
periodic O 0 0.00035457712
urinary O 0 0.007323403
cytology O 0 0.00019788399
is O 0 0.00010430877
suggested O 0 0.00011637598
in O 0 0.00017141113
patients O 0 0.00038745065
on O 0 0.0001838999
long O 0 0.00043642108
- O 0 0.0019566854
term O 0 0.0009674551
therapy O 0 0.0018985241
. O 0 0.0025659108

Variant O 0 0.1046766
ventricular B-Disease 0 0.9930829
tachycardia I-Disease 2 0.99958414
in O 0 0.021953518
desipramine B-Chemical 0 0.9999839
toxicity B-Disease 0 0.99160635
. O 0 0.011446215

We O 0 0.0034810165
report O 0 0.0038396977
a O 0 0.0024227544
case O 0 0.0013750545
of O 0 0.0011570222
variant O 0 0.0012213954
ventricular B-Disease 0 0.9968299
tachycardia I-Disease 2 0.999856
induced O 0 0.001875538
by O 0 0.0033557664
desipramine B-Chemical 0 0.9999958
toxicity B-Disease 0 0.9934623
. O 0 0.005169762

Unusual O 0 0.009367963
features O 0 0.0026483396
of O 0 0.0015521669
the O 0 0.0010850048
arrhythmia B-Disease 0 0.9811808
are O 0 0.00041392804
repetitive O 0 0.00032428806
group O 0 0.00045667877
beating O 0 0.00094151514
, O 0 0.0006060679
progressive O 0 0.0014911487
shortening O 0 0.0010397964
of O 0 0.00028809402
the O 0 0.00032373692
R O 0 0.9962921
- O 0 0.058261655
R O 0 0.9702327
interval O 0 0.0002990653
, O 0 0.00034521517
progressive O 0 0.0009265587
widening O 0 0.0005117206
of O 0 0.00016228593
the O 0 0.00014545326
QRS O 0 0.116922796
complex O 0 0.00015193607
with O 0 0.00015490848
eventual O 0 0.00045766655
failure O 0 0.0051735686
of O 0 0.0002365572
intraventricular O 0 0.77249014
conduction O 0 0.0019109324
, O 0 0.00026580825
and O 0 0.00016404525
changes O 0 0.00019600784
in O 0 0.00020630303
direction O 0 0.0004452144
of O 0 0.0005614678
the O 0 0.00074025226
QRS O 0 0.32832167
axis O 0 0.0038736276
. O 0 0.003254777

Recognition O 0 0.006088581
of O 0 0.002479777
variant O 0 0.0019108516
ventricular B-Disease 0 0.9936427
tachycardia I-Disease 2 0.9997818
is O 0 0.0005320391
important O 0 0.00024995906
because O 0 0.00023067008
therapy O 0 0.0003956095
differs O 0 0.00019948551
from O 0 0.00027443923
that O 0 0.000327274
of O 0 0.0008284414
classic O 0 0.013381828
ventricular B-Disease 0 0.99837327
tachycardia I-Disease 2 0.999762
. O 0 0.005055751

Rebound O 0 0.71109974
hypertensive B-Disease 0 0.99901485
after O 0 0.003593857
sodium B-Chemical 1 0.9997441
nitroprusside I-Chemical 1 0.99998987
prevented O 0 0.008174593
by O 0 0.003256982
saralasin B-Chemical 0 0.9998869
in O 0 0.0030080958
rats O 0 0.0046829423
. O 0 0.0048614577

The O 0 0.0016087727
role O 0 0.000877684
of O 0 0.001380743
the O 0 0.0013166643
renin O 0 0.9948236
- O 0 0.22776207
- O 0 0.15701045
angiotensin B-Chemical 0 0.999938
system O 0 0.00047529876
in O 0 0.00020476349
the O 0 0.00013126904
maintenance O 0 0.00016237386
of O 0 0.00016776322
blood O 0 0.0014813195
pressure O 0 0.0032301913
during O 0 0.00018094802
halothane B-Chemical 0 0.99992096
anesthesia O 0 0.01490154
and O 0 0.00038609453
sodium B-Chemical 1 0.99991107
nitroprusside I-Chemical 1 0.99999833
( O 0 0.0017733349
SNP B-Chemical 0 0.03982259
) O 0 0.0013102699
- O 0 0.0025788476
induced O 0 0.00072378
hypotension B-Disease 0 0.99975854
was O 0 0.0010506541
evaluated O 0 0.0014195456
. O 0 0.0026454167

Control O 0 0.0047991145
rats O 0 0.0029813587
received O 0 0.0021483563
halothane B-Chemical 0 0.9996246
anesthesia O 0 0.024495259
( O 0 0.0011590554
1 O 0 0.00056358654
MAC O 0 0.009747195
) O 0 0.000554722
for O 0 0.0001530715
one O 0 0.00016254178
hour O 0 0.00020809211
, O 0 0.0002760584
followed O 0 0.00013258349
by O 0 0.00018423478
SNP B-Chemical 0 0.0025882965
infusion O 0 0.0005768995
, O 0 0.00029937795
40 O 0 0.00021543854
microgram O 0 0.0028193695
/ O 0 0.0007183795
kg O 0 0.0004893879
/ O 0 0.00072177325
min O 0 0.0003006757
, O 0 0.00025036285
for O 0 0.000113530725
30 O 0 0.00014366809
min O 0 0.000248465
, O 0 0.00028594126
followed O 0 0.00015125916
by O 0 0.00021925087
a O 0 0.00042943927
30 O 0 0.00035471335
- O 0 0.0012662067
min O 0 0.0007515122
recovery O 0 0.0009089329
period O 0 0.00092368736
. O 0 0.0024601652

A O 0 0.01897896
second O 0 0.0018560217
group O 0 0.0015977237
of O 0 0.00084572996
rats O 0 0.00092755776
was O 0 0.00040621922
treated O 0 0.00057404983
identically O 0 0.00028976833
and O 0 0.000260416
, O 0 0.00034542437
in O 0 0.0001401304
addition O 0 8.6459244e-05
, O 0 0.00023902275
received O 0 0.00012149658
an O 0 0.00013709451
infusion O 0 0.00041476858
of O 0 0.0002892163
saralasin B-Chemical 0 0.9999871
( O 0 0.0007495774
a O 0 0.00031372768
competitive O 0 0.0004275216
inhibitor O 0 0.0015308637
of O 0 0.0012685419
angiotensin B-Chemical 1 0.99999654
II I-Chemical 1 0.9908565
) O 0 0.0017342838
throughout O 0 0.00026375384
the O 0 0.00034422925
experimental O 0 0.00067947037
period O 0 0.000941935
. O 0 0.002420968

In O 0 0.001947655
each O 0 0.0013352742
group O 0 0.0018374634
, O 0 0.0021164687
SNP B-Chemical 0 0.011552431
infusion O 0 0.0015670575
resulted O 0 0.00031122228
in O 0 0.00024318718
an O 0 0.00022332478
initial O 0 0.00014710051
decrease O 0 0.0001922011
in O 0 0.00017710715
blood O 0 0.0013881397
pressure O 0 0.0021701234
from O 0 0.0001834603
86 O 0 0.0003917586
torr O 0 0.021582028
and O 0 0.00029527477
83 O 0 0.0006348384
torr O 0 0.07052434
, O 0 0.0007819713
respectively O 0 0.00081373437
, O 0 0.00097489706
to O 0 0.00072040496
48 O 0 0.0014694296
torr O 0 0.114778
. O 0 0.0038883237

During O 0 0.002064683
the O 0 0.0017584118
SNP B-Chemical 0 0.009560283
infusion O 0 0.0016885945
the O 0 0.00035012153
control O 0 0.00029425885
animals O 0 0.000187765
demonstrated O 0 0.00020984586
a O 0 0.0003782645
progressive O 0 0.0012445244
increase B-Disease 0 0.0001646619
in I-Disease 0 0.00015551884
blood I-Disease 0 0.00128605
pressure I-Disease 0 0.0019047299
to O 0 0.00013430124
61 O 0 0.0002763549
torr O 0 0.07559764
, O 0 0.00034006473
whereas O 0 0.00019246463
the O 0 0.00028375673
saralasin B-Chemical 0 0.999982
- O 0 0.009996752
treated O 0 0.000566127
animals O 0 0.00025721136
showed O 0 0.0004520639
no O 0 0.000752575
change O 0 0.0015025666
. O 0 0.0027825492

Following O 0 0.002251539
discontinuation O 0 0.0073411786
of O 0 0.0017177542
SNP B-Chemical 0 0.022526728
, O 0 0.0015007005
blood O 0 0.004022727
pressure O 0 0.004649906
in O 0 0.00026931657
the O 0 0.00017178599
control O 0 0.00019557061
animals O 0 0.00017465022
rebounded O 0 0.0009729091
to O 0 0.00017687613
94 O 0 0.00037110425
torr O 0 0.069172025
, O 0 0.00034597807
as O 0 0.00015111655
compared O 0 0.00012181896
with O 0 0.00022813551
78 O 0 0.00058094435
torr O 0 0.10749941
in O 0 0.00034552123
the O 0 0.00051345414
saralasin B-Chemical 0 0.9999552
- O 0 0.0147280805
treated O 0 0.0019933823
rats O 0 0.0027066574
. O 0 0.0030552011

This O 0 0.0043184175
study O 0 0.0018813602
indicates O 0 0.0007014645
that O 0 0.0005337335
with O 0 0.0006558988
stable O 0 0.000866738
halothane B-Chemical 0 0.99991655
anesthesia O 0 0.018552627
, O 0 0.00035410837
the O 0 0.00011615569
partial O 0 0.0001737642
recovery O 0 0.00016222343
of O 0 0.00013715426
blood O 0 0.0011878647
pressure O 0 0.0019798551
during O 0 0.00011077056
SNP B-Chemical 0 0.0021306938
infusion O 0 0.0003211688
and O 0 9.869767e-05
the O 0 8.499871e-05
post O 0 0.00012855153
- O 0 0.0014199086
SNP B-Chemical 0 0.0064165257
rebound O 0 0.0008209906
of O 0 0.0002316259
blood O 0 0.006800713
pressure O 0 0.018308947
can O 0 0.00021641399
be O 0 0.00030729125
completely O 0 0.0004646832
blocked O 0 0.0015067516
by O 0 0.0021357099
saralasin B-Chemical 0 0.9999305
. O 0 0.0054452266

This O 0 0.0035833688
demonstrates O 0 0.00094847305
the O 0 0.00078235735
participation O 0 0.0007512104
of O 0 0.0006752602
the O 0 0.0006786033
renin O 0 0.99465936
- O 0 0.16190308
- O 0 0.10756468
angiotensin B-Chemical 0 0.999948
system O 0 0.00044303256
in O 0 0.00023612252
antagonizing O 0 0.00033297038
the O 0 0.00021086073
combined O 0 0.00047207842
hypotensive B-Disease 0 0.99106103
effects O 0 0.0005132863
of O 0 0.0013256257
halothane B-Chemical 0 0.99993503
and O 0 0.0026506635
SNP B-Chemical 0 0.17738882
. O 0 0.003288123

Clinical O 0 0.028927779
nephrotoxicity B-Disease 0 0.9991423
of O 0 0.013088906
tobramycin B-Chemical 0 0.999767
and O 0 0.012692724
gentamicin B-Chemical 0 0.9993556
. O 0 0.011577209

A O 0 0.08467704
prospective O 0 0.046139475
study O 0 0.02548326
. O 0 0.027163839

Nearly O 0 0.007092586
3 O 0 0.0023381684
. O 0 0.0016693899
2 O 0 0.0012775704
million O 0 0.0014115961
people O 0 0.0017319113
in O 0 0.00072482537
this O 0 0.00077307253
country O 0 0.0011950225
receive O 0 0.0010934388
aminoglycoside B-Chemical 0 0.9866194
antibiotics O 0 0.10396222
annually O 0 0.0037406036
. O 0 0.003870295

Gentamicin B-Chemical 0 0.99990344
sulfate I-Chemical 0 0.9994628
and O 0 0.013387564
tobramycin B-Chemical 0 0.9999901
sulfate I-Chemical 0 0.9997067
continue O 0 0.0007901016
to O 0 0.00034215246
demonstrate O 0 0.0002526471
ototoxicity B-Disease 0 0.9999037
and O 0 0.00093810615
nephrotoxicity B-Disease 0 0.9999552
in O 0 0.00036729756
both O 0 0.00027253578
animal O 0 0.0004314402
and O 0 0.0006173842
clinical O 0 0.0020954951
studies O 0 0.0017606331
. O 0 0.0027633905

In O 0 0.0021835258
this O 0 0.0020316415
study O 0 0.0016054598
, O 0 0.0016251752
62 O 0 0.0011253791
patients O 0 0.0007776176
with O 0 0.00031879728
confirmed O 0 0.00019496793
initial O 0 0.0001908461
normal O 0 0.0004540871
renal O 0 0.18133679
function O 0 0.00013707753
and O 0 0.00015557953
treated O 0 0.0002713364
with O 0 0.00014570772
2 O 0 0.00012332023
to O 0 7.6706696e-05
5 O 0 9.7661854e-05
mg O 0 0.0006595703
/ O 0 0.00036463715
kg O 0 0.00028621207
/ O 0 0.00043501722
day O 0 9.45641e-05
of O 0 0.00031358236
gentamicin B-Chemical 0 0.99999523
sulfate I-Chemical 0 0.9999436
or O 0 0.0009896089
tobramycin B-Chemical 0 0.9999988
sulfate I-Chemical 0 0.99991035
for O 0 0.0001268392
a O 0 0.00014935042
minimum O 0 6.437606e-05
of O 0 7.498954e-05
seven O 0 4.9731178e-05
days O 0 3.6998594e-05
were O 0 4.880088e-05
followed O 0 4.387105e-05
up O 0 6.7111825e-05
prospectively O 0 9.052608e-05
for O 0 4.6913086e-05
the O 0 6.000987e-05
development O 0 0.00012301886
of O 0 0.000194657
aminoglycoside B-Chemical 0 0.9994174
- O 0 0.005134002
related O 0 9.780592e-05
renal B-Disease 0 0.7323486
failure I-Disease 0 0.022180423
, O 0 0.00024575344
defined O 0 9.1010435e-05
as O 0 9.4537594e-05
at O 0 8.0862315e-05
least O 0 0.0001163771
a O 0 0.00022224379
one O 0 0.00018072593
- O 0 0.0010378961
third O 0 0.00026076584
reduction O 0 0.00046649796
in O 0 0.000609053
renal O 0 0.5631199
function O 0 0.0014596448
. O 0 0.002722124

In O 0 0.002321139
these O 0 0.0020964006
62 O 0 0.0026596666
patients O 0 0.0020714123
, O 0 0.0013749184
no O 0 0.0006016461
other O 0 0.0005690158
causes O 0 0.00076208287
for O 0 0.00067322067
renal B-Disease 0 0.8164823
failure I-Disease 0 0.028795017
could O 0 0.0007093356
be O 0 0.0010195922
identified O 0 0.0012549136
. O 0 0.0032378712

Five O 0 0.0044611483
of O 0 0.0029365793
33 O 0 0.0029880574
( O 0 0.0020876792
15 O 0 0.00088878674
% O 0 0.0011992404
) O 0 0.0010112439
of O 0 0.00048920594
the O 0 0.0005499161
tobramycin B-Chemical 0 0.9999572
- O 0 0.009600158
treated O 0 0.0006364753
patients O 0 0.00049332395
and O 0 0.00020906619
16 O 0 0.00021098986
of O 0 0.00020420685
29 O 0 0.00033314596
( O 0 0.00034058988
55 O 0 0.00023911761
. O 0 0.00015679924
2 O 0 0.00017649168
% O 0 0.00031944772
) O 0 0.00037570708
of O 0 0.00022666116
the O 0 0.00032035538
gentamicin B-Chemical 0 0.99993825
- O 0 0.009037327
treated O 0 0.0008428515
patients O 0 0.0010649425
had O 0 0.0007776994
renal B-Disease 0 0.84441
failure I-Disease 0 0.124571
. O 0 0.0031673762

Thus O 0 0.0028560234
, O 0 0.007724884
gentamicin B-Chemical 0 0.99967647
was O 0 0.0011141702
associated O 0 0.0006643371
with O 0 0.0006141613
renal B-Disease 0 0.6359159
failure I-Disease 0 0.010812795
more O 0 0.00036960669
than O 0 0.00016371427
three O 0 9.879691e-05
times O 0 0.00016461451
as O 0 0.00033190014
often O 0 0.00061312027
as O 0 0.0007835956
was O 0 0.0016620472
tobramycin B-Chemical 0 0.999757
. O 0 0.0047425977

Metabolic O 0 0.0720211
involvement O 0 0.012990907
in O 0 0.013387657
adriamycin B-Chemical 0 0.9996829
cardiotoxicity B-Disease 0 0.9997125
. O 0 0.018639108

The O 0 0.002727396
cardiotoxic B-Disease 0 0.96959263
effects O 0 0.0014506252
of O 0 0.0020942448
adriamycin B-Chemical 0 0.99993837
were O 0 0.0006193895
studied O 0 0.0005191997
in O 0 0.0003032939
mammalian O 0 0.00035442435
myocardial O 0 0.9856011
cells O 0 0.00054819125
in O 0 0.00039584283
culture O 0 0.0007179267
as O 0 0.00051311916
a O 0 0.00091766927
model O 0 0.00088636123
system O 0 0.0019589907
. O 0 0.0033373905

Adriamycin B-Chemical 0 0.9998318
inhibited O 0 0.009066414
cell O 0 0.004599894
growth O 0 0.008207923
and O 0 0.0010839377
the O 0 0.00063057663
rhythmic O 0 0.0014874594
contractions O 0 0.004737805
characteristic O 0 0.0007077961
of O 0 0.0009291613
myocardial O 0 0.98844635
cells O 0 0.0014607189
in O 0 0.0013935454
culture O 0 0.003413194
. O 0 0.0037075523

A O 0 0.019053737
possible O 0 0.001730661
involvement O 0 0.0020499795
of O 0 0.0014439552
energy O 0 0.0032844623
metabolism O 0 0.055043
was O 0 0.00044134058
suggested O 0 0.00025418086
previously O 0 0.00032268805
, O 0 0.00046075808
and O 0 0.00023133986
in O 0 0.00018074007
this O 0 0.00019656369
study O 0 0.00021470689
the O 0 0.0001732609
adenylate O 0 0.00091757975
energy O 0 0.0006979822
charge O 0 0.0010742567
and O 0 0.0005117574
phosphorylcreatine B-Chemical 0 0.9960504
mole O 0 0.37273696
fraction O 0 0.00023094492
were O 0 0.00015314652
determined O 0 0.0001384455
in O 0 0.00021628651
the O 0 0.00041878968
adriamycin B-Chemical 0 0.9999366
- O 0 0.018252598
treated O 0 0.0018251695
cells O 0 0.002239345
. O 0 0.0033383442

The O 0 0.0034804826
adenylate O 0 0.009545973
energy O 0 0.0048281914
charge O 0 0.003742623
was O 0 0.00084129814
found O 0 0.0005672335
to O 0 0.00038743365
be O 0 0.00035696384
significantly O 0 0.00043967753
decreased O 0 0.00069945806
, O 0 0.0006805916
while O 0 0.00036408834
the O 0 0.000408792
phophorylcreatine B-Chemical 0 0.0048720944
mole O 0 0.18853712
fraction O 0 0.0010473832
was O 0 0.0011392632
unchanged O 0 0.0022142678
. O 0 0.0031291265

Such O 0 0.0066953935
disparity O 0 0.0041867723
suggests O 0 0.0024824347
an O 0 0.0036834406
inhibition O 0 0.0052225078
of O 0 0.012098732
creatine B-Chemical 1 0.9998067
phosphokinase O 0 0.99970526
. O 0 0.012640075

The O 0 0.0020434794
addition O 0 0.0011944599
of O 0 0.0018041787
1 O 0 0.0020251032
mM O 0 0.2234751
adenosine B-Chemical 0 0.99678886
to O 0 0.00047693483
the O 0 0.0004154589
myocardial O 0 0.9905868
cell O 0 0.00053957576
cultures O 0 0.0003312356
markedly O 0 0.0007241563
increases O 0 0.0002796356
the O 0 0.00032106444
ATP B-Chemical 0 0.9983474
concentration O 0 0.00064960495
through O 0 0.00016311592
a O 0 0.0002742802
pathway O 0 0.00016753687
reportedly O 0 0.0006509027
leading O 0 0.0003740059
to O 0 0.00036114594
a O 0 0.0009895581
compartmentalized O 0 0.0016092982
ATP B-Chemical 0 0.9917493
pool O 0 0.002746022
. O 0 0.003623606

In O 0 0.0022867348
the O 0 0.0029545478
adriamycin B-Chemical 0 0.99984896
- O 0 0.029662082
treated O 0 0.0015721403
cells O 0 0.00074520684
, O 0 0.00072487484
the O 0 0.000232267
addition O 0 0.00016147541
of O 0 0.0005462858
adenosine B-Chemical 0 0.99921846
increased O 0 0.0005484954
the O 0 0.00021268484
adenylate O 0 0.0011752308
charge O 0 0.00061019347
and O 0 0.00018752545
, O 0 0.0002985442
concomitant O 0 0.0002921456
with O 0 0.00013602857
this O 0 0.00013363469
inrcease O 0 0.00028575974
, O 0 0.00025273574
the O 0 9.451803e-05
cells O 0 0.00016369463
' O 0 0.00031157443
functional O 0 0.00011258653
integrity O 0 0.00015622468
, O 0 0.00021198395
in O 0 8.853874e-05
terms O 0 7.670246e-05
of O 0 0.00011289466
percentage O 0 9.687585e-05
of O 0 0.00019067257
beating O 0 0.0006954717
cells O 0 0.00028211047
and O 0 0.00027962067
rate O 0 0.0004398423
of O 0 0.00047923168
contractions O 0 0.0121599715
, O 0 0.0012728402
was O 0 0.0008426367
maintained O 0 0.0016471556
. O 0 0.0028653624

Age O 0 0.031080378
- O 0 0.010969748
dependent O 0 0.0013238252
sensitivity O 0 0.001579549
of O 0 0.0011312972
the O 0 0.0007976483
rat O 0 0.001261745
to O 0 0.00089441903
neurotoxic B-Disease 0 0.72735107
effects O 0 0.0013862876
of O 0 0.0033887732
streptomycin B-Chemical 1 0.999956
. O 0 0.007812839

Streptomycin B-Chemical 0 0.9996557
sulfate O 0 0.9977422
( O 0 0.0049360385
300 O 0 0.0027031538
mg O 0 0.007188886
/ O 0 0.00198396
kg O 0 0.0011357681
s O 0 0.0006644954
. O 0 0.00039384075
c O 0 0.0011848203
. O 0 0.00031083685
) O 0 0.0004627648
was O 0 0.00014742812
injected O 0 0.00011865338
for O 0 8.58697e-05
various O 0 0.00010003882
periods O 0 0.000106069696
into O 0 8.996584e-05
preweanling O 0 0.002315741
rats O 0 0.0002612927
and O 0 0.0001523273
for O 0 0.000116536445
3 O 0 0.00014736572
weeks O 0 0.00012223542
into O 0 0.0002649965
weanling O 0 0.003457441
rats O 0 0.0021464499
. O 0 0.0025785188

Beginning O 0 0.0044782353
at O 0 0.0013700154
8 O 0 0.00090731104
days O 0 0.00047568107
of O 0 0.0005866866
age O 0 0.00077375426
, O 0 0.00076399156
body O 0 0.0006385487
movement O 0 0.0007029618
and O 0 0.00040495995
hearing O 0 0.03497073
were O 0 0.00021897283
examined O 0 0.00014764968
for O 0 0.0001454003
6 O 0 0.00015660739
and O 0 0.00022274425
up O 0 0.00029531168
to O 0 0.00027661456
17 O 0 0.0004975053
weeks O 0 0.0003238953
, O 0 0.0014091448
respectively O 0 0.0025711223
. O 0 0.0034158227

Abnormal B-Disease 0 0.07852035
movements I-Disease 0 0.020279942
and O 0 0.0043549757
deafness B-Disease 0 0.9996599
occurred O 0 0.00096325774
only O 0 0.00047387826
in O 0 0.00027754495
rats O 0 0.00039787457
treated O 0 0.00034090836
during O 0 0.000111517635
the O 0 0.000112858594
preweaning O 0 0.0009736518
period O 0 8.952682e-05
; O 0 0.00018570852
within O 0 4.5386525e-05
this O 0 7.337501e-05
period O 0 5.2230895e-05
the O 0 5.9583166e-05
greatest O 0 0.00010934424
sensitivities O 0 0.00010254099
for O 0 7.635981e-05
these O 0 0.000113671435
abnormalities O 0 0.0031119876
occurred O 0 0.000115418814
from O 0 8.860903e-05
2 O 0 0.00010796695
to O 0 8.4828825e-05
11 O 0 0.00015020663
- O 0 0.0006195814
17 O 0 0.00014141164
and O 0 9.542738e-05
5 O 0 7.676385e-05
to O 0 5.891033e-05
11 O 0 7.4208874e-05
days O 0 4.127895e-05
of O 0 8.508662e-05
age O 0 0.00018549121
, O 0 0.00023882001
respectively O 0 0.00028354715
, O 0 0.00022738565
indicating O 0 7.828843e-05
that O 0 7.589875e-05
the O 0 9.8010205e-05
cochlea O 0 0.00065815746
is O 0 8.4541105e-05
more O 0 0.00012740296
sensitive O 0 8.178094e-05
to O 0 0.00014481846
streptomycin B-Chemical 1 0.9999918
than O 0 0.00014083902
the O 0 9.1811955e-05
site O 0 9.181406e-05
( O 0 0.0003955564
vestibular O 0 0.028122239
or O 0 0.00019405248
central O 0 0.00042968988
) O 0 0.0006298889
responsible O 0 0.00027667443
for O 0 0.00044090036
the O 0 0.0012169175
dyskinesias B-Disease 0 0.9998171
. O 0 0.0036379304

Late O 0 0.03740177
, O 0 0.020758398
late O 0 0.03922035
doxorubicin B-Chemical 0 0.9993845
cardiotoxicity B-Disease 0 0.9996884
. O 0 0.022149652

Cardiac B-Disease 0 0.50010234
toxicity I-Disease 0 0.9725646
is O 0 0.0013033533
a O 0 0.0011692747
major O 0 0.00065612455
complication O 0 0.0021044253
which O 0 0.00041169382
limits O 0 0.00047562548
the O 0 0.0002531402
use O 0 0.0003075653
of O 0 0.00071375753
adriamycin B-Chemical 0 0.99986494
as O 0 0.00084807555
a O 0 0.0013722825
chemotherapeutic O 0 0.008885785
agent O 0 0.0038991263
. O 0 0.003441204

Cardiomyopathy B-Disease 0 0.9859148
is O 0 0.0018368819
frequent O 0 0.0012736735
when O 0 0.0004586162
the O 0 0.00037812514
total O 0 0.00035971723
dose O 0 0.000469362
exceeds O 0 0.0002868872
600 O 0 0.00084869354
mg O 0 0.005712157
/ O 0 0.0013810924
m2 O 0 0.0017665682
and O 0 0.00020013555
occurs O 0 0.00013504001
within O 0 7.487321e-05
one O 0 0.000104492545
to O 0 9.818878e-05
six O 0 7.4927564e-05
months O 0 8.1093975e-05
after O 0 0.00012439604
cessation O 0 0.0003646429
of O 0 0.00079483644
therapy O 0 0.001894052
. O 0 0.0026285243

A O 0 0.04548582
patient O 0 0.0028845626
is O 0 0.0010682477
reported O 0 0.00090759946
who O 0 0.00082797854
developed O 0 0.00062668347
progressive O 0 0.0071016448
cardiomyopathy B-Disease 0 0.99976057
two O 0 0.0001796307
and O 0 0.00019771083
one O 0 0.0001574705
- O 0 0.0005894868
half O 0 8.795265e-05
years O 0 0.00011799287
after O 0 5.7938134e-05
receiving O 0 0.0001565217
580 O 0 0.001209137
mg O 0 0.003408414
/ O 0 0.0012228847
m2 O 0 0.002141719
which O 0 0.00032422988
apparently O 0 0.00048733005
represents O 0 0.0003723717
late O 0 0.001379046
, O 0 0.0018661771
late O 0 0.00781773
cardiotoxicity B-Disease 0 0.9998524
. O 0 0.005044157

Attenuation O 0 0.007690937
of O 0 0.0028397255
the O 0 0.0024043566
lithium B-Chemical 0 0.9996488
- O 0 0.02300283
induced O 0 0.0015293405
diabetes B-Disease 0 0.9998621
- I-Disease 0 0.4670958
insipidus I-Disease 0 0.99980944
- I-Disease 0 0.035917595
like I-Disease 0 0.000735274
syndrome I-Disease 0 0.9409539
by O 0 0.0013746474
amiloride B-Chemical 0 0.99992645
in O 0 0.001817104
rats O 0 0.0031481814
. O 0 0.0032126843

The O 0 0.001752919
effect O 0 0.001488271
of O 0 0.0026356194
amiloride B-Chemical 0 0.9999392
on O 0 0.0015587356
lithium B-Chemical 0 0.9999485
- O 0 0.06874524
induced O 0 0.0006225396
polydipsia B-Disease 0 0.99995685
and O 0 0.000830172
polyuria B-Disease 0 0.998809
and O 0 0.0002070272
on O 0 9.8061246e-05
the O 0 0.00017536878
lithium B-Chemical 0 0.999894
concentration O 0 0.0004741017
in O 0 0.00013612016
the O 0 0.00013767103
plasma O 0 0.010017755
, O 0 0.00040247504
brain O 0 0.0009174214
, O 0 0.00040424138
kidney O 0 0.061187718
, O 0 0.0006051865
thyroid O 0 0.04224781
and O 0 0.0001976334
red O 0 0.00036249481
blood O 0 0.003651914
cells O 0 0.00021950126
was O 0 0.00013723368
investigated O 0 0.00013946761
in O 0 0.00017429022
rats O 0 0.00042441196
, O 0 0.000615757
chronically O 0 0.0021206483
treated O 0 0.0012898594
with O 0 0.001624097
LiCl B-Chemical 0 0.9822703
. O 0 0.0043107294

Amiloride B-Chemical 0 0.9997764
reduced O 0 0.0034835879
the O 0 0.0013335776
drinking O 0 0.01078647
and O 0 0.0009933421
urine O 0 0.015437303
volume O 0 0.00067348994
of O 0 0.00031904175
rats O 0 0.00042964643
in O 0 0.00022527369
an O 0 0.000281379
acute O 0 0.00438907
( O 0 0.00033773496
6 O 0 0.00010820266
or O 0 0.00010953846
12 O 0 0.00010658375
h O 0 0.00019400698
) O 0 0.0004248026
and O 0 0.00027119418
a O 0 0.0005667512
subacute O 0 0.6595872
( O 0 0.0007560667
3 O 0 0.0003400848
days O 0 0.0003217542
) O 0 0.0013018083
experiment O 0 0.0010352279
. O 0 0.0029608952

6 O 0 0.0022179773
h O 0 0.00160529
after O 0 0.0005709765
the O 0 0.0005801862
administration O 0 0.0010305803
of O 0 0.0010623079
amiloride B-Chemical 0 0.9999565
, O 0 0.0014553623
a O 0 0.0005022936
reduction O 0 0.0003142126
was O 0 0.00017573319
observed O 0 0.00014074761
in O 0 0.00016176252
the O 0 0.00021785703
lithium B-Chemical 0 0.9998204
content O 0 0.0003032199
of O 0 0.00022604974
the O 0 0.00024342288
renal O 0 0.9809841
medulla O 0 0.35784426
but O 0 0.00026197417
not O 0 0.00017671514
in O 0 0.0002204825
the O 0 0.0002616796
other O 0 0.00044114335
organs O 0 0.0015937566
studied O 0 0.002101362
. O 0 0.0027785457

At O 0 0.0015897184
12 O 0 0.0016814979
h O 0 0.0018366866
, O 0 0.0019117092
all O 0 0.0008538434
the O 0 0.0006721468
tissues O 0 0.00090750767
showed O 0 0.0006171459
a O 0 0.00096783106
slight O 0 0.0011628385
increase O 0 0.00092964526
in O 0 0.0015235591
lithium B-Chemical 0 0.99927694
levels O 0 0.002878189
. O 0 0.0043264916

After O 0 0.0014287062
3 O 0 0.001095033
days O 0 0.0005955353
of O 0 0.0006620503
combined O 0 0.000682138
treatment O 0 0.00055731833
, O 0 0.00079715793
a O 0 0.0005961904
marked O 0 0.0006187046
elevation O 0 0.005366617
in O 0 0.0003561263
plasma O 0 0.007907079
and O 0 0.00038649555
tissue O 0 0.0031158098
lithium B-Chemical 0 0.99984515
levels O 0 0.0003442204
accompanied O 0 0.0005999697
a O 0 0.00060978974
reduction O 0 0.00064500346
in O 0 0.0007179422
water O 0 0.0072123585
intake O 0 0.036089286
. O 0 0.0032080992

In O 0 0.0019966443
all O 0 0.0014922135
the O 0 0.00086856185
experiments O 0 0.00060377637
, O 0 0.0009437995
the O 0 0.00036066133
attenuation O 0 0.00039709007
of O 0 0.00037759164
the O 0 0.00042875906
lithium B-Chemical 0 0.9998833
- O 0 0.011006856
induced O 0 0.00047015998
diabetes B-Disease 0 0.99994683
- I-Disease 0 0.4234505
insipidus I-Disease 0 0.9999161
- I-Disease 0 0.03217907
like I-Disease 0 0.0002451394
syndrome I-Disease 0 0.9662229
by O 0 0.00042266637
amiloride B-Chemical 0 0.9999919
was O 0 0.00025536382
accompanied O 0 0.00026476794
by O 0 0.00011101166
a O 0 0.0001602482
reduction O 0 0.00012014702
of O 0 9.1613336e-05
the O 0 6.4054875e-05
ratio O 0 9.071169e-05
between O 0 7.1857175e-05
the O 0 0.00014809002
lithium B-Chemical 0 0.99992836
concentration O 0 0.0004250746
in O 0 0.000115741626
the O 0 0.00013191311
renal O 0 0.94811
medulla O 0 0.1118825
and O 0 0.00010868051
its O 0 0.00011884326
levels O 0 8.425998e-05
in O 0 0.0001002099
the O 0 0.00011214873
blood O 0 0.0017878441
and O 0 0.00020207107
an O 0 0.00027219742
elevation O 0 0.003735223
in O 0 0.0003080125
the O 0 0.00045968304
plasma O 0 0.12939222
potassium B-Chemical 0 0.99887043
level O 0 0.0019178439
. O 0 0.003101909

It O 0 0.004787318
is O 0 0.0014710306
concluded O 0 0.001164936
that O 0 0.00081550307
acute O 0 0.5672006
amiloride B-Chemical 0 0.9999738
administration O 0 0.0027756144
to O 0 0.00044738682
lithium B-Chemical 0 0.9999342
- O 0 0.0118933655
treated O 0 0.0005233757
patients O 0 0.00075175613
suffering O 0 0.018181553
from O 0 0.00020330053
polydipsia B-Disease 0 0.99996424
and O 0 0.00056776113
polyuria B-Disease 0 0.99930155
might O 0 7.128259e-05
relieve O 0 0.00017450324
these O 0 9.625631e-05
patients O 0 0.00030428587
but O 0 0.00016475993
prolonged O 0 0.00075185526
amiloride B-Chemical 0 0.99999416
supplementation O 0 0.78068787
would O 0 0.00016564377
result O 0 0.00015312535
in O 0 0.00022233746
elevated O 0 0.01908773
lithium B-Chemical 0 0.99991524
levels O 0 0.00036514451
and O 0 0.00042105274
might O 0 0.00032696774
be O 0 0.0008236376
hazardous O 0 0.0030332159
. O 0 0.0025078868

Cardiovascular B-Disease 0 0.42773908
complications I-Disease 0 0.31157228
associated O 0 0.0025129488
with O 0 0.0026576358
terbutaline B-Chemical 0 0.99971384
treatment O 0 0.0017814127
for O 0 0.0015311124
preterm B-Disease 0 0.8065656
labor I-Disease 0 0.4369258
. O 0 0.00631813

Severe O 0 0.26960808
cardiovascular B-Disease 0 0.9724125
complications I-Disease 0 0.5500497
occurred O 0 0.000872333
in O 0 0.0004222888
eight O 0 0.00023989672
of O 0 0.00035382577
160 O 0 0.0007507463
patients O 0 0.0006087401
treated O 0 0.0006721731
with O 0 0.0008023393
terbutaline B-Chemical 0 0.9998604
for O 0 0.0010209272
preterm B-Disease 0 0.92229116
labor I-Disease 0 0.53518665
. O 0 0.0041467403

Associated O 0 0.009935311
corticosteroid O 0 0.97758317
therapy O 0 0.0029596766
and O 0 0.001724687
twin O 0 0.03106053
gestations O 0 0.011136287
appear O 0 0.0009590102
to O 0 0.0008925577
be O 0 0.0012926776
predisposing O 0 0.0045935754
factors O 0 0.0046250317
. O 0 0.0052942303

Potential O 0 0.0048141624
mechanisms O 0 0.0025298689
of O 0 0.0030117163
the O 0 0.0024874392
pathophysiology O 0 0.011307169
are O 0 0.002208065
briefly O 0 0.0035865102
discussed O 0 0.003954055
. O 0 0.006842828

Toxic B-Disease 0 0.99577576
hepatitis I-Disease 0 0.9999373
induced O 0 0.0030340538
by O 0 0.0017486669
antithyroid O 0 0.98940456
drugs O 0 0.054417558
: O 0 0.0008333915
four O 0 0.00017093128
cases O 0 0.00033577974
including O 0 0.00014994589
one O 0 0.00018065631
with O 0 0.00028021343
cross O 0 0.0005146286
- O 0 0.002178127
reactivity O 0 0.0007972551
between O 0 0.000646041
carbimazole B-Chemical 0 0.9998042
and O 0 0.002196094
benzylthiouracil B-Chemical 0 0.9867185
. O 0 0.0038792365

OBJECTIVE O 0 0.02967651
: O 0 0.005373254
This O 0 0.0018327744
study O 0 0.0009498847
was O 0 0.0005177011
conducted O 0 0.00043830875
to O 0 0.00022466536
assess O 0 0.000121194345
the O 0 0.00018541588
occurrence O 0 0.00026804165
of O 0 0.00037012235
hepatic B-Disease 0 0.9839177
adverse I-Disease 0 0.0022504355
effects I-Disease 0 0.00040920803
encountered O 0 0.00055906555
with O 0 0.0009164503
antithyroid O 0 0.9874955
drugs O 0 0.09824597
. O 0 0.0030525895

METHODS O 0 0.0042443713
: O 0 0.0035084996
Retrospective O 0 0.0058564753
review O 0 0.0013407097
of O 0 0.0007282145
medical O 0 0.0013775311
records O 0 0.000700179
of O 0 0.00043875328
236 O 0 0.001231627
patients O 0 0.0007188226
with O 0 0.00057375326
hyperthyroidism B-Disease 0 0.99997306
admitted O 0 0.0017803395
in O 0 0.00017517873
our O 0 0.00015890964
department O 0 0.00041668845
( O 0 0.00037858484
in O 0 0.00021751372
- O 0 0.0011754518
or O 0 0.00020224434
out O 0 0.00026031348
- O 0 0.0021357618
patients O 0 0.0008166505
) O 0 0.00090568943
from O 0 0.00051084487
1986 O 0 0.002208599
to O 0 0.0010686528
1992 O 0 0.004249647
. O 0 0.0034184922

RESULTS O 0 0.005138612
: O 0 0.003580401
Four O 0 0.0014843208
patients O 0 0.00192202
( O 0 0.0015327521
1 O 0 0.00073550694
. O 0 0.00046203326
7 O 0 0.00033621571
% O 0 0.0006687807
) O 0 0.000671914
were O 0 0.00024432456
identified O 0 0.000199876
with O 0 0.0006240654
toxic B-Disease 0 0.9955419
hepatitis I-Disease 0 0.9999976
which O 0 0.0011458456
could O 0 0.00018828077
reasonably O 0 0.00031207266
be O 0 0.00019748815
attributed O 0 0.000171912
to O 0 0.00018168158
the O 0 0.00022088987
use O 0 0.00034633913
of O 0 0.00086895947
antithyroid O 0 0.973256
agent O 0 0.004951008
. O 0 0.0032293412

Two O 0 0.003529734
patients O 0 0.004684218
had O 0 0.0025671169
a O 0 0.006188065
cholestatic B-Disease 0 0.9999821
hepatitis I-Disease 0 0.99997044
induced O 0 0.0030274466
by O 0 0.0026545764
carbimazole B-Chemical 0 0.9998932
( O 0 0.0071188603
N B-Chemical 0 0.9976035
omercazole I-Chemical 0 0.009606126
) O 0 0.006981122
. O 0 0.004780832

Two O 0 0.003367067
others O 0 0.004261631
had O 0 0.0021128955
a O 0 0.0022536286
mixed O 0 0.0028610672
( O 0 0.005022067
cholestatic B-Disease 0 0.99993575
and O 0 0.0021844483
cytolytic O 0 0.0387218
) O 0 0.013134696
hepatitis B-Disease 0 0.9998876
following O 0 0.0030738954
carbimazole B-Chemical 0 0.99965394
. O 0 0.0050639845

One O 0 0.00372685
of O 0 0.0019744507
the O 0 0.0011163375
latter O 0 0.0014259217
two O 0 0.00042842238
patients O 0 0.00073436915
further O 0 0.00029425664
experienced O 0 0.0004921546
a O 0 0.00080741046
cytolytic O 0 0.08754685
hepatitis B-Disease 0 0.99997365
which O 0 0.00074253406
appeared O 0 0.00027114738
after O 0 0.00018808182
Benzylthiouracil B-Chemical 0 0.01069107
( O 0 0.0010896211
Basd B-Chemical 0 0.0073884134
ne I-Chemical 0 0.06024257
) O 0 0.0018124768
had O 0 0.000951323
replaced O 0 0.0016681984
carbimazole B-Chemical 0 0.9995403
. O 0 0.004935441

Biological O 0 0.010976754
features O 0 0.0036414254
of O 0 0.0037106536
hepatitis B-Disease 0 0.99989414
disappeared O 0 0.001965187
in O 0 0.00049614283
all O 0 0.00030743866
cases O 0 0.0003556303
after O 0 0.000102457314
cessation O 0 0.00016900546
of O 0 0.00018285238
the O 0 0.00018363427
incriminated O 0 0.0020232182
drug O 0 0.012938181
, O 0 0.0004944243
while O 0 0.00029017276
biliary O 0 0.906443
, O 0 0.0007903004
viral O 0 0.0005535492
and O 0 0.0003987844
immunological O 0 0.0007952997
searches O 0 0.00042416586
were O 0 0.00065399753
negative O 0 0.001328047
. O 0 0.0026955495

Only O 0 0.004485871
2 O 0 0.0024080903
patients O 0 0.00198308
of O 0 0.0010235148
our O 0 0.0008352884
retrospective O 0 0.0035259172
study O 0 0.0008582788
experienced O 0 0.00088317966
a O 0 0.0013792318
mild O 0 0.041978247
or O 0 0.0013505002
severe O 0 0.032454472
neutropenia B-Disease 0 0.99489355
. O 0 0.0043724463

CONCLUSION O 0 0.07194291
: O 0 0.019773586
Toxic B-Disease 0 0.9935394
hepatitis I-Disease 0 0.9999604
is O 0 0.0009764718
a O 0 0.00065260404
potential O 0 0.00024741516
adverse O 0 0.00070108584
effect O 0 0.00017111587
of O 0 0.00032683622
antithyroid O 0 0.9879617
drugs O 0 0.030099165
which O 0 0.00020839866
warrants O 0 0.00029097308
, O 0 0.00027879598
as O 0 0.00011620421
for O 0 0.00011384359
haematological O 0 0.31711754
disturbances O 0 0.25142747
, O 0 0.00027813198
a O 0 0.00018681854
pre O 0 0.00026315125
- O 0 0.00072164356
therapeutic O 0 0.00019035596
determination O 0 0.00018023136
and O 0 0.0001521064
a O 0 0.00021606308
careful O 0 0.00017149285
follow O 0 0.00017979553
- O 0 0.0011351022
up O 0 0.00036486125
of O 0 0.0004372448
relevant O 0 0.0005000763
biological O 0 0.0010568378
markers O 0 0.0027077997
. O 0 0.0031809756

Moreover O 0 0.0052179475
, O 0 0.013456344
hepatotoxicity B-Disease 0 0.99985194
may O 0 0.0015870166
not O 0 0.0008808995
be O 0 0.00064339116
restricted O 0 0.0004862125
to O 0 0.0004645286
one O 0 0.0005296577
class O 0 0.0013096473
of O 0 0.0016290684
antithyroid O 0 0.9662467
agents O 0 0.0071221096
. O 0 0.0043019364

Interactive O 0 0.008367371
effects O 0 0.0020625503
of O 0 0.0016817574
variations O 0 0.0011166597
in O 0 0.0011052081
[ O 0 0.006435099
Na B-Chemical 0 0.9922915
] O 0 0.004249818
o O 0 0.0027996914
and O 0 0.00083844026
[ O 0 0.007511747
Ca B-Chemical 0 0.9977011
] O 0 0.004592111
o O 0 0.002234439
on O 0 0.00040942227
rat O 0 0.0009841964
atrial O 0 0.017194832
spontaneous O 0 0.0021688514
frequency O 0 0.0014377547
. O 0 0.0029403917

The O 0 0.0017036063
effects O 0 0.001390844
of O 0 0.0012521268
varying O 0 0.0008991953
the O 0 0.0006165695
extracellular O 0 0.0013189724
concentrations O 0 0.0009081266
of O 0 0.0007897765
Na B-Chemical 0 0.99717134
and O 0 0.0010219807
Ca B-Chemical 0 0.9984896
( O 0 0.0016238698
[ O 0 0.005334993
Na B-Chemical 0 0.99523157
] O 0 0.0023775625
o O 0 0.0015739587
and O 0 0.00040652056
[ O 0 0.0054488434
Ca B-Chemical 0 0.99863005
] O 0 0.0032468461
o O 0 0.0017809422
) O 0 0.0004746952
on O 0 8.7431275e-05
both O 0 0.00010863628
, O 0 0.00022911887
the O 0 0.00010672695
spontaneous O 0 0.00040008954
beating O 0 0.00043637704
and O 0 0.00012337341
the O 0 9.5101444e-05
negative O 0 0.00018233305
chronotropic O 0 0.7949335
action O 0 0.00020891076
of O 0 0.00044047603
verapamil B-Chemical 0 0.9999964
, O 0 0.0010275289
were O 0 0.00020648645
studied O 0 0.00028990977
in O 0 0.0002320233
the O 0 0.00027866682
isolated O 0 0.00055977737
rat O 0 0.001441651
atria O 0 0.017127208
. O 0 0.0027083675

Basal O 0 0.020768924
frequency O 0 0.0029850644
( O 0 0.004239813
BF O 0 0.014499579
) O 0 0.0021925212
evaluated O 0 0.00070734764
by O 0 0.0006003978
surface O 0 0.0009669814
electrogram O 0 0.002560179
was O 0 0.00040925757
223 O 0 0.0011337893
+ O 0 0.0012484798
/ O 0 0.0016209594
- O 0 0.0012413888
4 O 0 0.00021719065
beats O 0 0.001683506
/ O 0 0.0010064413
min O 0 0.00037513557
. O 0 0.00017892558
in O 0 0.00016798254
control O 0 0.00030225993
Krebs O 0 0.04553067
- O 0 0.0031815246
Ringer O 0 0.010029418
containing O 0 0.00024693343
137 O 0 0.000859131
mM O 0 0.020484861
Na B-Chemical 0 0.9915849
and O 0 0.000581485
1 O 0 0.0005084659
. O 0 0.0004524349
35 O 0 0.00077072746
mM O 0 0.018292822
Ca B-Chemical 0 0.9970741
( O 0 0.008164694
N O 0 0.99512213
) O 0 0.011056461
. O 0 0.0054016993

It O 0 0.006130548
decreased O 0 0.003525351
by O 0 0.0016876173
16 O 0 0.0016378992
+ O 0 0.0033440446
/ O 0 0.004044745
- O 0 0.0027227302
3 O 0 0.0004357778
% O 0 0.00065228133
by O 0 0.00035694477
lowering O 0 0.0015858663
[ O 0 0.0063354326
Na B-Chemical 0 0.99705875
] O 0 0.0036516173
o O 0 0.0018068107
to O 0 0.00031605762
78 O 0 0.00071713835
mM O 0 0.0039884937
( O 0 0.0007488193
LNa O 0 0.039671034
) O 0 0.00064563047
, O 0 0.00041985855
23 O 0 0.00038133698
+ O 0 0.0009700763
/ O 0 0.0016974355
- O 0 0.0014259781
2 O 0 0.00021893316
% O 0 0.00028602878
by O 0 0.0001451821
lowering O 0 0.00050319073
simultaneously O 0 0.00025541303
[ O 0 0.0046644895
Na B-Chemical 0 0.9977787
] O 0 0.002653477
o O 0 0.0013067238
to O 0 0.00021371387
78 O 0 0.0005112026
mM O 0 0.0029346084
and O 0 0.00034432986
[ O 0 0.0049348534
Ca B-Chemical 0 0.99880815
] O 0 0.0037204784
o O 0 0.00154586
to O 0 0.00021830157
0 O 0 0.000325122
. O 0 0.00026471872
675 O 0 0.003193544
mM O 0 0.0030231792
( O 0 0.0006630041
LNa O 0 0.052317586
+ O 0 0.0016280914
LCa O 0 0.09645167
) O 0 0.0005652466
and O 0 0.00022843151
31 O 0 0.00035038264
+ O 0 0.0008766864
/ O 0 0.0014950181
- O 0 0.0012337064
5 O 0 0.00017551647
% O 0 0.00027874598
by O 0 0.00016594001
lowering O 0 0.0010767017
[ O 0 0.005719862
Na B-Chemical 0 0.9981646
] O 0 0.0028221807
o O 0 0.0012958567
to O 0 0.00019628405
78 O 0 0.000431433
mM O 0 0.0018486072
plus O 0 0.00020548087
increasing O 0 0.00028026817
[ O 0 0.007180151
Ca B-Chemical 0 0.99912006
] O 0 0.00423809
o O 0 0.0016230444
to O 0 0.0002313553
3 O 0 0.00021421512
. O 0 0.00023191184
6 O 0 0.00025792184
mM O 0 0.0024358612
( O 0 0.0013661288
LNa O 0 0.07059209
+ O 0 0.0050500385
HCa O 0 0.58170754
) O 0 0.0055706375
. O 0 0.0042296792

At O 0 0.0021803353
normal O 0 0.00524507
[ O 0 0.013650138
Na B-Chemical 0 0.99131787
] O 0 0.00867373
o O 0 0.005292028
, O 0 0.0016662712
decrease O 0 0.0007908786
( O 0 0.0009997336
0 O 0 0.00062736473
. O 0 0.000494529
675 O 0 0.005343864
mM O 0 0.0050812205
) O 0 0.00078667956
or O 0 0.00025015097
increase O 0 0.00025510977
( O 0 0.00043033488
3 O 0 0.0001831911
. O 0 0.00017554611
6 O 0 0.00015984166
mM O 0 0.0014881443
) O 0 0.0005524579
of O 0 0.0003583396
[ O 0 0.0078104995
Ca B-Chemical 0 0.99931645
] O 0 0.00954678
o O 0 0.003188143
did O 0 0.00029987842
not O 0 0.00017607602
modify O 0 0.00018713516
BF O 0 0.0144626405
; O 0 0.00038550168
a O 0 0.00018933845
reduction O 0 0.00014719352
of O 0 0.00011910873
ten O 0 7.3530595e-05
times O 0 8.524499e-05
( O 0 0.00024605167
0 O 0 0.00018969769
. O 0 0.00014210411
135 O 0 0.00035277643
mM O 0 0.0015429799
of O 0 0.00024233264
normal O 0 0.00065628585
[ O 0 0.0062222504
Ca B-Chemical 0 0.99901557
] O 0 0.0038555688
o O 0 0.0015689116
was O 0 0.00019399235
effective O 0 0.00016207778
to O 0 0.00015845965
reduce O 0 0.00018587237
BF O 0 0.0031351799
by O 0 0.00032274774
40 O 0 0.00048929354
+ O 0 0.0016487606
/ O 0 0.003220356
- O 0 0.003817768
13 O 0 0.0015433619
% O 0 0.0030136353
. O 0 0.0034712367

All O 0 0.0043948977
negative O 0 0.004856288
chronotropic O 0 0.6867785
effects O 0 0.0031961072
were O 0 0.0034693636
BF O 0 0.031566307
- O 0 0.010640537
dependent O 0 0.003484161
. O 0 0.0070346207

Dose O 0 0.015901003
- O 0 0.010672803
dependent O 0 0.0016142736
bradycardia B-Disease 0 0.98272747
induced O 0 0.0012538473
by O 0 0.0016170056
verapamil B-Chemical 0 0.99998116
was O 0 0.0012211064
potentiated O 0 0.00494777
by O 0 0.0010397097
LNa O 0 0.2805289
, O 0 0.0023404073
LCa O 0 0.15904915
, O 0 0.0025026677
and O 0 0.0023999915
HCa O 0 0.5583519
. O 0 0.0052673914

Independent O 0 0.005369157
but O 0 0.0023056802
not O 0 0.0010484554
additive O 0 0.001322657
effects O 0 0.0007193643
of O 0 0.0012231469
Na B-Chemical 0 0.9989704
and O 0 0.0014411934
Ca B-Chemical 0 0.99895215
are O 0 0.0002636734
shown O 0 0.0001036584
by O 0 0.00014422505
decreases O 0 0.00017414619
in O 0 0.0001232765
the O 0 0.00010166695
values O 0 0.0001347415
of O 0 0.0002312975
[ O 0 0.013166589
verapamil B-Chemical 0 0.99999464
] O 0 0.008847121
o O 0 0.0013471422
needed O 0 0.00012107214
to O 0 0.000112937734
reduce O 0 0.00010804348
BF O 0 0.0026903716
by O 0 0.00013210622
30 O 0 0.00012641923
% O 0 0.00031514777
( O 0 0.0006072865
IC30 O 0 0.9999114
) O 0 0.0006489973
with O 0 0.00013524144
the O 0 8.3582316e-05
following O 0 5.7090656e-05
order O 0 6.600335e-05
of O 0 0.00014094517
inhibitory O 0 0.00032043876
potency O 0 0.00073185196
: O 0 0.0010286783
LNa O 0 0.1549473
> O 0 0.0009493817
LCa O 0 0.117407046
> O 0 0.0011394226
HCa O 0 0.5515111
> O 0 0.0018632724
N O 0 0.9947429
, O 0 0.0010028874
resulting O 0 0.0004771995
LNa O 0 0.15407978
+ O 0 0.002841916
HCa O 0 0.22616147
similar O 0 0.0005721107
to O 0 0.0011447535
LNa O 0 0.10374544
. O 0 0.0034805352

The O 0 0.0036008253
[ O 0 0.03374501
verapamil B-Chemical 0 0.9999448
] O 0 0.024926933
o O 0 0.005258337
that O 0 0.0006350701
arrested O 0 0.0034466456
atrial O 0 0.16039775
beating O 0 0.0025047995
( O 0 0.0010751273
AC O 0 0.043666903
) O 0 0.0007562804
was O 0 0.00020285172
also O 0 0.00019758721
potentiated O 0 0.0008963079
with O 0 0.00024465536
the O 0 0.00016883874
order O 0 0.00017770869
LNa O 0 0.023339255
= O 0 0.0010041245
LNa O 0 0.020296445
+ O 0 0.0012762272
LCa O 0 0.032943673
= O 0 0.0013343418
LNa O 0 0.0249572
+ O 0 0.0019432656
HCa O 0 0.22603112
= O 0 0.0024668856
LCa O 0 0.07801596
> O 0 0.0034201092
HCa O 0 0.5977292
= O 0 0.008843668
N O 0 0.98575705
. O 0 0.0067951754

The O 0 0.0017255067
results O 0 0.0011661935
indicate O 0 0.00059266156
that O 0 0.0006162079
rat O 0 0.0011207735
atrial O 0 0.03228243
spontaneous O 0 0.0014739442
beating O 0 0.0010780869
is O 0 0.00021750003
more O 0 0.00028300643
dependent O 0 0.0001431576
on O 0 0.000173517
[ O 0 0.0024852033
Na B-Chemical 0 0.995329
] O 0 0.0019151295
o O 0 0.0010523791
than O 0 0.00016989378
on O 0 0.00015902072
[ O 0 0.003030819
Ca B-Chemical 0 0.9985409
] O 0 0.0029749633
o O 0 0.0012544355
in O 0 0.000186965
a O 0 0.0002299448
range O 0 0.00017010466
of O 0 0.00022611313
+ O 0 0.0010794156
/ O 0 0.002198715
- O 0 0.0020854285
50 O 0 0.00044843915
% O 0 0.00059780804
of O 0 0.0004500602
their O 0 0.00058714836
normal O 0 0.0016164682
concentration O 0 0.0028149968
. O 0 0.003219543

Also O 0 0.0028609
the O 0 0.0015208827
enhancement O 0 0.0015425063
of O 0 0.0015920526
verapamil B-Chemical 0 0.99995995
effects O 0 0.00067968416
on O 0 0.0003349022
atrial O 0 0.03469498
beating O 0 0.0010787195
was O 0 0.00024024189
more O 0 0.00031376895
pronounced O 0 0.0003408725
at O 0 0.00021416895
LNa O 0 0.008828166
than O 0 0.00024240102
at O 0 0.00029597574
LCa O 0 0.018897135
. O 0 0.0005638046
( O 0 0.0011184755
ABSTRACT O 0 0.0053208647
TRUNCATED O 0 0.013171844
AT O 0 0.012772583
250 O 0 0.006294273
WORDS O 0 0.028456682
) O 0 0.018278264

Pseudo O 0 0.38756728
- O 0 0.13289228
allergic B-Disease 0 0.9954035
reactions I-Disease 0 0.005229831
to O 0 0.0016591349
corticosteroids B-Chemical 0 0.993418
: O 0 0.0028565163
diagnosis O 0 0.0019515799
and O 0 0.0015621657
alternatives O 0 0.0024622842
. O 0 0.0047298637

Two O 0 0.0025341187
patients O 0 0.0029391856
treated O 0 0.0020347899
with O 0 0.0012482664
parenteral O 0 0.009400722
paramethasone B-Chemical 1 0.99976593
( O 0 0.0016499746
Triniol O 0 0.0009053327
) O 0 0.0013434977
and O 0 0.00085369294
dexamethasone B-Chemical 0 0.9990559
( O 0 0.0016800553
Sedionbel O 0 0.0012566928
) O 0 0.001975146
are O 0 0.0010185402
described O 0 0.0015692837
. O 0 0.0034335172

A O 0 0.012728741
few O 0 0.0011795816
minutes O 0 0.00089919055
after O 0 0.00037839884
administration O 0 0.00064211915
of O 0 0.00040842584
the O 0 0.00032083032
drugs O 0 0.005187055
, O 0 0.0005915989
they O 0 0.000256835
presented O 0 0.00036378126
urticaria B-Disease 0 0.9995148
( O 0 0.0007345179
patients O 0 0.0005048853
1 O 0 0.00022822668
and O 0 0.00021197081
2 O 0 0.00028291743
) O 0 0.00061845104
and O 0 0.00049880974
conjunctivitis B-Disease 0 0.93359244
( O 0 0.0012577754
patient O 0 0.0009183782
1 O 0 0.0011998117
) O 0 0.0030184186
. O 0 0.0031071927

The O 0 0.0016012295
purpose O 0 0.0010378071
of O 0 0.0011257961
our O 0 0.0007453084
study O 0 0.00069635303
was O 0 0.000364605
to O 0 0.000214004
determine O 0 8.655682e-05
the O 0 0.00016213562
cause O 0 0.00022259286
of O 0 0.00017838145
the O 0 0.00014312647
patients O 0 0.00038880395
' O 0 0.00037193406
reactions O 0 0.00022958989
, O 0 0.00024179257
the O 0 9.159735e-05
immunological O 0 0.0001997276
mechanisms O 0 7.171711e-05
involved O 0 8.680116e-05
and O 0 0.00010066387
whether O 0 4.3754397e-05
these O 0 0.00013296126
patients O 0 0.00035098792
would O 0 0.0001225468
be O 0 0.00014297437
able O 0 0.00013578804
to O 0 0.00021299739
tolerate O 0 0.0005059102
any O 0 0.00035927308
kind O 0 0.000941229
of O 0 0.001973466
corticoid O 0 0.99663466
. O 0 0.0039679087

Clinical O 0 0.005564537
examinations O 0 0.0021335639
and O 0 0.0015708295
skin O 0 0.0026299823
, O 0 0.0012731579
oral O 0 0.0013709296
and O 0 0.00042839296
parenteral O 0 0.00083792425
challenges O 0 0.00028502563
with O 0 0.00031832044
different O 0 0.00032369746
corticosteroids B-Chemical 0 0.9869047
and O 0 0.00074166065
ELISA O 0 0.026035111
tests O 0 0.0015525793
were O 0 0.00088544836
performed O 0 0.0012730415
. O 0 0.0027915877

In O 0 0.0018482341
the O 0 0.0013317544
two O 0 0.00084580097
patients O 0 0.001716001
, O 0 0.0014381271
skin O 0 0.0016754583
and O 0 0.0005416024
ELISA O 0 0.01277583
tests O 0 0.00084547827
with O 0 0.0005327417
paramethasone B-Chemical 1 0.99983513
were O 0 0.00025918987
negative O 0 0.00022762881
, O 0 0.00037736585
as O 0 0.0001928059
was O 0 0.00017581799
the O 0 0.00017870104
prick O 0 0.000585771
test O 0 0.00030943705
with O 0 0.00032047147
each O 0 0.00028494332
of O 0 0.00068757514
its O 0 0.0016576997
excipients O 0 0.6609038
. O 0 0.0042832554

A O 0 0.025018638
single O 0 0.0023421308
- O 0 0.008267487
blind O 0 0.0120412875
parenteral O 0 0.0020081461
challenge O 0 0.00031982744
with O 0 0.00031533017
Triniol O 0 0.00039335428
was O 0 0.00020834841
positive O 0 0.00019420039
in O 0 0.00014573481
both O 0 0.00012570186
patients O 0 0.0002198672
after O 0 5.9927057e-05
the O 0 8.894376e-05
administration O 0 0.0002035228
of O 0 0.00015782827
1 O 0 0.00018609849
ml O 0 0.00044043912
of O 0 0.00016875762
the O 0 0.00017569547
drug O 0 0.0035401208
, O 0 0.0005148008
and O 0 0.0003231529
negative O 0 0.0004330909
with O 0 0.0007539101
its O 0 0.0017918403
excipients O 0 0.7749546
. O 0 0.0042876014

We O 0 0.0025004975
also O 0 0.0014976942
carried O 0 0.0010126681
out O 0 0.00070370216
oral O 0 0.0013841281
and O 0 0.00042072978
parenteral O 0 0.00078336085
challenges O 0 0.00024546075
with O 0 0.00026182312
other O 0 0.00030630443
corticosteroids B-Chemical 0 0.9936063
and O 0 0.0003858745
found O 0 0.00042126796
intolerance O 0 0.10396968
to O 0 0.00041716264
some O 0 0.00063892675
of O 0 0.0010873366
them O 0 0.0023933332
. O 0 0.0032846045

These O 0 0.002384075
results O 0 0.0017877662
suggest O 0 0.0011741857
that O 0 0.0019107388
paramethasone B-Chemical 1 0.99973863
caused O 0 0.0026215857
pseudoallergic O 0 0.34787458
reactions O 0 0.0015577081
in O 0 0.0010478562
our O 0 0.0013697519
patients O 0 0.0039210115
. O 0 0.004003264

Corticosteroids O 0 0.09500248
different O 0 0.0014557462
from O 0 0.0015980264
paramethasone B-Chemical 1 0.9995086
also O 0 0.00070729683
produced O 0 0.00048098902
hypersensitivity B-Disease 0 0.0109169185
reactions O 0 0.00039125048
in O 0 0.00020843424
these O 0 0.00021480661
patients O 0 0.0005213013
; O 0 0.0004830889
however O 0 0.00032217533
, O 0 0.0005062958
a O 0 0.0004113541
few O 0 0.00022210905
of O 0 0.00048244788
them O 0 0.0008943275
were O 0 0.0009686738
tolerated O 0 0.0024408358
. O 0 0.0027821206

The O 0 0.002671661
basic O 0 0.0024040157
mechanisms O 0 0.001327531
of O 0 0.0016895973
those O 0 0.0015802492
reactions O 0 0.0014643206
are O 0 0.00086099905
not O 0 0.0009946446
yet O 0 0.0014445866
fully O 0 0.0017062301
understood O 0 0.005462861
. O 0 0.005873602

To O 0 0.0015219793
our O 0 0.0016994082
knowledge O 0 0.001998694
, O 0 0.0021093446
this O 0 0.00084867334
is O 0 0.00045156904
the O 0 0.00033054827
first O 0 0.00025426957
report O 0 0.00060441496
of O 0 0.00047817806
a O 0 0.0008529433
pseudo O 0 0.0031599877
- O 0 0.027726421
allergy B-Disease 0 0.9709138
caused O 0 0.0012460841
by O 0 0.0022513545
paramethasone B-Chemical 1 0.9996573
. O 0 0.005907074

Study O 0 0.007216788
of O 0 0.0019419091
the O 0 0.0010788097
role O 0 0.0007495608
of O 0 0.0036350177
vitamin B-Chemical 0 0.99998975
B12 I-Chemical 0 0.99999917
and O 0 0.8250474
folinic B-Chemical 0 0.99999964
acid I-Chemical 0 0.99974436
supplementation O 0 0.96400934
in O 0 0.00062680145
preventing O 0 0.00072187674
hematologic O 0 0.99623954
toxicity B-Disease 0 0.9962723
of O 0 0.0022929749
zidovudine B-Chemical 0 0.9833761
. O 0 0.0031509402

A O 0 0.030926952
prospective O 0 0.008542825
, O 0 0.0030730844
randomized O 0 0.0022671798
study O 0 0.0007055323
was O 0 0.00036443578
conducted O 0 0.00030654835
to O 0 0.00015038
evaluate O 0 7.896895e-05
the O 0 0.00012539118
role O 0 0.000120229524
of O 0 0.0009837002
vitamin B-Chemical 0 0.99999714
B12 I-Chemical 0 0.99999976
and O 0 0.7275556
folinic B-Chemical 0 0.9999999
acid I-Chemical 0 0.99982315
supplementation O 0 0.9593149
in O 0 0.00028833968
preventing O 0 0.0003169535
zidovudine B-Chemical 0 0.98958254
( O 0 0.0019271648
ZDV B-Chemical 0 0.9999082
) O 0 0.0013121302
- O 0 0.0021501775
induced O 0 0.00053908484
bone B-Disease 0 0.07734148
marrow I-Disease 0 0.5880947
suppression I-Disease 0 0.009915706
. O 0 0.0033650256

Seventy O 0 0.014982145
- O 0 0.011612152
five O 0 0.0015509716
human B-Disease 0 0.0051698154
immunodeficiency I-Disease 0 0.9995484
virus I-Disease 0 0.075158685
( I-Disease 0 0.0031147434
HIV I-Disease 0 0.120860636
) I-Disease 0 0.0018085333
- I-Disease 0 0.0019921893
infected I-Disease 0 0.000254161
patients O 0 0.00039371933
with O 0 0.00022791006
CD4 O 0 0.0026141887
+ O 0 0.00092097104
cell O 0 0.00025319715
counts O 0 0.00012498673
< O 0 0.00021356599
500 O 0 0.0002697326
/ O 0 0.00047866465
mm3 O 0 0.00030564074
were O 0 9.912739e-05
randomized O 0 0.00021067382
to O 0 7.377621e-05
receive O 0 9.527254e-05
either O 0 0.00016438251
ZDV B-Chemical 0 0.99984264
( O 0 0.00031592627
500 O 0 0.00034653494
mg O 0 0.0025722343
daily O 0 0.00014639721
) O 0 0.00022850864
alone O 0 0.00013317839
( O 0 0.0002600632
group O 0 0.00026342738
I O 0 0.0039286935
, O 0 0.00031163622
n O 0 0.00019898987
= O 0 0.00043487104
38 O 0 0.0001992346
) O 0 0.00026785387
or O 0 9.8076394e-05
in O 0 0.00012090347
combination O 0 0.00032202483
with O 0 0.0021940554
folinic B-Chemical 0 0.99999976
acid I-Chemical 0 0.99892163
( O 0 0.0011284096
15 O 0 0.00014943375
mg O 0 0.0015971077
daily O 0 0.0001355885
) O 0 0.00026243416
and O 0 0.00021852252
intramascular O 0 0.733094
vitamin B-Chemical 0 0.99999547
B12 I-Chemical 0 0.9999994
( O 0 0.0025827668
1000 O 0 0.00080484094
micrograms O 0 0.0015747681
monthly O 0 0.00016373878
) O 0 0.0004011178
( O 0 0.00039067963
group O 0 0.000461493
II O 0 0.0057186335
, O 0 0.00089682994
n O 0 0.0008155151
= O 0 0.0021618218
37 O 0 0.0023909572
) O 0 0.0037947982
. O 0 0.0035643526

Finally O 0 0.0031060672
, O 0 0.0038015498
15 O 0 0.0014816349
patients O 0 0.0014597845
were O 0 0.0005748484
excluded O 0 0.0005106499
from O 0 0.0002864638
the O 0 0.0002542376
study O 0 0.0003617397
( O 0 0.0005966019
noncompliance O 0 0.01123133
14 O 0 0.00027466644
, O 0 0.0005630812
death B-Disease 0 0.21232337
1 O 0 0.00032420424
) O 0 0.0005085561
; O 0 0.00035676037
thus O 0 0.00017856374
, O 0 0.00031897906
60 O 0 0.00020590369
patients O 0 0.00031631597
( O 0 0.00028479123
31 O 0 0.00022075091
in O 0 0.00014700965
group O 0 0.00033075354
I O 0 0.0045303856
and O 0 0.0002928486
29 O 0 0.0003674946
in O 0 0.00023269148
group O 0 0.00052628416
II O 0 0.01883951
) O 0 0.0009991742
were O 0 0.00038409358
eligible O 0 0.0005507008
for O 0 0.0005900571
analysis O 0 0.0013491663
. O 0 0.0026240754

No O 0 0.0052162637
significant O 0 0.0023154216
differences O 0 0.0014279506
between O 0 0.001307929
groups O 0 0.0019418519
were O 0 0.0014571588
found O 0 0.0015749092
at O 0 0.0018238219
enrollment O 0 0.0043108957
. O 0 0.005517876

During O 0 0.00210567
the O 0 0.0018263186
study O 0 0.0025220094
, O 0 0.011749573
vitamin B-Chemical 0 0.9999815
B12 I-Chemical 0 0.9999982
and O 0 0.018976282
folate B-Chemical 0 0.9998312
levels O 0 0.00037777293
were O 0 0.00019830406
significantly O 0 0.00018899646
higher O 0 0.00016884324
in O 0 0.00014788217
group O 0 0.0003132071
II O 0 0.022364033
patients O 0 0.00050659437
; O 0 0.0003129295
however O 0 0.00016686918
, O 0 0.00022074711
no O 0 0.00010392474
differences O 0 0.00010566075
in O 0 0.0001846722
hemoglobin O 0 0.63238764
, O 0 0.00063939096
hematocrit O 0 0.51751256
, O 0 0.00034870597
mean O 0 0.00019867593
corpuscular O 0 0.9765277
volume O 0 0.0005137451
, O 0 0.00033918064
and O 0 0.00018662463
white O 0 0.0004313598
- O 0 0.0022745426
cell O 0 0.00040844452
, O 0 0.00067563995
neutrophil O 0 0.048900962
and O 0 0.00033691814
platelet O 0 0.7923295
counts O 0 0.00012489108
were O 0 9.4737574e-05
observed O 0 8.189956e-05
between O 0 9.052426e-05
groups O 0 0.0001812666
at O 0 0.00012661274
3 O 0 0.00016803989
, O 0 0.0003329177
6 O 0 0.00019242043
, O 0 0.00044540688
9 O 0 0.00030975643
and O 0 0.00044483255
12 O 0 0.0005002669
months O 0 0.0006153959
. O 0 0.002207271

Severe O 0 0.51028544
hematologic O 0 0.99480647
toxicity B-Disease 0 0.99577796
( O 0 0.002935722
neutrophil O 0 0.005395145
count O 0 0.0004942929
< O 0 0.0005438489
1000 O 0 0.00062269974
/ O 0 0.0008680082
mm3 O 0 0.00059115875
and O 0 0.00028508954
/ O 0 0.00089383125
or O 0 0.00024387076
hemoglobin O 0 0.047068894
< O 0 0.00033454894
8 O 0 0.00017591071
g O 0 0.00060818513
/ O 0 0.0012724634
dl O 0 0.0032831356
) O 0 0.00052068953
occurred O 0 0.00015628072
in O 0 0.00012553847
4 O 0 0.00011629865
patients O 0 0.00020780994
assigned O 0 0.000110400535
to O 0 0.00014319856
group O 0 0.00039081372
I O 0 0.004747768
and O 0 0.00037889823
7 O 0 0.00028135136
assigned O 0 0.00032039752
to O 0 0.00053204136
group O 0 0.0016961778
II O 0 0.051263906
. O 0 0.0039942944

There O 0 0.0035228874
was O 0 0.0018262733
no O 0 0.0011917374
correlation O 0 0.0011300623
between O 0 0.0019187552
vitamin B-Chemical 0 0.9999796
B12 I-Chemical 0 0.99999774
or O 0 0.0072219796
folate B-Chemical 0 0.99970764
levels O 0 0.0009392174
and O 0 0.0009146176
development O 0 0.0013032374
of O 0 0.0022232758
myelosuppression B-Disease 0 0.99853396
. O 0 0.0046566566

Vitamin B-Chemical 0 0.99997866
B12 I-Chemical 0 0.9999926
and O 0 0.8813598
folinic B-Chemical 0 0.9999988
acid I-Chemical 0 0.9995827
supplementation O 0 0.98220557
of O 0 0.0036224048
ZDV B-Chemical 0 0.9999709
therapy O 0 0.000656401
does O 0 0.0001359899
not O 0 0.00013198344
seem O 0 0.00012342916
useful O 0 0.00010070421
in O 0 9.834048e-05
preventing O 0 0.00010452533
or O 0 0.00012252717
reducing O 0 0.00023958427
ZDV B-Chemical 0 0.99997604
- O 0 0.013029476
induced O 0 0.00026275413
myelotoxicity B-Disease 0 0.9999614
in O 0 0.00011101589
the O 0 6.6757566e-05
overall O 0 8.67319e-05
treated O 0 0.00024741184
population O 0 0.00024243338
, O 0 0.0002732888
although O 0 0.00011196783
a O 0 0.00016558502
beneficial O 0 0.00014616318
effect O 0 0.000114347866
in O 0 0.00015652229
certain O 0 0.00020655064
subgroups O 0 0.00043100346
of O 0 0.00039597964
patients O 0 0.0012942521
cannot O 0 0.002470097
be O 0 0.0009935574
excluded O 0 0.0018847827
. O 0 0.0026746397

Safety O 0 0.010759741
and O 0 0.005131518
side O 0 0.009116561
- O 0 0.012472245
effects O 0 0.004469933
of O 0 0.010955929
alprazolam B-Chemical 0 0.9999659
. O 0 0.01496315

Controlled O 0 0.009328471
study O 0 0.0062727225
in O 0 0.0077197826
agoraphobia B-Disease 0 0.9999838
with O 0 0.051462434
panic B-Disease 0 0.9999223
disorder I-Disease 0 0.9989504
. O 0 0.011995212

BACKGROUND O 0 0.013613847
: O 0 0.0033845343
The O 0 0.0006789403
widespread O 0 0.00067994907
use O 0 0.0005559537
of O 0 0.0009060829
benzodiazepines B-Chemical 1 0.99990726
has O 0 0.00035833652
led O 0 0.000364527
to O 0 0.00026397977
increasing O 0 0.0003093787
recognition O 0 0.00039597513
of O 0 0.0005375466
their O 0 0.0006180065
unwanted O 0 0.0018323332
effects O 0 0.0017364754
. O 0 0.003491143

The O 0 0.0014810826
efficacy O 0 0.0015026481
of O 0 0.0023371887
alprazolam B-Chemical 0 0.9999933
and O 0 0.001135891
placebo O 0 0.034587268
in O 0 0.00074009964
panic B-Disease 0 0.9999838
disorder I-Disease 0 0.9997495
with O 0 0.0018667731
agoraphobia B-Disease 0 0.99999976
, O 0 0.0009122421
and O 0 0.00017807457
the O 0 0.00012103577
side O 0 0.00063458335
- O 0 0.001093631
effect O 0 0.0001048137
and O 0 0.00014659698
adverse O 0 0.0004428529
effect O 0 0.000102886836
profiles O 0 0.00013109304
of O 0 0.00022187814
both O 0 0.00026509556
drug O 0 0.0036646207
groups O 0 0.0006484947
were O 0 0.0006840481
measured O 0 0.0012794044
. O 0 0.0023479636

METHOD O 0 0.010313287
: O 0 0.0038026078
In O 0 0.0010108396
London O 0 0.002778292
and O 0 0.0009035002
Toronto O 0 0.0012468748
154 O 0 0.0010530982
patients O 0 0.0006242126
who O 0 0.00040021964
met O 0 0.00036897548
DSM O 0 0.002731581
- O 0 0.0026354524
III O 0 0.0069047934
criteria O 0 0.00034384636
for O 0 0.00035393136
panic B-Disease 0 0.9999801
disorder I-Disease 0 0.99968266
with O 0 0.0017511991
agoraphobia B-Disease 0 0.9999995
were O 0 0.00050070084
randomised O 0 0.0013817627
to O 0 0.0005775845
alprazolam B-Chemical 0 0.9999937
or O 0 0.0011193266
placebo O 0 0.017425902
. O 0 0.002458766

Subjects O 0 0.0042214734
in O 0 0.0018034247
each O 0 0.0010530334
drug O 0 0.0040377397
group O 0 0.0010989745
also O 0 0.0006337068
received O 0 0.0006409974
either O 0 0.0006883859
exposure O 0 0.0011225584
or O 0 0.0013752563
relaxation O 0 0.007582823
. O 0 0.004184922

Treatment O 0 0.007505958
was O 0 0.0017058679
from O 0 0.00089072477
weeks O 0 0.00048840384
0 O 0 0.0006824794
to O 0 0.00038503503
8 O 0 0.00037997004
and O 0 0.0003784867
was O 0 0.0003312003
then O 0 0.0003361936
tapered O 0 0.00074820797
from O 0 0.0003447577
weeks O 0 0.00029996733
8 O 0 0.00061118824
to O 0 0.0008824676
16 O 0 0.0020580844
. O 0 0.0033844444

RESULTS O 0 0.0066092475
: O 0 0.0053803194
Mean O 0 0.0028727176
alprazolam B-Chemical 0 0.99989843
dose O 0 0.0035409047
was O 0 0.0016134299
5 O 0 0.0017567938
mg O 0 0.007935185
daily O 0 0.0031722966
. O 0 0.004577578

Compared O 0 0.0019107186
with O 0 0.001762295
placebo O 0 0.013923025
subjects O 0 0.0023251418
, O 0 0.0045506237
alprazolam B-Chemical 0 0.9999969
patients O 0 0.0018956637
developed O 0 0.00038354378
more O 0 0.00035734838
adverse O 0 0.00081953336
reactions O 0 0.00026982263
( O 0 0.00032599166
21 O 0 0.00019882736
% O 0 0.0003126772
v O 0 0.0006678094
. O 0 0.00016222033
0 O 0 0.00019495044
% O 0 0.00030705697
) O 0 0.0004024392
of O 0 0.00030944712
depression B-Disease 0 0.9997241
, O 0 0.0018360172
enuresis B-Disease 0 0.99986863
, O 0 0.0009511264
disinhibition O 0 0.81398064
and O 0 0.00032334554
aggression B-Disease 0 0.9994097
; O 0 0.0005263413
and O 0 0.00014088632
more O 0 0.0001857326
side O 0 0.0005170029
- O 0 0.00091518206
effects O 0 0.000118905824
, O 0 0.0002561495
particularly O 0 0.00018476976
sedation O 0 0.011349781
, O 0 0.00075799803
irritability B-Disease 0 0.9999385
, O 0 0.00082895544
impaired B-Disease 0 0.04264218
memory I-Disease 0 0.9630966
, O 0 0.0011883293
weight B-Disease 0 0.0009143623
loss I-Disease 0 0.0010081532
and O 0 0.0018431206
ataxia B-Disease 0 0.99981195
. O 0 0.0046201516

Side O 0 0.16086616
- O 0 0.015203621
effects O 0 0.001747909
tended O 0 0.0014680001
to O 0 0.0006645227
diminish O 0 0.0005626456
during O 0 0.0003790301
treatment O 0 0.0004933975
but O 0 0.0005558737
remained O 0 0.0006357808
significant O 0 0.00057313783
at O 0 0.00057159696
week O 0 0.00068124506
8 O 0 0.0014385778
. O 0 0.002880166

Despite O 0 0.0037392196
this O 0 0.0038320918
, O 0 0.0043370784
the O 0 0.0020499318
drop O 0 0.004021382
- O 0 0.0064878757
out O 0 0.0015060819
rate O 0 0.0023342562
was O 0 0.0021172082
low O 0 0.004031685
. O 0 0.0057600383

CONCLUSIONS O 0 0.09087721
: O 0 0.0355033
Alprazolam B-Chemical 0 0.99998057
caused O 0 0.001440475
side O 0 0.0034444435
- O 0 0.0030287534
effects O 0 0.00031143246
and O 0 0.00028867525
adverse O 0 0.0006227408
effects O 0 0.0001555224
during O 0 0.00012865775
treatment O 0 0.00018549334
but O 0 0.00021423899
many O 0 0.0001833984
patients O 0 0.00049912266
were O 0 0.00029348166
willing O 0 0.00068842754
to O 0 0.0005022099
accept O 0 0.0010657604
these O 0 0.0015935121
. O 0 0.0030514174

Crescentic O 0 0.99235135
fibrillary O 0 0.23513311
glomerulonephritis B-Disease 2 0.9995931
associated O 0 0.0018228169
with O 0 0.0013213702
intermittent O 0 0.0064714807
rifampin B-Chemical 0 0.9999192
therapy O 0 0.0017716594
for O 0 0.0010713311
pulmonary B-Disease 0 0.9415663
tuberculosis I-Disease 0 0.91626346
. O 0 0.005088875

This O 0 0.004681196
case O 0 0.002199078
study O 0 0.0013845612
reveals O 0 0.0006926496
an O 0 0.00074919296
unusual O 0 0.0009748284
finding O 0 0.00038889362
of O 0 0.00040165367
rapidly O 0 0.0005423004
proliferative O 0 0.15071344
crescentic O 0 0.9997428
glomerulonephritis B-Disease 2 0.99999094
in O 0 0.00021466309
a O 0 0.00020465712
patient O 0 0.00013977595
treated O 0 0.00025032516
with O 0 0.00032927323
rifampin B-Chemical 0 0.99999547
who O 0 0.00040607995
had O 0 0.00011626972
no O 0 0.000111748086
other O 0 0.00015611865
identifiable O 0 0.00047615988
causes O 0 0.00031029584
for O 0 0.00028705323
developing O 0 0.0011307767
this O 0 0.0013670569
disease O 0 0.5864699
. O 0 0.003074459

This O 0 0.004211665
patient O 0 0.0018826517
underwent O 0 0.001180959
a O 0 0.000885652
10 O 0 0.0005012883
- O 0 0.0009375035
month O 0 0.00014348092
regimen O 0 0.00022550448
of O 0 0.00036525453
rifampin B-Chemical 0 0.9999826
and O 0 0.00079124497
isoniazid B-Chemical 1 0.9999865
for O 0 0.00026447352
pulmonary B-Disease 0 0.99375075
tuberculosis I-Disease 0 0.95355856
and O 0 0.00019924314
was O 0 0.0001173271
discovered O 0 0.00013134653
to O 0 9.050295e-05
have O 0 9.06109e-05
developed O 0 0.0001465288
signs O 0 0.00065203186
of O 0 0.00018448773
severe O 0 0.0029346698
renal B-Disease 0 0.69529575
failure I-Disease 0 0.002056523
five O 0 6.812903e-05
weeks O 0 6.283866e-05
after O 0 8.735768e-05
completion O 0 0.000173496
of O 0 0.0005649396
therapy O 0 0.0014563702
. O 0 0.0021696826

Renal O 0 0.03181983
biopsy O 0 0.002628167
revealed O 0 0.0014379874
severe O 0 0.011688953
glomerulonephritis B-Disease 2 0.9998337
with O 0 0.001992431
crescents O 0 0.99055254
, O 0 0.0025527133
electron O 0 0.00938916
dense O 0 0.0011126386
fibrillar O 0 0.0066808756
deposits O 0 0.005552555
and O 0 0.00073437125
moderate O 0 0.004315538
lymphocytic O 0 0.9913933
interstitial O 0 0.30525064
infiltrate O 0 0.041502714
. O 0 0.0033338794

Other O 0 0.0041846638
possible O 0 0.0018672548
causes O 0 0.002008929
of O 0 0.0016973587
rapidly O 0 0.0019284061
progressive O 0 0.08308764
glomerulonephritis B-Disease 2 0.9998926
were O 0 0.0010128475
investigated O 0 0.0008346876
and O 0 0.0012662906
ruled O 0 0.0028050693
out O 0 0.0023137766
. O 0 0.0044036736

This O 0 0.0051625418
report O 0 0.003454618
documents O 0 0.0020324227
the O 0 0.0008798946
unusual O 0 0.0013639209
occurrence O 0 0.0005874959
of O 0 0.00048415287
rapidly O 0 0.000601726
progressive O 0 0.038267348
glomerulonephritis B-Disease 2 0.9999697
with O 0 0.00076433347
crescents O 0 0.9926167
and O 0 0.0006399615
fibrillar O 0 0.13057521
glomerulonephritis B-Disease 2 0.99996996
in O 0 0.00035581968
a O 0 0.00047956296
patient O 0 0.00046131486
treated O 0 0.0010201101
with O 0 0.0018570749
rifampin B-Chemical 0 0.999949
. O 0 0.004287813

Acute O 0 0.22737066
confusion B-Disease 0 0.19510682
induced O 0 0.0015165978
by O 0 0.0009832227
a O 0 0.0009992574
high O 0 0.0008040771
- O 0 0.0020879146
dose O 0 0.000670431
infusion O 0 0.0007474013
of O 0 0.00043006995
5 B-Chemical 0 0.0005635064
- I-Chemical 0 0.007097846
fluorouracil I-Chemical 0 0.9997925
and O 0 0.007003705
folinic B-Chemical 0 0.9999938
acid I-Chemical 0 0.99811435
. O 0 0.009729716

A O 0 0.030506242
61 O 0 0.0058094016
- O 0 0.0076565216
year O 0 0.0013976715
- O 0 0.003357786
old O 0 0.0009801241
man O 0 0.0024877908
was O 0 0.00034522457
treated O 0 0.00042360197
with O 0 0.0002199301
combination O 0 0.00025285024
chemotherapy O 0 0.0009202281
incorporating O 0 0.00018784542
cisplatinum B-Chemical 0 0.99995923
, O 0 0.0012891103
etoposide B-Chemical 0 0.9998777
, O 0 0.00042840748
high O 0 0.00024875157
- O 0 0.00103302
dose O 0 0.0002653335
5 B-Chemical 0 0.00016309929
- I-Chemical 0 0.001860549
fluorouracil I-Chemical 0 0.9997098
( O 0 0.00035407007
2 O 0 0.00015783458
, O 0 0.0002348553
250 O 0 0.0004362843
mg O 0 0.0021967816
/ O 0 0.00092416664
m2 O 0 0.0015861072
/ O 0 0.0007995767
24 O 0 0.00019625074
hours O 0 0.0001844093
) O 0 0.000790668
and O 0 0.0012321948
folinic B-Chemical 0 0.9999982
acid I-Chemical 0 0.9943283
for O 0 0.0007899853
an O 0 0.001455584
inoperable O 0 0.9797662
gastric B-Disease 0 0.9906222
adenocarcinoma I-Disease 0 0.99972564
. O 0 0.005642987

He O 0 0.0081348475
developed O 0 0.0030615095
acute O 0 0.12589052
neurologic O 0 0.8901552
symptoms O 0 0.013513009
of O 0 0.00070881675
mental O 0 0.20782733
confusion B-Disease 0 0.75764114
, O 0 0.0023703654
disorientation B-Disease 0 0.99986076
and O 0 0.00096007343
irritability B-Disease 0 0.99996483
, O 0 0.0005820351
and O 0 0.00019169379
then O 0 0.00016221878
lapsed O 0 0.0011024489
into O 0 9.288542e-05
a O 0 0.000276376
deep O 0 0.0016336752
coma B-Disease 0 0.9998313
, O 0 0.00028347955
lasting O 0 9.425709e-05
for O 0 5.851906e-05
approximately O 0 9.940332e-05
40 O 0 8.2094964e-05
hours O 0 5.2256153e-05
during O 0 4.5466844e-05
the O 0 5.4329503e-05
first O 0 5.5114764e-05
dose O 0 0.00018002423
( O 0 0.00019606166
day O 0 8.65659e-05
2 O 0 0.00015519946
) O 0 0.00030787193
of O 0 0.00021694621
5 B-Chemical 0 0.00031548712
- I-Chemical 0 0.005721891
fluorouracil I-Chemical 0 0.9998779
and O 0 0.0043131374
folinic B-Chemical 0 0.999997
acid I-Chemical 0 0.99831843
infusion O 0 0.11807559
. O 0 0.0036183645

This O 0 0.0050000586
complication O 0 0.010300457
reappeared O 0 0.002235532
on O 0 0.0004772755
day O 0 0.00036442725
25 O 0 0.0004353574
during O 0 0.00018516305
the O 0 0.00016885228
second O 0 0.00016740417
dose O 0 0.00029657
of O 0 0.0002235685
5 B-Chemical 0 0.00027295214
- I-Chemical 0 0.0064461287
fluorouracil I-Chemical 0 0.9999385
and O 0 0.005173991
folinic B-Chemical 0 0.9999995
acid I-Chemical 0 0.9991179
, O 0 0.0020610187
which O 0 0.0003765979
were O 0 0.00022428246
then O 0 0.00022065264
the O 0 0.0002709931
only O 0 0.00056023
drugs O 0 0.00596616
given O 0 0.0010156183
. O 0 0.0025091947

Because O 0 0.010150825
folinic B-Chemical 0 0.99999344
acid I-Chemical 0 0.9984182
was O 0 0.001760395
unlikely O 0 0.00044845577
to O 0 0.00035857406
be O 0 0.0002797639
associated O 0 0.00025183422
with O 0 0.00023015885
this O 0 0.00024061097
condition O 0 0.0006393684
, O 0 0.0009871738
neurotoxicity B-Disease 0 0.99324083
due O 0 0.00014351677
to O 0 0.00013830683
high O 0 0.00027415366
- O 0 0.0012338049
dose O 0 0.00041301106
5 B-Chemical 0 0.00030387883
- I-Chemical 0 0.0030962864
fluorouracil I-Chemical 0 0.999445
was O 0 0.0006594996
highly O 0 0.00084776
suspected O 0 0.004068632
. O 0 0.0029070403

The O 0 0.0023790523
pathogenesis O 0 0.0028500028
of O 0 0.0016161328
5 B-Chemical 0 0.0014398018
- I-Chemical 0 0.048195697
fluorouracil I-Chemical 0 0.9999292
neurotoxicity B-Disease 0 0.999209
may O 0 0.0003718485
be O 0 0.00024190925
due O 0 0.0001535864
to O 0 0.00018140979
a O 0 0.00042385748
Krebs O 0 0.012813196
cycle O 0 0.00026204888
blockade O 0 0.0012538322
by O 0 0.00059960724
fluoroacetate B-Chemical 0 0.9999788
and O 0 0.0038468519
fluorocitrate B-Chemical 0 0.9999896
, O 0 0.13445762
thiamine B-Chemical 0 0.99999166
deficiency O 0 0.92598814
, O 0 0.0031592099
or O 0 0.0013687251
dihydrouracil B-Chemical 0 0.9998029
dehydrogenase O 0 0.9904841
deficiency O 0 0.898969
. O 0 0.0045873006

High O 0 0.006437807
- O 0 0.008100452
dose O 0 0.0024146114
5 B-Chemical 0 0.0014042811
- I-Chemical 0 0.012668539
fluorouracil I-Chemical 0 0.9998516
/ O 0 0.871399
folinic B-Chemical 0 0.99999857
acid I-Chemical 0 0.99592555
infusion O 0 0.007046068
therapy O 0 0.00042174733
has O 0 0.00012648688
recently O 0 0.00018792727
become O 0 0.0002945614
a O 0 0.00036226423
popular O 0 0.00042544858
regimen O 0 0.00043887543
for O 0 0.00042538898
various O 0 0.0012074198
cancers B-Disease 0 0.899362
. O 0 0.0040829573

It O 0 0.004977551
is O 0 0.0014536266
necessary O 0 0.000705252
that O 0 0.0006105574
both O 0 0.0006223847
oncologists O 0 0.0015363686
and O 0 0.000719389
neurologists O 0 0.0023942776
be O 0 0.00046760164
fully O 0 0.00037353716
aware O 0 0.0005616045
of O 0 0.000782022
this O 0 0.0011565859
unusual O 0 0.0033725323
complication O 0 0.015813602
. O 0 0.0039008805

Effect O 0 0.0027129243
of O 0 0.0025124599
switching O 0 0.003517649
carbamazepine B-Chemical 1 0.99999225
to O 0 0.0024839053
oxcarbazepine B-Chemical 0 0.99999344
on O 0 0.0005988551
the O 0 0.00060058705
plasma O 0 0.004968806
levels O 0 0.00084066216
of O 0 0.0020835574
neuroleptics O 0 0.9992112
. O 0 0.0042514284

A O 0 0.08010569
case O 0 0.025132265
report O 0 0.030963566
. O 0 0.029539136

Carbamazepine B-Chemical 0 0.9999366
was O 0 0.0027376711
switched O 0 0.0020194282
to O 0 0.0007211795
its O 0 0.00091158086
10 O 0 0.00087481603
- O 0 0.06945918
keto O 0 0.99970514
analogue O 0 0.086165294
oxcarbazepine B-Chemical 0 0.99999857
among O 0 0.00031021633
six O 0 8.74567e-05
difficult O 0 0.00015998009
- O 0 0.00090042956
to O 0 0.00015193751
- O 0 0.0023988795
treat O 0 0.0013644906
schizophrenic B-Disease 0 0.99999297
or O 0 0.00070863735
organic B-Disease 0 0.9998683
psychotic I-Disease 0 0.99999976
patients O 0 0.0015582362
using O 0 0.00018805132
concomitantly O 0 0.007758554
haloperidol B-Chemical 1 0.9999989
, O 0 0.024067031
chlorpromazine B-Chemical 0 0.9999943
or O 0 0.002841511
clozapine B-Chemical 0 0.9999846
. O 0 0.0038463457

This O 0 0.0050180326
change O 0 0.0019009038
resulted O 0 0.001003241
within O 0 0.0004913391
2 O 0 0.0007173143
- O 0 0.0013379895
4 O 0 0.00022657496
weeks O 0 0.0001305997
in O 0 0.00018139697
the O 0 0.00018724617
50 O 0 0.0003475609
- O 0 0.0010944606
200 O 0 0.00036330943
% O 0 0.00035441454
increase O 0 0.00015054012
in O 0 0.00014533002
the O 0 0.00015460156
plasma O 0 0.0015093416
levels O 0 0.00013465824
of O 0 0.00019064239
these O 0 0.00026978017
neuroleptics O 0 0.9994386
and O 0 0.00028072437
the O 0 0.00024725645
appearance O 0 0.0006661758
of O 0 0.0015288878
extrapyramidal B-Disease 0 0.9999845
symptoms I-Disease 0 0.8956062
. O 0 0.0033264344

None O 0 0.003742152
of O 0 0.0020265577
the O 0 0.0011745029
patients O 0 0.0016017084
showed O 0 0.00058007764
any O 0 0.00046547473
clinical O 0 0.0013310424
deteriotation O 0 0.002099485
during O 0 0.00026573197
the O 0 0.0002641842
following O 0 0.00024325187
3 O 0 0.000434778
- O 0 0.001469403
6 O 0 0.00057851506
months O 0 0.000679507
. O 0 0.002385007

The O 0 0.0018191576
results O 0 0.001340318
of O 0 0.0012351684
this O 0 0.0008997631
case O 0 0.00069897965
report O 0 0.00069979194
support O 0 0.00027891988
the O 0 0.00019826999
idea O 0 0.00019501663
that O 0 0.00013976781
in O 0 0.00018002113
contrast O 0 0.0004099323
with O 0 0.0021861985
carbamazepine B-Chemical 1 0.9999999
oxcarbazepine B-Chemical 0 0.9999999
does O 0 0.0002229159
not O 0 0.00012844383
induce O 0 0.00010740926
the O 0 0.0002300055
hepatic O 0 0.9985526
microsomal O 0 0.99347186
enzyme O 0 0.0010043608
systems O 0 0.00014924863
regulating O 0 5.9514514e-05
the O 0 0.00014773294
inactivation O 0 0.0002332468
of O 0 0.0006493683
antipsychotic O 0 0.998808
drugs O 0 0.07487481
. O 0 0.0026565995

Time O 0 0.008799061
course O 0 0.003912376
of O 0 0.0045496537
lipid O 0 0.98682886
peroxidation O 0 0.9999653
in O 0 0.005060327
puromycin B-Chemical 0 0.99660385
aminonucleoside I-Chemical 0 0.9999856
- O 0 0.19945513
induced O 0 0.004113169
nephropathy B-Disease 0 0.9999281
. O 0 0.00805683

Reactive O 0 0.99922276
oxygen B-Chemical 1 0.9994765
species O 0 0.0035912062
have O 0 0.0009677897
been O 0 0.00062256743
implicated O 0 0.0004147067
in O 0 0.00033874455
the O 0 0.00027268237
pathogenesis O 0 0.00053009175
of O 0 0.00042382552
acute O 0 0.34009188
puromycin B-Chemical 0 0.99415094
aminonucleoside I-Chemical 0 0.999997
( O 0 0.017149908
PAN B-Chemical 0 0.99991906
) O 0 0.002592075
- O 0 0.0034648622
induced O 0 0.0004905728
nephropathy B-Disease 0 0.99999475
, O 0 0.002175322
with O 0 0.0007692339
antioxidants O 0 0.9989503
significantly O 0 0.0010304643
reducing O 0 0.00066810736
the O 0 0.0013367635
proteinuria B-Disease 0 0.9998803
. O 0 0.004292675

The O 0 0.0022134853
temporal O 0 0.0038552282
relationship O 0 0.0010109532
between O 0 0.0014101719
lipid O 0 0.97957796
peroxidation O 0 0.9999764
in O 0 0.0008346285
the O 0 0.00044379642
kidney O 0 0.038783588
and O 0 0.00083009136
proteinuria B-Disease 0 0.99988794
was O 0 0.00050009217
examined O 0 0.00037711175
in O 0 0.00058482686
this O 0 0.0010479909
study O 0 0.0018903824
. O 0 0.0029300526

Rats O 0 0.0062337634
were O 0 0.0017276641
treated O 0 0.001777315
with O 0 0.00088087306
a O 0 0.0008632022
single O 0 0.0004283105
IV O 0 0.0133408625
injection O 0 0.00031029023
of O 0 0.00048602186
puromycin B-Chemical 0 0.96033216
aminonucleoside I-Chemical 0 0.9999939
, O 0 0.002796453
( O 0 0.0020398332
PAN B-Chemical 0 0.99978286
, O 0 0.00055716507
7 O 0 0.00013946494
. O 0 0.00012605822
5 O 0 0.00012565043
mg O 0 0.0008394438
/ O 0 0.0004929876
kg O 0 0.000376756
) O 0 0.00030289165
and O 0 0.00013140442
24 O 0 0.00013401419
hour O 0 0.00015360618
urine O 0 0.0015940632
samples O 0 0.00013047684
were O 0 7.9191486e-05
obtained O 0 6.371469e-05
prior O 0 4.703578e-05
to O 0 7.6301294e-05
sacrifice O 0 0.00014984955
on O 0 6.852349e-05
days O 0 7.116475e-05
3 O 0 0.00011236378
, O 0 0.00023902685
5 O 0 0.00015163128
, O 0 0.00026845108
7 O 0 0.00015501636
, O 0 0.00032857925
10 O 0 0.00023325547
, O 0 0.0004083986
17 O 0 0.00036097525
, O 0 0.00046123992
27 O 0 0.00042725244
, O 0 0.00055779633
41 O 0 0.0007212916
( O 0 0.0010243952
N O 0 0.9711741
= O 0 0.0019149109
5 O 0 0.0005048455
- O 0 0.0014864553
10 O 0 0.0005484975
per O 0 0.0006252744
group O 0 0.0014296602
) O 0 0.00374863
. O 0 0.0037004906

The O 0 0.0035590406
kidneys O 0 0.007072989
were O 0 0.0024031615
removed O 0 0.0020006297
, O 0 0.0032730403
flushed O 0 0.0044150925
with O 0 0.0025241503
ice O 0 0.014182042
cold O 0 0.012315877
TRIS O 0 0.93874854
buffer O 0 0.010402044
. O 0 0.0065971888

Kidney O 0 0.022340996
cortices O 0 0.03747706
from O 0 0.0017451479
each O 0 0.00097051635
animal O 0 0.001181839
were O 0 0.0009972508
used O 0 0.00096969696
to O 0 0.0011920121
prepare O 0 0.0018878129
homogenates O 0 0.00492711
. O 0 0.005551096

Tissue O 0 0.80470437
lipid O 0 0.9924688
peroxidation O 0 0.9999354
was O 0 0.0013756453
measured O 0 0.0007163781
in O 0 0.00041160083
whole O 0 0.0003772529
homogenates O 0 0.0004677659
as O 0 0.00024198863
well O 0 0.00022274785
as O 0 0.00026705905
in O 0 0.00035156394
lipid O 0 0.24499862
extracts O 0 0.0008892628
from O 0 0.0005447252
homogenates O 0 0.0041089905
as O 0 0.010251369
thiobarbituric B-Chemical 0 0.9999995
acid I-Chemical 0 0.99976057
reactive O 0 0.995676
substances O 0 0.8826613
. O 0 0.0042464216

Proteinuria B-Disease 0 0.99941456
was O 0 0.0027950075
evident O 0 0.0012303658
at O 0 0.000639692
day O 0 0.00048997835
5 O 0 0.0005032655
, O 0 0.00070611574
peaked O 0 0.0005246381
at O 0 0.00029800957
day O 0 0.00027029484
7 O 0 0.00031471928
and O 0 0.0004242811
persisted O 0 0.00046473902
to O 0 0.0006498102
day O 0 0.0009073608
27 O 0 0.0026381852
. O 0 0.0036678705

Lipid O 0 0.9991504
peroxidation O 0 0.9999242
in O 0 0.0026276943
homogenates O 0 0.0017510892
was O 0 0.00050699606
maximal O 0 0.00044706836
at O 0 0.00019368205
day O 0 0.00016166014
3 O 0 0.00018286408
and O 0 0.0002400148
declined O 0 0.00037640615
rapidly O 0 0.00030091056
to O 0 0.00024344608
control O 0 0.0003629646
levels O 0 0.00046120933
by O 0 0.00069467083
day O 0 0.0007924138
17 O 0 0.0021452163
. O 0 0.0029447328

This O 0 0.004688645
study O 0 0.0021518571
supports O 0 0.001007298
the O 0 0.00071712164
role O 0 0.0004684975
of O 0 0.0014555749
lipid O 0 0.9873526
peroxidation O 0 0.9999821
in O 0 0.0006641072
mediating O 0 0.00027570623
the O 0 0.0008051474
proteinuric B-Disease 0 0.99999523
injury I-Disease 0 0.9921136
in O 0 0.0031715203
PAN B-Chemical 0 0.99987805
nephropathy B-Disease 0 0.99997914
. O 0 0.0066359746

Composition O 0 0.007133715
of O 0 0.004981367
gall B-Disease 0 0.9851409
bladder I-Disease 0 0.27738926
stones I-Disease 0 0.9742724
associated O 0 0.0013992537
with O 0 0.0012693246
octreotide B-Chemical 0 0.99817896
: O 0 0.0017204259
response O 0 0.00069265655
to O 0 0.0009621208
oral O 0 0.10689846
ursodeoxycholic B-Chemical 0 0.9999652
acid I-Chemical 0 0.99320376
. O 0 0.008240497

Octreotide B-Chemical 0 0.99801517
, O 0 0.0050053806
an O 0 0.0014204787
effective O 0 0.00076895626
treatment O 0 0.0006926657
for O 0 0.0006839487
acromegaly B-Disease 0 0.99924576
, O 0 0.001506637
induces O 0 0.00063891674
gall B-Disease 0 0.9963864
bladder I-Disease 0 0.48333216
stones I-Disease 0 0.97952306
in O 0 0.0006114507
13 O 0 0.00064934714
- O 0 0.0016981788
60 O 0 0.0006140411
% O 0 0.0010680921
of O 0 0.0011483333
patients O 0 0.0032075227
. O 0 0.003417412

Because O 0 0.0019261892
knowledge O 0 0.002477075
of O 0 0.0020214203
stone O 0 0.3320392
composition O 0 0.0013207259
is O 0 0.0004123922
essential O 0 0.00025656156
for O 0 0.0001824026
studies O 0 0.00024214786
of O 0 0.00020168071
their O 0 0.00017943827
pathogenesis O 0 0.00037674757
, O 0 0.00033737966
treatment O 0 0.00017928454
, O 0 0.0002845052
and O 0 0.00016640555
prevention O 0 0.00027432464
, O 0 0.00032484034
this O 0 0.0001473771
was O 0 0.0001035445
investigated O 0 9.418863e-05
by O 0 8.749632e-05
direct O 0 6.566784e-05
and O 0 0.00010761193
indirect O 0 0.00016575294
methods O 0 0.00010760495
in O 0 0.00012946593
14 O 0 0.00021086012
octreotide B-Chemical 0 0.996518
treated O 0 0.0022877303
acromegalic B-Disease 0 0.999887
patients O 0 0.002869952
with O 0 0.0014191024
gall B-Disease 0 0.999074
stones I-Disease 0 0.9992035
. O 0 0.0065235714

Chemical O 0 0.024030363
analysis O 0 0.002892253
of O 0 0.0028582728
gall B-Disease 0 0.9967344
stones I-Disease 0 0.9962685
retrieved O 0 0.0005980691
at O 0 0.00032584873
cholecystectomy O 0 0.0025361993
from O 0 0.00017790875
two O 0 0.00012955509
patients O 0 0.0003867963
, O 0 0.0003352242
showed O 0 0.00017421659
that O 0 0.00014433471
they O 0 0.00018106331
contained O 0 0.00016974077
71 O 0 0.00053960795
% O 0 0.0005596717
and O 0 0.00041349363
87 O 0 0.0010390081
% O 0 0.0016008851
cholesterol B-Chemical 0 0.9976769
by O 0 0.001627783
weight O 0 0.0032715346
. O 0 0.0035329275

In O 0 0.0019163532
the O 0 0.0013735376
remaining O 0 0.0009775892
12 O 0 0.0006296752
patients O 0 0.00089568266
, O 0 0.00067526597
localised O 0 0.0003124311
computed O 0 0.00023852465
tomography O 0 0.00048346294
of O 0 0.00026455574
the O 0 0.0002673079
gall O 0 0.8316992
bladder O 0 0.023851609
showed O 0 0.00014313958
that O 0 8.1543345e-05
eight O 0 7.32577e-05
had O 0 0.000121417936
stones O 0 0.109081075
with O 0 0.00014370219
maximum O 0 0.00012334564
attenuation O 0 0.00010245868
scores O 0 8.1014194e-05
of O 0 9.136113e-05
< O 0 0.00016149743
100 O 0 0.00018001924
Hounsfield O 0 0.00018486261
units O 0 0.000106370324
( O 0 0.00017846366
values O 0 0.000110249566
of O 0 0.0001550094
< O 0 0.00033856666
100 O 0 0.0005864059
HU O 0 0.10761789
predict O 0 0.00035507942
cholesterol B-Chemical 0 0.99951434
rich O 0 0.0032391732
, O 0 0.0020452724
dissolvable O 0 0.23454887
stones O 0 0.9604121
) O 0 0.009391409
. O 0 0.0040444555

Gall O 0 0.28841415
bladder O 0 0.25436378
bile O 0 0.9767785
was O 0 0.001603515
obtained O 0 0.0006867317
by O 0 0.0005517169
ultrasound O 0 0.0007846376
guided O 0 0.0004379869
, O 0 0.00077895104
fine O 0 0.0007086776
needle O 0 0.0007459273
puncture O 0 0.0014477735
from O 0 0.00068727846
six O 0 0.0007390452
patients O 0 0.0028103644
. O 0 0.0037081155

All O 0 0.0021548336
six O 0 0.0012867998
patients O 0 0.002480145
had O 0 0.0016363725
supersaturated O 0 0.93059534
bile O 0 0.98962104
( O 0 0.0013841287
mean O 0 0.00035947352
( O 0 0.00063197274
SEM O 0 0.0008853589
) O 0 0.0011888874
cholesterol B-Chemical 0 0.9991316
saturation O 0 0.07430927
index O 0 0.0003871846
of O 0 0.0002618421
1 O 0 0.00024995644
. O 0 0.00018202401
19 O 0 0.00024266558
( O 0 0.00030782816
0 O 0 0.0002463512
. O 0 0.00020866848
08 O 0 0.0020066423
) O 0 0.0005503627
( O 0 0.00033516317
range O 0 0.00019139097
1 O 0 0.00020551888
. O 0 0.00020073086
01 O 0 0.0012907609
- O 0 0.001033401
1 O 0 0.0002151803
. O 0 0.00016863056
53 O 0 0.0002782529
) O 0 0.0004135443
) O 0 0.00037928837
and O 0 0.0001674072
all O 0 0.00015125064
had O 0 0.00020166377
abnormally O 0 0.0014571149
rapid O 0 0.0007583669
cholesterol B-Chemical 0 0.9999238
microcrystal O 0 0.96788263
nucleation O 0 0.0019813634
times O 0 0.00010886504
( O 0 0.00021583495
< O 0 0.00015023498
4 O 0 6.720328e-05
days O 0 5.464032e-05
( O 0 0.00015902634
range O 0 0.00012340305
1 O 0 0.00016379001
- O 0 0.0005229503
4 O 0 0.00012912552
) O 0 0.00035869406
) O 0 0.0004083215
, O 0 0.00031231612
whilst O 0 0.0002502755
in O 0 0.00017244687
four O 0 0.00012883834
, O 0 0.00039427142
the O 0 0.00027741032
bile O 0 0.9768305
contained O 0 0.0005790871
cholesterol B-Chemical 0 0.9998467
microcrystals O 0 0.70038056
immediately O 0 0.0004952816
after O 0 0.0004235533
sampling O 0 0.0010213208
. O 0 0.0022292146

Of O 0 0.0045530507
the O 0 0.0016032077
12 O 0 0.0009766783
patients O 0 0.0012829645
considered O 0 0.0006488782
for O 0 0.00065341056
oral O 0 0.14273638
ursodeoxycholic B-Chemical 0 0.9999945
acid I-Chemical 0 0.99859625
( O 0 0.22538309
UDCA B-Chemical 0 0.9999994
) O 0 0.004678424
treatment O 0 0.00025058637
, O 0 0.00026577225
two O 0 9.0750975e-05
had O 0 0.00014355742
a O 0 0.00025481713
blocked O 0 0.0004227512
cystic O 0 0.26244953
duct O 0 0.6240198
and O 0 0.00021508636
were O 0 0.0001209677
not O 0 0.00011390733
started O 0 0.00019648347
on O 0 0.00027538123
UDCA B-Chemical 0 0.9999987
while O 0 0.0005305379
one O 0 0.0002890812
was O 0 0.000302417
lost O 0 0.00041027262
to O 0 0.00042984658
follow O 0 0.0005517335
up O 0 0.0015004377
. O 0 0.0026486244

After O 0 0.0015764349
one O 0 0.0013545156
year O 0 0.000927487
of O 0 0.0007423525
treatment O 0 0.0005919715
, O 0 0.0006407864
five O 0 0.0001847435
of O 0 0.00024472887
the O 0 0.00016531053
remaining O 0 0.00016331545
nine O 0 0.00015008349
patients O 0 0.00028341362
showed O 0 0.00012094774
either O 0 0.00012888467
partial O 0 0.00021256282
( O 0 0.0002322433
n O 0 0.00017126312
= O 0 0.00036906393
3 O 0 0.00011170974
) O 0 0.00023143383
or O 0 9.497909e-05
complete O 0 0.000102115446
( O 0 0.00022356551
n O 0 0.00019576334
= O 0 0.0005253905
2 O 0 0.00025501713
) O 0 0.0010621146
gall B-Disease 0 0.9981516
stone I-Disease 0 0.99874663
dissolution O 0 0.87975556
, O 0 0.00064981054
suggesting O 0 0.0001643156
that O 0 0.0001990973
their O 0 0.00040418276
stones O 0 0.6345724
were O 0 0.0014700014
cholesterol B-Chemical 0 0.999198
rich O 0 0.008819983
. O 0 0.003739058

This O 0 0.0050054323
corresponds O 0 0.0016771506
, O 0 0.0019912198
by O 0 0.0008741486
actuarial O 0 0.0024037983
( O 0 0.0009394121
life O 0 0.00042992772
table O 0 0.00038052571
) O 0 0.0007488838
analysis O 0 0.00030903998
, O 0 0.0004442677
to O 0 0.00022723914
a O 0 0.00044177208
combined O 0 0.0007583173
gall B-Disease 0 0.9992619
stone I-Disease 0 0.99914527
dissolution O 0 0.8634133
rate O 0 0.0005992322
of O 0 0.00034003006
58 O 0 0.00049552054
. O 0 0.00025181888
3 O 0 0.000239648
( O 0 0.00050015916
15 O 0 0.0003492729
. O 0 0.00043495087
9 O 0 0.00062964845
% O 0 0.0018340085
) O 0 0.0036508006
. O 0 0.0037833147

In O 0 0.0018318745
conclusion O 0 0.0014748912
, O 0 0.0042813234
octreotide B-Chemical 0 0.99897254
induced O 0 0.002583186
gall B-Disease 0 0.9994394
stones I-Disease 0 0.9993494
are O 0 0.0004746124
generally O 0 0.00034548467
small O 0 0.0004068945
, O 0 0.0004106962
multiple O 0 0.00019706924
, O 0 0.00040187407
and O 0 0.00035655976
cholesterol B-Chemical 0 0.9997836
rich O 0 0.0011799616
although O 0 0.00021559492
, O 0 0.00032153464
in O 0 0.00012980042
common O 0 0.000155864
with O 0 0.00021329754
spontaneous O 0 0.011478241
gall B-Disease 0 0.9999521
stone I-Disease 0 0.99985063
disease I-Disease 0 0.997401
, O 0 0.00039818836
at O 0 8.687328e-05
presentation O 0 0.0002315994
some O 0 0.00012389023
patients O 0 0.00024988924
will O 0 8.7750086e-05
have O 0 0.000111768546
a O 0 0.00025992832
blocked O 0 0.00049867947
cystic O 0 0.35391143
duct O 0 0.7714945
and O 0 0.00054019043
some O 0 0.00077614724
gall B-Disease 0 0.9988477
stones I-Disease 0 0.99916375
containing O 0 0.0027952057
calcium B-Chemical 0 0.9975889
. O 0 0.0046227053

Erythema B-Disease 0 0.99175066
multiforme I-Disease 0 0.99857104
and O 0 0.0068204356
hypersensitivity B-Disease 0 0.9815285
myocarditis I-Disease 0 0.99988306
caused O 0 0.005070259
by O 0 0.0058091544
ampicillin B-Chemical 1 0.9996674
. O 0 0.0090632

OBJECTIVE O 0 0.019968571
: O 0 0.0038987543
To O 0 0.00075536175
report O 0 0.0016364143
a O 0 0.0012612051
case O 0 0.0009473883
of O 0 0.0014438864
erythema B-Disease 0 0.99691147
multiforme I-Disease 0 0.9987697
and O 0 0.0011341976
hypersensitivity B-Disease 0 0.97271395
myocarditis I-Disease 0 0.99996555
caused O 0 0.00189581
by O 0 0.0025755283
ampicillin B-Chemical 1 0.9998493
. O 0 0.0051493216

CASE O 0 0.2347188
SUMMARY O 0 0.007428039
: O 0 0.004327946
A O 0 0.0070329225
13 O 0 0.0014147816
- O 0 0.00285764
year O 0 0.0006276575
- O 0 0.0017695298
old O 0 0.0005978936
boy O 0 0.0012057098
was O 0 0.00032644699
treated O 0 0.0006679584
with O 0 0.00074906595
ampicillin B-Chemical 1 0.99995315
and O 0 0.0013854707
gentamicin B-Chemical 0 0.99990106
because O 0 0.00059139205
of O 0 0.0011916935
suspected O 0 0.02434619
septicemia B-Disease 0 0.9982424
. O 0 0.0044191694

Medications O 0 0.03875225
were O 0 0.0023294273
discontinued O 0 0.004088254
when O 0 0.001368147
erythema B-Disease 0 0.9872751
multiforme I-Disease 0 0.9970733
and O 0 0.0012653333
congestive B-Disease 0 0.9994287
heart I-Disease 0 0.24029435
failure I-Disease 0 0.028783198
caused O 0 0.0008488354
by O 0 0.0014271538
myocarditis B-Disease 0 0.99956423
occurred O 0 0.002898933
. O 0 0.0035217998

The O 0 0.0028506694
patient O 0 0.0027386446
was O 0 0.0017731356
treated O 0 0.002636808
with O 0 0.0026665737
methylprednisolone B-Chemical 0 0.99961156
and O 0 0.0026100555
gradually O 0 0.0034941381
improved O 0 0.004445889
. O 0 0.00514094

Macrophage O 0 0.8597034
- O 0 0.03285155
migration O 0 0.007938325
inhibition O 0 0.0036828138
( O 0 0.005427404
MIF O 0 0.7658918
) O 0 0.0035956996
test O 0 0.0017735477
with O 0 0.0021781453
ampicillin B-Chemical 1 0.9997222
was O 0 0.0022526938
positive O 0 0.0028997022
. O 0 0.004470266

DISCUSSION O 0 0.005762923
: O 0 0.0029130394
After O 0 0.0007611448
most O 0 0.0014906154
infections B-Disease 0 0.028006157
causing O 0 0.0032663017
erythema B-Disease 0 0.99776685
multiforme I-Disease 0 0.9989505
and O 0 0.00086037983
myocarditis B-Disease 0 0.9998041
were O 0 0.0004047106
ruled O 0 0.00054174406
out O 0 0.0002473437
, O 0 0.00055769004
a O 0 0.0005961611
drug B-Disease 0 0.027857488
- I-Disease 0 0.0054044514
induced I-Disease 0 0.000812393
allergic I-Disease 0 0.99899596
reaction I-Disease 0 0.0020763187
was O 0 0.0012282552
suspected O 0 0.0058161477
. O 0 0.0029830541

Positive O 0 0.013984619
MIF O 0 0.43908927
test O 0 0.0026264088
for O 0 0.0014243257
ampicillin B-Chemical 1 0.99971086
showed O 0 0.0006929701
sensitization O 0 0.0006328968
of O 0 0.0004257614
the O 0 0.00035042907
patient O 0 0.0005342364
' O 0 0.0009652863
s O 0 0.0011144918
lymphocytes O 0 0.012370943
to O 0 0.0018087581
ampicillin B-Chemical 1 0.9996871
. O 0 0.004797803

CONCLUSIONS O 0 0.04871881
: O 0 0.014169282
Hypersensitivity B-Disease 0 0.98183066
myocarditis I-Disease 0 0.99984765
is O 0 0.0012170369
a O 0 0.0014361632
rare O 0 0.0023333868
and O 0 0.0007875215
dangerous O 0 0.00355877
manifestation O 0 0.0057359766
of O 0 0.0013923415
allergy B-Disease 0 0.9801911
to O 0 0.0021118452
penicillins B-Chemical 0 0.9988433
. O 0 0.0049593826

Clomipramine B-Chemical 0 0.9999453
- O 0 0.22679384
induced O 0 0.0038213418
sleep B-Disease 0 0.9952042
disturbance I-Disease 0 0.9541937
does O 0 0.0007857943
not O 0 0.00065130205
impair O 0 0.0008620604
its O 0 0.001876024
prolactin O 0 0.9937919
- O 0 0.014280121
releasing O 0 0.0020703755
action O 0 0.0024100475
. O 0 0.0038852403

The O 0 0.0019308471
present O 0 0.0013643975
study O 0 0.0012616448
was O 0 0.00063690403
undertaken O 0 0.00040960012
to O 0 0.00022705505
examine O 0 0.00010454418
the O 0 0.00014426949
role O 0 0.00010345291
of O 0 0.00036998003
sleep B-Disease 0 0.9796984
disturbance I-Disease 0 0.8943323
, O 0 0.00043780575
induced O 0 0.00017833912
by O 0 0.0003535021
clomipramine B-Chemical 0 0.99999917
administration O 0 0.0007088403
, O 0 0.00022986543
on O 0 7.396696e-05
the O 0 0.000104637125
secretory O 0 0.0003947884
rate O 0 0.00030108562
of O 0 0.00043618216
prolactin O 0 0.99885774
( O 0 0.008901703
PRL O 0 0.9999497
) O 0 0.0011895825
in O 0 0.00016429916
addition O 0 0.0001077447
to O 0 0.00018996485
the O 0 0.00024505923
direct O 0 0.00035669643
drug O 0 0.0055613294
effect O 0 0.0014002357
. O 0 0.0031398837

Two O 0 0.0020664325
groups O 0 0.0018241362
of O 0 0.001133704
supine O 0 0.0017163922
subjects O 0 0.0008497447
were O 0 0.00032375485
studied O 0 0.00033468325
under O 0 0.00023239327
placebo O 0 0.0033368876
- O 0 0.0010293459
controlled O 0 0.00018254839
conditions O 0 0.00017953465
, O 0 0.0002966345
one O 0 0.000115845745
during O 0 9.11421e-05
the O 0 0.0001139158
night O 0 0.0003248809
, O 0 0.00028329907
when O 0 0.00012240898
sleeping O 0 0.0022053667
( O 0 0.00027649934
n O 0 0.00017484534
= O 0 0.0003551947
7 O 0 0.0001042022
) O 0 0.00023882366
and O 0 0.00011821755
the O 0 9.752402e-05
other O 0 0.000118035074
at O 0 0.00014165929
daytime O 0 0.0014319993
, O 0 0.00035477628
when O 0 0.00018233409
awake O 0 0.0009804729
( O 0 0.0005852127
n O 0 0.0005507969
= O 0 0.0013633715
6 O 0 0.0007970314
) O 0 0.0027568066
. O 0 0.0031386723

Each O 0 0.0017177124
subject O 0 0.00096235046
received O 0 0.0008129695
a O 0 0.0007911549
single O 0 0.000374386
50 O 0 0.00056031434
mg O 0 0.0032352158
dose O 0 0.0005978215
of O 0 0.000620902
clomipramine B-Chemical 0 0.9999963
given O 0 0.00025108526
orally O 0 0.00052808016
2 O 0 0.0002733547
hours O 0 0.00022392135
before O 0 0.00027873457
blood O 0 0.0027065468
collection O 0 0.0016151745
. O 0 0.002798669

Plasma O 0 0.9709212
PRL O 0 0.9994789
concentrations O 0 0.004311506
were O 0 0.0009830854
analysed O 0 0.0006408136
at O 0 0.00031319575
10 O 0 0.00031029555
min O 0 0.0003365319
intervals O 0 0.00019145376
and O 0 0.00024235067
underlying O 0 0.00035457034
secretory O 0 0.0006004806
rates O 0 0.00040294725
calculated O 0 0.00035518827
by O 0 0.00049289834
a O 0 0.0010187373
deconvolution O 0 0.0014787664
procedure O 0 0.0013109614
. O 0 0.0028997986

For O 0 0.0013505432
both O 0 0.0011356269
experiments O 0 0.00074499735
the O 0 0.0007296111
drug O 0 0.007760492
intake O 0 0.0055677732
led O 0 0.00040747307
to O 0 0.00022106094
significant O 0 0.00023598816
increases O 0 0.00028784585
in O 0 0.0004811509
PRL O 0 0.9999418
secretion O 0 0.008914475
, O 0 0.00046180433
acting O 0 0.00013532257
preferentially O 0 7.411651e-05
on O 0 8.133646e-05
tonic O 0 0.0004709732
secretion O 0 0.00047350596
as O 0 0.00011889133
pulse O 0 0.00024371523
amplitude O 0 0.00033041404
and O 0 0.00013064292
frequency O 0 0.000121370365
did O 0 0.00017350607
not O 0 0.00015455867
differ O 0 0.00020014548
significantly O 0 0.00027131158
from O 0 0.00024489878
corresponding O 0 0.00024930952
control O 0 0.0006591279
values O 0 0.001293358
. O 0 0.002434243

During O 0 0.0018921304
the O 0 0.0018181058
night O 0 0.012818481
clomipramine B-Chemical 0 0.9999962
ingestion O 0 0.18433957
altered O 0 0.0005275028
the O 0 0.00025082062
complete O 0 0.00025613265
sleep O 0 0.02056849
architecture O 0 0.00035575745
in O 0 0.00017043343
that O 0 0.00014642891
it O 0 0.0003814526
suppressed O 0 0.0007258312
REM O 0 0.99984586
sleep O 0 0.2684586
and O 0 0.00022097708
the O 0 0.00018394376
sleep O 0 0.0034947211
cycles O 0 0.00013977355
and O 0 0.0002825492
induced O 0 0.00050956436
increased O 0 0.0017529031
wakefulness O 0 0.6452521
. O 0 0.002905465

As O 0 0.0018601002
the O 0 0.0013427082
relative O 0 0.0009320955
increase O 0 0.0010022807
in O 0 0.0013724444
PRL O 0 0.9998073
secretion O 0 0.0042900206
expressed O 0 0.00022897538
as O 0 0.00023972343
a O 0 0.00026254053
percentage O 0 0.000118729535
of O 0 0.00015611136
the O 0 0.00011293633
mean O 0 0.000113836104
did O 0 0.00014345464
not O 0 0.00010951599
significantly O 0 0.00015735386
differ O 0 0.000100554025
between O 0 6.979951e-05
the O 0 8.606546e-05
night O 0 0.00018731527
and O 0 9.580047e-05
day O 0 5.8973394e-05
time O 0 6.591567e-05
studies O 0 0.00015820102
( O 0 0.0002729644
46 O 0 0.0002716245
+ O 0 0.00072902965
/ O 0 0.0012639512
- O 0 0.0010466699
19 O 0 0.00021902793
% O 0 0.00024689836
vs O 0 0.0002073468
34 O 0 0.00022201272
+ O 0 0.0007494143
/ O 0 0.0014984421
- O 0 0.0015249648
10 O 0 0.00020831721
% O 0 0.00041207622
) O 0 0.0005714799
, O 0 0.0004125902
it O 0 0.00026912047
can O 0 0.00011100615
be O 0 0.00012355139
concluded O 0 0.00013798685
that O 0 9.9352896e-05
the O 0 0.00013731823
observed O 0 0.00026372465
sleep B-Disease 0 0.994279
disturbance I-Disease 0 0.9526634
did O 0 0.00026086232
not O 0 0.00015403403
interfere O 0 0.0001652185
with O 0 0.00023719115
the O 0 0.00027327053
drug O 0 0.004441568
action O 0 0.0007238897
per O 0 0.00096186285
se O 0 0.0036890234
. O 0 0.0028112477

The O 0 0.0024714286
presence O 0 0.00231707
of O 0 0.0036642568
REM O 0 0.9996278
sleep O 0 0.65621984
was O 0 0.0004791202
shown O 0 0.00016712205
not O 0 0.00019517251
to O 0 0.00017258307
be O 0 0.00017211668
a O 0 0.00023091146
determining O 0 0.000104659484
factor O 0 0.0008963079
either O 0 0.00013446118
for O 0 0.000100035104
secretory O 0 0.0002701148
pulse O 0 0.00019811356
amplitude O 0 0.00023256906
and O 0 0.00010320018
frequency O 0 0.000100047604
, O 0 0.00022551845
as O 0 0.000120848716
, O 0 0.00020138726
for O 0 7.8624355e-05
both O 0 9.482145e-05
, O 0 0.00019606053
mean O 0 0.00011002859
nocturnal O 0 0.0025060591
values O 0 0.00011464516
were O 0 9.306451e-05
similar O 0 7.9569516e-05
with O 0 0.00016563824
and O 0 0.00024214253
without O 0 0.00037285747
prior O 0 0.0005503217
clomipramine B-Chemical 0 0.99999475
ingestion O 0 0.25941983
. O 0 0.0029315127

Survey O 0 0.007753849
of O 0 0.004011602
complications O 0 0.012377494
of O 0 0.0042792712
indocyanine B-Chemical 0 0.9904917
green I-Chemical 0 0.0037082639
angiography O 0 0.007907328
in O 0 0.0023438502
Japan O 0 0.0063999565
. O 0 0.0053934488

PURPOSE O 0 0.008401193
: O 0 0.0038680385
We O 0 0.00095173053
evaluated O 0 0.0007319873
the O 0 0.0005534627
safety O 0 0.0006715379
of O 0 0.00095662655
indocyanine B-Chemical 0 0.98781615
green I-Chemical 0 0.00092150696
for O 0 0.00039195849
use O 0 0.0005123267
in O 0 0.00079324626
fundus O 0 0.012742206
angiography O 0 0.010342956
. O 0 0.0032278262

METHODS O 0 0.0041596694
: O 0 0.0026825494
We O 0 0.0007719951
sent O 0 0.0006622737
a O 0 0.00060228584
questionnaire O 0 0.0002797009
concerning O 0 0.00025170078
complications O 0 0.0019179261
of O 0 0.0005732144
indocyanine B-Chemical 0 0.9974605
green I-Chemical 0 0.000456325
to O 0 0.00016085088
32 O 0 0.00022326027
institutions O 0 0.00038494676
in O 0 0.00015515432
Japan O 0 0.0004791305
, O 0 0.00026814773
which O 0 0.00013130934
were O 0 8.250991e-05
selected O 0 6.396587e-05
on O 0 5.5365614e-05
the O 0 6.941459e-05
basis O 0 8.613599e-05
of O 0 0.00012462721
the O 0 0.0001015534
client O 0 0.00016802513
list O 0 7.204869e-05
from O 0 9.404342e-05
the O 0 0.00011792483
Topcon O 0 0.0031889419
Company O 0 0.008557003
, O 0 0.0004772741
which O 0 0.0003333611
manufactures O 0 0.0013729681
the O 0 0.0005686588
indocyanine B-Chemical 0 0.990612
green I-Chemical 0 0.0014503628
fundus O 0 0.030795112
camera O 0 0.0040658335
. O 0 0.0030492998

RESULTS O 0 0.0047566015
: O 0 0.0035846988
Ophthalmologists O 0 0.0031369124
at O 0 0.0006326784
15 O 0 0.0005695058
institutions O 0 0.0009857921
responded O 0 0.0007282894
, O 0 0.0007035341
reporting O 0 0.0003931983
a O 0 0.00040341102
total O 0 0.0002637571
of O 0 0.00027525
3 O 0 0.00024847826
, O 0 0.00055069354
774 O 0 0.0023022757
indocyanine B-Chemical 0 0.9503897
green I-Chemical 0 0.00033974767
angiograms O 0 0.0019036008
performed O 0 0.0001441008
on O 0 0.00012077925
2 O 0 0.00023379718
, O 0 0.00043759125
820 O 0 0.0010188228
patients O 0 0.00045362697
between O 0 0.0002857276
June O 0 0.0005095947
1984 O 0 0.0014634228
and O 0 0.00092123746
September O 0 0.0011993587
1992 O 0 0.0037918503
. O 0 0.003542682

Before O 0 0.002548783
angiography O 0 0.005708521
, O 0 0.0022849415
intradermal O 0 0.0013733113
or O 0 0.000611783
intravenous O 0 0.004700511
indocyanine B-Chemical 0 0.98314846
green I-Chemical 0 0.0006277478
testing O 0 0.00028867193
, O 0 0.00045901118
or O 0 0.00022633035
both O 0 0.00022497315
was O 0 0.0002493628
performed O 0 0.00025000982
at O 0 0.00027339827
13 O 0 0.0004972609
of O 0 0.00065999443
15 O 0 0.00095188234
institutions O 0 0.0031959934
. O 0 0.0034166605

For O 0 0.0015619679
three O 0 0.0010803902
patients O 0 0.0022472793
, O 0 0.0015642949
the O 0 0.00059038005
decision O 0 0.0006932502
was O 0 0.00041278513
made O 0 0.00035737618
not O 0 0.00030513504
to O 0 0.00027748942
proceed O 0 0.00042086674
with O 0 0.00032151715
angiography O 0 0.0012944746
after O 0 0.00022867534
positive O 0 0.00057507056
preangiographic O 0 0.0029687395
testing O 0 0.0014889041
. O 0 0.002870648

The O 0 0.0023642709
dosage O 0 0.005084305
of O 0 0.0022079067
indocyanine B-Chemical 0 0.9902784
green I-Chemical 0 0.0009844388
used O 0 0.00032254163
for O 0 0.00023152409
angiography O 0 0.0011002185
varied O 0 0.00029416714
from O 0 0.00019634246
25 O 0 0.0002908871
to O 0 0.00021427638
75 O 0 0.00056046183
mg O 0 0.0037627618
, O 0 0.0007160481
depending O 0 0.0005672013
upon O 0 0.00045727732
the O 0 0.00086276466
institution O 0 0.002820163
. O 0 0.0034181855

There O 0 0.0040729353
were O 0 0.0021873303
13 O 0 0.0017679477
cases O 0 0.0015494189
of O 0 0.00087334344
adverse O 0 0.0022697086
reactions O 0 0.00068616326
( O 0 0.0006763351
0 O 0 0.00037719932
. O 0 0.00022415184
34 O 0 0.0002620726
% O 0 0.0004231637
) O 0 0.00046226586
, O 0 0.00028725367
ten O 0 0.000105529754
of O 0 0.00017575896
which O 0 0.0002029798
were O 0 0.0001656387
mild O 0 0.0027334432
reactions O 0 0.00019016948
such O 0 0.0001257221
as O 0 0.0002348291
nausea B-Disease 0 0.9994672
, O 0 0.0014448995
exanthema B-Disease 0 0.94413656
, O 0 0.0012436215
urtication B-Disease 0 0.9939096
, O 0 0.0014742195
itchiness B-Disease 0 0.81471074
, O 0 0.00035207192
and O 0 0.00019947524
urgency O 0 0.0009317017
to O 0 0.00021223028
defecate O 0 0.001779223
, O 0 0.0005240312
and O 0 0.0003529665
did O 0 0.00046043692
not O 0 0.00049479725
require O 0 0.00065644196
treatment O 0 0.0014333267
. O 0 0.0027887602

Also O 0 0.0029193899
recorded O 0 0.0018091138
were O 0 0.00095812156
one O 0 0.00062834553
case O 0 0.00059123087
of O 0 0.000569102
pain B-Disease 0 0.008090638
of O 0 0.0003726908
the O 0 0.00028667282
vein O 0 0.03144589
, O 0 0.00053802406
which O 0 0.00023571495
required O 0 0.00012710677
treatment O 0 0.0002689263
, O 0 0.0005058754
and O 0 0.00036696473
two O 0 0.0003393522
cases O 0 0.0012130667
of O 0 0.0019678543
hypotension B-Disease 0 0.9997067
. O 0 0.0042928765

The O 0 0.003034514
two O 0 0.0026710895
hypotensive B-Disease 0 0.98008865
patients O 0 0.0033707058
required O 0 0.0010763075
treatment O 0 0.001840807
for O 0 0.0024333817
shock B-Disease 0 0.7700944
. O 0 0.008078391

CONCLUSIONS O 0 0.022419326
: O 0 0.0050692465
A O 0 0.005740223
comparison O 0 0.00066544156
of O 0 0.0005420121
frequency O 0 0.0003513371
of O 0 0.00037402604
adverse O 0 0.0011197552
reactions O 0 0.00032411062
to O 0 0.00022856638
indocyanine B-Chemical 0 0.9942913
green I-Chemical 0 0.00026980744
with O 0 0.00012964258
the O 0 8.770022e-05
previously O 0 0.00012053303
reported O 0 0.000103516075
frequency O 0 7.500563e-05
of O 0 0.000100021076
such O 0 9.137576e-05
reactions O 0 0.00016847979
to O 0 0.00016138537
fluorescein B-Chemical 0 0.9995266
sodium I-Chemical 0 0.9997862
indicated O 0 0.00011294407
that O 0 0.0001513069
indocyanine B-Chemical 0 0.99803764
green I-Chemical 0 0.0003118588
is O 0 0.0001266707
a O 0 0.0002384405
safe O 0 0.00027112232
as O 0 0.0002798236
fluorescein B-Chemical 0 0.7320508
for O 0 0.00028687489
use O 0 0.00040461033
in O 0 0.00071213
angiography O 0 0.0065663513
. O 0 0.0024288648

Angioedema B-Disease 0 0.99681586
following O 0 0.0022736054
the O 0 0.0020981221
intravenous O 0 0.0071650534
administration O 0 0.0037566125
of O 0 0.0052650557
metoprolol B-Chemical 1 0.99996054
. O 0 0.010646663

A O 0 0.031789564
72 O 0 0.0047927857
- O 0 0.007122278
year O 0 0.0014424701
- O 0 0.0034983878
old O 0 0.0010821801
woman O 0 0.0017585902
was O 0 0.000498206
admitted O 0 0.00085804827
to O 0 0.0002382069
the O 0 0.00021297546
hospital O 0 0.0003464719
with O 0 0.00026890606
" O 0 0.0005312637
flash O 0 0.00090535893
" O 0 0.00084188825
pulmonary B-Disease 0 0.72033834
edema I-Disease 0 0.99986756
, O 0 0.00065316685
preceded O 0 0.00027959666
by O 0 0.00026621658
chest B-Disease 0 0.00087815704
pain I-Disease 0 0.0075777215
, O 0 0.000862579
requiring O 0 0.00076057314
intubation O 0 0.002617207
. O 0 0.0023305924

Her O 0 0.005418767
medical O 0 0.0046429806
history O 0 0.0020983445
included O 0 0.0009861905
coronary B-Disease 0 0.037673
artery I-Disease 0 0.28657165
disease I-Disease 0 0.1164383
with O 0 0.00044133535
previous O 0 0.00046726965
myocardial B-Disease 0 0.9988827
infarctions I-Disease 0 0.9993174
, O 0 0.0030107226
hypertension B-Disease 2 0.9999715
, O 0 0.0025000954
and O 0 0.0018594151
diabetes B-Disease 0 0.9998361
mellitus I-Disease 0 0.9999143
. O 0 0.006758612

A O 0 0.043236017
history O 0 0.0075000105
of O 0 0.0055904393
angioedema B-Disease 0 0.9997521
secondary O 0 0.0028835516
to O 0 0.0017877052
lisinopril B-Chemical 0 0.9999502
therapy O 0 0.0027172158
was O 0 0.0013458154
elicited O 0 0.0018205002
. O 0 0.003929388

Current O 0 0.0070862416
medications O 0 0.013161139
did O 0 0.0018922924
not O 0 0.0011842872
include O 0 0.0015555018
angiotensin B-Chemical 0 0.9999585
- O 0 0.26904935
converting O 0 0.002637726
enzyme O 0 0.0027841346
inhibitors O 0 0.001807203
or O 0 0.001359303
beta O 0 0.9267917
- O 0 0.2795953
blockers O 0 0.98527074
. O 0 0.00600786

She O 0 0.008107028
had O 0 0.0031124006
no O 0 0.0022286843
previous O 0 0.0024483406
beta O 0 0.62979484
- O 0 0.022677815
blocking O 0 0.0034532084
drug O 0 0.028770138
exposure O 0 0.004514839
. O 0 0.0056735436

During O 0 0.0017644747
the O 0 0.0011228027
first O 0 0.00059211144
day O 0 0.0004890225
of O 0 0.00055535266
hospitalization O 0 0.00076588243
( O 0 0.00055858085
while O 0 0.00028908617
intubated O 0 0.0009740879
) O 0 0.000641749
, O 0 0.00059573463
intravenous O 0 0.033223692
metoprolol B-Chemical 1 0.99999535
was O 0 0.00037081493
given O 0 0.00022377961
, O 0 0.00062004005
resulting O 0 0.00047427436
in O 0 0.00093310705
severe O 0 0.08077936
angioedema B-Disease 0 0.9997249
. O 0 0.0042745336

The O 0 0.004219132
angioedema B-Disease 0 0.9987093
resolved O 0 0.0017258016
after O 0 0.00050970545
therapy O 0 0.00080293743
with O 0 0.00073472195
intravenous O 0 0.01558669
steroids B-Chemical 0 0.9977742
and O 0 0.0052117924
diphenhydramine B-Chemical 0 0.9999943
hydrochloride O 0 0.9990509
. O 0 0.0056528524

Effect O 0 0.0054793674
of O 0 0.0063230773
coniine B-Chemical 1 0.9939938
on O 0 0.0024059867
the O 0 0.0022671248
developing O 0 0.0049702707
chick O 0 0.014418739
embryo O 0 0.008474954
. O 0 0.0073457705

Coniine B-Chemical 0 0.9321451
, O 0 0.0086028585
an O 0 0.003907972
alkaloid O 0 0.9263179
from O 0 0.0015922041
Conium O 0 0.9555528
maculatum O 0 0.044687565
( O 0 0.002426338
poison O 0 0.04852527
hemlock O 0 0.75907224
) O 0 0.0024854206
, O 0 0.0008155529
has O 0 0.00023623263
been O 0 0.0002903778
shown O 0 0.00019785755
to O 0 0.0003878154
be O 0 0.00075347023
teratogenic O 0 0.9842152
in O 0 0.0015861592
livestock O 0 0.008638002
. O 0 0.0037943223

The O 0 0.0026453615
major O 0 0.003066465
teratogenic O 0 0.98281235
outcome O 0 0.0022624137
is O 0 0.0012531087
arthrogryposis B-Disease 0 0.9991985
, O 0 0.0024651263
presumably O 0 0.00097596855
due O 0 0.00065225054
to O 0 0.0011825812
nicotinic O 0 0.9971403
receptor O 0 0.01694434
blockade O 0 0.016287299
. O 0 0.0048227888

However O 0 0.0043864287
, O 0 0.009946256
coniine B-Chemical 1 0.99644804
has O 0 0.0010248271
failed O 0 0.0008032252
to O 0 0.00049206364
produce O 0 0.00045036964
arthrogryposis B-Disease 0 0.9982734
in O 0 0.00031523578
rats O 0 0.00036494646
or O 0 0.00015780974
mice O 0 8.402696e-05
and O 0 0.00023697056
is O 0 0.00025680728
only O 0 0.00048630754
weakly O 0 0.0009633486
teratogenic O 0 0.9936852
in O 0 0.0013777602
rabbits O 0 0.0027942134
. O 0 0.0030141007

The O 0 0.0015789346
purpose O 0 0.0010319876
of O 0 0.0011575696
this O 0 0.00083496777
study O 0 0.00061943504
was O 0 0.0003058005
to O 0 0.00017691728
evaluate O 0 8.8026325e-05
and O 0 0.00015104252
compare O 0 7.274181e-05
the O 0 0.00011739112
effects O 0 0.00019408175
of O 0 0.0004890361
coniine B-Chemical 1 0.99935764
and O 0 0.001155423
nicotine B-Chemical 0 0.99850523
in O 0 0.00054116553
the O 0 0.0005458377
developing O 0 0.0019481065
chick O 0 0.008552947
. O 0 0.0031884538

Concentrations O 0 0.022654487
of O 0 0.0050014732
coniine B-Chemical 1 0.99824166
and O 0 0.0055599557
nicotine B-Chemical 0 0.99969184
sulfate O 0 0.99924076
were O 0 0.00070398045
0 O 0 0.0006213197
. O 0 0.0004204317
015 O 0 0.0032703965
% O 0 0.0007060121
, O 0 0.00055550877
0 O 0 0.00041897796
. O 0 0.0003341183
03 O 0 0.0018481507
% O 0 0.00061926624
, O 0 0.0005267494
0 O 0 0.000403017
. O 0 0.00032390488
075 O 0 0.002649743
% O 0 0.00061160134
, O 0 0.0004833408
0 O 0 0.00034325157
. O 0 0.00022808048
15 O 0 0.00021286706
% O 0 0.00041356852
, O 0 0.00041552505
0 O 0 0.00033009355
. O 0 0.00024272341
75 O 0 0.00038748555
% O 0 0.0004940383
, O 0 0.00046185346
1 O 0 0.00028148043
. O 0 0.00020931591
5 O 0 0.00019324396
% O 0 0.00037956852
, O 0 0.00036011473
3 O 0 0.00019898608
% O 0 0.00041148174
, O 0 0.0003720272
and O 0 0.00022838645
6 O 0 0.00017763858
% O 0 0.00039399773
and O 0 0.00026113403
1 O 0 0.00031720498
% O 0 0.00052465836
, O 0 0.00052155805
5 O 0 0.00032470166
% O 0 0.00064986636
, O 0 0.00071014534
and O 0 0.0005710963
10 O 0 0.0007219892
% O 0 0.0015211855
, O 0 0.0021918097
respectively O 0 0.0034257304
. O 0 0.004066216

Both O 0 0.004245577
compounds O 0 0.02030629
caused O 0 0.0028916122
deformations B-Disease 0 0.14681953
and O 0 0.0019347921
lethality O 0 0.0060717207
in O 0 0.00092950533
a O 0 0.0013486332
dose O 0 0.001981041
- O 0 0.0038590939
dependent O 0 0.0010624911
manner O 0 0.002192756
. O 0 0.004353843

All O 0 0.002333084
concentrations O 0 0.00342687
of O 0 0.0031132558
nicotine B-Chemical 0 0.9996953
sulfate O 0 0.9995889
caused O 0 0.00093091506
some O 0 0.0006777036
lethality O 0 0.009987926
but O 0 0.00043645813
a O 0 0.0003433131
no O 0 0.00017253928
effect O 0 0.00018995636
level O 0 0.00027147977
for O 0 0.00039585057
coniine B-Chemical 1 0.99912626
lethality O 0 0.028853666
was O 0 0.0005343199
0 O 0 0.0007350651
. O 0 0.0006808319
75 O 0 0.0015053671
% O 0 0.0025430454
. O 0 0.003035808

The O 0 0.002808326
deformations B-Disease 0 0.021277625
caused O 0 0.0015703092
by O 0 0.0010608804
both O 0 0.0010768366
coniine B-Chemical 1 0.9985494
and O 0 0.0022978815
nicotine B-Chemical 0 0.9997602
sulfate O 0 0.99937314
were O 0 0.0004272653
excessive B-Disease 0 0.00090850954
flexion I-Disease 0 0.008433743
or I-Disease 0 0.0002486773
extension I-Disease 0 0.00027057074
of I-Disease 0 0.0003617755
one I-Disease 0 0.00041040033
or I-Disease 0 0.000638122
more I-Disease 0 0.0017896038
toes I-Disease 0 0.050228246
. O 0 0.0040019904

No O 0 0.004864178
histopathological O 0 0.005567588
alterations O 0 0.00214549
or O 0 0.00070147176
differences O 0 0.00043463588
in O 0 0.0004838631
bone O 0 0.0019628326
formation O 0 0.0005433441
were O 0 0.00021920617
seen O 0 0.00019923839
in O 0 0.00015172239
the O 0 0.00015212003
limbs O 0 0.0023285376
or O 0 0.00018520877
toes O 0 0.012570618
of O 0 0.00021777811
any O 0 0.0001538727
chicks O 0 0.00062703533
from O 0 0.00012589138
any O 0 0.000111861744
group O 0 0.00024262624
; O 0 0.00036337422
however O 0 0.00021760292
, O 0 0.0004063408
extensive O 0 0.0003654445
cranial B-Disease 0 0.98253286
hemorrhage I-Disease 2 0.99998784
occurred O 0 0.0002633714
in O 0 0.00021182455
all O 0 0.00038589066
nicotine B-Chemical 0 0.9993217
sulfate O 0 0.99947256
- O 0 0.027952509
treated O 0 0.0024698537
chicks O 0 0.0068445522
. O 0 0.0034358453

There O 0 0.0044235038
was O 0 0.0024180147
a O 0 0.0021246083
statistically O 0 0.0014344129
significant O 0 0.00082258583
( O 0 0.0012352265
P O 0 0.006579139
< O 0 0.0006538034
or O 0 0.00032103684
= O 0 0.0007877474
0 O 0 0.00038298112
. O 0 0.00027547526
01 O 0 0.0012306108
) O 0 0.000526097
decrease O 0 0.0002360541
in O 0 0.00020865635
movement O 0 0.0005687428
in O 0 0.00037547972
coniine B-Chemical 1 0.99866104
and O 0 0.001144867
nicotine B-Chemical 0 0.9998074
sulfate O 0 0.9996228
treated O 0 0.0018582331
chicks O 0 0.002049996
as O 0 0.0004933613
determined O 0 0.00051446253
by O 0 0.00089966366
ultrasound O 0 0.0028038172
. O 0 0.0029068536

Control O 0 0.006570085
chicks O 0 0.005569811
were O 0 0.0013168462
in O 0 0.00084035867
motion O 0 0.0010297495
an O 0 0.00056029565
average O 0 0.0003188994
of O 0 0.00039084468
33 O 0 0.00054829573
. O 0 0.00028383682
67 O 0 0.00039928162
% O 0 0.00035709824
of O 0 0.0001821089
the O 0 0.00013474842
time O 0 0.00013333111
, O 0 0.00041731913
while O 0 0.0003482073
coniine B-Chemical 1 0.9993481
- O 0 0.025235444
treated O 0 0.0006086113
chicks O 0 0.0009507123
were O 0 0.00014692331
only O 0 0.00014814538
moving O 0 0.00022434877
8 O 0 0.00013002612
. O 0 0.00011851824
95 O 0 0.00023259055
% O 0 0.00021669586
of O 0 0.0001432253
a O 0 0.00022253112
5 O 0 0.000154494
- O 0 0.0005504618
min O 0 0.00018225031
interval O 0 0.00013094685
, O 0 0.00019457273
and O 0 0.00013200409
no O 0 0.0001444881
movement O 0 0.0004209516
was O 0 0.00021536667
observed O 0 0.00024529465
for O 0 0.00043968757
nicotine B-Chemical 0 0.99937266
sulfate O 0 0.99926573
treated O 0 0.005517363
chicks O 0 0.010458096
. O 0 0.003665392

In O 0 0.0018256805
summary O 0 0.0011025538
, O 0 0.0024567153
the O 0 0.0010713765
chick O 0 0.0033713165
embryo O 0 0.0010429443
provides O 0 0.00025102138
a O 0 0.0004097276
reliable O 0 0.0002270754
and O 0 0.00025301496
simple O 0 0.00029000986
experimental O 0 0.00028840758
animal O 0 0.00034294048
model O 0 0.0003868
of O 0 0.00094869855
coniine B-Chemical 1 0.99918765
- O 0 0.07232822
induced O 0 0.0024750317
arthrogryposis B-Disease 0 0.9993044
. O 0 0.005448365

Data O 0 0.0041952515
from O 0 0.0015689033
this O 0 0.0010762126
model O 0 0.00068938127
support O 0 0.00061624544
a O 0 0.000794836
mechanism O 0 0.00044358362
involving O 0 0.0013842593
nicotinic O 0 0.99864954
receptor O 0 0.005956086
blockade O 0 0.0028646975
with O 0 0.00065509946
subsequent O 0 0.00061947486
decreased O 0 0.0019911428
fetal O 0 0.067279525
movement O 0 0.004511737
. O 0 0.003399705

Immediate O 0 0.025189823
allergic B-Disease 0 0.9901147
reactions I-Disease 0 0.018222688
to O 0 0.009175217
amoxicillin B-Chemical 0 0.9980558
. O 0 0.013674536

A O 0 0.025962166
large O 0 0.0033788113
group O 0 0.0022134031
of O 0 0.0013116598
patients O 0 0.0018247813
with O 0 0.0010186518
suspected O 0 0.008876036
allergic B-Disease 0 0.999121
reactions I-Disease 0 0.0030057058
to O 0 0.0007477632
beta B-Chemical 0 0.98651516
- I-Chemical 0 0.2269371
lactam I-Chemical 0 0.9562263
antibiotics O 0 0.23336157
was O 0 0.0011717471
evaluated O 0 0.0016181545
. O 0 0.002983738

A O 0 0.014962552
detailed O 0 0.0013936961
clinical O 0 0.0028311342
history O 0 0.0016874584
, O 0 0.0011829664
together O 0 0.0005423514
with O 0 0.0006299795
skin O 0 0.0017596193
tests O 0 0.0010734372
, O 0 0.0011188996
RAST O 0 0.8418745
( O 0 0.0005804484
radioallergosorbent O 0 0.0013465778
test O 0 0.0003475657
) O 0 0.0005606397
, O 0 0.0003056833
and O 0 0.00015035493
controlled O 0 0.00015680732
challenge O 0 0.000108199565
tests O 0 0.00033901722
, O 0 0.00026069029
was O 0 0.00010195025
used O 0 7.9785306e-05
to O 0 6.530863e-05
establish O 0 4.2714953e-05
whether O 0 4.2667314e-05
patients O 0 0.00048150995
allergic B-Disease 0 0.92481434
to O 0 0.00020546324
beta B-Chemical 0 0.991147
- I-Chemical 0 0.27649438
lactam I-Chemical 0 0.95764345
antibiotics O 0 0.16987538
had O 0 0.00012136447
selective O 0 0.0001467374
immediate O 0 0.00023593123
allergic B-Disease 0 0.7629621
responses O 0 0.00012145765
to O 0 0.00016711265
amoxicillin B-Chemical 0 0.99991405
( O 0 0.0012688693
AX B-Chemical 0 0.99977666
) O 0 0.00067130756
or O 0 0.00014924863
were O 0 0.0001738545
cross O 0 0.00037664414
- O 0 0.0025785214
reacting O 0 0.0011691817
with O 0 0.000579029
other O 0 0.0011125044
penicillin B-Chemical 1 0.9999523
derivatives O 0 0.24134049
. O 0 0.004386862

Skin O 0 0.012537728
tests O 0 0.0036714412
were O 0 0.0012664685
performed O 0 0.00089792436
with O 0 0.0011573981
benzylpenicilloyl B-Chemical 0 0.062727556
- I-Chemical 0 0.0073946095
poly I-Chemical 0 0.003551834
- I-Chemical 0 0.032271042
L I-Chemical 0 0.94637644
- I-Chemical 0 0.058780856
lysine I-Chemical 0 0.003897904
( O 0 0.006638911
BPO B-Chemical 0 0.99996495
- I-Chemical 0 0.2541454
PLL I-Chemical 0 0.9827938
) O 0 0.0023155732
, O 0 0.0012752393
benzylpenicilloate B-Chemical 0 0.97872055
, O 0 0.0024013366
benzylpenicillin B-Chemical 0 0.999592
( O 0 0.0033814893
PG B-Chemical 0 0.99976116
) O 0 0.0039326698
, O 0 0.0023833446
ampicillin B-Chemical 1 0.999951
( O 0 0.006992893
AMP B-Chemical 0 0.99907696
) O 0 0.0036443449
, O 0 0.0023965437
and O 0 0.0027235432
AX B-Chemical 0 0.99828327
. O 0 0.005605848

RAST O 0 0.9650298
for O 0 0.013061701
BPO B-Chemical 0 0.99946123
- I-Chemical 0 0.41438758
PLL I-Chemical 0 0.98264205
and O 0 0.008669438
AX B-Chemical 0 0.9991673
- O 0 0.16465056
PLL O 0 0.6140386
was O 0 0.0032225149
done O 0 0.003535404
. O 0 0.0060877614

When O 0 0.0021266746
both O 0 0.0020873563
skin O 0 0.0036940742
test O 0 0.0015309404
and O 0 0.0013388096
RAST O 0 0.8605404
for O 0 0.0007834526
BPO B-Chemical 0 0.99947685
were O 0 0.00033200486
negative O 0 0.0002650814
, O 0 0.00041424285
single O 0 0.00019903106
- O 0 0.0017589016
blind O 0 0.012149133
, O 0 0.0005428754
placebo O 0 0.00688392
- O 0 0.00085805473
controlled O 0 0.00014904441
challenge O 0 9.863838e-05
tests O 0 0.00025327396
were O 0 0.00010993463
done O 0 0.00010132038
to O 0 9.984821e-05
ensure O 0 8.714892e-05
tolerance O 0 0.0010980112
of O 0 0.00066501304
PG B-Chemical 0 0.9994585
or O 0 0.0006882606
sensitivity O 0 0.0015983537
to O 0 0.0017283388
AX B-Chemical 0 0.9988788
. O 0 0.004290053

A O 0 0.023788102
total O 0 0.0035313934
of O 0 0.0025601597
177 O 0 0.0048888777
patients O 0 0.002168635
were O 0 0.0010129203
diagnosed O 0 0.0028828843
as O 0 0.001181942
allergic B-Disease 0 0.90474045
to O 0 0.0014741998
beta B-Chemical 0 0.98268986
- I-Chemical 0 0.29259425
lactam I-Chemical 0 0.979886
antibiotics O 0 0.65224737
. O 0 0.0053421687

We O 0 0.0029314386
selected O 0 0.0017140971
the O 0 0.0013403356
54 O 0 0.0019057193
( O 0 0.0015036158
30 O 0 0.0006172636
. O 0 0.0004934006
5 O 0 0.00042088624
% O 0 0.00076487235
) O 0 0.0008551457
cases O 0 0.00062198855
of O 0 0.00051842746
immediate O 0 0.0014092058
AX B-Chemical 0 0.9996979
allergy B-Disease 0 0.98626363
with O 0 0.000674824
good O 0 0.0009975928
tolerance O 0 0.0053037386
of O 0 0.0028790215
PG B-Chemical 0 0.99924797
. O 0 0.0064459066

Anaphylaxis B-Disease 0 0.8113593
was O 0 0.002481991
seen O 0 0.0015422021
in O 0 0.001002897
37 O 0 0.001544372
patients O 0 0.0011871204
( O 0 0.00089584384
69 O 0 0.0006551054
% O 0 0.00083564385
) O 0 0.00087336096
, O 0 0.00057564303
the O 0 0.00025846288
other O 0 0.00029146034
17 O 0 0.00047873627
( O 0 0.0005515886
31 O 0 0.0004798924
% O 0 0.0006481094
) O 0 0.00090116897
having O 0 0.00072481326
urticaria B-Disease 0 0.9991648
and O 0 0.0012026528
/ O 0 0.007925417
or O 0 0.0024342232
angioedema B-Disease 0 0.99966466
. O 0 0.004933086

All O 0 0.0023175683
the O 0 0.0017277127
patients O 0 0.0022284032
were O 0 0.0009814107
skin O 0 0.0016518483
test O 0 0.0007110351
negative O 0 0.0005622925
to O 0 0.00069236814
BPO B-Chemical 0 0.9996517
; O 0 0.0010824328
49 O 0 0.00043141673
of O 0 0.0002825988
51 O 0 0.0004345441
( O 0 0.00045294105
96 O 0 0.00055377063
% O 0 0.0004614655
) O 0 0.00044788053
were O 0 0.00015503069
also O 0 0.00015026478
negative O 0 0.0002211014
to O 0 0.00029388207
MDM B-Disease 0 0.74299604
, O 0 0.0006653985
and O 0 0.0003146365
44 O 0 0.00040891478
of O 0 0.00035064985
46 O 0 0.0006244227
( O 0 0.00080876495
96 O 0 0.0012562171
% O 0 0.001354482
) O 0 0.0021473055
to O 0 0.0018381446
PG B-Chemical 0 0.9983437
. O 0 0.006603033

Skin O 0 0.01692259
tests O 0 0.0061614076
with O 0 0.0039979173
AX B-Chemical 0 0.9967488
were O 0 0.001421359
positive O 0 0.0010743288
in O 0 0.00092449575
34 O 0 0.0012790797
( O 0 0.0017608644
63 O 0 0.0019133168
% O 0 0.0026034254
) O 0 0.0038963864
patients O 0 0.004772766
. O 0 0.005224808

RAST O 0 0.9185353
was O 0 0.0029855033
positive O 0 0.002057251
for O 0 0.0016992931
AX B-Chemical 0 0.99756867
in O 0 0.0009680704
22 O 0 0.00096151466
patients O 0 0.0008988342
( O 0 0.0007651242
41 O 0 0.0007298485
% O 0 0.0008083559
) O 0 0.00086610304
and O 0 0.0004901075
to O 0 0.00064787356
BPO B-Chemical 0 0.9994344
in O 0 0.0006220191
just O 0 0.00067661935
5 O 0 0.00056591776
( O 0 0.0010444405
9 O 0 0.0008139853
% O 0 0.002127705
) O 0 0.0039833765
. O 0 0.0040497794

None O 0 0.0049001174
of O 0 0.0028343266
the O 0 0.0018053107
sera O 0 0.0030165336
with O 0 0.001481999
negative O 0 0.0018386882
RAST O 0 0.88404274
for O 0 0.0015041921
AX B-Chemical 0 0.99788254
were O 0 0.0013476651
positive O 0 0.0016659668
to O 0 0.002644267
BPO B-Chemical 0 0.9981444
. O 0 0.0064703617

Challenge O 0 0.007794125
tests O 0 0.0051606707
with O 0 0.003131641
AX B-Chemical 0 0.9972247
were O 0 0.0008379119
performed O 0 0.0004583369
in O 0 0.00038882098
23 O 0 0.0005260309
subjects O 0 0.0005302813
( O 0 0.0005222945
43 O 0 0.00042103193
% O 0 0.00049388997
) O 0 0.00042895795
to O 0 0.00012458896
establish O 0 8.330747e-05
the O 0 0.00012478729
diagnosis O 0 0.00028920305
of O 0 0.00020125383
immediate O 0 0.0005761701
allergic B-Disease 0 0.9991683
reaction I-Disease 0 0.0006251468
to O 0 0.0002910147
AX B-Chemical 0 0.99981445
, O 0 0.00049683516
and O 0 0.00017025914
in O 0 0.0001421243
15 O 0 0.00014367371
cases O 0 0.00024155155
( O 0 0.0002649778
28 O 0 0.00016783187
% O 0 0.0003231206
) O 0 0.00039907423
both O 0 0.0001983986
skin O 0 0.0007732269
test O 0 0.0004490947
and O 0 0.0006147539
RAST O 0 0.84557575
for O 0 0.0008037661
AX B-Chemical 0 0.998596
were O 0 0.0011842956
negative O 0 0.001697551
. O 0 0.0030783536

PG B-Chemical 0 0.99623257
was O 0 0.005284371
well O 0 0.003316824
tolerated O 0 0.0046777045
by O 0 0.0023879365
all O 0 0.0025105425
54 O 0 0.004809134
patients O 0 0.0062608677
. O 0 0.0066467747

We O 0 0.00268666
describe O 0 0.001806773
the O 0 0.0012146118
largest O 0 0.0016207093
group O 0 0.0013755274
of O 0 0.001510783
AX B-Chemical 0 0.99969673
- O 0 0.09396592
allergic B-Disease 0 0.9636271
patients O 0 0.0008690017
who O 0 0.00046487898
have O 0 0.000364206
tolerated O 0 0.0020820203
PG B-Chemical 0 0.99937433
reported O 0 0.0014510134
so O 0 0.0012195847
far O 0 0.0019015325
. O 0 0.0035650085

Diagnosis O 0 0.0116880005
of O 0 0.0024724773
these O 0 0.00154405
patients O 0 0.001972809
can O 0 0.00054246746
be O 0 0.00048269075
achieved O 0 0.0005281013
only O 0 0.0004689803
if O 0 0.00036380574
specific O 0 0.00056317245
AX B-Chemical 0 0.99942625
- O 0 0.0072813565
related O 0 0.00052232086
reagents O 0 0.0018795558
are O 0 0.0009919661
employed O 0 0.001933096
. O 0 0.0034929279

Further O 0 0.0024734582
studies O 0 0.0021794734
are O 0 0.0009230513
necessary O 0 0.0004641794
to O 0 0.00038893384
determine O 0 0.0001553875
the O 0 0.00025533416
exact O 0 0.00038004687
extent O 0 0.0002188528
of O 0 0.0002660603
this O 0 0.00024879235
problem O 0 0.00029931767
and O 0 0.00022440116
to O 0 0.00015656812
improve O 0 0.00013832253
the O 0 0.00017960998
efficacy O 0 0.00030571886
of O 0 0.0005050662
diagnostic O 0 0.00093399704
methods O 0 0.0012926469
. O 0 0.0027623023

Reversal O 0 0.016930168
by O 0 0.0035210417
phenylephrine B-Chemical 0 0.99964404
of O 0 0.0009858636
the O 0 0.00040146057
beneficial O 0 0.0003790225
effects O 0 0.00029636794
of O 0 0.00047524978
intravenous O 0 0.12953319
nitroglycerin B-Chemical 0 0.9999852
in O 0 0.0004087069
patients O 0 0.00078721123
with O 0 0.00073118415
acute B-Disease 0 0.9400159
myocardial I-Disease 0 0.99977344
infarction I-Disease 0 0.9999809
. O 0 0.004600893

Nitroglycerin B-Chemical 0 0.9998766
has O 0 0.0022218218
been O 0 0.0011787001
shown O 0 0.00043768768
to O 0 0.0004523603
reduce O 0 0.00041425787
ST O 0 0.46048433
- O 0 0.0037440544
segment O 0 0.00043816064
elevation O 0 0.0027540328
during O 0 0.00022814966
acute B-Disease 0 0.8138109
myocardial I-Disease 0 0.9998934
infarction I-Disease 0 0.9999975
, O 0 0.000554123
an O 0 0.00014063533
effect O 0 0.000115213836
potentiated O 0 0.0012165015
in O 0 0.00015293961
the O 0 0.000120407254
dog O 0 0.00024339896
by O 0 0.00014160362
agents O 0 0.00044421584
that O 0 0.00021488588
reverse O 0 0.00139275
nitroglycerin B-Chemical 0 0.99999154
- O 0 0.05562739
induced O 0 0.0016467832
hypotension B-Disease 0 0.9997856
. O 0 0.0035696747

Our O 0 0.0025754168
study O 0 0.0022322966
was O 0 0.0010958972
designed O 0 0.0006570951
to O 0 0.00041410982
determine O 0 0.00016487071
the O 0 0.00026813315
effects O 0 0.00034276236
of O 0 0.0005820601
combined O 0 0.0015931209
nitroglycerin B-Chemical 0 0.99998295
and O 0 0.0027338462
phenylephrine B-Chemical 0 0.99986374
therapy O 0 0.003327146
. O 0 0.0026778143

Ten O 0 0.0035861763
patients O 0 0.003092631
with O 0 0.0015211087
acute O 0 0.049211025
transmural O 0 0.78170455
myocardial B-Disease 0 0.99836975
infarctions I-Disease 0 0.9934088
received O 0 0.00032167506
intravenous O 0 0.021157729
nitroglycerin B-Chemical 0 0.99998605
, O 0 0.00032233138
sufficient O 0 7.1996015e-05
to O 0 7.3329e-05
reduce O 0 5.7429857e-05
mean O 0 9.3238166e-05
arterial O 0 0.014818752
pressure O 0 0.0012944912
from O 0 0.00011891047
107 O 0 0.00023766066
+ O 0 0.0006437444
/ O 0 0.001085417
- O 0 0.0008194615
6 O 0 0.00010524374
to O 0 0.0001111557
85 O 0 0.00026259062
+ O 0 0.0006462556
/ O 0 0.000985549
- O 0 0.0007513632
6 O 0 0.00012399472
mm O 0 0.0006001516
Hg O 0 0.49000168
( O 0 0.0005484398
P O 0 0.004727088
less O 0 0.00031432285
than O 0 0.00021835446
0 O 0 0.0003880193
. O 0 0.00038702687
001 O 0 0.0036928812
) O 0 0.0011949451
, O 0 0.0009802479
for O 0 0.0006135022
60 O 0 0.0011997317
minutes O 0 0.0014463251
. O 0 0.0028890723

Left O 0 0.013745383
ventricular O 0 0.11419578
filling O 0 0.0054179914
pressure O 0 0.008136553
decreased O 0 0.0013107536
from O 0 0.00056914875
19 O 0 0.00077999313
+ O 0 0.0017174524
/ O 0 0.0024216233
- O 0 0.0018519661
2 O 0 0.0003440595
to O 0 0.00022558942
11 O 0 0.00033533317
+ O 0 0.00092778
/ O 0 0.0014295725
- O 0 0.0012344716
2 O 0 0.00031387608
mm O 0 0.0010055499
Hg O 0 0.49147585
( O 0 0.00089668203
P O 0 0.005573534
less O 0 0.00059648475
than O 0 0.00046735632
0 O 0 0.0009135737
. O 0 0.0011079742
001 O 0 0.009596183
) O 0 0.005112725
. O 0 0.00453919

SigmaST O 0 0.018643137
, O 0 0.0041487096
the O 0 0.0013280873
sum O 0 0.0010949017
of O 0 0.0012597367
ST O 0 0.5154508
- O 0 0.0047542998
segment O 0 0.00065022195
elevations O 0 0.0018028755
in O 0 0.0002954674
16 O 0 0.00035335656
precordial O 0 0.016953824
leads O 0 0.00021516572
, O 0 0.0004131475
decreased O 0 0.0004437528
( O 0 0.00054989394
P O 0 0.011642399
less O 0 0.00033378083
than O 0 0.00021869782
0 O 0 0.00038008412
. O 0 0.00037385212
02 O 0 0.0048269904
) O 0 0.0010583634
with O 0 0.0008992026
intravenous O 0 0.067521624
nitroglycerin B-Chemical 0 0.9998933
. O 0 0.0042046485

Subsequent O 0 0.001965838
addition O 0 0.001070925
of O 0 0.0020598648
phenylephrine B-Chemical 0 0.99983907
infusion O 0 0.0045996103
, O 0 0.00074116996
sufficient O 0 0.00021063045
to O 0 0.00024874305
re O 0 0.0010878469
- O 0 0.0011613397
elevate O 0 0.00031492216
mean O 0 0.00014975014
arterial O 0 0.010057903
pressure O 0 0.0011927425
to O 0 0.00012864586
106 O 0 0.00021571193
+ O 0 0.0006384684
/ O 0 0.00096903153
- O 0 0.00073433237
4 O 0 0.00012259693
mm O 0 0.00054140546
Hg O 0 0.51190907
( O 0 0.0004381439
P O 0 0.004634777
less O 0 0.00021689656
than O 0 0.00013354133
0 O 0 0.00021172482
. O 0 0.00017175339
001 O 0 0.0016179635
) O 0 0.00032152236
for O 0 9.320146e-05
30 O 0 0.0001002839
minutes O 0 0.000102616395
, O 0 0.00018237895
increased O 0 0.00015324455
left O 0 0.00030337195
ventricular O 0 0.024431737
filling O 0 0.00059868995
pressure O 0 0.0012556141
to O 0 0.00012226222
17 O 0 0.00020266847
+ O 0 0.00054936344
/ O 0 0.000908281
- O 0 0.00076669455
2 O 0 0.00015731531
mm O 0 0.0005641126
Hg O 0 0.5838973
( O 0 0.0004308141
P O 0 0.005072023
less O 0 0.00021478141
than O 0 0.00013576655
0 O 0 0.0002282258
. O 0 0.00019647318
05 O 0 0.004093313
) O 0 0.00042985377
and O 0 0.00017184675
also O 0 0.0001593922
significantly O 0 0.00027057744
increased O 0 0.00046443453
sigmaST O 0 0.051438577
( O 0 0.0006149459
P O 0 0.008130218
less O 0 0.0004526238
than O 0 0.0003615573
0 O 0 0.00074782944
. O 0 0.00092178566
05 O 0 0.01316626
) O 0 0.0041979384
. O 0 0.0037337823

Our O 0 0.0019107023
results O 0 0.0012164841
suggest O 0 0.0006040426
that O 0 0.0005435552
addition O 0 0.00039873653
of O 0 0.0011824397
phenylephrine B-Chemical 0 0.99997044
to O 0 0.0010705782
nitroglycerin B-Chemical 0 0.99999356
is O 0 0.00021472324
not O 0 0.00013980408
beneficial O 0 0.0001974697
in O 0 0.00013964673
the O 0 0.00012831701
treatment O 0 0.00017359147
of O 0 0.00025363837
patients O 0 0.0007509985
with O 0 0.00072448043
acute B-Disease 0 0.9698882
myocardial I-Disease 0 0.99983287
infarction I-Disease 0 0.9999845
. O 0 0.004351347

Acetazolamide B-Chemical 0 0.9999229
- O 0 0.15807882
induced O 0 0.004184719
nephrolithiasis B-Disease 0 0.99970156
: O 0 0.003153714
implications O 0 0.0009171583
for O 0 0.0006960966
treatment O 0 0.0010103784
of O 0 0.001917363
neuromuscular B-Disease 0 0.96183485
disorders I-Disease 0 0.99912006
. O 0 0.0071347114

Carbonic O 0 0.99892336
anhydrase O 0 0.999553
inhibitors O 0 0.027075743
can O 0 0.0074886708
cause O 0 0.01578248
nephrolithiasis B-Disease 0 0.99932754
. O 0 0.018689517

We O 0 0.0025580344
studied O 0 0.0021754783
20 O 0 0.0011812369
patients O 0 0.0011029211
receiving O 0 0.0006588798
long O 0 0.0006841857
- O 0 0.0042056236
term O 0 0.0017925749
carbonic O 0 0.9999527
anhydrase O 0 0.99998546
inhibitor O 0 0.021405075
treatment O 0 0.0007036438
for O 0 0.0005142324
periodic O 0 0.0023171736
paralysis B-Disease 0 0.9980634
and O 0 0.0029138997
myotonia B-Disease 0 0.99946254
. O 0 0.0044130725

Three O 0 0.004048704
patients O 0 0.005075106
on O 0 0.002861013
acetazolamide B-Chemical 0 0.99985623
( O 0 0.0038484915
15 O 0 0.0014497766
% O 0 0.0022764923
) O 0 0.0029328647
developed O 0 0.0029132888
renal B-Disease 0 0.9940202
calculi I-Disease 0 0.9976992
. O 0 0.008467793

Extracorporeal O 0 0.0068078535
lithotripsy O 0 0.0071509937
successfully O 0 0.00154564
removed O 0 0.0010165632
a O 0 0.0019350472
renal B-Disease 0 0.9988808
calculus I-Disease 0 0.9990115
in O 0 0.00045683663
one O 0 0.00024714565
patient O 0 0.00024986707
and O 0 0.00019867119
surgery O 0 0.00025838308
removed O 0 0.00017531627
a O 0 0.00046768386
staghorn O 0 0.99344
calculus B-Disease 0 0.98217803
in O 0 0.00048152395
another O 0 0.000617788
, O 0 0.0008537413
permitting O 0 0.00077771134
continued O 0 0.00095655443
treatment O 0 0.001517661
. O 0 0.0028281584

Renal O 0 0.031354565
function O 0 0.0034345114
remained O 0 0.0040873867
normal O 0 0.0041916477
in O 0 0.002796772
all O 0 0.0032960125
patients O 0 0.00682305
. O 0 0.007295761

Nephrolithiasis B-Disease 0 0.9961665
is O 0 0.0026648433
a O 0 0.002676043
complication O 0 0.010207566
of O 0 0.0032202825
acetazolamide B-Chemical 0 0.99998426
but O 0 0.00191406
does O 0 0.0007282273
not O 0 0.0007946611
preclude O 0 0.0011282687
its O 0 0.0018362936
use O 0 0.0021289294
. O 0 0.004067892

Effects O 0 0.0050825393
of O 0 0.0048518563
calcium B-Chemical 0 0.99444443
channel O 0 0.038703967
blockers O 0 0.9890304
on O 0 0.002657469
bupivacaine B-Chemical 0 0.99993837
- O 0 0.02589706
induced O 0 0.0025016181
toxicity B-Disease 0 0.79875726
. O 0 0.0058073453

The O 0 0.0016033999
purpose O 0 0.0010547459
of O 0 0.001192371
this O 0 0.0008702882
study O 0 0.0006567464
was O 0 0.00032909744
to O 0 0.00019207214
investigate O 0 9.252254e-05
the O 0 0.00015064208
influence O 0 0.00014569508
of O 0 0.00040771533
calcium B-Chemical 0 0.9970515
channel O 0 0.012547496
blockers O 0 0.98222685
on O 0 0.00064831914
bupivacaine B-Chemical 0 0.9999794
- O 0 0.010780594
induced O 0 0.0008021284
acute O 0 0.283287
toxicity B-Disease 0 0.9112435
. O 0 0.0035248452

For O 0 0.0015022374
each O 0 0.0010548916
of O 0 0.00092717644
the O 0 0.00051418925
three O 0 0.00027278482
tested O 0 0.0005178255
calcium B-Chemical 0 0.98967755
channel O 0 0.012032112
blockers O 0 0.9944165
( O 0 0.01163312
diltiazem B-Chemical 1 0.99999833
, O 0 0.017251126
verapamil B-Chemical 0 0.99999714
and O 0 0.0013623824
bepridil B-Chemical 1 0.99999547
) O 0 0.0007046564
6 O 0 7.0943046e-05
groups O 0 8.8811204e-05
of O 0 7.502201e-05
mice O 0 3.3700628e-05
were O 0 7.1935894e-05
treated O 0 0.00015069582
by O 0 7.604632e-05
two O 0 5.2531705e-05
different O 0 6.866452e-05
doses O 0 0.00029669786
, O 0 0.0002869153
i O 0 0.0003412407
. O 0 0.00016500203
e O 0 0.00038511227
. O 0 0.00012526821
2 O 0 0.000115152114
and O 0 0.00010981476
10 O 0 0.00013363775
mg O 0 0.00096278754
/ O 0 0.00050798
kg O 0 0.00040939843
/ O 0 0.0006369362
i O 0 0.0002985815
. O 0 0.00014118313
p O 0 0.00025321526
. O 0 0.00013866191
, O 0 0.00021844733
or O 0 0.0001111165
an O 0 0.00012860647
equal O 0 0.0001258484
volume O 0 0.00021283903
of O 0 0.0001305082
saline O 0 0.00033481244
for O 0 6.602935e-05
the O 0 6.87514e-05
control O 0 9.970007e-05
group O 0 0.00017609195
( O 0 0.00020993833
n O 0 0.00015744587
= O 0 0.00036249709
20 O 0 0.0001359947
) O 0 0.00027093577
; O 0 0.00021213522
15 O 0 8.983828e-05
minutes O 0 8.213357e-05
later O 0 8.337344e-05
, O 0 0.00015758359
all O 0 7.5690165e-05
the O 0 6.257316e-05
animals O 0 5.8313726e-05
were O 0 7.291411e-05
injected O 0 7.815924e-05
with O 0 0.00010564402
a O 0 0.00016067155
single O 0 9.6009724e-05
50 O 0 0.00020634632
mg O 0 0.001683731
/ O 0 0.0006719374
kg O 0 0.00053614634
/ O 0 0.0008231754
i O 0 0.00044728405
. O 0 0.000252558
p O 0 0.00047857047
. O 0 0.0003715196
dose O 0 0.00089913665
of O 0 0.0016328496
bupivacaine B-Chemical 0 0.9998124
. O 0 0.0038937535

The O 0 0.0032596614
convulsant O 0 0.98271334
activity O 0 0.0011882506
, O 0 0.0013667574
the O 0 0.00043192494
time O 0 0.000293616
of O 0 0.00041672742
latency O 0 0.0008081279
to O 0 0.0003566009
convulse O 0 0.1631353
and O 0 0.0002996372
the O 0 0.00023065975
mortality O 0 0.0010068475
rate O 0 0.00042619792
were O 0 0.00028302532
assessed O 0 0.00035210914
in O 0 0.00047746458
each O 0 0.0005723105
group O 0 0.0018497831
. O 0 0.0029268248

The O 0 0.002195698
local O 0 0.0023156484
anesthetic O 0 0.024528908
- O 0 0.0053256922
induced O 0 0.0007332342
mortality O 0 0.0023892247
was O 0 0.00040740182
significantly O 0 0.00042909698
increased O 0 0.00044005638
by O 0 0.0002791529
the O 0 0.00023321943
three O 0 0.00018290592
different O 0 0.0004323569
calcium B-Chemical 0 0.9809512
channel O 0 0.018696262
blockers O 0 0.9842414
. O 0 0.0051719937

The O 0 0.0027777134
convulsant O 0 0.9780571
activity O 0 0.0011041332
of O 0 0.0018302073
bupivacaine B-Chemical 0 0.99996066
was O 0 0.00045716268
not O 0 0.00023664879
significantly O 0 0.0002909115
modified O 0 0.00024781958
but O 0 0.00045422456
calcium B-Chemical 0 0.9972435
channel O 0 0.011689952
blockers O 0 0.97343296
decreased O 0 0.00041101113
the O 0 8.9112604e-05
time O 0 6.60597e-05
of O 0 0.00011348018
latency O 0 0.00025050517
to O 0 9.348308e-05
obtain O 0 0.00012054396
bupivacaine B-Chemical 0 0.9999851
- O 0 0.008822197
induced O 0 0.00032701393
convulsions B-Disease 0 0.9999523
; O 0 0.0006260781
this O 0 0.0001729737
effect O 0 0.00017557942
was O 0 0.0002757506
less O 0 0.0005437702
pronounced O 0 0.0010517697
with O 0 0.0017934206
bepridil B-Chemical 1 0.99995995
. O 0 0.0043789297

Epidural O 0 0.067785926
blood O 0 0.019734541
flow O 0 0.016656885
during O 0 0.0035954162
prostaglandin B-Chemical 1 0.99998534
E1 I-Chemical 1 0.9988802
or O 0 0.0066921087
trimethaphan B-Chemical 0 0.99996364
induced O 0 0.007083052
hypotension B-Disease 0 0.99975675
. O 0 0.006441501

To O 0 0.0011628274
evaluate O 0 0.00072915433
the O 0 0.00086532644
effect O 0 0.00094773417
of O 0 0.0036011294
prostaglandin B-Chemical 1 0.9999974
E1 I-Chemical 1 0.99981207
( O 0 0.34972993
PGE1 B-Chemical 0 0.99999905
) O 0 0.016918704
or O 0 0.00066339975
trimethaphan B-Chemical 0 0.99999225
( O 0 0.0088410685
TMP B-Chemical 0 0.99998593
) O 0 0.001179602
induced O 0 0.00023544003
hypotension B-Disease 0 0.9998368
on O 0 0.00010857506
epidural O 0 0.004586713
blood O 0 0.0019682515
flow O 0 0.0016462056
( O 0 0.00034837853
EBF O 0 0.0035353855
) O 0 0.00026798132
during O 0 6.802925e-05
spinal O 0 0.00013992505
surgery O 0 0.00015880603
, O 0 0.00021261815
EBF O 0 0.0014573996
was O 0 0.00010958484
measured O 0 0.000115072326
using O 0 8.3237115e-05
the O 0 0.00010050293
heat O 0 0.0004267705
clearance O 0 0.00074268115
method O 0 0.00012420486
in O 0 9.736447e-05
30 O 0 9.657433e-05
patients O 0 0.00018336099
who O 0 0.00015893161
underwent O 0 0.00020787139
postero O 0 0.01278433
- O 0 0.001370717
lateral O 0 0.001060506
interbody O 0 0.0026460558
fusion O 0 0.00040064412
under O 0 0.00063208805
isoflurane B-Chemical 1 0.99850816
anaesthesia O 0 0.027886042
. O 0 0.0023184062

An O 0 0.0027703582
initial O 0 0.0013912015
dose O 0 0.0017589603
of O 0 0.0009797254
0 O 0 0.000924612
. O 0 0.00055476883
1 O 0 0.0005532804
microgram O 0 0.0035537465
. O 0 0.0003533178
kg O 0 0.0008051429
- O 0 0.0012736971
1 O 0 0.0002930103
. O 0 0.00023381191
min O 0 0.000409361
- O 0 0.0010510274
1 O 0 0.0002838398
of O 0 0.0004986421
PGE1 B-Chemical 0 0.9999962
( O 0 0.0010141587
15 O 0 0.00020055771
patients O 0 0.00033788214
) O 0 0.00037768582
, O 0 0.00025608894
or O 0 0.00012935116
10 O 0 0.00016164735
micrograms O 0 0.0009029382
. O 0 0.00014226165
kg O 0 0.00041125214
- O 0 0.00078226015
1 O 0 0.00016683419
. O 0 0.00014034705
min O 0 0.0002751382
- O 0 0.0008184603
1 O 0 0.0001922
of O 0 0.00031560237
TMP B-Chemical 0 0.9999684
( O 0 0.00052252004
15 O 0 0.00012609633
patients O 0 0.00020029838
) O 0 0.00020211152
was O 0 7.378247e-05
administered O 0 0.000113962305
intravenously O 0 0.00013027384
after O 0 3.755452e-05
the O 0 7.71453e-05
dural O 0 0.3040635
opening O 0 0.00032800526
and O 0 9.749677e-05
the O 0 7.277587e-05
dose O 0 0.00015220608
was O 0 6.667372e-05
adjusted O 0 5.7070676e-05
to O 0 5.7382236e-05
maintain O 0 5.935309e-05
the O 0 7.609261e-05
mean O 0 0.00011124807
arterial O 0 0.055133317
blood O 0 0.0027053196
pressure O 0 0.010370089
( O 0 0.0008770854
MAP O 0 0.17343727
) O 0 0.000755555
at O 0 0.00030019306
about O 0 0.0006314907
60 O 0 0.0010611842
mmHg O 0 0.0049802233
. O 0 0.0030336848

The O 0 0.0034955482
hypotensive B-Disease 0 0.9930287
drug O 0 0.04226446
was O 0 0.0010841365
discontinued O 0 0.001673482
at O 0 0.00039161523
the O 0 0.0003647324
completion O 0 0.00032579873
of O 0 0.0005894214
the O 0 0.0006727416
operative O 0 0.0014979037
procedure O 0 0.0015202704
. O 0 0.0033845035

After O 0 0.002564703
starting O 0 0.003623362
PGE1 B-Chemical 0 0.9999726
or O 0 0.007262881
TMP B-Chemical 0 0.999962
, O 0 0.005994502
MAP O 0 0.62304795
and O 0 0.00046764934
rate O 0 0.00047873694
pressure O 0 0.002961736
product O 0 0.00037841813
( O 0 0.00071771746
RPP O 0 0.8628409
) O 0 0.0005636184
decreased O 0 0.00026685317
significantly O 0 0.0001632832
compared O 0 0.00010135054
with O 0 0.00018445238
preinfusion O 0 0.021625994
values O 0 0.00015100492
( O 0 0.00027067962
P O 0 0.0025776864
< O 0 0.00023940411
0 O 0 0.0001943899
. O 0 0.00016212014
01 O 0 0.0009782056
) O 0 0.00043759108
, O 0 0.00028395426
and O 0 0.0001576661
the O 0 0.0001252527
degree O 0 0.0002864567
of O 0 0.00042198866
hypotension B-Disease 0 0.99993086
due O 0 0.00019477321
to O 0 0.00036845246
PGE1 B-Chemical 0 0.999998
remained O 0 0.000601305
constant O 0 0.00028392614
until O 0 0.00013556474
60 O 0 0.00024605944
min O 0 0.00033854373
after O 0 0.00020580439
its O 0 0.00077880744
discontinuation O 0 0.0045754127
. O 0 0.0022737244

Heart O 0 0.01680965
rate O 0 0.0059071137
( O 0 0.005871071
HR O 0 0.045217425
) O 0 0.004126639
did O 0 0.001589573
not O 0 0.0011764208
change O 0 0.0012389927
in O 0 0.001330026
either O 0 0.0018454179
group O 0 0.0039835335
. O 0 0.0053051626

EBFF O 0 0.22357026
did O 0 0.0030582603
not O 0 0.001346122
change O 0 0.0009963604
during O 0 0.0010179223
PGE1 B-Chemical 0 0.9999914
infusion O 0 0.0068302946
whereas O 0 0.0003724622
in O 0 0.00027737117
the O 0 0.00037083917
TMP B-Chemical 0 0.99996924
group O 0 0.0008145285
, O 0 0.00065423275
EBF O 0 0.0152174905
decreased O 0 0.00037515452
significantly O 0 0.00017801582
at O 0 9.1080685e-05
30 O 0 9.1897e-05
and O 0 9.431051e-05
60 O 0 0.00010749788
min O 0 0.0001227853
after O 0 4.5242108e-05
the O 0 7.043862e-05
start O 0 8.109212e-05
of O 0 0.00033188556
TMP B-Chemical 0 0.99997437
( O 0 0.0012771051
preinfusion O 0 0.12449739
: O 0 0.00035138652
45 O 0 0.00014151321
. O 0 0.00011596312
9 O 0 0.00012748258
+ O 0 0.0005632152
/ O 0 0.0011600207
- O 0 0.00116932
13 O 0 0.00021373507
. O 0 0.00015110531
9 O 0 0.00015140806
ml O 0 0.0006193585
/ O 0 0.0015134203
100g O 0 0.21191438
/ O 0 0.0010981943
min O 0 0.00032118414
. O 0 0.00014597904
30 O 0 0.00012019653
min O 0 0.00020488593
: O 0 0.00027220676
32 O 0 0.00019432226
. O 0 0.0001342234
3 O 0 0.00014231104
+ O 0 0.0006068841
/ O 0 0.0011682933
- O 0 0.0011074971
9 O 0 0.00017065361
. O 0 0.0001542804
9 O 0 0.00015291029
ml O 0 0.00054039597
/ O 0 0.0007833213
100 O 0 0.00045552186
g O 0 0.00074290205
/ O 0 0.0008493002
min O 0 0.0003638815
( O 0 0.00037287717
P O 0 0.00282003
< O 0 0.000319821
0 O 0 0.00026569626
. O 0 0.00023289792
05 O 0 0.003081153
) O 0 0.0005073558
. O 0 0.00019376997
60 O 0 0.00020194548
min O 0 0.00027008928
: O 0 0.0003390061
30 O 0 0.00018639097
+ O 0 0.0006699226
/ O 0 0.0012190929
- O 0 0.0011325561
7 O 0 0.00018338895
. O 0 0.00018941719
5 O 0 0.00020053552
ml O 0 0.0006446065
/ O 0 0.0009409022
100 O 0 0.0006016042
g O 0 0.0009768562
/ O 0 0.0011611427
min O 0 0.00056768156
( O 0 0.000653746
P O 0 0.003769444
< O 0 0.0007305924
0 O 0 0.00072899036
. O 0 0.0008557379
05 O 0 0.009658391
) O 0 0.0036608675
) O 0 0.004983504
. O 0 0.0047238367

These O 0 0.0021505326
results O 0 0.0016049662
suggest O 0 0.0010681556
that O 0 0.0020280492
PGE1 B-Chemical 0 0.99999166
may O 0 0.0009424341
be O 0 0.00046373712
preferable O 0 0.00033540413
to O 0 0.0004453296
TMP B-Chemical 0 0.9999399
for O 0 0.0003927458
hypotensive B-Disease 0 0.99650574
anaesthesia O 0 0.0033313958
in O 0 0.0001887001
spinal O 0 0.00032318465
surgery O 0 0.00045012822
because O 0 0.00054039515
TMP B-Chemical 0 0.999856
decreased O 0 0.0061600995
EBF O 0 0.1757217
. O 0 0.0042040623

Dup B-Chemical 0 0.98741585
753 I-Chemical 0 0.8231856
prevents O 0 0.0025623864
the O 0 0.001569191
development O 0 0.0018670612
of O 0 0.0023670853
puromycin B-Chemical 0 0.99003637
aminonucleoside I-Chemical 0 0.999982
- O 0 0.26149482
induced O 0 0.0047885883
nephrosis B-Disease 2 0.99989164
. O 0 0.009015072

The O 0 0.0023829322
appearance O 0 0.0030850703
of O 0 0.0038540417
nephrotic B-Disease 0 0.9999875
syndromes I-Disease 0 0.90448606
such O 0 0.0006007719
as O 0 0.0007505871
proteinuria B-Disease 0 0.999964
, O 0 0.0051653264
hypoalbuminemia B-Disease 0 0.99992
, O 0 0.0031263328
hypercholesterolemia B-Disease 0 0.9999893
and O 0 0.0003531387
increase O 0 0.00020193412
in O 0 0.00027396527
blood B-Chemical 0 0.9027729
nitrogen I-Chemical 0 0.9999254
urea I-Chemical 0 0.99998283
, O 0 0.0007320898
induced O 0 0.000119647164
in O 0 9.4708295e-05
rats O 0 0.00014983668
by O 0 7.317853e-05
injection O 0 7.6899756e-05
of O 0 0.00017279827
puromycin B-Chemical 0 0.971255
aminonucleoside I-Chemical 0 0.9999976
was O 0 0.00025857627
markedly O 0 0.0005989285
inhibited O 0 0.00026390023
by O 0 0.00013824788
oral O 0 0.00078736915
administration O 0 0.00028391503
of O 0 0.00027070285
Dup B-Chemical 0 0.98973083
753 I-Chemical 0 0.954609
( O 0 0.001283907
losartan B-Chemical 1 0.9999908
) O 0 0.0011021543
, O 0 0.0003431985
a O 0 0.00029634786
novel O 0 0.00039026872
angiotensin B-Chemical 1 0.9999976
II I-Chemical 1 0.9981651
receptor O 0 0.040749595
antagonist O 0 0.48413792
, O 0 0.00048477118
at O 0 0.00011796283
a O 0 0.000223982
dose O 0 0.00027552698
of O 0 0.00018446556
1 O 0 0.00020728694
or O 0 0.00016866915
2 O 0 0.00030536263
mg O 0 0.0019371114
/ O 0 0.001287517
kg O 0 0.0011254498
per O 0 0.0006815906
day O 0 0.0008525146
. O 0 0.0024326365

The O 0 0.0018049509
results O 0 0.001231017
suggest O 0 0.000672546
a O 0 0.0010136169
possible O 0 0.00043026125
involvement O 0 0.000695591
of O 0 0.00052307395
the O 0 0.000557254
renin O 0 0.9980751
- O 0 0.3782322
angiotensin B-Chemical 0 0.9999653
system O 0 0.0004652071
in O 0 0.00023664358
the O 0 0.00019743203
development O 0 0.00037204206
of O 0 0.0006260889
puromycin B-Chemical 0 0.98974216
aminonucleoside I-Chemical 0 0.9999937
- O 0 0.24011765
induced O 0 0.0027336187
nephrosis B-Disease 2 0.9999465
. O 0 0.0061019734

Neuroplasticity O 0 0.020928372
of O 0 0.002585633
the O 0 0.0014125131
adult O 0 0.0015877557
primate O 0 0.0012353372
auditory O 0 0.0035209265
cortex O 0 0.004524837
following O 0 0.0006168275
cochlear O 0 0.003119086
hearing B-Disease 0 0.050050784
loss I-Disease 0 0.0031728307
. O 0 0.0040118624

Tonotopic O 0 0.016028786
organization O 0 0.0022073486
is O 0 0.0011719938
an O 0 0.00092221884
essential O 0 0.0005167498
feature O 0 0.0005169166
of O 0 0.0004812904
the O 0 0.00034700008
primary O 0 0.000418422
auditory O 0 0.0017854151
area O 0 0.0007061643
( O 0 0.0010683032
A1 O 0 0.06752513
) O 0 0.0016702438
of O 0 0.0010137917
primate O 0 0.0018865634
cortex O 0 0.025295863
. O 0 0.0039782114

In O 0 0.003102039
A1 O 0 0.06801866
of O 0 0.0014121071
macaque O 0 0.00056907744
monkeys O 0 0.0005740052
, O 0 0.0007770812
low O 0 0.0004878539
frequencies O 0 0.00030475273
are O 0 0.00026937615
represented O 0 0.00032700953
rostrolaterally O 0 0.0017144888
and O 0 0.000387008
high O 0 0.0004852236
frequencies O 0 0.0004523898
are O 0 0.0006032553
represented O 0 0.0011126742
caudomedially O 0 0.011302164
. O 0 0.0038476174

The O 0 0.0016489726
purpose O 0 0.0010929562
of O 0 0.0012463167
this O 0 0.0009252126
study O 0 0.0007210242
was O 0 0.00037097107
to O 0 0.00022129418
determine O 0 9.0746136e-05
if O 0 0.00015212134
changes O 0 0.00025110057
occur O 0 0.0001983171
in O 0 0.00017450872
this O 0 0.00022815031
tonotopic O 0 0.00096987485
organization O 0 0.00028238975
following O 0 0.00026065024
cochlear O 0 0.0020197462
hearing B-Disease 0 0.063304745
loss I-Disease 0 0.0020506177
. O 0 0.0026913658

Under O 0 0.004486472
anesthesia O 0 0.010063591
, O 0 0.0022350312
the O 0 0.0007588504
superior O 0 0.0011841474
temporal O 0 0.0033201075
gyrus O 0 0.52055657
of O 0 0.00039847015
adult O 0 0.00030800194
macaque O 0 0.00011049142
monkeys O 0 0.00014179604
was O 0 0.00013747558
exposed O 0 0.00019338827
, O 0 0.00028089786
and O 0 0.00015651589
the O 0 0.00013026875
tonotopic O 0 0.0007481752
organization O 0 0.00019495715
of O 0 0.00029595007
A1 O 0 0.09130995
was O 0 0.00020375192
mapped O 0 0.00013283938
using O 0 0.00014828148
conventional O 0 0.00024050157
microelectrode O 0 0.00067066104
recording O 0 0.00049035816
techniques O 0 0.0010604565
. O 0 0.0024097646

Following O 0 0.0022607655
recovery O 0 0.0026386569
, O 0 0.0019689202
the O 0 0.0006888473
monkeys O 0 0.00058871484
were O 0 0.0004448262
selectively O 0 0.00042223852
deafened O 0 0.0037173547
for O 0 0.0002612628
high O 0 0.00039137228
frequencies O 0 0.00036200564
using O 0 0.0006156631
kanamycin B-Chemical 0 0.99748623
and O 0 0.0030825448
furosemide B-Chemical 0 0.9999323
. O 0 0.005433397

The O 0 0.0019076621
actual O 0 0.0013822338
frequencies O 0 0.0011647948
deafened O 0 0.010754208
were O 0 0.0006349264
determined O 0 0.00038769725
by O 0 0.0003547296
the O 0 0.00029518444
loss O 0 0.0004197417
of O 0 0.0004534774
tone O 0 0.024059385
- O 0 0.0039899657
burst O 0 0.0008838151
elicited O 0 0.00045108545
auditory O 0 0.0028831938
brainstem O 0 0.0027530547
responses O 0 0.0013676065
. O 0 0.002656107

Three O 0 0.004040494
months O 0 0.0022554304
after O 0 0.0023505543
deafening O 0 0.011746139
, O 0 0.008113121
A1 O 0 0.12602776
was O 0 0.005165319
remapped O 0 0.0071450137
. O 0 0.008357233

Postmortem O 0 0.019784842
cytoarchitectural O 0 0.008635715
features O 0 0.0022949567
identifying O 0 0.0015245932
A1 O 0 0.10265145
were O 0 0.001093208
correlated O 0 0.000882267
with O 0 0.0010022551
the O 0 0.0011257672
electrophysiologic O 0 0.0054704784
data O 0 0.0026806658
. O 0 0.0041240114

The O 0 0.0017598949
results O 0 0.0011877522
indicate O 0 0.0005980084
that O 0 0.00059464626
the O 0 0.00056768965
deprived O 0 0.0010659858
area O 0 0.0007333593
of O 0 0.00060697086
A1 O 0 0.1943751
undergoes O 0 0.00025274564
extensive O 0 0.00030165364
reorganization O 0 0.0003363236
and O 0 0.0002708983
becomes O 0 0.00027776018
responsive O 0 0.00022364908
to O 0 0.000349186
intact O 0 0.00072533224
cochlear O 0 0.0025079767
frequencies O 0 0.0012469693
. O 0 0.002759048

The O 0 0.0019485479
region O 0 0.0012592145
of O 0 0.0014017193
cortex O 0 0.0070572738
that O 0 0.00043765845
represents O 0 0.00034511826
the O 0 0.00025304515
low O 0 0.0003577399
frequencies O 0 0.00024560635
was O 0 0.0002727279
not O 0 0.00028249645
obviously O 0 0.0008881768
affected O 0 0.0004998997
by O 0 0.00044924117
the O 0 0.0005090716
cochlear O 0 0.0035753015
hearing B-Disease 0 0.14750153
loss I-Disease 0 0.002467542
. O 0 0.0030543706

Sodium B-Chemical 0 0.9998772
bicarbonate I-Chemical 0 0.9998548
alleviates O 0 0.07428689
penile B-Disease 0 0.7653708
pain I-Disease 0 0.8885872
induced O 0 0.00087400194
by O 0 0.0008022113
intracavernous O 0 0.46266836
injections O 0 0.0007281916
for O 0 0.00075070374
erectile B-Disease 0 0.8008827
dysfunction I-Disease 0 0.6763437
. O 0 0.0039634653

In O 0 0.0021592234
an O 0 0.0018938131
attempt O 0 0.0011155664
to O 0 0.00047168034
determine O 0 0.00015724722
whether O 0 0.00017246611
penile B-Disease 0 0.09129247
pain I-Disease 0 0.69024134
associated O 0 0.00023273763
with O 0 0.00016757826
intracorporeal O 0 0.0003731368
injections O 0 0.0001585727
could O 0 8.051943e-05
be O 0 9.7525684e-05
due O 0 7.285726e-05
to O 0 8.904381e-05
the O 0 0.000115151684
acidity O 0 0.11136929
of O 0 0.00015214397
the O 0 0.00010107229
medication O 0 0.0008586461
, O 0 0.00014187218
we O 0 3.839579e-05
performed O 0 6.506644e-05
a O 0 0.00012563882
randomized O 0 0.00023372722
study O 0 7.0524715e-05
comparing O 0 3.4534947e-05
the O 0 5.9091948e-05
incidence O 0 0.00018868534
of O 0 0.00014295011
penile B-Disease 0 0.16767484
pain I-Disease 0 0.3885112
following O 0 4.1890362e-05
intracorporeal O 0 0.00014491114
injections O 0 7.308884e-05
with O 0 7.454749e-05
or O 0 7.176179e-05
without O 0 9.200748e-05
the O 0 8.617008e-05
addition O 0 8.833753e-05
of O 0 0.00046456474
sodium B-Chemical 0 0.9998791
bicarbonate I-Chemical 0 0.9998971
to O 0 0.0003436312
the O 0 0.00033677812
intracorporeal O 0 0.0013162814
medications O 0 0.005606037
. O 0 0.002250741

A O 0 0.021383092
total O 0 0.0024344446
of O 0 0.001407018
38 O 0 0.0011675622
consecutive O 0 0.00055997726
patients O 0 0.00072785374
who O 0 0.0004074816
presented O 0 0.00018980878
to O 0 0.00014994503
our O 0 0.00015525732
clinic O 0 0.00025882092
with O 0 0.0002662623
impotence B-Disease 0 0.68287426
received O 0 0.00018486085
0 O 0 0.00019625186
. O 0 0.00012328968
2 O 0 0.00013736788
ml O 0 0.00037432
. O 0 0.0001070333
of O 0 0.000113074464
a O 0 0.00016175542
combination O 0 0.0001391467
of O 0 0.0001273936
3 O 0 0.00011046666
drugs O 0 0.0013685185
: O 0 0.00026867338
6 O 0 9.481847e-05
mg O 0 0.0019930673
. O 0 0.00019555997
papaverine B-Chemical 0 0.9999602
, O 0 0.0004734448
100 O 0 0.00048769484
micrograms O 0 0.009809687
. O 0 0.00028474673
phentolamine B-Chemical 0 0.9999908
and O 0 0.00025107927
10 O 0 0.00020928957
micrograms O 0 0.0119594745
. O 0 0.0005204473
prostaglandin B-Chemical 1 0.999998
E1 I-Chemical 1 0.9991379
with O 0 0.00069144036
( O 0 0.00093109685
pH O 0 0.00616938
7 O 0 0.00015256788
. O 0 0.00017635021
05 O 0 0.004773659
) O 0 0.0003984096
or O 0 0.00013870475
without O 0 0.00020199092
( O 0 0.0005406
pH O 0 0.0031421697
4 O 0 0.00016504261
. O 0 0.00015573714
17 O 0 0.00020436928
) O 0 0.0002823572
the O 0 0.00011249253
addition O 0 0.00011498884
of O 0 0.0005361622
sodium B-Chemical 0 0.9998456
bicarbonate I-Chemical 0 0.99993193
( O 0 0.0013012219
0 O 0 0.0005803547
. O 0 0.0005331206
03 O 0 0.005950525
mEq O 0 0.26840833
. O 0 0.0013711464
) O 0 0.0036256006
. O 0 0.0037821396

Of O 0 0.0048487815
the O 0 0.0018555835
19 O 0 0.0019675696
patients O 0 0.0020930378
without O 0 0.0015669127
sodium B-Chemical 0 0.99972504
bicarbonate I-Chemical 0 0.99988806
added O 0 0.0007502235
to O 0 0.00023162545
the O 0 0.00018034516
medication O 0 0.00080762024
11 O 0 0.00019766863
( O 0 0.00026111063
58 O 0 0.00024654623
% O 0 0.00033848328
) O 0 0.0004710581
complained O 0 0.0006037623
of O 0 0.0002626452
penile B-Disease 0 0.35713166
pain I-Disease 0 0.85763276
due O 0 9.981185e-05
to O 0 9.095769e-05
the O 0 9.835568e-05
medication O 0 0.0011139064
, O 0 0.00024520906
while O 0 0.00012437245
only O 0 0.00015122266
1 O 0 0.00014366547
of O 0 0.00012266044
the O 0 0.000109862514
19 O 0 0.00021424206
men O 0 0.0006456167
( O 0 0.00026491465
5 O 0 0.00012950815
% O 0 0.0002654661
) O 0 0.00035926313
who O 0 0.00028221108
received O 0 0.0003669369
sodium B-Chemical 0 0.9996063
bicarbonate I-Chemical 0 0.99991703
complained O 0 0.011236987
of O 0 0.0011991583
penile B-Disease 0 0.6400913
pain I-Disease 0 0.9564018
. O 0 0.0035498766

From O 0 0.0028173164
these O 0 0.0015329155
data O 0 0.0010598147
we O 0 0.00036120316
conclude O 0 0.00033618687
that O 0 0.00029345817
the O 0 0.0003342974
penile B-Disease 0 0.07470304
pain I-Disease 0 0.31861988
following O 0 9.072312e-05
intracorporeal O 0 0.00025528108
injections O 0 0.00012888848
is O 0 8.52202e-05
most O 0 0.00012614878
likely O 0 6.523897e-05
due O 0 7.271864e-05
to O 0 9.210475e-05
the O 0 0.00012178377
acidity O 0 0.12995213
of O 0 0.00017886364
the O 0 0.00013061438
medication O 0 0.0022625024
, O 0 0.00032192568
which O 0 0.00016968833
can O 0 9.6082156e-05
be O 0 0.000117454045
overcome O 0 0.00010379877
by O 0 0.00024460242
elevating O 0 0.0024674702
the O 0 0.0004037834
pH O 0 0.007411253
to O 0 0.00052296504
a O 0 0.0011533062
neutral O 0 0.0027945228
level O 0 0.0017800931
. O 0 0.0033912575

The O 0 0.0017852231
use O 0 0.001445936
and O 0 0.0015437389
toxicity B-Disease 0 0.3017961
of O 0 0.0018373958
didanosine B-Chemical 0 0.9999063
( O 0 0.0064661386
ddI B-Chemical 0 0.9997569
) O 0 0.0012538682
in O 0 0.00034213034
HIV B-Disease 0 0.020388773
antibody I-Disease 0 0.00057131407
- I-Disease 0 0.0017200819
positive I-Disease 0 0.00031200395
individuals O 0 0.00063965126
intolerant O 0 0.0013095839
to O 0 0.00063619425
zidovudine B-Chemical 0 0.9634999
( O 0 0.0046837893
AZT B-Chemical 0 0.9981729
) O 0 0.011608582

One O 0 0.003504459
hundred O 0 0.0023148651
and O 0 0.0013728418
fifty O 0 0.001657324
- O 0 0.002971856
one O 0 0.00047260144
patients O 0 0.0007872799
intolerant O 0 0.00091336225
to O 0 0.00032718072
zidovudine B-Chemical 0 0.91282886
( O 0 0.0010798938
AZT B-Chemical 0 0.99882334
) O 0 0.000673981
received O 0 0.00028481375
didanosine B-Chemical 0 0.9998498
( O 0 0.0015413498
ddI B-Chemical 0 0.99965143
) O 0 0.00045505597
to O 0 0.00011211226
a O 0 0.0001850358
maximum O 0 0.0001731623
dose O 0 0.00024875824
of O 0 0.00017731635
12 O 0 0.00013791834
. O 0 0.0001818998
5 O 0 0.00024852494
mg O 0 0.0016301996
/ O 0 0.0014552097
kg O 0 0.0015135912
/ O 0 0.0028475984
day O 0 0.0012050465
. O 0 0.0029759817

Patient O 0 0.0030677917
response O 0 0.001393832
was O 0 0.0008822796
assessed O 0 0.0005981566
using O 0 0.00039702322
changes O 0 0.00042564856
in O 0 0.00038663778
CD4 O 0 0.002850404
+ O 0 0.0018647824
lymphocyte O 0 0.0036381637
subset O 0 0.00028644686
count O 0 0.000471883
, O 0 0.0011434173
HIV O 0 0.28561574
p24 O 0 0.45303315
antigen O 0 0.0031149476
, O 0 0.00072291284
weight O 0 0.0006071256
, O 0 0.0006336397
and O 0 0.00042381443
quality O 0 0.00045086257
of O 0 0.0010200896
life O 0 0.0018935303
. O 0 0.00321833

Seventy O 0 0.009259383
patients O 0 0.0034646944
developed O 0 0.001500359
major O 0 0.0010127013
opportunistic B-Disease 0 0.0022062957
infections I-Disease 0 0.015918205
whilst O 0 0.00061794027
on O 0 0.00026108001
therapy O 0 0.00051601126
; O 0 0.0005853469
this O 0 0.00030814114
was O 0 0.0002807533
the O 0 0.0002987478
first O 0 0.00043029245
AIDS B-Disease 0 0.99474514
diagnosis O 0 0.0020651703
in O 0 0.0011826786
17 O 0 0.0023647882
. O 0 0.0029475847

Only O 0 0.004175299
minor O 0 0.0027343116
changes O 0 0.0013233273
in O 0 0.0009455362
CD4 O 0 0.005467682
+ O 0 0.003009209
lymphocyte O 0 0.0042464253
subset O 0 0.0002801351
count O 0 0.00029674088
were O 0 0.00019074896
observed O 0 0.00019084428
in O 0 0.00033302687
AIDS B-Disease 0 0.99886
patients O 0 0.0009530558
, O 0 0.00036948832
although O 0 0.00016383077
a O 0 0.0002515271
more O 0 0.00021412015
significant O 0 0.00014754062
rise O 0 0.00018418806
occurred O 0 0.00015011671
in O 0 0.00015175392
those O 0 0.00022308918
with O 0 0.00028636112
earlier O 0 0.0005046124
stages O 0 0.001190501
of O 0 0.0017239478
disease O 0 0.6789066
. O 0 0.003652842

Of O 0 0.0051958757
those O 0 0.002584336
positive O 0 0.001692773
for O 0 0.0012660928
p24 O 0 0.14507408
antigen O 0 0.0024004963
at O 0 0.0003261297
the O 0 0.00023536483
commencement O 0 0.00022093639
of O 0 0.00020802327
the O 0 0.00016741613
study O 0 0.00022618838
67 O 0 0.00031206015
% O 0 0.000294507
showed O 0 0.00013121897
a O 0 0.00019668404
positive O 0 0.00014696774
response O 0 0.00015255011
, O 0 0.0002972987
and O 0 0.00015805507
this O 0 0.00015251464
was O 0 0.00012232683
most O 0 0.00014489333
likely O 0 7.1645896e-05
in O 0 0.000108187916
those O 0 0.00015324088
with O 0 0.00020142952
CD4 O 0 0.0038609968
+ O 0 0.0017815805
lymphocyte O 0 0.0040324833
subset O 0 0.00028853162
counts O 0 0.00032955306
above O 0 0.0005596371
100 O 0 0.0017170388
mm3 O 0 0.0032665671
. O 0 0.002706929

A O 0 0.020927181
positive O 0 0.0031243898
weight O 0 0.0028865258
response O 0 0.0015478869
was O 0 0.0012509318
seen O 0 0.0011838739
in O 0 0.0010613111
16 O 0 0.0014207981
% O 0 0.0022412434
of O 0 0.0020871467
patients O 0 0.0048852023
. O 0 0.005056128

Most O 0 0.003981799
patients O 0 0.002835129
showed O 0 0.00094458257
improvement O 0 0.0008547405
in O 0 0.0004763969
individual O 0 0.00033172703
parameters O 0 0.00043203263
and O 0 0.00040935125
global O 0 0.00048423363
score O 0 0.00039022422
of O 0 0.0005049851
quality O 0 0.0005484902
of O 0 0.0012058126
life O 0 0.002167525
. O 0 0.003623324

Adverse O 0 0.006606624
reactions O 0 0.0034120232
possibly O 0 0.002523644
attributable O 0 0.0016399372
to O 0 0.0023322515
didanosine B-Chemical 0 0.9985806
were O 0 0.0025011275
common O 0 0.0032867643
. O 0 0.0050461823

The O 0 0.0021692116
most O 0 0.0021872325
common O 0 0.00159615
side O 0 0.003640114
- O 0 0.0050837765
effect O 0 0.0005929993
was O 0 0.0007392583
diarrhoea B-Disease 0 0.9445051
, O 0 0.0008482302
which O 0 0.00033379675
resulted O 0 0.00022626
in O 0 0.00023002678
cessation O 0 0.00029151954
of O 0 0.0003764015
therapy O 0 0.0006279857
in O 0 0.00055609475
19 O 0 0.0012586482
individuals O 0 0.002366591
. O 0 0.002990327

Peripheral B-Disease 0 0.9345341
neuropathy I-Disease 0 0.99980515
occurred O 0 0.002700774
in O 0 0.001333377
12 O 0 0.00091721077
patients O 0 0.0016579207
and O 0 0.0017328284
pancreatitis B-Disease 0 0.99920744
in O 0 0.002355176
six O 0 0.0017943016
. O 0 0.0041998243

Thirteen O 0 0.007980003
patients O 0 0.004969297
developed O 0 0.0026276358
a O 0 0.002607383
raised O 0 0.002294414
serum O 0 0.10738303
amylase O 0 0.8918442
without O 0 0.002464512
abdominal B-Disease 0 0.006919902
pain I-Disease 0 0.088312626
. O 0 0.0047499132

Seven O 0 0.0047439523
patients O 0 0.0036701073
developed O 0 0.0023476253
glucose B-Disease 1 0.99762803
tolerance I-Disease 0 0.0035340367
curves I-Disease 0 0.00058811647
characteristic O 0 0.000370848
of O 0 0.0005200886
diabetes B-Disease 0 0.99980706
but O 0 0.0005010928
these O 0 0.00023851101
were O 0 0.00023426108
mild O 0 0.021655312
, O 0 0.00042017788
did O 0 0.00018523722
not O 0 0.00012675214
require O 0 0.00010490908
treatment O 0 0.00015776807
and O 0 0.00019365878
returned O 0 0.00022649895
to O 0 0.00022056302
normal O 0 0.0005771085
on O 0 0.00046829082
ceasing O 0 0.0051373662
didanosine B-Chemical 0 0.9991429
. O 0 0.0032978079

Immunohistochemical O 0 0.0034892836
studies O 0 0.0023078553
with O 0 0.001497205
antibodies O 0 0.0013562008
to O 0 0.00091543584
neurofilament O 0 0.009183379
proteins O 0 0.0006675046
on O 0 0.00055500545
axonal B-Disease 0 0.26486036
damage I-Disease 0 0.5534976
in O 0 0.00053955696
experimental O 0 0.0006816425
focal O 0 0.003176905
lesions O 0 0.0059962496
in O 0 0.0010975411
rat O 0 0.0024705257
. O 0 0.00295691

Immunohistochemistry O 0 0.005341092
with O 0 0.0022510546
monoclonal O 0 0.0022462734
antibodies O 0 0.0012468542
against O 0 0.00062752294
neurofilament O 0 0.024434632
( O 0 0.002849545
NF O 0 0.9597338
) O 0 0.0010915513
proteins O 0 0.0002638829
of O 0 0.00028520965
middle O 0 0.00064826227
and O 0 0.0002283897
high O 0 0.00025022635
molecular O 0 0.00037757237
weight O 0 0.0004272435
class O 0 0.0006670175
, O 0 0.0013016862
NF O 0 0.9927188
- O 0 0.055220276
M O 0 0.81574816
and O 0 0.00088422035
NF O 0 0.9980171
- O 0 0.31536674
H O 0 0.99987924
, O 0 0.0010148687
was O 0 0.00018073592
used O 0 0.00013593909
to O 0 0.00015153602
study O 0 0.00030686206
axonal B-Disease 0 0.069775455
injury I-Disease 0 0.35977888
in O 0 0.00027133123
the O 0 0.00032727246
borderzone O 0 0.99757427
of O 0 0.0004736859
focal O 0 0.0022166744
lesions O 0 0.003960125
in O 0 0.00076588534
rats O 0 0.0019099704
. O 0 0.0023861045

Focal O 0 0.039940212
injury B-Disease 0 0.02096526
in I-Disease 0 0.0014607746
the I-Disease 0 0.0009333868
cortex I-Disease 0 0.00553317
was O 0 0.0004325325
produced O 0 0.00028370612
by O 0 0.00033522735
infusion O 0 0.0011433527
of O 0 0.00067557435
lactate B-Chemical 0 0.99298906
at O 0 0.00048508483
acid O 0 0.7135927
pH O 0 0.063791215
or O 0 0.0003697741
by O 0 0.00041694634
stab O 0 0.0057362346
caused O 0 0.0005038494
by O 0 0.00061813544
needle O 0 0.0010912342
insertion O 0 0.0011769197
. O 0 0.0027095526

Infarcts B-Disease 0 0.9849317
in I-Disease 0 0.00435264
substantia I-Disease 0 0.017776886
nigra I-Disease 0 0.0077785486
pars I-Disease 0 0.0027936222
reticulata I-Disease 0 0.0034309893
were O 0 0.00038425837
evoked O 0 0.0007182782
by O 0 0.00042975787
prolonged O 0 0.0014348398
pilocarpine B-Chemical 0 0.99996173
- O 0 0.010552182
induced O 0 0.001014728
status B-Disease 0 0.0022567315
epilepticus I-Disease 0 0.9984498
. O 0 0.0041013607

Immunohistochemical O 0 0.00439976
staining O 0 0.0021931035
for O 0 0.0013485458
NFs O 0 0.0024662358
showed O 0 0.0008829377
characteristic O 0 0.0008860864
terminal O 0 0.0012498165
clubs O 0 0.00149177
of O 0 0.0007897863
axons O 0 0.0009838735
in O 0 0.00072863477
the O 0 0.0010825585
borderzone O 0 0.9954888
of O 0 0.002114002
lesions O 0 0.013917168
. O 0 0.0039483774

Differences O 0 0.0026145084
in O 0 0.0016101273
the O 0 0.000988449
labelling O 0 0.0008572723
pattern O 0 0.0004792648
occurred O 0 0.0003960797
with O 0 0.00032128274
different O 0 0.00019810544
antibodies O 0 0.00033590654
which O 0 0.00032506156
apparently O 0 0.00038402324
depended O 0 0.00023103389
on O 0 0.00015735868
molecular O 0 0.00043593132
weight O 0 0.000526299
class O 0 0.000685803
of O 0 0.0006080064
NFs O 0 0.0015169531
and O 0 0.00083783886
phosphorylation O 0 0.0010593565
state O 0 0.0022125745
. O 0 0.0033080585

These O 0 0.0025604393
immunohistochemical O 0 0.002250059
changes O 0 0.0016192457
of O 0 0.0014248976
NFs O 0 0.00214889
can O 0 0.00048705048
serve O 0 0.0005341231
as O 0 0.0004561265
a O 0 0.00062181026
marker O 0 0.0005602097
for O 0 0.00039856587
axonal B-Disease 0 0.264676
damage I-Disease 0 0.5134478
in O 0 0.00034751522
various O 0 0.00033843564
experimental O 0 0.0006620229
traumatic B-Disease 0 0.9744694
or O 0 0.0013970454
ischemic O 0 0.9998159
lesions O 0 0.78611255
. O 0 0.0036383697

Pharmacokinetic O 0 0.016002651
and O 0 0.0020990558
clinical O 0 0.0023647938
studies O 0 0.0010946244
in O 0 0.00079825433
patients O 0 0.0016893535
with O 0 0.0019478442
cimetidine B-Chemical 0 0.99998975
- O 0 0.13009305
associated O 0 0.0021366165
mental O 0 0.2169556
confusion B-Disease 0 0.6131382
. O 0 0.0048026573

15 O 0 0.004887887
cases O 0 0.005182844
of O 0 0.005235267
cimetidine B-Chemical 0 0.9999795
- O 0 0.20024365
associated O 0 0.0023382662
mental O 0 0.200091
confusion B-Disease 0 0.34204224
have O 0 0.0013665856
been O 0 0.0016553829
reported O 0 0.0026927919
. O 0 0.0043886593

In O 0 0.0018939683
order O 0 0.0012378967
that O 0 0.0009981755
this O 0 0.0013817587
syndrome O 0 0.8073355
might O 0 0.0002989817
be O 0 0.00029206704
investigated O 0 0.000246503
changes O 0 0.00027979666
in O 0 0.00025884958
mental O 0 0.0061695003
status O 0 0.00030551254
( O 0 0.00077530125
M O 0 0.6199762
. O 0 0.0004199164
S O 0 0.88338405
. O 0 0.00027450782
) O 0 0.0004074818
were O 0 0.000116215524
correlated O 0 0.000113941554
with O 0 0.00016520148
serum O 0 0.006369758
concentrations O 0 0.0004002969
and O 0 0.00022034335
renal O 0 0.6833817
and O 0 0.0002082779
hepatic O 0 0.73852843
function O 0 0.00010744317
in O 0 9.505013e-05
36 O 0 0.00011618571
patients O 0 0.0001903496
, O 0 0.00016268504
30 O 0 8.788768e-05
patients O 0 0.00018006163
had O 0 0.00011290941
no O 0 0.00018582544
M O 0 0.8001974
. O 0 0.0004018919
S O 0 0.94643146
. O 0 0.00023409052
change O 0 0.00017321417
on O 0 0.00020498892
cimetidine B-Chemical 0 0.9999906
and O 0 0.00033842563
6 O 0 0.00018482526
had O 0 0.0002549911
moderate O 0 0.00090732187
to O 0 0.00053472543
severe O 0 0.0036680803
changes O 0 0.0015973663
. O 0 0.0025310041

These O 0 0.0019814952
6 O 0 0.0013983253
patients O 0 0.0017286415
had O 0 0.0007679764
both O 0 0.0006455951
renal B-Disease 0 0.51365054
and I-Disease 0 0.00088364177
liver I-Disease 0 0.9508305
dysfunction I-Disease 0 0.9969036
( O 0 0.0010406487
P O 0 0.030624542
less O 0 0.0002606087
than O 0 0.00014388948
0 O 0 0.00022265824
. O 0 0.00018534003
05 O 0 0.0031559966
) O 0 0.00043754038
, O 0 0.00027014696
as O 0 0.00014400671
well O 0 0.00016478378
as O 0 0.00038279666
cimetidine B-Chemical 0 0.9999969
trough O 0 0.5525834
- O 0 0.0029764555
concentrations O 0 0.00027911246
of O 0 0.00016318298
more O 0 0.0002147769
than O 0 0.00012885455
1 O 0 0.00016482669
. O 0 0.00014588078
25 O 0 0.00026432733
microgram O 0 0.0045618657
/ O 0 0.0011830442
ml O 0 0.0010423372
( O 0 0.0005702464
P O 0 0.0071618357
less O 0 0.00046045094
than O 0 0.00036805464
0 O 0 0.0007593145
. O 0 0.00093375053
05 O 0 0.013227139
) O 0 0.0042348956
. O 0 0.0037692024

The O 0 0.002887477
severity O 0 0.0051621497
of O 0 0.0029026428
M O 0 0.8391715
. O 0 0.0019862899
S O 0 0.87933666
. O 0 0.0007214521
changes O 0 0.000452329
increased O 0 0.0004810092
as O 0 0.00040027554
trough O 0 0.010560928
- O 0 0.0023551164
concentrations O 0 0.000710304
rose O 0 0.0012813634
, O 0 0.00069931324
5 O 0 0.0003829224
patients O 0 0.0006952252
had O 0 0.00062785676
lumbar O 0 0.0035431262
puncture O 0 0.0039790734
. O 0 0.0030331514

The O 0 0.0031180352
cerebrospinal O 0 0.21143474
fluid O 0 0.005068862
: O 0 0.0025585697
serum O 0 0.005207999
ratio O 0 0.0008066454
of O 0 0.001197519
cimetidine B-Chemical 0 0.9999937
concentrations O 0 0.0015687498
was O 0 0.0002550694
0 O 0 0.00026140484
. O 0 0.00014956603
24 O 0 0.0001458737
: O 0 0.0002483757
1 O 0 0.00013010437
and O 0 0.000112115464
indicates O 0 9.640365e-05
that O 0 0.00019057989
cimetidine B-Chemical 0 0.9999926
passes O 0 0.000564069
the O 0 0.00016796829
blood O 0 0.020997679
- O 0 0.0079109585
brain O 0 0.0010169656
barrier O 0 0.0009351412
; O 0 0.00036291344
it O 0 0.00015281687
also O 0 8.014462e-05
raises O 0 3.7064914e-05
the O 0 7.3037e-05
possibility O 0 7.8385696e-05
that O 0 0.00017665011
M O 0 0.914508
. O 0 0.000453289
S O 0 0.96451503
. O 0 0.00021676467
changes O 0 0.00014463549
are O 0 8.783355e-05
due O 0 7.960026e-05
to O 0 0.00012414399
blockade O 0 0.0010356614
of O 0 0.0010142941
histamine B-Chemical 0 0.9999659
H2 O 0 0.9998017
- O 0 0.16468632
receptors O 0 0.0011888167
in O 0 0.00037355407
the O 0 0.00040627285
central O 0 0.0011517945
nervous O 0 0.004797541
system O 0 0.0016909731
. O 0 0.002658363

Patients O 0 0.0040396177
likely O 0 0.0009692301
to O 0 0.0007249933
have O 0 0.0004831497
both O 0 0.00040067203
raised O 0 0.0005299026
trough O 0 0.011669057
- O 0 0.0025086734
concentrations O 0 0.00053884904
and O 0 0.00038313126
mental O 0 0.05217025
confusion B-Disease 0 0.13720307
are O 0 0.0001723609
those O 0 0.00019843303
with O 0 0.00021743265
both O 0 0.000275
severe O 0 0.003614869
renal B-Disease 0 0.81425023
and I-Disease 0 0.0013484514
hepatic I-Disease 0 0.99934286
dysfunction I-Disease 0 0.9989241
. O 0 0.004296115

They O 0 0.0050910315
should O 0 0.0013900818
be O 0 0.0012845729
closely O 0 0.00079535774
observed O 0 0.000636505
and O 0 0.00064614473
should O 0 0.00032976456
be O 0 0.00044250453
given O 0 0.00035909656
reduced O 0 0.00081614294
doses O 0 0.0026359714
of O 0 0.0035357603
cimetidine B-Chemical 0 0.9999596
. O 0 0.007346229

Prospective O 0 0.015658913
study O 0 0.0020349505
of O 0 0.001101184
the O 0 0.0006410824
long O 0 0.00064368255
- O 0 0.0015584967
term O 0 0.0003160317
effects O 0 0.00027040232
of O 0 0.00042570475
somatostatin O 0 0.29551905
analog O 0 0.0006993249
( O 0 0.0008780759
octreotide B-Chemical 0 0.9985662
) O 0 0.00059990684
on O 0 0.00013251019
gallbladder O 0 0.04089355
function O 0 0.00023723049
and O 0 0.00054385903
gallstone B-Disease 0 0.9999063
formation O 0 0.0013728
in O 0 0.00064619654
Chinese O 0 0.010769692
acromegalic B-Disease 0 0.99975854
patients O 0 0.0053889537
. O 0 0.002612492

This O 0 0.0044720215
article O 0 0.0026499475
reports O 0 0.0012289609
the O 0 0.00064441265
changes O 0 0.00057975895
in O 0 0.00045212038
gallbladder O 0 0.028008884
function O 0 0.00021155975
examined O 0 0.00014061388
by O 0 0.0001394877
ultrasonography O 0 0.0004052534
in O 0 0.00012381487
20 O 0 0.00012831873
Chinese O 0 0.0003523408
patients O 0 0.00023900022
with O 0 0.00012257602
active O 0 0.00024088137
acromegaly B-Disease 0 0.9996123
treated O 0 0.00028429533
with O 0 0.0001111042
sc O 0 0.00037526255
injection O 0 5.1754472e-05
of O 0 6.469367e-05
the O 0 7.2556344e-05
somatostatin O 0 0.072243
analog O 0 0.00034008562
octreotide B-Chemical 0 0.9981981
in O 0 9.737059e-05
dosages O 0 0.0006122972
of O 0 0.00012403727
300 O 0 0.00036269412
- O 0 0.0010697249
1500 O 0 0.00052987755
micrograms O 0 0.0011081737
/ O 0 0.00040657408
day O 0 6.4799e-05
for O 0 6.973744e-05
a O 0 0.00014964992
mean O 0 0.00010269393
of O 0 0.0001629597
24 O 0 0.0001913293
. O 0 0.00017587564
2 O 0 0.0002553429
+ O 0 0.0009120443
/ O 0 0.0018459623
- O 0 0.002001195
13 O 0 0.00056328654
. O 0 0.000500941
9 O 0 0.0006095419
months O 0 0.0006660688
. O 0 0.0023406455

During O 0 0.0019784651
treatment O 0 0.0018503676
with O 0 0.0019175063
octreotide B-Chemical 0 0.9975292
, O 0 0.0019791815
17 O 0 0.00086857175
patients O 0 0.000808849
developed O 0 0.0005587555
sludge O 0 0.0066132178
, O 0 0.0006654435
10 O 0 0.00034114308
had O 0 0.00043142494
gallstones B-Disease 0 0.99980694
, O 0 0.0009872683
and O 0 0.00037414517
1 O 0 0.0003920132
developed O 0 0.00055012904
acute B-Disease 0 0.83810854
cholecystitis I-Disease 0 0.9999552
requiring O 0 0.0014659975
surgery O 0 0.0019006016
. O 0 0.0022267532

In O 0 0.0020475725
all O 0 0.0016000607
of O 0 0.001219669
7 O 0 0.00075231644
patients O 0 0.0009686854
examined O 0 0.0004562376
acutely O 0 0.0025114922
, O 0 0.001238831
gallbladder O 0 0.5480288
contractility O 0 0.6998505
was O 0 0.0003856715
inhibited O 0 0.00046561254
after O 0 0.00018499135
a O 0 0.0004418795
single O 0 0.000319537
100 O 0 0.001082147
- O 0 0.0030091656
micrograms O 0 0.0045132213
injection O 0 0.0011671208
. O 0 0.002401997

In O 0 0.0021126773
8 O 0 0.0017842641
patients O 0 0.0016896357
followed O 0 0.00059931044
for O 0 0.00043192864
24 O 0 0.00046527293
weeks O 0 0.00028969755
, O 0 0.0009635386
gallbladder O 0 0.090620026
contractility O 0 0.56145376
remained O 0 0.0023488551
depressed B-Disease 2 0.9841171
throughout O 0 0.0011425316
therapy O 0 0.0023666685
. O 0 0.0030460272

After O 0 0.0017513885
withdrawal O 0 0.0050789183
of O 0 0.0018202368
octreotide B-Chemical 0 0.99699366
in O 0 0.00068855943
10 O 0 0.000462054
patients O 0 0.0005933461
without O 0 0.00044552644
gallstones B-Disease 0 0.9998103
, O 0 0.0007199047
8 O 0 0.00019956332
patients O 0 0.00027389452
assessed O 0 0.00014714328
had O 0 0.0001686941
return O 0 0.00022220207
of O 0 0.00026390553
normal O 0 0.0007480126
gallbladder O 0 0.42323452
contractility O 0 0.37460744
within O 0 0.0003614479
1 O 0 0.000733857
month O 0 0.00063094724
. O 0 0.001881627

In O 0 0.002015368
8 O 0 0.0015757326
of O 0 0.0010772691
the O 0 0.00061880425
remaining O 0 0.00050901825
10 O 0 0.00043677774
patients O 0 0.00055389036
who O 0 0.00037706233
developed O 0 0.0003929742
gallstones B-Disease 0 0.99968624
during O 0 0.00018054488
treatment O 0 0.00020901277
, O 0 0.00042096688
gallbladder O 0 0.28468397
contractility O 0 0.26526305
normalized O 0 8.090442e-05
in O 0 0.00010702106
5 O 0 0.00010461198
patients O 0 0.00019994767
( O 0 0.00016420407
3 O 0 7.354539e-05
of O 0 9.9754565e-05
whom O 0 0.00018842069
has O 0 6.991563e-05
disappearance O 0 0.00022760732
of O 0 0.00011203191
their O 0 0.00011480194
stones O 0 0.16021149
within O 0 5.7948575e-05
3 O 0 6.419558e-05
weeks O 0 4.6728463e-05
) O 0 0.00021159867
, O 0 0.00020158381
and O 0 0.00015968077
remained O 0 0.0004182092
depressed B-Disease 2 0.9919967
in O 0 0.0001935408
3 O 0 0.00014677967
( O 0 0.00024148062
2 O 0 0.00014294861
of O 0 0.00015833082
whom O 0 0.0003163111
had O 0 0.00024348438
stones O 0 0.1282204
present O 0 0.00029253686
at O 0 0.00027943568
6 O 0 0.00034181654
months O 0 0.00038007434
) O 0 0.0020748454
. O 0 0.0025784748

Our O 0 0.0020319142
results O 0 0.001314707
suggest O 0 0.0006653062
that O 0 0.000602218
the O 0 0.00051171886
suppression O 0 0.0005594997
of O 0 0.00070520455
gallbladder O 0 0.8178964
contractility O 0 0.8154762
is O 0 0.0002377309
the O 0 0.0001627119
cause O 0 0.00021131217
of O 0 0.00016730619
the O 0 0.00012531815
successive O 0 0.00013974783
formation O 0 0.000308031
of O 0 0.00032852977
bile O 0 0.9984591
sludge O 0 0.6085021
, O 0 0.0016076319
gallstones B-Disease 0 0.99994564
, O 0 0.00067899167
and O 0 0.00029608552
cholecystitis B-Disease 0 0.9998486
during O 0 0.00024340105
octreotide B-Chemical 0 0.99691427
therapy O 0 0.00047906907
in O 0 0.00036736604
Chinese O 0 0.004603778
acromegalic B-Disease 0 0.99971527
patients O 0 0.0052677915
. O 0 0.0025876418

It O 0 0.005052775
is O 0 0.0015767877
therefore O 0 0.0011460601
very O 0 0.0009685825
important O 0 0.00038902005
to O 0 0.00032209148
follow O 0 0.00020093902
the O 0 0.0001893565
changes O 0 0.00022439197
of O 0 0.000264847
gallbladder O 0 0.02794748
function O 0 0.00017141375
during O 0 0.00013495698
long O 0 0.00022757132
- O 0 0.00091432006
term O 0 0.00037490085
octreotide B-Chemical 0 0.99266607
therapy O 0 0.0008668722
of O 0 0.0010527982
acromegalic B-Disease 0 0.9996147
patients O 0 0.005876181
. O 0 0.0028914665

Increase O 0 0.012396995
of O 0 0.00867136
Parkinson B-Disease 0 0.9993678
disability I-Disease 0 0.8188697
after O 0 0.0032092626
fluoxetine B-Chemical 0 0.9999199
medication O 0 0.08630577
. O 0 0.0067997924

Depression B-Disease 0 0.99388653
is O 0 0.0028776801
a O 0 0.0026731917
major O 0 0.0015999357
clinical O 0 0.0024691867
feature O 0 0.0014388812
of O 0 0.0024188245
Parkinson B-Disease 0 0.9956832
' I-Disease 0 0.00424572
s I-Disease 0 0.0041569876
disease I-Disease 0 0.25864506
. O 0 0.0054815672

We O 0 0.0025460338
report O 0 0.0025266884
the O 0 0.0009412052
increased O 0 0.000857579
amount O 0 0.00036002224
of O 0 0.0005910165
motor B-Disease 0 0.081439674
disability I-Disease 0 0.2888336
in O 0 0.00019111087
four O 0 9.9749035e-05
patients O 0 0.00027639497
with O 0 0.00025434402
idiopathic B-Disease 0 0.9830887
Parkinson I-Disease 0 0.9991322
' I-Disease 0 0.0005537793
s I-Disease 0 0.0004075535
disease I-Disease 0 0.01908155
after O 0 0.00010621402
exposure O 0 0.00023153271
to O 0 0.00026076208
the O 0 0.00064025074
antidepressant B-Chemical 0 0.99993026
fluoxetine B-Chemical 0 0.9999838
. O 0 0.0041549043

The O 0 0.0016071743
possibility O 0 0.00095474167
of O 0 0.0013353766
a O 0 0.0015698867
clinically O 0 0.0036126166
relevant O 0 0.0007690823
dopamine B-Chemical 0 0.99967825
- O 0 0.004463034
antagonistic O 0 0.00032740476
capacity O 0 0.00063577533
of O 0 0.00077675836
fluoxetine B-Chemical 0 0.9999962
in O 0 0.00083779334
Parkinson B-Disease 0 0.9990854
' I-Disease 0 0.0008545642
s I-Disease 0 0.00072259567
disease I-Disease 0 0.17329627
patients O 0 0.00090065517
must O 0 0.00033775799
be O 0 0.0007179531
considered O 0 0.0013191797
. O 0 0.0026245096

Sinus B-Disease 0 0.5522576
arrest I-Disease 0 0.045439597
associated O 0 0.0030424541
with O 0 0.0023056758
continuous O 0 0.002282283
- O 0 0.011139023
infusion O 0 0.021253549
cimetidine B-Chemical 0 0.9998673
. O 0 0.010062015

The O 0 0.0015265499
administration O 0 0.0016483276
of O 0 0.00089161843
intermittent O 0 0.0014577411
intravenous O 0 0.0027091121
infusions O 0 0.0012458218
of O 0 0.0007813649
cimetidine B-Chemical 0 0.99999046
is O 0 0.00043817383
infrequently O 0 0.0006351537
associated O 0 0.00034445676
with O 0 0.00037011088
the O 0 0.00039489003
development O 0 0.00087928155
of O 0 0.0016875901
bradyarrhythmias B-Disease 0 0.99829155
. O 0 0.0036558707

A O 0 0.026244331
40 O 0 0.003840626
- O 0 0.006648793
year O 0 0.0012778869
- O 0 0.0032232776
old O 0 0.0010031984
man O 0 0.004270397
with O 0 0.00091405347
leukemia B-Disease 0 0.99972695
and O 0 0.00041780816
no O 0 0.000218584
history O 0 0.00038770225
of O 0 0.00025188277
cardiac B-Disease 0 0.0043530515
disease I-Disease 0 0.36846268
developed O 0 0.00027528987
recurrent O 0 0.0010496785
, O 0 0.0002162989
brief O 0 0.000120938166
episodes O 0 0.0002787771
of O 0 0.00013488879
apparent O 0 0.00018623692
sinus B-Disease 0 0.2129685
arrest I-Disease 0 0.0062228907
while O 0 9.989963e-05
receiving O 0 0.000119077966
continuous O 0 0.00012973337
- O 0 0.0012727154
infusion O 0 0.0026718492
cimetidine B-Chemical 0 0.9999826
50 O 0 0.0011494287
mg O 0 0.015287221
/ O 0 0.0030114113
hour O 0 0.0013891171
. O 0 0.0022497461

The O 0 0.0028917827
arrhythmias B-Disease 2 0.9974623
were O 0 0.0013734957
temporally O 0 0.0008939178
related O 0 0.0003870117
to O 0 0.00063107384
cimetidine B-Chemical 0 0.99998426
administration O 0 0.0017534855
, O 0 0.0006150845
disappeared O 0 0.0003109059
after O 0 0.00016188565
dechallenge O 0 0.343553
, O 0 0.00047766915
and O 0 0.00028704037
did O 0 0.00035945757
not O 0 0.00041235777
recur O 0 0.003514588
during O 0 0.0006547368
ranitidine B-Chemical 1 0.9999206
treatment O 0 0.0021420107
. O 0 0.0029067541

This O 0 0.0048301616
is O 0 0.0015799956
the O 0 0.0009455191
first O 0 0.00059307925
reported O 0 0.00074839656
case O 0 0.0006359563
of O 0 0.000724146
sinus B-Disease 0 0.2672619
arrest I-Disease 0 0.02476786
associated O 0 0.0004841122
with O 0 0.0004486095
continuous O 0 0.00057467876
- O 0 0.0044156965
infusion O 0 0.0098182885
cimetidine B-Chemical 0 0.9999336
. O 0 0.005120473

Phase O 0 0.015403862
II O 0 0.02318596
trial O 0 0.003920164
of O 0 0.003061134
vinorelbine B-Chemical 0 0.9985392
in O 0 0.0028094824
metastatic O 0 0.7930136
squamous B-Disease 0 0.86869395
cell I-Disease 0 0.0070581078
esophageal I-Disease 0 0.99056715
carcinoma I-Disease 0 0.9994708
. O 0 0.008958176

European O 0 0.005315242
Organization O 0 0.002164976
for O 0 0.0018092643
Research O 0 0.0033110266
and O 0 0.0016712872
Treatment O 0 0.0026599169
of O 0 0.0019241386
Cancer B-Disease 0 0.052560493
Gastrointestinal O 0 0.009030203
Treat O 0 0.031465996
Cancer B-Disease 0 0.030308694
Cooperative O 0 0.006372752
Group O 0 0.009935554
. O 0 0.00573041

PURPOSE O 0 0.006262702
: O 0 0.0023957414
To O 0 0.000374893
evaluate O 0 0.00026632522
the O 0 0.00033494685
response O 0 0.00034239545
rate O 0 0.00046356657
and O 0 0.00033599685
toxic O 0 0.0018332876
effects O 0 0.00022941154
of O 0 0.0004247963
vinorelbine B-Chemical 0 0.9997441
( O 0 0.0014610925
VNB B-Chemical 0 0.9931512
) O 0 0.00047971614
administered O 0 0.0002250828
as O 0 0.00014858591
a O 0 0.00024601415
single O 0 0.00016737786
agent O 0 0.00068922056
in O 0 0.0005485715
metastatic O 0 0.83128846
squamous B-Disease 0 0.9189713
cell I-Disease 0 0.004139712
esophageal I-Disease 0 0.9950178
carcinoma I-Disease 0 0.9997588
. O 0 0.0057614646

PATIENTS O 0 0.0021007964
AND O 0 0.0013912108
METHODS O 0 0.0012806753
: O 0 0.0012411459
Forty O 0 0.0011321283
- O 0 0.0013107385
six O 0 0.00022097539
eligible O 0 0.00033746118
patients O 0 0.00044448843
with O 0 0.000275589
measurable O 0 0.0003605553
lesions O 0 0.0013869625
were O 0 0.00017894963
included O 0 0.00015555207
and O 0 0.00019335878
were O 0 0.00018182454
stratified O 0 0.00023016083
according O 0 0.00022406103
to O 0 0.00034449057
previous O 0 0.0006623381
chemotherapy O 0 0.004389841
. O 0 0.002406058

Thirty O 0 0.005892856
patients O 0 0.0025988962
without O 0 0.00090869307
prior O 0 0.00043472083
chemotherapy O 0 0.0015535437
and O 0 0.00036257136
16 O 0 0.00037018818
pretreated O 0 0.00097613415
with O 0 0.0005676145
cisplatin B-Chemical 0 0.9998417
- O 0 0.0029417325
based O 0 0.00022164386
chemotherapy O 0 0.0008994884
were O 0 0.00019266862
assessable O 0 0.00053868396
for O 0 0.0002694373
toxicity B-Disease 0 0.039778557
and O 0 0.0009565335
response O 0 0.0015088582
. O 0 0.0029008258

VNB B-Chemical 0 0.9787846
was O 0 0.0019498196
administered O 0 0.0014145282
weekly O 0 0.00067358324
as O 0 0.0005451444
a O 0 0.0006822671
25 O 0 0.0007166895
- O 0 0.0020584438
mg O 0 0.0037730555
/ O 0 0.0013916582
m2 O 0 0.0014715055
short O 0 0.00031423479
intravenous O 0 0.0013893673
( O 0 0.0006279857
i O 0 0.0007290376
. O 0 0.0005405701
v O 0 0.0019452297
. O 0 0.0009494487
) O 0 0.0024241183
infusion O 0 0.0036907378
. O 0 0.0034198295

RESULTS O 0 0.0047654565
: O 0 0.0030356883
Six O 0 0.0010739231
of O 0 0.00093505613
30 O 0 0.0007002415
patients O 0 0.0009274605
( O 0 0.000771831
20 O 0 0.00040582436
% O 0 0.0006018096
) O 0 0.0005291745
without O 0 0.00020706373
prior O 0 0.00012639668
chemotherapy O 0 0.000684366
achieved O 0 0.0002018396
a O 0 0.00027373736
partial O 0 0.00029598616
response O 0 0.0002614614
( O 0 0.0007278933
PR O 0 0.09261205
) O 0 0.0007941918
( O 0 0.00043722874
95 O 0 0.00041729986
% O 0 0.0003437408
confidence O 0 0.0005113263
interval O 0 0.00033497147
[ O 0 0.0011877058
CI O 0 0.006882555
] O 0 0.0012551192
, O 0 0.0006115758
8 O 0 0.00037209684
% O 0 0.0007132408
to O 0 0.0005013475
39 O 0 0.0012281799
% O 0 0.0023365684
) O 0 0.00412717
. O 0 0.003932339

The O 0 0.0015713262
median O 0 0.00094586326
duration O 0 0.00071169715
of O 0 0.00081471866
response O 0 0.0006453201
was O 0 0.0005225706
21 O 0 0.00049394806
weeks O 0 0.0002690694
( O 0 0.0007370467
range O 0 0.0006002314
, O 0 0.0011195804
17 O 0 0.0010480224
to O 0 0.0008915517
28 O 0 0.0016802473
) O 0 0.004283166
. O 0 0.004510114

One O 0 0.0043180897
of O 0 0.0024346507
16 O 0 0.001889357
patients O 0 0.0018417009
( O 0 0.0011865072
6 O 0 0.00042908266
% O 0 0.0007826378
) O 0 0.0006742373
with O 0 0.00027698535
prior O 0 0.00015914922
chemotherapy O 0 0.00092871836
had O 0 0.00017480431
a O 0 0.00022461629
complete O 0 0.00013469113
response O 0 0.0001875925
( O 0 0.00044056197
CR O 0 0.0019332339
) O 0 0.00038980207
of O 0 0.00017227202
31 O 0 0.00021149118
weeks O 0 8.3750965e-05
' O 0 0.00027584896
duration O 0 0.00015380801
( O 0 0.00042906502
95 O 0 0.00056219473
% O 0 0.0006313115
CI O 0 0.0040732087
, O 0 0.00069897436
0 O 0 0.00055409205
% O 0 0.0007819802
to O 0 0.00050929806
30 O 0 0.0007698111
% O 0 0.0020241088
) O 0 0.0038486102
. O 0 0.0038638995

The O 0 0.0019921323
overall O 0 0.0015706127
response O 0 0.0012506406
rate O 0 0.0015077873
( O 0 0.001453372
World O 0 0.0010083853
Health O 0 0.0004973156
Organization O 0 0.00033380886
[ O 0 0.0013328436
WHO O 0 0.00065201597
] O 0 0.001038723
criteria O 0 0.00039642988
) O 0 0.0006535716
was O 0 0.00026810195
15 O 0 0.0002714239
% O 0 0.0005298256
( O 0 0.00061185204
CR O 0 0.0022363875
, O 0 0.0005689372
2 O 0 0.0003792497
% O 0 0.0006961779
; O 0 0.00090896327
PR O 0 0.01573585
13 O 0 0.00046466614
% O 0 0.0006454508
; O 0 0.0006729243
95 O 0 0.00071465806
% O 0 0.0007720999
CI O 0 0.0041014208
, O 0 0.00076578907
6 O 0 0.00037762456
% O 0 0.00085000467
to O 0 0.0006207828
29 O 0 0.0015398918
% O 0 0.0026313323
) O 0 0.0046042236
. O 0 0.0043786457

The O 0 0.0019580447
median O 0 0.0014576631
dose O 0 0.0026517536
- O 0 0.004066664
intensity O 0 0.0007646143
( O 0 0.0019064386
DI O 0 0.112377115
) O 0 0.0018009029
was O 0 0.00069068396
20 O 0 0.00083979825
mg O 0 0.0045024985
/ O 0 0.0033343483
m2 O 0 0.005115736
/ O 0 0.0044433097
wk O 0 0.0017799082
. O 0 0.0042286757

VNB B-Chemical 0 0.9858451
was O 0 0.0021281538
well O 0 0.0012502081
tolerated O 0 0.00174582
and O 0 0.0007399433
zero O 0 0.0006160129
instances O 0 0.00046911085
of O 0 0.0006922595
WHO O 0 0.0011285777
grade O 0 0.004518812
4 O 0 0.0007926211
nonhematologic O 0 0.45873588
toxicity B-Disease 0 0.3252647
occurred O 0 0.0022114464
. O 0 0.0034211169

At O 0 0.0013287454
least O 0 0.0015641802
one O 0 0.0010385248
episode O 0 0.0010928337
of O 0 0.0008506735
grade O 0 0.0043344167
3 O 0 0.0004599114
or O 0 0.000374466
4 O 0 0.00047816552
granulocytopenia B-Disease 0 0.99734676
was O 0 0.00040609296
seen O 0 0.00042364118
in O 0 0.00044722267
59 O 0 0.00087758445
% O 0 0.0012378802
of O 0 0.0012526051
patients O 0 0.0034684283
. O 0 0.0035083846

A O 0 0.09250925
grade O 0 0.027563427
2 O 0 0.0021738657
or O 0 0.0010460658
3 O 0 0.00078641274
infection B-Disease 0 0.0016089046
occurred O 0 0.0004942246
in O 0 0.00037615615
16 O 0 0.00043664378
% O 0 0.0006169163
of O 0 0.00042652042
patients O 0 0.0009750113
, O 0 0.0009210886
but O 0 0.0007212266
no O 0 0.0008658447
toxic O 0 0.10614952
deaths B-Disease 0 0.15244934
occurred O 0 0.0024231637
. O 0 0.003525902

Other O 0 0.0037003076
side O 0 0.0040068263
effects O 0 0.0015280959
were O 0 0.0012994101
rare O 0 0.0031339673
, O 0 0.0014052456
and O 0 0.0008807568
peripheral B-Disease 0 0.23416373
neurotoxicity I-Disease 0 0.9997936
has O 0 0.00040243458
been O 0 0.00041661598
minor O 0 0.0007020978
( O 0 0.0009317576
26 O 0 0.00076852256
% O 0 0.0012696527
grade O 0 0.0051489575
1 O 0 0.0017378094
) O 0 0.0037706457
. O 0 0.0037106571

CONCLUSION O 0 0.015964013
: O 0 0.0036471824
These O 0 0.00086283917
data O 0 0.0009065903
indicate O 0 0.00044576218
that O 0 0.0007615275
VNB B-Chemical 0 0.9811398
is O 0 0.00044559862
an O 0 0.00046520465
active O 0 0.00049907883
agent O 0 0.0011618364
in O 0 0.0007920982
metastatic O 0 0.7082136
esophageal B-Disease 0 0.53503424
squamous I-Disease 0 0.9849755
cell I-Disease 0 0.0074021104
carcinoma I-Disease 0 0.9993389
. O 0 0.0063382154

Given O 0 0.0012790504
its O 0 0.0016734652
excellent O 0 0.0013439698
tolerance O 0 0.0020565004
profile O 0 0.0005141339
and O 0 0.00049305346
low O 0 0.00071947055
toxicity B-Disease 0 0.32015896
, O 0 0.00058493996
further O 0 0.00020956995
evaluation O 0 0.00026972903
of O 0 0.00045653302
VNB B-Chemical 0 0.9578878
in O 0 0.00030706724
combination O 0 0.00046466014
therapy O 0 0.00065862556
is O 0 0.00058831373
warranted O 0 0.0012101579
. O 0 0.0026658662

Evaluation O 0 0.003721647
of O 0 0.0028496017
adverse O 0 0.0049601835
reactions O 0 0.0020135522
of O 0 0.0017742129
aponidine B-Chemical 0 0.006403303
hydrochloride I-Chemical 0 0.9980019
ophthalmic O 0 0.62800807
solution O 0 0.008184123
. O 0 0.0052435827

We O 0 0.0021290234
prospectively O 0 0.0017109963
evaluated O 0 0.00082147424
the O 0 0.00054538145
adverse O 0 0.001447488
reactions O 0 0.00055995025
of O 0 0.00067014963
apraclonidine B-Chemical 0 0.9999896
in O 0 0.00029878257
20 O 0 0.00020148177
normal O 0 0.00026486313
volunteers O 0 0.00035325147
by O 0 0.00015425774
instilling O 0 0.001046008
a O 0 0.000244156
single O 0 0.0001296416
drop O 0 0.00033880223
of O 0 0.00025702015
1 O 0 0.00035539898
% O 0 0.0010646903
apraclonidine B-Chemical 0 0.9999713
in O 0 0.0004720269
their O 0 0.0005144954
right O 0 0.0020527863
eyes O 0 0.08032759
. O 0 0.0031876913

Examinations O 0 0.005611215
, O 0 0.0032255827
including O 0 0.0011299773
blood O 0 0.004063139
pressure O 0 0.0065046367
, O 0 0.0011588369
pulse O 0 0.00089222996
rate O 0 0.00077042787
, O 0 0.0010393324
conjunctiva O 0 0.011820854
and O 0 0.0003892265
cornea O 0 0.0037451943
, O 0 0.0005001325
intraocular O 0 0.077954926
pressure O 0 0.0053500775
( O 0 0.0005774463
IOP O 0 0.74116355
) O 0 0.00055228407
, O 0 0.0003441943
pupil O 0 0.0014378923
diameter O 0 0.0029231717
, O 0 0.00055647857
basal O 0 0.0006434237
tear O 0 0.23522262
secretion O 0 0.0014117601
and O 0 0.0002439903
margin O 0 0.0024593682
reflex O 0 0.0037711938
distance O 0 0.00015569171
of O 0 0.000104750536
both O 0 8.530044e-05
upper O 0 0.00015882403
and O 0 0.00010901015
lower O 0 0.00019293703
eyelids O 0 0.04762658
, O 0 0.00023264179
were O 0 8.144536e-05
performed O 0 6.8332294e-05
prior O 0 4.752861e-05
to O 0 7.8767545e-05
entry O 0 0.00012439142
and O 0 0.00013910755
at O 0 0.00011646402
1 O 0 0.00019794983
, O 0 0.00029561136
3 O 0 0.00017557139
, O 0 0.00033774815
5 O 0 0.00020579614
and O 0 0.00024164323
7 O 0 0.00025137368
hours O 0 0.00031878968
after O 0 0.00043921906
instillation O 0 0.0020975391
. O 0 0.0027122314

The O 0 0.0030340594
ocular B-Disease 0 0.96428984
hypotensive I-Disease 0 0.99940944
effects O 0 0.00090338994
were O 0 0.0004489367
statistically O 0 0.00044816948
significant O 0 0.00027086548
for O 0 0.0003375396
apraclonidine B-Chemical 0 0.9999937
- O 0 0.015838582
treated O 0 0.00052717555
eyes O 0 0.020866616
throughout O 0 8.384663e-05
the O 0 8.163025e-05
study O 0 0.00011128689
and O 0 9.699906e-05
also O 0 8.7004184e-05
statistically O 0 0.00015716582
significant O 0 9.672817e-05
for O 0 8.53548e-05
contralateral O 0 0.00043559942
eyes O 0 0.0044584046
from O 0 7.8816985e-05
three O 0 4.0842664e-05
hours O 0 7.2640185e-05
after O 0 7.806784e-05
topical O 0 0.0031939582
administration O 0 0.0004305224
of O 0 0.0004425805
1 O 0 0.0008098698
% O 0 0.0027525886
apraclonidine B-Chemical 0 0.9999292
. O 0 0.0040134694

Decreases B-Disease 0 0.0063418415
in I-Disease 0 0.0019974692
systolic I-Disease 0 0.024611736
blood I-Disease 0 0.006654255
pressure I-Disease 0 0.00681174
were O 0 0.00081431004
statistically O 0 0.0010746463
, O 0 0.0013831542
but O 0 0.0010117432
not O 0 0.0010062271
clinically O 0 0.0039381767
, O 0 0.0027734346
significant O 0 0.0026367728
. O 0 0.004666848

No O 0 0.0038534026
significant O 0 0.001609302
changes O 0 0.0011557081
in O 0 0.0008117077
diastolic O 0 0.11203272
blood O 0 0.0044067376
pressure O 0 0.0046142195
, O 0 0.0008400024
pulse O 0 0.0007095716
rate O 0 0.00066046976
and O 0 0.00063575956
basal O 0 0.0016686821
tear O 0 0.24897431
secretion O 0 0.0050913184
were O 0 0.0014666916
noted O 0 0.0021643024
. O 0 0.0036287368

Conjunctival B-Disease 0 0.4968732
blanching I-Disease 0 0.9781029
and O 0 0.007162242
mydriasis B-Disease 0 0.9988997
were O 0 0.003743478
commonly O 0 0.0035572993
found O 0 0.0042103007
. O 0 0.0072034667

Upper O 0 0.03361321
lid O 0 0.04105178
retraction O 0 0.0323521
was O 0 0.006346273
frequently O 0 0.0060495576
noted O 0 0.0073874244
. O 0 0.011083392

While O 0 0.0020425539
the O 0 0.0016269014
elevations O 0 0.00400192
of O 0 0.0009248516
the O 0 0.00054596475
upper O 0 0.00088308036
lid O 0 0.0038363445
margin O 0 0.0023387915
in O 0 0.0002391942
most O 0 0.00024766012
subjects O 0 0.00030299075
were O 0 0.00012722805
not O 0 0.000113467846
more O 0 0.00017776362
than O 0 0.000109528424
2 O 0 0.00013527251
mm O 0 0.00046879193
and O 0 0.00016471907
did O 0 0.0001644264
not O 0 0.00013140004
cause O 0 0.00021408382
noticeable O 0 0.00027460753
change O 0 0.00014142618
in O 0 0.000121738034
appearance O 0 0.0002071838
, O 0 0.00022269368
one O 0 9.194241e-05
subject O 0 9.151432e-05
suffered O 0 0.000428199
from O 0 0.00010932516
mechanical O 0 0.00033618318
entropion B-Disease 0 0.9982674
and O 0 0.00022105293
marked O 0 0.00043417126
corneal B-Disease 0 0.9049017
abrasion I-Disease 0 0.55787134
3 O 0 0.00012650822
hours O 0 9.540227e-05
after O 0 9.1666116e-05
instillation O 0 0.00038369466
of O 0 0.00038427688
the O 0 0.00057891663
medication O 0 0.0042558536
. O 0 0.00242555

This O 0 0.006033599
may O 0 0.0022532907
well O 0 0.0016543808
be O 0 0.0013642475
a O 0 0.0016343085
particularly O 0 0.0012562213
notable O 0 0.0015595655
finding O 0 0.0014581408
in O 0 0.001787924
Asian O 0 0.0075055207
people O 0 0.008917013
. O 0 0.006013649

Thiopentone B-Chemical 0 0.9988952
pretreatment O 0 0.014616205
for O 0 0.0020337396
propofol B-Chemical 0 0.99895895
injection O 0 0.0013421566
pain B-Disease 0 0.009058709
in O 0 0.0010423195
ambulatory O 0 0.0024574695
patients O 0 0.0032464464
. O 0 0.0037798656

This O 0 0.0041206684
study O 0 0.0020613119
investigated O 0 0.0015153773
propofol B-Chemical 0 0.99907863
injection O 0 0.000956812
pain B-Disease 0 0.0084839035
in O 0 0.0004992773
patients O 0 0.00081706303
undergoing O 0 0.00069942046
ambulatory O 0 0.0017122158
anaesthesia O 0 0.0047739944
. O 0 0.0027341633

In O 0 0.0023045375
a O 0 0.002974058
randomized O 0 0.0031267507
, O 0 0.00169213
double O 0 0.00086951564
- O 0 0.005139087
blind O 0 0.017893799
trial O 0 0.00087644625
, O 0 0.0005576855
90 O 0 0.000282291
women O 0 0.00046620698
were O 0 0.00013966403
allocated O 0 0.00015108226
to O 0 0.00010017991
receive O 0 0.00010174551
one O 0 8.325681e-05
of O 0 0.00010322784
three O 0 5.5987657e-05
treatments O 0 0.00013390178
prior O 0 7.518846e-05
to O 0 0.0001256592
induction O 0 0.00017439744
of O 0 0.00040404752
anaesthesia O 0 0.0049667726
with O 0 0.0011781893
propofol B-Chemical 0 0.99946696
. O 0 0.0031832263

Patients O 0 0.0052516074
in O 0 0.0025544136
Group O 0 0.009127871
C O 0 0.67991334
received O 0 0.0010129599
2 O 0 0.00073359767
ml O 0 0.0013243625
normal O 0 0.00068136095
saline O 0 0.0010157798
, O 0 0.00076320866
Group O 0 0.0030274936
L O 0 0.25629193
, O 0 0.00080403115
2 O 0 0.00038507997
ml O 0 0.0010876734
, O 0 0.00084954826
lidocaine B-Chemical 0 0.99952686
2 O 0 0.00029231468
% O 0 0.00036075577
( O 0 0.00030975617
40 O 0 0.00022438042
mg O 0 0.0015333855
) O 0 0.00040842994
and O 0 0.00024009032
Group O 0 0.0016097825
T O 0 0.0026830453
, O 0 0.000563972
2 O 0 0.00036634709
ml O 0 0.0023436116
thiopentone B-Chemical 0 0.9999598
2 O 0 0.00041444352
. O 0 0.00026570132
5 O 0 0.00029186244
% O 0 0.0006887289
( O 0 0.000977152
50 O 0 0.0012524644
mg O 0 0.008805513
) O 0 0.0040744366
. O 0 0.003684529

Venous O 0 0.015518357
discomfort O 0 0.004201933
was O 0 0.0009625716
assessed O 0 0.0006022206
with O 0 0.00053453696
a O 0 0.00063216186
visual O 0 0.0019194137
analogue O 0 0.00068802544
scale O 0 0.00039661265
( O 0 0.00047792765
VAS O 0 0.0012570837
) O 0 0.00039954012
5 O 0 0.00015946898
- O 0 0.0004110993
15 O 0 9.5265365e-05
sec O 0 0.000105630534
after O 0 5.060532e-05
commencing O 0 0.00016127338
propofol B-Chemical 0 0.995118
administration O 0 0.00019636491
using O 0 7.369858e-05
an O 0 0.00011434591
infusion O 0 0.00033888992
pump O 0 0.0008032473
( O 0 0.00026778568
rate O 0 0.00022647604
1000 O 0 0.00046478814
micrograms O 0 0.0012482236
. O 0 0.00019372342
kg O 0 0.0005696857
- O 0 0.0011160191
1 O 0 0.00036374404
. O 0 0.00038451984
min O 0 0.00085866905
- O 0 0.0025570444
1 O 0 0.0013546847
) O 0 0.0031979976
. O 0 0.0033331506

Loss B-Disease 0 0.014300848
of I-Disease 0 0.0068172296
consciousness I-Disease 0 0.8611171
occurred O 0 0.0031816806
in O 0 0.0024183597
60 O 0 0.002912886
- O 0 0.0058826883
90 O 0 0.0030663074
sec O 0 0.004389745
. O 0 0.005958295

Visual O 0 0.028458469
analogue O 0 0.003674794
scores O 0 0.0013849059
( O 0 0.0014049367
mean O 0 0.0006820925
+ O 0 0.0021031348
/ O 0 0.003277595
- O 0 0.0046307812
SD O 0 0.011512718
) O 0 0.00072555133
during O 0 0.00017316628
induction O 0 0.000162506
were O 0 0.0001721111
lower O 0 0.00022707801
in O 0 0.00022818748
Groups O 0 0.0017609212
L O 0 0.31030253
( O 0 0.0005462377
3 O 0 0.00016984761
. O 0 0.0001542083
3 O 0 0.00015825366
+ O 0 0.0006669066
/ O 0 0.0013338341
- O 0 0.0014117385
2 O 0 0.00024042018
. O 0 0.00017840613
5 O 0 0.00016886741
) O 0 0.00037067747
and O 0 0.00024254646
T O 0 0.0020954951
( O 0 0.00044601806
4 O 0 0.00016666693
. O 0 0.00016949623
1 O 0 0.00021614034
+ O 0 0.00072000286
/ O 0 0.001391356
- O 0 0.0013634786
2 O 0 0.00021992905
. O 0 0.00015385494
7 O 0 0.00012900934
) O 0 0.00031023522
than O 0 0.00014948592
in O 0 0.00022721273
Group O 0 0.003927313
C O 0 0.94745463
( O 0 0.000710795
5 O 0 0.00020585995
. O 0 0.00016811873
6 O 0 0.0001581081
+ O 0 0.0007431949
/ O 0 0.0015325652
- O 0 0.0016428642
2 O 0 0.0003453778
. O 0 0.00027847957
3 O 0 0.0002935186
) O 0 0.0007876105
; O 0 0.0010280972
P O 0 0.008027251
= O 0 0.0020213383
0 O 0 0.0013795221
. O 0 0.0016032731
0031 O 0 0.008672057
. O 0 0.004741499

The O 0 0.0021953774
incidence O 0 0.0028016893
of O 0 0.0016362282
venous O 0 0.21759608
discomfort O 0 0.0021279964
was O 0 0.0004376862
lower O 0 0.00045074633
in O 0 0.000419119
Group O 0 0.0039778943
L O 0 0.43482837
( O 0 0.00093173544
76 O 0 0.00056738604
. O 0 0.00022944677
6 O 0 0.00016594098
% O 0 0.0003917997
; O 0 0.0004750825
P O 0 0.0028530373
< O 0 0.00039939999
0 O 0 0.00031605552
. O 0 0.00026149256
05 O 0 0.0029542877
) O 0 0.0005254053
than O 0 0.00019516324
in O 0 0.00026677558
Group O 0 0.004684805
C O 0 0.96922475
( O 0 0.001043145
100 O 0 0.0007066348
% O 0 0.0006482265
) O 0 0.00065037253
but O 0 0.00028646542
not O 0 0.0002094399
different O 0 0.00020339282
from O 0 0.00036175415
Group O 0 0.0027405936
T O 0 0.0047456683
( O 0 0.0013653883
90 O 0 0.0010423313
% O 0 0.0021438194
) O 0 0.003847705
. O 0 0.0037845082

The O 0 0.0018250976
VAS O 0 0.0042069657
scores O 0 0.0008142386
for O 0 0.00047566608
recall O 0 0.0011038275
of O 0 0.0005522402
pain B-Disease 0 0.0075981747
in O 0 0.0002385931
the O 0 0.00016427739
recovery O 0 0.00024597195
room O 0 0.00022319576
were O 0 0.00010825768
correlated O 0 9.630938e-05
with O 0 0.00010691957
the O 0 0.00010414021
VAS O 0 0.000574514
scores O 0 0.00010446824
during O 0 7.840558e-05
induction O 0 0.00011940326
( O 0 0.000322474
r O 0 0.0004635502
= O 0 0.000620496
0 O 0 0.00034363463
. O 0 0.00031115586
7045 O 0 0.0016619681
; O 0 0.00082229346
P O 0 0.0042665424
< O 0 0.000872784
0 O 0 0.00087965984
. O 0 0.0010374191
0001 O 0 0.007012476
) O 0 0.004984329
. O 0 0.004660018

Recovery O 0 0.0071822284
room O 0 0.0025803468
discharge O 0 0.0012190174
times O 0 0.000558804
were O 0 0.00057985453
similar O 0 0.00048319323
: O 0 0.00163972
C O 0 0.85703945
( O 0 0.0013392714
75 O 0 0.0006942856
. O 0 0.00031992196
9 O 0 0.0002861581
+ O 0 0.0010258558
/ O 0 0.0018602703
- O 0 0.0018533911
19 O 0 0.00039492635
. O 0 0.0002222262
4 O 0 0.00018429926
min O 0 0.00035477438
) O 0 0.0005826653
; O 0 0.0006710402
L O 0 0.079565264
73 O 0 0.00066234474
. O 0 0.00022937456
6 O 0 0.00018063547
+ O 0 0.0007821967
/ O 0 0.0014752987
- O 0 0.0014679905
21 O 0 0.00028662605
. O 0 0.00018752205
6 O 0 0.0001526383
min O 0 0.0003354966
) O 0 0.00056792004
; O 0 0.0006290616
T O 0 0.0022419153
( O 0 0.0006897515
77 O 0 0.00065223844
. O 0 0.00032242478
1 O 0 0.00040753913
+ O 0 0.0012510146
/ O 0 0.0022805994
- O 0 0.0023745853
18 O 0 0.0006571744
. O 0 0.0005968417
9 O 0 0.0007393368
min O 0 0.0016445911
) O 0 0.003600379
. O 0 0.0037271865

Assessing O 0 0.0031115974
their O 0 0.0016491705
overall O 0 0.0013575564
satisfaction O 0 0.0024596164
, O 0 0.0018445925
89 O 0 0.0015243262
. O 0 0.000721992
7 O 0 0.00054653717
% O 0 0.0010095094
would O 0 0.0005986402
choose O 0 0.0012288298
propofol B-Chemical 0 0.99917525
anaesthesia O 0 0.022499584
again O 0 0.0022579064
. O 0 0.0035283605

We O 0 0.0020908476
conclude O 0 0.0012520457
that O 0 0.0013352749
lidocaine B-Chemical 0 0.99969316
reduces O 0 0.0005159997
the O 0 0.00030973874
incidence O 0 0.00048928853
and O 0 0.00022399503
severity O 0 0.00045633502
of O 0 0.00022566816
propofol B-Chemical 0 0.99976605
injection O 0 0.00014978583
pain B-Disease 0 0.0018663452
in O 0 8.788064e-05
ambulatory O 0 0.0002583769
patients O 0 0.00029720238
whereas O 0 0.0003259662
thiopentone B-Chemical 0 0.9999777
only O 0 0.0005174071
reduces O 0 0.00046485933
its O 0 0.0012693534
severity O 0 0.004434077
. O 0 0.0027563034

Persistent O 0 0.021487514
paralysis B-Disease 0 0.9809769
after O 0 0.0009602934
prolonged O 0 0.0011335987
use O 0 0.00072135194
of O 0 0.0011846664
atracurium B-Chemical 0 0.9993105
in O 0 0.0007738269
the O 0 0.00058518257
absence O 0 0.00070113625
of O 0 0.0021200671
corticosteroids O 0 0.9961467
. O 0 0.0048817815

Neuromuscular O 0 0.01305998
blocking O 0 0.0023258855
agents O 0 0.003539169
( O 0 0.00268248
NMBAs O 0 0.017466145
) O 0 0.0012892712
are O 0 0.00034413737
often O 0 0.000373892
used O 0 0.00026660698
for O 0 0.00026940773
patients O 0 0.0006210864
requiring O 0 0.00041933457
prolonged O 0 0.00077769865
mechanical O 0 0.0011955713
ventilation O 0 0.0033725614
. O 0 0.0028837668

Reports O 0 0.00568746
of O 0 0.0023803466
persistent O 0 0.0040834225
paralysis B-Disease 0 0.99175173
after O 0 0.00033914877
the O 0 0.00032155242
discontinuance O 0 0.0020507863
of O 0 0.0002277682
these O 0 0.00019106678
drugs O 0 0.0024186315
have O 0 0.00014616972
most O 0 0.0001821492
often O 0 0.00018307533
involved O 0 0.0001707884
aminosteroid O 0 0.7420407
- O 0 0.0020640497
based O 0 0.00014408844
NMBAs O 0 0.0015850359
such O 0 0.00011622448
as O 0 0.00022539485
vecuronium B-Chemical 0 0.99966705
bromide I-Chemical 0 0.9909236
, O 0 0.0004195825
especially O 0 0.00018170822
when O 0 0.00012747833
used O 0 0.0002069808
in O 0 0.00030966496
conjunction O 0 0.00055930566
with O 0 0.0011882574
corticosteroids O 0 0.9967294
. O 0 0.0031871705

Atracurium B-Chemical 0 0.99812883
besylate I-Chemical 0 0.9999285
, O 0 0.004235125
a O 0 0.0014250366
short O 0 0.000748075
- O 0 0.0040337606
acting O 0 0.00097638025
benzylisoquinolinium B-Chemical 0 0.9996592
NMBA O 0 0.99272317
that O 0 0.00019814509
is O 0 0.00014455896
eliminated O 0 0.00013220427
independently O 0 9.970435e-05
of O 0 0.00020646282
renal O 0 0.69620687
or O 0 0.000185677
hepatic O 0 0.8448896
function O 0 0.00015231901
, O 0 0.00026578087
has O 0 6.7689514e-05
also O 0 8.8008615e-05
been O 0 0.00010366503
associated O 0 0.00013783078
with O 0 0.00018742784
persistent O 0 0.0012341606
paralysis B-Disease 0 0.9993206
, O 0 0.00059272547
but O 0 0.00027361
only O 0 0.00024913347
when O 0 0.00021345155
used O 0 0.00041840083
with O 0 0.0011795026
corticosteroids O 0 0.99731076
. O 0 0.0030597462

We O 0 0.0027989487
report O 0 0.0029575583
a O 0 0.0017800293
case O 0 0.001062971
of O 0 0.0012898865
atracurium B-Chemical 0 0.99989665
- O 0 0.026107283
related O 0 0.00034377718
paralysis B-Disease 0 0.9939726
persisting O 0 0.00040498193
for O 0 0.00012376778
approximately O 0 0.00018757067
50 O 0 0.00017951017
hours O 0 0.000109483415
in O 0 0.00013198258
a O 0 0.0002445131
patient O 0 0.00023332464
who O 0 0.00027212218
was O 0 0.00021764255
not O 0 0.00030449365
treated O 0 0.0010323047
with O 0 0.001545813
corticosteroids O 0 0.9980064
. O 0 0.0034711147

A O 0 0.030763485
phase O 0 0.008394387
I O 0 0.07823078
/ O 0 0.010928871
II O 0 0.020928696
study O 0 0.000847962
of O 0 0.0007401665
paclitaxel B-Chemical 1 0.99869484
plus O 0 0.0008968205
cisplatin B-Chemical 0 0.99977916
as O 0 0.00026008947
first O 0 0.00014599672
- O 0 0.0008605398
line O 0 0.00019867196
therapy O 0 0.00027132992
for O 0 0.00017635575
head B-Disease 0 0.0011468154
and I-Disease 0 0.0005941089
neck I-Disease 0 0.07673943
cancers I-Disease 0 0.9462794
: O 0 0.0018290804
preliminary O 0 0.0011335765
results O 0 0.0015312
. O 0 0.00330147

Improved O 0 0.0037472448
outcomes O 0 0.001954438
among O 0 0.0015008864
patients O 0 0.0017954089
with O 0 0.0009087676
head B-Disease 0 0.002661972
and I-Disease 0 0.00083909393
neck I-Disease 0 0.01734772
carcinomas I-Disease 0 0.05021883
require O 0 0.00026392037
investigations O 0 0.0003641152
of O 0 0.00036263294
new O 0 0.00053824537
drugs O 0 0.004495097
for O 0 0.000503606
induction O 0 0.00081521453
therapy O 0 0.002143189
. O 0 0.0027267905

Preliminary O 0 0.003973257
results O 0 0.001919135
of O 0 0.0017498768
an O 0 0.0014495613
Eastern O 0 0.0020366365
Cooperative O 0 0.0013879891
Oncology O 0 0.0005998336
Group O 0 0.0010717879
study O 0 0.00030638298
of O 0 0.00026686766
single O 0 0.00024082993
- O 0 0.0016097105
agent O 0 0.001217063
paclitaxel B-Chemical 1 0.9995536
( O 0 0.0022097037
Taxol B-Chemical 0 0.9998343
; O 0 0.0013743077
Bristol O 0 0.0015377838
- O 0 0.0021175698
Myers O 0 0.0022386825
Squibb O 0 0.21375075
Company O 0 0.023546545
, O 0 0.00065617106
Princeton O 0 0.0037741852
, O 0 0.00081470696
NJ O 0 0.50125426
) O 0 0.0008546367
reported O 0 0.00021349941
a O 0 0.00023729181
37 O 0 0.0002969891
% O 0 0.00024120865
response O 0 0.000113406524
rate O 0 0.00017938441
in O 0 0.00011964556
patients O 0 0.00027656418
with O 0 0.00015902771
head B-Disease 0 0.0009879438
and I-Disease 0 0.00026834387
neck I-Disease 0 0.103817
cancer I-Disease 0 0.9645363
, O 0 0.0003503544
and O 0 0.00013350858
the O 0 0.00014471177
paclitaxel B-Chemical 1 0.9997173
/ O 0 0.057948157
cisplatin B-Chemical 0 0.9999459
combination O 0 0.00021288409
has O 0 6.30654e-05
been O 0 7.518868e-05
used O 0 7.228494e-05
successfully O 0 0.000104611085
and O 0 0.00010009693
has O 0 5.946442e-05
significantly O 0 0.00010546979
improved O 0 0.00013688656
median O 0 7.223451e-05
response O 0 0.00012725024
duration O 0 0.0001731184
in O 0 0.00051634904
ovarian B-Disease 0 0.9900539
cancer I-Disease 0 0.9994661
patients O 0 0.01306766
. O 0 0.0030997954

We O 0 0.0028766664
initiated O 0 0.002153787
a O 0 0.0022648845
phase O 0 0.00307443
I O 0 0.070422046
/ O 0 0.009853721
II O 0 0.042694077
trial O 0 0.0006381545
to O 0 0.00016562385
determine O 0 5.99951e-05
the O 0 0.000102139704
response O 0 0.00012185662
and O 0 0.0001652267
toxicity B-Disease 0 0.08492927
of O 0 0.0001862627
escalating O 0 0.011460274
paclitaxel B-Chemical 1 0.99906796
doses O 0 0.00030646677
combined O 0 0.00010716913
with O 0 9.576705e-05
fixed O 0 0.00015614902
- O 0 0.0015002412
dose O 0 0.0005435381
cisplatin B-Chemical 0 0.9999194
with O 0 0.00045776926
granulocyte O 0 0.99986327
colony O 0 0.51507896
- O 0 0.052899815
stimulating O 0 0.0005251374
factor O 0 0.0023388872
support O 0 0.00011740667
in O 0 0.00012031349
patients O 0 0.00028766366
with O 0 0.00015769919
untreated O 0 0.00048026012
locally O 0 0.0011363681
advanced O 0 0.013178279
inoperable O 0 0.83584243
head B-Disease 0 0.00305658
and I-Disease 0 0.0010124819
neck I-Disease 0 0.25758845
carcinoma I-Disease 0 0.99810165
. O 0 0.0041115982

To O 0 0.0015014868
date O 0 0.0014406668
, O 0 0.002393495
23 O 0 0.001571615
men O 0 0.0021625122
with O 0 0.00054219883
a O 0 0.00046704768
median O 0 0.00019870585
age O 0 0.00034324027
of O 0 0.00024966133
50 O 0 0.00029281396
years O 0 0.00023974078
and O 0 0.00018233356
good O 0 0.0002530999
performance O 0 0.0003494962
status O 0 0.0003703447
have O 0 0.00041178564
entered O 0 0.00095534953
the O 0 0.0008626513
trial O 0 0.0024759865
. O 0 0.003099557

Primary O 0 0.007282197
tumor B-Disease 0 0.088957764
sites O 0 0.0014430548
were O 0 0.0012792539
oropharynx O 0 0.0058326367
, O 0 0.001107973
10 O 0 0.0005198241
patients O 0 0.00076934753
; O 0 0.0009514599
hypopharynx O 0 0.032909445
, O 0 0.00046616505
four O 0 0.00017173521
; O 0 0.0005530469
larynx O 0 0.0016298875
, O 0 0.00033308248
two O 0 0.00013156941
; O 0 0.0004077072
oral O 0 0.00059495063
cavity O 0 0.00025773817
, O 0 0.0002492475
three O 0 8.162496e-05
; O 0 0.0003085398
unknown O 0 0.00017998938
primary O 0 0.00016448818
, O 0 0.00027604576
two O 0 0.00012185569
; O 0 0.00037860902
and O 0 0.00023101187
nasal O 0 0.0005930249
cavity O 0 0.0004379431
and O 0 0.0004828578
parotid O 0 0.09571226
gland O 0 0.0046620215
, O 0 0.0012611997
one O 0 0.0007698657
each O 0 0.0009886448
. O 0 0.0026062934

Of O 0 0.005159501
20 O 0 0.0023068872
patients O 0 0.002087237
evaluable O 0 0.0016600323
for O 0 0.000609228
toxicity B-Disease 0 0.09485131
, O 0 0.0009259961
four O 0 0.00028544717
had O 0 0.00045409662
stage O 0 0.0017883631
III O 0 0.02923898
and O 0 0.000657113
16 O 0 0.0007047108
had O 0 0.0007642443
stage O 0 0.0042669885
IV O 0 0.69274706
disease O 0 0.65906
. O 0 0.0045981263

Treatment O 0 0.008526897
, O 0 0.0031376278
given O 0 0.00075823895
every O 0 0.00041161122
21 O 0 0.00046118014
days O 0 0.00021310261
for O 0 0.00021299861
a O 0 0.00034106246
maximum O 0 0.0002497785
of O 0 0.00017597346
three O 0 7.805466e-05
cycles O 0 8.7861445e-05
, O 0 0.00020868462
consisted O 0 0.00014872372
of O 0 0.0002345183
paclitaxel B-Chemical 1 0.99778616
by O 0 0.00015551127
3 O 0 0.000119676944
- O 0 0.00043168003
hour O 0 9.868882e-05
infusion O 0 0.00016462048
followed O 0 5.2588497e-05
the O 0 5.0168066e-05
next O 0 3.7108843e-05
day O 0 6.465821e-05
by O 0 0.00010051291
a O 0 0.0001839492
fixed O 0 0.00018254404
dose O 0 0.0003464636
of O 0 0.00038317157
cisplatin B-Chemical 0 0.999726
( O 0 0.00094894716
75 O 0 0.00081242813
mg O 0 0.0054452866
/ O 0 0.0030165797
m2 O 0 0.0065043336
) O 0 0.0037256144
. O 0 0.0032052016

The O 0 0.001641314
dose O 0 0.0018894766
levels O 0 0.0007290012
incorporate O 0 0.000521034
escalating O 0 0.006144387
paclitaxel B-Chemical 1 0.99812394
doses O 0 0.0011981495
, O 0 0.0005569291
and O 0 0.0003223074
intrapatient O 0 0.06335559
escalations O 0 0.0026752593
within O 0 7.3350406e-05
a O 0 0.00016604099
given O 0 9.767227e-05
dose O 0 0.00026303282
level O 0 0.00018812036
are O 0 0.00022329985
permitted O 0 0.00044943538
if O 0 0.0005102533
toxicity B-Disease 0 0.27168566
permits O 0 0.0017151469
. O 0 0.0031317244

At O 0 0.0012313266
the O 0 0.0012395155
time O 0 0.00079495116
of O 0 0.00091899186
this O 0 0.00079453393
writing O 0 0.0017681621
, O 0 0.00095146126
dose O 0 0.00065670797
level O 0 0.00028033872
4 O 0 0.00026911098
( O 0 0.00051864743
260 O 0 0.001111701
, O 0 0.0005230737
270 O 0 0.0007577062
, O 0 0.000412313
and O 0 0.00027934485
280 O 0 0.001693376
mg O 0 0.005426658
/ O 0 0.0013855426
m2 O 0 0.0022568046
) O 0 0.0004845167
is O 0 0.00013495442
being O 0 0.00016264207
evaluated O 0 0.00017836245
; O 0 0.00033164676
three O 0 0.000103235616
patients O 0 0.00037273503
from O 0 0.0002440524
this O 0 0.00039045513
level O 0 0.00053288916
are O 0 0.0008277273
evaluable O 0 0.0027765092
. O 0 0.0024681226

With O 0 0.003154215
paclitaxel B-Chemical 1 0.9932708
doses O 0 0.0027108102
of O 0 0.0009488979
200 O 0 0.0012753716
mg O 0 0.008789763
/ O 0 0.0019722888
m2 O 0 0.002074174
and O 0 0.0003184668
higher O 0 0.00038882782
, O 0 0.0011748441
granulocyte O 0 0.99931645
colony O 0 0.27553263
- O 0 0.020112675
stimulating O 0 0.0006601373
factor O 0 0.0019800907
5 O 0 0.00020945848
micrograms O 0 0.0013118002
/ O 0 0.0006942363
kg O 0 0.00049388426
/ O 0 0.0007046833
d O 0 0.00029674848
is O 0 0.00015957485
given O 0 0.00014791799
( O 0 0.0003827041
days O 0 0.00017180844
4 O 0 0.00028331098
through O 0 0.00043250856
12 O 0 0.0007061071
) O 0 0.002605722
. O 0 0.0030568636

Of O 0 0.0052351155
18 O 0 0.0024469914
patients O 0 0.002056518
evaluable O 0 0.0014003364
for O 0 0.00042047474
response O 0 0.00045953802
, O 0 0.0006959308
seven O 0 0.00030880378
( O 0 0.00054936553
39 O 0 0.00041771654
% O 0 0.00053799996
) O 0 0.00050034706
achieved O 0 0.0002539425
a O 0 0.00027984043
complete O 0 0.00015058952
response O 0 0.00017505184
and O 0 0.00020610465
six O 0 0.00014231591
( O 0 0.00044315847
33 O 0 0.0004802789
% O 0 0.0006378474
) O 0 0.00079811754
achieved O 0 0.0005999843
a O 0 0.0010328892
partial O 0 0.0014181134
response O 0 0.0017341106
. O 0 0.0032860723

Three O 0 0.0035291973
patients O 0 0.0039990963
had O 0 0.0017493904
no O 0 0.0013106137
change O 0 0.0014007604
and O 0 0.0018632987
disease O 0 0.23615968
progressed O 0 0.0037866875
in O 0 0.0017282291
two O 0 0.0018750455
. O 0 0.0044038636

The O 0 0.0040816953
overall O 0 0.0037693654
response O 0 0.0035871952
rate O 0 0.0047405697
is O 0 0.0035684956
72 O 0 0.0057877623
% O 0 0.00904483
. O 0 0.009313744

Eleven O 0 0.006348203
responding O 0 0.002929158
patients O 0 0.002648075
had O 0 0.0011479537
subsequent O 0 0.00086588564
surgery O 0 0.0014573155
/ O 0 0.0035098086
radiotherapy O 0 0.00646601
or O 0 0.0014609928
radical O 0 0.025763407
radiotherapy O 0 0.018937571
. O 0 0.0043519605

Two O 0 0.0027178219
pathologic O 0 0.0055339285
complete O 0 0.0009180326
responses O 0 0.00073687185
were O 0 0.00054237805
observed O 0 0.00041000205
in O 0 0.00043535282
patients O 0 0.00082090026
who O 0 0.0005562232
had O 0 0.0003978854
achieved O 0 0.00061196875
clinical O 0 0.0015070172
complete O 0 0.0008413253
responses O 0 0.0016522682
. O 0 0.003228847

Alopecia B-Disease 0 0.9908173
, O 0 0.008986889
paresthesias B-Disease 0 0.9886596
, O 0 0.0031271458
and O 0 0.0016662609
arthralgias B-Disease 0 0.99303377
/ O 0 0.054782875
myalgias B-Disease 0 0.99910104
have O 0 0.00028077952
occurred O 0 0.00024215107
frequently O 0 0.0002398485
, O 0 0.00038320024
but O 0 0.00021553432
with O 0 0.00018327183
one O 0 0.00014612052
exception O 0 0.0001660516
( O 0 0.00036847914
a O 0 0.0003338594
grade O 0 0.0052787648
3 O 0 0.00034299592
myalgia B-Disease 0 0.9989297
) O 0 0.00062370894
they O 0 0.00021380722
have O 0 0.00025248816
been O 0 0.0004014445
grade O 0 0.004600326
1 O 0 0.0008418819
or O 0 0.00080167106
2 O 0 0.0016364868
. O 0 0.0026649537

No O 0 0.006525809
dose O 0 0.006671395
- O 0 0.012735694
limiting O 0 0.0038735433
hematologic O 0 0.99128425
toxicity B-Disease 0 0.99225205
has O 0 0.0017174949
been O 0 0.0021653017
seen O 0 0.0033605061
. O 0 0.0052521955

Paclitaxel B-Chemical 0 0.99933904
/ O 0 0.2916295
cisplatin B-Chemical 0 0.9995803
is O 0 0.0008385721
an O 0 0.0005198452
effective O 0 0.0002931025
first O 0 0.00020552751
- O 0 0.00086501025
line O 0 0.00021509106
regimen O 0 0.00024035257
for O 0 0.00018833412
locoregionally O 0 0.0509071
advanced O 0 0.0015959857
head B-Disease 0 0.0013917935
and I-Disease 0 0.0004651543
neck I-Disease 0 0.07947445
cancer I-Disease 0 0.9186383
and O 0 0.0004926487
continued O 0 0.00046772466
study O 0 0.0006355098
is O 0 0.00064874993
warranted O 0 0.0012606189
. O 0 0.002704285

Results O 0 0.0025236942
thus O 0 0.0016286853
far O 0 0.00097410794
suggest O 0 0.00045415966
no O 0 0.0005889934
dose O 0 0.0011295343
- O 0 0.0016911621
response O 0 0.00027541036
effect O 0 0.00024790416
for O 0 0.00033418968
paclitaxel B-Chemical 1 0.9965203
doses O 0 0.0010642643
above O 0 0.00051543367
200 O 0 0.0012933223
mg O 0 0.010394852
/ O 0 0.004582057
m2 O 0 0.008952796
. O 0 0.0034653891

Improvement O 0 0.0112463
of O 0 0.0069067385
levodopa B-Chemical 0 0.99996245
- O 0 0.10356612
induced O 0 0.0031848883
dyskinesia B-Disease 0 0.9999932
by O 0 0.0030938452
propranolol B-Chemical 0 0.9999876
in O 0 0.002826612
Parkinson B-Disease 0 0.9981414
' I-Disease 0 0.0028757872
s I-Disease 0 0.0028760522
disease I-Disease 0 0.24066566
. O 0 0.0041683735

Seven O 0 0.005718907
patients O 0 0.0054186853
suffering O 0 0.02214063
from O 0 0.0015490782
Parkinson B-Disease 0 0.9953425
' I-Disease 0 0.0015560546
s I-Disease 0 0.0011528779
disease I-Disease 0 0.36218223
( O 0 0.0019978266
PD B-Disease 0 0.9992341
) O 0 0.00092795066
with O 0 0.00029964175
severely O 0 0.01119699
disabling O 0 0.9245752
dyskinesia B-Disease 0 0.9999968
received O 0 0.00016438284
low O 0 0.00022230379
- O 0 0.002206618
dose O 0 0.00094035675
propranolol B-Chemical 0 0.9999919
as O 0 0.00021227622
an O 0 0.00017634078
adjunct O 0 0.00022722178
to O 0 0.00012714812
the O 0 0.00015669088
currently O 0 0.000244169
used O 0 0.00040772388
medical O 0 0.0020810566
treatment O 0 0.001376768
. O 0 0.0025203102

There O 0 0.004085846
was O 0 0.002164776
a O 0 0.0017674807
significant O 0 0.0008708283
40 O 0 0.0007659705
% O 0 0.00086914835
improvement O 0 0.0004642396
in O 0 0.00034395224
the O 0 0.0004783768
dyskinesia B-Disease 0 0.9999831
score O 0 0.00034366036
without O 0 0.00031188977
increase O 0 0.00041387792
of O 0 0.0011783128
parkinsonian B-Disease 2 0.9999306
motor B-Disease 0 0.39201897
disability I-Disease 0 0.7394217
. O 0 0.0033412601

Ballistic O 0 0.03307457
and O 0 0.011945296
choreic O 0 0.99987936
dyskinesia B-Disease 0 0.99999
were O 0 0.0023000936
markedly O 0 0.0039025634
ameliorated O 0 0.13095272
, O 0 0.0037701821
whereas O 0 0.0030791436
dystonia B-Disease 0 0.9999511
was O 0 0.002309249
not O 0 0.0023428872
. O 0 0.004261572

This O 0 0.004124562
study O 0 0.0017176012
suggests O 0 0.000568312
that O 0 0.00046984438
administration O 0 0.00071462535
of O 0 0.00038730053
low O 0 0.00044651687
doses O 0 0.0007896902
of O 0 0.0005190797
beta O 0 0.870969
- O 0 0.10430737
blockers O 0 0.9299951
may O 0 0.00026382724
improve O 0 0.00034473962
levodopa B-Chemical 0 0.9999906
- O 0 0.004305484
induced O 0 0.00034526867
ballistic O 0 0.0077065784
and O 0 0.0018691559
choreic O 0 0.9999684
dyskinesia B-Disease 0 0.9999963
in O 0 0.003108726
PD B-Disease 0 0.9984055
. O 0 0.003741286

Habitual O 0 0.018320598
use O 0 0.0024130922
of O 0 0.0032072023
acetaminophen B-Chemical 0 0.9999567
as O 0 0.0014113124
a O 0 0.0013350181
risk O 0 0.0068727443
factor O 0 0.0041082106
for O 0 0.00040338407
chronic B-Disease 0 0.278619
renal I-Disease 0 0.9317432
failure I-Disease 0 0.26372555
: O 0 0.0009944467
a O 0 0.00062107283
comparison O 0 0.00053344545
with O 0 0.0018226737
phenacetin B-Chemical 0 0.99995875
. O 0 0.0054464405

Six O 0 0.0027899884
epidemiologic O 0 0.0027707994
studies O 0 0.0013549647
in O 0 0.00074550946
the O 0 0.0005042547
United O 0 0.0006367168
States O 0 0.00058637594
and O 0 0.00030762164
Europe O 0 0.00043146138
indicate O 0 8.890347e-05
that O 0 0.000120625366
habitual O 0 0.0010833839
use O 0 0.00017310982
of O 0 0.00047985904
phenacetin B-Chemical 0 0.9999968
is O 0 0.00018220999
associated O 0 0.00014049954
with O 0 0.00011137152
the O 0 8.099598e-05
development O 0 0.00013257768
of O 0 0.00015242115
chronic B-Disease 0 0.23968808
renal I-Disease 0 0.92015713
failure I-Disease 0 0.09808287
and O 0 0.000105366154
end B-Disease 0 7.748452e-05
- I-Disease 0 0.0020572129
stage I-Disease 0 0.0028706451
renal I-Disease 0 0.9996706
disease I-Disease 0 0.99840647
( O 0 0.0033280693
ESRD B-Disease 2 0.9999852
) O 0 0.0010619103
, O 0 0.00028789163
with O 0 0.00015632361
a O 0 0.0002247594
relative O 0 0.00013759112
risk O 0 0.0012784427
in O 0 0.00019383187
the O 0 0.00018106606
range O 0 0.00027606526
of O 0 0.000354596
4 O 0 0.0004044148
to O 0 0.0006006311
19 O 0 0.0016303359
. O 0 0.0023365906

As O 0 0.0023070604
a O 0 0.0024642982
result O 0 0.0010270621
of O 0 0.0008244256
these O 0 0.0005327425
and O 0 0.00046389145
other O 0 0.00035936284
studies O 0 0.00064914423
, O 0 0.002289444
phenacetin B-Chemical 0 0.9999901
has O 0 0.00027353698
now O 0 0.0002823669
been O 0 0.0002584915
withdrawn O 0 0.0006883384
from O 0 0.00022380266
the O 0 0.00025355397
market O 0 0.0007350224
in O 0 0.0005907296
most O 0 0.0011488989
countries O 0 0.0028085634
. O 0 0.0031143301

However O 0 0.002896961
, O 0 0.00288712
three O 0 0.0006764118
case O 0 0.0008298643
control O 0 0.00064414
studies O 0 0.00070098334
, O 0 0.00078089896
one O 0 0.00030509083
each O 0 0.00020137978
in O 0 0.0002594933
North O 0 0.00046996304
Carolina O 0 0.0004745857
, O 0 0.0005229678
northern O 0 0.0007285307
Maryland O 0 0.0007640783
, O 0 0.00039470132
and O 0 0.0002207665
West O 0 0.0002975593
Berlin O 0 0.0003835906
, O 0 0.0003654151
Germany O 0 0.0006424252
, O 0 0.0002548142
showed O 0 0.000107229855
that O 0 9.135529e-05
habitual O 0 0.0010027427
use O 0 0.0001264284
of O 0 0.00032802054
acetaminophen B-Chemical 0 0.9999957
is O 0 0.00012982369
also O 0 8.897803e-05
associated O 0 0.00010974535
with O 0 0.0001456202
chronic B-Disease 0 0.22931904
renal I-Disease 0 0.94631207
failure I-Disease 0 0.43053997
and O 0 0.0003806088
ESRD B-Disease 2 0.9999807
, O 0 0.00041227424
with O 0 0.00015141947
a O 0 0.00020698752
relative O 0 0.00012486
risk O 0 0.0012218213
in O 0 0.00018364373
the O 0 0.00017569363
range O 0 0.0002758529
of O 0 0.00036673265
2 O 0 0.00051915785
to O 0 0.0005607907
4 O 0 0.0010152404
. O 0 0.002138897

These O 0 0.0017697039
studies O 0 0.0015943797
suggest O 0 0.000637371
that O 0 0.00070031016
both O 0 0.0012942693
phenacetin B-Chemical 0 0.9999933
and O 0 0.0054555037
acetaminophen B-Chemical 0 0.9999949
may O 0 0.00028406884
contribute O 0 0.0001543775
to O 0 0.00011620443
the O 0 0.000110441804
burden O 0 0.00020076131
of O 0 0.0003532668
ESRD B-Disease 2 0.9999807
, O 0 0.00051475054
with O 0 0.00015723045
the O 0 0.00011927421
risk O 0 0.0009450984
of O 0 0.00015623482
the O 0 0.0001256363
latter O 0 0.00039403662
being O 0 0.00018542116
somewhat O 0 0.00028457466
less O 0 0.00029408414
than O 0 0.00021522626
that O 0 0.00025053552
of O 0 0.0006104576
the O 0 0.00088708784
former O 0 0.0048112026
. O 0 0.0033162942

This O 0 0.00509149
apparent O 0 0.0021112445
difference O 0 0.0011893979
in O 0 0.0011433993
risk O 0 0.0047349525
may O 0 0.00053253095
not O 0 0.00040034956
be O 0 0.00031615858
due O 0 0.00019826583
to O 0 0.0001988247
differences O 0 0.00020055388
in O 0 0.0003398865
nephrotoxic B-Disease 0 0.9750656
potential O 0 0.00035932177
of O 0 0.00054934586
the O 0 0.00065615075
drugs O 0 0.018568676
themselves O 0 0.0030990676
. O 0 0.003413027

A O 0 0.024650125
lower O 0 0.002877099
relative O 0 0.0013282138
risk O 0 0.005688215
would O 0 0.0006039994
be O 0 0.0004099235
expected O 0 0.000257078
for O 0 0.00035472383
acetaminophen B-Chemical 0 0.9999807
if O 0 0.0001707884
the O 0 0.00014542456
risk O 0 0.00075592485
of O 0 0.0001333208
both O 0 0.00010333756
drugs O 0 0.0020942988
in O 0 8.913029e-05
combination O 0 0.00011033928
with O 0 9.820086e-05
other O 0 9.870765e-05
analgesics O 0 0.009969615
was O 0 9.7460514e-05
higher O 0 0.00013153942
than O 0 0.00012180956
the O 0 0.00015871624
risk O 0 0.001303675
of O 0 0.00040859196
either O 0 0.0005259805
agent O 0 0.0020011372
alone O 0 0.0017689309
. O 0 0.0028993548

Thus O 0 0.0029696557
, O 0 0.0108618885
acetaminophen B-Chemical 0 0.99994624
has O 0 0.0008366785
been O 0 0.00046773316
used O 0 0.00028521186
both O 0 0.00023683524
as O 0 0.0002327616
a O 0 0.00027396684
single O 0 0.00012843515
agent O 0 0.00030616077
and O 0 0.00014223073
in O 0 0.00010947496
combination O 0 0.00014460417
with O 0 0.00013669221
other O 0 0.00015060575
analgesics O 0 0.061721787
, O 0 0.0005599679
whereas O 0 0.0005546913
phenacetin B-Chemical 0 0.9999926
was O 0 0.00040466548
available O 0 0.00026555243
only O 0 0.00044792003
in O 0 0.00059113506
combinations O 0 0.0009948625
. O 0 0.0024760598

The O 0 0.001505613
possibility O 0 0.000843021
that O 0 0.00083042757
habitual O 0 0.003616465
use O 0 0.0005906491
of O 0 0.0009812047
acetaminophen B-Chemical 0 0.99998534
alone O 0 0.0005856839
increases O 0 0.0002711559
the O 0 0.00021122575
risk O 0 0.0022966156
of O 0 0.0006472486
ESRD B-Disease 2 0.9999783
has O 0 0.00019035143
not O 0 0.00017940254
been O 0 0.00020313312
clearly O 0 0.00018644288
demonstrated O 0 0.00033225247
, O 0 0.00104977
but O 0 0.0009827886
cannot O 0 0.004265384
be O 0 0.0016678163
dismissed O 0 0.006394365
. O 0 0.003881094

Acetaminophen B-Chemical 0 0.99954396
- O 0 0.18397082
induced O 0 0.017920835
hypotension B-Disease 0 0.9987507
. O 0 0.02152549

Through O 0 0.0031754738
30 O 0 0.001723448
years O 0 0.0013186872
of O 0 0.00081733917
widespread O 0 0.00066643616
use O 0 0.00061301974
, O 0 0.0026033015
acetaminophen B-Chemical 0 0.9999846
has O 0 0.0003314271
been O 0 0.00023859926
shown O 0 0.00011162116
to O 0 0.00015582479
be O 0 0.00018221921
a O 0 0.00029807154
remarkably O 0 0.00041984837
safe O 0 0.00042839258
medication O 0 0.0011552244
in O 0 0.0004580262
therapeutic O 0 0.0012050874
dosages O 0 0.0060289917
. O 0 0.0030529203

The O 0 0.0020662558
potential O 0 0.0016831099
for O 0 0.0020610315
acetaminophen B-Chemical 0 0.999918
to O 0 0.0012106062
produce O 0 0.0009060829
cardiovascular B-Disease 0 0.9657526
toxicities I-Disease 0 0.9848763
is O 0 0.001069386
very O 0 0.001812306
low O 0 0.0031254946
. O 0 0.004254892

However O 0 0.0040308484
, O 0 0.012749209
acetaminophen B-Chemical 0 0.9999504
has O 0 0.0009797702
been O 0 0.0005742536
demonstrated O 0 0.00034872378
to O 0 0.0002827373
produce O 0 0.00024444735
symptoms O 0 0.0020040006
of O 0 0.00048394842
anaphylaxis B-Disease 2 0.99618465
, O 0 0.00079058105
including O 0 0.0004017603
hypotension B-Disease 0 0.99984
, O 0 0.0010997258
in O 0 0.00055482273
sensitive O 0 0.0007845
individuals O 0 0.0025569543
. O 0 0.0030305914

This O 0 0.005069052
article O 0 0.0031145273
describes O 0 0.0014975991
two O 0 0.0007224087
critically B-Disease 0 0.003682653
ill I-Disease 0 0.9590271
patients O 0 0.0014510257
in O 0 0.0003252429
whom O 0 0.000488398
transient O 0 0.0004721907
episodes O 0 0.00069566723
of O 0 0.00043586356
hypotension B-Disease 0 0.9998696
reproducibly O 0 0.00048309306
developed O 0 0.0002871986
after O 0 0.00017837007
administration O 0 0.000801791
of O 0 0.0015004855
acetaminophen B-Chemical 0 0.99994946
. O 0 0.0043585063

Other O 0 0.0066734273
symptoms O 0 0.017965343
of O 0 0.0048411717
allergic B-Disease 0 0.997535
reactions I-Disease 0 0.0065535544
were O 0 0.0015966531
not O 0 0.0015956317
clinically O 0 0.005144563
detectable O 0 0.0024663683
. O 0 0.004886245

The O 0 0.0037961144
hypotensive B-Disease 0 0.99001336
episodes O 0 0.0054816473
were O 0 0.0014740089
severe O 0 0.003316627
enough O 0 0.0009242754
to O 0 0.0007895048
require O 0 0.00094077084
vasopressor O 0 0.09578587
administration O 0 0.0037224616
. O 0 0.003825981

The O 0 0.0018922141
reports O 0 0.0015725243
illustrate O 0 0.0007146788
the O 0 0.0006022324
need O 0 0.0004477077
for O 0 0.00033749934
clinicians O 0 0.00062237284
to O 0 0.00029512253
consider O 0 0.00035256846
acetaminophen B-Chemical 0 0.9999801
in O 0 0.00045953208
patients O 0 0.0008142118
with O 0 0.0006194609
hypotension B-Disease 0 0.99974793
of O 0 0.0008744806
unknown O 0 0.0011253672
origin O 0 0.0022015967
. O 0 0.0029060054

Reduction O 0 0.007933909
of O 0 0.0073114084
heparan B-Chemical 0 0.9993186
sulphate I-Chemical 0 0.9998646
- O 0 0.13874316
associated O 0 0.0012419856
anionic O 0 0.013502785
sites O 0 0.00036035292
in O 0 0.00039095982
the O 0 0.00046067726
glomerular O 0 0.9974936
basement O 0 0.72844577
membrane O 0 0.0014202786
of O 0 0.00027229605
rats O 0 0.00045515294
with O 0 0.00054470653
streptozotocin B-Chemical 0 0.9999298
- O 0 0.04374145
induced O 0 0.002048713
diabetic B-Disease 2 0.99997795
nephropathy I-Disease 0 0.99999595
. O 0 0.01009273

Heparan B-Chemical 0 0.993778
sulphate I-Chemical 0 0.9994597
- O 0 0.0750347
associated O 0 0.0019821047
anionic O 0 0.014658405
sites O 0 0.0005242635
in O 0 0.0005186059
the O 0 0.00056931935
glomerular O 0 0.99817646
basement O 0 0.86940634
membrane O 0 0.0022075505
were O 0 0.00016942786
studied O 0 0.00017606057
in O 0 9.954304e-05
rats O 0 0.00014121355
8 O 0 6.5452215e-05
months O 0 3.102614e-05
after O 0 3.275039e-05
induction O 0 6.5256085e-05
of O 0 0.00019638982
diabetes B-Disease 0 0.9997845
by O 0 0.00032920853
streptozotocin B-Chemical 0 0.9999597
and O 0 0.00022731825
in O 0 0.00013742695
age O 0 0.00033885954
- O 0 0.0022063535
adn O 0 0.02151913
sex O 0 0.0005206311
- O 0 0.00088312913
matched O 0 0.00011463915
control O 0 0.00017258784
rats O 0 0.000379634
, O 0 0.00044738938
employing O 0 0.00027769982
the O 0 0.00046764195
cationic O 0 0.0034510037
dye O 0 0.06669273
cuprolinic B-Chemical 0 0.7431399
blue I-Chemical 0 0.005696212
. O 0 0.0038393638

Morphometric O 0 0.008969494
analysis O 0 0.002291377
at O 0 0.0012077269
the O 0 0.0010342964
ultrastructural O 0 0.0019695002
level O 0 0.0007626205
was O 0 0.00067168224
performed O 0 0.0005610139
using O 0 0.00055599934
a O 0 0.0010691243
computerized O 0 0.001955559
image O 0 0.0016607264
processor O 0 0.0060212985
. O 0 0.0044094305

The O 0 0.0054379185
heparan B-Chemical 0 0.9981432
sulphate I-Chemical 0 0.9994599
specificity O 0 0.002986531
of O 0 0.0012649357
the O 0 0.0009429129
cuprolinic B-Chemical 0 0.69002783
blue I-Chemical 0 0.0013858025
staining O 0 0.00031266053
was O 0 0.00021669338
demonstrated O 0 0.00020406106
by O 0 0.00036067527
glycosaminoglycan B-Chemical 0 0.99960536
- O 0 0.077960484
degrading O 0 0.0007268982
enzymes O 0 0.0012097372
, O 0 0.00039929338
showing O 0 0.00012207654
that O 0 0.00010357215
pretreatment O 0 0.0009860242
of O 0 0.00015688241
the O 0 0.00010740342
sections O 0 0.00013373526
with O 0 0.00037558767
heparitinase O 0 0.9999348
abolished O 0 0.00049640896
all O 0 0.00021514973
staining O 0 0.00024228088
, O 0 0.000617396
whereas O 0 0.0006093984
chondroitinase O 0 0.9989957
ABC O 0 0.07245295
had O 0 0.000583791
no O 0 0.00065678987
effect O 0 0.0013479923
. O 0 0.0033113805

The O 0 0.002256507
majority O 0 0.0017617197
of O 0 0.0019172508
anionic O 0 0.013777729
sites O 0 0.000768264
( O 0 0.0012676005
74 O 0 0.00090303976
% O 0 0.0008590643
in O 0 0.00048280004
diabetic B-Disease 2 0.9984303
and O 0 0.00046199388
81 O 0 0.0005794846
% O 0 0.00040313034
in O 0 0.00015639071
control O 0 0.00018272377
rats O 0 0.00037306242
) O 0 0.00047278142
were O 0 0.00015134453
found O 0 0.00015340258
within O 0 0.0001122342
the O 0 0.00023777172
lamina O 0 0.0017114312
rara O 0 0.79946965
externa O 0 0.70587575
of O 0 0.0007818651
the O 0 0.0009503116
glomerular O 0 0.99851936
basement O 0 0.93654895
membrane O 0 0.016851882
. O 0 0.0036404948

A O 0 0.029746316
minority O 0 0.0050521954
of O 0 0.002397536
anionic O 0 0.018795306
sites O 0 0.0006437973
were O 0 0.0005341246
scattered O 0 0.00059219636
throughout O 0 0.00023806476
the O 0 0.00029454235
lamina O 0 0.0012494578
densa O 0 0.061681107
and O 0 0.0005683337
lamina O 0 0.0033706005
rara O 0 0.9101212
interna O 0 0.72255224
, O 0 0.0005500168
and O 0 0.00018601918
were O 0 0.00012386318
significantly O 0 0.00014846187
smaller O 0 0.00017699997
than O 0 0.000115297815
those O 0 0.00014536854
in O 0 0.00013256504
the O 0 0.00016460933
lamina O 0 0.0014270914
rara O 0 0.8701909
externa O 0 0.74372804
of O 0 0.0002964273
the O 0 0.00028855007
glomerular O 0 0.9991731
basement O 0 0.8551723
membrane O 0 0.0014853079
( O 0 0.00027797322
p O 0 0.00022484556
< O 0 0.00019938624
0 O 0 0.0001743163
. O 0 0.00014325918
001 O 0 0.0009241565
and O 0 0.00015459744
p O 0 0.00026365704
< O 0 0.00025716846
0 O 0 0.0002309859
. O 0 0.00019577453
01 O 0 0.0009390067
for O 0 0.00025498212
diabetic B-Disease 2 0.99681646
and O 0 0.0004494778
control O 0 0.00045166243
rats O 0 0.00096979766
, O 0 0.0014137627
respectively O 0 0.0020291854
) O 0 0.003765664
. O 0 0.0033359395

Diabetic B-Disease 0 0.9985561
rats O 0 0.005108419
progressively O 0 0.0022934952
developed O 0 0.001900627
albuminuria B-Disease 2 0.99984
reaching O 0 0.001392971
40 O 0 0.0005298816
. O 0 0.00030345385
3 O 0 0.00022959056
( O 0 0.0004013833
32 O 0 0.00032324597
. O 0 0.00023022578
2 O 0 0.00027842622
- O 0 0.0008838455
62 O 0 0.00034435972
. O 0 0.00018830862
0 O 0 0.00025497386
) O 0 0.00051489216
mg O 0 0.0027378898
/ O 0 0.00073313224
24 O 0 0.0001507096
h O 0 0.000116645846
after O 0 5.2108957e-05
8 O 0 7.287984e-05
months O 0 4.512594e-05
in O 0 7.780126e-05
contrast O 0 0.00013792806
to O 0 9.742206e-05
the O 0 9.440012e-05
control O 0 0.00012584144
animals O 0 0.00011369041
( O 0 0.0002915918
0 O 0 0.0002016082
. O 0 0.00013060441
8 O 0 0.00012816953
( O 0 0.00024188802
0 O 0 0.00020239926
. O 0 0.00015680224
2 O 0 0.00020493635
- O 0 0.0006875425
0 O 0 0.00023202795
. O 0 0.00016430604
9 O 0 0.00017048528
) O 0 0.00051193597
mg O 0 0.0024425155
/ O 0 0.00093793194
24 O 0 0.00028420103
h O 0 0.00031001112
, O 0 0.0005106039
p O 0 0.0006342653
< O 0 0.0007715737
0 O 0 0.0008870671
. O 0 0.0011181587
002 O 0 0.007172568
) O 0 0.005011007
. O 0 0.004696506

At O 0 0.0013299012
the O 0 0.0013519754
same O 0 0.00080600876
time O 0 0.00063243334
, O 0 0.0010779728
the O 0 0.0004599011
number O 0 0.00042515606
of O 0 0.0011624077
heparan B-Chemical 0 0.99980277
sulphate I-Chemical 0 0.9999567
anionic O 0 0.32624736
sites O 0 0.00020738064
and O 0 0.0002160736
the O 0 0.00015634479
total O 0 0.00021631664
anionic O 0 0.0066455305
site O 0 0.00012513605
surface O 0 0.00036563078
( O 0 0.0002830229
number O 0 0.000100574354
of O 0 0.00016335468
anionic O 0 0.0024815516
sites O 0 0.00010367274
x O 0 0.0005693834
mean O 0 0.0001441647
anionic O 0 0.0027275248
site O 0 0.000108257576
surface O 0 0.00037028175
) O 0 0.00044862874
in O 0 0.00015048988
the O 0 0.00016964464
lamina O 0 0.0014948217
rara O 0 0.8793941
externa O 0 0.7549288
of O 0 0.00028577883
the O 0 0.00028389393
glomerular O 0 0.9994899
basement O 0 0.9436208
membrane O 0 0.0024999173
was O 0 0.00015353458
reduced O 0 0.00017201366
by O 0 0.00014562506
19 O 0 0.0002145168
% O 0 0.00027044825
( O 0 0.00022513475
p O 0 0.00023356058
< O 0 0.00023843165
0 O 0 0.000230612
. O 0 0.00021928287
021 O 0 0.003455725
) O 0 0.00054517505
and O 0 0.00023702228
by O 0 0.0002301762
26 O 0 0.00034596273
% O 0 0.00047328373
( O 0 0.00043968466
p O 0 0.00047907658
< O 0 0.00053572666
0 O 0 0.000566844
. O 0 0.00064420176
02 O 0 0.007849914
) O 0 0.0022591862
, O 0 0.0025081662
respectively O 0 0.0037539224
. O 0 0.0045225304

Number O 0 0.0043607587
and O 0 0.0024497616
total O 0 0.0019292423
anionic O 0 0.013287509
site O 0 0.00061221345
surface O 0 0.0010483105
in O 0 0.00039313314
the O 0 0.00026208212
remaining O 0 0.00025000435
part O 0 0.00021719934
of O 0 0.0002849338
the O 0 0.00036358973
glomerular O 0 0.99844617
basement O 0 0.8937424
membrane O 0 0.005243717
( O 0 0.0008459138
lamina O 0 0.0014658134
densa O 0 0.12434261
and O 0 0.000584719
lamina O 0 0.0038175571
rara O 0 0.91584057
interna O 0 0.78703713
) O 0 0.0015965673
were O 0 0.0004529184
not O 0 0.0005363065
significantly O 0 0.0011721596
changed O 0 0.002132558
. O 0 0.003462461

We O 0 0.0021387304
conclude O 0 0.0011559728
that O 0 0.00092503976
in O 0 0.0012907836
streptozotocin B-Chemical 0 0.9999161
- O 0 0.2556053
diabetic B-Disease 2 0.9995146
rats O 0 0.0007256043
with O 0 0.00026198442
an O 0 0.00025208842
increased O 0 0.00043269395
urinary O 0 0.31751224
albumin O 0 0.9991954
excretion O 0 0.9578594
, O 0 0.0006406646
a O 0 0.00045934995
reduced O 0 0.0009134535
heparan B-Chemical 0 0.99992096
sulphate I-Chemical 0 0.99997365
charge O 0 0.0059177247
barrier O 0 0.0031332327
/ O 0 0.002007048
density O 0 0.00031815967
is O 0 0.00013619858
found O 0 0.0001561258
at O 0 0.00014559715
the O 0 0.00023138266
lamina O 0 0.0017948039
rara O 0 0.83616906
externa O 0 0.727791
of O 0 0.00072679773
the O 0 0.00088895316
glomerular O 0 0.9986058
basement O 0 0.93828905
membrane O 0 0.016750986
. O 0 0.0035150242

Mediation O 0 0.021206202
of O 0 0.0032629613
enhanced O 0 0.0025529102
reflex O 0 0.10428702
vagal O 0 0.308334
bradycardia B-Disease 0 0.99806803
by O 0 0.001982967
L B-Chemical 1 0.99896276
- I-Chemical 1 0.9840954
dopa I-Chemical 1 0.99996877
via O 0 0.0009511997
central O 0 0.00373213
dopamine B-Chemical 0 0.99948007
formation O 0 0.0017661342
in O 0 0.0011998833
dogs O 0 0.0032477318
. O 0 0.0032255966

L B-Chemical 0 0.99574643
- I-Chemical 0 0.9674914
Dopa I-Chemical 0 0.9986325
( O 0 0.003503535
5 O 0 0.0011311992
mg O 0 0.0042264354
/ O 0 0.0017506266
kg O 0 0.0010740162
i O 0 0.0007394999
. O 0 0.00037662603
v O 0 0.0010976399
. O 0 0.00030457813
) O 0 0.0005282694
decreased O 0 0.00038834868
blood O 0 0.0019107469
pressure O 0 0.0041654157
and O 0 0.00026704173
heart O 0 0.00831857
rate O 0 0.0003278083
after O 0 0.00016036008
extracerebral O 0 0.9863055
decarboxylase O 0 0.006903165
inhibition O 0 0.0004280309
with O 0 0.0005847984
MK B-Chemical 0 0.99814045
- I-Chemical 0 0.04500322
486 I-Chemical 0 0.0131156165
( O 0 0.0003703073
25 O 0 0.00024620703
mg O 0 0.0016190745
/ O 0 0.00063000416
kg O 0 0.00044505674
i O 0 0.00038514956
. O 0 0.00023333755
v O 0 0.0010355785
. O 0 0.00032763177
) O 0 0.0008387626
in O 0 0.0005889497
anesthetize O 0 0.33077723
MAO B-Chemical 0 0.99999475
- O 0 0.09401911
inhibited O 0 0.0029397893
dogs O 0 0.005437699
. O 0 0.0038869714

In O 0 0.0019073796
addition O 0 0.0012756159
, O 0 0.003172689
reflex O 0 0.15307003
bradycardia B-Disease 0 0.99730384
caused O 0 0.0006029029
by O 0 0.00044164638
injected O 0 0.000686936
norepinephrine B-Chemical 0 0.9999232
was O 0 0.0002749594
significantly O 0 0.000267631
enhanced O 0 0.00029959207
by O 0 0.00052489276
L B-Chemical 1 0.9992888
- I-Chemical 1 0.9809411
dopa I-Chemical 1 0.99998784
, O 0 0.0026240253
DL B-Chemical 0 0.94096977
- I-Chemical 0 0.014418591
Threo I-Chemical 0 0.002396284
- I-Chemical 0 0.005525344
dihydroxyphenylserine I-Chemical 0 0.056675006
had O 0 0.00011923078
no O 0 8.387501e-05
effect O 0 9.4030685e-05
on O 0 0.000108680826
blood O 0 0.0027699023
pressure O 0 0.017771382
, O 0 0.0005323886
heart O 0 0.006060083
rate O 0 0.00034746452
or O 0 0.00026824002
reflex O 0 0.0041317977
responses O 0 0.00060508354
to O 0 0.0011928935
norepinephrine B-Chemical 0 0.9997898
. O 0 0.0036373672

FLA B-Chemical 0 0.94164914
- I-Chemical 0 0.024884505
63 I-Chemical 0 0.004563784
, O 0 0.003902658
a O 0 0.0046001035
dopamine B-Chemical 0 0.9997224
- O 0 0.34573492
beta O 0 0.98903406
- O 0 0.89077127
oxidase O 0 0.9997501
inhibitor O 0 0.04548464
, O 0 0.0012446097
did O 0 0.0003246246
not O 0 0.00017001889
have O 0 0.000122077
any O 0 9.43975e-05
effect O 0 9.701535e-05
on O 0 9.9260666e-05
the O 0 0.00019227553
hypotension B-Disease 0 0.99992895
, O 0 0.0008270993
bradycardia B-Disease 0 0.99211085
or O 0 0.0002108322
reflex O 0 0.009245702
- O 0 0.0011698881
enhancing O 0 0.0002445446
effect O 0 0.0004337605
of O 0 0.0018295308
L B-Chemical 1 0.9992137
- I-Chemical 1 0.9836119
dopa I-Chemical 1 0.9999299
. O 0 0.005780556

Pimozide B-Chemical 0 0.9999089
did O 0 0.004140361
not O 0 0.0012683771
affect O 0 0.0006176326
the O 0 0.0005096049
actions O 0 0.0009023371
of O 0 0.0014392601
L B-Chemical 1 0.9993754
- I-Chemical 1 0.98224616
dopa I-Chemical 1 0.9999695
on O 0 0.00025995015
blood O 0 0.0030240947
pressure O 0 0.0074536414
and O 0 0.00031886657
heart O 0 0.01848622
rate O 0 0.00047075868
but O 0 0.00037801973
completely O 0 0.0003444978
blocked O 0 0.00070513337
the O 0 0.00045742755
enhancement O 0 0.0009668994
of O 0 0.0014501066
reflexes O 0 0.11278467
. O 0 0.0032797374

Removal O 0 0.0050938367
of O 0 0.0020515341
the O 0 0.0012672805
carotid O 0 0.07734459
sinuses O 0 0.02769334
caused O 0 0.00048289896
an O 0 0.0004492709
elevation O 0 0.0028786026
blood O 0 0.0026508917
pressure O 0 0.004124583
and O 0 0.00028715396
heart O 0 0.005078928
rate O 0 0.00031601815
and O 0 0.0002269001
abolished O 0 0.00029077675
the O 0 0.00025485866
negative O 0 0.0005365824
chronotropic O 0 0.9205631
effect O 0 0.0007944608
of O 0 0.0029577494
norepinephrine B-Chemical 0 0.99992096
. O 0 0.0043987595

However O 0 0.005599717
, O 0 0.017925225
L B-Chemical 1 0.998408
- I-Chemical 1 0.9945509
dopa I-Chemical 1 0.9999641
restored O 0 0.002078728
the O 0 0.0008130272
bradycardia B-Disease 0 0.99811184
caused O 0 0.00055077113
by O 0 0.00066269864
norepinephrine B-Chemical 0 0.9999441
in O 0 0.00022908476
addition O 0 0.00010787979
to O 0 0.00016863683
decreasing O 0 0.00029949096
blood O 0 0.003642773
pressure O 0 0.0099337315
and O 0 0.00082740234
heart O 0 0.014502352
rate O 0 0.002260372
. O 0 0.002857618

5 B-Chemical 0 0.006331279
- I-Chemical 0 0.01414049
HTP I-Chemical 0 0.03475645
( O 0 0.0026199478
5 O 0 0.0010508563
mg O 0 0.0039983974
/ O 0 0.0017821674
kg O 0 0.001106925
i O 0 0.0007657836
. O 0 0.0003917567
v O 0 0.0011344899
. O 0 0.0003202601
) O 0 0.00055504247
decreased O 0 0.00041449448
blood O 0 0.0019091145
pressure O 0 0.0036943757
and O 0 0.00029572245
heart O 0 0.0041998
rate O 0 0.00032862904
and O 0 0.00025653615
decreased O 0 0.0004917139
the O 0 0.0003808921
reflex O 0 0.1074265
bradycardia B-Disease 0 0.9980647
to O 0 0.0016574094
norepinephrine B-Chemical 0 0.9998253
. O 0 0.0036983537

It O 0 0.0062136883
is O 0 0.0022884456
concluded O 0 0.0022703393
that O 0 0.0022787754
L B-Chemical 1 0.9984951
- I-Chemical 1 0.98874027
dopa I-Chemical 1 0.9999579
enhances O 0 0.00097076606
reflex O 0 0.24743342
bradycardia B-Disease 0 0.99642605
through O 0 0.0006013451
central O 0 0.0015145607
alpha O 0 0.5648673
- O 0 0.010845343
receptor O 0 0.002878975
stimulation O 0 0.0015693719
. O 0 0.003371592

Furthermore O 0 0.0028962658
, O 0 0.002930618
the O 0 0.00089720555
effects O 0 0.00070816005
are O 0 0.00047931116
mediated O 0 0.00032838163
through O 0 0.00063958473
dopamine B-Chemical 0 0.9995409
rather O 0 0.00048401955
than O 0 0.0005962862
norepinephrine B-Chemical 0 0.99993694
and O 0 0.00038172363
do O 0 0.000257761
not O 0 0.00023436498
require O 0 0.00023531931
the O 0 0.00039654685
carotid O 0 0.055914946
sinus O 0 0.007649695
baroreceptors O 0 0.006561924
. O 0 0.0023730923

Microangiopathic B-Disease 0 0.99135053
hemolytic I-Disease 0 0.999936
anemia I-Disease 0 0.9999832
complicating O 0 0.9886326
FK506 B-Chemical 0 0.9999517
( O 0 0.05031901
tacrolimus B-Chemical 0 0.9998956
) O 0 0.007221815
therapy O 0 0.0038542317
. O 0 0.00438066

We O 0 0.0024958577
describe O 0 0.0016875667
3 O 0 0.0012041637
episodes O 0 0.00216986
of O 0 0.0019401986
microangiopathic B-Disease 0 0.99977976
hemolytic I-Disease 0 0.99999654
anemia I-Disease 0 0.9999988
( O 0 0.1625005
MAHA B-Disease 2 0.9998903
) O 0 0.0012979017
in O 0 0.00021177041
2 O 0 0.00021015383
solid O 0 0.00042782674
organ O 0 0.00028095575
recipients O 0 0.00017261236
under O 0 0.00035990763
FK506 B-Chemical 0 0.9998715
( O 0 0.0038550447
tacrolimus B-Chemical 0 0.99992275
) O 0 0.003210361
therapy O 0 0.0020304527
. O 0 0.0025005774

In O 0 0.00189386
both O 0 0.0016374486
cases O 0 0.0022101484
, O 0 0.001846938
discontinuation O 0 0.0063724862
of O 0 0.000997774
FK506 B-Chemical 0 0.9999169
and O 0 0.0004721878
treatment O 0 0.0002831117
with O 0 0.00029669615
plasma O 0 0.0051769027
exchange O 0 0.00029342572
, O 0 0.0003473236
fresh O 0 0.0003841062
frozen O 0 0.00047388233
plasma O 0 0.00219402
replacement O 0 0.00019684275
, O 0 0.00044542557
corticosteroids B-Chemical 0 0.9982875
, O 0 0.0012140012
aspirin B-Chemical 0 0.99992096
, O 0 0.00088312913
and O 0 0.00055694155
dipyridamole B-Chemical 0 0.99991953
led O 0 0.0005345105
to O 0 0.00045235688
resolution O 0 0.002151204
of O 0 0.0025670726
MAHA B-Disease 2 0.9992393
. O 0 0.0039364165

In O 0 0.002487122
one O 0 0.002178048
patient O 0 0.0020786785
, O 0 0.002317921
reintroduction O 0 0.001538716
of O 0 0.0019890706
FK506 B-Chemical 0 0.9998319
led O 0 0.0014961096
to O 0 0.00093134
rapid O 0 0.0018086461
recurrence O 0 0.026480274
of O 0 0.0034504298
MAHA B-Disease 2 0.9985037
. O 0 0.0056484076

FK506 B-Chemical 0 0.99978775
- O 0 0.3614561
associated O 0 0.0056224563
MAHA B-Disease 2 0.9991153
is O 0 0.001099463
probably O 0 0.001148541
rare O 0 0.0029049537
but O 0 0.00070410926
physicians O 0 0.0011384744
must O 0 0.0002721201
be O 0 0.00037847296
aware O 0 0.00048007292
of O 0 0.0006796268
this O 0 0.0010732377
severe O 0 0.007202914
complication O 0 0.017174026
. O 0 0.0035228909

In O 0 0.0018572048
our O 0 0.0015946416
experience O 0 0.0020674418
and O 0 0.0009331693
according O 0 0.00045614672
to O 0 0.00035954535
the O 0 0.00034739863
literature O 0 0.0010111699
, O 0 0.0022314135
FK506 B-Chemical 0 0.99996305
does O 0 0.00034598072
not O 0 0.00024254785
seem O 0 0.00021420674
to O 0 0.00017721561
cross O 0 0.00038456346
- O 0 0.0027205814
react O 0 0.0005442812
with O 0 0.00049624447
cyclosporin B-Chemical 0 0.99999547
A I-Chemical 0 0.86599004
( O 0 0.0031285968
CyA B-Chemical 0 0.99993277
) O 0 0.0011189871
, O 0 0.0004575695
an O 0 0.0003313718
immuno O 0 0.03169902
- O 0 0.0033717472
suppressive O 0 0.0006201793
drug O 0 0.016488539
already O 0 0.00040492573
known O 0 0.0004941876
to O 0 0.00067119364
induce O 0 0.0013433235
MAHA B-Disease 2 0.9991793
. O 0 0.004216157

Effect O 0 0.0028892623
of O 0 0.0022754949
some O 0 0.0017895414
anticancer O 0 0.014336046
drugs O 0 0.010738813
and O 0 0.00095882785
combined O 0 0.0011217257
chemotherapy O 0 0.0043593072
on O 0 0.0010302445
renal B-Disease 0 0.9954247
toxicity I-Disease 0 0.99612373
. O 0 0.0057383585

The O 0 0.0024585684
nephrotoxic B-Disease 0 0.94608516
action O 0 0.0013109428
of O 0 0.001006099
anticancer O 0 0.022837492
drugs O 0 0.015339104
such O 0 0.0004413951
as O 0 0.00058952364
nitrogranulogen B-Chemical 0 0.99894875
( O 0 0.00186735
NG B-Chemical 0 0.9699791
) O 0 0.0015368118
, O 0 0.0012996441
methotrexate B-Chemical 0 0.9999696
( O 0 0.0033593266
MTX B-Chemical 1 0.99996734
) O 0 0.00097296137
, O 0 0.00037497768
5 B-Chemical 0 0.00020710359
- I-Chemical 0 0.0019736267
fluorouracil I-Chemical 0 0.99962914
( O 0 0.00039420172
5 B-Chemical 0 0.00017100805
- I-Chemical 0 0.0009966342
FU I-Chemical 0 0.06943338
) O 0 0.00038887735
and O 0 0.00024234419
cyclophosphamide B-Chemical 0 0.9997969
( O 0 0.0009997579
CY B-Chemical 1 0.9996841
) O 0 0.0005631223
administered O 0 0.00019092926
alone O 0 0.000120832
or O 0 9.872252e-05
in O 0 0.00011986036
combination O 0 0.00027459263
[ O 0 0.00691586
MTX B-Chemical 1 0.99996126
+ O 0 0.0014165746
5 B-Chemical 0 0.00021565065
- I-Chemical 0 0.0012987797
FU I-Chemical 0 0.18599118
+ O 0 0.002306278
CY B-Chemical 1 0.99953747
( O 0 0.0011792874
CMF O 0 0.8148483
) O 0 0.0007473963
] O 0 0.0008334582
was O 0 0.00019968477
evaluated O 0 0.0002128971
in O 0 0.00023495476
experiments O 0 0.00024972492
on O 0 0.00041125724
Wistar O 0 0.00285845
rats O 0 0.0022037139
. O 0 0.002587462

After O 0 0.0016922565
drug O 0 0.00844724
administration O 0 0.0024990244
, O 0 0.002544059
creatinine B-Chemical 0 0.98642737
concentrations O 0 0.0010051348
in O 0 0.00034630625
the O 0 0.0002894127
plasma O 0 0.0026342284
and O 0 0.0002326478
in O 0 0.00018077469
the O 0 0.0001819024
urine O 0 0.0043951124
of O 0 0.0001831115
the O 0 0.00013443451
rats O 0 0.00026454512
were O 0 0.00015897176
determined O 0 0.00017057259
, O 0 0.00043874892
as O 0 0.00031872524
well O 0 0.00045805302
as O 0 0.0009616351
creatinine B-Chemical 0 0.9961105
clearance O 0 0.020657215
. O 0 0.0034676904

Histopathologic O 0 0.00787904
evaluation O 0 0.0027847874
of O 0 0.002389618
the O 0 0.0019100994
kidneys O 0 0.0050998228
was O 0 0.002124866
also O 0 0.0022101894
performed O 0 0.0031092374
. O 0 0.0058442284

After O 0 0.0034712825
MTX B-Chemical 1 0.9995321
administration O 0 0.003293751
a O 0 0.0012180744
significant O 0 0.0005586783
increase O 0 0.00042971363
( O 0 0.0006101886
p O 0 0.00057657907
= O 0 0.00075740163
0 O 0 0.00034793557
. O 0 0.00025321936
0228 O 0 0.00088616787
) O 0 0.00049988827
in O 0 0.00018800041
the O 0 0.00021452068
plasma O 0 0.029230408
creatinine B-Chemical 0 0.9960247
concentration O 0 0.0004438323
and O 0 0.0001825258
a O 0 0.00020971264
significant O 0 0.0001469997
( O 0 0.0002539149
p O 0 0.0002729511
= O 0 0.00040174907
0 O 0 0.00019810958
. O 0 0.00015792462
0001 O 0 0.0012380483
) O 0 0.0004173118
decrease O 0 0.00022744073
in O 0 0.00029987557
creatinine B-Chemical 0 0.9928074
clearance O 0 0.002317708
was O 0 0.00028055877
noted O 0 0.00033103264
compared O 0 0.0003344415
to O 0 0.0006572066
controls O 0 0.0020371047
. O 0 0.00301434

After O 0 0.0017390918
the O 0 0.0015954108
administration O 0 0.002077283
of O 0 0.0016229013
NG B-Chemical 0 0.9019806
, O 0 0.0015759817
5 B-Chemical 0 0.000632126
- I-Chemical 0 0.0030963286
FU I-Chemical 0 0.21360695
and O 0 0.0005412284
CY B-Chemical 1 0.9990447
neither O 0 0.00023386697
a O 0 0.00029245546
statistically O 0 0.00024121141
significant O 0 0.00013493127
increase O 0 0.00013034962
in O 0 0.00017724706
creatinine B-Chemical 0 0.9910188
concentration O 0 0.00027231837
nor O 0 8.122059e-05
an O 0 0.00011974258
increase O 0 0.00010859826
in O 0 0.00017103855
creatinine B-Chemical 0 0.99612516
clearance O 0 0.0014943007
was O 0 0.00010574653
observed O 0 8.901121e-05
compared O 0 8.729872e-05
to O 0 0.00011593625
the O 0 0.00015436368
group O 0 0.0003724452
receiving O 0 0.00050779193
no O 0 0.00083374605
cytostatics O 0 0.90258443
. O 0 0.0033985255

Following O 0 0.003198177
polytherapy O 0 0.9982957
according O 0 0.0009529518
to O 0 0.0005943303
the O 0 0.00056987995
CMF O 0 0.66961133
regimen O 0 0.0006663078
, O 0 0.00053379155
a O 0 0.00036780056
statistically O 0 0.0003276071
significant O 0 0.00019895176
decrease O 0 0.00022265804
( O 0 0.00031344156
p O 0 0.00032085297
= O 0 0.00045984282
0 O 0 0.00021555423
. O 0 0.00016642078
0343 O 0 0.000869669
) O 0 0.0004179836
in O 0 0.00021928476
creatinine B-Chemical 0 0.9907646
clearance O 0 0.0018305446
was O 0 0.00015158573
found O 0 0.00016981296
, O 0 0.00044105487
but O 0 0.00043231237
creatinine B-Chemical 0 0.99773395
concentration O 0 0.0006296674
did O 0 0.0002505331
not O 0 0.0001912299
increase O 0 0.00023393298
significantly O 0 0.00036085464
compared O 0 0.0003147643
to O 0 0.0005889379
controls O 0 0.001844875
. O 0 0.0026853879

CY B-Chemical 1 0.9989441
caused O 0 0.010194345
hemorrhagic B-Disease 2 0.9997348
cystitis I-Disease 0 0.99946946
in O 0 0.0009908981
40 O 0 0.00062000524
% O 0 0.00067556655
of O 0 0.00033537135
rats O 0 0.0006351207
, O 0 0.0006885368
but O 0 0.0003890036
it O 0 0.00038890235
did O 0 0.00025799903
not O 0 0.00018233286
cause O 0 0.00024394142
this O 0 0.00020349953
complication O 0 0.0011365875
when O 0 0.00013159376
combined O 0 0.0002831457
with O 0 0.00035650894
5 B-Chemical 0 0.00048264518
- I-Chemical 0 0.003743309
FU I-Chemical 0 0.4172772
and O 0 0.0020442563
MTX B-Chemical 1 0.9997358
. O 0 0.0042778645

Histologic O 0 0.0048453473
changes O 0 0.0018939053
were O 0 0.0009952427
found O 0 0.00068076345
in O 0 0.0004937701
rat O 0 0.00058557175
kidneys O 0 0.0008286672
after O 0 0.00015165181
administration O 0 0.00038927177
of O 0 0.00049648696
MTX B-Chemical 1 0.9999634
, O 0 0.0022072247
CY B-Chemical 1 0.9997875
and O 0 0.000537524
NG B-Chemical 0 0.981487
, O 0 0.00047748393
while O 0 0.00014441537
no O 0 0.000121710866
such O 0 0.00012084595
change O 0 0.00012928728
was O 0 0.00010275801
observed O 0 8.7883236e-05
after O 0 6.5169515e-05
5 B-Chemical 0 0.00013387982
- I-Chemical 0 0.00092969934
FU I-Chemical 0 0.03840446
and O 0 0.00014409571
joint O 0 0.0003837576
administration O 0 0.0003046879
of O 0 0.00037075698
MTX B-Chemical 1 0.99994564
+ O 0 0.0016888106
5 B-Chemical 0 0.00029899456
- I-Chemical 0 0.0018362001
FU I-Chemical 0 0.24771479
+ O 0 0.0028937194
CY B-Chemical 1 0.99800223
compared O 0 0.0004997558
to O 0 0.0007644119
controls O 0 0.0022086285
. O 0 0.0031552976

Our O 0 0.0021450745
studies O 0 0.0019032548
indicate O 0 0.0008024115
that O 0 0.0011634218
nephrotoxicity B-Disease 0 0.9998325
of O 0 0.0027796547
MTX B-Chemical 1 0.9999502
+ O 0 0.0034622354
5 B-Chemical 0 0.00042107745
- I-Chemical 0 0.0018877429
FU I-Chemical 0 0.16717197
+ O 0 0.0024945957
CY B-Chemical 1 0.9991454
administered O 0 0.0005823616
jointly O 0 0.00057104323
is O 0 0.00024554128
lower O 0 0.00042177865
than O 0 0.00045056184
in O 0 0.00087425986
monotherapy O 0 0.08993598
. O 0 0.0029311252

The O 0 0.0033476695
interpeduncular O 0 0.0104429815
nucleus O 0 0.0011314573
regulates O 0 0.00047118182
nicotine B-Chemical 0 0.85051197
' O 0 0.001609512
s O 0 0.0008941184
effects O 0 0.00056713866
on O 0 0.0005729877
free O 0 0.0014802669
- O 0 0.0043182746
field O 0 0.0019626562
activity O 0 0.0017873171
. O 0 0.0039979834

Partial O 0 0.0070450474
lesions O 0 0.010291614
were O 0 0.0016222639
made O 0 0.0015510604
with O 0 0.0050160596
kainic B-Chemical 0 0.99996614
acid I-Chemical 0 0.98263955
in O 0 0.0008413794
the O 0 0.00049257145
interpeduncular O 0 0.005361363
nucleus O 0 0.00021636987
of O 0 0.00026552205
the O 0 0.00029401854
ventral O 0 0.0009912073
midbrain O 0 0.0019105268
of O 0 0.00064810505
the O 0 0.00082794385
rat O 0 0.0024306343
. O 0 0.0030590233

Compared O 0 0.0022438844
with O 0 0.0018502147
sham O 0 0.0019343384
- O 0 0.0046393615
operated O 0 0.0020391315
controls O 0 0.0010575842
, O 0 0.0010945013
lesions O 0 0.0024207963
significantly O 0 0.00042656963
( O 0 0.00045502666
p O 0 0.00038241784
< O 0 0.00032891118
0 O 0 0.00026062812
. O 0 0.00019077605
25 O 0 0.0002763091
) O 0 0.00049694267
blunted O 0 0.0010121921
the O 0 0.00016274603
early O 0 0.00027624215
( O 0 0.00028719887
< O 0 0.00023014919
60 O 0 0.00016047191
min O 0 0.00024060319
) O 0 0.0003841527
free O 0 0.00031146748
- O 0 0.0018416744
field O 0 0.00059115177
locomotor B-Disease 0 0.9504991
hypoactivity I-Disease 0 0.99997735
caused O 0 0.00025036235
by O 0 0.00025350755
nicotine B-Chemical 0 0.99656713
( O 0 0.00040745953
0 O 0 0.00017423455
. O 0 0.00010177365
5 O 0 0.000102651546
mg O 0 0.0007051743
kg O 0 0.00034381554
( O 0 0.00034490004
- O 0 0.00087378756
1 O 0 0.00020576712
) O 0 0.00038624916
, O 0 0.00031054742
i O 0 0.00036808837
. O 0 0.00021220562
m O 0 0.0011396125
. O 0 0.00022049554
) O 0 0.00045249035
, O 0 0.00029677595
enhanced O 0 0.00016618989
the O 0 0.00012922862
later O 0 0.00014787527
( O 0 0.00028164985
60 O 0 0.00018533473
- O 0 0.0005422421
120 O 0 0.00018231252
min O 0 0.00026461427
) O 0 0.00064250303
nicotine B-Chemical 0 0.99032927
- O 0 0.004636504
induced O 0 0.00052114704
hyperactivity B-Disease 2 0.9999949
, O 0 0.0013029941
and O 0 0.00042542059
raised O 0 0.00054583536
spontaneous O 0 0.0023236203
nocturnal O 0 0.08181353
activity O 0 0.0011439889
. O 0 0.0025645224

Lesions O 0 0.015480784
reduced O 0 0.0021276444
the O 0 0.0009520793
extent O 0 0.0007183436
of O 0 0.00079515035
immunohistological O 0 0.0012915885
staining O 0 0.0006430755
for O 0 0.0007766126
choline B-Chemical 0 0.999863
acetyltransferase O 0 0.1980853
in O 0 0.00033988614
the O 0 0.0002520788
interpeduncular O 0 0.0029031907
nucleus O 0 0.00012335034
( O 0 0.00019547946
p O 0 0.0002045463
< O 0 0.00020967748
0 O 0 0.00020142969
. O 0 0.00019143459
025 O 0 0.0033390117
) O 0 0.00064449647
, O 0 0.00046852385
but O 0 0.00030951647
not O 0 0.00026893374
for O 0 0.00045575903
tyrosine B-Chemical 0 0.60646945
hydroxylase O 0 0.7587249
in O 0 0.0003621948
the O 0 0.00033990477
surrounding O 0 0.0006552766
catecholaminergic O 0 0.005115059
A10 O 0 0.08339669
region O 0 0.0011353986
. O 0 0.0024149872

We O 0 0.0023179804
conclude O 0 0.001299251
that O 0 0.0010218569
the O 0 0.0010420107
interpeduncular O 0 0.017193347
nucleus O 0 0.0004295048
mediates O 0 0.00033947243
nicotinic O 0 0.99889696
depression B-Disease 0 0.9998029
of O 0 0.0004883817
locomotor O 0 0.007409934
activity O 0 0.00013916033
and O 0 0.00023944474
dampens O 0 0.0005346034
nicotinic O 0 0.99563736
arousal O 0 0.20626579
mechanisms O 0 0.00019327913
located O 0 0.00026995465
elsewhere O 0 0.0005059521
in O 0 0.00047739604
the O 0 0.0007567389
brain O 0 0.0037164579
. O 0 0.0027177238

Lithium B-Chemical 0 0.9997893
- O 0 0.073842965
associated O 0 0.0023733883
cognitive B-Disease 0 0.67715913
and I-Disease 0 0.00076374045
functional I-Disease 0 0.0005130818
deficits I-Disease 0 0.17929743
reduced O 0 0.0005337768
by O 0 0.00033653734
a O 0 0.00045313904
switch O 0 0.00035312775
to O 0 0.0005870389
divalproex B-Chemical 0 0.99998546
sodium I-Chemical 0 0.99904186
: O 0 0.0019543357
a O 0 0.001138078
case O 0 0.0011702626
series O 0 0.0021873668
. O 0 0.0031900774

BACKGROUND O 0 0.04052951
: O 0 0.015652133
Lithium B-Chemical 0 0.999582
remains O 0 0.0008228735
a O 0 0.0008750786
first O 0 0.00037440707
- O 0 0.001573094
line O 0 0.0003345537
treatment O 0 0.0002658118
for O 0 0.00018652271
the O 0 0.00023996951
acute O 0 0.0031528028
and O 0 0.00033195197
maintenance O 0 0.00042185994
treatment O 0 0.00053818716
of O 0 0.0015537766
bipolar B-Disease 2 0.99994993
disorder I-Disease 0 0.9993424
. O 0 0.004887539

Although O 0 0.001973605
much O 0 0.0018173244
has O 0 0.0008465411
been O 0 0.0006748854
written O 0 0.0005358467
about O 0 0.00041421523
the O 0 0.00024363368
management O 0 0.00028046974
of O 0 0.00021010212
the O 0 0.00015146553
more O 0 0.00021418734
common O 0 0.00015167783
adverse O 0 0.00037403495
effects O 0 0.00012235974
of O 0 0.0003080322
lithium B-Chemical 0 0.9999374
, O 0 0.00044067262
such O 0 0.00012702015
as O 0 0.00020576008
polyuria B-Disease 0 0.99928075
and O 0 0.0006223129
tremor B-Disease 0 0.9999627
, O 0 0.0004894877
more O 0 0.0002500127
subtle O 0 0.0004761413
lithium B-Chemical 0 0.99989486
side O 0 0.0005507661
effects O 0 0.00011411085
such O 0 0.00012103728
as O 0 0.00022837425
cognitive B-Disease 2 0.9997396
deficits I-Disease 2 0.9986424
, O 0 0.00061156
loss B-Disease 0 0.00040454665
of I-Disease 0 0.00029271626
creativity I-Disease 0 0.94193196
, O 0 0.0006124624
and O 0 0.0003391797
functional B-Disease 0 0.0008262241
impairments I-Disease 0 0.96035725
remain O 0 0.0009867788
understudied O 0 0.005375782
. O 0 0.0028503565

This O 0 0.004405541
report O 0 0.0026288019
summarizes O 0 0.0007067557
our O 0 0.00056465
experience O 0 0.00087087136
in O 0 0.0004222872
switching O 0 0.0006168648
bipolar B-Disease 2 0.99993443
patients O 0 0.0014485808
from O 0 0.00036579565
lithium B-Chemical 0 0.99988246
to O 0 0.00064802286
divalproex B-Chemical 0 0.9999962
sodium I-Chemical 0 0.9993956
to O 0 0.00022703882
alleviate O 0 0.0003080002
such O 0 0.00035836524
cognitive B-Disease 0 0.8274691
and I-Disease 0 0.0007860685
functional I-Disease 0 0.0020153672
impairments I-Disease 0 0.9873784
. O 0 0.003752496

METHOD O 0 0.024990862
: O 0 0.013370002
Open O 0 0.010154515
, O 0 0.0076047173
case O 0 0.0051976405
series O 0 0.006574204
design O 0 0.009570987
. O 0 0.011276962

RESULTS O 0 0.0048642084
: O 0 0.0032094868
We O 0 0.00092835916
report O 0 0.0011961706
seven O 0 0.00054894056
cases O 0 0.00088849466
where O 0 0.000471204
substitution O 0 0.0007966001
of O 0 0.00085958664
lithium B-Chemical 0 0.9999472
, O 0 0.00087582273
either O 0 0.00018688301
fully O 0 0.00011533519
or O 0 0.00011706549
partially O 0 0.00014185473
, O 0 0.00037866097
with O 0 0.00055435306
divalproex B-Chemical 0 0.999998
sodium I-Chemical 0 0.9997733
was O 0 0.00017104247
extremely O 0 0.0002800972
helpful O 0 0.00013311808
in O 0 8.595335e-05
reducing O 0 8.6652544e-05
the O 0 0.00013355291
cognitive B-Disease 0 0.8572678
, I-Disease 0 0.0004484139
motivational I-Disease 0 0.0062696473
, I-Disease 0 0.0003070222
or I-Disease 0 0.00015708269
creative I-Disease 0 0.0026835608
deficits I-Disease 0 0.55899286
attributed O 0 0.0002773392
to O 0 0.00039094864
lithium B-Chemical 0 0.99977535
in O 0 0.000585319
our O 0 0.00095895526
bipolar B-Disease 2 0.9998872
patients O 0 0.0066421824
. O 0 0.0028970067

CONCLUSION O 0 0.013668426
: O 0 0.0030344292
In O 0 0.00066521525
this O 0 0.00068899366
preliminary O 0 0.00068213226
report O 0 0.0013788587
, O 0 0.004395242
divalproex B-Chemical 0 0.99999416
sodium I-Chemical 0 0.99951947
was O 0 0.00025610946
a O 0 0.00021706974
superior O 0 0.00019736127
alternative O 0 7.512353e-05
to O 0 0.00015389426
lithium B-Chemical 0 0.9998331
in O 0 0.0004026393
bipolar B-Disease 2 0.99997985
patients O 0 0.0013234995
experiencing O 0 0.0016372771
cognitive B-Disease 2 0.9997279
deficits I-Disease 2 0.9982206
, O 0 0.000744876
loss B-Disease 0 0.00054174144
of I-Disease 0 0.0004287335
creativity I-Disease 0 0.9478548
, O 0 0.001081709
and O 0 0.0007041851
functional B-Disease 0 0.0019425785
impairments I-Disease 0 0.9859883
. O 0 0.003904087

Effect O 0 0.0032292781
of O 0 0.0042565227
nifedipine B-Chemical 1 0.99996233
on O 0 0.0013487758
renal O 0 0.53999895
function O 0 0.0005389641
in O 0 0.0005039091
liver O 0 0.0046977145
transplant O 0 0.0007418102
recipients O 0 0.00044423787
receiving O 0 0.0012551324
tacrolimus B-Chemical 0 0.9994748
. O 0 0.0037417642

The O 0 0.0016109464
effect O 0 0.0013320562
of O 0 0.0022955209
nifedipine B-Chemical 1 0.9999827
on O 0 0.00073757576
renal O 0 0.6146417
function O 0 0.00025285676
in O 0 0.0002089281
liver O 0 0.00301267
transplant O 0 0.00021282928
recipients O 0 7.664872e-05
who O 0 0.00011734557
were O 0 8.877124e-05
receiving O 0 0.0002172132
tacrolimus B-Chemical 0 0.99987006
was O 0 0.00018685433
evaluated O 0 0.00018294396
between O 0 0.00021464405
January O 0 0.00031002238
1992 O 0 0.00093312125
and O 0 0.0007108082
January O 0 0.0008529746
1996 O 0 0.002860874
. O 0 0.0030989177

Two O 0 0.0018724637
groups O 0 0.0016457431
of O 0 0.0010222138
patients O 0 0.0012566143
receiving O 0 0.0010063349
tacrolimus B-Chemical 0 0.99989533
were O 0 0.000244401
compared O 0 0.000120971505
over O 0 0.000109880115
a O 0 0.0001689708
period O 0 8.76107e-05
of O 0 0.00013639263
1 O 0 0.00014327106
year O 0 9.900836e-05
, O 0 0.00015523453
one O 0 7.883706e-05
group O 0 0.00014877506
comprising O 0 0.00017919346
hypertensive B-Disease 0 0.999818
patients O 0 0.00037575368
who O 0 0.0001267061
were O 0 7.3292635e-05
receiving O 0 0.00022749299
nifedipine B-Chemical 1 0.99999523
, O 0 0.00044946687
and O 0 0.00012918278
the O 0 9.244651e-05
other O 0 0.00012096874
comprising O 0 0.000295091
nonhypertensive O 0 0.99898714
patients O 0 0.00084196695
not O 0 0.0003853771
receiving O 0 0.0015543987
nifedipine B-Chemical 1 0.9999707
. O 0 0.0044118953

The O 0 0.0018648889
time O 0 0.0011953901
from O 0 0.0010373564
transplant O 0 0.0012268703
to O 0 0.00059725257
baseline O 0 0.0005879503
was O 0 0.00060684874
similar O 0 0.0005292686
in O 0 0.0009102989
all O 0 0.0014077056
patients O 0 0.0036832655
. O 0 0.0040953853

Nifedipine B-Chemical 0 0.99991786
significantly O 0 0.0031541863
improved O 0 0.0020895298
kidney O 0 0.011522195
function O 0 0.00044316397
as O 0 0.00034236262
indicated O 0 0.00018599807
by O 0 0.00023245777
a O 0 0.0003120893
significant O 0 0.00022360518
lowering O 0 0.00096351065
of O 0 0.00043869094
serum O 0 0.18002203
creatinine B-Chemical 0 0.99575233
levels O 0 0.00028011538
at O 0 0.00021742913
6 O 0 0.00024235803
and O 0 0.0003881253
12 O 0 0.00043995614
months O 0 0.00055033225
. O 0 0.0020240068

The O 0 0.0017016764
observed O 0 0.0011338795
positive O 0 0.0008647318
impact O 0 0.0005234715
of O 0 0.0011478948
nifedipine B-Chemical 1 0.9999893
on O 0 0.00030425802
reducing O 0 0.00021323675
the O 0 0.00025399437
nephrotoxicity B-Disease 0 0.99996793
associated O 0 0.00027380313
with O 0 0.00031640218
tacrolimus B-Chemical 0 0.9999882
in O 0 0.00015326923
liver O 0 0.01077794
transplant O 0 0.00015946045
recipients O 0 4.9549355e-05
should O 0 3.5214656e-05
be O 0 6.666227e-05
an O 0 9.588099e-05
important O 0 8.065669e-05
factor O 0 0.0007603264
in O 0 0.000110578796
selecting O 0 8.088822e-05
an O 0 0.00015751254
agent O 0 0.00038058555
to O 0 0.00021889682
treat O 0 0.0016215598
hypertension B-Disease 2 0.9999796
in O 0 0.00075906777
this O 0 0.00095254835
population O 0 0.0020176664
. O 0 0.0026710606

Alpha O 0 0.07423661
and O 0 0.0070734946
beta O 0 0.9478024
coma B-Disease 0 0.9996331
in O 0 0.0028737953
drug O 0 0.30401272
intoxication O 0 0.9982691
uncomplicated O 0 0.21484001
by O 0 0.002806198
cerebral B-Disease 0 0.9992105
hypoxia I-Disease 2 0.9993125
. O 0 0.0066788886

Four O 0 0.0034715184
patients O 0 0.003594861
who O 0 0.0019594084
were O 0 0.0009685483
rendered O 0 0.0016027457
comatose B-Disease 0 0.99448895
or O 0 0.00116945
stuporous B-Disease 0 0.9994199
by O 0 0.00055943365
drug O 0 0.099343486
intoxication O 0 0.99790704
, O 0 0.0010573243
but O 0 0.00044791642
who O 0 0.00050622824
were O 0 0.00033720344
not O 0 0.00052194786
hypoxic O 0 0.932957
, O 0 0.001698837
are O 0 0.0008465963
described O 0 0.0012649584
. O 0 0.002764573

Three O 0 0.0019459539
patients O 0 0.0018442185
received O 0 0.00073345157
high O 0 0.0006780118
doses O 0 0.0012511935
of O 0 0.0011470787
chlormethiazole B-Chemical 0 0.9999976
for O 0 0.0006800732
alcohol B-Chemical 0 0.99970204
withdrawal B-Disease 0 0.8369316
symptoms I-Disease 0 0.36010608
, O 0 0.00044998474
and O 0 0.0002227009
one O 0 0.00020435992
took O 0 0.000338389
a O 0 0.0012202959
suicidal O 0 0.9998847
overdose B-Disease 0 0.99986637
of O 0 0.01021237
nitrazepam B-Chemical 0 0.9999987
. O 0 0.007512238

The O 0 0.0019930142
patient O 0 0.002497711
with O 0 0.0050595975
nitrazepam B-Chemical 0 0.99999964
overdose B-Disease 0 0.999918
and O 0 0.000491912
two O 0 0.00015383263
of O 0 0.00021534572
those O 0 0.00027544322
with O 0 0.0006426833
chlormethiazole B-Chemical 0 0.9999995
intoxication O 0 0.9997496
conformed O 0 0.00029843408
to O 0 8.437093e-05
the O 0 7.412663e-05
criteria O 0 0.000120322664
of O 0 0.00016901676
' O 0 0.0010761414
alpha O 0 0.9717068
coma B-Disease 0 0.9999671
' O 0 0.0012583266
, O 0 0.00039975366
showing O 0 0.000167741
non O 0 0.00069791364
- O 0 0.055270154
reactive O 0 0.26845118
generalized O 0 0.003113105
or O 0 0.00030189444
frontally O 0 0.6867567
predominant O 0 0.0006820769
alpha O 0 0.25932226
activity O 0 0.0004128457
in O 0 0.00063987524
the O 0 0.0010921999
EEG O 0 0.72102493
. O 0 0.003028438

The O 0 0.002071848
fourth O 0 0.0024167176
patient O 0 0.0014765853
who O 0 0.001150396
was O 0 0.00061466673
unconscious O 0 0.0050704493
after O 0 0.00045720147
chlormethiazole B-Chemical 0 0.99999547
administration O 0 0.002859173
exhibite O 0 0.028501224
generalized O 0 0.0029861773
non O 0 0.0011218672
- O 0 0.030347923
reactive O 0 0.059565067
activity O 0 0.00028229665
in O 0 0.0003609768
the O 0 0.00047149786
slow O 0 0.0019552838
beta O 0 0.29586864
range O 0 0.0025264723
. O 0 0.003057619

All O 0 0.002033129
four O 0 0.0011511007
recovered O 0 0.0010541813
completely O 0 0.00090857834
without O 0 0.0011577344
neurological B-Disease 0 0.9949385
sequelae I-Disease 0 0.26751295
following O 0 0.000292788
the O 0 0.00033466314
withdrawal O 0 0.0013317106
of O 0 0.0005376032
the O 0 0.00063218625
offending O 0 0.0055779703
agents O 0 0.004516481
. O 0 0.003549445

The O 0 0.001653765
similarities O 0 0.00111846
between O 0 0.0007459212
the O 0 0.0005777868
effects O 0 0.00050853105
of O 0 0.0005492954
structural O 0 0.000545299
lesions O 0 0.003130742
and O 0 0.0004043963
pharmacological O 0 0.0032029995
depression B-Disease 0 0.9994116
of O 0 0.00043419524
the O 0 0.00034364624
brain O 0 0.0024254886
stem O 0 0.002990859
reticular O 0 0.0098020295
formation O 0 0.0009722877
are O 0 0.00067129446
discussed O 0 0.0011805253
. O 0 0.0026043714

It O 0 0.0050494466
is O 0 0.0015325149
suggested O 0 0.0008830858
that O 0 0.00057782186
in O 0 0.0005251434
both O 0 0.00042375628
situations O 0 0.00084672624
disturbed O 0 0.009695535
reticulo O 0 0.6283895
- O 0 0.006478619
thalamic O 0 0.0010202297
interactions O 0 0.0002073733
are O 0 0.00017561493
important O 0 0.00017057601
in O 0 0.00028236664
the O 0 0.0003820314
pathogenesis O 0 0.001207922
of O 0 0.0017613423
alpha O 0 0.9745194
coma B-Disease 0 0.99976987
. O 0 0.005733306

It O 0 0.0048910463
is O 0 0.0014688412
concluded O 0 0.0010597688
that O 0 0.00053293875
when O 0 0.0003951979
this O 0 0.00052680366
electroencephalographic O 0 0.20302749
and O 0 0.00032008515
behavioural O 0 0.0009929773
picture O 0 0.00029328867
is O 0 0.0001363164
seen O 0 0.00016909909
in O 0 0.00017793165
drug O 0 0.04875446
intoxication O 0 0.99750656
, O 0 0.00044475688
in O 0 0.00012363958
the O 0 9.466713e-05
absence O 0 8.750918e-05
of O 0 0.00018826175
significant O 0 0.00035543027
hypoxaemia B-Disease 0 0.99985135
, O 0 0.00057454465
a O 0 0.00037008975
favourable O 0 0.000584976
outcome O 0 0.00043559817
may O 0 0.00036555267
be O 0 0.0006409947
anticipated O 0 0.001116754
. O 0 0.002582999

Magnetic O 0 0.010484949
resonance O 0 0.005795123
volumetry O 0 0.0040767635
of O 0 0.0012804894
the O 0 0.0009304659
cerebellum O 0 0.0032343578
in O 0 0.0011742472
epileptic B-Disease 0 0.9995023
patients O 0 0.0022956193
after O 0 0.0010933038
phenytoin B-Chemical 0 0.9999801
overdosages B-Disease 0 0.99664235
. O 0 0.0049996506

The O 0 0.0015995076
aim O 0 0.0010194291
of O 0 0.0010952594
this O 0 0.0007921039
study O 0 0.0005852771
was O 0 0.0002804213
to O 0 0.00015543688
evaluate O 0 7.3584604e-05
the O 0 0.00010298145
relationship O 0 9.523502e-05
between O 0 0.00024214646
phenytoin B-Chemical 0 0.99999785
medication O 0 0.05540943
and O 0 0.00050078216
cerebellar B-Disease 0 0.99799466
atrophy I-Disease 2 0.9999517
in O 0 0.00026997188
patients O 0 0.0005347965
who O 0 0.00032186892
had O 0 0.00027264078
experienced O 0 0.0006031219
clinical O 0 0.0051266737
intoxication O 0 0.9933177
. O 0 0.0033448806

Five O 0 0.004538251
females O 0 0.0046955347
and O 0 0.001696899
6 O 0 0.0009466421
males O 0 0.001542633
, O 0 0.0012887905
21 O 0 0.0008015301
- O 0 0.0016228803
59 O 0 0.00050088984
years O 0 0.0003376144
of O 0 0.00027563656
age O 0 0.00043530532
, O 0 0.00042618712
were O 0 0.00018057003
examined O 0 0.00014870682
with O 0 0.00023149123
a O 0 0.00034115903
1 O 0 0.00023838527
. O 0 0.00017506286
5 O 0 0.00018570037
- O 0 0.0008557856
T O 0 0.0014180474
whole O 0 0.00028331342
- O 0 0.0010198978
body O 0 0.00034366525
system O 0 0.0002543843
using O 0 0.00024076359
a O 0 0.00054879877
circular O 0 0.0009312037
polarized O 0 0.001345759
head O 0 0.0038471005
coil O 0 0.0035667904
. O 0 0.0037700871

Conventional O 0 0.0045232605
spin O 0 0.005583324
echo O 0 0.0025637955
images O 0 0.0013585471
were O 0 0.00093208393
acquired O 0 0.0012291715
in O 0 0.00065084687
the O 0 0.0006296004
sagittal O 0 0.0020094
and O 0 0.0013555016
transverse O 0 0.0035774556
orientation O 0 0.0028840646
. O 0 0.0050110025

In O 0 0.0019896745
addition O 0 0.001209906
, O 0 0.0018304837
we O 0 0.00049168366
performed O 0 0.00053625746
a O 0 0.000667372
high O 0 0.00057285745
- O 0 0.0013097965
resolution O 0 0.00050344213
3D O 0 0.00050516246
gradient O 0 0.00041124586
echo O 0 0.0005130079
, O 0 0.00053518894
T1 O 0 0.0014235941
- O 0 0.00095050264
weighted O 0 0.00018511273
sequences O 0 0.00014125342
at O 0 0.00022242124
a O 0 0.0005365553
1 O 0 0.00058140326
- O 0 0.0016442179
mm O 0 0.0018791283
slice O 0 0.0019736013
thickness O 0 0.006553595
. O 0 0.003752796

The O 0 0.0021503456
images O 0 0.00208419
were O 0 0.0013204518
subsequently O 0 0.0009707031
processed O 0 0.0005852855
to O 0 0.00047753737
obtain O 0 0.00038947113
volumetric O 0 0.0013328107
data O 0 0.00086886715
for O 0 0.0007525241
the O 0 0.0013145868
cerebellum O 0 0.0061178156
. O 0 0.0040119793

Cerebellar O 0 0.41199166
volume O 0 0.003140466
for O 0 0.0009070335
the O 0 0.0006504667
patient O 0 0.0006216807
group O 0 0.0005614686
ranged O 0 0.00038699547
between O 0 0.0002631919
67 O 0 0.00060306845
. O 0 0.0003214476
66 O 0 0.00046413208
and O 0 0.00036307154
131 O 0 0.000822315
. O 0 0.00042417133
08 O 0 0.00274665
ml O 0 0.0013120115
( O 0 0.0006777646
mean O 0 0.00036933552
108 O 0 0.00078043144
. O 0 0.0006449318
9 O 0 0.00085487205
ml O 0 0.0031713936
) O 0 0.00432759
. O 0 0.0041960413

In O 0 0.0017090475
addition O 0 0.00097411213
3D O 0 0.0018239017
gradient O 0 0.0012115124
echo O 0 0.0010434004
data O 0 0.0004652022
sets O 0 0.00027028506
from O 0 0.00023782611
10 O 0 0.00025767405
healthy O 0 0.0006061996
male O 0 0.0004194689
and O 0 0.00019818818
10 O 0 0.00017981269
healthy O 0 0.00045858228
female O 0 0.00037735252
age O 0 0.00035567128
- O 0 0.0008033415
matched O 0 0.00015050625
volunteers O 0 0.00042263497
were O 0 0.00018797748
used O 0 0.00020119516
to O 0 0.0002739188
compare O 0 0.00032386967
cerebellar O 0 0.03376594
volumes O 0 0.0029075684
. O 0 0.0029852903

Using O 0 0.0014385545
linear O 0 0.0012797364
regression O 0 0.0010444218
we O 0 0.00036011543
found O 0 0.00041810417
that O 0 0.00025446774
no O 0 0.00023728095
correlation O 0 0.00020103944
exists O 0 0.00017612737
between O 0 0.00025009472
seizure B-Disease 0 0.99562365
duration O 0 0.0002046737
, O 0 0.0005451405
elevation O 0 0.0072301347
of O 0 0.0010051314
phenytoin B-Chemical 0 0.9999976
serum O 0 0.21037307
levels O 0 0.0005856839
and O 0 0.000996263
cerebellar O 0 0.21224938
volume O 0 0.003259125
. O 0 0.002822288

However O 0 0.0026320717
, O 0 0.0026637728
multiple O 0 0.0009003634
regression O 0 0.0007657022
for O 0 0.00031296353
the O 0 0.0002656841
daily O 0 0.00034494605
dosage O 0 0.000617166
, O 0 0.00029688064
duration O 0 0.00013537225
of O 0 0.0004187198
phenytoin B-Chemical 0 0.99999595
treatment O 0 0.0003619206
and O 0 0.00031805775
cerebellar O 0 0.057261318
volume O 0 0.00046046963
revealed O 0 0.00020896517
a O 0 0.00038829775
correlation O 0 0.0003053949
of O 0 0.0005486125
these O 0 0.00079063897
parameters O 0 0.0017365103
. O 0 0.0028224972

We O 0 0.002358176
conclude O 0 0.0016345365
that O 0 0.002894047
phenytoin B-Chemical 0 0.9999981
overdosage B-Disease 0 0.9999777
does O 0 0.00066341023
not O 0 0.00038178166
necessarily O 0 0.00039384412
result O 0 0.0002449847
in O 0 0.0004152748
cerebellar B-Disease 0 0.9985909
atrophy I-Disease 2 0.99996936
and O 0 0.0002859571
it O 0 0.00021487685
is O 0 8.561338e-05
unlikely O 0 6.943121e-05
that O 0 0.00015888797
phenytoin B-Chemical 0 0.99999857
medication O 0 0.011753801
was O 0 0.000111540816
the O 0 9.766175e-05
only O 0 0.00016658571
cause O 0 0.0002888619
of O 0 0.00057166157
cerebellar B-Disease 0 0.9991066
atrophy I-Disease 2 0.9999423
in O 0 0.00044289196
the O 0 0.00036822943
remaining O 0 0.0006578969
patients O 0 0.0022165752
. O 0 0.002148795

Quantitative O 0 0.0025686237
morphometric O 0 0.0027217576
studies O 0 0.0015401946
of O 0 0.0010625053
the O 0 0.000712649
cerebellum O 0 0.0013596624
provide O 0 0.00025940844
valuable O 0 0.0002831365
insights O 0 0.00033042414
into O 0 0.00028868817
the O 0 0.000473429
pathogenesis O 0 0.0013680812
of O 0 0.0019602
cerebellar B-Disease 0 0.99697006
disorders I-Disease 0 0.9995797
. O 0 0.006175822

Late O 0 0.011566532
recovery O 0 0.0034228598
of O 0 0.0021134296
renal O 0 0.27367526
function O 0 0.00088457845
in O 0 0.0008222045
a O 0 0.001246769
woman O 0 0.0023221236
with O 0 0.0011338994
the O 0 0.002079943
hemolytic B-Disease 0 0.99995244
uremic I-Disease 0 0.99997604
syndrome I-Disease 0 0.99906176
. O 0 0.0062201484

A O 0 0.03178518
case O 0 0.0030557942
is O 0 0.0013773901
reported O 0 0.001197478
of O 0 0.0010939768
the O 0 0.0016480875
hemolytic B-Disease 0 0.9999739
uremic I-Disease 0 0.9999931
syndrome I-Disease 0 0.9998361
( O 0 0.06886103
HUS B-Disease 0 0.9999943
) O 0 0.0022931069
in O 0 0.00040214352
a O 0 0.00073403964
woman O 0 0.0018012928
taking O 0 0.001159582
oral B-Chemical 0 0.0154946195
contraceptives I-Chemical 0 0.7895796
. O 0 0.003842248

She O 0 0.0054186317
was O 0 0.0017873205
treated O 0 0.0021526173
with O 0 0.0015334726
heparin B-Chemical 0 0.9984652
, O 0 0.0036541424
dipyridamole B-Chemical 0 0.99991536
and O 0 0.0004967514
hemodialysis O 0 0.029483842
; O 0 0.000377309
and O 0 0.00012475421
after O 0 6.157927e-05
more O 0 0.00012620917
than O 0 6.899151e-05
three O 0 3.9265302e-05
months O 0 5.18417e-05
, O 0 0.0001820766
her O 0 0.00017223817
urinary O 0 0.0018733204
output O 0 0.0001910646
rose O 0 0.00045139776
above O 0 0.000159177
500 O 0 0.00041649208
ml O 0 0.0006576975
; O 0 0.00023441907
and O 0 8.5587e-05
six O 0 4.1924126e-05
months O 0 3.7984177e-05
after O 0 4.471965e-05
the O 0 9.018874e-05
onset O 0 0.00024618287
of O 0 0.0003273236
anuria B-Disease 0 0.99295676
, O 0 0.0007216535
dialysis O 0 0.0009943557
treatment O 0 0.0005101874
was O 0 0.00075012306
stopped O 0 0.0019245041
. O 0 0.0028948889

This O 0 0.004912892
case O 0 0.002131738
emphasizes O 0 0.0011969922
the O 0 0.0006858187
possibility O 0 0.00048553286
that O 0 0.0009966171
HUS B-Disease 0 0.9999906
in O 0 0.0007379157
adults O 0 0.0027562839
is O 0 0.00022612629
not O 0 0.00022597692
invariably O 0 0.0009058542
irreversible O 0 0.0017237423
and O 0 0.00016536965
that O 0 0.00010655305
, O 0 0.0002577969
despite O 0 0.00013988875
prolonged O 0 0.0004925531
oliguria B-Disease 0 0.9995408
, O 0 0.000464288
recovery O 0 0.00031010748
of O 0 0.00031542336
renal O 0 0.39795274
function O 0 0.00038302536
can O 0 0.00038908632
be O 0 0.0006742204
obtained O 0 0.0009801227
. O 0 0.0023418688

Therefore O 0 0.002370671
, O 0 0.0037822363
in O 0 0.0014869175
adult O 0 0.0016831814
patients O 0 0.001823598
affected O 0 0.0008906093
by O 0 0.0012377977
HUS B-Disease 0 0.9999894
, O 0 0.0013487949
dialysis O 0 0.00085466105
should O 0 0.00010286683
not O 0 0.00013714026
be O 0 0.00016694589
discontinued O 0 0.001025994
prematurely O 0 0.0012626222
; O 0 0.0003620721
moreover O 0 0.00039426313
, O 0 0.00033494591
bilateral O 0 0.0022485983
nephrectomy O 0 0.095790595
, O 0 0.0001796499
for O 0 6.558168e-05
treatment O 0 9.841684e-05
of O 0 0.00016335904
severe O 0 0.017222703
hypertension B-Disease 2 0.9999949
and O 0 0.0020739115
microangiopathic B-Disease 0 0.99995995
hemolytic I-Disease 0 0.9999988
anemia I-Disease 0 0.9999989
, O 0 0.0015150763
should O 0 0.00017775412
be O 0 0.00028948692
performed O 0 0.00036101314
with O 0 0.00076974876
caution O 0 0.0018926959
. O 0 0.0025047925

Morphological O 0 0.0063710944
features O 0 0.0030868002
of O 0 0.002735612
encephalopathy B-Disease 2 0.9998234
after O 0 0.000538219
chronic O 0 0.0038008348
administration O 0 0.0006865374
of O 0 0.00039599912
the O 0 0.00045080073
antiepileptic O 0 0.9990588
drug O 0 0.4699313
valproate B-Chemical 0 0.99995315
to O 0 0.0010570101
rats O 0 0.0023337523
. O 0 0.0026922557

A O 0 0.03592708
transmission O 0 0.004122363
electron O 0 0.009810966
microscopic O 0 0.0022961502
study O 0 0.001553576
of O 0 0.001552623
capillaries O 0 0.07537804
in O 0 0.0014623151
the O 0 0.0016539699
cerebellar O 0 0.28639752
cortex O 0 0.062805034
. O 0 0.004903814

Long O 0 0.009164563
- O 0 0.0069356486
term O 0 0.001471459
intragastric O 0 0.004112114
application O 0 0.0005556444
of O 0 0.0004715972
the O 0 0.00044877248
antiepileptic O 0 0.9991279
drug O 0 0.5223712
sodium B-Chemical 0 0.9998883
valproate I-Chemical 0 0.99999213
( O 0 0.00089789013
Vupral O 0 0.00139518
" O 0 0.0007724665
Polfa O 0 0.93201876
" O 0 0.0005217599
) O 0 0.00040675513
at O 0 0.000118144184
the O 0 0.00012787375
effective O 0 0.00017499646
dose O 0 0.0003691707
of O 0 0.00036672622
200 O 0 0.0009513394
mg O 0 0.005906588
/ O 0 0.0026082762
kg O 0 0.002430366
b O 0 0.003435832
. O 0 0.0034297195

w O 0 0.00768026
. O 0 0.0022018547
once O 0 0.0010081389
daily O 0 0.00090696185
to O 0 0.00046463363
rats O 0 0.000648985
for O 0 0.00031770955
1 O 0 0.0003974328
, O 0 0.00047158956
3 O 0 0.00023063335
, O 0 0.0003554122
6 O 0 0.0001597423
, O 0 0.00027651805
9 O 0 0.00013115068
and O 0 0.00012237804
12 O 0 8.180543e-05
months O 0 6.449385e-05
revealed O 0 0.00016597814
neurological B-Disease 0 0.99684453
disorders I-Disease 0 0.9998215
indicating O 0 0.0004416916
cerebellum B-Disease 0 0.5090108
damage I-Disease 0 0.869472
( O 0 0.0016705203
" O 0 0.003518426
valproate B-Chemical 0 0.9999887
encephalopathy B-Disease 2 0.99997807
" O 0 0.0059207208
) O 0 0.004424549
. O 0 0.0032051683

The O 0 0.0020074188
first O 0 0.0013282683
ultrastructural O 0 0.0027738328
changes O 0 0.0009433805
in O 0 0.0005578727
structural O 0 0.00047327875
elements O 0 0.00037183944
of O 0 0.00036005006
the O 0 0.00031488645
blood O 0 0.009146486
- O 0 0.006343336
brain O 0 0.0018984112
- O 0 0.00289757
barrier O 0 0.0015589909
( O 0 0.0011252891
BBB O 0 0.99806195
) O 0 0.0007930695
in O 0 0.00017651691
the O 0 0.00019422777
cerebellar O 0 0.14228912
cortex O 0 0.009007683
were O 0 0.00014827895
detectable O 0 0.00010368955
after O 0 8.5222724e-05
3 O 0 0.00014420734
months O 0 0.00012186463
of O 0 0.00035301616
the O 0 0.00054357667
experiment O 0 0.0009571142
. O 0 0.002781639

They O 0 0.0056734686
became O 0 0.00338026
more O 0 0.00235109
severe O 0 0.0037836381
in O 0 0.0005321271
the O 0 0.00029715706
later O 0 0.00021465735
months O 0 0.00010892111
of O 0 0.0001617892
the O 0 0.00013004869
experiment O 0 0.00012549225
, O 0 0.00031870246
and O 0 0.00018369101
were O 0 0.00014170412
most O 0 0.00018087124
severe O 0 0.00039607438
after O 0 5.5062592e-05
12 O 0 6.2959705e-05
months O 0 5.3406005e-05
, O 0 0.00018702741
located O 0 0.00012645843
mainly O 0 0.00016639332
in O 0 0.00017625875
the O 0 0.00021510337
molecular O 0 0.0006554458
layer O 0 0.0010778989
of O 0 0.0006504488
the O 0 0.00085474417
cerebellar O 0 0.50456434
cortex O 0 0.1058231
. O 0 0.0032349636

Lesions O 0 0.018641358
of O 0 0.0041868184
the O 0 0.0032267605
capillary O 0 0.49182415
included O 0 0.004744961
necrosis B-Disease 2 0.9996068
of O 0 0.006319219
endothelial O 0 0.99563026
cells O 0 0.00809623
. O 0 0.007313616

Organelles O 0 0.011176645
of O 0 0.0024126032
these O 0 0.0014121432
cells O 0 0.0014357317
, O 0 0.0015119489
in O 0 0.00054040446
particular O 0 0.00030763866
the O 0 0.0003387636
mitochondria O 0 0.0016168485
( O 0 0.00056123873
increased O 0 0.000270756
number O 0 0.00013759428
and O 0 0.00018948872
size O 0 0.00033500534
, O 0 0.0003801577
distinct O 0 0.00016864792
degeneration O 0 0.18458827
of O 0 0.00022011282
their O 0 0.00021427374
matrix O 0 0.001338718
and O 0 0.00045159832
cristae O 0 0.5496046
) O 0 0.0011525024
and O 0 0.00043606304
Golgi O 0 0.0006922537
apparatus O 0 0.000939136
were O 0 0.000806099
altered O 0 0.0015481729
. O 0 0.0027526151

Reduced O 0 0.006594662
size O 0 0.003339918
of O 0 0.0020425804
capillary O 0 0.2606462
lumen O 0 0.0025850737
and O 0 0.00073614396
occlusion O 0 0.40433693
were O 0 0.0003405301
caused O 0 0.0002845885
by O 0 0.00035192943
swollen O 0 0.002828616
endothelial O 0 0.9894292
cells O 0 0.00074311055
which O 0 0.0005466614
had O 0 0.000530252
luminal B-Chemical 0 0.46823266
protrusions O 0 0.011133725
and O 0 0.0012116029
swollen O 0 0.0056805285
microvilli O 0 0.066340946
. O 0 0.003866433

Pressure O 0 0.018976526
on O 0 0.0022865008
the O 0 0.002102182
vessel O 0 0.020524913
wall O 0 0.0070126886
was O 0 0.0012581227
produced O 0 0.0009622611
by O 0 0.0013931632
enlarged O 0 0.014567895
perivascular O 0 0.07182822
astrocytic O 0 0.037251532
processes O 0 0.0040896987
. O 0 0.004615711

Fragments O 0 0.008841336
of O 0 0.004978482
necrotic B-Disease 0 0.87214726
endothelial O 0 0.99151284
cells O 0 0.0014539514
were O 0 0.0005463374
in O 0 0.0003796257
the O 0 0.00037314888
vascular O 0 0.783581
lumens O 0 0.048824172
and O 0 0.0002919718
in O 0 0.00018548414
these O 0 0.00016842486
there O 0 0.00016667836
was O 0 0.00025427103
loosening O 0 0.0024452251
and O 0 0.00037479206
breaking O 0 0.00082910986
of O 0 0.00060562446
tight O 0 0.0011684642
cellular O 0 0.0018447863
junctions O 0 0.0018137436
. O 0 0.0031234128

Damage O 0 0.023867702
to O 0 0.004083739
the O 0 0.003992328
vascular O 0 0.9442609
basement O 0 0.8307679
lamina O 0 0.008303825
was O 0 0.0023008655
also O 0 0.0022935474
observed O 0 0.0031619186
. O 0 0.0061385725

Damage O 0 0.017028062
to O 0 0.0021527964
the O 0 0.0016351935
capillary O 0 0.20757145
was O 0 0.0009915833
accompanied O 0 0.0010354539
by O 0 0.0005564184
marked O 0 0.00090754667
damage O 0 0.017328735
to O 0 0.0004670844
neuroglial O 0 0.09851213
cells O 0 0.0005495876
, O 0 0.0007355416
mainly O 0 0.00041904082
to O 0 0.00043128687
perivascular O 0 0.0050625894
processes O 0 0.0011188072
of O 0 0.0014219758
astrocytes O 0 0.009416253
. O 0 0.0036435225

The O 0 0.003239592
proliferation O 0 0.016501505
of O 0 0.0028379762
astrocytes O 0 0.01238663
( O 0 0.0031748551
Bergmann O 0 0.024245553
' O 0 0.0013101733
s O 0 0.00078485627
in O 0 0.00040407298
particular O 0 0.00032456886
) O 0 0.0009915517
and O 0 0.00056521886
occasionally O 0 0.0010387859
of O 0 0.00096610567
oligodendrocytes O 0 0.0057713906
was O 0 0.0013684793
found O 0 0.002079465
. O 0 0.003795703

Alterations O 0 0.0052840896
in O 0 0.0018983794
the O 0 0.0010687434
structural O 0 0.00093788723
elements O 0 0.00072853104
of O 0 0.0007255365
the O 0 0.0007268096
BBB O 0 0.99809796
coexisted O 0 0.0030285493
with O 0 0.00037997833
marked O 0 0.00046597043
lesions O 0 0.0018433338
of O 0 0.00024459357
neurons O 0 0.00023163427
of O 0 0.00022248697
the O 0 0.00023489358
cerebellum O 0 0.0017161024
( O 0 0.0006608652
Purkinje O 0 0.0010588847
cells O 0 0.0005742246
are O 0 0.0005654427
earliest O 0 0.0013655258
) O 0 0.0036658796
. O 0 0.0033117617

In O 0 0.002696811
electron O 0 0.007868274
micrographs O 0 0.0015745328
both O 0 0.0011896158
luminal B-Chemical 0 0.14224853
and O 0 0.0013110158
antiluminal O 0 0.13550116
sides O 0 0.001798333
of O 0 0.0006440433
the O 0 0.00061211106
BBB O 0 0.9938152
of O 0 0.0005960276
the O 0 0.0004915583
cerebellar O 0 0.20390324
cortex O 0 0.0142769795
had O 0 0.00067303714
similar O 0 0.0007052352
lesions O 0 0.007376268
. O 0 0.0030679433

The O 0 0.0018537474
possible O 0 0.001096057
influence O 0 0.00080330396
of O 0 0.0011092927
the O 0 0.0011236768
hepatic B-Disease 0 0.9995053
damage I-Disease 0 0.98194134
, O 0 0.0021921135
mainly O 0 0.001024384
hyperammonemia B-Disease 0 0.99995756
, O 0 0.00082251447
upon O 0 0.00017054283
the O 0 0.00022141299
development O 0 0.0004765906
of O 0 0.0011724539
valproate B-Chemical 0 0.9999933
encephalopathy B-Disease 2 0.99998045
is O 0 0.0012550283
discussed O 0 0.0014629309
. O 0 0.0027252922

Fatal O 0 0.11036889
intracranial B-Disease 0 0.99752396
bleeding I-Disease 0 0.99799037
associated O 0 0.002244699
with O 0 0.001674251
prehospital O 0 0.004479011
use O 0 0.0015375356
of O 0 0.003312572
epinephrine B-Chemical 0 0.99853396
. O 0 0.0061302343

We O 0 0.0025394002
present O 0 0.0015563834
a O 0 0.0017796126
case O 0 0.0010099318
of O 0 0.0008499475
paramedic O 0 0.0038222894
misjudgment O 0 0.030113395
in O 0 0.00032400744
the O 0 0.00021562085
execution O 0 0.0004593731
of O 0 0.00023143273
a O 0 0.0002505128
protocol O 0 0.00012987928
for O 0 8.9070985e-05
the O 0 0.00010475413
treatment O 0 0.00015975449
of O 0 0.00030520515
allergic B-Disease 0 0.99907756
reaction I-Disease 0 0.0005374231
in O 0 0.00020258538
a O 0 0.00032697085
case O 0 0.00029128924
of O 0 0.00050932274
pulmonary B-Disease 0 0.9103525
edema I-Disease 0 0.9998642
with O 0 0.0022756963
wheezing B-Disease 0 0.9871718
. O 0 0.0026868887

The O 0 0.0025967888
sudden O 0 0.024819737
onset O 0 0.0026909567
of O 0 0.0015243667
respiratory B-Disease 0 0.5861187
distress I-Disease 0 0.9963961
, O 0 0.0026318803
rash B-Disease 0 0.95546705
, O 0 0.0005855372
and O 0 0.0002493359
a O 0 0.0003025635
history O 0 0.00033226042
of O 0 0.00020327863
a O 0 0.00028299025
new O 0 0.0002399768
medicine O 0 0.0018696666
led O 0 0.0001980905
the O 0 0.00011861977
two O 0 8.977003e-05
paramedics O 0 0.0002403251
on O 0 0.00010758669
the O 0 0.00015382588
scene O 0 0.00044435303
to O 0 0.0003337767
administer O 0 0.0010045465
subcutaneous O 0 0.0036905766
epinephrine B-Chemical 0 0.9978929
. O 0 0.0025960985

Subsequently O 0 0.005574752
, O 0 0.0078866845
acute O 0 0.13649528
cardiac B-Disease 0 0.27826852
arrest I-Disease 0 0.30531952
and O 0 0.0036508716
fatal O 0 0.9660346
subarachnoid B-Disease 0 0.99975437
hemorrhage I-Disease 2 0.9997564
occurred O 0 0.0034540305
. O 0 0.004079589

Epinephrine B-Chemical 0 0.99935097
has O 0 0.001885732
a O 0 0.0016950872
proven O 0 0.00082986156
role O 0 0.00030132997
in O 0 0.0005313491
cardiac B-Disease 0 0.03451915
arrest I-Disease 0 0.045371227
in O 0 0.00032051362
prehospital O 0 0.001249976
care O 0 0.00027266677
; O 0 0.00034329869
however O 0 0.0001861063
, O 0 0.00024171513
use O 0 0.00011248051
by O 0 0.00011951899
paramedics O 0 0.00026582245
in O 0 0.00013833503
patients O 0 0.0003346462
with O 0 0.00021992487
suspected O 0 0.004829428
allergic B-Disease 0 0.9995795
reaction I-Disease 0 0.0005959106
and O 0 0.00030406896
severe O 0 0.026829978
hypertension B-Disease 2 0.99998355
should O 0 0.000202088
be O 0 0.0003029139
viewed O 0 0.00062457507
with O 0 0.0008201353
caution O 0 0.0019573784
. O 0 0.0025219712

Role O 0 0.0029455042
of O 0 0.0022511662
activation O 0 0.0017079561
of O 0 0.0031076847
bradykinin B-Chemical 0 0.99994373
B2 O 0 0.9989214
receptors O 0 0.0033034927
in O 0 0.00040865256
disruption O 0 0.00029458222
of O 0 0.00033677777
the O 0 0.0003210629
blood O 0 0.0147706615
- O 0 0.0057788137
brain O 0 0.0014966789
barrier O 0 0.0014994622
during O 0 0.00063039275
acute O 0 0.30599934
hypertension B-Disease 2 0.999926
. O 0 0.004523338

Cellular O 0 0.009595766
mechanisms O 0 0.0015845267
which O 0 0.0013952253
account O 0 0.0007456579
for O 0 0.0004247042
disruption O 0 0.00041586187
the O 0 0.0004216884
blood O 0 0.008529252
- O 0 0.0054736077
brain O 0 0.0012951615
barrier O 0 0.0010589624
during O 0 0.0003474917
acute O 0 0.16053656
hypertension B-Disease 2 0.9999583
are O 0 0.00071762275
not O 0 0.00079151266
clear O 0 0.0012853667
. O 0 0.0029552123

The O 0 0.0019096014
goal O 0 0.0017406157
of O 0 0.0013314816
this O 0 0.00094351044
study O 0 0.0007008337
was O 0 0.0003441311
to O 0 0.00019368445
determine O 0 7.547883e-05
the O 0 0.00012124533
role O 0 8.6522494e-05
of O 0 0.00024650677
synthesis O 0 0.00080492
/ O 0 0.0037660222
release O 0 0.000765297
of O 0 0.00047417282
bradykinin B-Chemical 0 0.99992895
to O 0 0.00018946975
activate O 0 0.00011656067
B2 O 0 0.9793554
receptors O 0 0.00076842
in O 0 0.0001416898
disruption O 0 0.00012954026
of O 0 0.00017535055
the O 0 0.00018825063
blood O 0 0.020675397
- O 0 0.006174467
brain O 0 0.0012892226
barrier O 0 0.001298878
during O 0 0.00050927105
acute O 0 0.34675828
hypertension B-Disease 2 0.99994135
. O 0 0.0040133875

Permeability O 0 0.05699087
of O 0 0.0023466963
the O 0 0.0014423343
blood O 0 0.014498762
- O 0 0.009574191
brain O 0 0.0019470304
barrier O 0 0.0012082602
was O 0 0.00029938764
quantitated O 0 0.0004041225
by O 0 0.00023347641
clearance O 0 0.0009044373
of O 0 0.00025357958
fluorescent O 0 0.00047156189
- O 0 0.0016939258
labeled O 0 0.00026071706
dextran B-Chemical 1 0.991418
before O 0 8.449863e-05
and O 0 0.00014415907
during O 0 0.00017347847
phenylephrine B-Chemical 0 0.99997604
- O 0 0.006687217
induced O 0 0.00017466472
acute O 0 0.32682565
hypertension B-Disease 2 0.9999926
in O 0 0.0001518525
rats O 0 0.00021837027
treated O 0 0.00023296964
with O 0 0.0001627502
vehicle O 0 0.0012609197
and O 0 0.00045422823
Hoe B-Chemical 0 0.999405
- I-Chemical 0 0.009680742
140 I-Chemical 0 0.0005365236
( O 0 0.00054372795
0 O 0 0.00047204018
. O 0 0.0004686574
1 O 0 0.0008875897
microM O 0 0.029074427
) O 0 0.0045596575
. O 0 0.0035993236

Phenylephrine B-Chemical 0 0.999428
infusion O 0 0.0068941214
increased O 0 0.0016737514
arterial O 0 0.15527466
pressure O 0 0.014884689
, O 0 0.0015683268
arteriolar O 0 0.9983038
diameter O 0 0.0050700237
and O 0 0.0004239894
clearance O 0 0.0013065613
of O 0 0.00039113863
fluorescent O 0 0.000907506
dextran B-Chemical 1 0.9961403
by O 0 0.0003562426
a O 0 0.00043504627
similar O 0 0.00021873537
magnitude O 0 0.00039462565
in O 0 0.0005393729
both O 0 0.0007850975
groups O 0 0.0018795005
. O 0 0.0031019358

These O 0 0.0018353508
findings O 0 0.0015934737
suggest O 0 0.0006297772
that O 0 0.00055876106
disruption O 0 0.00051530404
of O 0 0.00052856153
the O 0 0.00041764983
blood O 0 0.024810571
- O 0 0.009632072
brain O 0 0.0010933528
barrier O 0 0.0007045094
during O 0 0.00015873622
acute O 0 0.15290414
hypertension B-Disease 2 0.9999889
is O 0 0.00015677413
not O 0 0.00010596092
related O 0 7.7518955e-05
to O 0 0.00011064831
the O 0 0.00014855407
synthesis O 0 0.00064776733
/ O 0 0.0031746724
release O 0 0.0009131312
of O 0 0.0007234097
bradykinin B-Chemical 0 0.99986994
to O 0 0.0005756406
activate O 0 0.00054141885
B2 O 0 0.98132056
receptors O 0 0.009928039
. O 0 0.0038693212

Risk O 0 0.011450852
factors O 0 0.00552274
of O 0 0.005100237
sensorineural B-Disease 0 0.9994746
hearing I-Disease 0 0.92377526
loss I-Disease 0 0.0057590674
in O 0 0.0029158883
preterm O 0 0.8949074
infants O 0 0.12006392
. O 0 0.0066020754

Among O 0 0.0058812024
547 O 0 0.034282375
preterm O 0 0.67832416
infants O 0 0.008521489
of O 0 0.00083496777
< O 0 0.0008164536
or O 0 0.00036141978
= O 0 0.0006582208
34 O 0 0.00024340593
weeks O 0 0.00010508308
gestation O 0 0.00024394678
born O 0 0.0003823584
between O 0 0.00017365123
1987 O 0 0.000782439
and O 0 0.0002687028
1991 O 0 0.0005405116
, O 0 0.0004510706
8 O 0 0.00023466058
children O 0 0.00060902775
( O 0 0.00042116438
1 O 0 0.00023555523
. O 0 0.000188601
46 O 0 0.00029886316
% O 0 0.0004297962
) O 0 0.0005419393
developed O 0 0.00035861472
severe O 0 0.001754667
progressive O 0 0.0024908942
and O 0 0.0005480429
bilateral O 0 0.040173348
sensorineural B-Disease 0 0.99978966
hearing I-Disease 0 0.82562584
loss I-Disease 0 0.004408846
. O 0 0.0030425268

Perinatal O 0 0.025058776
risk O 0 0.008678775
factors O 0 0.0020133571
of O 0 0.0010311537
infants O 0 0.0019019707
with O 0 0.0005795546
hearing B-Disease 0 0.16917044
loss I-Disease 0 0.0003465548
were O 0 0.00013827662
compared O 0 8.915383e-05
with O 0 0.00012150226
those O 0 0.00012203533
of O 0 9.8829616e-05
two O 0 5.894304e-05
control O 0 9.5118754e-05
groups O 0 0.00012514525
matched O 0 7.339216e-05
for O 0 6.8138645e-05
gestation O 0 0.00014897932
and O 0 0.00014266564
birth O 0 0.0002718429
weight O 0 0.00033878203
and O 0 0.00030902345
for O 0 0.00038570585
perinatal O 0 0.0040850053
complications O 0 0.030061522
. O 0 0.0029058158

Our O 0 0.0021923732
observations O 0 0.0018530751
demonstrated O 0 0.0010688697
an O 0 0.00088444236
association O 0 0.0004463262
of O 0 0.0006913284
hearing B-Disease 0 0.19282149
loss I-Disease 0 0.00066930096
with O 0 0.00045338165
a O 0 0.00059477746
higher O 0 0.00050781947
incidence O 0 0.00096485176
of O 0 0.0008701087
perinatal O 0 0.007943591
complications O 0 0.056125768
. O 0 0.0033359146

Ototoxicity B-Disease 0 0.9993963
appeared O 0 0.0020965703
closely O 0 0.0008015485
related O 0 0.00038380313
to O 0 0.0003388384
a O 0 0.0004141059
prolonged O 0 0.00033262838
administration O 0 0.00032176307
and O 0 0.00017348093
higher O 0 0.00017625623
total O 0 0.00017637695
dose O 0 0.00033090013
of O 0 0.00032787363
ototoxic B-Disease 0 0.99871206
drugs O 0 0.05758621
, O 0 0.0008594556
particularly O 0 0.00082544977
aminoglycosides B-Chemical 0 0.99855846
and O 0 0.002999026
furosemide B-Chemical 0 0.99996066
. O 0 0.0046353666

Finally O 0 0.0028661091
, O 0 0.003158956
we O 0 0.0007379991
strongly O 0 0.0007187986
recommend O 0 0.00046993166
to O 0 0.00028954016
prospectively O 0 0.00034815585
and O 0 0.00019052754
regularly O 0 0.00012488513
perform O 0 9.704709e-05
audiologic O 0 0.00052228407
assessment O 0 0.00010597537
in O 0 0.0001157381
sick O 0 0.00048232326
preterm O 0 0.019566515
children O 0 0.00063345436
as O 0 0.00016402616
hearing B-Disease 0 0.13565852
loss I-Disease 0 0.00022759169
is O 0 0.00010734075
of O 0 0.00016321956
delayed O 0 0.00060604536
onset O 0 0.0003436068
and O 0 0.00020450163
in O 0 0.00021742228
most O 0 0.00038749017
cases O 0 0.0007901667
bilateral O 0 0.0046517085
and O 0 0.0010741574
severe O 0 0.007066023
. O 0 0.0027257274

Seizure B-Disease 2 0.9912766
resulting O 0 0.0055828714
from O 0 0.0046852855
a O 0 0.011623375
venlafaxine B-Chemical 0 0.9998994
overdose B-Disease 0 0.9991235
. O 0 0.012003617

OBJECTIVE O 0 0.023895625
: O 0 0.00520056
To O 0 0.0011402823
report O 0 0.002577891
a O 0 0.0023079922
case O 0 0.0020890725
of O 0 0.004159843
venlafaxine B-Chemical 0 0.9999639
overdose B-Disease 0 0.99958163
. O 0 0.007657718

CASE O 0 0.22662912
SUMMARY O 0 0.00692973
: O 0 0.003979001
A O 0 0.00646734
40 O 0 0.0012257342
- O 0 0.0025623122
year O 0 0.0005301277
- O 0 0.0015324755
old O 0 0.00049190543
woman O 0 0.000934244
with O 0 0.0004091969
major B-Disease 0 0.0015425355
depression I-Disease 0 0.999918
took O 0 0.00043553277
an O 0 0.00048695697
overdose B-Disease 0 0.9996081
of O 0 0.00089712907
venlafaxine B-Chemical 0 0.99998164
in O 0 0.00049282296
an O 0 0.00061123277
apparent O 0 0.0008978871
suicide O 0 0.22550829
attempt O 0 0.0021884753
. O 0 0.00306593

After O 0 0.0017307955
the O 0 0.0016807152
ingestion O 0 0.005264594
of O 0 0.001184983
26 O 0 0.0017399315
venlafaxine B-Chemical 0 0.99992526
50 O 0 0.0011339529
- O 0 0.004153734
mg O 0 0.020530578
tablets O 0 0.05200504
, O 0 0.0006107672
the O 0 0.0002747822
patient O 0 0.00041991138
experienced O 0 0.00053150736
a O 0 0.0010286493
witnessed O 0 0.005028803
generalized O 0 0.07186673
seizure B-Disease 0 0.9989717
. O 0 0.0047149127

She O 0 0.006667165
was O 0 0.0021549454
admitted O 0 0.0026041735
to O 0 0.0006092474
the O 0 0.00043355298
medical O 0 0.0009196496
intensive O 0 0.0004221902
care O 0 0.00034615258
unit O 0 0.00033176347
, O 0 0.0010820997
venlafaxine B-Chemical 0 0.9999654
was O 0 0.00035903597
discontinued O 0 0.0011878607
, O 0 0.00044849937
and O 0 0.00027585894
no O 0 0.00028966885
further O 0 0.0004353684
sequelae O 0 0.0068267602
were O 0 0.00102644
seen O 0 0.0016926837
. O 0 0.002918593

DISCUSSION O 0 0.005088967
: O 0 0.002302682
To O 0 0.00046303173
our O 0 0.0006318682
knowledge O 0 0.0008864693
, O 0 0.0010553035
this O 0 0.000444078
is O 0 0.00023844096
the O 0 0.00017607366
first O 0 0.00013132587
reported O 0 0.00022129671
case O 0 0.0002563787
of O 0 0.0006165636
venlafaxine B-Chemical 0 0.99999595
overdose B-Disease 0 0.9998951
that O 0 0.00027803626
resulted O 0 0.00034310727
in O 0 0.0005050527
a O 0 0.0013832109
generalized O 0 0.023622202
seizure B-Disease 0 0.9987405
. O 0 0.00374382

Based O 0 0.0034867164
on O 0 0.0013489272
nonoverdose O 0 0.013612331
pharmacokinetics O 0 0.07909024
and O 0 0.00069527654
pharmacodynamics O 0 0.024087835
of O 0 0.00063217
venlafaxine B-Chemical 0 0.99997485
and O 0 0.0002478635
the O 0 0.000118639
potential O 0 0.000112517955
risks O 0 0.00024809307
of O 0 0.00016101709
available O 0 0.0001226167
interventions O 0 0.00019266567
, O 0 0.00038647844
no O 0 0.00027480317
emergent O 0 0.00065304106
therapy O 0 0.00073382066
was O 0 0.0007796914
instituted O 0 0.0024618006
. O 0 0.0028969694

CONCLUSIONS O 0 0.020446343
: O 0 0.004649758
The O 0 0.0014112857
venlafaxine B-Chemical 0 0.99995947
overdose B-Disease 0 0.99966145
in O 0 0.0005121344
our O 0 0.00029479183
patient O 0 0.00031105828
resulted O 0 0.00018777075
in O 0 0.0001911218
a O 0 0.00027103085
single O 0 0.00013944367
episode O 0 0.00025174182
of O 0 0.0002962866
generalized O 0 0.011668326
seizure B-Disease 0 0.99961144
but O 0 0.00046890075
elicited O 0 0.00030031212
no O 0 0.00044741924
further O 0 0.000793255
sequelae O 0 0.027476719
. O 0 0.0032423877

Combined O 0 0.0047321245
effects O 0 0.002024939
of O 0 0.0023624012
prolonged O 0 0.014184043
prostaglandin B-Chemical 1 0.99999547
E1 I-Chemical 1 0.99963224
- O 0 0.30202731
induced O 0 0.0012145285
hypotension B-Disease 0 0.9999207
and O 0 0.0010425661
haemodilution B-Disease 0 0.9907698
on O 0 0.0004369627
human O 0 0.00088262523
hepatic O 0 0.854001
function O 0 0.0019054163
. O 0 0.0031404886

Combined O 0 0.004720253
effects O 0 0.0020072325
of O 0 0.0023196463
prolonged O 0 0.013159378
prostaglandin B-Chemical 1 0.99999547
E1 I-Chemical 1 0.999703
( O 0 0.32205865
PGE1 B-Chemical 0 0.9999987
) O 0 0.033699207
- O 0 0.008101872
induced O 0 0.00039728204
hypotension B-Disease 0 0.999923
and O 0 0.00041153096
haemodilution B-Disease 0 0.9899184
on O 0 0.00013895839
hepatic O 0 0.63497293
function O 0 0.00014941095
were O 0 0.00013416952
studied O 0 0.00019248463
in O 0 0.00015399333
30 O 0 0.00017690497
patients O 0 0.00038933338
undergoing O 0 0.00045202186
hip O 0 0.0043547675
surgery O 0 0.0015212941
. O 0 0.0020280958

The O 0 0.0020059126
patients O 0 0.0023802514
were O 0 0.0007989621
randomly O 0 0.00037723006
allocated O 0 0.00046748866
to O 0 0.00026588628
one O 0 0.00021172482
of O 0 0.00020947863
three O 0 0.000105360625
groups O 0 0.00026921518
; O 0 0.00041147094
those O 0 0.00020319047
in O 0 0.0001658568
group O 0 0.00031433842
A O 0 0.0024209332
( O 0 0.0003400848
n O 0 0.0002030731
= O 0 0.000412852
10 O 0 0.00013436402
) O 0 0.00022009917
were O 0 7.5727636e-05
subjected O 0 5.7586105e-05
to O 0 8.036188e-05
controlled O 0 0.00021334374
hypotension B-Disease 0 0.9998423
alone O 0 0.00020411224
, O 0 0.00026171727
those O 0 0.00014020967
in O 0 0.00011739458
group O 0 0.00025648894
B O 0 0.017117161
( O 0 0.00031837204
n O 0 0.00017029226
= O 0 0.00036817117
10 O 0 0.00011507902
) O 0 0.00022841278
to O 0 0.00010954828
haemodilution B-Disease 0 0.96066517
alone O 0 0.00015562253
and O 0 0.00013243743
those O 0 0.0001455279
in O 0 0.000134184
group O 0 0.00036038572
C O 0 0.9380971
( O 0 0.00046980378
n O 0 0.000230572
= O 0 0.00048234855
10 O 0 0.00017160966
) O 0 0.00031409398
to O 0 0.00014545466
both O 0 0.00022380354
controlled O 0 0.0007169945
hypotension B-Disease 0 0.9997223
and O 0 0.0017478389
haemodilution B-Disease 0 0.995
. O 0 0.0033456422

Haemodilution B-Disease 0 0.9789645
in O 0 0.0027478468
groups O 0 0.0027485644
B O 0 0.09419289
and O 0 0.0019653293
C O 0 0.9738811
was O 0 0.00060608785
produced O 0 0.00031652502
by O 0 0.00032401175
withdrawing O 0 0.0016616271
approximately O 0 0.0003234386
1000 O 0 0.00056492264
mL O 0 0.0011417532
of O 0 0.00019320857
blood O 0 0.0015238725
and O 0 0.00016935535
replacing O 0 0.0001435321
it O 0 0.00019412872
with O 0 0.00013931157
the O 0 0.000101866666
same O 0 8.482769e-05
amount O 0 9.399653e-05
of O 0 0.00031658445
dextran B-Chemical 1 0.99943906
solution O 0 0.0017231618
, O 0 0.00044718495
and O 0 0.00022114949
final O 0 0.00036451427
haematocrit O 0 0.90606254
values O 0 0.0003012797
were O 0 0.00027827657
21 O 0 0.0004167651
or O 0 0.0004712759
22 O 0 0.0012622584
% O 0 0.0024007733
. O 0 0.0029345888

Controlled O 0 0.008685144
hypotension B-Disease 0 0.9987274
in O 0 0.0018854602
groups O 0 0.0018329944
A O 0 0.013186517
and O 0 0.0013633715
C O 0 0.9711121
was O 0 0.0005628853
induced O 0 0.00044716365
with O 0 0.0010564825
PGE1 B-Chemical 0 0.99999714
to O 0 0.000265397
maintain O 0 0.00014393903
mean O 0 0.00017270852
arterial O 0 0.044266142
blood O 0 0.0016314961
pressure O 0 0.0016204686
at O 0 0.00019995624
55 O 0 0.00038470118
mmHg O 0 0.0011883898
for O 0 0.00045970146
180 O 0 0.0011744325
min O 0 0.0020000546
. O 0 0.0028263598

Measurements O 0 0.0043389895
included O 0 0.0030154684
arterial O 0 0.676289
ketone O 0 0.990803
body O 0 0.0020838135
ratio O 0 0.0012785455
( O 0 0.0028844224
AKBR O 0 0.999183
, O 0 0.003597906
aceto B-Chemical 0 0.992393
- I-Chemical 0 0.23603877
acetate I-Chemical 0 0.9973437
/ O 0 0.0063976133
3 B-Chemical 0 0.00052505307
- I-Chemical 0 0.0095635895
hydroxybutyrate I-Chemical 0 0.9996555
) O 0 0.0012417607
and O 0 0.00047743748
clinical O 0 0.0016528253
hepatic O 0 0.52742994
function O 0 0.0009445177
parameters O 0 0.0018964787
. O 0 0.00285345

AKBR O 0 0.99647516
and O 0 0.002884982
biological O 0 0.0017578177
hepatic O 0 0.5245286
function O 0 0.0005729577
tests O 0 0.00090709835
showed O 0 0.00030053293
no O 0 0.00024789353
change O 0 0.00023297274
throughout O 0 0.00014440094
the O 0 0.00016108435
time O 0 0.00016967246
course O 0 0.00033041247
in O 0 0.00041687602
groups O 0 0.000927505
A O 0 0.0091756545
and O 0 0.0022911243
B O 0 0.16506381
. O 0 0.0055485726

In O 0 0.003172743
group O 0 0.006295233
C O 0 0.98712254
, O 0 0.012629919
AKBR O 0 0.9990376
showed O 0 0.00086320593
a O 0 0.00071242225
significant O 0 0.00035209235
decrease O 0 0.00030710557
at O 0 0.00018566124
120 O 0 0.0002934682
min O 0 0.0003509294
( O 0 0.00041849978
- O 0 0.00080810516
40 O 0 0.00022021504
% O 0 0.00034760055
) O 0 0.00034853278
and O 0 0.00015172412
at O 0 0.000114292816
180 O 0 0.00021702606
min O 0 0.00028477982
( O 0 0.0003615852
- O 0 0.0007741721
49 O 0 0.00024963872
% O 0 0.0003037398
) O 0 0.00027172655
after O 0 6.338483e-05
the O 0 8.3939834e-05
start O 0 7.893779e-05
of O 0 0.00022812244
hypotension B-Disease 0 0.99973756
and O 0 0.00016941447
at O 0 9.6644435e-05
60 O 0 0.00014631278
min O 0 0.00021791436
( O 0 0.00028632456
- O 0 0.00061576837
32 O 0 0.00018882212
% O 0 0.0002459466
) O 0 0.00023085115
after O 0 6.1310915e-05
recovery O 0 0.00015970484
of O 0 0.00019513829
normotension O 0 0.97587776
, O 0 0.0008444589
and O 0 0.0009634179
SGOT O 0 0.99999535
, O 0 0.18276311
SGPT O 0 0.99999845
, O 0 0.039795276
LDH O 0 0.99973744
and O 0 0.0005045802
total O 0 0.00057382305
bilirubin B-Chemical 0 0.99988556
showed O 0 0.00038765423
significant O 0 0.0003734804
increases O 0 0.00046140814
after O 0 0.00040505413
operation O 0 0.0010408775
. O 0 0.0021605303

The O 0 0.0017260956
results O 0 0.0011499417
suggest O 0 0.00059164694
that O 0 0.0005651001
a O 0 0.0007446932
prolonged O 0 0.00054463773
combination O 0 0.0003756545
of O 0 0.00029146674
more O 0 0.0003112793
than O 0 0.00016529145
120 O 0 0.00023041444
min O 0 0.0003122146
of O 0 0.00047643794
PGE1 B-Chemical 0 0.99999845
- O 0 0.07183166
induced O 0 0.00037646503
hypotension B-Disease 0 0.99994445
and O 0 0.00032406242
moderate O 0 0.0026650778
haemodilution B-Disease 0 0.99660397
would O 0 0.00023473128
cause O 0 0.00047844637
impairment B-Disease 0 0.33970305
of I-Disease 0 0.0009799412
hepatic I-Disease 0 0.95963776
function I-Disease 0 0.0016147486
. O 0 0.0025743037

Cardiovascular B-Disease 0 0.55956185
alterations I-Disease 0 0.011239685
in O 0 0.0021041017
rat O 0 0.0025007615
fetuses O 0 0.004546612
exposed O 0 0.0015416582
to O 0 0.0015201848
calcium B-Chemical 0 0.99102
channel O 0 0.034101155
blockers O 0 0.98614097
. O 0 0.0076632416

Preclinical O 0 0.014453442
toxicologic O 0 0.008340084
investigation O 0 0.0015025923
suggested O 0 0.0006571844
that O 0 0.00049536646
a O 0 0.00088385266
new O 0 0.0009800727
calcium B-Chemical 0 0.99781466
channel O 0 0.022943826
blocker O 0 0.8716292
, O 0 0.0015889964
Ro B-Chemical 0 0.3726849
40 I-Chemical 0 0.00042285863
- I-Chemical 0 0.0018183949
5967 I-Chemical 0 0.0007434343
, O 0 0.00034109922
induced O 0 0.00024600525
cardiovascular B-Disease 0 0.9689614
alterations I-Disease 0 0.0059068506
in O 0 0.00021240358
rat O 0 0.0003655621
fetuses O 0 0.000968751
exposed O 0 0.00024345604
to O 0 0.00020273105
this O 0 0.0003481826
agent O 0 0.0009917921
during O 0 0.0006777646
organogenesis O 0 0.008409876
. O 0 0.0030408523

The O 0 0.001930011
present O 0 0.0013517181
study O 0 0.0012209626
was O 0 0.0006039741
designed O 0 0.0003690511
to O 0 0.00023631532
investigate O 0 0.000108762426
the O 0 0.00016810479
hypothesis O 0 0.00021221288
that O 0 0.00025738432
calcium B-Chemical 0 0.9982004
channel O 0 0.02360036
blockers O 0 0.98293674
in O 0 0.00026255407
general O 0 0.00022261727
induce O 0 0.00021906638
cardiovascular B-Disease 0 0.9977149
malformations I-Disease 0 0.9999863
indicating O 0 0.00036372006
a O 0 0.00068148883
pharmacologic O 0 0.002026441
class O 0 0.0013442468
effect O 0 0.0013797751
. O 0 0.0031511697

We O 0 0.0024623368
studied O 0 0.0022192905
three O 0 0.0009283259
calcium B-Chemical 0 0.98264647
channel O 0 0.008912463
blockers O 0 0.91898257
of O 0 0.000534871
different O 0 0.00024354519
structure O 0 0.0003773806
, O 0 0.0019091489
nifedipine B-Chemical 1 0.9999964
, O 0 0.02528418
diltiazem B-Chemical 1 0.99999785
, O 0 0.0019981954
and O 0 0.0008087696
verapamil B-Chemical 0 0.99999034
, O 0 0.0011156795
along O 0 0.00036697765
with O 0 0.00046710137
the O 0 0.00052137405
new O 0 0.001169927
agent O 0 0.0035294488
. O 0 0.0033614982

Pregnant O 0 0.008319925
rats O 0 0.0022971858
were O 0 0.00090490445
administered O 0 0.0008095114
one O 0 0.00038135008
of O 0 0.0004101121
these O 0 0.00047164556
calcium B-Chemical 0 0.99463516
channel O 0 0.00800399
blockers O 0 0.9158264
during O 0 0.00014259166
the O 0 9.764014e-05
period O 0 7.9171856e-05
of O 0 0.00014129221
cardiac O 0 0.000808587
morphogenesis O 0 0.00033873456
and O 0 0.00014123657
the O 0 0.000105063256
offspring O 0 0.00027172058
examined O 0 9.528681e-05
on O 0 8.598819e-05
day O 0 9.821819e-05
20 O 0 0.00015721483
of O 0 0.00021091984
gestation O 0 0.00046216432
for O 0 0.0006050902
cardiovascular B-Disease 0 0.9927416
malformations I-Disease 0 0.99992526
. O 0 0.0052322284

A O 0 0.02590506
low O 0 0.0033423128
incidence O 0 0.0030432842
of O 0 0.0019043772
cardiovascular B-Disease 0 0.99839896
malformations I-Disease 0 0.99998045
was O 0 0.00048260586
observed O 0 0.00018220581
after O 0 8.596777e-05
exposure O 0 0.00013882491
to O 0 8.621669e-05
each O 0 6.4522086e-05
of O 0 0.00010079547
the O 0 8.955876e-05
four O 0 9.688084e-05
calcium B-Chemical 0 0.9878154
channel O 0 0.008181271
blockers O 0 0.990686
, O 0 0.00083651906
but O 0 0.00023970331
this O 0 0.00018373287
incidence O 0 0.00035814426
was O 0 0.00013855644
statistically O 0 0.00023924802
significant O 0 0.00018769341
only O 0 0.00030221528
for O 0 0.00049891457
verapamil B-Chemical 0 0.9999882
and O 0 0.006438682
nifedipine B-Chemical 1 0.9999863
. O 0 0.0055733486

All O 0 0.0016671584
four O 0 0.00092286925
agents O 0 0.0017103807
were O 0 0.0006794299
associated O 0 0.0005585752
with O 0 0.0005699288
aortic O 0 0.14930224
arch O 0 0.63666993
branching O 0 0.002920685
variants O 0 0.0002469478
, O 0 0.00046199083
although O 0 0.00021454174
significantly O 0 0.00028429533
increased O 0 0.00034036214
only O 0 0.00028175834
for O 0 0.00027842543
Ro B-Chemical 0 0.11398413
40 I-Chemical 0 0.00067590724
- I-Chemical 0 0.0027939528
5967 I-Chemical 0 0.0024421413
and O 0 0.0017005275
verapamil B-Chemical 0 0.99991596
. O 0 0.0053766184

The O 0 0.0028859943
site O 0 0.0019812805
of O 0 0.0025231687
common O 0 0.0024351024
side O 0 0.0042797807
effects O 0 0.002947683
of O 0 0.0069488706
sumatriptan B-Chemical 0 0.9998466
. O 0 0.008896396

Atypical B-Disease 0 0.5891324
sensations I-Disease 0 0.024596425
following O 0 0.0007394091
the O 0 0.0005480288
use O 0 0.00047223014
of O 0 0.000663066
subcutaneous O 0 0.0036082335
sumatriptan B-Chemical 0 0.9999145
are O 0 0.00037053737
common O 0 0.00045671847
, O 0 0.00081925263
but O 0 0.0006857311
of O 0 0.0009125498
uncertain O 0 0.0015631835
origin O 0 0.0028025708
. O 0 0.0036868544

They O 0 0.005771651
are O 0 0.0022181252
almost O 0 0.0020277558
always O 0 0.0027220426
benign O 0 0.6189288
, O 0 0.00211237
but O 0 0.00085394393
can O 0 0.00039101182
be O 0 0.00045609998
mistaken O 0 0.0015685159
for O 0 0.00029232807
a O 0 0.0005775754
serious O 0 0.0010858637
adverse O 0 0.0018591895
event O 0 0.00079294783
by O 0 0.0006156546
the O 0 0.0008088767
patient O 0 0.0018103487
. O 0 0.0027520757

Two O 0 0.0023485078
patients O 0 0.0025172364
are O 0 0.0008198207
presented O 0 0.0006293394
with O 0 0.0007206422
tingling B-Disease 0 0.0071966895
or I-Disease 0 0.0004984532
burning I-Disease 0 0.0027499092
sensations I-Disease 0 0.0015879226
limited O 0 0.00036404445
to O 0 0.00034123645
areas O 0 0.0006357021
of O 0 0.0005803599
heat O 0 0.0016622847
exposure O 0 0.0011278943
or O 0 0.0015611612
sunburn B-Disease 0 0.98501205
. O 0 0.0041072783

In O 0 0.0021053154
these O 0 0.0019323297
individuals O 0 0.0024476512
, O 0 0.0019203759
side O 0 0.0018546652
effects O 0 0.00071467
are O 0 0.00051239
most O 0 0.0005885221
likely O 0 0.0003102116
generated O 0 0.00031955313
superficially O 0 0.0014400992
in O 0 0.00088310975
the O 0 0.0012753954
skin O 0 0.0051840195
. O 0 0.003786828

Macula O 0 0.69611794
toxicity B-Disease 0 0.514712
after O 0 0.0064136046
intravitreal O 0 0.9700493
amikacin B-Chemical 0 0.99950516
. O 0 0.013952199

BACKGROUND O 0 0.011355449
: O 0 0.0030032948
Although O 0 0.0007765235
intravitreal O 0 0.76595575
aminoglycosides B-Chemical 0 0.9947583
have O 0 0.00037994268
substantially O 0 0.00031257293
improved O 0 0.00045023055
visual O 0 0.00281728
prognosis O 0 0.08844937
in O 0 0.00046594735
endophthalmitis B-Disease 0 0.99945766
, O 0 0.013874005
macular O 0 0.9999933
infarction B-Disease 0 0.99998987
may O 0 0.0003320267
impair O 0 0.00032377028
full O 0 0.00038714678
visual O 0 0.003572525
recovery O 0 0.0018610584
. O 0 0.0022678326

METHODS O 0 0.0042574243
: O 0 0.0028066037
We O 0 0.0007829383
present O 0 0.0006047884
a O 0 0.000840991
case O 0 0.0005576796
of O 0 0.00055545004
presumed O 0 0.001503613
amikacin B-Chemical 0 0.99999285
retinal B-Disease 0 0.99955624
toxicity I-Disease 0 0.99413574
following O 0 0.00010749922
treatment O 0 0.00013899578
with O 0 0.00025645224
amikacin B-Chemical 0 0.99997425
and O 0 0.00048027385
vancomycin B-Chemical 0 0.99932444
for O 0 0.00041115397
alpha O 0 0.8657611
- O 0 0.28805003
haemolytic O 0 0.99664706
streptococcal B-Disease 0 0.9994006
endophthalmitis I-Disease 0 0.99989367
. O 0 0.0054831216

RESULTS O 0 0.005242339
: O 0 0.005277848
Endophthalmitis B-Disease 0 0.47871852
resolved O 0 0.0010785182
with O 0 0.00056907826
improvement O 0 0.0005321843
in O 0 0.0003789264
visual O 0 0.0019707857
acuity O 0 0.3670066
to O 0 0.00035230003
6 O 0 0.00030414146
/ O 0 0.001036074
24 O 0 0.00041340909
at O 0 0.00033720408
three O 0 0.00037935638
months O 0 0.00071513123
. O 0 0.0025176231

Fundus O 0 0.037237212
fluorescein B-Chemical 0 0.793173
angiography O 0 0.014700517
confirmed O 0 0.0035815632
macular O 0 0.99960667
capillary O 0 0.86455154
closure O 0 0.015194093
and O 0 0.00477004
telangiectasis B-Disease 0 0.9989102
. O 0 0.007911415

CONCLUSIONS O 0 0.016308757
: O 0 0.0036394654
Currently O 0 0.0010919091
accepted O 0 0.001431203
intravitreal O 0 0.26903182
antibiotic O 0 0.0024312434
regimens O 0 0.0007699971
may O 0 0.00047691257
cause O 0 0.0011746595
retinal B-Disease 0 0.9975431
toxicity I-Disease 0 0.999172
and O 0 0.0076422207
macular O 0 0.99996483
ischaemia B-Disease 0 0.9998838
. O 0 0.0044711023

Treatment O 0 0.006931735
strategies O 0 0.0022438949
aimed O 0 0.0019454152
at O 0 0.0015700266
avoiding O 0 0.0024735949
retinal B-Disease 0 0.9932893
toxicity I-Disease 0 0.99492574
are O 0 0.0024675708
discussed O 0 0.0028980759
. O 0 0.0051249685

The O 0 0.0021188094
role O 0 0.0013322334
of O 0 0.0026988662
nicotine B-Chemical 0 0.9909615
in O 0 0.0020139492
smoking O 0 0.07865552
- O 0 0.007720499
related O 0 0.001412961
cardiovascular B-Disease 0 0.45780796
disease I-Disease 0 0.55234265
. O 0 0.005496292

Nicotine B-Chemical 0 0.999313
activates O 0 0.0016877151
the O 0 0.0013943599
sympathetic O 0 0.006774867
nervous O 0 0.0040510274
system O 0 0.0005898209
and O 0 0.00050364516
in O 0 0.0003984314
this O 0 0.00041779858
way O 0 0.00041389314
could O 0 0.00036543666
contribute O 0 0.000571034
to O 0 0.000938259
cardiovascular B-Disease 0 0.60356104
disease I-Disease 0 0.6059211
. O 0 0.0038692434

Animal O 0 0.004853805
studies O 0 0.0019954576
and O 0 0.0010649094
mechanistic O 0 0.0007099419
studies O 0 0.00065397285
indicate O 0 0.00027220184
that O 0 0.00040800794
nicotine B-Chemical 0 0.99267477
could O 0 0.00020541584
play O 0 0.00013864685
a O 0 0.0002063662
role O 0 7.8533834e-05
in O 0 0.00018722955
accelerating O 0 0.0019597122
atherosclerosis B-Disease 0 0.9999759
, O 0 0.00097652717
but O 0 0.00018620925
evidence O 0 0.00010201481
among O 0 0.00017219399
humans O 0 0.00025099193
is O 0 0.00010830228
too O 0 0.00017183856
inadequate O 0 0.00026941262
to O 0 0.00015406516
be O 0 0.00018627015
definitive O 0 0.00029773585
about O 0 0.00040506263
such O 0 0.0004880504
an O 0 0.00089163845
effect O 0 0.0013550809
. O 0 0.003322633

Almost O 0 0.005733763
certainly O 0 0.0031896513
, O 0 0.004255573
nicotine B-Chemical 0 0.9877631
via O 0 0.0005677282
its O 0 0.00055383134
hemodynamic O 0 0.001546817
effects O 0 0.00020061625
contributes O 0 0.00012779135
to O 0 0.0001576129
acute O 0 0.011516447
cardiovascular O 0 0.11647357
events O 0 0.00028366965
, O 0 0.0002386839
although O 0 9.075773e-05
current O 0 9.504705e-05
evidence O 0 6.231936e-05
suggests O 0 4.464857e-05
that O 0 5.09635e-05
the O 0 5.8269532e-05
effects O 0 8.936152e-05
of O 0 0.00020040578
nicotine B-Chemical 0 0.9973578
are O 0 8.0214806e-05
much O 0 7.464601e-05
less O 0 9.8601435e-05
important O 0 5.0776973e-05
than O 0 6.517791e-05
are O 0 6.217073e-05
the O 0 8.8860594e-05
prothrombotic O 0 0.11911076
effects O 0 0.000112020476
of O 0 0.00017943181
cigarette O 0 0.0025022177
smoking O 0 0.01129789
or O 0 0.00019298302
the O 0 0.0002103914
effects O 0 0.0004418879
of O 0 0.0014902863
carbon B-Chemical 0 0.9986278
monoxide I-Chemical 0 0.999948
. O 0 0.0061236434

Nicotine B-Chemical 0 0.99943477
does O 0 0.003778666
not O 0 0.0023160756
appear O 0 0.001560448
to O 0 0.0013254792
enhance O 0 0.0017476501
thrombosis B-Disease 0 0.99919325
among O 0 0.003912548
humans O 0 0.00519973
. O 0 0.0054038186

Clinical O 0 0.005357889
studies O 0 0.0018910699
of O 0 0.0013085366
pipe O 0 0.005899558
smokers O 0 0.002627482
and O 0 0.000554065
people O 0 0.0009274716
using O 0 0.00032471155
transdermal O 0 0.83365744
nicotine B-Chemical 0 0.9861391
support O 0 0.00015700347
the O 0 0.000104704006
idea O 0 0.00011910101
that O 0 0.00010597769
toxins O 0 0.0013208656
other O 0 0.00017957471
than O 0 0.00022927354
nicotine B-Chemical 0 0.9929766
are O 0 0.0001363839
the O 0 0.00011978667
most O 0 0.0001916799
important O 0 0.00013933337
causes O 0 0.00031170214
of O 0 0.0005666108
acute O 0 0.12673819
cardiovascular O 0 0.48723996
events O 0 0.0025291133
. O 0 0.0025907774

Finally O 0 0.00249745
, O 0 0.0027392947
the O 0 0.0008834872
dose O 0 0.00096827943
response O 0 0.00040245705
for O 0 0.00029518275
cardiovascular O 0 0.016982386
events O 0 0.00051857927
of O 0 0.00044001255
nicotine B-Chemical 0 0.99720025
appears O 0 0.00013321076
to O 0 0.000121394674
be O 0 0.00014056574
flat O 0 0.0009995745
, O 0 0.00026366836
suggesting O 0 7.6846314e-05
that O 0 8.069454e-05
if O 0 0.00011547913
nicotine B-Chemical 0 0.99580365
is O 0 0.00011726457
involved O 0 0.00010223393
, O 0 0.00024297417
adverse O 0 0.00045611628
effects O 0 9.632041e-05
might O 0 6.495702e-05
be O 0 0.000110289315
seen O 0 0.00013694256
with O 0 0.00017328585
relatively O 0 0.00034102765
low O 0 0.00055226806
- O 0 0.0021232632
level O 0 0.0005196317
cigarette O 0 0.0035321547
exposures O 0 0.0027034304
. O 0 0.0026447964

Iatrogenically O 0 0.2896492
induced O 0 0.0033445389
intractable O 0 0.30320778
atrioventricular B-Disease 0 0.9943287
reentrant I-Disease 0 0.8628131
tachycardia I-Disease 2 0.9994815
after O 0 0.00041312602
verapamil B-Chemical 0 0.99995065
and O 0 0.00030267978
catheter O 0 0.00036868593
ablation O 0 0.00015281058
in O 0 0.00012432016
a O 0 0.00021338809
patient O 0 0.00020694807
with O 0 0.00028476195
Wolff B-Disease 0 0.16546309
- I-Disease 0 0.040851265
Parkinson I-Disease 0 0.99910885
- I-Disease 0 0.003916267
White I-Disease 0 0.0026433917
syndrome I-Disease 0 0.8689424
and O 0 0.0012242643
idiopathic B-Disease 0 0.9993332
dilated I-Disease 0 0.999728
cardiomyopathy I-Disease 0 0.9999895
. O 0 0.0070510344

In O 0 0.002405084
a O 0 0.0030679156
patient O 0 0.0021643846
with O 0 0.003089213
WPW B-Disease 0 0.99998164
syndrome I-Disease 0 0.9993911
and O 0 0.0017689435
idiopathic B-Disease 0 0.9995554
dilated I-Disease 0 0.99984825
cardiomyopathy I-Disease 0 0.9999981
, O 0 0.006280476
intractable O 0 0.31749016
atrioventricular B-Disease 0 0.99477994
reentrant I-Disease 0 0.8344089
tachycardia I-Disease 2 0.99970657
( O 0 0.0020313202
AVRT B-Disease 0 0.9993624
) O 0 0.0016844453
was O 0 0.00077444466
iatrogenically O 0 0.014087634
induced O 0 0.0017120423
. O 0 0.0033638475

QRS O 0 0.6183723
without O 0 0.0050249635
preexcitation O 0 0.99345064
, O 0 0.0027910646
caused O 0 0.0008480201
by O 0 0.0006560717
junctional O 0 0.0018314507
escape O 0 0.00080547936
beats O 0 0.007138455
after O 0 0.0002704737
verapamil B-Chemical 0 0.99997234
or O 0 0.000273965
unidirectional O 0 0.00046814617
antegrade O 0 0.0021473076
block O 0 0.00015141889
of O 0 0.00015612104
accessory O 0 0.00021112086
pathway O 0 0.00010484146
after O 0 8.472632e-05
catheter O 0 0.00031891765
ablation O 0 0.0002448138
, O 0 0.000511149
established O 0 0.0005706612
frequent O 0 0.0017470538
AVRT B-Disease 0 0.99924016
attack O 0 0.02685367
. O 0 0.0037951835

Epidemic O 0 0.0232432
of O 0 0.005513965
liver B-Disease 0 0.9900025
disease I-Disease 0 0.9921367
caused O 0 0.0013621286
by O 0 0.0010294234
hydrochlorofluorocarbons B-Chemical 0 0.3490466
used O 0 0.00063222484
as O 0 0.0008640461
ozone B-Chemical 0 0.99353784
- O 0 0.008317942
sparing O 0 0.0019085893
substitutes O 0 0.0015715851
of O 0 0.0018223536
chlorofluorocarbons B-Chemical 0 0.36297387
. O 0 0.004701876

BACKGROUND O 0 0.022472167
: O 0 0.0076567386
Hydrochlorofluorocarbons B-Chemical 0 0.040937856
( O 0 0.0038419415
HCFCs B-Chemical 0 0.16049536
) O 0 0.0017269406
are O 0 0.0003932484
used O 0 0.00032865285
increasingly O 0 0.00037819397
in O 0 0.0003096165
industry O 0 0.00068509654
as O 0 0.00036064367
substitutes O 0 0.0006594006
for O 0 0.0004775747
ozone B-Chemical 0 0.99157834
- O 0 0.006697443
depleting O 0 0.0012018833
chlorofluorocarbons B-Chemical 0 0.45725146
( O 0 0.0034931472
CFCs B-Chemical 0 0.06553384
) O 0 0.0049650357
. O 0 0.0038668334

Limited O 0 0.010556757
studies O 0 0.002554217
in O 0 0.0012126813
animals O 0 0.0006845415
indicate O 0 0.00050185766
potential O 0 0.001013796
hepatotoxicity B-Disease 0 0.9998512
of O 0 0.0013657503
some O 0 0.0010362981
of O 0 0.0012623654
these O 0 0.001685063
compounds O 0 0.030780442
. O 0 0.0049078083

We O 0 0.0026970266
investigated O 0 0.0019374415
an O 0 0.0018267182
epidemic O 0 0.0023604285
of O 0 0.0013798387
liver B-Disease 0 0.99355173
disease I-Disease 0 0.9920913
in O 0 0.00031134873
nine O 0 0.00020233827
industrial O 0 0.00090111827
workers O 0 0.0002611734
who O 0 0.00024876295
had O 0 0.00012750019
had O 0 0.000112746304
repeated O 0 8.318943e-05
accidental O 0 0.0013053574
exposure O 0 0.00015752575
to O 0 0.000104914085
a O 0 0.00019112216
mixture O 0 0.00023921883
of O 0 0.00019592617
1 B-Chemical 0 0.00022396578
, I-Chemical 0 0.0003492669
1 I-Chemical 0 0.00029293488
- I-Chemical 0 0.0035457015
dichloro I-Chemical 0 0.9320141
- I-Chemical 0 0.0033757174
2 I-Chemical 0 0.00024119116
, I-Chemical 0 0.00031402992
2 I-Chemical 0 0.00021382127
, I-Chemical 0 0.00033991985
2 I-Chemical 0 0.00029199605
- I-Chemical 0 0.0016711312
trifluoroethane I-Chemical 0 0.007679097
( O 0 0.0013916899
HCFC B-Chemical 0 0.99918646
123 I-Chemical 0 0.006825202
) O 0 0.00071528344
and O 0 0.0002906171
1 B-Chemical 0 0.00041873718
- I-Chemical 0 0.005093827
chloro I-Chemical 0 0.97344166
- I-Chemical 0 0.006671638
1 I-Chemical 0 0.00038894237
, I-Chemical 0 0.0004823945
2 I-Chemical 0 0.00033555352
, I-Chemical 0 0.00051949173
2 I-Chemical 0 0.00040866094
, I-Chemical 0 0.0007083745
2 I-Chemical 0 0.0006988957
- I-Chemical 0 0.0034926145
tetrafluoroethane I-Chemical 0 0.2472219
( O 0 0.0038192295
HCFC B-Chemical 0 0.9972372
124 I-Chemical 0 0.0110117635
) O 0 0.0057098046
. O 0 0.0043925387

All O 0 0.003128853
nine O 0 0.002494945
exposed O 0 0.0025473768
workers O 0 0.0025773065
were O 0 0.0017833344
affected O 0 0.0019037791
to O 0 0.0017626262
various O 0 0.002664799
degrees O 0 0.024112232
. O 0 0.008237422

Both O 0 0.0035505279
compounds O 0 0.024565835
are O 0 0.0021064659
metabolised O 0 0.22678797
in O 0 0.0006887846
the O 0 0.00039885516
same O 0 0.00027317106
way O 0 0.0003510408
as O 0 0.0004268259
1 B-Chemical 0 0.00063901994
- I-Chemical 0 0.010380582
bromo I-Chemical 0 0.97916967
- I-Chemical 0 0.017053492
1 I-Chemical 0 0.0005885409
- I-Chemical 0 0.0064161844
chloro I-Chemical 0 0.96678436
- I-Chemical 0 0.004708252
2 I-Chemical 0 0.0003027704
, I-Chemical 0 0.00036680943
2 I-Chemical 0 0.00023509501
, I-Chemical 0 0.00035444397
2 I-Chemical 0 0.0002879732
- I-Chemical 0 0.0016536815
trifluoroethane I-Chemical 0 0.008044066
( O 0 0.0014599778
halothane B-Chemical 0 0.99996114
) O 0 0.001516075
to O 0 0.00023870255
form O 0 0.00045218415
reactive O 0 0.835462
trifluoroacetyl B-Chemical 0 0.9996269
halide O 0 0.7264703
intermediates O 0 0.0021451183
, O 0 0.000537837
which O 0 0.00024045892
have O 0 0.00017104018
been O 0 0.00020517467
implicated O 0 0.00024132365
in O 0 0.00035676768
the O 0 0.0006570404
hepatotoxicity B-Disease 0 0.999933
of O 0 0.0043657925
halothane B-Chemical 0 0.9998995
. O 0 0.0045359186

We O 0 0.0027869642
aimed O 0 0.0019669123
to O 0 0.0013009618
test O 0 0.0013346659
whether O 0 0.00056473986
HCFCs B-Chemical 0 0.24336013
123 I-Chemical 0 0.0030770092
and I-Chemical 0 0.00074449525
124 I-Chemical 0 0.001289677
can O 0 0.00041493645
result O 0 0.0005494944
in O 0 0.00087544555
serious O 0 0.0057019372
liver B-Disease 0 0.9895465
disease I-Disease 0 0.9951556
. O 0 0.005644148

METHODS O 0 0.0037468406
: O 0 0.0024668549
For O 0 0.000590335
one O 0 0.0008202727
severely O 0 0.0026316212
affected O 0 0.0008019357
worker O 0 0.0010420255
liver O 0 0.054786388
biopsy O 0 0.00049268134
and O 0 0.0002629659
immunohistochemical O 0 0.00025553335
stainings O 0 0.00033281487
for O 0 0.00018300921
the O 0 0.00022689534
presence O 0 0.0003505796
of O 0 0.00080324966
trifluoroacetyl B-Chemical 0 0.9949987
protein O 0 0.001485216
adducts O 0 0.07905667
were O 0 0.001074797
done O 0 0.0013471697
. O 0 0.0026939537

The O 0 0.0026358522
serum O 0 0.00881447
of O 0 0.0012547127
six O 0 0.0004931686
affected O 0 0.0005901508
workers O 0 0.0005462874
and O 0 0.0003275524
five O 0 0.00015814281
controls O 0 0.00031789526
was O 0 0.00017925478
tested O 0 0.00016284848
for O 0 0.00017312399
autoantibodies O 0 0.0050428915
that O 0 0.00021185867
react O 0 0.00066721585
with O 0 0.00035689506
human O 0 0.0006577254
liver O 0 0.96753347
cytochrome O 0 0.99992526
- O 0 0.9919234
P450 O 0 0.99998546
2E1 O 0 0.9999951
( O 0 0.65666
P450 O 0 0.9999788
2E1 O 0 0.99998784
) O 0 0.018982723
and O 0 0.00069281727
P58 O 0 0.3165044
protein O 0 0.001115365
disulphide O 0 0.8287157
isomerase O 0 0.16637649
isoform O 0 0.0010308031
( O 0 0.0032107104
P58 O 0 0.20050281
) O 0 0.0055011185
. O 0 0.003672378

FINDINGS O 0 0.008722699
: O 0 0.0040839426
The O 0 0.0010081567
liver O 0 0.008506275
biopsy O 0 0.0010322931
sample O 0 0.00097059127
showed O 0 0.0012259468
hepatocellular O 0 0.9999918
necrosis B-Disease 2 0.99999714
which O 0 0.0010817349
was O 0 0.00029095757
prominent O 0 0.00074049534
in O 0 0.0002798863
perivenular O 0 0.9887495
zone O 0 0.00068771676
three O 0 5.3758577e-05
and O 0 0.00011028384
extended O 0 0.0001268479
focally O 0 0.00060744915
from O 0 0.00010912476
portal O 0 0.0027075524
tracts O 0 0.0001426772
to O 0 0.00011897853
portal O 0 0.004537398
tracts O 0 0.0002562482
and O 0 0.00036627127
centrilobular O 0 0.9882174
areas O 0 0.0010434721
( O 0 0.0012291564
bridging O 0 0.0048370976
necrosis B-Disease 2 0.9997793
) O 0 0.008868991
. O 0 0.0035289591

Trifluoroacetyl B-Chemical 0 0.8988774
- O 0 0.080451034
adducted O 0 0.021326238
proteins O 0 0.0026078024
were O 0 0.0019465089
detected O 0 0.0014184822
in O 0 0.0020932348
surviving O 0 0.0058553293
hepatocytes O 0 0.032955907
. O 0 0.0078548705

Autoantibodies O 0 0.022547467
against O 0 0.00491365
P450 O 0 0.9997383
2E1 O 0 0.9999217
or O 0 0.0038322303
P58 O 0 0.534863
, O 0 0.0014411554
previously O 0 0.0005674257
associated O 0 0.00053202844
with O 0 0.0010963504
halothane B-Disease 0 0.999992
hepatitis I-Disease 0 0.99999154
, O 0 0.001869899
were O 0 0.00023738955
detected O 0 0.0001475962
in O 0 0.00021762679
the O 0 0.0002746002
serum O 0 0.00386791
of O 0 0.0005257342
five O 0 0.00039687983
affected O 0 0.0009869467
workers O 0 0.002184809
. O 0 0.0033317946

INTERPRETATION O 0 0.00920152
: O 0 0.004062039
Repeated O 0 0.001703093
exposure O 0 0.0009695413
of O 0 0.000751078
human O 0 0.0007257927
beings O 0 0.0034122583
to O 0 0.00058205624
HCFCs B-Chemical 0 0.28916433
123 I-Chemical 0 0.0016264142
and I-Chemical 0 0.0003165555
124 I-Chemical 0 0.0005682018
can O 0 0.00014083607
result O 0 0.00016121694
in O 0 0.00021690753
serious O 0 0.0014774497
liver B-Disease 0 0.9718326
injury I-Disease 0 0.7897545
in O 0 0.00025663475
a O 0 0.00032811722
large O 0 0.00030260623
proportion O 0 0.00023508293
of O 0 0.00037600793
the O 0 0.0004197609
exposed O 0 0.00093452574
population O 0 0.0020553402
. O 0 0.002797687

Although O 0 0.0018893498
the O 0 0.0014467569
exact O 0 0.0014014057
mechanism O 0 0.0006049725
of O 0 0.0012272794
hepatotoxicity B-Disease 0 0.9999299
of O 0 0.00057957164
these O 0 0.00028218175
agents O 0 0.0006743669
is O 0 0.00018020609
not O 0 0.00017348159
known O 0 0.00019751262
, O 0 0.00033502677
the O 0 0.00013382161
results O 0 0.00013436799
suggest O 0 0.00012559378
that O 0 0.00030123087
trifluoroacetyl B-Chemical 0 0.9980963
- O 0 0.055165213
altered O 0 0.00071157306
liver O 0 0.061634917
proteins O 0 0.0006983132
are O 0 0.00073168176
involved O 0 0.0012321285
. O 0 0.0027782947

In O 0 0.0017855945
view O 0 0.0018658973
of O 0 0.0012764003
the O 0 0.00069516123
potentially O 0 0.0005475437
widespread O 0 0.0004382941
use O 0 0.0003067094
of O 0 0.00034802183
these O 0 0.00033617986
compounds O 0 0.0060084006
, O 0 0.00062687666
there O 0 0.00022367042
is O 0 0.00023094207
an O 0 0.00030405042
urgent O 0 0.00036784352
need O 0 0.00026496264
to O 0 0.00032692973
develop O 0 0.0005913109
safer O 0 0.0011803585
alternatives O 0 0.0014975686
. O 0 0.003073629

Bile B-Disease 0 0.99672145
duct I-Disease 0 0.98874843
hamartoma I-Disease 0 0.99667394
occurring O 0 0.001623525
in O 0 0.00065203774
association O 0 0.00039417614
with O 0 0.0005854437
long O 0 0.00071992225
- O 0 0.002282296
term O 0 0.0008106052
treatment O 0 0.0010405107
with O 0 0.0024649852
danazol B-Chemical 0 0.999424
. O 0 0.005990015

We O 0 0.0031426805
report O 0 0.0034762148
a O 0 0.0022146238
case O 0 0.0013406995
of O 0 0.0015165934
bile B-Disease 0 0.99878246
duct I-Disease 0 0.99819535
hamartoma I-Disease 0 0.99941194
which O 0 0.00054076745
developed O 0 0.00030549162
in O 0 0.00018517434
a O 0 0.00028403202
patient O 0 0.00022967615
who O 0 0.00023745182
had O 0 0.0001654171
been O 0 0.00017160934
on O 0 0.00016736954
long O 0 0.00040798457
- O 0 0.0025266188
term O 0 0.0011966878
danazol B-Chemical 0 0.99953425
treatment O 0 0.002264167
. O 0 0.0031484654

Such O 0 0.004813527
patients O 0 0.0035381936
should O 0 0.00079468684
be O 0 0.00072514423
under O 0 0.00049516547
close O 0 0.00048172363
follow O 0 0.00039400996
- O 0 0.0017224753
up O 0 0.0004816649
, O 0 0.0006380019
preferably O 0 0.0004797097
with O 0 0.000365844
periodic O 0 0.0005149161
ultrasound O 0 0.0006320983
examination O 0 0.00039935816
of O 0 0.0007050043
the O 0 0.0011056683
liver O 0 0.093851425
. O 0 0.004302206

If O 0 0.0023179771
the O 0 0.0017913696
patient O 0 0.0017728066
develops O 0 0.0018003414
a O 0 0.001440936
liver B-Disease 0 0.65573394
mass I-Disease 0 0.0023462342
, O 0 0.00064372795
because O 0 0.00018414958
of O 0 0.00025756992
non O 0 0.00045589093
- O 0 0.0011603113
specific O 0 9.8788245e-05
clinical O 0 0.00034161043
features O 0 0.00016363281
and O 0 0.00013473327
imaging O 0 0.00020546539
appearances O 0 0.00040613324
, O 0 0.0003572653
biopsy O 0 0.00021603114
may O 0 0.0001107619
be O 0 0.00012720026
the O 0 0.00012543915
only O 0 0.00018261524
way O 0 0.00019794267
to O 0 0.00021612905
achieve O 0 0.00028254327
a O 0 0.000771187
definitive O 0 0.0010862667
diagnosis O 0 0.0027071007
. O 0 0.0028446552

Endocrine O 0 0.03114362
screening O 0 0.0023991512
in O 0 0.0016333768
1 O 0 0.001446597
, O 0 0.0019176332
022 O 0 0.02519781
men O 0 0.0028096975
with O 0 0.000872839
erectile B-Disease 0 0.8839666
dysfunction I-Disease 0 0.47763908
: O 0 0.0009408417
clinical O 0 0.0006762265
significance O 0 0.00033290687
and O 0 0.0004206612
cost O 0 0.0008423059
- O 0 0.002407687
effective O 0 0.00089509273
strategy O 0 0.0015410815
. O 0 0.0034475648

PURPOSE O 0 0.008238311
: O 0 0.0039054276
We O 0 0.0009755999
reviewed O 0 0.0012144697
the O 0 0.00048120777
results O 0 0.00044072868
of O 0 0.000787541
serum O 0 0.5147397
testosterone B-Chemical 0 0.99992585
and O 0 0.0016880969
prolactin O 0 0.99593747
determination O 0 0.00051354954
in O 0 0.00018795273
1 O 0 0.00021086294
, O 0 0.0003668313
022 O 0 0.018615765
patients O 0 0.0003410776
referred O 0 0.00014890505
because O 0 7.892484e-05
of O 0 0.00019886886
erectile B-Disease 0 0.9542257
dysfunction I-Disease 0 0.52608013
and O 0 0.00011308913
compared O 0 5.788589e-05
the O 0 6.125118e-05
data O 0 8.9107256e-05
with O 0 9.7635486e-05
history O 0 0.0002107743
, O 0 0.00015577901
results O 0 6.413935e-05
of O 0 9.1285096e-05
physical O 0 0.00015606717
examination O 0 7.581151e-05
, O 0 0.00014208176
other O 0 7.996979e-05
etiological O 0 0.0005567614
investigations O 0 0.00012508249
and O 0 8.281046e-05
effects O 0 9.069725e-05
of O 0 0.00016797101
endocrine O 0 0.11843383
therapy O 0 0.00019007428
to O 0 6.451747e-05
refine O 0 0.00011992015
the O 0 7.878219e-05
rules O 0 0.000102695885
of O 0 0.00013028998
cost O 0 0.0002864152
- O 0 0.0013778027
effective O 0 0.00014322558
endocrine O 0 0.016683389
screening O 0 0.00014195607
and O 0 0.0001533723
to O 0 0.00013719809
pinpoint O 0 0.00018512899
actual O 0 0.00021498835
responsibility O 0 0.0007470605
for O 0 0.0004553207
hormonal O 0 0.003670055
abnormalities O 0 0.038407046
. O 0 0.0027050914

MATERIALS O 0 0.0043541323
AND O 0 0.002085462
METHODS O 0 0.0026329863
: O 0 0.00477244
Testosterone B-Chemical 0 0.99816316
and O 0 0.0032940358
prolactin O 0 0.88080424
were O 0 0.0017904114
determined O 0 0.0015552028
by O 0 0.0026799275
radioimmunoassay O 0 0.14524952
. O 0 0.006971397

Every O 0 0.0034116453
patient O 0 0.0022447768
was O 0 0.0011159282
screened O 0 0.0009457623
for O 0 0.00080610474
testosterone B-Chemical 0 0.99933916
and O 0 0.0008758619
451 O 0 0.0023954643
were O 0 0.0002329783
screened O 0 0.00022196872
for O 0 0.00019127037
prolactin O 0 0.71713775
on O 0 0.00010696026
the O 0 9.3602794e-05
basis O 0 0.00010350975
of O 0 0.00016854634
low B-Disease 0 0.0006230539
sexual I-Disease 0 0.0043378696
desire I-Disease 0 0.0062141297
, O 0 0.0016750753
gynecomastia B-Disease 0 0.9997216
or O 0 0.000517357
testosterone B-Chemical 0 0.9997919
less O 0 0.0005325251
than O 0 0.00024237073
4 O 0 0.00026740858
ng O 0 0.0008129746
. O 0 0.0007222232
/ O 0 0.00327518
ml O 0 0.0049030134
. O 0 0.00321559

Determination O 0 0.006004623
was O 0 0.0025905678
repeated O 0 0.0013306424
in O 0 0.0014492052
case O 0 0.0015752173
of O 0 0.0017709385
abnormal O 0 0.004096975
first O 0 0.0014701091
results O 0 0.0026819166
. O 0 0.0054181735

Prolactin O 0 0.99319744
results O 0 0.0018041125
were O 0 0.0009532752
compared O 0 0.00050441094
with O 0 0.0005292191
those O 0 0.00046394006
of O 0 0.00037074127
a O 0 0.0004093616
previous O 0 0.0002237391
personal O 0 0.00078130845
cohort O 0 0.00063903636
of O 0 0.00027450547
1 O 0 0.00029444604
, O 0 0.00045747682
340 O 0 0.0013296423
patients O 0 0.00044315
with O 0 0.00035026672
erectile B-Disease 0 0.91319966
dysfunction I-Disease 0 0.5971895
and O 0 0.0006609748
systematic O 0 0.0015004948
prolactin O 0 0.98072606
determination O 0 0.0032455253
. O 0 0.002926811

Main O 0 0.0059645674
clinical O 0 0.003011049
criteria O 0 0.00092465593
tested O 0 0.00048473978
regarding O 0 0.00028204912
efficiency O 0 0.00041652386
in O 0 0.0005281614
hormone O 0 0.04765932
determination O 0 0.0005993976
were O 0 0.00030013383
low B-Disease 0 0.0007426314
sexual I-Disease 0 0.0024777257
desire I-Disease 0 0.0026911097
, O 0 0.0011829033
small O 0 0.0013533565
testes O 0 0.0029344088
and O 0 0.0027848445
gynecomastia B-Disease 0 0.9982851
. O 0 0.005102168

Endocrine O 0 0.018524252
therapy O 0 0.0028836846
consisted O 0 0.0015690551
of O 0 0.0022044794
testosterone B-Chemical 0 0.99986947
heptylate I-Chemical 0 0.82964855
or O 0 0.00096208695
human O 0 0.0014175781
chorionic O 0 0.99975294
gonadotropin O 0 0.9992913
for O 0 0.0008971718
hypogonadism B-Disease 0 0.9998035
and O 0 0.002358027
bromocriptine B-Chemical 0 0.99997604
for O 0 0.0019970054
hyperprolactinemia B-Disease 0 0.9998828
. O 0 0.0043329746

RESULTS O 0 0.00690529
: O 0 0.00963388
Testosterone B-Chemical 0 0.9992899
was O 0 0.0012081756
less O 0 0.00089458877
than O 0 0.00042445326
3 O 0 0.00034065446
ng O 0 0.0006649028
. O 0 0.00039951652
/ O 0 0.0012683492
ml O 0 0.0011015487
. O 0 0.0002620674
in O 0 0.0002169696
107 O 0 0.00041033616
patients O 0 0.000531927
but O 0 0.0003424553
normal O 0 0.00049310183
in O 0 0.00032582326
40 O 0 0.00045937137
% O 0 0.0007545861
at O 0 0.0004576229
repeat O 0 0.0007468573
determination O 0 0.0019278749
. O 0 0.00305123

The O 0 0.0019614142
prevalence O 0 0.002103187
of O 0 0.0013380514
repeatedly O 0 0.0010160247
low O 0 0.0019734942
testosterone B-Chemical 0 0.99967337
increased O 0 0.0009580229
with O 0 0.00041948873
age O 0 0.00051345903
( O 0 0.00040012941
4 O 0 0.00015344954
% O 0 0.00025489388
before O 0 8.6707434e-05
age O 0 0.00025455194
50 O 0 0.00024821967
years O 0 0.00024310139
and O 0 0.00022446836
9 O 0 0.00024034867
% O 0 0.00052438164
50 O 0 0.00048625888
years O 0 0.00059897464
or O 0 0.0006777476
older O 0 0.0036573294
) O 0 0.004394727
. O 0 0.0037495524

Two O 0 0.008107067
pituitary B-Disease 0 0.9830952
tumors I-Disease 0 0.98895246
were O 0 0.0033628307
discovered O 0 0.0031443648
after O 0 0.002482535
testosterone B-Chemical 0 0.9974291
determination O 0 0.008854668
. O 0 0.007441569

Most O 0 0.0037109354
of O 0 0.0018631502
the O 0 0.0010219602
other O 0 0.00090757344
low O 0 0.0022341
testosterone B-Chemical 0 0.9997454
levels O 0 0.000607066
seemed O 0 0.00042186395
to O 0 0.00021957642
result O 0 0.00021123483
from O 0 0.00031260448
nonorganic O 0 0.9987136
hypothalamic B-Disease 0 0.18997502
dysfunction I-Disease 0 0.9929892
because O 0 0.0001296762
of O 0 0.00020116559
normal O 0 0.0007050607
serum O 0 0.20516638
luteinizing O 0 0.79346484
hormone O 0 0.7423573
and O 0 0.00046232188
prolactin O 0 0.99006224
and O 0 0.00014680988
to O 0 7.5581396e-05
have O 0 6.91614e-05
only O 0 9.07849e-05
a O 0 0.00013235789
small O 0 0.00012874573
role O 0 4.9051665e-05
in O 0 0.0001456666
erectile B-Disease 0 0.94712955
dysfunction I-Disease 0 0.70077056
( O 0 0.00031314796
definite O 0 0.00048150306
improvement O 0 0.00012965567
in O 0 8.114967e-05
only O 0 0.00010178462
16 O 0 0.00011012883
of O 0 0.00010843373
44 O 0 0.00018471849
[ O 0 0.00045413407
36 O 0 0.00012853538
% O 0 0.00022640651
] O 0 0.00045738326
after O 0 8.8433364e-05
androgen O 0 0.91864747
therapy O 0 0.00028402766
, O 0 0.00025192575
normal O 0 0.00028546187
morning O 0 0.0004940517
or O 0 0.00014631501
nocturnal O 0 0.062434874
erections O 0 0.043740936
in O 0 0.00012486297
30 O 0 0.00011847508
% O 0 0.00025482292
and O 0 0.00021872953
definite O 0 0.0022293227
vasculogenic O 0 0.94499433
contributions O 0 0.0007522204
in O 0 0.000654876
42 O 0 0.0011073131
% O 0 0.0019565343
) O 0 0.0033822332
. O 0 0.003108144

Determining O 0 0.005224171
testosterone B-Chemical 0 0.9989085
only O 0 0.0019329046
in O 0 0.0008895912
cases O 0 0.0010086942
of O 0 0.0005287903
low B-Disease 0 0.0011604661
sexual I-Disease 0 0.0036504588
desire I-Disease 0 0.0018485353
or O 0 0.00022592262
abnormal O 0 0.0007099755
physical O 0 0.000249042
examination O 0 0.00010818616
would O 0 9.3221104e-05
have O 0 9.449883e-05
missed O 0 0.00012274853
40 O 0 0.00015330681
% O 0 0.00023015687
of O 0 0.00012546331
the O 0 0.00010803678
cases O 0 0.0002479347
with O 0 0.00019117756
low O 0 0.00065180036
testosterone B-Chemical 0 0.9998889
, O 0 0.00057553966
including O 0 0.0001360742
37 O 0 0.00034713806
% O 0 0.00031527423
of O 0 0.00019786021
those O 0 0.0002618798
subsequently O 0 0.00031199027
improved O 0 0.00067350554
by O 0 0.00081526645
androgen O 0 0.9826167
therapy O 0 0.0027148174
. O 0 0.002513458

Prolactin O 0 0.9936008
exceeded O 0 0.0032808522
20 O 0 0.0017511749
ng O 0 0.0021058875
. O 0 0.0010618931
/ O 0 0.0027482752
ml O 0 0.0021654991
. O 0 0.00048027752
in O 0 0.00034641504
5 O 0 0.00034987743
men O 0 0.0009998225
and O 0 0.0003951406
was O 0 0.0003743416
normal O 0 0.00064356136
in O 0 0.00043482197
2 O 0 0.00056340755
at O 0 0.00049513625
repeat O 0 0.0008038895
determination O 0 0.0020378365
. O 0 0.0032536928

Only O 0 0.018120177
1 O 0 0.017622145
prolactinoma B-Disease 2 0.9980063
was O 0 0.010912626
discovered O 0 0.012087276
. O 0 0.014802448

These O 0 0.0019241872
data O 0 0.001749906
are O 0 0.0008008067
lower O 0 0.00082222215
than O 0 0.00047708763
those O 0 0.0004037299
we O 0 0.00016790887
found O 0 0.00022798004
during O 0 0.00014661558
the O 0 0.0001281781
last O 0 8.456715e-05
2 O 0 0.0001617332
decades O 0 0.00026567903
( O 0 0.00030156336
overall O 0 0.00019900675
prolactin O 0 0.7092346
greater O 0 0.00022287977
than O 0 0.000118776195
20 O 0 0.00013250942
ng O 0 0.0002989837
. O 0 0.0001797947
/ O 0 0.0008687103
ml O 0 0.0008280934
. O 0 0.00016665008
in O 0 0.00014497778
1 O 0 0.00018123274
. O 0 0.00014686842
86 O 0 0.00025956306
% O 0 0.0002965234
of O 0 0.00020701652
1 O 0 0.00026644103
, O 0 0.00047797846
821 O 0 0.0018762025
patients O 0 0.0007639312
, O 0 0.0010112826
prolactinomas B-Disease 0 0.9997297
in O 0 0.00040972486
7 O 0 0.00030124723
, O 0 0.00060274696
0 O 0 0.0005783637
. O 0 0.0005532069
38 O 0 0.0011272031
% O 0 0.0021350048
) O 0 0.003934871
. O 0 0.0038797304

Bromocriptine B-Chemical 0 0.99979025
was O 0 0.0032042384
definitely O 0 0.004451832
effective O 0 0.0009611899
in O 0 0.00075282314
cases O 0 0.0011777529
with O 0 0.0009252632
prolactin O 0 0.927415
greater O 0 0.0007712121
than O 0 0.000448695
35 O 0 0.00059620664
ng O 0 0.0012714033
. O 0 0.001067732
/ O 0 0.004264902
ml O 0 0.006114722
. O 0 0.004079529

( O 0 0.006429187
8 O 0 0.0019201557
of O 0 0.001229376
12 O 0 0.00063528016
compared O 0 0.00042739772
to O 0 0.0003958838
only O 0 0.00040849266
9 O 0 0.0003039177
of O 0 0.00033265725
22 O 0 0.00046860022
cases O 0 0.0004991541
with O 0 0.00043412036
prolactin O 0 0.8220064
between O 0 0.00024178518
20 O 0 0.00027255138
and O 0 0.00025258836
35 O 0 0.00032688357
ng O 0 0.0007172125
. O 0 0.00055670773
/ O 0 0.0022691558
ml O 0 0.0028294874
. O 0 0.0013757121
) O 0 0.0037591837
. O 0 0.0036770934

Testosterone B-Chemical 0 0.99956197
was O 0 0.0027911311
low O 0 0.0017702576
in O 0 0.0008717082
less O 0 0.00086506223
than O 0 0.0004715145
50 O 0 0.0005616581
% O 0 0.00067517837
of O 0 0.00039885248
cases O 0 0.0006845062
with O 0 0.00059307925
prolactin O 0 0.93142396
greater O 0 0.0005819322
than O 0 0.00034589428
35 O 0 0.00047987027
ng O 0 0.0010806337
. O 0 0.00091274455
/ O 0 0.003849526
ml O 0 0.005593484
. O 0 0.0036800404

CONCLUSIONS O 0 0.017210253
: O 0 0.00414787
Low O 0 0.002770333
prevalences O 0 0.0014253291
and O 0 0.00057158386
effects O 0 0.00042365855
of O 0 0.0005470187
low O 0 0.0012452934
testosterone B-Chemical 0 0.9997627
and O 0 0.0006408637
high O 0 0.00087273633
prolactin O 0 0.99171454
in O 0 0.0005585848
erectile B-Disease 0 0.9833521
dysfunction I-Disease 0 0.8369732
cannot O 0 0.001773427
justify O 0 0.000491474
their O 0 0.00048091475
routine O 0 0.000600952
determination O 0 0.0017138321
. O 0 0.002610793

However O 0 0.003112115
, O 0 0.0039422503
cost O 0 0.0026008908
- O 0 0.004121197
effective O 0 0.0005497789
screening O 0 0.00034988194
strategies O 0 0.00031816965
recommended O 0 0.00031191146
so O 0 0.00025821582
far O 0 0.0002344526
missed O 0 0.00023955504
40 O 0 0.00024636107
to O 0 0.00015908881
50 O 0 0.00024396564
% O 0 0.00031639074
of O 0 0.00019188342
cases O 0 0.00032390366
improved O 0 0.00032042715
with O 0 0.0003150237
endocrine O 0 0.06581852
therapy O 0 0.00060168793
and O 0 0.00047067992
the O 0 0.00079160545
pituitary B-Disease 0 0.9935027
tumors I-Disease 0 0.99792445
. O 0 0.004348117

We O 0 0.002471746
now O 0 0.0018211979
advocate O 0 0.0017278567
that O 0 0.000574713
before O 0 0.00034452422
age O 0 0.0007086407
50 O 0 0.0006007985
years O 0 0.0007620839
testosterone B-Chemical 0 0.9989831
be O 0 0.00027604785
determined O 0 0.00015911584
only O 0 0.00017935346
in O 0 0.00014976026
cases O 0 0.00026178765
of O 0 0.0001718456
low B-Disease 0 0.0005477095
sexual I-Disease 0 0.0022911208
desire I-Disease 0 0.001228395
and O 0 0.00016295005
abnormal O 0 0.000582302
physical O 0 0.00019411059
examination O 0 9.60153e-05
but O 0 0.00013099183
that O 0 9.8451485e-05
it O 0 0.00021374118
be O 0 0.00014774178
measured O 0 0.00018474844
in O 0 0.00018278841
all O 0 0.00024636695
men O 0 0.0014474693
older O 0 0.0014434479
than O 0 0.0005141926
50 O 0 0.0010721264
years O 0 0.0016365765
. O 0 0.002494679

Prolactin O 0 0.996671
should O 0 0.0015659491
be O 0 0.0011313121
determined O 0 0.00064642663
only O 0 0.00059278903
in O 0 0.0004334587
cases O 0 0.00060671376
of O 0 0.0003788825
low B-Disease 0 0.0009557693
sexual I-Disease 0 0.0041461005
desire I-Disease 0 0.004824472
, O 0 0.0015972584
gynecomastia B-Disease 0 0.999228
and O 0 0.00047767465
/ O 0 0.003083852
or O 0 0.00044600124
testosterone B-Chemical 0 0.99961287
less O 0 0.0005665076
than O 0 0.0002699953
4 O 0 0.00029736932
ng O 0 0.0008813218
. O 0 0.00078825234
/ O 0 0.003458687
ml O 0 0.005142804
. O 0 0.0034263686

Extrapyramidal O 0 0.98307174
side O 0 0.0044182297
effects O 0 0.0014710734
with O 0 0.0027576485
risperidone B-Chemical 0 0.99999547
and O 0 0.0035468962
haloperidol B-Chemical 1 0.9999943
at O 0 0.00057229557
comparable O 0 0.000570369
D2 O 0 0.90927863
receptor O 0 0.0028893035
occupancy O 0 0.0014689636
levels O 0 0.0020201553
. O 0 0.0037737724

Risperidone B-Chemical 0 0.99992454
is O 0 0.0020512696
an O 0 0.0016694845
antipsychotic O 0 0.9969785
drug O 0 0.009414755
with O 0 0.00043038023
high O 0 0.0004819859
affinity O 0 0.00069742306
at O 0 0.00068303087
dopamine B-Chemical 0 0.99990606
D2 O 0 0.9978836
and O 0 0.0014446139
serotonin B-Chemical 0 0.9995264
5 I-Chemical 0 0.0010501641
- I-Chemical 0 0.008343288
HT2 I-Chemical 0 0.90049076
receptors O 0 0.006644508
. O 0 0.004041677

Previous O 0 0.0019468302
clinical O 0 0.0026914056
studies O 0 0.0011185879
have O 0 0.0005378444
proposed O 0 0.00043210946
that O 0 0.00051023025
risperidone B-Chemical 0 0.9999931
' O 0 0.0009844885
s O 0 0.0003661456
pharmacologic O 0 0.00051148067
profile O 0 0.00011990712
may O 0 7.700293e-05
produce O 0 5.666347e-05
improved O 0 0.00011154304
efficacy O 0 8.866549e-05
for O 0 8.460998e-05
negative O 0 0.00045515902
psychotic B-Disease 0 0.99999964
symptoms I-Disease 0 0.79429287
and O 0 0.00015788364
decreased O 0 0.00024399167
propensity O 0 0.00022533446
for O 0 0.0001572931
extrapyramidal O 0 0.9999491
side O 0 0.0004843361
effects O 0 0.00014271178
; O 0 0.00033694252
features O 0 0.00019535629
shared O 0 0.00020076321
by O 0 0.00019009659
so O 0 0.00027696477
- O 0 0.00246209
called O 0 0.0006184611
' O 0 0.00164632
atypical O 0 0.040920552
' O 0 0.0071449596
neuroleptics O 0 0.9995407
. O 0 0.0038308727

To O 0 0.0009510385
determine O 0 0.00044982004
if O 0 0.00053188595
routine O 0 0.0007469086
risperidone B-Chemical 0 0.99999094
treatment O 0 0.0004718265
is O 0 0.00019103398
associated O 0 0.000198808
with O 0 0.00018825101
a O 0 0.00023455275
unique O 0 0.00013042273
degree O 0 0.00030560637
of O 0 0.00047835626
D2 O 0 0.99509794
receptor O 0 0.0011415433
occupancy O 0 0.00017206352
and O 0 0.00012644372
pattern O 0 9.260047e-05
of O 0 0.00012640175
clinical O 0 0.0003667874
effects O 0 0.00011440567
, O 0 0.00019874169
we O 0 6.0954306e-05
used O 0 0.0001420189
[ O 0 0.0041194297
123I O 0 0.99901664
] O 0 0.020855032
IBZM O 0 0.99980086
SPECT O 0 0.52893746
to O 0 7.859355e-05
determine O 0 4.2893247e-05
D2 O 0 0.71181494
occupancy O 0 0.00010875215
in O 0 8.0234466e-05
subjects O 0 0.00016460588
treated O 0 0.0001543747
with O 0 7.973883e-05
routine O 0 5.6046527e-05
clinical O 0 0.00025711354
doses O 0 0.00025918838
of O 0 0.0002671031
risperidone B-Chemical 0 0.99999774
( O 0 0.0003218852
n O 0 0.00016014997
= O 0 0.00034402736
12 O 0 0.000107921674
) O 0 0.00036001916
or O 0 0.00032623849
haloperidol B-Chemical 1 0.9999896
( O 0 0.00096825266
n O 0 0.000625091
= O 0 0.0014584296
7 O 0 0.00081295636
) O 0 0.0026486104
. O 0 0.0029498765

Both O 0 0.0051836455
risperidone B-Chemical 0 0.9999778
and O 0 0.008593457
haloperidol B-Chemical 1 0.999995
produced O 0 0.0015211652
D2 O 0 0.96535057
occupancy O 0 0.00043958682
levels O 0 0.00023204013
between O 0 0.00019896125
approximately O 0 0.00031575133
60 O 0 0.0002674729
and O 0 0.00023656599
90 O 0 0.00028889056
% O 0 0.000470459
at O 0 0.00027500576
standard O 0 0.0005428856
clinical O 0 0.0018852708
doses O 0 0.0029957283
. O 0 0.0031998616

There O 0 0.0034353454
was O 0 0.0016744431
no O 0 0.00094714377
significant O 0 0.00068206777
difference O 0 0.00045037523
between O 0 0.0003755016
occupancy O 0 0.000486509
levels O 0 0.0004139152
obtained O 0 0.00047034063
with O 0 0.0013627353
haloperidol B-Chemical 1 0.9999931
or O 0 0.0038586245
risperidone B-Chemical 0 0.9999826
. O 0 0.004693661

Drug B-Disease 0 0.94951534
- I-Disease 0 0.064600796
induced I-Disease 0 0.0037906324
parkinsonism I-Disease 2 0.9999665
was O 0 0.0007662121
observed O 0 0.00034160604
in O 0 0.0002773421
subjects O 0 0.00046513233
treated O 0 0.0005407842
with O 0 0.0005953605
risperidone B-Chemical 0 0.9999976
( O 0 0.0006046001
42 O 0 0.00023110838
% O 0 0.00033899152
) O 0 0.00047637057
and O 0 0.00040868658
haloperidol B-Chemical 1 0.999997
( O 0 0.0006788435
29 O 0 0.00031781587
% O 0 0.0003743446
) O 0 0.00040313802
and O 0 0.00018390517
was O 0 0.00016114702
observed O 0 0.00015854322
at O 0 0.00016944531
occupancy O 0 0.00030825165
levels O 0 0.0003838163
above O 0 0.0006685972
60 O 0 0.0011755548
% O 0 0.0024943065
. O 0 0.0028576779

Based O 0 0.0039329543
on O 0 0.0012925079
these O 0 0.0011231434
observations O 0 0.0011162577
, O 0 0.0015682209
it O 0 0.0008443881
is O 0 0.00034799761
concluded O 0 0.0003401643
that O 0 0.00022764508
5 O 0 0.0003191878
- O 0 0.0028560054
HT2 O 0 0.68044823
blockade O 0 0.0007572298
obtained O 0 0.00014287556
with O 0 0.00036953148
risperidone B-Chemical 0 0.99999833
at O 0 0.0002382819
D2 O 0 0.8738441
occupancy O 0 0.00015478402
rates O 0 0.00014230506
of O 0 0.00013617339
60 O 0 0.00015525435
% O 0 0.00024059997
and O 0 0.00013053794
above O 0 0.00014661936
does O 0 0.00011982529
not O 0 0.00014386124
appear O 0 0.00013116107
to O 0 0.00011742761
protect O 0 0.00014765165
against O 0 9.776472e-05
the O 0 0.00021783417
risk O 0 0.002955177
for O 0 0.0005903015
extrapyramidal O 0 0.9998956
side O 0 0.0032151868
effects O 0 0.0016573042
. O 0 0.0030358315

Treatment O 0 0.0065969485
of O 0 0.0021539961
previously O 0 0.0018274228
treated O 0 0.00475335
metastatic O 0 0.9604717
breast B-Disease 0 0.99695194
cancer I-Disease 0 0.9993864
by O 0 0.0007491451
mitoxantrone B-Chemical 0 0.9998702
and O 0 0.00026694246
48 O 0 0.00017292488
- O 0 0.00039935054
hour O 0 8.3148414e-05
continuous O 0 6.255091e-05
infusion O 0 0.00015849952
of O 0 9.538335e-05
high O 0 0.00016837927
- O 0 0.00073957955
dose O 0 0.00022981898
5 B-Chemical 0 0.00014373878
- I-Chemical 0 0.0009146303
FU I-Chemical 0 0.0808275
and O 0 0.00033072985
leucovorin B-Chemical 0 0.9999857
( O 0 0.0012896702
MFL B-Chemical 0 0.98347616
) O 0 0.000569505
: O 0 0.0003052994
low O 0 0.00018831328
palliative O 0 0.00031205863
benefit O 0 0.0001600625
and O 0 0.0001950055
high O 0 0.00036315154
treatment O 0 0.0005136034
- O 0 0.0028038612
related O 0 0.00076628255
toxicity B-Disease 0 0.56953275
. O 0 0.003634106

For O 0 0.0019284557
previously O 0 0.0025081688
treated O 0 0.0043686433
advanced O 0 0.14447446
breast B-Disease 0 0.9975001
cancer I-Disease 0 0.99935967
, O 0 0.0018392052
there O 0 0.00042467867
is O 0 0.0003522236
no O 0 0.0003730594
standard O 0 0.0004961463
second O 0 0.00058308453
- O 0 0.0026210255
line O 0 0.0012517625
therapy O 0 0.0024460603
. O 0 0.0032415248

Combination O 0 0.010396876
chemotherapy O 0 0.008377046
with O 0 0.0019820763
mitoxantrone B-Chemical 0 0.99944276
, O 0 0.0015082649
high O 0 0.00075586507
- O 0 0.002038535
dose O 0 0.0005573893
5 B-Chemical 0 0.00032354286
- I-Chemical 0 0.0021994305
fluorouracil I-Chemical 0 0.9993662
( O 0 0.0005137601
5 B-Chemical 0 0.00022756742
- I-Chemical 0 0.0011533304
FU I-Chemical 0 0.058036815
) O 0 0.0005063219
and O 0 0.00035330365
leucovorin B-Chemical 0 0.9999809
( O 0 0.0012421368
MFL B-Chemical 0 0.99370486
regimen I-Chemical 0 0.0004705969
) O 0 0.00043293863
had O 0 0.00016279305
been O 0 0.00016292458
reported O 0 0.00020286294
as O 0 0.00018236677
an O 0 0.00022549287
effective O 0 0.00021881421
and O 0 0.00031953273
well O 0 0.00043821824
tolerated O 0 0.0012598562
regimen O 0 0.0014681931
. O 0 0.0024225207

From O 0 0.004588847
October O 0 0.0028593007
1993 O 0 0.0034302492
to O 0 0.0010750941
November O 0 0.0008742327
1995 O 0 0.0013212046
, O 0 0.00072497566
we O 0 0.0002143371
treated O 0 0.00051938876
13 O 0 0.00030587454
patients O 0 0.00032793204
with O 0 0.00017893907
previously O 0 0.00023375264
chemotherapy O 0 0.0030588228
- O 0 0.0017591772
treated O 0 0.0008275105
metastatic O 0 0.9255434
breast B-Disease 0 0.9964139
cancer I-Disease 0 0.9996761
by O 0 0.00040589887
mitoxantrone B-Chemical 0 0.99993825
, O 0 0.0003645541
12 O 0 9.7143566e-05
mg O 0 0.0013652652
/ O 0 0.0006630635
m2 O 0 0.0010718666
, O 0 0.00017828745
on O 0 5.9254126e-05
day O 0 6.0440256e-05
1 O 0 8.465775e-05
and O 0 7.0842325e-05
continuous O 0 7.210167e-05
infusion O 0 0.0001955682
of O 0 0.00011371719
5 B-Chemical 0 0.00013783998
- I-Chemical 0 0.0009564561
FU I-Chemical 0 0.06998925
, O 0 0.00028371342
3000 O 0 0.0005009532
mg O 0 0.0019644569
/ O 0 0.000720474
m2 O 0 0.0010419819
, O 0 0.00021683826
together O 0 0.00012714107
with O 0 0.0003053812
leucovorin B-Chemical 0 0.999987
, O 0 0.00057783583
300 O 0 0.0005106501
mg O 0 0.0046210247
/ O 0 0.0010677447
m2 O 0 0.0015748191
, O 0 0.0003169408
for O 0 0.00014111272
48 O 0 0.00020894203
h O 0 0.00024559605
from O 0 0.0002401984
day O 0 0.0002768602
1 O 0 0.0005882243
to O 0 0.0007154629
2 O 0 0.0016246128
. O 0 0.002741806

Each O 0 0.0030092488
course O 0 0.002578286
of O 0 0.0023029363
chemotherapy O 0 0.004864164
was O 0 0.0011196752
given O 0 0.00073465164
every O 0 0.00071153813
4 O 0 0.001130346
weeks O 0 0.0012888188
. O 0 0.0039791143

Most O 0 0.004118989
of O 0 0.002101244
these O 0 0.0013336457
patients O 0 0.0017452585
had O 0 0.0007151329
more O 0 0.000723074
than O 0 0.00040570836
two O 0 0.00035653292
metastatic O 0 0.012523662
sites O 0 0.00040017426
, O 0 0.0010531935
with O 0 0.0011002886
lung O 0 0.15465334
metastasis O 0 0.999435
predominant O 0 0.0036629534
. O 0 0.003890703

Seven O 0 0.00896219
patients O 0 0.0068116533
had O 0 0.0034699896
been O 0 0.0030080185
treated O 0 0.0054601966
with O 0 0.0067140087
anthracycline B-Chemical 0 0.99919015
. O 0 0.010196144

Seven O 0 0.004973125
patients O 0 0.0031817893
had O 0 0.0012172388
previously O 0 0.0009059104
received O 0 0.000771054
radiotherapy O 0 0.0028632786
and O 0 0.0005287737
seven O 0 0.00041953666
had O 0 0.00061651337
received O 0 0.0009456822
hormone O 0 0.036389448
therapy O 0 0.003281295
. O 0 0.0034837588

Median O 0 0.0016648798
number O 0 0.0010872221
of O 0 0.0010697839
courses O 0 0.0013401678
of O 0 0.0010135246
MFL B-Chemical 0 0.9808853
regimen I-Chemical 0 0.0007037953
given O 0 0.00017145852
was O 0 0.00015166932
six O 0 8.113535e-05
and O 0 0.00011736615
the O 0 8.561427e-05
median O 0 7.557404e-05
cumulative O 0 0.00013295418
dose O 0 0.00028414358
of O 0 0.0003480736
mitoxantrone B-Chemical 0 0.999739
was O 0 0.00035704838
68 O 0 0.0005099555
. O 0 0.00034309895
35 O 0 0.00056807324
mg O 0 0.004443314
/ O 0 0.00394787
m2 O 0 0.008417602
. O 0 0.0034891048

One O 0 0.0038624185
patient O 0 0.0020487653
had O 0 0.0009896429
complete O 0 0.0005685583
response O 0 0.00053531904
, O 0 0.0007467651
seven O 0 0.00029000462
had O 0 0.00031241798
stable O 0 0.00039419366
disease O 0 0.10964353
, O 0 0.0005144753
none O 0 0.0002641036
had O 0 0.00023126886
partial O 0 0.00031649935
response O 0 0.00024091927
and O 0 0.00031133744
five O 0 0.00026594562
had O 0 0.0006854427
progressive O 0 0.01161583
disease O 0 0.45909107
. O 0 0.0034422737

The O 0 0.00234235
overall O 0 0.0018982529
objective O 0 0.0016636469
response O 0 0.001469906
rate O 0 0.0019131027
was O 0 0.0012889979
7 O 0 0.0011777602
. O 0 0.0014390998
6 O 0 0.0016813482
% O 0 0.004650691
. O 0 0.0057032113

The O 0 0.0025761076
median O 0 0.0018658041
follow O 0 0.0017984214
- O 0 0.004767424
up O 0 0.0017091173
period O 0 0.0011160428
was O 0 0.0014470787
14 O 0 0.001702459
months O 0 0.0015969716
. O 0 0.004707342

Median O 0 0.0058514858
survival O 0 0.008319531
was O 0 0.00542577
16 O 0 0.006072561
months O 0 0.004394589
. O 0 0.010739629

Median O 0 0.004390921
progression O 0 0.011553454
- O 0 0.011634627
free O 0 0.003958497
survival O 0 0.0037102902
was O 0 0.002252385
5 O 0 0.0022721998
months O 0 0.0019434144
. O 0 0.0054313415

A O 0 0.018875815
complete O 0 0.0025379525
responder O 0 0.0061558476
had O 0 0.002145052
relapse O 0 0.17895682
- O 0 0.0059827715
free O 0 0.0014099778
survival O 0 0.0014844559
up O 0 0.0010289244
to O 0 0.0009040892
17 O 0 0.0015927068
months O 0 0.0010777367
. O 0 0.0032828676

Major O 0 0.013422369
toxicities B-Disease 0 0.35115305
were O 0 0.008807175
cardiotoxicity B-Disease 0 0.9992778
and O 0 0.012905606
leukopenia B-Disease 0 0.99845743
. O 0 0.012689916

Eight O 0 0.00429627
patients O 0 0.0035085778
were O 0 0.0013327004
dead O 0 0.0018240737
in O 0 0.00061767286
the O 0 0.00038318415
last O 0 0.00023179136
follow O 0 0.00029262505
- O 0 0.0012880727
up O 0 0.0003811556
; O 0 0.00049001747
two O 0 0.00017104784
of O 0 0.00030758878
them O 0 0.00050529616
died O 0 0.000837603
of O 0 0.0004951252
treatment O 0 0.0007151268
- O 0 0.003472477
related O 0 0.0009518562
toxicity B-Disease 0 0.55128175
. O 0 0.004137987

The O 0 0.0030250032
MFL B-Chemical 0 0.8543272
regimen I-Chemical 0 0.0017123977
achieves O 0 0.0006760367
little O 0 0.0006156511
palliative O 0 0.0010689502
benefit O 0 0.0004362017
and O 0 0.00040878615
induces O 0 0.00037698162
severe O 0 0.005159951
toxicity B-Disease 0 0.4086614
at O 0 0.00039687642
a O 0 0.00078729365
fairly O 0 0.0013075734
high O 0 0.0014646845
rate O 0 0.0027126572
. O 0 0.0034366352

Administration O 0 0.0070773163
of O 0 0.0018315067
this O 0 0.0011298831
regimen O 0 0.0010606444
to O 0 0.00081483315
breast B-Disease 0 0.9896891
cancer I-Disease 0 0.9995295
patients O 0 0.0020683373
who O 0 0.00037351047
have O 0 0.00013019722
been O 0 0.0001297268
treated O 0 0.00026160802
by O 0 0.00014706656
chemotherapy O 0 0.00096502324
and O 0 0.00012307681
those O 0 0.00015005658
with O 0 0.00020409454
impaired B-Disease 0 0.00310514
heart I-Disease 0 0.009780194
function I-Disease 0 0.00035093472
requires O 0 0.00027194322
careful O 0 0.0007297759
attention O 0 0.0040851706
. O 0 0.002952436

Ticlopidine B-Chemical 0 0.99971837
- O 0 0.1213686
induced O 0 0.005246872
aplastic B-Disease 0 0.9998529
anemia I-Disease 0 0.99997365
: O 0 0.003426665
report O 0 0.0008823302
of O 0 0.0003828636
three O 0 0.00019381469
Chinese O 0 0.0010185592
patients O 0 0.0007592215
and O 0 0.00046263376
review O 0 0.0008490094
of O 0 0.0007566029
the O 0 0.0009843844
literature O 0 0.0033352817
. O 0 0.003629052

In O 0 0.0020605195
this O 0 0.001863017
study O 0 0.0013748849
, O 0 0.0011663218
three O 0 0.00032829744
Chinese O 0 0.0013633104
patients O 0 0.0010837358
with O 0 0.0010071396
ticlopidine B-Chemical 0 0.9999962
- O 0 0.11735491
induced O 0 0.0009581526
aplastic B-Disease 0 0.99997485
anemia I-Disease 0 0.9999943
were O 0 0.0002680616
reported O 0 0.00019056062
and O 0 0.00016158246
another O 0 0.00021020531
13 O 0 0.00019763358
patients O 0 0.00028615538
in O 0 0.00016836899
the O 0 0.00021887431
English O 0 0.00071346207
literature O 0 0.00095729117
were O 0 0.0007923802
reviewed O 0 0.0023259947
. O 0 0.0028284395

We O 0 0.0027728847
attempted O 0 0.0024015605
to O 0 0.0010387626
find O 0 0.0006747301
underlying O 0 0.0007770283
similarities O 0 0.00044383615
, O 0 0.0006227989
evaluate O 0 0.00016028975
the O 0 0.00027366844
risk O 0 0.0017108268
factors O 0 0.00064252503
, O 0 0.0005623249
and O 0 0.00024707333
identify O 0 0.00012504264
appropriate O 0 0.00019673616
treatment O 0 0.00030247614
for O 0 0.00035505238
this O 0 0.0009133074
complication O 0 0.007911949
. O 0 0.0029464355

All O 0 0.00259555
but O 0 0.0022522793
one O 0 0.00107963
of O 0 0.00089364056
the O 0 0.0005686504
patients O 0 0.00078049215
were O 0 0.00027529197
over O 0 0.00018995836
60 O 0 0.00024031248
years O 0 0.00024840413
old O 0 0.0002693985
, O 0 0.00036835237
and O 0 0.00022676428
the O 0 0.00018477064
6 O 0 0.00019169798
who O 0 0.00036422946
died O 0 0.0005777918
were O 0 0.00029826284
all O 0 0.0004116834
older O 0 0.0017298696
than O 0 0.00092087407
65 O 0 0.0021320242
. O 0 0.0028376158

Therefore O 0 0.0027468982
, O 0 0.0043621873
old O 0 0.0025139274
age O 0 0.0021790494
may O 0 0.000991353
be O 0 0.0009436539
a O 0 0.0014655007
risk O 0 0.0064875046
factor O 0 0.0058061145
for O 0 0.0008020522
developing O 0 0.001771462
this O 0 0.0017643453
complication O 0 0.013837284
. O 0 0.00391914

Agranulocytosis B-Disease 0 0.99894124
occurred O 0 0.0024297475
3 O 0 0.0011609215
- O 0 0.0021170026
20 O 0 0.000372382
weeks O 0 0.00014978583
after O 0 0.00012562756
initiation O 0 0.00017787145
of O 0 0.0005431786
ticlopidine B-Chemical 0 0.99998903
, O 0 0.00072144176
so O 0 0.00020093384
frequent O 0 0.0002163385
examination O 0 0.00012749192
of O 0 0.00018696483
white O 0 0.00036140584
cell O 0 0.0004159441
count O 0 0.00037457934
during O 0 0.00027481522
treatment O 0 0.0004930057
is O 0 0.0006534726
recommended O 0 0.0013166141
. O 0 0.0026570319

There O 0 0.0038198757
seemed O 0 0.0022885837
to O 0 0.0010478864
be O 0 0.0006414045
no O 0 0.0003774391
direct O 0 0.00022657993
correlation O 0 0.00021480068
between O 0 0.00017451987
the O 0 0.00018287245
dose O 0 0.000302612
or O 0 0.00013218458
duration O 0 0.00010452533
used O 0 0.00014438016
and O 0 0.00021870219
the O 0 0.00023666369
severity O 0 0.00088683434
of O 0 0.0006715184
bone B-Disease 0 0.047828883
marrow I-Disease 0 0.46314958
suppression I-Disease 0 0.00848197
. O 0 0.0034365505

Treatment O 0 0.009343564
for O 0 0.0037484446
ticlopidine B-Chemical 0 0.99997485
- O 0 0.15204106
induced O 0 0.0027737115
aplastic B-Disease 0 0.9999349
anemia I-Disease 0 0.9999882
with O 0 0.0017454214
colony O 0 0.29946265
- O 0 0.020796534
stimulating O 0 0.0007767096
factors O 0 0.0007330676
seemed O 0 0.00048198685
to O 0 0.0003811244
have O 0 0.0004559109
little O 0 0.0008105538
effect O 0 0.0015385617
. O 0 0.0036155253

The O 0 0.002033822
fact O 0 0.0012223101
that O 0 0.00086928287
5 O 0 0.0006978302
of O 0 0.00050437293
the O 0 0.00029747112
6 O 0 0.00021320138
patients O 0 0.00033888716
who O 0 0.00022948963
received O 0 0.00016555944
concurrent O 0 0.00048324154
calcium B-Chemical 0 0.9950063
channel O 0 0.013430858
blockers O 0 0.9930443
died O 0 0.0019592694
, O 0 0.0003308793
should O 0 7.6131575e-05
alert O 0 0.00019092107
clinicians O 0 0.00023015228
to O 0 0.00011007571
be O 0 0.00012807583
more O 0 0.0002062336
cautious O 0 0.00034417398
when O 0 0.00013482079
using O 0 0.00018398267
these O 0 0.00027607416
two O 0 0.00032719664
drugs O 0 0.0047228
simultaneously O 0 0.0014150011
. O 0 0.0027954425

Upregulation O 0 0.0059779948
of O 0 0.0021167588
the O 0 0.0011381886
expression O 0 0.0009164455
of O 0 0.0014166394
vasopressin B-Chemical 0 0.9987571
gene O 0 0.0005628443
in O 0 0.00038602424
the O 0 0.00032026804
paraventricular O 0 0.00078310596
and O 0 0.0002810235
supraoptic O 0 0.0005931154
nuclei O 0 0.00024622487
of O 0 0.0002700604
the O 0 0.0004060823
lithium B-Chemical 0 0.9998623
- O 0 0.020909075
induced O 0 0.00127974
diabetes B-Disease 0 0.9999126
insipidus I-Disease 0 0.999853
rat O 0 0.0078793755
. O 0 0.0033897331

The O 0 0.0024239374
expression O 0 0.0021224348
of O 0 0.002874901
arginine B-Chemical 0 0.26204482
vasopressin I-Chemical 0 0.99972695
( O 0 0.024888946
AVP B-Chemical 0 0.99977237
) O 0 0.0021884826
gene O 0 0.00031839815
in O 0 0.00027985484
the O 0 0.00027294742
paraventricular O 0 0.00083945424
( O 0 0.00055015465
PVN O 0 0.0018226383
) O 0 0.0005534972
and O 0 0.0002423227
supraoptic O 0 0.00063478784
nuclei O 0 0.0002793931
( O 0 0.0005011387
SON O 0 0.0016487372
) O 0 0.00039742503
was O 0 0.00011510974
investigated O 0 0.00011111417
in O 0 0.0001261964
rats O 0 0.0002982452
with O 0 0.00036996964
lithium B-Chemical 0 0.9999145
( O 0 0.00119747
Li B-Chemical 0 0.04780052
) O 0 0.0014151899
- O 0 0.002596975
induced O 0 0.00034506197
polyuria B-Disease 0 0.99903595
, O 0 0.0007227909
using O 0 0.00023258435
in O 0 0.00031140097
situ O 0 0.00057121634
hybridization O 0 0.00037673628
histochemistry O 0 0.0010134663
and O 0 0.0012154763
radioimmunoassay O 0 0.26951742
. O 0 0.0037709738

The O 0 0.0022846763
male O 0 0.003309153
Wistar O 0 0.003979878
rats O 0 0.0014184829
consuming O 0 0.0013884868
a O 0 0.00080688286
diet O 0 0.0017729374
that O 0 0.00030372533
contained O 0 0.00032709492
LiCl B-Chemical 0 0.88748777
( O 0 0.0008342217
60 O 0 0.00042575202
mmol O 0 0.04552034
/ O 0 0.0012042416
kg O 0 0.0007037396
) O 0 0.00050722493
for O 0 0.00017752072
4 O 0 0.00021733565
weeks O 0 0.00020566669
developed O 0 0.00067624165
marked O 0 0.0019435622
polyuria B-Disease 0 0.99469733
. O 0 0.004670165

The O 0 0.0038098039
Li B-Chemical 0 0.037151366
- O 0 0.009886733
treated O 0 0.0022086788
rats O 0 0.0013841952
produced O 0 0.00060846086
a O 0 0.000818644
large O 0 0.000690275
volume O 0 0.00082609156
of O 0 0.00061209063
hypotonic O 0 0.023035835
urine O 0 0.047743168
with O 0 0.0007320678
low O 0 0.001299326
ionic O 0 0.01568555
concentrations O 0 0.0044014333
. O 0 0.0038185332

Plasma O 0 0.89683366
sodium B-Chemical 0 0.9980823
concentrations O 0 0.0035856003
were O 0 0.00085066137
found O 0 0.00055540446
to O 0 0.0003748067
be O 0 0.00033535555
slightly O 0 0.00044197193
increased O 0 0.0004176666
in O 0 0.00026808406
the O 0 0.00028458983
Li B-Chemical 0 0.015168919
- O 0 0.0024738114
treated O 0 0.00049104507
rats O 0 0.0004138132
compared O 0 0.00021889851
with O 0 0.00041550305
those O 0 0.0006387806
in O 0 0.00084557285
controls O 0 0.0022192905
. O 0 0.0031275025

Plasma O 0 0.31171626
concentration O 0 0.0050574373
of O 0 0.003255368
AVP B-Chemical 0 0.9991326
and O 0 0.0010776607
transcripts O 0 0.0005040673
of O 0 0.000982753
AVP B-Chemical 0 0.99952805
gene O 0 0.00038486675
in O 0 0.00026873665
the O 0 0.00023676411
PVN O 0 0.0019200415
and O 0 0.0002660014
SON O 0 0.0012248806
were O 0 0.0001467346
significantly O 0 0.00018785778
increased O 0 0.00024374056
in O 0 0.00018869812
the O 0 0.00023686099
Li B-Chemical 0 0.018116603
- O 0 0.0027408206
treated O 0 0.00059897866
rats O 0 0.0005772915
compared O 0 0.00036203966
with O 0 0.0008445461
controls O 0 0.0021980873
. O 0 0.0030423151

These O 0 0.0019584124
results O 0 0.0013765842
suggest O 0 0.0007786008
that O 0 0.000958431
dehydration B-Disease 0 0.5278499
and O 0 0.0008471196
/ O 0 0.0023167569
or O 0 0.0002793883
the O 0 0.0001903496
activation O 0 0.0001973415
of O 0 0.0002600074
visceral O 0 0.0018700528
afferent O 0 0.00036971204
inputs O 0 0.00011493097
may O 0 7.819682e-05
contribute O 0 8.870575e-05
to O 0 9.263165e-05
the O 0 0.00011476121
elevation O 0 0.0030879532
of O 0 0.00030511295
plasma O 0 0.27715427
AVP B-Chemical 0 0.99984276
and O 0 0.00018179559
the O 0 0.000100482524
upregulation O 0 0.00016416667
of O 0 0.00035548504
AVP B-Chemical 0 0.99982435
gene O 0 0.00016099405
expression O 0 0.00012749885
in O 0 0.0001390956
the O 0 0.00014285526
PVN O 0 0.0012224277
and O 0 0.00016268255
the O 0 0.00016226397
SON O 0 0.0010805473
of O 0 0.00025513946
the O 0 0.00030823285
Li B-Chemical 0 0.05332497
- O 0 0.009638831
induced O 0 0.0012610621
diabetes B-Disease 0 0.99991596
insipidus I-Disease 0 0.9998591
rat O 0 0.008085183
. O 0 0.0033920556

Antinociceptive O 0 0.6600049
and O 0 0.0032945336
antiamnesic O 0 0.092891775
properties O 0 0.0009778272
of O 0 0.0011903408
the O 0 0.0010378794
presynaptic O 0 0.006754932
cholinergic O 0 0.025927244
amplifier O 0 0.0054686107
PG B-Chemical 0 0.99931157
- I-Chemical 0 0.036063757
9 I-Chemical 0 0.0026745112
. O 0 0.003971653

The O 0 0.0025246523
antinociceptive O 0 0.010761751
effect O 0 0.0012017854
of O 0 0.0012941585
3 B-Chemical 0 0.0010937602
alpha I-Chemical 0 0.44401556
- I-Chemical 0 0.012686487
tropyl I-Chemical 0 0.007559283
2 I-Chemical 0 0.0005558165
- I-Chemical 0 0.0013616657
( I-Chemical 0 0.00055930327
p I-Chemical 0 0.00075665384
- I-Chemical 0 0.0036094375
bromophenyl I-Chemical 0 0.26131025
) I-Chemical 0 0.0034313824
propionate I-Chemical 0 0.9988381
[ O 0 0.0042377803
( O 0 0.0007051589
+ O 0 0.0012615246
/ O 0 0.002342017
- O 0 0.003541746
) O 0 0.0013876427
- O 0 0.017714173
PG B-Chemical 0 0.9997502
- I-Chemical 0 0.0075015295
9 I-Chemical 0 0.00023580778
] O 0 0.0007161757
( O 0 0.00034136692
10 O 0 0.00018984462
- O 0 0.0005962004
40 O 0 0.0001907042
mg O 0 0.0011743713
kg O 0 0.000494056
- O 0 0.0007852988
1 O 0 0.00019321502
s O 0 0.00024760817
. O 0 0.0001889752
c O 0 0.00071284326
. O 0 0.00020669564
; O 0 0.0003323361
30 O 0 0.0001572877
- O 0 0.0005212543
60 O 0 0.00018113099
mg O 0 0.00096365606
kg O 0 0.00044530182
- O 0 0.0006781659
1 O 0 0.00017154767
p O 0 0.00026683713
. O 0 0.00017446213
o O 0 0.0007192783
. O 0 0.00022407557
; O 0 0.0003660514
10 O 0 0.00019013413
- O 0 0.0005700915
30 O 0 0.00014532407
mg O 0 0.00093968154
kg O 0 0.00047584588
- O 0 0.0008200461
1 O 0 0.00019452766
i O 0 0.00030626555
. O 0 0.00019067802
v O 0 0.00072923984
. O 0 0.00020463331
; O 0 0.0003459482
10 O 0 0.0001898696
- O 0 0.0006370628
30 O 0 0.00015702248
micrograms O 0 0.0010641307
/ O 0 0.0006639282
mouse O 0 0.00014490563
i O 0 0.00034518176
. O 0 0.00020125826
c O 0 0.0009112082
. O 0 0.00021099429
v O 0 0.0009833459
. O 0 0.0001936826
) O 0 0.0003457931
was O 0 0.00010657033
examined O 0 8.282081e-05
in O 0 9.085142e-05
mice O 0 4.673573e-05
, O 0 0.0001898316
rats O 0 0.00019537772
and O 0 0.00012014965
guinea O 0 0.00019120931
pigs O 0 0.000106774794
by O 0 7.91477e-05
use O 0 8.134709e-05
of O 0 0.000118020216
the O 0 0.000117223324
hot O 0 0.00027664306
- O 0 0.0020827765
plate O 0 0.005046857
, O 0 0.00045272568
abdominal O 0 0.000824631
- O 0 0.0019407452
constriction O 0 0.08396103
, O 0 0.00043385683
tail O 0 0.00025186452
- O 0 0.0015981877
flick O 0 0.0017514603
and O 0 0.00050378364
paw O 0 0.0037798062
- O 0 0.0032476515
pressure O 0 0.0092924675
tests O 0 0.0036400605
. O 0 0.003287767

( O 0 0.010897887
+ O 0 0.011852574
/ O 0 0.013269935
- O 0 0.015026149
) O 0 0.0061309
- O 0 0.0632962
PG B-Chemical 0 0.99951804
- I-Chemical 0 0.02051599
9 I-Chemical 0 0.0006439372
antinociception O 0 0.19784023
peaked O 0 0.0005018198
15 O 0 0.00026599912
min O 0 0.00029615528
after O 0 0.00012638766
injection O 0 0.00021538373
and O 0 0.00038577427
then O 0 0.0005655998
slowly O 0 0.0016685558
diminished O 0 0.0028355415
. O 0 0.0036174892

The O 0 0.0030406509
antinociception O 0 0.34698832
produced O 0 0.0013750264
by O 0 0.0011402066
( O 0 0.0017635511
+ O 0 0.002920306
/ O 0 0.0046537756
- O 0 0.0064355657
) O 0 0.00247528
- O 0 0.037581686
PG B-Chemical 0 0.9997719
- I-Chemical 0 0.014343379
9 I-Chemical 0 0.0002412068
was O 0 0.0001726517
prevented O 0 0.00028333798
by O 0 0.00018910319
the O 0 0.0002295658
unselective O 0 0.7366016
muscarinic O 0 0.9980876
antagonist O 0 0.9723511
atropine B-Chemical 0 0.9999939
, O 0 0.00079602
the O 0 0.00017469667
M1 O 0 0.3875975
- O 0 0.0072310385
selective O 0 0.0004005489
antagonists O 0 0.8688513
pirenzepine B-Chemical 0 0.9999995
and O 0 0.0071854996
dicyclomine B-Chemical 0 0.9999993
and O 0 0.0005972696
the O 0 0.00056634995
acetylcholine B-Chemical 1 0.99998975
depletor O 0 0.9999832
hemicholinium B-Chemical 0 0.99999714
- I-Chemical 0 0.083110385
3 I-Chemical 0 0.00011516343
, O 0 0.00020066599
but O 0 0.00011428475
not O 0 8.0539096e-05
by O 0 0.000100930025
the O 0 0.00014333814
opioid O 0 0.9145114
antagonist O 0 0.8707939
naloxone B-Chemical 0 0.9999895
, O 0 0.0008996084
the O 0 0.00025961455
gamma B-Chemical 0 0.95365816
- I-Chemical 0 0.97261465
aminobutyric I-Chemical 0 0.99998987
acidB I-Chemical 0 0.99867046
antagonist O 0 0.6861921
3 B-Chemical 0 0.00032842235
- I-Chemical 0 0.01039515
aminopropyl I-Chemical 0 0.4970669
- I-Chemical 0 0.28348142
diethoxy I-Chemical 0 0.9995815
- I-Chemical 0 0.7829844
methyl I-Chemical 0 0.99946994
- I-Chemical 0 0.9276581
phosphinic I-Chemical 0 0.99960583
acid I-Chemical 0 0.9884862
, O 0 0.0015550829
the O 0 0.00026361356
H3 O 0 0.0018366117
agonist O 0 0.32237718
R B-Chemical 0 0.9994906
- I-Chemical 0 0.07008713
( I-Chemical 0 0.00090404303
alpha I-Chemical 0 0.60176724
) I-Chemical 0 0.0036192667
- I-Chemical 0 0.122894876
methylhistamine I-Chemical 0 0.99966514
, O 0 0.0009351452
the O 0 0.000358797
D2 O 0 0.99930835
antagonist O 0 0.982285
quinpirole B-Chemical 0 0.999992
, O 0 0.00056386256
the O 0 0.000116185365
5 B-Chemical 0 0.00013489704
- I-Chemical 0 0.0007462739
hydroxytryptamine4 I-Chemical 0 0.00035453486
antagonist O 0 0.049159363
2 B-Chemical 0 0.00040022327
- I-Chemical 0 0.012110506
methoxy I-Chemical 0 0.99463046
- I-Chemical 0 0.009906086
4 I-Chemical 0 0.00023547593
- I-Chemical 0 0.003615644
amino I-Chemical 0 0.24582978
- I-Chemical 0 0.011004154
5 I-Chemical 0 0.0003335531
- I-Chemical 0 0.016605554
chlorobenzoic I-Chemical 0 0.70400363
acid I-Chemical 0 0.8061975
2 I-Chemical 0 0.000620469
- I-Chemical 0 0.009120395
( I-Chemical 0 0.0012140566
diethylamino I-Chemical 0 0.99583745
) I-Chemical 0 0.117845744
ethyl I-Chemical 0 0.9999579
ester I-Chemical 0 0.99988353
hydrochloride O 0 0.9998197
, O 0 0.0006014523
the O 0 0.00012493014
5 B-Chemical 0 0.00014240225
- I-Chemical 0 0.00074062526
hydroxytryptamin1A I-Chemical 0 0.00033431046
antagonist O 0 0.01866386
1 B-Chemical 0 0.00031379142
- I-Chemical 0 0.0013574376
( I-Chemical 0 0.00039043432
2 I-Chemical 0 0.00028243527
- I-Chemical 0 0.0031620085
methoxyphenyl I-Chemical 0 0.8285908
) I-Chemical 0 0.0010403275
- I-Chemical 0 0.0012861553
4 I-Chemical 0 0.00018605839
- I-Chemical 0 0.0009715247
[ I-Chemical 0 0.00072388485
4 I-Chemical 0 0.00018936011
- I-Chemical 0 0.0009287449
( I-Chemical 0 0.00040266485
2 I-Chemical 0 0.0003240111
- I-Chemical 0 0.0036923739
phthalimido I-Chemical 0 0.8751802
) I-Chemical 0 0.005449397
butyl I-Chemical 0 0.9994085
] I-Chemical 0 0.66292363
piperazine I-Chemical 0 0.9999831
hydrobromide O 0 0.9999399
and O 0 0.0010171343
the O 0 0.0009139494
polyamines O 0 0.99676657
depletor O 0 0.9999517
reserpine B-Chemical 0 0.999992
. O 0 0.007935359

Based O 0 0.0044455216
on O 0 0.0015477056
these O 0 0.0014254383
data O 0 0.0014972569
, O 0 0.0018366065
it O 0 0.0010236151
can O 0 0.00039339837
be O 0 0.00037336256
postulated O 0 0.00038429812
that O 0 0.00025243039
( O 0 0.0006730866
+ O 0 0.0015076782
/ O 0 0.003008093
- O 0 0.004546223
) O 0 0.0015521803
- O 0 0.026283305
PG B-Chemical 0 0.99980813
- I-Chemical 0 0.0075666485
9 I-Chemical 0 0.00016992309
exerted O 0 0.00021156398
an O 0 0.00023336872
antinociceptive O 0 0.0050174445
effect O 0 0.00014713657
mediated O 0 0.00012673426
by O 0 0.00024242184
a O 0 0.00047770608
central O 0 0.0006901447
potentiation O 0 0.006086002
of O 0 0.00090460276
cholinergic O 0 0.034177683
transmission O 0 0.0012242385
. O 0 0.0023162565

( O 0 0.011256023
+ O 0 0.012229553
/ O 0 0.01365063
- O 0 0.015227871
) O 0 0.0062311026
- O 0 0.052174315
PG B-Chemical 0 0.99939406
- I-Chemical 0 0.010820077
9 I-Chemical 0 0.0005487104
( O 0 0.0006757765
10 O 0 0.00035892767
- O 0 0.0009206578
40 O 0 0.0002977327
mg O 0 0.0015529166
kg O 0 0.00067312445
- O 0 0.001016204
1 O 0 0.0002217944
i O 0 0.00030873602
. O 0 0.00017352658
p O 0 0.0003190609
. O 0 0.00019301249
) O 0 0.00039446546
was O 0 0.00014014711
able O 0 0.00011244996
to O 0 0.00014698133
prevent O 0 0.00024815556
amnesia B-Disease 0 0.99987245
induced O 0 0.00031920781
by O 0 0.00051435153
scopolamine B-Chemical 0 0.99999845
( O 0 0.000696941
1 O 0 0.00018040636
mg O 0 0.0012589121
kg O 0 0.00037282475
- O 0 0.0006148132
1 O 0 0.0001288392
i O 0 0.00019576315
. O 0 0.00011215343
p O 0 0.00022127159
. O 0 0.00014308402
) O 0 0.00042095702
and O 0 0.00038316302
dicyclomine B-Chemical 0 0.99999285
( O 0 0.00056721317
2 O 0 0.00020366588
mg O 0 0.0015435398
kg O 0 0.00047239396
- O 0 0.0007700803
1 O 0 0.0001702494
i O 0 0.00026056054
. O 0 0.00015710994
p O 0 0.00030809594
. O 0 0.00020373135
) O 0 0.000431995
in O 0 0.00020731699
the O 0 0.0002173259
mouse O 0 0.00028906853
passive O 0 0.0007130974
- O 0 0.0027047223
avoidance O 0 0.0024073194
test O 0 0.0025018584
. O 0 0.003369428

Affinity O 0 0.0064424113
profiles O 0 0.0019582177
of O 0 0.0019120903
( O 0 0.002652184
+ O 0 0.003985337
/ O 0 0.005754034
- O 0 0.00745549
) O 0 0.0029542993
- O 0 0.035732027
PG B-Chemical 0 0.9997067
- I-Chemical 0 0.01551881
9 I-Chemical 0 0.00031143663
for O 0 0.00026168436
muscarinic O 0 0.8004021
receptor O 0 0.0014186442
subtypes O 0 0.0006322818
, O 0 0.00035039734
determined O 0 0.00011775324
by O 0 0.00011454692
functional O 0 0.0001133169
studies O 0 0.00020936463
( O 0 0.0003856531
rabbit O 0 0.0004866996
vas O 0 0.54761595
deferens O 0 0.49246332
for O 0 0.00015937016
M1 O 0 0.03569386
, O 0 0.000308976
guinea O 0 0.00024929811
pig O 0 0.0001577392
atrium O 0 0.029985966
for O 0 0.000145873
M2 O 0 0.02172072
, O 0 0.0003489886
guinea O 0 0.00031129533
pig O 0 0.00019801705
ileum O 0 0.03068943
for O 0 0.00016875056
M3 O 0 0.8220038
and O 0 0.0001924784
immature O 0 0.00044063566
guinea O 0 0.0002949436
pig O 0 0.00014364671
uterus O 0 0.00039529926
for O 0 8.723514e-05
putative O 0 0.00011354577
M4 O 0 0.99130577
) O 0 0.0007958888
, O 0 0.00029971832
have O 0 0.00011036021
shown O 0 7.789346e-05
an O 0 0.00026746292
M4 O 0 0.9960861
/ O 0 0.009200702
M1 O 0 0.07809239
selectivity O 0 0.0003126224
ratio O 0 0.00016214859
of O 0 0.00015021121
10 O 0 0.00013543424
. O 0 9.8902296e-05
2 O 0 9.3273644e-05
that O 0 5.561474e-05
might O 0 4.801602e-05
be O 0 7.753212e-05
responsible O 0 6.577909e-05
for O 0 6.938004e-05
the O 0 0.000103579856
antinociception O 0 0.40479854
and O 0 0.00013105193
the O 0 0.00010808747
anti O 0 0.0006843839
- O 0 0.13168511
amnesic B-Disease 0 0.9999907
effect O 0 0.00017184445
induced O 0 0.00017038874
by O 0 0.00019009603
( O 0 0.0004486435
+ O 0 0.0011063858
/ O 0 0.0024418344
- O 0 0.003959854
) O 0 0.001296358
- O 0 0.025464935
PG B-Chemical 0 0.99982244
- I-Chemical 0 0.00806386
9 I-Chemical 0 0.00019916719
through O 0 0.00017058707
an O 0 0.00029589448
increase O 0 0.000369495
in O 0 0.00077657495
acetylcholine B-Chemical 1 0.9992619
extracellular O 0 0.0040146667
levels O 0 0.0017053693
. O 0 0.0031725077

In O 0 0.0019575765
the O 0 0.00167095
antinociceptive O 0 0.014332031
and O 0 0.0010725417
antiamnesic O 0 0.07761663
dose O 0 0.00095115986
range O 0 0.00042762552
, O 0 0.00061010045
( O 0 0.00065278594
+ O 0 0.0013247611
/ O 0 0.0025776557
- O 0 0.0042837253
) O 0 0.0017337151
- O 0 0.03931035
PG B-Chemical 0 0.9998548
- I-Chemical 0 0.025243139
9 I-Chemical 0 0.00021561714
did O 0 0.00018265564
not O 0 0.00013068081
impair O 0 0.00014051094
mouse O 0 0.00011036938
performance O 0 0.00019027157
evaluated O 0 0.0001621475
by O 0 0.00017917415
the O 0 0.00023531324
rota O 0 0.015188592
- O 0 0.0027139257
rod O 0 0.0016193275
test O 0 0.0007774371
and O 0 0.00087875087
Animex O 0 0.004999283
apparatus O 0 0.002918449
. O 0 0.0031960935

The O 0 0.0017597685
effect O 0 0.0012305772
of O 0 0.001147775
different O 0 0.0006557785
anaesthetic O 0 0.0026759976
agents O 0 0.0012740955
in O 0 0.00060878077
hearing B-Disease 0 0.04356129
loss I-Disease 0 0.0007909261
following O 0 0.00045764627
spinal O 0 0.0012536531
anaesthesia O 0 0.005295607
. O 0 0.002701762

The O 0 0.002883937
cause O 0 0.0029280998
of O 0 0.002235832
hearing B-Disease 0 0.11828261
loss I-Disease 0 0.0014995878
after O 0 0.00061726006
spinal O 0 0.0012829491
anaesthesia O 0 0.0037497876
is O 0 0.0012652314
unknown O 0 0.002516414
. O 0 0.004271762

Up O 0 0.011402966
until O 0 0.0016938346
now O 0 0.0016090614
, O 0 0.0018233531
the O 0 0.0007015106
only O 0 0.000803961
factor O 0 0.0044285986
studied O 0 0.0006527658
has O 0 0.00019065983
been O 0 0.00017575762
the O 0 0.0001232256
effect O 0 0.00012435738
of O 0 0.00017631557
the O 0 0.00014177388
diameter O 0 0.0011239896
of O 0 0.00016665166
the O 0 0.00010851069
spinal O 0 0.00015695662
needle O 0 0.00014256827
on O 0 0.000101908445
post O 0 0.00019735676
- O 0 0.0012643496
operative O 0 0.0010223853
sensorineural B-Disease 0 0.9994253
hearing I-Disease 0 0.6682204
loss I-Disease 0 0.0043263678
. O 0 0.0032151896

The O 0 0.0016669204
aim O 0 0.0010745095
of O 0 0.0011675645
this O 0 0.0008668635
study O 0 0.0006726124
was O 0 0.0003524942
to O 0 0.0002341809
describe O 0 0.00023596566
this O 0 0.00029092425
hearing B-Disease 0 0.106446825
loss I-Disease 0 0.00029209378
and O 0 0.00016678394
to O 0 0.000104165636
investigate O 0 6.032533e-05
other O 0 0.00014426674
factors O 0 0.00032800934
influencing O 0 0.00016938943
the O 0 0.00024829878
degree O 0 0.0006486708
of O 0 0.00091447774
hearing B-Disease 0 0.44016892
loss I-Disease 0 0.0026174418
. O 0 0.0029364142

Two O 0 0.0024207442
groups O 0 0.002227086
of O 0 0.0014120355
22 O 0 0.0012390733
similar O 0 0.0004499993
patients O 0 0.0007780441
were O 0 0.00032828614
studied O 0 0.00040795852
: O 0 0.0004786124
one O 0 0.00017365007
group O 0 0.00024841644
received O 0 0.00017684222
6 O 0 0.00017504682
mL O 0 0.003630789
prilocaine B-Chemical 0 0.99991894
2 O 0 0.00026176075
% O 0 0.0003361702
; O 0 0.00029259716
and O 0 0.00014626885
the O 0 0.00011935227
other O 0 0.00014885778
received O 0 0.00021336142
3 O 0 0.00028787626
mL O 0 0.0048296303
bupivacaine B-Chemical 0 0.9997986
0 O 0 0.0007564029
. O 0 0.00056827115
5 O 0 0.00081037113
% O 0 0.0022394496
. O 0 0.0029341688

Patients O 0 0.004752118
given O 0 0.0019852717
prilocaine B-Chemical 0 0.9998331
were O 0 0.0008546237
more O 0 0.00066575274
likely O 0 0.0002281949
to O 0 0.00023719341
develop O 0 0.0003201319
hearing B-Disease 0 0.04757721
loss I-Disease 0 0.0003820573
( O 0 0.00038758104
10 O 0 0.00015923937
out O 0 0.00010936456
of O 0 0.0001564932
22 O 0 0.00023278715
) O 0 0.00029369496
than O 0 0.00011094434
those O 0 0.00016272771
given O 0 0.0001741236
bupivacaine B-Chemical 0 0.99993587
( O 0 0.0004013584
4 O 0 0.0001310388
out O 0 0.00013050197
of O 0 0.00023179114
22 O 0 0.00041600267
) O 0 0.00064080657
( O 0 0.000650649
P O 0 0.0049404507
< O 0 0.0008101672
0 O 0 0.00084092293
. O 0 0.0010277692
05 O 0 0.01291167
) O 0 0.0047247126
. O 0 0.0042374106

The O 0 0.0019188401
average O 0 0.0015946203
hearing B-Disease 0 0.029820003
loss I-Disease 0 0.001175344
for O 0 0.0005781694
speech O 0 0.0051895897
frequencies O 0 0.00036362317
was O 0 0.0002992649
about O 0 0.00032162812
10 O 0 0.00028808825
dB O 0 0.000695708
after O 0 0.00026504704
prilocaine B-Chemical 0 0.99961096
and O 0 0.00048374367
15 O 0 0.0004553999
dB O 0 0.0013332448
after O 0 0.0007888997
bupivacaine B-Chemical 0 0.99921453
. O 0 0.0035943983

None O 0 0.005042023
of O 0 0.002969362
the O 0 0.001988972
patients O 0 0.003219161
complained O 0 0.003720358
of O 0 0.0017875937
subjective O 0 0.004423195
hearing B-Disease 0 0.21045859
loss I-Disease 0 0.0049275937
. O 0 0.0056331893

Long O 0 0.012611783
- O 0 0.010147007
term O 0 0.0024044802
follow O 0 0.0014403666
- O 0 0.004210335
up O 0 0.0012437758
of O 0 0.0010569869
the O 0 0.00093571516
patients O 0 0.0018314326
was O 0 0.0011588566
not O 0 0.0013823113
possible O 0 0.0020480969
. O 0 0.0048190467

A O 0 0.07051261
transient O 0 0.01021185
neurological B-Disease 0 0.9976674
deficit I-Disease 0 0.91069615
following O 0 0.00045127343
intrathecal O 0 0.002579045
injection O 0 0.0002558683
of O 0 0.00030563172
1 O 0 0.00039669962
% O 0 0.001065326
hyperbaric O 0 0.99834013
bupivacaine B-Chemical 0 0.99991596
for O 0 0.00038526964
unilateral O 0 0.004302459
spinal O 0 0.0010017568
anaesthesia O 0 0.004254155
. O 0 0.0020703422

We O 0 0.00249269
describe O 0 0.0017601168
a O 0 0.0017455302
case O 0 0.0009613306
of O 0 0.00081252266
transient O 0 0.003099737
neurological B-Disease 0 0.9994074
deficit I-Disease 0 0.97989136
that O 0 0.00018645231
occurred O 0 0.00015048114
after O 0 7.352603e-05
unilateral O 0 0.0010575138
spinal O 0 0.0001506244
anaesthesia O 0 0.00046304407
with O 0 8.860125e-05
8 O 0 9.776676e-05
mg O 0 0.0007853246
of O 0 0.00012436094
1 O 0 0.00017307945
% O 0 0.0005737599
hyperbaric O 0 0.9993284
bupivacaine B-Chemical 0 0.9999763
slowly O 0 0.00027476178
injected O 0 0.00010178957
through O 0 0.000106596155
a O 0 0.00024306016
25 O 0 0.00031364037
- O 0 0.0009738193
gauge O 0 0.00074464857
pencil O 0 0.0017461502
- O 0 0.001702741
point O 0 0.00041377344
spinal O 0 0.0010006097
needle O 0 0.001605716
. O 0 0.0026386194

The O 0 0.0019915977
surgery O 0 0.0021562644
and O 0 0.0011931742
anaesthesia O 0 0.0029899317
were O 0 0.0005006123
uneventful O 0 0.00068793865
, O 0 0.0005745395
but O 0 0.00028568268
3 O 0 0.00015505006
days O 0 9.386729e-05
after O 0 8.599188e-05
surgery O 0 0.00020992273
, O 0 0.00023728707
the O 0 0.00012749885
patient O 0 0.00018690404
reported O 0 0.00015685293
an O 0 0.00015772734
area O 0 0.00019548544
of O 0 0.00017926437
hypoaesthesia O 0 0.02344514
over O 0 0.00013023657
L3 O 0 0.0010569384
- O 0 0.0022067335
L4 O 0 0.0014506757
dermatomes O 0 0.00061058503
of O 0 0.0001324445
the O 0 0.00011693708
leg O 0 0.0006448516
which O 0 0.00016562165
had O 0 0.00012940062
been O 0 0.000121541416
operated O 0 0.00035057674
on O 0 9.157439e-05
( O 0 0.0002328091
loss B-Disease 0 0.00016681763
of I-Disease 0 0.00018790754
pinprick I-Disease 0 0.0016564124
sensation I-Disease 0 0.0021992119
) O 0 0.00052951963
without O 0 0.00029436382
reduction O 0 0.0005948137
in O 0 0.0007859558
muscular O 0 0.07321342
strength O 0 0.0019659896
. O 0 0.0029108438

Sensation O 0 0.018980019
in O 0 0.0027478533
this O 0 0.0019298051
area O 0 0.001712528
returned O 0 0.0009516031
to O 0 0.00063311245
normal O 0 0.000936075
over O 0 0.00049478834
the O 0 0.00052230724
following O 0 0.0005231794
2 O 0 0.0010937246
weeks O 0 0.0010012873
. O 0 0.0031461827

Prospective O 0 0.027307693
multicentre O 0 0.024165206
studies O 0 0.0014698774
with O 0 0.0009191512
a O 0 0.00094168016
large O 0 0.0006707352
population O 0 0.0005286197
and O 0 0.00031836177
a O 0 0.0003378396
long O 0 0.00021707555
follow O 0 0.00015358141
- O 0 0.0008823864
up O 0 0.00017282712
should O 0 7.677637e-05
be O 0 0.00010947538
performed O 0 0.000102609454
in O 0 0.00010434977
order O 0 7.946685e-05
to O 0 9.3091585e-05
evaluate O 0 6.6366694e-05
the O 0 0.00015259058
incidence O 0 0.00044003245
of O 0 0.00036255413
this O 0 0.0005437925
unusual O 0 0.0015942962
side O 0 0.0022619793
effect O 0 0.0016368289
. O 0 0.003542803

However O 0 0.0030319733
, O 0 0.0030199138
we O 0 0.0006782318
suggest O 0 0.00046532592
that O 0 0.00047879358
a O 0 0.00074892887
low O 0 0.00067497225
solution O 0 0.0012610201
concentration O 0 0.00049337663
should O 0 9.446657e-05
be O 0 0.000106591986
preferred O 0 9.234113e-05
for O 0 8.899856e-05
unilateral O 0 0.0013024992
spinal O 0 0.00016133704
anaesthesia O 0 0.00065294217
with O 0 0.00011369247
a O 0 0.00029088266
hyperbaric O 0 0.992605
anaesthetic O 0 0.0020560543
solution O 0 0.00028904484
( O 0 0.0001685338
if O 0 6.629295e-05
pencil O 0 0.0006136584
- O 0 0.0005481395
point O 0 5.9547372e-05
needle O 0 0.000104315935
and O 0 9.0713336e-05
slow O 0 0.00018579671
injection O 0 8.041784e-05
rate O 0 0.00012884778
are O 0 7.0889764e-05
employed O 0 0.00012114235
) O 0 0.0003549476
, O 0 0.00022235316
in O 0 9.361672e-05
order O 0 6.308056e-05
to O 0 6.9250884e-05
minimize O 0 4.86379e-05
the O 0 9.411016e-05
risk O 0 0.00080672756
of O 0 0.00014342171
a O 0 0.00017553288
localized O 0 6.5027605e-05
high O 0 0.00011900384
peak O 0 0.0001553628
anaesthetic O 0 0.0013227144
concentration O 0 0.00031021424
, O 0 0.0003263819
which O 0 0.0001909524
might O 0 0.00011854638
lead O 0 0.0010829082
to O 0 0.0002887782
a O 0 0.0007584976
transient O 0 0.0028710507
neurological B-Disease 0 0.9987205
deficit I-Disease 0 0.9925568
. O 0 0.0038971396

Transient B-Disease 0 0.073776774
neurologic I-Disease 0 0.85750145
symptoms I-Disease 0 0.019833378
after O 0 0.0003627588
spinal O 0 0.00054874335
anesthesia O 0 0.0016033584
: O 0 0.0005569315
a O 0 0.00032944873
lower O 0 0.00029605674
incidence O 0 0.0005272789
with O 0 0.0006050896
prilocaine B-Chemical 0 0.9999746
and O 0 0.0011025345
bupivacaine B-Chemical 0 0.9999428
than O 0 0.0006025189
with O 0 0.0013200822
lidocaine B-Chemical 0 0.9995623
. O 0 0.0032202108

BACKGROUND O 0 0.0142751485
: O 0 0.0035987198
Recent O 0 0.0011985404
evidence O 0 0.0006352491
suggests O 0 0.0003971548
that O 0 0.00042792544
transient B-Disease 0 0.0032503232
neurologic I-Disease 0 0.95072675
symptoms I-Disease 0 0.21588816
( O 0 0.0008564917
TNSs B-Disease 0 0.10093562
) O 0 0.00052493217
frequently O 0 0.00017066143
follow O 0 0.0001470747
lidocaine B-Chemical 0 0.9989931
spinal O 0 0.00031736592
anesthesia O 0 0.0011701366
but O 0 0.00026629225
are O 0 0.00025893794
infrequent O 0 0.0009378671
with O 0 0.0014285524
bupivacaine B-Chemical 0 0.9998354
. O 0 0.003420444

However O 0 0.0028808943
, O 0 0.0030755203
identification O 0 0.0009766207
of O 0 0.0009269671
a O 0 0.00090806396
short O 0 0.0005266249
- O 0 0.0018362096
acting O 0 0.0003214166
local O 0 0.00031608684
anesthetic O 0 0.0017998804
to O 0 0.00013616287
substitute O 0 0.00012548054
for O 0 0.00017281475
lidocaine B-Chemical 0 0.999263
for O 0 0.000140213
brief O 0 0.00018105019
surgical O 0 0.00026914
procedures O 0 0.00019924296
remains O 0 0.00020773963
an O 0 0.0005078689
important O 0 0.0005589656
goal O 0 0.0016197738
. O 0 0.0030550312

Prilocaine B-Chemical 0 0.99721813
is O 0 0.0027242089
an O 0 0.0022957951
amide O 0 0.046429485
local O 0 0.0009481369
anesthetic O 0 0.004515962
with O 0 0.00036757323
a O 0 0.00034696105
duration O 0 0.00016125309
of O 0 0.00025017388
action O 0 0.00029857896
similar O 0 0.00024288986
to O 0 0.0003735471
that O 0 0.0005528447
of O 0 0.001955278
lidocaine B-Chemical 0 0.9996531
. O 0 0.004299772

Accordingly O 0 0.002474189
, O 0 0.0031267118
the O 0 0.001024686
present O 0 0.0007187441
, O 0 0.0012341775
prospective O 0 0.0017677558
double O 0 0.00048100506
- O 0 0.003273477
blind O 0 0.009068126
study O 0 0.0003400333
compares O 0 0.00029736222
prilocaine B-Chemical 0 0.99997044
with O 0 0.000516481
lidocaine B-Chemical 0 0.9999571
and O 0 0.00042938013
bupivacaine B-Chemical 0 0.99997234
with O 0 0.00012448612
respect O 0 7.0550006e-05
to O 0 7.129972e-05
duration O 0 7.1298906e-05
of O 0 0.00014329402
action O 0 0.00021193465
and O 0 0.00029596107
relative O 0 0.0003524205
risk O 0 0.0047953604
of O 0 0.0018845003
TNSs B-Disease 0 0.6128475
. O 0 0.003349543

METHODS O 0 0.0037216912
: O 0 0.0026925795
Ninety O 0 0.0018953065
patients O 0 0.0010775723
classified O 0 0.0006277505
as O 0 0.00040420165
American O 0 0.00045767636
Society O 0 0.00029107745
of O 0 0.00023697056
Anesthesiologists O 0 0.00019864923
physical O 0 0.00029447384
status O 0 0.00026230907
I O 0 0.0039961594
or O 0 0.000292764
II O 0 0.015806504
who O 0 0.00026652619
were O 0 8.853622e-05
scheduled O 0 4.9519833e-05
for O 0 5.1240397e-05
short O 0 6.775436e-05
gynecologic O 0 0.00012707138
procedures O 0 6.581963e-05
under O 0 6.1080114e-05
spinal O 0 0.00011231033
anesthesia O 0 0.00038047275
were O 0 5.7536476e-05
randomly O 0 3.8912403e-05
allocated O 0 8.304295e-05
to O 0 7.097581e-05
receive O 0 9.0552145e-05
2 O 0 0.00011077025
. O 0 9.639041e-05
5 O 0 0.000102088095
ml O 0 0.0003312082
2 O 0 0.00016048184
% O 0 0.0004475801
lidocaine B-Chemical 0 0.99955016
in O 0 0.00014722231
7 O 0 0.00010600923
. O 0 0.000116439805
5 O 0 0.00013119908
% O 0 0.00041553655
glucose B-Chemical 1 0.9874884
, O 0 0.0005043335
2 O 0 0.00024807133
% O 0 0.0007588147
prilocaine B-Chemical 0 0.99995625
in O 0 0.00017191298
7 O 0 0.000114184644
. O 0 0.00012179376
5 O 0 0.00013675557
% O 0 0.00043913638
glucose B-Chemical 1 0.9891607
, O 0 0.0004735326
or O 0 0.0001745821
0 O 0 0.00025578175
. O 0 0.00017880567
5 O 0 0.00020100591
% O 0 0.0006970077
bupivacaine B-Chemical 0 0.99982053
in O 0 0.00033609202
7 O 0 0.0002948365
. O 0 0.00041322212
5 O 0 0.0006426074
% O 0 0.0022014042
glucose B-Chemical 1 0.98158526
. O 0 0.0045181927

All O 0 0.0026749517
solutions O 0 0.0030311577
were O 0 0.0013529069
provided O 0 0.0008998532
in O 0 0.0010107096
blinded O 0 0.0018800551
vials O 0 0.0027432106
by O 0 0.001015333
the O 0 0.0010985751
hospital O 0 0.0024755273
pharmacy O 0 0.007853831
. O 0 0.0046562855

Details O 0 0.0015850497
of O 0 0.0016974742
spinal O 0 0.0015792579
puncture O 0 0.0022517368
, O 0 0.0009931655
extension O 0 0.0004156356
and O 0 0.00033438025
regression O 0 0.00035794458
of O 0 0.00026866133
spinal O 0 0.00031627194
block O 0 0.00023293923
, O 0 0.00037951223
and O 0 0.00020636285
the O 0 0.00015040726
times O 0 0.00013088644
to O 0 0.00019226015
reach O 0 0.00034168197
discharge O 0 0.00041509426
criteria O 0 0.00050962967
were O 0 0.0006951464
noted O 0 0.0014639985
. O 0 0.002945637

In O 0 0.0018361834
the O 0 0.001445101
evening O 0 0.0018925654
of O 0 0.00076293666
postoperative O 0 0.00072966743
day O 0 0.00030985687
1 O 0 0.00036334613
, O 0 0.0004590311
patients O 0 0.00038116233
were O 0 0.00015487912
evaluated O 0 0.00015239717
for O 0 0.00015683094
TNSs B-Disease 0 0.016881516
by O 0 0.00016354391
a O 0 0.000256993
physician O 0 0.000498823
unaware O 0 0.00029464235
of O 0 0.0001723752
the O 0 0.000147082
drug O 0 0.0027117685
administered O 0 0.00026879917
and O 0 0.00015944343
the O 0 0.00013266987
details O 0 0.000118754906
of O 0 0.0003079362
the O 0 0.00043172017
anesthetic O 0 0.0053648124
procedure O 0 0.0010089042
. O 0 0.0021960398

RESULTS O 0 0.004280576
: O 0 0.0028244385
Nine O 0 0.0013499485
of O 0 0.0007428426
30 O 0 0.0005033443
patients O 0 0.0006617532
receiving O 0 0.00063733576
lidocaine B-Chemical 0 0.9996586
experienced O 0 0.0006500014
TNSs B-Disease 0 0.11027701
, O 0 0.000401174
1 O 0 0.00017287394
of O 0 0.00013433764
30 O 0 0.00011517529
patients O 0 0.00021651761
receiving O 0 0.0002731101
prilocaine B-Chemical 0 0.9999417
( O 0 0.00046962517
P O 0 0.018091708
= O 0 0.00052446435
0 O 0 0.00021197829
. O 0 0.00016719854
03 O 0 0.0013898583
) O 0 0.00037607725
had O 0 0.00015621723
them O 0 0.00023376287
, O 0 0.00031595185
and O 0 0.00017890715
none O 0 0.00019224711
of O 0 0.00022086543
30 O 0 0.00020897931
patients O 0 0.0004722688
receiving O 0 0.00070337096
bupivacaine B-Chemical 0 0.9998591
had O 0 0.0014109603
TNSs B-Disease 0 0.17845519
. O 0 0.002758228

Times O 0 0.0049588177
to O 0 0.0020287356
ambulate O 0 0.0034602059
and O 0 0.0008888299
to O 0 0.0005123624
void O 0 0.00067350426
were O 0 0.00028437993
similar O 0 0.0001769237
after O 0 0.0002006878
lidocaine B-Chemical 0 0.99959105
and O 0 0.0005958241
prilocaine B-Chemical 0 0.999964
( O 0 0.0004223001
150 O 0 0.00019650316
vs O 0 0.00020801493
. O 0 0.00014230519
165 O 0 0.0003171953
min O 0 0.00020752463
and O 0 0.00014386821
238 O 0 0.00036923637
vs O 0 0.00021313412
. O 0 0.00014965818
253 O 0 0.0004372396
min O 0 0.00024687932
, O 0 0.00026466345
respectively O 0 0.000318349
) O 0 0.00038975858
but O 0 0.00016547076
prolonged O 0 0.00020569983
after O 0 0.00013543683
bupivacaine B-Chemical 0 0.9999269
( O 0 0.00041113005
200 O 0 0.00028599496
and O 0 0.0002021493
299 O 0 0.0008527599
min O 0 0.0003679631
, O 0 0.00041400047
respectively O 0 0.0005037063
; O 0 0.000731342
P O 0 0.004632057
< O 0 0.00080857164
0 O 0 0.00084530906
. O 0 0.001039108
05 O 0 0.012735958
) O 0 0.00477978
. O 0 0.004301519

CONCLUSIONS O 0 0.05230526
: O 0 0.011817195
Prilocaine B-Chemical 0 0.9961249
may O 0 0.00079583155
be O 0 0.00046343997
preferable O 0 0.00032648805
to O 0 0.00035409947
lidocaine B-Chemical 0 0.999097
for O 0 0.0001550715
short O 0 0.00013097707
surgical O 0 0.00019535144
procedures O 0 0.00011549213
because O 0 9.71343e-05
it O 0 0.00019078296
has O 0 8.893299e-05
a O 0 0.00015984896
similar O 0 7.377424e-05
duration O 0 8.2223996e-05
of O 0 0.00016178165
action O 0 0.00024063072
but O 0 0.0003416919
a O 0 0.000514765
lower O 0 0.00058092276
incidence O 0 0.0013266954
of O 0 0.0015889835
TNSs B-Disease 0 0.44397312
. O 0 0.003308742

Suxamethonium B-Chemical 0 0.99516594
- O 0 0.03072404
induced O 0 0.0025619431
cardiac B-Disease 0 0.18234968
arrest I-Disease 0 0.22716069
and O 0 0.0017019867
death B-Disease 0 0.26902378
following O 0 0.0004967786
5 O 0 0.00056547916
days O 0 0.0004538783
of O 0 0.0011497983
immobilization O 0 0.0028140654
. O 0 0.0040536625

The O 0 0.0021059457
present O 0 0.0015892878
report O 0 0.0022266349
describes O 0 0.0012355831
a O 0 0.000969309
case O 0 0.000579977
of O 0 0.0005736054
cardiac B-Disease 0 0.11066177
arrest I-Disease 0 0.10656114
and O 0 0.00034526174
subsequent O 0 0.00024244866
death B-Disease 0 0.43094018
as O 0 0.00019288738
a O 0 0.0002260166
result O 0 0.00011911271
of O 0 0.0002075563
hyperkalaemia B-Disease 0 0.9988745
following O 0 8.0374986e-05
the O 0 8.083402e-05
use O 0 0.00010607758
of O 0 0.0002604982
suxamethonium B-Chemical 0 0.99954236
in O 0 0.00019698696
a O 0 0.000319972
23 O 0 0.00041193858
- O 0 0.001216063
year O 0 0.00035616974
- O 0 0.0016708069
old O 0 0.0010297933
Malawian O 0 0.0030649565
woman O 0 0.004564818
. O 0 0.0034070653

Five O 0 0.0025773065
days O 0 0.0010141085
after O 0 0.000570872
the O 0 0.0005874134
onset O 0 0.0007727086
of O 0 0.00047476712
the O 0 0.0003769168
symptoms O 0 0.002764021
of O 0 0.0005596696
meningitis B-Disease 0 0.98866045
, O 0 0.0006345423
the O 0 0.00021510788
patient O 0 0.00031552502
aspirated O 0 0.0005191102
stomach O 0 0.0024150019
contents O 0 0.0006929315
and O 0 0.00040781312
needed O 0 0.00040182064
endotracheal O 0 0.0011432153
intubation O 0 0.0023033428
. O 0 0.002170242

Forty O 0 0.0052359747
seconds O 0 0.0017123397
after O 0 0.00073672045
injection O 0 0.0008631635
of O 0 0.0015015347
suxamethonium B-Chemical 0 0.99911994
, O 0 0.0031862794
bradycardia B-Disease 0 0.9929812
and O 0 0.0015294373
cardiac B-Disease 0 0.062749445
arrest I-Disease 0 0.09306488
occurred O 0 0.0028344132
. O 0 0.004057615

Attempts O 0 0.007491323
to O 0 0.004641009
resuscitate O 0 0.021848705
the O 0 0.002407537
patient O 0 0.0024874276
were O 0 0.0019454401
not O 0 0.0022905488
successful O 0 0.004063191
. O 0 0.0067138374

The O 0 0.003306553
serum O 0 0.012967932
level O 0 0.001984947
of O 0 0.0027539753
potassium B-Chemical 0 0.99883515
was O 0 0.0010370886
observed O 0 0.000567253
to O 0 0.00046496282
be O 0 0.00046813794
8 O 0 0.00046350577
. O 0 0.00052507984
4 O 0 0.00074533396
mequiv O 0 0.7866465
L O 0 0.7587824
- O 0 0.012962782
1 O 0 0.0032238492
. O 0 0.004168627

Apart O 0 0.0030111517
from O 0 0.0015651621
the O 0 0.0010009726
reduction O 0 0.00095649663
in O 0 0.0005462296
the O 0 0.00037692182
patient O 0 0.0004199332
' O 0 0.0005390956
s O 0 0.0003745874
level O 0 0.0002036453
of O 0 0.00033973536
consciousness O 0 0.50732607
, O 0 0.00038051012
there O 0 0.00011968677
were O 0 0.00011795057
no O 0 0.00011711997
signs O 0 0.0006126247
of O 0 0.00020119247
motor O 0 0.0028476245
neurone O 0 0.006655025
damage O 0 0.0055931383
or O 0 9.8630124e-05
of O 0 0.000109892906
any O 0 8.2721584e-05
of O 0 0.00010593535
the O 0 8.1832186e-05
other O 0 9.233586e-05
known O 0 0.000118404714
predisposing O 0 0.0006089693
conditions O 0 0.0001404074
for O 0 0.00014956233
hyperkalaemia B-Disease 0 0.998353
following O 0 0.00013945697
the O 0 0.00020911802
administration O 0 0.0007238786
of O 0 0.0011659029
suxamethonium B-Chemical 0 0.9992324
. O 0 0.0025793049

It O 0 0.0057326737
is O 0 0.0019131474
postulated O 0 0.0016380068
that O 0 0.0008671382
her O 0 0.0014057786
death B-Disease 0 0.45981202
was O 0 0.000515124
caused O 0 0.00037486135
by O 0 0.0003785426
hypersensitivity B-Disease 0 0.015529427
to O 0 0.00040752767
suxamethonium B-Chemical 0 0.99966705
, O 0 0.00059393817
associated O 0 0.0002954975
with O 0 0.00034016994
her O 0 0.0004812835
5 O 0 0.00046740132
- O 0 0.0016670987
day O 0 0.0005946349
immobilization O 0 0.0019426413
. O 0 0.003036853

Acute O 0 0.8611963
hepatitis B-Disease 0 0.9998252
, O 0 0.19440253
autoimmune B-Disease 0 0.9997409
hemolytic I-Disease 0 0.9999913
anemia I-Disease 0 0.9999945
, O 0 0.0054696533
and O 0 0.0012687811
erythroblastocytopenia B-Disease 0 0.0044556796
induced O 0 0.0016245517
by O 0 0.0029789768
ceftriaxone B-Chemical 0 0.9996735
. O 0 0.0053636725

An O 0 0.0044643516
80 O 0 0.0043071066
- O 0 0.0066112764
yr O 0 0.0022274016
- O 0 0.0041352445
old O 0 0.0015161436
man O 0 0.0066855825
developed O 0 0.0019445292
acute O 0 0.99067557
hepatitis B-Disease 0 0.9999862
shortly O 0 0.0017424278
after O 0 0.00058575114
ingesting O 0 0.027855422
oral O 0 0.020415733
ceftriaxone B-Chemical 0 0.9995466
. O 0 0.0039109285

Although O 0 0.0023187725
the O 0 0.0027623444
transaminases O 0 0.9954091
gradually O 0 0.0017341338
returned O 0 0.0005162765
to O 0 0.00023242852
baseline O 0 0.00018654707
after O 0 0.000121686026
withholding O 0 0.00039931206
the O 0 0.00027261814
beta B-Chemical 0 0.8534626
lactam I-Chemical 0 0.94114184
antibiotic O 0 0.012642108
, O 0 0.0004160643
there O 0 0.00012560109
was O 0 0.00014040459
a O 0 0.00020505303
gradual O 0 0.00017670619
increase O 0 0.00013384037
in O 0 0.0001921696
serum O 0 0.2975788
bilirubin B-Chemical 0 0.9999683
and O 0 0.0002673704
a O 0 0.00025475782
decrease O 0 0.00018285325
in O 0 0.00019569317
hemoglobin O 0 0.8317669
concentration O 0 0.0005636232
caused O 0 0.00023176505
by O 0 0.00030965195
an O 0 0.0009647783
autoimmune B-Disease 0 0.9998041
hemolytic I-Disease 0 0.9999958
anemia I-Disease 0 0.99999595
and O 0 0.0027871921
erythroblastocytopenia B-Disease 0 0.043274917
. O 0 0.0038189504

These O 0 0.0045190006
responded O 0 0.0058905715
to O 0 0.004155934
systemic O 0 0.4763194
steroids B-Chemical 0 0.9963684
and O 0 0.007270159
immunoglobulins O 0 0.64616054
. O 0 0.009451501

Despite O 0 0.0018869593
the O 0 0.0013546479
widespread O 0 0.0009848403
use O 0 0.00058851705
of O 0 0.00051085016
these O 0 0.00036633713
agents O 0 0.0008539773
this O 0 0.00037266134
triad O 0 0.00082060037
of O 0 0.00026420964
side O 0 0.00069518073
effects O 0 0.00021298682
has O 0 0.00013204248
not O 0 0.00015907153
previously O 0 0.00024167134
been O 0 0.00021887766
reported O 0 0.00026603034
in O 0 0.0002576097
connection O 0 0.00046034562
with O 0 0.0009947314
beta B-Chemical 0 0.9796865
lactam I-Chemical 0 0.99295807
antibiotics O 0 0.79403853
. O 0 0.004102463

Thyroxine B-Chemical 0 0.99933535
abuse O 0 0.9910397
: O 0 0.00811464
an O 0 0.0026071179
unusual O 0 0.0030626887
case O 0 0.0018623432
of O 0 0.0028122384
thyrotoxicosis B-Disease 0 0.9994375
in O 0 0.0031852184
pregnancy O 0 0.010870946
. O 0 0.0054951585

Eating B-Disease 0 0.9101397
disorders I-Disease 0 0.9979977
and O 0 0.0019921097
the O 0 0.0009084698
associated O 0 0.00088435644
behavioural O 0 0.0027249567
problems O 0 0.002701668
and O 0 0.0010079569
drug B-Disease 0 0.84270203
abuse I-Disease 0 0.99889696
are O 0 0.000949119
uncommon O 0 0.0031041396
in O 0 0.0011583313
pregnancy O 0 0.0045995302
. O 0 0.0035713147

When O 0 0.001981654
they O 0 0.0017000837
do O 0 0.0011856303
occur O 0 0.00074293744
they O 0 0.00045759437
are O 0 0.00032255362
often O 0 0.00039011842
unrecognized O 0 0.00040460107
because O 0 0.00018097597
of O 0 0.00034099907
denial O 0 0.038913533
but O 0 0.0003277289
when O 0 0.00014572355
significant O 0 0.00020934548
may O 0 0.00016374378
pose O 0 0.0002403253
a O 0 0.00039345463
risk O 0 0.001390307
to O 0 0.00020388348
both O 0 0.00022763663
the O 0 0.00029979262
mother O 0 0.0009898295
and O 0 0.0007754893
her O 0 0.0013878344
fetus O 0 0.005002847
. O 0 0.0034442847

This O 0 0.004596804
case O 0 0.001949519
illustrates O 0 0.00083048374
a O 0 0.00096922356
number O 0 0.00041221498
of O 0 0.00049246795
problems O 0 0.0016030227
that O 0 0.00024249071
may O 0 0.00019113746
be O 0 0.00016709113
encountered O 0 0.00020240851
in O 0 0.00015467277
women O 0 0.0005618948
with O 0 0.00031564356
eating B-Disease 0 0.99013877
disorders I-Disease 0 0.99979776
in O 0 0.00020558434
pregnancy O 0 0.00087662507
, O 0 0.00025062892
including O 0 9.4869836e-05
prolonged O 0 0.00021926405
and O 0 0.00024296004
recurrent O 0 0.003261676
metabolic O 0 0.75011146
disturbances O 0 0.99467963
and O 0 0.0014493226
diuretic O 0 0.9998085
abuse O 0 0.9955539
. O 0 0.003779754

In O 0 0.0019767352
particular O 0 0.0013218422
it O 0 0.001419831
illustrates O 0 0.0005669252
the O 0 0.0005724552
derangements O 0 0.19644822
of O 0 0.0006430534
thyroid O 0 0.04181184
function O 0 0.0002142398
seen O 0 0.00020912538
in O 0 0.00016097409
pregnant O 0 0.00076017785
women O 0 0.0006930804
with O 0 0.0003318403
eating B-Disease 0 0.9950452
disorders I-Disease 0 0.99989605
and O 0 0.00037649987
reminds O 0 0.001204634
us O 0 0.00019838459
that O 0 8.549051e-05
when O 0 8.932455e-05
a O 0 0.0002337925
cause O 0 0.00021088647
for O 0 0.00017860052
thyrotoxicosis B-Disease 0 0.99989736
remains O 0 0.00015504015
obscure O 0 0.00094091165
, O 0 0.001929313
thyroxine B-Chemical 0 0.999944
abuse O 0 0.9936474
should O 0 0.0002162826
be O 0 0.00031516782
considered O 0 0.0004299667
and O 0 0.00072644255
explored O 0 0.0014143687
. O 0 0.0028279943

Repeated O 0 0.026281072
trimipramine B-Chemical 0 0.99999154
induces O 0 0.00870263
dopamine B-Chemical 0 0.999907
D2 O 0 0.9991659
/ O 0 0.49280003
D3 O 0 0.99971706
and O 0 0.002859895
alpha1 O 0 0.96861
- O 0 0.13187084
adrenergic O 0 0.87526625
up O 0 0.0015929054
- O 0 0.0039392314
regulation O 0 0.0011958993
. O 0 0.0037213974

Trimipramine B-Chemical 0 0.9992987
( O 0 0.024151657
TRI B-Chemical 1 0.9974533
) O 0 0.0046267263
, O 0 0.0014512871
which O 0 0.0005127911
shows O 0 0.00018085091
a O 0 0.00046720574
clinical O 0 0.0020739725
antidepressant B-Chemical 0 0.99984825
activity O 0 0.00018430033
, O 0 0.0003779754
is O 0 0.00013431304
chemically O 0 0.00050427654
related O 0 0.0001229293
to O 0 0.0003644521
imipramine B-Chemical 0 0.9999994
but O 0 0.0004945252
does O 0 0.00010603349
not O 0 0.0001002231
inhibit O 0 0.00010300522
the O 0 0.00019006342
reuptake O 0 0.99016994
of O 0 0.0004807892
noradrenaline B-Chemical 1 0.99998903
and O 0 0.0002735482
5 B-Chemical 0 0.00020445156
- I-Chemical 0 0.006463474
hydroxytryptamine I-Chemical 0 0.9527614
, O 0 0.0004095167
nor O 0 0.00013085749
does O 0 0.00015902818
it O 0 0.0003602126
induce O 0 0.00029616398
beta O 0 0.9281762
- O 0 0.26962182
adrenergic O 0 0.9363805
down O 0 0.0009508613
- O 0 0.0040518087
regulation O 0 0.00086653733
. O 0 0.0027714164

The O 0 0.0024169683
mechanism O 0 0.0017549968
of O 0 0.0025114992
its O 0 0.0038527874
antidepressant B-Chemical 0 0.9995185
activity O 0 0.0013972545
is O 0 0.0013145143
still O 0 0.0018207817
unknown O 0 0.003623663
. O 0 0.0053513465

The O 0 0.0016616484
aim O 0 0.0010553706
of O 0 0.001082643
the O 0 0.00064765965
present O 0 0.00048308383
study O 0 0.0005409448
was O 0 0.00030319332
to O 0 0.00020407897
find O 0 0.0001648737
out O 0 0.00017192643
whether O 0 0.00011934851
TRI B-Chemical 1 0.9952178
given O 0 0.0001276446
repeatedly O 0 0.00012965259
was O 0 0.0001049571
able O 0 7.803368e-05
to O 0 8.774992e-05
induce O 0 7.544343e-05
adaptive O 0 0.00017899023
changes O 0 0.00012529128
in O 0 0.00010327176
the O 0 0.00011342154
dopaminergic O 0 0.0013178318
and O 0 0.00023467938
alpha1 O 0 0.87900525
- O 0 0.06461453
adrenergic O 0 0.72645384
systems O 0 0.00023292613
, O 0 0.00034674842
demonstrated O 0 0.00017307828
by O 0 0.00022192637
us O 0 0.00036003048
previously O 0 0.00038642684
for O 0 0.00041768275
various O 0 0.0012307996
antidepressants B-Chemical 0 0.999734
. O 0 0.0036723418

TRI B-Chemical 1 0.992588
was O 0 0.0025499272
given O 0 0.0009090919
to O 0 0.0007035076
male O 0 0.0011824167
Wistar O 0 0.0016549652
rats O 0 0.00055973575
and O 0 0.00033301485
male O 0 0.00061237195
Albino O 0 0.0008724918
Swiss O 0 0.00029293823
mice O 0 0.000112269736
perorally O 0 0.0009724546
twice O 0 0.00022023162
daily O 0 0.00036675346
for O 0 0.00034833603
14 O 0 0.0006598693
days O 0 0.0007940518
. O 0 0.0024947322

In O 0 0.0022914633
the O 0 0.0020612413
acute O 0 0.015901003
experiment O 0 0.0013528538
TRI B-Chemical 1 0.99460334
( O 0 0.0011926867
given O 0 0.0002670547
i O 0 0.000537758
. O 0 0.00026282403
p O 0 0.0004436077
. O 0 0.0002471487
) O 0 0.0004906443
does O 0 0.00014244625
not O 0 0.00015775437
antagonize O 0 0.00028739337
the O 0 0.0004785187
reserpine B-Chemical 0 0.99999785
hypothermia B-Disease 0 0.99988186
in O 0 0.00016287409
mice O 0 4.9959628e-05
and O 0 0.00012648436
does O 0 0.00010301162
not O 0 0.00013357097
potentiate O 0 0.00023076862
the O 0 0.00018924604
5 B-Chemical 0 0.00031292683
- I-Chemical 0 0.006599174
hydroxytryptophan I-Chemical 0 0.83667684
head O 0 0.24651703
twitches O 0 0.95314187
in O 0 0.0010778055
rats O 0 0.0023173112
. O 0 0.0026655672

TRI B-Chemical 1 0.99236286
given O 0 0.0015355854
repeatedly O 0 0.0009547699
to O 0 0.0005517461
rats O 0 0.00074375176
increases O 0 0.0004243228
the O 0 0.0004626102
locomotor O 0 0.9252659
hyperactivity B-Disease 2 0.9999981
induced O 0 0.00042829866
by O 0 0.00030985393
d B-Chemical 0 0.0023248475
- I-Chemical 0 0.49727708
amphetamine I-Chemical 1 0.9999981
, O 0 0.0070227766
quinpirole B-Chemical 0 0.9999615
and O 0 0.00029967603
( O 0 0.00043359716
+ O 0 0.00089149317
) O 0 0.0007228543
- O 0 0.0015523488
7 O 0 0.000261947
- O 0 0.009277743
hydroxy O 0 0.9996817
- O 0 0.038363177
dipropyloaminotetralin O 0 0.001502362
( O 0 0.0056926445
dopamine B-Chemical 0 0.9999081
D2 O 0 0.9971169
and O 0 0.0017316244
D3 O 0 0.99917895
effects O 0 0.0020825774
) O 0 0.0055320556
. O 0 0.003651397

The O 0 0.004743027
stereotypies O 0 0.99948835
induced O 0 0.0023433552
by O 0 0.0017013217
d B-Chemical 0 0.00736715
- I-Chemical 0 0.6142212
amphetamine I-Chemical 1 0.99999297
or O 0 0.0026727451
apomorphine B-Chemical 0 0.9999584
are O 0 0.00068070897
not O 0 0.00075141015
potentiated O 0 0.0056109726
by O 0 0.0028840522
TRI B-Chemical 1 0.99499834
. O 0 0.0053189066

It O 0 0.003996469
increases O 0 0.0013777353
the O 0 0.0007620161
behaviour O 0 0.0009159253
stimulation O 0 0.00037597527
evoked O 0 0.0010077936
by O 0 0.000556876
phenylephrine B-Chemical 0 0.9999287
( O 0 0.00071316975
given O 0 0.00014671193
intraventricularly O 0 0.0035193006
) O 0 0.00033457988
in O 0 0.00010503901
rats O 0 0.0001949802
, O 0 0.00018983992
evaluated O 0 9.4288924e-05
in O 0 8.15484e-05
the O 0 7.25179e-05
open O 0 0.000117867035
field O 0 0.00014157595
test O 0 0.00014942848
as O 0 0.00010307262
well O 0 0.0001018552
as O 0 0.00012379562
the O 0 0.00016461844
aggressiveness B-Disease 2 0.994732
evoked O 0 0.0010052099
by O 0 0.00022944633
clonidine B-Chemical 0 0.9999695
in O 0 0.00010748005
mice O 0 3.9584153e-05
, O 0 0.00014756805
both O 0 7.5536496e-05
these O 0 8.901826e-05
effects O 0 0.0001227243
being O 0 0.00017381458
mediated O 0 0.00013130008
by O 0 0.00031635727
an O 0 0.000790584
alpha1 O 0 0.9551016
- O 0 0.28925475
adrenergic O 0 0.9821806
receptor O 0 0.008912867
. O 0 0.003652733

It O 0 0.0052297446
may O 0 0.0015948191
be O 0 0.00100672
concluded O 0 0.000748316
that O 0 0.00045445797
, O 0 0.00079320703
like O 0 0.00034923275
other O 0 0.0004678921
tricyclic O 0 0.99977976
antidepressants B-Chemical 0 0.99998343
studied O 0 0.0007047091
previously O 0 0.00036547604
, O 0 0.0010081931
TRI B-Chemical 1 0.9958269
given O 0 8.7618726e-05
repeatedly O 0 8.674496e-05
increases O 0 8.523897e-05
the O 0 7.222465e-05
responsiveness O 0 0.0001284251
of O 0 0.0002582099
brain O 0 0.070516735
dopamine B-Chemical 0 0.9999738
D2 O 0 0.99905306
and O 0 0.0008095784
D3 O 0 0.999931
( O 0 0.0013493514
locomotor O 0 0.007376655
activity O 0 9.315427e-05
but O 0 0.0001679204
not O 0 0.00018636964
stereotypy O 0 0.9991099
) O 0 0.0006086961
as O 0 0.00014520757
well O 0 0.00016859199
as O 0 0.00032664
alpha1 O 0 0.9586418
- O 0 0.25732312
adrenergic O 0 0.95721954
receptors O 0 0.0011332321
to O 0 0.00045660743
their O 0 0.00077614945
agonists O 0 0.01565696
. O 0 0.0032464785

A O 0 0.02175971
question O 0 0.0016175044
arises O 0 0.00075550174
whether O 0 0.0002954209
the O 0 0.0006374224
reuptake O 0 0.9631134
inhibition O 0 0.00049629324
is O 0 0.00020275755
of O 0 0.0002100168
any O 0 0.0001308031
importance O 0 9.69789e-05
to O 0 0.00010992791
the O 0 0.000101777434
adaptive O 0 0.00017559149
changes O 0 0.000119042765
induced O 0 0.000106834275
by O 0 0.00012335587
repeated O 0 0.00013239335
antidepressants B-Chemical 0 0.99993277
, O 0 0.00046493355
suggested O 0 0.00013914205
to O 0 0.00015116845
be O 0 0.0001814885
responsible O 0 0.0001769598
for O 0 0.0002491905
the O 0 0.00056327385
antidepressant B-Chemical 0 0.9995166
activity O 0 0.0012593241
. O 0 0.0026125147

Pethidine B-Chemical 0 0.9996902
- O 0 0.10393839
associated O 0 0.0030080418
seizure B-Disease 0 0.99763703
in O 0 0.00077084027
a O 0 0.00081957894
healthy O 0 0.0015919413
adolescent O 0 0.0035362071
receiving O 0 0.0009226697
pethidine B-Chemical 0 0.99990845
for O 0 0.0005179618
postoperative B-Disease 0 0.0027569141
pain I-Disease 0 0.2851019
control O 0 0.0017265495
. O 0 0.0031408572

A O 0 0.04114416
healthy O 0 0.0092624705
17 O 0 0.002827631
- O 0 0.004090769
year O 0 0.00076656195
- O 0 0.0015434722
old O 0 0.00042186174
male O 0 0.00046077167
received O 0 0.00018662873
standard O 0 0.00016703858
intermittent O 0 0.0003393723
doses O 0 0.0003399832
of O 0 0.00032249984
pethidine B-Chemical 0 0.9999701
via O 0 0.000161312
a O 0 0.00023610902
patient O 0 0.00020666646
- O 0 0.00068329164
controlled O 0 0.00021601532
analgesia O 0 0.13822556
( O 0 0.000526332
PCA O 0 0.040885024
) O 0 0.0005566213
pump O 0 0.0009122524
for O 0 0.00015363387
management O 0 0.0002980016
of O 0 0.00041160162
postoperative B-Disease 0 0.003192304
pain I-Disease 0 0.4999949
control O 0 0.0015570816
. O 0 0.0028478897

Twenty O 0 0.007278365
- O 0 0.006164103
three O 0 0.000827115
h O 0 0.0012256888
postoperatively O 0 0.0010290962
he O 0 0.0010325144
developed O 0 0.0008643058
a O 0 0.001088403
brief O 0 0.0010437116
self O 0 0.003658652
- O 0 0.00793906
limited O 0 0.0032643012
seizure B-Disease 0 0.99709237
. O 0 0.006372474

Both O 0 0.003775749
plasma O 0 0.25501418
pethidine B-Chemical 0 0.9999504
and O 0 0.003776265
norpethidine B-Chemical 0 0.9995703
were O 0 0.0005291866
elevated O 0 0.0009040892
in O 0 0.0002120796
the O 0 0.00015406882
range O 0 0.00018706007
associated O 0 0.00019188065
with O 0 0.00024187191
clinical O 0 0.0010397672
manifestations O 0 0.007951351
of O 0 0.0004945002
central O 0 0.0010373698
nervous O 0 0.0041193217
system O 0 0.0012341752
excitation O 0 0.009323102
. O 0 0.0028082402

No O 0 0.0063984203
other O 0 0.0035363985
risk O 0 0.0098800985
factors O 0 0.003966032
for O 0 0.0022641541
CNS O 0 0.039326664
toxicity B-Disease 0 0.4340392
were O 0 0.0021668144
identified O 0 0.002094921
. O 0 0.0047670617

This O 0 0.0036053553
method O 0 0.0016424123
allowed O 0 0.0010742013
frequent O 0 0.0010023897
self O 0 0.0017847099
- O 0 0.0023221415
dosing O 0 0.0004932334
of O 0 0.00045239367
pethidine B-Chemical 0 0.99991
at O 0 0.00016022053
short O 0 0.00011520967
time O 0 8.755725e-05
intervals O 0 0.0001278941
and O 0 0.00017897676
rapid O 0 0.00031487414
accumulation O 0 0.00040513522
of O 0 0.0009755674
pethidine B-Chemical 0 0.99997187
and O 0 0.0034388471
norpethidine B-Chemical 0 0.9992824
. O 0 0.0037263473

The O 0 0.0016188371
routine O 0 0.0010464097
use O 0 0.0010141782
of O 0 0.0015822048
pethidine B-Chemical 0 0.9999175
via O 0 0.00083261286
PCA O 0 0.067545846
even O 0 0.00042369688
for O 0 0.00023931693
a O 0 0.0004075226
brief O 0 0.00033813753
postoperative O 0 0.0006231456
analgesia O 0 0.018753475
should O 0 0.0003847017
be O 0 0.000891856
reconsidered O 0 0.0024063839
. O 0 0.0033065681

An O 0 0.0056346664
unusual O 0 0.007383795
toxic O 0 0.022067377
reaction O 0 0.0016857963
to O 0 0.0012116687
axillary O 0 0.017566362
block O 0 0.0011216492
by O 0 0.0017105441
mepivacaine B-Chemical 0 0.99977523
with O 0 0.004286567
adrenaline B-Chemical 0 0.99974674
. O 0 0.005733801

An O 0 0.0029757004
increase B-Disease 0 0.0016021607
in I-Disease 0 0.0012450188
blood I-Disease 0 0.0049533695
pressure I-Disease 0 0.012352042
, O 0 0.0012618953
accompanied O 0 0.00068872684
by O 0 0.00040635417
atrial B-Disease 0 0.085231304
fibrillation I-Disease 0 0.999474
, O 0 0.0016323933
agitation B-Disease 2 0.99862075
, O 0 0.0013283083
incomprehensible B-Disease 0 0.06899963
shouts I-Disease 0 0.036475256
and O 0 0.0003165947
loss B-Disease 0 0.0005023322
of I-Disease 0 0.00034667124
consciousness I-Disease 0 0.97585434
, O 0 0.0004360589
was O 0 0.00012802516
observed O 0 0.00010518114
in O 0 0.00012265494
an O 0 0.00019762585
elderly O 0 0.089656875
, O 0 0.00060243276
ASA O 0 0.98214966
classification O 0 0.00018994168
group O 0 0.00032027293
II O 0 0.06263637
, O 0 0.00066632725
cardiovascularly O 0 0.25949326
medicated O 0 0.84041244
male O 0 0.00043462694
, O 0 0.00019454547
12 O 0 5.9792226e-05
min O 0 9.067036e-05
after O 0 3.328808e-05
performance O 0 9.768363e-05
of O 0 0.00012573398
axillary O 0 0.005943119
block O 0 0.000116352785
with O 0 0.00026028795
mepivacaine B-Chemical 0 0.99997544
850 O 0 0.002474809
mg O 0 0.003951241
containing O 0 0.000169892
adrenaline B-Chemical 0 0.99993265
0 O 0 0.00026158258
. O 0 0.00015434895
225 O 0 0.00055338966
mg O 0 0.0018664552
, O 0 0.00033705565
for O 0 0.00020489337
correction O 0 0.001164427
of O 0 0.0009234634
Dupuytren B-Disease 0 0.97627956
' I-Disease 0 0.002621587
s I-Disease 0 0.003426559
contracture I-Disease 0 0.9973592
. O 0 0.0041810153

After O 0 0.0013953861
intravenous O 0 0.00450127
administration O 0 0.0017584169
of O 0 0.0017263504
labetalol B-Chemical 0 0.9999968
, O 0 0.036711287
metoprolol B-Chemical 1 0.99999857
and O 0 0.0019291708
midazolam B-Chemical 0 0.9999877
the O 0 0.0002257607
patient O 0 0.0002133598
' O 0 0.00029840847
s O 0 0.0002605951
condition O 0 0.00034208398
improved O 0 0.00039133924
, O 0 0.0004597006
and O 0 0.00031367716
15 O 0 0.00032607748
min O 0 0.00054420624
later O 0 0.000505273
he O 0 0.0011381718
woke O 0 0.0032726228
up O 0 0.002316944
. O 0 0.00365872

The O 0 0.00214921
block O 0 0.0017879809
was O 0 0.0011030886
successful O 0 0.0008703479
and O 0 0.00075539696
surgery O 0 0.0007674848
was O 0 0.00040305546
conducted O 0 0.00045077596
as O 0 0.00036504844
scheduled O 0 0.00027840867
despite O 0 0.00048313997
persisting O 0 0.0015905806
atrial B-Disease 0 0.15905905
fibrillation I-Disease 0 0.99750537
. O 0 0.0044307457

Postoperatively O 0 0.0071150903
, O 0 0.0045413235
the O 0 0.001770346
patient O 0 0.001892941
refused O 0 0.003093879
DC O 0 0.0063777813
cardioversion O 0 0.001593916
and O 0 0.0011141946
was O 0 0.0013615919
treated O 0 0.0038758218
medically O 0 0.28470272
. O 0 0.0057076854

Both O 0 0.002352578
the O 0 0.0014604902
temporal O 0 0.002290038
relationship O 0 0.0004770249
of O 0 0.0005565886
events O 0 0.0006208124
and O 0 0.0003149366
the O 0 0.00017539904
response O 0 0.00015897752
to O 0 0.000120337
treatment O 0 0.00011587614
suggest O 0 6.115838e-05
that O 0 8.629416e-05
a O 0 0.0001983084
rapid O 0 0.00025747073
systemic O 0 0.16852584
absorption O 0 0.06864642
of O 0 0.0003167674
mepivacaine B-Chemical 0 0.99998283
with O 0 0.0003557717
adrenaline B-Chemical 0 0.99998033
and O 0 0.00016586883
/ O 0 0.0006097947
or O 0 6.68068e-05
interaction O 0 5.665764e-05
of O 0 9.240721e-05
these O 0 9.554155e-05
drugs O 0 0.00268328
with O 0 0.000113411814
the O 0 8.2792845e-05
patient O 0 0.00012579648
' O 0 0.00021606803
s O 0 0.00022866837
cardiovascular O 0 0.054418255
medications O 0 0.0013814139
were O 0 0.00013203116
responsible O 0 0.00012280041
for O 0 0.00016582961
the O 0 0.0003109939
perioperative O 0 0.0020640935
complications O 0 0.009502592
. O 0 0.002341889

Drug O 0 0.88942856
- O 0 0.018999062
associated O 0 0.0024872264
acute O 0 0.07153696
- O 0 0.008605087
onset O 0 0.001777965
vanishing B-Disease 0 0.036846515
bile I-Disease 0 0.99698585
duct I-Disease 0 0.98782176
and O 0 0.0011719888
Stevens B-Disease 0 0.00706604
- I-Disease 0 0.008552777
Johnson I-Disease 0 0.014070506
syndromes I-Disease 0 0.2915041
in O 0 0.0010710311
a O 0 0.0021393208
child O 0 0.003799726
. O 0 0.0040193233

Acute O 0 0.28771076
vanishing B-Disease 0 0.3842828
bile I-Disease 0 0.9986027
duct I-Disease 0 0.9989009
syndrome O 0 0.9967513
is O 0 0.00072875805
a O 0 0.0009826763
rare O 0 0.0021105434
but O 0 0.00035658103
established O 0 0.00024782194
cause O 0 0.00028543302
of O 0 0.00031431837
progressive O 0 0.088826254
cholestasis B-Disease 0 0.9999943
in O 0 0.0003704957
adults O 0 0.0016995643
, O 0 0.00031805775
is O 0 0.00010597951
most O 0 0.00016397268
often O 0 0.00020088616
drug O 0 0.0028596364
or O 0 0.0001898258
toxin O 0 0.004710556
related O 0 0.00020427168
, O 0 0.00056335446
and O 0 0.00036820138
is O 0 0.00035489618
of O 0 0.0006903796
unknown O 0 0.0012449523
pathogenesis O 0 0.0032658358
. O 0 0.003177411

It O 0 0.0078080976
has O 0 0.0026127207
not O 0 0.0023661465
been O 0 0.002168416
reported O 0 0.002277273
previously O 0 0.0023662038
in O 0 0.0029014866
children O 0 0.008871607
. O 0 0.006730699

Stevens B-Disease 0 0.030254615
- I-Disease 0 0.046849374
Johnson I-Disease 0 0.07349031
syndrome I-Disease 0 0.882945
is O 0 0.00084952655
a O 0 0.00090765994
well O 0 0.0005471968
- O 0 0.002629201
recognized O 0 0.00034600284
immune O 0 0.0010720652
complex O 0 0.0003610014
- O 0 0.0017383057
mediated O 0 0.0001379616
hypersensitivity B-Disease 0 0.0041666753
reaction O 0 0.00013189235
that O 0 7.675008e-05
affects O 0 6.9237285e-05
all O 0 9.7267686e-05
age O 0 0.00018179577
groups O 0 0.00017054054
, O 0 0.00025313778
is O 0 0.00011912259
drug O 0 0.0030889637
or O 0 0.00015359797
infection B-Disease 0 0.0010333788
induced O 0 0.00019121457
, O 0 0.00040732182
and O 0 0.00020943531
has O 0 0.00015148474
classic O 0 0.0020664053
systemic O 0 0.35052532
, O 0 0.00096597127
mucosal O 0 0.007838628
, O 0 0.0010010795
and O 0 0.00083277863
dermatologic O 0 0.037010223
manifestations O 0 0.075939514
. O 0 0.0028816822

A O 0 0.036667295
previously O 0 0.0031870701
healthy O 0 0.005630158
child O 0 0.001962088
who O 0 0.0011348433
developed O 0 0.0007692912
acute O 0 0.028136164
, O 0 0.0010748114
severe O 0 0.0027607542
, O 0 0.00061397254
rapidly O 0 0.00037935676
progressive O 0 0.0072179907
vanishing B-Disease 0 0.12377101
bile I-Disease 0 0.9995378
duct I-Disease 0 0.99954873
syndrome I-Disease 0 0.99018854
shortly O 0 0.00020771446
after O 0 8.359889e-05
Stevens B-Disease 0 0.0011672822
- I-Disease 0 0.0031402986
Johnson I-Disease 0 0.012391905
syndrome I-Disease 0 0.8148747
is O 0 0.00016896549
described O 0 0.00016951529
; O 0 0.00039775457
this O 0 0.00022179016
was O 0 0.00022743357
temporally O 0 0.00037207204
associated O 0 0.00045564456
with O 0 0.000989542
ibuprofen B-Chemical 0 0.99989533
use O 0 0.0019876598
. O 0 0.0029098198

Despite O 0 0.0023742034
therapy O 0 0.004375655
with O 0 0.0059005874
ursodeoxycholic B-Chemical 0 0.99998844
acid I-Chemical 0 0.996557
, O 0 0.019004025
prednisone B-Chemical 0 0.9998882
, O 0 0.0008303634
and O 0 0.00029659263
then O 0 0.00034569713
tacrolimus B-Chemical 0 0.9999753
, O 0 0.0009940605
her O 0 0.0009484496
cholestatic B-Disease 0 0.9999989
disease I-Disease 0 0.999363
was O 0 0.0003248013
unrelenting O 0 0.003944252
, O 0 0.00043878093
with O 0 0.00039654403
cirrhosis B-Disease 0 0.9999857
shown O 0 0.00014987642
by O 0 0.00018331483
biopsy O 0 0.00022929434
6 O 0 0.00013773197
months O 0 0.00013542314
after O 0 0.0002839946
presentation O 0 0.0015982091
. O 0 0.0024497397

This O 0 0.0046113054
case O 0 0.0022444522
documents O 0 0.0023696406
acute O 0 0.07115491
drug O 0 0.101070724
- O 0 0.005679785
related O 0 0.0003433008
vanishing B-Disease 0 0.05219975
bile I-Disease 0 0.99933714
duct I-Disease 0 0.9994677
syndrome I-Disease 0 0.991335
in O 0 0.00018590233
the O 0 0.00011227938
pediatric O 0 0.000269774
age O 0 0.00017357277
group O 0 0.0001541047
and O 0 0.00011008778
suggests O 0 6.7812856e-05
shared O 0 0.00015713122
immune O 0 0.0004075881
mechanisms O 0 9.195363e-05
in O 0 0.00011610851
the O 0 0.0001078517
pathogenesis O 0 0.00023495588
of O 0 0.00015683872
both O 0 0.00017354992
Stevens B-Disease 0 0.0025177498
- I-Disease 0 0.0056841015
Johnson I-Disease 0 0.019423455
syndrome I-Disease 0 0.89506155
and O 0 0.00078069884
vanishing B-Disease 0 0.22011009
bile I-Disease 0 0.9993666
duct I-Disease 0 0.99937373
syndrome I-Disease 0 0.9975731
. O 0 0.0045999987

High O 0 0.0054296777
incidence O 0 0.0036415865
of O 0 0.0018267687
primary B-Disease 0 0.0027484908
pulmonary I-Disease 2 0.99781656
hypertension I-Disease 2 0.99999714
associated O 0 0.0017543432
with O 0 0.0013092353
appetite B-Chemical 0 0.87066144
suppressants I-Chemical 0 0.982418
in O 0 0.0019283905
Belgium O 0 0.006535892
. O 0 0.0039640605

Primary B-Disease 0 0.012847674
pulmonary I-Disease 2 0.9961888
hypertension I-Disease 2 0.9999927
is O 0 0.0014553651
a O 0 0.0014300899
rare O 0 0.0024978681
, O 0 0.0009594342
progressive O 0 0.0030567455
and O 0 0.00053758576
incurable O 0 0.37189564
disease O 0 0.49510664
, O 0 0.0006137523
which O 0 0.00024812383
has O 0 0.00012054212
been O 0 0.00015581484
associated O 0 0.00019077514
with O 0 0.00020917147
the O 0 0.00022338143
intake O 0 0.003039985
of O 0 0.0006901543
appetite B-Chemical 0 0.80039805
suppressant I-Chemical 0 0.7781697
drugs O 0 0.16385154
. O 0 0.0036758778

The O 0 0.0016375047
importance O 0 0.0010493576
of O 0 0.0011382976
this O 0 0.0007369568
association O 0 0.00036861934
was O 0 0.00034633582
evaluated O 0 0.00029054622
in O 0 0.00026305468
Belgium O 0 0.00078824896
while O 0 0.000201763
this O 0 0.0001966698
country O 0 0.00026305392
still O 0 0.00013734208
had O 0 0.0001450638
no O 0 0.00013056547
restriction O 0 0.00020267616
on O 0 0.00015486803
the O 0 0.00023809701
prescription O 0 0.0011162312
of O 0 0.0008769889
appetite B-Chemical 0 0.867336
suppressants I-Chemical 0 0.99160004
. O 0 0.003909721

Thirty O 0 0.0074368543
- O 0 0.006009153
five O 0 0.0007187335
patients O 0 0.0011845778
with O 0 0.000644737
primary B-Disease 0 0.0011028758
pulmonary I-Disease 2 0.9974699
hypertension I-Disease 2 0.9999987
and O 0 0.00052705046
85 O 0 0.0003408736
matched O 0 0.00012398702
controls O 0 0.00021100353
were O 0 0.00012847017
recruited O 0 0.00013178411
over O 0 0.00011474775
32 O 0 0.00021171937
months O 0 0.000117509386
( O 0 0.00045615088
1992 O 0 0.0010072177
- O 0 0.0021326838
1994 O 0 0.001745855
) O 0 0.0019374542
in O 0 0.0014091382
Belgium O 0 0.00581682
. O 0 0.0041172174

Exposure O 0 0.0082599195
to O 0 0.0028391327
appetite B-Chemical 0 0.8525677
- I-Chemical 0 0.068507
suppressants I-Chemical 0 0.9678553
was O 0 0.00064756727
assessed O 0 0.00038009445
on O 0 0.00022441293
the O 0 0.00023721831
basis O 0 0.00027567756
of O 0 0.0004287848
hospital O 0 0.00065315474
records O 0 0.0007155296
and O 0 0.0006096727
standardized O 0 0.00083042757
interview O 0 0.0013726549
. O 0 0.002628928

Twenty O 0 0.006335582
- O 0 0.0054240944
three O 0 0.0005785727
of O 0 0.00070877007
the O 0 0.00046580282
patients O 0 0.0007110107
had O 0 0.0002908139
previously O 0 0.00027332167
taken O 0 0.00024803303
appetite B-Chemical 0 0.44065994
suppressants I-Chemical 0 0.97780174
, O 0 0.0005850903
mainly O 0 0.00028106183
fenfluramines B-Chemical 0 0.8497311
, O 0 0.0003280287
as O 0 0.00012449929
compared O 0 9.311839e-05
with O 0 0.00014682248
only O 0 0.00015594237
5 O 0 0.00011811523
of O 0 0.00012269296
the O 0 0.00011375841
controls O 0 0.00025332344
( O 0 0.00030689104
66 O 0 0.0002375868
versus O 0 0.00013339876
6 O 0 0.00014158257
% O 0 0.00036676202
, O 0 0.00043394306
p O 0 0.00055726897
< O 0 0.000673401
0 O 0 0.0007583881
. O 0 0.00092219247
0001 O 0 0.006692864
) O 0 0.004590742
. O 0 0.0042759688

Five O 0 0.003995239
patients O 0 0.0039063725
died O 0 0.0023979817
before O 0 0.0005174108
the O 0 0.0005684104
interview O 0 0.0006247584
, O 0 0.0008657838
all O 0 0.00047616716
of O 0 0.0006009323
them O 0 0.00088571256
had O 0 0.000841628
taken O 0 0.0011031559
appetite B-Chemical 0 0.5858742
suppressants I-Chemical 0 0.98175436
. O 0 0.0054784454

In O 0 0.001893094
8 O 0 0.0016070481
patients O 0 0.001562084
the O 0 0.00061695854
diagnosis O 0 0.0008803649
of O 0 0.00055494223
primary B-Disease 0 0.0010751955
pulmonary I-Disease 2 0.9982339
hypertension I-Disease 2 0.9999988
was O 0 0.00052987353
uncertain O 0 0.00040840797
, O 0 0.0004392607
5 O 0 0.0002122305
of O 0 0.0002603743
them O 0 0.00044709182
had O 0 0.00047820315
taken O 0 0.0006995951
appetite B-Chemical 0 0.56350046
suppressants I-Chemical 0 0.9806985
. O 0 0.004209656

The O 0 0.0020602783
patients O 0 0.0030386022
who O 0 0.0016094614
had O 0 0.0007181683
been O 0 0.00047743044
exposed O 0 0.00050646113
to O 0 0.00039505365
appetite B-Chemical 0 0.7241649
suppressants I-Chemical 0 0.9846357
tended O 0 0.00034571416
to O 0 0.00013767589
be O 0 0.00011162285
on O 0 7.634998e-05
average O 0 0.00010716209
more O 0 0.0002676754
severely O 0 0.0029122934
ill O 0 0.29625487
, O 0 0.0003876773
and O 0 0.00014213339
to O 0 9.670344e-05
have O 0 8.745536e-05
a O 0 0.00012770243
shorter O 0 7.245111e-05
median O 0 6.986017e-05
delay O 0 0.0001906613
between O 0 0.00014518914
onset O 0 0.00041690798
of O 0 0.00044599277
symptoms O 0 0.0037337367
and O 0 0.00090253307
diagnosis O 0 0.0026900477
. O 0 0.0027384937

A O 0 0.023335658
policy O 0 0.0030152118
of O 0 0.0014897968
unrestricted O 0 0.001659184
prescription O 0 0.0020699105
of O 0 0.0008585209
appetite B-Chemical 0 0.85847443
suppressants I-Chemical 0 0.9928135
may O 0 0.00042129203
lead O 0 0.0013433171
to O 0 0.00023831594
a O 0 0.00035502156
high O 0 0.00033697142
incidence O 0 0.0005515621
of O 0 0.00039454552
associated O 0 0.0006094896
primary B-Disease 0 0.0017199377
pulmonary I-Disease 2 0.99834514
hypertension I-Disease 2 0.99999464
. O 0 0.0057896674

Intake O 0 0.2574478
of O 0 0.005296978
appetite B-Chemical 0 0.92039925
suppressants I-Chemical 0 0.99235195
may O 0 0.0015672543
accelerate O 0 0.0015231436
the O 0 0.001080187
progression O 0 0.0033932563
of O 0 0.0017404584
the O 0 0.0020979533
disease O 0 0.33882657
. O 0 0.0052560433

Inappropriate O 0 0.006437334
use O 0 0.0027509572
of O 0 0.0047899885
carbamazepine B-Chemical 1 0.9999889
and O 0 0.007383809
vigabatrin B-Chemical 0 0.9999678
in O 0 0.0019190117
typical O 0 0.002160411
absence B-Disease 0 0.0045442437
seizures I-Disease 0 0.99994135
. O 0 0.008058183

Carbamazepine B-Chemical 0 0.9999385
and O 0 0.011780468
vigabatrin B-Chemical 0 0.9999392
are O 0 0.00208239
contraindicated O 0 0.006875316
in O 0 0.0014190476
typical O 0 0.0021378202
absence B-Disease 0 0.0048959553
seizures I-Disease 0 0.9999237
. O 0 0.009320798

Of O 0 0.004482776
18 O 0 0.0019076029
consecutive O 0 0.0010291733
referrals O 0 0.0014264656
of O 0 0.00064835127
children O 0 0.0012021832
with O 0 0.0004228822
resistant O 0 0.00050463167
typical O 0 0.00042402942
absences O 0 0.009285867
only O 0 0.00022387484
, O 0 0.00026637956
eight O 0 8.914992e-05
were O 0 0.00012123573
erroneously O 0 0.0005881879
treated O 0 0.00040179057
with O 0 0.0005476854
carbamazepine B-Chemical 1 0.9999987
either O 0 0.00025985352
as O 0 0.00022744812
monotherapy O 0 0.07236494
or O 0 0.00023332486
as O 0 0.0003123623
an O 0 0.0005148049
add O 0 0.00079318736
- O 0 0.004628679
on O 0 0.0012164089
. O 0 0.0029129093

Vigabatrin B-Chemical 0 0.999718
was O 0 0.0030676285
also O 0 0.0014736089
used O 0 0.0010319233
in O 0 0.0009096702
the O 0 0.00078148226
treatment O 0 0.0009115826
of O 0 0.0012084692
two O 0 0.0012654978
children O 0 0.0055789994
. O 0 0.0048608948

Frequency O 0 0.003999528
of O 0 0.002482219
absences O 0 0.021951582
increased O 0 0.0010729837
in O 0 0.0004534454
four O 0 0.00024652624
children O 0 0.0008418433
treated O 0 0.00073396345
with O 0 0.0008483976
carbamazepine B-Chemical 1 0.999998
and O 0 0.00028739747
two O 0 0.00010821288
of O 0 0.00017726024
these O 0 0.00021530958
developed O 0 0.0009210264
myoclonic B-Disease 0 0.99999106
jerks I-Disease 0 0.99994373
, O 0 0.0008444701
which O 0 0.00031103188
resolved O 0 0.00032718727
on O 0 0.0002637357
withdrawal O 0 0.0031114905
of O 0 0.002116236
carbamazepine B-Chemical 1 0.9999881
. O 0 0.004815814

Absences O 0 0.035888217
were O 0 0.0029365094
aggravated O 0 0.01076739
in O 0 0.0010981787
both O 0 0.00080425106
cases O 0 0.0014392197
where O 0 0.0011502858
vigabatrin B-Chemical 0 0.9999553
was O 0 0.0006370876
added O 0 0.00060266216
on O 0 0.00037608194
to O 0 0.00056946423
concurrent O 0 0.0015392731
treatment O 0 0.0016639219
. O 0 0.0030474393

Optimal O 0 0.0033053525
control O 0 0.0018419122
of O 0 0.0013745701
the O 0 0.000941494
absences O 0 0.0070823543
was O 0 0.00044555444
achieved O 0 0.00046495371
with O 0 0.00074228185
sodium B-Chemical 0 0.9998248
valproate I-Chemical 0 0.99999547
, O 0 0.019845357
lamotrigine B-Chemical 0 0.9999976
, O 0 0.0017213263
or O 0 0.00070018106
ethosuximide B-Chemical 0 0.9999957
alone O 0 0.0008000771
or O 0 0.00055282185
in O 0 0.0008088474
combination O 0 0.001874181
. O 0 0.0028358528

Choreoathetoid B-Disease 0 0.33333108
movements I-Disease 0 0.01576378
associated O 0 0.003186993
with O 0 0.002269665
rapid O 0 0.0024577805
adjustment O 0 0.002032959
to O 0 0.0028493053
methadone B-Chemical 0 0.9940698
. O 0 0.007041499

Choreatiform B-Disease 0 0.12640159
hyperkinesias I-Disease 0 0.99864036
are O 0 0.0014678779
known O 0 0.0008568054
to O 0 0.0005491289
be O 0 0.000496035
occasional O 0 0.0009786773
movement B-Disease 0 0.0042827525
abnormalities I-Disease 0 0.47382644
during O 0 0.00044095307
intoxications O 0 0.9969807
with O 0 0.0011836778
cocaine B-Chemical 0 0.99972945
but O 0 0.0012955797
not O 0 0.0012666296
opiates O 0 0.98495317
. O 0 0.0037543576

This O 0 0.004703559
is O 0 0.0016428125
a O 0 0.0016143204
case O 0 0.0009528874
report O 0 0.0011769207
of O 0 0.0010181487
euphoria O 0 0.99973005
and O 0 0.002008017
choreoathetoid B-Disease 0 0.99999106
movements I-Disease 0 0.016380845
both O 0 0.00018287942
transiently O 0 0.0002733873
induced O 0 0.00013424108
by O 0 0.00011145257
rapid O 0 0.00014414918
adjustment O 0 8.512672e-05
to O 0 6.427184e-05
the O 0 7.392706e-05
selective O 0 0.00021233816
mu O 0 0.20542118
- O 0 0.0613083
opioid O 0 0.8562538
receptor O 0 0.002471084
agonist O 0 0.21366961
methadone B-Chemical 0 0.9997923
in O 0 0.00017962418
an O 0 0.00021006264
inpatient O 0 0.00091985735
previously O 0 0.00041497406
abusing O 0 0.41924372
heroine B-Chemical 0 0.1035044
and O 0 0.0021004563
cocaine B-Chemical 0 0.9994742
. O 0 0.0040166425

In O 0 0.0042422703
addition O 0 0.0033842784
, O 0 0.007830132
minor O 0 0.008062135
EEG O 0 0.89175946
abnormalities O 0 0.08023703
occurred O 0 0.00550424
. O 0 0.0074100955

Possible O 0 0.009891612
underlying O 0 0.00790086
neurobiological O 0 0.024592148
phenomena O 0 0.010892115
are O 0 0.0049273763
discussed O 0 0.006302175
. O 0 0.010559956

Adverse O 0 0.0068997564
effects O 0 0.0035438049
of O 0 0.004168116
the O 0 0.004188071
atypical O 0 0.06010704
antipsychotics O 0 0.9957092
. O 0 0.009938868

Collaborative O 0 0.016088698
Working O 0 0.010449054
Group O 0 0.011278531
on O 0 0.0034659686
Clinical O 0 0.0074868323
Trial O 0 0.008217909
Evaluations O 0 0.005684818
. O 0 0.008169395

Adverse O 0 0.00469746
effects O 0 0.0023105578
of O 0 0.0031699303
antipsychotics O 0 0.9957983
often O 0 0.00327325
lead O 0 0.006739593
to O 0 0.0027632364
noncompliance O 0 0.13765916
. O 0 0.006197981

Thus O 0 0.0023267008
, O 0 0.0032959622
clinicians O 0 0.0017185481
should O 0 0.00037815003
address O 0 0.00022684126
patients O 0 0.0006621248
' O 0 0.00055687735
concerns O 0 0.00025978562
about O 0 0.00025295996
adverse O 0 0.00060983567
effects O 0 0.00014572215
and O 0 0.00015578094
attempt O 0 0.00014128211
to O 0 8.79524e-05
choose O 0 0.00011591758
medications O 0 0.0007612018
that O 0 6.840219e-05
will O 0 6.1920095e-05
improve O 0 5.954828e-05
their O 0 9.1745176e-05
patients O 0 0.00022670592
' O 0 0.0002219979
quality O 0 0.00010534766
of O 0 0.00018978528
life O 0 0.0002538157
as O 0 0.00026345978
well O 0 0.00034408952
as O 0 0.00052015495
overall O 0 0.00092831487
health O 0 0.004171623
. O 0 0.0032735718

The O 0 0.0018711246
side O 0 0.0028266876
effect O 0 0.00083014305
profiles O 0 0.00059809734
of O 0 0.0005952158
the O 0 0.00045478236
atypical O 0 0.01066401
antipsychotics O 0 0.9962872
are O 0 0.00021160352
more O 0 0.00025724032
advantageous O 0 0.00017864989
than O 0 0.00018917787
those O 0 0.00028551221
of O 0 0.0003867884
the O 0 0.00048765555
conventional O 0 0.0011561337
neuroleptics O 0 0.9984586
. O 0 0.0034363216

Conventional O 0 0.0032493083
agents O 0 0.0032691238
are O 0 0.0009768672
associated O 0 0.0008264368
with O 0 0.0007017202
unwanted O 0 0.0014186023
central O 0 0.0007834732
nervous O 0 0.0015627198
system O 0 0.0002066113
effects O 0 0.00019870019
, O 0 0.00049321697
including O 0 0.00035452557
extrapyramidal B-Disease 0 0.9999957
symptoms I-Disease 0 0.9229659
( O 0 0.0024514229
EPS B-Disease 0 0.9999182
) O 0 0.0036442168
, O 0 0.00383841
tardive B-Disease 0 0.9999982
dyskinesia I-Disease 0 0.9999993
, O 0 0.00057557144
sedation O 0 0.0069298577
, O 0 0.00016817066
and O 0 8.157952e-05
possible O 0 6.894147e-05
impairment O 0 0.04621919
of O 0 0.00013057605
some O 0 0.00014228592
cognitive O 0 0.5216363
measures O 0 0.00010506086
, O 0 0.00017235037
as O 0 8.24889e-05
well O 0 7.7680124e-05
as O 0 8.962214e-05
cardiac O 0 0.00041033656
effects O 0 0.00013622442
, O 0 0.00092701294
orthostatic B-Disease 0 0.99996066
hypotension I-Disease 0 0.99999666
, O 0 0.0009139159
hepatic O 0 0.9166958
changes O 0 0.00021403645
, O 0 0.00042417357
anticholinergic O 0 0.9972166
side O 0 0.00050551747
effects O 0 0.00020482244
, O 0 0.0007761617
sexual B-Disease 0 0.3439138
dysfunction I-Disease 0 0.9979284
, O 0 0.0010933205
and O 0 0.0005521943
weight B-Disease 0 0.0011311033
gain I-Disease 0 0.0015362464
. O 0 0.0024176629

The O 0 0.0021645369
newer O 0 0.0046194876
atypical O 0 0.0058743013
agents O 0 0.001982299
have O 0 0.00056224456
a O 0 0.000689198
lower O 0 0.000612978
risk O 0 0.0044135517
of O 0 0.0011364515
EPS B-Disease 0 0.99993443
, O 0 0.0014423273
but O 0 0.00030522668
are O 0 0.00012293163
associated O 0 0.00012687393
in O 0 9.4094205e-05
varying O 0 0.000115099305
degrees O 0 0.0015758617
with O 0 0.00016547044
sedation O 0 0.003924654
, O 0 0.00019919015
cardiovascular O 0 0.0057672528
effects O 0 0.00010369528
, O 0 0.00033521908
anticholinergic O 0 0.9936521
effects O 0 0.00010233283
, O 0 0.0001848205
weight B-Disease 0 0.00017139675
gain I-Disease 0 0.00016388328
, O 0 0.00038431553
sexual B-Disease 0 0.16763437
dysfunction I-Disease 0 0.99845016
, O 0 0.00084292097
hepatic O 0 0.8843885
effects O 0 0.0001851694
, O 0 0.000441095
lowered O 0 0.0036980354
seizure B-Disease 0 0.99920183
threshold O 0 0.00013397112
( O 0 0.00032093926
primarily O 0 0.00028833197
clozapine B-Chemical 0 0.99999547
) O 0 0.001299618
, O 0 0.0005710565
and O 0 0.0006497434
agranulocytosis B-Disease 0 0.99998295
( O 0 0.011202226
clozapine B-Chemical 0 0.99999106
only O 0 0.0018446986
) O 0 0.0038147767
. O 0 0.002759501

Since O 0 0.0017197799
the O 0 0.0014749961
incidence O 0 0.0019100587
and O 0 0.0008728859
severity O 0 0.0012306372
of O 0 0.00034622222
specific O 0 0.00015676636
adverse O 0 0.00057613326
effects O 0 0.00015537416
differ O 0 0.00014383049
among O 0 0.0001325878
the O 0 9.771288e-05
various O 0 0.00015422008
atypicals O 0 0.9710833
, O 0 0.0002828546
the O 0 8.998198e-05
clinician O 0 0.00025126344
should O 0 3.844723e-05
carefully O 0 4.0205305e-05
consider O 0 4.9453476e-05
which O 0 9.66531e-05
side O 0 0.00027251913
effects O 0 0.00010681043
are O 0 8.565616e-05
most O 0 0.00011796283
likely O 0 5.638571e-05
to O 0 8.200913e-05
lead O 0 0.00045527337
to O 0 7.2244766e-05
the O 0 6.208897e-05
individual O 0 6.660325e-05
' O 0 0.00019136941
s O 0 0.00017282068
dissatisfaction O 0 0.0008141898
and O 0 0.00012972743
noncompliance O 0 0.0025245345
before O 0 5.9127462e-05
choosing O 0 0.000113254035
an O 0 0.00027270862
antipsychotic O 0 0.9841815
for O 0 0.00026520275
a O 0 0.00062102126
particular O 0 0.0005182909
patient O 0 0.0014296869
. O 0 0.0022744297

A O 0 0.02583283
randomized O 0 0.0055483067
, O 0 0.002774127
placebo O 0 0.011553057
- O 0 0.0025682184
controlled O 0 0.00050300756
dose O 0 0.0006460037
- O 0 0.0010202806
comparison O 0 0.00017474932
trial O 0 0.00037355247
of O 0 0.00048584444
haloperidol B-Chemical 1 0.99999785
for O 0 0.00051303
psychosis B-Disease 0 0.99996066
and O 0 0.0005715545
disruptive B-Disease 0 0.4423553
behaviors I-Disease 0 0.01797102
in O 0 0.001192852
Alzheimer B-Disease 0 0.99987996
' I-Disease 0 0.0029768376
s I-Disease 0 0.002508728
disease I-Disease 0 0.3545546
. O 0 0.0034508691

OBJECTIVE O 0 0.02132795
: O 0 0.0036249182
The O 0 0.0006567955
goal O 0 0.0007029511
of O 0 0.00060448487
this O 0 0.00047012945
study O 0 0.00037055416
was O 0 0.00018535295
to O 0 0.000109573135
compare O 0 5.359948e-05
the O 0 7.398841e-05
efficacy O 0 9.874191e-05
and O 0 0.00010488097
side O 0 0.0002390305
effects O 0 8.905986e-05
of O 0 9.553937e-05
two O 0 5.6859797e-05
doses O 0 0.0002835901
of O 0 0.0002924747
haloperidol B-Chemical 1 0.99999905
and O 0 0.00019121822
placebo O 0 0.0030024655
in O 0 6.613723e-05
the O 0 5.8845755e-05
treatment O 0 9.50233e-05
of O 0 0.0002216669
psychosis B-Disease 0 0.9999771
and O 0 0.00036152883
disruptive B-Disease 0 0.47579664
behaviors I-Disease 0 0.004744515
in O 0 0.00025970835
patients O 0 0.00081281527
with O 0 0.0008739229
Alzheimer B-Disease 0 0.99991214
' I-Disease 0 0.0028082645
s I-Disease 0 0.0022967784
disease I-Disease 0 0.4321673
. O 0 0.0031707063

METHOD O 0 0.010596457
: O 0 0.0036733537
In O 0 0.0008759695
a O 0 0.0011751872
6 O 0 0.00060397206
- O 0 0.0015513307
week O 0 0.00030609014
random O 0 0.0005586679
- O 0 0.0015496277
assignment O 0 0.00038424117
, O 0 0.00047434936
double O 0 0.0002943874
- O 0 0.0025692019
blind O 0 0.015837919
, O 0 0.0006479068
placebo O 0 0.0075763236
- O 0 0.001059912
controlled O 0 0.00020369986
trial O 0 0.00030671494
( O 0 0.00032962122
phase O 0 0.00050316454
A O 0 0.017749246
) O 0 0.0014314859
, O 0 0.0016552567
haloperidol B-Chemical 1 0.999998
, O 0 0.0006430439
2 O 0 0.00021407258
- O 0 0.0005969176
3 O 0 0.00011555768
mg O 0 0.0008701945
/ O 0 0.00037962277
day O 0 8.035346e-05
( O 0 0.00017285862
standard O 0 0.000115246694
dose O 0 0.00024704082
) O 0 0.00041261886
, O 0 0.00037698448
and O 0 0.00046814303
haloperidol B-Chemical 1 0.9999981
, O 0 0.00067603705
0 O 0 0.0002502583
. O 0 0.00014589693
50 O 0 0.00020948802
- O 0 0.0006776926
0 O 0 0.00017803941
. O 0 0.0001238308
75 O 0 0.00021801452
mg O 0 0.0011563225
/ O 0 0.00045439476
day O 0 9.313723e-05
( O 0 0.00020544228
low O 0 0.00018215198
dose O 0 0.0003327876
) O 0 0.0004228941
, O 0 0.00027256177
were O 0 0.00012923538
compared O 0 0.0001157381
in O 0 0.00020234521
71 O 0 0.0006344029
outpatients O 0 0.005855509
with O 0 0.0010321431
Alzheimer B-Disease 0 0.99985373
' I-Disease 0 0.0030111491
s I-Disease 0 0.0026060767
disease I-Disease 0 0.39504796
. O 0 0.0035750365

For O 0 0.001657938
the O 0 0.0013484347
subsequent O 0 0.0008706033
6 O 0 0.00067317125
- O 0 0.0016746735
week O 0 0.00030006169
double O 0 0.00039371182
- O 0 0.0023428737
blind O 0 0.008283434
crossover O 0 0.0019236148
phase O 0 0.00076531194
( O 0 0.00060615054
phase O 0 0.00070416805
B O 0 0.07210895
) O 0 0.00088184385
, O 0 0.0003402207
patients O 0 0.00025998263
taking O 0 0.00014762886
standard O 0 0.00013503307
- O 0 0.0005745624
or O 0 9.4062976e-05
low O 0 0.0002072225
- O 0 0.0022627357
dose O 0 0.0010085347
haloperidol B-Chemical 1 0.9999981
were O 0 0.000114931405
switched O 0 0.00013471258
to O 0 7.0539514e-05
placebo O 0 0.0014360838
, O 0 0.00015489887
and O 0 8.7599095e-05
patients O 0 0.00017896225
taking O 0 0.00012350688
placebo O 0 0.0008724586
were O 0 6.522193e-05
randomly O 0 4.166228e-05
assigned O 0 6.387517e-05
to O 0 8.539657e-05
standard O 0 0.00016918233
- O 0 0.0007817873
or O 0 0.00021897492
low O 0 0.00061757193
- O 0 0.0059855054
dose O 0 0.0056966706
haloperidol B-Chemical 1 0.99998355
. O 0 0.0041517126

RESULTS O 0 0.0041056983
: O 0 0.0024539884
For O 0 0.0005127039
the O 0 0.00055475294
60 O 0 0.00059598114
patients O 0 0.00064181327
who O 0 0.00042015786
completed O 0 0.00031942094
phase O 0 0.00056704297
A O 0 0.0032606113
, O 0 0.00046813814
standard O 0 0.00025584683
- O 0 0.001757443
dose O 0 0.0010460763
haloperidol B-Chemical 1 0.99999714
was O 0 0.00013617676
efficacious O 0 0.00011054453
and O 0 7.418256e-05
superior O 0 0.0001220372
to O 0 5.4697553e-05
both O 0 6.233316e-05
low O 0 0.00016132397
- O 0 0.0016095234
dose O 0 0.0007177267
haloperidol B-Chemical 1 0.99999785
and O 0 0.00014595508
placebo O 0 0.0008176048
for O 0 5.018932e-05
scores O 0 6.5820255e-05
on O 0 4.9580784e-05
the O 0 8.316356e-05
Brief O 0 0.0003688186
Psychiatric O 0 0.00089173106
Rating O 0 0.0019071456
Scale O 0 0.016353661
psychosis B-Disease 0 0.99981767
factor O 0 0.004715996
and O 0 0.00067338167
on O 0 0.0008423328
psychomotor B-Disease 0 0.99971896
agitation I-Disease 2 0.9987319
. O 0 0.0043711807

Response O 0 0.0052252314
rates O 0 0.0019223207
according O 0 0.00073385244
to O 0 0.00044634874
three O 0 0.00020714547
sets O 0 0.00026144867
of O 0 0.0002866277
criteria O 0 0.0002709213
were O 0 0.00017965332
greater O 0 0.00021599224
with O 0 0.0001728825
the O 0 0.0001262939
standard O 0 0.00016022925
dose O 0 0.00027734684
( O 0 0.00028984292
55 O 0 0.00022373334
% O 0 0.00035312487
- O 0 0.00072863477
60 O 0 0.00017988661
% O 0 0.00028326665
) O 0 0.00029679292
than O 0 0.00010366562
the O 0 0.0001005153
low O 0 0.00020227539
dose O 0 0.00035389676
( O 0 0.00034436694
25 O 0 0.00026347738
% O 0 0.0004158131
- O 0 0.00083448377
35 O 0 0.00022827106
% O 0 0.00038812772
) O 0 0.00047204018
and O 0 0.00029526884
placebo O 0 0.002915212
( O 0 0.00068536727
25 O 0 0.00060665247
% O 0 0.0010177608
- O 0 0.0021818588
30 O 0 0.0008058279
% O 0 0.002003763
) O 0 0.00379163
. O 0 0.003815701

The O 0 0.0016161043
advantage O 0 0.0010031989
of O 0 0.001107779
standard O 0 0.00086383737
dose O 0 0.0009437618
over O 0 0.00043563324
low O 0 0.00069875096
dose O 0 0.00099664
was O 0 0.0006215098
replicated O 0 0.0008645131
in O 0 0.0010941208
phase O 0 0.003707279
B O 0 0.17410439
. O 0 0.0061807646

In O 0 0.0025703178
phase O 0 0.005776258
A O 0 0.14531371
, O 0 0.020424604
extrapyramidal B-Disease 0 0.9999894
signs I-Disease 0 0.5945654
tended O 0 0.0006167381
to O 0 0.00021700247
be O 0 0.00015954563
greater O 0 0.00017114214
with O 0 0.00012658269
the O 0 8.6036984e-05
standard O 0 0.000103855404
dose O 0 0.00016601171
than O 0 7.615787e-05
in O 0 7.409856e-05
the O 0 6.491491e-05
other O 0 6.6758206e-05
two O 0 5.5173445e-05
conditions O 0 0.00012069705
, O 0 0.00025497412
primarily O 0 0.00012305079
because O 0 9.0909045e-05
of O 0 0.00016693411
a O 0 0.00028678274
subgroup O 0 0.00055528193
( O 0 0.00035957227
20 O 0 0.00018923449
% O 0 0.00036639106
) O 0 0.00049386144
who O 0 0.00033655422
developed O 0 0.00035926246
moderate O 0 0.0011448807
to O 0 0.00062933797
severe O 0 0.006738734
signs O 0 0.008018166
. O 0 0.002881071

Low O 0 0.013918541
- O 0 0.032422256
dose O 0 0.017820692
haloperidol B-Chemical 1 0.99999285
did O 0 0.0012603205
not O 0 0.0004469819
differ O 0 0.0003352472
from O 0 0.0002516866
placebo O 0 0.0014894024
on O 0 0.00014307925
any O 0 0.00015164487
measure O 0 0.00013784143
of O 0 0.00026598113
efficacy O 0 0.0003820385
or O 0 0.0004842297
side O 0 0.0018238513
effects O 0 0.0018097492
. O 0 0.0035523942

CONCLUSIONS O 0 0.017301278
: O 0 0.0032383879
The O 0 0.00058579474
results O 0 0.00047473094
indicated O 0 0.00032328846
a O 0 0.00051446055
favorable O 0 0.0005611283
therapeutic O 0 0.00032385578
profile O 0 0.00021651016
for O 0 0.00029059607
haloperidol B-Chemical 1 0.9999964
in O 0 0.00021717635
doses O 0 0.00034757002
of O 0 0.00016708141
2 O 0 0.00018695965
- O 0 0.00059134356
3 O 0 0.00012062077
mg O 0 0.0011022289
/ O 0 0.0004898597
day O 0 0.00010623854
, O 0 0.000261624
although O 0 0.00016677614
a O 0 0.00030435607
subgroup O 0 0.00057298417
developed O 0 0.00036442603
moderate O 0 0.0012245955
to O 0 0.00056364766
severe O 0 0.18375771
extrapyramidal B-Disease 0 0.9999832
signs I-Disease 0 0.6718423
. O 0 0.0033230623

A O 0 0.016054444
starting O 0 0.0016273306
dose O 0 0.0020148156
of O 0 0.0010920567
1 O 0 0.0010039485
mg O 0 0.004920162
/ O 0 0.0014899422
day O 0 0.0003082117
with O 0 0.00040764207
gradual O 0 0.0005939487
, O 0 0.0008970277
upward O 0 0.0023612957
dose O 0 0.0011208033
titration O 0 0.0008320627
is O 0 0.00084084243
recommended O 0 0.0016233813
. O 0 0.0032203512

The O 0 0.0016510377
narrow O 0 0.0021119006
therapeutic O 0 0.0011840933
window O 0 0.00073618605
observed O 0 0.0005716545
with O 0 0.0013270455
haloperidol B-Chemical 1 0.99999726
may O 0 0.00029422186
also O 0 0.00016128445
apply O 0 0.000120341705
to O 0 0.00011475782
other O 0 0.00017721359
neuroleptics O 0 0.9991597
used O 0 0.00019358975
in O 0 0.00035608062
Alzheimer B-Disease 0 0.9999459
' I-Disease 0 0.0007584951
s I-Disease 0 0.00051412923
disease I-Disease 0 0.22172233
patients O 0 0.00077487476
with O 0 0.0006098272
psychosis B-Disease 0 0.9999465
and O 0 0.001303704
disruptive B-Disease 0 0.6741158
behaviors I-Disease 0 0.04335069
. O 0 0.0034499231

Effects O 0 0.0067457757
of O 0 0.014770057
acetylsalicylic B-Chemical 0 0.99999034
acid I-Chemical 0 0.9990081
, O 0 0.06937258
dipyridamole B-Chemical 0 0.99996305
, O 0 0.0026175962
and O 0 0.001098483
hydrocortisone B-Chemical 0 0.9999455
on O 0 0.0006801033
epinephrine B-Chemical 0 0.9998852
- O 0 0.0139530655
induced O 0 0.00086018885
myocardial B-Disease 0 0.99982446
injury I-Disease 0 0.8704426
in O 0 0.001190702
dogs O 0 0.0028684526
. O 0 0.0026209187

A O 0 0.015582359
reproducible O 0 0.0015992931
model O 0 0.00091823906
for O 0 0.0006252075
producing O 0 0.0007654933
diffuse O 0 0.019585308
myocardial B-Disease 0 0.9998116
injury I-Disease 0 0.93079484
( O 0 0.0019715354
epinephrine B-Chemical 0 0.99971384
infusion O 0 0.0010273199
) O 0 0.00035908958
has O 0 7.416445e-05
been O 0 9.33071e-05
developed O 0 0.00011666253
to O 0 7.9667996e-05
study O 0 0.000102489175
the O 0 7.308654e-05
cardioprotective O 0 0.00091094105
effects O 0 9.5558134e-05
of O 0 0.00012707963
agents O 0 0.00042137422
or O 0 0.0001239564
maneuvers O 0 0.00052560616
which O 0 0.00016379922
might O 0 8.124273e-05
alter O 0 0.00013247735
the O 0 0.00016750845
evolution O 0 0.00032058943
of O 0 0.0007167718
acute O 0 0.9674705
myocardial B-Disease 0 0.99982697
infarction I-Disease 0 0.9999839
. O 0 0.004237396

Infusions O 0 0.062031027
of O 0 0.0040693954
epinephrine B-Chemical 0 0.999215
( O 0 0.001709866
4 O 0 0.00045775532
mug O 0 0.0007024408
per O 0 0.0003000228
kilogram O 0 0.0006260578
per O 0 0.0001636272
minute O 0 0.00014617447
for O 0 8.141429e-05
6 O 0 8.471048e-05
hours O 0 0.00011036885
) O 0 0.00037129762
increased O 0 0.00046457094
radiocalcium B-Chemical 0 0.9998373
uptakes O 0 0.13743092
into O 0 0.00010073744
intact O 0 0.00018469665
myocardium O 0 0.007408113
and O 0 0.00010969817
each O 0 5.741058e-05
of O 0 9.14578e-05
its O 0 0.00011016066
subcellular O 0 5.4327324e-05
components O 0 8.101713e-05
with O 0 0.0001194397
the O 0 0.00010792496
mitochondrial O 0 0.003357108
fraction O 0 0.00010634964
showing O 0 7.208765e-05
the O 0 6.219006e-05
most O 0 8.740067e-05
consistent O 0 5.2844378e-05
changes O 0 6.0573428e-05
when O 0 3.9314305e-05
compared O 0 4.800952e-05
to O 0 6.7577035e-05
saline O 0 0.00046655707
- O 0 0.0007344308
infused O 0 0.00036694936
control O 0 8.667469e-05
animals O 0 7.6220786e-05
( O 0 0.00019849247
4 O 0 0.00010180898
, O 0 0.00024231554
957 O 0 0.0010949841
vs O 0 0.00022737567
. O 0 0.00016475852
827 O 0 0.0008081529
counts O 0 0.0001246106
per O 0 0.00013966775
minute O 0 0.00020715535
per O 0 0.00021647882
gram O 0 0.0007321603
of O 0 0.00041711333
dried O 0 0.0024025205
tissue O 0 0.0014468691
or O 0 0.0005893959
fraction O 0 0.0011198188
) O 0 0.003748913
. O 0 0.0031392842

Myocardial O 0 0.6250776
concentrations O 0 0.0042278077
of O 0 0.002329842
calcium B-Chemical 0 0.9875049
also O 0 0.00085086713
increased O 0 0.00082418125
significantly O 0 0.0005686686
( O 0 0.00058982626
12 O 0 0.00018127213
. O 0 0.00017588705
0 O 0 0.00021599328
vs O 0 0.00025958705
. O 0 0.00018111683
5 O 0 0.00016121664
. O 0 0.00017168463
0 O 0 0.0002814206
mg O 0 0.0016048485
. O 0 0.00022699746
per O 0 0.00023818306
100 O 0 0.00064831943
Gm O 0 0.016977308
. O 0 0.00035912925
of O 0 0.0005627373
fat O 0 0.80755806
- O 0 0.006595352
free O 0 0.0012955348
dry O 0 0.004724217
weight O 0 0.0021938633
) O 0 0.0040104347
. O 0 0.0034440819

Infusions O 0 0.14426357
of O 0 0.0051880884
calcium B-Chemical 0 0.9989668
chloride I-Chemical 0 0.9995684
sufficient O 0 0.00061165093
to O 0 0.0004372052
raise O 0 0.00040933976
serum O 0 0.07071575
calcium B-Chemical 0 0.9948833
concentrations O 0 0.0009966267
2 O 0 0.00041199062
mEq O 0 0.4944585
. O 0 0.0002069453
per O 0 0.0001845736
liter O 0 0.0011506344
failed O 0 0.0001975631
to O 0 0.00019460167
increase O 0 0.00035136705
calcium B-Chemical 0 0.9870157
influx O 0 0.005516513
into O 0 0.00035125538
the O 0 0.00073226844
myocardial O 0 0.9857584
cell O 0 0.0034019966
. O 0 0.0033790236

Mitochondrial O 0 0.989792
radiocalcium B-Chemical 0 0.9997582
uptakes O 0 0.7677181
were O 0 0.0008984143
significantly O 0 0.0006123883
decreased O 0 0.0005822609
in O 0 0.00025159595
animals O 0 0.00021255655
pretreated O 0 0.0041860705
with O 0 0.0025200658
acetylsalicylic B-Chemical 0 0.99999905
acid I-Chemical 0 0.99927455
or O 0 0.0008895327
dipyridamole B-Chemical 0 0.9999863
or O 0 0.0001772009
when O 0 0.00015747665
hydrocortisone B-Chemical 0 0.9999758
was O 0 0.00014010689
added O 0 0.00014140476
to O 0 9.3552735e-05
the O 0 0.00014246527
epinephrine B-Chemical 0 0.9996854
infusion O 0 0.00067481527
( O 0 0.00024863041
2 O 0 0.00015884946
, O 0 0.00031700608
682 O 0 0.0011044502
, O 0 0.00032370735
2 O 0 0.00021070456
, O 0 0.0003857937
803 O 0 0.002112585
, O 0 0.00033690833
and O 0 0.00018407009
3 O 0 0.00016031513
, O 0 0.00032187445
424 O 0 0.00069894147
counts O 0 0.00014791856
per O 0 0.00015990902
minute O 0 0.00022841519
per O 0 0.0002315689
gram O 0 0.0007028
of O 0 0.00040230938
dried O 0 0.0015636948
fraction O 0 0.0006627151
, O 0 0.001583866
respectively O 0 0.0022851978
) O 0 0.004026893
. O 0 0.0033553345

Myocardial O 0 0.9562156
calcium B-Chemical 0 0.9922633
concentrations O 0 0.0032616295
also O 0 0.00092214457
were O 0 0.00066805765
decreased O 0 0.00095688814
( O 0 0.0008806574
11 O 0 0.00042706134
. O 0 0.00029010666
2 O 0 0.0002827804
, O 0 0.00038478183
8 O 0 0.00021065997
. O 0 0.00018706628
3 O 0 0.0001604084
, O 0 0.0002874413
and O 0 0.00018509154
8 O 0 0.00016562875
. O 0 0.00015446717
9 O 0 0.00015804422
mg O 0 0.0012619153
. O 0 0.00016743754
per O 0 0.00016336542
100 O 0 0.00043406695
Gm O 0 0.017200043
. O 0 0.00018908335
of O 0 0.0002616721
fat O 0 0.84483105
- O 0 0.0043370603
free O 0 0.00032686116
dry O 0 0.0012467833
weight O 0 0.0002787375
, O 0 0.00029082943
respectively O 0 0.00030970332
) O 0 0.0003072892
in O 0 8.9139045e-05
the O 0 6.646423e-05
three O 0 4.254181e-05
treatment O 0 9.61377e-05
groups O 0 0.00016641444
, O 0 0.00028652255
being O 0 0.00018464754
significantly O 0 0.00027327053
decreased O 0 0.0004945295
only O 0 0.0003401816
in O 0 0.0003254442
the O 0 0.0003506224
last O 0 0.00037098894
two O 0 0.0007899386
. O 0 0.0023364385

Evidence O 0 0.005401707
of O 0 0.00279676
microscopic O 0 0.0030325353
damage O 0 0.012812231
was O 0 0.00087824947
graded O 0 0.001163699
as O 0 0.00057794794
less O 0 0.0007917386
severe O 0 0.0017881485
in O 0 0.00044609013
the O 0 0.00040054426
three O 0 0.0003476534
treatment O 0 0.00087781524
groups O 0 0.0019939658
. O 0 0.0034894678

Acetylsalicylic B-Chemical 0 0.9999651
acid I-Chemical 0 0.99790645
, O 0 0.09067695
dipyridamole B-Chemical 0 0.99994814
, O 0 0.0049688704
and O 0 0.0017971018
hydrocortisone B-Chemical 0 0.9999474
all O 0 0.00046047854
appear O 0 0.00022305237
to O 0 0.00016920266
have O 0 0.00018065062
cardioprotective O 0 0.0017074886
effects O 0 0.0002579961
when O 0 0.00024611503
tested O 0 0.00041425473
in O 0 0.000579016
this O 0 0.00094062294
model O 0 0.0014247714
. O 0 0.0029536197

Clinical O 0 0.0057207188
and O 0 0.0016998757
histopathologic O 0 0.001984523
examination O 0 0.0005744839
of O 0 0.0006306181
renal O 0 0.12620457
allografts O 0 0.0012978257
treated O 0 0.0007296055
with O 0 0.000716558
tacrolimus B-Chemical 0 0.99997795
( O 0 0.004036697
FK506 B-Chemical 0 0.99994147
) O 0 0.0012503059
for O 0 0.00026176174
at O 0 0.0002938305
least O 0 0.00045372188
one O 0 0.00068948435
year O 0 0.0012140134
. O 0 0.0025611483

BACKGROUND O 0 0.017300714
: O 0 0.0041512907
We O 0 0.0010502017
clinically O 0 0.002198486
and O 0 0.00082801754
pathologically O 0 0.023512013
analyzed O 0 0.00042680083
renal O 0 0.20906867
allografts O 0 0.0007346688
from O 0 0.00014726455
1 O 0 0.00014368028
9 O 0 0.000108317974
renal O 0 0.0065654432
transplant O 0 0.00021665494
patients O 0 0.0001976217
treated O 0 0.00024370338
with O 0 0.00035615618
tacrolimus B-Chemical 0 0.99998736
( O 0 0.0033935274
FK506 B-Chemical 0 0.9999652
) O 0 0.0011684468
for O 0 0.00024431458
more O 0 0.0005077491
than O 0 0.00044322768
1 O 0 0.00081169157
year O 0 0.0009922619
. O 0 0.002162324

METHODS O 0 0.004264331
: O 0 0.0032450797
Twenty O 0 0.0020153536
- O 0 0.0024473162
six O 0 0.00045712828
renal O 0 0.031152168
allograft O 0 0.002013625
biopsy O 0 0.00042495932
specimens O 0 0.00023722668
from O 0 0.00017224178
1 O 0 0.00019582588
9 O 0 0.00015483834
renal O 0 0.009039753
transplant O 0 0.00029047695
patients O 0 0.00023590562
who O 0 0.00016985717
underwent O 0 0.00017176862
transplantations O 0 0.0002836918
between O 0 0.0001795658
1991 O 0 0.0006603282
and O 0 0.000547918
1993 O 0 0.0016476833
were O 0 0.0008501063
evaluated O 0 0.0014108986
. O 0 0.0029033746

Thirteen O 0 0.004687163
biopsies O 0 0.0015165298
were O 0 0.0007610549
performed O 0 0.00047999335
from O 0 0.0003614846
stable O 0 0.0003619377
functioning O 0 0.00088118203
renal O 0 0.21031028
allografts O 0 0.0009811542
with O 0 0.00028094318
informed O 0 0.0003345247
consent O 0 0.00028906632
( O 0 0.0002715274
nonepisode O 0 0.00049854495
biopsy O 0 0.0002102809
) O 0 0.00028046008
and O 0 0.00012188763
the O 0 9.222506e-05
other O 0 0.000101686834
13 O 0 0.00013455263
were O 0 8.9271656e-05
from O 0 9.739232e-05
dysfunctional O 0 0.0005769924
renal O 0 0.21335457
allografts O 0 0.0005112896
with O 0 0.0001451356
a O 0 0.00020518465
clinical O 0 0.00033797458
indication O 0 9.4898336e-05
for O 0 0.0001394889
biopsy O 0 0.00034060626
( O 0 0.0005528724
episode O 0 0.0006433133
biopsy O 0 0.0010574054
) O 0 0.0025337876
. O 0 0.0027419662

RESULTS O 0 0.004482889
: O 0 0.0028908341
The O 0 0.00070835144
main O 0 0.00091682543
pathologic O 0 0.0037987768
diagnoses O 0 0.0015289676
( O 0 0.00075647247
some O 0 0.00033536993
overlap O 0 0.00029967946
) O 0 0.00065194204
were O 0 0.00026085708
acute O 0 0.0043337587
rejection O 0 0.005037193
( O 0 0.00067108177
AR O 0 0.0030679596
; O 0 0.0003903104
n O 0 0.00022261938
= O 0 0.0004436642
4 O 0 0.00014410507
) O 0 0.0003595047
, O 0 0.00033400365
chronic O 0 0.001900976
rejection O 0 0.0031101704
( O 0 0.000499681
CR O 0 0.0015373704
; O 0 0.00032251675
n O 0 0.00021499245
= O 0 0.00047847393
5 O 0 0.00018696251
) O 0 0.00045887113
, O 0 0.00050061115
AR O 0 0.004262121
+ O 0 0.0013265894
CR O 0 0.0023016995
( O 0 0.0003123152
n O 0 0.0002103856
= O 0 0.00044298611
4 O 0 0.00015239455
) O 0 0.00043903524
, O 0 0.0005202101
recurrent O 0 0.0058332845
IgA B-Disease 0 0.99857974
nephropathy I-Disease 0 0.99999833
( O 0 0.000901475
n O 0 0.0002604165
= O 0 0.00047689804
5 O 0 0.00013707046
) O 0 0.0002952573
, O 0 0.00023368688
normal O 0 0.00021034325
findings O 0 0.00016653984
( O 0 0.00023246133
n O 0 0.00018428364
= O 0 0.00042150798
2 O 0 0.00017100463
) O 0 0.00032223336
, O 0 0.00025016456
minimal O 0 0.00017610085
- O 0 0.0015643894
type O 0 0.0006380019
chronic O 0 0.42472246
FK506 B-Chemical 0 0.9999944
nephropathy B-Disease 0 0.9999975
( O 0 0.0007572244
n O 0 0.00021854191
= O 0 0.00040308383
9 O 0 0.00012607277
) O 0 0.00031633858
, O 0 0.0002939496
and O 0 0.00026786537
mild O 0 0.046364035
- O 0 0.0070010633
type O 0 0.0026680096
FK506 B-Chemical 0 0.9999877
nephropathy B-Disease 0 0.9999943
( O 0 0.002061365
n O 0 0.00079330837
= O 0 0.0017439189
11 O 0 0.0011429845
) O 0 0.0026922724
. O 0 0.0028447052

Of O 0 0.005503785
the O 0 0.0022671483
nonepisode O 0 0.004559136
biopsies O 0 0.0012587155
, O 0 0.0011957701
7 O 0 0.00043631875
and O 0 0.00038003197
4 O 0 0.00025720918
biopsies O 0 0.00024671413
showed O 0 0.00020822229
minimal O 0 0.00028383653
- O 0 0.0016481441
type O 0 0.0006201226
and O 0 0.0004884969
mild O 0 0.08332513
- O 0 0.0055948705
type O 0 0.0014754357
chronic O 0 0.6513155
FK506 B-Chemical 0 0.9999869
nephropathy B-Disease 0 0.9999927
, O 0 0.007270872
respectively O 0 0.003928988
. O 0 0.0032118415

Chronic O 0 0.5282811
FK506 B-Chemical 0 0.9999018
nephropathy B-Disease 0 0.9999571
consisted O 0 0.0015906608
of O 0 0.0008785909
rough O 0 0.0010395839
and O 0 0.00078928214
foamy O 0 0.01745294
tubular O 0 0.90903634
vacuolization O 0 0.08638815
( O 0 0.0005634804
5 O 0 0.0001618054
biopsies O 0 0.00016338896
) O 0 0.00035664492
, O 0 0.00039710145
arteriolopathy O 0 0.8595604
( O 0 0.00034361042
angiodegeneration O 0 0.0002704351
of O 0 0.00021040044
the O 0 0.00024114428
arteriolar O 0 0.99966466
wall O 0 0.007516591
; O 0 0.00042646818
20 O 0 0.00013616911
biopsies O 0 0.00014129381
) O 0 0.00032564127
, O 0 0.00034974553
focal B-Disease 0 0.004574279
segmental I-Disease 0 0.11479564
glomerulosclerosis I-Disease 0 0.9999975
( O 0 0.0005921055
4 O 0 0.00010964211
biopsies O 0 0.00012528422
) O 0 0.00023832005
and O 0 0.00013035099
the O 0 0.00013510737
striped O 0 0.0004208605
form O 0 0.00027544794
of O 0 0.0005467726
interstitial B-Disease 0 0.9666545
fibrosis I-Disease 0 0.999864
( O 0 0.0016400457
11 O 0 0.00072925584
biopsies O 0 0.0009027094
) O 0 0.0024474931
. O 0 0.0026696417

The O 0 0.0029280193
serum O 0 0.055721067
creatinine B-Chemical 0 0.9819058
levels O 0 0.00086957286
of O 0 0.00071565714
patients O 0 0.00089976215
in O 0 0.00033331593
the O 0 0.0003080889
mild O 0 0.03103065
- O 0 0.003531341
type O 0 0.00079349126
chronic O 0 0.4591698
FK506 B-Chemical 0 0.99999535
nephropathy B-Disease 0 0.99999857
group O 0 0.0012363177
, O 0 0.0003665698
which O 0 0.00012605594
included O 0 7.796005e-05
7 O 0 6.0737693e-05
episode O 0 9.0335845e-05
biopsies O 0 8.449765e-05
, O 0 0.00012881658
were O 0 6.576372e-05
statistically O 0 0.000113391594
higher O 0 9.508131e-05
than O 0 7.6722055e-05
those O 0 9.831179e-05
in O 0 8.142174e-05
the O 0 8.110016e-05
minimum O 0 0.0001182622
- O 0 0.0011349774
type O 0 0.00051786826
chronic O 0 0.28749388
FK506 B-Chemical 0 0.9999896
- O 0 0.5484155
nephropathy B-Disease 0 0.99999166
group O 0 0.0009180116
( O 0 0.00073210377
P O 0 0.00828307
< O 0 0.00064175786
0 O 0 0.0006485311
. O 0 0.00078791403
001 O 0 0.0082901595
) O 0 0.0041406755
. O 0 0.0037194903

CONCLUSIONS O 0 0.023339877
: O 0 0.004630637
This O 0 0.0015595552
study O 0 0.0007581699
demonstrates O 0 0.00031484655
that O 0 0.00041166868
chronic O 0 0.24263175
FK506 B-Chemical 0 0.9999896
nephropathy B-Disease 0 0.99999547
consists O 0 0.00026510973
primarily O 0 0.00017855114
of O 0 0.00025219203
arteriolopathy O 0 0.9947088
manifesting O 0 0.02079075
as O 0 0.00020356066
insudative O 0 0.13776731
hyalinosis O 0 0.98074037
of O 0 0.00020643092
the O 0 0.00018735207
arteriolar O 0 0.99985445
wall O 0 0.014026762
, O 0 0.00030324617
and O 0 0.000108577755
suggests O 0 6.06838e-05
that O 0 9.9158395e-05
mild O 0 0.06320505
- O 0 0.00535353
type O 0 0.00067740335
chronic O 0 0.6885991
FK506 B-Chemical 0 0.99999785
nephropathy B-Disease 0 0.99999905
is O 0 0.00021891645
a O 0 0.00025554968
condition O 0 0.0003581852
which O 0 0.00019158122
may O 0 0.00013295114
lead O 0 0.00076177646
to O 0 0.00018794
deterioration O 0 0.003353683
of O 0 0.00044984664
renal O 0 0.6163982
allograft O 0 0.004900369
function O 0 0.0011158559
. O 0 0.0022980121

Different O 0 0.0051608444
lobular O 0 0.3765651
distributions O 0 0.0011909044
of O 0 0.001428702
altered O 0 0.0014807385
hepatocyte O 0 0.39405766
tight O 0 0.00096815533
junctions O 0 0.0004884407
in O 0 0.00037526005
rat O 0 0.0005045254
models O 0 0.0003634764
of O 0 0.00067632325
intrahepatic B-Disease 0 0.69403774
and I-Disease 0 0.002845892
extrahepatic I-Disease 0 0.9997619
cholestasis I-Disease 0 0.9999895
. O 0 0.009570131

Hepatocyte O 0 0.9707366
tight O 0 0.004140186
junctions O 0 0.0021173903
( O 0 0.002553169
TJs O 0 0.002711517
) O 0 0.0020760016
, O 0 0.0010850633
the O 0 0.00043644797
only O 0 0.0005516896
intercellular O 0 0.0069092833
barrier O 0 0.0010955349
between O 0 0.00020551223
the O 0 0.00021761164
sinusoidal O 0 0.003703681
and O 0 0.00030045732
the O 0 0.0002718953
canalicular O 0 0.97916394
spaces O 0 0.0016519112
, O 0 0.0004718369
play O 0 0.00018773208
a O 0 0.00035883614
key O 0 0.00023861109
role O 0 0.00028404637
in O 0 0.0009826492
bile O 0 0.989028
formation O 0 0.007819062
. O 0 0.0044093747

Although O 0 0.0034415084
hepatocyte O 0 0.4588538
TJs O 0 0.004912846
are O 0 0.0010502449
impaired O 0 0.0023625114
in O 0 0.0011251915
cholestasis B-Disease 0 0.9999672
, O 0 0.0013810812
attempts O 0 0.00035435034
to O 0 0.00016295411
localize O 0 6.548506e-05
the O 0 0.00011177889
precise O 0 0.000111551555
site O 0 0.00013779568
of O 0 0.0004581858
hepatocyte O 0 0.9761109
TJ O 0 0.99863064
damage O 0 0.3158359
by O 0 0.00036351246
freeze O 0 0.0010550392
- O 0 0.006112773
fracture O 0 0.93469226
electron O 0 0.0039478885
microscopy O 0 0.00044555104
have O 0 0.00030180352
produced O 0 0.00039938817
limited O 0 0.00083380094
information O 0 0.0015944684
. O 0 0.002946657

Recently O 0 0.0045549627
, O 0 0.005349448
several O 0 0.0022472346
TJ O 0 0.91007066
- O 0 0.010807864
associated O 0 0.0010192645
proteins O 0 0.0007399222
like O 0 0.0010447846
ZO O 0 0.99904007
- O 0 0.031441186
1 O 0 0.0007193674
and O 0 0.000629323
7H6 O 0 0.018701924
have O 0 0.000531201
been O 0 0.00055352255
identified O 0 0.0005731283
and O 0 0.0013355757
characterized O 0 0.0027988183
. O 0 0.0040927487

Immunolocalization O 0 0.005413217
of O 0 0.004954996
7H6 O 0 0.09568846
appears O 0 0.0017256078
to O 0 0.0014597873
closely O 0 0.0012986467
correlate O 0 0.0015885541
with O 0 0.0025276828
paracellular O 0 0.53415823
permeability O 0 0.8948299
. O 0 0.0077174674

We O 0 0.0024471346
used O 0 0.0014939087
rat O 0 0.0014782667
models O 0 0.0008061893
of O 0 0.0011852904
intrahepatic B-Disease 0 0.9991683
cholestasis I-Disease 0 0.99999774
by O 0 0.0033490828
ethinyl B-Chemical 0 0.9999807
estradiol I-Chemical 0 0.99997044
( O 0 0.0033976005
EE B-Chemical 0 0.9893554
) O 0 0.0005951968
treatment O 0 0.00017708182
and O 0 0.00030003625
extrahepatic B-Disease 0 0.99989855
cholestasis I-Disease 0 0.99999917
by O 0 0.0007714252
bile O 0 0.9982659
duct O 0 0.87407327
ligation O 0 0.00048802453
( O 0 0.000841997
BDL O 0 0.9975464
) O 0 0.00064174685
to O 0 0.00014424694
precisely O 0 0.000119774675
determine O 0 8.35173e-05
the O 0 0.00023436945
site O 0 0.00033183527
of O 0 0.0012986127
TJ O 0 0.9774655
damage O 0 0.5543893
. O 0 0.0044204765

Alterations O 0 0.007404955
in O 0 0.003441106
hepatocyte O 0 0.35128787
TJs O 0 0.0032575487
were O 0 0.0007173308
assessed O 0 0.00048466376
by O 0 0.00040671398
double O 0 0.0004567775
- O 0 0.0020283512
immunolabeling O 0 0.0003644997
for O 0 0.00031252048
7H6 O 0 0.0195096
and O 0 0.00082796474
ZO O 0 0.99840146
- O 0 0.0053728716
1 O 0 0.00042158415
using O 0 0.0002598337
a O 0 0.0005313374
confocal O 0 0.0008824957
laser O 0 0.0018807336
scanning O 0 0.0011995637
microscope O 0 0.0026056748
. O 0 0.0029810523

In O 0 0.0020495262
control O 0 0.0020017512
rats O 0 0.0023489033
, O 0 0.0019009345
immunostaining O 0 0.00069179764
for O 0 0.00061929686
7H6 O 0 0.030680878
and O 0 0.001202567
ZO O 0 0.99867344
- O 0 0.008032219
1 O 0 0.00040337176
colocalized O 0 0.00013862542
to O 0 0.00026357055
outline O 0 0.00064920087
bile O 0 0.993072
canaliculi O 0 0.9361886
in O 0 0.00082388404
a O 0 0.0010482776
continuous O 0 0.0008252021
fashion O 0 0.0019984944
. O 0 0.0030420334

In O 0 0.002767209
contrast O 0 0.003671855
, O 0 0.004793276
7H6 O 0 0.12061142
and O 0 0.0028873065
ZO O 0 0.9988098
- O 0 0.0289562
1 O 0 0.0007704996
immunostaining O 0 0.00038095543
was O 0 0.00036904478
more O 0 0.00054280675
discontinuous O 0 0.00075407757
, O 0 0.00079158467
outlining O 0 0.00066041347
the O 0 0.0007348774
bile O 0 0.98890835
canaliculi O 0 0.9544982
after O 0 0.0018467216
BDL O 0 0.9930952
. O 0 0.0055731055

Immunostaining O 0 0.0044463277
for O 0 0.0026174642
7H6 O 0 0.049252294
, O 0 0.0033616198
not O 0 0.0017238557
ZO O 0 0.9981742
- O 0 0.02390814
1 O 0 0.0007520893
, O 0 0.000764063
decreased O 0 0.00058938324
and O 0 0.00033778758
predominantly O 0 0.0002556374
appeared O 0 0.0002099071
as O 0 0.00019200364
discrete O 0 0.00017120695
signals O 0 0.0001337355
in O 0 0.00021635213
the O 0 0.00027737964
submembranous O 0 0.002212299
cytoplasm O 0 0.00035904744
of O 0 0.000719465
periportal O 0 0.9054236
hepatocytes O 0 0.011549877
after O 0 0.00096006604
BDL O 0 0.9874135
. O 0 0.0039724815

After O 0 0.002816976
EE B-Chemical 0 0.87897265
treatment O 0 0.0019113764
, O 0 0.0017991285
changes O 0 0.000754763
in O 0 0.00049336534
immunostaining O 0 0.00035810992
for O 0 0.00034733684
7H6 O 0 0.028635057
and O 0 0.00077056774
ZO O 0 0.9991704
- O 0 0.010391682
1 O 0 0.00026916535
were O 0 0.00013119134
similar O 0 9.026197e-05
to O 0 0.000119546465
those O 0 0.00019135175
seen O 0 0.00020713007
in O 0 0.0002467955
periportal O 0 0.82147336
hepatocytes O 0 0.003464187
after O 0 0.0001621084
BDL O 0 0.99751943
, O 0 0.0006252517
but O 0 0.00028661653
distributed O 0 0.00021598978
more O 0 0.00042891063
diffusely O 0 0.0005843129
throughout O 0 0.0003993132
the O 0 0.00089644844
lobule O 0 0.93979836
. O 0 0.0034951433

This O 0 0.0046377983
study O 0 0.0020859274
is O 0 0.00084159756
the O 0 0.0005132303
first O 0 0.00028961638
to O 0 0.00025430595
demonstrate O 0 0.00014103242
that O 0 0.00024940106
impairment O 0 0.31268874
of O 0 0.00069624657
hepatocyte O 0 0.8963661
TJs O 0 0.0018537439
occurs O 0 0.00023684383
heterogenously O 0 0.00047837978
in O 0 0.00012934647
the O 0 0.00014256379
liver O 0 0.092592895
lobule O 0 0.99000716
after O 0 0.00012172039
BDL O 0 0.98824966
and O 0 0.000165691
suggests O 0 7.942117e-05
that O 0 0.0001388678
BDL O 0 0.99710256
and O 0 0.00042903543
EE B-Chemical 0 0.9643651
treatments O 0 0.00024672682
produce O 0 0.00012880344
different O 0 0.00018551367
lobular O 0 0.28718856
distributions O 0 0.00024296746
of O 0 0.000535873
increased O 0 0.0014325979
paracellular O 0 0.7620923
permeability O 0 0.9467073
. O 0 0.0039636474

Memory O 0 0.21034975
facilitation O 0 0.005506098
and O 0 0.0013158569
stimulation O 0 0.0006575894
of O 0 0.00078372366
endogenous O 0 0.0006573945
nerve O 0 0.1713527
growth O 0 0.016631292
factor O 0 0.033653084
synthesis O 0 0.0023596673
by O 0 0.00071439997
the O 0 0.001092993
acetylcholine B-Chemical 1 0.9998758
releaser O 0 0.99894184
PG B-Chemical 0 0.9998416
- I-Chemical 0 0.080175124
9 I-Chemical 0 0.0019860778
. O 0 0.0029943062

The O 0 0.002357143
effects O 0 0.0024276194
of O 0 0.0039562075
PG B-Chemical 0 0.9995005
- I-Chemical 0 0.06294531
9 I-Chemical 0 0.001123695
( O 0 0.0023028092
3alpha B-Chemical 0 0.90805674
- I-Chemical 0 0.021002868
tropyl I-Chemical 0 0.008433731
2 I-Chemical 0 0.00048035264
- I-Chemical 0 0.0012071416
( I-Chemical 0 0.00047612473
p I-Chemical 0 0.0006620478
- I-Chemical 0 0.003787166
bromophenyl I-Chemical 0 0.38285616
) I-Chemical 0 0.0047205323
propionate I-Chemical 0 0.9995547
) O 0 0.002288464
, O 0 0.00068852043
the O 0 0.00038290065
acetylcholine B-Chemical 1 0.9998684
releaser O 0 0.9521351
, O 0 0.00041479923
on O 0 0.0001281165
memory O 0 0.051161066
processes O 0 0.000511865
and O 0 0.00041273
nerve O 0 0.1051865
growth O 0 0.010198474
factor O 0 0.09335796
( O 0 0.01029154
NGF O 1 0.99988997
) O 0 0.004056936
synthesis O 0 0.001813053
were O 0 0.0009134241
evaluated O 0 0.0013759559
. O 0 0.0026427836

In O 0 0.0021018302
the O 0 0.001554353
mouse O 0 0.001112523
passive O 0 0.0014722841
- O 0 0.0033954228
avoidance O 0 0.0016630936
test O 0 0.0011534557
, O 0 0.002372677
PG B-Chemical 0 0.99965537
- I-Chemical 0 0.010128087
9 I-Chemical 0 0.00033758592
( O 0 0.00044530202
10 O 0 0.00024798381
- O 0 0.0006911966
30 O 0 0.00018144405
mg O 0 0.001066385
/ O 0 0.0006399414
kg O 0 0.00048172547
, O 0 0.00033309488
i O 0 0.00033136513
. O 0 0.00016623203
p O 0 0.00028443793
. O 0 0.00016137614
) O 0 0.0003380511
, O 0 0.00024973872
administered O 0 0.00018444534
20 O 0 0.000110446854
min O 0 0.00011795676
before O 0 3.7177346e-05
the O 0 5.123722e-05
training O 0 7.902636e-05
session O 0 0.00010473496
, O 0 0.00027576007
prevented O 0 0.00053628837
amnesia B-Disease 0 0.99989843
induced O 0 0.00016098206
by O 0 0.00010308619
both O 0 7.6759745e-05
the O 0 7.215794e-05
non O 0 0.00017080811
selective O 0 0.00029628037
antimuscarinic O 0 0.9970728
drug O 0 0.7002897
scopolamine B-Chemical 0 0.9999989
and O 0 0.00030854213
the O 0 0.00019766939
M1 O 0 0.34990954
- O 0 0.005271893
selective O 0 0.00052830996
antagonist O 0 0.5207186
S B-Chemical 0 0.9971687
- I-Chemical 0 0.067458265
( I-Chemical 0 0.001356226
- I-Chemical 0 0.0043591745
) I-Chemical 0 0.0021364375
- I-Chemical 0 0.009972779
ET I-Chemical 0 0.82240516
- I-Chemical 0 0.008106584
126 I-Chemical 0 0.0044675977
. O 0 0.003552889

In O 0 0.002073082
the O 0 0.0014863703
same O 0 0.000869176
experimental O 0 0.00092175865
conditions O 0 0.0010508383
, O 0 0.003196273
PG B-Chemical 0 0.9996201
- I-Chemical 0 0.013599237
9 I-Chemical 0 0.00041606033
( O 0 0.00053062715
5 O 0 0.0002675749
- O 0 0.00078589236
20 O 0 0.00021032742
microg O 0 0.0003295018
per O 0 0.00017042368
mouse O 0 0.00015014417
, O 0 0.00034022474
i O 0 0.0004288126
. O 0 0.00024267226
c O 0 0.0010465742
. O 0 0.000241906
v O 0 0.0011193639
. O 0 0.00022330305
) O 0 0.00041702008
was O 0 0.00013176879
also O 0 0.00011306325
able O 0 9.9744095e-05
to O 0 0.0001231696
prevent O 0 0.00016773926
antimuscarine O 0 0.033678386
- O 0 0.007169434
induced O 0 0.00040766812
amnesia B-Disease 0 0.99990785
, O 0 0.0006161046
demonstrating O 0 0.00016713352
a O 0 0.00037117445
central O 0 0.00039294557
localization O 0 0.00016467668
of O 0 0.0004816887
the O 0 0.00060574745
activity O 0 0.0010002757
. O 0 0.002546742

At O 0 0.0011651875
the O 0 0.0011941463
highest O 0 0.0009887024
effective O 0 0.0008480343
doses O 0 0.0022322116
, O 0 0.0034682357
PG B-Chemical 0 0.9997912
- I-Chemical 0 0.045869596
9 I-Chemical 0 0.00037180274
did O 0 0.00028940692
not O 0 0.00018751454
produce O 0 0.00014203
any O 0 0.00019098136
collateral O 0 0.16364464
symptoms O 0 0.0023305991
as O 0 0.00012720523
revealed O 0 0.00010201812
by O 0 0.00012184395
the O 0 0.00013278972
Irwin O 0 0.0020537183
test O 0 0.00028975093
, O 0 0.00036657872
and O 0 0.00019294072
it O 0 0.00025679506
did O 0 0.00016947035
not O 0 0.0001130585
modify O 0 0.000112312155
spontaneous O 0 0.00064230216
motility O 0 0.0017365152
and O 0 0.00014642473
inspection O 0 0.00012213521
activity O 0 0.000114111936
, O 0 0.0003177298
as O 0 0.00018643167
revealed O 0 0.00020126114
by O 0 0.00030348072
the O 0 0.0004197831
hole O 0 0.011170097
- O 0 0.0058472077
board O 0 0.0016746058
test O 0 0.0022793738
. O 0 0.003188678

PG B-Chemical 0 0.998949
- I-Chemical 0 0.05739094
9 I-Chemical 0 0.0017050016
was O 0 0.00088140497
also O 0 0.000538724
able O 0 0.0003588182
to O 0 0.00031745186
increase O 0 0.00027926711
the O 0 0.00022479541
amount O 0 0.00021692138
of O 0 0.00083928916
NGF O 1 0.999895
secreted O 0 0.00059190975
in O 0 0.0002780254
vitro O 0 0.00027674172
by O 0 0.00029253686
astrocytes O 0 0.001482622
in O 0 0.00030081157
a O 0 0.0005644025
dose O 0 0.0010000765
- O 0 0.0023716232
dependent O 0 0.0006278923
manner O 0 0.0014664456
. O 0 0.0031038357

The O 0 0.0038341896
maximal O 0 0.007978293
NGF O 1 0.9990839
contents O 0 0.0038366783
obtained O 0 0.0010341732
by O 0 0.0013516425
PG B-Chemical 0 0.99951696
- I-Chemical 0 0.010467178
9 I-Chemical 0 0.00043758255
were O 0 0.0003146443
17 O 0 0.00040706503
. O 0 0.00028256592
6 O 0 0.00027472773
- O 0 0.0011510904
fold O 0 0.0005374239
of O 0 0.0006435334
the O 0 0.00067182403
control O 0 0.0011816104
value O 0 0.002261052
. O 0 0.003625132

During O 0 0.0026427733
culture O 0 0.0035713012
, O 0 0.0026678827
no O 0 0.0010601737
morphological O 0 0.0016103222
changes O 0 0.0007735633
were O 0 0.00047411752
found O 0 0.00040155434
at O 0 0.00033545052
effective O 0 0.00049986417
concentrations O 0 0.0013021871
of O 0 0.0019745727
PG B-Chemical 0 0.9994766
- I-Chemical 0 0.04523383
9 I-Chemical 0 0.002406926
. O 0 0.0035748258

The O 0 0.0020004562
current O 0 0.0018736306
work O 0 0.0012584626
indicates O 0 0.0005605243
the O 0 0.0004912281
ability O 0 0.0005092223
of O 0 0.0011976035
PG B-Chemical 0 0.99988616
- I-Chemical 0 0.03197846
9 I-Chemical 0 0.00020830172
to O 0 0.00011294644
induce O 0 8.30885e-05
beneficial O 0 0.00014800983
effects O 0 0.00013823653
on O 0 0.00014841899
cognitive O 0 0.8126548
processes O 0 0.00033591822
and O 0 0.00019921504
stimulate O 0 0.00016552582
activity O 0 0.00025664235
of O 0 0.0011841299
NGF O 1 0.99993134
synthesis O 0 0.009670344
in O 0 0.0012925577
astroglial O 0 0.3095551
cells O 0 0.00284967
. O 0 0.0035493942

Therefore O 0 0.0036455037
, O 0 0.0116769085
PG B-Chemical 0 0.9992731
- I-Chemical 0 0.032581672
9 I-Chemical 0 0.00087056105
could O 0 0.00039224123
represent O 0 0.00033816264
a O 0 0.00038857735
potential O 0 0.00020673052
useful O 0 0.00026401752
drug O 0 0.0018835338
able O 0 0.00017125887
to O 0 0.00016348776
improve O 0 0.00014208326
the O 0 0.00017963875
function O 0 0.00026308178
of O 0 0.00059905177
impaired O 0 0.00503564
cognitive O 0 0.94895506
processes O 0 0.003354645
. O 0 0.0032589394

Mechanisms O 0 0.009909379
of O 0 0.007887363
FK B-Chemical 0 0.9976144
506 I-Chemical 0 0.95601094
- O 0 0.024060449
induced O 0 0.0032909936
hypertension B-Disease 2 0.9998987
in O 0 0.0026811422
the O 0 0.0021177724
rat O 0 0.004493838
. O 0 0.005028316

- O 0 0.25789416
Tacrolimus B-Chemical 0 0.9993703
( O 0 0.016465804
FK B-Chemical 0 0.9976598
506 I-Chemical 0 0.75546026
) O 0 0.0033034428
is O 0 0.0009001803
a O 0 0.0012746145
powerful O 0 0.0013461505
, O 0 0.0018868227
widely O 0 0.0012520553
used O 0 0.0017690151
immunosuppressant O 0 0.2349677
. O 0 0.0053886217

The O 0 0.0022582223
clinical O 0 0.0030489233
utility O 0 0.001273227
of O 0 0.0023838799
FK B-Chemical 0 0.99824
506 I-Chemical 0 0.7332419
is O 0 0.0008455846
complicated O 0 0.0015861728
by O 0 0.00082093984
substantial O 0 0.0017228518
hypertension B-Disease 2 0.9999517
and O 0 0.005857722
nephrotoxicity B-Disease 0 0.99987805
. O 0 0.0058881287

To O 0 0.0013237213
clarify O 0 0.0008246687
the O 0 0.0008416257
mechanisms O 0 0.00073110964
of O 0 0.0015937551
FK B-Chemical 0 0.9992244
506 I-Chemical 0 0.9560058
- O 0 0.0110364575
induced O 0 0.000647638
hypertension B-Disease 2 0.9999856
, O 0 0.0007421414
we O 0 0.000102230995
studied O 0 0.00020712572
the O 0 0.00012400984
chronic O 0 0.0012448746
effects O 0 0.00017653192
of O 0 0.000425537
FK B-Chemical 0 0.9995197
506 I-Chemical 0 0.5137153
on O 0 0.00010791838
the O 0 0.00013135355
synthesis O 0 0.0005275911
of O 0 0.00056414644
endothelin O 0 0.99996233
- O 0 0.074761406
1 O 0 0.0003026951
( O 0 0.0005668187
ET O 0 0.7506228
- O 0 0.0017657158
1 O 0 0.00018279626
) O 0 0.00031802923
, O 0 0.00021062563
the O 0 9.6764044e-05
expression O 0 0.000114577626
of O 0 0.0001858575
mRNA O 0 0.00025832097
of O 0 0.0004263133
ET O 0 0.9711556
- O 0 0.0044291494
1 O 0 0.00021706747
and O 0 0.00029763367
endothelin O 0 0.9998895
- O 0 0.0573378
converting O 0 0.00078119006
enzyme O 0 0.0016435806
- O 0 0.003738243
1 O 0 0.00025863544
( O 0 0.00047905464
ECE O 0 0.14943668
- O 0 0.0018708638
1 O 0 0.00022626389
) O 0 0.00046947968
, O 0 0.00043757586
the O 0 0.00036525694
endothelial O 0 0.9997377
nitric B-Chemical 0 0.9999492
oxide I-Chemical 0 0.99947935
synthase O 0 0.61568147
( O 0 0.0022095828
eNOS O 0 0.12457331
) O 0 0.0006134462
activity O 0 0.00010907275
, O 0 0.00024283498
and O 0 0.00013062173
the O 0 0.000100906254
expression O 0 0.000122058846
of O 0 0.00020385647
mRNA O 0 0.00028540663
of O 0 0.00041999243
eNOS O 0 0.13140249
and O 0 0.0006186697
C O 0 0.99706835
- O 0 0.019554427
type O 0 0.0006798658
natriuretic O 0 0.022187259
peptide O 0 0.00032979192
( O 0 0.0009362574
CNP O 0 0.07020688
) O 0 0.0012033312
in O 0 0.00050377264
rat O 0 0.0012830934
blood O 0 0.015874105
vessels O 0 0.338663
. O 0 0.0035517865

In O 0 0.0018718444
addition O 0 0.0011528834
, O 0 0.0018956593
the O 0 0.00064390275
effect O 0 0.0004913555
of O 0 0.00058094773
the O 0 0.0004136265
specific O 0 0.00039867626
endothelin O 0 0.9998197
type O 0 0.0046544075
A O 0 0.47818464
receptor O 0 0.028491614
antagonist O 0 0.93598884
FR B-Chemical 0 0.9988691
139317 I-Chemical 0 0.99998665
on O 0 0.00057468016
FK B-Chemical 0 0.99947995
506 I-Chemical 0 0.9173874
- O 0 0.004556996
induced O 0 0.0005297907
hypertension B-Disease 2 0.9999727
in O 0 0.0006568194
rats O 0 0.0010377883
was O 0 0.0008252905
studied O 0 0.0017944153
. O 0 0.0026384084

FK B-Chemical 0 0.9922294
506 I-Chemical 0 0.8480458
, O 0 0.021419678
5 O 0 0.012605182
mg O 0 0.043562304
. O 0 0.01723255

kg O 0 0.048872348
- O 0 0.05206339
1 O 0 0.025494797
. O 0 0.028273828

d O 0 0.0077614835
- O 0 0.010445826
1 O 0 0.0013889162
given O 0 0.00047226608
for O 0 0.00034542402
4 O 0 0.00028546544
weeks O 0 0.00019417316
, O 0 0.00051778374
elevated O 0 0.0008384599
blood O 0 0.0015435184
pressure O 0 0.001863063
from O 0 0.00022989743
102 O 0 0.00048313354
+ O 0 0.0009394358
/ O 0 0.001409287
- O 0 0.0011446188
13 O 0 0.00022170178
to O 0 0.0001500968
152 O 0 0.0004432795
+ O 0 0.00077721267
/ O 0 0.0011005518
- O 0 0.00084992644
15 O 0 0.00014787428
mm O 0 0.00055549847
Hg O 0 0.48278564
and O 0 0.00021137361
increased O 0 0.00022737827
the O 0 0.00015540025
synthesis O 0 0.00048594846
of O 0 0.00043617305
ET O 0 0.969028
- O 0 0.0031151047
1 O 0 0.00015737877
and O 0 0.00011222276
the O 0 9.508965e-05
levels O 0 0.00013333964
of O 0 0.0003330739
ET O 0 0.9466884
- O 0 0.0031759432
1 O 0 0.00019395426
mRNA O 0 0.0001644835
in O 0 0.00014315786
the O 0 0.00016941043
mesenteric O 0 0.10545422
artery O 0 0.05863694
( O 0 0.00044713952
240 O 0 0.00039919672
% O 0 0.00046901856
and O 0 0.00039288
230 O 0 0.0013492884
% O 0 0.0011342155
, O 0 0.0014637565
respectively O 0 0.002247887
) O 0 0.0043195067
. O 0 0.003833288

Little O 0 0.011623343
change O 0 0.0029179077
was O 0 0.0015983537
observed O 0 0.0009800709
in O 0 0.00080697896
the O 0 0.0006227422
expression O 0 0.0006720059
of O 0 0.0012243107
ECE O 0 0.56507313
- O 0 0.006808118
1 O 0 0.0010217509
mRNA O 0 0.0011608867
and O 0 0.0017582722
CNP O 0 0.056313027
mRNA O 0 0.004052659
. O 0 0.0053888694

FK B-Chemical 0 0.9978532
506 I-Chemical 0 0.95509857
decreased O 0 0.008909805
eNOS O 0 0.10223659
activity O 0 0.0006962628
and O 0 0.0006193736
the O 0 0.00039702005
levels O 0 0.00041255422
of O 0 0.0007004213
eNOS O 0 0.057940826
mRNA O 0 0.0005343408
in O 0 0.00032148004
the O 0 0.00029671256
aorta O 0 0.0069745565
( O 0 0.00058600167
48 O 0 0.00031865234
% O 0 0.0005296549
and O 0 0.0004018038
55 O 0 0.00069003855
% O 0 0.0011447317
, O 0 0.0015964729
respectively O 0 0.0024793006
) O 0 0.0047886795
. O 0 0.0042488175

The O 0 0.0024708055
administration O 0 0.0034915307
of O 0 0.002883412
FR B-Chemical 0 0.9803878
139317 I-Chemical 0 0.99991477
( O 0 0.0021990112
10 O 0 0.0006144898
mg O 0 0.0026396008
. O 0 0.000332629
kg O 0 0.0007777783
- O 0 0.0012999262
1 O 0 0.00031891765
. O 0 0.00025873707
d O 0 0.0004982651
- O 0 0.0017532585
1 O 0 0.00044420478
) O 0 0.0009185874
prevented O 0 0.0013312395
FK B-Chemical 0 0.99916863
506 I-Chemical 0 0.93973356
- O 0 0.007900722
induced O 0 0.0011401762
hypertension B-Disease 2 0.99994564
in O 0 0.0017603642
rats O 0 0.003094497
. O 0 0.003176775

These O 0 0.0020276736
results O 0 0.0014834738
indicate O 0 0.00088162924
that O 0 0.0013836918
FK B-Chemical 0 0.99858946
506 I-Chemical 0 0.7094922
may O 0 0.00043587107
increase O 0 0.00034295177
blood O 0 0.002318799
pressure O 0 0.003838186
not O 0 0.00020143393
only O 0 0.00020749416
by O 0 0.00020065125
increasing O 0 0.00035904298
ET O 0 0.94513863
- O 0 0.004604184
1 O 0 0.00024783728
production O 0 0.00026413586
but O 0 0.00025517985
also O 0 0.00022575942
by O 0 0.00033607727
decreasing O 0 0.0009077196
NO B-Chemical 0 0.998836
synthesis O 0 0.0029291734
in O 0 0.00080678216
the O 0 0.0010439876
vasculature O 0 0.17631014
. O 0 0.003248578

